﻿FN Clarivate Analytics Web of Science
VR 1.0
PT J
AU Wu, Y
   Tian, L
   Huang, YF
AF Wu, Ying
   Tian, Lei
   Huang, Yifei
TI Correlation between the interactions of ABCA4 polymorphisms and smoking
   with the susceptibility to age-related macular degeneration
SO INTERNATIONAL JOURNAL OF CLINICAL AND EXPERIMENTAL PATHOLOGY
LA English
DT Article
DE ABCA4; polymorphisms; smoking; Interactions; AMD
ID RISK-FACTORS; STARGARDT-DISEASE; GENE ABCR; MACULOPATHY; MUTATIONS;
   VARIANTS; EYE
AB Objective: Our study was aimed to analyze the relationship between retina-specific ATP-binding cassette, sub-family A, member 4 (ABCA4) gene polymorphisms and gene-environment interactions with age-related macular degeneration (AMD) susceptibility. Methods: 98 AMD patients and 110 healthy controls, matched in age and sex, were enrolled in this study. ABCA4 polymorphisms (2633C> A, 5646G> A and 6389T> A) were determined by direct sequencing. Differences of genotype and allele distributions were analyzed by X-2 test. Odds ratios (ORs) and 95% confidence intervals (95% CIs) were adopted to represent the relative risk of AMD. Gene-environment interactions were analyzed using crossover analysis. Results: 2633C> A polymorphism had no obvious correlation with AMD risk. Genotype AA and allele A in 5646G> A polymorphism significantly increased the risk of AMD (OR= 4.753, 95% CI= 1.249-18.085; OR= 1.944, 95% CI= 1.209-3.126). 6389T> A polymorphism AA genotype had no significant correlation with AMD risk, but the A allele distinctly enhanced the AMD risk (OR= 1.681, 95% CI= 1.071-2.639). Afterwards, we analyzed the interactions between ABCA4 polymorphisms and smoking on AMD. Smoking had interactions with all of 2633C> A (CC+ CA), 5646G> A and 6389T> A polymorphisms, and the interactions were significantly correlated with AMD. Conclusions: 2633C> A (CC+ CA) genotype, 5646G> A and 6389T> A polymorphisms of ABCA4 gene and smoking are susceptible factors for AMD, and the interactions of ABCA4 polymorphisms with smoking increased the risk of AMD.
C1 [Wu, Ying] Nankai Univ, Sch Med, Tianjin 300071, Peoples R China.
   [Tian, Lei; Huang, Yifei] Chinese Peoples Liberat Army Gen Hosp, Dept Ophthalmol, Beijing 100853, Peoples R China.
C3 Nankai University; Chinese People's Liberation Army General Hospital
RP Huang, YF (通讯作者)，Peoples Liberat Army, Gen Hosp, Dept Ophthalmol, 28 Fuxing Rd, Beijing 100853, Peoples R China.
EM huyf078@126.com
RI Huang, Yifei/ABE-7566-2020; Huang, Yifei/ABE-4692-2020
OI Huang, Yifei/0000-0002-7089-6426
CR Allikmets R, 1997, NAT GENET, V15, P236, DOI 10.1038/ng0397-236
   Allikmets R, 1997, SCIENCE, V277, P1805, DOI 10.1126/science.277.5333.1805
   Babanejad M., 2015, OPHTHALMIC GENET, V21, P1
   Baum L, 2003, OPHTHALMOLOGICA, V217, P111, DOI 10.1159/000068553
   Cheng CY, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms7063
   Cheung LK, 2013, PHARMACOTHERAPY, V33, P838, DOI 10.1002/phar.1264
   Curcio CA, 2009, PROG RETIN EYE RES, V28, P393, DOI 10.1016/j.preteyeres.2009.08.001
   Ersoy L, 2014, BIOMED RES INT, V2014, P413
   Evans JR, 2001, PROG RETIN EYE RES, V20, P227, DOI 10.1016/S1350-9462(00)00023-9
   Fisher SA, 2005, HUM MOL GENET, V14, P2257, DOI 10.1093/hmg/ddi230
   Gorin MB, 1999, MOL VIS, V5, pU31
   Guymer RH, 2006, MED J AUSTRALIA, V184, P455, DOI 10.5694/j.1326-5377.2006.tb00318.x
   Jonasson F, 2011, OPHTHALMOLOGY, V118, P825, DOI 10.1016/j.ophtha.2010.08.044
   Klevering BJ, 2005, GRAEF ARCH CLIN EXP, V243, P90, DOI 10.1007/s00417-004-1079-4
   Milton RC, 2005, OPHTHALMOLOGY, V112, P533, DOI 10.1016/j.ophtha.2004.10.047
   Mitchell P, 2002, ARCH OPHTHALMOL-CHIC, V120, P1357, DOI 10.1001/archopht.120.10.1357
   Rivera A, 2000, AM J HUM GENET, V67, P800, DOI 10.1086/303090
   Schmidt S, 2003, INVEST OPHTH VIS SCI, V44, P2868, DOI 10.1167/iovs.02-0957
   Seddon JM, 2003, ARCH OPHTHALMOL-CHIC, V121, P785, DOI 10.1001/archopht.121.6.785
   Sigler EJ, 2014, EYE, V28, P838, DOI 10.1038/eye.2014.100
   Souied EH, 2000, INVEST OPHTH VIS SCI, V41, P244
   Stenirri S, 2012, CLIN CHEM LAB MED, V50, P1021, DOI 10.1515/cclm-2011-0854
   Veloso Carlos Eduardo, 2014, Rev. Col. Bras. Cir., V41, P386, DOI 10.1590/0100-69912014006002
   Wong Ian Yat Hin, 2011, International Ophthalmology, V31, P73, DOI 10.1007/s10792-010-9397-5
   Yates JRW, 2000, J MED GENET, V37, P83, DOI 10.1136/jmg.37.2.83
   Yi JH, 2012, MOL MED REP, V6, P1045, DOI 10.3892/mmr.2012.1063
NR 26
TC 4
Z9 4
U1 0
U2 5
PU E-CENTURY PUBLISHING CORP
PI MADISON
PA 40 WHITE OAKS LN, MADISON, WI 53711 USA
SN 1936-2625
J9 INT J CLIN EXP PATHO
JI Int. J. Clin. Exp. Pathol.
PY 2015
VL 8
IS 6
BP 7403
EP 7408
PG 6
WC Oncology; Pathology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology; Pathology
GA CO6PD
UT WOS:000359277700166
PM 26261643
DA 2022-11-30
ER

PT J
AU Sakurada, Y
   Parikh, R
   Gal-Or, O
   Balaratnasingam, C
   Leong, BCS
   Tanaka, K
   Cherepanoff, S
   Spaide, RF
   Freund, KB
   Yannuzzi, LA
AF Sakurada, Yoichi
   Parikh, Ravi
   Gal-Or, Orly
   Balaratnasingam, Chandrakumar
   Leong, Belinda C. S.
   Tanaka, Koji
   Cherepanoff, Svetlana
   Spaide, Richard F.
   Freund, K. Bailey
   Yannuzzi, Lawrence A.
TI CUTICULAR DRUSEN Risk of Geographic Atrophy and Macular
   Neovascularization
SO RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES
LA English
DT Article
DE cuticular drusen; age-related macular degeneration; geographic atrophy;
   macular neovascularization
ID DEGENERATION; VARIANTS; SUBTYPE
AB Purpose: Cuticular drusen (CD) have been associated with manifestations of age-related macular degeneration such as atrophy and neovascularization in the macula. In this study, eyes with CD were followed and investigated for the estimated 5-year risk of progression to sequelae of age-related macular degeneration such as geographic atrophy (GA) and macular neovascularization (MNV). Methods: A consecutive series of patients with CD were followed for the development of GA and MNV. Whenever possible, they were also studied retrospectively. The patients with CD were categorized into three phenotypic groups. Phenotype 1: eyes had concentrated, densely populated CD in the macular and paramacular area, Phenotype 2: eyes showed scattered CD in the posterior fundus, and Phenotype 3: involved eyes with CD mixed with large drusen (>200 mu m). The 5-year incidence of progression was then estimated using a Kaplan-Meier estimator. Results: A total of 63 eyes from 38 patients (35 women with a mean age at presentation of 58.9 +/- 14.2 years) were studied and followed for a mean of 40 +/- 18 months. Thirteen patients had single eyes with GA (84.5%; 11/13) or MNV (15.5%; 2/13) in one eye at presentation and were subsequently excluded. Geographic atrophy developed in 19.0% (12/63) of eyes and MNV in 4.8% (3/63) of eyes. The cumulative estimated 5-year risk of GA and MNV was 28.4% and 8.7%, respectively. The estimated 5-year incidence of MNV or GA was 12.6%, 50.0%, and 51.6% in Phenotype 1, Phenotype 2, and Phenotype 3, respectively (P = 0.0015, log-rank test). No difference in risk was found in the development of GA or MNV (P = 0.11) between the subgroup of patients presenting with GA or MNV in their fellow eye and those with both eyes included. Conclusion: When patients with CD are followed longitudinally, there was a significant risk of progression to GA or MNV for Phenotype 2 and Phenotype 3. Patients with CD are commonly first diagnosed in the fifth decade of life, and there is a female predominance. Clinicians should use multimodal imaging to detect and be aware of the risk of progression to manifestations of GA and MNV. These risks of GA and MNV suggest that patients with CD may be part of the overall spectrum of age-related macular degeneration.
C1 [Sakurada, Yoichi; Parikh, Ravi; Gal-Or, Orly; Leong, Belinda C. S.; Spaide, Richard F.; Freund, K. Bailey; Yannuzzi, Lawrence A.] Manhattan Eye Ear & Throat Hosp, LuEsther T Mertz Retinal Res Ctr, New York, NY 10021 USA.
   [Sakurada, Yoichi; Parikh, Ravi; Gal-Or, Orly; Leong, Belinda C. S.; Spaide, Richard F.; Freund, K. Bailey; Yannuzzi, Lawrence A.] Vitreous Retina Macula Consultants New York, 460 Pk Ave, New York, NY 10022 USA.
   [Sakurada, Yoichi] Univ Yamanashi, Fac Med, Dept Ophthalmol, Kofu, Yamanashi, Japan.
   [Gal-Or, Orly] Rabin Med Ctr, Dept Ophthalmol, Petah Tiqwa, Israel.
   [Balaratnasingam, Chandrakumar] Univ Western Australia, Ctr Ophthalmol & Visual Sci, Perth, WA, Australia.
   [Balaratnasingam, Chandrakumar] Sir Charles Gairdner Hosp, Dept Ophthalmol, Nedlands, WA, Australia.
   [Tanaka, Koji] Nihon Univ, Dept Ophthalmol, Sch Med, Tokyo, Japan.
   [Cherepanoff, Svetlana] Univ Sydney, Sydney, NSW, Australia.
   [Freund, K. Bailey; Yannuzzi, Lawrence A.] New York Univ Med, Dept Ophthalmol, New York, NY USA.
   [Freund, K. Bailey; Yannuzzi, Lawrence A.] Columbia Univ, Edward S Harkness Eye Inst, Med Ctr, New York, NY USA.
C3 Manhattan Eye Ear & Throat Hospital; Vitreous Retina Macula Consultants
   of New York; University of Yamanashi; Rabin Medical Center; University
   of Western Australia; University of Western Australia; Nihon University;
   University of Sydney; New York University; Columbia University
RP Yannuzzi, LA (通讯作者)，Vitreous Retina Macula Consultants New York, 460 Pk Ave, New York, NY 10022 USA.
EM layannuzzi@gmail.com
RI Tanaka, Koji/H-3119-2019; Spaide, Richard/ABD-7368-2020
OI Tanaka, Koji/0000-0003-3323-4148; 
FU LuEsther T. Mertz Center for Retinal Research; Macula Foundation, Inc,
   New York, NY
FX Supported by the LuEsther T. Mertz Center for Retinal Research and the
   Macula Foundation, Inc, New York, NY. The funding bodies had no role in
   the design or execution of this study or the decision to publish.
CR Balaratnasingam C, 2018, OPHTHALMOLOGY, V125, P100, DOI 10.1016/j.ophtha.2017.08.033
   Boon CJE, 2008, AM J HUM GENET, V82, P516, DOI 10.1016/j.ajhg.2007.11.007
   Boon CJF, 2013, PROG RETIN EYE RES, V37, P90, DOI 10.1016/j.preteyeres.2013.08.003
   COHEN Y, 1994, BRIT J OPHTHALMOL, V78, P437
   Duvvari MR, 2015, MOL VIS, V21, P285
   Ferris FL, 2005, ARCH OPHTHALMOL-CHIC, V123, P1570
   Freund KB, 2011, RETINA-J RET VIT DIS, V31, P13, DOI 10.1097/IAE.0b013e3181ea48ba
   Gass JD., 1977, STEREOSCOPIC ATLAS M, V2
   GASS JDM, 1985, AM J OPHTHALMOL, V99, P445
   Grassi MA, 2007, ARCH OPHTHALMOL-CHIC, V125, P93, DOI 10.1001/archopht.125.1.93
   Guigui B, 2011, BRIT J OPHTHALMOL, V95, P238, DOI 10.1136/bjo.2009.178400
   Khan KN, 2016, PROG RETIN EYE RES, V53, P70, DOI 10.1016/j.preteyeres.2016.04.008
   Nathoo NA, 2014, AM J OPHTHALMOL, V158, P757, DOI 10.1016/j.ajo.2014.06.021
   Russell SR, 2000, AM J OPHTHALMOL, V129, P205, DOI 10.1016/S0002-9394(99)00345-1
   SARKS SH, 1976, BRIT J OPHTHALMOL, V60, P324, DOI 10.1136/bjo.60.5.324
   Treacher Collins E, 1894, LANCET, V144, P1387
   van de Ven JPH, 2012, MOL VIS, V18, P2271
NR 17
TC 13
Z9 13
U1 0
U2 1
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0275-004X
EI 1539-2864
J9 RETINA-J RET VIT DIS
JI Retin.-J. Retin. Vitr. Dis.
PD FEB
PY 2020
VL 40
IS 2
BP 257
EP 265
DI 10.1097/IAE.0000000000002399
PG 9
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA LA1QP
UT WOS:000523729800014
PM 31972795
DA 2022-11-30
ER

PT J
AU Prenner, JL
   Halperin, LS
   Rycroft, C
   Hogue, S
   Liu, ZW
   Seibert, R
AF Prenner, Jonathan L.
   Halperin, Lawrence S.
   Rycroft, Catherine
   Hogue, Susan
   Liu, Zinaria Williams
   Seibert, Robert
TI Disease Burden in the Treatment of Age-Related Macular Degeneration:
   Findings From a Time-and-Motion Study
SO AMERICAN JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
ID QUALITY-OF-LIFE; VISUAL IMPAIRMENT; RANIBIZUMAB; INDIVIDUALS;
   VERTEPORFIN; BEVACIZUMAB; IMPACT; TRIAL; COSTS; EYE
AB PURPOSE: To examine the time burden of managing neovascular age-related macular degeneration (AMD) imposed on physicians, staff, patients, and caregivers.
   DESIGN: Mixed-methods, prospective, observational time- and-motion study.
   METHODS: The multicenter study was conducted from March 2011 >= 50 through August 2012. Retina specialists administering vascular endothelial growth factor (VEGF)-inhibitor injections monthly were surveyed and completed records for >= 5 patients scheduled for office visits within 3 weeks for anti-VEGF injection or monitoring. A survey was administered to 75 neovascular AMD patients aged >= 50 years who received >= 1 anti-VEGF injection in the past 6 months. Telephone interviews were conducted with 13 neovascular AMD patient caregivers.
   RESULTS: Fifty-six physicians provided data for 221 patients with neovascular AMD. Patients accounted for 20% of the health care staff's time per week, with an average of 23 staff members. An average patient visit for neovascular AMD was 90 minutes (range: 13 minutes to >4 hours). Patients reported an average time per visit of almost 12 hours, including preappointment preparation (16 minutes), travel (66 minutes), waiting time (37 minutes), treatment time (43 minutes), and postappointment recovery (9 hours). Patients stated that caregivers took time away from work (22%) and personal activities (28%) to provide transportation to appointments.
   CONCLUSIONS: Neovascular AMD management imposes a substantial time burden on physicians, staff, patients, and caregivers. There may be a need for additional support and/or reimbursement for services required by patients and caregivers and provided by physicians. (C) 2015 The Authors. Published by Elsevier Inc.
C1 [Prenner, Jonathan L.] Rutgers State Univ, Robert Wood Johnson Med Sch, NJ Retina, New Brunswick, NJ 08901 USA.
   [Halperin, Lawrence S.] Florida Atlantic Univ, Charles E Schmidt Coll Med, Retina Grp Florida, Boca Raton, FL 33431 USA.
   [Rycroft, Catherine] RTI Hlth Solut, Manchester, Lancs, England.
   [Hogue, Susan] RTI Hlth Solut, Res Triangle Pk, NC USA.
   [Liu, Zinaria Williams; Seibert, Robert] Regeneron Pharmaceut Inc, Tarrytown, NY 10591 USA.
C3 Rutgers State University New Brunswick; Rutgers State University Medical
   Center; State University System of Florida; Florida Atlantic University;
   Research Triangle Institute; Research Triangle Institute; Regeneron
RP Prenner, JL (通讯作者)，Rutgers State Univ, Robert Wood Johnson Med Sch, 10 Plum St 600, New Brunswick, NJ 08901 USA.
EM jonathanprenner@gmail.com
FU Regeneron Pharmaceuticals, Inc.; Regeneron Pharmaceuticals, Inc
FX This study was sponsored by Regeneron Pharmaceuticals, Inc. S.H. is a
   full-time employee of RTI Health Solutions. C.R. was a full-time
   employee of RTI Health Solutions at the time of the study and is
   currently employed at BresMed. Z.W.L. and R.S. are full-time employees
   of Regeneron Pharmaceuticals, Inc. J.P. and L.H. received consulting
   fees from Regeneron Pharmaceuticals, Inc for the analysis of the data
   used for this manuscript. All the authors attest to independence in
   reporting the study data and interpretation of the data. All authors
   attest that they meet the current ICMJE requirements to qualify as
   authors.
CR Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Brown DM, 2009, OPHTHALMOLOGY, V116, P57, DOI 10.1016/j.ophtha.2008.10.018
   Brown Gary C, 2005, Trans Am Ophthalmol Soc, V103, P173
   Friedman DS, 2011, ARCH OPHTHALMOL-CHIC, V129, P1188
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P564
   Gragoudas ES, 2004, NEW ENGL J MED, V351, P2805, DOI 10.1056/NEJMoa042760
   Heier JS, 2012, OPHTHALMOLOGY, V119, P2537, DOI 10.1016/j.ophtha.2012.09.006
   Hochberg C, 2012, INVEST OPHTH VIS SCI, V53, P3201, DOI 10.1167/iovs.12-9469
   Jackson CA, 1998, ARCH OPHTHALMOL-CHIC, V116, P922, DOI 10.1001/archopht.116.7.922
   Kodjikian L, 2013, OPHTHALMOLOGY, V120, P2300, DOI 10.1016/j.ophtha.2013.06.020
   Krebs I, 2013, BRIT J OPHTHALMOL, V97, P266, DOI 10.1136/bjophthalmol-2012-302391
   Mathew RS, 2011, OPHTHAL PHYSL OPT, V31, P375, DOI 10.1111/j.1475-1313.2011.00848.x
   Mitchell J, 2006, HEALTH QUAL LIFE OUT, V4, DOI 10.1186/1477-7525-4-97
   Qualls LG, 2013, RETINA-J RET VIT DIS, V33, P854, DOI 10.1097/IAE.0b013e31826f065e
   Rovner BW, 2009, ALZHEIMERS DEMENT, V5, P12, DOI 10.1016/j.jalz.2008.06.001
   Schmier JK, 2006, PHARMACOECONOMICS, V24, P319, DOI 10.2165/00019053-200624040-00003
   Schmier JK, 2006, RETINA-J RET VIT DIS, V26, P1056, DOI 10.1097/01.iae.0000254890.48272.5a
   Schmier JK, 2006, DISABIL REHABIL, V28, P1331, DOI 10.1080/09638280600621436
   Schmier JK, 2012, AM J OPHTHALMOL, V154, P675, DOI 10.1016/j.ajo.2012.04.017
   World Health Organisation, 2013, PRIOR EYE DIS AG REL
NR 20
TC 91
Z9 91
U1 0
U2 16
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0002-9394
EI 1879-1891
J9 AM J OPHTHALMOL
JI Am. J. Ophthalmol.
PD OCT
PY 2015
VL 160
IS 4
BP 725
EP 731
DI 10.1016/j.ajo.2015.06.023
PG 7
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA CR7BR
UT WOS:000361503400014
PM 26142721
OA hybrid
DA 2022-11-30
ER

PT J
AU Nonyane, BAS
   Nitsch, D
   Whittaker, JC
   Sofat, R
   Smeeth, L
   Chakravarthy, U
   Fletcher, AE
AF Nonyane, Bareng A. S.
   Nitsch, Dorothea
   Whittaker, John C.
   Sofat, Reecha
   Smeeth, Liam
   Chakravarthy, Usha
   Fletcher, Astrid E.
TI An Ecological Correlation Study of Late Age-Related Macular Degeneration
   and the Complement Factor H Y402H Polymorphism
SO INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE
LA English
DT Article
ID HY402H GENE POLYMORPHISM; BLUE-MOUNTAINS-EYE; JAPANESE POPULATION;
   RISK-FACTORS; MYOCARDIAL-INFARCTION; HEMICENTIN-1 GENES; CHINESE
   POPULATION; CHROMOSOME 10Q26; GRADING SYSTEM; NO ASSOCIATION
AB PURPOSE. To investigate whether variation in the distribution of the risk allele frequency of the Y402H single-nucleotide polymorphism (SNP) across various ethnicities and geographic regions reflects differences in the prevalence of late age-related macular degeneration (AMD) in those ethnicities.
   METHODS. Published data were obtained via a systematic search. Study samples were grouped into clusters by ethnicity and geographic location and the Spearman correlation coefficient of the prevalence of late AMD and risk allele frequencies was calculated across clusters.
   RESULTS. Across all ethnicities, AMD prevalence was seen to increase with age. Populations of European descent had both higher risk allele frequencies and prevalence of late AMD than did Japanese, Chinese, and Hispanic descendants. Results for African descendants were anomalous: although allele frequency was similar to that in European populations, the age-specific prevalence of late AMD was considerably lower. The correlation coefficient for the association between allele frequency and AMD prevalence was 0.40 (95% confidence interval [CI] = -0.36 to 0.84, P = 0.28) in all populations combined and 0.71 (95% CI = 0.02-0.94, P = 0.04) when people of African descent were excluded.
   CONCLUSIONS. Evidence was found at the population level to support a positive association between the Y204H risk allele and the prevalence of AMD after exclusion of studies undertaken on persons of African ancestry. Data in African, Middle Eastern, and South American populations are needed to provide a better understanding of the association of late AMD genetic risk across ethnicities. (Invest Ophthalmol Vis Sci. 2010; 51: 2393-2402) DOI: 10.1167/iovs.09-4228
C1 [Nonyane, Bareng A. S.; Nitsch, Dorothea; Whittaker, John C.; Smeeth, Liam; Fletcher, Astrid E.] Univ London London Sch Hyg & Trop Med, Dept Epidemiol & Populat Hlth, London WC1E 7HT, England.
   [Sofat, Reecha] UCL, Dept Med, Ctr Clin Pharmacol, London, England.
   [Chakravarthy, Usha] Queens Univ Belfast, Ctr Vis & Vasc Sci, Belfast, Antrim, North Ireland.
C3 University of London; London School of Hygiene & Tropical Medicine;
   University of London; University College London; Queens University
   Belfast
RP Nonyane, BAS (通讯作者)，Univ London London Sch Hyg & Trop Med, Dept Epidemiol & Populat Hlth, Keppel St, London WC1E 7HT, England.
EM aletta.nonyane@lshtm.ac.uk
RI Whittaker, John C/B-8609-2012; Nonyane, Bareng A.S./AAC-8118-2020;
   Smeeth, Liam/X-5862-2018
OI Whittaker, John C/0000-0002-3529-2379; Nonyane, Bareng
   A.S./0000-0001-5633-7487; Smeeth, Liam/0000-0002-9168-6022;
   Chakravarthy, Usha/0000-0002-2606-3734; Nitsch,
   Dorothea/0000-0001-5767-248X; Sofat, Reecha/0000-0002-0242-6115
FU British Heart Foundation [FS/07/011]; Wellcome Trust Senior Clinical
   Fellowship; MRC [G0601354] Funding Source: UKRI; Medical Research
   Council [G0601354] Funding Source: researchfish
FX Supported by British Heart Foundation (Schillingford) Clinical Training
   Fellowship FS/07/011 (RS) and by a Wellcome Trust Senior Clinical
   Fellowship (LS).
CR Andersen MVN, 2008, OPHTHALMOLOGY, V115, P700, DOI 10.1016/j.ophtha.2007.12.013
   Augood CA, 2006, ARCH OPHTHALMOL-CHIC, V124, P529, DOI 10.1001/archopht.124.4.529
   Baird PN, 2006, INVEST OPHTH VIS SCI, V47, P4194, DOI 10.1167/iovs.05-1285
   Beckmann JS, 2007, NAT REV GENET, V8, P639, DOI 10.1038/nrg2149
   BIRD AEC, 1995, SURV OPHTHALMOL, V39, P367, DOI 10.1016/S0039-6257(05)80092-X
   Brantley MA, 2007, OPHTHALMOLOGY, V114, P2168, DOI 10.1016/j.ophtha.2007.09.008
   Chen LJ, 2006, MOL VIS, V12, P1536
   Chen SJ, 2008, INVEST OPHTH VIS SCI, V49, P3126, DOI 10.1167/iovs.08-1803
   Chowers I, 2008, MOL VIS, V14, P1829
   Conley YP, 2005, HUM MOL GENET, V14, P1991, DOI 10.1093/hmg/ddi204
   de Jong FJ, 2007, INVEST OPHTH VIS SCI, V48, P3014, DOI 10.1167/iovs.06-1460
   Despriet DDG, 2006, JAMA-J AM MED ASSOC, V296, P301, DOI 10.1001/jama.296.3.301
   Droz I, 2008, BRIT J OPHTHALMOL, V92, P513, DOI 10.1136/bjo.2007.127811
   Edwards AO, 2005, SCIENCE, V308, P421, DOI 10.1126/science.1110189
   Fisher SA, 2007, BRIT J OPHTHALMOL, V91, P576, DOI 10.1136/bjo.2006.105577
   Friedman DS, 1999, OPHTHALMOLOGY, V106, P1049, DOI 10.1016/S0161-6420(99)90267-1
   Fuse N, 2006, AM J OPHTHALMOL, V142, P1074, DOI 10.1016/j.ajo.2006.07.030
   Gotting C, 2008, GENET TEST, V12, P431, DOI 10.1089/gte.2008.0026
   Gotoh N, 2006, HUM GENET, V120, P139, DOI 10.1007/s00439-006-0187-0
   Grassi MA, 2006, HUM MUTAT, V27, P921, DOI 10.1002/humu.20359
   Gupta SK, 2007, INVEST OPHTH VIS SCI, V48, P1007, DOI 10.1167/iovs.06-0712
   Haddad S, 2006, SURV OPHTHALMOL, V51, P316, DOI 10.1016/j.survophthal.2006.05.001
   Hageman GS, 2006, ANN MED, V38, P592, DOI 10.1080/07853890601097030
   Hageman GS, 2005, P NATL ACAD SCI USA, V102, P7227, DOI 10.1073/pnas.0501536102
   Haines JL, 2005, SCIENCE, V308, P419, DOI 10.1126/science.1110359
   Hughes AE, 2006, NAT GENET, V38, P1173, DOI 10.1038/ng1890
   Jakobsdottir J, 2005, AM J HUM GENET, V77, P389, DOI 10.1086/444437
   Jonasson F, 2003, ARCH OPHTHALMOL-CHIC, V121, P379, DOI 10.1001/archopht.121.3.379
   Kaur I, 2006, INVEST OPHTH VIS SCI, V47, P3729, DOI 10.1167/iovs.05-1430
   Kawasaki R, 2008, OPHTHALMOLOGY, V115, P1735, DOI 10.1016/j.ophtha.2008.02.012
   Kawasaki R, 2008, OPHTHALMOLOGY, V115, P1376, DOI 10.1016/j.ophtha.2007.11.015
   Kim NR, 2008, INVEST OPHTH VIS SCI, V49, P2071, DOI 10.1167/iovs.07-1195
   Klein R, 2006, OPHTHALMOLOGY, V113, P373, DOI 10.1016/j.ophtha.2005.12.013
   Klein R, 2003, OPHTHALMOLOGY, V110, P25, DOI 10.1016/S0161-6420(02)01565-8
   KLEIN R, 1992, OPHTHALMOLOGY, V99, P933
   KLEIN R, 1991, OPHTHALMOLOGY, V98, P1128
   Klein R, 1999, OPHTHALMOLOGY, V106, P1056, DOI 10.1016/S0161-6420(99)90255-5
   Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557
   Klein R, 2007, OPHTHAL EPIDEMIOL, V14, P184, DOI 10.1080/09286580701344381
   Krishnaiah S, 2005, INVEST OPHTH VIS SCI, V46, P4442, DOI 10.1167/iovs.05-0853
   Lau LI, 2006, INVEST OPHTH VIS SCI, V47, P3242, DOI 10.1167/iovs.05-1532
   Le Fur I, 2010, NEUROBIOL AGING, V31, P165, DOI 10.1016/j.neurobiolaging.2008.03.003
   Lee KY, 2008, INVEST OPHTH VIS SCI, V49, P2613, DOI 10.1167/iovs.07-0860
   Li YB, 2006, AM J OPHTHALMOL, V142, P788, DOI 10.1016/j.ajo.2006.06.001
   Lin JM, 2008, RETINA-J RET VIT DIS, V28, P309, DOI 10.1097/IAE.0b013e31814cef3a
   Magnusson KP, 2006, PLOS MED, V3, P109, DOI 10.1371/journal.pmed.0030005
   Maller J, 2006, NAT GENET, V38, P1055, DOI 10.1038/ng1873
   MITCHELL P, 1995, OPHTHALMOLOGY, V102, P1450
   Oguido APMT, 2008, ARQ BRAS OFTALMOL, V71, P375, DOI 10.1590/S0004-27492008000300013
   Mooijaart SP, 2007, EXP GERONTOL, V42, P1116, DOI 10.1016/j.exger.2007.08.001
   Mori K, 2007, INVEST OPHTH VIS SCI, V48, P5315, DOI 10.1167/iovs.07-0426
   Munoz B, 2005, ARCH OPHTHALMOL-CHIC, V123, P1575, DOI 10.1001/archopht.123.11.1575
   Narayanan R, 2007, OPHTHALMOLOGY, V114, P1327, DOI 10.1016/j.ophtha.2006.10.035
   Ng TK, 2008, INVEST OPHTH VIS SCI, V49, P3312, DOI 10.1167/iovs.07-1517
   Okamoto H, 2006, MOL VIS, V12, P156
   Oshima Y, 2001, BRIT J OPHTHALMOL, V85, P1153, DOI 10.1136/bjo.85.10.1153
   Pai JK, 2007, EUR HEART J, V28, P1297, DOI 10.1093/eurheartj/ehm090
   Pulido JS, 2007, MAYO CLIN PROC, V82, P301, DOI 10.4065/82.3.301
   Rivera A, 2005, HUM MOL GENET, V14, P3227, DOI 10.1093/hmg/ddi353
   SCHACHAT AP, 1995, ARCH OPHTHALMOL-CHIC, V113, P728, DOI 10.1001/archopht.1995.01100060054032
   Schaumberg DA, 2007, ARCH OPHTHALMOL-CHIC, V125, P55, DOI 10.1001/archopht.125.1.55
   Seddon JM, 2006, HUM HERED, V61, P157, DOI 10.1159/000094141
   Seitsonen S, 2006, MOL VIS, V12, P796
   Sepp T, 2006, INVEST OPHTH VIS SCI, V47, P536, DOI 10.1167/iovs.05-1143
   Simonelli F, 2006, BRIT J OPHTHALMOL, V90, P1142, DOI 10.1136/bjo.2006.096487
   Smith W, 2001, OPHTHALMOLOGY, V108, P697, DOI 10.1016/S0161-6420(00)00580-7
   Souied EH, 2005, MOL VIS, V11, P1135
   Stark K, 2007, CLIN SCI, V113, P213, DOI 10.1042/CS20070028
   Tanimoto S, 2007, NEUROSCI LETT, V414, P71, DOI 10.1016/j.neulet.2006.12.011
   Tedeschi-Blok N, 2007, OPHTHALMOLOGY, V114, P99, DOI 10.1016/j.ophtha.2006.07.043
   Thakkinstian A, 2006, HUM MOL GENET, V15, P2784, DOI 10.1093/hmg/ddl220
   Uka J, 2006, RETINA-J RET VIT DIS, V26, P985, DOI 10.1097/01.iae.0000244068.18520.3e
   VanNewkirk MR, 2000, OPHTHALMOLOGY, V107, P1593, DOI 10.1016/S0161-6420(00)00175-5
   Varma R, 2004, OPHTHALMOLOGY, V111, P1288, DOI 10.1016/j.ophtha.2004.01.023
   VINGERLING JR, 1995, OPHTHALMOLOGY, V102, P205
   Voick KA, 2008, AM J HYPERTENS, V21, P533, DOI 10.1038/ajh.2007.81
   Wegscheider BJ, 2007, OPHTHALMOLOGY, V114, P738, DOI 10.1016/j.ophtha.2006.07.048
   Xing C, 2008, GENES IMMUN, V9, P231, DOI 10.1038/gene.2008.10
   Xu YL, 2008, MOL VIS, V14, P1373
   Zareparsi S, 2005, AM J HUM GENET, V77, P149, DOI 10.1086/431426
   Zee RYL, 2006, ATHEROSCLEROSIS, V187, P332, DOI 10.1016/j.atherosclerosis.2005.09.009
   Zetterberg M, 2008, AM J MED GENET B, V147B, P720, DOI 10.1002/ajmg.b.30668
   Ziskind A, 2008, OPHTHALMIC GENET, V29, P117, DOI 10.1080/13816810802216472
NR 83
TC 15
Z9 15
U1 0
U2 1
PU ASSOC RESEARCH VISION OPHTHALMOLOGY INC
PI ROCKVILLE
PA 12300 TWINBROOK PARKWAY, ROCKVILLE, MD 20852-1606 USA
SN 0146-0404
EI 1552-5783
J9 INVEST OPHTH VIS SCI
JI Invest. Ophthalmol. Vis. Sci.
PD MAY
PY 2010
VL 51
IS 5
BP 2393
EP 2402
DI 10.1167/iovs.09-4228
PG 10
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 589UU
UT WOS:000277180500016
PM 20042653
OA Green Published
DA 2022-11-30
ER

PT J
AU Cherepanoff, S
   Mitchell, P
   Wang, JJ
   Gillies, MC
AF Cherepanoff, Svetlana
   Mitchell, Paul
   Wang, Jie Jin
   Gillies, Mark C.
TI Retinal autoantibody profile in early age-related macular degeneration:
   preliminary findings from the Blue Mountains Eye Study
SO CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY
LA English
DT Article
DE autoantibody; blindness; macular degeneration; serum; Western blot
ID FACTOR-H POLYMORPHISM; BRUCHS MEMBRANE; ANTIBODIES; DRUSEN; MACULOPATHY;
   ATHEROSCLEROSIS; PATHOGENESIS; REPERTOIRES; INVOLVEMENT; PREVALENCE
AB To compare the retinal autoantibody profile in individuals with and without early age-related macular degeneration (AMD) and to determine whether baseline autoantibodies are associated with progression to advanced AMD 5 and 10 years later.
   Western immunoblotting was used to detect the presence of retinal autoantibodies in the baseline serum of 47 individuals with early AMD and 16 healthy controls from the Blue Mountains Eye Study. Autoantibody isotype, IgG subclass distribution and target antigens in the early AMD group were compared with the control group. The association between baseline autoantibodies and progression to advanced AMD 5 and 10 years later was evaluated using the chi-square test.
   Retinal autoantibodies were found in a higher proportion of the early AMD group compared with controls (57% vs. 25%, chi(2) = 5.028, P = 0.025). Autoantibodies targeted a range of retinal polypeptides in both AMD cases and controls. The commonest polypeptide antigens occurred between 20-35 kDa and 50-60 kDa. More than one IgG subclass was often present in participants with autoantibodies. Over a 10-year period, 11 participants (23.4%) with early AMD progressed to advanced AMD. No association was found between baseline autoantibodies and the development of advanced AMD over 10 years (chi(2) = 0.16, Fisher's exact P = 0.59).
   The retinal autoantibody profile in early AMD is complex, both in terms of antigenic targets and immunoglobulin isotypes. Detection of potential disease-associated autoantibodies will require a larger sample size and full characterization of the retinal antigens involved.
C1 Westmead Millennium Inst, Ctr Vis Res, Westmead, NSW, Australia.
   Univ Sydney, Save Sight Inst, Sydney, NSW 2006, Australia.
C3 University of Sydney; Westmead Institute for Medical Research;
   University of Sydney
RP Cherepanoff, S (通讯作者)，Prince Wales Med Res Inst, Barker St, Randwick, NSW, Australia.
EM cherepanoff@yahoo.com
RI wang, jie/GRS-0942-2022; Mitchell, Paul/P-1498-2014; gillies, mark
   c/B-3242-2012; Wang, Jie Jin/P-1499-2014
OI Wang, Jie Jin/0000-0001-9491-4898
CR Ambati J, 2003, NAT MED, V9, P1390, DOI 10.1038/nm950
   Binder CJ, 2003, NAT MED, V9, P736, DOI 10.1038/nm876
   Carayannopoulos MO, 2000, SCAND J IMMUNOL, V51, P327
   Chen H, 1993, Yan Ke Xue Bao, V9, P113
   COHEN J, 1994, CLIN EXP IMMUNOL, V97, P181
   Coutinho A, 1995, CURR OPIN IMMUNOL, V7, P812, DOI 10.1016/0952-7915(95)80053-0
   Crabb JW, 2002, P NATL ACAD SCI USA, V99, P14682, DOI 10.1073/pnas.222551899
   Edwards AO, 2005, SCIENCE, V308, P421, DOI 10.1126/science.1110189
   FORRESTER JV, 1995, PROG RETIN EYE RES, V14, P393, DOI 10.1016/1350-9462(94)00012-5
   Grus FH, 2004, MOL VIS, V10, P132
   Gu XR, 2003, J BIOL CHEM, V278, P42027, DOI 10.1074/jbc.M305460200
   GURNE DH, 1991, OPHTHALMOLOGY, V98, P602
   Hageman GS, 1999, MOL VIS, V5
   Hageman GS, 2001, PROG RETIN EYE RES, V20, P705, DOI 10.1016/S1350-9462(01)00010-6
   Hageman GS, 2005, P NATL ACAD SCI USA, V102, P7227, DOI 10.1073/pnas.0501536102
   Haines JL, 2005, SCIENCE, V308, P419, DOI 10.1126/science.1110359
   Joachim SC, 2003, EUR J OPHTHALMOL, V13, P752, DOI 10.1177/1120672103013009-1003
   Johnson LV, 2000, EXP EYE RES, V70, P441, DOI 10.1006/exer.1999.0798
   KLEIN R, 1992, OPHTHALMOLOGY, V99, P933
   KLEIN R, 1991, OPHTHALMOLOGY, V98, P1128
   Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557
   Lacroix-Desmazes S, 1998, J IMMUNOL METHODS, V216, P117, DOI 10.1016/S0022-1759(98)00074-X
   MITCHELL P, 1995, OPHTHALMOLOGY, V102, P1450
   Mullins RF, 2000, FASEB J, V14, P835, DOI 10.1096/fasebj.14.7.835
   NEWSOME DA, 1987, AM J OPHTHALMOL, V104, P373, DOI 10.1016/0002-9394(87)90227-3
   Patel N, 2005, IMMUNOLOGY, V115, P422, DOI 10.1111/j.1365-2567.2005.02173.x
   PENFOLD P, 1984, AUST J OPHTHALMOL, V12, P23
   PENFOLD PL, 1987, GRAEF ARCH CLIN EXP, V225, P70, DOI 10.1007/BF02155808
   PENFOLD PL, 1986, INVEST OPHTH VIS SCI, V27, P364
   PENFOLD PL, 1985, GRAEF ARCH CLIN EXP, V223, P69, DOI 10.1007/BF02150948
   PENFOLD PL, 1990, GRAEF ARCH CLIN EXP, V228, P270, DOI 10.1007/BF00920033
   Penfold PL, 2001, PROG RETIN EYE RES, V20, P385, DOI 10.1016/S1350-9462(00)00025-2
   Quintana FJ, 2004, BIOMED PHARMACOTHER, V58, P276, DOI 10.1016/j.biopha.2004.04.011
   Sarks JP, 1997, EYE, V11, P515, DOI 10.1038/eye.1997.137
   Shaw PX, 2000, J CLIN INVEST, V105, P1731, DOI 10.1172/JCI8472
   Tou JS, 2004, FASEB J, V18, P1297, DOI 10.1096/fj.04-1862fje
   Zarbin MA, 2004, ARCH OPHTHALMOL-CHIC, V122, P598, DOI 10.1001/archopht.122.4.598
   Zareparsi S, 2005, HUM MOL GENET, V14, P1449, DOI 10.1093/hmg/ddi154
NR 38
TC 36
Z9 39
U1 0
U2 0
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1442-6404
EI 1442-9071
J9 CLIN EXP OPHTHALMOL
JI Clin. Exp. Ophthalmol.
PD AUG
PY 2006
VL 34
IS 6
BP 590
EP 595
DI 10.1111/j.1442-9071.2006.01281.x
PG 6
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 074FO
UT WOS:000239798300015
PM 16925708
DA 2022-11-30
ER

PT J
AU Petrus-Reurer, S
   Kumar, P
   Sanchez, SP
   Aronsson, M
   Andre, H
   Bartuma, H
   Reyes, AP
   Nandrot, EF
   Kvanta, A
   Lanner, F
AF Petrus-Reurer, Sandra
   Kumar, Pankaj
   Sanchez, Sara Padrell
   Aronsson, Monica
   Andre, Helder
   Bartuma, Hammurabi
   Reyes, Alvaro Plaza
   Nandrot, Emeline F.
   Kvanta, Anders
   Lanner, Fredrik
TI Preclinical safety studies of human embryonic stem cell-derived retinal
   pigment epithelial cells for the treatment of age-related macular
   degeneration
SO STEM CELLS TRANSLATIONAL MEDICINE
LA English
DT Article
DE age-related macular degeneration; biodistribution; cellular therapy;
   chemically defined; human embryonic stem cells; retinal pigment
   epithelium; safety studies; subretinal injection; tumorigenicity; whole
   genome sequencing; xeno-free
ID SUBRETINAL IMPLANTATION; TERATOCARCINOMAS; DIFFERENTIATION; MONOLAYER;
   SURVIVAL; LINES
AB As pluripotent stem cell (PSC)-based reparative cell therapies are reaching the bedside, there is a growing need for the standardization of studies concerning safety of the derived products. Clinical trials using these promising strategies are in development, and treatment for age-related macular degeneration is one of the first that has reached patients. We have previously established a xeno-free and defined differentiation protocol to generate functional human embryonic stem cells (hESCs)-derived retinal pigment epithelial (RPE) cells. In this study, we perform preclinical safety studies including karyotype and whole-genome sequencing to assess genome stability, single cell RNA sequencing to ensure cell purity, and biodistribution and tumorigenicity analysis to rule out potential migratory or tumorigenic properties of these cells. Whole-genome sequencing analysis illustrates that existing germline variants load is higher than the introduced variants acquired through in vitro culture or differentiation, and enforces the importance to examine the genome integrity at a deeper level than just karyotype. Altogether, we provide a strategy for preclinical evaluation of PSC-based therapies and the data support safety of the hESC-RPE cells generated through our in vitro differentiation methodology.
C1 [Petrus-Reurer, Sandra; Kumar, Pankaj; Sanchez, Sara Padrell; Reyes, Alvaro Plaza; Lanner, Fredrik] Karolinska Inst, Dept Clin Sci Intervent & Technol, S-14186 Solna, Sweden.
   [Petrus-Reurer, Sandra; Kumar, Pankaj; Sanchez, Sara Padrell; Reyes, Alvaro Plaza; Lanner, Fredrik] Karolinska Univ Sjukhuset, Div Obstet & Gynecol, Stockholm, Sweden.
   [Petrus-Reurer, Sandra; Kumar, Pankaj; Sanchez, Sara Padrell; Reyes, Alvaro Plaza; Lanner, Fredrik] Karolinska Inst, Ming Wai Lau Ctr Reparat Med, Stockholm, Sweden.
   [Aronsson, Monica; Andre, Helder; Bartuma, Hammurabi; Kvanta, Anders] Karolinska Inst, St Erik Eye Hosp, Div Eye & Vis, Dept Clin Neurosci, Stockholm, Sweden.
   [Nandrot, Emeline F.] Sorbonne Univ, CNRS, Inst Vis, INSERM, Paris, France.
C3 Karolinska Institutet; Karolinska Institutet; Karolinska Institutet;
   Centre National de la Recherche Scientifique (CNRS); Institut National
   de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research
   Universities; Sorbonne Universite; Universite Paris Cite
RP Lanner, F (通讯作者)，Karolinska Inst, Dept Clin Sci Intervent & Technol, S-14186 Solna, Sweden.
EM fredrik.lanner@ki.se
RI Reyes, Alvaro Plaza/AAX-7992-2020; Nandrot, Emeline F./AAN-3925-2020;
   Plaza Reyes, Alvaro/AAC-1723-2022
OI Reyes, Alvaro Plaza/0000-0003-1167-6316; Nandrot,
   Emeline/0000-0003-3087-078X; KUMAR, PANKAJ/0000-0002-8411-1634;
   Petrus-Reurer, Sandra/0000-0002-7051-1741; Andre,
   Helder/0000-0002-2926-2376; Lanner, Fredrik/0000-0002-2771-7445
FU Jonasson donation; Knut and Alice Wallenberg Foundation; Centre National
   de la Recherche Scientifique; Agence Nationale de la Recherche;
   Cronqvist Foundation; King Gustav V and Queen Victoria Foundation; Ulla
   och Ingemar Dahlberg Foundation; ARMEC Lindeberg Foundation; Strategic
   Research Area (SRA) Stem Cells and Regenerative Medicine; Crown Princess
   Margareta's Foundation for the Visually Impaired; Stockholm County
   Council (ALF project); Karolinska Institute; Wallenberg Academy Fellow;
   Center for Innovative Medicine; Ming Wai Lau Center for Reparative
   Medicine; Ragnar Soderberg Foundation; Swedish Research Council
FX Jonasson donation; Knut and Alice Wallenberg Foundation; Centre National
   de la Recherche Scientifique; Agence Nationale de la Recherche;
   Cronqvist Foundation; King Gustav V and Queen Victoria Foundation; the
   Ulla och Ingemar Dahlberg Foundation; ARMEC Lindeberg Foundation;
   Strategic Research Area (SRA) Stem Cells and Regenerative Medicine;
   Crown Princess Margareta's Foundation for the Visually Impaired;
   Karolinska Institute; Stockholm County Council (ALF project); Wallenberg
   Academy Fellow; Center for Innovative Medicine; Ming Wai Lau Center for
   Reparative Medicine; Ragnar Soderberg Foundation; Swedish Research
   Council
CR Adewumi O, 2007, NAT BIOTECHNOL, V25, P803, DOI 10.1038/nbt1318
   Allison TF, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-04011-3
   Ambati J, 2003, SURV OPHTHALMOL, V48, P257, DOI 10.1016/S0039-6257(03)00030-4
   Amps K, 2011, NAT BIOTECHNOL, V29, P1132, DOI 10.1038/nbt.2051
   Andrews PW, 2017, STEM CELL REP, V9, P1, DOI 10.1016/j.stemcr.2017.05.029
   Bailey MH, 2018, CELL, V174, P1034, DOI 10.1016/j.cell.2018.07.034
   Bhutto I, 2012, MOL ASPECTS MED, V33, P295, DOI 10.1016/j.mam.2012.04.005
   Blum B, 2009, CELL CYCLE, V8, P3822, DOI 10.4161/cc.8.23.10067
   Butler A, 2018, NAT BIOTECHNOL, V36, P411, DOI 10.1038/nbt.4096
   Chen XY, 2016, BIOINFORMATICS, V32, P1220, DOI 10.1093/bioinformatics/btv710
   Chen YH, 2010, MOL INTERV, V10, P271, DOI 10.1124/mi.10.5.4
   Cibulskis K, 2013, NAT BIOTECHNOL, V31, P213, DOI 10.1038/nbt.2514
   da Cruz L, 2018, NAT BIOTECHNOL, V36, P1, DOI 10.1038/nbt.4114
   Diniz B, 2013, INVEST OPHTH VIS SCI, V54, P5087, DOI 10.1167/iovs.12-11239
   Dobin A, 2013, BIOINFORMATICS, V29, P15, DOI 10.1093/bioinformatics/bts635
   Dolgin E, 2017, NAT BIOTECHNOL, V35, P600, DOI 10.1038/nbt0717-600
   Futreal PA, 2004, NAT REV CANCER, V4, P177, DOI 10.1038/nrc1299
   Garitaonandia I, 2018, STEM CELLS DEV, V27, P951, DOI 10.1089/scd.2018.0001
   Gropp M, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0045532
   Idelson M, 2009, CELL STEM CELL, V5, P396, DOI 10.1016/j.stem.2009.07.002
   Kamao H, 2014, STEM CELL REP, V2, P205, DOI 10.1016/j.stemcr.2013.12.007
   Kanemura H, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0085336
   Kashani AH, 2018, SCI TRANSL MED, V10, DOI 10.1126/scitranslmed.aao4097
   Koss MJ, 2016, GRAEF ARCH CLIN EXP, V254, P1553, DOI 10.1007/s00417-016-3386-y
   Li H, 2010, BIOINFORMATICS, V26, P589, DOI 10.1093/bioinformatics/btp698
   Liao Y, 2014, BIOINFORMATICS, V30, P923, DOI 10.1093/bioinformatics/btt656
   Lim CY, 2015, STEM CELLS DEV, V24, P1515, DOI 10.1089/scd.2015.0033
   Lu B, 2009, STEM CELLS, V27, P2126, DOI 10.1002/stem.149
   Lund RD, 2001, P NATL ACAD SCI USA, V98, P9942, DOI 10.1073/pnas.171266298
   Mandai M, 2017, NEW ENGL J MED, V376, P1038, DOI 10.1056/NEJMoa1608368
   McGill TJ, 2017, TRANSL VIS SCI TECHN, V6, DOI 10.1167/tvst.6.3.17
   Menasche P, 2015, EUR HEART J, V36, P2011, DOI 10.1093/eurheartj/ehv189
   Merkle FT, 2017, NATURE, V545, P229, DOI 10.1038/nature22312
   MILLER SS, 1990, J PHYSIOL-LONDON, V424, P283, DOI 10.1113/jphysiol.1990.sp018067
   Okonechnikov K, 2016, BIOINFORMATICS, V32, P292, DOI 10.1093/bioinformatics/btv566
   Parinot C, 2014, JOVE-J VIS EXP, DOI 10.3791/52100
   Petrus-Reurer S, 2017, INVEST OPHTH VIS SCI, V58, DOI 10.1167/iovs.16-20738
   Picelli S, 2013, NAT METHODS, V10, P1096, DOI [10.1038/NMETH.2639, 10.1038/nmeth.2639]
   Reyes AP, 2016, STEM CELL REP, V6, P9, DOI 10.1016/j.stemcr.2015.11.008
   Rodin S, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms4195
   Schwartz SD, 2016, INVEST OPHTH VIS SCI, V57, DOI 10.1167/iovs.15-18681
   Schwartz SD, 2015, LANCET, V385, P509, DOI 10.1016/S0140-6736(14)61376-3
   Schwartz SD, 2012, LANCET, V379, P713, DOI 10.1016/S0140-6736(12)60028-2
   Sharma R, 2019, SCI TRANSL MED, V11, DOI 10.1126/scitranslmed.aat5580
   Shibata T, 2018, CANCER SCI, V109, P1282, DOI 10.1111/cas.13582
   Shihab HA, 2013, BIOINFORMATICS, V29, P1504, DOI 10.1093/bioinformatics/btt182
   Sondka Z, 2018, NAT REV CANCER, V18, P696, DOI 10.1038/s41568-018-0060-1
   Song WK, 2015, STEM CELL REP, V4, P860, DOI 10.1016/j.stemcr.2015.04.005
   STEVENS LC, 1970, DEV BIOL, V21, P364, DOI 10.1016/0012-1606(70)90130-2
   Strauss O, 2005, PHYSIOL REV, V85, P845, DOI 10.1152/physrev.00021.2004
   Takahashi J, 2019, REGEN MED, V14, P93, DOI 10.2217/rme-2018-0158
   Talevich E, 2016, PLOS COMPUT BIOL, V12, DOI 10.1371/journal.pcbi.1004873
   Thomas BB, 2016, INVEST OPHTH VIS SCI, V57, P2877, DOI 10.1167/iovs.16-19238
   Vaajasaari H, 2011, MOL VIS, V17, P558
   Wang K, 2010, NUCLEIC ACIDS RES, V38, DOI 10.1093/nar/gkq603
   WHO, 2010, REC EV AN CELL CULT
   YOUNG RW, 1969, J CELL BIOL, V42, P392, DOI 10.1083/jcb.42.2.392
NR 57
TC 4
Z9 4
U1 0
U2 7
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 2157-6564
EI 2157-6580
J9 STEM CELL TRANSL MED
JI Stem Cells Transl. Med.
PD AUG
PY 2020
VL 9
IS 8
BP 936
EP 953
DI 10.1002/sctm.19-0396
EA APR 2020
PG 18
WC Cell & Tissue Engineering
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Cell Biology
GA MP0NN
UT WOS:000527366600001
PM 32319201
OA Green Published, gold
DA 2022-11-30
ER

PT J
AU La Schiazza, O
   Bille, JF
AF La Schiazza, Olivier
   Bille, Josef F.
TI High-speed two-photon excited autofluorescence imaging of ex vivo human
   retinal pigment epithelial cells toward age-related macular degeneration
   diagnostic
SO JOURNAL OF BIOMEDICAL OPTICS
LA English
DT Article
DE Two-photon excited fluorescence; scanning laser ophthalmoscope; RPE;
   lipofuscin; age-related macular degeneration
ID FUNDUS AUTOFLUORESCENCE; FLUORESCENCE MICROSCOPY; RPE CELLS; EXCITATION;
   LIPOFUSCIN; ACCUMULATION; COMPONENT; INCREASE
AB Age-related macular degeneration (AMD) is among the major concerns in ophthalmology, as it is the primary cause for irreversible blindness in developed countries. Nevertheless, there is poor understanding of the origins and mechanisms that trigger this important ocular disease. In common clinical pratice, AMD is monitored by autofluorescence imaging of the retinal pigment epithelial (RPE) cells through a confocal scanning laser ophthalmoscope. The RPE cells derive their dominant autofluorescence from the lipofuscin granules that accumulate in the cytoplasm with increasing age and disease. We explored a different approach to retinal RPE imaging using two-photon excited autofluorescence, offering intrinsic three-dimensional resolution, larger sensing depth and reduced photodamage compared to single-photon excited fluorescence ophthalmoscopy. A two-photon microscope, based on the architecture of a conventional scanning laser ophthalmoscope (HRT, Heidelberg Engineering, Germany), was designed for autofluorescence imaging on retina samples from postmortem human-donor eyes. We were able to visualize at video-rate speed single RPE lipofuscin granules, demonstrating the potential to develop this method toward clinical practice for patients with RPE-related retinal disease like AMD. (C) 2008 Society of Photo-Optical Instrumentation Engineers. [DOI: 10.1117/1.2999607]
C1 [La Schiazza, Olivier; Bille, Josef F.] Heidelberg Univ, Kirchhoff Inst Phys, Heidelberg, Germany.
C3 Ruprecht Karls University Heidelberg
RP La Schiazza, O (通讯作者)，Heidelberg Univ, Kirchhoff Inst Phys, Heidelberg, Germany.
EM olivier.la.schiazza@kip.uni-heidelberg.de
FU Ministere de la Culture, de l'Enseignement Superieur et de la Recherche;
   G.-D. de Luxembourg; Centre de Recherche Public Gabriel Lippmann
FX The authors thank Heidelberg Engineering GmbH (Heidelberg, Germany),
   Professor W. Denk for using his laser system and microscope facility at
   the Max-Planck Institute for Medical Research, Heidelberg, and Professor
   F. G. Holz from the Department of Ophthalmology, University of Bonn,
   Germany for providing the postmortem human-retina samples. This research
   was supported with a scholarship from the Ministere de la Culture, de
   l'Enseignement Superieur et de la Recherche, G.-D. de Luxembourg and the
   Centre de Recherche Public Gabriel Lippmann.
CR Borlinghaus RT, 2006, MICROSC RES TECHNIQ, V69, P689, DOI 10.1002/jemt.20363
   BOULTON M, 1989, INVEST OPHTH VIS SCI, V30, P82
   Centonze VE, 1998, BIOPHYS J, V75, P2015, DOI 10.1016/S0006-3495(98)77643-X
   Delori FC, 2000, INVEST OPHTH VIS SCI, V41, P496
   Delori FC, 2001, INVEST OPHTH VIS SCI, V42, P1855
   DELORI FC, 1995, INVEST OPHTH VIS SCI, V36, P718
   Delori FC, 2007, J OPT SOC AM A, V24, P1250, DOI 10.1364/JOSAA.24.001250
   DENK W, 1990, SCIENCE, V248, P73, DOI 10.1126/science.2321027
   Diabet Control Complications Trial Res Grp, 1995, OPHTHALMOLOGY, V102, P647
   Diaspro A., 2006, HDB BIOL CONFOCAL MI, P690, DOI [DOI 10.1007/978-0-387-45524-2_39, 10.1007/978-0-387-45524-2_39]
   Donnert G, 2007, NAT METHODS, V4, P81, DOI 10.1038/NMETH986
   DOREY CK, 1989, INVEST OPHTH VIS SCI, V30, P1691
   Fan GY, 1999, BIOPHYS J, V76, P2412, DOI 10.1016/S0006-3495(99)77396-0
   Goppert-Mayer M, 1931, ANN PHYS-BERLIN, V9, P273
   Han M, 2006, J BIOMED OPT, V11, DOI 10.1117/1.2171649
   Holz FG, 2001, INVEST OPHTH VIS SCI, V42, P1051
   Holz FG, 2001, OPHTHALMOLOGE, V98, P10, DOI 10.1007/s003470170194
   Holz FG, 1999, INVEST OPHTH VIS SCI, V40, P737
   Imanishi Y, 2004, J CELL BIOL, V164, P373, DOI 10.1083/jcb.200311079
   KAISER W, 1961, PHYS REV LETT, V7, P229, DOI 10.1103/PhysRevLett.7.229
   KATZ ML, 1989, INVEST OPHTH VIS SCI, V30, P37
   KLEIN R, 1992, OPHTHALMOLOGY, V99, P933
   Mainen ZF, 1999, METHODS, V18, P231, DOI 10.1006/meth.1999.0776
   Periasamy A, 1999, MICROSC RES TECHNIQ, V47, P172, DOI 10.1002/(SICI)1097-0029(19991101)47:3<172::AID-JEMT3>3.0.CO;2-A
   Schutt F, 2000, INVEST OPHTH VIS SCI, V41, P2303
   Squirrell JM, 1999, NAT BIOTECHNOL, V17, P763, DOI 10.1038/11698
   Strathaus RS, 2005, FLEISCHWIRTSCHAFT, V85, P3
   vonRuckmann A, 1997, INVEST OPHTH VIS SCI, V38, P478
   vonRuckmann A, 1997, ARCH OPHTHALMOL-CHIC, V115, P609, DOI 10.1001/archopht.1997.01100150611006
   YOUNG RW, 1987, SURV OPHTHALMOL, V31, P291, DOI 10.1016/0039-6257(87)90115-9
   Zipfel Warren R., 2003, Nature Biotechnology, V21, P1369, DOI 10.1038/nbt899
   [No title captured]
   [No title captured]
   [No title captured]
   [No title captured]
   [No title captured]
NR 36
TC 17
Z9 18
U1 0
U2 10
PU SPIE-SOC PHOTO-OPTICAL INSTRUMENTATION ENGINEERS
PI BELLINGHAM
PA 1000 20TH ST, PO BOX 10, BELLINGHAM, WA 98225 USA
SN 1083-3668
EI 1560-2281
J9 J BIOMED OPT
JI J. Biomed. Opt.
PD NOV-DEC
PY 2008
VL 13
IS 6
AR 064008
DI 10.1117/1.2999607
PG 6
WC Biochemical Research Methods; Optics; Radiology, Nuclear Medicine &
   Medical Imaging
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Optics; Radiology, Nuclear Medicine &
   Medical Imaging
GA 403RY
UT WOS:000263100900014
PM 19123655
DA 2022-11-30
ER

PT J
AU Jaffe, GJ
   Schmitz-Valckenberg, S
   Boyer, D
   Heier, J
   Wolf-Schnurrbusch, U
   Staurenghi, G
   Schmidt-Erfurth, U
   Holz, FG
AF Jaffe, Glenn J.
   Schmitz-Valckenberg, Steffen
   Boyer, David
   Heier, Jeffrey
   Wolf-Schnurrbusch, Ute
   Staurenghi, Giovanni
   Schmidt-Erfurth, Ursula
   Holz, Frank G.
TI Randomized Trial to Evaluate Tandospirone in Geographic Atrophy
   Secondary to Age-Related Macular Degeneration: The GATE Study
SO AMERICAN JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
ID 5-HT1A RECEPTOR AGONIST; FUNDUS AUTOFLUORESCENCE; COMPLEMENT INHIBITION;
   PROGRESSION; PREVALENCE; MODELS
AB PURPOSE: To determine the safety and efficacy of AL-8309B (tandospirone) in the management of patients with geographic atrophy (GA) secondary to age-related macular degeneration (AMD) and obtain standardized data on GA lesion growth progression.
   DESIGN: Prospective, controlled, double-masked, ran-domized, multicenter phase 3 clinical trial.
   METHODS: SETTING: Forty-eight clinical sites. PATIENTS: Patients with GA associated with AMD were enrolled. All patients were followed for, a minimum of 30 months, and up to 36 months. INTERVENTION PROCEDURES: Patients were randomized (1:1:1) to receive AL8309B ophthalmic solution 1.0%, 1.75%, or vehicle, administered as a twice-daily topical ocular drop. MAIN OUTCOME MEASURES: The primary efficacy endpoint was mean annualized lesion enlargement from baseline as assessed with fundus autofluorescence (FAF) imaging.
   RESULTS: A total of 768 eyes of 768 patients were enrolled and treated with AL-8309B 1.0% (n = 250), AL-8309B 1.75% (n = 258), or vehicle (n = 260). An increase in mean lesion size was observed in both the AL-8309B and vehicle treatment groups, and growth rates were similar in all treatment groups. Annualized lesion growth rates were 1.73, 1.76, and 1.71 mm(2) for AL-8309B 1.0%, AL-8309B 1.75%, and vehicle, respectively,
   CONCLUSIONS: AL-8309B 1.0% and 1.75% did not affect lesion growth in eyes with GA secondary to AMD. There were no clinically relevant safety issues identified for AL-8309B. The large natural history dataset from this study is a valuable repository for future comparisons. (C) 2015 The Authors. Published by Elsevier Inc.
C1 [Jaffe, Glenn J.] Duke Univ, Dept Ophthalmol, Duke Reading Ctr, Durham, NC USA.
   [Schmitz-Valckenberg, Steffen; Holz, Frank G.] Univ Bonn, Dept Ophthalmol, D-53127 Bonn, Germany.
   [Schmitz-Valckenberg, Steffen; Holz, Frank G.] Univ Bonn, GRADE Reading Ctr, D-53127 Bonn, Germany.
   [Boyer, David] Retina Vitreous Associates Med Grp, Beverly Hills, CA USA.
   [Boyer, David] Univ So Calif, Keck Sch Med, Los Angeles, CA 90033 USA.
   [Heier, Jeffrey] Ophthalm Consultants Boston, Boston, MA USA.
   [Wolf-Schnurrbusch, Ute] Univ Bern, Inselspital, Univ Hosp, Photog Reading Ctr,Dept Ophthalmol, CH-3010 Bern, Switzerland.
   [Wolf-Schnurrbusch, Ute] Univ Bern, Bern, Switzerland.
   [Staurenghi, Giovanni] Univ Milan, Luigi Sacco Sacco Hosp, Dept Biomed & Clin Sci, Eye Clin, Milan, Italy.
   [Schmidt-Erfurth, Ursula] Med Univ Vienna, Dept Ophthalmol, Vienna, Austria.
C3 Duke University; University of Bonn; University of Bonn; Retina Vitreous
   Associates Medical Group; University of Southern California; Ophthalmic
   Consultants of Boston; University of Bern; University Hospital of Bern;
   University of Bern; University of Milan; Luigi Sacco Hospital; Medical
   University of Vienna
RP Holz, FG (通讯作者)，Univ Bonn, Dept Ophthalmol, Ernst Abbe Str 2, D-53127 Bonn, Germany.
EM Frank.Holz@ukb.uni-bonn.de
RI Wolf, Sebastian/B-8782-2008; Staurenghi, Giovanni/K-4388-2017
OI Wolf, Sebastian/0000-0002-7467-7028; Heier, Jeffrey/0000-0003-4625-3145;
   Schmidt-Erfurth, Ursula/0000-0002-7788-7311; Staurenghi,
   Giovanni/0000-0002-2299-5251
FU ALCON (FORT WORTH, TEXAS); ALLERGAN (DUBLIN, Ireland); Bayer Healthcare
   (Leverkusen, Germany); Heidelberg Engineering (Heidelberg, Germany);
   Genentech (San Francisco, California); Novartis (Basel, Switzerland);
   Roche (Basel, Switzerland)
FX F.H. RECEIVES RESEARCH GRANT SUPPORT FROM ALCON (FORT WORTH, TEXAS),
   ALLERGAN (DUBLIN, Ireland), Bayer Healthcare (Leverkusen, Germany),
   Heidelberg Engineering (Heidelberg, Germany), Genentech (San Francisco,
   California), Novartis (Basel, Switzerland), and Roche (Basel,
   Switzerland). Financial Disclosures: Glenn J. Jaffe is a consultant to
   Heidelberg Engineering. Ursula Schmidt- Erfurth is a consultant for
   Alcon, Boehringer Ingelheim (Ingelheim am Rhein, Rhineland-Palatinate,
   Germany), Bayer Healthcare, and Novartis, and performs contract research
   under the regulations of the Medical University of Vienna (Vienna,
   Austria). Frank G. Holz is a consultant for Alcon, Allergan, Bayer
   Healthcare, Heidelberg Engineering, Genentech, Novartis, and Roche.
   Jeffrey Heier is a consultant for Acucela (Seattle, Washington),
   Genentech, Janssen R&D (New Brunswick, New Jersey), Neurotech (Elm
   Grove, Wisconsin), Novartis, and Stealth BioTherapeutics (Newton,
   Massachusetts), and performs clinical research for Alcon, Acucela,
   Genentech, Novartis, and Stealth BioTherapeutics. The following authors
   have no financial disclosures: Steffen Schmitz-Valckenberg, David Boyer,
   Ute Wolf-Schnurrbusch, Giovanni Staurenghi. All authors attest that they
   meet the current ICMJE criteria for authorship.
CR Ach T, 2014, INVEST OPHTH VIS SCI, V55, P4832, DOI 10.1167/iovs.14-14802
   Ambati J, 2012, NEURON, V75, P26, DOI 10.1016/j.neuron.2012.06.018
   Beatty S, 2000, SURV OPHTHALMOL, V45, P115, DOI 10.1016/S0039-6257(00)00140-5
   BODEGREUEL KM, 1990, STROKE, V21, P164
   Campagne MV, 2014, J PATHOL, V232, P151, DOI 10.1002/path.4266
   Collier RJ, 2011, INVEST OPHTH VIS SCI, V52
   Crabb JW, 2002, P NATL ACAD SCI USA, V99, P14682, DOI 10.1073/pnas.222551899
   Garcia CAD, 2014, OSLI RETINA, V45, P18, DOI 10.3928/23258160-20131217-01
   Grunwald JE, 2015, OPHTHALMOLOGY, V122, P809, DOI 10.1016/j.ophtha.2014.11.007
   Gu XR, 2003, J BIOL CHEM, V278, P42027, DOI 10.1074/jbc.M305460200
   Holz FG, 2007, AM J OPHTHALMOL, V143, P463, DOI 10.1016/j.ajo.2006.11.041
   Holz FG, 2014, OPHTHALMOLOGY, V121, P1079, DOI 10.1016/j.ophtha.2013.11.023
   Kamei K, 2001, BIOORG MED CHEM LETT, V11, P595, DOI 10.1016/S0960-894X(01)00008-7
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1417, DOI 10.1001/archopht.119.10.1417
   Klein R, 2008, AM J OPHTHALMOL, V146, P692, DOI 10.1016/j.ajo.2008.05.050
   Kline AE, 2002, NEUROSCI LETT, V333, P179, DOI 10.1016/S0304-3940(02)01101-1
   Lindekleiv H, 2013, ACTA OPHTHALMOL, V91, P307, DOI 10.1111/j.1755-3768.2012.02399.x
   Mauler F, 2005, J CEREBR BLOOD F MET, V25, P451, DOI 10.1038/sj.jcbfm.9600038
   Milton RC, 2005, OPHTHALMOLOGY, V112, P533, DOI 10.1016/j.ophtha.2004.10.047
   Oosterink BJ, 1998, EUR J PHARMACOL, V358, P147, DOI 10.1016/S0014-2999(98)00614-1
   PREHN JHM, 1991, EUR J PHARMACOL, V203, P213, DOI 10.1016/0014-2999(91)90717-5
   Rudnicka AR, 2012, OPHTHALMOLOGY, V119, P571, DOI 10.1016/j.ophtha.2011.09.027
   Schmitz-Valckenberg S, 2011, INVEST OPHTH VIS SCI, V52, P7640, DOI 10.1167/iovs.11-7457
   Shen JK, 2007, HISTOL HISTOPATHOL, V22, P1301, DOI 10.14670/HH-22.1301
   Simader C, 2014, AM J OPHTHALMOL, V158, P557, DOI 10.1016/j.ajo.2014.05.026
   Sunness JS, 1999, OPHTHALMOLOGY, V106, P1768, DOI 10.1016/S0161-6420(99)90340-8
   Thampi P, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0034468
   Winkler BS, 1999, MOL VIS, V5
   Yehoshua Z, 2014, OPHTHALMOLOGY, V121, P693, DOI 10.1016/j.ophtha.2013.09.044
   Zarbin MA, 2010, RETINA-J RET VIT DIS, V30, P1350, DOI 10.1097/IAE.0b013e3181f57e30
NR 30
TC 42
Z9 43
U1 0
U2 7
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 0002-9394
EI 1879-1891
J9 AM J OPHTHALMOL
JI Am. J. Ophthalmol.
PD DEC
PY 2015
VL 160
IS 6
BP 1226
EP 1234
DI 10.1016/j.ajo.2015.08.024
PG 9
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA CW8IS
UT WOS:000365243400019
PM 26310670
OA Green Published, hybrid
DA 2022-11-30
ER

PT J
AU Ates, O
   Azizi, S
   Alp, HH
   Kiziltunc, A
   Beydemir, S
   Cinici, E
   Kocer, I
   Baykal, O
AF Ates, Orhan
   Azizi, Sedat
   Alp, H. Hakan
   Kiziltunc, Ahmet
   Beydemir, Sukru
   Cinici, Emine
   Kocer, Ibrahim
   Baykal, Orhan
TI Decreased Serum Paraoxonase 1 Activity and Increased Serum Homocysteine
   and Malondialdehyde Levels in Age-Related Macular Degeneration
SO TOHOKU JOURNAL OF EXPERIMENTAL MEDICINE
LA English
DT Article
DE age-related macular degeneration; paraoxonase; lipid peroxidation;
   homocysteine; oxidative stress
ID OXIDATIVE STRESS; LIPID-PEROXIDATION; NITRIC-OXIDE; RISK-FACTORS;
   FOLIC-ACID; PLASMA; ASSOCIATION; LIPOPROTEIN; PATHOGENESIS; VITAMIN-B12
AB Age-related macular degeneration (AMD) is one of the most common causes of vision loss. AMD has been classified into two forms: atrophic and exudative forms. The exudative form is associated with choroidal neovascularization of the subretinal macular region, resulting in a sudden loss of central vision. However, the exact cause of AMD remains unknown. Several risk factors have been postulated, including smoking, atherosclerosis, and low levels of antioxidant enzymes. Malondialdehyde (MDA), a lipid peroxidation product, is used as a marker of oxidative stress. Paraoxonase 1 (PON1) metabolizes lipid peroxides and prevents oxidation of low-density lipoprotein. Increased levels of homocysteine may cause vascular endothelial injury by releasing free radicals. The purpose of this study is to investigate the relationships between serum POW activity and the serum levels of homocysteine and MDA in AMD. Forty patients with exudative-type AMD (63.3 +/- 5 years) and 40 controls (61 +/- 4 years) were assessed in a cross-sectional study. The serum POW activity was significantly lower in the patients with AMD than that in the controls (p < 0.001). In contrast, the serum levels of MDA and homocysteine were significantly higher in the patients than those in the controls (p < 0.001, for both). In AMD patients, significant negative correlation was found between POW activity and MDA level (r = -0.493, p < 0.05) and between PON1 activity and homocysteine level (r = -0.557, p < 0.05). Increased serum homocysteine and MDA levels may be responsible for the decreased POW activity in patients with AMD.
C1 [Ates, Orhan] Ataturk Univ, Tip Fak, Goz Hastaliklari ABD, Dept Ophthalmol, TR-25100 Erzurum, Turkey.
   [Alp, H. Hakan; Kiziltunc, Ahmet] Ataturk Univ, Fac Med, Dept Biochem, TR-25100 Erzurum, Turkey.
   [Beydemir, Sukru] Ataturk Univ, Dept Chem, Sci & Arts Fac, TR-25100 Erzurum, Turkey.
C3 Ataturk University; Ataturk University; Ataturk University
RP Ates, O (通讯作者)，Ataturk Univ, Tip Fak, Goz Hastaliklari ABD, Dept Ophthalmol, TR-25100 Erzurum, Turkey.
EM orhanates69@hotmail.com
RI ALP, Hamit Hakan/U-2671-2018; Koçer, İbrahim/GXO-3707-2022
OI alp, hamit hakan/0000-0002-9202-4944
CR Delfino VDA, 2007, NUTRITION, V23, P242, DOI 10.1016/j.nut.2007.01.002
   Axer-Siegel R, 2004, AM J OPHTHALMOL, V137, P84, DOI 10.1016/S0002-9394(03)00864-X
   Baskol G, 2006, OPHTHALMOLOGICA, V220, P12, DOI 10.1159/000089269
   BASKOL G., 2004, ERCIYES MED J, V26, P7
   Beatty S, 2000, SURV OPHTHALMOL, V45, P115, DOI 10.1016/S0039-6257(00)00140-5
   COHEN SM, 1994, BRIT J OPHTHALMOL, V78, P791, DOI 10.1136/bjo.78.10.791
   Delcourt C, 1999, ARCH OPHTHALMOL-CHIC, V117, P1384, DOI 10.1001/archopht.117.10.1384
   Desmettre T, 2004, J FR OPHTALMOL, V27, p3S38
   Drobek-Slowik Monika, 2007, Postepy Hig Med Dosw (Online), V61, P28
   Evereklioglu C, 2003, DOC OPHTHALMOL, V106, P129, DOI 10.1023/A:1022512402811
   Feher J, 2005, OPHTHALMOLOGICA, V219, P154, DOI 10.1159/000085248
   Ferretti G, 2008, CLIN BIOCHEM, V41, P381, DOI 10.1016/j.clinbiochem.2007.12.011
   Genser D, 2006, ANN NUTR METAB, V50, P413, DOI 10.1159/000094632
   Gocmen AY, 2004, CLIN CARDIOL, V27, P426
   Gocmen YA, 2005, EUR J CARDIOV PREV R, V12, P185, DOI 10.1097/01.hjr.0000161442.11550.75
   HALLIWELL B, 1991, AM J MED S3C, V91, P14, DOI DOI 10.1016/0002-9343(91)90279-7
   Hankey GJ, 1999, LANCET, V354, P407, DOI 10.1016/S0140-6736(98)11058-9
   Harangi M, 2008, CEREBROVASC DIS, V25, P122, DOI 10.1159/000112322
   Ikeda T, 2001, AM J OPHTHALMOL, V132, P191, DOI 10.1016/S0002-9394(01)00975-8
   Irshad M., 2002, Indian Journal of Experimental Biology, V40, P1233
   Isik B, 2007, INHAL TOXICOL, V19, P767, DOI 10.1080/08958370701401418
   Jakubowski H, 1997, J BIOL CHEM, V272, P1935
   Jakubowski H, 2003, CLIN CHEM LAB MED, V41, P1462, DOI 10.1515/CCLM.2003.224
   Janel N, 2004, THROMB HAEMOSTASIS, V92, P221
   Kaemmerer E, 2007, INVEST OPHTH VIS SCI, V48, P1342, DOI 10.1167/iovs.06-0549
   Kamburoglu G, 2006, GRAEF ARCH CLIN EXP, V244, P565, DOI 10.1007/s00417-005-0108-2
   Kamei M, 2007, INVEST OPHTH VIS SCI, V48, P1801, DOI 10.1167/iovs.06-0699
   LEIBOVITZ BE, 1980, J GERONTOL, V35, P45, DOI 10.1093/geronj/35.1.45
   Marchegiani F, 2008, REJUV RES, V11, P113, DOI 10.1089/rej.2007.0582
   Nowak JZ, 2006, PHARMACOL REP, V58, P353
   Nowak M, 2005, EUR J OPHTHALMOL, V15, P764, DOI 10.1177/112067210501500617
   Nowak Michal, 2005, Klin Oczna, V107, P715
   Ohira Akihiro, 2008, Nippon Ganka Gakkai Zasshi, V112, P22
   Ozdemir R, 2004, AM J CARDIOL, V94, P522, DOI 10.1016/j.amjcard.2004.04.073
   Papandreou D, 2006, CLIN NUTR, V25, P797, DOI 10.1016/j.clnu.2006.02.006
   Papatheodorou L, 2007, ANTIOXID REDOX SIGN, V9, P1941, DOI 10.1089/ars.2007.1750
   Seddon JM, 2006, AM J OPHTHALMOL, V141, P201, DOI 10.1016/j.ajo.2005.07.059
   SEDDON JM, 1994, JAMA-J AM MED ASSOC, V272, P1413, DOI 10.1001/jama.272.18.1413
   STAMLER JS, 1993, J CLIN INVEST, V91, P308, DOI 10.1172/JCI116187
   UELAND PM, 1993, CLIN CHEM, V39, P1764
   Upchurch GR, 1997, J BIOL CHEM, V272, P17012, DOI 10.1074/jbc.272.27.17012
   Valko M, 2007, INT J BIOCHEM CELL B, V39, P44, DOI 10.1016/j.biocel.2006.07.001
   van Leeuwen R, 2003, ARCH OPHTHALMOL-CHIC, V121, P519, DOI 10.1001/archopht.121.4.519
   VINGERLING JR, 1995, AM J EPIDEMIOL, V142, P404, DOI 10.1093/oxfordjournals.aje.a117648
   Vingerling JR, 1996, ARCH OPHTHALMOL-CHIC, V114, P1193, DOI 10.1001/archopht.1996.01100140393005
   Wiggs JL, 2007, ARCH OPHTHALMOL-CHIC, V125, P1264, DOI 10.1001/archopht.125.9.1264
   Winkler BS, 1999, MOL VIS, V5
   YOUNG RW, 1988, SURV OPHTHALMOL, V32, P252, DOI 10.1016/0039-6257(88)90174-9
NR 48
TC 52
Z9 53
U1 0
U2 6
PU TOHOKU UNIV MEDICAL PRESS
PI SENDAI
PA 2-1, SEIRYO-MACHI, AOBA-KU, SENDAI, MIYAGI 980-8575, JAPAN
SN 0040-8727
EI 1349-3329
J9 TOHOKU J EXP MED
JI Tohoku J. Exp. Med.
PD JAN
PY 2009
VL 217
IS 1
BP 17
EP 22
DI 10.1620/tjem.217.17
PG 6
WC Medicine, General & Internal; Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine; Research & Experimental Medicine
GA 400VP
UT WOS:000262897800003
PM 19155603
OA Bronze
DA 2022-11-30
ER

PT J
AU Sarwar, S
   Clearfield, E
   Soliman, MK
   Sadiq, MA
   Baldwin, AJ
   Hanout, M
   Agarwal, A
   Sepah, YJ
   Do, DV
   Nguyen, QD
AF Sarwar, Salman
   Clearfield, Elizabeth
   Soliman, Mohamed Kamel
   Sadiq, Mohammad Ali
   Baldwin, Andrew J.
   Hanout, Mostafa
   Agarwal, Aniruddha
   Sepah, Yasir J.
   Do, Diana V.
   Quan Dong Nguyen
TI Aflibercept for neovascular age-related macular degeneration
SO COCHRANE DATABASE OF SYSTEMATIC REVIEWS
LA English
DT Review
ID ENDOTHELIAL GROWTH-FACTOR; OF-LIFE FINDINGS; FACTOR TRAP-EYE;
   INTRAVITREAL AFLIBERCEPT; VEGF-TRAP; CHOROIDAL NEOVASCULARIZATION;
   RANIBIZUMAB; INJECTION; BEVACIZUMAB; EFFICACY
AB Background
   Central vision loss caused by age-related macular degeneration (AMD) is the leading cause of blindness among the elderly in developed countries. Neovascular AMD is characterized by choroidal neovascularization (CNV). Growth of new blood vessels in patients with neovascular AMD is driven by a complex process that involves a signal protein called vascular endothelial growth factor A (VEGF-A). Anti-VEGF drugs that block this protein include ranibizumab, bevacizumab, and aflibercept.
   Objectives
   To assess and compare the effectiveness and safety of intravitreal injections of aflibercept versus ranibizumab, bevacizumab, or sham for treatment of patients with neovascular AMD.
   Search methods
   We searched the Cochrane Central Register of Controlled Trials (CENTRAL) (which contains the Cochrane Eyes and Vision Trials Register) (Issue 11, 2015), Ovid MEDLINE, Ovid MEDLINE In-Process and Other Non-Indexed Citations, Ovid MEDLINE Daily, Ovid OLDMEDLINE (January 1946 to November 2015), EMBASE (January 1980 to November 2015), PubMed (1948 to November 2015), Latin American and Caribbean Health Sciences Literature Database (LILACS) (1982 to November 2015), the metaRegister of Controlled Trials (mRCT) (www.controlled-trials.com) (last searched December 4, 2014), ClinicalTrials.gov (www.clinicaltrials.gov), and the World Health Organization (WHO) International Clinical Trials Registry Platform (ICTRP) (www.who.int/ictrp/search/en). We did not use any date or language restrictions in the electronic search for trials. We last searched the electronic databases on November 30, 2015.
   Selection criteria
   We included randomized controlled trials (RCTs) in which aflibercept monotherapy was compared with ranibizumab, bevacizumab, or sham for participants with neovascular AMD who were treatment-naive.
   Data collection and analysis
   We used standard methodological procedures of The Cochrane Collaboration for screening, data abstraction, and study assessment. Two review authors independently screened records, abstracted data, and assessed risk of bias of included studies; we resolved discrepancies by discussion or with the help of a third review author when needed.
   Main results
   We included two RCTs (total of 2457 participants, 2457 eyes). Trial participants had neovascular AMD with active subfoveal choroidal neovascular lesions. Both trials followed the same protocol and compared aflibercept at various doses versus ranibizumab, but they were carried out in different countries. One trial enrolled participants from the United States and Canada, and the second trial was conducted at 172 sites in Europe, Asia Pacific, Latin America, and the Middle East. The overall quality of the evidence was high, and included trials were at low risk for most bias domains assessed; however, both trials were funded by the manufacturers of aflibercept. For the purposes of analysis, we combined aflibercept groups regardless of dosing and analyzed them as a single group.
   Visual acuity outcomes were similar between aflibercept and ranibizumab groups; at one year, participants in the aflibercept groups showed mean change in best-corrected visual acuity (BCVA) from baseline similar to that of participants in the ranibizumab groups (mean difference (MD) -0.15 Early Treatment Diabetic Retinopathy Study (ETDRS) letters, 95% confidence interval (95% CI) -1.47 to 1.17; high-quality evidence). At two years, the mean change in BCVA from baseline was 7.2 ETDRS letters for aflibercept groups versus 7.9 for ranibizumab groups. Sufficient data were not available for calculation of confidence intervals.
   The proportion of participants who gained 15 or more letters of BCVA by one year of follow-up was approximately 32% for both aflibercept and ranibizumab (RR 0.97, 95% CI 0.85 to 1.11; high-quality evidence), and by two years of follow-up was approximately 31%(RR0.98, 95% CI 0.85 to 1.12; high-quality evidence). Similar small proportions of participants in the aflibercept and ranibizumab groups lost 15 or more letters of BCVA at one year (RR 0.89, 95% CI 0.61 to 1.30; high-quality evidence); this outcome was not reported for two-year follow-up. Data were not reported on the proportion of participants with BCVA worse than 20/200 at one-or two-year follow-up.
   Participants treated with aflibercept or ranibizumab showed similar improvement in morphological outcomes, as assessed from images (central retinal thickness and CNV size). At one year, the proportion of eyes that achieved dry retina was similar between aflibercept and ranibizumab groups (absence of cystic intraretinal fluid and subretinal fluid on optical coherence tomography (OCT); RR 1.06, 95% CI 0.98 to 1.14; high-quality evidence). In addition, investigators reported no difference in reduction of CNV area between aflibercept-and ranibizumab-treated eyes at one year (MD -0.24 mm(2), 95% CI -0.78 to 0.29; high-quality evidence). Data were not reported for the proportion of eyes with absence of leakage on fluorescein angiography at one-or two-year follow-up.
   Overall, occurrence of serious systemic adverse events was similar and comparable in aflibercept-and ranibizumab-treated groups at one year (RR 0.99, 95% CI 0.79 to 1.25). Risk of any serious ocular adverse event was lower in the aflibercept group than in the ranibizumab group, but the risk estimate is imprecise (RR 0.62, 95% CI 0.36 to 1.07). As the result of imprecision, we graded the quality of evidence for all adverse events as moderate.
   Authors' conclusions
   Results of this review document the comparative effectiveness of aflibercept versus ranibizumab for visual acuity and morphological outcomes in eyes with neovascular AMD. Current available information on adverse effects of each medication suggests that the safety profile of aflibercept is comparable with that of ranibizumab; however, the number of participants who experienced adverse events was small, leading to imprecise estimates of absolute and relative effect sizes. The eight-week dosing regimen of aflibercept represents reduced treatment requirements in comparison with monthly dosing regimens and thus has the potential to reduce treatment burden and risks associated with frequent injections.
C1 [Sarwar, Salman; Soliman, Mohamed Kamel; Sadiq, Mohammad Ali; Baldwin, Andrew J.; Hanout, Mostafa; Agarwal, Aniruddha; Sepah, Yasir J.; Do, Diana V.; Quan Dong Nguyen] Univ Nebraska Med Ctr, Stanley M Truhlsen Eye Inst, 3902 Leavenworth St, Omaha 68105, NE USA.
   [Clearfield, Elizabeth] Johns Hopkins Bloomberg Sch Publ Hlth, Dept Epidemiol, Baltimore, MD USA.
C3 University of Nebraska System; University of Nebraska Medical Center;
   Johns Hopkins University; Johns Hopkins Bloomberg School of Public
   Health
RP Sarwar, S (通讯作者)，Univ Nebraska Med Ctr, Stanley M Truhlsen Eye Inst, 3902 Leavenworth St, Omaha 68105, NE USA.
EM ss@oirrc.net
RI Soliman, Mohamed/M-4243-2019; Hanout, Mostafa/Q-6840-2017
OI Soliman, Mohamed/0000-0003-1671-8925; Hanout,
   Mostafa/0000-0001-7829-9776; Clearfield, Elizabeth/0000-0003-1789-6635
FU National Eye Institute, National Institutes of Health, USA [1 U01
   EY020522]; National Institute for Health Research (NIHR), UK; Department
   of Health through National Institute for Health Research to Moorfields
   Eye Hospital NHS Foundation Trust; UCL Institute of Ophthalmology for a
   Specialist Biomedical Research Centre for Ophthalmology; NIHR; NATIONAL
   EYE INSTITUTE [U01EY020522] Funding Source: NIH RePORTER
FX External sources; Elizabeth Clearfield works for the Cochrane Eyes and
   Vision US Project, supported by cooperative agreement 1 U01 EY020522,
   National Eye Institute, National Institutes of Health, USA.; National
   Institute for Health Research (NIHR), UK.; Richard Wormald,
   Co-ordinating Editor for the Cochrane Eyes and Vision (CEV) acknowledges
   financial support for his CEV research sessions from the Department of
   Health through the award made by the National Institute for Health
   Research to Moorfields Eye Hospital NHS Foundation Trust and UCL
   Institute of Ophthalmology for a Specialist Biomedical Research Centre
   for Ophthalmology.; The NIHR also funds the CEV Editorial Base in
   London.; The views expressed in this publication are those of the
   authors and not necessarily those of the NIHR, NHS, or the Department of
   Health.
CR Abba K, 2011, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD008122.pub2
   American Academy of Ophthalmology Retina/Vitreous Panel, 2015, PREF PRACT PATT GUID
   BIRD AEC, 1995, SURV OPHTHALMOL, V39, P367, DOI 10.1016/S0039-6257(05)80092-X
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Brown DM, 2011, OPHTHALMOLOGY, V118, P1089, DOI 10.1016/j.ophtha.2011.02.039
   Chakravarthy U, 2013, LANCET, V382, P1258, DOI 10.1016/S0140-6736(13)61501-9
   Chakravarthy U, 2010, BMC OPHTHALMOL, V10, DOI 10.1186/1471-2415-10-31
   Childs AL, 2004, OPHTHALMOLOGY, V111, P2007, DOI 10.1016/j.ophtha.2004.07.024
   Clemons TE, 2003, ARCH OPHTHALMOL-CHIC, V121, P211
   Do DV, 2012, OPHTHALMOLOGY, V119, P771, DOI 10.1016/j.ophtha.2011.10.019
   Elshout M, 2014, GRAEF ARCH CLIN EXP, V252, P1911, DOI 10.1007/s00417-014-2641-3
   Ferrara N, 2009, EUR CYTOKINE NETW, V20, P158, DOI 10.1684/ecn.2009.0170
   FINE AM, 1986, ARCH OPHTHALMOL-CHIC, V104, P513
   Freund KB, 2015, OPHTHALMOLOGY, V122, P1802, DOI 10.1016/j.ophtha.2015.04.018
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P564
   Haller JA, 2013, OPHTHALMOLOGY, V120, pS3, DOI 10.1016/j.ophtha.2013.01.057
   Heier JS, 2012, OPHTHALMOLOGY, V119, P2537, DOI 10.1016/j.ophtha.2012.09.006
   Heier JS, 2011, OPHTHALMOLOGY, V118, P1098, DOI 10.1016/j.ophtha.2011.03.020
   HIGGINS JPT, 2011, COCHRANE HDB SYSTEMA, V0001
   Holash J, 2002, P NATL ACAD SCI USA, V99, P11393, DOI 10.1073/pnas.172398299
   Hyman Leslie, 2002, Curr Opin Ophthalmol, V13, P171
   Jansen RM, 2013, MED LAW, V32, P65
   Lindblad AS, 2005, ARCH OPHTHALMOL-CHIC, V123, P1207
   Mangione CM, 1999, AM J OPHTHALMOL, V128, P45, DOI 10.1016/S0002-9394(99)00169-5
   Martin DF, 2011, NEW ENGL J MED, V364, P1897, DOI 10.1056/NEJMoa1102673
   Mejico LJ, 2004, AM J OPHTHALMOL, V137, P908, DOI 10.1016/j.ajo.2003.12.038
   Miskala PH, 2004, OPHTHALMOLOGY, V111, P1981, DOI 10.1016/j.ophtha.2004.07.022
   Mitchell P, 2012, CLIN EXP OPHTHALMOL, V40, P44
   Mitchell P, 2011, CURR MED RES OPIN, V27, P1465, DOI 10.1185/03007995.2011.585394
   Moja L, 2014, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD011230.pub2
   Nguyen QD, 2006, OPHTHALMOLOGY, V113, P1522, DOI 10.1016/j.ophtha.2006.05.055
   Nordic Cochrane Centre, 2014, REV MAN REVMAN COMP
   Ogura Y, 2015, BRIT J OPHTHALMOL, V99, P92, DOI 10.1136/bjophthalmol-2014-305076
   Richard G, 2015, OPHTHALMOLOGY, V122, P2497, DOI 10.1016/j.ophtha.2015.08.014
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Rudge JS, 2007, P NATL ACAD SCI USA, V104, P18363, DOI 10.1073/pnas.0708865104
   Sarwar S, 2014, COCHRANE DB SYST REV, DOI [10.1002/14651858.CD011346, DOI 10.1002/14651858.CD011346]
   Schmid MK, 2015, BRIT J OPHTHALMOL, V99, P141, DOI 10.1136/bjophthalmol-2014-305149
   Schmidt-Erfurth U, 2015, OPHTHALMOLOGY, V122, P822, DOI 10.1016/j.ophtha.2014.11.017
   Schmidt-Erfurth U, 2014, OPHTHALMOLOGY, V121, P193, DOI 10.1016/j.ophtha.2013.08.011
   Schmucker C, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0042701
   Schmucker C, 2010, CURR OPIN OPHTHALMOL, V21, P218, DOI 10.1097/ICU.0b013e3283386783
   Schultz DW, 2003, HUM MOL GENET, V12, P3315, DOI 10.1093/hmg/ddg348
   Solomon SD, 2014, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD005139.pub3
   Stewart MW, 2008, BRIT J OPHTHALMOL, V92, P667, DOI 10.1136/bjo.2007.134874
   Thomas M, 2013, CLIN OPHTHALMOL, V7, P495, DOI 10.2147/OPTH.S29974
   Thornton J, 2005, EYE, V19, P935, DOI 10.1038/sj.eye.6701978
   Wong T, 2008, OPHTHALMOLOGY, V115, P116, DOI 10.1016/j.ophtha.2007.03.008
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
   Yoshida I, 2014, GRAEF ARCH CLIN EXP, V252, P1483, DOI 10.1007/s00417-014-2717-0
   Yuzawa M, 2015, OPHTHALMOLOGY, V122, P571, DOI 10.1016/j.ophtha.2014.09.024
   Zehetner C, 2015, ACTA OPHTHALMOL, V93, pE154, DOI 10.1111/aos.12604
   Zinkernagel MS, 2015, INVEST OPHTH VIS SCI, V56, P1894, DOI 10.1167/iovs.14-16204
NR 53
TC 81
Z9 88
U1 0
U2 11
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1469-493X
EI 1361-6137
J9 COCHRANE DB SYST REV
JI Cochrane Database Syst Rev.
PY 2016
IS 2
AR CD011346
DI 10.1002/14651858.CD011346.pub2
PG 48
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine
GA DI1VP
UT WOS:000373285000073
PM 26857947
OA Green Accepted, Green Published
DA 2022-11-30
ER

PT J
AU Arnold, C
   Jentsch, S
   Dawczynski, J
   Bohm, V
AF Arnold, Christin
   Jentsch, Susanne
   Dawczynski, Jens
   Boehm, Volker
TI Age-related macular degeneration: Effects of a short-term intervention
   with an oleaginous kale extract-a pilot study
SO NUTRITION
LA English
DT Article
DE Lutein; Zeaxanthin; Kale; Maculopathy; Optical density
ID PIGMENT OPTICAL-DENSITY; VISUAL FUNCTION; SERUM LUTEIN; VITAMIN-C;
   CAROTENOIDS; ZEAXANTHIN; MACULOPATHY; NUTRITION; MELANIN; PLASMA
AB Objective: Age-related macular degeneration (AMD) is a multifactorial degenerative disease of the retina, which accounts for slowly progressive visual impairment in the elderly. An increased dietary intake of xanthophylls is suggested to be inversely related to the risk of macular disease.
   Methods: The present study was designed as a randomized, double-blind, placebo-controlled, parallel trial examining the influence of a short-term intervention with an oleaginous extract of Brassica oleracea var. sabellica L (kale) on plasma xanthophyll concentrations and the optical density of the macular pigment xanthophylls (MPOD). Twenty patients with non-exudative AMD were recruited for a 10-wk study period (2-wk run-in, 4-wk intervention, 4-wk washout). All participants received 50 mL of a beverage containing either an oleaginous extract of kale (kale) or refined rapeseed oil (placebo). The verum product provides 10 mg lutein and 3 mg zeaxanthin per day.
   Results: The concentrations of the xanthophylls in plasma and the MPOD increased significantly in the kale group after 4 wk of intervention. The successive washout period resulted in a significant decline of the values in plasma and macula. The values at the end of the study were still significantly higher than the initial values. Nevertheless, the improvements did not persist over 4 wk of washout.
   Conclusion: The distribution of the xanthophylls in the macula seems to be more dynamic than originally assumed. (C) 2013 Elsevier Inc. All rights reserved.
C1 [Arnold, Christin; Boehm, Volker] Univ Jena, Inst Nutr, Jena, Germany.
   [Jentsch, Susanne; Dawczynski, Jens] Univ Jena, Univ Eye Hosp, Jena, Germany.
C3 Friedrich Schiller University of Jena; Friedrich Schiller University of
   Jena
RP Bohm, V (通讯作者)，Univ Jena, Inst Nutr, Jena, Germany.
EM Volker.Boehm@uni-jena.de
FU Institut Danone Ernahrung fur Gesundheit e.V. (Germany)
FX This work was supported by Institut Danone Ernahrung fur Gesundheit e.V.
   (Germany). Special thanks go to BioActive Food GmbH (Germany) for the
   development and the production of the study beverages. The skillful
   technical support of Lisa Winter is gratefully acknowledged. Last but
   not least, a great thanks to all volunteers for participation.
CR Age-Related Eye Dis Study Res Grp, 2001, AM J OPHTHALMOL, V132, P668
   Anand R, 2000, OPHTHALMOLOGY, V107, P2224
   Berendschot TTJM, 2002, INVEST OPHTH VIS SCI, V43, P1928
   Bernstein PS, 2002, OPHTHALMOLOGY, V109, P1780, DOI 10.1016/S0161-6420(02)01173-9
   Bone RA, 2001, INVEST OPHTH VIS SCI, V42, P235
   Chakravarthy U, 2007, OPHTHALMOLOGY, V114, P1157, DOI 10.1016/j.ophtha.2006.09.022
   Dietzel M, 2011, INVEST OPHTH VIS SCI, V52, P3452, DOI 10.1167/iovs.10-6713
   Evans M, 2013, EUR J NUTR, V52, P1381, DOI 10.1007/s00394-012-0447-9
   Frohlich K, 2006, BRIT J NUTR, V95, P734, DOI 10.1079/BJN20051657
   Goodrow EF, 2006, J NUTR, V136, P2519, DOI 10.1093/jn/136.10.2519
   Hammond BR, 2013, INVEST OPHTH VIS SCI, V54, P476, DOI 10.1167/iovs.12-10411
   Jahn C, 2006, OPHTHALMOLOGE, V103, P136, DOI 10.1007/s00347-005-1282-7
   Jahn C, 2005, GRAEF ARCH CLIN EXP, V243, P222, DOI 10.1007/s00417-004-0995-7
   Kanis MJ, 2007, GRAEF ARCH CLIN EXP, V245, P767, DOI 10.1007/s00417-006-0478-0
   Landrum JT, 1997, EXP EYE RES, V65, P57, DOI 10.1006/exer.1997.0309
   LaRowe TL, 2008, OPHTHALMOLOGY, V115, P876, DOI 10.1016/j.ophtha.2007.06.015
   Ma L, 2012, OPHTHALMOLOGY, V119, P2290, DOI 10.1016/j.ophtha.2012.06.014
   Mares-Perlman JA, 2001, AM J EPIDEMIOL, V153, P424, DOI 10.1093/aje/153.5.424
   Mozaffarieh M, 2003, NUTR J, V2, DOI 10.1186/1475-2891-2-20
   Neuner B, 2009, ADDICT BEHAV, V34, P938, DOI 10.1016/j.addbeh.2009.05.015
   Obana A, 2008, OPHTHALMOLOGY, V115, P147, DOI 10.1016/j.ophtha.2007.02.028
   Pratt S, 1999, J Am Optom Assoc, V70, P39
   Richer Stuart, 2007, Optometry, V78, P213, DOI 10.1016/j.optm.2006.10.019
   Richer SP, 2011, OPTOMETRY, V82, P667, DOI 10.1016/j.optm.2011.08.008
   Roberts JE, 2011, EYE CONTACT LENS, V37, P246, DOI 10.1097/ICL.0b013e31821cbcc9
   Ros MM, 2012, AM J CLIN NUTR, V96, P902, DOI 10.3945/ajcn.111.032920
   Schweitzer D, 2010, J BIOMED OPT, V15, DOI 10.1117/1.3526358
   SEDDON JM, 1994, JAMA-J AM MED ASSOC, V272, P1413, DOI 10.1001/jama.272.18.1413
   Seybold C, 2004, J AGR FOOD CHEM, V52, P7005, DOI 10.1021/jf049169c
   TAYLOR HR, 1992, ARCH OPHTHALMOL-CHIC, V110, P99, DOI 10.1001/archopht.1992.01080130101035
   Tomany SC, 2004, ARCH OPHTHALMOL-CHIC, V122, P750, DOI 10.1001/archopht.122.5.750
   Trieschmann M, 2007, EXP EYE RES, V84, P718, DOI 10.1016/j.exer.2006.12.010
   van het Hof KH, 1999, AM J CLIN NUTR, V70, P261
   Wenzel AJ, 2006, J NUTR, V136, P2568, DOI 10.1093/jn/136.10.2568
NR 34
TC 15
Z9 15
U1 0
U2 31
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 0899-9007
EI 1873-1244
J9 NUTRITION
JI Nutrition
PD NOV-DEC
PY 2013
VL 29
IS 11-12
BP 1412
EP 1417
DI 10.1016/j.nut.2013.05.012
PG 6
WC Nutrition & Dietetics
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Nutrition & Dietetics
GA 241BW
UT WOS:000326142400022
PM 24103519
DA 2022-11-30
ER

PT J
AU Yaspan, BL
   Williams, DF
   Holz, FG
   Regillo, CD
   Li, ZR
   Dressen, A
   Campagne, MV
   Le, KN
   Graham, RR
   Beres, T
   Bhangale, TR
   Honigberg, LA
   Smith, A
   Henry, EC
   Ho, C
   Strauss, EC
AF Yaspan, Brian L.
   Williams, David F.
   Holz, Frank G.
   Regillo, Carl D.
   Li, Zhengrong
   Dressen, Amy
   Campagne, Menno van Lookeren
   Le, Kha N.
   Graham, Robert R.
   Beres, Tatiana
   Bhangale, Tushar R.
   Honigberg, Lee A.
   Smith, Ashley
   Henry, Erin C.
   Ho, Carole
   Strauss, Erich C.
CA MAHALO Study Investigators
TI Targeting factor D of the alternative complement pathway reduces
   geographic atrophy progression secondary to age-related macular
   degeneration
SO SCIENCE TRANSLATIONAL MEDICINE
LA English
DT Article
ID GENETIC-VARIANTS; HIGH-RISK; CFI GENE; ACTIVATION; SYSTEM; RANIBIZUMAB;
   FRAGMENT; DISEASE
AB Geographic atrophy is an advanced form of age-related macular degeneration (AMD) and a leading cause of vision loss for which there are no approved treatments. Genetic studies in AMD patients have implicated dys-regulation of the alternative complement pathway in the pathogenesis of geographic atrophy. Lampalizumab is a potential therapeutic that targets complement factor D, a pivotal activator of the alternative complement pathway. The MAHALO phase 2 clinical trial was a multicenter, randomized, controlled study that evaluated lampalizumab administered by intravitreal injection monthly (n = 42) and every other month (n = 41) versus sham control (n = 40) in patients with geographic atrophy secondary to AMD. The primary endpoint was the mean change in lesion area from baseline to month 18 as measured by fundus autofluorescence. Specific AMD-associated genetic polymorphisms were also analyzed. The MAHALO study met its primary efficacy endpoint with an acceptable safety profile; monthly lampalizumab treatment demonstrated a 20% reduction in lesion area progression versus sham control [80% confidence interval (CI), 4 to 37%]. A more substantial monthly treatment benefit of 44% reduction in geographic atrophy area progression versus sham control (95% CI, 15 to 73%) was observed in a subgroup of complement factor I (CFI) risk-allele carriers (57% of the patients analyzed were CFI risk-allele carriers). The MAHALO study shows a potential treatment effect in patients with geographic atrophy and supports therapeutic targeting of the alternative complement pathway for treating AMD pathogenesis.
C1 [Yaspan, Brian L.; Li, Zhengrong; Dressen, Amy; Campagne, Menno van Lookeren; Le, Kha N.; Graham, Robert R.; Beres, Tatiana; Bhangale, Tushar R.; Honigberg, Lee A.; Smith, Ashley; Henry, Erin C.; Ho, Carole; Strauss, Erich C.] Genentech Inc, San Francisco, CA 94080 USA.
   [Williams, David F.] VitreoRetinal Surg PA, Minneapolis, MN 55404 USA.
   [Holz, Frank G.] Univ Bonn, Dept Ophthalmol, Bonn, Germany.
   [Regillo, Carl D.] Wills Eye Hosp & Res Inst, Philadelphia, PA 19107 USA.
C3 Roche Holding; Genentech; University of Bonn; Jefferson University
RP Strauss, EC (通讯作者)，Genentech Inc, San Francisco, CA 94080 USA.
EM strauss.erich@gene.com
OI Yaspan, Brian/0000-0002-3787-2510
FU Genentech Inc.
FX Genentech Inc. supported and contributed to all aspects of the study,
   including the study design, data collection and analyses, statistical
   analyses, data interpretation, and report writing. Support for
   third-party writing assistance for this article was provided by the
   sponsor. All authors had access to the data, contributed to the
   manuscript, and provided approval for publication. The corresponding
   author had final responsibility for the decision to submit the
   manuscript for publication.
CR Altshuler D, 2005, NATURE, V437, P1299, DOI 10.1038/nature04226
   Ardlie KG, 2015, SCIENCE, V348, P648, DOI 10.1126/science.1262110
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Campagne MV, 2014, J PATHOL, V232, P151, DOI 10.1002/path.4266
   Cannistra SA, 2009, J CLIN ONCOL, V27, P3073, DOI 10.1200/JCO.2009.23.1811
   Do DV, 2014, RETINA-J RET VIT DIS, V34, P313, DOI 10.1097/IAE.0b013e3182979ddd
   Feuer WJ, 2013, JAMA OPHTHALMOL, V131, P110, DOI 10.1001/jamaophthalmol.2013.572
   Fritsche LG, 2013, NAT GENET, V45, P433, DOI 10.1038/ng.2578
   Gorin MB, 2012, MOL ASPECTS MED, V33, P467, DOI 10.1016/j.mam.2012.04.004
   Grassmann F, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0126636
   Holz FG, 2007, AM J OPHTHALMOL, V143, P463, DOI 10.1016/j.ajo.2006.11.041
   Holz FG, 2014, OPHTHALMOLOGY, V121, P1079, DOI 10.1016/j.ophtha.2013.11.023
   Holz FG, 2014, J CLIN INVEST, V124, P1430, DOI 10.1172/JCI71029
   Katschke KJ, 2012, J BIOL CHEM, V287, P12886, DOI 10.1074/jbc.M112.345082
   Kavanagh D, 2015, HUM MOL GENET, V24, P3861, DOI 10.1093/hmg/ddv091
   Le KN, 2015, CPT-PHARMACOMET SYST, V4, P595, DOI 10.1002/psp4.12031
   Lim LS, 2012, LANCET, V379, P1728, DOI 10.1016/S0140-6736(12)60282-7
   Loyet KM, 2014, J PHARMACOL EXP THER, V351, P527, DOI 10.1124/jpet.114.215921
   Loyet KM, 2012, INVEST OPHTH VIS SCI, V53, P6628, DOI 10.1167/iovs.12-9587
   McHarg S, 2015, MOL IMMUNOL, V67, P43, DOI 10.1016/j.molimm.2015.02.032
   Pau G., HTSEQGENIE NGS ANAL
   Ricklin D, 2010, NAT IMMUNOL, V11, P785, DOI 10.1038/ni.1923
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Rubinstein L, 2009, CLIN CANCER RES, V15, P1883, DOI 10.1158/1078-0432.CCR-08-2031
   Scholl HPN, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002593
   Schramm EC, 2014, MOL IMMUNOL, V61, P118, DOI 10.1016/j.molimm.2014.06.032
   Seddon JM, 2013, NAT GENET, V45, P1366, DOI 10.1038/ng.2741
   Stanton CM, 2011, INVEST OPHTH VIS SCI, V52, P8828, DOI 10.1167/iovs.11-7933
   Sunness JS, 1997, OPHTHALMOLOGY, V104, P1677, DOI 10.1016/S0161-6420(97)30079-7
   van de Ven JPH, 2013, NAT GENET, V45, P813, DOI 10.1038/ng.2640
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
   Wu C, 2009, GENOME BIOL, V10, DOI 10.1186/gb-2009-10-11-r130
   Wu TD, 2010, BIOINFORMATICS, V26, P873, DOI 10.1093/bioinformatics/btq057
NR 33
TC 105
Z9 105
U1 0
U2 7
PU AMER ASSOC ADVANCEMENT SCIENCE
PI WASHINGTON
PA 1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA
SN 1946-6234
EI 1946-6242
J9 SCI TRANSL MED
JI Sci. Transl. Med.
PD JUN 21
PY 2017
VL 9
IS 395
AR eaaf1443
DI 10.1126/scitranslmed.aaf1443
PG 13
WC Cell Biology; Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Cell Biology; Research & Experimental Medicine
GA EY2HJ
UT WOS:000403788900001
PM 28637922
DA 2022-11-30
ER

PT J
AU Lamin, A
   Oakley, JD
   Dubis, AM
   Russakoff, DB
   Sivaprasad, S
AF Lamin, Ali
   Oakley, Jonathan D.
   Dubis, Adam M.
   Russakoff, Daniel B.
   Sivaprasad, Sobha
TI Changes in volume of various retinal layers over time in early and
   intermediate age-related macular degeneration
SO EYE
LA English
DT Article
ID GANGLION-CELL COMPLEX; ABNORMALITIES; MACULOPATHY; THICKNESS; DRUSEN;
   RAT
AB Purpose To evaluate longitudinally volume changes in inner and outer retinal layers in early and intermediate age-related macular degeneration (AMD) compared to healthy control eyes using optical coherence tomography (OCT).
   Methods 71 eyes with AMD and 31 control eyes were imaged at two time points: baseline and after 2 years. Automated OCT layer segmentation was performed using Orion (TM). This software is able to measure volumes of retinal layers with distinct boundaries including Retinal Nerve Fibre Layer (RNFL), Ganglion Cell-Inner Plexiform Layer (GCIPL), Inner Nuclear Layer (INL), Outer Plexiform Layer (OPL), Outer Nuclear Layer (ONL), Photoreceptors (PR) and Retinal Pigment Epithelium-Bruch's Membrane complex (RPE-BM). The mean retinal layer volumes and volume changes at 2 years were compared between groups.
   Results Mean GCIPL and INL volumes were lower, while PR and RPE-BM volumes were higher in AMD eyes than controls at baseline (all P < 0.05) and year 2 (all P < 0.05). In AMD eyes, RNFL and ONL volumes decreased by 0.0232 (P = 0.033) and 0.0851 (P = 0.001), respectively. In contrast, OPL and RPE-BM volumes increased in AMD eyes by 0.0391 (P = 0.000) and 0.0209 (P = 0.000) respectively. Moreover, there were significant differences in longitudinal volume change of OPL (P = 0.02), ONL (P = 0.008) and RPE-BM (P = 0.02) between AMD eyes and controls.
   Conclusions There were abnormal retinal layer volumes and volume changes in eyes with early and intermediate AMD.
C1 [Lamin, Ali; Dubis, Adam M.; Sivaprasad, Sobha] Moorfields Eye Hosp NHS Fdn Trust, NIHR Moorfields Biomed Res Ctr, London, England.
   [Lamin, Ali; Dubis, Adam M.; Sivaprasad, Sobha] UCL Inst Ophthalmol, London, England.
   [Oakley, Jonathan D.; Russakoff, Daniel B.] Voxeleron LLC, Pleasanton, CA USA.
C3 University of London; University College London; Moorfields Eye Hospital
   NHS Foundation Trust; University of London; University College London
RP Sivaprasad, S (通讯作者)，Moorfields Eye Hosp NHS Fdn Trust, NIHR Moorfields Biomed Res Ctr, London, England.; Sivaprasad, S (通讯作者)，UCL Inst Ophthalmol, London, England.
EM sobha.sivaprasad@moorfields.nhs.uk
RI Sivaprasad, S./D-6876-2015
OI Sivaprasad, S./0000-0001-8952-0659
FU National Institute for Health Research (NIHR) Biomedical Research Centre
   based at Moorfields Eye Hospital NHS Foundation Trust; UCL Institute of
   Ophthalmology
FX The research was supported by the National Institute for Health Research
   (NIHR) Biomedical Research Centre based at Moorfields Eye Hospital NHS
   Foundation Trust and UCL Institute of Ophthalmology. The views expressed
   are those of the author(s) and not necessarily those of the NHS, the
   NIHR or the Department of Health.
CR Behbehani R, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0172120
   Borrelli E, 2017, AM J OPHTHALMOL, V181, P1, DOI 10.1016/j.ajo.2017.06.005
   Camacho P, 2017, OPHTHALMOLOGICA, V238, P31, DOI 10.1159/000468965
   Campochiaro P A, 1999, Mol Vis, V5, P34
   Curcio CA, 1996, INVEST OPHTH VIS SCI, V37, P1236
   Feigl B, 2007, EYE, V21, P689, DOI 10.1038/sj.eye.6702389
   Ferrara D, 2017, INVEST OPHTH VIS SCI, V58, P3519, DOI 10.1167/iovs.17-21696
   FERRIS FL, 1984, ARCH OPHTHALMOL-CHIC, V102, P1640
   Ferris FL, 2013, OPHTHALMOLOGY, V120, P844, DOI 10.1016/j.ophtha.2012.10.036
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P564
   GARTNER S, 1981, BRIT J OPHTHALMOL, V65, P23, DOI 10.1136/bjo.65.1.23
   GREEN WR, 1993, OPHTHALMOLOGY, V100, P1519
   Hartmann KI, 2012, RETINA-J RET VIT DIS, V32, P1492, DOI 10.1097/IAE.0b013e318242b949
   Jackson GR, 2002, AGEING RES REV, V1, P381, DOI 10.1016/S1568-1637(02)00007-7
   Lee EK, 2015, INVEST OPHTH VIS SCI, V56, P3976, DOI 10.1167/iovs.15-17013
   Machida S, 2000, INVEST OPHTH VIS SCI, V41, P3200
   Medeiros NE, 2001, INVEST OPHTH VIS SCI, V42, P795
   Muftuoglu IK, 2017, RETINA, V38, P1478
   Resnikoff S, 2004, B WORLD HEALTH ORGAN, V82, P844
   Sadigh S, 2015, CURR EYE RES, V40, P398, DOI 10.3109/02713683.2014.925934
   Sadigh S, 2013, INVEST OPHTH VIS SCI, V54, P1603, DOI 10.1167/iovs.12-11286
   Savastano MC, 2014, INVEST OPHTH VIS SCI, V55, P560, DOI 10.1167/iovs.13-12172
   Schuman SG, 2009, OPHTHALMOLOGY, V116, P488, DOI 10.1016/j.ophtha.2008.10.006
   Shelley EJ, 2009, ARCH OPHTHALMOL-CHIC, V127, P483, DOI 10.1001/archophthalmol.2008.622
   Strettoi E, 2002, J NEUROSCI, V22, P5492
   Tan J, 2016, CLIN OPHTHALMOL, V10, P2403, DOI 10.2147/OPTH.S117494
   Terry L, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0162001
   Toto L, 2017, BRIT J OPHTHALMOL, V101, P774, DOI 10.1136/bjophthalmol-2016-309160
   Toto L, 2016, RETINA-J RET VIT DIS, V36, P1566, DOI 10.1097/IAE.0000000000000962
   van Leeuwen R, 2003, EUR J EPIDEMIOL, V18, P845, DOI 10.1023/A:1025643303914
   Villegas-Perez MP, 1998, J COMP NEUROL, V392, P58, DOI 10.1002/(SICI)1096-9861(19980302)392:1<58::AID-CNE5>3.0.CO;2-O
   Yenice E, 2015, EYE, V29, P1076, DOI 10.1038/eye.2015.86
   Zucchiatti I, 2015, AM J OPHTHALMOL, V160, P602, DOI 10.1016/j.ajo.2015.05.030
NR 33
TC 33
Z9 33
U1 0
U2 7
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 0950-222X
EI 1476-5454
J9 EYE
JI Eye
PD MAR
PY 2019
VL 33
IS 3
BP 428
EP 434
DI 10.1038/s41433-018-0234-9
PG 7
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA HN9UD
UT WOS:000460544800015
PM 30310161
OA Green Published, Bronze
DA 2022-11-30
ER

PT J
AU Robison, CD
   Jivrajka, RV
   Bababeygy, SR
   Fink, W
   Sadun, AA
   Sebag, J
AF Robison, Craig D.
   Jivrajka, Renu V.
   Bababeygy, Simon R.
   Fink, Wolfgang
   Sadun, Alfredo A.
   Sebag, J.
TI Distinguishing wet from dry age-related macular degeneration using
   three-dimensional computer-automated threshold Amsler grid testing
SO BRITISH JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
ID PREFERENTIAL HYPERACUITY PERIMETER; VISUAL-FIELD TEST; BEVACIZUMAB
   AVASTIN; UNITED-STATES; IMPAIRMENT; PREVALENCE; POPULATION; BLINDNESS;
   SCOTOMAS; GLAUCOMA
AB Background/aims With the increased efficacy of current therapy for wet age-related macular degeneration (AMD), better ways to detect wet AMD are needed. This study was designed to test the ability of three-dimensional contrast threshold Amsler grid (3D-CTAG) testing to distinguish wet AMD from dry AMD.
   Methods Conventional paper Amsler grid and 3D-CTAG tests were performed in 90 eyes: 63 with AMD (34 dry, 29 wet) and 27 controls. Qualitative comparisons were based upon the three-dimensional shapes of central visual field (VF) defects. Quantitative analyses considered the number and volume of the three-dimensional defects.
   Results 25/34 (74%) dry AMD and 6/29 (21%) wet AMD eyes had no distortions on paper Amsler grid. Of these, 5/25 (20%) dry and 6/6 (100%) wet (p=0.03) AMD eyes exhibited central VF defects with 3D-CTAG. Wet AMD displayed stepped defects in 16/28 (57%) eyes, compared with only 2/34 (6%) of dry AMD eyes (p=0.002). All three volumetric indices of VF defects were two- to four-fold greater in wet than dry AMD (p<0.006). 3D-CTAG had 83.9% positive and 90.6% negative predictive values for wet AMD.
   Conclusions 3D-CTAG has a higher likelihood of detecting central VF defects than conventional Amsler grid, especially in wet AMD. Wet AMD can be distinguished from dry AMD by qualitative and quantitative 3D-CTAG criteria. Thus, 3D-CTAG may be useful in screening for wet AMD, quantitating disease severity, and providing a quantitative outcome measure of therapy.
C1 [Robison, Craig D.; Jivrajka, Renu V.; Bababeygy, Simon R.; Sebag, J.] VMR Inst, Huntington Beach, CA 92647 USA.
   [Robison, Craig D.; Jivrajka, Renu V.; Bababeygy, Simon R.; Fink, Wolfgang; Sadun, Alfredo A.; Sebag, J.] Univ So Calif, Doheny Eye Inst, Keck Sch Med, Los Angeles, CA USA.
   [Fink, Wolfgang] CALTECH, Visual & Autonomous Explorat Syst Res Lab, Pasadena, CA 91125 USA.
   [Fink, Wolfgang] Univ Arizona, Dept Elect & Comp Engn & Biomed Engn, Tucson, AZ USA.
C3 Doheny Eye Institute; University of Southern California; California
   Institute of Technology; University of Arizona
RP Sebag, J (通讯作者)，VMR Inst, 7677 Ctr Ave,Suite 400, Huntington Beach, CA 92647 USA.
EM jsebag@VMRinstitute.com
RI Sebag, J./AAF-3602-2020
OI Sebag, J/0000-0001-8648-5747
FU NIH [EY03040]; NATIONAL EYE INSTITUTE [P30EY003040] Funding Source: NIH
   RePORTER
FX VMR Consulting, Inc., Huntington Beach, California, USA (study design;
   collection, analysis and interpretation of data; writing of article;
   decision to submit article); NIH grant EY03040 (no involvement in study
   design, analysis, interpretation, writing, or decision to submit).
CR Ahlers C, 2010, INVEST OPHTH VIS SCI, V51, P2149, DOI 10.1167/iovs.09-3817
   Alster Y, 2005, OPHTHALMOLOGY, V112, P1758, DOI 10.1016/j.ophtha.2005.06.008
   AMSLER M, 1953, BRIT J OPHTHALMOL, V37, P521, DOI 10.1136/bjo.37.9.521
   Avery RL, 2006, OPHTHALMOLOGY, V113, P363, DOI 10.1016/j.ophtha.2005.11.019
   Congdon N, 2004, ARCH OPHTHALMOL-CHIC, V122, P477
   Crossland M, 2007, BRIT J OPHTHALMOL, V91, P391, DOI 10.1136/bjo.2006.095315
   Fink W, 2004, J BIOMED OPT, V9, P149, DOI 10.1117/1.1625952
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P564
   Goldstein M, 2005, RETINA-J RET VIT DIS, V25, P296
   Heijl A, 1995, Curr Opin Ophthalmol, V6, P46
   Jivrajka R, 2009, GRAEF ARCH CLIN EXP, V247, P165, DOI 10.1007/s00417-008-0971-8
   KATZ J, 1986, ARCH OPHTHALMOL-CHIC, V104, P65
   Kim JK, 2008, CLIN EXP OPHTHALMOL, V36, P484, DOI 10.1111/j.1442-9071.2008.01807.x
   Klaver CCW, 1998, ARCH OPHTHALMOL-CHIC, V116, P653, DOI 10.1001/archopht.116.5.653
   Mills R P, 1984, J Am Intraocul Implant Soc, V10, P347
   Munoz B, 2000, ARCH OPHTHALMOL-CHIC, V118, P819, DOI 10.1001/archopht.118.6.819
   Nazemi PP, 2007, BRIT J OPHTHALMOL, V91, P1331, DOI 10.1136/bjo.2007.116103
   Nazemi PP, 2005, RETINA-J RET VIT DIS, V25, P446, DOI 10.1097/00006982-200506000-00009
   Nguyen DT, 2009, EUR J OPHTHALMOL, V19, P776, DOI 10.1177/112067210901900515
   Prager F, 2008, RETINA-J RET VIT DIS, V28, P682, DOI 10.1097/IAE.0b013e318161dc70
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   SCHUCHARD RA, 1993, ARCH OPHTHALMOL-CHIC, V111, P776, DOI 10.1001/archopht.1993.01090060064024
   Schwabe R, 2001, PERIMETRY UPDATE 2000/2001, P71
   Wang JJ, 2000, CLIN EXP OPHTHALMOL, V28, P268, DOI 10.1046/j.1442-9071.2000.00315.x
NR 24
TC 12
Z9 14
U1 1
U2 13
PU B M J PUBLISHING GROUP
PI LONDON
PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND
SN 0007-1161
J9 BRIT J OPHTHALMOL
JI Br. J. Ophthalmol.
PD OCT
PY 2011
VL 95
IS 10
BP 1419
EP 1423
DI 10.1136/bjo.2010.194886
PG 5
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 822VL
UT WOS:000295078000018
PM 21270434
OA Green Accepted
DA 2022-11-30
ER

PT J
AU Li, CX
   Li, JQ
   Chen, XZ
   Lu, PR
AF Li, Caixin
   Li, Jianqing
   Chen, Xinzhu
   Lu, Peirong
TI Laser-induced choroidal neovascularization A case report and some
   reflection on animal models for age-related macular degeneration
SO MEDICINE
LA English
DT Article
DE age-related macular degeneration; antivascular endothelial growth
   factor; case report; choroidal neovascularization; laser
ID INJURY; EYE
AB Rationale: Laser induced maculopathy includes retinal photoreceptor disruption, macular hole, macular hemorrhage, and rarely choroidal neovascularization (CNV). Here we report a case of laser induced CNV that was treated by intravitreal anti-vascular endothelial growth factor (VEGF) injection and resulted in visual improvement and CNV resolution during 1-year follow up. In addition, the case of laser induced CNV treated with intravitreal anti-VEGF injections are reviewed for the first time in literature. Patient concerns: A 7-year-old boy presented to our department with blurred vision in his right eye for 2 months. The symptom immediately happened after the boy staring at the laser beam for a few seconds. Examination of ocular fundus with slit lamp showed yellowish lesion in macula in his right eye. Diagnoses: CNV was confirmed by fundus examinations, including color fundus photograph, spectral domain optical coherence tomography, fluorescein angiography, and spectral domain optical coherence tomography angiography. Interventions: After the diagnosis of laser induced CNV, intravitreal ranibizumab (LUCENTIS, NOVARTIS) injection was performed. Outcomes: After 1 injection of intravitreal ranibizumab, the best corrected visual acuity improved from 20/50 to 30/50 and CNV gradually regressed during 1-year follow up. Lessons: For young patients with laser induced CNV, intravitreal anti-VEGF injections may be helpful in visual improvement and CNV regression. Moreover, age seems to be a significant factor thus we propose that old animals may be more appropriate for laser induced CNV animal models of age-related macular degeneration.
C1 [Li, Caixin; Li, Jianqing; Lu, Peirong] Soochow Univ, Dept Ophthalmol, Affiliated Hosp 1, 188 Shizi St, Suzhou, Jiangsu, Peoples R China.
   [Chen, Xinzhu] Suzhou EENT Hosp, Dept Ophthalmol, Suzhou, Jiangsu, Peoples R China.
C3 Soochow University - China
RP Lu, PR (通讯作者)，Soochow Univ, Dept Ophthalmol, Affiliated Hosp 1, 188 Shizi St, Suzhou, Jiangsu, Peoples R China.
EM lupeirong@suda.edu.cn
FU National Natural Science Foundation in China (NSFC) [81671641]; Jiangsu
   Provincial Medical Innovation Team [CXTDA2017039]; Jiangsu Provincial
   Natural Science Foundation [BK20151208]; Soochow Scholar Project of
   Soochow University [R5122001]
FX This work was supported by the National Natural Science Foundation in
   China (NSFC) (81671641), Jiangsu Provincial Medical Innovation Team
   (CXTDA2017039), Jiangsu Provincial Natural Science Foundation
   (BK20151208), and the Soochow Scholar Project of Soochow University
   (R5122001).
CR Alsulaiman SM, 2014, OPHTHALMOLOGY, V121, P566, DOI 10.1016/j.ophtha.2013.09.006
   Barkana Y, 2000, SURV OPHTHALMOL, V44, P459, DOI 10.1016/S0039-6257(00)00112-0
   Chang CY, 2018, OPHTHAL PLAST RECONS, V34, pE129, DOI 10.1097/IOP.0000000000001142
   Diafas A, 2020, CUREUS, V12, DOI 10.7759/cureus.8294
   Espinosa-Heidmann DG, 2002, INVEST OPHTH VIS SCI, V43, P1567
   Forshaw TRJ, 2018, ACTA OPHTHALMOL, V96, pE899, DOI 10.1111/aos.13743
   Grossniklaus HE, 2010, PROG RETIN EYE RES, V29, P500, DOI 10.1016/j.preteyeres.2010.05.003
   KEARNEY JJ, 1987, LASER SURG MED, V7, P499, DOI 10.1002/lsm.1900070611
   Lee YH, 2019, MEDICINE, V98, DOI 10.1097/MD.0000000000015429
   Mtanes K, 2018, J PEDIAT OPHTH STRAB, V55, P312, DOI 10.3928/01913913-20180405-01
   Raoof N, 2014, EYE, V28, P231, DOI 10.1038/eye.2013.315
   Rastoin O, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21134627
   Scollo P, 2014, OCCUP MED-OXFORD, V64, P220, DOI 10.1093/occmed/kqt165
   Sun ZH, 2006, GRAEF ARCH CLIN EXP, V244, P888, DOI 10.1007/s00417-005-0169-2
   Tofolean Ioana Teodora, 2019, Rom J Ophthalmol, V63, P281
   Tran K, 2020, EYE, V34, P1958, DOI 10.1038/s41433-020-0830-3
   US Food and Drug Administration, 2017, IMP INF LAS POINT MA
   Veronese Chiara, 2016, Am J Ophthalmol Case Rep, V2, P37
   Xu KY, 2016, PEDIATRICS, V138, DOI 10.1542/peds.2016-1188
   Young S, 1998, CLIN DERMATOL, V16, P477, DOI 10.1016/S0738-081X(98)00021-2
NR 20
TC 0
Z9 0
U1 2
U2 2
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0025-7974
EI 1536-5964
J9 MEDICINE
JI Medicine (Baltimore)
PD JUN 11
PY 2021
VL 100
IS 23
AR e26239
DI 10.1097/MD.0000000000026239
PG 4
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine
GA SS3FH
UT WOS:000661625000034
PM 34115011
OA gold, Green Published
DA 2022-11-30
ER

PT J
AU Nguyen, QD
   Schachar, RA
   Nduaka, CI
   Sperling, M
   Basile, AS
   Klamerus, KJ
   Chi-Burris, K
   Yan, E
   Paggiarino, DA
   Rosenblatt, I
   Khan, A
   Aitchison, R
   Erlich, SS
AF Nguyen, Q. D.
   Schachar, R. A.
   Nduaka, C. I.
   Sperling, M.
   Basile, A. S.
   Klamerus, K. J.
   Chi-Burris, K.
   Yan, E.
   Paggiarino, D. A.
   Rosenblatt, I.
   Khan, A.
   Aitchison, R.
   Erlich, S. S.
CA PF-04523655 Study Grp
TI Phase 1 dose-escalation study of a siRNA targeting the RTP801 gene in
   age-related macular degeneration patients
SO EYE
LA English
DT Article
DE siRNA; neovascular age-related macular degeneration; phase 1
ID RANIBIZUMAB; BEVACIZUMAB; REDD1
AB Background To evaluate the safety, tolerability, pharmacokinetics, and dose-limiting toxicities of a single intravitreal (IVT) injection of PF-04523655, a 19-nucleotide, O-methyl stabilized, double-stranded small interfering ribonucleic acid targeting the RTP801 gene in patients with neovascular age-related macular degeneration (AMD).
   Methods Prospective, phase 1, clinical multicentre trial, enrolled 27 patients with neovascular AMD unresponsive to prior treatment and best corrected visual acuity (BCVA) <= 20/200 in the study eye in stratum 1: (dose-escalating, open-label: 50 to 3000 mu g of PF-04523655) and 27 patients who had potential to benefit from therapy and BCVA of <= 20/100 and >= 20/800 in stratum 2 (parallel, masked study of 1000, 1500, 2250, and 3000 mu g of PF-04523655). The primary outcome was safety and tolerability assessment as well as pharmacokinetic profiling following a single IVT injection of PF-04523655.
   Results Doses of PF-04523655 >= 400 mu g were generally detectable in the plasma at 1, 4, and 24 h post-injection. And all doses were below the lowest level of quantification by day 14. A single IVT injection of 50 to 3000 mu g of PF-045237655 was generally safe and well tolerated over 24 months. There were no dose-limiting toxicities.
   Conclusion A single IVT injection of PF-0523655 <= 3000 mu g seems safe and well tolerated in eyes with neovascular AMD. Eye (2012) 26, 1099-1105; doi: 10.1038/eye.2012.106; published online 25 May 2012
C1 [Schachar, R. A.; Nduaka, C. I.; Sperling, M.; Basile, A. S.; Klamerus, K. J.; Chi-Burris, K.; Yan, E.; Paggiarino, D. A.] Pfizer Inc, San Diego, CA 92121 USA.
   [Nguyen, Q. D.] Johns Hopkins Univ, Wilmer Eye Inst, Baltimore, MD 21218 USA.
   [Rosenblatt, I.] Rabin Med Ctr, Petah Tiqwa, Israel.
   [Khan, A.; Aitchison, R.; Erlich, S. S.] Quark Pharmaceut Inc, Fremont, CA USA.
C3 Pfizer; Johns Hopkins University; Johns Hopkins Medicine; Rabin Medical
   Center
RP Schachar, RA (通讯作者)，Pfizer Inc, 10646 Sci Ctr Dr,CB10-2109, San Diego, CA 92121 USA.
EM ronald.schachar@pfizer.com
OI Kaiser, Peter/0000-0001-5126-045X
FU Pfizer Inc. San Diego, California, USA
FX This study was supported by Pfizer Inc. San Diego, California, USA.
CR Avery RL, 2006, OPHTHALMOLOGY, V113, P363, DOI 10.1016/j.ophtha.2005.11.019
   Brafman A, 2004, INVEST OPHTH VIS SCI, V45, P3796, DOI 10.1167/iovs.04-0052
   Ellisen LW, 2002, MOL CELL, V10, P995, DOI 10.1016/S1097-2765(02)00706-2
   Feinstein E, 2009, INVEST OPHTHALMOL VI, V50
   Heier JS, 2011, OPHTHALMOLOGY, V118, P1098, DOI 10.1016/j.ophtha.2011.03.020
   Jin HO, 2007, CELL SIGNAL, V19, P1393, DOI 10.1016/j.cellsig.2006.12.014
   Jonasson F, 2011, OPHTHALMOLOGY, V118, P825, DOI 10.1016/j.ophtha.2010.08.044
   Kaiser PK, 2010, AM J OPHTHALMOL, V150, P33, DOI 10.1016/j.ajo.2010.02.006
   KLEIN R, 1992, OPHTHALMOLOGY, V99, P933
   Martin DF, 2011, NEW ENGL J MED, V364, P1897, DOI 10.1056/NEJMoa1102673
   Perkel JM, 2009, SCIENCE, V326, P454, DOI 10.1126/science.opms.p0900039
   Rittenhouse KD, 2010, INVEST OPHTH VIS SCI, V51
   Rittenhouse KD, 2011, INVEST OPHTHALMOL VI, V52
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Shoshani T, 2002, MOL CELL BIOL, V22, P2283, DOI 10.1128/MCB.22.7.2283-2293.2002
   Whitehead KA, 2009, NAT REV DRUG DISCOV, V8, P129, DOI 10.1038/nrd2742
NR 16
TC 48
Z9 55
U1 1
U2 12
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 0950-222X
EI 1476-5454
J9 EYE
JI Eye
PD AUG
PY 2012
VL 26
IS 8
BP 1099
EP 1105
DI 10.1038/eye.2012.106
PG 7
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 991TW
UT WOS:000307726000014
PM 22627477
OA Green Published, Bronze
DA 2022-11-30
ER

PT J
AU Kuroiwa, S
   Tateiwa, H
   Hisatomi, T
   Ishibashi, T
   Yoshimura, N
AF Kuroiwa, S
   Tateiwa, H
   Hisatomi, T
   Ishibashi, T
   Yoshimura, N
TI Pathological features of surgically excised polypoidal choroidal
   vasculopathy membranes
SO CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY
LA English
DT Article
DE arteriosclerosis; choroidal vessels; pathology; polypoidal choroidal
   vasculopathy; surgical specimens
ID PIGMENT EPITHELIAL DETACHMENTS; CLINICOPATHOLOGICAL CORRELATION; MACULAR
   DEGENERATION; BLACK-WOMEN; IPCV
AB The histopathological features are reported of surgically excised specimens from five patients with polypoidal choroidal vasculopathy, which had been diagnosed by indocyanine green angiography. On stereomicroscopy, four of the five cases demonstrated large choroidal arterioles with an inner elastic layer. Disruption of the inner elastic layer and arteriosclerotic changes of the vessels were identified by light microscopy. Transmission electron microscopy demonstrated increased deposition of basement membrane-like material, together with collagen fibres, in the arteriolar walls. This study indicates that large choroidal arterioles and venules can be found in excised specimens from patients with polypoidal choroidal vasculopathy and arteriosclerosis is an important pathological feature.
C1 Shinshu Univ, Sch Med, Dept Ophthalmol, Matsumoto, Nagano 3908621, Japan.
   Kyushu Univ, Grad Sch Med, Dept Ophthalmol, Fukuoka 812, Japan.
C3 Shinshu University; Kyushu University
RP Yoshimura, N (通讯作者)，Shinshu Univ, Sch Med, Dept Ophthalmol, Matsumoto, Nagano 3908621, Japan.
EM nagaeye@hsp.md.shinshu-u.ac.jp
OI Hisatomi, Toshio/0000-0003-2552-9595
CR GREEN WR, 1985, OPHTHALMOLOGY, V92, P615
   KLEINER RC, 1990, RETINA-J RET VIT DIS, V10, P9, DOI 10.1097/00006982-199001010-00002
   Lafaut BA, 2000, RETINA-J RET VIT DIS, V20, P650, DOI 10.1097/00006982-200011000-00010
   MACCUMBER MW, 1994, RETINA-J RET VIT DIS, V14, P143, DOI 10.1097/00006982-199414020-00007
   Okubo A, 2002, BRIT J OPHTHALMOL, V86, P1093, DOI 10.1136/bjo.86.10.1093
   PERKOVICH BT, 1990, RETINA-J RET VIT DIS, V10, P18, DOI 10.1097/00006982-199001010-00003
   Rosa RH, 2002, ARCH OPHTHALMOL-CHIC, V120, P502
   Rosa RH, 1996, ARCH OPHTHALMOL-CHIC, V114, P480, DOI 10.1001/archopht.1996.01100130476025
   Ross RD, 1996, RETINA-J RET VIT DIS, V16, P105, DOI 10.1097/00006982-199616020-00003
   Spraul CW, 1997, KLIN MONATSBL AUGENH, V210, P405, DOI 10.1055/s-2008-1035085
   STERN RM, 1985, AM J OPHTHALMOL, V100, P560, DOI 10.1016/0002-9394(85)90682-8
   Uyama M, 2002, AM J OPHTHALMOL, V133, P639, DOI 10.1016/S0002-9394(02)01404-6
   Verhoeff FH, 1937, ARCH OPHTHALMOL-CHIC, V18, P561
   Yannuzzi LA, 1999, ARCH OPHTHALMOL-CHIC, V117, P1503
   YANNUZZI LA, 1990, RETINA-J RET VIT DIS, V10, P1, DOI 10.1097/00006982-199001010-00001
NR 15
TC 69
Z9 76
U1 0
U2 2
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1442-6404
EI 1442-9071
J9 CLIN EXP OPHTHALMOL
JI Clin. Exp. Ophthalmol.
PD JUN
PY 2004
VL 32
IS 3
BP 297
EP 302
DI 10.1111/j.1442-9071.2004.00827.x
PG 6
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 825GG
UT WOS:000221743400014
PM 15180844
DA 2022-11-30
ER

PT J
AU Cruz-Guilloty, F
   Saeed, AM
   Duffort, S
   Cano, M
   Ebrahimi, KB
   Ballmick, A
   Tan, YH
   Wang, H
   Laird, JM
   Salomon, RG
   Handa, JT
   Perez, VL
AF Cruz-Guilloty, Fernando
   Saeed, Ali M.
   Duffort, Stephanie
   Cano, Marisol
   Ebrahimi, Katayoon B.
   Ballmick, Asha
   Tan, Yaohong
   Wang, Hua
   Laird, James M.
   Salomon, Robert G.
   Handa, James T.
   Perez, Victor L.
TI T Cells and Macrophages Responding to Oxidative Damage Cooperate in
   Pathogenesis of a Mouse Model of Age-Related Macular Degeneration
SO PLOS ONE
LA English
DT Article
ID FACTOR-H POLYMORPHISM; ADAPTIVE IMMUNITY; DRUSEN; ACTIVATION;
   BIOMARKERS; RISK; IDENTIFICATION; POLARIZATION; PLASTICITY; INDUCTION
AB Age-related macular degeneration (AMD) is a major disease affecting central vision, but the pathogenic mechanisms are not fully understood. Using a mouse model, we examined the relationship of two factors implicated in AMD development: oxidative stress and the immune system. Carboxyethylpyrrole (CEP) is a lipid peroxidation product associated with AMD in humans and AMD-like pathology in mice. Previously, we demonstrated that CEP immunization leads to retinal infiltration of pro-inflammatory M1 macrophages before overt retinal degeneration. Here, we provide direct and indirect mechanisms for the effect of CEP on macrophages, and show for the first time that antigen-specific T cells play a leading role in AMD pathogenesis. In vitro, CEP directly induced M1 macrophage polarization and production of M1-related factors by retinal pigment epithelial (RPE) cells. In vivo, CEP eye injections in mice induced acute pro-inflammatory gene expression in the retina and human AMD eyes showed distinctively diffuse CEP immunolabeling within RPE cells. Importantly, interferon-gamma (IFN-gamma ) and interleukin-17 (IL-17)-producing CEP-specific T cells were identified ex vivo after CEP immunization and promoted M1 polarization in co-culture experiments. Finally, T cell immunosuppressive therapy inhibited CEP-mediated pathology. These data indicate that T cells and M1 macrophages activated by oxidative damage cooperate in AMD pathogenesis.
C1 [Cruz-Guilloty, Fernando; Saeed, Ali M.; Duffort, Stephanie; Ballmick, Asha; Tan, Yaohong; Perez, Victor L.] Univ Miami, Miller Sch Med, Dept Ophthalmol, Bascom Palmer Eye Inst, Miami, FL 33136 USA.
   [Cruz-Guilloty, Fernando; Perez, Victor L.] Univ Miami, Miller Sch Med, Dept Microbiol & Immunol, Miami, FL 33136 USA.
   [Cano, Marisol; Ebrahimi, Katayoon B.; Handa, James T.] Johns Hopkins Univ, Sch Med, Dept Ophthalmol, Wilmer Eye Inst, Baltimore, MD 21205 USA.
   [Wang, Hua; Laird, James M.; Salomon, Robert G.] Case Western Reserve Univ, Dept Chem, Cleveland, OH 44106 USA.
C3 Bascom Palmer Eye Institute; University of Miami; University of Miami;
   Johns Hopkins University; Johns Hopkins Medicine; Case Western Reserve
   University
RP Cruz-Guilloty, F (通讯作者)，Univ Miami, Miller Sch Med, Dept Ophthalmol, Bascom Palmer Eye Inst, Miami, FL 33136 USA.
EM fcruzguilloty@gmail.com; Vperez4@med.miami.edu
RI Perez, Victor L./AAY-8633-2020; Wang, Hua/N-9400-2015
OI Wang, Hua/0000-0002-2109-5497; Salomon, Robert/0000-0001-9456-3557
FU Edward N. & Della L. Thome Memorial Foundation Bank of America N.A.
   Trustee Award Program in Macular Degeneration Research; NIH
   [P30EY14801]; Prevent Blindness (Unrestricted Grant to the Bascom Palmer
   Eye Institute) [NIH R01-GM21249, NIH EY14005, EY019904]; RPB Senior
   Scientist Award; Sheila and David Fuente Graduate Program in Cancer
   Biology, Sylvester Comprehensive Cancer Center; Howard Hughes Medical
   Institute Fellowship of the Life Sciences Research Foundation; NATIONAL
   EYE INSTITUTE [R01EY016813, R01EY019904, R01EY014005, P30EY014801]
   Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL
   SCIENCES [R01GM021249] Funding Source: NIH RePORTER
FX This work was supported by The Edward N. & Della L. Thome Memorial
   Foundation Bank of America N.A. Trustee Award Program in Macular
   Degeneration Research (VLP, JTH); NIH P30EY14801 (Center Grant);
   Research to Prevent Blindness (Unrestricted Grant to the Bascom Palmer
   Eye Institute); NIH R01-GM21249 (RGS), NIH EY14005 (JTH), EY019904
   (JTH), and RPB Senior Scientist Award (JTH). JTH is the Robert Bond
   Welch Professor. A. M. S. acknowledges partial support and assistance
   from the Sheila and David Fuente Graduate Program in Cancer Biology,
   Sylvester Comprehensive Cancer Center. FCG was supported by a Howard
   Hughes Medical Institute Fellowship of the Life Sciences Research
   Foundation. The funders had no role in study design, data collection and
   analysis, decision to publish, or preparation of the manuscript.
CR Ambati J, 2003, NAT MED, V9, P1390, DOI 10.1038/nm950
   Ambati J, 2013, NAT REV IMMUNOL, V13, P438, DOI 10.1038/nri3459
   Ambati J, 2012, NEURON, V75, P26, DOI 10.1016/j.neuron.2012.06.018
   Apte RS, 2006, PLOS MED, V3, P1371, DOI 10.1371/journal.pmed.0030310
   Barshes NR, 2004, FRONT BIOSCI-LANDMRK, V9, P411, DOI 10.2741/1249
   Binder CJ, 2004, J CLIN INVEST, V114, P427, DOI 10.1172/jci200420479
   Bird AC, 2010, J CLIN INVEST, V120, P3033, DOI 10.1172/JCI42437
   Biswas SK, 2010, NAT IMMUNOL, V11, P889, DOI 10.1038/ni.1937
   BRESSLER SB, 1990, ARCH OPHTHALMOL-CHIC, V108, P1442, DOI 10.1001/archopht.1990.01070120090035
   Buschini E, 2011, PROG NEUROBIOL, V95, P14, DOI 10.1016/j.pneurobio.2011.05.011
   Cao XG, 2011, PATHOL INT, V61, P528, DOI 10.1111/j.1440-1827.2011.02695.x
   Cherepanoff S, 2010, BRIT J OPHTHALMOL, V94, P918, DOI 10.1136/bjo.2009.165563
   Coleman HR, 2008, LANCET, V372, P1835, DOI 10.1016/S0140-6736(08)61759-6
   Cousins SW, 2004, ARCH OPHTHALMOL-CHIC, V122, P1013, DOI 10.1001/archopht.122.7.1013
   Crabb JW, 2002, P NATL ACAD SCI USA, V99, P14682, DOI 10.1073/pnas.222551899
   Cruz-Guilloty F, 2013, INT J INFLAMM, V2013, DOI 10.1155/2013/503725
   Cruz-Guilloty F, 2011, NATURE, V478, P42, DOI 10.1038/478042a
   Doyle SL, 2012, NAT MED, V18, P791, DOI 10.1038/nm.2717
   Edwards AO, 2005, SCIENCE, V308, P421, DOI 10.1126/science.1110189
   Faber C, 2013, OPHTHALMOLOGY
   Gold B, 2006, NAT GENET, V38, P458, DOI 10.1038/ng1750
   Gu JY, 2010, ADV EXP MED BIOL, V664, P411, DOI 10.1007/978-1-4419-1399-9_47
   Gu XR, 2003, J BIOL CHEM, V278, P42027, DOI 10.1074/jbc.M305460200
   Hageman GS, 2005, P NATL ACAD SCI USA, V102, P7227, DOI 10.1073/pnas.0501536102
   Haines JL, 2005, SCIENCE, V308, P419, DOI 10.1126/science.1110359
   Handa JT, 2012, MOL ASPECTS MED, V33, P418, DOI 10.1016/j.mam.2012.03.006
   Hermansson A, 2010, J EXP MED, V207, P1081, DOI 10.1084/jem.20092243
   Hollyfield JG, 2008, NAT MED, V14, P194, DOI 10.1038/nm1709
   Hollyfield JG, 2010, MOL NEUROBIOL, V41, P290, DOI 10.1007/s12035-010-8110-z
   Iwasaki A, 2010, SCIENCE, V327, P291, DOI 10.1126/science.1183021
   Kadl A, 2010, CIRC RES, V107, P737, DOI 10.1161/CIRCRESAHA.109.215715
   Kaech SM, 2012, NAT REV IMMUNOL, V12, P749, DOI 10.1038/nri3307
   Kelly J, 2007, J CLIN INVEST, V117, P3421, DOI 10.1172/JCI32430
   Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557
   Lichtman AH, 2013, J CLIN INVEST, V123, P27, DOI 10.1172/JCI63108
   Liu BY, 2011, J TRANSL MED, V9, DOI 10.1186/1479-5876-9-111
   Lu L, 2009, BIOORGAN MED CHEM, V17, P7548, DOI 10.1016/j.bmc.2009.09.009
   Luger D, 2008, J EXP MED, V205, P799, DOI 10.1084/jem.20071258
   Lugo-Villarino G, 2003, P NATL ACAD SCI USA, V100, P7749, DOI 10.1073/pnas.1332767100
   Mitsdoerffer M, 2010, P NATL ACAD SCI USA, V107, P14292, DOI 10.1073/pnas.1009234107
   Morohoshi K, 2012, EXP MOL PATHOL, V93, P193, DOI 10.1016/j.yexmp.2012.03.007
   Morohoshi K, 2012, EXP MOL PATHOL, V92, P64, DOI 10.1016/j.yexmp.2011.09.017
   Morohoshi K, 2009, J AUTOIMMUN, V33, P247, DOI 10.1016/j.jaut.2009.09.003
   Nussenblatt RB, 2007, AM J OPHTHALMOL, V144, P618, DOI 10.1016/j.ajo.2007.06.025
   Nussenblatt RB, 2009, CURR OPIN INVEST DR, V10, P434
   Palm NW, 2009, IMMUNOL REV, V227, P221, DOI 10.1111/j.1600-065X.2008.00731.x
   Parmeggiani F, 2012, MEDIAT INFLAMM, V2012, DOI 10.1155/2012/546786
   Pipkin ME, 2010, IMMUNITY, V32, P79, DOI 10.1016/j.immuni.2009.11.012
   SARKS SH, 1980, T OPHTHAL SOC UK, V100, P414
   Sene A, 2013, CELL METAB, V17, P549, DOI 10.1016/j.cmet.2013.03.009
   Sica A, 2012, J CLIN INVEST, V122, P787, DOI 10.1172/JCI59643
   Tuo JS, 2012, OCUL IMMUNOL INFLAMM, V20, P27, DOI 10.3109/09273948.2011.628432
   Wei L, 2012, CELL REP, V2, P1151, DOI 10.1016/j.celrep.2012.10.013
   Weismann D, 2011, NATURE, V478, P76, DOI 10.1038/nature10449
   West XZ, 2010, NATURE, V467, P972, DOI 10.1038/nature09421
   Whitcup SM, 2013, INT J INFLAMM, V2013, DOI 10.1155/2013/348092
   Yamane H, 2012, NAT IMMUNOL, V13, P1037, DOI 10.1038/ni.2431
   Yates JRW, 2007, NEW ENGL J MED, V357, P553, DOI 10.1056/NEJMoa072618
   Yuan C, 1998, COMP BIOCHEM PHYS B, V120, P785, DOI 10.1016/S0305-0491(98)10079-2
   Zhao C, 2011, J CLIN INVEST, V121, P369, DOI 10.1172/JCI44303
NR 60
TC 48
Z9 49
U1 0
U2 17
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD FEB 19
PY 2014
VL 9
IS 2
AR e88201
DI 10.1371/journal.pone.0088201
PG 15
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA AB3TA
UT WOS:000331711900025
PM 24586307
OA Green Published, gold, Green Submitted
DA 2022-11-30
ER

PT J
AU Yang, JM
   Moon, SY
   Lee, JY
   Agalliu, DRITAN
   Yon, DK
   Lee, SW
AF Yang, Jee Myung
   Moon, Sung Yong
   Lee, Joo Yong
   Agalliu, D. R. I. T. A. N.
   Yon, Dong Keon
   Lee, Seung Won
TI COVID-19 Morbidity and Severity in Patients With Age-Related Macular
   Degeneration: A Korean Nationwide Cohort Study
SO AMERICAN JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
ID CHLAMYDIA-PNEUMONIAE; CLINICAL-OUTCOMES; MENTAL-ILLNESS; OPTIMAL NUMBER;
   SOUTH-KOREA; INFLAMMATION; ASSOCIATION; SUSCEPTIBILITY; TMPRSS2; HEALTH
AB PURPOSE: To determine the potential association between age-related macular degeneration (AMD), a representative chronic age-related degenerative disease of the retina associated with inflammation and aging, and susceptibility to SARS-CoV-2 infection and severe COVID-19 outcomes. DESIGN: Nationwide cohort study with propensity-score matching. METHODS: A population-based nationwide cohort in Korea was examined. Data were obtained from the Health Insurance Review & Assessment Service of Korea, including all patients aged >= 40 years who underwent SARS-CoV-2 testing in South Korea between January 1, 2020 and May 15, 2020 (excluding self-referral). The primary outcome was SARS-CoV-2 test positivity and the secondary outcome was severe clinical outcome of COVID-19. RESULTS: The unmatched cohort consisted of 135,435 patients who were tested for SARS-CoV-2: 4531 patients (3.3%) tested positive for SARS-CoV-2 and 5493 (4.1%) had AMD. After propensity score matching, exudative AMD was associated with an increased likelihood of susceptibility to SARS-CoV-2 infection (adjusted odds ratio [aOR], 1.50; 95% confidence interval [CI], 1.03-2.25), and a considerably greater risk of severe clinical outcomes of COVID-19 (aOR, 2.26; 95% CI, 1.02-5.26), but not any AMD and non-exudative AMD. CONCLUSIONS: In a Korean nationwide cohort, data suggest that clinicians should be aware of the greater risk of susceptibility to severe clinical outcomes of COVID-19 in patients with exudative AMD. These findings provide an improved understanding of the relationship between the pathogenesis of COVID-19 and chronic neurological disorders.((C) 2021ElsevierInc.Allrightsreserved.)
C1 [Yang, Jee Myung; Lee, Joo Yong] Univ Ulsan, Asan Med Ctr, Coll Med, Dept Ophthalmol, Goyang, South Korea.
   [Moon, Sung Yong; Yon, Dong Keon; Lee, Seung Won] Dongguk Univ, Ilsan Hosp, Dept Ophthalmol, Goyang, South Korea.
   [Moon, Sung Yong; Yon, Dong Keon; Lee, Seung Won] Sejong Univ, Coll Software Convergence, Dept Data Sci, Seoul, South Korea.
   [Agalliu, D. R. I. T. A. N.] Columbia Univ, Irving Med Ctr, Dept Neurol, Columbia, NY USA.
   [Yon, Dong Keon] Kyung Hee Univ, Coll Med, Med Sci Res Inst, Ctr Digital Hlth, Seoul, South Korea.
   [Lee, Seung Won] Sungkyunkwan Univ, Sch Med, Dept Precis Med, Suwon, South Korea.
   [Yon, Dong Keon] Kyung Hee Univ, Coll Med, 23 Kyungheedae Ro, Seoul 02447, South Korea.
   [Lee, Seung Won] Sejong Univ, Coll Software Convergence, Dept Data Sci, 209 Neungdong Ro, Seoul 05006, South Korea.
C3 University of Ulsan; Dongguk University; NHIS Ilsan Hospital; Sejong
   University; Columbia University; Kyung Hee University; Sungkyunkwan
   University (SKKU); Kyung Hee University; Sejong University
RP Yon, DK (通讯作者)，Kyung Hee Univ, Coll Med, 23 Kyungheedae Ro, Seoul 02447, South Korea.; Lee, SW (通讯作者)，Sejong Univ, Coll Software Convergence, Dept Data Sci, 209 Neungdong Ro, Seoul 05006, South Korea.
EM yonkkang@gmail.com; swlsejong@sejong.ac.kr
RI Lee, Seung Won/GQQ-7259-2022; Lee, Seung Won/AAK-9460-2021; Yon, Dong
   Keon/M-1264-2017
OI Lee, Seung Won/0000-0001-5632-5208; Lee, Seung Won/0000-0001-5632-5208;
   Yon, Dong Keon/0000-0003-1628-9948; Agalliu, Dritan/0000-0002-5375-4143;
   Yang, Jee Myung/0000-0001-5729-2233
FU National Research Foundation of Korea (NRF) - Korea government
   [NRF2019R1G1A109977912]; Health Fellowship Foundation - Yuhan
   Foundation; Leducq Foundation [15CDV-02]; Newport Equities LLC
FX This work was supported by the National Research Foundation of Korea
   (NRF) grant funded by the Korea government (NRF2019R1G1A109977912; Dr
   Seung Won Lee) , Health Fellowship Foundation funded by the Yuhan
   Foundation (Dr Jee Myung Yang) , and the Leducq Foundation (#15CDV-02)
   and unrestricted gifts from both John. F. Castle and Newport Equities
   LLC to the Division of Cerebrovascular Diseases and Stroke, Department
   of Neurology, Columbia University Irving Medical Center (Dr Dritan
   Agalliu) .
CR Akbar AN, 2020, SCIENCE, V369, P256, DOI 10.1126/science.abb0762
   Ambati J, 2013, NAT REV IMMUNOL, V13, P438, DOI 10.1038/nri3459
   [Anonymous], 2020, LANCET NEUROL, V19, P471, DOI 10.1016/S1474-4422(20)30142-3
   Austin PC, 2010, AM J EPIDEMIOL, V172, P1092, DOI 10.1093/aje/kwq224
   Bradding P, 2020, J ALLERGY CLIN IMMUN, V146, P208, DOI 10.1016/j.jaci.2020.05.013
   Choi S, 2020, AM J OPHTHALMOL, V210, P41, DOI 10.1016/j.ajo.2019.11.001
   Choudhary R, 2017, J CURR OPHTHALMOL, V29, P7, DOI 10.1016/j.joco.2016.09.009
   Cugno M, 2020, J ALLERGY CLIN IMMUN, V146, P215, DOI 10.1016/j.jaci.2020.05.006
   Ellul MA, 2020, LANCET NEUROL, V19, P767, DOI 10.1016/S1474-4422(20)30221-0
   Franceschi C, 2014, J GERONTOL A-BIOL, V69, pS4, DOI 10.1093/gerona/glu057
   Gallenga CE, 2014, INFLAMM RES, V63, P105, DOI 10.1007/s00011-013-0684-2
   Gheblawi M, 2020, CIRC RES, V126, P1456, DOI 10.1161/CIRCRESAHA.120.317015
   Guan WJ, 2020, EUR RESPIR J, V55, DOI 10.1183/13993003.00547-2020
   Ha Jihyun, 2020, Clin Exp Pediatr, V63, P278, DOI 10.3345/cep.2019.01291
   He MS, 2018, DIABETES CARE, V41, P2202, DOI 10.2337/dc18-0707
   Hoffmann M, 2020, CELL, V181, P271, DOI 10.1016/j.cell.2020.02.052
   Jager MJ, 2021, ASIA-PAC J OPHTHALMO, V10, P114, DOI 10.1097/APO.0000000000000346
   Kalayoglu MV, 2005, GRAEF ARCH CLIN EXP, V243, P1080, DOI 10.1007/s00417-005-1169-y
   Klein R, 2008, ARCH OPHTHALMOL-CHIC, V126, P840, DOI 10.1001/archopht.126.6.840
   Koh HY, 2019, J ALLER CL IMM-PRACT, V7, P2912, DOI 10.1016/j.jaip.2019.05.015
   Lee SW, 2021, GUT, V70, P2013, DOI 10.1136/gutjnl-2020-323672
   Lee SW, 2021, GUT, V70, P76, DOI 10.1136/gutjnl-2020-322248
   Lee SW, 2021, LANCET PSYCHIAT, V8, P271, DOI 10.1016/S2215-0366(21)00043-2
   Lee SW, 2020, LANCET PSYCHIAT, V7, P1025, DOI 10.1016/S2215-0366(20)30421-1
   Lee SW, 2020, JMIR MED INF, V8, DOI 10.2196/20992
   Linden A, 2013, J EVAL CLIN PRACT, V19, P968, DOI 10.1111/jep.12072
   Nagai N, 2006, ARTERIOSCL THROM VAS, V26, P2252, DOI 10.1161/01.ATV.0000240050.15321.fe
   Park SJ, 2016, JAMA OPHTHALMOL, V134, P621, DOI 10.1001/jamaophthalmol.2016.0453
   Park SJ, 2014, OPHTHALMOLOGY, V121, P1756, DOI 10.1016/j.ophtha.2014.03.022
   Ramlall V, 2020, NAT MED, V26, P1609, DOI 10.1038/s41591-020-1021-2
   Rea IM, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.00586
   Rim TH, 2018, JAMA OPHTHALMOL, V136, P132, DOI 10.1001/jamaophthalmol.2017.5682
   Risitano AM, 2020, NAT REV IMMUNOL, V20, P343, DOI 10.1038/s41577-020-0320-7
   Shen D, 2009, BRIT J OPHTHALMOL, V93, P405, DOI 10.1136/bjo.2008.145383
   Stoermer KA, 2011, VIROLOGY, V411, P362, DOI 10.1016/j.virol.2010.12.045
   Teuwen LA, 2020, NAT REV IMMUNOL, V20, P389, DOI 10.1038/s41577-020-0343-0
   Varatharaj A, 2020, LANCET PSYCHIAT, V7, P875, DOI 10.1016/S2215-0366(20)30287-X
   Woo A, 2021, J ALLERGY CLIN IMMUN, V147, P135, DOI 10.1016/j.jaci.2020.04.041
   Yang JM, 2020, J ALLERGY CLIN IMMUN, V146, P790, DOI 10.1016/j.jaci.2020.08.008
   Yang JM, 2020, CIRC RES, V126, P767, DOI 10.1161/CIRCRESAHA.119.316476
   Zhu ZT, 2019, JAMA OPHTHALMOL, V137, P248, DOI 10.1001/jamaophthalmol.2018.6150
NR 41
TC 2
Z9 2
U1 1
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 0002-9394
EI 1879-1891
J9 AM J OPHTHALMOL
JI Am. J. Ophthalmol.
PD JUL
PY 2022
VL 239
BP 159
EP 169
DI 10.1016/j.ajo.2021.05.024
PG 11
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 1V7CL
UT WOS:000806243000017
PM 34102151
OA Bronze, Green Published
DA 2022-11-30
ER

PT J
AU Johnson, LV
   Forest, DL
   Banna, CD
   Radeke, CM
   Maloney, MA
   Hu, J
   Spencer, CN
   Walker, AM
   Tsie, MS
   Bok, D
   Radeke, MJ
   Anderson, DH
AF Johnson, Lincoln V.
   Forest, David L.
   Banna, Christopher D.
   Radeke, Carolyn M.
   Maloney, Michelle A.
   Hu, Jane
   Spencer, Christine N.
   Walker, Aimee M.
   Tsie, Marlene S.
   Bok, Dean
   Radeke, Monte J.
   Anderson, Don H.
TI Cell culture model that mimics drusen formation and triggers complement
   activation associated with age-related macular degeneration
SO PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF
   AMERICA
LA English
DT Article
ID RETINAL-PIGMENT EPITHELIUM; APOLIPOPROTEIN-B; BRUCHS MEMBRANE; IN-VITRO;
   RPE; DEPOSITS; EXPRESSION; C1Q; CHOLESTEROL; MODULATION
AB We introduce a human retinal pigmented epithelial (RPE) cell-culture model that mimics several key aspects of early stage age-related macular degeneration (AMD). These include accumulation of sub-RPE deposits that contain molecular constituents of human drusen, and activation of complement leading to formation of deposit-associated terminal complement complexes. Abundant sub-RPE deposits that are rich in apolipoprotein E (APOE), a prominent drusen constituent, are formed by RPE cells grown on porous supports. Exposure to human serum results in selective, deposit-associated accumulation of additional known drusen components, including vitronectin, clusterin, and serum amyloid P, thus suggesting that specific protein-protein interactions contribute to the accretion of plasma proteins during drusen formation. Serum exposure also leads to complement activation, as evidenced by the generation of C5b-9 immunoreactive terminal complement complexes in association with APOE-containing deposits. Ultrastructural analyses reveal two morphologically distinct forms of deposits: One consisting of membrane-bounded multivescicular material, and the other of nonmembrane-bounded particle conglomerates. Collectively, these results suggest that drusen formation involves the accumulation of sub-RPE material rich in APOE, a prominent biosynthetic product of the RPE, which interacts with a select group of drusen-associated plasma proteins. Activation of the complement cascade appears to be mediated via the classical pathway by the binding of C1q to ligands in APOE-rich deposits, triggering direct activation of complement by C1q, deposition of terminal complement complexes and inflammatory sequelae. This model system will facilitate the analysis of molecular and cellular aspects of AMD pathogenesis, and the testing of new therapeutic agents for its treatment.
C1 [Johnson, Lincoln V.; Forest, David L.; Banna, Christopher D.; Radeke, Carolyn M.; Maloney, Michelle A.; Spencer, Christine N.; Walker, Aimee M.; Tsie, Marlene S.; Radeke, Monte J.; Anderson, Don H.] Univ Calif Santa Barbara, Neurosci Res Inst, Ctr Study Macular Degenerat, Santa Barbara, CA 93106 USA.
   [Hu, Jane] Univ Calif Los Angeles, Dept Ophthalmol, Los Angeles, CA 90095 USA.
   [Bok, Dean] Univ Calif Los Angeles, Brain Res Inst, Jules Stein Eye Inst, David Geffen Sch Med,Dept Neurobiol, Los Angeles, CA 90095 USA.
C3 University of California System; University of California Santa Barbara;
   University of California System; University of California Los Angeles;
   University of California System; University of California Los Angeles;
   University of California Los Angeles Medical Center; David Geffen School
   of Medicine at UCLA
RP Johnson, LV (通讯作者)，Univ Calif Santa Barbara, Neurosci Res Inst, Ctr Study Macular Degenerat, Santa Barbara, CA 93106 USA.
EM l_johnso@lifesci.ucsb.edu
FU National Eye Institute [EY R24 EY017404]; NATIONAL EYE INSTITUTE
   [R24EY017404, P30EY000331] Funding Source: NIH RePORTER
FX We thank Drs. Catherine Bowes Rickman and Gregory S. Hageman for
   insightful comments on the manuscript. This work was supported by Grant
   EY R24 EY017404 from the National Eye Institute and by generous
   benefactors of the Center for the Study of Macular Degeneration at the
   University of California, Santa Barbara.
CR Alcazar O, 2009, MOL CELL PROTEOMICS, V8, P2201, DOI 10.1074/mcp.M900203-MCP200
   Amin S, 2004, INVEST OPHTH VIS SCI, V45, P1281, DOI 10.1167/iovs.03-0671
   An E, 2006, J PROTEOME RES, V5, P2599, DOI 10.1021/pr060121j
   Anderson DH, 2004, EXP EYE RES, V78, P243, DOI 10.1016/j.exer.2003.10.011
   Anderson DH, 2002, AM J OPHTHALMOL, V134, P411, DOI 10.1016/S0002-9394(02)01624-0
   Anderson DH, 1999, INVEST OPHTH VIS SCI, V40, P3305
   Anderson DH, 2001, AM J OPHTHALMOL, V131, P767, DOI 10.1016/S0002-9394(00)00961-2
   Anderson DH, 2010, PROG RETIN EYE RES, V29, P95, DOI 10.1016/j.preteyeres.2009.11.003
   Bohlson SS, 2007, MOL IMMUNOL, V44, P33, DOI 10.1016/j.molimm.2006.06.021
   Burns R P, 1980, Trans Am Ophthalmol Soc, V78, P206
   Crabb JW, 2002, P NATL ACAD SCI USA, V99, P14682, DOI 10.1073/pnas.222551899
   Curcio CA, 2001, INVEST OPHTH VIS SCI, V42, P265
   Curcio CA, 2010, J LIPID RES, V51, P451, DOI 10.1194/jlr.R002238
   FARKAS TG, 1971, AM J OPHTHALMOL, V71, P1196, DOI 10.1016/0002-9394(71)90963-9
   Gaboriaud C, 2004, TRENDS IMMUNOL, V25, P368, DOI 10.1016/j.it.2004.04.008
   Gehrs KM, 2010, ARCH OPHTHALMOL-CHIC, V128, P349, DOI 10.1001/archophthalmol.2010.18
   Green W Richard, 2005, Retina, V25, P180, DOI 10.1097/00006982-200507001-00005
   Hageman GS, 1999, MOL VIS, V5
   Hageman GS, 2001, PROG RETIN EYE RES, V20, P705, DOI 10.1016/S1350-9462(01)00010-6
   Hecker LA, 2010, ADV EXP MED BIOL, V703, P49, DOI 10.1007/978-1-4419-5635-4_4
   Holers VM, 2008, IMMUNOL REV, V223, P300, DOI 10.1111/j.1600-065X.2008.00641.x
   Hollyfield JG, 2010, MOL NEUROBIOL, V41, P290, DOI 10.1007/s12035-010-8110-z
   Hu J, 2001, MOL VIS, V7, P14
   ISHIBASHI T, 1986, AM J OPHTHALMOL, V101, P342, DOI 10.1016/0002-9394(86)90830-5
   Ishida BY, 2004, J LIPID RES, V45, P263, DOI 10.1194/jlr.M300306-JLR200
   Johnson LV, 2000, EXP EYE RES, V70, P441, DOI 10.1006/exer.1999.0798
   Johnson LV, 2001, EXP EYE RES, V73, P887, DOI 10.1006/exer.2001.1094
   KILLINGSWORTH MC, 1987, GRAEF ARCH CLIN EXP, V225, P406, DOI 10.1007/BF02334166
   Kim YH, 2009, GRAEF ARCH CLIN EXP, V247, P651, DOI 10.1007/s00417-009-1049-y
   Kliffen M, 1997, MICROSC RES TECHNIQ, V36, P106, DOI 10.1002/(SICI)1097-0029(19970115)36:2<106::AID-JEMT4>3.0.CO;2-N
   Li CM, 2005, INVEST OPHTH VIS SCI, V46, P2576, DOI 10.1167/iovs.05-0034
   Malek G, 2003, AM J PATHOL, V162, P413, DOI 10.1016/S0002-9440(10)63836-9
   Maminishkis A, 2006, INVEST OPHTH VIS SCI, V47, P3612, DOI 10.1167/iovs.05-1622
   Marin-Castano ME, 2006, INVEST OPHTH VIS SCI, V47, P4098, DOI 10.1167/iovs.05-1230
   MERI S, 1990, EUR J IMMUNOL, V20, P2555, DOI 10.1002/eji.1830201205
   Mullins RF, 2001, EYE, V15, P390, DOI 10.1038/eye.2001.142
   Mullins RF, 2000, FASEB J, V14, P835, DOI 10.1096/fasebj.14.7.835
   Nauta AJ, 2002, EUR J IMMUNOL, V32, P1726, DOI 10.1002/1521-4141(200206)32:6<1726::AID-IMMU1726>3.0.CO;2-R
   Navratil JS, 2001, J IMMUNOL, V166, P3231, DOI 10.4049/jimmunol.166.5.3231
   Paidassi H, 2008, J IMMUNOL, V180, P2329, DOI 10.4049/jimmunol.180.4.2329
   Russell SR, 2000, AM J OPHTHALMOL, V129, P205, DOI 10.1016/S0002-9394(99)00345-1
   SARKS SH, 1976, BRIT J OPHTHALMOL, V60, P324, DOI 10.1136/bjo.60.5.324
   Sarks SH, 1999, BRIT J OPHTHALMOL, V83, P358, DOI 10.1136/bjo.83.3.358
   Sarks S, 2007, INVEST OPHTH VIS SCI, V48, P968, DOI 10.1167/iovs.06-0443
   Sparrow JR, 2010, ADV EXP MED BIOL, V703, P63, DOI 10.1007/978-1-4419-5635-4_5
   Suuronen T, 2007, BIOCHEM BIOPH RES CO, V357, P397, DOI 10.1016/j.bbrc.2007.03.135
   Tylman M, 2003, TRANSFUSION, V43, P395, DOI 10.1046/j.1537-2995.2003.00311.x
   ULSHAFER RJ, 1987, INVEST OPHTH VIS SCI, V28, P683
   Vogt SD, 2006, EXP EYE RES, V83, P834, DOI 10.1016/j.exer.2006.04.002
   Wang L, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0010329
   Wasmuth S, 2009, INVEST OPHTH VIS SCI, V50, P5304, DOI 10.1167/iovs.08-3326
   Yang P, 2009, INVEST OPHTH VIS SCI, V50, P3473, DOI 10.1167/iovs.08-3202
   [No title captured]
NR 53
TC 148
Z9 150
U1 0
U2 14
PU NATL ACAD SCIENCES
PI WASHINGTON
PA 2101 CONSTITUTION AVE NW, WASHINGTON, DC 20418 USA
SN 0027-8424
J9 P NATL ACAD SCI USA
JI Proc. Natl. Acad. Sci. U. S. A.
PD NOV 8
PY 2011
VL 108
IS 45
BP 18277
EP 18282
DI 10.1073/pnas.1109703108
PG 6
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA 843UT
UT WOS:000296700000030
PM 21969589
OA Green Published, Bronze
DA 2022-11-30
ER

PT J
AU Cioffi, CL
   Dobri, N
   Freeman, EE
   Conlon, MP
   Chen, P
   Stafford, DG
   Schwarz, DMC
   Golden, KC
   Zhu, L
   Kitchen, DB
   Barnes, KD
   Racz, B
   Qin, Q
   Michelotti, E
   Cywin, CL
   Martin, WH
   Pearson, PG
   Johnson, G
   Petrukhin, K
AF Cioffi, Christopher L.
   Dobri, Nicoleta
   Freeman, Emily E.
   Conlon, Michael P.
   Chen, Ping
   Stafford, Douglas G.
   Schwarz, Daniel M. C.
   Golden, Kathy C.
   Zhu, Lei
   Kitchen, Douglas B.
   Barnes, Keith D.
   Racz, Boglarka
   Qin, Qiong
   Michelotti, Enrique
   Cywin, Charles L.
   Martin, William H.
   Pearson, Paul G.
   Johnson, Graham
   Petrukhin, Konstantin
TI Design, Synthesis, and Evaluation of Nonretinoid Retinol Binding Protein
   4 Antagonists for the Potential Treatment of Atrophic Age-Related
   Macular Degeneration and Stargardt Disease
SO JOURNAL OF MEDICINAL CHEMISTRY
LA English
DT Article
ID PIGMENT EPITHELIAL-CELLS; VITAMIN-A METABOLISM; FUNDUS AUTOFLUORESCENCE;
   GEOGRAPHIC ATROPHY; LIPOFUSCIN ACCUMULATION; 3-DIMENSIONAL STRUCTURE;
   INSULIN-RESISTANCE; MOUSE MODEL; IN-VIVO; A2E
AB Accumulation of lipofuscin in the retina is associated with pathogenesis of atrophic age-related macular degeneration and Stargardt disease. Lipofuscin bisretinoids (exemplified by N-retinylidene-N-retinylethanolamine) seem to mediate lipofuscin toxicity. Synthesis of lipofuscin bisretinoids depends on the influx of retinol from serum to the retina. Compounds antagonizing the retinol-dependent interaction of retinol-binding protein 4 (RBP4) with transthyretin in the serum would reduce serum RBP4 and retinol and inhibit bisretinoid formation. We recently showed that A1120 (3), a potent carboxylic acid based RBP4 antagonist, can significantly reduce lipofuscin bisretinoid formation in the retinas of Abca4(-/-). mice. As part of the NIH Blueprint Neurotherapeutics Network project we undertook the in vitro exploration to identify novel conformationally flexible and constrained RBP4 antagonists with improved potency and metabolic stability. We also demonstrate that upon acute and chronic dosing in rats, 43, a potent cyclopentyl fused pyrrolidine antagonist, reduced circulating plasma RBP4 protein levels by approximately 60%.
C1 [Cioffi, Christopher L.; Freeman, Emily E.; Conlon, Michael P.; Chen, Ping; Stafford, Douglas G.; Schwarz, Daniel M. C.; Golden, Kathy C.; Zhu, Lei; Kitchen, Douglas B.; Barnes, Keith D.] Albany Mol Res Inc, Dept Med Chem, Rensselaer, NY 12144 USA.
   [Dobri, Nicoleta; Racz, Boglarka; Qin, Qiong; Petrukhin, Konstantin] Columbia Univ, Med Ctr, Dept Ophthalmol, New York, NY 10032 USA.
   [Johnson, Graham] NuPharmAdvise LLC, Sanbornton, NH 03269 USA.
   [Pearson, Paul G.] Pearson Pharma Partners, Westlake Village, CA 91361 USA.
   [Martin, William H.] WHM Consulting LLC, Lyme, CT 06371 USA.
   [Michelotti, Enrique] NIMH, NIH, Bethesda, MD 20892 USA.
   [Cywin, Charles L.] NINDS, NIH, Bethesda, MD 20892 USA.
C3 Columbia University; National Institutes of Health (NIH) - USA; NIH
   National Institute of Mental Health (NIMH); National Institutes of
   Health (NIH) - USA; NIH National Institute of Neurological Disorders &
   Stroke (NINDS)
RP Cioffi, CL (通讯作者)，Albany Mol Res Inc, Dept Med Chem, East Campus,C Wing, Rensselaer, NY 12144 USA.
EM christopher.cioffi@amriglobal.com; kep4@cumc.columbia.edu
OI Kitchen, Douglas/0000-0001-8988-759X; Schwarz,
   Daniel/0000-0002-5756-5710; Petrukhin, Konstantin/0000-0002-5545-6924
FU NIH [U01 NS074476, P30 EY019007]; Research To Prevent Blindness (New
   York, NY); National Institute of Neurological Disorders and Stroke,
   Neurosciences Blueprint Program, National Institutes of Health,
   Department of Health and Human Services [HHSN271201100013C]; NATIONAL
   EYE INSTITUTE [P30EY019007] Funding Source: NIH RePORTER; NATIONAL
   INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [U01NS074476] Funding
   Source: NIH RePORTER
FX This study was supported by NIH Grants U01 NS074476 (to K.P.) and P30
   EY019007 (Core Support for Vision Research) and unrestricted funds from
   Research To Prevent Blindness (New York, NY) to the Department of
   Ophthalmology, Columbia University, NY. The authors thank The Burch
   Family Foundation, the Mary Jaharis-John Catsimatidis Scholarship Fund,
   the Kaplen Foundation, and the Eye Surgery Fund for gifts supporting
   this study. This project has also been funded in whole or in part with
   federal funds from the National Institute of Neurological Disorders and
   Stroke, Neurosciences Blueprint Program, National Institutes of Health,
   Department of Health and Human Services, under Contract No.
   HHSN271201100013C.
CR ADAMS WR, 1995, P SOC EXP BIOL MED, V208, P178, DOI 10.3181/00379727-208-43849
   [Anonymous], 2004, Patent No. [WO 2004016604A2, 2004016604, W02004016604A2]
   Balagopal P, 2007, J CLIN ENDOCR METAB, V92, P1971, DOI 10.1210/jc.2006-2712
   Ben-Shabat S, 2002, J BIOL CHEM, V277, P7183, DOI 10.1074/jbc.M108981200
   Bergmann M, 2004, FASEB J, V18, P562, DOI 10.1096/fj.03-0289fje
   BERNI R, 1992, FEBS LETT, V308, P43, DOI 10.1016/0014-5793(92)81046-O
   BLOMHOFF R, 1991, PHYSIOL REV, V71, P951, DOI 10.1152/physrev.1991.71.4.951
   Burkhard J, 2008, ORG LETT, V10, P3525, DOI 10.1021/ol801293f
   Campos-Sandoval JA, 2011, J MED CHEM, V54, P4378, DOI 10.1021/jm200256g
   Cho YM, 2006, DIABETES CARE, V29, P2457, DOI 10.2337/dc06-0360
   COGAN U, 1976, EUR J BIOCHEM, V65, P71, DOI 10.1111/j.1432-1033.1976.tb10390.x
   COWAN SW, 1990, PROTEINS, V8, P44, DOI 10.1002/prot.340080108
   Dart M. J., 2004, PCT Int. Appl., Patent No. [WO2009042444 A2, 2009042444, WO2004016604 A2]
   De S, 2002, J GEN PHYSIOL, V120, P147, DOI 10.1085/jgp.20028566
   Delori F. C., 1995, RETINAL PIGMENT EPIT, V62, P37
   Dobri N, 2013, INVEST OPHTH VIS SCI, V54, P85, DOI 10.1167/iovs.12-10050
   Dontsov AE, 2009, DOKL BIOCHEM BIOPHYS, V425, P98, DOI 10.1134/S1607672909020112
   DOREY CK, 1989, INVEST OPHTH VIS SCI, V30, P1691
   Finnemann SC, 2002, P NATL ACAD SCI USA, V99, P3842, DOI 10.1073/pnas.052025899
   Graham TE, 2006, NEW ENGL J MED, V354, P2552, DOI 10.1056/NEJMoa054862
   Guillemont J. E. G., 2013, Google Patents PCT Int. Appl., Patent No. [W02013021054A1, 2013021054]
   Holz FG, 1999, GRAEF ARCH CLIN EXP, V237, P145, DOI 10.1007/s004170050209
   Holz FG, 2007, AM J OPHTHALMOL, V143, P463, DOI 10.1016/j.ajo.2006.11.041
   Hubschman JP, 2009, CLIN OPHTHALMOL, V3, P155
   KANAI M, 1968, J CLIN INVEST, V47, P2025, DOI 10.1172/JCI105889
   Kotnik P, 2011, EUR J ENDOCRINOL, V165, P703, DOI 10.1530/EJE-11-0431
   Lauffer D, 2009, Patent No. [W02009/045992A2, 2009045992]
   Maeda A, 2006, MOL PHARMACOL, V70, P1220, DOI 10.1124/mol.106.026823
   Mata NL, 2013, RETINA-J RET VIT DIS, V33, P498, DOI 10.1097/IAE.0b013e318265801d
   McHardy S. F., 2003, [No title captured], Patent No. [WO 2003035622, 2003035622]
   Meyer EA, 2003, ANGEW CHEM INT EDIT, V42, P1210, DOI 10.1002/anie.200390319
   Monaco HL, 2000, BBA-PROTEIN STRUCT M, V1482, P65, DOI 10.1016/S0167-4838(00)00140-0
   MONACO HL, 1995, SCIENCE, V268, P1039, DOI 10.1126/science.7754382
   Monaco HL, 2002, CLIN CHEM LAB MED, V40, P1229, DOI 10.1515/CCLM.2002.213
   Motani A, 2009, J BIOL CHEM, V284, P7673, DOI 10.1074/jbc.M809654200
   Naylor HM, 1999, BIOCHEMISTRY-US, V38, P2647, DOI 10.1021/bi982291i
   NEWCOMER ME, 1984, EMBO J, V3, P1451, DOI 10.1002/j.1460-2075.1984.tb01995.x
   NOY N, 1992, BIOCHEMISTRY-US, V31, P11118, DOI 10.1021/bi00160a023
   NOY N, 1990, BIOCHEMISTRY-US, V29, P3878, DOI 10.1021/bi00468a012
   Palczewski K, 2010, TRENDS PHARMACOL SCI, V31, P284, DOI 10.1016/j.tips.2010.03.001
   Petrukhin K, 2007, EXPERT OPIN THER TAR, V11, P625, DOI 10.1517/14728222.11.5.625
   Petrukhin Konstantin, 2013, Drug Discov Today Ther Strateg, V10, pe11
   Pettersson M, 2011, BIOORG MED CHEM LETT, V21, P865, DOI 10.1016/j.bmcl.2010.11.066
   Qi QB, 2007, J CLIN ENDOCR METAB, V92, P4827, DOI 10.1210/jc.2007-1219
   Radu RA, 2005, INVEST OPHTH VIS SCI, V46, P4393, DOI 10.1167/iovs.05-0820
   Radu RA, 2003, P NATL ACAD SCI USA, V100, P4742, DOI 10.1073/pnas.0737855100
   Radu RA, 2011, J BIOL CHEM, V286, P18593, DOI 10.1074/jbc.M110.191866
   ROZANOWSKA M, 1995, J BIOL CHEM, V270, P18825, DOI 10.1074/jbc.270.32.18825
   Schlehuber S, 2005, DRUG DISCOV TODAY, V10, P23, DOI 10.1016/S1359-6446(04)03294-5
   Schmitz-Valckenberg S, 2009, SURV OPHTHALMOL, V54, P96, DOI 10.1016/j.survophthal.2008.10.004
   Sparrow JR, 2012, PROG RETIN EYE RES, V31, P121, DOI 10.1016/j.preteyeres.2011.12.001
   Sparrow JR, 1999, INVEST OPHTH VIS SCI, V40, P2988
   Sparrow JR, 2003, VISION RES, V43, P2983, DOI 10.1016/S0042-6989(03)00475-9
   Sparrow JR, 2002, INVEST OPHTH VIS SCI, V43, P1222
   Sparrow JR, 2001, INVEST OPHTH VIS SCI, V42, P1356
   Sporn M. B., 1984, THE RETINOIDS, P41
   Stefan N, 2007, DIABETES CARE, V30, P1173, DOI 10.2337/dc06-2342
   Suter M, 2000, J BIOL CHEM, V275, P39625, DOI 10.1074/jbc.M007049200
   Swanson DM, 2005, J MED CHEM, V48, P1857, DOI 10.1021/jm0495071
   Vives-Bauza C, 2008, J BIOL CHEM, V283, P24770, DOI 10.1074/jbc.M800706200
   WOLF G, 1984, PHYSIOL REV, V64, P873, DOI 10.1152/physrev.1984.64.3.873
   Yang Q, 2005, NATURE, V436, P356, DOI 10.1038/nature03711
   YOUNG RW, 1987, SURV OPHTHALMOL, V31, P291, DOI 10.1016/0039-6257(87)90115-9
   ZANOTTI G, 1994, J BIOL CHEM, V269, P29613
   Zanotti G, 2008, FEBS J, V275, P5841, DOI 10.1111/j.1742-4658.2008.06705.x
   Zhou JL, 2006, P NATL ACAD SCI USA, V103, P16182, DOI 10.1073/pnas.0604255103
NR 66
TC 32
Z9 40
U1 2
U2 17
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 0022-2623
EI 1520-4804
J9 J MED CHEM
JI J. Med. Chem.
PD SEP 25
PY 2014
VL 57
IS 18
BP 7731
EP 7757
DI 10.1021/jm5010013
PG 27
WC Chemistry, Medicinal
WE Science Citation Index Expanded (SCI-EXPANDED); Index Chemicus (IC)
SC Pharmacology & Pharmacy
GA AP9JN
UT WOS:000342396200019
PM 25210858
OA Green Published, hybrid
DA 2022-11-30
ER

PT J
AU Kim, SW
   Woo, JE
   Yoon, YS
   Lee, S
   Woo, JM
   Min, JK
AF Kim, Sang Woo
   Woo, Jong Eun
   Yoon, Yo Sep
   Lee, Seunghwan
   Woo, Je Moon
   Min, Jung Kee
TI Retinal and Choroidal Changes after Anti Vascular Endothelial Growth
   Factor Therapy for Neovascular Age-related Macular Degeneration
SO CURRENT PHARMACEUTICAL DESIGN
LA English
DT Article
DE Aflibercept; choroid; ganglion cell-inner plexiform layer; neovascular
   age-related macular degeneration; ranibizumab; vascular endothelial
   growth factor
ID NERVE-FIBER LAYER; INNER PLEXIFORM LAYER; INTRAVITREAL RANIBIZUMAB;
   RISK-FACTORS; THICKNESS; AFLIBERCEPT; REPEATABILITY; INJECTIONS;
   EXPRESSION; VEGF
AB Objective: To investigate changes in retinal nerve fiber layer, ganglion cell-inner plexiform layer, and choroidal thickness in the macular area in patients with neovascular age-related macular degeneration who received repeated intravitreal ranibizumab and aflibercept treatments.
   Methods: This retrospective study included 90 eyes of 90 treatment-naive patients. Fifty eyes were treated with intravitreal injections of aflibercept, and 40 were treated with intravitreal injections of ranibizumab. Unaffected fellow eyes (71 eyes) were used as controls. The dosage was one injection per month for 3 consecutive months as an initial treatment. The patients were examined monthly for 6 months following the initial injection. Additional intravitreal injections were given reactively in an optical coherence tomography-guided "pro re nata" protocol. Measurements of the retinal nerve fiber layer, ganglion cell-inner plexiform layer, full retina, and choroidal thickness were simultaneously obtained via swept-source optical coherence tomography in the nine Early Treatment Diabetic Retinopathy Study subfields.
   Results: The retinal nerve fiber layer thickness in the nine Early Treatment Diabetic Retinopathy Study subfields did not differ significantly among the three study groups (aflibercept vs. ranibizumab vs. control). The ganglion cell-inner plexiform layer thickness was significantly reduced in the aflibercept group, while the choroidal thickness was reduced in both the aflibercept and ranibizumab groups.
   Conclusion: Excessive long-term vascular endothelial growth factor inhibition by an anti-vascular endothelial growth factor agent that is trapped by neuronal and retinal pigment epithelium cells may adversely affect the function of physiological vascular endothelial growth factor and harm retinal cells and vessels.
C1 [Kim, Sang Woo; Woo, Jong Eun; Yoon, Yo Sep; Lee, Seunghwan; Woo, Je Moon; Min, Jung Kee] Univ Ulsan, Coll Med, Ulsan Univ Hosp, Dept Ophthalmol, 290-3 Jeonha Dong, Ulsan 44033, South Korea.
C3 University of Ulsan; Ulsan University Hospital
RP Min, JK (通讯作者)，Univ Ulsan, Coll Med, Ulsan Univ Hosp, Dept Ophthalmol, 290-3 Jeonha Dong, Ulsan 44033, South Korea.
EM jkmin@uuh.ulsan.kr
RI Min, Jung Kee/V-5010-2019
OI Min, Jung Kee/0000-0002-8006-8560
CR Avery RL, 2014, BRIT J OPHTHALMOL, V98, P1636, DOI 10.1136/bjophthalmol-2014-305252
   Beck M, 2016, AM J OPHTHALMOL, V167, P10, DOI 10.1016/j.ajo.2016.04.003
   Cho HJ, 2015, AM J OPHTHALMOL, V159, P285, DOI 10.1016/j.ajo.2014.10.035
   Demirel S, 2015, CURR EYE RES, V40, P87, DOI 10.3109/02713683.2014.917190
   Heier JS, 2012, OPHTHALMOLOGY, V119, P2537, DOI 10.1016/j.ophtha.2012.09.006
   Heier JS, 2006, OPHTHALMOLOGY, V113, P633, DOI 10.1016/j.ophtha.2005.10.052
   Ho AC, 2014, OPHTHALMOLOGY, V121, P2181, DOI 10.1016/j.ophtha.2014.05.009
   Julien S, 2014, BRIT J OPHTHALMOL, V98, P813, DOI 10.1136/bjophthalmol-2013-304019
   Kim JH, 2016, BRIT J OPHTHALMOL, V100, P1634, DOI 10.1136/bjophthalmol-2015-308074
   Kliffen M, 1997, BRIT J OPHTHALMOL, V81, P154, DOI 10.1136/bjo.81.2.154
   Koizumi H, 2015, AM J OPHTHALMOL, V159, P627, DOI 10.1016/j.ajo.2014.12.025
   Lambert NG, 2016, PROG RETIN EYE RES, V54, P64, DOI 10.1016/j.preteyeres.2016.04.003
   Lee HJ, 2015, AM J OPHTHALMOL, V160, P283, DOI 10.1016/j.ajo.2015.05.015
   Mansouri K, 2014, AM J OPHTHALMOL, V157, P1022, DOI 10.1016/j.ajo.2014.02.008
   Marneros AG, 2005, AM J PATHOL, V167, P1451, DOI 10.1016/S0002-9440(10)61231-X
   Martinez-de-la-Casa JM, 2012, INVEST OPHTH VIS SCI, V53, P6214, DOI 10.1167/iovs.12-9875
   McKibbin M, 2015, EYE, V29, pS1, DOI 10.1038/eye.2015.77
   Parlak M, 2015, INT OPHTHALMOL, V35, P473, DOI 10.1007/s10792-014-9972-2
   Perdicchi A, 2015, BIOMED RES INT, V2015, DOI 10.1155/2015/268796
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Saint-Geniez M, 2009, P NATL ACAD SCI USA, V106, P18751, DOI 10.1073/pnas.0905010106
   Schmidt-Erfurth U, 2014, OPHTHALMOLOGY, V121, P193, DOI 10.1016/j.ophtha.2013.08.011
   Schraermeyer U, 2012, GRAEF ARCH CLIN EXP, V250, P1303, DOI 10.1007/s00417-012-2055-z
   Schwesinger C, 2001, AM J PATHOL, V158, P1161, DOI 10.1016/S0002-9440(10)64063-1
   Shin IH, 2018, RETINA-J RET VIT DIS, V38, P253, DOI 10.1097/IAE.0000000000001535
   Witmer AN, 2003, PROG RETIN EYE RES, V22, P1, DOI 10.1016/S1350-9462(02)00043-5
NR 26
TC 4
Z9 5
U1 0
U2 3
PU BENTHAM SCIENCE PUBL LTD
PI SHARJAH
PA EXECUTIVE STE Y-2, PO BOX 7917, SAIF ZONE, 1200 BR SHARJAH, U ARAB
   EMIRATES
SN 1381-6128
EI 1873-4286
J9 CURR PHARM DESIGN
JI Curr. Pharm. Design
PY 2019
VL 25
IS 2
BP 184
EP 189
DI 10.2174/1381612825666190319165824
PG 6
WC Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Pharmacology & Pharmacy
GA HZ9UG
UT WOS:000469202300009
PM 30892159
DA 2022-11-30
ER

PT J
AU Gonzalez-Garcia, E
   Vilela, C
   Navea, A
   Arnal, E
   Muriach, M
   Romero, FJ
AF Gonzalez-Garcia, Emilio
   Vilela, Concepcion
   Navea, Amparo
   Arnal, Emma
   Muriach, Maria
   Romero, Francisco J.
TI Electrophysiological and clinical tests in dry age-related macular
   degeneration follow-up: differences between mfERG and OCT
SO DOCUMENTA OPHTHALMOLOGICA
LA English
DT Article
DE Dry AMD; OCT; Electrophysiology; Pattern ERG; mfERG
ID OPTICAL COHERENCE TOMOGRAPHY; MULTIFOCAL ELECTRORETINOGRAM;
   EVOKED-POTENTIALS; ISCEV STANDARD; ABNORMALITIES; MACULOPATHY;
   GUIDELINES; TOPOGRAPHY; UPDATE; DRUSEN
AB Age-related macular degeneration (AMD) is one of the major causes of progressive and debilitating visual impairment in developed countries and has become a growing health and social issue that needs to be addressed. Imaging techniques and functional tests are useful to assess the degree of macular dysfunction and AMD progression. However, given the slow progression of the disease, it is necessary to identify which techniques are more sensitive for the diagnosis and monitoring of patients with AMD.
   To study changes observed with both imaging techniques and electrophysiological tests in dry AMD-diagnosed patients during 2 years in order to identify the most sensitive technique.
   Fundus photography, OCT (macular thickness and number of drusen), Pattern VEP (P100 wave), Pattern ERG (P50 wave) and multifocal ERG (central rings) were carried out in 30 patients that were diagnosed with dry AMD in both eyes. The tests were repeated 1 and 2 years later.
   No statistically significant changes were observed in visual acuity or in the severity of the disease throughout the study. OCT showed an increase in the number of drusen, as well as in macular thickness. As for the electrophysiological techniques, no significant changes were observed throughout the study in Pattern VEP or Pattern ERG. mfERG showed significant alterations. Statistical analysis showed that mfERG is more efficient in detecting changes throughout the experimental period.
   OCT and mfERG are useful in the diagnosis and monitoring of dry AMD patients, whilst mfERG is the most sensitive technique to study the progression of this disease in short periods of time.
C1 [Gonzalez-Garcia, Emilio; Vilela, Concepcion; Navea, Amparo; Arnal, Emma] Fisabio Oftalmol Med, C Alfons Blat 33 Manises, Valencia, Spain.
   [Muriach, Maria] Univ Jaume 1, Unidad Predept Med, Castellon de La Plana, Spain.
   [Romero, Francisco J.] Univ Catolica Valencia San Vicente Martir, Fac Med & Odontol, Valencia, Spain.
C3 Universitat Jaume I; Universidad Catolica de Valencia San Vicente Martir
RP Gonzalez-Garcia, E (通讯作者)，Fisabio Oftalmol Med, C Alfons Blat 33 Manises, Valencia, Spain.
EM egongar@gmail.com
RI Muriach, María/AAB-2003-2019; Navea, Amparo/D-4577-2009; González
   García, Emilio/ABF-8766-2021
OI Navea, Amparo/0000-0002-9856-5370; González García,
   Emilio/0000-0002-6065-1871; Romero, Francisco J/0000-0001-8701-5907
CR [Anonymous], 1991, OPHTHALMOLOGY, V98, P741
   Bach M, 2013, DOC OPHTHALMOL, V126, P1, DOI 10.1007/s10633-012-9353-y
   Berrow EJ, 2010, DOC OPHTHALMOL, V121, P51, DOI 10.1007/s10633-010-9226-1
   BRESSLER NM, 1994, RETINA-J RET VIT DIS, V14, P130, DOI 10.1097/00006982-199414020-00006
   Catalá-Mora J, 2005, Arch Soc Esp Oftalmol, V80, P395
   CHIAPPA KH, 1982, NEW ENGL J MED, V306, P1140, DOI 10.1056/NEJM198205133061904
   Einbock W, 2005, GRAEF ARCH CLIN EXP, V243, P300, DOI 10.1007/s00417-004-1027-3
   Elner SG, 1999, CLIN GERIATR MED, V15, P25
   Fine SL, 2000, NEW ENGL J MED, V342, P483, DOI 10.1056/NEJM200002173420707
   Gallego-Pinazo R., 2012, Arch Soc Esp Oftalmol, V87, P247, DOI 10.1016/j.oftal.2011.09.018
   Garcia-Garcia JG, 2013, CLIN OPHTHALMOL, V7, P1303, DOI 10.2147/OPTH.S39258
   Gerth C, 2003, ARCH OPHTHALMOL-CHIC, V121, P1404, DOI 10.1001/archopht.121.10.1404
   Gerth C, 2002, GRAEF ARCH CLIN EXP, V240, P202, DOI 10.1007/s00417-002-0442-6
   Gin TJ, 2011, INVEST OPHTH VIS SCI, V52, P9267, DOI 10.1167/iovs.11-8517
   Gomez-Ulla de Irazazabal F, 1993, LA MACULA SENIL, P95
   Holder GE, 2007, DOC OPHTHALMOL, V114, P111, DOI 10.1007/s10633-007-9053-1
   Hood DC, 2008, DOC OPHTHALMOL, V116, P1, DOI 10.1007/s10633-007-9089-2
   HUANG D, 1991, SCIENCE, V254, P1178, DOI 10.1126/science.1957169
   Keane PA, 2012, SURV OPHTHALMOL, V57, P389, DOI 10.1016/j.survophthal.2012.01.006
   Marmor MF, 2003, DOC OPHTHALMOL, V106, P105, DOI 10.1023/A:1022591317907
   Odom JV, 2010, DOC OPHTHALMOL, V120, P111, DOI 10.1007/s10633-009-9195-4
   Seddon JM, 2006, OPHTHALMOLOGY, V113, P260, DOI 10.1016/j.ophtha.2005.11.001
   SUTTER EE, 1992, VISION RES, V32, P433, DOI 10.1016/0042-6989(92)90235-B
   Tam WK, 2006, EYE, V20, P18, DOI 10.1038/sj.eye.6701777
   Tam WK, 2004, EYE, V18, P691, DOI 10.1038/sj.eye.6701318
   VAEGAN, 1986, DOC OPHTHALMOL, V63, P399
   Yavas GF, 2014, DOC OPHTHALMOL, V129, P167, DOI 10.1007/s10633-014-9460-z
NR 27
TC 5
Z9 5
U1 0
U2 6
PU SPRINGER
PI DORDRECHT
PA VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS
SN 0012-4486
EI 1573-2622
J9 DOC OPHTHALMOL
JI Doc. Ophthalmol.
PD AUG
PY 2016
VL 133
IS 1
BP 31
EP 39
DI 10.1007/s10633-016-9545-y
PG 9
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA DS4AL
UT WOS:000380723700004
PM 27290699
DA 2022-11-30
ER

PT J
AU Wolf-Schnurrbusch, UEK
   Brinkmann, CK
   Berger, L
   Wolf, S
AF Wolf-Schnurrbusch, Ute E. K.
   Brinkmann, Christian K.
   Berger, Lisa
   Wolf, Sebastian
TI Effects of combination therapy with verteporfin photodynamic therapy and
   ranibizumab in patients with age-related macular degeneration
SO ACTA OPHTHALMOLOGICA
LA English
DT Article
DE choroidal neovascularization; macular degeneration; ranibizumab;
   vascular endothelial growth factor; verteporfin
ID SUBFOVEAL CHOROIDAL NEOVASCULARIZATION; RANDOMIZED CLINICAL-TRIAL;
   ENDOTHELIAL GROWTH-FACTOR; OCCULT; CELLS
AB Purpose: This open-label, prospective, small-scale study investigated the benefits of same-day verteporfin and intravitreal ranibizumab in patients with predominantly classic, minimally classic or occult subfoveal choroidal neovascularization (CNV) secondary to age-related macular degeneration.
   Methods: Patients received verteporfin at baseline and at month 3, if leakage persisted. Ranibizumab (0.5 mg) was given at baseline and months 1, 2 and 3, and thereafter at monthly intervals if required. Same-day ranibizumab was given >= 1 hr after verteporfin.
   Results: Fifteen patients [11 male, four female; mean age 75.5 years (range 54-94 years)] were treated. At day 360, mean visual acuity (VA) had improved by 10.9 letters. An increase of >= 15 and >= 30 letters (i.e. >= 3 and >= 6 lines) was observed in seven (47%) patients and one patient (7%), respectively. Mean central retinal thickness (CRT) decreased by 85 lm. At days 7, 14 and 30, CNV perfusion was absent in 14/15 patients. Mean lesion area had reduced from baseline by 23.1% at day 120, 25.5% at day 180 and 23.6% at day 360. There were no visual safety concerns and intraocular pressures remained normal. Only two serious adverse events were recorded over the 12-month period, and neither was considered to be related to treatment.
   Conclusion: Same-day verteporfin plus ranibizumab improved VA, reduced CRT, prevented CNV perfusion and reduced lesion area safely over 12 months. Further investigation is warranted to confirm whether this combination improves long-term vision and reduces the need for retreatment.
C1 [Wolf, Sebastian] Univ Bern, Inselspital, Univ Klin Augenheilkunde, Dept Ophthalmol, CH-3010 Bern, Switzerland.
C3 University of Bern; University Hospital of Bern
RP Wolf, S (通讯作者)，Univ Bern, Inselspital, Univ Klin Augenheilkunde, Dept Ophthalmol, CH-3010 Bern, Switzerland.
EM sebastian.wolf@insel.ch
RI Wolf, Sebastian/B-8782-2008
OI Wolf, Sebastian/0000-0002-7467-7028
CR AIELLO LP, 1995, P NATL ACAD SCI USA, V92, P10457, DOI 10.1073/pnas.92.23.10457
   Arnold J, 2001, AM J OPHTHALMOL, V131, P541
   Blumenkranz MS, 2001, ARCH OPHTHALMOL-CHIC, V119, P198
   BRESSLER NM, 1988, SURV OPHTHALMOL, V32, P375, DOI 10.1016/0039-6257(88)90052-5
   BRESSLER SB, 1982, AM J OPHTHALMOL, V93, P157, DOI 10.1016/0002-9394(82)90410-X
   Campochiaro PA, 2004, EXPERT OPIN BIOL TH, V4, P1395, DOI 10.1517/14712598.4.9.1395
   Cruess AF, 2009, ACTA OPHTHALMOL, V87, P118, DOI 10.1111/j.1755-3768.2008.01218.x
   FERRIS FL, 1984, ARCH OPHTHALMOL-CHIC, V102, P1640
   Greve MDJ, 2005, ARCH OPHTHALMOL-CHIC, V123, P448
   Grunwald JE, 2005, INVEST OPHTH VIS SCI, V46, P1033, DOI 10.1167/iovs.04-1050
   Heier JS, 2006, ARCH OPHTHALMOL-CHIC, V124, P1532, DOI 10.1001/archopht.124.11.1532
   Hiromatsu Y, 2003, MICROSC RES TECHNIQ, V60, P64, DOI 10.1002/jemt.10244
   Hyman L, 1992, AGE RELATED MACULAR, P1
   Kaiser PK, 2007, CURR MED RES OPIN, V23, P477, DOI 10.1185/030079907X167624
   LIE S, 2008, ACTA OPHTHALMOL
   Mennel S, 2005, AM J OPHTHALMOL, V140, P758, DOI 10.1016/j.ajo.2005.04.041
   Mennel S, 2006, GRAEF ARCH CLIN EXP, V244, P1015, DOI 10.1007/s00417-005-0237-7
   PEER J, 1995, LAB INVEST, V72, P638
   Pieramici DJ, 2006, EXPERT OPIN BIOL TH, V6, P1237, DOI 10.1517/14712598.6.11.1237
   Schmidt-Erfurth U, 2000, SURV OPHTHALMOL, V45, P195, DOI 10.1016/S0039-6257(00)00158-2
   Schmidt-Erfurth U, 2008, BRIT J OPHTHALMOL, V92, P1628, DOI 10.1136/bjo.2007.135277
   Zarbin MA, 2004, ARCH OPHTHALMOL-CHIC, V122, P598, DOI 10.1001/archopht.122.4.598
NR 22
TC 6
Z9 6
U1 0
U2 4
PU WILEY-BLACKWELL
PI MALDEN
PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA
SN 1755-375X
J9 ACTA OPHTHALMOL
JI Acta Ophthalmol.
PD SEP
PY 2011
VL 89
IS 6
BP 585
EP 590
DI 10.1111/j.1755-3768.2009.01747.x
PG 6
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 812BE
UT WOS:000294261900033
PM 19878113
OA Bronze
DA 2022-11-30
ER

PT J
AU Gao, Y
   Li, YB
   Xu, L
   Li, Y
   Zhang, HT
   Jonas, JB
   Sun, BC
AF Gao, Ya
   Li, Yibin
   Xu, Liang
   Li, Yang
   Zhang, Hai-Tao
   Jonas, Jost B.
   Sun, Bao-Chen
TI COMPLEMENT FACTOR H POLYMORPHISM IN AGE-RELATED MACULOPATHY IN THE
   CHINESE POPULATION The Beijing Eye Study
SO RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES
LA English
DT Article
ID MACULAR DEGENERATION; VISUAL IMPAIRMENT; GRADING SYSTEM; RISK-FACTORS;
   LOW-VISION; PREVALENCE; BLINDNESS; ASSOCIATION; ROTTERDAM; VARIANT
AB Purpose: The purpose of this study was to analyze the association between the Y402H polymorphism in the complement factor H and soft drusen of the macula as part of age-related maculopathy in the Chinese population.
   Methods: In the population-based Beijing Eye Study, the participants underwent a detailed ophthalmic examination including fundus photography. All fundus photographs were graded using the Wisconsin Grading System. Of 515 subjects with soft drusen in the macula, 208 (40.4%) subjects had blood samples taken and were thus eligible for the present study. These subjects were compared with 140 randomly selected control subjects from the Beijing Eye Study matched for age, sex, and rural versus urban area with the study group. The analysis of the genotype was performed by allele-specific digestion of polymerase chain reaction products.
   Results: Dividing the study group into subjects with bilateral soft drusen and unilateral soft drusen showed a significant association between the Y402H polymorphism in the complement factor H gene and the study group with bilateral soft drusen with an odds ratio of 2.29 (95% confidence interval, 1.06-4.95).
   Conclusion: Also in the Chinese population, soft drusen as part of age-related maculopathy are associated with the Y402H polymorphism in the complement factor H gene despite a markedly lower frequency of C allele in the Chinese population than in white populations. RETINA 30: 443-446, 2010
C1 [Gao, Ya; Li, Yibin; Xu, Liang; Li, Yang; Zhang, Hai-Tao; Sun, Bao-Chen] Capital Med Univ, Beijing Tongren Eye Ctr, Beijing Inst Ophthalmol, Beijing 100005, Peoples R China.
   [Jonas, Jost B.] Univ Heidelberg, Fac Clin Med Mannheim, Dept Ophthalmol, D-6800 Mannheim, Germany.
C3 Capital Medical University; Ruprecht Karls University Heidelberg
RP Sun, BC (通讯作者)，Capital Med Univ, Beijing Tongren Eye Ctr, Beijing Inst Ophthalmol, 17 Hou Gou Lane,Chong Nei St, Beijing 100005, Peoples R China.
EM sun.baochen@yahoo.com.cn
FU Beijing Key Laboratory
FX Supported by Beijing Key Laboratory.
CR Arnarsson A, 2006, AM J OPHTHALMOL, V142, P419, DOI 10.1016/j.ajo.2006.04.015
   BIRD AEC, 1995, SURV OPHTHALMOL, V39, P367, DOI 10.1016/S0039-6257(05)80092-X
   Chang TS, 1999, CAN J OPHTHALMOL, V34, P266
   Dineen BP, 2003, BRIT J OPHTHALMOL, V87, P820, DOI 10.1136/bjo.87.7.820
   Edwards AO, 2005, SCIENCE, V308, P421, DOI 10.1126/science.1110189
   Haines JL, 2005, SCIENCE, V308, P419, DOI 10.1126/science.1110359
   HOLZ FG, 1994, OPHTHALMOLOGY, V101, P1522
   Hsu WM, 2004, OPHTHALMOLOGY, V111, P62, DOI 10.1016/j.ophtha.2003.05.011
   Kaur I, 2006, INVEST OPHTH VIS SCI, V47, P3729, DOI 10.1167/iovs.05-1430
   Kim NR, 2008, INVEST OPHTH VIS SCI, V49, P2071, DOI 10.1167/iovs.07-1195
   Klaver CCW, 1998, ARCH OPHTHALMOL-CHIC, V116, P653, DOI 10.1001/archopht.116.5.653
   Klein R, 2004, AM J OPHTHALMOL, V137, P486, DOI 10.1016/j.ajo.2003.11.069
   KLEIN R, 1991, OPHTHALMOLOGY, V98, P1128
   Klein R, 1999, PROG RETIN EYE RES, V18, P371, DOI 10.1016/S1350-9462(98)00025-1
   Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557
   Lau LI, 2006, INVEST OPHTH VIS SCI, V47, P3242, DOI 10.1167/iovs.05-1532
   Li YB, 2006, AM J OPHTHALMOL, V142, P788, DOI 10.1016/j.ajo.2006.06.001
   Lim JI, 1998, RETINA-J RET VIT DIS, V18, P435
   Magnusson KP, 2006, PLOS MED, V3, P109, DOI 10.1371/journal.pmed.0030005
   MITCHELL P, 1995, OPHTHALMOLOGY, V102, P1450
   Moshfeghi DM, 2007, RETINA-J RET VIT DIS, V27, P269, DOI 10.1097/IAE.0b013e31802e3e9b
   Saw SM, 2004, OPHTHALMOLOGY, V111, P1161, DOI 10.1016/j.ophtha.2003.09.040
   SCHACHAT AP, 1995, ARCH OPHTHALMOL-CHIC, V113, P728, DOI 10.1001/archopht.1995.01100060054032
   SOMMER A, 1991, NEW ENGL J MED, V325, P1412, DOI 10.1056/NEJM199111143252004
   Souied EH, 2005, MOL VIS, V11, P1135
   Thulasiraj RD, 2003, OPHTHALMOLOGY, V110, P1491, DOI 10.1016/S0161-6420(03)00565-7
   Tsai SY, 2003, OPHTHALMOLOGY, V110, P1089, DOI 10.1016/S0161-6420(03)00243-4
   van Leeuwen R, 2003, ARCH OPHTHALMOL-CHIC, V121, P519, DOI 10.1001/archopht.121.4.519
NR 28
TC 9
Z9 9
U1 0
U2 1
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0275-004X
EI 1539-2864
J9 RETINA-J RET VIT DIS
JI Retin.-J. Retin. Vitr. Dis.
PD MAR
PY 2010
VL 30
IS 3
BP 443
EP 446
DI 10.1097/IAE.0b013e3181c2e086
PG 4
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 608AD
UT WOS:000278548800010
PM 20038862
DA 2022-11-30
ER

PT J
AU Brown, DM
   Tuomi, L
   Shapiro, H
AF Brown, David M.
   Tuomi, Lisa
   Shapiro, Howard
CA PIER Study Grp
TI ANATOMICAL MEASURES AS PREDICTORS OF VISUAL OUTCOMES IN
   RANIBIZUMAB-TREATED EYES WITH NEOVASCULAR AGE-RELATED MACULAR
   DEGENERATION
SO RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES
LA English
DT Article
DE neovascular AMD; ocular coherence tomography; fundus fluorescein
   angiography; anatomic predictors; ranibizumab; anti-VEGF therapy
ID SUBGROUP ANALYSIS
AB Purpose: To investigate if anatomical characteristics of eyes undergoing ranibizumab therapy were predictive of best-corrected visual acuity (BCVA) outcomes over 2 years.
   Methods: Post hoc analyses of patients with age-related macular degeneration from PIER studies, defined by fundus fluorescein angiography, quantitative optical coherence tomography (OCT), and qualitative OCT, were performed to determine if associations with BCVA outcomes could be found.
   Results: Ranibizumab-treated subgroups defined by baseline fundus fluorescein angiography lesion size and composition did not differ in BCVA outcomes at Month 24 (P = 0.13-1.0). Inactivity on fundus fluorescein angiography at Month 3 was associated with a 12-letter gain by Month 12 (P < 0.01), whereas inactivity on Month 3 qualitative OCT was not (P > 0.05). Qualitative OCT inactivity at Month 5 and separately at Month 8 was associated with greater BCVA gains by Month 24 (7.1 and 9.5 letters, respectively; P <= 0.045) versus eyes with OCT activity.
   Conclusion: When assessed separately, eyes with qualitative OCT (Months 5 and 8) or fundus fluorescein angiography (Months 3 and 5) inactivity maintained vision gain from baseline at Month 24, while those with leakage not only lost initial vision gains achieved by intraocular ranibizumab but also had net vision losses from baseline at Month 24. The PIER infrequent dosing regimen likely exaggerated and accelerated the deleterious effects of retinal fluid on BCVA, and it is not known whether these findings are applicable to treatment regimens that use more frequent monitoring and dosing of ranibizumab. RETINA 33:23-34, 2013
C1 [Brown, David M.] Methodist Hosp, Retina Consultants Houston, Houston, TX 77030 USA.
   [Tuomi, Lisa; Shapiro, Howard] Genentech Inc, San Francisco, CA 94080 USA.
C3 The Methodist Hospital System; The Methodist Hospital - Houston; Roche
   Holding; Genentech
RP Brown, DM (通讯作者)，Methodist Hosp, Retina Consultants Houston, 6560 Fannin,Suite 750, Houston, TX 77030 USA.
EM dmbmd@houstonretina.com
CR Abraham P, 2010, AM J OPHTHALMOL, V150, P315, DOI 10.1016/j.ajo.2010.04.011
   Boyer DS, 2007, OPHTHALMOLOGY, V114, P246, DOI 10.1016/j.ophtha.2006.10.045
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Kaiser PK, 2007, AM J OPHTHALMOL, V144, P850, DOI 10.1016/j.ajo.2007.08.012
   Lalwani GA, 2009, AM J OPHTHALMOL, V148, P43, DOI 10.1016/j.ajo.2009.01.024
   Martin DF, 2011, NEW ENGL J MED, V364, P1897, DOI 10.1056/NEJMoa1102673
   Regillo CD, 2008, AM J OPHTHALMOL, V145, P239, DOI 10.1016/j.ajo.2007.10.004
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
NR 8
TC 55
Z9 55
U1 0
U2 1
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0275-004X
EI 1539-2864
J9 RETINA-J RET VIT DIS
JI Retin.-J. Retin. Vitr. Dis.
PD JAN
PY 2013
VL 33
IS 1
BP 23
EP 34
DI 10.1097/IAE.0b013e318263cedf
PG 12
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 069GE
UT WOS:000313422500004
PM 23073338
DA 2022-11-30
ER

PT J
AU Schramm, K
   Mueller, M
   Koch, FH
   Singh, P
   Kohnen, T
   Koss, MJ
AF Schramm, Katharina
   Mueller, Michael
   Koch, Frank H.
   Singh, Pankaj
   Kohnen, Thomas
   Koss, Michael J.
TI Effects of core vitrectomy in the treatment of age-related macular
   degeneration
SO ACTA OPHTHALMOLOGICA
LA English
DT Article
DE ARMD; core vitrectomy; ranibizumab; reinjection
ID POSTERIOR VITREOMACULAR ADHESION; VERTEPORFIN PHOTODYNAMIC THERAPY;
   OPTICAL COHERENCE TOMOGRAPHY; CHOROIDAL NEOVASCULARIZATION; INTRAVITREAL
   BEVACIZUMAB; TRIPLE THERAPY; RANIBIZUMAB; PATHOGENESIS; REGIMEN; RISK
AB Purpose: To investigate the clinical efficacy and safety of an additional core vitrectomy to the standard therapy in patients with exudative age-related macular degeneration (ARMD).
   Methods: In this prospective, controlled, single-centre study, 50 eyes of 50 patients (mean age: 74.1 +/- 7.1; median 74 (69/78)) with ARMD were enrolled and randomized 1: 1 to group 1 - core vitrectomy additional to three times injections of ranibizumab (3x Rbz) and Group 2 - 3x Rbz (control). 1 16 of 25 eyes in Group 1(64%) and 12 of 25 (48%) in Group 2 had a posterior vitreous detachment (PVD) prior to start of the study. Changes in best-corrected visual acuity (BCVA) using ETDRS charts, central macular thickness and macular volume (OCT) as well as the rate of reinjection with an OCT-based pro renata (PRN) protocol were monitored prospectively over 48 weeks. Forty-seven eyes completed follow-up at week 48.
   Results: In Group 1, 4 of 24 lost 1 line of BCVA (16.7%) and 3 of 24 lost 2 lines (12.5%), whereas 17 of 24 gained more than 1 line (70.8%) and improved in average by 9.8 letters. In Group 2, 3 of 23 remained stable and 20 of 23 gained more than or exactly 1 line (78.3%), resulting in 14.3 letters, with no loss of lines. Central macular thickness decreased by 85.58 mu m (28.8%) in Group 1 and by 121.43 mu m (32.68%) in Group 2 compared with baseline. In Group 1, four patients received three additional and two patients, two additional Rbz injections. In Group 2, three patients received three additional, three patients two and 12 patients one additional Rbz injections. This yielded in an average injection rate of 3.66 in Group 1 and 4.17 in Group 2 over 48 weeks. Posterior vitreous detachment (PVD) was identified in Group 1 in 16 of 24 (66.7%) and in Group 2 in 12 of 23 (52.2%) patients at baseline. At week 48, 6 of 8 (75%) of the patients in Group 1 with initial attached vitreous showed a vitreal detachment, whereas only 1 of 11 (9%) in Group 2 had a new occurred detachment of the vitreous. No systemic or ocular adverse events were noticed.
   Conclusion: An initial core vitrectomy combined with a conventional ranibizumab injection regimen for exudative AMD patients was safe and lead to similar functional results with less intravitreal ranibizumab injections over 48 weeks.
C1 [Schramm, Katharina; Mueller, Michael; Koch, Frank H.; Singh, Pankaj; Kohnen, Thomas; Koss, Michael J.] Goethe Univ Frankfurt, Retina Unit, Dept Ophthalmol, D-60590 Frankfurt, Germany.
   [Koss, Michael J.] Doheny Eye Inst, Los Angeles, CA 90033 USA.
C3 Goethe University Frankfurt; Doheny Eye Institute
RP Koch, FH (通讯作者)，Goethe Univ Frankfurt, Retina Unit, Dept Ophthalmol, Theodor Stern Kai 7, D-60590 Frankfurt, Germany.
EM fkoch1@me.com
RI Kohnen, Thomas/AAA-2172-2020
OI Kohnen, Thomas/0000-0002-6933-9585
CR Ambati J, 2003, SURV OPHTHALMOL, V48, P257, DOI 10.1016/S0039-6257(03)00030-4
   Antoszyk AN, 2008, AM J OPHTHALMOL, V145, P862, DOI 10.1016/j.ajo.2007.12.029
   Augustin AJ, 2007, DRUG AGING, V24, P979, DOI 10.2165/00002512-200724120-00002
   Augustin AJ, 2007, RETINA-J RET VIT DIS, V27, P133, DOI 10.1097/IAE.0b013e3180323de7
   Azad Rajvardhan, 2007, Indian Journal of Ophthalmology, V55, P441
   Boyer DS, 2009, OPHTHALMOLOGY, V116, P1731, DOI 10.1016/j.ophtha.2009.05.024
   Brown DM, 2009, OPHTHALMOLOGY, V116, P57, DOI 10.1016/j.ophtha.2008.10.018
   Cruess AF, 2008, PHARMACOECONOMICS, V26, P57, DOI 10.2165/00019053-200826010-00006
   Da Costa J, 2008, COMBINED PHOTODYNAMI
   Dhalla MS, 2006, RETINA-J RET VIT DIS, V26, P988, DOI 10.1097/01.iae.0000247164.70376.91
   Donoso LA, 2006, SURV OPHTHALMOL, V51, P137, DOI 10.1016/j.survophthal.2005.12.001
   Fung AE, 2007, AM J OPHTHALMOL, V143, P566, DOI 10.1016/j.ajo.2007.01.028
   Holekamp NM, 2010, AM J OPHTHALMOL, V149, P171, DOI 10.1016/j.ajo.2009.09.005
   Holekamp NM, 2010, AM J OPHTHALMOL, V149, P32, DOI 10.1016/j.ajo.2009.07.036
   Holz FG, 2010, INVEST OPHTH VIS SCI, V51, P405, DOI 10.1167/iovs.09-3813
   Insight Instruments I, 2008, SINGL STICK 23 GAUG
   Kaiser PK, 2009, OPHTHALMOLOGY, V116, P747, DOI 10.1016/j.ophtha.2008.12.057
   Koss MJ, 2010, OPHTHALMOLOGICA, V224, P72, DOI 10.1159/000235724
   Koss MJ, 2011, OPHTHALMOLOGICA, V226, P45, DOI 10.1159/000327702
   Koss MJ, 2009, EFFECTS COMBINED VS
   Krebs I, 2007, AM J OPHTHALMOL, V144, P741, DOI 10.1016/j.ajo.2007.07.024
   Krebs I, 2011, BRIT J OPHTHALMOL, V95, P1415, DOI 10.1136/bjo.2010.192385
   Lazic R, 2007, OPHTHALMOLOGY, V114, P1179, DOI 10.1016/j.ophtha.2007.03.006
   Lee SJ, 2009, AM J OPHTHALMOL, V147, P621, DOI 10.1016/j.ajo.2008.10.003
   Lee SS, 2010, INVEST OPHTH VIS SCI, V51, P2135, DOI 10.1167/iovs.09-3582
   Liggett PE, 2006, AM J OPHTHALMOL, V142, P1072, DOI 10.1016/j.ajo.2006.07.029
   Mennel S, 2011, KLIN MONATSBL AUGENH, V228, P460, DOI 10.1055/s-0029-1245448
   Mitchell P, 2010, BRIT J OPHTHALMOL, V94, P2, DOI 10.1136/bjo.2009.159160
   Mojana F, 2008, AM J OPHTHALMOL, V146, P218, DOI 10.1016/j.ajo.2008.04.027
   Ondes F, 2000, JPN J OPHTHALMOL, V44, P91, DOI 10.1016/S0021-5155(99)00174-4
   Pauleikhoff D, 2009, OPHTHALMOLOGE, V106, P242, DOI 10.1007/s00347-008-1797-9
   Polak BCP, 2012, ACTA OPHTHALMOL, V90, pe652, DOI 10.1111/j.1755-3768.2012.02539.x
   Pournaras CJ, 1997, ARCH OPHTHALMOL-CHIC, V115, P1553, DOI 10.1001/archopht.1997.01100160723009
   Querques G, 2009, AM J OPHTHALMOL, V147, P375, DOI 10.1016/j.ajo.2008.10.008
   Rasmussen A, 2013, OPHTHALMOLOGY, V120, P2630, DOI 10.1016/j.ophtha.2013.05.018
   Regillo CD, 2008, AM J OPHTHALMOL, V145, P239, DOI 10.1016/j.ajo.2007.10.004
   Roller AB, 2010, OPHTHALMOLOGY, V117, P1381, DOI 10.1016/j.ophtha.2009.11.007
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Rosenfeld PJ, 2011, OPHTHALMOLOGY, V118, P523, DOI 10.1016/j.ophtha.2010.07.011
   Schmidt-Erfurth U, 2011, OPHTHALMOLOGY, V118, P831, DOI 10.1016/j.ophtha.2010.09.004
   Schulze S, 2008, ACTA OPHTHALMOL, V86, P470, DOI 10.1111/j.1755-3768.2008.01210.x
   Schulze S, 2012, ACTA OPHTHALMOL, V90, P244, DOI 10.1111/j.1755-3768.2010.01929.x
   Shui YB, 2009, ARCH OPHTHALMOL-CHIC, V127, P475, DOI 10.1001/archophthalmol.2008.621
   Sin M, 2014, ACTA OPHTHALMOL, V92, P328, DOI 10.1111/aos.12238
   Spaide RF, 2006, AM J OPHTHALMOL, V141, P149, DOI 10.1016/j.ajo.2005.07.025
   STEFANSSON E, 1982, RETINA-J RET VIT DIS, V2, P159, DOI 10.1097/00006982-198200230-00006
   Stefansson E, 2006, ACTA OPHTHALMOL SCAN, V84, P718, DOI 10.1111/j.1600-0420.2006.00778.x
   Stefansson E, 2009, GRAEF ARCH CLIN EXP, V247, P147, DOI 10.1007/s00417-008-0980-7
   Weber-Krause Brigitte, 1996, Ophthalmologe, V93, P660, DOI 10.1007/s003470050054
NR 49
TC 8
Z9 8
U1 0
U2 4
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1755-375X
EI 1755-3768
J9 ACTA OPHTHALMOL
JI Acta Ophthalmol.
PD AUG
PY 2014
VL 92
IS 5
BP 465
EP 472
DI 10.1111/aos.12326
PG 8
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA AL9SZ
UT WOS:000339482700036
PM 24690440
DA 2022-11-30
ER

PT J
AU Wittenborn, JS
   Clemons, T
   Regillo, C
   Rayess, N
   Kruger, DL
   Rein, D
AF Wittenborn, John S.
   Clemons, Traci
   Regillo, Carl
   Rayess, Nadim
   Kruger, Danielle Liffmann
   Rein, David
TI Economic Evaluation of a Home-Based Age-Related Macular Degeneration
   Monitoring System
SO JAMA OPHTHALMOLOGY
LA English
DT Article
ID UNITED-STATES; CHOROIDAL NEOVASCULARIZATION; CLINICAL CHARACTERISTICS;
   RANDOMIZED-TRIAL; VISUAL-ACUITY; EYE HOME; RANIBIZUMAB; PREVALENCE;
   BEVACIZUMAB; MEDICINE
AB BACKGROUND Medicare recently approved coverage of home telemonitoring for early detection of incident choroidal neovascularization (CNV) among patients with age-related macular degeneration (AMD), but no economic evaluation has yet assessed its cost-effectiveness and budgetary impact.
   OBJECTIVES To evaluate a home-based daily visual-field monitoring system using simulation methods and to apply the findings of the Home Monitoring of the Eye study to the US population at high risk for wet-form AMD.
   DESIGN, SETTING, AND PARTICIPANTS In this economic analysis, an evaluation of the potential cost, cost-effectiveness, and government budgetary impact of adoption of a home-based daily visual-field monitoring system among eligible Medicare patients was performed. Effectiveness and visual outcomes data from the Age-Related Eye Disease Study 2 Home Monitoring of the Eye study, treatment data from the Wills Eye Hospital Treat & Extend study, and AMD progression data from the Age-Related Eye Disease Study 1 were used to simulate the long-term effects of telemonitoring patients with CNV in one eye or large drusen and/or pigment abnormalities in both eyes. Univariate and probabilistic sensitivity analysis and an alternative scenario using the Treat & Extend study control group outcomes were used to examine uncertainty in these data and assumptions.
   INTERVENTIONS Home telemonitoring of patients with AMD for early detection of CNV vs usual care.
   MAIN OUTCOMES AND MEASURES Incremental cost-effectiveness ratio, net present value of lifetime societal costs, and 10-year nominal government expenditures.
   RESULT Telemonitoring of patients with existing unilateral CNV or multiple bilateral risk factors for CNV (large drusen and retinal pigment abnormalities) incurs $907 (95% CI, -$6302 to $2809) in net lifetime societal costs, costs $1312 (95% CI, $222-$2848) per patient during 10 years from the federal government's perspective, and results in an incremental cost-effectiveness ratio of $35 663 (95% CI, cost savings to $235 613) per quality-adjusted life-year gained.
   CONCLUSIONS AND RELEVANCE Home telemonitoring of patients with AMD who are at risk for CNV was cost-effective compared with scheduled examinations alone. Monitoring patients with existing CNV in one eye is cost saving, but monitoring is generally not cost-effective among patients with low risk of CNV, including those with no or few risk factors. With Medicare coverage, monitoring incurs budgetary expenditures for the government but is cost-saving for patients at high risk of AMD. Monitoring could be cost saving to society if monitoring reduced the frequency of scheduled examinations or led to a reduction of one or more injections of ranibizumab.
C1 [Wittenborn, John S.; Rein, David] Univ Chicago, NORC, 55 E Monroe St,30th Floor, Chicago, IL 60603 USA.
   [Clemons, Traci] Emmes Corp, Rockville, MD USA.
   [Regillo, Carl; Rayess, Nadim] Wills Eye Hosp & Res Inst, Bryn Mawr, PA USA.
   [Kruger, Danielle Liffmann] Chartis Grp, Chicago, IL USA.
C3 University of Chicago; Emmes Corporation
RP Wittenborn, JS (通讯作者)，Univ Chicago, NORC, 55 E Monroe St,30th Floor, Chicago, IL 60603 USA.
EM wittenborn-john@norc.org
OI Rein, David/0000-0002-1271-5789
FU Notal Vision LLC, Tel Aviv, Israel
FX This study was funded by an unrestricted grant from Notal Vision LLC,
   Tel Aviv, Israel.
CR Acharya N, 2009, BRIT J OPHTHALMOL, V93, P627, DOI 10.1136/bjo.2008.147231
   [Anonymous], 2014, TENNESSEE RETIN 0214
   Braithwaite RS, 2008, MED CARE, V46, P349, DOI 10.1097/MLR.0b013e31815c31a7
   Brown MM, 2003, SURV OPHTHALMOL, V48, P204, DOI 10.1016/S0039-6257(02)00457-5
   Brown MM, 2001, OPHTHALMOLOGY, V108, P643, DOI 10.1016/S0161-6420(00)00635-7
   Centers for Medicare & Medicaid Services, 2014, MED FEE SCHED CPT 99
   Chakravarthy U, 2012, OPHTHALMOLOGY, V119, DOI 10.1016/j.ophtha.2012.04.015
   Chew EY, 2014, CONTEMP CLIN TRIALS, V37, P294, DOI 10.1016/j.cct.2014.02.003
   Chew EY, 2014, OPHTHALMOLOGY, V121, P535, DOI 10.1016/j.ophtha.2013.10.027
   Cohen SY, 2009, AM J OPHTHALMOL, V148, P409, DOI 10.1016/j.ajo.2009.04.001
   Congdon N, 2004, ARCH OPHTHALMOL-CHIC, V122, P477
   Day S, 2011, AM J OPHTHALMOL, V152, P1014, DOI 10.1016/j.ajo.2011.05.008
   Ferris FL, 2005, ARCH OPHTHALMOL-CHIC, V123, P1570
   Fong DS, 2010, OPHTHALMOLOGY, V117, P298, DOI 10.1016/j.ophtha.2009.07.023
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P564
   Friedman DS, 2012, VIS PROBL US
   Gold MR, 1998, MED CARE, V36, P778, DOI 10.1097/00005650-199806000-00002
   Gold MR., 1996, COST EFFECTIVENESS H
   Halpern MT, 2006, HEALTH CARE FINANC R, V27, P37
   He W., 2011, 90 US 2006 2008 AM C
   Hirami Y, 2009, JPN J OPHTHALMOL, V53, P396, DOI 10.1007/s10384-009-0669-4
   Keenan TDL, 2013, BRIT J OPHTHALMOL, V97, P1168, DOI 10.1136/bjophthalmol-2013-303233
   Loewenstein A, 2007, RETINA-J RET VIT DIS, V27, P873, DOI 10.1097/IAE.0b013e318050d2ec
   Martin DF, 2012, OPHTHALMOLOGY, V119, DOI 10.1016/j.ophtha.2012.03.053
   Neumann PJ, 2009, HEALTH AFFAIR, V28, P1366, DOI 10.1377/hlthaff.28.5.1366
   Olsen TW, 2004, OPHTHALMOLOGY, V111, P250, DOI 10.1016/j.ophtha.2003.05.030
   Pare G, 2007, J AM MED INFORM ASSN, V14, P269, DOI 10.1197/jamia.M2270
   Rofagha S, 2013, OPHTHALMOLOGY, V120, P2292, DOI 10.1016/j.ophtha.2013.03.046
   Schmier JK, 2006, PHARMACOECONOMICS, V24, P319, DOI 10.2165/00019053-200624040-00003
   Sunness JS, 1999, OPHTHALMOLOGY, V106, P910, DOI 10.1016/S0161-6420(99)00509-6
   Wittenborn J, 2013, COST VISION PROBLEMS
   Wittenborn JS, 2014, FUTURE VISION FORECA
   Ying GS, 2013, OPHTHALMOLOGY, V120, P122, DOI 10.1016/j.ophtha.2012.07.042
   Zawinka C, 2005, RETINA-J RET VIT DIS, V25, P324, DOI 10.1097/00006982-200504000-00012
NR 34
TC 24
Z9 26
U1 0
U2 4
PU AMER MEDICAL ASSOC
PI CHICAGO
PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA
SN 2168-6165
EI 2168-6173
J9 JAMA OPHTHALMOL
JI JAMA Ophthalmol.
PD MAY
PY 2017
VL 135
IS 5
BP 452
EP 459
DI 10.1001/jamaophthalmol.2017.0255
PG 8
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA EU5ZN
UT WOS:000401113400013
PM 28358948
OA Green Published
DA 2022-11-30
ER

PT J
AU Weber, PA
   Wirostko, BM
   Xu, XA
   Goss, TF
   Zlateva, G
AF Weber, Pamela A.
   Wirostko, Barbara M.
   Xu, Xiao
   Goss, Thomas F.
   Zlateva, Gergana
TI Newly diagnosed exudative age-related macular degeneration treated with
   pegaptanib sodium monotherapy in US community-based practices: medical
   chart review study
SO BMC OPHTHALMOLOGY
LA English
DT Article
ID VISUAL IMPAIRMENT; CHOROIDAL NEOVASCULARIZATION; RESOURCE UTILIZATION;
   HIP FRACTURE; BURDEN; MULTICOUNTRY; VERTEPORFIN; THERAPY; RISK; ZINC
AB Background: Studies have shown that early detection and treatment of neovascular age-related macular degeneration (NV-AMD) can delay vision loss and blindness. The objective of this study was to evaluate the efficacy/safety of intravitreal pegaptanib sodium monotherapy in treatment-naive subjects with newly diagnosed NV-AMD and to gain insight into characteristics of lesions treated in community-based practices.
   Methods: From seven private US practices, charts were retrospectively reviewed on 73 subjects with previously untreated subfoveal choroidal NV-AMD treated with their first dose of pegaptanib monotherapy on/after 4/1/2005 through 6/5/2006, receiving >= 4 treatments at 6-week intervals over 21 weeks. Primary endpoint: mean visual acuity (VA) change from baseline to month 6.
   Results: 75% of lesions were occult, and 82% were subfoveal. From baseline to month 6, mean VA change was -0.68 lines; 58% and 16% gained >= 0 and >= 3 lines of VA, and 70% were responders (<3 lines lost). In 35 subjects with early disease, 80% were responders with a mean gain of 0.46 lines.
   Conclusion: Pegaptanib is effective in real-world patients with treatment-naive NV-AMD in uncontrolled community-based retina practices.
C1 [Wirostko, Barbara M.; Zlateva, Gergana] Pfizer Inc, New York, NY 10017 USA.
   [Weber, Pamela A.] Isl Retina, New York, NY 11967 USA.
   [Xu, Xiao; Goss, Thomas F.] Covance Market Access Serv Inc, Gaithersburg, MD 20878 USA.
C3 Pfizer; Covance
RP Wirostko, BM (通讯作者)，Pfizer Inc, 235 E 42nd St, New York, NY 10017 USA.
EM barbara.wirostko@pfizer.com
FU Pfizer Inc; (OSI) Eyetech, Inc
FX The research was funded by Pfizer Inc and (OSI) Eyetech, Inc. Editorial
   assistance was provided by Jane G. Murphy, PhD, of Zola Associates and
   was funded by Pfizer Inc, New York, New York, USA.
CR Ambati J, 2003, SURV OPHTHALMOL, V48, P257, DOI 10.1016/S0039-6257(03)00030-4
   *AMD ALL INT, FACTS AMD
   Benjamin LE, 1998, DEVELOPMENT, V125, P1591
   Blinder KJ, 2003, AM J OPHTHALMOL, V136, P407, DOI 10.1016/S0002-9394(03)00223-X
   BONSASTRE J, 2003, PHARMACOECONOMICS, V21, P181
   Boyer DS, 2007, OPHTHALMOLOGY, V114, P246, DOI 10.1016/j.ophtha.2006.10.045
   Bressler NM, 1999, ARCH OPHTHALMOL-CHIC, V117, P1329
   Chakravarthy U, 2006, OPHTHALMOLOGY, V113, P1508, DOI 10.1016/j.ophtha.2006.02.064
   Cruess AF, 2008, PHARMACOECONOMICS, V26, P57, DOI 10.2165/00019053-200826010-00006
   DargentMolina P, 1996, LANCET, V348, P145, DOI 10.1016/S0140-6736(96)01440-7
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P564
   Gonzales CR, 2005, RETINA-J RET VIT DIS, V25, P815
   GOTTLIEB MD, 2002, JAMA-J AM MED ASSOC, V288, P2233
   Gragoudas ES, 2004, NEW ENGL J MED, V351, P2805, DOI 10.1056/NEJMoa042760
   Hopley C, 2004, BRIT J OPHTHALMOL, V88, P450, DOI 10.1136/bjo.2003.035279
   Ivers RQ, 2003, J AM GERIATR SOC, V51, P356, DOI 10.1046/j.1532-5415.2003.51109.x
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1417, DOI 10.1001/archopht.119.10.1417
   Lee DJ, 2003, AM J OPHTHALMOL, V136, P1152, DOI 10.1016/S0002-9394(03)00573-7
   Lotery A, 2007, BRIT J OPHTHALMOL, V91, P1303, DOI 10.1136/bjo.2007.116939
   Marx J, 2003, SCIENCE, V301, P452, DOI 10.1126/science.301.5632.452
   Olsen TW, 2004, OPHTHALMOLOGY, V111, P250, DOI 10.1016/j.ophtha.2003.05.030
   Resnikoff S, 2004, B WORLD HEALTH ORGAN, V82, P844
   Soubrane G, 2007, ARCH OPHTHALMOL-CHIC, V125, P1249, DOI 10.1001/archopht.125.9.1249
   Wong T, 2008, OPHTHALMOLOGY, V115, P116, DOI 10.1016/j.ophtha.2007.03.008
NR 24
TC 3
Z9 3
U1 0
U2 0
PU BIOMED CENTRAL LTD
PI LONDON
PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND
SN 1471-2415
J9 BMC OPHTHALMOL
JI BMC Ophthalmol.
PD FEB 9
PY 2010
VL 10
AR 2
DI 10.1186/1471-2415-10-2
PG 10
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 677RS
UT WOS:000284010100001
PM 20144224
OA gold, Green Published
DA 2022-11-30
ER

PT J
AU Weyer-Wendl, H
   Walter, P
AF Weyer-Wendl, Hannah
   Walter, Peter
TI Financial burden and quality of life of informal caregivers of patients
   with wet age-related macular degeneration
SO HEALTH ECONOMICS REVIEW
LA English
DT Article
DE Age-related macular degeneration; Caregivers; Costs; Quality of life
ID HEALTH; IMPACT; CARE; ASSOCIATION; IMPAIRMENT; GERMANY; COSTS
AB Purpose: The purpose of this research is to quantify the cost burden, care times and the impact on the quality of life (QoL) of informal caring relatives caring for patients with wet age-related macular degeneration (wet AMD). Moreover we investigated the impact of care times on the QoL.
   Methods: Through a specifically designed questionnaire, 150 caring relatives were interviewed retrospectively on all accrued financial costs, caring times incurred and the current QoL, assessed by a Visual Analogue Scale for happiness (VAS).
   Results: The caring time incurred was on average 6.4 +/- 8.5 (mean +/- SD) hours per week. The QoL was on average rated at 6.7 +/- 1.9 on a ten point scale. Financial strain was incurred by the direct non-medical costs of on average (sic) 405 +/- 1104 and the direct medical costs of on average (sic) 134 +/- 340 per year. Indirect costs were stated by two caregivers as amounting to (sic) 2400 and (sic) 6000 net income loss per year respectively. Caregivers of privately insured patients with wet AMD carried a financial cost burden which was up to six times higher than caregivers of patients who were on state insurance while showing the same visual acuity.
   Conclusion: The evaluation shows that caregivers of privately insured patients with wet AMD have higher costs than caregivers of patients with state insurance coverage. This burden seems to be a factor to be considered independently since it does not appear to have any relation to patients AMD acuity.
C1 [Weyer-Wendl, Hannah; Walter, Peter] Rhein Westfal TH Aachen, Dept Ophthalmol, Pauwelsstr 30, D-52074 Aachen, Germany.
C3 RWTH Aachen University
RP Weyer-Wendl, H (通讯作者)，Rhein Westfal TH Aachen, Dept Ophthalmol, Pauwelsstr 30, D-52074 Aachen, Germany.
EM weyer.wendl@gmail.com
RI Walter, Peter/L-5982-2018
OI Walter, Peter/0000-0001-8745-6593
CR Bambara JK, 2009, INVEST OPHTH VIS SCI, V50, P1585, DOI 10.1167/iovs.08-2744
   Bandello F, 2008, DRUG AGING, V25, P255, DOI 10.2165/00002512-200825030-00007
   Bonastre J, 2003, PHARMACOECONOMICS, V21, P181, DOI 10.2165/00019053-200321030-00003
   Brouwer WBF, 2006, QUAL LIFE RES, V15, P1005, DOI 10.1007/s11136-005-5994-6
   Espallargues M, 2005, INVEST OPHTH VIS SCI, V46, P4016, DOI 10.1167/iovs.05-0072
   Finger RP, 2011, BRIT J OPHTHALMOL, V95, P1061, DOI 10.1136/bjo.2010.194712
   Finger RP, 2011, INVEST OPHTH VIS SCI, V52, P3613, DOI 10.1167/iovs.10-7127
   Javitt JC, 2007, OPHTHALMOLOGY, V114, P238, DOI 10.1016/j.ophtha.2006.07.054
   Lamoureux E, 2011, AM J OPHTHALMOL, V151, P195, DOI 10.1016/j.ajo.2010.09.020
   Mangione CM, 1999, AM J OPHTHALMOL, V128, P45, DOI 10.1016/S0002-9394(99)00169-5
   Nijboer C, 1999, SOC SCI MED, V48, P1259, DOI 10.1016/S0277-9536(98)00426-2
   Pauleikhoff D, 2009, OPHTHALMOLOGE, V106, P242, DOI 10.1007/s00347-008-1797-9
   Porz G, 2010, OPHTHALMOLOGE, V107, P216, DOI 10.1007/s00347-009-2036-8
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Schmier JK, 2006, RETINA-J RET VIT DIS, V26, P1056, DOI 10.1097/01.iae.0000254890.48272.5a
   Smith W, 2001, OPHTHALMOLOGY, V108, P697, DOI 10.1016/S0161-6420(00)00580-7
   Strawbridge WJ, 2007, J GERONTOL B-PSYCHOL, V62, pS315, DOI 10.1093/geronb/62.5.S315
   Weyer-Wendl H, 2016, OPHTHALMOLOGE, V113, P230, DOI 10.1007/s00347-015-0135-2
NR 18
TC 5
Z9 5
U1 0
U2 5
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 2191-1991
J9 HEALTH ECON REV
JI Health Econ. Rev.
PD AUG 26
PY 2016
VL 6
AR 37
DI 10.1186/s13561-016-0116-4
PG 10
WC Economics; Health Policy & Services
WE Social Science Citation Index (SSCI)
SC Business & Economics; Health Care Sciences & Services
GA FE3TY
UT WOS:000408139800001
PM 27562805
OA Green Published, gold
DA 2022-11-30
ER

PT J
AU Braun, PX
   Mehta, N
   Gendelman, I
   Alibhai, AY
   Moult, EM
   Zhao, Y
   Ishibazawa, A
   Sorour, O
   Konstantinou, EK
   Baumal, CR
   Witkin, AJ
   Fujimoto, JG
   Duker, JS
   Waheed, NK
AF Braun, Phillip X.
   Mehta, Nihaal
   Gendelman, Isaac
   Alibhai, A. Yasin
   Moult, Eric M.
   Zhao, Yi
   Ishibazawa, Akihiro
   Sorour, Osama
   Konstantinou, Eleni K.
   Baumal, Caroline R.
   Witkin, Andre J.
   Fujimoto, James G.
   Duker, Jay S.
   Waheed, Nadia K.
TI Global Analysis of Macular Choriocapillaris Perfusion in Dry Age-Related
   Macular Degeneration using Swept-Source Optical Coherence Tomography
   Angiography
SO INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE
LA English
DT Article
DE OCTA; macula; choriocapillaris; retina; dry age-related macular
   degeneration
ID GEOGRAPHIC ATROPHY; MORPHOMETRIC-ANALYSIS; DRUSEN; EYES
AB PURPOSE. Swept-source optical coherence tomography angiography (SS-OCTA) was used to investigate if the clinical stage of dry age-related macular degeneration (AMD) was correlated with global and regional macular choriocapillaris (CC) perfusion.
   METHODS. In this retrospective, cross-sectional study, 6 x 6-mm SS-OCTA images from eyes with early, intermediate, and advanced dry AMD (56 eyes, 41 patients) were analyzed using algorithms described in the literature to assess regional flow deficit percentage (FD%) and average flow deficit size. Regions were defined by concentric areas centered on the fovea: a 1-mm-diameter area, 3-mm-diameter ring, 5-mm-diameter area, 5-mm-diameter ring, and 6 x 6-mm whole image. Data were modeled using the generalized estimating equations approach.
   RESULTS. The relationship between age and CC FD% and average flow deficit size was statistically significant (P <= 0.05) in all regions of analysis by linear modeling. The relationship between dry AMD stage and FD% was statistically significant by linear modeling in the 5-mm ring, and between dry AMD stage and average flow deficit size in the 3-mm ring, 5-mm area, 5-mm ring, and 6 x 6-mm whole image.
   CONCLUSIONS. Linear modeling suggests a statistically significant relationship between dry AMD stage and CC perfusion, most prominent in the more peripheral regions of the macula.
C1 [Braun, Phillip X.; Mehta, Nihaal; Gendelman, Isaac; Alibhai, A. Yasin; Ishibazawa, Akihiro; Sorour, Osama; Konstantinou, Eleni K.; Baumal, Caroline R.; Witkin, Andre J.; Duker, Jay S.; Waheed, Nadia K.] Tufts Med Ctr, New England Eye Ctr, Boston, MA 02111 USA.
   [Braun, Phillip X.] Yale Univ, Sch Med, New Haven, CT USA.
   [Mehta, Nihaal] Brown Univ, Warren Alpert Med Sch, Providence, RI 02912 USA.
   [Gendelman, Isaac] Tufts Univ, Sch Med, Boston, MA 02111 USA.
   [Moult, Eric M.; Fujimoto, James G.] MIT, Dept Elect Engn & Comp Sci, Cambridge, MA 02139 USA.
   [Zhao, Yi] Tufts Univ, Friedman Sch Nutr Sci & Policy, Boston, MA 02111 USA.
   [Ishibazawa, Akihiro] Asahikawa Med Univ, Dept Ophthalmol, Asahikawa, Hokkaido, Japan.
   [Sorour, Osama] Tanta Univ, Dept Ophthalmol, Tanta, Egypt.
C3 Tufts Medical Center; Yale University; Brown University; Tufts
   University; Massachusetts Institute of Technology (MIT); Tufts
   University; Asahikawa Medical College; Egyptian Knowledge Bank (EKB);
   Tanta University
RP Waheed, NK (通讯作者)，New England Eye Ctr, 260 Tremont St, Boston, MA 02116 USA.
EM nadiakwaheed@gmail.com
RI Sorour, Osama/Q-2759-2019; Konstantinou, Eleni/ABD-1753-2020
OI Sorour, Osama/0000-0003-0946-4285; Gendelman, Isaac/0000-0002-1694-137X
FU Macula Vision Research Foundation (West Conshohocken, PA, USA);
   Massachusetts Lions Clubs (Belmont, MA, USA); National Institutes of
   Health [5-R01-EY011289-31]; Air Force Office of Scientific Research
   [FA9550-15-1-0473]; Champalimaud Vision Award (Lisbon, Portugal);
   Beckman-Argyros Award in Vision Research (Irvine, CA, USA); NIH-National
   Institute of Diabetes and Digestive and Kidney Diseases Medical Student
   Research Fellowship [T35DK104689]; National Center for Advancing
   Translational Sciences of the NIH [TL1 TR001864]; Yale School of
   Medicine Medical Student Fellowship (New Haven, CT, USA); NATIONAL
   CENTER FOR ADVANCING TRANSLATIONAL SCIENCES [UL1TR001863, TL1TR001864]
   Funding Source: NIH RePORTER; NATIONAL EYE INSTITUTE [R01EY011289]
   Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND
   DIGESTIVE AND KIDNEY DISEASES [T35DK104689] Funding Source: NIH RePORTER
FX Supported by the Macula Vision Research Foundation (West Conshohocken,
   PA, USA), the Massachusetts Lions Clubs (Belmont, MA, USA), the National
   Institutes of Health (Grant Number 5-R01-EY011289-31), the Air Force
   Office of Scientific Research (Grant Number FA9550-15-1-0473), the
   Champalimaud Vision Award (Lisbon, Portugal), the Beckman-Argyros Award
   in Vision Research (Irvine, CA, USA), an NIH-National Institute of
   Diabetes and Digestive and Kidney Diseases Medical Student Research
   Fellowship (Award Number T35DK104689), the National Center for Advancing
   Translational Sciences of the NIH (Award Number TL1 TR001864), and a
   Yale School of Medicine Medical Student Fellowship (New Haven, CT, USA).
CR Alten F, 2016, GRAEF ARCH CLIN EXP, V254, P2165, DOI 10.1007/s00417-016-3375-1
   Biesemeier A, 2014, NEUROBIOL AGING, V35, P2562, DOI 10.1016/j.neurobiolaging.2014.05.003
   Borrelli E, 2018, AM J OPHTHALMOL, V196, P34, DOI 10.1016/j.ajo.2018.08.014
   Borrelli E, 2018, RETINA-J RET VIT DIS, V38, P1968, DOI 10.1097/IAE.0000000000002198
   Borrelli E, 2017, INVEST OPHTH VIS SCI, V58, P4792, DOI 10.1167/iovs.17-22360
   Choi W, 2015, OPHTHALMOLOGY, V122, P2532, DOI 10.1016/j.ophtha.2015.08.029
   Cicinelli MV, 2017, BRIT J OPHTHALMOL, V101, P1193, DOI 10.1136/bjophthalmol-2016-309481
   Fleckenstein M, 2018, OPHTHALMOLOGY, V125, P369, DOI 10.1016/j.ophtha.2017.08.038
   Garrity ST, 2018, INVEST OPHTH VIS SCI, V59, pAMD48, DOI 10.1167/iovs.18-24158
   Jr Brantley MA, 2018, INVEST OPHTHALMOL VI, V59
   Lane M, 2016, INVEST OPHTH VIS SCI, V57, pOCT585, DOI 10.1167/iovs.15-18915
   McLeod DS, 2009, INVEST OPHTH VIS SCI, V50, P4982, DOI 10.1167/iovs.09-3639
   Miller Joan W, 2017, US Ophthalmic Rev, V10, P119, DOI 10.17925/USOR.2017.10.02.119
   Miller JW, 2016, TRANSL VIS SCI TECHN, V5, DOI 10.1167/tvst.5.2.9
   Moult EM, 2016, RETINA-J RET VIT DIS, V36, pS2, DOI 10.1097/IAE.0000000000001287
   Mullins RE, 2011, INVEST OPHTH VIS SCI, V52, P1606, DOI 10.1167/iovs.10-6476
   Nassisi M, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0212563
   Nassisi M, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0207638
   Nassisi M, 2019, BRIT J OPHTHALMOL, V103, P911, DOI 10.1136/bjophthalmol-2018-312643
   Nesper PL, 2017, AM J OPHTHALMOL, V174, P42, DOI 10.1016/j.ajo.2016.10.005
   Rabiolo A, 2017, CLIN OPHTHALMOL, V11, P1707, DOI 10.2147/OPTH.S130165
   RAMRATTAN RS, 1994, INVEST OPHTH VIS SCI, V35, P2857
   Rosenfeld PJ, 2018, OPHTHALMOLOGY, V125, P794, DOI 10.1016/j.ophtha.2018.02.027
   Sacconi R, 2018, RETINA-J RET VIT DIS, V38, P2350, DOI 10.1097/IAE.0000000000001873
   Sacconi R, 2019, BRIT J OPHTHALMOL, V103, P1320, DOI 10.1136/bjophthalmol-2018-313004
   Seddon JM, 2016, JAMA OPHTHALMOL, V134, P1272, DOI 10.1001/jamaophthalmol.2016.3519
   Sohn EH, 2019, AM J PATHOL, V189, P1473, DOI 10.1016/j.ajpath.2019.04.005
   Spaide RF, 2018, PROG RETIN EYE RES, V64, P1, DOI 10.1016/j.preteyeres.2017.11.003
   Spaide RF, 2016, AM J OPHTHALMOL, V170, P58, DOI 10.1016/j.ajo.2016.07.023
   Spaide RF, 2015, RETINA-J RET VIT DIS, V35, P2163, DOI 10.1097/IAE.0000000000000765
   THULLIEZ M, 2019, IMAGING OPHTHALMOL R, V3, P478, DOI DOI 10.1016/j.oret.2019.01.024
   Waheed NK, 2016, DEV OPHTHALMOL, V56, P91, DOI 10.1159/000442784
   Wightman AJ, 2018, CLIN EXP OPTOM, V102, P455
   Ying GS, 2017, OPHTHAL EPIDEMIOL, V24, P130, DOI 10.1080/09286586.2016.1259636
   Zhang QQ, 2018, INVEST OPHTH VIS SCI, V59, P203, DOI 10.1167/iovs.17-22953
   Zheng F, 2019, AM J OPHTHALMOL, V200, P110, DOI 10.1016/j.ajo.2018.12.025
NR 36
TC 11
Z9 11
U1 0
U2 2
PU ASSOC RESEARCH VISION OPHTHALMOLOGY INC
PI ROCKVILLE
PA 12300 TWINBROOK PARKWAY, ROCKVILLE, MD 20852-1606 USA
SN 0146-0404
EI 1552-5783
J9 INVEST OPHTH VIS SCI
JI Invest. Ophthalmol. Vis. Sci.
PD DEC
PY 2019
VL 60
IS 15
BP 4985
EP 4990
DI 10.1167/iovs.19-27861
PG 6
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA KD1NV
UT WOS:000507640100005
PM 31791062
OA Green Published, gold
DA 2022-11-30
ER

PT J
AU Kodjikian, L
   Parravano, M
   Clemens, A
   Dolz-Marco, R
   Holz, FG
   Munk, MR
   Nicolo, M
   Ricci, F
   Silva, R
   Talks, SJ
   Verma, RK
   Zarranz-Ventura, J
   Zweifel, SA
AF Kodjikian, Laurent
   Parravano, Mariacristina
   Clemens, Andreas
   Dolz-Marco, Rosa
   Holz, Frank G.
   Munk, Marion R.
   Nicolo, Massimo
   Ricci, Federico
   Silva, Rufino
   Talks, S. James
   Verma, Rohini Kumar
   Zarranz-Ventura, Javier
   Zweifel, Sandrine A.
TI Fluid as a critical biomarker in neovascular age-related macular
   degeneration management: literature review and consensus recommendations
SO EYE
LA English
DT Review
AB Current guidelines on the management of patients with neovascular age-related macular degeneration (nAMD) lack clear recommendations on the interpretation of fluid as seen on optical coherence tomography (OCT) imaging and the incorporation of this information into an ongoing disease treatment strategy. Our objective was to review current guidelines and scientific evidence on the role of fluid as a biomarker in the management of nAMD, and develop a clinically oriented, practical algorithm for diagnosis and management based on a consensus of expert European retinal specialists. PubMed was searched for articles published since 2006 relating to the role of fluid in nAMD. A total of 654 publications were screened for relevance and 66 publications were included for review. Of these, 14 were treatment guidelines, consensus statements and systematic reviews or meta-analyses, in which OCT was consistently recommended as an important tool in the initial diagnosis and ongoing management of nAMD. However, few guidelines distinguished between types of fluid when providing recommendations. A total of 52 publications reported primary evidence from clinical trials, studies, and chart reviews. Observations from these were sometimes inconsistent, but trends were observed with regard to features reported as being predictive of visual outcomes. Based on these findings, diagnostic recommendations and a treatment algorithm based on a treat-and-extend (T&E) regimen were developed. These provide guidance on the diagnosis of nAMD as well as a simple treatment pathway based on the T&E regimen, with treatment decisions made according to the observations of fluid as a critical biomarker for disease activity.
C1 [Kodjikian, Laurent] Hosp Civils Lyon, Croix Rousse Univ Hosp, Dept Ophthalmol, Lyon, France.
   [Kodjikian, Laurent] Univ Lyon, Univ Claude Bernard Lyon 1, INSA Lyon, UMR CNRS Mateis 5510, Lyon, France.
   [Parravano, Mariacristina] IRCCS Fdn Bietti, Rome, Italy.
   [Clemens, Andreas; Verma, Rohini Kumar] Novartis Pharma AG, Basel, Switzerland.
   [Clemens, Andreas] Univ Freiburg, Fac Med, Heart Ctr Freiburg Univ, Dept Cardiol & Angiol 1, Freiburg, Germany.
   [Dolz-Marco, Rosa] Oftalvist Clin, Macula Unit, Valencia, Spain.
   [Holz, Frank G.] Univ Bonn, Dept Ophthalmol, Bonn, Germany.
   [Munk, Marion R.] Univ Hosp Bern, Dept Ophthalmol, Inselspital, Bern, Switzerland.
   [Nicolo, Massimo] Osped Policlin San Martino IRCCS, Univ Eye Clin Genoa DINOGMI, Genoa, Italy.
   [Ricci, Federico] Univ Tor Vergata, Dept Expt Med, Rome, Italy.
   [Silva, Rufino] Univ Coimbra ICBR FMUC, Coimbra Inst Clin & Biomed Res, Fac Med, Coimbra, Portugal.
   [Silva, Rufino] Ctr Hosp & Univ Coimbra CHUC, Dept Ophthalmol, Coimbra, Portugal.
   [Silva, Rufino] Assoc Innovat & Biomed Res Light & Image AIBILI, Coimbra, Portugal.
   [Talks, S. James] Newcastle Upon Tyne Hosp NHS Fdn Trust, Newcastle Upon Tyne, Tyne & Wear, England.
   [Zarranz-Ventura, Javier] Hosp Clin Barcelona, Barcelona, Spain.
   [Zarranz-Ventura, Javier] Inst Invest Biomed August Pi & Sunyer IDIBAPS, Barcelona, Spain.
   [Zweifel, Sandrine A.] Univ Hosp Zurich, Dept Ophthalmol, Zurich, Switzerland.
   [Zweifel, Sandrine A.] Univ Zurich, Zurich, Switzerland.
C3 CHU Lyon; Institut National des Sciences Appliquees de Lyon - INSA Lyon;
   UDICE-French Research Universities; Universite Claude Bernard Lyon 1;
   IRCCS - Fondazione "G.B. Bietti" per lo Studio e la Ricerca in
   Oftalmologia; Novartis; Universitats Herzzentrum Freiburg; University of
   Freiburg; University of Bonn; University of Bern; University Hospital of
   Bern; University of Rome Tor Vergata; Universidade de Coimbra;
   Universidade de Coimbra; Centro Hospitalar e Universitario de Coimbra
   (CHUC); Universidade de Coimbra; Newcastle Upon Tyne Hospitals NHS
   Foundation Trust; University of Barcelona; Hospital Clinic de Barcelona;
   University of Barcelona; Hospital Clinic de Barcelona; IDIBAPS;
   University of Zurich; University Zurich Hospital; University of Zurich
RP Zweifel, SA (通讯作者)，Univ Hosp Zurich, Dept Ophthalmol, Zurich, Switzerland.; Zweifel, SA (通讯作者)，Univ Zurich, Zurich, Switzerland.
EM Sandrine.Zweifel@usz.ch
RI Zarranz-Ventura, Javier/AAB-5390-2021
OI Zarranz-Ventura, Javier/0000-0003-2338-8143; Silva,
   Rufino/0000-0001-8676-0833; Clemens, Andreas/0000-0001-6192-1557; Talks,
   James/0000-0001-6126-6476
FU Novartis Pharma AG (Basel, Switzerland); Universitat Zurich
FX Financial support for medical writing assistance was provided by
   Novartis Pharma AG (Basel, Switzerland). The authors did not receive
   financial compensation for this work. Open Access funding provided by
   Universitat Zurich.
CR American Academy of Ophthalmology, 2015, AGE RELATED MACULAR
   Amoaku W, 2009, EYE, V23, P2140, DOI 10.1038/eye.2008.241
   Amoaku WM, 2015, EYE, V29, P721, DOI 10.1038/eye.2015.48
   Androudi S, 2016, ADV THER, V33, P715, DOI 10.1007/s12325-016-0332-7
   Arnold JJ, 2016, BMC OPHTHALMOL, V16, DOI 10.1186/s12886-016-0207-3
   Ashraf M, 2018, ACTA OPHTHALMOL, V96, P120, DOI 10.1111/aos.13565
   Baek J, 2016, INVEST OPHTH VIS SCI, V57, P1500, DOI 10.1167/iovs.15-18837
   Brown DM, 2013, RETINA-J RET VIT DIS, V33, P23, DOI 10.1097/IAE.0b013e318263cedf
   Casalino G, 2016, INVEST OPHTH VIS SCI, V57, pOCT288, DOI 10.1167/iovs.15-18753
   Chakravarthy U, 2006, BRIT J OPHTHALMOL, V90, P1188, DOI 10.1136/bjo.2005.082255
   Chakravarthy U, 2013, EYE, V27, P1429, DOI 10.1038/eye.2013.233
   Chatziralli I, 2016, OPHTHALMOLOGY, V123, P1762, DOI 10.1016/j.ophtha.2016.05.002
   Dadgostar H, 2009, OPHTHALMOLOGY, V116, P1740, DOI 10.1016/j.ophtha.2009.05.033
   Dervenis N, 2016, CLIN OPHTHALMOL, V10, DOI 10.2147/OPTH.S106734
   Fulcher C, 2020, EUR J OPHTHALMOL, V30, P543, DOI 10.1177/1120672119839299
   Gianniou C, 2015, RETINA-J RET VIT DIS, V35, P1195, DOI 10.1097/IAE.0000000000000465
   Gillies MC, 2015, OPHTHALMOLOGY, V122, P1837, DOI 10.1016/j.ophtha.2015.05.010
   Gune S, 2020, OPHTHALMOLOGY, V127, P523, DOI 10.1016/j.ophtha.2019.09.030
   Guymer RH, 2019, OPHTHALMOLOGY, V126, P723, DOI 10.1016/j.ophtha.2018.11.025
   Haga A, 2018, ACTA OPHTHALMOL, V96, pE393, DOI 10.1111/aos.13607
   Ho AC, 2014, OPHTHALMOLOGY, V121, P2181, DOI 10.1016/j.ophtha.2014.05.009
   Hu XF, 2020, RETINA-J RET VIT DIS, V40, P1070, DOI 10.1097/IAE.0000000000002531
   Jaffe GJ, 2019, OPHTHALMOLOGY, V126, P252, DOI 10.1016/j.ophtha.2018.08.035
   Jaffe GJ, 2016, OPHTHALMOLOGY, V123, P1856, DOI 10.1016/j.ophtha.2016.05.016
   Jaffe GJ, 2013, OPHTHALMOLOGY, V120, P1860, DOI 10.1016/j.ophtha.2013.01.073
   Kashani AH, 2009, INVEST OPHTH VIS SCI, V50, P3366, DOI 10.1167/iovs.08-2691
   Keane PA, 2010, INVEST OPHTH VIS SCI, V51, P5431, DOI 10.1167/iovs.09-4846
   Keane PA, 2008, OPHTHALMOLOGY, V115, P2206, DOI 10.1016/j.ophtha.2008.08.016
   Khurana RN, 2019, AM J OPHTHALMOL, V200, P161, DOI 10.1016/j.ajo.2019.01.005
   Kim JH, 2019, INT J OPHTHALMOL-CHI, V12, P480, DOI 10.18240/ijo.2019.03.20
   Kodjikian L, 2018, RETINA-J RET VIT DIS, V38, P1492, DOI 10.1097/IAE.0000000000001736
   Kodjikian L, 2013, OPHTHALMOLOGY, V120, P2300, DOI 10.1016/j.ophtha.2013.06.020
   Koizumi H, 2016, OPHTHALMOLOGY, V123, P617, DOI 10.1016/j.ophtha.2015.10.039
   Kolb S, 2012, KLIN MONATSBL AUGENH, V229, P343, DOI 10.1055/s-0031-1299250
   Kumar JB, 2019, BRIT J OPHTHALMOL, V103, P918, DOI 10.1136/bjophthalmol-2018-312625
   Lai TT, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-018-36704-6
   Lee H, 2017, INVEST OPHTH VIS SCI, V58, DOI 10.1167/iovs.16-20637
   Lee H, 2016, RETINA-J RET VIT DIS, V36, P465, DOI 10.1097/IAE.0000000000000645
   Li YX, 2018, PHOTONICS-BASEL, V5, DOI 10.3390/photonics5020009
   Lin TZ, 2020, BRIT J OPHTHALMOL, V104, P58, DOI 10.1136/bjophthalmol-2018-313447
   Mariani A, 2011, GRAEF ARCH CLIN EXP, V249, P1635, DOI 10.1007/s00417-011-1734-5
   Martin DF, 2011, NEW ENGL J MED, V364, P1897, DOI 10.1056/NEJMoa1102673
   Moshfeghi DM, 2016, OSLI RETINA, V47, P238, DOI 10.3928/23258160-20160229-06
   Mowatt G, 2014, HEALTH TECHNOL ASSES, V18, P1, DOI 10.3310/hta18690
   Mrejen S, 2015, J CLIN MED, V4, P1380, DOI 10.3390/jcm4071380
   National Institute for Health and Care Excellence, 2018, NICE GUIDELINES NG82
   Ohji M, 2020, ADV THER, V37, P1173, DOI 10.1007/s12325-020-01236-x
   Padnick-Silver L, 2012, RETINA-J RET VIT DIS, V32, P1045, DOI 10.1097/IAE.0b03e31823fb82b
   Patel PJ, 2017, CLIN OPHTHALMOL, V11, P1957, DOI 10.2147/OPTH.S145732
   Pauleikhoff D, 2011, GRAEF ARCH CLIN EXP, V249, P631, DOI 10.1007/s00417-011-1639-3
   Pokroy R, 2018, RETINA-J RET VIT DIS, V38, P1485, DOI 10.1097/IAE.0000000000001748
   Regillo CD, 2015, AM J OPHTHALMOL, V160, P1014, DOI 10.1016/j.ajo.2015.07.034
   Ritter M, 2014, BRIT J OPHTHALMOL, V98, P1629, DOI 10.1136/bjophthalmol-2014-305186
   Rodrigues IA, 2016, AM J OPHTHALMOL, V168, P1, DOI 10.1016/j.ajo.2016.04.012
   Roh M, 2019, BRIT J OPHTHALMOL, V103, P1769, DOI 10.1136/bjophthalmol-2018-313316
   Sadda SR, 2018, OPHTHALMOLOGY, V125, P878, DOI 10.1016/j.ophtha.2017.12.026
   Sagiv O, 2017, OPHTHALMOLOGICA, V238, P217, DOI 10.1159/000479437
   Schmidt-Erfurth U, 2017, EYE, V31, P26, DOI 10.1038/eye.2016.227
   Schmidt-Erfurth U, 2018, OPHTHALMOL RETINA, V2, P24, DOI 10.1016/j.oret.2017.03.015
   Schmidt-Erfurth U, 2016, PROG RETIN EYE RES, V50, P1, DOI 10.1016/j.preteyeres.2015.07.007
   Schmidt-Erfurth U, 2015, OPHTHALMOLOGY, V122, P822, DOI 10.1016/j.ophtha.2014.11.017
   Schmidt-Erfurth U, 2014, BRIT J OPHTHALMOL, V98, P1144, DOI 10.1136/bjophthalmol-2014-305702
   Segal O, 2016, RETINA-J RET VIT DIS, V36, P2175, DOI 10.1097/IAE.0000000000001033
   Segal O, 2016, RETINA-J RET VIT DIS, V36, P259, DOI 10.1097/IAE.0000000000000690
   Shah N, 2016, OPHTHALMOLOGY, V123, P858, DOI 10.1016/j.ophtha.2015.11.030
   Sharma S, 2016, OPHTHALMOLOGY, V123, P865, DOI 10.1016/j.ophtha.2015.12.002
   Shin JY, 2015, ACTA OPHTHALMOL, V93, P524, DOI 10.1111/aos.12653
   Shin Joo Young, 2013, Korean J Ophthalmol, V27, P425, DOI 10.3341/kjo.2013.27.6.425
   Silva R, 2018, OPHTHALMOLOGY, V125, P57, DOI 10.1016/j.ophtha.2017.07.014
   Silva R, 2011, OPHTHALMOLOGICA, V226, DOI 10.1159/000329473
   Simader C, 2014, OPHTHALMOLOGY, V121, P1237, DOI 10.1016/j.ophtha.2013.12.029
   Spaide RF, 2020, OPHTHALMOLOGY, V127, P616, DOI 10.1016/j.ophtha.2019.11.004
   Staurenghi G, 2014, OPHTHALMOLOGY, V121, P1572, DOI 10.1016/j.ophtha.2014.02.023
   Unver YB, 2009, EYE, V23, P453, DOI 10.1038/eye.2008.349
   Vogel RN, 2017, RETINA-J RET VIT DIS, V37, P257, DOI 10.1097/IAE.0000000000001150
   Waldstein SM, 2016, OPHTHALMOLOGY, V123, P1521, DOI 10.1016/j.ophtha.2016.03.037
   Waldstein SM, 2016, OPHTHALMOLOGY, V123, P60, DOI 10.1016/j.ophtha.2015.09.013
   Wickremasinghe SS, 2016, RETINA-J RET VIT DIS, V36, P1331, DOI 10.1097/IAE.0000000000000902
   Wickremasinghe SS, 2012, OPHTHALMOLOGY, V119, P2413, DOI 10.1016/j.ophtha.2012.06.056
   Xu LN, 2015, RETINA-J RET VIT DIS, V35, P176, DOI 10.1097/IAE.0000000000000374
   Ying GS, 2018, OPHTHALMOL RETINA, V2, P525, DOI 10.1016/j.oret.2017.10.003
   Ying GS, 2014, JAMA OPHTHALMOL, V132, P915, DOI 10.1001/jamaophthalmol.2014.1019
   Zarbin M, 2019, OPHTHALMOLOGY, V126, P849, DOI 10.1016/j.ophtha.2019.01.003
   Zweifel SA, 2009, ARCH OPHTHALMOL-CHIC, V127, P1596, DOI 10.1001/archophthalmol.2009.326
NR 84
TC 11
Z9 11
U1 1
U2 4
PU SPRINGERNATURE
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND
SN 0950-222X
EI 1476-5454
J9 EYE
JI Eye
PD AUG
PY 2021
VL 35
IS 8
BP 2119
EP 2135
DI 10.1038/s41433-021-01487-0
EA APR 2021
PG 17
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA TS0VQ
UT WOS:000635837700001
PM 33795837
OA Green Published, hybrid
DA 2022-11-30
ER

PT J
AU Odergren, A
   Algvere, PV
   Seregard, S
   Libert, C
   Kvanta, A
AF Odergren, Anne
   Algvere, Peep V.
   Seregard, Stefan
   Libert, Carina
   Kvanta, Anders
TI Vision-related function after low-dose transpupillary thermotherapy
   versus photodynamic therapy for neovascular age-related macular
   degeneration
SO ACTA OPHTHALMOLOGICA
LA English
DT Article
DE age-related macular degeneration; diodlaser; experimental treatment;
   photodynamic therapy; quality of life; transpupillary thermotheraly
ID VISUAL FUNCTION QUESTIONNAIRE; QUALITY-OF-LIFE; SUBFOVEAL CHOROIDAL
   NEOVASCULARIZATION; RANIBIZUMAB
AB Purpose:
   To compare the effects of low-dose transpupillary thermotherapy (TTT) and verteporfin photodynamic therapy (PDT) on patient-reported visual function using the National Eye Institute Visual Function Questionnaire 25 (NEI VFQ-25) in patients with occult neovascular age-related macular degeneration (AMD).
   Methods:
   Patients were randomized to receive either low-dose TTT (and sham PDT) (n = 52) or PDT (and sham TTT) (n = 46). Patients were followed for 12 months with retreatment according to clinical assessment. The clinical outcome of this study has been recently reported. The NEI VFQ-25 questionnaire was administered at baseline and at 12 months.
   Results:
   Forty-two patients (80.1%) in the TTT group and 37 patients (80.0%) in the PDT group completed the questionnaire at the 12-month follow-up. The mean change in the NEI VFQ-25 composite score was +1.2 for the TTT group (p > 0.05) and +0.7 for PDT group (p > 0.05). None of the subscale categories showed significant changes between treatment groups at 12 months. Subgroup analysis showed that NEI VFQ-25 scores were lower in patients treated in their better-seeing eye.
   Conclusion:
   In this randomized study on patients with occult neovascular AMD, low-dose TTT and PDT appeared to be equally potent at stabilizing patient-reported visual function. However, the study was underpowered for this conclusion to be made firmly. Also, given the impressive results obtained with ranibizumab for all types of neovascular AMD, neither PDT nor low-dose TTT should be considered as first-line treatments.
C1 [Odergren, Anne; Algvere, Peep V.; Seregard, Stefan; Libert, Carina; Kvanta, Anders] St Eriks Eye Hosp, Vitreoretinal Dept, Karolinska Inst, SE-11282 Stockholm, Sweden.
C3 Karolinska Institutet
RP Odergren, A (通讯作者)，St Eriks Eye Hosp, Vitreoretinal Dept, Karolinska Inst, Polhemsgatan 50, SE-11282 Stockholm, Sweden.
EM anne.odergren@sankterik.se
CR Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Cahill MT, 2005, OPHTHALMOLOGY, V112, P152, DOI 10.1016/j.ophtha.2004.06.036
   Chang TS, 2007, ARCH OPHTHALMOL-CHIC, V125, P1460, DOI 10.1001/archopht.125.11.1460
   Clemons TE, 2003, ARCH OPHTHALMOL-CHIC, V121, P211
   Mangione CM, 1998, ARCH OPHTHALMOL-CHIC, V116, P227
   Mangione CM, 2001, ARCH OPHTHALMOL-CHIC, V119, P1050, DOI 10.1001/archopht.119.7.1050
   Miskala PH, 2004, OPHTHALMOLOGY, V111, P1981, DOI 10.1016/j.ophtha.2004.07.022
   Miskala PH, 2003, ARCH OPHTHALMOL-CHIC, V121, P531
   Odergren A, 2008, BRIT J OPHTHALMOL, V92, P757, DOI 10.1136/bjo.2007.133561
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Slakter JS, 2006, OPHTHALMOLOGY, V113, P3, DOI 10.1016/j.ophtha.2005.10.019
   Varma R, 2006, OPHTHALMOLOGY, V113, P1846, DOI 10.1016/j.ophtha.2006.04.028
NR 12
TC 7
Z9 7
U1 0
U2 1
PU WILEY-BLACKWELL
PI MALDEN
PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA
SN 1755-375X
J9 ACTA OPHTHALMOL
JI Acta Ophthalmol.
PD JUN
PY 2010
VL 88
IS 4
BP 426
EP 430
DI 10.1111/j.1755-3768.2009.01567.x
PG 5
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 603BD
UT WOS:000278182000008
PM 20597872
DA 2022-11-30
ER

PT J
AU Leal, C
   De Bats, F
   Morales, M
   Decullier, E
   Denis, P
   Amoaku, W
   Kodjikian, L
AF Leal, Cecilia
   De Bats, Flore
   Morales, Marco
   Decullier, Evelyne
   Denis, Philippe
   Amoaku, Winfried
   Kodjikian, Laurent
TI Anatomical-functional concordance of microperimetry and the simplified
   age-related macular degeneration study classification: A pilot study
SO EUROPEAN JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
DE Age-related macular degeneration; retina; techniques of retinal
   examination; retinal pathology; research; diagnostic techniques
ID FUNDUS AUTOFLUORESCENCE; RETINAL SENSITIVITY; GEOGRAPHIC ATROPHY;
   VISUAL-ACUITY; FIXATION STABILITY; RANIBIZUMAB; THICKNESS; SECONDARY
AB Purpose: The principal aim of this pilot study was to investigate the concordance between the different stages of Age-Related Macular Degeneration (AMD), as determined by the simplified classification of the Age Related Eye Disease Study Group (AREDS), and new evaluation criteria using a microperimetry system. Methods: A complete eye examination and a microperimetry MAIATM (Macular Integrity Assessment, CenterVue, Padova, Italy) examination was performed on 59 eyes with early, intermediate or advanced AMD. We analysed 19 evaluation criteria for every clinical group category. Results: There were 20 female and 12 male participants included with a median age of 74 years (min: 54, max: 87). Thirteen eyes (22%) were classified as category 1, 11 eyes (18.6%) as category 2, 17 eyes (28.8%) as category 3 and 18 eyes (30.6%) as category 4 AMD. All evaluated microperimetry criteria related to retinal sensitivity were found to have a statistically significant difference among the stages (p < 0.05). Fixation stability was unstable in 55.6% of the eyes classified as stage 4 (p = 0.001). The analysis of the distance between the two PRLs - PRL_initial and PRL_final was larger for the stage 4 (p = 0.0258). The mean sensitivity in stages 2 and 3 correlated with the presence or not of reticular pseudodrusen (p = 0.0137). Conclusions: The mean sensitivity and the categorized sensitivity (set to 25, 15 and 5 dB), the five higher and lower stimuli sensitivity appeared to be the most sensitive criteria to differentiate the four AMD categories. Microperimetry provides a new reproducible method of anatomical-functional macular analysis.
C1 [Leal, Cecilia] Pasteur 2 Teaching Hosp, Dept Ophthalmol, 30 Voie Romaine, F-06000 Nice, France.
   [De Bats, Flore] Pole Vis, Ecully, France.
   [Morales, Marco; Amoaku, Winfried] Univ Nottingham, Div Clin Neurosci, Acad Ophthalmol, Nottingham, England.
   [Decullier, Evelyne] Unite Rech Clin, Pole Informat Med Evaluat Rech, Lyon, France.
   [Denis, Philippe; Kodjikian, Laurent] Croix Rousse Teaching Hosp, Dept Ophthalmol, Lyon, France.
C3 CHU Nice; University of Nottingham; CHU Lyon
RP Leal, C (通讯作者)，Pasteur 2 Teaching Hosp, Dept Ophthalmol, 30 Voie Romaine, F-06000 Nice, France.
EM leal.c@chu-nice.fr
OI Amoaku, Winfried/0000-0001-5028-7984
CR Acton JH, 2012, INVEST OPHTH VIS SCI, V53, P7618, DOI 10.1167/iovs.12-10361
   Alexander P, 2012, EYE, V26, P678, DOI 10.1038/eye.2012.7
   Bolz M, 2010, BRIT J OPHTHALMOL, V94, P185, DOI 10.1136/bjo.2008.143974
   Cho HJ, 2013, AM J OPHTHALMOL, V155, P118, DOI 10.1016/j.ajo.2012.07.009
   Congdon N, 2004, ARCH OPHTHALMOL-CHIC, V122, P477
   Crossland MD, 2009, RETINA-J RET VIT DIS, V29, P651, DOI 10.1097/IAE.0b013e318196bd65
   Dinc UA, 2008, EUR J OPHTHALMOL, V18, P595, DOI 10.1177/112067210801800416
   Ferris FL, 2005, ARCH OPHTHALMOL-CHIC, V123, P1570
   Fujii GY, 2003, AM J OPHTHALMOL, V136, P1067, DOI 10.1016/S0002-9394(03)00663-9
   Fujii GY, 2002, OPHTHALMOLOGY, V109, P1737, DOI 10.1016/S0161-6420(02)01120-X
   Kassoff A, 1999, CONTROL CLIN TRIALS, V20, P573
   Kodjikian, 2015, MICROPERIMETRY EYE P
   Landa G, 2011, RETINA-J RET VIT DIS, V31, P364, DOI 10.1097/IAE.0b013e3181e91132
   Meleth AD, 2011, INVEST OPHTH VIS SCI, V52, P1119, DOI 10.1167/iovs.10-6075
   Midena E, 2007, BRIT J OPHTHALMOL, V91, P1499, DOI 10.1136/bjo.2007.119685
   Midena Edoardo, 2004, Semin Ophthalmol, V19, P55, DOI 10.1080/08820530490882896
   Morales MU, 2013, CAN J OPHTHALMOL, V48, P368, DOI 10.1016/j.jcjo.2013.05.022
   Okada K, 2009, CLIN OPHTHALMOL, V3, P483
   Ozdemir H, 2012, ACTA OPHTHALMOL, V90, P71, DOI 10.1111/j.1755-3768.2009.01838.x
   Parravano M, 2010, RETINA-J RET VIT DIS, V30, P1017, DOI 10.1097/IAE.0b013e3181cfd3c6
   Patel PJ, 2008, INVEST OPHTH VIS SCI, V49, P4347, DOI 10.1167/iovs.08-1935
   Pilotto E, 2013, BRIT J OPHTHALMOL, V97, P622, DOI 10.1136/bjophthalmol-2012-302633
   Pilotto E, 2011, BRIT J OPHTHALMOL, V95, P1140, DOI 10.1136/bjo.2010.187344
   Prager F, 2008, RETINA-J RET VIT DIS, V28, P682, DOI 10.1097/IAE.0b013e318161dc70
   Querques G, 2008, J FR OPHTALMOL, V31, P515, DOI 10.1016/S0181-5512(08)72469-0
   Querques L, 2012, AM J OPHTHALMOL, V153, P1110, DOI 10.1016/j.ajo.2011.11.002
   Souied E., 2007, DMLAS, P1
   Squirrell DM, 2010, RETINA-J RET VIT DIS, V30, P436, DOI 10.1097/IAE.0b013e3181bd2f29
   Sulzbacher F, 2012, INVEST OPHTH VIS SCI, V53, P6448, DOI 10.1167/iovs.11-9162
   Tarita-Nistor L, 2009, INVEST OPHTH VIS SCI, V50, P84, DOI 10.1167/iovs.08-2342
   Vujosevic S, 2011, OPHTHALMOLOGICA, V225, P155, DOI 10.1159/000320340
NR 31
TC 2
Z9 2
U1 0
U2 1
PU SAGE PUBLICATIONS LTD
PI LONDON
PA 1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND
SN 1120-6721
EI 1724-6016
J9 EUR J OPHTHALMOL
JI Eur. J. Ophthalmol.
PD JAN
PY 2022
VL 32
IS 1
BP 402
EP 409
AR 1120672121999348
DI 10.1177/1120672121999348
EA MAR 2021
PG 8
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA YK3MJ
UT WOS:000678258500001
PM 33648371
DA 2022-11-30
ER

PT J
AU Dorrepaal, SJ
   Markowitz, SN
AF Dorrepaal, Stephen J.
   Markowitz, Samuel N.
TI Impact of colour in the assessment of potential visual acuity in
   patients with age-related macular degeneration
SO CANADIAN JOURNAL OF OPHTHALMOLOGY-JOURNAL CANADIEN D OPHTALMOLOGIE
LA English
DT Article
ID SCOTOPIC SENSITIVITY; DARK-ADAPTATION; MACULOPATHY; CONTRAST; VISION;
   EYES; AMD
AB Objective: To compare chromatic and achromatic potential visual acuity (PVA) in patients with bilateral low vision caused by age-related macular degeneration (AMD).
   Design: Prospective, nonrandomized, observational case series.
   Participants: Fifty-five patients, representing a consecutive series of patients all presenting with bilateral AMD.
   Methods: Best-corrected visual acuity of each eye was measured using an Early Treatment in Diabetic Retinopathy Study (ETDRS) chart with appropriate near correction. Included were cases with visual acuity of 0.4 logMAR (20/50) or worse in both eyes. Achromatic and chromatic PVA were measured in each eye using white on black and red on yellow flooding E charts at 50 cm in controlled lighting conditions.
   Results: One hundred and seven eyes from 55 patients were included in the analysis. Mean achromatic and chromatic PVA were 0.69 +/- 0.26 and 0.65 +/- 0.22 logMAR, respectively. Overall, patients had a significantly higher chromatic than achromatic PVA, with a median difference of 0.1 logMAR (p < 0.05). Patients with ETDRS visual acuity worse than 0.9 logMAR also had a significantly higher chromatic than achromatic PVA, with a median difference of 0.1 logMAR (p < 0.05). Patients with ETDRS visual acuity between 0.4 and 0.9 logMAR had a trend toward a higher chromatic than achromatic visual acuity that was not significant, with a median difference of 0.1 logMAR (p = 0.8539).
   Conclusions: Patients with low vision caused by AMD can discern smaller targets when a red on yellow colour scheme is used than when using achromatic white on black charts.
C1 [Dorrepaal, Stephen J.] Queens Univ, Hotel Dieu Hosp, Dept Ophthalmol, Kingston, ON K7L 5G2, Canada.
   [Markowitz, Samuel N.] Univ Toronto, Dept Ophthalmol & Vis Sci, Toronto, ON, Canada.
C3 Queens University - Canada; University of Toronto
RP Dorrepaal, SJ (通讯作者)，Queens Univ, Hotel Dieu Hosp, Dept Ophthalmol, 166 Brock St, Kingston, ON K7L 5G2, Canada.
EM 11sjd1@queensu.ca
CR Alizadeh-Ebadi M, J OPTOMETRY IN PRESS
   Arden GB, 2004, BRIT J OPHTHALMOL, V88, P1180, DOI 10.1136/bjo.2003.033480
   Boucart M, 2008, VISUAL NEUROSCI, V25, P685, DOI 10.1017/S0952523808080826
   CHAPARRO A, 1993, NATURE, V361, P348, DOI 10.1038/361348a0
   Chen CZ, 2004, DOC OPHTHALMOL, V109, P1
   Curcio CA, 2000, INVEST OPHTH VIS SCI, V41, P2015
   Curcio CA, 2001, EYE, V15, P376, DOI 10.1038/eye.2001.140
   EISNER A, 1987, INVEST OPHTH VIS SCI, V28, P1832
   FERRIS FL, 1982, AM J OPHTHALMOL, V94, P91, DOI 10.1016/0002-9394(82)90197-0
   Frennesson C, 1998, BRIT J OPHTHALMOL, V82, P1169, DOI 10.1136/bjo.82.10.1169
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P564
   Gonzalez EG, 2007, INVEST OPHTH VIS SCI, V48, P4838, DOI 10.1167/iovs.06-1240
   Holz F G, 1995, Ger J Ophthalmol, V4, P336
   Jackson GR, 1999, VISION RES, V39, P3975, DOI 10.1016/S0042-6989(99)00092-9
   Jackson GR, 1999, INVEST OPHTH VIS SCI, V40, pS739
   Jackson GR, 1998, VISION RES, V38, P3655, DOI 10.1016/S0042-6989(98)00044-3
   Jackson GR, 2000, VISION RES, V40, P2467, DOI 10.1016/S0042-6989(00)00108-5
   KLEINER RC, 1988, ARCH OPHTHALMOL-CHIC, V106, P55
   Midena E, 1997, INVEST OPHTH VIS SCI, V38, P469
   Mitrut I, 2010, OPHTHALMOLOGY, V117, P1280, DOI 10.1016/j.ophtha.2010.01.047
   Owsley C, 2000, INVEST OPHTH VIS SCI, V41, P267
   Shima N, 2008, COLOR VISION ACUITY
NR 22
TC 0
Z9 1
U1 0
U2 5
PU CANADIAN OPHTHAL SOC
PI OTTAWA
PA 1525 CARLING AVE SUITE 610, OTTAWA, ONTARIO K1Z 8R9, CANADA
SN 0008-4182
EI 1715-3360
J9 CAN J OPHTHALMOL
JI Can. J. Opthalmol.-J. Can. Opthalmol.
PD JUN
PY 2013
VL 48
IS 3
BP 199
EP 203
DI 10.1016/j.jcjo.2013.01.010
PG 5
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA AA5OD
UT WOS:000331148400023
PM 23769782
DA 2022-11-30
ER

PT J
AU Graham, KW
   Chakravarthy, U
   Hogg, RE
   Muldrew, KA
   Young, IS
   Kee, F
AF Graham, Katie W.
   Chakravarthy, Usha
   Hogg, Ruth E.
   Muldrew, K. Alyson
   Young, Ian S.
   Kee, Frank
TI IDENTIFYING FEATURES OF EARLY AND LATE AGE-RELATED MACULAR DEGENERATION
   A Comparison of Multicolor Versus Traditional Color Fundus Photography
SO RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES
LA English
DT Article
DE multimodal imaging; age-related macular degeneration; Multicolor
ID SCANNING LASER OPHTHALMOSCOPY; RETICULAR PSEUDODRUSEN; CLASSIFICATION;
   MACULOPATHY; PEOPLE
AB Purpose: To compare multicolor (MC) and traditional color fundus photography (CFP) in their ability to detect features of early and late age-related macular degeneration (AMD).
   Methods: Study design: Observational case series. Participants: fundus images captured using standard CFP and MC imaging from 33 patients attending hospital clinics and 26 participants from the pilot phase of the Northern Ireland Cohort for the Longitudinal Study of Ageing (NICOLA). Systematic grading of early and late AMD features; (hard drusen, soft drusen, reticular pseudodrusen, pigment clumping, non-geographic atrophy hypopigmentation, atrophy, hemorrhage, and fibrosis) on CFP and MC.
   Results: There were 105 eyes with gradable images for comparison. Using CFP as the gold standard, sensitivity values for MC ranged from 100% for atrophy, non-geographic atrophy hypopigmentation, and fibrosis to 69.7% for pigment clumping. Specificity values were high: >80% for all features. On using MC as the comparator, CFP had lower sensitivity for the detection of early AMD features (27.8% for reticular drusen to 77.8% for non-geographic atrophy hypopigmention). Analysis of OCT in discrepant cases showed better agreement with MC for all AMD lesions, except hemorrhage and non-geographic atrophy hypopigmentation. For pigment clumping, CFP and MC were in equal agreement with OCT.
   Conclusion: Multicolor retinal imaging allowed for improved detection and definition of AMD features.
C1 [Graham, Katie W.; Chakravarthy, Usha; Hogg, Ruth E.; Muldrew, K. Alyson; Young, Ian S.; Kee, Frank] Queens Univ, Inst Clin Sci, Ctr Publ Hlth, Block A,Grosvenor Rd, Belfast, Antrim, North Ireland.
C3 Queens University Belfast
RP Hogg, RE (通讯作者)，Queens Univ, Inst Clin Sci, Ctr Publ Hlth, Block A,Grosvenor Rd, Belfast, Antrim, North Ireland.
EM r.e.hogg@qub.ac.uk
RI Hogg, Ruth E./ABC-9602-2020
OI Hogg, Ruth E./0000-0001-9413-2669; Young, Ian/0000-0003-3890-3152
FU ESRC [ES/L008459/1] Funding Source: UKRI
CR Ben Moussa N, 2015, BRIT J OPHTHALMOL, V99, P842, DOI 10.1136/bjophthalmol-2014-305643
   BIRD AEC, 1995, SURV OPHTHALMOL, V39, P367, DOI 10.1016/S0039-6257(05)80092-X
   Elsner AE, 1996, VISION RES, V36, P191, DOI 10.1016/0042-6989(95)00100-E
   Evans JR, 2002, BRIT J OPHTHALMOL, V86, P795, DOI 10.1136/bjo.86.7.795
   Evans JR, 2005, BRIT J OPHTHALMOL, V89, P550, DOI 10.1136/bjo.2004.049726
   Ferris FL, 2013, OPHTHALMOLOGY, V120, P844, DOI 10.1016/j.ophtha.2012.10.036
   Gordois A, 2012, GLOB PUBLIC HEALTH, V7, P465, DOI 10.1080/17441692.2011.634815
   Helb HM, 2010, ACTA OPHTHALMOL, V88, P842, DOI 10.1111/j.1755-3768.2009.01602.x
   Hogg RE, 2014, OPTOMETRY VISION SCI, V91, P854, DOI 10.1097/OPX.0000000000000287
   Hu DN, 2008, PHOTOCHEM PHOTOBIOL, V84, P639, DOI 10.1111/j.1751-1097.2008.00316.x
   Issa PC, 2008, INVEST OPHTH VIS SCI, V49, P1172, DOI 10.1167/iovs.07-0636
   Jaffe GJ, 2013, OPHTHALMOLOGY, V120, P1860, DOI 10.1016/j.ophtha.2013.01.073
   Kellner S, 2014, INVEST OPHTH VIS SCI, V55
   Kernt M, 2010, CLIN OPHTHALMOL, V4, P829
   Klein ML, 2008, OPHTHALMOLOGY, V115, P1026, DOI 10.1016/j.ophtha.2007.08.030
   KLEIN R, 1991, OPHTHALMOLOGY, V98, P1128
   Lim LS, 2012, LANCET, V379, P1728, DOI 10.1016/S0140-6736(12)60282-7
   Querques G, 2014, OPHTHALMOLOGY, V121, P173, DOI 10.1016/j.ophtha.2013.06.024
   SARKS SH, 1976, BRIT J OPHTHALMOL, V60, P324, DOI 10.1136/bjo.60.5.324
   Smith RT, 2009, AM J OPHTHALMOL, V148, P733, DOI 10.1016/j.ajo.2009.06.028
   Tan ACS, 2016, OPHTHALMOLOGICA, V236, P8, DOI 10.1159/000446857
   Ueda-Arakawa N, 2013, RETINA-J RET VIT DIS, V33, P490, DOI 10.1097/IAE.0b013e318276e0ae
   Usher-Smith JA, 2016, BMJ-BRIT MED J, V353, DOI 10.1136/bmj.i3139
   Vingolo EM, 2011, CLIN OPHTHALMOL, V5, P1007, DOI 10.2147/OPTH.S23080
NR 24
TC 33
Z9 37
U1 0
U2 4
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0275-004X
EI 1539-2864
J9 RETINA-J RET VIT DIS
JI Retin.-J. Retin. Vitr. Dis.
PD SEP
PY 2018
VL 38
IS 9
BP 1751
EP 1758
DI 10.1097/IAE.0000000000001777
PG 8
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA HF1VL
UT WOS:000454003500014
PM 28834946
DA 2022-11-30
ER

PT J
AU Piermarocchi, S
   Miotto, S
   Colavito, D
   Leon, A
   Segato, T
AF Piermarocchi, Stefano
   Miotto, Stefania
   Colavito, Davide
   Leon, Alberta
   Segato, Tatiana
TI Combined effects of genetic and non-genetic risk factors affect response
   to ranibizumab in exudative age-related macular degeneration
SO ACTA OPHTHALMOLOGICA
LA English
DT Article
DE age-related macular degeneration; ARMS2; arterial hypertension; C3; CFH;
   ranibizumab; smoking habit
ID COMPLEMENT FACTOR-H; INTRAVITREAL RANIBIZUMAB; DIETARY ANTIOXIDANTS;
   VISUAL-ACUITY; ASSOCIATION; POLYMORPHISM; PHARMACOGENETICS;
   SUSCEPTIBILITY; LOC387715; SEVERITY
AB Purpose: To investigate whether genetic and non-genetic risk factors influence 12-month response to ranibizumab treatment for exudative age-related macular degeneration (AMD).
   Methods: A cohort of 94 Caucasian patients with unilateral exudative AMD received intravitreal ranibizumab. After a three-injection loading phase, a PRN regimen was followed. Patients were genotyped for three single-nucleotide polymorphisms: CFH rs1061170, ARMS2 rs10490924 and C3 rs2230199. Non-genetic risk factors [choroidal neovascularization (CNV) phenotype, smoking habit, hypertension and body mass index] were considered. The selected end-point was the 12-month variation of number of ETDRS letters.
   Results: Complement factor H (CFH) risk alleles, smoking history and arterial hypertension each independently influenced treatment response, with worse 12-month BCVA outcomes (p = 0.036, 0.037, 0.043, respectively). A significant cumulative effect of these risk factors was also observed: patients homozygous for the CFH risk alleles and with a positive smoking history showed a mean loss of 8.0 ETDRS letters (p = 0.010). Patients with CFH risk alleles, smoking history and hypertension had a mean loss of 13.9 ETDRS letters (p = 0.013). CNV phenotypes did not influence visual outcomes, nor were they associated with other genetic/non-genetic risk factors.
   Conclusions: Complement factor H risk alleles, smoking history and hypertension affect the mid-term response to ranibizumab in exudative AMD.
C1 [Piermarocchi, Stefano; Miotto, Stefania; Segato, Tatiana] Univ Padua, Dept Neurosci, I-35128 Padua, Italy.
   [Colavito, Davide; Leon, Alberta] Res & Innovat Srl, Padua, Italy.
C3 University of Padua
RP Piermarocchi, S (通讯作者)，Univ Padua, Dept Neurosci, Via Giustiniani 2, I-35128 Padua, Italy.
EM stefano.piermarocchi@unipd.it
CR Anand R, 2000, OPHTHALMOLOGY, V107, P2224
   Andreoli MT, 2009, AM J OPHTHALMOL, V148, P869, DOI 10.1016/j.ajo.2009.07.002
   Brantley MA, 2007, OPHTHALMOLOGY, V114, P2168, DOI 10.1016/j.ophtha.2007.09.008
   Brown DM, 2009, OPHTHALMOLOGY, V116, P57, DOI 10.1016/j.ophtha.2008.10.018
   Cohen SY, 2013, RETINA-J RET VIT DIS, V33, P474, DOI 10.1097/IAE.0b013e31827b6324
   Despriet DDG, 2007, ARCH OPHTHALMOL-CHIC, V125, P1270, DOI 10.1001/archopht.125.9.1270
   Evans JR, 2001, PROG RETIN EYE RES, V20, P227, DOI 10.1016/S1350-9462(00)00023-9
   Gehrs KM, 2010, ARCH OPHTHALMOL-CHIC, V128, P349, DOI 10.1001/archophthalmol.2010.18
   Hageman Gregory S., 2011, Human Genomics, V5, P420
   Hagstrom SA, 2013, OPHTHALMOLOGY, V120, P593, DOI 10.1016/j.ophtha.2012.11.037
   Ho L, 2011, ARCH OPHTHALMOL-CHIC, V129, P758, DOI 10.1001/archophthalmol.2011.141
   Hogg RE, 2012, RETINA-J RET VIT DIS, V32, P1950, DOI 10.1097/IAE.0b013e31824dadf1
   Kanda A, 2007, P NATL ACAD SCI USA, V104, P16227, DOI 10.1073/pnas.0703933104
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1417, DOI 10.1001/archopht.119.10.1417
   Klein Ronald, 2003, Ophthalmology, V110, P1273, DOI 10.1016/S0161-6420(03)00599-2
   Kloeckener-Gruissem B, 2011, INVEST OPHTH VIS SCI, V52, P4694, DOI 10.1167/iovs.10-6080
   Lalwani GA, 2009, AM J OPHTHALMOL, V148, P43, DOI 10.1016/j.ajo.2009.01.024
   Lee S, 2013, J KOREAN MED SCI, V28, P769, DOI 10.3346/jkms.2013.28.5.769
   Leveziel N, 2008, INVEST OPHTH VIS SCI, V49, P3090, DOI 10.1167/iovs.07-1540
   Leveziel N, 2010, INVEST OPHTH VIS SCI, V51, P2620, DOI 10.1167/iovs.09-4423
   Lotery AJ, 2013, OPHTHALMOLOGY, V120, P2637, DOI 10.1016/j.ophtha.2013.07.046
   MAGUIRE MG, 1986, ARCH OPHTHALMOL-CHIC, V104, P503
   Malarcher A., 2009, Morbidity and Mortality Weekly Report, V58, P1232
   Metelitsina TI, 2006, BRIT J OPHTHALMOL, V90, P342, DOI 10.1136/bjo.2005.082974
   Milton RC, 2005, OPHTHALMOLOGY, V112, P533, DOI 10.1016/j.ophtha.2004.10.047
   Nischler C, 2011, ACTA OPHTHALMOL, V89, pE344, DOI 10.1111/j.1755-3768.2010.02080.x
   Orlin A, 2012, RETINA-J RET VIT DIS, V32, P4, DOI 10.1097/IAE.0b013e31822a2c7c
   Piermarocchi S, 2014, OPHTHALMOLOGY, V121, pE43, DOI 10.1016/j.ophtha.2013.12.044
   Resnikoff S, 2004, B WORLD HEALTH ORGAN, V82, P844
   Rivera A, 2005, HUM MOL GENET, V14, P3227, DOI 10.1093/hmg/ddi353
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Rosenfeld PJ, 2011, OPHTHALMOLOGY, V118, P523, DOI 10.1016/j.ophtha.2010.07.011
   Seddon JM, 2005, ARCH OPHTHALMOL-CHIC, V123, P321, DOI 10.1001/archopht.123.3.321
   Seddon JM, 2007, JAMA-J AM MED ASSOC, V297, P1793, DOI 10.1001/jama.297.16.1793
   Seddon JM, 2009, INVEST OPHTH VIS SCI, V50, P2044, DOI 10.1167/iovs.08-3064
   Seitsonen S, 2008, ACTA OPHTHALMOL, V86, P390, DOI 10.1111/j.1600-0420.2007.01050.x
   Smailhodzic D, 2012, OPHTHALMOLOGY, V119, P2304, DOI 10.1016/j.ophtha.2012.05.040
   Sobrin L, 2012, OPHTHALMOLOGY, V119, P1874, DOI 10.1016/j.ophtha.2012.03.014
   Spencer KL, 2008, HUM MOL GENET, V17, P1821, DOI 10.1093/hmg/ddn075
   Spencer KL, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0017784
   Suner IJ, 2004, INVEST OPHTH VIS SCI, V45, P311, DOI 10.1167/iovs.03-0733
   Teper SJ, 2010, MOL VIS, V16, P2598
   Thornton J, 2005, EYE, V19, P935, DOI 10.1038/sj.eye.6701978
   Tufail A, 2014, OPHTHALMOLOGY, V121, P1092, DOI 10.1016/j.ophtha.2013.11.031
   Wang JJ, 2014, OPHTHALMOLOGY, V121, P667, DOI 10.1016/j.ophtha.2013.10.017
   Wegscheider BJ, 2007, OPHTHALMOLOGY, V114, P738, DOI 10.1016/j.ophtha.2006.07.048
   Zanke B, 2010, CAN J OPHTHALMOL, V45, P22, DOI 10.3129/i09-209
NR 47
TC 24
Z9 25
U1 0
U2 5
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1755-375X
EI 1755-3768
J9 ACTA OPHTHALMOL
JI Acta Ophthalmol.
PD SEP
PY 2015
VL 93
IS 6
BP E451
EP E457
DI 10.1111/aos.12587
PG 7
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA CS1BO
UT WOS:000361797700004
PM 25402348
DA 2022-11-30
ER

PT J
AU Ozkaya, A
   Alkin, Z
   Ozkaya, HM
   Agca, A
   Ozgurhan, EB
   Karakucuk, Y
   Yazici, AT
   Demirok, A
AF Ozkaya, Abdullah
   Alkin, Zeynep
   Ozkaya, Hande Mefkure
   Agca, Alper
   Ozgurhan, Engin Bilge
   Karakucuk, Yalcin
   Yazici, Ahmet Taylan
   Demirok, Ahmet
TI Is Spectral-Domain Optical Coherence Tomography Essential for Flexible
   Treatment Regimens with Ranibizumab for Neovascular Age-Related Macular
   Degeneration?
SO JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
ID VISUAL-ACUITY; VERTEPORFIN; EYES
AB Purpose. To evaluate the ability of spectral-domain optical coherence tomography to detect subtle amounts of retinal fluid when the choroidal neovascularization is detected as inactive via time-domain optical coherence tomography and clinical examination in neovascular age-related macular degeneration (nAMD) patients. Methods. Forty-nine eyes of 49 patients with nAMD after ranibizumab treatment were included in this cross-sectional, prospective study. All patients were imaged with TD-OCT and SD-OCT at the same visit one month after a ranibizumab injection. The presence of subretinal, intraretinal, and subretinal pigment epithelium fluid (subRPE) in SD-OCT was evaluated; also mean central retinal thickness (CRT) and the rate of vitreoretinal surface disorders detected via the two devices were evaluated. Results. The mean CRT via TD-OCT and SD-OCT was 218.1 +/- 51.3 and 325.7 +/- 78.8 microns. Sixteen patients (32.6%) showed any kind of retinal fluid via SD-OCT. In detail, 8 patients (16.3%) showed subretinal fluid, 10 patients (20.4%) showed intraretinal fluid, and 3 patients (6.1%) showed SubRPE fluid. The ability of detecting vitreoretinal surface disorders was comparable between the two devices, except vitreomacular traction. Conclusion. SD-OCT is essential for the nAMD patients who are on an as-needed treatment regimen with ranibizumab. Only TD-OCT and clinical examination may cause insufficient treatment in this group of patients.
C1 [Ozkaya, Abdullah; Alkin, Zeynep; Agca, Alper; Ozgurhan, Engin Bilge; Karakucuk, Yalcin; Yazici, Ahmet Taylan; Demirok, Ahmet] Beyoglu Eye Training & Res Hosp, TR-34421 Istanbul, Turkey.
   [Ozkaya, Hande Mefkure] Sisli Etfal Training & Res Hosp, TR-34360 Istanbul, Turkey.
   [Demirok, Ahmet] Medeniyet Univ, Dept Ophthalmol, TR-34772 Istanbul, Turkey.
C3 Istanbul Prof Dr N Resat Belger Beyoglu Eye Training & Research
   Hospital; Istanbul Sisli Hamidiye Etfal Training & Research Hospital;
   Istanbul Medeniyet University
RP Ozkaya, A (通讯作者)，Beyoglu Eye Training & Res Hosp, Bereketzade Camii Sok, TR-34421 Istanbul, Turkey.
EM abdozkaya@gmail.com
RI Demirok, Ahmet/AAE-1713-2020; Agca, Alper/E-2166-2013; Alkin,
   Zeynep/V-7252-2017; ozkaya, hande mefkure/AAH-8200-2019; Ozkaya,
   Abdullah/L-5745-2013
OI Demirok, Ahmet/0000-0001-8197-2458; Agca, Alper/0000-0001-5435-075X;
   Alkin, Zeynep/0000-0002-5363-1944; ozkaya, hande
   mefkure/0000-0001-6207-7941; Ozkaya, Abdullah/0000-0002-1940-8669;
   karakucuk, Yalcin/0000-0001-6430-2233
CR Akduman L, 1999, RETINA-J RET VIT DIS, V19, P418, DOI 10.1097/00006982-199909000-00009
   Arias L, 2009, EYE, V23, P326, DOI 10.1038/sj.eye.6703053
   Baba T, 2012, OPHTHALMOLOGICA, V228, P102, DOI 10.1159/000337251
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Cukras C, 2010, EYE, V24, P775, DOI 10.1038/eye.2009.211
   Eriksson U, 2012, ACTA OPHTHALMOL, V90, P620, DOI 10.1111/j.1755-3768.2011.02112.x
   Gerding H, 2011, GRAEF ARCH CLIN EXP, V249, P653, DOI 10.1007/s00417-011-1636-6
   Hariprasad SM, 2012, J OPHTHALMOL, V2012, DOI 10.1155/2012/690641
   Hatef E, 2012, J OPHTHALMOL, V2012, DOI 10.1155/2012/354783
   Kakinoki M, 2012, J OPHTHALMOL, V2012, DOI 10.1155/2012/959721
   Kovach JL, 2012, J OPHTHALMOL, V2012, DOI 10.1155/2012/786870
   Krebs I, 2011, BRIT J OPHTHALMOL, V95, P1552, DOI 10.1136/bjo.2010.194670
   Lalwani GA, 2009, AM J OPHTHALMOL, V148, P43, DOI 10.1016/j.ajo.2009.01.024
   Luviano DM, 2009, OPHTHAL SURG LAS IM, V40, P325, DOI 10.3928/15428877-20090430-20
   Mariani A, 2011, GRAEF ARCH CLIN EXP, V249, P1635, DOI 10.1007/s00417-011-1734-5
   Martin DF, 2011, NEW ENGL J MED, V364, P1897, DOI 10.1056/NEJMoa1102673
   Mones J, 2012, GRAEF ARCH CLIN EXP, V250, P1737, DOI 10.1007/s00417-012-2009-5
   Muether PS, 2011, GRAEF ARCH CLIN EXP, V249, P633, DOI 10.1007/s00417-010-1520-9
   Ngai LY, 2011, EYE, V25, P784, DOI 10.1038/eye.2011.56
   Ozkaya A., 2010, RET VIT, V4, P289
   Querques G, 2011, OPHTHALMIC RES, V46, P152, DOI 10.1159/000325027
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   ROY M, 1990, Eye (London), V4, P813
   Rubin GS, 2002, RETINA-J RET VIT DIS, V22, P536, DOI 10.1097/00006982-200210000-00002
   Sayanagi K, 2009, OPHTHALMOLOGY, V116, P947, DOI 10.1016/j.ophtha.2008.11.002
   Schmidt-Erfurth U, 2011, OPHTHALMOLOGY, V118, P831, DOI 10.1016/j.ophtha.2010.09.004
   STERNBERG P, 1991, ARCH OPHTHALMOL-CHIC, V109, P1220
   Votruba M, 2001, EYE, V15, P424, DOI 10.1038/eye.2001.147
   Zampros I, 2012, J OPHTHALMOL, V2012, DOI 10.1155/2012/319728
NR 29
TC 1
Z9 1
U1 0
U2 0
PU HINDAWI LTD
PI LONDON
PA ADAM HOUSE, 3RD FLR, 1 FITZROY SQ, LONDON, W1T 5HF, ENGLAND
SN 2090-004X
EI 2090-0058
J9 J OPHTHALMOL
JI J. Ophthalmol.
PY 2013
VL 2013
AR 786107
DI 10.1155/2013/786107
PG 5
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 303HE
UT WOS:000330664300001
PM 24324880
OA Green Published, gold, Green Submitted
DA 2022-11-30
ER

PT J
AU Binley, K
   Widdowson, PS
   Kelleher, M
   de Belin, J
   Loader, J
   Ferrige, G
   Carlucci, M
   Esapa, M
   Chipchase, D
   Angell-Manning, D
   Ellis, S
   Mitrophanous, K
   Miskin, J
   Bantseev, V
   Nork, TM
   Miller, P
   Naylor, S
AF Binley, Katie
   Widdowson, Peter S.
   Kelleher, Michelle
   de Belin, Jackie
   Loader, Julie
   Ferrige, Georgina
   Carlucci, Marie
   Esapa, Margaret
   Chipchase, Daniel
   Angell-Manning, Diana
   Ellis, Scott
   Mitrophanous, Kyriacos
   Miskin, James
   Bantseev, Vlad
   Nork, T. Michael
   Miller, Paul
   Naylor, Stuart
TI Safety and Biodistribution of an Equine Infectious Anemia Virus-Based
   Gene Therapy, RetinoStat (R), for Age-Related Macular Degeneration
SO HUMAN GENE THERAPY
LA English
DT Article
ID LEBERS CONGENITAL AMAUROSIS; LENTIVIRAL VECTOR; CHOROIDAL
   NEOVASCULARIZATION; RANIBIZUMAB; EFFICACY; ANGIOSTATIN; VERTEPORFIN;
   COMBINATION; ENDOSTATIN; INJECTION
AB RetinoStat (R) is an equine infectious anemia virus-based lentiviral gene therapy vector that expresses the angiostatic proteins endostatin and angiostatin that is delivered via a subretinal injection for the treatment of the wet form of age-related macular degeneration. We initiated 6-month safety and biodistribution studies in two species; rhesus macaques and Dutch belted rabbits. After subretinal administration of RetinoStat the level of human endostatin and angiostatin proteins in the vitreous of treated rabbit eyes peaked at similar to 1 month after dosing and remained elevated for the duration of the study. Regular ocular examinations revealed a mild to moderate transient ocular inflammation that resolved within 1 month of dosing in both species. There were no significant long-term changes in the electroretinograms or intraocular pressure measurements in either rabbits or macaques postdosing compared with the baseline reading in RetinoStat-treated eyes. Histological evaluation did not reveal any structural changes in the eye although there was an infiltration of mononuclear cells in the vitreous, retina, and choroid. No antibodies to any of the RetinoStat vector components or the transgenes could be detected in the serum from either species, and biodistribution analysis demonstrated that the RetinoStat vector was maintained within the ocular compartment. In summary, these studies found RetinoStat to be well tolerated, localized, and capable of persistent expression after subretinal delivery.
C1 [Binley, Katie] Oxford BioMed UK Ltd, Medawar Ctr, Oxford OX4 4GA, England.
   [Bantseev, Vlad] Covance Labs, Madison, WI 53704 USA.
   [Nork, T. Michael; Miller, Paul] Univ Wisconsin Madison Sch Vet Med, Comparat Ophthalm Res Labs, Madison, WI 53792 USA.
C3 Oxford Biomedica (UK) Ltd; Covance; University of Wisconsin System;
   University of Wisconsin Madison
RP Binley, K (通讯作者)，Oxford BioMed UK Ltd, Medawar Ctr, Oxford Sci Pk, Oxford OX4 4GA, England.
EM k.binley@oxfordbiomedica.co.uk
FU Sanofi
FX The authors are grateful to the manufacturing and PAR teams at Oxford
   BioMedica for the production of RetinoStat IH39 vector. The authors
   thank Sanofi for supporting this work.
CR Azzouz M, 2002, J NEUROSCI, V22, P10302
   Bainbridge JWB, 2008, NEW ENGL J MED, V358, P2231, DOI 10.1056/NEJMoa0802268
   Balaggan KS, 2006, J GENE MED, V8, P275, DOI 10.1002/jgm.845
   Bienemann AS, 2003, MOL THER, V7, P588, DOI 10.1016/S1525-0016(03)00069-8
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Campochiaro PA, 2006, HUM GENE THER, V17, P167, DOI 10.1089/hum.2006.17.167
   DePolo NJ, 2000, MOL THER, V2, P218, DOI 10.1006/mthe.2000.0116
   Hamirally S, 2009, INVEST OPHTH VIS SCI, V50, P3026
   Hauswirth WW, 2008, HUM GENE THER, V19, P979, DOI 10.1089/hum.2008.107
   Husain D, 2005, ARCH OPHTHALMOL-CHIC, V123, P509, DOI 10.1001/archopht.123.4.509
   Jacobson SG, 2006, HUM GENE THER, V17, P845, DOI 10.1089/hum.2006.17.845
   Kaiser PK, 2010, AM J OPHTHALMOL, V150, P33, DOI 10.1016/j.ajo.2010.02.006
   Lai C.M., 2011, GENE THER, P1
   Lamikanra A, 2005, GENE THER, V12, P988, DOI 10.1038/sj.gt.3302484
   Macclachlan T.K., 2011, AM SOC GENE CELL THE, V19, P326
   Maguire AM, 2008, NEW ENGL J MED, V358, P2240, DOI 10.1056/NEJMoa0802315
   Miskin J, 2006, GENE THER, V13, P196, DOI 10.1038/sj.gt.3302666
   Mitrophanous KA, 1999, GENE THER, V6, P1808, DOI 10.1038/sj.gt.3301023
   Nork TM, 2012, ARCH OPHTHALMOL-CHIC, V130, P65, DOI 10.1001/archophthalmol.2011.295
   RASMUSSEN HS, 2003, PRECLINICA, V1, P77
   Rohll JB, 2002, METHOD ENZYMOL, V346, P466
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Scappaticci FA, 2001, MOL THER, V3, P186, DOI 10.1006/mthe.2000.0243
   Schwab I.R., 2011, EVOLUTIONS WITNESS E, P252
   SELLON DC, 1992, J VIROL, V66, P5906, DOI 10.1128/JVI.66.10.5906-5913.1992
   Sickenberg M, 2001, OPHTHALMOLOGICA, V215, P247, DOI 10.1159/000050869
   Simonelli F, 2010, MOL THER, V18, P643, DOI 10.1038/mt.2009.277
   Stewart HJ, 2009, GENE THER, V16, P805, DOI 10.1038/gt.2009.20
   Truran R, 2009, WO 2009153563 A1, Patent No. 2009153563
   Wanisch K, 2009, MOL THER, V17, P1316, DOI 10.1038/mt.2009.122
   Yokoyama Y, 2000, CANCER RES, V60, P2190
   Yu DY, 2004, AM J PHYSIOL-HEART C, V286, pH419, DOI 10.1152/ajpheart.00643.2003
NR 32
TC 42
Z9 53
U1 0
U2 3
PU MARY ANN LIEBERT INC
PI NEW ROCHELLE
PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA
SN 1043-0342
J9 HUM GENE THER
JI Hum. Gene Ther.
PD SEP
PY 2012
VL 23
IS 9
BP 980
EP 991
DI 10.1089/hum.2012.008
PG 12
WC Biotechnology & Applied Microbiology; Genetics & Heredity; Medicine,
   Research & Experimental
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biotechnology & Applied Microbiology; Genetics & Heredity; Research &
   Experimental Medicine
GA 007VM
UT WOS:000308916500007
PM 22716662
DA 2022-11-30
ER

PT J
AU Samanta, A
   Jhingan, M
   Arora, S
   Singh, S
   Tucci, D
   Cagini, C
   Lupidi, M
   Chhablani, J
AF Samanta, Anindya
   Jhingan, Mahima
   Arora, Supriya
   Singh, Sumit
   Tucci, Davide
   Cagini, Carlo
   Lupidi, Marco
   Chhablani, Jay
TI Intraretinal, sub-retinal, and sub-retinal pigmented epithelium fluid in
   non-exudative age-related macular degeneration: follow-up with OCT
   imaging
SO EUROPEAN JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
DE Non-exudative AMD; fluid; fluid in dry AMD
ID CLASSIFICATION; DETACHMENTS; THERAPIES
AB Background/objectives: To evaluate the presence and evolution of fluid in non-exudative age-related macular degeneration (AMD) through serial OCT. Subjects/methods: A retrospective analysis of eyes with non-exudative AMD with a minimum of 4 year follow-up was done. Parameters including intraretinal fluid (IRF), subretinal fluid (SRF), and sub-retinal pigment epithelium (RPE) fluid (SRPEF); subfoveal choroidal thickness (SFCT) and type of drusen were evaluated using optical coherence tomography (OCT) scans at baseline and follow up visits. Results: Seventy-two eyes (in 63 patients) were followed up for an average of 5.83 +/- 2.17 years. A total of 26/72 (36%) and 29/65 (52%) of the non-exudative eyes had fluid during baseline and the last visit. Seven eyes (10%) out of 72 eyes converted into exudative AMD or neo-vascular AMD (nAMD) during the study period. SRPEF at baseline was most common fluid location for non-exudative eyes that eventually converted to nAMD. Conclusion: Non-exudative fluid including IRF, SRF, and SRPEF is seen in patients with non-exudative AMD with increasing incidence during long term follow-up.
C1 [Samanta, Anindya] Texas Tech Univ, Hlth Sci Ctr, Dept Ophthalmol & Visual Sci, Lubbock, TX 79430 USA.
   [Jhingan, Mahima; Singh, Sumit] Univ Calif San Diego, Jacobs Retina Ctr, San Diego, CA 92103 USA.
   [Arora, Supriya] Princess Margaret Hosp, Dept Surg, Div Ophthalmol, Nassau, Bahamas.
   [Tucci, Davide; Cagini, Carlo; Lupidi, Marco] Univ Perugia, Dept Biomed & Surg Sci, Sect Ophthalmol, Perugia, Italy.
   [Chhablani, Jay] Univ Pittsburgh, UPMC Eye Ctr, Pittsburgh, PA USA.
C3 Texas Tech University System; Texas Tech University; Texas Tech
   University Health Science Center; University of California System;
   University of California San Diego; University of Perugia; Pennsylvania
   Commonwealth System of Higher Education (PCSHE); University of
   Pittsburgh
RP Chhablani, J (通讯作者)，Univ Pittsburgh, UPMC, 203 Lothrop St, Pittsburgh, PA 15213 USA.
EM jay.chhablani@gmail.com
RI Cagini, Carlo/L-2914-2016; Cagini, Carlo/H-3431-2019
OI Cagini, Carlo/0000-0002-3812-9219; Cagini, Carlo/0000-0002-3812-9219;
   Lupidi, Marco/0000-0002-6817-2488
CR Amoaku WM, 2015, EYE, V29, P721, DOI 10.1038/eye.2015.48
   Astafurov K, 2014, MOL VIS, V20, P140
   Barbazetto IA, 2010, AM J OPHTHALMOL, V149, P939, DOI 10.1016/j.ajo.2010.01.007
   CASSWELL AG, 1985, BRIT J OPHTHALMOL, V69, P397, DOI 10.1136/bjo.69.6.397
   Cohen SY, 2010, AM J OPHTHALMOL, V150, P211, DOI 10.1016/j.ajo.2010.02.019
   Daniel E, 2019, OPHTHALMOLOGY, V126, P743, DOI 10.1016/j.ophtha.2018.11.020
   Hahn P, 2003, ARCH OPHTHALMOL-CHIC, V121, P1099, DOI 10.1001/archopht.121.8.1099
   HARTNETT ME, 1992, GRAEF ARCH CLIN EXP, V230, P11, DOI 10.1007/BF00166756
   Heier J., 2019, AM SOC RET SPEC ANN
   Hilely A, 2021, BRIT J OPHTHALMOL, V105, P1415, DOI 10.1136/bjophthalmol-2020-317326
   Jaffe GJ, 2019, OPHTHALMOLOGY, V126, P252, DOI 10.1016/j.ophtha.2018.08.035
   Kaiser PK., 2019, RETIN PHYS, V16, P1
   Kassoff A, 1999, CONTROL CLIN TRIALS, V20, P573
   Khlifi, 2017, OPHTHALMOL POINT CAR, DOI [10.5301/oapoc.0000009, DOI 10.5301/OAPOC.0000009]
   Lek JJ, 2018, OPHTHALMOL RETINA, V2, P792, DOI 10.1016/j.oret.2018.01.005
   Martin DF, 2012, OPHTHALMOLOGY, V119, DOI 10.1016/j.ophtha.2012.03.053
   MedlinePlus, 2020, GENETICS HOME REFERE
   Mrejen S, 2013, SURV OPHTHALMOL, V58, P387, DOI 10.1016/j.survophthal.2012.12.001
   Mullins RF, 2014, AM J PATHOL, V184, P3142, DOI 10.1016/j.ajpath.2014.07.017
   Samanta A, 2020, ASIA-PAC J OPHTHALMO, V9, P250, DOI 10.1097/APO.0000000000000291
   Schmidt-Erfurth U, 2018, INVEST OPHTH VIS SCI, V59, P3199, DOI 10.1167/iovs.18-24106
   Schultz H, 2019, EXP EYE RES, V186, DOI 10.1016/j.exer.2019.05.026
   Sleiman K, 2017, OPHTHALMOLOGY, V124, P1764, DOI 10.1016/j.ophtha.2017.06.032
   Spaide RF, 2016, RETINA-J RET VIT DIS, V36, P1823, DOI 10.1097/IAE.0000000000001158
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
   Zweifel SA, 2009, ARCH OPHTHALMOL-CHIC, V127, P1596, DOI 10.1001/archophthalmol.2009.326
NR 26
TC 0
Z9 0
U1 0
U2 9
PU SAGE PUBLICATIONS LTD
PI LONDON
PA 1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND
SN 1120-6721
EI 1724-6016
J9 EUR J OPHTHALMOL
JI Eur. J. Ophthalmol.
PD JUL
PY 2022
VL 32
IS 4
BP 2419
EP 2426
AR 11206721211036289
DI 10.1177/11206721211036289
EA AUG 2021
PG 8
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 3B9CF
UT WOS:000683082800001
PM 34340599
DA 2022-11-30
ER

PT J
AU Borrelli, E
   Lei, JQ
   Balasubramanian, S
   Uji, A
   Cozzi, M
   Sarao, V
   Lanzetta, P
   Staurenghi, G
   Sadda, SR
AF Borrelli, Enrico
   Lei, Jianqin
   Balasubramanian, Siva
   Uji, Akihito
   Cozzi, Mariano
   Sarao, Valentina
   Lanzetta, Paolo
   Staurenghi, Giovanni
   Sadda, SriniVas R.
TI Green emission fluorophores in eyes with atrophic age-related macular
   degeneration: a colour fundus autofluorescence pilot study
SO BRITISH JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
DE imaging; retina; autofluorescence
ID COHERENCE TOMOGRAPHY ANGIOGRAPHY; GEOGRAPHIC ATROPHY;
   NEOVASCULARIZATION; POPULATION; DIAGNOSIS; RETINA; TOOL
AB Background/Aims To investigate the presence of short-wave fluorophores within regions of age-related macular degeneration (AMD)-associated macular atrophy (MA) area.
   Methods This is a prospective, observational, cross-sectional case series. 25 eyes (18 patients) with late AMD and clinically identified MA were enrolled. Eyes were imaged using a confocal light-emitting diode blue-light fundus autofluorescence (FAF) device (EIDON, CenterVue, Padua, Italy) with 450nm excitation wavelength and the capability for colour' FAF imaging, including both the individual red and green components of the emission spectrum. To produce images with a high contrast for isolating the green component, the red component was subtracted from the total FAF image. The main outcome measure was the presence of green emission fluorescence component (GEFC) within the MA area. Volume spectral domain optical coherence tomography (SD-OCT) scans were obtained through the macula and the OCT was correlated with the MA lesions identified on the FAF images, including regions of increased GEFC.
   Results Of the investigated eyes, 11 out of 25 (44.0 %) showed the absence of GEFC in the MA area, whereas 14 eyes (56.0%) were characterised by GEFC within the MA area. The presence and distribution of GEFC in the MA area correlated with the presence of hyper-reflective material over Bruch's membrane on the corresponding SD-OCT scans.
   Conclusion Short-wave fluorophores, which contribute to the GEFC, are present in the MA area and appear to correspond to residual debris or drusenoid material. Short-wavelength fluorophores revealed by colour FAF imaging may warrant further study.
C1 [Borrelli, Enrico; Lei, Jianqin; Balasubramanian, Siva; Uji, Akihito; Sadda, SriniVas R.] Doheny Image Reading Ctr, Doheny Eye Inst, Los Angeles, CA USA.
   [Borrelli, Enrico; Lei, Jianqin; Balasubramanian, Siva; Uji, Akihito; Sadda, SriniVas R.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Ophthalmol, Los Angeles, CA 90095 USA.
   [Borrelli, Enrico] Univ G dAnnunzio, Dept Med & Sci, Ageing Ophthalmol Clin, Chieti, Italy.
   [Lei, Jianqin] Xi An Jiao Tong Univ, Affiliated Hosp 1, Xian, Shaanxi, Peoples R China.
   [Cozzi, Mariano; Staurenghi, Giovanni] Univ Milan, Luigi Sacco Hosp, Eye Clin, Dept Biomed & Clin Sci, Milan, Italy.
   [Sarao, Valentina; Lanzetta, Paolo] IEMO, Udine, Italy.
   [Sarao, Valentina; Lanzetta, Paolo] Univ Udine, Dept Ophthalmol, Piazzale S Maria Misericordia, Udine, Italy.
C3 Doheny Eye Institute; University of California System; University of
   California Los Angeles; University of California Los Angeles Medical
   Center; David Geffen School of Medicine at UCLA; G d'Annunzio University
   of Chieti-Pescara; Xi'an Jiaotong University; University of Milan; Luigi
   Sacco Hospital; University of Udine
RP Sadda, SR (通讯作者)，Doheny Image Reading Ctr, 1355 San Pablo St,Suite 211, Los Angeles, CA 90033 USA.
EM ssadda@doheny.org
RI Borrelli, Enrico/AAR-3693-2020
OI Borrelli, Enrico/0000-0003-2815-5031; Cozzi, Mariano/0000-0001-7777-2461
FU Bayer; Centervue; Genentech; Novartis; Roche; Alcon; Allergan;
   Boehringer Ingelheim; Zeiss Meditec; Heidelberg Engineering; Optos; Carl
   Zeiss Meditec; Iconic; Optovue; Regeneron; Thrombogenics
FX PL: financial support-Bayer, Centervue, Genentech, Novartis, Roche; GS:
   financial support-Novartis, Alcon, Bayer, Allergan, Boehringer
   Ingelheim, Genentech, Roche, Zeiss Meditec, Heidelberg Engineering,
   Optos, Centervue; SRS: financial support-Allergan, Carl Zeiss Meditec,
   Genentech, Iconic, Novartis, Optos, Optovue, Regeneron, Thrombogenics.
CR Abdelfattah NS, 2017, OPHTHALMOLOGY, V124, P215, DOI 10.1016/j.ophtha.2016.10.002
   Alter A, 1988, PHYS PRINCIPLES MED
   Carnevali A, 2016, AM J OPHTHALMOL, V169, P189, DOI 10.1016/j.ajo.2016.06.042
   Croce AC, 2014, EUR J HISTOCHEM, V58, P320, DOI 10.4081/ejh.2014.2461
   Domalpally A, 2016, OPHTHALMOLOGY, V123, P2401, DOI 10.1016/j.ophtha.2016.06.025
   Ferris FL, 2013, OPHTHALMOLOGY, V120, P844, DOI 10.1016/j.ophtha.2012.10.036
   Fleckenstein M, 2008, INVEST OPHTH VIS SCI, V49, P4137, DOI 10.1167/iovs.08-1967
   Grunwald JE, 2015, OPHTHALMOLOGY, V122, P809, DOI 10.1016/j.ophtha.2014.11.007
   Hammer M, IOVS 2017
   Hariri AH, 2016, AM J OPHTHALMOL, V168, P122, DOI 10.1016/j.ajo.2016.05.007
   Hirvela H, 1996, OPHTHALMOLOGY, V103, P871, DOI 10.1016/S0161-6420(96)30593-9
   Holz FG, 2001, INVEST OPHTH VIS SCI, V42, P1051
   Holz FG, 2017, OPHTHALMOLOGY, V124, P464, DOI 10.1016/j.ophtha.2016.12.002
   Ishibashi T, 1998, ARCH OPHTHALMOL-CHIC, V116, P1629, DOI 10.1001/archopht.116.12.1629
   Keane PA, 2014, OPHTHALMOLOGY, V121, P2489, DOI 10.1016/j.ophtha.2014.07.054
   Klein R, 2011, ARCH OPHTHALMOL-CHIC, V129, P75, DOI 10.1001/archophthalmol.2010.318
   Nagai R, 1997, BIOCHEM BIOPH RES CO, V234, P167, DOI 10.1006/bbrc.1997.6608
   Ooto S, 2014, JAMA OPHTHALMOL, V132, P806, DOI 10.1001/jamaophthalmol.2014.1871
   Roisman L, 2016, OPHTHALMOLOGY, V123, P1309, DOI 10.1016/j.ophtha.2016.01.044
   SARKS JP, 1988, EYE, V2, P552, DOI 10.1038/eye.1988.106
   Schmitz-Valckenberg S, 2004, INVEST OPHTH VIS SCI, V45, P4470, DOI 10.1167/iovs.03-1311
   Schmitz-Valckenberg S, 2016, OPHTHALMOLOGY, V123, P361, DOI 10.1016/j.ophtha.2015.09.036
   Schmitz-Valckenberg S, 2009, SURV OPHTHALMOL, V54, P96, DOI 10.1016/j.survophthal.2008.10.004
   Schweitzer D, 2007, MICROSC RES TECHNIQ, V70, P410, DOI 10.1002/jemt.20427
   Sparrow JR, 2010, INVEST OPHTH VIS SCI, V51, P4351, DOI 10.1167/iovs.10-5852
   Yung Madeline, 2016, Int J Retina Vitreous, V2, P12, DOI 10.1186/s40942-016-0035-x
NR 26
TC 18
Z9 18
U1 0
U2 3
PU BMJ PUBLISHING GROUP
PI LONDON
PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND
SN 0007-1161
EI 1468-2079
J9 BRIT J OPHTHALMOL
JI Br. J. Ophthalmol.
PD JUN
PY 2018
VL 102
IS 6
BP 827
EP 832
DI 10.1136/bjophthalmol-2017-310881
PG 6
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA GH2KR
UT WOS:000433231300019
PM 28972030
DA 2022-11-30
ER

PT J
AU Cheung, N
   Liao, DP
   Islam, FMA
   Klein, R
   Wang, JJ
   Wong, TY
AF Cheung, Ning
   Liao, Duanping
   Islam, F. M. Amirul
   Klein, Ronald
   Wang, Jie Jin
   Wong, Tien Yin
TI Is early age-related macular degeneration related to carotid artery
   stiffness? The Atherosclerosis Risk in Communities Study
SO BRITISH JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
ID MACULOPATHY; PREVALENCE; ROTTERDAM
AB Background/ Purpose: Atherosclerosis and vascular stiffness have been implicated in the pathogenesis of age- related macular degeneration ( AMD). The association of carotid artery stiffness, a measure of arterial elasticity reflecting early atherosclerosis, with early AMD, was examined in this study.
   Methods: A population- based, cross- sectional study of 9954 middle- aged people ( age range 51 - 72 years). The presence of AMD signs was determined from fundus photographs according to the Wisconsin grading protocol. Carotid arterial stiffness was measured from high- resolution ultrasonic echo tracking of the left common carotid artery, and was defined as an adjusted arterial diameter change ( AADCm). A smaller AADC reflects greater carotid artery stiffness. The associations of pulse pressure and carotid artery intima - media thickness ( IMT) with early AMD signs were also analysed.
   Results: In the study population, 454 ( 4.6%) had early AMD. The mean ( SD) AADC was 403 ( 127) m. After adjusting for age, sex, race/ centre, education, cigarette smoking, fasting glucose, lipid profile and inflammatory markers, a smaller AADC was found to be not associated with early AMD ( odds ratio 0.94; 95% confidence interval, 0.71 to 1.25) or its component lesions. Other measures of arterial stiffness ( pulse pressure) and atherosclerosis ( carotid IMT) were also not associated with early AMD.
   Conclusions: Carotid artery stiffness was not associated with signs of early AMD in this middle- aged population. These data provide no evidence of a link between age- related elastoid changes and early atherosclerotic processes in the carotid arteries and early AMD.
C1 Univ Melbourne, Ctr Eye Res, Melbourne, Vic 3002, Australia.
   Penn State Univ, Dept Hlth Evaluat Sci, Coll Med, Hershey, PA USA.
   Univ Wisconsin, Dept Ophthalmol & Visual Sci, Madison, WI USA.
   Univ Sydney, Ctr Vis Res, Sydney, NSW 2006, Australia.
C3 University of Melbourne; Pennsylvania Commonwealth System of Higher
   Education (PCSHE); Pennsylvania State University; Penn State Health;
   University of Wisconsin System; University of Wisconsin Madison;
   University of Sydney
RP Wong, TY (通讯作者)，Univ Melbourne, Ctr Eye Res, 32 Gisborne St, Melbourne, Vic 3002, Australia.
EM twong@unimelb.edu.au
RI Islam, Fakir M Amirul/P-6665-2015; Wang, Jie Jin/P-1499-2014; wang,
   jie/GRS-0942-2022; Wong, Tien Yin/AAC-9724-2020; Cheung, Ning
   Danny/F-2043-2013
OI Islam, Fakir M Amirul/0000-0003-3897-3302; Wang, Jie
   Jin/0000-0001-9491-4898; Wong, Tien Yin/0000-0002-8448-1264; 
FU DIVISION OF EPIDEMIOLOGY AND CLINICAL APPLICATIONS [N01HC055018,
   N01HC055022, N01HC035126, N01HC055015, N01HC055020, N01HC055021,
   N01HC055019, N01HC035125, N01HC055016] Funding Source: NIH RePORTER;
   NHLBI NIH HHS [N01-HC-35125, N01-HC-55018, N01-HC-35126, N01-HC-55022,
   N01-HC-55016, N01-HC-55021, N01-HC-55019, N01-HC-55020, N01-HC-55015]
   Funding Source: Medline
CR *ARIC STUD GROUP, 1991, J NEUROIMAGING, V1, P168
   Arnett DK, 1999, ULTRASOUND MED BIOL, V25, P175, DOI 10.1016/S0301-5629(98)00165-3
   Fine SL, 2000, NEW ENGL J MED, V342, P483, DOI 10.1056/NEJM200002173420707
   Friedman E, 2004, BRIT J OPHTHALMOL, V88, P161, DOI 10.1136/bjo.2003.036277
   Friedman E, 2000, AM J OPHTHALMOL, V130, P658, DOI 10.1016/S0002-9394(00)00643-7
   Jackson R, 1996, J CLIN EPIDEMIOL, V49, P1441, DOI 10.1016/0895-4356(95)00047-X
   Klein R, 2003, OPHTHALMOLOGY, V110, P25, DOI 10.1016/S0161-6420(02)01565-8
   Klein R, 1999, ARCH OPHTHALMOL-CHIC, V117, P1203
   Klein R, 2002, OPHTHALMOLOGY, V109, P1225, DOI 10.1016/S0161-6420(02)01074-6
   Klein Ronald, 2003, Ophthalmology, V110, P1273, DOI 10.1016/S0161-6420(03)00599-2
   Liao DP, 2004, STROKE, V35, P837, DOI 10.1161/01.STR.0000120310.43457.AD
   Metelitsina TI, 2006, BRIT J OPHTHALMOL, V90, P342, DOI 10.1136/bjo.2005.082974
   Moss SE, 2005, AM J OPHTHALMOL, V140, P1159, DOI 10.1016/j.ajo.2005.07.029
   *NAT HEART LUNG BL, 1988, ATH RISK COMM STUD O
   Oliver JJ, 2003, ARTERIOSCL THROM VAS, V23, P554, DOI 10.1161/01.ATV.0000060460.52916.D6
   PAULEIKHOFF D, 1990, AM J OPHTHALMOL, V109, P211, DOI 10.1016/S0002-9394(14)75989-6
   RILEY WA, 1992, STROKE, V23, P952, DOI 10.1161/01.STR.23.7.952
   van Leeuwen R, 2003, INVEST OPHTH VIS SCI, V44, P3771, DOI 10.1167/iovs.03-0121
   Vine AK, 2005, OPHTHALMOLOGY, V112, P2076, DOI 10.1016/j.ophtha.2005.07.004
   VINGERLING JR, 1995, AM J EPIDEMIOL, V142, P404, DOI 10.1093/oxfordjournals.aje.a117648
NR 20
TC 16
Z9 17
U1 0
U2 3
PU B M J PUBLISHING GROUP
PI LONDON
PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND
SN 0007-1161
J9 BRIT J OPHTHALMOL
JI Br. J. Ophthalmol.
PD APR
PY 2007
VL 91
IS 4
BP 430
EP 433
DI 10.1136/bjo.2006.106054
PG 4
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 147XH
UT WOS:000245037700010
PM 17035267
OA Green Published
DA 2022-11-30
ER

PT J
AU Patel, KH
   Chow, CC
   Rathod, R
   Mieler, WF
   Lim, JI
   Ulanski, LJ
   Leiderman, YI
   Arun, V
   Chau, FY
AF Patel, K. H.
   Chow, C. C.
   Rathod, R.
   Mieler, W. F.
   Lim, J. I.
   Ulanski, L. J., II
   Leiderman, Y. I.
   Arun, V.
   Chau, F. Y.
TI Rapid response of retinal pigment epithelial detachments to intravitreal
   aflibercept in neovascular age-related macular degeneration refractory
   to bevacizumab and ranibizumab
SO EYE
LA English
DT Article
DE aflibercept; retinal pigment epithelial detachment; age-related macular
   degeneration
ID CHOROIDAL NEOVASCULARIZATION; TACHYPHYLAXIS
AB Purpose The aim of this study is to report the short-term efficacy of aflibercept in the treatment of neovascular age-related macular degeneration (AMD) with associated retinal pigment epithelial detachment (PED) which is refractory or develops tachyphylaxis to bevacizumab and ranibizumab.
   Methods The method comprised a retrospective review of the medical records of patients with neovascular AMD and associated PEDs recently treated with aflibercept and previously treated with bevacizumab and ranibizumab.
   Results Three eyes of three female patients of ages 49, 55, and 65 years old with large serous PEDs and subretinal fluid (SRF) associated with occult choroidal neovascularization and neovascular AMD were treated with aflibercept after intravitreal bevacizumab and/or ranibizumab failed to resolve the lesions. All had complete resolution of SRF and complete or nearcomplete resolution of the PEDs after aflibercept injections over a 3-month period. Visual acuity improved in all three eyes.
   Conclusion Intravitreal aflibercept may be an effective treatment option for serous PED in neovascular AMD patients after bevacizumab and ranibizumab have previously failed. Larger studies with longer follow-up are required to determine the role of aflibercept in treatment of PED in neovascular AMD.
C1 [Patel, K. H.; Chow, C. C.; Rathod, R.; Mieler, W. F.; Lim, J. I.; Ulanski, L. J., II; Leiderman, Y. I.; Chau, F. Y.] Univ Illinois, Illinois Eye & Ear Infirm, Dept Ophthalmol & Visual Sci, Chicago, IL 60612 USA.
   [Arun, V.] Univ Ophthalmol, Chicago, IL USA.
C3 University of Illinois System; University of Illinois Chicago;
   University of Illinois Chicago Hospital
RP Chau, FY (通讯作者)，Univ Illinois, Illinois Eye & Ear Infirm, Dept Ophthalmol & Visual Sci, 1905 West Taylor St, Chicago, IL 60612 USA.
EM felixychaumd@gmail.com
FU NEI NIH HHS [K12 EY021475] Funding Source: Medline; NATIONAL EYE
   INSTITUTE [K12EY021475] Funding Source: NIH RePORTER
CR Arias L, 2010, CLIN OPHTHALMOL, V4, P369
   Binder S, 2012, BRIT J OPHTHALMOL, V96, P1, DOI 10.1136/bjophthalmol-2011-301236
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Cho M, 2009, AM J OPHTHALMOL, V148, P70, DOI 10.1016/j.ajo.2009.02.012
   Coscas F, 2007, AM J OPHTHALMOL, V144, P592, DOI 10.1016/j.ajo.2007.06.014
   Eghoj MS, 2012, BRIT J OPHTHALMOL, V96, P21, DOI 10.1136/bjo.2011.203893
   Forooghian F, 2009, RETINA-J RET VIT DIS, V29, P723, DOI 10.1097/IAE.0b013e3181a2c1c3
   Gasperini JL, 2012, BRIT J OPHTHALMOL, V96, P14, DOI 10.1136/bjo.2011.204685
   Ohr M, 2012, EXPERT OPIN PHARMACO, V13, P585, DOI 10.1517/14656566.2012.658368
   Pauleikhoff D, 2002, GRAEF ARCH CLIN EXP, V240, P533, DOI 10.1007/s00417-002-0505-8
   Pepple K, 2011, SEMIN OPHTHALMOL, V26, P198, DOI 10.3109/08820538.2011.570850
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   STERNBERG P, 1991, ARCH OPHTHALMOL-CHIC, V109, P1220
NR 13
TC 52
Z9 56
U1 0
U2 12
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 0950-222X
J9 EYE
JI Eye
PD MAY
PY 2013
VL 27
IS 5
BP 664
EP 667
DI 10.1038/eye.2013.31
PG 4
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 140XF
UT WOS:000318689100014
PM 23558214
OA Green Published, Bronze
DA 2022-11-30
ER

PT J
AU Veritti, D
   Lanzetta, P
AF Veritti, Daniele
   Lanzetta, Paolo
TI Triple Therapy for Anti-Vascular Endothelial Growth Factor Nonresponders
   in Neovascular Age-Related Macular Degeneration: Impact of Different
   Photodynamic Therapy Parameters
SO OPHTHALMOLOGICA
LA English
DT Article
DE Choroidal neovascularization; Age-related macular degeneration;
   Ranibizumab; Triamcinolone acetonide; Photodynamic therapy
ID CHOROIDAL NEOVASCULARIZATION; INTRAVITREAL DEXAMETHASONE; TRIAMCINOLONE
   ACETONIDE; VERTEPORFIN THERAPY; BEVACIZUMAB
AB Purpose: To evaluate the safety and exploratory efficacy of triple therapy (TT) with single-session intravitreal ranibizum-ab, modified juxtascleral triamcinolone, and photodynamic therapy (PDT) in exudative age-related macular degeneration non-responder to anti-vascular endothelial growth factor. Methods: Thirty consecutive eyes were included. The first 10 eyes (cohort 1) enrolled received same-day TT with reduced-fluence/reduced-irradiance PDT, 10 eyes (cohort 2) received same-day TT with reduced-fluence/standard irradiance PDT, the last 10 eyes (cohort 3) received same-day TT with standard fluence/standard irradiance PDT. Results: All patients completed the 6-month follow-up. Mean best corrected visual acuity (BCVA) at baseline was 1.1 (cohort 1), 0.9 (cohort 2) and 1.1 (cohort 3) logMAR. After 6 months, mean BCVA change was -0.15 (not significant), -0.13 (not significant) and 0.29 (p < 0.05) logMAR, respectively. Among eyes treated with standard fluence/standard irradiance PDT, 2 showed choroidal ischemia. Conclusions: The combination of modified juxtascleral triamcinolone, reduced-fluence PDT, and ranibizumab appears as a safe treatment option. (C) 2013 S. Karger AG, Basel
C1 [Lanzetta, Paolo] Univ Udine, Dept Ophthalmol, IT-33100 Udine, Italy.
   Ist Europeo Microchirurg Oculare, Udine, Italy.
C3 University of Udine
RP Lanzetta, P (通讯作者)，Univ Udine, Dept Ophthalmol, Piazza Santa Maria Misericordia, IT-33100 Udine, Italy.
EM paolo.lanzetta@uniud.it
OI VERITTI, Daniele/0000-0003-0148-5348
CR Ahmadieh Hamid, 2007, BMC Ophthalmol, V7, P10, DOI 10.1186/1471-2415-7-10
   Augustin AJ, 2006, OPHTHALMOLOGY, V113, P14, DOI 10.1016/j.ophtha.2005.09.002
   Augustin AJ, 2007, RETINA-J RET VIT DIS, V27, P133, DOI 10.1097/IAE.0b013e3180323de7
   Bakri SJ, 2009, RETINA-J RET VIT DIS, V29, P573, DOI 10.1097/IAE.0b013e3181a46a8a
   Congdon N, 2004, ARCH OPHTHALMOL-CHIC, V122, P477
   Ehmann D, 2010, CAN J OPHTHALMOL, V45, P36, DOI 10.3129/i09-243
   Forte R, 2011, OPHTHALMIC RES, V45, P129, DOI 10.1159/000318877
   Hatta Y, 2010, RETINA-J RET VIT DIS, V30, P495, DOI 10.1097/IAE.0b013e3181bcedbe
   Jo N, 2006, AM J PATHOL, V168, P2036, DOI 10.2353/ajpath.2006.050588
   Michels S, 2006, INVEST OPHTH VIS SCI, V47, P371, DOI 10.1167/iovs.05-0354
   Mitchell P, 2010, BRIT J OPHTHALMOL, V94, P2, DOI 10.1136/bjo.2009.159160
   QLT Inc, 2010, QLT ANN FIN RES RAD
   Saranadasa M, 2011, CYTOKINE, V53, P115, DOI 10.1016/j.cyto.2010.06.012
   Schmidt-Erfurth U, 2003, INVEST OPHTH VIS SCI, V44, P4473, DOI 10.1167/iovs.02-1115
   Veritti D, 2009, INVEST OPHTH VIS SCI, V50, P2391, DOI 10.1167/iovs.08-2518
   Yip PP, 2009, BRIT J OPHTHALMOL, V93, P754, DOI 10.1136/bjo.2008.150987
   Zarbin MA, 2004, ARCH OPHTHALMOL-CHIC, V122, P598, DOI 10.1001/archopht.122.4.598
NR 17
TC 6
Z9 6
U1 0
U2 1
PU KARGER
PI BASEL
PA ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND
SN 0030-3755
EI 1423-0267
J9 OPHTHALMOLOGICA
JI Ophthalmologica
PY 2013
VL 230
IS 3
BP 131
EP 137
DI 10.1159/000351651
PG 7
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 231MO
UT WOS:000325421000005
PM 23948986
DA 2022-11-30
ER

PT J
AU Wang, K
   Zhong, YY
   Yang, FK
   Hu, CY
   Liu, X
   Zhu, YA
   Yao, K
AF Wang, Kai
   Zhong, Yueyang
   Yang, Fangkun
   Hu, Chenyang
   Liu, Xin
   Zhu, Yanan
   Yao, Ke
TI Causal Effects of N-6 Polyunsaturated Fatty Acids on Age-related Macular
   Degeneration: A Mendelian Randomization Study
SO JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
LA English
DT Article
DE N-6 polyunsaturated fatty acids; linoleic acid; arachidonic acid;
   age-related macular degeneration; Mendelian randomization
ID MULTIPLE GENETIC-VARIANTS; GENOME-WIDE ASSOCIATION; LINOLEIC-ACID;
   DIETARY-FAT; RISK; INFLAMMATION; DISEASE
AB Context: Although the role of n-6 polyunsaturated fatty acids (PUFAs) in age-related macular degeneration (AMD) has been studied in previous observational studies, the precise manner in which 1 or more n-6 PUFAs account for this relationship remains unclear.
   Objective: Using genetic instruments for n-6 PUFAs traits implemented through mendelian randomization (MR), we aimed to study possible causal associations between n-6 PUFAs and AMD.
   Methods: The 2-sample MR method was used to obtain unconfounded causal estimates. We selected genetic variants strongly associated (P < 5 x 10(-8)) with circulating linoleic acid (LA) and arachidonic acid (AA) from a study involving 8631 individuals and applied to an AMD case-control study (33 526 participants and 16 144 cases). The weighted median and MR Egger methods were used for the sensitivity analysis.
   Results: Our MR analysis suggested that circulating LA was a causal protective factor for AMD, with an odds ratio (OR) estimate of 0.967 (95% CI 0.945 to 0.990; P = .005) per percentage in total fatty acid increase in LA. In contrast, higher genetically predicted circulating AA causally increased the AMD risk (OR = 1.034; 95% CI 1.012 to 1.056; P = .002). Sensitivity analysis provided no indication of unknown pleiotropy.The findings from different single-nucleotide polymorphism selections and analytic methods were consistent, suggesting the robustness of the causal associations.
   Conclusion: Our study provided genetic evidence that circulating LA accounted for protective effects of n-6 PUFAs against the risk of AMD, whereas AA was responsible for deleterious effects on higher AMD risk.
C1 [Wang, Kai; Zhong, Yueyang; Hu, Chenyang; Liu, Xin; Zhu, Yanan; Yao, Ke] Zhejiang Univ, Eye Ctr, Sch Med, Affiliated Hosp 2, Hangzhou 310009, Zhejiang, Peoples R China.
   [Yang, Fangkun] Zhejiang Univ, Dept Cardiol, Sch Med, Affiliated Hosp 2, Hangzhou 310009, Zhejiang, Peoples R China.
C3 Zhejiang University; Zhejiang University
RP Yao, K (通讯作者)，Zhejiang Univ, Eye Ctr, Affiliated Hosp 2, Med Coll, Hangzhou 310009, Zhejiang, Peoples R China.
EM xlren@zju.edu.cn
RI Zhong, Yueyang/GQI-2317-2022
FU National Natural Science Foundation of China [81870641, 81970779,
   82070939]; Key Research and Development Project of Zhejiang Province
   [2020C03035]
FX This work was supported by grants from the National Natural Science
   Foundation of China (81870641, 81970779, 82070939) and Key Research and
   Development Project of Zhejiang Province (2020C03035). The sponsor or
   funding organization had no role in the design or conduct of this
   research.
CR Adams CD, 2019, NUTR METAB CARDIOVAS, V29, P1176, DOI 10.1016/j.numecd.2019.06.020
   Anderson DH, 2010, PROG RETIN EYE RES, V29, P95, DOI 10.1016/j.preteyeres.2009.11.003
   Belury MA, 2018, PROSTAG LEUKOTR ESS, V132, P30, DOI 10.1016/j.plefa.2018.03.001
   Bowden J, 2016, GENET EPIDEMIOL, V40, P304, DOI 10.1002/gepi.21965
   Buhler AD, 2016, BMC OPHTHALMOL, V16, DOI 10.1186/s12886-016-0335-9
   Burgess S, 2017, OPHTHALMOLOGY, V124, P1165, DOI 10.1016/j.ophtha.2017.03.042
   Burgess S, 2017, EUR J EPIDEMIOL, V32, P377, DOI 10.1007/s10654-017-0255-x
   Burgess S, 2013, GENET EPIDEMIOL, V37, P658, DOI 10.1002/gepi.21758
   Calder PC, 2003, LIPIDS, V38, P343, DOI 10.1007/s11745-003-1068-y
   Cho E, 2001, AM J CLIN NUTR, V73, P209
   Chong EWT, 2009, ARCH OPHTHALMOL-CHIC, V127, P674, DOI 10.1001/archophthalmol.2009.60
   Christen WG, 2011, ARCH OPHTHALMOL-CHIC, V129, P921, DOI 10.1001/archophthalmol.2011.34
   CONNOR WE, 1992, NUTR REV, V50, P21
   Dams I, 2013, PROSTAG OTH LIPID M, V104, P109, DOI 10.1016/j.prostaglandins.2013.01.001
   Dooper MMBW, 2003, IMMUNOLOGY, V110, P348, DOI 10.1046/j.1365-2567.2003.01749.x
   Emdin CA, 2017, JAMA-J AM MED ASSOC, V318, P1925, DOI 10.1001/jama.2017.17219
   Fritsche LG, 2016, NAT GENET, V48, P134, DOI 10.1038/ng.3448
   Fuke G, 2017, CRIT REV FOOD SCI, V57, P1, DOI 10.1080/10408398.2012.716800
   Gorin MB, 2012, MOL ASPECTS MED, V33, P467, DOI 10.1016/j.mam.2012.04.004
   Guan WH, 2014, CIRC-CARDIOVASC GENE, V7, P321, DOI 10.1161/CIRCGENETICS.113.000208
   Jump DB, 2002, J BIOL CHEM, V277, P8755, DOI 10.1074/jbc.R100062200
   Kauppinen A, 2016, CELL MOL LIFE SCI, V73, P1765, DOI 10.1007/s00018-016-2147-8
   Khankari NK, 2020, CANCER EPIDEM BIOMAR, V29, P860, DOI 10.1158/1055-9965.EPI-19-0891
   Kodali HP, 2018, AM J CLIN NUTR, V108, P237, DOI 10.1093/ajcn/nqy129
   Lawrenson JG, 2019, NUTRIENTS, V11, DOI 10.3390/nu11040823
   Liu JQ, 2019, CANCER MED-US, V8, P1817, DOI 10.1002/cam4.2018
   Liyanage UE, 2019, CANCER EPIDEM BIOMAR, V28, P1015, DOI 10.1158/1055-9965.EPI-18-0940
   Liyanage UE, 2018, INT J CANCER, V143, P508, DOI 10.1002/ijc.31334
   Machiela MJ, 2015, BIOINFORMATICS, V31, P3555, DOI 10.1093/bioinformatics/btv402
   May-Wilson S, 2017, EUR J CANCER, V84, P228, DOI 10.1016/j.ejca.2017.07.034
   Milaneschi Y, 2019, TRANSL PSYCHIAT, V9, DOI 10.1038/s41398-019-0554-y
   Mitchell JA, 2019, BRIT J PHARMACOL, V176, P1038, DOI 10.1111/bph.14167
   Mitchell P, 2018, LANCET, V392, P1147, DOI 10.1016/S0140-6736(18)31550-2
   Ng ALK, 2019, NUTRIENTS, V11, DOI 10.3390/nu11081720
   Orban T, 2015, FASEB J, V29, P4579, DOI 10.1096/fj.15-275289
   Palmer TM, 2012, STAT METHODS MED RES, V21, P223, DOI 10.1177/0962280210394459
   Prommaban A, 2019, PHYTOTHER RES, V33, P2749, DOI 10.1002/ptr.6449
   Ramsden CE, 2016, BMJ-BRIT MED J, V353, DOI 10.1136/bmj.i1246
   Ramsden CE, 2013, BMJ-BRIT MED J, V346, DOI 10.1136/bmj.e8707
   Ricciotti E, 2011, ARTERIOSCL THROM VAS, V31, P986, DOI 10.1161/ATVBAHA.110.207449
   Diez GR, 2013, EXP EYE RES, V113, P172, DOI 10.1016/j.exer.2013.05.019
   Diez GR, 2012, NEUROCHEM INT, V61, P749, DOI 10.1016/j.neuint.2012.06.012
   SanGiovanni JP, 2007, ARCH OPHTHALMOL-CHIC, V125, P671, DOI 10.1001/archopht.125.5.671
   SanGiovanni JP, 2005, PROG RETIN EYE RES, V24, P87, DOI 10.1016/j.preteyeres.2004.06.002
   Seddon JM, 2001, ARCH OPHTHALMOL-CHIC, V119, P1191, DOI 10.1001/archopht.119.8.1191
   Smith GD, 2003, INT J EPIDEMIOL, V32, P1, DOI 10.1093/ije/dyg070
   Tan JSL, 2009, ARCH OPHTHALMOL-CHIC, V127, P656, DOI 10.1001/archophthalmol.2009.76
   Thompson JR, 2016, INT J BIOSTAT, V12, DOI 10.1515/ijb-2015-0074
   Tomata Y, 2020, EUR J NUTR, V59, P1763, DOI 10.1007/s00394-019-02126-x
   van Leeuwen EM, 2018, PROG RETIN EYE RES, V67, P56, DOI 10.1016/j.preteyeres.2018.04.006
   Weikel KA, 2012, MOL ASPECTS MED, V33, P318, DOI 10.1016/j.mam.2012.03.005
   Wu JHY, 2017, LANCET DIABETES ENDO, V5, P965, DOI [10.1016/s2213-8587(17)30307-8, 10.1016/S2213-8587(17)30307-8]
   Zhao JV, 2019, BMC MED, V17, DOI 10.1186/s12916-019-1293-x
   Zhao JV, 2019, ANN RHEUM DIS, V78, P711, DOI 10.1136/annrheumdis-2018-214519
NR 54
TC 2
Z9 2
U1 0
U2 8
PU ENDOCRINE SOC
PI WASHINGTON
PA 2055 L ST NW, SUITE 600, WASHINGTON, DC 20036 USA
SN 0021-972X
EI 1945-7197
J9 J CLIN ENDOCR METAB
JI J. Clin. Endocrinol. Metab.
PD SEP
PY 2021
VL 106
IS 9
BP E3565
EP E3572
DI 10.1210/clinem/dgab338
EA MAY 2021
PG 8
WC Endocrinology & Metabolism
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Endocrinology & Metabolism
GA UL4LZ
UT WOS:000692625700048
PM 33982092
OA Bronze
DA 2022-11-30
ER

PT J
AU Krebs, I
   Marlovits, VV
   Bodenstorfer, J
   Glittenberg, C
   Shahrezaei, SA
   Ristl, R
   Binder, S
AF Krebs, Ilse
   Marlovits, Veronika Vecsei
   Bodenstorfer, Johannes
   Glittenberg, Carl
   Shahrezaei, Siamak Ansari
   Ristl, Robin
   Binder, Susanne
TI Comparison of Ranibizumab monotherapy versus combination of Ranibizumab
   with photodynamic therapy with neovascular age-related macular
   degeneration
SO ACTA OPHTHALMOLOGICA
LA English
DT Article
DE age-related macular degeneration; choroidal neovascularization;
   photodynamic therapy (Verteporfin (R)); Ranibizumab (Lucentis (R));
   vascular endothelial growth factor
ID SUBFOVEAL CHOROIDAL NEOVASCULARIZATION; VERTEPORFIN PLUS RANIBIZUMAB;
   INTRAVITREAL RANIBIZUMAB; DOSING REGIMEN; TRIAL; DISEASE; AMD
AB Purpose: Modern therapy of neovascular age-related macular degeneration consists in intravitreal injections of inhibitors of the vascular endothelial growth factor. An increasing number of these injections is required not only in monthly but also in as-needed treatment regimen. In this study, it should be examined whether an additional administered photodynamic therapy (PDT) can considerably reduce the number of injection.
   Methods: In this prospective, randomized study carried out in three large hospitals of Vienna eyes with neovascular age-related macula degeneration were included. Patients were randomized to either Ranibizumab monotherapy or combined standard fluence PDT and Ranibizumab therapy. All patients received a loading dose of three intravitreal Ranibizumab injections and were thereafter treated in an as-needed regimen based on distance acuity and retinal thickness values. In the combined treatment group, PDT was administered 1 day after the first Ranibizumab injection.
   Results: Fifty-one patients were randomized, 44 were finally included (four screening failures and three withdrawals). Twenty-four patients were assigned to the monotherapy and 20 patients to the combined treatment group. Fewer injections were required in the combined treatment group (4.7 versus 6.3). Overall the patients lost 0.5 letters; in the combined treatment group, the patients lost mean 7.1 letters; in the monotherapy group, they gained mean 5.1 letters. Retinal thickness decreased significantly in both groups.
   Conclusion: A significant reduction of the number of required intravitreal injections could be achieved by the additional PDT treatment, but was accompanied by a worse functional outcome in this group.
C1 [Krebs, Ilse; Glittenberg, Carl; Shahrezaei, Siamak Ansari; Binder, Susanne] Ludwig Boltzmann Inst Retinol & Biomicroscop Lase, Vienna, Austria.
   [Krebs, Ilse; Glittenberg, Carl; Shahrezaei, Siamak Ansari; Binder, Susanne] Rudolf Fdn Clin, Dept Ophthalmol, A-1030 Vienna, Austria.
   [Marlovits, Veronika Vecsei] Hosp Hietzing, Dept Ophthalmol, Vienna, Austria.
   [Bodenstorfer, Johannes] Med Ctr East, Dept Ophthalmol, Vienna, Austria.
   [Ristl, Robin] Med Univ, Sect Med Stat, Ctr Med Stat Informat & Intelligent Syst, Vienna, Austria.
C3 Ludwig Boltzmann Institute; Hietzing Hospital; Donauspital
RP Krebs, I (通讯作者)，Rudolf Fdn Clin, Dept Ophthalmol, Juchgasse 25, A-1030 Vienna, Austria.
EM ilse.krebs@wienkav.at
OI Ristl, Robin/0000-0002-4163-9236
FU Novartis Pharma Austria
FX Supported by Novartis Pharma Austria.
CR Antoszyk AN, 2008, AM J OPHTHALMOL, V145, P862, DOI 10.1016/j.ajo.2007.12.029
   Bashshur ZF, 2011, RETINA-J RET VIT DIS, V31, P636, DOI 10.1097/IAE.0b013e3181fe54ab
   Blumenkranz MS, 2001, ARCH OPHTHALMOL-CHIC, V119, P198
   Bressler NM, 2002, AM J OPHTHALMOL, V133, P168, DOI 10.1016/S0002-9394(01)01237-5
   Chen E, 2010, CLIN OPHTHALMOL, V4, P1073, DOI 10.2147/OPTH.S13969
   Cohen SY, 2012, RETINA-J RET VIT DIS, V32, P1480, DOI 10.1097/IAE.0b013e318240a516
   Francis Peter James, 2011, Trans Am Ophthalmol Soc, V109, P115
   Fung AE, 2007, AM J OPHTHALMOL, V143, P566, DOI 10.1016/j.ajo.2007.01.028
   Holz FG, 2010, INVEST OPHTH VIS SCI, V51, P405, DOI 10.1167/iovs.09-3813
   Kaiser PK, 2007, AM J OPHTHALMOL, V144, P850, DOI 10.1016/j.ajo.2007.08.012
   Kaiser PK, 2012, OPHTHALMOLOGY, V119, P1001, DOI 10.1016/j.ophtha.2012.02.003
   Kiss CG, 2008, BRIT J OPHTHALMOL, V92, P1620, DOI 10.1136/bjo.2007.135335
   Krebs I, 2011, INVEST OPHTH VIS SCI, V52, P6925, DOI 10.1167/iovs.10-6612
   Krebs I, 2011, BRIT J OPHTHALMOL, V95, P1552, DOI 10.1136/bjo.2010.194670
   Kumar A, 2008, RETINA-J RET VIT DIS, V28, P1132, DOI 10.1097/IAE.0b013e318170d76d
   Larsen M, 2012, OPHTHALMOLOGY, V119, P992, DOI 10.1016/j.ophtha.2012.02.002
   Lim JY, 2012, ACTA OPHTHALMOL, V90, P61, DOI 10.1111/j.1755-3768.2009.01841.x
   Menghini M, 2010, KLIN MONATSBL AUGENH, V227, P244, DOI 10.1055/s-0029-1245203
   Moshfeghi AA, 2011, RETINA-J RET VIT DIS, V31, P662, DOI 10.1097/IAE.0b013e31821067c4
   Regillo CD, 2008, AM J OPHTHALMOL, V145, P239, DOI 10.1016/j.ajo.2007.10.004
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Singer MA, 2012, OPHTHALMOLOGY, V119, P1175, DOI 10.1016/j.ophtha.2011.12.016
   Spielberg L, 2010, GRAEF ARCH CLIN EXP, V248, P943, DOI 10.1007/s00417-009-1256-6
   Tolentino M, 2011, SURV OPHTHALMOL, V56, P95, DOI 10.1016/j.survophthal.2010.08.006
   Ueta T, 2009, OPHTHALMOLOGY, V116, P362, DOI 10.1016/j.ophtha.2008.09.046
   Vallance JH, 2010, EYE, V24, P1561, DOI 10.1038/eye.2010.84
   Wolf-Schnurrbusch UEK, 2011, ACTA OPHTHALMOL, V89, P585, DOI 10.1111/j.1755-3768.2009.01747.x
NR 27
TC 20
Z9 20
U1 0
U2 9
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1755-375X
J9 ACTA OPHTHALMOL
JI Acta Ophthalmol.
PD MAY
PY 2013
VL 91
IS 3
BP E178
EP E183
DI 10.1111/aos.12018
PG 6
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 131HH
UT WOS:000317983000002
PM 23241227
DA 2022-11-30
ER

PT J
AU Davis, MD
   Gangnon, RE
   Lee, LY
   Hubbard, LD
   Klein, BEK
   Klein, R
   Ferris, FL
   Bressler, SB
   Milton, RC
AF Davis, MD
   Gangnon, RE
   Lee, LY
   Hubbard, LD
   Klein, BEK
   Klein, R
   Ferris, FL
   Bressler, SB
   Milton, RC
CA Age-Related Eye Dis Study Res
TI The age-related eye disease study severity scale for age-related macular
   degeneration - AREDS report no. 17
SO ARCHIVES OF OPHTHALMOLOGY
LA English
DT Article
ID PROGRESSION; MACULOPATHY; RISK
AB Objective: To develop a fundus photographic severity scale for age-related macular degeneration (AMD).
   Methods: In the Age-Related Eye Disease Study, stereoscopic color fundus photographs were taken at baseline, at the 2-year follow-up visit, and annually thereafter. Photographs were graded for drusen characteristics (size, type, area), pigmentary abnormalities (increased pigment, depigmentation, geographic atrophy), and presence of abnormalities characteristic of neovascular AMD (retinal pigment epithelial detachment, serous or hemorrhagic sensory retinal detachment, subretinal or sub-retinal pigment epithelial hemorrhage, subretinal fibrous tissue). Advanced AMD was defined as presence of 1 or more neovascular AMD abnormalities, photocoagulation for AMD, or geographic atrophy involving the center of the macula. We explored associations among right eyes of 3212 participants between severity of drusen characteristics and pigmentary abnormalities at baseline and development of advanced AMD within 5 years of follow-up.
   Results: A 9-step severity scale that combines a 6-step drusen area scale with a 5-step pigmentary abnormality scale was developed, on which the 5-year risk of advanced AMD increased progressively from less than 1% in step 1 to about 50% in step 9. Among the 334 eyes that had at least a 3-step progression on the scale between the baseline and 5-year visits, almost half showed stepwise progression through intervening severity levels at intervening visits. Replicate gradings showed agreement within 1. step on the scale in 87% of eyes.
   Conclusions: The scale provides convenient risk categories and has acceptable reproducibility. Progression along it may prove to be useful as a surrogate for progression to advanced AMD.
C1 EMMES Corp, AREDS Coordinat Ctr, Rockville, MD 20850 USA.
C3 Emmes Corporation
RP Davis, MD (通讯作者)，EMMES Corp, AREDS Coordinat Ctr, 401 N Washington St,Suite 700, Rockville, MD 20850 USA.
OI Ferris, Frederick/0000-0002-4933-0639; Gangnon,
   Ronald/0000-0003-2587-6714
FU NATIONAL EYE INSTITUTE [Z01EY000394] Funding Source: NIH RePORTER; NEI
   NIH HHS [Z01 EY000394-03] Funding Source: Medline
CR Age-Related Eye Dis Study Res Grp, 2001, AM J OPHTHALMOL, V132, P668
   Anand R, 2000, OPHTHALMOLOGY, V107, P2224
   [Anonymous], 2017, STAT MODELS S
   [Anonymous], 2005, ARCH OPHTHALMOL-CHIC, V123, P1570, DOI DOI 10.1001/ARCHOPHT.123.11.1570
   Au Eong KG, 2002, AGE RELATED MACULAR, P389
   BURGESS DB, 1993, ARCH OPHTHALMOL-CHIC, V111, P1189
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1439, DOI 10.1001/archopht.119.10.1439
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1417, DOI 10.1001/archopht.119.10.1417
   Klein R, 1997, OPHTHALMOLOGY, V104, P7, DOI 10.1016/S0161-6420(97)30368-6
   Klein R, 2002, OPHTHALMOLOGY, V109, P1767, DOI 10.1016/S0161-6420(02)01146-6
   Maguire MG, 1997, ARCH OPHTHALMOL-CHIC, V115, P741
   SHAMOON H, 1995, ARCH OPHTHALMOL-CHIC, V113, P36
   van Leeuwen R, 2003, ARCH OPHTHALMOL-CHIC, V121, P519, DOI 10.1001/archopht.121.4.519
   VENABLES WN, 1997, MODERN APPL STAT S P
   Wang JJ, 2003, ARCH OPHTHALMOL-CHIC, V121, P658, DOI 10.1001/archopht.121.5.658
   Zhang HP, 1999, RECURSIVE PARTITIONI
NR 16
TC 487
Z9 502
U1 0
U2 26
PU AMER MEDICAL ASSOC
PI CHICAGO
PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA
SN 0003-9950
EI 1538-3601
J9 ARCH OPHTHALMOL-CHIC
JI Arch. Ophthalmol.
PD NOV
PY 2005
VL 123
IS 11
BP 1484
EP 1498
PG 15
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 981BM
UT WOS:000233062100001
PM 16286610
DA 2022-11-30
ER

PT J
AU Muftuoglu, IK
   Ramkumar, HL
   Bartsch, DU
   Meshi, A
   Gaber, R
   Freeman, WR
AF Muftuoglu, Ilkay Kilic
   Ramkumar, Hema L.
   Bartsch, Dirk-Uwe
   Meshi, Amit
   Gaber, Raouf
   Freeman, William R.
TI QUANTITATIVE ANALYSIS OF THE INNER RETINAL LAYER THICKNESSES IN
   AGE-RELATED MACULAR DEGENERATION USING CORRECTED OPTICAL COHERENCE
   TOMOGRAPHY SEGMENTATION
SO RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES
LA English
DT Article
DE dry age-related macular degeneration; OCT; ganglion cell layer; ganglion
   cell complex; inner retinal layers; retinal layer segmentation;
   age-related macular degeneration
ID GANGLION-CELL COMPLEX; PLEXIFORM LAYER; PREVALENCE; DISEASE; EYE
AB Purpose: To characterize inner retinal damage in patients with dry age-related macular degeneration (AMD) using high-resolution spectral domain optical coherence tomography images.
   Methods: Sixty eyes of 60 patients with AMD were categorized using the Age-Related Eye Disease Study (AREDS) severity scale. Spectral domain optical coherence tomography images of these patients were quantified by manually correcting the segmentation of each retinal layer, including the retinal nerve fiber layer, ganglion cell layer, and inner plexiform layer to ensure accurate delineation of layers. The mean ganglion cell complex thickness values (ganglion cell layer + inner plexiform layer + retinal nerve fiber layer) were compared with 30 eyes of 30 healthy subjects.
   Results: Ninety percent of eyes (81 eyes) required manual correction of segmentation. Compared with healthy subjects, mean ganglion cell complex thicknesses significantly decreased in more advanced dry AMD eyes, and this decrease was predominantly related to a change in inner plexiform layer thickness. There was no significant difference in thickness-related measurements between milder dry AMD (AREDS-2) eyes and healthy eyes (P > 0.05).
   Conclusion: In patients with dry AMD, automatic optical coherence tomography segmentation algorithms may be erroneous. As the severity of dry AMD increases, the inner plexiform layer layer becomes thinned, suggesting that transsynaptic degeneration may be occurring, as the photoreceptor layer is affected by AMD.
C1 [Muftuoglu, Ilkay Kilic; Ramkumar, Hema L.; Bartsch, Dirk-Uwe; Meshi, Amit; Gaber, Raouf; Freeman, William R.] Univ Calif San Diego, Dept Ophthalmol, Shiley Eye Inst, Dept Ophthalmol,Jacobs Retina Ctr, La Jolla, CA 92093 USA.
   [Muftuoglu, Ilkay Kilic] Istanbul Training & Res Hosp, Dept Ophthalmol, Istanbul, Turkey.
C3 University of California System; University of California San Diego;
   Istanbul Training & Research Hospital
RP Freeman, WR (通讯作者)，Univ Calif San Diego, Jacobs Retina Ctr, Shiley Eye Inst, 9415 Campus Point Dr, La Jolla, CA 92037 USA.
EM wrfreeman@ucsd.edu
RI Gaber, Raouf/GSN-8206-2022
FU NIH [R01 EY016323-09A1]; National Eye Institute [P30 EY022589]; Research
   to Prevent Blindness, NY; NATIONAL EYE INSTITUTE [P30EY022589,
   R01EY016323] Funding Source: NIH RePORTER
FX Supported in part by NIH grant R01 EY016323-09A1 (D.-U.B.), a core grant
   from the National Eye Institute P30 EY022589 (W.R.F.), and an
   unrestricted grant from Research to Prevent Blindness, NY (W.R.F.). The
   funding organizations had no role in the design or conduct of this
   research.
CR Alshareef RA, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0155319
   Barteselli G, 2016, RETINA-J RET VIT DIS, V36, P1153, DOI 10.1097/IAE.0000000000000842
   Barteselli G, 2013, AM J OPHTHALMOL, V156, P588, DOI 10.1016/j.ajo.2013.04.030
   Chhablani J, 2015, INVEST OPHTH VIS SCI, V56, P6333, DOI 10.1167/iovs.15-17334
   Chhablani J, 2015, INVEST OPHTH VIS SCI, V56, P1416, DOI 10.1167/iovs.14-15672
   Choudhary P, 2016, STEM CELL TRANSL MED, V5, P925, DOI 10.5966/sctm.2015-0247
   Davis MD, 2005, ARCH OPHTHALMOL-CHIC, V123, P1484
   Eng JG, 2011, INVEST OPHTH VIS SCI, V52, P4610, DOI 10.1167/iovs.09-4936
   Hwang YH, 2016, OPHTHALMOLOGY, V123, P950, DOI 10.1016/j.ophtha.2015.12.032
   Kim HJ, 2016, INVEST OPHTH VIS SCI, V57, P4799, DOI 10.1167/iovs.16-19214
   Klein R, 2011, ARCH OPHTHALMOL-CHIC, V129, P75, DOI 10.1001/archophthalmol.2010.318
   Lee EK, 2015, INVEST OPHTH VIS SCI, V56, P3976, DOI 10.1167/iovs.15-17013
   Lee HJ, 2015, AM J OPHTHALMOL, V160, P283, DOI 10.1016/j.ajo.2015.05.015
   Medeiros NE, 2001, INVEST OPHTH VIS SCI, V42, P795
   Saha S, 2016, NEUROSCIENCE, V329, P1, DOI 10.1016/j.neuroscience.2016.04.032
   Savastano MC, 2014, INVEST OPHTH VIS SCI, V55, P560, DOI 10.1167/iovs.13-12172
   Schwartz SD, 2016, INVEST OPHTH VIS SCI, V57, DOI 10.1167/iovs.15-18681
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
   Yenice E, 2015, EYE, V29, P1076, DOI 10.1038/eye.2015.86
   Zucchiatti I, 2015, AM J OPHTHALMOL, V160, P602, DOI 10.1016/j.ajo.2015.05.030
NR 20
TC 23
Z9 23
U1 0
U2 1
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0275-004X
EI 1539-2864
J9 RETINA-J RET VIT DIS
JI Retin.-J. Retin. Vitr. Dis.
PD AUG
PY 2018
VL 38
IS 8
BP 1478
EP 1484
DI 10.1097/IAE.0000000000001759
PG 7
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA HF1VJ
UT WOS:000454002400015
PM 28650925
OA Green Accepted
DA 2022-11-30
ER

PT J
AU Szatmari-Toth, M
   Kristof, E
   Vereb, Z
   Akhtar, S
   Facsko, A
   Fesus, L
   Kauppinen, A
   Kaarniranta, K
   Petrovski, G
AF Szatmari-Toth, M.
   Kristof, E.
   Vereb, Z.
   Akhtar, S.
   Facsko, A.
   Fesus, L.
   Kauppinen, A.
   Kaarniranta, K.
   Petrovski, G.
TI Clearance of autophagy-associated dying retinal pigment epithelial cells
   - a possible source for inflammation in age-related macular degeneration
SO CELL DEATH & DISEASE
LA English
DT Article
ID INTRAVITREAL TRIAMCINOLONE ACETONIDE; OXIDATIVE STRESS; DENDRITIC CELLS;
   DEATH; PHAGOCYTOSIS; RPE; INDUCTION; DRUSEN; LEADS; DYSREGULATION
AB Retinal pigment epithelial (RPE) cells can undergo different forms of cell death, including autophagy-associated cell death during age-related macular degeneration (AMD). Failure of macrophages or dendritic cells (DCs) to engulf the different dying cells in the retina may result in the accumulation of debris and progression of AMD. ARPE-19 and primary human RPE cells undergo autophagy-associated cell death upon serum depletion and oxidative stress induced by hydrogen peroxide (H2O2). Autophagy was revealed by elevated light-chain-3 II (LC3-II) expression and electron microscopy, while autophagic flux was confirmed by blocking the autophago-lysosomal fusion using chloroquine (CQ) in these cells. The autophagy-associated dying RPE cells were engulfed by human macrophages, DCs and living RPE cells in an increasing and time-dependent manner. Inhibition of autophagy by 3-methyladenine (3-MA) decreased the engulfment of the autophagy-associated dying cells by macrophages, whereas sorting out the GFP-LC3-positive/autophagic cell population or treatment by the glucocorticoid triamcinolone (TC) enhanced it. Increased amounts of IL-6 and IL-8 were released when autophagy-associated dying RPEs were engulfed by macrophages. Our data suggest that cells undergoing autophagy-associated cell death engage in clearance mechanisms guided by professional and nonprofessional phagocytes, which is accompanied by inflammation as part of an in vitro modeling of AMD pathogenesis.
C1 [Szatmari-Toth, M.; Kristof, E.; Fesus, L.; Petrovski, G.] Univ Debrecen, Dept Biochem & Mol Biol, Debrecen, Hungary.
   [Szatmari-Toth, M.; Kristof, E.; Fesus, L.; Petrovski, G.] Univ Debrecen, Apoptosis & Genom Res Grp, MTA DE Stem Cell, Debrecen, Hungary.
   [Vereb, Z.; Facsko, A.; Petrovski, G.] Univ Szeged, Fac Med, Dept Ophthalmol, Stem Cells & Eye Res Lab, Koranyi Fasor 10-11, H-6720 Szeged, Hungary.
   [Akhtar, S.] King Saud Univ, Coll Appl Med, Dept Optometry, Riyadh, Saudi Arabia.
   [Kauppinen, A.; Kaarniranta, K.] Univ Eastern Finland, Facil Hlth Sci, Sch Pharm, Kuopio, Finland.
   [Petrovski, G.] Univ Oslo, Oslo Univ Hosp, Dept Ophthalmol, Ctr Eye Res, Oslo, Norway.
C3 University of Debrecen; University of Debrecen; Szeged University; King
   Saud University; University of Eastern Finland; University of Oslo
RP Petrovski, G (通讯作者)，Univ Szeged, Fac Med, Dept Ophthalmol, Stem Cells & Eye Res Lab, Koranyi Fasor 10-11, H-6720 Szeged, Hungary.
EM petrovski.goran@med.u-szeged.hu
RI Vereb, Zoltan/AAR-4092-2020; Kristóf, Endre/AGB-5046-2022; Vereb,
   Zoltan/I-6356-2019; Akhtar, Saeed/AGY-3605-2022
OI Kristóf, Endre/0000-0002-2215-6984; Vereb, Zoltan/0000-0002-9518-2155;
   Petrovski, Goran/0000-0003-2905-9252; Szatmari-Toth,
   Maria/0000-0003-3028-5097
FU European Social Fund [TAMOP-4.2.4.A/2-11/1-2012-0001,
   TAMOP-4.2.2.A-11/1/KONV-2012-0023, TAMOP-4.2.2. A-11/1/KONV-2012-0025];
   Hungarian Academy of Sciences; OTKA [NK 105046]; National Brain Research
   Program [KTIA_NAP_13-A_III/9]
FX This research was co-financed by the European Social Fund in the
   framework of TAMOP-4.2.4.A/2-11/1-2012-0001 'National Excellence
   Program' which provided personal support to Kristof EK,
   TAMOP-4.2.2.A-11/1/KONV-2012-0023, TAMOP-4.2.2. A-11/1/KONV-2012-0025
   grant, OTKA NK 105046 and the Hungarian Academy of Sciences, and the
   National Brain Research Program (KTIA_NAP_13-A_III/9). We would like to
   thank Dr. Mate Demeny for his internal revision of the manuscript, Mr.
   Pal Boto for his technical help with cell sorting and Mr. Zoltan Doro
   for his help with the transfections (all members of the Department of
   Biochemistry and Molecular Biology, University of Debrecen).
CR Albert R, 2015, BBA-GEN SUBJECTS, V1850, P435, DOI 10.1016/j.bbagen.2014.10.026
   Ambreen F, 2015, MOL VIS, V21, P985
   Amelio I, 2011, BIOCHEM BIOPH RES CO, V414, P277, DOI 10.1016/j.bbrc.2011.09.080
   Ardeljan CP, 2014, J CLIN MED, V3, P1542, DOI 10.3390/jcm3041542
   Ashabi G, 2013, TOXICOL IN VITRO, V27, P1780, DOI 10.1016/j.tiv.2013.05.005
   Ayna G, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0040069
   Baehrecke EH, 2005, NAT REV MOL CELL BIO, V6, P505, DOI 10.1038/nrm1666
   Baudhuin P, 1966, Brux Med, V46, P1059
   Becerra EM, 2011, CURR DRUG TARGETS, V12, P149
   Blasiak J, 2014, BIOMED RES INT, V2014, DOI 10.1155/2014/768026
   Boulton M, 2001, EYE, V15, P384, DOI 10.1038/eye.2001.141
   Bursch W, 2000, J CELL SCI, V113, P1189
   Buschini E, 2011, PROG NEUROBIOL, V95, P14, DOI 10.1016/j.pneurobio.2011.05.011
   Cascella R, 2014, J OPHTHALMOL, V2014, DOI 10.1155/2014/582842
   Chang YC, 2015, TOXICOL IN VITRO, V29, P1358, DOI 10.1016/j.tiv.2015.05.014
   Chiras D, 2015, CRIT REV CL LAB SCI, V52, P12, DOI 10.3109/10408363.2014.968703
   Cho KS, 2012, INVEST OPHTH VIS SCI, V53, P5344, DOI 10.1167/iovs.12-9827
   Codogno P, 2005, CELL DEATH DIFFER, V12, P1509, DOI 10.1038/sj.cdd.4401751
   Danis RP, 2000, RETINA-J RET VIT DIS, V20, P244, DOI 10.1097/00006982-200003000-00004
   DEDUVE C, 1966, ANNU REV PHYSIOL, V28, P435, DOI 10.1146/annurev.ph.28.030166.002251
   Ding XY, 2009, PROG RETIN EYE RES, V28, P1, DOI 10.1016/j.preteyeres.2008.10.001
   Edelman JL, 2010, OPHTHALMOLOGICA, V224, P25, DOI 10.1159/000315158
   Essick EE, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0068697
   Ferguson TA, 2014, AUTOPHAGY, V10, P165, DOI 10.4161/auto.26735
   Filomeni G, 2015, CELL DEATH DIFFER, V22, P377, DOI 10.1038/cdd.2014.150
   Gogolak P, 2007, BLOOD, V109, P643, DOI 10.1182/blood-2006-04-016840
   Gopal Lekha, 2007, Indian Journal of Ophthalmology, V55, P431
   Ha JH, 2012, CELL BIOL TOXICOL, V28, P19, DOI 10.1007/s10565-011-9202-x
   Hageman GS, 2001, PROG RETIN EYE RES, V20, P705, DOI 10.1016/S1350-9462(01)00010-6
   Hariharan N, 2011, ANTIOXID REDOX SIGN, V14, P2179, DOI 10.1089/ars.2010.3488
   Hodrea J, 2012, J LEUKOCYTE BIOL, V91, P127, DOI 10.1189/jlb.0511243
   Hu ZP, 2015, MOL NEUROBIOL, V52, P1190, DOI 10.1007/s12035-014-8921-4
   Hyttinen JMT, 2011, REJUV RES, V14, P651, DOI 10.1089/rej.2011.1220
   Irschick EU, 2004, OPHTHALMIC RES, V36, P200, DOI 10.1159/000078778
   Jonas JB, 2005, ACTA OPHTHALMOL SCAN, V83, P645, DOI 10.1111/j.1600-0420.2005.00592.x
   Jonas JB, 2005, EYE, V19, P163, DOI 10.1038/sj.eye.6701438
   Jonas JB, 2004, BRIT J OPHTHALMOL, V88, P1557, DOI 10.1136/bjo.2003.039552
   Jonas JB, 2003, BRIT J OPHTHALMOL, V87, P462, DOI 10.1136/bjo.87.4.462
   Jonas JB, 2006, OPHTHALMIC RES, V38, P218, DOI 10.1159/000093796
   Jonuleit H, 1997, EUR J IMMUNOL, V27, P3135, DOI 10.1002/eji.1830271209
   Kaarniranta K, 2013, AUTOPHAGY, V9, P973, DOI 10.4161/auto.24546
   Kevany BM, 2010, PHYSIOLOGY, V25, P8, DOI 10.1152/physiol.00038.2009
   Kim JY, 2013, CELL, V154, P365, DOI 10.1016/j.cell.2013.06.012
   Kis-Toth K, 2013, IMMUNOBIOLOGY, V218, P1361, DOI 10.1016/j.imbio.2013.06.012
   Klettner A, 2013, INT J BIOCHEM CELL B, V45, P1457, DOI 10.1016/j.biocel.2013.04.013
   Klionsky DJ, 2012, AUTOPHAGY, V8, P445, DOI 10.4161/auto.19496
   Kovala AT, 2000, FASEB J, V14, P2486, DOI 10.1096/fj.00-0147com
   Kulkarni AD, 2005, ADV DRUG DELIVER REV, V57, P1994, DOI 10.1016/j.addr.2005.09.003
   Kunchithapautham K, 2007, AUTOPHAGY, V3, P433, DOI 10.4161/auto.4294
   Li W, 2012, J CELL PHYSIOL, V227, P1291, DOI 10.1002/jcp.22815
   Li Y, 2014, CAN J PHYSIOL PHARM, V92, P765, DOI 10.1139/cjpp-2014-0018
   Majai G, 2006, IMMUNOL LETT, V104, P94, DOI 10.1016/j.imlet.2005.11.016
   Mao HY, 2014, INVEST OPHTH VIS SCI, V55, P4613, DOI 10.1167/iovs.14-14633
   Mazzoni F, 2014, EXP EYE RES, V126, P51, DOI 10.1016/j.exer.2014.01.010
   Mitter SK, 2014, AUTOPHAGY, V10, P1989, DOI 10.4161/auto.36184
   Navarro-Yepes J, 2014, ANTIOXID REDOX SIGN, V21, P66, DOI 10.1089/ars.2014.5837
   Patel M, 2008, SEMIN IMMUNOPATHOL, V30, P97, DOI 10.1007/s00281-008-0112-9
   Petrovski G, 2007, CELL DEATH DIFFER, V14, P1117, DOI 10.1038/sj.cdd.4402112
   Petrovski G, 2007, AUTOPHAGY, V3, P509
   Petrovski G, 2011, AUTOPHAGY, V7, P321, DOI 10.4161/auto.7.3.14583
   Petrovski G, 2011, ACTA OPHTHALMOL, V89, pE30, DOI 10.1111/j.1755-3768.2010.02047.x
   Qu XP, 2007, CELL, V128, P931, DOI 10.1016/j.cell.2006.12.044
   Rickman CB, 2013, INVEST OPHTH VIS SCI, V54, pORSF68, DOI 10.1167/iovs.13-12757
   Sarvari AK, 2015, CELL DEATH DIS, V6, DOI 10.1038/cddis.2014.579
   Sato E, 2008, MED MOL MORPHOL, V41, P211, DOI 10.1007/s00795-008-0414-y
   Scherz-Shouval R, 2007, EMBO J, V26, P1749, DOI 10.1038/sj.emboj.7601623
   Seitz HM, 2007, J IMMUNOL, V178, P5635, DOI 10.4049/jimmunol.178.9.5635
   Sharma K, 2014, FRONT AGING NEUROSCI, V6, DOI 10.3389/fnagi.2014.00151
   Shiloach T, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0101075
   Shvets E, 2008, AUTOPHAGY, V4, P621, DOI 10.4161/auto.5939
   Shvets E, 2009, METHOD ENZYMOL, V452, P131, DOI 10.1016/S0076-6879(08)03609-4
   Smith AG, 2014, EXPERT OPIN EMERG DR, V19, P157, DOI 10.1517/14728214.2014.884559
   Song CJ, 2014, CYTOTHERAPY, V16, P1361, DOI 10.1016/j.jcyt.2014.04.006
   Sparrow JR, 2012, MOL ASPECTS MED, V33, P436, DOI 10.1016/j.mam.2012.03.007
   Strauss O, 2005, PHYSIOL REV, V85, P845, DOI 10.1152/physrev.00021.2004
   Viiri J, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0069563
   Wada Y, 2014, CURR OPIN GENET DEV, V27, P60, DOI 10.1016/j.gde.2014.03.010
   Wang AL, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0004160
   Xu W, 2006, IMMUNOBIOLOGY, V211, P567, DOI 10.1016/j.imbio.2006.05.023
   Yao JY, 2015, AUTOPHAGY, V11, P939, DOI 10.1080/15548627.2015.1041699
   Yilmaz T, 2009, OPHTHALMOLOGY, V116, P902, DOI 10.1016/j.ophtha.2009.02.002
   Yoon YH, 2010, INVEST OPHTH VIS SCI, V51, P6030, DOI 10.1167/iovs.10-5278
NR 82
TC 41
Z9 41
U1 0
U2 15
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 2041-4889
J9 CELL DEATH DIS
JI Cell Death Dis.
PD SEP
PY 2016
VL 7
AR e2367
DI 10.1038/cddis.2016.133
PG 13
WC Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Cell Biology
GA EC2QF
UT WOS:000387968100001
PM 27607582
OA Green Accepted, gold, Green Published
DA 2022-11-30
ER

PT J
AU Chevreaud, O
   Semoun, O
   Blanco-Garavito, R
   Kamami-Levy, C
   Merle, B
   Jung, C
   Querques, G
   Souied, EH
AF Chevreaud, Olivier
   Semoun, Oudy
   Blanco-Garavito, Rocio
   Kamami-Levy, Cynthia
   Merle, Benedicte
   Jung, Camille
   Querques, Giuseppe
   Souied, Eric H.
TI Visual acuity at presentation in the second eye versus first eye in
   patients with exudative age-related macular degeneration
SO EUROPEAN JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
DE Age-related macular degeneration; Optical coherence tomography; Patient
   management; Visual acuity
ID CHOROIDAL NEOVASCULARIZATION; PHOTODYNAMIC THERAPY; SUBGROUP ANALYSIS;
   RISK-FACTORS; FELLOW EYES; RANIBIZUMAB; PROGRESSION; PREVALENCE;
   SEVERITY; OUTCOMES
AB Purpose: To assess the difference in best-corrected visual acuity (BCVA) at presentation between the first and second eye in patients with bilateral neovascular age-related macular degeneration (AMD).
   Methods: We reviewed the charts of all patients who had a clinical examination for neovascular AMD at the University Eye Clinic of Creteil in January 2013. We retrospectively analyzed demographic and clinical data for 264 patients.
   Results: In the fellow eye, choroidal neovascularization (CNV) developed in 75/264 patients (28.4%) with a time interval between the 2 events of 30.3 months (range 6-145). Data were available on 65 patients: 14/65 (21.5%) were asymptomatic, 24/65 (36.9%) had BCVA > 20/40, whereas at the time of CNV diagnosis in the first eye, no patient was asymptomatic (p<0.0001), and 11/65 (16.9%) eyes had BCVA > 20/40 (p<0.0001). The mean BCVA of the first affected eye was 0.68 (+/- 0.41) logarithm of minimum angle of resolution (logMAR) and the mean BCVA for the second eye was 0.36 (+/- 0.29) logMAR (p<0.0001).
   Conclusions: The BCVA at the time of diagnosis of CNV was higher in the second eye than in the first affected eye. This was possibly due to several factors including systematic bilateral examination in follow-up of unilateral exudative AMD that allowed detection of 20% of cases.
C1 [Chevreaud, Olivier; Semoun, Oudy; Blanco-Garavito, Rocio; Kamami-Levy, Cynthia; Merle, Benedicte; Querques, Giuseppe; Souied, Eric H.] Univ Paris Est Creteil, Ctr Hosp Intercommunal Creteil, Dept Ophthalmol, Creteil, France.
   [Blanco-Garavito, Rocio; Merle, Benedicte; Jung, Camille; Querques, Giuseppe; Souied, Eric H.] Ctr Hosp Intercommunal Creteil, Ctr Rech Clin, Creteil, France.
C3 Universite Paris-Est-Creteil-Val-de-Marne (UPEC); CHI Creteil;
   Universite Paris-Est-Creteil-Val-de-Marne (UPEC); CHI Creteil
RP Souied, EH (通讯作者)，Ctr Hosp Intercommunal Creteil, Dept Ophthalmol, 40 Ave Verdun, F-94000 Creteil, France.
EM ericsouied@chicreteil.fr
RI Merle, Benedicte MJ/AAQ-5021-2021; Merle, Benedicte MJ/F-1247-2015
OI Merle, Benedicte MJ/0000-0003-1332-0954; Merle, Benedicte
   MJ/0000-0003-1332-0954; Kamami-Levy, Cynthia/0000-0002-5770-5269; JUNG,
   Camille/0000-0001-8486-8939; Querques, Giuseppe/0000-0002-3292-9581
CR BAUN O, 1993, ACTA OPHTHALMOL, V71, P398
   Boyer DS, 2007, OPHTHALMOLOGY, V114, P246, DOI 10.1016/j.ophtha.2006.10.045
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   BURGESS DB, 1993, ARCH OPHTHALMOL-CHIC, V111, P1189
   Gangnon RE, 2015, JAMA OPHTHALMOL, V133, P125, DOI 10.1001/jamaophthalmol.2014.4252
   Gudnadottir GS, 2005, ACTA OPHTHALMOL SCAN, V83, P333, DOI 10.1111/j.1600-0420.2005.00451.x
   Heier JS, 2012, OPHTHALMOLOGY, V119, P2537, DOI 10.1016/j.ophtha.2012.09.006
   Kaiser PK, 2007, AM J OPHTHALMOL, V144, P850, DOI 10.1016/j.ajo.2007.08.012
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1417, DOI 10.1001/archopht.119.10.1417
   Klaver CCW, 1998, ARCH OPHTHALMOL-CHIC, V116, P653, DOI 10.1001/archopht.116.5.653
   Lalwani GA, 2009, AM J OPHTHALMOL, V148, P43, DOI 10.1016/j.ajo.2009.01.024
   Lechanteur YTE, 2012, INVEST OPHTH VIS SCI, V53, P5846, DOI 10.1167/iovs.11-7731
   Leveziel N, 2010, INVEST OPHTH VIS SCI, V51, P2620, DOI 10.1167/iovs.09-4423
   Lichtinger A, 2012, ISR MED ASSOC J, V14, P363
   Lim JH, 2012, AM J OPHTHALMOL, V153, P678, DOI 10.1016/j.ajo.2011.09.013
   Maguire MG, 2013, OPHTHALMOLOGY, V120, P2035, DOI 10.1016/j.ophtha.2013.03.017
   Mataix J, 2010, RETINA-J RET VIT DIS, V30, P1190, DOI 10.1097/IAE.0b013e3181d2f172
   Owen CG, 2012, BRIT J OPHTHALMOL, V96, P752, DOI 10.1136/bjophthalmol-2011-301109
   Querques G, 2010, BRIT J OPHTHALMOL, V94, P292, DOI 10.1136/bjo.2009.170670
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Smith W, 2001, OPHTHALMOLOGY, V108, P697, DOI 10.1016/S0161-6420(00)00580-7
   Solomon SD, 2007, ARCH OPHTHALMOL-CHIC, V125, P1323
   Spielberg L, 2010, GRAEF ARCH CLIN EXP, V248, P943, DOI 10.1007/s00417-009-1256-6
NR 23
TC 6
Z9 6
U1 0
U2 7
PU SAGE PUBLICATIONS LTD
PI LONDON
PA 1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND
SN 1120-6721
EI 1724-6016
J9 EUR J OPHTHALMOL
JI Eur. J. Ophthalmol.
PD JAN-FEB
PY 2016
VL 26
IS 1
BP 44
EP 47
DI 10.5301/ejo.5000649
PG 4
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA DG7IQ
UT WOS:000372258400008
PM 26165330
DA 2022-11-30
ER

PT J
AU Chang, CC
   Huang, CH
   Chou, YC
   Chang, JY
   Sun, CA
AF Chang, Chao-Chien
   Huang, Chi-Hung
   Chou, Yu-Ching
   Chang, Jin-Yin
   Sun, Chien-An
TI Association Between Age-Related Macular Degeneration and Risk of Heart
   Failure: A Population-Based Nested Case-Control Study
SO JOURNAL OF THE AMERICAN HEART ASSOCIATION
LA English
DT Article
DE age-related macular degeneration; heart failure; National Health
   Insurance Research Database; nested case-control study
ID COMPLEMENT FACTOR-H; HEALTH INSURANCE RESEARCH; CARDIOVASCULAR-DISEASE;
   MYOCARDIAL-INFARCTION; OXIDATIVE STRESS; INFLAMMATION; DYSFUNCTION;
   RETINOPATHY; LOC387715; MORTALITY
AB Background Heart failure (HF) is a major health problem worldwide because of its high morbidity and mortality. Recently, the role of the microvasculature in HF has gained more attention. Age-related macular degeneration (AMD) is manifested through geographic atrophy or the development of neovascularization. However, there are limited data on investigations about the association between AMD and HF. The purpose of this study was to examine the association of AMD with the risk of HF in a large population-based cohort of men and women. Methods and Results A nested case-control study using Taiwan's National Health Insurance Research Database was conducted between 2000 and 2012. Newly diagnosed heart failure cases (n=13 721) and matched controls (n=54 884) in the database were recruited. Patients who had >= 2 clinical visits with a diagnosis of AMD at least 1 year before the diagnosis of HF were identified as patients with AMD. Conditional logistic regressions were performed to calculate odds ratios and 95% CIs to assess the association between AMD and risk of HF. AMD was associated with a 1.58-fold increased risk of HF (95% CI, 1.16-1.87) (P<0.001) after adjustment for potential confounders. This significant association was evident in both nonexudative and exudative AMD subgroups. Conclusions Our study provides evidence that AMD was associated with an increased risk of HF. Further molecular and pathophysiological studies are needed to clarify the underlying pathophysiological mechanisms behind the association of AMD with HF.
C1 [Chang, Chao-Chien; Sun, Chien-An] Fu Jen Catholic Univ, Coll Med, Dept Publ Hlth, 510 Zhongzheng Rd, New Taipei 24205, Taiwan.
   [Chang, Chao-Chien; Huang, Chi-Hung] Cathay Gen Hosp, Dept Internal Med, Div Cardiol, Taipei, Taiwan.
   [Chang, Jin-Yin] Cathay Gen Hosp, Dept Med Res, Taipei, Taiwan.
   [Chang, Chao-Chien] Taipei Med Univ, Coll Med, Grad Inst Med Sci, Taipei, Taiwan.
   [Chang, Chao-Chien] Taipei Med Univ, Sch Med, Dept Pharmacol, Taipei, Taiwan.
   [Huang, Chi-Hung] Taipei Med Univ, Coll Oral Med, Sch Dent, Taipei, Taiwan.
   [Chang, Chao-Chien] Fu Jen Catholic Univ, Coll Med, Sch Med, New Taipei, Taiwan.
   [Chang, Chao-Chien] Fu Jen Catholic Univ, Coll Med, Big Data Res Ctr, New Taipei, Taiwan.
   [Chou, Yu-Ching] Natl Def Med Ctr, Sch Publ Hlth, Taipei, Taiwan.
C3 Fu Jen Catholic University; Cathay General Hospital; Cathay General
   Hospital; Taipei Medical University; Taipei Medical University; Taipei
   Medical University; Fu Jen Catholic University; Fu Jen Catholic
   University; National Defense Medical Center
RP Sun, CA (通讯作者)，Fu Jen Catholic Univ, Coll Med, Dept Publ Hlth, 510 Zhongzheng Rd, New Taipei 24205, Taiwan.
EM 040866@mail.fju.edu.tw
CR Beatty S, 2000, SURV OPHTHALMOL, V45, P115, DOI 10.1016/S0039-6257(00)00140-5
   Camici PG, 2007, NEW ENGL J MED, V356, P830, DOI 10.1056/NEJMra061889
   Chan CKW, 2015, OPHTHALMOLOGY, V122, P2278, DOI 10.1016/j.ophtha.2015.06.050
   Chang KH, 2019, J INVEST MED, V67, P1076, DOI 10.1136/jim-2019-001007
   Chang SH, 2017, JAMA-J AM MED ASSOC, V318, P1250, DOI 10.1001/jama.2017.13883
   Chen X, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0108196
   Cheng CL, 2011, PHARMACOEPIDEM DR S, V20, P236, DOI 10.1002/pds.2087
   Cheung N, 2007, J AM COLL CARDIOL, V50, P48, DOI 10.1016/j.jacc.2007.03.029
   de Jong FJ, 2007, ANN NEUROL, V61, P491, DOI 10.1002/ana.21129
   Dolgin M, 1994, NOMENCLATURE CRITERI
   Duan YK, 2007, OPHTHALMOLOGY, V114, P732, DOI 10.1016/j.ophtha.2006.07.045
   Dunlay Shannon M, 2014, Curr Heart Fail Rep, V11, P404, DOI 10.1007/s11897-014-0220-x
   Fang K, 2015, J OPHTHALMOL, V2015, DOI 10.1155/2015/821918
   Fernandez AB, 2012, OPHTHALMOLOGY, V119, P765, DOI 10.1016/j.ophtha.2011.09.044
   Fisher DE, 2015, OPHTHALMOLOGY, V122, P382, DOI 10.1016/j.ophtha.2014.08.006
   Flammer AJ, 2012, CIRCULATION, V126, P753, DOI 10.1161/CIRCULATIONAHA.112.093245
   Golan S, 2011, GRAEF ARCH CLIN EXP, V249, P179, DOI 10.1007/s00417-010-1489-4
   Gottlieb JL, 2002, JAMA-J AM MED ASSOC, V288, P2233, DOI 10.1001/jama.288.18.2233
   Greenberg BH, 2007, AM HEART J, V154, P646, DOI 10.1016/j.ahj.2007.05.001
   Haines JL, 2005, SCIENCE, V308, P419, DOI 10.1126/science.1110359
   Hsiao FY, 2007, J FOOD DRUG ANAL, V15, P99
   Kao WH, 2018, PHARMACOEPIDEM DR S, V27, P1060, DOI 10.1002/pds.4267
   Klein R, 2004, AM J OPHTHALMOL, V137, P486, DOI 10.1016/j.ajo.2003.11.069
   Lee JF, 2016, HEART, V102, P278, DOI 10.1136/heartjnl-2015-308403
   Lin LY, 2018, EPIDEMIOL HEALTH, V40, DOI 10.4178/epih.e2018062
   Mitchell P, 2018, LANCET, V392, P1147, DOI 10.1016/S0140-6736(18)31550-2
   Murphy SP, 2020, J AM COLL CARDIOL, V75, P1324, DOI 10.1016/j.jacc.2020.01.014
   Naegele MP, 2018, EUR HEART J, V39, P47, DOI 10.1093/eurheartj/ehx565
   Paulus WJ, 2013, J AM COLL CARDIOL, V62, P263, DOI 10.1016/j.jacc.2013.02.092
   Phan K, 2015, INT J CARDIOL, V182, P213, DOI 10.1016/j.ijcard.2014.12.146
   Poelzl G, 2005, EUR J HEART FAIL, V7, P43, DOI 10.1016/j.ejheart.2004.04.008
   Pulido JS, 2007, MAYO CLIN PROC, V82, P301, DOI 10.4065/82.3.301
   Rastogi N, 2016, SURV OPHTHALMOL, V61, P422, DOI 10.1016/j.survophthal.2015.10.003
   Rivera A, 2005, HUM MOL GENET, V14, P3227, DOI 10.1093/hmg/ddi353
   Savarese Gianluigi, 2017, Card Fail Rev, V3, P7, DOI 10.15420/cfr.2016:25:2
   Smith W, 1998, ARCH OPHTHALMOL-CHIC, V116, P583, DOI 10.1001/archopht.116.5.583
   Snow K K, 1999, Ophthalmic Epidemiol, V6, P125, DOI 10.1076/opep.6.2.125.1558
   Sun C, 2009, OPHTHALMOLOGY, V116, P1913, DOI 10.1016/j.ophtha.2009.03.046
   Tan JSL, 2008, BRIT J OPHTHALMOL, V92, P509, DOI 10.1136/bjo.2007.131706
   Tan W, 2020, INT J BIOL SCI, V16, P2989, DOI 10.7150/ijbs.49890
   Tsutsui H, 2011, AM J PHYSIOL-HEART C, V301, pH2181, DOI 10.1152/ajpheart.00554.2011
   van der Pol A, 2019, EUR J HEART FAIL, V21, P425, DOI 10.1002/ejhf.1320
   Wang J, 2016, BIOMED RES INT, V2016, DOI 10.1155/2016/8212063
   Wong TY, 2007, OPHTHALMOLOGY, V114, P86, DOI 10.1016/j.ophtha.2006.06.039
   Wong TY, 2005, JAMA-J AM MED ASSOC, V293, P63, DOI 10.1001/jama.293.1.63
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
   Wu CY, 2012, JAMA-J AM MED ASSOC, V308, P1906, DOI 10.1001/2012.jama.11975
   Wu J, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0089600
NR 48
TC 1
Z9 1
U1 0
U2 1
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
EI 2047-9980
J9 J AM HEART ASSOC
JI J. Am. Heart Assoc.
PD AUG 3
PY 2021
VL 10
IS 15
AR e020071
DI 10.1161/JAHA.120.020071
PG 8
WC Cardiac & Cardiovascular Systems
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Cardiovascular System & Cardiology
GA TT5ZN
UT WOS:000680426800058
PM 34325520
OA gold, Green Published
DA 2022-11-30
ER

PT J
AU Ma, L
   Dou, HL
   Wu, YQ
   Huang, YM
   Huang, YB
   Xu, XR
   Zou, ZY
   Lin, XM
AF Ma, Le
   Dou, Hong-Liang
   Wu, Yi-Qun
   Huang, Yang-Mu
   Huang, Yu-Bei
   Xu, Xian-Rong
   Zou, Zhi-Yong
   Lin, Xiao-Ming
TI Lutein and zeaxanthin intake and the risk of age-related macular
   degeneration: a systematic review and meta-analysis
SO BRITISH JOURNAL OF NUTRITION
LA English
DT Review
DE Lutein; Zeaxanthin; Age-related macular degeneration; Meta-analysis
ID PIGMENT DENSITY; US TWIN; LIGHT; CAROTENOIDS; MACULOPATHY; ASSOCIATIONS;
   SMOKING; ANTIOXIDANTS; PROTECTION; RETINA
AB Lutein and zeaxanthin are thought to decrease the incidence of age-related macular degeneration (AMD); however, findings have been inconsistent. We conducted a systematic literature review and meta-analysis to evaluate the relationship between dietary intake of lutein and zeaxanthin and AMD risk. Relevant studies were identified by searching five databases up to April 2010. Reference lists of articles were retrieved, and experts were contacted. Literature search, data extraction and study quality assessment were performed independently by two reviewers and results were pooled quantitatively using meta-analysis methods. The potential sources of heterogeneity and publication bias were also estimated. The search yielded six longitudinal cohort studies. The pooled relative risk (RR) for early AMD, comparing the highest with the lowest category of lutein and zeaxanthin intake, was 0.96 (95% CI 0.78, 1.17). Dietary intake of these carotenoids was significantly related with a reduction in risk of late AMD (RR 0.74; 95% CI 0.57, 0.97); and a statistically significant inverse association was observed between lutein and zeaxanthin intake and neovascular AMD risk (RR 0.68; 95% CI 0.51, 0.92). The results were essentially consistent among subgroups stratified by participant characteristics. The findings of the present meta-analysis indicate that dietary lutein and zeaxanthin is not significantly associated with a reduced risk of early AMD, whereas an increase in the intake of these carotenoids may be protective against late AMD. However, additional studies are needed to confirm these relationships.
C1 [Ma, Le; Huang, Yang-Mu; Xu, Xian-Rong; Zou, Zhi-Yong; Lin, Xiao-Ming] Peking Univ, Sch Publ Hlth, Dept Nutr & Food Hyg, Beijing 100191, Peoples R China.
   [Dou, Hong-Liang] Peking Univ, Ctr Eye, Hosp 3, Beijing 100191, Peoples R China.
   [Wu, Yi-Qun; Huang, Yu-Bei] Peking Univ, Sch Publ Hlth, Dept Epidemiol & Biostat, Beijing 100191, Peoples R China.
C3 Peking University; Peking University; Peking University
RP Lin, XM (通讯作者)，Peking Univ, Sch Publ Hlth, Dept Nutr & Food Hyg, 38 Xueyuan Rd, Beijing 100191, Peoples R China.
EM linbjmu@bjmu.edu.cn
RI Zou, Zhiyong/P-8066-2019; Huang, Yubei/AAE-8296-2020
OI Zou, Zhiyong/0000-0001-5049-5425; Wu, Yiqun/0000-0002-5554-1678; Huang,
   Yangmu/0000-0002-3660-1276; ma, le/0000-0001-7592-9779
FU National Natural Science Foundation of China [NSFC-30872113]; Ministry
   of Education of China
FX The present study was supported by a grant from the National Natural
   Science Foundation of China (NSFC-30872113) and Academic Award for
   Excellent Doctorial Candidates of the Ministry of Education of China.
   X.-M. L., H.-L. D. and L. M. proposed the study concept and design;
   X.-M. L. and H.-L. D. supervised the study; L. M. and Y.-Q. W. conducted
   the study; L. M. and Y.-Q. W. collected the data; L. M., Y.-Q. W. and
   X.-R. X. carried out analysis and interpretation of the data; L. M.,
   Y.-Q. W. and Y.-B. H. carried out statistical analysis; Y.-Q. W., H.-L.
   D., Y.-B. H., Y.-M. H., X.-R. X, Z.-Y. Z. and X.-M. L. provided
   technical or material support; L. M. and Y.-B. H. drafted the
   manuscript; and Y.-Q. W., H.-L. D., Y.-B. H. and X.-M. L. aided in
   critical revision of the manuscript. The authors declare no conflict of
   interest.
CR Beatty S, 2001, INVEST OPHTH VIS SCI, V42, P439
   Berendschot TTJM, 2002, INVEST OPHTH VIS SCI, V43, P1928
   Bone RA, 2001, INVEST OPHTH VIS SCI, V42, P235
   Bone RA, 2000, EXP EYE RES, V71, P239, DOI 10.1006/exer.2000.0870
   Cai JY, 2000, PROG RETIN EYE RES, V19, P205, DOI 10.1016/S1350-9462(99)00009-9
   Chiu CJ, 2009, OPHTHALMOLOGY, V116, P939, DOI 10.1016/j.ophtha.2008.12.025
   Cho EY, 2008, AM J CLIN NUTR, V87, P1837, DOI 10.1093/ajcn/87.6.1837
   Cho EY, 2004, ARCH OPHTHALMOL-CHIC, V122, P883, DOI 10.1001/archopht.122.6.883
   Choi JS, 2006, NUTRITION, V22, P668, DOI 10.1016/j.nut.2005.08.011
   Dillon J, 2004, EXP EYE RES, V79, P753, DOI 10.1016/j.exer.2004.06.025
   Donoso LA, 2006, SURV OPHTHALMOL, V51, P137, DOI 10.1016/j.survophthal.2005.12.001
   Egger M, 1997, BMJ-BRIT MED J, V315, P629, DOI 10.1136/bmj.315.7109.629
   Evans JR, 2004, OPHTHALMOLOGY, V111, P513, DOI 10.1016/j.ophtha.2003.07.012
   Flood V, 2002, OPHTHALMOLOGY, V109, P2272, DOI 10.1016/S0161-6420(02)01263-0
   Freeman WR, 2004, ARCH OPHTHALMOL-CHIC, V122, P1647, DOI 10.1001/archopht.122.11.1647
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P564
   Haegele AD, 2000, CANCER EPIDEM BIOMAR, V9, P421
   Higgins JPT, 2003, BRIT MED J, V327, P557, DOI 10.1136/bmj.327.7414.557
   Izumi-Nagai K, 2007, ARTERIOSCL THROM VAS, V27, P2555, DOI 10.1161/ATVBAHA.107.151431
   Jager RD, 2008, NEW ENGL J MED, V358, P2606, DOI 10.1056/NEJMra0801537
   Jahn C, 2005, GRAEF ARCH CLIN EXP, V243, P222, DOI 10.1007/s00417-004-0995-7
   Junghans A, 2001, ARCH BIOCHEM BIOPHYS, V391, P160, DOI 10.1006/abbi.2001.2411
   Khachik F, 1997, INVEST OPHTH VIS SCI, V38, P1802
   Khan JC, 2006, BRIT J OPHTHALMOL, V90, P29, DOI 10.1136/bjo.2005.073825
   Klein R, 2004, AM J OPHTHALMOL, V137, P486, DOI 10.1016/j.ajo.2003.11.069
   Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557
   Kowluru RA, 2008, INVEST OPHTH VIS SCI, V49, P1645, DOI 10.1167/iovs.07-0764
   Krinsky NI, 2003, ANNU REV NUTR, V23, P171, DOI 10.1146/annurev.nutr.23.011702.073307
   Krishnadev N, 2010, CURR OPIN OPHTHALMOL, V21, P184, DOI 10.1097/ICU.0b013e32833866ee
   Ma L, 2010, J SCI FOOD AGR, V90, P2, DOI 10.1002/jsfa.3785
   Mares-Perlman JA, 2001, AM J EPIDEMIOL, V153, P424, DOI 10.1093/aje/153.5.424
   Margrain TH, 2004, PROG RETIN EYE RES, V23, P523, DOI 10.1016/j.preteyeres.2004.05.001
   Moeller SM, 2006, ARCH OPHTHALMOL-CHIC, V124, P1151, DOI 10.1001/archopht.124.8.1151
   Muni RH, 2008, RETINA-J RET VIT DIS, V28, P1421, DOI 10.1097/IAE.0b013e3181814470
   Rapp LM, 2000, INVEST OPHTH VIS SCI, V41, P1200
   SanGiovanni JP, 2007, ARCH OPHTHALMOL-CHIC, V125, P1225, DOI 10.1001/archopht.125.9.1225
   Schmidt S, 2005, MOL VIS, V11, P941
   Seddon JM, 2005, ARCH OPHTHALMOL-CHIC, V123, P321, DOI 10.1001/archopht.123.3.321
   Seddon JM, 2004, JAMA-J AM MED ASSOC, V291, P704, DOI 10.1001/jama.291.6.704
   SEDDON JM, 1994, JAMA-J AM MED ASSOC, V272, P1413, DOI 10.1001/jama.272.18.1413
   Seddon JM, 2006, ARCH OPHTHALMOL-CHIC, V124, P995, DOI 10.1001/archopht.124.7.995
   Smith W, 2001, OPHTHALMOLOGY, V108, P697, DOI 10.1016/S0161-6420(00)00580-7
   STAHL W, 1993, ANN NY ACAD SCI, V691, P10, DOI 10.1111/j.1749-6632.1993.tb26153.x
   Sterne JAC, 2001, J CLIN EPIDEMIOL, V54, P1046, DOI 10.1016/S0895-4356(01)00377-8
   Subramanian ML, 2009, AM J OPHTHALMOL, V148, P875, DOI 10.1016/j.ajo.2009.07.009
   Tan JSL, 2008, OPHTHALMOLOGY, V115, P334, DOI 10.1016/j.ophtha.2007.03.083
   Thomson LR, 2002, INVEST OPHTH VIS SCI, V43, P3538
   Thomson LR, 2002, EXP EYE RES, V75, P529, DOI 10.1006/exer.2002.2050
   Thornton J, 2005, EYE, V19, P935, DOI 10.1038/sj.eye.6701978
   van Leeuwen R, 2005, JAMA-J AM MED ASSOC, V294, P3101, DOI 10.1001/jama.294.24.3101
   VandenLangenberg GM, 1996, J AM DIET ASSOC, V96, P1271, DOI 10.1016/S0002-8223(96)00332-X
   VandenLangenberg GM, 1998, AM J EPIDEMIOL, V148, P204, DOI 10.1093/oxfordjournals.aje.a009625
   Wells G.A, 2010, NEWCASTLEOTTAWA SCAL
   Wustemeyer H, 2002, GRAEF ARCH CLIN EXP, V240, P666, DOI 10.1007/s00417-002-0515-6
   Zhang X, 2008, INT J OBESITY, V32, P1130, DOI 10.1038/ijo.2008.63
NR 55
TC 133
Z9 144
U1 0
U2 44
PU CAMBRIDGE UNIV PRESS
PI CAMBRIDGE
PA EDINBURGH BLDG, SHAFTESBURY RD, CB2 8RU CAMBRIDGE, ENGLAND
SN 0007-1145
EI 1475-2662
J9 BRIT J NUTR
JI Br. J. Nutr.
PD FEB
PY 2012
VL 107
IS 3
BP 350
EP 359
DI 10.1017/S0007114511004260
PG 10
WC Nutrition & Dietetics
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Nutrition & Dietetics
GA 886UL
UT WOS:000299879300004
PM 21899805
OA Bronze
DA 2022-11-30
ER

PT J
AU Fackler, TK
   Reddy, S
   Bearelly, S
   Stinnett, S
   Fekrat, S
   Cooney, MJ
AF Fackler, Tamara K.
   Reddy, Shantan
   Bearelly, Srilaxmi
   Stinnett, Sandra
   Fekrat, Sharon
   Cooney, Michael J.
TI Retrospective review of eyes with neovascular age-related macular
   degeneration treated with photodynamic therapy with verteporfin and
   intravitreal triamcinolone
SO ANNALS ACADEMY OF MEDICINE SINGAPORE
LA English
DT Review
DE choroidal neovascularisation; macular degeneration; photodynamic
   therapy; triamcinolone; verteporfin
ID CHOROIDAL NEOVASCULARIZATION; BRUCHS MEMBRANE; ACETONIDE; LEUKOCYTES;
   EXPRESSION; BREAKDOWN
AB Aim: To review the outcomes of eyes with neovascular age-related macular degeneration (AMD) treated with photodynamic therapy (PDT) with verteporfin and intravitreal triamcinolone acetonide injection. Materials and Methods: We retrospectively reviewed the outcomes of consecutive eyes with neovascular AMD that received an intravitreal triamcinolone injection within 1 week of their first PDT and had at least 6 months of follow-up. Eyes were retreated with PDT at 3-month intervals if angiographic leakage was present. Results: Twenty-six eyes from 24 patients were identified. The mean visual acuity at baseline was 20/118 (median 20/112). The mean visual acuity decreased to 20/138 at 9 months (P= 0.24, n = 15) and to 20/174 at 12 months (P = 0.23, n = 8). The change in visual acuity from baseline was not statistically significant at any time point. The mean central foveal thickness by OCT measured 342 mu m at baseline and decreased to 296 mu m at 12 months (P= 0.31). Sixty-two per cent of eyes required no additional PDT at 12 months. Nineteen per cent of 26 eyes had a rise in intraocular pressure that was controlled with topical medication alone. Conclusion: Photodynamic therapy with verteporfin combined with intravitreal triamcinolone injection in the treatment of neovascular AMD may be superior to PDT alone by decreasing visual loss and reducing the number or retreatments.
C1 Vitreous Retina Macula Consultants New York, New York, NY 10022 USA.
   Manhattan Eye Ear & Throat Hosp, New York, NY 10021 USA.
   Duke Univ, Ctr Eye, Albert Eye Res Inst, Durham, NC 27706 USA.
C3 Vitreous Retina Macula Consultants of New York; Manhattan Eye Ear &
   Throat Hospital; Duke University
RP Cooney, MJ (通讯作者)，Vitreous Retina Macula Consultants New York, 460 Pk Ave, New York, NY 10022 USA.
EM m.cooney@vrmny.com
OI Stinnett, Sandra/0000-0001-7192-0195
CR ANTOSZYK AN, 1993, GRAEF ARCH CLIN EXP, V231, P34, DOI 10.1007/BF01681698
   Arnold J, 2001, AM J OPHTHALMOL, V131, P541
   Augustin AJ, 2006, OPHTHALMOLOGY, V113, P14, DOI 10.1016/j.ophtha.2005.09.002
   Bressler NM, 1999, ARCH OPHTHALMOL-CHIC, V117, P1329
   Challa JK, 1998, AUST NZ J OPHTHALMOL, V26, P277, DOI 10.1111/j.1442-9071.1998.tb01330.x
   Chylack L T Jr, 1989, Lens Eye Toxic Res, V6, P515
   Ciulla TA, 2001, ARCH OPHTHALMOL-CHIC, V119, P399, DOI 10.1001/archopht.119.3.399
   Danis RP, 2000, RETINA-J RET VIT DIS, V20, P244, DOI 10.1097/00006982-200003000-00004
   DASTGHEIB K, 1994, ARCH OPHTHALMOL-CHIC, V112, P813, DOI 10.1001/archopht.1994.01090180111045
   FERRIS FL, 1984, ARCH OPHTHALMOL-CHIC, V102, P1640
   GEHRS KM, 1992, ARCH OPHTHALMOL-CHIC, V110, P833, DOI 10.1001/archopht.1992.01080180105036
   Haines JL, 2005, SCIENCE, V308, P419, DOI 10.1126/science.1110359
   ISHIBASHI T, 1985, ARCH OPHTHALMOL-CHIC, V103, P708
   KILLINGSWORTH MC, 1990, EYE, V4, P613, DOI 10.1038/eye.1990.86
   KLEIN R, 1995, INVEST OPHTH VIS SCI, V36, P182
   Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557
   Kvanta A, 1996, INVEST OPHTH VIS SCI, V37, P1929
   LOPEZ PF, 1991, AM J OPHTHALMOL, V112, P647, DOI 10.1016/S0002-9394(14)77270-8
   MCCUEN BW, 1981, AM J OPHTHALMOL, V91, P785, DOI 10.1016/0002-9394(81)90013-1
   MILLER JW, 1995, ARCH OPHTHALMOL-CHIC, V113, P810, DOI 10.1001/archopht.1995.01100060136048
   Oh H, 1999, INVEST OPHTH VIS SCI, V40, P1891
   PENFOLD P, 1984, AUST J OPHTHALMOL, V12, P23
   Penfold PL, 1995, AUST NZ J OPHTHALMOL, V23, P293, DOI 10.1111/j.1442-9071.1995.tb00179.x
   PENFOLD PL, 1987, GRAEF ARCH CLIN EXP, V225, P70, DOI 10.1007/BF02155808
   Penfold PL, 2002, INVEST OPHTH VIS SCI, V43, P3125
   Penfold PL, 2001, CLIN EXP OPHTHALMOL, V29, P188, DOI 10.1046/j.1442-9071.2001.00407.x
   Rechtman E, 2004, BRIT J OPHTHALMOL, V88, P344, DOI 10.1136/bjo.2003.027177
   Schmidt-Erfurth U, 2002, INVEST OPHTH VIS SCI, V43, P830
   Schmidt-Erfurth U, 1998, GRAEF ARCH CLIN EXP, V236, P365, DOI 10.1007/s004170050092
   SCHMIDTERFURTH U, 1994, OPHTHALMOLOGY, V101, P1953
   SCHMIDTERFURTH U, 1995, LASER SURG MED, V17, P178, DOI 10.1002/lsm.1900170207
   Spaide RF, 2005, OPHTHALMOLOGY, V112, P301, DOI 10.1016/j.ophtha.2004.08.012
   WILSON CA, 1992, ARCH OPHTHALMOL-CHIC, V110, P1155, DOI 10.1001/archopht.1992.01080200135041
NR 33
TC 9
Z9 9
U1 0
U2 0
PU ACAD MEDICINE SINGAPORE
PI REPUBLIC SINGAPORE
PA 142 NEIL RD, REPUBLIC SINGAPORE 088871, SINGAPORE
SN 0304-4602
J9 ANN ACAD MED SINGAP
JI Ann. Acad. Med. Singap.
PD OCT
PY 2006
VL 35
IS 10
BP 701
EP 705
PG 5
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine
GA 105NB
UT WOS:000242035900008
PM 17102894
DA 2022-11-30
ER

PT J
AU Cioffi, CL
   Racz, B
   Freeman, EE
   Conlon, MP
   Chen, P
   Stafford, DG
   Schwarz, DMC
   Zhu, L
   Kitchen, DB
   Barnes, KD
   Dobri, N
   Michelotti, E
   Cywin, CL
   Martin, WH
   Pearson, PG
   Johnson, G
   Petrukhin, K
AF Cioffi, Christopher L.
   Racz, Boglarka
   Freeman, Emily E.
   Conlon, Michael P.
   Chen, Ping
   Stafford, Douglas G.
   Schwarz, Daniel M. C.
   Zhu, Lei
   Kitchen, Douglas B.
   Barnes, Keith D.
   Dobri, Nicoleta
   Michelotti, Enrique
   Cywin, Charles L.
   Martin, William H.
   Pearson, Paul G.
   Johnson, Graham
   Petrukhin, Konstantin
TI Bicyclic [3.3.0]-Octahydrocyclopenta[c]pyrrolo Antagonists of Retinol
   Binding Protein 4: Potential Treatment of Atrophic Age-Related Macular
   Degeneration and Stargardt Disease
SO JOURNAL OF MEDICINAL CHEMISTRY
LA English
DT Article
ID PIGMENT EPITHELIAL-CELLS; FUNDUS AUTOFLUORESCENCE; GEOGRAPHIC ATROPHY;
   VITAMIN-A; LIPOFUSCIN ACCUMULATION; SERUM RETINOL; MOUSE MODEL; IN-VIVO;
   A2E; TRANSTHYRETIN
AB Antagonists of retinol-binding protein 4 (RBP4) impede ocular uptake of serum all-trans retinol (1) and have been shown to reduce cytotoxic bisretinoid formation in the retinal pigment epithelium (RPE), which is associated with the pathogenesis of both dry age-related macular degeneration (AIVID) and Stargardt disease. Thus, these agents show promise as a potential pharmacotherapy by which to stem further neurodegeneration and concomitant -vision loss associated with geographic atrophy of the macula. We previously disdosed the discovery of a novel series of nonretinoid RBP4 antagonists, represented by bicyclic [3.3.0]-octahydrocydopenta[c]pyrrolo analogue 4. We describe herein the utilization of a pyrimidine-4-carboxylic acid fragment as a suitable isostere for the anthranilic acid appendage of 4, which led to the discovery of standout antagonist 33. Analogue 33 possesses exquisite in vitro RBP4 binding affinity and favorable drug-like characteristics and was found to reduce circulating plasma RBP4 levels in vivo in a robust manner (>90%).
C1 [Cioffi, Christopher L.; Freeman, Emily E.; Conlon, Michael P.; Chen, Ping; Stafford, Douglas G.; Schwarz, Daniel M. C.; Barnes, Keith D.] AMRI, Dept Med Chem, Rensselaer, NY 12144 USA.
   [Zhu, Lei; Kitchen, Douglas B.] AMRI, Comp Assisted Drug Discovery, Rensselaer, NY 12144 USA.
   [Racz, Boglarka; Dobri, Nicoleta; Petrukhin, Konstantin] Columbia Univ, Med Ctr, Dept Ophthalmol, New York, NY 10032 USA.
   [Pearson, Paul G.; Johnson, Graham] iCuraVision LLC, Westlake Village, CA 91362 USA.
   [Martin, William H.] WHM Consulting LLC, Lyme, CT 06371 USA.
   [Michelotti, Enrique] NIMH, NIH, Bethesda, MD 20892 USA.
   [Cywin, Charles L.] NINDS, NIH, Bethesda, MD 20892 USA.
C3 Columbia University; National Institutes of Health (NIH) - USA; NIH
   National Institute of Mental Health (NIMH); National Institutes of
   Health (NIH) - USA; NIH National Institute of Neurological Disorders &
   Stroke (NINDS)
RP Cioffi, CL (通讯作者)，AMRI, Dept Med Chem, East Campus,3 Univ Pl, Rensselaer, NY 12144 USA.
EM christopher.cioffi@amriglobal.com; kep4@cumc.columbia.edu;
   kep4@cumc.columbia.edu
OI Petrukhin, Konstantin/0000-0002-5545-6924; Schwarz,
   Daniel/0000-0002-5756-5710; Cioffi, Christopher/0000-0003-0642-7905;
   Kitchen, Douglas/0000-0001-8988-759X
FU NIH [U01 NS074476, P30 EY019007]; Research to Prevent Blindness (New
   York, NY); National Institute of Neurological Disorders and Stroke, the
   National Eye Institute, the NIH Blueprint Neurotherapeutics Network,
   Blueprint for Neuroscience Research Program, National Institutes of
   Health, Department of Health and Human Services [HHSN271201100013C];
   NATIONAL EYE INSTITUTE [P30EY019007] Funding Source: NIH RePORTER;
   NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [U01NS074476,
   R21NS067594] Funding Source: NIH RePORTER
FX This study was supported by NIH Grants U01 NS074476 (to K.P.), P30
   EY019007 (Core Support for Vision Research), and unrestricted funds from
   Research to Prevent Blindness (New York, NY) to the Department of
   Ophthalmology, Columbia University. We thank The Burch Family
   Foundation, the Mary Jaharis-John Catsimatidis Scholarship Fund, the
   Kaplen Foundation, and the Eye Surgery Fund for gifts supporting this
   study. This project has also been funded in whole or in part with
   Federal funds from the National Institute of Neurological Disorders and
   Stroke, the National Eye Institute, the NIH Blueprint Neurotherapeutics
   Network, Blueprint for Neuroscience Research Program, National
   Institutes of Health, Department of Health and Human Services, under
   Contract No. HHSN271201100013C.
CR ADAMS WR, 1995, P SOC EXP BIOL MED, V208, P178, DOI 10.3181/00379727-208-43849
   [Anonymous], 2004, Patent No. [WO 2004016604A2, 2004016604, W02004016604A2]
   Ben-Shabat S, 2002, J BIOL CHEM, V277, P7183, DOI 10.1074/jbc.M108981200
   Bergmann M, 2004, FASEB J, V18, P562, DOI 10.1096/fj.03-0289fje
   BERNI R, 1992, FEBS LETT, V308, P43, DOI 10.1016/0014-5793(92)81046-O
   Cioffi CL, 2014, J MED CHEM, V57, P7731, DOI 10.1021/jm5010013
   COGAN U, 1976, EUR J BIOCHEM, V65, P71, DOI 10.1111/j.1432-1033.1976.tb10390.x
   De S, 2002, J GEN PHYSIOL, V120, P147, DOI 10.1085/jgp.20028566
   Delori F. C., 1995, RETINAL PIGMENT EPIT, V62, P37
   Dobri N, 2013, INVEST OPHTH VIS SCI, V54, P85, DOI 10.1167/iovs.12-10050
   Dontsov AE, 2009, DOKL BIOCHEM BIOPHYS, V425, P98, DOI 10.1134/S1607672909020112
   DOREY CK, 1989, INVEST OPHTH VIS SCI, V30, P1691
   Finnemann SC, 2002, P NATL ACAD SCI USA, V99, P3842, DOI 10.1073/pnas.052025899
   Gamble MV, 2001, AM J CLIN NUTR, V73, P594
   Guillemont J. E. G., 2013, Google Patents PCT Int. Appl., Patent No. [W02013021054A1, 2013021054]
   Holz FG, 2001, INVEST OPHTH VIS SCI, V42, P1051
   Holz FG, 1999, GRAEF ARCH CLIN EXP, V237, P145, DOI 10.1007/s004170050209
   Holz FG, 2007, AM J OPHTHALMOL, V143, P463, DOI 10.1016/j.ajo.2006.11.041
   Hubschman JP, 2009, CLIN OPHTHALMOL, V3, P155
   KANAI M, 1968, J CLIN INVEST, V47, P2025, DOI 10.1172/JCI105889
   Lauffer D, 2009, Patent No. [W02009/045992A2, 2009045992]
   Maeda A, 2006, MOL PHARMACOL, V70, P1220, DOI 10.1124/mol.106.026823
   Mata NL, 2013, RETINA-J RET VIT DIS, V33, P498, DOI 10.1097/IAE.0b013e318265801d
   Monaco HL, 2000, BBA-PROTEIN STRUCT M, V1482, P65, DOI 10.1016/S0167-4838(00)00140-0
   MONACO HL, 1995, SCIENCE, V268, P1039, DOI 10.1126/science.7754382
   Monaco HL, 2002, CLIN CHEM LAB MED, V40, P1229, DOI 10.1515/CCLM.2002.213
   Motani A, 2009, J BIOL CHEM, V284, P7673, DOI 10.1074/jbc.M809654200
   Naylor HM, 1999, BIOCHEMISTRY-US, V38, P2647, DOI 10.1021/bi982291i
   NOY N, 1992, BIOCHEMISTRY-US, V31, P11118, DOI 10.1021/bi00160a023
   NOY N, 1990, BIOCHEMISTRY-US, V29, P3878, DOI 10.1021/bi00468a012
   Palczewski K, 2010, TRENDS PHARMACOL SCI, V31, P284, DOI 10.1016/j.tips.2010.03.001
   Petrukhin K, 2007, EXPERT OPIN THER TAR, V11, P625, DOI 10.1517/14728222.11.5.625
   Petrukhin Konstantin, 2013, Drug Discov Today Ther Strateg, V10, pe11
   Radu RA, 2005, INVEST OPHTH VIS SCI, V46, P4393, DOI 10.1167/iovs.05-0820
   Radu RA, 2003, P NATL ACAD SCI USA, V100, P4742, DOI 10.1073/pnas.0737855100
   Radu RA, 2011, J BIOL CHEM, V286, P18593, DOI 10.1074/jbc.M110.191866
   ROZANOWSKA M, 1995, J BIOL CHEM, V270, P18825, DOI 10.1074/jbc.270.32.18825
   Schlehuber S, 2005, DRUG DISCOV TODAY, V10, P23, DOI 10.1016/S1359-6446(04)03294-5
   Schmitz-Valckenberg S, 2009, SURV OPHTHALMOL, V54, P96, DOI 10.1016/j.survophthal.2008.10.004
   Sparrow JR, 2012, PROG RETIN EYE RES, V31, P121, DOI 10.1016/j.preteyeres.2011.12.001
   Sparrow JR, 1999, INVEST OPHTH VIS SCI, V40, P2988
   Sparrow JR, 2003, VISION RES, V43, P2983, DOI 10.1016/S0042-6989(03)00475-9
   Sparrow JR, 2002, INVEST OPHTH VIS SCI, V43, P1222
   Sparrow JR, 2001, INVEST OPHTH VIS SCI, V42, P1356
   Suter M, 2000, J BIOL CHEM, V275, P39625, DOI 10.1074/jbc.M007049200
   Swanson DM, 2005, J MED CHEM, V48, P1857, DOI 10.1021/jm0495071
   Vives-Bauza C, 2008, J BIOL CHEM, V283, P24770, DOI 10.1074/jbc.M800706200
   Weng J, 1999, CELL, V98, P13, DOI 10.1016/S0092-8674(00)80602-9
   WOLF G, 1984, PHYSIOL REV, V64, P873, DOI 10.1152/physrev.1984.64.3.873
   YOUNG RW, 1987, SURV OPHTHALMOL, V31, P291, DOI 10.1016/0039-6257(87)90115-9
   Zhou JL, 2006, P NATL ACAD SCI USA, V103, P16182, DOI 10.1073/pnas.0604255103
NR 51
TC 22
Z9 29
U1 2
U2 12
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 0022-2623
EI 1520-4804
J9 J MED CHEM
JI J. Med. Chem.
PD AUG 13
PY 2015
VL 58
IS 15
BP 5863
EP 5888
DI 10.1021/acs.jmedchem.5b00423
PG 26
WC Chemistry, Medicinal
WE Science Citation Index Expanded (SCI-EXPANDED); Index Chemicus (IC)
SC Pharmacology & Pharmacy
GA CP2BY
UT WOS:000359683700013
PM 26181715
OA Green Accepted
DA 2022-11-30
ER

PT J
AU Seddon, JM
   Yu, Y
   Miller, EC
   Reynolds, R
   Tan, PL
   Gowrisankar, S
   Goldstein, JI
   Triebwasser, M
   Anderson, HE
   Zerbib, J
   Kavanagh, D
   Souied, E
   Katsanis, N
   Daly, MJ
   Atkinson, JP
   Raychaudhuri, S
AF Seddon, Johanna M.
   Yu, Yi
   Miller, Elizabeth C.
   Reynolds, Robyn
   Tan, Perciliz L.
   Gowrisankar, Sivakumar
   Goldstein, Jacqueline I.
   Triebwasser, Michael
   Anderson, Holly E.
   Zerbib, Jennyfer
   Kavanagh, David
   Souied, Eric
   Katsanis, Nicholas
   Daly, Mark J.
   Atkinson, John P.
   Raychaudhuri, Soumya
TI Rare variants in CFI, C3 and C9 are associated with high risk of
   advanced age-related macular degeneration
SO NATURE GENETICS
LA English
DT Article
ID HEMOLYTIC-UREMIC SYNDROME; COMPLEMENT FACTOR-I; WHOLE-GENOME
   ASSOCIATION; DNA-SEQUENCING DATA; FACTOR-H; MISSENSE MUTATION; WIDE
   ASSOCIATION; COMMON VARIANTS; FACTOR B; SUSCEPTIBILITY
AB To define the role of rare variants in advanced age-related macular degeneration (AMD) risk, we sequenced the exons of 681 genes within all reported AMD loci and related pathways in 2,493 cases and controls. We first tested each gene for increased or decreased burden of rare variants in cases compared to controls. We found that 7.8% of AMD cases compared to 2.3% of controls are carriers of rare missense CFI variants (odds ratio (OR) = 3.6; P = 2 x 10-8). There was a predominance of dysfunctional variants in cases compared to controls. We then tested individual variants for association with disease. We observed significant association with rare missense alleles in genes other than CFI. Genotyping in 5,115 independent samples confirmed associations with AMD of an allele in C3 encoding p. Lys155Gln (replication P = 3.5 x 10(-5), OR = 2.8; joint P = 5.2 x 10(-9), OR = 3.8) and an allele in C9 encoding p. Pro167Ser (replication P = 2.4 x 10(-5), OR = 2.2; joint P = 6.5 x 10(-7), OR = 2.2). Finally, we show that the allele of C3 encoding Gln155 results in resistance to proteolytic inactivation by CFH and CFI. These results implicate loss of C3 protein regulation and excessive alternative complement activation in AMD pathogenesis, thus informing both the direction of effect and mechanistic underpinnings of this disorder.
C1 [Seddon, Johanna M.; Yu, Yi; Reynolds, Robyn] Tufts Med Ctr, New England Eye Ctr, Ophthalm Epidemiol & Genet Serv, Boston, MA USA.
   [Seddon, Johanna M.] Tufts Univ, Sch Med, Dept Ophthalmol, Boston, MA 02111 USA.
   [Seddon, Johanna M.] Tufts Univ, Sackler Sch Grad Biomed Sci, Boston, MA 02111 USA.
   [Miller, Elizabeth C.; Triebwasser, Michael; Atkinson, John P.] Washington Univ, Sch Med, Dept Med, Div Rheumatol, St Louis, MO 63110 USA.
   [Tan, Perciliz L.; Katsanis, Nicholas] Duke Univ, Ctr Human Dis Modeling, Durham, NC USA.
   [Tan, Perciliz L.; Katsanis, Nicholas] Duke Univ, Dept Cell Biol, Durham, NC USA.
   [Tan, Perciliz L.; Katsanis, Nicholas] Duke Univ, Dept Pediat, Durham, NC 27706 USA.
   [Gowrisankar, Sivakumar; Raychaudhuri, Soumya] Partners HealthCare Ctr Personalized Genet Med, Boston, MA USA.
   [Goldstein, Jacqueline I.; Daly, Mark J.; Raychaudhuri, Soumya] Broad Inst, Program Med & Populat Genet, Cambridge, MA USA.
   [Goldstein, Jacqueline I.; Daly, Mark J.] Massachusetts Gen Hosp, Analyt & Translat Genet Unit, Boston, MA 02114 USA.
   [Anderson, Holly E.; Kavanagh, David] Newcastle Univ, Int Ctr Life, Inst Med Genet, Newcastle Upon Tyne NE1 7RU, Tyne & Wear, England.
   [Zerbib, Jennyfer; Souied, Eric] Univ Paris Est Creteil, Hop Henri Mondor, Hop Intercommunal Creteil, Dept Ophthalmol, Creteil, France.
   [Raychaudhuri, Soumya] Brigham & Womens Hosp, Div Genet, Boston, MA 02115 USA.
   [Raychaudhuri, Soumya] Brigham & Womens Hosp, Div Rheumatol Allergy & Immunol, Boston, MA 02115 USA.
   [Raychaudhuri, Soumya] Univ Manchester, Fac Med & Human Sci, Manchester, Lancs, England.
C3 Tufts Medical Center; Tufts University; Tufts University; Washington
   University (WUSTL); Duke University; Duke University; Duke University;
   Partners Healthcare System; Harvard University; Massachusetts Institute
   of Technology (MIT); Broad Institute; Harvard University; Massachusetts
   General Hospital; Newcastle University - UK; Assistance Publique
   Hopitaux Paris (APHP); Universite Paris-Est-Creteil-Val-de-Marne (UPEC);
   Hopital Universitaire Henri-Mondor - APHP; CHI Creteil; Harvard
   University; Brigham & Women's Hospital; Harvard University; Brigham &
   Women's Hospital; University of Manchester
RP Seddon, JM (通讯作者)，Tufts Med Ctr, New England Eye Ctr, Ophthalm Epidemiol & Genet Serv, Boston, MA USA.
EM jseddon@tuftsmedicalcenter.org; soumya@broadinstitute.org
RI Daly, Mark J/B-2453-2017; Kavanagh, David/E-8498-2011
OI Daly, Mark J/0000-0002-0949-8752; Kavanagh, David/0000-0003-4718-0072;
   Raychaudhuri, Soumya/0000-0002-1901-8265; Katsanis,
   Nicholas/0000-0002-2480-0171; Goldstein, Jacqueline/0000-0003-1902-6916
FU US National Institutes of Health (NIH) [R01-EY11309, K08AR055688,
   U01HG0070033, F30HL103072]; Doris Duke Foundation; Edward N. & Della L.
   Thome Memorial Foundation; Massachusetts Lions Eye Research Fund, Inc.;
   Foundation Fighting Blindness; Macular Vision Research Foundation; New
   England Eye Center, Department of Ophthalmology, Tufts University School
   of Medicine; NATIONAL EYE INSTITUTE [R01EY011309] Funding Source: NIH
   RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [F30HL103072]
   Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND
   INFECTIOUS DISEASES [R01AI041592] Funding Source: NIH RePORTER; NATIONAL
   INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES
   [R01AR062886, K08AR055688] Funding Source: NIH RePORTER
FX We thank the participants and numerous ophthalmologists throughout the
   country who took part in this study as well as the Age-Related Eye
   Disease Study Research Group. This research was supported in part by
   grants R01-EY11309 (J. M. S.), K08AR055688 (S. R.), U01HG0070033 (S.
   R.), F30HL103072 (M. T.) and R01-AI041592 (J. P. A. and E. C. M.) from
   the US National Institutes of Health (NIH); The Doris Duke Foundation
   (S. R.); the Edward N. & Della L. Thome Memorial Foundation (J. P. A.);
   the Massachusetts Lions Eye Research Fund, Inc. (J. M. S.); the
   Foundation Fighting Blindness (J. M. S.); the Macular Vision Research
   Foundation (J. M. S.); a Research to Prevent Blindness Challenge Grant
   to the New England Eye Center, Department of Ophthalmology, Tufts
   University School of Medicine; the American Macular Degeneration
   Foundation (J. M. S.); The Arnold and Mabel Beckman Initiative for
   Macular Research (J. M. S. and S. R.); and the Macular Degeneration
   Research Fund of the Ophthalmic Epidemiology and Genetics Service, New
   England Eye Center, Tufts Medical Center, Tufts University School of
   Medicine. N. K. is a Distinguished Brumley Professor. D. K. is a
   Wellcome Intermediate Clinical Fellow. We thank the French national
   Programme Hospitalier de Recherche Clinique (PHRC; E. S.).
CR Adzhubei IA, 2010, NAT METHODS, V7, P248, DOI 10.1038/nmeth0410-248
   Altshuler D, 2010, NATURE, V467, P1061, DOI 10.1038/nature09534
   Bienaime F, 2010, KIDNEY INT, V77, P339, DOI 10.1038/ki.2009.472
   Browning SR, 2006, AM J HUM GENET, V78, P903, DOI 10.1086/503876
   Caprioli J, 2006, BLOOD, V108, P1267, DOI 10.1182/blood-2005-10-007252
   Chen W, 2010, P NATL ACAD SCI USA, V107, P7401, DOI 10.1073/pnas.0912702107
   Cingolani P, 2012, FLY, V6, P80, DOI 10.4161/fly.19695
   Clark SJ, 2013, J IMMUNOL, V190, P2049, DOI 10.4049/jimmunol.1201751
   Daly AK, 2009, NAT GENET, V41, P816, DOI 10.1038/ng.379
   DePristo MA, 2011, NAT GENET, V43, P491, DOI 10.1038/ng.806
   Fagerness JA, 2009, EUR J HUM GENET, V17, P100, DOI 10.1038/ejhg.2008.140
   Fremeaux-Bacchi V, 2004, J MED GENET, V41, DOI 10.1136/jmg.2004.019083
   Fremeaux-Bacchi V, 2008, BLOOD, V112, P4948, DOI 10.1182/blood-2008-01-133702
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P532
   Fritsche LG, 2013, NAT GENET, V45, P433, DOI 10.1038/ng.2578
   Geelen J, 2007, PEDIATR NEPHROL, V22, P371, DOI 10.1007/s00467-006-0320-2
   Goldstein JI, 2012, BIOINFORMATICS, V28, P2543, DOI 10.1093/bioinformatics/bts479
   Heurich M, 2011, P NATL ACAD SCI USA, V108, P8761, DOI 10.1073/pnas.1019338108
   Hicks S, 2011, HUM MUTAT, V32, P661, DOI 10.1002/humu.21490
   Huyghe JR, 2013, NAT GENET, V45, P197, DOI 10.1038/ng.2507
   Jozsi M, 2006, J AM SOC NEPHROL, V17, P170, DOI 10.1681/ASN.2005080868
   Kavanagh D, 2008, MOL IMMUNOL, V45, P95, DOI 10.1016/j.molimm.2007.05.004
   Li BS, 2008, AM J HUM GENET, V83, P311, DOI 10.1016/j.ajhg.2008.06.024
   Li H, 2009, BIOINFORMATICS, V25, P1754, DOI 10.1093/bioinformatics/btp324
   Li M, 2006, NAT GENET, V38, P1049, DOI 10.1038/ng1871
   Lim LS, 2012, LANCET, V379, P1728, DOI 10.1016/S0140-6736(12)60282-7
   Lohmueller KE, 2003, NAT GENET, V33, P177, DOI 10.1038/ng1071
   MacArthur DG, 2012, SCIENCE, V335, P823, DOI 10.1126/science.1215040
   Maller J, 2006, NAT GENET, V38, P1055, DOI 10.1038/ng1873
   Maller JB, 2007, NAT GENET, V39, P1200, DOI 10.1038/ng2131
   Manuelian T, 2003, J CLIN INVEST, V111, P1181, DOI 10.1172/JCI200316651
   McKenna A, 2010, GENOME RES, V20, P1297, DOI 10.1101/gr.107524.110
   Montes T, 2009, P NATL ACAD SCI USA, V106, P4366, DOI 10.1073/pnas.0812584106
   Neale BM, 2011, PLOS GENET, V7, DOI 10.1371/journal.pgen.1001322
   Neale BM, 2010, P NATL ACAD SCI USA, V107, P7395, DOI 10.1073/pnas.0912019107
   Nilsson SC, 2007, MOL IMMUNOL, V44, P1835, DOI 10.1016/j.molimm.2006.10.005
   Nishiguchi KM, 2012, INVEST OPHTH VIS SCI, V53, P508, DOI 10.1167/iovs.11-8425
   Price AL, 2006, NAT GENET, V38, P904, DOI 10.1038/ng1847
   Purcell S, 2007, AM J HUM GENET, V81, P559, DOI 10.1086/519795
   Raychaudhuri S, 2011, NAT GENET, V43, P1232, DOI 10.1038/ng.976
   Raychaudhuri S, 2010, NAT GENET, V42, P553, DOI 10.1038/ng0710-553
   Rivas MA, 2011, NAT GENET, V43, P1066, DOI 10.1038/ng.952
   Sanchez-Corral P, 2002, AM J HUM GENET, V71, P1285, DOI 10.1086/344515
   Seddon JM, 2006, OPHTHALMOLOGY, V113, P260, DOI 10.1016/j.ophtha.2005.11.001
   Seddon JM, 2005, ARCH OPHTHALMOL-CHIC, V123, P321, DOI 10.1001/archopht.123.3.321
   Seddon JM, 2003, AM J HUM GENET, V73, P780, DOI 10.1086/378505
   Seddon JM, 2003, ARCH OPHTHALMOL-CHIC, V121, P785, DOI 10.1001/archopht.121.6.785
   Seddon JM, 2001, ARCH OPHTHALMOL-CHIC, V119, P1191, DOI 10.1001/archopht.119.8.1191
   Sellier-Leclerc AL, 2007, J AM SOC NEPHROL, V18, P2392, DOI 10.1681/ASN.2006080811
   Sklar P, 2008, MOL PSYCHIATR, V13, P558, DOI 10.1038/sj.mp.4002151
   Tennessen JA, 2012, SCIENCE, V337, P64, DOI 10.1126/science.1219240
   Wu J, 2009, NAT IMMUNOL, V10, P728, DOI 10.1038/ni.1755
   Yang ZL, 2008, NEW ENGL J MED, V359, P1456, DOI 10.1056/NEJMoa0802437
   Yang ZL, 2010, PLOS GENET, V6, DOI 10.1371/journal.pgen.1000836
   Yates JRW, 2007, NEW ENGL J MED, V357, P553, DOI 10.1056/NEJMoa072618
   Yu Y, 2011, HUM MOL GENET, V20, P3699, DOI 10.1093/hmg/ddr270
NR 56
TC 235
Z9 248
U1 0
U2 24
PU NATURE PUBLISHING GROUP
PI NEW YORK
PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA
SN 1061-4036
EI 1546-1718
J9 NAT GENET
JI Nature Genet.
PD NOV
PY 2013
VL 45
IS 11
BP 1366
EP +
DI 10.1038/ng.2741
PG 8
WC Genetics & Heredity
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Genetics & Heredity
GA 244JL
UT WOS:000326384100018
PM 24036952
OA Green Accepted
DA 2022-11-30
ER

PT J
AU Buch, H
   Vinding, T
   la Cour, M
   Jensen, GB
   Prause, JU
   Nielsen, NV
AF Buch, H
   Vinding, T
   la Cour, M
   Jensen, GB
   Prause, JU
   Nielsen, NV
TI Risk factors for age-related maculopathy in a 14-year followup study:
   the Copenhagen City Eye Study
SO ACTA OPHTHALMOLOGICA SCANDINAVICA
LA English
DT Article
DE risk factors; age-related maculopathy; incidence; AMD; ARM
ID SENILE MACULAR DEGENERATION; ISCHEMIC-HEART-DISEASE; BEAVER DAM; 5-YEAR
   INCIDENCE; APOLIPOPROTEIN-E; CARDIOVASCULAR-DISEASE;
   ALCOHOL-CONSUMPTION; VISUAL IMPAIRMENT; POOLED FINDINGS; INVARIANT
   ASSOCIATIONS
AB Purpose: To examine the association between potential risk factors and the 14-year incidence of age-related maculopathy (ARM).
   Design: Population-based cohort study.
   Participants: At baseline, 946 volunteers participated in the study during 1986-88. These subjects were between 60 and 80 years of age and lived in the Osterbro district of Copenhagen. Excluding participants who had died since baseline, 359 subjects (97.3% of survivors) were re-examined 14 years later, during 2000-2002. A total of 31.8% (301/946) of the original material was included in the risk factor analyses.
   Methods: Participants underwent an ophthalmological examination at Rigshospitalet, the National University Hospital of Copenhagen. Similar standardized protocols for physical examination were used at the baseline and follow-up examinations. Age-related maculopathy lesions were determined by the same grader grading colour fundus photographs from both examinations using a modification of the Wisconsin Age-related Maculopathy Grading System protocol.
   Results: Of the 359 participants, 94 had incident early ARM and 52 had incident late ARM at follow-up in either eye. In logistic regression, the risk factors for early ARM or worse were as follows: cataract (odds ratio [OR] 2.8 95% confidence interval [CI] 1.2-6.2); family history of ARM (OR 4.5, 95% Cl 1.3-15.5), and alcohol consumption > 250 g/week (OR 4.6, 95% CI 1.1-19.2). High levels of apolipoprotein B ( > 100 mg/l) decreased the risk of development of early ARM or worse (OR 0.4, 95% Cl 0.2-0.8), while high levels of apolipoprotein A1 (>= 150 mg/l) increased the risk of late ARM (OR 2.5, 95% CI 1.2-5.3). Advanced age at baseline was also associated with the incidence of late ARM (OR 2.0, 95% CI 1.4-2.9).
   Conclusions: These findings indicate a direct correlation between age, cataract, family history, alcohol consumption, the apolipoproteins A1 and B and the 14-year incidence of ARM.
C1 Natl Univ Hosp, Rigshosp, Dept Ophthalmol, DK-2100 Copenhagen, Denmark.
   Univ Copenhagen, Herlev Hosp, Dept Ophthalmol, DK-2730 Herlev, Denmark.
   Bispebjerg Hosp, Epidemiol Res Unit, Copenhagen City Heart Study, Copenhagen, Denmark.
   Hvidovre Univ Hosp, Dept Cardiol, DK-2650 Hvidovre, Denmark.
C3 Rigshospitalet; University of Copenhagen; University of Copenhagen;
   Herlev & Gentofte Hospital; University of Copenhagen; Bispebjerg
   Hospital; University of Copenhagen
RP Buch, H (通讯作者)，Natl Univ Hosp, Rigshosp, Dept Ophthalmol, Blegdamsvej 9, DK-2100 Copenhagen, Denmark.
EM hbh@dadlnet.dk
RI la Cour, Morten/L-1600-2013; Hesgaard, Helena Buch/E-8226-2011
OI Hesgaard, Helena Buch/0000-0002-2097-0202; Dornonville de la Cour,
   Morten/0000-0002-7712-9772
CR Allikmets R, 2000, AM J HUM GENET, V67, P793, DOI 10.1086/303100
   Allikmets R, 2000, AM J HUM GENET, V67, P487, DOI 10.1086/303018
   Anand R, 2000, OPHTHALMOLOGY, V107, P2224
   APPLEYARD M, 1989, SCAND J SOC MED S, V41
   Baird PN, 2004, INVEST OPHTH VIS SCI, V45, P1311, DOI 10.1167/iovs.03-1121
   Bellows J G, 1971, Ann Ophthalmol, V3, P687
   Borger PH, 2003, OPHTHALMOLOGY, V110, P1292, DOI 10.1016/S0161-6420(03)00450-0
   BRESSLER NM, 1995, ARCH OPHTHALMOL-CHIC, V113, P301, DOI 10.1001/archopht.1995.01100030055022
   Buch H, 2005, OPHTHALMOLOGY, V112, P787, DOI 10.1016/j.ophtha.2004.11.040
   Buch H, 2005, OPHTHALMOLOGY, V112, P305, DOI 10.1016/j.ophtha.2004.08.025
   Buch H, 2001, ACTA OPHTHALMOL SCAN, V79, P441, DOI 10.1034/j.1600-0420.2001.790503.x
   Buch H, 2001, OPHTHALMOLOGY, V108, P2347, DOI 10.1016/S0161-6420(01)00823-5
   Chaine G, 1998, BRIT J OPHTHALMOL, V82, P996, DOI 10.1136/bjo.82.9.996
   Cho EY, 2000, ARCH OPHTHALMOL-CHIC, V118, P681, DOI 10.1001/archopht.118.5.681
   CRUICKSHANKS KJ, 1993, ARCH OPHTHALMOL-CHIC, V111, P514, DOI 10.1001/archopht.1993.01090040106042
   Cruickshanks KJ, 2001, ARCH OPHTHALMOL-CHIC, V119, P246
   de Jong PTVM, 2001, EYE, V15, P396, DOI 10.1038/eye.2001.143
   DeJong PTVM, 1997, AM J OPHTHALMOL, V124, P862, DOI 10.1016/S0002-9394(14)71715-5
   Evans JR, 2001, PROG RETIN EYE RES, V20, P227, DOI 10.1016/S1350-9462(00)00023-9
   Frikke-Schmidt R, 2000, J LIPID RES, V41, P1812
   Frikke-Schmidt R, 2000, SCAND J CLIN LAB INV, V60, P3
   Frikke-Schmidt R, 2000, J AM COLL CARDIOL, V35, P1192, DOI 10.1016/S0735-1097(00)00520-9
   GOLDBERG J, 1988, AM J EPIDEMIOL, V128, P700, DOI 10.1093/oxfordjournals.aje.a115023
   Gorin MB, 1999, MOL VIS, V5, pU31
   HEIBA IM, 1993, AM J MED GENET, V47, P1208, DOI 10.1002/ajmg.1320470816
   HEIBA IM, 1994, GENET EPIDEMIOL, V11, P51, DOI 10.1002/gepi.1370110106
   Hirvela H, 1996, OPHTHALMOLOGY, V103, P871, DOI 10.1016/S0161-6420(96)30593-9
   HYMAN LG, 1983, AM J EPIDEMIOL, V118, P213, DOI 10.1093/oxfordjournals.aje.a113629
   KAHN HA, 1977, AM J EPIDEMIOL, V106, P33, DOI 10.1093/oxfordjournals.aje.a112429
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1417, DOI 10.1001/archopht.119.10.1417
   KATZ ML, 1982, EXP EYE RES, V34, P339, DOI 10.1016/0014-4835(82)90082-3
   Klaver CCW, 1998, AM J HUM GENET, V63, P200, DOI 10.1086/301901
   Klaver CCW, 1998, ARCH OPHTHALMOL-CHIC, V116, P1646, DOI 10.1001/archopht.116.12.1646
   Klaver CCW, 2001, INVEST OPHTH VIS SCI, V42, P2237
   Klein ML, 1998, ARCH OPHTHALMOL-CHIC, V116, P1082, DOI 10.1001/archopht.116.8.1082
   Klein R, 1998, ARCH OPHTHALMOL-CHIC, V116, P506, DOI 10.1001/archopht.116.4.506
   Klein R, 1997, OPHTHALMOLOGY, V104, P7, DOI 10.1016/S0161-6420(97)30368-6
   KLEIN R, 1995, ARCH OPHTHALMOL-CHIC, V113, P333, DOI 10.1001/archopht.1995.01100030089026
   Klein R, 2003, OPHTHALMOLOGY, V110, P636, DOI 10.1016/S0161-6420(02)01448-3
   Klein R, 1997, OPHTHALMOLOGY, V104, P1804, DOI 10.1016/S0161-6420(97)30023-2
   Klein R, 2002, ARCH OPHTHALMOL-CHIC, V120, P1551, DOI 10.1001/archopht.120.11.1551
   Klein R, 2002, OPHTHALMOLOGY, V109, P1767, DOI 10.1016/S0161-6420(02)01146-6
   Klein R, 2002, AM J EPIDEMIOL, V156, P589, DOI 10.1093/aje/kwf092
   KLEIN R, 1991, OPHTHALMOLOGY, V98, P1128
   Klein R, 1999, OPHTHALMOLOGY, V106, P1056, DOI 10.1016/S0161-6420(99)90255-5
   KLEIN R, 1994, ARCH OPHTHALMOL-CHIC, V112, P191, DOI 10.1001/archopht.1994.01090140067025
   KLEIN R, 1993, OPHTHALMOLOGY, V100, P406
   LINN S, 1993, AM J PUBLIC HEALTH, V83, P811, DOI 10.2105/AJPH.83.6.811
   MALTZMAN BA, 1979, ANN OPHTHALMOL, V11, P1197
   MANNINEN V, 1988, JAMA-J AM MED ASSOC, V260, P641, DOI 10.1001/jama.260.5.641
   MaresPerlman JA, 1996, ARCH OPHTHALMOL-CHIC, V114, P991, DOI 10.1001/archopht.1996.01100140199014
   MARESPERLMAN JA, 1995, AM J EPIDEMIOL, V141, P322, DOI 10.1093/aje/141.4.322
   McCarty CA, 2001, ARCH OPHTHALMOL-CHIC, V119, P1455
   Meyers S M, 1994, Trans Am Ophthalmol Soc, V92, P775
   Mitchell P, 2002, OPHTHALMOLOGY, V109, P1092, DOI 10.1016/S0161-6420(02)01055-2
   Moss SE, 1998, OPHTHALMOLOGY, V105, P789, DOI 10.1016/S0161-6420(98)95016-3
   RIKANS LE, 1990, ALCOHOL CLIN EXP RES, V14, P872, DOI 10.1111/j.1530-0277.1990.tb01830.x
   ROSENBLUM ER, 1989, FREE RADICAL BIO MED, V7, P569, DOI 10.1016/0891-5849(89)90034-8
   Rothman K J, 1990, Epidemiology, V1, P43, DOI 10.1097/00001648-199001000-00010
   Schnohr P, 2001, EUR HEART J SUPPL, V3, pH1
   Schnohr P, 1977, Ugeskr Laeger, V139, P1921
   Seddon JM, 1997, AM J OPHTHALMOL, V123, P199, DOI 10.1016/S0002-9394(14)71036-0
   SILVESTRI G, 1994, EYE, V8, P564, DOI 10.1038/eye.1994.138
   Smith W, 1998, ARCH OPHTHALMOL-CHIC, V116, P583, DOI 10.1001/archopht.116.5.583
   Smith W, 2001, OPHTHALMOLOGY, V108, P697, DOI 10.1016/S0161-6420(00)00580-7
   Smith W, 1998, AUST NZ J OPHTHALMOL, V26, P203, DOI 10.1111/j.1442-9071.1998.tb01311.x
   Smith W, 1996, AM J OPHTHALMOL, V122, P743, DOI 10.1016/S0002-9394(14)70503-3
   Souied EH, 1998, AM J OPHTHALMOL, V125, P353, DOI 10.1016/S0002-9394(99)80146-9
   Sparrow JM, 1997, EYE, V11, P315, DOI 10.1038/eye.1997.67
   SPERDUTO RD, 1981, ARCH OPHTHALMOL-CHIC, V99, P1004
   Taylor H R, 2000, Trans Am Ophthalmol Soc, V98, P91
   Tomany SC, 2004, OPHTHALMOLOGY, V111, P1280, DOI 10.1016/j.ophtha.2003.11.010
   Tuo JS, 2004, PROG RETIN EYE RES, V23, P229, DOI 10.1016/j.preteyeres.2004.02.001
   van Leeuwen R, 2004, AM J OPHTHALMOL, V137, P750, DOI 10.1016/S0002-9394(03)01089-4
   van Leeuwen R, 2003, ARCH OPHTHALMOL-CHIC, V121, P519, DOI 10.1001/archopht.121.4.519
   Vinding T, 1995, ACTA OPHTHALMOL SCAN, V73, P3
   VINDING T, 1992, ACTA OPHTHALMOL, V70, P66
   Wang JJ, 2001, ARCH OPHTHALMOL-CHIC, V119, P1186, DOI 10.1001/archopht.119.8.1186
   Wang JJ, 2003, OPHTHALMOLOGY, V110, P1960, DOI 10.1016/S0161-6420(03)00816-9
   WEST SK, 1989, ARCH OPHTHALMOL-CHIC, V107, P875, DOI 10.1001/archopht.1989.01070010897038
   YANNUZZI LA, 1992, ARCH OPHTHALMOL-CHIC, V110, P1701
   Zareparsi S, 2004, INVEST OPHTH VIS SCI, V45, P1306, DOI 10.1167/iovs.03-1253
NR 82
TC 92
Z9 96
U1 0
U2 5
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1395-3907
J9 ACTA OPHTHALMOL SCAN
JI Acta Ophthalmol. Scand.
PD AUG
PY 2005
VL 83
IS 4
BP 409
EP 418
DI 10.1111/J.1600-0420.2005.00492.x
PG 10
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 953FY
UT WOS:000231063200002
PM 16029262
DA 2022-11-30
ER

PT J
AU Zola, M
   D'Alessandro, E
   Sherif, M
   Nguyen, A
   De Azevedo, D
   Haeller, C
   Forestier, E
   Mantel, I
AF Zola, Marta
   D'Alessandro, Elisa
   Sherif, Mohamed
   Nguyen, Audrey
   De Azevedo, Dominique
   Haeller, Celine
   Forestier, Edwige
   Mantel, Irmela
TI Refractory neovascular age-related macular degeneration: time-dependent
   changes of central retinal thickness with anti-VEGF treatment
SO GRAEFES ARCHIVE FOR CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY
LA English
DT Article
DE Aflibercept; Anti-VEGF; Central retinal thickness; Neovascular
   age-related macular degeneration; Optical coherence tomography;
   Ranibizumab
ID RANIBIZUMAB TREATMENT; CLINICAL BURDEN; AFLIBERCEPT
AB Purpose To assess the influence of time interval since last injection and time from baseline on central retinal thickness (CRT) in neovascular age-related macular degeneration (nAMD) with fluid refractory to monthly anti-VEGF treatment.
   Methods This retrospective study included nAMD eyes with incomplete response to anti-VEGF defined by the presence of intra- or subretinal fluid on optical coherence tomography despite maximal (monthly) anti-VEGF dosing. The outcome measure was CRT, and two time variables (time from last injection ant time from baseline) were the independent factors included in the individual correlation analyses. In addition, an association analysis was performed.
   Results Sixty eyes of 56 patients (67.9% females, mean age: 78.7 +/- 6.8 years) were included with a mean included time period of 35.6 months. A significant positive correlation between CRT and the time from last injection occurred in 24 (40%) and 25 (42%) eyes by univariate and multivariate analysis, respectively. Time from baseline was significantly correlated with CRT in 29 (48.3%) and 30 (50%) eyes by univariate and multivariate analysis, respectively. This correlation was positive in 12 (20%) and negative in 18 eyes (30%). No association with such correlation was found.
   Conclusion So-called refractory nAMD frequently shows a correlation of CRT with the interval in days from the preceding anti-VEGF injection, revealing that there is a subgroup of short-term responsiveness of the residual fluid. Moreover, slower CRT changes may occur over the years, either decrease or increase. In case of a slow CRT increase, this might require a diagnostic workup and therapeutic change.
C1 [Zola, Marta; D'Alessandro, Elisa; Sherif, Mohamed; Nguyen, Audrey; De Azevedo, Dominique; Haeller, Celine; Forestier, Edwige; Mantel, Irmela] Univ Lausanne, Jules Gonin Eye Hosp, Dept Ophthalmol, Fdn Asile Aveugles, Lausanne, Switzerland.
C3 University of Lausanne
RP Mantel, I (通讯作者)，Univ Lausanne, Jules Gonin Eye Hosp, Dept Ophthalmol, Fdn Asile Aveugles, Lausanne, Switzerland.
EM irmela.mantel@fa2.ch
CR Bontzos GBS, 2019, OPHTHALMOL RETINA, VS2468-6530, P30628
   Calvo-Gonzalez C, 2019, INT OPHTHALMOL, V39, P2441, DOI 10.1007/s10792-019-01082-z
   Chakravarthy U, 2013, EYE, V27, P1429, DOI 10.1038/eye.2013.233
   Despreaux R, 2016, GRAEF ARCH CLIN EXP, V254, P639, DOI 10.1007/s00417-015-3084-1
   Dirani A, 2018, CLIN OPHTHALMOL, V12, P593, DOI 10.2147/OPTH.S160367
   Gianniou C, 2015, EYE, V29, P342, DOI 10.1038/eye.2014.258
   Gomi F, 2015, RETINA-J RET VIT DIS, V35, P1569, DOI 10.1097/IAE.0000000000000526
   Guymer RH, 2019, OPHTHALMOLOGY, V126, P723, DOI 10.1016/j.ophtha.2018.11.025
   Heier JS, 2012, OPHTHALMOLOGY, V119, P2537, DOI 10.1016/j.ophtha.2012.09.006
   Jaffe GJ, 2019, OPHTHALMOLOGY, V126, P252, DOI 10.1016/j.ophtha.2018.08.035
   Kauppinen A, 2016, CELL MOL LIFE SCI, V73, P1765, DOI 10.1007/s00018-016-2147-8
   Knickelbein Jared E, 2015, Int Ophthalmol Clin, V55, P63, DOI 10.1097/IIO.0000000000000073
   Lim LS, 2012, LANCET, V379, P1728, DOI 10.1016/S0140-6736(12)60282-7
   Mantel I, 2018, SURV OPHTHALMOL, V63, P638, DOI 10.1016/j.survophthal.2018.02.004
   Mantel I, 2014, BRIT J OPHTHALMOL, V98, P1192, DOI 10.1136/bjophthalmol-2013-304556
   Mitchell P, 2010, BRIT J OPHTHALMOL, V94, P2, DOI 10.1136/bjo.2009.159160
   Rosenfeld Philip J, 2006, Ophthalmol Clin North Am, V19, P361
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Rutar M, 2016, ADV EXP MED BIOL, V854, P11, DOI 10.1007/978-3-319-17121-0_2
   Seguin-Greenstein S, 2016, J OPHTHALMOL, V2016, DOI 10.1155/2016/4095852
   Tosi GM, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19113363
NR 21
TC 1
Z9 1
U1 0
U2 1
PU SPRINGER
PI NEW YORK
PA ONE NEW YORK PLAZA, SUITE 4600, NEW YORK, NY, UNITED STATES
SN 0721-832X
EI 1435-702X
J9 GRAEF ARCH CLIN EXP
JI Graefes Arch. Clin. Exp. Ophthalmol.
PD JUN
PY 2021
VL 259
IS 6
BP 1477
EP 1486
DI 10.1007/s00417-020-05000-3
EA NOV 2020
PG 10
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA SK9OI
UT WOS:000593446800001
PM 33245426
OA Green Published, hybrid
DA 2022-11-30
ER

PT J
AU Gonzalez-Buendia, L
   Delgado-Tirado, S
   Sanabria, MR
   Fernandez, I
   Coco, RM
AF Gonzalez-Buendia, Lucia
   Delgado-Tirado, Santiago
   Rosa Sanabria, M.
   Fernandez, Itziar
   Coco, Rosa M.
TI Predictive models of long-term anatomic outcome in age-related macular
   degeneration treated with as-needed Ranibizumab
SO BMC OPHTHALMOLOGY
LA English
DT Article
DE Age-related macular degeneration; Choroidal neovascularization;
   Anti-VEGF
ID TREATMENTS TRIALS; FUNDUS AUTOFLUORESCENCE; GEOGRAPHIC ATROPHY;
   FOLLOW-UP; PROGRESSION; PREVALENCE; RISK
AB Background: To analyze predictors and develop predictive models of anatomic outcome in neovascular age-related macular degeneration (AMD) treated with as-needed ranibizumab after 4 years of follow-up.
   Methods: A multicenter consecutive case series non-interventional study was performed. Clinical, funduscopic and OCT characteristics of 194 treatment-naive patients with AMD treated with as-needed ranibizumab for at least 2 years and up to 4 years were analyzed at baseline, 3 months and each year until the end of the follow-up. Baseline demographic and angiographic characteristics were also evaluated. R Statistical Software was used for statistical analysis. Main outcome measure was final anatomic status.
   Results: Factors associated with less probability of preserved macula were diagnosis in 2009, older age, worse vision, presence of atrophy/fibrosis, pigment epithelium detachment, and geographic atrophy/fibrotic scar/neovascular AMD in the fellow eye. Factors associated with higher probability of GA were presence of atrophy and greater number of injections, whereas male sex, worse vision, lesser change in central macular thickness and presence of fibrosis were associated with less probability of GA as final macular status. Predictive model of preserved macula vs. GA/fibrotic scar showed sensibility of 77.78% and specificity of 69.09%. Predictive model of GA vs. fibrotic scar showed sensibility of 68. 89% and specificity of 72.22%.
   Conclusions: We identified predictors of final macular status, and developed two predictive models. Predictive models that we propose are based on easily harvested variables, and, if validated, could be a useful tool for individual patient management and clinical research studies.
C1 [Gonzalez-Buendia, Lucia; Delgado-Tirado, Santiago; Rosa Sanabria, M.; Fernandez, Itziar; Coco, Rosa M.] Univ Valladolid, Inst Oftalmobiol Aplicada IOBA, Campus Miguel Delibes,Po Belen 17, E-47011 Valladolid, Spain.
   [Gonzalez-Buendia, Lucia; Delgado-Tirado, Santiago] Clin Univ Hosp Valladolid, Valladolid, Spain.
   [Rosa Sanabria, M.] Hlth Complex Palencia, Palencia, Spain.
   [Fernandez, Itziar] Ciber BBN, Zaragoza, Spain.
C3 Universidad de Valladolid; CIBER - Centro de Investigacion Biomedica en
   Red; CIBERBBN
RP Gonzalez-Buendia, L (通讯作者)，Univ Valladolid, Inst Oftalmobiol Aplicada IOBA, Campus Miguel Delibes,Po Belen 17, E-47011 Valladolid, Spain.; Gonzalez-Buendia, L (通讯作者)，Clin Univ Hosp Valladolid, Valladolid, Spain.
EM luciaglezbuendia@gmail.com
RI Gonzalez-Buendia, Lucia/AAC-9445-2022; Fernández, Itziar/AAF-9590-2020;
   Martin, Rosa Maria Coco/H-4511-2015; Sanabria, Maria Rosa/AAH-5766-2019
OI Fernández, Itziar/0000-0002-5077-4448; Martin, Rosa Maria
   Coco/0000-0002-1811-1417; Sanabria, Maria Rosa/0000-0002-1818-9812
FU Novartis-Spain
FX Novartis-Spain funded this study. The views expressed are those of the
   authors and not necessarily the funding body. The researchers are
   independent of the funders.
CR Akaike H., 1973, 2 INT S INF THEOR, P267, DOI DOI 10.1007/978-1-4612-1694-0_15
   [Anonymous], 2014, LANG ENV STAT COMP
   BIRD AEC, 1995, SURV OPHTHALMOL, V39, P367, DOI 10.1016/S0039-6257(05)80092-X
   Brier G.W., 1950, MONTHLY WEATHER REVI, V78, P1, DOI DOI 10.1175/1520-0493(1950)078<0001:VOFEIT>2.0.CO;2
   Buitendijk GHS, 2013, OPHTHALMOLOGY, V120, P2644, DOI 10.1016/j.ophtha.2013.07.053
   Coco RM, 2014, BMC OPHTHALMOL, V14, DOI 10.1186/1471-2415-14-138
   Daniel E, 2014, OPHTHALMOLOGY, V121, P656, DOI 10.1016/j.ophtha.2013.10.019
   de Sisternes L, 2014, INVEST OPHTH VIS SCI, V55, P7093, DOI 10.1167/iovs.14-14918
   Fox J., 2019, R COMPANION APPL REG, DOI DOI 10.1177/0049124105277200
   Fung AE, 2007, AM J OPHTHALMOL, V143, P566, DOI 10.1016/j.ajo.2007.01.028
   Genolini C, 2016, COMPUT METH PROG BIO, V132, P29, DOI 10.1016/j.cmpb.2016.04.010
   Gregori NZ, 2010, RETINA-J RET VIT DIS, V30, P1046, DOI 10.1097/IAE.0b013e3181d87e04
   Grunwald JE, 2015, OPHTHALMOLOGY, V122, P809, DOI 10.1016/j.ophtha.2014.11.007
   Grunwald JE, 2014, OPHTHALMOLOGY, V121, P150, DOI 10.1016/j.ophtha.2013.08.015
   Hanout M, 2013, BIOMED RES INT, V2013, DOI 10.1155/2013/830837
   Hosmer D, 1989, APPL LOGISTIC REGRES, P147
   Kuehlewein L, 2016, OSLI RETINA, V47, P224, DOI 10.3928/23258160-20160229-04
   Kumar N, 2013, OPHTHALMOLOGY, V120, P334, DOI 10.1016/j.ophtha.2012.07.076
   Lalwani GA, 2009, AM J OPHTHALMOL, V148, P43, DOI 10.1016/j.ajo.2009.01.024
   McLeod AI, 2014, XC BESTGLM BEST SUBS
   Robin X, 2011, BMC BIOINFORMATICS, V12, DOI 10.1186/1471-2105-12-77
   Rofagha S, 2013, OPHTHALMOLOGY, V120, P2292, DOI 10.1016/j.ophtha.2013.03.046
   Schutze C, 2015, AM J OPHTHALMOL, V159, P1100, DOI 10.1016/j.ajo.2015.02.020
   Seddon JM, 2009, INVEST OPHTH VIS SCI, V50, P2044, DOI 10.1167/iovs.08-3064
   Tanaka E, 2015, OPHTHALMOLOGY, V122, P153, DOI 10.1016/j.ophtha.2014.07.046
   Wong T, 2008, OPHTHALMOLOGY, V115, P116, DOI 10.1016/j.ophtha.2007.03.008
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
   Ying GS, 2015, OPHTHALMOLOGY, V122, P2523, DOI 10.1016/j.ophtha.2015.08.015
NR 28
TC 9
Z9 9
U1 0
U2 0
PU BIOMED CENTRAL LTD
PI LONDON
PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND
SN 1471-2415
J9 BMC OPHTHALMOL
JI BMC Ophthalmol.
PD AUG 18
PY 2017
VL 17
AR 147
DI 10.1186/s12886-017-0544-x
PG 14
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA FE2KT
UT WOS:000408045900001
PM 28821236
OA gold, Green Published
DA 2022-11-30
ER

PT J
AU Ali, ZC
   Silvioli, R
   Rajai, A
   Aslam, TM
AF Ali, Zaria Christine
   Silvioli, Richard
   Rajai, Azita
   Aslam, Tariq Mehmood
TI Feasibility of Use of a Mobile Application for Nutrition Assessment
   Pertinent to Age-Related Macular Degeneration (MANAGER2)
SO TRANSLATIONAL VISION SCIENCE & TECHNOLOGY
LA English
DT Article
DE mobile application; nutrition; monitoring; AMD
ID WEIGHT-LOSS; PHONE APP; DISEASE; INTERVENTION; RANIBIZUMAB; USABILITY;
   QUALITY; OBESITY; WEB
AB Purpose: This is a feasibility study assessing use of a mobile phone application (app.) to measure nutrient intake relevant to age-related macular degeneration (AMD).
   Methods: Inclusion criteria were age over 40 and ownership of a smartphone. Participants included healthy volunteers and those with ophthalmic conditions. They were asked to record daily food intake for a minimum of 3 days in a paper food diary and the app. A dietician analyzed the food diaries, and an independent researcher analyzed data from the app. Average daily intake of nutrients relevant to AMD (docosahexaenoic acid [DHA], eicosapentaenoic acid [EPA], vitamins E and C, copper, zinc, and lutein + zeaxanthin) were calculated for both and then compared.
   Results: A total of 54 participants completed the app. and food diary. Male-to-female ratio was 7: 20. Median (interquartile range [IQR]) age was 57 years (45.3-68.7 years). More than 90% of all values were within the limits of agreement for all micronutrients. Bland Altman agreement plots demonstrated clinically acceptable agreement between the two systems of analysis.
   Conclusions: This study has demonstrated that the app. is a feasible alternative to the food diary for assessing nutrient intake relevant to AMD. Further studies are suggested to assess long-term adherence and effect of the app. on nutrient intake in AMD patients.
   Translational Relevance: After smoking, nutritional modification is the key modifiable factor to reduce incidence of AMD. Use of the app. could be an efficient, easy way to monitor and improve dietary intake of required nutrients pertinent to AMD.
C1 [Ali, Zaria Christine; Aslam, Tariq Mehmood] Manchester Royal Eye Hosp, Manchester Acad Hlth Sci Ctr, CMFT, Manchester, Lancs, England.
   [Silvioli, Richard] RS Nutr & Dietet Ltd, 7 Bickley Close, Hough, England.
   [Rajai, Azita] Univ Manchester, Inst Populat Hlth, Fac Med & Human Sci, Manchester, Lancs, England.
   [Rajai, Azita] Cent Manchester Univ Hosp NHS Fdn Trust, Manchester Acad Hlth Sci Ctr, Res & Innovat, Manchester, Lancs, England.
   [Aslam, Tariq Mehmood] Univ Manchester, Sch Hlth Sci, Div Pharm & Optometry, Manchester, Lancs, England.
   [Aslam, Tariq Mehmood] Univ Manchester, Manchester, Lancs, England.
   [Aslam, Tariq Mehmood] Heriot Watt Univ, Edinburgh Campus, Edinburgh, Midlothian, Scotland.
C3 Manchester Royal Eye Hospital; University of Manchester; University of
   Manchester; University of Manchester; University of Manchester;
   University of Manchester; Heriot Watt University
RP Aslam, TM (通讯作者)，Manchester Royal Eye Hosp, Res Dept, 4th Floor,Oxford Rd, Manchester M13 9WL, Lancs, England.
EM Tariq.Aslam@cmft.nhs.uk
RI ; Aslam, Tariq/A-8532-2016
OI Ali, Zaria/0000-0002-8382-1415; Aslam, Tariq/0000-0002-9739-7280
FU Laboratoires Thea
FX Supported by a research grant from Laboratoires Thea.
CR Aslam Tariq, 2014, Clin Ophthalmol, V8, P2045, DOI 10.2147/OPTH.S63937
   Bartlett H, 2004, NUTR J, V3, DOI 10.1186/1475-2891-3-16
   Block G, 2015, J MED INTERNET RES, V17, DOI 10.2196/jmir.4897
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Campbell J, 2015, NEPHROLOGY, V20, P744, DOI 10.1111/nep.12500
   Carter MC, 2013, J MED INTERNET RES, V15, DOI 10.2196/jmir.2283
   Chew EY, 2013, JAMA-J AM MED ASSOC, V309, P2005, DOI 10.1001/jama.2013.4997
   Chong V, 2016, EYE, V30, P270, DOI 10.1038/eye.2015.217
   Delisle C, 2015, BMC PUBLIC HEALTH, V15, DOI 10.1186/s12889-015-1444-8
   FERRIS FL, 1984, ARCH OPHTHALMOL-CHIC, V102, P1640
   Goodman S, 2015, J NUTR EDUC BEHAV, V47, P242, DOI 10.1016/j.jneb.2014.11.006
   Hale K, 2015, JMIR MHEALTH UHEALTH, V3, DOI 10.2196/mhealth.4532
   Hathcock JN, 2005, AM J CLIN NUTR, V81, P736, DOI 10.1093/ajcn/81.4.736
   Hongu N, 2015, NUTR RES PRACT, V9, P207, DOI 10.4162/nrp.2015.9.2.207
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1417, DOI 10.1001/archopht.119.10.1417
   Knight-Agarwal C, 2015, JMIR MHEALTH UHEALTH, V3, DOI 10.2196/mhealth.4071
   Krebs P, 2015, JMIR MHEALTH UHEALTH, V3, P107, DOI 10.2196/mhealth.4924
   Lubans DR, 2014, FRONT PUBLIC HEALTH, V2, DOI 10.3389/fpubh.2014.00042
   Mann D, 2015, JMIR MHEALTH UHEALTH, V3, DOI 10.2196/mhealth.4300
   Miller JW, 2013, AM J OPHTHALMOL, V155, P1, DOI 10.1016/j.ajo.2012.10.018
   Moeller SM, 2006, ARCH OPHTHALMOL-CHIC, V124, P1151, DOI 10.1001/archopht.124.8.1151
   O'Malley G, 2014, JMIR MHEALTH UHEALTH, V2, DOI 10.2196/mhealth.3262
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Svensson A, 2015, JMIR MHEALTH UHEALTH, V3, P15, DOI 10.2196/mhealth.4804
   Tan JSL, 2008, OPHTHALMOLOGY, V115, P334, DOI 10.1016/j.ophtha.2007.03.083
   Thornton J, 2005, EYE, V19, P935, DOI 10.1038/sj.eye.6701978
   Wharton CM, 2014, J NUTR EDUC BEHAV, V46, P440, DOI 10.1016/j.jneb.2014.04.291
NR 27
TC 8
Z9 8
U1 1
U2 10
PU ASSOC RESEARCH VISION OPHTHALMOLOGY INC
PI ROCKVILLE
PA 12300 TWINBROOK PARKWAY, ROCKVILLE, MD 20852-1606 USA
SN 2164-2591
J9 TRANSL VIS SCI TECHN
JI Transl. Vis. Sci. Technol.
PD JAN
PY 2017
VL 6
IS 1
AR 4
DI 10.1167/tvst.6.1.4
PG 7
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA EK1GW
UT WOS:000393674800003
PM 28138414
OA gold, Green Published, Green Submitted
DA 2022-11-30
ER

PT J
AU Saxena, N
   George, PP
   Hoon, HB
   Han, LT
   Onn, YS
AF Saxena, Nakul
   George, Pradeep Paul
   Hoon, Heng Bee
   Han, Lim Tock
   Onn, Yong Shao
TI Burden of Wet Age-Related Macular Degeneration and Its Economic
   Implications in Singapore in the Year 2030
SO OPHTHALMIC EPIDEMIOLOGY
LA English
DT Article
DE Age-related macular degeneration; antioxidant vitamins; burden;
   forecasting; Singapore
ID COST-OF-ILLNESS; VISUAL IMPAIRMENT; RISK-FACTORS; PREVALENCE; EYE; ZINC
AB Purpose: To estimate the prevalence of wet age-related macular degeneration (AMD) in Singapore in the year 2030. This projection will help in planning appropriate care provision and build health services capacity to cater to the increasing healthcare demand in 2030.
   Methods: The number of AMD patients aged 40-79 years from all Singaporeans was estimated using prevalence rates from a local study and using the United Nations population projections for Singapore to 2030. Age-specific mortality was accounted for. Additionally, two main scenarios were presented: (1) Projected number of wet AMD cases if patients were not taking preventive antioxidant vitamins; (2) projected number of wet AMD cases if patients were taking preventive antioxidant vitamins. Based on these scenarios, the economic burden was calculated. The number of quality-adjusted life years (QALYs) gained as a result of improvement in visual acuity (VA) due to anti-vascular endothelial growth factor (VEGF) treatment was also calculated.
   Results: An estimated growth of 42% in the number of wet AMD cases is expected by 2030. The estimated economic burden of wet AMD in 2030 for scenarios 1 and 2 is Singapore $203.1 million and $162.9 million, respectively. The QALYs gained as a result of improved VA from wet AMD treatment ranged from 10,114.4 to 14,058.8 over a 5-year period for the 2030 cohort.
   Conclusion: The burden of wet AMD is set to increase over the next 15 years. Appropriate measures to build healthcare capacity and plan for this expected surge in patients should be a priority in Singapore.
C1 [Saxena, Nakul; George, Pradeep Paul; Hoon, Heng Bee] Natl Healthcare Grp, Dept Hlth Serv & Outcomes Res, 3 Fusionopolis Link,03-08 Nexus One North, Singapore 138543, Singapore.
   [Han, Lim Tock; Onn, Yong Shao] Tan Tock Seng Hosp, Dept Ophthalmol, Singapore, Singapore.
C3 Tan Tock Seng Hospital
RP Saxena, N (通讯作者)，Natl Healthcare Grp, Dept Hlth Serv & Outcomes Res, 3 Fusionopolis Link,03-08 Nexus One North, Singapore 138543, Singapore.
EM nakul_saxena@nhg.com.sg
RI George, Pradeep Paul/ABE-9925-2020
OI George, Pradeep Paul/0000-0003-4743-1425
CR Brown, 2005, T AM OPHTHAL SOC, P184
   Brown Gary C, 2005, Trans Am Ophthalmol Soc, V103, P173
   Brown MM, 2005, CAN J OPHTHALMOL, V40, P277, DOI 10.1016/S0008-4182(05)80070-5
   Cheung CMG, 2014, OPHTHALMOLOGY, V121, P1598, DOI 10.1016/j.ophtha.2014.02.004
   Cheung CMG, 2012, ARCH OPHTHALMOL-CHIC, V130, P480, DOI 10.1001/archophthalmol.2011.376
   Chew EY, 2013, OPHTHALMOLOGY, V120, P1604, DOI 10.1016/j.ophtha.2013.01.021
   Dilokthornsakul P, 2014, INT J OPHTHALMOL-CHI, V7, P145, DOI 10.3980/j.issn.2222-3959.2014.01.27
   Durand-Zaleski I, 2008, VASC MED, V13, P251, DOI 10.1177/1358863X08091738
   Eong KGA, 2006, ANN ACAD MED SINGAP, V35, P133
   Garattini Livio, 2004, Eur J Health Econ, V5, P22
   Heier JS, 2012, OPHTHALMOLOGY, V119, P2537, DOI 10.1016/j.ophtha.2012.09.006
   Jo C, 2014, CLIN MOL HEPATOL, V20, P327, DOI 10.3350/cmh.2014.20.4.327
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1417, DOI 10.1001/archopht.119.10.1417
   Kawasaki R, 2010, OPHTHALMOLOGY, V117, P921, DOI 10.1016/j.ophtha.2009.10.007
   Lindekleiv H, 2013, ACTA OPHTHALMOL, V91, P307, DOI 10.1111/j.1755-3768.2012.02399.x
   MITCHELL P, 1995, OPHTHALMOLOGY, V102, P1450
   Pascolini D, 2012, BRIT J OPHTHALMOL, V96, P614, DOI 10.1136/bjophthalmol-2011-300539
   Patel JJ, 2012, J EVAL CLIN PRACT, V18, P247, DOI 10.1111/j.1365-2753.2010.01546.x
   Rein DB, 2009, ARCH OPHTHALMOL-CHIC, V127, P533, DOI 10.1001/archophthalmol.2009.58
   Rein DB, 2006, ARCH OPHTHALMOL-CHIC, V124, P1754, DOI 10.1001/archopht.124.12.1754
   Resnikoff S, 2004, B WORLD HEALTH ORGAN, V82, P844
   Saxena N, 2015, INDIAN J OPHTHALMOL, V63, P516, DOI 10.4103/0301-4738.158533
   United Nations Department of Economic and Social Affairs Population Division Population Estimates and Projections Section, UN POP EST
   Varma R, 2004, OPHTHALMOLOGY, V111, P1288, DOI 10.1016/j.ophtha.2004.01.023
   Wagle AM, 2015, ANN ACAD MED SINGAP, V44, P116
   Wong TY, 2006, BRIT J OPHTHALMOL, V90, P506, DOI 10.1136/bjo.2005.083733
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
   Woo JH, 2008, SINGAP MED J, V49, P850
NR 28
TC 10
Z9 10
U1 0
U2 6
PU TAYLOR & FRANCIS INC
PI PHILADELPHIA
PA 530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA
SN 0928-6586
EI 1744-5086
J9 OPHTHAL EPIDEMIOL
JI Ophthalmic Epidemiol.
PY 2016
VL 23
IS 4
BP 232
EP 237
DI 10.1080/09286586.2016.1193617
PG 6
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA DR9XD
UT WOS:000380248500003
PM 27340738
DA 2022-11-30
ER

PT J
AU Jia, LH
   Dong, YD
   Yang, HM
   Pan, XY
   Fan, R
   Zhai, LL
AF Jia, Lihong
   Dong, Youdan
   Yang, Hongmei
   Pan, Xingyue
   Fan, Rui
   Zhai, Lingling
TI Serum superoxide dismutase and malondialdehyde levels in a group of
   Chinese patients with age-related macular degeneration
SO AGING CLINICAL AND EXPERIMENTAL RESEARCH
LA English
DT Article
DE Age-related macular degeneration; malondialdehyde; superoxide dismutase
ID ANTIOXIDANT ENZYME-ACTIVITIES; RETINAL-PIGMENT EPITHELIUM;
   LIPID-PEROXIDATION; OXIDATIVE STRESS; MACULOPATHY
AB Background and aims: The aim of this study was to investigate superoxide dismutase (SOD) activity together with malondialdehyde (MDA) levels in a group of Chinese patients with age-related macular degeneration (AMD). Methods: Serum SOD activity and MDA levels were analysed in 56 AMD patients with subtypes (early dry, geographic atrophy, and wet) and 34 healthy controls matched with age and sex. Results: Serum MDA levels were significantly higher in AMD (3.68+/-1.06 nmol/mL) than in controls (2.83+/-0.43 nmol/mL; p=0.000), and was significantly higher in wet AMD (3.79+/-0.79 nmol/mL) than in early dry AMD (3.26+/-0.99 nmamL; p=0.038). Serum SOD activity was significantly higher in AMD (87.12+/-13.22 U/mL) than in controls (79.91+/-11.80 U/mL; p=0.012), and slightly higher in wet AMD (89.52+/-16.25 U/mL) than in GA (83.62+/-9.75 U/mL; p=0.275) and early dry AMD (81.64+/-18.90 U/mL; p=0.093). There was a positive correlation between serum MDA levels and SOD activities in AMD patients and controls (r=0.320, p=0.002). Conclusions: The observed increase in SOD activity in our study may be related to increased MDA levels, as a compensatory regulation in response to oxidative stress in AMD patients. The present data also demonstrate that oxido-reduction disturbance may be hypothesized in the pathogenesis of AMD. (Aging Clin Exp Res 2011; 23: 264-267) (C) 2011, Editrice Kurtis
C1 [Jia, Lihong; Dong, Youdan; Yang, Hongmei; Pan, Xingyue; Zhai, Lingling] China Med Univ, Sch Publ Hlth, Shenyang 110001, Peoples R China.
   [Fan, Rui] Shenyang AIER Ophthalmol Hosp, Shenyang, Peoples R China.
C3 China Medical University
RP Jia, LH (通讯作者)，China Med Univ, Sch Publ Hlth, Shenyang 110001, Peoples R China.
EM lhjia@mail.cmu.edu.cn
FU Nutritional Science Foundation of the Chinese Nutrition Society, China
   [07016]
FX This research was supported by the Nutritional Science Foundation of the
   Chinese Nutrition Society (no. 07016), China.
CR BIRD AEC, 1995, SURV OPHTHALMOL, V39, P367, DOI 10.1016/S0039-6257(05)80092-X
   Bloomer RJ, 2009, NICOTINE TOB RES, V11, P3, DOI 10.1093/ntr/ntn005
   Decanini A, 2007, AM J OPHTHALMOL, V143, P607, DOI 10.1016/j.ajo.2006.12.006
   DELAPAZ MA, 1992, INVEST OPHTH VIS SCI, V33, P2091
   Dominguez LJ, 2010, J AM COLL NUTR, V29, P1
   Evereklioglu C, 2003, DOC OPHTHALMOL, V106, P129, DOI 10.1023/A:1022512402811
   Feher J, 2006, NEUROBIOL AGING, V27, P983, DOI 10.1016/j.neurobiolaging.2005.05.012
   Hamdi HK, 2002, BIOCHEM BIOPH RES CO, V295, P668, DOI 10.1016/S0006-291X(02)00728-3
   Hashizume K, 2008, AM J PATHOL, V172, P1325, DOI 10.2353/ajpath.2008.070730
   ITO T, 1995, ARCH BIOCHEM BIOPHYS, V316, P864, DOI 10.1006/abbi.1995.1116
   Jager RD, 2008, NEW ENGL J MED, V358, P2606, DOI 10.1056/NEJMra0801537
   JAIN SK, 1988, BIOCHIM BIOPHYS ACTA, V937, P205, DOI 10.1016/0005-2736(88)90242-8
   Justilien V, 2007, INVEST OPHTH VIS SCI, V48, P4407, DOI 10.1167/iovs.07-0432
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1417, DOI 10.1001/archopht.119.10.1417
   Katta S, 2009, J GENET, V88, P425, DOI 10.1007/s12041-009-0064-4
   Klein R, 2006, OPHTHALMOLOGY, V113, P373, DOI 10.1016/j.ophtha.2005.12.013
   Klein R, 1997, OPHTHALMOLOGY, V104, P7, DOI 10.1016/S0161-6420(97)30368-6
   Likidlilid Atip, 2010, Journal of the Medical Association of Thailand, V93, P682
   Liu Y, 2007, GRAEF ARCH CLIN EXP, V245, P1441, DOI 10.1007/s00417-007-0575-8
   Nayak D U, 2001, Heart Dis, V3, P28
   Nowak M, 2003, EUR J OPHTHALMOL, V13, P281, DOI 10.1177/112067210301300307
   O'Connell ED, 2008, AM J CLIN NUTR, V87, P712, DOI 10.1093/ajcn/87.3.712
   Shen JK, 2007, HISTOL HISTOPATHOL, V22, P1301, DOI 10.14670/HH-22.1301
   Thornton J, 2005, EYE, V19, P935, DOI 10.1038/sj.eye.6701978
   Uno K, 2010, BIOMARK MED, V4, P361, DOI [10.2217/bmm.10.57, 10.2217/BMM.10.57]
   Xu YL, 2008, MOL VIS, V14, P1373
   Yildirim O, 2004, OPHTHALMOLOGICA, V218, P202, DOI 10.1159/000076845
   YOUNG RW, 1987, SURV OPHTHALMOL, V31, P291, DOI 10.1016/0039-6257(87)90115-9
NR 28
TC 17
Z9 17
U1 0
U2 3
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 1594-0667
EI 1720-8319
J9 AGING CLIN EXP RES
JI Aging Clin. Exp. Res.
PD AUG
PY 2011
VL 23
IS 4
BP 264
EP 267
DI 10.1007/BF03324965
PG 4
WC Geriatrics & Gerontology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Geriatrics & Gerontology
GA 871UK
UT WOS:000298763000003
PM 22067370
DA 2022-11-30
ER

PT J
AU Chen, W
   Stambolian, D
   Edwards, AO
   Branham, KE
   Othman, M
   Jakobsdottir, J
   Tosakulwong, N
   Pericak-Vance, MA
   Campochiaro, PA
   Klein, ML
   Tan, PL
   Conley, YP
   Kanda, A
   Kopplin, L
   Li, YM
   Augustaitis, KJ
   Karoukis, AJ
   Scott, WK
   Agarwal, A
   Kovach, JL
   Schwartz, SG
   Postel, EA
   Brooks, M
   Baratz, KH
   Brown, WL
   Brucker, AJ
   Orlin, A
   Brown, G
   Ho, A
   Regillo, C
   Donoso, L
   Tian, LF
   Kaderli, B
   Hadley, D
   Hagstrom, SA
   Peachey, NS
   Klein, R
   Klein, BEK
   Gotoh, N
   Yamashiro, K
   Ferris, F
   Fagerness, JA
   Reynolds, R
   Farrer, LA
   Kim, IK
   Miller, JW
   Corton, M
   Carracedo, A
   Sanchez-Salorio, M
   Pugh, EW
   Doheny, KF
   Brion, M
   DeAngelis, MM
   Weeks, DE
   Zack, DJ
   Chew, EY
   Heckenlively, JR
   Yoshimura, N
   Iyengar, SK
   Francis, PJ
   Katsanis, N
   Seddon, JM
   Haines, JL
   Gorin, MB
   Abecasis, GR
   Swaroop, A
AF Chen, Wei
   Stambolian, Dwight
   Edwards, Albert O.
   Branham, Kari E.
   Othman, Mohammad
   Jakobsdottir, Johanna
   Tosakulwong, Nirubol
   Pericak-Vance, Margaret A.
   Campochiaro, Peter A.
   Klein, Michael L.
   Tan, Perciliz L.
   Conley, Yvette P.
   Kanda, Atsuhiro
   Kopplin, Laura
   Li, Yanming
   Augustaitis, Katherine J.
   Karoukis, Athanasios J.
   Scott, William K.
   Agarwal, Anita
   Kovach, Jaclyn L.
   Schwartz, Stephen G.
   Postel, Eric A.
   Brooks, Matthew
   Baratz, Keith H.
   Brown, William L.
   Brucker, Alexander J.
   Orlin, Anton
   Brown, Gary
   Ho, Allen
   Regillo, Carl
   Donoso, Larry
   Tian, Lifeng
   Kaderli, Brian
   Hadley, Dexter
   Hagstrom, Stephanie A.
   Peachey, Neal S.
   Klein, Ronald
   Klein, Barbara E. K.
   Gotoh, Norimoto
   Yamashiro, Kenji
   Ferris, Frederick, III
   Fagerness, Jesen A.
   Reynolds, Robyn
   Farrer, Lindsay A.
   Kim, Ivana K.
   Miller, Joan W.
   Corton, Marta
   Carracedo, Angel
   Sanchez-Salorio, Manuel
   Pugh, Elizabeth W.
   Doheny, Kimberly F.
   Brion, Maria
   DeAngelis, Margaret M.
   Weeks, Daniel E.
   Zack, Donald J.
   Chew, Emily Y.
   Heckenlively, John R.
   Yoshimura, Nagahisa
   Iyengar, Sudha K.
   Francis, Peter J.
   Katsanis, Nicholas
   Seddon, Johanna M.
   Haines, Jonathan L.
   Gorin, Michael B.
   Abecasis, Goncalo R.
   Swaroop, Anand
CA Complications Age-Related Macular
TI Genetic variants near TIMP3 and high-density lipoprotein-associated loci
   influence susceptibility to age-related macular degeneration
SO PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF
   AMERICA
LA English
DT Article
DE genome-wide association study; single nucleotide polymorphism
ID COMPLEMENT FACTOR-H; GENOME-WIDE ASSOCIATION; RISK-FACTORS; DISEASE;
   POLYMORPHISM; MACULOPATHY; COMMON; METAANALYSIS; DEPOSITS; DRUSEN
AB We executed a genome-wide association scan for age-related macular degeneration (AMD) in 2,157 cases and 1,150 controls. Our results validate AMD susceptibility loci near CFH (P < 10(-75)), ARMS2 (P < 10(-59)), C2/CFB (P < 10(-20)), C3 (P < 10(-9)), and CFI (P < 10(-6)). We compared our top findings with the Tufts/Massachusetts General Hospital genome-wide association study of advanced AMD (821 cases, 1,709 controls) and genotyped 30 promising markers in additional individuals (up to 7,749 cases and 4,625 controls). With these data, we identified a susceptibility locus near TIMP3 (overall P = 1.1 x 10(-11)), a metalloproteinase involved in degradation of the extracellular matrix and previously implicated in early-onset maculopathy. In addition, our data revealed strong association signals with alleles at two loci (LIPC, P = 1.3 x 10(-7); CETP, P = 7.4 x 10(-7)) that were previously associated with high-density lipoprotein cholesterol (HDL-c) levels in blood. Consistent with the hypothesis that HDL metabolism is associated with AMD pathogenesis, we also observed association with AMD of HDL-c-associated alleles near LPL (P = 3.0 x 10(-3)) and ABCA1 (P = 5.6 x 10(-4)). Multilocus analysis including all susceptibility loci showed that 329 of 331 individuals (99%) with the highest-risk genotypes were cases, and 85% of these had advanced AMD. Our studies extend the catalog of AMD associated loci, help identify individuals at high risk of disease, and provide clues about underlying cellular pathways that should eventually lead to new therapies.
C1 [Chen, Wei; Li, Yanming; Abecasis, Goncalo R.] Univ Michigan, Ctr Stat Genet, Ann Arbor, MI 48109 USA.
   [Edwards, Albert O.; Tosakulwong, Nirubol; Baratz, Keith H.; Brown, William L.] Mayo Clin, Rochester, MN 55906 USA.
   [Branham, Kari E.; Othman, Mohammad; Augustaitis, Katherine J.; Karoukis, Athanasios J.; Heckenlively, John R.] Univ Michigan, Ann Arbor, MI 48105 USA.
   [Jakobsdottir, Johanna; Conley, Yvette P.; Weeks, Daniel E.] Univ Pittsburgh, Pittsburgh, PA 15260 USA.
   [Pericak-Vance, Margaret A.; Scott, William K.; Kovach, Jaclyn L.; Schwartz, Stephen G.] Univ Miami, Miller Sch Med, Miami, FL USA.
   [Campochiaro, Peter A.; Tan, Perciliz L.; Zack, Donald J.; Katsanis, Nicholas] Johns Hopkins Univ, Sch Med, Baltimore, MD 21205 USA.
   [Klein, Michael L.; Francis, Peter J.] Oregon Hlth & Sci Univ, Portland, OR 97239 USA.
   [Kanda, Atsuhiro; Brooks, Matthew] NEI, Neurobiol Neurodegenerat & Repair Lab, Bethesda, MD 20892 USA.
   [Kopplin, Laura; Hagstrom, Stephanie A.; Peachey, Neal S.; Iyengar, Sudha K.] Case Western Reserve Univ, Cleveland, OH 44106 USA.
   [Agarwal, Anita; Haines, Jonathan L.] Vanderbilt Univ, Med Ctr, Nashville, TN 37232 USA.
   [Postel, Eric A.] Duke Univ, Med Ctr, Durham, NC 27705 USA.
   [Complications Age-Related Macular] Univ Penn, CAPT Coordinating Ctr, Philadelphia, PA 19104 USA.
   [Brown, Gary; Ho, Allen; Regillo, Carl] Mid Atlantic Retina, Cherry Hill, NJ 08002 USA.
   [Brown, Gary; Ho, Allen; Regillo, Carl] Thomas Jefferson Univ, Philadelphia, PA 19107 USA.
   [Donoso, Larry] Philadelphia Retina Endowment Fund, Philadelphia, PA 19107 USA.
   [Hagstrom, Stephanie A.; Peachey, Neal S.] Cleveland Clin Fdn, Cleveland, OH 44195 USA.
   [Peachey, Neal S.] Vet Affairs Med Ctr, Louis Stokes Cleveland Dept, Cleveland, OH 44106 USA.
   [Klein, Ronald; Klein, Barbara E. K.] Univ Wisconsin, Sch Med & Publ Hlth, Madison, WI 53705 USA.
   [Gotoh, Norimoto; Yamashiro, Kenji; Yoshimura, Nagahisa] Kyoto Univ, Grad Sch Med, Kyoto 6068501, Japan.
   [Fagerness, Jesen A.] Massachusetts Gen Hosp, Cambridge, MA 02114 USA.
   [Fagerness, Jesen A.] Broad Inst, Cambridge, MA 02114 USA.
   [Reynolds, Robyn; Seddon, Johanna M.] Tufts Med Ctr, Boston, MA 02111 USA.
   [Farrer, Lindsay A.] Boston Univ, Boston, MA 02215 USA.
   [Kim, Ivana K.; Miller, Joan W.; DeAngelis, Margaret M.] Harvard Univ, Sch Med, Massachusetts Eye & Ear Infirm, Boston, MA 02114 USA.
   [Corton, Marta; Brion, Maria] Complexo Hosp Univ Santiago, Santiago De Compostela 15706, Spain.
   [Corton, Marta; Carracedo, Angel; Brion, Maria] Univ Santiago de Compostela, Santiago De Compostela 15705, Spain.
   [Sanchez-Salorio, Manuel] Inst Gallego Oftalmol, Santiago De Compostela 15706, Spain.
   [Pugh, Elizabeth W.; Doheny, Kimberly F.] Johns Hopkins Sch Med, Ctr Inherited Dis Res, Baltimore, MD 21287 USA.
   [Seddon, Johanna M.] Tufts Univ, Sch Med, Boston, MA 02111 USA.
   [Gorin, Michael B.] Univ Calif Los Angeles, Los Angeles, CA 90095 USA.
C3 University of Michigan System; University of Michigan; Mayo Clinic;
   University of Michigan System; University of Michigan; Pennsylvania
   Commonwealth System of Higher Education (PCSHE); University of
   Pittsburgh; University of Miami; Johns Hopkins University; Oregon Health
   & Science University; National Institutes of Health (NIH) - USA; NIH
   National Eye Institute (NEI); Case Western Reserve University;
   Vanderbilt University; Duke University; University of Pennsylvania;
   Jefferson University; Cleveland Clinic Foundation; US Department of
   Veterans Affairs; Veterans Health Administration (VHA); Case Western
   Reserve University; Louis Stokes Cleveland Veterans Affairs Medical
   Center; University of Wisconsin System; University of Wisconsin Madison;
   Kyoto University; Harvard University; Massachusetts General Hospital;
   Harvard University; Massachusetts Institute of Technology (MIT); Broad
   Institute; Tufts Medical Center; Boston University; Harvard University;
   Harvard Medical School; Massachusetts Eye & Ear Infirmary; Complexo
   Hospitalario Universitario de Santiago de Compostela; Universidade de
   Santiago de Compostela; Johns Hopkins University; Johns Hopkins
   Medicine; Tufts University; University of California System; University
   of California Los Angeles
RP Abecasis, GR (通讯作者)，Univ Michigan, Ctr Stat Genet, Ann Arbor, MI 48109 USA.
EM goncalo@umich.edu; swaroopa@nei.nih.gov
RI Abecasis, Goncalo R/B-7840-2010; Katsanis, Nicholas/E-1837-2012;
   Carracedo, Angel/D-4257-2012; Hadley, Dexter/ABB-7568-2021;
   /S-1190-2019; Weeks, Daniel E/B-2995-2012; Peachey, Neal/G-5533-2010;
   Haines, Jonathan/C-3374-2012; Farrer, Lindsay/AAS-1035-2020; Branham,
   Kari/AAA-8336-2022; li, yan/GTI-4638-2022; DeAngelis, e/J-7863-2015;
   Brion, Maria/J-8059-2014; Brown, William/GXN-2777-2022
OI Carracedo, Angel/0000-0003-1085-8986; Hadley,
   Dexter/0000-0003-0990-4674; /0000-0001-7488-250X; Weeks, Daniel
   E/0000-0001-9410-7228; Peachey, Neal/0000-0002-4419-7226; Haines,
   Jonathan/0000-0002-4351-4728; Brion, Maria/0000-0001-7463-2148; Kim,
   Ivana/0000-0003-0310-6129; Klein, Ronald/0000-0002-4428-6237; Katsanis,
   Nicholas/0000-0002-2480-0171; Ho, Allen/0000-0003-3921-608X; Farrer,
   Lindsay/0000-0001-5533-4225; Folk, James/0000-0002-6271-2906;
   Jakobsdottir, Johanna/0000-0002-8019-9683; Boldt, H.
   Culver/0000-0002-7292-2093; Zack, Don/0000-0002-7966-1973; Russell,
   Stephen/0000-0003-3776-1367; Abecasis, Goncalo/0000-0003-1509-1825;
   Scott, William/0000-0001-9336-6404; Ferris,
   Frederick/0000-0002-4933-0639; Yamashiro, Kenji/0000-0001-9354-8558;
   Swaroop, Anand/0000-0002-1975-1141; Miller, Joan/0000-0003-2046-3996;
   Branham, Kari/0000-0002-2492-254X; Corton, Marta/0000-0003-0087-1626;
   Chen, Wei/0000-0001-7196-8703
FU National Eye Institute; National Institutes of Health [EY016862,
   EY007758, EY09859, EY012118, P30-EY014801, EY-014458, EY014467,
   HL084729, HG002651, HHSN268200782096C]; Foundation Fighting Blindness;
   Macula Vision Research Foundation; American Health Assistance
   Foundation; Research to Prevent Blindness; Pew Charitable Trusts; Mayo
   Clinic Foundation; Casey Macular Degeneration Center; Marion W. and
   Edward F. Knight AMD Fund; Harold and Pauline Price Foundation; National
   Genotyping Centre of Spain; Elmer and Sylvia Sramek Foundation; Center
   for Inherited Disease Research; NATIONAL EYE INSTITUTE [R01EY007758,
   R01EY009859, R01EY011309, ZIAEY000475, R01EY016862, R01EY012118,
   U10EY012118, R01EY009769, R01EY014467, P30EY014801, R01EY014458] Funding
   Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE
   [U01HL084729] Funding Source: NIH RePORTER; NATIONAL HUMAN GENOME
   RESEARCH INSTITUTE [R01HG002651] Funding Source: NIH RePORTER; NATIONAL
   INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007250] Funding Source: NIH
   RePORTER
FX We thank numerous clinicians, clinical staff, patients, and their
   families for their participation in and dedication to the project; the
   Kellogg Eye Center AMD group, the Complications of Age-Related Macular
   Degeneration Prevention Trial consortium, the Spanish AMD research
   group, staff at the National Center for Biotechnology Information, and
   Dr. Hemin Chin; and the Tufts Medical Center/Massachusetts General
   Hospital group for sharing genome-wide association results. This
   research was supported in part by the intramural program of the National
   Eye Institute and by National Institutes of Health Grants EY016862,
   EY007758, EY09859, EY012118, P30-EY014801, EY-014458, EY014467,
   HL084729, and HG002651, by the Foundation Fighting Blindness, the Macula
   Vision Research Foundation, the American Health Assistance Foundation,
   Research to Prevent Blindness, the Pew Charitable Trusts, the Mayo
   Clinic Foundation, the Casey Macular Degeneration Center Fund, the
   Marion W. and Edward F. Knight AMD Fund, the Harold and Pauline Price
   Foundation, National Genotyping Centre of Spain, and the Elmer and
   Sylvia Sramek Foundation. The Center for Inherited Disease Research,
   fully funded through a federal contract (HHSN268200782096C) from
   National Institutes of Health to The Johns Hopkins University, performed
   genotyping of the discovery cohort.
CR Abecasis GR, 2004, AM J HUM GENET, V74, P482, DOI 10.1086/382786
   Barrett JC, 2008, NAT GENET, V40, P955, DOI 10.1038/ng.175
   Curcio CA, 2005, EXP EYE RES, V81, P731, DOI 10.1016/j.exer.2005.04.012
   Devlin B, 1999, BIOMETRICS, V55, P997, DOI 10.1111/j.0006-341X.1999.00997.x
   Dewan A, 2006, SCIENCE, V314, P989, DOI 10.1126/science.1133807
   Edwards AO, 2005, SCIENCE, V308, P421, DOI 10.1126/science.1110189
   Fagerness JA, 2009, EUR J HUM GENET, V17, P100, DOI 10.1038/ejhg.2008.140
   Feng J, 2002, J NEUROSCI, V22, P4372, DOI 10.1523/JNEUROSCI.22-11-04372.2002
   Fisher SA, 2005, HUM MOL GENET, V14, P2257, DOI 10.1093/hmg/ddi230
   Frazer KA, 2007, NATURE, V449, P851, DOI 10.1038/nature06258
   Gold B, 2006, NAT GENET, V38, P458, DOI 10.1038/ng1750
   Goring HHH, 2001, AM J HUM GENET, V69, P1357, DOI 10.1086/324471
   Haines JL, 2005, SCIENCE, V308, P419, DOI 10.1126/science.1110359
   Jakobsdottir J, 2005, AM J HUM GENET, V77, P389, DOI 10.1086/444437
   Jakobsdottir J, 2009, PLOS GENET, V5, DOI 10.1371/journal.pgen.1000337
   Kanda A, 2007, P NATL ACAD SCI USA, V104, P16227, DOI 10.1073/pnas.0703933104
   Kathiresan S, 2009, NAT GENET, V41, P56, DOI 10.1038/ng.291
   KLEIN R, 1993, OPHTHALMOLOGY, V100, P406
   Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557
   Li M, 2006, NAT GENET, V38, P1049, DOI 10.1038/ng1871
   Maller J, 2006, NAT GENET, V38, P1055, DOI 10.1038/ng1873
   Maller JB, 2007, NAT GENET, V39, P1200, DOI 10.1038/ng2131
   Mullins RF, 2000, FASEB J, V14, P835, DOI 10.1096/fasebj.14.7.835
   Nair RP, 2009, NAT GENET, V41, P199, DOI 10.1038/ng.311
   Neale BM, 2010, P NATL ACAD SCI USA, V107, P7395, DOI 10.1073/pnas.0912019107
   Price AL, 2006, NAT GENET, V38, P904, DOI 10.1038/ng1847
   Rivera A, 2005, HUM MOL GENET, V14, P3227, DOI 10.1093/hmg/ddi353
   Swaroop A, 2009, ANNU REV GENOM HUM G, V10, P19, DOI 10.1146/annurev.genom.9.081307.164350
   Thornton T, 2007, AM J HUM GENET, V81, P321, DOI 10.1086/519497
   Tian C, 2008, PLOS GENET, V4, DOI 10.1371/journal.pgen.0040004
   Tomany SC, 2004, OPHTHALMOLOGY, V111, P1280, DOI 10.1016/j.ophtha.2003.11.010
   WEBER BHF, 1994, NAT GENET, V8, P352, DOI 10.1038/ng1294-352
   Willer CJ, 2008, NAT GENET, V40, P161, DOI 10.1038/ng.76
   Willer CJ, 2009, NAT GENET, V41, P25, DOI 10.1038/ng.287
   Yates JRW, 2007, NEW ENGL J MED, V357, P553, DOI 10.1056/NEJMoa072618
   Zeggini E, 2008, NAT GENET, V40, P638, DOI 10.1038/ng.120
NR 36
TC 396
Z9 412
U1 0
U2 25
PU NATL ACAD SCIENCES
PI WASHINGTON
PA 2101 CONSTITUTION AVE NW, WASHINGTON, DC 20418 USA
SN 0027-8424
J9 P NATL ACAD SCI USA
JI Proc. Natl. Acad. Sci. U. S. A.
PD APR 20
PY 2010
VL 107
IS 16
BP 7401
EP 7406
DI 10.1073/pnas.0912702107
PG 6
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA 586FU
UT WOS:000276892300054
PM 20385819
OA Bronze, Green Published
DA 2022-11-30
ER

PT J
AU Callanan, D
   Kunimoto, D
   Maturi, RK
   Patel, SS
   Staurenghi, G
   Wolf, S
   Cheetham, JK
   Hohman, TC
   Kim, K
   Lopez, FJ
   Schneider, S
AF Callanan, David
   Kunimoto, Derek
   Maturi, Raj K.
   Patel, Sunil S.
   Staurenghi, Giovanni
   Wolf, Sebastian
   Cheetham, Janet K.
   Hohman, Thomas C.
   Kim, Kimmie
   Lopez, Francisco J.
   Schneider, Susan
CA REACH Study Grp
TI Double-Masked, Randomized, Phase 2 Evaluation of Abicipar Pegol (an
   Anti-VEGF DARPin Therapeutic) in Neovascular Age-Related Macular
   Degeneration
SO JOURNAL OF OCULAR PHARMACOLOGY AND THERAPEUTICS
LA English
DT Article
DE abicipar pegol; age-related macular degeneration; anti-VEGF; choroidal
   neovascularization; optical coherence tomography; vascular endothelial
   growth factor
ID ENDOTHELIAL GROWTH-FACTOR; VISION-RELATED FUNCTION; ANKYRIN REPEAT
   PROTEIN; RANIBIZUMAB TREATMENT; RETINAL MORPHOLOGY; DOSING REGIMEN;
   VISUAL-ACUITY; AFLIBERCEPT; BINDING; TRIAL
AB Purpose: To evaluate safety and efficacy of the vascular endothelial growth factor binding protein abicipar pegol (abicipar) versus ranibizumab for neovascular age-related macular degeneration. Methods: Phase 2, multicenter, randomized, double-masked comparison (REACH study, stage 3). Patients (n=64) received intravitreal injections of abicipar 1mg or 2mg at baseline, week 4, and week 8 (3 injections) or ranibizumab 0.5mg at baseline and monthly (5 injections). Results: In the abicipar 1mg (n=25), abicipar 2mg (n=23), and ranibizumab (n=16) arms, respectively, least-squares mean best-corrected visual acuity (BCVA) change from baseline was +6.2, +8.3, and +5.6 letters at week 16 (primary endpoint) and +8.2, +10.0, and +5.3 letters at week 20. Least-squares mean central retinal thickness (CRT) reduction from baseline was 134, 113, and 131m at week 16 and 116, 103, and 138m at week 20. Intraocular inflammation adverse events (AEs), reported in 5/48 (10.4%) abicipar-treated patients, resolved without sustained vision loss or other sequelae. Conclusions: Abicipar demonstrated durability of effect: BCVA and CRT improvements were similar between abicipar and ranibizumab at weeks 16 and 20 (8 and 12 weeks after the last abicipar injection and 4 weeks after the last ranibizumab injection). No serious AEs were reported.
C1 [Callanan, David] Texas Retina Associates, 801 W Randol Mill Rd,Suite 101, Arlington, TX 76012 USA.
   [Kunimoto, Derek] Retinal Consultants Arizona, Phoenix, AZ USA.
   [Maturi, Raj K.] Midwest Eye Inst, Indianapolis, IN USA.
   [Maturi, Raj K.] Indiana Univ Sch Med, Dept Ophthalmol, Indianapolis, IN 46202 USA.
   [Patel, Sunil S.] West Texas Retina, Abilene, TX USA.
   [Staurenghi, Giovanni] Univ Milan, Luigi Sacco Hosp, Eye Clin, Dept Biomed & Clin Sci, Milan, Italy.
   [Wolf, Sebastian] Univ Bern, Bern Univ Hosp, Dept Ophthalmol, Bern, Switzerland.
   [Wolf, Sebastian] Univ Bern, Bern Univ Hosp, Bern Photog Reading Ctr, Inselspital, Bern, Switzerland.
   [Cheetham, Janet K.; Hohman, Thomas C.; Kim, Kimmie; Lopez, Francisco J.; Schneider, Susan] Allergan Plc, Irvine, CA USA.
   [Cheetham, Janet K.] Celeris Consulting, Laguna Niguel, CA USA.
   [Hohman, Thomas C.] Envis Consulting LLC, Ocean City, NJ USA.
C3 Indiana University System; Indiana University Bloomington; University of
   Milan; Luigi Sacco Hospital; University of Bern; University Hospital of
   Bern; University of Bern; University Hospital of Bern; AbbVie; Allergan
RP Callanan, D (通讯作者)，Texas Retina Associates, 801 W Randol Mill Rd,Suite 101, Arlington, TX 76012 USA.
EM dcallanan@texasretina.com
RI Wolf, Sebastian/B-8782-2008
OI Wolf, Sebastian/0000-0002-7467-7028
FU Allergan plc, Dublin, Ireland; Allergan plc
FX This study was sponsored by Allergan plc, Dublin, Ireland. The authors
   thank the investigators and patients who participated in the REACH
   study. They also acknowledge the research collaboration of Molecular
   Partners (Zurich, Switzerland) with Allergan in the clinical development
   of abicipar. Molecular Partners was responsible for preclinical and
   early clinical development of abicipar. Writing and editorial assistance
   was provided to the authors by Jamie L Weiss, PhD, Allergan plc,
   Bridgewater, NJ and funded by Allergan plc. Immunogenicity and
   pharmacokinetic support for the study was provided by Swati Gupta, PhD,
   Allergan plc, Irvine, CA. All authors met the ICMJE authorship criteria.
   Neither honoraria nor payments were made for authorship.
CR [Anonymous], 1999, CONTROL CLIN TRIALS, DOI 10.1016/S0197-2456(99)00031-8
   [Anonymous], 1994, BMJ, V308, P1540
   Avery RL, 2014, BRIT J OPHTHALMOL, V98, P1636, DOI 10.1136/bjophthalmol-2014-305252
   Bressler NM, 2010, OPHTHALMOLOGY, V117, P747, DOI 10.1016/j.ophtha.2009.09.002
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Campochiaro PA, 2013, AM J OPHTHALMOL, V155, P697, DOI 10.1016/j.ajo.2012.09.032
   Chang TS, 2007, ARCH OPHTHALMOL-CHIC, V125, P1460, DOI 10.1001/archopht.125.11.1460
   Eggel A, 2011, ALLERGY, V66, P961, DOI 10.1111/j.1398-9995.2011.02546.x
   Ferris FL, 2013, OPHTHALMOLOGY, V120, P844, DOI 10.1016/j.ophtha.2012.10.036
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P532
   Fung AE, 2007, AM J OPHTHALMOL, V143, P566, DOI 10.1016/j.ajo.2007.01.028
   Golbaz I, 2011, INVEST OPHTH VIS SCI, V52, P1599, DOI 10.1167/iovs.09-5018
   Heier JS, 2012, OPHTHALMOLOGY, V119, P2537, DOI 10.1016/j.ophtha.2012.09.006
   Holekamp NM, 2014, AM J OPHTHALMOL, V157, P825, DOI 10.1016/j.ajo.2013.12.018
   Holz FG, 2011, OPHTHALMOLOGY, V118, P663, DOI 10.1016/j.ophtha.2010.12.019
   Jaffe GJ, 2013, OPHTHALMOLOGY, V120, P1860, DOI 10.1016/j.ophtha.2013.01.073
   Kiss CG, 2009, INVEST OPHTH VIS SCI, V50, P2376, DOI 10.1167/iovs.08-2017
   Krohne TU, 2012, AM J OPHTHALMOL, V154, P682, DOI 10.1016/j.ajo.2012.03.047
   Papadopoulos N, 2012, ANGIOGENESIS, V15, P171, DOI 10.1007/s10456-011-9249-6
   Pluckthun A, 2015, ANNU REV PHARMACOL, V55, P489, DOI 10.1146/annurev-pharmtox-010611-134654
   Ritter M, 2014, BRIT J OPHTHALMOL, V98, P1629, DOI 10.1136/bjophthalmol-2014-305186
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Schmidt-Erfurth U, 2015, OPHTHALMOLOGY, V122, P822, DOI 10.1016/j.ophtha.2014.11.017
   Singer MA, 2012, OPHTHALMOLOGY, V119, P1175, DOI 10.1016/j.ophtha.2011.12.016
   Souied EH, 2014, AM J OPHTHALMOL, V158, P724, DOI 10.1016/j.ajo.2014.05.037
   Sulzbacher F, 2015, INVEST OPHTH VIS SCI, V56, P1158, DOI 10.1167/iovs.14-14298
   Vazquez-Lombardi R, 2015, DRUG DISCOV TODAY, V20, P1271, DOI 10.1016/j.drudis.2015.09.004
   Waldstein SM, 2016, OPHTHALMOLOGY, V123, P1521, DOI 10.1016/j.ophtha.2016.03.037
   Yonekawa Y, 2015, CSH PERSPECT MED, V5, DOI 10.1101/cshperspect.a017178
NR 29
TC 45
Z9 46
U1 0
U2 0
PU MARY ANN LIEBERT, INC
PI NEW ROCHELLE
PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA
SN 1080-7683
EI 1557-7732
J9 J OCUL PHARMACOL TH
JI J. Ocular Pharmacol. Ther.
PD DEC 1
PY 2018
VL 34
IS 10
BP 700
EP 709
DI 10.1089/jop.2018.0062
EA NOV 2018
PG 10
WC Ophthalmology; Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology; Pharmacology & Pharmacy
GA HD6AF
UT WOS:000449622500001
PM 30412448
OA Green Submitted, Green Published, hybrid
DA 2022-11-30
ER

PT J
AU Nakata, I
   Yamashiro, K
   Kawaguchi, T
   Nakanishi, H
   Akagi-Kurashige, Y
   Miyake, M
   Tsujikawa, A
   Yamada, R
   Matsuda, F
   Yoshimura, N
AF Nakata, Isao
   Yamashiro, Kenji
   Kawaguchi, Takahisa
   Nakanishi, Hideo
   Akagi-Kurashige, Yumiko
   Miyake, Masahiro
   Tsujikawa, Akitaka
   Yamada, Ryo
   Matsuda, Fumihiko
   Yoshimura, Nagahisa
CA Nagahama Study Grp
TI Calcium, ARMS2 Genotype, and Chlamydia Pneumoniae Infection in Early
   Age-Related Macular Degeneration: a Multivariate Analysis from the
   Nagahama Study
SO SCIENTIFIC REPORTS
LA English
DT Article
ID BLUE-MOUNTAINS EYE; POLYPOIDAL CHOROIDAL VASCULOPATHY; JAPANESE
   POPULATION; RISK-FACTORS; MACULOPATHY; ASSOCIATION; PROGRESSION;
   PREVALENCE; POLYMORPHISMS; INFLAMMATION
AB Although various risk factors have been identified for the development of age-related macular degeneration (AMD), risk factors of early AMD have been relatively under studied. We aimed to investigate AMD risk factors by evaluating multiple factors in association with large drusen, an important component of AMD, simultaneously. In a community-based cross-sectional survey in Japan, 971 large drusen cases and 3,209 controls were compared for 65 variables, including systemic, environmental, and genetic factors. The association and the effect size of each factor were evaluated with logistic regression analysis using a backward-elimination approach. Multivariate analyses identified a significant association in serum calcium level (odds ratio [OR] = 0.932, P = 1.05 x 10(-3)), ARMS2 A69S (rs10490924) genotype (OR = 1.046, P < 0.001), Chlamydia pneumoniae IgG (OR = 1.020, P = 0.0440), and age (OR = 1.013, P < 0.001) for large drusen. Hypocalcemia was observed in 7.2% of large drusen cases and in 5.5% of controls (P = 0.0490). C. pneumoniae infections was more frequent in large drusen cases (56.4%) than in conrols (51.7%, P = 0.00956). These results suggest that calcium, ARMS2 genotype, C. pneumonia infection, and age are significant factors in the development of the early stages of AMD.
C1 [Nakata, Isao; Yamashiro, Kenji; Nakanishi, Hideo; Akagi-Kurashige, Yumiko; Miyake, Masahiro; Tsujikawa, Akitaka; Yoshimura, Nagahisa] Kyoto Univ, Dept Ophthalmol, Grad Sch Med, Kyoto 606, Japan.
   [Nakata, Isao; Kawaguchi, Takahisa; Nakanishi, Hideo; Akagi-Kurashige, Yumiko; Miyake, Masahiro; Yamada, Ryo; Matsuda, Fumihiko] Kyoto Univ, Grad Sch Med, Ctr Genom Med Inserm U852, Kyoto, Japan.
C3 Kyoto University; Kyoto University
RP Yamashiro, K (通讯作者)，Kyoto Univ, Dept Ophthalmol, Grad Sch Med, Kyoto 606, Japan.
EM yamashro@kuhp.kyoto-u.ac.jp
RI Miyake, Masahiro/V-1261-2019; KOSUGI, Shinji/GYR-2946-2022
OI Miyake, Masahiro/0000-0001-7410-3764; Tsujikawa,
   Akitaka/0000-0003-0779-7799; Yamashiro, Kenji/0000-0001-9354-8558;
   Yamada, Ryo/0000-0002-1587-630X
FU Ministry of Education, Culture, Sports, Science and Technology of Japan;
   Japan Society for the Promotion of Science [19390442, 22791706,
   22791653]; Japanese National Society for the Prevention of Blindness;
   Takeda Science Foundation
FX We thank the participants of the Nagahama Study, Nagahama City Office,
   and the nonprofit organization Zero-ji Club for Health Promotion. The
   following investigators are core members of the Nagahama Study Group:
   Takeo Nakayama (Department of Health Informatics, Kyoto University
   School of Public Health, Kyoto, Japan), Akihiro Sekine (Department of
   Genome Informatics, Kyoto University School of Public Health, Kyoto,
   Japan), Shinji Kosugi (Department of Medical Ethics, Kyoto University
   School of Public Health, Kyoto, Japan), Yasuharu Tabara (Center for
   Genomic Medicine, Graduate School of Medicine, Kyoto University), and
   Michiaki Mishima (Department of Respiratory Medicine, Kyoto University
   Graduate School of Medicine, Kyoto, Japan). This study was partly
   supported by grants-in-aid from the following organizations: the
   Ministry of Education, Culture, Sports, Science and Technology of Japan
   (2006-2012); the Japan Society for the Promotion of Science (Nos.
   19390442, 22791706, and 22791653); the Japanese National Society for the
   Prevention of Blindness; and the Takeda Science Foundation (2008-2012).
   The funders had no role in study design, data collection and analysis,
   decision to publish, or preparation of the manuscript.
CR Anderson DH, 2002, AM J OPHTHALMOL, V134, P411, DOI 10.1016/S0002-9394(02)01624-0
   [Anonymous], 2012, INVEST OPHTHALMOL VI, V53, P794
   Boekhoorn SS, 2007, ARCH OPHTHALMOL-CHIC, V125, P1396, DOI 10.1001/archopht.125.10.1396
   BRINKMAN GL, 1963, AM REV RESPIR DIS, V87, P684
   Buch H, 2005, ACTA OPHTHALMOL SCAN, V83, P409, DOI 10.1111/J.1600-0420.2005.00492.x
   Chen JH, 2013, MOL VIS, V19, P944
   Day S, 2011, AM J OPHTHALMOL, V152, P1014, DOI 10.1016/j.ajo.2011.05.008
   de Jong PTVM, 2006, NEW ENGL J MED, V355, P1474, DOI 10.1056/NEJMra062326
   Despriet DDG, 2006, JAMA-J AM MED ASSOC, V296, P301, DOI 10.1001/jama.296.3.301
   Ferris FL, 2005, ARCH OPHTHALMOL-CHIC, V123, P1570
   Flinn JM, 2014, METALLOMICS, V6, P1223, DOI 10.1039/c4mt00058g
   Gold B, 2006, NAT GENET, V38, P458, DOI 10.1038/ng1750
   Goswami R, 2012, CLIN ENDOCRINOL, V77, P200, DOI 10.1111/j.1365-2265.2012.04353.x
   Haas P, 2009, EYE, V23, P2228, DOI 10.1038/eye.2008.422
   Hageman GS, 2005, P NATL ACAD SCI USA, V102, P7227, DOI 10.1073/pnas.0501536102
   Hayashi H, 2010, INVEST OPHTH VIS SCI, V51, P5914, DOI 10.1167/iovs.10-5554
   Hogg RE, 2006, PROG RETIN EYE RES, V25, P249, DOI 10.1016/j.preteyeres.2005.11.002
   Holliday EG, 2013, PLOS ONE, V8, DOI [10.1371/journal.pone.0082305, 10.1371/journal.pone.0053830]
   Hyman L, 2000, ARCH OPHTHALMOL-CHIC, V118, P351, DOI 10.1001/archopht.118.3.351
   Ishida O, 2003, BRIT J OPHTHALMOL, V87, P523, DOI 10.1136/bjo.87.5.523
   Jakobsdottir J, 2005, AM J HUM GENET, V77, P389, DOI 10.1086/444437
   Kalayoglu MV, 2005, GRAEF ARCH CLIN EXP, V243, P1080, DOI 10.1007/s00417-005-1169-y
   Kalayoglu MV, 2003, ARCH OPHTHALMOL-CHIC, V121, P478, DOI 10.1001/archopht.121.4.478
   Klein R, 2005, AM J OPHTHALMOL, V140, P35, DOI 10.1016/j.ajo.2005.01.051
   Klein R, 1997, OPHTHALMOLOGY, V104, P7, DOI 10.1016/S0161-6420(97)30368-6
   Klein R, 2003, OPHTHALMOLOGY, V110, P25, DOI 10.1016/S0161-6420(02)01565-8
   Miller DM, 2004, AM J OPHTHALMOL, V138, P323, DOI 10.1016/j.ajo.2004.03.018
   Nakata I, 2013, AM J OPHTHALMOL, V156, P1002, DOI 10.1016/j.ajo.2013.06.007
   Oshima Y, 2001, BRIT J OPHTHALMOL, V85, P1153, DOI 10.1136/bjo.85.10.1153
   Park JH, 2011, P NATL ACAD SCI USA, V108, P18026, DOI 10.1073/pnas.1114759108
   Robman L, 2005, AM J EPIDEMIOL, V161, P1013, DOI 10.1093/aje/kwi130
   Robman L, 2007, INVEST OPHTH VIS SCI, V48, P4007, DOI 10.1167/iovs.06-1434
   Seddon JM, 2003, ARCH OPHTHALMOL-CHIC, V121, P785, DOI 10.1001/archopht.121.6.785
   Smith W, 1996, ARCH OPHTHALMOL-CHIC, V114, P1518, DOI 10.1001/archopht.1996.01100140716016
   Tan JSL, 2007, OPHTHALMOLOGY, V114, P1143, DOI 10.1016/j.ophtha.2006.09.033
   Tomany SC, 2004, OPHTHALMOLOGY, V111, P1280, DOI 10.1016/j.ophtha.2003.11.010
   ULSHAFER RJ, 1987, INVEST OPHTH VIS SCI, V28, P683
   Yasuda M, 2009, OPHTHALMOLOGY, V116, P2135, DOI 10.1016/j.ophtha.2009.04.017
NR 38
TC 12
Z9 12
U1 0
U2 2
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 2045-2322
J9 SCI REP-UK
JI Sci Rep
PD MAR 20
PY 2015
VL 5
AR 9345
DI 10.1038/srep09345
PG 5
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA CD7SC
UT WOS:000351290700004
PM 25792034
OA Green Published, gold
DA 2022-11-30
ER

PT J
AU Sobrin, L
   Maller, JB
   Neale, BM
   Reynolds, RC
   Fagerness, JA
   Daly, MJ
   Seddon, JM
AF Sobrin, Lucia
   Maller, Julian B.
   Neale, Benjamin M.
   Reynolds, Robyn C.
   Fagerness, Jesen A.
   Daly, Mark J.
   Seddon, Johanna M.
TI Genetic profile for five common variants associated with age-related
   macular degeneration in densely affected families: a novel analytic
   approach
SO EUROPEAN JOURNAL OF HUMAN GENETICS
LA English
DT Article
DE AMD; complex trait; simulation; SNPs; liability threshold model
ID COMPLEMENT FACTOR-H; RISK; POLYMORPHISM
AB About 40% of the genetic variance of age-related macular degeneration (AMD) can be explained by a common variation at five common single-nucleotide polymorphisms (SNPs). We evaluated the degree to which these known variants explain the clustering of AMD in a group of densely affected families. We sought to determine whether the actual number of risk alleles at the five variants in densely affected families matched the expected number. Using data from 322 families with AMD, we used a simulation strategy to generate comparison groups of families and determined whether their genetic profile at the known AMD risk loci differed from the observed genetic profile, given the density of disease observed. Overall, the genotypic loads for the five SNPs in the families did not deviate significantly from the genotypic loads predicted by the simulation. However, for a subset of densely affected families, the mean genotypic load in the families was significantly lower than the expected load determined from the simulation. Given that these densely affected families may harbor rare, more penetrant variants for AMD, linkage analyses and resequencing targeting these families may be an effective approach to finding additional implicated genes. European Journal of Human Genetics (2010) 18, 496-501; doi:10.1038/ejhg.2009.185; published online 21 October 2009
C1 [Sobrin, Lucia] Massachusetts Eye & Ear Infirm, Dept Ophthalmol, Boston, MA 02114 USA.
   [Sobrin, Lucia; Daly, Mark J.] Harvard Univ, Sch Med, Boston, MA USA.
   [Sobrin, Lucia; Maller, Julian B.; Neale, Benjamin M.; Fagerness, Jesen A.; Daly, Mark J.] Massachusetts Gen Hosp, Ctr Human Genet Res, Boston, MA 02114 USA.
   [Maller, Julian B.; Neale, Benjamin M.; Fagerness, Jesen A.; Daly, Mark J.] Broad Inst Harvard & MIT, Program Med & Populat Genet, Cambridge, MA USA.
   [Maller, Julian B.] Univ Oxford, Dept Stat, Oxford OX1 3TG, England.
   [Neale, Benjamin M.] Kings Coll London, Inst Psychiat, Social Genet & Dev Psychiat Ctr, London WC2R 2LS, England.
   [Seddon, Johanna M.] Tufts Univ, Sch Med, Dept Ophthalmol, Boston, MA 02111 USA.
   [Reynolds, Robyn C.; Seddon, Johanna M.] Ophthalm Epidemiol & Genet Serv, Tufts Med Ctr, New England Eye Ctr, Boston, MA 02111 USA.
C3 Harvard University; Massachusetts Eye & Ear Infirmary; Harvard
   University; Harvard Medical School; Harvard University; Massachusetts
   General Hospital; Harvard University; Massachusetts Institute of
   Technology (MIT); Broad Institute; University of Oxford; University of
   London; King's College London; Tufts University; Tufts Medical Center
RP Seddon, JM (通讯作者)，Ophthalm Epidemiol & Genet Serv, Tufts Med Ctr, New England Eye Ctr, 800 Washington St 450, Boston, MA 02111 USA.
EM jseddon@tuftsmedicalcenter.org
RI Daly, Mark J/B-2453-2017
OI Daly, Mark J/0000-0002-0949-8752; Maller, Julian/0000-0002-1565-9559;
   Sobrin, Lucia/0000-0003-1575-0819
FU National Eye Institute [EY16335-02]; US National Institutes of Health
   [EY11309]; Foundation Fighting Blindness; Massachusetts Lions Research
   Fund, Inc; Ophthalmic Epidemiology and Genetics Service, Tufts Medical
   Center; Broad Institute Center for Genotyping and Analysis; NCRR [U54
   RR020278]; Prevent Blindness Career Development Award; Research to
   Prevent Blindness; NATIONAL CENTER FOR RESEARCH RESOURCES [U54RR020278]
   Funding Source: NIH RePORTER; NATIONAL EYE INSTITUTE [K12EY016335,
   R01EY011309] Funding Source: NIH RePORTER
FX This research was supported by EY16335-02 (National Eye Institute K12
   Harvard Vision Clinician Scientist Development Award); EY11309 from the
   US National Institutes of Health (National Eye Institute RO1 Grant,
   JMS); the Foundation Fighting Blindness; Massachusetts Lions Research
   Fund, Inc; the Macular Degeneration Research Fund, Ophthalmic
   Epidemiology and Genetics Service, Tufts Medical Center; and by the
   Broad Institute Center for Genotyping and Analysis, supported by Grant
   U54 RR020278 from the NCRR. LS is a recipient of a Research to Prevent
   Blindness Career Development Award and JMS was a recipient of the
   Research to Prevent Blindness Lew R Wasserman Award.
CR Edwards AO, 2005, SCIENCE, V308, P421, DOI 10.1126/science.1110189
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P564
   Gold B, 2006, NAT GENET, V38, P458, DOI 10.1038/ng1750
   Haddad S, 2006, SURV OPHTHALMOL, V51, P316, DOI 10.1016/j.survophthal.2006.05.001
   Hageman GS, 2005, P NATL ACAD SCI USA, V102, P7227, DOI 10.1073/pnas.0501536102
   Haines JL, 2005, SCIENCE, V308, P419, DOI 10.1126/science.1110359
   Klein R, 2004, AM J OPHTHALMOL, V137, P486, DOI 10.1016/j.ajo.2003.11.069
   Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557
   Maller J, 2006, NAT GENET, V38, P1055, DOI 10.1038/ng1873
   Montezuma Sandra R, 2007, Semin Ophthalmol, V22, P229, DOI 10.1080/08820530701745140
   Pearson K, 1901, PHILOS T R SOC LOND, V195, P79
   Rivera A, 2005, HUM MOL GENET, V14, P3227, DOI 10.1093/hmg/ddi353
   Seddon JM, 2006, OPHTHALMOLOGY, V113, P260, DOI 10.1016/j.ophtha.2005.11.001
   Seddon JM, 2005, ARCH OPHTHALMOL-CHIC, V123, P321, DOI 10.1001/archopht.123.3.321
   Seddon JM, 2003, AM J HUM GENET, V73, P780, DOI 10.1086/378505
   Seddon JM, 2003, ARCH OPHTHALMOL-CHIC, V121, P785, DOI 10.1001/archopht.121.6.785
NR 16
TC 23
Z9 23
U1 0
U2 1
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 1018-4813
EI 1476-5438
J9 EUR J HUM GENET
JI Eur. J. Hum. Genet.
PD APR
PY 2010
VL 18
IS 4
BP 496
EP 501
DI 10.1038/ejhg.2009.185
PG 6
WC Biochemistry & Molecular Biology; Genetics & Heredity
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Genetics & Heredity
GA 571CF
UT WOS:000275726900020
PM 19844262
OA Green Accepted, Bronze, Green Published
DA 2022-11-30
ER

PT J
AU Nowak, MS
   Jurowski, P
   Grzybowski, A
   Gos, R
   Pastuszka, M
   Kapica, A
   Smigielski, J
AF Nowak, Michal S.
   Jurowski, Piotr
   Grzybowski, Andrzej
   Gos, Roman
   Pastuszka, Miroslaw
   Kapica, Andrzej
   Smigielski, Janusz
TI A prospective study on different methods for the treatment of choroidal
   neovascularization. The efficacy of verteporfin photodynamic therapy,
   intravitreal bevacizumab and transpupillary thermotherapy in patients
   with neovascular age-related macular degeneration
SO MEDICAL SCIENCE MONITOR
LA English
DT Article
DE age-related macular degeneration; intravitreal bevacizumab; verteporfin
   photodynamic therapy; transpupillary thermotherapy
ID RANIBIZUMAB; POLYMORPHISM; INJECTION; OUTCOMES; AVASTIN; GENE
AB Background: The aim of this study was to compare the efficacy of verteporfin photodynamic therapy (PDT), intravitreal injections of bevacizumab (IVB) and transpupillary thermotherapy (TIT) in patients with neovascular age-related macular degeneration (AMD).
   Material/Methods: The study design was a prospective, interventional, comparative case series. Between December 2006 and March 2009, 426 eyes of 426 consecutive patients presenting with neovascular AMD were included into the study. Patients presented with subfoveal CNV predominantly classic, minimally classic, and occult with no classic component; lesion size less than 5000 pm in the greatest linear dimension, and the area of hemorrhages <1/3 were randomized to receive either PDT (group I) or IVB (group II) in a 1:1 ratio. Other patients with CNV were included into the group III and received TTT.
   Results: One hundred eyes were treated with PDT. Mean baseline logMAR BCVA was 0.62 and final visual acuity decreased to 0.74 (p<0.05, Wilcoxon test); 104 eyes were treated with IVB. Mean baseline BCVA was 0.82 and final visual acuity increased to 0.79 (p>0.05, Wilcoxon test); 222 patients were treated with TTT. Mean baseline BCVA was 1.10 and final visual acuity decreased to 1.15 (p>0.05, Wilcoxon test). Among all eyes the average number of treatment sessions was 2.34 (SD 1.17).
   Conclusions: Our study shows that IVB injections had the best efficacy in the improvement of final BCVA. However, both IVB and TTT demonstrated good stabilization of vision. Although after PDT final BCVA was significantly worse from baseline, it may also be beneficial for some patients with neovascular age-related macular degeneration.
C1 [Nowak, Michal S.; Jurowski, Piotr; Gos, Roman; Pastuszka, Miroslaw; Kapica, Andrzej] Med Univ Lodz, Dept Ophthalmol & Visual Rehabil, PL-90549 Lodz, Poland.
   [Grzybowski, Andrzej] City Hosp, Dept Ophthalmol, Poznan, Poland.
   [Smigielski, Janusz] Med Univ Lodz, Dept Informat & Med Stat, PL-90549 Lodz, Poland.
C3 Medical University Lodz; Medical University Lodz
RP Nowak, MS (通讯作者)，Med Univ Lodz, Dept Ophthalmol & Visual Rehabil, Zeromskiego 113 St, PL-90549 Lodz, Poland.
EM michaelnovak@interia.pl
RI Grzybowski, A/E-4486-2010; Nowak, Michal Szymon/W-6290-2019
OI Grzybowski, A/0000-0002-3724-2391; Nowak, Michal
   Szymon/0000-0001-6304-1545
CR Arias L, 2008, BRIT J OPHTHALMOL, V92, P1636, DOI 10.1136/bjo.2008.141721
   Augustin AJ, 2009, CLIN OPHTHALMOL, V3, P175
   Barbazetto I, 2003, ARCH OPHTHALMOL-CHIC, V121, P1253
   Bashshur ZF, 2009, AM J OPHTHALMOL, V148, P59, DOI 10.1016/j.ajo.2009.02.006
   Blumenkranz MS, 2001, ARCH OPHTHALMOL-CHIC, V119, P198
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Caputo M, 2011, CURR DRUG TARGETS, V12, P234, DOI 10.2174/138945011794182791
   Chan WM, 2006, BRIT J OPHTHALMOL, V90, P337, DOI 10.1136/bjo.2005.081299
   Cheng CL, 2009, SINGAP MED J, V50, P126
   Christoforidis JB, 2011, CURR DRUG TARGETS, V12, P221
   Conrad PW, 2008, CLIN OPHTHALMOL, V2, P727
   Das RA, 2011, CURR DRUG TARGETS, V12, P182
   Arevalo JF, 2010, OPHTHALMOLOGY, V117, P1974, DOI 10.1016/j.ophtha.2010.01.056
   Ferraz D, 2010, EUR J OPHTHALMOL, V20, P740, DOI 10.1177/112067211002000415
   Fong DS, 2010, OPHTHALMOLOGY, V117, P298, DOI 10.1016/j.ophtha.2009.07.023
   Kowalski M, 2010, MED SCI MONITOR, V16, pCR190
   Landa G, 2009, OPHTHALMOLOGICA, V223, P370, DOI 10.1159/000227783
   Melamud A, 2008, AM J OPHTHALMOL, V146, P91, DOI 10.1016/j.ajo.2008.03.014
   Newsom RSB, 2001, BRIT J OPHTHALMOL, V85, P173, DOI 10.1136/bjo.85.2.173
   Nowak Michal, 2005, Klin Oczna, V107, P715
   Odergren A, 2008, BRIT J OPHTHALMOL, V92, P757, DOI 10.1136/bjo.2007.133561
   Odergren A, 2010, ACTA OPHTHALMOL, V88, P426, DOI 10.1111/j.1755-3768.2009.01567.x
   Okada K, 2009, CLIN OPHTHALMOL, V3, P483
   Reichel E, 1999, OPHTHALMOLOGY, V106, P1908, DOI 10.1016/S0161-6420(99)90400-1
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Schouten JSAG, 2009, GRAEF ARCH CLIN EXP, V247, P1, DOI 10.1007/s00417-008-0952-y
   Smith BT, 2008, RETINA-J RET VIT DIS, V28, P675, DOI 10.1097/IAE.0b013e31816b316e
   Stepien KE, 2009, RETINA-J RET VIT DIS, V29, P1067, DOI 10.1097/IAE.0b013e3181b1bb06
   Subramanian ML, 2010, EYE, V24, P1708, DOI 10.1038/eye.2010.147
   Wan MJ, 2010, CAN J OPHTHALMOL, V45, P375, DOI 10.3129/i10-011
   Wysokinski D, 2011, MED SCI MONITOR, V17, pCR449, DOI 10.12659/MSM.881906
   Yip PP, 2009, BRIT J OPHTHALMOL, V93, P754, DOI 10.1136/bjo.2008.150987
NR 32
TC 8
Z9 10
U1 0
U2 6
PU INT SCIENTIFIC INFORMATION, INC
PI MELVILLE
PA 150 BROADHOLLOW RD, STE 114, MELVILLE, NY 11747 USA
SN 1643-3750
J9 MED SCI MONITOR
JI Med. Sci. Monitor
PD JUN
PY 2012
VL 18
IS 6
BP CR374
EP CR380
DI 10.12659/MSM.882907
PG 7
WC Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Research & Experimental Medicine
GA 995WG
UT WOS:000308044600014
PM 22648253
OA Green Published, Green Submitted
DA 2022-11-30
ER

PT J
AU Ma, ZX
   Liu, JJ
   Li, J
   Jiang, H
   Kong, J
AF Ma, Zhongxu
   Liu, Jingjing
   Li, Jing
   Jiang, Hao
   Kong, Jun
TI Klotho Levels are Decreased and Associated with Enhanced Oxidative
   Stress and Inflammation in the Aqueous Humor in Patients with Exudative
   Age-related Macular Degeneration
SO OCULAR IMMUNOLOGY AND INFLAMMATION
LA English
DT Article
DE Age-related macular degeneration; klotho; oxidative stress; inflammation
ID ENDOTHELIAL GROWTH-FACTOR; ACUTE KIDNEY INJURY; EPITHELIAL-CELLS;
   PROTEIN KLOTHO; IN-VITRO; EXPRESSION; DEFICIENCY; ACTIVATION; CYTOKINES;
   MEMBRANES
AB Purpose To evaluate anti-aging protein klotho levels in the aqueous humor and its association with oxidative stress and inflammation in patients with age-related macular degeneration (AMD). Methods Levels of klotho, oxidative, and antioxidative stress markers, and proinflammatory and anti-inflammatory markers in the aqueous humor from 28 patients with exudative AMD and 35 age-matched controls were measured. Results Patients with AMD had lower levels of klotho, which were negatively correlated with macular lesion size. Patients with AMD also exhibited increased levels of 8-hydroxy-2MODIFIER LETTER PRIME-deoxyguanosine (8-OHdG) and interleukin (IL)-6 but not tumor necrosis factor-alpha, and decreased levels of total antioxidant status (TAS) and IL-10. Moreover, levels of klotho were negatively correlated with levels of 8-OHdG and IL-6, but positively correlated with levels of TSA and IL-10. Conclusion Klotho levels in the aqueous humor are decreased and associated with oxidative stress and inflammation in patients with exudative AMD.
C1 [Ma, Zhongxu; Li, Jing; Jiang, Hao] Tianjin Med Univ, Tianjin Eye Hosp, Clin Coll Ophthalmol, Tianjin Key Lab Ophthalmol & Vis Sci, Tianjin 300020, Peoples R China.
   [Liu, Jingjing; Kong, Jun] China Med Univ, Affiliated Hosp 4, Prov Key Lab Lens Res, Shenyang 110005, Liaoning, Peoples R China.
C3 Tianjin Medical University; China Medical University
RP Ma, ZX (通讯作者)，Tianjin Med Univ, Tianjin Eye Hosp, Clin Coll Ophthalmol, Tianjin Key Lab Ophthalmol & Vis Sci, Tianjin 300020, Peoples R China.; Kong, J (通讯作者)，China Med Univ, Affiliated Hosp 4, Prov Key Lab Lens Res, Shenyang 110005, Liaoning, Peoples R China.
EM mazhongxu-teh@outlook.com; kongjun1970@yahoo.com
FU Science Foundation of Tianjin Eye Hospital [YKYB1909]
FX This work was supported by Science Foundation of Tianjin Eye Hospital
   (No. YKYB1909).
CR Agrawal R, 2019, INVEST OPHTH VIS SCI, V60, P376, DOI 10.1167/iovs.18-24387
   Ahoor MH, 2016, J GLAUCOMA, V25, P919, DOI 10.1097/IJG.0000000000000553
   Ammar MJ, 2020, CURR OPIN OPHTHALMOL, V31, P215, DOI 10.1097/ICU.0000000000000657
   Anand R, 2000, OPHTHALMOLOGY, V107, P2224
   Ayoub T, 2009, J ROY SOC MED, V102, P56, DOI 10.1258/jrsm.2009.080298
   Chew EY, 2013, JAMA-J AM MED ASSOC, V309, P2005, DOI 10.1001/jama.2013.4997
   Chung EJ, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-17744-w
   Colak E, 2018, CURR EYE RES, V43, P659, DOI 10.1080/02713683.2018.1437452
   Dalton GD, 2017, FRONT ENDOCRINOL, V8, DOI 10.3389/fendo.2017.00323
   Hernandez-Zimbron LF, 2018, OXID MED CELL LONGEV, V2018, DOI 10.1155/2018/8374647
   Frank RN, 1996, AM J OPHTHALMOL, V122, P393, DOI 10.1016/S0002-9394(14)72066-5
   Funk M, 2009, OPHTHALMOLOGY, V116, P2393, DOI 10.1016/j.ophtha.2009.05.039
   Gao W, 2015, CLIN SCI, V129, P1011, DOI 10.1042/CS20150273
   George AK, 2018, INT J OPHTHALMOL-CHI, V11, P881, DOI 10.18240/ijo.2018.05.26
   GROSSNIKLAUS HE, 1992, AM J OPHTHALMOL, V114, P464, DOI 10.1016/S0002-9394(14)71859-8
   Grossniklaus HE, 2002, MOL VIS, V8, P119
   Guo Y, 2018, BBA-MOL BASIS DIS, V1864, P238, DOI 10.1016/j.bbadis.2017.09.029
   Hicklin DJ, 2005, J CLIN ONCOL, V23, P1011, DOI 10.1200/JCO.2005.06.081
   Hollyfield JG, 2008, NAT MED, V14, P194, DOI 10.1038/nm1709
   Hsia CCW, 2017, BONE, V100, P100, DOI 10.1016/j.bone.2017.03.047
   Imura A, 2004, FEBS LETT, V565, P143, DOI 10.1016/j.febslet.2004.03.090
   Izumi-Nagai K, 2007, AM J PATHOL, V170, P2149, DOI 10.2353/ajpath.2007.061018
   Kannan R, 2006, MOL VIS, V12, P1649
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1417, DOI 10.1001/archopht.119.10.1417
   Kauppinen A, 2016, CELL MOL LIFE SCI, V73, P1765, DOI 10.1007/s00018-016-2147-8
   Kimura T, 2018, AM J PHYSIOL-RENAL, V315, pF345, DOI 10.1152/ajprenal.00486.2017
   Kokkinaki M, 2011, MOL BIOL CELL, V22
   Kokkinaki M, 2013, J NEUROSCI, V33, P16346, DOI 10.1523/JNEUROSCI.0402-13.2013
   Kuroki M, 1996, J CLIN INVEST, V98, P1667, DOI 10.1172/JCI118962
   Kvanta A, 1996, INVEST OPHTH VIS SCI, V37, P1929
   Lau LI, 2010, INVEST OPHTH VIS SCI, V51, P5486, DOI 10.1167/iovs.10-5663
   Li XL, 2019, LIFE SCI, V234, DOI 10.1016/j.lfs.2019.116773
   Lim LS, 2012, LANCET, V379, P1728, DOI 10.1016/S0140-6736(12)60282-7
   Litwinska Z, 2019, FRONT AGING NEUROSCI, V11, DOI 10.3389/fnagi.2019.00286
   Maltese G, 2017, J CELL MOL MED, V21, P621, DOI 10.1111/jcmm.12996
   Martin-Nunez E, 2017, CLIN SCI, V131, P2601, DOI 10.1042/CS20171242
   Matsumura N, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0039890
   McLeod DS, 2009, INVEST OPHTH VIS SCI, V50, P4982, DOI 10.1167/iovs.09-3639
   Mencke R, 2017, AGEING RES REV, V35, P124, DOI 10.1016/j.arr.2016.09.001
   Moos WH, 2020, BIORESEARCH OPEN ACC, V9, P94, DOI 10.1089/biores.2020.0004
   Motohashi R, 2018, J INFLAMM-LOND, V15, DOI 10.1186/s12950-018-0203-x
   Nagineni CN, 2012, J CELL PHYSIOL, V227, P116, DOI 10.1002/jcp.22708
   Oh HJ, 2019, AM J PHYSIOL-RENAL, V317, pF881, DOI 10.1152/ajprenal.00297.2018
   Ohki Y, 2005, FASEB J, V19, P2005, DOI 10.1096/fj.04-3496fje
   Olejnik A, 2018, BIOMED RES INT, V2018, DOI 10.1155/2018/5171945
   Ravikumar P, 2016, J APPL PHYSIOL, V120, P723, DOI 10.1152/japplphysiol.00792.2015
   Reish NJ, 2013, INVEST OPHTH VIS SCI, V54, P6675, DOI 10.1167/iovs.13-12550
   Rivera JC, 2017, OXID MED CELL LONGEV, V2017, DOI 10.1155/2017/3940241
   Slominski B, 2018, BBA-MOL BASIS DIS, V1864, P758, DOI 10.1016/j.bbadis.2017.12.015
   Takenaka T, 2019, ACTA PHYSIOL, V225, DOI 10.1111/apha.13190
   Tong JP, 2006, AM J OPHTHALMOL, V141, P456, DOI 10.1016/j.ajo.2005.10.012
   Wang JY, 2009, J CELL PHYSIOL, V220, P119, DOI 10.1002/jcp.21742
   Wang YH, 2009, AGEING RES REV, V8, P43, DOI 10.1016/j.arr.2008.10.002
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
   Yamamoto M, 2005, J BIOL CHEM, V280, P38029, DOI 10.1074/jbc.M509039200
   Yang SQ, 2016, DRUG DES DEV THER, V10, P1857, DOI 10.2147/DDDT.S97653
NR 56
TC 5
Z9 6
U1 3
U2 8
PU TAYLOR & FRANCIS INC
PI PHILADELPHIA
PA 530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA
SN 0927-3948
EI 1744-5078
J9 OCUL IMMUNOL INFLAMM
JI Ocul. Immunol. Inflamm.
PD APR 3
PY 2022
VL 30
IS 3
BP 630
EP 637
DI 10.1080/09273948.2020.1828488
EA OCT 2020
PG 8
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 3I3WA
UT WOS:000577382000001
PM 33048602
DA 2022-11-30
ER

PT J
AU Tuerksever, C
   Pruente, C
   Hatz, K
AF Tuerksever, Cengiz
   Pruente, Christian
   Hatz, Katja
TI High frequency SD-OCT follow-up leading to up to biweekly intravitreal
   ranibizumab treatment in neovascular age-related macular degeneration
SO SCIENTIFIC REPORTS
LA English
DT Article
AB A remarkable proportion of neovascular age-related macular degeneration (nAMD) patients respond rather poorly to ranibizumab treatment, in spite of the minimum 4-week follow-up and treatment interval. Usually, retreatments are based on nAMD activity as evaluated by Spectral-domain Optical coherence Tomography (SD-OCT), biomicroscopic fundus examination and visual acuity changes. In this prospective pilot study, we aimed to study SD-OCT changes in a high-frequent follow-up manner (weekly (month 0-6), biweekly (month 7-12)) throughout the first year, which consequently led to intravitreal ranibizumab being administered up to biweekly. Best corrected visual acuity (BCVA) was already significantly improved at week 2. Central retinal thickness (CRT), intraretinal and subretinal fluid (SRF) were significantly improved from week 1 onwards. Half of the patients showed nAMD activity at week 2 or 3 and received the first retreatment earlier than 4 weeks after baseline injection. In total, 46% of retreatments were already applied 2 or 3 weeks after the previous treatment. Greater range of CRT and SRF fluctuation during follow-up was associated with lower final BCVA. Lower baseline BCVA and better SRF improvement at week 2 was associated with greater BCVA improvement. In conclusion, high-frequency SD-OCT follow-up provided a good option for adapting treatment in nAMD individually.
C1 [Tuerksever, Cengiz; Hatz, Katja] Vista Klin Binningen, Hauptstr 55, CH-4102 Binningen, Switzerland.
   [Pruente, Christian] Univ Basel, Dept Ophthalmol, Basel, Switzerland.
   [Pruente, Christian] Inst Mol & Clin Ophthalmol Basel IOB, Basel, Switzerland.
   [Hatz, Katja] Univ Basel, Fac Med, Basel, Switzerland.
C3 University of Basel; University of Basel; University of Geneva
RP Hatz, K (通讯作者)，Vista Klin Binningen, Hauptstr 55, CH-4102 Binningen, Switzerland.; Hatz, K (通讯作者)，Univ Basel, Fac Med, Basel, Switzerland.
EM katja.hatz@vista.ch
FU Novartis Switzerland
FX Novartis Switzerland supported this investigator initiated study in part
   (study fees for study conduction). There was no supervision, board
   support, writing or correction support provided by Novartis. Novartis
   Switzerland had no influence on the study or the content of the
   manuscript.
CR Aghdam KA, 2015, INVEST OPHTH VIS SCI, V56, P6448, DOI 10.1167/iovs.15-17338
   Amoaku WM, 2015, EYE, V29, P721, DOI 10.1038/eye.2015.48
   Ashraf M, 2018, ACTA OPHTHALMOL, V96, P120, DOI 10.1111/aos.13565
   Augustin AJ, 2007, RETINA-J RET VIT DIS, V27, P133, DOI 10.1097/IAE.0b013e3180323de7
   Berg K, 2015, OPHTHALMOLOGY, V122, P146, DOI 10.1016/j.ophtha.2014.07.041
   Bikbov MM, 2020, SCI REP-UK, V10, DOI 10.1038/s41598-020-69439-4
   Bloch SB, 2012, AM J OPHTHALMOL, V153, P209, DOI 10.1016/j.ajo.2011.10.016
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Chan CK, 2015, EYE, V29, P80, DOI 10.1038/eye.2014.233
   Coscas G, 2013, OPHTHALMOLOGICA, V229, P32, DOI 10.1159/000342159
   Grzybowski A, 2018, OPHTHALMOLOGICA, V239, P181, DOI 10.1159/000486145
   Guymer RH, 2019, OPHTHALMOLOGY, V126, P723, DOI 10.1016/j.ophtha.2018.11.025
   Hatz K, 2018, OPHTHALMOLOGICA, V239, P205, DOI 10.1159/000485852
   Hatz K, 2017, RETINA-J RET VIT DIS, V37, P1185, DOI 10.1097/IAE.0000000000001318
   Hatz K, 2016, BRIT J OPHTHALMOL, V100, P1341, DOI 10.1136/bjophthalmol-2015-307299
   Hatz K, 2015, OPHTHALMOLOGICA, V233, P66, DOI 10.1159/000367603
   Ho AC, 2014, OPHTHALMOLOGY, V121, P2181, DOI 10.1016/j.ophtha.2014.05.009
   Hsia Y, 2020, GRAEF ARCH CLIN EXP, V258, P273, DOI 10.1007/s00417-019-04546-1
   Landa G, 2011, RETINA-J RET VIT DIS, V31, P364, DOI 10.1097/IAE.0b013e3181e91132
   Martin DF, 2012, OPHTHALMOLOGY, V119, DOI 10.1016/j.ophtha.2012.03.053
   Mimouni M, 2018, JPN J OPHTHALMOL, V62, P652, DOI 10.1007/s10384-018-0619-0
   Miura M, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-03529-8
   Novais EA, 2016, J OPHTHALMOL, V2016, DOI 10.1155/2016/6971831
   Real JP, 2018, GRAEF ARCH CLIN EXP, V256, P1079, DOI 10.1007/s00417-018-3974-0
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Schmidt-Erfurth U, 2016, PROG RETIN EYE RES, V50, P1, DOI 10.1016/j.preteyeres.2015.07.007
   Segal O, 2016, RETINA-J RET VIT DIS, V36, P2175, DOI 10.1097/IAE.0000000000001033
   Seguin-Greenstein S, 2016, J OPHTHALMOL, V2016, DOI 10.1155/2016/4095852
   Sharma S, 2016, OPHTHALMOLOGY, V123, P865, DOI 10.1016/j.ophtha.2015.12.002
   Stewart MW, 2012, RETINA-J RET VIT DIS, V32, P434, DOI 10.1097/IAE.0B013E31822C290F
   Takahashi H, 2018, CLIN OPHTHALMOL, V12, P369, DOI 10.2147/OPTH.S151999
   Wecker T, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-38934-8
   Witkin AJ, 2017, SEMIN OPHTHALMOL, V32, P309, DOI 10.3109/08820538.2015.1072222
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
   Ying GS, 2018, OPHTHALMOL RETINA, V2, P525, DOI 10.1016/j.oret.2017.10.003
   Ying GS, 2013, OPHTHALMOLOGY, V120, P122, DOI 10.1016/j.ophtha.2012.07.042
   Zandi S, 2017, OSLI RETINA, V48, P326, DOI 10.3928/23258160-20170329-07
NR 37
TC 2
Z9 2
U1 0
U2 0
PU NATURE RESEARCH
PI BERLIN
PA HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY
SN 2045-2322
J9 SCI REP-UK
JI Sci Rep
PD MAR 25
PY 2021
VL 11
IS 1
AR 6816
DI 10.1038/s41598-021-86348-2
PG 10
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA RG7EY
UT WOS:000635698500003
PM 33767261
OA gold, Green Published
DA 2022-11-30
ER

PT J
AU Krebs, I
   Glittenberg, C
   Zeiler, F
   Binder, S
AF Krebs, Ilse
   Glittenberg, Carl
   Zeiler, Florian
   Binder, Susanne
TI Spectral domain optical coherence tomography for higher precision in the
   evaluation of vitreoretinal adhesions in exudative age-related macular
   degeneration
SO BRITISH JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
ID RETINAL ANGIOMATOUS PROLIFERATION; POSTERIOR VITREOMACULAR ADHESION;
   CHOROIDAL NEOVASCULARIZATION; RISK
AB Aim The role of changes at the vitreoretinal interface and vitreomacular traction forces in pathogenesis, and the course of exudative age-related macular degeneration (AMD) need further exploration. This study examines the localisation of adhesion and the direction of traction lines in eyes with exudative AMD.
   Methods The cubes 512x128 of Cirrus optical coherence tomography (OCT) and volume scans of Spectralis OCT were reviewed in a consecutive series of patients presenting between December 2008 and March 2009 with vitreomacular adhesion in exudative AMD.
   Results 30 eyes of 25 patients with exudative AMD and vitreomacular adhesion were studied. 50% had type III lesions, 46.7% occult and 3.3% predominantly classic lesions. The localisation of the adhesion corresponded in 100% with the area of the neovascularisation (CNV), in 73.3% traction directed towards the CNV and in 83.3% towards the optic disc could be noted. Spectral domain OCT and 3D visualisation enabled clearer localisation of vitreomacular adhesion and definition of resulting traction lines.
   Conclusion There is a high prevalence of type III lesions within eyes with vitreomacular adhesions, and complete correspondence between the location of the adhesion and the CNV. There is also a high incidence of vitreopapillary adhesion in these cases, suggesting a possible role in pathogenesis.
C1 [Krebs, Ilse] Rudolf Fdn Clin, Dept Ophthalmol, A-1030 Vienna, Austria.
   Ludwig Boltzmann Inst Retinol & Biomicroscop Lase, Vienna, Austria.
C3 Ludwig Boltzmann Institute
RP Krebs, I (通讯作者)，Rudolf Fdn Clin, Dept Ophthalmol, A-1030 Vienna, Austria.
EM ilse.krebs@wienkav.at
FU Ludwig Boltzmann Institute of Retinology and Biomicroscopic Lasersurgery
FX Ludwig Boltzmann Institute of Retinology and Biomicroscopic
   Lasersurgery.
CR Freund KB, 2008, RETINA-J RET VIT DIS, V28, P201, DOI 10.1097/IAE.0b013e3181669504
   Fung AE, 2007, AM J OPHTHALMOL, V143, P566, DOI 10.1016/j.ajo.2007.01.028
   Gupta P, 2011, BRIT J OPHTHALMOL, V95, P376, DOI 10.1136/bjo.2009.175109
   Johnson Mark W, 2005, Trans Am Ophthalmol Soc, V103, P537
   Krebs I, 2009, SPEKTRUM AUGENHEILKD, V23, P2, DOI 10.1007/s00717-009-0309-x
   Krebs I, 2007, AM J OPHTHALMOL, V144, P741, DOI 10.1016/j.ajo.2007.07.024
   Krebs I, 2007, GRAEF ARCH CLIN EXP, V245, P376, DOI 10.1007/s00417-006-0424-1
   Lee SJ, 2009, AM J OPHTHALMOL, V147, P621, DOI 10.1016/j.ajo.2008.10.003
   Mojana F, 2008, AM J OPHTHALMOL, V146, P218, DOI 10.1016/j.ajo.2008.04.027
   Robison CD, 2009, AM J OPHTHALMOL, V148, P79, DOI 10.1016/j.ajo.2009.01.014
   Sebag J, 2008, GRAEF ARCH CLIN EXP, V246, P329, DOI 10.1007/s00417-007-0743-x
   Sebag J, 2009, Trans Am Ophthalmol Soc, V107, P35
   Sebag J, 2010, AM J OPHTHALMOL, V149, P172, DOI 10.1016/j.ajo.2009.09.004
   Spaide RF, 2003, RETINA-J RET VIT DIS, V23, P595, DOI 10.1097/00006982-200310000-00001
   Tufail A, 2010, BMJ-BRIT MED J, V340, DOI 10.1136/bmj.c2459
   Yannuzzi LA, 2001, RETINA-J RET VIT DIS, V21, P416, DOI 10.1097/00006982-200110000-00003
NR 16
TC 29
Z9 34
U1 0
U2 4
PU B M J PUBLISHING GROUP
PI LONDON
PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND
SN 0007-1161
J9 BRIT J OPHTHALMOL
JI Br. J. Ophthalmol.
PD OCT
PY 2011
VL 95
IS 10
BP 1415
EP 1418
DI 10.1136/bjo.2010.192385
PG 4
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 822VL
UT WOS:000295078000017
PM 21270433
DA 2022-11-30
ER

PT J
AU Sun, YD
   Dong, YD
   Fan, R
   Zhai, LL
   Bai, YL
   Jia, LH
AF Sun, Ying-Dong
   Dong, You-Dan
   Fan, Rui
   Zhai, Ling-Ling
   Bai, Ying-Long
   Jia, Li-Hong
TI Effect of (R)-alpha-Lipoic Acid Supplementation on Serum Lipids and
   Antioxidative Ability in Patients with Age-Related Macular Degeneration
SO ANNALS OF NUTRITION AND METABOLISM
LA English
DT Article
DE (R)-alpha-lipoic acid; Age-related macular degeneration; Serum lipids;
   Malondialdehyde; Superoxide dismutase
ID RETINAL-PIGMENT EPITHELIUM; LIPOIC ACID; NITRIC-OXIDE; PEROXIDATION;
   DYSFUNCTION; APOPTOSIS; PROTECTS; CELLS; ZINC
AB Background/Aims: Supplementation with antioxidants is of special interest in preventing or delaying the development and progression of age-related macular degeneration (AMD). This investigation aimed to assess the effect of alpha-lipoic acid (LA) on serum lipids, serum malondialdehyde (MDA) and superoxide dismutase (SOD) in patients with AMD. Methods: A total of 62 patients (50-75 years old) with early and intermediate dry form of AMD were randomly assigned to two groups, i.e. LA administration (n = 32) and placebo (n = 30). The levels of serum lipids and MDA and SOD activity were measured before and after LA and placebo intervention. Results: Compared with the parameters at baseline, serum total cholesterol (CHO), triglyceride and high- and low-density lipoprotein CHO (HDL and LDL) levels were not significantly different after LA and placebo intervention. There was a slight but statistically nonsignificant decrease in serum MDA levels and a statistically significant increase in serum SOD activity after LA intervention. There were no statistically significant differences in serum MDA levels or SOD activity after placebo intervention. Conclusion: The apparent increase in SOD activity caused by LA supplementation indicates that LA may have a possible preventive effect in the development of AMD through an antioxidant mechanism. Copyright (C) 2012 S. Karger AG, Basel
C1 [Sun, Ying-Dong; Dong, You-Dan; Zhai, Ling-Ling; Bai, Ying-Long; Jia, Li-Hong] China Med Univ, Sch Publ Hlth, Shenyang 110001, Peoples R China.
   [Fan, Rui] Shenyang AIER Ophthalmol Hosp, Shenyang, Peoples R China.
C3 China Medical University
RP Jia, LH (通讯作者)，China Med Univ, Sch Publ Hlth, Shenyang 110001, Peoples R China.
EM lhjia@mail.cmu.edu.cn
RI 白, 英龙/AAF-6124-2020
FU Chinese Nutrition Society Sciences [07016]
FX The authors thank Jiangsu Tohope Pharmaceutical Co. for supplying LA
   products. This research was supported by the Chinese Nutrition Society
   Sciences Grant 07016.
CR Baskol G, 2006, OPHTHALMOLOGICA, V220, P12, DOI 10.1159/000089269
   Biewenga GP, 1997, GEN PHARMACOL, V29, P315, DOI 10.1016/S0306-3623(96)00474-0
   de Oliveira AM, 2011, DIABETES RES CLIN PR, V92, P253, DOI 10.1016/j.diabres.2011.02.010
   Evereklioglu C, 2003, DOC OPHTHALMOL, V106, P129, DOI 10.1023/A:1022512402811
   Feher J, 2006, NEUROBIOL AGING, V27, P983, DOI 10.1016/j.neurobiolaging.2005.05.012
   Feng ZH, 2010, J NUTR BIOCHEM, V21, P1222, DOI 10.1016/j.jnutbio.2009.10.010
   GAILLARD ER, 1995, PHOTOCHEM PHOTOBIOL, V61, P448, DOI 10.1111/j.1751-1097.1995.tb02343.x
   Huk-Kolega Halina, 2011, Pol Merkur Lekarski, V31, P183
   Jager RD, 2008, NEW ENGL J MED, V358, P2606, DOI 10.1056/NEJMra0801537
   JAIN SK, 1988, BIOCHIM BIOPHYS ACTA, V937, P205, DOI 10.1016/0005-2736(88)90242-8
   Jia L, 2007, INVEST OPHTH VIS SCI, V48, P399
   Jin GF, 2001, CURR EYE RES, V23, P11, DOI 10.1076/ceyr.23.1.11.5423
   Johnsen-Soriano S, 2008, FREE RADICAL RES, V42, P613, DOI 10.1080/10715760802206791
   Justilien V, 2007, INVEST OPHTH VIS SCI, V48, P4407, DOI 10.1167/iovs.07-0432
   Kamenova Petya, 2006, Hormones (Athens), V5, P251
   Kasahara E, 2005, INVEST OPHTH VIS SCI, V46, P3426, DOI 10.1167/iovs.05-0344
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1417, DOI 10.1001/archopht.119.10.1417
   Lee AY, 2008, PHARMACOGENOMICS, V9, P1547, DOI 10.2217/14622416.9.10.1547
   Liu JK, 2005, NUTR NEUROSCI, V8, P67, DOI 10.1080/10284150500047161
   Packer L, 1997, Adv Pharmacol, V38, P79
   Srivastava S, 1995, BIOCHEM BIOPH RES CO, V217, P741, DOI 10.1006/bbrc.1995.2835
   TATE DJ, 1995, INVEST OPHTH VIS SCI, V36, P1271
   Totan Y, 2001, BRIT J OPHTHALMOL, V85, P1426, DOI 10.1136/bjo.85.12.1426
   Wang W, 2007, AM J CLIN NUTR, V85, P762, DOI 10.1093/ajcn/85.3.762
NR 24
TC 22
Z9 22
U1 1
U2 8
PU KARGER
PI BASEL
PA ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND
SN 0250-6807
EI 1421-9697
J9 ANN NUTR METAB
JI Ann. Nutr. Metab.
PY 2012
VL 60
IS 4
BP 293
EP 297
DI 10.1159/000338444
PG 5
WC Endocrinology & Metabolism; Nutrition & Dietetics
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Endocrinology & Metabolism; Nutrition & Dietetics
GA 966BS
UT WOS:000305812400008
PM 22678104
DA 2022-11-30
ER

PT J
AU Shaw, LT
   Mackin, A
   Shah, R
   Jain, S
   Jain, P
   Nayak, R
   Hariprasad, SM
AF Shaw, Lincoln T.
   Mackin, Anna
   Shah, Reanna
   Jain, Siona
   Jain, Prisha
   Nayak, Ravi
   Hariprasad, Seenu M.
TI Risuteganib-a novel integrin inhibitor for the treatment of
   non-exudative (dry) age-related macular degeneration and diabetic
   macular edema
SO EXPERT OPINION ON INVESTIGATIONAL DRUGS
LA English
DT Article
DE Risuteganib; Luminate; ALG-1001; integrin inhibitor; RGD peptide;
   intravitreal; dry age-related macular degeneration; non-exudative
   age-related macular degeneration; diabetic macular edema
ID EYE DISEASE; TRIAL
AB Introduction: Non-exudative (dry) age-related macular degeneration (AMD) and diabetic macular edema (DME) are leading causes of vision loss worldwide. Besides age-related eye disease study (AREDS) vitamin supplements, there are no efficacious pharmaceutical interventions for dry AMD available. While numerous pharmacologics are available to treat diabetic macular edema (DME), many patients respond suboptimally to existing therapies. Risuteganib is a novel anti-integrin peptide that targets the multiple integrin heterodimers involved in the pathophysiology of dry AMD and DME. Inhibiting these selected integrin heterodimers may benefit patients with these conditions. Areas covered: This article offers a brief overview of current pharmaceuticals available for dry AMD and DME. The proposed role of integrins in AMD and DME is reviewed and later, risuteganib, a novel anti-integrin peptide is introduced. The data from initial Phase 1 and Phase 2 risuteganib clinical trials are discussed in the latter part of the paper. Expert opinion: While there are currently limited treatment options for dry AMD, more data are needed before we can truly evaluate the benefits of adopting risuteganib into the clinic. Conversely, several effective treatment options exist for DME; hence, risuteganib must show that it can add to these results, especially in those with refractory disease, before retina specialists adopt risuteganib into their treatment regimens.
C1 [Shaw, Lincoln T.; Mackin, Anna; Hariprasad, Seenu M.] Univ Chicago, Dept Ophthalmol & Visual Sci, 5841 S Maryland Ave,MC 2114, Chicago, IL 60637 USA.
   [Shah, Reanna] Duke Univ, Durham, NC USA.
   [Jain, Siona; Jain, Prisha] Phillips Exeter Acad, Exeter, NH USA.
   [Nayak, Ravi] Univ Chicago, Chicago, IL 60637 USA.
C3 University of Chicago; Duke University; University of Chicago
RP Hariprasad, SM (通讯作者)，Univ Chicago, Dept Ophthalmol & Visual Sci, 5841 S Maryland Ave,MC 2114, Chicago, IL 60637 USA.
EM retina@uchicago.edu
OI Shaw, Lincoln/0000-0003-4485-1678
CR Age-Related Eye Disease Study 2 Research G., 2013, JAMA, V309, pE1
   [Anonymous], 2017, ALL OPHTH ANN POS TO
   [Anonymous], 2019, RETINA TODAY
   [Anonymous], 2018, ALL OPHTH PREP TAK L
   [Anonymous], 2016, RETINA TODAY
   [Anonymous], 2019, STUD EV EFF SAF FAR
   [Anonymous], 2018, RIS LUMINATE POT PAR
   [Anonymous], 2019, ALL OPHTH ANN POS TO
   [Anonymous], 2019, PHAS 2 RAND CLIN TRI
   Askew BC, 2018, J PHARMACOL EXP THER, V366, P244, DOI 10.1124/jpet.118.248427
   Beatty S, 2000, SURV OPHTHALMOL, V45, P115, DOI 10.1016/S0039-6257(00)00140-5
   Boyer DS, 2014, OPHTHALMOLOGY, V121, P1904, DOI 10.1016/j.ophtha.2014.04.024
   Bucolo C, 2018, J PHARMACOL SCI, V138, P219, DOI 10.1016/j.jphs.2018.11.001
   Campochiaro PA, 2016, CURR DIABETES REP, V16, DOI 10.1007/s11892-016-0816-5
   Campochiaro PA, 2012, OPHTHALMOLOGY, V119, P2125, DOI 10.1016/j.ophtha.2012.04.030
   Chew EY, 2014, JAMA OPHTHALMOL, V132, P272, DOI 10.1001/jamaophthalmol.2013.6636
   Das UN, 2016, ARCH MED SCI, V12, P1142, DOI 10.5114/aoms.2016.61918
   DeAngelis MM, 2017, HUM MOL GENET, V26, pR45, DOI 10.1093/hmg/ddx228
   Dugel PU, 2017, OPHTHALMOLOGY, V124, P1296, DOI 10.1016/j.ophtha.2017.03.057
   Dugel PU, 2016, OSLI RETINA, V47, P258, DOI 10.3928/23258160-20160229-09
   Edwards D, 2018, INVEST OPHTH VIS SCI, V59
   Ellis MP, 2019, CURR DIABETES REP, V19, DOI 10.1007/s11892-019-1276-5
   Friedlander M, 1996, P NATL ACAD SCI USA, V93, P9764, DOI 10.1073/pnas.93.18.9764
   Gorusupudi A, 2017, ADV NUTR, V8, P40, DOI 10.3945/an.116.013177
   Hanus J, 2016, BRIT J OPHTHALMOL, V100, P122, DOI 10.1136/bjophthalmol-2015-306972
   Jawhara S, 2017, INFECT IMMUN, V85, DOI 10.1128/IAI.00644-16
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1417, DOI 10.1001/archopht.119.10.1417
   Kim HJ, 2008, INT J BIOCHEM CELL B, V40, P991, DOI 10.1016/j.biocel.2007.11.001
   Ley K, 2016, NAT REV DRUG DISCOV, V15, P173, DOI 10.1038/nrd.2015.10
   Luo BH, 2007, ANNU REV IMMUNOL, V25, P619, DOI 10.1146/annurev.immunol.25.022106.141618
   Moisseiev E, 2020, EYE, V34, P605, DOI 10.1038/s41433-019-0584-y
   Quiroz-Mercado H., 2013, RETINA TODAY
   Quiroz-Mercado H, 2018, INVEST OPHTH VIS SCI, V59
   Ramakrishnan V, 2006, J EXP THER ONCOL, V5, P273
   Sacconi Riccardo, 2019, F1000Res, V8, DOI 10.12688/f1000research.19198.1
   Shin Eui Seok, 2014, J Ophthalmic Vis Res, V9, P362, DOI 10.4103/2008-322X.143378
   Telander DG, 2011, SEMIN OPHTHALMOL, V26, P192, DOI 10.3109/08820538.2011.570849
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
   Wright CB, 2017, HANDB EXP PHARMACOL, V242, P321, DOI 10.1007/164_2016_36
   Yang Y, 2015, RETINA-J RET VIT DIS, V35, P2440, DOI 10.1097/IAE.0000000000000726
NR 40
TC 17
Z9 18
U1 2
U2 9
PU TAYLOR & FRANCIS LTD
PI ABINGDON
PA 2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND
SN 1354-3784
EI 1744-7658
J9 EXPERT OPIN INV DRUG
JI Expert Opin. Investig. Drugs
PD JUN 2
PY 2020
VL 29
IS 6
BP 547
EP 553
DI 10.1080/13543784.2020.1763953
EA MAY 2020
PG 7
WC Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Pharmacology & Pharmacy
GA MV5MO
UT WOS:000534684300001
PM 32349559
DA 2022-11-30
ER

PT J
AU Sonoda, S
   Sreekumar, PG
   Kase, S
   Spee, C
   Ryan, SJ
   Kannan, R
   Hinton, DR
AF Sonoda, Shozo
   Sreekumar, Parameswaran G.
   Kase, Satoru
   Spee, Christine
   Ryan, Stephen J.
   Kannan, Ram
   Hinton, David R.
TI Attainment of polarity promotes growth factor secretion by retinal
   pigment epithelial cells: Relevance to age-related macular degeneration
SO AGING-US
LA English
DT Article
DE retinal pigment epithelial cell; cell polarity; VEGF-A; PEDF; BMP-4;
   age-related macular degeneration
ID BONE MORPHOGENETIC PROTEINS; OXIDATIVE STRESS; ENDOTHELIAL-CELLS;
   ION-TRANSPORT; RPE CELLS; EXPRESSION; VEGF; CULTURE; DIFFERENTIATION;
   ANGIOGENESIS
AB The antiangiogenic and neurotrophic growth factor, pigment epithelial derived factor (PEDF), and the proangiogenic growth factor, vascular endothelial growth factor-A (VEGF), are released from retinal pigment epithelial (RPE) cells where they play a critical role in the pathogenesis of age-related macular degeneration (AMD). Since RPE polarity may be altered in advanced AMD, we studied the effect of polarization of differentiated, human RPE monolayer cultures on expression and secretion of PEDF and VEGF. Polarized RPE demonstrated apical microvilli, expression of tight junction proteins, apical localization of Na/K- ATPase, and high transepithelial resistance (490 +/- 17 Omega center dot cm(2)). PEDF secretion was about 1000 fold greater than that for VEGF in both polarized and non-polarized cultures. Polarization of the RPE monolayer increased PEDF secretion, which was predominantly apical, by 34 fold (p<0.02) and VEGF secretion, which was predominantly basolateral, by 5.7 fold (p<0.02). Treatment of non-polarized RPE cultures with bone morphogenetic protein-4 (BMP-4) had no effect on PEDF or VEGF secretion, but resulted in a dose-dependent >2-fold increase in basolateral VEGF secretion (p<0.05) in polarized cultures. Our data show that polarity is an important determinant of the level of PEDF and VEGF secretion in RPE and support the contention that loss of polarity of RPE in AMD results in marked loss of neurotrophic and vascular support for the retina potentially leading to photoreceptor loss and blindness.
C1 [Hinton, David R.] Univ So Calif, Keck Sch Med, Dept Pathol, Los Angeles, CA 90089 USA.
   [Sonoda, Shozo; Sreekumar, Parameswaran G.; Kase, Satoru; Spee, Christine; Ryan, Stephen J.; Kannan, Ram; Hinton, David R.] Univ So Calif, Keck Sch Med, Dept Ophthalmol, Los Angeles, CA 90089 USA.
   [Sonoda, Shozo; Sreekumar, Parameswaran G.; Kase, Satoru; Ryan, Stephen J.; Kannan, Ram; Hinton, David R.] Doheny Eye Inst, Arnold & Mabel Beckman Macular Res Ctr, Los Angeles, CA 90033 USA.
   [Sonoda, Shozo] Kagoshima Univ, Dept Ophthalmol, Grad Sch Med & Dent Sci, Kagoshima 890, Japan.
C3 University of Southern California; University of Southern California;
   Doheny Eye Institute; Kagoshima University
RP Hinton, DR (通讯作者)，Univ So Calif, Keck Sch Med, Dept Pathol, 2011 Zonal Ave,HMR 209, Los Angeles, CA 90089 USA.
EM dhinton@usc.edu
RI kannan, ram/ABB-7154-2020
OI kannan, ram/0000-0002-1583-3414; /0000-0002-9425-3986
FU Arnold and Mabel Beckman Foundation; National Institutes of Health
   [EY01545, EY03040]; Department of Ophthalmology by Research to Prevent
   Blindness, Inc.; NATIONAL EYE INSTITUTE [P30EY003040, R01EY001545]
   Funding Source: NIH RePORTER
FX The authors thank Ernesto Barron for extensive technical assistance with
   confocal and electron microscopy and for preparation of figures.
   Supported by The Arnold and Mabel Beckman Foundation, National
   Institutes of Health Grants (EY01545, EY03040), and a grant to the
   Department of Ophthalmology by Research to Prevent Blindness, Inc.
CR Ablonczy Z, 2009, J BIOL CHEM, V284, P30177, DOI 10.1074/jbc.M109.032391
   ADAMIS AP, 1994, AM J OPHTHALMOL, V118, P445, DOI 10.1016/S0002-9394(14)75794-0
   Balemans W, 2002, DEV BIOL, V250, P231, DOI 10.1006/dbio.2002.0779
   Ban Y, 1997, Mol Vis, V3, P18
   Becerra SP, 2004, EXP EYE RES, V78, P223, DOI 10.1016/j.exer.2003.10.013
   Bian ZM, 2007, EXP EYE RES, V84, P812, DOI 10.1016/j.exer.2006.12.016
   Blaauwgeers HGT, 1999, AM J PATHOL, V155, P421, DOI 10.1016/S0002-9440(10)65138-3
   Dawson DW, 1999, SCIENCE, V285, P245, DOI 10.1126/science.285.5425.245
   Dunn KC, 1996, EXP EYE RES, V62, P155, DOI 10.1006/exer.1996.0020
   Furuta Y, 1997, DEVELOPMENT, V124, P2203
   Gao GQ, 2001, FEBS LETT, V489, P270, DOI 10.1016/S0014-5793(01)02110-X
   Geisen P, 2006, CURR EYE RES, V31, P739, DOI 10.1080/02713680600837408
   Handa JT, 1998, EXP EYE RES, V66, P411, DOI 10.1006/exer.1997.0442
   HOGAN M J, 1972, Transactions of the American Academy of Ophthalmology and Oto-Laryngology, V76, P64
   Holtkamp GM, 1998, CLIN EXP IMMUNOL, V112, P34
   Hu J, 2001, MOL VIS, V7, P14
   Kannan R, 2006, MOL VIS, V12, P1649
   Karakousis PC, 2001, MOL VIS, V7, P154
   Kojima T, 2006, MOL CELL BIOCHEM, V293, P63, DOI 10.1007/s11010-006-2680-0
   Lopez PF, 1996, INVEST OPHTH VIS SCI, V37, P855
   Luo Y, 2006, INVEST OPHTH VIS SCI, V47, P3644, DOI 10.1167/iovs.06-0166
   Maminishkis A, 2006, INVEST OPHTH VIS SCI, V47, P3612, DOI 10.1167/iovs.05-1622
   Marin-Castano ME, 2005, INVEST OPHTH VIS SCI, V46, P3331, DOI 10.1167/iovs.04-1224
   Mathura JR, 2000, INVEST OPHTH VIS SCI, V41, P592
   McLeod DS, 2009, INVEST OPHTH VIS SCI, V50, P4982, DOI 10.1167/iovs.09-3639
   MILLER H, 1986, INVEST OPHTH VIS SCI, V27, P1644
   Muller F, 2007, DEVELOPMENT, V134, P3483, DOI 10.1242/dev.02884
   Mukherjee PK, 2007, P NATL ACAD SCI USA, V104, P13152, DOI 10.1073/pnas.0705949104
   Nagineni CN, 2003, J CELL PHYSIOL, V197, P453, DOI 10.1002/jcp.10378
   Ohno-Matsui K, 2001, J CELL PHYSIOL, V189, P323, DOI 10.1002/jcp.10026
   Peng SM, 2003, INVEST OPHTH VIS SCI, V44, P808, DOI 10.1167/iovs.02-0473
   Pfeffer B, 2004, MOL VIS, V10, P23
   Pignolo RJ, 2003, J CELL PHYSIOL, V195, P12, DOI 10.1002/jcp.10212
   Pollina EA, 2008, CELL CYCLE, V7, P2056, DOI 10.4161/cc.7.13.6240
   QUINN RH, 1992, INVEST OPHTH VIS SCI, V33, P3513
   Quinn RH, 2001, INVEST OPHTH VIS SCI, V42, P255
   Rahner C, 2004, J CELL SCI, V117, P3307, DOI 10.1242/jcs.01181
   ROBERTS WG, 1995, J CELL SCI, V108, P2369
   Rothhammer T, 2007, ONCOGENE, V26, P4158, DOI 10.1038/sj.onc.1210182
   SAKAMOTO T, 1995, CURR EYE RES, V14, P621, DOI 10.3109/02713689508998488
   SHEEDLO HJ, 1992, BRAIN RES, V587, P327, DOI 10.1016/0006-8993(92)91015-7
   Shi G, 2008, INVEST OPHTH VIS SCI, V49, P4620, DOI 10.1167/iovs.08-1816
   SHWEIKI D, 1992, NATURE, V359, P845
   Sonoda S, 2009, NAT PROTOC, V4, P662, DOI 10.1038/nprot.2009.33
   Sreekumar PG, 2005, BIOCHEM BIOPH RES CO, V334, P245, DOI 10.1016/j.bbrc.2005.06.081
   TOMBRANTINK J, 1995, J NEUROSCI, V15, P4992
   TOMBRANTINK J, 1989, INVEST OPHTH VIS SCI, V30, P1700
   Vogt RR, 2006, J CELL BIOCHEM, V98, P1196, DOI 10.1002/jcb.20831
   VOGT SD, 2009, INVEST OPHTHALMOL VI, V50
   Wordinger RJ, 2007, EXP BIOL MED, V232, P979, DOI 10.3181/0510-MR-345
   Yokomori H, 2003, LIVER INT, V23, P467, DOI 10.1111/j.1478-3231.2003.00880.x
   Zamiri P, 2006, INVEST OPHTH VIS SCI, V47, P3912, DOI 10.1167/iovs.05-1267
   Zhu DH, 2009, AGING-US, V1, P740, DOI 10.18632/aging.100078
   Zhu DH, 2009, J BIOL CHEM, V284, P9529, DOI 10.1074/jbc.M809393200
NR 54
TC 70
Z9 70
U1 0
U2 4
PU IMPACT JOURNALS LLC
PI ORCHARD PARK
PA 6666 E QUAKER ST, STE 1, ORCHARD PARK, NY 14127 USA
SN 1945-4589
J9 AGING-US
JI Aging-US
PD JAN
PY 2010
VL 2
IS 1
BP 28
EP 42
DI 10.18632/aging.100111
PG 15
WC Cell Biology; Geriatrics & Gerontology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Cell Biology; Geriatrics & Gerontology
GA 579VC
UT WOS:000276403300004
PM 20228934
OA Green Published, Green Submitted, gold
DA 2022-11-30
ER

PT J
AU Muller, PL
   Liefers, B
   Treis, T
   Rodrigues, FG
   Olvera-Barrios, A
   Paul, B
   Dhingra, N
   Lotery, A
   Bailey, C
   Taylor, P
   Sanchez, CI
   Tufail, A
AF Mueller, Philipp L.
   Liefers, Bart
   Treis, Tim
   Rodrigues, Filipa Gomes
   Olvera-Barrios, Abraham
   Paul, Bobby
   Dhingra, Narendra
   Lotery, Andrew
   Bailey, Clare
   Taylor, Paul
   Sanchez, Clarisa I.
   Tufail, Adnan
TI Reliability of Retinal Pathology Quantification in Age-Related Macular
   Degeneration: Implications for Clinical Trials and Machine Learning
   Applications
SO TRANSLATIONAL VISION SCIENCE & TECHNOLOGY
LA English
DT Article
DE retina; AMD; optical coherence tomography; OCT; imaging; interreader;
   interrater; agreement; annotation; artificial intelligence; machine
   learning; deep learning
ID OPTICAL COHERENCE TOMOGRAPHY; GEOGRAPHIC ATROPHY; FUNDUS
   AUTOFLUORESCENCE; EYE DISEASE; END-POINTS; RANIBIZUMAB; PROGRESSION;
   SECONDARY; OUTCOMES; FLUID
AB Purpose: To investigate the interreader agreement for grading of retinal alterations in age-related macular degeneration (AMD) using a reading center setting.
   Methods: In this cross-sectional case series, spectral-domain optical coherence tomography (OCT; Topcon 3D OCT, Tokyo, Japan) scans of 112 eyes of 112 patients with neovascular AMD (56 treatment naive, 56 after three anti-vascular endothelial growth factor injections) were analyzed by four independent readers. Imaging features specific for AMD were annotated using a novel custom-built annotation platform. Dice score, Bland Altman plots, coefficients of repeatability, coefficients of variation, and intraclass correlation coefficients were assessed.
   Results: Loss of ellipsoid zone, pigment epithelium detachment, subretinal fluid, and drusen were the most abundant features in our cohort. Subretinal fluid, intraretinal fluid, hypertransmission, descent of the outer plexiform layer, and pigment epithelium detachment showed highest interreader agreement, while detection and measures of loss of ellipsoid zone and retinal pigment epithelium were more variable. The agreement on the size and location of the respective annotation was more consistent throughout all features.
   Conclusions: The interreader agreement depended on the respective OCT-based feature. A selection of reliable features might provide suitable surrogate markers for disease progression and possible treatment effects focusing on different disease stages.
   Translational Relevance: This might give opportunities for a more time-and costeffective patient assessment and improved decision making as well as have implications for clinical trials and training machine learning algorithms.
C1 [Mueller, Philipp L.; Liefers, Bart; Rodrigues, Filipa Gomes; Olvera-Barrios, Abraham; Tufail, Adnan] Moorfields Eye Hosp NHS Fdn Trust, 162 City Rd, London EC1V 2PD, England.
   [Mueller, Philipp L.; Rodrigues, Filipa Gomes; Olvera-Barrios, Abraham; Tufail, Adnan] UCL, Inst Ophthalmol, London, England.
   [Mueller, Philipp L.] Univ Bonn, Dept Ophthalmol, Bonn, Germany.
   [Liefers, Bart; Sanchez, Clarisa I.] Radboud Univ Nijmegen Med Ctr, Dept Radiol & Nucl Med, Diagnost Image Anal Grp, Nijmegen, Netherlands.
   [Liefers, Bart; Sanchez, Clarisa I.] Radboud Univ Nijmegen Med Ctr, Dept Ophthalmol, Nijmegen, Netherlands.
   [Treis, Tim] Heidelberg Univ, BioQuant, Heidelberg, Germany.
   [Paul, Bobby] Barking Havering & Redbridge Univ Hosp NHS Trust, Romford, Essex, England.
   [Dhingra, Narendra] Mid Yorkshire Hosp NHS Trust, Wakefield, W Yorkshire, England.
   [Lotery, Andrew] Univ Hosp Southampton NHS Fdn Trust, Southampton, Hants, England.
   [Bailey, Clare] Univ Hosp Bristol NHS Fdn Trust, Bristol, Avon, England.
   [Taylor, Paul] UCL, Inst Hlth Informat, London, England.
   [Sanchez, Clarisa I.] Univ Amsterdam, Inst Informat, Fac Sci, Amsterdam, Netherlands.
C3 University of London; University College London; Moorfields Eye Hospital
   NHS Foundation Trust; University of London; University College London;
   University of Bonn; Radboud University Nijmegen; Radboud University
   Nijmegen; Ruprecht Karls University Heidelberg; University of
   Southampton; University Hospital Southampton NHS Foundation Trust;
   University of Bristol; University of London; University College London;
   University of Amsterdam
RP Tufail, A (通讯作者)，Moorfields Eye Hosp NHS Fdn Trust, 162 City Rd, London EC1V 2PD, England.
EM adnan.tufail@nhs.net
RI Olvera-Barrios, Abraham/AAG-1197-2020; Olvera-Barrios,
   Abraham/GQH-4711-2022
OI Olvera-Barrios, Abraham/0000-0002-3305-4465; Olvera-Barrios,
   Abraham/0000-0002-3305-4465; Tufail, Adnan/0000-0001-6131-7640; Lotery,
   Andrew/0000-0001-5541-4305; Gomes Rodrigues, Filipa/0000-0002-8087-1177;
   Treis, Tim/0000-0002-9686-4799
FU German Research Foundation [MU4279/2-1]; United Kingdom's National
   Institute for Health Research of Health's Biomedical Research Centre for
   Ophthalmology atMoorfields Eye Hospital; UCL Institute of Ophthalmology
FX The authors thank the members of the CAM group for setting the standards
   of the feature grading for this work. This work was supported by the
   German Research Foundation (grant MU4279/2-1 to PLM), the United
   Kingdom's National Institute for Health Research of Health's Biomedical
   Research Centre for Ophthalmology atMoorfields Eye Hospital, and UCL
   Institute of Ophthalmology. The views expressed are those of the authors
   and not necessarily those of the Department of Health. The funder had no
   role in the design and conduct of the study; collection, management,
   analysis, and interpretation of the data; prepa-ration, review, or
   approval of the manuscript; and decision to submit the manuscript for
   publication.
CR Age-Related Eye Dis Study Res Grp, 2001, AM J OPHTHALMOL, V132, P668
   Al-Sheikh Mayss, 2017, Int J Retina Vitreous, V3, P13, DOI 10.1186/s40942-017-0068-9
   Arnold JJ, 2016, BMC OPHTHALMOL, V16, DOI 10.1186/s12886-016-0207-3
   BLAND JM, 1986, LANCET, V1, P307, DOI 10.1016/s0140-6736(86)90837-8
   Chew EY, 2014, JAMA OPHTHALMOL, V132, P272, DOI 10.1001/jamaophthalmol.2013.6636
   Csaky KG, 2008, INVEST OPHTH VIS SCI, V49, P479, DOI 10.1167/iovs.07-1132
   Cukras C, 2010, EYE, V24, P775, DOI 10.1038/eye.2009.211
   De Fauw J, 2018, NAT MED, V24, P1342, DOI 10.1038/s41591-018-0107-6
   DICE LR, 1945, ECOLOGY, V26, P297, DOI 10.2307/1932409
   Ferris FL, 2013, OPHTHALMOLOGY, V120, P844, DOI 10.1016/j.ophtha.2012.10.036
   Finger RP, 2019, OPHTHALMOLOGICA, V241, P61, DOI 10.1159/000491402
   Flaxman SR, 2017, LANCET GLOB HEALTH, V5, pE1221, DOI 10.1016/S2214-109X(17)30393-5
   Folgar FA, 2014, OPHTHALMOLOGY, V121, P1956, DOI 10.1016/j.ophtha.2014.04.020
   Guymer RH, 2020, OPHTHALMOLOGY, V127, P394, DOI 10.1016/j.ophtha.2019.09.035
   Guymer RH, 2019, OPHTHALMOLOGY, V126, P829, DOI 10.1016/j.ophtha.2018.09.015
   Holz FG, 2004, AM J OPHTHALMOL, V137, P504, DOI 10.1016/j.ajo.2003.11.026
   Holz FG, 2018, JAMA OPHTHALMOL, V136, P666, DOI 10.1001/jamaophthalmol.2018.1544
   Holz FG, 2017, OPHTHALMOLOGY, V124, P464, DOI 10.1016/j.ophtha.2016.12.002
   Holz FG, 2014, OPHTHALMOLOGY, V121, P1079, DOI 10.1016/j.ophtha.2013.11.023
   Holz FG, 2014, J CLIN INVEST, V124, P1430, DOI 10.1172/JCI71029
   Holz FG, 2011, OPHTHALMOLOGY, V118, P663, DOI 10.1016/j.ophtha.2010.12.019
   Isabel FRM, 2019, CURR MED CHEM, V26, P1
   Kashani AH, 2009, INVEST OPHTH VIS SCI, V50, P3366, DOI 10.1167/iovs.08-2691
   Khan Muhammad, 2014, ISRN Ophthalmol, V2014, P608390, DOI 10.1155/2014/608390
   Koo TK, 2016, J CHIROPR MED, V15, P155, DOI 10.1016/j.jcm.2016.02.012
   Krause J, 2018, OPHTHALMOLOGY, V125, P1264, DOI 10.1016/j.ophtha.2018.01.034
   LANDIS JR, 1977, BIOMETRICS, V33, P159, DOI 10.2307/2529310
   Lee A, 2017, OPHTHALMOLOGY, V124, P1726, DOI 10.1016/j.ophtha.2017.08.046
   Lee A, 2020, J OPHTHAL VIS RES, V15, P331, DOI 10.18502/jovr.v15i3.7452
   Liefers B, 2020, OPHTHALMOLOGY, V127, P1086, DOI 10.1016/j.ophtha.2020.02.009
   Lindblad AS, 2009, ARCH OPHTHALMOL-CHIC, V127, P1168, DOI 10.1001/archophthalmol.2009.198
   Liu XX, 2019, LANCET DIGIT HEALTH, V1, pE271, DOI 10.1016/S2589-7500(19)30123-2
   Mair G, 2015, NEURORADIOLOGY, V57, P1, DOI 10.1007/s00234-014-1441-0
   Maloca PM, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0220063
   Mitsch C, 2020, BRIT J OPHTHALMOL, V104, P868, DOI 10.1136/bjophthalmol-2019-314591
   Muller PL, 2020, RETINA-J RET VIT DIS, V40, P2343, DOI 10.1097/IAE.0000000000002747
   Muller PL, 2020, AM J OPHTHALMOL, V218, P136, DOI 10.1016/j.ajo.2020.05.023
   Muller PL, 2020, J CLIN MED, V9, DOI 10.3390/jcm9082428
   Muller PL, 2019, TRANSL VIS SCI TECHN, V8, DOI 10.1167/tvst.8.6.46
   Muller PL, 2018, TRANSL VIS SCI TECHN, V7, DOI 10.1167/tvst.7.5.13
   Muller P.L., 2019, HIGH RESOLUTION IMAG, P87
   Muller PL, 2020, AM J OPHTHALMOL, V213, P134, DOI 10.1016/j.ajo.2020.01.013
   Ohayon A, 2019, OSLI RETINA, V50, pE242, DOI 10.3928/23258160-20190905-16
   Pfau M, 2020, OPHTHALMOLOGE, V117, P973, DOI 10.1007/s00347-020-01209-z
   Pfau M, 2019, RETINA-J RET VIT DIS, V39, P1527, DOI 10.1097/IAE.0000000000002206
   Pfau M, 2017, INVEST OPHTH VIS SCI, V58, pBIO121, DOI 10.1167/iovs.17-21764
   Quellec G, 2019, ACTA OPHTHALMOL, V97, pE719, DOI 10.1111/aos.14055
   Rofagha S, 2013, OPHTHALMOLOGY, V120, P2292, DOI 10.1016/j.ophtha.2013.03.046
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Rosenfeld PJ, 2018, OPHTHALMOLOGY, V125, P1556, DOI 10.1016/j.ophtha.2018.03.059
   Rosenfeld PJ, 2016, INVEST OPHTH VIS SCI, V57, pOCT14, DOI 10.1167/iovs.16-19969
   Sadda SR, 2020, OPHTHALMOLOGY, V127, P1360, DOI 10.1016/j.ophtha.2020.03.031
   Sadda SR, 2018, OPHTHALMOLOGY, V125, P537, DOI 10.1016/j.ophtha.2017.09.028
   Sayegh RG, 2011, OPHTHALMOLOGY, V118, P1844, DOI 10.1016/j.ophtha.2011.01.043
   Schaal KB, 2016, OPHTHALMOLOGY, V123, P1060, DOI 10.1016/j.ophtha.2016.01.034
   Schmidt-Erfurth U, 2017, EYE, V31, P26, DOI 10.1038/eye.2016.227
   Schmidt-Erfurth U, 2020, AM J OPHTHALMOL, V216, P257, DOI 10.1016/j.ajo.2020.03.042
   Schmidt-Erfurth U, 2016, PROG RETIN EYE RES, V50, P1, DOI 10.1016/j.preteyeres.2015.07.007
   Schmitz-Valckenberg S, 2011, INVEST OPHTH VIS SCI, V52, P7640, DOI 10.1167/iovs.11-7457
   Schmitz-Valckenberg S, 2009, INVEST OPHTH VIS SCI, V50, P3915, DOI 10.1167/iovs.08-2484
   SHROUT PE, 1979, PSYCHOL BULL, V86, P420, DOI 10.1037/0033-2909.86.2.420
   Simader C, 2014, OPHTHALMOLOGY, V121, P1237, DOI 10.1016/j.ophtha.2013.12.029
   Sleiman K, 2017, OPHTHALMOLOGY, V124, P1764, DOI 10.1016/j.ophtha.2017.06.032
   Suter M, 2000, J BIOL CHEM, V275, P39625, DOI 10.1074/jbc.M007049200
   Tan CS, 2015, OSLI RETINA, V46, P172, DOI 10.3928/23258160-20150213-23
   Team RC, 2013, R LANG ENV STAT COMP
   Terheyden JH, 2020, TRIALS, V21, DOI 10.1186/s13063-020-04595-6
   Thiele S, 2020, OPHTHALMOL RETINA, V4, P31, DOI 10.1016/j.oret.2019.08.003
   Toth CA, 2015, RETINA-J RET VIT DIS, V35, P1303, DOI 10.1097/IAE.0000000000000483
   Venhuizen FG, 2018, BIOMED OPT EXPRESS, V9, P1545, DOI 10.1364/BOE.9.001545
   Waldstein SM, 2016, JAMA OPHTHALMOL, V134, P182, DOI 10.1001/jamaophthalmol.2015.4948
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
   Ying GS, 2013, OPHTHALMOLOGY, V120, P122, DOI 10.1016/j.ophtha.2012.07.042
NR 73
TC 5
Z9 5
U1 0
U2 2
PU ASSOC RESEARCH VISION OPHTHALMOLOGY INC
PI ROCKVILLE
PA 12300 TWINBROOK PARKWAY, ROCKVILLE, MD 20852-1606 USA
SN 2164-2591
J9 TRANSL VIS SCI TECHN
JI Transl. Vis. Sci. Technol.
PD MAR
PY 2021
VL 10
IS 3
AR 4
DI 10.1167/tvst.10.3.4
PG 11
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA RI9HE
UT WOS:000637215200004
PM 34003938
OA Green Published, Green Accepted, gold, Green Submitted
DA 2022-11-30
ER

PT J
AU Sasaki, M
   Harada, S
   Kawasaki, Y
   Watanabe, M
   Ito, H
   Tanaka, H
   Takeuchi, A
   Tsubota, K
   Takebayashi, T
   Nishiwaki, Y
   Kawasaki, R
AF Sasaki, Mariko
   Harada, Sei
   Kawasaki, Yumiko
   Watanabe, Miki
   Ito, Hidemi
   Tanaka, Hideo
   Takeuchi, Ayano
   Tsubota, Kazuo
   Takebayashi, Toru
   Nishiwaki, Yuji
   Kawasaki, Ryo
TI Gender-specific association of early age-related macular degeneration
   with systemic and genetic factors in a Japanese population
SO SCIENTIFIC REPORTS
LA English
DT Article
ID ESTER TRANSFER PROTEIN; CARDIOVASCULAR RISK-FACTORS; FACTOR-H GENE;
   CHOLESTERYL ESTER; MACULOPATHY; PREVALENCE; DISEASE; POLYMORPHISM;
   PLASMA; CFH
AB The Tsuruoka Metabolomics Cohort Study included subjects aged 35-74 years from participants in annual health check-up programs in Tsuruoka, Japan. The gender-specific associations of early age-related macular degeneration (AMD) with systemic and genetic factors was assessed cross-sectionally. Of these, 3,988 subjects had fundus photographs of sufficient quality, and early AMD was present in 12.3% and 10.3% of men and women, respectively. In men, higher levels of high-density lipoprotein cholesterol and lower levels of triglycerides were associated with increased odds of having early AMD after adjusting for potential risk factors (for each 1 mmol/L increase, odds ratio [OR]: 1.61 and 0.78, 95% confidence interval [CI]: 1.17-2.23 and 0.64-0.96, respectively). In women, higher levels of total cholesterol and low-density lipoprotein cholesterol were associated with increased risk of having early AMD (OR: 1.21 and 1.26, 95% CI: 1.01-1.44 and 1.03-1.53, respectively). Sub-analysis demonstrated that women with ARMS2 A69S polymorphisms had a stronger risk for early AMD (OR: 3.25, 95% CI: 2.10-5.04) than men (OR: 1.65, 95% CI: 1.02-2.69). Differential associations of early AMD with both systemic and genetic factors by sex were demonstrated in a Japanese cohort, which suggests that disease process of early AMD could be different by sex.
C1 [Sasaki, Mariko; Tsubota, Kazuo] Keio Univ, Dept Ophthalmol, Tokyo 1600016, Japan.
   [Sasaki, Mariko] Tachikawa Hosp, Tokyo 1908531, Japan.
   [Sasaki, Mariko] Natl Tokyo Med Ctr, Natl Inst Sensory Organs, Tokyo 1528902, Japan.
   [Harada, Sei; Takeuchi, Ayano; Takebayashi, Toru] Keio Univ, Dept Prevent Med & Publ Hlth, Tokyo 1608582, Japan.
   [Kawasaki, Yumiko; Kawasaki, Ryo] Yamagata Univ, Grad Sch Med Sci, Dept Publ Hlth, Yamagata 9902331, Japan.
   [Watanabe, Miki] Nagoya City Univ, Grad Sch Med Sci, Dept Publ Hlth, Nagoya, Aichi 4678601, Japan.
   [Ito, Hidemi] Aichi Canc Res Inst, Div Mol & Clin Epidemiol, Nagoya, Aichi 4648681, Japan.
   [Tanaka, Hideo] Kishiwada Publ Hlth Ctr, Osaka 5960076, Japan.
   [Nishiwaki, Yuji] Toho Univ, Dept Environm & Occupat Hlth, Tokyo 1438540, Japan.
C3 Keio University; Tachikawa Hospital; Keio University; Yamagata
   University; Nagoya City University; Aichi Cancer Center; Toho University
RP Kawasaki, R (通讯作者)，Yamagata Univ, Grad Sch Med Sci, Dept Publ Hlth, Yamagata 9902331, Japan.
EM ryok@med.id.yamagata-u.ac.jp
RI Kawasaki, Ryo/H-9716-2019; Takebayashi, Toru/AAB-9356-2019; Takeuchi,
   Ayano/C-3130-2019; Harada, Sei/ABA-5975-2020; Takebayashi,
   Toru/K-7526-2013; Kawasaki, Ryo/B-7266-2009; Tsubota, Kazuo/M-1915-2013
OI Takebayashi, Toru/0000-0002-8268-8026; Takeuchi,
   Ayano/0000-0002-0908-1850; Harada, Sei/0000-0003-2666-4932; Takebayashi,
   Toru/0000-0002-8268-8026; Kawasaki, Ryo/0000-0002-7492-6303; Tsubota,
   Kazuo/0000-0002-8874-7111; Ito, Hidemi/0000-0002-8023-4581
FU Grants-in-Aid for Scientific Research [17K09150] Funding Source: KAKEN
CR Adams MKM, 2012, HUM MOL GENET, V21, P5229, DOI 10.1093/hmg/dds364
   Afridi I, 2003, J HYPERTENS, V21, P1983, DOI 10.1097/01.hjh.0000084751-37215.d2
   Aoki A, 2015, INVEST OPHTH VIS SCI, V56, P2580, DOI 10.1167/iovs.14-16339
   Arai H, 2005, J ATHEROSCLER THROMB, V12, P98, DOI 10.5551/jat.12.98
   Barton M, 2013, CURR OPIN LIPIDOL, V24, P214, DOI 10.1097/MOL.0b013e3283613a94
   Burgess S, 2017, OPHTHALMOLOGY, V124, P1165, DOI 10.1016/j.ophtha.2017.03.042
   Cackett P, 2008, AM J OPHTHALMOL, V146, P960, DOI 10.1016/j.ajo.2008.06.026
   Cheng CY, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms7063
   Colak E, 2011, OPHTHALMIC RES, V46, P125, DOI 10.1159/000323815
   Delcourt C, 2001, Ophthalmic Epidemiol, V8, P237, DOI 10.1076/opep.8.4.237.1613
   Erke MG, 2014, ACTA OPHTHALMOL, V92, P662, DOI 10.1111/aos.12346
   Fritsche LG, 2013, NAT GENET, V45, P433, DOI 10.1038/ng.2578
   GORDON T, 1981, ARCH INTERN MED, V141, P1128, DOI 10.1001/archinte.141.9.1128
   Gotoh N, 2006, HUM GENET, V120, P139, DOI 10.1007/s00439-006-0187-0
   Harada S, 2016, ENVIRON HEALTH PREV, V21, P18, DOI 10.1007/s12199-015-0494-y
   Hayashi H, 2010, INVEST OPHTH VIS SCI, V51, P5914, DOI 10.1167/iovs.10-5554
   Holliday EG, 2013, PLOS ONE, V8, DOI [10.1371/journal.pone.0082305, 10.1371/journal.pone.0053830]
   INAZU A, 1994, J CLIN INVEST, V94, P1872, DOI 10.1172/JCI117537
   Kawasaki R, 2010, OPHTHALMOLOGY, V117, P921, DOI 10.1016/j.ophtha.2009.10.007
   Klein R, 2003, OPHTHALMOLOGY, V110, P25, DOI 10.1016/S0161-6420(02)01565-8
   KLEIN R, 1992, OPHTHALMOLOGY, V99, P933
   KLEIN R, 1991, OPHTHALMOLOGY, V98, P1128
   Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557
   Kondo N, 2011, OPHTHALMOLOGY, V118, P339, DOI 10.1016/j.ophtha.2010.06.040
   Kuwabara K, 2016, J ATHEROSCLER THROMB, V23, P477, DOI 10.5551/jat.33100
   Lim LS, 2012, LANCET, V379, P1728, DOI 10.1016/S0140-6736(12)60282-7
   MARCEL YL, 1990, J CLIN INVEST, V85, P10, DOI 10.1172/JCI114397
   Maruko I, 2007, AM J OPHTHALMOL, V144, P15, DOI 10.1016/j.ajo.2007.03.047
   MITCHELL P, 1995, OPHTHALMOLOGY, V102, P1450
   Mori K, 2007, INVEST OPHTH VIS SCI, V48, P5315, DOI 10.1167/iovs.07-0426
   Munch IC, 2013, INVEST OPHTH VIS SCI, V54, P3932, DOI 10.1167/iovs.12-10785
   Neale BM, 2010, P NATL ACAD SCI USA, V107, P7395, DOI 10.1073/pnas.0912019107
   Ng TK, 2008, INVEST OPHTH VIS SCI, V49, P3312, DOI 10.1167/iovs.07-1517
   OHNISHI T, 1994, BIOCHEMISTRY-US, V33, P4533, DOI 10.1021/bi00181a014
   Oshima Y, 2001, BRIT J OPHTHALMOL, V85, P1153, DOI 10.1136/bjo.85.10.1153
   Pikuleva IA, 2014, PROG RETIN EYE RES, V41, P64, DOI 10.1016/j.preteyeres.2014.03.002
   Rader DJ, 2012, NAT MED, V18, P1344, DOI 10.1038/nm.2937
   Rudnicka AR, 2012, OPHTHALMOLOGY, V119, P571, DOI 10.1016/j.ophtha.2011.09.027
   SanGiovanni JP, 2008, ARCH OPHTHALMOL-CHIC, V126, P1274, DOI 10.1001/archopht.126.9.1274
   SanGiovanni JP, 2007, ARCH OPHTHALMOL-CHIC, V125, P1225, DOI 10.1001/archopht.125.9.1225
   Seino Y, 2010, J DIABETES INVEST, V1, P212, DOI 10.1111/j.2040-1124.2010.00074.x
   Snow KK, 2002, AM J OPHTHALMOL, V134, P842, DOI 10.1016/S0002-9394(02)01755-5
   Spaide RF, 2003, RETINA-J RET VIT DIS, V23, P595, DOI 10.1097/00006982-200310000-00001
   TAKAHASHI K, 1993, J CLIN INVEST, V92, P2060, DOI 10.1172/JCI116802
   Teramoto T, 2007, J ATHEROSCLER THROMB, V14, P155, DOI 10.5551/jat.E537
   Tserentsoodol N, 2006, MOL VIS, V12, P1306
   Upston JM, 2002, AM J PATHOL, V160, P701, DOI 10.1016/S0002-9440(10)64890-0
   van Leeuwen R, 2004, AM J OPHTHALMOL, V137, P750, DOI 10.1016/S0002-9394(03)01089-4
   Wang SB, 2015, BRIT J OPHTHALMOL, V99, P365, DOI 10.1136/bjophthalmol-2014-305793
   Wang Y., 2016, NUTRIENTS, V8, P15
   Wang YF, 2016, NUTRIENTS, V8, DOI 10.3390/nu8100663
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
   Yamashiro K, 2011, INVEST OPHTH VIS SCI, V52, P8780, DOI 10.1167/iovs.11-8205
NR 53
TC 20
Z9 20
U1 0
U2 4
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 2045-2322
J9 SCI REP-UK
JI Sci Rep
PD JAN 15
PY 2018
VL 8
AR 785
DI 10.1038/s41598-017-18487-4
PG 8
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA FS8CE
UT WOS:000422637200044
PM 29335418
OA gold, Green Published
DA 2022-11-30
ER

PT J
AU Nowomiejska, K
   Oleszczuk, A
   Brzozowska, A
   Grzybowski, A
   Ksiazek, K
   Maciejewski, R
   Ksiazek, P
   Juenemann, A
   Rejdak, R
AF Nowomiejska, Katarzyna
   Oleszczuk, Agnieszka
   Brzozowska, Agnieszka
   Grzybowski, Andrzej
   Ksiazek, Katarzyna
   Maciejewski, Ryszard
   Ksiazek, Piotr
   Juenemann, Anselm
   Rejdak, Robert
TI M-charts as a tool for quantifying metamorphopsia in age-related macular
   degeneration treated with the bevacizumab injections
SO BMC OPHTHALMOLOGY
LA English
DT Article
DE Age-related macular degeneration; M-charts; Amsler grid; Metamorphopsia;
   Intravitreal injections
ID QUANTIFICATION
AB Background: This article is aimed to assess quantitatively metamorphopsia using M-charts in patients suffering from wet age-related macular degeneration (AMD) treated with the intravitreal bevacizumab injections and to compare the results with traditional Amsler grid and ocular coherence tomography (OCT).
   Methods: Thirty-six patients diagnosed with wet AMD were examined one day before and one month after the intraocular injection of bevacizumab. Horizontal and vertical metamorphopsia scores using M-charts, distance visual acuity, Amsler test and OCT were performed at each visit. Additionally, 23 healthy subjects were examined as a control group.
   Results: The rate of metamorphopsia detection was 89% with M-charts and 69% with Amsler test. The horizontal metamorphopsia score improved in 22 patients, the vertical metamorphopsia score improved in 16 patients, the Amsler grid results improved in 6 patients, visual acuity improved in 17 patients. There was no correlation between the degree of metamorphopsia and the visual acuity or the central retinal thickness (CRT). The specificity of both the M-charts and Amsler grid was 100%.
   Conclusions: The rate of metamorphopsia detection in wet AMD patients was better with M-charts than with Amsler grid. M-charts may be used in the assessment of efficacy of treatment with intravitreal bevacizumab injections as another outcome measure, moreover they can be used even at home for the self-assessment. M-charts provide additional information concerning the visual function, independent of the visual acuity, CRT and morphological changes in OCT.
C1 [Nowomiejska, Katarzyna; Oleszczuk, Agnieszka; Ksiazek, Katarzyna; Rejdak, Robert] Med Univ, Dept Gen Ophthalmol, Lublin, Poland.
   [Brzozowska, Agnieszka] Med Univ, Dept Math & Med Biostat, Lublin, Poland.
   [Grzybowski, Andrzej] Poznan City Hosp, Dept Ophthalmol, Poznan, Poland.
   [Grzybowski, Andrzej] Univ Warmia & Mazury, Fac Med, Olsztyn, Poland.
   [Maciejewski, Ryszard] Med Univ, Dept Human Anat, Lublin, Poland.
   [Ksiazek, Piotr] Med Univ, Dept Publ Hlth, Lublin, Poland.
   [Juenemann, Anselm] Univ Erlangen Nurnberg, Dept Ophthalmol, Erlangen, Germany.
   [Rejdak, Robert] Univ Tubingen, Inst Ophthalm Res, Ctr Ophthalmol, Tubingen, Germany.
   [Rejdak, Robert] Polish Acad Sci, Med Res Ctr, Dept Expt Pharmacol, Warsaw, Poland.
C3 Medical University of Lublin; Medical University of Lublin; University
   of Warmia & Mazury; Medical University of Lublin; Medical University of
   Lublin; University of Erlangen Nuremberg; Eberhard Karls University of
   Tubingen; Eberhard Karls University Hospital; Polish Academy of Sciences
RP Nowomiejska, K (通讯作者)，Med Univ, Dept Gen Ophthalmol, Lublin, Poland.
EM katarzynanowomiejska@mailcity.com
RI Grzybowski, A/E-4486-2010
OI Grzybowski, A/0000-0002-3724-2391; Rejdak, Robert/0000-0003-3321-2723;
   Ksiazek, Piotr/0000-0001-9975-6630
FU Medical University of Lublin [DS 507/12]
FX This study was supported by a grant from the Medical University of
   Lublin (DS 507/12).
CR AMSLER M, 1947, OPHTHALMOLOGICA, V114, P248, DOI 10.1159/000300476
   AMSLER M, 1953, BRIT J OPHTHALMOL, V37, P521, DOI 10.1136/bjo.37.9.521
   Arimura E, 2005, INVEST OPHTH VIS SCI, V46, P2961, DOI 10.1167/iovs.04-1104
   Arimura E, 2007, ACTA OPHTHALMOL SCAN, V85, P55, DOI 10.1111/j.1600-0420.2006.00729.x
   Arimura E, 2011, INVEST OPHTH VIS SCI, V52, P128, DOI 10.1167/iovs.09-3535
   Azuma Noriyuki, 2000, Nippon Ganka Gakkai Zasshi, V104, P960
   Crossland MD, 2005, OPHTHALMOLOGY, V112, P1579, DOI 10.1016/j.ophtha.2005.03.027
   Drexler W, 2008, PROG RETIN EYE RES, V27, P45, DOI 10.1016/j.preteyeres.2007.07.005
   Emerson MV, 2007, RETINA-J RET VIT DIS, V27, P439, DOI 10.1097/IAE.0b013e31804b3e15
   Fukuda S, 2009, BRIT J OPHTHALMOL, V93, P1595, DOI 10.1136/bjo.2008.155440
   Goldstein M, 2005, RETINA-J RET VIT DIS, V25, P296
   Loewenstein A, 2003, OPHTHALMOLOGY, V110, P966, DOI 10.1016/S0161-6420(03)00074-5
   Martin DF, 2011, NEW ENGL J MED, V364, P1897, DOI 10.1056/NEJMoa1102673
   MATSUMOTO C, 1990, Rinsho Ganka, V44, P271
   Matsumoto C, 2003, INVEST OPHTH VIS SCI, V44, P4012, DOI 10.1167/iovs.03-0117
   Nakagawa Tomoya, 2007, Nippon Ganka Gakkai Zasshi, V111, P331
   Parkes L, 2001, NAT NEUROSCI, V4, P739, DOI 10.1038/89532
   Querques G, 2011, INVEST OPHTH VIS SCI, V52, P7012, DOI 10.1167/iovs.11-7517
   SCHUCHARD RA, 1993, INVEST OPHTH VIS SCI, V34, P1420
   SCHUCHARD RA, 1993, ARCH OPHTHALMOL-CHIC, V111, P776, DOI 10.1001/archopht.1993.01090060064024
   WALL M, 1986, ARCH OPHTHALMOL-CHIC, V104, P520, DOI 10.1001/archopht.1986.01050160076015
   WOLFE KA, 1991, GRAEF ARCH CLIN EXP, V229, P219, DOI 10.1007/BF00167871
   YANNUZZI LA, 1986, OPHTHALMOLOGY, V93, P611
NR 23
TC 24
Z9 25
U1 0
U2 12
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 1471-2415
J9 BMC OPHTHALMOL
JI BMC Ophthalmol.
PD APR 15
PY 2013
VL 13
AR 13
DI 10.1186/1471-2415-13-13
PG 6
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 139WF
UT WOS:000318615000001
PM 23587218
OA Green Published, gold
DA 2022-11-30
ER

PT J
AU Casparis, H
   Lindsley, K
   Kuo, IC
   Sikder, S
   Bressler, NB
AF Casparis, Heather
   Lindsley, Kristina
   Kuo, Irene C.
   Sikder, Shameema
   Bressler, Neil B.
TI Surgery for cataracts in people with age-related macular degeneration
SO COCHRANE DATABASE OF SYSTEMATIC REVIEWS
LA English
DT Review
DE Cataract [*complications]; Cataract Extraction [*adverse effects];
   Disease Progression; Macular Degeneration [complications; *pathology];
   Humans
ID QUALITY-OF-LIFE; INTRAOCULAR-LENS; CIGARETTE-SMOKING; VISUAL-ACUITY;
   RISK-FACTORS; BEAVER DAM; MACULOPATHY; EXTRACTION; RANIBIZUMAB;
   PROGRESSION
AB Background
   Cataract and age-related macular degeneration (AMD) are common causes of decreased vision that often occur simultaneously in people over age 50. Although cataract surgery is an effective treatment for cataract-induced visual loss, some clinicians suspect that such an intervention may increase the risk of worsening of underlying AMD and thus have deleterious effects on vision.
   Objectives
   The objective of this review was to evaluate the effectiveness and safety of cataract surgery in eyes with AMD.
   Search methods
   We searched CENTRAL (which contains the Cochrane Eyes and Vision Group Trials Register) (The Cochrane Library 2012, Issue 4), MEDLINE (January 1950 to April 2012), EMBASE (January 1980 to April 2012), Latin American and Caribbean Literature on Health Sciences (LILACS) (January 1982 to April 2012), the meta Register of Controlled Trials (m RCT) (www.controlled-trials.com), ClinicalTrials.gov (www.clinicaltrials.gov) and the WHO International Clinical Trials Registry Platform (ICTRP) (www.who.int/ictrp/search/en). There were no date or language restrictions in the electronic searches for trials. The electronic databases were last searched on 16 April 2012.
   Selection criteria
   We included randomized controlled trials (RCTs) and quasi-randomized trials of eyes affected by both cataract and AMD in which cataract surgery would be compared to no surgery.
   Data collection and analysis
   Two authors independently evaluated the search results against the inclusion and exclusion criteria. Two authors independently extracted data and assessed risk of bias for included studies. We resolved discrepancies by discussion.
   Main results
   One RCT with 60 participants with visually significant cataract and AMD was included in this review. Participants were randomized to immediate cataract surgery (within two weeks of enrollment) (n = 29) or delayed cataract surgery (six months after enrollment) (n = 31). At six months, four participants were lost to follow-up; two participants from each group. The immediate surgery group showed mean improvement in best-corrected visual acuity (BCVA) compared with the delayed surgery group at six months (mean difference (MD) 0.15 LogMAR, 95% confidence interval (CI) 0.28 to 0.02). There was no significant difference in the development of choroidal neovascularization between groups (1/27 eyes in the immediate surgery group versus 0/29 eyes in the delayed surgery group). Results from Impact of Vision Impairment (IVI) questionnaires suggested that the immediate surgery group faired better with quality of life outcomes than the delayed surgery group (MD in IVI logit scores 1.60, 95% CI 0.61 to 2.59). No postoperative complication was reported. We identified a second potentially relevant study of immediate versus delayed cataract surgery in 54 people with AMD. Results for the study are not yet available, but may be eligible for future updates of this review.
   Authors' conclusions
   At this time, it is not possible to draw reliable conclusions from the available data to determine whether cataract surgery is beneficial or harmful in people with AMD. Physicians will have to make practice decisions based on best clinical judgment until controlled trials are conducted and their findings published.
   It would be valuable for future research to investigate prospective RCTs comparing cataract surgery to no surgery in patients with AMD to better evaluate whether cataract surgery is beneficial or harmful in this group. However ethical considerations need to be addressed when delaying a potentially beneficial treatment and it may not be feasible to conduct a long-term study where surgery is withheld from the control group. Utilization of pre-existing, standardized systems for grading cataract and AMD and measuring outcomes (visual acuity, change in visual acuity, worsening of AMD and quality of life measures) should be encouraged.
C1 [Casparis, Heather] Jules Gonin Eye Hosp, Unite Chirurg Vitreoretinienne, CH-1004 Lausanne, Switzerland.
   [Lindsley, Kristina] Johns Hopkins Bloomberg Sch Publ Hlth, Dept Epidemiol, Ctr Clin Trials, Baltimore, MD USA.
   [Kuo, Irene C.; Sikder, Shameema; Bressler, Neil B.] Johns Hopkins Univ, Sch Med, Wilmer Ophthalmol Inst, Baltimore, MD 21205 USA.
C3 Johns Hopkins University; Johns Hopkins Bloomberg School of Public
   Health; Johns Hopkins University; Johns Hopkins Medicine
RP Casparis, H (通讯作者)，Jules Gonin Eye Hosp, Unite Chirurg Vitreoretinienne, CH-1004 Lausanne, Switzerland.
EM Heather.BartlettCasparis@fa2.ch
FU Department of Health through the National Institute for Health Research;
   UCL Institute of Ophthalmology for a Specialist Biomedical Research
   Centre for Ophthalmology; Johns Hopkins University, USA; National Eye
   Institute, National Institutes of Health, USA [N-01-EY-2-1003, 1 U01
   EY020522-01]; NATIONAL EYE INSTITUTE [U01EY020522, N01EY021003] Funding
   Source: NIH RePORTER
FX Richard Wormald (Co-ordinating Editor for CEVG) acknowledges financial
   support for his CEVG research sessions from the Department of Health
   through the award made by the National Institute for Health Research to
   Moorfields Eye Hospital NHS Foundation Trust and UCL Institute of
   Ophthalmology for a Specialist Biomedical Research Centre for
   Ophthalmology. The views expressed in this publication are those of the
   authors and not necessarily those of the Department of Health.; Internal
   sources; Johns Hopkins University, USA.; External sources; Contract
   N-01-EY-2-1003 and Grant 1 U01 EY020522-01, National Eye Institute,
   National Institutes of Health, USA.
CR Abba K, 2011, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD008122.pub2
   Age-Related Eye Disease Study Research Group, 2001, ARCH OPHTHALMOL-CHIC, V119, P1471
   Albrecht S, 2011, US PHARM, V36, P29
   American Academy of Ophthalmology Cataract and Anterior Segment Panel, 2011, PREF PRACT PATT GUID
   Anand R, 2000, OPHTHALMOLOGY, V107, P2224
   Ang M, 2012, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD008811.pub2
   Armbrecht AM, 2003, J CATARACT REFR SURG, V29, P686, DOI 10.1016/S0886-3350(02)01650-4
   Armbrecht AM, 2000, BRIT J OPHTHALMOL, V84, P1343, DOI 10.1136/bjo.84.12.1343
   Benson WB., 2009, EVIDENCE BASED OPHTH, V10, P158
   BIRD AEC, 1995, SURV OPHTHALMOL, V39, P367, DOI 10.1016/S0039-6257(05)80092-X
   Blumenkranz MS, 2001, ARCH OPHTHALMOL-CHIC, V119, P198
   Bockelbrink A, 2008, SURV OPHTHALMOL, V53, P359, DOI 10.1016/j.survophthal.2008.04.001
   Bressler NM, 1999, ARCH OPHTHALMOL-CHIC, V117, P1329
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Brown GC, 2008, EVIDENCE BASED OPHTH, V9, P158
   Brunner S, 2005, INVEST OPHTH VIS SCI, V46
   BRUNNER S, 2001, SPEKTRUM AUGENHEILKU, V15, P178
   Buch H, 2005, ACTA OPHTHALMOL SCAN, V83, P409, DOI 10.1111/J.1600-0420.2005.00492.x
   Casparis H, 2009, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD006757.pub2
   Chew EY, 2009, OPHTHALMOLOGY, V116, P297, DOI 10.1016/j.ophtha.2008.09.019
   Chew EY., 2001, EVIDENCE BASED EYE C, V2, P136
   Cugati S, 2006, OPHTHALMOLOGY, V113, P2020, DOI 10.1016/j.ophtha.2006.05.047
   D'Amico DJ, 2006, OPHTHALMOLOGY, V113, P992, DOI 10.1016/j.ophtha.2006.02.027
   Dong LM, 2009, ARCH OPHTHALMOL-CHIC, V127, P1412, DOI 10.1001/archophthalmol.2009.152
   Donoso LA, 2006, SURV OPHTHALMOL, V51, P137, DOI 10.1016/j.survophthal.2005.12.001
   Evans JR, 2006, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD000254.pub2
   FERRIS FL, 1984, ARCH OPHTHALMOL-CHIC, V102, P1640
   FINE SL, 1982, ARCH OPHTHALMOL-CHIC, V100, P912
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P564
   Glanville JM, 2006, J MED LIBR ASSOC, V94, P130
   HAWKINS BS, 1991, ARCH OPHTHALMOL-CHIC, V109, P1109
   HIGGINS JPT, 2011, COCHRANE HDB SYSTEMA, V0001
   Hiller R, 1997, ARCH OPHTHALMOL-CHIC, V115, P1113, DOI 10.1001/archopht.1997.01100160283003
   Hooper CY, 2009, CLIN EXP OPHTHALMOL, V37, P570, DOI 10.1111/j.1442-9071.2009.02095.x
   Jacques PF, 2005, ARCH OPHTHALMOL-CHIC, V123, P517, DOI 10.1001/archopht.123.4.517
   Javitt JC, 2000, OPHTHALMOLOGY, V107, P2040, DOI 10.1016/S0161-6420(00)00368-7
   Javitt JC, 2001, EVIDENCE BASED EYE C, V2, P138
   Kaiserman I, 2007, OPHTHALMOLOGY, V114, P278, DOI 10.1016/j.ophtha.2006.10.019
   Kertes PJ., 2003, EVIDENCE BASED EYE C, V4, P110
   KLEIN R, 1995, OPHTHALMOLOGY, V102, P371
   Klein R, 2002, ARCH OPHTHALMOL-CHIC, V120, P1551, DOI 10.1001/archopht.120.11.1551
   Kuo IC, 2011, CAN J OPHTHALMOL, V46, P391, DOI 10.1016/j.jcjo.2011.07.008
   Lamoureux EL, 2007, OPTOMETRY VISION SCI, V84, P683, DOI 10.1097/OPX.0b013e31812f755f
   Lundstrom M, 2002, BRIT J OPHTHALMOL, V86, P1330, DOI 10.1136/bjo.86.12.1330
   Martin DF, 2011, NEW ENGL J MED, V364, P1897, DOI 10.1056/NEJMoa1102673
   Ohr M, 2012, EXPERT OPIN PHARMACO, V13, P585, DOI 10.1517/14656566.2012.658368
   Pollack A, 1998, OPHTHALMIC SURG LAS, V29, P286
   Pollack A, 1996, OPHTHALMOLOGY, V103, P1546, DOI 10.1016/S0161-6420(96)30464-8
   POWE NR, 1994, ARCH OPHTHALMOL-CHIC, V112, P239, DOI 10.1001/archopht.1994.01090140115033
   Prajna  NV, 1998, AM J OPHTHALMOL, V125, P14, DOI 10.1016/S0002-9394(99)80230-X
   Riaz Y, 2006, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD001323.pub2
   Rohart C, 2008, J FR OPHTALMOL, V31, P571, DOI 10.1016/S0181-5512(08)75457-3
   Rosen E, 2009, EYE, V23, P1120, DOI 10.1038/eye.2008.203
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Seddon JM, 2006, ARCH OPHTHALMOL-CHIC, V124, P995, DOI 10.1001/archopht.124.7.995
   Shuttleworth GN, 1998, BRIT J OPHTHALMOL, V82, P611, DOI 10.1136/bjo.82.6.611
   Sutter FKP, 2007, INVEST OPHTH VIS SCI, V48, P1472, DOI 10.1167/iovs.06-0766
   Talukder Abdul Khaleque, 2009, Mymensingh Med J, V18, pS15
   The Nordic Cochrane Centre The Cochrane Collaboration, 2011, REV MAN REVMAN 5 1
   Wang JJ, 2003, OPHTHALMOLOGY, V110, P1960, DOI 10.1016/S0161-6420(03)00816-9
   WEST SK, 1989, ARCH OPHTHALMOL-CHIC, V107, P875, DOI 10.1001/archopht.1989.01070010897038
   World Health Organization (WHO), 2011, MAGN CAUS VIS IMP FA
   Zhao JL, 2010, OPHTHALMOLOGY, V117, P2120, DOI 10.1016/j.ophtha.2010.03.005
NR 63
TC 14
Z9 14
U1 0
U2 8
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1469-493X
EI 1361-6137
J9 COCHRANE DB SYST REV
JI Cochrane Database Syst Rev.
PY 2012
IS 6
AR CD006757
DI 10.1002/14651858.CD006757.pub3
PG 25
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine
GA 957VD
UT WOS:000305192500014
PM 22696359
OA Green Accepted
DA 2022-11-30
ER

PT J
AU Clemens, CR
   Krohne, TU
   Issa, PC
   Helb, HM
   Kosanetzky, N
   Lommatzsch, A
   Holz, FG
   Eter, N
AF Clemens, Christoph R.
   Krohne, Tim U.
   Issa, Peter Charbel
   Helb, Hans-Martin
   Kosanetzky, Nina
   Lommatzsch, Albrecht
   Holz, Frank G.
   Eter, Nicole
TI High-resolution optical coherence tomography of subpigment epithelial
   structures in patients with pigment epithelium detachment secondary to
   age-related macular degeneration
SO BRITISH JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
ID NEAR-INFRARED REFLECTANCE
AB Background The pathophysiology of pigment epithelial detachment (PED) secondary to age-related macular degeneration (AMD) is as yet incompletely understood and treatment remains challenging. Spectral domain optical coherence tomography (SD-OCT) allows for improved morphological characterisation of the space underneath the retinal pigment epithelium (RPE).
   Objective To investigate eyes with PED for structures underneath the detached RPE cell layer.
   Methods In a retrospective observational case study, SD-OCT scans of AMD-related PEDs were assessed for the presence of distinctive morphological features in the space between the detached RPE and inner Bruch's membrane.
   Results Structures present in the space between the detached RPE and Bruch's membrane were found in 14 of 90 eyes with AMD-related PED. Each of these eyes shows hyper-reflective material underneath the PED, presenting as highly reflective, multilayered, laminar structures, usually orientated parallel to Bruch's membrane.
   Conclusions The findings indicate that SD-OCT may be useful for a more refined phenotypic stratification of AMD-associated PED. Further studies are warranted to explore the correlates on other imaging modalities, to investigate the composition of this material and to assess the potential prognostic relevance of this new finding.
C1 [Clemens, Christoph R.; Eter, Nicole] Univ Munster, Dept Ophthalmol, D-48149 Munster, Germany.
   [Clemens, Christoph R.; Krohne, Tim U.; Issa, Peter Charbel; Helb, Hans-Martin; Kosanetzky, Nina; Holz, Frank G.; Eter, Nicole] Univ Bonn, Dept Ophthalmol, Bonn, Germany.
   [Lommatzsch, Albrecht] St Franziskus Hosp, Dept Ophthalmol, Munster, Germany.
C3 University of Munster; University of Bonn; St. Franziskus-Hospital
RP Eter, N (通讯作者)，Univ Munster, Dept Ophthalmol, Domagkstr 15, D-48149 Munster, Germany.
EM eter@uni-muenster.de
RI Issa, Peter Charbel/O-2580-2019; Krohne, Tim/D-1497-2013; Krohne,
   Tim/AAG-4412-2020; Issa, Peter Charbel/E-8935-2018
OI Issa, Peter Charbel/0000-0002-0351-6673; Krohne,
   Tim/0000-0003-2280-925X; Issa, Peter Charbel/0000-0002-0351-6673
CR Ahlers C, 2008, OPHTHALMOLOGE, V105, P248, DOI 10.1007/s00347-007-1597-7
   BIRD AC, 1986, T OPHTHAL SOC UK, V105, P674
   Gass J Donald, 2003, Retina, V23, P990
   Green W Richard, 2005, Retina, V25, P615, DOI 10.1097/00006982-200507001-00011
   Helb HM, 2010, ACTA OPHTHALMOL, V88, P842, DOI 10.1111/j.1755-3768.2009.01602.x
   Issa PC, 2009, INVEST OPHTH VIS SCI, V50, P5913, DOI 10.1167/iovs.09-3541
   Lafaut BA, 2000, BRIT J OPHTHALMOL, V84, P239, DOI 10.1136/bjo.84.3.239
   Murphy R P, 1985, Trans Am Ophthalmol Soc, V83, P63
   Ojima Y, 2009, RETINA-J RET VIT DIS, V29, P52, DOI 10.1097/IAE.0b013e3181884fbf
   PAULEIKHOFF D, 1990, OPHTHALMOLOGY, V97, P171
   Spaide RF, 2008, AM J OPHTHALMOL, V146, P496, DOI 10.1016/j.ajo.2008.05.032
   Spaide RF, 2009, AM J OPHTHALMOL, V147, P644, DOI 10.1016/j.ajo.2008.10.005
   Theelen T, 2009, GRAEF ARCH CLIN EXP, V247, P1625, DOI 10.1007/s00417-009-1148-9
   Verhoeff F H, 1937, Trans Am Ophthalmol Soc, V35, P262
   Zayit-Soudry S, 2007, SURV OPHTHALMOL, V52, P227, DOI 10.1016/j.survophthal.2007.02.008
NR 15
TC 17
Z9 17
U1 0
U2 4
PU B M J PUBLISHING GROUP
PI LONDON
PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND
SN 0007-1161
J9 BRIT J OPHTHALMOL
JI Br. J. Ophthalmol.
PD AUG
PY 2012
VL 96
IS 8
BP 1088
EP 1091
DI 10.1136/bjophthalmol-2011-301415
PG 4
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 978BK
UT WOS:000306713700011
PM 22694959
DA 2022-11-30
ER

PT J
AU Saunders, DJ
   Muether, PS
   Fauser, S
AF Saunders, Derek J.
   Muether, Philipp S.
   Fauser, Sascha
TI A model of the ocular pharmacokinetics involved in the therapy of
   neovascular age-related macular degeneration with ranibizumab
SO BRITISH JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
ID ENDOTHELIAL GROWTH-FACTOR; SINGLE INTRAVITREAL INJECTION; AQUEOUS-HUMOR
   LEVELS; 2.0 MG RANIBIZUMAB; INTRAOCULAR PHARMACOKINETICS; VITREOUS
   LEVELS; BEVACIZUMAB; CYTOKINES; EFFICACY; BINDING
AB Background To develop a model of the pharmacokinetics of vascular endothelial growth factor (VEGF-A) determined in samples of aqueous humour from patients with neovascular age-related macular degeneration (AMD) treated with ranibizumab (Lucentis).
   Methods Post hoc analysis of data from 31 eyes of 31 patients with AMD treated with ranibizumab gathered in a non-randomised, prospective clinical study. VEGF-A concentrations were measured in 440 aqueous humour samples by Luminex multiplex bead analysis (Luminex, Austin, Texas, USA).
   Results The kinetics of recovery of VEGF-A from suppression by ranibizumab were well described by a simple model: VEGF-A is produced at a constant individual rate; VEGF-A and ranibizumab disperse rapidly within the vitreous chamber and bind with a known affinity; both are eliminated at identical rates from the vitreous chamber in a constant but individual flow into the anterior chamber, and are finally cleared by draining into the peripheral circulation. Average rates of VEGF-A production were predicted to be 5.8 fmol/day (range: 2.7-10.1 fmol), and elimination half-times predicted to be 3.5 days (range: 2.3-5.5 days). The duration of complete VEGF-A suppression in the aqueous humour averaged 41 days (range: 28-67 days).
   Conclusions The ocular pharmacokinetics of VEGF-A and ranibizumab have been linked for the first time in a simple and plausible model which suggests that it might be possible to anticipate individual VEGF-A suppression times.
C1 [Saunders, Derek J.; Muether, Philipp S.; Fauser, Sascha] Univ Hosp Cologne, Dept Ophthalmol, D-50924 Cologne, Germany.
C3 University of Cologne
RP Fauser, S (通讯作者)，Univ Hosp Cologne, Dept Ophthalmol, Kerpener Str 62, D-50924 Cologne, Germany.
EM sascha.fauser@uk-koeln.de
FU Novartis, Germany
FX This work was supported by a grant from Novartis, Germany.
CR Ahn SJ, 2014, INVEST OPHTH VIS SCI, V55, P567, DOI 10.1167/iovs.13-13054
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Busbee BG, 2013, OPHTHALMOLOGY, V120, P1046, DOI 10.1016/j.ophtha.2012.10.014
   Christoforidis JB, 2013, RETINA-J RET VIT DIS, V33, P946, DOI 10.1097/IAE.0b013e3182753b12
   Funatsu H, 2005, GRAEF ARCH CLIN EXP, V243, P3, DOI 10.1007/s00417-004-0950-7
   Goel M, 2010, OPEN OPHTHALMOL J, V4, P52, DOI 10.2174/1874364101004010052
   Ho AC, 2014, OPHTHALMOLOGY, V121, P2181, DOI 10.1016/j.ophtha.2014.05.009
   Hulme EC, 2010, BRIT J PHARMACOL, V161, P1219, DOI 10.1111/j.1476-5381.2009.00604.x
   Krohne TU, 2015, RETINA-J RET VIT DIS, V35, P69, DOI 10.1097/IAE.0000000000000265
   Krohne TU, 2012, AM J OPHTHALMOL, V154, P682, DOI 10.1016/j.ajo.2012.03.047
   Martin DF, 2012, OPHTHALMOLOGY, V119, DOI 10.1016/j.ophtha.2012.03.053
   Martin DF, 2011, NEW ENGL J MED, V364, P1897, DOI 10.1056/NEJMoa1102673
   McLaren JW, 2009, EXP EYE RES, V88, P641, DOI 10.1016/j.exer.2008.10.018
   Meyer CH, 2011, EYE, V25, P661, DOI 10.1038/eye.2011.66
   Meyer CH, 2011, RETINA-J RET VIT DIS, V31, P1877, DOI 10.1097/IAE.0b013e318217373c
   Muether PS, 2013, AM J OPHTHALMOL, V156, P989, DOI 10.1016/j.ajo.2013.06.020
   Muether PS, 2012, OPHTHALMOLOGY, V119, P2082, DOI 10.1016/j.ophtha.2012.07.041
   Noma H, 2008, EYE, V22, P42, DOI 10.1038/sj.eye.6702498
   Papadopoulos N, 2012, ANGIOGENESIS, V15, P171, DOI 10.1007/s10456-011-9249-6
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Stewart MW, 2012, RETINA-J RET VIT DIS, V32, P434, DOI 10.1097/IAE.0B013E31822C290F
   Xu L, 2013, INVEST OPHTH VIS SCI, V54, P1616, DOI 10.1167/iovs.12-10260
NR 22
TC 13
Z9 14
U1 0
U2 4
PU BMJ PUBLISHING GROUP
PI LONDON
PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND
SN 0007-1161
EI 1468-2079
J9 BRIT J OPHTHALMOL
JI Br. J. Ophthalmol.
PD NOV
PY 2015
VL 99
IS 11
BP 1554
EP 1559
DI 10.1136/bjophthalmol-2015-306771
PG 6
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA CU4BA
UT WOS:000363469800022
PM 25957377
DA 2022-11-30
ER

PT J
AU Ong, BB
   Lee, N
   Lee, WP
   Pearce, E
   Sivaprasad, S
   Klaver, CC
   Smith, RT
   Chong, NV
AF Ong, B. B.
   Lee, N.
   Lee, W. P.
   Pearce, E.
   Sivaprasad, S.
   Klaver, C. C.
   Smith, R. T.
   Chong, N. V.
TI Optimisation of an automated drusen-quantifying software for the
   analysis of drusen distribution in patients with age-related macular
   degeneration
SO EYE
LA English
DT Article
DE age-related macular degeneration; automated drusen delineation; image
   processing
ID THRESHOLD SELECTION; ROTTERDAM
AB Purpose The purpose of this study is to optimise the settings of the Retinal Image Analysis Laboratory (RIALAB), a semiautomatic drusen quantification software, in planning for high-throughput quantification of drusen in clinical studies of age-related macular degeneration (AMD).
   Patients and methods A comparison of five different settings in RIALAB was made on 67 images from the Rotterdam eye study (population-based study) and 56 images from the fellow eye of patients with active neovascular AMD in King's College Hospital, London (hospital-based study).
   Results The 'Few Outer' setting was the best setting, with it being most appropriate for 52 (77.6%) of the Rotterdam cohort and 47 (83.9%) for the London cohort. Pearson's chi(2)-test revealed both results to be statistically significant (P<0.0001).
   Conclusions RIALAB is a viable algorithm and software package that can detect, quantify, and analyse drusen efficiently in both population-based and hospital-based studies. We have shown that the 'Few Outer' drusen setting can be employed as the default setting, with fine-tuning only needed in a minority of cases, thus helping to speed up workflow. Eye (2013) 27, 554-560; doi:10.1038/eye.2012.292; published online 11 January 2013
C1 [Ong, B. B.; Lee, W. P.; Chong, N. V.] Oxford Eye Hosp, Oxford, England.
   [Ong, B. B.; Lee, W. P.; Chong, N. V.] Univ Oxford, Oxford, England.
   [Lee, N.; Smith, R. T.] Columbia Univ, New York, NY USA.
   [Pearce, E.; Sivaprasad, S.] Kings Coll Hosp, London, England.
   [Klaver, C. C.] Erasmus Univ, Med Ctr, Rotterdam, Netherlands.
C3 University of Oxford; Columbia University; King's College Hospital NHS
   Foundation Trust; King's College Hospital; Erasmus University Rotterdam;
   Erasmus MC
RP Ong, BB (通讯作者)，John Radcliffe Hosp, Dept Ophthalmol, Oxford Eye Hosp, Oxford OX1 3DU, England.
EM ongbeng2@doctors.org.uk
RI Klaver, Caroline C.W./A-2013-2016; Chong, Victor/Q-6565-2018;
   Sivaprasad, S./D-6876-2015
OI Chong, Victor/0000-0002-7693-522X; Sivaprasad, S./0000-0001-8952-0659;
   smith, theodore/0000-0002-1693-943X; Klaver,
   Caroline/0000-0002-2355-5258
CR Erasmus MC Department of Epidemiology, 2011, ROTT STUD
   HOFMAN A, 1991, EUR J EPIDEMIOL, V7, P403, DOI 10.1007/BF00145007
   Hofman A, 2009, EUR J EPIDEMIOL, V24, P553, DOI 10.1007/s10654-009-9386-z
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1417, DOI 10.1001/archopht.119.10.1417
   Klaver CCW, 2001, INVEST OPHTH VIS SCI, V42, P2237
   Lee N, RIALAB DOCUMENTATION
   OTSU N, 1979, IEEE T SYST MAN CYB, V9, P62, DOI 10.1109/TSMC.1979.4310076
   Pearce E, 2012, 2012 ANN M ASS RES V
   PELI E, 1986, OPHTHALMOLOGY, V93, P1575
   Quellec G, 2011, INVEST OPHTH VIS SCI, V52, P2976, DOI 10.1167/iovs.10-6232
   Rapantzikos K, 2003, MED IMAGE ANAL, V7, P95, DOI 10.1016/S1361-8415(02)00093-2
   Schlanitz FG, 2010, INVEST OPHTH VIS SCI, V51, P6715, DOI 10.1167/iovs.10-5288
   Shin DS, 1999, OPHTHALMOLOGY, V106, P1119, DOI 10.1016/S0161-6420(99)90257-9
   Smith RT, 2005, ARCH OPHTHALMOL-CHIC, V123, P200, DOI 10.1001/archopht.123.2.200
   World Medical Association, 2008, DECL HELS ETH PRINC
NR 15
TC 4
Z9 4
U1 0
U2 2
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 0950-222X
J9 EYE
JI Eye
PD APR
PY 2013
VL 27
IS 4
BP 554
EP 560
DI 10.1038/eye.2012.292
PG 7
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 126ED
UT WOS:000317594000014
PM 23306729
OA Green Published, Bronze
DA 2022-11-30
ER

PT J
AU Fauser, S
   Smailhodzic, D
   Caramoy, A
   van de Ven, JPH
   Kirchhof, B
   Hoyng, CB
   Klevering, BJ
   Liakopoulos, S
   den Hollander, AI
AF Fauser, Sascha
   Smailhodzic, Dzenita
   Caramoy, Albert
   van de Ven, Johannes P. H.
   Kirchhof, Bernd
   Hoyng, Carel B.
   Klevering, B. Jeroen
   Liakopoulos, Sandra
   den Hollander, Anneke I.
TI Evaluation of Serum Lipid Concentrations and Genetic Variants at
   High-Density Lipoprotein Metabolism Loci and TIMP3 in Age-Related
   Macular Degeneration
SO INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE
LA English
DT Article
ID COMPLEMENT FACTOR-H; RISK-FACTORS; METALLOPROTEINASES-3 TIMP3; TISSUE
   INHIBITOR; SUSCEPTIBILITY; POLYMORPHISM; ASSOCIATION; CHOLESTEROL;
   MACULOPATHY; INCREASES
AB PURPOSE. To analyze the association between polymorphisms in the TIMP3 gene and genes of the high-density lipoprotein (HDL) metabolism and age-related macular degeneration (AMD), and evaluate serum lipid and lipoprotein levels in AMD patients compared with control individuals.
   METHODS. Single nucleotide polymorphisms in or near the TIMP3, ABCA1, FADS1-3, CETP, LIPC, and LPL genes were genotyped. Serum levels of apolipoprotein B (ApoB), apolipoprotein A2, lipoprotein a, cholesterol, triglycerides, and HDL-cholesterol were determined.
   RESULTS. Significant associations were found between AMD and variants in ABCA1 and FADS1-3, and a nearly significant association in TIMP3. No significant associations were observed for variants in LPL, LIPC, and CETP. We also observed a significant elevation of ApoB levels in serum of AMD patients. Other lipids and lipoproteins were not significantly altered.
   CONCLUSIONS. These results confirm associations of AMD with variants near the TIMP3 gene and at loci involved in HDL metabolism. They further highlight a role of the extracellular matrix and the HDL metabolism in the pathogenesis of AMD. This study identified increased ApoB levels as a possible new serum biomarker for AMD. (Invest Ophthalmol Vis Sci. 2011; 52: 5525-5528) DOI: 10.1167/iovs.10-6827
C1 [Smailhodzic, Dzenita; van de Ven, Johannes P. H.; Hoyng, Carel B.; Klevering, B. Jeroen; den Hollander, Anneke I.] Radboud Univ Nijmegen, Med Ctr, Dept Ophthalmol, NL-6526 EX Nijmegen, Netherlands.
   [den Hollander, Anneke I.] Radboud Univ Nijmegen, Med Ctr, Dept Human Genet, NL-6526 EX Nijmegen, Netherlands.
   [Fauser, Sascha; Caramoy, Albert; Kirchhof, Bernd] Univ Cologne, Dept Vitreoretinal Surg, Cologne, Germany.
   [Kirchhof, Bernd; Liakopoulos, Sandra] Univ Cologne, Ctr Ophthalmol, Cologne Image Reading Ctr, Cologne, Germany.
C3 Radboud University Nijmegen; Radboud University Nijmegen; University of
   Cologne; University of Cologne
RP Fauser, S (通讯作者)，Radboud Univ Nijmegen, Med Ctr, Dept Ophthalmol, Philips van Leydenlaan 15, NL-6526 EX Nijmegen, Netherlands.
EM a.denhollander@ohk.umcn.nl
RI Klevering, B.J./L-4434-2015; Hollander, Anneke den/N-4911-2014; Hoyng,
   C.B./H-8050-2014
FU Netherlands Organisation for Scientific Research [016.096.309]; MD
   fonds; Oogfonds; Landelijke Stichting voor Blinden en Slechtzienden;
   Algemene Nederlandse Vereniging ter Voorkoming van Blindheid; Stichting
   Researchfonds Oogheelkunde; Stichting Nederlands Oogheelkundig
   Onderzoek; Stichting Blindenhulp; Gelderse Blindenstichting; Forschung
   fur das Sehen; Retinovit Stiftung
FX Supported by the Netherlands Organisation for Scientific Research (Grant
   016.096.309), MD fonds, Oogfonds, Landelijke Stichting voor Blinden en
   Slechtzienden, Algemene Nederlandse Vereniging ter Voorkoming van
   Blindheid, Stichting Researchfonds Oogheelkunde, Stichting Nederlands
   Oogheelkundig Onderzoek, Stichting Blindenhulp, Gelderse
   Blindenstichting, Forschung fur das Sehen, and Retinovit Stiftung.
CR Abalain JH, 2002, CLIN CHIM ACTA, V326, P97, DOI 10.1016/S0009-8981(02)00288-7
   Anderson DH, 2010, PROG RETIN EYE RES, V29, P95, DOI 10.1016/j.preteyeres.2009.11.003
   Chen W, 2010, P NATL ACAD SCI USA, V107, P7401, DOI 10.1073/pnas.0912702107
   Delcourt C, 2001, Ophthalmic Epidemiol, V8, P237, DOI 10.1076/opep.8.4.237.1613
   Dewan A, 2006, SCIENCE, V314, P989, DOI 10.1126/science.1133807
   Fagerness JA, 2009, EUR J HUM GENET, V17, P100, DOI 10.1038/ejhg.2008.140
   Fan Jianglin, 2003, J Atheroscler Thromb, V10, P63
   Fujihara M, 2009, EXP EYE RES, V88, P1115, DOI 10.1016/j.exer.2009.01.017
   Gold B, 2006, NAT GENET, V38, P458, DOI 10.1038/ng1750
   Hageman GS, 2005, P NATL ACAD SCI USA, V102, P7227, DOI 10.1073/pnas.0501536102
   Haines JL, 2005, SCIENCE, V308, P419, DOI 10.1126/science.1110359
   Hawkins JR, 2002, HUM MUTAT, V19, P543, DOI 10.1002/humu.10060
   Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557
   Kortvely E, 2010, INVEST OPHTH VIS SCI, V51, P79, DOI 10.1167/iovs.09-3850
   Maller J, 2006, NAT GENET, V38, P1055, DOI 10.1038/ng1873
   Montezuma Sandra R, 2007, Semin Ophthalmol, V22, P229, DOI 10.1080/08820530701745140
   Neale BM, 2010, P NATL ACAD SCI USA, V107, P7395, DOI 10.1073/pnas.0912019107
   Nowak M, 2005, CLIN EXP MED, V4, P183, DOI 10.1007/s10238-004-0054-z
   Qi JH, 2003, NAT MED, V9, P407, DOI 10.1038/nm846
   Reynolds R, 2010, OPHTHALMOLOGY, V117, P1989, DOI 10.1016/j.ophtha.2010.07.009
   Rivera A, 2005, HUM MOL GENET, V14, P3227, DOI 10.1093/hmg/ddi353
   Seddon JM, 2005, ARCH OPHTHALMOL-CHIC, V123, P321, DOI 10.1001/archopht.123.3.321
   Seddon JM, 1997, AM J OPHTHALMOL, V123, P199, DOI 10.1016/S0002-9394(14)71036-0
   Tan JSL, 2007, OPHTHALMOLOGY, V114, P1143, DOI 10.1016/j.ophtha.2006.09.033
   Vaisman BL, 2001, J CLIN INVEST, V108, P303
   Van Leeuwen R, 2004, OPHTHALMOLOGY, V111, P1169, DOI 10.1016/j.ophtha.2003.10.024
   Wachter A, 2004, OPHTHALMOLOGE, V101, P50, DOI 10.1007/s00347-003-0868-1
   WEBER BHF, 1994, NAT GENET, V8, P352, DOI 10.1038/ng1294-352
   Weissglas-Volkov D, 2010, J LIPID RES, V51, P2032, DOI 10.1194/jlr.R004739
   Yang ZL, 2006, SCIENCE, V314, P992, DOI 10.1126/science.1133811
   Yates JRW, 2007, NEW ENGL J MED, V357, P553, DOI 10.1056/NEJMoa072618
   1992, ARCH OPHTHALMOL, V110, P1701
NR 32
TC 52
Z9 55
U1 0
U2 4
PU ASSOC RESEARCH VISION OPHTHALMOLOGY INC
PI ROCKVILLE
PA 12300 TWINBROOK PARKWAY, ROCKVILLE, MD 20852-1606 USA
SN 0146-0404
J9 INVEST OPHTH VIS SCI
JI Invest. Ophthalmol. Vis. Sci.
PD JUL
PY 2011
VL 52
IS 8
BP 5525
EP 5528
DI 10.1167/iovs.10-6827
PG 4
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 800QC
UT WOS:000293377400066
PM 21613373
DA 2022-11-30
ER

PT J
AU Qureshi, MA
   Robbie, SJ
   Hengerer, FH
   Auffarth, GU
   Conrad-Hengerer, I
   Artal, P
AF Qureshi, Muhammad A.
   Robbie, Scott J.
   Hengerer, Fritz H.
   Auffarth, Gerd U.
   Conrad-Hengerer, Ina
   Artal, Pablo
TI Consecutive case series of 244 age-related macular degeneration patients
   undergoing implantation with an extended macular vision IOL
SO EUROPEAN JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
DE Age-related macular degeneration; Cataract; Eccentric fixation;
   Intraocular lens; Macular degeneration; Preferred retinal locus
ID CATARACT-SURGERY; INTRAOCULAR TELESCOPE; IMAGE QUALITY; RANIBIZUMAB;
   PREVALENCE; OUTCOMES; LENS
AB Purpose: To determine safety and visual outcomes in eyes with age-related macular degeneration (AMD) implanted with a novel intraocular lens (IOL) that delivers an optimized retinal image to all macular areas within 10 degrees of retinal eccentricity.
   Methods: This was a consecutive case series of 244 eyes with dry/stable wet AMD and IogMAR visual acuity >= 3 implanted with ioIAMD Eyemax mono (TM) (London Eye Hospital Pharma), a single-piece, injectable, hydrophobic acrylic IOL sited in the capsular bag. Primary outcome was safety. Secondary outcomes were changes in corrected distance visual acuity (CDVA) and corrected near visual acuity (CNVA) (IogMAR).
   Results: Mean age at surgery was 80 years. Mean duration of follow-up was 3 months (range 1-16 months). No eyes had worsening of CDVA. Frequency of perioperative complications was equivalent to standard IOL implantation. Postoperative refractive outcomes were within +/- 1 D of the target refraction in 88% of cases. Mean preoperative CDVA improved from 1.06 to 0.71 postoperatively (mean of differences -0.35; 95% confidence interval [CI] -0.3886 to -0.3223; p<0.0001), equating to an approximate Early Treatment Diabetic Retinopathy Study gain of 18 letters. Mean preoperative CNVA (N-point; IogMAR conversion) improved from 1.36 to 0.88 postoperatively (mean of differences -0.48; 95% CI -0.53 to -0.44; p<0.0001).
   Conclusions: This novel IOL appears safe in the short to medium term. Improvements in postoperative CDVA and CNVA exceed those observed with standard implants.
C1 [Qureshi, Muhammad A.; Robbie, Scott J.; Hengerer, Fritz H.] London Eye Hosp, 4 Harley St, London W1G 9PB, England.
   [Auffarth, Gerd U.; Conrad-Hengerer, Ina] Heidelberg Univ, Dept Ophthalmol, Heidelberg, Germany.
   [Artal, Pablo] Univ Murcia, Opt Lab, Murcia, Spain.
C3 Ruprecht Karls University Heidelberg; University of Murcia
RP Robbie, SJ (通讯作者)，London Eye Hosp, 4 Harley St, London W1G 9PB, England.
EM dr.scottrobbie@gmail.com
RI Auffarth, Gerd/AAE-6805-2021; Artal, Pablo/AGV-7547-2022; Artal,
   Pablo/AAG-4485-2020
OI Artal, Pablo/0000-0003-1284-6591; Artal, Pablo/0000-0003-1284-6591
CR ARTAL P, 1995, VISION RES, V35, P939, DOI 10.1016/0042-6989(94)00180-T
   Artal P, 2009, J CATARACT REFR SURG, V35, P962, DOI 10.1016/j.jcrs.2009.02.023
   Buckle M, 2016, BRIT J OPHTHALMOL, V100, P240, DOI 10.1136/bjophthalmol-2014-306423
   Casparis H, 2009, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD006757.pub2
   Chew EY, 2013, OPHTHALMOLOGY, V120, P1604, DOI 10.1016/j.ophtha.2013.01.021
   Chong V, 2016, EYE, V30, P270, DOI 10.1038/eye.2015.217
   Crossland MD, 2005, OPHTHALMOLOGY, V112, P1579, DOI 10.1016/j.ophtha.2005.03.027
   CURCIO CA, 1990, J COMP NEUROL, V292, P497, DOI 10.1002/cne.902920402
   Frampton GK, 2014, HEALTH TECHNOL ASSES, V18, P1, DOI 10.3310/hta18150
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P532
   Gale RP, 2009, EYE, V23, P149, DOI 10.1038/sj.eye.6702954
   Gogate P, 2010, J CATARACT REFR SURG, V36, P247, DOI 10.1016/j.jcrs.2009.09.023
   Gollogly HE, 2013, J CATARACT REFR SURG, V39, P1383, DOI 10.1016/j.jcrs.2013.03.027
   Guirao A, 2002, ARCH OPHTHALMOL-CHIC, V120, P1143
   Hengerer FH, 2015, J REFRACT SURG, V31, P158, DOI 10.3928/1081597X-20150220-03
   Hudson HL, 2006, OPHTHALMOLOGY, V113, P1987, DOI 10.1016/j.ophtha.2006.07.010
   Jaeken B, 2013, INVEST OPHTH VIS SCI, V54, P3594, DOI 10.1167/iovs.13-11956
   Kessel L, 2015, ACTA OPHTHALMOL, V93, P593, DOI 10.1111/aos.12665
   Orzalesi N, 2007, OPHTHALMOLOGY, V114, P860, DOI 10.1016/j.ophtha.2007.01.005
   Qureshi MA, 2015, J CATARACT REFR SURG, V41, P2125, DOI 10.1016/j.jcrs.2015.03.021
   Rosenfeld PJ, 2011, AM J OPHTHALMOL, V152, P793, DOI 10.1016/j.ajo.2011.04.025
   Scharioth GB, 2015, J CATARACT REFR SURG, V41, P1559, DOI 10.1016/j.jcrs.2015.07.018
   Singer MA, 2012, CLIN OPHTHALMOL, V6, P33, DOI 10.2147/OPTH.S15028
   Tabernero J, 2015, BIOMED OPT EXPRESS, V6, P1010, DOI 10.1364/BOE.6.001010
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
   Yang HS, 2013, AM J OPHTHALMOL, V156, P89, DOI 10.1016/j.ajo.2013.02.003
NR 26
TC 11
Z9 11
U1 0
U2 4
PU SAGE PUBLICATIONS LTD
PI LONDON
PA 1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND
SN 1120-6721
EI 1724-6016
J9 EUR J OPHTHALMOL
JI Eur. J. Ophthalmol.
PD MAR
PY 2018
VL 28
IS 2
BP 198
EP 203
DI 10.5301/ejo.5001052
PG 6
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA GF6FL
UT WOS:000432062400011
PM 28983894
DA 2022-11-30
ER

PT J
AU Dashti, N
   McGwin, G
   Owsley, C
   Curcio, CA
AF Dashti, N.
   McGwin, G.
   Owsley, C.
   Curcio, C. A.
TI Plasma apolipoproteins and risk for age related maculopathy
SO BRITISH JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
ID CORONARY-ARTERY DISEASE; FACTOR-H POLYMORPHISM; HIGH-FAT DIET; MACULAR
   DEGENERATION; BRUCHS MEMBRANE; BASAL DEPOSITS; CARDIOVASCULAR-DISEASE;
   A-I; CONTAINING LIPOPROTEINS; NATIONAL-HEALTH
AB Aim: To determine if elevated plasma levels of atherogenic and/or anti-atherogenic lipoproteins are risk factors for developing age related maculopathy (ARM).
   Methods: In a cross sectional study in a university clinic setting, 129 patients (72 women and 57 men) underwent colour fundus photography, acuity and contrast sensitivity assessment, and electroimmuno-assays of plasma apolipoproteins B (apoB) and A-I (apoA-I), the principal proteins of low density and high density lipoproteins, respectively. Maculopathy stage was assigned using the AREDS grading system.
   Results: Levels of apoB in no ARM, mild, intermediate, and advanced ARM groups were 93.3, 91.8, 95.2, and 98.2 mg/dl, respectively. Levels of apoA-I were 147.4, 148.6, 141.0, and 144.9 mg/dl in the same groups. There was no significant association between these measures, typical for age, and maculopathy stage.
   Conclusion: Although drusen associated with ARM and ageing contain cholesterol and apoB, like the lipid rich core of an atherosclerotic plaque, the results of this study and our previous work in toto make the prospects of a plasma origin for these lesion constituents increasingly untenable. This conclusion is consistent with an emerging hypothesis that a large lipoprotein of intraocular origin is an important pathway for constituent retinal lipid processing and the biogenesis of drusen.
C1 Univ Alabama Birmingham, Sch Med, Callahan Eye Fdn Hosp, Dept Ophthalmol, Birmingham, AL 35294 USA.
   Univ Alabama Birmingham, Dept Med, Atherosclerosis Res Unit, Sch Med,Div Geriatr & Gerontol, Birmingham, AL 35294 USA.
C3 University of Alabama System; University of Alabama Birmingham;
   University of Alabama System; University of Alabama Birmingham
RP Curcio, CA (通讯作者)，Univ Alabama Birmingham, Sch Med, Callahan Eye Fdn Hosp, Dept Ophthalmol, 700 S 18th St Room H020a, Birmingham, AL 35294 USA.
EM curcio@uab.edu
RI Owsley, Cynthia/B-7986-2014
FU NATIONAL EYE INSTITUTE [R21EY014071, R01EY006109] Funding Source: NIH
   RePORTER; NATIONAL INSTITUTE ON AGING [R01AG004212] Funding Source: NIH
   RePORTER; NEI NIH HHS [R01 EY006109, R21 EY014071, EY06109, R21-EY14071]
   Funding Source: Medline; NIA NIH HHS [R01 AG004212, R01-AG04212] Funding
   Source: Medline
CR Abalain JH, 2002, CLIN CHIM ACTA, V326, P97, DOI 10.1016/S0009-8981(02)00288-7
   ALAUPOVIC P, 1988, CLIN CHEM, V34, pB13
   ALBRINK MJ, 1963, AM J OPHTHALMOL, V55, P709, DOI 10.1016/0002-9394(63)92428-0
   Anderson DH, 2001, AM J OPHTHALMOL, V131, P767, DOI 10.1016/S0002-9394(00)00961-2
   Belda Sanchis J I, 2001, Arch Soc Esp Oftalmol, V76, P13
   BLUMENKRANZ MS, 1986, OPHTHALMOLOGY, V93, P552
   Bressler NM, 2005, RETINA-J RET VIT DIS, V25, P119
   Bressler NM, 2004, OPHTHALMOLOGY, V111, P1993, DOI 10.1016/j.ophtha.2004.07.023
   BRUNZELL JD, 1984, ARTERIOSCLEROSIS, V4, P79, DOI 10.1161/01.ATV.4.2.79
   Carroll MD, 2005, JAMA-J AM MED ASSOC, V294, P1773, DOI 10.1001/jama.294.14.1773
   Cleeman JI, 2001, JAMA-J AM MED ASSOC, V285, P2486, DOI 10.1001/jama.285.19.2486
   Conley YP, 2005, HUM MOL GENET, V14, P1991, DOI 10.1093/hmg/ddi204
   Corsetti JP, 2004, ATHEROSCLEROSIS, V177, P367, DOI 10.1016/j.atherosclerosis.2004.07.019
   Cousins SW, 2002, EXP EYE RES, V75, P543, DOI 10.1006/exer.2002.2047
   Curcio CA, 2005, EXP EYE RES, V81, P731, DOI 10.1016/j.exer.2005.04.012
   Curcio CA, 2005, EXP EYE RES, V80, P761, DOI 10.1016/j.exer.2004.09.017
   Curcio CA, 2001, INVEST OPHTH VIS SCI, V42, P265
   CURRY MD, 1978, CLIN CHEM, V24, P280
   CURRY MD, 1976, CLIN CHEM, V22, P315
   Dasch B, 2005, GRAEF ARCH CLIN EXP, V243, P1028, DOI 10.1007/s00417-005-1176-z
   Dashti N, 2000, J LIPID RES, V41, P1980
   Dashti N, 2004, J LIPID RES, V45, P1919, DOI 10.1194/jlr.M400251-JLR200
   Dashti N, 2002, J NUTR, V132, P2651, DOI 10.1093/jn/132.9.2651
   Davis MD, 2005, ARCH OPHTHALMOL-CHIC, V123, P1484
   Delcourt C, 2001, Ophthalmic Epidemiol, V8, P237, DOI 10.1076/opep.8.4.237.1613
   Dithmar S, 2001, ARCH OPHTHALMOL-CHIC, V119, P1643, DOI 10.1001/archopht.119.11.1643
   Dithmar S, 2000, INVEST OPHTH VIS SCI, V41, P2035
   Edwards AO, 2005, SCIENCE, V308, P421, DOI 10.1126/science.1110189
   ELLIOTT DB, 1991, CLIN VISION SCI, V6, P471
   Espinosa-Heidmann DG, 2004, INVEST OPHTH VIS SCI, V45, P260, DOI 10.1167/iovs.03-0910
   FARKAS TG, 1971, AM J OPHTHALMOL, V71, P1206, DOI 10.1016/0002-9394(71)90964-0
   FERRIS FL, 1982, AM J OPHTHALMOL, V94, P91, DOI 10.1016/0002-9394(82)90197-0
   GOLDBERG J, 1988, AM J EPIDEMIOL, V128, P700, DOI 10.1093/oxfordjournals.aje.a115023
   Gragoudas ES, 2004, NEW ENGL J MED, V351, P2805, DOI 10.1056/NEJMoa042760
   GROVER SA, 1995, JAMA-J AM MED ASSOC, V274, P801, DOI 10.1001/jama.274.10.801
   GRUNDY SM, 1990, J LIPID RES, V31, P1149
   Haidari M, 2001, CLIN BIOCHEM, V34, P149, DOI 10.1016/S0009-9120(01)00192-8
   Haimovici R, 2001, INVEST OPHTH VIS SCI, V42, P1592
   Haines JL, 2005, SCIENCE, V308, P419, DOI 10.1126/science.1110359
   HOLZ FG, 1994, ARCH OPHTHALMOL-CHIC, V112, P402, DOI 10.1001/archopht.1994.01090150132035
   Hyman L, 2000, ARCH OPHTHALMOL-CHIC, V118, P351, DOI 10.1001/archopht.118.3.351
   Ikeda T, 2001, AM J OPHTHALMOL, V132, P191, DOI 10.1016/S0002-9394(01)00975-8
   Klaver CCW, 1998, AM J HUM GENET, V63, P200, DOI 10.1086/301901
   Klein R, 2003, OPHTHALMOLOGY, V110, P636, DOI 10.1016/S0161-6420(02)01448-3
   Klein R, 1997, OPHTHALMOLOGY, V104, P1804, DOI 10.1016/S0161-6420(97)30023-2
   Klein R, 1999, ARCH OPHTHALMOL-CHIC, V117, P1203
   Klein R, 1999, OPHTHALMOLOGY, V106, P1056, DOI 10.1016/S0161-6420(99)90255-5
   KLEIN R, 1993, OPHTHALMOLOGY, V100, P406
   Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557
   Kliffen M, 2000, BRIT J OPHTHALMOL, V84, P1415, DOI 10.1136/bjo.84.12.1415
   KWITEROVICH PO, 1992, AM J CARDIOL, V69, P1015, DOI 10.1016/0002-9149(92)90856-T
   LANDOLFO V, 1978, OPHTHALMOLOGICA, V177, P248, DOI 10.1159/000308775
   Lewis GF, 2005, CIRC RES, V96, P1221, DOI 10.1161/01.RES.0000170946.56981.5c
   Li CM, 2005, INVEST OPHTH VIS SCI, V46, P2576, DOI 10.1167/iovs.05-0034
   Li CM, 2005, J LIPID RES, V46, P628, DOI 10.1194/jlr.M400428-JLR200
   LI CM, 2006, IN PRESS INVEST OPHT
   Malek G, 2005, P NATL ACAD SCI USA, V102, P11900, DOI 10.1073/pnas.0503015102
   Malek G, 2003, AM J PATHOL, V162, P413, DOI 10.1016/S0002-9440(10)63836-9
   Manchekar M, 2004, J BIOL CHEM, V279, P39757, DOI 10.1074/jbc.M406302200
   McGwin G, 2005, OPHTHALMOLOGY, V112, P488, DOI 10.1016/j.ophtha.2004.10.027
   Miceli MV, 2000, CURR EYE RES, V20, P8, DOI 10.1076/0271-3683(200001)20:1;1-H;FT008
   Miyazaki M, 2003, BRIT J OPHTHALMOL, V87, P469, DOI 10.1136/bjo.87.4.469
   Mullins RF, 2000, FASEB J, V14, P835, DOI 10.1096/fasebj.14.7.835
   Nowak M, 2005, CLIN EXP MED, V4, P183, DOI 10.1007/s10238-004-0054-z
   Owsley C, 2006, INVEST OPHTH VIS SCI, V47, P1310, DOI 10.1167/iovs.05-1292
   PAULEIKHOFF D, 1990, OPHTHALMOLOGY, V97, P171
   PAULEIKHOFF D, 1992, OPHTHALMOLOGY, V99, P1548
   PELLI DG, 1988, CLIN VISION SCI, V2, P187
   Pulido JS, 2005, CAN J OPHTHALMOL, V40, P332, DOI 10.1016/S0008-4182(05)80076-6
   Ruberti JW, 2003, INVEST OPHTH VIS SCI, V44, P1753, DOI 10.1167/iovs.02-0496
   Rudolf M, 2005, BRIT J OPHTHALMOL, V89, P1627, DOI 10.1136/bjo.2005.071183
   SANDERS TAB, 1993, AM J CLIN NUTR, V57, P428, DOI 10.1093/ajcn/57.3.428
   SEGREST JP, 1994, ADV PROTEIN CHEM, V45, P303
   SEGREST JP, 1992, J LIPID RES, V33, P141
   SHERAIDAH G, 1993, OPHTHALMOLOGY, V100, P47
   Smith W, 1998, ARCH OPHTHALMOL-CHIC, V116, P583, DOI 10.1001/archopht.116.5.583
   Sniderman AD, 1997, AM J CARDIOL, V79, P64
   Snow K K, 1999, Ophthalmic Epidemiol, V6, P125, DOI 10.1076/opep.6.2.125.1558
   Spaide RF, 1999, RETINA-J RET VIT DIS, V19, P141, DOI 10.1097/00006982-199902000-00010
   STERNBERG P, 1991, ARCH OPHTHALMOL-CHIC, V109, P1242
   Tomany SC, 2004, OPHTHALMOLOGY, V111, P1280, DOI 10.1016/j.ophtha.2003.11.010
   TSANG NCK, 1992, DOC OPHTHALMOL, V81, P387
   Tuo JS, 2004, PROG RETIN EYE RES, V23, P229, DOI 10.1016/j.preteyeres.2004.02.001
   van Leeuwen R, 2005, JAMA-J AM MED ASSOC, V294, P3101, DOI 10.1001/jama.294.24.3101
   van Leeuwen R, 2004, AM J OPHTHALMOL, V137, P750, DOI 10.1016/S0002-9394(03)01089-4
   VERSCHUREN WMM, 1995, JAMA-J AM MED ASSOC, V274, P131, DOI 10.1001/jama.274.2.131
   VIDAURRI JS, 1984, OPHTHALMOLOGICA, V188, P243, DOI 10.1159/000309370
   Von Eckardstein Arnold, 1994, Current Opinion in Lipidology, V5, P404, DOI 10.1097/00041433-199412000-00003
   Wachter A, 2004, OPHTHALMOLOGE, V101, P50, DOI 10.1007/s00347-003-0868-1
   Walldius G, 2001, LANCET, V358, P2026, DOI 10.1016/S0140-6736(01)07098-2
   Wilson HL, 2004, AM J OPHTHALMOL, V137, P615, DOI 10.1016/j.ajo.2003.10.025
   YANNUZZI LA, 1992, ARCH OPHTHALMOL-CHIC, V110, P1701
NR 92
TC 38
Z9 39
U1 0
U2 3
PU BMJ PUBLISHING GROUP
PI LONDON
PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND
SN 0007-1161
EI 1468-2079
J9 BRIT J OPHTHALMOL
JI Br. J. Ophthalmol.
PD AUG
PY 2006
VL 90
IS 8
BP 1028
EP 1033
DI 10.1136/bjo.2006.093856
PG 6
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 064TC
UT WOS:000239111000029
PM 16723359
OA Green Published
DA 2022-11-30
ER

PT J
AU Mantel, I
   Zola, M
   Mir, O
   Gaillard, R
   Behar-Cohen, F
AF Mantel, Irmela
   Zola, Marta
   Mir, Olivier
   Gaillard, Raphael
   Behar-Cohen, Francine
TI Antidepressant medication and ocular factors in association with the
   need for anti-VEGF retreatment in neovascular age-related macular
   degeneration
SO BRITISH JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
ID ENDOTHELIAL GROWTH-FACTOR; INTRAVITREAL AFLIBERCEPT; BEHAVIORAL ACTIONS;
   RANIBIZUMAB; EXPRESSION; BEVACIZUMAB; DEPRESSION; OUTCOMES; FLUID
AB Background/Aims Vascular endothelial growth factor (VEGF) is a key player in the pathogenesis of neovascular age-related macular degeneration (nAMD) and is also involved in the final common pathway of antidepressant medication. This study investigated the relationship between the need for anti-VEGF retreatment in patients with nAMD and antidepressant medication, and the potential impact of ocular structural factors.
   Methods Data from two identical prospective 2-year treatment protocols using ranibizumab or aflibercept in a variable-dosing regimen (' Observe-and-Plan') were analysed. Retreatment requirement was compared with antidepressant medication intake (primary outcome) and a variety of ocular factors from baseline and from month 3 response (secondary outcomes), using univariate and multivariate analyses.
   Results Of the 206 included patients (227 eyes), 19 were on antidepressant medication. Their nAMD eyes significantly more often had pigment epithelium detachment (PED, p=0.04). Multivariate analysis revealed a significant association between anti-VEGF retreatment requirement and antidepressant medication use (p=0.027), as well as thicker central retinal thickness at month 3 (p<0.0001) and month 3 PED height (p=0.001).
   Conclusion This study provides evidence that treatment with antidepressant medication increases the anti-VEGF retreatment requirement in patients with nAMD, possibly through the interplay of antidepressant medication, depression status and VEGF levels.
C1 [Mantel, Irmela; Zola, Marta] Univ Lausanne, Fdn Asile Aveugles, Jules Gonin Eye Hosp, Dept Ophthalmol, Lausanne, Switzerland.
   [Mir, Olivier] Univ Paris Saclay, Dept Ambulatory Care, Villejuif, France.
   [Gaillard, Raphael] Univ Paris 05, Ctr Hosp St Anne, Fac Med Paris Descartes, Serv Psychiat,Sorbonne Paris Cite, Paris, France.
   [Gaillard, Raphael] Inst Pasteur, Human Histopathol & Anim Models, Infect & Epidemiol Dept, Paris, France.
   [Behar-Cohen, Francine] Univ Lausanne, Dept Ophthalmol, Lausanne, Switzerland.
   [Behar-Cohen, Francine] Univ Paris 05, Ctr Rech Cordeliers, Physiopathol Ocular Dis Clin Dev, Inserm U1138,Team 17,Sorbonne Paris Cite, Paris, France.
C3 University of Lausanne; UDICE-French Research Universities; Universite
   Paris Saclay; GHU PARIS Psychiatrie Neurosciences; UDICE-French Research
   Universities; Universite Paris Cite; Le Reseau International des
   Instituts Pasteur (RIIP); Institut Pasteur Paris; University of
   Lausanne; Institut National de la Sante et de la Recherche Medicale
   (Inserm); UDICE-French Research Universities; Sorbonne Universite;
   Universite Paris Cite
RP Mantel, I (通讯作者)，Jules Gonin Eye Hosp, CH-1002 Lausanne, Switzerland.
EM irmela.mantel@fa2.ch
RI Mir, Olivier/GNP-7828-2022
OI Mir, Olivier/0000-0002-6761-4002
CR Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Cuilla TA, 2015, OPHTHALMOLOGY, V122, P1203, DOI 10.1016/j.ophtha.2015.02.031
   Fornaro M, 2013, J AFFECT DISORDERS, V151, P590, DOI 10.1016/j.jad.2013.06.055
   Galecki P, 2013, J AFFECT DISORDERS, V147, P144, DOI 10.1016/j.jad.2012.10.025
   Gianniou C, 2015, RETINA-J RET VIT DIS, V35, P1195, DOI 10.1097/IAE.0000000000000465
   Greene J, 2009, NEUROPSYCHOPHARMACOL, V34, P2459, DOI 10.1038/npp.2009.68
   Heier JS, 2012, OPHTHALMOLOGY, V119, P2537, DOI 10.1016/j.ophtha.2012.09.006
   Ibrahim L, 2011, BRAIN RES BULL, V86, P129, DOI 10.1016/j.brainresbull.2011.06.003
   Iga J, 2007, PROG NEURO-PSYCHOPH, V31, P658, DOI 10.1016/j.pnpbp.2006.12.011
   Inoue M, 2016, AM J OPHTHALMOL, V169, P95, DOI 10.1016/j.ajo.2016.06.021
   Kiuchi T, 2012, NEUROSCIENCE, V207, P208, DOI 10.1016/j.neuroscience.2012.01.023
   Kumar N, 2013, RETINA-J RET VIT DIS, V33, P1605, DOI 10.1097/IAE.0b013e31828e8551
   Kuroda Y, 2015, OPHTHALMOLOGY, V122, P2303, DOI 10.1016/j.ophtha.2015.06.053
   Lee BH, 2012, J AFFECT DISORDERS, V136, P181, DOI 10.1016/j.jad.2011.07.021
   Lee JS, 2009, J NEUROSCI, V29, P8493, DOI 10.1523/JNEUROSCI.1321-09.2009
   Mantel I, 2018, RETINA
   Mantel I, 2014, BRIT J OPHTHALMOL, V98, P1192, DOI 10.1136/bjophthalmol-2013-304556
   Martin DF, 2011, NEW ENGL J MED, V364, P1897, DOI 10.1056/NEJMoa1102673
   Parvin P, 2017, GRAEF ARCH CLIN EXP, V255, P2127, DOI 10.1007/s00417-017-3762-2
   Schaal S, 2016, RETINA-J RET VIT DIS, V36, P791, DOI 10.1097/IAE.0000000000000981
   Senra H, 2017, AM J OPHTHALMOL, V177, P213, DOI 10.1016/j.ajo.2017.03.005
   Traband A, 2017, RETINA-J RET VIT DIS, V37, P41, DOI 10.1097/IAE.0000000000001226
   Warner-Schmidt JL, 2007, P NATL ACAD SCI USA, V104, P4647, DOI 10.1073/pnas.0610282104
   Xie T, 2017, TRANSL PSYCHIAT, V7, DOI 10.1038/tp.2017.36
NR 24
TC 1
Z9 1
U1 0
U2 0
PU BMJ PUBLISHING GROUP
PI LONDON
PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND
SN 0007-1161
EI 1468-2079
J9 BRIT J OPHTHALMOL
JI Br. J. Ophthalmol.
PD JUN
PY 2019
VL 103
IS 6
BP 811
EP 815
DI 10.1136/bjophthalmol-2018-312318
PG 5
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)
SC Ophthalmology
GA ID7PW
UT WOS:000471875800015
PM 30030393
OA Green Published, hybrid
DA 2022-11-30
ER

PT J
AU Heesterbeek, TJ
   de Jong, EK
   Acar, IE
   Groenewoud, JMM
   Liefers, B
   Sanchez, CI
   Peto, T
   Hoyng, CB
   Pauleikhoff, D
   Hense, HW
   den Hollander, AI
AF Heesterbeek, Thomas J.
   de Jong, Eiko K.
   Acar, Ilhan E.
   Groenewoud, Joannes M. M.
   Liefers, Bart
   Sanchez, Clara I.
   Peto, Tunde
   Hoyng, Carel B.
   Pauleikhoff, Daniel
   Hense, Hans W.
   den Hollander, Anneke I.
TI Genetic risk score has added value over initial clinical grading stage
   in predicting disease progression in age-related macular degeneration
SO SCIENTIFIC REPORTS
LA English
DT Article
ID SIMPLIFIED SEVERITY SCALE; NATURAL-HISTORY; ASSOCIATION; MACULOPATHY;
   PREVALENCE; SUSCEPTIBILITY; ALLELES
AB Several prediction models for progression of age-related macular degeneration (AMD) have been developed, but the added value of using genetic information in those models in addition to clinical characteristics is ambiguous. In this prospective cohort study, we explored the added value of genetics using a genetic risk score (GRS) based on 52 AMD-associated variants, in addition to the clinical severity grading at baseline as quantified by validated drusen detection software, to predict disease progression in 177 AMD patients after 6.5 years follow-up. The GRS was strongly associated with the drusen coverage at baseline (P< 0.001) and both the GRS and drusen coverage were associated with disease progression. When the GRS was added as predictor in addition to the drusen coverage, R-2 increased from 0.46 to 0.56. This improvement by the GRS was predominantly seen in patients with a drusen coverage < 15%. In patients with a larger drusen coverage, the GRS had less added value to predict progression. Thus, genetic information has added value over clinical characteristics in predicting disease progression in AMD, but only in patients with a less severe disease stage. Patients with a high GRS should be made aware of their risk and could be selected for clinical trials for arresting progression.
C1 [Heesterbeek, Thomas J.; de Jong, Eiko K.; Acar, Ilhan E.; Liefers, Bart; Sanchez, Clara I.; Hoyng, Carel B.; den Hollander, Anneke I.] Radboud Univ Nijmegen, Med Ctr, Donders Inst Brain Cognit & Behav, Dept Ophthalmol, Nijmegen, Netherlands.
   [de Jong, Eiko K.; Acar, Ilhan E.; den Hollander, Anneke I.] Radboud Univ Nijmegen, Med Ctr, Donders Inst Brain Cognit & Behav, Dept Human Genet, Nijmegen, Netherlands.
   [Groenewoud, Joannes M. M.] Radboud Univ Nijmegen, Med Ctr, Dept Hlth Evidence, Nijmegen, Netherlands.
   [Liefers, Bart; Sanchez, Clara I.] Radboud Univ Nijmegen, Med Ctr, Diagnost Image Anal Grp, Nijmegen, Netherlands.
   [Peto, Tunde] Queens Univ Belfast, Dept Ophthalmol, Belfast, Antrim, North Ireland.
   [Peto, Tunde] Queens Univ Belfast, Ctr Publ Hlth, Belfast, Antrim, North Ireland.
   [Pauleikhoff, Daniel] St Franziskus Hosp, Dept Ophthalmol, Munster, Germany.
   [Hense, Hans W.] Westfalische Wilhelms Univ, Inst Epidemiol & Social Med, Munster, Germany.
C3 Radboud University Nijmegen; Radboud University Nijmegen; Radboud
   University Nijmegen; Radboud University Nijmegen; Queens University
   Belfast; Queens University Belfast; St. Franziskus-Hospital; University
   of Munster
RP den Hollander, AI (通讯作者)，Radboud Univ Nijmegen, Med Ctr, Donders Inst Brain Cognit & Behav, Dept Ophthalmol, Nijmegen, Netherlands.; den Hollander, AI (通讯作者)，Radboud Univ Nijmegen, Med Ctr, Donders Inst Brain Cognit & Behav, Dept Human Genet, Nijmegen, Netherlands.
EM Anneke.denHollander@radboudumc.nl
RI Heesterbeek, Thomas Johannes/N-4732-2019; Groenewoud, Hans
   JMM/R-3588-2017; Acar, İlhan Erkin/B-7758-2018; Peto, Tunde/M-2081-2013
OI Heesterbeek, Thomas Johannes/0000-0002-3232-2587; Groenewoud, Hans
   JMM/0000-0002-4974-150X; Acar, İlhan Erkin/0000-0002-2078-9905; Peto,
   Tunde/0000-0001-6265-0381
FU Global Ophthalmology Awards Program (GOAP), a Bayer; Dutch Organization
   for Scientific Research [016.Vici.170.024]; Oogfonds; Landelijke
   Stichting voor Blinden en Slechtzienden; Vereniging Bartimeus
   Sonneheerdt [Uitzicht 201602, 2016-26]; Deutsche Forschungsgesellschaft
   [HE 2293/5-1, HE 2293/5-2, HE 2293/5-3, PA 357/7-1]; Intramural
   International Monetary Fund of the University of Muenster; Pro Retina
   Foundation; Jackstaedt Foundation; European Union [634479]; Macula Fonds
FX The authors would like to thank the contribution of the International
   AMD Genomics Consortium (IAMDGC) for making the ORs of the 52 AMD
   variants available for computing the GRS, and Birte Claes for her
   involvement in the data management of the MARS cohort. This research was
   supported by: the Global Ophthalmology Awards Program (GOAP), a
   Bayer-sponsored initiative committed to supporting ophthalmic research
   across the world (EKDJ), the Dutch Organization for Scientific Research
   (016.Vici.170.024 to AIdH), Oogfonds, Landelijke Stichting voor Blinden
   en Slechtzienden, Macula Fonds, Vereniging Bartimeus Sonneheerdt
   (Uitzicht 201602 and 2016-26 to AIdH, EKdJ, CBH), Deutsche
   Forschungsgesellschaft Grants HE 2293/5-1, 5-2, 5-3, and PA 357/7-1, the
   Intramural International Monetary Fund of the University of Muenster,
   the Pro Retina Foundation and the Jackstaedt Foundation (DP, HWH). This
   project has also received funding from the European Union's Horizon 2020
   research and innovation program under grant agreement No. 634479
   (EYE-RISK).
CR [Anonymous], 2018, COMP AID DET AG REL, V12
   BIRD AEC, 1995, SURV OPHTHALMOL, V39, P367, DOI 10.1016/S0039-6257(05)80092-X
   Buitendijk GHS, 2014, INVEST OPHTH VIS SCI, V55, P6167, DOI 10.1167/iovs.14-15142
   Buitendijk GHS, 2013, OPHTHALMOLOGY, V120, P2644, DOI 10.1016/j.ophtha.2013.07.053
   Cheung CMG, 2017, OPHTHALMOLOGY, V124, P1305, DOI 10.1016/j.ophtha.2017.03.056
   Colijn JM, 2017, OPHTHALMOLOGY, V124, P1753, DOI 10.1016/j.ophtha.2017.05.035
   Congdon N, 2004, ARCH OPHTHALMOL-CHIC, V122, P477
   Das S, 2016, NAT GENET, V48, P1284, DOI 10.1038/ng.3656
   Ding Y, 2017, GENETICS, V206, P119, DOI 10.1534/genetics.116.196998
   Farwick A, 2010, INVEST OPHTH VIS SCI, V51, P731, DOI 10.1167/iovs.09-3953
   Ferris FL, 2005, ARCH OPHTHALMOL-CHIC, V123, P1570
   Fritsche LG, 2016, NAT GENET, V48, P134, DOI 10.1038/ng.3448
   Grassmann F, 2017, GENOME MED, V9, DOI 10.1186/s13073-017-0418-0
   Hoffman JD, 2016, INVEST OPHTH VIS SCI, V57, P2225, DOI 10.1167/iovs.15-18571
   Joachim N, 2017, BRIT J OPHTHALMOL, V101, P1185, DOI 10.1136/bjophthalmol-2016-309729
   Joachim N, 2015, OPHTHALMOLOGY, V122, P2482, DOI 10.1016/j.ophtha.2015.08.002
   Jonasson F, 2014, OPHTHALMOLOGY, V121, P1766, DOI 10.1016/j.ophtha.2014.03.013
   Klaver CCW, 2001, INVEST OPHTH VIS SCI, V42, P2237
   Klein ML, 2011, ARCH OPHTHALMOL-CHIC, V129, P1543, DOI 10.1001/archophthalmol.2011.216
   Liew G, 2016, OPHTHALMOLOGY, V123, P1874, DOI 10.1016/j.ophtha.2016.05.043
   Machiela MJ, 2015, BIOINFORMATICS, V31, P3555, DOI 10.1093/bioinformatics/btv402
   Merle BMJ, 2015, AM J CLIN NUTR, V102, P1196, DOI 10.3945/ajcn.115.111047
   Mora AD, 2011, BIOMED ENG ONLINE, V10, DOI 10.1186/1475-925X-10-59
   Myers CE, 2014, OPHTHALMOLOGY, V121, P1949, DOI 10.1016/j.ophtha.2014.04.040
   Ong BB, 2013, EYE, V27, P554, DOI 10.1038/eye.2012.292
   Purcell S, 2007, AM J HUM GENET, V81, P559, DOI 10.1086/519795
   Sardell RJ, 2016, INVEST OPHTH VIS SCI, V57, P6107, DOI 10.1167/iovs.16-19519
   Schick T, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0156778
   Seddon JM, 2015, INVEST OPHTH VIS SCI, V56, P2192, DOI 10.1167/iovs.14-15841
   Seddon JM, 2011, OPHTHALMOLOGY, V118, P2203, DOI 10.1016/j.ophtha.2011.04.029
   Smith W, 2001, OPHTHALMOLOGY, V108, P697, DOI 10.1016/S0161-6420(00)00580-7
   van Grinsven MJJP, 2013, INVEST OPHTH VIS SCI, V54, P3019, DOI 10.1167/iovs.12-11449
   Vitale S, 2016, JAMA OPHTHALMOL, V134, P1041, DOI 10.1001/jamaophthalmol.2016.2383
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
   Yehoshua Z, 2011, OPHTHALMOLOGY, V118, P2434, DOI 10.1016/j.ophtha.2011.05.008
   Zhang QY, 2016, INVEST OPHTH VIS SCI, V57, P1276, DOI 10.1167/iovs.15-18637
NR 36
TC 11
Z9 11
U1 0
U2 2
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 2045-2322
J9 SCI REP-UK
JI Sci Rep
PD APR 29
PY 2019
VL 9
AR 6611
DI 10.1038/s41598-019-43144-3
PG 8
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA HV6XW
UT WOS:000466127100036
PM 31036867
OA Green Published, gold
DA 2022-11-30
ER

PT J
AU Enders, P
   Sitnilska, V
   Altay, L
   Schaub, F
   Muether, PS
   Fauser, S
AF Enders, Philip
   Sitnilska, Vasilena
   Altay, Lebriz
   Schaub, Friederike
   Muether, Philipp S.
   Fauser, Sascha
TI Retinal Nerve Fiber Loss in Anti-VEGF Therapy for Age-Related Macular
   Degeneration Can Be Decreased by Anterior Chamber Paracentesis
SO OPHTHALMOLOGICA
LA English
DT Article
DE Intravitreal injection; Neovascular age-related macular degeneration;
   Retinal nerve fiber loss; Anterior chamber paracentesis; Intraocular
   pressure spikes
ID ENDOTHELIAL GROWTH-FACTOR; INTRAOCULAR-PRESSURE; LAYER THICKNESS;
   INTRAVITREAL RANIBIZUMAB; OCULAR HYPERTENSION; FACTOR INJECTIONS;
   GLAUCOMA; DELAY; RIM
AB Purpose: To analyze peripapillary retinal nerve fiber layer thickness (RNFLT) change after long-term intravitreal anti-VEGF therapy. Patients with regular anterior chamber paracentesis (ACP) prior to intravitreal injections (IVIs) were compared to those without ACP. Methods: Neovascular age-related macular degeneration (nAMD) was treated in a pro re nata regimen with a minimum of 9 IVIs. RNFLT change was determined in spectral domain optical coherence tomography. Results: In 32 patients without ACP, mean RNFLT loss (-2.16 +/- 3.60 mu m) was significantly higher than in 44 patients with regular ACP (0.16 +/- 3.60; p = 0.029). Both groups were comparable in age (75.0 vs. 76.8 years; p = 0.35), number of IVIs (16.2 vs. 16.6; p = 0.98), and observational time (30.0 vs. 32.3 months; p = 0.32). In patients without ACP, RNFLT loss was higher compared to IVI-naive fellow eyes (p = 0.005), whereas in ACP patients, no difference was detected (p = 0.5). Conclusions: A moderate RNFLT loss is found in nonglaucomatous patients after injection therapy for nAMD. As it is decreased with regular ACP, tight management of intraocular pressure seems advisable. (C) 2017 S. Karger AG, Basel
C1 [Enders, Philip; Sitnilska, Vasilena; Altay, Lebriz; Schaub, Friederike; Muether, Philipp S.; Fauser, Sascha] Univ Hosp Cologne, Dept Ophthalmol, Kerpener Str 62, DE-50924 Cologne, Germany.
   [Fauser, Sascha] F Hoffmann La Roche & Cie AG, Basel, Switzerland.
C3 University of Cologne; Roche Holding
RP Enders, P (通讯作者)，Univ Hosp Cologne, Dept Ophthalmol, Kerpener Str 62, DE-50924 Cologne, Germany.
EM philip-enders@web.de
OI Enders, Philip/0000-0002-9527-4957
FU  [FOR 2240]
FX We thank all technical experts of our imaging laboratory as well as FOR
   2240 for their support.
CR Agard E, 2015, CAN J OPHTHALMOL, V50, P127, DOI 10.1016/j.jcjo.2014.11.004
   Aref AA, 2012, CURR OPIN OPHTHALMOL, V23, P105, DOI 10.1097/ICU.0b013e32834ff41d
   Beck M, 2016, AM J OPHTHALMOL, V167, P10, DOI 10.1016/j.ajo.2016.04.003
   Bressler SB, 2015, JAMA OPHTHALMOL, V133, P589, DOI 10.1001/jamaophthalmol.2015.186
   Chauhan BC, 2015, OPHTHALMOLOGY, V122, P1786, DOI 10.1016/j.ophtha.2015.06.001
   Demirel S, 2015, INT OPHTHALMOL, V35, P541, DOI 10.1007/s10792-014-9981-1
   Demirel S, 2015, CURR EYE RES, V40, P87, DOI 10.3109/02713683.2014.917190
   El-Ashry MF, 2015, CLIN OPHTHALMOL, V9, P1269, DOI 10.2147/OPTH.S80704
   Enders P, 2017, BRIT J OPHTHALMOL, V101, P138, DOI 10.1136/bjophthalmol-2015-307730
   Enders P, 2015, RETINA-J RET VIT DIS, V35, P454, DOI 10.1097/IAE.0000000000000320
   Fauser S, 2016, BR J OPHTHALMOL, DOI [10.1136/bjophthalmo1-2015-308264, DOI 10.1136/BJOPHTHALMO1-2015-308264]
   Goktas A, 2013, CUTAN OCUL TOXICOL, V32, P23, DOI 10.3109/15569527.2012.696569
   Horsley MB, 2010, AM J OPHTHALMOL, V150, P558, DOI 10.1016/j.ajo.2010.04.029
   Kim YJ, 2014, AM J OPHTHALMOL, V157, P1266, DOI 10.1016/j.ajo.2014.02.035
   Kiss S, 2014, OSLI RETINA, V45, P285, DOI 10.3928/23258160-20140709-04
   Martinez-de-la-Casa JM, 2012, INVEST OPHTH VIS SCI, V53, P6214, DOI 10.1167/iovs.12-9875
   Morshedi RG, 2016, J GLAUCOMA, V25, P291, DOI 10.1097/IJG.0000000000000173
   Muether PS, 2013, AM J OPHTHALMOL, V156, P989, DOI 10.1016/j.ajo.2013.06.020
   Muether PS, 2013, GRAEF ARCH CLIN EXP, V251, P453, DOI 10.1007/s00417-012-2038-0
   Muether PS, 2011, GRAEF ARCH CLIN EXP, V249, P633, DOI 10.1007/s00417-010-1520-9
   Parlak M, 2015, INT OPHTHALMOL, V35, P473, DOI 10.1007/s10792-014-9972-2
   Shin HJ, 2016, INVEST OPHTH VIS SCI, V57, P1798, DOI 10.1167/iovs.15-18404
   Solomon SD, 2014, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD005139.pub3
   Vianna JR, 2015, OPHTHALMOLOGY, V122, P2392, DOI 10.1016/j.ophtha.2015.08.020
   Ziemssen F, 2015, OPHTHALMOLOGE, V112, P246, DOI 10.1007/s00347-014-3217-7
NR 25
TC 12
Z9 12
U1 1
U2 5
PU KARGER
PI BASEL
PA ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND
SN 0030-3755
EI 1423-0267
J9 OPHTHALMOLOGICA
JI Ophthalmologica
PY 2017
VL 237
IS 2
BP 111
EP 118
DI 10.1159/000457907
PG 8
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA EQ7EV
UT WOS:000398247400007
PM 28245446
DA 2022-11-30
ER

PT J
AU Coco, RM
   Sanabria, MR
   Hernandez, AG
   Munoz, MF
AF Coco, Rosa M.
   Rosa Sanabria, M.
   Hernandez, Arturo G.
   Fernandez Munoz, Marta
TI Retinal Pigment Epithelium Tears in Age-Related Macular Degeneration
   Treated with Antiangiogenic Drugs: A Controlled Study with Long
   Follow-Up
SO OPHTHALMOLOGICA
LA English
DT Article
DE Age-related macular degeneration; Anti-VEGF therapy; Retinal pigment
   epithelium tear; Controlled study
ID OPTICAL COHERENCE TOMOGRAPHY; CHOROIDAL NEOVASCULARIZATION SECONDARY;
   INTRAVITREAL BEVACIZUMAB INJECTION; ANTI-VEGF THERAPY; PHOTODYNAMIC
   THERAPY; NATURAL-HISTORY; RANIBIZUMAB; DETACHMENT; PEGAPTANIB;
   VERTEPORFIN
AB Purpose: To study whether anti-vascular endothelial growth factor (VEGF) therapy improves visual acuity (VA) in patients with exudative age-related macular degeneration (AMD) complicated with retinal pigment epithelium (RPE) tears. Methods: Retrospective case-control series. Group I (control group) included 9 patients with RPE tears that received no treatment, and group II (intervention group) in-corporated 12 patients treated with anti-VEGF. Results: A statistically significant difference was found in VA between the groups from the 3rd month to the final follow-up (p = 0.034). Final VA improved in the treatment group (p = 0.015). No differences were found in central macular thickness between the groups either before or after treatment. Mean number of injections in group II was 5.75 (SD = 1.19). Most patients presented a grade 3 rip. All lesions were inactive at the end of follow-up in group II and 1 remained active in group I. The number of final atrophic/disciform scars was 6/8 in group I and 7/5 in group II. Conclusions: RPE tears treated with antiangiogenic drugs experienced functional benefit. To the authors' knowledge, this is the first controlled series reporting effectiveness of suppression of neovascular activity with antiangiogenic treatment after RPE rip in AMD. Copyright (C) 2012 S. Karger AG, Basel
C1 [Coco, Rosa M.; Rosa Sanabria, M.; Hernandez, Arturo G.] Univ Valladolid, Inst Appl Ophthalmobiol IOBA, ES-47011 Valladolid, Spain.
   [Rosa Sanabria, M.; Fernandez Munoz, Marta] Complejo Asistencial Palencia, Palencia, Spain.
C3 Universidad de Valladolid
RP Coco, RM (通讯作者)，Univ Valladolid, Inst Appl Ophthalmobiol IOBA, Campus Miguel Delibes Paseo de Belen 17, ES-47011 Valladolid, Spain.
EM rosa@ioba.med.uva.es
RI Sanabria, Maria Rosa/AAH-5766-2019; Martin, Rosa Maria Coco/H-4511-2015
OI Martin, Rosa Maria Coco/0000-0002-1811-1417; Hernandez Pena, Arturo
   Gabriel/0000-0002-1890-8469; Sanabria, Maria Rosa/0000-0002-1818-9812
FU Castilla and Leon local government [CC.AA 141-B]
FX Funding was obtained from the Castilla and Leon local government: CC.AA
   141-B.
CR Avery RL, 2006, OPHTHALMOLOGY, V113, P363, DOI 10.1016/j.ophtha.2005.11.019
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Caramoy A, 2011, ARCH OPHTHALMOL-CHIC, V129, P575, DOI 10.1001/archophthalmol.2011.105
   CASSWELL AG, 1985, BRIT J OPHTHALMOL, V69, P397, DOI 10.1136/bjo.69.6.397
   Chakravarthy U, 2006, OPHTHALMOLOGY, V113, P1508, DOI 10.1016/j.ophtha.2006.02.064
   Chan CK, 2007, EUR J OPHTHALMOL, V17, P674, DOI 10.1177/112067210701700432
   Chan CK, 2007, RETINA-J RET VIT DIS, V27, P541, DOI 10.1097/IAE.0b013e3180cc2612
   Chan CK, 2010, RETINA-J RET VIT DIS, V30, P203, DOI 10.1097/IAE.0b013e3181babda5
   Chang LK, 2007, RETINA-J RET VIT DIS, V27, P523, DOI 10.1097/IAE.0b013e3180a032db
   Chiang A, 2008, RETINA-J RET VIT DIS, V28, P1265, DOI 10.1097/IAE.0b013e31817d5d03
   CHUANG EL, 1988, BRIT J OPHTHALMOL, V72, P918, DOI 10.1136/bjo.72.12.918
   DECKER WL, 1983, OPHTHALMOLOGY, V90, P507
   Dhalla MS, 2006, AM J OPHTHALMOL, V141, P752, DOI 10.1016/j.ajo.2005.10.053
   Fung AE, 2007, AM J OPHTHALMOL, V143, P566, DOI 10.1016/j.ajo.2007.01.028
   Garg S, 2008, CLIN EXP OPHTHALMOL, V36, P252, DOI 10.1111/j.1442-9071.2008.01710.x
   Gelisken F, 2001, AM J OPHTHALMOL, V131, P518, DOI 10.1016/S0002-9394(00)00813-8
   Giovannini A, 2000, RETINA-J RET VIT DIS, V20, P37, DOI 10.1097/00006982-200001000-00007
   Goldstein M, 2005, EYE, V19, P1315, DOI 10.1038/sj.eye.6701765
   Gutfleisch M, 2011, EYE, V25, P1181, DOI 10.1038/eye.2011.146
   HOSKIN A, 1981, BRIT J OPHTHALMOL, V65, P417, DOI 10.1136/bjo.65.6.417
   Karadimas P, 2006, EUR J OPHTHALMOL, V16, P767, DOI 10.1177/112067210601600520
   Konstantinidis L, 2010, ACTA OPHTHALMOL, V88, P736, DOI 10.1111/j.1755-3768.2009.01547.x
   Lalwani GA, 2009, AM J OPHTHALMOL, V148, P43, DOI 10.1016/j.ajo.2009.01.024
   Lesniak SP, 2011, EUR J OPHTHALMOL, V21, P73, DOI 10.5301/EJO.2010.2285
   Maguire MG, 1997, ARCH OPHTHALMOL-CHIC, V115, P741
   MEREDITH TA, 1979, AM J OPHTHALMOL, V88, P643, DOI 10.1016/0002-9394(79)90659-7
   Michels S, 2006, AM J OPHTHALMOL, V141, P396, DOI 10.1016/j.ajo.2005.08.046
   NOROSE K, 1988, BRIT J OPHTHALMOL, V72, P621, DOI 10.1136/bjo.72.8.621
   Pece A, 2001, RETINA-J RET VIT DIS, V21, P661, DOI 10.1097/00006982-200112000-00017
   Peiretti E, 2006, RETINA-J RET VIT DIS, V26, P1097, DOI 10.1097/01.iae.0000233328.68999.5f
   POLINER LS, 1986, OPHTHALMOLOGY, V93, P543
   Polito A, 2011, BRIT J OPHTHALMOL, V95, P74, DOI 10.1136/bjo.2009.170381
   Ronan SM, 2007, RETINA-J RET VIT DIS, V27, P535, DOI 10.1097/IAE.0b013e3180cc2645
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Rouvas AA, 2011, RETINA-J RET VIT DIS, V31, P1083, DOI 10.1097/IAE.0b013e318207d1a3
   Sarraf D, 2010, RETINA-J RET VIT DIS, V30, P1039, DOI 10.1097/IAE.0b013e3181cdf366
   Singh RP, 2006, AM J OPHTHALMOL, V142, P160, DOI 10.1016/j.ajo.2006.03.051
   SLAKTER JS, 1994, ARCH OPHTHALMOL-CHIC, V112, P465, DOI 10.1001/archopht.1994.01090160041020
   Spaide R, 2007, AM J OPHTHALMOL, V143, P679, DOI 10.1016/j.ajo.2007.02.024
   Weinberger AWA, 2007, AM J OPHTHALMOL, V144, P294, DOI 10.1016/j.ajo.2007.03.024
   Zayit-Soudry S, 2007, SURV OPHTHALMOL, V52, P227, DOI 10.1016/j.survophthal.2007.02.008
NR 41
TC 20
Z9 22
U1 0
U2 4
PU KARGER
PI BASEL
PA ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND
SN 0030-3755
EI 1423-0267
J9 OPHTHALMOLOGICA
JI Ophthalmologica
PY 2012
VL 228
IS 2
BP 78
EP 83
DI 10.1159/000338730
PG 6
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 981EP
UT WOS:000306950000002
PM 22710369
DA 2022-11-30
ER

PT J
AU Kucuk, B
   Kadayifcilar, S
   Eldem, B
AF Kucuk, Bekir
   Kadayifcilar, Sibel
   Eldem, Bora
TI Assessment of the long-term visual and anatomical outcomes of
   ranibizumab to treat neovascular age-related macular degeneration
SO INTERNATIONAL JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
DE intravitreal injection; neovascular age-related macular degeneration;
   ranibizumab
ID CLINICAL-PRACTICE; THERAPY; EXPERIENCE; GERMANY; HORIZON; ANCHOR;
   ACUITY; AMD
AB AIM: To investigate the long-term visual and anatomical outcomes of patients who underwent intravitreal ranibizumab monotherapy to treat neovascular age-related macular degeneration (AMD) and followed-up for at least 2y.
   METHODS: A total of 74 eyes of 74 patients who underwent ranibizumab monotherapy for neovascular AMD were included in this retrospective study.
   RESULTS: The average patient age was 72.1 +/- 6.5 (range, 57-85)y, the average follow-up time 46.2 +/- 13.1 (range, 24-75)mo, and the average number of visits 24.1 +/- 9.5 (range, 8-48). The mean number of injections in year 1 was 4.5, 1.6 in year 2, 0.9 in year 3, 0.4 on year 4, and 0.1 in the following years. Within the entire follow-up period, the mean number of injections was 7.6 +/- 4.4 (range, 2-21). The mean visual acuity was 48.1 +/- 15 (range, 15-76) letters at baseline and 45.7 +/- 19 (range, 7-75) at year 5. The mean central macular thickness was 303 +/- 78 (range, 178-552) mu m at baseline and 251 +/- 51 (range, 138-359) mu m at year 5. Scars developed in 47 (63.5%) eyes at the end of the follow-up period, and atrophy was evident in 6 (8.1%) eyes.
   CONCLUSION: Ranibizumab monotherapy can stabilize visual acuity for a mean period of 4y in patients with neovascular AMD.
C1 [Kucuk, Bekir; Kadayifcilar, Sibel; Eldem, Bora] Hacettepe Univ, Dept Ophthalmol, TR-06100 Ankara, Turkey.
C3 Hacettepe University
RP Kucuk, B (通讯作者)，Hacettepe Univ, Dept Ophthalmol, TR-06100 Ankara, Turkey.
EM bekirkucuk1983@hotmail.com
CR Brown DM, 2009, OPHTHALMOLOGY, V116, P57, DOI 10.1016/j.ophtha.2008.10.018
   Chakravarthy U, 2013, LANCET, V382, P1258, DOI 10.1016/S0140-6736(13)61501-9
   Cohen SY, 2013, RETINA-J RET VIT DIS, V33, P474, DOI 10.1097/IAE.0b013e31827b6324
   Cohen SY, 2009, AM J OPHTHALMOL, V148, P409, DOI 10.1016/j.ajo.2009.04.001
   Finger RP, 2012, OPHTHALMOLOGE, V109, P474, DOI 10.1007/s00347-012-2554-7
   Finger RP, 2013, ACTA OPHTHALMOL, V91, P540, DOI 10.1111/j.1755-3768.2012.02493.x
   Freund KB, 2013, EXPERT OPIN PHARMACO, V14, P1017, DOI 10.1517/14656566.2013.787410
   Holz FG, 2015, BRIT J OPHTHALMOL, V99, P220, DOI 10.1136/bjophthalmol-2014-305327
   Holz FG, 2013, BRIT J OPHTHALMOL, V97, P1161, DOI 10.1136/bjophthalmol-2013-303232
   Klein R, 2007, OPHTHALMOLOGY, V114, P253, DOI 10.1016/j.ophtha.2006.10.040
   Kulkarni AD, 2005, ADV DRUG DELIVER REV, V57, P1994, DOI 10.1016/j.addr.2005.09.003
   Martin DF, 2012, OPHTHALMOLOGY, V119, DOI 10.1016/j.ophtha.2012.03.053
   Rofagha S, 2013, OPHTHALMOLOGY, V120, P2292, DOI 10.1016/j.ophtha.2013.03.046
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Rotsos T, 2010, CLIN OPHTHALMOL, V4, P1271, DOI 10.2147/OPTH.S14684
   Singer MA, 2012, OPHTHALMOLOGY, V119, P1175, DOI 10.1016/j.ophtha.2011.12.016
   Smith W, 2001, OPHTHALMOLOGY, V108, P697, DOI 10.1016/S0161-6420(00)00580-7
   Ziemssen F, 2015, OPHTHALMOLOGE, V112, P246, DOI 10.1007/s00347-014-3217-7
NR 18
TC 5
Z9 5
U1 0
U2 1
PU IJO PRESS
PI XI AN
PA NO 269 YOUYI EAST RD, XI AN, 710054, PEOPLES R CHINA
SN 2222-3959
EI 2227-4898
J9 INT J OPHTHALMOL-CHI
JI Int. J. Ophthalmol.
PD APR 18
PY 2018
VL 11
IS 4
BP 645
EP 649
DI 10.18240/ijo.2018.04.18
PG 5
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA GC9QQ
UT WOS:000430133900018
PM 29675385
OA Green Published, gold, Green Submitted
DA 2022-11-30
ER

PT J
AU Hata, M
   Oishi, A
   Tsujikawa, A
   Yamashiro, K
   Miyake, M
   Ooto, S
   Tamura, H
   Nakanishi, H
   Takahashi, A
   Yoshikawa, M
   Yoshimura, N
AF Hata, Masayuki
   Oishi, Akio
   Tsujikawa, Akitaka
   Yamashiro, Kenji
   Miyake, Masahiro
   Ooto, Sotaro
   Tamura, Hiroshi
   Nakanishi, Hideo
   Takahashi, Ayako
   Yoshikawa, Munemitsu
   Yoshimura, Nagahisa
TI Efficacy of Intravitreal Injection of Aflibercept in Neovascular
   Age-Related Macular Degeneration With or Without Choroidal Vascular
   Hyperpermeability
SO INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE
LA English
DT Article
DE age-related macular degeneration; polypoidal choroidal vasculopathy;
   choroidal vascular hyperpermeability; optical coherence tomography
ID ENDOTHELIAL GROWTH-FACTOR; CENTRAL SEROUS CHORIORETINOPATHY;
   INDOCYANINE-GREEN ANGIOGRAPHY; OPTICAL COHERENCE TOMOGRAPHY; VEGF-TRAP;
   PHOTODYNAMIC THERAPY; RANIBIZUMAB; VASCULOPATHY; THICKNESS; BEVACIZUMAB
AB PURPOSE. To compare therapeutic responses to intravitreal aflibercept and ranibizumab in neovascular age-related macular degeneration (AMD)-affected eyes with and without choroidal vascular hyperpermeability (CVH).
   METHODS. Medical records of 216 consecutive patients (216 eyes) with treatment-naive exudative AMD who had received three monthly intravitreal injections of aflibercept (2 mg) and ranibizumab (0.5 mg) at a single institution were analyzed. The associations of CVH with functional and morphologic changes were compared between the treatment groups.
   RESULTS. Although foveal thickness (P = 0.85) and visual acuity (P = 0.13) changes were not significantly different between the treatment groups, subfoveal choroidal thickness (CT) (P = 0.001) and pigment epithelial detachment (PED) height (P = 0.043) decreased more profoundly in the aflibercept-treated group. The incidence of dry macula after treatments was lower in the ranibizumab-treated eyes with CVH than in those without CVH (P = 0.043), but it showed no significant difference between the aflibercept-treated eyes with and without CVH (P = 0.74). The aflibercept-treated eyes with CVH showed a higher incidence of dry macula (P = 0.04) and greater decrease in subfoveal CT (P = 0.002) than the ranibizumab-treated eyes with CVH.
   CONCLUSIONS. Intravitreal aflibercept can achieve remission of exudative retinal changes in eyes with AMD even in the presence of CVH. In addition, it showed greater effects on the choroid and PED than intravitreal ranibizumab. The possible relationship between CVH suppression and decrease in CT warrants further study.
C1 [Hata, Masayuki; Oishi, Akio; Tsujikawa, Akitaka; Yamashiro, Kenji; Miyake, Masahiro; Ooto, Sotaro; Tamura, Hiroshi; Nakanishi, Hideo; Takahashi, Ayako; Yoshikawa, Munemitsu; Yoshimura, Nagahisa] Kyoto Univ, Grad Sch Med, Dept Ophthalmol & Visual Sci, Kyoto 6068507, Japan.
C3 Kyoto University
RP Oishi, A (通讯作者)，Kyoto Univ, Grad Sch Med, Dept Ophthalmol & Visual Sci, Sakyo Ku, Kyoto 6068507, Japan.
EM aquio@kuhp.kyoto-u.ac.jp
RI Oishi, Akio/AAE-9996-2020; TAMURA, Hiroshi/H-1855-2011; Miyake,
   Masahiro/V-1261-2019
OI Oishi, Akio/0000-0002-0977-9458; TAMURA, Hiroshi/0000-0002-7740-2732;
   Miyake, Masahiro/0000-0001-7410-3764; Tsujikawa,
   Akitaka/0000-0003-0779-7799; Yamashiro, Kenji/0000-0001-9354-8558
CR Bakall B, 2013, AM J OPHTHALMOL, V156, P15, DOI 10.1016/j.ajo.2013.02.017
   Branchini L, 2013, JAMA OPHTHALMOL, V131, P693, DOI 10.1001/jamaophthalmol.2013.692
   Cao XS, 2014, RETINA-J RET VIT DIS, V34, P1554, DOI 10.1097/IAE.0000000000000122
   Cho HJ, 2013, AM J OPHTHALMOL, V156, P1192, DOI 10.1016/j.ajo.2013.07.001
   Dixon JA, 2009, EXPERT OPIN INV DRUG, V18, P1573, DOI 10.1517/13543780903201684
   Fassnacht-Riederle H, 2014, GRAEF ARCH CLIN EXP, V252, P1705, DOI 10.1007/s00417-014-2589-3
   GUYER DR, 1992, OPHTHALMOLOGY, V99, P287
   Heier JS, 2012, OPHTHALMOLOGY, V119, P2537, DOI 10.1016/j.ophtha.2012.09.006
   Ho VY, 2013, AM J OPHTHALMOL, V156, P23, DOI 10.1016/j.ajo.2013.02.009
   Holash J, 2002, P NATL ACAD SCI USA, V99, P11393, DOI 10.1073/pnas.172398299
   Jirarattanasopa P, 2012, INVEST OPHTH VIS SCI, V53, P3663, DOI 10.1167/iovs.12-9619
   Julien S, 2014, BRIT J OPHTHALMOL, V98, P813, DOI 10.1136/bjophthalmol-2013-304019
   Koizumi H, 2013, AM J OPHTHALMOL, V155, P305, DOI 10.1016/j.ajo.2012.07.018
   Kumar N, 2013, RETINA-J RET VIT DIS, V33, P1605, DOI 10.1097/IAE.0b013e31828e8551
   Lafaut BA, 1998, GRAEF ARCH CLIN EXP, V236, P513, DOI 10.1007/s004170050114
   LEUNG DW, 1989, SCIENCE, V246, P1306, DOI 10.1126/science.2479986
   Maruko I, 2013, AM J OPHTHALMOL, V156, P548, DOI 10.1016/j.ajo.2013.03.041
   Michels S, 2003, INVEST OPHTH VIS SCI, V44, P2147, DOI 10.1167/iovs.02-0604
   Nagy JA, 2008, ANGIOGENESIS, V11, P109, DOI 10.1007/s10456-008-9099-z
   Papadopoulos N, 2012, ANGIOGENESIS, V15, P171, DOI 10.1007/s10456-011-9249-6
   Patel KH, 2013, EYE, V27, P664, DOI 10.1038/eye.2013.31
   Sasahara M, 2006, AM J OPHTHALMOL, V142, P601, DOI 10.1016/j.ajo.2006.05.051
   Schmidt-Erfurth U, 2000, SURV OPHTHALMOL, V45, P195, DOI 10.1016/S0039-6257(00)00158-2
   Schmidt-Erfurth U, 2002, INVEST OPHTH VIS SCI, V43, P830
   Spaide RF, 1996, RETINA-J RET VIT DIS, V16, P203, DOI 10.1097/00006982-199616030-00004
   Spaide RF, 2008, AM J OPHTHALMOL, V146, P496, DOI 10.1016/j.ajo.2008.05.032
   Stewart MW, 2008, BRIT J OPHTHALMOL, V92, P667, DOI 10.1136/bjo.2007.134874
   Witmer AN, 2003, PROG RETIN EYE RES, V22, P1, DOI 10.1016/S1350-9462(02)00043-5
   Yonekawa Y, 2013, AM J OPHTHALMOL, V156, P29, DOI 10.1016/j.ajo.2013.03.030
NR 29
TC 45
Z9 45
U1 0
U2 4
PU ASSOC RESEARCH VISION OPHTHALMOLOGY INC
PI ROCKVILLE
PA 12300 TWINBROOK PARKWAY, ROCKVILLE, MD 20852-1606 USA
SN 0146-0404
EI 1552-5783
J9 INVEST OPHTH VIS SCI
JI Invest. Ophthalmol. Vis. Sci.
PD DEC
PY 2014
VL 55
IS 12
BP 7874
EP 7880
DI 10.1167/iovs.14-14610
PG 7
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA AX9KR
UT WOS:000347222300018
PM 25395483
DA 2022-11-30
ER

PT J
AU Monestam, E
   Lundqvist, B
AF Monestam, Eva
   Lundqvist, Britta
TI Long-term visual outcome after cataract surgery: Comparison of healthy
   eyes and eyes with age-related macular degeneration
SO JOURNAL OF CATARACT AND REFRACTIVE SURGERY
LA English
DT Article
ID BLUE MOUNTAINS EYE; POPULATION; RISK; MACULOPATHY; ASSOCIATION; DISEASE
AB PURPOSE: To compare the long-term longitudinal visual acuity outcomes after cataract surgery in eyes with age-related macular degeneration (AMD) at surgery and eyes without comorbidity.
   SETTING: University-based eye clinic.
   DESIGN: Longitudinal cohort study.
   METHODS: Patients having cataract surgery were evaluated over 1 year. A clinical eye examination and corrected distance visual acuity (CDVA) measurement were performed preoperatively and postoperatively as well as 5 and 10 years postoperatively for eligible patients. The patients were divided into functional groups depending on postoperative signs of macular degeneration and postoperative CDVA.
   RESULTS: The study evaluated 810 patients. The rate of CDVA decline with age was faster in AMD patients than in patients without comorbidity. The slope of the visual acuity decline was similar in the 2 subgroups with AMD (almost normal CDVA and reduced CDVA postoperatively). After adjustment for age, there was a mean loss of 2.3 logMAR letters in patients with no comorbidity and 6.4 letters in patients with AMD at surgery for each decade of increasing age. More than 75% of AMD patients had better CDVA 10 years after surgery than before surgery.
   CONCLUSIONS: Patients with signs of AMD at cataract surgery had a longitudinally worse visual outcome than patients without clinical signs of AMD. However, there is no reason to discourage patients with concurrent visually significant cataract and AMD from having surgery because most AMD patients had better CDVA 10 years after surgery than before surgery.
C1 [Monestam, Eva; Lundqvist, Britta] Umea Univ, Dept Clin Sci Ophthalmol, Fac Med, Norrlands Univ Hosp, S-90185 Umea, Sweden.
C3 Umea University
RP Monestam, E (通讯作者)，Umea Univ, Dept Clin Sci Ophthalmol, S-90185 Umea, Sweden.
EM eva.monestam@vll.se
FU Vasterbottens County Council, Umea; Swedish Medical Society, Stockholm;
   Crown Princess Margareta's Committee for the Blind, Stockholm, Sweden
FX Supported in part by grants from Vasterbottens County Council Research
   Fund, Umea, the Swedish Medical Society, Stockholm, and Crown Princess
   Margareta's Committee for the Blind, Stockholm, Sweden.
CR Armbrecht AM, 2003, J CATARACT REFR SURG, V29, P686, DOI 10.1016/S0886-3350(02)01650-4
   Armbrecht AM, 2000, BRIT J OPHTHALMOL, V84, P1343, DOI 10.1136/bjo.84.12.1343
   Baatz H, 2008, INVEST OPHTH VIS SCI, V49, P1079, DOI 10.1167/iovs.07-0557
   Chew EY, 2009, OPHTHALMOLOGY, V116, P297, DOI 10.1016/j.ophtha.2008.09.019
   Cugati S, 2006, OPHTHALMOLOGY, V113, P2020, DOI 10.1016/j.ophtha.2006.05.047
   Elliott BE, 1995, OPTOMETRY VISION SCI, V72, P186
   Forooghian F, 2009, OPHTHALMOLOGY, V116, P2093, DOI 10.1016/j.ophtha.2009.04.033
   Freeman EE, 2003, AM J OPHTHALMOL, V135, P849, DOI 10.1016/S0002-9394(02)02253-5
   Ho L, 2008, INVEST OPHTH VIS SCI, V49, P4795, DOI 10.1167/iovs.08-2066
   Klein R, 2002, ARCH OPHTHALMOL-CHIC, V120, P1551, DOI 10.1001/archopht.120.11.1551
   Krishnaiah S, 2005, INVEST OPHTH VIS SCI, V46, P4442, DOI 10.1167/iovs.05-0853
   Lundqvist B, 2006, J CATARACT REFR SURG, V32, P1944, DOI 10.1016/j.jcrs.2006.06.023
   Monestam E, 2005, BRIT J OPHTHALMOL, V89, P459, DOI 10.1136/bjo.2004.051151
   Monestam EI, 2009, OPHTHALMOLOGY, V116, P2315, DOI 10.1016/j.ophtha.2009.05.015
   Sjostrand J, 2011, ACTA OPHTHALMOL, V89, P116, DOI 10.1111/j.1755-3768.2009.01653.x
   Sutter FKP, 2007, INVEST OPHTH VIS SCI, V48, P1472, DOI 10.1167/iovs.06-0766
   Wang JJ, 2000, CLIN EXP OPHTHALMOL, V28, P268, DOI 10.1046/j.1442-9071.2000.00315.x
   Wong T, 2008, OPHTHALMOLOGY, V115, P116, DOI 10.1016/j.ophtha.2007.03.008
NR 18
TC 20
Z9 20
U1 0
U2 2
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0886-3350
J9 J CATARACT REFR SURG
JI J. Cataract. Refract. Surg.
PD MAR
PY 2012
VL 38
IS 3
BP 409
EP 414
DI 10.1016/j.jcrs.2011.09.041
PG 6
WC Ophthalmology; Surgery
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology; Surgery
GA 904OS
UT WOS:000301208400006
PM 22245170
DA 2022-11-30
ER

PT J
AU Sarks, S
   Cherepanoff, S
   Killingsworth, M
   Sarks, J
AF Sarks, Shirley
   Cherepanoff, Svetlana
   Killingsworth, Murray
   Sarks, John
TI Relationship of basal laminar deposit and membranous debris to the
   clinical presentation of early age-related macular degeneration
SO INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE
LA English
DT Article
ID RETINAL-PIGMENT EPITHELIUM; BRUCHS MEMBRANE; LINEAR DEPOSIT;
   CLINICOPATHOLOGICAL CORRELATION; 5-YEAR INCIDENCE; DRUSEN; MACULOPATHY;
   ABNORMALITIES; EYES; PREVALENCE
AB PURPOSE. To correlate basallaminar deposit (BLamD) and membranous debris, including basal linear deposit (BLinD), with the evolution of early age-related macular degeneration (AMD).
   METHODs. A clinicopathologic collection of 132 eyes with a continuous layer of BLamD was reviewed. The thickness and type of BLamD and the sites of membranous debris deposition were correlated with the clinical progression of the disease.
   RESULTS. Two types of BLamD, termed early and late, were identified based on light microscopic appearance by using the picro-Mallory stain. The progressive accumulation of late type BLamD correlated well with increasing BLamD, thickness, advancing RPE degeneration, poorer vision, increasing age, and clinically evident pigment changes. Membranous debris initially accumulated diffusely as BLinD, most eyes with BLinD and early BLamD remaining funduscopically normal. However, membranous debris also formed focal collections as basal mounds internal to the RPE basement membrane and as soft drusen external to the basement membrane. Eyes in which membranous debris remained confined to basal mounds belonged to older patients with poorer vision, whereas patients with soft drusen were younger and had better vision.
   CONCLUSIONS. The presence of BUILD and early BLamD define threshold AMD, which manifests clinically as a normal fundus. Although late BLamD correlates most closely with clinical pigment abnormalities, it is the quantity and sites of membranous debris accumulation that appear to determine whether the disease develops pigment changes only or follows the alternative pathway of soft drusen formation with its attendant greater risk of choroidal neovascularization (CNV).
C1 Prince Wales Med Res Inst, Randwick, NSW, Australia.
   SW Area Pathol Serv, Sydney, NSW, Australia.
C3 Prince Wales Medical Research Institute
RP Sarks, S (通讯作者)，15 Parnell St, Strathfield, NSW 2135, Australia.
EM shsarks@bigpond.net.au
RI Killingsworth, Murray C/G-5908-2015; Mitchell, Paul/P-1498-2014;
   Killingsworth, Murray/O-3736-2019
OI Killingsworth, Murray/0000-0002-6125-1183
CR [Anonymous], 2005, ARCH OPHTHALMOL-CHIC, V123, P1570, DOI DOI 10.1001/ARCHOPHT.123.11.1570
   BRESSLER NM, 1995, ARCH OPHTHALMOL-CHIC, V113, P301, DOI 10.1001/archopht.1995.01100030055022
   BRESSLER NM, 1994, RETINA-J RET VIT DIS, V14, P130, DOI 10.1097/00006982-199414020-00006
   BRESSLER SB, 1990, ARCH OPHTHALMOL-CHIC, V108, P1442, DOI 10.1001/archopht.1990.01070120090035
   Curcio CA, 2005, EXP EYE RES, V80, P761, DOI 10.1016/j.exer.2004.09.017
   Curcio CA, 1999, ARCH OPHTHALMOL-CHIC, V117, P329, DOI 10.1001/archopht.117.3.329
   Dubovy SR, 2000, RETINA-J RET VIT DIS, V20, P638, DOI 10.1097/00006982-200011000-00009
   Green W R, 1999, Mol Vis, V5, P27
   GREEN WR, 1993, OPHTHALMOLOGY, V100, P1519
   GREEN WR, 1985, OPHTHALMOLOGY, V92, P615
   Guidry C, 2002, INVEST OPHTH VIS SCI, V43, P267
   Hillenkamp J, 2004, INVEST OPHTH VIS SCI, V45, P1493, DOI 10.1167/iovs.03-0765
   Hussain AA, 2002, J OPT SOC AM A, V19, P166, DOI 10.1364/JOSAA.19.000166
   KILLINGSWORTH MC, 1990, EYE, V4, P613, DOI 10.1038/eye.1990.86
   Klein R, 1997, OPHTHALMOLOGY, V104, P7, DOI 10.1016/S0161-6420(97)30368-6
   KLEIN R, 1992, OPHTHALMOLOGY, V99, P933
   Li CM, 2006, INVEST OPHTH VIS SCI, V47, P3119, DOI 10.1167/iovs.05-1446
   Li CM, 2005, INVEST OPHTH VIS SCI, V46, P2576, DOI 10.1167/iovs.05-0034
   LOFFLER KU, 1986, GRAEF ARCH CLIN EXP, V224, P493, DOI 10.1007/BF02154735
   MALORNI W, 1992, ANN NY ACAD SCI, V663, P218, DOI 10.1111/j.1749-6632.1992.tb38666.x
   MALORNI W, 1991, CHEM-BIOL INTERACT, V80, P217, DOI 10.1016/0009-2797(91)90026-4
   Marin-Castano ME, 2005, INVEST OPHTH VIS SCI, V46, P3331, DOI 10.1167/iovs.04-1224
   MARSHALL GE, 1992, BRIT J OPHTHALMOL, V76, P607, DOI 10.1136/bjo.76.10.607
   MITCHELL P, 1995, OPHTHALMOLOGY, V102, P1450
   Moore DJ, 2001, INVEST OPHTH VIS SCI, V42, P2970
   PAULEIKHOFF D, 1990, OPHTHALMOLOGY, V97, P171
   SARKS JP, 1988, EYE, V2, P552, DOI 10.1038/eye.1988.106
   SARKS JP, 1994, EYE, V8, P269, DOI 10.1038/eye.1994.57
   SARKS SH, 1976, BRIT J OPHTHALMOL, V60, P324, DOI 10.1136/bjo.60.5.324
   Sarks SH, 1999, BRIT J OPHTHALMOL, V83, P358, DOI 10.1136/bjo.83.3.358
   SARKS SH, 1980, T OPHTHAL SOC UK, V100, P414
   SARKS SH, 2001, MED RETINA, P1064
   Sarraf D, 1999, RETINA-J RET VIT DIS, V19, P513, DOI 10.1097/00006982-199911000-00006
   Spraul CW, 1999, SURV OPHTHALMOL, V44, pS10, DOI 10.1016/S0039-6257(99)00086-7
   Starita C, 1996, EXP EYE RES, V62, P565, DOI 10.1006/exer.1996.0066
   VANDERSCHAFT TL, 1993, BRIT J OPHTHALMOL, V77, P657, DOI 10.1136/bjo.77.10.657
   VANDERSCHAFT TL, 1994, GRAEF ARCH CLIN EXP, V232, P40, DOI 10.1007/BF00176436
   Wang JJ, 2003, ARCH OPHTHALMOL-CHIC, V121, P658, DOI 10.1001/archopht.121.5.658
   Zarbin MA, 2004, ARCH OPHTHALMOL-CHIC, V122, P598, DOI 10.1001/archopht.122.4.598
NR 39
TC 157
Z9 159
U1 0
U2 6
PU ASSOC RESEARCH VISION OPHTHALMOLOGY INC
PI ROCKVILLE
PA 12300 TWINBROOK PARKWAY, ROCKVILLE, MD 20852-1606 USA
SN 0146-0404
EI 1552-5783
J9 INVEST OPHTH VIS SCI
JI Invest. Ophthalmol. Vis. Sci.
PD MAR
PY 2007
VL 48
IS 3
BP 968
EP 977
DI 10.1167/iovs.06-0443
PG 10
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 142YF
UT WOS:000244686500003
PM 17325134
DA 2022-11-30
ER

PT J
AU Foo, VHX
   Yanagi, Y
   Nguyen, QD
   Sabanayagam, C
   Lim, SH
   Neelam, K
   Wang, JJ
   Mitchell, P
   Cheng, CY
   Wong, TY
   Cheung, CMG
AF Foo, Valencia Hui Xian
   Yanagi, Yasuo
   Quang Duc Nguyen
   Sabanayagam, Charumathi
   Lim, Sing Hui
   Neelam, Kumari
   Wang, Jie Jin
   Mitchell, Paul
   Cheng, Ching-Yu
   Wong, Tien Yin
   Cheung, Chui Ming Gemmy
TI Six-Year Incidence and Risk Factors of Age-Related Macular Degeneration
   in Singaporean Indians: The Singapore Indian Eye Study
SO SCIENTIFIC REPORTS
LA English
DT Article
ID POLYPOIDAL CHOROIDAL VASCULOPATHY; RETINAL-PIGMENT EPITHELIUM; FACTOR-H
   GENE; 5-YEAR INCIDENCE; JAPANESE POPULATION; LIPID-PEROXIDATION; NO
   ASSOCIATION; NATURAL COURSE; UNITED-STATES; FELLOW EYES
AB We aimed to determine the 6-year incidence and risk factors of age-related macular degeneration (AMD) in first and second generations of Singaporean Indians. Baseline examination was conducted in 2007-9 and 6-year propsective follow-up examination of this Indian population in 2013-5. All participants underwent interviews with questionnaires and comprehensive medical and eye examinations. Incidence was age-standardized to Singaporean 2010 census. Risk factors associated with AMD incidence were assessed and compared between first and second generations of immigrants. Among 2200 persons who participated in the follow-up examination (75.5% response rate), gradable fundus photographs were available in 2105. The 6-year age-standardized incidences of early and late AMD were 5.26% and 0.51% respectively. Incident early AMD was associated with cardiovascular disease history (HR 1.59, 95% CI 1.04-2.45), underweight body mass index (BMI) (HR 3.12, 95% CI 1.37-7.14) (BMI of < 18.5 vs 18.51-25 kg/m(2)), heavy alcohol drinking (HR 3.14 95% CI 1.25-7.89) and ARMS2 rs3750847 homozygous genetic loci carrier (HR 2.52, 95% CI 1.59-3.99). We found a relatively low incidence of early AMD in this Singaporean Indian population compared to Caucasian populations. Both first and second-generation Indian immigrants have similar incidence and risk factor patterns for early AMD.
C1 [Foo, Valencia Hui Xian; Yanagi, Yasuo; Quang Duc Nguyen; Sabanayagam, Charumathi; Neelam, Kumari; Cheng, Ching-Yu; Wong, Tien Yin; Cheung, Chui Ming Gemmy] Singapore Natl Eye Ctr, Singapore Eye Res Inst, Singapore, Singapore.
   [Yanagi, Yasuo; Neelam, Kumari; Cheng, Ching-Yu; Wong, Tien Yin; Cheung, Chui Ming Gemmy] Duke NUS Med Sch, Ophthalmol & Visual Sci Acad Clin Program Eye ACP, Singapore, Singapore.
   [Sabanayagam, Charumathi; Cheng, Ching-Yu] Duke NUS Med Sch, Ctr Quantitat Med, Singapore, Singapore.
   [Lim, Sing Hui; Wong, Tien Yin; Cheung, Chui Ming Gemmy] Singapore Natl Eye Ctr, Singapore, Singapore.
   [Wang, Jie Jin] Duke NUS Med Sch, Acad Med Res Inst, Singapore, Singapore.
   [Mitchell, Paul] Univ Sydney, Westmead Millennium Inst Med Res, Ctr Vis Res, Sydney, NSW, Australia.
C3 National University of Singapore; Singapore National Eye Center;
   National University of Singapore; National University of Singapore;
   Singapore National Eye Center; National University of Singapore;
   University of Sydney
RP Cheung, CMG (通讯作者)，Singapore Natl Eye Ctr, Singapore Eye Res Inst, Singapore, Singapore.; Cheung, CMG (通讯作者)，Duke NUS Med Sch, Ophthalmol & Visual Sci Acad Clin Program Eye ACP, Singapore, Singapore.; Cheung, CMG (通讯作者)，Singapore Natl Eye Ctr, Singapore, Singapore.
EM gemmy.cheung.c.m@singhealth.com.sg
RI wang, jie/GRS-0942-2022; Yanagi, Yasuo/AAF-2670-2020; Sabanayagam,
   Charumathi/C-1294-2011; Wang, Jie Jin/P-1499-2014; Yanagi,
   Yasuo/AAA-5441-2022; Wong, Tien Yin/AAC-9724-2020; Cheng,
   Ching-Yu/Y-2229-2019
OI Sabanayagam, Charumathi/0000-0002-4042-4719; Wang, Jie
   Jin/0000-0001-9491-4898; Wong, Tien Yin/0000-0002-8448-1264; Cheng,
   Ching-Yu/0000-0003-0655-885X; Yanagi, Yasuo/0000-0002-0362-7285; Cheung,
   Chui Ming Gemmy/0000-0003-3358-3516
FU National Medical Research Council [0796/2003]; Biomedical Research
   Council [501/25-5]
FX National Medical Research Council grants no. 0796/2003 and Biomedical
   Research Council Grant no. 501/25-5.
CR Abouzeid M, 2013, BMC PUBLIC HEALTH, V13, DOI 10.1186/1471-2458-13-252
   Agar E, 2003, INT J NEUROSCI, V113, P1643, DOI 10.1080/00207450390245207
   Alexander SL, 2007, OPHTHALMOLOGY, V114, P2174, DOI 10.1016/j.ophtha.2007.09.017
   [Anonymous], 2012, AM J KIDNEY DIS S, V39, pS1
   Aoki A, 2015, INVEST OPHTH VIS SCI, V56, P2580, DOI 10.1167/iovs.14-16339
   Barbazetto IA, 2010, AM J OPHTHALMOL, V149, P939, DOI 10.1016/j.ajo.2010.01.007
   BAUN O, 1993, ACTA OPHTHALMOL, V71, P398
   BRESSLER NM, 1995, ARCH OPHTHALMOL-CHIC, V113, P301, DOI 10.1001/archopht.1995.01100030055022
   BRESSLER SB, 1990, ARCH OPHTHALMOL-CHIC, V108, P1442, DOI 10.1001/archopht.1990.01070120090035
   Buch H, 2005, OPHTHALMOLOGY, V112, P787, DOI 10.1016/j.ophtha.2004.11.040
   BURGESS DB, 1993, ARCH OPHTHALMOL-CHIC, V111, P1189
   CEDERBAUM AI, 1989, FREE RADICAL BIO MED, V7, P537, DOI 10.1016/0891-5849(89)90029-4
   Chakravarthy U, 2010, BMC OPHTHALMOL, V10, DOI 10.1186/1471-2415-10-31
   CHANG B, 1995, OPHTHALMOLOGY, V102, P1380, DOI 10.1016/S0161-6420(95)30860-3
   Chen HY, 2012, MOL VIS, V18, P816
   Chen JH, 2013, MOL VIS, V19, P944
   Cheng CY, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms7063
   Cheung CMG, 2017, OPHTHALMOLOGY, V124, P1305, DOI 10.1016/j.ophtha.2017.03.056
   Cheung CMG, 2013, AM J OPHTHALMOL, V155, P764, DOI 10.1016/j.ajo.2012.10.013
   Chong EWT, 2008, AM J OPHTHALMOL, V145, P707, DOI 10.1016/j.ajo.2007.12.005
   Driver SL, 2016, J AM COLL CARDIOL, V67, P1227, DOI 10.1016/j.jacc.2015.12.047
   Ferris FL, 2005, ARCH OPHTHALMOL-CHIC, V123, P1570
   Fisher DE, 2016, OPHTHALMOLOGY, V123, P1297, DOI 10.1016/j.ophtha.2015.12.026
   GASS JDM, 1973, ARCH OPHTHALMOL-CHIC, V90, P206
   Gotoh N, 2008, CLIN EXP OPHTHALMOL, V36, P437, DOI 10.1111/j.1442-9071.2008.01791.x
   Gotoh N, 2006, HUM GENET, V120, P139, DOI 10.1007/s00439-006-0187-0
   Gregor Z, 1997, BR J OPHTHALMOL, V61, P141
   Gupta SK, 2007, INVEST OPHTH VIS SCI, V48, P1007, DOI 10.1167/iovs.06-0712
   Holliday EG, 2013, PLOS ONE, V8, DOI [10.1371/journal.pone.0082305, 10.1371/journal.pone.0053830]
   HOLZ FG, 1994, OPHTHALMOLOGY, V101, P1522
   Jakobsdottir J, 2009, PLOS GENET, V5, DOI 10.1371/journal.pgen.1000337
   Jonasson F, 2005, OPHTHALMOLOGY, V112, P132, DOI 10.1016/j.ophtha.2004.07.020
   Kanda A, 2007, P NATL ACAD SCI USA, V104, P16227, DOI 10.1073/pnas.0703933104
   KATZ ML, 1982, EXP EYE RES, V34, P339, DOI 10.1016/0014-4835(82)90082-3
   Kaushal N, 2009, HEALTH ECON, V18, P291, DOI 10.1002/hec.1368
   Kawasaki R, 2010, OPHTHALMOLOGY, V117, P921, DOI 10.1016/j.ophtha.2009.10.007
   Klaver CCW, 2001, INVEST OPHTH VIS SCI, V42, P2237
   Klein R, 1997, OPHTHALMOLOGY, V104, P7, DOI 10.1016/S0161-6420(97)30368-6
   Klein R, 2002, OPHTHALMOLOGY, V109, P1767, DOI 10.1016/S0161-6420(02)01146-6
   KLEIN R, 1991, OPHTHALMOLOGY, V98, P1128
   Klein R, 1999, PROG RETIN EYE RES, V18, P371, DOI 10.1016/S1350-9462(98)00025-1
   Klein R, 2007, OPHTHALMOLOGY, V114, P253, DOI 10.1016/j.ophtha.2006.10.040
   Kondo N, 2011, OPHTHALMOLOGY, V118, P339, DOI 10.1016/j.ophtha.2010.06.040
   Kulkarni SR, 2013, INDIAN J OPHTHALMOL, V61, P196, DOI 10.4103/0301-4738.99870
   Langsted A, 2008, CIRCULATION, V118, P2047, DOI 10.1161/CIRCULATIONAHA.108.804146
   Lara M, 2005, ANNU REV PUBL HEALTH, V26, P367, DOI 10.1146/annurev.publhealth.26.021304.144615
   Lavanya R, 2009, OPHTHAL EPIDEMIOL, V16, P325, DOI 10.3109/09286580903144738
   Lee Christina S, 2013, J Ethn Subst Abuse, V12, P356, DOI 10.1080/15332640.2013.836730
   Lee JWR, 2011, DIABETES CARE, V34, P353, DOI 10.2337/dc10-0746
   Lin JM, 2008, RETINA-J RET VIT DIS, V28, P1416, DOI 10.1097/IAE.0b013e318184661d
   Maguire MG, 1997, ARCH OPHTHALMOL-CHIC, V115, P741
   Mitchell P, 2002, OPHTHALMOLOGY, V109, P1092, DOI 10.1016/S0161-6420(02)01055-2
   MITCHELL P, 1995, OPHTHALMOLOGY, V102, P1450
   Miyazaki M, 2005, INVEST OPHTH VIS SCI, V46, P1907, DOI 10.1167/iovs.04-0923
   Mori K, 2007, INVEST OPHTH VIS SCI, V48, P5315, DOI 10.1167/iovs.07-0426
   Nakata I, 2015, SCI REP-UK, V5, DOI 10.1038/srep09345
   Ng TK, 2008, INVEST OPHTH VIS SCI, V49, P3312, DOI 10.1167/iovs.07-1517
   Nowak JZ, 2006, PHARMACOL REP, V58, P353
   Perez-Escamilla R, 2007, J NUTR, V137, P860, DOI 10.1093/jn/137.4.860
   ROY M, 1990, Eye (London), V4, P813
   Sabanayagam C, 2017, CLIN EXPT OPHTHALMOL, V1
   Sandberg MA, 1998, OPHTHALMOLOGY, V105, P441, DOI 10.1016/S0161-6420(98)93025-1
   Sasaki M, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-017-18487-4
   Schaumberg DA, 2001, ARCH OPHTHALMOL-CHIC, V119, P1259
   SEDDON JM, 1994, JAMA-J AM MED ASSOC, V272, P1413, DOI 10.1001/jama.272.18.1413
   SMIDDY WE, 1984, OPHTHALMOLOGY, V91, P271
   Smith W, 2001, OPHTHALMOLOGY, V108, P697, DOI 10.1016/S0161-6420(00)00580-7
   Stalenhoef AFH, 2008, CURR OPIN LIPIDOL, V19, P355, DOI 10.1097/MOL.0b013e328304b63c
   Swaroop A, 2007, HUM MOL GENET, V16, pR174, DOI 10.1093/hmg/ddm212
   van Leeuwen R, 2003, ARCH OPHTHALMOL-CHIC, V121, P519, DOI 10.1001/archopht.121.4.519
   Wieberdink RG, 2011, STROKE, V42, P2138, DOI 10.1161/STROKEAHA.111.616359
   Wong T, 2008, OPHTHALMOLOGY, V115, P116, DOI 10.1016/j.ophtha.2007.03.008
   Wong TY, 2007, OPHTHALMOLOGY, V114, P86, DOI 10.1016/j.ophtha.2006.06.039
   Wong TY, 2006, ANN INTERN MED, V145, P98, DOI 10.7326/0003-4819-145-2-200607180-00007
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
   You QS, 2012, OPHTHALMOLOGY, V119, P2519, DOI 10.1016/j.ophtha.2012.06.043
   Zheng YF, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0034829
NR 77
TC 7
Z9 7
U1 1
U2 5
PU NATURE PORTFOLIO
PI BERLIN
PA HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY
SN 2045-2322
J9 SCI REP-UK
JI Sci Rep
PD JUN 11
PY 2018
VL 8
AR 8869
DI 10.1038/s41598-018-27202-w
PG 8
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA GI8MA
UT WOS:000434777700015
PM 29891972
OA Green Published, gold
DA 2022-11-30
ER

PT J
AU Mun, Y
   Park, KH
   Park, SJ
   Cho, HJ
   Kim, CG
   Kim, JW
   Park, DG
   Sagong, M
   Kim, JH
   Woo, SJ
AF Mun, Yongseok
   Park, Kyu Hyung
   Park, Sang Jun
   Cho, Han Joo
   Kim, Chul Gu
   Kim, Jong Woo
   Park, Dong Geun
   Sagong, Min
   Kim, Jae Hui
   Woo, Se Joon
TI Comparison of treatment methods for submacular hemorrhage in neovascular
   age-related macular degeneration: conservative versus active surgical
   strategy
SO SCIENTIFIC REPORTS
LA English
DT Article
ID TISSUE-PLASMINOGEN-ACTIVATOR; ENDOTHELIAL GROWTH-FACTOR; SUBRETINAL
   HEMORRHAGE; PNEUMATIC DISPLACEMENT; CHOROIDAL NEOVASCULARIZATION;
   INTRAVITREAL RANIBIZUMAB; RETINAL TOXICITY; NATURAL-HISTORY; SECONDARY;
   OUTCOMES
AB The optimal treatment of submacular hemorrhage (SMH) following neovascular age-related macular degeneration (nAMD) is controversial. This study aimed to compare visual outcomes of conservative versus active surgical treatment. Two hundred thirty-six eyes of 236 patients with SMH (>= 1 disc diameter) were stratified into four groups: observation (n = 21); anti-vascular endothelial growth factor (VEGF) monotherapy (n = 161); non-surgical gas tamponade (n = 31); and subretinal surgery (n = 23). The primary outcome was best-corrected visual acuity (BCVA) at 12 months. The baseline BCVAs of the observation, anti-VEGF monotherapy, non-surgical gas tamponade, and subretinal surgery groups were 1.50 +/- 0.70, 1.09 +/- 0.70, 1.31 +/- 0.83, and 1.62 +/- 0.77 logarithm of minimal angle resolution (LogMAR), respectively. The mean BCVAs at 12 months were 1.39 +/- 0.84, 0.90 +/- 0.83, 1.35 +/- 0.88, and 1.44 +/- 0.91 LogMAR, respectively. After adjusting for age, baseline BCVA, SMH size, and the number of intravitreal anti-VEGF injections before SMH, the mean BCVA showed no significant difference among treatments at 12 months (P = 0.204). The anti-VEGF monotherapy group showed better mean BCVA significantly at 3 months (P < 0.001). Only baseline BCVA was associated with VA gain at 12 months (Odds ratio = 3.53, P < 0.001). This study demonstrated that there was no difference in 12 month visual outcomes among treatments and a better early visual outcome can be expected with anti-VEGF monotherapy.
C1 [Mun, Yongseok] Hallym Univ, Coll Med, Kangnam Sacred Heart Hosp, Dept Ophthalmol, 665-3 Siheung Daero, Seoul 07442, South Korea.
   [Park, Kyu Hyung; Park, Sang Jun; Woo, Se Joon] Seoul Natl Univ, Bundang Hosp, Coll Med, Dept Ophthalmol, 82 Gumi Ro 173 Beon Gil, Seongnam Si 13620, Gyeonggi Do, South Korea.
   [Cho, Han Joo; Kim, Chul Gu; Kim, Jong Woo; Kim, Jae Hui] Kims Eye Hosp, Dept Ophthalmol, 136 Yeongshin Ro, Seoul 07301, South Korea.
   [Park, Dong Geun; Sagong, Min] Yeungnam Univ, Coll Med, Dept Ophthalmol, 170 Hyunchung Ro, Daegu 42415, South Korea.
C3 Hallym University; Seoul National University (SNU); Yeungnam University
RP Woo, SJ (通讯作者)，Seoul Natl Univ, Bundang Hosp, Coll Med, Dept Ophthalmol, 82 Gumi Ro 173 Beon Gil, Seongnam Si 13620, Gyeonggi Do, South Korea.; Kim, JH (通讯作者)，Kims Eye Hosp, Dept Ophthalmol, 136 Yeongshin Ro, Seoul 07301, South Korea.; Sagong, M (通讯作者)，Yeungnam Univ, Coll Med, Dept Ophthalmol, 170 Hyunchung Ro, Daegu 42415, South Korea.
EM msagong@ynu.ac.kr; kimoph@gmail.com; sejoon1@snu.ac.kr
FU NRF - Korean government (MSIT) [2020R1F1A1072795]; Seoul National
   University Bundang Hospital [13-2019-003]
FX Funding This study was supported by an NRF grant (Grant No.
   2020R1F1A1072795) funded by the Korean government (MSIT) and a research
   grant from Seoul National University Bundang Hospital (13-2019-003). The
   funders had no role in the design and conduct of the study; collection,
   management, analysis, and interpretation of the data; preparation,
   review, or approval of the manuscript; or decision to submit the
   manuscript for publication.
CR Altaweel MM, 2015, OPHTHALMOLOGY, V122, P391, DOI 10.1016/j.ophtha.2014.08.020
   Avery RL, 1996, RETINA-J RET VIT DIS, V16, P183, DOI 10.1097/00006982-199616030-00001
   Bakri SJ, 2006, OPHTHAL SURG LAS IM, V37, P278, DOI 10.3928/15428877-20060701-03
   BENNER JD, 1994, OPHTHALMOLOGY, V101, P672
   Berrocal MH, 1996, AM J OPHTHALMOL, V122, P486, DOI 10.1016/S0002-9394(14)72107-5
   Bressler NM, 2004, OPHTHALMOLOGY, V111, P1993, DOI 10.1016/j.ophtha.2004.07.023
   Chang MA, 2010, RETINA-J RET VIT DIS, V30, P1171, DOI 10.1097/IAE.0b013e3181dd6d8a
   Chang W, 2014, AM J OPHTHALMOL, V157, P1250, DOI 10.1016/j.ajo.2014.02.007
   Cho HJ, 2015, RETINA-J RET VIT DIS, V35, P205, DOI 10.1097/IAE.0000000000000295
   De Jong JH, 2016, RETINA-J RET VIT DIS, V36, P914, DOI 10.1097/IAE.0000000000000954
   Fine HF, 2010, RETINA-J RET VIT DIS, V30, P1588, DOI 10.1097/IAE.0b013e3181e2263c
   Iacono P, 2014, RETINA-J RET VIT DIS, V34, P281, DOI 10.1097/IAE.0b013e3182979e33
   IRVINE WD, 1991, ARCH OPHTHALMOL-CHIC, V109, P718, DOI 10.1001/archopht.1991.01080050134044
   JOHNSON MW, 1990, ARCH OPHTHALMOL-CHIC, V108, P259, DOI 10.1001/archopht.1990.01070040111042
   Kadonosono K, 2015, OPHTHALMOLOGY, V122, P123, DOI 10.1016/j.ophtha.2014.07.027
   Kim JH, 2014, OPHTHALMOLOGY, V121, P926, DOI 10.1016/j.ophtha.2013.11.004
   Kitagawa Y, 2016, OPHTHALMOLOGY, V123, P1278, DOI 10.1016/j.ophtha.2016.01.035
   Lee H, 2016, RETINA-J RET VIT DIS, V36, P465, DOI 10.1097/IAE.0000000000000645
   Schulze-Bonsel K, 2006, INVEST OPHTH VIS SCI, V47, P1236, DOI 10.1167/iovs.05-0981
   Scupola A, 1999, OPHTHALMOLOGICA, V213, P97, DOI 10.1159/000027400
   Shienbaum G, 2013, AM J OPHTHALMOL, V155, P1009, DOI 10.1016/j.ajo.2013.01.012
   Shin JY, 2015, AM J OPHTHALMOL, V159, P904, DOI 10.1016/j.ajo.2015.01.024
   Sniatecki JJ, 2021, EUR J OPHTHALMOL, V31, P643, DOI 10.1177/1120672119891625
   Soliman W, 2006, ACTA OPHTHALMOL SCAN, V84, P707, DOI 10.1111/j.1600-0420.2006.00736.x
   TOTH CA, 1991, ARCH OPHTHALMOL-CHIC, V109, P723, DOI 10.1001/archopht.1991.01080050139046
NR 25
TC 0
Z9 0
U1 1
U2 1
PU NATURE PORTFOLIO
PI BERLIN
PA HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY
SN 2045-2322
J9 SCI REP-UK
JI Sci Rep
PD SEP 1
PY 2022
VL 12
IS 1
AR 14875
DI 10.1038/s41598-022-18619-5
PG 11
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA 4F8LB
UT WOS:000848760800098
PM 36050401
OA gold, Green Published
DA 2022-11-30
ER

PT J
AU Farinha, CVL
   Cachulo, ML
   Alves, D
   Pires, I
   Marques, JP
   Barreto, P
   Nunes, S
   Costa, J
   Martins, A
   Sobral, I
   Lains, I
   Figueira, J
   Ribeiro, L
   Cunha-Vaz, J
   Silva, R
AF Louro Farinha, Claudia Virginia
   Cachulo, Maria Luz
   Alves, Dalila
   Pires, Isabel
   Marques, Joao Pedro
   Barreto, Patricia
   Nunes, Sandrina
   Costa, Jose
   Martins, Amelia
   Sobral, Isa
   Lains, Ines
   Figueira, Joao
   Ribeiro, Luisa
   Cunha-Vaz, Jose
   Silva, Rufino
TI Incidence of Age-Related Macular Degeneration in the Central Region of
   Portugal: The Coimbra Eye Study - Report 5
SO OPHTHALMIC RESEARCH
LA English
DT Article
DE Age-related macular degeneration; Incidence; Epidemiology; Early
   age-related macular degeneration; Late age-related macular degeneration
ID 5-YEAR INCIDENCE; 10-YEAR INCIDENCE; 6-YEAR INCIDENCE; RISK-FACTORS;
   FOLLOW-UP; MACULOPATHY; PROGRESSION; PREVALENCE; CLASSIFICATION
AB Purpose: To describe the 6.5-year incidence and progression of age-related macular degeneration (AMD) in a coastal town of central Portugal. Methods: Population-based cohort study. Participants underwent standardized interviews and ophthalmological examination. Color fundus photographs were graded according to the International Classification and Grading System for AMD and ARM. The crude and age-standardized incidence of early and late AMD was calculated, and progression was analyzed. Results: The 6.5-year cumulative incidence of early AMD was 10.7%, and of late AMD it was 0.8%. The incidence of early AMD was 7.2, 13.1 and 17.7% for participants aged 55-64, 65-74 and 75-84 years (p < 0.001). The late AMD incidence was 0.3, 0.9 and 2.8% for the corresponding age groups (p = 0.003). The age-standardized incidence was 10.8% (95% CI, 10.74-10.80%) for early and 1.0% (95% CI, 1.00-1.02%) for late AMD. The incidence of both neovascular AMD and geographic atrophy was 0.4%. Progression occurred in 17.2% of patients. Conclusion: The early AMD incidence in a coastal town of central Portugal was found to be similar to that of major epidemiological studies of European-descent populations; however, the incidence of late AMD was lower, and further analysis on risk factors will be conducted. (C) 2019 S. Karger AG, Basel
C1 [Louro Farinha, Claudia Virginia; Cachulo, Maria Luz; Alves, Dalila; Pires, Isabel; Marques, Joao Pedro; Barreto, Patricia; Nunes, Sandrina; Costa, Jose; Martins, Amelia; Sobral, Isa; Figueira, Joao; Ribeiro, Luisa; Cunha-Vaz, Jose; Silva, Rufino] AIBILI Assoc Innovat & Biomed Res Light & Image, PT-3000548 Coimbra, Portugal.
   [Louro Farinha, Claudia Virginia; Cachulo, Maria Luz; Pires, Isabel; Marques, Joao Pedro; Costa, Jose; Martins, Amelia; Sobral, Isa; Lains, Ines; Figueira, Joao; Silva, Rufino] CHUC, Ophthalmol Dept, Coimbra, Portugal.
   [Louro Farinha, Claudia Virginia; Cachulo, Maria Luz; Pires, Isabel; Marques, Joao Pedro; Costa, Jose; Sobral, Isa; Lains, Ines; Figueira, Joao; Ribeiro, Luisa; Cunha-Vaz, Jose; Silva, Rufino] Univ Coimbra FMUC, Fac Med, Coimbra, Portugal.
   [Lains, Ines] Harvard Med Sch, Massachusetts Eye & Ear, Boston, MA 02115 USA.
   [Silva, Rufino] Univ Coimbra, FMUC, iCBR, Coimbra Inst Clin & Biomed Res,Fac Med, Coimbra, Portugal.
C3 Universidade de Coimbra; Universidade de Coimbra; Universidade de
   Coimbra; Harvard University; Harvard Medical School; Massachusetts Eye &
   Ear Infirmary; Universidade de Coimbra
RP Farinha, CVL (通讯作者)，AIBILI Assoc Innovat & Biomed Res Light & Image, PT-3000548 Coimbra, Portugal.
EM claudia.farinha@hotmail.com
RI Marques, João Pedro/J-3584-2012; Silva, Rufino M/J-2817-2012; Farinha,
   Claudia/R-1392-2017
OI Marques, João Pedro/0000-0002-1014-0483; Silva, Rufino
   M/0000-0001-8676-0833; Figueira, Joao P/0000-0002-3511-1515; Ribeiro,
   Maria Luisa/0000-0002-5801-8487; Nunes, Sandrina/0000-0001-5401-9637;
   Cunha-Vaz, Jose/0000-0002-0947-9850; Farinha,
   Claudia/0000-0003-4596-0913
FU Novartis
FX This investigator-initiated study was financially supported by Novartis.
CR Bastawrous A, 2017, JAMA OPHTHALMOL, V135, P631, DOI 10.1001/jamaophthalmol.2017.1109
   BIRD AEC, 1995, SURV OPHTHALMOL, V39, P367, DOI 10.1016/S0039-6257(05)80092-X
   BRESSLER NM, 1995, ARCH OPHTHALMOL-CHIC, V113, P301, DOI 10.1001/archopht.1995.01100030055022
   Cachulo MD, 2016, ACTA OPHTHALMOL, V94, pE442, DOI 10.1111/aos.12950
   Cachulo MD, 2015, OPHTHALMOLOGICA, V233, P119, DOI 10.1159/000371584
   Cheung CMG, 2017, OPHTHALMOLOGY, V124, P1305, DOI 10.1016/j.ophtha.2017.03.056
   Ferris FL, 2005, ARCH OPHTHALMOL-CHIC, V123, P1570
   Joachim N, 2015, OPHTHALMOLOGY, V122, P2482, DOI 10.1016/j.ophtha.2015.08.002
   Jonasson F, 2005, OPHTHALMOLOGY, V112, P132, DOI 10.1016/j.ophtha.2004.07.020
   Klaver CCW, 2001, INVEST OPHTH VIS SCI, V42, P2237
   Klein R, 1997, OPHTHALMOLOGY, V104, P7, DOI 10.1016/S0161-6420(97)30368-6
   Klein R, 2002, OPHTHALMOLOGY, V109, P1767, DOI 10.1016/S0161-6420(02)01146-6
   KLEIN R, 1991, OPHTHALMOLOGY, V98, P1128
   Klein R, 2007, OPHTHALMOLOGY, V114, P253, DOI 10.1016/j.ophtha.2006.10.040
   Klein R, 2014, OPHTHAL EPIDEMIOL, V21, P14, DOI 10.3109/09286586.2013.867512
   Marques JP, 2013, ISRN OPHTHALMOL
   Mitchell P, 2002, OPHTHALMOLOGY, V109, P1092, DOI 10.1016/S0161-6420(02)01055-2
   Mukesh BN, 2004, OPHTHALMOLOGY, V111, P1176, DOI 10.1016/j.ophtha.2003.08.042
   Nunes S, 2018, NUTRITION, V51-52, P6, DOI 10.1016/j.nut.2017.12.010
   Raimundo M, 2018, ACTA OPHTHALMOL, V96, pE926, DOI 10.1111/aos.13775
   Sadda SR, 2018, OPHTHALMOLOGY, V125, P537, DOI 10.1016/j.ophtha.2017.09.028
   Saunier V, 2018, JAMA OPHTHALMOL, V136, P473, DOI 10.1001/jamaophthalmol.2018.0504
   Sparrow JM, 1997, EYE, V11, P315, DOI 10.1038/eye.1997.67
   Tomany SC, 2004, OPHTHALMOLOGY, V111, P1280, DOI 10.1016/j.ophtha.2003.11.010
   Tsikata E, 2017, TRANSL VIS SCI TECHN, V6, DOI 10.1167/tvst.6.2.3
   van Leeuwen R, 2003, ARCH OPHTHALMOL-CHIC, V121, P519, DOI 10.1001/archopht.121.4.519
   Wang JJ, 2007, OPHTHALMOLOGY, V114, P92, DOI 10.1016/j.ophtha.2006.07.017
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
   You QS, 2012, OPHTHALMOLOGY, V119, P2519, DOI 10.1016/j.ophtha.2012.06.043
   2015, AM J OPHTHALMOL, V160, P85, DOI DOI 10.1016/J.AJO.2015.04.003
   2013, OPHTHALMOLOGY, V120, P844, DOI DOI 10.1016/J.OPHTHA.2012.10.036
   2009, OPHTHALMOLOGY, V116, P2135, DOI DOI 10.1016/J.OPHTHA.2009.04.017
   2005, OPHTHALMOLOGY, V112, P787, DOI DOI 10.1016/J.OPHTHA.2004.11.040
NR 33
TC 11
Z9 11
U1 0
U2 2
PU KARGER
PI BASEL
PA ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND
SN 0030-3747
EI 1423-0259
J9 OPHTHALMIC RES
JI Ophthalmic Res.
PY 2019
VL 61
IS 4
BP 226
EP 235
DI 10.1159/000496393
PG 10
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA HV7CM
UT WOS:000466139100007
PM 30820012
DA 2022-11-30
ER

PT J
AU Pham, TQ
   Cugati, S
   Rochtchina, E
   Mitchell, P
   Maloof, A
   Wang, JJ
AF Pham, T. Q.
   Cugati, S.
   Rochtchina, E.
   Mitchell, P.
   Maloof, A.
   Wang, J. J.
TI Early age-related maculopathy in eyes after cataract surgery
SO EYE
LA English
DT Article
DE cataract surgery; age-related; maculopathy; prevalence; Blue Mountains
   Eye Study
ID BLUE-MOUNTAINS EYE; BEAVER DAM EYE; MACULAR DEGENERATION;
   INTRAOCULAR-LENS; CIGARETTE-SMOKING; VISUAL IMPAIRMENT; POPULATION;
   PREVALENCE; ASSOCIATION; EXTRACTION
AB Purpose To assess age-related maculopathy (ARM) in eyes of patients who had undergone cataract surgery for at least a year.
   Methods Consecutive patients aged 60 + years who had undergone cataract surgery at Westmead Hospital, Sydney, Australia, during 2001-2003 were examined in 2004. Interview using standardized questionnaires and stereo retinal photography was performed. Retinal photographs were graded using the Wisconsin ARM grading system. The proportions with ARM were compared between surgical and nonsurgical eyes, and between this surgical cohort and the Blue Mountains Eye Study (BMES) population.
   Results Of the 622 eligible patients, 454 (73%) were re-examined, with a mean follow-period of 2.8 years. Surgical eyes had a higher proportion of early ARM compared to nonsurgical eyes (15.2 vs 10.3%, P = 0.07) and to the early ARM prevalence found in BMES participants of similar age (14.5 vs 6.9%, P < 0.01), which persisted after age standardization to the BMES population (9.7 vs 6.9%, P < 0.05).
   Conclusions We found an increased prevalence of early ARM in surgical eyes of patients 1-3 years after cataract surgery. Whether this increased early ARM prevalence leads to an increased prevalence of late ARM in the long-term warrants further investigation.
C1 Univ Sydney, Westmead Hosp, Dept Ophthalmol, Ctr Vis Res,Westmead Millenium Inst, Westmead, NSW 2145, Australia.
   Westmead Hosp, Dept Ophthalmol, Westmead, NSW 2145, Australia.
C3 University of Sydney; Westmead Institute for Medical Research;
   University of Sydney
RP Wang, JJ (通讯作者)，Univ Sydney, Westmead Hosp, Dept Ophthalmol, Ctr Vis Res,Westmead Millenium Inst, Hawkesbury Rd, Westmead, NSW 2145, Australia.
EM jiejin_wang@wmi.usyd.edu.au
RI Cugati, Sudha/ABB-1331-2021; Wang, Jie Jin/P-1499-2014; wang,
   jie/GRS-0942-2022; Mitchell, Paul/P-1498-2014
OI Wang, Jie Jin/0000-0001-9491-4898; 
CR Anderson DH, 2002, AM J OPHTHALMOL, V134, P411, DOI 10.1016/S0002-9394(02)01624-0
   Attebo K, 1996, OPHTHALMOLOGY, V103, P357
   BLAIR CJ, 1979, AM J OPHTHALMOL, V87, P77, DOI 10.1016/0002-9394(79)90195-8
   Braunstein RE, 2005, ARCH OPHTHALMOL-CHIC, V123, P547, DOI 10.1001/archopht.123.4.547
   Chaine G, 1998, BRIT J OPHTHALMOL, V82, P996, DOI 10.1136/bjo.82.9.996
   CHRISTEN WG, 1992, JAMA-J AM MED ASSOC, V268, P989
   CRUICKSHANKS KJ, 1992, AM J PUBLIC HEALTH, V82, P1658, DOI 10.2105/AJPH.82.12.1658
   Cumming RG, 1997, ARCH OPHTHALMOL-CHIC, V115, P1296, DOI 10.1001/archopht.1997.01100160466015
   ETDRS Coordinating Center UoMDoEaPM, 1980, EARL TREATM DIAB RET
   Freeman EE, 2003, AM J OPHTHALMOL, V135, P849, DOI 10.1016/S0002-9394(02)02253-5
   HEIBA IM, 1993, AM J MED GENET, V47, P1208, DOI 10.1002/ajmg.1320470816
   HEIBA IM, 1994, GENET EPIDEMIOL, V11, P51, DOI 10.1002/gepi.1370110106
   Javitt JC, 1996, ANNU REV PUBL HEALTH, V17, P159
   Klaver CCW, 1998, ARCH OPHTHALMOL-CHIC, V116, P653, DOI 10.1001/archopht.116.5.653
   KLEIN BEK, 1993, AM J PREV MED, V9, P27, DOI 10.1016/S0749-3797(18)30763-3
   KLEIN R, 1995, INVEST OPHTH VIS SCI, V36, P182
   Klein R, 1998, AM J EPIDEMIOL, V147, P103
   Klein R, 1998, ARCH OPHTHALMOL-CHIC, V116, P506, DOI 10.1001/archopht.116.4.506
   Klein R, 2002, ARCH OPHTHALMOL-CHIC, V120, P1551, DOI 10.1001/archopht.120.11.1551
   KLEIN R, 1991, OPHTHALMOLOGY, V98, P1128
   KLEIN R, 1994, ARCH OPHTHALMOL-CHIC, V112, P191, DOI 10.1001/archopht.1994.01090140067025
   Mainster MA, 2005, ARCH OPHTHALMOL-CHIC, V123, P550, DOI 10.1001/archopht.123.4.550
   Mares-Perlman JA, 2000, ARCH OPHTHALMOL-CHIC, V118, P1556, DOI 10.1001/archopht.118.11.1556
   MaresPerlman JA, 1996, ARCH OPHTHALMOL-CHIC, V114, P991, DOI 10.1001/archopht.1996.01100140199014
   Mitchell P, 1997, OPHTHALMOLOGY, V104, P581, DOI 10.1016/S0161-6420(97)30266-8
   MITCHELL P, 1995, OPHTHALMOLOGY, V102, P1450
   PENFOLD PL, 1987, GRAEF ARCH CLIN EXP, V225, P70, DOI 10.1007/BF02155808
   Pham TQ, 2004, CLIN EXP OPHTHALMOL, V32, P383, DOI 10.1111/j.1442-9071.2004.00842.x
   Pollack A, 1997, EYE, V11, P523, DOI 10.1038/eye.1997.138
   Pollack A, 1996, OPHTHALMOLOGY, V103, P1546, DOI 10.1016/S0161-6420(96)30464-8
   Rahmani B, 1996, OPHTHALMOLOGY, V103, P1721, DOI 10.1016/S0161-6420(96)30435-1
   Smith W, 1996, ARCH OPHTHALMOL-CHIC, V114, P1518, DOI 10.1001/archopht.1996.01100140716016
   TAYLOR HR, 1992, ARCH OPHTHALMOL-CHIC, V110, P99, DOI 10.1001/archopht.1992.01080130101035
   VANDERSCHAFT TL, 1994, BRIT J OPHTHALMOL, V78, P441, DOI 10.1136/bjo.78.6.441
   Vingerling JR, 1996, ARCH OPHTHALMOL-CHIC, V114, P1193, DOI 10.1001/archopht.1996.01100140393005
   Wang J J, 1999, Ophthalmic Epidemiol, V6, P317, DOI 10.1076/opep.6.4.317.4182
   Wang JJ, 2003, OPHTHALMOLOGY, V110, P1960, DOI 10.1016/S0161-6420(03)00816-9
   Wang JJ, 1998, BRIT J OPHTHALMOL, V82, P743, DOI 10.1136/bjo.82.7.743
NR 38
TC 7
Z9 7
U1 0
U2 0
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 0950-222X
J9 EYE
JI Eye
PD APR
PY 2007
VL 21
IS 4
BP 512
EP 517
DI 10.1038/sj.eye.6702254
PG 6
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 153WY
UT WOS:000245469700011
PM 16440007
OA Bronze
DA 2022-11-30
ER

PT J
AU Tamashiro, T
   Tanaka, K
   Itagaki, K
   Nakayama, M
   Maruko, I
   Wakugawa, S
   Terao, N
   Onoe, H
   Wakatsuki, Y
   Ogasawara, M
   Sugano, Y
   Yamamoto, A
   Kataoka, K
   Izumi, T
   Kawai, M
   Mori, R
   Sekiryu, T
   Okada, AA
   Iida, T
   Koizumi, H
AF Tamashiro, Tamaki
   Tanaka, Koji
   Itagaki, Kanako
   Nakayama, Makiko
   Maruko, Ichiro
   Wakugawa, Sorako
   Terao, Nobuhiro
   Onoe, Hajime
   Wakatsuki, Yu
   Ogasawara, Masashi
   Sugano, Yukinori
   Yamamoto, Akiko
   Kataoka, Keiko
   Izumi, Takahiko
   Kawai, Moeko
   Mori, Ryusaburo
   Sekiryu, Tetsuju
   Okada, Annabelle A.
   Iida, Tomohiro
   Koizumi, Hideki
CA Japan AMD Res
TI Subfoveal choroidal thickness after brolucizumab therapy for neovascular
   age-related macular degeneration: a short-term multicenter study
SO GRAEFES ARCHIVE FOR CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY
LA English
DT Article
DE Age-related macular degeneration; Brolucizumab; Choroidal thickness;
   Choroidal neovascularizaton; Polypoidal choroidal vasculopathy; Retinal
   angiomatous proliferation
ID INTRAVITREAL AFLIBERCEPT; RANIBIZUMAB INJECTIONS; EXTEND REGIMEN; VEGF
   TRAP; VASCULOPATHY; VERTEPORFIN; ATROPHY
AB Background/purpose Observation of choroidal thickness after anti-vascular endothelial growth factor (VEGF) therapy may be important for the ideal management of neovascular age-related macular degeneration (AMD). This study investigated changes in subfoveal choroidal thickness (SCT) during loading doses of intravitreal injections of brolucizumab in eyes with neovascular AMD.
   Methods This study included 73 eyes of 72 patients with neovascular AMD at five university hospitals in Japan. All 73 eyes underwent three monthly 6.0 mg intravitreal injections of brolucizumab at baseline, 1 month, and 2 months. The SCT at 3 months was evaluated using optical coherence tomography.
   Results The 73 eyes were classified into the treatment-naive group (43 eyes) and the switched group (30 eyes) that were switched from other anti-VEGF treatments. After three intravitreal injections of brolucizumab, SCT significantly decreased from 236.5 +/- 98.8 mu m at baseline to 200.4 +/- 98.3 mu m at 3 months (percent of baseline 84.7%, P < 0.001) in the treatment-naive group. In the switched group, SCT also significantly decreased from 229.0 +/- 113.2 mu m at baseline to 216.9 +/- 110.2 mu m at 3 months (percent of baseline 94.7%, P= 0.039), although the decrease was not as marked compared to that of the treatment-naive group.
   Conclusion Intravitreal injections of brolucizumab for neovascular AMD significantly reduced the SCT in both the treatment-naive and switched groups. Brolucizumab may cause significant anatomic changes in the choroid, particularly in treatment-naive AMD eyes, possibly more than that previously reported for other anti-VEGF agents.
C1 [Tamashiro, Tamaki; Wakugawa, Sorako; Terao, Nobuhiro; Koizumi, Hideki] Univ Ryukyus, Grad Sch Med, Dept Ophthalmol, 207 Uehara Nishihara Cho, Okinawa 9030215, Japan.
   [Tanaka, Koji; Onoe, Hajime; Wakatsuki, Yu] Nihon Univ, Dept Ophthalmol, Sch Med, Tokyo, Japan.
   [Itagaki, Kanako; Ogasawara, Masashi; Sugano, Yukinori; Sekiryu, Tetsuju] Fukushima Med Univ, Dept Ophthalmol, Fukushima, Japan.
   [Nakayama, Makiko; Yamamoto, Akiko; Kataoka, Keiko; Okada, Annabelle A.] Kyorin Univ, Sch Med, Dept Ophthalmol, Tokyo, Japan.
   [Maruko, Ichiro; Izumi, Takahiko; Kawai, Moeko; Iida, Tomohiro] Tokyo Womens Med Univ, Dept Ophthalmol, Tokyo, Japan.
C3 University of Ryukyus; Nihon University; Fukushima Medical University;
   Kyorin University; Tokyo Women's Medical University
RP Koizumi, H (通讯作者)，Univ Ryukyus, Grad Sch Med, Dept Ophthalmol, 207 Uehara Nishihara Cho, Okinawa 9030215, Japan.
EM hkoizumi@med.u-ryukyu.ac.jp
RI Maruko, Ichiro/AFP-1311-2022
OI Maruko, Ichiro/0000-0001-5647-6372
FU JSPS KAKENHI [JP21K09746]; Japan Society for the Promotion of Science
   [JP21K09746]
FX This work was supported by JSPS KAKENHI Grant Number JP21K09746 (Prof.
   Koizumi). Japan Society for the Promotion of Science, JP21K09746,Hideki
   Koizumi
CR Baumal CR, 2021, OPHTHALMOL RETINA, V5, P519, DOI 10.1016/j.oret.2020.09.020
   Brown D., 2017, J VITREORETINAL DIS, V1, P294, DOI [10.1177/2474126417725946, DOI 10.1177/2474126417725946]
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Chung SE, 2011, OPHTHALMOLOGY, V118, P840, DOI 10.1016/j.ophtha.2010.09.012
   Dugel PU, 2020, OPHTHALMOLOGY, V127, P72, DOI 10.1016/j.ophtha.2019.04.017
   Eghoj MS, 2012, BRIT J OPHTHALMOL, V96, P21, DOI 10.1136/bjo.2011.203893
   Ellabban AA, 2012, CLIN OPHTHALMOL, V6, P837, DOI 10.2147/OPTH.S30907
   Freund KB, 2015, RETINA-J RET VIT DIS, V35, P1489, DOI 10.1097/IAE.0000000000000627
   Heier JS, 2012, OPHTHALMOLOGY, V119, P2537, DOI 10.1016/j.ophtha.2012.09.006
   Ikuno Y, 2011, INVEST OPHTH VIS SCI, V52, P5536, DOI 10.1167/iovs.10-6811
   Ikuno Y, 2010, INVEST OPHTH VIS SCI, V51, P2173, DOI 10.1167/iovs.09-4383
   Jabs DA, 2005, AM J OPHTHALMOL, V140, P509, DOI 10.1016/j.ajo.2005.03.057
   Kikushima W, 2017, SCI REP-UK, V7, DOI 10.1038/srep44020
   Koizumi H, 2020, JPN J OPHTHALMOL, V64, P338, DOI 10.1007/s10384-020-00745-0
   Koizumi H, 2016, OPHTHALMOLOGY, V123, P617, DOI 10.1016/j.ophtha.2015.10.039
   Koizumi H, 2015, BRIT J OPHTHALMOL, V99, P1284, DOI 10.1136/bjophthalmol-2014-306432
   Koizumi H, 2015, AM J OPHTHALMOL, V159, P627, DOI 10.1016/j.ajo.2014.12.025
   Koizumi H, 2011, GRAEF ARCH CLIN EXP, V249, P1123, DOI 10.1007/s00417-011-1620-1
   Kuroda Y, 2018, RETINA-J RET VIT DIS, V38, P1743, DOI 10.1097/IAE.0000000000001765
   Lowe J, 2007, EXP EYE RES, V85, P425, DOI 10.1016/j.exer.2007.05.008
   Maruko I, 2007, AM J OPHTHALMOL, V144, P15, DOI 10.1016/j.ajo.2007.03.047
   Maruko I, 2021, GRAEF ARCH CLIN EXP, V259, P2857, DOI 10.1007/s00417-021-05136-w
   Maruko I, 2011, AM J OPHTHALMOL, V151, P594, DOI 10.1016/j.ajo.2010.10.030
   Matsumoto H, 2021, SCI REP-UK, V11, DOI 10.1038/s41598-021-86014-7
   Matsumoto H, 2016, RETINA-J RET VIT DIS, V36, P2282, DOI 10.1097/IAE.0000000000001104
   Mones J, 2021, OPHTHALMOLOGY, V128, P1050, DOI 10.1016/j.ophtha.2020.11.011
   Morimoto M, 2017, GRAEF ARCH CLIN EXP, V255, P1891, DOI 10.1007/s00417-017-3718-6
   Papadopoulos N, 2012, ANGIOGENESIS, V15, P171, DOI 10.1007/s10456-011-9249-6
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Sadda SR, 2020, OPHTHALMOLOGY, V127, P1360, DOI 10.1016/j.ophtha.2020.03.031
   Saito M, 2016, JPN J OPHTHALMOL, V60, P35, DOI 10.1007/s10384-015-0411-3
   SPAIDE RF, 1995, RETINA-J RET VIT DIS, V15, P100, DOI 10.1097/00006982-199515020-00003
   Spaide RF, 2008, AM J OPHTHALMOL, V146, P496, DOI 10.1016/j.ajo.2008.05.032
   Spaide RF, 2020, OPHTHALMOLOGY, V127, P616, DOI 10.1016/j.ophtha.2019.11.004
   Wong T, 2008, OPHTHALMOLOGY, V115, P116, DOI 10.1016/j.ophtha.2007.03.008
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
   Yamazaki T, 2014, RETINA-J RET VIT DIS, V34, P1316, DOI 10.1097/IAE.0000000000000086
   Yamazaki T, 2012, OPHTHALMOLOGY, V119, P1621, DOI 10.1016/j.ophtha.2012.02.022
   Yannuzzi LA, 2001, RETINA-J RET VIT DIS, V21, P416, DOI 10.1097/00006982-200110000-00003
   Yun C, 2016, GRAEF ARCH CLIN EXP, V254, P1693, DOI 10.1007/s00417-015-3260-3
NR 40
TC 6
Z9 6
U1 0
U2 1
PU SPRINGER
PI NEW YORK
PA ONE NEW YORK PLAZA, SUITE 4600, NEW YORK, NY, UNITED STATES
SN 0721-832X
EI 1435-702X
J9 GRAEF ARCH CLIN EXP
JI Graefes Arch. Clin. Exp. Ophthalmol.
PD JUN
PY 2022
VL 260
IS 6
BP 1857
EP 1865
DI 10.1007/s00417-021-05517-1
EA JAN 2022
PG 9
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 0X7EL
UT WOS:000742799800002
PM 35034215
DA 2022-11-30
ER

PT J
AU Mahendra, CK
   Tan, LTH
   Pusparajah, P
   Htar, TT
   Chuah, LH
   Lee, VS
   Low, LE
   Tang, SY
   Chan, KG
   Goh, BH
AF Mahendra, Camille Keisha
   Tan, Loh Teng Hern
   Pusparajah, Priyia
   Htar, Thet Thet
   Chuah, Lay-Hong
   Lee, Vannajan Sanghiran
   Low, Liang Ee
   Tang, Siah Ying
   Chan, Kok-Gan
   Goh, Bey Hing
TI Detrimental Effects of UVB on Retinal Pigment Epithelial Cells and Its
   Role in Age-Related Macular Degeneration
SO OXIDATIVE MEDICINE AND CELLULAR LONGEVITY
LA English
DT Review
ID B-INDUCED DAMAGE; NLRP3 INFLAMMASOME ACTIVATION; OXIDATIVE STRESS;
   ULTRAVIOLET-RADIATION; RPE CELLS; INDUCED APOPTOSIS; ARPE-19 CELLS;
   CATALASE OVEREXPRESSION; VEGF EXPRESSION; DOWN-REGULATION
AB Retinal pigment epithelial (RPE) cells are an essential part of the human eye because they not only mediate and control the transfer of fluids and solutes but also protect the retina against photooxidative damage and renew photoreceptor cells through phagocytosis. However, their function necessitates cumulative exposure to the sun resulting in UV damage, which may lead to the development of age-related macular degeneration (AMD). Several studies have shown that UVB induces direct DNA damage and oxidative stress in RPE cells by increasing ROS and dysregulating endogenous antioxidants. Activation of different signaling pathways connected to inflammation, cell cycle arrest, and intrinsic apoptosis was reported as well. Besides that, essential functions like phagocytosis, osmoregulation, and water permeability of RPE cells were also affected. Although the melanin within RPE cells can act as a photoprotectant, this photoprotection decreases with age. Nevertheless, the changes in lens epithelium-derived growth factor (LEDGF) and autophagic activity or application of bioactive compounds from natural products can reverse the detrimental effect of UVB. Additionally,in vivostudies on the whole retina demonstrated that UVB irradiation induces gene and protein level dysregulation, indicating cellular stress and aberrations in the chromosome level. Morphological changes like retinal depigmentation and drusen formation were noted as well which is similar to the etiology of AMD, suggesting the connection of UVB damage with AMD. Therefore, future studies, which include mechanism studies viain vitroorin vivoand other potential bioactive compounds, should be pursued for a better understanding of the involvement of UVB in AMD.
C1 [Mahendra, Camille Keisha; Htar, Thet Thet; Chuah, Lay-Hong; Low, Liang Ee; Goh, Bey Hing] Monash Univ Malaysia, Sch Pharm, Biofunct Mol Exploratory Res Grp, Bandar Sunway 47500, Selangor Darul, Malaysia.
   [Tan, Loh Teng Hern] Monash Univ, Jeffrey Cheah Sch Med & Hlth Sci, Novel Bacteria & Drug Discovery Res Grp, Microbiome & Bioresource Res Strength, Bandar Sunway 47500, Malaysia.
   [Pusparajah, Priyia] Monash Univ Malaysia, Jeffrey Cheah Sch Med & Hlth Sci, Med Hlth & Translat Res Grp, Bandar Sunway 47500, Selangor Darul, Malaysia.
   [Chuah, Lay-Hong; Tang, Siah Ying] Monash Univ Malaysia, Adv Engn Platform, Bandar Sunway 47500, Selangor, Malaysia.
   [Lee, Vannajan Sanghiran] Univ Malaya, Fac Sci, Ctr Theoret Computat Phys, Dept Chem,DDDRG, Kuala Lumpur 50603, Malaysia.
   [Low, Liang Ee] Zhejiang Univ, Coll Pharmaceut Sci, Inst Pharmaceut, 866 Yuhangtang Rd, Hangzhou 310058, Peoples R China.
   [Low, Liang Ee] Zhejiang Univ, Coll Biomed Engn & Instrument Sci, Key Lab Biomed Engn, Minist Educ, Hangzhou 310058, Peoples R China.
   [Tang, Siah Ying] Monash Univ Malaysia, Sch Engn, Chem Engn Discipline, Jalan Lagoon Selatan,Bandar Sunway, Subang Jaya 47500, Selangor, Malaysia.
   [Chan, Kok-Gan] Univ Malaya, Fac Sci, Inst Biol Sci, Div Genet & Mol Biol, Kuala Lumpur, Malaysia.
   [Chan, Kok-Gan] Jiangsu Univ, Int Genome Ctr, Zhenjiang, Jiangsu, Peoples R China.
   [Goh, Bey Hing] Zhejiang Univ, Coll Pharmaceut Sci, 866 Yuhangtang Rd, Hangzhou 310058, Peoples R China.
   [Goh, Bey Hing] Monash Univ Malaysia, Hlth & Well Being Cluster, Global Asia 21st Century GA21 Platform, Bandar Sunway 47500, Malaysia.
C3 Monash University; Monash University Sunway; Monash University; Monash
   University Sunway; Monash University; Monash University Sunway; Monash
   University; Monash University Sunway; Universiti Malaya; Zhejiang
   University; Zhejiang University; Monash University; Monash University
   Sunway; Universiti Malaya; Jiangsu University; Zhejiang University;
   Monash University; Monash University Sunway
RP Goh, BH (通讯作者)，Monash Univ Malaysia, Sch Pharm, Biofunct Mol Exploratory Res Grp, Bandar Sunway 47500, Selangor Darul, Malaysia.; Chan, KG (通讯作者)，Univ Malaya, Fac Sci, Inst Biol Sci, Div Genet & Mol Biol, Kuala Lumpur, Malaysia.; Chan, KG (通讯作者)，Jiangsu Univ, Int Genome Ctr, Zhenjiang, Jiangsu, Peoples R China.; Goh, BH (通讯作者)，Zhejiang Univ, Coll Pharmaceut Sci, 866 Yuhangtang Rd, Hangzhou 310058, Peoples R China.; Goh, BH (通讯作者)，Monash Univ Malaysia, Hlth & Well Being Cluster, Global Asia 21st Century GA21 Platform, Bandar Sunway 47500, Malaysia.
EM camille.mahendra@monash.edu; loh.teng.hern@monash.edu;
   priyia.pusparajah@monash.edu; thet.thet.htar@monash.edu;
   alice.chuah@monash.edu; vannajan@um.edu.my; zack_1129@hotmail.com;
   patrick.tang@monash.edu; kokgan@um.edu.my; goh.bey.hing@monash.edu
RI Goh, Bey Hing/I-4880-2015; Chan, Kok Gan/B-8347-2010; Mahendra, Camille
   Keisha/ACG-8233-2022; Htar, Thet Thet/AAA-2029-2021; Tan, Loh Teng
   Hern/AAU-6101-2021; Goh, Bey Hing/ABA-3131-2021; Chuah, Lay
   Hong/K-4176-2013
OI Goh, Bey Hing/0000-0003-1006-3649; Chan, Kok Gan/0000-0002-1883-1115;
   Mahendra, Camille Keisha/0000-0002-8809-7454; Htar, Thet
   Thet/0000-0001-6193-1237; Tan, Loh Teng Hern/0000-0003-1421-3130; Goh,
   Bey Hing/0000-0003-1006-3649; Chuah, Lay Hong/0000-0001-8283-0849;
   Pusparajah, Priyia/0000-0002-9245-0177
FU Taylor's University Emerging Grant [TRGS/ERFS/2/2018/SBS/016];
   University of Malaya [FP022-2018A, H-500001A000027]; Biotek Abadi Sdn
   Bhd [GBA-81811A]; Monash Global Asia in the 21st Century (GA21) research
   grant [GA-HW-19-L01, GA-HW-19-S02]; Fundamental Research Grant Scheme
   [FRGS/1/2019/WAB09/MUSM/02/1]
FX This work was inspired by Monash Pharmacy Degree Course, Unit PAC3512,
   entitled "Current aspects of pharmaceutical research," and financially
   supported by Taylor's University Emerging Grant
   (TRGS/ERFS/2/2018/SBS/016), University of Malaya Research Grants FRGS
   grant to KGC (grant no. FP022-2018A) and HIR grant (H-500001A000027),
   External Industry Grants from Biotek Abadi Sdn Bhd (vote no.
   GBA-81811A), Monash Global Asia in the 21st Century (GA21) research
   grant (GA-HW-19-L01 and GA-HW-19-S02), and Fundamental Research Grant
   Scheme (FRGS/1/2019/WAB09/MUSM/02/1).
CR Abbasi S., 2017, OZONE HOLE, P51, DOI [10.1007/978-1-4939-6710-0_4, DOI 10.1007/978-1-4939-6710-0_4]
   Ablonczy Z, 2011, INVEST OPHTH VIS SCI, V52, P8614, DOI 10.1167/iovs.11-8021
   Ahmad I, 2011, INVEST OPHTH VIS SCI, V52, P2868, DOI 10.1167/iovs.10-6608
   Aimjongjun S, 2013, J PHOTOCH PHOTOBIO B, V124, P34, DOI 10.1016/j.jphotobiol.2013.04.003
   Amjadi Shahriar, 2013, ISRN Ophthalmol, V2013, P632302, DOI 10.1155/2013/632302
   An E, 2006, J PROTEOME RES, V5, P2599, DOI 10.1021/pr060121j
   An MJ, 2018, ENVIRON TOXICOL, V33, P52, DOI 10.1002/tox.22494
   [Anonymous], 2017, PROTECTION CONTROL M, DOI DOI 10.1109/CAC.2017.8242885
   Araki M, 2007, DEV GROWTH DIFFER, V49, P109, DOI 10.1111/j.1440-169x.2007.00911.x
   Balaiya S, 2010, CLIN OPHTHALMOL, V4, P33
   Bantseev V, 2006, ANN NY ACAD SCI, V1091, P17, DOI 10.1196/annals.1378.051
   Bao ZZ, 1997, J NEUROSCI, V17, P1425
   Betz C, 2013, J CELL BIOL, V203, P563, DOI 10.1083/jcb.201306041
   Bharti K, 2011, PIGM CELL MELANOMA R, V24, P21, DOI 10.1111/j.1755-148X.2010.00772.x
   Bhutto I, 2012, MOL ASPECTS MED, V33, P295, DOI 10.1016/j.mam.2012.04.005
   Biesemeier A, 2011, EXP EYE RES, V93, P29, DOI 10.1016/j.exer.2011.04.004
   Biesemeier A, 2010, CELL TISSUE RES, V339, P551, DOI 10.1007/s00441-009-0920-9
   Bilbao J, 2013, RENEW ENERG, V53, P79, DOI 10.1016/j.renene.2012.10.055
   Bonilha VL, 2004, MOL CELL PROTEOMICS, V3, P1119, DOI 10.1074/mcp.M400106-MCP200
   Bossaller L, 2012, J IMMUNOL, V189, P5508, DOI 10.4049/jimmunol.1202121
   BOULTON M, 1993, J PHOTOCH PHOTOBIO B, V19, P201, DOI 10.1016/1011-1344(93)87085-2
   Boulton M, 2001, EYE, V15, P384, DOI 10.1038/eye.2001.141
   Brockmann C, 2008, J CATARACT REFR SURG, V34, P1161, DOI 10.1016/j.jcrs.2008.03.039
   Burke JM, 2000, INVEST OPHTH VIS SCI, V41, P1945
   Cao GF, 2012, MOL MED REP, V5, P54, DOI 10.3892/mmr.2011.582
   Chakravarti S, 2003, INVEST OPHTH VIS SCI, V44, P2422, DOI 10.1167/iovs.02-0783
   Chakravarti S, 1998, J CELL BIOL, V141, P1277, DOI 10.1083/jcb.141.5.1277
   Chan CM, 2015, INT J MOL SCI, V16, P5789, DOI 10.3390/ijms16035789
   Chawla-Sarkar M, 2004, CELL DEATH DIFFER, V11, P915, DOI 10.1038/sj.cdd.4401416
   Chen PN, 2006, CANCER LETT, V235, P248, DOI 10.1016/j.canlet.2005.04.033
   Chen X, 2014, CURR MOL MED, V14, P523, DOI 10.2174/1566524014666140331230411
   Chen Y, 2015, BBA-MOL CELL RES, V1853, P396, DOI 10.1016/j.bbamcr.2014.11.012
   Choi SW, 2001, BRIT J DERMATOL, V145, P535, DOI 10.1046/j.1365-2133.2001.04410.x
   Chou WW, 2013, TOXICOL IN VITRO, V27, P1728, DOI 10.1016/j.tiv.2013.05.002
   Chou WW, 2012, CELL IMMUNOL, V273, P79, DOI 10.1016/j.cellimm.2011.11.003
   Costagliola C, 2008, PHOTOCHEM PHOTOBIOL, V84, P1294, DOI 10.1111/j.1751-1097.2008.00404.x
   Cunha-Vaz J, 2011, EUR J OPHTHALMOL, V21, pS3, DOI 10.5301/EJO.2010.6049
   Davies S, 2001, FREE RADICAL BIO MED, V31, P256, DOI 10.1016/S0891-5849(01)00582-2
   DAVIS AA, 1995, INVEST OPHTH VIS SCI, V36, P955
   De Luca G, 2001, METABOLISM, V50, P60, DOI 10.1053/meta.2001.19432
   Dontsov AE, 2017, BIOCHEMISTRY-MOSCOW+, V82, P916, DOI 10.1134/S0006297917080065
   Dontsov AE, 2015, RUSS CHEM B+, V64, P1623, DOI 10.1007/s11172-015-1051-y
   Doyle SL, 2012, NAT MED, V18, P791, DOI 10.1038/nm.2717
   Dunn KC, 1996, EXP EYE RES, V62, P155, DOI 10.1006/exer.1996.0020
   El-Sherbeny A, 2004, INVEST OPHTH VIS SCI, V45, P694, DOI 10.1167/iovs.03-0503
   Eves P, 1999, PIGM CELL RES, V12, P22, DOI 10.1111/j.1600-0749.1999.tb00504.x
   Fasler-Kan E, 2005, OPHTHALMOLOGICA, V219, P214, DOI 10.1159/000085730
   Fernandez-Godino R, 2016, NAT PROTOC, V11, P1206, DOI 10.1038/nprot.2016.065
   Fronk AH, 2016, J TISSUE ENG, V7, DOI 10.1177/2041731416650838
   Geisen P, 2006, CURR EYE RES, V31, P739, DOI 10.1080/02713680600837408
   Hanus J, 2015, AGEING RES REV, V24, P286, DOI 10.1016/j.arr.2015.09.002
   He Y, 2016, TRENDS BIOCHEM SCI, V41, P1012, DOI 10.1016/j.tibs.2016.09.002
   Heck DE, 2003, J BIOL CHEM, V278, P22432, DOI 10.1074/jbc.C300048200
   Hong L, 2007, J PHYS CHEM B, V111, P7938, DOI 10.1021/jp071439h
   Hsieh FC, 2018, OXID MED CELL LONGEV, V2018, DOI 10.1155/2018/4814928
   Hydbring P, 2016, NAT REV MOL CELL BIO, V17, P280, DOI 10.1038/nrm.2016.27
   Inana G, 2018, J TRANSL MED, V16, DOI 10.1186/s12967-018-1434-6
   Jarrett SG, 2012, MOL ASPECTS MED, V33, P399, DOI 10.1016/j.mam.2012.03.009
   Jeyaseelan K, 2006, EXPERT OPIN THER TAR, V10, P889, DOI 10.1517/14728222.10.6.889
   Jia ZQ, 2009, NEUROCHEM RES, V34, P1924, DOI 10.1007/s11064-009-9978-8
   Jiang Q, 2009, INT J MOL MED, V23, P771, DOI 10.3892/ijmm_00000191
   Jin S, 2013, ONCOGENE, V32, P4892, DOI 10.1038/onc.2012.517
   Jo EK, 2016, CELL MOL IMMUNOL, V13, P148, DOI 10.1038/cmi.2015.95
   Kaemmerer E, 2007, INVEST OPHTH VIS SCI, V48, P1342, DOI 10.1167/iovs.06-0549
   Kannan R, 2011, INVEST OPHTH VIS SCI, V52, P9047, DOI 10.1167/iovs.11-8737
   Kansanen E, 2013, REDOX BIOL, V1, P45, DOI 10.1016/j.redox.2012.10.001
   Kao WWY, 2002, GLYCOCONJUGATE J, V19, P275, DOI 10.1023/A:1025396316169
   Katiyar SK, 2001, CARCINOGENESIS, V22, P287, DOI 10.1093/carcin/22.2.287
   Kauppinen A, 2012, IMMUNOL LETT, V147, P29, DOI 10.1016/j.imlet.2012.05.005
   Kim YC, 2015, J CLIN INVEST, V125, P25, DOI 10.1172/JCI73939
   Kolozsvari L, 2002, INVEST OPHTH VIS SCI, V43, P2165
   Korhonen E, 2020, FASEB J, V34, P6437, DOI 10.1096/fj.201902355RR
   Lei L, 2017, INT J MOL SCI, V18, DOI 10.3390/ijms18040728
   Lengyel I, 2007, EXP EYE RES, V84, P772, DOI 10.1016/j.exer.2006.12.015
   LERMAN S, 1982, J NATL CANCER I, V69, P287
   Leung KW, 2012, J MOL NEUROSCI, V46, P122, DOI 10.1007/s12031-011-9536-0
   Li CP, 2013, BIOCHEM BIOPH RES CO, V438, P739, DOI 10.1016/j.bbrc.2013.07.097
   Li K, 2013, PLOS ONE, V8, DOI [10.1371/journal.pone.0084171, 10.1371/journal.pone.0067018, 10.1371/journal.pone.0058057, 10.1371/journal.pone.0063139, 10.1371/journal.pone.0068157]
   Li KR, 2016, SCI REP-UK, V6, DOI 10.1038/srep25525
   Liu LY, 2017, MOL MED REP, V16, P730, DOI 10.3892/mmr.2017.6625
   LIU W, 2013, SCI WORLD J, V2013, DOI DOI 10.1155/2013/178708
   Liu YX, 2016, J AGR FOOD CHEM, V64, P416, DOI 10.1021/acs.jafc.5b05436
   Luo Y, 2006, INVEST OPHTH VIS SCI, V47, P3644, DOI 10.1167/iovs.06-0166
   Ma DSL, 2018, FRONT PHARMACOL, V9, DOI 10.3389/fphar.2018.00102
   Machida S, 2001, INVEST OPHTH VIS SCI, V42, P1087
   MAHENDRA CK, 2019, PROGR DRUG DISCOVERY, V2, P1, DOI DOI 10.36877/pddbs.a0000021
   Maiuri MC, 2007, NAT REV MOL CELL BIO, V8, P741, DOI 10.1038/nrm2239
   Mandinova A, 2008, EMBO J, V27, P1243, DOI 10.1038/emboj.2008.45
   Marchitti SA, 2011, EYE CONTACT LENS, V37, P206, DOI 10.1097/ICL.0b013e3182212642
   Matsumoto Y, 2004, SCIENCE, V306, P885, DOI 10.1126/science.1103544
   Mauget-Fa M, 2001, GRAEF ARCH CLIN EXP, V239, P501, DOI 10.1007/s004170100307
   Mazzoni F, 2014, EXP EYE RES, V126, P51, DOI 10.1016/j.exer.2014.01.010
   MCLAREN MJ, 1993, EXP CELL RES, V204, P311, DOI 10.1006/excr.1993.1038
   MCMANUS ML, 1995, NEW ENGL J MED, V333, P1260, DOI 10.1056/NEJM199511093331906
   Mitter SK, 2014, AUTOPHAGY, V10, P1989, DOI 10.4161/auto.36184
   Molday LL, 2000, NAT GENET, V25, P257, DOI 10.1038/77004
   Moschos MM, 2014, J CHEM-NY, V2014, DOI 10.1155/2014/317536
   Munoz-Planillo R, 2013, IMMUNITY, V38, P1142, DOI 10.1016/j.immuni.2013.05.016
   Murad N, 2014, FEBS J, V281, P5251, DOI 10.1111/febs.13066
   Nambi KSN, 2015, ZEBRAFISH, V12, P21, DOI 10.1089/zeb.2014.1012
   Nicolas MG, 1996, EXP EYE RES, V62, P399, DOI 10.1006/exer.1996.0045
   Olchawa MM, 2017, FREE RADICAL RES, V51, P799, DOI 10.1080/10715762.2017.1380307
   Orban T, 2011, J BIOL CHEM, V286, P17248, DOI 10.1074/jbc.M110.195198
   Park S.W., 2012, BIOMED PREV NUTR, V2, P77, DOI [DOI 10.1016/j.bionut.2011.12.009, 10.1016/j.bionut.2011.12.009]
   Patton WP, 1999, INVEST OPHTH VIS SCI, V40, P3268
   Patton WP, 2002, EXP EYE RES, V74, P513, DOI 10.1006/exer.2001.1160
   Pavelic SK, 2015, BBA-MOL BASIS DIS, V1852, P1833, DOI 10.1016/j.bbadis.2015.06.006
   Perry A, 2009, J FOOD COMPOS ANAL, V22, P9, DOI 10.1016/j.jfca.2008.07.006
   Pfeffer B.A., 1991, PROG RETIN RES, V10, P251
   Rakoczy PE, 2006, EXP EYE RES, V82, P741, DOI 10.1016/j.exer.2005.10.012
   Rathinam VAK, 2012, NAT IMMUNOL, V13, P333, DOI 10.1038/ni.2237
   Rauch I, 2017, IMMUNITY, V46, P649, DOI 10.1016/j.immuni.2017.03.016
   Reichrath S, 2012, DERM-ENDOCRINOL, V4, P49, DOI 10.4161/derm.19027
   Rezvani HR, 2008, CANCER GENE THER, V15, P241, DOI 10.1038/sj.cgt.7701102
   Rezvani HR, 2006, J BIOL CHEM, V281, P17999, DOI 10.1074/jbc.M600536200
   Ribnicky DM, 2009, INT J PHARMACEUT, V370, P87, DOI 10.1016/j.ijpharm.2008.11.012
   Roberts JE, 2001, J PHOTOCH PHOTOBIO B, V64, P136, DOI 10.1016/S1011-1344(01)00196-8
   Roberts JE, 2002, PHOTOCHEM PHOTOBIOL, V75, P184, DOI 10.1562/0031-8655(2002)075<0184:TROAIP>2.0.CO;2
   Roca H, 2008, AUTOPHAGY, V4, P969, DOI 10.4161/auto.6822
   Rozanowska M, 1999, FREE RADICAL BIO MED, V26, P518, DOI 10.1016/S0891-5849(98)00234-2
   Sahm M, 2001, GRAEF ARCH CLIN EXP, V239, P302, DOI 10.1007/s004170100271
   Samsen A, 2017, ANN ONCOL, V28
   Samuel W, 2017, MOL VIS, V23, P60
   Sarna T, 2003, EXP EYE RES, V76, P89, DOI 10.1016/S0014-4835(02)00247-6
   SAVOLAINEN H, 1992, J APPL TOXICOL, V12, P191, DOI 10.1002/jat.2550120307
   SCHMIDT SY, 1986, INVEST OPHTH VIS SCI, V27, P1063
   Schouwey K, 2011, ONCOGENE, V30, P313, DOI 10.1038/onc.2010.428
   Shamsi FA, 2001, INVEST OPHTH VIS SCI, V42, P3041
   Shang YL, 2016, PROTEIN CELL, V7, P159, DOI 10.1007/s13238-016-0250-0
   Shin S, 2001, BIOCHEMISTRY-US, V40, P1117, DOI 10.1021/bi001603q
   Silvan JM, 2016, FOOD FUNCT, V7, P1067, DOI [10.1039/c5fo01368b, 10.1039/C5FO01368B]
   Simo R, 2010, J BIOMED BIOTECHNOL, DOI 10.1155/2010/190724
   Singer Michael, 2014, F1000Prime Rep, V6, P29, DOI 10.12703/P6-29
   Singh DP, 2001, BIOCHEM BIOPH RES CO, V283, P943, DOI 10.1006/bbrc.2001.4887
   Sparrow JR, 1999, INVEST OPHTH VIS SCI, V40, P2988
   Sparrrow JR, 2010, CURR MOL MED, V10, P802
   Stahl A, 2008, FEBS LETT, V582, P3097, DOI 10.1016/j.febslet.2008.08.005
   Stamer WD, 2003, INVEST OPHTH VIS SCI, V44, P2803, DOI 10.1167/iovs.03-0001
   Sundelin S, 1998, CURR EYE RES, V17, P851, DOI 10.1076/ceyr.17.8.851.5146
   Suter M, 2000, J BIOL CHEM, V275, P39625, DOI 10.1074/jbc.M007049200
   Tamm I, 1998, CANCER RES, V58, P5315
   Tan L.T.H., 2019, PROG DRUG DISCOV BIO, V2, P1, DOI DOI 10.36877/pddbs.a0000017
   Tan LTH, 2015, EVID-BASED COMPL ALT, V2015, DOI 10.1155/2015/896314
   Tan LTH, 2015, FRONT MICROBIOL, V6, DOI 10.3389/fmicb.2015.01316
   Tang BR, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0103364
   Tang CZ, 2018, FREE RADICAL BIO MED, V117, P238, DOI 10.1016/j.freeradbiomed.2018.02.001
   Tanida I, 2005, AUTOPHAGY, V1, P84, DOI 10.4161/auto.1.2.1697
   Thiele S, 2020, OPHTHALMOL RETINA, V4, P31, DOI 10.1016/j.oret.2019.08.003
   Tran TL, 2013, ACTA OPHTHALMOL, V91, P557, DOI 10.1111/j.1755-3768.2012.02547.x
   Tripathi DN, 2013, P NATL ACAD SCI USA, V110, pE2950, DOI 10.1073/pnas.1307736110
   Vishwanathan R, 2016, NUTR NEUROSCI, V19, P95, DOI 10.1179/1476830514Y.0000000141
   Wang AL, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0004160
   Wang KJ, 2015, BIOCHEM BIOPH RES CO, V468, P541, DOI 10.1016/j.bbrc.2015.10.117
   Wang Y., 2016, NANOADV, V1, P17, DOI DOI 10.1016/J.APENERGY.2016.05.081
   Warburton S, 2007, MOL VIS, V13, P318
   Wehner F, 2004, REV PHYSIOL BIOCH P, V148, P1, DOI 10.1007/s10254-003-0009-x
   West KA, 2001, EXP EYE RES, V73, P479, DOI 10.1006/exer.2001.1058
   Willoughby CE, 2010, CLIN EXP OPHTHALMOL, V38, P2, DOI 10.1111/j.1442-9071.2010.02363.x
   Wimmers S, 2007, PROG RETIN EYE RES, V26, P263, DOI 10.1016/j.preteyeres.2006.12.002
   WING GL, 1978, INVEST OPHTH VIS SCI, V17, P601
   Wu DY, 2015, CUTAN OCUL TOXICOL, V34, P189, DOI 10.3109/15569527.2014.944649
   Xu JY, 2010, INVEST OPHTH VIS SCI, V51, P6665, DOI 10.1167/iovs.10-5698
   Yacout SM, 2019, PHOTOCHEM PHOTOBIOL, V95, P183, DOI 10.1111/php.12934
   Yan JZ, 2018, J PHOTOCH PHOTOBIO B, V186, P9, DOI 10.1016/j.jphotobiol.2018.04.005
   Yang ZY, 2015, ONCOTARGET, V6, P5072, DOI 10.18632/oncotarget.3241
   You YH, 2001, J BIOL CHEM, V276, P44688, DOI 10.1074/jbc.M107696200
   Youn HY., 2010, OPEN TOXICOL J, V4, P13, DOI DOI 10.2174/1874340401004010013
   Youn HY, 2007, J PHOTOCH PHOTOBIO B, V88, P21, DOI 10.1016/j.jphotobiol.2007.04.012
   Zajac-Pytrus HM, 2015, ADV CLIN EXP MED, V24, P1099, DOI 10.17219/acem/27093
   Zarbin MA, 2004, ARCH OPHTHALMOL-CHIC, V122, P598, DOI 10.1001/archopht.122.4.598
   Zareba M, 2006, PHOTOCHEM PHOTOBIOL, V82, P1024, DOI 10.1562/2006-03-08-RA-836
   Zhang H, 2014, FREE RADICAL BIO MED, V69, P219, DOI 10.1016/j.freeradbiomed.2014.01.025
   Zhang L, 2012, ACTA PHYS SIN-CH ED, V61
   Zheng YP, 2004, INVEST OPHTH VIS SCI, V45, P668, DOI 10.1167/iovs.02-0808
   Zhou RB, 2011, NATURE, V469, P221, DOI 10.1038/nature09663
NR 175
TC 10
Z9 10
U1 5
U2 14
PU HINDAWI LTD
PI LONDON
PA ADAM HOUSE, 3RD FLR, 1 FITZROY SQ, LONDON, W1T 5HF, ENGLAND
SN 1942-0900
EI 1942-0994
J9 OXID MED CELL LONGEV
JI Oxidative Med. Cell. Longev.
PD AUG 13
PY 2020
VL 2020
AR 1904178
DI 10.1155/2020/1904178
PG 29
WC Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Cell Biology
GA NI3BQ
UT WOS:000565231700005
PM 32855763
OA Green Published, gold
DA 2022-11-30
ER

PT J
AU Hariri, AH
   Tepelus, TC
   Akil, H
   Nittala, MG
   Sadda, SR
AF Hariri, Amir H.
   Tepelus, Tudor C.
   Akil, Handan
   Nittala, Muneeswar G.
   Sadda, Srinivas R.
TI Retinal Sensitivity at the Junctional Zone of Eyes With Geographic
   Atrophy Due to Age-Related Macular Degeneration
SO AMERICAN JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
ID SCANNING LASER OPHTHALMOSCOPY; OPTICAL COHERENCE TOMOGRAPHY; FUNDUS
   AUTOFLUORESCENCE; MICROPERIMETRY; PROGRESSION; ENLARGEMENT; IMPACT
AB PURPOSE: To compare the retinal sensitivity at the junctional zone and uninvolved retina of eyes with geographic atrophy (GA) due to age-related macular degeneration (AMD).
   DESIGN: Cross-sectional, observational study.
   METHODS: Patients with dry AMD were evaluated by microperimetry and Cirrus optical coherence tomography (OCT). The GA lesion was segmented on en face OCT images and registered to color images with the microperimetric sensitivity values. The junctional zone, a ring 500 mu m in width, surrounding the region of atrophy was further subdivided into "subzones": Zone 1 at the precise border of atrophy; Zone 2 as the center of this junctional region; Zone 3 at the border between the junctional zone and adjacent "normal" retina. An additional Zone 4 was defined as "normal" retina, at least 500 from the edge of the GA lesion. The mean sensitivities of all stimuli within each of these zones (across the entire cohort) were compared.
   RESULTS: In 36 eyes with GA, the mean retinal sensitivity in the various subzones was as follows: Zone 1 = 13.7 +/- 4.7, Zone 2 = 20.3 +/- 3.9, Zone 3 = 20.9 +/- 3.9, and Zone 4 = 21.1 +/- 4.1 (all in dB). Zone 1 (atrophic margin) sensitivity was significantly lower than all other zones (P < .001 for all comparisons), but there were no differences between the other zones.
   CONCLUSION: Retinal sensitivity appears to drop precipitously at the margins of GA lesions. The retinal sensitivity in the bulk of the junctional zone is similar to apparently uninvolved distant regions. 2016 Elsevier Inc. All rights reserved.
C1 Univ Calif Los Angeles, David Geffen Sch Med, Dept Ophthalmol, Los Angeles, CA 90095 USA.
   Doheny Eye Inst, 1355 San Pablo St, Los Angeles, CA 90033 USA.
C3 University of California System; University of California Los Angeles;
   University of California Los Angeles Medical Center; David Geffen School
   of Medicine at UCLA; Doheny Eye Institute
RP Sadda, SR (通讯作者)，Univ Calif Los Angeles, David Geffen Sch Med, Doheny Eye Inst, Los Angeles, CA 90095 USA.
EM ssadda@doheny.org
RI Nittala, Muneeswar/AAT-7533-2020
FU Allergan; Carl Zeiss Meditec; Genentech; Optos
FX NO FUNDING OR GRANT SUPPORT. FINANCIAL DISCLOSURES: SRINIVAS R. SADDA IS
   A CO-INVENTOR OF Doheny intellectual property related to optical
   coherence tomography that has been licensed by Topcon Medical Systems
   and is a member of the scientific advisory board for Heidelberg
   Engineering. Dr Sadda receives research support from and serves as a
   consultant for Allergan, Carl Zeiss Meditec, Genentech, and Optos, and
   has also served as a consultant for Alcon, Novartis, and Roche. The
   following authors have no financial disclosures: Amir H. Hariri, Tudor
   C. Tepelus, Handan Akil, and Muneeswar G. Nittala. All authors attest
   that they meet the current ICMJE criteria for authorship.
CR Chen FK, 2011, RETINA-J RET VIT DIS, V31, P371, DOI 10.1097/IAE.0b013e3181e46af3
   Grunwald JE, 2014, OPHTHALMOLOGY, V121, P150, DOI 10.1016/j.ophtha.2013.08.015
   Hanout M, 2015, CURR OPIN OPHTHALMOL, V26, P149, DOI 10.1097/ICU.0000000000000153
   Hariri A, 2015, OPHTHALMOLOGY, V122, P407, DOI 10.1016/j.ophtha.2014.08.035
   Hartmann KI, 2011, RETINA-J RET VIT DIS, V31, P1323, DOI 10.1097/IAE.0b013e31820a6850
   Helb HM, 2010, ACTA OPHTHALMOL, V88, P842, DOI 10.1111/j.1755-3768.2009.01602.x
   Holz FG, 2007, AM J OPHTHALMOL, V143, P463, DOI 10.1016/j.ajo.2006.11.041
   Klein R, 2007, OPHTHALMOLOGY, V114, P253, DOI 10.1016/j.ophtha.2006.10.040
   Markowitz SN, 2013, CAN J OPHTHALMOL, V48, P350, DOI 10.1016/j.jcjo.2012.03.004
   Meleth AD, 2011, INVEST OPHTH VIS SCI, V52, P1119, DOI 10.1167/iovs.10-6075
   Nunes RP, 2013, OSLI RETINA, V44, P344, DOI 10.3928/23258160-20130715-06
   Ooto S, 2015, RETINA-J RET VIT DIS, V35, P1726, DOI 10.1097/IAE.0000000000000608
   Pilotto E, 2013, CAN J OPHTHALMOL, V48, P386, DOI 10.1016/j.jcjo.2013.03.022
   SARKS JP, 1988, EYE, V2, P552, DOI 10.1038/eye.1988.106
   Sayegh RG, 2014, BRIT J OPHTHALMOL, V98, P1050, DOI 10.1136/bjophthalmol-2014-305195
   Seiple W, 2012, OPTOMETRY VISION SCI, V89, P1182, DOI 10.1097/OPX.0b013e3182640c83
   Sunness JS, 1999, OPHTHALMOLOGY, V106, P1768, DOI 10.1016/S0161-6420(99)90340-8
   TIMBERLAKE GT, 1982, INVEST OPHTH VIS SCI, V22, P91
   Wong WT, 2010, INVEST OPHTH VIS SCI, V51, P6131, DOI 10.1167/iovs.10-5637
   Wu ZC, 2015, INVEST OPHTH VIS SCI, V56, P2606, DOI 10.1167/iovs.14-15977
   Wu ZC, 2015, INVEST OPHTH VIS SCI, V56, P2100, DOI 10.1167/iovs.14-16210
   Wu ZC, 2015, INVEST OPHTH VIS SCI, V56, P115, DOI 10.1167/iovs.14-15614
   Wu ZC, 2013, INVEST OPHTH VIS SCI, V54, P7378, DOI 10.1167/iovs.13-12617
NR 23
TC 25
Z9 25
U1 0
U2 5
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0002-9394
EI 1879-1891
J9 AM J OPHTHALMOL
JI Am. J. Ophthalmol.
PD AUG
PY 2016
VL 168
BP 122
EP 128
DI 10.1016/j.ajo.2016.05.007
PG 7
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA DT0IG
UT WOS:000381166600013
PM 27189929
DA 2022-11-30
ER

PT J
AU Garcia, M
   Alvarez, L
   Nogacka, AM
   Gonzalez-Iglesias, H
   Escribano, J
   Fernandez-Vega, B
   Fernandez-Vega, A
   Fernandez-Vega, L
   Coca-Prados, M
AF Garcia, Montserrat
   Alvarez, Lydia
   Nogacka, Alicja M.
   Gonzalez-Iglesias, Hector
   Escribano, Julio
   Fernandez-Vega, Beatriz
   Fernandez-Vega, Alvaro
   Fernandez-Vega, Luis
   Coca-Prados, Miguel
TI CFH polymorphisms in a Northern Spanish population with neovascular and
   dry forms of age-related macular degeneration
SO ACTA OPHTHALMOLOGICA
LA English
DT Article
DE age-related macular degeneration; CFH gene; dry AMD; genetic
   association; haplotypes; Neovascular; Northern Spanish population;
   single-nucleotide polymorphism
ID COMPLEMENT-FACTOR-H; GENOME-WIDE ASSOCIATION; GEOGRAPHIC ATROPHY; GENE
   POLYMORPHISMS; CIGARETTE-SMOKING; HTRA1 POLYMORPHISMS; Y402H
   POLYMORPHISM; VISUAL IMPAIRMENT; PREVALENCE; RISK
AB Purpose: To elucidate the potential role of single-nucleotide polymorphisms (SNPs) in complement factor H (CFH) gene in Northern Spanish patients with age-related macular degeneration (AMD).
   Methods: A case-control study of 130 unrelated native Northern Spanish diagnosed with AMD (46 dry, 35 neovascular and 49 mixed) and 96 healthy controls matched by age and ethnicity were enrolled. DNA was isolated from peripheral blood and genotyped forAMD-associated SNPs (rs3753394, rs529825, rs800292, rs3766404, rs203674, rs10671170, rs3753396 and rs1065489) using TaqMan probes and restriction fragment length polymorphism (RFLP). The association study was performed using the HAPLoVIEW 4.0 software.
   Results: The allelic frequency analysis revealed that rs529825, rs800292, rs203674 and rs10671170 were significantly associated with an increased risk for AMD. The haplotypes CGG (rs3753394, rs529825 and rs800292) and GCAG (rs203674, rs1061170, rs3753396 and rs1065489) were significantly associated with AMD while the haplotypesCAA (rs3753394, rs529825 and rs800292) and TTAG (rs203674, rs1061170, rs3753396 and rs1065489) were found to be protective. Small differences in allelic frequencies were found between dry and neovascular cases; however, these differences were not significant and did not distinguish one form the other.
   Conclusions: This study found significant association of SNPs rs529825, rs800292, rs203674 and rs1061170 in the CFH gene with susceptibility to AMD. We identified haplotypes that confer protection or increased risk of AMD but not specific genetic variants in CFH capable to distinguish the different clinical forms of AMD in this cohort. Collectively, our results confirmed that CFH represents a strong genetic risk factor for this disease in the Northern Spanish population.
C1 [Garcia, Montserrat; Alvarez, Lydia; Nogacka, Alicja M.; Gonzalez-Iglesias, Hector; Fernandez-Vega, Beatriz; Fernandez-Vega, Alvaro; Fernandez-Vega, Luis; Coca-Prados, Miguel] Fdn Invest Oftalmol, Inst Oftalmol Fernandez Vega, Oviedo 33012, Spain.
   [Escribano, Julio] Univ Castilla La Mancha, Inst Invest Neurol Disabil IDINE, Fac Med, Lab Human Mol Genet, Albacete, Spain.
   [Coca-Prados, Miguel] Yale Univ, Sch Med, Dept Ophthalmol & Visual Sci, New Haven, CT 06510 USA.
C3 Universidad de Castilla-La Mancha; Yale University
RP Coca-Prados, M (通讯作者)，Fdn Invest Oftalmol, Inst Oftalmol Fernandez Vega, Ave Doctores Fernandez Vega 34, Oviedo 33012, Spain.
EM miguel.coca-prados@fio.as
RI Gonzalez-Iglesias, Hector/K-2447-2014; Garcia, Montserrat/AAA-7781-2019;
   Alvarez, Lydia/AAA-7736-2019; García Diaz, Montserrat/GXV-7857-2022;
   Escribano, Julio/D-9742-2015; Gonzalez-Iglesias, Hector/AAB-5993-2019;
   Sanz, Beatriz Fernandez-Vega/AAB-5990-2019
OI Gonzalez-Iglesias, Hector/0000-0001-5251-0967; Garcia,
   Montserrat/0000-0001-9983-546X; Escribano, Julio/0000-0002-8919-8134;
   Sanz, Beatriz Fernandez-Vega/0000-0002-0600-5916; Alvarez Fernandez,
   Lydia/0000-0002-0604-7411; Nogacka, Alicja/0000-0001-8300-6149
FU CENIT-CeyeC research grant from the Spanish Ministry of Innovation and
   Development; Fundacion de Investigacion Oftalmologica Fernandez-Vega;
   Fundacion Ma Cristina Masaveu Peterson; Fundacion Rafael del Pino;
   Torres Quevedo Fellowship from the Spanish Ministry of Economy and
   Competitiveness [PTQ-12-05444]; Fondo de Investigacion Sanitaria
   (FIS)-Instituto de Salud Carlos III [PI13/01961]; Plan de Ciencia,
   Tecnologia e Innovacion de Asturias (PCTI) [IE14-030]; Fondo Europeo de
   Desarrollo Regional (FEDER); Cooperative Research Network on Prevention,
   Diagnosis and Treatment of Prevalent, Degenerative and Chronic Eye
   Diseases, Instituto de Salud Carlos III [RD07/0062/0014, RD12/0034]
FX This study has been supported in part by a CENIT-CeyeC research grant
   CEN-20091021 from the Spanish Ministry of Innovation and Development,
   Fundacion de Investigacion Oftalmologica Fernandez-Vega
   (http://fio.fernandez-vega.com), Fundacion M<SUP>a</SUP> Cristina
   Masaveu Peterson (http:// www.fundacioncristinamasaveu.com), Fundacion
   Rafael del Pino (http://www.frdelpino.es), Torres Quevedo Fellowship
   (PTQ-12-05444) from the Spanish Ministry of Economy and Competitiveness,
   grant PI13/01961 from the 'Fondo de Investigacion Sanitaria
   (FIS)-Instituto de Salud Carlos III', grant IE14-030 from the 'Plan de
   Ciencia, Tecnologia e Innovacion de Asturias (PCTI) 'and 'Fondo Europeo
   de Desarrollo Regional (FEDER)', and Cooperative Research Network on
   Prevention, Diagnosis and Treatment of Prevalent, Degenerative and
   Chronic Eye Diseases, Instituto de Salud Carlos III (RD07/0062/0014 and
   RD12/0034; http://www.retics.net). Miguel Coca-Prados is 'Catedratico
   Rafael del Pino en Oftalmologia' in the 'Fundacion de Investigacion
   Oftalmologica, Instituto Oftalmologico Fernandez-Vega' Oviedo, Spain.
CR Arakawa S, 2011, NAT GENET, V43, P1001, DOI 10.1038/ng.938
   Armitage P, 2002, STAT METHODS MED RES, P671
   Baatz H, 2009, KLIN MONATSBL AUGENH, V226, P654, DOI 10.1055/s-0028-1109318
   Bhutto I, 2012, MOL ASPECTS MED, V33, P295, DOI 10.1016/j.mam.2012.04.005
   Brion M, 2011, ACTA OPHTHALMOL, V89, pE12, DOI 10.1111/j.1755-3768.2010.02040.x
   Buentello-Volante B, 2012, MOL VIS, V18, P2518
   Cackett P, 2011, OPHTHALMOLOGY, V118, P846, DOI 10.1016/j.ophtha.2010.09.026
   Caire J, 2014, JAMA OPHTHALMOL, V132, P528, DOI 10.1001/jamaophthalmol.2013.8175
   Chen LJ, 2006, MOL VIS, V12, P1536
   Chen YH, 2010, MOL INTERV, V10, P271, DOI 10.1124/mi.10.5.4
   Cruz-Gonzalez F, 2013, Arch Soc Esp Oftalmol, V88, P3, DOI 10.1016/j.oftal.2012.04.019
   Dong L, 2011, NEUROSCI LETT, V488, P283, DOI 10.1016/j.neulet.2010.11.048
   Francis PJ, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0001197
   Fritsche LG, 2013, NAT GENET, V45, P433, DOI 10.1038/ng.2578
   Gabriel SB, 2002, SCIENCE, V296, P2225, DOI 10.1126/science.1069424
   Goto Asako, 2009, J Ocul Biol Dis Infor, V2, P164
   Gotoh N, 2006, HUM GENET, V120, P139, DOI 10.1007/s00439-006-0187-0
   Hageman GS, 2005, P NATL ACAD SCI USA, V102, P7227, DOI 10.1073/pnas.0501536102
   Huang LZ, 2014, INVEST OPHTH VIS SCI, V55, P2534, DOI 10.1167/iovs.13-13437
   Kabasawa S, 2011, OPHTHALMOLOGY, V118, P1082, DOI 10.1016/j.ophtha.2010.10.012
   Katta S, 2009, J GENET, V88, P425, DOI 10.1007/s12041-009-0064-4
   Kawasaki R, 2008, OPHTHALMOLOGY, V115, P1735, DOI 10.1016/j.ophtha.2008.02.012
   Khan JC, 2006, BRIT J OPHTHALMOL, V90, P75, DOI 10.1136/bjo.2005.073643
   Kim NR, 2008, INVEST OPHTH VIS SCI, V49, P2071, DOI 10.1167/iovs.07-1195
   Kim YH, 2013, OPHTHALMIC GENET, V34, P151, DOI 10.3109/13816810.2012.749287
   Klein R, 2004, AM J OPHTHALMOL, V137, P486, DOI 10.1016/j.ajo.2003.11.069
   KLEIN R, 1992, OPHTHALMOLOGY, V99, P933
   Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557
   Klein R, 2011, ARCH OPHTHALMOL-CHIC, V129, P75, DOI 10.1001/archophthalmol.2010.318
   Kondo N, 2011, OPHTHALMOLOGY, V118, P339, DOI 10.1016/j.ophtha.2010.06.040
   Lau LI, 2006, INVEST OPHTH VIS SCI, V47, P3242, DOI 10.1167/iovs.05-1532
   Leske MC, 2004, OPHTHALMOLOGY, V111, P706, DOI 10.1016/j.ophtha.2003.07.003
   Li M, 2006, NAT GENET, V38, P1049, DOI 10.1038/ng1871
   Liu K, 2014, OPHTHALMOLOGY, V121, P911, DOI 10.1016/j.ophtha.2013.10.042
   Liu MM, 2012, HUM GENOMICS, V6, DOI 10.1186/1479-7364-6-13
   Liu XQ, 2010, RETINA-J RET VIT DIS, V30, P1177, DOI 10.1097/IAE.0b013e3181cea676
   Losonczy G, 2011, ACTA OPHTHALMOL, V89, P255, DOI 10.1111/j.1755-3768.2009.01687.x
   Magnusson KP, 2006, PLOS MED, V3, P109, DOI 10.1371/journal.pmed.0030005
   Martinez-Barricarte R, 2012, INVEST OPHTH VIS SCI, V53, P1087, DOI 10.1167/iovs.11-8709
   MITCHELL P, 1995, OPHTHALMOLOGY, V102, P1450
   Mori K, 2007, INVEST OPHTH VIS SCI, V48, P5315, DOI 10.1167/iovs.07-0426
   Mori K, 2010, OPHTHALMOLOGY, V117, P928, DOI 10.1016/j.ophtha.2009.10.001
   Mukesh BN, 2004, OPHTHALMOLOGY, V111, P1176, DOI 10.1016/j.ophtha.2003.08.042
   Ng TK, 2008, INVEST OPHTH VIS SCI, V49, P3312, DOI 10.1167/iovs.07-1517
   Okamoto H, 2006, MOL VIS, V12, P156
   Pascolini D, 2004, OPHTHAL EPIDEMIOL, V11, P67, DOI 10.1076/opep.11.2.67.28158
   Purcell S, 2007, AM J HUM GENET, V81, P559, DOI 10.1086/519795
   Ricci F, 2009, ARCH OPHTHALMOL-CHIC, V127, P1368, DOI 10.1001/archophthalmol.2009.237
   SCHACHAT AP, 1995, ARCH OPHTHALMOL-CHIC, V113, P728, DOI 10.1001/archopht.1995.01100060054032
   Seddon JM, 2003, ARCH OPHTHALMOL-CHIC, V121, P1728, DOI 10.1001/archopht.121.12.1728
   Seddon JM, 2003, ARCH OPHTHALMOL-CHIC, V121, P785, DOI 10.1001/archopht.121.6.785
   Seddon JM, 2006, ARCH OPHTHALMOL-CHIC, V124, P995, DOI 10.1001/archopht.124.7.995
   Sepp T, 2006, INVEST OPHTH VIS SCI, V47, P536, DOI 10.1167/iovs.05-1143
   Sharma NK, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0070193
   Sobrin L, 2012, OPHTHALMOLOGY, V119, P1874, DOI 10.1016/j.ophtha.2012.03.014
   SOMMER A, 1991, NEW ENGL J MED, V325, P1412, DOI 10.1056/NEJM199111143252004
   Souied EH, 2005, MOL VIS, V11, P1135
   Spencer KL, 2007, INVEST OPHTH VIS SCI, V48, P4277, DOI 10.1167/iovs.06-1427
   Tanaka K, 2011, MOL VIS, V17, P2751
   Teixeira AG, 2010, ACTA OPHTHALMOL, V88, pE165, DOI 10.1111/j.1755-3768.2010.01932.x
   Teper SJ, 2012, MED SCI MONITOR, V18, pPR1, DOI 10.12659/MSM.882447
   Tian J, 2012, INVEST OPHTH VIS SCI, V53, P4262, DOI 10.1167/iovs.11-8542
   Varma R, 2004, OPHTHALMOLOGY, V111, P1288, DOI 10.1016/j.ophtha.2004.01.023
   Weger M, 2007, MOL VIS, V13, P1274
   Wegscheider BJ, 2007, OPHTHALMOLOGY, V114, P738, DOI 10.1016/j.ophtha.2006.07.048
   Wu L, 2013, INVEST OPHTH VIS SCI, V54, P170, DOI 10.1167/iovs.12-10453
   Xu YL, 2008, MOL VIS, V14, P1373
   Yang X, 2010, BRIT J OPHTHALMOL, V94, P1211, DOI 10.1136/bjo.2009.165811
   Yucel D, 2012, OPHTHALMIC GENET, V33, P144, DOI 10.3109/13816810.2012.660225
   Zerbib J, 2014, GRAEF ARCH CLIN EXP, V252, P899, DOI 10.1007/s00417-013-2537-7
   Zhuang WJ, 2014, OPHTHALMIC GENET, V35, P156, DOI 10.3109/13816810.2014.921314
   Ziskind A, 2008, OPHTHALMIC GENET, V29, P117, DOI 10.1080/13816810802216472
NR 72
TC 10
Z9 11
U1 0
U2 11
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1755-375X
EI 1755-3768
J9 ACTA OPHTHALMOL
JI Acta Ophthalmol.
PD DEC
PY 2015
VL 93
IS 8
BP E658
EP E666
DI 10.1111/aos.12790
PG 9
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA DA2VI
UT WOS:000367654500009
PM 26152901
DA 2022-11-30
ER

PT J
AU Loyet, KM
   DeForge, LE
   Katschke, KJ
   Diehl, L
   Graham, RR
   Pao, L
   Sturgeon, L
   Lewin-Koh, SC
   Hollyfield, JG
   Campagne, MV
AF Loyet, Kelly M.
   DeForge, Laura E.
   Katschke, Kenneth J., Jr.
   Diehl, Lauri
   Graham, Robert R.
   Pao, Lily
   Sturgeon, Lizette
   Lewin-Koh, Sock-Cheng
   Hollyfield, Joe G.
   Campagne, Menno van Lookeren
TI Activation of the Alternative Complement Pathway in Vitreous is
   Controlled by Genetics in Age-Related Macular Degeneration
SO INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE
LA English
DT Article
ID FACTOR-H POLYMORPHISM; FACTOR-B; RISK-FACTORS; RANIBIZUMAB; VARIANT;
   DRUSEN; SYSTEM; C3; EXPRESSION; CFH
AB PURPOSE. To determine if the progression of age-related macular degeneration (AMD) is associated with complement activation in the eye.
   METHODS. Immunohistochemistry and ELISAs were used to determine the distribution, concentration, and activation of the alternative pathway complement proteases factor B (FB) and factor D (FD) and the central complement protein C3 in genotyped human postmortem donor eyes graded as having no or minimal drusen (category 1; controls), large drusen (category 3), and large drusen with advanced AMD (category 4).
   RESULTS. C3, FB, and FD were present in vitreous and Bruch's membrane choroid (BM/C) interface of the macula of eyes in all tested AMD severity categories (n = 100). C3, FB, and FD were predominantly located to the choroidal vasculature and Bruch's membrane and, together with the serum proteins transferrin and albumin, elevated in BM/C extracts of category 4 eyes (n = 23) compared with category 1 eyes (n = 24). A significant increase in FB activation was found only in vitreous of category 4 eyes (n = 23) compared with category 1 eyes (n = 25). Genetic variants of complement factor H (CFH), C3, C2, and FB associated with increased risk of AMD were correlated with alternative pathway complement activation in vitreous, but not with complement proteins in BM/C protein extracts
   CONCLUSIONS. Increased activation of the alternative complement pathway in vitreous was controlled by disease stage and genetic variation in the complement pathway, supporting a role for complement activation in AMD disease pathogenesis. (Invest Ophthalmol Vis Sci. 2012;53:6628-6637) DOI:10.1167/iovs.12-9587
C1 [Loyet, Kelly M.; DeForge, Laura E.; Katschke, Kenneth J., Jr.; Diehl, Lauri; Graham, Robert R.; Pao, Lily; Sturgeon, Lizette; Lewin-Koh, Sock-Cheng; Campagne, Menno van Lookeren] Genentech Inc, San Francisco, CA 94080 USA.
   [Hollyfield, Joe G.] Cleveland Clin, Cleveland, OH 44106 USA.
C3 Roche Holding; Genentech; Cleveland Clinic Foundation
RP Campagne, MV (通讯作者)，Genentech Inc, 1 DNA Way, San Francisco, CA 94080 USA.
EM menno@gene.com
RI Loyet, Kelly/AAD-7544-2021
FU Genentech, Inc.
FX Supported by Genentech, Inc. Support for third-party writing assistance
   by Ivo Stoilov, MD, CMPP, of Envision Scientific Solutions, was provided
   by Genentech, Inc.
CR Anderson DH, 2002, AM J OPHTHALMOL, V134, P411, DOI 10.1016/S0002-9394(02)01624-0
   Anderson DH, 2010, PROG RETIN EYE RES, V29, P95, DOI 10.1016/j.preteyeres.2009.11.003
   Bora NS, 2006, J IMMUNOL, V177, P1872, DOI 10.4049/jimmunol.177.3.1872
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Brown DM, 2009, OPHTHALMOLOGY, V116, P57, DOI 10.1016/j.ophtha.2008.10.018
   Coleman HR, 2008, LANCET, V372, P1835, DOI 10.1016/S0140-6736(08)61759-6
   Dewan A, 2006, SCIENCE, V314, P989, DOI 10.1126/science.1133807
   Edwards AO, 2005, SCIENCE, V308, P421, DOI 10.1126/science.1110189
   Ferrara N, 2006, RETINA-J RET VIT DIS, V26, P859, DOI 10.1097/01.iae.0000242842.14624.e7
   Francis PJ, 2009, J MED GENET, V46, P300, DOI 10.1136/jmg.2008.062737
   Francis PJ, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0001197
   Gold B, 2006, NAT GENET, V38, P458, DOI 10.1038/ng1750
   Hageman GS, 2001, PROG RETIN EYE RES, V20, P705, DOI 10.1016/S1350-9462(01)00010-6
   Hageman GS, 2005, P NATL ACAD SCI USA, V102, P7227, DOI 10.1073/pnas.0501536102
   Haines JL, 2005, SCIENCE, V308, P419, DOI 10.1126/science.1110359
   Hecker LA, 2010, HUM MOL GENET, V19, P209, DOI 10.1093/hmg/ddp472
   Heurich M, 2011, P NATL ACAD SCI USA, V108, P8761, DOI 10.1073/pnas.1019338108
   Katschke KJ, 2009, J BIOL CHEM, V284, P10473, DOI 10.1074/jbc.M809106200
   Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557
   Klein R, 2010, ARCH OPHTHALMOL-CHIC, V128, P750, DOI 10.1001/archophthalmol.2010.92
   Luo C, 2011, MOL VIS, V17, P1588
   Magnusson KP, 2006, PLOS MED, V3, P109, DOI 10.1371/journal.pmed.0030005
   Maller J, 2006, NAT GENET, V38, P1055, DOI 10.1038/ng1873
   MULLEREBERHARD HJ, 1988, ANNU REV BIOCHEM, V57, P321, DOI 10.1146/annurev.bi.57.070188.001541
   Nakanishi T, 2002, J CHROMATOGR B, V776, P89, DOI 10.1016/S1570-0232(02)00078-8
   Olsen TW, 2004, INVEST OPHTH VIS SCI, V45, P4484, DOI 10.1167/iovs.04-0342
   Reynolds R, 2009, INVEST OPHTH VIS SCI, V50, P5818, DOI 10.1167/iovs.09-3928
   Ricklin D, 2010, NAT IMMUNOL, V11, P785, DOI 10.1038/ni.1923
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Rutar M, 2011, INVEST OPHTH VIS SCI, V52, P5347, DOI 10.1167/iovs.10-7119
   Scholl HPN, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002593
   Smith W, 2001, OPHTHALMOLOGY, V108, P697, DOI 10.1016/S0161-6420(00)00580-7
   Stanton CM, 2011, INVEST OPHTH VIS SCI, V52, P8828, DOI 10.1167/iovs.11-7933
   Vogt SD, 2011, EXP EYE RES, V93, P413, DOI 10.1016/j.exer.2011.06.002
   Wang JY, 2009, J CELL PHYSIOL, V220, P119, DOI 10.1002/jcp.21742
   Yang ZL, 2006, SCIENCE, V314, P992, DOI 10.1126/science.1133811
   Yates JRW, 2007, NEW ENGL J MED, V357, P553, DOI 10.1056/NEJMoa072618
   Yu Y, 2011, HUM MOL GENET, V20, P3699, DOI 10.1093/hmg/ddr270
   Yuan XL, 2010, MOL CELL PROTEOMICS, V9, P1031, DOI 10.1074/mcp.M900523-MCP200
NR 39
TC 52
Z9 63
U1 0
U2 6
PU ASSOC RESEARCH VISION OPHTHALMOLOGY INC
PI ROCKVILLE
PA 12300 TWINBROOK PARKWAY, ROCKVILLE, MD 20852-1606 USA
SN 0146-0404
J9 INVEST OPHTH VIS SCI
JI Invest. Ophthalmol. Vis. Sci.
PD SEP
PY 2012
VL 53
IS 10
BP 6628
EP 6637
DI 10.1167/iovs.12-9587
PG 10
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 016NQ
UT WOS:000309526200082
PM 22930722
DA 2022-11-30
ER

PT J
AU Barboni, MTS
   Szepessy, Z
   Ventura, DF
   Nemeth, J
AF Salgueiro Barboni, Mirella Telles
   Szepessy, Zsuzsanna
   Ventura, Dora Fix
   Nemeth, Janos
TI Individual Test Point Fluctuations of Macular Sensitivity in Healthy
   Eyes and Eyes With Age-Related Macular Degeneration Measured With
   Microperimetry
SO TRANSLATIONAL VISION SCIENCE & TECHNOLOGY
LA English
DT Article
DE microperimetry; macular sensitivity; sensitivity fluctuation;
   age-related macular degeneration; retina
ID TEST-RETEST VARIABILITY; MAIA MICROPERIMETRY; FIXATION STABILITY;
   OUTCOME MEASURE; REPEATABILITY; PERIMETRY; RELIABILITY; TRIALS; MP-1
AB Purpose: To establish fluctuation limits, it was considered that not only overall macular sensitivity but also fluctuations of individual test points in the macula might have clinical value.
   Methods: Three repeated measuremets of microperimetry were performed using the Standard Expert test of Macular Integrity Assessment (MAIA) in healthy subjects (N = 12, age = 23.8 +/- 1.5 years old) and in patients with age-related macular degeneration (AMD) (N = 11, age = 68.5 +/- 7.4 years old). A total of 37 macular points arranged in four concentric rings and in four quadrants were analyzed individually and in groups.
   Results: The data show low fluctuation of macular sensitivity of individual test points in healthy subjects (average = 1.38 +/- 0.28 dB) and AMD patients (average = 2.12 +/- 0.60 dB). Lower sensitivity points are more related to higher fluctuation than to the distance from the central point. Fixation stability showed no effect on the sensitivity fluctuation. The 95th percentile of the standard deviations of healthy subjects was, on average, 2.7 dB, ranging from 1.2 to 4 dB, depending on the point tested.
   Conclusion: Point analysis and regional analysis might be considered prior to evaluating macular sensitivity fluctuation in order to distinguish between normal variation and a clinical change.
C1 [Salgueiro Barboni, Mirella Telles; Szepessy, Zsuzsanna; Nemeth, Janos] Semmelweis Univ, Dept Ophthalmol, Maria U 39, H-1085 Budapest, Hungary.
   [Salgueiro Barboni, Mirella Telles; Ventura, Dora Fix] Univ Sao Paulo, Inst Psychol, Dept Expt Psychol, Sao Paulo, Brazil.
   [Szepessy, Zsuzsanna; Nemeth, Janos] Bion Innovat Ctr, Budapest, Hungary.
C3 Semmelweis University; Universidade de Sao Paulo
RP Nemeth, J (通讯作者)，Semmelweis Univ, Dept Ophthalmol, Maria U 39, H-1085 Budapest, Hungary.
EM nemeth.janos@med.semmelweis-univ.hu
RI Ventura, Dora F/B-9071-2012; Barboni, Mirella T. S./C-9874-2014
OI Ventura, Dora F/0000-0002-7616-4031; Nemeth, Janos/0000-0001-8575-4888
FU Sao Paulo Research Foundation (FAPESP) [2016/22007-5, 2016/04538-3,
   2014/26818-2]; National Council for Scientific and Technological
   Development (CNPq) [404239/2016-1]
FX This work was supported by the Sao Paulo Research Foundation (FAPESP
   grant numbers 2016/22007-5 and 2016/04538-3 to MTSB and 2014/26818-2 to
   DFV), and the National Council for Scientific and Technological
   Development (CNPq grant number 404239/2016-1 to MTSB). DFV is a CNPq 1A
   productivity fellow.
CR Anastasakis A, 2011, EYE, V25, P245, DOI 10.1038/eye.2010.158
   Andersen IVN, 1996, ACTA OPHTHALMOL SCAN, V74, P135
   Chen FK, 2011, OPTOMETRY VISION SCI, V88, P742, DOI 10.1097/OPX.0b013e3182167641
   Chen FK, 2009, INVEST OPHTH VIS SCI, V50, P3464, DOI 10.1167/iovs.08-2926
   Cideciyan AV, 2012, INVEST OPHTH VIS SCI, V53, P841, DOI 10.1167/iovs.11-8415
   Denniss J, 2016, OPHTHAL PHYSL OPT, V36, P453, DOI 10.1111/opo.12304
   Dimopoulos IS, 2016, INVEST OPHTH VIS SCI, V57, P4151, DOI 10.1167/iovs.16-19338
   Jones PR, 2016, INVEST OPHTH VIS SCI, V57, P6349, DOI 10.1167/iovs.16-20037
   Liu HT, 2015, GRAEF ARCH CLIN EXP, V253, P2137, DOI 10.1007/s00417-015-2974-6
   Midena E, 1997, INVEST OPHTH VIS SCI, V38, P469
   Midena E, 2017, EYE, V31, P985, DOI 10.1038/eye.2017.34
   Rohrschneider K, 2008, PROG RETIN EYE RES, V27, P536, DOI 10.1016/j.preteyeres.2008.07.003
   STEWART WC, 1993, SURV OPHTHALMOL, V37, P353, DOI 10.1016/0039-6257(93)90065-F
   SUNNESS JS, 1995, INVEST OPHTH VIS SCI, V36, P1863
   Szepessy Zs, 2017, J CLIN EXP OPHTHAL, V8, P697, DOI DOI 10.4172/2155-9570
   Vingolo EM, 2007, APPL PSYCHOPHYS BIOF, V32, P185, DOI [10.1007/s10484-007-9038-6, 10.1007/sl0484-007-9038-6]
   Weingessel B, 2009, EYE, V23, P1052, DOI 10.1038/eye.2008.237
   Wong EN, 2017, CLIN OPHTHALMOL, V11, P745, DOI 10.2147/OPTH.S131371
   Wong EN, 2017, ASIA-PAC J OPHTHALMO, V6, P70, DOI 10.22608/APO.201643
   Wu ZC, 2015, INVEST OPHTH VIS SCI, V56, P2606, DOI 10.1167/iovs.14-15977
   Wu ZC, 2013, INVEST OPHTH VIS SCI, V54, P7378, DOI 10.1167/iovs.13-12617
NR 21
TC 6
Z9 6
U1 0
U2 4
PU ASSOC RESEARCH VISION OPHTHALMOLOGY INC
PI ROCKVILLE
PA 12300 TWINBROOK PARKWAY, ROCKVILLE, MD 20852-1606 USA
SN 2164-2591
J9 TRANSL VIS SCI TECHN
JI Transl. Vis. Sci. Technol.
PD MAR
PY 2018
VL 7
IS 2
AR 25
DI 10.1167/tvst.7.2.25
PG 12
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA GD7KS
UT WOS:000430691400003
PM 29696099
OA Green Published, gold
DA 2022-11-30
ER

PT J
AU Fritsche, LG
   Lauer, N
   Hartmann, A
   Stippa, S
   Keilhauer, CN
   Oppermann, M
   Pandey, MK
   Kohl, J
   Zipfel, PF
   Weber, BHF
   Skerka, C
AF Fritsche, Lars G.
   Lauer, Nadine
   Hartmann, Andrea
   Stippa, Selina
   Keilhauer, Claudia N.
   Oppermann, Martin
   Pandey, Manoj K.
   Koehl, Joerg
   Zipfel, Peter F.
   Weber, Bernhard H. F.
   Skerka, Christine
TI An imbalance of human complement regulatory proteins CFHR1, CFHR3 and
   factor H influences risk for age-related macular degeneration (AMD)
SO HUMAN MOLECULAR GENETICS
LA English
DT Article
ID HEMOLYTIC-UREMIC SYNDROME; BINDING-PROTEIN; GENES; SUSCEPTIBILITY;
   POLYMORPHISM; ASSOCIATION; HAPLOTYPE; VARIANT; AUTOANTIBODIES;
   PROTECTION
AB A frequent deletion of complement factor H (CFH)-related genes CFHR3 and CFHR1 (Delta CFHR3/CFHR1) is considered to have a protective effect against age-related macular degeneration (AMD), although the underlying mechanism remains elusive. The deletion seems to be linked to one of the two protective CFH haplotypes which are both tagged by the protective allele of single nucleotide polymorphism rs2274700 (CFH:A473A). In a German cohort of 530 AMD patients, we now show that protection against AMD conferred by Delta CFHR3/CFHR1 is independent of the effects of rs2274700 and rs1061170 (CFH:Y402H). This suggests a functional role of CFHR1 and/or CFHR3 in disease pathogenesis. We therefore characterized the CFHR3 function and identified CFHR3 as a novel human complement regulator that inhibits C3 convertase activity. CFHR3 displays anti-inflammatory effects by blocking C5a generation and C5a-mediated chemoattraction of neutrophils. In addition, CFHR3 and CFHR1 compete with factor H for binding to the central complement component C3. Thus, deficiency of CFHR3 and CFHR1 results in a loss of complement control but enhances local regulation by factor H. Our findings allude to a critical balance between the complement regulators CFHR3, CFHR1 and factor H and further emphasize the central role of complement regulation in AMD pathology.
C1 [Fritsche, Lars G.; Weber, Bernhard H. F.] Univ Regensburg, Inst Human Genet, D-93054 Regensburg, Germany.
   [Lauer, Nadine; Hartmann, Andrea; Stippa, Selina; Zipfel, Peter F.; Skerka, Christine] Leibniz Inst Nat Prod Res & Infect Biol, Dept Infect Biol, D-07745 Jena, Germany.
   [Keilhauer, Claudia N.] Univ Hosp Wurzburg, Dept Ophthalmol, Wurzburg, Germany.
   [Oppermann, Martin] Univ Gottingen, Dept Cellular & Mol Immunol, Gottingen, Germany.
   [Pandey, Manoj K.; Koehl, Joerg] Cincinnati Childrens Hosp, Res Fdn, Div Mol Immunol, Cincinnati, OH USA.
   [Koehl, Joerg] Med Univ Lubeck, Inst Syst Inflammat Res, D-23538 Lubeck, Germany.
   [Zipfel, Peter F.] Univ Jena, Jena, Germany.
C3 University of Regensburg; Hans Knoll Institute (HKI); University of
   Wurzburg; University of Gottingen; Cincinnati Children's Hospital
   Medical Center; Cincinnati Children's Hospital Research Foundation;
   University System of Ohio; University of Cincinnati; University of
   Lubeck; Friedrich Schiller University of Jena
RP Weber, BHF (通讯作者)，Univ Regensburg, Inst Human Genet, Franz Josef Strauss Allee 11, D-93054 Regensburg, Germany.
EM bweb@klinik.uni-regensburg.de; christine.skerka@hki-jena.de
RI Pandey, Manoj Kumar/V-4557-2019; Fritsche, Lars G/AAF-9387-2019; Koehl,
   Joerg/C-8531-2011
OI Pandey, Manoj Kumar/0000-0002-0495-830X; Fritsche, Lars
   G/0000-0002-2110-1690; Koehl, Joerg/0000-0003-1121-3178; Weber, Bernhard
   H.F./0000-0002-8808-7723
FU Deutsche Forschungsgemeinschaft (DFG) [Sk46, WE1259/18-1, WE1259/19-1];
   Ruth and Milton Steinbach Foundation New York; Alcon Research Institute;
   German ProRetina Foundation
FX The work of the authors is supported in part by grants from the Deutsche
   Forschungsgemeinschaft (DFG) to C. S. (Sk46), to B. H. F. W.
   (WE1259/18-1 and WE1259/19-1), The Ruth and Milton Steinbach Foundation
   New York (B. H. F. W.) and the Alcon Research Institute (B. H. F. W.).
   N.L. is supported by a PhD research grant from the German ProRetina
   Foundation.
CR Abarrategui-Garrido C, 2009, BLOOD, V114, P4261, DOI 10.1182/blood-2009-05-223834
   Barrett JC, 2005, BIOINFORMATICS, V21, P263, DOI 10.1093/bioinformatics/bth457
   Conley YP, 2006, HUM MOL GENET, V15, P3206, DOI 10.1093/hmg/ddl396
   Diaz-Guillen MA, 1999, IMMUNOGENETICS, V49, P549, DOI 10.1007/s002510050534
   Dudbridge F, 2008, HUM HERED, V66, P87, DOI 10.1159/000119108
   Edwards AO, 2005, SCIENCE, V308, P421, DOI 10.1126/science.1110189
   Ferreira VP, 2007, BLOOD, V110, P2190, DOI 10.1182/blood-2007-04-083170
   Francis PJ, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0001197
   Fremeaux-Bacchi V, 2008, BLOOD, V112, P4948, DOI 10.1182/blood-2008-01-133702
   Hageman GS, 2006, ANN MED, V38, P592, DOI 10.1080/07853890601097030
   Hageman GS, 2005, P NATL ACAD SCI USA, V102, P7227, DOI 10.1073/pnas.0501536102
   Haines JL, 2005, SCIENCE, V308, P419, DOI 10.1126/science.1110359
   Heinen S, 2009, BLOOD, V114, P2439, DOI 10.1182/blood-2009-02-205641
   Hellwage J, 1999, FEBS LETT, V462, P345, DOI 10.1016/S0014-5793(99)01554-9
   Hughes AE, 2006, NAT GENET, V38, P1173, DOI 10.1038/ng1890
   Jozsi M, 2008, BLOOD, V111, P1512, DOI 10.1182/blood-2007-09-109876
   Jozsi M, 2007, BLOOD, V110, P1516, DOI 10.1182/blood-2007-02-071472
   Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557
   Kunert A, 2007, J IMMUNOL, V179, P2979, DOI 10.4049/jimmunol.179.5.2979
   Li M, 2006, NAT GENET, V38, P1049, DOI 10.1038/ng1871
   Licht C, 2009, BLOOD, V114, P4538, DOI 10.1182/blood-2009-03-205096
   Male DA, 2000, MOL IMMUNOL, V37, P41, DOI 10.1016/S0161-5890(00)00024-9
   Maller J, 2006, NAT GENET, V38, P1055, DOI 10.1038/ng1873
   Park CT, 1996, J BIOL CHEM, V271, P18054, DOI 10.1074/jbc.271.30.18054
   Pascolini D, 2004, OPHTHAL EPIDEMIOL, V11, P67, DOI 10.1076/opep.11.2.67.28158
   Purcell S, 2007, AM J HUM GENET, V81, P559, DOI 10.1086/519795
   Rivera A, 2005, HUM MOL GENET, V14, P3227, DOI 10.1093/hmg/ddi353
   Schmid-Kubista KE, 2009, INVEST OPHTH VIS SCI, V50, P5070, DOI 10.1167/iovs.09-3975
   Scholl HPN, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002593
   SKERKA C, 1991, J BIOL CHEM, V266, P12015
   SKERKA C, 1993, J BIOL CHEM, V268, P2904
   Skerka C, 2008, VACCINE, V26, pI9, DOI 10.1016/j.vaccine.2008.11.021
   Skerka C, 2007, MOL IMMUNOL, V44, P3398, DOI 10.1016/j.molimm.2007.02.012
   Spencer KL, 2008, HUM MOL GENET, V17, P971, DOI 10.1093/hmg/ddm369
   Wu J, 2009, NAT IMMUNOL, V10, P728, DOI 10.1038/ni.1755
   Yu JM, 2007, BIOCHEMISTRY-US, V46, P8451, DOI 10.1021/bi700459a
   Zipfel PF, 2007, PLOS GENET, V3, P387, DOI 10.1371/journal.pgen.0030041
   Zipfel PF, 2009, NAT REV IMMUNOL, V9, P729, DOI 10.1038/nri2620
NR 38
TC 159
Z9 164
U1 0
U2 11
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 0964-6906
J9 HUM MOL GENET
JI Hum. Mol. Genet.
PD DEC 1
PY 2010
VL 19
IS 23
BP 4694
EP 4704
DI 10.1093/hmg/ddq399
PG 11
WC Biochemistry & Molecular Biology; Genetics & Heredity
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Genetics & Heredity
GA 676QV
UT WOS:000283930200013
PM 20843825
OA Bronze
DA 2022-11-30
ER

PT J
AU Sun, R
   Zhang, AA
   Ge, Y
   Gou, JX
   Yin, T
   He, HB
   Wang, YJ
   Zhang, GM
   Kong, J
   Shang, LX
   Tao, XM
   Zhang, Y
   Tang, X
AF Sun, Rong
   Zhang, Anan
   Ge, Ying
   Gou, Jingxin
   Yin, Tian
   He, Haibing
   Wang, Yanjiao
   Zhang, Guimin
   Kong, Jun
   Shang, Lixia
   Tao, Xiumei
   Zhang, Yu
   Tang, Xing
TI Ultra-small-size Astragaloside-IV loaded lipid nanocapsules eye drops
   for the effective management of dry age-related macular degeneration
SO EXPERT OPINION ON DRUG DELIVERY
LA English
DT Article
DE Dry age-related macular degeneration; astragaloside-IV; lipid
   nanocapsules; eye drops; ultra-small size
ID OXIDATIVE STRESS; GEOGRAPHIC ATROPHY; SODIUM IODATE; IN-VITRO; DELIVERY;
   NANOPARTICLES; STABILITY; CELLS; VIVO
AB Background Age-related macular degeneration (AMD) is a major cause of severe visual loss in elderly people. The treatments for dry AMD (dAMD) are severely limited so far. In this work, we aim to develop an eye drop to protect retinal functions against oxidative stress and apoptosis for improving dAMD management. Methods Astragaloside-IV (ASIV) was prepared into phospholipid complex and loaded into three sizes (20, 50 and 90 nm) of ASIV lipid nanocapsules (ASIV-LNCs). The penetration and distribution of LNCs were investigated. DAMD mice model was induced by NaIO3, and therapeutic effect was evaluated by electroretinography (ERG), histological examination, apoptosis and ROS detection. Results The ocular penetration and pharmacokinetic studies corroborated the feasibility of the LNCs to reach the fundus, and ultra-small-size LNCs (ASIV-LNCs-20) had the best delivery effect. ASIV-LNCs-20 was able to decrease ROS production and reduce the apoptosis rate from 5.12% to 0.533%. ERG and H&E staining results confirmed ASIV-LNCs-20 had a good protective effect on the morphology and function of the retina. Conclusions These results suggest that ASIV-LNCs can be a promising therapy approach for dAMD, and this research also offers new possibilities for further applications of LNCs as a drug delivery system for other eye diseases.
C1 [Sun, Rong; Zhang, Anan; Ge, Ying; Gou, Jingxin; He, Haibing; Wang, Yanjiao; Zhang, Yu; Tang, Xing] Shenyang Pharmaceut Univ, Sch Pharm, Dept Pharmaceut, Shenyang 110016, Liaoning, Peoples R China.
   [Yin, Tian] Shenyang Pharmaceut Univ, Sch Funct Food & Wine, Shenyang, Liaoning, Peoples R China.
   [Zhang, Guimin; Zhang, Yu] Lunan Pharmaceut Grp Co Ltd, Lunan, Shandong, Peoples R China.
   [Kong, Jun] China Med Univ, Affiliated Hosp 4, Ophthalmol, Shenyang, Liaoning, Peoples R China.
   [Shang, Lixia; Tao, Xiumei] NKD Pharma Co Ltd, Beijing, Peoples R China.
C3 Shenyang Pharmaceutical University; Shenyang Pharmaceutical University;
   China Medical University
RP Zhang, Y (通讯作者)，Shenyang Pharmaceut Univ, Sch Pharm, Dept Pharmaceut, Shenyang 110016, Liaoning, Peoples R China.
EM pharmzy@163.com
FU National Mega-project for Innovative Drugs [2019ZX09721001]; Major
   Project of National Science and Technology 'Creation of Major New Drugs'
   from China [2018ZX09721002-002]; China Postdoctoral Science Foundation
   [2019M651149]; Liaoning Revitalization Talents Program [XLYC1907111,
   XLYC1908031]; Liaoning Province Doctoral Start-up Fund Program
   [2019BS-226]; Liaoning Province Natural Science Fund Project
   [20180551031]; Overseas Returnees Start-up Fund from Shenyang
   Pharmaceutical University [GGJJ2018102]
FX This work was supported by the National Mega-project for Innovative
   Drugs [2019ZX09721001], Major Project of National Science and Technology
   `Creation of Major New Drugs' from China [2018ZX09721002-002], China
   Postdoctoral Science Foundation Grant [2019M651149], Liaoning
   Revitalization Talents Program [XLYC1907111, XLYC1908031], Liaoning
   Province Doctoral Start-up Fund Program [2019BS-226], Liaoning Province
   Natural Science Fund Project [20180551031], Overseas Returnees Start-up
   Fund from Shenyang Pharmaceutical University [GGJJ2018102].
CR Alizadeh M, 2001, INVEST OPHTH VIS SCI, V42, P2706
   Anton N, 2007, J PHYS CHEM B, V111, P3651, DOI 10.1021/jp0664768
   Berkowitz BA, 2017, INVEST OPHTH VIS SCI, V58, P3286, DOI 10.1167/iovs.17-21850
   Bhattacharjee S, 2016, J CONTROL RELEASE, V235, P337, DOI 10.1016/j.jconrel.2016.06.017
   Boltz A, 2010, INVEST OPHTH VIS SCI, V51, P4220, DOI 10.1167/iovs.09-4968
   Buschini E, 2015, CLIN OPHTHALMOL, V9, P563, DOI 10.2147/OPTH.S59724
   Carradori D, 2016, J CONTROL RELEASE, V238, P253, DOI 10.1016/j.jconrel.2016.08.006
   Chen PJ, 2019, J CELL BIOCHEM, V120, P1028, DOI 10.1002/jcb.27599
   Chen QQ, 2018, BIOMED PHARMACOTHER, V108, P679, DOI 10.1016/j.biopha.2018.09.049
   Chiras D, 2015, CRIT REV CL LAB SCI, V52, P12, DOI 10.3109/10408363.2014.968703
   Cholkar Kishore, 2012, Recent Pat Nanomed, V2, P82
   Chopra P, 2010, INT J PHARMACEUT, V388, P107, DOI 10.1016/j.ijpharm.2009.12.046
   Chou SF, 2017, SCI REP-UK, V7, DOI 10.1038/srep42344
   Chou SF, 2016, ACTA BIOMATER, V38, P116, DOI 10.1016/j.actbio.2016.04.035
   CROWE PJ, 1985, JPEN-PARENTER ENTER, V9, P720, DOI 10.1177/0148607185009006720
   del Amo EM, 2017, PROG RETIN EYE RES, V57, P134, DOI 10.1016/j.preteyeres.2016.12.001
   Due WW, 2018, OXID MED CELL LONGEV, V2018, DOI 10.1155/2018/1610751
   FANGUEIRO JF, 2016, CURR PHARM DESIGN, V22, P1
   Hernandez-Zimbron LF, 2018, OXID MED CELL LONGEV, V2018, DOI 10.1155/2018/8374647
   Ge L, 2018, EUROINTERVENTION, V14, P538, DOI 10.4244/EIJ-D-17-00515
   Ge Y, 2020, EXPERT OPIN DRUG DEL, V17, P603, DOI 10.1080/17425247.2020.1735348
   Heurtault B., 2002, PHARM RES, V19, P6
   Hunter RJ, 2001, J COLLOID INTERF SCI, V237, P147, DOI 10.1006/jcis.2001.7423
   Jin X, 2012, INT J NANOMED, V7, P4907, DOI 10.2147/IJN.S35965
   Jumaa M, 1998, INT J PHARM, V163, P81, DOI 10.1016/S0378-5173(97)00369-4
   Kassem MA, 2007, INT J PHARMACEUT, V340, P126, DOI 10.1016/j.ijpharm.2007.03.011
   Kozlowski MR, 2015, INVEST OPHTH VIS SCI, V56
   Lancon A, 2016, MOLECULES, V21, DOI 10.3390/molecules21030304
   Lee CH, 2017, NANOSCALE, V9, P11754, DOI 10.1039/c7nr03221h
   Leng B, 2019, MEDIAT INFLAMM, V2019, DOI 10.1155/2019/1082497
   Liu DH, 2010, CRIT REV THER DRUG, V27, P371
   Liu YL, 2018, FRONT AGING NEUROSCI, V10, DOI 10.3389/fnagi.2018.00389
   Luo LJ, 2020, BIOMATERIALS, V243, DOI 10.1016/j.biomaterials.2020.119961
   Mata NL, 2013, RETINA-J RET VIT DIS, V33, P498, DOI 10.1097/IAE.0b013e318265801d
   Nita M, 2016, OXID MED CELL LONGEV, V2016, DOI 10.1155/2016/3164734
   Odom JV, 2016, DOC OPHTHALMOL, V133, P1, DOI 10.1007/s10633-016-9553-y
   Qaddoumi MG, 2004, PHARM RES-DORDR, V21, P641, DOI 10.1023/B:PHAM.0000022411.47059.76
   Qin SM, 2019, FRONT PHARMACOL, V10, DOI 10.3389/fphar.2019.00894
   Sanvicens N, 2004, J BIOL CHEM, V279, P39268, DOI 10.1074/jbc.M402202200
   Sasso MS, 2016, BIOMATERIALS, V96, P47, DOI 10.1016/j.biomaterials.2016.04.010
   Schwartz SD, 2012, LANCET, V379, P713, DOI 10.1016/S0140-6736(12)60028-2
   Suda K, 2017, J CONTROL RELEASE, V266, P301, DOI 10.1016/j.jconrel.2017.09.036
   The Age-related Eye Disease Study, 2012, OPHTHALMOLOGY, V119
   Vadlapudi AD, 2013, THER DELIV, V4, P1, DOI [10.4155/tde.12.122, 10.4155/TDE.12.122]
   Wang JM, 2014, INVEST OPHTH VIS SCI, V55, P1941, DOI 10.1167/iovs.13-13075
   Waugh N, 2018, HEALTH TECHNOL ASSES, V22, P1, DOI 10.3310/hta22270
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
   Wu LB, 2011, ADV DRUG DELIVER REV, V63, P456, DOI 10.1016/j.addr.2011.02.001
   Yadav M, 2020, DRUG DELIV TRANSL RE, V10, P919, DOI 10.1007/s13346-020-00733-4
   Yan YT, 2018, INT J BIOL MACROMOL, V115, P600, DOI 10.1016/j.ijbiomac.2018.04.011
   Yang C, 2019, INT IMMUNOPHARMACOL, V75, DOI 10.1016/j.intimp.2019.05.036
   Yoncheva K, 2005, EUR J PHARM SCI, V24, P411, DOI 10.1016/j.ejps.2004.12.002
   Zhai YJ, 2015, J NANOSCI NANOTECHNO, V15, P2643, DOI 10.1166/jnn.2015.9514
   Zhang K, 2011, P NATL ACAD SCI USA, V108, P6241, DOI 10.1073/pnas.1018987108
   Zhang L, 2015, ACS APPL MATER INTER, V7, P25147, DOI 10.1021/acsami.5b06488
NR 55
TC 9
Z9 10
U1 3
U2 34
PU TAYLOR & FRANCIS LTD
PI ABINGDON
PA 2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND
SN 1742-5247
EI 1744-7593
J9 EXPERT OPIN DRUG DEL
JI Expert Opin. Drug Deliv.
PD SEP 1
PY 2020
VL 17
IS 9
BP 1305
EP 1319
DI 10.1080/17425247.2020.1783236
EA JUL 2020
PG 15
WC Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Pharmacology & Pharmacy
GA NC3OJ
UT WOS:000549623200001
PM 32538226
DA 2022-11-30
ER

PT J
AU Sabour-Pickett, S
   Nolan, JM
   Loughman, J
   Beatty, S
AF Sabour-Pickett, Sarah
   Nolan, John M.
   Loughman, James
   Beatty, Stephen
TI A review of the evidence germane to the putative protective role of the
   macular carotenoids for age-related macular degeneration
SO MOLECULAR NUTRITION & FOOD RESEARCH
LA English
DT Review
DE Age-related macular degeneration; Lutein; Macular pigment;
   Meso-zeaxanthin; Zeaxanthin
ID PIGMENT EPITHELIAL-CELLS; BEAVER DAM EYE; POLYUNSATURATED FATTY-ACIDS;
   COMPLEMENT FACTOR-H; BLUE MOUNTAINS EYE; QUALITY-OF-LIFE; LUTEIN
   SUPPLEMENTATION; OPTICAL-DENSITY; HUMAN RETINA; RISK-FACTORS
AB There is a consensus that age-related macular degeneration (AMD) is the result of (photo)oxidative-induced retinal injury and its inflammatory sequelae, the latter being influenced by genetic background. The dietary carotenoids, lutein (L), zeaxanthin (Z), and meso-zeaxanthin (meso-Z), accumulate at the macula, where they are collectively known as macular pigment (MP). The anatomic (central retinal), biochemical (anti-oxidant) and optical (short-wavelength-filtering) properties of this pigment have generated interest in the biologically plausible rationale that MP may confer protection against AMD. Level 1 evidence has shown that dietary supplementation with broad-spectrum anti-oxidants results in risk reduction for AMD progression. Studies have demonstrated that MP rises in response to supplementation with the macular carotenoids, although level 1 evidence that such supplementation results in risk reduction of AMD and/or its progression is still lacking. Although appropriately weighted attention should be accorded to higher levels of evidence, the totality of available data should be appraised in an attempt to inform professional practice. In this context, the literature demonstrates that supplementation with the macular carotenoids is probably the best means of fortifying the anti-oxidant defences of the macula, thus putatively reducing the risk of AMD and/or its progression.
C1 [Nolan, John M.; Beatty, Stephen] Whitfield Clin, Inst Vis Res, Waterford, Ireland.
   [Sabour-Pickett, Sarah; Loughman, James] Dublin Inst Technol, Coll Sci & Hlth, Dept Optometry, Dublin, Ireland.
   [Sabour-Pickett, Sarah; Nolan, John M.; Beatty, Stephen] Waterford Inst Technol, Dept Chem & Life Sci, Macular Pigment Res Grp, Waterford, Ireland.
   [Loughman, James] Univ KwaZulu Natal, Fac Hlth Sci, African Vis Res Inst, Durban, South Africa.
C3 Technological University Dublin; South East Technological University
   (SETU); University of Kwazulu Natal
RP Sabour-Pickett, S (通讯作者)，Whitfield Clin, Inst Vis Res, Suite 14,Cork Rd, Waterford, Ireland.
EM sarah.sabourpickett@gmail.com
RI ; Nolan, John/N-4921-2014
OI Loughman, James/0000-0003-3130-8991; Nolan, John/0000-0002-5503-7084
CR Aleman TS, 2001, INVEST OPHTH VIS SCI, V42, P1873
   Algvere PV, 2006, ACTA OPHTHALMOL SCAN, V84, P4, DOI 10.1111/j.1600-0420.2005.00627.x
   Anderson DH, 2002, AM J OPHTHALMOL, V134, P411, DOI 10.1016/S0002-9394(02)01624-0
   Attebo K, 1996, OPHTHALMOLOGY, V103, P357
   Barker FM, 2011, INVEST OPHTHALMOL VI
   Bartlett HE, 2007, EUR J CLIN NUTR, V61, P1121, DOI 10.1038/sj.ejcn.1602626
   Bazan N G, 1989, Prog Clin Biol Res, V312, P95
   Beatty S, 1999, BRIT J OPHTHALMOL, V83, P867, DOI 10.1136/bjo.83.7.867
   Beatty S, 2000, SURV OPHTHALMOL, V45, P115, DOI 10.1016/S0039-6257(00)00140-5
   Berendschot TTJM, 2000, INVEST OPHTH VIS SCI, V41, P3322
   Bernstein PS, 2004, ARCH BIOCHEM BIOPHYS, V430, P163, DOI 10.1016/j.abb.2004.07.004
   Bhosale P, 2005, BBA-MOL BASIS DIS, V1740, P116, DOI 10.1016/j.bbadis.2005.02.002
   Billsten HH, 2003, PHOTOCHEM PHOTOBIOL, V78, P138, DOI 10.1562/0031-8655(2003)078<0138:PPOXIC>2.0.CO;2
   Black N, 1996, BRIT MED J, V312, P1215
   BOK D, 1993, J CELL SCI, P189
   Bone RA, 1997, EXP EYE RES, V64, P211, DOI 10.1006/exer.1996.0210
   Bone RA, 2003, J NUTR, V133, P992, DOI 10.1093/jn/133.4.992
   BONE RA, 1985, VISION RES, V25, P1531, DOI 10.1016/0042-6989(85)90123-3
   BONE RA, 1993, INVEST OPHTH VIS SCI, V34, P2033
   Bone RA, 2007, NUTR METAB, V4, DOI 10.1186/1743-7075-4-12
   Bone RA, 2010, ARCH BIOCHEM BIOPHYS, V504, P50, DOI 10.1016/j.abb.2010.06.019
   BORISH ET, 1987, CARCINOGENESIS, V8, P1517, DOI 10.1093/carcin/8.10.1517
   BOULTON M, 1993, J PHOTOCH PHOTOBIO B, V19, P201, DOI 10.1016/1011-1344(93)87085-2
   Bressler Neil M, 2004, JAMA, V291, P1900, DOI 10.1001/jama.291.15.1900
   Bressler NM, 2010, OPHTHALMOLOGY, V117, P747, DOI 10.1016/j.ophtha.2009.09.002
   Brown DM, 2009, OPHTHALMOLOGY, V116, P57, DOI 10.1016/j.ophtha.2008.10.018
   Buzzi F., 1792, NUOVE SPERIENZE FATT
   Cahill MT, 2005, OPHTHALMOLOGY, V112, P152, DOI 10.1016/j.ophtha.2004.06.036
   Cai JY, 2000, PROG RETIN EYE RES, V19, P205, DOI 10.1016/S1350-9462(99)00009-9
   Cantrell A, 2003, ARCH BIOCHEM BIOPHYS, V412, P47, DOI 10.1016/S0003-9861(03)00014-6
   Cardinault N, 2005, CLIN CHIM ACTA, V357, P34, DOI 10.1016/j.cccn.2005.01.030
   Chakravarthy U., 2009, FUNCTIONAL MORPHOLOG
   Chevalleraeu A., 1907, ANN OCUL, P241
   Chong EWT, 2008, ARCH OPHTHALMOL-CHIC, V126, P826, DOI 10.1001/archopht.126.6.826
   Chucair AJ, 2007, INVEST OPHTH VIS SCI, V48, P5168, DOI 10.1167/iovs.07-0037
   Chung HY, 2004, J NUTR, V134, P1887, DOI 10.1093/jn/134.8.1887
   Connolly EE, 2010, CURR EYE RES, V35, P335, DOI 10.3109/02713680903521951
   Curcio CA, 1996, INVEST OPHTH VIS SCI, V37, P1236
   DeCarlo DK, 2003, OPTOMETRY VISION SCI, V80, P207, DOI 10.1097/00006324-200303000-00010
   Delcourt C, 2006, INVEST OPHTH VIS SCI, V47, P2329, DOI 10.1167/iovs.05-1235
   Dentchev T, 2003, MOL VIS, V9, P184
   Doney ASF, 2009, DIABETIC MED, V26, P460, DOI 10.1111/j.1464-5491.2009.02719.x
   Donoso LA, 2006, SURV OPHTHALMOL, V51, P137, DOI 10.1016/j.survophthal.2005.12.001
   Erhard H., 1924, ZOOL JB ZOOL PHYSL, P489
   Ferrero-Miliani L, 2007, CLIN EXP IMMUNOL, V147, P227, DOI 10.1111/j.1365-2249.2006.03261.x
   Fletcher AE, 2008, ARCH OPHTHALMOL-CHIC, V126, P1396, DOI 10.1001/archopht.126.10.1396
   Flood V, 2002, OPHTHALMOLOGY, V109, P2272, DOI 10.1016/S0161-6420(02)01263-0
   Francis PJ, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0001197
   Gale CR, 2003, INVEST OPHTH VIS SCI, V44, P2461, DOI 10.1167/iovs.02-0929
   Hageman GS, 2001, PROG RETIN EYE RES, V20, P705, DOI 10.1016/S1350-9462(01)00010-6
   HALLIWELL B, 1997, NUTR REV, V55, P44, DOI DOI 10.1111/J.1753-4887.1997.TB06100.X.PMID:9155225
   HAM WT, 1976, NATURE, V260, P153, DOI 10.1038/260153a0
   HAM WT, 1978, INVEST OPHTH VIS SCI, V17, P1029
   Hammond BR, 1997, INVEST OPHTH VIS SCI, V38, P1795
   HANDELMAN GJ, 1988, INVEST OPHTH VIS SCI, V29, P850
   Harbour R, 2001, BRIT MED J, V323, P334, DOI 10.1136/bmj.323.7308.334
   HARMAN D, 1972, J AM GERIATR SOC, V20, P145, DOI 10.1111/j.1532-5415.1972.tb00787.x
   HARMAN D, 1956, J GERONTOL, V11, P298, DOI 10.1093/geronj/11.3.298
   Hennekens C. H., 1993, ANN NY ACAD SCI, V703, P24
   HENNEKENS CH, 1993, ANN NY ACAD SCI, V703, P18, DOI 10.1111/j.1749-6632.1993.tb26330.x
   Henning H., 1920, ARCH GESPHYSIOL, P91
   HIRSCH J, 1989, VISION RES, V29, P1095, DOI 10.1016/0042-6989(89)90058-8
   Hodge WG, 2007, RETINA-J RET VIT DIS, V27, P216, DOI 10.1097/01.iae.0000233322.83713.2d
   Hollyfield JG, 2008, NAT MED, V14, P194, DOI 10.1038/nm1709
   Home E, 1798, PHILOS T R SOC LOND, V2, P332
   Hopley C, 2003, CLIN EXP OPHTHALMOL, V31, P522, DOI 10.1046/j.1442-9071.2003.00715.x
   Huang LL, 2008, INVEST OPHTH VIS SCI, V49, P3864, DOI 10.1167/iovs.07-1420
   Hughes DA, 2000, J INFECT DIS, V182, pS11, DOI 10.1086/315910
   Jentsch S., 2011, KLIN MONBL AUGENHEIL
   Johnson EJ, 2005, INVEST OPHTH VIS SCI, V46, P692, DOI 10.1167/iovs.02-1192
   Johnson EJ, 2000, AM J CLIN NUTR, V71, P1555
   Johnson EJ, 2008, AM J CLIN NUTR, V87, P1521, DOI 10.1093/ajcn/87.5.1521
   Johnson LV, 2001, EXP EYE RES, V73, P887, DOI 10.1006/exer.2001.1094
   JORGENSEN K, 1993, Z LEBENSM UNTERS FOR, V196, P423, DOI 10.1007/BF01190806
   Katz ML, 2002, ARCH GERONTOL GERIAT, V34, P169, DOI 10.1016/S0167-4943(02)00005-5
   Kearney P. M., 2010, INT J EPIDEMIOL, P1464
   Kelliher C, 2006, BRIT J OPHTHALMOL, V90, P367, DOI 10.1136/bjo.2005.075861
   Kennedy CJ, 1995, EYE, V9, P763, DOI 10.1038/eye.1995.192
   Khachik F, 1997, INVEST OPHTH VIS SCI, V38, P1802
   Khachik F, 2006, INVEST OPHTH VIS SCI, V47, P5234, DOI 10.1167/iovs.06-0504
   Kirby ML, 2010, INVEST OPHTH VIS SCI, V51, P6722, DOI 10.1167/iovs.10-5344
   KIRSCHFELD K, 1982, PROC R SOC SER B-BIO, V216, P71, DOI 10.1098/rspb.1982.0061
   Klaver CCW, 1998, ARCH OPHTHALMOL-CHIC, V116, P653, DOI 10.1001/archopht.116.5.653
   Klein R, 1998, AM J EPIDEMIOL, V147, P103
   Klein R, 2010, ARCH OPHTHALMOL-CHIC, V128, P750, DOI 10.1001/archophthalmol.2010.92
   Koh HH, 2004, EXP EYE RES, V79, P21, DOI 10.1016/j.exer.2004.03.001
   LAM S, 1990, ARCH OPHTHALMOL-CHIC, V108, P1751, DOI 10.1001/archopht.1990.01070140105039
   Lamoureux EL, 2004, AM J OPHTHALMOL, V137, P265, DOI 10.1016/j.ajo.2003.08.003
   Landrum JT, 1997, EXP EYE RES, V65, P57, DOI 10.1006/exer.1997.0309
   Landrum JT, 2001, ARCH BIOCHEM BIOPHYS, V385, P28, DOI 10.1006/abbi.2000.2171
   Landrum JT, 1999, METHOD ENZYMOL, V299, P457
   Li BX, 2010, ARCH BIOCHEM BIOPHYS, V504, P56, DOI 10.1016/j.abb.2010.07.024
   Li CM, 2006, INVEST OPHTH VIS SCI, V47, P3119, DOI 10.1167/iovs.05-1446
   Lu L, 2006, J CELL PHYSIOL, V206, P119, DOI 10.1002/jcp.20439
   Machlin L. B., 1987, FASEB J, V1, P1
   MAOKA T, 1986, COMP BIOCHEM PHYS B, V83, P121, DOI 10.1016/0305-0491(86)90341-X
   Mares JA, 2010, ARCH OPHTHALMOL-CHIC
   Mares-Perlman JA, 2001, AM J EPIDEMIOL, V153, P424, DOI 10.1093/aje/153.5.424
   MARESPERLMAN JA, 1995, ARCH OPHTHALMOL-CHIC, V113, P1518, DOI 10.1001/archopht.1995.01100120048007
   McCord JM, 2000, AM J MED, V108, P652, DOI 10.1016/S0002-9343(00)00412-5
   Moeller SM, 2006, ARCH OPHTHALMOL-CHIC, V124, P1151, DOI 10.1001/archopht.124.8.1151
   Nebeling LC, 1997, AM J PUBLIC HEALTH, V87, P268, DOI 10.2105/AJPH.87.2.268
   Neelam K, 2008, OPHTHAL EPIDEMIOL, V15, P389, DOI 10.1080/09286580802154275
   Neuringer M, 2004, INVEST OPHTH VIS SCI, V45, P3234, DOI 10.1167/iovs.02-1243
   Noell W K, 1966, Invest Ophthalmol, V5, P450
   Nolan JM, 2007, EXP EYE RES, V84, P61, DOI 10.1016/j.exer.2006.08.016
   Nolan JM, 2011, VISION RES, V51, P459, DOI 10.1016/j.visres.2010.12.016
   Nolan JM, 2010, OPHTHALMIC RES, V44, P131, DOI 10.1159/000315531
   Nussbaum J J, 1981, Retina, V1, P296, DOI 10.1097/00006982-198101040-00007
   Olmedilla B, 2001, J SCI FOOD AGR, V81, P904, DOI 10.1002/jsfa.905
   Owen CG, 2003, BRIT J OPHTHALMOL, V87, P312, DOI 10.1136/bjo.87.3.312
   Perry A, 2009, J FOOD COMPOS ANAL, V22, P9, DOI 10.1016/j.jfca.2008.07.006
   PITTS DG, 1970, AMER J OPT ARCH AM A, V47, P535
   Rein DB, 2006, ARCH OPHTHALMOL-CHIC, V124, P1754, DOI 10.1001/archopht.124.12.1754
   Resnikoff S, 2004, B WORLD HEALTH ORGAN, V82, P844
   Richer S, 1999, J Am Optom Assoc, V70, P24
   Richer Stuart, 2004, Optometry, V75, P216, DOI 10.1016/S1529-1839(04)70049-4
   Richer Stuart, 2007, Optometry, V78, P213, DOI 10.1016/j.optm.2006.10.019
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   ROZANOWSKA M, 1995, J BIOL CHEM, V270, P18825, DOI 10.1074/jbc.270.32.18825
   RUFFOLO JJ, 1984, INVEST OPHTH VIS SCI, V25, P893
   Rychetnik L, 2002, J EPIDEMIOL COMMUN H, V56, P119, DOI 10.1136/jech.56.2.119
   Sackett D L, 1994, ACP J Club, V120 Suppl 3, pA11
   SanGiovanni JP, 2007, ARCH OPHTHALMOL-CHIC, V125, P1225, DOI 10.1001/archopht.125.9.1225
   SanGiovanni JP, 2005, PROG RETIN EYE RES, V24, P87, DOI 10.1016/j.preteyeres.2004.06.002
   Schalch W, 1992, EXS, V62, P280
   Schalch W, 2007, ARCH BIOCHEM BIOPHYS, V458, P128, DOI 10.1016/j.abb.2006.09.032
   Schork NJ, 1997, AM J RESP CRIT CARE, V156, pS103, DOI 10.1164/ajrccm.156.4.12-tac-5
   Schultze M, 1866, UEBER GELBEN FLECK R
   Seddon JM, 2004, JAMA-J AM MED ASSOC, V291, P704, DOI 10.1001/jama.291.6.704
   SEDDON JM, 1994, JAMA-J AM MED ASSOC, V272, P1413, DOI 10.1001/jama.272.18.1413
   Seddon JM, 2007, JAMA-J AM MED ASSOC, V297, P1793, DOI 10.1001/jama.297.16.1793
   Shaban H, 2002, EXP EYE RES, V75, P99, DOI 10.1006/exer.2001.1192
   Sie H, 1991, AM J MED, V9, P31, DOI DOI 10.1016/0002-9343(91)90281-2
   Siems WG, 1999, BIOFACTORS, V10, P105, DOI 10.1002/biof.5520100204
   SILVESTRI G, 1994, EYE, V8, P564, DOI 10.1038/eye.1994.138
   Simonelli F, 2002, CLIN CHIM ACTA, V320, P111, DOI 10.1016/S0009-8981(02)00056-6
   Smith W, 2001, OPHTHALMOLOGY, V108, P697, DOI 10.1016/S0161-6420(00)00580-7
   Snellen ELM, 2002, ACTA OPHTHALMOL SCAN, V80, P368, DOI 10.1034/j.1600-0420.2002.800404.x
   SNODDERLY DM, 1984, INVEST OPHTH VIS SCI, V25, P674
   Soemmering S., 1799, COMMENT SOC REG SCI, P13
   Sommerburg O, 1998, BRIT J OPHTHALMOL, V82, P907, DOI 10.1136/bjo.82.8.907
   Sparrow JR, 2003, J BIOL CHEM, V278, P18207, DOI 10.1074/jbc.M300457200
   STEINBERG RH, 1985, DOC OPHTHALMOL, V60, P327, DOI 10.1007/BF00158922
   Stephenson J, 1998, BMJ-BRIT MED J, V316, P611, DOI 10.1136/bmj.316.7131.611
   STONE WL, 1979, EXP EYE RES, V28, P387, DOI 10.1016/0014-4835(79)90114-3
   Stringham JM, 2008, OPTOMETRY VISION SCI, V85, P82, DOI 10.1097/OPX.0b013e318162266e
   Sujak A, 1999, ARCH BIOCHEM BIOPHYS, V371, P301, DOI 10.1006/abbi.1999.1437
   Sundelin S, 1998, CURR EYE RES, V17, P851, DOI 10.1076/ceyr.17.8.851.5146
   Sundelin SP, 2001, FREE RADICAL BIO MED, V31, P217, DOI 10.1016/S0891-5849(01)00573-1
   Suzuki M, 2007, MOL VIS, V13, P772
   Tan JSL, 2008, OPHTHALMOLOGY, V115, P334, DOI 10.1016/j.ophtha.2007.03.083
   Taylor H R, 1990, Trans Am Ophthalmol Soc, V88, P163
   Taylor HR, 1990, T AM OPHTHAL SOC, V88, P173
   Thomson LR, 2002, INVEST OPHTH VIS SCI, V43, P3538
   Thurnham DI, 2007, NUTR RES REV, V20, P163, DOI 10.1017/S0954422407842235
   Thurnham DI, 2008, BRIT J NUTR, V100, P1307, DOI 10.1017/S0007114508971336
   Tomany SC, 2004, ARCH OPHTHALMOL-CHIC, V122, P750, DOI 10.1001/archopht.122.5.750
   Trevithick-Sutton CC, 2006, MOL VIS, V12, P1127
   Trieschmann M, 2008, EYE, V22, P132, DOI 10.1038/sj.eye.6702780
   Trieschmann M, 2007, EXP EYE RES, V84, P718, DOI 10.1016/j.exer.2006.12.010
   Umeda S, 2005, FASEB J, V19, P1683, DOI 10.1096/fj.04-3525fje
   VandenLangenberg GM, 1998, AM J EPIDEMIOL, V148, P204, DOI 10.1093/oxfordjournals.aje.a009625
   WALD G, 1945, SCIENCE, V101, P653, DOI 10.1126/science.101.2635.653
   WALLS G. L., 1933, BRIT JOUR OPHTHALMOL, V17, P641, DOI 10.1136/bjo.17.11.641
   Weigert G, 2011, INVEST OPHTH VIS SCI, V52, P8174, DOI 10.1167/iovs.11-7522
   Wenzel AJ, 2007, OPHTHAL PHYSL OPT, V27, P329, DOI 10.1111/j.1475-1313.2007.00495.x
   Whitehead AJ, 2006, ARCH OPHTHALMOL-CHIC, V124, P1038, DOI 10.1001/archopht.124.7.1038
   WIEGAND RD, 1983, INVEST OPHTH VIS SCI, V24, P1433
   Wrona M, 2004, FREE RADICAL BIO MED, V36, P1094, DOI 10.1016/j.freeradbiomed.2004.02.005
   Wu JM, 2006, SURV OPHTHALMOL, V51, P461, DOI 10.1016/j.survophthal.2006.06.009
   Zhao XF, 2006, AM J CLIN NUTR, V83, P163
   1993, ARCH OPHTHALMOL, V111, P104
NR 173
TC 58
Z9 61
U1 0
U2 25
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1613-4125
J9 MOL NUTR FOOD RES
JI Mol. Nutr. Food Res.
PD FEB
PY 2012
VL 56
IS 2
SI SI
BP 270
EP 286
DI 10.1002/mnfr.201100219
PG 17
WC Food Science & Technology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Food Science & Technology
GA 956BX
UT WOS:000305065900008
PM 22121091
OA Green Submitted
DA 2022-11-30
ER

PT J
AU Brockmann, C
   Brockmann, T
   Dawczynski, J
AF Brockmann, C.
   Brockmann, T.
   Dawczynski, J.
TI Influence of seasonal sunlight intensity and iris color on the anti-VEGF
   therapy for neovascular age-related macular degeneration
SO EYE
LA English
DT Article
DE age-related macular degeneration; anti-VEGF therapy; ranibizumab;
   bevacizumab; iris color; sunlight
ID PIGMENT OPTICAL-DENSITY; SKIN SUN SENSITIVITY; COMPLEMENT FACTOR-H; BLUE
   MOUNTAINS EYE; BEAVER DAM EYE; INTRAVITREAL RANIBIZUMAB; SUBGROUP
   ANALYSIS; 5-YEAR INCIDENCE; RISK-FACTOR; BEVACIZUMAB
AB Purpose To investigate the influence of seasonal light intensity and patients' iris color on the visual recovery after anti-vascular endothelial growth factor (VEGF) therapy with ranibizumab or bevacizumab for neovascular age-related macular degeneration (AMD).
   Methods The visual acuity of 555 eyes (529 patients) with neovascular AMD was evaluated after intravitreal injections of either ranibizumab or bevacizumab in respect to global radiation intensity and iris color.
   Results The functional results during anti-VEGF therapy revealed a seasonal oscillation with a negative correlation between visual recovery and global radiation intensity (R-2 = -0.756, P = 0.004). Although the influence of the sunlight intensity on the visual recovery was significant after the first injection, this effect vanished within the continuous course of treatment. Regarding the improvement of functional recovery depending on iris color, dark-colored eyes (16.0%) gained 8.5 +/- 10.0 letters after the first injection and 9.9 +/- 12.8 letters after the second injection, compared with 3.4 +/- 8.6 letters and 4.4 +/- 11.0 letters in light-colored eyes (84.0%), respectively (P = 0.005 and P = 0.019).
   Conclusions Our results indicate that seasonal sunlight intensity and iris color might influence the visual recovery of neovascular AMD patients undergoing anti-VEGF therapy. Our findings may be used as suggestions to refine individual anti-VEGF therapy regimens, especially in patients with light-colored eyes.
C1 [Brockmann, C.; Brockmann, T.] Charite, Dept Ophthalmol, D-13353 Berlin, Germany.
   [Dawczynski, J.] Univ Leipzig, Fac Med, Dept Ophthalmol, D-04103 Leipzig, Germany.
   [Dawczynski, J.] Univ Leipzig, Hosp Eye, D-04103 Leipzig, Germany.
C3 Free University of Berlin; Humboldt University of Berlin; Charite
   Universitatsmedizin Berlin; Leipzig University; Leipzig University
RP Dawczynski, J (通讯作者)，Univ Leipzig, Fac Med, Dept Ophthalmol, Liebigstr 10-14, D-04103 Leipzig, Germany.
EM Jens.Dawczynski@medizin.uni-leipzig.de
OI Brockmann, Tobias/0000-0001-6939-1159
CR Abedi F, 2013, OPHTHALMOLOGY, V120, P115, DOI 10.1016/j.ophtha.2012.10.006
   Alperovitch A, 2009, ARCH INTERN MED, V169, P75, DOI 10.1001/archinternmed.2008.512
   Bito LZ, 1997, ARCH OPHTHALMOL-CHIC, V115, P659, DOI 10.1001/archopht.1997.01100150661017
   Boyer DS, 2007, OPHTHALMOLOGY, V114, P246, DOI 10.1016/j.ophtha.2006.10.045
   Brantley MA, 2007, OPHTHALMOLOGY, V114, P2168, DOI 10.1016/j.ophtha.2007.09.008
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Browning DJ, 2012, AM J OPHTHALMOL, V154, P222, DOI 10.1016/j.ajo.2012.04.020
   Chakravarthy U, 2012, OPHTHALMOLOGY, V119, DOI 10.1016/j.ophtha.2012.04.015
   Chong V, 2012, OPHTHALMOLOGICA, V227, P2, DOI 10.1159/000337152
   Cruickshanks KJ, 2001, ARCH OPHTHALMOL-CHIC, V119, P246
   Francis Peter James, 2011, Trans Am Ophthalmol Soc, V109, P115
   Fraser-Bell S, 2010, AM J OPHTHALMOL, V149, P735, DOI 10.1016/j.ajo.2009.11.013
   Grisanti S, 2010, OPHTHALMOLOGE, V107, P1123, DOI 10.1007/s00347-010-2299-0
   Hammond BR, 1996, EXP EYE RES, V62, P293, DOI 10.1006/exer.1996.0035
   Heier JS, 2012, OPHTHALMOLOGY, V119, P2537, DOI 10.1016/j.ophtha.2012.09.006
   HOLZ FG, 1994, AM J OPHTHALMOL, V117, P19, DOI 10.1016/S0002-9394(14)73010-7
   Jakovljevic D, 1996, STROKE, V27, P1774, DOI 10.1161/01.STR.27.10.1774
   Kaiser PK, 2007, AM J OPHTHALMOL, V144, P850, DOI 10.1016/j.ajo.2007.08.012
   Khan JC, 2006, BRIT J OPHTHALMOL, V90, P29, DOI 10.1136/bjo.2005.073825
   Kloeckener-Gruissem B, 2011, INVEST OPHTH VIS SCI, V52, P4694, DOI 10.1167/iovs.10-6080
   Ladas ID, 2012, OPHTHALMOLOGICA, V228, P93, DOI 10.1159/000337347
   Lux A, 2007, BRIT J OPHTHALMOL, V91, P1318, DOI 10.1136/bjo.2006.113902
   Margrain TH, 2004, PROG RETIN EYE RES, V23, P523, DOI 10.1016/j.preteyeres.2004.05.001
   Martin DF, 2011, NEW ENGL J MED, V364, P1897, DOI 10.1056/NEJMoa1102673
   McKibbin M, 2012, BRIT J OPHTHALMOL, V96, P208, DOI 10.1136/bjo.2010.193680
   Menghini M, 2010, KLIN MONATSBL AUGENH, V227, P244, DOI 10.1055/s-0029-1245203
   Mitchell P, 1998, OPHTHALMOLOGY, V105, P1359, DOI 10.1016/S0161-6420(98)98013-7
   Mones J, 2011, OPHTHALMOLOGICA, V225, P112, DOI 10.1159/000319906
   Nischler C, 2011, ACTA OPHTHALMOL, V89, pE344, DOI 10.1111/j.1755-3768.2010.02080.x
   Raman R, 2012, EYE, V26, P950, DOI 10.1038/eye.2012.69
   Regillo CD, 2008, AM J OPHTHALMOL, V145, P239, DOI 10.1016/j.ajo.2007.10.004
   Reme C, 2005, INVEST OPHTH VIS SCI, V46, P2672, DOI 10.1167/iovs.04-1095
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Ruiz Y, 2013, FORENSIC SCI INT-GEN, V7, P28, DOI 10.1016/j.fsigen.2012.05.009
   SANDBERG MA, 1994, INVEST OPHTH VIS SCI, V35, P2734
   SEDDON JM, 1990, INVEST OPHTH VIS SCI, V31, P1592
   Sui GY, 2013, BRIT J OPHTHALMOL, V97, P389, DOI 10.1136/bjophthalmol-2012-302281
   Sun C, 2009, OPHTHALMOLOGY, V116, P1913, DOI 10.1016/j.ophtha.2009.03.046
   Teper SJ, 2010, MOL VIS, V16, P2598
   Tomany SC, 2004, ARCH OPHTHALMOL-CHIC, V122, P750, DOI 10.1001/archopht.122.5.750
   Veritti D, 2012, OPHTHALMOLOGICA, V227, P11, DOI 10.1159/000337154
   Wang JJ, 2003, CLIN EXP OPHTHALMOL, V31, P317, DOI 10.1046/j.1442-9071.2003.00659.x
NR 42
TC 5
Z9 5
U1 0
U2 8
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 0950-222X
EI 1476-5454
J9 EYE
JI Eye
PD OCT
PY 2013
VL 27
IS 10
BP 1169
EP 1173
DI 10.1038/eye.2013.159
PG 5
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 235NB
UT WOS:000325724700008
PM 23907626
OA Green Published, Bronze
DA 2022-11-30
ER

PT S
AU Choudhary, M
   Malek, G
AF Choudhary, Mayur
   Malek, Goldis
BE Rickman, CB
   Grimm, C
   Anderson, RE
   Ash, JD
   LaVail, MM
   Hollyfield, JG
TI A Review of Pathogenic Drivers of Age-Related Macular Degeneration,
   Beyond Complement, with a Focus on Potential Endpoints for Testing
   Therapeutic Interventions in Preclinical Studies
SO RETINAL DEGENERATIVE DISEASES: MECHANISMS AND EXPERIMENTAL THERAPY
SE Advances in Experimental Medicine and Biology
LA English
DT Review
CT 18th International Symposium on Retinal Degeneration (RD)
CY SEP 03-08, 2018
CL Killarney, IRELAND
DE Age-related macular degeneration; Lipid metabolism; Inflammation;
   Quick-freeze/deep etch; Retinal pigment epithelial cells; Cholesterol;
   Apolipoprotein
ID DRUSEN; MOUSE; MACROPHAGES; FEATURES; DISEASE; APOB100; LIPIDS; GENES;
   MODEL; EYES
AB Age-related macular degeneration (AMD) continues to be the leading cause of visual impairment for the elderly in developed countries. It is a complex, multifactorial, progressive disease with diverse molecular pathways regulating its pathogenesis. One of the cardinal features of the early clinical subtype of AMD is the accumulation of lipid- and protein-rich deposits within Bruch's membrane, called drusen, which can be visualized by fundus imaging. Currently, multiple in vitro and in vivo model systems exist, which can be used to help tease out mechanisms associated with different molecular pathways driving disease initiation and progression. Given the lack of treatments for patients suffering from the dry form of AMD, it is imperative to appreciate the different known morphological endpoints associated with the various pathogenic pathways, in order to derive further insights, for the ultimate purpose of disease modeling and development of effective therapeutic interventions.
C1 [Choudhary, Mayur; Malek, Goldis] Duke Univ, Sch Med, Dept Ophthalmol, Durham, NC 27708 USA.
   [Malek, Goldis] Duke Univ, Sch Med, Dept Pathol, Durham, NC 27706 USA.
   [Malek, Goldis] Albert Eye Res Inst, Durham, NC 27705 USA.
C3 Duke University; Duke University
RP Malek, G (通讯作者)，Duke Univ, Sch Med, Dept Ophthalmol, Durham, NC 27708 USA.; Malek, G (通讯作者)，Duke Univ, Sch Med, Dept Pathol, Durham, NC 27706 USA.; Malek, G (通讯作者)，Albert Eye Res Inst, Durham, NC 27705 USA.
EM gmalek@duke.edu
RI Choudhary, Mayur/AAU-3497-2021
OI Choudhary, Mayur/0000-0001-8056-011X; Malek, Goldis/0000-0003-0026-2388
FU NEI [R01EY027802, R01EY028160, EY005722]; Research to Prevent Blindness
   core grant
FX This study was supported by NEI grants: R01EY027802 (GM), R01EY028160
   (GM), and EY005722 (Duke Eye Center) and Research to Prevent Blindness
   core grant (Duke Eye Center).
CR Anand R, 2000, OPHTHALMOLOGY, V107, P2224
   Chirco KR, 2016, EXP EYE RES, V146, P393, DOI 10.1016/j.exer.2015.09.003
   Curcio CA, 2011, BRIT J OPHTHALMOL, V95, P1638, DOI 10.1136/bjophthalmol-2011-300344
   Espinosa-Heidmann DG, 2004, INVEST OPHTH VIS SCI, V45, P260, DOI 10.1167/iovs.03-0910
   Fujihara M, 2014, INVEST OPHTH VIS SCI, V55, P7285, DOI 10.1167/iovs.14-15195
   Fujihara M, 2009, EXP EYE RES, V88, P1115, DOI 10.1016/j.exer.2009.01.017
   Harris LALS, 2013, METHOD CELL BIOL, V116, P213, DOI 10.1016/B978-0-12-408051-5.00011-5
   Ismail EN, 2017, EXP EYE RES, V162, P62, DOI 10.1016/j.exer.2017.06.013
   KLEIN R, 1991, OPHTHALMOLOGY, V98, P1128
   Klein R, 2014, AM J OPHTHALMOL, V158, P513, DOI 10.1016/j.ajo.2014.05.027
   Kliffen M, 2000, BRIT J OPHTHALMOL, V84, P1415, DOI 10.1136/bjo.84.12.1415
   Lad EM, 2015, GRAEF ARCH CLIN EXP, V253, P1941, DOI 10.1007/s00417-015-3094-z
   Malek G, 2005, P NATL ACAD SCI USA, V102, P11900, DOI 10.1073/pnas.0503015102
   Malek G, 2003, AM J PATHOL, V162, P413, DOI 10.1016/S0002-9440(10)63836-9
   Malek G, 2014, CELL MOL LIFE SCI, V71, P4617, DOI 10.1007/s00018-014-1709-x
   Merle BMJ, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0079848
   Miller Joan W, 2017, US Ophthalmic Rev, V10, P119, DOI 10.17925/USOR.2017.10.02.119
   Natoli R, 2017, INVEST OPHTH VIS SCI, V58, P2977, DOI 10.1167/iovs.17-21672
   Rudolf M, 2018, CURR EYE RES, V43, P135, DOI 10.1080/02713683.2017.1370118
   Schroder K, 2010, CELL, V140, P821, DOI 10.1016/j.cell.2010.01.040
   Tarallo V, 2012, CELL, V149, P847, DOI 10.1016/j.cell.2012.03.036
   Vavvas DG, 2016, EBIOMEDICINE, V5, P198, DOI 10.1016/j.ebiom.2016.01.033
   Wang JCC, 2015, MOL VIS, V21, P264
   Wang L, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0010329
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
   Yu Y, 2011, INVEST OPHTH VIS SCI, V52, P4663, DOI 10.1167/iovs.10-7070
NR 26
TC 8
Z9 8
U1 0
U2 1
PU SPRINGER INTERNATIONAL PUBLISHING AG
PI CHAM
PA GEWERBESTRASSE 11, CHAM, CH-6330, SWITZERLAND
SN 0065-2598
EI 2214-8019
BN 978-3-030-27378-1; 978-3-030-27377-4
J9 ADV EXP MED BIOL
JI Adv.Exp.Med.Biol.
PY 2019
VL 1185
BP 9
EP 13
DI 10.1007/978-3-030-27378-1_2
PG 5
WC Medicine, Research & Experimental; Ophthalmology
WE Conference Proceedings Citation Index - Science (CPCI-S); Science Citation Index Expanded (SCI-EXPANDED)
SC Research & Experimental Medicine; Ophthalmology
GA BO4FI
UT WOS:000514087200003
PM 31884581
OA Green Accepted
DA 2022-11-30
ER

PT J
AU Gunay, BO
   Esenulku, CM
AF Gunay, Betul Onal
   Esenulku, Cenap Mahmut
TI Retinal nerve fibre layer and ganglion cell layer thickness changes
   following intravitreal aflibercept for age-related macular degeneration
SO CUTANEOUS AND OCULAR TOXICOLOGY
LA English
DT Article
DE Aflibercept; ganglion cell layer thickness; retinal nerve fibre layer
   thickness
ID ENDOTHELIAL GROWTH-FACTOR; INNER PLEXIFORM LAYER; ANTI-VEGF; RANIBIZUMAB
AB Purpose To evaluate the effect of intravitreal aflibercept (IVA) injections on peripapillary retinal nerve fibre layer thickness (RNFLT) and macular ganglion cell layer thickness (GCLT) in neovascular age-related macular degeneration (nAMD) patients during a 1-year follow-up. Methods This is a prospective study including 34 patients who were treated with aflibercept for treatment-naive nAMD. Following a loading phase of 3-monthly aflibercept, re-injections were performed on a pro re nata regimen for 12 months. Best-corrected visual acuity, intraocular pressure, and spectral-domain-optical coherence tomography analysis were performed at baseline and 1 month, 3 months, 6 months, and 12 months following treatment. Peripapillary RNFLT and macular GCLT along with the central macular thickness (CMT) and subfoveal choroidal thickness (SFCT) were evaluated at each visit. Results Mean number of aflibercept injections was 6.0 +/- 1.8. Significant thinning was observed at the central macular ganglion cell layer and at 1 mm superior, temporal, and nasal ganglion cell layer compared to baseline at 1-year (p < 0.05). No significant change of RNFLT was shown (p > 0.05). Mean CMT and SFCT were significantly reduced after IVA therapy (p < 0.05, for both). No correlation was found between injection number and GCLT change. Conclusions Intravitreal aflibercept caused significant ganglion cell layer thinning during a 1-year follow-up without any changes in RNFLT. Intravitreal aflibercept itself may have a chance to induce decreased GCLT in nAMD patients.
C1 [Gunay, Betul Onal; Esenulku, Cenap Mahmut] Univ Hlth Sci, Trabzon Kanuni Training & Res Hosp, Trabzon, Turkey.
C3 Trabzon Kanuni Training & Research Hospital; University of Health
   Sciences Turkey
RP Gunay, BO (通讯作者)，Trabzon Kanuni Egitim & Arastirma Hastanesi, Numune Kampusu, TR-61250 Trabzon, Turkey.
EM drbetulonal@yahoo.com
OI Gunay, Betul Onal/0000-0001-5465-2635
CR Abdolrahimzadeh S, 2019, CURR EYE RES, V44, P1000, DOI 10.1080/02713683.2019.1610179
   Beck M, 2016, AM J OPHTHALMOL, V167, P10, DOI 10.1016/j.ajo.2016.04.003
   Demir N, 2021, CUTAN OCUL TOXICOL, V40, P135, DOI 10.1080/15569527.2021.1919136
   Demirel S, 2015, CURR EYE RES, V40, P87, DOI 10.3109/02713683.2014.917190
   Foxton R, 2016, CELL DEATH DIS, V7, DOI 10.1038/cddis.2016.110
   Froger N, 2020, SCI REP-UK, V10, DOI 10.1038/s41598-020-68488-z
   Gharbiya M, 2018, CURR EYE RES, V43, P391, DOI 10.1080/02713683.2017.1405045
   Julien S, 2014, BRIT J OPHTHALMOL, V98, P813, DOI 10.1136/bjophthalmol-2013-304019
   Kopic A, 2017, ACTA CLIN CROAT, V56, P406, DOI 10.20471/acc.2017.56.03.07
   Krebs I, 2007, AM J OPHTHALMOL, V144, P741, DOI 10.1016/j.ajo.2007.07.024
   Lee WJ, 2017, J GLAUCOMA, V26, P980, DOI 10.1097/IJG.0000000000000776
   Li E, 2020, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD012208.pub2
   Martinez-de-la-Casa JM, 2012, INVEST OPHTH VIS SCI, V53, P6214, DOI 10.1167/iovs.12-9875
   Parlak M, 2015, INT OPHTHALMOL, V35, P473, DOI 10.1007/s10792-014-9972-2
   Saint-Geniez M, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003554
   Saleh R, 2017, GRAEF ARCH CLIN EXP, V255, P817, DOI 10.1007/s00417-017-3590-4
   Shin HY, 2013, INVEST OPHTH VIS SCI, V54, P7344, DOI 10.1167/iovs.13-12667
   Young M, 2014, RETINA-J RET VIT DIS, V34, P1308, DOI 10.1097/IAE.0000000000000081
   Zachary I, 2005, NEUROSIGNALS, V14, P207, DOI 10.1159/000088637
   Zucchiatti I, 2017, RETINA-J RET VIT DIS, V37, P1314, DOI 10.1097/IAE.0000000000001360
NR 20
TC 0
Z9 0
U1 0
U2 1
PU TAYLOR & FRANCIS LTD
PI ABINGDON
PA 2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND
SN 1556-9527
EI 1556-9535
J9 CUTAN OCUL TOXICOL
JI Cutan. Ocul. Toxicol.
PD JAN 2
PY 2022
VL 41
IS 1
BP 91
EP 97
DI 10.1080/15569527.2022.2034843
EA FEB 2022
PG 7
WC Ophthalmology; Toxicology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology; Toxicology
GA 1M1WE
UT WOS:000753203900001
PM 35135401
DA 2022-11-30
ER

PT J
AU Newsome, DA
AF Newsome, David A.
TI A randomized, prospective, placebo-controlled clinical trial of a novel
   zinc-monocysteine compound in age-related macular degeneration
SO CURRENT EYE RESEARCH
LA English
DT Article
DE age-related macular degeneration; macular contrast sensitivity; macular
   photorecovery; macular visual acuity; zinc-monocysteine
ID RETINAL-PIGMENT EPITHELIUM; ANTIOXIDANT; SUPPLEMENTATION; GLUTATHIONE;
   DRUSEN; EYE; PROTECTION; STRESS; CELLS; ACIDS
AB Purpose: To test the hypothesis that daily use of zinc-monocysteine (ZMC) supplement will be well tolerated and result in improved macular function in persons with dry age-related macular degeneration (AMD). Methods: Eligible, consenting subjects were randomized to either ZMC 25 mg or placebo twice daily for 6 months. Both ZMC and placebo groups enrolled 40 participants, with best corrected visual acuity 20/25 to 20/70, macular drusen, and pigment changes. Masked personnel determined baseline, 3- and 6-month best-corrected visual acuity, contrast sensitivity, and light flash recovery time. Differences between ZMC and placebo were analyzed by a one-sided unpaired t-test of the paired differences between baseline and 3- and 6-month timepoints for right and left eyes separately. Results: By 6 months the ZMC group showed improved visual acuity (p < 0.0001) and contrast sensitivity (p < 0.0001). Macular light flash recovery time shortened in the ZMC group at 3 months by 2.1 sec (left eye, p = 0.0001) to 3.6 sec (right eye, p < 0.0001), and at 6 months by 7.2 sec (left eye, p < 0.0001) to 7.4 sec (right eye, p < 0.0001). This variable had no improvement in the placebo group. ZMC had a gastrointestinal irritation rate of under 2%. Conclusion: ZMC 25 mg twice daily was well tolerated and was associated with improved macular function in comparison to a placebo in persons with dry AMD.
C1 [Newsome, David A.] Retinal Inst Louisiana, New Orleans, LA USA.
RP Newsome, DA (通讯作者)，1764 Brightwaters Blvd NE, St Petersburg, FL 33704 USA.
EM doctordavel618@aol.com
CR ABOUMOHAMED G, 1995, PHARMACOLOGY, V50, P266, DOI 10.1159/000139292
   Anderson DH, 2002, AM J OPHTHALMOL, V134, P411, DOI 10.1016/S0002-9394(02)01624-0
   Beck RW, 2007, OPHTHALMOLOGY, V114, P1804, DOI 10.1016/j.ophtha.2007.06.047
   BRAY TM, 1990, FREE RADICAL BIO MED, V8, P281, DOI 10.1016/0891-5849(90)90076-U
   CAMPBELL NR, 1974, NATURE, V251, P158, DOI 10.1038/251158a0
   Clemons TE, 2004, ARCH OPHTHALMOL-CHIC, V122, P716
   Crabb JW, 2002, P NATL ACAD SCI USA, V99, P14682, DOI 10.1073/pnas.222551899
   Darley-Usmar V, 2000, ANTIOXID REDOX SIGN, V2, P375, DOI 10.1089/15230860050192143
   DAVIDSON PC, 1994, INVEST OPHTH VIS SCI, V35, P2843
   Falsini B, 2003, OPHTHALMOLOGY, V110, P51, DOI 10.1016/S0161-6420(02)01547-6
   Feher J, 2005, OPHTHALMOLOGICA, V219, P154, DOI 10.1159/000085248
   Giblin FJ, 2000, J OCUL PHARMACOL TH, V16, P121, DOI 10.1089/jop.2000.16.121
   Hageman GS, 2005, P NATL ACAD SCI USA, V102, P7227, DOI 10.1073/pnas.0501536102
   Imamura Y, 2006, P NATL ACAD SCI USA, V103, P11282, DOI 10.1073/pnas.0602131103
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1417, DOI 10.1001/archopht.119.10.1417
   Kregel KC, 2007, AM J PHYSIOL-REG I, V292, pR18, DOI 10.1152/ajpregu.00327.2006
   Mantyjarvi M, 2001, J CATARACT REFR SURG, V27, P261, DOI 10.1016/S0886-3350(00)00562-9
   MILBURY PE, 2003, OXIDATIVE STRESS AGI
   *NAT ADV EY COUNC, 1993, PUBL NIH
   NEWSOME DA, 1994, ARCH OPHTHALMOL-CHIC, V112, P729, DOI 10.1001/archopht.1994.01090180027007
   NEWSOME DA, 1988, ARCH OPHTHALMOL-CHIC, V106, P192
   NEWSOME DA, 1992, CURR EYE RES, V11, P213, DOI 10.3109/02713689209001772
   Newsome DA, 1995, J TRACE ELEM EXP MED, V8, P193
   NEWSOME DA, REPRODUCIBLE M UNPUB
   Rein DB, 2007, OPHTHALMOLOGY, V114, P1319, DOI 10.1016/j.ophtha.2006.10.041
   RICHARD MJ, 1993, BIOL TRACE ELEM RES, V37, P187, DOI 10.1007/BF02783794
   Richer Stuart, 2004, Optometry, V75, P216, DOI 10.1016/S1529-1839(04)70049-4
   SNODDERLY DM, 1995, AM J CLIN NUTR, V62, P1448
   STERNBERG P, 1993, INVEST OPHTH VIS SCI, V34, P3661
   STIPANUK MH, 1986, ANNU REV NUTR, V6, P179, DOI 10.1146/annurev.nu.06.070186.001143
   STIPANUK MH, 1999, MODERN NUTR HLTH DIS
   Tan JSL, 2008, OPHTHALMOLOGY, V115, P334, DOI 10.1016/j.ophtha.2007.03.083
   Taniguchi N., 1989, GLUTATHIONE CENTENNI
   Tate DJ, 2007, SYNTHETIC COMMUN, V37, P909, DOI 10.1080/00397910601163612
   Tate DJ, 2006, CURR EYE RES, V31, P675, DOI 10.1080/02713680600801024
   VALLEE BL, 1990, BIOCHEMISTRY-US, V29, P5647, DOI 10.1021/bi00476a001
   van Leeuwen R, 2005, JAMA-J AM MED ASSOC, V294, P3101, DOI 10.1001/jama.294.24.3101
   Youdim KA, 2000, NUTR NEUROSCI, V3, P383, DOI 10.1080/1028415X.2000.11747338
NR 38
TC 39
Z9 39
U1 0
U2 7
PU TAYLOR & FRANCIS INC
PI PHILADELPHIA
PA 530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA
SN 0271-3683
EI 1460-2202
J9 CURR EYE RES
JI Curr. Eye Res.
PY 2008
VL 33
IS 7
BP 591
EP 598
DI 10.1080/02713680802178437
PG 8
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 321WT
UT WOS:000257337900009
PM 18600492
DA 2022-11-30
ER

PT J
AU Jackson, TL
   Nicod, E
   Angelis, A
   Grimaccia, F
   Prevost, AT
   Simpson, ARH
   Kanavos, P
AF Jackson, Timothy L.
   Nicod, Elena
   Angelis, Aris
   Grimaccia, Federico
   Prevost, A. Toby
   Simpson, Andrew R. H.
   Kanavos, Panos
TI VITREOUS ATTACHMENT IN AGE-RELATED MACULAR DEGENERATION, DIABETIC
   MACULAR EDEMA, AND RETINAL VEIN OCCLUSION A Systematic Review and
   Metaanalysis
SO RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES
LA English
DT Review
DE vitreomacular adhesion; vitreomacular traction; posterior vitreous
   detachment; diabetic macular edema; retinal vein occlusion; age-related
   macular degeneration; vitrectomy; metaanalysis; review
ID OPTICAL COHERENCE TOMOGRAPHY; POSTERIOR VITREOMACULAR ADHESION;
   PARS-PLANA VITRECTOMY; CHOROIDAL NEOVASCULARIZATION; VISUAL-ACUITY;
   DETACHMENT; TRACTION; SURGERY; RISK; SHEATHOTOMY
AB Purpose: To determine if there is an association of vitreous attachment and wet age-related macular degeneration (AMD), diabetic macular edema, and retinal vein occlusion.
   Methods: Systematic review and metaanalysis.
   Results: Sixteen of 1,025 articles were eligible. In wet AMD, the prevalence of vitreomacular adhesion and posterior vitreous detachment was 23% (654 eyes) and 41% (251), respectively. Vitreomacular adhesion prevalence was 2.15 times that of controls (95% confidence interval, 1.34-3.48; p = 0.002) and 2.54 times that of dry AMD (confidence interval, 0.88-7.36; p 0.09); posterior vitreous detachment prevalence was lower than controls (relative risk 0.77; confidence interval, 0.64-0.93; p = 0.007) and dry AMD (0.56; confidence interval, 0.27-1.14; p = 0.11). It was not possible to determine the prevalence of vitreous attachment in diabetic macular edema, but vitreomacular traction was present in 29% of 188 surgical cases. The prevalence of posterior vitreous detachment in eyes with central and branch retinal vein occlusion was 30% (56 eyes) and 31% (71 eyes), respectively, versus 25% (64 eyes) in controls.
   Conclusion: Observational studies of sufficient quality indicate that eyes with wet AMD have double the expected prevalence of vitreomacular adhesion and are less likely to have a posterior vitreous detachment. More controlled studies of diabetic macular edema and retinal vein occlusion are needed.
C1 [Jackson, Timothy L.; Simpson, Andrew R. H.] Kings Coll Hosp London, Guthrie Clin, London SE5 9RS, England.
   [Nicod, Elena; Angelis, Aris; Grimaccia, Federico; Kanavos, Panos] Univ London London Sch Econ & Polit Sci, LSE Hlth, Dept Social Policy, London WC2A 2AE, England.
   [Prevost, A. Toby] Kings Coll Hosp London, Dept Primary Care & Publ Hlth Sci, London SE5 9RS, England.
   [Simpson, Andrew R. H.] Kings Coll Hosp London, Dept Ophthalmol, London SE5 9RS, England.
C3 King's College Hospital NHS Foundation Trust; King's College Hospital;
   University of London; London School Economics & Political Science;
   King's College Hospital NHS Foundation Trust; King's College Hospital;
   King's College Hospital NHS Foundation Trust; King's College Hospital
RP Jackson, TL (通讯作者)，Kings Coll Hosp London, Guthrie Clin, London SE5 9RS, England.
EM t.jackson1@nhs.net
RI Angelis, Aris/AAH-1532-2021
OI Angelis, Aris/0000-0002-0261-4634; Nicod, Elena/0000-0001-6798-9923;
   Prevost, A. Toby/0000-0003-1723-0796; Jackson,
   Timothy/0000-0001-7618-1555
FU Thrombogenics
FX This project was supported by an unrestricted educational grant from
   Thrombogenics.
CR AKIBA J, 1993, OPHTHALMOLOGY, V100, P1384
   [Anonymous], 1989, GUID CLIN PREV SERV, P24
   Charbonnel J, 2004, GRAEF ARCH CLIN EXP, V242, P223, DOI 10.1007/s00417-003-0824-4
   Chuo JY, 2006, AM J OPHTHALMOL, V142, P931, DOI 10.1016/j.ajo.2006.08.002
   Gandorfer A, 2005, AM J OPHTHALMOL, V139, P638, DOI 10.1016/j.ajo.2004.11.035
   Hayreh SS, 2004, OPHTHALMOLOGICA, V218, P333, DOI 10.1159/000079476
   HIKICHI T, 1995, RETINA-J RET VIT DIS, V15, P29, DOI 10.1097/00006982-199515010-00006
   Hvarfner C, 2006, ACTA OPHTHALMOL SCAN, V84, P812, DOI 10.1111/j.1600-0420.2006.00749.x
   Ikeda T, 2000, ACTA OPHTHALMOL SCAN, V78, P460, DOI 10.1034/j.1600-0420.2000.078004460.x
   Jackson TL, 2001, OPHTHALMOLOGICA, V215, P271, DOI 10.1159/000050873
   JAVITT JC, 1993, ARCH OPHTHALMOL-CHIC, V111, P686, DOI 10.1001/archopht.1993.01090050120041
   KADO M, 1990, OPHTHALMIC SURG LAS, V21, P544
   Krebs I, 2007, AM J OPHTHALMOL, V144, P741, DOI 10.1016/j.ajo.2007.07.024
   Kumagai K, 2007, RETINA-J RET VIT DIS, V27, P49, DOI 10.1097/01.iae.0000221996.77421.69
   Laidlaw DAH, 2008, EYE, V22, P1337, DOI 10.1038/eye.2008.84
   Lee SJ, 2011, OPHTHALMOLOGY, V118, P101, DOI 10.1016/j.ophtha.2010.04.015
   Lee SJ, 2009, AM J OPHTHALMOL, V147, P621, DOI 10.1016/j.ajo.2008.10.003
   LEWIS H, 1992, OPHTHALMOLOGY, V99, P753
   Leyland RD, 1999, EYE, V13, P348, DOI 10.1038/eye.1999.88
   Liu YL, 2011, ACTA OPHTHALMOL, V89, pE291, DOI 10.1111/j.1755-3768.2009.01814.x
   Massin P, 2003, AM J OPHTHALMOL, V135, P169, DOI 10.1016/S0002-9394(02)01837-8
   Mojana F, 2008, AM J OPHTHALMOL, V146, P218, DOI 10.1016/j.ajo.2008.04.027
   Murakami T, 2007, RETINA-J RET VIT DIS, V27, P1031, DOI 10.1097/IAE.0b013e318074bc39
   NASRALLAH FP, 1988, OPHTHALMOLOGY, V95, P1335
   Nomura Y, 2011, OPHTHALMOLOGY, V118, P853, DOI 10.1016/j.ophtha.2010.09.001
   Ondes F, 2000, JPN J OPHTHALMOL, V44, P91, DOI 10.1016/S0021-5155(99)00174-4
   Ophir A, 2010, EYE, V24, P347, DOI 10.1038/eye.2009.106
   Ophir A, 2010, EUR J OPHTHALMOL, V20, P733, DOI 10.1177/112067211002000414
   Quiram PA, 2007, RETINA-J RET VIT DIS, V27, P1090, DOI 10.1097/IAE.0b013e3180654229
   Robison CD, 2009, AM J OPHTHALMOL, V148, P79, DOI 10.1016/j.ajo.2009.01.014
   Roller AB, 2010, OPHTHALMOLOGY, V117, P1381, DOI 10.1016/j.ophtha.2009.11.007
   Rouberol F, 2005, J FR OPHTALMOL, V28, P474, DOI 10.1016/S0181-5512(05)81083-6
   Sakamoto T, 2010, RETINA-J RET VIT DIS, V30, P856, DOI 10.1097/IAE.0b013e3181c969cb
   Schulze S, 2012, ACTA OPHTHALMOL, V90, P244, DOI 10.1111/j.1755-3768.2010.01929.x
   Sebag J, 2007, GRAEF ARCH CLIN EXP, V245, P576, DOI 10.1007/s00417-006-0394-3
   Shah SP, 2006, BRIT J OPHTHALMOL, V90, P33, DOI 10.1136/bjo.2005.072934
   Simpson ARH, 2012, SURV OPHTHALMOL, V57, P498, DOI 10.1016/j.survophthal.2012.01.011
   Sivaprasad S, 2008, RETINA-J RET VIT DIS, V28, P1435, DOI 10.1097/IAE.0b013e31817f2dae
   SNEAD MP, 1994, EYE, V8, P204, DOI 10.1038/eye.1994.47
   Stefansson E, 2009, GRAEF ARCH CLIN EXP, V247, P147, DOI 10.1007/s00417-008-0980-7
   Takahashi MK, 1997, OPHTHALMIC SURG LAS, V28, P294
   Thomas D, 2005, RETINA-J RET VIT DIS, V25, P883, DOI 10.1097/00006982-200510000-00011
   Weber-Krause Brigitte, 1996, Ophthalmologe, V93, P660, DOI 10.1007/s003470050054
   WESTHEIMER G, 1979, ARCH OPHTHALMOL-CHIC, V97, P327
   Yamamoto T, 2007, JPN J OPHTHALMOL, V51, P285, DOI 10.1007/s10384-007-0448-z
   YONEMOTO J, 1994, GRAEF ARCH CLIN EXP, V232, P67, DOI 10.1007/BF00171665
NR 46
TC 49
Z9 52
U1 0
U2 11
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0275-004X
EI 1539-2864
J9 RETINA-J RET VIT DIS
JI Retin.-J. Retin. Vitr. Dis.
PD JUN
PY 2013
VL 33
IS 6
BP 1099
EP 1108
DI 10.1097/IAE.0b013e31828991d6
PG 10
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 151IU
UT WOS:000319454700003
PM 23591535
DA 2022-11-30
ER

PT J
AU Ranjbar, M
   Kurz, M
   Holzhey, A
   Melchert, C
   Rades, D
   Grisanti, S
AF Ranjbar, Mahdy
   Kurz, Maximilian
   Holzhey, Annekatrin
   Melchert, Corinna
   Rades, Dirk
   Grisanti, Salvatore
TI Stereotactic radiotherapy in neovascular age-related macular
   degeneration Real-life efficacy and morphological evaluation of the
   outer retina-choroid complex
SO MEDICINE
LA English
DT Article
DE Intravitreal injection; neovascular age-related macular degeneration;
   optical coherence tomography; stereotactic radiotherapy; vascular
   endothelial growth factor
ID OPTICAL COHERENCE TOMOGRAPHY; PIGMENT EPITHELIAL ATROPHY; GROWTH-FACTOR
   THERAPY; HUMAN RPE CELLS; EPIMACULAR BRACHYTHERAPY; QUANTITATIVE
   SUBANALYSIS; RADIATION-THERAPY; RANIBIZUMAB; THICKNESS; BEVACIZUMAB
AB Stereotactic radiotherapy (SRT) is a new approach to treat neovascular age-related macular degeneration (nAMD). The INTREPID trial suggested that SRT could reduce the frequency of regular intravitreal injections (IVIs) with antivascular endothelial growth factor drugs, which are necessary to control disease activity. However, the efficacy of SRT in nAMD and resulting morphological changes have not been validated under real-life circumstances, an issue, which we would like to address in this retrospective analysis.
   Patients who met the INTREPID criteria for best responders were eligible for SRT. A total of 32 eyes of 32 patients were treated. Thereafter, patients were examined monthly for 12 months and received pro re nata IVI of aflibercept or ranibizumab. Outcome measures were: mean number of injections, best-corrected visual acuity, and morphological changes of the outer retina-choroid complex as well as patient safety.
   Mean number of IVI decreased by almost 50% during the 12 months after SRT compared to the year before, whereas visual acuity increased by one line (logMAR). Morphological evaluation showed that most changes affect outer retinal layers.
   Stereotactic radiotherapy significantly reduced IVI retreatment in nAMD patients under real-life circumstances. Therefore, SRT might be the first step to stop visual loss as a result of IVI undertreatment, which is a major risk.
C1 [Ranjbar, Mahdy; Kurz, Maximilian; Grisanti, Salvatore] Univ Lubeck, Dept Ophthalmol, Lubeck, Germany.
   [Ranjbar, Mahdy; Kurz, Maximilian; Holzhey, Annekatrin] Univ Lubeck, Lab Angiogenesis & Ocular Cell Transplantat, Lubeck, Germany.
   [Melchert, Corinna; Rades, Dirk] Univ Lubeck, Dept Radiat Oncol, Lubeck, Germany.
C3 University of Lubeck; University of Lubeck; University of Lubeck
RP Ranjbar, M (通讯作者)，Ratzeburger Allee 160, D-23538 Lubeck, Germany.
EM eye.research101@gmail.com
CR Amoaku WM, 2015, EYE, V29, P721, DOI 10.1038/eye.2015.48
   Bhutto I, 2012, MOL ASPECTS MED, V33, P295, DOI 10.1016/j.mam.2012.04.005
   Branchini L, 2013, JAMA OPHTHALMOL, V131, P693, DOI 10.1001/jamaophthalmol.2013.692
   Broadhead G, 2014, INVEST OPHTH VIS SCI, V55
   Cantley JL, 2013, PHYS MED BIOL, V58, P6887, DOI 10.1088/0031-9155/58/19/6887
   Casalino G, 2016, INVEST OPHTH VIS SCI, V57
   Chakravarthy U, 2012, OPHTHALMOLOGY, V119, DOI 10.1016/j.ophtha.2012.04.015
   Dugel PU, 2013, OPHTHALMOLOGY, V120, P317, DOI 10.1016/j.ophtha.2012.07.068
   Dugel PU, 2012, OPHTHALMOLOGY, V119, DOI 10.1016/j.ophtha.2012.01.014
   Esmaeelpour M, 2014, INVEST OPHTH VIS SCI, V55, P5074, DOI 10.1167/iovs.14-14646
   Evans JR, 2010, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD004004.pub3
   Gesellschaft Deutsche Ophthalmologische, 2015, Klin Monbl Augenheilkd, V232, P202, DOI 10.1055/s-0034-1396162
   Grunwald JE, 2014, OPHTHALMOLOGY, V121, P150, DOI 10.1016/j.ophtha.2013.08.015
   Holz FG, 1997, FRONT RADIAT THER ON, V30, P238
   Holz FG, 2015, BRIT J OPHTHALMOL, V99, P220, DOI 10.1136/bjophthalmol-2014-305327
   Jaakkola A, 2005, OPHTHALMOLOGY, V112, P567, DOI 10.1016/j.ophtha.2004.11.029
   Jackson TL, 2015, RETINA-J RET VIT DIS, V35, P194, DOI 10.1097/IAE.0000000000000283
   Jackson TL, 2015, OPHTHALMOLOGY, V122, P138, DOI 10.1016/j.ophtha.2014.07.043
   Jackson TL, 2013, OPHTHALMOLOGY, V120, P1893, DOI 10.1016/j.ophtha.2013.02.016
   Jackson TL, 2013, OPHTHALMOLOGY, V120, P1597, DOI 10.1016/j.ophtha.2013.01.074
   Joeres S, 2008, OPHTHALMOLOGY, V115, P347, DOI 10.1016/j.ophtha.2007.03.082
   Kaiser PK, 2013, OPHTHALMOLOGY, V120, pS11, DOI 10.1016/j.ophtha.2013.01.061
   Kashani AH, 2009, INVEST OPHTH VIS SCI, V50, P3366, DOI 10.1167/iovs.08-2691
   Keane PA, 2008, INVEST OPHTH VIS SCI, V49, P3115, DOI 10.1167/iovs.08-1689
   Lois N, 2013, RETINA-J RET VIT DIS, V33, P13, DOI 10.1097/IAE.0b013e3182657fff
   Mantel I, 2015, TRANSL VIS SCI TECHN, V4, DOI 10.1167/tvst.4.3.6
   Martin DF, 2012, OPHTHALMOLOGY, V119, DOI 10.1016/j.ophtha.2012.03.053
   Martin DF, 2011, NEW ENGL J MED, V364, P1897, DOI 10.1056/NEJMoa1102673
   Neffendorf JE, 2015, CLIN OPHTHALMOL, V9, P1829, DOI 10.2147/OPTH.S75638
   Petrarca R, 2011, CLIN OPHTHALMOL, V5, P57, DOI 10.2147/OPTH.S16444
   Ranjbar M, 2016, CYTOKINE, V83, P210, DOI 10.1016/j.cyto.2016.04.014
   Ranjbar M, 2016, CELL PHYSIOL BIOCHEM, V38, P737, DOI 10.1159/000443030
   Razavi S, 2015, AM J OPHTHALMOL, V160, P1006, DOI 10.1016/j.ajo.2015.08.009
   Rofagha S, 2013, OPHTHALMOLOGY, V120, P2292, DOI 10.1016/j.ophtha.2013.03.046
   Schutze C, 2015, AM J OPHTHALMOL, V159, P1100, DOI 10.1016/j.ajo.2015.02.020
   Shin JY, 2015, ACTA OPHTHALMOL, V93, P524, DOI 10.1111/aos.12653
   Simader C, 2014, OPHTHALMOLOGY, V121, P1237, DOI 10.1016/j.ophtha.2013.12.029
   Sivagnanavel V, 2004, COCHRANE DB SYST REV, DOI DOI 10.1002/14651858.CD004004.PUB2
   Taddei PJ, 2010, PHYS MED BIOL, V55, P7037, DOI 10.1088/0031-9155/55/23/S06
   Ting DSW, 2016, AM J OPHTHALMOL, V164, P128, DOI 10.1016/j.ajo.2015.12.024
   Wecker T, 2017, BRIT J OPHTHALMOL, V101, P353, DOI 10.1136/bjophthalmol-2016-308668
   Yamazaki T, 2012, OPHTHALMOLOGY, V119, P1621, DOI 10.1016/j.ophtha.2012.02.022
NR 42
TC 14
Z9 14
U1 0
U2 1
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0025-7974
EI 1536-5964
J9 MEDICINE
JI Medicine (Baltimore)
PD DEC
PY 2016
VL 95
IS 52
AR e5729
DI 10.1097/MD.0000000000005729
PG 8
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine
GA EH2WB
UT WOS:000391628200038
PM 28033280
OA Green Published, gold
DA 2022-11-30
ER

PT J
AU Jung, JJ
   Soh, YQ
   Yu, DJG
   Rofagha, S
   Lee, SS
   Freund, KB
   Hoang, QV
AF Jung, Jesse J.
   Soh, Yu Qiang
   Yu, Daryle Jason G.
   Rofagha, Soraya
   Lee, Scott S.
   Freund, K. Bailey
   Hoang, Quan, V
TI BACILLARY LAYER DETACHMENT BECAUSE OF MACULAR NEOVASCULARIZATION
SO RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES
LA English
DT Article
DE bacillary layer detachment; external limiting membrane; ellipsoid zone;
   macular neovascularization; multimodal imaging
ID OPTICAL COHERENCE TOMOGRAPHY; OUTER RETINAL BANDS; DEGENERATION; OCT
AB Purpose: To describe the clinical and multimodal imaging features of bacillary layer detachment (BD), and its response to intravitreal anti-vascular endothelial growth factor therapy, in eyes with macular neovascularization. Methods: Retrospective, observational case series of 14 eyes (14 patients, 7 men) imaged with eyes (14 patients, 7 men) were imaged with spectral-domain optical coherence tomography, and either fluorescein angiography or optical coherence tomography angiography. Therapeutic response was monitored with serial imaging and best-corrected visual acuity assessments. Results: The mean age was 75 +/- 13 (range: 45-96) years, with mean follow-up duration of 27 +/- 21 (range: 1-56) months. Neovascular age-related macular degeneration was found in 71% (10/14) eyes. Type 2 macular neovascularization lesions were associated with BD in all 14 eyes. Subretinal hemorrhage was noted in 79% (11/14) eyes. BD promptly resolved after intravitreal antivascular endothelial growth factor therapy in all eyes. The baseline best-corrected visual acuity improved from logarithm of the minimum angle of resolution 0.84 +/- 0.32 (Snellen equivalent 20/138) to logarithm of the minimum angle of resolution 0.48 +/- 0.31 (Snellen equivalent 20/60) at the last follow-up, with treatment of the macular neovascularization. Conclusion: Type 2 macular neovascularization and subretinal hemorrhage are associated with BDs, which may be due to a rapid influx of exudative fluid into the potential space between the external limiting membrane and ellipsoid zone. Intravitreal antivascular endothelial growth factor therapy results in rapid resolution of BDs and visual improvement in most eyes.
C1 [Jung, Jesse J.; Rofagha, Soraya; Lee, Scott S.] East Bay Retina Consultants Inc, 3300 Telegraph Ave, Oakland, CA 94609 USA.
   [Jung, Jesse J.; Rofagha, Soraya] Univ Calif San Francisco, Dept Ophthalmol, San Francisco, CA 94143 USA.
   [Soh, Yu Qiang] Christchurch Hosp, Dept Ophthalmol, Canterbury Dist Hlth Board, Christchurch, New Zealand.
   [Yu, Daryle Jason G.; Hoang, Quan, V] Duke NUS Med Sch, Singapore Natl Eye Ctr, Singapore Eye Res Inst, Singapore, Singapore.
   [Freund, K. Bailey] Vitreous Retina Macula Consultants New York, New York, NY USA.
   [Freund, K. Bailey] NYU, Dept Ophthalmol, Robert I Grossman Sch Med, 550 1St Ave, New York, NY 10016 USA.
   [Hoang, Quan, V] Columbia Coll Phys & Surg, Edward S Harkness Eye Inst, Dept Ophthalmol, New York, NY USA.
C3 University of California System; University of California San Francisco;
   Christchurch Hospital New Zealand; National University of Singapore;
   Singapore National Eye Center; Vitreous Retina Macula Consultants of New
   York; New York University; Columbia University
RP Jung, JJ (通讯作者)，East Bay Retina Consultants Inc, 3300 Telegraph Ave, Oakland, CA 94609 USA.
EM jung.jesse@gmail.com
RI Freund, K. Bailey/V-7488-2018
OI Freund, K. Bailey/0000-0002-7888-9773
FU National Eye Institute, NIH [1 K08 EY023595]
FX Supported in part by a K08 Grant (Q. V. Hoang, 1 K08 EY023595, National
   Eye Institute, NIH). The sponsor or funding organization had no role in
   the design or conduct of this research.
CR Cicinelli MV, 2020, OPHTHALMOL RETINA, V4, P454, DOI 10.1016/j.oret.2019.12.003
   Cuenca N, 2018, OPHTHALMOLOGY, V125, P407, DOI 10.1016/j.ophtha.2017.09.016
   Dolz-Marco R, 2017, RETINA-J RET VIT DIS, V37, P222, DOI 10.1097/IAE.0000000000001279
   Drexler W, 2001, NAT MED, V7, P502, DOI 10.1038/86589
   Fernandez-Avellaneda Pedro, 2022, Retin Cases Brief Rep, V16, P59, DOI 10.1097/ICB.0000000000000943
   Hoang QV, 2002, VISUAL NEUROSCI, V19, P395, DOI 10.1017/S0952523802194028
   Hwang JC, 2011, OPHTHAL SURG LAS IM, V42, DOI 10.3928/15428877-20100924-01
   Ishihara K, 2009, OPHTHALMOLOGY, V116, P1799, DOI 10.1016/j.ophtha.2009.04.002
   Jaffe GJ, 2019, OPHTHALMOLOGY, V126, P252, DOI 10.1016/j.ophtha.2018.08.035
   Jonnal RS, 2014, INVEST OPHTH VIS SCI, V55, P7904, DOI 10.1167/iovs.14-14907
   Liakopoulos S, 2013, OSLI RETINA, V44, pS11, DOI 10.3928/23258160-20131101-03
   Litts KM, 2018, RETINA-J RET VIT DIS, V38, P445, DOI 10.1097/IAE.0000000000001946
   Litts KM, 2015, INVEST OPHTH VIS SCI, V56, P2243, DOI 10.1167/iovs.14-15838
   Mehta Nitish, 2021, Retin Cases Brief Rep, V15, P391, DOI 10.1097/ICB.0000000000000817
   Ouyang YL, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0086626
   Polyak SL, 1941, RETINA-J RET VIT DIS, P607
   Ramtohul P, 2020, OPHTHALMOL RETINA, V4, P587, DOI 10.1016/j.oret.2020.01.017
   Ross DH, 2015, INVEST OPHTH VIS SCI, V56, P4166, DOI 10.1167/iovs.14-15256
   Spaide RF, 2020, OPHTHALMOLOGY, V127, P616, DOI 10.1016/j.ophtha.2019.11.004
   Spaide RF, 2011, RETINA-J RET VIT DIS, V31, P1609, DOI 10.1097/IAE.0b013e3182247535
   Tekin K, 2019, CLIN EXP OPTOM, V102, P343, DOI 10.1111/cxo.12876
   TOTH CA, 1992, AM J OPHTHALMOL, V113, P175, DOI 10.1016/S0002-9394(14)71530-2
   TOTH CA, 1991, ARCH OPHTHALMOL-CHIC, V109, P723, DOI 10.1001/archopht.1991.01080050139046
NR 23
TC 4
Z9 4
U1 0
U2 0
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0275-004X
EI 1539-2864
J9 RETINA-J RET VIT DIS
JI Retin.-J. Retin. Vitr. Dis.
PD OCT
PY 2021
VL 41
IS 10
BP 2106
EP 2114
DI 10.1097/IAE.0000000000003153
PG 9
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA WN5GS
UT WOS:000711796500014
PM 33625111
OA Green Accepted
DA 2022-11-30
ER

PT J
AU Zhang, Z
   Wu, Y
   Lyu, YL
   Chang, MQ
   Xu, QJ
   Liu, YM
   Kang, WY
   Wang, QY
   La, CL
AF Zhang, Zhen
   Wu, Ying
   Lyu, Ya-Li
   Chang, Meng-Qi
   Xu, Qiu-Jin
   Liu, Yi-Ming
   Kang, Wen-Ying
   Wang, Qing-Yu
   La, Chuan-Ling
TI Efficacy and safety of intravitreal HLX04-O, an anti-VEGF monoclonal
   antibody, for the treatment of wet age-related macular degeneration
SO INTERNATIONAL JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
DE ? wet age-related macular degeneration; anti-vascular endothelial growth
   factor; bevacizumab; HLX04; HLX04-O
ID BEVACIZUMAB; RANIBIZUMAB; TRIAL
AB AIM: To evaluate the efficacy and safety of HLX04-O, an investigational ophthalmic formulation of HLX04 (bevacizumab biosimilar) for intravitreal injection, as a treatment for wet age-related macular degeneration (wAMD) in a phase 1/2 clinical trial (NCT04993352). METHODS: Eligible patients with wAMD were enrolled to receive HLX04-O intravitreal injections at a dose of 1.25 mg/0.05 mL every four weeks. Efficacy and adverse events were evaluated every month during study visits. RESULTS: A 76-year-old male with wAMD in his left eye participated in the trial and completed six cycles of HLX04-O intravitreal injections. Changes were observed in macular center point thickness (baseline vs last study visit, 437 vs 255 mu m) and best-corrected visual acuity letter score (baseline vs last study visit, 36 vs 77) of the affected eye, which indicated an improvement in wAMD over treatment. No adverse events were reported by the data cutoff date. CONCLUSION: HLX04-O at 1.25 mg/0.05 mL every four weeks is well tolerated in this patient, demonstrating promising safety and efficacy in wAMD treatment. Large-scale studies are required to confirm the outcomes.
C1 [Zhang, Zhen] Xuzhou Cent Hosp, Dept Ophthalmol, Xuzhou 221009, Jiangsu, Peoples R China.
   [Wu, Ying] Fudan Univ, Eye & ENT Hosp, Dept Ophthalmol, Shanghai 200031, Peoples R China.
   [Lyu, Ya-Li; Liu, Yi-Ming; Kang, Wen-Ying; Wang, Qing-Yu] Shanghai Henlius Biotech Inc, Shanghai 200233, Peoples R China.
   [Chang, Meng-Qi; Xu, Qiu-Jin; La, Chuan-Ling] Xuzhou Cent Hosp, Dept Phase Clin Trial 1, Xuzhou 221009, Jiangsu, Peoples R China.
   [La, Chuan-Ling] Xuzhou Cent Hosp, Dept Phase Clin Trial 1, 199 Jiefang South Rd, Xuzhou 221009, Jiangsu, Peoples R China.
C3 Fudan University
RP La, CL (通讯作者)，Xuzhou Cent Hosp, Dept Phase Clin Trial 1, 199 Jiefang South Rd, Xuzhou 221009, Jiangsu, Peoples R China.
EM Licl318@126.com
FU Shanghai Henlius Biotech, Inc
FX Supported by Shanghai Henlius Biotech, Inc.
CR [Anonymous], HENLIUS 4 BIOLOGICS
   Ba J, 2015, DRUG DES DEV THER, V9, DOI 10.2147/DDDT.S86269
   Bro T, 2020, GRAEF ARCH CLIN EXP, V258, P503, DOI 10.1007/s00417-019-04569-8
   Chakravarthy U, 2015, HEALTH TECHNOL ASSES, V19, P1, DOI 10.3310/hta19780
   de Jong EK, 2020, GENETICS AND GENOMICS OF EYE DISEASE: ADVANCING TO PRECISION MEDICINE, P155, DOI 10.1016/B978-0-12-816222-4.00010-1
   Garcia-Quintanilla L, 2019, PHARMACEUTICS, V11, DOI 10.3390/pharmaceutics11080365
   Holz FG, 2014, J CLIN INVEST, V124, P1430, DOI 10.1172/JCI71029
   Khan P, 2016, INDIAN J OPHTHALMOL, V64, P694, DOI 10.4103/0301-4738.99855
   Kodjikian L, 2013, OPHTHALMOLOGY, V120, P2300, DOI 10.1016/j.ophtha.2013.06.020
   Krebs I, 2013, BRIT J OPHTHALMOL, V97, P266, DOI 10.1136/bjophthalmol-2012-302391
   Low A, 2019, BRIT J OPHTHALMOL, V103, P442, DOI 10.1136/bjophthalmol-2018-312691
   Martin DF, 2020, OPHTHALMOLOGY, V127, pS135, DOI 10.1016/j.ophtha.2020.01.029
   Mitchell P, 2018, LANCET, V392, P1147, DOI 10.1016/S0140-6736(18)31550-2
   Qin SK, 2021, BIODRUGS, V35, P445, DOI 10.1007/s40259-021-00484-9
   Schargus M, 2018, RETINA-J RET VIT DIS, V38, P2088, DOI 10.1097/IAE.0000000000001809
   Vitreoretinal Society of India, 2016, GUIDELINES INTRAVITR
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
NR 17
TC 0
Z9 0
U1 2
U2 2
PU IJO PRESS
PI XI AN
PA NO 269 YOUYI EAST RD, XI AN, 710054, PEOPLES R CHINA
SN 2222-3959
EI 2227-4898
J9 INT J OPHTHALMOL-CHI
JI Int. J. Ophthalmol.
PD SEP 18
PY 2022
VL 15
IS 9
BP 1549
EP 1553
DI 10.18240/ijo.2022.09.20
PG 5
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 5B1AM
UT WOS:000863308000020
PM 36124180
OA gold, Green Published
DA 2022-11-30
ER

PT J
AU Liutkeviciene, R
   Zaliaduonyte-Peksiene, D
   Zaliuniene, D
   Gustiene, O
   Jasinskas, V
   Lesauskaite, V
   Tamosiunas, A
   Zaliunas, R
AF Liutkeviciene, Rasa
   Zaliaduonyte-Peksiene, Diana
   Zaliuniene, Dalia
   Gustiene, Olivija
   Jasinskas, Vytautas
   Lesauskaite, Vaiva
   Tamosiunas, Abdonas
   Zaliunas, Remigijus
TI Does Matrix Metalloproteinase-3 Polymorphism Play a Role in Age-Related
   Macular Degeneration in Patients With Myocardial Infarction?
SO MEDICINA-LITHUANIA
LA English
DT Article
DE age-related macular degeneration; myocardial infarction;
   neovascularization; matrix metalloproteinase-3 gene polymorphism
ID CORONARY-HEART-DISEASE; CARDIOVASCULAR-DISEASE; GENE POLYMORPHISM; RISK;
   ATHEROSCLEROSIS; SUSCEPTIBILITY; PATHOGENESIS; ASSOCIATION; EXPRESSION;
   INHIBITORS
AB Objective. The aim of our study was to determine if the genotype of the matrix metalloproteinase-3 (MMP-3) gene might carry the risk of age-related macular degeneration (ARMD) in patients with myocardial infarction.
   Material and Methods. A total of 499 patients with an acute myocardial infarction or with a history of myocardial infarction were enrolled into the study. They were subdivided into 2 groups: 273 patients with ARMD and 226 patients without ARMD. The control group comprised 560 persons from a random sample of the Lithuanian population. DNA was analyzed using real-time polymerase chain reaction to genotype polymorphism 5A/6A at a position - 1171 of the MMP-3 gene promoter.
   Results. Of the 499 patients with myocardial infarction, 47% had early-stage ARMD. The patients with ARMD were older than the patients in the group without ARMD (62.1 +/- 10.8 vs. 59.6 +/- 11.1, P<0.01). The analysis of MMP-3 gene polymorphism did not reveal any differences in the distribution of 5A/5A, 5A/6A, and 6A/6A genotypes between the ARMD group, non-ARMD group, and the control group (24.2%, 52.5%, and 23.3% in the ARMD group; 28.7%, 51.9%, and 19.4% in non-ARMD group; and 25.7%, 49.3% and 25.0%, in the control group, respectively).
   Conclusions. MMP-3 gene polymorphism had no predominant effect on the development of ARMD in patients with myocardial infarction.
C1 [Liutkeviciene, Rasa; Zaliuniene, Dalia; Jasinskas, Vytautas] Lithuanian Univ Hlth Sci, Med Acad, Dept Ophthalmol, Eiveniu 2, LT-50028 Kaunas, Lithuania.
   [Zaliaduonyte-Peksiene, Diana; Gustiene, Olivija; Zaliunas, Remigijus] Lithuanian Univ Hlth Sci, Med Acad, Dept Cardiol, LT-50028 Kaunas, Lithuania.
   [Lesauskaite, Vaiva; Tamosiunas, Abdonas] Lithuanian Univ Hlth Sci, Med Acad, Inst Cardiol, LT-50028 Kaunas, Lithuania.
C3 Lithuanian University of Health Sciences; Lithuanian University of
   Health Sciences; Lithuanian University of Health Sciences
RP Liutkeviciene, R (通讯作者)，Lithuanian Univ Hlth Sci, Med Acad, Dept Ophthalmol, Eiveniu 2, LT-50028 Kaunas, Lithuania.
EM rliutkeviciene@gmail.com
RI Tamosiunas, Abdonas/AAD-4274-2021
OI Lesauskaite, Vaiva/0000-0003-2736-3111
FU Research Council of Lithuania [MIP-10330]; Wellcome Trust
   [064947/Z/01/Z]; National Institute on Aging [IR0I AG23522-01];
   MacArthur Foundation (Health and Social Up-heaval Network); NATIONAL
   INSTITUTE ON AGING [R01AG023522] Funding Source: NIH RePORTER
FX This study was supported by the Research Council of Lithuania (grant No.
   MIP-10330), the Wellcome Trust (grant No. 064947/Z/01/Z), the National
   Institute on Aging (grant No. IR0I AG23522-01), and the MacArthur
   Foundation (Health and Social Up-heaval Network).
CR Abilleira S, 2006, J MED GENET, V43, P897, DOI 10.1136/jmg.2006.040808
   Alge-Priglinger CS, 2009, INVEST OPHTH VIS SCI, V50, P5495, DOI 10.1167/iovs.08-3193
   Beyzade S, 2003, J AM COLL CARDIOL, V41, P2130, DOI 10.1016/S0735-1097(03)00482-0
   CHYLACK LT, 1993, ARCH OPHTHALMOL-CHIC, V111, P831, DOI 10.1001/archopht.1993.01090060119035
   Cimbalas A, 2004, MED LITH, V39, P37
   Curcio CA, 2001, INVEST OPHTH VIS SCI, V42, P265
   Djuric T, 2008, CLIN BIOCHEM, V41, P1326, DOI 10.1016/j.clinbiochem.2008.08.081
   Duan YK, 2007, OPHTHALMOLOGY, V114, P732, DOI 10.1016/j.ophtha.2006.07.045
   Fraser-Bell S, 2006, AM J OPHTHALMOL, V141, P79, DOI 10.1016/j.ajo.2005.08.024
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P564
   Friedman E, 2000, AM J OPHTHALMOL, V130, P658, DOI 10.1016/S0002-9394(00)00643-7
   Guo L, 1999, INVEST OPHTH VIS SCI, V40, P2676
   Klein R, 2004, AM J OPHTHALMOL, V137, P486, DOI 10.1016/j.ajo.2003.11.069
   Kohri T, 2003, GRAEF ARCH CLIN EXP, V241, P943, DOI 10.1007/s00417-003-0761-2
   Lesauskaite V, 2008, MEDICINA-LITHUANIA, V44, P386, DOI 10.3390/medicina44050050
   Liutkeviciene R, 2010, MEDICINA-LITHUANIA, V46, P89, DOI 10.3390/medicina46020013
   Milton RC, 2005, OPHTHALMOLOGY, V112, P533, DOI 10.1016/j.ophtha.2004.10.047
   Morrow DA, 2007, BRAUNWALDS HEART DIS, P1281
   Nguyen-Khoa BA, 2008, ARCH OPHTHALMOL-CHIC, V126, P1280, DOI 10.1001/archopht.126.9.1280
   Ogata N, 2002, INVEST OPHTH VIS SCI, V43, P1168
   Redberg RF, 2009, CIRCULATION, V120, P1296, DOI 10.1161/CIRCULATIONAHA.109.192617
   Samnegard A, 2005, J INTERN MED, V258, P411, DOI 10.1111/j.1365-2796.2005.01561.x
   Seddon JM, 2006, ARCH OPHTHALMOL-CHIC, V124, P995, DOI 10.1001/archopht.124.7.995
   Seifi M, 2009, ARCH MED RES, V40, P600, DOI 10.1016/j.arcmed.2009.08.008
   Spilsbury K, 2000, AM J PATHOL, V157, P135, DOI 10.1016/S0002-9440(10)64525-7
   Steen B, 1998, INVEST OPHTH VIS SCI, V39, P2194
   Sun C, 2009, OPHTHALMOLOGY, V116, P1913, DOI 10.1016/j.ophtha.2009.03.046
   Tan JSL, 2008, BRIT J OPHTHALMOL, V92, P509, DOI 10.1136/bjo.2007.131706
   Tan JSL, 2007, OPHTHALMOLOGY, V114, P1143, DOI 10.1016/j.ophtha.2006.09.033
   Tatar O, 2007, BRIT J OPHTHALMOL, V91, P1183, DOI 10.1136/bjo.2007.114769
   Wilson PWF, 1998, CIRCULATION, V97, P1837, DOI 10.1161/01.CIR.97.18.1837
   WOESSNER JF, 1991, FASEB J, V5, P2145, DOI 10.1096/fasebj.5.8.1850705
   Wong TY, 2007, OPHTHALMOLOGY, V114, P86, DOI 10.1016/j.ophtha.2006.06.039
   Ye S, 2000, MATRIX BIOL, V19, P623, DOI 10.1016/S0945-053X(00)00102-5
   Zaliuniene D, 2008, EUR J OPHTHALMOL, V18, P384, DOI 10.1177/112067210801800312
   Zarbin MA, 2004, ARCH OPHTHALMOL-CHIC, V122, P598, DOI 10.1001/archopht.122.4.598
NR 36
TC 5
Z9 6
U1 0
U2 0
PU MDPI
PI BASEL
PA ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND
SN 1010-660X
EI 1648-9144
J9 MEDICINA-LITHUANIA
JI Med. Lith.
PY 2012
VL 48
IS 8
BP 404
EP 409
DI 10.3390/medicina48080060
PG 6
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine
GA 047BJ
UT WOS:000311812400004
PM 23128460
OA gold
DA 2022-11-30
ER

PT J
AU Chuo, JY
   Wiens, M
   Etminan, M
   Maberley, DAL
AF Chuo, Jean Y.
   Wiens, Matthew
   Etminan, Mahyar
   Maberley, David A. L.
TI Use of lipid-lowering agents for the prevention of age-related macular
   degeneration: A meta-analysis of observational studies
SO OPHTHALMIC EPIDEMIOLOGY
LA English
DT Article
DE age-related macular degeneration; HMG-CoA reductase inhibitors;
   lipid-lowering agents; meta-analysis; statins
ID C-REACTIVE PROTEIN; ENDOTHELIAL GROWTH-FACTOR; 5-YEAR INCIDENCE; VISUAL
   IMPAIRMENT; POOLED FINDINGS; MEDICATION USE; RISK-FACTORS; DIETARY-FAT;
   STATIN USE; S-PROTEIN
AB Purpose: To examine the effect of lipid-lowering agents in the development of age-related macular degeneration (AMD) through the techniques of meta-analysis. Methods: Case-control and cohort studies presenting relative risks and 95% confidence intervals were identified through a literature review. Inclusion was limited to studies where both the exposure of interest (lipid-lowering agents) and outcome (AMD) were explicitly defined. Pooled estimates were computed using the random effects model. To quantify heterogeneity we calculated the proportion of total variance of between study variance using the Ri statistic. The Q statistic for heterogeneity was also calculated. Results: Eight studies were identified. The pooled relative risk (RR) for all studies was 0.74 (95% CI, 0.55-1.00). When only those studies examining the use of statins were pooled (n = 7), the RR was 0.70 (95% CI, 0.48-1.03). Using the Ri statistic, the heterogeneity between studies was found to be 0.85 for all studies and 0.89 for studies examining statins. Conclusion: Lipid-lowering agents, including statins, do not appear to lower the risk of developing AMD, although clinically significant effects cannot be excluded. The use of these agents in the prevention of AMD cannot be recommended until well designed prospective studies with long follow up have demonstrated a benefit.
C1 [Chuo, Jean Y.; Maberley, David A. L.] Univ British Columbia, VGH Eye Care Ctr, Fac Med, Dept Ophthalmol & Visual Sci, Vancouver, BC V5Z 3N9, Canada.
   [Wiens, Matthew] Univ British Columbia, Fac Pharmaceut Sci, Vancouver, BC V5Z 3N9, Canada.
   [Etminan, Mahyar] Vancouver Hosp, Ctr Clin Epidemiol & Evaluat, Vancouver, BC V5Z 3N9, Canada.
C3 University of British Columbia; University of British Columbia;
   University of British Columbia
RP Chuo, JY (通讯作者)，Univ British Columbia, VGH Eye Care Ctr, Fac Med, Dept Ophthalmol & Visual Sci, 2550 Willow St, Vancouver, BC V5Z 3N9, Canada.
EM chuo@interchange.ubc.ca
OI Wiens, Matthew/0000-0002-3287-5181
CR Ambati J, 2003, SURV OPHTHALMOL, V48, P257, DOI 10.1016/S0039-6257(03)00030-4
   Anand R, 2000, OPHTHALMOLOGY, V107, P2224
   Anderson DH, 2002, AM J OPHTHALMOL, V134, P411, DOI 10.1016/S0002-9394(02)01624-0
   BABAEV VR, 1990, ATHEROSCLEROSIS, V85, P239, DOI 10.1016/0021-9150(90)90116-Z
   BROWN G, 1990, NEW ENGL J MED, V323, P1289, DOI 10.1056/NEJM199011083231901
   Cho E, 2001, AM J CLIN NUTR, V73, P209
   *CNIB, 2006, SPOTL AMD
   Collins R, 2002, LANCET, V360, P7, DOI 10.1016/S0140-6736(02)09327-3
   Congdon N, 2004, ARCH OPHTHALMOL-CHIC, V122, P477
   Costa-Bouzas J, 2001, COMPUT METH PROG BIO, V64, P101, DOI 10.1016/S0169-2607(00)00087-0
   Curcio CA, 2001, INVEST OPHTH VIS SCI, V42, P265
   Delcourt C, 2001, Ophthalmic Epidemiol, V8, P237, DOI 10.1076/opep.8.4.237.1613
   DERSIMONIAN R, 1986, CONTROL CLIN TRIALS, V7, P177, DOI 10.1016/0197-2456(86)90046-2
   Dichtl W, 2003, ARTERIOSCL THROM VAS, V23, P58, DOI 10.1161/01.ATV.0000043456.48735.20
   Egger M, 1997, BMJ-BRIT MED J, V315, P629, DOI 10.1136/bmj.315.7109.629
   FARKAS TG, 1971, AM J OPHTHALMOL, V71, P1206, DOI 10.1016/0002-9394(71)90964-0
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P564
   Friedman E, 2005, IOVS, V46, P199
   Green W R, 1977, Trans Am Ophthalmol Soc, V75, P180
   Guymer RH, 2005, SURV OPHTHALMOL, V50, P194, DOI 10.1016/j.survophthal.2004.12.002
   Hageman GS, 1999, FASEB J, V13, P477, DOI 10.1096/fasebj.13.3.477
   Hall NF, 2001, BRIT MED J, V323, P375, DOI 10.1136/bmj.323.7309.375
   Hyman L, 2000, ARCH OPHTHALMOL-CHIC, V118, P351, DOI 10.1001/archopht.118.3.351
   Jialal I, 2001, CIRCULATION, V103, P1933
   KAHN HA, 1977, AM J EPIDEMIOL, V106, P17, DOI 10.1093/oxfordjournals.aje.a112428
   Klaver CCW, 2001, INVEST OPHTH VIS SCI, V42, P2237
   Klein R, 1997, OPHTHALMOLOGY, V104, P7, DOI 10.1016/S0161-6420(97)30368-6
   Klein R, 2003, ARCH OPHTHALMOL-CHIC, V121, P1151, DOI 10.1001/archopht.121.8.1151
   Klein R, 2001, ARCH OPHTHALMOL-CHIC, V119, P1354
   Kuvin JT, 2003, CURR OPIN CARDIOL, V18, P295, DOI 10.1097/00001573-200307000-00009
   Li JJ, 2003, CORONARY ARTERY DIS, V14, P329, DOI 10.1097/01.mca.0000078062.22445.60
   Lopez PF, 1996, INVEST OPHTH VIS SCI, V37, P855
   MARESPERLMAN JA, 1995, ARCH OPHTHALMOL-CHIC, V113, P743, DOI 10.1001/archopht.1995.01100060069034
   McCarty CA, 2001, ARCH OPHTHALMOL-CHIC, V119, P1455
   McCarty CA, 2001, MED J AUSTRALIA, V175, P340, DOI 10.5694/j.1326-5377.2001.tb143604.x
   McGwin G, 2006, ARCH OPHTHALMOL-CHIC, V124, P33, DOI 10.1001/archopht.124.1.33
   McGwin G, 2005, OPHTHALMOLOGY, V112, P488, DOI 10.1016/j.ophtha.2004.10.027
   McGwin G, 2003, BRIT J OPHTHALMOL, V87, P1121, DOI 10.1136/bjo.87.9.1121
   Mitchell P, 2002, ARCH OPHTHALMOL-CHIC, V120, P1357, DOI 10.1001/archopht.120.10.1357
   Mullins RF, 2000, FASEB J, V14, P835, DOI 10.1096/fasebj.14.7.835
   NICULESCU F, 1987, ATHEROSCLEROSIS, V65, P1, DOI 10.1016/0021-9150(87)90002-5
   NICULESCU F, 1989, ATHEROSCLEROSIS, V78, P197, DOI 10.1016/0021-9150(89)90223-2
   OLIVER MF, 1994, LANCET, V344, P633
   PEDERSEN TR, 1994, LANCET, V344, P1383
   Plenge JK, 2002, CIRCULATION, V106, P1447, DOI 10.1161/01.CIR.0000029743.68247.31
   Pruefer D, 1999, ARTERIOSCL THROM VAS, V19, P2894, DOI 10.1161/01.ATV.19.12.2894
   REBLIN T, 1995, ATHEROSCLEROSIS, V113, P179, DOI 10.1016/0021-9150(94)05445-O
   Seddon JM, 2003, ARCH OPHTHALMOL-CHIC, V121, P785, DOI 10.1001/archopht.121.6.785
   Smeeth L, 2005, BRIT J OPHTHALMOL, V89, P1171, DOI 10.1136/bjo.2004.064477
   Smith W, 2001, OPHTHALMOLOGY, V108, P697, DOI 10.1016/S0161-6420(00)00580-7
   STARY HC, 1995, CIRCULATION, V92, P1355, DOI 10.1161/01.CIR.92.5.1355
   Takkouche B, 1999, AM J EPIDEMIOL, V150, P206
   Tan JSL, 2007, AM J OPHTHALMOL, V143, P685, DOI 10.1016/j.ajo.2006.11.021
   *US BUR CENS, 1998, 1998 POP EST
   Van Leeuwen R, 2004, OPHTHALMOLOGY, V111, P1169, DOI 10.1016/j.ophtha.2003.10.024
   van Leeuwen R, 2003, BRIT MED J, V326, P255, DOI 10.1136/bmj.326.7383.255
   VanNewkirk MR, 2000, OPHTHALMOLOGY, V107, P1593, DOI 10.1016/S0161-6420(00)00175-5
   VINDING T, 1992, ACTA OPHTHALMOL, V70, P66
   VINGERLING JR, 1995, AM J EPIDEMIOL, V142, P404, DOI 10.1093/oxfordjournals.aje.a117648
   YANNUZZI LA, 1992, ARCH OPHTHALMOL-CHIC, V110, P1701
   Yi XJ, 1997, GRAEF ARCH CLIN EXP, V235, P313, DOI 10.1007/BF01739641
NR 61
TC 26
Z9 27
U1 0
U2 3
PU TAYLOR & FRANCIS INC
PI PHILADELPHIA
PA 530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA
SN 0928-6586
EI 1744-5086
J9 OPHTHAL EPIDEMIOL
JI Ophthalmic Epidemiol.
PD NOV-DEC
PY 2007
VL 14
IS 6
BP 367
EP 374
DI 10.1080/09286580701421684
PG 8
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 245JX
UT WOS:000251932000006
PM 18161610
DA 2022-11-30
ER

PT J
AU Teper, SJ
   Nowinska, A
   Figurska, M
   Rekas, M
   Wylegala, E
AF Teper, Slawomir Jan
   Nowinska, Anna
   Figurska, Malgorzata
   Rekas, Marek
   Wylegala, Edward
TI The Need for Treatment of Neovascular Age-Related Macular Degeneration:
   A Study Based on the Polish National Registry
SO OPHTHALMOLOGY AND THERAPY
LA English
DT Article
DE Age-related macular degeneration; COVID-19; Macular neovascularization;
   National registry; Treatment demand; Treatment need; VEGF inhibitors
ID OUTCOMES
AB Introduction The Polish National AMD Therapeutic Program offered us a unique opportunity to determine the need for treatment of neovascular age-related macular degeneration (nAMD). Methods A search, extraction, and analysis of data from the monitoring system of the Therapeutic Program of the National Health Fund was performed. Demographic data from the Central Statistical Office were also obtained and analyzed. All national data, and from the Silesian Voivodeship specifically, from patients who had received treatment prior to January 14, 2022 (57,876 eyes) were analyzed. Results Approximately 0.1% of the Polish population requires treatment for nAMD when the best-corrected visual acuity (BCVA) criteria exclude irreversible severe changes in the fovea (0.2-0.8 by Snellen). There were 30,771 eyes in the therapeutic program in January 2022, and 4898 (15.9%) of them were in Silesia, which contains 11.7% of the total population and 12.4% of the elderly population (65 years of age and older). However, as a result of the COVID-19 pandemic, the average number of monthly enrollments in the therapeutic program decreased from 717 in the first quarter of 2020 to 505 in the second quarter (with a low of 407 in April). Moreover, in 2020, a negative balance was recorded between included and excluded patients. Conclusion The need for nAMD treatment in the elderly community (65 years of age and older) is estimated to be 0.55-0.66%.
C1 [Teper, Slawomir Jan; Nowinska, Anna; Wylegala, Edward] Med Univ Silesia, Fac Med Sci Zabrze, Okregowy Szpital Kolejowy Katowicach, Chair & Clin Dept Ophthalmol, Panewnicka 65, PL-40760 Katowice, Poland.
   [Figurska, Malgorzata; Rekas, Marek] Minist Natl Def, Cent Clin Hosp, Mil Inst Med, Dept Ophthalmol, Warsaw, Poland.
C3 Medical University Silesia; Military Institute of Aviation Medicine
RP Teper, SJ (通讯作者)，Med Univ Silesia, Fac Med Sci Zabrze, Okregowy Szpital Kolejowy Katowicach, Chair & Clin Dept Ophthalmol, Panewnicka 65, PL-40760 Katowice, Poland.
EM slawomir.teper@sum.edu.pl; mfigurska@wim.mil.pl
RI Teper, Slawomir/AAQ-1938-2021; Nowinska, Anna K/G-6165-2013; Wylegala,
   Edward/AAD-3961-2019
OI Teper, Slawomir/0000-0002-0935-8880; Nowinska, Anna
   K/0000-0002-8418-3486; 
FU Medical University of Silesia and Military Institute of Medicine
FX This research received no external funding. The journal's Rapid Service
   fees were funded by the Medical University of Silesia and Military
   Institute of Medicine.
CR Colijn JM, 2017, OPHTHALMOLOGY, V124, P1753, DOI 10.1016/j.ophtha.2017.05.035
   Figurska M, 2020, EUR J OPHTHALMOL, V30, P586, DOI 10.1177/1120672119874598
   Kristiansen IS, 2020, ACTA OPHTHALMOL, V98, P279, DOI 10.1111/aos.14262
   Lad EM, 2014, AM J OPHTHALMOL, V158, P537, DOI 10.1016/j.ajo.2014.05.014
   Leng T, 2021, OPHTHALMOLOGY, V128, P1782, DOI 10.1016/j.ophtha.2021.06.011
   Leszko M, 2015, GERONTOLOGIST, V55, P707, DOI 10.1093/geront/gnu171
   Li E, 2020, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD012208.pub2
   Mehta H, 2020, CLIN OPHTHALMOL, V14, P3331, DOI 10.2147/OPTH.S275977
   Okada M, 2021, OPHTHALMOLOGY, V128, P234, DOI 10.1016/j.ophtha.2020.07.060
   Rasmussen A, 2015, ACTA OPHTHALMOL, V93, P616, DOI 10.1111/aos.12781
   Rich WL, 2018, OPHTHALMOLOGY, V125, P782, DOI 10.1016/j.ophtha.2017.11.033
   Rudnicka AR, 2015, AM J OPHTHALMOL, V160, P85, DOI 10.1016/j.ajo.2015.04.003
   Taylor DJ, 2016, BMJ OPEN, V6, DOI 10.1136/bmjopen-2016-011504
   Teper SJ, 2012, MED SCI MONITOR, V18, pPR1, DOI 10.12659/MSM.882447
   Velilla S, 2013, J OPHTHALMOL, V2013, DOI 10.1155/2013/895147
NR 15
TC 0
Z9 0
U1 0
U2 0
PU SPRINGER INT PUBL AG
PI CHAM
PA GEWERBESTRASSE 11, CHAM, CH-6330, SWITZERLAND
SN 2193-8245
EI 2193-6528
J9 OPHTHALMOL THER
JI OPHTHALMOL. THER.
PD OCT
PY 2022
VL 11
IS 5
BP 1805
EP 1816
DI 10.1007/s40123-022-00545-4
EA JUL 2022
PG 12
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 4I0YA
UT WOS:000830361000001
PM 35871711
OA Green Published, gold
DA 2022-11-30
ER

PT J
AU Tan, JSL
   Wang, JJ
   Flood, V
   Mitchell, P
AF Tan, Jennifer S. L.
   Wang, Jie Jin
   Flood, Victoria
   Mitchell, Paul
TI Dietary Fatty Acids and the 10-Year Incidence of Age-Related Macular
   Degeneration The Blue Mountains Eye Study
SO ARCHIVES OF OPHTHALMOLOGY
LA English
DT Article
ID CORONARY-HEART-DISEASE; LONG-TERM INCIDENCE; CIGARETTE-SMOKING;
   MACULOPATHY; RISK; ANTIOXIDANTS; QUESTIONNAIRE; CHOLESTEROL;
   CONSUMPTION; PROGRESSION
AB Objective: To assess the relationship between baseline dietary fatty acids and 10-year incident age-related macular degeneration (AMD).
   Methods: In an elderly Australian cohort, 3654 participants were examined at baseline and 2454 were examined 5 and/or 10 years later. We assessed AMD from retinal photographs. Participants completed a semiquantitative food frequency questionnaire.
   Results: After adjusting for age, sex, and smoking, 1 serving of fish per week was associated with reduced risk of incident early AMD (relative risk, 0.69 [95% confidence interval, 0.49-0.98]), primarily among participants with less than the median linoleic acid consumption (0.57 [0.36-0.891). Findings were similar for intake of long-chain omega-3 polyunsaturated fatty acids. One to 2 servings of nuts per week was associated with reduced risk of incident early AMD (relative risk, 0.65 [95% confidence interval, 0.47-0.91]). Protective associations between the intake of nuts and reduced risk of pigmentary abnormalities were seen among nonsmokers, participants with less than the median ratio of serum total to high-density lipoprotein cholesterol, and those with beta carotene intake greater than the median level.
   Conclusions: This study provides evidence of protection against early AMD from regularly eating fish, greater consumption of w-3 polyunsaturated fatty acids, and low intakes of foods rich in linoleic acid. Regular consumption of nuts may also reduce AMD risk. joint effects from multiple factors are suggested.
C1 [Tan, Jennifer S. L.; Wang, Jie Jin; Flood, Victoria; Mitchell, Paul] Westmead Hosp, Dept Ophthalmol, Ctr Vis Res, Westmead Millennium Inst, Westmead, NSW 2145, Australia.
   [Flood, Victoria] Univ Sydney, Human Nutr Unit, Dept Mol & Microbial Biosci, Sydney, NSW 2006, Australia.
C3 University of Sydney; Westmead Institute for Medical Research;
   University of Sydney
RP Mitchell, P (通讯作者)，Westmead Hosp, Dept Ophthalmol, Ctr Vis Res, Westmead Millennium Inst, Hawkesbury Rd, Westmead, NSW 2145, Australia.
EM paul_mitchell@wmi.usyd.edu.au
RI Flood, Victoria M/A-8732-2016; Wang, Jie Jin/P-1499-2014; Flood,
   Victoria/H-2279-2011; Mitchell, Paul/P-1498-2014; wang,
   jie/GRS-0942-2022
OI Flood, Victoria M/0000-0001-5310-7221; Wang, Jie
   Jin/0000-0001-9491-4898; 
FU Australian National Health and Medical Research Council [974159, 211069]
FX Funding/Support: This study was supported by grants 974159 and 211069
   from the Australian National Health and Medical Research Council.
CR Afridi I, 2003, J HYPERTENS, V21, P1983, DOI 10.1097/01.hjh.0000084751-37215.d2
   *AG REL EYE DIS ST, 2006, AG REL EYE DIS STUD
   [Anonymous], 1993, Arch Ophthalmol, V111, P104
   BIRD AEC, 1995, SURV OPHTHALMOL, V39, P367, DOI 10.1016/S0039-6257(05)80092-X
   Bok D, 2005, P NATL ACAD SCI USA, V102, P7053, DOI 10.1073/pnas.0502819102
   Cho E, 2001, AM J CLIN NUTR, V73, P209
   Chua B, 2006, ARCH OPHTHALMOL-CHIC, V124, P981, DOI 10.1001/archopht.124.7.981
   CHURCH DF, 1985, ENVIRON HEALTH PERSP, V64, P111, DOI 10.2307/3430003
   Connor WE, 2000, AM J CLIN NUTR, V71, p171S, DOI 10.1093/ajcn/71.1.171S
   Department of Community Services and Health, 1990, NUTTAB 90 NUTR DAT T
   Duncan JL, 2005, BRIT J OPHTHALMOL, V89, P1549, DOI 10.1136/bjo.2005.077370
   Espinosa-Heidmann DG, 2004, INVEST OPHTH VIS SCI, V45, P260, DOI 10.1167/iovs.03-0910
   Fazio Sergio, 2003, Mol Interv, V3, P436, DOI 10.1124/mi.3.8.436
   Flood VM, 2007, ASIA PAC J CLIN NUTR, V16, P322
   Heeschen C, 2001, NAT MED, V7, P833, DOI 10.1038/89961
   Heuberger RA, 2001, ARCH OPHTHALMOL-CHIC, V119, P1833, DOI 10.1001/archopht.119.12.1833
   Hu FB, 1997, NEW ENGL J MED, V337, P1491, DOI 10.1056/NEJM199711203372102
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1417, DOI 10.1001/archopht.119.10.1417
   KINOSIAN B, 1994, ANN INTERN MED, V121, P641, DOI 10.7326/0003-4819-121-9-199411010-00002
   Kris-Etherton Penny M., 2002, American Journal of Medicine, V113, p71S
   Mann N. J., 2003, Nutrition & Dietetics, V60, P42
   MITCHELL P, 1995, OPHTHALMOLOGY, V102, P1450
   Plotnick GD, 1997, JAMA-J AM MED ASSOC, V278, P1682, DOI 10.1001/jama.278.20.1682
   ROBBINS RA, 1991, AM J PHYSIOL, V260, pL254, DOI 10.1152/ajplung.1991.260.4.L254
   SanGiovanni JP, 2007, ARCH OPHTHALMOL-CHIC, V125, P671, DOI 10.1001/archopht.125.5.671
   SanGiovanni JP, 2005, PROG RETIN EYE RES, V24, P87, DOI 10.1016/j.preteyeres.2004.06.002
   Seddon JM, 2003, ARCH OPHTHALMOL-CHIC, V121, P1728, DOI 10.1001/archopht.121.12.1728
   SEDDON JM, 1994, JAMA-J AM MED ASSOC, V272, P1413, DOI 10.1001/jama.272.18.1413
   Seddon JM, 2001, ARCH OPHTHALMOL-CHIC, V119, P1191, DOI 10.1001/archopht.119.8.1191
   Seddon JM, 2006, ARCH OPHTHALMOL-CHIC, V124, P995, DOI 10.1001/archopht.124.7.995
   Simopoulos AP, 2002, BIOMED PHARMACOTHER, V56, P365, DOI 10.1016/S0753-3322(02)00253-6
   Smith W, 1999, OPHTHALMOLOGY, V106, P761, DOI 10.1016/S0161-6420(99)90164-1
   Smith W, 1998, AUST NZ J PUBL HEAL, V22, P456, DOI 10.1111/j.1467-842X.1998.tb01414.x
   Smith W, 2000, ARCH OPHTHALMOL-CHIC, V118, P401, DOI 10.1001/archopht.118.3.401
   Snellen ELM, 2002, ACTA OPHTHALMOL SCAN, V80, P368, DOI 10.1034/j.1600-0420.2002.800404.x
   Snow K K, 1999, Ophthalmic Epidemiol, V6, P125, DOI 10.1076/opep.6.2.125.1558
   STRYKER WS, 1988, AM J EPIDEMIOL, V127, P283, DOI 10.1093/oxfordjournals.aje.a114804
   Tan JSL, 2008, OPHTHALMOLOGY, V115, P334, DOI 10.1016/j.ophtha.2007.03.083
   Tan JSL, 2007, ARCH OPHTHALMOL-CHIC, V125, P1089, DOI 10.1001/archopht.125.8.1089
   van Leeuwen R, 2005, JAMA-J AM MED ASSOC, V294, P3101, DOI 10.1001/jama.294.24.3101
   Wang JJ, 2007, OPHTHALMOLOGY, V114, P92, DOI 10.1016/j.ophtha.2006.07.017
   WILLETT W, 1986, AM J EPIDEMIOL, V124, P17, DOI 10.1093/oxfordjournals.aje.a114366
   WILLETT WC, 1988, AM J EPIDEMIOL, V127, P188, DOI 10.1093/oxfordjournals.aje.a114780
NR 43
TC 142
Z9 145
U1 0
U2 16
PU AMER MEDICAL ASSOC
PI CHICAGO
PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA
SN 0003-9950
EI 1538-3601
J9 ARCH OPHTHALMOL-CHIC
JI Arch. Ophthalmol.
PD MAY
PY 2009
VL 127
IS 5
BP 656
EP 665
DI 10.1001/archophthalmol.2009.76
PG 10
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 442NK
UT WOS:000265847700011
PM 19433717
OA Bronze
DA 2022-11-30
ER

PT J
AU Ardeljan, D
   Wang, Y
   Park, S
   Shen, D
   Chu, XK
   Yu, CR
   Abu-Asab, M
   Tuo, J
   Eberhart, CG
   Olsen, TW
   Mullins, RF
   White, G
   Wadsworth, S
   Scaria, A
   Chan, CC
AF Ardeljan, Daniel
   Wang, Yujuan
   Park, Stanley
   Shen, Defen
   Chu, Xi Kathy
   Yu, Cheng-Rong
   Abu-Asab, Mones
   Tuo, Jingsheng
   Eberhart, Charles G.
   Olsen, Timothy W.
   Mullins, Robert F.
   White, Gary
   Wadsworth, Sam
   Scaria, Abraham
   Chan, Chi-Chao
TI Interleukin-17 Retinotoxicity Is Prevented by Gene Transfer of a Soluble
   Interleukin-17 Receptor Acting as a Cytokine Blocker: Implications for
   Age-Related Macular Degeneration
SO PLOS ONE
LA English
DT Article
ID NLRP3 INFLAMMASOME; PIGMENT EPITHELIUM; THERAPEUTIC LEVELS; MICE;
   COMPLEMENT; ACTIVATION; EXPRESSION; INDUCTION; PROMOTER; MODEL
AB Age-related macular degeneration (AMD) is a common yet complex retinal degeneration that causes irreversible central blindness in the elderly. Pathology is widely believed to follow loss of retinal pigment epithelium (RPE) and photoreceptor degeneration. Here we report aberrant expression of interleukin-17A (IL17A) and the receptor IL17RC in the macula of AMD patients. In vitro, IL17A induces RPE cell death characterized by the accumulation of cytoplasmic lipids and autophagosomes with subsequent activation of pro-apoptotic Caspase-3 and Caspase-9. This pathology is reduced by siRNA knockdown of IL17RC. IL17-dependent retinal degeneration in a mouse model of focal retinal degeneration can be prevented by gene therapy with adeno-associated virus vector encoding soluble IL17 receptor. This intervention rescues RPE and photoreceptors in a MAPK-dependent process. The IL17 pathway plays a key role in RPE and photoreceptor degeneration and could hold therapeutic potential in AMD.
C1 [Ardeljan, Daniel; Wang, Yujuan; Park, Stanley; Shen, Defen; Chu, Xi Kathy; Tuo, Jingsheng; Chan, Chi-Chao] NEI, Immunopathol Sect, Immunol Lab, NIH, Bethesda, MD 20892 USA.
   [Ardeljan, Daniel] Johns Hopkins Univ, Sch Med, Baltimore, MD USA.
   [Wang, Yujuan] Sun Yat Sen Univ, Zhongshan Ophthalm Ctr, Guangzhou 510275, Guangdong, Peoples R China.
   [Park, Stanley] Howard Hughes Med Inst, Chevy Chase, MD USA.
   [Yu, Cheng-Rong] NEI, Mol Immunol Sect, Immunol Lab, NIH, Bethesda, MD USA.
   [Abu-Asab, Mones] NEI, Histol Core, Immunol Lab, NIH, Bethesda, MD USA.
   [Eberhart, Charles G.] Johns Hopkins Univ, Dept Pathol, Baltimore, MD USA.
   [Olsen, Timothy W.] Emory Univ, Dept Ophthalmol, Atlanta, GA 30322 USA.
   [Mullins, Robert F.] Univ Iowa, Carver Coll Med, Dept Ophthalmol & Visual Sci, Iowa City, IA USA.
   [White, Gary; Wadsworth, Sam; Scaria, Abraham] Genzyme Corp, Framingham, MA 01701 USA.
C3 National Institutes of Health (NIH) - USA; NIH National Eye Institute
   (NEI); Johns Hopkins University; Sun Yat Sen University; Howard Hughes
   Medical Institute; National Institutes of Health (NIH) - USA; NIH
   National Eye Institute (NEI); National Institutes of Health (NIH) - USA;
   NIH National Eye Institute (NEI); Johns Hopkins University; Emory
   University; University of Iowa; Sanofi-Aventis; Genzyme Corporation
RP Chan, CC (通讯作者)，NEI, Immunopathol Sect, Immunol Lab, NIH, Bethesda, MD 20892 USA.
EM chanc@nei.nih.gov
RI wang, yujuan/C-8428-2016; Mullins, Robert F/I-6717-2013
OI Yu, Cheng-Rong/0000-0001-7246-0362; Ardeljan,
   Daniel/0000-0002-5593-421X; Mullins, Robert/0000-0002-5006-0891
FU National Eye Institute Intramural Research Program; Genzyme; NATIONAL
   EYE INSTITUTE [ZIAEY000418, ZICEY000461, ZIAEY000222] Funding Source:
   NIH RePORTER
FX The National Eye Institute Intramural Research Program & Genzyme funded
   the work. The funder Genzyme provided support in the form of salaries
   for authors GW, SW, and AS, but did not have any additional role in the
   study design, data collection and analysis, decision to publish, or
   preparation of the manuscript.
CR Anderson OA, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0067263
   Ardeljan D, 2013, PROG RETIN EYE RES, V37, P68, DOI 10.1016/j.preteyeres.2013.07.003
   Ben-Shabat S, 2001, BIOORG MED CHEM LETT, V11, P1533, DOI 10.1016/S0960-894X(01)00314-6
   Campbell M, 2013, J MOL MED, V91, P1059, DOI 10.1007/s00109-013-1050-0
   Chan CC, 2008, OPHTHALMIC RES, V40, P124, DOI 10.1159/000119862
   Chen M, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0061381
   Chen Y, 2011, MOL VIS, V17, P3072
   Chu XK, 2013, BIOENGINEERED, V4, P130, DOI 10.4161/bioe.22949
   Chu XK, 2013, ARVO SEATTL WA
   Coleman HR, 2008, LANCET, V372, P1835, DOI 10.1016/S0140-6736(08)61759-6
   Congdon N, 2004, ARCH OPHTHALMOL-CHIC, V122, P477
   Curcio CA, 1996, INVEST OPHTH VIS SCI, V37, P1236
   Doyle SL, 2012, NAT MED, V18, P791, DOI 10.1038/nm.2717
   Dridi S, 2012, P NATL ACAD SCI USA, V109, P13781, DOI 10.1073/pnas.1206494109
   Dungan LS, 2011, CYTOKINE, V56, P126, DOI 10.1016/j.cyto.2011.07.007
   Gaffen SL, 2011, CURR OPIN IMMUNOL, V23, P613, DOI 10.1016/j.coi.2011.07.006
   Gaffen SL, 2009, NAT REV IMMUNOL, V9, P556, DOI 10.1038/nri2586
   Hecker LA, 2010, HUM MOL GENET, V19, P209, DOI 10.1093/hmg/ddp472
   Ishigame H, 2009, IMMUNITY, V30, P108, DOI 10.1016/j.immuni.2008.11.009
   Kaneko H, 2011, NATURE, V471, P325, DOI 10.1038/nature09830
   Karan G, 2005, P NATL ACAD SCI USA, V102, P4164, DOI 10.1073/pnas.0407698102
   Klettner A, 2013, INT J BIOCHEM CELL B, V45, P1457, DOI 10.1016/j.biocel.2013.04.013
   Lalor SJ, 2011, J IMMUNOL, V186, P5738, DOI 10.4049/jimmunol.1003597
   Liu BY, 2011, J TRANSL MED, V9, DOI 10.1186/1479-5876-9-111
   Luger D, 2008, J EXP MED, V205, P799, DOI 10.1084/jem.20071258
   Marneros AG, 2013, CELL REP, V4, P945, DOI 10.1016/j.celrep.2013.08.002
   Mattapallil MJ, 2012, INVEST OPHTH VIS SCI, V53, P2921, DOI 10.1167/iovs.12-9662
   Mills KHG, 2013, J LEUKOCYTE BIOL, V93, P489, DOI 10.1189/jlb.1012543
   Mori K, 2002, INVEST OPHTH VIS SCI, V43, P1994
   Pechan P, 2009, GENE THER, V16, P10, DOI 10.1038/gt.2008.115
   PENFOLD PL, 1985, GRAEF ARCH CLIN EXP, V223, P69, DOI 10.1007/BF02150948
   Popp N, 2013, J CLIN EXP OPHTHALMO, V4
   Reynolds R, 2009, INVEST OPHTH VIS SCI, V50, P5818, DOI 10.1167/iovs.09-3928
   Rosenbaum JT, 2012, NEW ENGL J MED, V367, P768, DOI 10.1056/NEJMcibr1204973
   Ross RJ, 2008, EXP EYE RES, V86, P675, DOI 10.1016/j.exer.2008.01.014
   Scholl HPN, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002593
   Shen DF, 2011, INVEST OPHTH VIS SCI, V52, P2897, DOI 10.1167/iovs.10-6114
   Simon MM, 2013, GENOME BIOL, V14, DOI 10.1186/gb-2013-14-7-r82
   Tarallo V, 2012, CELL, V149, P847, DOI 10.1016/j.cell.2012.03.036
   Tuo JS, 2007, INVEST OPHTH VIS SCI, V48, P3827, DOI 10.1167/iovs.07-0051
   Tuo JS, 2012, J NEUROINFLAMM, V9, DOI 10.1186/1742-2094-9-59
   Vincent KA, 1997, J VIROL, V71, P1897, DOI 10.1128/JVI.71.3.1897-1905.1997
   Wang Y, 2013, ARVO SEATTL WA
   Wei L, 2012, CELL REP, V2, P1151, DOI 10.1016/j.celrep.2012.10.013
   Xu LF, 2001, HUM GENE THER, V12, P563, DOI 10.1089/104303401300042500
   Ziegler RJ, 2004, MOL THER, V9, P231, DOI 10.1016/j.ymthe.2003.11.015
   Zolotukhin S, 2002, METHODS, V28, P158, DOI 10.1016/S1046-2023(02)00220-7
NR 47
TC 31
Z9 35
U1 0
U2 13
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD APR 29
PY 2014
VL 9
IS 4
AR e95900
DI 10.1371/journal.pone.0095900
PG 10
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA AG6CA
UT WOS:000335504900011
PM 24780906
OA gold, Green Submitted, Green Published
DA 2022-11-30
ER

PT J
AU Kim, MH
   Chung, YR
   Song, JH
AF Kim, Min Ho
   Chung, Yoo-Ri
   Song, Ji Hun
TI Transient accumulation of subretinal fluid after half-fluence
   photodynamic therapy in neovascular age-related macular degeneration
SO BMC OPHTHALMOLOGY
LA English
DT Article
DE Blood-retinal barrier; Photodynamic therapy; Retinal pigment epithelium
ID OCCULT CHOROIDAL NEOVASCULARIZATION; PIGMENT EPITHELIAL TEAR;
   VERTEPORFIN; COMBINATION; VASCULOPATHY; RANIBIZUMAB; MEMBRANES;
   EFFICACY; SAFETY
AB Background Photodynamic therapy (PDT) is known to occlude choroidal neovascularisation selectively, and there have been several reports on its adverse effects on the normal choroid and retinal pigment epithelium, resulting in decreased vision. Methods This retrospective interventional case series aimed to investigate the changes in visual acuity and retinal thickness in the immediate post-treatment period after half-fluence PDT, administered alone or with anti-vascular endothelial growth factor and steroids, in 29 eyes (26 patients) with neovascular age-related macular degeneration. The patients' best-corrected visual acuity (BCVA) and central foveal thickness (CFT) on optical coherence tomography images were measured 1 day, 1 week, and 1 month post-treatment. Results Compared to the pre-treatment CFT (270.38 mu m), the mean CFT was significantly increased 1 day post-treatment (387.07 mu m, P = 0.001), which then started to decrease, with a mean CFT of 269.32 mu m (P = 0.516) at 1 week, and of 240.66 mu m (P = 0.066) at 1 month post-treatment. All CFT increases were due to the accumulation of subretinal fluid (SRF), rather than the intraretinal or subretinal pigment epithelium fluid. Relative to the pre-treatment BCVA (0.59 logMAR), the mean BCVA at 1 day (0.74 logMAR, P = 0.005) and 1 week (0.75 logMAR, P = 0.002) post-treatment was significantly deteriorated; however, it recovered to 0.62 logMAR at 1 month. The patterns of change in CFT and BCVA did not differ according to treatment modality. Conclusions Half-fluence PDT resulted in accumulation of SRF in the immediate post-treatment period; this damage mostly recovered within a week, and the BCVA was restored within a month.
C1 [Kim, Min Ho] Allbarun Eye Clin, Suwon, South Korea.
   [Chung, Yoo-Ri; Song, Ji Hun] Ajou Univ, Sch Med, Dept Ophthalmol, 164 World Cup Ro, Suwon 16499, South Korea.
C3 Ajou University
RP Song, JH (通讯作者)，Ajou Univ, Sch Med, Dept Ophthalmol, 164 World Cup Ro, Suwon 16499, South Korea.
EM dreyesong@naver.com
OI Song, Ji Hun/0000-0002-2860-2340
FU National Research Foundation of Korea (NRF) - Korean government (MSIT)
   [NRF-2020R1C1C1010497]
FX This work was supported by a National Research Foundation of Korea (NRF)
   grant funded by the Korean government (MSIT) (No. NRF-2020R1C1C1010497).
CR [Anonymous], 1991, Arch Ophthalmol, V109, P1220
   Arnold J, 2001, AM J OPHTHALMOL, V131, P541
   Bandello F, 2010, OPHTHALMOLOGICA, V224, P41, DOI 10.1159/000315161
   Bressler NM, 1999, ARCH OPHTHALMOL-CHIC, V117, P1329
   Colijn JM, 2017, OPHTHALMOLOGY, V124, P1753, DOI 10.1016/j.ophtha.2017.05.035
   Fingar VH, 1999, BRIT J CANCER, V79, P1702, DOI 10.1038/sj.bjc.6690271
   Gelisken F, 2001, AM J OPHTHALMOL, V131, P518, DOI 10.1016/S0002-9394(00)00813-8
   Izumi T, 2017, BRIT J OPHTHALMOL, V101, P433, DOI 10.1136/bjophthalmol-2016-308921
   Jalil A, 2007, EYE, V21, P1541, DOI 10.1038/sj.eye.6703018
   Koh A, 2017, JAMA OPHTHALMOL, V135, P1206, DOI 10.1001/jamaophthalmol.2017.4030
   Koh A, 2012, RETINA-J RET VIT DIS, V32, P1453, DOI 10.1097/IAE.0b013e31824f91e8
   Lim LS, 2013, ASIA-PAC J OPHTHALMO, V2, P32, DOI 10.1097/APO.0b013e31827ff5bc
   Lo Giudice G, 2008, EUR J OPHTHALMOL, V18, P652, DOI 10.1177/112067210801800429
   Maruko I, 2011, AM J OPHTHALMOL, V151, P594, DOI 10.1016/j.ajo.2010.10.030
   Mennel S, 2005, AM J OPHTHALMOL, V140, P758, DOI 10.1016/j.ajo.2005.04.041
   Mennel S, 2006, GRAEF ARCH CLIN EXP, V244, P1015, DOI 10.1007/s00417-005-0237-7
   Michels S, 2003, INVEST OPHTH VIS SCI, V44, P2147, DOI 10.1167/iovs.02-0604
   Nowak-Sliwinska P, 2013, PROG RETIN EYE RES, V37, P182, DOI 10.1016/j.preteyeres.2013.09.003
   Rishi P, 2016, BRIT J OPHTHALMOL, V100, P1337, DOI 10.1136/bjophthalmol-2015-307802
   Rogers AH, 2002, AM J OPHTHALMOL, V134, P566, DOI 10.1016/S0002-9394(02)01566-0
   Rosenfeld PJ, 2007, AM J OPHTHALMOL, V144, P970, DOI 10.1016/j.ajo.2007.08.017
   Schmidt-Erfurth U, 2005, OPHTHALMOLOGY, V112, P2061, DOI 10.1016/j.ophtha.2005.09.007
   Schmidt-Erfurth U, 1999, ARCH OPHTHALMOL-CHIC, V117, P1177
   Schmidt-Erfurth U, 2002, INVEST OPHTH VIS SCI, V43, P830
   SCHMIDTERFURTH U, 1994, OPHTHALMOLOGY, V101, P1953
   Schnurrbusch UEK, 2001, BRIT J OPHTHALMOL, V85, P1086, DOI 10.1136/bjo.85.9.1086
   Shah CP, 2006, AM J OPHTHALMOL, V142, P1070, DOI 10.1016/j.ajo.2006.07.037
   Smretschnig E, 2013, RETINA-J RET VIT DIS, V33, P316, DOI 10.1097/IAE.0b013e318280769c
   Solomon SD, 2019, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD005139.pub4
   Tatar O, 2007, RETINA-J RET VIT DIS, V27, P713, DOI 10.1097/IAE.0b013e318042d3b0
   Wong CW, 2016, PROG RETIN EYE RES, V53, P107, DOI 10.1016/j.preteyeres.2016.04.002
NR 31
TC 0
Z9 0
U1 0
U2 3
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
EI 1471-2415
J9 BMC OPHTHALMOL
JI BMC Ophthalmol.
PD FEB 22
PY 2021
VL 21
IS 1
AR 98
DI 10.1186/s12886-021-01867-w
PG 9
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA QM7AH
UT WOS:000621927400002
PM 33618709
OA gold, Green Published
DA 2022-11-30
ER

PT J
AU Chua, SYL
   Warwick, A
   Peto, T
   Balaskas, K
   Moore, AT
   Reisman, C
   Desai, P
   Lotery, AJ
   Dhillon, B
   Khaw, PT
   Owen, CG
   Khawaja, AP
   Foster, PJ
   Patel, PJ
AF Chua, Sharon Y. L.
   Warwick, Alasdair
   Peto, Tunde
   Balaskas, Konstantinos
   Moore, Anthony T.
   Reisman, Charles
   Desai, Parul
   Lotery, Andrew J.
   Dhillon, Baljean
   Khaw, Peng T.
   Owen, Christopher G.
   Khawaja, Anthony P.
   Foster, Paul J.
   Patel, Praveen J.
CA UK Biobank Eye Vision Consortium
TI Association of ambient air pollution with age-related macular
   degeneration and retinal thickness in UK Biobank
SO BRITISH JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
DE epidemiology; public health; retina; macula; imaging
ID OXIDATIVE-STRESS; CARDIOVASCULAR-DISEASE; PREVALENCE; PARTICLES; BURDEN;
   HEALTH; CELLS; PM2.5
AB Aim To examine the associations of air pollution with both self-reported age-related macular degeneration (AMD), and in vivo measures of retinal sublayer thicknesses. Methods We included 115 954 UK Biobank participants aged 40-69 years old in this cross-sectional study. Ambient air pollution measures included particulate matter, nitrogen dioxide (NO2) and nitrogen oxides (NOx). Participants with self-reported ocular conditions, high refractive error (< -6 or > +6 diopters) and poor spectral-domain optical coherence tomography (SD-OCT) image were excluded. Self-reported AMD was used to identify overt disease. SD-OCT imaging derived photoreceptor sublayer thickness and retinal pigment epithelium (RPE) layer thickness were used as structural biomarkers of AMD for 52 602 participants. We examined the associations of ambient air pollution with self-reported AMD and both photoreceptor sublayers and RPE layer thicknesses. Results After adjusting for covariates, people who were exposed to higher fine ambient particulate matter with an aerodynamic diameter <2.5 mu m (PM2.5, per IQR increase) had higher odds of self-reported AMD (OR=1.08, p=0.036), thinner photoreceptor synaptic region (beta=-0.16 mu m, p=2.0 x 10(-5)), thicker photoreceptor inner segment layer (beta=0.04 mu m, p=0.001) and thinner RPE (beta=-0.13 mu m, p=0.002). Higher levels of PM2.5 absorbance and NO2 were associated with thicker photoreceptor inner and outer segment layers, and a thinner RPE layer. Higher levels of PM10 (PM with an aerodynamic diameter <10 mu m) was associated with thicker photoreceptor outer segment and thinner RPE, while higher exposure to NOx was associated with thinner photoreceptor synaptic region. Conclusion Greater exposure to PM2.5 was associated with self-reported AMD, while PM2.5, PM2.5 absorbance, PM10, NO2 and NOx were all associated with differences in retinal layer thickness.
C1 [Chua, Sharon Y. L.; Balaskas, Konstantinos; Khaw, Peng T.; Khawaja, Anthony P.; Foster, Paul J.; Patel, Praveen J.] Moorfields Eye Hosp NHS Fdn Trust, Biomed Res Ctr, Natl Inst Hlth Res, UCL Inst Ophthalmol, London, England.
   [Chua, Sharon Y. L.; Balaskas, Konstantinos; Khaw, Peng T.; Khawaja, Anthony P.; Foster, Paul J.; Patel, Praveen J.] UCL Inst Ophthalmol, 11-43 Bath St, London EC1V 9EL, England.
   [Warwick, Alasdair] UCL, UCL Inst Cardiovasc Sci, London, England.
   [Peto, Tunde] Queens Univ Belfast, Sch Med Dent & Biomed Sci, Belfast, Antrim, North Ireland.
   [Balaskas, Konstantinos] Univ Manchester, Sch Biol Sci, Manchester, Lancs, England.
   [Moore, Anthony T.] Univ Calif San Francisco, Dept Ophthalmol, San Francisco, CA USA.
   [Reisman, Charles] Topcon Healthcare Solut Res & Dev, Oakland, NJ USA.
   [Desai, Parul; Khaw, Peng T.; Khawaja, Anthony P.; Foster, Paul J.; Patel, Praveen J.] Moorfields Eye Hosp, London, England.
   [Lotery, Andrew J.] Univ Southampton, Fac Med, Clin & Expt Sci, Southampton, Hants, England.
   [Dhillon, Baljean] Univ Edinburgh, Sch Clin Sci, Ctr Clin Brain Sci, Edinburgh, Midlothian, Scotland.
   [Dhillon, Baljean] NHS Lothian Princess Alexandra Eye Pavil, Edinburgh, Midlothian, Scotland.
   [Owen, Christopher G.] St Georges Univ London, Populat Hlth Res Inst, London, England.
C3 University of London; University College London; Moorfields Eye Hospital
   NHS Foundation Trust; University of London; University College London;
   University of London; University College London; Queens University
   Belfast; University of Manchester; University of California System;
   University of California San Francisco; University of London; University
   College London; Moorfields Eye Hospital NHS Foundation Trust; University
   of Southampton; University of Edinburgh; St Georges University London
RP Foster, PJ (通讯作者)，UCL Inst Ophthalmol, 11-43 Bath St, London EC1V 9EL, England.
EM p.foster@ucl.ac.uk
RI Balaskas, Konstantinos/ABD-5979-2020; Peto, Tunde/M-2081-2013
OI Balaskas, Konstantinos/0000-0002-7690-6277; Khawaja,
   Anthony/0000-0001-6802-8585; Chua, Sharon/0000-0002-2501-0948; Owen,
   Christopher/0000-0003-1135-5977; Foster, Paul/0000-0002-4755-177X; Khaw,
   Sir Peng Tee/0000-0002-8087-2268; Peto, Tunde/0000-0001-6265-0381
FU Moorfields Eye Charity; NIHR Biomedical Research Centre at Moorfields
   Eye Hospital NHS Foundation Trust and UCL Institute of Ophthalmology;
   Alcon Research Institute; International Glaucoma Association (UK); Helen
   Hamlyn Trust; Richard Desmond Charitable Trust, via Fight for Sight,
   London; Moorfields Eye Charity Career Development Fellowship
FX The UK Biobank Eye and Vision Consortium is supported by grants from
   Moorfields Eye Charity, The NIHR Biomedical Research Centre at
   Moorfields Eye Hospital NHS Foundation Trust and UCL Institute of
   Ophthalmology, the Alcon Research Institute and the International
   Glaucoma Association (UK). SYLC, PTK, PJF and PJP received salary
   support from the NIHR BRC at Moorfields Eye Hospital. PTK is supported
   in part by the Helen Hamlyn Trust. PJF received support from the Richard
   Desmond Charitable Trust, via Fight for Sight, London. APK is supported
   by a Moorfields Eye Charity Career Development Fellowship. This research
   used data from the UK Biobank Resource, under data access request number
   2112.
CR Aung N, 2018, CIRCULATION, V138, P2175, DOI 10.1161/CIRCULATIONAHA.118.034856
   Brook RD, 2010, CIRCULATION, V121, P2331, DOI 10.1161/CIR.0b013e3181dbece1
   Brown DM, 2001, TOXICOL APPL PHARM, V175, P191, DOI 10.1006/taap.2001.9240
   Chang KH, 2019, J INVEST MED, V67, P1076, DOI 10.1136/jim-2019-001007
   Choi JK, 2011, ARCH OPHTHALMOL-CHIC, V129, P196, DOI 10.1001/archophthalmol.2010.355
   Chua SYL, 2019, INVEST OPHTH VIS SCI, V60, P4915, DOI 10.1167/iovs.19-28346
   Chua SYL, 2019, BMJ OPEN, V9, DOI 10.1136/bmjopen-2018-025077
   Cohen AJ, 2017, LANCET, V389, P1907, DOI [10.1016/S0140-6736(17)30505-6, 10.1016/s0140-6736(17)30505-6]
   Colijn JM, 2017, OPHTHALMOLOGY, V124, P1753, DOI 10.1016/j.ophtha.2017.05.035
   Cruz-Herranz A, 2016, NEUROLOGY, V86, P2303, DOI 10.1212/WNL.0000000000002774
   Cumberland PM, 2016, JAMA OPHTHALMOL, V134, P959, DOI 10.1001/jamaophthalmol.2016.1778
   Cumberland PM, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0139780
   Eeftens M, 2012, ENVIRON SCI TECHNOL, V46, P11195, DOI 10.1021/es301948k
   Ferris FL, 2013, OPHTHALMOLOGY, V120, P844, DOI 10.1016/j.ophtha.2012.10.036
   Fry A, 2017, AM J EPIDEMIOL, V186, P1026, DOI 10.1093/aje/kwx246
   Gaffin JM, 2018, J ALLERGY CLIN IMMUN, V141, P2249, DOI 10.1016/j.jaci.2017.08.028
   Hyman L, 2000, ARCH OPHTHALMOL-CHIC, V118, P351, DOI 10.1001/archopht.118.3.351
   Ibald-Mulli A, 2001, AM J PUBLIC HEALTH, V91, P571, DOI 10.2105/AJPH.91.4.571
   Icopal, NITR OX NOX POLL
   Jarrett SG, 2012, MOL ASPECTS MED, V33, P399, DOI 10.1016/j.mam.2012.03.009
   Jiang SN, 2005, INVEST OPHTH VIS SCI, V46, P1054, DOI 10.1167/iovs.04-0949
   Johnson PT, 2005, INVEST OPHTH VIS SCI, V46, P4788, DOI 10.1167/iovs.05-0767
   Khawaja AP, 2020, OPHTHALMOLOGY, V127, P62, DOI 10.1016/j.ophtha.2019.08.015
   Ko F, 2017, OPHTHALMOLOGY, V124, P105, DOI 10.1016/j.ophtha.2016.07.033
   Lelieveld J, 2015, NATURE, V525, P367, DOI 10.1038/nature15371
   Lodovici M, 2011, J TOXICOL-US, V2011, DOI 10.1155/2011/487074
   McLeod DS, 2009, INVEST OPHTH VIS SCI, V50, P4982, DOI 10.1167/iovs.09-3639
   Mitchell P, 2018, LANCET, V392, P1147, DOI 10.1016/S0140-6736(18)31550-2
   Nwanaji-Enwerem JC, 2019, JAMA OPHTHALMOL, V137, P129, DOI 10.1001/jamaophthalmol.2018.5313
   Owen CG, 2012, BRIT J OPHTHALMOL, V96, P752, DOI 10.1136/bjophthalmol-2011-301109
   Patel PJ, 2016, OPHTHALMOLOGY, V123, P829, DOI 10.1016/j.ophtha.2015.11.009
   PULIAFITO CA, 1995, OPHTHALMOLOGY, V102, P217
   REPACE JL, 1980, SCIENCE, V208, P464, DOI 10.1126/science.7367873
   Rodriguez-Padilla JA, 2007, ARCH OPHTHALMOL-CHIC, V125, P775, DOI 10.1001/archopht.125.6.775
   SARKS JP, 1988, EYE, V2, P552, DOI 10.1038/eye.1988.106
   Schuman SG, 2009, OPHTHALMOLOGY, V116, P488, DOI 10.1016/j.ophtha.2008.10.006
   Seddon JM, 2007, JAMA-J AM MED ASSOC, V297, P1793, DOI 10.1001/jama.297.16.1793
   Tomany SC, 2004, OPHTHALMOLOGY, V111, P1280, DOI 10.1016/j.ophtha.2003.11.010
   Vujosevic S, 2013, J DIABETES RES, V2013, DOI 10.1155/2013/905058
   Wang W, 2019, ACTA OPHTHALMOL, V97, pE349, DOI 10.1111/aos.14044
   Wilson JD, 2005, BIOPHYS J, V88, P2929, DOI 10.1529/biophysj.104.054528
   Wilson WE, 1997, J AIR WASTE MANAGE, V47, P1238, DOI 10.1080/10473289.1997.10464074
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
   World Health Organization, AIR QUAL GUID GLOB U
   Yang Q, 2010, OPT EXPRESS, V18, P21293, DOI 10.1364/OE.18.021293
NR 45
TC 17
Z9 17
U1 7
U2 10
PU BMJ PUBLISHING GROUP
PI LONDON
PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND
SN 0007-1161
EI 1468-2079
J9 BRIT J OPHTHALMOL
JI Br. J. Ophthalmol.
PD MAY
PY 2022
VL 106
IS 5
BP 705
EP 711
DI 10.1136/bjophthalmol-2020-316218
EA JAN 2021
PG 7
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 0V8MH
UT WOS:000727744500001
PM 33495162
OA Green Submitted, Green Accepted
DA 2022-11-30
ER

PT J
AU Binns, AM
   Taylor, DJ
   Edwards, LA
   Crabb, DP
AF Binns, Alison M.
   Taylor, Deanna J.
   Edwards, Laura A.
   Crabb, David P.
TI Determining Optimal Test Parameters for Assessing Dark Adaptation in
   People With Intermediate Age-Related Macular Degeneration
SO INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE
LA English
DT Article
DE dark adaptation; age-related macular degeneration; rod intercept time
ID QUALITY-OF-LIFE; RETICULAR PSEUDODRUSEN; FLASH-PHOTOLYSIS; VISUAL
   FUNCTION; OLDER-ADULTS; ROD; MACULOPATHY; POPULATION; PREVALENCE;
   CLASSIFICATION
AB PURPOSE. The primary aim was to determine optimal test conditions for evaluating dark adaptation in intermediate age-related macular degeneration (iAMD) in order to minimize test time while maintaining diagnostic sensitivity.
   METHODS. People with AMD and age-similar controls were recruited (aged > 55 years). Rod intercept time (RIT) was assessed after a 76%, 70%, and 65% rhodopsin bleach at 5 degrees eccentricity and 76% and 70% bleach at 12 degrees. Test order was randomized and a 30-minute washout period added between tests.
   RESULTS. were compared between control and iAMD groups and receiver operating characteristics (ROC) curves were constructed. RESULTS. A total of 26 participants with variable grades of macular health attended for two visits. There was a statistically significant difference in average RIT between the control and iAMD groups at 5 degrees (median, IQR controls = 5.8 minutes, 3.8-7.5; iAMD = 20.6 minutes, 11.1-30.0; Mann-Whitney, P = 0.01) and at 12 degrees (mean, controls: 4.54 minutes +/- 2.12 SD, iAMD = 7.72 minutes +/- 3.37 SD; independent samples t-test, P = 0.03) following a 76% bleach. Area under the ROC curves was 0.83 (confidence interval [CI]: 0.64-1.0) and 0.79 (CI: 0.59-0.99) for these two test conditions, respectively. Five participants (45%) in the iAMD group had RITs > 20 minutes for 76% bleach at 5 degrees, but none for any other test condition.
   CONCLUSIONS. Nearly half of the participants with iAMD produced unacceptably long recovery times (> 20 minutes) using a 76% bleach at 5 degrees eccentricity. The 76% bleach at 12 degrees provided almost equivalent separation between AMD and controls but recovery was achieved within 20 minutes.
C1 [Binns, Alison M.; Taylor, Deanna J.; Edwards, Laura A.; Crabb, David P.] City Univ London, Sch Optometry & Visual Sci, London, England.
C3 City University London
RP Binns, AM (通讯作者)，City Univ London, Sch Hlth Sci, Div Optometry & Visual Sci, London EC1V 0HB, England.
EM Alison.binns.1@city.ac.uk
RI Edwards, Laura/AAO-7792-2020
OI Crabb, David/0000-0001-8754-3902; Taylor, Deanna/0000-0001-8261-5225
FU Innovative Medicines Initiative 2 Joint Undertaking [116076]; European
   Union's Horizon 2020 research and innovation programme; EFPIA; Novartis
   Pharma AG; Bayer Aktiengesellschaft; Carl Zeiss Meditec AG; F.
   Hoffman-LA Roche Ltd.
FX Supported by the Innovative Medicines Initiative 2 Joint Undertaking
   under grant agreement No116076. This Joint Undertaking receives support
   from the European Union's Horizon 2020 research and innovation programme
   and EFPIA and Novartis Pharma AG, Bayer Aktiengesellschaft, Carl Zeiss
   Meditec AG, F. Hoffman-LA Roche Ltd. The AdaptDx adaptometer was on loan
   from Maculogix for the duration of the study, and has since been donated
   to City, University of London. Maculogix had no role in the design or
   conduct of this research, or in the drafting of this manuscript.
CR Augood CA, 2006, ARCH OPHTHALMOL-CHIC, V124, P529, DOI 10.1001/archopht.124.4.529
   Buitendijk GHS, 2016, INVEST OPHTH VIS SCI, V57, P5593, DOI 10.1167/iovs.15-18816
   Buyse M, 2007, EJC SUPPL, V5, P89, DOI 10.1016/S1359-6349(07)70028-9
   Casten RJ, 2013, CURR OPIN OPHTHALMOL, V24, P239, DOI 10.1097/ICU.0b013e32835f8e55
   Chan H, 2016, INVEST OPHTH VIS SCI, V57, P3058, DOI 10.1167/iovs.16-19487
   CHYLACK LT, 1993, ARCH OPHTHALMOL-CHIC, V111, P831, DOI 10.1001/archopht.1993.01090060119035
   Cimarolli VR, 2017, CLIN REHABIL, V31, P115, DOI 10.1177/0269215515624479
   Cruess A, 2007, CAN J OPHTHALMOL, V42, P836, DOI 10.3129/i07-153
   Curcio CA, 1996, INVEST OPHTH VIS SCI, V37, P1236
   Dawson SR, 2014, BMC OPHTHALMOL, V14, DOI 10.1186/1471-2415-14-78
   Dimitrov PN, 2008, INVEST OPHTH VIS SCI, V49, P55, DOI 10.1167/iovs.06-1048
   Ferris FL, 2013, OPHTHALMOLOGY, V120, P844, DOI 10.1016/j.ophtha.2012.10.036
   Flamendorf J, 2015, OPHTHALMOLOGY, V122, P2053, DOI 10.1016/j.ophtha.2015.06.023
   Fraser RG, 2016, INVEST OPHTH VIS SCI, V57, P5436, DOI 10.1167/iovs.16-19295
   Freidlin B, 2010, J NATL CANCER I, V102, P152, DOI 10.1093/jnci/djp477
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P532
   Gaffney AJ, 2011, OPTOMETRY VISION SCI, V88, P1080, DOI 10.1097/OPX.0b013e3182223697
   Gopinath B, 2014, MATURITAS, V77, P263, DOI 10.1016/j.maturitas.2013.12.001
   Hassell JB, 2006, BRIT J OPHTHALMOL, V90, P593, DOI 10.1136/bjo.2005.086595
   HUDSON C, 1994, INVEST OPHTH VIS SCI, V35, P268
   Jackson GR, 2014, OPTOMETRY VISION SCI, V91, P925, DOI 10.1097/OPX.0000000000000247
   Jackson GR, 2014, INVEST OPHTH VIS SCI, V55, DOI 10.1167/iovs.13-13745
   Jackson Gregory R, 2008, J Ocul Biol Dis Infor, V1, P7, DOI 10.1007/s12177-008-9002-6
   Jonas JB, 2014, LANCET GLOB HEALTH, V2, pE65, DOI 10.1016/S2214-109X(13)70163-3
   Klein R, 2011, ARCH OPHTHALMOL-CHIC, V129, P75, DOI 10.1001/archophthalmol.2010.318
   Lains I, 2017, OPHTHALMOLOGY, V124, P1340, DOI 10.1016/j.ophtha.2017.03.061
   Lengyel I, 2015, OPHTHALMOLOGY, V122, P1340, DOI 10.1016/j.ophtha.2015.03.005
   Mathew RS, 2011, OPHTHAL PHYSL OPT, V31, P375, DOI 10.1111/j.1475-1313.2011.00848.x
   Munch IC, 2016, BMC OPHTHALMOL, V16, DOI 10.1186/s12886-016-0273-6
   Nguyen CT, 2018, INVEST OPHTH VIS SCI, V59, DOI 10.1167/iovs.17-23084
   Owsley C, 2000, INVEST OPHTH VIS SCI, V41, P267
   Owsley C, 2001, OPHTHALMOLOGY, V108, P1196, DOI 10.1016/S0161-6420(01)00580-2
   Owsley C, 2017, TRANSL VIS SCI TECHN, V6, DOI 10.1167/tvst.6.3.15
   Owsley C, 2016, CURR EYE RES, V41, P266, DOI 10.3109/02713683.2015.1011282
   Owsley C, 2016, OPHTHALMOLOGY, V123, P344, DOI 10.1016/j.ophtha.2015.09.041
   Owsley C, 2014, INVEST OPHTH VIS SCI, V55, P4776, DOI 10.1167/iovs.14-14502
   PUGH EN, 1975, J PHYSIOL-LONDON, V248, P393, DOI 10.1113/jphysiol.1975.sp010981
   PUGH EN, 1975, J PHYSIOL-LONDON, V248, P413, DOI 10.1113/jphysiol.1975.sp010982
   Sevilla MB, 2016, AM J OPHTHALMOL, V165, P65, DOI 10.1016/j.ajo.2016.02.021
   Taylor DJ, 2018, OPHTHAL PHYSL OPT, V38, P98, DOI 10.1111/opo.12419
   Taylor DJ, 2016, BMJ OPEN, V6, DOI 10.1136/bmjopen-2016-011504
   van Landingham SW, 2014, BMC OPHTHALMOL, V14, DOI 10.1186/1471-2415-14-10
   Walter P, 1999, GRAEF ARCH CLIN EXP, V237, P962, DOI 10.1007/s004170050331
   Wood JM, 2011, INVEST OPHTH VIS SCI, V52, P5088, DOI 10.1167/iovs.10-6644
   Yazdanie M, 2017, OPHTHALMOLOGY, V124, P1332, DOI 10.1016/j.ophtha.2017.05.005
NR 45
TC 8
Z9 8
U1 0
U2 0
PU ASSOC RESEARCH VISION OPHTHALMOLOGY INC
PI ROCKVILLE
PA 12300 TWINBROOK PARKWAY, ROCKVILLE, MD 20852-1606 USA
SN 0146-0404
EI 1552-5783
J9 INVEST OPHTH VIS SCI
JI Invest. Ophthalmol. Vis. Sci.
PD MAR
PY 2018
VL 59
IS 4
SI SI
BP AMD114
EP AMD121
DI 10.1167/iovs.18-24211
PG 8
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA GR8YP
UT WOS:000443024700001
PM 30105357
OA gold, Green Accepted
DA 2022-11-30
ER

PT J
AU Schmitz-Valckenberg, S
   Gobel, AP
   Saur, SC
   Steinberg, JS
   Thiele, S
   Wojek, C
   Russmann, C
   Holz, FG
AF Schmitz-Valckenberg, Steffen
   Gobel, Arno P.
   Saur, Stefan C.
   Steinberg, Julia S.
   Thiele, Sarah
   Wojek, Christian
   Russmann, Christoph
   Holz, Frank G.
CA Modiamd-Study Grp
TI Automated Retinal Image Analysis for Evaluation of Focal Hyperpigmentary
   Changes in Intermediate Age-Related Macular Degeneration
SO TRANSLATIONAL VISION SCIENCE & TECHNOLOGY
LA English
DT Article
DE age-related macular degeneration; focal hyperpigmentary changes; fundus
   autofluorescence; drusen; fundus camera
ID GEOGRAPHIC ATROPHY; DRUSEN QUANTIFICATION; RETINITIS-PIGMENTOSA; SD-OCT;
   PROGRESSION; CLASSIFICATION; IDENTIFICATION; MACULOPATHY; MICROGLIA;
   EYES
AB Purpose: To develop and evaluate a software tool for automated detection of focal hyperpigmentary changes (FHC) in eyes with intermediate age-related macular degeneration (AMD).
   Methods: Color fundus (CFP) and autofluorescence (AF) photographs of 33 eyes with FHC of 28 AMD patients (mean age 71 years) from the prospective longitudinal natural history MODIAMD-study were included. Fully automated to semiautomated registration of baseline to corresponding follow-up images was evaluated. Following the manual circumscription of individual FHC (four different readings by two readers), a machine-learning algorithm was evaluated for automatic FHC detection.
   Results: The overall pixel distance error for the semiautomated (CFP follow-up to CFP baseline: median 5.7; CFP to AF images from the same visit: median 6.5) was larger as compared for the automated image registration (4.5 and 5.7; P<0.001 and P<0.001). The total number of manually circumscribed objects and the corresponding total size varied between 637 to 1163 and 520,848 pixels to 924,860 pixels, respectively. Performance of the learning algorithms showed a sensitivity of 96% at a specificity level of 98% using information from both CFP and AF images and defining small areas of FHC ("speckle appearance'') as "neutral.''
   Conclusions: FHC as a high-risk feature for progression of AMD to late stages can be automatically assessed at different time points with similar sensitivity and specificity as compared to manual outlining. Upon further development of the research prototype, this approach may be useful both in natural history and interventional large-scale studies for a more refined classification and risk assessment of eyes with intermediate AMD.
   Translational Relevance: Automated FHC detection opens the door for a more refined and detailed classification and risk assessment of eyes with intermediate AMD in both natural history and future interventional studies.
C1 [Schmitz-Valckenberg, Steffen; Gobel, Arno P.; Steinberg, Julia S.; Thiele, Sarah; Holz, Frank G.] Univ Bonn, Dept Ophthalmol, Ernst Abbe Str 2, D-53127 Bonn, Germany.
   [Saur, Stefan C.; Wojek, Christian] Carl Zeiss, Oberkochen, Germany.
   [Russmann, Christoph] Carl Zeiss Meditec AG, Jena, Germany.
C3 University of Bonn; Carl Zeiss AG; Carl Zeiss AG
RP Schmitz-Valckenberg, S (通讯作者)，Univ Bonn, Dept Ophthalmol, Ernst Abbe Str 2, D-53127 Bonn, Germany.
EM schmitz-valckenberg@ukb.uni-bonn.de
RI Russmann, Christoph/GWC-7062-2022
FU German Ministry of Education and Research (BMBF) [FKZ 13N10349]
FX Supported by the German Ministry of Education and Research (BMBF), FKZ
   13N10349.
CR Abramoff Michael D, 2010, IEEE Rev Biomed Eng, V3, P169, DOI 10.1109/RBME.2010.2084567
   Age-Related Eye Dis Study Res Grp, 2001, AM J OPHTHALMOL, V132, P668
   Anderson DH, 2002, AM J OPHTHALMOL, V134, P411, DOI 10.1016/S0002-9394(02)01624-0
   Chen Q, 2013, MED IMAGE ANAL, V17, P1058, DOI 10.1016/j.media.2013.06.003
   Christenbury JG, 2013, OPHTHALMOLOGY, V120, P1038, DOI 10.1016/j.ophtha.2012.10.018
   Ferris FL, 2005, ARCH OPHTHALMOL-CHIC, V123, P1570
   Ferris FL, 2013, OPHTHALMOLOGY, V120, P844, DOI 10.1016/j.ophtha.2012.10.036
   GASS JDM, 1993, OPHTHALMOLOGY, V100, P1536
   Gupta N, 2003, EXP EYE RES, V76, P463, DOI 10.1016/S0014-4835(02)00332-9
   Heussen FM, 2012, RETINOLOGISCHE GESEL, V25, P15
   Ho J, 2011, OPHTHALMOLOGY, V118, P687, DOI 10.1016/j.ophtha.2010.08.010
   Jain N, 2010, INVEST OPHTH VIS SCI, V51, P4875, DOI 10.1167/iovs.09-4962
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1417, DOI 10.1001/archopht.119.10.1417
   Klein ML, 2008, OPHTHALMOLOGY, V115, P1026, DOI 10.1016/j.ophtha.2007.08.030
   KLEIN R, 1991, OPHTHALMOLOGY, V98, P1128
   Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557
   Klein R, 2007, OPHTHALMOLOGY, V114, P253, DOI 10.1016/j.ophtha.2006.10.040
   Leuschen JN, 2013, OPHTHALMOLOGY, V120, P140, DOI 10.1016/j.ophtha.2012.07.004
   LI ZY, 1995, OPHTHALMOLOGY, V102, P805, DOI 10.1016/S0161-6420(95)30953-0
   Lim LS, 2012, LANCET, V379, P1728, DOI 10.1016/S0140-6736(12)60282-7
   Ma WX, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0007945
   Mauschitz MM, 2012, INVEST OPHTH VIS SCI, V53, P4932, DOI 10.1167/iovs.12-9711
   Mora AD, 2011, BIOMED ENG ONLINE, V10, DOI 10.1186/1475-925X-10-59
   Ouyang YL, 2013, OPHTHALMOLOGY, V120, P2656, DOI 10.1016/j.ophtha.2013.05.029
   Saksens NTM, 2014, PROG RETIN EYE RES, V39, P23, DOI 10.1016/j.preteyeres.2013.11.001
   Schmitz-Valckenberg S, 2010, OPHTHALMOLOGE, V107, P1016, DOI 10.1007/s00347-010-2160-5
   Schmitz-Valckenberg S, 2011, INVEST OPHTH VIS SCI, V52, P7640, DOI 10.1167/iovs.11-7457
   Schuman SG, 2009, OPHTHALMOLOGY, V116, P488, DOI 10.1016/j.ophtha.2008.10.006
   Sivagnanavel V, 2005, BRIT J OPHTHALMOL, V89, P554, DOI 10.1136/bjo.2004.046813
   Steinberg JS, 2015, RETINA
   Steinberg JS, 2015, BRIT J OPHTHALMOL, V99, P1289, DOI 10.1136/bjophthalmol-2014-306535
   van Grinsven MJJP, 2015, INVEST OPHTH VIS SCI, V56, P633, DOI 10.1167/iovs.14-15019
   van Grinsven MJJP, 2013, INVEST OPHTH VIS SCI, V54, P3019, DOI 10.1167/iovs.12-11449
   Wang JJ, 2007, OPHTHALMOLOGY, V114, P92, DOI 10.1016/j.ophtha.2006.07.017
   Wu ZC, 2014, OPHTHALMOLOGY, V121, P2415, DOI 10.1016/j.ophtha.2014.06.034
NR 35
TC 11
Z9 11
U1 0
U2 4
PU ASSOC RESEARCH VISION OPHTHALMOLOGY INC
PI ROCKVILLE
PA 12300 TWINBROOK PARKWAY, ROCKVILLE, MD 20852-1606 USA
SN 2164-2591
J9 TRANSL VIS SCI TECHN
JI Transl. Vis. Sci. Technol.
PD MAR
PY 2016
VL 5
IS 2
AR 3
DI 10.1167/tvst.5.2.3
PG 9
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA ED2JD
UT WOS:000388669300003
PM 26966639
OA Green Published, gold, Green Submitted
DA 2022-11-30
ER

PT J
AU Matamoros, E
   Maurel, F
   Leon, N
   Solomiac, A
   Bardoulat, I
   Joubert, M
   Hermans, M
   Moser, E
   Le Picard, S
   Souied, EH
   Leveziel, N
AF Matamoros, Emilie
   Maurel, Frederique
   Leon, Nadia
   Solomiac, Agnes
   Bardoulat, Isabelle
   Joubert, Marc
   Hermans, Martine
   Moser, Eric
   Le Picard, Serge
   Souied, Eric H.
   Leveziel, Nicolas
TI Quality of Life in Patients Suffering from Active Exudative Age-Related
   Macular Degeneration: The EQUADE Study
SO OPHTHALMOLOGICA
LA English
DT Article
DE Quality of Life; Age-related macular degeneration; Ranibizumab;
   Anti-vascular endothelial growth factor
ID VISION-RELATED FUNCTION; VISUAL-ACUITY; RANIBIZUMAB; EYE; BLINDNESS;
   THERAPY; BURDEN; FRANCE
AB Purpose: Age-related macular degeneration (AMD) is the main cause of visual loss in the elderly population. With the use of anti-vascular endothelial growth factor, the visual outcomes of exudative AMD patients have been improved. This study was aimed at assessing the quality of life (QoL) of exudative AMD patients treated with ranibizumab and at determining its drivers in a real-life setting. Methods: We performed a national, cross-sectional, observational survey based on questionnaires sent to members of French associations relative to AMD between December 2012 and March 2013. Patients suffering from exudative AMD with at least one intravitreal injection of ranibizumab within the last 6 months were included. Demographics, AMD characteristics, visual acuity (VA) and past and ongoing treatments were collected. The 25-item National Eye Institute Visual Function Questionnaire (NEI-VFQ-25) was self-administered. A multivariate model was used to identify QoL drivers. Results: 416 questionnaires fulfilled the complete criteria for both QoL and cost analyses. The mean age of exudative AMD patients was 78.0 years and bilateral involvement was reported in 60.4%. The overall mean QoL score was 53.4. Mental health, driving and role difficulties were the most widely affected domains. After bivariate analyses, long-term illness status, worse VA and higher number of unpaid aids were associated with worse QoL, with odds ratios of 2.4, 5.2 and 11.6, respectively. The mean cost per year and per patient was 1,741 EUR. The main components of costs were aids and services and the purchase of visual equipment. Conclusions: The main predictors of QoL in exudative AMD patients treated with ranibizumab are VA outcomes, home healthcare and social services provided to the patients. (C) 2015 S. Karger AG, Basel
C1 [Matamoros, Emilie; Leveziel, Nicolas] Univ Hosp Poitiers, Dept Ophthalmol, FR-86000 Poitiers, France.
   [Leveziel, Nicolas] Univ Poitiers, Poitiers, France.
   [Maurel, Frederique; Leon, Nadia; Solomiac, Agnes; Bardoulat, Isabelle] IMS Hlth, Paris, France.
   [Joubert, Marc] Assoc DMLA, Paris, France.
   [Hermans, Martine; Moser, Eric; Le Picard, Serge] Retina France, Colomiers, France.
   [Souied, Eric H.] Creteil Eye Univ, Creteil, France.
C3 CHU Poitiers; Universite de Poitiers; Universite de Poitiers; Universite
   Paris-Est-Creteil-Val-de-Marne (UPEC)
RP Leveziel, N (通讯作者)，Univ Hosp Poitiers, Dept Ophthalmol, 2 Rue Mil, FR-86000 Poitiers, France.
EM nicolas.leveziel@chu-poitiers.fr
OI Nicolas, Leveziel/0000-0001-8533-9457
CR Ambati J, 2003, SURV OPHTHALMOL, V48, P257, DOI 10.1016/S0039-6257(03)00030-4
   Bandello F, 2008, DRUG AGING, V25, P255, DOI 10.2165/00002512-200825030-00007
   Berdeaux GH, 2005, AM J OPHTHALMOL, V139, P271, DOI 10.1016/j.ajo.2004.09.028
   Bressler NM, 2009, ARCH OPHTHALMOL-CHIC, V127, P13, DOI 10.1001/archophthalmol.2008.562
   Campbell JP, 2012, ARCH OPHTHALMOL-CHIC, V130, P794, DOI 10.1001/archophthalmol.2011.2480
   Chang TS, 2007, ARCH OPHTHALMOL-CHIC, V125, P1460, DOI 10.1001/archopht.125.11.1460
   Claessen H, 2012, EUR J EPIDEMIOL, V27, P519, DOI 10.1007/s10654-012-9705-7
   Cohen SY, 2013, RETINA-J RET VIT DIS, V33, P474, DOI 10.1097/IAE.0b013e31827b6324
   Cohen SY, 2009, AM J OPHTHALMOL, V148, P409, DOI 10.1016/j.ajo.2009.04.001
   Cohen SY, 2011, GRAEF ARCH CLIN EXP, V249, P521, DOI 10.1007/s00417-010-1553-0
   Cruess AF, 2008, PHARMACOECONOMICS, V26, P57, DOI 10.2165/00019053-200826010-00006
   Heier JS, 2012, OPHTHALMOLOGY, V119, P2537, DOI 10.1016/j.ophtha.2012.09.006
   Leys A, 2008, EYE, V22, P792, DOI 10.1038/sj.eye.6702900
   Mangione CM, 2001, ARCH OPHTHALMOL-CHIC, V119, P1050, DOI 10.1001/archopht.119.7.1050
   Martin DF, 2011, NEW ENGL J MED, V364, P1897, DOI 10.1056/NEJMoa1102673
   Oubraham H, 2011, RETINA-J RET VIT DIS, V31, P26, DOI 10.1097/IAE.0b013e3181de5609
   Querques G, 2010, BRIT J OPHTHALMOL, V94, P292, DOI 10.1136/bjo.2009.170670
   Revicki DA, 2010, INVEST OPHTH VIS SCI, V51, P712, DOI 10.1167/iovs.09-3766
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Sahel JA, 2007, ARCH OPHTHALMOL-CHIC, V125, P945, DOI 10.1001/archopht.125.7.945
   Soubrane G, 2007, ARCH OPHTHALMOL-CHIC, V125, P1249, DOI 10.1001/archopht.125.9.1249
   Velez-Montoya R, 2014, RETINA-J RET VIT DIS, V34, P423, DOI 10.1097/IAE.0000000000000036
   Verma Lalit, 2000, Indian Journal of Ophthalmology, V48, P263
NR 23
TC 21
Z9 25
U1 0
U2 5
PU KARGER
PI BASEL
PA ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND
SN 0030-3755
EI 1423-0267
J9 OPHTHALMOLOGICA
JI Ophthalmologica
PY 2015
VL 234
IS 3
BP 151
EP 159
DI 10.1159/000433448
PG 9
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA CU3NV
UT WOS:000363433000005
PM 26337381
OA hybrid
DA 2022-11-30
ER

PT J
AU Schmier, JK
   Halpern, MT
   Covert, D
AF Schmier, JK
   Halpern, MT
   Covert, D
TI Validation of the Daily Living Tasks Dependent on Vision (DLTV)
   questionnaire in a US population with age-related macular degeneration
SO OPHTHALMIC EPIDEMIOLOGY
LA English
DT Article
DE activities of daily living; DLTV questionnaire; questionnaire
   validation; macular degeneration; quality of life; vision impairment;
   visual acuity; low vision aids
ID NURSING-HOME PLACEMENT; QUALITY-OF-LIFE; VISUAL-ACUITY; HEALTH;
   DISABILITY
AB Purpose: The Daily Living Tasks Dependent on Vision questionnaire (DLTV) has been used to assess functional impairment among patients with age-related macular degeneration (AMD). This study evaluated the psychometric properties of the DLTV using patient-reported rates of use of services and devices in an outpatient population. Methods: The DLTV was included in a survey mailed to members of an AMD advocacy organization. Included in the survey were questions about demographic and clinical characteristics as well as questions about use of low vision aids and care-giving. Respondents provided informed consent. Data were analyzed in SAS. Results: Four respondents of 803 did not complete the DLTV; missing data were uncommon. Most (56%) respondents were male; the mean age was 73 years. Internal consistency reliability of the DLTV was 0.9699. Construct validity was demonstrated with moderate to high correlations between the DLTV and use of services and devices. The DLTV demonstrated discriminant validity and could distinguish between respondents with different levels of impairment, i.e., those who reported regular care-giving compared to those without regular care-giving. Conclusions: In this outpatient population, the DLTV demonstrated reliability and validity. This analysis complements existing research and supports the use of the DLTV in AMD patients.
C1 Exponent Inc, Alexandria, VA 22314 USA.
   Alcon Res Ltd, Hlth Econ, Ft Worth, TX USA.
C3 Exponent; Novartis; Alcon
RP Schmier, JK (通讯作者)，Exponent Inc, 1800 Diagonal Rd,Suite 300, Alexandria, VA 22314 USA.
EM jschmier@exponent.com
RI Schmier, Jordana/I-2994-2019
OI Schmier, Jordana/0000-0002-4662-8800
CR Aditya BS, 2003, CLIN REHABIL, V17, P108, DOI 10.1191/0269215503cr567oa
   Booth-Jones AD, 1998, AM IND HYG ASSOC J, V59, P20, DOI 10.1202/0002-8894(1998)059<0020:ROQIMM>2.0.CO;2
   Brennan M, 2000, GERONTOLOGIST, V40, P327, DOI 10.1093/geront/40.3.327
   Bressler NM, 2003, ARCH OPHTHALMOL-CHIC, V121, P1621
   Brody BL, 2001, OPHTHALMOLOGY, V108, P1893, DOI 10.1016/S0161-6420(01)00754-0
   Childs AL, 2004, AM J OPHTHALMOL, V137, P373, DOI 10.1016/S0002-9394(03)00911-5
   Cronbach LJ, 1951, PSYCHOMETRIKA, V16, P297
   Hart PM, 2005, BRIT J OPHTHALMOL, V89, P1127, DOI 10.1136/bjo.2004.059683
   Hart PM, 1999, BRIT J OPHTHALMOL, V83, P1115, DOI 10.1136/bjo.83.10.1115
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1417, DOI 10.1001/archopht.119.10.1417
   Mangione CM, 1999, AM J OPHTHALMOL, V128, P45, DOI 10.1016/S0002-9394(99)00169-5
   McClure ME, 2000, BRIT J OPHTHALMOL, V84, P244, DOI 10.1136/bjo.84.3.244
   Mejico LJ, 2004, AM J OPHTHALMOL, V137, P908, DOI 10.1016/j.ajo.2003.12.038
   Miskala PH, 2004, OPHTHALMOLOGY, V111, P1981, DOI 10.1016/j.ophtha.2004.07.022
   Nunnally J.C, 1978, PSYCHOMETRIC THEORY
   Ormel J, 1997, PSYCHOL MED, V27, P1065, DOI 10.1017/S0033291797005321
   SCHMIER JK, 2004, INT SOC PHARM OUTC R
   Stevenson MR, 2005, BRIT J OPHTHALMOL, V89, P1045, DOI 10.1136/bjo.2003.030445
   Stevenson MR, 2004, BRIT J OPHTHALMOL, V88, P1125, DOI 10.1136/bjo.2003.032383
   Wang JJ, 2003, OPHTHALMIC EPIDEMIOL, V10, P3, DOI 10.1076/opep.10.1.3.13773
NR 20
TC 9
Z9 10
U1 0
U2 3
PU TAYLOR & FRANCIS INC
PI PHILADELPHIA
PA 530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA
SN 0928-6586
EI 1744-5086
J9 OPHTHAL EPIDEMIOL
JI Ophthalmic Epidemiol.
PD APR
PY 2006
VL 13
IS 2
BP 137
EP 143
DI 10.1080/09286580600573049
PG 7
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 035RV
UT WOS:000237020300008
PM 16581618
DA 2022-11-30
ER

PT J
AU Geerlings, MJ
   Volokhina, EB
   de Jong, EK
   van de Kar, N
   Pauper, M
   Hoyng, CB
   van den Heuvel, LP
   den Hollander, AI
AF Geerlings, M. J.
   Volokhina, E. B.
   de Jong, E. K.
   van de Kar, N.
   Pauper, M.
   Hoyng, C. B.
   van den Heuvel, L. P.
   den Hollander, A. I.
TI Genotype-phenotype correlations of low-frequency variants in the
   complement system in renal disease and age-related macular degeneration
SO CLINICAL GENETICS
LA English
DT Article
DE age-related macular degeneration; alternative pathway; atypical
   hemolytic uremic syndrome; C3 glomerulopathy; complement system
ID HEMOLYTIC-UREMIC SYNDROME; FACTOR-H MUTATIONS; FACTOR-I; C3
   GLOMERULOPATHY; STRUCTURAL BASIS; RARE VARIANTS; BINDING-SITES;
   HIGH-RISK; GENE; RECOGNITION
AB Genetic alterations in the complement system have been linked to a variety of diseases, including atypical hemolytic uremic syndrome (aHUS), C3 glomerulopathy (C3G), and age-related macular degeneration (AMD). We performed sequence analysis of the complement genes complement factor H (CFH), complement factor I (CFI), and complement C3 (C3) in 866 aHUS/C3G and 697 AMD patients. In total, we identified 505 low-frequency alleles, representing 121 unique variants, of which 51 are novel. CFH contained the largest number of unique low-frequency variants (n=64; 53%), followed by C3 (n=32; 26%) and CFI (n=25; 21%). A substantial number of variants were found in both patients groups (n=48; 40%), while 41 (34%) variants were found only in aHUS/C3G and 32 (26%) variants were AMD specific. Genotype-phenotype correlations between the disease groups identified a higher frequency of protein altering alleles in short consensus repeat 20 (SCR20) of factor H (FH), and in the serine protease domain of factor I (FI) in aHUS/C3G patients. In AMD, a higher frequency of protein-altering alleles was observed in SCR3, SCR5, and SCR7 of FH, the SRCR domain of FI, and in the MG3 domain of C3. In conclusion, we observed a substantial overlap of variants between aHUS/C3G and AMD; however, there is a distinct clustering of variants within specific domains.
C1 [Geerlings, M. J.; de Jong, E. K.; Pauper, M.; Hoyng, C. B.; den Hollander, A. I.] Radboud Univ Nijmegen, Med Ctr, Donders Inst Brain Cognit & Behav, Dept Ophthalmol, Nijmegen, Netherlands.
   [Volokhina, E. B.; van de Kar, N.; van den Heuvel, L. P.] Radboud Univ Nijmegen, Radboud Inst Mol Life Sci, Amalia Childrens Hosp, Med Ctr,Dept Pediat Nephrol, Nijmegen, Netherlands.
   [Volokhina, E. B.; van den Heuvel, L. P.] Radboud Univ Nijmegen, Med Ctr, Dept Lab Med, Nijmegen, Netherlands.
   [van den Heuvel, L. P.] Univ Hosp Leuven, Dept Growth & Regenerat, Dept Pediat, Leuven, Belgium.
   [den Hollander, A. I.] Radboud Univ Nijmegen, Med Ctr, Donders Inst Brain Cognit & Behav, Dept Human Genet, Nijmegen, Netherlands.
C3 Radboud University Nijmegen; Radboud University Nijmegen; Radboud
   University Nijmegen; KU Leuven; University Hospital Leuven; Radboud
   University Nijmegen
RP den Hollander, AI (通讯作者)，Radboud Univ Nijmegen, Med Ctr, Dept Ophthalmol, POB 9101, NL-6500 HB Nijmegen, Netherlands.
EM anneke.denhollander@radboudumc.nl
RI Volokhina, Elena/L-4725-2015; Geerlings, Maartje/P-3338-2019; Pauper,
   Marc/AGZ-0438-2022; Hollander, Anneke den/N-4911-2014
OI Volokhina, Elena/0000-0002-4294-8460; Geerlings,
   Maartje/0000-0003-1164-3573; Pauper, Marc/0000-0001-6274-9891; 
FU European Research Council under the European Union [310644]; Dutch
   Kidney Foundation [CP 14.27, 13OI116, KFB 11.007, IP 10.22]
FX The research leading to these results has received funding from the
   European Research Council under the European Union's Seventh Framework
   Programme (FP/2007-2013)/ERC Grant Agreement no. 310644 (MACULA). This
   study received funding from the Dutch Kidney Foundation (CP 14.27 COMBAT
   consortium, 13OI116, KFB 11.007, IP 10.22)
CR Berman HM, 2000, NUCLEIC ACIDS RES, V28, P235, DOI 10.1093/nar/28.1.235
   Caprioli J, 2003, HUM MOL GENET, V12, P3385, DOI 10.1093/hmg/ddg363
   Caprioli J, 2006, BLOOD, V108, P1267, DOI 10.1182/blood-2005-10-007252
   Clark SJ, 2015, J CLIN MED, V4, P18, DOI 10.3390/jcm4010018
   Clark SJ, 2014, J IMMUNOL, V193, P4962, DOI 10.4049/jimmunol.1401613
   Clark SJ, 2013, J IMMUNOL, V190, P2049, DOI 10.4049/jimmunol.1201751
   Ferreira VP, 2009, J IMMUNOL, V182, P7009, DOI 10.4049/jimmunol.0804031
   Forneris F, 2016, EMBO J, V35, P1133, DOI 10.15252/embj.201593673
   Forneris F, 2010, SCIENCE, V330, P1816, DOI 10.1126/science.1195821
   Fritsche LG, 2016, NAT GENET, V48, P134, DOI 10.1038/ng.3448
   Geerlings MJ, 2017, MOL IMMUNOL, V84, P65, DOI 10.1016/j.molimm.2016.11.016
   Geerlings MJ, 2017, JAMA OPHTHALMOL, V135, P39, DOI 10.1001/jamaophthalmol.2016.4604
   Hageman GS, 2005, P NATL ACAD SCI USA, V102, P7227, DOI 10.1073/pnas.0501536102
   Jokiranta TS, 2005, AM J PATHOL, V167, P1173, DOI 10.1016/S0002-9440(10)61205-9
   Jozsi M, 2006, J AM SOC NEPHROL, V17, P170, DOI 10.1681/ASN.2005080868
   Kavanagh D, 2013, SEMIN NEPHROL, V33, P508, DOI 10.1016/j.semnephrol.2013.08.003
   Kavanagh D, 2012, CLIN J AM SOC NEPHRO, V7, P417, DOI 10.2215/CJN.05750611
   Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557
   Krieger E, 2014, BIOINFORMATICS, V30, P2981, DOI 10.1093/bioinformatics/btu426
   Lek M, 2016, NATURE, V536, P285, DOI 10.1038/nature19057
   Liszewski MK, 2017, ANNU REV PATHOL-MECH, V12, P25, DOI 10.1146/annurev-pathol-012615-044145
   Maga TK, 2010, HUM MUTAT, V31, pE1445, DOI 10.1002/humu.21256
   Malina Michal, 2012, Presse Med, V41, pe105, DOI 10.1016/j.lpm.2011.10.028
   Martinez-Barricarte R, 2008, J AM SOC NEPHROL, V19, P639, DOI 10.1681/ASN.2007080923
   Martinez-Barricarte R, 2015, MOL IMMUNOL, V66, P263, DOI 10.1016/j.molimm.2015.03.248
   Mohlin FC, 2015, MOL IMMUNOL, V65, P367, DOI 10.1016/j.molimm.2015.02.013
   Neumann HPH, 2003, J MED GENET, V40, P676, DOI 10.1136/jmg.40.9.676
   Nilsson SC, 2010, J BIOL CHEM, V285, P6235, DOI 10.1074/jbc.M109.097212
   Noris M, 2015, AM J KIDNEY DIS, V66, P359, DOI 10.1053/j.ajkd.2015.03.040
   Pickering MC, 2013, KIDNEY INT, V84, P1079, DOI 10.1038/ki.2013.377
   Prosser BE, 2007, J EXP MED, V204, P2277, DOI 10.1084/jem.20071069
   Recalde S, 2016, J AM SOC NEPHROL, V27, P1305, DOI 10.1681/ASN.2015050580
   Richards A, 2001, AM J HUM GENET, V68, P485, DOI 10.1086/318203
   de Cordoba SR, 2012, IMMUNOBIOLOGY, V217, P1034, DOI 10.1016/j.imbio.2012.07.021
   Rodriguez E, 2014, BIOSCIENCE REP, V34, P635, DOI 10.1042/BSR20140117
   Rooijakkers SHM, 2009, NAT IMMUNOL, V10, P721, DOI 10.1038/ni.1756
   Roumenina LT, 2012, BLOOD, V119, P4182, DOI 10.1182/blood-2011-10-383281
   Roversi P, 2011, P NATL ACAD SCI USA, V108, P12839, DOI 10.1073/pnas.1102167108
   Sanchez-Gallego JI, 2012, J BIOL CHEM, V287, P13572, DOI 10.1074/jbc.M111.326298
   Seddon JM, 2013, NAT GENET, V45, P1366, DOI 10.1038/ng.2741
   Servais A, 2012, KIDNEY INT, V82, P454, DOI 10.1038/ki.2012.63
   Stahl AL, 2008, BLOOD, V111, P5307, DOI 10.1182/blood-2007-08-106153
   van de Ven JPH, 2013, NAT GENET, V45, P813, DOI 10.1038/ng.2640
   Volokhina E, 2012, PEDIATR NEPHROL, V27, P1519, DOI 10.1007/s00467-012-2183-z
   Wagner EK, 2016, SCI REP-UK, V6, DOI 10.1038/srep31531
   Wang K, 2010, NUCLEIC ACIDS RES, V38, P3
   Warwicker P, 1998, KIDNEY INT, V53, P836, DOI 10.1046/j.1523-1755.1998.00824.x
   Westra D, 2010, NEPHROL DIAL TRANSPL, V25, P2195, DOI 10.1093/ndt/gfq010
   Xue XG, 2017, NAT STRUCT MOL BIOL, V24, P643, DOI 10.1038/nsmb.3427
   Yu Y, 2014, HUM MOL GENET, V23, P5283, DOI 10.1093/hmg/ddu226
   Zipfel PF, 2015, MOL IMMUNOL, V67, P21, DOI 10.1016/j.molimm.2015.03.012
NR 51
TC 13
Z9 14
U1 0
U2 2
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0009-9163
EI 1399-0004
J9 CLIN GENET
JI Clin. Genet.
PD OCT
PY 2018
VL 94
IS 3-4
BP 330
EP 338
DI 10.1111/cge.13392
PG 9
WC Genetics & Heredity
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Genetics & Heredity
GA GS9VQ
UT WOS:000444076300006
PM 29888403
OA hybrid, Green Published
DA 2022-11-30
ER

PT J
AU Lu, YY
   Huang, JF
   Zhao, J
   Yu, XB
   Long, L
   Dai, H
AF Lu, Yingyi
   Huang, Jianfeng
   Zhao, Jing
   Yu, Xiaobing
   Long, Li
   Dai, Hong
TI Effects of Intravitreal Ranibizumab Injection on Chinese Patients with
   Wet Age-Related Macular Degeneration: 5-Year Follow-Up Results
SO JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
ID OUTCOMES; AMD
AB Purpose. To observe the effect of intravitreal ranibizumab injection on wet age-related macular degeneration (wAMD) over 5 years in Chinese patients. Methods. Thirty-seven patients who were diagnosed with wAMD in our hospital from June 2007 to June 2014 were retrospectively reviewed. The PRN regimen and the treatment and extend regimen were applied. Best corrected visual acuity (BCVA), number of ranibizumab injections, and changes in the choroidal neovascularization (CNV) lesion over 5 years were analyzed. Results. The mean BCVA measured by the ETDRS chart at baseline was 47.4 and 5 years after the treatment it was 34.89 letters, which was significantly different (p = 0.013). Fourteen eyes (37.8%) had improved visual acuity after 5 years. The number of injections in 5 years was 11.53, and most of the injections were in the first two years. Seventeen (45.9%) cases developed fibrous lesions, and 2 (5.4%) cases had atrophic lesions after 5 years. The fibrosis/atrophy was significantly correlated with the injection numbers (Pearson, p = 0.663, and p = 0.000). Conclusion. Most of the patients can maintain visual acuity treated by ranibizumab in the first 3 years. After 5 years, some patients can still improve or maintain visual acuity. Fibrous scarring of the lesion is the main reason for a decrease in vision of wAMD patients.
C1 [Lu, Yingyi; Huang, Jianfeng; Zhao, Jing; Yu, Xiaobing; Long, Li; Dai, Hong] Beijing Hosp, Dept Ophthalmol, Natl Ctr Gerontol, 1 Dahua Rd, Beijing 100730, Peoples R China.
C3 Beijing Hospital
RP Dai, H (通讯作者)，Beijing Hosp, Dept Ophthalmol, Natl Ctr Gerontol, 1 Dahua Rd, Beijing 100730, Peoples R China.
EM dai-hong@x263.net
FU National Natural Science Foundation of China (NSFC) [81441026]; Beijing
   Natural Science Foundation (BNSF) [7152123]; Beijing Municipal Science &
   Technology Commission (the Capital Characteristic Clinic Project)
   [Z151100004015147]
FX This work was supported by the National Natural Science Foundation of
   China (NSFC Grant 81441026), the Beijing Natural Science Foundation
   (BNSF Grant 7152123), and the Beijing Municipal Science & Technology
   Commission (the Capital Characteristic Clinic Project Z151100004015147).
CR Bloch SB, 2013, ACTA OPHTHALMOL, V91, P42, DOI 10.1111/j.1755-3768.2011.02268.x
   Chan CK, 2015, EYE, V29, P80, DOI 10.1038/eye.2014.233
   Dai H., 2010, CHINESE J OCULAR FUN, V26
   Dai H., 2011, CHINESE J OPTOMETRY, V13, P84
   [戴虹 Dai Hong], 2016, [中华眼底病杂志, Chinese Journal of Ocular Fundus Diseases], V32, P8
   [戴虹 Dai Hong], 2016, [中华实验眼科杂志, Chinese Journal of Experimental Ophthalmology], V34, P1
   [戴虹 Dai Hong], 2011, [中华眼底病杂志, Chinese Journal of Ocular Fundus Diseases], V27, P503
   Daniel E, 2014, OPHTHALMOLOGY, V121, P656, DOI 10.1016/j.ophtha.2013.10.019
   Droege KM, 2014, GRAEF ARCH CLIN EXP, V252, P31, DOI 10.1007/s00417-013-2412-6
   Frennesson CI, 2014, ACTA OPHTHALMOL, V92, P216, DOI 10.1111/aos.12091
   Gu XY, 2014, CURR EYE RES, V39, P518, DOI 10.3109/02713683.2013.848899
   Gupta OP, 2010, OPHTHALMOLOGY, V117, P2134, DOI 10.1016/j.ophtha.2010.02.032
   Huang JF, 2014, CHINESE MED J-PEKING, V127, P2053, DOI 10.3760/cma.j.issn.0366-6999.20133045
   Klein R., 2013, INVEST OPHTHALMOL, V54, P13
   Lanzetta P, 2013, BRIT J OPHTHALMOL, V97, P1497, DOI 10.1136/bjophthalmol-2013-303394
   Maguire MG, 2016, OPHTHALMOLOGY, V123, P1751, DOI 10.1016/j.ophtha.2016.03.045
   Pagliarini S, 2014, J OPHTHALMOL, V2014, DOI 10.1155/2014/857148
   Rayess N, 2015, AM J OPHTHALMOL, V159, P3
   Real JP, 2015, GRAEF ARCH CLIN EXP, V253, P1859, DOI 10.1007/s00417-014-2885-y
   Rofagha S, 2013, OPHTHALMOLOGY, V120, P2292, DOI 10.1016/j.ophtha.2013.03.046
   Rosenfeld PJ, 2011, OPHTHALMOLOGY, V118, P523, DOI 10.1016/j.ophtha.2010.07.011
   Xu Y, 2014, CHINESE MED J-PEKING, V127, P2906, DOI 10.3760/cma.j.issn.0366-6999.20132990
   Ziemssen F, 2015, OPHTHALMOLOGE, V112, P246, DOI 10.1007/s00347-014-3217-7
NR 23
TC 3
Z9 4
U1 0
U2 1
PU HINDAWI LTD
PI LONDON
PA ADAM HOUSE, 3RD FLR, 1 FITZROY SQ, LONDON, W1T 5HF, ENGLAND
SN 2090-004X
EI 2090-0058
J9 J OPHTHALMOL
JI J. Ophthalmol.
PY 2016
VL 2016
AR 6538192
DI 10.1155/2016/6538192
PG 5
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA EB9KS
UT WOS:000387713900001
PM 27885338
OA Green Submitted, Green Published, gold
DA 2022-11-30
ER

PT J
AU Sodi, A
   Passerini, I
   Bacherini, D
   Boni, L
   Palchetti, S
   Murro, V
   Caporossi, O
   Mucciolo, DP
   Franco, F
   Vannozzi, L
   Torricelli, F
   Pelo, E
   Rizzo, S
   Virgili, G
AF Sodi, Andrea
   Passerini, Ilaria
   Bacherini, Daniela
   Boni, Luca
   Palchetti, Simona
   Murro, Vittoria
   Caporossi, Orsola
   Mucciolo, Dario Pasquale
   Franco, Fabrizio
   Vannozzi, Lorenzo
   Torricelli, Francesca
   Pelo, Elisabetta
   Rizzo, Stanislao
   Virgili, Gianni
TI CFH Y402H polymorphism in Italian patients with age-related macular
   degeneration, retinitis pigmentosa, and Stargardt disease
SO OPHTHALMIC GENETICS
LA English
DT Article
DE AMD; CFHY402H polymorphism; RP; STGD
ID COMPLEMENT FACTOR-H; CHRONIC INFLAMMATORY REACTION; GENE POLYMORPHISMS;
   ISCEV STANDARD; ASSOCIATION; VARIANT; SYSTEM; ARMS2; PATHOGENESIS;
   ACTIVATION
AB Background: The complement system has been implicated in the pathogenesis of age-related macular degeneration (AMD) and the CFH Y402H polymorphism has been suggested as a major risk factor for AMD. Recent evidences supported the role of inflammation in the pathogenesis of some retinal dystrophies. Aim of this study was to evaluate the prevalence of CFHY402H polymorphism in a group of Italian patients affected by atrophic AMD, Stargardt disease (STGD), or retinitis pigmentosa(RP). Materials and Methods: Our case-control association study included 116 patients with atrophic AMD, 77 with RP, 86 with STGD, and 100 healthy controls. All the patients were evaluated by a standard ophthalmologic examination and OCT. ERG was performed on STGD and RP patients. All the subjects underwent a blood drawing for genetic testing and the CFHY402H polymorphism was genotyped with the TaqMan real-time polymerase chain reaction single nucleotide polymorphism assay. Results: The prevalence of the risk genotype C/C was higher in the AMD group than in controls (p < 0.001). The risk allele C was more frequent in the AMD group than in controls (p < 0.001). The prevalence of the risk genotype was higher in the RP patients than in controls (p < 0.001) and similarly the risk allele C was more frequent in the RP group (p = 0.008). The CFHY402H genotype distribution was not different between patients with STGD and the controls, for the biallelic (p = 0.531) and for the monoallelic (p = 0.318) evaluation. Conclusions: In our series of Italian patients, the CFHY402H genotype is associated with atrophic AMD and RP, but not with STGD. This result may support the hypothesis of a complement system dysregulation in the pathogenesis of AMD and RP
C1 [Sodi, Andrea; Bacherini, Daniela; Murro, Vittoria; Caporossi, Orsola; Mucciolo, Dario Pasquale; Franco, Fabrizio; Vannozzi, Lorenzo; Rizzo, Stanislao; Virgili, Gianni] Univ Florence, Careggi Teaching Hosp, Dept Surg & Translat Med, Eye Clin, Florence, Italy.
   [Passerini, Ilaria; Palchetti, Simona; Torricelli, Francesca; Pelo, Elisabetta] Careggi Teaching Hosp, Dept Genet Diag, Florence, Italy.
   [Boni, Luca] Careggi Teaching Hosp, Clin Trials Coordinating Ctr, Florence, Italy.
C3 University of Florence; Azienda Ospedaliero Universitaria Careggi;
   University of Florence; Azienda Ospedaliero Universitaria Careggi;
   University of Florence; Azienda Ospedaliero Universitaria Careggi
RP Bacherini, D (通讯作者)，Univ Florence, Dept Surg & Translat Med, Eye Clin, Largo Palagi 1, I-50134 Florence, Italy.
EM daniela.bacherini@gmail.com
RI Mucciolo, Dario Pasquale/K-1307-2018; murro, vittoria/K-1309-2018;
   Bacherini, Daniela/T-6009-2019; Boni, Luca/ABI-6243-2020; Virgili,
   Gianni/P-6607-2014
OI Mucciolo, Dario Pasquale/0000-0002-1661-5312; murro,
   vittoria/0000-0002-9249-4460; Boni, Luca/0000-0003-2217-4047; Virgili,
   Gianni/0000-0002-9960-2989; RIZZO, Stanislao/0000-0001-6302-063X
CR Ascaso FJ, 2014, MEDIAT INFLAMM, V2014, DOI 10.1155/2014/432685
   Awh CC, 2013, OPHTHALMOLOGY, V120, P2317, DOI 10.1016/j.ophtha.2013.07.039
   Baird PN, 2006, INVEST OPHTH VIS SCI, V47, P4194, DOI 10.1167/iovs.05-1285
   Ballanti E, 2013, IMMUNOL RES, V56, P477, DOI 10.1007/s12026-013-8422-y
   Camelo S, 2014, AUTOIMMUN DIS, V2014, DOI 10.1155/2014/532487
   Cao SJ, 2013, AM J OPHTHALMOL, V156, P1176, DOI 10.1016/j.ajo.2013.08.003
   Chen GH, 2015, SCI REP-UK, V5, DOI 10.1038/srep14517
   Cuenca N, 2014, PROG RETIN EYE RES, V43, P17, DOI 10.1016/j.preteyeres.2014.07.001
   Deobhakta A, 2013, INT J INFLAMM, V2013, DOI 10.1155/2013/438412
   Donoso LA, 2006, SURV OPHTHALMOL, V51, P137, DOI 10.1016/j.survophthal.2005.12.001
   Donoso LA, 2010, SURV OPHTHALMOL, V55, P227, DOI 10.1016/j.survophthal.2009.11.001
   Gologorsky D, 2012, MEDIAT INFLAMM, V2012, DOI 10.1155/2012/629452
   Gotoh N, 2006, HUM GENET, V120, P139, DOI 10.1007/s00439-006-0187-0
   Gupta N, 2003, EXP EYE RES, V76, P463, DOI 10.1016/S0014-4835(02)00332-9
   Habibi I, 2013, OPHTHALMIC RES, V49, P177, DOI 10.1159/000345068
   Hao XF, 2015, INT J CLIN EXP PATHO, V8, P3186
   Heckenlively JR, 1999, AM J OPHTHALMOL, V127, P565, DOI 10.1016/S0002-9394(98)00446-2
   Huda R, 2014, REV NEUROSCIENCE, V25, P575, DOI 10.1515/revneuro-2014-0021
   Joussen AM, 2004, FASEB J, V18, P1450, DOI 10.1096/fj.03-1476fje
   Karlstetter M, 2015, PROG RETIN EYE RES, V45, P30, DOI 10.1016/j.preteyeres.2014.11.004
   Kastelan S, 2013, MEDIAT INFLAMM, V2013, DOI 10.1155/2013/213130
   Kim NR, 2008, INVEST OPHTH VIS SCI, V49, P2071, DOI 10.1167/iovs.07-1195
   Kondo N, 2011, OPHTHALMOLOGY, V118, P339, DOI 10.1016/j.ophtha.2010.06.040
   Lau LI, 2006, INVEST OPHTH VIS SCI, V47, P3242, DOI 10.1167/iovs.05-1532
   Lee HBH, 2007, CAN J OPHTHALMOL, V42, P131, DOI 10.3129/canjophthalmol.06-101
   Leffler J, 2014, ANN RHEUM DIS, V73, P1601, DOI 10.1136/annrheumdis-2014-205287
   Magnusson KP, 2006, PLOS MED, V3, P109, DOI 10.1371/journal.pmed.0030005
   Maier R, 2011, OPHTHALMOLOGY, V118, P1125, DOI 10.1016/j.ophtha.2010.10.014
   Marmor MF, 2009, DOC OPHTHALMOL, V118, P69, DOI 10.1007/s10633-008-9155-4
   McCulloch DL, 2015, DOC OPHTHALMOL, V130, P1, DOI 10.1007/s10633-014-9473-7
   McHarg S, 2015, MOL IMMUNOL, V67, P43, DOI 10.1016/j.molimm.2015.02.032
   Moshfeghi DM, 2007, RETINA-J RET VIT DIS, V27, P269, DOI 10.1097/IAE.0b013e31802e3e9b
   Murakami Y, 2015, AM J OPHTHALMOL, V159, P958, DOI 10.1016/j.ajo.2015.02.001
   Nazari Khanamiri Hossein, 2014, J Ophthalmic Vis Res, V9, P181
   NEWSOME DA, 1988, OPHTHALMOLOGY, V95, P1696
   Ni Z, 2009, OPHTHALMOLOGICA, V223, P401, DOI 10.1159/000228926
   Noma H, 2013, JAMA OPHTHALMOL, V131, P160, DOI 10.1001/2013.jamaophthalmol.228
   Noris M, 2013, SEMIN NEPHROL, V33, P479, DOI 10.1016/j.semnephrol.2013.08.001
   Ozaki E, 2014, ADV EXP MED BIOL, V801, P229, DOI 10.1007/978-1-4614-3209-8_30
   Parmeggiani F, 2012, MEDIAT INFLAMM, V2012, DOI 10.1155/2012/546786
   Passerini I, 2010, EYE, V24, P158, DOI 10.1038/eye.2009.35
   Patel N, 2008, EYE, V22, P768, DOI 10.1038/sj.eye.6702844
   Popat RJ, 2014, NEPHRON CLIN PRACT, V128, P238, DOI 10.1159/000368591
   Quan YL, 2012, INT J OPHTHALMOL-CHI, V5, P242, DOI 10.3980/j.issn.2222-3959.2012.02.25
   Radu RA, 2014, J BIOL CHEM, V289, P9113, DOI 10.1074/jbc.M114.548669
   Radu RA, 2011, J BIOL CHEM, V286, P18593, DOI 10.1074/jbc.M110.191866
   Ricci F, 2009, ARCH OPHTHALMOL-CHIC, V127, P1368, DOI 10.1001/archophthalmol.2009.237
   Rodrigues EB, 2007, OPHTHALMOLOGICA, V221, P143, DOI 10.1159/000099293
   Salanti G, 2005, EUR J HUM GENET, V13, P840, DOI 10.1038/sj.ejhg.5201410
   Scholl HPN, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0007418
   Sepp T, 2006, INVEST OPHTH VIS SCI, V47, P536, DOI 10.1167/iovs.05-1143
   Sharma NK, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0070193
   Simonelli F, 2006, BRIT J OPHTHALMOL, V90, P1142, DOI 10.1136/bjo.2006.096487
   Smailhodzic D, 2012, OPHTHALMOLOGY, V119, P2304, DOI 10.1016/j.ophtha.2012.05.040
   Sofat R, 2012, INT J EPIDEMIOL, V41, P250, DOI 10.1093/ije/dyr204
   Souied EH, 2005, MOL VIS, V11, P1135
   Stanton CM, 2014, ADV EXP MED BIOL, V801, P251, DOI 10.1007/978-1-4614-3209-8_32
   Tang J, 2011, PROG RETIN EYE RES, V30, P343, DOI 10.1016/j.preteyeres.2011.05.002
   Thakkinstian A, 2006, HUM MOL GENET, V15, P2784, DOI 10.1093/hmg/ddl220
   Viringipurampeer IA, 2013, INT J INFLAMM, V2013, DOI 10.1155/2013/581751
   Warwick A, 2014, J CLIN MED, V3, P1234, DOI 10.3390/jcm3041234
   Yoshida N, 2013, OPHTHALMOLOGY, V120, pE5, DOI 10.1016/j.ophtha.2012.07.008
   Yoshida N, 2013, OPHTHALMOLOGY, V120, P100, DOI 10.1016/j.ophtha.2012.07.006
   Yucel D, 2012, OPHTHALMIC GENET, V33, P144, DOI 10.3109/13816810.2012.660225
   Zerbib J, 2014, GRAEF ARCH CLIN EXP, V252, P899, DOI 10.1007/s00417-013-2537-7
NR 65
TC 4
Z9 4
U1 0
U2 6
PU TAYLOR & FRANCIS INC
PI PHILADELPHIA
PA 530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA
SN 1381-6810
EI 1744-5094
J9 OPHTHALMIC GENET
JI Ophthalmic Genet.
PD NOV 2
PY 2018
VL 39
IS 6
BP 699
EP 705
DI 10.1080/13816810.2018.1525753
PG 7
WC Genetics & Heredity; Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Genetics & Heredity; Ophthalmology
GA HC3DP
UT WOS:000451681700004
PM 30285522
DA 2022-11-30
ER

PT J
AU Mones, J
   Biarnes, M
   Trindade, F
AF Mones, Jordi
   Biarnes, Marc
   Trindade, Fabio
TI Hyporeflective Wedge-Shaped Band in Geographic Atrophy Secondary to
   Age-Related Macular Degeneration
SO OPHTHALMOLOGY
LA English
DT Article
ID OPTICAL COHERENCE TOMOGRAPHY; RETINAL-PIGMENT EPITHELIUM; FUNDUS
   AUTOFLUORESCENCE; MACULOPATHY; RPE; PREVALENCE; CELLS; RAT
AB Objective: To describe and interpret the frequently observed spectral-domain optical coherence tomography (SD-OCT) finding of a marked hyporeflective wedge-shaped structure at the boundaries of the areas of atrophy.
   Design: A prospective, longitudinal follow-up study.
   Participants: Consecutive patients (n = 71) 50 years of age and older with geographic atrophy (GA) secondary to age-related macular degeneration (AMD) were examined between January 2010 and June 2011.
   Methods: Patients were evaluated with the use of imaging techniques that included 35 fundus photography, infrared, fundus autofluorescence (FAF), and SD-OCT. Visualization of the fundus with FAF was done simultaneously with OCT. Two acquisition protocols were followed: a macular cube for coverage (19 horizontal B-scans centered on the fovea) and high-resolution horizontal B-scan for qualitative foveal detail.
   Main Outcomes Measures: Estimation of the prevalence of a hyporeflective wedge-shaped band among patients with GA.
   Results: A marked hyporeflective wedge-shaped structure, with its base on Bruch's membrane and its apex pointing toward the inner limit of the outer plexiform layer (OPL) adjacent to the margin between the atrophied area and the preserved retina, was observed in 72.9% of eyes (70/96; 95% confidence interval, 63.9-82.0). This hyporeflective band appeared to be within the OPL. Using eccentric SD-OCT acquisition, the boundaries between the outer nuclear layer (ONL) and Henle's fiber layer (HFL) were well defined, showing that the ONL ends before the margin of atrophy of the retinal pigment epithelium (RPE). A narrow hyperreflective band separated the margin of the ONL and RPE from the hyporeflective band, already within the atrophic area.
   Conclusions: A hyporeflective wedge-shaped structure appears frequently within the boundaries of the OPL in patients with GA secondary to AMD, corresponding to an increase in the width of the HFL, presumably because of axonal swelling or interaxonal edema. This finding may improve the interpretation of SD-OCT images of the outer layers, may help in understanding better the interactions between photoreceptor cells and the RPE, and may help in the development of monitoring techniques and therapies for GA secondary to AMD.
   Financial Disclosure(s): Proprietary or commercial disclosure may be found after the references. Ophthalmology 2012;xx:xxx (C) 2012 by the American Academy of Ophthalmology.
C1 [Mones, Jordi] Ctr Med Teknon, Inst Macula & Retina, Barcelona 08021, Spain.
   Ctr Med Teknon, Barcelona Macula Fdn, Barcelona 08021, Spain.
RP Mones, J (通讯作者)，Ctr Med Teknon, Inst Macula & Retina, Vilana 12, Barcelona 08021, Spain.
EM jmones@institutmacularetina.com
RI mones, jordi/CAJ-2963-2022
OI mones, jordi/0000-0003-3685-2160; Trindade, Fabio/0000-0001-9993-5188;
   Biarnes, Marc/0000-0003-2584-4894
FU Barcelona Macula Foundation, Barcelona, Spain
FX Supported by Barcelona Macula Foundation, Barcelona, Spain.
CR Augood CA, 2006, ARCH OPHTHALMOL-CHIC, V124, P529, DOI 10.1001/archopht.124.4.529
   Bearelly S, 2009, OPHTHALMOLOGY, V116, P1762, DOI 10.1016/j.ophtha.2009.04.015
   Brar M, 2009, AM J OPHTHALMOL, V148, P439, DOI 10.1016/j.ajo.2009.04.022
   Bringmann A, 2006, PROG RETIN EYE RES, V25, P397, DOI 10.1016/j.preteyeres.2006.05.003
   Chen YM, 2011, INVEST OPHTH VIS SCI, V52, P3281, DOI 10.1167/iovs.10-6538
   Curcio CA, 1996, INVEST OPHTH VIS SCI, V37, P1236
   Curcio CA, 2011, INVEST OPHTH VIS SCI, V52, P3943, DOI 10.1167/iovs.10-6377
   DILORETO DA, 1995, BRAIN RES, V698, P1, DOI 10.1016/0006-8993(95)00647-9
   Dunaief JL, 2002, ARCH OPHTHALMOL-CHIC, V120, P1435, DOI 10.1001/archopht.120.11.1435
   Eagle Jr RC, 2011, EYE PATHOLOGY ATLAS, P3
   FERRIS FL, 1984, ARCH OPHTHALMOL-CHIC, V102, P1640
   Fleckenstein M, 2008, INVEST OPHTH VIS SCI, V49, P4137, DOI 10.1167/iovs.08-1967
   Fleckenstein M, 2010, INVEST OPHTH VIS SCI, V51, P3846, DOI 10.1167/iovs.09-4533
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P564
   Green W R, 1977, Trans Am Ophthalmol Soc, V75, P180
   Green W R, 1999, Mol Vis, V5, P27
   Hageman GS, 2001, PROG RETIN EYE RES, V20, P705, DOI 10.1016/S1350-9462(01)00010-6
   Hartmann KI, 2011, RETINA-J RET VIT DIS, V31, P1323, DOI 10.1097/IAE.0b013e31820a6850
   Klein R, 2007, OPHTHALMOLOGY, V114, P253, DOI 10.1016/j.ophtha.2006.10.040
   Li YW, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0009495
   Lujan BJ, 2011, INVEST OPHTH VIS SCI, V52, P1486, DOI 10.1167/iovs.10-5946
   Otani T, 2011, RETINA-J RET VIT DIS, V31, P497, DOI 10.1097/IAE.0b013e3181ed8dae
   PENFOLD PL, 1986, INVEST OPHTH VIS SCI, V27, P364
   Pow DV, 2007, EXP EYE RES, V84, P850, DOI 10.1016/j.exer.2007.01.005
   SARKS JP, 1988, EYE, V2, P552, DOI 10.1038/eye.1988.106
   SARKS SH, 1976, BRIT J OPHTHALMOL, V60, P324, DOI 10.1136/bjo.60.5.324
   Scholl HPN, 2004, INVEST OPHTH VIS SCI, V45, P574, DOI 10.1167/iovs.03-0495
   Shelley EJ, 2009, ARCH OPHTHALMOL-CHIC, V127, P483, DOI 10.1001/archophthalmol.2008.622
   Spaide RF, 2008, AM J OPHTHALMOL, V146, P496, DOI 10.1016/j.ajo.2008.05.032
   Sparrow JR, 2010, INVEST OPHTH VIS SCI, V51, P4351, DOI 10.1167/iovs.10-5852
   Sparrow JR, 2003, INVEST OPHTH VIS SCI, V44, P2245, DOI 10.1167/iovs.02-0746
   Tao W, 2002, INVEST OPHTH VIS SCI, V43, P3292
   Wolf-Schnurrbusch UEK, 2008, INVEST OPHTH VIS SCI, V49, P3095, DOI 10.1167/iovs.07-1460
   Zarbin MA, 2010, RETINA-J RET VIT DIS, V30, P1350, DOI 10.1097/IAE.0b013e3181f57e30
   Zhang K, 2011, P NATL ACAD SCI USA, V108, P6241, DOI 10.1073/pnas.1018987108
   Zhou J, 2009, INVEST OPHTH VIS SCI, V50, P1392, DOI 10.1167/iovs.08-2868
NR 36
TC 35
Z9 36
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0161-6420
J9 OPHTHALMOLOGY
JI Ophthalmology
PD JUL
PY 2012
VL 119
IS 7
DI 10.1016/j.ophtha.2012.01.026
PG 8
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 968UQ
UT WOS:000306011000023
PM 22440276
DA 2022-11-30
ER

PT J
AU Tanaka, M
   Kakihara, S
   Hirabayashi, K
   Imai, A
   Toriyama, Y
   Iesato, Y
   Sakurai, T
   Kamiyoshi, A
   Ichikawa-Shindo, Y
   Kawate, H
   Tanaka, M
   Cui, NQ
   Wei, YX
   Zhao, YL
   Aruga, K
   Yamauchi, A
   Murata, T
   Shindo, T
AF Tanaka, Masaaki
   Kakihara, Shinji
   Hirabayashi, Kazutaka
   Imai, Akira
   Toriyama, Yuichi
   Iesato, Yasuhiro
   Sakurai, Takayuki
   Kamiyoshi, Akiko
   Ichikawa-Shindo, Yuka
   Kawate, Hisaka
   Tanaka, Megumu
   Cui, Nanqi
   Wei, Yangxuan
   Zhao, Yunlu
   Aruga, Kohsuke
   Yamauchi, Akihiro
   Murata, Toshinori
   Shindo, Takayuki
TI Adrenomedullin-Receptor Activity-Modifying Protein 2 System Ameliorates
   Subretinal Fibrosis by Suppressing Epithelial-Mesenchymal Transition in
   Age-Related Macular Degeneration
SO AMERICAN JOURNAL OF PATHOLOGY
LA English
DT Article
AB Age-related macular degeneration (AMD) is a leading cause of visual impairment. Anti-vascular endothelial growth factor drugs used to treat AMD carry the risk of inducing subretinal fibrosis. We investigated the use of adrenomedullin (AM), a vasoactive peptide, and its receptor activity-modifying protein 2, RAMP2, which regulate vascular homeostasis and suppress fibrosis. The therapeutic potential of the AM-RAMP2 system was evaluated after laser-induced choroidal neovascularization (LI-CNV), a mouse model of AMD. Neovascular formation, subretinal fibrosis, and macrophage invasion were all enhanced in both AM and RAMP2 knockout mice compared with those in wild-type mice. These pathologic changes were suppressed by intravitreal injection of AM. Comprehensive gene expression analysis of the choroid after LI-CNV with or without AM administration revealed that fibrosis-related molecules, including Tgfb, Cxcr4, Ccn2, and Thbs1, were all down-regulated by AM. In retinal pigment epithelial cells, co-administration of transforming growth factor-beta and tumor necrosis factor-alpha induced epithelial-mesenchymal transition, which was also prevented by AM. Finally, transforming growth factor-beta and C-X-C chemokine receptor type 4 (CXCR4) inhibitors eliminated the difference in subretinal fibrosis between RAMP2 knockout and wild-type mice. These findings suggest the AM-RAMP2 system suppresses subretinal fibrosis in LI-CNV by suppressing epithelial-mesenchymal transition.
C1 [Tanaka, Masaaki; Kakihara, Shinji; Sakurai, Takayuki; Kamiyoshi, Akiko; Ichikawa-Shindo, Yuka; Kawate, Hisaka; Tanaka, Megumu; Cui, Nanqi; Wei, Yangxuan; Zhao, Yunlu; Aruga, Kohsuke; Yamauchi, Akihiro; Shindo, Takayuki] Shinshu Univ, Sch Med, Dept Cardiovasc Res, Asahi 3-1-1, Matsumoto, Nagano 3908621, Japan.
   [Tanaka, Masaaki; Kakihara, Shinji; Hirabayashi, Kazutaka; Imai, Akira; Toriyama, Yuichi; Iesato, Yasuhiro; Murata, Toshinori] Shinshu Univ, Sch Med, Dept Ophthalmol, Matsumoto, Nagano, Japan.
   [Sakurai, Takayuki; Kamiyoshi, Akiko; Shindo, Takayuki] Shinshu Univ, Inst Biomed Sci, Interdisciplinary Cluster Cutting Edge Res, Dept Life Innovat, Nagano, Japan.
C3 Shinshu University; Shinshu University; Shinshu University
RP Shindo, T (通讯作者)，Shinshu Univ, Sch Med, Dept Cardiovasc Res, Asahi 3-1-1, Matsumoto, Nagano 3908621, Japan.
EM tshindo@shinshu-u.ac.jp
RI Kakihara, Shinji/AAR-1855-2021
OI Kakihara, Shinji/0000-0002-8433-8169; Hirabayashi,
   Kazutaka/0000-0002-1342-6700; Aruga, Kohsuke/0000-0002-1888-3070
FU Japan Science and Technology Agency; Japan Agency for Medical Research
   and Development; SENSHIN Medical Research Foundation grant; Naito
   Foundation grant; Novartis Foundation for the Promotion of Science
   grant; Akaeda Medical Research Foundation; Hoyu Science Foundation;
   Takahashi Industrial and Economic Research Foundation; BristolMyers
   Squibb research grant
FX Supported by Japan Science and Technology Agency grantinaid for
   scientific research (KAKENHI) , Core Research for Evolutionary Science
   and Technology, the Japan Agency for Medical Research and Development,
   SENSHIN Medical Research Foundation grant, Naito Foundation grant,
   Novartis Foundation for the Promotion of Science grant, Akaeda Medical
   Research Foundation, Hoyu Science Foundation, Takahashi Industrial and
   Economic Research Foundation, and BristolMyers Squibb research grant
   (T.S.) .
CR Nieto MA, 2016, CELL, V166, P21, DOI 10.1016/j.cell.2016.06.028
   Brain SD, 2004, PHYSIOL REV, V84, P903, DOI 10.1152/physrev.00037.2003
   Chen S, 2005, IMMUNOLOGY, V114, P565, DOI 10.1111/j.1365-2567.2004.02110.x
   Chen YF, 2017, AM J TRANSL RES, V9, P4125
   Chow LN, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0151765
   Chu PY, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0133616
   Cohen SY, 2012, RETINA-J RET VIT DIS, V32, P1480, DOI 10.1097/IAE.0b013e318240a516
   Daniel E, 2014, OPHTHALMOLOGY, V121, P656, DOI 10.1016/j.ophtha.2013.10.019
   Davies MR, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0155486
   Feng Y, 1996, SCIENCE, V272, P872, DOI 10.1126/science.272.5263.872
   Feng YF, 2014, MOL CELL BIOCHEM, V397, P131, DOI 10.1007/s11010-014-2180-6
   Fine SL, 2000, NEW ENGL J MED, V342, P483, DOI 10.1056/NEJM200002173420707
   Fleming YM, 2009, ONCOGENE, V28, P983, DOI 10.1038/onc.2008.449
   Hanabusa K, 2005, STROKE, V36, P853, DOI 10.1161/01.STR.0000157661.69482.76
   Hirabayashi K, 2019, AM J PATHOL, V189, P449, DOI 10.1016/j.ajpath.2018.10.021
   Hirasawa M, 2011, MOL VIS, V17, P1222
   Hobara N, 2007, NEUROSCIENCE, V144, P721, DOI 10.1016/j.neuroscience.2006.09.031
   Hollanders K, 2015, INVEST OPHTH VIS SCI, V56, P1335, DOI 10.1167/iovs.14-15681
   HORIO T, 1995, CIRC RES, V77, P660, DOI 10.1161/01.RES.77.4.660
   Hu W, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-16008-x
   Hwang JC, 2011, OPHTHAL SURG LAS IM, V42, DOI 10.3928/15428877-20100924-01
   Ichikawa-Shindo Y, 2008, J CLIN INVEST, V118, P29, DOI 10.1172/JCI33022
   Iimuro S, 2004, CIRC RES, V95, P415, DOI 10.1161/01.RES.0000138018.61065.d1
   Imai A, 2017, AM J PATHOL, V187, P999, DOI 10.1016/j.ajpath.2017.01.014
   Ishikawa K, 2016, EXP EYE RES, V142, P19, DOI 10.1016/j.exer.2015.03.009
   Iwase T, 2005, CIRCULATION, V111, P356, DOI 10.1161/01.CIR.0000153352.29335.B9
   Kato J, 2005, ARTERIOSCL THROM VAS, V25, P2480, DOI 10.1161/01.ATV.0000184759.91369.f8
   Kimura K, 2015, J MOL MED, V93, P749, DOI 10.1007/s00109-015-1289-8
   Kumar S, 2014, JOVE-J VIS EXP, DOI 10.3791/51061
   Lee E, 2010, INVEST OPHTH VIS SCI, V51, P3666, DOI 10.1167/iovs.09-3802
   Lyu Y, 2018, INT J OPHTHALMOL-CHI, V11, P726, DOI 10.18240/ijo.2018.05.04
   Maki T, 2011, STROKE, V42, P1122, DOI 10.1161/STROKEAHA.110.603399
   Mandal J, 2019, PULM PHARMACOL THER, V56, P8, DOI 10.1016/j.pupt.2019.01.006
   Martin DF, 2011, NEW ENGL J MED, V364, P1897, DOI 10.1056/NEJMoa1102673
   Matoba R, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0181481
   McLatchie LM, 1998, NATURE, V393, P333, DOI 10.1038/30666
   Miller JW, 2010, JPN J OPHTHALMOL, V54, P523, DOI 10.1007/s10384-010-0863-4
   Nagaya N, 2005, AM J PHYSIOL-REG I, V288, pR1432, DOI 10.1152/ajpregu.00662.2004
   Peacock JG, 2007, MOL BIOL CELL, V18, P3860, DOI 10.1091/mbc.E07-01-0075
   Rosenfeld PJ, 2011, OPHTHALMOLOGY, V118, P523, DOI 10.1016/j.ophtha.2010.07.011
   Sakimoto S, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0058096
   Sawada O, 2016, DEV OPHTHALMOL, V55, P147, DOI 10.1159/000438971
   Schaal S, 2008, OPHTHALMOLOGY, V115, P2199, DOI 10.1016/j.ophtha.2008.07.007
   Schmidt-Erfurth U, 2014, OPHTHALMOLOGY, V121, P193, DOI 10.1016/j.ophtha.2013.08.011
   SHIMEKAKE Y, 1995, J BIOL CHEM, V270, P4412, DOI 10.1074/jbc.270.9.4412
   Shimosawa T, 2003, HYPERTENSION, V41, P1080, DOI 10.1161/01.HYP.0000066846.46422.2C
   Shindo T, 2001, CIRCULATION, V104, P1964, DOI 10.1161/hc4101.097111
   Shindo T, 2019, PEPTIDES, V111, P55, DOI 10.1016/j.peptides.2018.04.004
   Stramer BM, 2007, J INVEST DERMATOL, V127, P1009, DOI 10.1038/sj.jid.5700811
   Tanaka M, 2016, CARDIOVASC RES, V111, P398, DOI 10.1093/cvr/cvw166
   Thiery JP, 2006, NAT REV MOL CELL BIO, V7, P131, DOI 10.1038/nrm1835
   Tosi GM, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19113363
   Udono-Fujimori R, 2003, REGUL PEPTIDES, V112, P95, DOI 10.1016/S0167-0115(03)00027-2
   Uetake R, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0087667
   Wang Y, 2006, INT J EXP PATHOL, V87, P177, DOI 10.1111/j.1365-2613.2006.00466.x
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
   Yamauchi A, 2014, J MOL CELL CARDIOL, V77, P73, DOI 10.1016/j.yjmcc.2014.09.017
   Yoshimatsu Y, 2011, INT J INFLAMM, V2011, DOI 10.4061/2011/724080
   Yuan A, 2015, AM J PHYSIOL-RENAL, V308, pF459, DOI 10.1152/ajprenal.00146.2014
   Yuda K, 2012, AM J PATHOL, V181, P1464, DOI 10.1016/j.ajpath.2012.06.028
   Zhang JQ, 2020, BRAIN RES, V1727, DOI 10.1016/j.brainres.2019.146555
NR 61
TC 3
Z9 3
U1 1
U2 4
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 0002-9440
EI 1525-2191
J9 AM J PATHOL
JI Am. J. Pathol.
PD APR
PY 2021
VL 191
IS 4
BP 652
EP 668
DI 10.1016/j.ajpath.2020.12.012
EA MAR 2021
PG 17
WC Pathology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Pathology
GA RC3FX
UT WOS:000632690300003
PM 33385343
OA Green Submitted, Green Published, Bronze
DA 2022-11-30
ER

PT J
AU Kim, JH
   Lee, DW
   Chang, YS
   Kim, JW
   Kim, CG
AF Kim, Jae Hui
   Lee, Dong Won
   Chang, Young Suk
   Kim, Jong Woo
   Kim, Chul Gu
TI Twelve-month outcomes of treatment using ranibizumab or aflibercept for
   neovascular age-related macular degeneration: a comparative study
SO GRAEFES ARCHIVE FOR CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY
LA English
DT Article
DE Age-related macular degeneration; Choroidal neovascularization;
   Anti-vascular endothelial growth factor; Ranibizumab; Aflibercept
ID POLYPOIDAL CHOROIDAL VASCULOPATHY; MEDICARE BENEFICIARIES; VISUAL
   IMPAIRMENT; PREVALENCE; THERAPY; INJECTIONS; BLINDNESS; ADULTS; EYES
AB To compare the 12-month treatment outcome of ranibizumab with that of aflibercept in cases of neovascular age-related macular degeneration (AMD).
   This retrospective single-institution study included patients who had been diagnosed with treatment-na < ve neovascular AMD and treated using either ranibizumab (ranibizumab group, n = 30) or aflibercept (aflibercept group, n = 21) monotherapy over a 12-month follow-up period. Patients initially received three monthly injections, and were re-treated when neovascularization recurred. The best-corrected visual acuity (BCVA) at diagnosis and at 12 months, as well as the number of injections, were compared between the two groups.
   In the ranibizumab group, the mean logarithm of the minimum angle of resolution BCVA values at diagnosis and at 12 months were 0.86 +/- 0.45 and 0.72 +/- 0.56, respectively. The equivalent values were 0.73 +/- 0.37 and 0.58 +/- 0.41 in the aflibercept group. The mean number of injections was 4.5 +/- 1.3 in the ranibizumab group and 4.3 +/- 0.9 in the aflibercept group. There was no difference in BCVA between the two groups at either diagnosis (P = 0.560) or 12 months (P = 0.702). There was also no difference between the two groups in the number of injections (P = 0.847).
   The 12-month treatment outcome of intravitreal ranibizumab was similar to that of intravitreal aflibercept, with a comparable injection frequency. Further prospective studies with a more controlled design are needed to confirm our findings.
C1 [Kim, Jae Hui; Lee, Dong Won; Kim, Jong Woo; Kim, Chul Gu] Konyang Univ, Kims Eye Hosp, Dept Ophthalmol, Coll Med, 156 Youngdeungpo Dong 4Ga, Seoul 150034, South Korea.
   [Chang, Young Suk] Konyang Univ, Dept Ophthalmol, Coll Med, Daejeon, South Korea.
C3 Konyang University; Konyang University Hospital; Konyang University;
   Konyang University Hospital
RP Lee, DW (通讯作者)，Konyang Univ, Kims Eye Hosp, Dept Ophthalmol, Coll Med, 156 Youngdeungpo Dong 4Ga, Seoul 150034, South Korea.
EM mediceye@kimeye.com
FU Kim's Eye Hospital (Seoul, South Korea)
FX Kim's Eye Hospital (Seoul, South Korea) provided financial support in
   the form of funding for English editing support. The sponsor had no role
   in the design or conduct of this research.
CR Bohni SC, 2015, BMC OPHTHALMOL, V15, DOI 10.1186/s12886-015-0101-4
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Buch H, 2004, OPHTHALMOLOGY, V111, P53, DOI 10.1016/j.ophtha.2003.05.010
   Chae B, 2015, INVEST OPHTH VIS SCI, V56, P5040, DOI 10.1167/iovs.15-16494
   Cho M, 2009, AM J OPHTHALMOL, V148, P70, DOI 10.1016/j.ajo.2009.02.012
   Cohen SY, 2014, OPHTHALMOLOGICA, V231, P80, DOI 10.1159/000356401
   Congdon N, 2004, ARCH OPHTHALMOL-CHIC, V122, P477
   Curtis LH, 2012, AM J OPHTHALMOL, V153, P1116, DOI 10.1016/j.ajo.2011.11.032
   Fine HF, 2015, RETINA-J RET VIT DIS, V35, P681, DOI 10.1097/IAE.0000000000000398
   Fung AE, 2007, AM J OPHTHALMOL, V143, P566, DOI 10.1016/j.ajo.2007.01.028
   Hasler PW, 2015, ACTA OPHTHALMOL, V93, P122, DOI 10.1111/aos.12589
   Heier JS, 2012, OPHTHALMOLOGY, V119, P2537, DOI 10.1016/j.ophtha.2012.09.006
   Julien S, 2014, BRIT J OPHTHALMOL, V98, P813, DOI 10.1136/bjophthalmol-2013-304019
   Klettner A, 2014, GRAEF ARCH CLIN EXP, V252, P1593, DOI 10.1007/s00417-014-2719-y
   Koh AHC, 2013, RETINA-J RET VIT DIS, V33, P686, DOI 10.1097/IAE.0b013e3182852446
   Lee JH, 2016, GRAEF ARCH CLIN EXP, V254, P645, DOI 10.1007/s00417-015-3092-1
   Maberley DAL, 2006, EYE, V20, P341, DOI 10.1038/sj.eye.6701879
   Niwa Y, 2015, INVEST OPHTH VIS SCI, V56, P6501, DOI 10.1167/iovs.15-17279
   Qualls LG, 2013, RETINA-J RET VIT DIS, V33, P854, DOI 10.1097/IAE.0b013e31826f065e
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Sawada T, 2014, GRAEF ARCH CLIN EXP, V252, P1545, DOI 10.1007/s00417-014-2612-8
   Schmidt-Erfurth U, 2014, OPHTHALMOLOGY, V121, P193, DOI 10.1016/j.ophtha.2013.08.011
   Schmidt-Erfurth U, 2011, OPHTHALMOLOGY, V118, P831, DOI 10.1016/j.ophtha.2010.09.004
   Schutze C, 2015, AM J OPHTHALMOL, V159, P1100, DOI 10.1016/j.ajo.2015.02.020
   Wong T, 2008, OPHTHALMOLOGY, V115, P116, DOI 10.1016/j.ophtha.2007.03.008
   Yonekawa Y, 2013, AM J OPHTHALMOL, V156, P29, DOI 10.1016/j.ajo.2013.03.030
   Zinkernagel MS, 2015, INVEST OPHTH VIS SCI, V56, P1894, DOI 10.1167/iovs.14-16204
NR 27
TC 21
Z9 21
U1 0
U2 3
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0721-832X
EI 1435-702X
J9 GRAEF ARCH CLIN EXP
JI Graefes Arch. Clin. Exp. Ophthalmol.
PD NOV
PY 2016
VL 254
IS 11
BP 2101
EP 2109
DI 10.1007/s00417-016-3353-7
PG 9
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA EB1QJ
UT WOS:000387128900004
PM 27230919
DA 2022-11-30
ER

PT J
AU Anand, A
   Sharma, NK
   Gupta, A
   Prabhakar, S
   Sharma, SK
   Singh, R
   Gupta, PK
AF Anand, Akshay
   Sharma, Neel Kamal
   Gupta, Amod
   Prabhakar, Sudesh
   Sharma, Suresh Kumar
   Singh, Ramandeep
   Gupta, Pawan Kumar
TI Single Nucleotide Polymorphisms in MCP-1 and Its Receptor Are Associated
   with the Risk of Age Related Macular Degeneration
SO PLOS ONE
LA English
DT Article
ID MONOCYTE CHEMOATTRACTANT PROTEIN-1; CCL2; INHIBITION; EXPRESSION;
   CHEMOKINES; TLR4; CCR2
AB Background: Age-related macular degeneration (AMD) is the leading cause of blindness in the elderly population. We have shown previously that mice deficient in monocyte chemoattractant protein-1 (MCP1/CCL2) or its receptor (CCR2) develop the features of AMD in senescent mice, however, the human genetic evidence so far is contradictory. We hypothesized that any dysfunction in the CCL2 and its receptor result could be the contributing factor in pathogenesis of AMD.
   Methods and Findings: 133 AMD patients and 80 healthy controls were enrolled for this study. Single neucleotid Polymorphism for CCL2 and CCR2 was analyzed by real time PCR. CCL2 levels were determined by enzyme-linked immunosorbent assay (ELISA) after normalization to total serum protein and percentage (%) of CCR2 expressing peripheral blood mononuclear cells (PBMCs) was evaluated using Flow Cytometry. The genotype and allele frequency for both CCL2 and CCR2 was found to be significantly different between AMD and normal controls. The CCL2 ELISA levels were significantly higher in AMD patients and flow Cytometry analysis revealed significantly reduced CCR2 expressing PBMCs in AMD patients as compared to normal controls.
   Conclusions: We analyzed the association between single neucleotide polymorphisms (SNPs) of CCL2 (rs4586) and CCR2 (rs1799865) with their respective protein levels. Our results revealed that individuals possessing both SNPs are at a higher risk of development of AMD.
C1 [Anand, Akshay; Sharma, Neel Kamal; Prabhakar, Sudesh; Gupta, Pawan Kumar] PGIMER, Dept Neurol, Chandigarh, India.
   [Gupta, Amod; Singh, Ramandeep] PGIMER, Dept Ophthalmol, Chandigarh, India.
   [Sharma, Suresh Kumar] Panjab Univ, Dept Stat, Chandigarh 160014, India.
C3 Post Graduate Institute of Medical Education & Research (PGIMER),
   Chandigarh; Post Graduate Institute of Medical Education & Research
   (PGIMER), Chandigarh; Panjab University
RP Anand, A (通讯作者)，PGIMER, Dept Neurol, Chandigarh, India.
EM akshay1anand@rediffmail.com
RI Gupta, Amod/V-7633-2017
OI Gupta, Amod/0000-0001-8427-5738
FU Department of Science and Technology [SR/SO/HS-109/205]
FX The funding of study was from Department of Science and Technology(F.
   No. SR/SO/HS-109/205 dated 1-05-2007). The funders had no role in study
   design, data collection and analysis, decision to publish, or
   preparation of the manuscript.
CR Ambati J, 2003, NAT MED, V9, P1390, DOI 10.1038/nm950
   Charo IF, 2004, CIRC RES, V95, P858, DOI 10.1161/01.RES.0000146672.10582.17
   CHARO IF, 1994, P NATL ACAD SCI USA, V91, P2752, DOI 10.1073/pnas.91.7.2752
   Chen M, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0022818
   Combadiere C, 2008, CIRCULATION, V117, P1649, DOI 10.1161/CIRCULATIONAHA.107.745091
   Despriet DDG, 2008, INVEST OPHTH VIS SCI, V49, P364, DOI 10.1167/iovs.07-0656
   Feng WX, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0014652
   Haas P, 2011, CURR EYE RES, V36, P143, DOI 10.3109/02713683.2010.533808
   Harmon BT, 2010, J APPL PHYSIOL, V109, P1779, DOI 10.1152/japplphysiol.00633.2010
   Higgins GT, 2003, INVEST OPHTH VIS SCI, V44, P1775, DOI 10.1167/iovs.02-0742
   Jemaa R, 2008, CLIN CHIM ACTA, V390, P122, DOI 10.1016/j.cca.2008.01.004
   Jonas JB, 2010, ARCH OPHTHALMOL-CHIC, V128, P1281, DOI 10.1001/archophthalmol.2010.227
   Kaur I, 2006, INVEST OPHTH VIS SCI, V47, P3729, DOI 10.1167/iovs.05-1430
   Kim MP, 2007, ATHEROSCLEROSIS, V193, P366, DOI 10.1016/j.atherosclerosis.2006.06.029
   Lommatzsch A, 2008, GRAEF ARCH CLIN EXP, V246, P803, DOI 10.1007/s00417-007-0749-4
   Luhmann UFO, 2009, INVEST OPHTH VIS SCI, V50, P5934, DOI 10.1167/iovs.09-3462
   Luster AD, 1998, NEW ENGL J MED, V338, P436, DOI 10.1056/NEJM199802123380706
   Ma WX, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0007945
   McDermott DH, 2005, CIRCULATION, V112, P1113, DOI 10.1161/CIRCULATIONAHA.105.543579
   Nakazawa T, 2007, P NATL ACAD SCI USA, V104, P2425, DOI 10.1073/pnas.0608167104
   Ormsby RJ, 2008, INVEST OPHTH VIS SCI, V49, P1763, DOI 10.1167/iovs.07-1297
   Patel M, 2008, SEMIN IMMUNOPATHOL, V30, P97, DOI 10.1007/s00281-008-0112-9
   Raoul W, 2010, J NEUROINFLAMM, V7, DOI 10.1186/1742-2094-7-87
   Scholl HPN, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002593
   Sharma NK, 2009, ANN NEUROSCI, V16, P62, DOI 10.5214/ans.0972.7531.2009.160208
   Simonelli F, 2006, BRIT J OPHTHALMOL, V90, P1142, DOI 10.1136/bjo.2006.096487
   Tuo JS, 2007, INVEST OPHTH VIS SCI, V48, P3827, DOI 10.1167/iovs.07-0051
   Yamada K, 2007, INVEST OPHTH VIS SCI, V48, P1839, DOI 10.1167/iovs.06-1085
NR 28
TC 45
Z9 45
U1 0
U2 4
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD NOV 21
PY 2012
VL 7
IS 11
AR e49905
DI 10.1371/journal.pone.0049905
PG 10
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA 047ER
UT WOS:000311821000140
PM 23185481
OA Green Published, Green Submitted, gold
DA 2022-11-30
ER

PT J
AU Suri, R
   Neupane, YR
   Mehra, N
   Nematullah, M
   Khan, F
   Alam, O
   Iqubal, A
   Jain, GK
   Kohli, K
AF Suri, Reshal
   Neupane, Yub Raj
   Mehra, Nikita
   Nematullah, Md
   Khan, Farah
   Alam, Ozair
   Iqubal, Ashif
   Jain, Gaurav Kumar
   Kohli, Kanchan
TI Sirolimus loaded chitosan functionalized poly (lactic-co-glycolic acid)
   (PLGA) nanoparticles for potential treatment of age-related macular
   degeneration
SO INTERNATIONAL JOURNAL OF BIOLOGICAL MACROMOLECULES
LA English
DT Article
DE Sirolimus; Age-related macular degeneration (AMD); Chorioallantoic
   membrane (CAM); PLGA; Chitosan; Box-Behnken Design; Raw 264; 7 cells
ID IN-VITRO; DRUG-DELIVERY; SUBCONJUNCTIVAL SIROLIMUS; POLYMERIC
   NANOPARTICLES; CONTROLLED-RELEASE; OCULAR DELIVERY; EX-VIVO;
   OPTIMIZATION; FORMULATION; EYE
AB The usefulness of sirolimus (SIR) in the treatment of diseases that involve retinal degeneration like age-related macular degeneration (AMD) has been well documented. However, the problem still remains probably owing to the peculiar environment of the eye and/or unfavourable physiochemical profile of SIR. In the present work, we aimed to fabricate sirolimus loaded PLGA nanoparticles (SIR-PLGA-NP) and chitosan decorated PLGA nano particles (SIR-CH-PLGA-NP) to be administered via non-invasive subconjunctival route. Both the nanoparticles were characterized in terms of size, zeta potential, DSC, FTIR and XRD analysis. Quality by Design (QbD) approach was employed during the preparation of nanoparticles and the presence of chitosan coating was confirmed through thermogravimetric analysis and contact angle studies. Cationic polymer modification showed sustained in-vitro SIR release and enhanced ex-vivo scleral permeation and penetration. Further, SIR-CH-PLGA-NP revealed enhanced cellular uptake and thus, reduced lipopolysaccharide (LPS)-induced free-radicals generation by RAW 264.7 cells. The prepared nanoparticles were devoid of residual solvent and were found to be safe in HET-CAM analysis, RBCs damage analysis and histopathology studies. Moreover, high anti-angiogenic potential was observed in SIR-CH-PLGA-NP compared with SIR-PLGA-NP in chorioallantoic membrane (CAM) test. Overall, the current work opens up an avenue for further investigation of CH-PLGA-NP as SIR nanocarrier in the treatment of AMD.
C1 [Suri, Reshal; Mehra, Nikita; Kohli, Kanchan] Jamia Hamdard, Dept Pharmaceut, Sch Pharmaceut Educ & Res, New Delhi 110062, India.
   [Neupane, Yub Raj] Natl Univ Singapore, Dept Pharm, Singapore 117559, Singapore.
   [Nematullah, Md; Khan, Farah] Jamia Hamdard, Dept Biochem, Sch Chem & Life Sci, New Delhi 110062, India.
   [Alam, Ozair] Jamia Hamdard, Dept Pharmaceut Chem, Med Chem & Mol Modelling Lab, Sch Pharmaceut Educ & Res, New Delhi 110062, India.
   [Iqubal, Ashif] Jamia Hamdard, Dept Pharmacol, Sch Pharmaceut Educ & Res, New Delhi 110062, India.
   [Jain, Gaurav Kumar] Delhi Pharmaceut Sci & Res Univ, Dept Pharmaceut, New Delhi 110017, India.
C3 Jamia Hamdard University; National University of Singapore; Jamia
   Hamdard University; Jamia Hamdard University; Jamia Hamdard University;
   Meenakshi Academy of Higher Education & Research (MAHER); Delhi
   Pharmaceutical Sciences & Research University (DPSRU)
RP Kohli, K (通讯作者)，Jamia Hamdard, Dept Pharmaceut, Sch Pharmaceut Educ & Res, New Delhi 110062, India.; Neupane, YR (通讯作者)，Natl Univ Singapore, Dept Pharm, Singapore 117559, Singapore.
EM yub@u.nus.edu; dr.kanchankohli65@gmail.com
RI Khan, Farah/AFT-6960-2022; Neupane, Yub Raj/ABG-1685-2020
OI Suri, Reshal/0000-0002-1741-7449; Neupane, Yub Raj/0000-0002-4535-5396
CR Al-Nemrawi NK, 2018, PHARMACEUTICALS-BASE, V11, DOI 10.3390/ph11010028
   Amrite AC, 2005, J PHARM PHARMACOL, V57, P1555, DOI 10.1211/jpp.57.12.0005
   Ansary RH, 2014, TROP J PHARM RES, V13, P1179, DOI 10.4314/tjpr.v13i7.24
   B'Hymer C, 2003, PHARMACEUT RES, V20, P337, DOI 10.1023/A:1022693516409
   Bhatt P, 2020, AAPS PHARMSCITECH, V21, DOI 10.1208/s12249-020-01836-4
   Biarnes M, 2018, EXPERT REV PRECIS ME, V3, P249, DOI 10.1080/23808993.2018.1502037
   Bin-Jumah M, 2021, INT J NANOMED, V15, P7861, DOI 10.2147/IJN.S269004
   Brako F, 2018, ACS APPL MATER INTER, V10, P13381, DOI 10.1021/acsami.8b03329
   Chang PC, 2020, INT J BIOL MACROMOL, V158, P627, DOI 10.1016/j.ijbiomac.2020.04.183
   Chatzitaki AT, 2020, INT J PHARMACEUT, V589, DOI 10.1016/j.ijpharm.2020.119776
   Cheraga N., 2020, J DRUG DELIV SCI TEC, V61, P1
   Cheruvu NPS, 2006, INVEST OPHTH VIS SCI, V47, P4513, DOI 10.1167/iovs.06-0404
   Danhier F, 2009, J CONTROL RELEASE, V133, P11, DOI 10.1016/j.jconrel.2008.09.086
   Dugel P.U., 2009, RETIN TODAY, P38
   Escalona-Rayo O, 2019, J DRUG DELIV SCI TEC, V52, P488, DOI 10.1016/j.jddst.2019.05.026
   Espinoza SM, 2019, PHARM DEV TECHNOL, V24, P751, DOI 10.1080/10837450.2019.1592189
   Guo CQ, 2008, EUR J PHARM BIOPHARM, V70, P597, DOI 10.1016/j.ejpb.2008.06.008
   Hady WEA, 2019, INT J NANOMED, V14, P7191, DOI 10.2147/IJN.S213836
   Haeri A, 2018, ARTIF CELL NANOMED B, V46, pS1, DOI 10.1080/21691401.2017.1408123
   Holz FG, 2014, J CLIN INVEST, V124, P1430, DOI 10.1172/JCI71029
   Iavicoli I, 2017, TOXICOL IN VITRO, V42, P191, DOI 10.1016/j.tiv.2017.04.024
   Ibrahim MA, 2015, TRANSL VIS SCI TECHN, V4, DOI 10.1167/tvst.4.2.4
   Iqubal A, 2019, LIFE SCI, V236, DOI 10.1016/j.lfs.2019.116867
   Jain GK, 2011, COLLOID SURFACE B, V82, P397, DOI 10.1016/j.colsurfb.2010.09.010
   Javiya C, 2016, DRUG DEV IND PHARM, V42, P1504, DOI 10.3109/03639045.2016.1151030
   Jiang G, 2020, INT J NANOMED, V15, P9373, DOI 10.2147/IJN.S272750
   Joseph RR, 2017, NANOMEDICINE-UK, V12, P683, DOI 10.2217/nnm-2016-0379
   Kamaly N, 2016, CHEM REV, V116, P2602, DOI 10.1021/acs.chemrev.5b00346
   Kim BS, 2008, ARCH PHARM RES, V31, P1050, DOI 10.1007/s12272-001-1267-5
   Koyano T, 2000, POLYMER, V41, P4461, DOI 10.1016/S0032-3861(99)00675-8
   Krishnadev N, 2011, GRAEF ARCH CLIN EXP, V249, P1627, DOI 10.1007/s00417-011-1694-9
   Law KY, 2014, J PHYS CHEM LETT, V5, P686, DOI 10.1021/jz402762h
   Lu BT, 2019, POLYMERS-BASEL, V11, DOI 10.3390/polym11020304
   Madni A, 2017, INT J PHARMACEUT, V530, P326, DOI 10.1016/j.ijpharm.2017.07.065
   Mahaling B, 2016, NANOMED-NANOTECHNOL, V12, P2149, DOI 10.1016/j.nano.2016.05.017
   Mahaling B, 2016, INT J PHARMACEUT, V501, P1, DOI 10.1016/j.ijpharm.2016.01.053
   Mahtab A, 2020, CARBOHYD POLYM, V250, DOI 10.1016/j.carbpol.2020.116926
   Mengke NS, 2016, MOL MED REP, V14, P4957, DOI 10.3892/mmr.2016.5883
   Meza-Rios A, 2020, OPHTHALMOL THER, DOI 10.1007/s40123-020-00257-7
   Minturn RJ, 2021, INT J RETINA VITR, V7, DOI 10.1186/s40942-021-00281-0
   Moschos MM, 2014, J CHEM-NY, V2014, DOI 10.1155/2014/317536
   Musumeci T, 2014, J PHARM SCI-US, V103, P628, DOI 10.1002/jps.23836
   Nasef MM, 2011, E-J CHEM, V8, pS409
   Neupane YR, 2014, INT J PHARMACEUT, V477, P601, DOI 10.1016/j.ijpharm.2014.11.001
   Pandit J, 2017, ARTIF CELL NANOMED B, V45, P1397, DOI 10.1080/21691401.2016.1243545
   Park K, 2007, J CONTROL RELEASE, V120, P1, DOI 10.1016/j.jconrel.2007.05.003
   Parveen S, 2011, EUR J PHARMACOL, V670, P372, DOI 10.1016/j.ejphar.2011.09.023
   Preetham AC, 2011, J DISPER SCI TECHNOL, V32, P778, DOI 10.1080/01932691.2010.488129
   Pujari A, 2019, INDIAN J OPHTHALMOL, V67, P1327, DOI 10.4103/ijo.IJO_1779_18
   Puranik S.B., 2008, INT J CHEM SCI, V6, P693
   Qiu FF, 2019, MOL PHARMACEUT, V16, P1958, DOI 10.1021/acs.molpharmaceut.8b01319
   Radhakrishnan K, 2019, PHARMACEUTICS, V11, DOI 10.3390/pharmaceutics11070330
   Sahoo SK, 2002, J CONTROL RELEASE, V82, P105, DOI 10.1016/S0168-3659(02)00127-X
   Sanna V, 2012, INT J NANOMED, V7, P5501, DOI 10.2147/IJN.S36684
   Senel B, 2019, DRUG DEV IND PHARM, V45, P1835, DOI 10.1080/03639045.2019.1665061
   Shahab MS, 2020, INT J BIOL MACROMOL, V163, P2392, DOI 10.1016/j.ijbiomac.2020.09.185
   Shen HH, 2015, NANOMEDICINE-UK, V10, P2093, DOI [10.2217/NNM.15.47, 10.2217/nnm.15.47]
   Shim H, 2020, PHARMACEUTICS, V12, DOI 10.3390/pharmaceutics12070626
   Singh A, 2019, J PHARM SCI-US, V108, P3382, DOI 10.1016/j.xphs.2019.06.003
   Singh PK, 2016, RSC ADV, V6, P71705, DOI 10.1039/c6ra06007b
   Stahl A, 2008, FEBS LETT, V582, P3097, DOI 10.1016/j.febslet.2008.08.005
   Suri R., EXP PHARM PROD DEV, P117
   Suri R, 2020, EUR J PHARM SCI, V153, DOI 10.1016/j.ejps.2020.105489
   Tavaszi J, 2007, Commun Agric Appl Biol Sci, V72, P137
   Wang GF, 2012, INT J OPHTHALMOL-CHI, V5, P609, DOI 10.3980/j.issn.2222-3959.2012.05.13
   Wong WT, 2013, INVEST OPHTH VIS SCI, V54, P2941, DOI 10.1167/iovs.13-11650
   Yuan XB, 2008, INT J PHARM, V349, P241, DOI 10.1016/j.ijpharm.2007.07.045
   Yurtdas-Kirimlioglu G, 2021, J DRUG DELIV SCI TEC, V61, DOI 10.1016/j.jddst.2020.102145
   Zafar A, 2020, IRAN J PHARM RES, V19, P292, DOI 10.22037/ijpr.2019.15318.13016
   Zafar S, 2020, COLLOID SURFACE B, V186, DOI 10.1016/j.colsurfb.2019.110603
   Zahir-Jouzdani F, 2019, J CELL PHYSIOL, V234, P4702, DOI 10.1002/jcp.27243
   Zhang K, 2012, NAT REV DRUG DISCOV, V11, P541, DOI 10.1038/nrd3745
NR 72
TC 6
Z9 6
U1 5
U2 16
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 0141-8130
EI 1879-0003
J9 INT J BIOL MACROMOL
JI Int. J. Biol. Macromol.
PD NOV 30
PY 2021
VL 191
BP 548
EP 559
DI 10.1016/j.ijbiomac.2021.09.069
EA SEP 2021
PG 12
WC Biochemistry & Molecular Biology; Chemistry, Applied; Polymer Science
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Chemistry; Polymer Science
GA WL2MD
UT WOS:000710244900006
PM 34536476
DA 2022-11-30
ER

PT J
AU Potter, MJ
   Claudio, CC
   Szabo, SM
AF Potter, M. J.
   Claudio, C. C.
   Szabo, S. M.
TI A randomised trial of bevacizumab and reduced light dose photodynamic
   therapy in age-related macular degeneration: the VIA study
SO BRITISH JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
ID CHOROIDAL NEOVASCULARIZATION; INTRAVITREAL BEVACIZUMAB; VERTEPORFIN
   THERAPY; RANIBIZUMAB; COMBINATION; INJECTION; AVASTIN; FOCUS; PDT
AB Aim To determine if reduced light-dose photodynamic therapy (PDT) combined with bevacizumab will decrease the number of bevacizumab treatments required over 6 months compared with bevacizumab monotherapy in neovascular age-related macular degeneration (AMD).
   Methods Thirty-six patients with neovascular AMD were recruited for this randomised, double-masked, controlled clinical trial. Patients received intravitreal bevacizumab plus PDT using a light dose of either 25 J/cm(2) (group 1) or 12 J/cm(2) (group 2), or intravitreal bevacizumab plus sham PDT (group 3). Patients returned monthly for possible retreatment with bevacizumab or combination therapy (with a 3-month minimum interval between combination treatments); retreatment decisions were primarily based on optical coherence tomography. The main outcome measure was the mean number of bevacizumab treatments required over 6 months.
   Results Patients required a mean of 2.8 bevacizumab treatments in group 1 and 2.5 in group 2, compared with 5.1 in group 3 (p = 0.005 and p<0.001, respectively).
   Conclusions Combination bevacizumab and 25 J/cm(2) or 12 J/cm(2) PDT significantly reduced the number of bevacizumab treatments required over 6 months. This study was powered to examine number of treatments, but not visual acuities. Nevertheless, visual acuities responded favourably in all three groups. Further studies will be helpful to explore visual outcomes.
C1 [Potter, M. J.] Univ British Columbia, Eye Care Ctr, VH, Dept Ophthalmol & Visual Sci, Vancouver, BC V5Z 3N9, Canada.
C3 University of British Columbia
RP Potter, MJ (通讯作者)，Univ British Columbia, Eye Care Ctr, VH, Dept Ophthalmol & Visual Sci, 2550 Willow St,Sect B, Vancouver, BC V5Z 3N9, Canada.
EM michael.potter88@gmail.com
CR Aggio FB, 2006, ACTA OPHTHALMOL SCAN, V84, P831, DOI 10.1111/j.1600-0420.2006.00764.x
   Antoszyk AN, 2008, AM J OPHTHALMOL, V145, P862, DOI 10.1016/j.ajo.2007.12.029
   Augustin AJ, 2007, RETINA-J RET VIT DIS, V27, P133, DOI 10.1097/IAE.0b013e3180323de7
   Avery RL, 2006, OPHTHALMOLOGY, V113, P363, DOI 10.1016/j.ophtha.2005.11.019
   Bashshur ZF, 2006, AM J OPHTHALMOL, V142, P1, DOI 10.1016/j.ajo.2006.02.037
   Bressler NM, 1999, ARCH OPHTHALMOL-CHIC, V117, P1329
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Costa RA, 2007, GRAEF ARCH CLIN EXP, V245, P1273, DOI 10.1007/s00417-007-0557-x
   Dhalla MS, 2006, RETINA-J RET VIT DIS, V26, P988, DOI 10.1097/01.iae.0000247164.70376.91
   Greve MDJ, 2005, ARCH OPHTHALMOL-CHIC, V123, P448
   Heier JS, 2006, ARCH OPHTHALMOL-CHIC, V124, P1532, DOI 10.1001/archopht.124.11.1532
   Kiss CG, 2008, BRIT J OPHTHALMOL, V92, P1620, DOI 10.1136/bjo.2007.135335
   Krebs I, 2005, BRIT J OPHTHALMOL, V89, P1184, DOI 10.1136/bjo.2005.067389
   Ladewig MS, 2008, GRAEF ARCH CLIN EXP, V246, P17, DOI 10.1007/s00417-007-0654-x
   Lazic R, 2007, OPHTHALMOLOGY, V114, P1179, DOI 10.1016/j.ophtha.2007.03.006
   Miller JW, 1999, ARCH OPHTHALMOL-CHIC, V117, P1161
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Rosenfeld PJ, 2005, OPHTHAL SURG LAS IM, V36, P331, DOI 10.3928/1542-8877-20050701-14
   Sacu S, 2008, BRIT J OPHTHALMOL, V92, P1347, DOI 10.1136/bjo.2008.137885
   Schmidt-Erfurth U, 2008, BRIT J OPHTHALMOL, V92, P1628, DOI 10.1136/bjo.2007.135277
   Spaide RF, 2006, RETINA-J RET VIT DIS, V26, P383, DOI 10.1097/00006982-200604000-00001
   van Velthoven MEJ, 2006, GRAEF ARCH CLIN EXP, V244, P1119, DOI 10.1007/s00417-005-0209-y
NR 22
TC 28
Z9 32
U1 0
U2 4
PU B M J PUBLISHING GROUP
PI LONDON
PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND
SN 0007-1161
J9 BRIT J OPHTHALMOL
JI Br. J. Ophthalmol.
PD FEB
PY 2010
VL 94
IS 2
BP 174
EP 179
DI 10.1136/bjo.2008.155531
PG 6
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 552WR
UT WOS:000274325500009
PM 19520690
DA 2022-11-30
ER

PT J
AU Mendrinos, E
   Pournaras, CJ
AF Mendrinos, Efstratios
   Pournaras, Constantin J.
TI Topographic variation of the choroidal watershed zone and its
   relationship to neovascularization in patients with age-related macular
   degeneration
SO ACTA OPHTHALMOLOGICA
LA English
DT Article
DE choroidal neovascularization; choroidal watershed zone; patterns
ID INDOCYANINE GREEN ANGIOGRAPHY; BLOOD-FLOW; CIRCULATION; DISEASE;
   CHORIOCAPILLARIS; HYPERTENSION; MACULOPATHY; FLUORESCEIN; THERAPY;
   LESIONS
AB To evaluate the patterns of choroidal watershed zones (WZs) in exudative age-related macular degeneration (AMD) and to describe their relationship with choroidal neovascularization (CNV).
   We retrospectively evaluated 50 digital indocyanine green video-angiograms of 50 patients with exudative AMD demonstrating one or more WZs. In addition, the relationship between the site of CNV and the WZ was analysed.
   A stellate WZ was observed in 30 of 50 (60%) patients. Choroidal neovascularization occurred within the centre of the WZ in all cases. The WZ was vertically oriented in 18 of 50 (36%) patients. When the WZ coursed through or extended into the fovea, CNV occurred within the WZ, but it occurred at its margin when the WZ did not involve the fovea. An angled WZ coursing through the fovea with CNV occurring within it was observed in two of 50 (4%) patients.
   In exudative AMD, the WZ most commonly conformed to the stellate pattern, followed by the vertical and angled patterns. Choroidal neovascularization occurred within the WZ in 44 of 50 (88%) patients. When the WZ did not involve the fovea (12%), CNV occurred at its margin. The relationship between the site of CNV and macular WZs suggests that macular WZs may be areas which are vulnerable to AMD and which are predisposed to CNV by the resulting hypoxia-ischaemia.
C1 [Mendrinos, Efstratios; Pournaras, Constantin J.] Univ Hosp Geneva, Dept Ophthalmol, Vitreoretinal Unit, CH-1211 Geneva 14, Switzerland.
C3 University of Geneva
RP Pournaras, CJ (通讯作者)，Univ Hosp Geneva, Dept Ophthalmol, Vitreoretinal Unit, 22 Rue Alcide Jentzer, CH-1211 Geneva 14, Switzerland.
EM constantin.pournaras@hcuge.ch
CR BARTSCH DU, 1995, AM J OPHTHALMOL, V120, P642, DOI 10.1016/S0002-9394(14)72211-1
   Bressler NM, 1999, ARCH OPHTHALMOL-CHIC, V117, P1329
   Dimitrova G, 2002, EYE, V16, P580, DOI 10.1038/sj.eye.6700161
   FLOWER RW, 1993, INVEST OPHTH VIS SCI, V34, P2720
   Freeman WR, 1998, ARCH OPHTHALMOL-CHIC, V116, P455, DOI 10.1001/archopht.116.4.455
   FRIEDMAN E, 1995, OPHTHALMOLOGY, V102, P640, DOI 10.1016/S0161-6420(95)30974-8
   GIOVANNINI A, 1994, OPHTHALMOLOGICA, V208, P185, DOI 10.1159/000310483
   GIUFFRE G, 1989, DOC OPHTHALMOL, V72, P175, DOI 10.1007/BF00156707
   Grunwald JE, 2005, INVEST OPHTH VIS SCI, V46, P1033, DOI 10.1167/iovs.04-1050
   HAYASHI K, 1985, OPHTHALMOLOGICA, V190, P20, DOI 10.1159/000309488
   HAYASHI K, 1985, OPHTHALMOLOGICA, V190, P30, DOI 10.1159/000309489
   HAYREH SS, 1983, INT OPHTHALMOL, V6, P161, DOI 10.1007/BF00127645
   HAYREH SS, 1986, OPHTHALMOLOGY, V93, P1383
   HAYREH SS, 1974, A GRAEF ARCH KLIN EX, V192, P165
   HAYREH SS, 1981, OPHTHALMOLOGICA, V183, P11
   Hayreh SS, 2004, INVEST OPHTH VIS SCI, V45, P749, DOI 10.1167/iovs.03-0469
   HAYREH SS, 1990, EYE, V4, P273, DOI 10.1038/eye.1990.39
   HAYREH SS, 1983, INT OPHTHALMOL, V6, P85, DOI 10.1007/BF00127636
   HAYREH SS, 1975, BRIT J OPHTHALMOL, V59, P631, DOI 10.1136/bjo.59.11.631
   Kvanta A, 2006, ACTA OPHTHALMOL SCAN, V84, P282, DOI 10.1111/j.1600-0420.2006.00659.x
   LEIBOWITZ H, 1973, SURV OPHTHALMOL, V24, P335
   Pauleikhoff D, 1999, ARCH OPHTHALMOL-CHIC, V117, P1353, DOI 10.1001/archopht.117.10.1353
   Pournaras CJ, 2006, INVEST OPHTH VIS SCI, V47, P1581, DOI 10.1167/iovs.05-0434
   REMULLA JFC, 1995, BRIT J OPHTHALMOL, V79, P558, DOI 10.1136/bjo.79.6.558
   Ross RD, 1998, AM J OPHTHALMOL, V125, P71, DOI 10.1016/S0002-9394(99)80237-2
   SPERDUTO RD, 1986, ARCH OPHTHALMOL-CHIC, V104, P216
   TORVIK A, 1984, STROKE, V15, P221, DOI 10.1161/01.STR.15.2.221
   Uretmen O, 2003, OPHTHALMOLOGICA, V217, P137, DOI 10.1159/000068559
   Yannuzzi LA, 2001, RETINA-J RET VIT DIS, V21, P416, DOI 10.1097/00006982-200110000-00003
   YANNUZZI LA, 1992, RETINA-J RET VIT DIS, V12, P191, DOI 10.1097/00006982-199212030-00003
   Zhang SX, 2007, PROG RETIN EYE RES, V26, P1, DOI 10.1016/j.preteyeres.2006.09.002
   ZHAO J, 1995, INT OPHTHALMOL, V19, P1, DOI 10.1007/BF00156412
NR 32
TC 19
Z9 21
U1 0
U2 1
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1755-375X
EI 1755-3768
J9 ACTA OPHTHALMOL
JI Acta Ophthalmol.
PD MAY
PY 2009
VL 87
IS 3
BP 290
EP 296
DI 10.1111/j.1755-3768.2008.01247.x
PG 7
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 434BY
UT WOS:000265251400010
PM 18577185
DA 2022-11-30
ER

PT J
AU Thiele, S
   Nadal, J
   Fleckenstein, M
   Fang, PP
   Pfau, M
   Schmid, M
   Hua, R
   Holz, FG
   Schmitz-Valckenberg, S
AF Thiele, Sarah
   Nadal, Jennifer
   Fleckenstein, Monika
   Fang, Petra P.
   Pfau, Maximilian
   Schmid, Matthias
   Hua, Rui
   Holz, Frank G.
   Schmitz-Valckenberg, Steffen
CA MODIAMD Study Grp
TI Longitudinal Analysis of Drusen Volume in Intermediate Age-Related
   Macular Degeneration Using Two Spectral-Domain Optical Coherence
   Tomography Scan Patterns
SO OPHTHALMOLOGICA
LA English
DT Article
DE Conversion; Spectral-domain optical coherence tomography; Biomarker;
   Agreement; Image analysis
ID RETINAL-PIGMENT EPITHELIUM; VISUAL IMPAIRMENT; CLINICAL-TRIAL; EYE
   DISEASE; SOFT DRUSEN; PROGRESSION; ASSOCIATIONS; MORPHOLOGY; DENSITY;
   LESIONS
AB Purpose: To evaluate two different spectral-domain optical coherence tomography (SD-OCT) scan patterns in eyes with intermediate age-related macular degeneration (AMD) for the longitudinal assessment of drusen volume. Methods: The data of 38 eyes of 38 AMD patients (age 69.97 +/- 6.08 years) were included. The longitudinal drusen volume over 4 years was analyzed by annual SD-OCT raster scanning (field size 20 x 15 degrees). Two raster scan patterns (A/B) differed in the distance between neighboring B-scans (240 vs. 30 mu m) and in the number of averaged frames (4 vs. 15). Results: The mean drusen volume at baseline was 0.213 +/- 0.100 mm(3) (pattern A) and 0.219 +/- 0.103 mm(3) (pattern B) (p = 0.937). Linear mixed-effect models showed no significant difference for the change within 4 years for both pattern A (p = 0.8) and pattern B (p = 0.8). Conclusions: The results indicate that the performance of interpolation algorithms may be sufficient to balance for less dense raster scanning with regard to quantification of longitudinal drusen volume, which can be used as a surrogate marker for AMD progression in future clinical trials. (c) 2018 S. Karger AG, Basel.
C1 [Thiele, Sarah; Fleckenstein, Monika; Fang, Petra P.; Pfau, Maximilian; Hua, Rui; Holz, Frank G.; Schmitz-Valckenberg, Steffen] Univ Bonn, Dept Ophthalmol, Ernst Abbe Str 2, DE-53127 Bonn, Germany.
   [Nadal, Jennifer; Schmid, Matthias] Univ Bonn, Inst Med Biometry Informat & Epidemiol, Bonn, Germany.
C3 University of Bonn; University of Bonn
RP Schmitz-Valckenberg, S (通讯作者)，Univ Bonn, Dept Ophthalmol, Ernst Abbe Str 2, DE-53127 Bonn, Germany.
EM steffen.schmitz-valckenberg@ukbonn.de
RI Pfau, Maximilian/N-1888-2019; Larsen, Petra/AAV-3114-2020
OI Pfau, Maximilian/0000-0001-9761-9640; Larsen, Petra/0000-0003-2486-632X;
   Schmid, Matthias/0000-0002-0788-0317
CR Abdelfattah NS, 2016, INVEST OPHTH VIS SCI, V57, P1839, DOI 10.1167/iovs.15-18572
   Age-Related Eye Dis Study Res Grp, 2001, AM J OPHTHALMOL, V132, P668
   Balaratnasingam C, 2016, AM J OPHTHALMOL, V172, P28, DOI 10.1016/j.ajo.2016.09.008
   Balaratnasingam C, 2016, INVEST OPHTH VIS SCI, V57, P5479, DOI 10.1167/iovs.16-19816
   Bartlett H, 2007, SURV OPHTHALMOL, V52, P655, DOI 10.1016/j.survophthal.2007.08.022
   BRESSLER NM, 1995, ARCH OPHTHALMOL-CHIC, V113, P301, DOI 10.1001/archopht.1995.01100030055022
   Bressler NM, 2006, AGE RELATED MACULAR, VII, P1041
   Chew EY, 2014, JAMA OPHTHALMOL, V132, P272, DOI 10.1001/jamaophthalmol.2013.6636
   Congdon N, 2004, ARCH OPHTHALMOL-CHIC, V122, P477
   Cukras C, 2010, OPHTHALMOLOGY, V117, P489, DOI 10.1016/j.ophtha.2009.12.002
   Davis MD, 2005, ARCH OPHTHALMOL-CHIC, V123, P1484
   de Sisternes L, 2014, INVEST OPHTH VIS SCI, V55, P7093, DOI 10.1167/iovs.14-14918
   Ferris FL, 2013, OPHTHALMOLOGY, V120, P844, DOI 10.1016/j.ophtha.2012.10.036
   Fiore T, 2015, OPHTHALMOLOGICA, V234, P167, DOI 10.1159/000435841
   Folgar FA, 2016, OPHTHALMOLOGY, V123, P39, DOI 10.1016/j.ophtha.2015.09.016
   Guymer RH, 2014, CLIN EXP OPHTHALMOL, V42, P466, DOI 10.1111/ceo.12247
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1417, DOI 10.1001/archopht.119.10.1417
   Khanifar AA, 2008, OPHTHALMOLOGY, V115, P1883, DOI 10.1016/j.ophtha.2008.04.041
   KLEIN R, 1991, OPHTHALMOLOGY, V98, P1128
   Klein R, 2007, OPHTHALMOLOGY, V114, P253, DOI 10.1016/j.ophtha.2006.10.040
   Leuschen JN, 2013, OPHTHALMOLOGY, V120, P140, DOI 10.1016/j.ophtha.2012.07.004
   Muftuoglu IK, 2017, QUANTITATIVE ANAL IN
   Nittala MG, 2011, EYE, V25, P1347, DOI 10.1038/eye.2011.173
   Odell D, 2011, J OPHTHALMOL, V2011, DOI 10.1155/2011/692574
   Resnikoff S, 2004, B WORLD HEALTH ORGAN, V82, P844
   Sadda SR, 2010, INVEST OPHTH VIS SCI, V51, P1071, DOI 10.1167/iovs.09-4325
   Sallo FB, 2009, BRIT J OPHTHALMOL, V93, P1345, DOI 10.1136/bjo.2008.150334
   SARKS JP, 1994, EYE, V8, P269, DOI 10.1038/eye.1994.57
   Schaal KB, 2016, OPHTHALMOLOGY, V123, P1060, DOI 10.1016/j.ophtha.2016.01.034
   Schlanitz FG, 2017, BRIT J OPHTHALMOL, V101, P198, DOI 10.1136/bjophthalmol-2016-308422
   Schuman SG, 2009, OPHTHALMOLOGY, V116, P488, DOI 10.1016/j.ophtha.2008.10.006
   Sevilla MB, 2016, AM J OPHTHALMOL, V165, P65, DOI 10.1016/j.ajo.2016.02.021
   Smith RT, 2010, BRIT J OPHTHALMOL, V94, P1618, DOI 10.1136/bjo.2009.166843
   Spaide RF, 2010, RETINA-J RET VIT DIS, V30, P1441, DOI 10.1097/IAE.0b013e3181ee5ce8
   Staurenghi G, 2014, OPHTHALMOLOGY, V121, P1572, DOI 10.1016/j.ophtha.2014.02.023
   Steinberg JS, 2016, RETINA-J RET VIT DIS, V36, P1548, DOI 10.1097/IAE.0000000000000951
   Steinberg JS, 2015, BRIT J OPHTHALMOL, V99, P1289, DOI 10.1136/bjophthalmol-2014-306535
   Sunness JS, 1999, OPHTHALMOLOGY, V106, P1768, DOI 10.1016/S0161-6420(99)90340-8
   Wu ZC, 2016, INVEST OPHTH VIS SCI, V57, P3714, DOI 10.1167/iovs.15-18294
   Yehoshua Z, 2011, OPHTHALMOLOGY, V118, P2434, DOI 10.1016/j.ophtha.2011.05.008
NR 40
TC 8
Z9 8
U1 0
U2 2
PU KARGER
PI BASEL
PA ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND
SN 0030-3755
EI 1423-0267
J9 OPHTHALMOLOGICA
JI Ophthalmologica
PY 2018
VL 239
IS 2-3
BP 110
EP 120
DI 10.1159/000485260
PG 11
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA FZ0QL
UT WOS:000427276000006
PM 29306951
DA 2022-11-30
ER

PT J
AU Colucciello, M
AF Colucciello, Michael
TI Intravitreal bevacizumab and triamcinolone acetonide combination therapy
   for exudative neovascular age-related macular degeneration: Short-term
   optical coherence tomography results
SO JOURNAL OF OCULAR PHARMACOLOGY AND THERAPEUTICS
LA English
DT Article
ID ENDOTHELIAL GROWTH-FACTOR; CHOROIDAL NEOVASCULARIZATION; BRUCHS
   MEMBRANE; RANIBIZUMAB; MACROPHAGES; VERTEPORFIN; AVASTIN; SAFETY; CELLS
AB Purpose: The aim of this study to describe the short-term anatomical results after an intravitreal injection of bevacizumab and triamcinolone acetonide in patients with foveal edema and/or subfoveal fluid associated with neovascularization (NV) due to age-related macular degeneration (AMD).
   Methods: A retrospective, noncomparative case series was conducted in patients with foveal edema and/or subfoveal fluid associated with NV due. to AMD during a 3-month period. Patients were treated with intravitreal injections of bevacizumab (1.25 mg/0.05 mL) and followed immediately with triamcinolone acetonide (2 mg/0.05 mL) in separate syringes. Ophthalmoscopic examination with optical coherence tomography analysis of foveal edema and subfoveal fluid volume was performed at baseline and follow-up visits.
   Results: There were 30 consecutive eyes of 27 patients who received a short-term follow-up between 1 and 8 weeks after injection. Foveal thickness and subfoveal fluid volume were each statistically significantly reduced in the short term (paired Student t test; P < 0.01). No complications of intraocular pressure greater than 30 mmHg, endophthalmitis, retinal detachment, or vitreous hemorrhage developed.
   Conclusions: Reduction of foveal edema and subfoveal fluid in patients with NV due to AMD suggests that combination treatment with intravitreal bevacizumab and triamcinolone merits further investigation.
C1 S Jersey Eye Phys, Retina Dept, Moorestown, NJ 08057 USA.
RP Colucciello, M (通讯作者)，S Jersey Eye Phys, Retina Dept, 509 S Lenola Rd,Suite 11, Moorestown, NJ 08057 USA.
EM rnichael@macula.us
RI Colucciello, Michael/P-8580-2014
OI Colucciello, Michael/0000-0002-1693-9587
CR Ahmad K, 2007, LANCET INFECT DIS, V7, P10, DOI 10.1016/S1473-3099(06)70670-3
   Aiello LP, 2004, RETINA, V24, P13
   Augustin AJ, 2007, RETINA-J RET VIT DIS, V27, P133, DOI 10.1097/IAE.0b013e3180323de7
   Avery RL, 2006, OPHTHALMOLOGY, V113, P363, DOI 10.1016/j.ophtha.2005.11.019
   Bashshur ZF, 2006, AM J OPHTHALMOL, V142, P1, DOI 10.1016/j.ajo.2006.02.037
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Challa JK, 1998, AUST NZ J OPHTHALMOL, V26, P277, DOI 10.1111/j.1442-9071.1998.tb01330.x
   Crane IJ, 2000, J IMMUNOL, V165, P4372, DOI 10.4049/jimmunol.165.8.4372
   Danis RP, 2000, RETINA-J RET VIT DIS, V20, P244, DOI 10.1097/00006982-200003000-00004
   DASTGHEIB K, 1994, ARCH OPHTHALMOL-CHIC, V112, P813, DOI 10.1001/archopht.1994.01090180111045
   Ferrara N, 1997, ENDOCR REV, V18, P4, DOI 10.1210/er.18.1.4
   Fung AE, 2006, BRIT J OPHTHALMOL, V90, P1344, DOI 10.1136/bjo.2006.099598
   Gillies MC, 2007, AM J OPHTHALMOL, V144, P134, DOI 10.1016/j.ajo.2007.03.019
   Gragoudas ES, 2004, NEW ENGL J MED, V351, P2805, DOI 10.1056/NEJMoa042760
   Hollborn M, 2007, INVEST OPHTH VIS SCI, V48, P4360, DOI 10.1167/iovs.06-1234
   KILLINGSWORTH MC, 1990, EYE, V4, P613, DOI 10.1038/eye.1990.86
   Klein R, 2004, AM J OPHTHALMOL, V137, P486, DOI 10.1016/j.ajo.2003.11.069
   Kvanta A, 1996, INVEST OPHTH VIS SCI, V37, P1929
   Nozaki M, 2006, P NATL ACAD SCI USA, V103, P2328, DOI 10.1073/pnas.0408835103
   Oh H, 1999, INVEST OPHTH VIS SCI, V40, P1891
   Penfold PL, 1995, AUST NZ J OPHTHALMOL, V23, P293, DOI 10.1111/j.1442-9071.1995.tb00179.x
   Rich RM, 2006, RETINA-J RET VIT DIS, V26, P495, DOI 10.1097/01.iae.0000225766.75009.3a
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Schnurrbusch UEK, 2005, ARCH OPHTHALMOL-CHIC, V123, P1347, DOI 10.1001/archopht.123.10.1347
   Shimada H, 2007, GRAEF ARCH CLIN EXP, V245, P295, DOI 10.1007/s00417-006-0367-6
   Spaide RF, 2006, RETINA-J RET VIT DIS, V26, P383, DOI 10.1097/00006982-200604000-00001
NR 26
TC 16
Z9 17
U1 0
U2 0
PU MARY ANN LIEBERT, INC
PI NEW ROCHELLE
PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA
SN 1080-7683
EI 1557-7732
J9 J OCUL PHARMACOL TH
JI J. Ocular Pharmacol. Ther.
PD FEB
PY 2008
VL 24
IS 1
BP 15
EP 24
DI 10.1089/jop.2007.0080
PG 10
WC Ophthalmology; Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology; Pharmacology & Pharmacy
GA 257QS
UT WOS:000252814200003
PM 18201136
DA 2022-11-30
ER

PT J
AU Cohen, SY
   Bourgeois, H
   Corbe, C
   Chaine, G
   Espinasse-Berrod, MA
   Garcia-Sanchez, J
   Gaudric, A
   Hullo, A
   Leys, A
   Soubrane, G
   Sahel, JA
AF Cohen, Salomon-Yves
   Bourgeois, Hubert
   Corbe, Christian
   Chaine, Gilles
   Espinasse-Berrod, Marie-Andree
   Garcia-Sanchez, Julian
   Gaudric, Alain
   Hullo, Alain
   Leys, Anita
   Soubrane, Gisele
   Sahel, Jose A.
TI RANDOMIZED CLINICAL TRIAL FRANCE DMLA2 Effect of Trimetazidine on
   Exudative and Nonexudative Age-Related Macular Degeneration
SO RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES
LA English
DT Article
DE age-related macular degeneration; randomized clinical trial;
   trimetazidine; choroidal neovascularization; geographic atrophy
ID RISK-FACTORS; ISCHEMIA-REPERFUSION; GEOGRAPHIC ATROPHY; OXIDATIVE
   STRESS; POOLED FINDINGS; MACULOPATHY; MODEL
AB Purpose: To evaluate the effect of trimetazidine (TMZ) in a randomized, double-blind, placebo-controlled clinical trial on the occurrence of choroidal neovascularization or geographic atrophy in age-related macular degeneration.
   Methods: A total of 1,086 patients from France, Belgium, and Spain with soft drusen and/or retinal pigment epithelium abnormalities in the study eye and choroidal neovascularization in the contralateral eye were randomly assigned to receive orally placebo or TMZ 70 mg daily (35 mg x 2) and followed-up for 3 years to 5 years.
   Results: Treatment duration ranged between 0.4 months and 67.8 months with a mean +/- SD of 38 +/- 16 months. Three hundred and fifty-eight patients developed choroidal neovascularization (incidence per 100 patient-years: TMZ 10.86; placebo 11.13). Trimetazidine did not prevent the choroidal neovascularization (hazard ratio = 0.97; 95% confidence interval, 0.77-1.20; P = 0.781). However, there was a trend favoring TMZ for retinal atrophy, a secondary endpoint (HR = 0.76; 95% confidence interval, 0.56-1.02; P = 0.069). Overall, the difference in atrophy incidence between TMZ and placebo was not statistically different. Differences within some prespecified subgroups of patients showed superiority of TMZ in men (HR = 0.50; 95% confidence interval, 0.28-0.89; p = 0.016), in patients aged <= 75 years (HR = 0.58; 95% confidence interval, 0.38-0.88; p = 0.010), or in patients presenting with isolated pigmentary changes (HR = 0.19; 95% confidence interval, 0.05-0.70; p = 0.005).
   Conclusion: Trimetazidine failed to prevent choroidal neovascularization. Subgroup analyses suggest that this drug could be tested as preventive therapy for geographic atrophy, although the overall comparison showed no statistically significant differences in the progression of geographic atrophy. RETINA 32: 834-843, 2012
C1 [Cohen, Salomon-Yves] Ctr Ophtalmol Imagerie & Laser, F-75015 Paris, France.
   [Bourgeois, Hubert] Val de Grace Hosp, Paris, France.
   [Corbe, Christian] Invalids Hosp, Paris, France.
   [Chaine, Gilles] Avicenne Hosp, Bobigny, France.
   [Garcia-Sanchez, Julian] Univ Complutense Madrid, San Carlos Clin Hosp, Madrid, Spain.
   [Espinasse-Berrod, Marie-Andree] Hop Necker Enfants Malad, Paris, France.
   [Gaudric, Alain] Lariboisiere Hosp, Paris, France.
   [Hullo, Alain] Lyon Sud Hosp, Lyon, France.
   [Leys, Anita] Katholieke Univ Leuven, Louvain, Belgium.
   [Soubrane, Gisele] Univ Eye Clin, Creteil, France.
   [Sahel, Jose A.] XV XX Hosp, Paris, France.
C3 Val-de-Grace Hospital; Assistance Publique Hopitaux Paris (APHP);
   Hopital Universitaire Avicenne - APHP; Complutense University of Madrid;
   Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire
   Necker-Enfants Malades - APHP; UDICE-French Research Universities;
   Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP);
   Hopital Universitaire Lariboisiere-Fernand-Widal - APHP; UDICE-French
   Research Universities; Universite Paris Cite; CHU Lyon; KU Leuven; CHNO
   des Quinze-Vingts; UDICE-French Research Universities; Sorbonne
   Universite
RP Cohen, SY (通讯作者)，Ctr Ophtalmol Imagerie & Laser, 11 Rue Antoine Bourdelle, F-75015 Paris, France.
EM sycsyc75@gmail.com
RI Sahel, Jose-Alain/F-3172-2017
OI Sahel, Jose-Alain/0000-0002-4831-1153; Gaudric,
   Alain/0000-0002-2486-4722
CR Beatty S, 2000, SURV OPHTHALMOL, V45, P115, DOI 10.1016/S0039-6257(00)00140-5
   BIRD AEC, 1995, SURV OPHTHALMOL, V39, P367, DOI 10.1016/S0039-6257(05)80092-X
   Bonne C, 2000, J FR OPHTALMOL, V23, P835
   BRESSLER NM, 1988, SURV OPHTHALMOL, V32, P375, DOI 10.1016/0039-6257(88)90052-5
   BURGESS DB, 1993, ARCH OPHTHALMOL-CHIC, V111, P1189
   Chaine G, 1998, BRIT J OPHTHALMOL, V82, P996, DOI 10.1136/bjo.82.9.996
   Complications Age-Related Macular, 2008, OPHTHALMOLOGY, V115, P1474, DOI 10.1016/j.ophtha.2008.03.008
   Cox DavidRoxbee., 1984, ANAL SURVIVAL DATA, DOI [10.1201/9781315137438/analysis-survival-data-cox-oakes, DOI 10.1201/9781315137438/ANALYSIS-SURVIVAL-DATA-COX-OAKES]
   Davis MD, 2005, ARCH OPHTHALMOL-CHIC, V123, P1484
   DELBARRE B, 1994, ANN NY ACAD SCI, V738, P334
   FERRIS FL, 1984, ARCH OPHTHALMOL-CHIC, V102, P1640
   Ferris FL, 2005, ARCH OPHTHALMOL-CHIC, V123, P1570
   Fine SL, 2000, NEW ENGL J MED, V342, P483, DOI 10.1056/NEJM200002173420707
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P564
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1417, DOI 10.1001/archopht.119.10.1417
   Khan JC, 2006, BRIT J OPHTHALMOL, V90, P75, DOI 10.1136/bjo.2005.073643
   Klaver CCW, 1998, ARCH OPHTHALMOL-CHIC, V116, P1646, DOI 10.1001/archopht.116.12.1646
   Klein ML, 2008, OPHTHALMOLOGY, V115, P1026, DOI 10.1016/j.ophtha.2007.08.030
   Klein R, 2004, AM J OPHTHALMOL, V137, P486, DOI 10.1016/j.ajo.2003.11.069
   KLEIN R, 1991, OPHTHALMOLOGY, V98, P1128
   Maguire MG, 2008, OPHTHALMOLOGY, V115, P1468, DOI 10.1016/j.ophtha.2008.02.028
   Maguire MG, 1997, ARCH OPHTHALMOL-CHIC, V115, P741
   Mohand-Said S, 2002, OPHTHALMIC RES, V34, P300, DOI 10.1159/000065603
   Ozden S, 2001, OPHTHALMOLOGICA, V215, P309, DOI 10.1159/000050880
   Payet O, 2004, J OCUL PHARMACOL TH, V20, P85, DOI 10.1089/108076804772745491
   PIGUET B, 1992, AM J OPHTHALMOL, V113, P657, DOI 10.1016/S0002-9394(14)74790-7
   Pournaras CJ, 2006, INVEST OPHTH VIS SCI, V47, P1581, DOI 10.1167/iovs.05-0434
   QUANTIN C, 1990, REV EPIDEMIOL SANTE, V38, P341
   Richer Stuart, 2004, Optometry, V75, P216, DOI 10.1016/S1529-1839(04)70049-4
   SanGiovanni JP, 2007, ARCH OPHTHALMOL-CHIC, V125, P1225, DOI 10.1001/archopht.125.9.1225
   SARKS SH, 1980, AUST J OPHTHALMOL, V8, P117, DOI 10.1111/j.1442-9071.1980.tb01670.x
   Seddon J, 2004, RETINA, V2
   Smith W, 2001, OPHTHALMOLOGY, V108, P697, DOI 10.1016/S0161-6420(00)00580-7
   Snow K K, 1999, Ophthalmic Epidemiol, V6, P125, DOI 10.1076/opep.6.2.125.1558
   Soubrane G., 2007, LES DMLAS
   Souied EH, 2000, INVEST OPHTH VIS SCI, V41, P244
   Sunness JS, 1999, MOL VIS, V5
   Tomany SC, 2004, OPHTHALMOLOGY, V111, P1280, DOI 10.1016/j.ophtha.2003.11.010
NR 38
TC 7
Z9 8
U1 0
U2 6
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0275-004X
EI 1539-2864
J9 RETINA-J RET VIT DIS
JI Retin.-J. Retin. Vitr. Dis.
PD APR
PY 2012
VL 32
IS 4
BP 834
EP 843
DI 10.1097/IAE.0b013e31822058a3
PG 10
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 918ET
UT WOS:000302232800027
PM 21822162
DA 2022-11-30
ER

PT J
AU Rimbergas, S
   Raghuram, A
   Boothroyd, G
   Vatianou, A
   Lakshminarayanan, V
   Stelmack, J
   Stelmack, T
AF Rimbergas, S
   Raghuram, A
   Boothroyd, G
   Vatianou, A
   Lakshminarayanan, V
   Stelmack, J
   Stelmack, T
TI Change in contrast sensitivity functions with Corning CPF filters in
   patients with age related macular degeneration
SO JOURNAL OF MODERN OPTICS
LA English
DT Article
ID LOW-VISION PATIENTS; OCULAR DISEASE; MODEL
AB Do Corning CPF filters change contrast sensitivity in patients with age related macular degeneration (AMD)? A retrospective review was conducted of 54 charts of veterans with AMD receiving comprehensive low vision services at VICTORS (VA Chicago West Side). CSF measurements with the VISTECH 6500 test system were compared before and after introduction of Corning CPF filters. Veterans were asked if filters made a noticeable change in contrast. Pre/post-filter CSF data was obtained for 63 trials at 1 m test distance and 60 trials at the 3 m test distance. To evaluate the data we used an analytic function to fit the contrast sensitivity data previously described by Lakshminarayanan [Optom. Vis. Sci. 72 511 ( 1995)]. An index was used to compare pre- and post-filter information. Veterans were prescribed filters if improvement in contrast was noted, or a subjective improvement was made. Patients were then contacted post-filter during this retrospective study to determine if the filters still enhanced daily activities. Mean improvement in the contrast sensitivity for each spatial frequency ranged from +0.344 to +0.422 patches with the filters at 1 m and +0.183 to +0.548 patches at 3 m. 87.5% of patients reported improvement in contrast while performing activities of daily living with Corning filters. Paired t test are t = - 3.8298 ( p = 0.003) at 1 m and t = - 4.957 ( p = 0.00001) at 3 m test distance. While the changes in the CSF with filters are statistically significant and consistent with report of self-improvement by patients, the change in the number of patches on the VISTECH 6500 chart is not clinically significant. Clinical implications are that the chart in its current format is not useful for the prescription of filters leaving patient perception of change as a better guideline.
C1 Univ Missouri, Coll Optometry, St Louis, MO 63121 USA.
   VA Chicago Healthcare Syst, Westside Div, Chicago, IL USA.
   Edward Hines Jr Vet Adm Hosp, Blind Rehabil Ctr, Hines, IL 60141 USA.
   Univ Missouri, Dept Phys & Astron, St Louis, MO 63121 USA.
   Illinois Coll Optometry, Chicago, IL USA.
   Univ Illinois, Dept Ophthalmol & Visual Sci, Chicago, IL USA.
C3 University of Missouri System; University of Missouri Saint Louis; US
   Department of Veterans Affairs; Veterans Health Administration (VHA);
   Edward Hines Jr. VA Hospital; University of Missouri System; University
   of Missouri Saint Louis; University of Illinois System; University of
   Illinois Chicago; University of Illinois Chicago Hospital
RP Lakshminarayanan, V (通讯作者)，Univ Missouri, Coll Optometry, St Louis, MO 63121 USA.
EM LakshminarayananV@msx.umsl.edu
RI ; Lakshminarayanan, Vasudevan/L-6055-2018
OI Raghuram, Aparna/0000-0002-2913-6046; Lakshminarayanan,
   Vasudevan/0000-0002-3473-1245
CR Allen M. J., 1979, INTRO MEASUREMENT TH, P77
   BROWN B, 1981, AM J OPTOM PHYS OPT, V58, P218
   Cummings RW, 1999, ESSENTIALS OF LOW VISION PRACTICE, P47
   ELLIOTT DB, 1992, OPTOMETRY VISION SCI, V69, P378, DOI 10.1097/00006324-199205000-00007
   FRENNESSON IC, 1993, DOC OPHTHALMOL, V84, P135, DOI 10.1007/BF01206248
   GAWANDE A, 1992, J VISUAL IMPAIR BLIN, V86, P255
   GINSBURG AP, 1987, LOW VISION PRINCIPLE, P17
   GORMEZAO S, 1997, PRESCRIBING CORNING
   HOEFT WW, 1981, AM J OPTOM PHYS OPT, V58, P841
   KENNEDY RS, 1990, OPTOMETRY VISION SCI, V67, P248, DOI 10.1097/00006324-199004000-00003
   KLEINER R, 1998, ARCH OPHTHALMOL-CHIC, V106, P55
   LAKSHMINARAYANAN V, 1995, OPTOMETRY VISION SCI, V72, P511, DOI 10.1097/00006324-199507000-00012
   LANG AJ, 1993, J OPT SOC AM A, V10, P1600, DOI 10.1364/JOSAA.10.001600
   LEGUIRE LE, 1993, OPHTHAL PHYSL OPT, V13, P124, DOI 10.1111/j.1475-1313.1993.tb00440.x
   LENNERSTRAND G, 1989, ACTA OPHTHALMOL, V67, P225
   LOSHIN DS, 1984, ARCH OPHTHALMOL-CHIC, V102, P1303, DOI 10.1001/archopht.1984.01040031053022
   Maino J H, 1986, J Am Optom Assoc, V57, P532
   MITCHELL RA, 1993, OPTOMETRY VISION SCI, V70, P102, DOI 10.1097/00006324-199302000-00003
   NGUYEN T, 1994, J VIS REHAB, V7, P15
   RUBIN G, 1987, LOW VISION, P323
   RUBIN GS, 1988, CLIN VISION SCI, V2, P169
   SJOSTRAND J, 1977, ACTA OPHTHALMOL, V55, P507
   *VIST CONS INC, 1985, IMP FACTS YOU SHOULD
   WILLIAMS CS, 1989, INTRO OPTICAL TRANSF, P101
   ZIGMAN S, 1990, OPTOMETRY VISION SCI, V67, P100, DOI 10.1097/00006324-199002000-00007
NR 25
TC 2
Z9 2
U1 0
U2 8
PU TAYLOR & FRANCIS LTD
PI ABINGDON
PA 2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND
SN 0950-0340
EI 1362-3044
J9 J MOD OPTIC
JI J. Mod. Opt.
PD JUN 15
PY 2005
VL 52
IS 9
BP 1255
EP 1262
DI 10.1080/09500340512331330837
PG 8
WC Optics
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Optics
GA 921ZT
UT WOS:000228805600005
DA 2022-11-30
ER

PT J
AU Shastry, BS
AF Shastry, Barkur S.
TI Further support for the common variants in complement factor H (Y402H)
   and LOC387715 (A69S) genes as major risk factors for the exudative
   age-related macular degeneration
SO OPHTHALMOLOGICA
LA English
DT Article
DE macular degeneration; Candidate gene; mutation
ID LARGE FAMILY; SUSCEPTIBILITY; DISEASE; POLYMORPHISM; LOCUS; SCAN
AB In developed countries, age-related macular degeneration (ARMD) is a common cause of blindness in the elderly. It is a clinically complex and genetically heterogeneous disorder. The etiology of the disorder may involve interactions between genetic and environmental factors. Recently it has been reported that a polymorphism in the complement factor H (CFH) and LOC387715 gene may determine the susceptibility of individuals to ARMD. In order to replicate and to determine the frequency of this polymorphism in ARMD patients, we have analyzed two unrelated families having exudative ARMD. Our analysis has identified the same common polymorphism (Y402H) in the CFH gene in one family and the A69S polymorphism in the LOC387715 gene in the second family. These results further support the notion that CFH and LOC387715 genes are the major risk factors for ARMD. Copyright (c) 2006 S. Karger AG, Basel
C1 Oakland Univ, Dept Biol Sci, Rochester, MI 48309 USA.
C3 Oakland University
RP Shastry, BS (通讯作者)，Oakland Univ, Dept Biol Sci, Rochester, MI 48309 USA.
EM shastry@oakland.edu
CR Abecasis GR, 2004, AM J HUM GENET, V74, P482, DOI 10.1086/382786
   Edwards AO, 2005, SCIENCE, V308, P421, DOI 10.1126/science.1110189
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P564
   Hageman GS, 2005, P NATL ACAD SCI USA, V102, P7227, DOI 10.1073/pnas.0501536102
   Haines JL, 2005, SCIENCE, V308, P419, DOI 10.1126/science.1110359
   Iyengar SK, 2004, AM J HUM GENET, V74, P20, DOI 10.1086/380912
   Klein ML, 1998, ARCH OPHTHALMOL-CHIC, V116, P1082, DOI 10.1001/archopht.116.8.1082
   Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557
   Maguire MG, 1997, OPHTHALMOLOGY, V104, P5, DOI 10.1016/S0161-6420(97)30369-8
   Michaelides M, 2003, J MED GENET, V40, P641, DOI 10.1136/jmg.40.9.641
   Rivera A, 2005, HUM MOL GENET, V14, P3227, DOI 10.1093/hmg/ddi353
   Schmidt Silke, 2002, Ophthalmic Genet, V23, P209, DOI 10.1076/opge.23.4.209.13883
   Schultz DW, 2003, HUM MOL GENET, V12, P3315, DOI 10.1093/hmg/ddg348
   Shastry BS, 1999, OPHTHALMOLOGICA, V213, P165, DOI 10.1159/000027413
   SHASTRY BS, 2002, RRD BIO BIO, V2, P99
   Stone EM, 1998, NAT GENET, V20, P328, DOI 10.1038/3798
NR 16
TC 15
Z9 15
U1 0
U2 1
PU KARGER
PI BASEL
PA ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND
SN 0030-3755
J9 OPHTHALMOLOGICA
JI Ophthalmologica
PY 2006
VL 220
IS 5
BP 291
EP 295
DI 10.1159/000094617
PG 5
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 083EF
UT WOS:000240438500003
PM 16954704
DA 2022-11-30
ER

PT J
AU Ghanbari, M
   Erkeland, SJ
   Xu, L
   Colijn, JM
   Franco, OH
   Dehghan, A
   Klaver, CCW
   Meester-Smoor, MA
AF Ghanbari, Mohsen
   Erkeland, Stefan J.
   Xu, Lei
   Colijn, Johanna M.
   Franco, Oscar H.
   Dehghan, Abbas
   Klaver, Caroline C. W.
   Meester-Smoor, Magda A.
TI Genetic variants in microRNAs and their binding sites within gene 3UTRs
   associate with susceptibility to age-related macular degeneration
SO HUMAN MUTATION
LA English
DT Article
DE Age-related macular degeneration; AMD; GWAS; microRNA; miRNA-binding
   site; miRNA genetic variants
ID GENOME-WIDE IDENTIFICATION; NUCLEOTIDE POLYMORPHISMS; TARGET SITES;
   MOUSE RETINA; SEED REGION; EXPRESSION; RISK; BIOGENESIS; COMMON;
   DETERMINANTS
AB Age-related macular degeneration (AMD), the leading cause of blindness in the elderly, is a complex disease that results from multiple genetic and environmental factors. MicroRNAs (miRNAs) are small noncoding RNAs that post-transcriptionally regulate target mRNAs and are frequently implicated in human diseases. Here, we investigated the association of genetic variants in miRNAs and miRNA-binding sites within gene 3-untranslated regions (3UTRs) with AMD using data from the largest AMD genome-wide association study. First, we identified three variants in miRNAs significantly associated with AMD. These include rs2168518:G>A in the miR-4513 seed sequence, rs41292412:C>T in pre-miR-122/miR-3591, and rs4351242:C>T in the terminal-loop of pre-miR-3135b. We demonstrated that these variants reduce expression levels of the mature miRNAs in vitro and pointed the target genes that may mediate downstream effects of these miRNAs in AMD. Second, we identified 54 variants (in 31 genes) in miRNA-binding sites associated with AMD. Based on stringent prioritization criteria, we highlighted the variants that are more likely to have an impact on the miRNA-target interactions. Further, we selected rs4151672:C>T within the CFB 3UTR and experimentally showed that while miR-210-5p downregulates expression of CFB, the variant decreases miR-210-5p-mediated repression of CFB. Together, our findings support the notion that miRNAs may play a role in AMD.
C1 [Ghanbari, Mohsen; Colijn, Johanna M.; Franco, Oscar H.; Dehghan, Abbas; Klaver, Caroline C. W.; Meester-Smoor, Magda A.] Erasmus Univ, Dept Epidemiol, Med Ctr, POB 2040, NL-3000 CA Rotterdam, Netherlands.
   [Ghanbari, Mohsen] Mashhad Univ Med Sci, Sch Med, Dept Genet, Mashhad, Iran.
   [Erkeland, Stefan J.] Erasmus Univ, Med Ctr, Dept Immunol, Rotterdam, Netherlands.
   [Xu, Lei] Erasmus Univ, Dept Gastroenterol & Hepatol, Med Ctr, Rotterdam, Netherlands.
   [Colijn, Johanna M.; Klaver, Caroline C. W.; Meester-Smoor, Magda A.] Erasmus Univ, Dept Ophthalmol, Med Ctr, POB 2040, NL-3000 CA Rotterdam, Netherlands.
   [Dehghan, Abbas] Imperial Coll London, Sch Publ Hlth, Dept Epidemiol & Biostat, London, England.
   [Klaver, Caroline C. W.] Radboud Univ Nijmegen, Dept Ophthalmol, Med Ctr, Nijmegen, Netherlands.
C3 Erasmus University Rotterdam; Erasmus MC; Mashhad University Medical
   Science; Erasmus University Rotterdam; Erasmus MC; Erasmus University
   Rotterdam; Erasmus MC; Erasmus University Rotterdam; Erasmus MC;
   Imperial College London; Radboud University Nijmegen
RP Ghanbari, M (通讯作者)，Erasmus Univ, Dept Epidemiol, Med Ctr, POB 2040, NL-3000 CA Rotterdam, Netherlands.; Klaver, CCW (通讯作者)，Erasmus Univ, Dept Ophthalmol, Med Ctr, POB 2040, NL-3000 CA Rotterdam, Netherlands.
EM m.ghanbari@erasmusmc.nl; c.c.w.klaver@erasmusmc.nl
RI Klaver, Caroline C.W./A-2013-2016; Dehghan, Abbas/ABE-7377-2020; Franco,
   Óscar H/ABE-2305-2020; Ghanbari, Mohsen/AAH-1340-2020; Dehghan,
   Abbas/B-9896-2008
OI Franco, Óscar H/0000-0002-4606-4929; Ghanbari,
   Mohsen/0000-0002-9476-7143; Dehghan, Abbas/0000-0001-6403-016X;
   Erkeland, Stefan/0000-0002-1019-7957; Klaver,
   Caroline/0000-0002-2355-5258
FU Glaucoomfonds; Oogfonds; Landelijke Stichting voor Blinden en
   Slechtzienden; Novartis Foundation [2015-37.916.12.154]; NWO grant
   [175.010.2005.011, 911-03-012]; Iranian Ministry of health and Mashhad
   University of Medical Sciences; Netherlands Organisation of Scientific
   Research NWO Investments; Netherlands Genomics Initiative
   (NGI)/Netherlands Organisation for Scientific Research (NWO)
   [050-060-810]; Erasmus Medical Center and Erasmus University, Rotterdam;
   Netherlands Organization for the Health Research and Development
   (ZonMw); Research Institute for Diseases in the Elderly (RIDE); Ministry
   of Education, Culture and Science; Ministry for Health, Welfare and
   Sports; European Commission (DG XII); Municipality of Rotterdam
FX Contract grant sponsors: Glaucoomfonds, Oogfonds, Landelijke Stichting
   voor Blinden en Slechtzienden, Novartis Foundation (Uitzicht grant
   2015-37.916.12.154); NWO grant (veni, 175.010.2005.011, 911-03-012);
   Iranian Ministry of health and Mashhad University of Medical Sciences;
   Netherlands Organisation of Scientific Research NWO Investments;
   Netherlands Genomics Initiative (NGI)/Netherlands Organisation for
   Scientific Research (NWO) (project number 050-060-810); Erasmus Medical
   Center and Erasmus University, Rotterdam; Netherlands Organization for
   the Health Research and Development (ZonMw); Research Institute for
   Diseases in the Elderly (RIDE); Ministry of Education, Culture and
   Science; Ministry for Health, Welfare and Sports; European Commission
   (DG XII); Municipality of Rotterdam.
CR Agarwal V, 2015, ELIFE, V4, DOI 10.7554/eLife.05005
   Bao L, 2007, NUCLEIC ACIDS RES, V35, pD51, DOI 10.1093/nar/gkl797
   Bartel DP, 2009, CELL, V136, P215, DOI 10.1016/j.cell.2009.01.002
   Bihrer V, 2011, AM J GASTROENTEROL, V106, P1663, DOI 10.1038/ajg.2011.161
   Bulik-Sullivan B, 2013, HUM MUTAT, V34, P1049, DOI 10.1002/humu.22337
   Cammaerts S, 2015, FRONT GENET, V6, DOI 10.3389/fgene.2015.00186
   Chatterjee S, 2009, BIOL CELL, V101, P251, DOI 10.1042/BC20080104
   Chen YH, 2010, MOL INTERV, V10, P271, DOI 10.1124/mi.10.5.4
   Chou CH, 2016, NUCLEIC ACIDS RES, V44, pD239, DOI 10.1093/nar/gkv1258
   Ebert MS, 2012, CELL, V149, P515, DOI 10.1016/j.cell.2012.04.005
   Fritsche LG, 2016, NAT GENET, V48, P134, DOI 10.1038/ng.3448
   Fritsche LG, 2013, NAT GENET, V45, P433, DOI 10.1038/ng.2578
   Fu XH, 2015, J CLIN INVEST, V125, P2497, DOI 10.1172/JCI75438
   Ghanbari M, 2016, SCI REP-UK, V6, DOI 10.1038/srep28387
   Ghanbari M, 2016, HUM MUTAT, V37, P292, DOI 10.1002/humu.22943
   Ghanbari M, 2015, CIRC-CARDIOVASC GENE, V8, P473, DOI 10.1161/CIRCGENETICS.114.000968
   Ghanbari M, 2014, HUM MUTAT, V35, P1524, DOI 10.1002/humu.22706
   Gong J, 2015, DATABASE-OXFORD, DOI 10.1093/database/bav029
   Gong J, 2012, HUM MUTAT, V33, P254, DOI 10.1002/humu.21641
   Grimson A, 2007, MOL CELL, V27, P91, DOI 10.1016/j.molcel.2007.06.017
   Han JJ, 2006, CELL, V125, P887, DOI 10.1016/j.cell.2006.03.043
   Harboe M, 2008, J CELL MOL MED, V12, P1074, DOI 10.1111/j.1582-4934.2008.00350.x
   Huang X, 2009, MOL CELL, V35, P856, DOI 10.1016/j.molcel.2009.09.006
   Keklikoglou I, 2015, ONCOGENE, V34, P4867, DOI 10.1038/onc.2014.408
   Kozomara A, 2014, NUCLEIC ACIDS RES, V42, pD68, DOI 10.1093/nar/gkt1181
   Krol J, 2004, J BIOL CHEM, V279, P42230, DOI 10.1074/jbc.M404931200
   Krol J, 2010, NAT REV GENET, V11, P597, DOI 10.1038/nrg2843
   Lim LS, 2012, LANCET, V379, P1728, DOI 10.1016/S0140-6736(12)60282-7
   Lingzi X., 2016, ONCOTARGET, V7, P3114
   Liu SC, 2014, CELL DEATH DIS, V5, DOI 10.1038/cddis.2014.453
   Lorenz R, 2011, ALGORITHM MOL BIOL, V6, DOI 10.1186/1748-7188-6-26
   Luo C, 2011, MOL VIS, V17, P1588
   Meenhuis A, 2011, BLOOD, V118, P916, DOI 10.1182/blood-2011-02-336487
   Mencia A, 2009, NAT GENET, V41, P609, DOI 10.1038/ng.355
   Mullins RF, 2000, FASEB J, V14, P835, DOI 10.1096/fasebj.14.7.835
   Murad N, 2014, FEBS J, V281, P5251, DOI 10.1111/febs.13066
   Nashine S, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0159828
   Nicoloso MS, 2010, CANCER RES, V70, P2789, DOI 10.1158/0008-5472.CAN-09-3541
   Nozaki M, 2006, P NATL ACAD SCI USA, V103, P2328, DOI 10.1073/pnas.0408835103
   Persson H, 2011, CANCER RES, V71, P78, DOI 10.1158/0008-5472.CAN-10-1869
   Piskounova E, 2008, J BIOL CHEM, V283, P21310, DOI 10.1074/jbc.C800108200
   Pritchard CC, 2012, NAT REV GENET, V13, P358, DOI 10.1038/nrg3198
   Pruim RJ, 2010, BIOINFORMATICS, V26, P2336, DOI 10.1093/bioinformatics/btq419
   Ragusa M, 2013, MOL VIS, V19, P430
   Ramdas WD, 2011, HUM MOL GENET, V20, P2464, DOI 10.1093/hmg/ddr120
   Ricklin D, 2007, NAT BIOTECHNOL, V25, P1265, DOI 10.1038/nbt1342
   Ryan BM, 2010, NAT REV CANCER, V10, P389, DOI 10.1038/nrc2867
   Saba R, 2014, HUM MUTAT, V35, P1233, DOI 10.1002/humu.22627
   Shukla Girish C, 2011, Mol Cell Pharmacol, V3, P83
   Smailhodzic D, 2012, OPHTHALMOLOGY, V119, P339, DOI 10.1016/j.ophtha.2011.07.056
   Sun GH, 2009, RNA, V15, P1640, DOI 10.1261/rna.1560209
   Szabo G, 2013, NAT REV GASTRO HEPAT, V10, P542, DOI 10.1038/nrgastro.2013.87
   Szemraj M, 2015, MED SCI MONITOR, V21, P2734, DOI 10.12659/MSM.893697
   Tsai WC, 2012, J CLIN INVEST, V122, P2884, DOI 10.1172/JCI63455
   Wagschal A, 2015, NAT MED, V21, P1290, DOI 10.1038/nm.3980
   Wang SS, 2012, FUTURE MED CHEM, V4, P277, DOI 10.4155/fmc.11.176
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
   Wu MQ, 2008, CARCINOGENESIS, V29, P1710, DOI 10.1093/carcin/bgn073
   Xiong XX, 2013, MOL CELLS, V36, P518, DOI 10.1007/s10059-013-0171-1
   Xu SB, 2007, J BIOL CHEM, V282, P25053, DOI 10.1074/jbc.M700501200
   Yates JRW, 2007, NEW ENGL J MED, V357, P553, DOI 10.1056/NEJMoa072618
   Zhang F, 2015, HUM MOL GENET, V24, pR102, DOI 10.1093/hmg/ddv259
   Zhang XX, 2010, NUCLEIC ACIDS RES, V38, P7689, DOI 10.1093/nar/gkq645
   Zhou QB, 2011, P NATL ACAD SCI USA, V108, P8287, DOI 10.1073/pnas.1105254108
NR 64
TC 23
Z9 24
U1 0
U2 6
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1059-7794
EI 1098-1004
J9 HUM MUTAT
JI Hum. Mutat.
PD JUL
PY 2017
VL 38
IS 7
BP 827
EP 838
DI 10.1002/humu.23226
PG 12
WC Genetics & Heredity
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Genetics & Heredity
GA EX6KV
UT WOS:000403352100008
PM 28397307
DA 2022-11-30
ER

PT J
AU Kokki, E
   Karttunen, T
   Olsson, V
   Kinnunen, K
   Yla-Herttuala, S
AF Kokki, Emmi
   Karttunen, Tommi
   Olsson, Venla
   Kinnunen, Kati
   Yla-Herttuala, Seppo
TI Human Vascular Endothelial Growth Factor A(165) Expression Induces the
   Mouse Model of Neovascular Age-Related Macular Degeneration
SO GENES
LA English
DT Article
DE adenovirus; age-related macular degeneration; animal model; gene
   therapy; gene transfer; neovascularization; subretinal; vascular
   endothelial growth factor
ID RETINAL-PIGMENT EPITHELIUM; POLYPOIDAL CHOROIDAL VASCULOPATHY;
   ANIMAL-MODELS; SUBRETINAL FIBROSIS; GENE-TRANSFER; ADENOVIRAL VECTOR;
   MULLER CELLS; OPTIC-NERVE; EYE DISEASE; MACROPHAGES
AB Vascular endothelial growth factor (VEGF) expression induces age-related macular degeneration (AMD), which is a common vision-threatening disease due to choroidal neovascularization and a fibrovascular membrane. We describe a mouse model of neovascular AMD with the local expression of human VEGF-A(165) in the eye. We use a transgenic mouse in which human VEGF-A(165) has been silenced with the loxP-STOP fragment. The choroidal neovascularization and human VEGF-A(165) expression in the mouse are induced by subretinal adenoviral Cre gene delivery. Cre gene transfer is compared with adenoviral LacZ gene transfer control. We characterize the AMD phenotype and changes in the vasculature by using fluorescein angiography, optical coherence tomography, and immunohistochemistry. At early time points, mice exhibit increases in retinal thickness (348 +/- 114 mu m vs. 231 +/- 32 mu m) and choroidal neovascularization area (12000 +/- 15174 mu m(2) vs. 2169 +/- 3495 mu m(2)) compared with the control. At later time points, choroidal neovascularization develops into subretinal fibrovascular membrane. Human VEGF-A(165) expression lasts several weeks. In conclusion, the retinas display vascular abnormalities consistent with choroidal neovascularization. Together with immunohistochemical findings, these changes resemble clinical AMD-like ocular pathologies. We conclude that this mouse model of Cre-induced choroidal neovascularization is useful for mimicking the pathogenesis of AMD, studying the effects of human VEGF-A(165) in the retina, and evaluating anti-VEGF treatments for choroidal neovascularization.
C1 [Kokki, Emmi; Olsson, Venla; Yla-Herttuala, Seppo] Univ Eastern Finland, AI Virtanen Inst Mol Sci, Kuopio 70150, Finland.
   [Karttunen, Tommi; Kinnunen, Kati] Kuopio Univ Hosp, Dept Ophthalmol, Kuopio 70210, Finland.
   [Kinnunen, Kati] Univ Eastern Finland, Inst Clin Med, Dept Ophthalmol, Kuopio 70029, Finland.
   [Yla-Herttuala, Seppo] Kuopio Univ Hosp, Heart Ctr, Kuopio 70029, Finland.
   [Yla-Herttuala, Seppo] Kuopio Univ Hosp, Gene Therapy Unit, Kuopio 70029, Finland.
C3 University of Eastern Finland; Kuopio University Hospital; University of
   Eastern Finland; University of Eastern Finland; Kuopio University
   Hospital; University of Eastern Finland; Kuopio University Hospital;
   University of Eastern Finland
RP Yla-Herttuala, S (通讯作者)，Univ Eastern Finland, AI Virtanen Inst Mol Sci, Kuopio 70150, Finland.; Yla-Herttuala, S (通讯作者)，Kuopio Univ Hosp, Heart Ctr, Kuopio 70029, Finland.; Yla-Herttuala, S (通讯作者)，Kuopio Univ Hosp, Gene Therapy Unit, Kuopio 70029, Finland.
EM emmi.kokki@uef.fi; tommi.karttunen@kuh.fi; venla.olsson@uef.fi;
   kati.kinnunen@kuh.fi; seppo.ylaherttuala@uef.fi
OI Kokki, Emmi/0000-0003-1900-0134; Karttunen, Tommi/0000-0001-7302-9451
FU Finnish Academy Center of Excellence; Finnish Cultural Foundation;
   Diabetes Research Foundation; Otto A. Malm Foundation; Eye and Tissue
   Bank Foundation
FX This research was funded by The Finnish Academy Center of Excellence,
   Finnish Cultural Foundation, The Diabetes Research Foundation, Otto A.
   Malm Foundation and Eye and Tissue Bank Foundation.
CR Amadio M, 2016, PHARMACOL RES, V103, P253, DOI 10.1016/j.phrs.2015.11.027
   Ambati J, 2003, NAT MED, V9, P1390, DOI 10.1038/nm950
   BENNETT J, 1994, INVEST OPHTH VIS SCI, V35, P2535
   Bloch SB, 2013, AM J OPHTHALMOL, V156, P116, DOI 10.1016/j.ajo.2013.02.012
   Cao JT, 2010, INVEST OPHTH VIS SCI, V51, P6009, DOI 10.1167/iovs.09-4956
   Cherepanoff S, 2010, BRIT J OPHTHALMOL, V94, P918, DOI 10.1136/bjo.2009.165563
   Chinnery HR, 2012, NEUROBIOL AGING, V33, P1769, DOI 10.1016/j.neurobiolaging.2011.03.010
   Daniel E, 2014, OPHTHALMOLOGY, V121, P656, DOI 10.1016/j.ophtha.2013.10.019
   Dudus L, 1999, VISION RES, V39, P2545, DOI 10.1016/S0042-6989(98)00308-3
   Edelman JL, 2000, EXP EYE RES, V71, P523, DOI 10.1006/exer.2000.0907
   Friedlander M, 2007, J CLIN INVEST, V117, P576, DOI 10.1172/JCI31030
   Funk M, 2009, OPHTHALMOLOGY, V116, P2393, DOI 10.1016/j.ophtha.2009.05.039
   Giani A, 2011, INVEST OPHTH VIS SCI, V52, P3880, DOI 10.1167/iovs.10-6266
   Grossniklaus HE, 2010, PROG RETIN EYE RES, V29, P500, DOI 10.1016/j.preteyeres.2010.05.003
   Grossniklaus HE, 2002, MOL VIS, V8, P119
   Hellstrom M, 2009, GENE THER, V16, P521, DOI 10.1038/gt.2008.178
   Herrmann P, 2015, NEUROBIOL AGING, V36, P2637, DOI 10.1016/j.neurobiolaging.2015.05.019
   Hu WZ, 2008, INVEST OPHTH VIS SCI, V49, P407, DOI 10.1167/iovs.07-0870
   Ishikawa K, 2016, AM J PATHOL, V186, P859, DOI 10.1016/j.ajpath.2015.11.014
   Ishikawa K, 2016, EXP EYE RES, V142, P19, DOI 10.1016/j.exer.2015.03.009
   Jo YJ, 2011, INVEST OPHTH VIS SCI, V52, P6089, DOI 10.1167/iovs.10-5189
   Kalesnykas G, 2017, CURR GENE THER, V17, P235, DOI 10.2174/1566523217666171003170348
   Kliffen M, 1997, BRIT J OPHTHALMOL, V81, P154, DOI 10.1136/bjo.81.2.154
   Kvanta A, 1996, INVEST OPHTH VIS SCI, V37, P1929
   Lambert NG, 2016, PROG RETIN EYE RES, V54, P64, DOI 10.1016/j.preteyeres.2016.04.003
   Lebherz C, 2008, J GENE MED, V10, P375, DOI 10.1002/jgm.1126
   Lei L, 2012, MOL VIS, V18, P103
   Leppanen P, 2006, PLOS ONE, V1, DOI 10.1371/journal.pone.0000013
   LI TS, 1994, INVEST OPHTH VIS SCI, V35, P2543
   Liang FQ, 2001, MOL THER, V4, P461, DOI 10.1006/mthe.2001.0473
   Liu CH, 2017, FASEB J, V31, P4665, DOI 10.1096/fj.201700336R
   Liu JY, 2013, PLOS ONE, V8, DOI [10.1371/journal.pone.0050719, 10.1371/journal.pone.0064143, 10.1371/journal.pone.0057473]
   Lopez PF, 1996, INVEST OPHTH VIS SCI, V37, P855
   Luhmann UFO, 2013, EXP EYE RES, V107, P80, DOI 10.1016/j.exer.2012.11.015
   Luhmann UFO, 2009, INVEST OPHTH VIS SCI, V50, P5934, DOI 10.1167/iovs.09-3462
   Luo L, 2013, ELIFE, V2, DOI 10.7554/eLife.00324
   Luo L, 2013, ACS NANO, V7, P3264, DOI 10.1021/nn305958y
   Malek G, 2005, P NATL ACAD SCI USA, V102, P11900, DOI 10.1073/pnas.0503015102
   Matsuoka M, 2004, BRIT J OPHTHALMOL, V88, P809, DOI 10.1136/bjo.2003.032466
   Miere A, 2015, RETINA-J RET VIT DIS, V35, P2275, DOI 10.1097/IAE.0000000000000819
   Nagai N, 2014, INVEST OPHTH VIS SCI, V55, P3709, DOI 10.1167/iovs.14-13989
   Penn JS, 2008, PROG RETIN EYE RES, V27, P331, DOI 10.1016/j.preteyeres.2008.05.001
   Pennesi ME, 2012, MOL ASPECTS MED, V33, P487, DOI 10.1016/j.mam.2012.06.003
   Petit L, 2016, HUM GENE THER, V27, P563, DOI 10.1089/hum.2016.040
   Provost N, 2005, MOL THER, V11, P275, DOI 10.1016/j.ymthe.2004.09.022
   Rakoczy PE, 2006, EXP EYE RES, V82, P741, DOI 10.1016/j.exer.2005.10.012
   Ramakrishnan S, 2014, J NEUROIMMUNE PHARM, V9, P142, DOI 10.1007/s11481-014-9531-7
   Sakamoto T, 1998, GENE THER, V5, P1088, DOI 10.1038/sj.gt.3300701
   Schmack I, 2009, MOL VIS, V15, P146
   Skeie JM, 2009, EYE, V23, P747, DOI 10.1038/eye.2008.206
   Tong JP, 2006, AM J OPHTHALMOL, V141, P456, DOI 10.1016/j.ajo.2005.10.012
   Ueyama K, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0108071
   VERDERBER L, 1995, INVEST OPHTH VIS SCI, V36, P1137
   Viegas MS, 2007, EUR J HISTOCHEM, V51, P59
   Wang F, 2003, INVEST OPHTH VIS SCI, V44, P781, DOI 10.1167/iovs.02-0281
   *WHO, PRIOR EYE DIS
   Witmer AN, 2003, PROG RETIN EYE RES, V22, P1, DOI 10.1016/S1350-9462(02)00043-5
   Xu HP, 2008, AGING CELL, V7, P58, DOI 10.1111/j.1474-9726.2007.00351.x
   Yang Y, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0080288
   Yla-Herttuala S, 2017, EUR HEART J, V38, P1365, DOI 10.1093/eurheartj/ehw547
   Zhang H, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0068173
NR 61
TC 2
Z9 3
U1 1
U2 3
PU MDPI
PI BASEL
PA ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND
SN 2073-4425
J9 GENES-BASEL
JI Genes
PD SEP
PY 2018
VL 9
IS 9
AR 438
DI 10.3390/genes9090438
PG 17
WC Genetics & Heredity
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Genetics & Heredity
GA GY2UI
UT WOS:000448398700019
PM 30200369
OA gold, Green Submitted, Green Published
DA 2022-11-30
ER

PT J
AU Boyle, J
   Vukicevic, M
   Koklanis, K
   Itsiopoulos, C
AF Boyle, Jessica
   Vukicevic, Meri
   Koklanis, Konstandina
   Itsiopoulos, Catherine
TI Experiences of patients undergoing anti-VEGF treatment for neovascular
   age-related macular degeneration: A systematic review
SO Psychology Health & Medicine
LA English
DT Article
DE systematic review; treatment; wet; anti-VEGF; neovascular; age-related
   macular degeneration; patient experience; intra-vitreal injection
ID QUALITY-OF-LIFE; VISION; INJECTION; SURGERY; ANXIETY; DEPRESSION;
   DISCOMFORT; PAIN
AB Current therapy to slow disease progression in patients with neovascular age-related macular degeneration (AMD) often entails intra-vitreal injection of an anti-vascular endothelial growth factor (VEGF) agent, that begins with a three-month loading phase of four weekly injections followed by regular monthly visits with clinician-determined re-treatment. The effects of AMD on quality of life and visual function have been extensively reported in the literature, however, less is known about the burden imposed on patients by the arduous and often indefinite treatment schedule which habitually follows a diagnosis of wet AMD. To date, no systematic review has been conducted of research investigating patients' experiences of anti-VEGF treatment for AMD. A systematic search of the Embase, Medline, PsycINFO and PubMed electronic databases was undertaken to identify all studies between January 2004 and December 2013, published in the English language and involving human participants. A hand-search of an additional four journals was conducted. Ten articles were identified for inclusion in this review. A critical appraisal was undertaken using the Critical Appraisal Skills Programme Qualitative Research Checklist and the results synthesised to form a narrative review. Few studies to date have investigated patients' experiences of treatment for AMD. These studies have focused primarily on patients' experiences of the injection procedure with respect to pain and anxiety. Anticipated discomfort is often greater than actual discomfort experienced during intra-vitreal injection. However, different stages of the treatment procedure produce varying levels of patient discomfort. No one method of anaesthesia has consistently been shown to be more effective in reducing discomfort associated with treatment. Common reasons underlying patient apprehension surrounding treatment include the thought of having an injection, fear of losing eyesight and fear of the unknown. Whilst these studies have not been without their methodological limitations, they provide a platform for further exploration of the patient experience.
C1 [Boyle, Jessica; Vukicevic, Meri; Koklanis, Konstandina] La Trobe Univ, Fac Hlth Sci, Sch Allied Hlth, Dept Clin Vis Sci, Melbourne, Vic, Australia.
   [Boyle, Jessica; Vukicevic, Meri] Eye Surg Associates, Cabrini Med Ctr, Malvern, Australia.
   [Koklanis, Konstandina] Royal Childrens Hosp, Dept Ophthalmol, Melbourne, Vic, Australia.
   [Itsiopoulos, Catherine] La Trobe Univ, Fac Hlth Sci, Sch Allied Hlth, Dept Dietet & Human Nutr, Melbourne, Vic, Australia.
C3 La Trobe University; Cabrini Health; Royal Children's Hospital
   Melbourne; La Trobe University
RP Boyle, J (通讯作者)，La Trobe Univ, Fac Hlth Sci, Sch Allied Hlth, Dept Clin Vis Sci, Melbourne, Vic, Australia.
EM Jess.Boyle@latrobe.edu.au
OI Itsiopoulos, Catherine/0000-0003-1397-4149; Koklanis,
   Konstandina/0000-0002-6740-9586; Vukicevic, Meri/0000-0002-0887-6248
FU Orthoptics Australia Research Grant; La Trobe University Postgraduate
   Support Grant; La Trobe University Postgraduate Research Scholarship
FX This work was supported by an Orthoptics Australia Research Grant and a
   La Trobe University Postgraduate Support Grant, and was carried out
   whilst the first author was the recipient holder of a La Trobe
   University Postgraduate Research Scholarship.
CR AMD Alliance International, 2010, GLOB EC COST VIS IMP
   Avci R., 2013, ASRS 31 ANN M TOR
   Berdeaux GH, 2005, AM J OPHTHALMOL, V139, P271, DOI 10.1016/j.ajo.2004.09.028
   Blaha GR, 2011, RETINA-J RET VIT DIS, V31, P535, DOI 10.1097/IAE.0b013e3181eac724
   Brody BL, 2001, OPHTHALMOLOGY, V108, P1893, DOI 10.1016/S0161-6420(01)00754-0
   Cahill MT, 2005, OPHTHALMOLOGY, V112, P152, DOI 10.1016/j.ophtha.2004.06.036
   Chua PYS, 2009, ARCH OPHTHALMOL-CHIC, V127, P939, DOI 10.1001/archophthalmol.2009.139
   Coleman HR, 2008, LANCET, V372, P1835, DOI 10.1016/S0140-6736(08)61759-6
   Hassell JB, 2006, BRIT J OPHTHALMOL, V90, P593, DOI 10.1136/bjo.2005.086595
   Henriksen K., 2013, INT J OPHTHALMIC PRA, V1, P68, DOI [10.12968/ijop.2010.1.2.68, DOI 10.12968/ijop.2010.1.2.68, DOI 10.12968/IJOP.2010.1.2.68]
   LaHood BR, 2011, CLIN EXP OPHTHALMOL, V39, P184, DOI 10.1111/j.1442-9071.2010.02432.x
   Macular Degeneration Foundation, 2011, EYES FUT CLEAR OUTL
   Mitchell J, 2006, HEALTH QUAL LIFE OUT, V4, DOI 10.1186/1477-7525-4-97
   Moisseiev E, 2012, CURR EYE RES, V37, P813, DOI 10.3109/02713683.2012.681335
   Nijkamp MD, 2004, BRIT J OPHTHALMOL, V88, P1310, DOI 10.1136/bjo.2003.037788
   Pager CK, 2005, BRIT J OPHTHALMOL, V89, P10, DOI 10.1136/bjo.2004.048637
   Rifkin L, 2012, RETINA-J RET VIT DIS, V32, P696, DOI 10.1097/IAE.0b013e3182252ad3
   Roth DB, 2006, AM J OPHTHALMOL, V142, P492, DOI 10.1016/j.ajo.2006.03.042
   Rovner BW, 2002, AM J GERIAT PSYCHIAT, V10, P305
   Royal College of Ophthalmologists (UK), 2013, AG REL MAC DEG GUID
   Smith W, 2001, OPHTHALMOLOGY, V108, P697, DOI 10.1016/S0161-6420(00)00580-7
   Stevenson MR, 2004, BRIT J OPHTHALMOL, V88, P1125, DOI 10.1136/bjo.2003.032383
   Tailor R, 2011, CLIN OPHTHALMOL, V5, P1499, DOI 10.2147/OPTH.S24358
   Talic I, 2022, LEARN INSTR, V81, DOI [10.1016/j.learninstruc.2022.101594, 10.1016/j.ajo.2004.02.011]
   Thetford C, 2013, BRIT J VISUAL IMPA, V31, P89, DOI 10.1177/0264619613481778
   Trento M, 2006, DIABETIC MED, V23, P1106, DOI 10.1111/j.1464-5491.2006.01957.x
   Wong T, 2008, OPHTHALMOLOGY, V115, P116, DOI 10.1016/j.ophtha.2007.03.008
   Yau GL, 2011, AM J OPHTHALMOL, V151, P333, DOI 10.1016/j.ajo.2010.08.031
NR 28
TC 42
Z9 43
U1 0
U2 36
PU ROUTLEDGE JOURNALS, TAYLOR & FRANCIS LTD
PI ABINGDON
PA 4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXFORDSHIRE, ENGLAND
SN 1354-8506
EI 1465-3966
J9 PSYCHOL HEALTH MED
JI Psychol. Health Med.
PD APR 3
PY 2015
VL 20
IS 3
BP 296
EP 310
DI 10.1080/13548506.2014.936886
PG 15
WC Public, Environmental & Occupational Health
WE Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)
SC Public, Environmental & Occupational Health
GA CA6IN
UT WOS:000349015200005
PM 25034616
DA 2022-11-30
ER

PT J
AU Hudson, HL
   Stulting, RD
   Heier, JS
   Lane, SS
   Chang, DF
   Singerman, LJ
   Bradford, CA
   Leonard, RE
AF Hudson, Henry L.
   Stulting, R. Doyle
   Heier, Jeffrey S.
   Lane, Stephen S.
   Chang, David F.
   Singerman, Lawrence J.
   Bradford, Cynthia A.
   Leonard, Robert E.
CA IMT002 Study Grp
TI Implantable Telescope for End-Stage Age-related Macular Degeneration:
   Long-term Visual Acuity and Safety Outcomes
SO AMERICAN JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
ID ENDOTHELIAL-CELL LOSS; QUALITY-OF-LIFE; SITU KERATOMILEUSIS LASIK;
   REPORT NO. 14; MINIATURE TELESCOPE; LENS IMPLANTATION; CHOROIDAL
   NEOVASCULARIZATION; FUNCTION-QUESTIONNAIRE; CORNEAL ENDOTHELIUM;
   CATARACT-EXTRACTION
AB PURPOSE: To evaluate long-term safety and best-corrected visual acuity (BCVA) results of a telescope prosthesis in patients with end-stage age-related macular degeneration (AMD).
   DESIGN: Prospective, open-label clinical trial with fellow-eye controls.
   METHODS: Patients with end-stage AMD (bilateral geographic atrophy or disciform scars; BCVA, 20/80 to 20/800) received the telescope prosthesis at 28 centers. Methods were similar to those described in the one-year results, with follow-up visits continuing at 18 and 24 months. Main outcome measures included BCVA change from baseline, endothelial cell density (ECD) and morphometry, and incidence of complications.
   RESULTS: At two years, data from 174 (92.6%) of 188 available patients were analyzed. Overall, 103 (59.5%) of 173 telescope-implanted eyes gained three lines or more (doubling of visual angle) of BCVA compared with 18 (10.3%) of 174 fellow control eyes (P < .0001). Mean BCVA improved 3.6 lines (standard deviation [SDI, 1.9 lines) and 2.8 lines (SD, 2.3 lines) from baseline in eyes with the 3X and 2.2X device models, respectively. Mean ECD stabilized through two years, with 2.4% mean cell loss occurring from one to two years. There was no significant change in coefficient of variation or percentage of hexagonal endothelial cells from within six months to two years after surgery. The most common complication was inflammatory deposits.
   CONCLUSIONS: Long-term results of this telescope prosthesis show the substantial BCVA improvement at one year is maintained at two years. Key indicators of corneal health demonstrate ECD change that reflects remodeling of the endothelium associated with the implantation procedure. ECD stabilizes over time, and there is no evidence of any ongoing endothelial trauma. (Am J Ophthalmol 2008;146:664-673. (C) 2008 by Elsevier Inc. All rights reserved.)
C1 [Hudson, Henry L.] PC, Retina Ctr, Tucson, AZ USA.
   [Stulting, R. Doyle] Emory Univ, Ctr Eye, Atlanta, GA 30322 USA.
   [Heier, Jeffrey S.] Ophthalm Consultants Boston, Boston, MA USA.
   [Lane, Stephen S.] Associated Eye Care, Stillwater, MN USA.
   [Chang, David F.] Altos Eye Phys, Los Altos, CA USA.
   [Singerman, Lawrence J.] Retina Associates Cleveland, Cleveland, OH USA.
   [Bradford, Cynthia A.; Leonard, Robert E.] Univ Oklahoma, Hlth Sci Ctr, Dean A McGee Eye Inst, Oklahoma City, OK USA.
C3 Emory University; Ophthalmic Consultants of Boston; Retina Associates of
   Cleveland, Inc.; University of Oklahoma System; University of Oklahoma
   Health Sciences Center
RP Hudson, HL (通讯作者)，6585 N Oracle Rd,Suite A, Tucson, AZ 85704 USA.
EM henhud@msn.com
FU VISIONCARE OPHTHALMIC TECHNOLOGIES Inc, Saratoga, California
FX THIS STUDY WAS SUPPORTED BY A CLINICAL RESEARCH TRIAL SPONSORED BY
   VISIONCARE OPHTHALMIC TECHNOLOGIES Inc, Saratoga, California, The
   authors indicate no financial conflict of interest. Drs Heier, Lane, and
   Stulting serve on the medical advisory board for the study sponsor as
   consultants. Involved in design of study (S.S.L.); conduct of study
   (H.L.H., R.D.S., J.S.H., S.S.L., D.F.C., L.S., C.A.B., R.E.L.);
   collection (H.L.H., R.D.S., J.S.H., S.S.L., D.F.C., L.S., C.A.B.,
   R.E.L.), analysis (H.L.H., R.D.S., J.S.H., S.S.L.), and interpretation
   of data (H.L.H., R.D.S., J.S.H., S.S.L., D.F.C., L.S., C.A.B., R.E.L.);
   and preparation, review, or approval of manuscript R.D.S., J.S.H.,
   S.S.L., D.F.C., L.S., C.A.B., R.E.L.). The study and data accumulation
   were carried out With approval front the appropriate Institutional
   Review Boards (local boards Or Western Institutional Review Board), and
   informed consent for research was obtained from all study patients. All
   authors served as investigators in the clinical research trial sponsored
   by VisionCare Ophthalmic Technologies.
CR Augood CA, 2006, ARCH OPHTHALMOL-CHIC, V124, P529, DOI 10.1001/archopht.124.4.529
   Azar RG, 2001, J REFRACT SURG, V17, P542
   BOURNE WM, 1994, OPHTHALMOLOGY, V101, P1014
   Bressler NM, 2003, ARCH OPHTHALMOL-CHIC, V121, P1621
   Brown GC, 2000, ARCH OPHTHALMOL-CHIC, V118, P47
   Brown MM, 2006, CURR OPIN OPHTHALMOL, V17, P257
   Cahill MT, 2005, OPHTHALMOLOGY, V112, P152, DOI 10.1016/j.ophtha.2004.06.036
   Childs AL, 2004, OPHTHALMOLOGY, V111, P2007, DOI 10.1016/j.ophtha.2004.07.024
   Chun DW, 2005, EXPERT REV MED DEVIC, V2, P657, DOI 10.1586/17434440.2.6.657
   Colby KA, 2007, ARCH OPHTHALMOL-CHIC, V125, P1118, DOI 10.1001/archopht.125.8.1118
   Collins MJ, 2001, AM J OPHTHALMOL, V131, P1, DOI 10.1016/S0002-9394(00)00664-4
   Edelhauser HF, 2004, J CATARACT REFR SURG, V30, P576, DOI 10.1016/j.jcrs.2003.09.047
   Evans JR, 2004, OPHTHALMOLOGY, V111, P513, DOI 10.1016/j.ophtha.2003.07.012
   Garfinkel RA, 2006, AM J OPHTHALMOL, V141, P766, DOI 10.1016/j.ajo.2005.11.005
   GLASSER DB, 1985, ARCH OPHTHALMOL-CHIC, V103, P1347
   Globe DR, 2004, OPHTHALMOLOGY, V111, P1141, DOI 10.1016/j.ophtha.2004.02.003
   Hooper P, 2008, CAN J OPHTHALMOL, V43, P180, DOI 10.3129/i08-001
   Hudson HL, 2006, OPHTHALMOLOGY, V113, P1987, DOI 10.1016/j.ophtha.2006.07.010
   Jager RD, 2008, NEW ENGL J MED, V358, P2606, DOI 10.1056/NEJMra0801537
   Jones SS, 1998, AM J OPHTHALMOL, V125, P465, DOI 10.1016/S0002-9394(99)80186-X
   Klein BEK, 1998, OPHTHALMOLOGY, V105, P160, DOI 10.1016/S0161-6420(98)91911-X
   Lane SS, 2006, CURR OPIN OPHTHALMOL, V17, P94, DOI 10.1097/01.icu.0000193067.86627.a1
   Lane SS, 2004, AM J OPHTHALMOL, V137, P993, DOI 10.1016/j.ajo.2004.01.030
   LEVY JH, 1988, J CATARACT REFR SURG, V14, P299, DOI 10.1016/S0886-3350(88)80120-2
   LIESEGANG TJ, 1984, AM J OPHTHALMOL, V97, P32, DOI 10.1016/0002-9394(84)90442-2
   Lindblad AS, 2005, ARCH OPHTHALMOL-CHIC, V123, P1207
   Miskala PH, 2007, OPHTHAL EPIDEMIOL, V14, P205, DOI 10.1080/09286580701502970
   Miskala PH, 2004, OPHTHALMOLOGY, V111, P1981, DOI 10.1016/j.ophtha.2004.07.022
   Owen CG, 2003, BRIT J OPHTHALMOL, V87, P312, DOI 10.1136/bjo.87.3.312
   Peli E, 2002, OPTOMETRY VISION SCI, V79, P225, DOI 10.1097/00006324-200204000-00009
   Richard J, 2008, CORNEA, V27, P17, DOI 10.1097/ICO.0b013e3181583115
   Schein OD, 2005, ARCH OPHTHALMOL-CHIC, V123, P58, DOI 10.1001/archopht.123.1.58
   Schmier JK, 2006, RETINA-J RET VIT DIS, V26, P1056, DOI 10.1097/01.iae.0000254890.48272.5a
   Shuttleworth GN, 1998, BRIT J OPHTHALMOL, V82, P611, DOI 10.1136/bjo.82.6.611
   Wang JJ, 1998, BRIT J OPHTHALMOL, V82, P743, DOI 10.1136/bjo.82.7.743
NR 35
TC 23
Z9 24
U1 0
U2 7
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0002-9394
EI 1879-1891
J9 AM J OPHTHALMOL
JI Am. J. Ophthalmol.
PD NOV
PY 2008
VL 146
IS 5
BP 664
EP 673
DI 10.1016/j.ajo.2008.07.003
PG 10
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 368MA
UT WOS:000260624000007
PM 18760765
DA 2022-11-30
ER

PT J
AU Leveziel, N
   Zerbib, J
   Richard, F
   Querques, G
   Morineau, G
   Fremeaux-Bacchi, V
   Coscas, G
   Soubrane, G
   Benlian, P
   Souied, EH
AF Leveziel, Nicolas
   Zerbib, Jennyfer
   Richard, Florence
   Querques, Giuseppe
   Morineau, Gilles
   Fremeaux-Bacchi, Veronique
   Coscas, Gabriel
   Soubrane, Gisele
   Benlian, Pascale
   Souied, Eric H.
TI Genotype-phenotype correlations for exudative age-related macular
   degeneration associated with homozygous HTRA1 and CFH genotypes
SO INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE
LA English
DT Article
ID COMPLEMENT FACTOR-H; BEAVER DAM EYE; CHOROIDAL NEOVASCULARIZATION;
   SUSCEPTIBILITY LOCI; GENOMEWIDE-SCAN; RISK-FACTORS; FRENCH POPULATION;
   EXTENDED FAMILIES; APOLIPOPROTEIN-E; POOLED FINDINGS
AB PURPOSE. Major genetic factors for age-related macular degeneration (AMD) have recently been identified as susceptibility risk factors, including polymorphisms of HTRA1 and CFH genes. The purpose was to analyze the angiographic features of patients harboring homozygous genotypes for HTRA1 and CFH genes in a French exudative AMD population.
   METHODS. Two hundred patients affected with exudative AMD were genotyped for the polymorphisms rs11200638 of the HTRA1 gene and rs10611710 of the CFH gene. Four homozygous groups were extracted from the entire cohort: double homozygous for wild-type alleles of both genes (group 1), homozygous for the polymorphism of the HTRA1 gene only (group 2), homozygous for the polymorphism of the CFH gene only (group 3), and double homozygous carriers for both polymorphisms (group 4). Choroidal neovascularization (CNV) was graded as classic and predominantly classic (PC), occult, minimally classic (MC), or retinal angiomatosis proliferation (RAP).
   RESULTS. Group 1 (n = 9) presented 44.4% classic and PC, 33.3% occult, 11.1% MC, and 11.1% RAP. Group 2 (n = 12) presented 50.0% classic and PC, 33.3% occult, no MC CNV and 16.7% RAP. Group 3 (n = 28) presented 10.7% classic and PC, 67.9% occult, 14.3% MC, and 7.1% RAP. Group 4 (n = 17) presented 29.4% classic and PC, 52.9% occult, 11.8% MC, and 5.9% RAP. Occult CNV or MC CNV was more frequently observed in group 3 than in group 2 (82.1% vs 33.3%; P < 0.02). Classic and PC CNV were more frequently observed in group 2 than in group 3 (50% vs. 10.7%; P < 0.03).
   CONCLUSIONS. This attempt at a genotypic- angiographic correlation in an exudative AMD sample suggests an association between occult or MC CNV and the CFH polymorphism and between classic and PC CNV and the HTRA1 polymorphism.
C1 [Leveziel, Nicolas; Zerbib, Jennyfer; Querques, Giuseppe; Coscas, Gabriel; Soubrane, Gisele; Souied, Eric H.] Creteil Univ, Fac Med Henri Mondor, Eye Clin, F-94000 Creteil, France.
   [Zerbib, Jennyfer; Morineau, Gilles; Benlian, Pascale] CHU Saint Antoine, INSERM, UMRS 538, Paris, France.
   [Richard, Florence] Univ Lille 2, Inst Pasteur, INSERM, UMR 744, Lille, France.
   [Fremeaux-Bacchi, Veronique] Hop Europeen Georges Pompidou, Serv Immunol Biol, Paris, France.
   [Fremeaux-Bacchi, Veronique] INSERM, U255, Paris, France.
   [Benlian, Pascale] Univ Paris 06, CHU, Fac Med Pierre & Marie Curie, Paris, France.
C3 Assistance Publique Hopitaux Paris (APHP); Universite
   Paris-Est-Creteil-Val-de-Marne (UPEC); Hopital Universitaire
   Henri-Mondor - APHP; Assistance Publique Hopitaux Paris (APHP); Hopital
   Universitaire Saint-Antoine - APHP; Institut National de la Sante et de
   la Recherche Medicale (Inserm); UDICE-French Research Universities;
   Sorbonne Universite; Institut National de la Sante et de la Recherche
   Medicale (Inserm); Le Reseau International des Instituts Pasteur (RIIP);
   Universite de Lille - ISITE; Institut Pasteur Lille; Universite de
   Lille; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire
   Europeen Georges-Pompidou - APHP; UDICE-French Research Universities;
   Universite Paris Cite; Institut National de la Sante et de la Recherche
   Medicale (Inserm); Assistance Publique Hopitaux Paris (APHP);
   UDICE-French Research Universities; Sorbonne Universite
RP Souied, EH (通讯作者)，Creteil Univ, Fac Med Henri Mondor, Eye Clin, 40 Ave Verdun, F-94000 Creteil, France.
EM eric.souied@chicreteil.fr
OI Nicolas, Leveziel/0000-0001-8533-9457; Querques,
   Giuseppe/0000-0002-3292-9581
CR Abecasis GR, 2004, AM J HUM GENET, V74, P482, DOI 10.1086/382786
   Allikmets R, 2000, AM J HUM GENET, V67, P487, DOI 10.1086/303018
   Allikmets R, 1997, SCIENCE, V277, P1805, DOI 10.1126/science.277.5333.1805
   Axer-Siegel R, 2002, OPHTHALMOLOGY, V109, P1726, DOI 10.1016/S0161-6420(02)01149-1
   BIRD AEC, 1995, SURV OPHTHALMOL, V39, P367, DOI 10.1016/S0039-6257(05)80092-X
   Brantley MA, 2007, AM J OPHTHALMOL, V144, P404, DOI 10.1016/j.ajo.2007.05.018
   Cohen SY, 2007, BRIT J OPHTHALMOL, V91, P1173, DOI 10.1136/bjo.2007.115501
   Dewan A, 2006, SCIENCE, V314, P989, DOI 10.1126/science.1133807
   Edwards AO, 2005, SCIENCE, V308, P421, DOI 10.1126/science.1110189
   Fisher SA, 2005, HUM MOL GENET, V14, P2257, DOI 10.1093/hmg/ddi230
   Fremeaux-Bacchi V, 2005, J MED GENET, V42, P852, DOI 10.1136/jmg.2005.030783
   FREUND KB, 1993, AM J OPHTHALMOL, V115, P786, DOI 10.1016/S0002-9394(14)73649-9
   Gold B, 2006, NAT GENET, V38, P458, DOI 10.1038/ng1750
   Haddad WM, 2002, BRIT J OPHTHALMOL, V86, P663, DOI 10.1136/bjo.86.6.663
   Hageman GS, 2005, P NATL ACAD SCI USA, V102, P7227, DOI 10.1073/pnas.0501536102
   Haines JL, 2005, SCIENCE, V308, P419, DOI 10.1126/science.1110359
   Iyengar SK, 2004, AM J HUM GENET, V74, P20, DOI 10.1086/380912
   Jakobsdottir J, 2005, AM J HUM GENET, V77, P389, DOI 10.1086/444437
   KAHN HA, 1977, AM J EPIDEMIOL, V106, P17, DOI 10.1093/oxfordjournals.aje.a112428
   Khan JC, 2006, BRIT J OPHTHALMOL, V90, P75, DOI 10.1136/bjo.2005.073643
   Klaver CCW, 1998, AM J HUM GENET, V63, P200, DOI 10.1086/301901
   Klaver CCW, 1998, ARCH OPHTHALMOL-CHIC, V116, P653, DOI 10.1001/archopht.116.5.653
   Klein ML, 1998, ARCH OPHTHALMOL-CHIC, V116, P1082, DOI 10.1001/archopht.116.8.1082
   Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557
   Klein R, 2006, AM J OPHTHALMOL, V142, P539, DOI 10.1016/j.ajo.2006.06.015
   Leveziel N, 2007, MOL VIS, V13, P2153
   Majewski J, 2003, AM J HUM GENET, V73, P540, DOI 10.1086/377701
   Maruko I, 2007, AM J OPHTHALMOL, V144, P15, DOI 10.1016/j.ajo.2007.03.047
   Rivera A, 2005, HUM MOL GENET, V14, P3227, DOI 10.1093/hmg/ddi353
   Schaumberg DA, 2007, ARCH OPHTHALMOL-CHIC, V125, P55, DOI 10.1001/archopht.125.1.55
   Schick JH, 2003, AM J HUM GENET, V72, P1412, DOI 10.1086/375500
   Schultz DW, 2003, HUM MOL GENET, V12, P3315, DOI 10.1093/hmg/ddg348
   Seddon JM, 2005, ARCH OPHTHALMOL-CHIC, V123, P321, DOI 10.1001/archopht.123.3.321
   Seddon JM, 2003, AM J HUM GENET, V73, P780, DOI 10.1086/378505
   Shuler RK, 2007, ARCH OPHTHALMOL-CHIC, V125, P63, DOI 10.1001/archopht.125.1.63
   Smith W, 2001, OPHTHALMOLOGY, V108, P697, DOI 10.1016/S0161-6420(00)00580-7
   SOUBRANE G, 1990, OPHTHALMOLOGY, V97, P649
   Souied EH, 1998, AM J OPHTHALMOL, V125, P353, DOI 10.1016/S0002-9394(99)80146-9
   Souied EH, 2005, MOL VIS, V11, P1135
   Stone EM, 2004, NEW ENGL J MED, V351, P346, DOI 10.1056/NEJMoa040833
   Tomany SC, 2004, OPHTHALMOLOGY, V111, P1280, DOI 10.1016/j.ophtha.2003.11.010
   VINGERLING JR, 1995, OPHTHALMOLOGY, V102, P205
   Weeks DE, 2000, HUM MOL GENET, V9, P1329, DOI 10.1093/hmg/9.9.1329
   Weeks DE, 2004, AM J HUM GENET, V75, P174, DOI 10.1086/422476
   Weeks DE, 2001, AM J OPHTHALMOL, V132, P682, DOI 10.1016/S0002-9394(01)01214-4
   Wegscheider BJ, 2007, OPHTHALMOLOGY, V114, P738, DOI 10.1016/j.ophtha.2006.07.048
   Yang ZL, 2006, SCIENCE, V314, P992, DOI 10.1126/science.1133811
   Yannuzzi LA, 2001, RETINA-J RET VIT DIS, V21, P416, DOI 10.1097/00006982-200110000-00003
   Zareparsi S, 2005, AM J HUM GENET, V77, P149, DOI 10.1086/431426
NR 49
TC 36
Z9 38
U1 0
U2 1
PU ASSOC RESEARCH VISION OPHTHALMOLOGY INC
PI ROCKVILLE
PA 12300 TWINBROOK PARKWAY, ROCKVILLE, MD 20852-1606 USA
SN 0146-0404
J9 INVEST OPHTH VIS SCI
JI Invest. Ophthalmol. Vis. Sci.
PD JUL
PY 2008
VL 49
IS 7
BP 3090
EP 3094
DI 10.1167/iovs.07-1540
PG 5
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 318WR
UT WOS:000257124000039
PM 18362109
DA 2022-11-30
ER

PT J
AU de Jong, S
   Koolen, L
   Vazquez-Dominguez, I
   de Breuk, A
   Albert, S
   Hoyng, CB
   Katti, S
   den Hollander, AI
   Garanto, A
AF de Jong, Sarah
   Koolen, Louet
   Vazquez-Dominguez, Irene
   de Breuk, Anita
   Albert, Silvia
   Hoyng, Carel B.
   Katti, Suresh
   den Hollander, Anneke, I
   Garanto, Alejandro
TI Generation of an iPSC line (SCTCi015-A) and isogenic control line
   (SCTCi015-A-1) from an age-related macular degeneration patient carrying
   the variant c.355G > A in the CFI gene
SO STEM CELL RESEARCH
LA English
DT Article
ID RARE
AB Age-related macular degeneration (AMD) is a common eye disease among the elderly in the Western world. AMD is a multifactorial disease, with a strong association with genetic variation in the complement system. One of the AMD-associated variants is the c.355G>A (p.Gly119Arg) variant in complement factor I (CFI), a central regulator of complement activation. Here, we report the generation of an iPSC line and its isogenic wildtype control derived from peripheral blood mononuclear cells of a female AMD-affected individual carrying the heterozygous variant c.355G>A (p.Gly119Arg). This line can be utilized to study the effects of this variant in disease-specific cell types.
C1 [de Jong, Sarah; Koolen, Louet; de Breuk, Anita; Hoyng, Carel B.; den Hollander, Anneke, I] Radboud Univ Nijmegen, Donders Inst Brain Cognit & Behav, Dept Ophthalmol, Med Ctr, Nijmegen, Netherlands.
   [Vazquez-Dominguez, Irene; Albert, Silvia; den Hollander, Anneke, I] Radboud Univ Nijmegen, Donders Inst Brain Cognit & Behav, Dept Human Genet, Med Ctr, Nijmegen, Netherlands.
   [Katti, Suresh] Gemini Therapeut Inc, Cambridge, MA USA.
   [Garanto, Alejandro] Radboud Univ Nijmegen, Amalia Childrens Hosp, Radboud Inst Mol Life Sci, Dept Pediat,Med Ctr, Nijmegen, Netherlands.
   [Garanto, Alejandro] Radboud Univ Nijmegen, Amalia Childrens Hosp, Radboud Inst Mol Life Sci, Dept Human Genet,Med Ctr, Nijmegen, Netherlands.
C3 Radboud University Nijmegen; Radboud University Nijmegen; Radboud
   University Nijmegen; Radboud University Nijmegen
RP Garanto, A (通讯作者)，Radboud Univ Nijmegen, Amalia Childrens Hosp, Radboud Inst Mol Life Sci, Dept Pediat,Med Ctr, Nijmegen, Netherlands.; Garanto, A (通讯作者)，Radboud Univ Nijmegen, Amalia Childrens Hosp, Radboud Inst Mol Life Sci, Dept Human Genet,Med Ctr, Nijmegen, Netherlands.
EM alex.garanto@radboudumc.nl
RI Garanto, Alejandro/D-5022-2014
OI Garanto, Alejandro/0000-0001-5721-1560
FU Dutch Research Council [016.Vici.170.024]; Stichting Toegepast
   Wetenschappelijk Instituut voor Neuromodulatie (TWIN project
   "Inflammation and Edema in an Organ-on-a-Chip Model of Wet Age-Related
   Macular Degeneration""); Gemini Therapeutics
FX The authors acknowledge the funding received from the Dutch Research
   Council (016.Vici.170.024 to AIdH) , Stichting Toegepast
   Wetenschappelijk Instituut voor Neuromodulatie (TWIN project
   "Inflammation and Edema in an Organ-on-a-Chip Model of Wet Age-Related
   Macular Degeneration"") , and a sponsored research agreement from Gemini
   Therapeutics.
CR De Jong S, 2022, STEM CELL RES, V62, DOI 10.1016/j.scr.2022.102797
   de Jong S, 2020, HUM MOL GENET, V29, P2313, DOI 10.1093/hmg/ddaa114
   Fritsche LG, 2016, NAT GENET, V48, P134, DOI 10.1038/ng.3448
   Geerlings MJ, 2017, JAMA OPHTHALMOL, V135, P39, DOI 10.1001/jamaophthalmol.2016.4604
   Vazquez-Dominguez I, 2022, STEM CELL RES, V60, DOI 10.1016/j.scr.2022.102689
NR 5
TC 1
Z9 1
U1 0
U2 0
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 1873-5061
EI 1876-7753
J9 STEM CELL RES
JI Stem Cell Res.
PD JUL
PY 2022
VL 62
AR 102796
DI 10.1016/j.scr.2022.102796
PG 6
WC Cell & Tissue Engineering; Biotechnology & Applied Microbiology; Cell
   Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Cell Biology; Biotechnology & Applied Microbiology
GA 1S1HI
UT WOS:000803808500002
PM 35526389
OA gold
DA 2022-11-30
ER

PT J
AU van Dijk, EHC
   Mohabati, D
   Veselinovic, S
   Chung, WH
   Dijkman, G
   Boon, CJF
AF van Dijk, Elon H. C.
   Mohabati, Danial
   Veselinovic, Simona
   Chung, Wing H.
   Dijkman, Greet
   Boon, Camiel J. F.
TI The spectrum of polypoidal choroidal vasculopathy in Caucasians:
   clinical characteristics and proposal of a classification
SO GRAEFES ARCHIVE FOR CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY
LA English
DT Article
DE Aneurysmal type 1 neovascularization; Caucasians; Classification;
   Clinical characteristics; Polypoidal choroidal vasculopathy; Sub-retinal
   pigment epithelium neovascularization
ID AGE-RELATED MACULOPATHY; FACTOR-H CFH; MACULAR DEGENERATION;
   GENETIC-VARIANTS; SUBTYPES; DIAGNOSIS; JAPANESE; DISEASE; ASSOCIATION;
   PREVALENCE
AB Purpose To describe the clinical characteristics and outcome of polypoidal choroidal vasculopathy (PCV), also known as aneurysmal type 1 (sub-retinal pigment epithelium (RPE)) neovascularization, in Caucasian patients. Methods Single-centre study in 66 Caucasian patients with a diagnosis of PCV based on optical coherence tomography scan and indocyanine green angiography. Clinical characteristics and multimodal imaging were collected and assessed by an experienced retina specialist. Results This study involved 74 eyes of 66 patients with PCV, with a mean age at onset of 73 years and a female preponderance of 66%. The mean number of polypoidal lesions per eye was 1 (range: 1-5 lesions), out of which 75% was located in the macula and 19% in the peripapillary region. Of the 74 eyes, 37 eyes (50%) had PCV associated with a drusenoidal neovascular age-related macular degeneration (AMD) phenotype (PCV-AMD) and 18 eyes (24%) had PCV associated with non-polypoidal type 1 choroidal neovascularization/branching vascular network (PCV-BVN) without signs of drusenoidal AMD, while 19 eyes (26%) had idiopathic, isolated PCV (iPCV). The mean subfoveal choroidal thickness measured in 22 patients was 245 mu m (range: 71-420 mu m). In 51% of patients, the initially performed therapy showed good anatomical recovery (resolution of intra- and subretinal fluid). Conclusions A spectrum of PCV (aneurysmal type 1/sub-RPE neovascularization) can be seen in Caucasian patients. PCV associated with a drusenoidal neovascular AMD phenotype in Caucasians is phenotypically and presumably pathophysiologically more associated with neovascular AMD (PCV-AMD: type A PCV). However, this may not be the case for patients with PCV with non-polypoidal type 1 choroidal neovascularization or BVN and no signs of drusenoidal AMD (PCV-BVN: type B PCV), and for patients with idiopathic PCV without associated drusen or BVN (iPCV; type C PCV). Most patients have a thin choroid, even when drusen are absent. For the entire patient group, a moderate anatomical recovery was observed after treatment.
C1 [van Dijk, Elon H. C.; Mohabati, Danial; Veselinovic, Simona; Chung, Wing H.; Dijkman, Greet; Boon, Camiel J. F.] Leiden Univ, Med Ctr, Dept Ophthalmol, Albinusdreef 2, NL-2333 ZA Leiden, Netherlands.
   [Boon, Camiel J. F.] Univ Amsterdam, Amsterdam Univ, Med Ctr, Dept Ophthalmol, Amsterdam, Netherlands.
   [Boon, Camiel J. F.] Leiden Univ, Med Ctr, Dept Ophthalmol, POB 9600, NL-2300 RC Leiden, Netherlands.
C3 Leiden University; Leiden University Medical Center (LUMC); Leiden
   University - Excl LUMC; University of Amsterdam; Leiden University;
   Leiden University Medical Center (LUMC); Leiden University - Excl LUMC
RP Boon, CJF (通讯作者)，Leiden Univ, Med Ctr, Dept Ophthalmol, Albinusdreef 2, NL-2333 ZA Leiden, Netherlands.; Boon, CJF (通讯作者)，Univ Amsterdam, Amsterdam Univ, Med Ctr, Dept Ophthalmol, Amsterdam, Netherlands.
EM c.j.f.boan@lumc.nl
FU Mathilde Grant; Stichting Leids Oogheelkundig Ondersteuningsfonds;
   Rotterdamse Stichting Blindenbelangen; Stichting Blindenhulp;
   Netherlands Organisation for Scientific Research (NWO); MD Fonds;
   Landelijke Stichting voor Blinden en Slechtzienden; Retina Netherlands;
   BlindenPenning through UitZicht
FX This research was supported by the Mathilde Grant, Stichting Leids
   Oogheelkundig Ondersteuningsfonds, Rotterdamse Stichting
   Blindenbelangen, Stichting Blindenhulp, and the Netherlands Organisation
   for Scientific Research (NWO). The funding organizations MD Fonds,
   Landelijke Stichting voor Blinden en Slechtzienden, Retina Netherlands,
   and BlindenPenning contributed through UitZicht. The aforementioned
   funding sources provided unrestricted grants and had no role in the
   design or conduct of this research.
CR Agorogiannis EI, 2018, EYE, V32, P1731, DOI 10.1038/s41433-018-0168-2
   Augood CA, 2006, ARCH OPHTHALMOL-CHIC, V124, P529, DOI 10.1001/archopht.124.4.529
   Balaratnasingam C, 2016, RETINA-J RET VIT DIS, V36, P1, DOI 10.1097/IAE.0000000000000774
   BIRD AEC, 1995, SURV OPHTHALMOL, V39, P367, DOI 10.1016/S0039-6257(05)80092-X
   Cackett P, 2009, RETINA-J RET VIT DIS, V29, P187, DOI 10.1097/IAE.0b013e318188c839
   Chang YC, 2020, RETINA-J RET VIT DIS, V40, P1403, DOI 10.1097/IAE.0000000000002583
   Cheung CMG, 2019, EYE, V33, P14, DOI 10.1038/s41433-018-0158-4
   Cheung CMG, 2018, OPHTHALMOLOGY, V125, P708, DOI 10.1016/j.ophtha.2017.11.019
   Cheung CMG, 2014, RETINA-J RET VIT DIS, V34, P2397, DOI 10.1097/IAE.0000000000000255
   Chung WH, 2017, CLIN OPHTHALMOL, V11, P63, DOI 10.2147/OPTH.S122568
   Coscas G, 2015, INVEST OPHTH VIS SCI, V56, P3187, DOI 10.1167/iovs.14-16236
   Coscas G, 2014, AM J OPHTHALMOL, V158, P309, DOI 10.1016/j.ajo.2014.05.004
   Dansingani KK, 2018, CLIN EXP OPHTHALMOL, V46, P189, DOI 10.1111/ceo.13114
   Davis SJ, 2014, RETINA-J RET VIT DIS, V34, P2185, DOI 10.1097/IAE.0000000000000206
   de Jong EK, 2015, OPHTHALMOLOGY, V122, P562, DOI 10.1016/j.ophtha.2014.09.026
   Erke MG, 2012, OPHTHALMOLOGY, V119, P1737, DOI 10.1016/j.ophtha.2012.03.016
   Ferris FL, 2013, OPHTHALMOLOGY, V120, P844, DOI 10.1016/j.ophtha.2012.10.036
   Freund KB, 2010, RETINA-J RET VIT DIS, V30, P1333, DOI 10.1097/IAE.0b013e3181e7976b
   George S, 2010, EYE, V24, P1247, DOI 10.1038/eye.2009.301
   Imamura Y, 2010, SURV OPHTHALMOL, V55, P501, DOI 10.1016/j.survophthal.2010.03.004
   Jung JJ, 2014, AM J OPHTHALMOL, V158, P769, DOI 10.1016/j.ajo.2014.07.006
   Koh A, 2012, RETINA-J RET VIT DIS, V32, P1453, DOI 10.1097/IAE.0b013e31824f91e8
   Koh AHC, 2013, RETINA-J RET VIT DIS, V33, P686, DOI 10.1097/IAE.0b013e3182852446
   Kokame GT, 2020, OPHTHALMOLOGICA, V243, P178, DOI 10.1159/000503834
   Kokame GT, 2019, OPHTHALMOL RETINA, V3, P744, DOI 10.1016/j.oret.2019.04.018
   Kwok AKH, 2002, BRIT J OPHTHALMOL, V86, P892, DOI 10.1136/bjo.86.8.892
   Lafaut BA, 2000, GRAEF ARCH CLIN EXP, V238, P752, DOI 10.1007/s004170000180
   Laude A, 2010, PROG RETIN EYE RES, V29, P19, DOI 10.1016/j.preteyeres.2009.10.001
   Lehmann M, 2015, RETINA-J RET VIT DIS, V35, P10, DOI 10.1097/IAE.0000000000000287
   Lip PL, 2000, EYE, V14, P695, DOI 10.1038/eye.2000.186
   Lorentzen TD, 2018, RETINA-J RET VIT DIS, V38, P2363, DOI 10.1097/IAE.0000000000001872
   Ma L, 2015, OPHTHALMOLOGY, V122, P1854, DOI 10.1016/j.ophtha.2015.05.012
   Maruko I, 2007, AM J OPHTHALMOL, V144, P15, DOI 10.1016/j.ajo.2007.03.047
   Miki A, 2013, OPHTHALMIC GENET, V34, P146, DOI 10.3109/13816810.2012.749288
   Ojima Y, 2009, RETINA-J RET VIT DIS, V29, P52, DOI 10.1097/IAE.0b013e3181884fbf
   Pereira FB, 2015, OPHTHALMOLOGICA, V234, P233, DOI 10.1159/000439359
   Sato T, 2007, RETINA-J RET VIT DIS, V27, P589, DOI 10.1097/01.iae.0000249386.63482.05
   Sho K, 2003, ARCH OPHTHALMOL-CHIC, V121, P1392, DOI 10.1001/archopht.121.10.1392
   Spaide RF, 2020, OPHTHALMOLOGY, V127, P616, DOI 10.1016/j.ophtha.2019.11.004
   Spaide RF, 2018, RETINA-J RET VIT DIS, V38, P891, DOI 10.1097/IAE.0000000000001732
   Spaide RF, 2015, RETINA-J RET VIT DIS, V35, P2161, DOI 10.1097/IAE.0000000000000881
   Tanaka K, 2011, INVEST OPHTH VIS SCI, V52, P7441, DOI 10.1167/iovs.11-7546
   Uyama M, 2002, AM J OPHTHALMOL, V133, P639, DOI 10.1016/S0002-9394(02)01404-6
   Uyama M, 1999, ARCH OPHTHALMOL-CHIC, V117, P1035
   van Dijk EHC, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0180312
   Wen F, 2004, GRAEF ARCH CLIN EXP, V242, P625, DOI 10.1007/s00417-003-0667-z
   Wong CW, 2016, PROG RETIN EYE RES, V53, P107, DOI 10.1016/j.preteyeres.2016.04.002
   Yannuzzi LA, 1997, ARCH OPHTHALMOL-CHIC, V115, P478, DOI 10.1001/archopht.1997.01100150480005
   YANNUZZI LA, 1990, RETINA-J RET VIT DIS, V10, P1, DOI 10.1097/00006982-199001010-00001
   Yuzawa M, 2005, BRIT J OPHTHALMOL, V89, P602, DOI 10.1136/bjo.2004.049296
NR 50
TC 7
Z9 7
U1 0
U2 1
PU SPRINGER
PI NEW YORK
PA ONE NEW YORK PLAZA, SUITE 4600, NEW YORK, NY, UNITED STATES
SN 0721-832X
EI 1435-702X
J9 GRAEF ARCH CLIN EXP
JI Graefes Arch. Clin. Exp. Ophthalmol.
PD FEB
PY 2021
VL 259
IS 2
BP 351
EP 361
DI 10.1007/s00417-020-04844-z
EA AUG 2020
PG 11
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA QA9UY
UT WOS:000561826600002
PM 32812132
OA hybrid, Green Published
DA 2022-11-30
ER

PT J
AU Chen, PYJ
   Wan, L
   Lai, JN
   Chen, CS
   Chen, JJY
   Yen, WM
   Chiu, LT
   Hu, KC
   Tien, PT
   Lin, HJ
AF Chen, Po-Yu Jay
   Wan, Lei
   Lai, Jung-Nien
   Chen, Chih Sheng
   Chen, Jamie Jiin-Yi
   Yen, Wu Ming
   Chiu, Lu-Ting
   Hu, Kai-Chieh
   Tien, Peng-Tai
   Lin, Hui-Ju
TI Increased risk of Parkinson's disease among patients with age-related
   macular degeneration
SO BMC OPHTHALMOLOGY
LA English
DT Article
DE Parkinson's disease (PD); Age-related macular degeneration (AMD);
   Retinal inflammation
ID INFLAMMATION; ASSOCIATION; MECHANISMS; SEVERITY; LAYER
AB Background This study aimed to investigate the risk of Parkinson's disease (PD) among patients with age-related macular degeneration (AMD) and its association with confounding comorbidities. Methods A population-based retrospective cohort study was conducted using Longitudinal Health Insurance Database 2000 (LHID2000). We established AMD and non-AMD cohorts from January 1, 2000 to December 31, 2012 to determine the diagnosis of PD. A total of 20,848 patients were enrolled, with 10,424 AMD patients and 10,424 controls matched for age, sex, and index year at a 1:1 ratio. The follow-up period was from the index date of AMD diagnosis to the diagnosis of PD, death, withdrawal from the insurance program, or end of 2013. Multivariable Cox regression analysis was performed to examine the hazard ratio (HR) and 95% confidence interval (CI) for the risk of PD between the AMD and non-AMD cohorts. Result After adjusting for potential confounders, there was a higher risk of developing PD in the AMD cohort than in the non-AMD cohort (adjusted HR = 1.35, 95% CI = 1.16-1.58). A significant association could be observed in both female (aHR = 1.42, 95% CI = 1.13-1.80) and male (aHR = 1.28, 95% CI = 1.05-1.57) patients, aged more than 60 years (60-69: aHR = 1.51, 95% CI = 1.09-2.09, 70-79: aHR = 1.30, 95% CI = 1.05-1.60; 80-100: aHR = 1.40, 95% CI = 1.01-1.95), and with more than one comorbidity (aHR = 1.40, 95% CI = 1.20-1.64). A significant association between increased risk of PD and AMD was observed among patients with comorbidities of osteoporosis (aHR = 1.68, 95% CI = 1.22-2.33), diabetes (aHR = 1.41, 95% CI = 1.12-1.78) and hypertension (aHR = 1.36, 95% CI = 1.15-1.62) and medications of statin (aHR = 1.42, 95% CI = 1.19-1.69) and calcium channel blocker (CCB) (aHR = 1.32, 95% CI = 1.11-1.58). The cumulative incidence of PD was significantly higher over the 12-year follow-up period in AMD cohort (log-rank test, p < 0.001). Conclusions Patients with AMD may exhibit a higher risk of PD than those without AMD.
C1 [Chen, Po-Yu Jay; Chen, Jamie Jiin-Yi; Yen, Wu Ming; Tien, Peng-Tai; Lin, Hui-Ju] China Med Univ Hosp, Eye Ctr, Taichung, Taiwan.
   [Chen, Po-Yu Jay; Chen, Jamie Jiin-Yi; Yen, Wu Ming; Tien, Peng-Tai; Lin, Hui-Ju] China Med Univ Hosp, Dept Mol Genet, Taichung, Taiwan.
   [Wan, Lei; Lai, Jung-Nien; Chen, Jamie Jiin-Yi; Yen, Wu Ming; Lin, Hui-Ju] China Med Univ, Sch Chinese Med, Taichung, Taiwan.
   [Wan, Lei] Asia Univ, Dept Med Lab Sci & Biotechnol, Taichung, Taiwan.
   [Wan, Lei] China Med Univ Hosp, Dept Obstet & Gynecol, Taichung, Taiwan.
   [Chen, Chih Sheng] Asia Univ Hosp, Div Chinese Med, Taichung, Taiwan.
   [Chiu, Lu-Ting; Hu, Kai-Chieh] China Med Univ Hosp, Management Off Hlth Data, Taichung, Taiwan.
   [Tien, Peng-Tai] China Med Univ, Grad Inst Clin Med Sci, Coll Med, Taichung, Taiwan.
   [Tien, Peng-Tai] China Med Univ, Sch Med, Coll Med, Taichung, Taiwan.
   [Tien, Peng-Tai; Lin, Hui-Ju] China Med Univ Hosp, Dept Ophthalmol, Taichung, Taiwan.
   [Tien, Peng-Tai; Lin, Hui-Ju] China Med Univ Hosp, Dept Mol Genet, Taichung, Taiwan.
C3 China Medical University Taiwan; China Medical University Hospital -
   Taiwan; China Medical University Taiwan; China Medical University
   Hospital - Taiwan; China Medical University Taiwan; Asia University
   Taiwan; China Medical University Taiwan; China Medical University
   Hospital - Taiwan; China Medical University Taiwan; China Medical
   University Hospital - Taiwan; China Medical University Taiwan; China
   Medical University Taiwan; China Medical University Taiwan; China
   Medical University Hospital - Taiwan; China Medical University Taiwan;
   China Medical University Hospital - Taiwan
RP Tien, PT; Lin, HJ (通讯作者)，China Med Univ Hosp, Dept Ophthalmol, Taichung, Taiwan.; Tien, PT; Lin, HJ (通讯作者)，China Med Univ Hosp, Dept Mol Genet, Taichung, Taiwan.
EM miketien913@gmail.com; irisluu2396@gmail.com
OI Chen, Po-Yu/0000-0002-5594-678X
FU Taiwan Ministry of Health and Welfare Clinical Trial Center
   [MOHW109-TDU-B-212-114004]; MOST Clinical Trial Consortium for Stroke
   [MOST 109-2321-B-039-002]; China Medical University Hospital
   [DMR-106-216]; China Medical University, Taichung, Taiwan
   [CMU109-ASIA-06, CMU109-MF-62]; Tseng-Lien Lin Foundation, Taichung,
   Taiwan
FX This study is supported in part by Taiwan Ministry of Health and Welfare
   Clinical Trial Center (MOHW109-TDU-B-212-114004), MOST Clinical Trial
   Consortium for Stroke (MOST 109-2321-B-039-002), China Medical
   University Hospital (DMR-106-216), China Medical University, Taichung,
   Taiwan (CMU109-ASIA-06; CMU109-MF-62), and Tseng-Lien Lin Foundation,
   Taichung, Taiwan.
CR Al-Salem Khalil M, 2014, Retina, V34, P868, DOI 10.1097/IAE.0000000000000006
   Archibald NK, 2011, PARKINSONISM RELAT D, V17, P431, DOI 10.1016/j.parkreldis.2011.03.004
   Balk LJ, 2014, AM J OPHTHALMOL, V158, P845, DOI 10.1016/j.ajo.2014.06.022
   Beatty S, 2000, SURV OPHTHALMOL, V45, P115, DOI 10.1016/S0039-6257(00)00140-5
   Bressler Neil M, 2004, JAMA, V291, P1900, DOI 10.1001/jama.291.15.1900
   Buschini E, 2011, PROG NEUROBIOL, V95, P14, DOI 10.1016/j.pneurobio.2011.05.011
   Choi S, 2020, AM J OPHTHALMOL, V210, P41, DOI 10.1016/j.ajo.2019.11.001
   Chung SD, 2014, AM J OPHTHALMOL, V157, P464, DOI 10.1016/j.ajo.2013.09.026
   Dauer W, 2003, NEURON, V39, P889, DOI 10.1016/S0896-6273(03)00568-3
   de Jong PTVM, 2006, NEW ENGL J MED, V355, P1474, DOI 10.1056/NEJMra062326
   Etminan M, 2018, J CURR OPHTHALMOL, V30, P365, DOI 10.1016/j.joco.2018.08.004
   Figueroa AG, 2021, AM J MED, V134, P122, DOI 10.1016/j.amjmed.2020.05.038
   Golestaneh N, 2017, CELL DEATH DIS, V8, DOI 10.1038/cddis.2016.453
   Hindle JV, 2010, AGE AGEING, V39, P156, DOI 10.1093/ageing/afp223
   Hsieh CY, 2019, CLIN EPIDEMIOL, V11, P349, DOI 10.2147/CLEP.S196293
   Jimenez B, 2014, MOVEMENT DISORD, V29, P68, DOI 10.1002/mds.25747
   Kaarniranta K, 2011, J ALZHEIMERS DIS, V24, P615, DOI 10.3233/JAD-2011-101908
   Lee EK, 2015, INVEST OPHTH VIS SCI, V56, P3976, DOI 10.1167/iovs.15-17013
   Liu GD, 2017, MOVEMENT DISORD, V32, P913, DOI 10.1002/mds.27006
   Miller RL, 2009, NEUROCHEM RES, V34, P55, DOI 10.1007/s11064-008-9656-2
   Noyce AJ, 2012, ANN NEUROL, V72, P893, DOI 10.1002/ana.23687
   Pajares M, 2020, CELLS-BASEL, V9, DOI 10.3390/cells9071687
   Pringsheim T, 2014, MOVEMENT DISORD, V29, P1583, DOI 10.1002/mds.25945
   Rozzini L, 2014, AM J ALZHEIMERS DIS, V29, P256, DOI 10.1177/1533317513517032
   Satue M, 2014, BRIT J OPHTHALMOL, V98, P350, DOI 10.1136/bjophthalmol-2013-304152
   Shin HW, 2012, J CLIN NEUROL, V8, P15, DOI 10.3988/jcn.2012.8.1.15
   Smith W, 2001, OPHTHALMOLOGY, V108, P697, DOI 10.1016/S0161-6420(00)00580-7
   Telander DG, 2011, SEMIN OPHTHALMOL, V26, P192, DOI 10.3109/08820538.2011.570849
   Wei CC, 2019, ENVIRON POLLUT, V254, DOI 10.1016/j.envpol.2019.113031
   Wei CC, 2018, EBIOMEDICINE, V28, P274, DOI 10.1016/j.ebiom.2018.01.024
   Zetterberg M, 2008, AM J MED GENET B, V147B, P720, DOI 10.1002/ajmg.b.30668
NR 31
TC 3
Z9 3
U1 0
U2 0
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
EI 1471-2415
J9 BMC OPHTHALMOL
JI BMC Ophthalmol.
PD DEC 9
PY 2021
VL 21
IS 1
AR 426
DI 10.1186/s12886-021-02196-8
PG 9
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA XM1BF
UT WOS:000728569900001
PM 34886822
OA gold, Green Published
DA 2022-11-30
ER

PT J
AU Aldebert, G
   Faillie, JL
   Hillaire-Buys, D
   Mura, T
   Carriere, I
   Delcourt, C
   Creuzot-Garcher, C
   Villain, M
   Daien, V
AF Aldebert, Gauthier
   Faillie, Jean-Luc
   Hillaire-Buys, Dominique
   Mura, Thibault
   Carriere, Isabelle
   Delcourt, Cecile
   Creuzot-Garcher, Catherine
   Villain, Max
   Daien, Vincent
TI Association of Anticholinergic Drug Use With Risk for Late Age-Related
   Macular Degeneration
SO JAMA OPHTHALMOLOGY
LA English
DT Article
ID INAPPROPRIATE MEDICATION USE; PIGMENT EPITHELIAL-CELLS; AMYLOID-BETA;
   COGNITIVE IMPAIRMENT; COMPLEMENT ACTIVATION; ALZHEIMERS-DISEASE;
   CONSENSUS PANEL; BEERS CRITERIA; VISION LOSS; EXPOSURE
AB IMPORTANCE Amyloid-beta is a major component of retinal drusen, the primary lesions of age-related macular degeneration (AMD), and autopsy and animal models suggested that anticholinergic drug (ACD) use increased brain amyloid-beta deposition.
   OBJECTIVE To investigate the association between exposure to ACDs and late AMD (features of neovascular AMD or geographic atrophy of the retinal pigment epithelium in at least 1 eye).
   DESIGN, SETTING AND PARTICIPANTS A multicenter case-control study in 4 French ophthalmologic centers comprising 200 cases with late AMD and 200 controls enrolled from July 2016 to June 2017.
   EXPOSURES Exposure to at least 3 months of ACDs started before AMD diagnosis was recorded during a specific interview. A dose-effect association with cumulative exposure duration and Anticholinergic Burden Score was explored. The association between ACD exposure and AMD was assessed by multivariate logistic regression analysis adjusted for age, sex, smoking status, family history of AMD, alcohol consumption, and use of anticoagulant and anti-inflammatory drugs. Odds ratios (ORs) and 95% confidence intervals were estimated.
   MAIN OUTCOMES AND MEASURES Association between exposure to ACDs and late AMD.
   RESULTS Among case participants, the mean (SD) age was 74.8 (9.2) years, 129 (64.5%) were women, 192 (96%) were white, 65 (32.5%) had geographic atrophy, 135 (67.5%) had neovascular AMD, 116 (58%) had unilateral AMD, and 84 (42%) had bilateral AMD. Among control participants, the mean (SD) age was 75.5 (7.2) years, with 116 (58%) women and 187 (93.5%) white participants. Twenty-six cases (13%) and 10 controls (5%) were exposed to ACDs throughout life for at least 3 months before AMD onset. Risk of AMD was increased with ever exposure to ACDs (adjusted OR [aOR], 2.84; 95% CI, 1.33-6.06; P =.007), high Anticholinergic Burden Score (>= 3) (aOR, 6.42; 95% CI, 1.38-29.92; P =.02), and longest cumulative exposure to ACD (>= 15 years) (aOR, 5.88; 95% CI, 1.22-28.31; P =.03).
   CONCLUSIONS AND RELEVANCE Risk of late AMD may be increased with at least 3 months' use of ACDs. A dose-effect association was suggested by a greater association with prolonged use and high Anticholinergic Burden Score. Further studies, in particular those with longitudinal design, are needed to confirm this association.
C1 [Aldebert, Gauthier; Villain, Max; Daien, Vincent] Gui De Chauliac Hosp, Dept Ophthalmol, Montpellier, France.
   [Faillie, Jean-Luc; Hillaire-Buys, Dominique] Lapeyronie Hosp, Dept Med Pharmacol & Toxicol, Montpellier, France.
   [Mura, Thibault] La Colombiere Hosp, Dept Epidemiol & Clin Res, Montpellier, France.
   [Mura, Thibault; Carriere, Isabelle; Daien, Vincent] Univ Montpellier, INSERM, Neuropsychiat Epidemiol & Clin Res, Montpellier, France.
   [Delcourt, Cecile] Univ Bordeaux, INSERM, Bordeaux Populat Hlth Res Ctr, Bordeaux, France.
   [Creuzot-Garcher, Catherine] CHU Dijon, Dept Ophthalmol, Dijon, France.
   [Daien, Vincent] Univ Sydney, Sydney Med Sch, Save Sight Inst, Sydney, NSW, Australia.
C3 Universite de Montpellier; CHU de Montpellier; Universite de
   Montpellier; CHU de Montpellier; Universite de Montpellier; CHU de
   Montpellier; Institut National de la Sante et de la Recherche Medicale
   (Inserm); Universite de Montpellier; Institut National de la Sante et de
   la Recherche Medicale (Inserm); UDICE-French Research Universities;
   Universite de Bordeaux; CHU Dijon Bourgogne; University of Sydney
RP Daien, V (通讯作者)，CHU Montpellier, Guide Chauliac Hosp, Dept Ophthalmol, 80 Ave Augustin Fliche, F-34295 Montpellier, France.
EM v-daien@chu-montpellier.fr
RI DAIEN, Vincent/Z-5516-2019; mura, Thibault/X-7279-2019; Carrière,
   Isabelle/W-8728-2019; Faillie, Jean-Luc/AAA-6009-2019; Delcourt,
   Cecile/I-2627-2013
OI DAIEN, Vincent/0000-0001-5675-0861; mura, Thibault/0000-0001-6420-1336;
   Faillie, Jean-Luc/0000-0003-0100-4073; Delcourt,
   Cecile/0000-0002-2099-0481; Carriere, Isabelle/0000-0002-3617-0752
FU University Hospital of Montpellier, France
FX This study was funded by the University Hospital of Montpellier, France.
CR Ambati J, 2012, NEURON, V75, P26, DOI 10.1016/j.neuron.2012.06.018
   Ancelin ML, 2006, BMJ-BRIT MED J, V332, P455, DOI 10.1136/bmj.38740.439664.DE
   Anderson DH, 2004, EXP EYE RES, V78, P243, DOI 10.1016/j.exer.2003.10.011
   Augood CA, 2006, ARCH OPHTHALMOL-CHIC, V124, P529, DOI 10.1001/archopht.124.4.529
   Bastiaans J, 2013, GRAEF ARCH CLIN EXP, V251, P1723, DOI 10.1007/s00417-013-2335-2
   Beach TG, 2000, NEUROSCI LETT, V283, P9, DOI 10.1016/S0304-3940(00)00916-2
   Bourne RRA, 2014, BRIT J OPHTHALMOL, V98, P629, DOI 10.1136/bjophthalmol-2013-304033
   Bourne RRA, 2013, LANCET GLOB HEALTH, V1, pE339, DOI 10.1016/S2214-109X(13)70113-X
   Boustani M., 2008, AGING HLTH, V4, P311, DOI [DOI 10.2217/1745509X.4.3.311, 10.2217/1745509XA3.311]
   Bruban J, 2009, AGING CELL, V8, P162, DOI 10.1111/j.1474-9726.2009.00456.x
   Carnahan RM, 2006, J CLIN PHARMACOL, V46, P1481, DOI 10.1177/0091270006292126
   Carriere I, 2009, ARCH INTERN MED, V169, P1317, DOI 10.1001/archinternmed.2009.229
   Chakravarthy U, 2010, BMC OPHTHALMOL, V10, DOI 10.1186/1471-2415-10-31
   Delcourt C, 2001, ARCH OPHTHALMOL-CHIC, V119, P1463
   Delcourt C, 2014, INVEST OPHTH VIS SCI, V55, P7619, DOI 10.1167/iovs.14-14471
   Dentchev T, 2003, MOL VIS, V9, P184
   Duran CE, 2013, EUR J CLIN PHARMACOL, V69, P1485, DOI 10.1007/s00228-013-1499-3
   Ellett LMK, 2014, J AM GERIATR SOC, V62, P1916, DOI 10.1111/jgs.13054
   Fick DM, 2003, ARCH INTERN MED, V163, P2716, DOI 10.1001/archinte.163.22.2716
   Fisher A, 2003, J MOL NEUROSCI, V20, P349, DOI 10.1385/JMN:20:3:349
   Fox C, 2011, J AM GERIATR SOC, V59, P1477, DOI 10.1111/j.1532-5415.2011.03491.x
   Gehlbach P, 2015, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD006927.pub4
   Gopinath B, 2016, INVEST OPHTH VIS SCI, V57, P5273, DOI 10.1167/iovs.16-19735
   Gray SL, 2015, JAMA INTERN MED, V175, P401, DOI 10.1001/jamainternmed.2014.7663
   Han L, 2008, J AM GERIATR SOC, V56, P2203, DOI 10.1111/j.1532-5415.2008.02009.x
   Ionov ID, 2010, NEUROSCI LETT, V480, P83, DOI 10.1016/j.neulet.2010.06.010
   Johnson LV, 2002, P NATL ACAD SCI USA, V99, P11830, DOI 10.1073/pnas.192203399
   Klein R, 2014, OPHTHALMOLOGY, V121, P1604, DOI 10.1016/j.ophtha.2014.03.005
   Laroche ML, 2007, EUR J CLIN PHARMACOL, V63, P725, DOI 10.1007/s00228-007-0324-2
   Lechevallier-Michel N, 2005, BRIT J CLIN PHARMACO, V59, P143, DOI 10.1111/j.1365-2125.2004.02232.x
   Li L, 2015, J CLIN PHARM THER, V40, P144, DOI 10.1111/jcpt.12241
   Lim LS, 2012, LANCET, V379, P1728, DOI 10.1016/S0140-6736(12)60282-7
   Liu RT, 2013, INVEST OPHTH VIS SCI, V54, P2225, DOI 10.1167/iovs.12-10849
   Mebarki S, 2012, NPG NEUROL PSYCHIATR, V12, P131
   Montastruc F, 2014, EUR J CLIN PHARMACOL, V70, P1147, DOI 10.1007/s00228-014-1717-7
   Moulis F, 2015, J AM MED DIR ASSOC, V16, P253, DOI 10.1016/j.jamda.2014.11.017
   Ness Jose, 2006, Am J Geriatr Pharmacother, V4, P42, DOI 10.1016/j.amjopharm.2006.03.008
   Pham TQ, 2006, GERONTOLOGY, V52, P353, DOI 10.1159/000094984
   Radcliff S, 2015, J AM GERIATR SOC, V63, P2227, DOI 10.1111/jgs.13702
   Roher AE, 2000, ANN NY ACAD SCI, V903, P366, DOI 10.1111/j.1749-6632.2000.tb06388.x
   Rudolph JL, 2008, ARCH INTERN MED, V168, P508, DOI 10.1001/archinternmed.2007.106
   Sui GY, 2013, BRIT J OPHTHALMOL, V97, P389, DOI 10.1136/bjophthalmol-2012-302281
   Swanson MW, 2008, OPTOMETRY VISION SCI, V85, P947, DOI 10.1097/OPX.0b013e31818883e0
   Tsai DC, 2015, OPHTHALMOLOGY, V122, P2327, DOI 10.1016/j.ophtha.2015.07.033
   Van Leeuwen R, 2004, OPHTHALMOLOGY, V111, P1169, DOI 10.1016/j.ophtha.2003.10.024
   von Elm E, 2007, ANN INTERN MED, V147, P573, DOI 10.7326/0003-4819-147-8-200710160-00010
   Walsh DT, 2005, NEUROPATH APPL NEURO, V31, P491, DOI 10.1111/j.1365-2990.2005.00666.x
   Wang JY, 2008, J IMMUNOL, V181, P712, DOI 10.4049/jimmunol.181.1.712
   Wang JY, 2009, J CELL PHYSIOL, V220, P119, DOI 10.1002/jcp.21742
   Wang JJ, 2003, OPHTHALMIC EPIDEMIOL, V10, P37, DOI 10.1076/opep.10.1.37.13776
   Woo SJ, 2012, OPHTHALMOLOGY, V119, P2094, DOI 10.1016/j.ophtha.2012.04.026
   Zhao YH, 2015, MOL NEUROBIOL, V52, P533, DOI 10.1007/s12035-014-8886-3
   Zhou LX, 2016, CLIN INTERV AGING, V11, P215, DOI 10.2147/CIA.S102213
NR 53
TC 2
Z9 2
U1 0
U2 2
PU AMER MEDICAL ASSOC
PI CHICAGO
PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA
SN 2168-6165
EI 2168-6173
J9 JAMA OPHTHALMOL
JI JAMA Ophthalmol.
PD JUL
PY 2018
VL 136
IS 7
BP 770
EP 778
DI 10.1001/jamaophthalmol.2018.1719
PG 9
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)
SC Ophthalmology
GA GM9GK
UT WOS:000438554300014
PM 29800005
OA Green Published, Bronze
DA 2022-11-30
ER

PT J
AU Holz, FG
   Dugel, PU
   Weissgerber, G
   Hamilton, R
   Silva, R
   Bandello, F
   Larsen, M
   Weichselberger, A
   Wenzel, A
   Schmidt, A
   Escher, D
   Sararols, L
   Souied, E
AF Holz, Frank G.
   Dugel, Pravin U.
   Weissgerber, Georges
   Hamilton, Robin
   Silva, Rufino
   Bandello, Francesco
   Larsen, Michael
   Weichselberger, Andreas
   Wenzel, Andreas
   Schmidt, Anne
   Escher, Dominik
   Sararols, Laura
   Souied, Eric
TI Single-Chain Antibody Fragment VEGF Inhibitor RTH258 for Neovascular
   Age-Related Macular Degeneration
SO OPHTHALMOLOGY
LA English
DT Article
ID ENDOTHELIAL GROWTH-FACTOR; 2.0 MG RANIBIZUMAB; BLINDNESS; EFFICACY;
   SAFETY
AB Purpose: To assess the safety and efficacy of different doses of RTH258 applied as single intravitreal administration compared with ranibizumab 0.5 mg in patients with neovascular age-related macular degeneration (AMD).
   Design: Six-month, phase 1/2, prospective, multicenter, double-masked, randomized, ascending singledose, active-controlled, parallel-group study.
   Participants: A total of 194 treatment-naive patients, aged >= 50 years, with primary subfoveal choroidal neovascularization secondary to AMD.
   Methods: Patients received a single intravitreal injection of RTH258 0.5 mg (n = 11), 3.0 mg (n = 31), 4.5 mg (n = 47), or 6.0 mg (n = 44), or ranibizumab 0.5 mg (n = 61).
   Main Outcome Measures: The primary efficacy end point was the change from baseline to month 1 in central subfield thickness (CSFT) measured by spectral-domain optical coherence tomography. The secondary efficacy end point was the duration of treatment effect measured as time from the initial injection to receipt of post-baseline therapy (PBT) guided by protocol-defined criteria. Adverse events (AEs) were recorded throughout the study.
   Results: RTH258 demonstrated noninferiority compared with ranibizumab in mean change in CSFT from baseline to month 1 for the 4.5-and 6.0-mg dose groups (margin: 40 mm, 1-sided alpha 0.05). The difference in CSFT change at month 1 comparison with ranibizumab was 22.86 mm (90% confidence interval [CI], -9.28 to 54.99) and 19.40 mu m (95% CI, -9.00 to 47.80) for RTH258 4.5 and 6 mg, respectively. The median time to PBT after baseline therapy was 60 and 75 days for patients in the RTH258 4.5-and 6.0-mg groups, respectively, compared with 45 days for ranibizumab. Changes in best-corrected visual acuity with RTH258 were comparable to those observed with ranibizumab. The most frequent AEs reported for the RTH258 groups were conjunctival hemorrhage, eye pain, and conjunctival hyperemia; the majority of these events were mild in intensity.
   Conclusions: This first-in-human study of RTH258 demonstrated noninferiority in the change in CSFT at 1 month for the 4.5-and 6.0-mg doses compared with ranibizumab and an increase of 30 days in the median time to PBT for the 6.0-mg dose. There were no unexpected safety concerns, and the results support the continued development of RTH258 for the treatment of neovascular AMD. (C) 2016 by the American Academy of Ophthalmology.
C1 [Holz, Frank G.] Univ Bonn, Dept Ophthalmol, Bonn, Germany.
   [Dugel, Pravin U.] Retinal Consultants Arizona, 1101 E Missouri Ave, Phoenix, AZ 85014 USA.
   [Dugel, Pravin U.] Univ So Calif, Keck Sch Med, Inst Eye, Los Angeles, CA 90033 USA.
   [Weissgerber, Georges; Weichselberger, Andreas; Wenzel, Andreas] Alcon Labs Inc, Ft Worth, TX 76101 USA.
   [Hamilton, Robin] Moorfields Eye Hosp, NIHR BRC, London, England.
   [Hamilton, Robin] Moorfields Eye Hosp, NHS Fdn Trust, Ophthalmol, London, England.
   [Silva, Rufino] Univ Coimbra, Fac Med, Ctr Hosp & Univ Coimbra, Coimbra, Portugal.
   [Silva, Rufino] Assoc Innovat & Biomed Res Light & Image, Coimbra, Portugal.
   [Bandello, Francesco] Univ Vita Salute, Ist Sci San Raffaele, Milan, Italy.
   [Larsen, Michael] Rigshosp, Dept Ophthalmol, DK-2100 Copenhagen, Denmark.
   [Larsen, Michael] Univ Copenhagen, Copenhagen, Denmark.
   [Schmidt, Anne; Escher, Dominik] ESBATech, Zurich, Switzerland.
   [Sararols, Laura] Hosp Gen Cataluna, Barcelona, Spain.
   [Souied, Eric] Univ Paris Est, Hop Intercommunal, Serv Univ Ophtalmol, Creteil, France.
C3 University of Bonn; University of Southern California; Novartis; Alcon;
   University of London; University College London; Moorfields Eye Hospital
   NHS Foundation Trust; Oxford University Hospitals NHS Foundation Trust;
   University of London; University College London; Moorfields Eye Hospital
   NHS Foundation Trust; Universidade de Coimbra; Centro Hospitalar e
   Universitario de Coimbra (CHUC); Universidade de Coimbra; Vita-Salute
   San Raffaele University; IRCCS Ospedale San Raffaele; Rigshospitalet;
   University of Copenhagen; University of Copenhagen; Universite
   Paris-Est-Creteil-Val-de-Marne (UPEC); CHI Creteil
RP Dugel, PU (通讯作者)，Retinal Consultants Arizona, 1101 E Missouri Ave, Phoenix, AZ 85014 USA.
EM pdugel@gmail.com
RI bandello, francesco/AAH-2405-2019; Larsen, Michael/E-9620-2010; Silva,
   Rufino M/J-2817-2012
OI bandello, francesco/0000-0003-3238-9682; Larsen,
   Michael/0000-0002-5172-5891; Silva, Rufino M/0000-0001-8676-0833
FU Alcon; Allergan; Bayer Healthcare; Pfizer; Heidelberg Engineering;
   Novartis; Optos; GlaxoSmithKline; Carl Zeiss Meditec; Alimera Sciences;
   Bayer Schering; Bausch Lomb; Farmila Thea; Genentech; Hoffman La Roche;
   Novagali Pharma; Sanofi Aventis; Thrombogenics; Ophthotech; Roche; Thea;
   Alcon Research, Ltd. (Fort Worth, TX); Advisory board member - Alcon;
   Alimera; Bayer
FX The authors have made the following disclosure(s): F.G.H.: Consultant -
   Acucela, Boehringer-Ingelheim, Genentech, and Merz; Consultant and has
   received grants - Alcon and Allergan; Consultant for and has received
   lecture and speaker fees - Bayer Healthcare and Pfizer; Consultant for
   and has received grants, lecture fees, and speaker's bureau fees -
   Heidelberg Engineering and Novartis; received grants - Optos,
   GlaxoSmithKline, and Carl Zeiss Meditec.; R.S.: Grants - Alcon; Advisory
   board member - Alcon, Alimera, Allergan, Bayer, Novartis, and Thea.;
   F.B.: Personal fees - Alcon, Alimera Sciences, Allergan, Bayer Schering,
   Bausch & Lomb, Farmila Thea, Genentech, Hoffman La Roche, Novagali
   Pharma, Novartis, Sanofi Aventis, and Thrombogenics.; M.L. and the
   Rigshospitalet have received contractual payments from Ophthotech,
   Bayer, Novartis, and Alcon for clinical trials and related work.; L.S.:
   Grants and Advisory Boards - Novartis, Alcon, Bayer, Roche.; E.S.:
   Personal fees - Novartis, Bayer, Thea, and Allergan.; Funded by Alcon
   Research, Ltd. (Fort Worth, TX). Alcon participated in the design and
   conduct of the study, data management, data analysis, interpretation of
   the data, and preparation and approval of the manuscript.
CR American Academy of Ophthalmology Retina/Vitreous Panel, PREF PRACT PATT GUID
   Bloch SB, 2012, AM J OPHTHALMOL, V153, P209, DOI 10.1016/j.ajo.2011.10.016
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Busbee BG, 2013, OPHTHALMOLOGY, V120, P1046, DOI 10.1016/j.ophtha.2012.10.014
   Gaudreault J., 2012, INVEST OPHTHALMOL VI, V53, P3025
   Heier JS, 2012, OPHTHALMOLOGY, V119, P2537, DOI 10.1016/j.ophtha.2012.09.006
   Ho AC, 2014, OPHTHALMOLOGY, V121, P2181, DOI 10.1016/j.ophtha.2014.05.009
   Holz FG, 2015, BRIT J OPHTHALMOL, V99, P220, DOI 10.1136/bjophthalmol-2014-305327
   Holz FG, 2014, J CLIN INVEST, V124, P1430, DOI 10.1172/JCI71029
   Ishikawa M, 2015, J OPHTHALMOL, V2015, DOI 10.1155/2015/138070
   Jonas JB, 2014, AM J OPHTHALMOL, V158, P808, DOI 10.1016/j.ajo.2014.06.012
   Kaiser PK, 2013, OPHTHALMOLOGY, V120, pS11, DOI 10.1016/j.ophtha.2013.01.061
   Martin DF, 2011, NEW ENGL J MED, V364, P1897, DOI 10.1056/NEJMoa1102673
   Regatieri Caio V, 2011, Ophthalmic Surg Lasers Imaging, V42 Suppl, pS56, DOI 10.3928/15428877-20110627-05
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Schmidt-Erfurth U, 2014, BRIT J OPHTHALMOL, V98, P1144, DOI 10.1136/bjophthalmol-2014-305702
   Schmidt-Erfurth U, 2011, OPHTHALMOLOGY, V118, P831, DOI 10.1016/j.ophtha.2010.09.004
   Singerman LJ., 2015, INVEST OPHTHALMOL VI, V56, P4801
   Skaat A, 2012, AM J OPHTHALMOL, V153, P214, DOI 10.1016/j.ajo.2011.08.035
   Souied EH, 2015, INVEST OPHTH VIS SCI, V56
   Tietz J, 2015, INVEST OPHTH VIS SCI, V56
   Ying GS, 2014, JAMA OPHTHALMOL, V132, P915, DOI 10.1001/jamaophthalmol.2014.1019
NR 22
TC 84
Z9 91
U1 0
U2 15
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0161-6420
EI 1549-4713
J9 OPHTHALMOLOGY
JI Ophthalmology
PD MAY
PY 2016
VL 123
IS 5
BP 1080
EP 1089
DI 10.1016/j.ophtha.2015.12.030
PG 10
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA DL9DS
UT WOS:000375942300029
PM 26906165
OA hybrid
DA 2022-11-30
ER

PT J
AU Hernandez-Pastor, LJ
   Ortega, A
   Garcia-Layana, A
   Giraldez, J
AF Javier Hernandez-Pastor, Luis
   Ortega, Ana
   Garcia-Layana, Alfredo
   Giraldez, Joaquin
TI Cost-effectiveness of ranibizumab compared with pegaptanib in
   neovascular age-related macular degeneration
SO GRAEFES ARCHIVE FOR CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY
LA English
DT Article
DE Age-related macular degeneration; Ranibizumab; Pegaptanib;
   Cost-effectiveness; Cost-utility
ID INTRAVITREAL BEVACIZUMAB; CHOROIDAL NEOVASCULARIZATION; TRIAL; LUCENTIS
AB To assess the cost-effectiveness of ranibizumab compared with pegaptanib in the treatment of patients with minimally classic/occult neovascular age-related macular degeneration (AMD), from a societal perspective in Spain.
   We constructed a Markov model with five states defined by visual acuity (VA) in the better-seeing eye (Snellen scale): VA > 20/40, a parts per thousand currency sign20/40 to > 20/80, a parts per thousand currency sign20/80 to > 20/200, a parts per thousand currency sign20/200 to > 20/400, a parts per thousand currency sign20/400, and an additional death state. Two cohorts of patients were distributed along the VA states, and treated with either ranibizumab or pegaptanib. Transition probabilities assigned for movement between these states with both drugs were obtained from published randomized clinical trials. Medical costs related to AMD treatment and follow-up, medical costs related to AMD comorbidities, and non-medical-related costs were taken into account. Costs (2008 Euro), health outcomes (Quality-adjusted life years-QALYs), both discounted at a 3.5% annual rate, and incremental cost-effectiveness ratios (ICER: a,not sign/QALY), were determined for a lifetime horizon in the base case analysis. Sensitivity analyses were conducted to explore different scenarios and assumptions in the model.
   Treating patients with varying degrees of visual impairment with monthly ranibizumab instead of pegaptanib was a,not sign71,206 more costly and provided 2.437 additional QALYs (a,not sign29,224/QALY). When administered on an as-needed basis, as in the Prospective Optical Coherence Tomography Imaging of Patients with Neovascular AMD Treated with Intraocular Ranibizumab (PrONTO) trial, the cost per QALY gained with ranibizumab was reduced to a,not sign4,623.
   The cost per QALY gained with monthly ranibizumab compared with pegaptanib in the minimally classic/occult neovascular AMD population is just below the a,not sign30,000 threshold below which new drugs are sometimes regarded as cost-effective strategies in Spain. In this model, the key variables with greater impact on the cost-effectiveness results were the selected time horizon and the chosen extrapolation method, the source for data on pegaptanib efficacy and the number of ranibizumab injections. When administered on an as-needed basis, ranibizumab was a cost-effective strategy compared to pegaptanib in this population.
C1 [Javier Hernandez-Pastor, Luis; Ortega, Ana; Giraldez, Joaquin] Univ Navarra Clin, Dept Pharm, Navarra 31008, Spain.
   [Garcia-Layana, Alfredo] Univ Navarra Clin, Dept Ophthalmol, Navarra 31008, Spain.
C3 University of Navarra; University of Navarra
RP Hernandez-Pastor, LJ (通讯作者)，Univ Navarra Clin, Dept Pharm, AV Pio XII 36, Navarra 31008, Spain.
EM luisjaher@unav.es
RI ORTEGA, ANA/D-2408-2017
OI ORTEGA, ANA/0000-0003-1456-2437
CR ALVAREZ JS, 2004, FARM HOSP, V28, P299
   Arias L, 2009, EYE, V23, P326, DOI 10.1038/sj.eye.6703053
   Avery RL, 2006, OPHTHALMOLOGY, V113, P363, DOI 10.1016/j.ophtha.2005.11.019
   Bashshur ZF, 2008, AM J OPHTHALMOL, V145, P249, DOI 10.1016/j.ajo.2007.09.031
   Bashshur ZF, 2006, AM J OPHTHALMOL, V142, P1, DOI 10.1016/j.ajo.2006.02.037
   Bhisitkul RB, 2006, BRIT J OPHTHALMOL, V90, P1542, DOI 10.1136/bjo.2006.098426
   Birch S, 2006, PHARMACOECONOMICS, V24, P1121, DOI 10.2165/00019053-200624110-00008
   Briggs A, 1998, PHARMACOECONOMICS, V13, P397, DOI 10.2165/00019053-199813040-00003
   Briggs AH, 2000, PHARMACOECONOMICS, V17, P479, DOI 10.2165/00019053-200017050-00006
   Brown DM, 2007, AM J OPHTHALMOL, V144, P627, DOI 10.1016/j.ajo.2007.06.039
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Brown GC, 2007, OPHTHALMOLOGY, V114, P1170, DOI 10.1016/j.ophtha.2006.09.019
   Brown GC, 2000, ARCH OPHTHALMOL-CHIC, V118, P47
   Chakravarthy U, 2006, OPHTHALMOLOGY, V113, P1508, DOI 10.1016/j.ophtha.2006.02.064
   Cruess AF, 2008, PHARMACOECONOMICS, V26, P57, DOI 10.2165/00019053-200826010-00006
   Drummond M, 2005, MED CARE, V43, P5
   Drummond M, 2005, METHODS ECONOMICEVAL, P7
   Drummond MF, 2005, METHODS EC EVALUATIO, P277
   Fung AE, 2007, AM J OPHTHALMOL, V143, P566, DOI 10.1016/j.ajo.2007.01.028
   Gragoudas ES, 2004, NEW ENGL J MED, V351, P2805, DOI 10.1056/NEJMoa042760
   *I NAC EST, TABL SUP POBL ESP
   Instituto Nacional de Estadistica, IND PREC CONS
   Ip MS, 2008, OPHTHALMOLOGY, V115, P1837, DOI 10.1016/j.ophtha.2008.08.012
   Jager RD, 2008, NEW ENGL J MED, V358, P2606, DOI 10.1056/NEJMra0801537
   Hernandez-Pastor LJ, 2008, CLIN THER, V30, P2436, DOI 10.1016/j.clinthera.2008.12.025
   Lynch SS, 2007, ANN PHARMACOTHER, V41, P614, DOI 10.1345/aph.1H316
   McCabe C, 2008, PHARMACOECONOMICS, V26, P733, DOI 10.2165/00019053-200826090-00004
   Mills E, 2007, J CLIN EPIDEMIOL, V60, P456, DOI 10.1016/j.jclinepi.2006.09.001
   *MIN SAN CONS, 2005, PES ESP COST SNS
   *NAT EYE I, COMP AMD TREATM TRIA
   NICE, 2008, GUID METH TECHN APPR
   Quiram PA, 2007, RETINA-J RET VIT DIS, V27, P851, DOI 10.1097/IAE.0b013e31806458f0
   Raftery J, 2007, BRIT J OPHTHALMOL, V91, P1244, DOI 10.1136/bjo.2007.116616
   Resnikoff S, 2004, B WORLD HEALTH ORGAN, V82, P844
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   ROSENFELD PJ, 2007, RANIBIZUMAB PRONTO S
   Schouten JSAG, 2009, GRAEF ARCH CLIN EXP, V247, P1, DOI 10.1007/s00417-008-0952-y
   Sculpher MJ, 2006, HEALTH ECON, V15, P677, DOI 10.1002/hec.1093
   Spaide RF, 2006, RETINA-J RET VIT DIS, V26, P383, DOI 10.1097/00006982-200604000-00001
NR 39
TC 21
Z9 24
U1 0
U2 7
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0721-832X
EI 1435-702X
J9 GRAEF ARCH CLIN EXP
JI Graefes Arch. Clin. Exp. Ophthalmol.
PD APR
PY 2010
VL 248
IS 4
BP 467
EP 476
DI 10.1007/s00417-009-1156-9
PG 10
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 563CX
UT WOS:000275105200002
PM 19669678
DA 2022-11-30
ER

PT J
AU White, UE
   Black, AA
   Delbaere, K
   Wood, JM
AF White, Ursula E.
   Black, Alex A.
   Delbaere, Kim
   Wood, Joanne M.
TI Longitudinal Impact of Vision Impairment on Concern About Falling in
   People With Age-Related Macular Degeneration
SO TRANSLATIONAL VISION SCIENCE & TECHNOLOGY
LA English
DT Article
DE age-related macular degeneration (AMD); fear of falling; concern about
   falling; falls; vision impairment
ID BINOCULAR VISUAL-FIELD; OLDER-ADULTS; ACTIVITY RESTRICTION; CONTRAST
   SENSITIVITY; LOSS INCREASES; FEAR; RISK; DEPRESSION; PREVALENCE; ANXIETY
AB Purpose: To explore the longitudinal impact of central vision loss on concern about falling (CF), over a 12-month period, in people with age-related macular degeneration (AMD).
   Methods: Participants included 60 community-dwelling older people (age, 79.7 +/- 6.4 years) with central vision impairment due to AMD. Binocular highcontrast visual acuity, contrast sensitivity, and visual fields were assessed at baseline and at 12 months. CF was assessed at both time points using the Falls Efficacy Scale-International (FES-I). Sensorimotor function (sit to stand, knee extension, postural sway, and walking speed) and neuropsychological function (reaction time, symptoms of anxiety and depression) were also assessed at both time points using validated instruments. Falls data were collected using monthly diaries during the 12 months.
   Results: CF increased by a small but significant amount over the 12-month follow-up (2.1 units; P = 0.01), with increasing prevalence of high levels of CF (FES-I score = 23), from 48% at baseline to 65% at 12 months. Linear mixed models showed that reduced contrast sensitivity was significantly associated with increased concern about falling (P = 0.004), whereas declines in both visual acuity and contrast sensitivity during the follow-up periodwere associated with increases in CF over the 12-month follow-up (P= 0.041 and P = 0.054, respectively), independent of age, gender, falls history, or number of comorbidities.
   Conclusions: Higher levels of CF are common in older people with AMD, and levels increase over time; this increase is associated with declines in both visual acuity and contrast sensitivity. These findings highlight the need for regular assessment of both visual acuity and contrast sensitivity to identify those at greatest risk of developing higher CF.
   Translational Relevance: Routine assessment of visual acuity and contrast sensitivity in older people with AMD will assist in identifying those at risk of developing high CF.
C1 [White, Ursula E.; Black, Alex A.; Wood, Joanne M.] Queensland Univ Technol, Sch Optometry & Vision Sci, Ctr Vision & Eye Res, Kelvin Grove, Brisbane, Qld 4059, Australia.
   [Delbaere, Kim] Neurosci Res Australia, Balance & Injury Res Ctr, Falls, Randwick, NSW, Australia.
   [Delbaere, Kim] Univ New South Wales, Sch Publ Hlth & Community Med, Kensington, NSW, Australia.
C3 Queensland University of Technology (QUT); Neuroscience Research
   Australia; University of New South Wales Sydney
RP Black, AA (通讯作者)，Queensland Univ Technol, Sch Optometry & Vision Sci, Ctr Vision & Eye Res, Kelvin Grove, Brisbane, Qld 4059, Australia.
EM aa.black@qut.edu.au
RI ; Black, Alex/I-9727-2012
OI White, Ursula/0000-0003-2112-2851; Black, Alex/0000-0002-8671-5167
FU Australian Government Research Training Program scholarship
FX Supported by an Australian Government Research Training Program
   scholarship.
CR Augustin A, 2007, INVEST OPHTH VIS SCI, V48, P1498, DOI 10.1167/iovs.06-0761
   Austin N, 2007, J AM GERIATR SOC, V55, P1598, DOI 10.1111/j.1532-5415.2007.01317.x
   Bohannon RW, 2011, J STRENGTH COND RES, V25, P3205, DOI 10.1519/JSC.0b013e318234e59f
   Brody BL, 2001, OPHTHALMOLOGY, V108, P1893, DOI 10.1016/S0161-6420(01)00754-0
   Byrne GJ, 2010, AGING MENT HEALTH, V14, P247, DOI 10.1080/13607861003587628
   Chakravarthy U, 2018, OPHTHALMOLOGY, V125, P842, DOI 10.1016/j.ophtha.2017.11.036
   CHYLACK LT, 1993, ARCH OPHTHALMOL-CHIC, V111, P831, DOI 10.1001/archopht.1993.01090060119035
   Coleman AL, 2007, J AM GERIATR SOC, V55, P357, DOI 10.1111/j.1532-5415.2007.01094.x
   Delbaere K, 2010, AGE AGEING, V39, P210, DOI 10.1093/ageing/afp225
   Deshpande N, 2008, J AM GERIATR SOC, V56, P615, DOI 10.1111/j.1532-5415.2007.01639.x
   Duggan E, 2017, J GERONTOL A-BIOL, V72, P1663, DOI 10.1093/gerona/glx021
   Ferris FL, 2013, OPHTHALMOLOGY, V120, P844, DOI 10.1016/j.ophtha.2012.10.036
   Freeman EE, 2007, INVEST OPHTH VIS SCI, V48, P4445, DOI 10.1167/iovs.07-0326
   Friedman SM, 2002, J AM GERIATR SOC, V50, P1329, DOI 10.1046/j.1532-5415.2002.50352.x
   Garweg JG, 2018, GRAEF ARCH CLIN EXP, V256, P823, DOI 10.1007/s00417-018-3907-y
   Gibbons RD, 2010, ANNU REV CLIN PSYCHO, V6, P79, DOI 10.1146/annurev.clinpsy.032408.153550
   Grossman DC, 2018, JAMA-J AM MED ASSOC, V319, P1696, DOI 10.1001/jama.2018.3097
   Hassell JB, 2006, BRIT J OPHTHALMOL, V90, P593, DOI 10.1136/bjo.2005.086595
   Hauer K, 2006, AGE AGEING, V35, P5, DOI 10.1093/ageing/afi218
   Ho VWT, 2019, J AGING HEALTH
   Howard AL, 2015, EMERG ADULTHOOD, V3, P400, DOI 10.1177/2167696815592726
   Howland J, 1998, GERONTOLOGIST, V38, P549, DOI 10.1093/geront/38.5.549
   Klein Barbara E K, 2003, Trans Am Ophthalmol Soc, V101, P191
   Klein BEK, 1998, OPHTHALMOLOGY, V105, P160, DOI 10.1016/S0161-6420(98)91911-X
   Lachman ME, 1998, J GERONTOL B-PSYCHOL, V53, pP43, DOI 10.1093/geronb/53B.1.P43
   Laitinen A, 2007, OPHTHAL EPIDEMIOL, V14, P333, DOI 10.1080/01658100701473713
   Lamoureux EL, 2009, OPTOMETRY VISION SCI, V86, P139, DOI 10.1097/OPX.0b013e318194eb47
   Litwin H, 2018, J AGING HEALTH, V30, P987, DOI 10.1177/0898264317704096
   Loprinzi PD, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0125394
   Lord SR, 2003, PHYS THER, V83, P237, DOI 10.1093/ptj/83.3.237
   Lord SR, 2002, J GERONTOL A-BIOL, V57, pM539, DOI 10.1093/gerona/57.8.M539
   LORD SR, 1991, J AM GERIATR SOC, V39, P1194, DOI 10.1111/j.1532-5415.1991.tb03574.x
   Martin A, 2006, GEN HOSP PSYCHIAT, V28, P71, DOI 10.1016/j.genhosppsych.2005.07.003
   Murphy SL, 2003, J GERONTOL A-BIOL, V58, P943
   Murphy SL, 2002, J AM GERIATR SOC, V50, P516, DOI 10.1046/j.1532-5415.2002.50119.x
   Nguyen AM, 2015, BMC GERIATR, V15, DOI 10.1186/s12877-015-0062-8
   Nixon DR, 2017, CLIN OPHTHALMOL, V11, P715, DOI 10.2147/OPTH.S131343
   Oh-Park M, 2011, J AM GERIATR SOC, V59, P1225, DOI 10.1111/j.1532-5415.2011.03475.x
   Owsley C, 1999, J GERONTOL A-BIOL, V54, pM203, DOI 10.1093/gerona/54.4.M203
   Painter JA, 2012, AM J OCCUP THER, V66, P169, DOI 10.5014/ajot.2012.002535
   Patil R, 2014, GERONTOLOGY, V60, P22, DOI 10.1159/000354335
   Pye A, 2017, INT PSYCHOGERIATR, V29, P1771, DOI 10.1017/S104161021700120X
   Scheffer AC, 2008, AGE AGEING, V37, P19, DOI 10.1093/ageing/afm169
   Sengupta S, 2015, BMC OPHTHALMOL, V15, DOI 10.1186/1471-2415-15-9
   Szabo SM, 2010, OSTEOPOROSIS INT, V21, P855, DOI 10.1007/s00198-009-1025-8
   Szabo SM, 2008, J AM GERIATR SOC, V56, P800, DOI 10.1111/j.1532-5415.2008.01666.x
   Tabrett DR, 2012, OPHTHAL PHYSL OPT, V32, P156, DOI 10.1111/j.1475-1313.2012.00892.x
   van Landingham SW, 2014, BMC OPHTHALMOL, V14, DOI 10.1186/1471-2415-14-10
   VERBAKEN JH, 1986, AM J OPTOM PHYS OPT, V63, P724
   Wang MY, 2012, INVEST OPHTH VIS SCI, V53, P7967, DOI 10.1167/iovs.12-10701
   White UE, 2021, OPHTHAL PHYSL OPT, V41, P245, DOI 10.1111/opo.12777
   Wittich W, 2010, J VISUAL IMPAIR BLIN, V104, P360, DOI 10.1177/0145482X1010400606
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
   Wood JM, 2011, INVEST OPHTH VIS SCI, V52, P5088, DOI 10.1167/iovs.10-6644
   Wood JM, 2009, INVEST OPHTH VIS SCI, V50, P482, DOI 10.1167/iovs.08-1942
   Xiong YZ, 2020, INVEST OPHTH VIS SCI, V61, DOI 10.1167/iovs.61.6.40
   Yardley L, 2005, AGE AGEING, V34, P614, DOI 10.1093/ageing/afi196
NR 57
TC 0
Z9 0
U1 0
U2 0
PU ASSOC RESEARCH VISION OPHTHALMOLOGY INC
PI ROCKVILLE
PA 12300 TWINBROOK PARKWAY, ROCKVILLE, MD 20852-1606 USA
SN 2164-2591
J9 TRANSL VIS SCI TECHN
JI Transl. Vis. Sci. Technol.
PD JAN
PY 2022
VL 11
IS 1
AR 34
DI 10.1167/tvst.11.1.34
PG 11
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 1L9DR
UT WOS:000799581700033
PM 35077531
OA Green Published, gold
DA 2022-11-30
ER

PT J
AU Taddei, PJ
   Chell, E
   Hansen, S
   Gertner, M
   Newhauser, WD
AF Taddei, Phillip J.
   Chell, Erik
   Hansen, Steven
   Gertner, Michael
   Newhauser, Wayne D.
TI Assessment of targeting accuracy of a low-energy stereotactic
   radiosurgery treatment for age-related macular degeneration
SO PHYSICS IN MEDICINE AND BIOLOGY
LA English
DT Article
ID RATE SR-90 BRACHYTHERAPY; PROTON THERAPY; UVEAL MELANOMA;
   RADIATION-THERAPY; BEAM IRRADIATION; OCULAR MELANOMA; CLINICAL-TRIAL;
   RADIOTHERAPY; DOSIMETRY; RANIBIZUMAB
AB Age-related macular degeneration (AMD), a leading cause of blindness in the United States, is a neovascular disease that may be controlled with radiation therapy. Early patient outcomes of external beam radiotherapy, however, have been mixed. Recently, a novel multimodality treatment was developed, comprising external beam radiotherapy and concomitant treatment with a vascular endothelial growth factor inhibitor. The radiotherapy arm is performed by stereotactic radiosurgery, delivering a 16 Gy dose in the macula (clinical target volume, CTV) using three external low-energy x-ray fields while adequately sparing normal tissues. The purpose of our study was to test the sensitivity of the delivery of the prescribed dose in the CTV using this technique and of the adequate sparing of normal tissues to all plausible variations in the position and gaze angle of the eye. Using Monte Carlo simulations of a 16 Gy treatment, we varied the gaze angle by +/-5 degrees in the polar and azimuthal directions, the linear displacement of the eye +/-1 mm in all orthogonal directions, and observed the union of the three fields on the posterior wall of spheres concentric with the eye that had diameters between 20 and 28 mm. In all cases, the dose in the CTV fluctuated <6%, the maximum dose in the sclera was <20 Gy, the dose in the optic disc, optic nerve, lens and cornea were <0.7 Gy and the three-field junction was adequately preserved. The results of this study provide strong evidence that for plausible variations in the position of the eye during treatment, either by the setup error or intrafraction motion, the prescribed dose will be delivered to the CTV and the dose in structures at risk will be kept far below tolerance doses.
C1 [Taddei, Phillip J.; Newhauser, Wayne D.] Univ Texas MD Anderson Canc Ctr, Dept Radiat Phys, Houston, TX 77030 USA.
   [Chell, Erik; Hansen, Steven; Gertner, Michael] Oraya Therapeut Inc, Newark, CA 94560 USA.
C3 University of Texas System; UTMD Anderson Cancer Center
RP Taddei, PJ (通讯作者)，Univ Texas MD Anderson Canc Ctr, Dept Radiat Phys, 1515 Holcombe Blvd, Houston, TX 77030 USA.
EM ptaddei@mdanderson.org
OI Taddei, Phillip/0000-0002-4689-1625
FU Oraya Therapeutics, Inc.; National Cancer Institute [1R01CA131463-01A1];
   Fogarty International Center [K01TW008409]; FOGARTY INTERNATIONAL CENTER
   [K01TW008409] Funding Source: NIH RePORTER; NATIONAL CANCER INSTITUTE
   [R01CA131463] Funding Source: NIH RePORTER
FX The authors are grateful to Ms Kate Newberry for her assistance in
   preparing this manuscript and to Dr Nicholas Koch, Dr Dragan Mirkovic,
   and Mr Michael Firpo for helpful discussions. This work was supported in
   part by a research grant from Oraya Therapeutics, Inc., by award number
   1R01CA131463-01A1 from the National Cancer Institute, and by award
   number K01TW008409 from the Fogarty International Center. The content is
   solely the responsibility of the authors and dose not necessarily
   represent the official views of the National Cancer Institute, the
   Fogarty International Center, or the National Institutes of Health.
CR Avila MP, 2009, BRIT J OPHTHALMOL, V93, P305, DOI 10.1136/bjo.2008.145912
   Avila MP, 2009, RETINA-J RET VIT DIS, V29, P157, DOI 10.1097/IAE.0b013e3181985915
   Bressler NM, 2003, ARCH OPHTHALMOL-CHIC, V121, P1621
   Brown MM, 2008, OPHTHALMOLOGY, V115, P1039, DOI 10.1016/j.ophtha.2007.08.033
   Dobler B, 2002, PHYS MED BIOL, V47, P593, DOI 10.1088/0031-9155/47/4/304
   Finger PT, 1998, ARCH OPHTHALMOL-CHIC, V116, P1507, DOI 10.1001/archopht.116.11.1507
   Hanlon J, 2009, MED PHYS, V36, P3671, DOI 10.1118/1.3168554
   Herault J, 2005, MED PHYS, V32, P910, DOI 10.1118/1.1871392
   Hermann RM, 2002, INT J RADIAT ONCOL, V52, P1360, DOI 10.1016/S0360-3016(01)02763-8
   Jaakkola A, 2005, OPHTHALMOLOGY, V112, P567, DOI 10.1016/j.ophtha.2004.11.029
   Jager RD, 2008, NEW ENGL J MED, V358, P2606, DOI 10.1056/NEJMra0801537
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1417, DOI 10.1001/archopht.119.10.1417
   Koch N, 2005, RADIAT PROT DOSIM, V115, P159, DOI 10.1093/rpd/nci224
   Koch N, 2008, PHYS MED BIOL, V53, P1581, DOI 10.1088/0031-9155/53/6/005
   Koch NC, 2010, PHYS MED BIOL, V55, P833, DOI 10.1088/0031-9155/55/3/019
   Lee C, 2008, MED PHYS, V35, P5151, DOI 10.1118/1.2990780
   Ma CM, 2001, MED PHYS, V28, P868, DOI 10.1118/1.1374247
   Marcus DM, 2001, ARCH OPHTHALMOL-CHIC, V119, P171
   Missotten L, 1998, GRAEF ARCH CLIN EXP, V236, P164, DOI 10.1007/s004170050059
   Mourtada F, 2005, RADIAT PROT DOSIM, V116, P454, DOI 10.1093/rpd/nci266
   Moyers MF, 1999, MED PHYS, V26, P777, DOI 10.1118/1.598587
   Newhauser WD, 2007, PHYS MED BIOL, V52, P3979, DOI 10.1088/0031-9155/52/13/021
   Pelowitz D. B., 2008, MCNPX USERS MANUAL V
   Rivard MJ, 2006, MED PHYS, V33, P4020, DOI 10.1118/1.2357021
   Rivard MJ, 2009, MED PHYS, V36, P486, DOI 10.1118/1.3056463
   Rosenfeld Philip J, 2006, Ophthalmol Clin North Am, V19, P361
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   van Ginderdeuren R, 2005, BRIT J OPHTHALMOL, V89, P1306, DOI 10.1136/bjo.2005.068460
   YONEMOTO LT, 2000, J RADIOSURG, V3, P47
   Zambarakji HJ, 2006, OPHTHALMOLOGY, V113, P2012, DOI 10.1016/j.ophtha.2006.05.036
NR 30
TC 17
Z9 17
U1 0
U2 0
PU IOP PUBLISHING LTD
PI BRISTOL
PA TEMPLE CIRCUS, TEMPLE WAY, BRISTOL BS1 6BE, ENGLAND
SN 0031-9155
J9 PHYS MED BIOL
JI Phys. Med. Biol.
PD DEC 7
PY 2010
VL 55
IS 23
BP 7037
EP 7054
DI 10.1088/0031-9155/55/23/S06
PG 18
WC Engineering, Biomedical; Radiology, Nuclear Medicine & Medical Imaging
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Engineering; Radiology, Nuclear Medicine & Medical Imaging
GA 680UN
UT WOS:000284261000007
PM 21076198
OA Green Accepted, Green Submitted
DA 2022-11-30
ER

PT J
AU Ma, ZZ
   Han, L
   Wang, CG
   Dou, HL
   Hu, YT
   Feng, XF
   Xu, YM
   Wang, ZQ
   Yin, ZQ
   Liu, YL
AF Ma, Zhizhong
   Han, Liang
   Wang, Changguan
   Dou, Hongliang
   Hu, Yuntao
   Feng, Xuefeng
   Xu, Yimin
   Wang, Zhiqiang
   Yin, Zhengqin
   Liu, Yuling
TI Autologous Transplantation of Retinal Pigment Epithelium-Bruch's
   Membrane Complex for Hemorrhagic Age-Related Macular Degeneration
SO INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE
LA English
DT Article
ID SUBFOVEAL CHOROIDAL NEOVASCULARIZATION; RANDOMIZED CLINICAL-TRIAL;
   BEAVER DAM EYE; SUBRETINAL HEMORRHAGE; PHOTODYNAMIC THERAPY; OPHTHALMIC
   FINDINGS; SUBMACULAR SURGERY; NATURAL-HISTORY; FOLLOW-UP; TRANSLOCATION
AB PURPOSE. To evaluate a surgical procedure for patients with hemorrhagic age-related macular degeneration (AMD).
   METHODS. This procedure consisted of excision of the choroidal neovascular membrane and transplantation of autologous retinal pigment epithelium (RPE)-Bruch's membrane complex. The RPE-Bruch's membrane complex for transplantation was surgically developed by dissecting Bruch's membrane with the choriocapillaris from the medium size choroidal vessel layer at the midperipheral region of the choroid. Twenty-one eyes of 21 patients had this surgical procedure. Visual function tests included best corrected visual acuity (BCVA), multifocal (mf) ERG, and microperimetry. Optical coherence tomography (OCT), fluorescein angiography, and autofluorescence examinations were performed to study the status of the transplanted graft.
   RESULTS. Among the 21 eyes, 17 with complete clinical data and qualified follow-up durations, which were 20.35 +/- 10.31 months on average, were analyzed in this series. On the last follow-up visit, the mean for the ETDRS scores increased from 28.65 +/- 23.99 before surgery to 47.76 +/- 17.22 after surgery. Microperimetry showed that after surgery, seven eyes gained central fixation at the 12-month follow-up examination. However, two eyes lost their central fixation on the last follow-up visit. Fourteen (82.35%) of the transplanted patches preserved normal color without depigmentation. Among the 21 eyes, proliferative vitreoretinopathy (PVR) occurred in 3 (14.29%), and a recurrent neovascular membrane was observed in one eye (4.76%).
   CONCLUSIONS. The transplantation of the autologous RPE-Bruch's membrane complex can increase the visual acuity of patients with hemorrhagic AMD. The surviving transplanted graft with functional overlying retina was observed after surgery. (Invest Ophthalmol Vis Sci. 2009; 50: 2975-2981) DOI: 10.1167/iovs.08-2573
C1 [Ma, Zhizhong; Han, Liang; Wang, Changguan; Dou, Hongliang; Hu, Yuntao; Feng, Xuefeng; Xu, Yimin; Liu, Yuling] Peking Univ, Hosp 3, Ctr Eye, Beijing 100083, Peoples R China.
   [Wang, Zhiqiang] PLA 254th Hosp, Tianjin, Peoples R China.
   [Yin, Zhengqin] Third Mil Med Univ, SW Eye Hosp, Chongqing, Peoples R China.
C3 Peking University; Army Medical University
RP Ma, ZZ (通讯作者)，Peking Univ, Hosp 3, Ctr Eye, 49 N Garden Rd, Beijing 100083, Peoples R China.
EM yk@bjmu.edu.cn
FU National Basic Research Program of China [2007CB512203]; Peking
   University Third Hospital
FX Supported by a grant from the National Basic Research Program of China
   (973 Grant 2007CB512203), and a research grant from Peking University
   Third Hospital.
CR Abdel-Meguid A, 2003, BRIT J OPHTHALMOL, V87, P615, DOI 10.1136/bjo.87.5.615
   Arnold J, 2002, RETINA-J RET VIT DIS, V22, P6
   Arnold J, 2001, AM J OPHTHALMOL, V131, P541
   Avery RL, 1996, RETINA-J RET VIT DIS, V16, P183, DOI 10.1097/00006982-199616030-00001
   Barbazetto I, 2003, ARCH OPHTHALMOL-CHIC, V121, P1253
   BENNETT SR, 1990, AM J OPHTHALMOL, V109, P33, DOI 10.1016/S0002-9394(14)75575-8
   Berrocal MH, 1996, AM J OPHTHALMOL, V122, P486, DOI 10.1016/S0002-9394(14)72107-5
   Binder S, 2004, INVEST OPHTH VIS SCI, V45, P4151, DOI 10.1167/iovs.04-0118
   Bindewald A, 2004, OPHTHALMOLOGE, V101, P886, DOI 10.1007/s00347-004-1077-2
   Bressler NM, 2004, OPHTHALMOLOGY, V111, P1993, DOI 10.1016/j.ophtha.2004.07.023
   BRESSLER NM, 1988, SURV OPHTHALMOL, V32, P375, DOI 10.1016/0039-6257(88)90052-5
   Bressler NM, 1999, ARCH OPHTHALMOL-CHIC, V117, P1329
   COUGDON N, 2004, ARCH OPHTHALMOL-CHIC, V122, P477
   de Juan E, 1998, AM J OPHTHALMOL, V125, P635, DOI 10.1016/S0002-9394(98)00018-X
   Eckardt C, 1999, GRAEF ARCH CLIN EXP, V237, P313, DOI 10.1007/s004170050239
   FERRIS FL, 1984, ARCH OPHTHALMOL-CHIC, V102, P1640
   Hawkins BS, 2004, OPHTHALMOLOGY, V111, P1967, DOI 10.1016/j.ophtha.2004.07.021
   Holz FG, 2003, BIOMED TECH, V48, P82
   Joussen AM, 2006, AM J OPHTHALMOL, V142, P17, DOI 10.1016/j.ajo.2006.01.090
   Klaver CCW, 2001, INVEST OPHTH VIS SCI, V42, P2237
   Klein R, 2006, OPHTHALMOLOGY, V113, P373, DOI 10.1016/j.ophtha.2005.12.013
   Klein R, 1997, OPHTHALMOLOGY, V104, P7, DOI 10.1016/S0161-6420(97)30368-6
   KLEIN R, 1992, OPHTHALMOLOGY, V99, P933
   Leibowitz H M, 1980, Surv Ophthalmol, V24, P335
   Maaijwee K, 2008, INVEST OPHTH VIS SCI, V49, P758, DOI 10.1167/iovs.07-0510
   Maaijwee K, 2007, GRAEF ARCH CLIN EXP, V245, P1681, DOI 10.1007/s00417-007-0607-4
   Maaijwee K, 2006, OPHTHALMOLOGY, V113, P1471, DOI 10.1016/j.ophtha.2006.04.011
   MacLaren RE, 2005, OPHTHALMOLOGY, V112, P2081, DOI 10.1016/j.ophtha.2005.06.029
   MacLaren RE, 2007, OPHTHALMOLOGY, V114, P561, DOI 10.1016/j.ophtha.2006.06.049
   Midena Edoardo, 2004, Semin Ophthalmol, V19, P55, DOI 10.1080/08820530490882896
   Ohji M, 2001, AM J OPHTHALMOL, V132, P888, DOI 10.1016/S0002-9394(01)01255-7
   Scupola A, 1999, OPHTHALMOLOGICA, V213, P97, DOI 10.1159/000027400
   Stanga PE, 2002, OPHTHALMOLOGY, V109, P1492, DOI 10.1016/S0161-6420(02)01099-0
   STERNBERG P, 1991, ARCH OPHTHALMOL-CHIC, V109, P1242
   STERNBERG P, 1991, ARCH OPHTHALMOL-CHIC, V109, P1232
   van Leeuwen R, 2003, EUR J EPIDEMIOL, V18, P845, DOI 10.1023/A:1025643303914
   Van Meurs JC, 2003, AM J OPHTHALMOL, V136, P688, DOI 10.1016/S0002-9394(03)00384-2
   VANMEURS J, 2004, VITR M VAIL CO
   VINGERLING JR, 1995, OPHTHALMOLOGY, V102, P205
   Wolf S, 1999, GRAEF ARCH CLIN EXP, V237, P51, DOI 10.1007/s004170050194
   Wu L Z, 1987, Yan Ke Xue Bao, V3, P179
   Wu L Z, 1987, Yan Ke Xue Bao, V3, P175
NR 42
TC 37
Z9 45
U1 0
U2 5
PU ASSOC RESEARCH VISION OPHTHALMOLOGY INC
PI ROCKVILLE
PA 12300 TWINBROOK PARKWAY, ROCKVILLE, MD 20852-1606 USA
SN 0146-0404
EI 1552-5783
J9 INVEST OPHTH VIS SCI
JI Invest. Ophthalmol. Vis. Sci.
PD JUN
PY 2009
VL 50
IS 6
BP 2975
EP 2981
DI 10.1167/iovs.08-2573
PG 7
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 450ME
UT WOS:000266403800060
PM 19117919
DA 2022-11-30
ER

PT J
AU Hwang, S
   Kang, SW
   Choi, J
   Son, KY
   Lim, DH
   Shin, DW
   Kim, K
   Kim, SJ
AF Hwang, Sungsoon
   Kang, Se Woong
   Choi, Jaehwan
   Son, Ki Young
   Lim, Dong Hui
   Shin, Dong Wook
   Kim, Kyunga
   Kim, Sang Jin
TI Lipid profile and future risk of exudative age-related macular
   degeneration development: a nationwide cohort study from South Korea
SO SCIENTIFIC REPORTS
LA English
DT Article
ID GENOME-WIDE ASSOCIATION; PREVALENCE; HEALTH; HDL
AB This nationwide population-based cohort study evaluated the association between lipid profiles and the future risk of exudative age-related macular degeneration (AMD) using authorized clinical data provided by the Korean National Health Insurance Service. A total of 6,129,616 subjects over 50 years of age who participated in the Korean National Health Screening Program in 2013 or 2014 were included. Data on risk factors, including age, sex, comorbidities, behavioral factors, and baseline lipid profiles, including total cholesterol, high-density lipoprotein (HDL) cholesterol, low-density lipoprotein (LDL) cholesterol, and triglyceride (TG) levels were collected. Patients were followed-up patients until December 2018, and incident cases of exudative AMD were identified using registered diagnostic codes. During an average follow-up period of 4.91 years, 18,803 patients were newly diagnosed with exudative AMD. Compared to the lowest HDL cholesterol quartile group, the highest HDL cholesterol quartile group had a greater risk of future exudative AMD development with a hazard ratio (95% confidence interval) of 1.13 (1.08-1.18) in the fully adjusted model. The highest TG quartile group had a lower risk of exudative AMD than the lowest TG quartile group, with a hazard ratio (95% confidence interval) of 0.84 (0.81-0.88). High HDL cholesterol and low TG levels were prospectively associated with exudative AMD incidence.
C1 [Hwang, Sungsoon; Kang, Se Woong; Choi, Jaehwan; Son, Ki Young; Lim, Dong Hui; Kim, Sang Jin] Sungkyunkwan Univ, Samsung Med Ctr, Dept Ophthalmol, Sch Med, 81 Irwon Ro, Seoul 06351, South Korea.
   [Hwang, Sungsoon; Lim, Dong Hui; Shin, Dong Wook] Sungkyunkwan Univ, Samsung Adv Inst Hlth Sci & Technol SAIHST, Dept Clin Res Design & Evaluat, Seoul, South Korea.
   [Shin, Dong Wook] Sungkyunkwan Univ, Samsung Med Ctr, Dept Family Med & Support Care Ctr, Sch Med, Seoul, South Korea.
   [Shin, Dong Wook; Kim, Kyunga] Sungkyunkwan Univ, Samsung Adv Inst Hlth Sci & Technol SAIHST, Dept Digital Hlth, Seoul, South Korea.
   [Kim, Kyunga] Samsung Med Ctr, Stat & Data Ctr, Res Inst Future Med, Seoul, South Korea.
C3 Sungkyunkwan University (SKKU); Samsung Medical Center; Samsung;
   Sungkyunkwan University (SKKU); Sungkyunkwan University (SKKU); Samsung
   Medical Center; Samsung; Sungkyunkwan University (SKKU); Sungkyunkwan
   University (SKKU); Samsung Medical Center
RP Kim, SJ (通讯作者)，Sungkyunkwan Univ, Samsung Med Ctr, Dept Ophthalmol, Sch Med, 81 Irwon Ro, Seoul 06351, South Korea.
EM sangjin.kim.md@gmail.com
CR Betzler BK, 2020, BIOMOLECULES, V10, DOI 10.3390/biom10040645
   Bourne RRA, 2013, LANCET GLOB HEALTH, V1, pE339, DOI 10.1016/S2214-109X(13)70113-X
   Burgess S, 2017, OPHTHALMOLOGY, V124, P1165, DOI 10.1016/j.ophtha.2017.03.042
   Chakravarthy U, 2010, BMC OPHTHALMOL, V10, DOI 10.1186/1471-2415-10-31
   Cheung CMG, 2017, J LIPID RES, V58, P1785, DOI 10.1194/jlr.M073684
   Cheung CMG, 2017, OPHTHALMOLOGY, V124, P1305, DOI 10.1016/j.ophtha.2017.03.056
   Cheung CMG, 2012, ARCH OPHTHALMOL-CHIC, V130, P480, DOI 10.1001/archophthalmol.2011.376
   Colijn JM, 2019, OPHTHALMOLOGY, V126, P393, DOI 10.1016/j.ophtha.2018.09.045
   Fan Q, 2017, INT J EPIDEMIOL, V46, P1891, DOI 10.1093/ije/dyx189
   Fritsche LG, 2016, NAT GENET, V48, P134, DOI 10.1038/ng.3448
   Han XK, 2021, INT J EPIDEMIOL, V50, P325, DOI 10.1093/ije/dyaa178
   Hwang SUNGSOON, 2022, AM J OPHTHALMOL, V235, P188, DOI 10.1016/j.ajo.2021.09.027
   Kersten E, 2018, SURV OPHTHALMOL, V63, P9, DOI 10.1016/j.survophthal.2017.05.003
   Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557
   KOSIS KOrean Statistical Information Service, US
   Lim LS, 2012, LANCET, V379, P1728, DOI 10.1016/S0140-6736(12)60282-7
   Lin JB, 2016, J LIPID RES, V57, P258, DOI 10.1194/jlr.M064469
   Liu K, 2014, OPHTHALMOLOGY, V121, P911, DOI 10.1016/j.ophtha.2013.10.042
   Neale BM, 2010, P NATL ACAD SCI USA, V107, P7395, DOI 10.1073/pnas.0912019107
   Nordestgaard BG, 2014, LANCET, V384, P626, DOI 10.1016/S0140-6736(14)61177-6
   Nordestgaard LT, 2021, J CLIN ENDOCR METAB, V106, pE2749, DOI 10.1210/clinem/dgab095
   Park SJ, 2015, OPHTHALMOLOGY, V122, P2063, DOI 10.1016/j.ophtha.2015.06.018
   Park SJ, 2014, OPHTHALMOLOGY, V121, P1756, DOI 10.1016/j.ophtha.2014.03.022
   Rader DJ, 2014, LANCET, V384, P618, DOI 10.1016/S0140-6736(14)61217-4
   Seong SC, 2017, INT J EPIDEMIOL, V46, P799, DOI 10.1093/ije/dyw253
   Snow K K, 1999, Ophthalmic Epidemiol, V6, P125, DOI 10.1076/opep.6.2.125.1558
   van Leeuwen EM, 2018, PROG RETIN EYE RES, V67, P56, DOI 10.1016/j.preteyeres.2018.04.006
   Wang L, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0010329
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
   World Health Organization. Regional Office for the Western P, 2000, ASIA PACIFIC PERSPEC, P55
   Yu Y, 2011, HUM MOL GENET, V20, P3699, DOI 10.1093/hmg/ddr270
NR 31
TC 0
Z9 0
U1 1
U2 1
PU NATURE PORTFOLIO
PI BERLIN
PA HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY
SN 2045-2322
J9 SCI REP-UK
JI Sci Rep
PD NOV 5
PY 2022
VL 12
IS 1
AR 18777
DI 10.1038/s41598-022-23607-w
PG 10
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA 5Z1FH
UT WOS:000879722100027
PM 36335257
OA Green Published, gold
DA 2022-11-30
ER

PT J
AU Liu, JX
   Luo, LF
   Xu, F
   Li, G
   Chen, JC
   Teng, LS
   Li, YX
   Sun, FY
AF Liu, Jiaxin
   Luo, Lifu
   Xu, Fei
   Li, Ge
   Chen, Jicong
   Teng, Lesheng
   Li, Youxin
   Sun, Fengying
TI Cyclic RGD Peptide Targeting Coated Nano Drug Co-Delivery System for
   Therapeutic Use in Age-Related Macular Degeneration Disease
SO MOLECULES
LA English
DT Article
DE vascular endothelial growth factor; age-related macular degeneration;
   anti-angiogenic drug; retinal pigment epithelial cells; nanoparticles
ID ENDOTHELIAL GROWTH-FACTOR; VERTEPORFIN PHOTODYNAMIC THERAPY; CHOROIDAL
   NEOVASCULARIZATION; INTRAVITREAL DEXAMETHASONE; TRIPLE THERAPY;
   BEVACIZUMAB; RANIBIZUMAB; INVOLVEMENT; INTEGRINS
AB Vascular endothelial growth factor (VEGF) expression increased significantly in the pathogenesis of age-related macular degeneration, which induced the formation of pathological blood vessels. Dexamethasone is an exogenous anti-angiogenic drug while bevacizumab is an endogenous anti-angiogenic drug. They both have been widely used in ophthalmology. However, independent administration is not enough to completely block the development of choroidal neovascularization (CNV), and the number of eyes vitreous injections is limited. Reasonable combination of drugs may produce significantly better therapeutic effect than single drug treatment. The cyclic RGD (cRGD) peptide has a particularly high affinity with retinal pigment epithelial cells, where VEGF secretes from. In this study, we prepared nanoparticles of bevacizumab and dexamethasone with cRGD peptide as the target (aBev/cRGD-DPPNs). The particle size of the aBev/cRGD-DPPNs was 213.8 +/- 1.5 nm, SEM results showed that the nano-carriers were well dispersed and spherical. The cell uptake study demonstrated the selectivity of the aBev/cRGD-DPPN to ARPE-19 with alpha(V)beta(3) over expressed. The aBev/cRGD-DPPNs had a better apoptosis induction effect and an obvious inhibitory effect on migration, invasion, and capillary-like structures formation of human umbilical vein epithelial cells. The fluorescein fundus angiography study, immunohistochemistry and histopathological evaluation showed the aBev/cRGD-DPPNs greatly reduced the development of CNV on a rabbit model.
C1 [Liu, Jiaxin; Xu, Fei; Li, Ge; Chen, Jicong; Teng, Lesheng; Li, Youxin; Sun, Fengying] Jilin Univ, Sch Life Sci, Changchun 130012, Peoples R China.
   [Luo, Lifu] Jilin Univ, Clin Coll Norman Bethune 2, Med Div, Dept Ophthalmol, Changchun 130041, Peoples R China.
C3 Jilin University; Jilin University
RP Li, YX; Sun, FY (通讯作者)，Jilin Univ, Sch Life Sci, Changchun 130012, Peoples R China.
EM jxliu328@163.com; luolf@jlu.edu.cn; xufei19@mails.jlu.edu.cn;
   lige18@mails.jlu.edu.cn; chenjc20@mails.jlu.edu.cn;
   tenglesheng@jlu.edu.cn; liyouxin@jlu.edu.cn; sunfengying@jlu.edu.cn
OI Teng, Lesheng/0000-0003-1623-5384; Liu, Jiaxin/0000-0002-8770-2093; Sun,
   Fengying/0000-0001-6199-9311; Li, Youxin/0000-0002-0812-744X
CR Ambati J, 2012, NEURON, V75, P26, DOI 10.1016/j.neuron.2012.06.018
   Angi M, 2008, GRAEF ARCH CLIN EXP, V246, P1643, DOI 10.1007/s00417-008-0889-1
   Augustin AJ, 2007, RETINA-J RET VIT DIS, V27, P133, DOI 10.1097/IAE.0b013e3180323de7
   Bakri SJ, 2009, RETINA-J RET VIT DIS, V29, P573, DOI 10.1097/IAE.0b013e3181a46a8a
   Bourne RRA, 2017, LANCET GLOB HEALTH, V5, pE888, DOI 10.1016/S2214-109X(17)30293-0
   Caputo M, 2011, CURR DRUG TARGETS, V12, P234, DOI 10.2174/138945011794182791
   Ciulla TA, 2009, CURR OPIN OPHTHALMOL, V20, P166, DOI 10.1097/ICU.0b013e328329d173
   Costa R, 2009, J CELL BIOCHEM, V108, P1410, DOI 10.1002/jcb.22378
   Costagliola C, 2008, EUR J OPHTHALMOL, V18, P955, DOI 10.1177/112067210801800616
   Dunehoo AL, 2006, J PHARM SCI-US, V95, P1856, DOI 10.1002/jps.20676
   Ehmann D, 2010, CAN J OPHTHALMOL, V45, P36, DOI 10.3129/i09-243
   Fangueiro JF, 2015, EUR J PHARM BIOPHARM, V95, P307, DOI 10.1016/j.ejpb.2014.12.023
   Ferrara N, 2010, NAT MED, V16, P1107, DOI 10.1038/nm1010-1107
   FERRIS FL, 1984, ARCH OPHTHALMOL-CHIC, V102, P1640
   Forte R, 2010, ACTA OPHTHALMOL, V88, pe305, DOI 10.1111/j.1755-3768.2010.02021.x
   Friedlander M, 1996, P NATL ACAD SCI USA, V93, P9764, DOI 10.1073/pnas.93.18.9764
   Fujita N, 2011, INVEST OPHTH VIS SCI, V52, P9310, DOI 10.1167/iovs.10-7050
   Gong CY, 2013, BIOMATERIALS, V34, P1413, DOI 10.1016/j.biomaterials.2012.10.068
   Hurwitz H, 2004, NEW ENGL J MED, V350, P2335, DOI 10.1056/NEJMoa032691
   Hutton-Smith LA, 2018, MOL PHARMACEUT, V15, P2770, DOI 10.1021/acs.molpharmaceut.8b00280
   Hynes RO, 2002, CELL, V110, P673, DOI 10.1016/S0092-8674(02)00971-6
   Jager RD, 2008, NEW ENGL J MED, V358, P2606, DOI 10.1056/NEJMra0801537
   Kim JM, 2017, RETINA-J RET VIT DIS, V37, P2047, DOI 10.1097/IAE.0000000000001435
   Liu JX, 2019, INT J NANOMED, V14, P8819, DOI 10.2147/IJN.S217038
   Loyet KM, 2019, MOL PHARMACEUT, V16, P86, DOI 10.1021/acs.molpharmaceut.8b00871
   Marneros AG, 2005, AM J PATHOL, V167, P1451, DOI 10.1016/S0002-9440(10)61231-X
   Mas-Moruno C, 2010, ANTI-CANCER AGENT ME, V10, P753, DOI 10.2174/187152010794728639
   Michels S, 2005, OPHTHALMOLOGY, V112, P1035, DOI 10.1016/j.ophtha.2005.02.007
   Millard M, 2011, THERANOSTICS, V1, P154, DOI 10.7150/thno/v01p0154
   Penn JS, 2008, PROG RETIN EYE RES, V27, P331, DOI 10.1016/j.preteyeres.2008.05.001
   Peyman G, 2011, EUR J OPHTHALMOL, V21, P162, DOI 10.5301/EJO.2010.3272
   Ruoslahti E, 1996, ANNU REV CELL DEV BI, V12, P697, DOI 10.1146/annurev.cellbio.12.1.697
   Sakurai E, 2001, OPHTHALMIC RES, V33, P31, DOI 10.1159/000055638
   Segal O, 2016, ACTA OPHTHALMOL, V94, P203, DOI 10.1111/aos.12802
   Sivaprasad S, 2011, OPHTHALMOLOGICA, V225, P200, DOI 10.1159/000322363
   Tamura A, 2017, MOL PHARMACEUT, V14, P4714, DOI 10.1021/acs.molpharmaceut.7b00859
   Tian SQ, 2015, INT J NANOMED, V10, P5751, DOI 10.2147/IJN.S88109
   Wang M, 2008, ACTA OPHTHALMOL, V86, P126, DOI 10.1111/j.1600-0420.2007.00889.x
NR 38
TC 2
Z9 2
U1 4
U2 37
PU MDPI
PI BASEL
PA ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND
EI 1420-3049
J9 MOLECULES
JI Molecules
PD NOV
PY 2020
VL 25
IS 21
AR 4897
DI 10.3390/molecules25214897
PG 14
WC Biochemistry & Molecular Biology; Chemistry, Multidisciplinary
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Chemistry
GA OR2NE
UT WOS:000589311000001
PM 33113897
OA gold, Green Published
DA 2022-11-30
ER

PT J
AU De Jong, S
   Koolen, L
   Vazquez-Dominguez, I
   De Breuk, A
   Albert, S
   Hoyng, CB
   Katti, S
   Hollander, AID
   Garanto, A
AF De Jong, Sarah
   Koolen, Louet
   Vazquez-Dominguez, Irene
   De Breuk, Anita
   Albert, Silvia
   Hoyng, Carel B.
   Katti, Suresh
   Hollander, Anneke I. den
   Garanto, Alejandro
TI Generation of an iPSC line (SCTCi014-A) and isogenic control line
   (SCTCi014-A-1) from an age-related macular degeneration patient carrying
   the variant c.355G > A in the CFI gene
SO STEM CELL RESEARCH
LA English
DT Article
ID RARE
AB Age-related macular degeneration (AMD) is a common eye disease among the elderly in the Western world. AMD is a multifactorial disease, with a strong association with genetic variation in the complement system. One of the AMD-associated variants is the c.355G>A (p.Gly119Arg) variant in complement factor I (CFI), a central regulator of complement activation. Here, we report the generation of an iPSC line and its isogenic wildtype control derived from peripheral blood mononuclear cells of a male AMD-affected individual carrying the heterozygous variant c.355G>A (p.Gly119Arg). The line can be utilized to study the effects of this variant in disease specific cell types.
C1 [De Jong, Sarah; Koolen, Louet; De Breuk, Anita; Hoyng, Carel B.; Hollander, Anneke I. den] Radboud Univ Nijmegen Med Ctr, Donders Inst Brain Cognit & Behav, Dept Ophthalmol, Nijmegen, Netherlands.
   [Vazquez-Dominguez, Irene; Albert, Silvia; Hollander, Anneke I. den] Radboud Univ Nijmegen Med Ctr, Donders Inst Brain Cognit & Behav, Dept Human Genet, Nijmegen, Netherlands.
   [Katti, Suresh] Gemini Therapeut Inc, Cambridge, MA USA.
   [Garanto, Alejandro] Radboud Univ Nijmegen Med Ctr, Amalia Childrens Hosp, Radboud Inst Mol Life Sci, Dept Pediat, Nijmegen, Netherlands.
C3 Radboud University Nijmegen; Radboud University Nijmegen; Radboud
   University Nijmegen
RP Garanto, A (通讯作者)，Radboud Univ Nijmegen Med Ctr, Amalia Childrens Hosp, Radboud Inst Mol Life Sci, Dept Pediat, Nijmegen, Netherlands.
EM alex.garanto@radboudumc.nl
RI Garanto, Alejandro/D-5022-2014
OI Garanto, Alejandro/0000-0001-5721-1560
FU Dutch Research Council [016.Vici.170.024]; Stichting Toegepast
   Wetenschappelijk Instituut voor Neuromodulatie (TWIN project
   'Inflammation and Edema in an Organ-on-a-Chip Model of Wet AgeRelated
   Macular Degeneration'"); Gemini Therapeutics
FX The authors acknowledge the funding received from the Dutch Research
   Council (016.Vici.170.024 to AIdH), Stichting Toegepast Wetenschappelijk
   Instituut voor Neuromodulatie (TWIN project `Inflammation and Edema in
   an Organ-on-a-Chip Model of Wet AgeRelated Macular Degeneration'"), and
   a sponsored research agreement from Gemini Therapeutics.
CR de Jong S, 2022, STEM CELL RES, V62, DOI 10.1016/j.scr.2022.102796
   de Jong S, 2020, HUM MOL GENET, V29, P2313, DOI 10.1093/hmg/ddaa114
   Fritsche LG, 2016, NAT GENET, V48, P134, DOI 10.1038/ng.3448
   Geerlings MJ, 2017, JAMA OPHTHALMOL, V135, P39, DOI 10.1001/jamaophthalmol.2016.4604
   Vazquez-Dominguez I, 2022, STEM CELL RES, V60, DOI 10.1016/j.scr.2022.102689
NR 5
TC 1
Z9 1
U1 1
U2 1
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 1873-5061
EI 1876-7753
J9 STEM CELL RES
JI Stem Cell Res.
PD JUL
PY 2022
VL 62
AR 102797
DI 10.1016/j.scr.2022.102797
PG 6
WC Cell & Tissue Engineering; Biotechnology & Applied Microbiology; Cell
   Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Cell Biology; Biotechnology & Applied Microbiology
GA 1P4KQ
UT WOS:000801980000001
PM 35526386
OA gold
DA 2022-11-30
ER

PT J
AU Zazeckyte, G
   Gedvilaite, G
   Vilkeviciute, A
   Kriauciuniene, L
   Balciuniene, VJ
   Mockute, R
   Liutkeviciene, R
AF Zazeckyte, Guoda
   Gedvilaite, Greta
   Vilkeviciute, Alvita
   Kriauciuniene, Loresa
   Balciuniene, Vilma Jurate
   Mockute, Ruta
   Liutkeviciene, Rasa
TI Associations of Tumor Necrosis Factor-Alpha Gene Polymorphisms
   (TNF)-alpha TNF-863A/C (rs1800630), TNF-308A/G (rs1800629), TNF-238A/G
   (rs361525), and TNF-Alpha Serum Concentration with Age-Related Macular
   Degeneration
SO LIFE-BASEL
LA English
DT Article
DE age-related macular degeneration (AMD)-1; TNF-alpha-2; rs18006303-3;
   rs1800629-4; rs361525-5
ID EXPRESSION
AB Age-related macular degeneration (AMD) is a neurodegenerative disease leading to irreversible central vision loss among the elderly in developed countries. While the disease accounts for 9% of all cases of vision loss, the prevalence of AMD is likely to increase due to the exponential aging of the population. Due to this reason, our study aimed to determine the associations of tumor necrosis factor-alpha (TNF-alpha) gene single-nucleotide polymorphisms (SNPs) TNF-863A/C (rs1800630), TNF-308A/G (rs1800629), TNF-238A/G (rs361525), and TNF-alpha serum concentration with age-related macular degeneration. Analysis of TNF-alpha rs1800630, rs1800629, and rs361525 polymorphisms showed that the TNF-alpha rs1800630 A allele was statistically significantly more frequent in the exudative AMD group compared to the control group (p = 0.029). Additionally, the TNF-alpha rs1800630 A allele was more frequent in females with exudative AMD than in the control group of healthy females (p = 0.027). The TNF-alpha rs1800630 A allele was more frequent in females with exudative AMD than in females with early AMD (p = 0.014). TNF-alpha rs1800630, rs1800629, and rs361525 haplotype A-A-G were associated with decreased odds of exudative AMD (p < 0.0001), and haplotype A-G-G was associated with 24-fold increased exudative AMD occurrence (p < 0.0001). TNF-alpha protein levels were lower in subjects with exudative AMD compared to the control group (p < 0.001). The study showed significant associations between inflammatory cytokine TNF-alpha single-nucleotide polymorphisms and serum level with AMD pathogenesis. Analysis of TNF-alpha genotypes and serum concentration may be helpful for the AMD diagnosis.
C1 [Zazeckyte, Guoda; Mockute, Ruta] Lithuanian Univ Hlth Sci, Med Acad, Eiveniu Str 2, LT-50161 Kaunas, Lithuania.
   [Gedvilaite, Greta; Vilkeviciute, Alvita; Kriauciuniene, Loresa; Liutkeviciene, Rasa] Lithuanian Univ Hlth Sci, Med Acad, Neurosci Inst, Eiveniu Str 2, LT-50161 Kaunas, Lithuania.
   [Balciuniene, Vilma Jurate] Lithuanian Univ Hlth Sci, Med Acad, Dept Ophthalmol, Eiveniu Str 2, LT-50161 Kaunas, Lithuania.
C3 Lithuanian University of Health Sciences; Lithuanian University of
   Health Sciences; Lithuanian University of Health Sciences
RP Gedvilaite, G (通讯作者)，Lithuanian Univ Hlth Sci, Med Acad, Neurosci Inst, Eiveniu Str 2, LT-50161 Kaunas, Lithuania.
EM gouda.zazeckyte@stud.lsmuni.lt; greta.gedvilaite@lsmuni.lt;
   alvita.vilkeviciute@lsmuni.lt; loresa.kriauciuniene@lsmuni.lt;
   jurate.balciuniene@lsmuni.lt; ruta.mockute@gmail.com;
   rasalutkeviciene@lsmuni.lt
OI Gedvilaite, Greta/0000-0001-7469-8825
CR Age-Related Eye Dis Study Res Grp, 2001, AM J OPHTHALMOL, V132, P668
   Al-Zamil WM, 2017, CLIN INTERV AGING, V12, P1313, DOI 10.2147/CIA.S143508
   Albert R, 2015, BBA-GEN SUBJECTS, V1850, P435, DOI 10.1016/j.bbagen.2014.10.026
   Behniafard N, 2012, EUR CYTOKINE NETW, V23, P163, DOI 10.1684/ecn.2012.0323
   Cascella R, 2014, J OPHTHALMOL, V2014, DOI 10.1155/2014/582842
   Charles P., 2006, RETINA-J RET VIT DIS, V3
   Chernykh V, 2019, INT J OPHTHALMOL-CHI, V12, P25, DOI 10.18240/ijo.2019.01.04
   DeAngelis MM, 2017, HUM MOL GENET, V26, pR45, DOI 10.1093/hmg/ddx228
   DeAngelis MM, 2011, SEMIN OPHTHALMOL, V26, P77, DOI 10.3109/08820538.2011.577129
   Ding XY, 2009, PROG RETIN EYE RES, V28, P1, DOI 10.1016/j.preteyeres.2008.10.001
   El-Tahan RR, 2016, SPRINGERPLUS, V5, DOI 10.1186/s40064-016-3197-y
   Fan N, 2015, SCHIZOPHR RES, V169, P10, DOI 10.1016/j.schres.2015.11.006
   Gao ST, 2022, IMMUNOL INVEST, V51, P859, DOI 10.1080/08820139.2021.1882485
   Garcia-Layana A, 2017, CLIN INTERV AGING, V12, P1579, DOI 10.2147/CIA.S142685
   Guo SC, 2019, BMC OPHTHALMOL, V19, DOI 10.1186/s12886-019-1101-6
   Hammond CJ, 2002, OPHTHALMOLOGY, V109, P730, DOI 10.1016/S0161-6420(01)01049-1
   Han SH, 2020, GENES GENOM, V42, P743, DOI 10.1007/s13258-020-00946-4
   Khan S, 2016, SCI REP-UK, V6, DOI 10.1038/srep32677
   Mathenge Wanjiku, 2014, Community Eye Health, V27, P49
   Mirshahi Alireza, 2012, J Ophthalmic Vis Res, V7, P39
   Moorchung NN, 2015, INDIAN J DERMATOL, V60, P345, DOI 10.4103/0019-5154.160477
   Nagineni CN, 2012, J CELL PHYSIOL, V227, P116, DOI 10.1002/jcp.22708
   Parameswaran N, 2010, CRIT REV EUKAR GENE, V20, P87, DOI 10.1615/CritRevEukarGeneExpr.v20.i2.10
   Ratnapriya R, 2013, CLIN GENET, V84, P160, DOI 10.1111/cge.12206
   Schwartz SG, 2016, CLIN OPHTHALMOL, V10, P1229, DOI 10.2147/OPTH.S109723
   Sergejeva O, 2016, MEDICINA-LITHUANIA, V52, P79, DOI 10.1016/j.medici.2016.02.004
   Sharma K, 2014, FRONT AGING NEUROSCI, V6, DOI 10.3389/fnagi.2014.00151
   Shi LX, 2021, J PERIODONTAL RES, V56, P226, DOI 10.1111/jre.12820
   Smith W, 2001, OPHTHALMOLOGY, V108, P697, DOI 10.1016/S0161-6420(00)00580-7
   Stahl A, 2020, DTSCH ARZTEBL INT, V117, P513, DOI 10.3238/arztebl.2020.0513
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
   Xu TS, 2018, FRONT PHYSIOL, V9, DOI 10.3389/fphys.2018.00469
   Yan Q, 2021, ADV EXP MED BIOL, V1256, P191, DOI 10.1007/978-3-030-66014-7_7
   Zahorska-Markiewicz B, 2000, INT J OBESITY, V24, P1392, DOI 10.1038/sj.ijo.0801398
   Zhang Yixin, 2017, Oncotarget, V8, P111456, DOI 10.18632/oncotarget.22824
NR 35
TC 0
Z9 0
U1 2
U2 2
PU MDPI
PI BASEL
PA ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND
EI 2075-1729
J9 LIFE-BASEL
JI Life-Basel
PD JUL
PY 2022
VL 12
IS 7
AR 928
DI 10.3390/life12070928
PG 12
WC Biology; Microbiology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Life Sciences & Biomedicine - Other Topics; Microbiology
GA 3G8SN
UT WOS:000831617700001
PM 35888018
OA gold, Green Published
DA 2022-11-30
ER

PT J
AU Chu, XK
   Meyerle, CB
   Liang, XL
   Chew, EY
   Chan, CC
   Tuo, JS
AF Chu, Xi K.
   Meyerle, Catherine B.
   Liang, Xiaoling
   Chew, Emily Y.
   Chan, Chi-Chao
   Tuo, Jingsheng
TI In-depth analyses unveil the association and possible functional
   involvement of novel RAD51B polymorphisms in age-related macular
   degeneration
SO AGE
LA English
DT Article
DE Age-related macular degeneration; RAD51B; DNA repair; Single-nucleotide
   polymorphism; Functional genomicsl; Gene expression
ID HTRA1 PROMOTER POLYMORPHISM; CASE-CONTROL SAMPLES; COMPLEMENT FACTOR-H;
   RECOMBINATIONAL REPAIR; EYE DISEASE; DNA-DAMAGE; RISK-FACTORS; AREDS;
   MITOCHONDRIAL; STABILITY
AB The contribution of DNA damage to the pathogenesis of age-related macular degeneration (AMD) has been reported. Recently, a genomewide association study detected the association of a single-nucleotide polymorphism (SNP) in RAD51B (rs8017304 A> G) with AMD. RAD51B is involved in recombinational repair of DNA double-strand breaks. We analyzed RAD51B influence on AMD using two cohorts from Caucasian and Han Chinese populations. The Caucasian set replicated the rs8017304 A>G association and revealed two novel AMD-associated SNPs in RAD51B, rs17105278 T>C and rs4902566 C>T. Under the dominant model, these two SNPs exhibit highly significant disease risk. SNP-SNP interaction analysis on rs17105278 T>C and rs4902566 C>T homozygous demonstrated a synergistic effect on AMD risk, reaching an odds ratio multifold higher than well-established AMD susceptibility loci in genes such as CFH, HTRA1, and ARMS2. Functional study revealed lower RAD51B mRNA expression in cultured primary human fetal retinal pigment epithelium (hfRPE) carrying rs17105278 T>C variants than in hfRPE carrying rs17105278 wild type. We concluded that the risk of developing AMD exhibits dose dependency as well as an epistatic combined effect in rs17105278 T>C and rs4902566 C>T carriers and that the elevated risk for rs17105278 T>C carriers may be due to decreased transcription of RAD51B. This study further confirms the role of DNA damage/DNA repair in AMD pathogenesis.
C1 [Chu, Xi K.; Chan, Chi-Chao; Tuo, Jingsheng] NEI, Immunol Lab, NIH, Bethesda, MD 20892 USA.
   [Meyerle, Catherine B.; Chew, Emily Y.] NEI, Div Epidemiol & Clin Applicat, NIH, Bethesda, MD 20892 USA.
   [Liang, Xiaoling] Zhongshan Ophthalm Ctr, State Key Lab Ophthalmol, Guangzhou, Guangdong, Peoples R China.
C3 National Institutes of Health (NIH) - USA; NIH National Eye Institute
   (NEI); National Institutes of Health (NIH) - USA; NIH National Eye
   Institute (NEI)
RP Tuo, JS (通讯作者)，NEI, Immunol Lab, NIH, 10-10N103,10 Ctr Dr, Bethesda, MD 20892 USA.
EM tuoj@nei.nih.gov
FU National Eye Institute, NIH; Specialized Research Foundation for
   Doctoral Program of Higher Education in China [20120171110086]; Science
   and Technology Planning Project of Guangzhou City of China
   [11C22060787]; NATIONAL EYE INSTITUTE [ZIAEY000489, ZIAEY000418,
   ZIEEY000487, ZIAEY000222, ZIAEY000485] Funding Source: NIH RePORTER
FX The authors thank Angel Garced, R.N., Katherine Shimel, R.N., and
   Sun-min Ro, R.N. for their assistance in contacting study participants
   and collecting blood samples; Arvydas Maminishkis, Ph.D. for providing
   fhRPE cells. We also thank the study participants and their families for
   enrolling in this study. This research was supported by "The Intramural
   Research Program of the National Eye Institute, NIH," the "Specialized
   Research Foundation for Doctoral Program of Higher Education in China
   (20120171110086)," and the "Science and Technology Planning Project of
   Guangzhou City (11C22060787) of China."
CR [Anonymous], 2000, OPHTHALMOLOGY, V107, P2224
   Ardeljan D, 2013, EUR J HUM GENET, V21, P1152, DOI 10.1038/ejhg.2013.14
   Beatty S, 2000, SURV OPHTHALMOL, V45, P115, DOI 10.1016/S0039-6257(00)00140-5
   Blasiak J, 2013, INT J MOL SCI, V14, P2996, DOI 10.3390/ijms14022996
   Blasiak J, 2012, INT J MOL SCI, V13, P13378, DOI 10.3390/ijms131013378
   Chan Chi-Chao, 2007, Trans Am Ophthalmol Soc, V105, P92
   Chen LJ, 2006, MOL VIS, V12, P1536
   Chou CF, 2013, AM J PREV MED, V45, P29, DOI 10.1016/j.amepre.2013.02.018
   Coleman HR, 2008, LANCET, V372, P1835, DOI 10.1016/S0140-6736(08)61759-6
   Davis MD, 2005, ARCH OPHTHALMOL-CHIC, V123, P1484
   Dewan A, 2006, SCIENCE, V314, P989, DOI 10.1126/science.1133807
   Ding XY, 2009, PROG RETIN EYE RES, V28, P1, DOI 10.1016/j.preteyeres.2008.10.001
   Dudbridge F, 2004, AM J HUM GENET, V75, P424, DOI 10.1086/423738
   Fritsche LG, 2013, NAT GENET, V45, P433, DOI 10.1038/ng.2578
   Hageman GS, 2005, P NATL ACAD SCI USA, V102, P7227, DOI 10.1073/pnas.0501536102
   Kanda A, 2007, P NATL ACAD SCI USA, V104, P16227, DOI 10.1073/pnas.0703933104
   Keller-Seitz MU, 2004, MOL BIOL CELL, V15, P4321, DOI 10.1091/mbc.E04-05-0375
   Maminishkis A, 2006, INVEST OPHTH VIS SCI, V47, P3612, DOI 10.1167/iovs.05-1622
   Milton RC, 2005, OPHTHALMOLOGY, V112, P533, DOI 10.1016/j.ophtha.2004.10.047
   Ross RJ, 2007, INVEST OPHTH VIS SCI, V48, P1128, DOI 10.1167/iovs.06-0999
   Singh DK, 2009, BIOGERONTOLOGY, V10, P235, DOI 10.1007/s10522-008-9205-z
   Strunnikova N, 2005, FREE RADICAL BIO MED, V39, P781, DOI 10.1016/j.freeradbiomed.2005.04.029
   Suwaki N, 2011, SEMIN CELL DEV BIOL, V22, P898, DOI 10.1016/j.semcdb.2011.07.019
   Szaflik JP, 2009, MUTAT RES-FUND MOL M, V669, P169, DOI 10.1016/j.mrfmmm.2009.06.008
   Takata M, 2000, MOL CELL BIOL, V20, P6476, DOI 10.1128/MCB.20.17.6476-6482.2000
   Tuo J, 2008, OPHTHALMOLOGY, V115, P1891, DOI 10.1016/j.ophtha.2008.05.021
   Tuo JS, 2006, P NATL ACAD SCI USA, V103, P9256, DOI 10.1073/pnas.0603485103
   Wilson DM, 2007, DNA REPAIR, V6, P544, DOI 10.1016/j.dnarep.2006.10.017
   Wozniak K, 2009, J BIOMED BIOTECHNOL, DOI 10.1155/2009/827562
   Yang ZL, 2006, SCIENCE, V314, P992, DOI 10.1126/science.1133811
   Yao YL, 2013, PLANT CELL PHYSIOL, V54, P982, DOI 10.1093/pcp/pct051
   2001, ARCH OPHTHALMOL, V119, P1417
NR 32
TC 12
Z9 12
U1 0
U2 1
PU SPRINGER
PI DORDRECHT
PA VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS
SN 0161-9152
EI 1574-4647
J9 AGE
JI Age
PD JUN
PY 2014
VL 36
IS 3
BP 1453
EP 1462
DI 10.1007/s11357-014-9627-2
PG 10
WC Geriatrics & Gerontology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Geriatrics & Gerontology
GA AP5TT
UT WOS:000342142300036
PM 24526414
OA Green Published
DA 2022-11-30
ER

PT J
AU Souied, EH
   Leveziel, N
   Richard, F
   Dragon-Durey, MA
   Coscas, G
   Soubrane, G
   Benlian, P
   Fremeaux-Bacchi, V
AF Souied, EH
   Leveziel, N
   Richard, F
   Dragon-Durey, MA
   Coscas, G
   Soubrane, G
   Benlian, P
   Fremeaux-Bacchi, V
TI Y402H complement factor H polymorphism associated with exudative
   age-related macular degeneration in the French population
SO MOLECULAR VISION
LA English
DT Article
ID STARGARDT-DISEASE GENE; SUSCEPTIBILITY LOCI; APOLIPOPROTEIN-E;
   GENOMEWIDE-SCAN; LARGE FAMILY; MACULOPATHY; RISK; ABCR;
   NEOVASCULARIZATION; MUTATION
AB Purpose: Identification of genetic factors for age-related macular degeneration (AMD) is of crucial importance in this common cause of blindness. A positive association between Y402H polymorphism of the complement factor H (CFH) gene and AMD has been recently reported in North American populations but not yet in European populations. The exudative form of AMD is rapidly progressive and usually associated with a severe prognosis. Our purpose was to investigate this association in a French population specifically affected with exudative AMD, in a case-control study.
   Methods: Two series of unrelated exudative AMD patients, sporadic cases (n=60, mean age 74.9 +/- 5.7) and familial cases (n=81, mean age 74.0 +/- 9.4) were compared with healthy controls (n=91, mean age 74.6 +/- 6.3). The coding region of exon 9 of CFH was examined for the Y402H polymorphism by PCR-direct sequencing.
   Results: The 1,279-C allele frequencies were significantly higher in exudative AMD patients than controls (0.564 compared to 0.302; p < 0.0001). Genotypic distribution of the Y402H polymorphism was significantly different between sporadic cases compared to controls (chi(2)=14.48 with 2 df, p < 0.0007) and between familial cases compared to controls (chi(2)=23.78 with 2 df, p < 0.0001). The odds ratio (OR) for exudative AMD was 3.00 CI95% (1.60-5.62) for heterozygotes (CT) and 6.93 CI95% (3.11-15.46) for homozygotes (CC).
   Conclusions: These results suggest the contribution of the Y402H polymorphism of the CFH gene to exudative AMD susceptibility also in the French population. This relationship with the CFH may lead to early detection and new strategies for prevention and treatment of AMD.
C1 Creteil Univ, Eye Clin, Fac Med Henri Mondor, F-94000 Creteil, France.
   UFRC, Creteil, France.
   INSERM, U538, Creteil, France.
   Fac Med Pierre & Marie Curie, Paris, France.
   Univ Lille 2, Lille, France.
   INSERM, U508, F-59045 Lille, France.
   Hop Europeen Georges Pompidou, Serv Immunol Biol, Paris, France.
   INSERM, U255, Paris, France.
C3 Assistance Publique Hopitaux Paris (APHP); Universite
   Paris-Est-Creteil-Val-de-Marne (UPEC); Hopital Universitaire
   Henri-Mondor - APHP; Institut National de la Sante et de la Recherche
   Medicale (Inserm); UDICE-French Research Universities; Sorbonne
   Universite; Universite de Lille - ISITE; Universite de Lille; Institut
   National de la Sante et de la Recherche Medicale (Inserm); Assistance
   Publique Hopitaux Paris (APHP); Hopital Universitaire Europeen
   Georges-Pompidou - APHP; UDICE-French Research Universities; Universite
   Paris Cite; Institut National de la Sante et de la Recherche Medicale
   (Inserm)
RP Souied, EH (通讯作者)，Creteil Univ, Eye Clin, Fac Med Henri Mondor, 40 Ave Verdun, F-94000 Creteil, France.
EM eric.souied@chicreteil.fr
RI , Dragon-Durey/AGM-3653-2022
OI Nicolas, Leveziel/0000-0001-8533-9457; Dragon-Durey,
   Marie-Agnes/0000-0002-5809-8122
CR Abecasis GR, 2004, AM J HUM GENET, V74, P482, DOI 10.1086/382786
   Allikmets R, 2000, AM J HUM GENET, V67, P487, DOI 10.1086/303018
   Allikmets R, 1997, SCIENCE, V277, P1805, DOI 10.1126/science.277.5333.1805
   Anderson DH, 2002, AM J OPHTHALMOL, V134, P411, DOI 10.1016/S0002-9394(02)01624-0
   Bora PS, 2005, J IMMUNOL, V174, P491, DOI 10.4049/jimmunol.174.1.491
   Conley YP, 2005, HUM MOL GENET, V14, P1991, DOI 10.1093/hmg/ddi204
   Edwards AO, 2005, SCIENCE, V308, P421, DOI 10.1126/science.1110189
   Fremeaux-Bacchi V, 2005, J MED GENET, V42, P852, DOI 10.1136/jmg.2005.030783
   Green W R, 1977, Trans Am Ophthalmol Soc, V75, P180
   Guymer RH, 2001, ARCH OPHTHALMOL-CHIC, V119, P745, DOI 10.1001/archopht.119.5.745
   Hageman GS, 2005, P NATL ACAD SCI USA, V102, P7227, DOI 10.1073/pnas.0501536102
   Haines JL, 2005, SCIENCE, V308, P419, DOI 10.1126/science.1110359
   Iyengar SK, 2004, AM J HUM GENET, V74, P20, DOI 10.1086/380912
   Johnson LV, 2001, EXP EYE RES, V73, P887, DOI 10.1006/exer.2001.1094
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1417, DOI 10.1001/archopht.119.10.1417
   KLAVER CC, 1998, AM J HUM GENET, V63, P1252
   Klaver CCW, 1998, AM J HUM GENET, V63, P200, DOI 10.1086/301901
   Klaver CCW, 1998, ARCH OPHTHALMOL-CHIC, V116, P1646, DOI 10.1001/archopht.116.12.1646
   Klein ML, 1998, ARCH OPHTHALMOL-CHIC, V116, P1082, DOI 10.1001/archopht.116.8.1082
   Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557
   Russell S, 2003, OPHTHALMOLOGY, V110, P2372, DOI 10.1016/j.ophtha.2003.08.020
   Schmidt S, 2004, BMC GENET, V5, DOI 10.1186/1471-2156-5-18
   Schultz DW, 2003, HUM MOL GENET, V12, P3315, DOI 10.1093/hmg/ddg348
   Seddon JM, 2005, ARCH OPHTHALMOL-CHIC, V123, P774, DOI 10.1001/archopht.123.6.774
   Seddon JM, 2005, ARCH OPHTHALMOL-CHIC, V123, P321, DOI 10.1001/archopht.123.3.321
   Souied EH, 1998, AM J OPHTHALMOL, V125, P353, DOI 10.1016/S0002-9394(99)80146-9
   Souied EH, 2000, INVEST OPHTH VIS SCI, V41, P244
   Stone EM, 2004, NEW ENGL J MED, V351, P346, DOI 10.1056/NEJMoa040833
   Tomany SC, 2004, OPHTHALMOLOGY, V111, P1280, DOI 10.1016/j.ophtha.2003.11.010
   Weeks DE, 2004, AM J HUM GENET, V75, P174, DOI 10.1086/422476
   Zareparsi S, 2005, AM J HUM GENET, V77, P149, DOI 10.1086/431426
NR 31
TC 136
Z9 141
U1 0
U2 2
PU MOLECULAR VISION
PI ATLANTA
PA C/O JEFF BOATRIGHT, LAB B, 5500 EMORY EYE CENTER, 1327 CLIFTON RD, N E,
   ATLANTA, GA 30322 USA
SN 1090-0535
J9 MOL VIS
JI Mol. Vis.
PD DEC 19
PY 2005
VL 11
IS 131-32
BP 1135
EP 1140
PG 6
WC Biochemistry & Molecular Biology; Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Ophthalmology
GA 996JV
UT WOS:000234171100001
PM 16379025
DA 2022-11-30
ER

PT J
AU Wickremasinghe, SS
   Michalova, K
   Gilhotra, J
   Guymer, RH
   Harper, CA
   Wong, TY
   Qureshi, S
AF Wickremasinghe, Sanjeewa S.
   Michalova, Kira
   Gilhotra, Jagjit
   Guymer, Robyn H.
   Harper, C. Alex
   Wong, Tien Y.
   Qureshi, Salmaan
TI Acute Intraocular Inflammation after Intravitreous Injections of
   Bevacizumab for Treatment of Neovascular Age-related Macular
   Degeneration
SO OPHTHALMOLOGY
LA English
DT Article
ID SHORT-TERM; AVASTIN; SAFETY; RANIBIZUMAB
AB Purpose: Bevacizumab is an inhibitor of vascular enclothelial growth factor widely used as an "off-label" treatment of neovascular age-related macular degeneration (AMD), despite the lack of clinical trial data on efficacy or safety of this drug. We describe acute intraocular inflammation after intravitreous injection of bevacizumab for the treatment of neovascular AMD.
   Design: A retrospective case series.
   Participants: Patients with neovascular AMD treated with intravitreous injection of bevacizumab from clinical practices in 2 states (Victoria and South Australia) in Australia.
   Methods: We retrospectively reviewed cases of acute intraocular inflammation after intravitreous injection of bevacizumab for the treatment of neovascular AMD.
   Main Outcome Measures: The detection and description of inflammation in a large cohort of patients.
   Results: There were 14 cases (111 women and 3 men), from a total of 1278 injections given. The mean age of patients was 83.7 years (range, 74-98). The majority had a prior injection of bevacizumab, with a mean number of injections of 2.7 (range, 1-6). Most patients presented within 24 hours of intravitreous injection, with rapid reduction in vision, but minimal discomfort. There were associated signs of ocular inflammation in the anterior and posterior segments of the eye. Visual acuity at presentation was substantially reduced compared with the preinjection acuity, although the vision rapidly improved with treatment over a period of 7-25 days toward preinjection visual acuity.
   Conclusions: Intravitreous injection of bevacizumab for the treatment of neovascular AMD may be associated with acute intraocular inflammation. Differentiation from infectious endophthalmitis is important for appropriate management of this condition.
   Financial Disclosure(s): The authors have no proprietary or commercial interest in any materials discussed in this article. Ophthalmology 2008;115:1911-1915 (C) 2008 by the American Academy of Ophthalmology.
C1 [Wickremasinghe, Sanjeewa S.; Michalova, Kira; Guymer, Robyn H.; Harper, C. Alex; Wong, Tien Y.; Qureshi, Salmaan] Royal Victorian Eye & Ear Hosp, Med Retina Unit, Melbourne, Vic 3002, Australia.
   [Michalova, Kira; Guymer, Robyn H.; Harper, C. Alex; Wong, Tien Y.; Qureshi, Salmaan] Univ Melbourne, Ctr Eye Res Australia, Melbourne, Vic, Australia.
   [Gilhotra, Jagjit] Royal Adelaide Hosp, Adelaide, SA 5000, Australia.
   [Wong, Tien Y.] Natl Univ Singapore, Yong Loo Lin Sch Med, Singapore Eye Res Inst, Singapore, Singapore.
C3 Royal Victorian Eye & Ear Hospital; Centre for Eye Research Australia;
   University of Melbourne; Royal Adelaide Hospital; National University of
   Singapore; Singapore National Eye Center
RP Wong, TY (通讯作者)，Univ Melbourne, Ctr Eye Res Australia, 32 Gisborne St, Melbourne, Vic 3002, Australia.
EM twong@unimelb.edu.au
RI Wong, Tien Yin/AAC-9724-2020
OI Wong, Tien Yin/0000-0002-8448-1264; Guymer, Robyn/0000-0002-9441-4356
CR Aggio FB, 2007, EYE, V21, P408, DOI 10.1038/sj.eye.6702683
   Aiello LP, 2004, RETINA-J RET VIT DIS, V24, pS3, DOI 10.1097/00006982-200410001-00002
   Avery RL, 2006, OPHTHALMOLOGY, V113, P363, DOI 10.1016/j.ophtha.2005.11.019
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Chen CY, 2007, AM J OPHTHALMOL, V143, P510, DOI 10.1016/j.ajo.2006.10.004
   FOSTER CS, 1986, J IMMUNOL, V136, P2787
   Fung AE, 2006, BRIT J OPHTHALMOL, V90, P1344, DOI 10.1136/bjo.2006.099598
   *GEN INC, 2008, AV BEV REG FIN LAB, P43
   Hochuli E, 1997, J INTERF CYTOK RES, V17, pS15
   Koren E., 2002, Current Pharmaceutical Biotechnology, V3, P349, DOI 10.2174/1389201023378175
   Mamalis N, 2006, J CATARACT REFR SURG, V32, P324, DOI 10.1016/j.jcrs.2006.01.065
   Pieramici DJ, 2006, RETINA-J RET VIT DIS, V26, P841, DOI 10.1097/01.iae.0000234629.22614.cd
   REMICK DG, 1987, LAB INVEST, V56, P583
   Rich RM, 2006, RETINA-J RET VIT DIS, V26, P495, DOI 10.1097/01.iae.0000225766.75009.3a
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Rosenfeld PJ, 2006, AM J OPHTHALMOL, V142, P141, DOI 10.1016/j.ajo.2006.03.036
   Spaide RF, 2006, RETINA-J RET VIT DIS, V26, P383, DOI 10.1097/00006982-200604000-00001
   *US PHARM NAT FORM, 2008, GEN CHAPT 797 PHARM, P1
   Wong TY, 2007, LANCET, V370, P204, DOI 10.1016/S0140-6736(07)61104-0
   Wu L, 2008, GRAEF ARCH CLIN EXP, V246, P81, DOI 10.1007/s00417-007-0660-z
NR 20
TC 85
Z9 89
U1 0
U2 6
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0161-6420
J9 OPHTHALMOLOGY
JI Ophthalmology
PD NOV
PY 2008
VL 115
IS 11
BP 1911
EP 1915
DI 10.1016/j.ophtha.2008.05.007
PG 5
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 365ZO
UT WOS:000260448900009
PM 18672291
DA 2022-11-30
ER

PT J
AU McGwin, G
   Hall, TA
   Xie, A
   Owsley, C
AF McGwin, G
   Hall, TA
   Xie, A
   Owsley, C
TI The relation between C reactive protein and age related macular
   degeneration in the Cardiovascular Health Study
SO BRITISH JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
ID RISK-FACTORS; INFLAMMATORY MARKERS; ATHEROSCLEROSIS RISK; 5-YEAR
   INCIDENCE; MEDICATION USE; STATIN USE; MACULOPATHY; ASSOCIATION; DRUSEN;
   INTERLEUKIN-6
AB Aim: To test the hypothesis that individuals with age related macular degeneration (AMD) have increased C reactive protein (CRP) levels.
   Methods: A cross sectional study design using data from the Cardiovascular Health Study (CHS), a longitudinal study that enrolled older adults from four communities in the United States from 1989 to 1990, was employed to investigate the existence of an association between AMD and CRP levels in this population. Fundus photographs from 1997 and 1998 were used to identify individuals with (n=390) and without AMD (n=2365). The association between AMD and CRP levels (measured at baseline) was compared, adjusting for the potentially confounding effect of demographic, lifestyle, and health related characteristics.
   Results: Among the 2755 CHS participants with gradable fundus photographs, 390 were identified as having AMD. Overall, median CRP levels among those with AMD (1.76 mg/l) were similar to those without AMD (1.77 mg/l). CRP levels were categorised into quartiles and compared between those with and without AMD. Relative to those in the lowest quartile (0.07-0.93 mg/l), the odds ratios (OR) in the higher quartiles, adjusted for demographic, lifestyle, and health related characteristics were increased but not statistically significant (0.94-1.77 mg/l: OR=1.14, 95% CI 0.82 to 1.60; 1.78-3.04 mg/l: OR=1.24, 95% CI 0.88 to 1.75; >3.04 mg/l: OR=1.24, 95% CI 0.87 to 1.78).
   Conclusions: In the CHS, there is no evidence that CRP levels are associated with AMD. These data do not support the theory alleging non-specific systemic inflammation in the aetiology and natural history of this disease.
C1 Univ Alabama Birmingham, Sch Med, Dept Ophthalmol, Birmingham, AL 35294 USA.
   Univ Alabama Birmingham, Sch Publ Hlth, Dept Epidemiol & Int Hlth, Birmingham, AL 35294 USA.
   Univ Alabama Birmingham, Sch Med, Dept Surg,Div Gen Surg, Sect Trauma Burns & Surg Crit Care, Birmingham, AL 35294 USA.
C3 University of Alabama System; University of Alabama Birmingham;
   University of Alabama System; University of Alabama Birmingham;
   University of Alabama System; University of Alabama Birmingham
RP McGwin, G (通讯作者)，Univ Alabama Birmingham, Sch Med, Dept Ophthalmol, 700 S 18th St,Suite 609, Birmingham, AL 35294 USA.
EM mcgwin@uab.edu
FU NEI NIH HHS [R21 EY14071, R21 EY014071] Funding Source: Medline;
   NATIONAL EYE INSTITUTE [R21EY014071] Funding Source: NIH RePORTER
CR Anand R, 2000, OPHTHALMOLOGY, V107, P2224
   Anderson DH, 2002, AM J OPHTHALMOL, V134, P411, DOI 10.1016/S0002-9394(02)01624-0
   [Anonymous], [No title captured]
   Barzilay JI, 2001, DIABETES, V50, P2384, DOI 10.2337/diabetes.50.10.2384
   Bautista LE, 2005, J HUM HYPERTENS, V19, P149, DOI 10.1038/sj.jhh.1001785
   Bautista LE, 2001, J HYPERTENS, V19, P857, DOI 10.1097/00004872-200105000-00004
   Christen WG, 2001, ARCH OPHTHALMOL-CHIC, V119, P1143, DOI 10.1001/archopht.119.8.1143
   Clemons TE, 2004, ARCH OPHTHALMOL-CHIC, V122, P716
   CUSHMAN M, 1995, CLIN CHEM, V41, P264
   Freeman DJ, 2002, DIABETES, V51, P1596, DOI 10.2337/diabetes.51.5.1596
   Fried Linda P., 1991, Annals of Epidemiology, V1, P263
   Hageman GS, 2001, PROG RETIN EYE RES, V20, P705, DOI 10.1016/S1350-9462(01)00010-6
   Hall NF, 2001, BRIT MED J, V323, P375, DOI 10.1136/bmj.323.7309.375
   Hubbard LD, 1999, OPHTHALMOLOGY, V106, P2269, DOI 10.1016/S0161-6420(99)90525-0
   Johnson LV, 2000, EXP EYE RES, V70, P441, DOI 10.1006/exer.1999.0798
   Johnson LV, 2001, EXP EYE RES, V73, P887, DOI 10.1006/exer.2001.1094
   Klein R, 2004, AM J OPHTHALMOL, V137, P486, DOI 10.1016/j.ajo.2003.11.069
   Klein R, 2003, ARCH OPHTHALMOL-CHIC, V121, P1151, DOI 10.1001/archopht.121.8.1151
   Klein R, 2003, ARCH OPHTHALMOL-CHIC, V121, P674, DOI 10.1001/archopht.121.5.674
   Klein R, 2003, OPHTHALMOLOGY, V110, P25, DOI 10.1016/S0161-6420(02)01565-8
   Klein R, 1999, ARCH OPHTHALMOL-CHIC, V117, P1203
   KLEIN R, 1991, OPHTHALMOLOGY, V98, P1128
   Klein R, 1999, OPHTHALMOLOGY, V106, P1056, DOI 10.1016/S0161-6420(99)90255-5
   Klein R, 2001, ARCH OPHTHALMOL-CHIC, V119, P1354
   KLEIN R, 1999, AGE RELATED MACULAR, P31
   Klein Ronald, 2003, Ophthalmology, V110, P1273, DOI 10.1016/S0161-6420(03)00599-2
   Macy EM, 1997, CLIN CHEM, V43, P52
   McCarty CA, 2001, ARCH OPHTHALMOL-CHIC, V119, P1455
   McCarty CA, 2001, MED J AUSTRALIA, V175, P340, DOI 10.5694/j.1326-5377.2001.tb143604.x
   McGwin G, 2003, BRIT J OPHTHALMOL, V87, P1121, DOI 10.1136/bjo.87.9.1121
   Pedrinelli R, 2004, ARTERIOSCL THROM VAS, V24, P2414, DOI 10.1161/01.ATV.0000147415.40692.7f
   Penfold PL, 2001, PROG RETIN EYE RES, V20, P385, DOI 10.1016/S1350-9462(00)00025-2
   Pepys MB, 2003, J CLIN INVEST, V111, P1805, DOI 10.1172/JCI200318921
   Pradhan AD, 2001, JAMA-J AM MED ASSOC, V286, P327, DOI 10.1001/jama.286.3.327
   Sattar N, 2004, DIABETES, V53, P2855, DOI 10.2337/diabetes.53.11.2855
   Seddon JM, 2004, JAMA-J AM MED ASSOC, V291, P704, DOI 10.1001/jama.291.6.704
   Sharif M, 1997, BRIT J RHEUMATOL, V36, P140
   Smith W, 1998, ARCH OPHTHALMOL-CHIC, V116, P583, DOI 10.1001/archopht.116.5.583
   Sowers M, 2002, OSTEOARTHR CARTILAGE, V10, P595, DOI 10.1053/joca.2002.0800
   Spector TD, 1997, ARTHRITIS RHEUM, V40, P723, DOI 10.1002/art.1780400419
   Streilein JW, 2000, ANN NY ACAD SCI, V917, P297
   Sung KC, 2003, AM J HYPERTENS, V16, P429, DOI 10.1016/S0895-7061(03)00566-1
   Tell G S, 1993, Ann Epidemiol, V3, P358, DOI 10.1016/1047-2797(93)90062-9
   Tomany SC, 2004, OPHTHALMOLOGY, V111, P1280, DOI 10.1016/j.ophtha.2003.11.010
   Van Leeuwen R, 2004, OPHTHALMOLOGY, V111, P1169, DOI 10.1016/j.ophtha.2003.10.024
   Visser M, 1999, JAMA-J AM MED ASSOC, V282, P2131, DOI 10.1001/jama.282.22.2131
   YANNUZZI LA, 1992, ARCH OPHTHALMOL-CHIC, V110, P1701
   YOUNG RW, 1987, SURV OPHTHALMOL, V31, P291, DOI 10.1016/0039-6257(87)90115-9
   Zarbin MA, 2004, ARCH OPHTHALMOL-CHIC, V122, P598, DOI 10.1001/archopht.122.4.598
NR 49
TC 48
Z9 51
U1 0
U2 1
PU BMJ PUBLISHING GROUP
PI LONDON
PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND
SN 0007-1161
EI 1468-2079
J9 BRIT J OPHTHALMOL
JI Br. J. Ophthalmol.
PD SEP
PY 2005
VL 89
IS 9
BP 1166
EP 1170
DI 10.1136/bjo.2005.067397
PG 5
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 956PW
UT WOS:000231313300026
PM 16113374
OA Green Published, Green Submitted, Bronze
DA 2022-11-30
ER

PT J
AU Parodi, MB
   Da Pozzo, S
   Ravalico, G
AF Parodi, MB
   Da Pozzo, S
   Ravalico, G
TI Angiographic features after photodynamic therapy for choroidal
   neovascularisation in age related macular degeneration and pathological
   myopia
SO BRITISH JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
ID MEMBRANES; BENZOPORPHYRIN
AB Aim: To describe the angiographic features after photodynamic therapy (PDT) with verteporfin in choroidal neovascularisation (CNV) associated both with age related macular degeneration (AMD) and pathological myopia (PM).
   Methods: 36 patients affected by subfoveal CNV in AMD and 25 patients with subfoveal CNV in PM underwent an ophthalmological examination including fluorescein angiography (FA) and indocyanine green angiography (ICGA) using the IMAGEnet System. Post-PDT examinations were performed 7, 30, and 90 days later.
   Results: The typical angiographic aspect after PDT for AMD related CNV was a round hypofluorescence visible both on FA and on ICGA, which included both CNV and the surrounding tissues and corresponded to the area exposed to laser light. In PM the CNV appeared hypofluorescent during the early phases and gradually became hyperfluorescent during the late phases on FA, whereas on ICGA it was detectable in its whole extension as a hyperfluorescent lesion since the early phases. Differently from AMD, there was no round hypofluorescence surrounding the CNV on FA or on ICGA. Moreover, five patients in the AMD group showed hot spots on ICGA, which spontaneously disappeared during the follow up. Classic and occult components of the AMD related CNV revealed a different angiographic response to PDT, showing with the latter only a partial closure 1 week after PDT followed by a complete reopening at the first month in 100% of cases.
   Conclusion: The post-PDT hypofluorescence typical of AMD related CNV, especially visible on FA, might be secondary to a combination of choriocapillary occlusion and masking effect due to swelling of retinal pigment epithelium cells. Hot spots in the AMD affected patients could be interpreted as the expression of a non-thermal choroidal vasculitis secondary to PDT.
C1 Univ Trieste, Eye Clin, I-34127 Trieste, Italy.
C3 University of Trieste
RP Parodi, MB (通讯作者)，Univ Trieste, Osped Maggiore, Eye Clin, I-34129 Trieste, Italy.
RI Parodi, Maurizio Battaglia/K-7876-2016
OI Battaglia Parodi, Maurizio/0000-0002-0385-7961
CR Arnold J, 2001, OPHTHALMOLOGY, V108, P841
   Arnold J, 2001, AM J OPHTHALMOL, V131, P541
   Blumenkranz MS, 2001, ARCH OPHTHALMOL-CHIC, V119, P198
   Bressler NM, 1999, ARCH OPHTHALMOL-CHIC, V117, P1329
   Delori FC, 2001, INVEST OPHTH VIS SCI, V42, P1855
   Flower RW, 1999, RETINA-J RET VIT DIS, V19, P365
   Ghazi NG, 2001, RETINA-J RET VIT DIS, V21, P478, DOI 10.1097/00006982-200110000-00010
   GREEN J L, 1981, International Ophthalmology Clinics, V21, P27, DOI 10.1097/00004397-198102130-00005
   GREEN WR, 1985, OPHTHALMOLOGY, V92, P615
   Grossniklaus HE, 1998, AM J OPHTHALMOL, V126, P59, DOI 10.1016/S0002-9394(98)00145-7
   GROSSNIKLAUS HE, 1994, OPHTHALMOLOGY, V101, P1099
   Grossniklaus HE, 1998, ARCH OPHTHALMOL-CHIC, V116, P745, DOI 10.1001/archopht.116.6.745
   Lutty G, 1999, MOL VIS, V03, P5
   OKABE S, 1982, ACTA MED OKAYAMA, V36, P11
   RABB M F, 1981, International Ophthalmology Clinics, V21, P51, DOI 10.1097/00004397-198102130-00006
   Schmidt-Erfurth U, 1998, GRAEF ARCH CLIN EXP, V236, P365, DOI 10.1007/s004170050092
   Schmidt-Erfurth U., 1994, Ophthalmologe, V91, P348
   Schmidt-Erfurth U, 1999, Semin Ophthalmol, V14, P35, DOI 10.3109/08820539909056061
   SchmidtErfurth U, 1996, EXP EYE RES, V62, P1, DOI 10.1006/exer.1996.0001
   SCHMIDTERFURTH U, 1994, OPHTHALMOLOGY, V101, P89
   Schnurrbusch UEK, 2001, BRIT J OPHTHALMOL, V85, P1086, DOI 10.1136/bjo.85.9.1086
NR 21
TC 17
Z9 17
U1 0
U2 0
PU BRITISH MED JOURNAL PUBL GROUP
PI LONDON
PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND
SN 0007-1161
J9 BRIT J OPHTHALMOL
JI Br. J. Ophthalmol.
PD FEB
PY 2003
VL 87
IS 2
BP 177
EP 183
DI 10.1136/bjo.87.2.177
PG 7
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 640NR
UT WOS:000180695300014
PM 12543747
OA Green Published, Green Submitted, Bronze
DA 2022-11-30
ER

PT J
AU Shah, AR
   Del Priore, LV
AF Shah, Ankoor R.
   Del Priore, Lucian V.
TI Progressive visual loss in subfoveal exudation in age-related macular
   degeneration: A meta-analysis using Lineweaver-Burke plots
SO AMERICAN JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
ID RETINAL-PIGMENT EPITHELIUM; INTRAVITREAL BEVACIZUMAB AVASTIN;
   QUALITY-OF-LIFE; CHOROIDAL NEOVASCULARIZATION; PHOTODYNAMIC THERAPY;
   HISTORICAL CONTROLS; CLINICOPATHOLOGICAL CORRELATION; SUBMACULAR
   MEMBRANECTOMY; PERIPHERAL RETINECTOMY; ANECORTAVE ACETATE
AB PURPOSE: To analyze the randomized clinical trials in exudative age related macular degeneration (AMD) to reveal apparent differences in the behavior of untreated control eyes among these trials. Herein we test the hypothesis that the behavior of untreated control eyes is actually the same in all studies, with apparent differences arising from differences in the time of entry of eyes into clinical trials.
   DESIGN: Retrospective meta-analysis of prior clinical trials.
   METHODS: Control eye data from six AMD studies (Macular Photocoagulation Study, Subfoveal Surgery Trial, Photodynamic Therapy [TAP] With Visudyne, pegaptanib trial for neovascular AMD, anecortave acetate trial, and 360 degree Macular Translocation Study) were plotted on a double reciprocal plot of 1/(Letters Lost) vs 1/(Months After Enrollment). To account for differences in time of entry into clinical trials, we introduced a horizontal translation factor to shift each data subset horizontally to maximize r(2) for the cumulative trend line.
   RESULTS: Cumulative data for untreated control eyes fits a straight line on a double reciprocal plot (r(2) = .9521); an untreated eye would eventually deteriorate to a final vision of 20/640. The slope of the line predicts that patients would experience half of the maximum final vision within 10.88 months after exudation onset.
   CONCLUSIONS: The pattern of vision loss experienced in AMD eyes with subfoveal neovascularization is uniform across a wide range of clinical trials, with apparent differences arising from differences in the time of entry of patients into clinical trials.
C1 Columbia Univ, Dept Ophthalmol, New York, NY 10027 USA.
C3 Columbia University
RP Del Priore, LV (通讯作者)，635 W 165th St, New York, NY 10032 USA.
EM ldelpriore@yahoo.com
CR ADELBERG DA, 1995, RETINA-J RET VIT DIS, V15, P198, DOI 10.1097/00006982-199515030-00003
   Algvere PV, 1997, GRAEF ARCH CLIN EXP, V235, P149, DOI 10.1007/BF00941722
   ALGVERE PV, 1994, GRAEF ARCH CLIN EXP, V232, P707, DOI 10.1007/BF00184273
   [Anonymous], 1991, Arch Ophthalmol, V109, P1220
   ARIYOSHI M, 1987, BRAIN RES, V435, P241, DOI 10.1016/0006-8993(87)91607-6
   Avery RL, 2006, OPHTHALMOLOGY, V113, P363, DOI 10.1016/j.ophtha.2005.11.019
   Baker S G, 2001, BMC Med Res Methodol, V1, P9, DOI 10.1186/1471-2288-1-9
   Bass E, 2000, AM J OPHTHALMOL, V130, P408
   Bergink GJ, 1998, GRAEF ARCH CLIN EXP, V236, P321, DOI 10.1007/s004170050085
   Blinder K, 2003, RETINA-J RET VIT DIS, V23, P14
   BRESSLER NM, 1988, SURV OPHTHALMOL, V32, P375, DOI 10.1016/0039-6257(88)90052-5
   Bressler NM, 1999, ARCH OPHTHALMOL-CHIC, V117, P1329
   Cahill MT, 2005, OPHTHALMOLOGY, V112, P152, DOI 10.1016/j.ophtha.2004.06.036
   Cahill MT, 2005, OPHTHALMOLOGY, V112, P144, DOI 10.1016/j.ophtha.2004.06.035
   Cekic O, 1999, LANCET, V354, P340, DOI 10.1016/S0140-6736(05)75249-1
   Chang Myron N, 2004, J Biopharm Stat, V14, P189, DOI 10.1081/BIP-120028514
   Char DH, 1999, AM J OPHTHALMOL, V127, P574, DOI 10.1016/S0002-9394(99)00038-0
   de Juan E, 1999, AM J OPHTHALMOL, V128, P380, DOI 10.1016/S0002-9394(99)00142-7
   Del Priore LV, 2001, AM J OPHTHALMOL, V131, P472, DOI 10.1016/S0002-9394(00)00850-3
   Eckardt C, 1999, GRAEF ARCH CLIN EXP, V237, P313, DOI 10.1007/s004170050239
   Fujii GY, 2003, AM J OPHTHALMOL, V135, P109, DOI 10.1016/S0002-9394(02)01854-8
   Gragoudas ES, 2004, NEW ENGL J MED, V351, P2805, DOI 10.1056/NEJMoa042760
   GREEN WR, 1993, OPHTHALMOLOGY, V100, P1519
   Holz FG, 1999, OPHTHALMOLOGY, V106, P2239
   HSU JK, 1995, RETINA-J RET VIT DIS, V15, P43, DOI 10.1097/00006982-199515010-00009
   Hutton JL, 1996, HEALTH CARE ANAL, V4, P95
   Ibrahim JG, 1996, BIOMETRICS, V52, P1478, DOI 10.2307/2532862
   Kaplan H J, 1999, Chem Immunol, V73, P207
   Kaplan HJ, 1998, RETINA-J RET VIT DIS, V18, P99
   Lappas A, 2004, GRAEF ARCH CLIN EXP, V242, P638, DOI 10.1007/s00417-003-0764-z
   Lee JJ, 2001, CONTROL CLIN TRIALS, V22, P390, DOI 10.1016/S0197-2456(01)00143-X
   Lewis H, 1998, AM J OPHTHALMOL, V126, P127
   Maturi RK, 2006, RETINA-J RET VIT DIS, V26, P270, DOI 10.1097/00006982-200603000-00003
   McLeod DS, 2002, INVEST OPHTH VIS SCI, V43, P1986
   MICCIOLO R, 1985, CONTROL CLIN TRIALS, V6, P259, DOI 10.1016/0197-2456(85)90102-3
   Michels S, 2005, OPHTHALMOLOGY, V112, P1035, DOI 10.1016/j.ophtha.2005.02.007
   Mruthyunjaya P, 2005, RETINA-J RET VIT DIS, V25, P597, DOI 10.1097/00006982-200507000-00010
   Mruthyunjaya P, 2004, OPHTHALMOLOGY, V111, P1715, DOI 10.1016/j.ophtha.2004.03.022
   Pauleikhoff D, 2002, GRAEF ARCH CLIN EXP, V240, P539, DOI 10.1007/s00417-002-0507-6
   Pollack JS, 1996, BRIT J OPHTHALMOL, V80, P314, DOI 10.1136/bjo.80.4.314
   Reichel E, 1999, OPHTHALMOLOGY, V106, P1908, DOI 10.1016/S0161-6420(99)90400-1
   Rosa RH, 1996, ARCH OPHTHALMOL-CHIC, V114, P480, DOI 10.1001/archopht.1996.01100130476025
   Rosenfeld PJ, 2005, OPHTHALMOLOGY, V112, P1048, DOI 10.1016/j.ophtha.2005.01.043
   Rosenfeld PJ, 2005, OPHTHAL SURG LAS IM, V36, P331, DOI 10.3928/1542-8877-20050701-14
   RYAN L, 1993, BIOMETRICS, V49, P1126, DOI 10.2307/2532254
   Sarks JP, 1997, EYE, V11, P515, DOI 10.1038/eye.1997.137
   SARKS SH, 1973, BRIT J OPHTHALMOL, V57, P951, DOI 10.1136/bjo.57.12.951
   Schmidt-Erfurth U, 2005, EUR J OPHTHALMOL, V15, P482, DOI 10.1177/112067210501500411
   Sebestyen A, 2000, TUMOR BIOL, V21, P349, DOI 10.1159/000030140
   Shahar J, 2006, RETINA-J RET VIT DIS, V26, P262, DOI 10.1097/00006982-200603000-00002
   Slakter JS, 2006, OPHTHALMOLOGY, V113, P3, DOI 10.1016/j.ophtha.2005.10.019
   SMALL ML, 1976, ARCH OPHTHALMOL-CHIC, V94, P601, DOI 10.1001/archopht.1976.03910030287008
   STRAHLMAN ER, 1983, ARCH OPHTHALMOL-CHIC, V101, P1191
   THOMAS MA, 1994, OPHTHALMOLOGY, V101, P1384
   THOMAS MA, 1992, OPHTHALMOLOGY, V99, P952
   Toth CA, 2001, RETINA-J RET VIT DIS, V21, P293, DOI 10.1097/00006982-200108000-00001
   West SK, 2000, EPIDEMIOL REV, V22, P64, DOI 10.1093/oxfordjournals.epirev.a018025
   YOUNG RW, 1988, SURV OPHTHALMOL, V32, P252, DOI 10.1016/0039-6257(88)90174-9
NR 58
TC 34
Z9 34
U1 0
U2 6
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 0002-9394
EI 1879-1891
J9 AM J OPHTHALMOL
JI Am. J. Ophthalmol.
PD JAN
PY 2007
VL 143
IS 1
BP 83
EP 89
DI 10.1016/j.ajo.2006.09.043
PG 7
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 123QY
UT WOS:000243311700011
PM 17188044
DA 2022-11-30
ER

PT J
AU Waksmunski, AR
   Miskimen, K
   Song, YE
   Grunin, M
   Laux, R
   Fuzzell, D
   Fuzzell, S
   Adams, LD
   Caywood, L
   Prough, M
   Stambolian, D
   Scott, WK
   Pericak-Vance, MA
   Haines, JL
AF Waksmunski, Andrea R.
   Miskimen, Kristy
   Song, Yeunjoo E.
   Grunin, Michelle
   Laux, Renee
   Fuzzell, Denise
   Fuzzell, Sarada
   Adams, Larry D.
   Caywood, Laura
   Prough, Michael
   Stambolian, Dwight
   Scott, William K.
   Pericak-Vance, Margaret A.
   Haines, Jonathan L.
TI Consequences of a Rare Complement Factor H Variant for Age-Related
   Macular Degeneration in the Amish
SO INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE
LA English
DT Article
DE age-related macular degeneration; complement factor H; rare variant;
   protein structure
ID FAMILIAL AGGREGATION; US TWIN; RISK; POLYMORPHISM; INDIVIDUALS;
   MACULOPATHY; CFH; ASSOCIATION; DISEASE; SYSTEM
AB PURPOSE. Genetic variants in the complement factor H gene (CFH) have been consistently implicated in age-related macular degeneration (AMD) risk. However, their functional effects are not fully characterized. We previously identified a rare, AMD-associated variant in CFH (P503A, rs570523689) in 19 Amish individuals, but its functional consequences were not investigated. METHODS. We performed genotyping for CFH P503A in 1326 Amish individuals to identify additional risk allele carriers. We examined differences for age at AMD diagnosis between carriers and noncarriers. In blood samples from risk allele carriers and noncarriers, we quantified (i) CFH RNA expression, (ii) CFH protein expression, and (iii) C -reactive protein (CRP) expression. Potential changes to the CFH protein structure were interrogated computationally with Phyre2 and Chimera software programs. RESULTS. We identified 39 additional carriers from Amish communities in Ohio and Indiana. On average, carriers were younger than noncarriers at AMD diagnosis, but this difference was not significant. CFH transcript and protein levels in blood samples from Amish carriers and noncarriers were also not significantly different. CRP levels were also comparable in plasma samples from carriers and noncarriers. Computational protein modeling showed slight changes in the CFH protein conformation that were predicted to alter interactions between the CFH 503 residue and other neighboring residues. CONCLUSIONS. In total, we have identified 58 risk allele carriers for CFH P503A in the Ohio and Indiana Amish. Although we did not detect significant differences in age at AMD diagnosis or expression levels of CFH in blood samples from carriers and noncarriers, we observed modest structural changes to the CFH protein through in silico modeling. Based on our functional and computational observations, we hypothesize that CFH P503A may affect CFH binding or function rather than expression, which would require additional research to confirm.
C1 [Waksmunski, Andrea R.; Haines, Jonathan L.] Case Western Reserve Univ, Dept Genet & Genome Sci, Cleveland, OH USA.
   [Waksmunski, Andrea R.; Grunin, Michelle; Haines, Jonathan L.] Case Western Reserve Univ, Cleveland Inst Computat Biol, Cleveland, OH USA.
   [Waksmunski, Andrea R.; Miskimen, Kristy; Song, Yeunjoo E.; Grunin, Michelle; Laux, Renee; Fuzzell, Denise; Fuzzell, Sarada; Haines, Jonathan L.] Case Western Reserve Univ, Dept Populat & Quantitat Hlth Sci, Cleveland, OH USA.
   [Adams, Larry D.; Caywood, Laura; Prough, Michael; Scott, William K.; Pericak-Vance, Margaret A.] Univ Miami, John P Hussman Inst Human Genom, Miller Sch Med, Miami, FL USA.
   [Stambolian, Dwight] Univ Penn, Dept Ophthalmol, Philadelphia, PA USA.
   [Haines, Jonathan L.] Case Western Reserve Univ, Dept Populat & Quantitat Hlth Sci, 10900 Euclid Ave, Cleveland, OH 44106 USA.
C3 Case Western Reserve University; Case Western Reserve University; Case
   Western Reserve University; University of Miami; University of
   Pennsylvania; Case Western Reserve University
RP Haines, JL (通讯作者)，Case Western Reserve Univ, Dept Populat & Quantitat Hlth Sci, 10900 Euclid Ave, Cleveland, OH 44106 USA.
EM jlh213@case.edu
FU National Institutes of Health (NIH); postdoctoral NIH Visual Sciences
   Training Program [EY023164]; CWRU Visual Sciences Training Program
   [T32EY007157-18]; Clinical and Translational Science Collaborative
   (CTSC) of Cleveland - National Institutes of Health (NIH), National
   Center for Advancing Translational Science (NCATS), Clinical and
   Translational Science Award (CTSA) grant [T32 EY 7157-19]; 
   [TL1TR002549]
FX Supported by the National Institutes of Health (NIH; EY023164). M.G. was
   supported by a postdoctoral NIH Visual Sciences Training Program
   (T32EY007157-18). A.R.W. was supported by the CWRU Visual Sciences
   Training Program (T32 EY 7157-19) and the Clinical and Translational
   Science Collaborative (CTSC) of Cleveland which is funded by the
   National Institutes of Health (NIH), National Center for Advancing
   Translational Science (NCATS), Clinical and Translational Science Award
   (CTSA) grant (TL1TR002549). The content is solely the responsibility of
   the authors and do not necessarily represent the official views of the
   NIH.
CR Agarwala R, 2003, AM J MED GENET C, V121C, P32, DOI 10.1002/ajmg.c.20004
   Anderson DH, 2010, PROG RETIN EYE RES, V29, P95, DOI 10.1016/j.preteyeres.2009.11.003
   [Anonymous], BRAVO VARIANT BROWSE
   Ansari M, 2013, HUM MOL GENET, V22, P4857, DOI 10.1093/hmg/ddt336
   Ayoub T, 2009, J ROY SOC MED, V102, P56, DOI 10.1258/jrsm.2009.080298
   Bailey JNC, 2013, HUM MOL GENET, V22, pR59, DOI 10.1093/hmg/ddt396
   Cao SJ, 2016, BRIT J OPHTHALMOL, V100, P713, DOI 10.1136/bjophthalmol-2015-307213
   Carey DJ, 2016, GENET MED, V18, P906, DOI 10.1038/gim.2015.187
   Cipriani V, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-14499-3
   Cummings AC, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0062615
   Davarinejad H., 2017, QUANTIFICATIONS W BL
   DeJong PTVM, 1997, AM J OPHTHALMOL, V124, P862, DOI 10.1016/S0002-9394(14)71715-5
   Dewey FE, 2016, SCIENCE, V354, DOI 10.1126/science.aaf6814
   Ferreira VP, 2010, MOL IMMUNOL, V47, P2187, DOI 10.1016/j.molimm.2010.05.007
   Fritsche LG, 2016, NAT GENET, V48, P134, DOI 10.1038/ng.3448
   Garbe J., 2008, PEDIGRAPH SOFTWARE T
   Grunin M, 2012, INVEST OPHTH VIS SCI, V53, P5292, DOI 10.1167/iovs.11-9165
   Hageman GS, 2005, P NATL ACAD SCI USA, V102, P7227, DOI 10.1073/pnas.0501536102
   Haines JL, 2005, SCIENCE, V308, P419, DOI 10.1126/science.1110359
   Hammond CJ, 2002, OPHTHALMOLOGY, V109, P730, DOI 10.1016/S0161-6420(01)01049-1
   Hoffman JD, 2014, INVEST OPHTH VIS SCI, V55, P4455, DOI 10.1167/iovs.13-13684
   Johnson PT, 2006, P NATL ACAD SCI USA, V103, P17456, DOI 10.1073/pnas.0606234103
   Karczewski KJ, 2020, NATURE, V581, P434, DOI 10.1038/s41586-020-2308-7
   Kelley LA, 2015, NAT PROTOC, V10, P845, DOI 10.1038/nprot.2015.053
   Kersten E, 2017, JAMA OPHTHALMOL, V135, P1037, DOI 10.1001/jamaophthalmol.2017.3195
   Klaver CCW, 1998, ARCH OPHTHALMOL-CHIC, V116, P1646, DOI 10.1001/archopht.116.12.1646
   KLEIN ML, 1994, ARCH OPHTHALMOL-CHIC, V112, P932, DOI 10.1001/archopht.1994.01090190080025
   Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557
   Levine JA, 2013, US OPHTHALMIC REV, V06, P52
   McHarg S, 2015, MOL IMMUNOL, V67, P43, DOI 10.1016/j.molimm.2015.02.032
   MCKUSICK VA, 1964, B JOHNS HOPKINS HOSP, V115, P203
   MEYERS SM, 1995, AM J OPHTHALMOL, V120, P757, DOI 10.1016/S0002-9394(14)72729-1
   Mitchell P, 2018, LANCET, V392, P1147, DOI 10.1016/S0140-6736(18)31550-2
   Nittala MG, 2019, RETINA-J RET VIT DIS, V39, P1540, DOI 10.1097/IAE.0000000000002210
   Olsen TW, 2020, OPHTHALMOLOGY, V127, pP1, DOI 10.1016/j.ophtha.2019.09.024
   Pettersen EF, 2004, J COMPUT CHEM, V25, P1605, DOI 10.1002/jcc.20084
   Raychaudhuri S, 2011, NAT GENET, V43, P1232, DOI 10.1038/ng.976
   Sardell RJ, 2016, OPHTHALMOLOGY, V123, P2537, DOI 10.1016/j.ophtha.2016.09.001
   Schneider CA, 2012, NAT METHODS, V9, P671, DOI 10.1038/nmeth.2089
   Scholl HPN, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002593
   Seddon JM, 2006, OPHTHALMOLOGY, V113, P260, DOI 10.1016/j.ophtha.2005.11.001
   Seddon JM, 2005, ARCH OPHTHALMOL-CHIC, V123, P321, DOI 10.1001/archopht.123.3.321
   Seddon JM, 1997, AM J OPHTHALMOL, V123, P199, DOI 10.1016/S0002-9394(14)71036-0
   Seddon JM, 2006, ARCH OPHTHALMOL-CHIC, V124, P995, DOI 10.1001/archopht.124.7.995
   Shaw PX, 2012, P NATL ACAD SCI USA, V109, P13757, DOI 10.1073/pnas.1121309109
   Shijo T, 2020, INT OPHTHALMOL, V40, P2735, DOI 10.1007/s10792-020-01460-y
   Sinnwell JP, 2014, HUM HERED, V78, P91, DOI 10.1159/000363105
   Thornton T, 2010, AM J HUM GENET, V86, P172, DOI 10.1016/j.ajhg.2010.01.001
   Thornton T, 2007, AM J HUM GENET, V81, P321, DOI 10.1086/519497
   Tortajada A, 2009, HUM MOL GENET, V18, P3452, DOI 10.1093/hmg/ddp289
   Triebwasser MP, 2015, INVEST OPHTH VIS SCI, V56, P6873, DOI 10.1167/iovs.15-17432
   Wagner EK, 2016, SCI REP-UK, V6, DOI 10.1038/srep31531
   Waksmunski AR, 2019, HUM GENET, V138, P1171, DOI 10.1007/s00439-019-02050-4
   Warwick A, 2014, J CLIN MED, V3, P1234, DOI 10.3390/jcm3041234
   Weber BHF, 2014, DTSCH ARZTEBL INT, V111, DOI 10.3238/arztebl.2014.0133
   Yu JM, 2007, BIOCHEMISTRY-US, V46, P8451, DOI 10.1021/bi700459a
   Zhou Ru, 2010, F1000 Biol Rep, V2, DOI 10.3410/B2-3
NR 57
TC 0
Z9 0
U1 1
U2 1
PU ASSOC RESEARCH VISION OPHTHALMOLOGY INC
PI ROCKVILLE
PA 12300 TWINBROOK PARKWAY, ROCKVILLE, MD 20852-1606 USA
SN 0146-0404
EI 1552-5783
J9 INVEST OPHTH VIS SCI
JI Invest. Ophthalmol. Vis. Sci.
PD AUG
PY 2022
VL 63
IS 9
AR 8
DI 10.1167/iovs.63.9.8
PG 12
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 3X4AL
UT WOS:000842984700002
PM 35930268
OA Green Published, gold
DA 2022-11-30
ER

PT J
AU Schick, T
   Ersoy, L
   Hoyng, CB
   Kirchhof, B
   Liakopoulos, S
AF Schick, Tina
   Ersoy, Lebriz
   Hoyng, Carel B.
   Kirchhof, Bernd
   Liakopoulos, Sandra
TI Phenotype Characteristics of Fellow Eyes in Patients With Early Onset of
   Neovascular Age-Related Macular Degeneration
SO INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE
LA English
DT Article
DE neovascular age-related macular degeneration; fellow eye;
   spectral-domain optical coherence tomography; reticular pseudodrusen
ID OPTICAL COHERENCE TOMOGRAPHY; SUBRETINAL DRUSENOID DEPOSITS; CHOROIDAL
   NEOVASCULARIZATION; RETICULAR PSEUDODRUSEN; RISK-FACTORS; FOLLOW-UP;
   HYPERREFLECTIVE FOCI; SEVERITY SCALE; UNITED-STATES; 2ND EYE
AB PURPOSE. To investigate phenotype characteristics of fellow eyes in patients with early onset of neovascular age-related macular degeneration (NVAMD).
   METHODS. Patients with new-onset unilateral NVAMD between 50 and 65 years (n = 57, early-onset choroidal neovascularization [CNV] group) or > 80 years (n = 47, late-onset CNV group) or with nonneovascular AMD (n = 98, no-CNV group) were included. Fellow eyes in both CNV groups and the eyes with the more severe AMD staging in the no-CNV group were used to evaluate number and size of macular drusen, extramacular drusen (EMD), pigmentary abnormalities, and retinal pigment epithelium (RPE) atrophy on color photographs and hyperreflective dots (HRD) and reticular pseudodrusen (RPD) on spectral-domain optical coherence tomography (SDOCT) scans. Regression analysis was used to compare groups.
   RESULTS. Occurrence of > 20 macular drusen was more frequent in the early-onset CNV group than the late-onset CNV group (odds ratio [OR] 2.93; P = 0.01) or the no-CNV group (OR 2.17; P = 0.02). Retinal pigment epithelium atrophy, RPD, and HRD appeared less frequently in the early-onset CNV group than in the late-onset CNV group (RPE atrophy: OR 0.11; P = 0.005; RPD: OR 0.04; P = 9.38 x 10(-10), HRD: OR 0.30; P = 0.004) and no-CNV group (RPE atrophy: OR 0.12; P = 0.005; RPD: OR 0.40, P = 0.03, HRD: not significant). No differences were detected regarding presence of large drusen, pigmentary abnormalities, and EMD.
   CONCLUSIONS. A large number of macular drusen in the fellow eye appeared to be characteristic for early onset of NVAMD, whereas RPE atrophy, HRD, and RPD were more frequently present in AMD patients > 80 years. Prospective trials with patients converting to NVAMD are required to further analyze morphologic characteristics for early versus late development of advanced AMD.
C1 [Schick, Tina; Ersoy, Lebriz] Univ Cologne, Dept Ophthalmol, Cologne Image Reading Ctr, D-50924 Cologne, Germany.
   [Schick, Tina; Ersoy, Lebriz; Kirchhof, Bernd; Liakopoulos, Sandra] Univ Cologne, Dept Ophthalmol, D-50924 Cologne, Germany.
   [Hoyng, Carel B.] Radboud Univ Nijmegen, Dept Ophthalmol, Med Ctr, NL-6525 ED Nijmegen, Netherlands.
C3 University of Cologne; University of Cologne; Radboud University
   Nijmegen
RP Liakopoulos, S (通讯作者)，Univ Cologne, Dept Ophthalmol, Kerpener Str 62, D-50924 Cologne, Germany.
EM Sandra.liakopoulos@uk-koeln.de
FU Ilse Palm Foundation, Essen, Germany
FX Supported in part by the Ilse Palm Foundation, Essen, Germany.
CR ARNOLD JJ, 1995, RETINA-J RET VIT DIS, V15, P183, DOI 10.1097/00006982-199515030-00001
   Boddu S, 2014, AM J OPHTHALMOL, V157, P985, DOI 10.1016/j.ajo.2014.01.023
   Bolz M, 2009, OPHTHALMOLOGY, V116, P914, DOI 10.1016/j.ophtha.2008.12.039
   Bressler NM, 2011, ARCH OPHTHALMOL-CHIC, V129, P709, DOI 10.1001/archophthalmol.2011.140
   BRESSLER NM, 1995, ARCH OPHTHALMOL-CHIC, V113, P301, DOI 10.1001/archopht.1995.01100030055022
   BURGESS DB, 1993, ARCH OPHTHALMOL-CHIC, V111, P1189
   Chew EY, 2014, JAMA OPHTHALMOL, V132, P272, DOI 10.1001/jamaophthalmol.2013.6636
   Christenbury JG, 2013, OPHTHALMOLOGY, V120, P1038, DOI 10.1016/j.ophtha.2012.10.018
   Coscas G, 2013, OPHTHALMOLOGICA, V229, P32, DOI 10.1159/000342159
   Davis MD, 2005, ARCH OPHTHALMOL-CHIC, V123, P1484
   Ferris FL, 2005, ARCH OPHTHALMOL-CHIC, V123, P1570
   Finger RP, 2014, OPHTHALMOLOGY, V121, P1252, DOI 10.1016/j.ophtha.2013.12.034
   Friberg TR, 2012, INVEST OPHTH VIS SCI, V53, P1742, DOI 10.1167/iovs.11-9338
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P564
   Fritsche LG, 2013, NAT GENET, V45, P433, DOI 10.1038/ng.2578
   Gangnon RE, 2015, JAMA OPHTHALMOL, V133, P125, DOI 10.1001/jamaophthalmol.2014.4252
   Giani A, 2011, INVEST OPHTH VIS SCI, V52, P5579, DOI 10.1167/iovs.10-6617
   GREGOR Z, 1977, BRIT J OPHTHALMOL, V61, P141, DOI 10.1136/bjo.61.2.141
   HUANG D, 1991, SCIENCE, V254, P1178, DOI 10.1126/science.1957169
   Keane PA, 2012, SURV OPHTHALMOL, V57, P389, DOI 10.1016/j.survophthal.2012.01.006
   Klein ML, 2011, ARCH OPHTHALMOL-CHIC, V129, P1543, DOI 10.1001/archophthalmol.2011.216
   Klein R, 2007, OPHTHALMOLOGY, V114, P253, DOI 10.1016/j.ophtha.2006.10.040
   Lechanteur YTE, 2015, JAMA OPHTHALMOL, V133, P533, DOI 10.1001/jamaophthalmol.2015.18
   Maguire MG, 1997, ARCH OPHTHALMOL-CHIC, V115, P741
   Munch IC, 2010, INVEST OPHTH VIS SCI, V51, P2317, DOI 10.1167/iovs.09-4482
   Ouyang YL, 2013, OPHTHALMOLOGY, V120, P2656, DOI 10.1016/j.ophtha.2013.05.029
   Pieramici D J, 1998, Curr Opin Ophthalmol, V9, P38, DOI 10.1097/00055735-199806000-00007
   Pumariega NM, 2011, OPHTHALMOLOGY, V118, P1619, DOI 10.1016/j.ophtha.2011.01.029
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   ROY M, 1990, Eye (London), V4, P813
   Schmitz-Valckenberg S, 2010, OPHTHALMOLOGY, V117, P1169, DOI 10.1016/j.ophtha.2009.10.044
   Schuman SG, 2009, OPHTHALMOLOGY, V116, P488, DOI 10.1016/j.ophtha.2008.10.006
   Silva R, 2011, OPHTHALMOLOGICA, V226, DOI 10.1159/000329473
   Smith W, 2001, OPHTHALMOLOGY, V108, P697, DOI 10.1016/S0161-6420(00)00580-7
   Suzuki M, 2015, RETINA-J RET VIT DIS, V35, P859, DOI 10.1097/IAE.0000000000000503
   Toy BC, 2013, AM J OPHTHALMOL, V156, P532, DOI 10.1016/j.ajo.2013.04.031
   Zweifel SA, 2010, OPHTHALMOLOGY, V117, P1775, DOI 10.1016/j.ophtha.2010.01.027
   Zweifel SA, 2010, OPHTHALMOLOGY, V117, P303, DOI 10.1016/j.ophtha.2009.07.014
NR 38
TC 4
Z9 4
U1 0
U2 1
PU ASSOC RESEARCH VISION OPHTHALMOLOGY INC
PI ROCKVILLE
PA 12300 TWINBROOK PARKWAY, ROCKVILLE, MD 20852-1606 USA
SN 0146-0404
EI 1552-5783
J9 INVEST OPHTH VIS SCI
JI Invest. Ophthalmol. Vis. Sci.
PD NOV
PY 2015
VL 56
IS 12
BP 7269
EP 7273
DI 10.1167/iovs.15-16989
PG 5
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA DB0ZS
UT WOS:000368238200034
PM 26551330
OA Green Published
DA 2022-11-30
ER

PT J
AU Zhang, XY
   Guo, XF
   Zhang, SD
   He, JN
   Sun, CY
   Zou, Y
   Bi, HS
   Qu, Y
AF Zhang, Xiao-Yu
   Guo, Xiao-Fan
   Zhang, Shao-Dan
   He, Jing-Na
   Sun, Cao-Yu
   Zou, Yin
   Bi, Han-Si
   Qu, Yang
TI Comparison of bevacizumab and ranibizumab in age-related macular
   degeneration: a systematic review and meta-analysis
SO INTERNATIONAL JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
DE age-related macular degeneration; bevacizumab; ranibizumab
ID VERTEPORFIN PHOTODYNAMIC THERAPY; INTRAVITREAL BEVACIZUMAB; VISUAL
   IMPAIRMENT; PREVALENCE; INJECTIONS; LUCENTIS; QUALITY; AVASTIN; EVENTS;
   SERIES
AB AIM: To compare the effectiveness and safety between bevacizumab and ranibizumab in the treatment of age-related macular degeneration (AMD) through a systematic review and meta-analysis.
   METHODS: We performed a comprehensive search of randomized controlled trials (RCTs), non -RCTs, case -control and cohort studies that compared bevacizumab and ranibizumab using PubMed and the Cochrane Library. After the related data were extracted by two investigators independently, pooled weighted mean differences (WMDs) and risk ratios (RRs) with 95% confidence intervals (CIs) were estimated using a random-effects or a fixed-effects model.
   RESULTS: A total of four RCTs involving 1927 patients and eleven retrospective case series involving 2296 patients were included. For the primary outcomes, no significant differences were found between ranibizumab group and bevacizumab group in visual acuity (WMD: -0.04; 95% CI: -0.08 to 0.00; P=0.06), best corrected visual acuity (WMD: -0.05; 95%CI: -0.10 to 0.00; P=0.05), retina thickness (WMD: -4.69; 95%Cl: -13.15 to 3.76; P=0.86) and foveal thickness (WMD: 10.91; 95%Cl: -14.73 to 36.56; P=0.40). The pooled analyses in the evaluation of safety showed that compared to bevacizumab, ranibizumab was associated with decreased risks of ocular inflammation (RR: 0.45; 95% CI: 0.23 to 0.89; P=0.02) and venous thrombotic events (RR: 0.27; 95% CI: 0.08 to 0.89; P=0.03). However, there were no significant differences observed in deaths (P=0.69) and arterial thromboembolic events (P =0.71) between the two groups.
   CONCLUSION: With equal clinical efficacy, ranibizumab was found to be associated with less adverse events compared to bevacizumab, indicating that ranibizumab might be a safer management.
C1 [Zhang, Xiao-Yu; Zhang, Shao-Dan; He, Jing-Na; Sun, Cao-Yu; Zou, Yin; Bi, Han-Si; Qu, Yang] Fourth Peoples Hosp Shenyang, Dept Ophthalmol, Shenyang 110031, Liaoning, Peoples R China.
   [Guo, Xiao-Fan] China Med Univ, Hosp 1, Dept Cardiol, Shenyang 110001, Liaoning, Peoples R China.
C3 China Medical University
RP Qu, Y (通讯作者)，Fourth Peoples Hosp Shenyang, Dept Ophthalmol, 20 Huanghe North St, Shenyang 110031, Liaoning, Peoples R China.
EM zxy_sy@hotmail.com
CR Abouammoh M, 2011, CURR OPIN OPHTHALMOL, V22, P152, DOI 10.1097/ICU.0b013e32834595d0
   Bashshur ZF, 2007, ARCH OPHTHALMOL-CHIC, V125, P1357, DOI 10.1001/archopht.125.10.1357
   Bellerive C, 2012, CAN J OPHTHALMOL, V47, P165, DOI 10.1016/j.jcjo.2012.01.011
   Biswas P, 2011, INDIAN J OPHTHALMOL, V59, P191, DOI 10.4103/0301-4738.81023
   Brown DM, 2009, OPHTHALMOLOGY, V116, P57, DOI 10.1016/j.ophtha.2008.10.018
   Carneiro AM, 2011, OPHTHALMOLOGICA, V225, P211, DOI 10.1159/000323943
   Chakravarthy U, 2012, OPHTHALMOLOGY, V119, DOI 10.1016/j.ophtha.2012.04.015
   Chakravarthy U, 2010, BMC OPHTHALMOL, V10, DOI 10.1186/1471-2415-10-31
   Chang TS, 2009, RETINA-J RET VIT DIS, V29, P1235, DOI 10.1097/IAE.0b013e3181b20eed
   Chew EY, 2009, ARCH OPHTHALMOL-CHIC, V127, P1678, DOI 10.1001/archophthalmol.2009.312
   Chou R, 2010, J CLIN EPIDEMIOL, V63, P502, DOI 10.1016/j.jclinepi.2008.06.007
   De Bats F, 2012, J FR OPHTALMOL, V35, P661, DOI 10.1016/j.jfo.2012.01.015
   Emerson MV, 2008, CLIN OPHTHALMOL, V2, P377
   Evans J, 1996, BRIT J OPHTHALMOL, V80, P9, DOI 10.1136/bjo.80.1.9
   Feng XF, 2011, INT J OPHTHALMOL-CHI, V4, P85, DOI 10.3980/j.issn.2222-3959.2011.01.20
   Ferrara N, 2003, NAT MED, V9, P669, DOI 10.1038/nm0603-669
   Fong DS, 2010, OPHTHALMOLOGY, V117, P298, DOI 10.1016/j.ophtha.2009.07.023
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P564
   Gamulescu Maria-Andreea, 2010, International Ophthalmology, V30, P261, DOI 10.1007/s10792-009-9318-7
   Gragoudas ES, 2004, NEW ENGL J MED, V351, P2805, DOI 10.1056/NEJMoa042760
   Harvey KJ, 2011, MED J AUSTRALIA, V194, P567, DOI 10.5694/j.1326-5377.2011.tb03105.x
   Jadad AR, 1996, CONTROL CLIN TRIALS, V17, P1, DOI 10.1016/0197-2456(95)00134-4
   Kliffen M, 1997, BRIT J OPHTHALMOL, V81, P154, DOI 10.1136/bjo.81.2.154
   Kroll P, 2006, BRIT J OPHTHALMOL, V90, P128, DOI 10.1136/bjo.2005.083337
   Ladas ID, 2009, RETINA-J RET VIT DIS, V29, P313, DOI 10.1097/IAE.0b013e31819a5f98
   Landa G, 2009, OPHTHALMOLOGICA, V223, P370, DOI 10.1159/000227783
   Lazic R, 2007, OPHTHALMOLOGY, V114, P1179, DOI 10.1016/j.ophtha.2007.03.006
   Magdelaine-Beuzelin C, 2010, MABS-AUSTIN, V2, P176, DOI 10.4161/mabs.2.2.11205
   Martin DF, 2012, OPHTHALMOLOGY, V119, DOI 10.1016/j.ophtha.2012.03.053
   Martin DF, 2011, NEW ENGL J MED, V364, P1897, DOI 10.1056/NEJMoa1102673
   Martínez-Carpio P.A., 2008, Arch Soc Esp Oftalmol, V83, P579
   Mir O, 2012, INVEST NEW DRUG, V30, P1756, DOI 10.1007/s10637-011-9690-9
   Niederhauser N, 2013, KLIN MONATSBL AUGENH, V230, P405, DOI 10.1055/s-0032-1328373
   Resnikoff S, 2004, B WORLD HEALTH ORGAN, V82, P844
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Rosenfeld PJ, 2005, OPHTHAL SURG LAS IM, V36, P331, DOI 10.3928/1542-8877-20050701-14
   Schmucker C, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0042701
   Schmucker C, 2010, CURR OPIN OPHTHALMOL, V21, P218, DOI 10.1097/ICU.0b013e3283386783
   Shah AR, 2009, BR J OPHTHALMOL, V93, P1027
   Sharma S, 2012, CAN J OPHTHALMOL, V47, P275, DOI 10.1016/j.jcjo.2012.03.026
   Singer MA, 2013, CLIN OPHTHALMOL, V7, P1377, DOI 10.2147/OPTH.S46235
   Stang A, 2010, EUR J EPIDEMIOL, V25, P603, DOI 10.1007/s10654-010-9491-z
   Steinbrook R, 2006, NEW ENGL J MED, V355, P1409, DOI 10.1056/NEJMp068185
   Subramanian ML, 2010, EYE, V24, P1708, DOI 10.1038/eye.2010.147
   Van der Reis MI, 2011, RETINA-J RET VIT DIS, V31, P1449, DOI 10.1097/IAE.0b013e3182278ab4
   VanNewkirk MR, 2001, OPHTHALMOLOGY, V108, P960, DOI 10.1016/S0161-6420(01)00554-1
   Yeung YA, 2010, CANCER RES, V70, P3269, DOI 10.1158/0008-5472.CAN-09-4580
   Zou LH, 2011, THERANOSTICS, V1, P395, DOI 10.7150/thno/v01p0395
NR 48
TC 20
Z9 20
U1 0
U2 19
PU IJO PRESS
PI XI AN
PA NO 269 YOUYI EAST RD, XI AN, 710054, PEOPLES R CHINA
SN 2222-3959
EI 2227-4898
J9 INT J OPHTHALMOL-CHI
JI Int. J. Ophthalmol.
PD APR 18
PY 2014
VL 7
IS 2
BP 355
EP 364
DI 10.3980/j.issn.2222-3959.2014.02.30
PG 10
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA AF4BI
UT WOS:000334656000030
PM 24790885
DA 2022-11-30
ER

PT J
AU Forshaw, TRJ
   Subhi, Y
   Andreasson, S
   Sorensen, TL
AF Forshaw, Thomas Richard Johansen
   Subhi, Yousif
   Andreasson, Sten
   Sorensen, Torben Lykke
TI Full-Field Electroretinography Changes Associated with Age-Related
   Macular Degeneration: A Systematic Review with Meta-Analyses
SO OPHTHALMOLOGICA
LA English
DT Review
DE Age-related macular degeneration; Full-field electroretinography;
   Functional testing; Peripheral retina
ID PHOTORECEPTOR DEGENERATION; DARK-ADAPTATION; MACULOPATHY; ACTIVATION
AB Background: The aim of this study was to systematically review the literature and to perform meta-analyses on full-field electroretinography (ffERG) between healthy controls and age-related macular degeneration (AMD) to map the extent of retinal dysfunction. Summary: We systematically searched 11 databases on 3 March 2021. Eligible studies had to measure retinal function using ffERG in eyes with AMD and in healthy controls. We extracted data on a-wave and b-wave function in dark- and light-adapted ffERG and calculated summary estimates on differences between eyes with AMD and controls using weighted mean differences (WMD). Subgroup analyses were made for early and late AMD. Six studies (n = 481 eyes) were eligible for review (301 with any AMD, 180 controls). For dark-adapted data, any AMD was associated with reduced a-wave amplitude (WMD: -17.16 mu V; 95% CI: -31.79 to -2.52 mu V; p = 0.02) and b-wave amplitude (WMD: -28.70 mu V; 95% CI: -51.40 to -6.01 mu V; p = 0.01). For light-adapted data, any AMD was associated with longer a-wave implicit time (WMD: 0.92 ms; 95% CI: 0.12-1.72 ms; p = 0.02), reduced b-wave amplitude (WMD: -13.26 mu V; 95% CI: -18.64 to -7.88 mu V; p < 0.0001), and longer b-wave implicit time (WMD: 0.69 ms; 95% CI: 0.30-1.08 ms; p = 0.0006). Subgroup analyses found that these changes were only statistically significant in eyes with late AMD, not early AMD. Key Messages: Reduced retinal function on ffERG is present in eyes with AMD, in particular those with late AMD. These findings suggest that AMD is a pan-retinal disease with AMD-associated photoreceptor dysfunction beyond the macula.
C1 [Forshaw, Thomas Richard Johansen; Subhi, Yousif; Sorensen, Torben Lykke] Zealand Univ Hosp, Dept Ophthalmol, Roskilde, Denmark.
   [Forshaw, Thomas Richard Johansen; Subhi, Yousif] Rigshosp Glostrup, Dept Ophthalmol, Glostrup, Denmark.
   [Andreasson, Sten] Lund Univ, Dept Ophthalmol, Lund, Sweden.
   [Sorensen, Torben Lykke] Univ Copenhagen, Dept Clin Med, Copenhagen, Denmark.
C3 Lund University; University of Copenhagen
RP Forshaw, TRJ (通讯作者)，Zealand Univ Hosp, Dept Ophthalmol, Roskilde, Denmark.; Forshaw, TRJ (通讯作者)，Rigshosp Glostrup, Dept Ophthalmol, Glostrup, Denmark.
EM forshawthomas@yahoo.co.uk
RI Subhi, Yousif/ABG-6330-2020; Forshaw, Thomas Richard
   Johansen/AGF-9674-2022
OI Subhi, Yousif/0000-0001-6620-5365; Forshaw, Thomas Richard
   Johansen/0000-0003-0667-6514
CR Binns AM, 2007, INVEST OPHTH VIS SCI, V48, P2806, DOI 10.1167/iovs.06-0392
   Curcio CA, 1996, INVEST OPHTH VIS SCI, V37, P1236
   Dimopoulos IS, 2013, INVEST OPHTH VIS SCI, V54, P5186, DOI 10.1167/iovs.13-12194
   Forshaw TRJ, 2021, ACTA OPHTHALMOL, V99, pE253, DOI 10.1111/aos.14571
   Forshaw TRJ, 2019, OPHTHALMOL RETINA, V3, P734, DOI 10.1016/j.oret.2019.04.014
   Jackson GR, 2004, INVEST OPHTH VIS SCI, V45, P3271, DOI 10.1167/iovs.04-0019
   Jackson GR, 2002, AGEING RES REV, V1, P381, DOI 10.1016/S1568-1637(02)00007-7
   Luu CD, 2018, OPHTHALMOL RETINA, V2, P1206, DOI 10.1016/j.oret.2018.06.016
   McCannel CA., 2019, 2019 2020 BASIC CLIN, P41
   McCulloch DL, 2015, DOC OPHTHALMOL, V130, P1, DOI 10.1007/s10633-014-9473-7
   Moher D, 2009, BMJ-BRIT MED J, V339, DOI [10.1186/2046-4053-4-1, 10.1136/bmj.b2535, 10.1136/bmj.i4086]
   Pfau M, 2020, JAMA OPHTHALMOL, V138, P1026, DOI 10.1001/jamaophthalmol.2020.2914
   Quinn N, 2019, PROG RETIN EYE RES, V68, P83, DOI 10.1016/j.preteyeres.2018.10.001
   Reiter GS, 2020, INVEST OPHTH VIS SCI, V61, DOI 10.1167/iovs.61.6.11
   Ronan Shawn, 2006, Trans Am Ophthalmol Soc, V104, P232
   Sorensen MS, 2011, DAN MED BULL, V58
   Stroup DF, 2000, JAMA-J AM MED ASSOC, V283, P2008, DOI 10.1001/jama.283.15.2008
   Tarsilla M., 2010, COCHRANE HDB SYSTEMA, V6, P142, DOI [DOI 10.1002/9781119536604, 10.1002/9781119536604.ch23]
   Walter P, 1999, GRAEF ARCH CLIN EXP, V237, P962, DOI 10.1007/s004170050331
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
   Zeng Xiantao, 2015, J Evid Based Med, V8, P2, DOI 10.1111/jebm.12141
NR 21
TC 0
Z9 0
U1 0
U2 0
PU KARGER
PI BASEL
PA ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND
SN 0030-3755
EI 1423-0267
J9 OPHTHALMOLOGICA
JI Ophthalmologica
PD JUN
PY 2022
VL 245
IS 3
BP 195
EP 203
DI 10.1159/000521834
PG 9
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 3E9GV
UT WOS:000830285800001
PM 35016191
OA Bronze
DA 2022-11-30
ER

PT J
AU Li, JQ
   Welchowski, T
   Schmid, M
   Mauschitz, MM
   Holz, FG
   Finger, RP
AF Li, Jeany Q.
   Welchowski, Thomas
   Schmid, Matthias
   Mauschitz, Matthias Marten
   Holz, Frank G.
   Finger, Robert P.
TI Prevalence and incidence of age-related macular degeneration in Europe:
   a systematic review and meta-analysis
SO BRITISH JOURNAL OF OPHTHALMOLOGY
LA English
DT Review
DE epidemiology; macula; retina
ID RISK-FACTORS; MACULOPATHY; POPULATION; EYE; CLASSIFICATION; PROGRESSION;
   DISEASE
AB Background/Aims
   Age-related macular degeneration (AMD) is the main cause of visual impairment and blindness in Europe. A further increase in the number of affected persons is expected and current European data are needed for healthcare resource planning.
   Methods
   We performed a systematic review on the prevalence and incidence of AMD based on the meta-analysis of observational studies in epidemiology guideline. Meta-analysis and meta-regression on time-trends, age, countries, regions, sex and classification systems for AMD were performed. Based on Eurostat population projections, the pooled prevalence estimates were extrapolated to the year 2050.
   Results
   Twenty-two prevalence and four incidence studies published since 1996 were included. Our pooled prevalence estimate of early or intermediate AMD and any late AMD in those 60 years and older was 25.3% (95% CI 18.0% to 34.4%) and 2.4% (95% CI 1.8% to 3.3%), respectively. A significant increase in prevalence was seen in older populations. In the meta-analysis of incidence, the pooled annual incidence of any late AMD was 1.4 per 1 000 individuals (95% CI 0.8 to 2.6). Overall, the number of EU inhabitants with any AMD is expected to increase from 67 to 77 million until 2050. Incident late AMD is estimated to increase from 400 000 per year today to 700 000 per year in 2050.
   Conclusions
   Approximately 67 million people in the EU are currently affected by any AMD and, due to population ageing, this number is expected to increase by 15% until 2050. Monitoring and treatment of people with advanced disease stages will require additional healthcare resources and thorough healthcare planning in the years and decades to come.
C1 [Li, Jeany Q.; Mauschitz, Matthias Marten; Holz, Frank G.; Finger, Robert P.] Univ Bonn, Dept Ophthalmol, D-53127 Bonn, Germany.
   [Welchowski, Thomas; Schmid, Matthias] Univ Bonn, Dept Med Biometry Informat & Epidemiol, Bonn, Germany.
C3 University of Bonn; University of Bonn
RP Finger, RP (通讯作者)，Univ Bonn, Dept Ophthalmol, D-53127 Bonn, Germany.
EM Robert.Finger@ukbonn.de
OI Welchowski, Thomas/0000-0003-2940-647X; Schmid,
   Matthias/0000-0002-0788-0317
FU European Society of Retina Specialists (EURETINA) project grant;
   Jackstaedt Stiftung; Else Kroehner Fresenius
FX European Society of Retina Specialists (EURETINA) project grant, the
   Jackstaedt Stiftung and the Else Kroehner Fresenius.
CR Akuffo KO, 2015, BRIT J OPHTHALMOL, V99, P1037, DOI 10.1136/bjophthalmol-2014-305768
   Augood CA, 2006, ARCH OPHTHALMOL-CHIC, V124, P529, DOI 10.1001/archopht.124.4.529
   BIRD AEC, 1995, SURV OPHTHALMOL, V39, P367, DOI 10.1016/S0039-6257(05)80092-X
   Bjornsson OM, 2006, ACTA OPHTHALMOL SCAN, V84, P636, DOI 10.1111/j.1600-0420.2006.00696.x
   Brandl C, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-26629-5
   Brandl C, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0167181
   Brandll C, 2016, ACTA OPHTHALMOL, V94, DOI 10.1111/j.1755-3768.2016.0297
   Buch H, 2005, OPHTHALMOLOGY, V112, P787, DOI 10.1016/j.ophtha.2004.11.040
   Cachulo MD, 2015, OPHTHALMOLOGICA, V233, P119, DOI 10.1159/000371584
   Casaroli-Marano R, 2011, BRIT J OPHTHALMOL, V95, P931, DOI 10.1136/bjo.2010.187773
   COCHRAN WG, 1950, BIOMETRIKA, V37, P256, DOI 10.1093/biomet/37.3-4.256
   Colijn JM, 2017, OPHTHALMOLOGY, V124, P1753, DOI 10.1016/j.ophtha.2017.05.035
   Creuzot-Garcher C, 2016, ACTA OPHTHALMOL, V94, pE90, DOI 10.1111/aos.12842
   de LA, 2015, ACTA OPHTHALMOL, P93
   Delcourt C, 2005, AM J OPHTHALMOL, V140, P924, DOI 10.1016/j.ajo.2005.05.002
   Delcourt C, 1998, ARCH OPHTHALMOL-CHIC, V116, P1031, DOI 10.1001/archopht.116.8.1031
   Delcourt C, 2010, J NUTR HEALTH AGING, V14, P854, DOI 10.1007/s12603-010-0131-9
   Downie LE, 2018, JAMA OPHTHALMOL, V136, P1051, DOI 10.1001/jamaophthalmol.2018.2620
   Erke MG, 2012, OPHTHALMOLOGY, V119, P1737, DOI 10.1016/j.ophtha.2012.03.016
   Eurostat, 2016, POPULATION PROJECTIO
   Ferris FL, 2013, OPHTHALMOLOGY, V120, P844, DOI 10.1016/j.ophtha.2012.10.036
   Higgins JPT, 2002, STAT MED, V21, P1539, DOI 10.1002/sim.1186
   Hirvela H, 1996, OPHTHALMOLOGY, V103, P871, DOI 10.1016/S0161-6420(96)30593-9
   Jonasson F, 2005, OPHTHALMOLOGY, V112, P132, DOI 10.1016/j.ophtha.2004.07.020
   Jonasson F, 2011, OPHTHALMOLOGY, V118, P825, DOI 10.1016/j.ophtha.2010.08.044
   JQ L, 2018, OPHTHALMOLOGICA, P1
   Klaver CCW, 2001, INVEST OPHTH VIS SCI, V42, P2237
   Klein R, 2006, OPHTHALMOLOGY, V113, P373, DOI 10.1016/j.ophtha.2005.12.013
   Klein R, 2014, AM J OPHTHALMOL, V158, P513, DOI 10.1016/j.ajo.2014.05.027
   Klein R, 2014, OPHTHAL EPIDEMIOL, V21, P14, DOI 10.3109/09286586.2013.867512
   Korb CA, 2014, GRAEF ARCH CLIN EXP, V252, P1403, DOI 10.1007/s00417-014-2591-9
   Kozobolis VP, 1999, ARCH OPHTHALMOL-CHIC, V117, P664
   Krasnik V, 2018, SEMIN OPHTHALMOL, V33, P506, DOI 10.1080/08820538.2017.1316861
   Lewis, 1982, PRIMARY CARDIOLOGY S, P31
   Meurer P, 2015, WISSENSCHAFTLICHES A
   Moher David, 2009, BMJ, V339, pb2535, DOI [10.1016/j.ijsu.2010.02.007, 10.1136/bmj.b2535]
   Pagliarini S, 1997, ARCH OPHTHALMOL-CHIC, V115, P616, DOI 10.1001/archopht.1997.01100150618007
   Peters JL, 2006, JAMA-J AM MED ASSOC, V295, P676, DOI 10.1001/jama.295.6.676
   Piermarocchi S, 2011, OPHTHAL EPIDEMIOL, V18, P129, DOI 10.3109/09286586.2011.574334
   Rudnicka AR, 2015, AM J OPHTHALMOL, V160, P85, DOI 10.1016/j.ajo.2015.04.003
   Rudnicka AR, 2012, OPHTHALMOLOGY, V119, P571, DOI 10.1016/j.ophtha.2011.09.027
   Saunier V, 2018, JAMA OPHTHALMOL, V136, P473, DOI 10.1001/jamaophthalmol.2018.0504
   Schwarzer G., 2007, R NEWS, V7, P40, DOI DOI 10.1007/978-3-319-21416-0
   Stroup DF, 2000, JAMA-J AM MED ASSOC, V283, P2008, DOI 10.1001/jama.283.15.2008
   Team RC, 2013, R LANG ENV STAT COMP
   Topouzis F, 2006, AM J OPHTHALMOL, V142, P1076, DOI 10.1016/j.ajo.2006.07.042
   Viechtbauer W, 2010, J STAT SOFTW, V36, P1, DOI 10.18637/jss.v036.i03
   VINGERLING JR, 1995, OPHTHALMOLOGY, V102, P205
   WHO, 2011, GLOBAL HLTH AGING
   Wilde C, 2017, EYE, V31, P1042, DOI 10.1038/eye.2017.30
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
   Yip JLY, 2015, PUBLIC HEALTH, V129, P103, DOI 10.1016/j.puhe.2014.10.012
NR 52
TC 74
Z9 77
U1 4
U2 18
PU BMJ PUBLISHING GROUP
PI LONDON
PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND
SN 0007-1161
EI 1468-2079
J9 BRIT J OPHTHALMOL
JI Br. J. Ophthalmol.
PD AUG
PY 2020
VL 104
IS 8
BP 1077
EP 1084
DI 10.1136/bjophthalmol-2019-314422
PG 8
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA PK2OA
UT WOS:000602289600009
PM 31712255
DA 2022-11-30
ER

PT J
AU Braimah, IZ
   Agarwal, K
   Mansour, A
   Chhablani, J
AF Braimah, Imoro Zeba
   Agarwal, Komal
   Mansour, Ahmad
   Chhablani, Jay
CA Ziv-Aflibercept Study Grp
TI One-year outcome of intravitreal ziv-aflibercept therapy for
   non-responsive neovascular age-related macular degeneration
SO BRITISH JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
ID ENDOTHELIAL GROWTH-FACTOR; RANIBIZUMAB; BEVACIZUMAB; RESISTANT; EYES;
   TACHYPHYLAXIS; CONVERSION; SAFETY
AB Aim To evaluate 12-month outcome of intravitreal ziv-aflibercept (IVZ) therapy in eyes with neovascular age-related macular degeneration (nAMD) that are non-responsive to bevacizumab and ranibizumab.
   Methods This retrospective study included 16 eyes (14 patients) with nAMD who were on prior treatment with bevacizumab and ranibizumab and were treated with as-needed IVZ (1.25 mg/0.05 mL) for 12 months. The primary outcome measure was the mean change in best corrected visual acuity (BCVA) and secondary outcome measures included mean change in central macular thickness (CMT), retinal pigment epithelial detachment (RPED) heights, longest treatment free interval, presence of subretinal fluid (SRF) and intraretinal fluid (IRF) and adverse events.
   Results There was no change in the mean logarithm of minimum angle of resolution (logMAR) BCVA at baseline and following treatment with IVZ therapy (p=0.978). The mean number of IVZ injections during 12 months was 5.9 +/- 3.3, and the mean number of antivascular endothelial growth factors (VEGFs) injections prior to switching to IVZ was 8.4 +/- 4.7. The mean treatment free interval was longer during IVZ therapy (114.4 +/- 67.1 days) compared with 76.3 +/- 54.6 days before IVZ therapy (p=0.03). Five (31.25%) eyes had visual gains of at least 0.1 logMAR, 3 (18.75%) eyes had stable BCVA (within 0.1 logMAR) and 8 (50%) eyes had BCVA decline of at least 0.1 logMAR. There was no significant difference in the mean CMT, RPED heights and presence of IRF and SRF at 12 months compared with baseline. No adverse events were noted.
   Conclusion IVZ increased the treatment free interval in non-responders but no significant change in visual and anatomic outcomes.
C1 [Braimah, Imoro Zeba] Univ Ghana, Coll Hlth Sci, Sch Med & Dent, Accra, Ghana.
   [Braimah, Imoro Zeba; Agarwal, Komal; Chhablani, Jay] LV Prasad Eye Inst, Srimati Kanuri Santhamma Ctr Vitreo Retinal Dis, KAR Campus, Hyderabad, Telangana, India.
   [Mansour, Ahmad] Amer Univ Beirut, Dept Ophthalmol, Beirut, Lebanon.
   [Mansour, Ahmad] Rafic Hariri Univ Hosp, Dept Ophthalmol, Beirut, Lebanon.
C3 University of Ghana; L. V. Prasad Eye Institute; American University of
   Beirut; American University of Beirut
RP Chhablani, J (通讯作者)，LV Prasad Eye Inst, Banjara Hills,Rd 2, Hyderabad 500034, Andhra Pradesh, India.
EM jay.chhablani@gmail.com
RI Braimah, Imoro Zeba/ABB-2168-2020
OI Braimah, Imoro Zeba/0000-0002-2573-9026
CR Aghdam KA, 2016, EUR J OPHTHALMOL, V26, P473, DOI 10.5301/ejo.5000757
   Amoaku WM, 2015, EYE, V29, P721, DOI 10.1038/eye.2015.48
   Bakall B, 2013, AM J OPHTHALMOL, V156, P15, DOI 10.1016/j.ajo.2013.02.017
   Broadhead GK, 2015, RETINA-J RET VIT DIS, V35, P975, DOI 10.1097/IAE.0000000000000409
   Chan Clement K, 2014, Trans Am Ophthalmol Soc, V112, P160
   Chang AA, 2016, OPHTHALMIC RES, V55, P84, DOI 10.1159/000440886
   Chang AA, 2014, OPHTHALMOLOGY, V121, P188, DOI 10.1016/j.ophtha.2013.08.035
   Chhablani J, 2016, RETINA-J RET VIT DIS, V36, P1126, DOI 10.1097/IAE.0000000000000913
   Chin-Yee D, 2016, BR J OPHTHALMOL, V100
   Eghoj MS, 2012, BRIT J OPHTHALMOL, V96, P21, DOI 10.1136/bjo.2011.203893
   Gasperini JL, 2012, BRIT J OPHTHALMOL, V96, P14, DOI 10.1136/bjo.2011.204685
   Gharbiya M, 2014, BIOMED RES INT, V2014, P1
   Gokce G, 2016, ARQ BRAS OFTALMOL, V79, P384, DOI 10.5935/0004-2749.20160109
   Hariri A, 2015, OSLI RETINA, V46, P195, DOI 10.3928/23258160-20150213-18
   Hatz K, 2017, RETINA-J RET VIT DIS, V37, P1185, DOI 10.1097/IAE.0000000000001318
   Ho VY, 2013, AM J OPHTHALMOL, V156, P23, DOI 10.1016/j.ajo.2013.02.009
   Kanesa-Thasan A, 2015, OSLI RETINA, V46, P638, DOI 10.3928/23258160-20150610-07
   Krebs I, 2013, BRIT J OPHTHALMOL, V97, P1443, DOI 10.1136/bjophthalmol-2013-303513
   Mansour AM, 2016, BRIT J OPHTHALMOL, V100, P1629, DOI 10.1136/bjophthalmol-2015-308319
   Mansour AM, 2015, BRIT J OPHTHALMOL, V99, P1055, DOI 10.1136/bjophthalmol-2014-306319
   Nagai N, 2016, SCI REP-UK, V6, DOI 10.1038/srep29619
   Patel KH, 2013, EYE, V27, P664, DOI 10.1038/eye.2013.31
   Pfau M, 2016, KLIN MONATSBL AUGENH, V233, P945, DOI 10.1055/s-0042-101348
   Seguin-Greenstein S, 2016, J OPHTHALMOL, V2016, DOI 10.1155/2016/4095852
   Singh RP, 2015, CLIN OPHTHALMOL, V9, P1759, DOI 10.2147/OPTH.S87043
   Suzuki M, 2014, BRIT J OPHTHALMOL, V98, P1186, DOI 10.1136/bjophthalmol-2013-304670
   Yonekawa Y, 2013, AM J OPHTHALMOL, V156, P29, DOI 10.1016/j.ajo.2013.03.030
NR 27
TC 6
Z9 6
U1 0
U2 2
PU BMJ PUBLISHING GROUP
PI LONDON
PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND
SN 0007-1161
EI 1468-2079
J9 BRIT J OPHTHALMOL
JI Br. J. Ophthalmol.
PD JAN
PY 2018
VL 102
IS 1
BP 91
EP 96
DI 10.1136/bjophthalmol-2017-310318
PG 6
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA FQ2NY
UT WOS:000418194700017
PM 28596286
DA 2022-11-30
ER

PT J
AU Grisanti, S
   Tatar, O
AF Grisanti, Salvatore
   Tatar, Olcay
TI The role of vascular endothelial growth factor and other endogenous
   interplayers in age-related macular degeneration
SO PROGRESS IN RETINAL AND EYE RESEARCH
LA English
DT Review
DE age-related macular degeneration; vascular endothelial growth factor;
   angiogenesis
ID CHOROIDAL NEOVASCULAR MEMBRANES; EPITHELIUM-DERIVED FACTOR; VERTEPORFIN
   PHOTODYNAMIC THERAPY; RETINAL-PIGMENT EPITHELIUM; RECEPTOR-BINDING
   PROPERTIES; PERMEABILITY FACTOR; MATRIX METALLOPROTEINASES; BRUCHS
   MEMBRANE; FACTOR EXPRESSION; FACTOR VEGF
AB Age-related macular degeneration (AMD) is a multifaceted disease characterized by early subclinical changes at the choroidea-retinal pigment epithelium interface. Both the causal and formal pathogenesis of the disease is still puzzling. Similarly, the reason for progression into two distinct late forms which are "geographic atrophy" and "choroidal neovascularization" remains enigmatic. Late changes are usually responsible for the dramatic loss in central function that has a devastating effect on quality of life.
   In industrialized countries the disease is a major cause for visual disability among persons over 60 years of age. Due to demographic right-shift and increased life expectancy, AMD is not only a medical problem but will have a pronounced socio-economic effect.
   Neovascular AMD with the development of choroidal neovascularization in the macular area accounts for 80% of the severe loss of visual acuity due to AMD. In the last decades, treatment modes were merely based on the destruction or surgical removal of the neovascular complex. In the present, however, the philosophical approach to treat the disease is changing to a pathology modifying manner. Intelligent targeting of the involved relevant factors and pathways should stop disease progression, reduce complications and improve vision. The first step into this new era has been accomplished with the introduction of antiangiogenic agents. The new agents act either directly on vascular endothelial growth factor (VEGF) or indirectly on its functional cascade.
   VEGF makes a fundamental contribution to neovascular processes but it also acts in physiological pathways. The main purpose of this review is to summarize its physiological role especially within the eye, the role in the development of AMD and to understand and foresee both the benefits and potential side-effects of the anti-VEGF-based therapy. (C) 2008 Elsevier Ltd. All rights reserved.
C1 [Grisanti, Salvatore] Univ Lubeck, Dept Ophthalmol, D-23538 Lubeck, Germany.
   [Tatar, Olcay] Univ Tubingen, Dept Ophthalmol, D-72076 Tubingen, Germany.
C3 University of Lubeck; Eberhard Karls University of Tubingen; Eberhard
   Karls University Hospital
RP Grisanti, S (通讯作者)，Univ Lubeck, Dept Ophthalmol, Ratzeburger Allee 160, D-23538 Lubeck, Germany.
EM Salvatore.Grisanti@uk-sh.de
CR Abdollahi A, 2003, CANCER RES, V63, P8890
   Achen MG, 1998, P NATL ACAD SCI USA, V95, P548, DOI 10.1073/pnas.95.2.548
   Adamis AP, 1996, ARCH OPHTHALMOL-CHIC, V114, P66, DOI 10.1001/archopht.1996.01100130062010
   ADAMIS AP, 1993, BIOCHEM BIOPH RES CO, V193, P631, DOI 10.1006/bbrc.1993.1671
   AIELLO LP, 1995, P NATL ACAD SCI USA, V92, P10457, DOI 10.1073/pnas.92.23.10457
   Amano S, 1998, INVEST OPHTH VIS SCI, V39, P18
   Ambati J, 2003, SURV OPHTHALMOL, V48, P257, DOI 10.1016/S0039-6257(03)00030-4
   Ambili M, 1998, BBA-MOL CELL RES, V1403, P219, DOI 10.1016/S0167-4889(98)00030-5
   AMIN R, 1994, INVEST OPHTH VIS SCI, V35, P3178
   Anderson DH, 2002, AM J OPHTHALMOL, V134, P411, DOI 10.1016/S0002-9394(02)01624-0
   Anderson DH, 2001, AM J OPHTHALMOL, V131, P767, DOI 10.1016/S0002-9394(00)00961-2
   Arras M, 1998, J CLIN INVEST, V101, P40, DOI 10.1172/JCI119877
   Auricchio A, 2002, MOL THER, V6, P490, DOI 10.1006/mthe.2002.0702
   Balaggan KS, 2006, GENE THER, V13, P1153, DOI 10.1038/sj.gt.3302769
   Bates DO, 2002, CANCER RES, V62, P4123
   Beatty S, 2000, SURV OPHTHALMOL, V45, P115, DOI 10.1016/S0039-6257(00)00140-5
   BENEZRA D, 1990, ARCH OPHTHALMOL-CHIC, V108, P573, DOI 10.1001/archopht.1990.01070060121061
   Berglin L, 2003, INVEST OPHTH VIS SCI, V44, P403, DOI 10.1167/iovs.02-0180
   Bhutto IA, 2006, EXP EYE RES, V82, P99, DOI 10.1016/j.exer.2005.05.007
   Bhutto IA, 2004, INVEST OPHTH VIS SCI, V45, P1544, DOI 10.1167/iovs.03-0862
   Blaauwgeers HGT, 1999, AM J PATHOL, V155, P421, DOI 10.1016/S0002-9440(10)65138-3
   Bok D, 2005, P NATL ACAD SCI USA, V102, P7053, DOI 10.1073/pnas.0502819102
   Bora PS, 2005, J IMMUNOL, V174, P491, DOI 10.4049/jimmunol.174.1.491
   BRESSLER NM, 1994, RETINA-J RET VIT DIS, V14, P130, DOI 10.1097/00006982-199414020-00006
   Bressler NM, 2000, INVEST OPHTH VIS SCI, V41, P624
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Campochiaro PA, 2000, J CELL PHYSIOL, V184, P301, DOI 10.1002/1097-4652(200009)184:3<301::AID-JCP3>3.0.CO;2-H
   Campochiaro PA, 2004, EXPERT OPIN BIOL TH, V4, P1395, DOI 10.1517/14712598.4.9.1395
   Carmeliet P, 1996, NATURE, V380, P435, DOI 10.1038/380435a0
   CLAUSS M, 1990, J EXP MED, V172, P1535, DOI 10.1084/jem.172.6.1535
   Cohen T, 1996, J BIOL CHEM, V271, P736, DOI 10.1074/jbc.271.2.736
   CONNOLLY DT, 1989, J CLIN INVEST, V84, P1470, DOI 10.1172/JCI114322
   CONNOLLY DT, 1989, J BIOL CHEM, V264, P20017
   Cousins SW, 2004, ARCH OPHTHALMOL-CHIC, V122, P1013, DOI 10.1001/archopht.122.7.1013
   Crowther M, 2001, J LEUKOCYTE BIOL, V70, P478
   Cui JZ, 2000, GRAEF ARCH CLIN EXP, V238, P326, DOI 10.1007/s004170050360
   Curcio CA, 2001, EYE, V15, P376, DOI 10.1038/eye.2001.140
   Curcio CA, 1999, ARCH OPHTHALMOL-CHIC, V117, P329, DOI 10.1001/archopht.117.3.329
   DAMORE PA, 1994, INVEST OPHTH VIS SCI, V35, P3974
   DAS A, 1992, OPHTHALMOLOGY, V99, P1368
   Das A, 2003, PROG RETIN EYE RES, V22, P721, DOI 10.1016/j.preteyeres.2003.08.001
   DASTGHEIB K, 1994, ARCH OPHTHALMOL-CHIC, V112, P813, DOI 10.1001/archopht.1994.01090180111045
   Davis GE, 2001, J CELL SCI, V114, P917
   Dawson DW, 1999, SCIENCE, V285, P245, DOI 10.1126/science.285.5425.245
   DIPIETRO LA, 1993, BEHR INST MITT, V92, P238
   Dobryansky M, 2004, ANN PLAS SURG, V52, P512, DOI 10.1097/01.sap.0000123022.98361.c5
   DOREY CK, 1989, INVEST OPHTH VIS SCI, V30, P1691
   Duncan WC, 1998, J CLIN ENDOCR METAB, V83, P2470, DOI 10.1210/jc.83.7.2470
   Dunlop AAS, 1998, ARCH OPHTHALMOL-CHIC, V116, P801, DOI 10.1001/archopht.116.6.801
   DVORAK HF, 1995, AM J PATHOL, V146, P1029
   El Bradey M, 2004, J OCUL PHARMACOL TH, V20, P217, DOI 10.1089/1080768041223657
   Emerson MV, 2007, BIODRUGS, V21, P245, DOI 10.2165/00063030-200721040-00005
   Ergun S, 2001, ANGIOGENESIS, V4, P193, DOI DOI 10.1023/A:1014027218980
   Eriksson K, 2003, FEBS LETT, V536, P19, DOI 10.1016/S0014-5793(03)00003-6
   Eriksson U, 1999, CURR TOP MICROBIOL, V237, P41
   Espinosa-Heidmann DG, 2003, INVEST OPHTH VIS SCI, V44, P3586, DOI 10.1167/iovs.03-0038
   FEENEYBURNS L, 1985, AM J OPHTHALMOL, V100, P686, DOI 10.1016/0002-9394(85)90625-7
   FEENEYBURNS L, 1984, INVEST OPHTH VIS SCI, V25, P195
   Feiner L, 2006, RETINA-J RET VIT DIS, V26, P882, DOI 10.1097/01.iae.0000230717.85319.f5
   Ferrara N, 2004, ENDOCR REV, V25, P581, DOI 10.1210/er.2003-0027
   FERRARA N, 1989, BIOCHEM BIOPH RES CO, V161, P851, DOI 10.1016/0006-291X(89)92678-8
   Ferrara N, 2003, NAT MED, V9, P669, DOI 10.1038/nm0603-669
   Ferrara N, 1996, NATURE, V380, P439, DOI 10.1038/380439a0
   Ferrara N, 1999, CURR TOP MICROBIOL, V237, P1
   Ferreras M, 2000, FEBS LETT, V486, P247, DOI 10.1016/S0014-5793(00)02249-3
   Finnemann SC, 2002, P NATL ACAD SCI USA, V99, P3842, DOI 10.1073/pnas.052025899
   Folkman J, 2004, APMIS, V112, P496, DOI 10.1111/j.1600-0463.2004.apm11207-0809.x
   Frank RN, 1996, AM J OPHTHALMOL, V122, P393, DOI 10.1016/S0002-9394(14)72066-5
   Friedman E, 1997, AM J OPHTHALMOL, V124, P677, DOI 10.1016/S0002-9394(14)70906-7
   Friedman E, 2000, AM J OPHTHALMOL, V130, P658, DOI 10.1016/S0002-9394(00)00643-7
   Fukai N, 2002, EMBO J, V21, P1535, DOI 10.1093/emboj/21.7.1535
   GASS JDM, 1973, ARCH OPHTHALMOL-CHIC, V90, P206
   Gelisken F, 2004, BRIT J OPHTHALMOL, V88, P207, DOI 10.1136/bjo.2003.018754
   Ghazi NG, 2001, RETINA-J RET VIT DIS, V21, P478, DOI 10.1097/00006982-200110000-00010
   Gilbert RE, 1998, LAB INVEST, V78, P1017
   Gillitzer R, 2001, J LEUKOCYTE BIOL, V69, P513
   Gollnick SO, 2003, BRIT J CANCER, V88, P1772, DOI 10.1038/sj.bjc.6600864
   Gollnick SO, 1997, CANCER RES, V57, P3904
   Gragoudas ES, 2004, NEW ENGL J MED, V351, P2805, DOI 10.1056/NEJMoa042760
   GRANT WE, 1994, BRIT J CANCER, V70, P72, DOI 10.1038/bjc.1994.252
   Green W R, 1977, Trans Am Ophthalmol Soc, V75, P180
   GREEN WR, 1986, OPHTHALMOLOGY, V93, P1169
   GREEN WR, 1993, OPHTHALMOLOGY, V100, P1519
   GRINDLE CFJ, 1978, T OPHTHAL SOC UK, V98, P172
   Grisanti S, 2004, AM J OPHTHALMOL, V137, P914, DOI 10.1016/j.ajo.2003.12.049
   Grisanti S, 2004, EXP EYE RES, V78, P207, DOI 10.1016/j.exer.2003.11.008
   Grossniklaus HE, 2005, ARCH OPHTHALMOL-CHIC, V123, P914
   GROSSNIKLAUS HE, 1992, AM J OPHTHALMOL, V114, P464, DOI 10.1016/S0002-9394(14)71859-8
   Grossniklaus HE, 2002, MOL VIS, V8, P119
   Grunwald JE, 1998, ARCH OPHTHALMOL-CHIC, V116, P150
   Grunwald JE, 1998, INVEST OPHTH VIS SCI, V39, P385
   GUERRIN M, 1995, J CELL PHYSIOL, V164, P385, DOI 10.1002/jcp.1041640219
   Guo L, 1999, INVEST OPHTH VIS SCI, V40, P2676
   Hajitou A, 2002, FASEB J, V16, P1802, DOI 10.1096/fj.02-0109fje
   Hammond CJ, 2002, OPHTHALMOLOGY, V109, P730, DOI 10.1016/S0161-6420(01)01049-1
   HATHCOCK KS, 1994, J EXP MED, V180, P631, DOI 10.1084/jem.180.2.631
   Heljasvaara R, 2005, EXP CELL RES, V307, P292, DOI 10.1016/j.yexcr.2005.03.021
   Hera R, 2005, AM J OPHTHALMOL, V139, P589, DOI 10.1016/j.ajo.2004.11.064
   Hinton DR, 1998, ARCH OPHTHALMOL-CHIC, V116, P203
   Hoffmann S, 2006, RETINA-J RET VIT DIS, V26, P454, DOI 10.1097/00006982-200604000-00012
   Holekamp NM, 2002, AM J OPHTHALMOL, V134, P220, DOI 10.1016/S0002-9394(02)01549-0
   Hunt D. W., 1999, DRUGS, V2, P231
   Hunt DWC, 1999, IMMUNOPHARMACOLOGY, V41, P31, DOI 10.1016/S0162-3109(98)00051-4
   Iliopoulos O, 1996, P NATL ACAD SCI USA, V93, P10595, DOI 10.1073/pnas.93.20.10595
   Inan UU, 2007, INVEST OPHTH VIS SCI, V48, P1773, DOI 10.1167/iovs.06-0828
   Ishibashi T, 1997, GRAEF ARCH CLIN EXP, V235, P159, DOI 10.1007/BF00941723
   ISHIBASHI T, 1986, AM J OPHTHALMOL, V101, P342, DOI 10.1016/0002-9394(86)90830-5
   Ishida S, 2003, J EXP MED, V198, P483, DOI 10.1084/jem.20022027
   JAFFE GJ, 1995, EXP EYE RES, V60, P533, DOI 10.1016/S0014-4835(05)80068-5
   Jia Yun-He, 2004, World J Gastroenterol, V10, P3361
   Johnson LV, 2000, EXP EYE RES, V70, P441, DOI 10.1006/exer.1999.0798
   Johnson LV, 2001, EXP EYE RES, V73, P887, DOI 10.1006/exer.2001.1094
   Joukov V, 1996, EMBO J, V15, P290
   KECK PJ, 1989, SCIENCE, V246, P1309, DOI 10.1126/science.2479987
   KENDALL RL, 1993, P NATL ACAD SCI USA, V90, P10705, DOI 10.1073/pnas.90.22.10705
   Kijlstra A, 2005, OCUL IMMUNOL INFLAMM, V13, P3, DOI 10.1080/09273940590909185
   KILLINGSWORTH MC, 1987, GRAEF ARCH CLIN EXP, V225, P406, DOI 10.1007/BF02334166
   KILLINGSWORTH MC, 1990, EYE, V4, P613, DOI 10.1038/eye.1990.86
   Kim I, 1999, INVEST OPHTH VIS SCI, V40, P2115
   Kinose F, 2005, MOL VIS, V11, P366
   Klaver CCW, 1998, ARCH OPHTHALMOL-CHIC, V116, P1646, DOI 10.1001/archopht.116.12.1646
   Kohri T, 2003, GRAEF ARCH CLIN EXP, V241, P943, DOI 10.1007/s00417-003-0761-2
   KONDO S, 1993, BIOCHEM BIOPH RES CO, V194, P1234, DOI 10.1006/bbrc.1993.1955
   Kraling BM, 1999, J CELL SCI, V112, P1599
   Krzystolik MG, 2002, ARCH OPHTHALMOL-CHIC, V120, P338
   Kuehn BM, 2005, JAMA-J AM MED ASSOC, V293, P1841, DOI 10.1001/jama.293.15.1841
   Kuroki M, 1996, J CLIN INVEST, V98, P1667, DOI 10.1172/JCI118962
   Kvanta A, 1996, INVEST OPHTH VIS SCI, V37, P1929
   Kwak N, 2000, INVEST OPHTH VIS SCI, V41, P3158
   Lambert V, 2003, FASEB J, V17, P2290, DOI 10.1096/fj.03-0113fje
   Lambert V, 2002, AM J PATHOL, V161, P1247, DOI 10.1016/S0002-9440(10)64401-X
   Lambooij AC, 2003, INVEST OPHTH VIS SCI, V44, P2192, DOI 10.1167/iovs.02-0410
   Lamoreaux WJ, 1998, MICROVASC RES, V55, P29, DOI 10.1006/mvre.1997.2056
   Lee S, 2007, CELL, V130, P691, DOI 10.1016/j.cell.2007.06.054
   Lee WS, 1998, CIRC RES, V82, P845
   Lee Yong C, 2005, Curr Opin Investig Drugs, V6, P1124
   LEEK RD, 1994, J LEUKOCYTE BIOL, V56, P423, DOI 10.1002/jlb.56.4.423
   LEIBOVICH SJ, 1987, NATURE, V329, P630, DOI 10.1038/329630a0
   LEUNG DW, 1989, SCIENCE, V246, P1306, DOI 10.1126/science.2479986
   Li WY, 1999, MECH AGEING DEV, V110, P137, DOI 10.1016/S0047-6374(99)00047-0
   Lim JI, 2005, AM J OPHTHALMOL, V140, P1044, DOI 10.1016/j.ajo.2005.07.021
   LOPEZ PF, 1993, OPHTHALMOLOGY, V100, P415
   LOPEZ PF, 1991, AM J OPHTHALMOL, V112, P647, DOI 10.1016/S0002-9394(14)77270-8
   Lopez PF, 1996, INVEST OPHTH VIS SCI, V37, P855
   Lu M, 1998, J CLIN INVEST, V101, P1219, DOI 10.1172/JCI1277
   Luke M, 2006, BRIT J OPHTHALMOL, V90, P1178, DOI 10.1136/bjo.2006.094995
   Luthra S, 2006, RETINA-J RET VIT DIS, V26, P512, DOI 10.1097/01.iae.0000222547.35820.52
   Lutty G, 1999, MOL VIS, V5
   Macpherson GR, 2003, MOL CANCER THER, V2, P845
   MAGLIONE D, 1991, P NATL ACAD SCI USA, V88, P9267, DOI 10.1073/pnas.88.20.9267
   MAGLIONE D, 1993, ONCOGENE, V8, P925
   Manzano RPA, 2006, RETINA-J RET VIT DIS, V26, P257, DOI 10.1097/00006982-200603000-00001
   Marneros AG, 2004, EMBO J, V23, P89, DOI 10.1038/sj.emboj.7600014
   MATSUMURA M, 1985, OPHTHALMIC RES, V17, P148, DOI 10.1159/000265366
   McLeod DS, 2002, INVEST OPHTH VIS SCI, V43, P1986
   Melter M, 2000, BLOOD, V96, P3801, DOI 10.1182/blood.V96.12.3801.h8003801_3801_3808
   MEYERS SM, 1995, AM J OPHTHALMOL, V120, P757, DOI 10.1016/S0002-9394(14)72729-1
   Michels S, 2003, INVEST OPHTH VIS SCI, V44, P2147, DOI 10.1167/iovs.02-0604
   Mignatti P, 1996, ENZYME PROTEIN, V49, P117, DOI 10.1159/000468621
   Miller JW, 1999, ARCH OPHTHALMOL-CHIC, V117, P1161
   MILLER JW, 1994, AM J PATHOL, V145, P574
   MOORE DJ, 1995, INVEST OPHTH VIS SCI, V36, P1290
   Mori K, 2002, INVEST OPHTH VIS SCI, V43, P1994
   Mori K, 2001, J CELL PHYSIOL, V188, P253, DOI 10.1002/jcp.1114
   Mori K, 2001, AM J PATHOL, V159, P313, DOI 10.1016/S0002-9440(10)61697-5
   Moschos MM, 2007, DOC OPHTHALMOL, V114, P37, DOI 10.1007/s10633-006-9036-7
   Moshfeghi DM, 2003, AM J OPHTHALMOL, V135, P343, DOI 10.1016/S0002-9394(02)01936-0
   Mousa SA, 1999, J CELL BIOCHEM, V74, P135, DOI 10.1002/(SICI)1097-4644(19990701)74:1<135::AID-JCB15>3.0.CO;2-#
   Mullins RF, 2000, FASEB J, V14, P835, DOI 10.1096/fasebj.14.7.835
   Nasu K, 2004, FERTIL STERIL, V82, P756, DOI 10.1016/j.fertnstert.2004.03.032
   Nguyen QD, 2006, OPHTHALMOLOGY, V113, P1522, DOI 10.1016/j.ophtha.2006.05.055
   Nishijima K, 2007, AM J PATHOL, V171, P53, DOI 10.2353/ajpath.2007.061237
   NISHIMURA T, 1990, OPHTHALMOLOGICA, V200, P39, DOI 10.1159/000310075
   Notari L, 2005, INVEST OPHTH VIS SCI, V46, P2736, DOI 10.1167/iovs.04-1489
   Ogata N, 2002, INVEST OPHTH VIS SCI, V43, P1168
   Oh H, 1999, INVEST OPHTH VIS SCI, V40, P1891
   Ohno-Matsui K, 2003, BIOCHEM BIOPH RES CO, V303, P962, DOI 10.1016/S0006-291X(03)00446-7
   Ohno-Matsui K, 2001, J CELL PHYSIOL, V189, P323, DOI 10.1002/jcp.10026
   Okamoto N, 1997, AM J PATHOL, V151, P281
   Olofsson B, 1996, P NATL ACAD SCI USA, V93, P2576, DOI 10.1073/pnas.93.6.2576
   OReilly MS, 1997, CELL, V88, P277, DOI 10.1016/S0092-8674(00)81848-6
   Pan X, 2004, WORLD J GASTROENTERO, V10, P1409
   Penfold PL, 2001, PROG RETIN EYE RES, V20, P385, DOI 10.1016/S1350-9462(00)00025-2
   Persico MG, 1999, CURR TOP MICROBIOL, V237, P31
   Petermeier K, 2006, BRIT J OPHTHALMOL, V90, P1034, DOI 10.1136/bjo.2006.090852
   Peters S, 1999, GRAEF ARCH CLIN EXP, V237, P976, DOI 10.1007/s004170050333
   Peters S, 2007, AM J OPHTHALMOL, V143, P995, DOI 10.1016/j.ajo.2007.03.007
   PIERCE EA, 1995, P NATL ACAD SCI USA, V92, P905, DOI 10.1073/pnas.92.3.905
   Plantner JJ, 1998, EXP EYE RES, V67, P637, DOI 10.1006/exer.1998.0552
   PLATE KH, 1992, NATURE, V359, P845, DOI 10.1038/359845a0
   Pugh CW, 2003, NAT MED, V9, P677, DOI 10.1038/nm0603-677
   Punglia RS, 1997, DIABETES, V46, P1619, DOI 10.2337/diabetes.46.10.1619
   Rahat MA, 2006, J LEUKOCYTE BIOL, V79, P706, DOI 10.1189/jlb.0605302
   Rakic JM, 2003, INVEST OPHTH VIS SCI, V44, P3186, DOI 10.1167/iovs.02-1092
   RAMRATTAN RS, 1994, INVEST OPHTH VIS SCI, V35, P2857
   Reinke MH, 1999, OPHTHALMOLOGY, V106, P1915, DOI 10.1016/S0161-6420(99)90401-3
   Renno RZ, 2002, INVEST OPHTH VIS SCI, V43, P1574
   ROBERTS WG, 1995, J CELL SCI, V108, P2369
   Robinson GS, 2001, FASEB J, V15, P1215, DOI 10.1096/fj.00-0598fje
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   ROZANOWSKA M, 1995, J BIOL CHEM, V270, P18825, DOI 10.1074/jbc.270.32.18825
   Rudolf M, 2005, BRIT J OPHTHALMOL, V89, P1627, DOI 10.1136/bjo.2005.071183
   RUNGGERBRANDLE E, 1987, INVEST OPHTH VIS SCI, V28, P2026
   RUTHERFORD MS, 1993, J LEUKOCYTE BIOL, V53, P602, DOI 10.1002/jlb.53.5.602
   RYAN SJ, 1982, ARCH OPHTHALMOL-CHIC, V100, P1804, DOI 10.1001/archopht.1982.01030040784015
   Safran M, 2003, J CLIN INVEST, V111, P779, DOI 10.1172/JCI200318181
   Saishin Y, 2005, HUM GENE THER, V16, P473, DOI 10.1089/hum.2005.16.473
   Sakurai E, 2003, INVEST OPHTH VIS SCI, V44, P3578, DOI 10.1167/iovs.03-0097
   SALAMONSEN LA, 1994, CELL BIOL INT, V18, P1139, DOI 10.1006/cbir.1994.1040
   Sasaki T, 1998, EMBO J, V17, P4249, DOI 10.1093/emboj/17.15.4249
   SAXE SJ, 1993, ARCH OPHTHALMOL-CHIC, V111, P88, DOI 10.1001/archopht.1993.01090010092033
   Schlingemann RO, 2004, GRAEF ARCH CLIN EXP, V242, P91, DOI 10.1007/s00417-003-0828-0
   Schmidt-Erfurth U, 2000, SURV OPHTHALMOL, V45, P195, DOI 10.1016/S0039-6257(00)00158-2
   Schmidt-Erfurth U, 2002, ARCH OPHTHALMOL-CHIC, V120, P835
   Schmidt-Erfurth U, 1999, ARCH OPHTHALMOL-CHIC, V117, P1177
   Schmidt-Erfurth U, 2002, INVEST OPHTH VIS SCI, V43, P830
   Schmidt-Erfurth U, 2003, INVEST OPHTH VIS SCI, V44, P4473, DOI 10.1167/iovs.02-1115
   Schmidt-Erfurth UM, 2003, OPHTHALMOLOGY, V110, P1306, DOI 10.1016/S0161-6420(03)00452-4
   Schnurrbusch UEK, 2001, BRIT J OPHTHALMOL, V85, P1086, DOI 10.1136/bjo.85.9.1086
   SENGER DR, 1983, SCIENCE, V219, P983, DOI 10.1126/science.6823562
   SEREGARD S, 1994, GRAEF ARCH CLIN EXP, V232, P325, DOI 10.1007/BF00175983
   Sertie AL, 2000, HUM MOL GENET, V9, P2051, DOI 10.1093/hmg/9.13.2051
   Shamsi FA, 2001, INVEST OPHTH VIS SCI, V42, P3041
   Shang Qing-Li, 2004, Zhonghua Yan Ke Za Zhi, V40, P266
   Shen WY, 1998, BRIT J OPHTHALMOL, V82, P1063, DOI 10.1136/bjo.82.9.1063
   SHIMA DT, 1995, MOL MED, V1, P182, DOI 10.1007/BF03401566
   Skerra A, 2007, CURR OPIN MOL THER, V9, P336
   SMITH LEH, 1994, INVEST OPHTH VIS SCI, V35, P101
   Sparrow JR, 2005, EXP EYE RES, V80, P595, DOI 10.1016/j.exer.2005.01.007
   SPARROW JR, 2005, EXP EYE RES, V85, P845
   Spilsbury K, 2000, AM J PATHOL, V157, P135, DOI 10.1016/S0002-9440(10)64525-7
   Spitzer M. S., 2007, GRAEFES ARCH CLIN EX
   STARITA C, 1995, AM J MED GENET, V57, P235, DOI 10.1002/ajmg.1320570224
   Steen B, 1998, INVEST OPHTH VIS SCI, V39, P2194
   Stitt AW, 1998, J PATHOL, V186, P306, DOI 10.1002/(SICI)1096-9896(1998110)186:3<306::AID-PATH183>3.0.CO;2-B
   Sundelin S, 1998, CURR EYE RES, V17, P851, DOI 10.1076/ceyr.17.8.851.5146
   SUNDERKOTTER C, 1994, J LEUKOCYTE BIOL, V55, P410, DOI 10.1002/jlb.55.3.410
   Suter M, 2000, J BIOL CHEM, V275, P39625, DOI 10.1074/jbc.M007049200
   Takahashi H, 2005, CLIN SCI, V109, P227, DOI 10.1042/CS20040370
   Takahashi H, 2006, J OCUL PHARMACOL TH, V22, P213, DOI 10.1089/jop.2006.22.213
   Tatar O, 2007, BRIT J OPHTHALMOL, V91, P1183, DOI 10.1136/bjo.2007.114769
   Tatar O, 2007, RETINA-J RET VIT DIS, V27, P713, DOI 10.1097/IAE.0b013e318042d3b0
   Tatar O, 2007, BRIT J OPHTHALMOL, V91, P166, DOI 10.1136/bjo.2006.105288
   Tatar O, 2006, AM J OPHTHALMOL, V142, P95, DOI 10.1016/j.ajo.2006.01.085
   Tatar O, 2006, EXP EYE RES, V83, P329, DOI 10.1016/j.exer.2005.12.017
   Tatar O, 2006, ARCH OPHTHALMOL-CHIC, V124, P815, DOI 10.1001/archopht.124.6.815
   Tezel TH, 2004, TRENDS MOL MED, V10, P417, DOI 10.1016/j.molmed.2004.07.004
   TOMBRANTINK J, 1995, J NEUROSCI, V15, P4992
   Traboulsi EI, 2005, AM J OPHTHALMOL, V139, P908, DOI 10.1016/j.ajo.2005.01.045
   Tripathi RC, 1998, OPHTHALMOLOGY, V105, P232, DOI 10.1016/S0161-6420(98)92782-8
   Tsutsumi C, 2003, J LEUKOCYTE BIOL, V74, P25, DOI 10.1189/jlb.0902436
   Tsutsumi-Miyahara C, 2004, BRIT J OPHTHALMOL, V88, P1217, DOI 10.1136/bjo.2003.036392
   Tuo JS, 2004, PROG RETIN EYE RES, V23, P229, DOI 10.1016/j.preteyeres.2004.02.001
   Volanti C, 2004, ONCOGENE, V23, P8649, DOI 10.1038/sj.onc.1207871
   Wada M, 1999, CURR EYE RES, V18, P203, DOI 10.1076/ceyr.18.3.203.5368
   Wang F, 2003, INVEST OPHTH VIS SCI, V44, P781, DOI 10.1167/iovs.02-0281
   Wang H, 1998, CIRC RES, V83, P832, DOI 10.1161/01.RES.83.8.832
   WILCOX DK, 1988, INVEST OPHTH VIS SCI, V29, P1205
   Witmer AN, 2002, INVEST OPHTH VIS SCI, V43, P849
   Woolard J, 2004, CANCER RES, V64, P7822, DOI 10.1158/0008-5472.CAN-04-0934
   Wu PH, 2001, BIOCHEM BIOPH RES CO, V288, P1149, DOI 10.1006/bbrc.2001.5903
   Yamada H, 2000, J CELL PHYSIOL, V185, P135, DOI 10.1002/1097-4652(200010)185:1<135::AID-JCP13>3.0.CO;2-Y
   Yeh DC, 2004, INVEST OPHTH VIS SCI, V45, P2368, DOI 10.1167/iovs.03-0981
   Yi XJ, 1997, GRAEF ARCH CLIN EXP, V235, P313, DOI 10.1007/BF01739641
   Young T L, 1997, J AAPOS, V1, P105, DOI 10.1016/S1091-8531(97)90008-2
   Zarbin MA, 2004, ARCH OPHTHALMOL-CHIC, V122, P598, DOI 10.1001/archopht.122.4.598
   Zatterstrom UK, 2000, CELL STRUCT FUNCT, V25, P97
   Zeng Jun, 2004, Yan Ke Xue Bao, V20, P191
   Zhao WL, 2005, EUR J IMMUNOL, V35, P3468, DOI 10.1002/eji.200526262
   Zhu WH, 2000, LAB INVEST, V80, P545, DOI 10.1038/labinvest.3780060
NR 270
TC 132
Z9 138
U1 0
U2 17
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 1350-9462
EI 1873-1635
J9 PROG RETIN EYE RES
JI Prog. Retin. Eye Res.
PD JUL
PY 2008
VL 27
IS 4
BP 372
EP 390
DI 10.1016/j.preteyeres.2008.05.002
PG 19
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 345SU
UT WOS:000259017700002
PM 18621565
DA 2022-11-30
ER

PT J
AU Dreyhaupt, J
   Dolor-Szczasny, J
   Bindewald, A
   Holz, FG
   Mansmann, U
AF Dreyhaupt, J.
   Dolor-Szczasny, J.
   Bindewald, A.
   Holz, F. G.
   Mansmann, U.
TI Discovery of factors influencing the growth of geographic atrophy in
   patients with age-related macular degeneration
SO METHODS OF INFORMATION IN MEDICINE
LA English
DT Article
DE macular degeneration; regression analyses; likelihood ratio test; risk
   factors; natural history
ID LOGISTIC-REGRESSION; NATURAL-HISTORY
AB Objectives. Identifying factors influencing the growth of geographic atrophy (GA) in patients with age-related macular degeneration (AMD).
   Methods. Data on the natural course and suspected modifying factors were collected as part of the multicenter, longitudinal, observational FAM-study in 178 eyes of 114 patients with atrophic AMD. The endpoint of interest - the size of GA - was measured in fundus outofluorescence images. The influence of different putative risk factors on progression of GA is investigated with a forward selection procedure based on the likelihood ratio test. In order to interpret non-significant results of the forward selection procedure, the power of the tests used was quantified by a parametric post-hoc bootstrap approach.
   Results: A mean increase in GA of 1.75 mm(2) per year was estimated for the given population (95% Cl: [1.46; 2.02]). Patient and eye-specific random effects could be assessed. Neither patient-specific risk factors nor ocular-specific risk factors show any significant influence on GA growth. The post-hoc bootstrap procedure shows that only very strong effects can be detected on the basis of the given data. For example, the hypercholesteremia which would result in an additional increase of GA by near 4 mm(2) per year can be detected with a power of 80%.
   Conclusions. The use of linear mixed effects regression models offers a convenient way to explore sources of variation in the natural course of GA. Data from further follow-up examinations and data about other putative risk factors than those investigated will be needed to further investigate of the GA growth process. The procedure described in this article is easily applicable to other putative risk factors-as well as to other fields of application.
C1 Heidelberg Univ, Inst Med Biometry & Informat, D-69120 Heidelberg, Germany.
   Med Univ Lublin, Eye Hosp 1, Lublin, Poland.
   Univ Bonn, Dept Ophthalmol, D-5300 Bonn, Germany.
   Ludwig Maximilians Univ Munchen, Sch Med, IBE, Chair Biometry & Bioinformat, Munich, Germany.
C3 Ruprecht Karls University Heidelberg; Medical University of Lublin;
   University of Bonn; University of Munich
RP Dreyhaupt, J (通讯作者)，Heidelberg Univ, Inst Med Biometry & Informat, INF 305, D-69120 Heidelberg, Germany.
EM dreyhoupt@imbi.uni-heidelberg.de
RI Mitchell, Paul/P-1498-2014
OI Bindewald-Wittich, Almut/0000-0002-8151-3953; Dolar-Szczasny,
   Joanna/0000-0003-4206-4371
CR BAETEN S, 1988, METHOD INFORM MED, V27, P135
   BAHNSEN U, 2006, LICHTBLICK ALTER Z, P39
   BERAN R, 1986, ANN STAT, V14, P151, DOI 10.1214/aos/1176349847
   BINDEWALD A, FUNDUS AUTOFLUORESCE
   BINDEWALD A, PRECLINICAL STUDY IN
   COLES LS, 1980, METHOD INFORM MED, V19, P42
   Deckert A, 2005, BMC Ophthalmol, V5, P8, DOI 10.1186/1471-2415-5-8
   Dreyhaupt J, 2005, OPHTHAL EPIDEMIOL, V12, P353, DOI 10.1080/09286580591005723
   EVANS JR, 2000, COCHRANE DB SYST REV
   GOURAS P, 1985, CURR EYE RES, V4, P253, DOI 10.3109/02713688509000857
   GREHN F, 2003, AUGENHEILKUNDE
   JORZIK JJ, COMPUTER ASSISTED AU
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1439, DOI 10.1001/archopht.119.10.1439
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1417, DOI 10.1001/archopht.119.10.1417
   Molenberghs G., 2000, LINEAR MIXED MODELS
   PEARSON JD, 1994, STAT MED, V13, P587, DOI 10.1002/sim.4780130520
   Pinheiro J.C., 2000, MIXED EFFECTS MODELS
   PINHEIRO JC, 1999, IME NIME MIXED EFFE
   ROTH F, FUNDUS AUTOFLUORESCE
   Sauerbrei W, 1998, METHOD INFORM MED, V37, P226
   Schmitz-Valckenberg S, 2002, GRAEF ARCH CLIN EXP, V240, P73, DOI 10.1007/s00417-001-0413-3
   Seuchter SA, 2004, METHOD INFORM MED, V43, P184
   Sunness JS, 1999, MOL VIS, V5
   Sunness JS, 1999, OPHTHALMOLOGY, V106, P1768, DOI 10.1016/S0161-6420(99)90340-8
   van Leeuwen R, 2004, AM J OPHTHALMOL, V137, P750, DOI 10.1016/S0002-9394(03)01089-4
   van Leeuwen R, 2001, BRIT MED J, V323, P1308, DOI 10.1136/bmj.323.7324.1308a
NR 26
TC 2
Z9 2
U1 0
U2 2
PU GEORG THIEME VERLAG KG
PI STUTTGART
PA RUDIGERSTR 14, D-70469 STUTTGART, GERMANY
SN 0026-1270
EI 2511-705X
J9 METHOD INFORM MED
JI Methods Inf. Med.
PY 2007
VL 46
IS 4
BP 432
EP 439
DI 10.1160/ME0328
PG 8
WC Computer Science, Information Systems; Health Care Sciences & Services;
   Medical Informatics
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Computer Science; Health Care Sciences & Services; Medical Informatics
GA 205DP
UT WOS:000249094000009
PM 17694237
DA 2022-11-30
ER

PT J
AU Sawitzke, J
   Im, KM
   Kostiha, B
   Dean, M
   Gold, B
AF Sawitzke, Julie
   Im, Kate M.
   Kostiha, Brittany
   Dean, Michael
   Gold, Bert
TI Association Assessment of Copy Number Polymorphism and Risk of
   Age-Related Macular Degeneration
SO OPHTHALMOLOGY
LA English
DT Article
ID FACTOR-H; COMPLEMENT; CFH
AB Purpose: We previously identified a genetic copy number polymorphism (CNP147) that was statistically associated with age-related macular degeneration (AMD) and that resides downstream of the complement factor H (CFH) gene. Factor H protein is polymorphic at amino acid 402, in which the resulting histidine containing moiety has been established to impart significant risk of AMD. We present a method to precisely determine the exact copy number of CNP147 and examine in more detail the association with AMD.
   Design: Case-control study.
   Participants: A total of 421 Age-Related Eye Disease Study (AREDS) subjects, of whom approximately 35% were diagnosed with neovascular disease, 19% were diagnosed with geographic atrophy, 16% were diagnosed with both, 30% were diagnosed with large drusen, and 215 were controls.
   Methods: By using copy number assays available from Applied Biosystems Inc. (Carlsbad, CA), we examined 4 loci spanning CNP147 and neighboring CNP148 in an AREDS matched case-control sample set. We analyzed these data by copy number while controlling for 2 high-risk CFH variants, rs1061170 (Y402H) and rs1410996. We phased the high-risk CFH variants with CNP147 and analyzed haplotype frequencies in cases and controls. To further validate copy numbers, 6 Utah Centre D'etude du Polymorphism Humaine (CEPH) families were typed for CNP147, and the segregation was assessed.
   Main Outcome Measures: Increased or decreased risk of AMD from genetic loci.
   Results: Having fewer than 2 copies of CNP147 was associated with an estimated 43% reduction in odds of having AMD in this sample set (adjusted odds ratio [OR] = 0.57, P = 0.006). CNP148 variation is rare in Caucasians and was not statistically significant. Common haplotypes reveal that the risk alleles for rs1061170 and rs1410996 most frequently segregate with higher copy numbers for CNP147, but not exclusively, and that 1 haplotype that carried a deletion of CNP147 was highly protective (OR = 0.25 P=1.3x10(-13)) when compared with the reference.
   Conclusions: In this matched subset of AREDS subjects, after adjusting for 2 known risk variants in CFH, CNP147 deletion statistically associates with diminished risk for AMD.
   Financial Disclosure(s): The author(s) have no proprietary or commercial interest in any materials discussed in this article. Ophthalmology 2011; 118: 2442-2446 (C) 2011 by the American Academy of Ophthalmology.
C1 [Sawitzke, Julie] SAIC Frederick Inc, Frederick, MD USA.
   [Im, Kate M.; Kostiha, Brittany; Dean, Michael; Gold, Bert] NCI, Ctr Canc Res, Canc Inflammat Program, Human Genet Sect, Frederick, MD 21701 USA.
C3 Science Applications International Corporation (SAIC); SAIC-Frederick;
   National Institutes of Health (NIH) - USA; NIH National Cancer Institute
   (NCI)
RP Gold, B (通讯作者)，NCI Frederick, Box B,Boyles St, Frederick, MD 21702 USA.
EM golda@mail.nih.gov
RI Dean, Michael/R-7501-2019; Dean, Michael C/G-8172-2012
OI Dean, Michael C/0000-0003-2234-0631; Sawitzke, Julie/0000-0002-1715-4626
FU SAIC-Frederick [NO1-CO-12400]; National Institutes of Health, National
   Cancer Institute, Center for Cancer Research; NATIONAL CANCER INSTITUTE
   [ZIABC011301] Funding Source: NIH RePORTER
FX This work was supported in part by federal funds from the Intramural
   Research Program of the National Institutes of Health, National Cancer
   Institute, Center for Cancer Research, and SAIC-Frederick under contract
   number NO1-CO-12400. The content of this publication does not
   necessarily reflect the views of the Department of Health and Human
   Services nor does its mention of trade names, commercial products, or
   organizations imply endorsement by the U.S. Government.
CR Barrett JC, 2005, BIOINFORMATICS, V21, P263, DOI 10.1093/bioinformatics/bth457
   Bergeron-Sawitzke J, 2009, EUR J HUM GENET, V17, P1190, DOI 10.1038/ejhg.2009.23
   Bradley DT, 2011, EYE, V25, P683, DOI 10.1038/eye.2011.37
   Edwards AO, 2005, SCIENCE, V308, P421, DOI 10.1126/science.1110189
   Hageman GS, 2006, ANN MED, V38, P592, DOI 10.1080/07853890601097030
   Haines JL, 2005, SCIENCE, V308, P419, DOI 10.1126/science.1110359
   Heinen S, 2009, BLOOD, V114, P2439, DOI 10.1182/blood-2009-02-205641
   Jozsi M, 2007, BLOOD, V110, P1516, DOI 10.1182/blood-2007-02-071472
   Mitchell P, 2005, ARCH OPHTHALMOL-CHIC, V123, P1598, DOI 10.1001/archopht.123.11.1598
   Prosser BE, 2007, J EXP MED, V204, P2277, DOI 10.1084/jem.20071069
   Raychaudhuri S, 2010, NAT GENET, V42, P553, DOI 10.1038/ng0710-553
   Seddon JM, 1997, AM J OPHTHALMOL, V123, P199, DOI 10.1016/S0002-9394(14)71036-0
   TOLENTINO MJ, 1994, VISION RES, V34, P409, DOI 10.1016/0042-6989(94)90099-X
   Zipfel PF, 2009, IMMUNOL LETT, V126, P1, DOI 10.1016/j.imlet.2009.07.005
NR 14
TC 17
Z9 17
U1 0
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 0161-6420
EI 1549-4713
J9 OPHTHALMOLOGY
JI Ophthalmology
PD DEC
PY 2011
VL 118
IS 12
BP 2442
EP 2446
DI 10.1016/j.ophtha.2011.05.027
PG 5
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 863BO
UT WOS:000298138000020
PM 21856016
OA Green Accepted
DA 2022-11-30
ER

PT J
AU Wykoff, CC
   Clark, WL
   Nielsen, JS
   Brill, JV
   Greene, LS
   Heggen, CL
AF Wykoff, Charles C.
   Clark, W. Lloyd
   Nielsen, Jared S.
   Brill, Joel V.
   Greene, Laurence S.
   Heggen, Cherilyn L.
TI Optimizing Anti-VEGF Treatment Outcomes for Patients with Neovascular
   Age-Related Macular Degeneration
SO JOURNAL OF MANAGED CARE & SPECIALTY PHARMACY
LA English
DT Article
ID OPTICAL COHERENCE TOMOGRAPHY; RANDOMIZED-TRIAL; INTRAVITREAL
   RANIBIZUMAB; POLYPROPYLENE SYRINGES; MONITORING-SYSTEM; SUBGROUP
   ANALYSIS; VISUAL OUTCOMES; CLINICAL-TRIAL; UNITED-STATES; TRAP-EYE
AB BACKGROUND: The introduction of anti-vascular endothelial growth factor (anti-VEGF) drugs to ophthalmology has revolutionized the treatment of neovascular age-related macular degeneration (nAMD). Despite this significant progress, gaps and challenges persist in the diagnosis of nAMD, initiation of treatment, and management of frequent intravitreal injections. Thus, nAMD remains a leading cause of blindness in the United States.
   OBJECTIVE: To present current knowledge, evidence, and expert perspectives on anti-VEGF therapies in nAMD to support managed care professionals and providers in decision making and collaborative strategies to overcome barriers to optimize anti-VEGF treatment outcomes among nAMD patients.
   SUMMARY: Three anti-VEGF therapies currently form the mainstay of treatment for nAMD, including 2 therapies approved by the FDA for treatment of nAMD (aflibercept and ranibizumab) and 1 therapy approved by the FDA for oncology indications and used off-label for treatment of nAMD (bevacizumab). In clinical trials, each of the 3 agents maintained visual acuity (VA) in approximately 90% or more of nAMD patients over 2 years. However, in long-term and real-world settings, significant gaps and challenges in diagnosis, treatment, and management pose barriers to achieving optimal outcomes for patients with nAMD. Many considerations, including individual patient characteristics, on-label versus off-label treatment, repackaging, and financial considerations, add to the complexity of nAMD decision making and management. Many factors may contribute to additional challenges leading to suboptimal long-term outcomes among nAMD patients, such as delays in diagnosis and/or treatment approval and initiation, individual patient response to different anti-VEGF therapies, lapses in physician regimentation of anti-VEGF injection and monitoring, and inadequate patient adherence to treatment and monitoring. These latter factors highlight the considerable logistical, emotional, and financial burdens of long-term, frequent intravitreal injections and the vital importance of personalized approaches to anti-VEGF treatment decision making and management for patients with nAMD. To address these challenges and reduce the number of yearly injections, studies have examined alternative dosing regimens, including extended fixed intervals, as needed, and treat-and-extend strategies in specific nAMD patient populations. New clinical evidence and insights into expert clinical practice discussed in this article can support managed care professionals in the key role they play in addressing challenges in nAMD treatment and management and optimizing patient outcomes through appropriate management of anti-VEGF treatment. Copyright (c) 2018, Academy of Managed Care Pharmacy. All rights reserved.
C1 [Wykoff, Charles C.] Retina Consultants Houston, Res, Houston, TX 77030 USA.
   [Wykoff, Charles C.] Greater Houston Retina Res Fdn, Clin Res, Houston, TX 77030 USA.
   [Wykoff, Charles C.] Greater Houston Retina Res Fdn, Houston, TX 77030 USA.
   [Wykoff, Charles C.] Blanton Eye Inst, Houston, TX 77030 USA.
   [Wykoff, Charles C.] Houston Methodist Hosp Texas, Houston, TX 77030 USA.
   [Clark, W. Lloyd] Palmetto Retina Ctr, W Columbia, SC USA.
   [Nielsen, Jared S.] Northwestern Univ, Ophthalmol, Chicago, IL 60611 USA.
   [Nielsen, Jared S.] Wolfe Eye Clin, W Des Moines, IA USA.
   [Nielsen, Jared S.] Wolfe Surg Ctr, W Des Moines, IA USA.
   [Nielsen, Jared S.] Diabet Retinopathy Clin Res Network, Tampa, FL USA.
   [Brill, Joel V.] Univ Arizona, Coll Med, Med, Phoenix, AZ USA.
   [Brill, Joel V.] AGA Ctr GI Innovat & Technol, Bethesda, MD USA.
   [Brill, Joel V.] Amer Coll Physicians, Philadelphia, PA USA.
   [Brill, Joel V.] Amer Gastroenterol Assoc, Bethesda, MD USA.
   [Brill, Joel V.] Amer Soc Gastrointestinal Endoscopy, Downers Grove, IL USA.
   [Brill, Joel V.] Amer Coll Gastroenterol, Bethesda, MD USA.
   [Greene, Laurence S.; Heggen, Cherilyn L.] PRIME Educ, Tamarac, FL USA.
C3 The Methodist Hospital System; The Methodist Hospital - Houston;
   Northwestern University; University of Arizona; American College of
   Physicians
RP Wykoff, CC (通讯作者)，Retina Consultants Houston, Res, Houston, TX 77030 USA.; Wykoff, CC (通讯作者)，Greater Houston Retina Res Fdn, Clin Res, Houston, TX 77030 USA.; Wykoff, CC (通讯作者)，Greater Houston Retina Res Fdn, Houston, TX 77030 USA.; Wykoff, CC (通讯作者)，Blanton Eye Inst, Houston, TX 77030 USA.; Wykoff, CC (通讯作者)，Houston Methodist Hosp Texas, Houston, TX 77030 USA.
OI Nielsen, Jared/0000-0003-4321-1978
CR Agarwal A, 2015, CLIN OPHTHALMOL, V9, P1001, DOI [10.2147/OPTH.S59725, 10.2147/OPTH.S74959]
   American Academy of Ophthalmology, 2014, CLIN STAT VER SOURC
   American Academy of Ophthmalogy, AG REL MAC DEG PREF
   [Anonymous], 1991, OPHTHALMOLOGY, V98, P741
   [Anonymous], 2011, EYEL AFL INJ INTR IN
   [Anonymous], 2017, LUC RAN INJ INTR INJ
   [Anonymous], 2010, PHARM COMP STER PREP
   Berg K, 2016, OPHTHALMOLOGY, V123, P51, DOI 10.1016/j.ophtha.2015.09.018
   Berg K, 2015, OPHTHALMOLOGY, V122, P146, DOI 10.1016/j.ophtha.2014.07.041
   Boxell EM, 2017, BMJ OPEN, V7, DOI 10.1136/bmjopen-2016-012790
   Boyer DS, 2007, OPHTHALMOLOGY, V114, P246, DOI 10.1016/j.ophtha.2006.10.045
   Boyer DS, 2009, OPHTHALMOLOGY, V116, P1731, DOI 10.1016/j.ophtha.2009.05.024
   Boyle J, 2018, PSYCHOL HEALTH MED, V23, P127, DOI 10.1080/13548506.2016.1274040
   Brown DM, 2009, OPHTHALMOLOGY, V116
   Brown Gary C, 2005, Trans Am Ophthalmol Soc, V103, P173
   Busbee BG, 2013, OPHTHALMOLOGY, V120, P1046, DOI 10.1016/j.ophtha.2012.10.014
   Canan H, 2014, CLIN INTERV AGING, V9, P141, DOI 10.2147/CIA.S56863
   Castillo MM, 2015, OPHTHALMOLOGY, V122, P399, DOI 10.1016/j.ophtha.2014.07.055
   Chakravarthy U, 2013, LANCET, V382, P1258, DOI 10.1016/S0140-6736(13)61501-9
   Chew EY, 2014, OPHTHALMOLOGY, V121, P535, DOI 10.1016/j.ophtha.2013.10.027
   Chew EY, 2013, JAMA OPHTHALMOL, V131, P843, DOI 10.1001/jamaophthalmol.2013.4412
   Congdon N, 2004, ARCH OPHTHALMOL-CHIC, V122, P477
   Decroos FC, 2017, AM J OPHTHALMOL, V180, P142, DOI 10.1016/j.ajo.2017.06.002
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P532
   Fung AE, 2007, AM J OPHTHALMOL, V143, P566, DOI 10.1016/j.ajo.2007.01.028
   Gibson DM, 2012, AM J PREV MED, V43, P48, DOI 10.1016/j.amepre.2012.02.028
   Goldberg RA, 2012, AM J OPHTHALMOL, V153, P204, DOI 10.1016/j.ajo.2011.11.035
   Gonzalez S, 2012, AM J OPHTHALMOL, V153, P196, DOI 10.1016/j.ajo.2011.11.023
   Heier JS, 2012, OPHTHALMOLOGY, V119, P2537, DOI 10.1016/j.ophtha.2012.09.006
   Ho AC, 2017, JAMA OPHTHALMOL, V135, P268, DOI 10.1001/jamaophthalmol.2016.5314
   Jaffe GJ, 2016, OPHTHALMOLOGY, V123, P1856, DOI 10.1016/j.ophtha.2016.05.016
   Kaiser PK, 2007, AM J OPHTHALMOL, V144, P850, DOI 10.1016/j.ajo.2007.08.012
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1417, DOI 10.1001/archopht.119.10.1417
   Keane PA, 2015, CLIN OPHTHALMOL, V9, P353, DOI 10.2147/OPTH.S59012
   Keehan SP, 2017, HEALTH AFFAIR, V36, P553, DOI 10.1377/hlthaff.2016.1627
   Khalili H, 2015, EYE, V29, P820, DOI 10.1038/eye.2015.28
   KLEIN R, 1992, OPHTHALMOLOGY, V99, P933
   Klein R, 2011, ARCH OPHTHALMOL-CHIC, V129, P75, DOI 10.1001/archophthalmol.2010.318
   Kodjikian L, 2013, OPHTHALMOLOGY, V120, P2300, DOI 10.1016/j.ophtha.2013.06.020
   Lalwani GA, 2009, AM J OPHTHALMOL, V148, P43, DOI 10.1016/j.ajo.2009.01.024
   Lambert NG, 2016, PROG RETIN EYE RES, V54, P64, DOI 10.1016/j.preteyeres.2016.04.003
   Liu TYA, 2013, JAMA OPHTHALMOL, V131, P335, DOI 10.1001/jamaophthalmol.2013.818
   Maguire MG, 2016, OPHTHALMOLOGY, V123, P1751, DOI 10.1016/j.ophtha.2016.03.045
   Martin DF, 2012, OPHTHALMOLOGY, V119, DOI 10.1016/j.ophtha.2012.03.053
   Martin DF, 2011, NEW ENGL J MED, V364, P1897, DOI 10.1056/NEJMoa1102673
   Mathew RS, 2011, OPHTHAL PHYSL OPT, V31, P375, DOI 10.1111/j.1475-1313.2011.00848.x
   Miller JW, 2013, AM J OPHTHALMOL, V155, P1, DOI 10.1016/j.ajo.2012.10.018
   Mitchell J, 2006, HEALTH QUAL LIFE OUT, V4, DOI 10.1186/1477-7525-4-97
   Modi YS, 2015, DRUG SAFETY, V38, P279, DOI 10.1007/s40264-015-0273-0
   Moreno TA, 2016, SEMIN OPHTHALMOL, V31, P378, DOI 10.3109/08820538.2016.1154174
   Neely DC, 2017, JAMA OPHTHALMOL, V135, P570, DOI 10.1001/jamaophthalmol.2017.0830
   Paul M., 2012, Annales Pharmaceutiques Francaises, V70, P139, DOI 10.1016/j.pharma.2012.03.006
   Prenner JL, 2015, AM J OPHTHALMOL, V160, P725, DOI 10.1016/j.ajo.2015.06.023
   Rauch R, 2012, RETINA-J RET VIT DIS, V32, P1260, DOI 10.1097/IAE.0b013e3182018df6
   Regillo CD, 2008, AM J OPHTHALMOL, V145, P239, DOI 10.1016/j.ajo.2007.10.004
   Rofagha S, 2013, OPHTHALMOLOGY, V120, P2292, DOI 10.1016/j.ophtha.2013.03.046
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Rovner BW, 2009, ALZHEIMERS DEMENT, V5, P12, DOI 10.1016/j.jalz.2008.06.001
   Schmidt-Erfurth U, 2014, OPHTHALMOLOGY, V121, P193, DOI 10.1016/j.ophtha.2013.08.011
   Schmidt-Erfurth U, 2011, OPHTHALMOLOGY, V118, P831, DOI 10.1016/j.ophtha.2010.09.004
   Schmucker CM, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0137866
   Schwartz Roy, 2015, Int J Retina Vitreous, V1, P20, DOI 10.1186/s40942-015-0022-7
   Silva R, 2018, OPHTHALMOLOGY, V125, P57, DOI 10.1016/j.ophtha.2017.07.014
   Singer MA, 2012, OPHTHALMOLOGY, V119, P1175, DOI 10.1016/j.ophtha.2011.12.016
   Spaide R, 2007, AM J OPHTHALMOL, V143, P679, DOI 10.1016/j.ajo.2007.02.024
   Stein JD, 2014, OPHTHALMOLOGY, V121, P936, DOI 10.1016/j.ophtha.2013.10.037
   Stewart MW, 2015, J CLIN MED, V4, P1079, DOI 10.3390/jcm4051079
   Stewart MW, 2012, RETINA-J RET VIT DIS, V32, P434, DOI 10.1097/IAE.0B013E31822C290F
   Wittenborn JS, 2017, JAMA OPHTHALMOL, V135, P452, DOI 10.1001/jamaophthalmol.2017.0255
   Wong T, 2008, OPHTHALMOLOGY, V115, P116, DOI 10.1016/j.ophtha.2007.03.008
   Wykoff CC, 2017, OPHTHALMOL RETINA, V1, P314, DOI 10.1016/j.oret.2016.12.004
   Wykoff CC, 2015, OPHTHALMOLOGY, V122, P2514, DOI 10.1016/j.ophtha.2015.08.009
   Yannuzzi NA, 2015, JAMA OPHTHALMOL, V133, P32, DOI 10.1001/jamaophthalmol.2014.3591
   Ying GS, 2013, OPHTHALMOLOGY, V120, P122, DOI 10.1016/j.ophtha.2012.07.042
NR 74
TC 62
Z9 65
U1 2
U2 3
PU ACAD MANAGED CARE PHARMACY
PI ALEXANDRIA
PA 100 N PITT ST, 400, ALEXANDRIA, VA 22314-3134 USA
SN 2376-0540
EI 2376-1032
J9 J MANAG CARE SPEC PH
JI J. Manag. Care Spec. Pharm.
PD FEB
PY 2018
VL 24
IS 2
SU A
BP S3
EP S15
DI 10.18553/jmcp.2018.24.2-a.s3
PG 13
WC Health Care Sciences & Services; Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Health Care Sciences & Services; Pharmacology & Pharmacy
GA FX1GT
UT WOS:000425797900001
PM 29383980
OA Bronze
DA 2022-11-30
ER

PT J
AU Iizuka, M
   Gorfinkel, J
   Mandelcorn, M
   Lam, WC
   Devenyl, R
   Markowitz, SN
AF Iizuka, Megumi
   Gorfinkel, John
   Mandelcorn, Mark
   Lam, Wai-Ching
   Devenyl, Robert
   Markowitz, Samuel N.
TI Modified cataract surgery with telescopic magnification for patients
   with age-related macular degeneration
SO CANADIAN JOURNAL OF OPHTHALMOLOGY-JOURNAL CANADIEN D OPHTALMOLOGIE
LA English
DT Article
DE implantable intraocular telescope; cataract surgery; macular
   degeneration
ID LENS POWER CALCULATIONS; VISUAL-ACUITY; SYSTEM
AB Background: The most desirable effect following cataract surgery in the presence of age-related macular degeneration (AMD) is to obtain an improvement in distance resolution acuity, and the only optical solution to this is the use of telescopic magnification. The purpose of the study was to develop and verify the clinical utility of inducing low-grade telescopic magnification (<33%) at the time of cataract surgery by the choice of an appropriate intraocular lens power and spectacle glasses in patients with AMD and cataract.
   Methods: The design was a prospective, nonrandomized, interventional case series involving 6 patients aged 74-86 (mean 80; SD 4) years with AMD and cataract. Participants were males and females, equal in number, who had visual acuity of less than 20/400 in the weaker eye. Standard cataract surgery was performed in the weaker eye. The power of the intraocular lens was derived from the reduced Gullstrand model of the eye in such a way that at the intraocular lens plane a minus lens was created, which, together with a plus lens in matching glasses, formed a Galilean telescopic system with magnification of up to 33%. Outcome measures were visual acuity, contrast sensitivity, and activities of daily living (ADL) scores.
   Results: The mean power of the implanted intraocular lenses was 6.31 (SD 2.42) diopters and, according to the theoretical derivations, achieved magnification between 20% and 30% (mean 26%; SD 4.92%). Visual acuity improved for the group from a mean of 20/525 (logMAR 1.48; SD 0.13) to a mean of 20/290 (logMAR 1.20; SD 0.21). Contrast sensitivity improved significantly (p < 0.001) only in the lower spatial frequencies. Postoperatively, ADL scores improved significantly in all patients except one. At the end of the follow-up period, 3 patients reported that they would like to proceed with similar surgery for the other eye.
   Interpretation: An optimal surgical telescopic device based on low-grade telescopic magnification may improve functional vision for usage in all tasks in AMD patients. All patients from this study were satisfied following surgery and viewed study outcomes as positive and beneficial, and some patients responded with enthusiasm. Surgeons are encouraged to use this modified technique of cataract surgery in low-vision patients with AMD and cataract.
C1 [Iizuka, Megumi; Markowitz, Samuel N.] Univ Toronto, Low Vis Serv, Toronto, ON M6H2H1, Canada.
   [Gorfinkel, John] Univ Toronto, Cataract Surg Serv, Toronto, ON, Canada.
   [Mandelcorn, Mark; Lam, Wai-Ching; Devenyl, Robert] Univ Toronto, Univ Hlth Network Hosp, Dept Ophthalmol, Retina Serv, Toronto, ON, Canada.
C3 University of Toronto; University of Toronto; University of Toronto;
   University Health Network Toronto
RP Markowitz, SN (通讯作者)，Univ Toronto, Low Vis Serv, 1225 Davenport Rd, Toronto, ON M6H2H1, Canada.
EM snm1@rogers.corn
OI Lam, Wai-Ching/0000-0003-2057-9374
CR BALESTRAZZI E, 2005, S LOW VIS REH AM AC
   CHOYCE P, 1964, INTRA OCULAR LENSES
   COURTNEY P, 1992, EYE, V6, P487, DOI 10.1038/eye.1992.103
   Dandona L, 1998, ARCH OPHTHALMOL-CHIC, V116, P545, DOI 10.1001/archopht.116.4.514
   DONN A, 1986, CLAO Journal, V12, P81
   FERRIS FL, 1982, AM J OPHTHALMOL, V94, P91, DOI 10.1016/0002-9394(82)90197-0
   GINSBURG AP, 1984, AM J OPTOM PHYS OPT, V61, P403
   Gonzalez EG, 2007, INVEST OPHTH VIS SCI, V48, P4838, DOI 10.1167/iovs.06-1240
   Hart PM, 1999, BRIT J OPHTHALMOL, V83, P1115, DOI 10.1136/bjo.83.10.1115
   Holladay JT, 1997, J CATARACT REFR SURG, V23, P1356, DOI 10.1016/S0886-3350(97)80115-0
   HOLLADAY JT, 1988, J CATARACT REFR SURG, V14, P17, DOI 10.1016/S0886-3350(88)80059-2
   Hudson HL, 2006, OPHTHALMOLOGY, V113, P1987, DOI 10.1016/j.ophtha.2006.07.010
   JAFFE NS, 1997, CTARACT SURG ITS COM
   KOZIOL JE, 1994, OPHTHALMIC SURG LAS, V25, P675
   Markowitz SN, 2005, CAN J OPHTHALMOL, V40, P541, DOI 10.1016/S0008-4182(05)80047-X
   PORTNEY W, 1991, Patent No. 5030231
   SCHEIN OD, 1995, OPHTHALMOLOGY, V102, P817, DOI 10.1016/S0161-6420(95)30952-9
   STEINBERG EP, 1993, ARCH OPHTHALMOL-CHIC, V111, P1041, DOI 10.1001/archopht.1993.01090080037016
   *US DEP HHS, 1993, CAT ADULTS MAN FUNCT
   WHO, 2004, MAGN CAUS VIS IMP
   WILLIS TR, 1989, EUR J IMPLANT REFRAC, V1, P271
NR 21
TC 3
Z9 3
U1 0
U2 3
PU CANADIAN OPHTHAL SOC
PI OTTAWA
PA 1525 CARLING AVE SUITE 610, OTTAWA, ONTARIO K1Z 8R9, CANADA
SN 0008-4182
EI 1715-3360
J9 CAN J OPHTHALMOL
JI Can. J. Opthalmol.-J. Can. Opthalmol.
PD DEC
PY 2007
VL 42
IS 6
BP 854
EP 859
DI 10.3129/i07-152
PG 6
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 241MJ
UT WOS:000251660200014
PM 17965754
DA 2022-11-30
ER

PT J
AU Arai, Y
   Takahashi, H
   Inoda, S
   Tan, X
   Sakamoto, S
   Inoue, Y
   Fujino, Y
   Kawashima, H
   Yanagi, Y
AF Arai, Yusuke
   Takahashi, Hidenori
   Inoda, Satoru
   Tan, Xue
   Sakamoto, Shinichi
   Inoue, Yuji
   Fujino, Yujiro
   Kawashima, Hidetoshi
   Yanagi, Yasuo
TI Aqueous humour proteins and treatment outcomes of anti-VEGF therapy in
   neovascular age-related macular degeneration
SO PLOS ONE
LA English
DT Article
ID SUBFOVEAL CHOROIDAL THICKNESS; VISUAL-ACUITY LOSS; MATRIX
   METALLOPROTEINASES; BRUCHS MEMBRANE; RANIBIZUMAB; CYTOKINE; EYES;
   CHEMOKINES; ADHESION; PROFILE
AB We aimed to construct a better model for predicting treatment outcomes of anti-vascular endothelial growth factor therapy for neovascular age-related macular degeneration (nAMD) using the concentrations of aqueous humour proteins at baseline and during treatment. From the data of 48 treatment-naive nAMD eyes that received intravitreal ranibizumab pro re nata for up to 12 months, we used the aqueous humour concentrations of C-X-C motif chemokine ligand 1 (CXCL1), CXCL12, CXCL13, interferon-gamma-induced protein 10, monocyte chemoattractant protein 1 (MCP-1), C-C motif chemokine ligand 11, interleukin 6 (IL-6), IL-10, and matrix metalloproteinase 9 (MMP-9). After stepwise regression, multivariate analysis was performed to identify which predictors were significantly associated with best-corrected visual acuity (BCVA) changes and the number of injections. The results demonstrated that besides male sex (beta coefficient = -0.088, P = 0.040) and central retinal thickness (beta coefficient = 0.00051 per mu m, P = 0.027), MCP-1 (beta coefficient = 0.44, P < 0.001) and IL-10 (beta coefficient = -0.16, P = 0.033) were significantly correlated with baseline BCVA. Additionally, high MCP-1 at baseline (beta coefficient = -0.20, P = 0.015) and low CXCL13 at baseline (beta coefficient = 0.10, P = 0.0054) were independently associated with better BCVA change at 12 months. High MMP-9 at the first injection (beta coefficient = 0.56, P = 0.01), CXCL12 at the third injection (beta coefficient = 0.10, P = 0.0002), and IL-10 at the third injection (beta coefficient = 1.3, P = 0.001) were predictor variables associated with the increased number of injections. In conclusion, aqueous humour protein concentrations may have predictive abilities of BCVA change over 12 months and the number of injections in pro re nata treatment of exudative nAMD.
C1 [Arai, Yusuke; Takahashi, Hidenori; Inoda, Satoru; Sakamoto, Shinichi; Inoue, Yuji; Kawashima, Hidetoshi] Jichi Med Univ, Dept Ophthalmol, Shimotsuke, Tochigi, Japan.
   [Takahashi, Hidenori; Tan, Xue; Inoue, Yuji] Univ Tokyo, Grad Sch Med, Dept Ophthalmol, Bunkyo Ku, Tokyo, Japan.
   [Takahashi, Hidenori; Tan, Xue; Fujino, Yujiro] Tokyo Shinjuku Med Ctr, Japan Community Hlth Care Org, Shinjuku Ku, Tokyo, Japan.
   [Yanagi, Yasuo] Asahikawa Med Univ, Dept Ophthalmol, Asahikawa, Hokkaido, Japan.
   [Yanagi, Yasuo] Singapore Natl Eye Ctr, Med Retina, Singapore, Singapore.
   [Yanagi, Yasuo] Singapore Eye Res Inst, Med Retina, Singapore, Singapore.
C3 Jichi Medical University; University of Tokyo; Asahikawa Medical
   College; Singapore National Eye Center; National University of
   Singapore; Singapore National Eye Center
RP Takahashi, H (通讯作者)，Jichi Med Univ, Dept Ophthalmol, Shimotsuke, Tochigi, Japan.; Takahashi, H (通讯作者)，Univ Tokyo, Grad Sch Med, Dept Ophthalmol, Bunkyo Ku, Tokyo, Japan.; Takahashi, H (通讯作者)，Tokyo Shinjuku Med Ctr, Japan Community Hlth Care Org, Shinjuku Ku, Tokyo, Japan.
EM takahah-tky@umin.ac.jp
RI Yanagi, Yasuo/AAA-5441-2022
OI Takahashi, Hidenori/0000-0001-5331-4730; ARAI,
   YUSUKE/0000-0003-1677-3713
FU KAKENHI grant from the Japan Society for the Promotion of Science
   [15K10899]
FX This work was supported by a KAKENHI grant from the Japan Society for
   the Promotion of Science, Grant Number 15K10899.
CR Agawa T, 2014, RETINA-J RET VIT DIS, V34, P1811, DOI 10.1097/IAE.0000000000000157
   Austin BA, 2009, INVEST OPHTH VIS SCI, V50, P2896, DOI 10.1167/iovs.08-2495
   Belperio JA, 2000, J LEUKOCYTE BIOL, V68, P1
   Brown DM, 2013, RETINA-J RET VIT DIS, V33, P23, DOI 10.1097/IAE.0b013e318263cedf
   Campochiaro PA, 2016, AM J OPHTHALMOL, V168, P13, DOI 10.1016/j.ajo.2016.04.017
   CHONG V, 2013, INVEST OPHTH VIS SCI, V54
   DASTGHEIB K, 1994, ARCH OPHTHALMOL-CHIC, V112, P813, DOI 10.1001/archopht.1994.01090180111045
   Ecker SM, 2012, MOL VIS, V18, P1658
   Ecker SM, 2011, MOL VIS, V17, P2856
   ELDEM MB, 2009, INVEST OPHTH VIS SCI, V50, P2374
   Funk M, 2009, OPHTHALMOLOGY, V116, P2393, DOI 10.1016/j.ophtha.2009.05.039
   Ghasemi H, 2012, OCUL IMMUNOL INFLAMM, V20, P406, DOI 10.3109/09273948.2012.723109
   Goldberger AS., 1991, COURSE ECONOMETRICS, P245
   Ho A S, 1994, Ther Immunol, V1, P173
   Huang H, 2017, PLOS ONE, V12
   HUTCHINSON AK, 1993, ARCH OPHTHALMOL-CHIC, V111, P734, DOI 10.1001/archopht.1993.01090060020010
   Jonas JB, 2012, ACTA OPHTHALMOL, V90, pe381, DOI 10.1111/j.1755-3768.2012.02414.x
   Jonas JB, 2010, ARCH OPHTHALMOL-CHIC, V128, P1281, DOI 10.1001/archophthalmol.2010.227
   Kang HM, 2014, AM J OPHTHALMOL, V157, P1013, DOI 10.1016/j.ajo.2014.01.019
   Kiefer F, 2011, CELL MOL LIFE SCI, V68, P2811, DOI 10.1007/s00018-011-0677-7
   KILLINGSWORTH MC, 1990, EYE, V4, P613, DOI 10.1038/eye.1990.86
   Kim BJ, 2014, AM J OPHTHALMOL, V158, P128, DOI 10.1016/j.ajo.2014.04.004
   Koh A, 2012, RETINA-J RET VIT DIS, V32, P1453, DOI 10.1097/IAE.0b013e31824f91e8
   Kown JW, 2018, PLOS ONE, V13, DOI [10.1371/journal.pone.0207902, DOI 10.1371/JOURNAL.PONE.0207902]
   Krebs I, 2007, AM J OPHTHALMOL, V144, P741, DOI 10.1016/j.ajo.2007.07.024
   Liutkeviciene R, 2015, OPHTHALMIC GENET, V36, P149, DOI 10.3109/13816810.2013.838274
   Maguire MG, 2016, OPHTHALMOLOGY, V123, P1751, DOI 10.1016/j.ophtha.2016.03.045
   Mo FM, 2010, INVEST OPHTH VIS SCI, V51, P4226, DOI 10.1167/iovs.09-3910
   Nakamura R, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms8847
   Nielsen MK, 2019, ACTA OPHTHALMOL, V97, P84, DOI 10.1111/aos.13894
   Nomura Y, 2016, RETINA-J RET VIT DIS, V36, P192, DOI 10.1097/IAE.0000000000000668
   Ondes F, 2000, JPN J OPHTHALMOL, V44, P91, DOI 10.1016/S0021-5155(99)00174-4
   Patel M, 2008, SEMIN IMMUNOPATHOL, V30, P97, DOI 10.1007/s00281-008-0112-9
   PENFOLD PL, 1985, GRAEF ARCH CLIN EXP, V223, P69, DOI 10.1007/BF02150948
   Regillo CD, 2008, AM J OPHTHALMOL, V145, P239, DOI 10.1016/j.ajo.2007.10.004
   Rezar-Dreindl S, 2017, ACTA OPHTHALMOL, V95, pE119, DOI 10.1111/aos.13152
   Rezar-Dreindl S, 2016, INVEST OPHTH VIS SCI, V57, P4144, DOI 10.1167/iovs.16-19772
   Robison CD, 2009, AM J OPHTHALMOL, V148, P79, DOI 10.1016/j.ajo.2009.01.014
   Rofagha S, 2013, OPHTHALMOLOGY, V120, P2292, DOI 10.1016/j.ophtha.2013.03.046
   Roh MI, 2009, RETINA-J RET VIT DIS, V29, P523, DOI 10.1097/IAE.0b013e318195cb15
   Sakamoto S, 2018, BRIT J OPHTHALMOL, V102, P448, DOI 10.1136/bjophthalmol-2017-310284
   Sakurada Y, 2015, OPHTHALMIC RES, V53, P2, DOI 10.1159/000365487
   Sakurai E, 2003, INVEST OPHTH VIS SCI, V44, P3578, DOI 10.1167/iovs.03-0097
   Sato T, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-19594-6
   Schmidt-Erfurth U, 2011, OPHTHALMOLOGY, V118, P831, DOI 10.1016/j.ophtha.2010.09.004
   Simader C, 2014, OPHTHALMOLOGY, V121, P1237, DOI 10.1016/j.ophtha.2013.12.029
   Siquira Miletto B, 2015, J NEUROSCI, V35, P1631
   Steen B, 1998, INVEST OPHTH VIS SCI, V39, P2194
   STRIETER RM, 1989, BIOCHEM BIOPH RES CO, V162, P694, DOI 10.1016/0006-291X(89)92366-8
   Takahashi H, 2015, BRIT J OPHTHALMOL, V99, P1065, DOI 10.1136/bjophthalmol-2014-306051
   Tan X, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0160985
   Tanaka T, 2010, BIOCHEM BIOPH RES CO, V399, P677, DOI 10.1016/j.bbrc.2010.07.141
   Tatar O, 2007, BRIT J OPHTHALMOL, V91, P1183, DOI 10.1136/bjo.2007.114769
   Weber-Krause Brigitte, 1996, Ophthalmologe, V93, P660, DOI 10.1007/s003470050054
   Wolf S, 2008, JPN J OPHTHALMOL, V52, P433, DOI 10.1007/s10384-008-0580-4
   Yang Y, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0080288
   Ying GS, 2014, JAMA OPHTHALMOL, V132, P915, DOI 10.1001/jamaophthalmol.2014.1019
NR 57
TC 3
Z9 3
U1 0
U2 1
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD MAR 10
PY 2020
VL 15
IS 3
AR e0229342
DI 10.1371/journal.pone.0229342
PG 14
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA LQ8WI
UT WOS:000535278500015
PM 32155173
OA Green Published, gold
DA 2022-11-30
ER

PT J
AU Lee, J
   Choi, S
   Lee, CS
   Kim, M
   Kim, SS
   Koh, HJ
   Lee, SC
   Byeon, SH
AF Lee, Junwon
   Choi, Seonghee
   Lee, Christopher Seungkyu
   Kim, Min
   Kim, Sung Soo
   Koh, Hyoung Jun
   Lee, Sung Chul
   Byeon, Suk Ho
TI Neovascularization in Fellow Eye of Unilateral Neovascular Age-related
   Macular Degeneration According to Different Drusen Types
SO AMERICAN JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
ID SEVERITY SCALE; CHOROIDAL NEOVASCULARIZATION; RETICULAR PSEUDODRUSEN;
   PREVALENCE; RISK; DISEASE
AB PURPOSE: To investigate the incidence of fellow eye (FE) neovascular age-related macular degeneration (nAMD) in patients with unilateral nAMD according to FE drusen type.
   DESIGN: Retrospective cohort study.
   METHODS: Between January 2013 and June 2016, 434 consecutive patients with nave nAMD were enrolled. We selected 280 eligible patients with treatment-nave, unilateral nAMD for analysis (280/280 = 100% patients were followed up at 2 years; 50/280 = 17.9% patients were followed up at 5 years). The incidence and hazard ratios (HR) of FE nAMD according to age, sex, choroidal thickness, nAMD subtype, and drusen type were analyzed.
   RESULTS: The 5-year incidence of FE nAMD was 20.9%. The incidences of the soft plus subretinal drusenoid deposits (SDD), soft drusen only, and SDD only groups were 76.4%, 46.2%, and 25.7%, respectively; they were significantly higher than the no drusen group (vs 3.6%; P < .001, P < .001, P < .001). There was no significant difference between the pachydrusen and no drusen groups (7.1% vs 3.6%; P = .101). The multivariate Cox regression hazard model revealed older age (HR, 1.053; P = .031) and drusen type were significant (P = .001). Compared with the no drusen group, the soft drusen plus SDD, soft drusen only, and SDD groups showed an HR of 18.460 (P =.001), 8.302 (P = .015), and 5.465 (P = .082), respectively. Pachydrusen was not shown to be a significant risk factor compared to the no drusen group (HR, 2.417; P = .281).
   CONCLUSION: The incidence of FE nAMD was significantly different with respect to drusen type. Soft drusen plus SDD had the highest risk of neovascular AMD, followed by soft drusen only and SDD only. ((C) 2019 Elsevier Inc. All rights reserved.)
C1 [Lee, Junwon; Choi, Seonghee; Kim, Sung Soo; Koh, Hyoung Jun; Lee, Sung Chul; Byeon, Suk Ho] Yonsei Univ, Coll Med, Eye & ENT Hosp, Dept Ophthalmol,Severance Hosp,Inst Vis Res, Seoul, South Korea.
   [Lee, Christopher Seungkyu; Kim, Min] Yonsei Univ, Coll Med, Gangnam Severance Hosp, Dept Ophthalmol,Inst Human Barrier Res, Seoul, South Korea.
C3 Yonsei University; Yonsei University Health System; Yonsei University;
   Yonsei University Health System
RP Byeon, SH (通讯作者)，Yonsei Univ, Coll Med, Inst Vis Res, Dept Ophthalmol, Yonsei Ro 50-1, Seoul 03722, South Korea.
EM shbyeon@yuhs.ac.kr
OI Kim, Min/0000-0003-1873-6959; Lee, Christopher/0000-0001-5054-9470; ,
   Sung Chul/0000-0001-9438-2385; Byeon, suk ho/0000-0001-8101-0830; Lee,
   Junwon/0000-0003-0543-7132; Kim, Sung Soo/0000-0002-0574-7993; Koh,
   Hyoung Jun/0000-0002-5932-8516
FU National Research Foundation of Korea (NRF) - Ministry of Science, ICT &
   Future Planning [2017R1A2B4011045]; Korea Health Technology R&D Project
   through the Korea Health Industry Development Institute (KHIDI) -
   Ministry of Health (Si. Welfare, Republic of Korea) [HI17C1567]
FX THIS RESEARCH WAS SUPPORTED BY GRANTS FOR THE BASIC SCIENCE RESEARCH
   PROGRAM THROUGH the National Research Foundation of Korea (NRF), funded
   by the Ministry of Science, ICT & Future Planning (grant number:
   2017R1A2B4011045), and the Korea Health Technology R&D Project through
   the Korea Health Industry Development Institute (KHIDI), funded by the
   Ministry of Health (Si. Welfare, Republic of Korea (grant number:
   HI17C1567).
CR Baek J, 2019, CLIN EXP OPHTHALMOL, V47, P498, DOI 10.1111/ceo.13438
   Bhisitkul RB, 2016, OPHTHALMOLOGY, V123, P1269, DOI 10.1016/j.ophtha.2016.01.033
   Bochicchio S, 2019, OPHTHALMOL RETINA, V3, P27, DOI 10.1016/j.oret.2018.08.003
   BRESSLER SB, 1990, ARCH OPHTHALMOL-CHIC, V108, P1442, DOI 10.1001/archopht.1990.01070120090035
   BURGESS DB, 1993, ARCH OPHTHALMOL-CHIC, V111, P1189
   CHANG B, 1995, OPHTHALMOLOGY, V102, P1380, DOI 10.1016/S0161-6420(95)30860-3
   Cheung CMG, 2012, CLIN EXP OPHTHALMOL, V40, P727, DOI 10.1111/j.1442-9071.2012.02765.x
   Cheung CMG, 2016, JAMA OPHTHALMOL, V134, P1047, DOI 10.1001/jamaophthalmol.2016.2407
   Cohen SY, 2007, BRIT J OPHTHALMOL, V91, P354, DOI 10.1136/bjo.2006.101022
   Davis MD, 2005, ARCH OPHTHALMOL-CHIC, V123, P1484
   Ferris FL, 2005, ARCH OPHTHALMOL-CHIC, V123, P1570
   Ferris FL, 2013, OPHTHALMOLOGY, V120, P844, DOI 10.1016/j.ophtha.2012.10.036
   Cheung CM, 2018, OPHTHALMOL RETINA, V2, P1196, DOI 10.1016/j.oret.2018.06.014
   GREGOR Z, 1977, BRIT J OPHTHALMOL, V61, P141, DOI 10.1136/bjo.61.2.141
   Gross NE, 2005, RETINA-J RET VIT DIS, V25, P713, DOI 10.1097/00006982-200509000-00005
   HARRELL FE, 1982, JAMA-J AM MED ASSOC, V247, P2543, DOI 10.1001/jama.247.18.2543
   Klein R, 2002, OPHTHALMOLOGY, V109, P1767, DOI 10.1016/S0161-6420(02)01146-6
   KLEIN R, 1991, OPHTHALMOLOGY, V98, P1128
   Laude A, 2010, PROG RETIN EYE RES, V29, P19, DOI 10.1016/j.preteyeres.2009.10.001
   Lee J, 2019, RETINA-J RET VIT DIS, V39, P670, DOI 10.1097/IAE.0000000000002019
   Lee J, 2020, RETINA-J RET VIT DIS, V40, P490, DOI 10.1097/IAE.0000000000002419
   Margolis R, 2009, AM J OPHTHALMOL, V147, P811, DOI 10.1016/j.ajo.2008.12.008
   Maruko I, 2007, AM J OPHTHALMOL, V144, P15, DOI 10.1016/j.ajo.2007.03.047
   Roh M, 2018, OPHTHALMOL RETINA, V2, P475, DOI 10.1016/j.oret.2017.08.021
   Solomon SD, 2007, ARCH OPHTHALMOL-CHIC, V125, P1323
   SPAIDE RF, 1995, RETINA-J RET VIT DIS, V15, P100, DOI 10.1097/00006982-199515020-00003
   Spaide RF, 2008, AM J OPHTHALMOL, V146, P496, DOI 10.1016/j.ajo.2008.05.032
   Spaide RF, 2018, RETINA-J RET VIT DIS, V38, P708, DOI 10.1097/IAE.0000000000001689
   Thornton J, 2005, EYE, V19, P935, DOI 10.1038/sj.eye.6701978
   Tsai ASH, 2017, SURV OPHTHALMOL, V62, P462, DOI 10.1016/j.survophthal.2017.01.008
   Tufail A, 2014, OPHTHALMOLOGY, V121, P1092, DOI 10.1016/j.ophtha.2013.11.031
   Wang JJ, 2003, ARCH OPHTHALMOL-CHIC, V121, P658, DOI 10.1001/archopht.121.5.658
   Wong CW, 2016, PROG RETIN EYE RES, V53, P107, DOI 10.1016/j.preteyeres.2016.04.002
   Yanagi Y, 2017, INVEST OPHTH VIS SCI, V58, P3488, DOI 10.1167/iovs.16-21167
   Yannuzzi LA, 2001, RETINA-J RET VIT DIS, V21, P416, DOI 10.1097/00006982-200110000-00003
   Zarranz-Ventura J, 2014, OPHTHALMOLOGY, V121, P1966, DOI 10.1016/j.ophtha.2014.04.026
   Zweifel SA, 2010, OPHTHALMOLOGY, V117, P1775, DOI 10.1016/j.ophtha.2010.01.027
NR 37
TC 21
Z9 21
U1 0
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 0002-9394
EI 1879-1891
J9 AM J OPHTHALMOL
JI Am. J. Ophthalmol.
PD DEC
PY 2019
VL 208
BP 103
EP 110
DI 10.1016/j.ajo.2019.07.013
PG 8
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA JZ0OI
UT WOS:000504803400013
PM 31377285
DA 2022-11-30
ER

PT J
AU Seiple, W
   Rosen, RB
   Garcia, PMT
AF Seiple, William
   Rosen, Richard B.
   Garcia, Patricia M. T.
TI Abnormal Fixation in Individuals With Age-Related Macular Degeneration
   When Viewing an Image of a Face
SO OPTOMETRY AND VISION SCIENCE
LA English
DT Article
DE low vision; age-related macular degeneration; fixation
ID PREFERRED RETINAL LOCI; EYE-MOVEMENTS; FACIAL RECOGNITION; VISION;
   ATTENTION; IDENTIFICATION; PERCEPTION; GAZE; DISCRIMINATION; OBSERVERS
AB Purpose. It has been reported that patients with macular disease have difficulties with face perception. Some of this difficulty may be caused by the sensory and perceptual consequences of using peripheral retina. However, strong correlations have not always been found between performance on face tasks and clinical measure of function. Based on the evidence of abnormal eye movements by patients with age-related macular degeneration (AMD), we explored whether abnormal fixation patterns occur when these patients view an image of a face.
   Methods. An OPKO OCT/SLO was used to collect structural and functional data. For each subject, the structural location of disease was determined, and the locus and stability of fixation were quantified. A SLO movie of fundus movements was recorded while the subject viewed an image of a face.
   Results. The number of fixations on internal (eyes, nose, and mouth) and external features were measured. A two-way repeated-measures analysis of variance found significant differences between the control and patient groups and among locations. A significant interaction between group and location was also found. Post hoc comparisons found a significantly greater proportion of fixations on external features for the AMD group than that in the control group.
   Conclusions. The observed patterns of fixations of our subjects with AMD were similar to those observed in other groups of patients who have difficulties with face perception. For example, individuals with social phobias, Williams syndrome, autism, schizophrenia, or prosopagnosia have altered face perceptions and also have a significantly greater proportion of fixations on external features of faces. Abnormal eye movement patterns and fixations may contribute to deficits in face perception in AMD patients. (Optom Vis Sci 2013;90:45-56)
C1 [Seiple, William] Lighthouse Int, New York, NY 10022 USA.
   [Seiple, William] NYU, Sch Med, New York, NY USA.
   [Seiple, William; Rosen, Richard B.; Garcia, Patricia M. T.] New York Eye & Ear Infirm, New York, NY 10003 USA.
   [Seiple, William] Jesse Brown VAMC, Chicago, IL USA.
C3 New York University; New York Eye & Ear Infirmary of Mount Sinai
RP Seiple, W (通讯作者)，Lighthouse Int, 111 E 59th St, New York, NY 10022 USA.
EM whs4@nyu.edu
OI Seiple, William/0000-0002-5750-650X
FU US Department of Veterans Affairs; Bendheim Family Retina Center of the
   New York Eye and Ear Infirmary
FX This work was supported in part by a grant from the US Department of
   Veterans Affairs and by the Bendheim Family Retina Center of the New
   York Eye and Ear Infirmary.
CR ALEXANDER MF, 1988, ARCH OPHTHALMOL-CHIC, V106, P1543, DOI 10.1001/archopht.1988.01060140711040
   Althoff RR, 1999, J EXP PSYCHOL LEARN, V25, P997, DOI 10.1037/0278-7393.25.4.997
   Barnes CS, 2011, OPTOMETRY VISION SCI, V88, P188, DOI 10.1097/OPX.0b013e318205a17c
   Bayle DJ, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0021584
   Buchan JN, 2007, SOC NEUROSCI-UK, V2, P1, DOI 10.1080/17470910601043644
   BULLIMORE MA, 1991, INVEST OPHTH VIS SCI, V32, P2020
   Castelhano MS, 2009, J VISION, V9, DOI 10.1167/9.3.6
   Crossland MD, 2004, OPHTHAL PHYSL OPT, V24, P327, DOI 10.1111/j.1475-1313.2004.00213.x
   Crossland MD, 2005, OPHTHALMOLOGY, V112, P1579, DOI 10.1016/j.ophtha.2005.03.027
   Crossland MD, 2004, VISION RES, V44, P1537, DOI 10.1016/j.visres.2004.01.006
   Crossland MD, 2011, INVEST OPHTH VIS SCI, V52, P411, DOI 10.1167/iovs.10-5473
   Deubel H, 2003, ANN NY ACAD SCI, V1004, P289, DOI 10.1196/annals.1303.026
   Dulin D, 2011, Q J EXP PSYCHOL, V64, P1955, DOI 10.1080/17470218.2011.608852
   Duret F, 1999, VISION RES, V39, P873, DOI 10.1016/S0042-6989(98)00179-5
   ELLIS HD, 1979, PERCEPTION, V8, P431, DOI 10.1068/p080431
   Findlay JM, 2001, VISION RES, V41, P87, DOI 10.1016/S0042-6989(00)00236-4
   Guo K, 2006, EXP BRAIN RES, V171, P91, DOI 10.1007/s00221-005-0248-y
   Guo K, 2011, PERCEPTION, V40, P191, DOI 10.1068/p6849
   Gutierrez A, 2009, SPAN J PSYCHOL, V12, P414, DOI 10.1017/S1138741600001803
   Haxby JV, 2000, NEUROIMAGE, V11, P380, DOI 10.1006/nimg.2000.0592
   Henderson JM, 2005, MEM COGNITION, V33, P98, DOI 10.3758/BF03195300
   HESS RF, 1994, VISUAL NEUROSCI, V11, P1033, DOI 10.1017/S0952523800003977
   Hooge LTC, 1996, PERCEPT PSYCHOPHYS, V58, P969, DOI 10.3758/BF03206825
   Horley K, 2004, PSYCHIAT RES, V127, P43, DOI 10.1016/j.psychres.2004.02.016
   Isaacowitz DM, 2009, PSYCHOL AGING, V24, P989, DOI 10.1037/a0017706
   Ishai A, 2005, BRAIN RES BULL, V67, P87, DOI 10.1016/j.brainresbull.2005.05.027
   KEATING CF, 1982, PERCEPTION, V11, P211, DOI 10.1068/p110211
   KOWLER E, 1977, VISION RES, V17, P141, DOI 10.1016/0042-6989(77)90212-7
   Lei H, 1997, INVEST OPHTH VIS SCI, V38, P1812
   LEVI DM, 1987, VISION RES, V27, P581, DOI 10.1016/0042-6989(87)90044-7
   Lingnau A, 2008, J VISION, V8, DOI 10.1167/8.5.6
   LOOMIS JM, 1978, VISION RES, V18, P335, DOI 10.1016/0042-6989(78)90168-2
   Lott LA, 2005, OPTOMETRY VISION SCI, V82, P874, DOI 10.1097/01.opx.0000180764.68737.91
   Loughland CM, 2002, BIOL PSYCHIAT, V52, P338, DOI 10.1016/S0006-3223(02)01356-2
   Mackeben M, 1999, SPATIAL VISION, V12, P51, DOI 10.1163/156856899X00030
   Makela P, 2001, VISION RES, V41, P599, DOI 10.1016/S0042-6989(00)00259-5
   Manor BR, 1999, BIOL PSYCHIAT, V46, P963, DOI 10.1016/S0006-3223(99)00038-4
   McCulloch DL, 2011, OPHTHAL PHYSL OPT, V31, P240, DOI 10.1111/j.1475-1313.2011.00828.x
   McKone E, 2004, J EXP PSYCHOL LEARN, V30, P181, DOI 10.1037/0278-7393.30.1.181
   MCMAHON TT, 1993, OPTOMETRY VISION SCI, V70, P506, DOI 10.1097/00006324-199306000-00010
   MCMAHON TT, 1991, INVEST OPHTH VIS SCI, V32, P567
   MERTENS I, 1993, NEUROPSYCHOLOGIA, V31, P989, DOI 10.1016/0028-3932(93)90154-R
   OWSLEY C, 1981, INVEST OPHTH VIS SCI, V21, P362
   Pitcher D, 2011, EXP BRAIN RES, V209, P481, DOI 10.1007/s00221-011-2579-1
   Riby DM, 2009, Q J EXP PSYCHOL, V62, P189, DOI 10.1080/17470210701855629
   RIZZO M, 1986, NEUROLOGY, V36, P1254, DOI 10.1212/WNL.36.9.1254
   RIZZO M, 1987, ANN NEUROL, V22, P41, DOI 10.1002/ana.410220111
   Rubin GS, 1990, OPT SOC AM, V3, P130
   SALTHOUSE TA, 1980, AM J PSYCHOL, V93, P207, DOI 10.2307/1422228
   SCHLINGENSIEPEN KH, 1986, VISION RES, V26, P1111, DOI 10.1016/0042-6989(86)90045-3
   Schmalzl L, 2008, COGN NEUROPSYCHOL, V25, P704, DOI 10.1080/02643290802299350
   Schutz AC, 2011, J VIS, V5, P111
   Seiple W, 2005, INVEST OPHTH VIS SCI, V46, P2886, DOI 10.1167/iovs.04-1296
   Seiple W, 2002, VISION RES, V42, P1513, DOI 10.1016/S0042-6989(02)00079-2
   Seiple W, 2011, INVEST OPHTH VIS SCI, V52, P2938, DOI 10.1167/iovs.10-6137
   Sereno SC, 2000, BRAIN COGNITION, V42, P78, DOI 10.1006/brcg.1999.1167
   STEINMAN RM, 1965, J OPT SOC AM, V55, P1158, DOI 10.1364/JOSA.55.001158
   Stephan BCM, 2009, BRAIN COGNITION, V69, P262, DOI 10.1016/j.bandc.2008.07.015
   Strasburger H, 2011, J VISION, V11, DOI 10.1167/11.5.13
   Sunness JS, 1996, OPHTHALMOLOGY, V103, P1458, DOI 10.1016/S0161-6420(96)30483-1
   SZLYK JP, 1995, VISION RES, V35, P1633, DOI 10.1016/0042-6989(94)00275-Q
   Tarita-Nistor L, 2008, RETINA-J RET VIT DIS, V28, P125, DOI 10.1097/IAE.0b013e3180ed4571
   Tatler BW, 2011, J VISION, V11, DOI 10.1167/11.5.5
   Tejeria L, 2002, BRIT J OPHTHALMOL, V86, P1019, DOI 10.1136/bjo.86.9.1019
   TEMME LA, 1985, AM J OPTOM PHYS OPT, V62, P736
   Thompson RW, 2003, INVEST OPHTH VIS SCI, V44, P5035, DOI 10.1167/iovs.03-0341
   Timberlake GT, 2006, J REHABIL RES DEV, V43, P749, DOI 10.1682/JRRD.2005.06.0102
   Timberlake GT, 2005, OPTOMETRY VISION SCI, V82, P177
   TIMBERLAKE GT, 1987, INVEST OPHTH VIS SCI, V28, P1268
   TIMBERLAKE GT, 1986, INVEST OPHTH VIS SCI, V27, P1137
   TURANO K, 1991, CLIN VISION SCI, V6, P289
   Vuilleumier P, 2001, NEURON, V30, P829, DOI 10.1016/S0896-6273(01)00328-2
   WALKERSMITH GJ, 1977, PERCEPTION, V6, P313, DOI 10.1068/p060313
   WHITE JM, 1990, INVEST OPHTH VIS SCI, V31, P1149
   WHITTAKER SG, 1988, INVEST OPHTH VIS SCI, V29, P268
   WHITTAKER SG, 1991, VISION RES, V31, P2209, DOI 10.1016/0042-6989(91)90173-3
   Wojciulik E, 1998, J NEUROPHYSIOL, V79, P1574, DOI 10.1152/jn.1998.79.3.1574
   Yarbus A. L., 1967, EYE MOVEMENTS VISION
   Yu DY, 2011, OPTOMETRY VISION SCI, V88, P724, DOI 10.1097/OPX.0b013e318213933c
NR 79
TC 35
Z9 35
U1 1
U2 28
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 1040-5488
EI 1538-9235
J9 OPTOMETRY VISION SCI
JI Optom. Vis. Sci.
PD JAN
PY 2013
VL 90
IS 1
BP 45
EP 56
DI 10.1097/OPX.0b013e3182794775
PG 12
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 063QP
UT WOS:000313015200016
PM 23238260
DA 2022-11-30
ER

PT J
AU Christen, WG
   Schaumberg, DA
   Glynn, RJ
   Buring, JE
AF Christen, William G.
   Schaumberg, Debra A.
   Glynn, Robert J.
   Buring, Julie E.
TI Dietary omega-3 Fatty Acid and Fish Intake and Incident Age-Related
   Macular Degeneration in Women
SO ARCHIVES OF OPHTHALMOLOGY
LA English
DT Article
ID CORONARY-HEART-DISEASE; FATTY-ACID INTAKE; ALPHA-LINOLENIC ACID;
   LOW-DOSE ASPIRIN; DOCOSAHEXAENOIC ACID; PRIMARY PREVENTION;
   CIGARETTE-SMOKING; CARDIOVASCULAR-DISEASE; 10-YEAR INCIDENCE; RISK
AB Objective: To examine whether intake of omega-3 fatty acids and fish affects incidence of age-related macular degeneration (AMD) in women.
   Design: A detailed food-frequency questionnaire was administered at baseline among 39 876 female health professionals (mean [SD] age: 54.6 [7.0] years). A total of 38 022 women completed the questionnaire and were free of a diagnosis of AMD. The main outcome measure was incident AMD responsible for a reduction in best-corrected visual acuity to 20/30 or worse based on self-report confirmed by medical record review.
   Results: A total of 235 cases of AMD, most characterized by some combination of drusen and retinal pigment epithelial changes, were confirmed during an average of 10 years of follow-up. Women in the highest tertile of intake for docosahexaenoic acid, compared with those in the lowest, had a multivariate-adjusted relative risk of AMD of 0.62 (95% confidence interval, 0.44-0.87). For eicosapentaenoic acid, women in the highest tertile of intake had a relative risk of 0.66 (95% confidence interval, 0.48-0.92). Consistent with the findings for docosahexaenoic acid and eicosapentaenoic acid, women who consumed 1 or more servings of fish per week, compared with those who consumed less than 1 serving per month, had a relative risk of AMD of 0.58 (95% confidence interval, 0.38-0.87).
   Conclusion: These prospective data from a large cohort of female health professionals without a diagnosis of AMD at baseline indicate that regular consumption of docosahexaenoic acid and eicosapentaenoic acid and fish was associated with a significantly decreased risk of incident AMD and may be of benefit in primary prevention of AMD.
C1 [Christen, William G.; Schaumberg, Debra A.; Glynn, Robert J.; Buring, Julie E.] Brigham & Womens Hosp, Div Prevent Med, Dept Med, Boston, MA 02115 USA.
   [Buring, Julie E.] Brigham & Womens Hosp, Div Aging, Dept Med, Boston, MA 02115 USA.
   [Glynn, Robert J.] Harvard Univ, Sch Publ Hlth, Dept Biostat, Sch Med, Boston, MA 02115 USA.
   [Buring, Julie E.] Harvard Univ, Sch Med, Dept Ambulatory Care & Prevent, Boston, MA USA.
C3 Harvard University; Brigham & Women's Hospital; Harvard University;
   Brigham & Women's Hospital; Harvard University; Harvard Medical School;
   Harvard T.H. Chan School of Public Health; Harvard University; Harvard
   Medical School
RP Christen, WG (通讯作者)，900 Commonwealth Ave E, Boston, MA 02215 USA.
EM wchristen@rics.bwh.harvard.edu
FU National Institutes of Health [CA 47988, HL 43851, EY 06633]; Bayer
   Healthcare; Natural Source Vitamin E Association; NATIONAL CANCER
   INSTITUTE [R01CA047988] Funding Source: NIH RePORTER; NATIONAL EYE
   INSTITUTE [R01EY006633] Funding Source: NIH RePORTER; NATIONAL HEART,
   LUNG, AND BLOOD INSTITUTE [R01HL043851] Funding Source: NIH RePORTER
FX Supported by research grants CA 47988, HL 43851, and EY 06633 from the
   National Institutes of Health.; Pills and packaging were provided by
   Bayer Healthcare and the Natural Source Vitamin E Association.
CR Alexander JW, 1998, NUTRITION, V14, P627, DOI 10.1016/S0899-9007(98)00004-5
   ANDERSON RE, 1970, EXP EYE RES, V10, P339, DOI 10.1016/S0014-4835(70)80046-X
   [Anonymous], 1991, Arch Ophthalmol, V109, P1109
   [Anonymous], 1993, Arch Ophthalmol, V111, P1200
   Arnarsson A, 2006, AM J OPHTHALMOL, V142, P419, DOI 10.1016/j.ajo.2006.04.015
   Arnold J, 2001, AM J OPHTHALMOL, V131, P541
   Augood C, 2008, AM J CLIN NUTR, V88, P398, DOI 10.1093/ajcn/88.2.398
   Baylin A, 2005, AM J EPIDEMIOL, V162, P373, DOI 10.1093/aje/kwi213
   Blumenkranz MS, 2001, ARCH OPHTHALMOL-CHIC, V119, P198
   Calder PC, 2002, P NUTR SOC, V61, P345, DOI 10.1079/PNS2002166
   Cho E, 2001, AM J CLIN NUTR, V73, P209
   Chong EWT, 2009, ARCH OPHTHALMOL-CHIC, V127, P674, DOI 10.1001/archophthalmol.2009.60
   Chong EWT, 2008, ARCH OPHTHALMOL-CHIC, V126, P826, DOI 10.1001/archopht.126.6.826
   Christen WG, 2005, AM J CLIN NUTR, V81, P1417
   Christen WG, 1996, JAMA-J AM MED ASSOC, V276, P1147, DOI 10.1001/jama.276.14.1147
   Chua B, 2006, ARCH OPHTHALMOL-CHIC, V124, P981, DOI 10.1001/archopht.124.7.981
   *CLIN TRIALS, AG REL EYE DIS STUD
   Connor KM, 2007, NAT MED, V13, P868, DOI 10.1038/nm1591
   Cook NR, 2005, JAMA-J AM MED ASSOC, V294, P47, DOI 10.1001/jama.294.1.47
   COREY EJ, 1983, P NATL ACAD SCI-BIOL, V80, P3581, DOI 10.1073/pnas.80.12.3581
   COX DR, 1972, J R STAT SOC B, V34, P187
   CULP BR, 1979, PROSTAG LEUKOTR ESS, V3, P269, DOI 10.1016/0161-4630(79)90068-5
   Delcourt C, 2007, EUR J CLIN NUTR, V61, P1341, DOI 10.1038/sj.ejcn.1602685
   Ferris FL, 2005, ARCH OPHTHALMOL-CHIC, V123, P1570
   FESKANICH D, 1993, J AM DIET ASSOC, V93, P790, DOI 10.1016/0002-8223(93)91754-E
   FLIESLER SJ, 1983, PROG LIPID RES, V22, P79
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P564
   Gerster H, 1998, INT J VITAM NUTR RES, V68, P159
   Gragoudas ES, 2004, NEW ENGL J MED, V351, P2805, DOI 10.1056/NEJMoa042760
   Hageman GS, 2001, PROG RETIN EYE RES, V20, P705, DOI 10.1016/S1350-9462(01)00010-6
   Harris WS, 2008, ATHEROSCLEROSIS, V197, P12, DOI 10.1016/j.atherosclerosis.2007.11.008
   He K, 2004, CIRCULATION, V109, P2705, DOI 10.1161/01.CIR.0000132503.19410.6B
   Heuberger RA, 2001, ARCH OPHTHALMOL-CHIC, V119, P1833, DOI 10.1001/archopht.119.12.1833
   Hodge WG, 2006, OPHTHALMOLOGY, V113, P1165, DOI 10.1016/j.ophtha.2006.02.043
   Hogg RE, 2006, PROG RETIN EYE RES, V25, P249, DOI 10.1016/j.preteyeres.2005.11.002
   Hollyfield JG, 2010, INVEST OPHTH VIS SCI, V51, P1276, DOI 10.1167/iovs.09-4478
   Hu FB, 2002, JAMA-J AM MED ASSOC, V287, P1815, DOI 10.1001/jama.287.14.1815
   HUNTER DJ, 1992, AM J EPIDEMIOL, V135, P418, DOI 10.1093/oxfordjournals.aje.a116302
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1417, DOI 10.1001/archopht.119.10.1417
   KLEIN R, 1995, INVEST OPHTH VIS SCI, V36, P182
   Klein R, 1998, AM J EPIDEMIOL, V147, P103
   Klein R, 2002, OPHTHALMOLOGY, V109, P1767, DOI 10.1016/S0161-6420(02)01146-6
   Kleinbaum D.G., 1982, EPIDEMIOLOGIC RES PR, P1
   Kris-Etherton PM, 2002, CIRCULATION, V106, P2747, DOI 10.1161/01.CIR.0000038493.65177.94
   Lavie CJ, 2009, J AM COLL CARDIOL, V54, P585, DOI 10.1016/j.jacc.2009.02.084
   Lecomte M, 1996, J NEUROCHEM, V66, P2160
   Lee IM, 2005, JAMA-J AM MED ASSOC, V294, P56, DOI 10.1001/jama.294.1.56
   MARESPERLMAN JA, 1995, ARCH OPHTHALMOL-CHIC, V113, P743, DOI 10.1001/archopht.1995.01100060069034
   MARSHALL LA, 1982, LIPIDS, V17, P905, DOI 10.1007/BF02534586
   Michels S, 2005, OPHTHALMOLOGY, V112, P1035, DOI 10.1016/j.ophtha.2005.02.007
   Miljanovic B, 2005, AM J CLIN NUTR, V82, P887, DOI 10.1093/ajcn/82.4.887
   Mukherjee PK, 2004, P NATL ACAD SCI USA, V101, P8491, DOI 10.1073/pnas.0402531101
   NEURINGER M, 1986, P NATL ACAD SCI USA, V83, P4021, DOI 10.1073/pnas.83.11.4021
   Parekh N, 2009, ARCH OPHTHALMOL-CHIC, V127, P1483, DOI 10.1001/archophthalmol.2009.130
   Ridker PM, 2005, NEW ENGL J MED, V352, P1293, DOI 10.1056/NEJMoa050613
   Robinson JG, 2006, AM J CARDIOL, V98, p39I, DOI 10.1016/j.amjcard.2005.12.026
   SANDERS TAB, 1989, J INTERN MED, V225, P99, DOI 10.1111/j.1365-2796.1989.tb01442.x
   SanGiovanni JP, 2008, ARCH OPHTHALMOL-CHIC, V126, P1274, DOI 10.1001/archopht.126.9.1274
   SanGiovanni JP, 2007, ARCH OPHTHALMOL-CHIC, V125, P671, DOI 10.1001/archopht.125.5.671
   SanGiovanni JP, 2009, AM J CLIN NUTR, V90, P1601, DOI 10.3945/ajcn.2009.27594
   SanGiovanni JP, 2005, PROG RETIN EYE RES, V24, P87, DOI 10.1016/j.preteyeres.2004.06.002
   Schaumberg DA, 2001, ARCH OPHTHALMOL-CHIC, V119, P1259
   SCHAUMBERG DA, 2010, ARVO 2010 MAY 3 FORT
   Schaumberg DA, 2007, ARCH OPHTHALMOL-CHIC, V125, P55, DOI 10.1001/archopht.125.1.55
   Schaumberg DA, 2006, INVEST OPHTH VIS SCI, V47, P2336, DOI 10.1167/iovs.05-1456
   Seddon JM, 2003, ARCH OPHTHALMOL-CHIC, V121, P1728, DOI 10.1001/archopht.121.12.1728
   Seddon JM, 1996, JAMA-J AM MED ASSOC, V276, P1141, DOI 10.1001/jama.276.14.1141
   Seddon JM, 2001, ARCH OPHTHALMOL-CHIC, V119, P1191, DOI 10.1001/archopht.119.8.1191
   Seddon JM, 2006, ARCH OPHTHALMOL-CHIC, V124, P995, DOI 10.1001/archopht.124.7.995
   Serhan CN, 2002, J EXP MED, V196, P1025, DOI 10.1084/jem.20020760
   Simopoulos AP, 2002, BIOMED PHARMACOTHER, V56, P365, DOI 10.1016/S0753-3322(02)00253-6
   Smith W, 2000, ARCH OPHTHALMOL-CHIC, V118, P401, DOI 10.1001/archopht.118.3.401
   Snow K K, 1999, Ophthalmic Epidemiol, V6, P125, DOI 10.1076/opep.6.2.125.1558
   Swenor BK, 2010, OPHTHALMOLOGY, V117, P2395, DOI 10.1016/j.ophtha.2010.03.058
   Tan JSL, 2009, ARCH OPHTHALMOL-CHIC, V127, P656, DOI 10.1001/archophthalmol.2009.76
   Tian HB, 2009, INVEST OPHTH VIS SCI, V50, P3613, DOI 10.1167/iovs.08-3146
   van Leeuwen R, 2003, ARCH OPHTHALMOL-CHIC, V121, P519, DOI 10.1001/archopht.121.4.519
   Weaver KL, 2009, J BIOL CHEM, V284, P15400, DOI 10.1074/jbc.M109.004861
   Whelton SP, 2004, AM J CARDIOL, V93, P1119, DOI 10.1016/j.amjcard.2004.01.038
   WILLETT W, 1986, AM J EPIDEMIOL, V124, P17, DOI 10.1093/oxfordjournals.aje.a114366
   Willett W., 2013, NUTR EPIDEMIOLOGY, V3rd
NR 81
TC 92
Z9 93
U1 0
U2 13
PU AMER MEDICAL ASSOC
PI CHICAGO
PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA
SN 0003-9950
EI 1538-3601
J9 ARCH OPHTHALMOL-CHIC
JI Arch. Ophthalmol.
PD JUL
PY 2011
VL 129
IS 7
BP 921
EP 929
DI 10.1001/archophthalmol.2011.34
PG 9
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 790QJ
UT WOS:000292604000017
PM 21402976
OA Bronze, Green Accepted
DA 2022-11-30
ER

PT J
AU Upasani, D
   Dhingra, N
AF Upasani, Deepa
   Dhingra, Narendra
TI Ten-year outcome of anti-vascular endothelial growth factor treatment
   for neovascular age-related macular degeneration
SO INDIAN JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
DE 10-year results; anti-VEGF; nAMD; switching
ID TERM VISUAL OUTCOMES; INTRAVITREAL AFLIBERCEPT; RANIBIZUMAB; VEGF; DELAY
AB Purpose: The aim of this study was to report the 10-year visual outcome in eyes treated with anti-vascular endothelial growth factor (anti-VEGF) agents for neovascular age-related macular degeneration (nAMD) and to assess the impact of switching treatment as part of routine clinical care. Methods: Electronic records of treatment-naive eyes initiated on intravitreal ranibizumab between January and December 2009 were accessed. The primary outcome measured was the change in visual acuity (VA) in Early Treatment of Diabetic Retinopathy Study letters. The frequency and reasons for treatment discontinuation during each year of follow-up and the impact of switching from ranibizumab to aflibercept were some of the secondary outcomes. Results: Of the 223 eyes (203 patients), 60 eyes completed 10 years of continuous follow-up. After a mean follow-up of 121.4 months, VA declined by 5.6 letters (95% confidence interval [CI] -0.25 to -11.1, P = 0.04). Final VA of >= 70 letters was seen in 20% of eyes and 35% had VA <= 35 letters. VA gain of >= 10 letters was seen in 23% and loss of >= 10 letters was seen in 40% of the eyes. Twenty-nine eyes remained on ranibizumab monotherapy and 31 switched to aflibercept. Switched eyes showed a visual decline of 7.1 letters (5.5 letters in monotherapy eyes, P = 0.32) and received a significantly higher number of injections (39.6 +/- 9.9 vs. 24.4 +/- 13.1, P < 0.0001). Patients discontinuing treatment were older and had lower baseline vision compared to completers. Conclusion: VA declined below the baseline after 10 years of follow-up and switching did not have any effect on the final visual outcome.
C1 [Upasani, Deepa; Dhingra, Narendra] Mid Yorkshire NHS Trust, Macula Serv, Ctr Eye, Wakefield, England.
RP Dhingra, N (通讯作者)，Mid Yorkshire NHS Trust, Pinderfields Hosp, Ctr Eye, Wakefield, England.
EM narendra.dhingra@nhs.net
CR Arias L, 2009, EYE, V23, P326, DOI 10.1038/sj.eye.6703053
   Berg K, 2017, ACTA OPHTHALMOL, V95, P796, DOI 10.1111/aos.13522
   Borooah S, 2015, EYE, V29, P1156, DOI 10.1038/eye.2015.83
   Brown DM, 2009, OPHTHALMOLOGY, V116, P57, DOI 10.1016/j.ophtha.2008.10.018
   Chandra S, 2020, EYE, V34, P1888, DOI 10.1038/s41433-020-0764-9
   Evans RN, 2020, OPHTHALMOLOGY, V127, P1191, DOI 10.1016/j.ophtha.2020.03.020
   Gillies M, 2020, AM J OPHTHALMOL, V210, P116, DOI 10.1016/j.ajo.2019.10.007
   Heier JS, 2012, OPHTHALMOLOGY, V119, P2537, DOI 10.1016/j.ophtha.2012.09.006
   Kaiser PK, 2017, OPHTHALMOL RETINA, V1, P304, DOI 10.1016/j.oret.2017.01.004
   Lee CS, 2018, RETINA-J RET VIT DIS, V38, P951, DOI 10.1097/IAE.0000000000001637
   Maguire MG, 2016, OPHTHALMOLOGY, V123, P1751, DOI 10.1016/j.ophtha.2016.03.045
   Mitchell P, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0101072
   Muether PS, 2011, GRAEF ARCH CLIN EXP, V249, P633, DOI 10.1007/s00417-010-1520-9
   Obeid A, 2018, JAMA OPHTHALMOL, V136, P1251, DOI 10.1001/jamaophthalmol.2018.3578
   Oliver-Fernandez M, 2005, CAN J OPHTHALMOL, V40, P313, DOI 10.1016/S0008-4182(05)80074-2
   Rofagha S, 2013, OPHTHALMOLOGY, V120, P2292, DOI 10.1016/j.ophtha.2013.03.046
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Wolff B, 2020, CLIN EXP OPHTHALMOL, V48, P636, DOI 10.1111/ceo.13742
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
NR 19
TC 0
Z9 0
U1 0
U2 0
PU WOLTERS KLUWER MEDKNOW PUBLICATIONS
PI MUMBAI
PA WOLTERS KLUWER INDIA PVT LTD , A-202, 2ND FLR, QUBE, C T S  NO 1498A-2
   VILLAGE MAROL, ANDHERI EAST, MUMBAI, Maharashtra, INDIA
SN 0301-4738
EI 1998-3689
J9 INDIAN J OPHTHALMOL
JI Indian J. Ophthalmol.
PD SEP
PY 2021
VL 69
IS 9
BP 2350
EP 2354
DI 10.4103/ijo.IJO_2868_20
PG 5
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA YN2DP
UT WOS:000747074100030
PM 34427220
OA Green Published, gold
DA 2022-11-30
ER

PT J
AU Shahid, A
   Bhatt, P
   Miller, A
   Sutariya, V
AF Shahid, Amna
   Bhatt, Priyanka
   Miller, Abraian
   Sutariya, Vijaykumar
TI Honokiol-Loaded Methoxy Poly (Ethylene Glycol) Polycaprolactone Micelles
   for the Treatment of Age-Related Macular Degeneration
SO ASSAY AND DRUG DEVELOPMENT TECHNOLOGIES
LA English
DT Article
DE anti-HIF agent; anti-VEGF agent; sustained release; age-related macular
   degeneration; choroidal neovascularization
ID DRUG-DELIVERY; NEOVASCULARIZATION; ANGIOGENESIS; EXPRESSION; VEGF
AB Age-related macular degeneration (AMD), a multifactorial age-related retinal hypoxic disorder resulting in irreversible loss of vision, is the foremost cause of blindness in the United States. Current treatment strategies involve multiple intraocular injections of antivascular endothelial growth factor (VEGF) agents into the vitreous of eye. In addition to the challenges of drug localization and targeted delivery, the need of frequent injections into the eye raises patient compliance issues, and thus call for development of sustained drug delivery systems. In this study, a sustained drug delivery system was prepared by loading an antihypoxia-induced factor (HIF) agent, honokiol (HON), into methoxy poly (ethylene glycol) polycaprolactone (MPEG-PCL) polymer. These HON-MPEG-PCL micelles were characterized by evaluating size, zeta potential, in vitro drug release profile, and morphology by transmission electron microscopy. The cytotoxic nature of developed micelles was assessed on human retinal pigment epithelial cell line (ARPE-19) cells by cytotoxicity assay. The cellular uptake and HIF and VEGF expression levels were determined in in vitro settings. Micelles formed had a particle size of 30.8 +/- 0.8 nm with the poly dispersity index of 0.19 +/- 0.0004 and zeta potential was found to be -5.46 +/- 0.49 mv. Entrapment efficiency was calculated to be 64 +/- 0.135%. In vitro drug release showed sustained release of drug from the formulation. Result from in vitro cytotoxicity study confirmed noncytotoxic nature of HON-MPEG-PCL micelles compared to HON drug solution. Furthermore, enzyme-linked immunosorbent assay studies performed showed the periodic downregulation of HIF and VEGF, which are major growth factors involved in underlying mechanism of AMD. The results showed successful development of HON-MPEG-PCL micelles, which may be useful for the effective treatment of AMD.
C1 [Shahid, Amna; Bhatt, Priyanka; Miller, Abraian; Sutariya, Vijaykumar] Univ S Florida, Dept Pharmaceut Sci, Taneja Coll Pharm, Tampa, FL 33620 USA.
C3 State University System of Florida; University of South Florida
RP Sutariya, V (通讯作者)，Univ S Florida, Dept Pharmaceut Sci, Taneja Coll Pharm, Tampa, FL 33620 USA.
EM vsutariy@usf.edu
CR Al Gwairi O, 2016, J OPHTHALMOL, V2016, DOI 10.1155/2016/2913612
   Ambati J, 2012, NEURON, V75, P26, DOI 10.1016/j.neuron.2012.06.018
   Bhatt P, 2020, AAPS PHARMSCITECH, V21, DOI 10.1208/s12249-020-01836-4
   Bhatt P, 2019, THER DELIV, V10, P737, DOI 10.4155/tde-2019-0025
   Bhatt P, 2019, AAPS PHARMSCITECH, V20, DOI 10.1208/s12249-019-1474-0
   Bhatt P, 2018, INT J PHARMACEUT, V536, P95, DOI 10.1016/j.ijpharm.2017.11.048
   Blasiak J, 2014, BIOMED RES INT, V2014, DOI 10.1155/2014/768026
   Campochiaro PA, 2004, EXPERT OPIN BIOL TH, V4, P1395, DOI 10.1517/14712598.4.9.1395
   Carmeliet P, 2005, ONCOLOGY-BASEL, V69, P4, DOI 10.1159/000088478
   Danafar H., 2016, COGENT MED, V3, DOI [10.1080/2331205X.2016.1142411, DOI 10.1080/2331205X.2016.1142411]
   Ferris FL, 2013, OPHTHALMOLOGY, V120, P844, DOI 10.1016/j.ophtha.2012.10.036
   Geroski DH, 2000, INVEST OPHTH VIS SCI, V41, P961
   Gottlieb JL, 2002, JAMA-J AM MED ASSOC, V288, P2233, DOI 10.1001/jama.288.18.2233
   Huo MR, 2017, J CONTROL RELEASE, V245, P81, DOI 10.1016/j.jconrel.2016.11.013
   Kaur IP, 2004, INT J PHARMACEUT, V269, P1, DOI 10.1016/j.ijpharm.2003.09.016
   Kelly BD, 2003, CIRC RES, V93, P1074, DOI 10.1161/01.RES.0000102937.50486.1B
   Kovach JL, 2012, J OPHTHALMOL, V2012, DOI 10.1155/2012/786870
   Lim LS, 2012, LANCET, V379, P1728, DOI 10.1016/S0140-6736(12)60282-7
   Ma GL, 2010, J APPL POLYM SCI, V116, P1985, DOI 10.1002/app.31654
   Misra, 2018, IN VITRO IN VIVO TOO
   Narvekar P, 2019, ASSAY DRUG DEV TECHN, V17, P167, DOI 10.1089/adt.2019.920
   Nickla DL, 2010, PROG RETIN EYE RES, V29, P144, DOI 10.1016/j.preteyeres.2009.12.002
   Patil S, 2018, RSC ADV, V8, P35461, DOI 10.1039/c8ra06298f
   Streets J, 2020, SCI PHARM, V88, DOI 10.3390/scipharm88030030
   Subhani S, 2016, ANGIOGENESIS, V19, P257, DOI 10.1007/s10456-016-9510-0
   Vavilala DT, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0113717
   Vavilala DT, 2013, BIOCHEM BIOPH RES CO, V438, P697, DOI 10.1016/j.bbrc.2013.07.118
   Vavilala DT, 2012, BIOCHEM BIOPH RES CO, V422, P369, DOI 10.1016/j.bbrc.2012.04.143
   Ventrice P, 2013, J PHARMACOL PHARMACO, V4, pS38, DOI 10.4103/0976-500X.120947
   Wang S, 2019, AAPS PHARMSCITECH, V20, DOI 10.1208/s12249-019-1491-z
   Wong LJ, 2008, RETINA-J RET VIT DIS, V28, P1151, DOI 10.1097/IAE.0b013e31817e100f
NR 31
TC 2
Z9 2
U1 1
U2 6
PU MARY ANN LIEBERT, INC
PI NEW ROCHELLE
PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA
SN 1540-658X
EI 1557-8127
J9 ASSAY DRUG DEV TECHN
JI ASSAY DRUG DEV. TECHNOL.
PD SEP 1
PY 2021
VL 19
IS 6
BP 350
EP 360
DI 10.1089/adt.2021.003
EA JUL 2021
PG 11
WC Biochemical Research Methods; Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Pharmacology & Pharmacy
GA UQ4JI
UT WOS:000669983400001
PM 34227879
DA 2022-11-30
ER

PT J
AU Haddad, WM
   Le Minous, F
   Legeai, J
   Souied, EH
AF Haddad, Walid-Michel
   Le Minous, Florence
   Legeai, Jeremy
   Souied, Eric H.
TI LONG-TERM OUTCOMES AND INCIDENCE OF RECURRENCE OF NEOVASCULARIZATION IN
   TREATED EXUDATIVE AGE-RELATED MACULAR DEGENERATION
SO RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES
LA English
DT Article
DE neovascular age-related macular degeneration; anti-VEGF therapy;
   incidence of recurrence of neovascularization; long-term follow-up;
   long-term remission
ID BASE-LINE PREDICTORS; VISUAL OUTCOMES; INTRAVITREAL RANIBIZUMAB;
   SUBGROUP ANALYSIS; DOSING REGIMEN; FOLLOW-UP; BEVACIZUMAB; LESIONS;
   ANCHOR; MARINA
AB Purpose: To assess the long-term visual outcome and incidence of recurrence of neovascular age-related macular degeneration (NAMD) treated with intravitreal anti-VEGF injections (IVAI).
   Methods: One hundred and thirty-two consecutive eyes treated with IVAI for NAMD based on an as-needed regimen with a follow-up >= 5 years (mean 7.55, range 5-9.67) were retrospectively reviewed. Main outcome measures included visual acuity, yearly number of IVAI, and occurrence of a long-term remission, defined as no recurrence of NAMD for >= 12 consecutive months.
   Results: Mean baseline visual acuity was 20/100. Mean final visual acuity change was -3.41 letters. Mean overall IVAI number was 22.8 +/- 17.4 (range 2-71), decreasing from 4.6 during Year 1 to 2.21 during Year 8. A significant positive correlation was found between the number of IVAI during the first year of treatment and the overall number of IVAI during 5 years, 6 years, 7 years, or 8 years follow-up (r =0.67-0.70,P <0.0001). Longterm remission occurred at least once in 83/132 eyes (63%) and was associated with a better visual outcome (-1.04 vs. -7.43 letters, P = 0.034). Incidence of yearly remission of NAMD increased from 28% during Year 2 to 59% during Year 8, fitting along a single straight line (+5.231%/ year, R-2 = 0.9511).
   Conclusion: The incidence of recurrence of treated NAMD decreases slowly but steadily during follow-up. The number of years of follow-up is the main factor to assess the proportion of treated eyes at remission at a given moment. Incidence of recurrence of neovascularization during year 1 and length of follow-up are significant factors when tailoring an optimal long-term follow-up regimen.
C1 [Haddad, Walid-Michel; Souied, Eric H.] Univ Paris Est, Ctr Hosp Intercommunal Creteil, Dept Ophthalmol, Creteil, France.
   [Haddad, Walid-Michel; Legeai, Jeremy] Polyclin Baie, Ctr Ophtalmol Baie, 1 Ave Quesnoy, F-50300 St Martin Des Champs, France.
   [Le Minous, Florence] Auditime Conseils, Rennes, France.
C3 Universite Paris-Est-Creteil-Val-de-Marne (UPEC); CHI Creteil
RP Haddad, WM (通讯作者)，Polyclin Baie, Ctr Ophtalmol Baie, 1 Ave Quesnoy, F-50300 St Martin Des Champs, France.
EM wmhadd@gmail.com
CR Amstutz CA, 2015, KLIN MONATSBL AUGENH, V232, P533, DOI 10.1055/s-0035-1545673
   Boulanger-Scemama E, 2015, J FR OPHTALMOL, V38, P620, DOI 10.1016/j.jfo.2014.11.015
   Boyer DS, 2007, OPHTHALMOLOGY, V114, P246, DOI 10.1016/j.ophtha.2006.10.045
   Chae B, 2015, INVEST OPHTH VIS SCI, V56, P5040, DOI 10.1167/iovs.15-16494
   Chakravarthy U, 2012, OPHTHALMOLOGY, V119, DOI 10.1016/j.ophtha.2012.04.015
   Cohen SY, 2009, AM J OPHTHALMOL, V148, P409, DOI 10.1016/j.ajo.2009.04.001
   Fung AE, 2007, AM J OPHTHALMOL, V143, P566, DOI 10.1016/j.ajo.2007.01.028
   Gillies MC, 2015, OPHTHALMOLOGY, V122, P1837, DOI 10.1016/j.ophtha.2015.05.010
   HAWKINS BS, 1991, ARCH OPHTHALMOL-CHIC, V109, P1109
   Holz FG, 2011, OPHTHALMOLOGY, V118, P663, DOI 10.1016/j.ophtha.2010.12.019
   Jaffe GJ, 2013, OPHTHALMOLOGY, V120, P1860, DOI 10.1016/j.ophtha.2013.01.073
   Kaiser PK, 2007, AM J OPHTHALMOL, V144, P850, DOI 10.1016/j.ajo.2007.08.012
   Kodjikian L, 2013, OPHTHALMOLOGY, V120, P2300, DOI 10.1016/j.ophtha.2013.06.020
   Liew G, 2006, NEW ENGL J MED, V355, P1432
   Maguire MG, 2016, OPHTHALMOLOGY, V123, P1751, DOI 10.1016/j.ophtha.2016.03.045
   MAGUIRE MG, 1990, ARCH OPHTHALMOL-CHIC, V108, P825
   Martin DF, 2012, OPHTHALMOLOGY, V119, DOI 10.1016/j.ophtha.2012.03.053
   Mrejen S, 2015, J CLIN MED, V4, P1380, DOI 10.3390/jcm4071380
   National Institute of Demographic Studies, LIF EXP ACC AG
   Ores R, 2014, AM J OPHTHALMOL, V158, P354, DOI 10.1016/j.ajo.2014.04.025
   Peden MC, 2015, OPHTHALMOLOGY, V122, P803, DOI 10.1016/j.ophtha.2014.11.018
   Rasmussen A, 2013, OPHTHALMOLOGY, V120, P2630, DOI 10.1016/j.ophtha.2013.05.018
   Regillo CD, 2008, AM J OPHTHALMOL, V145, P239, DOI 10.1016/j.ajo.2007.10.004
   Rofagha S, 2013, OPHTHALMOLOGY, V120, P2292, DOI 10.1016/j.ophtha.2013.03.046
   Schmidt-Erfurth U, 2014, BRIT J OPHTHALMOL, V98, P1144, DOI 10.1136/bjophthalmol-2014-305702
   Schmidt-Erfurth U, 2011, OPHTHALMOLOGY, V118, P831, DOI 10.1016/j.ophtha.2010.09.004
   Shah AR, 2007, AM J OPHTHALMOL, V143, P83, DOI 10.1016/j.ajo.2006.09.043
   Shah VP, 2014, RETINA-J RET VIT DIS, V34, P1281, DOI 10.1097/IAE.0000000000000166
   Silva R, 2013, OPHTHALMOLOGY, V120, P130, DOI 10.1016/j.ophtha.2012.07.026
   Singer MA, 2012, OPHTHALMOLOGY, V119, P1175, DOI 10.1016/j.ophtha.2011.12.016
   Social Security, LIF EXP CALC
   Souied EH, 2015, RETINA-J RET VIT DIS, V35, P1743, DOI 10.1097/IAE.0000000000000548
   Tanaka E, 2015, OPHTHALMOLOGY, V122, P153, DOI 10.1016/j.ophtha.2014.07.046
   Tufail A, 2014, OPHTHALMOLOGY, V121, P1092, DOI 10.1016/j.ophtha.2013.11.031
   Wong T, 2008, OPHTHALMOLOGY, V115, P116, DOI 10.1016/j.ophtha.2007.03.008
   Ying GS, 2013, OPHTHALMOLOGY, V120, P122, DOI 10.1016/j.ophtha.2012.07.042
   Zweifel SA, 2009, ARCH OPHTHALMOL-CHIC, V127, P1596, DOI 10.1001/archophthalmol.2009.326
NR 37
TC 14
Z9 16
U1 1
U2 3
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0275-004X
EI 1539-2864
J9 RETINA-J RET VIT DIS
JI Retin.-J. Retin. Vitr. Dis.
PD MAY
PY 2017
VL 37
IS 5
BP 951
EP 961
DI 10.1097/IAE.0000000000001282
PG 11
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA EW0IO
UT WOS:000402173400037
PM 27617541
DA 2022-11-30
ER

PT J
AU Micklisch, S
   Lin, YC
   Jacob, S
   Karlstetter, M
   Dannhausen, K
   Dasari, P
   von der Heide, M
   Dahse, HM
   Schmolz, L
   Grassmann, F
   Alene, M
   Fauser, S
   Neumann, H
   Lorkowski, S
   Pauly, D
   Weber, BH
   Joussen, AM
   Langmann, T
   Zipfel, PF
   Skerka, C
AF Micklisch, Sven
   Lin, Yuchen
   Jacob, Saskia
   Karlstetter, Marcus
   Dannhausen, Katharina
   Dasari, Prasad
   von der Heide, Monika
   Dahse, Hans-Martin
   Schmoelz, Lisa
   Grassmann, Felix
   Alene, Medhanie
   Fauser, Sascha
   Neumann, Harald
   Lorkowski, Stefan
   Pauly, Diana
   Weber, Bernhard H.
   Joussen, Antonia M.
   Langmann, Thomas
   Zipfel, Peter F.
   Skerka, Christine
TI Age-related macular degeneration associated polymorphism rs10490924 in
   ARMS2 results in deficiency of a complement activator
SO JOURNAL OF NEUROINFLAMMATION
LA English
DT Article
ID APOPTOTIC CELLS; PROPERDIN BINDS; MESSENGER-RNA; HIGH-RISK; VARIANT;
   RARE; EXPRESSION; REGULATORS; DISEASE; CONFERS
AB Background: Age-related macular degeneration (AMD) is the leading cause of blindness in developed countries. The polymorphism rs10490924 in the ARMS2 gene is highly associated with AMD and linked to an indel mutation (del443ins54), the latter inducing mRNA instability. At present, the function of the ARMS2 protein, the exact cellular sources in the retina and the biological consequences of the rs10490924 polymorphism are unclear.
   Methods: Recombinant ARMS2 was expressed in Pichia pastoris, and protein functions were studied regarding cell surface binding and complement activation in human serum using fluoresence-activated cell sorting (FACS) as well as laser scanning microscopy (LSM). Biolayer interferometry defined protein interactions. Furthermore, endogenous ARMS2 gene expression was studied in human blood derived monocytes and in human induced pluripotent stem cell-derived microglia (iPSdM) by PCR and LSM. The ARMS2 protein was localized in human genotyped retinal sections and in purified monocytes derived from AMD patients without the ARMS2 risk variant by LSM. ARMS2 expression in monocytes under oxidative stress was determined by Western blot analysis.
   Results: Here, we demonstrate for the first time that ARMS2 functions as surface complement regulator. Recombinant ARMS2 binds to human apoptotic and necrotic cells and initiates complement activation by recruiting the complement activator properdin. ARMS2-properdin complexes augment C3b surface opsonization for phagocytosis. We also demonstrate for the first time expression of ARMS2 in human monocytes especially under oxidative stress and in microglia cells of the human retina. The ARMS2 protein is absent in monocytes and also in microglia cells, derived from patients homozygous for the ARMS2 AMD risk variant (rs10490924).
   Conclusions: ARMS2 is likely involved in complement-mediated clearance of cellular debris. As AMD patients present with accumulated proteins and lipids on Bruch's membrane, ARMS2 protein deficiency due to the genetic risk variant might be involved in drusen formation.
C1 [Micklisch, Sven; Lin, Yuchen; Dasari, Prasad; von der Heide, Monika; Dahse, Hans-Martin; Alene, Medhanie; Zipfel, Peter F.; Skerka, Christine] Leibniz Inst Nat Prod Res & Infect Biol, Dept Infect Biol, Beutenbergstr 11, D-07745 Jena, Germany.
   [Jacob, Saskia; Joussen, Antonia M.] Charite, Dept Ophthalmol, Augustenburger Pl 1, D-13353 Berlin, Germany.
   [Karlstetter, Marcus; Dannhausen, Katharina; Fauser, Sascha; Langmann, Thomas] Univ Cologne, Dept Ophthalmol, Lab Expt Immunol Eye, Joseph Stelzmann Str 9, D-50931 Cologne, Germany.
   [Schmoelz, Lisa; Lorkowski, Stefan] Friedrich Schiller Univ Jena, Inst Nutr, Dornburger Str 25, D-07743 Jena, Germany.
   [Grassmann, Felix; Weber, Bernhard H.] Univ Regensburg, Inst Human Genet, Franz Josef Strauss Allee 11, D-93053 Regensburg, Germany.
   [Neumann, Harald] Univ Bonn, Inst Reconstruct Neurobiol, Sigmund Freud Str 25, D-53127 Bonn, Germany.
   [Pauly, Diana] Univ Hosp Regenburg, Dept Ophthalmol, Franz Josef Strauss Allee 11, D-93053 Regensburg, Germany.
   [Zipfel, Peter F.] Friedrich Schiller Univ, D-07743 Jena, Germany.
C3 Hans Knoll Institute (HKI); Free University of Berlin; Humboldt
   University of Berlin; Charite Universitatsmedizin Berlin; University of
   Cologne; Friedrich Schiller University of Jena; University of
   Regensburg; University of Bonn; University of Regensburg; Friedrich
   Schiller University of Jena
RP Skerka, C (通讯作者)，Leibniz Inst Nat Prod Res & Infect Biol, Dept Infect Biol, Beutenbergstr 11, D-07745 Jena, Germany.
EM christine.skerka@hki-jena.de
RI Lorkowski, Stefan/B-9689-2008; Joussen, Antonia/AAA-6901-2022; Neumann,
   Harald/A-9718-2010
OI Lorkowski, Stefan/0000-0002-9649-840X; Neumann,
   Harald/0000-0002-5071-5202; Grassmann, Felix/0000-0003-1390-7528; Weber,
   Bernhard H.F./0000-0002-8808-7723
FU German Council "Deutsche Forschungs-Gemeinschaft" [SK46, Zi432, LA1206];
   "Pro Retina" foundation; Thuringian Ministry of Science and Education,
   Germany; DFG [EXC 1023]
FX This research was supported by the German Council "Deutsche
   Forschungs-Gemeinschaft" SK46, Zi432, LA1206, the "Pro Retina"
   foundation and the Thuringian Ministry of Science and Education,
   Germany. HN is a member of the DFG-funded excellence cluster
   ImmunoSensation (EXC 1023). YL is a doctoral researcher at the
   International Leibniz Research School (ILRS), part of the Jena school of
   Microbial Communication (JSMC).
CR Allikmets R, 2008, NAT GENET, V40, P820, DOI 10.1038/ng0708-820
   Ambati J, 2013, NAT REV IMMUNOL, V13, P438, DOI 10.1038/nri3459
   Beutner C, 2010, NAT PROTOC, V5, P1481, DOI 10.1038/nprot.2010.90
   Cortes C, 2013, FRONT IMMUNOL, V3, DOI 10.3389/fimmu.2012.00412
   Crabb JW, 2002, P NATL ACAD SCI USA, V99, P14682, DOI 10.1073/pnas.222551899
   Eberhardt HU, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0078617
   Elkon KB, 2012, ADV EXP MED BIOL, V750, P14, DOI 10.1007/978-1-4614-3461-0_2
   Francis PJ, 2008, HUM MOL GENET, V17, P2673, DOI 10.1093/hmg/ddn167
   Friedrich U, 2011, HUM MOL GENET, V20, P1387, DOI 10.1093/hmg/ddr020
   Fritsche LG, 2008, NAT GENET, V40, P892, DOI 10.1038/ng.170
   Fritsche LG, 2016, NAT GENET, V48, P134, DOI 10.1038/ng.3448
   Fritsche LG, 2013, NAT GENET, V45, P433, DOI 10.1038/ng.2578
   Heinen S, 2009, BLOOD, V114, P2439, DOI 10.1182/blood-2009-02-205641
   Kanda A, 2007, P NATL ACAD SCI USA, V104, P16227, DOI 10.1073/pnas.0703933104
   Kemper C, 2008, P NATL ACAD SCI USA, V105, P9023, DOI 10.1073/pnas.0801015105
   Kortvely E, 2010, INVEST OPHTH VIS SCI, V51, P79, DOI 10.1167/iovs.09-3850
   Langford-Smith A, 2014, J INNATE IMMUN, V6, P407, DOI 10.1159/000356513
   Lauer N, 2011, J IMMUNOL, V187, P4374, DOI 10.4049/jimmunol.1002488
   Lesher AM, 2013, MOL IMMUNOL, V56, P191, DOI 10.1016/j.molimm.2013.06.002
   Montes T, 2009, P NATL ACAD SCI USA, V106, P4366, DOI 10.1073/pnas.0812584106
   Pauly D, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0096371
   Penfold PL, 2001, PROG RETIN EYE RES, V20, P385, DOI 10.1016/S1350-9462(00)00025-2
   Raychaudhuri S, 2011, NAT GENET, V43, P1232, DOI 10.1038/ng.976
   Ricklin D, 2012, IMMUNOBIOLOGY, V217, P1057, DOI 10.1016/j.imbio.2012.07.016
   Spencer KL, 2008, HUM MOL GENET, V17, P1821, DOI 10.1093/hmg/ddn075
   Trouw LA, 2008, MOL IMMUNOL, V45, P1199, DOI 10.1016/j.molimm.2007.09.008
   van de Ven JPH, 2013, NAT GENET, V45, P813, DOI 10.1038/ng.2640
   Wang GF, 2010, HUM GENET, V127, P595, DOI 10.1007/s00439-010-0805-8
   Weigelt K, 2007, J LEUKOCYTE BIOL, V82, P1564, DOI 10.1189/jlb.0707447
   Weismann D, 2011, NATURE, V478, P76, DOI 10.1038/nature10449
   Xu W, 2008, J IMMUNOL, V180, P7613, DOI 10.4049/jimmunol.180.11.7613
   Yu WH, 2013, MOL BIOL REP, V40, P5551, DOI 10.1007/s11033-013-2656-6
   Zhan XW, 2013, NAT GENET, V45, P1375, DOI 10.1038/ng.2758
   Zipfel PF, 2010, ADV EXP MED BIOL, V703, P9, DOI 10.1007/978-1-4419-5635-4_2
   Zipfel PF, 2009, NAT REV IMMUNOL, V9, P729, DOI 10.1038/nri2620
NR 35
TC 55
Z9 56
U1 1
U2 16
PU BIOMED CENTRAL LTD
PI LONDON
PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND
SN 1742-2094
J9 J NEUROINFLAMM
JI J. Neuroinflamm.
PD JAN 5
PY 2017
VL 14
AR 4
DI 10.1186/s12974-016-0776-3
PG 15
WC Immunology; Neurosciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Immunology; Neurosciences & Neurology
GA EH6PF
UT WOS:000391895000002
PM 28086806
OA Green Published, gold
DA 2022-11-30
ER

PT J
AU Novack, RL
   Staurenghi, G
   Girach, A
   Narendran, N
   Tolentino, M
AF Novack, Roger L.
   Staurenghi, Giovanni
   Girach, Aniz
   Narendran, Nirodhini
   Tolentino, Michael
TI Safety of Intravitreal Ocriplasmin for Focal Vitreomacular Adhesion in
   Patients with Exudative Age-Related Macular Degeneration
SO OPHTHALMOLOGY
LA English
DT Article
ID ENDOTHELIAL GROWTH-FACTOR; OPTICAL COHERENCE TOMOGRAPHY; POSTERIOR
   VITREOUS DETACHMENT; TIME-DOMAIN; ENZYMATIC VITREOLYSIS; RANIBIZUMAB;
   MECHANISMS; EXPRESSION; TRACTION; STRETCH
AB Purpose: The evaluation of the safety and preliminary efficacy of 125 mu g ocriplasmin intravitreal injection in patients with focal vitreomacular adhesion (VMA) and exudative age-related macular degeneration (AMD).
   Design: Randomized, sham-injection controlled, double-masked, multicenter, phase II trial.
   Participants: A total of 100 patients with VMA and wet AMD were randomized 3: 1 to receive 125 mg ocriplasmin intravitreal injection or sham injection.
   Methods: Study treatment was administered in the mid-vitreous cavity by injection. Post-treatment safety and efficacy assessments were made at baseline and on days 7, 14, and 28 and months 3, 6, and 12 after injection. Secondary efficacy end points were exploratory in nature.
   Main Outcome Measures: The safety and tolerability of ocriplasmin were evaluated. The primary efficacy end point was the proportion of patients with VMA release at day 28 after injection. Secondary end points reported included VMA release over time, total posterior vitreous detachment (PVD), change in visual acuity from baseline, and number of anti-vascular endothelial growth factor (VEGF) injections.
   Results: The safety of ocriplasmin in patients with VMA and wet AMD was shown to be comparable to the known safety profile, with the majority of adverse events in the study eye occurring in the first 7 days after study treatment. A greater proportion of patients achieved VMA resolution and total PVD at month 12 with ocriplasmin compared with sham treatment. There was a decrease in the number of anti-VEGF injections with ocriplasmin at month 12 compared with the sham group, although no differences in visual acuity were observed.
   Conclusions: Ocriplasmin treatment in this population seems to be generally safe and well tolerated and resulted in more patients achieving VMA resolution and PVD with less anti-VEGF use compared with sham treatment. (C) 2015 by the American Academy of Ophthalmology.
C1 [Novack, Roger L.] Retina Vitreous Assoc, Los Angeles, CA USA.
   [Staurenghi, Giovanni] Luigi Sacco Hosp, Dept Biomed & Clin Sci, Milan, Italy.
   [Girach, Aniz] NightstaRx Ltd, London, England.
   [Narendran, Nirodhini] Royal Wolverhampton Hosp NHS Trust, Wolverhampton, W Midlands, England.
   [Tolentino, Michael] Ctr Retina & Macular Dis, Winter Haven, FL USA.
C3 Retina Vitreous Associates Medical Group; University of Milan; Luigi
   Sacco Hospital
RP Novack, RL (通讯作者)，1127 Wilshire Blvd,Suite 1620, Los Angeles, CA 90017 USA.
EM rognov@laretina.com
RI Staurenghi, Giovanni/K-4388-2017
OI Staurenghi, Giovanni/0000-0002-2299-5251
FU ThromboGenics NV
FX Funding for this study was provided by ThromboGenics NV. ThromboGenics
   NV participated in the design and conduct of the study; collection,
   management, analysis, and interpretation of data; and preparation,
   review, and approval of the manuscript.
CR [Anonymous], 2014, JETREA PACK INS
   [Anonymous], 2013, JETREA SUMM PROD CHA
   Campagne MV, 2014, J PATHOL, V232, P151, DOI 10.1002/path.4266
   Cheung LK, 2013, PHARMACOTHERAPY, V33, P838, DOI 10.1002/phar.1264
   Folgar FA, 2012, INVEST OPHTH VIS SCI, V53, P7395, DOI 10.1167/iovs.12-10379
   Forooghian F, 2008, INVEST OPHTH VIS SCI, V49, P4290, DOI 10.1167/iovs.08-2113
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P564
   Gandorfer A, 2004, INVEST OPHTH VIS SCI, V45, P641, DOI 10.1167/iovs.03-0930
   Green-Simms AE, 2011, SEMIN OPHTHALMOL, V26, P137, DOI 10.3109/08820538.2011.559512
   Holz FG, 2011, OPHTHALMOLOGY, V118, P663, DOI 10.1016/j.ophtha.2010.12.019
   Jackson TL, 2013, RETINA-J RET VIT DIS, V33, P1099, DOI 10.1097/IAE.0b013e31828991d6
   Kaiser PK, 2012, GRAEF ARCH CLIN EXP, V250, P1563, DOI 10.1007/s00417-012-2123-4
   Krebs I, 2007, AM J OPHTHALMOL, V144, P741, DOI 10.1016/j.ajo.2007.07.024
   Krebs I, 2013, BRIT J OPHTHALMOL, V97, P1443, DOI 10.1136/bjophthalmol-2013-303513
   Lee SJ, 2011, OPHTHALMOLOGY, V118, P101, DOI 10.1016/j.ophtha.2010.04.015
   Leung CKS, 2008, INVEST OPHTH VIS SCI, V49, P4893, DOI 10.1167/iovs.07-1326
   Mayr-Sponer U, 2013, OPHTHALMOLOGY, V120, P2620, DOI 10.1016/j.ophtha.2013.05.032
   Mojana F, 2008, AM J OPHTHALMOL, V146, P218, DOI 10.1016/j.ajo.2008.04.027
   Qian CX, 2012, US OPHTHALMIC REV, V5, P119
   Scupola A, 1999, OPHTHALMOLOGICA, V213, P97, DOI 10.1159/000027400
   Sebag J, 2004, GRAEF ARCH CLIN EXP, V242, P690, DOI 10.1007/s00417-004-0980-1
   Simpson ARH, 2012, SURV OPHTHALMOL, V57, P498, DOI 10.1016/j.survophthal.2012.01.011
   Smith AG, 2014, EXPERT OPIN EMERG DR, V19, P157, DOI 10.1517/14728214.2014.884559
   Stalmans P, 2013, INVEST OPHTH VIS SCI, V54, P6620, DOI 10.1167/iovs.13-11811
   Stalmans P, 2012, NEW ENGL J MED, V367, P606, DOI 10.1056/NEJMoa1110823
   Steel DHW, 2011, BRIT J OPHTHALMOL, V95, P1051, DOI 10.1136/bjo.2010.182253
   Stewart MW, 2012, MAYO CLIN PROC, V87, P77, DOI 10.1016/j.mayocp.2011.10.001
   Sunness JS, 1999, OPHTHALMOLOGY, V106, P910, DOI 10.1016/S0161-6420(99)00509-6
   Suzuma I, 2002, J BIOL CHEM, V277, P1047, DOI 10.1074/jbc.M105336200
   Suzuma I, 2001, DIABETES, V50, P444, DOI 10.2337/diabetes.50.2.444
   Tranos P, 2013, DRUG DES DEV THER, V7, P485, DOI 10.2147/DDDT.S43470
NR 31
TC 21
Z9 21
U1 1
U2 3
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0161-6420
EI 1549-4713
J9 OPHTHALMOLOGY
JI Ophthalmology
PD APR
PY 2015
VL 122
IS 4
BP 796
EP 802
DI 10.1016/j.ophtha.2014.10.006
PG 7
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA CE3EX
UT WOS:000351710100027
PM 25435217
DA 2022-11-30
ER

PT J
AU Kenney, MC
   Hertzog, D
   Chak, G
   Atilano, SR
   Khatibi, N
   Soe, K
   Nobe, A
   Yang, E
   Chwa, M
   Zhu, FL
   Memarzadeh, M
   King, J
   Langberg, J
   Small, K
   Nesburn, AB
   Boyer, DS
   Udar, N
AF Kenney, M. Cristina
   Hertzog, Dieter
   Chak, Garrick
   Atilano, Shari R.
   Khatibi, Nikan
   Soe, Kyaw
   Nobe, Andrew
   Yang, Elizabeth
   Chwa, Marilyn
   Zhu, Feilin
   Memarzadeh, Masood
   King, Jacqueline
   Langberg, Jonathan
   Small, Kent
   Nesburn, Anthony B.
   Boyer, David S.
   Udar, Nitin
TI Mitochondrial DNA haplogroups confer differences in risk for age-related
   macular degeneration: a case control study
SO BMC MEDICAL GENETICS
LA English
DT Article
DE Age-related macular degeneration; Mitochondrial haplogroups; mtDNA; CFH;
   ARMS2
ID COMPLEMENT FACTOR-H; HEREDITARY OPTIC NEUROPATHY; LOC387715 GENE;
   POLYMORPHISM; ASSOCIATION; VARIANTS; SUSCEPTIBILITY; MUTATIONS; DISEASE;
   CFH
AB Background: Age-related macular degeneration (AMD) is the leading cause of vision loss in elderly, Caucasian populations. There is strong evidence that mitochondrial dysfunction and oxidative stress play a role in the cell death found in AMD retinas. The purpose of this study was to examine the association of the Caucasian mitochondrial JTU haplogroup cluster with AMD. We also assessed for gender bias and additive risk with known high risk nuclear gene SNPs, ARMS2/LOC387715 (G > T; Ala69Ser, rs10490924) and CFH (T > C; Try402His, rs1061170).
   Methods: Total DNA was isolated from 162 AMD subjects and 164 age-matched control subjects located in Los Angeles, California, USA. Polymerase chain reaction (PCR) and restriction enzyme digestion were used to identify the J, U, T, and H mitochondrial haplogroups and the ARMS2-rs10490924 and CFH-rs1061170 SNPs. PCR amplified products were sequenced to verify the nucleotide substitutions for the haplogroups and ARMS2 gene.
   Results: The JTU haplogroup cluster occurred in 34% (55/162) of AMD subjects versus 15% (24/164) of normal (OR = 2.99; p = 0.0001). This association was slightly greater in males (OR = 3.98, p = 0.005) than the female population (OR = 3.02, p = 0.001). Assuming a dominant effect, the risk alleles for the ARMS2 (rs10490924; p = 0.00001) and CFH (rs1061170; p = 0.027) SNPs were significantly associated with total AMD populations. We found there was no additive risk for the ARMS2 (rs10490924) or CFH (rs1061170) SNPs on the JTU haplogroup background.
   Conclusions: There is a strong association of the JTU haplogroup cluster with AMD. In our Southern California population, the ARMS2 (rs10490924) and CFH (rs1061170) genes were significantly but independently associated with AMD. SNPs defining the JTU mitochondrial haplogroup cluster may change the retinal bioenergetics and play a significant role in the pathogenesis of AMD.
C1 [Kenney, M. Cristina; Hertzog, Dieter; Chak, Garrick; Atilano, Shari R.; Khatibi, Nikan; Soe, Kyaw; Nobe, Andrew; Chwa, Marilyn; Zhu, Feilin; Memarzadeh, Masood; King, Jacqueline; Langberg, Jonathan; Nesburn, Anthony B.; Udar, Nitin] Univ Calif Irvine, Gavin Herbert Eye Inst, Irvine, CA 92697 USA.
   [Hertzog, Dieter] Loma Linda Univ, Sch Med, Loma Linda, CA USA.
   [Yang, Elizabeth] NW Feinberg Sch Med, Chicago, IL USA.
   [Small, Kent; Nesburn, Anthony B.] Cedars Sinai Med Ctr, Los Angeles, CA 90048 USA.
   [Boyer, David S.] Retina Vitreous Associates Med Grp, Beverly Hills, CA USA.
C3 University of California System; University of California Irvine; Loma
   Linda University; Northwestern University; Feinberg School of Medicine;
   Cedars Sinai Medical Center; Retina Vitreous Associates Medical Group
RP Kenney, MC (通讯作者)，Univ Calif Irvine, Gavin Herbert Eye Inst, Hewitt Hall,Room 2028,843 Hlth Sci Rd, Irvine, CA 92697 USA.
EM mkenney@uci.edu
OI Atilano, Shari/0000-0002-7729-7864; Udar, Nitin/0000-0001-8533-9190
FU Discovery Eye Foundation; Lincy Foundation; Beckman Macular Research
   Initiative; Henry Guenther Foundation; Polly and Michael Smith
   Foundation; Research to Prevent Blindness Foundation
FX We thank the individuals who donated blood samples to be used in this
   study and the research coordinators who worked on the study. This
   research was supported by the Discovery Eye Foundation, Lincy
   Foundation, Beckman Macular Research Initiative, Henry Guenther
   Foundation, Polly and Michael Smith Foundation, and Research to Prevent
   Blindness Foundation.
CR Abu-Amero KK, 2011, MOL VIS, V17, P1468
   Abu-Amero KK, 2011, MOL VIS, V17, P543
   Baas DC, 2012, MOL VIS, V18, P657
   Bravo-Nuevo A, 2003, ADV EXP MED BIOL, V533, P241
   Brown MD, 1997, AM J HUM GENET, V60, P381
   Canter JA, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002091
   Conley YP, 2005, HUM MOL GENET, V14, P1991, DOI 10.1093/hmg/ddi204
   Conley YP, 2006, HUM MOL GENET, V15, P3206, DOI 10.1093/hmg/ddl396
   Coskun PE, 2004, P NATL ACAD SCI USA, V101, P10726, DOI 10.1073/pnas.0403649101
   Coskun P, 2012, BBA-GEN SUBJECTS, V1820, P553, DOI 10.1016/j.bbagen.2011.08.008
   Edwards AO, 2005, SCIENCE, V308, P421, DOI 10.1126/science.1110189
   Esparza-Gordillo J, 2004, IMMUNOGENETICS, V56, P77, DOI 10.1007/s00251-004-0660-7
   Francis PJ, 2007, HUM HERED, V63, P212, DOI 10.1159/000100046
   Fritsche LG, 2008, NAT GENET, V40, P892, DOI 10.1038/ng.170
   Gomez-Duran A, 2012, BBA-MOL BASIS DIS, V1822, P1216, DOI 10.1016/j.bbadis.2012.04.014
   Gomez-Duran A, 2010, HUM MOL GENET, V19, P3343, DOI 10.1093/hmg/ddq246
   Gotoh N, 2006, HUM GENET, V120, P139, DOI 10.1007/s00439-006-0187-0
   Grassi MA, 2006, HUM MUTAT, V27, P921, DOI 10.1002/humu.20359
   Haines JL, 2005, SCIENCE, V308, P419, DOI 10.1126/science.1110359
   Hendrickson SL, 2010, JAIDS-J ACQ IMM DEF, V53, P451, DOI 10.1097/QAI.0b013e3181cb8319
   Hofmann S, 1997, GENOMICS, V39, P8, DOI 10.1006/geno.1996.4474
   Howell N, 2003, AM J MED GENET A, V119A, P147, DOI 10.1002/ajmg.a.20135
   Hudson G, 2007, AM J HUM GENET, V81, P228, DOI 10.1086/519394
   Huerta C, 2005, J NEUROL SCI, V236, P49, DOI 10.1016/j.jns.2005.04.016
   Jones MM, 2007, ARCH OPHTHALMOL-CHIC, V125, P1235, DOI 10.1001/archopht.125.9.1235
   Kanda A, 2007, P NATL ACAD SCI USA, V104, P16227, DOI 10.1073/pnas.0703933104
   Katta S, 2009, J GENET, V88, P425, DOI 10.1007/s12041-009-0064-4
   Kaur I, 2008, INVEST OPHTH VIS SCI, V49, P1771, DOI 10.1167/iovs.07-0560
   Kenney MC, 2010, INVEST OPHTH VIS SCI, V51, P4289, DOI 10.1167/iovs.09-4778
   Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557
   Kofler B, 2009, BMC MED GENET, V10, DOI 10.1186/1471-2350-10-35
   Kondo N, 2007, AM J OPHTHALMOL, V144, P608, DOI 10.1016/j.ajo.2007.06.003
   Kortvely E, 2010, INVEST OPHTH VIS SCI, V51, P79, DOI 10.1167/iovs.09-3850
   Lau LI, 2006, INVEST OPHTH VIS SCI, V47, P3242, DOI 10.1167/iovs.05-1532
   Liang FQ, 2003, EXP EYE RES, V76, P397, DOI 10.1016/S0014-4835(03)00023-X
   Maller J, 2006, NAT GENET, V38, P1055, DOI 10.1038/ng1873
   Mishmar D, 2003, P NATL ACAD SCI USA, V100, P171, DOI 10.1073/pnas.0136972100
   Montiel-Sosa F, 2006, GENE, V368, P21, DOI 10.1016/j.gene.2005.09.015
   Mori K, 2007, INVEST OPHTH VIS SCI, V48, P5315, DOI 10.1167/iovs.07-0426
   Moshfeghi DM, 2007, RETINA-J RET VIT DIS, V27, P269, DOI 10.1097/IAE.0b013e31802e3e9b
   Mueller EE, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0030874
   Muller-Eberhard H J, 1980, Adv Immunol, V29, P1, DOI 10.1016/S0065-2776(08)60042-5
   Nag TC, 2006, BRAIN RES BULL, V71, P224, DOI 10.1016/j.brainresbull.2006.09.007
   Narayanan R, 2007, OPHTHALMOLOGY, V114, P1327, DOI 10.1016/j.ophtha.2006.10.035
   Nordgaard CL, 2008, INVEST OPHTH VIS SCI, V49, P2848, DOI 10.1167/iovs.07-1352
   Okamoto H, 2006, MOL VIS, V12, P156
   Rivera A, 2005, HUM MOL GENET, V14, P3227, DOI 10.1093/hmg/ddi353
   Ross RJ, 2007, EXPERT REV OPHTHALMO, V2, P443, DOI 10.1586/17469899.2.3.443
   Ross RJ, 2007, INVEST OPHTH VIS SCI, V48, P1128, DOI 10.1167/iovs.06-0999
   Ruiz-Pesini E, 2004, SCIENCE, V303, P223, DOI 10.1126/science.1088434
   SanGiovanni JP, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0005508
   Schaumberg DA, 2007, ARCH OPHTHALMOL-CHIC, V125, P55, DOI 10.1001/archopht.125.1.55
   Schmidt S, 2006, AM J HUM GENET, V78, P852, DOI 10.1086/503822
   Seddon JM, 2006, OPHTHALMOLOGY, V113, P260, DOI 10.1016/j.ophtha.2005.11.001
   Seddon JM, 2007, JAMA-J AM MED ASSOC, V297, P1793, DOI 10.1001/jama.297.16.1793
   Shastry BS, 2006, OPHTHALMOLOGICA, V220, P291, DOI 10.1159/000094617
   Shuler RK, 2007, ARCH OPHTHALMOL-CHIC, V125, P63, DOI 10.1001/archopht.125.1.63
   Suissa S, 2009, PLOS GENET, V5, DOI 10.1371/journal.pgen.1000474
   Tanimoto S, 2007, NEUROSCI LETT, V414, P71, DOI 10.1016/j.neulet.2006.12.011
   Torroni A, 1996, GENETICS, V144, P1835
   Torroni A, 1997, AM J HUM GENET, V60, P1107
   TORRONI A, 1993, AM J HUM GENET, V53, P563
   Udar N, 2009, INVEST OPHTH VIS SCI, V50, P2966, DOI 10.1167/iovs.08-2646
   van der Walt JM, 2004, NEUROSCI LETT, V365, P28, DOI 10.1016/j.neulet.2004.04.051
   van der Walt JM, 2003, AM J HUM GENET, V72, P804, DOI 10.1086/373937
   WALLACE DC, 1994, J BIOENERG BIOMEMBR, V26, P241, DOI 10.1007/BF00763096
   Wallace DC, 2005, ANNU REV GENET, V39, P359, DOI 10.1146/annurev.genet.39.110304.095751
   WALLACE DC, 1992, ANNU REV BIOCHEM, V61, P1175, DOI 10.1146/annurev.bi.61.070192.005523
   Wang GF, 2009, INVEST OPHTH VIS SCI, V50, P3084, DOI 10.1167/iovs.08-3240
   Wolf C, 2010, BMC GENET, V11, DOI 10.1186/1471-2156-11-8
NR 70
TC 34
Z9 35
U1 0
U2 10
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 1471-2350
J9 BMC MED GENET
JI BMC Med. Genet.
PD JAN 9
PY 2013
VL 14
AR 4
DI 10.1186/1471-2350-14-4
PG 9
WC Genetics & Heredity
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Genetics & Heredity
GA 088ES
UT WOS:000314817200001
PM 23302509
OA gold, Green Published
DA 2022-11-30
ER

PT J
AU Erie, JC
   Good, JA
   Butz, JA
   Pulido, JS
AF Erie, Jay C.
   Good, Jonathan A.
   Butz, John A.
   Pulido, Jose S.
TI Reduced Zinc and Copper in the Retinal Pigment Epithelium and Choroid in
   Age-related Macular Degeneration
SO AMERICAN JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
ID INTRACELLULAR ZINC; PATHOGENESIS; APOPTOSIS; DEPLETION; DISEASE
AB PURPOSE: To measure zinc and copper levels in the retinal pigment epithelium (RPE) and choroid complex and in the neural retina in subjects with and without age-related macular degeneration (AMD).
   DESIGN: Laboratory investigation.
   METHODS: Eighty-eight donor eyes (44 subjects) were analyzed. After retinal dissection, the RPE and choroid complex was photographed. Using the Minnesota Grading System (MGS), the RPE and choroid complex was classified into 1 of 4 stages as defined by the Age,Related Eye Disease Study. Subjects without AMD were defined as both eyes having MGS stage 1; subjects with AMD were defined as both eyes having MGS stages 2 through 4. Zinc and copper levels were determined by using a inductively coupled plasma-mass spectrometer. Metal levels from two eyes of the same subject were averaged and treated as one observation. Differences in metal levels were examined by using Wilcoxon rank,sum tests.
   RESULTS: The mean RPE and choroid complex zinc level in subjects with AMD (+/- standard deviation, 223.7 +/- 94.0 mu g/g; n = 15) was reduced 24% when compared with that of subjects without AMD (292.1 +/- 98.5 mu g/g; n = 29; P = .01). The mean RPE and choroid complex copper level in subjects with AMD (5.1 +/- 1.1 mu g/g) was reduced 23% when compared with that of subjects without AMD (6.6 +/- 1.4 mu g/g; P = .002). No difference was detected in retinal zinc and copper levels in subjects with and without AMD (P > .09).
   CONCLUSIONS: Reduced RPE and choroid complex zinc and copper levels in AMD eyes combined with previous information that oral supplementation of zinc plus copper reduces the risk of progression of AMD suggests that metal homeostasis plays a role in AMD and in retinal health. (Am J Ophthalmol 2009;147:276-282. (C) 2009 by Elsevier Inc. All rights reserved.)
C1 [Erie, Jay C.; Pulido, Jose S.] Mayo Clin, Dept Ophthalmol, Rochester, MN 55905 USA.
   [Good, Jonathan A.; Butz, John A.] Mayo Clin, Met Lab, Rochester, MN 55905 USA.
C3 Mayo Clinic; Mayo Clinic
RP Erie, JC (通讯作者)，Mayo Clin, Dept Ophthalmol, 200 1st St SW, Rochester, MN 55905 USA.
EM erie.jay@mayo.edu
FU MAYO FOUNDATION, ROCHESTER, MINNESOTA; RESEARCH TO Prevent. Blindness
   Inc, New York, New York
FX THIS STUDY WAS SUPPORTED IN PART BY THE MAYO FOUNDATION, ROCHESTER,
   MINNESOTA, AND BY RESEARCH TO Prevent. Blindness Inc, New York, New
   York. The authors indicate no financial conflict of interest. Involved
   in design and conduct of study (J.C.E., J.A.G., J.A.B., J.S.P.);
   collection, management, and analysis of data (J.C.E., J.A.G., J.A.B.);
   interpretation of data (J.C.E., J.A.G., J.A.B., J.S.P.); preparation Of
   manuscript (J.C.E.); and review and approval (if manuscript (J.C.E.,
   J.A.G., J.A.B., J.S.P.). The study protocol was reviewed and approved by
   the Institutional Review Board of the Mayo Clinic. All tissue was
   Obtained with consent for use in medical research from the donor or
   donor's family in accordance with the principles Outlined in the
   Declaration of Helsinki.; We thank Dr David O. Hodge, Department of
   Biostatistics, Mayo Clinic, Rochester, Minnesota for assistance and
   statistical consultation.
CR Age-Related Eye Dis Study Res Grp, 2001, AM J OPHTHALMOL, V132, P668
   Beatty S, 2000, SURV OPHTHALMOL, V45, P115, DOI 10.1016/S0039-6257(00)00140-5
   Crabb JW, 2002, P NATL ACAD SCI USA, V99, P14682, DOI 10.1073/pnas.222551899
   Curcio CA, 1996, INVEST OPHTH VIS SCI, V37, P1236
   DANCIS A, 1994, J BIOL CHEM, V269, P25660
   Decanini A, 2007, AM J OPHTHALMOL, V143, P607, DOI 10.1016/j.ajo.2006.12.006
   Dunaief JL, 2006, INVEST OPHTH VIS SCI, V47, P4660, DOI 10.1167/iovs.06-0568
   Fabe JS, 2000, BIOL TRACE ELEM RES, V75, P43, DOI 10.1385/BTER:75:1-3:43
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P564
   GALIN MA, 1962, INVEST OPHTH VISUAL, V1, P142
   Gensler G, 2002, J NUTR, V132, P697
   Grahn BH, 2001, J AM COLL NUTR, V20, P106, DOI 10.1080/07315724.2001.10719022
   Hyun HJ, 2000, BRAIN RES, V869, P39, DOI 10.1016/S0006-8993(00)02340-4
   Hyun HJ, 2001, INVEST OPHTH VIS SCI, V42, P460
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1417, DOI 10.1001/archopht.119.10.1417
   KING JC, 1986, J AM DIET ASSOC, V86, P1523
   Klevay LM, 1998, J AM COLL NUTR, V17, P322, DOI 10.1080/07315724.1998.10718769
   Krajacic P, 2006, INVEST OPHTH VIS SCI, V47, P3129, DOI 10.1167/iovs.05-1601
   Kuo YM, 2006, J NUTR, V136, P21, DOI 10.1093/jn/136.1.21
   Leiner M., 1942, Biologisches Zentralblatt Leipzig, V62, P119
   MaresPerlman JA, 1996, ARCH OPHTHALMOL-CHIC, V114, P991, DOI 10.1001/archopht.1996.01100140199014
   NEWSOME DA, 1988, ARCH OPHTHALMOL-CHIC, V106, P192
   NEWSOME DA, 1992, CURR EYE RES, V11, P213, DOI 10.3109/02713689209001772
   NEWSOME DA, 1987, INVEST OPHTH VIS SCI, V28, P1795
   Newsome DA, 1995, J TRACE ELEM EXP MED, V8, P193
   Nicolas MG, 1996, EXP EYE RES, V62, P399, DOI 10.1006/exer.1996.0045
   Olsen TW, 2004, INVEST OPHTH VIS SCI, V45, P4484, DOI 10.1167/iovs.04-0342
   SARKS JP, 1988, EYE, V2, P552, DOI 10.1038/eye.1988.106
   Tate DJ, 2006, CURR EYE RES, V31, P675, DOI 10.1080/02713680600801024
   Ugarte M, 2001, PROG NEUROBIOL, V64, P219, DOI 10.1016/S0301-0082(00)00057-5
   VALLEE BL, 1990, BIOCHEMISTRY-US, V29, P5647, DOI 10.1021/bi00476a001
   van Leeuwen R, 2005, JAMA-J AM MED ASSOC, V294, P3101, DOI 10.1001/jama.294.24.3101
   WAGNER PA, 1985, GERIATRICS, V40, P111
   WILLIAMS DM, 1983, SEMIN HEMATOL, V20, P118
   Wills NK, 2008, EXP EYE RES, V87, P80, DOI 10.1016/j.exer.2008.04.013
   WRAY SH, 1976, INVEST OPHTH VISUAL, V15, P128
   Zarbin MA, 2004, ARCH OPHTHALMOL-CHIC, V122, P598, DOI 10.1001/archopht.122.4.598
NR 37
TC 51
Z9 51
U1 1
U2 7
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 0002-9394
EI 1879-1891
J9 AM J OPHTHALMOL
JI Am. J. Ophthalmol.
PD FEB
PY 2009
VL 147
IS 2
BP 276
EP 282
DI 10.1016/j.ajo.2008.08.014
PG 7
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 397SZ
UT WOS:000262683700013
PM 18848316
DA 2022-11-30
ER

PT J
AU Jia, YL
   Bailey, ST
   Wilson, DJ
   Tan, O
   Klein, ML
   Flaxel, CJ
   Potsaid, B
   Liu, JJ
   Lu, CD
   Kraus, MF
   Fujimoto, JG
   Huang, D
AF Jia, Yali
   Bailey, Steven T.
   Wilson, David J.
   Tan, Ou
   Klein, Michael L.
   Flaxel, Christina J.
   Potsaid, Benjamin
   Liu, Jonathan J.
   Lu, Chen D.
   Kraus, Martin F.
   Fujimoto, James G.
   Huang, David
TI Quantitative Optical Coherence Tomography Angiography of Choroidal
   Neovascularization in Age-Related Macular Degeneration
SO OPHTHALMOLOGY
LA English
DT Article
ID RETINAL BLOOD-FLOW; LASER-DOPPLER FLOWMETRY; AMPLITUDE-DECORRELATION
   ANGIOGRAPHY; INDOCYANINE GREEN ANGIOGRAPHY; SWEPT-SOURCE;
   MOTION-CORRECTION; DOMAIN OCT; MICROCIRCULATION; DISEASES;
   MICROVASCULATURE
AB Purpose: To detect and quantify choroidal neovascularization (CNV) in patients with age-related macular degeneration (AMD) using optical coherence tomography (OCT) angiography.
   Design: Observational, cross-sectional study.
   Participants: A total of 5 normal subjects and 5 subjects with neovascular AMD were included.
   Methods: A total of 5 eyes with neovascular AMD and 5 normal age-matched controls were scanned by a high-speed (100 000 A-scans/seconds) 1050-nm wavelength swept-source OCT. The macular angiography scan covered a 3 x 3-mm area and comprised 200 x 200 x 8 A-scans acquired in 3.5 seconds. Flow was detected using the split-spectrum amplitude-decorrelation angiography (SSADA) algorithm. Motion artifacts were removed by 3-dimensional (3D) orthogonal registration and merging of 4 scans. The 3D angiography was segmented into 3 layers: inner retina (to show retinal vasculature), outer retina (to identify CNV), and choroid. En face maximum projection was used to obtain 2-dimensional angiograms from the 3 layers. The CNV area and flow index were computed from the en face OCT angiogram of the outer retinal layer. Flow (decorrelation) and structural data were combined in composite color angiograms for both en face and cross-sectional views.
   Main Outcome Measures: The CNV angiogram, CNV area, and CNV flow index.
   Results: En face OCT angiograms of CNV showed sizes and locations that were confirmed by fluorescein angiography (FA). Optical coherence tomography angiography provided more distinct vascular network patterns that were less obscured by subretinal hemorrhage. The en face angiograms also showed areas of reduced choroidal flow adjacent to the CNV in all cases and significantly reduced retinal flow in 1 case. Cross-sectional angiograms were used to visualize CNV location relative to the retinal pigment epithelium and Bruch's layer and classify type I and type II CNV. A feeder vessel could be identified in 1 case. Higher flow indexes were associated with larger CNV and type II CNV.
   Conclusions: Optical coherence tomography angiography provides depth-resolved information and detailed images of CNV in neovascular AMD. Quantitative information regarding CNV flow and area can be obtained. Further studies are needed to assess the role of quantitative OCT angiography in the evaluation and treatment of neovascular AMD. (C) 2014 by the American Academy of Ophthalmology.
C1 [Jia, Yali; Bailey, Steven T.; Wilson, David J.; Tan, Ou; Klein, Michael L.; Flaxel, Christina J.; Huang, David] Oregon Hlth & Univ, Casey Eye Inst, Portland, OR 97239 USA.
   [Potsaid, Benjamin; Liu, Jonathan J.; Lu, Chen D.; Kraus, Martin F.; Fujimoto, James G.] MIT, Dept Elect Engn & Comp Sci, Cambridge, MA 02139 USA.
   [Potsaid, Benjamin] Thorlabs Inc, Adv Imaging Grp, Newton, NJ USA.
   [Kraus, Martin F.] Univ Erlangen Nurnberg, Pattern Recognit Lab, D-91054 Erlangen, Germany.
   [Kraus, Martin F.] Univ Erlangen Nurnberg, Sch Adv Opt Technol, D-91054 Erlangen, Germany.
C3 Oregon Health & Science University; Massachusetts Institute of
   Technology (MIT); University of Erlangen Nuremberg; University of
   Erlangen Nuremberg
RP Huang, D (通讯作者)，Oregon Hlth & Univ, Casey Eye Inst, 3375 SW Terwilliger Blvd, Portland, OR 97239 USA.
EM davidhuang@alum.mit.edu
OI Jia, Yali/0000-0002-2784-1905; Bailey, Steven/0000-0003-4949-1464
FU National Institutes of Health [1R01 EY023285-01, R01 EY013516]; Clinical
   and Translational Science Award [UL1TR000128]; Research to Prevent
   Blindness [R01-EY11289-26]; German Research Foundation
   [DFG-HO-1791/11-1, DFG-GSC80-SAOT]; AFOSR [FA9550-10-1-0551]; 
   [P30EY010572]; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES
   [UL1TR000128] Funding Source: NIH RePORTER; NATIONAL EYE INSTITUTE
   [R01EY011289, P30EY010572, R01EY013516, R01EY023285] Funding Source: NIH
   RePORTER
FX Supported by National Institutes of Health Grants 1R01 EY023285-01 and
   R01 EY013516, Rosenbaum's P30EY010572, Clinical and Translational
   Science Award Grant UL1TR000128, an unrestricted grant from Research to
   Prevent Blindness, R01-EY11289-26 and AFOSR FA9550-10-1-0551, and German
   Research Foundation DFG-HO-1791/11-1 and DFG-GSC80-SAOT.
CR Ambati J, 2003, SURV OPHTHALMOL, V48, P257, DOI 10.1016/S0039-6257(03)00030-4
   Baumann B, 2011, BIOMED OPT EXPRESS, V2, P1539, DOI 10.1364/BOE.2.001539
   BRIERS JD, 1982, INVEST OPHTH VIS SCI, V22, P255
   Chan TF, 2001, IEEE T IMAGE PROCESS, V10, P266, DOI 10.1109/83.902291
   Congdon N, 2004, ARCH OPHTHALMOL-CHIC, V122, P477
   Coscas F, 2007, AM J OPHTHALMOL, V144, P592, DOI 10.1016/j.ajo.2007.06.014
   de Bruin DM, 2008, INVEST OPHTH VIS SCI, V49, P4545, DOI 10.1167/iovs.07-1553
   Do DV, 2012, OPHTHALMOLOGY, V119, P771, DOI 10.1016/j.ophtha.2011.10.019
   Enfield J, 2011, BIOMED OPT EXPRESS, V2, P1184, DOI 10.1364/BOE.2.001184
   FERRIS FL, 1984, ARCH OPHTHALMOL-CHIC, V102, P1640
   Fingler J, 2009, OPT EXPRESS, V17, P22190, DOI 10.1364/OE.17.022190
   Framme C, 2010, INVEST OPHTH VIS SCI, V51, P1671, DOI 10.1167/iovs.09-4496
   Giovannini A, 1999, BRIT J OPHTHALMOL, V83, P438, DOI 10.1136/bjo.83.4.438
   Grulkowski I, 2009, OPT EXPRESS, V17, P23736, DOI 10.1364/OE.17.023736
   HAYASHI K, 1985, OPHTHALMOLOGICA, V190, P30, DOI 10.1159/000309489
   Hee MR, 1996, OPHTHALMOLOGY, V103, P1260, DOI 10.1016/S0161-6420(96)30512-5
   Hendargo HC, 2013, BIOMED OPT EXPRESS, V4, P803, DOI 10.1364/BOE.4.000803
   Hiro-Oka H., 2012, BIOMED OPT EXPRESS, V3, P3067, DOI DOI 10.1364/B0E.3.003067
   Hong YJ, 2013, INVEST OPHTH VIS SCI, V54, P3621, DOI 10.1167/iovs.12-11184
   Hong YJ, 2012, OPT EXPRESS, V20, P2740, DOI 10.1364/OE.20.002740
   HUANG D, 1991, SCIENCE, V254, P1178, DOI 10.1126/science.1957169
   Jia YL, 2012, BIOMED OPT EXPRESS, V3, DOI 10.1364/BOE.3.003127
   Jia YL, 2014, OPHTHALMOLOGY, V121, P1322, DOI 10.1016/j.ophtha.2014.01.021
   Jia YL, 2012, OPT EXPRESS, V20, P4710, DOI 10.1364/OE.20.004710
   Jonathan E, 2011, J BIOPHOTONICS, V4, P583, DOI 10.1002/jbio.201000103
   Jonescu-Cuypers CP, 2001, BRIT J OPHTHALMOL, V85, P304, DOI 10.1136/bjo.85.3.304
   Kim DY, 2011, BIOMED OPT EXPRESS, V2, P1504, DOI 10.1364/BOE.2.001504
   Klein T, 2012, P SOC PHOTO-OPT INS
   Kraus MF, 2012, BIOMED OPT EXPRESS, V3, P1182, DOI 10.1364/BOE.3.001182
   Laser Institute of America, 2007, Z136 ANSI, P1
   Liu GJ, 2012, BIOMED OPT EXPRESS, V3, P2669, DOI 10.1364/BOE.3.002669
   Liu GJ, 2011, OPT EXPRESS, V19, P3657, DOI 10.1364/OE.19.003657
   Lopez-Saez MP, 1998, ANN ALLERG ASTHMA IM, V81, P428, DOI 10.1016/S1081-1206(10)63140-7
   Mariampillai A, 2008, OPT LETT, V33, P1530, DOI 10.1364/OL.33.001530
   Mariampillai A, 2010, OPT LETT, V35, P1257, DOI 10.1364/OL.35.001257
   McLeod DS, 2009, INVEST OPHTH VIS SCI, V50, P4982, DOI 10.1167/iovs.09-3639
   MELROSE MA, 1987, ANN OPHTHALMOL, V19, P396
   Michelson G, 1996, J GLAUCOMA, V5, P99
   Miura M, 2011, INVEST OPHTH VIS SCI, V52, P2689, DOI 10.1167/iovs.10-6282
   Motaghiannezam R, 2012, BIOMED OPT EXPRESS, V3, P503, DOI 10.1364/BOE.3.000503
   OBEID AN, 1990, J MED ENG TECHNOL, V14, P178, DOI 10.3109/03091909009009955
   Pedersen CJ, 2007, OPT LETT, V32, P506, DOI 10.1364/OL.32.000506
   Petrig BL, 1999, AM J OPHTHALMOL, V127, P413, DOI 10.1016/S0002-9394(98)00437-1
   Petrig BL, 1995, OCULAR BLOOD FLOW, P120
   Potsaid B, 2012, P SOC PHOTO-OPT INS
   Potsaid B, 2010, OPT EXPRESS, V18, P20029, DOI 10.1364/OE.18.020029
   Riva Charles E., 2001, International Ophthalmology, V23, P183, DOI 10.1023/A:1014433913240
   Sayanagi K, 2009, OPHTHALMOLOGY, V116, P947, DOI 10.1016/j.ophtha.2008.11.002
   Srinivasan VJ, 2010, OPT EXPRESS, V18, P2477, DOI 10.1364/OE.18.002477
   Stanga PE, 2003, OPHTHALMOLOGY, V110, P15, DOI 10.1016/S0161-6420(02)01563-4
   TAMAKI Y, 1994, INVEST OPHTH VIS SCI, V35, P3825
   Tan O, 2008, OPHTHALMOLOGY, V115, P949, DOI 10.1016/j.ophtha.2007.08.011
   Tan O, 2009, OPHTHALMOLOGY, V116, P2305, DOI 10.1016/j.ophtha.2009.05.025
   Tokayer J, 2013, BIOMED OPT EXPRESS, V4, P1909, DOI 10.1364/BOE.4.001909
   Wang L, 2004, OPT COMMUN, V242, P345, DOI 10.1016/j.optcom.2004.08.035
   Wang YM, 2011, INVEST OPHTH VIS SCI, V52, P840, DOI 10.1167/iovs.10-5985
   Wang YM, 2008, J BIOMED OPT, V13, DOI 10.1117/1.2998480
   Yu LF, 2010, J BIOMED OPT, V15, DOI 10.1117/1.3302806
   Zhi ZW, 2012, BIOMED OPT EXPRESS, V3, P2976, DOI 10.1364/BOE.3.002976
NR 59
TC 547
Z9 588
U1 2
U2 109
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0161-6420
EI 1549-4713
J9 OPHTHALMOLOGY
JI Ophthalmology
PD JUL
PY 2014
VL 121
IS 7
BP 1435
EP 1444
DI 10.1016/j.ophtha.2014.01.034
PG 10
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA AO2II
UT WOS:000341142800025
PM 24679442
OA Green Accepted, Green Published
HC Y
HP N
DA 2022-11-30
ER

PT J
AU Yehoshua, Z
   Garcia, CAA
   Nunes, RP
   Gregori, G
   Penha, FM
   Moshfeghi, AA
   Zhang, K
   Sadda, S
   Feuer, W
   Rosenfeld, PJ
AF Yehoshua, Zohar
   Garcia Filho, Carlos Alexandre de Amorim
   Nunes, Renata Portella
   Gregori, Giovanni
   Penha, Fernando M.
   Moshfeghi, Andrew A.
   Zhang, Kang
   Sadda, SriniVas
   Feuer, William
   Rosenfeld, Philip J.
TI Systemic Complement Inhibition with Eculizumab for Geographic Atrophy in
   Age-Related Macular Degeneration
SO OPHTHALMOLOGY
LA English
DT Article
ID FACTOR-H POLYMORPHISM; RISK; SUSCEPTIBILITY; PROGRESSION; VARIANT;
   GENES; CFH; C3
AB Purpose: To evaluate the effect of eculizumab, a systemic inhibitor of complement component (C5), on the growth of geographic atrophy (GA) in patients with age-related macular degeneration (AMD).
   Design: Prospective, double-masked, randomized clinical trial.
   Participants: Patients with GA measuring from 1.25 to 18 mm(2) based on spectral-domain optical coherence tomography imaging.
   Methods: Patients were randomized 2:1 to receive intravenous eculizumab or placebo over 6 months. In the eculizumab treatment arm, the first 10 patients received a low-dose regimen of 600 mg weekly for 4 weeks followed by 900 mg every 2 weeks until week 24, and the next 10 patients received a high-dose regimen of 900 mg weekly for 4 weeks followed by 1200 mg every 2 weeks until week 24. The placebo group was infused with saline. Patients were observed off treatment for an additional 26 weeks. Both normal-luminance and low-luminance visual acuities were measured throughout the study, and the low-luminance deficits were calculated as the difference between the letter scores.
   Main Outcome Measures: Change in area of GA at 26 weeks.
   Results: Thirty eyes of 30 patients were enrolled. Eighteen fellow eyes also met inclusion criteria and were analyzed as a secondary endpoint. For the 30 study eyes, mean square root of GA area measurements +/-standard deviation at baseline were 2.55+/-0.94 and 2.02+/-0.74 mm in the eculizumab and placebo groups, respectively (P = 0.13). At 26 weeks, GA enlarged by a mean of 0.19+/-0.12 and 0.18+/-0.15 mm in the eculizumab and placebo groups, respectively (P = 0.96). At 52 weeks of follow-up, GA enlarged by a mean of 0.37+/-0.22 mm in the eculizumab-treated eyes and by a mean of 0.37+/-0.21 mm in the placebo group (P = 0.93, 2 sample t test). None of the eyes converted to wet AMD. No drug-related adverse events were identified.
   Conclusions: Systemic complement inhibition with eculizumab was well tolerated through 6 months but did not decrease the growth rate ofGAsignificantly. However, there was a statistically significant correlation between the low-luminance deficit at baseline and the progression of GA over 6 months. (C) 2014 by the American Academy of Ophthalmology.
C1 [Yehoshua, Zohar; Garcia Filho, Carlos Alexandre de Amorim; Nunes, Renata Portella; Gregori, Giovanni; Penha, Fernando M.; Moshfeghi, Andrew A.; Feuer, William; Rosenfeld, Philip J.] Univ Miami, Miller Sch Med, Bascom Palmer Eye Inst, Dept Ophthalmol, Miami, FL 33136 USA.
   [Garcia Filho, Carlos Alexandre de Amorim; Penha, Fernando M.] Univ Fed Sao Paulo, UNIFESP, Dept Ophthalmol, Sao Paulo, Brazil.
   [Zhang, Kang] Univ Calif San Diego, Inst Genom Med, La Jolla, CA 92093 USA.
   [Zhang, Kang] Univ Calif San Diego, Shiley Eye Ctr, La Jolla, CA 92093 USA.
   [Sadda, SriniVas] Univ So Calif, Keck Sch Med, Doheny Eye Inst, Los Angeles, CA 90033 USA.
C3 Bascom Palmer Eye Institute; University of Miami; Universidade Federal
   de Sao Paulo (UNIFESP); University of California System; University of
   California San Diego; University of California System; University of
   California San Diego; Doheny Eye Institute; University of Southern
   California
RP Rosenfeld, PJ (通讯作者)，Univ Miami, Miller Sch Med, Bascom Palmer Eye Inst, 900 NW 17th St, Miami, FL 33136 USA.
EM prosenfeld@med.miami.edu
RI Zhang, Kang/Y-2740-2019
OI Zhang, Kang/0000-0002-4549-1697
FU Alexion Pharmaceuticals; Macula Vision Research Foundation; Carl Zeiss
   Meditec, Inc., Dublin, California; Research to Prevent Blindness, Inc.,
   New York, New York; National Eye Institute, National Institutes of
   Health, Bethesda, Maryland [P30 EY014801]; Department of Defense,
   Washington, DC [W81XWH-09-10675]; Jerome A. Yavitz Charitable
   Foundation; Emma Clyde Hodge Memorial Foundation; Florman Family
   Foundation, Inc.; Gemcon Family Foundation; NATIONAL EYE INSTITUTE
   [P30EY014801] Funding Source: NIH RePORTER
FX Supported by Alexion Pharmaceuticals; the Macula Vision Research
   Foundation; Carl Zeiss Meditec, Inc., Dublin, California; an
   unrestricted grant from Research to Prevent Blindness, Inc., New York,
   New York; the National Eye Institute, National Institutes of Health,
   Bethesda, Maryland (core center grant no.: P30 EY014801 to the
   University of Miami); the Department of Defense, Washington, DC (grant
   no.: W81XWH-09-10675); the Jerome A. Yavitz Charitable Foundation; the
   Emma Clyde Hodge Memorial Foundation; the Florman Family Foundation,
   Inc.; and the Gemcon Family Foundation.
CR Anderson DH, 2002, AM J OPHTHALMOL, V134, P411, DOI 10.1016/S0002-9394(02)01624-0
   Baas DC, 2010, OPHTHALMOLOGY, V117, P500, DOI 10.1016/j.ophtha.2009.08.032
   Chen YH, 2011, ARCH OPHTHALMOL-CHIC, V129, P344, DOI 10.1001/archophthalmol.2011.10
   Chew EY, 2013, JAMA OPHTHALMOL, V131, P843, DOI 10.1001/jamaophthalmol.2013.4412
   Edwards AO, 2005, SCIENCE, V308, P421, DOI 10.1126/science.1110189
   Ferris FL, 2013, OPHTHALMOLOGY, V120, P844, DOI 10.1016/j.ophtha.2012.10.036
   Gehrs KM, 2010, ARCH OPHTHALMOL-CHIC, V128, P349, DOI 10.1001/archophthalmol.2010.18
   Gold B, 2006, NAT GENET, V38, P458, DOI 10.1038/ng1750
   Hageman GS, 2006, ANN MED, V38, P592, DOI 10.1080/07853890601097030
   Hageman GS, 2005, P NATL ACAD SCI USA, V102, P7227, DOI 10.1073/pnas.0501536102
   Haines JL, 2005, SCIENCE, V308, P419, DOI 10.1126/science.1110359
   Hill A, 2005, BLOOD, V106, P2559, DOI 10.1182/blood-2005-02-0564
   Hill Anita, 2005, Clin Adv Hematol Oncol, V3, P849
   Hillmen P, 2006, NEW ENGL J MED, V355, P1233, DOI 10.1056/NEJMoa061648
   Khandhadia S, 2012, IMMUNOBIOLOGY, V217, P127, DOI 10.1016/j.imbio.2011.07.019
   Klein ML, 2010, OPHTHALMOLOGY, V117, P1554, DOI 10.1016/j.ophtha.2009.12.012
   Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557
   Li Y, 2011, OPT EXPRESS, V19, P7
   Lim LS, 2012, LANCET, V379, P1728, DOI 10.1016/S0140-6736(12)60282-7
   Maga TK, 2010, HUM MUTAT, V31, pE1445, DOI 10.1002/humu.21256
   Mullins RF, 2001, EYE, V15, P390, DOI 10.1038/eye.2001.142
   ROSS SC, 1984, MEDICINE, V63, P243, DOI 10.1097/00005792-198409000-00001
   Scholl HPN, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0007418
   Sunness JS, 2008, OPHTHALMOLOGY, V115, P1480, DOI 10.1016/j.ophtha.2008.03.009
   Thakkinstian A, 2011, AM J EPIDEMIOL, V173, P1365, DOI 10.1093/aje/kwr025
   Thomas TC, 1996, MOL IMMUNOL, V33, P1389, DOI 10.1016/S0161-5890(96)00078-8
   VANDERSCHAFT TL, 1993, BRIT J OPHTHALMOL, V77, P657, DOI 10.1136/bjo.77.10.657
   Yates JRW, 2007, NEW ENGL J MED, V357, P553, DOI 10.1056/NEJMoa072618
   Yehoshua Z, 2013, OSLI RETINA, V44, P127, DOI 10.3928/23258160-20130313-05
   Yehoshua Z, 2011, SEMIN OPHTHALMOL, V26, P167, DOI 10.3109/08820538.2011.577132
   Yehoshua Z, 2011, OPHTHALMOLOGY, V118, P679, DOI 10.1016/j.ophtha.2010.08.018
   Zarbin MA, 2010, RETINA-J RET VIT DIS, V30, P1350, DOI 10.1097/IAE.0b013e3181f57e30
NR 32
TC 187
Z9 190
U1 2
U2 15
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 0161-6420
EI 1549-4713
J9 OPHTHALMOLOGY
JI Ophthalmology
PD MAR
PY 2014
VL 121
IS 3
BP 693
EP 701
DI 10.1016/j.ophtha.2013.09.044
PG 9
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA AC3FT
UT WOS:000332401800019
PM 24289920
OA Green Accepted
DA 2022-11-30
ER

PT J
AU Sun, KT
   Hsia, NY
   Chen, SC
   Lin, CL
   Chen, IA
   Wu, IT
   Palanisamy, K
   Shen, TC
   Li, CY
AF Sun, Kuo-Ting
   Hsia, Ning-Yi
   Chen, Shih-Chueh
   Lin, Cheng-Li
   Chen, I-An
   Wu, I-Ting
   Palanisamy, Kalaiselvi
   Shen, Te-Chun
   Li, Chi-Yuan
TI RISK OF AGE-RELATED MACULAR DEGENERATION IN PATIENTS WITH PERIODONTITIS
   A Nationwide Population-Based Cohort Study
SO RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES
LA English
DT Article
DE AMD; periodontitis retrospective; cohort study
ID DISEASE
AB Purpose: Periodontitis is an inflammatory disease that results in loss of connective tissue and bone support. Evidence shows a possible relationship between periodontitis and age-related macular degeneration (AMD).
   Methods: This population-based cohort study was conducted using data from the National Health Insurance Research Database in Taiwan, with a 13-year follow-up, to investigate the risk of AMD in patients with periodontitis. The periodontitis cohort included patients with newly diagnosed periodontitis between 2000 and 2012. The nonperiodontitis cohort was frequency-matched with the periodontitis cohort by age and sex, with a sample size of 41,661 in each cohort.
   Results: Patients with periodontitis had an increased risk of developing AMD compared with individuals without periodontitis (5.95 vs. 3.41 per 1,000 person-years, adjusted hazard ratio = 1.58 [95% confidence interval, 1.46-1.70]). The risk of developing AMD remained significant after stratification by age (adjusted hazard ratio = 1.48 [1.34-1.64] for age,65 years and 1.76 [1.57-1.97] for age >= 65 years), sex (adjusted hazard ratio = 1.40 [1.26-1.55] for women and 1.82 [1.63-2.04] for men), and presence of comorbidity (adjusted hazard ratio = 1.52 [1.40-1.66] for with comorbidity and 1.92 [1.63-2.26] for without comorbidity). In addition, patients with periodontitis showed an increased incidence for both nonexudative type AMD (5.43 vs. 3.13 per 1,000 person-years) and exudative type AMD (0.52 vs. 0.28 per 1,000 person-years).
   Conclusion: People with periodontitis could be at a greater risk of developing AMD than those without periodontitis. However, we need more evidence to support this association.
C1 [Sun, Kuo-Ting] China Med Univ, Coll Dent, Sch Dent, Taichung, Taiwan.
   [Sun, Kuo-Ting] China Med Univ Hosp, Dept Pediat Dent, Taichung, Taiwan.
   [Hsia, Ning-Yi] China Med Univ Hosp, Dept Ophthalmol, Taichung, Taiwan.
   [Chen, Shih-Chueh] Cheng Ching Hosp, Dept Endocrinol, Taichung, Taiwan.
   [Lin, Cheng-Li] China Med Univ Hosp, Management Off Hlth Data, Taichung, Taiwan.
   [Chen, I-An; Wu, I-Ting] China Med Univ Hosp, Dept Periodontal Dent, Taichung, Taiwan.
   [Palanisamy, Kalaiselvi; Shen, Te-Chun; Li, Chi-Yuan] China Med Univ, Grad Inst Clin Med Sci, Taichung, Taiwan.
   [Shen, Te-Chun] China Med Univ Hosp, Dept Internal Med, 2 Yude Rd, Taichung 404, Taiwan.
C3 China Medical University Taiwan; China Medical University Taiwan; China
   Medical University Hospital - Taiwan; China Medical University Taiwan;
   China Medical University Hospital - Taiwan; China Medical University
   Taiwan; China Medical University Hospital - Taiwan; China Medical
   University Taiwan; China Medical University Hospital - Taiwan; China
   Medical University Taiwan; China Medical University Taiwan; China
   Medical University Hospital - Taiwan
RP Shen, TC (通讯作者)，China Med Univ Hosp, Dept Internal Med, 2 Yude Rd, Taichung 404, Taiwan.
EM chestshen@gmail.com
OI Shen, Te-Chun/0000-0002-9427-1068
FU Taiwan Ministry of Health and Welfare Clinical Trial Center
   [MOHW108-TDU-B-212-133004]; China Medical University Hospital
   [DMR-105-024]; Academia Sinica Stroke Biosignature Project
   [BM10701010021]; MOST Clinical Trial Consortium for Stroke [MOST
   107-2321-B-039-004]; Tseng-Lien Lin Foundation, Taichung, Taiwan;
   Katsuzo and Kiyo Aoshima Memorial Funds, Japan
FX Supported by Taiwan Ministry of Health and Welfare Clinical Trial Center
   (MOHW108-TDU-B-212-133004), China Medical University Hospital
   (DMR-105-024), Academia Sinica Stroke Biosignature Project
   (BM10701010021), MOST Clinical Trial Consortium for Stroke (MOST
   107-2321-B-039-004), Tseng-Lien Lin Foundation, Taichung, Taiwan, and
   Katsuzo and Kiyo Aoshima Memorial Funds, Japan.
CR Adams MKM, 2011, AM J EPIDEMIOL, V173, P1246, DOI 10.1093/aje/kwr005
   Al-Zamil WM, 2017, CLIN INTERV AGING, V12, P1313, DOI 10.2147/CIA.S143508
   Ambreen F, 2015, MOL VIS, V21, P985
   Borgnakke WS, 2013, J CLIN PERIODONTOL, V40, pS135, DOI [10.1111/jcpe.12080, 10.1902/jop.2013.1340013]
   Brzozowska Aleksandra, 2012, Klin Oczna, V114, P29
   Chakravarthy U, 2010, BMC OPHTHALMOL, V10, DOI 10.1186/1471-2415-10-31
   Eke PI, 2012, J DENT RES, V91, P914, DOI 10.1177/0022034512457373
   Fernandez AB, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0142968
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P564
   Hujoel PP, 2001, J PERIODONTAL RES, V36, P48, DOI 10.1034/j.1600-0765.2001.00011.x
   Ioannidou E, 2013, J PUBLIC HEALTH DENT, V73, P112, DOI 10.1111/j.1752-7325.2012.00350.x
   Jager RD, 2008, NEW ENGL J MED, V358, P2606, DOI 10.1056/NEJMra0801537
   Kalayoglu MV, 2005, GRAEF ARCH CLIN EXP, V243, P1080, DOI 10.1007/s00417-005-1169-y
   Karesvuo P, 2013, J PERIODONTOL, V84, P58, DOI 10.1902/jop.2012.110643
   Kawabata Y, 2016, AM J HYPERTENS, V29, P388, DOI 10.1093/ajh/hpv117
   Kozak Maciej, 2018, Folia Med Cracov, V58, P67
   Kudelka MR, 2013, EXPERT REV OPHTHALMO, V8, P475, DOI 10.1586/17469899.2013.840095
   Lamster IB, 2017, INT DENT J, V67, P67, DOI 10.1111/idj.12264
   Lockhart PB, 2012, CIRCULATION, V125, P2520, DOI 10.1161/CIR.0b013e31825719f3
   Machalinska A, 2012, ACTA OPHTHALMOL, V90, P695, DOI 10.1111/j.1755-3768.2011.02295.x
   Maekawa T, 2016, J CLIN PERIODONTOL, V43, P238, DOI 10.1111/jcpe.12507
   Maralani HG, 2015, RETINA-J RET VIT DIS, V35, P459, DOI 10.1097/IAE.0000000000000338
   Pihlstrom BL, 2005, LANCET, V366, P1809, DOI 10.1016/S0140-6736(05)67728-8
   Pockpa ZAD, 2017, MED HYPOTHESES, V99, P63, DOI 10.1016/j.mehy.2016.12.011
   Samietz S, 2018, J CLIN PERIODONTOL, V45, P404, DOI 10.1111/jcpe.12872
   Seddon JM, 2005, ARCH OPHTHALMOL-CHIC, V123, P774, DOI 10.1001/archopht.123.6.774
   Shen TC, 2015, MEDICINE, V94, DOI 10.1097/MD.0000000000002047
   Shin YU, 2017, MEDICINE, V96, DOI 10.1097/MD.0000000000006418
   Stefani FA, 2013, IMMUNOBIOLOGY, V218, P1012, DOI 10.1016/j.imbio.2012.12.001
   Thomas J, 2015, SOUTH MED J, V108, P502, DOI 10.14423/SMJ.0000000000000329
   van Leeuwen R, 2005, JAMA-J AM MED ASSOC, V294, P3101, DOI 10.1001/jama.294.24.3101
   Wagley S, 2015, RETINA-J RET VIT DIS, V35, P982, DOI 10.1097/IAE.0000000000000427
   Wang IK, 2016, RETINA-J RET VIT DIS, V36, P1866, DOI 10.1097/IAE.0000000000001011
NR 33
TC 8
Z9 9
U1 1
U2 5
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0275-004X
EI 1539-2864
J9 RETINA-J RET VIT DIS
JI Retin.-J. Retin. Vitr. Dis.
PD DEC
PY 2020
VL 40
IS 12
BP 2312
EP 2318
DI 10.1097/IAE.0000000000002750
PG 7
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA QI4NW
UT WOS:000618957100008
PM 31895093
DA 2022-11-30
ER

PT J
AU Nishimura, T
   Machida, S
   Hara, Y
AF Nishimura, Tomoharu
   Machida, Shigeki
   Hara, Yuji
TI Changes in cone-driven functions after intravitreal aflibercept
   injections in patients with age-related macular degeneration
SO DOCUMENTA OPHTHALMOLOGICA
LA English
DT Article
DE Cone function; AMD; Focal macular ERG; Cone ERG; Aflibercept
ID POLYPOIDAL CHOROIDAL VASCULOPATHY; VERTEPORFIN PHOTODYNAMIC THERAPY;
   PHOTOPIC NEGATIVE RESPONSE; RANIBIZUMAB; VEGF; EFFICACY; OUTCOMES;
   BEVACIZUMAB; THICKNESS; SAFETY
AB Purpose To determine the changes in the cone-driven functions in patients with age-related macular degeneration (AMD) treated with intravitreal aflibercept. Methods We studied 44 eyes of 44 patients diagnosed with AMD whose mean age was 75 years. The contralateral unaffected eyes served as controls. All patients were initially treated with 3 consecutive monthly intravitreal aflibercept injections and thereafter with bimonthly injections for 12 months. Full-field cone electroretinograms (cone ERGs) were recorded at the baseline and at 3, 6, and 12 months after beginning the intravitreal aflibercept injections. The cone ERGs were elicited by red stimuli on a blue background. The focal macular ERGs (fmERGs) were elicited by 15 degrees white stimulus spot centered on the fovea. The amplitudes of the a- and b-waves, photopic negative response (PhNR), and sum of the oscillatory potentials (sigma OPs, sum of OP1-3 amplitudes) were analyzed. In addition, the implicit times of the a- and b-waves were also analyzed. Results The amplitudes and implicit times of all components of the fmERGs were significantly improved compared to the baseline at 3 months after beginning the intravitreal aflibercept injections (P < 0.0005-0.05). The amplitudes of the a-waves and PhNRs were further increased during the maintenance phase (P < 0.005-0.01). On the other hand, the amplitudes of the full-field a-waves and PhNR of the cone ERGs were significantly reduced at 6 and 12 months compared to the baseline. Conclusions The macular function improved continuously during the maintenance phase of the intravitreal aflibercept injections. In contrast, the cone-driven functions of the more peripheral retina decreased with repeated injections suggesting adverse effects of the intravitreal aflibercept injections on the function of the more peripheral normal retina.
C1 [Nishimura, Tomoharu; Machida, Shigeki; Hara, Yuji] Dokkyo Med Univ, Dept Ophthalmol, Saitama Med Ctr, 2-1-50 Minami Koshigaya, Koshigaya, Saitama 3438555, Japan.
C3 Dokkyo Medical University
RP Machida, S (通讯作者)，Dokkyo Med Univ, Dept Ophthalmol, Saitama Med Ctr, 2-1-50 Minami Koshigaya, Koshigaya, Saitama 3438555, Japan.
EM machidas@dokkyomed.ac.jp
FU JSPS KAKENHI [18K09420]; Dokkyo Medical University
FX This study was supported by JSPS KAKENHI Grant Number 18K09420 and
   Dokkyo Medical University Grant 2016.
CR Adrean SD, 2018, OPHTHALMOLOGY, V125, P1047, DOI 10.1016/j.ophtha.2018.01.012
   Berg K, 2015, OPHTHALMOLOGY, V122, P146, DOI 10.1016/j.ophtha.2014.07.041
   Brown DM, 2009, OPHTHALMOLOGY, V116, P57, DOI 10.1016/j.ophtha.2008.10.018
   CURCIO CA, 1990, J COMP NEUROL, V292, P497, DOI 10.1002/cne.902920402
   Frishman L, 2018, DOC OPHTHALMOL, V136, P207, DOI 10.1007/s10633-018-9638-x
   Julien S, 2014, BRIT J OPHTHALMOL, V98, P813, DOI 10.1136/bjophthalmol-2013-304019
   Koh A, 2012, RETINA-J RET VIT DIS, V32, P1453, DOI 10.1097/IAE.0b013e31824f91e8
   Koizumi H, 2016, OPHTHALMOLOGY, V123, P617, DOI 10.1016/j.ophtha.2015.10.039
   Lamb TD, 2006, INVEST OPHTH VIS SCI, V47, P5138, DOI 10.1167/iovs.06-0849
   Lee JE, 2017, GRAEF ARCH CLIN EXP, V255, P493, DOI 10.1007/s00417-016-3489-5
   Lee WK, 2018, JAMA OPHTHALMOL, V136, P786, DOI 10.1001/jamaophthalmol.2018.1804
   Liu Y, 2007, GRAEF ARCH CLIN EXP, V245, P1441, DOI 10.1007/s00417-007-0575-8
   Machida S, 2008, INVEST OPHTH VIS SCI, V49, P5636, DOI 10.1167/iovs.08-1946
   Machida S, 2008, INVEST OPHTH VIS SCI, V49, P2201, DOI 10.1167/iovs.07-0887
   Maruko I, 2007, AM J OPHTHALMOL, V144, P15, DOI 10.1016/j.ajo.2007.03.047
   Miyake Y, 1988, Nippon Ganka Gakkai Zasshi, V92, P1419
   MIYAKE Y, 1981, JPN J OPHTHALMOL, V25, P438
   Miyake Y., 2006, ELECTRODIAGNOSIS RET
   Morimoto M, 2017, GRAEF ARCH CLIN EXP, V255, P1891, DOI 10.1007/s00417-017-3718-6
   Nishijima K, 2007, AM J PATHOL, V171, P53, DOI 10.2353/ajpath.2007.061237
   Nishimura T, 2015, GRAEF ARCH CLIN EXP, V253, P1201, DOI 10.1007/s00417-014-2779-z
   Nishimura T, 2012, CLIN OPHTHALMOL, V6, P1073, DOI 10.2147/OPTH.S31674
   Niwa Y, 2015, INVEST OPHTH VIS SCI, V56, P6501, DOI 10.1167/iovs.15-17279
   Ogura Y, 2015, BRIT J OPHTHALMOL, V99, P92, DOI 10.1136/bjophthalmol-2014-305076
   Oshima Y, 2017, OPHTHALMOLOGICA, V238, P163, DOI 10.1159/000477448
   Papadopoulos N, 2012, ANGIOGENESIS, V15, P171, DOI 10.1007/s10456-011-9249-6
   Pedersen KB, 2010, RETINA-J RET VIT DIS, V30, P1025, DOI 10.1097/IAE.0b013e3181cafc8f
   Rangaswamy NV, 2004, INVEST OPHTH VIS SCI, V45, P3827, DOI 10.1167/iovs.04-0458
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Schmidt-Erfurth U, 2014, OPHTHALMOLOGY, V121, P193, DOI 10.1016/j.ophtha.2013.08.011
   Stewart MW, 2008, BRIT J OPHTHALMOL, V92, P667, DOI 10.1136/bjo.2007.134874
   Storkebaum E, 2004, BIOESSAYS, V26, P943, DOI 10.1002/bies.20092
   Strauss O, 2005, PHYSIOL REV, V85, P845, DOI 10.1152/physrev.00021.2004
   Takayama K, 2017, RETINA-J RET VIT DIS, V37, P553, DOI 10.1097/IAE.0000000000001225
   Yamamoto A, 2015, OPHTHALMOLOGY, V122, P1866, DOI 10.1016/j.ophtha.2015.05.024
NR 35
TC 4
Z9 4
U1 0
U2 2
PU SPRINGER
PI DORDRECHT
PA VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS
SN 0012-4486
EI 1573-2622
J9 DOC OPHTHALMOL
JI Doc. Ophthalmol.
PD OCT
PY 2020
VL 141
IS 2
BP 137
EP 147
DI 10.1007/s10633-020-09758-z
EA FEB 2020
PG 11
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA NP4BA
UT WOS:000516649600001
PM 32100141
DA 2022-11-30
ER

PT J
AU Keane, PA
   Patel, PJ
   Ouyang, YL
   Chen, FK
   Ikeji, F
   Walsh, AC
   Tufail, A
   Sadda, SR
AF Keane, Pearse A.
   Patel, Praveen J.
   Ouyang, Yanling
   Chen, Fred K.
   Ikeji, Felicia
   Walsh, Alexander C.
   Tufail, Adnan
   Sadda, Srinivas R.
TI Effects of Retinal Morphology on Contrast Sensitivity and Reading
   Ability in Neovascular Age-Related Macular Degeneration
SO INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE
LA English
DT Article
ID OPTICAL COHERENCE TOMOGRAPHY; OCCULT CHOROIDAL NEOVASCULARIZATION;
   QUANTITATIVE SUBANALYSIS; VISUAL FUNCTION; CLINICAL-TRIALS; RANIBIZUMAB;
   IDENTIFICATION; PARAMETERS; SECONDARY; FEATURES
AB PURPOSE. To investigate the effect of changes in retinal morphology on contrast sensitivity and reading ability in patients with neovascular age-related macular degeneration (AMD) in the Avastin (bevacizumab; Genentech, South San Francisco, CA) for choroidal neovascularization (ABC) Trial.
   METHODS. Contrast sensitivity obtained with Pelli-Robson charts, reading ability assessed with Minnesota Reading charts, and Early Treatment Diabetic Retinopathy Study (ETDRS) visual acuity (VA) obtained by protocol refraction, were recorded. Raw Stratus optical coherence tomography (OCT; Carl Zeiss Meditec, Inc., Dublin, CA) images were analyzed with the publicly available software OCTOR, which allows precise delineation of any retinal compartment of interest. Thickness and volume were calculated for neurosensory retina, subretinal fluid (SRF), subretinal tissue, and pigment epithelium detachment, and the resulting measurements were correlated with each visual function parameter.
   RESULTS. One hundred twenty-two patients with newly diagnosed neovascular AMD and enrolled in the ABC Trial, were evaluated. Increased subretinal tissue volume correlated with decreased contrast sensitivity (Pearson's correlation coefficient, r = -0.4944, P = 0.001). A modest correlation was detected between SRF volume and contrast sensitivity (r = -0.2562, P = 0.004). Increased retinal thickness at the foveal center also correlated with decreased visual function (ETDRS VA: r = -0.4530, P < 0.001).
   CONCLUSIONS. The strongest correlation detected between the functional parameters assessed and any of the OCT-derived morphologic parameters was that between decreased contrast sensitivity and increased subretinal tissue. In the future, assessment of contrast sensitivity and reading ability, in combination with quantitative subanalysis of retinal compartments, may lead to the identification of parameters relevant to functional improvement and ultimate prognosis in patients with newly diagnosed neovascular AMD (www.controlled-trials.com number, ISRCTN83325075). (Invest Ophthalmol Vis Sci. 2010; 51: 5431-5437) DOI: 10.1167/iovs.09-4846
C1 [Keane, Pearse A.; Ouyang, Yanling; Walsh, Alexander C.; Sadda, Srinivas R.] Univ So Calif, Keck Sch Med, Doheny Eye Inst, Doheny Image Reading Ctr, Los Angeles, CA 90033 USA.
   [Patel, Praveen J.; Chen, Fred K.; Ikeji, Felicia; Tufail, Adnan] Moorfields Eye Hosp, Clin Trials Unit, London, England.
C3 Doheny Eye Institute; University of Southern California; University of
   London; University College London; Moorfields Eye Hospital NHS
   Foundation Trust
RP Sadda, SR (通讯作者)，Univ So Calif, Keck Sch Med, Doheny Eye Inst, Doheny Image Reading Ctr, DEI 3623,1450 San Pablo St, Los Angeles, CA 90033 USA.
EM ssadda@dohenyeyeinstitute.org
RI Keane, Pearse A/H-1860-2011; , Fred/B-8158-2013; Keane,
   Pearse/AAE-5709-2019
OI , Fred/0000-0003-2809-9930; Keane, Pearse/0000-0002-9239-745X; Tufail,
   Adnan/0000-0001-6131-7640
FU National Institutes of Health [EY03040]; National Eye Institute [R01
   EY014375]; Carl Zeiss Meditec; Optovue, Inc.; NATIONAL EYE INSTITUTE
   [R01EY014375, P30EY003040] Funding Source: NIH RePORTER; National
   Institute for Health Research [CL-2010-18-004] Funding Source:
   researchfish
FX Supported in part by National Institutes of Health Grant EY03040 and
   National Eye Institute Grant R01 EY014375, and by research support from
   Carl Zeiss Meditec and Optovue, Inc. to the Doheny Image Reading Center.
CR Ahlers Christian, 2008, Ophthalmology, V115, pe39, DOI 10.1016/j.ophtha.2008.05.017
   Ahlers C, 2009, INVEST OPHTH VIS SCI, V50, P3417, DOI 10.1167/iovs.08-2759
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Coscas F, 2007, AM J OPHTHALMOL, V144, P592, DOI 10.1016/j.ajo.2007.06.014
   Csaky KG, 2008, INVEST OPHTH VIS SCI, V49, P479, DOI 10.1167/iovs.07-1132
   Duivenvoorden R, 2009, ATHEROSCLEROSIS, V206, P8, DOI 10.1016/j.atherosclerosis.2008.12.009
   Ergun E, 2003, OPHTHALMOLOGY, V110, P65, DOI 10.1016/S0161-6420(02)01566-X
   Fung AE, 2007, AM J OPHTHALMOL, V143, P566, DOI 10.1016/j.ajo.2007.01.028
   GASS JDM, 1997, STEREOSCOPIC ATLAS M, V1, P49
   Grossniklaus HE, 2004, AM J OPHTHALMOL, V137, P496, DOI 10.1016/j.ajo.2003.09.042
   Hayashi H, 2009, AM J OPHTHALMOL, V148, P83, DOI 10.1016/j.ajo.2009.01.017
   Hazel CA, 2000, INVEST OPHTH VIS SCI, V41, P1309
   Hogg RE, 2006, PROG RETIN EYE RES, V25, P249, DOI 10.1016/j.preteyeres.2005.11.002
   Jager RD, 2008, NEW ENGL J MED, V358, P2606, DOI 10.1056/NEJMra0801537
   Joeres S, 2007, INVEST OPHTH VIS SCI, V48, P4300, DOI 10.1167/iovs.07-0179
   Kashani AH, 2009, INVEST OPHTH VIS SCI, V50, P3366, DOI 10.1167/iovs.08-2691
   Keane PA, 2008, BRIT J OPHTHALMOL, V92, P1081, DOI 10.1136/bjo.2008.138891
   Keane PA, 2009, BRIT J OPHTHALMOL, V93, P1461, DOI 10.1136/bjo.2008.155846
   KEANE PA, OPHTHALMIC IN PRESS
   Keane PA, 2008, INVEST OPHTH VIS SCI, V49, P3115, DOI 10.1167/iovs.08-1689
   Keane PA, 2009, AM J OPHTHALMOL, V148, P242, DOI 10.1016/j.ajo.2009.03.004
   Keane PA, 2009, INVEST OPHTH VIS SCI, V50, P3378, DOI 10.1167/iovs.08-2728
   Keane PA, 2009, RETINA-J RET VIT DIS, V29, P592, DOI 10.1097/IAE.0b013e31819b17a5
   Keane PA, 2008, OPHTHALMOLOGY, V115, P2206, DOI 10.1016/j.ophtha.2008.08.016
   Lalwani GA, 2009, AM J OPHTHALMOL, V148, P43, DOI 10.1016/j.ajo.2009.01.024
   Lloyd R, 2008, CURR OPIN OPHTHALMOL, V19, P190, DOI 10.1097/ICU.0b013e3282f97fa1
   Mansfield J.S., 1993, OPT SOC AM TECHNOL D, V3, P232
   Moutray T, 2008, BRIT J OPHTHALMOL, V92, P361, DOI 10.1136/bjo.2007.123976
   Patel PJ, 2008, TRIALS, V9, DOI 10.1186/1745-6215-9-56
   Patel PJ, 2009, INVEST OPHTH VIS SCI, V50, P2621, DOI 10.1167/iovs.08-2407
   Pauleikhoff D, 2002, GRAEF ARCH CLIN EXP, V240, P533, DOI 10.1007/s00417-002-0505-8
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Sadda SR, 2007, INVEST OPHTH VIS SCI, V48, P839, DOI 10.1167/iovs.06-0554
   Sayanagi K, 2009, BRIT J OPHTHALMOL, V93, P622, DOI 10.1136/bjo.2008.151977
   Spaide RF, 2006, RETINA-J RET VIT DIS, V26, P383, DOI 10.1097/00006982-200604000-00001
   Spaide RF, 2009, AM J OPHTHALMOL, V147, P644, DOI 10.1016/j.ajo.2008.10.005
   STERNBERG P, 1991, ARCH OPHTHALMOL-CHIC, V109, P1242
   Sunness JS, 2006, BRIT J OPHTHALMOL, V90, P398, DOI 10.1136/bjo.2005.084830
   Ting TD, 2002, ARCH OPHTHALMOL-CHIC, V120, P731
NR 39
TC 38
Z9 38
U1 0
U2 10
PU ASSOC RESEARCH VISION OPHTHALMOLOGY INC
PI ROCKVILLE
PA 12300 TWINBROOK PARKWAY, ROCKVILLE, MD 20852-1606 USA
SN 0146-0404
EI 1552-5783
J9 INVEST OPHTH VIS SCI
JI Invest. Ophthalmol. Vis. Sci.
PD NOV
PY 2010
VL 51
IS 11
BP 5431
EP 5437
DI 10.1167/iovs.09-4846
PG 7
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 672BQ
UT WOS:000283558400004
PM 20554607
OA Green Published
DA 2022-11-30
ER

PT J
AU Katsimpris, A
   Jurgens, C
   Ludtke, L
   Martin, B
   Ittermann, T
   Glaser, S
   Dorr, M
   Ewert, R
   Volaklis, K
   Felix, SB
   Tost, F
   Volzke, H
   Meisinger, C
   Baumeister, SE
AF Katsimpris, Andreas
   Juergens, Clemens
   Luedtke, Lisa
   Martin, Bahls
   Ittermann, Till
   Glaeser, Sven
   Doerr, Marcus
   Ewert, Ralf
   Volaklis, Konstantinos
   Felix, Stephan B.
   Tost, Frank
   Voelzke, Henry
   Meisinger, Christa
   Baumeister, Sebastian E.
TI Association between cardiorespiratory fitness and handgrip strength with
   age-related macular degeneration: a population-based study
SO BRITISH JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
DE Macula; Epidemiology; Degeneration
ID INVERSE PROBABILITY WEIGHTS; PHYSICAL-ACTIVITY; BLOOD-PRESSURE;
   EXERCISE; RISK; HEALTH; OVERWEIGHT
AB Aim To assess whether cardiorespiratory fitness (CRF) and handgrip strength, two objective markers of physical fitness, are associated with age-related macular degeneration (AMD). Methods We analysed cross-sectional data from the population-based Study of Health in Pomerania (2008-2012) including 1173 adult men and women aged 20-79 years. Fundus photography of the central retina was recorded with a non-mydriatic camera, and images were graded according to an established clinical AMD classification scale by an experienced reader. CRF was measured using peak oxygen uptake (peakVO(2)), oxygen uptake at the anaerobic threshold (VO2@AT), and maximum power output (W-max) from standardised cardiopulmonary exercise testing on a bicycle ergometer according to a modified Jones protocol. Handgrip strength was assessed using a handheld dynamometer. Adjusted prevalence ratios (PR) for the associations of peakVO(2), VO2@AT, W-max and handgrip strength with AMD were derived from multivariable Poisson regression models. Results PeakVO(2), VO2@AT, W-max and handgrip strength were not associated with AMD. Adjusted PR for AMD associated with a 1-SD increment in peakVO(2), VO2@AT, W-max and handgrip strength were 1.05 (95% CI 0.82 to 1.34), 0.96 (95% CI 0.78 to 1.18), 1.10 (95% CI 0.86 to 1.41) and 1.01 (95% CI 0.79 to 1.30), respectively. These associations were not modified by age, sex, smoking, body mass index and diabetes. Estimates in sensitivity analysis for confounding, selection bias and missing data were similar. Conclusion In our study, CRF and handgrip strength were not associated with AMD. Nevertheless, longitudinal studies with bigger sample sizes are needed to furtherly examine these associations.
C1 [Katsimpris, Andreas; Volaklis, Konstantinos; Meisinger, Christa; Baumeister, Sebastian E.] UNIKA T Augsburg, Ludwig Maximilians Univ Munchen, Chair Epidemiol, Neusasser Str 47, D-86156 Augsburg, Germany.
   [Juergens, Clemens; Ittermann, Till; Voelzke, Henry] Univ Med, Inst Community Med, Greifswald, Germany.
   [Luedtke, Lisa; Tost, Frank] Univ Med Greifswald, Dept Ophthalmol, Greifswald, Germany.
   [Martin, Bahls; Glaeser, Sven; Doerr, Marcus; Ewert, Ralf; Felix, Stephan B.] Greifswald Univ Hosp, Clin & Polyclin Internal Med B, Cardiol Intens Care Pulm Med & Infect Dis Dept, Greifswald, Germany.
   [Martin, Bahls; Doerr, Marcus; Felix, Stephan B.; Voelzke, Henry] German Ctr Cardiovasc Res DZHK, Partner Site Greifswald, Greifswald, Germany.
   [Volaklis, Konstantinos] Tech Univ Munich, Dept Prevent & Sports Med, Munich, Germany.
   [Meisinger, Christa; Baumeister, Sebastian E.] Helmholtz Ctr Munich, German Res Ctr Environm Hlth, Independent Res Grp Clin Epidemiol, Neuherberg, Germany.
C3 University of Munich; Greifswald Medical School; German Centre for
   Cardiovascular Research; Technical University of Munich; Helmholtz
   Association; Helmholtz-Center Munich - German Research Center for
   Environmental Health
RP Katsimpris, A (通讯作者)，UNIKA T Augsburg, Ludwig Maximilians Univ Munchen, Chair Epidemiol, Neusasser Str 47, D-86156 Augsburg, Germany.
EM katsimprisandreas@hotmail.com
RI Dörr, Marcus/F-1919-2010; Katsimpris, Andreas/GPT-5070-2022; Bahls,
   Martin/Q-6639-2018
OI Dörr, Marcus/0000-0001-7471-475X; Katsimpris,
   Andreas/0000-0002-5805-105X; Bahls, Martin/0000-0002-2016-5852
FU German Federal Ministry for Education and Research (BMBF) [01ZZ0403,
   01ZZ0103, 01GI0883]; Ministry for Education, Research and Cultural
   Affairs; Ministry for Social Affairs of the State Mecklenburg-West
   Pomerania
FX The Study of Health in Pomerania is part of the Community Medicine
   Research Network of the University Medicine Greifswald, which was funded
   by the German Federal Ministry for Education and Research (BMBF, Grants
   01ZZ0403, 01ZZ0103, 01GI0883), the Ministry for Education, Research and
   Cultural Affairs, as well as the Ministry for Social Affairs of the
   State Mecklenburg-West Pomerania.
CR Agostinis-Sobrinho C, 2018, J PEDIATR-US, V192, P130, DOI 10.1016/j.jpeds.2017.09.055
   Al-Mallah MH, 2018, CURR ATHEROSCLER REP, V20, DOI 10.1007/s11883-018-0711-4
   Amaral JF, 2012, BRAZ J PHYS THER, V16, P216, DOI 10.1590/S1413-35552012000300007
   Atkinson AB, 1995, INCOME DISTRIBUTION
   Blair SN, 2001, MED SCI SPORT EXER, V33, pS379, DOI 10.1097/00005768-200106001-00007
   Bye A, 2020, PROG CARDIOVASC DIS, V63, P341, DOI 10.1016/j.pcad.2020.02.001
   CASPERSEN CJ, 1985, PUBLIC HEALTH REP, V100, P126
   Church TS, 2007, JAMA-J AM MED ASSOC, V297, P2081, DOI 10.1001/jama.297.19.2081
   Cole SR, 2008, AM J EPIDEMIOL, V168, P656, DOI 10.1093/aje/kwn164
   Cong RH, 2008, ANN EPIDEMIOL, V18, P647, DOI 10.1016/j.annepidem.2008.04.002
   DeFina LF, 2015, PROG CARDIOVASC DIS, V57, P324, DOI 10.1016/j.pcad.2014.09.008
   Dinu M, 2019, EUR J NUTR, V58, P2123, DOI 10.1007/s00394-018-1771-5
   Ferris FL, 2013, OPHTHALMOLOGY, V120, P844, DOI 10.1016/j.ophtha.2012.10.036
   Frank EH., 2015, REGRESSION MODELING
   Garber CE, 2011, MED SCI SPORT EXER, V43, P1334, DOI 10.1249/MSS.0b013e318213fefb
   Godino JG, 2014, BMC PUBLIC HEALTH, V14, DOI 10.1186/1471-2458-14-421
   Guerra RS, 2009, J NUTR HEALTH AGING, V13, P907, DOI 10.1007/s12603-009-0250-3
   JONES NL, 1985, AM REV RESPIR DIS, V131, P700
   Kaminsky LA, 2019, PROG CARDIOVASC DIS, V62, P86, DOI 10.1016/j.pcad.2019.01.002
   Keogh RH, 2014, STAT MED, V33, P2137, DOI 10.1002/sim.6095
   Klaver CCW, 2001, INVEST OPHTH VIS SCI, V42, P2237
   Koch B, 2009, EUR RESPIR J, V33, P389, DOI 10.1183/09031936.00074208
   Kohler A, 2018, SCAND J MED SCI SPOR, V28, P1628, DOI 10.1111/sms.13057
   Lavie CJ, 2015, CIRC RES, V117, P207, DOI 10.1161/CIRCRESAHA.117.305205
   Lee MR, 2018, MEDICINE, V97, DOI 10.1097/MD.0000000000010984
   Lin XC, 2015, J AM HEART ASSOC, V4, DOI 10.1161/JAHA.115.002014
   Mallah Manthar Ali, 2019, Chronic Dis Transl Med, V5, P113, DOI 10.1016/j.cdtm.2019.05.004
   Mokwa NF, 2013, J OPHTHALMOL, V2013, DOI 10.1155/2013/385915
   Naimi AI, 2014, EPIDEMIOLOGY, V25, P292, DOI 10.1097/EDE.0000000000000053
   Pirbhai A, 2005, AM J OPHTHALMOL, V139, P455, DOI 10.1016/j.ajo.2004.09.077
   Sallis R, 2015, PROG CARDIOVASC DIS, V57, P375, DOI 10.1016/j.pcad.2014.10.003
   Seaman SR, 2013, STAT METHODS MED RES, V22, P278, DOI 10.1177/0962280210395740
   Tarp J, 2019, DIABETOLOGIA, V62, P1129, DOI 10.1007/s00125-019-4867-4
   Sluijs EMF, 2007, INT J BEHAV NUTR PHY, V4, DOI 10.1186/1479-5868-4-53
   VanderWeele TJ, 2011, BIOMETRICS, V67, P1406, DOI 10.1111/j.1541-0420.2011.01619.x
   Volzke H, 2011, INT J EPIDEMIOL, V40, P294, DOI 10.1093/ije/dyp394
   Williams PT, 2001, MED SCI SPORT EXER, V33, P754, DOI 10.1097/00005768-200105000-00012
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
   Zhang QY, 2016, INVEST OPHTH VIS SCI, V57, P1276, DOI 10.1167/iovs.15-18637
   Zou GY, 2004, AM J EPIDEMIOL, V159, P702, DOI 10.1093/aje/kwh090
NR 40
TC 2
Z9 2
U1 1
U2 2
PU BMJ PUBLISHING GROUP
PI LONDON
PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND
SN 0007-1161
EI 1468-2079
J9 BRIT J OPHTHALMOL
JI Br. J. Ophthalmol.
PD AUG
PY 2021
VL 105
IS 8
BP 1127
EP 1132
DI 10.1136/bjophthalmol-2020-316255
PG 6
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA TQ6SQ
UT WOS:000678409900017
PM 32859720
DA 2022-11-30
ER

PT J
AU Bonyadi, M
   Mohammadian, T
   Bonyadi, MHJ
   Fotouhi, N
   Soheilian, M
   Javadzadeh, A
   Moein, H
   Yaseri, M
AF Bonyadi, Mortaza
   Mohammadian, Tahereh
   Bonyadi, Mohammad Hossein Jabbarpoor
   Fotouhi, Nikou
   Soheilian, Masoud
   Javadzadeh, Alireza
   Moein, Hamidreza
   Yaseri, Mehdi
TI Association of polymorphisms in complement component 3 with age-related
   macular degeneration in an Iranian population
SO OPHTHALMIC GENETICS
LA English
DT Article
DE Age-related macular degeneration (AMD); C3 rs2230199 (R102G) gene;
   single nucleotide polymorphism
ID FACTOR-H; CHINESE POPULATION; CHOROIDAL NEOVASCULARIZATION; DRUSEN
   FORMATION; FACTOR-B; C3; RISK; GENE; PATHOGENESIS; PROGRESSION
AB Background: Age related macular degeneration (AMD) is the leading cause of irreversible blindness in the elderly population. Inflammatory mediators play an important role in AMD pathogenesis and immune-related gene polymorphisms are shown to increase the risk. Complement system is an important mediator of the immunity system and several genes encoding proteins involved in this system are associated with susceptibility to AMD. The central element of the complement cascade, C3 has been a plausible candidate since its cleavage product C3a was found in drusen. This study was planned to evaluate the association of C3-rs2230199 (R102G) variants with advanced type AMD in this cohort.
   Materials and methods: In this case-control study, 494 participants consisting of 266 AMD patients (187 wet AMD and 79 advanced dry AMD) and 228 samples from unrelated healthy controls were enrolled for evaluation. Extracted-DNA samples were amplified to obtain fragments including the polymorphic region.
   Results: The distribution of the R102G genotypes was significantly different in the AMD patients compared to controls (p = 0.001). The Odds Ratio compared to CC individuals was 1.69 (95% CI 1.152.49) for GC individuals and 6.48 (95% CI1.87-22.43) for GG individuals. The Odds Ratio compared to the C allele was 2.31 (95% CI 0.48-11) for the G allele. GG and GC genotypes and G allele were significantly associated with both types of advanced-AMD. Individuals carrying GG genotype have over a six-fold risk of developing AMD in comparison to those carrying the CC genotype in this cohort. Our meta-analysis pooled data showed that our homozygous individuals for GG have a higher risk of AMD compared to previous publications in different nations (p = 0.017).
   Conclusions: Our study shows C3 to be a relatively strong susceptibility gene for advanced-type-AMD (exudative-and-geographic-atrophy) in an Iranian population.
C1 [Bonyadi, Mortaza; Mohammadian, Tahereh; Bonyadi, Mohammad Hossein Jabbarpoor; Fotouhi, Nikou] Univ Tabriz, Ctr Excellence Biodivers, Fac Nat Sci, Tabriz 516614776, Iran.
   [Bonyadi, Mortaza] Tabriz Univ Med Sci, Liver & Gastrointestinal Dis Res Ctr, Tabriz, Iran.
   [Bonyadi, Mohammad Hossein Jabbarpoor; Soheilian, Masoud; Moein, Hamidreza] Shahid Beheshti Univ Med Sci, Ocular Tissue Engn Res Ctr, Ophthalm Res Ctr, Tehran, Iran.
   [Javadzadeh, Alireza] Tabriz Univ Med Sci, Dept Ophthalmol, Tabriz, Iran.
   [Yaseri, Mehdi] Univ Tehran Med Sci, Dept Biostat & Epidemiol, Tehran, Iran.
C3 University of Tabriz; Tabriz University of Medical Science; Shahid
   Beheshti University Medical Sciences; Tabriz University of Medical
   Science; Tehran University of Medical Sciences
RP Bonyadi, M (通讯作者)，Univ Tabriz, Ctr Excellence Biodivers, Fac Nat Sci, Tabriz 516614776, Iran.
EM jabbarpour@tabrizu.ac.ir
RI Hossein, Jabbarpoor Bonyadi Mohammad/A-1886-2014; Javadzadeh,
   Aliehsadat/J-9830-2017; Javadzadeh, Alireza/L-6424-2017; Soheilian,
   Masoud/AAW-4743-2020; Yaseri, Mehdi/I-1645-2018
OI Javadzadeh, Alireza/0000-0002-5151-6125; Yaseri,
   Mehdi/0000-0002-4066-873X; Soheilian, Masoud/0000-0001-7508-426X
FU Center of Excellence for Biodiversity, Faculty of Natural Sciences,
   University of Tabriz
FX The Center of Excellence for Biodiversity, Faculty of Natural Sciences,
   University of Tabriz funded this study.
CR Anderson DH, 2002, AM J OPHTHALMOL, V134, P411, DOI 10.1016/S0002-9394(02)01624-0
   ARVILOMMI H, 1974, NATURE, V251, P740, DOI 10.1038/251740a0
   BIRD AEC, 1995, SURV OPHTHALMOL, V39, P367, DOI 10.1016/S0039-6257(05)80092-X
   Bora PS, 2003, P NATL ACAD SCI USA, V100, P2679, DOI 10.1073/pnas.0438014100
   BOTTO M, 1990, J EXP MED, V172, P1011, DOI 10.1084/jem.172.4.1011
   Chakravarthy U, 2007, OPHTHALMOLOGY, V114, P1157, DOI 10.1016/j.ophtha.2006.09.022
   Cui L, 2010, INVEST OPHTH VIS SCI, V51, P1116, DOI 10.1167/iovs.09-4265
   Despriet DDG, 2009, OPHTHALMOLOGY, V116, P474, DOI 10.1016/j.ophtha.2008.09.055
   Francis PJ, 2009, J MED GENET, V46, P300, DOI 10.1136/jmg.2008.062737
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P564
   Haddad S, 2006, SURV OPHTHALMOL, V51, P316, DOI 10.1016/j.survophthal.2006.05.001
   Hageman GS, 2005, P NATL ACAD SCI USA, V102, P7227, DOI 10.1073/pnas.0501536102
   Heurich M, 2011, P NATL ACAD SCI USA, V108, P8761, DOI 10.1073/pnas.1019338108
   Janssen BJC, 2006, NATURE, V444, P213, DOI 10.1038/nature05172
   Johnson LV, 2000, EXP EYE RES, V70, P441, DOI 10.1006/exer.1999.0798
   Johnson LV, 2001, EXP EYE RES, V73, P887, DOI 10.1006/exer.2001.1094
   Klein R, 2004, AM J OPHTHALMOL, V137, P486, DOI 10.1016/j.ajo.2003.11.069
   Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557
   Liu XQ, 2010, RETINA-J RET VIT DIS, V30, P1177, DOI 10.1097/IAE.0b013e3181cea676
   Maller JB, 2007, NAT GENET, V39, P1200, DOI 10.1038/ng2131
   Mckay GJ, 2010, MOL VIS, V16, P194
   Mullins Robert F., 2007, International Ophthalmology Clinics, V47, P1, DOI 10.1097/IIO.0b013e31802bd3e6
   Nozaki M, 2006, P NATL ACAD SCI USA, V103, P2328, DOI 10.1073/pnas.0408835103
   Ormsby RJ, 2008, INVEST OPHTH VIS SCI, V49, P1763, DOI 10.1167/iovs.07-1297
   Park KH, 2009, INVEST OPHTH VIS SCI, V50, P3386, DOI 10.1167/iovs.08-3231
   Pei XT, 2009, CURR EYE RES, V34, P615, DOI 10.1080/02713680903003484
   Scholl HPN, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0007418
   Seitsonen SP, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003833
   Spencer KL, 2008, HUM MOL GENET, V17, P1821, DOI 10.1093/hmg/ddn075
   Spencer KL, 2007, HUM MOL GENET, V16, P1986, DOI 10.1093/hmg/ddm146
   Thakkinstian A, 2011, AM J EPIDEMIOL, V173, P1365, DOI 10.1093/aje/kwr025
   Walport MJ, 2001, NEW ENGL J MED, V344, P1058, DOI 10.1056/NEJM200104053441406
   Yates JRW, 2007, NEW ENGL J MED, V357, P553, DOI 10.1056/NEJMoa072618
   Zarbin MA, 2004, ARCH OPHTHALMOL-CHIC, V122, P598, DOI 10.1001/archopht.122.4.598
   Zerbib J, 2010, MOL VIS, V16, P1324
NR 35
TC 8
Z9 8
U1 0
U2 3
PU TAYLOR & FRANCIS INC
PI PHILADELPHIA
PA 530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA
SN 1381-6810
EI 1744-5094
J9 OPHTHALMIC GENET
JI Ophthalmic Genet.
PY 2017
VL 38
IS 1
BP 61
EP 66
DI 10.3109/13816810.2015.1126612
PG 6
WC Genetics & Heredity; Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Genetics & Heredity; Ophthalmology
GA EK4KF
UT WOS:000393894800010
PM 27029644
DA 2022-11-30
ER

PT J
AU Haas, P
   Kubista, KE
   Krugluger, W
   Huber, J
   Binder, S
AF Haas, Paulina
   Kubista, Katharina E.
   Krugluger, Walter
   Huber, Johannes
   Binder, Susanne
TI Impact of visceral fat and pro-inflammatory factors on the pathogenesis
   of age-related macular degeneration
SO ACTA OPHTHALMOLOGICA
LA English
DT Article
DE AMD; body mass index; pro-inflammatory factors; visceral fat
ID C-REACTIVE PROTEIN; NECROSIS-FACTOR-ALPHA; BODY-MASS INDEX; CHOROIDAL
   NEOVASCULARIZATION; ADIPOSE-TISSUE; ABDOMINAL FAT; TNF-ALPHA;
   COMPLEMENT; EXPRESSION; ASSOCIATION
AB Purpose: Previous studies have indicated that the immune system is involved in the pathogenesis of the AMD. Increased visceral fat, in addition, has a pro-inflammatory effect on the organism by producing or influencing different kinds of inflammatory factors. The aim of this study is to determine the relationship of body fat distribution in patients with age-related macula degeneration in comparison to a control group in the Austrian population.
   Methods: In this case-control study, body weight and height, and body mass index (BMI) were measured for each subject in 54 patients with exudative AMD and compared to 46 gender-and age-matched healthy control subjects. Body composition and abdominal fat areas were measured using dual-energy X-ray absorptiometry (DEXA). Data on age, gender distribution, smoking history and systemic diseases, respectively, were compared. The inflammatory markers CRP, tumour necrosis factor-alpha (TNF-alpha), leptin, amyloid A, amyloid beta and interleukin-6 (IL-6) were assayed by ELISA (R&D).
   Results: DEXA revealed central-abdominal-to-total body fat ratio of 0.073 +/- 0.011 in AMD patients compared to 0.061 +/- 0.013 in the controls (p <0.001; d = 0.98). The calculation of BMI has provided a significant result (p =0.045). U-test results for A beta 1-42, IL-6, SAA and CRP each were significant (p < 0.05), with higher values in AMD patients. Leptin, TNF-alpha and A beta 1-40 showed no significant differences between the groups.
   Conclusion: Our results suggest that abdominal fat distribution is significantly associated with age-related macular degeneration. Analysis of patients with exudative AMD revealed higher levels of CRP, amyloid beta 1-42, IL-6 and amyloid alpha.
C1 [Haas, Paulina; Kubista, Katharina E.; Binder, Susanne] Rudolf Fdn Clin, Ludwig Boltzmann Inst Retinol & Biomicroscop Lase, Dept Ophthalmol, A-1030 Vienna, Austria.
   [Krugluger, Walter] Social Med Ctr East, Dept Lab Med, Vienna, Austria.
   [Huber, Johannes] Med Univ Vienna, Gynecol, Vienna, Austria.
C3 Ludwig Boltzmann Institute; Donauspital; Medical University of Vienna
RP Haas, P (通讯作者)，Rudolf Fdn Clin, LBI Retinol & Biomicroscop Lasersurg, A-1030 Vienna, Austria.
EM drpaulinahaas@gmail.com
FU Ludwig Boltzmann Institute for Retinology and Biomicroscopic
   Lasersurgery
FX Many thanks to our Ludwig Boltzmann Institute for Retinology and
   Biomicroscopic Lasersurgery to support this study.
CR Age-Related Eye Dis Study Res Grp, 2001, AM J OPHTHALMOL, V132, P668
   Ahima RS, 2000, TRENDS ENDOCRIN MET, V11, P327, DOI 10.1016/S1043-2760(00)00301-5
   Anderson DH, 2004, EXP EYE RES, V78, P243, DOI 10.1016/j.exer.2003.10.011
   Bernotiene E, 2006, ARTHRITIS RES THER, V8, DOI 10.1186/ar2004
   Boekhoorn SS, 2007, ARCH OPHTHALMOL-CHIC, V125, P1396, DOI 10.1001/archopht.125.10.1396
   Bray GA, 2004, J CLIN ENDOCR METAB, V89, P2583, DOI 10.1210/jc.2004-0535
   Carey DG, 1996, DIABETES, V45, P633, DOI 10.2337/diabetes.45.5.633
   CHYLACK LT, 1993, ARCH OPHTHALMOL-CHIC, V111, P831, DOI 10.1001/archopht.1993.01090060119035
   Coppack SW, 2001, P NUTR SOC, V60, P349, DOI 10.1079/PNS2001110
   Cui JZ, 2001, AM J OPHTHALMOL, V132, P792, DOI 10.1016/S0002-9394(01)01105-9
   DANIELS GL, 1995, VOX SANG, V69, P265, DOI 10.1111/j.1423-0410.1995.tb02611.x
   Fruhbeck G, 2001, AM J PHYSIOL-ENDOC M, V280, pE827, DOI 10.1152/ajpendo.2001.280.6.E827
   Furlaneto CJ, 2000, BIOCHEM BIOPH RES CO, V268, P405, DOI 10.1006/bbrc.2000.2143
   Gehrs KM, 2010, ARCH OPHTHALMOL-CHIC, V128, P349, DOI 10.1001/archophthalmol.2010.18
   Grundy SM, 2004, ARTERIOSCL THROM VAS, V24, pE13, DOI 10.1161/01.ATV.0000111245.75752.C6
   Hageman GS, 2005, P NATL ACAD SCI USA, V102, P7227, DOI 10.1073/pnas.0501536102
   Issa PC, 2005, OPHTHALMOLOGE, V102, P1036, DOI 10.1007/s00347-005-1269-4
   Jebb SA, 1997, BRIT J NUTR, V77, P151, DOI 10.1079/BJN19970021
   Jensen LE, 1998, BIOCHEM J, V334, P489, DOI 10.1042/bj3340489
   Jernas M, 2006, FASEB J, V20, P1540, DOI 10.1096/fj.05-5678fje
   Johnson LV, 2002, P NATL ACAD SCI USA, V99, P11830, DOI 10.1073/pnas.192203399
   Kamel EG, 1999, INT J OBESITY, V23, P686, DOI 10.1038/sj.ijo.0800904
   Klein B E, 2001, Ophthalmic Epidemiol, V8, P251, DOI 10.1076/opep.8.4.251.1612
   Lichtlen P, 2010, INVEST OPHTH VIS SCI, V51, P4738, DOI 10.1167/iovs.09-4890
   Lyon CJ, 2003, ENDOCRINOLOGY, V144, P2195, DOI 10.1210/en.2003-0285
   Martin G, 2004, GRAEF ARCH CLIN EXP, V242, P321, DOI 10.1007/s00417-003-0838-y
   Montague CT, 1997, DIABETES, V46, P342, DOI 10.2337/diabetes.46.3.342
   Montezuma Sandra R, 2007, Semin Ophthalmol, V22, P229, DOI 10.1080/08820530701745140
   Oh H, 1999, INVEST OPHTH VIS SCI, V40, P1891
   Olson JL, 2007, ARCH OPHTHALMOL-CHIC, V125, P1221, DOI 10.1001/archopht.125.9.1221
   Regatieri CV, 2009, INVEST OPHTH VIS SCI, V50, P5487, DOI 10.1167/iovs.08-3171
   Schaumberg DA, 2001, ARCH OPHTHALMOL-CHIC, V119, P1259
   Seddon JM, 2005, ARCH OPHTHALMOL-CHIC, V123, P774, DOI 10.1001/archopht.123.6.774
   Seddon JM, 2004, JAMA-J AM MED ASSOC, V291, P704, DOI 10.1001/jama.291.6.704
   Seddon JM, 2003, ARCH OPHTHALMOL-CHIC, V121, P785, DOI 10.1001/archopht.121.6.785
   Seddon JM, 1996, JAMA-J AM MED ASSOC, V276, P1141, DOI 10.1001/jama.276.14.1141
   Shi X, 2006, EXP EYE RES, V83, P1325, DOI 10.1016/j.exer.2006.07.007
   Sjoholm K, 2005, J CLIN ENDOCR METAB, V90, P2233, DOI 10.1210/jc.2004-1830
   Trayhurn P, 2004, BRIT J NUTR, V92, P347, DOI 10.1079/BJN20041213
   Uhlar CM, 1999, EUR J BIOCHEM, V265, P501, DOI 10.1046/j.1432-1327.1999.00657.x
   Vine AK, 2005, OPHTHALMOLOGY, V112, P2076, DOI 10.1016/j.ophtha.2005.07.004
   Wan L, 2010, RETINA-J RET VIT DIS, V30, P1595, DOI 10.1097/IAE.0b013e3181dc58a6
   Yang RZ, 2006, PLOS MED, V3, P884, DOI 10.1371/journal.pmed.0030287
NR 43
TC 23
Z9 23
U1 0
U2 8
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1755-375X
EI 1755-3768
J9 ACTA OPHTHALMOL
JI Acta Ophthalmol.
PD SEP
PY 2015
VL 93
IS 6
BP 533
EP 538
DI 10.1111/aos.12670
PG 6
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA CS1BO
UT WOS:000361797700032
PM 25683020
OA Bronze
DA 2022-11-30
ER

PT J
AU Hassan, SE
   Snyder, BD
AF Hassan, Shirin E.
   Snyder, Benjamin D.
TI Street-Crossing Decision-Making: A Comparison between Patients with
   Age-Related Macular Degeneration and Normal Vision
SO INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE
LA English
DT Article
ID CONTRAST SENSITIVITY; VISUAL IMPAIRMENT; BLIND PEDESTRIANS; GAP
   SELECTION; FIELD LOSS; JUDGMENTS; DESIGN; CHARTS; YOUNG
AB PURPOSE. We determined whether the street-crossing decisions of subjects with age-related macular degeneration (AMD) were as accurate and precise as those made by young and older subjects with normal vision.
   METHODS. Street-crossing decisions in 13 AMD subjects, and 20 young and 20 older control subjects with normal vision were measured along an un-signalized street for nine different gap times. After calculating the discriminability (d') of the street-crossing decision variable for all gap pairs and entering these d' values into a one-dimensional scaling model, the means of each distribution of the decision variable relative to a "center of gravity" were estimated and plotted against gap time. The resultant plot was a nonlinear function. Street-crossing decision accuracy was computed for each subject as the difference between the x-intercept of the nonlinear function (t(COG)) and subjects' measured street-crossing time. Street-crossing decision-making precision was computed as the value of the slope of the nonlinear function at t(COG).
   RESULTS. We found that all subjects were precise in their street-crossing decisions (P = 0.55). Significant differences in street-crossing accuracy were found as a function of age (P = 0.003). Compared to either the older normally-sighted (P = 0.018) or AMD (P = 0.019) subjects, the young normally-sighted subjects made the least accurate street-crossing decisions. No significant difference in accuracy was found between the AMD and age-matched normally-sighted subjects (P = 0.90).
   CONCLUSIONS. Our data suggested that age and mild central vision loss did not affect significantly a subject's precision in their street-crossing decisions. Age, but not mild central vision loss, significantly affected a subject's accuracy in their street-crossing decisions. (Invest Ophthalmol Vis Sci. 2012; 53: 6137-6144) DOI: 10.1167/iovs.12-10023
C1 [Hassan, Shirin E.; Snyder, Benjamin D.] Indiana Univ, Sch Optometry, Bloomington, IN 47405 USA.
C3 Indiana University System; Indiana University Bloomington
RP Hassan, SE (通讯作者)，Indiana Univ, Sch Optometry, 800 E Atwater Ave, Bloomington, IN 47405 USA.
EM shhassan@indiana.edu
FU NIH/NEI [R03 EY014874-05]; Beta Sigma Kappa Student Research Award;
   NATIONAL EYE INSTITUTE [R03EY014874, P30EY019008] Funding Source: NIH
   RePORTER
FX Supported by NIH/NEI Grant R03 EY014874-05 (SEH) and a Beta Sigma Kappa
   Student Research Award (BDS).
CR Ashmead DH, 2005, J TRANSP ENG, V131, P812, DOI 10.1061/(ASCE)0733-947X(2005)131:11(812)
   BAILEY IL, 1976, AM J OPTOM PHYS OPT, V53, P740
   Cheong AMY, 2008, OPTOMETRY VISION SCI, V85, P26, DOI 10.1097/OPX.0b013e31815ed6fd
   Coleman HR, 2008, LANCET, V372, P1835, DOI 10.1016/S0140-6736(08)61759-6
   Congdon N, 2004, ARCH OPHTHALMOL-CHIC, V122, P477
   Dommes A, 2011, OPHTHAL PHYSL OPT, V31, P292, DOI 10.1111/j.1475-1313.2011.00835.x
   ELLIOTT DB, 1990, OPHTHAL PHYSL OPT, V10, P323, DOI 10.1111/j.1475-1313.1990.tb00877.x
   ELLIOTT DB, 1991, CLIN VISION SCI, V6, P471
   Emerson RW, 2008, J VISUAL IMPAIR BLIN, V102, P747, DOI 10.1177/0145482X0810201203
   FERRIS FL, 1982, AM J OPHTHALMOL, V94, P91, DOI 10.1016/0002-9394(82)90197-0
   FOLSTEIN MF, 1975, J PSYCHIAT RES, V12, P189, DOI 10.1016/0022-3956(75)90026-6
   Geruschat DR, 2011, OPTOMETRY VISION SCI, V88, P208, DOI 10.1097/OPX.0b013e3182045988
   Guth D, 2005, HUM FACTORS, V47, P314, DOI 10.1518/0018720054679533
   Guth D, 2003, P 11 INT MOB C S AFR
   HAMPTON GR, 1992, AGE RELATED MACULAR
   Hassan SE, ACCID PREV IN PRESS
   Hassan SE, 2012, INVEST OPHTH VIS SCI, V53, P2593, DOI 10.1167/iovs.11-9340
   He W, 2005, 65 US CURRENT POPULA
   Jager RD, 2008, NEW ENGL J MED, V358, P2606, DOI 10.1056/NEJMra0801537
   Klein BEK, 2009, JAMA-J AM MED ASSOC, V301, P2152, DOI 10.1001/jama.2009.729
   Lobjois R, 2007, ACCIDENT ANAL PREV, V39, P934, DOI 10.1016/j.aap.2006.12.013
   LOSHIN DS, 1984, ARCH OPHTHALMOL-CHIC, V102, P1303, DOI 10.1001/archopht.1984.01040031053022
   Lovie-Kitchin JE., 1985, SENILE MACULAR DEGEN
   National Highway Traffic Safety Administration, 2009, TRAFF SAF FACTS 2009
   Oxley J, 1997, ACCIDENT ANAL PREV, V29, P839, DOI 10.1016/S0001-4575(97)00053-5
   Oxley JA, 2005, ACCIDENT ANAL PREV, V37, P962, DOI 10.1016/j.aap.2005.04.017
   PELLI DG, 1988, CLIN VISION SCI, V2, P187
   Rein DB, 2009, ARCH OPHTHALMOL-CHIC, V127, P533, DOI 10.1001/archophthalmol.2009.58
   Resnikoff S, 2004, B WORLD HEALTH ORGAN, V82, P844
   SWANN PG, 1991, OPHTHAL PHYSL OPT, V11, P59, DOI 10.1016/0275-5408(91)90012-8
   Vinding T, 1995, ACTA OPHTHALMOL SC S, V217, P2
NR 31
TC 6
Z9 6
U1 0
U2 17
PU ASSOC RESEARCH VISION OPHTHALMOLOGY INC
PI ROCKVILLE
PA 12300 TWINBROOK PARKWAY, ROCKVILLE, MD 20852-1606 USA
SN 0146-0404
J9 INVEST OPHTH VIS SCI
JI Invest. Ophthalmol. Vis. Sci.
PD SEP
PY 2012
VL 53
IS 10
BP 6137
EP 6144
DI 10.1167/iovs.12-10023
PG 8
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)
SC Ophthalmology
GA 016NQ
UT WOS:000309526200021
PM 22899756
OA Green Published
DA 2022-11-30
ER

PT J
AU Bressler, SB
   Munoz, B
   Solomon, SD
AF Bressler, Susan B.
   Munoz, Beatriz
   Solomon, Sharon D.
TI Racial differences in the prevalence of age-related macular degeneration
   - The Salisbury Eye Evaluation (SEE) Project
SO ARCHIVES OF OPHTHALMOLOGY
LA English
DT Article
ID VISUAL IMPAIRMENT; MACULOPATHY; POPULATION
AB Objective: To determine differences in the prevalence of age-related macular degeneration (AMD) and its fundus manifestations in a population-based sample of older black and white Americans.
   Design: Cross-sectional population-based study of 2520 participants of whom 1854 are white and 666 are black. Mean age was 73.5 years. Stereoscopic color fundus photographs were graded for presence, severity, and location of drusen, retinal pigment epithelium abnormalities, and choroidal neovascularization or disciform scarring.
   Results: Drusen at least 64 mu m in size were identified in 56% of black and white individuals within 3000 mu m of the foveal center, but drusen larger than 125 mu m were more common among white participants (16% white vs 11% black individuals). Drusen at least 250 mu m in size, confluent drusen, or a larger area (> 10%) occupied by drusen were each more common among white participants. White individuals were 3 times more likely to have focal hyperpigmentation than black individuals. Racial differences were most pronounced for features within the central 1500-mu m macular zone. Neovascular AMD was present in 1.7% of white participants and 1.1% of black participants (age-adjusted, P=.38), whereas geographic atrophy was more common in white than black individuals (1.8% vs 0.3%; age-adjusted, P=. 02).
   Conclusions: White persons are generally more likely than black persons to have medium or large drusen, focal pigment abnormalities, and advanced AMD. Racial differences were prominent for nonneovascular AMD features only when present in the central zone. These data suggest that black individuals may have a mechanism for protection in the central zone against these critical fundus features, which themselves convey high risk of progression to advanced AMD.
C1 [Bressler, Susan B.; Munoz, Beatriz; Solomon, Sharon D.] Johns Hopkins Univ, Wilmer Eye Inst, Retina Div,Sch Med, Dana Ctr Prevent Ophthalmol,Johns Hopkins Hosp, Baltimore, MD 21287 USA.
C3 Johns Hopkins University; Johns Hopkins Medicine
RP Bressler, SB (通讯作者)，Johns Hopkins Univ, Wilmer Eye Inst, Retina Div,Sch Med, Dana Ctr Prevent Ophthalmol,Johns Hopkins Hosp, Maumenee Bldg Room 229,600 N wolfe St, Baltimore, MD 21287 USA.
EM khansbe@jhmi.edu
RI Solomon, Scott/I-5789-2013
FU NATIONAL INSTITUTE ON AGING [R01AG016294] Funding Source: NIH RePORTER;
   NIA NIH HHS [AG16294] Funding Source: Medline
CR Davis MD, 2005, ARCH OPHTHALMOL-CHIC, V123, P1484
   Ferris FL, 2005, ARCH OPHTHALMOL-CHIC, V123, P1570
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P564
   Friedman DS, 1999, OPHTHALMOLOGY, V106, P1049, DOI 10.1016/S0161-6420(99)90267-1
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1417, DOI 10.1001/archopht.119.10.1417
   KLEIN R, 1992, OPHTHALMOLOGY, V99, P933
   Klein R, 2002, OPHTHALMOLOGY, V109, P1767, DOI 10.1016/S0161-6420(02)01146-6
   KLEIN R, 1991, OPHTHALMOLOGY, V98, P1128
   Klein R, 1999, OPHTHALMOLOGY, V106, P1056, DOI 10.1016/S0161-6420(99)90255-5
   Maguire MG, 1997, ARCH OPHTHALMOL-CHIC, V115, P741
   Munoz B, 1999, ANN EPIDEMIOL, V9, P53, DOI 10.1016/S1047-2797(98)00026-X
   SCHACHAT AP, 1995, ARCH OPHTHALMOL-CHIC, V113, P728, DOI 10.1001/archopht.1995.01100060054032
   Tell G S, 1993, Ann Epidemiol, V3, P358, DOI 10.1016/1047-2797(93)90062-9
   West SK, 1997, INVEST OPHTH VIS SCI, V38, P72
NR 14
TC 67
Z9 69
U1 0
U2 7
PU AMER MEDICAL ASSOC
PI CHICAGO
PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA
SN 0003-9950
EI 1538-3601
J9 ARCH OPHTHALMOL-CHIC
JI Arch. Ophthalmol.
PD FEB
PY 2008
VL 126
IS 2
BP 241
EP 245
DI 10.1001/archophthalmol.2007.53
PG 5
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 261DQ
UT WOS:000253059700012
PM 18268216
DA 2022-11-30
ER

PT J
AU Ou, WC
   Lesmes, LA
   Christie, AH
   Denlar, RA
   Csaky, KG
AF Ou, William C.
   Lesmes, Luis Andres
   Christie, Abigail H.
   Denlar, Renee A.
   Csaky, Karl G.
TI Normal- and Low-Luminance Automated Quantitative Contrast Sensitivity
   Assessment in Eyes With Age-Related Macular Degeneration
SO AMERICAN JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
ID VISUAL FUNCTION; DARK-ADAPTATION; MICROPERIMETRY; VISION; ACUITY;
   CLASSIFICATION; DYSFUNCTION
AB PURPOSE: To assess the effectiveness of an active learning approach to measuring the contrast sensitivity function (CSF) in patients with various degrees of dry age-related macular degeneration (AMD) under multiple luminance conditions.
   DESIGN: Cross-sectional study.
   METHODS: Patients with AMD (26 intermediate AMD, 19 AMD with subretinal drusenoid deposits [SDD], 20 geographic atrophy [GA]) and 23 age-matched controls were tested with the Manifold Contrast Vision Meter (Adaptive Sensory Technology) and the qCSF algorithm, which applies active learning to estimate a model of the CSF's global shape. Testing was performed under conditions of standard and low luminance. For each AMD severity, the area under log CSF (AULCSF) and contrast sensitivities at individual spatial frequencies were calculated for analysis. Low-luminance deficits (LLDs) for visual acuity (VA) and AULCSF were calculated as the difference between standard and low luminance values.
   RESULTS: Progressive decreases in AULCSF were observed as disease severity increased. For standard luminance, pairwise comparisons revealed significant differences between control/intermediate AMD (P < .0005), control/SDD (P < .0005), control/GA (P < .0005), and intermediate AMD/GA (P < .005). Similarly, for low luminance, pairwise comparisons revealed significant differences between the controls and each disease group (all P < .0005), in addition to significant differences between intermediate AMD/SDD (P < .005), and intermediate AMD/GA (P < .005). No correlations were found between LLD VA and LLD AULCSF in any AMD groups.
   CONCLUSIONS: Contrast sensitivity measured via qCSF under both standard-and low-luminance conditions correlates with advancing stages of dry AMD. The interaction between luminance and contrast sensitivity appears to reflect a different aspect of visual function than the interaction between luminance and VA. (C) 2021 Elsevier Inc. All rights reserved.
C1 [Ou, William C.; Christie, Abigail H.; Denlar, Renee A.; Csaky, Karl G.] Retina Fdn Southwest, 9600 N Cent Expressway,Suite 200, Dallas, TX 75231 USA.
   [Lesmes, Luis Andres] Adapt Sensory Technol Inc, San Diego, CA USA.
C3 Retina Foundation of the Southwest
RP Csaky, KG (通讯作者)，Retina Fdn Southwest, 9600 N Cent Expressway,Suite 200, Dallas, TX 75231 USA.
EM kcsaky@retinafoundation.org
CR Alahmadi BO, 2018, BMC OPHTHALMOL, V18, DOI 10.1186/s12886-018-0982-0
   BLAND JM, 1986, LANCET, V1, P307, DOI 10.1016/s0140-6736(86)90837-8
   Chandramohan A, 2016, RETINA-J RET VIT DIS, V36, P1021, DOI 10.1097/IAE.0000000000001002
   Cocce KJ, 2018, AM J OPHTHALMOL, V189, P127, DOI 10.1016/j.ajo.2018.02.012
   Csaky K, 2017, INVEST OPHTH VIS SCI, V58, P3456, DOI 10.1167/iovs.17-22339
   Curcio CA, 1996, INVEST OPHTH VIS SCI, V37, P1236
   Ferris FL, 2013, OPHTHALMOLOGY, V120, P844, DOI 10.1016/j.ophtha.2012.10.036
   Flamendorf J, 2015, OPHTHALMOLOGY, V122, P2053, DOI 10.1016/j.ophtha.2015.06.023
   Forte R, 2014, OPHTHALMIC RES, V51, P32, DOI 10.1159/000354117
   Ginsburg Arthur P., 2003, International Ophthalmology Clinics, V43, P5
   Hogg RE, 2006, PROG RETIN EYE RES, V25, P249, DOI 10.1016/j.preteyeres.2005.11.002
   Hou F, 2016, J VISION, V16, DOI 10.1167/16.6.18
   Hou F, 2015, J VISION, V15, DOI 10.1167/15.9.2
   Hou F, 2010, INVEST OPHTH VIS SCI, V51, P5365, DOI 10.1167/iovs.10-5468
   JINDRA LF, 1989, J CATARACT REFR SURG, V15, P141, DOI 10.1016/S0886-3350(89)80002-1
   Joltikov KA, 2017, INVEST OPHTH VIS SCI, V58, P277, DOI 10.1167/iovs.17-21863
   Karatepe AS, 2017, TURK OFTALMOL DERG, V47, P80, DOI 10.4274/tjo.93763
   KLEINER RC, 1988, ARCH OPHTHALMOL-CHIC, V106, P55
   Lains I, 2017, OPHTHALMOLOGY, V124, P1340, DOI 10.1016/j.ophtha.2017.03.061
   Lesmes LA, 2010, J VISION, V10, DOI 10.1167/10.3.17
   Maynard ML, 2016, ACTA OPHTHALMOL, V94, pE772, DOI 10.1111/aos.13112
   Midena E, 1997, INVEST OPHTH VIS SCI, V38, P469
   Nebbioso M, 2014, BIOMED RES INT, V2014
   Ooto S, 2013, AM J OPHTHALMOL, V156, P1184, DOI 10.1016/j.ajo.2013.06.036
   Ortiz C, 2010, CURR EYE RES, V35, P757, DOI 10.3109/02713683.2010.486521
   Owsley C, 2006, INVEST OPHTH VIS SCI, V47, P528, DOI 10.1167/iovs.05-1222
   Owsley C, 2016, CURR EYE RES, V41, P266, DOI 10.3109/02713683.2015.1011282
   Owsley Cynthia, 2003, Ophthalmol Clin North Am, V16, P171, DOI 10.1016/S0896-1549(03)00003-8
   Pelli DG, 2013, VISION RES, V90, P10, DOI 10.1016/j.visres.2013.04.015
   PELLI DG, 1988, CLIN VISION SCI, V2, P187
   Puell MC, 2012, INVEST OPHTH VIS SCI, V53, P7310, DOI 10.1167/iovs.11-8649
   Querques G, 2014, RETINA-J RET VIT DIS, V34, P321, DOI 10.1097/IAE.0b013e3182993df1
   Richman J, 2013, J CATARACT REFR SURG, V39, P1100, DOI 10.1016/j.jcrs.2013.05.001
   Scilley K, 2002, OPHTHALMOLOGY, V109, P1235, DOI 10.1016/S0161-6420(02)01060-6
   Shakarchi AF, 2019, INVEST OPHTH VIS SCI, V60, P4556, DOI 10.1167/iovs.19-28023
   STANGOS N, 1995, OPHTHALMOLOGICA, V209, P194, DOI 10.1159/000310612
   Steinberg JS, 2015, JAMA OPHTHALMOL, V133, P690, DOI 10.1001/jamaophthalmol.2015.0477
   Stellmann JP, 2015, MULT SCLER J-EXP TRA, V1
   Stockman A, 2006, OPHTHAL PHYSL OPT, V26, P225, DOI 10.1111/j.1475-1313.2006.00325.x
   Sunness JS, 2008, OPHTHALMOLOGY, V115, P1480, DOI 10.1016/j.ophtha.2008.03.009
   Tan R, 2018, INVEST OPHTH VIS SCI, V59, P4154, DOI 10.1167/iovs.18-23970
   Wu ZC, 2016, BRIT J OPHTHALMOL, V100, P395, DOI 10.1136/bjophthalmol-2015-306621
   Wu ZC, 2014, OPHTHALMOLOGY, V121, P1612, DOI 10.1016/j.ophtha.2014.02.005
NR 43
TC 7
Z9 7
U1 0
U2 4
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 0002-9394
EI 1879-1891
J9 AM J OPHTHALMOL
JI Am. J. Ophthalmol.
PD JUN
PY 2021
VL 226
BP 148
EP 155
DI 10.1016/j.ajo.2021.01.017
EA APR 2021
PG 8
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA TL1CP
UT WOS:000674592100016
PM 33529583
DA 2022-11-30
ER

PT J
AU Hammer, M
   Schultz, R
   Hasan, S
   Sauer, L
   Klemm, M
   Kreilkamp, L
   Zweifel, L
   Augsten, R
   Meller, D
AF Hammer, Martin
   Schultz, Rowena
   Hasan, Somar
   Sauer, Lydia
   Klemm, Matthias
   Kreilkamp, Lukas
   Zweifel, Lynn
   Augsten, Regine
   Meller, Daniel
TI Fundus Autofluorescence Lifetimes and Spectral Features of Soft Drusen
   and Hyperpigmentation in Age-Related Macular Degeneration
SO TRANSLATIONAL VISION SCIENCE & TECHNOLOGY
LA English
DT Article
DE age-related macular degeneration; fundus autofluorescence; fluorescence
   lifetime; drusen; hyperpigmentation
ID RETINAL-PIGMENT EPITHELIUM; OPTICAL COHERENCE TOMOGRAPHY; TIME-RESOLVED
   AUTOFLUORESCENCE; NATURAL-HISTORY; BRUCHS MEMBRANE; HIGH-RISK;
   FLUORESCENCE; LIPOFUSCIN; EYES; MIGRATION
AB Purpose: To investigate the autofluorescence lifetimes as well as spectral characteristics of soft drusen and retinal hyperpigmentation in age-related macular degeneration (AMD).
   Methods: Forty-three eyes with nonexudative AMD were included in this study. Fluorescence lifetime imaging ophthalmoscopy (FLIO), which detects autofluorescence decay over time in the short (SSC) and long (LSC) wavelength channel, was performed. The mean autofluorescence lifetime (tau(m)) and the spectral ratio (sr) of autofluorescence emission in the SSC and LSC were recorded and analyzed. In total, 2760 soft drusen and 265 hyperpigmented areas were identified from color fundus photographs and spectral domain optical coherence tomography (SD-OCT) images and superimposed onto their respective AF images. tau(m) and sr of these lesions were compared with fundus areas without drusen. For clearly hyperfluorescent drusen, the local differences compared to fundus areas without drusen were determined for lifetimes and sr.
   Results: Hyperpigmentation showed significantly longer tau(m) (SSC: 341 +/- 81 vs. 289 +/- 70 ps, P < 0.001; LSC: 406 +/- 42 vs. 343 +/- 42 ps, P < 0.001) and higher sr (0.621 +/- 0.077 vs. 0.539 +/- 0.083, P < 0.001) compared to fundus areas without hyperpigmentation or drusen. No significant difference in tau(m) was found between soft drusen and fundus areas without drusen. However, the sr was significantly higher in soft drusen (0.555 +/- 0.077 vs. 0.539 +/- 0.081, P < 0.0005). Hyperfluorescent drusen showed longer tau(m) than surrounding fundus areas without drusen (SSC: 18 +/- 42 ps, P = 0.074; LSC: 16 +/- 29 ps, P = 0.020).
   Conclusions: FLIO can quantitatively characterize the autofluorescence of the fundus, drusen, and hyperpigmentation in AMD.
   Translational Relevance : The experimental FLIO technique was applied in a clinical investigation. As FLIO yields information on molecular changes in AMD, it might support future diagnostics.
C1 [Hammer, Martin; Schultz, Rowena; Hasan, Somar; Kreilkamp, Lukas; Zweifel, Lynn; Augsten, Regine; Meller, Daniel] Univ Hosp Jena, Dept Ophthalmol, Klinikum 1, D-07747 Jena, Germany.
   [Hammer, Martin] Univ Jena, Ctr Med Opt & Photon, Jena, Germany.
   [Sauer, Lydia] John A Moran Eye Ctr, Salt Lake City, UT USA.
   [Klemm, Matthias] Tech Univ Ilmenau, Inst Biomed Tech & Informat, Ilmenau, Germany.
C3 Friedrich Schiller University of Jena; Friedrich Schiller University of
   Jena; Technische Universitat Ilmenau
RP Hammer, M (通讯作者)，Univ Hosp Jena, Dept Ophthalmol, Klinikum 1, D-07747 Jena, Germany.
EM martin.hammer@med.uni-jena.de
OI Simon, Rowena/0000-0002-1588-6268; Klemm, Matthias/0000-0002-2418-0259
CR Ablonczy Z, 2014, PROTEOMICS, V14, P936, DOI 10.1002/pmic.201300406
   Ablonczy Z, 2013, INVEST OPHTH VIS SCI, V54, P5535, DOI 10.1167/iovs.13-12250
   Ach T, 2015, INVEST OPHTH VIS SCI, V56, P3242, DOI 10.1167/iovs.14-16274
   Age-Related Eye Dis Study Res Grp, 2001, AM J OPHTHALMOL, V132, P668
   Anderson DMG, 2014, J AM SOC MASS SPECTR, V25, P1394, DOI 10.1007/s13361-014-0883-2
   Anderson DH, 2002, AM J OPHTHALMOL, V134, P411, DOI 10.1016/S0002-9394(02)01624-0
   Balaratnasingam C, 2016, INVEST OPHTH VIS SCI, V57, P5479, DOI 10.1167/iovs.16-19816
   Ben Ami T, 2016, TRANSL VIS SCI TECHN, V5, DOI 10.1167/tvst.5.3.5
   Bindewald A, 2005, INVEST OPHTH VIS SCI, V46, P3309, DOI 10.1167/iovs.04-0430
   Cankova Z, 2011, EXP EYE RES, V93, P947, DOI 10.1016/j.exer.2011.10.016
   Curcio CA, 2001, INVEST OPHTH VIS SCI, V42, P265
   Curcio CA, 2017, INVEST OPHTH VIS SCI, V58, P211, DOI 10.1167/iovs.17-21872
   Curcio CA, 2011, BRIT J OPHTHALMOL, V95, P1638, DOI 10.1136/bjophthalmol-2011-300344
   Delori FC, 2000, INVEST OPHTH VIS SCI, V41, P496
   Dysli C, 2017, INVEST OPHTH VIS SCI, V58, P4856, DOI 10.1167/iovs.17-22184
   Dysli C, 2016, INVEST OPHTH VIS SCI, V57, P2479, DOI 10.1167/iovs.15-18381
   Dysli C, 2014, INVEST OPHTH VIS SCI, V55, P2106, DOI 10.1167/iovs.13-13627
   Ehlers A, 2007, MICROSC RES TECHNIQ, V70, P154, DOI 10.1002/jemt.20395
   Einbock W, 2005, GRAEF ARCH CLIN EXP, V243, P300, DOI 10.1007/s00417-004-1027-3
   ELDRED GE, 1988, EXP EYE RES, V47, P71, DOI 10.1016/0014-4835(88)90025-5
   Ferris FL, 2005, ARCH OPHTHALMOL-CHIC, V123, P1570
   Ferris FL, 2013, OPHTHALMOLOGY, V120, P844, DOI 10.1016/j.ophtha.2012.10.036
   Folgar FA, 2012, INVEST OPHTH VIS SCI, V53, P4626, DOI 10.1167/iovs.12-9813
   GASS JDM, 1973, ARCH OPHTHALMOL-CHIC, V90, P206
   Gensure RH, 2018, INVEST OPHTH VIS SCI, V59
   Hammer M, 2018, BIOMED OPT EXPRESS, V9, P3078, DOI 10.1364/BOE.9.003078
   Handa JT, 2017, BBA-MOL CELL BIOL L, V1862, P430, DOI 10.1016/j.bbalip.2016.07.013
   Ho J, 2011, OPHTHALMOLOGY, V118, P687, DOI 10.1016/j.ophtha.2010.08.010
   Hogg PA, 2002, INVEST OPHTH VIS SCI, V43, P2749
   Jin ML, 2000, INVEST OPHTH VIS SCI, V41, P4324
   Keilhauer CN, 2006, INVEST OPHTH VIS SCI, V47, P3556, DOI 10.1167/iovs.06-0122
   Kishan AU, 2011, SURV OPHTHALMOL, V56, P195, DOI 10.1016/j.survophthal.2010.08.008
   Landa G, 2012, OPHTHALMIC RES, V47, P81, DOI 10.1159/000324988
   Linsenmeier RA, 2017, PROG RETIN EYE RES, V58, P115, DOI 10.1016/j.preteyeres.2017.01.003
   Loane E, 2008, SURV OPHTHALMOL, V53, P68, DOI 10.1016/j.survophthal.2007.10.008
   Lois N, 2002, AM J OPHTHALMOL, V133, P341, DOI 10.1016/S0002-9394(01)01404-0
   Marmorstein AD, 2002, INVEST OPHTH VIS SCI, V43, P2435
   Miura M, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-03529-8
   Ouyang YL, 2013, OPHTHALMOLOGY, V120, P2656, DOI 10.1016/j.ophtha.2013.05.029
   Pikuleva IA, 2014, PROG RETIN EYE RES, V41, P64, DOI 10.1016/j.preteyeres.2014.03.002
   Rossberger S, 2013, BRIT J OPHTHALMOL, V97, P518, DOI 10.1136/bjophthalmol-2012-302350
   Rudolf M, 2013, OPHTHALMOLOGY, V120, P821, DOI 10.1016/j.ophtha.2012.10.007
   Sauer L, 2015, INVEST OPHTH VIS SCI, V56, P4668, DOI 10.1167/iovs.14-15335
   Schweitzer D, 2007, MICROSC RES TECHNIQ, V70, P410, DOI 10.1002/jemt.20427
   Schweitzer D, 2004, J BIOMED OPT, V9, P1214, DOI 10.1117/1.1806833
   Schweitzer D, 2012, INVEST OPHTH VIS SCI, V53, P3376, DOI 10.1167/iovs.11-8970
   Smith RT, 2006, INVEST OPHTH VIS SCI, V47, P5495, DOI 10.1167/iovs.05-1318
   Smith RT, 2014, BIOMED OPT EXPRESS, V5, P4171, DOI 10.1364/BOE.5.004171
   Spaide RF, 2010, RETINA-J RET VIT DIS, V30, P1441, DOI 10.1097/IAE.0b013e3181ee5ce8
   Thompson RB, 2015, P NATL ACAD SCI USA, V112, P1565, DOI 10.1073/pnas.1413347112
   Tong YH, 2016, RETINA-J RET VIT DIS, V36, pS127, DOI 10.1097/IAE.0000000000001325
   Tserentsoodol N, 2006, MOL VIS, V12, P1306
   Wang L, 2009, INVEST OPHTH VIS SCI, V50, P870, DOI 10.1167/iovs.08-2376
   Yehoshua Z, 2011, OPHTHALMOLOGY, V118, P2434, DOI 10.1016/j.ophtha.2011.05.008
   Zacks DN, 2004, ARCH OPHTHALMOL-CHIC, V122, P406, DOI 10.1001/archopht.122.3.406
NR 55
TC 8
Z9 8
U1 0
U2 1
PU ASSOC RESEARCH VISION OPHTHALMOLOGY INC
PI ROCKVILLE
PA 12300 TWINBROOK PARKWAY, ROCKVILLE, MD 20852-1606 USA
SN 2164-2591
J9 TRANSL VIS SCI TECHN
JI Transl. Vis. Sci. Technol.
PD APR
PY 2020
VL 9
IS 5
AR 20
DI 10.1167/tvst.9.5.20
PG 11
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA MJ6XV
UT WOS:000548232200020
PM 32821492
OA Green Published, gold
DA 2022-11-30
ER

PT J
AU Duan, YK
   Mo, JP
   Klein, R
   Scott, IU
   Lin, HM
   Caulfield, J
   Patel, M
   Liao, DP
AF Duan, Yinkang
   Mo, Jingping
   Klein, Ronald
   Scott, Ingrid U.
   Lin, Hung-Mo
   Caulfield, Joanne
   Patel, Manju
   Liao, Duanping
TI Age-related macular degeneration is associated with incident myocardial
   infarction among elderly Americans
SO OPHTHALMOLOGY
LA English
DT Article
ID BEAVER DAM EYE; RISK-FACTORS; CARDIOVASCULAR-DISEASE; DIETARY-FAT;
   MACULOPATHY; PREVALENCE; ATHEROSCLEROSIS; ROTTERDAM; HEALTH;
   HYPERTENSION
AB Objective: To investigate whether age-related macular degeneration (AMD) is associated with the development of myocardial infarction (MI) among elderly Americans.
   Design: Population-based cross-sectional and cohort study.
   Participants: Five percent random sample of 2000 to 2003 Medicare enrollees.
   Methods: The cross-sectional study included the first 2-year (2000 and 2001) enrollees who were aged >= 65 years (n = 1 519 086). The cohort study included only baseline MI-free enrollees (n = 1 445 677).
   Main Outcome Measures: Chronic conditions (AMD and type, history of MI, hypertension, and diabetes) were defined based on any occurrence of relevant International Classification of Diseases 9 codes in relevant diagnosis fields of the baseline Medicare claim files. A total of 56 611 incident MI cases were identified from the follow-up data (2002 and 2003).
   Results: Baseline mean age was 76 years, with 60% women and 88% whites. The prevalence of neovascular AMD was 2.2% (2.3% in women vs. 1.7% in men and 2.3% in whites vs. 1.2% in blacks; P < 0.01 for both gender and race differences). The prevalence of nonneovascular AMD was 8.8% (9.9% in women vs. 7.3% in men and 9.5% in whites vs. 4.3% in blacks; P < 0.01 for both gender and race differences). Baseline age-, gender-, and race-adjusted prevalences of hypertension, diabetes, and history of MI were 75%, 33%, and 5.00%, respectively, in the neovascular AMD group. In contrast, they were 73%, 27%, and 4.68% in the nonneovascular AMD group, and 65%, 25%, and 4.54% in the non-AMD group (P < 0.01 for comparing the prevalence in neovascular and nonneovascular AMD vs. non-AMD groups). Prospectively, baseline age-, gender-, race-, hypertension-, and diabetes-adjusted 2-year incident odds ratios and 95% confidence intervals of MI associated with AMD are 1.19 (1.16-1.22) for all persons with AMD, 1.26 (1.20-1.33) for neovascular AMD, and 1.18 (1.14-1.21) for nonneovascular AMD.
   Conclusions: AMD is associated with older age, female gender, being white, and having a history of MI, hypertension, and diabetes. Furthermore, presence of AMD, especially neovascular AMD, is prospectively associated with a higher risk of incident MI. These findings, if confirmed by other studies that control for smoking and other lifestyle covariables, suggest the possibility of shared common antecedents between MI and AMD.
C1 Penn State Univ, Dept Hlth Evaluat Sci, Coll Med, Hershey, PA 17033 USA.
   Pfizer Inc, New York, NY USA.
   Univ Wisconsin, Madison, WI USA.
C3 Pennsylvania Commonwealth System of Higher Education (PCSHE);
   Pennsylvania State University; Penn State Health; Pfizer; University of
   Wisconsin System; University of Wisconsin Madison
RP Liao, DP (通讯作者)，Penn State Univ, Dept Hlth Evaluat Sci, Coll Med, 600 Centerview Dr,A210, Hershey, PA 17033 USA.
EM dliao@psu.edu
OI Scott, Ingrid/0000-0002-3908-7153
CR Allikmets R, 1997, SCIENCE, V277, P1805, DOI 10.1126/science.277.5333.1805
   Anand R, 2000, OPHTHALMOLOGY, V107, P2224
   Birman-Deych E, 2005, MED CARE, V43, P480, DOI 10.1097/01.mlr.0000160417.39497.a9
   Cai J, 2002, EYE, V16, P242, DOI 10.1038/sj.eye.6700133
   CRUICKSHANKS KJ, 1993, ARCH OPHTHALMOL-CHIC, V111, P514, DOI 10.1001/archopht.1993.01090040106042
   Darzins P, 1997, OPHTHALMOLOGY, V104, P770, DOI 10.1016/S0161-6420(97)30235-8
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P564
   GOLDBERG J, 1988, AM J EPIDEMIOL, V128, P700, DOI 10.1093/oxfordjournals.aje.a115023
   Hyman L, 2000, ARCH OPHTHALMOL-CHIC, V118, P351, DOI 10.1001/archopht.118.3.351
   HYMAN LG, 1983, AM J EPIDEMIOL, V118, P213, DOI 10.1093/oxfordjournals.aje.a113629
   Javitt JC, 2003, OPHTHALMOLOGY, V110, P1534, DOI 10.1016/S0161-6420(03)00495-0
   KAHN HA, 1977, AM J EPIDEMIOL, V106, P33, DOI 10.1093/oxfordjournals.aje.a112429
   Klaver CCW, 1998, AM J HUM GENET, V63, P200, DOI 10.1086/301901
   Klein R, 1998, AM J EPIDEMIOL, V147, P103
   Klein R, 2003, OPHTHALMOLOGY, V110, P25, DOI 10.1016/S0161-6420(02)01565-8
   Klein R, 1997, OPHTHALMOLOGY, V104, P1804, DOI 10.1016/S0161-6420(97)30023-2
   Klein R, 1999, ARCH OPHTHALMOL-CHIC, V117, P1203
   Lee PP, 2003, ARCH OPHTHALMOL-CHIC, V121, P1303, DOI 10.1001/archopht.121.9.1303
   Leibowitz H M, 1980, Surv Ophthalmol, V24, P335
   MARESPERLMAN JA, 1995, ARCH OPHTHALMOL-CHIC, V113, P743, DOI 10.1001/archopht.1995.01100060069034
   Rector TS, 2004, HEALTH SERV RES, V39, P1839, DOI 10.1111/j.1475-6773.2004.00321.x
   Schaumberg DA, 2001, ARCH OPHTHALMOL-CHIC, V119, P1259
   SEDDON JM, 1994, JAMA-J AM MED ASSOC, V272, P1413, DOI 10.1001/jama.272.18.1413
   Smith W, 1998, ARCH OPHTHALMOL-CHIC, V116, P583, DOI 10.1001/archopht.116.5.583
   Smith W, 2000, ARCH OPHTHALMOL-CHIC, V118, P401, DOI 10.1001/archopht.118.3.401
   SPERDUTO RD, 1986, ARCH OPHTHALMOL-CHIC, V104, P216
   van Leeuwen R, 2003, INVEST OPHTH VIS SCI, V44, P3771, DOI 10.1167/iovs.03-0121
   VINDING T, 1992, ACTA OPHTHALMOL, V70, P66
   Vine AK, 2005, OPHTHALMOLOGY, V112, P2076, DOI 10.1016/j.ophtha.2005.07.004
   VINGERLING JR, 1995, AM J EPIDEMIOL, V142, P404, DOI 10.1093/oxfordjournals.aje.a117648
   VINGERLING JR, 1995, OPHTHALMOLOGY, V102, P205
   YANNUZZI LA, 1992, ARCH OPHTHALMOL-CHIC, V110, P1701
NR 32
TC 98
Z9 102
U1 0
U2 3
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0161-6420
J9 OPHTHALMOLOGY
JI Ophthalmology
PD APR
PY 2007
VL 114
IS 4
BP 732
EP 737
DI 10.1016/j.ophtha.2006.07.045
PG 6
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 153MU
UT WOS:000245440400019
PM 17187863
DA 2022-11-30
ER

PT J
AU Ghosh, S
   Shang, P
   Yazdankhah, M
   Bhutto, I
   Hose, S
   Montezuma, SR
   Luo, TQ
   Chattopadhyay, S
   Qian, J
   Lutty, GA
   Ferrington, DA
   Zigler, JS
   Sinha, D
AF Ghosh, Sayan
   Shang, Peng
   Yazdankhah, Meysam
   Bhutto, Imran
   Hose, Stacey
   Montezuma, Sandra R.
   Luo, Tianqi
   Chattopadhyay, Sreya
   Qian, Jiang
   Lutty, Gerard A.
   Ferrington, Deborah A.
   Zigler, J. Samuel, Jr.
   Sinha, Debasish
TI Activating the AKT2-nuclear factor-kappa B-lipocalin-2 axis elicits an
   inflammatory response in age-related macular degeneration
SO JOURNAL OF PATHOLOGY
LA English
DT Article
DE age-related macular degeneration; AKT2-NF-kappa B-lipocalin-2 signalling
   axis; beta A3/A1-crystallin; inflammation; lysosomes
ID NF-KAPPA-B; RETINAL-PIGMENT EPITHELIUM; LIPOCALIN-2; EXPRESSION;
   INDUCTION; PROTEINS; CELLS; STAT1; MICE
AB Age-related macular degeneration (AMD) is a complex and progressive degenerative eye disease resulting in severe loss of central vision. Recent evidence indicates that immune system dysregulation could contribute to the development of AMD. We hypothesize that defective lysosome-mediated clearance causes accumulation of waste products in the retinal pigmented epithelium (RPE), activating the immune system and leading to retinal tissue injury and AMD. We have generated unique genetically engineered mice in which lysosome-mediated clearance (both by phagocytosis and autophagy) in RPE cells is compromised, causing the development of features of early AMD. Our recent data indicate a link between lipocalin-2 (LCN-2) and the inflammatory responses induced in this mouse model. We show that nuclear factor-B (NF-B) and STAT-1 may function as a complex in our animal model system, together controlling the upregulation of LCN-2 expression in the retina and stimulating an inflammatory response. This study revealed increased infiltration of LCN-2-positive neutrophils in the choroid and retina of early AMD patients as compared with age-matched controls. Our results demonstrate that, both in our animal model and in human AMD, the AKT2-NF-B-LCN-2 signalling axis is involved in activating the inflammatory response, making this pathway a potential target for AMD treatment. Copyright (c) 2016 Pathological Society of Great Britain and Ireland. Published by John Wiley & Sons, Ltd.
C1 [Ghosh, Sayan; Shang, Peng; Yazdankhah, Meysam; Bhutto, Imran; Hose, Stacey; Luo, Tianqi; Qian, Jiang; Lutty, Gerard A.; Zigler, J. Samuel, Jr.; Sinha, Debasish] Johns Hopkins Univ, Sch Med, Dept Ophthalmol, Baltimore, MD 21287 USA.
   [Ghosh, Sayan; Chattopadhyay, Sreya] Univ Calcutta, Dept Physiol, Kolkata, WB, India.
   [Montezuma, Sandra R.; Ferrington, Deborah A.] Univ Minnesota, Dept Ophthalmol & Visual Neurosci, Minneapolis, MN USA.
C3 Johns Hopkins University; University of Calcutta; University of
   Minnesota System; University of Minnesota Twin Cities
RP Sinha, D (通讯作者)，Johns Hopkins Univ, Sch Med, Dept Ophthalmol, Baltimore, MD 21287 USA.
EM Debasish@jhmi.edu
RI Ghosh, Sayan/ABB-8587-2021
OI /0000-0002-3780-5641; Ferrington, Deborah/0000-0003-2561-7464
FU Fulbright-Nehru Doctoral Research Fellowship; BrightFocus Foundation;
   Research to Prevent Blindness; National Eye Institute [EY019037-S,
   EY01765]; Arnold and Mabel and Beckman Foundation; NATIONAL EYE
   INSTITUTE [R01EY019037, P30EY001765] Funding Source: NIH RePORTER
FX We thank Drs Morton Goldberg and Eric Wawrousek for critical reading and
   discussions regarding this manuscript, and the personnel at the
   Minnesota Lions Eye Bank for assistance with procuring and processing
   donor eyes. We thank Drs Mariko Bennett and Ben Barres for the Tmem119
   antibody. SG is a recipient of a Fulbright-Nehru Doctoral Research
   Fellowship. DS is a recipient of the Carolyn K. McGillvray Memorial
   Award for Macular Degeneration Research from BrightFocus Foundation and
   the Sybil B. Harrington Special Scholar Award for Macular Degeneration
   from Research to Prevent Blindness. This research was supported by
   BrightFocus Foundation (DS), Research to Prevent Blindness (an
   unrestricted grant to the Wilmer Eye Institute and Department of
   Ophthalmology and Visual Sciences, University of Minnesota), National
   Eye Institute EY019037-S (DS) and EY01765 (Wilmer Imaging Core), the
   Arnold and Mabel and Beckman Foundation (DF), and an anonymous
   benefactor for AMD research (DF).
CR Bennett ML, 2016, P NATL ACAD SCI USA, V113, pE1738, DOI 10.1073/pnas.1525528113
   Burke SJ, 2014, AM J PHYSIOL-ENDOC M, V306, pE131, DOI 10.1152/ajpendo.00347.2013
   Choudhury S, 2015, FREE RADICAL RES, V49, P1371, DOI 10.3109/10715762.2015.1075016
   Decanini A, 2007, AM J OPHTHALMOL, V143, P607, DOI 10.1016/j.ajo.2006.12.006
   Gorin MB, 2012, MOL ASPECTS MED, V33, P467, DOI 10.1016/j.mam.2012.04.004
   Lechner J, 2015, SCI REP-UK, V5, DOI 10.1038/srep16754
   Lee JH, 2010, CELL, V141, P1146, DOI 10.1016/j.cell.2010.05.008
   Madrid LV, 2001, J BIOL CHEM, V276, P18934, DOI 10.1074/jbc.M101103200
   Nagineni CN, 2015, AGING DIS, V6, P444, DOI 10.14336/AD.2015.0323
   Parmar T, 2016, INVEST OPHTH VIS SCI, V57, P3257, DOI 10.1167/iovs.15-18993
   Sergeev YV, 2004, BIOCHEMISTRY-US, V43, P415, DOI 10.1021/bi034617f
   Sparrow JR, 2012, MOL ASPECTS MED, V33, P436, DOI 10.1016/j.mam.2012.03.007
   Tarallo V, 2012, CELL, V149, P847, DOI 10.1016/j.cell.2012.03.036
   Truax AD, 2012, METHODS MOL BIOL, V809, P175, DOI 10.1007/978-1-61779-376-9_12
   Valapala M, 2014, AGING CELL, V13, P1091, DOI 10.1111/acel.12274
   Valapala M, 2014, AUTOPHAGY, V10, P480, DOI 10.4161/auto.27292
   Whitcup SM, 2013, INT J INFLAMM, V2013, DOI 10.1155/2013/348092
   Zhao P, 2014, J BIOL CHEM, V289, P5960, DOI 10.1074/jbc.M113.532234
   Zhao P, 2013, MOL METAB, V2, P161, DOI 10.1016/j.molmet.2013.04.003
   Zhu T, 2015, CLIN EXP PHARMACOL P, V42, P537, DOI 10.1111/1440-1681.12376
NR 20
TC 33
Z9 35
U1 0
U2 5
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0022-3417
EI 1096-9896
J9 J PATHOL
JI J. Pathol.
PD APR
PY 2017
VL 241
IS 5
BP 583
EP 588
DI 10.1002/path.4870
PG 6
WC Oncology; Pathology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology; Pathology
GA EP6CS
UT WOS:000397466300003
PM 28026019
OA Green Accepted
DA 2022-11-30
ER

PT J
AU Muni, RH
   Altaweel, M
   Tennant, M
   Weaver, B
   Kertes, PJ
AF Muni, Rajeev H.
   Altaweel, Michael
   Tennant, Matthew
   Weaver, Bruce
   Kertes, Peter J.
TI AGREEMENT AMONG CANADIAN RETINA SPECIALISTS IN THE DETERMINATION OF
   TREATMENT ELIGIBILITY FOR PHOTODYNAMIC THERAPY IN AGE-RELATED MACULAR
   DEGENERATION
SO RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES
LA English
DT Article
DE agreement; PDT; AMD; Reading Centre; fluorescein angiogram
ID SUBFOVEAL CHOROIDAL NEOVASCULARIZATION; EVALUATING FLUORESCEIN
   ANGIOGRAMS; VERTEPORFIN THERAPY; TAP
AB Objectives: To determine inter- and intraobserver agreement among Canadian retina specialists in their angiographic classification of choroidal neovascularization and their decision to treat with photodynamic therapy. Agreement was also determined between retina specialists and a Reading Center.
   Methods: Forty retina specialists graded 24 cases of exudative age-related macular degeneration on two occasions separated by 6 months. Participants were asked to categorize the choroidal neovascularization and indicate if they would treat with photodynamic therapy. Agreement was determined for decision to treat and for interpretation of the fluorescein angiogram. Angiographic interpretation by participants was compared with that of the Reading Center.
   Results: The kappas among the 40 participants for lesion categorization and treatment decision were 0.43 (95% confidence interval: 0.36-0.52) and 0.29 (95% confidence interval: 0.18-0.42), respectively. The kappa for intraobserver agreement was 0.57 (95% confidence interval: 0.50-0.64) for lesion categorization and 0.58 (95% confidence interval: 0.43-0.74) for treatment decision. The mean percent agreement with the Reading Center for lesion categorization was 65.4%.
   Conclusions: There was moderate interobserver agreement for choroidal neovascularization categorization and poor agreement among Canadian retina specialists for decision to treat with photodynamic therapy. There was moderate intraobserver agreement for both treatment decision and lesion categorization. There was moderate agreement between observers and the Reading Center for angiographic choroidal neovascularization categorization.
C1 [Muni, Rajeev H.; Kertes, Peter J.] Univ Toronto, Sunnybrook Hlth Sci Ctr, Dept Ophthalmol & Vis Sci, Toronto, ON M4N 3M5, Canada.
   [Altaweel, Michael] Univ Wisconsin, Dept Ophthalmol & Visual Sci, Madison, WI 53706 USA.
   [Tennant, Matthew] Univ Alberta, Dept Ophthalmol, Edmonton, AB, Canada.
   [Weaver, Bruce] No Ontario Sch Med, Human Sci Div, Thunder Bay, ON, Canada.
C3 University of Toronto; Sunnybrook Research Institute; University Toronto
   Affiliates; Sunnybrook Health Science Center; University of Wisconsin
   System; University of Wisconsin Madison; University of Alberta; Northern
   Ontario School of Medicine
RP Kertes, PJ (通讯作者)，Univ Toronto, Sunnybrook Hlth Sci Ctr, Dept Ophthalmol & Vis Sci, 2075 Bayview Ave, Toronto, ON M4N 3M5, Canada.
EM peter.kertes@sunnybrook.ca
CR Arnold J, 2001, AM J OPHTHALMOL, V131, P541
   Blinder KJ, 2003, AM J OPHTHALMOL, V136, P407, DOI 10.1016/S0002-9394(03)00223-X
   Blumenkranz MS, 2001, ARCH OPHTHALMOL-CHIC, V119, P198
   Bressler NM, 1999, ARCH OPHTHALMOL-CHIC, V117, P1329
   Fleiss J L, 1993, Stat Methods Med Res, V2, P121, DOI 10.1177/096228029300200202
   Friedman SM, 2000, AM J OPHTHALMOL, V130, P839, DOI 10.1016/S0002-9394(00)00605-X
   Harvey PT, 2001, INVEST OPHTH VIS SCI, V42, pS305
   Holz FG, 2003, OPHTHALMOLOGY, V110, P400, DOI 10.1016/S0161-6420(02)01770-0
   Hooper CY, 2003, CLIN EXP OPHTHALMOL, V31, P376, DOI 10.1046/j.1442-9071.2003.00683.x
   Zayit-Soudry S, 2007, RETINA-J RET VIT DIS, V27, P798, DOI 10.1097/IAE.0b013e31802c50a3
   2002, RETINA, V22, P6
NR 11
TC 5
Z9 5
U1 0
U2 0
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0275-004X
J9 RETINA-J RET VIT DIS
JI Retin.-J. Retin. Vitr. Dis.
PD NOV-DEC
PY 2008
VL 28
IS 10
BP 1421
EP 1426
DI 10.1097/IAE.0b013e3181814470
PG 6
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 373LH
UT WOS:000260972600007
PM 18667952
DA 2022-11-30
ER

PT J
AU Chang, TS
   Bressler, NM
   Fine, JT
   Dolan, CW
   Ward, J
   Klesert, TR
AF Chang, Tom S.
   Bressler, Neil M.
   Fine, Jennifer T.
   Dolan, Chantal W.
   Ward, James
   Klesert, Todd R.
CA Marina Study Group
TI Improved vision-related function after ranibizumab treatment of
   Neovascular age-related macular degeneration - Results of a randomized
   clinical trial
SO ARCHIVES OF OPHTHALMOLOGY
LA English
DT Article
ID QUALITY-OF-LIFE; VISUAL FUNCTION QUESTIONNAIRE; SUBFOVEAL CHOROIDAL
   NEOVASCULARIZATION; EYE DISEASE; AREDS; RESPONSIVENESS; SURGERY
AB Objective: To examine the effects of ranibizumab on patient-reported visual function using the National Eye Institute Visual Function Questionnaire 25 (NEI VFQ-25) in patients with neovascular age-related macular degeneration (AMD).
   Design: In MARINA, a randomized, double-masked clinical trial, 716 patients with AMD with recent disease progression and minimally classic or occult with no classic lesion component were randomized 1: 1: 1 to monthly intravitreal ranibizumab (0.3 or 0.5 mg) or sham injections. The NEI VFQ-25 was administered at 0, 1, 2, 3, 6, 9, 12, 18, and 24 months.
   Main Outcome Measure: Mean change from baseline in NEI VFQ-25 scores at 12 and 24 months.
   Result: At 12 months, ranibizumab-treated patients (0.3 mg [n=238] and 0.5 mg [n=240]) had mean improvements in NEI VFQ-25 composite scores of +5.2 (95% confidence interval [CI], 3.5 to 6.9) and +5.6 (95% CI, 3.9 to 7.4), respectively; sham-injected patients (n=238) had a mean decline of -2.8 (95% CI, -4.6 to -1.1; P < .001 vs each dose). Ranibizurnab-treated patients were more likely to improve in near activities, distance activities, an vision-specific dependency through 24 months.
   Conclusions: In MARINA, ranibizumab-treated patients were more likely than sham-treated patients to report visual function improvements at 12 and 24 months.
C1 Retina Inst California, Pasadena, CA 91105 USA.
   Johns Hopkins Univ, Sch Med, Wilmer Eye Inst, Retina Div, Baltimore, MD 21205 USA.
   Genentech Inc, San Francisco, CA 94080 USA.
   Univ So Calif, Doheny Retina Inst, Los Angeles, CA USA.
C3 Johns Hopkins University; Johns Hopkins Medicine; Roche Holding;
   Genentech; University of Southern California
RP Chang, TS (通讯作者)，Retina Inst California, 800 S Fairmount Ave,Ste 312, Pasadena, CA 91105 USA.
EM tomschang@hotmail.com
CR Bass EB, 2004, ARCH OPHTHALMOL-CHIC, V122, P1856
   Bressler Neil M, 2004, JAMA, V291, P1900, DOI 10.1001/jama.291.15.1900
   Bressler NM, 2003, ARCH OPHTHALMOL-CHIC, V121, P1621
   Bressler NM, 1999, ARCH OPHTHALMOL-CHIC, V117, P1329
   Cahill MT, 2005, OPHTHALMOLOGY, V112, P144, DOI 10.1016/j.ophtha.2004.06.035
   Childs AL, 2004, OPHTHALMOLOGY, V111, P2007, DOI 10.1016/j.ophtha.2004.07.024
   Clemons TE, 2003, ARCH OPHTHALMOL-CHIC, V121, P211
   Dandona L, 1998, ARCH OPHTHALMOL-CHIC, V116, P545, DOI 10.1001/archopht.116.4.514
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P564
   Gragoudas ES, 2004, NEW ENGL J MED, V351, P2805, DOI 10.1056/NEJMoa042760
   Hawkins BS, 2005, ARCH OPHTHALMOL-CHIC, V123, P78, DOI 10.1001/archopht.123.1.78
   Hawkins BS, 2004, ARCH OPHTHALMOL-CHIC, V122, P1616, DOI 10.1001/archopht.122.11.1616
   Lindblad AS, 2005, ARCH OPHTHALMOL-CHIC, V123, P1207
   Linder M, 1999, ARCH OPHTHALMOL-CHIC, V117, P1611
   Maguire M, 2004, OPHTHALMOLOGY, V111, P1307
   Mangione C., 2000, NATL EYE I 25 ITEM V
   Mangione CM, 2001, ARCH OPHTHALMOL-CHIC, V119, P1050, DOI 10.1001/archopht.119.7.1050
   Mangione CM, 1998, ARCH OPHTHALMOL-CHIC, V116, P1496, DOI 10.1001/archopht.116.11.1496
   Margolis MK, 2002, PHARMACOECONOMICS, V20, P791, DOI 10.2165/00019053-200220120-00001
   Mejico LJ, 2004, AM J OPHTHALMOL, V137, P908, DOI 10.1016/j.ajo.2003.12.038
   Miskala PH, 2004, OPHTHALMOLOGY, V111, P1981, DOI 10.1016/j.ophtha.2004.07.022
   Miskala PH, 2003, ARCH OPHTHALMOL-CHIC, V121, P531
   Morimoto Takeshi, 2002, J Epidemiol, V12, P160
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Torrance G W, 1989, Int J Technol Assess Health Care, V5, P559
   WILSON IB, 1995, JAMA-J AM MED ASSOC, V273, P59, DOI 10.1001/jama.273.1.59
NR 26
TC 178
Z9 186
U1 0
U2 11
PU AMER MEDICAL ASSOC
PI CHICAGO
PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA
SN 0003-9950
EI 1538-3601
J9 ARCH OPHTHALMOL-CHIC
JI Arch. Ophthalmol.
PD NOV
PY 2007
VL 125
IS 11
BP 1460
EP 1469
DI 10.1001/archopht.125.11.1460
PG 10
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 229LU
UT WOS:000250806300001
PM 17998507
DA 2022-11-30
ER

PT J
AU Nishimura, T
   Machida, S
   Hashizume, K
   Kurosaka, D
AF Nishimura, Tomoharu
   Machida, Shigeki
   Hashizume, Kouhei
   Kurosaka, Daijiro
TI Structures affecting recovery of macular function in patients with
   age-related macular degeneration after intravitreal ranibizumab
SO GRAEFES ARCHIVE FOR CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY
LA English
DT Article
DE Age-related macular degeneration; Ranibizumab; Focal macular ERG; ERG;
   SD-OCT
ID PHOTOPIC NEGATIVE RESPONSE; CHOROIDAL NEOVASCULARIZATION; RETINAL
   SENSITIVITY; BEVACIZUMAB; THERAPY; EYES; OCT; ELECTRORETINOGRAMS;
   VERTEPORFIN; ERG
AB To determine the retinal structures affecting the recovery of macular function in patients with exudative age-related macular degeneration (AMD) treated with intravitreal ranibizumab (IVR).
   Thirty eyes of 30 patients with exudative AMD who were treated with IVR at monthly intervals for 3 months were studied. Focal macular electroretinograms (fmERGs) and spectral-domain optical coherence tomography (SD-OCT) were performed before and 3 months after beginning the IVR injections. The fmERGs were elicited by a 15A degrees white stimulus spot centered on the fovea. The thickness of different retinal layers, presence of a serous retinal detachment (SRD), and presence of a pigment epithelial detachment (PED) at the fovea was determined in the SD-OCT images. Measurements were made of the inner, middle, and outer layers of the retina and also of the SRD and PED in the horizontal and vertical meridians at 1.2 mm from the fovea (parafoveal regions). The significance of the correlations between these structural parameters and the a-wave amplitude of the fmERG was determined.
   There was no significant correlation between the structural parameters of the fovea and the a-wave amplitude. In the parafoveal regions, the thickness of the outer retinal layer was significantly correlated with an increase of the a-wave amplitude (R = 0.56, P = 0.001). In addition, the SRD thickness was negatively and significantly correlated with the a-wave amplitude (R = -0.54, P = 0.002). The change in the parafoveal SRD thickness after IVRs was the only independent determinant of recovery of the a-wave amplitude after the treatments (P < 0.05).
   The macular function measured by the fmERGs was determined by the parafoveal outer layer and SRD thickness in patients with exudative AMD. Of these, changes in the SRD thickness by IVRs most strongly affected the recovery of macular function.
C1 [Nishimura, Tomoharu; Machida, Shigeki; Hashizume, Kouhei; Kurosaka, Daijiro] Iwate Med Univ, Dept Ophthalmol, Sch Med, Morioka, Iwate 0208505, Japan.
   [Machida, Shigeki] Dokkyo Med Univ, Koshigaya Hosp, Dept Ophthalmol, Koshigaya, Saitama 3438555, Japan.
C3 Iwate Medical University; Dokkyo Medical University
RP Machida, S (通讯作者)，Dokkyo Med Univ, Koshigaya Hosp, Dept Ophthalmol, 2-1-50 Minami Koshigaya, Koshigaya, Saitama 3438555, Japan.
EM machidas@dokkyomed.ac.jp
FU JSPS KAKENHI [24592677]
FX This study was supported by JSPS KAKENHI Grant No. 24592677 (SM). We
   thank Professor Duco Hamasaki for discussions and editing the
   manuscript.
CR Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Brown DM, 2009, OPHTHALMOLOGY, V116, P57, DOI 10.1016/j.ophtha.2008.10.018
   BUSH RA, 1994, INVEST OPHTH VIS SCI, V35, P635
   Campa C, 2011, INVEST OPHTH VIS SCI, V52, P3446, DOI 10.1167/iovs.10-6588
   Cho HJ, 2013, AM J OPHTHALMOL, V155, P118, DOI 10.1016/j.ajo.2012.07.009
   Iwata E, 2012, INVEST OPHTH VIS SCI, V53, P4185, DOI 10.1167/iovs.11-9335
   Kim YM, 2012, AM J OPHTHALMOL, V154, P164, DOI 10.1016/j.ajo.2012.01.030
   Kizawa J, 2006, JPN J OPHTHALMOL, V50, P367, DOI 10.1007/s10384-006-0326-0
   Kondo M, 2008, VISION RES, V48, P273, DOI 10.1016/j.visres.2007.11.010
   Lalwani GA, 2009, AM J OPHTHALMOL, V148, P43, DOI 10.1016/j.ajo.2009.01.024
   Machida S, 2008, INVEST OPHTH VIS SCI, V49, P5636, DOI 10.1167/iovs.08-1946
   Martin DF, 2012, OPHTHALMOLOGY, V119, DOI 10.1016/j.ophtha.2012.03.053
   Mitchell P, 2010, BRIT J OPHTHALMOL, V94, P2, DOI 10.1136/bjo.2009.159160
   Miyake Y, 1988, Nippon Ganka Gakkai Zasshi, V92, P1419
   MIYAKE Y, 1981, JPN J OPHTHALMOL, V25, P438
   Moschos MM, 2007, DOC OPHTHALMOL, V114, P37, DOI 10.1007/s10633-006-9036-7
   Munk MR, 2013, AM J OPHTHALMOL, V156, P633, DOI 10.1016/j.ajo.2013.05.037
   Nishihara H, 2008, INVEST OPHTH VIS SCI, V49, P3121, DOI 10.1167/iovs.08-1835
   Nishimura T, 2012, CLIN OPHTHALMOL, V6, P1073, DOI 10.2147/OPTH.S31674
   Ogino K, 2014, JPN J OPHTHALMOL, V58, P155, DOI 10.1007/s10384-013-0295-z
   Ogino K, 2013, INVEST OPHTH VIS SCI, V54, P3771, DOI 10.1167/iovs.12-11494
   Oishi A, 2013, GRAEF ARCH CLIN EXP, V251, P435, DOI 10.1007/s00417-012-2034-4
   Ritter M, 2010, EYE, V24, P962, DOI 10.1038/eye.2009.265
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Shin HJ, 2013, RETINA-J RET VIT DIS, V33, P964, DOI 10.1097/IAE.0b013e3182835f70
   Shin HJ, 2011, RETINA-J RET VIT DIS, V31, P1627, DOI 10.1097/IAE.0b013e31820d3d01
   Sulzbacher F, 2013, INVEST OPHTH VIS SCI, V54, P1310, DOI 10.1167/iovs.12-11046
   Sulzbacher F, 2012, INVEST OPHTH VIS SCI, V53, P6448, DOI 10.1167/iovs.11-9162
   Unver YB, 2009, EYE, V23, P453, DOI 10.1038/eye.2008.349
NR 29
TC 5
Z9 5
U1 0
U2 0
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0721-832X
EI 1435-702X
J9 GRAEF ARCH CLIN EXP
JI Graefes Arch. Clin. Exp. Ophthalmol.
PD AUG
PY 2015
VL 253
IS 8
BP 1201
EP 1209
DI 10.1007/s00417-014-2779-z
PG 9
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA CN9AA
UT WOS:000358736700001
PM 25163415
DA 2022-11-30
ER

PT J
AU Keane, PA
   Liakopoulos, S
   Ongchin, SC
   Heussen, FM
   Msutta, S
   Chang, KT
   Walsh, AC
   Sadda, SR
AF Keane, Pearse A.
   Liakopoulos, Sandra
   Ongchin, Sharel C.
   Heussen, Florian M.
   Msutta, Sandeep
   Chang, Karen T.
   Walsh, Alexander C.
   Sadda, Srinivas R.
TI Quantitative subanalysis of optical coherence tomography after treatment
   with ranibizumab for neovascular age-related macular degeneration
SO INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE
LA English
DT Article
ID VERTEPORFIN
AB PURPOSE. To investigate the effects of ranibizumab on retinal morphology in patients with neovascular age-related macular degeneration (AMD) using optical coherence tomography (OCT) quantitative subanalysis.
   METHODS. Data from 95 patients receiving intravitreal ranibizumab for neovascular AMD were collected. StratusOCT images were analyzed using custom software that allows precise positioning of prespecified boundaries on every B-scan. Changes in thickness/volume of the retina, subretinal fluid (SRF), subretinal tissue (SRT), and pigment epithelial detachments (PEDs) at week 1 and at months 1, 3, 6, and 9 after treatment were calculated.
   RESULTS. Total retinal volume reached its nadir at month 1, with an average reduction of 0.43 mm(3) (P < 0.001). By month 9, this initial change had been reduced to a mean reduction of 0.32 mm(3) (P = 0.0011). Total SRF volume reached its lowest level by month 1, with an average reduction of 0.24 mm(3) (P < 0.001). This reduction lessened subsequently, to 0.18 mm3, by month 9. There was an average 0.3-mm(3) decrease in total PED volume by month 1 (P < 0.001), and this later declined further, to 0.45 mm(3), by month 9 (P = 0.0014). Total SRT volume was reduced by an average of 0.07 mm(3) at month 1 (P = 0.0159) and subsequently remained constant.
   CONCLUSIONS. Although neurosensory retinal edema and SRF showed an early reduction to nadir after the initiation of ranibizumab therapy, the effect on the retina was attenuated over time, suggesting possible tachyphylaxis. PED volume showed a slower but progressive reduction. Manual quantitative OCT subanalysis may allow a more precise understanding of anatomic outcomes and their correlation with visual acuity.
C1 [Sadda, Srinivas R.] Univ So Calif, Keck Sch Med, Doheny Eye Inst, Doheny Image Reading Ctr,DEI 3623, Los Angeles, CA 90033 USA.
   [Liakopoulos, Sandra] Univ Cologne, Ctr Ophthalmol, Dept Vitreoretinal Surg, Cologne, Germany.
C3 Doheny Eye Institute; University of Southern California; University of
   Cologne
RP Sadda, SR (通讯作者)，Univ So Calif, Keck Sch Med, Doheny Eye Inst, Doheny Image Reading Ctr,DEI 3623, 1450 San Pablo St, Los Angeles, CA 90033 USA.
EM sadda@usc.edu
RI Keane, Pearse A/H-1860-2011; Keane, Pearse/AAE-5709-2019
OI Keane, Pearse/0000-0002-9239-745X; Heussen, Florian
   Moritz/0000-0003-0536-9870
FU NEI NIH HHS [EY03040, R21 EY015914-03, R01 EY014375, R21 EY015914-04,
   R21 EY015914, P30 EY003040] Funding Source: Medline; NATIONAL EYE
   INSTITUTE [R01EY014375, P30EY003040, R21EY015914] Funding Source: NIH
   RePORTER
CR Avery RL, 2006, OPHTHALMOLOGY, V113, P363, DOI 10.1016/j.ophtha.2005.11.019
   Barbazetto I, 2003, ARCH OPHTHALMOL-CHIC, V121, P1253
   Bressler NM, 2003, ARCH OPHTHALMOL-CHIC, V121, P1621
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Fung AE, 2007, AM J OPHTHALMOL, V143, P566, DOI 10.1016/j.ajo.2007.01.028
   Gragoudas ES, 2004, NEW ENGL J MED, V351, P2805, DOI 10.1056/NEJMoa042760
   Hee MR, 2005, AM J OPHTHALMOL, V139, P154, DOI 10.1016/j.ajo.2004.08.066
   Joeres S, 2007, INVEST OPHTH VIS SCI, V48, P4300, DOI 10.1167/iovs.07-0179
   Kaiser PK, 2007, OPHTHALMOLOGY, V114, P1868, DOI 10.1016/j.ophtha.2007.04.030
   Klein R, 2004, AM J OPHTHALMOL, V137, P486, DOI 10.1016/j.ajo.2003.11.069
   Ray R, 2005, AM J OPHTHALMOL, V139, P18, DOI 10.1016/j.ajo.2004.07.050
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Sadda SR, 2006, OPHTHALMOLOGY, V113, P285, DOI 10.1016/j.ophtha.2005.10.005
   Sadda SR, 2007, INVEST OPHTH VIS SCI, V48, P839, DOI 10.1167/iovs.06-0554
   STERNBERG P, 1991, ARCH OPHTHALMOL-CHIC, V109, P1220
   Zayit-Soudry S, 2007, SURV OPHTHALMOL, V52, P227, DOI 10.1016/j.survophthal.2007.02.008
NR 16
TC 111
Z9 117
U1 1
U2 6
PU ASSOC RESEARCH VISION OPHTHALMOLOGY INC
PI ROCKVILLE
PA 12300 TWINBROOK PARKWAY, ROCKVILLE, MD 20852-1606 USA
SN 0146-0404
J9 INVEST OPHTH VIS SCI
JI Invest. Ophthalmol. Vis. Sci.
PD JUL
PY 2008
VL 49
IS 7
BP 3115
EP 3120
DI 10.1167/iovs.08-1689
PG 6
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 318WR
UT WOS:000257124000043
PM 18408176
OA Green Accepted
DA 2022-11-30
ER

PT J
AU Vujosevic, S
   Toma, C
   Villani, E
   Muraca, A
   Torti, E
   Florimbi, G
   Pezzotti, M
   Nucci, P
   De Cilla, S
AF Vujosevic, Stela
   Toma, Caterina
   Villani, Edoardo
   Muraca, Andrea
   Torti, Emanuele
   Florimbi, Giordana
   Pezzotti, Marco
   Nucci, Paolo
   De Cilla, Stefano
TI Quantitative choriocapillaris evaluation in intermediate age-related
   macular degeneration by swept-source optical coherence tomography
   angiography
SO ACTA OPHTHALMOLOGICA
LA English
DT Article
DE artefacts; choriocapillaris; drusen; flow voids; intermediate
   age-related macular degeneration; swept-source OCT angiography
ID CHOROIDAL BLOOD-FLOW; HUMAN EYES; NEOVASCULARIZATION; CLASSIFICATION;
   PREVALENCE; DRUSEN; DYE; RPE
AB Purpose To investigate choriocapillaris (CC) perfusion, by evaluating flow voids (FV), in eyes with intermediate age-related macular degeneration (iAMD) using swept-source optical coherence tomography angiography (SS-OCT-A). Methods Patients with bilateral or unilateral iAMD and normal controls underwent SS-OCT and OCT-A examination. Choriocapillaris (CC) FVs were quantitatively assessed on OCT-A images using matlab (version 2017b; MathWorks, Natick, MA, USA), after a preprocessing aimed at compensating for CC attenuation artefacts. Three different thresholds [1 standard deviation (SD), 1.25 SD and 1.5 SD] were applied. Final FV percentage (FV%) was calculated as the ratio between area with absent flow and total scanned area. Results Of 41 patients with iAMD and 16 normal subjects enrolled in the study, 39 eyes (39 patients) with iAMD and all 16 normal eyes (16 control subjects) were included in the final analysis. Mean FV% (1 SD) was 13.45 +/- 0.66 in controls, 14.19 +/- 1.23 in bilateral iAMD and 14.21 +/- 0.99 in unilateral iAMD (p = 0.03, for difference between controls and bilateral iAMD). Mean FV% (1.25 SD) was 6.55 +/- 0.65 in controls, 7.33 +/- 1.4 in bilateral iAMD and 7.06 +/- 1.4 in unilateral iAMD (p = 0.048, for difference between controls and bilateral iAMD). Mean FV% (1.5 SD) was 2.71 +/- 0.82 in controls, 2.55 +/- 1.12 in bilateral iAMD and 3.25 +/- 1.17 in unilateral iAMD (p = 0.038, for difference between bilateral and unilateral iAMD). Conclusion A significantly higher FV% was found in patients with iAMD versus controls. A higher trend in FV% was found in unilateral iAMD (with neovascular AMD in the fellow eye) versus bilateral iAMD, when applying the lowest threshold. Further, larger and longitudinal studies are needed to confirm this data.
C1 [Vujosevic, Stela; Toma, Caterina; Muraca, Andrea; Pezzotti, Marco; De Cilla, Stefano] Univ Hosp Maggiore Carita, Eye Clin, Corso Mazzini 18, I-28100 Novara, Italy.
   [Villani, Edoardo; Nucci, Paolo] Univ Milan, Dept Clin Sci & Community Hlth, Milan, Italy.
   [Villani, Edoardo; Nucci, Paolo] San Giuseppe Hosp, Eye Clin, Milan, Italy.
   [Torti, Emanuele; Florimbi, Giordana] Univ Pavia, Dept Elect Comp & Biomed Engn, Pavia, Italy.
   [De Cilla, Stefano] Univ East Piedmont A Avogadro, Dept Hlth Sci, Novara, Italy.
C3 Azienda Ospedaliera Maggiore della Carita di Novara; University of
   Milan; University of Pavia; University of Eastern Piedmont Amedeo
   Avogadro
RP Vujosevic, S (通讯作者)，Univ Hosp Maggiore Carita, Eye Clin, Corso Mazzini 18, I-28100 Novara, Italy.
EM stela.vujosevic@gmail.com
RI Vujosevic, Stela/AAI-4874-2020; Torti, Emanuele/AAB-8548-2020; nucci,
   paolo/J-9523-2016
OI Torti, Emanuele/0000-0001-8437-8227; nucci, paolo/0000-0002-4036-703X;
   Vujosevic, Stela/0000-0001-6773-9967
CR Alten F, 2017, GRAEF ARCH CLIN EXP, V255, P2347, DOI 10.1007/s00417-017-3813-8
   Alten F, 2016, GRAEF ARCH CLIN EXP, V254, P2165, DOI 10.1007/s00417-016-3375-1
   Anand R, 2000, OPHTHALMOLOGY, V107, P2224
   Bhutto I, 2012, MOL ASPECTS MED, V33, P295, DOI 10.1016/j.mam.2012.04.005
   BISCHOFF PM, 1985, DOC OPHTHALMOL, V60, P235, DOI 10.1007/BF00157827
   Bloom SM, 2011, RETINA-J RET VIT DIS, V31, P316, DOI 10.1097/IAE.0b013e3181ed8c9a
   Borrelli E, 2018, AM J OPHTHALMOL, V196, P34, DOI 10.1016/j.ajo.2018.08.014
   Borrelli E, 2018, INVEST OPHTH VIS SCI, V59, DOI 10.1167/iovs.18-23943
   Borrelli E, 2018, RETINA-J RET VIT DIS, V38, P1968, DOI 10.1097/IAE.0000000000002198
   Borrelli E, 2017, INVEST OPHTH VIS SCI, V58, P4792, DOI 10.1167/iovs.17-22360
   Borrelli E, 2017, AM J OPHTHALMOL, V181, P1, DOI 10.1016/j.ajo.2017.06.005
   Carnevali A, 2016, AM J OPHTHALMOL, V169, P189, DOI 10.1016/j.ajo.2016.06.042
   Chatziralli I, 2018, OPHTHALMOL THER, V7, P101, DOI 10.1007/s40123-018-0119-9
   Choi W, 2015, OPHTHALMOLOGY, V122, P2532, DOI 10.1016/j.ophtha.2015.08.029
   Choi W, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0081499
   Cicinelli MV, 2017, BRIT J OPHTHALMOL, V101, P1193, DOI 10.1136/bjophthalmol-2016-309481
   Cole ED, 2017, OPHTHALMOL RETINA, V1, P435, DOI 10.1016/j.oret.2017.01.019
   Dias JRD, 2018, OPHTHALMOLOGY, V125, P255, DOI 10.1016/j.ophtha.2017.08.030
   Ding XY, 2011, INVEST OPHTH VIS SCI, V52, P9555, DOI 10.1167/iovs.11-8076
   Ferris FL, 2013, OPHTHALMOLOGY, V120, P844, DOI 10.1016/j.ophtha.2012.10.036
   Fleckenstein M, 2008, INVEST OPHTH VIS SCI, V49, P4137, DOI 10.1167/iovs.08-1967
   FLOWER RW, 1993, INVEST OPHTH VIS SCI, V34, P2720
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P564
   Grunwald JE, 1998, ARCH OPHTHALMOL-CHIC, V116, P150
   Grunwald JE, 1998, INVEST OPHTH VIS SCI, V39, P385
   Grunwald JE, 2005, INVEST OPHTH VIS SCI, V46, P1033, DOI 10.1167/iovs.04-1050
   Howell DC, 2010, STAT METHODS PSYCHOL
   Kvanta A, 2017, RETINA-J RET VIT DIS, V37, P936, DOI 10.1097/IAE.0000000000001248
   Lane M, 2016, INVEST OPHTH VIS SCI, V57, pOCT585, DOI 10.1167/iovs.15-18915
   Lauermann JL, 2018, OPHTHALMOLOGICA, V239, P74, DOI 10.1159/000485261
   Mancia G, 2013, EUR HEART J, V34, P2159, DOI 10.1093/eurheartj/eht151
   Margolis R, 2009, AM J OPHTHALMOL, V147, P811, DOI 10.1016/j.ajo.2008.12.008
   McLeod DS, 2009, INVEST OPHTH VIS SCI, V50, P4982, DOI 10.1167/iovs.09-3639
   McLeod DS, 2002, INVEST OPHTH VIS SCI, V43, P1986
   Metelitsina TI, 2008, INVEST OPHTH VIS SCI, V49, P358, DOI 10.1167/iovs.07-0526
   Miller Joan W, 2017, US Ophthalmic Rev, V10, P119, DOI 10.17925/USOR.2017.10.02.119
   Mullins RE, 2011, INVEST OPHTH VIS SCI, V52, P1606, DOI 10.1167/iovs.10-6476
   Nesper PL, 2017, AM J OPHTHALMOL, V174, P42, DOI 10.1016/j.ajo.2016.10.005
   Nicolo M, 2017, INVEST OPHTH VIS SCI, V58, P2002, DOI 10.1167/iovs.17-21417
   Pepple K, 2011, SEMIN OPHTHALMOL, V26, P198, DOI 10.3109/08820538.2011.570850
   Pocock SJ, 2002, STAT MED, V21, P2917, DOI 10.1002/sim.1296
   Querques G, 2014, OPHTHALMIC RES, V52, P107, DOI 10.1159/000363187
   Seddon JM, 2017, INVEST OPHTH VIS SCI, V58, P6513, DOI 10.1167/iovs.17-23544
   Spaide RF, 2008, AM J OPHTHALMOL, V146, P496, DOI 10.1016/j.ajo.2008.05.032
   Spaide RF, 2018, PROG RETIN EYE RES, V64, P1, DOI 10.1016/j.preteyeres.2017.11.003
   Spaide RF, 2017, RETINA-J RET VIT DIS, V37, P2008, DOI 10.1097/IAE.0000000000001497
   Spaide RF, 2016, AM J OPHTHALMOL, V170, P58, DOI 10.1016/j.ajo.2016.07.023
   Spaide RF, 2015, RETINA-J RET VIT DIS, V35, P2163, DOI 10.1097/IAE.0000000000000765
   Waheed NK, 2016, DEV OPHTHALMOL, V56, P91, DOI 10.1159/000442784
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
   Zarbin MA, 2010, RETINA-J RET VIT DIS, V30, P1350, DOI 10.1097/IAE.0b013e3181f57e30
   Zhang QQ, 2018, INVEST OPHTH VIS SCI, V59, P203, DOI 10.1167/iovs.17-22953
   Zhu L, 2006, J BIOMECH ENG-T ASME, V128, P203, DOI 10.1115/1.2165692
NR 53
TC 17
Z9 17
U1 0
U2 3
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1755-375X
EI 1755-3768
J9 ACTA OPHTHALMOL
JI Acta Ophthalmol.
PD SEP
PY 2019
VL 97
IS 6
BP E919
EP E926
DI 10.1111/aos.14088
PG 8
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA IP7VT
UT WOS:000480256800027
PM 30900822
OA Green Submitted, Bronze
DA 2022-11-30
ER

PT J
AU Querques, G
   Azrya, S
   Martinelli, D
   Berboucha, E
   Feldman, A
   Pece, A
   Coscas, G
   Soubrane, G
   Souied, EH
AF Querques, Giuseppe
   Azrya, Sophie
   Martinelli, Domenico
   Berboucha, Elya
   Feldman, Audrey
   Pece, Alfredo
   Coscas, Gabriel
   Soubrane, Gisele
   Souied, Eric H.
TI Ranibizumab for exudative age-related macular degeneration: 24-month
   outcomes from a single-centre institutional setting
SO BRITISH JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
AB Background To analyse the 24-month outcomes of intravitreal ranibizumab injections for choroidal neovascularisation (CNV) secondary to age-related macular degeneration (AMD).
   Methods The authors reviewed the charts of all consecutive eyes with CNV secondary to AMD, who underwent one intravitreal ranibizumab injection (followed by a pro re nata (1+PRN) decision to retreat or to not retreat) at least 24 months before. Best-corrected visual acuity (BCVA) changes and central macular thickness (CMT) were retrospectively assessed, from baseline (m0) to month 12 (m12), and 24 (m24).
   Results Ninety-six eyes of 79 patients (23 male, 56 female, aged 63-90 years) were included for analysis. The number of intravitreal injections administered ranged from 1 to 16. The mean BCVA significantly improved from m0 (0.78 +/- 0.33) to m12 (0.61 +/- 0.39, p<0.001), and m24 (0.65 +/- 0.38, p<0.001). The mean CMT significantly decreased from m0 (323.7 +/- 118.1) to m12 (254.6 +/- 92.3, p<0.001), and m24 (259.0 +/- 89.9, p<0.001). At m24, subretinal fluid, cystoid macular oedema and pigment epithelium detachment were present in fewer eyes (13, 31 and 31 eyes respectively), compared with m0 (33, 61 and 72 eyes, respectively). Overall, at m12 and m24, 91 eyes (94.8%) and 84 eyes (87.5%) lost fewer than 15 letters, and 25 (26%) eyes and 24 eyes (25%) improved by 15 letters or more, respectively; five eyes (5.2%) and 12 eyes (12.5%) lost more than 15 letters, at m12 and m24, respectively.
   Conclusion In this study, similarly to other studies of variable dosing regimen over 24 months, intravitreal ranibizumab was effective in significantly increasing BCVA and reducing CMT.
C1 [Querques, Giuseppe; Azrya, Sophie; Berboucha, Elya; Feldman, Audrey; Coscas, Gabriel; Soubrane, Gisele; Souied, Eric H.] Univ Paris 12, Dept Ophthalmol, Ctr Hosp Intercommunal Creteil, F-94000 Creteil, France.
   [Querques, Giuseppe; Pece, Alfredo] Retina 3000 Fdn ONLUS, Milan, Italy.
   [Martinelli, Domenico] Univ Bari, Dept Hyg, Policlin Bari, Bari, Italy.
C3 Universite Paris-Est-Creteil-Val-de-Marne (UPEC); CHI Creteil;
   Universita degli Studi di Bari Aldo Moro
RP Querques, G (通讯作者)，Univ Paris 12, Dept Ophthalmol, Ctr Hosp Intercommunal Creteil, 40 Ave Verdun, F-94000 Creteil, France.
EM giuseppe.querques@hotmail.it
OI Querques, Giuseppe/0000-0002-3292-9581; Martinelli,
   Domenico/0000-0001-8028-3167
FU Retina 3000 Foundation
FX This study was supported thorough a research fellowship by the Retina
   3000 Foundation.
CR Bressler Neil M, 2004, JAMA, V291, P1900, DOI 10.1001/jama.291.15.1900
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Chen Y, 1999, J MOL BIOL, V293, P865, DOI 10.1006/jmbi.1999.3192
   Cohen SY, 2009, AM J OPHTHALMOL, V148, P409, DOI 10.1016/j.ajo.2009.04.001
   Fung AE, 2007, AM J OPHTHALMOL, V143, P566, DOI 10.1016/j.ajo.2007.01.028
   Lalwani GA, 2009, AM J OPHTHALMOL, V148, P43, DOI 10.1016/j.ajo.2009.01.024
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Rothenbuehler SP, 2009, AM J OPHTHALMOL, V147, P831, DOI 10.1016/j.ajo.2008.12.005
NR 8
TC 63
Z9 64
U1 0
U2 3
PU B M J PUBLISHING GROUP
PI LONDON
PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND
SN 0007-1161
J9 BRIT J OPHTHALMOL
JI Br. J. Ophthalmol.
PD MAR
PY 2010
VL 94
IS 3
BP 292
EP 296
DI 10.1136/bjo.2009.170670
PG 5
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 566BZ
UT WOS:000275346200009
PM 19951942
DA 2022-11-30
ER

PT J
AU Sun, C
   Klein, R
   Wong, TY
AF Sun, Cong
   Klein, Ronald
   Wong, Tien Y.
TI Age-related Macular Degeneration and Risk of Coronary Heart Disease and
   Stroke: The Cardiovascular Health Study
SO OPHTHALMOLOGY
LA English
DT Article
ID C-REACTIVE PROTEIN; MYOCARDIAL-INFARCTION; VISUAL IMPAIRMENT;
   APOLIPOPROTEIN-E; OLDER PERSONS; UNITED-STATES; MACULOPATHY;
   PATHOGENESIS; ASSOCIATION; EYE
AB Purpose: To examine the associations of age-related macular degeneration (AMD) with incident coronary heart disease (CHD) and stroke in the Cardiovascular Health Study.
   Design: Population-based prospective cohort study.
   Participants: A total of 1786 white and African-American participants free of CHID or 2228 participants free of stroke, aged 69 to 97 years.
   Methods: AMD was evaluated from photographs taken in 1997 and 1998.
   Main Outcome Measures: Incident CHD and stroke ascertained using standardized methods.
   Results: Of the 1786 persons free of CHD, 303 developed incident CHD over 7 years. Participants with early AMD (n = 277) had a higher cumulative incidence of CHID than participants without early AMD (25.8% vs. 18.9%, P = 0.001). By adjusting for age, gender, race, systolic and diastolic blood pressure, hypertension status, fasting glucose, triglyceride, low-density lipoprotein cholesterol, cigarette smoking, pack years of smoking, and C-reactive protein, the presence of early AMD was associated with an increased risk of incident CHID (hazard ratio 1.57; 95% confidence interval, 1.17-2.22). Late AMD (n = 25) was not associated with incident CHD (hazard ratio 0.78; 95% confidence interval, 0.25-2.48). Among 2228 persons at risk, 198 developed incident stroke; neither early nor late AMD was associated with incident stroke.
   Conclusions: This study suggests persons with early AMD have a higher risk of CHD but not stroke in a population aged 69 to 97 years. This provides further support that AMD is associated with underlying systemic vascular disease.
   Financial Disclosure(s): The author(s) have no proprietary or commercial interest in any materials discussed in this article. Ophthalmology 2009;116:1913-1919 (C) 2009 by the American Academy of Ophthalmology.
C1 [Klein, Ronald] Univ Wisconsin, Sch Med & Publ Hlth, Dept Ophthalmol & Visual Sci, Madison, WI USA.
   [Sun, Cong; Wong, Tien Y.] Univ Melbourne, Dept Ophthalmol, Ctr Eye Res Australia, Melbourne, Vic 3010, Australia.
   [Wong, Tien Y.] Natl Univ Singapore, Yong Loo Lin Sch Med, Singapore Eye Res Inst, Singapore Natl Eye Ctr, Singapore 168751, Singapore.
C3 University of Wisconsin System; University of Wisconsin Madison; Centre
   for Eye Research Australia; University of Melbourne; National University
   of Singapore; Singapore National Eye Center
RP Wong, TY (通讯作者)，Natl Univ Singapore, Yong Loo Lin Sch Med, Singapore Eye Res Inst, Singapore Natl Eye Ctr, 11 3rd Hosp Ave, Singapore 168751, Singapore.
EM ophwty@nus.edu.sg
RI Wong, Tien Yin/AAC-9724-2020
OI Wong, Tien Yin/0000-0002-8448-1264; Klein, Ronald/0000-0002-4428-6237
FU National Heart, Lung, and Blood Institute [N01-HC-85079, N01-HC-85086,
   N01-HC-35129, N01 HC-15103, N01 HC-55222, N01-HC-75150, N01-HC-45133,
   U01 HL08029, R21-HL0771665]; DIVISION OF EPIDEMIOLOGY AND CLINICAL
   APPLICATIONS [N01HC015103, N01HC055222, N01HC085079, N01HC075150,
   N01HC045133, N01HC085086, N01HC035129] Funding Source: NIH RePORTER;
   NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R21HL077166, U01HL080295]
   Funding Source: NIH RePORTER
FX The research reported in this article was supported by the National
   Heart, Lung, and Blood Institute (contracts N01-HC-85079 to
   N01-HC-85086, N01-HC-35129, N01 HC-15103, N01 HC-55222, N01-HC-75150,
   N01-HC-45133, and U01 HL080295], with additional contribution from the
   National Institute of Neurological Disorders and Stroke. Additional
   support was provided by the National Heart, Lung, and Blood Institute,
   National Institute of Health (grant number R21-HL077166) and the Sylvia
   and Charles Viertel Clinical Investigator Award (TYW). A full list of
   principal CHS investigators and institutions can be found at
   http://www.chs-nhlbi.org/pi.htm. The sponsor or funding organization had
   no role in the design or conduct of this research.
CR Cao JJ, 2007, CIRCULATION, V116, P32, DOI 10.1161/CIRCULATIONAHA.106.645606
   Donoso LA, 2006, SURV OPHTHALMOL, V51, P137, DOI 10.1016/j.survophthal.2005.12.001
   Duan YK, 2007, OPHTHALMOLOGY, V114, P732, DOI 10.1016/j.ophtha.2006.07.045
   Edwards AO, 2005, SCIENCE, V308, P421, DOI 10.1126/science.1110189
   Fried Linda P., 1991, Annals of Epidemiology, V1, P263
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P564
   Friedman E, 2000, AM J OPHTHALMOL, V130, P658, DOI 10.1016/S0002-9394(00)00643-7
   Holz FG, 2004, AM J OPHTHALMOL, V137, P504, DOI 10.1016/j.ajo.2003.11.026
   Hyman L, 2000, ARCH OPHTHALMOL-CHIC, V118, P351, DOI 10.1001/archopht.118.3.351
   Ives Diane G., 1995, Annals of Epidemiology, V5, P278, DOI 10.1016/1047-2797(94)00093-9
   Kardys I, 2006, J AM COLL CARDIOL, V47, P1568, DOI 10.1016/j.jacc.2005.11.076
   Klaver CCW, 1998, AM J HUM GENET, V63, P200, DOI 10.1086/301901
   KLEIN R, 1992, OPHTHALMOLOGY, V99, P1686
   Klein R, 2003, OPHTHALMOLOGY, V110, P25, DOI 10.1016/S0161-6420(02)01565-8
   KLEIN R, 1991, OPHTHALMOLOGY, V98, P1128
   Klein R, 1999, OPHTHALMOLOGY, V106, P1056, DOI 10.1016/S0161-6420(99)90255-5
   Klein R, 2007, ARCH OPHTHALMOL-CHIC, V125, P534, DOI 10.1001/archopht.125.4.534
   Klein R, 2007, AM J OPHTHALMOL, V143, P473, DOI 10.1016/j.ajo.2006.11.058
   Knudtson MD, 2006, ARCH OPHTHALMOL-CHIC, V124, P243, DOI 10.1001/archopht.124.2.243
   Lindsberg PJ, 1996, ANN NEUROL, V40, P587, DOI 10.1002/ana.410400408
   McCarron MO, 1999, NEUROLOGY, V53, P1308, DOI 10.1212/WNL.53.6.1308
   McCarty CA, 2001, ARCH OPHTHALMOL-CHIC, V119, P1455
   Nguyen-Khoa BA, 2008, ARCH OPHTHALMOL-CHIC, V126, P1280, DOI 10.1001/archopht.126.9.1280
   Price T R, 1993, Ann Epidemiol, V3, P504
   Psaty Bruce M., 1995, Annals of Epidemiology, V5, P270, DOI 10.1016/1047-2797(94)00092-8
   ROBBINS J, 1995, J AM GERIATR SOC, V43, P855, DOI 10.1111/j.1532-5415.1995.tb05526.x
   Seddon JM, 2004, JAMA-J AM MED ASSOC, V291, P704, DOI 10.1001/jama.291.6.704
   Smith W, 1998, ARCH OPHTHALMOL-CHIC, V116, P583, DOI 10.1001/archopht.116.5.583
   Snow K K, 1999, Ophthalmic Epidemiol, V6, P125, DOI 10.1076/opep.6.2.125.1558
   Song YQ, 2004, ANN INTERN MED, V141, P137, DOI 10.7326/0003-4819-141-2-200407200-00013
   Sun C, 2007, OPHTHAL EPIDEMIOL, V14, P127, DOI 10.1080/09286580601186742
   Tan JSL, 2008, BRIT J OPHTHALMOL, V92, P509, DOI 10.1136/bjo.2007.131706
   Tell G S, 1993, Ann Epidemiol, V3, P358, DOI 10.1016/1047-2797(93)90062-9
   TELL GS, 1994, HYPERTENSION, V23, P59, DOI 10.1161/01.HYP.23.1.59
   Topol EJ, 2006, HUM MOL GENET, V15, pR117, DOI 10.1093/hmg/ddl183
   Wong T, 2008, OPHTHALMOLOGY, V115, P116, DOI 10.1016/j.ophtha.2007.03.008
   Wong T, 2007, LANCET, V369, P425, DOI 10.1016/S0140-6736(07)60198-6
   Wong TY, 2007, LANCET, V370, P204, DOI 10.1016/S0140-6736(07)61104-0
   Wong TY, 2007, OPHTHALMOLOGY, V114, P86, DOI 10.1016/j.ophtha.2006.06.039
   Wong TY, 2006, ARCH INTERN MED, V166, P2388, DOI 10.1001/archinte.166.21.2388
   Wong TY, 2006, ANN INTERN MED, V145, P98, DOI 10.7326/0003-4819-145-2-200607180-00007
   Wong TY, 2003, OPHTHALMOLOGY, V110, P658, DOI 10.1016/S0161-6420(02)01931-0
NR 42
TC 72
Z9 72
U1 0
U2 8
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0161-6420
EI 1549-4713
J9 OPHTHALMOLOGY
JI Ophthalmology
PD OCT
PY 2009
VL 116
IS 10
BP 1913
EP 1919
DI 10.1016/j.ophtha.2009.03.046
PG 7
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 506RX
UT WOS:000270794600013
PM 19592102
OA Green Accepted
DA 2022-11-30
ER

PT J
AU Rai, BB
   Essex, RW
   Sabeti, F
   Maddess, T
   Rohan, EMF
   van Kleef, JP
   Carle, CF
AF Rai, Bhim B.
   Essex, Rohan W.
   Sabeti, Faran
   Maddess, Ted
   Rohan, Emilie M. F.
   van Kleef, Joshua P.
   Carle, Corinne F.
TI An Objective Perimetry Study of Central Versus Peripheral Sensitivities
   and Delays in Age-Related Macular Degeneration
SO TRANSLATIONAL VISION SCIENCE & TECHNOLOGY
LA English
DT Article
DE AMD; anti-VEGF; multifocal objective perimetry; central macula;
   peripheral macula; retinal sensitivity; time to peak
ID ANTI-VEGF DRUGS; MULTIFOCAL PUPILLOGRAPHY; RANIBIZUMAB; DYNAMICS;
   THERAPY
AB Purpose: The purpose of this study was to compare central versus peripheral retinal sensitivities and delays in neovascular age-related macular degeneration (nAMD) using US Food and Drug Administration (FDA)-cleared multifocal pupillographic objective perimetry (mfPOP). Methods: We recruited 18 patients with nAMD and commenced Pro re nata intravitreal anti- vascular endothelial growth factor (VEGF) injection. We compared macular (+/- 15 degrees) and wide-field (+/- 30 degrees) mfPOP variants. We examined temporal correlations between treated and untreated fellow eyes. We fitted linear models to selected treatment patterns, and compared the ability of central versus peripheral responses to predict the need for treatment. Results: Central sensitivity decreased by -2.23 +/- 0.051 dB/month (P < 0.0002) in treated eyes, and -0.17 +/- 0.07 dB/month (P = 0.033) in untreated eyes. Treated eyes showed quicker central responses by 13.08 +/- 3.77 ms than untreated eyes (P = 0.001). Based on peripheral responses, we identified two eye-types. Among positiveeyes peripheral sensitivity increased by 9.88 +/- 4.41 dB (P = 0.042) before treatment; delays increased by 3.49 +/- 1.75 ms/month (P = 0.049). For negative-eyes peripheral delays were shorter a month before treatment by 9.38 +/- 3.59 ms (P = 0.013). Correlations between treatment and peripheral sensitivities or delays peaked at 1 to 2 months post-treatment. Peripheral data significantly determined treatment frequency and final acuity (all P < 0.044). Conclusions: Peripheral macular function of treated and untreated eyes divided eyes into positive and negative groups. Those peripheral responses determined outcomes; changes preceding active disease by 1 to 3 months. Overall, mfPOP may provide potential biomarkers to assist nAMD management. Translational Relevance: Objective perimetry may identify the requirement for treatment in nAMD that accords with the decision of a skilled clinician based on optical coherence tomography (OCT) and clinical findings.
C1 [Rai, Bhim B.; Sabeti, Faran; Maddess, Ted; Rohan, Emilie M. F.; van Kleef, Joshua P.; Carle, Corinne F.] Australian Natl Univ, John Curtin Sch Med Res, Canberra, ACT 2601, Australia.
   [Essex, Rohan W.] Australian Natl Univ, ANU Med Sch, Acad Unit, Canberra, ACT, Australia.
   [Essex, Rohan W.] ACT Hlth, Canberra Hosp, Dept Ophthalmol, Canberra, ACT, Australia.
   [Sabeti, Faran] Univ Canberra, Sch Optometry, Canberra, ACT, Australia.
C3 Australian National University; John Curtin School of Medical Research;
   Australian National University; Australian National University; Canberra
   Hospital; University of Canberra
RP Rai, BB (通讯作者)，Australian Natl Univ, John Curtin Sch Med Res, Canberra, ACT 2601, Australia.
EM bhim.rai@anu.edu.au
RI Maddess, Teddy L/A-3200-2008; Bahadur, Bhim/C-2972-2017
OI Maddess, Teddy L/0000-0003-4591-3658; Bahadur, Bhim/0000-0003-0748-4581;
   SABETI, Faran/0000-0001-9187-7569; van Kleef, Joshua/0000-0003-2167-0348
FU ANU PhD Scholarship; NHMRC Project [1063458]; ANU intramural Our Health
   in Our Hands (OHIOH) grant
FX Supported by the ANU PhD Scholarship awarded to author Bhim B. Rai, and
   a NHMRC Project Grant 1063458. The study was partly supported by the ANU
   intramural Our Health in Our Hands (OHIOH) grant. Maddess and Carle have
   patents to Konan Medical USA.
CR Anderson AJ, 2011, OPTOMETRY VISION SCI, V88, P806, DOI 10.1097/OPX.0b013e31821861bd
   Avery RL, 2017, RETINA-J RET VIT DIS, V37, P1847, DOI 10.1097/IAE.0000000000001493
   Bakbak Berker, 2016, Oman J Ophthalmol, V9, P44, DOI 10.4103/0974-620X.176100
   Bell A, 2010, INVEST OPHTH VIS SCI, V51, P602, DOI 10.1167/iovs.09-3659
   Bremner FD, 2012, INVEST OPHTH VIS SCI, V53, P7343, DOI 10.1167/iovs.12-10881
   Brown Gary C, 2005, Trans Am Ophthalmol Soc, V103, P173
   Carle CF, 2020, NORMATIVE MODE UNPUB
   Carle CF, 2014, CLIN EXP OPHTHALMOL, V42, P815, DOI 10.1111/ceo.12346
   Carle CF, 2011, INVEST OPHTH VIS SCI, V52, P2365, DOI 10.1167/iovs.10-6335
   Cheung GCM, 2017, ASIA-PAC J OPHTHALMO, V6, P527, DOI 10.22608/APO.2017260
   Christoforidis JB, 2011, CURR DRUG TARGETS, V12, P221
   CHYLACK LT, 1993, ARCH OPHTHALMOL-CHIC, V111, P831, DOI 10.1001/archopht.1993.01090060119035
   Costagliola C, 2012, EXPERT OPIN BIOL TH, V12, P1299, DOI 10.1517/14712598.2012.707176
   El-Sanhouri A, 2008, INVEST OPHTHALMOL VI, V49, P2133
   Fan Q, 2017, INT J EPIDEMIOL, V46, P1891, DOI 10.1093/ije/dyx189
   Gelfand BD, 2016, TRENDS MOL MED, V22, P656, DOI 10.1016/j.molmed.2016.06.009
   Jager RD, 2008, NEW ENGL J MED, V358, P2606, DOI 10.1056/NEJMra0801537
   James AC, 2003, INVEST OPHTH VIS SCI, V44, P879, DOI 10.1167/iovs.02-0608
   James AC, 2005, VISUAL NEUROSCI, V22, P45, DOI 10.1017/S0952523805221053
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1417, DOI 10.1001/archopht.119.10.1417
   Kawczyk-Krupka A, 2015, PHOTODIAGN PHOTODYN, V12, P161, DOI 10.1016/j.pdpdt.2015.03.007
   Khurana RN, 2020, OPHTHALMOL RETINA, V4, P1054, DOI 10.1016/j.oret.2020.04.016
   Klein R, 2007, OPHTHALMOLOGY, V114, P253, DOI 10.1016/j.ophtha.2006.10.040
   Larsen M, 2012, OPHTHALMOLOGY, V119, P992, DOI 10.1016/j.ophtha.2012.02.002
   Lipecz A, 2019, GEROSCIENCE, V41, P813, DOI 10.1007/s11357-019-00138-3
   Maddess T, 2021, WORLD GLAUCOMA C, V9
   Maddess T, 2021, INVEST OPHTH VIS SCI, V62
   Maddess T, 2013, INVEST OPHTH VIS SCI, V54
   Maddess T, 2017, CLIN EXP OPHTHALMOL, V45, P437, DOI 10.1111/ceo.12984
   Maddess T, 2012, INVEST OPHTH VIS SCI, V53, P7644, DOI 10.1167/iovs.12-11105
   Maddess T, 2009, CLIN EXP OPHTHALMOL, V37, P678, DOI 10.1111/j.1442-9071.2009.02107.x
   Michalska-Malecka K, 2016, CLIN INTERV AGING, V11, P357, DOI 10.2147/CIA.S93820
   Pennington KL, 2016, EYE VISION, V3, DOI 10.1186/s40662-016-0063-5
   Rai BB, 2021, INVEST OPHTH VIS SCI, V62
   Rai BB, 2020, GRAEF ARCH CLIN EXP, V258, P191, DOI 10.1007/s00417-019-04523-8
   Rosli Y, 2012, VISION RES, V69, P42, DOI 10.1016/j.visres.2012.07.019
   Ruseckaite R, 2005, ANN NEUROL, V57, P904, DOI 10.1002/ana.20504
   Sabeti F, 2021, T VIS SCI TECH, V10, P1
   Sabeti F, 2017, SCI REP-UK, V7, DOI 10.1038/srep45847
   Sabeti F, 2015, INVEST OPHTH VIS SCI, V56
   Sabeti F, 2015, INVEST OPHTH VIS SCI, V56, P4504, DOI 10.1167/iovs.15-16712
   Sabeti F, 2014, OPTOMETRY VISION SCI, V91, P904, DOI 10.1097/OPX.0000000000000319
   Sabeti F, 2013, GRAEF ARCH CLIN EXP, V251, P1707, DOI 10.1007/s00417-013-2273-z
   Sabeti F, 2012, INVEST OPHTH VIS SCI, V53, P253, DOI 10.1167/iovs.11-8004
   Sabeti F, 2011, OPTOMETRY VISION SCI, V88, P1477, DOI 10.1097/OPX.0b013e318235af61
   Seigel D, 2002, ARCH OPHTHALMOL-CHIC, V120, P100
   Semeraro F, 2015, CURR DRUG METAB, V16, P572, DOI 10.2174/1389200216666151001120831
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
   Yanagi Y, 2019, EYE, V33, P34, DOI 10.1038/s41433-018-0225-x
   Zehetner C, 2015, ACTA OPHTHALMOL, V93, pE154, DOI 10.1111/aos.12604
NR 50
TC 0
Z9 0
U1 1
U2 1
PU ASSOC RESEARCH VISION OPHTHALMOLOGY INC
PI ROCKVILLE
PA 12300 TWINBROOK PARKWAY, ROCKVILLE, MD 20852-1606 USA
SN 2164-2591
J9 TRANSL VIS SCI TECHN
JI Transl. Vis. Sci. Technol.
PD DEC
PY 2021
VL 10
IS 14
AR 24
DI 10.1167/tvst.10.14.24
PG 14
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA XU8UJ
UT WOS:000734532600001
PM 34932115
OA Green Published, gold
DA 2022-11-30
ER

PT J
AU Lee, SC
   Tran, S
   Amin, A
   Morse, LS
   Moshiri, A
   Park, SS
   Yiu, G
AF Lee, Sophie C.
   Tran, Steven
   Amin, Aana
   Morse, Lawrence S.
   Moshiri, Ala
   Park, Susanna S.
   Yiu, Glenn
TI Retinal Vessel Density in Exudative and Nonexudative Age-Related Macular
   Degeneration on Optical Coherence Tomography Angiography
SO AMERICAN JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
ID GROWTH-FACTOR THERAPY; CHOROIDAL THICKNESS; QUANTITATIVE-ANALYSIS;
   OXIDATIVE STRESS; VASCULAR DENSITY; HUMAN EYES; CHORIOCAPILLARIS;
   PERFUSION; REPRODUCIBILITY; SEGMENTATION
AB PURPOSE: Although the choroid contributes to the pathogenesis of age-related macular degeneration (AMD), the role of retinal perfusion is unclear. We sought to compare retinal vascular measurements between eyes with nonexudative and exudative AMD using optical coherence tomography angiography (OCT-A).
   DESIGN: Retrospective, cross-sectional study.
   METHODS: OCT-A images were analyzed from 310 eyes of 182 patients (mean age +/- standard deviation [SD], 78.8 +/- 8.8 years) with nonexudative (54.2%) and exudative (45.8%) AMD to measure retinal vessel density (VD) from the superficial capillary plexus in the foveal, parafoveal, and full macular regions and foveal avascular zone (FAZ) area, perimeter, and circularity. Multivariate regressions were used to compare nonexudative and exudative AMD eyes and the impact of antivascular endothelial growth factor (anti-VEGF) treatments or geographic atrophy (GA).
   RESULTS: In eyes with AMD, VD decreases with age in the foveal (beta = - 0.211, P < .001), parafoveal (beta = - 0.305, P < .001), and full macular regions (beta = - 0.295, P < .001). Eyes with exudative AMD demonstrated lower VD, especially in the parafoveal (29.8% +/- 6.3% vs 33.0% +/- 5.7%, P < .001) and full regions (27.9% +/- 6.2% vs 31.2% +/- 5.5%, P < .001) compared with nonexudative AMD. There were no differences in FAZ area, perimeter, or circularity between the 2 groups (P = .503-.907). In eyes with exudative AMD, previous anti-VEGF treatments did not impact retinal vascular measurements (P = .324-.986). Nonexudative AMD severity and presence of central GA also impacted retinal VD and FAZ morphology.
   CONCLUSIONS: Retinal VD is decreased in eyes with exudative AMD compared with nonexudative AMD but is unaffected by anti-VEGF treatments, suggesting a retinal vascular contribution to the pathogenesis of AMD. (C) 2019 Elsevier Inc. All rights reserved.
C1 [Lee, Sophie C.; Tran, Steven; Amin, Aana; Morse, Lawrence S.; Moshiri, Ala; Park, Susanna S.; Yiu, Glenn] Univ Calif Davis, Dept Ophthalmol & Vis Sci, Sacramento, CA 95817 USA.
   [Tran, Steven] Rosalind Franklin Univ Med & Sci, N Chicago, IL USA.
C3 University of California System; University of California Davis;
   Rosalind Franklin University Medical & Science
RP Yiu, G (通讯作者)，Univ Calif Davis, Davis Eye Ctr, Dept Ophthalmol & Vis Sci, 4860 & St,Ste 2400, Sacramento, CA 95817 USA.
EM gyiu@ucdavis.edu
OI Amin, Aana/0000-0002-8173-7252; Lee, Sophie Camille/0000-0002-0730-5910
FU National Eye Institute, United States [K08 EY026101, R21 EY031108]; E.
   Matilda Ziegler Foundation for the Blind, United States; Barr Foundation
   for Retinal Research, United States; Macula Society, United States
FX Publication of this article was supported by National Eye Institute,
   United States grants K08 EY026101 and R21 EY031108, the E. Matilda
   Ziegler Foundation for the Blind, United States, the Barr Foundation for
   Retinal Research, United States, and the Macula Society, United States
   (to Dr Yiu).
CR Al-Zamil WM, 2017, CLIN INTERV AGING, V12, P1313, DOI 10.2147/CIA.S143508
   Alten F, 2017, GRAEF ARCH CLIN EXP, V255, P2347, DOI 10.1007/s00417-017-3813-8
   Alten F, 2016, GRAEF ARCH CLIN EXP, V254, P2165, DOI 10.1007/s00417-016-3375-1
   Boker T, 1993, Ger J Ophthalmol, V2, P10
   Borrelli E, 2018, AM J OPHTHALMOL, V196, P34, DOI 10.1016/j.ajo.2018.08.014
   Borrelli E, 2018, RETINA-J RET VIT DIS, V38, P1968, DOI 10.1097/IAE.0000000000002198
   Durbin MK, 2017, JAMA OPHTHALMOL, V135, P370, DOI 10.1001/jamaophthalmol.2017.0080
   Ferrington DA, 2016, PROG RETIN EYE RES, V51, P69, DOI 10.1016/j.preteyeres.2015.09.002
   Friedman E, 1997, AM J OPHTHALMOL, V124, P677, DOI 10.1016/S0002-9394(14)70906-7
   Garrity ST, 2017, INVEST OPHTH VIS SCI, V58, P5548, DOI 10.1167/iovs.17-22036
   Handa JT, 2017, BBA-MOL CELL BIOL L, V1862, P430, DOI 10.1016/j.bbalip.2016.07.013
   Hikichi T, 2019, INVEST OPHTH VIS SCI, V60, P1088, DOI 10.1167/iovs.18-24522
   Ho J, 2019, RETINA-J RET VIT DIS, V39, P259, DOI 10.1097/IAE.0000000000001951
   Iafe NA, 2016, INVEST OPHTH VIS SCI, V57, P5780, DOI 10.1167/iovs.16-20045
   Jarrett SG, 2012, MOL ASPECTS MED, V33, P399, DOI 10.1016/j.mam.2012.03.009
   Lee B, 2018, INVEST OPHTH VIS SCI, V59, P5246, DOI 10.1167/iovs.17-23600
   Lee MW, 2019, BRIT J OPHTHALMOL, V103, P704, DOI 10.1136/bjophthalmol-2018-312516
   Lei JQ, 2017, JAMA OPHTHALMOL, V135, P1092, DOI 10.1001/jamaophthalmol.2017.3431
   Lutty G, 1999, MOL VIS, V5
   Moult EM, 2020, RETINA-J RET VIT DIS, V40, P428, DOI 10.1097/IAE.0000000000002556
   Mullins RE, 2011, INVEST OPHTH VIS SCI, V52, P1606, DOI 10.1167/iovs.10-6476
   Nassisi M, 2019, GRAEF ARCH CLIN EXP, V257, P2079, DOI 10.1007/s00417-019-04403-1
   Nassisi M, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0212563
   PAULEIKHOFF D, 1990, AM J OPHTHALMOL, V109, P211, DOI 10.1016/S0002-9394(14)75989-6
   Reiter GS, 2019, INVEST OPHTH VIS SCI, V60, P2503, DOI 10.1167/iovs.18-26237
   Sacconi R, 2018, RETINA-J RET VIT DIS, V38, P2350, DOI 10.1097/IAE.0000000000001873
   Sadda SR, 2018, OPHTHALMOLOGY, V125, P537, DOI 10.1016/j.ophtha.2017.09.028
   Shahlaee A, 2016, AM J OPHTHALMOL, V165, P39, DOI 10.1016/j.ajo.2016.02.018
   Shaw PX, 2016, AIMS MOL SCI, V3, P196, DOI 10.3934/molsci.2016.2.196
   Snyder K, 2019, JAMA OPHTHALMOL, V137, P856, DOI [10.1001/jamaophthalmol.2019.1384, 10.1001/jamaophthalmol.2019.1115]
   Snyder K, 2018, JAMA OPHTHALMOL, V136, P1008, DOI 10.1001/jamaophthalmol.2018.2650
   Spaide RF, 2017, JAMA OPHTHALMOL, V135, P259, DOI 10.1001/jamaophthalmol.2016.5327
   Stavrev V., 2018, OPEN J OPHTHALMOL, V8, P133, DOI [10.4236/ojoph.2018.83017, DOI 10.4236/OJOPH.2018.83017]
   Thulliez M, 2019, OPHTHALMOL RETINA, V3, P478, DOI 10.1016/j.oret.2019.01.024
   Todorich B, 2014, EXPERT REV CLIN PHAR, V7, P375, DOI 10.1586/17512433.2014.890047
   Toto L, 2016, RETINA-J RET VIT DIS, V36, P1566, DOI 10.1097/IAE.0000000000000962
   Treister AD, 2018, TRANSL VIS SCI TECHN, V7, DOI 10.1167/tvst.7.5.19
   Vujosevic S, 2019, ACTA OPHTHALMOL, V97, pE919, DOI 10.1111/aos.14088
   Wang Q, 2016, AM J OPHTHALMOL, V168, P95, DOI 10.1016/j.ajo.2016.05.005
   Wei YT, 2017, INVEST OPHTH VIS SCI, V58, P3804, DOI 10.1167/iovs.17-21460
   Wong SS, 2017, AM J OPHTHALMOL, V184, P108, DOI 10.1016/j.ajo.2017.10.005
   Yiu G, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-41509-2
   Yiu G, 2015, AM J OPHTHALMOL, V159, P617, DOI 10.1016/j.ajo.2014.12.010
   Yiu G, 2014, AM J OPHTHALMOL, V158, P745, DOI 10.1016/j.ajo.2014.06.006
   Yu J, 2015, INVEST OPHTH VIS SCI, V56, P3212, DOI 10.1167/iovs.14-16270
NR 45
TC 14
Z9 14
U1 0
U2 4
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 0002-9394
EI 1879-1891
J9 AM J OPHTHALMOL
JI Am. J. Ophthalmol.
PD APR
PY 2020
VL 212
BP 7
EP 16
DI 10.1016/j.ajo.2019.11.031
PG 10
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA LG1DC
UT WOS:000527849400002
PM 31837316
OA Green Accepted
DA 2022-11-30
ER

PT J
AU Sengul, EA
   Artunay, O
   Kumral, ET
   Yenerel, M
   Rasier, R
   Kockar, A
   Yuzbasioglu, E
AF Sengul, Elvan Alper
   Artunay, Ozgur
   Kumral, Esra Turkseven
   Yenerel, Melda
   Rasier, Rifat
   Kockar, Alev
   Yuzbasioglu, Erdal
TI Retinal Nerve Fiber Layer Thickness Changes in Age-Related Macular
   Degeneration Treated with Multiple Intravitreal Ranibizumab
SO JOURNAL OF OCULAR PHARMACOLOGY AND THERAPEUTICS
LA English
DT Article
DE age-related macular degeneration; intravitreal ranibizumab; retinal
   nerve fiber layer
ID ENDOTHELIAL GROWTH-FACTOR; INTRAOCULAR-PRESSURE; CHOROIDAL
   NEOVASCULARIZATION; VEGF; INJECTIONS; NEUROPROTECTION; BEVACIZUMAB;
   ISCHEMIA; MACULOPATHY; EXPRESSION
AB Purpose: The objective of this study was to investigate the effect of multiple intravitreal ranibizumab (IVR) injections on the retinal nerve fiber layer (RNFL) in neovascular age-related macular degeneration (nAMD). Methods: One hundred sixty-eight eyes of 168 patients with nAMD who received an IVR at least 3 times were included in this prospective interventional case series. The RNFL thickness data on 80 healthy eyes, used as the control group, were obtained. The patients were grouped as follows: 3-10 injections (group 1, 62 eyes, 37%), 10-20 injections (group 2, 62 eyes, 37%), and 20 injections (group 3, 44 eyes, 26%). The RNFL thickness was measured by spectral domain optical coherence tomography. Results: The mean baseline measurement of the RNFL thickness was 97.46.4m in the control group, 96.4 +/- 5.6m in group 1, 93.8 +/- 4.6m in group 2, and 93.2 +/- 5.3m in group 3. At the last follow-up, it was 95.1 +/- 2.4m in the control group, 93.4 +/- 7.3m in group 1, 90.5 +/- 3.6m in group 2, and 89.2 +/- 4.9m in group 3 (all P values >0.050). A statistically significant difference was not found between the mean total RNFL thickness of the eyes that received injections and that of the eyes in the healthy control group (P value >0.050). A statistically significant difference was not found in all the treatment groups between the intraocular pressure level taken 1 day after the administration of the injections and that recorded preintervention (all P values >0.050). Conclusion: Repeated IVR did not lead to a significant change in RNFL thickness in patients with nAMD.
C1 [Sengul, Elvan Alper; Rasier, Rifat; Kockar, Alev; Yuzbasioglu, Erdal] TC Istanbul Bilim Univ, Fac Med, Dept Ophthalmol, Istanbul, Turkey.
   [Artunay, Ozgur] Istanbul Med Hosp, Dept Ophthalmol, Istanbul, Turkey.
   [Kumral, Esra Turkseven; Yenerel, Melda] Haydarpasa Numune Training & Res Hosp, Dept Ophthalmol, Istanbul, Turkey.
C3 Demiroglu Bilim University; Medipol Hospital; Istanbul Haydarpasa Numune
   Training & Research Hospital; Istanbul Haydarpasa Sultan Abdulhamid
   Training & Research Hospital
RP Sengul, EA (通讯作者)，TC Istanbul Bilim Univ, Sisli Florence Nightingale Hastanesi, Goz Hastaliklari Klin, Istanbul, Turkey.
EM ealper_sengul@yahoo.com
RI Türkseven Kumral, Esra/GRO-3413-2022; Rasier, Rifat/AHB-8857-2022;
   Rasier, Rifat/AAK-4259-2021; Koçkar, Alev/GPX-8090-2022
OI Rasier, Rifat/0000-0003-0963-7991; Koçkar, Alev/0000-0002-1457-8511
CR Adelman RA, 2010, J OCUL PHARMACOL TH, V26, P105, DOI 10.1089/jop.2009.0076
   Arikan G, 2011, INT J OPHTHALMOL-CHI, V4, P402, DOI 10.3980/j.issn.2222-3959.2011.04.16
   Baek JH, 2000, ONCOGENE, V19, P4621, DOI 10.1038/sj.onc.1203814
   Bakri SJ, 2008, GRAEF ARCH CLIN EXP, V246, P955, DOI 10.1007/s00417-008-0819-2
   Boyer DS, 2007, OPHTHALMOLOGY, V114, P246, DOI 10.1016/j.ophtha.2006.10.045
   Bressler Neil M, 2004, JAMA, V291, P1900, DOI 10.1001/jama.291.15.1900
   Falkenstein IA, 2007, RETINA-J RET VIT DIS, V27, P1044, DOI 10.1097/IAE.0b013e3180592ba6
   Feng S, 2011, MED HYPOTHESES, V76, P618, DOI 10.1016/j.mehy.2010.12.001
   FERRARA N, 1992, ENDOCR REV, V13, P18, DOI 10.1210/er.13.1.18
   Foxton RH, 2013, AM J PATHOL, V182, P1379, DOI 10.1016/j.ajpath.2012.12.032
   Frenkel REP, 2007, AM J OPHTHALMOL, V143, P1034, DOI 10.1016/j.ajo.2007.01.052
   Gao GQ, 2001, FEBS LETT, V489, P270, DOI 10.1016/S0014-5793(01)02110-X
   Good TJ, 2011, BRIT J OPHTHALMOL, V95, P1111, DOI 10.1136/bjo.2010.180729
   Gora-Kupilas K, 2005, FOLIA NEUROPATHOL, V43, P31
   Heier JS, 2012, OPHTHALMOLOGY, V119, P2537, DOI 10.1016/j.ophtha.2012.09.006
   Homer N, 2015, EYE, V29, P1152, DOI 10.1038/eye.2015.87
   Horsley MB, 2010, AM J OPHTHALMOL, V150, P558, DOI 10.1016/j.ajo.2010.04.029
   Hughes S., 2004, INVEST OPHTH VIS SCI, V41, P1217
   Ishibashi T, 1997, GRAEF ARCH CLIN EXP, V235, P159, DOI 10.1007/BF00941723
   Jin KL, 2000, P NATL ACAD SCI USA, V97, P10242, DOI 10.1073/pnas.97.18.10242
   Klaver CCW, 2001, INVEST OPHTH VIS SCI, V42, P2237
   Kwak N, 2000, INVEST OPHTH VIS SCI, V41, P3158
   Lushchyk T, 2013, ACTA OPHTHALMOL, V91, pe456, DOI 10.1111/aos.12119
   Martinez-de-la-Casa JM, 2012, INVEST OPHTH VIS SCI, V53, P6214, DOI 10.1167/iovs.12-9875
   MITCHELL P, 1995, OPHTHALMOLOGY, V102, P1450
   Nishijima K, 2007, AM J PATHOL, V171, P53, DOI 10.2353/ajpath.2007.061237
   Patel NB, 2014, INVEST OPHTH VIS SCI, V55, P5134, DOI 10.1167/iovs.14-14303
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Sharei V, 2010, EUR J OPHTHALMOL, V20, P174, DOI 10.1177/112067211002000124
   Sobaci G, 2013, INT J OPHTHALMOL-CHI, V6, P211, DOI 10.3980/j.issn.2222-3959.2013.02.20
   Storkebaum E, 2004, BIOESSAYS, V26, P943, DOI 10.1002/bies.20092
   Sun YJ, 2003, J CLIN INVEST, V111, P1843, DOI 10.1172/JCI200317977
   Wu L, 2008, GRAEF ARCH CLIN EXP, V246, P81, DOI 10.1007/s00417-007-0660-z
NR 33
TC 9
Z9 10
U1 1
U2 1
PU MARY ANN LIEBERT, INC
PI NEW ROCHELLE
PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA
SN 1080-7683
EI 1557-7732
J9 J OCUL PHARMACOL TH
JI J. Ocular Pharmacol. Ther.
PD DEC
PY 2016
VL 32
IS 10
BP 665
EP 670
DI 10.1089/jop.2016.0014
PG 6
WC Ophthalmology; Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology; Pharmacology & Pharmacy
GA EF5ZG
UT WOS:000390408000006
PM 27860530
DA 2022-11-30
ER

PT J
AU Rosengarth, K
   Keck, I
   Brandl-Ruhle, S
   Frolo, J
   Hufendiek, K
   Greenlee, MW
   Plank, T
AF Rosengarth, Katharina
   Keck, Ingo
   Brandl-Ruehle, Sabine
   Frolo, Jozef
   Hufendiek, Karsten
   Greenlee, Mark W.
   Plank, Tina
TI Functional and structural brain modifications induced by oculomotor
   training in patients with age-related macular degeneration
SO FRONTIERS IN PSYCHOLOGY
LA English
DT Article
DE age-related macular degeneration; fMRI BOLD; voxel-based morphometry;
   cortical plasticity; aging
ID SURFACE-BASED ANALYSIS; HUMAN CEREBRAL-CORTEX; GEOMETRICALLY ACCURATE;
   IMAGE REGISTRATION; RETINAL LOCUS; READING SPEED; NEURAL BASIS;
   FIXATION; SCOTOMA; REHABILITATION
AB Patients with age-related macular degeneration (AMD) are reliant on their peripheral visual field. Oculomotor training can help them to find the best area on intact peripheral retina and to efficiently stabilize eccentric fixation. In this study, nine patients with AMD were trained over a period of 6 months using oculomotor training protocols to improve fixation stability. They were followed over an additional period of 6 months, where they completed an auditory memory training as a sham training. In this cross-over design five patients started with the sham training and four with the oculomotor training. Seven healthy age-matched subjects, who did not take part in any training procedure, served as controls. During the 6 months of training the AMD subjects and the control group took part in three functional and structural magnetic resonance imaging (MRI) sessions to assess training-related changes in the brain function and structure. The sham-training phase was accompanied by two more fMRI measurements, resulting in five MRI sessions at intervals of 3 months for all participants. Despite substantial variability in the training effects, on average, AMD patients benefited from the training measurements as indexed by significant improvements in their fixation stability, visual acuity, and reading speed. The patients showed a significant positive correlation between brain activation changes and improvements in fixation stability in the visual cortex during training. These correlations were less pronounced on the long-term after training had ceased. We also found a significant increase in gray and white matter in the posterior cerebellum after training in the patient group. Our results show that functional and structural brain changes can be associated, at least on the short-term, with benefits of oculomotor and/or reading training in patients with central scotomata resulting from AMD.
C1 [Rosengarth, Katharina; Keck, Ingo; Frolo, Jozef; Greenlee, Mark W.; Plank, Tina] Univ Regensburg, Inst Expt Psychol, D-93053 Regensburg, Germany.
   [Brandl-Ruehle, Sabine; Hufendiek, Karsten] Univ Med Ctr Regensburg, Dept Ophthalmol, Regensburg, Germany.
C3 University of Regensburg; University of Regensburg
RP Greenlee, MW (通讯作者)，Univ Regensburg, Inst Expt Psychol, Univ Str 31, D-93053 Regensburg, Germany.
EM mark.greenlee@psychologie.uni-regensburg.de
RI Greenlee, Mark/M-6414-2018
OI Greenlee, Mark/0000-0003-2305-9286; Keck, Ingo R./0000-0002-9878-1698;
   Plank, Tina/0000-0001-5329-7037
CR Ahissar M, 1997, NATURE, V387, P401, DOI 10.1038/387401a0
   Ashburner J, 2007, NEUROIMAGE, V38, P95, DOI 10.1016/j.neuroimage.2007.07.007
   Backman O., 1979, LOW VISION TRAINING
   Beer AL, 2011, EXP BRAIN RES, V213, P299, DOI 10.1007/s00221-011-2715-y
   Beer AL, 2009, EUR J NEUROSCI, V30, P703, DOI 10.1111/j.1460-9568.2009.06857.x
   Bernard S., 2000, THESIS ERLANGEN NURN
   Boucard CC, 2009, BRAIN, V132, P1898, DOI 10.1093/brain/awp119
   Coco-Martin MB, 2013, OPHTHALMOLOGY, V120, P151, DOI 10.1016/j.ophtha.2012.07.035
   Cox RW, 1999, MAGNET RESON MED, V42, P1014, DOI 10.1002/(SICI)1522-2594(199912)42:6<1014::AID-MRM4>3.0.CO;2-F
   Crossland MD, 2004, OPHTHAL PHYSL OPT, V24, P327, DOI 10.1111/j.1475-1313.2004.00213.x
   Dale AM, 1999, NEUROIMAGE, V9, P179, DOI 10.1006/nimg.1998.0395
   Desikan RS, 2006, NEUROIMAGE, V31, P968, DOI 10.1016/j.neuroimage.2006.01.021
   DeYoe EA, 1996, P NATL ACAD SCI USA, V93, P2382, DOI 10.1073/pnas.93.6.2382
   Fahle M., 2002, PERCEPTUAL LEARNING
   Fischl B, 1999, HUM BRAIN MAPP, V8, P272, DOI 10.1002/(SICI)1097-0193(1999)8:4<272::AID-HBM10>3.0.CO;2-4
   Fischl B, 2004, CEREB CORTEX, V14, P11, DOI 10.1093/cercor/bhg087
   Fischl B, 2001, IEEE T MED IMAGING, V20, P70, DOI 10.1109/42.906426
   Fischl B, 1999, NEUROIMAGE, V9, P195, DOI 10.1006/nimg.1998.0396
   Fischl B, 2002, NEURON, V33, P341, DOI 10.1016/S0896-6273(02)00569-X
   Fischl B, 2000, P NATL ACAD SCI USA, V97, P11050, DOI 10.1073/pnas.200033797
   Fletcher DC, 1997, OPHTHALMOLOGY, V104, P632, DOI 10.1016/S0161-6420(97)30260-7
   Fulbright RK, 1999, AM J NEURORADIOL, V20, P1925
   Gilbert CD, 2001, NEURON, V31, P681, DOI 10.1016/S0896-6273(01)00424-X
   Grill-Spector K, 2003, CURR OPIN NEUROBIOL, V13, P159, DOI 10.1016/S0959-4388(03)00040-0
   Grill-Spector K, 1999, NEURON, V24, P187, DOI 10.1016/S0896-6273(00)80832-6
   GUEZ JE, 1993, VISION RES, V33, P1271, DOI 10.1016/0042-6989(93)90213-G
   Gustafsson J., 2004, TECHNOL DISABIL, V6, P211
   Habas C, 2009, J NEUROSCI, V29, P8586, DOI 10.1523/JNEUROSCI.1868-09.2009
   Hernowo A. T., 2013, CORTEX, DOI [10.1016/j.cortex.2013.01.003, DOI 10.1016/J.C0RTEX.2013.01.003.[]
   Ishiko S, 2010, CURR EYE RES, V35, P651, DOI 10.3109/02713681003707235
   Jack CR, 2008, J MAGN RESON IMAGING, V27, P685, DOI 10.1002/jmri.21049
   KARNI A, 1991, P NATL ACAD SCI USA, V88, P4966, DOI 10.1073/pnas.88.11.4966
   Kasten E, 2010, J VISUAL IMPAIR BLIN, V104, P303, DOI 10.1177/0145482X1010400506
   Little DM, 2008, INVEST OPHTH VIS SCI, V49, P1728, DOI 10.1167/iovs.07-0372
   Liu MM, 2012, HUM GENOMICS, V6, DOI 10.1186/1479-7364-6-13
   Liu TT, 2010, INVEST OPHTH VIS SCI, V51, P6826, DOI 10.1167/iovs.09-4926
   Mangione CM, 2001, ARCH OPHTHALMOL-CHIC, V119, P1050, DOI 10.1001/archopht.119.7.1050
   Masuda Y, 2008, CEREB CORTEX, V18, P2483, DOI 10.1093/cercor/bhm256
   Mitchell J., 2006, HEALTH QUAL LIFE OUT, V21, P4
   Nagy K, 2012, FRONT PSYCHOL, V3, DOI 10.3389/fpsyg.2012.00141
   Nguyen NX, 2011, ACTA OPHTHALMOL, V89, pE82, DOI 10.1111/j.1755-3768.2010.02081.x
   Nilsson UL, 1998, OPTOMETRY VISION SCI, V75, P873, DOI 10.1097/00006324-199812000-00009
   Nilsson UL, 2003, VISION RES, V43, P1777, DOI 10.1016/S0042-6989(03)00219-0
   NILSSON UL, 1986, DOC OPHTHALMOL, V62, P345, DOI 10.1007/BF00168266
   Plank T, 2013, HUM BRAIN MAPP, V34, P2607, DOI 10.1002/hbm.22088
   Plank T, 2011, NEUROIMAGE, V56, P1556, DOI 10.1016/j.neuroimage.2011.02.055
   Polat U, 2009, EXPERT REV OPHTHALMO, V4, P573, DOI 10.1586/EOP.09.54
   Rorden C, 2000, BEHAV NEUROL, V12, P191, DOI 10.1155/2000/421719
   Rovner BW, 2009, ALZHEIMERS DEMENT, V5, P12, DOI 10.1016/j.jalz.2008.06.001
   Rubin GS, 2009, NEURO-OPHTHALMOLOGY, V33, P120, DOI 10.1080/01658100902998732
   SCHOUPS AA, 1995, J PHYSIOL-LONDON, V483, P797, DOI 10.1113/jphysiol.1995.sp020623
   Segonne F, 2004, NEUROIMAGE, V22, P1060, DOI 10.1016/j.neuroimage.2004.03.032
   Segonne F, 2007, IEEE T MED IMAGING, V26, P518, DOI 10.1109/TMI.2006.887364
   Seiple W, 2005, INVEST OPHTH VIS SCI, V46, P2886, DOI 10.1167/iovs.04-1296
   Sled JG, 1998, IEEE T MED IMAGING, V17, P87, DOI 10.1109/42.668698
   Sunness JS, 1996, OPHTHALMOLOGY, V103, P1458, DOI 10.1016/S0161-6420(96)30483-1
   Szlyk JP, 2009, INVEST OPHTH VIS SCI, V50, P4487, DOI 10.1167/iovs.08-2258
   TIMBERLAKE GT, 1987, INVEST OPHTH VIS SCI, V28, P1268
   TrauzettelKlosinski S, 1996, NEURO-OPHTHALMOLOGY, V16, P241, DOI 10.3109/01658109609044632
   Watanabe T, 2001, NATURE, V413, P844, DOI 10.1038/35101601
   WHITTAKER SG, 1988, INVEST OPHTH VIS SCI, V29, P268
   Yotsumoto Y, 2008, NEURON, V57, P827, DOI 10.1016/j.neuron.2008.02.034
NR 62
TC 23
Z9 23
U1 0
U2 12
PU FRONTIERS MEDIA SA
PI LAUSANNE
PA AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND
SN 1664-1078
J9 FRONT PSYCHOL
JI Front. Psychol.
PD JUL 17
PY 2013
VL 4
AR 428
DI 10.3389/fpsyg.2013.00428
PG 21
WC Psychology, Multidisciplinary
WE Social Science Citation Index (SSCI)
SC Psychology
GA AA4YX
UT WOS:000331103700001
PM 23882237
OA Green Published, gold
DA 2022-11-30
ER

PT J
AU Flower, RW
AF Flower, RW
TI Optimizing treatment of choroidal neovascularization feeder vessels
   associated with age-related macular degeneration
SO AMERICAN JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
ID CHORIOCAPILLARIS BLOOD-FLOW; INDOCYANINE GREEN; PHOTODYNAMIC THERAPY;
   FLUORESCENCE
AB PURPOSE: To optimize the method of treating choroidal neovascularization (CNV) associated with age,related macular degeneration (AMD).
   DESIGN: Experimental study and interventional case series.
   METHODS: The parameters associated with locating and then photocoagulating CNV feeder vessels were identified and optimized using published data and data derived from modeling the choroidal vasculature. Based on these optimized parameters, a prototype diagnostic/treatment system was designed that captures high-speed indocyanine green (ICG) angiogram images and facilitates analysis of the images by enhancing visualization of dye movement through CNV feeder vessels (FVs). The system also permits precise aiming and delivery of 810-nm wavelength photocoagulation laser energy to target FVs on a real-time ICG angiogram image of the choroidal vasculature. Target FVs are tracked by a joy stick cone trolled laser aiming beam until an intravenously-injected high, concentration ICG dye bolus is observed to enter the target vessel, at which time the laser is fired. Proof of principle of the combined diagnosis/treatment system design for performing dye-enhanced photocoagulation (DEP) in the clinical setting and determination of the minimum DEP laser energy needed to close CNV FVs was made in 11 AMD patients requiring treatment of CNV, but for whom other treatment was not appropriate.
   RESULTS: Using ICG-DEP, CNV feeder vessels were closed with single pulse laser energy, delivering as little as 0.6 to 1.8 J of energy to the fundus, producing no visible change in the fundus. Successful FV closure was usually indicated immediately by presence of incarcerated ICG dye in the vessel adjacent to the burn site. The prototype system proved relatively easy to operate. After acquiring and interpreting diagnostic angiograms and repositioning a patient in front of the device, feeder vessel DEP and treatment evaluation required 15 to 20 minutes.
   CONCLUSIONS: Indocyanine green dye-enhanced photocoagulation of CNV feeder vessels, facilitated by use of a device that permits real-time visualization of the choroidal circulation while aiming the treatment laser beam, appears to minimize the amount of energy applied to the fundus and the volume of fundus tissue affected by treatment, compared with other treatment modalities. The combination diagnosis/treatment device should be useful in optimizing FV treatment and in refining and evaluating the efficacy of DEP in future clinical trials. (C) 2002 by Elsevier Science Inc. All rights reserved.
C1 Univ Maryland, Sch Med, Dept Ophthalmol, Baltimore, MD 21201 USA.
   NYU, Sch Med, Dept Ophthalmol, New York, NY USA.
   Manhattan Eye Ear & Throat Hosp, LuEsther T Mertz Retinal Res Lab, New York, NY 10021 USA.
   Manhattan Eye Ear & Throat Hosp, Macula Fdn, New York, NY 10021 USA.
C3 University System of Maryland; University of Maryland Baltimore; New
   York University; Manhattan Eye Ear & Throat Hospital; Manhattan Eye Ear
   & Throat Hospital
RP Flower, RW (通讯作者)，11 Dellwood Court, Hunt Valley, MD 21030 USA.
EM rflow001@umaryland.edu
CR BEHRENDT T, 1972, ARCH OPHTHALMOL-CHIC, V87, P629, DOI 10.1001/archopht.1972.01000020631003
   BENGTSSON B, 1977, ACTA OPHTHALMOL, V55, P123
   Costa RA, 2001, CURR EYE RES, V23, P271, DOI 10.1076/ceyr.23.4.271.5449
   Costa RA, 2001, AM J OPHTHALMOL, V132, P557, DOI 10.1016/S0002-9394(01)01138-2
   FLOWER RW, 1993, INVEST OPHTH VIS SCI, V34, P2720
   FLOWER RW, 1995, INVEST OPHTH VIS SCI, V36, P1247
   Flower RW, 2001, AM J OPHTHALMOL, V132, P85, DOI 10.1016/S0002-9394(01)00872-8
   FLOWER RW, 1976, JOHNS HOPKINS MED J, V138, P33
   Flower RW, 2000, AM J OPHTHALMOL, V129, P501, DOI 10.1016/S0002-9394(99)00411-0
   KOYAMA T, 1981, ACTA SOC OPHTHALMOL, V85, P1
   MAINSTER MA, 1970, J OPT SOC AM, V60, P848, DOI 10.1364/JOSA.60.000848
   Peyman GA, 2000, OPHTHALMOLOGY, V107, P29, DOI 10.1016/S0161-6420(99)00012-3
   Reindl S, 1997, J PHOTOCH PHOTOBIO A, V105, P65, DOI 10.1016/S1010-6030(96)04584-4
   Shiraga F, 1998, OPHTHALMOLOGY, V105, P662, DOI 10.1016/S0161-6420(98)94021-0
   Staurenghi G, 1998, OPHTHALMOLOGY, V105, P2297, DOI 10.1016/S0161-6420(98)91232-5
   Vogel A, 1992, TEMPERATURE PROFILES, V5, P9
   Wertheimer M, 1912, Z PSYCHOL PHYSIOL SI, V61, P161
NR 17
TC 25
Z9 38
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 0002-9394
EI 1879-1891
J9 AM J OPHTHALMOL
JI Am. J. Ophthalmol.
PD AUG
PY 2002
VL 134
IS 2
BP 228
EP 239
AR PII S0002-9394(02)01579-9
DI 10.1016/S0002-9394(02)01579-9
PG 12
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 579GB
UT WOS:000177169300011
PM 12140030
DA 2022-11-30
ER

PT J
AU de Breuk, A
   Acar, IE
   Kersten, E
   Schijvenaars, MMVAP
   Colijn, JM
   Haer-Wigman, L
   Bakker, B
   de Jong, S
   Meester-Smoor, MA
   Verzijden, T
   Missotten, TOAR
   Mones, J
   Biarnes, M
   Pauleikhoff, D
   Hense, HW
   Silva, R
   Nunes, S
   Melo, JB
   Fauser, S
   Hoyng, CB
   Ueffing, M
   Coenen, MJH
   Klaver, CCW
   den Hollander, AI
AF de Breuk, Anita
   Acar, Ilhan E.
   Kersten, Eveline
   Schijvenaars, Mascha M. V. A. P.
   Colijn, Johanna M.
   Haer-Wigman, Lonneke
   Bakker, Bjorn
   de Jong, Sarah
   Meester-Smoor, Magda A.
   Verzijden, Timo
   Missotten, Tom O. A. R.
   Mones, Jordi
   Biarnes, Marc
   Pauleikhoff, Daniel
   Hense, Hans W.
   Silva, Rufino
   Nunes, Sandrina
   Melo, Joana B.
   Fauser, Sascha
   Hoyng, Carel B.
   Ueffing, Marius
   Coenen, Marieke J. H.
   Klaver, Caroline C. W.
   den Hollander, Anneke, I
CA EYE-RISK Consortium
TI Development of a Genotype Assay for Age-Related Macular Degeneration The
   EYE-RISK Consortium
SO OPHTHALMOLOGY
LA English
DT Article
DE Age-related macular degeneration; Genetics; Genetic counseling; Genetic
   testing
ID RARE GENETIC-VARIANTS; STARGARDT-DISEASE; CFI GENE; MUTATIONS;
   DYSTROPHY; ABCR; ASSOCIATION; PREVALENCE; FAMILIES; DRUSEN
AB Purpose: To develop a genotype assay to assess associations with common and rare age-related macular degeneration (AMD) risk variants, to calculate an overall genetic risk score (GRS), and to identify potential misdiagnoses with inherited macular dystrophies that mimic AMD.
   Design: Case-control study.
   Participants: Individuals (n = 4740) from 5 European cohorts.
   Methods: We designed single-molecule molecular inversion probes for target selection and used next generation sequencing to sequence 87 single nucleotide polymorphisms (SNPs), coding and splice-site regions of 10 AMD-(related) genes (ARMS2, C3, C9, CD46, CFB, CFH, CFI, HTRA1, TIMP3, and SLC16A8), and 3 genes that cause inherited macular dystrophies (ABCA4, CTNNA1, and PRPH2). Genetic risk scores for common AMD risk variants were calculated based on effect size and genotype of 52 AMD-associated variants. Frequency of rare variants was compared between late AMD patients and control individuals with logistic regression analysis.
   Main Outcome Measures: Genetic risk score, association of genetic variants with AMD, and genotype-phenotype correlations.
   Results: We observed high concordance rates between our platform and other genotyping platforms for the 69 successfully genotyped SNPs (>96%) and for the rare variants (>99%). We observed a higher GRS for patients with late AMD compared with patients with early/intermediate AMD (P < 0.001) and individuals without AMD (P < 0.001). A higher proportion of pathogenic variants in the CFH (odds ratio [OR] = 2.88; P = 0.006), CFI (OR = 4.45; P = 0.005), and C3 (OR = 6.56; P = 0.0003) genes was observed in late AMD patients compared with control individuals. In 9 patients, we identified pathogenic variants in the PRPH2, ABCA4, and CTNNA1 genes, which allowed reclassification of these patients as having inherited macular dystrophy.
   Conclusions: This study reports a genotype assay for common and rare AMD genetic variants, which can identify individuals at intermediate to high genetic risk of late AMD and enables differential diagnosis of AMD-mimicking dystrophies. Our study supports sequencing of CFH, CFI, and C3 genes because they harbor rare high-risk variants. Carriers of these variants could be amendable for new treatments for AMD that currently are under development. (C) 2020 by the American Academy of Ophthalmology.
C1 [de Breuk, Anita; Acar, Ilhan E.; Kersten, Eveline; Bakker, Bjorn; de Jong, Sarah; Hoyng, Carel B.; Klaver, Caroline C. W.; den Hollander, Anneke, I] Radboud Univ Nijmegen, Donders Inst Brain Cognit & Behav, Dept Ophthalmol, Med Ctr, Nijmegen, Netherlands.
   [Schijvenaars, Mascha M. V. A. P.; Coenen, Marieke J. H.] Radboud Univ Nijmegen, Radboud Inst Hlth Sci, Dept Human Genet, Med Ctr, Nijmegen, Netherlands.
   [Colijn, Johanna M.; Meester-Smoor, Magda A.; Verzijden, Timo; Klaver, Caroline C. W.] Erasmus MC, Dept Ophthalmol, Rotterdam, Netherlands.
   [Colijn, Johanna M.; Meester-Smoor, Magda A.; Verzijden, Timo; Klaver, Caroline C. W.] Erasmus MC, Dept Epidemiol, Rotterdam, Netherlands.
   [Haer-Wigman, Lonneke] Radboud Univ Nijmegen, Donders Ctr Neurosci, Dept Human Genet, Med Ctr, Nijmegen, Netherlands.
   [Missotten, Tom O. A. R.] Rotterdam Eye Hosp, Rotterdam, Netherlands.
   [Mones, Jordi; Biarnes, Marc] Barcelona Macula Fdn, Barcelona, Spain.
   [Mones, Jordi; Biarnes, Marc] Inst Macula, 8, Barcelona, Spain.
   [Pauleikhoff, Daniel] St Franziskus Hosp, Dept Ophthalmol, Munster, Germany.
   [Hense, Hans W.] Westfalische Withelms Univ, Inst Epidemiol & Social Med, Munster, Germany.
   [Silva, Rufino] Ctr Hosp & Univ Coimbra CHUC, Dept Ophthalmol, Coimbra, Portugal.
   [Silva, Rufino] Univ Coimbra iCBR FMUC, Fac Med, Coimbra Inst Clin & Biomed Res, Coimbra, Portugal.
   [Silva, Rufino; Nunes, Sandrina] Assoc Innovat & Biomed Res Light & Image AIBILI, Coimbra, Portugal.
   [Melo, Joana B.] Univ Coimbra, Fac Med, Cytogenet & Genom Lab, Coimbra, Portugal.
   [Melo, Joana B.] Univ Coimbra, Fac Med, Ctr Invest Environm Genet & Oncobiol, iCBR CIMAGO, Coimbra, Portugal.
   [Fauser, Sascha] Univ Hosp Cologne, Dept Ophthalmol, Cologne, Germany.
   [Ueffing, Marius] Univ Tubingen, Ctr Ophthalmol, Inst Ophthalm Res, Tubingen, Germany.
   [Klaver, Caroline C. W.] Inst Mol & Clin Ophthalmol, Basel, Switzerland.
C3 Radboud University Nijmegen; Radboud University Nijmegen; Erasmus
   University Rotterdam; Erasmus MC; Erasmus University Rotterdam; Erasmus
   MC; Radboud University Nijmegen; Rotterdam Eye Hospital; St.
   Franziskus-Hospital; Universidade de Coimbra; Centro Hospitalar e
   Universitario de Coimbra (CHUC); Universidade de Coimbra; Universidade
   de Coimbra; Universidade de Coimbra; Universidade de Coimbra; University
   of Cologne; Eberhard Karls University of Tubingen; Eberhard Karls
   University Hospital
RP den Hollander, AI (通讯作者)，Radboud Univ Nijmegen, Dept Ophthalmol 409, Med Ctr, Philips van Leydenlaan 15, NL-6525 EX Nijmegen, Netherlands.
EM Anneke.denHollander@radboudumc.nl
RI Melo, Joana B/AAY-8984-2020; Melo, Joana B/K-8347-2014; Bakker,
   Bjorn/E-2842-2016; Kersten, Eveline/P-8173-2015; mones,
   jordi/CAJ-2963-2022; Acar, İlhan Erkin/B-7758-2018; Coenen,
   Marieke/A-2159-2010
OI Melo, Joana B/0000-0001-5049-2670; Melo, Joana B/0000-0001-5049-2670;
   mones, jordi/0000-0003-3685-2160; Acar, İlhan Erkin/0000-0002-2078-9905;
   Coenen, Marieke/0000-0001-8796-2031; de Breuk,
   Anita/0000-0001-7072-1928; de Jong, Sarah/0000-0002-3705-3371; Silva,
   Rufino/0000-0001-8676-0833
FU Dutch Organization for Scientific Research [016.Vici.170.024]; European
   Union [634479]; F. HoffmannLa Roche, Ltd., Basel, Switzerland
FX Supported by the Dutch Organization for Scientific Research (grant no.:
   016.Vici.170.024 [A.I.d.H.]); the European Union Horizon 2020 Research
   and Innovation Programme (grant no.: 634479 [EYE-RISK]); F. HoffmannLa
   Roche, Ltd., Basel, Switzerland. The sponsor or funding organizations
   had no role in the design or conduct of this research.
CR Allikmets R, 2000, AM J HUM GENET, V67, P487, DOI 10.1086/303018
   Allikmets R, 1997, SCIENCE, V277, P1805, DOI 10.1126/science.277.5333.1805
   Anand-Apte B, 2019, J NEUROSCI RES, V97, P88, DOI 10.1002/jnr.24317
   Biarnes M, 2015, AM J OPHTHALMOL, V160, P345, DOI 10.1016/j.ajo.2015.05.009
   Bienaime F, 2010, KIDNEY INT, V77, P339, DOI 10.1038/ki.2009.472
   Boon CJE, 2008, AM J HUM GENET, V82, P516, DOI 10.1016/j.ajhg.2007.11.007
   Boon CJF, 2007, BRIT J OPHTHALMOL, V91, P1504, DOI 10.1136/bjo.2007.115659
   Boon CJF, 2008, PROG RETIN EYE RES, V27, P213, DOI 10.1016/j.preteyeres.2008.01.002
   Boyle EA, 2014, BIOINFORMATICS, V30, P2670, DOI 10.1093/bioinformatics/btu353
   Braun TA, 2013, HUM MOL GENET, V22, P5136, DOI 10.1093/hmg/ddt367
   Buitendijk GHS, 2014, INVEST OPHTH VIS SCI, V55, P6167, DOI 10.1167/iovs.14-15142
   Buitendijk GHS, 2013, OPHTHALMOLOGY, V120, P2644, DOI 10.1016/j.ophtha.2013.07.053
   Cachulo MD, 2015, OPHTHALMOLOGICA, V233, P119, DOI 10.1159/000371584
   Chew EY, 2013, JAMA-J AM MED ASSOC, V309, P2005, DOI 10.1001/jama.2013.4997
   Colijn JM, 2017, OPHTHALMOLOGY, V124, P1753, DOI 10.1016/j.ophtha.2017.05.035
   Cornelis SS, 2017, HUM MUTAT, V38, P400, DOI 10.1002/humu.23165
   Corominas J, 2018, OPHTHALMOLOGY, V125, P1433, DOI 10.1016/j.ophtha.2018.03.040
   De La Paz MA, 1999, OPHTHALMOLOGY, V106, P1531, DOI 10.1016/S0161-6420(99)90449-9
   Dragon-Durey MA, 2004, J AM SOC NEPHROL, V15, P787, DOI 10.1097/01.ASN.0000115702.28859.A7
   Duvvari MR, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0094165
   Fritsche LG, 2016, NAT GENET, V48, P134, DOI 10.1038/ng.3448
   Fritsche LG, 2014, ANNU REV GENOM HUM G, V15, P151, DOI 10.1146/annurev-genom-090413-025610
   Fritsche LG, 2013, NAT GENET, V45, P433, DOI 10.1038/ng.2578
   Geerlings MJ, 2017, MOL IMMUNOL, V84, P65, DOI 10.1016/j.molimm.2016.11.016
   Geerlings MJ, 2017, JAMA OPHTHALMOL, V135, P39, DOI 10.1001/jamaophthalmol.2016.4604
   Grassmann F, 2017, GENOME MED, V9, DOI 10.1186/s13073-017-0418-0
   Heesterbeek TJ, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-43144-3
   Helgason H, 2013, NAT GENET, V45, P1371, DOI 10.1038/ng.2740
   Hoyng CB, 1996, AM J OPHTHALMOL, V121, P623, DOI 10.1016/S0002-9394(14)70627-0
   Jacobson SG, 1996, INVEST OPHTH VIS SCI, V37, P1662
   Kavanagh D, 2008, MOL IMMUNOL, V45, P95, DOI 10.1016/j.molimm.2007.05.004
   Kavanagh D, 2015, HUM MOL GENET, V24, P3861, DOI 10.1093/hmg/ddv091
   Kersten E, 2018, CLIN GENET, V94, P569, DOI 10.1111/cge.13447
   Kohl S, 1997, J MED GENET, V34, P620, DOI 10.1136/jmg.34.8.620
   Liszewski MK, 2015, HUM GENOMICS, V9, DOI 10.1186/s40246-015-0029-z
   Loss J, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0209328
   McCarty CA, 2018, OPTOMETRY VISION SCI, V95, P166, DOI 10.1097/OPX.0000000000001188
   Merle BMJ, 2019, OPHTHALMOLOGY, V126, P381, DOI 10.1016/j.ophtha.2018.08.006
   Neveling K, 2017, CLIN CHEM, V63, P503, DOI 10.1373/clinchem.2016.263897
   Raychaudhuri S, 2011, NAT GENET, V43, P1232, DOI 10.1038/ng.976
   Recalde S, 2016, J AM SOC NEPHROL, V27, P1305, DOI 10.1681/ASN.2015050580
   Renner AB, 2009, AM J OPHTHALMOL, V147, P518, DOI 10.1016/j.ajo.2008.09.007
   Richards A, 2003, P NATL ACAD SCI USA, V100, P12966, DOI 10.1073/pnas.2135497100
   Ristau T, 2014, INVEST OPHTH VIS SCI, V55, P210, DOI 10.1167/iovs.13-13248
   Saksens NTM, 2016, JAMA OPHTHALMOL, V134, P287, DOI 10.1001/jamaophthalmol.2015.5592
   Saksens NTM, 2016, NAT GENET, V48, P144, DOI 10.1038/ng.3474
   Saksens NTM, 2014, PROG RETIN EYE RES, V39, P23, DOI 10.1016/j.preteyeres.2013.11.001
   Seddon JM, 2005, ARCH OPHTHALMOL-CHIC, V123, P321, DOI 10.1001/archopht.123.3.321
   Seddon JM, 2013, NAT GENET, V45, P1366, DOI 10.1038/ng.2741
   Smailhodzic D, 2011, INVEST OPHTH VIS SCI, V52, P8908, DOI 10.1167/iovs.11-7926
   Stone EM, 2017, OPHTHALMOLOGY, V124, P1314, DOI 10.1016/j.ophtha.2017.04.008
   Stone EM, 2015, JAMA OPHTHALMOL, V133, P598, DOI 10.1001/jamaophthalmol.2015.0369
   Stone EM, 2012, OPHTHALMOLOGY, V119, P2408, DOI 10.1016/j.ophtha.2012.05.047
   Stone EM, 1998, NAT GENET, V20, P328, DOI 10.1038/3798
   Taylor RL, 2019, OPHTHALMOLOGY, V126, P1410, DOI 10.1016/j.ophtha.2019.03.013
   van de Ven JPH, 2013, NAT GENET, V45, P813, DOI 10.1038/ng.2640
   van de Ven JPH, 2012, ARCH OPHTHALMOL-CHIC, V130, P1038, DOI 10.1001/archophthalmol.2012.265
   Volokhina E, 2012, PEDIATR NEPHROL, V27, P1519, DOI 10.1007/s00467-012-2183-z
   Wagner EK, 2016, SCI REP-UK, V6, DOI 10.1038/srep31531
   Wang K, 2010, NUCLEIC ACIDS RES, V38, DOI 10.1093/nar/gkq603
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
   Yu Y, 2014, HUM MOL GENET, V23, P5283, DOI 10.1093/hmg/ddu226
   Yu Y, 2011, INVEST OPHTH VIS SCI, V52, P4663, DOI 10.1167/iovs.10-7070
   Zhan XW, 2013, NAT GENET, V45, P1375, DOI 10.1038/ng.2758
NR 64
TC 24
Z9 24
U1 2
U2 3
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 0161-6420
EI 1549-4713
J9 OPHTHALMOLOGY
JI Ophthalmology
PD NOV
PY 2021
VL 128
IS 11
BP 1604
EP 1617
DI 10.1016/j.ophtha.2020.07.037
EA OCT 2021
PG 14
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA WL5XV
UT WOS:000710479200028
PM 32717343
OA Green Published, hybrid
DA 2022-11-30
ER

PT J
AU Bordier, C
   Petra, J
   Dauxerre, C
   Vital-Durand, F
   Knoblauch, K
AF Bordier, Cecile
   Petra, Julie
   Dauxerre, Catherine
   Vital-Durand, Francois
   Knoblauch, Kenneth
TI Influence of background on image recognition in normal vision and
   age-related macular degeneration
SO OPHTHALMIC AND PHYSIOLOGICAL OPTICS
LA English
DT Article
DE age; age-related macular degeneration; eccentricity; image recognition;
   spatial frequency bandwidth
ID VISUAL-ACUITY; ENHANCEMENT; PSYCHOPHYSICS; PASS; REHABILITATION;
   IDENTIFICATION; SEARCH; PEOPLE
AB Purpose:
   The influence of background attenuation on the spatial frequency bandwidth requirements for image recognition was assessed in normal young and older groups and in a group with age-related macular degeneration (AMD). Bandwidth requirements were also assessed in the visual periphery of young normal observers.
   Methods:
   In Experiment 1, each observer was presented with 20 series of images. Each series consisted of a sequence of progressively low-pass filtered images, presented in an order of increasing bandwidth, i.e., according to an ascending method of limits. For half of the series, the background of the base image was selectively darkened by 80% of its original luminance. Three measures were analyzed: (1) the critical bandwidth defined as the bandwidth in cycles/image (cpi) at which 50% of the images were recognized, (2) the minimal bandwidth, defined as the minimal bandwidth at which images were recognized and (3) the proportion of images recognized at full bandwidth. In Experiment 2, young normal observers were similarly tested in central vision and at 5.5 degrees eccentricity (superior or inferior visual field). A third background attenuation condition was included, as well, in which the background was low-pass filtered.
   Results:
   The critical bandwidth for image recognition was significantly reduced by darkening the image background for normal young and old and the AMD groups. This improvement was found to be contrast dependent for the darkened background. In addition, AMD observers tended to recognize more images at full bandwidth if the background was darkened. For normal young observers, making the background low-pass was ineffective in lowering the critical bandwidth in the fovea. Fewer images were recognized at full bandwidth at 5.5 degrees eccentricity for a low-pass background and marginally fewer for a darkened background.
   Conclusions:
   Selective attenuation of the image background can lead to reductions in the bandwidth requirements for image recognition in AMD. However, performance of young normal observers for images presented in the periphery was unlike AMD performance under the conditions investigated. These results have interesting implications for the design of image enhancement algorithms to aid low vision observers.
C1 [Bordier, Cecile; Petra, Julie; Dauxerre, Catherine; Vital-Durand, Francois; Knoblauch, Kenneth] INSERM, Stem Cell & Brain Res Inst, Dept Integrat Neurosci, U846, F-69500 Bron, France.
   [Bordier, Cecile; Petra, Julie; Dauxerre, Catherine; Vital-Durand, Francois; Knoblauch, Kenneth] Univ Lyon, Lyon, France.
C3 Institut National de la Sante et de la Recherche Medicale (Inserm)
RP Bordier, C (通讯作者)，INSERM, Stem Cell & Brain Res Inst, Dept Integrat Neurosci, U846, F-69500 Bron, France.
EM cecile.bordier@ujf-grenoble.fr
RI Knoblauch, Kenneth/H-8156-2014
OI Knoblauch, Kenneth/0000-0002-4681-4638; Bordier,
   Cecile/0000-0003-2376-5922
FU INSERM; Region Rhone-Alpes (Emergence); European Union
   [QLK6-CT-2002-00214]
FX Supported by grants from INSERM, the Region Rhone-Alpes (Emergence) and
   the European Union, AMD-READ (QLK6-CT-2002-00214). Gary Rubin is thanked
   for helpful comments and criticisms of an earlier version.
CR [Anonymous], 2010, R LANG ENV STAT COMP
   BARON WS, 1973, J OPT SOC AM, V63, P212, DOI 10.1364/JOSA.63.000212
   Bordier C, 2005, INT C SERIES, V1282, P980
   Boucart M, 2008, VISUAL NEUROSCI, V25, P685, DOI 10.1017/S0952523808080826
   BOUMA H, 1970, NATURE, V226, P177, DOI 10.1038/226177a0
   BRAJE WL, 1995, VISION RES, V35, P2955, DOI 10.1016/0042-6989(95)00071-7
   Brown MM, 2002, ARCH OPHTHALMOL-CHIC, V120, P481
   Bryant R. C., 2004, Journal of the Society for Information Display, V12, P397, DOI 10.1889/1.1847738
   Cheong AMY, 2007, VISION RES, V47, P2943, DOI 10.1016/j.visres.2007.07.010
   Costen NP, 1996, PERCEPT PSYCHOPHYS, V58, P602, DOI 10.3758/BF03213093
   Crossland MD, 2005, OPHTHALMOLOGY, V112, P1579, DOI 10.1016/j.ophtha.2005.03.027
   Efron B, 1993, INTRO BOOTSTRAP, P202
   Everingham MR, 2003, INT J HUM-COMPUT INT, V15, P231, DOI 10.1207/S15327590IJHC1502_3
   FLOM MERTON C., 1963, SCIENCE, V142, P979, DOI 10.1126/science.142.3594.979
   Itti L, 2000, VISION RES, V40, P1489, DOI 10.1016/S0042-6989(99)00163-7
   Knoblauch K, 2001, COLOR RES APPL, V26, pS157, DOI 10.1002/1520-6378(2001)26:1+<::AID-COL34>3.0.CO;2-E
   Kupfer C, 2000, OPHTHALMOLOGY, V107, P229, DOI 10.1016/S0161-6420(99)00094-9
   Lawton TA, 1998, VISION RES, V38, P153, DOI 10.1016/S0042-6989(97)00140-5
   LEGGE GE, 1985, VISION RES, V25, P239, DOI 10.1016/0042-6989(85)90117-8
   LEGGE GE, 1985, VISION RES, V25, P253, DOI 10.1016/0042-6989(85)90118-X
   LEVI DM, 1985, VISION RES, V25, P963, DOI 10.1016/0042-6989(85)90207-X
   Lord SR, 2006, AGE AGEING, V35, P42, DOI 10.1093/ageing/afl085
   MANDELBAUM J, 1947, AM J OPHTHALMOL, V30, P581, DOI 10.1016/0002-9394(47)92311-8
   MASSOF RW, 1992, OPTOMETRY VISION SCI, V69, P32, DOI 10.1097/00006324-199201000-00005
   Mazoyer V, 1998, PERCEPTION, V27, P156
   Nasanen R, 1999, VISION RES, V39, P3824, DOI 10.1016/S0042-6989(99)00096-6
   Nilsson UL, 2003, VISION RES, V43, P1777, DOI 10.1016/S0042-6989(03)00219-0
   Park W, 1999, INT OPHTHALMOL CLIN, V39, P143, DOI 10.1097/00004397-199903940-00010
   Peli E, 2004, J OPT SOC AM A, V21, P937, DOI 10.1364/JOSAA.21.000937
   Peli E, 2009, INT J ARTIF INTELL T, V18, P415, DOI 10.1142/S0218213009000214
   PELLI DG, 1985, INVEST OPHTH VIS SCI, V26, P751
   Peters RJ, 2005, VISION RES, V45, P2397, DOI 10.1016/j.visres.2005.03.019
   Pinheiro J.C., 2000, MIX EFF MODELS PLUS, DOI [10.1198/jasa.2001.s411, 10.1007/0- 387-22747-4, DOI 10.1198/JASA.2001.S411]
   RUBIN GS, 1992, VISION RES, V32, P895, DOI 10.1016/0042-6989(92)90032-E
   RUBIN GS, 1994, VISION RES, V34, P1723, DOI 10.1016/0042-6989(94)90129-5
   Seiple W, 2001, OPTOMETRY VISION SCI, V78, P169, DOI 10.1097/00006324-200103000-00010
   SOLOMON JA, 1994, NATURE, V369, P395, DOI 10.1038/369395a0
   SOUBRANE G, 1990, OPHTHALMOLOGY, V97, P649
   Stelmack JA, 2008, ARCH OPHTHALMOL-CHIC, V126, P608, DOI 10.1001/archopht.126.5.608
   Stokkermans, 2000, Clin Eye Vis Care, V12, P15, DOI 10.1016/S0953-4431(99)00043-0
   Turano KA, 2002, VISION RES, V42, P2635, DOI 10.1016/S0042-6989(02)00299-7
   Venables W.N., 2002, MODERN APPL STAT S P
   Vettard S, 2004, J FR OPHTALMOL, V27, P589, DOI 10.1016/S0181-5512(04)96183-9
   Wang YZ, 2002, INVEST OPHTH VIS SCI, V43, P2055
   WATSON AB, 1979, VISION RES, V19, P515, DOI 10.1016/0042-6989(79)90136-6
   Webster MA, 2002, NAT NEUROSCI, V5, P839, DOI 10.1038/nn906
   Yssaad-Fesselier R, 2006, BEHAV RES METHODS, V38, P28, DOI 10.3758/BF03192747
   [No title captured]
   [No title captured]
   [No title captured]
   [No title captured]
   [No title captured]
   [No title captured]
   [No title captured]
   [No title captured]
NR 55
TC 8
Z9 8
U1 0
U2 9
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0275-5408
EI 1475-1313
J9 OPHTHAL PHYSL OPT
JI Ophthalmic Physiol. Opt.
PD MAY
PY 2011
VL 31
IS 3
BP 203
EP 215
DI 10.1111/j.1475-1313.2011.00820.x
PG 13
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 746NK
UT WOS:000289253800002
PM 21410743
DA 2022-11-30
ER

PT J
AU Gudauskiene, G
   Vilkeviciute, A
   Gedvilaite, G
   Liutkeviciene, R
   Zaliuniene, D
AF Gudauskiene, Gaile
   Vilkeviciute, Alvita
   Gedvilaite, Greta
   Liutkeviciene, Rasa
   Zaliuniene, Dalia
TI CCL2, CCR2 Gene Variants and CCL2, CCR2 Serum Levels Association with
   Age-Related Macular Degeneration
SO LIFE-BASEL
LA English
DT Article
DE AMD; CCL2 (rs1024611; rs4586; rs2857656); CCR2 rs1799865; CCL2 and CCR2
   serum level
ID MONOCYTE CHEMOATTRACTANT PROTEIN-1; CYTOKINE LIGAND 2; PREVALENCE;
   EXPRESSION; POLYMORPHISMS; INVOLVEMENT; PROGRESSION; CHEMOKINES;
   CLONING; MCP-1
AB Background: Age-related macular degeneration (AMD) is the most common cause of progressive and irreversible blindness in developed countries. Although the pathogenesis is not fully understood, AMD is a multifactorial pathology with an accumulation of inflammatory components and macrophages and a strong genetic predisposition. Our purpose was to investigate the association between early AMD and CCL2 (rs1024611, rs4586, rs2857656) and CCR2 (rs1799865) single nucleotide polymorphisms (SNPs) and CCL2, CCR2 serum levels in a Lithuanian population. Methods: The study included 310 patients with early AMD and 384 healthy subjects. Genotyping of CCL2 rs1024611, rs4586, rs2857656, and CCR2 rs1799865 was performed using a real-time polymerase chain reaction method, while CCL2 and CCR2 chemokines serum concentrations were analyzed using an enzyme-linked immunosorbent assay. Results: We found that the G allele at CCL2 rs1024611 was more prevalent in the early AMD group than in controls (29.2% vs. 24.1%, p = 0.032). Similarly, the C allele in CCL2 rs2857656 is more common in the early AMD group than in controls (29.2% vs. 24.2%, p = 0.037). Binomial logistic regression revealed that each G allele in rs1024611 was associated with 1.3-fold increased odds of developing early AMD under the additive model (OR = 1.322; 95% CI: 1.032-1.697, p = 0.027) as was each C allele in rs2857656 under the additive model (OR = 1.314; 95% CI: 1.025-1.684, p = 0.031). Haplotype analysis revealed that the C-A-G haplotype of CCL2 SNPs was associated with 35% decreased odds of early AMD development. Further analysis showed elevated CCL2 serum levels in the group with early AMD compared to controls (median (IQR): 1181.6 (522.6) pg/mL vs. 879.9 (494.4) pg/mL, p = 0.013); however, there were no differences between CCR2 serum levels within groups. Conclusions: We found the associations between minor alleles at CCL2 rs1024611 and rs2857656, elevated CCL2 serum levels, and early AMD development.
C1 [Gudauskiene, Gaile; Liutkeviciene, Rasa; Zaliuniene, Dalia] Lithuanian Univ Hlth Sci, Med Acad, Dept Ophthalmol, Eiveniu 2, LT-50161 Kaunas, Lithuania.
   [Vilkeviciute, Alvita; Gedvilaite, Greta; Liutkeviciene, Rasa] Lithuanian Univ Hlth Sci, Med Acad, Neurosci Inst, Lab Ophthalmol, Eiveniu 2, LT-50161 Kaunas, Lithuania.
C3 Lithuanian University of Health Sciences; Lithuanian University of
   Health Sciences
RP Gudauskiene, G (通讯作者)，Lithuanian Univ Hlth Sci, Med Acad, Dept Ophthalmol, Eiveniu 2, LT-50161 Kaunas, Lithuania.
EM gaile.gudauskiene@lsmuni.lt; alvita.vilkeviciute@lsmuni.lt;
   greta.gedvilaite@lsmuni.lt; rasa.liutkeviciene@lsmuni.lt;
   dalia.zaliuniene@lsmuni.lt
OI Gedvilaite, Greta/0000-0001-7469-8825
CR Anand A, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0049905
   [Anonymous], 2018, NCBI GEN RES
   BARNA BP, 1994, J NEUROIMMUNOL, V50, P101, DOI 10.1016/0165-5728(94)90220-8
   Bianconi V, 2018, CURR OPIN HEMATOL, V25, P44, DOI 10.1097/MOH.0000000000000389
   Bonyadi MHJ, 2016, OPHTHALMIC GENET, V37, P465, DOI 10.3109/13816810.2015.1120317
   Bonyadi M, 2016, ACTA OPHTHALMOL, V94, pE779, DOI 10.1111/aos.13143
   COCHRAN BH, 1983, CELL, V33, P939, DOI 10.1016/0092-8674(83)90037-5
   Conductier G, 2010, J NEUROIMMUNOL, V224, P93, DOI 10.1016/j.jneuroim.2010.05.010
   Despriet DDG, 2008, INVEST OPHTH VIS SCI, V49, P364, DOI 10.1167/iovs.07-0656
   Du ZJ, 2016, GRAEF ARCH CLIN EXP, V254, P2469, DOI 10.1007/s00417-016-3508-6
   Duan YK, 2007, OPHTHALMOLOGY, V114, P732, DOI 10.1016/j.ophtha.2006.07.045
   Falk MK, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0112473
   Fernandez AB, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0142968
   Forrester JV, 2003, NAT MED, V9, P1350, DOI 10.1038/nm1103-1350
   Fritsche LG, 2014, ANNU REV GENOM HUM G, V15, P151, DOI 10.1146/annurev-genom-090413-025610
   Garcia-Layana A, 2017, CLIN INTERV AGING, V12, P1579, DOI 10.2147/CIA.S142685
   Georgakis MK, 2019, CIRCULATION, V139, P256, DOI 10.1161/CIRCULATIONAHA.118.035905
   Grunin M, 2012, INVEST OPHTH VIS SCI, V53, P5292, DOI 10.1167/iovs.11-9165
   Guymer RH, 2011, INVEST OPHTH VIS SCI, V52, P4639, DOI 10.1167/iovs.10-7120
   Hernandez-Aguilera A, 2020, CYTOKINE, V126, DOI 10.1016/j.cyto.2019.154923
   Hyman Leslie, 2002, Curr Opin Ophthalmol, V13, P171
   Joachim N, 2017, BRIT J OPHTHALMOL, V101, P1185, DOI 10.1136/bjophthalmol-2016-309729
   Jonas JB, 2014, RETINA-J RET VIT DIS, V34, P1149, DOI 10.1097/IAE.0000000000000035
   Jonas JB, 2010, ARCH OPHTHALMOL-CHIC, V128, P1281, DOI 10.1001/archophthalmol.2010.227
   Kawasaki R, 2010, OPHTHALMOLOGY, V117, P921, DOI 10.1016/j.ophtha.2009.10.007
   Kersten E, 2018, SURV OPHTHALMOL, V63, P9, DOI 10.1016/j.survophthal.2017.05.003
   Klaver CCW, 2001, INVEST OPHTH VIS SCI, V42, P2237
   Klein R, 2004, AM J OPHTHALMOL, V137, P486, DOI 10.1016/j.ajo.2003.11.069
   Kramer M, 2012, CLIN EXP OPHTHALMOL, V40, P617, DOI 10.1111/j.1442-9071.2011.02747.x
   Kumar RA, 2018, INT IMMUNOPHARMACOL, V65, P348, DOI 10.1016/j.intimp.2018.10.016
   Lechner J, 2017, J NEUROINFLAMM, V14, DOI 10.1186/s12974-017-0820-y
   Lim SY, 2016, ONCOTARGET, V7, P28697, DOI 10.18632/oncotarget.7376
   Lubowicka E, 2018, BIOMED RES INT, V2018, DOI 10.1155/2018/2124390
   Mitchell P, 2018, LANCET, V392, P1147, DOI 10.1016/S0140-6736(18)31550-2
   Modenese A, 2019, INT ARCH OCC ENV HEA, V92, P1, DOI 10.1007/s00420-018-1355-y
   Mullins RF, 2000, FASEB J, V14, P835, DOI 10.1096/fasebj.14.7.835
   Nussenblatt RB, 2007, AM J OPHTHALMOL, V144, P618, DOI 10.1016/j.ajo.2007.06.025
   Nyquist PA, 2009, CEREBROVASC DIS, V28, P124, DOI 10.1159/000223437
   Owen CG, 2012, BRIT J OPHTHALMOL, V96, P752, DOI 10.1136/bjophthalmol-2011-301109
   Park HJ, 2013, INT J IMMUNOGENET, V40, P306, DOI 10.1111/iji.12009
   PENFOLD PL, 1985, GRAEF ARCH CLIN EXP, V223, P69, DOI 10.1007/BF02150948
   Raoul W, 2010, J NEUROINFLAMM, V7, DOI 10.1186/1742-2094-7-87
   Rossi D, 2000, ANNU REV IMMUNOL, V18, P217, DOI 10.1146/annurev.immunol.18.1.217
   Rudnicka AR, 2012, OPHTHALMOLOGY, V119, P571, DOI 10.1016/j.ophtha.2011.09.027
   Saddala MS, 2019, HUM GENOMICS, V13, DOI 10.1186/s40246-019-0199-1
   Sharma NK, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0193423
   Sole X, 2006, BIOINFORMATICS, V22, P1928, DOI 10.1093/bioinformatics/btl268
   Soria G, 2008, CANCER LETT, V267, P271, DOI 10.1016/j.canlet.2008.03.018
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
   Xie P, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0028933
   YOSHIMURA T, 1989, FEBS LETT, V244, P487, DOI 10.1016/0014-5793(89)80590-3
   Zhang Y, 2020, MED SCI MONITOR, V26, DOI 10.12659/MSM.921584
   Zor RK, 2020, THER ADV OPHTHALMOL, V12, DOI 10.1177/2515841420951682
NR 53
TC 0
Z9 0
U1 2
U2 2
PU MDPI
PI BASEL
PA ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND
EI 2075-1729
J9 LIFE-BASEL
JI Life-Basel
PD JUL
PY 2022
VL 12
IS 7
AR 1038
DI 10.3390/life12071038
PG 11
WC Biology; Microbiology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Life Sciences & Biomedicine - Other Topics; Microbiology
GA 3H5ON
UT WOS:000832085700001
PM 35888126
OA gold, Green Published
DA 2022-11-30
ER

PT J
AU Reeves, BC
   Harper, RA
   Russell, WB
AF Reeves, BC
   Harper, RA
   Russell, WB
TI Enhanced low vision rehabilitation for people with age related macular
   degeneration: a randomised controlled trial
SO BRITISH JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
ID QUALITY-OF-LIFE; UNITED-KINGDOM; QUESTIONNAIRE; DISABILITY; IMPACT;
   DESIGN
AB Aim: To compare the effectiveness of three models of low vision rehabilitation for people with age related macular degeneration (AMD) referred for low vision rehabilitation (LVR): ( a) an enhanced low vision rehabilitation model (ELVR) including supplementary home based low vision rehabilitation; (b) conventional low vision rehabilitation (CLVR) based in a hospital clinic; ( c) CLVR with home visits that did not include rehabilitation (CELVR), intended to act as a control for the additional contact time with ELVR.
   Method: A single centre parallel group randomised controlled trial in participants' homes and the low vision clinic, Manchester Royal Eye Hospital. People referred for LVR with a primary diagnosis of AMD and visual acuity worse than 6/18 in both eyes and equal to or better than 1/60 in the better eye. The main outcome measures were vision specific quality of life (QoL) ( primary outcome, VCM1) and generic health related QoL (SF-36); psychological adjustment to vision loss; measured task performance; restriction in everyday activities; use of low vision aids (LVAs).
   Results: 226 participants were recruited ( median age 82 years); 194 completed the trial (86%). Except for SF-36 physical and mental component summary scores, arms did not differ significantly for any of the outcomes. Differences for the VCM1 were ELVR v CLVR, 0.06 (95% CI to 0.17 to 0.30, p = 0.60); ELVR v CELVR, 0.12 ( 95% CI to 0.11 to 0.34, p = 0.31); CELVR v CLVR, - 0.05 ( 95% CI - 0.29 to 0.18, p = 0.64). Differences for the SF-36 favoured CLVR compared to ELVR ( ELVR v CLVR: physical = - 6.05, 95% CI - 10.2 to - 1.91, p = 0.004; mental = - 4.04, 95% CI - 7.44 to - 0.65, p = 0.02). At 12 months, 94% of participants reported using at least one LVA.
   Conclusion: ELVR was no more effective than CLVR. Researchers should be wary of proposing new LVR interventions without preliminary evidence of effectiveness, given the manifest lack of effectiveness of the model of enhanced LVR evaluated in the trial.
C1 Manchester Royal Eye Hosp, Acad Dept Ophthalmol, Manchester M13 9WH, Lancs, England.
   London Sch Hyg, Hlth Serv Res Unit, London, England.
   Univ Keele, Ctr Hlth Planning & Management, Keele ST5 5BG, Staffs, England.
C3 Manchester Royal Eye Hospital; University of London; London School of
   Hygiene & Tropical Medicine; Keele University
RP Harper, RA (通讯作者)，Manchester Royal Eye Hosp, Acad Dept Ophthalmol, Oxford Rd, Manchester M13 9WH, Lancs, England.
EM robert.harper@man.ac.uk
RI ; Russell, Wanda/O-9051-2014
OI Harper, Robert/0000-0001-5437-2553; Russell, Wanda/0000-0003-2671-1938
CR Beatty S, 1999, BRIT J OPHTHALMOL, V83, P1103, DOI 10.1136/bjo.83.10.1103
   Brody BL, 2001, OPHTHALMOLOGY, V108, P1893, DOI 10.1016/S0161-6420(01)00754-0
   Brody BL, 1999, ANN BEHAV MED, V21, P322, DOI 10.1007/BF02895965
   Chong NHV, 1998, BRIT J OPHTHALMOL, V82, P1441, DOI 10.1136/bjo.82.12.1441
   Culham LE, 2002, BRIT J OPHTHALMOL, V86, P743, DOI 10.1136/bjo.86.7.743
   DODDS AG, 1991, J VISUAL IMPAIR BLIN, V85, P306
   DODDS AG, 1993, INT J REHABIL RES, V16, P77
   Evans J, 1996, BRIT J OPHTHALMOL, V80, P9, DOI 10.1136/bjo.80.1.9
   Frost N A, 1998, Ophthalmic Epidemiol, V5, P185, DOI 10.1076/opep.5.4.185.4191
   Harper R, 1999, OPHTHAL PHYSL OPT, V19, P3, DOI 10.1046/j.1475-1313.1999.00411.x
   HARPER RA, 2001, OPHTHAL RES, V33, P102
   Harvey PT, 2003, GERONTOLOGY, V49, P1, DOI 10.1159/000066507
   JENKINSON C, 1996, UK SF 36 ANAL INTERP, P1
   *LOW VIS SERV CONS, 1999, REC FUT SERV DEL UK
   Mangione CM, 1999, AM J OPHTHALMOL, V128, P45, DOI 10.1016/S0002-9394(99)00169-5
   Mangione CM, 1998, ARCH OPHTHALMOL-CHIC, V116, P227
   McIlwaine G G, 1991, Eye (Lond), V5 ( Pt 5), P607
   Meads C, 2003, HEALTH TECHNOL ASSES, V7, p[v, 1], DOI [10.3310/hta7090, DOI 10.3310/hta7090]
   NILSSON UL, 1990, CLIN VISION SCI, V6, P3
   NILSSON UL, 1986, DOC OPHTHALMOL, V62, P345, DOI 10.1007/BF00168266
   RAASCH TW, 2002, ACTIVITY PARTICIPATI, P27
   ROSENBERG R, 1989, OPTOMETRY VISION SCI, V66, P747, DOI 10.1097/00006324-198911000-00004
   Rubin GS, 2001, INVEST OPHTH VIS SCI, V42, P64
   Russell W, 2001, OPHTHAL PHYSL OPT, V21, P36, DOI 10.1046/j.1475-1313.2001.00569.x
   RUSSELL WB, 2003, THESIS U MANCHESTER
   RYAN B, 1999, FRAGMENTED VISION SU
   SHUTTLEWORTH GN, 1995, BRIT J OPHTHALMOL, V79, P719, DOI 10.1136/bjo.79.8.719
   WARE JE, 1992, MED CARE, V30, P473, DOI 10.1097/00005650-199206000-00002
   Watson GR, 1997, OPTOMETRY VISION SCI, V74, P249, DOI 10.1097/00006324-199705000-00019
   Wiliams RA, 1998, ARCH OPHTHALMOL-CHIC, V116, P514
   Wolffsohn JS, 2000, AM J OPHTHALMOL, V130, P793, DOI 10.1016/S0002-9394(00)00610-3
NR 31
TC 104
Z9 105
U1 0
U2 15
PU BMJ PUBLISHING GROUP
PI LONDON
PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND
SN 0007-1161
EI 1468-2079
J9 BRIT J OPHTHALMOL
JI Br. J. Ophthalmol.
PD NOV
PY 2004
VL 88
IS 11
BP 1443
EP 1449
DI 10.1136/bjo.2003.037457
PG 7
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 862SF
UT WOS:000224510500021
PM 15489491
OA Green Published, Bronze
DA 2022-11-30
ER

PT J
AU Loss, J
   Muller, D
   Weigl, J
   Helbig, H
   Brandl, C
   Heid, IM
   Finger, RP
   Weber, BHF
   Curbach, J
AF Loss, Julika
   Mueller, Daniel
   Weigl, Johannes
   Helbig, Horst
   Brandl, Caroline
   Heid, Iris M.
   Finger, Robert P.
   Weber, Bernhard H. F.
   Curbach, Janina
TI Views of ophthalmologists on the genetics of age-related macular
   degeneration: Results of a qualitative study
SO PLOS ONE
LA English
DT Article
ID HEALTH-CARE; PREVALENCE; KNOWLEDGE; SUSCEPTIBILITY; EPIDEMIOLOGY;
   ACCELERATE; ATTITUDES; EDUCATION; SMOKING; US
AB Background
   Age-related macular degeneration (AMD) is the leading cause of blindness in industrialized countries. It is a multifactorial disease of the retina modified by environmental/individual (e.g. smoking) and genetic factors. 34 independent genomic loci are associated with the risk to develop AMD; an interaction between smoking and genetics is currently investigated. It is unclear how the knowledge on the strong genetic component has entered the knowledge base of practicing ophthalmologists, and how they inform and counsel their (AMD) patients about it. In this study, we explore the ophthalmologist's view on AMD genetics, and their inclination towards communicating genetic risks to patients.
   Methods
   We recruited a purposive sample of thirty German ophthalmologists (office based: n = 15, hospital employees: n = 15, f:8/30), who took part in a recorded semi-standardized interview. Transcripts were analyzed using content analysis.
   Results
   The majority of office-based ophthalmologists claimed to be unfamiliar with genetics of AMD, in contrast to hospital-affiliated ophthalmologists. Both office and hospital ophthalmologists were convinced that genetics lacks practical relevance in everyday patient care. Many withhold information on heritability or genetic background of AMD from patients and their relatives, for fear of unsettling those individuals. The relevance of the genetic component of AMD or an individual's high genetic risk for prevention, e.g. screening or lifestyle modifications in persons with adverse genetic profile, was rated low.
   Conclusion
   Developing genetic educational programs tailored to the routine care of ophthalmologists may be indicated, as well as a better two-way communication between research and practice. Exploring patient views about their expectations to being informed about genetic disease etiology, or about their individual risk, would help inform communication strategies.
C1 [Loss, Julika; Mueller, Daniel; Weigl, Johannes; Curbach, Janina] Univ Regensburg, Inst Epidemiol & Prevent Med, Med Sociol, Regensburg, Germany.
   [Helbig, Horst; Brandl, Caroline] Univ Hosp Regensburg, Dept Ophthalmol, Regensburg, Germany.
   [Brandl, Caroline; Heid, Iris M.] Univ Regensburg, Dept Genet Epidemiol, Regensburg, Germany.
   [Finger, Robert P.] Univ Bonn, Univ Eye Hosp, Bonn, Germany.
   [Weber, Bernhard H. F.] Univ Regensburg, Inst Human Genet, Regensburg, Germany.
C3 University of Regensburg; University of Regensburg; University of
   Regensburg; University of Bonn; University of Regensburg
RP Loss, J (通讯作者)，Univ Regensburg, Inst Epidemiol & Prevent Med, Med Sociol, Regensburg, Germany.
EM julika.loss@ukr.de
OI Brandl, Caroline/0000-0001-8223-6137
FU Bundesministerium fur Bildung und Forschung, Germany Ministry for
   Research and Education [FK 01GP1308]
FX The study is part of a Research Network: "Prevention in the postgenomic
   era: communication of genetic risks using the case of age-related
   macular degeneration (AMD)", funded by the Bundesministerium fur Bildung
   und Forschung, Germany Ministry for Research and Education (FK
   01GP1308), https://www.bmbf.de/ The funders had no role in study design,
   data collection and analysis, decision to publish, or preparation of the
   manuscript.
CR American Academy of Ophthalmology Retina Vitreous Panel, 2008, AG REL MAC DEG
   Anand A, 2014, CURR GENOMICS, V15, P266, DOI 10.2174/1389202915666140516204512
   [Anonymous], 2018, AG REL MAC DEG
   Bailey JNC, 2016, J CLIN MED, V5, DOI 10.3390/jcm5030031
   Batra S, 2002, AM J GASTROENTEROL, V97, P729
   Brandl C, 2016, OPHTHALMOLOGE, V113, P735, DOI 10.1007/s00347-016-0341-6
   Callard F, 2012, HEALTH EXPECT, V15, P389, DOI 10.1111/j.1369-7625.2011.00681.x
   Carroll JC, 2009, CAN FAM PHYSICIAN, V55, pE92
   Chakravarthy U, 2010, BMC OPHTHALMOL, V10, DOI 10.1186/1471-2415-10-31
   Cherkas LF, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0013473
   Chew EY, 2015, OPHTHALMOLOGY, V122, P2155, DOI 10.1016/j.ophtha.2015.08.007
   Chew EY, 2015, OPHTHALMOLOGY, V122, P212, DOI 10.1016/j.ophtha.2014.10.012
   Colijn JM, 2017, OPHTHALMOLOGY, V124, P1753, DOI 10.1016/j.ophtha.2017.05.035
   Delcourt C, 2001, Ophthalmic Epidemiol, V8, P237, DOI 10.1076/opep.8.4.237.1613
   Fernandez-Robredo P, 2014, J OPHTHALMOL, V2014, DOI 10.1155/2014/510285
   Fritsche LG, 2016, NAT GENET, V48, P134, DOI 10.1038/ng.3448
   Grassmann F, 2015, ANNU REV VIS SCI, V1, P73, DOI 10.1146/annurev-vision-082114-035609
   Haga SB, 2013, GENET TEST MOL BIOMA, V17, P327, DOI 10.1089/gtmb.2012.0350
   Houwink EJF, 2014, EUR J HUM GENET, V22, P310, DOI 10.1038/ejhg.2013.163
   Houwink EJF, 2011, BMC FAM PRACT, V12, DOI 10.1186/1471-2296-12-5
   Jain S, 2006, EYE, V20, P471, DOI 10.1038/sj.eye.6701916
   Joehanes R, 2016, CIRC-CARDIOVASC GENE, V9, P436, DOI 10.1161/CIRCGENETICS.116.001506
   Khoury MJ, 2007, GENET MED, V9, P665, DOI 10.1097/GIM.0b013e31815699d0
   Klein B E, 2001, Ophthalmic Epidemiol, V8, P251, DOI 10.1076/opep.8.4.251.1612
   Korb CA, 2014, GRAEF ARCH CLIN EXP, V252, P1403, DOI 10.1007/s00417-014-2591-9
   Kumaramanickavel G, 2016, ASIA-PAC J OPHTHALMO, V5, P229, DOI 10.1097/APO.0000000000000223
   Lim LS, 2012, LANCET, V379, P1728, DOI 10.1016/S0140-6736(12)60282-7
   Mares JA, 2011, ARCH OPHTHALMOL-CHIC, V129, P470, DOI 10.1001/archophthalmol.2010.314
   Marincola Francesco M, 2003, J Transl Med, V1, P1, DOI 10.1186/1479-5876-1-1
   Mays N, 2000, BMJ-BRIT MED J, V320, P50, DOI 10.1136/bmj.320.7226.50
   McCarty CA, 2018, OPTOMETRY VISION SCI, V95, P166, DOI 10.1097/OPX.0000000000001188
   Merle BMJ, 2015, AM J CLIN NUTR, V102, P1196, DOI 10.3945/ajcn.115.111047
   Narimatsu H, 2017, INT J MOL SCI, V18, DOI 10.3390/ijms18020302
   Oliveri S, 2016, BIOMED RES INT, V2016, DOI 10.1155/2016/6824581
   Paneque M, 2016, BMC FAM PRACT, V17, DOI 10.1186/s12875-016-0483-2
   Panic N, 2014, BIOMED RES INT, V2014, DOI 10.1155/2014/418416
   Patton MQ, 2015, QUALITATIVE RES EVAL
   Rim Priscila Hae Hyun, 2006, Arq. Bras. Oftalmol., V69, P481, DOI 10.1590/S0004-27492006000400005
   Rivera A, 2005, HUM MOL GENET, V14, P3227, DOI 10.1093/hmg/ddi353
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Schully SD, 2014, APPL TRANSL GENOM, V3, P82, DOI 10.1016/j.atg.2014.09.006
   Schwartz SG, 2016, CLIN OPHTHALMOL, V10, P1229, DOI 10.2147/OPTH.S109723
   Seddon JM, 2005, ARCH OPHTHALMOL-CHIC, V123, P321, DOI 10.1001/archopht.123.3.321
   Seddon JM, 1996, JAMA-J AM MED ASSOC, V276, P1141, DOI 10.1001/jama.276.14.1141
   Seddon JM, 2006, HUM HERED, V61, P157, DOI 10.1159/000094141
   Sobrin L, 2014, PROG RETIN EYE RES, V40, P1, DOI 10.1016/j.preteyeres.2013.12.004
   Stone EM, 2015, JAMA OPHTHALMOL, V133, P598, DOI 10.1001/jamaophthalmol.2015.0369
   Sutherland JE, 2009, CURR OPIN OPHTHALMOL, V20, P343, DOI 10.1097/ICU.0b013e32832f7f0d
   Tong A, 2007, INT J QUAL HEALTH C, V19, P349, DOI 10.1093/intqhc/mzm042
   Velez-Montoya R, 2014, RETINA-J RET VIT DIS, V34, P423, DOI 10.1097/IAE.0000000000000036
NR 50
TC 5
Z9 5
U1 0
U2 2
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD DEC 20
PY 2018
VL 13
IS 12
AR e0209328
DI 10.1371/journal.pone.0209328
PG 20
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA HF0HP
UT WOS:000453841700055
PM 30571778
OA Green Submitted, Green Published, gold
DA 2022-11-30
ER

PT J
AU Koss, MJ
   Kurz, P
   Tsobanelis, T
   Lehmacher, W
   Fassbender, C
   Klingel, R
   Koch, FHJ
AF Koss, Michael Janusz
   Kurz, Peter
   Tsobanelis, Theoharis
   Lehmacher, Walter
   Fassbender, Cordula
   Klingel, Reinhard
   Koch, Frank H. J.
TI Prospective, randomized, controlled clinical study evaluating the
   efficacy of Rheopheresis for dry age-related macular degeneration
SO GRAEFES ARCHIVE FOR CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY
LA English
DT Article
DE Dry AMD; Macular degeneration; Rheopheresis; Apheresis; Microcirculation
ID MEMBRANE DIFFERENTIAL FILTRATION; CHOROIDAL BLOOD-FLOW; MACULOPATHY;
   PROGRESSION; TRIAL; AMD
AB To evaluate Rheopheresis for the treatment of patients with high-risk dry age-related macular degeneration and no therapeutic alternative. Rheopheresis is a method of therapeutic apheresis using the methodology of double filtration plasmapheresis to treat microcirculatory disorders.
   The dry AMD treatment with Rheopheresis trial (ART) was a randomised, controlled clinical study. Patients with the diagnosis of AMD in both eyes, with the study eye presenting dry AMD and soft drusen (the fellow eye had advanced AMD) were randomly assigned in a 1:1 ratio to receive ten Rheopheresis treatments within 17 weeks or to remain untreated. The primary outcome was change in best-corrected ETDRS-visual acuity (mean logMar change) after 7.5 months compared to baseline visual acuity for both groups.
   Forty-three eyes of 43 patients (22 treatment and 21 control group) were analysed. The mean baseline BCVA in study eyes was 0.58 in the treatment group and 0.66 in the control group (n.s. p = 0.19). At the primary efficacy endpoint 7.5 months post baseline, there was a statistically significant mean difference of 0.95 ETDRS lines (p = 0.01) between the Rheopheresis and control groups. Nine percent of eyes in the group treated with Rheopheresis gained 2 or more ETDRS lines, as compared with 0% of eyes with no treatment. None of the treated patients had a loss in visual acuity in their study eyes, as compared with 24% of patients without treatment who lost 1 ETDRS line or more; 19% lost 2 ETDRS lines or more. Rheopheresis treatment was safe and well-tolerated.
   The results of ART provide further evidence that Rheopheresis is a safe and effective therapeutic option for high-risk patients with dry AMD and no therapeutic alternative. A series of Rheopheresis treatments can improve the natural course of AMD for selected patients.
C1 [Koss, Michael Janusz; Koch, Frank H. J.] Goethe Univ Frankfurt, Dept Ophthalmol, D-60590 Frankfurt, Germany.
   [Kurz, Peter; Tsobanelis, Theoharis] Ctr Nephrol Dialysis & Apheresis, D-60316 Frankfurt, Germany.
   [Lehmacher, Walter] Univ Cologne, Inst Med Stat Informat & Epidemiol, D-50924 Cologne, Germany.
   [Fassbender, Cordula; Klingel, Reinhard] Apheresis Res Inst, D-50935 Cologne, Germany.
C3 Goethe University Frankfurt; University of Cologne
RP Koch, FHJ (通讯作者)，Goethe Univ Frankfurt, Dept Ophthalmol, Theodor Stern Kai 7, D-60590 Frankfurt, Germany.
EM fkoch1@mac.com
OI Fassbender, Dr. Cordula/0000-0001-6498-0210
CR BOYER D, 2006, INVEST OPHTH VIS SCI, V47, P2176
   BRAUN O, 1993, ACTA OPHTHALMOL, V71, P398
   Brody BL, 2001, OPHTHALMOLOGY, V108, P1901
   Brunner R, 1996, TRANSFUS SCI, V17, P493, DOI 10.1016/S0955-3886(96)90083-1
   Brunner R, 2000, RETINA-J RET VIT DIS, V20, P483, DOI 10.1097/00006982-200009000-00009
   Fell AJ, 2002, OPHTHALMOLOGE, V99, P780, DOI 10.1007/s00347-002-0614-0
   Grunwald JE, 1998, ARCH OPHTHALMOL-CHIC, V116, P150
   Grunwald JE, 1998, INVEST OPHTH VIS SCI, V39, P385
   Grunwald JE, 2005, INVEST OPHTH VIS SCI, V46, P1033, DOI 10.1167/iovs.04-1050
   Hazel CA, 2000, INVEST OPHTH VIS SCI, V41, P1309
   HEIBGES A, 2007, NEPHRO NEWS SEPTEMBE, P30
   Jager RD, 2008, NEW ENGL J MED, V358, P2606, DOI 10.1056/NEJMra0801537
   Jampol LM, 2001, ARCH OPHTHALMOL-CHIC, V119, P1533
   Klaver CCW, 2001, INVEST OPHTH VIS SCI, V42, P2237
   Klein R, 1997, OPHTHALMOLOGY, V104, P7, DOI 10.1016/S0161-6420(97)30368-6
   Klein R., 2004, ARCH OPHTHALMOL-CHIC, V122, P564
   Klingel R, 2005, THER APHER DIAL, V9, P473, DOI 10.1111/j.1744-9987.2005.00276.x
   Klingel R, 2000, Ther Apher, V4, P348, DOI 10.1046/j.1526-0968.2000.004005348.x
   Klingel T, 2003, THER APHER DIAL, V7, P444, DOI 10.1046/j.1526-0968.2003.00082.x
   Luke C, 2001, J CLIN APHERESIS, V16, P23, DOI 10.1002/jca.1004
   Mosges R, 2008, OTOL NEUROTOL, V29, P769, DOI 10.1097/MAO.0b013e31817e5d03
   Mosges R, 2009, EUR ARCH OTO-RHINO-L, V266, P943, DOI 10.1007/s00405-008-0823-5
   Moshfeghi DM, 2007, RETINA-J RET VIT DIS, V27, P269, DOI 10.1097/IAE.0b013e31802e3e9b
   OWEN CG, 2006, BR J OPHTHALMOL, V87, P312
   Pulido Jose S, 2006, Trans Am Ophthalmol Soc, V104, P221
   Pulido Jose S, 2002, Trans Am Ophthalmol Soc, V100, P85
   Pulido JS, 2005, CAN J OPHTHALMOL, V40, P332, DOI 10.1016/S0008-4182(05)80076-6
   SOUDAVAR F, 1998, INVEST OPHTH VIS SCI, V39, P386
   Swartz M, 1999, INVEST OPHTH VIS SCI, V40, pS319
   Trautner C, 2003, INVEST OPHTH VIS SCI, V44, P1031, DOI 10.1167/iovs.02-0304
   Widder RA, 2002, INVEST OPHTH VIS SCI, V43, P2906
   Wild C, 2009, OPHTHALMOLOGE, V106, P127, DOI 10.1007/s00347-008-1768-1
   Wong T, 2008, OPHTHALMOLOGY, V115, P116, DOI 10.1016/j.ophtha.2007.03.008
NR 33
TC 26
Z9 28
U1 0
U2 3
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0721-832X
EI 1435-702X
J9 GRAEF ARCH CLIN EXP
JI Graefes Arch. Clin. Exp. Ophthalmol.
PD OCT
PY 2009
VL 247
IS 10
BP 1297
EP 1306
DI 10.1007/s00417-009-1113-7
PG 10
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 488AD
UT WOS:000269320000001
PM 19629514
DA 2022-11-30
ER

PT J
AU Soares, RR
   Gopal, AD
   Parikh, D
   Shields, CN
   Patel, S
   Hinkle, J
   Sharpe, J
   Ho, AC
   Regillo, CD
   Haller, J
   Yonekawa, Y
AF Soares, Rebecca R.
   Gopal, Anand D.
   Parikh, Devayu
   Shields, Charlotte N.
   Patel, Samir
   Hinkle, John
   Sharpe, James
   Ho, Allen C.
   Regillo, Carl D.
   Haller, Julia
   Yonekawa, Yoshihiro
TI Geographic Access Disparities of Clinical Trials in Neovascular
   Age-Related Macular Degeneration in the United States
SO AMERICAN JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
ID CARE; PREVALENCE
AB PURPOSE: To identify geographic and socioeconomic variables predictive of residential proximity to neovas-cular age-related macular degeneration (nAMD) clinical trial locations.
   DESIGN: Retrospective, cross-sectional study.
   METHODS: Census tract-level data from public datasets and trial-level data from ClinicalTrials.gov were analyzed. We calculated the driving distance (> 60 miles) and time (> 60 minutes) from the population-weighted US census tract centroid to the nearest clinical trial site.
   RESULTS: We identified 42 trials studying nAMD across 829 unique clinical trial sites in the United States. In a multivariable model, driving distance > 60 miles had a significant association with rural location (adjusted odds ratio [aOR] 5.54; 95% confidence interval [CI] 3.86-7.96, P < .0001) and with Midwest (aOR 2.30; 95% CI 1.21-4.38, P = .01) and South (aOR 2.43; 95% CI 1.21-4.91, P = .01) as compared to the Northeast region, and with some college or an associate's degree, as compared to a bachelor's degree (aOR 1.02; 95% CI 1.01-1.04, P = .0007, and aOR 1.05; 95% CI 1.00-1.10, P = .04, respectively). Lower odds of traveling > 60 miles to the nearest nAMD trial site were associated with cen-sus tracts with a higher percentage of blacks (aOR 0.98; 95% CI 0.97-0.99, P < .0001), Hispanics (aOR 0.97; 95% CI 0.95-0.99, P = .002), and Asians (aOR 0.90; 95% CI 0.88-0.93, P < .0001), as compared to whites, and with a lower percentage of the population < 200% of the federal poverty level. Similar predictors were found in time traveled > 60 minutes.
   CONCLUSIONS: There are geographic access disparities of clinical trial sites for nAMD in the United States. (C) 2021 Elsevier Inc. All rights reserved.
C1 Thomas Jefferson Univ, Wills Eye Hosp, Mid Atlantic Retina, Philadelphia, PA 19107 USA.
   Wills Eye Hosp & Res Inst, Biostat Consulting Core, Vickie & Jack Farber Vis Res Ctr, Philadelphia, PA USA.
C3 Jefferson University; Jefferson University
RP Yonekawa, Y (通讯作者)，Thomas Jefferson Univ, Wills Eye Hosp, Mid Atlantic Retina, Ophthalmol, 840 Walnut St,Ste 1020, Philadelphia, PA 19107 USA.
EM yonekawa@gmail.com
OI Shields, Charlotte/0000-0002-3497-6541; Hinkle,
   John/0000-0001-5333-2664; Ho, Allen/0000-0003-3921-608X; Gopal,
   Anand/0000-0002-5386-5396; Parikh, Devayu/0000-0003-4345-6262
FU J. Arch McNamara Memorial Fund; Wills Eye Foundation, Philadelphia,
   Pennsylvania, USA; Biostatistics Consulting Core, Vickie and Jack Farber
   Vision Research Center, Wills Eye Hospital
FX Financial support includes funding from the J. Arch McNamara Memorial
   Fund, Wills Eye Foundation, Philadelphia, Pennsylvania, USA. The sponsor
   or funding organization had no role in the design or conduct of this
   research. Financial Disclosures: Rebecca Soares reports grant from Jazz
   Pharmaceuticals (Dubland, Ireland). Allen Ho reports he is a consultant
   and/or has grants from for Adverum (Redwood City, California, USA),
   Chengdu Kanghong Biotechnology (Chengdu, China), Genentech (San
   Francisco, California, USA), Novartis (Cambridge, Massachusetts, USA),
   Regeneron (Tarrytown, New York, USA), and Regenxbio (Rockville,
   Maryland, USA). Carl Regillo discloses he is consultant and/or has
   grants from Genentech (San Francisco, California, USA), Novartis
   (Cambridge, Massachusetts, USA), Allergan (Westport, Ireland), NGM (San
   Francisco, California, USA), Annexon (San Francisco, California, USA),
   Adverum (Redwood City, California, USA), Iveric (Cranbury, New Jersey,
   USA), Regeneron (Tarrytown, New York, USA), Apellis (Waltham,
   Massachusetts, USA), and Regenxbio (Rockville, Maryland, USA). Julia
   Haller reports financial relationships with Bristol Myers Squibb (New
   York, New York, USA), Celgene (Summit, New Jersey, USA), Alcon (Geneva,
   Switzerland), Aura Bioscience (Cambridge, Massachusetts, USA), Janssen
   (Beerse, Belgium), KalVista (Cambridge, Massachusetts, USA), Lowy
   Medical Research Institute (New York, New York, USA), Merck (Lebanon,
   New Jersey, USA), Novartis (Basel, Switzerland), Spark Therapeutics
   (Philadelphia, Pennsylvania, USA), Bionic Sight (New York, New York,
   USA), and Regeneron (Tarrytown, New York, USA). Yoshihiro Yonekawa
   discloses that he is a consultant for Alcon (Geneva, Switzerland),
   Alimera (Alpharetta, Georgia, USA), Allergan (Dublin, Ireland), and
   Genentech (San Francisco, California, USA). There are no other financial
   disclosures. All authors attest that they meet the current ICMJE
   criteria for authorship..; The authors acknowledge the support of the
   Biostatistics Consulting Core, Vickie and Jack Farber Vision Research
   Center, Wills Eye Hospital.
CR [Anonymous], 2019, AGE RELATED MACULAR
   [Anonymous], 2016, NIH POL DISS NIH FUN
   Bruner DW, 2015, INT J RADIAT ONCOL, V93, P702, DOI 10.1016/j.ijrobp.2015.06.041
   Chino Fumiko, 2019, Am Soc Clin Oncol Educ Book, V39, P11, DOI 10.1200/EDBK_100019
   Clark Luther T, 2019, Curr Probl Cardiol, V44, P148, DOI 10.1016/j.cpcardiol.2018.11.002
   Dombernowsky T, 2019, TRIALS, V20, DOI 10.1186/s13063-019-3790-9
   Downing NS, 2016, TRIALS, V17, DOI 10.1186/s13063-016-1322-4
   Feyman Y, 2020, JAMA NETW OPEN, V3, DOI 10.1001/jamanetworkopen.2020.0172
   Finger RP, 2017, CLIN EXP OPHTHALMOL, V45, P143, DOI 10.1111/ceo.12804
   Gehring Marta, 2013, BMJ Open, V3, pe002957, DOI 10.1136/bmjopen-2013-002957
   Gower EW, 2017, AM J OPHTHALMOL, V184, P157, DOI 10.1016/j.ajo.2017.10.010
   Hale NL, 2010, J COMMUN HEALTH, V35, P365, DOI 10.1007/s10900-010-9259-0
   Kaiser PK, 2013, OPHTHALMOLOGY, V120, pS11, DOI 10.1016/j.ophtha.2013.01.061
   Kilmer G, 2010, J RURAL HEALTH, V26, P30, DOI 10.1111/j.1748-0361.2009.00262.x
   Klein R, 2011, ARCH OPHTHALMOL-CHIC, V129, P75, DOI 10.1001/archophthalmol.2010.318
   Murthy VH, 2004, JAMA-J AM MED ASSOC, V291, P2720, DOI 10.1001/jama.291.22.2720
   National Institutes of Health Department of Health and Human Services, 2016, Fed Regist, V81, P64981
   Obeid A, 2018, JAMA OPHTHALMOL, V136, P1251, DOI 10.1001/jamaophthalmol.2018.3578
   Patnaik JL, 2019, OPHTHALMOL RETINA, V3, P336, DOI 10.1016/j.oret.2018.11.004
   Soares RR, 2021, OPHTHALMOL RETINA, V5, P879, DOI 10.1016/j.oret.2020.12.006
   VanderBeek BL, 2011, AM J OPHTHALMOL, V152, P273, DOI 10.1016/j.ajo.2011.02.004
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
   Zhang XZ, 2012, AM J OPHTHALMOL, V154, pS53, DOI 10.1016/j.ajo.2011.08.045
   Zou MJ, 2021, ACTA OPHTHALMOL, V99, pE330, DOI 10.1111/aos.14589
NR 24
TC 3
Z9 3
U1 1
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 0002-9394
EI 1879-1891
J9 AM J OPHTHALMOL
JI Am. J. Ophthalmol.
PD SEP
PY 2021
VL 229
BP 160
EP 168
DI 10.1016/j.ajo.2021.04.001
EA JUN 2021
PG 9
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA WK0YU
UT WOS:000709461500019
PM 33848533
DA 2022-11-30
ER

PT J
AU Tozer, K
   Roller, AB
   Chong, LP
   Sadda, S
   Folk, JC
   Mahajan, VB
   Russell, SR
   Boldt, HC
   Sohn, EH
AF Tozer, Kevin
   Roller, A. Brock
   Chong, Lawrence P.
   Sadda, SriniVas
   Folk, James C.
   Mahajan, Vinit B.
   Russell, Stephen R.
   Boldt, H. Culver
   Sohn, Elliott H.
TI Combination Therapy for Neovascular Age-related Macular Degeneration
   Refractory to Anti-Vascular Endothelial Growth Factor Agents
SO OPHTHALMOLOGY
LA English
DT Article
ID VERTEPORFIN PHOTODYNAMIC THERAPY; INTRAVITREAL BEVACIZUMAB; CHOROIDAL
   NEOVASCULARIZATION; RANIBIZUMAB; VEGF; TRIAL; MACULOPATHY; SECONDARY;
   KINASE; CELLS
AB Objective: To examine the outcomes of combination antievascular endothelial growth factor (VEGF) and photodynamic therapy (PDT) for the treatment of neovascular age-related macular degeneration (AMD) refractory to anti-VEGF monotherapy.
   Design: Retrospective, interventional case series.
   Participants: Twenty-six eyes of 26 patients treated with anti-VEGF monotherapy for neovascular AMD with persistent subretinal or intraretinal fluid after at least 3 anti-VEGF injections in the 7 months before combination treatment.
   Intervention: Combination anti-VEGF treatment and PDT.
   Main Outcome Measures: Visual acuity at 1 or 2, 3, and 6 months and central retinal thickness at 1 or 2, 3, and 6 months. Secondary outcome measures were change in number of fluid-free visits and interval between treatments in the 7 months before and 6 months after combination therapy.
   Results: Statistically significant improvements in logarithm of the minimum angle of resolution visual acuities were present at 1 month (P = 0.01) and 3 months (P = 0.01). Significant decreases in central subfield retinal thickness on optic coherence tomography (OCT) were seen at 1 month (P = 4 x 10(-5)), 3 months (P = 3 x 10(-4)), and 6 months (P = 4 x 10(-5)) as compared with precombination treatment OCT scans. The percentage of patient visits with no subretinal fluid increased from 0.5% to 41% after the initiation of combination therapy (P = 1 x 10(-5)). The interval between treatments increased from once every 1.6 months in the 7 months before combination treatment to once every 2.7 months in the 6 months after combination treatment (P = 0.002). No ocular complications attributable to PDT were seen.
   Conclusions: Rescue therapy with the combination of anti-VEGF and PDT in eyes that have failed anti-VEGF monotherapy resulted in a mean improvement in vision, a decreased central subfield retinal thickness, and an increase in fluid-free intervals.
C1 [Tozer, Kevin; Chong, Lawrence P.; Sadda, SriniVas] Univ So Calif, Keck Sch Med, Doheny Eye Inst, Los Angeles, CA 90033 USA.
   [Tozer, Kevin; Chong, Lawrence P.; Sadda, SriniVas] Univ So Calif, Keck Sch Med, Dept Ophthalmol, Los Angeles, CA 90033 USA.
   [Tozer, Kevin; Chong, Lawrence P.] VMR Inst, Huntington Beach, CA 92647 USA.
   [Roller, A. Brock; Folk, James C.; Mahajan, Vinit B.; Russell, Stephen R.; Boldt, H. Culver; Sohn, Elliott H.] Univ Iowa, Dept Ophthalmol & Visual Sci, Carver Coll Med, Iowa City, IA USA.
C3 Doheny Eye Institute; University of Southern California; University of
   Southern California; University of Iowa
RP Chong, LP (通讯作者)，VMR Inst, 7677 Ctr Ave,Suite 400, Huntington Beach, CA 92647 USA.
EM lchong@usc.edu
OI Mahajan, Vinit/0000-0003-1886-1741; Sohn, Elliott/0000-0002-3778-9362;
   Folk, James/0000-0002-6271-2906; Boldt, H. Culver/0000-0002-7292-2093;
   Russell, Stephen/0000-0003-3776-1367
FU Research to Prevent Blindness, Inc, New York, New York; National
   Institutes of Health, Bethesda, Maryland [EY03040]; National Institutes
   of Health [K08EY020530]; Research to Prevent Blindness, Inc.; NATIONAL
   EYE INSTITUTE [K08EY015237, K08EY020530, P30EY003040] Funding Source:
   NIH RePORTER
FX Supported by a Medical Student Fellowship from Research to Prevent
   Blindness, Inc, New York, New York; the National Institutes of Health,
   Bethesda, Maryland (grant no.: EY03040). James C. Folk is the Judith
   (Gardner) and Donald H. Beisner, M.D., Professor of Vitreoretinal
   Diseases and Surgery at The University of Iowa. Vinit B. Mahajan is
   supported by the National Institutes of Health (grant no.: K08EY020530)
   and by Research to Prevent Blindness, Inc. The funding organizations had
   no role in the design or conduct of this research.
CR Abedi H, 1997, J BIOL CHEM, V272, P15442, DOI 10.1074/jbc.272.24.15442
   Antoszyk AN, 2008, AM J OPHTHALMOL, V145, P862, DOI 10.1016/j.ajo.2007.12.029
   Bakri SJ, 2009, RETINA-J RET VIT DIS, V29, P573, DOI 10.1097/IAE.0b013e3181a46a8a
   Benjamin LE, 1998, DEVELOPMENT, V125, P1591
   Bressler NM, 1999, ARCH OPHTHALMOL-CHIC, V117, P1329
   Brown DM, 2013, OPHTHALMOLOGY, V120, P349, DOI 10.1016/j.ophtha.2012.08.008
   Brown DM, 2009, OPHTHALMOLOGY, V116, P57, DOI 10.1016/j.ophtha.2008.10.018
   Dougherty TJ, 1998, JNCI-J NATL CANCER I, V90, P889, DOI 10.1093/jnci/90.12.889
   Ellis LM, 2008, NAT REV CANCER, V8, P579, DOI 10.1038/nrc2403
   FERRIS FL, 1984, ARCH OPHTHALMOL-CHIC, V102, P1640
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P564
   Goff MJ, 2007, RETINA-J RET VIT DIS, V27, P432, DOI 10.1097/IAE.0b013e318042b53f
   Kloos P, 2011, KLIN MONATSBL AUGENH, V228, P340, DOI 10.1055/s-0031-1273230
   Lalwani GA, 2009, AM J OPHTHALMOL, V148, P43, DOI 10.1016/j.ajo.2009.01.024
   Lim JY, 2012, ACTA OPHTHALMOL, V90, P61, DOI 10.1111/j.1755-3768.2009.01841.x
   Martin DF, 2012, OPHTHALMOLOGY, V119, DOI 10.1016/j.ophtha.2012.03.053
   Martin DF, 2011, NEW ENGL J MED, V364, P1897, DOI 10.1056/NEJMoa1102673
   Nguyen QD, 2009, OPHTHALMOLOGY, V116, P2141, DOI 10.1016/j.ophtha.2009.04.030
   Palanker D, 2006, RETINA, V1, P539
   Potter MJ, 2010, BRIT J OPHTHALMOL, V94, P174, DOI 10.1136/bjo.2008.155531
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Rosenfeld PJ, 2011, OPHTHALMOLOGY, V118, P523, DOI 10.1016/j.ophtha.2010.07.011
   Rousseau S, 1997, ONCOGENE, V15, P2169, DOI 10.1038/sj.onc.1201380
   Sacu S, 2009, EYE, V23, P2223, DOI 10.1038/eye.2008.423
   Shima C, 2009, GRAEF ARCH CLIN EXP, V247, P899, DOI 10.1007/s00417-009-1067-9
   Spielberg L, 2010, GRAEF ARCH CLIN EXP, V248, P943, DOI 10.1007/s00417-009-1256-6
   vanderZee R, 1997, CIRCULATION, V95, P1030
NR 27
TC 48
Z9 48
U1 0
U2 13
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0161-6420
EI 1549-4713
J9 OPHTHALMOLOGY
JI Ophthalmology
PD OCT
PY 2013
VL 120
IS 10
BP 2029
EP 2034
DI 10.1016/j.ophtha.2013.03.016
PG 6
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 227CQ
UT WOS:000325086400019
PM 23714319
DA 2022-11-30
ER

PT J
AU Lee, AY
   Kulkarni, M
   Fang, AM
   Edelstein, S
   Osborn, MP
   Brantley, MA
AF Lee, A. Y.
   Kulkarni, M.
   Fang, A. M.
   Edelstein, S.
   Osborn, M. P.
   Brantley, M. A.
TI The effect of genetic variants in SERPING1 on the risk of neovascular
   age-related macular degeneration
SO BRITISH JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
ID MACULOPATHY
AB Purpose Genetic factors influence an individual's risk for developing age-related macular degeneration (AMD), a leading cause of irreversible vision loss. Previous studies investigating the potential association between all AMD subtypes and the SERPING1 gene, which encodes a key regulator of the classic complement pathway, have yielded conflicting results. The purpose of this study is to determine whether variations in SERPING1 are associated with neovascular AMD.
   Methods A total of 556 patients with neovascular AMD and 256 ethnically matched controls were genotyped for polymorphisms in SERPING1. A tagging single nucleotide polymorphism (tSNP) approach was used to cover the SERPING1 gene plus 2 kb on each side, spanning the promoter and the 39 untranslated regions. Ten SNPs with a minor allele frequency of 0.10 were covered by three tSNPs (rs1005510, rs11603020, rs2511989).
   Results SERPING1 SNPs rs1005510 and rs2511989 were significantly associated with neovascular AMD in our cohort, with rs1005510 conferring an adverse risk effect (OR 1.49, 95% CI 1.18 to 1.88) and rs2511989 conferring a protective effect (OR 0.73, 95% CI 0.59 to 0.90). For both tSNPs, logistic regression of individual genotypes demonstrated statistically significant stepwise changes in the risk of developing AMD. Combined analysis of rs1005510 with variants in CFH and HTRA1 confirmed an independent risk effect. The rs11603020 variant had no effect on AMD susceptibility in this study (OR 0.98, 95% CI 0.78 to 1.24).
   Conclusions The SERPING1 gene is comprehensively investigated in this study (using three tSNPs), and its genetic variants are evaluated in the largest neovascular AMD cohort to date. The hypothesis that SERPING1 has a modest effect on the risk of neovascular AMD is supported by our results.
C1 [Lee, A. Y.; Kulkarni, M.; Fang, A. M.; Edelstein, S.; Osborn, M. P.; Brantley, M. A.] Washington Univ, Sch Med, Dept Ophthalmol & Visual Sci, St Louis, MO 63110 USA.
   [Brantley, M. A.] Barnes Retina Inst, St Louis, MO USA.
C3 Washington University (WUSTL); Washington University (WUSTL)
RP Brantley, MA (通讯作者)，Washington Univ, Sch Med, Dept Ophthalmol & Visual Sci, Campus Box 8096,660 S Euclid Ave, St Louis, MO 63110 USA.
EM brantley@vision.wustl.edu
RI Lee, Aaron/AAT-2839-2020
OI Lee, Aaron/0000-0002-7452-1648
FU NIH [T32RR023255, UL1RR024992]; American Geriatrics Society; Carl M. &
   Mildred A. Reeves Foundation; NEI Core Grant [5 P30 EY02687]; Research
   to Prevent Blindness; NATIONAL CENTER FOR RESEARCH RESOURCES
   [T32RR023255, UL1RR024992] Funding Source: NIH RePORTER; NATIONAL EYE
   INSTITUTE [P30EY002687] Funding Source: NIH RePORTER
FX This work was supported by NIH grants T32RR023255 and UL1RR024992 to the
   Washington University School of Medicine (AYL), the Jahnigen Career
   Development Award from the American Geriatrics Society (MAB), the Carl
   M. & Mildred A. Reeves Foundation (MAB), NEI Core Grant 5 P30 EY02687
   and a grant from Research to Prevent Blindness to the Department of
   Ophthalmology and Visual Sciences at Washington University School of
   Medicine.
CR Allikmets R, 2009, LANCET, V374, P875, DOI 10.1016/S0140-6736(09)61618-4
   Barrett JC, 2005, BIOINFORMATICS, V21, P263, DOI 10.1093/bioinformatics/bth457
   BRESSLER NM, 1988, SURV OPHTHALMOL, V32, P375, DOI 10.1016/0039-6257(88)90052-5
   CARTER JG, ACTA OPHTHALMOL, DOI DOI 10.1111/J.1755-3768.2009.01788.X
   Conley YP, 2006, HUM MOL GENET, V15, P3206, DOI 10.1093/hmg/ddl396
   Ennis S, 2008, LANCET, V372, P1828, DOI 10.1016/S0140-6736(08)61348-3
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P564
   Gold B, 2006, NAT GENET, V38, P458, DOI 10.1038/ng1750
   KLEIN R, 1993, AM J EPIDEMIOL, V137, P190, DOI 10.1093/oxfordjournals.aje.a116659
   MULLINS RF, 2009, EXP EYE RES, V30, P1
   Park KH, 2009, MOL VIS, V15, P200
   Scholl HPN, 2007, MOL VIS, V13, P196
   Yates JRW, 2007, NEW ENGL J MED, V357, P553, DOI 10.1056/NEJMoa072618
NR 13
TC 26
Z9 28
U1 0
U2 3
PU BMJ PUBLISHING GROUP
PI LONDON
PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND
SN 0007-1161
EI 1468-2079
J9 BRIT J OPHTHALMOL
JI Br. J. Ophthalmol.
PD JUL
PY 2010
VL 94
IS 7
BP 915
EP 917
DI 10.1136/bjo.2009.172007
PG 3
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 621GR
UT WOS:000279564400021
PM 20606025
OA Green Accepted
DA 2022-11-30
ER

PT J
AU Chen, ER
   Chen, AX
   Greenlee, TE
   Conti, TF
   Briskin, IN
   Urbano, CA
   Kalur, A
   Kaiser, PK
   Singh, RP
AF Chen, Eric R.
   Chen, Andrew X.
   Greenlee, Tyler E.
   Conti, Thais F.
   Briskin, Isaac N.
   Urbano, Catherine A.
   Kalur, Aneesha
   Kaiser, Peter K.
   Singh, Rishi P.
TI Macular thickness fluctuation in neovascular age-related macular
   degeneration treated with anti- vascular endothelial growth factor
SO CANADIAN JOURNAL OF OPHTHALMOLOGY-JOURNAL CANADIEN D OPHTALMOLOGIE
LA English
DT Article
ID OPTICAL COHERENCE TOMOGRAPHY; SUBGROUP ANALYSIS; VISUAL-ACUITY;
   RANIBIZUMAB; MARINA; EYES
AB Objective: To establish whether increased variability in macular thickness in neovascular age-related macular degeneration (nAMD) patients affects visual outcomes in clinical practice Design: Retrospective cohort study Participants: Treatment-naive nAMD patients studied over 24 months Methods: Central subfield thickness (CST) values from optical coherence tomography were collected quarterly from baseline to 24 months, and standard deviations (SDs) were calculated. The relationship was modeled with mixed-effects regression between CST SD and 24-month change in visual acuity (VA). Linear regression modeling determined predictors of CST SD. Results: A total of 422 eyes with nAMD were studied. Baseline and 24-month CST values (mean +/- SD) were 331.2 +/- 97.6 and 253.4 +/- 53.6 mu m (D =-77.8 +/- 104.7 mu m, p < 0.001), with CST SD across 24 months of 42.0 +/- 32.8 mu m. Baseline and 24-month VA were 58.8 +/- 19.2 and 62.4 +/- 20.6 Early Treatment of Diabetic Retinopathy Study letters (D = +3.7 +/- 20.8 letters, p = 0.008). CST SD over 24 months was a statistically significant negative predictor of 24-month change in VA (-15.41 [-20.98,-9.83] letters per 100 mu m, p < 0.001). Quartile analysis of 24-month VA by CST SD showed a +11.2-letter difference between the first and last quartiles (p < 0.001). Baseline CST was a predictor of 24-month CST SD (24.88 [22.69, 27.06] mu m per 100 mu m, p < 0.001). Conclusions: Higher macular thickness fluctuations are related to poorer visual outcomes at 24 months in patients with nAMD treated with anti-vascular endothelial growth factor injections. Macular thickness variability may be an important prognostic factor of visual outcomes in nAMD eyes.
C1 [Chen, Eric R.; Chen, Andrew X.; Urbano, Catherine A.; Kaiser, Peter K.; Singh, Rishi P.] Case Western Reserve Univ, Sch Med, Cleveland, OH USA.
   [Chen, Andrew X.; Greenlee, Tyler E.; Conti, Thais F.; Kalur, Aneesha; Kaiser, Peter K.; Singh, Rishi P.] Cleveland Clin, Cole Eye Inst, Ctr Ophthalm Bioin format, Cleveland, OH USA.
   [Briskin, Isaac N.] Cleveland Clin, Dept Quantitat Hlth Sci, Cleveland, OH USA.
   [Singh, Rishi P.] Cleveland Clin, Cole Eye Inst, 9500 Euclid Ave,I 32, Cleveland Hts, OH 44195 USA.
C3 Case Western Reserve University; Cleveland Clinic Foundation; Cleveland
   Clinic Foundation; Cleveland Clinic Foundation
RP Singh, RP (通讯作者)，Cleveland Clin, Cole Eye Inst, 9500 Euclid Ave,I 32, Cleveland Hts, OH 44195 USA.
EM drrishisingh@gmail.com
OI Conti, Thais/0000-0003-4729-0706; Greenlee, Tyler/0000-0003-0785-9099
FU National Institutes of Health (NIH) Institutional Training T32 Award;
   Research to Prevent Blindness (RPB) Medical Student Eye Research
   Fellowship; Apellis; Graybug
FX Andrew X. Chen: National Institutes of Health (NIH) Institutional
   Training T32 Award (grant) and Research to Prevent Blindness (RPB)
   Medical Student Eye Research Fellowship (grant); Rishi P. Singh:
   Genentech/Roche (personal fees), Alcon/Novartis (personal fees), Apellis
   (grant), Graybug (grant), Zeiss (personal fees), Bausch & Lomb (personal
   fees), Ophthea (personal fees), Regeneron Pharmaceuticals, Inc.
   (personal fees) ; Peter K. Kaiser: Alcon (consultant), Allergan
   (consultant, personal fees), Allegro (consultant), Bayer (consultant,
   personal fees), Genentech (personal fees), Kanghong (personal fees),
   Kodiak (personal fees), Regeneron (consultant, personal fees), and
   Novartis (consultant, personal fees); all other authors: none.
CR Ambati J, 2012, NEURON, V75, P26, DOI 10.1016/j.neuron.2012.06.018
   [Anonymous], 1991, OPHTHALMOLOGY, V98, P786
   Boyer DS, 2007, OPHTHALMOLOGY, V114, P246, DOI 10.1016/j.ophtha.2006.10.045
   Dugel PU, 2020, OPHTHALMOLOGY, V127, P72, DOI 10.1016/j.ophtha.2019.04.017
   Evans RN, 2020, JAMA OPHTHALMOL, V138, P1043, DOI 10.1001/jamaophthalmol.2020.3001
   FERRIS FL, 1983, AM J EPIDEMIOL, V118, P132, DOI 10.1093/oxfordjournals.aje.a113624
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P564
   Gerding H, 2011, GRAEF ARCH CLIN EXP, V249, P653, DOI 10.1007/s00417-011-1636-6
   Gregori NZ, 2010, RETINA-J RET VIT DIS, V30, P1046, DOI 10.1097/IAE.0b013e3181d87e04
   Gupta P, 2013, INVEST OPHTH VIS SCI, V54, P7968, DOI 10.1167/iovs.13-12436
   Hee MR, 1996, OPHTHALMOLOGY, V103, P1260, DOI 10.1016/S0161-6420(96)30512-5
   Holz FG, 2016, BRIT J OPHTHALMOL, V100, P1623, DOI 10.1136/bjophthalmol-2015-308166
   Kaiser PK, 2007, AM J OPHTHALMOL, V144, P850, DOI 10.1016/j.ajo.2007.08.012
   Kaiser PK, 2007, OPHTHALMOLOGY, V114, P1868, DOI 10.1016/j.ophtha.2007.04.030
   Keane PA, 2009, BRIT J OPHTHALMOL, V93, P1461, DOI 10.1136/bjo.2008.155846
   Moutray T, 2008, BRIT J OPHTHALMOL, V92, P361, DOI 10.1136/bjo.2007.123976
   Rosenfeld PJ, 2011, OPHTHALMOLOGY, V118, P523, DOI 10.1016/j.ophtha.2010.07.011
   Singh RP, 2009, BRIT J OPHTHALMOL, V93, P1353, DOI 10.1136/bjo.2008.141879
   Wecker T, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-38934-8
   Ying G-S, 2012, INVEST OPHTHALMOL VI, V53, P3681
NR 20
TC 0
Z9 0
U1 0
U2 0
PU CANADIAN OPHTHAL SOC
PI OTTAWA
PA 1525 CARLING AVE SUITE 610, OTTAWA, ONTARIO K1Z 8R9, CANADA
SN 0008-4182
EI 1715-3360
J9 CAN J OPHTHALMOL
JI Can. J. Opthalmol.-J. Can. Opthalmol.
PD OCT
PY 2022
VL 57
IS 5
BP 350
EP 356
DI 10.1016/j.jcjo.2021.06.004
PG 7
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 5D2BP
UT WOS:000864754300009
PM 34283969
DA 2022-11-30
ER

PT J
AU Tao, Y
   Jonas, JB
AF Tao, Y.
   Jonas, J. B.
TI Refractive error and smoking habits in exudative age-related macular
   degeneration in a hospital-based setting
SO EYE
LA English
DT Article
DE exudative age-related macular degeneration; hyperopia; smoking; macular
   degeneration; visual impairment
ID BLUE-MOUNTAINS EYE; LONG-TERM INCIDENCE; RISK-FACTORS;
   CIGARETTE-SMOKING; MACULOPATHY; PROGRESSION; POPULATION; ROTTERDAM
AB Purpose To assess and compare refractive error and smoking habits in patients with exudative age-related macular degeneration (AMD) in a clinical setting.
   Methods The clinical comparative study included 379 patients (379 eyes) who underwent intravitreal application of an anti-vascular growth factor drug for the treatment of exudative AMD, and 191 patients without exudative macular degeneration and who underwent surgery for age-related cataract. Smoking status was compared with an age-matched control group of the German population described in the census of 2003. The main outcome measures were refractive error, axial length, and data from a questionnaire on smoking habits.
   Results The AMD group compared with the cataract group showed a significantly shorter axial length (23.31 +/- 0.75 vs 24.20 +/- 1.56 mm; P < 0.001) and was significantly more hyperopic (0.65 +/- 2.14 vs -1.71 +/- 4.57 dioptres; P < 0.001). After the exclusion of pseudophakic AMD patients and matching by age and gender, the difference of refractive error and axial length between both groups remained to be statistically significant (P < 0.001). The AMD group and the matched population group did not vary significantly in smoking history (age group: 55-75 years, current smokers: 18.4% vs 16.8% (P = 0.64); former smokers: 23.2% vs 24.9% (P = 0.66); age group > 75 years, current smokers: 6.3% vs 6.4% (P = 0.97); former smokers: 19.7% vs 22.8% (P = 0.25)).
   Conclusions In our setting, an association was found between short axial length and AMD. We were not able to confirm the previously reported link between smoking and AMD. Eye (2010) 24, 648-652; doi:10.1038/eye.2009.160; published online 10 July 2009
C1 [Tao, Y.; Jonas, J. B.] Univ Heidelberg, Med Fac Mannheim, Dept Ophthalmol, Heidelberg, Germany.
   [Tao, Y.] Peking Univ, Peoples Hosp, Dept Ophthalmol, Beijing 100871, Peoples R China.
C3 Ruprecht Karls University Heidelberg; Peking University
RP Jonas, JB (通讯作者)，Univ Augenklin, Dept Ophthalmol, Theodor Kutzer Ufer 1-3, D-68167 Mannheim, Germany.
EM Jost.Jonas@augen.ma.uni-heidelberg.de
OI Tao, Yong/0000-0003-1443-2667
CR Anand R, 2000, OPHTHALMOLOGY, V107, P2224
   Arnarsson A, 2006, AM J OPHTHALMOL, V142, P419, DOI 10.1016/j.ajo.2006.04.015
   Boker T, 1993, Ger J Ophthalmol, V2, P10
   Buch H, 2005, ACTA OPHTHALMOL SCAN, V83, P409, DOI 10.1111/J.1600-0420.2005.00492.x
   Chaine G, 1998, BRIT J OPHTHALMOL, V82, P996, DOI 10.1136/bjo.82.9.996
   Chakravarthy U, 2007, OPHTHALMOLOGY, V114, P1157, DOI 10.1016/j.ophtha.2006.09.022
   Chang MA, 2008, INVEST OPHTH VIS SCI, V49, P2395, DOI 10.1167/iovs.07-1584
   Cong RH, 2008, ANN EPIDEMIOL, V18, P647, DOI 10.1016/j.annepidem.2008.04.002
   HYMAN LG, 1983, AM J EPIDEMIOL, V118, P213, DOI 10.1093/oxfordjournals.aje.a113629
   Ikram MK, 2003, INVEST OPHTH VIS SCI, V44, P3778, DOI 10.1167/iovs.03-0120
   Kawasaki R, 2008, OPHTHALMOLOGY, V115, P1376, DOI 10.1016/j.ophtha.2007.11.015
   Klein R, 1998, AM J EPIDEMIOL, V147, P103
   Klein R, 2008, ARCH OPHTHALMOL-CHIC, V126, P115, DOI 10.1001/archopht.126.1.115
   MALTZMAN BA, 1979, ANN OPHTHALMOL, V11, P1197
   Neuner B, 2007, ANN EPIDEMIOL, V17, P615, DOI 10.1016/j.annepidem.2007.03.005
   SANDBERG MA, 1993, OPHTHALMOLOGY, V100, P1009
   Seddon JM, 2006, ARCH OPHTHALMOL-CHIC, V124, P995, DOI 10.1001/archopht.124.7.995
   Smith W, 1996, ARCH OPHTHALMOL-CHIC, V114, P1518, DOI 10.1001/archopht.1996.01100140716016
   *STAT BUND, 2004, MIK 2003 TAB PRESS
   Tan JSL, 2007, ARCH OPHTHALMOL-CHIC, V125, P1089, DOI 10.1001/archopht.125.8.1089
   Vingerling JR, 1996, ARCH OPHTHALMOL-CHIC, V114, P1193, DOI 10.1001/archopht.1996.01100140393005
   Wang JJ, 2004, CLIN EXP OPHTHALMOL, V32, P255, DOI 10.1111/j.1442-9071.2004.00813.x
   Wang JJ, 1998, INVEST OPHTH VIS SCI, V39, P2167
   Wong TY, 2002, INVEST OPHTH VIS SCI, V43, P2869
   Xu L, 2006, BRIT J OPHTHALMOL, V90, P1087, DOI 10.1136/bjo.2006.096123
NR 25
TC 19
Z9 19
U1 0
U2 2
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 0950-222X
J9 EYE
JI Eye
PD APR
PY 2010
VL 24
IS 4
BP 648
EP 652
DI 10.1038/eye.2009.160
PG 5
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 583SY
UT WOS:000276701300021
PM 19590519
OA Bronze
DA 2022-11-30
ER

PT J
AU Szlyk, JP
   Little, DM
AF Szlyk, Janet P.
   Little, Deborah M.
TI An fMRI Study of Word-Level Recognition and Processing in Patients with
   Age-Related Macular Degeneration
SO INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE
LA English
DT Article
ID 10-YEAR INCIDENCE; CORTEX; EYE; MACULOPATHY; ACTIVATION; DYSTROPHY;
   SCOTOMAS; SACCADES; LOCUS
AB PURPOSE. To compare the cortical networks that underlie word recognition and processing in patients with age-related macular degeneration (AMD) with those of normally sighted control subjects using functional magnetic resonance imaging (fMRI).
   METHODS. Six patients with bilateral geographic atrophy who were using an eccentrically located preferred retinal location were recruited. Six younger and six older control subjects were also recruited. Patients and control subjects were asked to perform a three-letter (3Let) and a six-letter (6Let) word recognition task during fMRI on a 3.0-Tesla MRI scanner. The fMRI tasks were two-condition, blocked-design paradigms in which central fixation was alternated with a word recognition task requiring a forced, two-choice reaction time living/nonliving judgment.
   RESULTS. When contrasted with controls, patients showed increased brain activation in a widespread cortical network that included regions identified as the frontal eye fields, both superior and inferior parietal lobules, and regions within the prefrontal cortex. Peak activation within these prefrontal regions was correlated with increased accuracy (r = 0.875, P = 0.024; r = 0.848, P = 0.033) and decreased reaction times (r = -0.861, P = 0.028; r = -0.842, P = 0.036) for the 3Let task within the group of patients. Correlations between peak activity and behavioral performance were also found in both the right (-0.818, P = 0.047) and left (r = -0.839, P = 0.037) superior parietal lobules for the 3Let task. Similar relationships were found for the 6Let task.
   CONCLUSIONS. Patients with AMD demonstrate increased prefrontal and parietal activation compared with controls. The authors posit that these increases reflect increased top-down involvement in basic word recognition to compensate for decreased sensory function. ( Invest Ophthalmol Vis Sci. 2009;50:4487-4495) DOI:10.1167/iovs.08-2258
C1 [Szlyk, Janet P.] Jesse Brown VAMC, Res & Dev Serv, Chicago, IL 60612 USA.
   [Szlyk, Janet P.] Chicago Lighthouse People Who Are Blind Visually, Chicago, IL USA.
   [Szlyk, Janet P.; Little, Deborah M.] Univ Illinois, Coll Med, Dept Ophthalmol & Visual Sci, Chicago, IL USA.
   [Little, Deborah M.] Univ Illinois, Coll Med, Dept Neurol & Rehabil, Chicago, IL USA.
   [Little, Deborah M.] Univ Illinois, Coll Med, Dept Anat & Cell Biol, Chicago, IL USA.
   [Little, Deborah M.] Univ Illinois, Coll Med, Dept Psychol, Chicago, IL USA.
   [Little, Deborah M.] Univ Illinois, Coll Med, Ctr Stroke Res, Chicago, IL USA.
   [Little, Deborah M.] Univ Illinois, Coll Med, Ctr Cognit Med, Chicago, IL USA.
C3 University of Illinois System; University of Illinois Chicago;
   University of Illinois Chicago Hospital; University of Illinois System;
   University of Illinois Chicago; University of Illinois Chicago Hospital;
   University of Illinois System; University of Illinois Chicago;
   University of Illinois Chicago Hospital; University of Illinois System;
   University of Illinois Chicago; University of Illinois Chicago Hospital;
   University of Illinois System; University of Illinois Chicago;
   University of Illinois Chicago Hospital; University of Illinois System;
   University of Illinois Chicago; University of Illinois Chicago Hospital
RP Szlyk, JP (通讯作者)，Jesse Brown VAMC, Res & Dev Serv, MC-151,820 S Damen Ave, Chicago, IL 60612 USA.
EM janet.szlyk@chicagolighthouse.org
FU Department of Veterans Affairs Rehabilitation Research and Development
   Service (Washington, DC); Washington Square Health Foundation (Chicago,
   Illinois); Cless Family Foundation (Northbrook, Illinois); Research to
   Prevent Blindness, Inc. ( New York, New York); National Eye Institute
   [EY01792]; NATIONAL EYE INSTITUTE [P30EY001792] Funding Source: NIH
   RePORTER
FX Supported by grants from the Department of Veterans Affairs
   Rehabilitation Research and Development Service (Washington, DC),
   Washington Square Health Foundation (Chicago, Illinois), Cless Family
   Foundation (Northbrook, Illinois), and Research to Prevent Blindness,
   Inc. ( New York, New York), and by National Eye Institute Core Grant
   EY01792.
CR Baker CI, 2005, J NEUROSCI, V25, P614, DOI 10.1523/JNEUROSCI.3476-04.2005
   BRESSLER NM, 1988, SURV OPHTHALMOL, V32, P375, DOI 10.1016/0039-6257(88)90052-5
   Cohen MS, 1997, NEUROIMAGE, V6, P93, DOI 10.1006/nimg.1997.0278
   Cox RW, 1996, COMPUT BIOMED RES, V29, P162, DOI 10.1006/cbmr.1996.0014
   Crossland MD, 2005, OPHTHALMOLOGY, V112, P1579, DOI 10.1016/j.ophtha.2005.03.027
   Dassonville P, 1997, P NATL ACAD SCI USA, V94, P14015, DOI 10.1073/pnas.94.25.14015
   DeYoe EA, 1996, P NATL ACAD SCI USA, V93, P2382, DOI 10.1073/pnas.93.6.2382
   Eddy WF, 1996, P COMP STAT, P39
   Fletcher DC, 1999, J REHABIL RES DEV, V36, P356
   FORMAN SD, 1995, MAGNET RESON MED, V33, P636, DOI 10.1002/mrm.1910330508
   Frederikse ME, 1999, CEREB CORTEX, V9, P896, DOI 10.1093/cercor/9.8.896
   Genovese CR, 2002, NEUROIMAGE, V15, P870, DOI 10.1006/nimg.2001.1037
   Grosbras MH, 2001, CEREB CORTEX, V11, P936, DOI 10.1093/cercor/11.10.936
   Klein R, 2002, OPHTHALMOLOGY, V109, P1767, DOI 10.1016/S0161-6420(02)01146-6
   Klein R, 2002, AM J EPIDEMIOL, V156, P589, DOI 10.1093/aje/kwf092
   Little DM, 2008, INVEST OPHTH VIS SCI, V49, P1728, DOI 10.1167/iovs.07-0372
   Luna B, 1998, CEREB CORTEX, V8, P40, DOI 10.1093/cercor/8.1.40
   Masuda Y, 2008, CEREB CORTEX, V18, P2483, DOI 10.1093/cercor/bhm256
   Seiple W, 2006, INVEST OPHTH VIS SCI, V47, P1703, DOI 10.1167/iovs.05-0659
   Seiple W, 2005, INVEST OPHTH VIS SCI, V46, P2886, DOI 10.1167/iovs.04-1296
   Stelmack JA, 2004, INVEST OPHTH VIS SCI, V45, P3919, DOI 10.1167/iovs.04-0208
   Sunness JS, 2004, OPHTHALMOLOGY, V111, P1595, DOI 10.1016/j.ophtha.2003.12.050
   Szlyk JP, 2005, DOC OPHTHALMOL, V110, P181, DOI 10.1007/s10633-005-4313-4
   Szlyk JP, 2005, RETINA-J RET VIT DIS, V25, P489, DOI 10.1097/00006982-200506000-00015
   Szlyk JP, 2001, OPHTHALMOLOGY, V108, P65, DOI 10.1016/S0161-6420(00)00413-9
   Szlyk JP, 2004, J VISUAL IMPAIR BLIN, V98, P261
   Thulborn KR, 1999, MAGNET RESON MED, V41, P1039, DOI 10.1002/(SICI)1522-2594(199905)41:5<1039::AID-MRM24>3.3.CO;2-E
NR 27
TC 20
Z9 20
U1 0
U2 1
PU ASSOC RESEARCH VISION OPHTHALMOLOGY INC
PI ROCKVILLE
PA 12300 TWINBROOK PARKWAY, ROCKVILLE, MD 20852-1606 USA
SN 0146-0404
J9 INVEST OPHTH VIS SCI
JI Invest. Ophthalmol. Vis. Sci.
PD SEP
PY 2009
VL 50
IS 9
BP 4487
EP 4495
DI 10.1167/iovs.08-2258
PG 9
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 489RB
UT WOS:000269438400059
PM 19387076
DA 2022-11-30
ER

PT J
AU Schouten, JSAG
   La Heij, EC
   Webers, CAB
   Lundqvist, IJ
   Hendrikse, F
AF Schouten, Jan S. A. G.
   La Heij, Ellen C.
   Webers, Carroll A. B.
   Lundqvist, Igor J.
   Hendrikse, Fred
TI A systematic review on the effect of bevacizumab in exudative
   age-related macular degeneration
SO GRAEFES ARCHIVE FOR CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY
LA English
DT Review
DE Systematic review; Bevacizumab; Exudative macular degeneration; Visual
   acuity; Retinal thickness
ID CHOROIDAL NEOVASCULARIZATION SECONDARY; INTRAVITREAL BEVACIZUMAB;
   PHOTODYNAMIC THERAPY; AVASTIN TREATMENT; VISUAL-ACUITY; RANIBIZUMAB;
   VERTEPORFIN; PHARMACOKINETICS; PEGAPTANIB; 6-MONTH
AB Aim To provide evidence for the effect of bevacizumab on visual acuity (VA) and central retinal thickness (CRT) in exudative age-related macular degeneration
   Methods A systematic review of all articles of bevacizumab for exudative AMD was conducted. Articles published up to March 2008 were identified in Medline, Embase, the Cochrane Controlled Trials Register and references from included articles. Search terms were "Bevacizumab or Avastin" and "Macula* or ARMD or AMD or intra(-) vitreal or intra(-)vitreous". Three observers participated in the data retrieval and assignment of the quality scores.
   Results A total of 561 articles were retrieved. Three randomised controlled trials (RCT) and 23 before-and-after studies of patients (n=1,435) who had received bevacizumab were published. Inclusion criteria varied. Lack of masking was the main methodological shortcoming. These RCTs showed that bevacizumab is more effective than PDT. Bevacizumab was given intravenously or as intra-vitreal injection. The latter was given once, or repeatedly every 4 weeks, and with or without additional injection when a recurrence occurred, mostly based on visual acuity and/or findings from optical coherence tomography. After intravenous administration, the weighted mean change in VA was +12.8 ETDRS letters ( range +11 to +14) and the weighted mean change for CRT was - 129 mu m (range - 100 to -202). For the 23 studies with intravitreal injections, the change in VA was +8.6 letters ( range +2 to +26) and the change in CRTwas -90 mu m ( range -46 to -190). The incidence of adverse events was low. The change in VA was 2.7 letters higher for studies with a higher quality vs lower quality.
   Conclusion Visual acuity improves and central retinal thickness decreases in patients with exudative AMD after bevacizumab. There is no reasonable doubt that this is caused by bevacizumab. It is likely that a randomised controlled trial will show that bevacizumab is equivalent in effect to ranibizumab, which showed a change in ETDRS of +5.9 letters for occult or minimally classic CNV and +9.8 letters for classic CNV after three monthly injections in two large RCTs.
C1 [Schouten, Jan S. A. G.; La Heij, Ellen C.; Webers, Carroll A. B.; Lundqvist, Igor J.; Hendrikse, Fred] Maastricht Univ Hosp, Dept Ophthalmol, NL-6202 AZ Maastricht, Netherlands.
C3 Maastricht University; Maastricht University Medical Centre (MUMC)
RP Schouten, JSAG (通讯作者)，Maastricht Univ Hosp, Dept Ophthalmol, POB 5800, NL-6202 AZ Maastricht, Netherlands.
EM J.Schouten@MUMC.nl; ellen.laheij@mumc.nl
RI Webers, Carroll A.B./D-1130-2010; Schouten, Johannes S.A.G./M-9376-2016
OI Schouten, Johannes S.A.G./0000-0001-6495-7758
CR Aggio FB, 2007, GRAEF ARCH CLIN EXP, V245, P215, DOI 10.1007/s00417-006-0412-5
   Aisenbrey S, 2007, GRAEF ARCH CLIN EXP, V245, P941, DOI 10.1007/s00417-006-0471-7
   Avery RL, 2006, OPHTHALMOLOGY, V113, P363, DOI 10.1016/j.ophtha.2005.11.019
   Bakri SJ, 2007, OPHTHALMOLOGY, V114, P2179, DOI 10.1016/j.ophtha.2007.09.012
   Bakri SJ, 2007, OPHTHALMOLOGY, V114, P855, DOI 10.1016/j.ophtha.2007.01.017
   Bashshur ZF, 2008, AM J OPHTHALMOL, V145, P249, DOI 10.1016/j.ajo.2007.09.031
   Bashshur ZF, 2007, ARCH OPHTHALMOL-CHIC, V125, P1357, DOI 10.1001/archopht.125.10.1357
   Bashshur ZF, 2006, AM J OPHTHALMOL, V142, P1, DOI 10.1016/j.ajo.2006.02.037
   Bolz M, 2007, BRIT J OPHTHALMOL, V91, P785, DOI 10.1136/bjo.2006.102467
   Bressler NM, 2003, ARCH OPHTHALMOL-CHIC, V121, P1621
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Brown MM, 2006, CURR OPIN OPHTHALMOL, V17, P257
   Carvounis PE, 2007, AM J OPHTHALMOL, V143, P504, DOI 10.1016/j.ajo.2006.11.028
   Chakravarthy U, 2006, OPHTHALMOLOGY, V113, P1508, DOI 10.1016/j.ophtha.2006.02.064
   Chen CY, 2007, AM J OPHTHALMOL, V143, P510, DOI 10.1016/j.ajo.2006.10.004
   Chen E, 2007, RETINA-J RET VIT DIS, V27, P445, DOI 10.1097/01.iae.0000249574.89437.40
   Cleary CA, 2008, EYE, V22, P82, DOI 10.1038/sj.eye.6702936
   Emerson MV, 2007, RETINA-J RET VIT DIS, V27, P439, DOI 10.1097/IAE.0b013e31804b3e15
   Falkenstein IA, 2008, OPHTHALMOLOGY, V115, P319, DOI 10.1016/j.ophtha.2007.05.028
   Falkenstein IA, 2007, RETINA-J RET VIT DIS, V27, P701, DOI 10.1097/IAE.0b013e3180654240
   Fung AE, 2006, BRIT J OPHTHALMOL, V90, P1344, DOI 10.1136/bjo.2006.099598
   Fung AE, 2007, AM J OPHTHALMOL, V143, P566, DOI 10.1016/j.ajo.2007.01.028
   Geitzenauer W, 2006, KLIN MONATSBL AUGENH, V223, P822, DOI 10.1055/s-2006-926875
   Gelisken F, 2001, AM J OPHTHALMOL, V131, P518, DOI 10.1016/S0002-9394(00)00813-8
   Giansanti F, 2007, EUR J OPHTHALMOL, V17, P230, DOI 10.1177/112067210701700213
   Gragoudas ES, 2004, NEW ENGL J MED, V351, P2805, DOI 10.1056/NEJMoa042760
   Hahn R, 2007, OPHTHALMOLOGE, V104, P588, DOI 10.1007/s00347-007-1547-4
   Kliffen M, 1997, BRIT J OPHTHALMOL, V81, P154, DOI 10.1136/bjo.81.2.154
   Ladewig MS, 2006, OPHTHALMOLOGE, V103, P463, DOI 10.1007/s00347-006-1352-5
   Lazic R, 2007, COLLEGIUM ANTROPOL, V31, P77
   Lazic R, 2007, OPHTHALMOLOGY, V114, P1179, DOI 10.1016/j.ophtha.2007.03.006
   Lazic R, 2007, GRAEF ARCH CLIN EXP, V245, P68, DOI 10.1007/s00417-006-0466-4
   Madhusudhana KC, 2007, BRIT J OPHTHALMOL, V91, P1716, DOI 10.1136/bjo.2006.108639
   MARIN MLA, 2006, GRAEFES ARCH CLIN EX, V245, P651, DOI DOI 10.1007/S00417-006-0411-6
   Michels S, 2005, OPHTHALMOLOGY, V112, P1035, DOI 10.1016/j.ophtha.2005.02.007
   Moshfeghi AA, 2006, OPHTHALMOLOGY, V113, P2002, DOI 10.1016/j.ophtha.2006.05.070
   Mulcahy MF, 2005, EXPERT OPIN BIOL TH, V5, P997, DOI 10.1517/14712598.5.7.997
   Rich RM, 2006, RETINA-J RET VIT DIS, V26, P495, DOI 10.1097/01.iae.0000225766.75009.3a
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Sackett DL, 1991, CLIN EPIDEMIOLOGY BA
   Spaide RF, 2006, RETINA-J RET VIT DIS, V26, P383, DOI 10.1097/00006982-200604000-00001
   Stifter E, 2007, AM J OPHTHALMOL, V144, P886, DOI 10.1016/j.ajo.2007.07.034
   SUND NJ, 2007, INVEST OPHTHALMOL VI, V48
   Takeda AL, 2007, BRIT J OPHTHALMOL, V91, P1177, DOI 10.1136/bjo.2007.118562
   Verhagen AP, 1998, J CLIN EPIDEMIOL, V51, P1235, DOI 10.1016/S0895-4356(98)00131-0
   Wu L, 2008, GRAEF ARCH CLIN EXP, V246, P81, DOI 10.1007/s00417-007-0660-z
   Yang JC, 2003, NEW ENGL J MED, V349, P427, DOI 10.1056/NEJMoa021491
   Yoganathan P, 2006, RETINA-J RET VIT DIS, V26, P994, DOI 10.1097/01.iae.0000244380.34082.67
NR 48
TC 81
Z9 85
U1 0
U2 20
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0721-832X
EI 1435-702X
J9 GRAEF ARCH CLIN EXP
JI Graefes Arch. Clin. Exp. Ophthalmol.
PD JAN
PY 2009
VL 247
IS 1
BP 1
EP 11
DI 10.1007/s00417-008-0952-y
PG 11
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 384ND
UT WOS:000261750600001
PM 18843500
OA hybrid
DA 2022-11-30
ER

PT J
AU Ricci, F
   Staurenghi, G
   Lepre, T
   Missiroli, F
   Zampatti, S
   Cascella, R
   Borgiani, P
   Marsella, LT
   Eandi, CM
   Cusumano, A
   Novelli, G
   Giardina, E
AF Ricci, Federico
   Staurenghi, Giovanni
   Lepre, Tiziana
   Missiroli, Filippo
   Zampatti, Stefania
   Cascella, Raffaella
   Borgiani, Paola
   Marsella, Luigi Tonino
   Eandi, Chiara Maria
   Cusumano, Andrea
   Novelli, Giuseppe
   Giardina, Emiliano
TI Haplotypes in IL-8 Gene Are Associated to Age-Related Macular
   Degeneration: A Case-Control Study
SO PLOS ONE
LA English
DT Article
ID HUMAN INTERLEUKIN-8 RECEPTOR; C-REACTIVE PROTEIN; IN-VITRO; RISK;
   PROGRESSION; MODELS; CANCER; POLYMORPHISMS; INFLAMMATION; POPULATION
AB Background: Age-related macular degeneration (AMD) is the main cause of blindness in the developed world. The etiology of AMD is multifactorial due to the interaction between genetic and environmental factors. IL-8 has a role in inflammation and angiogenesis; we report the genetic characterization of IL-8 allele architecture and evaluate the role of SNPs or haplotypes in the susceptibility to wet AMD, case-control study.
   Methods: Case-control study including 721 AMD patients and 660 controls becoming from Italian population. Genotyping was carried out by Real Time-PCR. Differences in the frequencies were estimated by the chi-square test. Direct sequencing was carried out by capillary electrophoresis trough ABI3130xl.
   Results: rs2227306 showed a p-value of 4.15*10(-5) and an Odds Ratio (OR) for T allele of 1.39 [1.19-1.62]. After these positive results, we sequenced the entire IL-8 regulatory and coding regions of 60 patients and 30 controls stratified for their genotype at rs2227306. We defined two different haplotypes involving rs4073 (A/T), rs2227306 (C/T), rs2227346 (C/T) and rs1126647 (A/T): A-T-T-T (p-value: 2.08*10(-9); OR: 1.68 [1.43-1.97]) and T-C-C-A (p-value: 7.07*10(-11); OR: 0.60 [0.51-0.70]). To further investigate a potential functional role of associated haplotypes, we performed an expression study on RNA extracted from whole blood of 75 donors to verify a possible direct correlation between haplotype and gene expression, failing to reveal significant differences.
   Conclusions: These results suggest a possible secondary role of IL-8 gene in the development of the disease. This paper outlines the importance of association between inflammation and AMD. Moreover IL-8 is a new susceptibility genomic biomarker of AMD.
C1 [Ricci, Federico; Missiroli, Filippo; Cusumano, Andrea] Policlin Tor Vergata, UOSD Patol Retin Fdn, Rome, Italy.
   [Staurenghi, Giovanni] Univ Milan, Sacco Hosp, Eye Clin, Dept Clin Sci Luigi Sacco, Milan, Italy.
   [Lepre, Tiziana; Zampatti, Stefania; Cascella, Raffaella; Borgiani, Paola; Marsella, Luigi Tonino; Giardina, Emiliano] Univ Roma Tor Vergata, Sch Med, Ctr Excellence Genom Risk Assessment Multifactori, Dept Biomed & Prevent, Rome, Italy.
   [Eandi, Chiara Maria] Univ Turin, Eye Clin, Dept Clin Physiopathol, Turin, Italy.
   [Novelli, Giuseppe] Natl Agcy Evaluat Univ & Res ANVUR, Rome, Italy.
   [Novelli, Giuseppe] S Pietro Fatebenefratelli Hosp, Rome, Italy.
C3 University of Rome Tor Vergata; Policlin Tor Vergata; University of
   Milan; Luigi Sacco Hospital; University of Rome Tor Vergata; University
   of Turin
RP Giardina, E (通讯作者)，Univ Roma Tor Vergata, Sch Med, Ctr Excellence Genom Risk Assessment Multifactori, Dept Biomed & Prevent, Rome, Italy.
EM emiliano.giardina@uniroma2.it
RI Novelli, Giuseppe/GQB-3329-2022; Cascella, Raffaella/G-9040-2019;
   Zampatti, Stefania/AAC-4589-2022; ricci, federico/AAC-3836-2020;
   Giardina, Emiliano/J-1965-2012; Novelli, Giuseppe/T-8822-2019; Novelli,
   Giuseppe/A-5195-2013; Staurenghi, Giovanni/K-4388-2017
OI Novelli, Giuseppe/0000-0002-7781-602X; Cascella,
   Raffaella/0000-0002-2148-0758; Zampatti, Stefania/0000-0003-2502-7157;
   ricci, federico/0000-0002-4224-9280; Novelli,
   Giuseppe/0000-0002-7781-602X; Marsella, Luigi
   Tonino/0000-0002-7005-7526; Eandi, Chiara Maria/0000-0003-3656-1689;
   giardina, emiliano/0000-0002-2741-5009; BORGIANI,
   PAOLA/0000-0003-0859-4328; Staurenghi, Giovanni/0000-0002-2299-5251
FU Macula & Genoma Foundation-onlus
FX This work was supported by the "Macula & Genoma Foundation-onlus". We
   are very grateful to all the staff of the Centre of Excellence for
   Genomic risk Assessment in Multifactorial and Complex Diseases, School
   of Medicine, University of Rome "Tor Vergata" for their effort in our
   study.
CR Andia DC, 2012, ARCH ORAL BIOL
   Araki S, 2007, CANCER RES, V67, P6854, DOI 10.1158/0008-5472.CAN-07-1162
   Chen W, 2010, P NATL ACAD SCI USA, V107, P7401, DOI 10.1073/pnas.0912702107
   Fernandes AF, 2008, J BIOL CHEM, V283, P20745, DOI 10.1074/jbc.M800268200
   Fishman D, 1998, J CLIN INVEST, V102, P1369, DOI 10.1172/JCI2629
   Gao LB, 2010, EUR J CANCER, V46, P1333, DOI 10.1016/j.ejca.2010.03.011
   Goverdhan SV, 2008, BRIT J OPHTHALMOL, V92, P537, DOI 10.1136/bjo.2007.123190
   Hollyfield JG, 2008, NAT MED, V14, P194, DOI 10.1038/nm1709
   HOLMES WE, 1991, SCIENCE, V253, P1278, DOI 10.1126/science.1840701
   Klein R, 2011, ARCH OPHTHALMOL-CHIC, V129, P1605, DOI 10.1001/archophthalmol.2011.372
   Kroeger KM, 1997, MOL IMMUNOL, V34, P391, DOI 10.1016/S0161-5890(97)00052-7
   MacDermott RP, 1999, J CLIN IMMUNOL, V19, P266, DOI 10.1023/A:1020583306627
   Matsuo Y, 2009, INT J CANCER, V124, P853, DOI 10.1002/ijc.24040
   MURPHY PM, 1991, SCIENCE, V253, P1280, DOI 10.1126/science.1891716
   Nakagome K, 2012, INT ARCH ALLERGY IMM, V158, P96, DOI 10.1159/000337801
   Neale BM, 2010, P NATL ACAD SCI USA, V107, P7395, DOI 10.1073/pnas.0912019107
   Ning Y, 2011, INT J CANCER, V128, P2038, DOI 10.1002/ijc.25562
   Remick DG, 2005, CRIT CARE MED, V33, pS466, DOI 10.1097/01.CCM.0000186783.34908.18
   Rennie CA, 2012, EYE, V26, P109, DOI 10.1038/eye.2011.256
   Ricci F, 2009, ARCH OPHTHALMOL-CHIC, V127, P1368, DOI 10.1001/archophthalmol.2009.237
   Seddon JM, 2005, ARCH OPHTHALMOL-CHIC, V123, P774, DOI 10.1001/archopht.123.6.774
   Seddon JM, 2004, JAMA-J AM MED ASSOC, V291, P704, DOI 10.1001/jama.291.6.704
   Seddon JM, 2011, OPHTHALMOLOGY, V118, P2203, DOI 10.1016/j.ophtha.2011.04.029
   Simonini A, 2000, CIRCULATION, V101, P1519, DOI 10.1161/01.CIR.101.13.1519
   Spencer KL, 2012, ARCH OPHTHALMOL-CHIC, V130, P116, DOI 10.1001/archopthalmol.2011.1370
   Telander DG, 2011, SEMIN OPHTHALMOL, V26, P192, DOI 10.3109/08820538.2011.570849
   Tsai YY, 2008, INVEST OPHTH VIS SCI, V49, P693, DOI 10.1167/iovs.07-0125
   Vegran F, 2011, CANCER RES, V71, P2550, DOI 10.1158/0008-5472.CAN-10-2828
   Warle MC, 2003, LIVER TRANSPLANT, V9, P170, DOI 10.1053/jlts.2002.50014
   Wu GD, 1997, J BIOL CHEM, V272, P2396
   Yu Y, 2012, INVEST OPHTH VIS SCI, V53, P1548, DOI 10.1167/iovs.11-8657
   Zhou JL, 2006, P NATL ACAD SCI USA, V103, P16182, DOI 10.1073/pnas.0604255103
NR 32
TC 24
Z9 24
U1 0
U2 3
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD JUN 19
PY 2013
VL 8
IS 6
AR e66978
DI 10.1371/journal.pone.0066978
PG 5
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA 190ST
UT WOS:000322361200113
PM 23840568
OA Green Published, Green Submitted, gold
DA 2022-11-30
ER

PT J
AU Shen, YC
   Li, M
   Liu, K
   Xu, XY
   Zhu, SP
   Wang, N
   Guo, WK
   Zhao, QQ
   Lu, P
   Yu, FD
   Xu, X
AF Shen Yinchen
   Li Mo
   Liu Kun
   Xu Xiaoyin
   Zhu Shaopin
   Wang Ning
   Guo Wenke
   Zhao Qianqian
   Lu Ping
   Yu Fudong
   Xu Xun
TI Integrated bioinformatics analysis of aberrantly-methylated
   differentially-expressed genes and pathways in age-related macular
   degeneration
SO BMC OPHTHALMOLOGY
LA English
DT Article
DE Methylation; Gene expression; Age-related macular degeneration;
   Choroidal neovascularization; Bioinformatics analysis
ID COMPLEMENT FACTOR-H; ASSOCIATION; NEOVASCULARIZATION; SUSCEPTIBILITY;
   POLYMORPHISM; RANIBIZUMAB; BIOMARKERS; CALCIUM; CELLS; RISK
AB Background Age-related macular degeneration (AMD) represents the leading cause of visual impairment in the aging population. The goal of this study was to identify aberrantly-methylated, differentially-expressed genes (MDEGs) in AMD and explore the involved pathways via integrated bioinformatics analysis. Methods Data from expression profile GSE29801 and methylation profile GSE102952 were obtained from the Gene Expression Omnibus database. We analyzed differentially-methylated genes and differentially-expressed genes using R software. Functional enrichment and protein-protein interaction (PPI) network analysis were performed using the R package and Search Tool for the Retrieval of Interacting Genes online database. Hub genes were identified using Cytoscape. Results In total, 827 and 592 genes showed high and low expression, respectively, in GSE29801; 4117 hyper-methylated genes and 511 hypo-methylated genes were detected in GSE102952. Based on overlap, we categorized 153 genes as hyper-methylated, low-expression genes (Hyper-LGs) and 24 genes as hypo-methylated, high-expression genes (Hypo-HGs). Four Hyper-LGs (CKB, PPP3CA, TGFB2, SOCS2) overlapped with AMD risk genes in the Public Health Genomics and Precision Health Knowledge Base. KEGG pathway enrichment analysis indicated that Hypo-HGs were enriched in the calcium signaling pathway, whereas Hyper-LGs were enriched in sphingolipid metabolism. In GO analysis, Hypo-HGs were enriched in fibroblast migration, membrane raft, and coenzyme binding, among others. Hyper-LGs were enriched in mRNA transport, nuclear speck, and DNA binding, among others. In PPI network analysis, 23 nodes and two edges were established from Hypo-HGs, and 151 nodes and 73 edges were established from Hyper-LGs. Hub genes (DHX9, MAPT, PAX6) showed the greatest overlap. Conclusion This study revealed potentially aberrantly MDEGs and pathways in AMD, which might improve the understanding of this disease.
C1 [Shen Yinchen; Liu Kun; Xu Xiaoyin; Zhu Shaopin; Wang Ning; Xu Xun] Shanghai Jiao Tong Univ, Sch Med, Shanghai Gen Hosp, Dept Ophthalmol, Shanghai 200080, Peoples R China.
   [Shen Yinchen; Liu Kun; Xu Xiaoyin; Zhu Shaopin; Wang Ning; Xu Xun] Shanghai Engn Ctr Precise Diag & Treatment Eye Di, Natl Clin Res Ctr Eye Dis, Shanghai Key Lab Ocular Fundus Dis, Shanghai Engn Ctr Visual Sci & Photomed, Shanghai, Peoples R China.
   [Li Mo] Shanghai Jiao Tong Univ, Key Lab Genet Dev & Neuropsychiat Disorders, Minist Educ, BioX Inst, Shanghai, Peoples R China.
   [Guo Wenke; Zhao Qianqian; Lu Ping; Yu Fudong] Fudan Univ, NHC Key Lab Reprod Regulat, Shanghai Inst Planned Parenthood Res, Shanghai, Peoples R China.
C3 Shanghai Jiao Tong University; Shanghai Jiao Tong University; Fudan
   University
RP Xu, X (通讯作者)，Shanghai Jiao Tong Univ, Sch Med, Shanghai Gen Hosp, Dept Ophthalmol, Shanghai 200080, Peoples R China.; Xu, X (通讯作者)，Shanghai Engn Ctr Precise Diag & Treatment Eye Di, Natl Clin Res Ctr Eye Dis, Shanghai Key Lab Ocular Fundus Dis, Shanghai Engn Ctr Visual Sci & Photomed, Shanghai, Peoples R China.
EM drxuxun@sjtu.edu.cn
OI Li, Mo/0000-0002-9915-1348
FU National Key R&D Program of China [2016YFC0904800, 2019YFC0840607];
   National Natural Science Foundation of China [81800831, 81800799];
   National Science and Technology Major Project of China [2017ZX09304010];
   Shanghai Municipal Commission of Health and Family Planning [201740088]
FX This study was supported by National Key R&D Program of China
   (2016YFC0904800, 2019YFC0840607), National Natural Science Foundation of
   China (81800831, 81800799), National Science and Technology Major
   Project of China (2017ZX09304010) and Shanghai Municipal Commission of
   Health and Family Planning (201740088). The sponsor or funding
   organization had no role in the design or conduct of this research.
CR Akiyama M, 2018, J HUM GENET, V63, P1083, DOI 10.1038/s10038-018-0493-0
   [Anonymous], 1999, CONTROL CLIN TRIALS, DOI 10.1016/S0197-2456(99)00031-8
   Blasi MA, 2001, OPHTHALMOLOGICA, V215, P51, DOI 10.1159/000050826
   Bourne RRA, 2013, LANCET GLOB HEALTH, V1, pE339, DOI 10.1016/S2214-109X(13)70113-X
   Bressler Neil M, 2004, JAMA, V291, P1900, DOI 10.1001/jama.291.15.1900
   Cohen-Tayar Y, 2018, DEVELOPMENT, V145, DOI 10.1242/dev.163691
   DeAngelis MM, 2008, OPHTHALMOLOGY, V115, P1209, DOI 10.1016/j.ophtha.2007.10.032
   DeAngelis MM, 2017, HUM MOL GENET, V26, pR45, DOI 10.1093/hmg/ddx228
   Do DV, 2013, CURR OPIN OPHTHALMOL, V24, P244, DOI 10.1097/ICU.0b013e32835fd7dd
   Evans JR, 2005, BRIT J OPHTHALMOL, V89, P550, DOI 10.1136/bjo.2004.049726
   Feher J, 2005, OPHTHALMOLOGICA, V219, P154, DOI 10.1159/000085248
   Feng ZL, 2015, GRAEF ARCH CLIN EXP, V253, P875, DOI 10.1007/s00417-014-2922-x
   Francis JH, 2015, AM J OPHTHALMOL, V159, P169, DOI 10.1016/j.ajo.2014.10.011
   Fritsche LG, 2016, NAT GENET, V48, P134, DOI 10.1038/ng.3448
   Fritsche LG, 2013, NAT GENET, V45, P433, DOI 10.1038/ng.2578
   Haan S., 2016, FRONT BIOSCI-LANDMRK, V8, P189, DOI DOI 10.2741/E760
   Hageman GS, 2005, P NATL ACAD SCI USA, V102, P7227, DOI 10.1073/pnas.0501536102
   Haines JL, 2006, INVEST OPHTH VIS SCI, V47, P329, DOI 10.1167/iovs.05-0116
   Hammond CJ, 2002, OPHTHALMOLOGY, V109, P730, DOI 10.1016/S0161-6420(01)01049-1
   Handa JT, 2012, MOL ASPECTS MED, V33, P418, DOI 10.1016/j.mam.2012.03.006
   Hong N, 2016, ACTA OPHTHALMOL, V94, P334, DOI 10.1111/aos.13049
   Iglicki M, 2019, ACTA DIABETOL, V56, P1141, DOI 10.1007/s00592-019-01357-y
   Iglicki M, 2018, ACTA DIABETOL, V55, P541, DOI 10.1007/s00592-018-1117-z
   Iglicki M, 2019, RETINA-J RET VIT DIS, V39, P44, DOI 10.1097/IAE.0000000000002196
   Kimura K, 2015, J MOL MED, V93, P749, DOI 10.1007/s00109-015-1289-8
   Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557
   Klein R, 2007, OPHTHALMOLOGY, V114, P253, DOI 10.1016/j.ophtha.2006.10.040
   Koustenis A, 2017, BRIT J OPHTHALMOL, V101, P16, DOI 10.1136/bjophthalmol-2016-309389
   Kulasingam V, 2008, NAT CLIN PRACT ONCOL, V5, P588, DOI 10.1038/ncponc1187
   Kumar-Singh R, 2019, EXP EYE RES, V184, P266, DOI 10.1016/j.exer.2019.05.006
   Liu J, 2013, OPHTHALMOLOGICA, V230, P55, DOI 10.1159/000351660
   McGwin G, 2006, ARCH OPHTHALMOL-CHIC, V124, P33, DOI 10.1001/archopht.124.1.33
   Mello P, 2019, OPHTHALMOLOGICA, V241, P9, DOI 10.1159/000492132
   Newman AM, 2012, GENOME MED, V4, DOI [10.1186/PREACCEPT-1418491035586234, 10.1186/gm315]
   Paimela T, 2007, IMMUNOL LETT, V110, P139, DOI 10.1016/j.imlet.2007.04.008
   Pujol-Lereis LM, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0200739
   Radeke MJ, 2007, EXP EYE RES, V85, P366, DOI 10.1016/j.exer.2007.05.006
   Radeke MJ, 2015, GENOME MED, V7, DOI 10.1186/s13073-015-0183-x
   Remez LA, 2017, DEV BIOL, V432, P140, DOI 10.1016/j.ydbio.2017.09.030
   Rivera A, 2005, HUM MOL GENET, V14, P3227, DOI 10.1093/hmg/ddi353
   Rofagha S, 2013, OPHTHALMOLOGY, V120, P2292, DOI 10.1016/j.ophtha.2013.03.046
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   SanGiovanni JP, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0071239
   Santulli RJ, 2008, J PHARMACOL EXP THER, V324, P894, DOI 10.1124/jpet.107.131656
   Shahid H, 2012, BRIT J OPHTHALMOL, V96, P427, DOI 10.1136/bjophthalmol-2011-300193
   TERAO R, 2017, INT J MOL SCI, V19, P1, DOI DOI 10.3390/ijms19010112
   Theodoropoulou S, 2017, J PATHOL, V241, P45, DOI 10.1002/path.4816
   Wang FH, 2013, OPHTHALMOLOGY, V120, P355, DOI 10.1016/j.ophtha.2012.07.083
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
   Yang IH, 2015, INVEST OPHTH VIS SCI, V56, P761, DOI 10.1167/iovs.14-15299
   Yang P, 2014, INVEST OPHTH VIS SCI, V55, P3012, DOI 10.1167/iovs.13-13554
   Zur D, 2020, ACTA OPHTHALMOL, V98, pE217, DOI 10.1111/aos.14230
   Zur D, 2019, OPHTHALMIC RES, V62, P231, DOI 10.1159/000499540
NR 53
TC 4
Z9 4
U1 2
U2 5
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
EI 1471-2415
J9 BMC OPHTHALMOL
JI BMC Ophthalmol.
PD MAR 24
PY 2020
VL 20
IS 1
AR 119
DI 10.1186/s12886-020-01392-2
PG 12
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA LE5PX
UT WOS:000526772100001
PM 32209064
OA gold, Green Submitted, Green Published
DA 2022-11-30
ER

PT J
AU Yamashiro, K
   Oishi, A
   Hata, M
   Takahashi, A
   Tsujikawa, A
AF Yamashiro, Kenji
   Oishi, Akio
   Hata, Masayuki
   Takahashi, Ayako
   Tsujikawa, Akitaka
TI Visual acuity outcomes of anti-VEGF treatment for neovascular
   age-related macular degeneration in clinical trials
SO JAPANESE JOURNAL OF OPHTHALMOLOGY
LA English
DT Review
DE Age-related macular degeneration; Anti-VEGF treatment; Clinical trials;
   Visual acuity
ID POLYPOIDAL CHOROIDAL VASCULOPATHY; VERTEPORFIN PHOTODYNAMIC THERAPY;
   PIGMENT EPITHELIAL ATROPHY; EXTEND REGIMEN; INTRAVITREAL RANIBIZUMAB;
   THICKNESS CHANGES; PLUS RANIBIZUMAB; 7-YEAR OUTCOMES; AFLIBERCEPT;
   EFFICACY
AB Anti-VEGF treatment for neovascular age-related macular degeneration (nAMD) has been evaluated in clinical trials. To select the best anti-VEGF drug and the best treatment regimen for nAMD, a thorough understanding of the characteristics of each anti-VEGF drug and treatment regimen is essential. In this review, we summarized visual acuity (VA) changes in 30 previous clinical trials of anti-VEGF treatment for nAMD. In most studies, ranibizumab, aflibercept, and brolucizumab improved the VA by 6 to 12 letters from the baseline VA of 50-65 letters and maintained the VA improvement regardless of the treatment regimen; the VA improved from 0.2-0.4 to 0.3-0.7 in Snellen equivalents. The improvement was rapid during the first month and became slower after the second injection, and 60% to 90% of the VA improvement was attained within the first 3 months. The upper limit of the VA improvement should be determined according to eyes with nAMD themselves, not according to anti-VEGF drugs or treatment regimens. Since a fixed regimen can result in overtreatment, whilst a pro re nata regimen can result in insufficient treatment, a treat-and-extend regimen would be optimal to treat nAMD. Insufficient treatment fails to improve VA to the upper limit and/or to maintain the improved VA, whereas overtreatment can cause macular atrophy. One study reported no difference in the risk of macular atrophy between ranibizumab and aflibercept, whilst many studies have suggested that aflibercept causes more choroidal thinning, one of the risk factors for macular atrophy, than does ranibizumab. Further evaluation of drugs and regimens should be performed from the viewpoint of complications and minimum number of injections required to improve and maintain VA.
C1 [Yamashiro, Kenji; Hata, Masayuki; Takahashi, Ayako; Tsujikawa, Akitaka] Kyoto Univ, Grad Sch Med, Dept Ophthalmol & Visual Sci, Kyoto, Japan.
   [Yamashiro, Kenji] Japanese Red Cross Otsu Hosp, Dept Ophthalmol, Nagara 1-1-35, Shiga 5208511, Japan.
   [Oishi, Akio] Nagasaki Univ, Dept Ophthalmol & Visual Sci, Grad Sch Biomed Sci, Nagasaki, Japan.
C3 Kyoto University; Nagasaki University
RP Yamashiro, K (通讯作者)，Kyoto Univ, Grad Sch Med, Dept Ophthalmol & Visual Sci, Kyoto, Japan.; Yamashiro, K (通讯作者)，Japanese Red Cross Otsu Hosp, Dept Ophthalmol, Nagara 1-1-35, Shiga 5208511, Japan.
EM yamashro@kuhp.kyoto-u.ac.jp
RI Oishi, Akio/AAE-9996-2020
OI Oishi, Akio/0000-0002-0977-9458; Yamashiro, Kenji/0000-0001-9354-8558
CR Alam, 2019, EURETINA, V99, pE336
   Berg K, 2016, OPHTHALMOLOGY, V123, P51, DOI 10.1016/j.ophtha.2015.09.018
   Berg K, 2015, OPHTHALMOLOGY, V122, P146, DOI 10.1016/j.ophtha.2014.07.041
   Bhisitkul RB, 2016, OPHTHALMOLOGY, V123, P1269, DOI 10.1016/j.ophtha.2016.01.033
   Boyer DS, 2007, OPHTHALMOLOGY, V114, P246, DOI 10.1016/j.ophtha.2006.10.045
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Brown DM, 2009, OPHTHALMOLOGY, V116, P57, DOI 10.1016/j.ophtha.2008.10.018
   Chakravarthy U, 2013, LANCET, V382, P1258, DOI 10.1016/S0140-6736(13)61501-9
   Dugel PU, 2021, OPHTHALMOLOGY, V128, P89, DOI [10.1016/j.opatha.2020.06.028, 10.1016/j.ophtha.2020.06.028]
   Dugel PU, 2020, OPHTHALMOLOGY, V127, P72, DOI 10.1016/j.ophtha.2019.04.017
   Dugel PU, 2017, OPHTHALMOLOGY, V124, P1296, DOI 10.1016/j.ophtha.2017.03.057
   Ellabban AA, 2012, CLIN OPHTHALMOL, V6, P837, DOI 10.2147/OPTH.S30907
   Fan WY, 2018, GRAEF ARCH CLIN EXP, V256, P511, DOI 10.1007/s00417-017-3888-2
   Fung AE, 2007, AM J OPHTHALMOL, V143, P566, DOI 10.1016/j.ajo.2007.01.028
   Gao Y, 2018, INVEST OPHTH VIS SCI, V59, P4307, DOI 10.1167/iovs.17-23747
   Gillies MC, 2020, OPHTHALMOLOGY, V127, P198, DOI 10.1016/j.ophtha.2019.08.023
   Gomi F, 2015, RETINA-J RET VIT DIS, V35, P1569, DOI 10.1097/IAE.0000000000000526
   Grunwald JE, 2014, OPHTHALMOLOGY, V121, P150, DOI 10.1016/j.ophtha.2013.08.015
   Guymer RH, 2019, OPHTHALMOLOGY, V126, P723, DOI 10.1016/j.ophtha.2018.11.025
   Haga A, 2018, ACTA OPHTHALMOL, V96, pE393, DOI 10.1111/aos.13607
   Hata M, 2017, RETINA-J RET VIT DIS, V37, P2069, DOI 10.1097/IAE.0000000000001457
   Hata M, 2014, INVEST OPHTH VIS SCI, V55, P7874, DOI 10.1167/iovs.14-14610
   Heier JS, 2012, OPHTHALMOLOGY, V119, P2537, DOI 10.1016/j.ophtha.2012.09.006
   Hikichi T, 2014, BRIT J OPHTHALMOL, V98, P1201, DOI 10.1136/bjophthalmol-2013-304555
   Ho AC, 2014, OPHTHALMOLOGY, V121, P2181, DOI 10.1016/j.ophtha.2014.05.009
   Holz FG, 2016, OPHTHALMOLOGY, V123, P1080, DOI 10.1016/j.ophtha.2015.12.030
   Inoue M, 2014, RETINA-J RET VIT DIS, V34, P2178, DOI 10.1097/IAE.0000000000000229
   Kaiser PK, 2012, OPHTHALMOLOGY, V119, P1001, DOI 10.1016/j.ophtha.2012.02.003
   Khanani AM, 2020, JAMA OPHTHALMOL, V138, P964, DOI 10.1001/jamaophthalmol.2020.2699
   Kikushima W, 2017, SCI REP-UK, V7, DOI 10.1038/srep44020
   Kodjikian L, 2013, OPHTHALMOLOGY, V120, P2300, DOI 10.1016/j.ophtha.2013.06.020
   Koh A, 2017, JAMA OPHTHALMOL, V135, P1206, DOI 10.1001/jamaophthalmol.2017.4030
   Koh A, 2012, RETINA-J RET VIT DIS, V32, P1453, DOI 10.1097/IAE.0b013e31824f91e8
   Koizumi H, 2020, JPN J OPHTHALMOL, V64, P338, DOI 10.1007/s10384-020-00745-0
   Koizumi H, 2016, OPHTHALMOLOGY, V123, P617, DOI 10.1016/j.ophtha.2015.10.039
   Krebs I, 2013, BRIT J OPHTHALMOL, V97, P266, DOI 10.1136/bjophthalmol-2012-302391
   Kuroda Y, 2018, RETINA-J RET VIT DIS, V38, P1743, DOI 10.1097/IAE.0000000000001765
   Kuroda Y, 2016, AM J OPHTHALMOL, V161, P94, DOI 10.1016/j.ajo.2015.09.032
   Kuroda Y, 2015, OPHTHALMOLOGY, V122, P2303, DOI 10.1016/j.ophtha.2015.06.053
   Lalwani GA, 2009, AM J OPHTHALMOL, V148, P43, DOI 10.1016/j.ajo.2009.01.024
   Larsen M, 2012, OPHTHALMOLOGY, V119, P992, DOI 10.1016/j.ophtha.2012.02.002
   Lee JE, 2017, GRAEF ARCH CLIN EXP, V255, P493, DOI 10.1007/s00417-016-3489-5
   Lee WK, 2018, JAMA OPHTHALMOL, V136, P786, DOI 10.1001/jamaophthalmol.2018.1804
   Lim TH, 2020, JAMA OPHTHALMOL, V138, P935, DOI 10.1001/jamaophthalmol.2020.2443
   Maguire MG, 2016, OPHTHALMOLOGY, V123, P1751, DOI 10.1016/j.ophtha.2016.03.045
   Martin DF, 2012, OPHTHALMOLOGY, V119, DOI 10.1016/j.ophtha.2012.03.053
   Martin DF, 2011, NEW ENGL J MED, V364, P1897, DOI 10.1056/NEJMoa1102673
   Maruko I, 2015, RETINA-J RET VIT DIS, V35, P648, DOI 10.1097/IAE.0000000000000486
   Maruko I, 2013, AM J OPHTHALMOL, V156, P548, DOI 10.1016/j.ajo.2013.03.041
   Maruko I, 2011, AM J OPHTHALMOL, V151, P594, DOI 10.1016/j.ajo.2010.10.030
   Matsumoto H, 2018, OPHTHALMOL RETINA, V2, P462, DOI 10.1016/j.oret.2017.09.002
   Matsumoto H, 2018, JPN J OPHTHALMOL, V62, P144, DOI 10.1007/s10384-018-0562-0
   Matsumoto H, 2016, RETINA-J RET VIT DIS, V36, P2282, DOI 10.1097/IAE.0000000000001104
   Morimoto M, 2017, GRAEF ARCH CLIN EXP, V255, P1891, DOI 10.1007/s00417-017-3718-6
   Ohji M, 2020, ADV THER, V37, P2184, DOI 10.1007/s12325-020-01298-x
   Ohji M, 2020, ADV THER, V37, P1173, DOI 10.1007/s12325-020-01236-x
   Ohnaka M, 2017, GRAEF ARCH CLIN EXP, V255, P657, DOI 10.1007/s00417-016-3507-7
   Oishi A, 2013, AM J OPHTHALMOL, V156, P644, DOI 10.1016/j.ajo.2013.05.024
   Peden MC, 2015, OPHTHALMOLOGY, V122, P803, DOI 10.1016/j.ophtha.2014.11.018
   Qin VL, 2018, RETINA-J RET VIT DIS, V38, P1500, DOI 10.1097/IAE.0000000000001753
   Rofagha S, 2013, OPHTHALMOLOGY, V120, P2292, DOI 10.1016/j.ophtha.2013.03.046
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Sahni J, 2020, JAMA OPHTHALMOL, V138, P955, DOI 10.1001/jamaophthalmol.2020.2685
   Schauwvlieghe AME, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0153052
   Schmidt-Erfurth U, 2011, OPHTHALMOLOGY, V118, P831, DOI 10.1016/j.ophtha.2010.09.004
   Silva R, 2018, OPHTHALMOLOGY, V125, P57, DOI 10.1016/j.ophtha.2017.07.014
   Steinle NC, 2021, OPHTHALMOL RETINA, V5, P141, DOI 10.1016/j.oret.2020.07.003
   Wakazono T, 2017, RETINA-J RET VIT DIS, V37, P2062, DOI 10.1097/IAE.0000000000001451
   Wykoff CC, 2017, OPHTHALMOL RETINA, V1, P314, DOI 10.1016/j.oret.2016.12.004
   Wykoff CC, 2015, OPHTHALMOLOGY, V122, P2514, DOI 10.1016/j.ophtha.2015.08.009
   Yamazaki T, 2012, OPHTHALMOLOGY, V119, P1621, DOI 10.1016/j.ophtha.2012.02.022
   Ying GS, 2013, OPHTHALMOLOGY, V120, P122, DOI 10.1016/j.ophtha.2012.07.042
NR 72
TC 2
Z9 2
U1 1
U2 3
PU SPRINGER JAPAN KK
PI TOKYO
PA SHIROYAMA TRUST TOWER 5F, 4-3-1 TORANOMON, MINATO-KU, TOKYO, 105-6005,
   JAPAN
SN 0021-5155
EI 1613-2246
J9 JPN J OPHTHALMOL
JI Jpn. J. Ophthalmol.
PD NOV
PY 2021
VL 65
IS 6
BP 741
EP 760
DI 10.1007/s10384-021-00869-x
EA SEP 2021
PG 20
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA WL4KM
UT WOS:000693704600002
PM 34491474
DA 2022-11-30
ER

PT J
AU Brivio, D
   Zygmanski, P
   Arnoldussen, M
   Hanlon, J
   Chell, E
   Sajo, E
   Makrigiorgos, GM
   Ngwa, W
AF Brivio, D.
   Zygmanski, P.
   Arnoldussen, M.
   Hanlon, J.
   Chell, E.
   Sajo, E.
   Makrigiorgos, G. M.
   Ngwa, W.
TI Kilovoltage radiosurgery with gold nanoparticles for neovascular
   age-related macular degeneration (AMD): a Monte Carlo evaluation
SO PHYSICS IN MEDICINE AND BIOLOGY
LA English
DT Article
DE AMD; gold nanoparticles; Monte Carlo simulation; sterotactic
   radiosurgery; kilovoltage
ID STEREOTACTIC RADIOSURGERY; DOSE ENHANCEMENT; BRACHYTHERAPY;
   RADIOSENSITIZATION; THERAPY; ENERGY
AB This work uses Monte Carlo radiation transport simulation to assess the potential benefits of gold nanoparticles (AuNP) in the treatment of neovascular age-related macular degeneration with stereotactic radiosurgery. Clinically, a 100 kVp x-ray beam of 4 mm diameter is aimed at the macula to deliver an ablative dose in a single fraction. In the transport model, AuNP accumulated at the bottom of the macula are targeted with a source representative of the clinical beam in order to provide enhanced dose to the diseased macular endothelial cells. It is observed that, because of the AuNP, the dose to the endothelial cells can be significantly enhanced, allowing for greater sparing of optic nerve, retina and other neighboring healthy tissue. For 20 nm diameter AuNP concentration of 32 mg g(-1), which has been shown to be achievable in vivo, a dose enhancement ratio (DER) of 1.97 was found to be possible, which could potentially be increased through appropriate optimization of beam quality and/or AuNP targeting. A significant enhancement in dose is seen in the vicinity of the AuNP layer within 30 mu m, peaked at the AuNP-tissue interface. Different angular tilting of the 4 mm beam results in a similar enhancement. The DER inside and in the penumbra of the 4 mm irradiation-field are almost the same while the actual delivered dose is more than one order of magnitude lower outside the field leading to normal tissue sparing. The prescribed dose to macular endothelial cells can be delivered using almost half of the radiation allowing reduction of dose to the neighboring organs such as retina/optic nerve by 49% when compared to a treatment without AuNP.
C1 [Brivio, D.; Zygmanski, P.; Makrigiorgos, G. M.; Ngwa, W.] Harvard Univ, Brigham & Womans Hosp, Sch Med, Boston, MA USA.
   [Brivio, D.; Zygmanski, P.; Makrigiorgos, G. M.] Harvard Univ, Sch Med, Dana Farber Canc Inst, Boston, MA 02115 USA.
   [Arnoldussen, M.; Hanlon, J.; Chell, E.] Oraya Therapeut Inc, Newark, CA 94560 USA.
   [Sajo, E.; Ngwa, W.] Univ Massachusetts, Lowell, MA USA.
C3 Harvard University; Brigham & Women's Hospital; Harvard Medical School;
   Harvard University; Dana-Farber Cancer Institute; Harvard Medical
   School; University of Massachusetts System; University of Massachusetts
   Lowell
RP Brivio, D (通讯作者)，Harvard Univ, Brigham & Womans Hosp, Sch Med, Boston, MA USA.
EM dbrivio@lroc.harvard.edu
RI Brivio, Davide/R-1330-2016; Sajo, Erno/R-7204-2019; Zygmanski,
   Piotr/L-9104-2019; Brivio, Davide/L-3603-2019; Makrigiorgos,
   Mike/AFC-4575-2022
OI Brivio, Davide/0000-0002-4127-9955; Sajo, Erno/0000-0001-6802-0014;
   Brivio, Davide/0000-0002-4127-9955; 
FU NIH [R41EY024197]; NATIONAL EYE INSTITUTE [R41EY024197] Funding Source:
   NIH RePORTER
FX This work was supported by NIH R41EY024197.
CR Asadi S, 2014, ARXIV14064334V2
   Berbeco RI, 2011, INT J RADIAT ONCOL, V81, P270, DOI 10.1016/j.ijrobp.2010.10.022
   Berger M J, 2011, ESTAR STOPPING POWER
   Hanlon J, 2011, INVEST OPHTH VIS SCI, V52, P2334, DOI 10.1167/iovs.10-6421
   Hanlon J, 2009, MED PHYS, V36, P3671, DOI 10.1118/1.3168554
   Holz FG, 2015, BRIT J OPHTHALMOL, V99, P220, DOI 10.1136/bjophthalmol-2014-305327
   Kang SJ, 2009, ARCH OPHTHALMOL-CHIC, V127, P1043, DOI 10.1001/archophthalmol.2009.185
   Kim JH, 2011, BIOMATERIALS, V32, P1865, DOI 10.1016/j.biomaterials.2010.11.030
   LANL, 2013, MCNP6 VERS 1 0 REL 2
   Lechtman E, 2011, PHYS MED BIOL, V56, P4631, DOI 10.1088/0031-9155/56/15/001
   McMahon SJ, 2011, SCI REP-UK, V1, DOI 10.1038/srep00018
   NEI 2015 National Eye Institute, 2015, AG REL MAC DEG
   Ngwa W, 2014, NANOMEDICINE-UK, V9, P1063, DOI [10.2217/NNM.14.55, 10.2217/nnm.14.55]
   Ngwa W, 2013, NANOMED-NANOTECHNOL, V9, P25, DOI 10.1016/j.nano.2012.09.001
   Ngwa W, 2012, PHYS MED BIOL, V57, P6371, DOI 10.1088/0031-9155/57/20/6371
   Ngwa W, 2012, MED PHYS, V39, P392, DOI 10.1118/1.3671905
   Ngwa W, 2010, PHYS MED BIOL, V55, P6533, DOI 10.1088/0031-9155/55/21/013
   Saleet H., 2011, Proceedings of the 2011 IEEE Global Communications Conference (GLOBECOM 2011), DOI 10.1109/GLOCOM.2011.6133947
   Singh SR, 2009, GENE THER, V16, P645, DOI 10.1038/gt.2008.185
   Takeda A, 2009, NATURE, V460, P225, DOI 10.1038/nature08151
   Tsiamas P, 2014, MED PHYS, V41, DOI 10.1118/1.4859335
   Tufail A, 2014, OPHTHALMOLOGY, V121, P1092, DOI 10.1016/j.ophtha.2013.11.031
NR 22
TC 13
Z9 13
U1 0
U2 8
PU IOP PUBLISHING LTD
PI BRISTOL
PA TEMPLE CIRCUS, TEMPLE WAY, BRISTOL BS1 6BE, ENGLAND
SN 0031-9155
EI 1361-6560
J9 PHYS MED BIOL
JI Phys. Med. Biol.
PD DEC 21
PY 2015
VL 60
IS 24
BP 9203
EP 9213
DI 10.1088/0031-9155/60/24/9203
PG 11
WC Engineering, Biomedical; Radiology, Nuclear Medicine & Medical Imaging
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Engineering; Radiology, Nuclear Medicine & Medical Imaging
GA DJ2AO
UT WOS:000374006300001
PM 26576672
OA Green Accepted
DA 2022-11-30
ER

PT J
AU Chen, X
   Rong, SS
   Xu, QH
   Tang, FY
   Liu, Y
   Gu, H
   Tam, POS
   Chen, LJ
   Brelen, ME
   Pang, CP
   Zhao, C
AF Chen, Xue
   Rong, Shi Song
   Xu, Qihua
   Tang, Fang Yao
   Liu, Yuan
   Gu, Hong
   Tam, Pancy O. S.
   Chen, Li Jia
   Brelen, Marten E.
   Pang, Chi Pui
   Zhao, Chen
TI Diabetes Mellitus and Risk of Age-Related Macular Degeneration: A
   Systematic Review and Meta-Analysis
SO PLOS ONE
LA English
DT Review
ID GLYCATION END-PRODUCTS; CARDIOVASCULAR-DISEASE; MACROMOLECULAR DAMAGE;
   SEVERITY SCALE; EYE DISEASE; STATIN USE; MACULOPATHY; ASSOCIATION;
   APOLIPOPROTEINS; CLASSIFICATION
AB Age-related macular degeneration (AMD) is a major cause of severe vision loss in elderly people. Diabetes mellitus is a common endocrine disorder with serious consequences, and diabetic retinopathy (DR) is the main ophthalmic complication. DR and AMD are different diseases and we seek to explore the relationship between diabetes and AMD. MEDLINE, EMBASE, and the Cochrane Library were searched for potentially eligible studies. Studies based on longitudinal cohort, cross-sectional, and case-control associations, reporting evaluation data of diabetes as an independent factor for AMD were included. Reports of relative risks (RRs), hazard ratios (HRs), odds ratio (ORs), or evaluation data of diabetes as an independent factor for AMD were included. Review Manager and STATA were used for the meta-analysis. Twenty four articles involving 27 study populations were included for meta-analysis. In 7 cohort studies, diabetes was shown to be a risk factor for AMD (OR, 1.05; 95% CI, 1.00-1.14). Results of 9 cross-sectional studies revealed consistent association of diabetes with AMD (OR, 1.21; 95% CI, 1.00-1.45), especially for late AMD (OR, 1.48; 95% CI, 1.44-1.51). Similar association was also detected for AMD (OR, 1.29; 95% CI, 1.13-1.49) and late AMD (OR, 1.16; 95% CI, 1.11-1.21) in 11 case-control studies. The pooled ORs for risk of neovascular AMD (nAMD) were 1.10 (95% CI, 0.96-1.26), 1.48 (95% CI, 1.44-1.51), and 1.15 (95% CI, 1.11-1.21) from cohort, cross-sectional and case-control studies, respectively. No obvious divergence existed among different ethnic groups. Therefore, we find diabetes a risk factor for AMD, stronger for late AMD than earlier stages. However, most of the included studies only adjusted for age and sex; we thus cannot rule out confounding as a potential explanation for the association. More well-designed prospective cohort studies are still warranted to further examine the association.
C1 [Chen, Xue; Xu, Qihua; Liu, Yuan; Zhao, Chen] Nanjing Med Univ, Affiliated Hosp 1, Dept Ophthalmol, Nanjing, Jiangsu, Peoples R China.
   [Chen, Xue; Xu, Qihua; Liu, Yuan; Zhao, Chen] Nanjing Med Univ, State Key Lab Reprod Med, Nanjing, Jiangsu, Peoples R China.
   [Chen, Xue; Rong, Shi Song; Tang, Fang Yao; Gu, Hong; Tam, Pancy O. S.; Chen, Li Jia; Brelen, Marten E.; Pang, Chi Pui] Chinese Univ Hong Kong, Dept Ophthalmol & Visual Sci, Hong Kong, Hong Kong, Peoples R China.
   [Xu, Qihua] Southeast Univ, Affiliated Jiangyin Hosp, Coll Med, Dept Ophthalmol, Jiangyin, Peoples R China.
   [Gu, Hong] Lihuili Hosp, Ningbo Med Treatment Ctr, Dept Ophthalmol, Ningbo, Peoples R China.
C3 Nanjing Medical University; Nanjing Medical University; Chinese
   University of Hong Kong; Southeast University - China
RP Pang, CP (通讯作者)，Chinese Univ Hong Kong, Dept Ophthalmol & Visual Sci, Hong Kong, Hong Kong, Peoples R China.
EM cppang@cuhk.edu.hk; dr.zhaochen@gmail.com
RI Rong, Shi Song/L-9735-2019; TANG, Fangyao/AAF-2824-2020; Chen, Li
   Jia/I-5078-2014; Brelen, Marten E./D-1133-2016; liu, yuan/L-9239-2018
OI Rong, Shi Song/0000-0001-8352-6363; Chen, Li Jia/0000-0003-3500-5840;
   liu, yuan/0000-0003-4887-907X
FU National Key Basic Research Program of China [2013CB967500]; National
   Natural Science Foundation of China [81222009, 81170856]; Thousand Youth
   Talents Program of China; Jiangsu Outstanding Young Investigator Program
   [BK2012046]; Jiangsu Province's Key Provincial Talents Program
   [RC201149]; Jiangsu Province's Scientific Research Innovation Program
   for Postgraduates [CXZZ13_0590]; Endowment Fund for the Lim Por-Yen Eye
   Genetics Research Centre; General Research Fund from the Research Grants
   Council of Hong Kong [473410]; Priority Academic Program Development of
   Jiangsu Higher Education Institutions (PAPD)
FX This work was supported by National Key Basic Research Program of China
   (2013CB967500); National Natural Science Foundation of China (No.
   81222009 and 81170856); Thousand Youth Talents Program of China (to
   C.Z.); Jiangsu Outstanding Young Investigator Program (BK2012046);
   Jiangsu Province's Key Provincial Talents Program (RC201149); Jiangsu
   Province's Scientific Research Innovation Program for Postgraduates
   (CXZZ13_0590 to X.C.); an Endowment Fund for the Lim Por-Yen Eye
   Genetics Research Centre; the General Research Fund from the Research
   Grants Council of Hong Kong (No. 473410); and A Project Funded by the
   Priority Academic Program Development of Jiangsu Higher Education
   Institutions (PAPD). The sponsor or funding organization had no role in
   the design or conduct of this research.
CR Age-Related Eye Dis Study Res Grp, 2001, AM J OPHTHALMOL, V132, P668
   Alexander SL, 2007, OPHTHALMOLOGY, V114, P2174, DOI 10.1016/j.ophtha.2007.09.017
   [Anonymous], 2004, EVIDENCE REPORTS TEC
   Ardeljan D, 2013, PROG RETIN EYE RES, V37, P68, DOI 10.1016/j.preteyeres.2013.07.003
   Baker ML, 2009, ARCH OPHTHALMOL-CHIC, V127, P667, DOI 10.1001/archophthalmol.2009.30
   BEGG CB, 1994, BIOMETRICS, V50, P1088, DOI 10.2307/2533446
   BIRD AEC, 1995, SURV OPHTHALMOL, V39, P367, DOI 10.1016/S0039-6257(05)80092-X
   BLUMENKRANZ MS, 1986, OPHTHALMOLOGY, V93, P552
   Borger PH, 2003, OPHTHALMOLOGY, V110, P1292, DOI 10.1016/S0161-6420(03)00450-0
   Bressler Neil M, 2004, JAMA, V291, P1900, DOI 10.1001/jama.291.15.1900
   Cackett P, 2011, OPHTHALMOLOGY, V118, P846, DOI 10.1016/j.ophtha.2010.09.026
   Cao XR, 2010, DISCRETE EVENT DYN S, V20, P1, DOI 10.1007/s10626-010-0088-1
   Chakravarthy U, 2010, BMC OPHTHALMOL, V10, DOI 10.1186/1471-2415-10-31
   Cheung CMG, 2013, AM J OPHTHALMOL, V155, P764, DOI 10.1016/j.ajo.2012.10.013
   Cheung CMG, 2012, ARCH OPHTHALMOL-CHIC, V130, P480, DOI 10.1001/archophthalmol.2011.376
   Cheung N, 2007, ARCH OPHTHALMOL-CHIC, V125, P1241, DOI 10.1001/archopht.125.9.1241
   Choi JK, 2011, ARCH OPHTHALMOL-CHIC, V129, P196, DOI 10.1001/archophthalmol.2010.355
   Clemons TE, 2006, ARCH OPHTHALMOL-CHIC, V124, P537
   Davis MD, 2005, ARCH OPHTHALMOL-CHIC, V123, P1484
   Delcourt C, 2001, Ophthalmic Epidemiol, V8, P237, DOI 10.1076/opep.8.4.237.1613
   DERSIMONIAN R, 1986, CONTROL CLIN TRIALS, V7, P177, DOI 10.1016/0197-2456(86)90046-2
   Di Angelantonio E, 2009, JAMA-J AM MED ASSOC, V302, P1993, DOI 10.1001/jama.2009.1619
   Donath MY, 2011, NAT REV IMMUNOL, V11, P98, DOI 10.1038/nri2925
   Duan YK, 2007, OPHTHALMOLOGY, V114, P732, DOI 10.1016/j.ophtha.2006.07.045
   Egger M, 1997, BMJ-BRIT MED J, V315, P629, DOI 10.1136/bmj.315.7109.629
   Ferris FL, 2005, ARCH OPHTHALMOL-CHIC, V123, P1570
   Fraser-Bell S, 2008, AM J OPHTHALMOL, V145, P308, DOI 10.1016/j.ajo.2007.10.007
   Friedman DS, 1999, OPHTHALMOLOGY, V106, P1049, DOI 10.1016/S0161-6420(99)90267-1
   Gemmy Cheung CM, 2013, AM J OPHTHALMOL, V155, pe761
   Gemmy Cheung CM, 2013, AM J OPHTHALMOL, V155, P773
   Hahn P, 2013, RETINA-J RET VIT DIS, V33, P911, DOI 10.1097/IAE.0b013e3182831248
   Hammes HP, 1999, INVEST OPHTH VIS SCI, V40, P1855
   Higgins J, 2012, COCHRANE DB SYST REV, DOI 10.1002/14651858.ED000049
   Ho AC, 2012, OPHTHALMOLOGY, V119, P2179, DOI 10.1016/j.ophtha.2012.07.058
   Howes KA, 2004, INVEST OPHTH VIS SCI, V45, P3713, DOI 10.1167/iovs.04-0404
   Hu CC, 2010, STROKE, V41, P613, DOI 10.1161/STROKEAHA.109.571000
   Jager RD, 2008, NEW ENGL J MED, V358, P2606, DOI 10.1056/NEJMra0801537
   Jeganathan VSE, 2008, AM J OPHTHALMOL, V146, P954, DOI 10.1016/j.ajo.2008.07.006
   Karesvuo P, 2013, J PERIODONTOL, V84, P58, DOI 10.1902/jop.2012.110643
   Kawasaki R, 2010, OPHTHALMOLOGY, V117, P921, DOI 10.1016/j.ophtha.2009.10.007
   Kim IK, 2008, MOL VIS, V14, P1487
   KLEIN R, 1991, OPHTHALMOLOGY, V98, P1128
   Klein R, 2013, AM J OPHTHALMOL
   Klein R, 2008, AM J OPHTHALMOL, V145, P317, DOI 10.1016/j.ajo.2007.09.008
   Klein R, 2007, AM J OPHTHALMOL, V143, P473, DOI 10.1016/j.ajo.2006.11.058
   KURITZ SJ, 1988, ANNU REV PUBL HEALTH, V9, P123, DOI 10.1146/annurev.pu.09.050188.001011
   La Torre G, 2013, EUR J EPIDEMIOL, V28, P445, DOI 10.1007/s10654-013-9798-7
   Leske MC, 2006, OPHTHALMOLOGY, V113, P29, DOI 10.1016/j.ophtha.2005.08.012
   Lim LS, 2012, LANCET, V379, P1728, DOI 10.1016/S0140-6736(12)60282-7
   Lin JM, 2008, AM J OPHTHALMOL, V145, P716, DOI 10.1016/j.ajo.2007.11.006
   Mattes D, 2009, MOL VIS, V15, P343
   McGwin G, 2003, BRIT J OPHTHALMOL, V87, P1121, DOI 10.1136/bjo.87.9.1121
   Mitchell P, 1999, AUST NZ J OPHTHALMOL, V27, P197, DOI 10.1046/j.1440-1606.1999.00211.x
   Mitchell P, 2002, OPHTHALMOLOGY, V109, P1092, DOI 10.1016/S0161-6420(02)01055-2
   Monnier VM, 2005, ANN NY ACAD SCI, V1043, P567, DOI 10.1196/annals.1333.065
   Nitsch D, 2008, OPHTHALMOLOGY, V115, P1904, DOI 10.1016/j.ophtha.2008.06.035
   Pokharel S, 2009, J NEPAL MED ASSOC, V48, P217
   Rofagha S, 2013, OPHTHALMOLOGY, V120, P2292, DOI 10.1016/j.ophtha.2013.03.046
   Ross RD, 1998, AM J OPHTHALMOL, V125, P71, DOI 10.1016/S0002-9394(99)80237-2
   Sasongko MB, 2012, DIABETES, V61, P1785, DOI 10.2337/db11-1272
   Shalev V, 2011, OPHTHAL EPIDEMIOL, V18, P83, DOI 10.3109/09286586.2011.560746
   Smith W, 1998, ARCH OPHTHALMOL-CHIC, V116, P583, DOI 10.1001/archopht.116.5.583
   Sogut E, 2013, RETINA
   Sorriento D, 2014, SCIENTIFICWORLDJOURN, V2014
   Soulis T, 1997, DIABETOLOGIA, V40, P619, DOI 10.1007/s001250050725
   Stitt AW, 2010, INVEST OPHTH VIS SCI, V51, P4867, DOI 10.1167/iovs.10-5881
   Stroup DF, 2000, JAMA-J AM MED ASSOC, V283, P2008, DOI 10.1001/jama.283.15.2008
   Tan JSL, 2007, OPHTHALMOLOGY, V114, P1143, DOI 10.1016/j.ophtha.2006.09.033
   Tomany SC, 2004, OPHTHALMOLOGY, V111, P1280, DOI 10.1016/j.ophtha.2003.11.010
   Topouzis F, 2009, BRIT J OPHTHALMOL, V93, P1037, DOI 10.1136/bjo.2008.146316
   Totan Y, 2009, CURR EYE RES, V34, P1089, DOI 10.3109/02713680903353772
   Tuo JS, 2009, AM J PATHOL, V175, P799, DOI 10.2353/ajpath.2009.090089
   Turner N, 2014, MOL HUM REPROD
   Vaicaitiene Ramute, 2003, Medicina (Kaunas), V39, P1231
   Venza I, 2012, AGING CLIN EXP RES, V24, P21, DOI 10.3275/7659
   Vine AK, 2005, OPHTHALMOLOGY, V112, P2076, DOI 10.1016/j.ophtha.2005.07.004
   Weiner DE, 2011, NEPHROL DIAL TRANSPL, V26, P3159, DOI 10.1093/ndt/gfr022
   Wong TY, 2006, ANN INTERN MED, V145, P98, DOI 10.7326/0003-4819-145-2-200607180-00007
   Wu J, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0089600
   Xu L, 2009, EYE, V23, P676, DOI 10.1038/sj.eye.6703104
   Yang K, 2012, GRAEF ARCH CLIN EXP, V250, P741, DOI 10.1007/s00417-011-1824-4
   Yasuda M, 2009, OPHTHALMOLOGY, V116, P2135, DOI 10.1016/j.ophtha.2009.04.017
   Yuan DQ, 2013, OPHTHALMOLOGY, V120, P2051, DOI 10.1016/j.ophtha.2013.03.026
   Zhang Wenbo, 2011, J Cardiovasc Dis Res, V2, P96, DOI 10.4103/0975-3583.83035
NR 84
TC 31
Z9 31
U1 0
U2 20
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD SEP 19
PY 2014
VL 9
IS 9
AR e108196
DI 10.1371/journal.pone.0108196
PG 12
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA AQ0RY
UT WOS:000342491600085
PM 25238063
OA Green Published, Green Submitted, gold
DA 2022-11-30
ER

PT J
AU Wen, JC
   Reina-Torres, E
   Sherwood, JM
   Challa, P
   Liu, KC
   Li, GR
   Chang, JYH
   Cousins, SW
   Schuman, SG
   Mettu, PS
   Stamer, WD
   Overby, DR
   Allingham, RR
AF Wen, Joanne C.
   Reina-Torres, Ester
   Sherwood, Joseph M.
   Challa, Pratap
   Liu, Katy C.
   Li, Guorong
   Chang, Jason Y. H.
   Cousins, Scott W.
   Schuman, Stefanie G.
   Mettu, Priyatham S.
   Stamer, W. Daniel
   Overby, Darryl R.
   Allingham, R. Rand
TI Intravitreal Anti-VEGF Injections Reduce Aqueous Outflow Facility in
   Patients With Neovascular Age-Related Macular Degeneration
SO INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE
LA English
DT Article
DE anti-VEGF; aqueous outflow facility; ocular hypertension; intraocular
   pressure
ID INTRAOCULAR-PRESSURE ELEVATION; GROWTH-FACTOR THERAPY; SUSTAINED
   ELEVATION; CATARACT-EXTRACTION; BEVACIZUMAB; RANIBIZUMAB; EYES;
   PREDICTORS; PEGAPTANIB; GLAUCOMA
AB PURPOSE. We assess the effect of intravitreal anti-VEGF injections on tonographic outflow facility.
   METHODS. Patients with age-related macular degeneration who had received unilateral intravitreal anti-VEGF injections were recruited into two groups, those with <= 10 and those with >= 20 total anti-VEGF injections. Intraocular pressure and tonographic outflow facility of injected and uninjected fellow eyes were measured and compared between groups. Risk factors for development of reduced outflow facility also were assessed.
   RESULTS. Outflow facility was 12% lower in the injected eyes of patients who received >= 20 anti-VEGF injections, compared to contralateral uninjected eyes (P = 0.02). In contrast, there was no facility reduction for patients with <= 10 anti-VEGF injections (P = 0.4). In patients with ocular hypertension in the uninjected eye (IOP >21 mm Hg, n = 5), the outflow facility of injected eyes was on average 46% lower (P = 0.01) than in the uninjected fellow eyes. This was significantly greater than the difference observed in patients with IOP <= 21 mm Hg in the uninjected eye (P = 2 x 10(-4)). In patients with ocular hypertension in the injected eye (n = 6) the differences in facility and IOP between contralateral eyes were significantly greater than in patients with IOP <= 21 mm Hg in the injected eye (P = 2 x 10(-4) and P = 7 x 10(-4), respectively).
   CONCLUSIONS. Chronic anti-VEGF injections significantly reduce outflow facility in patients with AMD. The greatest facility reduction is observed in patients with baseline ocular hypertension. Ophthalmologists who administer anti-VEGF injections should be aware of these findings and monitor patients closely for changes in IOP or evidence of glaucoma, especially in those with pre-existing ocular hypertension.
C1 [Wen, Joanne C.] Univ Washington, Dept Ophthalmol, Seattle, WA 98195 USA.
   [Wen, Joanne C.; Challa, Pratap; Liu, Katy C.; Li, Guorong; Cousins, Scott W.; Schuman, Stefanie G.; Mettu, Priyatham S.; Stamer, W. Daniel; Allingham, R. Rand] Duke Univ, Ctr Eye, Dept Ophthalmol, Durham, NC USA.
   [Reina-Torres, Ester; Sherwood, Joseph M.; Chang, Jason Y. H.; Overby, Darryl R.] Imperial Coll London, Dept Bioengn, London SW7 2AZ, England.
C3 University of Washington; University of Washington Seattle; Duke
   University; Imperial College London
RP Overby, DR (通讯作者)，Imperial Coll London, Dept Bioengn, London SW7 2AZ, England.; Wen, JC (通讯作者)，Box 359608,325 Ninth Ave, Seattle, WA 98104 USA.
EM wenjc@uw.edu; d.overby@imperial.ac.uk
RI Chang, Jason Y.H./P-7972-2019; Sherwood, Joseph M/P-9619-2018; Overby,
   Darryl/G-1520-2011
OI Chang, Jason Y.H./0000-0002-2238-8232; Sherwood, Joseph
   M/0000-0002-4402-9767; Reina-Torres, Ester/0000-0002-4572-2539; Overby,
   Darryl/0000-0001-9894-7515
FU Research to Prevent Blindness; Fight for Sight (UK); NIH Grant
   [EY022359]; Research to Prevent Blindness Foundation; NATIONAL EYE
   INSTITUTE [R01EY022359, P30EY005722] Funding Source: NIH RePORTER; Fight
   for Sight [1385/86] Funding Source: researchfish
FX Supported by the Research to Prevent Blindness - 2014 Duke's
   Unrestricted Grant award, a PhD Studentship from Fight for Sight (UK)
   (to DRO, ERT), NIH Grant EY022359 (to DRO, WDS), and an International
   Research Scholar Award from the Research to Prevent Blindness Foundation
   (to DRO). The authors alone are responsible for the content and writing
   of this paper.
CR Adelman RA, 2010, J OCUL PHARMACOL TH, V26, P105, DOI 10.1089/jop.2009.0076
   Bakri SJ, 2009, EYE, V23, P181, DOI 10.1038/sj.eye.6702938
   Bakri SJ, 2008, GRAEF ARCH CLIN EXP, V246, P955, DOI 10.1007/s00417-008-0819-2
   Bakri SJ, 2014, OPHTHALMOLOGY, V121, P1102, DOI 10.1016/j.ophtha.2013.11.029
   BECKER B, 1958, AM J OPHTHALMOL, V46, P731, DOI 10.1016/0002-9394(58)91272-8
   Boyer DS, 2009, OPHTHALMOLOGY, V116, P1731, DOI 10.1016/j.ophtha.2009.05.024
   Choi DY, 2011, RETINA-J RET VIT DIS, V31, P1028, DOI 10.1097/IAE.0b013e318217ffde
   Dedania VS, 2015, RETINA-J RET VIT DIS, V35, P841, DOI 10.1097/IAE.0000000000000520
   DRANCE SM, 1980, SURV OPHTHALMOL, V25, P203, DOI 10.1016/0039-6257(80)90099-5
   Fujimoto T, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0161332
   Gal-Or O, 2016, EXP EYE RES, V145, P412, DOI 10.1016/j.exer.2016.02.006
   Good TJ, 2011, BRIT J OPHTHALMOL, V95, P1111, DOI 10.1136/bjo.2010.180729
   Hanhart J, 2014, EYE, V28, P646, DOI 10.1038/eye.2014.94
   Heier JS, 2012, OPHTHALMOLOGY, V119, P2537, DOI 10.1016/j.ophtha.2012.09.006
   Hoang QV, 2013, RETINA-J RET VIT DIS, V33, P179, DOI 10.1097/IAE.0b013e318261a6f7
   Kahook MY, 2010, J GLAUCOMA, V19, P437, DOI 10.1097/IJG.0b013e3181ca74de
   Kee C, 2000, BRIT J OPHTHALMOL, V84, P987, DOI 10.1136/bjo.84.9.987
   Kim JE, 2008, AM J OPHTHALMOL, V146, P930, DOI 10.1016/j.ajo.2008.07.007
   Kim YJ, 2014, AM J OPHTHALMOL, V157, P1266, DOI 10.1016/j.ajo.2014.02.035
   King AJ, 2016, JAMA OPHTHALMOL, V134, P742, DOI 10.1001/jamaophthalmol.2016.0994
   Liu L, 2011, INVEST OPHTH VIS SCI, V52, P1023, DOI 10.1167/iovs.10-6431
   Loukianou Eleni, 2011, International Ophthalmology, V31, P211, DOI 10.1007/s10792-010-9410-z
   Martin DF, 2012, OPHTHALMOLOGY, V119, DOI 10.1016/j.ophtha.2012.03.053
   Mathalone N, 2012, GRAEF ARCH CLIN EXP, V250, P1435, DOI 10.1007/s00417-012-1981-0
   Meyer MA, 1997, OPHTHALMOLOGY, V104, P1221, DOI 10.1016/S0161-6420(97)30154-7
   Nau CB, 2013, INVEST OPHTH VIS SCI, V54, P7623, DOI [10.1167/iovs.12-12690, 10.1167/iovs.13-12690]
   Reina-Torres E, 2017, VEGF PARACRINE REGUL, V58, P1899
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Segal O, 2013, ISR MED ASSOC J, V15, P352
   Selvadurai D, 2010, INVEST OPHTH VIS SCI, V51, P1453, DOI 10.1167/iovs.09-4058
   Shrivastava A, 2010, CURR OPIN OPHTHALMOL, V21, P118, DOI 10.1097/ICU.0b013e3283360ac3
   Sniegowski M, 2010, OPEN OPHTHALMOL J, V4, P28, DOI 10.2174/1874364101004010028
   Wehrli SJ, 2012, RETINA-J RET VIT DIS, V32, P1295, DOI 10.1097/IAE.0b013e31823f0c95
   Wen JC, 2016, RETINA
   Williams, 2014, REV OPHTHALMOLOGY
   Williams AL, 2013, J GLAUCOMA, V22, P215, DOI 10.1097/IJG.0b013e318237bfb8
   Yannuzzi NA, 2014, AM J OPHTHALMOL, V158, P319, DOI 10.1016/j.ajo.2014.04.029
NR 37
TC 33
Z9 35
U1 0
U2 1
PU ASSOC RESEARCH VISION OPHTHALMOLOGY INC
PI ROCKVILLE
PA 12300 TWINBROOK PARKWAY, ROCKVILLE, MD 20852-1606 USA
SN 0146-0404
EI 1552-5783
J9 INVEST OPHTH VIS SCI
JI Invest. Ophthalmol. Vis. Sci.
PD MAR
PY 2017
VL 58
IS 3
BP 1893
EP 1898
DI 10.1167/iovs.16-20786
PG 6
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA EQ4ZA
UT WOS:000398089000068
PM 28358961
OA Green Published, gold
DA 2022-11-30
ER

PT J
AU Sevilla, MB
   Mcgwin, G
   Lad, EM
   Clark, M
   Yuan, EL
   Farsiu, S
   Curcio, CA
   Owsley, C
   Toth, CA
AF Sevilla, Monica B.
   Mcgwin, Gerald, Jr.
   Lad, Eleonora M.
   Clark, Mark
   Yuan, Eric L.
   Farsiu, Sina
   Curcio, Christine A.
   Owsley, Cynthia
   Toth, Cynthia A.
TI Relating Retinal Morphology and Function in Aging and Early to
   Intermediate Age-related Macular Degeneration Subjects
SO AMERICAN JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
ID OPTICAL COHERENCE TOMOGRAPHY; SUBRETINAL DRUSENOID DEPOSITS; MEDIATED
   DARK-ADAPTATION; GEOGRAPHIC-ATROPHY; PIGMENT EPITHELIUM; PHOTORECEPTOR
   DEGENERATION; AUTOMATIC SEGMENTATION; RETICULAR PSEUDODRUSEN;
   MACULOPATHY; ROD
AB PURPOSE: To evaluate relationships between age-related macular degeneration (AMD) morphology on spectral domain optical coherence tomography (SDOCT) and visual function.
   DESIGN: Cross-sectional, observational.
   METHODS: From the Alabama Study on Early AMD baseline visit, visual acuity, cone-mediated sensitivity, rod-mediated dark adaptation, and SDOCT were obtained in 1 eye per subject with no apparent retinal aging (n = 15), normal aging (n = 15), early AMD (n = 15), and intermediate AMD (n = 46). The volumes of retinal pigment epithelium (RPE)-drusen complex, RPE-drusen complex abnormal thinning, RPE-drusen complex abnormal thickening, and inner and outer retina were calculated in specified regions using semi-automated SDOCT segmentation.
   RESULTS: Better cone-mediated sensitivity was associated with greater RPE-drusen complex volume (r = 0.34, P < .001) and less RPE-drusen complex abnormal thinning volume (r = -0.31, P = .003). Longer rod-mediated dark adaptation time, the duration for rod-mediated sensitivity to recover from photo bleach exposure, correlated with lower RPE-drusen complex volume (r = -0.34, P = .005) and greater RPE-drusen complex abnormal thinning volume (r = 0.280, P = .023). In 19 eyes with subretinal drusenoid deposits (SDD) vs 47 eyes without SDD, rod-mediated dark adaptation time was longer (mean +/- SD 13.5 +/- 7.0 vs 10.2 +/- 3.1 minutes, P = .004), RPE-drusen complex abnormal thinning volume was greater (P < .0001), and visual acuity and cone sensitivity did not differ.
   CONCLUSION: Decreased function relates to structural markers on SDOCT in AMD. Because the RPE-drusen complex includes the interdigitation of outer segments and RPE apical processes and SDD in eyes with AMD, slower dark adaptation might be related to structural abnormalities of the RPE, the RPE-photoreceptor interface, or both. (C) 2016 Elsevier Inc. All rights reserved.
C1 [Sevilla, Monica B.; Lad, Eleonora M.; Yuan, Eric L.; Farsiu, Sina; Toth, Cynthia A.] Duke Univ, Med Ctr, Dept Ophthalmol, 2351 Erwin Rd,Box 3802, Durham, NC 27710 USA.
   [Mcgwin, Gerald, Jr.; Clark, Mark; Curcio, Christine A.; Owsley, Cynthia] Univ Alabama Birmingham, Dept Ophthalmol, Sch Med, Birmingham, AL 35294 USA.
   [Farsiu, Sina; Toth, Cynthia A.] Duke Univ, Pratt Sch Engn, Dept Biomed Engn, Durham, NC 27710 USA.
   [Mcgwin, Gerald, Jr.] Univ Alabama Birmingham, Sch Publ Hlth, Dept Epidemiol, Birmingham, AL 35294 USA.
C3 Duke University; University of Alabama System; University of Alabama
   Birmingham; Duke University; University of Alabama System; University of
   Alabama Birmingham
RP Toth, CA (通讯作者)，Duke Univ, Med Ctr, Dept Ophthalmol, 2351 Erwin Rd,Box 3802, Durham, NC 27710 USA.
EM cynthia.toth@dm.duke.edu
RI Toth, Cynthia/L-5534-2019
OI Toth, Cynthia/0000-0002-2324-0854; Farsiu, Sina/0000-0003-4872-2902
FU THE ARNOLD AND MABEL BECKMAN INITIATIVE FOR MACULAR Research (Irvine,
   CA); Research to Prevent Blindness (New York, NY); Ernest and Della
   Thome Foundation (Boston, MA); National Eye Institute (NIH) [EY06109,
   P30 EY003039]; National Institute on Aging [R01AG04212]; Roche; NIH
   [EY06109, R01AG04212, 1R01EY023039]; National Eye Institute [P30
   EY003039]; Arnold and Mabel Beckman Initiative for Macular Research;
   International Retinal Research Foundation; Ernest and Della Thome
   Foundation; Research to Prevent Blindness [20090153802, 20110007276,
   20110141437]; EyeSight Foundation of Alabama; Alfreda J. Schueler Trust;
   Bioptigen; Genentech; NATIONAL EYE INSTITUTE [R01EY023039, P30EY003039,
   R01EY006109] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING
   [R01AG004212] Funding Source: NIH RePORTER
FX FUNDING/SUPPORT: THIS RESEARCH WAS SUPPORTED BY: THE ARNOLD AND MABEL
   BECKMAN INITIATIVE FOR MACULAR Research (Irvine, CA), Research to
   Prevent Blindness (New York, NY), the Ernest and Della Thome Foundation
   (Boston, MA), and the National Eye Institute (NIH EY06109; P30 EY003039)
   and the National Institute on Aging (R01AG04212). The funding
   organizations had no role in the design or conduct of this research.
   Financial disclosures: Eleonora M. Lad: Through her university, Dr Lad
   receives research support from Roche. Sina Farsiu: US Patent #8,811,745.
   Christine A. Curcio: Through her university, Dr Curcio receives research
   support through NIH EY06109, National Eye Institute P30 EY003039, Arnold
   and Mabel Beckman Initiative for Macular Research, International Retinal
   Research Foundation, Ernest and Della Thome Foundation, Research to
   Prevent Blindness, and EyeSight Foundation of Alabama. Cynthia Owsley:
   Through her university, Dr Owslcy receives research support through NIH
   R01AG04212, EyeSight Foundation of Alabama, Alfreda J. Schueler Trust,
   Research to Prevent Blindness, and is a patent holder on the apparatus
   used to measure dark adaptation in this study (#20090153802;
   #20110007276; #20110141437). Cynthia A. Toth: Through her university, Dr
   Toth receives research support from the Arnold and Mabel Beckman
   Initiative for Macular Research, Research to Prevent Blindness, NIH
   1R01EY023039, Bioptigen, Genentech, and royalties from Alcon
   Laboratories. The following authors have no financial disclosures:
   Monica B. Sevilla, Gerald McGwin Jr, Mark Clark, and Eric L. Yuan. All
   authors attest that they meet the current ICMJE criteria for authorship.
CR Beck RW, 2003, AM J OPHTHALMOL, V135, P194, DOI 10.1016/S0002-9394(02)01825-1
   Bonilha VL, 2004, EXP EYE RES, V79, P419, DOI 10.1016/j.exer.2004.04.001
   Bressler NM, 2006, AGE RELATED MACULAR, VII, P1041
   Chiu SJ, 2012, INVEST OPHTH VIS SCI, V53, P53, DOI 10.1167/iovs.11-7640
   Chiu SJ, 2010, OPT EXPRESS, V18, P19413, DOI 10.1364/OE.18.019413
   Curcio CA, 2000, INVEST OPHTH VIS SCI, V41, P2015
   Curcio CA, 1996, INVEST OPHTH VIS SCI, V37, P1236
   Curcio CA, 2013, RETINA-J RET VIT DIS, V33, P265, DOI 10.1097/IAE.0b013e31827e25e0
   Curcio CA, 2011, BRIT J OPHTHALMOL, V95, P1638, DOI 10.1136/bjophthalmol-2011-300344
   Dimitrov PN, 2008, INVEST OPHTH VIS SCI, V49, P55, DOI 10.1167/iovs.06-1048
   Farsiu S, 2014, OPHTHALMOLOGY, V121, P162, DOI 10.1016/j.ophtha.2013.07.013
   Ferris FL, 2013, OPHTHALMOLOGY, V120, P844, DOI 10.1016/j.ophtha.2012.10.036
   Finger RP, 2014, OPHTHALMOLOGY, V121, P1252, DOI 10.1016/j.ophtha.2013.12.034
   Fleckenstein M, 2010, INVEST OPHTH VIS SCI, V51, P3846, DOI 10.1167/iovs.09-4533
   Folgar FA, 2016, OPHTHALMOLOGY, V123, P39, DOI 10.1016/j.ophtha.2015.09.016
   Jackson GR, 2002, AGEING RES REV, V1, P381, DOI 10.1016/S1568-1637(02)00007-7
   Jackson GR, 2014, OPTOMETRY VISION SCI, V91, P925, DOI 10.1097/OPX.0000000000000247
   Jackson GR, 2014, INVEST OPHTH VIS SCI, V55, DOI 10.1167/iovs.13-13745
   Jackson Gregory R, 2008, J Ocul Biol Dis Infor, V1, P7, DOI 10.1007/s12177-008-9002-6
   Klein R, 2011, ARCH OPHTHALMOL-CHIC, V129, P75, DOI 10.1001/archophthalmol.2010.318
   Lamb TD, 2004, PROG RETIN EYE RES, V23, P307, DOI 10.1016/j.preteyeres.2004.03.001
   Mitamura Y, 2013, J OPHTHALMOL, V2013, DOI 10.1155/2013/518170
   Owsley C, 2000, INVEST OPHTH VIS SCI, V41, P267
   Owsley C, 2006, INVEST OPHTH VIS SCI, V47, P1310, DOI 10.1167/iovs.05-1292
   Owsley C, 2001, OPHTHALMOLOGY, V108, P1196, DOI 10.1016/S0161-6420(01)00580-2
   Owsley C, 2016, OPHTHALMOLOGY, V123, P344, DOI 10.1016/j.ophtha.2015.09.041
   Ross DH, 2015, INVEST OPHTH VIS SCI, V56, P4166, DOI 10.1167/iovs.14-15256
   Sadigh S, 2013, INVEST OPHTH VIS SCI, V54, P1603, DOI 10.1167/iovs.12-11286
   SARKS JP, 1988, EYE, V2, P552, DOI 10.1038/eye.1988.106
   SARKS SH, 1976, BRIT J OPHTHALMOL, V60, P324, DOI 10.1136/bjo.60.5.324
   Schuman SG, 2009, OPHTHALMOLOGY, V116, P488, DOI 10.1016/j.ophtha.2008.10.006
   Smith RT, 2010, BRIT J OPHTHALMOL, V94, P1618, DOI 10.1136/bjo.2009.166843
   Spaide RF, 2011, RETINA-J RET VIT DIS, V31, P1609, DOI 10.1097/IAE.0b013e3182247535
   Switzer DW, 2012, RETINA-J RET VIT DIS, V32, P1265, DOI 10.1097/IAE.0b013e31824453ac
   Wolf-Schnurrbusch UEK, 2008, INVEST OPHTH VIS SCI, V49, P3095, DOI 10.1167/iovs.07-1460
   Wu ZC, 2014, OPHTHALMOLOGY, V121, P1445, DOI 10.1016/j.ophtha.2014.01.025
   Xu LN, 2013, RETINA-J RET VIT DIS, V33, P1850, DOI 10.1097/IAE.0b013e31828991b2
   Zhang QX, 2013, SCI REP-UK, V3, DOI 10.1038/srep02644
   Zhao C, 2011, J CLIN INVEST, V121, P369, DOI 10.1172/JCI44303
   Zweifel SA, 2010, OPHTHALMOLOGY, V117, P303, DOI 10.1016/j.ophtha.2009.07.014
NR 40
TC 29
Z9 29
U1 0
U2 9
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0002-9394
EI 1879-1891
J9 AM J OPHTHALMOL
JI Am. J. Ophthalmol.
PD MAY
PY 2016
VL 165
BP 65
EP 77
DI 10.1016/j.ajo.2016.02.021
PG 13
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA DM3EF
UT WOS:000376228900012
PM 26940163
OA Green Accepted
DA 2022-11-30
ER

PT J
AU Chamard, C
   Lacombe, S
   Navarre, S
   Rohart, C
   Daures, JP
   Allieu, S
AF Chamard, C.
   Lacombe, S.
   Navarre, S.
   Rohart, C.
   Daures, J-P
   Allieu, S.
TI Is current age related macular degeneration self-monitoring a good tool
   for detecting exudative recurrence?
SO JOURNAL FRANCAIS D OPHTALMOLOGIE
LA English
DT Article
DE Age related macular degeneration; VEGF inhibitors; Self-monitoring;
   Amsler grid
ID RANIBIZUMAB; THERAPY
AB Purpose. - To assess the ability of patients with exudative AMD to detect exudative recurrence. Another objective was to assess if self-monitoring, as currently taught, improves this ability.
   Materials and methods. - An observational cross-sectional study was carried out in the ophthalmology center of BeauSoleil clinic in Montpellier between March 1 and April 1 2016. Inclusion criteria were presence of neovascutar age related macular degeneration treated with the loading dose of three monthly intravitreal anti-VEGF injections, with at least one injection in the past 12 months and at least one exudative recurrence. All patients underwent a visual acuity measurement with ETDRS charts at 4 meters. A questionnaire assessed familiarity with the Amster grid and its proper use, performance of and type of self-monitoring at home and the subjective feeling of an exudative recurrence at the visit with a 5-level Likert scale.
   Results. - A total of 94 eyes of 70 patients were included in this study with 69.0 % women and a median (interquartile range) age of 83 (77-96) years. Among them, 81 % performed regular self-monitoring, mostly with environmental Amster tests (70 %). Only 63 % of the patients knew of the Amster grid, among which 52 % used it correctly. Sensitivity (95 % confidence interval, 95 % CI) and specificity (95 % CI) of the subjective sensation of exudative recurrence were 0.32 (0.14-0.55) and 0.85 (0.74-0.92), respectively, for the entire population. Sensitivity (95 % CI) and specificity (95 % CI) were 0.33 (0.13-0.59) and 0.85 (0.74-0.93); 0.25 (0.0063-0.81) and 0.82 (0.48-0.98), respectively, in patients performing and not performing self-monitoring.
   Conclusion. - Patients' prediction in wet AMD is insufficient in detecting exudative recurrences, even if regular self-monitoring with Amster grid or environmental Mister is performed. (C) 2019 Elsevier Masson SAS. All rights reserved.
C1 [Chamard, C.] CHRU Montpellier, Hop Gui Chauliac, Serv Ophtalmol, 80 Ave Augustin Fliche, F-34090 Montpellier, France.
   [Lacombe, S.; Navarre, S.; Rohart, C.; Daures, J-P; Allieu, S.] Ctr Ophtalmol, Clin BeauSoleil Montpellier, 119 Ave Lodeve, F-34070 Montpellier, France.
C3 Universite de Montpellier; CHU de Montpellier; Beau Soleil Clinic
RP Chamard, C (通讯作者)，CHRU Montpellier, Hop Gui Chauliac, Serv Ophtalmol, 80 Ave Augustin Fliche, F-34090 Montpellier, France.
EM chloe.chamard@wanadoo.fr
RI CHAMARD, Chloé/Z-1728-2019
CR ACHARD OA, 1995, AM J OPHTHALMOL, V120, P322, DOI 10.1016/S0002-9394(14)72162-2
   AMSLER M, 1947, OPHTHALMOLOGICA, V114, P248, DOI 10.1159/000300476
   Aslam TM, 2016, GRAEF ARCH CLIN EXP, V254, P891, DOI 10.1007/s00417-016-3293-2
   Bourne RRA, 2018, BRIT J OPHTHALMOL, V102, P575, DOI 10.1136/bjophthalmol-2017-311258
   Claessen H, 2012, EUR J EPIDEMIOL, V27, P519, DOI 10.1007/s10654-012-9705-7
   Daien V, 2018, OPHTHALMOLOGY, V125, P66, DOI 10.1016/j.ophtha.2017.07.005
   Delcourt C, 2016, EUR J EPIDEMIOL, V31, P197, DOI 10.1007/s10654-015-0098-2
   Faes L, 2014, EYE, V28, P788, DOI 10.1038/eye.2014.104
   Gupta OP, 2010, OPHTHALMOLOGY, V117, P2134, DOI 10.1016/j.ophtha.2010.02.032
   Loewenstein A, 2003, OPHTHALMOLOGY, V110, P966, DOI 10.1016/S0161-6420(03)00074-5
   Mantel I, 2014, BRIT J OPHTHALMOL, V98, P1192, DOI 10.1136/bjophthalmol-2013-304556
   Mathew R, 2012, EYE, V26, P389, DOI 10.1038/eye.2011.326
   Morshedi RG, 2016, J GLAUCOMA, V25, P291, DOI 10.1097/IJG.0000000000000173
   SCHUCHARD RA, 1993, ARCH OPHTHALMOL-CHIC, V111, P776, DOI 10.1001/archopht.1993.01090060064024
   Schutze C, 2015, AM J OPHTHALMOL, V159, P1100, DOI 10.1016/j.ajo.2015.02.020
   Takahashi H, 2015, RETINA-J RET VIT DIS, V35, P1331, DOI 10.1097/IAE.0000000000000513
   von Elm E, 2008, GAC SANIT, V22, P144, DOI 10.1157/13119325
   Wolf S, 2014, OPHTHALMOLOGY, V121, P682, DOI 10.1016/j.ophtha.2013.10.023
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
NR 19
TC 5
Z9 5
U1 0
U2 4
PU MASSON EDITEUR
PI MOULINEAUX CEDEX 9
PA 21 STREET CAMILLE DESMOULINS, ISSY, 92789 MOULINEAUX CEDEX 9, FRANCE
SN 0181-5512
EI 1773-0597
J9 J FR OPHTALMOL
JI J. Fr. Ophthamol.
PD DEC
PY 2019
VL 42
IS 10
BP 1049
EP 1055
DI 10.1016/j.jfo.2019.02.017
PG 7
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA JR5RY
UT WOS:000499683200013
PM 31727329
OA Green Published
DA 2022-11-30
ER

PT J
AU Theodossiadis, PG
   Liarakos, VS
   Sfikakis, PP
   Vergados, IA
   Theodossiadis, GP
AF Theodossiadis, Panagiotis G.
   Liarakos, Vasilios S.
   Sfikakis, Petros P.
   Vergados, Ioannis A.
   Theodossiadis, George P.
TI Intravitreal Administration of the Anti-Tumor Necrosis Factor Agent
   Infliximab for Neovascular Age-related Macular Degeneration
SO AMERICAN JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
ID REFRACTORY UVEITIS; FACTOR-ALPHA; THERAPY; ADALIMUMAB; INHIBITION;
   EXPRESSION; SAFETY
AB PURPOSE: To present our preliminary experience on intravitreal administration of an anti-tumor necrosis factor (TNF) monoclonal antibody for neovascular age-related macular degeneration (AMD).
   DESIGN: Prospective, noncomparative series of 3 patients previously treated with an anti-vascular endothelial growth factor agent.
   METHODS: Two intravitreal injections of 0.05 ml containing infliximab were administered in the first (1 and 2 mg, 2 months apart), second (2 mg each, 2 months apart), and third patient (2 mg each, 3 months apart). Best-corrected visual acuity (BCVA) and central foveal thickness (CFT) were monthly assessed for up to 7 months.
   RESULTS: In the first patient, BCVA increased from 20/200 to 20/100 and CFT decreased from 462 to 386 mu m, 2 months after the first injection. The condition was further improved after the second injection (BCVA, 20/40; CFT, 210 mu m), but recurrence occurred 7 months post-baseline. In the second patient, BCVA increased from 20/200 to 20/70 and CFT decreased from 512 to 420 and 184 mu m, 2 and 4 months post-baseline, respectively. In the third patient, clinical improvement was documented after the first injection. A second injection attributable to recurrence resulted in improvement of BCVA from 20/100 to 20/30 and decrease of CFT from 388 to 282 mu m, 2 months after the second injection.
   CONCLUSIONS: These findings, although insufficient to consider "off-label" treatment with intravitreal infliximab, provide in vivo evidence of a pathogenetic link of locally produced and/or acting TNF to neovascular AMD. A randomized Study of consecutive intravitreal injections of infliximab for AMD may be warranted. (Am J Ophthalmol 2009;147:825-830. (c) 2009 by Elsevier Inc. All rights reserved.)
C1 [Theodossiadis, Panagiotis G.; Liarakos, Vasilios S.; Vergados, Ioannis A.] Univ Athens, Attikon Univ Hosp, Dept Ophthalmol 2, Athens, Greece.
   [Sfikakis, Petros P.] Univ Athens, Laikon Hosp, Dept Propedeut Med 1, Athens, Greece.
   [Theodossiadis, George P.] Henry Dunant Hosp, Dept Ophthalmol, Athens, Greece.
C3 National & Kapodistrian University of Athens; University Hospital
   Attikon; Laiko General Hospital; National & Kapodistrian University of
   Athens; Henry Dunant Hospital
RP Theodossiadis, PG (通讯作者)，13 Lykiou St, Athens 10675, Greece.
EM patheo@med.uoa.gr
RI Sfikakis, Petros/AAD-7289-2019
CR Armstrong D, 1998, OPHTHALMOLOGICA, V212, P410, DOI 10.1159/000027378
   Canete JD, 2004, ARTHRITIS RHEUM, V50, P1636, DOI 10.1002/art.20181
   Diaz-Llopis M, 2008, J OCUL PHARMACOL TH, V24, P351, DOI 10.1089/jop.2007.0104
   Giansanti F, 2008, INVEST OPHTH VIS SCI, V49, P1151, DOI 10.1167/iovs.07-0932
   Gragoudas ES, 2004, NEW ENGL J MED, V351, P2805, DOI 10.1056/NEJMoa042760
   Jin ML, 2000, INVEST OPHTH VIS SCI, V41, P4324
   Keystone EC, 2005, J RHEUMATOL, V32, P8
   Majka S, 2002, INVEST OPHTH VIS SCI, V43, P260
   Manzano RPA, 2008, GRAEF ARCH CLIN EXP, V246, P907, DOI 10.1007/s00417-008-0765-z
   Markomichelakis NN, 2005, AM J OPHTHALMOL, V139, P537, DOI 10.1016/j.ajo.2004.09.058
   Mitoma H, 2008, ARTHRITIS RHEUM-US, V58, P1248, DOI 10.1002/art.23447
   Nussenblatt RB, 2007, AM J OPHTHALMOL, V144, P618, DOI 10.1016/j.ajo.2007.06.025
   Oh H, 1999, INVEST OPHTH VIS SCI, V40, P1891
   Olson JL, 2007, ARCH OPHTHALMOL-CHIC, V125, P1221, DOI 10.1001/archopht.125.9.1221
   Sfikakis PP, 2005, ARTHRITIS RHEUM-US, V52, P2513, DOI 10.1002/art.21233
   Sfikakis PP, 2001, LANCET, V358, P295, DOI 10.1016/S0140-6736(01)05497-6
   Sfikakis PP, 2004, ANN INTERN MED, V140, P404, DOI 10.7326/0003-4819-140-5-200403020-00025
   Shi X, 2006, EXP EYE RES, V83, P1325, DOI 10.1016/j.exer.2006.07.007
   Sobrin L, 2007, ARCH OPHTHALMOL-CHIC, V125, P895, DOI 10.1001/archopht.125.7.895
   Suhler EB, 2005, ARCH OPHTHALMOL-CHIC, V123, P903, DOI 10.1001/archopht.123.7.903
   TANO Y, 1980, AM J OPHTHALMOL, V89, P131, DOI 10.1016/0002-9394(80)90239-1
   Theodossiadis PG, 2007, RETINA-J RET VIT DIS, V27, P399, DOI 10.1097/MAJ.0b013e3180318fbc
   Theodossiadis P, 2009, GRAEF ARCH CLIN EXP, V247, P273, DOI 10.1007/s00417-008-0967-4
   Tsilimbaris Miltiadis K, 2007, Semin Ophthalmol, V22, P75, DOI 10.1080/08820530701418243
   Tynjala P, 2008, RHEUMATOLOGY, V47, P339, DOI 10.1093/rheumatology/kem356
   Ueda Toshihiko, 1998, Angiogenesis, V1, P174
   van Laar JAM, 2007, ANN RHEUM DIS, V66, P565, DOI 10.1136/ard.2006.064279
   Vedula SS, 2008, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD005139.pub2
   Wegscheider BJ, 2007, EYE, V21, P547, DOI 10.1038/sj.eye.6702262
   Yang P, 2005, INVEST OPHTH VIS SCI, V46, P1755, DOI 10.1167/iovs.04-1039
   Yang P, 2004, INVEST OPHTH VIS SCI, V45, P2438, DOI 10.1167/iovs.03-0805
NR 31
TC 101
Z9 118
U1 0
U2 5
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 0002-9394
EI 1879-1891
J9 AM J OPHTHALMOL
JI Am. J. Ophthalmol.
PD MAY
PY 2009
VL 147
IS 5
BP 825
EP 830
DI 10.1016/j.ajo.2008.12.004
PG 6
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 441IQ
UT WOS:000265762900012
PM 19211094
DA 2022-11-30
ER

PT J
AU Evans, JR
   Igwe, C
   Jackson, TL
   Chong, V
AF Evans, Jennifer R.
   Igwe, Chinedu
   Jackson, Timothy L.
   Chong, Victor
TI Radiotherapy for neovascular age-related macular degeneration
SO COCHRANE DATABASE OF SYSTEMATIC REVIEWS
LA English
DT Review
ID SUBFOVEAL CHOROIDAL NEOVASCULARIZATION; RADIATION-THERAPY; EPIMACULAR
   BRACHYTHERAPY; STEREOTACTIC RADIOTHERAPY; BEAM IRRADIATION;
   CONTROLLED-TRIAL; VISUAL-ACUITY; MEMBRANES; SECONDARY; OUTCOMES
AB Background
   Radiotherapy has been proposed as a treatment for new vessel growth in people with neovascular age-related macular degeneration (AMD).
   Objectives
   To examine the effects of radiotherapy on neovascular AMD.
   Search methods
   We searched CENTRAL, MEDL1NE, Embase, LILACS and three trials registers and checked references of included studies. We last searched the databases on 4 May 2020.
   Selection criteria
   We included all randomised controlled trials in which radiotherapy was compared to another treatment, sham treatment, low dosage irradiation or no treatment in people with choroidal neovascularisation (CNV) secondary to AMD.
   Data collection and analysis
   We used standard procedures expected by Cochrane. We graded the certainty of the evidence using GRADE. We considered the following outcomes at 12 months: best-corrected visual acuity (BCVA) (loss of 3 or more lines, change in visual acuity), contrast sensitivity, new vessel growth, quality of life and adverse effects at any time point.
   Main results
   We included 18 studies (n = 2430 people, 2432 eyes) of radiation therapy with dosages ranging from 7.5 to 24 Gy. These studies mainly took place in Europe and North America but two studies were from Japan and one multicentre study included sites in South America. Three of these studies investigated brachytherapy (plaque and epimacular), the rest were studies of external beam radiotherapy (EBM) including one trial of stereotactic radiotherapy. Four studies compared radiotherapy combined with anti-vascular endothelial growth factor (antiVEGF) with anti-VEGF alone. Eleven studies gave no radiotherapy treatment to the control group; five studies used sham irradiation; and one study used very low-dose irradiation (1 Gy) One study used a mixture of sham irradiation and no treatment. Fifteen studies were judged to be at high risk of bias in one or more domains.
   Radiotherapy versus no radiotherapy
   There may be little or no difference in loss of 3 lines of vision at 12 months in eyes treated with radiotherapy compared with no radiotherapy (risk ratio (RR) 0.82, 95% confidence interval (CI) 0.64 to 1.04, 811 eyes, 8 studies, 12 = 660/0, low-certainty evidence). Low-certainty evidence suggests a small benefit in change in visual acuity (mean difference (MD)-0.10 logMAR, 95% CI-0.17 to-0.03; eyes =o83; studies = 10) and average contrast sensitivity at 12 months (MD 0.15 log units, 95% CI 0.05 to 0.25; eyes = 267; studies= 2). Growth of new vessels (largely change in CNV size) was variably reported and It was not possible to produce a summary estimate of this outcome. The studies were small with imprecise estimates and there was no consistent pattern to the study results (very low-certainty evidence). Quality of life was only reported in one study of 199 people; there was no clear difference between treatment and control groups (low certainty evidence). Low-certainty evidence was available on adverse effects from eight of 14 studies. Seven studies reported on radiation retinopathy and/or neuropathy. Five of these studies reported no radiation-associated adverse effects. One study of 88 eyes reported one case of possible radiation retinopathy. One study of 74 eyes graded retinal abnormalities in some detail and found that 72% of participants who had radiation compared with 71% of participants in the control group had retinal abnormalities resembling radiation retinopathy or choroidopathy. Four studies reported cataract surgery or progression: events were generally few with no consistent evidence of any increased occurrence in the radiation group. One study noted transient disturbance of the precorneal tear film but there was no evidence from the other two studies that reported dry eye of any increased risk with radiation therapy. None of the participants received anti-VEGF injections.
   Radiotherapy combined with anti-VEGF versus anti-VEGF alone
   People receiving radiotherapy/anti-VEGF were probably more likely to lose 3 or more lines of BCVA at 12 months compared with anti-VEGF alone (RR 2.11, 95% CI 1.40 to 3.17, 1050 eyes, 3 studies, moderate-certainty). Most of the data for this outcome come from two studies of epimacular brachytherapy (114 events) compared with 20 events from the one trial of EBM. Data on change in BCVA were heterogenous (12 = 82%). Individual study results ranged from a small difference of-0.03 logMAR in favour of radiotherapy/anti-VEGF to a difference of 0.13 logMAR in favour of anti-VEGF alone (low-certainty evidence). The effect differed depending on how the radiotherapy was delivered (test for interaction P = 0.0007). Epimacular brachytherapy was associated with worse visual outcomes (MD 0.10 logMAR, 9.50/s CI 0.05 to 0.15, 820 eyes, 2 studies) compared with EBM (MD-0.03 logMAR, 95% CI-0.09 to 0.03, 252 eyes, 2 studies). None of the included studies reported contrast sensitivity or quality of life. Growth of new vessels (largely change in CNV size) was variably reported in three studies (803 eyes). It was not possible to produce a summary estimate and there was no consistent pattern to the study results (very low-certainty evidence). For adverse outcomes, variable results were reported in the four studies. In three studies reports of adverse events were low and no radiation associated adverse events were reported. In one study of epimacular brachytherapy there was a higher proportion of ocular adverse events (54%) compared to the anti-VEGF alone (18%). The majority of these adverse events were cataract. Overall 5% of the treatment group had radiation device-related adverse events (17 cases); 10 of these cases were radiation retinopathy. There were differences in average number of injections given between the four studies (1072 eyes). In three of the four studies, the a nti-VEGF alone group on average received more injections (moderate-certainty evidence).
   Authors' conclusions
   The evidence is uncertain regarding the use of radiotherapy for neovascular AMD. Most studies took place before the routine use of anti-VEGF, and before the development of modern radiotherapy techniques such as stereotactic radiotherapy. Visual outcomes with epimacular brachytherapy are likely to be worse, with an increased risk of adverse events, probably related to vitrectomy. The role of stereotactic radiotherapy combined with anti-VEGF is currently uncertain. Further research on radiotherapy for neovascular AMD may not be justified until current ongoing studies have reported their results.
C1 [Evans, Jennifer R.] London Sch Hyg & Trop Med, ICEH, Cochrane Eyes & Vis, London, England.
   [Igwe, Chinedu] Sutton Hosp, Sutton, Surrey, England.
   [Jackson, Timothy L.] Kings Coll London, Dept Ophthalmol, London, England.
   [Chong, Victor] Oxford Eye Hosp, Oxford, England.
C3 University of London; London School of Hygiene & Tropical Medicine;
   University of London; King's College London
RP Chong, V (通讯作者)，Oxford Eye Hosp, Oxford, England.
EM victor@eretina.org
RI Chong, Victor/Q-6565-2018
OI Chong, Victor/0000-0002-7693-522X
FU Guide Dogs for the Blind Association, UK; National Institute for Health
   Research (NIHR), UK; Department of Health through the National Institute
   for Health Research; UCL Institute of Ophthalmology; NIHR, via Cochrane
   Infrastructure
FX Guide Dogs for the Blind Association, UK; National Institute for Health
   Research (NIHR), UK; Richard Wormald, Co-ordinating Editor for Cochrane
   Eyes and Vision (CEV) received financial support for his CEV research
   sessions (during this update) from the Department of Health through the
   award made by the National Institute for Health Research to Moorfields
   Eye Hospital NHS Foundation Trust and UCL Institute of Ophthalmology for
   a Specialist Biomedical Research Centre for Ophthalmology.; This review
   update was supported by the NIHR, via Cochrane Infrastructure funding to
   the CEV UK editorial base.
CR Anders N, 1998, OPHTHALMOLOGE, V95, P760, DOI 10.1007/s003470050349
   [Anonymous], 2003, Nippon Ganka Gakkai Zasshi, V107, P326
   Avila MP, 2009, BRIT J OPHTHALMOL, V93, P305, DOI 10.1136/bjo.2008.145912
   Barak A, 2005, BRIT J RADIOL, V78, P827, DOI 10.1259/bjr/17631422
   Bellmann C, 2003, GRAEF ARCH CLIN EXP, V241, P968, DOI 10.1007/s00417-003-0689-6
   Bergink GJ, 1998, GRAEF ARCH CLIN EXP, V236, P321, DOI 10.1007/s004170050085
   BERGINK GJ, 1995, DOC OPHTHALMOL, V90, P67, DOI 10.1007/BF01203296
   Brown GC, 1997, INT J RAD ONCOLOG S1, V39, P332
   Char DH, 1999, AM J OPHTHALMOL, V127, P574, DOI 10.1016/S0002-9394(99)00038-0
   Churei Hisahiko, 2004, Radiat Med, V22, P398
   Ciulla TA, 2002, AM J OPHTHALMOL, V134, P905, DOI 10.1016/S0002-9394(02)01821-4
   Dugel PU, 2013, OPHTHALMOLOGY, V120, P317, DOI 10.1016/j.ophtha.2012.07.068
   Englander M, 2013, CURR OPIN OPHTHALMOL, V24, P233, DOI 10.1097/ICU.0b013e32835f8eaa
   Eter N, 2001, GRAEF ARCH CLIN EXP, V239, P923, DOI 10.1007/s00417-001-0391-5
   Eter N, 2002, INT OPHTHALMOL, V24, P13
   Evans JR, 2012, EPIDEMIOLOGY EYE DIS
   Flaxman SR, 2017, LANCET GLOB HEALTH, V5, pE1221, DOI 10.1016/S2214-109X(17)30393-5
   Freiberg FJ, 2019, BRIT J OPHTHALMOL, V103, P469, DOI 10.1136/bjophthalmol-2018-311865
   Friedrichsen EJ, 1996, AM ACAD OPHTHALMOLOG, P135
   Glanville JM, 2006, J MED LIBR ASSOC, V94, P130
   GRADE Working Group McMaster University GRADEpro GDT, 2020, VERS ACC PRIOR 7 MAY
   Hart PM, 2002, ARCH OPHTHALMOL-CHIC, V120, P1029
   Hart PM, 1999, BRIT J OPHTHALMOL, V83, P1115, DOI 10.1136/bjo.83.10.1115
   Heier JS, 2008, MACULAR SOC, P186
   Holz FG, 1999, AM ACAD OPHTHALMOLOG, P247
   Holz FG, 2000, AM ACAD OPHTHALMOLOG, V115
   Honjo M, 1997, JAPANESE J CLIN OPHT, V51, P1563
   Hoyng CB, 2002, GRAEF ARCH CLIN EXP, V240, P337, DOI 10.1007/s00417-002-0428-4
   Jaakkola A, 2005, OPHTHALMOLOGY, V112, P567, DOI 10.1016/j.ophtha.2004.11.029
   Jackson TL, 2012, EYE, V26, P557, DOI 10.1038/eye.2011.351
   Jackson TL, 2016, OPHTHALMOLOGY, V123, P1287, DOI 10.1016/j.ophtha.2016.02.028
   Jackson TL, 2015, RETINA-J RET VIT DIS, V35, P194, DOI 10.1097/IAE.0000000000000283
   Jackson TL, 2015, OPHTHALMOLOGY, V122, P138, DOI 10.1016/j.ophtha.2014.07.043
   Jackson TL, 2013, OPHTHALMOLOGY, V120, P1893, DOI 10.1016/j.ophtha.2013.02.016
   Jackson TL, 2013, OPHTHALMOLOGY, V120, P1597, DOI 10.1016/j.ophtha.2013.01.074
   Jackson TL, 2020, JAMA OPHTHALMOLOGY, V138, P1
   Kacperek A, 2001, PHYS MEDICA, V17, P7
   Kim LN, 2016, RETINA-J RET VIT DIS, V36, P1418, DOI 10.1097/IAE.0000000000001142
   Kirkham JJ, 2010, BMJ-BRIT MED J, V340, pc365, DOI DOI 10.1136/BMJ.C365
   Kishan AU, 2013, INT J RADIAT ONCOL, V85, P583, DOI 10.1016/j.ijrobp.2012.07.2352
   Kobayashi H, 2000, AM J OPHTHALMOL, V130, P617, DOI 10.1016/S0002-9394(00)00534-1
   Li E, 2020, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD012208.pub2
   Lu J, 2017, INVESTIGATIVE OPHTHA, V58
   Mandai M, 2000, JAPANESE J OPHTHALMO, V44, P530
   Mandai M, 1998, JAPANESE J CLIN OPHT, V52, P567
   Marcus D, 2004, AM J OPHTHALMOL, V138, P818, DOI 10.1016/j.ajo.2004.06.081
   Marcus DM, 2004, BRIT J OPHTHALMOL, V88, P114, DOI 10.1136/bjo.88.1.114
   Marcus DM, 1999, RETINA-J RET VIT DIS, V19, P525, DOI 10.1097/00006982-199911000-00008
   Marcus DM, 2001, ARCH OPHTHALMOL-CHIC, V119, P171
   Matsuhashi H, 2000, JPN J OPHTHALMOL, V44, P653, DOI 10.1016/S0021-5155(00)00280-X
   Matsuhashi Hideaki, 1996, Nippon Ganka Gakkai Zasshi, V100, P803
   Mendez CAM, 2013, DEV OPHTHALMOL, V52, P75, DOI 10.1159/000351061
   Nordic Cochrane Centre, 2014, COCHR COLL REV MAN 5
   Osmanovic S, 2017, OPHTHALMOLOGY RETINA, V1, P217
   Postgens H, 1997, GRAEF ARCH CLIN EXP, V235, P656, DOI 10.1007/BF00946943
   Reichel E, 2007, INVESTIGATIVE OPHTHA, V48
   Saric B, 2001, COLLEGIUM ANTROPOL, V25, P89
   Silva RA, 2011, SEMIN OPHTHALMOL, V26, P121, DOI 10.3109/08820538.2011.554486
   Stevenson MR, 2005, BRIT J OPHTHALMOL, V89, P1045, DOI 10.1136/bjo.2003.030445
   Taniguchi T, 1996, JAPANESE J CLIN OPHT, V50, P1821
   The Radiation Therapy for Age -Related Macular Degeneration (RAD) Group, 1999, OPHTHALMOLOGY, V106, P2239
   Tholen AM, 2000, KLIN MONATSBL AUGENH, V216, P112, DOI 10.1055/s-2000-10528
   Tholen AM, 1998, OPHTHALMOLOGE, V95, P691, DOI 10.1007/s003470050337
   Vacha P, 2001, EUR J CANCER, V37, P275
   Valmaggia C, 2002, AM J OPHTHALMOL, V133, P521, DOI 10.1016/S0002-9394(02)01336-3
   Valmaggia Christophe, 2001, Documenta Ophthalmologica, V103, P201, DOI 10.1023/A:1013047722865
   Wong S, 2017, INVESTIGATIVE OPHTHA, V58
   Zambarakji HJ, 2006, OPHTHALMOLOGY, V113, P2012, DOI 10.1016/j.ophtha.2006.05.036
NR 68
TC 0
Z9 0
U1 0
U2 2
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1469-493X
EI 1361-6137
J9 COCHRANE DB SYST REV
JI Cochrane Database Syst Rev.
PY 2020
IS 8
AR CD004004
DI 10.1002/14551858.00004004.pub4
PG 92
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine
GA NN3IF
UT WOS:000568684200032
DA 2022-11-30
ER

PT J
AU Feigl, B
   Brown, B
   Lovie-Kitchin, J
   Swann, P
AF Feigl, B.
   Brown, B.
   Lovie-Kitchin, J.
   Swann, P.
TI Functional loss in early age-related maculopathy: the ischaemia
   postreceptoral hypothesis
SO EYE
LA English
DT Review
DE early age-related maculopathy; ARM; ischaemia; postreceptoral function;
   multifocal ERG; rod-mediated function
ID CHOROIDAL BLOOD-FLOW; MEDIATED MULTIFOCAL ELECTRORETINOGRAM; COMPLEMENT
   FACTOR-H; MACULAR DEGENERATION; BRUCHS MEMBRANE; DARK-ADAPTATION;
   GROWTH-FACTORS; OXYGEN DISTRIBUTION; RETINAL FUNCTION; CONE
AB We review proposed models and psychophysical and electrophysiological tests performed in many studies for early age-related maculopathy ( ARM). We suggest that ischaemia is the trigger for impaired retinal pigment epithelium function causing imbalance of secretion of vascular growth factors, reduced disc degradation capability and reduced metabolic activity and possible inflammatory response. This results in increased deposition of cell debris, such as drusen and thickens Bruch's membrane causing even more ischaemia of the overlying neurosensory retina. The photoreceptors are more resistant to ischaemia given their proximity to the choroid. Furthermore, being 'upstream' from the inner retinal layers, they act as an oxygen sink depriving retinal layers further from the choroid. Postreceptoral cell layers and especially parts of the inner nuclear layer that are located in the watershed zone between two sources of blood supply are preferentially vulnerable to ischaemia. Based on psychophysical and electrophysiological findings we propose that most of the function impairment in early ARM starts postreceptorally.
C1 Queensland Univ Technol, Ctr Hlth & Biomed Innovat, Sch Optometry, Inst Hlth & Biomed Innovat, Kelvin Grove, Qld 4059, Australia.
C3 Queensland University of Technology (QUT)
RP Feigl, B (通讯作者)，Queensland Univ Technol, Ctr Hlth & Biomed Innovat, Sch Optometry, Inst Hlth & Biomed Innovat, Victoria Pk Rd, Kelvin Grove, Qld 4059, Australia.
EM b.feigl@qut.edu.au
OI Feigl, Beatrix/0000-0001-7198-7373
CR Allikmets R, 2000, AM J HUM GENET, V67, P487, DOI 10.1086/303018
   Allikmets R, 1997, SCIENCE, V277, P1805, DOI 10.1126/science.277.5333.1805
   AMIN R, 1994, INVEST OPHTH VIS SCI, V35, P3178
   [Anonymous], 1993, Arch Ophthalmol, V111, P1200
   Arden GB, 2005, BRIT J OPHTHALMOL, V89, P764, DOI 10.1136/bjo.2004.062547
   Arden GB, 2003, INVEST OPHTH VIS SCI, V44, P3226, DOI 10.1167/iovs.02-0998
   Arden GB, 1998, VISION RES, V38, P1723, DOI 10.1016/S0042-6989(98)00004-2
   Avery RL, 2006, OPHTHALMOLOGY, V113, P363, DOI 10.1016/j.ophtha.2005.11.019
   Bird AC, 2003, CLIN EXP OPHTHALMOL, V31, P461, DOI 10.1046/j.1442-9071.2003.00721.x
   Bird AC, 2003, EYE, V17, P457, DOI 10.1038/sj.eye.6700562
   BIRD AC, 1991, EYE, V5, P1
   BIRD AEC, 1995, SURV OPHTHALMOL, V39, P367, DOI 10.1016/S0039-6257(05)80092-X
   Blaauwgeers HGT, 1999, AM J PATHOL, V155, P421, DOI 10.1016/S0002-9440(10)65138-3
   Block F, 1998, GEN PHARMACOL-VASC S, V30, P281, DOI 10.1016/S0306-3623(97)00359-5
   Blumenkranz MS, 2001, ARCH OPHTHALMOL-CHIC, V119, P198
   Bok D, 2005, P NATL ACAD SCI USA, V102, P7053, DOI 10.1073/pnas.0502819102
   Boulton M, 2001, EYE, V15, P384, DOI 10.1038/eye.2001.141
   Bressler NM, 2002, ARCH OPHTHALMOL-CHIC, V120, P1307
   BROWN B, 1983, AM J OPTOM PHYS OPT, V60, P788
   Brown B, 1987, CLIN EXP OPTOM, V70, P145
   Bui BV, 2003, EXP EYE RES, V77, P125, DOI 10.1016/S0014-4835(03)00132-5
   Chen Changzheng, 2003, Yan Ke Xue Bao, V19, P15
   Chen CZ, 2004, DOC OPHTHALMOL, V109, P1
   CHEN JC, 1992, INVEST OPHTH VIS SCI, V33, P334
   CHENG AS, 1993, OPTOMETRY VISION SCI, V70, P89, DOI 10.1097/00006324-199302000-00001
   Ciulla TA, 1999, AM J OPHTHALMOL, V128, P75, DOI 10.1016/S0002-9394(99)00061-6
   COLEMAN K, 1990, EUR J VASCULAR SURG, V4, P13
   COLLINS M, 1989, CLIN VISION SCI, V4, P155
   Collins MJ, 1986, CLIN EXP OPTOM, V69, P223, DOI DOI 10.1111/J.1444-0938.1986.TB04596.X
   Cringle SJ, 2002, INVEST OPHTH VIS SCI, V43, P1922
   Curcio CA, 2000, INVEST OPHTH VIS SCI, V41, P2015
   Curcio CA, 2001, EYE, V15, P376, DOI 10.1038/eye.2001.140
   EISNER A, 1991, INVEST OPHTH VIS SCI, V32, P8
   EISNER A, 1992, INVEST OPHTH VIS SCI, V33, P3091
   Elsner AE, 2002, J OPT SOC AM A, V19, P215, DOI 10.1364/JOSAA.19.000215
   EPERON G, 1975, INVEST OPHTH VISUAL, V14, P342
   Ezzati M, 2005, CIRCULATION, V112, P489, DOI 10.1161/CIRCULATIONAHA.104.521708
   Feigl B, 2005, EYE, V19, P1169, DOI 10.1038/sj.eye.6701711
   Feigl B, 2005, EYE, V19, P431, DOI 10.1038/sj.eye.6701503
   Feigl B, 2004, CURR EYE RES, V29, P327, DOI 10.1080/02713680490516198
   Feigl Beatrix, 2005, Clin Exp Optom, V88, P304
   Fine SL, 2005, AM J OPHTHALMOL, V139, P405, DOI 10.1016/j.ajo.2004.11.050
   FRIEDMAN E, 1995, OPHTHALMOLOGY, V102, P640, DOI 10.1016/S0161-6420(95)30974-8
   FRIEDMAN E, 1972, ARCH OPHTHALMOL-CHIC, V87, P70, DOI 10.1001/archopht.1972.01000020072015
   GASS JDM, 1967, AM J OPHTHALMOL, V64, P612
   Gonzales CR, 2005, RETINA-J RET VIT DIS, V25, P815
   Gragoudas ES, 2004, NEW ENGL J MED, V351, P2805, DOI 10.1056/NEJMoa042760
   GREENING HS, 1987, AQUAT BOT, V28, P113, DOI 10.1016/0304-3770(87)90034-9
   GREENSTEIN VC, 1989, INVEST OPHTH VIS SCI, V30, P1732
   Grozdanic SD, 2003, INVEST OPHTH VIS SCI, V44, P2597, DOI 10.1167/iovs.02-0600
   Grunwald JE, 1998, INVEST OPHTH VIS SCI, V39, P385
   Grunwald JE, 2005, INVEST OPHTH VIS SCI, V46, P1033, DOI 10.1167/iovs.04-1050
   Guymer R, 1999, PROG RETIN EYE RES, V18, P59, DOI 10.1016/S1350-9462(98)00012-3
   Hageman GS, 2001, PROG RETIN EYE RES, V20, P705, DOI 10.1016/S1350-9462(01)00010-6
   Hageman GS, 2005, P NATL ACAD SCI USA, V102, P7227, DOI 10.1073/pnas.0501536102
   Haimovici R, 2002, GRAEF ARCH CLIN EXP, V240, P90, DOI 10.1007/s00417-001-0417-z
   Haines JL, 2006, INVEST OPHTH VIS SCI, V47, P329, DOI 10.1167/iovs.05-0116
   Han Y, 2004, ARCH OPHTHALMOL-CHIC, V122, P1809, DOI 10.1001/archopht.122.12.1809
   Han Y, 2004, INVEST OPHTH VIS SCI, V45, P948, DOI 10.1167/iovs.03-1101
   Hankey GJ, 2005, J THROMB HAEMOST, V3, P1638, DOI 10.1111/j.1538-7836.2005.01427.x
   HAYREH SS, 1990, EYE, V4, P273, DOI 10.1038/eye.1990.39
   HEIER J, 2006, OPHTHALMOLOGY   0213
   Holz FG, 2004, AM J OPHTHALMOL, V137, P504, DOI 10.1016/j.ajo.2003.11.026
   HOLZ FG, 1994, ARCH OPHTHALMOL-CHIC, V112, P402, DOI 10.1001/archopht.1994.01090150132035
   Hood DC, 1998, INVEST OPHTH VIS SCI, V39, P1152
   Jackson GR, 2002, AGEING RES REV, V1, P381, DOI 10.1016/S1568-1637(02)00007-7
   Johnson MA, 2005, EXP EYE RES, V80, P37, DOI 10.1016/j.exer.2004.08.006
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1417, DOI 10.1001/archopht.119.10.1417
   Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557
   Kliffen M, 1997, BRIT J OPHTHALMOL, V81, P154, DOI 10.1136/bjo.81.2.154
   LINSENMEIER RA, 1990, GRAEF ARCH CLIN EXP, V228, P143, DOI 10.1007/BF02764309
   LINSENMEIER RA, 1992, J GEN PHYSIOL, V99, P177, DOI 10.1085/jgp.99.2.177
   Linsenmeier RA, 2000, INVEST OPHTH VIS SCI, V41, P3117
   Lip PL, 2001, OPHTHALMOLOGY, V108, P705, DOI 10.1016/S0161-6420(00)00663-1
   Lovie-Kitchin Jan, 2005, Clin Exp Optom, V88, P292
   MAYER MJ, 1992, INVEST OPHTH VIS SCI, V33, P3136
   MCLEOD DS, 1994, INVEST OPHTH VIS SCI, V35, P3799
   Medeiros NE, 2001, INVEST OPHTH VIS SCI, V42, P795
   Mitchell P, 2002, ARCH OPHTHALMOL-CHIC, V120, P1357, DOI 10.1001/archopht.120.10.1357
   Nguyen QD, 2004, INVEST OPHTH VIS SCI, V45, P617, DOI 10.1167/iovs.03-0557
   Owsley C, 2000, INVEST OPHTH VIS SCI, V41, P267
   Owsley C, 2001, OPHTHALMOLOGY, V108, P1196, DOI 10.1016/S0161-6420(01)00580-2
   PAULEIKHOFF D, 1990, OPHTHALMOLOGY, V97, P171
   Pauleikhoff D, 1999, ARCH OPHTHALMOL-CHIC, V117, P1353, DOI 10.1001/archopht.117.10.1353
   Pauleikhoff D., 1992, Ophthalmologe, V89, P363
   PAULEIKHOFF D, 1990, AM J OPHTHALMOL, V109, P211, DOI 10.1016/S0002-9394(14)75989-6
   PAULEIKHOFF D, 2005, RETINA, V25, P1062
   Phipps JA, 2004, INVEST OPHTH VIS SCI, V45, P3355, DOI 10.1167/iovs.04-0253
   Phipps JA, 2003, INVEST OPHTH VIS SCI, V44, P2277, DOI 10.1167/iovs.02-0769
   RAMRATTAN RS, 1994, INVEST OPHTH VIS SCI, V35, P2857
   ROBBINS S, 2004, ROBBINS COTRAN PATHO
   SAKAMOTO T, 1995, ARCH OPHTHALMOL-CHIC, V113, P512, DOI 10.1001/archopht.1995.01100040134039
   SANDBERG MA, 1993, INVEST OPHTH VIS SCI, V34, P3477
   SANSEVERINO ER, 1990, PANMINERVA MED, V32, P77
   SARKS JP, 1988, EYE, V2, P552, DOI 10.1038/eye.1988.106
   SARKS JP, 1994, EYE, V8, P269, DOI 10.1038/eye.1994.57
   SARKS SH, 2001, RETINA, V2, P1064
   Schlingemann RO, 2004, GRAEF ARCH CLIN EXP, V242, P91, DOI 10.1007/s00417-003-0828-0
   Schneck ME, 1997, INVEST OPHTH VIS SCI, V38, P800
   Scholl HPN, 2004, INVEST OPHTH VIS SCI, V45, P574, DOI 10.1167/iovs.03-0495
   Smith V C, 1976, Mod Probl Ophthalmol, V17, P248
   SMITH VC, 1988, J OPT SOC AM A, V5, P2113, DOI 10.1364/JOSAA.5.002113
   STEINMETZ RL, 1993, BRIT J OPHTHALMOL, V77, P549, DOI 10.1136/bjo.77.9.549
   Teichmann K D, 1997, Eur J Med Res, V2, P445
   VINGERLING JR, 1995, AM J EPIDEMIOL, V142, P404, DOI 10.1093/oxfordjournals.aje.a117648
   Witmer AN, 2003, PROG RETIN EYE RES, V22, P1, DOI 10.1016/S1350-9462(02)00043-5
   Yu DY, 2001, PROG RETIN EYE RES, V20, P175, DOI 10.1016/S1350-9462(00)00027-6
   Zarbin MA, 2004, ARCH OPHTHALMOL-CHIC, V122, P598, DOI 10.1001/archopht.122.4.598
   Zareparsi S, 2005, AM J HUM GENET, V77, P149, DOI 10.1086/431426
   Zele AJ, 2006, GRAEF ARCH CLIN EXP, V244, P425, DOI 10.1007/s00417-005-0121-5
NR 110
TC 37
Z9 39
U1 0
U2 9
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 0950-222X
EI 1476-5454
J9 EYE
JI Eye
PD JUN
PY 2007
VL 21
IS 6
BP 689
EP 696
DI 10.1038/sj.eye.6702389
PG 8
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 176WR
UT WOS:000247116100001
PM 16680100
OA Bronze
DA 2022-11-30
ER

PT J
AU Jung, W
   Yoon, JM
   Han, K
   Kim, B
   Hwang, S
   Lim, DH
   Shin, DW
AF Jung, Wonyoung
   Yoon, Je Moon
   Han, Kyungdo
   Kim, Bongseong
   Hwang, Sungsoon
   Lim, Dong Hui
   Shin, Dong Wook
TI Association between Age-Related Macular Degeneration and the Risk of
   Diabetes Mellitus: A Nationwide Cohort Study
SO BIOMEDICINES
LA English
DT Article
DE age-related macular degeneration; diabetes mellitus; visual disability
ID VISUAL-FIELD LOSS; QUALITY-OF-LIFE; VISION IMPAIRMENT;
   GREATER-THAN-OR-EQUAL-TO-65 YEARS; PHYSICAL-ACTIVITY; EYE DISEASE;
   HEALTH; POPULATION; IMPACT; PREVALENCE
AB Age-related macular degeneration (AMD) is a degenerative and progressive disease of the macula, the part of the retina that is responsible for central vision. AMD shares some risk factors with diabetes mellitus (DM), but little is known about the risk of DM in individuals with AMD. With the goal of establishing novel perspectives, this study aimed to investigate the association between AMD and the risk of DM using the Korean Nationwide Health Insurance Database. Individuals aged >= 50 years who underwent a national health screening program in 2009 were enrolled. Participants were categorized by the presence of AMD and visual disability (VD). The Cox hazard regression model was used to examine hazard ratios (HRs) of DM with adjustment for potential confounders. Stratified analyses by age, sex, and comorbidities (hypertension or dyslipidemia) were also performed. During a mean follow-up of 8.61 years, there were 403,367 (11.76%) DM incidences among the final 3,430,532 participants. The crude HR (95% confidence interval (CI)) was 1.16 (1.13-1.20) for AMD. After adjusting for potential confounders, AMD was associated with a 3% decreased risk of DM (aHR 0.97, 95% CI 0.95-1.00), but no significant association with the risk of DM was found in AMD with VD (aHR 1.03, 95% CI 0.93-1.14). In summary, we did not find an increased risk of DM in individuals with AMD. A 3% decreased risk of DM in patients with AMD is not clinically meaningful. Our study suggests that the association between AMD and the risk of DM is weak, considering the potential confounders. Further studies examining this association are needed to extend our knowledge.
C1 [Jung, Wonyoung; Shin, Dong Wook] Sungkyunkwan Univ, Samsung Med Ctr, Dept Family Med, Sch Med, Seoul 06351, South Korea.
   [Jung, Wonyoung; Shin, Dong Wook] Sungkyunkwan Univ, Samsung Med Ctr, Support Care Ctr, Sch Med, Seoul 06351, South Korea.
   [Jung, Wonyoung] Sungkyunkwan Univ, Dept Med, Sch Med, Seoul 06351, South Korea.
   [Yoon, Je Moon; Hwang, Sungsoon; Lim, Dong Hui] Sungkyunkwan Univ, Samsung Med Ctr, Dept Ophthalmol, Sch Med, Seoul 06351, South Korea.
   [Han, Kyungdo; Kim, Bongseong] Soongsil Univ, Dept Stat & Actuarial Sci, Seoul 06978, South Korea.
   [Hwang, Sungsoon; Lim, Dong Hui; Shin, Dong Wook] Sungkyunkwan Univ, Samsung Adv Inst Hlth Sci & Technol SAIHST, Dept Clin Res Design & Evaluat, Seoul 06355, South Korea.
C3 Sungkyunkwan University (SKKU); Samsung Medical Center; Sungkyunkwan
   University (SKKU); Samsung Medical Center; Sungkyunkwan University
   (SKKU); Sungkyunkwan University (SKKU); Samsung Medical Center; Soongsil
   University; Samsung; Sungkyunkwan University (SKKU)
RP Shin, DW (通讯作者)，Sungkyunkwan Univ, Samsung Med Ctr, Dept Family Med, Sch Med, Seoul 06351, South Korea.; Shin, DW (通讯作者)，Sungkyunkwan Univ, Samsung Med Ctr, Support Care Ctr, Sch Med, Seoul 06351, South Korea.; Yoon, JM (通讯作者)，Sungkyunkwan Univ, Samsung Med Ctr, Dept Ophthalmol, Sch Med, Seoul 06351, South Korea.; Shin, DW (通讯作者)，Sungkyunkwan Univ, Samsung Adv Inst Hlth Sci & Technol SAIHST, Dept Clin Res Design & Evaluat, Seoul 06355, South Korea.
EM jemun1010@gmail.com; dwshin.md@gmail.com
RI Shin, Dong Wook/J-6721-2016
OI Shin, Dong Wook/0000-0001-8128-8920; Jung, Wonyoung/0000-0003-4749-4637
FU Korea Health Technology R&D Project through the Korea Health Industry
   Development Institute (KHIDI) - Ministry of Health and Welfare, Republic
   of Korea [HI20C1073]; National Research Foundation of Korea - Ministry
   of Education, Republic of Korea [NRF-2021R1C1C1007795]
FX This research was partially supported by a grant from the Korea Health
   Technology R&D Project through the Korea Health Industry Development
   Institute (KHIDI), funded by the Ministry of Health and Welfare,
   Republic of Korea (grant number: HI20C1073), which was received by Dong
   Wook Shin, and by a grant from the National Research Foundation of
   Korea, funded by the Ministry of Education, Republic of Korea
   (NRF-2021R1C1C1007795), which was received by Dong Hui Lim.
CR Abokyi S, 2020, OXID MED CELL LONGEV, V2020, DOI 10.1155/2020/7901270
   [Anonymous], 2022, NUMBER REGISTERED PE
   Blitzer AL, 2021, JAMA OPHTHALMOL, V139, P302, DOI 10.1001/jamaophthalmol.2020.6331
   Bloch-Damti A, 2005, ANTIOXID REDOX SIGN, V7, P1553, DOI 10.1089/ars.2005.7.1553
   Bookwala J, 2011, GERONTOLOGIST, V51, P798, DOI 10.1093/geront/gnr051
   Cackett P, 2008, AM J OPHTHALMOL, V146, P960, DOI 10.1016/j.ajo.2008.06.026
   Carneiro A, 2017, OXID MED CELL LONGEV, V2017, DOI 10.1155/2017/6469138
   Cheung CMG, 2017, J LIPID RES, V58, P1785, DOI 10.1194/jlr.M073684
   Choi JK, 2011, ARCH OPHTHALMOL-CHIC, V129, P196, DOI 10.1001/archophthalmol.2010.355
   Choi S, 2020, AM J OPHTHALMOL, V210, P41, DOI 10.1016/j.ajo.2019.11.001
   Clarke Philippa, 2022, Disabil Health J, P101371, DOI 10.1016/j.dhjo.2022.101371
   Crews JE, 2004, AM J PUBLIC HEALTH, V94, P823, DOI 10.2105/AJPH.94.5.823
   Crews JE, 2017, AM J OPHTHALMOL, V182, P18, DOI 10.1016/j.ajo.2017.06.038
   Crews JE, 2014, OPHTHAL EPIDEMIOL, V21, P287, DOI 10.3109/09286586.2014.926556
   Cupples ME, 2012, BRIT MED J, V344, DOI 10.1136/bmj.e542
   DeAngelis MM, 2017, HUM MOL GENET, V26, pR45, DOI 10.1093/hmg/ddx228
   Delcourt C, 2001, Ophthalmic Epidemiol, V8, P237, DOI 10.1076/opep.8.4.237.1613
   Erke MG, 2014, ACTA OPHTHALMOL, V92, P662, DOI 10.1111/aos.12346
   Gorusupudi A, 2017, ADV NUTR, V8, P40, DOI 10.3945/an.116.013177
   Hahn P, 2013, RETINA-J RET VIT DIS, V33, P911, DOI 10.1097/IAE.0b013e3182831248
   He MS, 2018, DIABETES CARE, V41, P2202, DOI 10.2337/dc18-0707
   Jones N, 2018, BRIT J VISUAL IMPA, V36, P17, DOI 10.1177/0264619617730860
   Keenan TDL, 2021, ADV EXP MED BIOL, V1256, P1, DOI 10.1007/978-3-030-66014-7_1
   Kim Kyoung Hoon, 2010, J Prev Med Public Health, V43, P42, DOI 10.3961/jpmph.2010.43.1.42
   Klein Barbara E K, 2003, Trans Am Ophthalmol Soc, V101, P191
   Kolli AJAY, 2022, AM J OPHTHALMOL, V235, P163, DOI 10.1016/j.ajo.2021.09.004
   KyuHyung Park，, 2010, [Journal of The Korean Ophthalmological Society, 대한안과학회지], V51, P516
   Langelaan M, 2007, OPHTHAL EPIDEMIOL, V14, P119, DOI 10.1080/09286580601139212
   Lee YH, 2016, DIABETES METAB J, V40, P79, DOI 10.4093/dmj.2016.40.1.79
   Leske MC, 2006, OPHTHALMOLOGY, V113, P29, DOI 10.1016/j.ophtha.2005.08.012
   Lim LS, 2012, LANCET, V379, P1728, DOI 10.1016/S0140-6736(12)60282-7
   Liu XX, 2014, SPRINGERPLUS, V3, DOI 10.1186/2193-1801-3-356
   Ludtke L, 2019, MED SCI MONITOR, V25, P6383, DOI 10.12659/MSM.915493
   Milton RC, 2005, OPHTHALMOLOGY, V112, P533, DOI 10.1016/j.ophtha.2004.10.047
   Mitchell P, 1999, AUST NZ J OPHTHALMOL, V27, P197, DOI 10.1046/j.1440-1606.1999.00211.x
   Newsholme P, 2019, AM J PHYSIOL-CELL PH, V317, pC420, DOI 10.1152/ajpcell.00141.2019
   Nguyen AM, 2015, BMC GERIATR, V15, DOI 10.1186/s12877-015-0062-8
   Ramrattan RS, 2001, ARCH OPHTHALMOL-CHIC, V119, P1788, DOI 10.1001/archopht.119.12.1788
   Shin DW, 2022, PRECIS FUTURE MED, V6, P9, DOI 10.23838/pfm.2021.00135
   Shin DW, 2018, J CLIN ONCOL, V36, P2778, DOI [10.1200/JCO.2018.77.7912, 10.1200/jco.2018.77.7912]
   Skyler JS, 2004, J MED CHEM, V47, P4113, DOI 10.1021/jm0306273
   Snow K K, 1999, Ophthalmic Epidemiol, V6, P125, DOI 10.1076/opep.6.2.125.1558
   Song SO, 2016, ENDOCRINOL METAB, V31, P292, DOI 10.3803/EnM.2016.31.2.292
   Spencer KL, 2012, ARCH OPHTHALMOL-CHIC, V130, P116, DOI 10.1001/archopthalmol.2011.1370
   Srinivasan S, 2017, EYE, V31, P1176, DOI 10.1038/eye.2017.47
   Strunz T, 2020, SCI REP-UK, V10, DOI 10.1038/s41598-020-58510-9
   Swenor BK, 2015, J AM GERIATR SOC, V63, P46, DOI 10.1111/jgs.13183
   Tan JSL, 2007, OPHTHALMOLOGY, V114, P1143, DOI 10.1016/j.ophtha.2006.09.033
   Tisi A, 2021, CELLS-BASEL, V10, DOI 10.3390/cells10010064
   Tsai DC, 2015, OPHTHALMOLOGY, V122, P2327, DOI 10.1016/j.ophtha.2015.07.033
   van Landingham SW, 2012, OPHTHALMOLOGY, V119, P2486, DOI 10.1016/j.ophtha.2012.06.034
   Voutilainen-Kaunisto RM, 2000, DIABETES CARE, V23, P1672, DOI 10.2337/diacare.23.11.1672
   Vu HTV, 2005, BRIT J OPHTHALMOL, V89, P360, DOI 10.1136/bjo.2004.047498
   Wallhagen MI, 2001, J AM GERIATR SOC, V49, P1086, DOI 10.1046/j.1532-5415.2001.49213.x
   Willis JR, 2012, ARCH OPHTHALMOL-CHIC, V130, P329, DOI 10.1001/archopthalmol.2011.1773
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
NR 56
TC 0
Z9 0
U1 0
U2 0
PU MDPI
PI BASEL
PA ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND
EI 2227-9059
J9 BIOMEDICINES
JI Biomedicines
PD OCT
PY 2022
VL 10
IS 10
AR 2435
DI 10.3390/biomedicines10102435
PG 10
WC Biochemistry & Molecular Biology; Medicine, Research & Experimental;
   Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Research & Experimental Medicine;
   Pharmacology & Pharmacy
GA 5O1WC
UT WOS:000872271100001
PM 36289698
OA gold, Green Published
DA 2022-11-30
ER

PT J
AU Timberlake, GT
   Omoscharka, E
   Quaney, BM
   Grose, SA
   Maino, JH
AF Timberlake, George T.
   Omoscharka, Evanthia
   Quaney, Barbara M.
   Grose, Susan A.
   Maino, Joseph H.
TI Effect of Bilateral Macular Scotomas from Age-Related Macular
   Degeneration on Reach-to-Grasp Hand Movement
SO INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE
LA English
DT Article
ID PREHENSION MOVEMENTS; VISUAL INFORMATION; MONOCULAR VISION; BINOCULAR
   CUES; RETINAL LOCUS; SIZE; QUANTIFICATION; METAMORPHOPSIA; CONSEQUENCES;
   DISSOCIATION
AB PURPOSE. Vision plays a critical role in reaching and grasping objects. Consequently, bilateral macular scotomas from age-related macular degeneration (AMD) may affect reach-to-grasp movements. The purpose of this work was to investigate changes in reach-to-grasp movement dynamics and to relate those changes to the characteristics of subjects' preferred retinal loci (PRL), scotomas, and visual acuities.
   METHODS. Three-dimensional positions of the index finger and thumb were recorded while subjects with bilateral scotomas and subjects with normal vision reached for and grasped blocks of three widths at two distances under binocular and monocular viewing conditions. Reach-dynamic parameters and the grip aperture (thumb-index finger distance) were calculated. Retinal locations and sizes of subjects' scotomas and PRLs were mapped with a scanning laser ophthalmoscope.
   RESULTS. Scotoma subjects' hand trajectories had longer movement durations, lower maximum velocities, and longer visual reaction times than those of control subjects. With monocular viewing, maximum grip aperture (MGA) increased as a function of block width at a significantly higher rate for scotoma subjects than for control subjects. MGA decreased with increasing PRL bivariate normal ellipse area, and visual reaction time increased with decreasing acuity of the eye tested.
   CONCLUSIONS. Compared with normally sighted subjects, subjects with bilateral macular scotomas from AMD have reach-to-grasp movements with longer trajectories, longer visual reaction times, lower velocities, and altered MGA-block width scaling. Visual reaction time and MGA are directly related to PRL characteristics. Deficits in reach-to-grasp movement caused by macular scotomas are greater in degree than those reported by others for real or artificial peripheral scotomas. (Invest Ophthalmol Vis Sci. 2011;52:2540-2550) DOI:10.1167/iovs.10-6062
C1 [Timberlake, George T.; Omoscharka, Evanthia; Quaney, Barbara M.; Grose, Susan A.; Maino, Joseph H.] Kansas City Vet Affairs Med Ctr, Kansas City, MO USA.
   [Timberlake, George T.] Univ Kansas, Med Ctr, Dept Ophthalmol, Kansas City, KS 66103 USA.
   [Quaney, Barbara M.] Univ Kansas, Med Ctr, Ctr Aging, Kansas City, KS 66103 USA.
C3 University of Kansas; University of Kansas Medical Center; University of
   Kansas; University of Kansas Medical Center
RP Timberlake, GT (通讯作者)，Univ Kansas, Med Ctr, Dept Ophthalmol, 7400 State Line Rd, Prairie Village, KS 66208 USA.
EM gtimberl@kumc.edu
FU Department of Veterans Affairs, Rehabilitation Research and Development
   Service [C6218R]
FX Supported by Department of Veterans Affairs, Rehabilitation Research and
   Development Service Grant C6218R.
CR Arimura E, 2007, ACTA OPHTHALMOL SCAN, V85, P55, DOI 10.1111/j.1600-0420.2006.00729.x
   Bastian AJ, 1996, J NEUROPHYSIOL, V76, P492, DOI 10.1152/jn.1996.76.1.492
   Bradshaw MF, 2003, SPATIAL VISION, V16, P295, DOI 10.1163/156856803322467545
   Brown LE, 2005, EXP BRAIN RES, V165, P97, DOI 10.1007/s00221-005-2285-y
   Bulakowski PF, 2009, FRONT BEHAV NEUROSCI, V3, DOI 10.3389/neuro.08.049.2009
   Carmeli E, 2003, J GERONTOL A-BIOL, V58, P146, DOI 10.1093/gerona/58.2.M146
   Connolly JD, 1999, EXP BRAIN RES, V125, P281, DOI 10.1007/s002210050684
   Dolman P, 1919, AM J OPHTHALMOL, V2, P287
   Gonzalez-Alvarez C, 2007, OPHTHAL PHYSL OPT, V27, P265, DOI 10.1111/j.1475-1313.2007.00476.x
   GOODALE MA, 1991, NATURE, V349, P154, DOI 10.1038/349154a0
   Haggard P, 1997, J MOTOR BEHAV, V29, P282, DOI 10.1080/00222899709600842
   Jackson SR, 2002, CURR BIOL, V12, P237, DOI 10.1016/S0960-9822(01)00682-0
   JAKOBSON LS, 1991, EXP BRAIN RES, V86, P199
   JEANNEROD M, 1984, J MOTOR BEHAV, V16, P235
   Ketcham CJ, 2002, J GERONTOL B-PSYCHOL, V57, pP54, DOI 10.1093/geronb/57.1.P54
   Kotecha A, 2009, INVEST OPHTH VIS SCI, V50, P203, DOI 10.1167/iovs.08-2496
   Kroyer K, 2008, INVEST OPHTH VIS SCI, V49, P3741, DOI 10.1167/iovs.07-1452
   Kudoh N, 1997, EXP BRAIN RES, V117, P457, DOI 10.1007/s002210050241
   Lee YL, 2008, PERCEPT PSYCHOPHYS, V70, P1032, DOI 10.3758/PP.70.6.1032
   LEVI DM, 1987, VISION RES, V27, P581, DOI 10.1016/0042-6989(87)90044-7
   Loftus A, 2004, EXP BRAIN RES, V158, P317, DOI 10.1007/s00221-004-1905-2
   Ma-Wyatt A, 2007, EXP BRAIN RES, V179, P55, DOI 10.1007/s00221-006-0767-1
   Marotta JJ, 1997, EXP BRAIN RES, V116, P113, DOI 10.1007/PL00005731
   MAROTTA JJ, 1995, EXP BRAIN RES, V104, P107
   Mavrakanas NA, 2009, J NEURO-OPHTHALMOL, V29, P37, DOI 10.1097/WNO.0b013e318198ca37
   McCrea P, 2005, EXP BRAIN RES, V162, P70, DOI 10.1007/s00221-004-2106-8
   Mon-Williams M, 1999, EXP BRAIN RES, V128, P578, DOI 10.1007/s002210050885
   Mon-Williams M, 2001, EXP BRAIN RES, V137, P497
   Olivier I, 2007, EXP BRAIN RES, V179, P17, DOI 10.1007/s00221-006-0762-6
   PAULIGNAN Y, 1991, EXP BRAIN RES, V87, P407
   PAULIGNAN Y, 1990, EXP BRAIN RES, V79, P431, DOI 10.1007/BF00608255
   Rand MK, 2007, EXP BRAIN RES, V181, P447, DOI 10.1007/s00221-007-0945-9
   Saunders JA, 2003, EXP BRAIN RES, V152, P341, DOI 10.1007/s00221-003-1525-2
   Schuchard RA, 2005, CAN J OPHTHALMOL, V40, P303, DOI 10.1016/S0008-4182(05)80073-0
   Schuchard RA, 2000, RETINAL CORRES BINOC, P90
   SERVOS P, 1992, VISION RES, V32, P1513, DOI 10.1016/0042-6989(92)90207-Y
   Servos P, 1994, EXP BRAIN RES, V54, P121
   SIVAK B, 1990, NEUROPSYCHOLOGIA, V28, P1095, DOI 10.1016/0028-3932(90)90143-C
   SOMERS WW, 1984, OPHTHAL PHYSL OPT, V4, P245, DOI 10.1111/j.1475-1313.1984.tb00362.x
   Subramanian A, 2004, OPHTHAL PHYSL OPT, V24, P350, DOI 10.1111/j.1475-1313.2004.00221.x
   Timberlake GT, 2005, OPTOMETRY VISION SCI, V82, P177
   TIMBERLAKE GT, 1987, INVEST OPHTH VIS SCI, V28, P1268
   TIMBERLAKE GT, 1982, INVEST OPHTH VIS SCI, V22, P91
   Walker N, 1997, J GERONTOL B-PSYCHOL, V52, pP40, DOI 10.1093/geronb/52B.1.P40
   Watt SJ, 2000, NEUROPSYCHOLOGIA, V38, P1473, DOI 10.1016/S0028-3932(00)00065-8
   WING AM, 1986, J MOTOR BEHAV, V18, P245
   WING AM, 1983, Q J EXP PSYCHOL-A, V35, P297, DOI 10.1080/14640748308402135
NR 47
TC 26
Z9 26
U1 0
U2 7
PU ASSOC RESEARCH VISION OPHTHALMOLOGY INC
PI ROCKVILLE
PA 12300 TWINBROOK PARKWAY, ROCKVILLE, MD 20852-1606 USA
SN 0146-0404
EI 1552-5783
J9 INVEST OPHTH VIS SCI
JI Invest. Ophthalmol. Vis. Sci.
PD APR
PY 2011
VL 52
IS 5
BP 2540
EP 2550
DI 10.1167/iovs.10-6062
PG 11
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)
SC Ophthalmology
GA 757TQ
UT WOS:000290111000005
PM 21296817
DA 2022-11-30
ER

PT J
AU Ehmann, D
   Garcia, R
AF Ehmann, David
   Garcia, Raul
TI Triple therapy for neovascular age-related macular degeneration
   (verteporfin photodynamic therapy, intravitreal dexamethasone, and
   intravitreal bevacizumab)
SO CANADIAN JOURNAL OF OPHTHALMOLOGY-JOURNAL CANADIEN D OPHTALMOLOGIE
LA English
DT Article
DE choroidal neovascularization; bevacizumab; dexamethasone; verteporfin
   photodynamic therapy
ID SUBFOVEAL CHOROIDAL NEOVASCULARIZATION; CLINICAL-TRIALS; RANIBIZUMAB;
   PEGAPTANIB; SAFETY
AB Objective: Age-related macular degeneration is a multifactorial disease involving inflammation, neovascularization, and vascular leakage. As a result, a rationale exists for investigating combination treatments that target the different pathological processes involved in this disease. We propose triple therapy consisting of verteporfin photodynamic therapy (PDT), intravitreal bevacizumab, and intravitreal dexamethasone.
   Design: Retrospective chart review.
   Participants: Thirty-two eyes of 30 patients were included. None of the patients demonstrated concurrent eye pathology, and none of the patients had received previous treatment for their choroidal neovascularization.
   Methods: One cycle of triple therapy consisted of reduced-fluence PDT (300 mW/cm(2) for 83 seconds to deliver 25 J/cm(2)) followed immediately by an 800 mu g (0.08 mL) intravitreal dexamethasone (IVD) injection. At I and 7 weeks after PDT and IVD, patients received a 1.25 mg (0.05 mL) bevacizumab injection. At 13 weeks after PDT and IVD, each patient had a repeat optical coherence tomography and fluorescein angiography to assess choroidal neovascularization activity. Patients were followed for 12 months.
   Results: The mean number of treatment cycles was 1.4. The mean number of bevacizumab injections was 2.8. Visual acuity improved from 0.74 (SD 0.33) logMAR (20/100) to 0.53 (SD 0.32) logMAR (20/70) (p < 0.005). Foveal thickness decreased from 328 (SD 116) mu m to 216 (SD 85) pm (p < 0.001). Ninety-four percent of patients lost fewer than 3 lines, 31% gained more than 3 lines, and 6% lost more than 3 lines.
   Conclusions: By combining agents with complementary mechanisms of action, triple therapy could maintain visual acuity and macular anatomy while allowing a reduction in the number of anti-vascular endothelial growth factor injections required.
C1 [Ehmann, David; Garcia, Raul] Univ Saskatchewan, Pasqua Hosp, Ctr Eye, Regina, SK, Canada.
C3 University of Saskatchewan
RP Garcia, R (通讯作者)，1-4101 Dewdney Ave, Regina, SK S4T 1A5, Canada.
EM rgarcia@accesscomm.ca
CR Ahmad K, 2007, LANCET INFECT DIS, V7, P10, DOI 10.1016/S1473-3099(06)70670-3
   Antoszyk AN, 2008, AM J OPHTHALMOL, V145, P862, DOI 10.1016/j.ajo.2007.12.029
   Arnold J, 2001, AM J OPHTHALMOL, V131, P541
   Augustin AJ, 2007, RETINA-J RET VIT DIS, V27, P133, DOI 10.1097/IAE.0b013e3180323de7
   Bakri SJ, 2009, RETINA-J RET VIT DIS, V29, P573, DOI 10.1097/IAE.0b013e3181a46a8a
   Blumenkranz MS, 2001, ARCH OPHTHALMOL-CHIC, V119, P198
   Brown DM, 2009, OPHTHALMOLOGY, V116, P57, DOI 10.1016/j.ophtha.2008.10.018
   D'Amico DJ, 2006, OPHTHALMOLOGY, V113, P992, DOI 10.1016/j.ophtha.2006.02.027
   FREUND KB, 1993, AM J OPHTHALMOL, V115, P786, DOI 10.1016/S0002-9394(14)73649-9
   Fung AE, 2007, AM J OPHTHALMOL, V143, P566, DOI 10.1016/j.ajo.2007.01.028
   Gragoudas ES, 2004, NEW ENGL J MED, V351, P2805, DOI 10.1056/NEJMoa042760
   Iranmanesh R, 2007, EUR J OPHTHALMOL, V17, P75, DOI 10.1177/112067210701700111
   Navea A, 2009, RETINA-J RET VIT DIS, V29, P13, DOI 10.1097/IAE.0b013e31818a1fd3
   Rich RM, 2006, RETINA-J RET VIT DIS, V26, P495, DOI 10.1097/01.iae.0000225766.75009.3a
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Spaide RF, 2003, OPHTHALMOLOGY, V110, P1517, DOI 10.1016/S0161-6420(03)00544-X
   Spaide RF, 2006, RETINA-J RET VIT DIS, V26, P383, DOI 10.1097/00006982-200604000-00001
NR 17
TC 16
Z9 16
U1 0
U2 9
PU CANADIAN OPHTHAL SOC
PI OTTAWA
PA 1525 CARLING AVE SUITE 610, OTTAWA, ONTARIO K1Z 8R9, CANADA
SN 0008-4182
EI 1715-3360
J9 CAN J OPHTHALMOL
JI Can. J. Opthalmol.-J. Can. Opthalmol.
PD FEB
PY 2010
VL 45
IS 1
BP 36
EP 40
DI 10.3129/i09-243
PG 5
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 558YD
UT WOS:000274783900007
PM 20130708
DA 2022-11-30
ER

PT J
AU Lai, PH
   Cai, YH
   Zhong, YL
   Huang, X
AF Lai, Ping-Hong
   Cai, Yue-Hong
   Zhong, Yu-Lin
   Huang, Xin
TI Decreased spontaneous brain activity in the dorsal visual pathway in
   age-related macular degeneration patients revealed by fractional
   amplitude of low-frequency fluctuation
SO NEUROREPORT
LA English
DT Article
DE age-related macular degeneration; dorsal visual pathway; ractional
   amplitude of low-frequency fluctuations
AB Background Age-related macular degeneration (AMD) is the leading cause of visual loss in the developed world and damages the central retina. Growing evidences demonstrated that AMD patients were associated with brain structure changes in visual pathway. However, it remains unknown whether alterations of spontaneous brain activity changes occur in AMD patients. Purpose The purpose of this study was to investigate the effect of central vision loss on spontaneous brain activity in AMD patients. Material and methods Seventeen AMD patients and 17 healthy controls (HCs) underwent resting-state MRI scans. The fractional amplitude of low-frequency fluctuations (fALFFs) was applied to investigate the spontaneous brain activity changes in AMD patients. Results Compared with HC group, AMD patients showed significant decreased fALFF values in the right calcarine/cuneus (brodmann area 17,8) and right superior parietal lobule (brodmann area 7). Conclusion Our results showed that AMD patients had decreased brain activities in the dorsal visual pathway, which offer important insights into the neural mechanisms of central visual field defect in AMD patients.
C1 [Lai, Ping-Hong; Cai, Yue-Hong; Zhong, Yu-Lin; Huang, Xin] Jiangxi Prov Peoples Hosp, Dept Ophthalmol, 152 Ai Guo Rd, Nanchang 330006, Jiangxi, Peoples R China.
RP Huang, X (通讯作者)，Jiangxi Prov Peoples Hosp, Dept Ophthalmol, 152 Ai Guo Rd, Nanchang 330006, Jiangxi, Peoples R China.
EM 2017103020035@whu.edu.cn
FU Natural Science Foundation of Jiangxi Province [20192BAB205048,
   20212BAB216058]; National Nature Science Foundation of China [81060080]
FX The authors would like to acknowledge the assistance provided by the
   Natural Science Foundation of Jiangxi Province (20192BAB205048 and
   20212BAB216058) and National Nature Science Foundation of China
   (81060080).
CR Boucard CC, 2009, BRAIN, V132, P1898, DOI 10.1093/brain/awp119
   Burge WK, 2016, SCI REP-UK, V6, DOI 10.1038/srep23268
   DeAngelis MM, 2017, HUM MOL GENET, V26, pR246, DOI 10.1093/hmg/ddx343
   Detaram HD, 2020, CLIN EXP OPHTHALMOL, V48, P61, DOI 10.1111/ceo.13644
   Freud E, 2016, TRENDS COGN SCI, V20, P773, DOI 10.1016/j.tics.2016.08.003
   Haak KV, 2016, OPHTHAL PHYSL OPT, V36, P335, DOI 10.1111/opo.12279
   Hernowo AT, 2014, CORTEX, V56, P99, DOI 10.1016/j.cortex.2013.01.003
   Kujovic M, 2013, BRAIN STRUCT FUNCT, V218, P157, DOI 10.1007/s00429-012-0390-9
   Malania M, 2017, INVEST OPHTH VIS SCI, V58, P2939, DOI 10.1167/iovs.16-21191
   Mitchell P, 2018, LANCET, V392, P1147, DOI 10.1016/S0140-6736(18)31550-2
   Pardhan S, 2011, OPHTHAL PHYSL OPT, V31, P233, DOI 10.1111/j.1475-1313.2010.00819.x
   Plank T, 2014, FRONT PSYCHOL, V5, DOI 10.3389/fpsyg.2014.01189
   Prins D, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0146684
   Rosengarth K, 2013, FRONT PSYCHOL, V4, DOI 10.3389/fpsyg.2013.00428
   Safran AB, 1999, BRIT J OPHTHALMOL, V83, P137, DOI 10.1136/bjo.83.2.137
   Shu YP, 2020, J AFFECT DISORDERS, V276, P822, DOI 10.1016/j.jad.2020.07.038
   Verghese P, 2016, INVEST OPHTH VIS SCI, V57, P1476, DOI 10.1167/iovs.15-18336
   Wang JJ, 1999, HUM BRAIN MAPP, V8, P170, DOI 10.1002/(SICI)1097-0193(1999)8:4<170::AID-HBM2>3.3.CO;2-N
   Wiecek E, 2012, INVEST OPHTH VIS SCI, V53, P6600, DOI 10.1167/iovs.12-10012
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
   Woodell A, 2014, ADV EXP MED BIOL, V801, P301, DOI 10.1007/978-1-4614-3209-8_38
   Yan CG, 2016, NEUROINFORMATICS, V14, P339, DOI 10.1007/s12021-016-9299-4
   Yoshimine S, 2018, BRAIN STRUCT FUNCT, V223, P3889, DOI 10.1007/s00429-018-1702-5
   Zou QH, 2008, J NEUROSCI METH, V172, P137, DOI 10.1016/j.jneumeth.2008.04.012
NR 24
TC 0
Z9 0
U1 0
U2 0
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0959-4965
EI 1473-558X
J9 NEUROREPORT
JI Neuroreport
PD JUN 8
PY 2022
VL 33
IS 9
BP 386
EP 391
DI 10.1097/WNR.0000000000001797
PG 6
WC Neurosciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Neurosciences & Neurology
GA 1J6PT
UT WOS:000798040100003
PM 35594429
DA 2022-11-30
ER

PT J
AU Douglas, IJ
   Cook, C
   Chakravarthy, U
   Hubbard, R
   Fletcher, AE
   Smeeth, L
AF Douglas, Ian J.
   Cook, Claire
   Chakravarthy, Usha
   Hubbard, Richard
   Fletcher, Astrid E.
   Smeeth, Liam
TI A case-control study of drug risk factors for age-related macular
   degeneration
SO OPHTHALMOLOGY
LA English
DT Article
ID PRACTICE RESEARCH DATABASE; BEAVER DAM EYE; VISUAL IMPAIRMENT; 5-YEAR
   INCIDENCE; MACULOPATHY; SMOKING; DISEASE
AB Objective: To investigate the association between age-related macular degeneration (AMD) and exposure to antacids, antithyroids, thyroid hormones, and thiazide diuretics.
   Design: Matched case-control study.
   Participants: Population-based participants were selected from the United Kingdom General Practice Research Database. A total of 18 007 people with diagnosed AMD were compared with 86 169 controls matched for age, gender, and general practice.
   Methods: Conditional logistic regression was used to determine the association between exposure to each drug group of interest and a diagnosis of AMD, adjusting for relevant confounding variables.
   Main Outcome Measures: The primary outcome was the odds ratio for the association between exposure to antacids, antithyroids, thyroid hormones, or thiazide diuretics and AMD. Secondary analyses were conducted to assess the effect of recent exposure to the drugs of interest, the total number of prescriptions received, and restricting the data set to participants with more than 2 years of observation time.
   Results: The crude odds ratios for association between any record of drug exposure and AMD were as follows: 1.34 (95% confidence interval [CI], 1.29-1.39) for antacids; 1.15 (95% CI, 0.92-1.44) for antithyroids; 1.34 (95% CI, 1.29-1.39) for thyroid hormones; and 1.13 (95% CI, 1.08-1.17) for thiazide diuretics. After adjusting for consultation rate, observation time, diabetes, heart failure, hyperlipidemia, cardiovascular drug use, atherosclerosis, hypertension, aspirin use, hormone replacement therapy use, body mass index, alcohol consumption, and smoking, the odds ratios reduced to: 1.06 (95% CI, 1.02-1.10) for antacids, 0.98 (95% CI, 0.78-1.24) for antithyroids, 0.99 (95% CI, 0.92-1.06) for thyroid hormones, and 0.98 (95% CI, 0.94-1.02) for thiazides. Secondary analyses were consistent with these findings for all 4 drug categories.
   Conclusions: No association was detected between short- and medium-term use of antithyroids, thyroid hormones, and thiazide diuretics and the risk of AMD. Short- and medium-term use of antacids seems to be associated with a small increase in the risk of this disease. However, this increased risk is likely the result of residual confounding by smoking or uncontrolled confounding resulting from socioeconomic status. No conclusions could be drawn regarding longer-term use of each drug category.
C1 Univ London London Sch Hyg & Trop Med, Dept Epidemiol & Populat Hlth, London WC1E 7HT, England.
   Queens Univ Belfast, Ctr Vis Sci, Inst Clin Sci, Royal Hosp Belfast, Belfast, Antrim, North Ireland.
   Univ Nottingham, Div Resp Med, City Hosp, Nottingham NG7 2RD, England.
C3 University of London; London School of Hygiene & Tropical Medicine;
   Queens University Belfast; Nottingham University Hospital NHS Trust;
   Nottingham City Hospital; University of Nottingham
RP Douglas, IJ (通讯作者)，Univ London London Sch Hyg & Trop Med, Dept Epidemiol & Populat Hlth, Keppel St, London WC1E 7HT, England.
RI ; Smeeth, Liam/X-5862-2018
OI Chakravarthy, Usha/0000-0002-2606-3734; Smeeth, Liam/0000-0002-9168-6022
FU Medical Research Council [G108/492(60712), G108/492] Funding Source:
   Medline; Wellcome Trust Funding Source: Medline; MRC [G108/492] Funding
   Source: UKRI
CR Anand R, 2000, OPHTHALMOLOGY, V107, P2224
   [Anonymous], 2006, SOCIAL DETERMINANTS
   Cho E, 2001, AM J CLIN NUTR, V73, P209
   Cho EY, 2000, ARCH OPHTHALMOL-CHIC, V118, P681, DOI 10.1001/archopht.118.5.681
   Chopdar A, 2003, BRIT MED J, V326, P485, DOI 10.1136/bmj.326.7387.485
   Congdon NG, 2003, JAMA-J AM MED ASSOC, V290, P2057, DOI 10.1001/jama.290.15.2057
   de Jong PTVM, 2001, EYE, V15, P396, DOI 10.1038/eye.2001.143
   Delcourt C, 1998, ARCH OPHTHALMOL-CHIC, V116, P1031, DOI 10.1001/archopht.116.8.1031
   EVAN J, 1998, EPIDEMIOLOGY EYE DIS, P325
   Fine SL, 2000, NEW ENGL J MED, V342, P483, DOI 10.1056/NEJM200002173420707
   GOLDBERG J, 1988, AM J EPIDEMIOL, V128, P700, DOI 10.1093/oxfordjournals.aje.a115023
   Hollowell J, 1997, Popul Trends, P36
   HYMAN LG, 1983, AM J EPIDEMIOL, V118, P213, DOI 10.1093/oxfordjournals.aje.a113629
   JICK H, 1991, BRIT MED J, V302, P766, DOI 10.1136/bmj.302.6779.766
   KAHRILAS PJ, 1990, GUT, V31, P4, DOI 10.1136/gut.31.1.4
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1417, DOI 10.1001/archopht.119.10.1417
   KLEIN R, 1993, AM J EPIDEMIOL, V137, P190, DOI 10.1093/oxfordjournals.aje.a116659
   Klein R, 1997, OPHTHALMOLOGY, V104, P1804, DOI 10.1016/S0161-6420(97)30023-2
   Lawson DH, 1998, QJM-MON J ASSOC PHYS, V91, P445, DOI 10.1093/qjmed/91.6.445
   McCarty CA, 2001, ARCH OPHTHALMOL-CHIC, V119, P1455
   Mitchell P, 2002, OPHTHALMOLOGY, V109, P1092, DOI 10.1016/S0161-6420(02)01055-2
   NAZARETH I, 1993, BRIT MED J, V307, P32, DOI 10.1136/bmj.307.6895.32
   *OFF NAT STAT, 2006, SERIES MB6, V2
   Rodriguez LAG, 1998, BRIT J CLIN PHARMACO, V45, P419
   Smeeth L, 2005, BRIT J OPHTHALMOL, V89, P1171, DOI 10.1136/bjo.2004.064477
   Smith W, 1996, AM J OPHTHALMOL, V122, P743, DOI 10.1016/S0002-9394(14)70503-3
   SPERDUTO RD, 1986, ARCH OPHTHALMOL-CHIC, V104, P216
   van Leeuwen R, 2003, EUR J EPIDEMIOL, V18, P845, DOI 10.1023/A:1025643303914
   VINGERLING JR, 1995, AM J EPIDEMIOL, V142, P404, DOI 10.1093/oxfordjournals.aje.a117648
   WHO, 2004, MAGN CAUS VIS IMP
   YANNUZZI LA, 1992, ARCH OPHTHALMOL-CHIC, V110, P1701
   1995, SERIES MB5, V3
NR 32
TC 27
Z9 28
U1 0
U2 2
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0161-6420
J9 OPHTHALMOLOGY
JI Ophthalmology
PD JUN
PY 2007
VL 114
IS 6
BP 1164
EP 1169
DI 10.1016/j.ophtha.2006.09.018
PG 6
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 174AC
UT WOS:000246912600021
PM 17544775
DA 2022-11-30
ER

PT J
AU Singh, M
   Tyagi, SC
AF Singh, Mahavir
   Tyagi, Suresh C.
TI Hyperhomocysteinemia and Age-related Macular Degeneration: Role of
   Inflammatory Mediators and Pyroptosis; A Proposal
SO MEDICAL HYPOTHESES
LA English
DT Article
DE Age-related macular degeneration; Chemokines; Cytokines; Dry form;
   Inflammation; Pathogenesis; Risk factors; Vascular injury; Pyroptosis;
   Wet form
ID ENDOTHELIAL GROWTH-FACTOR; PLASMA HOMOCYSTEINE; RISK-FACTORS;
   METHYLMALONIC ACIDURIA; SERUM HOMOCYSTEINE; OXIDATIVE STRESS;
   FOLIC-ACID; EXPRESSION; PATHOGENESIS; VITAMIN-B12
AB Age-related macular degeneration (AMD) and pyroptosis cause irreversible vascular changes in the eyes leading to central vision loss in patients. It is the most common eye disease affecting millions of people aged 50 years or older, and is slowly becoming a major health problem worldwide. The disease mainly affects macula lutea, an oval-shaped pigmented area surrounding fovea near the center of retina, a region responsible for visual acuity. It is fairly a complex disease as genetics of patients, environmental triggers as well as risk factors such as age, family history of CVDs, diabetes, gender, obesity, race, hyperopia, iris color, smoking, diabetes, exposure to sun light and pyroptosis have all been clubbed together as probable causes of macular degeneration. Among genes that are known to play a role include variant polymorphisms in the complement cascade components such as CFH, C2, C3, and CFB as potential genetic risk factors. So far, AMD disease hypothesized theories have not resulted into the anticipated impact towards the development of effective or preventive therapies in order to help alleviate patients' suffering because, as of today, it is still unclear what actually initiates or leads to this dreaded eye condition. Based upon our extensive work on the metabolism of homocysteine (Hcy) in various disease conditions we, therefore, are proposing a novel hypothesis for AMD pathogenesis as we strongly believe that Hcy and events such as pyroptosis make a greater contribution to the overall etiology of AMD disease in a target population of susceptible hosts by inciting and accelerating the inherent inflammatory changes in the retina of these patients (Fig. 2). In this context, we further state that Hcy and pyroptosis should be considered as legitimate and valuable markers of retinal dysfunction as they not only aid and abet in the development but also in the progression of AMD in older people as discussed in this paper. This discussion should open up new avenues in tackling inflammatory and pyroptosis centered pathways that are up-regulated or solely promoted by Hcy interaction within the ocular compartment of AMD susceptible hosts. (C) 2017 Elsevier Ltd. All rights reserved.
C1 [Singh, Mahavir] Univ Louisville, Sch Med, Dept Physiol, Eye & Vis Sci Lab, Louisville, KY 40202 USA.
   [Singh, Mahavir; Tyagi, Suresh C.] Univ Louisville, Sch Med, Dept Physiol, Louisville, KY 40202 USA.
C3 University of Louisville; University of Louisville
RP Singh, M (通讯作者)，Univ Louisville, Sch Med, Dept Physiol, Eye & Vis Sci Lab, Louisville, KY 40202 USA.
EM mahavir.singh@louisville.edu
OI Singh, Mahavir/0000-0002-2415-3314
FU National Institute of Health (Heart, Lung, and Blood Institute)
   [HL-74815]; Institute of Neurological Disorders and Stroke [NS-084823]
FX Members in the laboratory are gratefully acknowledged for their
   continuous support and encouragement. This work was supported by grants
   from the National Institute of Health (Heart, Lung, and Blood Institute;
   No. HL-74815) and the Institute of Neurological Disorders and Stroke
   (No. NS-084823).
CR Ambati J, 2003, SURV OPHTHALMOL, V48, P257, DOI 10.1016/S0039-6257(03)00030-4
   Ates O, 2009, TOHOKU J EXP MED, V217, P17, DOI 10.1620/tjem.217.17
   Axer-Siegel R, 2004, AM J OPHTHALMOL, V137, P84, DOI 10.1016/S0002-9394(03)00864-X
   Aydin E, 2008, EUR J OPHTHALMOL, V18, P226, DOI 10.1177/112067210801800210
   Bharathselvi M, 2013, ANN CLIN BIOCHEM, V50, P330, DOI 10.1177/0004563213492146
   BOK D, 1993, J CELL SCI, P189
   Campochiaro PA, 2006, GENE THER, V13, P559, DOI 10.1038/sj.gt.3302653
   Cheung GTY, 2008, CAN J PHYSIOL PHARM, V86, P88, DOI [10.1139/Y08-002, 10.1139/y08-002]
   Christen WG, 2009, ARCH INTERN MED, V169, P335, DOI 10.1001/archinternmed.2008.574
   Clarke R, 2002, JAMA-J AM MED ASSOC, V288, P2015, DOI 10.1001/jama.288.16.2015
   Collison FT, 2015, OPHTHALMIC GENET, V36, P270, DOI 10.3109/13816810.2015.1010736
   Coral K, 2006, EYE, V20, P203, DOI 10.1038/sj.eye.6701853
   Duan YK, 2007, OPHTHALMOLOGY, V114, P732, DOI 10.1016/j.ophtha.2006.07.045
   Evans JR, 2012, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD000254.pub3
   Fritsche LG, 2014, ANNU REV GENOM HUM G, V15, P151, DOI 10.1146/annurev-genom-090413-025610
   Ghosh S, 2013, NEPAL J OPHTHALMOL, V5, P195, DOI 10.3126/nepjoph.v5i2.8728
   Gopinath B, 2013, AM J CLIN NUTR, V98, P129, DOI 10.3945/ajcn.112.057091
   Huang PR, 2015, SCI REP-UK, V5, DOI 10.1038/srep10585
   Ibrahim AS, 2016, ONCOTARGET, V7, P8532, DOI 10.18632/oncotarget.7384
   Kamburoglu G, 2006, GRAEF ARCH CLIN EXP, V244, P565, DOI 10.1007/s00417-005-0108-2
   Keles S, 2014, CLIN OPHTHALMOL, V8, P1573, DOI 10.2147/OPTH.S66160
   Lee I, 2007, BIOSCI BIOTECH BIOCH, V71, P1203, DOI 10.1271/bbb.60657
   Lerner-Ellis JP, 2006, NAT GENET, V38, P93, DOI 10.1038/ng1683
   Li JB, 2014, CURR EYE RES, V39, P730, DOI 10.3109/02713683.2013.877933
   Malinowska J, 2012, ACTA BIOCHIM POL, V59, P185
   Manresa N, 2015, RETINA-J RET VIT DIS, V35, P1765, DOI 10.1097/IAE.0000000000000552
   Marchegiani F, 2008, REJUV RES, V11, P113, DOI 10.1089/rej.2007.0582
   Mulero J, 2014, CLIN HEMORHEOL MICRO, V58, P447, DOI 10.3233/CH-141807
   Muntner P, 2004, ANN INTERN MED, V140, P9, DOI 10.7326/0003-4819-140-1-200401060-00006
   Nagineni CN, 2015, AGING DIS, V6, P444, DOI 10.14336/AD.2015.0323
   Lecumberri JJN, 2013, REV CLIN ESP, V213, P229, DOI 10.1016/j.rce.2013.01.012
   Nowak M, 2005, EUR J OPHTHALMOL, V15, P764, DOI 10.1177/112067210501500617
   Nowak Mariusz, 2004, Klin Oczna, V106, P429
   Ozaki E, 2014, ADV EXP MED BIOL, V801, P229, DOI 10.1007/978-1-4614-3209-8_30
   Parmeggiani F, 2007, PHARMACOGENET GENOM, V17, P1039, DOI 10.1097/FPC.0b013e3282f12a4e
   Robman L, 2004, OPHTHAL EPIDEMIOL, V11, P161, DOI 10.1080/09286580490514469
   Rochtchina E, 2007, AM J OPHTHALMOL, V143, P344, DOI 10.1016/j.ajo.2006.08.032
   Roybal CN, 2004, J BIOL CHEM, V279, P14844, DOI 10.1074/jbc.M312948200
   Rudolf M, 2008, INVEST OPHTH VIS SCI, V49, P1200, DOI 10.1167/iovs.07-1466
   Seddon JM, 2006, NUTRITION, V22, P441, DOI 10.1016/j.nut.2005.12.004
   Seddon JM, 2006, AM J OPHTHALMOL, V141, P201, DOI 10.1016/j.ajo.2005.07.059
   Sen U, 2011, AM J PHYSIOL-CELL PH, V300, pC155, DOI 10.1152/ajpcell.00143.2010
   Sen U, 2010, AM J NEPHROL, V31, P442, DOI 10.1159/000296717
   Sen U, 2009, AM J PHYSIOL-RENAL, V297, pF410, DOI 10.1152/ajprenal.00145.2009
   Sergejeva O, 2016, MEDICINA-LITHUANIA, V52, P79, DOI 10.1016/j.medici.2016.02.004
   Shastry S, 2009, J INFLAMM-LOND, V6, DOI 10.1186/1476-9255-6-27
   Singh M, 2006, FASEB J, V20, pA719
   Singh M, 2015, CHEM-BIOL INTERACT, V234, P261, DOI 10.1016/j.cbi.2014.12.028
   van Guldener C, 2006, NEPHROL DIAL TRANSPL, V21, P1161, DOI 10.1093/ndt/gfl044
   Vine AK, 2005, OPHTHALMOLOGY, V112, P2076, DOI 10.1016/j.ophtha.2005.07.004
   Wang JJ, 2008, OPHTHALMOLOGY, V115, P693, DOI 10.1016/j.ophtha.2007.05.038
   Wong TY, 2006, ANN INTERN MED, V145, P98, DOI 10.7326/0003-4819-145-2-200607180-00007
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
   Yi F, 2006, KIDNEY INT, V70, P88, DOI 10.1038/sj.ki.5001517
   Zarbin MA, 2004, ARCH OPHTHALMOL-CHIC, V122, P598, DOI 10.1001/archopht.122.4.598
NR 55
TC 11
Z9 11
U1 0
U2 12
PU CHURCHILL LIVINGSTONE
PI EDINBURGH
PA JOURNAL PRODUCTION DEPT, ROBERT STEVENSON HOUSE, 1-3 BAXTERS PLACE,
   LEITH WALK, EDINBURGH EH1 3AF, MIDLOTHIAN, SCOTLAND
SN 0306-9877
EI 1532-2777
J9 MED HYPOTHESES
JI Med. Hypotheses
PD AUG
PY 2017
VL 105
BP 17
EP 21
DI 10.1016/j.mehy.2017.06.012
PG 5
WC Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Research & Experimental Medicine
GA FD6SA
UT WOS:000407657000005
PM 28735646
DA 2022-11-30
ER

PT J
AU Liu, YQ
   Hou, SQ
   Lang, WH
   Dai, DS
   Wang, ZX
   Ji, XN
   Li, K
   Zhang, X
   Zou, YY
   Wang, JX
AF Liu, Yuqing
   Hou, Siqing
   Lang, Weihua
   Dai, Dongshu
   Wang, Zhixue
   Ji, Xiangning
   Li, Kun
   Zhang, Xi
   Zou, Yuanyuan
   Wang, Jingxian
TI Roles of Three Common VEGF Polymorphisms in the Risk of Age-Related
   Macular Degeneration
SO GENETIC TESTING AND MOLECULAR BIOMARKERS
LA English
DT Article
ID ENDOTHELIAL GROWTH-FACTOR; FACTOR GENE POLYMORPHISMS; CANCER-RISK;
   METAANALYSIS; ASSOCIATION; POPULATION; CARCINOMA; DISEASE; COHORT
AB Associations between vascular endothelial growth factor (VEGF) polymorphisms (rs833061, rs1413711, and rs3025039) and risk of age-related macular degeneration (AMD) have been extensively studied, but the currently available results are contentious rather than conclusive. Therefore, we performed the present meta-analysis to further assess the associations. Literature search in PubMed, Embase, and Web of Science databases was conducted until April 2013. The strength of the associations between VEGF polymorphisms and AMD risk was estimated by pooled odds ratios (ORs) and 95% confidence intervals (CIs). Both models of fixed effects and random effects were performed to summarize the pooled ORs. All data were analyzed by Stata software 12.0. The meta-analysis results based on nine case-control studies with 2427 cases and 2037 controls showed that rs833061 had protective effects on AMD risk (TT vs. CT+CC: OR=0.58, 95% CI=0.41-0.81), whereas rs1413711 (TT vs. CT+CC: OR=1.46, 95% CI=1.10-1.93) and rs3025039 (TT vs. CC: OR=1.87, 95% CI=1.15-3.02; TT vs. CT+CC: OR=2.09, 95% CI=1.30-3.37) represented as risk factors for AMD. Subgroup analysis by ethnicity suggested significantly reduced risk in Caucasians (TT vs. CT+CC: OR=0.60, 95% CI=0.36-0.99; T vs. C: OR=0.89, 95% CI=0.78-1.00) and Asians (TT+CT vs. CC: OR=0.57, 95% CI=0.34-0.96; TT vs. CT+CC: OR=0.54, 95% CI=0.33-0.90) for rs833061, yet elevated risk in Caucasians (TT vs. CT+CC: OR=2.05, 95% CI=1.24-3.38) for rs1413711 and in Asians (TT vs. CC: OR=2.06, 95% CI=1.24-3.43; TT vs. CC: OR=2.34, 95% CI=1.42-3.89) for rs3025039. In stratified analysis by type of AMD, rs833061 was observed to decrease wet AMD risk, while rs1413711 and rs3025039 were found to increase the risk of wet AMD. Based on the currently available data, this meta-analysis suggests that the VEGF polymorphisms may be associated with risk of AMD, particularly wet AMD.
C1 [Liu, Yuqing; Hou, Siqing; Lang, Weihua; Dai, Dongshu; Wang, Zhixue; Ji, Xiangning; Li, Kun; Zhang, Xi; Zou, Yuanyuan; Wang, Jingxian] Hebei Med Univ, Cangzhou Cent Hosp, Dept Ophthalmol, Cangzhou 061001, Hebei Province, Peoples R China.
C3 Hebei Medical University
RP Liu, YQ (通讯作者)，Hebei Med Univ, Cangzhou Cent Hosp, Dept Ophthalmol, 16 Xinhua West Rd, Cangzhou 061001, Hebei Province, Peoples R China.
EM waterlyq@sohu.com
CR Almeida LN, 2012, GRAEF ARCH CLIN EXP, V250, P185, DOI 10.1007/s00417-011-1807-5
   Churchill AJ, 2006, HUM MOL GENET, V15, P2955, DOI 10.1093/hmg/ddl238
   DERSIMONIAN R, 1986, CONTROL CLIN TRIALS, V7, P177, DOI 10.1016/0197-2456(86)90046-2
   Egger M, 1997, BMJ-BRIT MED J, V315, P629, DOI 10.1136/bmj.315.7109.629
   Ferrara N, 2003, NAT MED, V9, P669, DOI 10.1038/nm0603-669
   Ferrara N, 1999, J MOL MED, V77, P527, DOI 10.1007/s001099900019
   Ferris FL, 2005, ARCH OPHTHALMOL-CHIC, V123, P1570
   FOLKMAN J, 1971, NEW ENGL J MED, V285, P1182
   Galan A, 2010, OPHTHALMOLOGY, V117, P1769, DOI 10.1016/j.ophtha.2010.01.030
   Goncalves FM, 2010, DNA CELL BIOL, V29, P357, DOI 10.1089/dna.2010.1025
   Higgins JPT, 2003, BRIT MED J, V327, P557, DOI 10.1136/bmj.327.7414.557
   Huang C, 2013, MOL VIS, V19, P1211
   Jager RD, 2008, NEW ENGL J MED, V358, P2606, DOI 10.1056/NEJMra0801537
   Jang MJ, 2013, INT J CLIN ONCOL, V18, P1032, DOI 10.1007/s10147-012-0493-6
   Janik-Papis K, 2009, EXP MOL PATHOL, V87, P234, DOI 10.1016/j.yexmp.2009.09.005
   Jiang YM, 2013, J INT MED RES, V41, P317, DOI 10.1177/0300060513475570
   Lin JM, 2008, AM J OPHTHALMOL, V145, P1045, DOI 10.1016/j.ajo.2008.01.027
   Liu H, 2011, ASIAN PAC J CANCER P, V12, P1979
   Lu Y, 2012, MOL BIOL REP, V39, P6547, DOI 10.1007/s11033-012-1483-5
   MANTEL N, 1959, J NATL CANCER I, V22, P719
   Penn JS, 2008, PROG RETIN EYE RES, V27, P331, DOI 10.1016/j.preteyeres.2008.05.001
   Qu Y, 2011, OPHTHALMIC RES, V45, P142, DOI 10.1159/000319543
   Richardson AJ, 2007, MOL VIS, V13, P2148
   Seddon JM, 2011, OPHTHALMOLOGY, V118, P2203, DOI 10.1016/j.ophtha.2011.04.029
   Sun SF, 2013, MED ONCOL, V30, DOI 10.1007/s12032-012-0410-x
   Supic G, 2012, ORAL ONCOL, V48, P1171, DOI 10.1016/j.oraloncology.2012.05.023
   Szaflik Jacek P, 2009, Klin Oczna, V111, P125
   Ting AYC, 2009, CURR OPIN OPHTHALMOL, V20, P369, DOI 10.1097/ICU.0b013e32832f8016
   Vincenti V, 1996, CIRCULATION, V93, P1493, DOI 10.1161/01.CIR.93.8.1493
   Wang K, 2011, CYTOKINE, V56, P167, DOI 10.1016/j.cyto.2011.06.018
   Yachimski P, 2009, GASTROINTEST ENDOSC, V69, P205, DOI 10.1016/j.gie.2008.05.032
NR 31
TC 1
Z9 2
U1 0
U2 8
PU MARY ANN LIEBERT, INC
PI NEW ROCHELLE
PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA
SN 1945-0265
EI 1945-0257
J9 GENET TEST MOL BIOMA
JI Genet. Test. Mol. Biomark.
PD APR 1
PY 2014
VL 18
IS 4
BP 245
EP 252
DI 10.1089/gtmb.2013.0368
PG 8
WC Biochemistry & Molecular Biology; Genetics & Heredity
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Genetics & Heredity
GA AE0SN
UT WOS:000333676600005
OA Green Published
DA 2022-11-30
ER

PT J
AU Bharti, K
   Hollander, AID
   Lakkaraju, A
   Sinha, D
   Williams, DS
   Finnemann, SC
   Bowes-Rickman, C
   Malek, G
   D'Amore, PA
AF Bharti, Kapil
   Hollander, Anneke I. den
   Lakkaraju, Aparna
   Sinha, Debasish
   Williams, David S.
   Finnemann, Silvia C.
   Bowes-Rickman, Catherine
   Malek, Goldis
   D'Amore, Patricia A.
TI Cell culture models to study retinal pigment epithelium-related
   pathogenesis in age-related macular degeneration
SO EXPERIMENTAL EYE RESEARCH
LA English
DT Review
DE Retinal pigment epithelium; ARPE19; Primary cells; iPSC-RPE;
   Organ-on-a-Chip; Complement system
ID IMPAIRED CHOLESTEROL EFFLUX; GENOME-WIDE ASSOCIATION; FACTOR-H
   POLYMORPHISM; EMBRYONIC STEM-CELLS; ADULT HUMAN RPE; APOLIPOPROTEIN-E;
   IN-VITRO; OXIDATIVE STRESS; NLRP3 INFLAMMASOME; POOLED ANALYSIS
AB Age-related macular degeneration (AMD) is a disease that affects the macula - the central part of the retina. It is a leading cause of irreversible vision loss in the elderly. AMD onset is marked by the presence of lipid-and protein -rich extracellular deposits beneath the retinal pigment epithelium (RPE), a monolayer of polarized, pigmented epithelial cells located between the photoreceptors and the choroidal blood supply. Progression of AMD to the late nonexudative "dry" stage of AMD, also called geographic atrophy, is linked to progressive loss of areas of the RPE, photoreceptors, and underlying choriocapillaris leading to a severe decline in patients' vision. Differential susceptibility of macular RPE in AMD and the lack of an anatomical macula in most lab animal models has promoted the use of in vitro models of the RPE. In addition, the need for high throughput platforms to test potential therapies has driven the creation and characterization of in vitro model systems that recapitulate morphologic and functional abnormalities associated with human AMD. These models range from spontaneously formed cell line ARPE19, immortalized cell lines such as hTERT-RPE1, RPE-J, and D407, to primary human (fetal or adult) or animal (mouse and pig) RPE cells, and embryonic and induced pluripotent stem cell (iPSC) derived RPE. Hallmark RPE phenotypes, such as cobblestone morphology, pigmentation, and polarization, vary signif-icantly betweendifferent models and culture conditions used in different labs, which would directly impact their usability for investigating different aspects of AMD biology. Here the AMD Disease Models task group of the Ryan Initiative for Macular Research (RIMR) provides a summary of several currently used in vitro RPE models, his-torical aspects of their development, RPE phenotypes that are attainable in these models, their ability to model different aspects of AMD pathophysiology, and pros/cons for their use in the RPE and AMD fields. In addition, due to the burgeoning use of iPSC derived RPE cells, the critical need for developing standards for differentiating and rigorously characterizing RPE cell appearance, morphology, and function are discussed.
C1 [Bharti, Kapil; Finnemann, Silvia C.] NEI, Ocular & Stem Cell Translat Res Sect, NIH, Bethesda, MD 20892 USA.
   [Hollander, Anneke I. den] Radboud Univ Nijmegen, Dept Ophthalmol, Med Ctr, Nijmegen, Netherlands.
   [Hollander, Anneke I. den] AbbVie, Genom Res Ctr, Cambridge, MA 60064 USA.
   [Lakkaraju, Aparna] Univ Calif San Francisco, Sch Med, Dept Ophthalmol, San Francisco, CA USA.
   [Sinha, Debasish] Univ Pittsburgh, Dept Ophthalmol, Cell Biol & Dev Biol, Sch Med, Pittsburgh, PA 15260 USA.
   [Sinha, Debasish] Johns Hopkins Univ, Wilmer Eye Inst, Sch Med, Baltimore, MD 21218 USA.
   [Williams, David S.] Univ Calif Los Angeles, Stein Eye Inst, David Geffen Sch Med, Dept Ophthalmol & Neurobiol, Los Angeles, CA 90095 USA.
   [Finnemann, Silvia C.] Fordham Univ, Ctr Canc Genet Dis & Gene Regulat, Dept Biol Sci, Bronx, NY 10458 USA.
   [Bowes-Rickman, Catherine; Malek, Goldis] Duke Univ, Duke Eye Ctr, Dept Ophthalmol, Sch Med, Durham, NC USA.
   [Bowes-Rickman, Catherine] Duke Univ, Dept Cell Biol, Sch Med, Durham, NC USA.
   [Malek, Goldis] Duke Univ, Dept Pathol, Sch Med, Durham, NC USA.
   [D'Amore, Patricia A.] Harvard Med Sch, Dept Ophthalmol & Pathol, Mass Eye & Ear, Boston, MA 02115 USA.
   [Lakkaraju, Aparna] Univ Pittsburgh, Dept Ophthalmol, Sch Med, Pittsburgh, PA 15260 USA.
   [Bowes-Rickman, Catherine; Malek, Goldis] Duke Univ, Dept Ophthalmol, Sch Med, Durham, NC 27708 USA.
C3 National Institutes of Health (NIH) - USA; NIH National Eye Institute
   (NEI); Radboud University Nijmegen; AbbVie; University of California
   System; University of California San Francisco; Pennsylvania
   Commonwealth System of Higher Education (PCSHE); University of
   Pittsburgh; Johns Hopkins University; Johns Hopkins Medicine; University
   of California System; University of California Los Angeles; University
   of California Los Angeles Medical Center; David Geffen School of
   Medicine at UCLA; Fordham University; Duke University; Duke University;
   Duke University; Harvard University; Harvard Medical School;
   Pennsylvania Commonwealth System of Higher Education (PCSHE); University
   of Pittsburgh; Duke University
RP Bharti, K; Finnemann, SC (通讯作者)，NEI, Ocular & Stem Cell Translat Res Sect, NIH, Bethesda, MD 20892 USA.; Hollander, AID (通讯作者)，Radboud Univ Nijmegen, Dept Ophthalmol, Med Ctr, Nijmegen, Netherlands.; Hollander, AID (通讯作者)，AbbVie, Genom Res Ctr, Cambridge, MA 60064 USA.; Sinha, D (通讯作者)，Univ Pittsburgh, Dept Ophthalmol, Cell Biol & Dev Biol, Sch Med, Pittsburgh, PA 15260 USA.; Sinha, D (通讯作者)，Johns Hopkins Univ, Wilmer Eye Inst, Sch Med, Baltimore, MD 21218 USA.; Williams, DS (通讯作者)，Univ Calif Los Angeles, Stein Eye Inst, David Geffen Sch Med, Dept Ophthalmol & Neurobiol, Los Angeles, CA 90095 USA.; Finnemann, SC (通讯作者)，Fordham Univ, Ctr Canc Genet Dis & Gene Regulat, Dept Biol Sci, Bronx, NY 10458 USA.; Bowes-Rickman, C; Malek, G (通讯作者)，Duke Univ, Duke Eye Ctr, Dept Ophthalmol, Sch Med, Durham, NC USA.; Bowes-Rickman, C (通讯作者)，Duke Univ, Dept Cell Biol, Sch Med, Durham, NC USA.; Malek, G (通讯作者)，Duke Univ, Dept Pathol, Sch Med, Durham, NC USA.; D'Amore, PA (通讯作者)，Harvard Med Sch, Dept Ophthalmol & Pathol, Mass Eye & Ear, Boston, MA 02115 USA.; Lakkaraju, A (通讯作者)，Univ Pittsburgh, Dept Ophthalmol, Sch Med, Pittsburgh, PA 15260 USA.; Bowes-Rickman, C; Malek, G (通讯作者)，Duke Univ, Dept Ophthalmol, Sch Med, Durham, NC 27708 USA.
EM kapil.bharti@nih.gov; anneke.denhollander@abbvie.com;
   Aparna.Lakkaraju@ucsf.edu; DEBASISH@pitt.edu; dswilliams@ucla.edu;
   finnemann@fordham.edu; bowes007@duke.edu; gmalek@duke.edu;
   patricia_damore@meei.harvard.edu
FU National Eye Institute (NEI) [EY032751, EY028160, EY031748, P30
   EY005722, EY026539, EY031594-01A1, EY030668, EY023299, EY027442,
   M2021020I, P30EY002162, EY026215]; Research to Prevent
   Blindness/American Macular Degeneration Foundation Catalyst Award;
   BrightFocus Foundation [EY031109, P30 EY000331]; Foundation Fighting
   Blindness (DSW)
FX National Eye Institute (NEI) Intramural funds (KB) ; NEI EY032751 (GM) ,
   EY028160 (GM) , Research to Prevent Blindness (Duke Eye Cen- ter) ; NEI
   EY031748 (CBR) , P30 EY005722 (to Duke Eye Center) ; EY026539 (PAD) ;
   EY031594-01A1 (DS) ; NEI EY030668 (AL) , EY023299 (AL) , Research to
   Prevent Blindness/American Macular Degeneration Foundation Catalyst
   Award (AL) , BrightFocus Foundation M2021020I (AL) , and P30EY002162 (to
   UCSF - AL) ; NEI EY027442 (DSW) , EY031109 (DSW) , and P30 EY000331 (to
   UCLA-DSW) , and Foundation Fighting Blindness (DSW) ; EY026215 (SCF) .
CR Achberger K, 2019, ELIFE, V8, DOI 10.7554/eLife.46188
   Ahmado A, 2011, INVEST OPHTH VIS SCI, V52, P7148, DOI 10.1167/iovs.10-6374
   Amin S, 2004, INVEST OPHTH VIS SCI, V45, P1281, DOI 10.1167/iovs.03-0671
   An E, 2006, J PROTEOME RES, V5, P2599, DOI 10.1021/pr060121j
   Anderson DH, 2010, PROG RETIN EYE RES, V29, P95, DOI 10.1016/j.preteyeres.2009.11.003
   Ang LS, 2008, EXP GERONTOL, V43, P615, DOI 10.1016/j.exger.2008.03.010
   Arik YB, 2021, LAB CHIP, V21, P272, DOI 10.1039/d0lc00639d
   Armento A, 2020, SCI REP-UK, V10, DOI 10.1038/s41598-020-67292-z
   Becerra SP, 2004, EXP EYE RES, V78, P223, DOI 10.1016/j.exer.2003.10.013
   Benedicto I, 2017, NAT COMMUN, V8, DOI 10.1038/ncomms15374
   Bharti K, 2006, PIGM CELL RES, V19, P380, DOI 10.1111/j.1600-0749.2006.00318.x
   Bharti K, 2011, PIGM CELL MELANOMA R, V24, P21, DOI 10.1111/j.1755-148X.2010.00772.x
   Bhatia SN, 2014, NAT BIOTECHNOL, V32, P760, DOI 10.1038/nbt.2989
   Biswas L, 2017, HUM MOL GENET, V26, P4327, DOI 10.1093/hmg/ddx319
   Blenkinsop Timothy A, 2013, Methods Mol Biol, V945, P45, DOI 10.1007/978-1-62703-125-7_4
   Bodnar AG, 1998, SCIENCE, V279, P349, DOI 10.1126/science.279.5349.349
   Burstyn-Cohen T, 2012, NEURON, V76, P1123, DOI 10.1016/j.neuron.2012.10.015
   Busch C, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.00703
   Cerniauskas E, 2020, STEM CELL TRANSL MED, V9, P1585, DOI 10.1002/sctm.20-0211
   Chadha A, 2021, J NEUROSCI, V41, P7514, DOI 10.1523/JNEUROSCI.0357-21.2021
   Chen LJ, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-03788-5
   Choudhary M, 2020, JCI INSIGHT, V5, DOI 10.1172/jci.insight.131928
   Chung EJ, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-17744-w
   Chung M, 2018, ADV HEALTHC MATER, V7, DOI 10.1002/adhm.201700028
   Cowan CS, 2020, CELL, V182, P1623, DOI 10.1016/j.cell.2020.08.013
   Curcio Christine A, 2018, Invest Ophthalmol Vis Sci, V59, pAMD160, DOI 10.1167/iovs.18-24882
   D'Cruz PM, 2000, HUM MOL GENET, V9, P645, DOI 10.1093/hmg/9.4.645
   Datta S, 2017, PROG RETIN EYE RES, V60, P201, DOI 10.1016/j.preteyeres.2017.03.002
   DAVIS AA, 1995, INVEST OPHTH VIS SCI, V36, P955
   de Jong S, 2021, PROG RETIN EYE RES, V84, DOI 10.1016/j.preteyeres.2021.100952
   Ding JD, 2011, P NATL ACAD SCI USA, V108, pE279, DOI 10.1073/pnas.1100901108
   Dunn KC, 1996, EXP EYE RES, V62, P155, DOI 10.1006/exer.1996.0020
   Ebeling MC, 2021, CELLS-BASEL, V10, DOI 10.3390/cells10040789
   Edwards AO, 2005, SCIENCE, V308, P421, DOI 10.1126/science.1110189
   Esteve-Rudd J, 2018, P NATL ACAD SCI USA, V115, P5468, DOI 10.1073/pnas.1709211115
   Fanelli G, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-15212-z
   Fasler-Kan E, 2018, METHODS MOL BIOL, V1745, P305, DOI 10.1007/978-1-4939-7680-5_17
   Fernandez-Godino R, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-28143-0
   Fernandez-Godino R, 2018, HUM MOL GENET, V27, P147, DOI 10.1093/hmg/ddx392
   Fernandez-Godino R, 2016, NAT PROTOC, V11, P1206, DOI 10.1038/nprot.2016.065
   Fernandez-Godino R, 2015, HUM MOL GENET, V24, P5555, DOI 10.1093/hmg/ddv287
   Ferrer M, 2014, STEM CELL TRANSL MED, V3, P911, DOI 10.5966/sctm.2013-0192
   Ferrington DA, 2017, REDOX BIOL, V13, P255, DOI 10.1016/j.redox.2017.05.015
   Ferrington DA, 2016, EXP EYE RES, V145, P269, DOI 10.1016/j.exer.2016.01.018
   Finnemann SC, 1997, P NATL ACAD SCI USA, V94, P12932, DOI 10.1073/pnas.94.24.12932
   Finnemann SC, 2003, EMBO J, V22, P4143, DOI 10.1093/emboj/cdg416
   Fritsche LG, 2016, NAT GENET, V48, P134, DOI 10.1038/ng.3448
   Fronk AH, 2016, J TISSUE ENG, V7, DOI 10.1177/2041731416650838
   Frost LS, 2014, EXP EYE RES, V124, P56, DOI 10.1016/j.exer.2014.04.010
   Galloway CA, 2017, P NATL ACAD SCI USA, V114, pE8214, DOI 10.1073/pnas.1710430114
   Georgiannakis A, 2015, J IMMUNOL, V195, P3382, DOI 10.4049/jimmunol.1500937
   Gibbs D, 2003, ADV EXP MED BIOL, V533, P347
   Gibbs D, 2003, P NATL ACAD SCI USA, V100, P6481, DOI 10.1073/pnas.1130432100
   Gnanaguru G, 2016, INVEST OPHTH VIS SCI, V57, P4704, DOI 10.1167/iovs.15-18663
   Golestaneh N, 2016, J TRANSL MED, V14, DOI 10.1186/s12967-016-1101-8
   Gomez NM, 2018, FASEB J, V32, P782, DOI 10.1096/fj.201700220RR
   Hageman GS, 2005, P NATL ACAD SCI USA, V102, P7227, DOI 10.1073/pnas.0501536102
   Haines JL, 2005, SCIENCE, V308, P419, DOI 10.1126/science.1110359
   Hallam D, 2017, STEM CELLS, V35, P2305, DOI 10.1002/stem.2708
   Hartnett ME, 2003, EXP EYE RES, V77, P593, DOI 10.1016/S0014-4835(03)00189-1
   Hazim RA, 2019, EXP EYE RES, V179, P18, DOI 10.1016/j.exer.2018.10.009
   Hazim RA, 2017, STEM CELL RES THER, V8, DOI 10.1186/s13287-017-0652-9
   Heesterbeek TJ, 2020, OPHTHAL PHYSL OPT, V40, P140, DOI 10.1111/opo.12675
   Hendrickson A, 2002, EXP EYE RES, V74, P435, DOI 10.1006/exer.2002.1181
   Hu J, 2001, MOL VIS, V7, P14
   Hu ML, 2021, LIFE-BASEL, V11, DOI 10.3390/life11070635
   Hu P, 2013, P NATL ACAD SCI USA, V110, pE4069, DOI 10.1073/pnas.1307574110
   Idelson M, 2009, CELL STEM CELL, V5, P396, DOI 10.1016/j.stem.2009.07.002
   Jiang M, 2015, J CELL BIOL, V210, P595, DOI 10.1083/jcb.201410112
   Jiang XR, 1999, NAT GENET, V21, P111, DOI 10.1038/5056
   Johnson LV, 2011, P NATL ACAD SCI USA, V108, P18277, DOI 10.1073/pnas.1109703108
   Karunadharma PP, 2010, INVEST OPHTH VIS SCI, V51, P5470, DOI 10.1167/iovs.10-5429
   Kaur G, 2018, P NATL ACAD SCI USA, V115, P9014, DOI 10.1073/pnas.1805039115
   Keir LS, 2017, J CLIN INVEST, V127, P199, DOI 10.1172/JCI86418
   Kim JY, 2013, CELL, V154, P365, DOI 10.1016/j.cell.2013.06.012
   Klaver CCW, 1998, AM J HUM GENET, V63, P200, DOI 10.1086/301901
   Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557
   Klimanskaya I, 2004, CLONING STEM CELLS, V6, P217, DOI 10.1089/1536230042323420
   Klingeborn M, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-05102-9
   La Cunza N, 2021, JCI INSIGHT, V6, DOI 10.1172/jci.insight.142254
   Lakkaraju A, 2020, PROG RETIN EYE RES, V78, DOI 10.1016/j.preteyeres.2020.100846
   Landowski M, 2019, P NATL ACAD SCI USA, V116, P3703, DOI 10.1073/pnas.1814014116
   Lehmann GL, 2014, EXP EYE RES, V126, P5, DOI 10.1016/j.exer.2014.04.021
   Li SY, 2020, EYE, V34, P474, DOI 10.1038/s41433-019-0521-0
   Li XH, 2020, AGING DIS, V11, P1219, DOI 10.14336/AD.2019.1126
   Liu K, 2014, OPHTHALMOLOGY, V121, P911, DOI 10.1016/j.ophtha.2013.10.042
   Liu Q, 2007, MOL CELL PROTEOMICS, V6, P1299, DOI 10.1074/mcp.M700054-MCP200
   Lueck K, 2011, EYE, V25, P1074, DOI 10.1038/eye.2011.109
   Lyssenko NN, 2018, J LIPID RES, V59, P1927, DOI 10.1194/jlr.M087361
   Mair KH, 2014, DEV COMP IMMUNOL, V45, P321, DOI 10.1016/j.dci.2014.03.022
   Malek G, 2005, P NATL ACAD SCI USA, V102, P11900, DOI 10.1073/pnas.0503015102
   Maminishkis A, 2006, INVEST OPHTH VIS SCI, V47, P3612, DOI 10.1167/iovs.05-1622
   May-Simera HL, 2018, CELL REP, V22, P189, DOI 10.1016/j.celrep.2017.12.038
   Mazzoni F, 2019, METHODS MOL BIOL, V1834, P95, DOI 10.1007/978-1-4939-8669-9_7
   McKay GJ, 2011, HUM MUTAT, V32, P1407, DOI 10.1002/humu.21577
   McKay GJ, 2011, AM J EPIDEMIOL, V173, P1357, DOI 10.1093/aje/kwr015
   Menon M, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-12780-8
   Miller JML, 2021, GRAEF ARCH CLIN EXP, V259, P2051, DOI 10.1007/s00417-021-05101-7
   Miyagishima K.J., 2017, STEM CELL TRANSL INV, V4, P1497
   Miyagishima KJ, 2021, COMMUN BIOL, V4, DOI 10.1038/s42003-021-02872-x
   Miyagishima KJ, 2016, STEM CELL TRANSL MED, V5, P1562, DOI 10.5966/sctm.2016-0037
   Molla-Herman A, 2010, J CELL SCI, V123, P1785, DOI 10.1242/jcs.059519
   Morgan BP, 2016, IMMUNOBIOLOGY, V221, P747, DOI 10.1016/j.imbio.2015.04.006
   Muller C, 2018, STEM CELL REP, V10, P1075, DOI 10.1016/j.stemcr.2018.01.017
   NABI IR, 1993, J CELL SCI, V104, P37
   Nandrot EE, 2004, J EXP MED, V200, P1539, DOI 10.1084/jem.20041447
   Nandrot EF, 2007, P NATL ACAD SCI USA, V104, P12005, DOI 10.1073/pnas.0704756104
   Notomi S, 2019, P NATL ACAD SCI USA, V116, P23724, DOI 10.1073/pnas.1906643116
   Nozaki M, 2006, P NATL ACAD SCI USA, V103, P2328, DOI 10.1073/pnas.0408835103
   OKA MS, 1984, EXP CELL RES, V154, P537, DOI 10.1016/0014-4827(84)90178-2
   Orozco LD, 2020, CELL REP, V30, P1246, DOI 10.1016/j.celrep.2019.12.082
   Ortolan D, 2022, P NATL ACAD SCI USA, V119, DOI 10.1073/pnas.2117553119
   Osakada F, 2009, NAT PROTOC, V4, P811, DOI 10.1038/nprot.2009.51
   Paek J, 2019, ACS NANO, V13, P7627, DOI 10.1021/acsnano.9b00686
   Pappas CM, 2021, HUM GENOMICS, V15, DOI 10.1186/s40246-021-00359-8
   Parmar VM, 2018, STEM CELL RES, V27, P95, DOI 10.1016/j.scr.2018.01.014
   Peters F, 2021, INVEST OPHTH VIS SCI, V62
   Pfeffer B.A., 1991, PROG RETIN RES, V10, P251
   Pfeffer BA, 2014, EXP EYE RES, V126, P1, DOI 10.1016/j.exer.2014.07.010
   Pfeffer BAA, 2022, EXP EYE RES, V219, DOI 10.1016/j.exer.2022.109046
   Pilgrim MG, 2017, INVEST OPHTH VIS SCI, V58, DOI 10.1167/iovs.16-21060
   Rabin DM, 2013, AGING-US, V5, P51
   Rambhatla L, 2002, INVEST OPHTH VIS SCI, V43, P1622
   Rao SR, 2018, AUTOPHAGY, V14, P1796, DOI 10.1080/15548627.2018.1490851
   Rein DB, 2009, ARCH OPHTHALMOL-CHIC, V127, P533, DOI 10.1001/archophthalmol.2009.58
   Rudolf M, 2008, EXP EYE RES, V87, P402, DOI 10.1016/j.exer.2008.07.010
   Sachdeva MM, 2014, EXP EYE RES, V119, P111, DOI 10.1016/j.exer.2013.10.024
   Saini JS, 2017, CELL STEM CELL, V20, P635, DOI 10.1016/j.stem.2016.12.015
   Salero E, 2012, CELL STEM CELL, V10, P88, DOI 10.1016/j.stem.2011.11.018
   Samuel W, 2017, MOL VIS, V23, P60
   Sanchez I, 2011, GRAEF ARCH CLIN EXP, V249, P475, DOI 10.1007/s00417-011-1617-9
   Shang P, 2021, COMMUN BIOL, V4, DOI 10.1038/s42003-021-02386-6
   Sharma R, 2021, NAT COMMUN, V12, DOI 10.1038/s41467-021-27488-x
   Sharma R, 2020, ANNU REV PHARMACOL, V60, P553, DOI 10.1146/annurev-pharmtox-010919-023245
   Sharma R, 2019, SCI TRANSL MED, V11, DOI 10.1126/scitranslmed.aat5580
   Sonoda S, 2009, NAT PROTOC, V4, P662, DOI 10.1038/nprot.2009.33
   Sorkio A, 2014, TISSUE ENG PT A, V20, P622, DOI 10.1089/ten.TEA.2013.0049
   Srinivasan B, 2015, JALA-J LAB AUTOM, V20, P107, DOI 10.1177/2211068214561025
   Storti F, 2019, ELIFE, V8, DOI 10.7554/eLife.45100
   Strunnikova NV, 2010, HUM MOL GENET, V19, P2468, DOI 10.1093/hmg/ddq129
   Sugita S, 2018, INVEST OPHTH VIS SCI, V59, P4198, DOI 10.1167/iovs.18-24769
   Sullivan PM, 1998, J CLIN INVEST, V102, P130, DOI 10.1172/JCI2673
   Suzuki M, 2008, AM J RESP CELL MOL, V39, P673, DOI 10.1165/rcmb.2007-0424OC
   Swaroop A, 2009, ANNU REV GENOM HUM G, V10, P19, DOI 10.1146/annurev.genom.9.081307.164350
   Tan LX, 2016, P NATL ACAD SCI USA, V113, P8789, DOI 10.1073/pnas.1523061113
   Toops KA, 2015, MOL BIOL CELL, V26, P1, DOI 10.1091/mbc.E14-05-1028
   Toops KA, 2014, EXP EYE RES, V124, P74, DOI 10.1016/j.exer.2014.05.003
   Trivedi D, 2012, J NEUROSCI, V32, P10587, DOI 10.1523/JNEUROSCI.0015-12.2012
   Tsai YT, 2021, AM J HUM GENET, V108, P903, DOI 10.1016/j.ajhg.2021.04.006
   Tseng WA, 2013, INVEST OPHTH VIS SCI, V54, P110, DOI 10.1167/iovs.12-10655
   Valapala M, 2014, AUTOPHAGY, V10, P480, DOI 10.4161/auto.27292
   van Leeuwen EM, 2018, PROG RETIN EYE RES, V67, P56, DOI 10.1016/j.preteyeres.2018.04.006
   Wang J, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-03856-y
   Williams JA, 2017, EXP BIOL MED, V242, P781, DOI 10.1177/1535370216688802
   Wright C, 2020, TRANSL VIS SCI TECHN, V9, DOI 10.1167/tvst.9.7.49
   Xu YT, 2012, INT J OPHTHALMOL-CHI, V5, P125, DOI 10.3980/j.issn.2222-3959.2012.02.02
   Yang J, 2014, HUM MOL GENET, V23, P3445, DOI 10.1093/hmg/ddu053
   Yang J, 2021, J INFLAMM RES, V14, P1563, DOI 10.2147/JIR.S299010
   Zhang M, 2020, SCI REP-UK, V10, DOI 10.1038/s41598-020-59244-4
   Zigler JS, 2015, PROG RETIN EYE RES, V44, P62, DOI 10.1016/j.preteyeres.2014.11.002
   Zweifel SA, 2010, OPHTHALMOLOGY, V117, P303, DOI 10.1016/j.ophtha.2009.07.014
NR 161
TC 1
Z9 1
U1 3
U2 3
PU ACADEMIC PRESS LTD- ELSEVIER SCIENCE LTD
PI LONDON
PA 24-28 OVAL RD, LONDON NW1 7DX, ENGLAND
SN 0014-4835
EI 1096-0007
J9 EXP EYE RES
JI Exp. Eye Res.
PD SEP
PY 2022
VL 222
AR 109170
DI 10.1016/j.exer.2022.109170
PG 13
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 3M0JT
UT WOS:000835144900005
PM 35835183
DA 2022-11-30
ER

PT J
AU Jalbert, I
   Rahardjo, D
   Yashadhana, A
   Liew, G
   Gopinath, B
AF Jalbert, Isabelle
   Rahardjo, Dian
   Yashadhana, Aryati
   Liew, Gerald
   Gopinath, Bamini
TI A qualitative exploration of Australian eyecare professional
   perspectives on Age-Related Macular Degeneration (AMD) care
SO PLOS ONE
LA English
DT Article
ID AFRICAN-AMERICANS; DIABETIC-RETINOPATHY; REFERRAL PATHWAYS; BARRIERS;
   OPTOMETRISTS; PREVALENCE; ATTITUDES; GLAUCOMA; DISEASE; SUPPLEMENTATION
AB Despite the existence of evidence-based recommendations to decrease risk and progression of Age-Related Macular Degeneration (AMD) for some time, self-reported practices suggest that eyecare professionals' advice and people with AMD's adherence to these recommendations can be very poor. This study uses qualitative methods to explore Australian eyecare professionals' perspective on barriers to effective AMD care. Seven focus groups involving 65 optometrists were conducted by an experienced facilitator. A nominal group technique was used to identify, prioritize and semi-quantify barriers and enablers to AMD care. Participants individually ranked their perceived top five barriers and enablers with the most important granted a score of 5 and the least important a score of 1. For each barrier or enabler, the number of votes it received and its total score were recorded. Barriers and enablers selected by at least one participant in their top 5 were then qualitatively analysed, grouped using thematic analysis and total score calculated for each consolidated barrier or enabler. In-depth individual interviews were conducted with 10 ophthalmologists and 2 optometrists. Contributions were audio-recorded, transcribed verbatim and analysed with NVivo software. One hundred and sixty-nine barriers and 51 enablers to AMD care were identified in the focus groups. Of these, 102 barriers and 42 enablers were selected as one of their top 5 by at least one participant and further consolidated into 16 barriers and 10 enablers after thematic analysis. Factors impacting AMD care identified through analysis of the transcripts were coded to three categories of influence: patient-centered, practition-ercentered, and structural factors. Eyecare professionals considered poor care pathways, people with AMD's poor disease understanding / denial, and cost of care / lack of funding, as the most significant barriers to AMD care; they considered shared care model, access, and communication as the most significant enablers to good AMD care. These findings suggest that Australian eyecare professionals perceive that there is a need for improved patient support systems and appropriately funded, clearer care pathway to benefit people with AMD.
C1 [Jalbert, Isabelle; Rahardjo, Dian; Yashadhana, Aryati] UNSW Sydney, Sch Optometry & Vis Sci, Sydney, NSW, Australia.
   [Liew, Gerald; Gopinath, Bamini] Univ Sydney, Ctr Vis Res, Westmead Inst Med Res, Dept Ophthalmol, Sydney, NSW, Australia.
C3 University of New South Wales Sydney; University of Sydney; Westmead
   Institute for Medical Research
RP Jalbert, I (通讯作者)，UNSW Sydney, Sch Optometry & Vis Sci, Sydney, NSW, Australia.
EM i.jalbert@unsw.edu.au
RI Jalbert, Isabelle/T-5888-2017; Yashadhana, Aryati/AAB-6194-2021; Liew,
   Gerald/AAB-6870-2022
OI Jalbert, Isabelle/0000-0002-1351-0072; Yashadhana,
   Aryati/0000-0003-2573-8637; 
FU Blackmores Macular Disease Foundation Australia [RG151916]
FX IJ, GL, BG received the Blackmores Macular Disease Foundation Australia
   research grant RG151916 (www.mdfoundation.com.au).The funders had no
   role in the study design, data collection and analysis, decision to
   publish, or preparation of the manuscript.
CR Alnahedh T, 2015, CLIN EXP OPTOM, V98, P263, DOI 10.1111/cxo.12238
   American Academy of Ophthalmology Retina/Vitreous Panel, 2015, PREP PRACT PATT AG R
   Barrett C, 2018, CLIN EXP OPTOM, V101, P90, DOI 10.1111/cxo.12573
   Birken SA, 2017, IMPLEMENT SCI, V12, DOI 10.1186/s13012-016-0534-z
   Boxell EM, 2017, BMJ OPEN, V7, DOI 10.1136/bmjopen-2016-012790
   Caban-Martinez AJ, 2011, PREV CHRONIC DIS, V8
   Cabana MD, 1999, JAMA-J AM MED ASSOC, V282, P1458, DOI 10.1001/jama.282.15.1458
   Cane J, 2012, IMPLEMENT SCI, V7, DOI 10.1186/1748-5908-7-37
   Carlton Jill, 2019, Br Ir Orthopt J, V15, P133, DOI 10.22599/bioj.137
   Chang CW, 2003, CAN J OPHTHALMOL, V38, P27, DOI 10.1016/S0008-4182(03)80005-4
   Charkoudian LD, 2008, OPHTHALMOLOGY, V115, P1032, DOI 10.1016/j.ophtha.2007.08.003
   Congdon N, 2011, OPHTHALMOLOGY, V118, P2343, DOI 10.1016/j.ophtha.2011.06.016
   Corbin J., 2015, BASICS QUALITATIVE R, V4th ed.
   Dahlin-Ivanoff S, 1998, PATIENT EDUC COUNS, V34, P63, DOI 10.1016/S0738-3991(98)00041-X
   Department of Health, 2015, RUR CLASS REF FREQ A
   Downie LE, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0124533
   Dreer LE, 2013, OPTOMETRY VISION SCI, V90, P883, DOI 10.1097/OPX.0000000000000009
   Evans JR, 2012, COCHRANE DATABASE SY
   Gary TL, 2009, ARCH INTERN MED, V169, P1788, DOI 10.1001/archinternmed.2009.338
   GLASER BG, 1965, SOC PROBL, V12, P436, DOI 10.1525/sp.1965.12.4.03a00070
   Glaser BG., 1966, THEORETICAL SENSITIV, V31, P552, DOI 10.2307/2090784
   Gopinath B, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0122548
   Gopinath B, 2014, BRIT J NUTR, V111, P1673, DOI 10.1017/S000711451300408X
   Gopinath B, 2014, MATURITAS, V77, P263, DOI 10.1016/j.maturitas.2013.12.001
   Gopinath B, 2013, AM J CLIN NUTR, V98, P129, DOI 10.3945/ajcn.112.057091
   Jamous KF, 2014, CLIN EXP OPTOM, V97, P248, DOI 10.1111/cxo.12119
   Jamous KF, 2014, CLIN EXP OPTOM, V97, P152, DOI 10.1111/cxo.12102
   Jamous KF, 2014, CLIN EXP OPTOM, V97, P565, DOI 10.1111/cxo.12194
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1417, DOI 10.1001/archopht.119.10.1417
   Keel S, 2017, JAMA OPHTHALMOL, V135, P1242, DOI 10.1001/jamaophthalmol.2017.4182
   Lawrenson JG, 2013, BMC PUBLIC HEALTH, V13, DOI 10.1186/1471-2458-13-564
   Levesque JF, 2013, INT J EQUITY HEALTH, V12, DOI 10.1186/1475-9276-12-18
   Loughman J, 2011, OPTOMETRY PRACTICE, V12, P135
   Ly A, 2016, OPHTHAL PHYSL OPT, V36, P632, DOI 10.1111/opo.12322
   Mitchell J, 2002, BRIT J OPHTHALMOL, V86, P777, DOI 10.1136/bjo.86.7.777
   Mitchell P, 2011, EYES FUTURE CLEAR OU
   Mitchell P, 2018, LANCET, V392, P1147, DOI 10.1016/S0140-6736(18)31550-2
   Muen Wisam J, 2011, JRSM Short Rep, V2, P64, DOI 10.1258/shorts.2011.011042
   National Insitute for Health and Care Excellent [NICE], 2018, NICE GUIDELINE 82
   National Institute of Clinical Studies, 2006, IDENTIFYING BARRIERS
   Neely DC, 2017, JAMA OPHTHALMOL, V135, P570, DOI 10.1001/jamaophthalmol.2017.0830
   Ng WT, 2006, CLIN EXP OPHTHALMOL, V34, P9, DOI 10.1111/j.1442-9071.2006.01141.x
   Nicklas TA, 2013, J ACAD NUTR DIET, V113, P1317, DOI 10.1016/j.jand.2013.05.004
   O'Connor PM, 2012, MED J AUSTRALIA, V196, P646, DOI 10.5694/mja11.10856
   Owsley C, 2006, INVEST OPHTH VIS SCI, V47, P2797, DOI 10.1167/iovs.06-0107
   Parfitt A, 2019, BMJ OPEN OPHTHALMOL, V4, DOI 10.1136/bmjophth-2019-000276
   Shah R, 2009, BRIT J OPHTHALMOL, V93, P492, DOI 10.1136/bjo.2008.145623
   Sharma HE, 2014, BRIT J OPHTHALMOL, V98, P1625, DOI 10.1136/bjophthalmol-2014-304959
   Shickle D, 2014, OPHTHAL PHYSL OPT, V34, P38, DOI 10.1111/opo.12100
   Steele C., OPTOM TODAY
   Stevens R, 2017, BRIT J VISUAL IMPA, V35, P185, DOI 10.1177/0264619616683989
   Stevens R, 2014, BRIT J VISUAL IMPA, V32, P77, DOI 10.1177/0264619613519341
   Suttle CM, 2015, OPTOMETRY VISION SCI, V92, P514, DOI 10.1097/OPX.0000000000000550
   Suttle CM, 2012, CLIN EXP OPTOM, V95, P28, DOI 10.1111/j.1444-0938.2011.00663.x
   Taylor DJ, 2019, EYE LOND
   Tong A, 2007, INT J QUAL HEALTH C, V19, P349, DOI 10.1093/intqhc/mzm042
   Tong A, 2016, TRIALS, V17, DOI 10.1186/s13063-016-1528-5
   Townsend D, 2015, BMJ OPEN, V5, DOI 10.1136/bmjopen-2014-007400
   VANDEVEN AH, 1972, AM J PUBLIC HEALTH N, V62, P337, DOI 10.2105/AJPH.62.3.337
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
   Yan XX, 2012, ARCH OPHTHALMOL-CHIC, V130, P761, DOI 10.1001/archophthalmol.2012.145
NR 61
TC 3
Z9 3
U1 0
U2 2
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD FEB 11
PY 2020
VL 15
IS 2
AR e0228858
DI 10.1371/journal.pone.0228858
PG 22
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)
SC Science & Technology - Other Topics
GA LP9KA
UT WOS:000534633200043
PM 32045445
OA Green Published, gold
DA 2022-11-30
ER

PT J
AU Flamendorf, J
   Agron, E
   Wong, WT
   Thompson, D
   Wiley, HE
   Doss, EL
   Al-Holou, S
   Ferris, FL
   Chew, EY
   Cukras, C
AF Flamendorf, Jason
   Agron, Elvira
   Wong, Wai T.
   Thompson, Darby
   Wiley, Henry E.
   Doss, E. Lauren
   Al-Holou, Shaza
   Ferris, Frederick L., III
   Chew, Emily Y.
   Cukras, Catherine
TI Impairments in Dark Adaptation Are Associated with Age-Related Macular
   Degeneration Severity and Reticular Pseudodrusen
SO OPHTHALMOLOGY
LA English
DT Article
ID SUBRETINAL DRUSENOID DEPOSITS; FUNDUS AUTOFLUORESCENCE; MULTIFOCAL
   ELECTRORETINOGRAPHY; EYE DISEASE; HIGH-RISK; SENSITIVITY; MACULOPATHY;
   PREVALENCE; AREDS; CLASSIFICATION
AB Purpose: We investigate whether ocular and person-based characteristics were associated with dark adaptation (DA).
   Design: Cross-sectional, single-center, observational study.
   Participants: One hundred sixteen participants older than 50 years of age with a range of age-related macular degeneration (AMD) severity.
   Methods: Participants underwent best-corrected visual acuity (BCVA) testing, ophthalmoscopic examination, and multimodal imaging. Presence of reticular pseudodrusen (RPD) was assessed by masked grading of fundus images and was confirmed with optical coherence tomography. Eyes also were graded for AMD features (drusen, pigmentary changes, late AMD) to generate person-based AMD severity groups. One eye was designated the study eye for DA testing. Nonparametric statistical testing was performed on all comparisons.
   Main Outcome Measures: The primary outcome of this study was the rod intercept time (RIT), which is defined as the time for a participant's visual sensitivity to recover to a stimulus intensity of 5x10(-3) cd/m(2) (a decrease of 3 log units), or until a maximum test duration of 40 minutes was reached.
   Results: A total of 116 study eyes from 116 participants (mean age, 75.4 +/- 9.4 years; 58% female) were analyzed. Increased RIT was associated significantly with increasing AMD severity, increasing age (r = 0.34; P = 0.0002), decreasing BCVA (r = -0.54; P < 0.0001), pseudophakia (P = 0.03), and decreasing subfoveal choroidal thickness (r = -0.27; P = 0.003). Study eyes with RPD (15/116 [13%]) had a significantly greater mean RIT compared with eyes without RPD in any AMD severity group (P < 0.02 for all comparisons), with 80% reaching the DA test ceiling.
   Conclusions: Impairments in DA increased with age, worse visual acuity, presence of RPD, AMD severity, and decreased subfoveal choroidal thickness. Analysis of covariance found the multivariate model that best fit the data included age, AMD group, and presence of RPD (R-2 = 0.56), with the presence of RPD conferring the largest parameter estimate. (C) 2015 by the American Academy of Ophthalmology
C1 [Flamendorf, Jason; Agron, Elvira; Wong, Wai T.; Thompson, Darby; Wiley, Henry E.; Doss, E. Lauren; Al-Holou, Shaza; Ferris, Frederick L., III; Chew, Emily Y.; Cukras, Catherine] NEI, NIH, Bethesda, MD 20892 USA.
C3 National Institutes of Health (NIH) - USA; NIH National Eye Institute
   (NEI)
RP Cukras, C (通讯作者)，NEI, Div Epidemiol & Clin Res, NIH, Bethesda, MD 20892 USA.
EM cukrasc@nei.nih.gov
RI Wong, Wai/B-6118-2017
OI Wong, Wai/0000-0003-0681-4016; Ferris, Frederick/0000-0002-4933-0639
FU National Eye Institute Intramural Research Program, National Institutes
   of Health (NIH), Bethesda, Maryland; NIH Medical Research Scholars
   Program; NIH; Pfizer, Inc.; Doris Duke Charitable Foundation; Alexandria
   Real Estate Equities, Inc.; Howard Hughes Medical Institute; NATIONAL
   EYE INSTITUTE [ZIAEY000489, ZIAEY000509, ZIAEY000485] Funding Source:
   NIH RePORTER
FX Supported by the National Eye Institute Intramural Research Program,
   National Institutes of Health (NIH), Bethesda, Maryland; and the NIH
   Medical Research Scholars Program, a public-private partnership
   supported jointly by the NIH and generous contributions to the
   Foundation for the NIH from Pfizer, Inc., The Doris Duke Charitable
   Foundation, The Alexandria Real Estate Equities, Inc., Mr. and Mrs. Joel
   S. Marcus, the Howard Hughes Medical Institute, as well as other private
   donors.
CR Alten F, 2012, INVEST OPHTH VIS SCI, V53, P6263, DOI 10.1167/iovs.12-10094
   ARNOLD JJ, 1995, RETINA-J RET VIT DIS, V15, P183, DOI 10.1097/00006982-199515030-00001
   Bindewald A, 2005, INVEST OPHTH VIS SCI, V46, P3309, DOI 10.1167/iovs.04-0430
   Chew EY, 2014, JAMA OPHTHALMOL, V132, P272, DOI 10.1001/jamaophthalmol.2013.6636
   CURCIO CA, 1993, INVEST OPHTH VIS SCI, V34, P3278
   Curcio CA, 1996, INVEST OPHTH VIS SCI, V37, P1236
   Curcio CA, 2013, RETINA-J RET VIT DIS, V33, P265, DOI 10.1097/IAE.0b013e31827e25e0
   Farsiu S, 2014, OPHTHALMOLOGY, V121, P162, DOI 10.1016/j.ophtha.2013.07.013
   Ferris FL, 2005, ARCH OPHTHALMOL-CHIC, V123, P1570
   Garg A, 2013, INVEST OPHTH VIS SCI, V54, P7075, DOI 10.1167/iovs.13-12474
   Haas P, 2014, INVEST OPHTH VIS SCI, V55, P2674, DOI 10.1167/iovs.13-13338
   Hogg RE, 2014, OPHTHALMOLOGY, V121, P1748, DOI 10.1016/j.ophtha.2014.03.015
   Jackson GR, 1999, VISION RES, V39, P3975, DOI 10.1016/S0042-6989(99)00092-9
   Jackson GR, 1998, VISION RES, V38, P3655, DOI 10.1016/S0042-6989(98)00044-3
   Jackson GR, 2014, INVEST OPHTH VIS SCI, V55, DOI 10.1167/iovs.13-13745
   Jackson Gregory R, 2008, J Ocul Biol Dis Infor, V1, P7, DOI 10.1007/s12177-008-9002-6
   Johnson PT, 2003, INVEST OPHTH VIS SCI, V44, P4481, DOI 10.1167/iovs.03-0436
   Kassoff A, 1999, CONTROL CLIN TRIALS, V20, P573
   KLEIN R, 1992, OPHTHALMOLOGY, V99, P933
   Leibowitz H M, 1980, Surv Ophthalmol, V24, P335
   Lois N, 2002, AM J OPHTHALMOL, V133, P341, DOI 10.1016/S0002-9394(01)01404-0
   Ooto S, 2013, AM J OPHTHALMOL, V156, P1184, DOI 10.1016/j.ajo.2013.06.036
   Owsley C, 2000, INVEST OPHTH VIS SCI, V41, P267
   Owsley C, 2001, OPHTHALMOLOGY, V108, P1196, DOI 10.1016/S0161-6420(01)00580-2
   Querques G, 2014, RETINA-J RET VIT DIS, V34, P321, DOI 10.1097/IAE.0b013e3182993df1
   Querques G, 2012, INVEST OPHTH VIS SCI, V53, P1258, DOI 10.1167/iovs.11-8907
   Smith RT, 2006, INVEST OPHTH VIS SCI, V47, P5495, DOI 10.1167/iovs.05-1318
   Smith RT, 2009, AM J OPHTHALMOL, V148, P733, DOI 10.1016/j.ajo.2009.06.028
   Toy BC, 2013, AM J OPHTHALMOL, V156, P532, DOI 10.1016/j.ajo.2013.04.031
   Ueda-Arakawa N, 2013, RETINA-J RET VIT DIS, V33, P490, DOI 10.1097/IAE.0b013e318276e0ae
   Wu ZC, 2015, INVEST OPHTH VIS SCI, V56, P2100, DOI 10.1167/iovs.14-16210
   Zhang YH, 2014, AM J OPHTHALMOL, V158, P584, DOI 10.1016/j.ajo.2014.05.038
   Zweifel SA, 2010, OPHTHALMOLOGY, V117, P1775, DOI 10.1016/j.ophtha.2010.01.027
   Zweifel SA, 2010, OPHTHALMOLOGY, V117, P303, DOI 10.1016/j.ophtha.2009.07.014
NR 34
TC 106
Z9 108
U1 0
U2 8
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0161-6420
EI 1549-4713
J9 OPHTHALMOLOGY
JI Ophthalmology
PD OCT
PY 2015
VL 122
IS 10
BP 2053
EP 2062
DI 10.1016/j.ophtha.2015.06.023
PG 10
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA CU4IP
UT WOS:000363491500022
PM 26253372
OA Green Accepted
DA 2022-11-30
ER

PT J
AU Tsujikawa, A
   Nakanishi, H
   Ojima, Y
   Iwama, D
   Tamura, H
   Otani, A
   Yoshimura, N
AF Tsujikawa, Akitaka
   Nakanishi, Hideo
   Ojima, Yumiko
   Iwama, Daisuke
   Tamura, Hiroshi
   Otani, Atsushi
   Yoshimura, Nagahisa
TI Macular polypoidal choroidal vasculopathy with a remote lesion
SO CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY
LA English
DT Article
DE age-related macular degeneration (AMD); choroidal neovascularization
ID CHINESE PATIENTS; NEOVASCULARIZATION; DEGENERATION
AB To report cases of the macular type of polypoidal choroidal vasculopathy with a remote lesion.
   We report six patients (seven eyes) with polypoidal choroidal vasculopathy who had macular and remote lesions. These eyes were examined with angiography and tomography.
   All seven eyes showed an exudative macular lesion beneath the fovea. In addition, all eyes showed remote polypoidal lesions that were not connected to the macular lesions; the remote lesion was detected outside of the vascular arcade in five eyes, superotemporally beside the optic disc in one eye and on the nasal side of the optic disc in one eye. Indocyanine green angiography, fluorescein angiography and optical coherence tomography failed to reveal any sign of a branching vascular network or choroidal neovascularization that connected the macular lesion with the more remote lesion. At the initial visit, visual acuity in the seven eyes ranged from 6/150 to 6/9 (median, 6/15). Four eyes underwent photodynamic therapy to the exudative macular lesion. During 27.6 +/- 14.3 months of follow up, no worsening was detected in any of the remote lesions. Median visual acuity was 6/60 at the final visit.
   Some patients with macular polypoidal choroidal vasculopathy also have a remote lesion, although the remote lesion seems to have only a minor effect on visual outcome.
C1 [Tsujikawa, Akitaka] Kyoto Univ, Grad Sch Med, Dept Ophthalmol & Visual Sci, Sakyo Ku, Kyoto 6068507, Japan.
C3 Kyoto University
RP Tsujikawa, A (通讯作者)，Kyoto Univ, Grad Sch Med, Dept Ophthalmol & Visual Sci, Sakyo Ku, 54 Shogoin Kawahara Cho, Kyoto 6068507, Japan.
EM tujikawa@kuhp.kyoto-u.ac.jp
RI TAMURA, Hiroshi/H-1855-2011
OI TAMURA, Hiroshi/0000-0002-7740-2732; Tsujikawa,
   Akitaka/0000-0003-0779-7799
CR BERKOW JW, 1984, AM J OPHTHALMOL, V97, P143, DOI 10.1016/S0002-9394(14)76083-0
   BRESSLER NM, 1988, SURV OPHTHALMOL, V32, P375, DOI 10.1016/0039-6257(88)90052-5
   Chan WM, 2004, OPHTHALMOLOGY, V111, P1576, DOI 10.1016/j.ophtha.2003.12.056
   Ciardella AP, 2004, SURV OPHTHALMOL, V49, P25, DOI 10.1016/j.survophthal.2003.10.007
   KLEINER RC, 1990, RETINA-J RET VIT DIS, V10, P9, DOI 10.1097/00006982-199001010-00002
   Kwok AKH, 2002, BRIT J OPHTHALMOL, V86, P892, DOI 10.1136/bjo.86.8.892
   Lafaut BA, 2000, GRAEF ARCH CLIN EXP, V238, P752, DOI 10.1007/s004170000180
   MAGUIRE MG, 1994, ARCH OPHTHALMOL-CHIC, V112, P489
   Merle H, 2007, CAN J OPHTHALMOL, V42, P631, DOI 10.3129/i07-102
   Moorthy RS, 1998, OPHTHALMOLOGY, V105, P1380, DOI 10.1016/S0161-6420(98)98016-2
   Sho K, 2003, ARCH OPHTHALMOL-CHIC, V121, P1392, DOI 10.1001/archopht.121.10.1392
   SPAIDE RF, 1995, RETINA-J RET VIT DIS, V15, P100, DOI 10.1097/00006982-199515020-00003
   STERN RM, 1985, AM J OPHTHALMOL, V100, P560, DOI 10.1016/0002-9394(85)90682-8
   Tamura H, 2007, BRIT J OPHTHALMOL, V91, P1152, DOI 10.1136/bjo.2006.112318
   Tateiwa H, 2002, GRAEF ARCH CLIN EXP, V240, P354, DOI 10.1007/s00417-002-0459-x
   Tsujikawa A, 2007, AM J OPHTHALMOL, V143, P102, DOI 10.1016/j.ajo.2006.08.025
   Uyama M, 1999, ARCH OPHTHALMOL-CHIC, V117, P1035
   Wen F, 2004, GRAEF ARCH CLIN EXP, V242, P625, DOI 10.1007/s00417-003-0667-z
   Yannuzzi LA, 1998, ARCH OPHTHALMOL-CHIC, V116, P382
   Yannuzzi LA, 1997, ARCH OPHTHALMOL-CHIC, V115, P478, DOI 10.1001/archopht.1997.01100150480005
   YANNUZZI LA, 1990, RETINA-J RET VIT DIS, V10, P1, DOI 10.1097/00006982-199001010-00001
NR 21
TC 6
Z9 7
U1 0
U2 0
PU WILEY-BLACKWELL PUBLISHING, INC
PI MALDEN
PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA
SN 1442-6404
J9 CLIN EXP OPHTHALMOL
JI Clin. Exp. Ophthalmol.
PD DEC
PY 2008
VL 36
IS 9
BP 817
EP 823
DI 10.1111/j.1442-9071.2009.01907.x
PG 7
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 412SZ
UT WOS:000263745800004
PM 19278475
DA 2022-11-30
ER

PT J
AU Giannakaki-Zimmermann, H
   Ebneter, A
   Munk, MR
   Wolf, S
   Zinkernagel, MS
AF Giannakaki-Zimmermann, Helena
   Ebneter, Andreas
   Munk, Marion R.
   Wolf, Sebastian
   Zinkernagel, Martin S.
TI Outcomes when Switching from a pro re nata Regimen to a Treat and Extend
   Regimen Using Aflibercept in Neovascular Age-Related Macular
   Degeneration
SO OPHTHALMOLOGICA
LA English
DT Article
DE Neovascular age-related macular degeneration; Intravitreal injections;
   Aflibercept; Pro re nata regimen; Treat and extend regimen
ID PROSPECTIVE TRIAL; RANIBIZUMAB; PROTOCOL; THERAPY
AB Purpose: To investigate outcomes in patients with neovascular age-related macular degeneration (AMD) switched from a pro re nata regimen (PRN) to a treat and extend regimen (TER) under aflibercept. Procedure: Thirty-two patients were observed over 2 years: the first year on PRN and the second year on TER. Best-corrected visual acuity (BCVA) and central retinal thickness (CRT) were evaluated. Intra- and subretinal fluid as well as the number of visits and injections were assessed. Results: Both regimens resulted in a stable BCVA. Patients in TER had a significant decrease of CRT after 1 year compared to 1 year of treatment on PRN (p < 0.0001). TER resulted in significantly less visits; however, significantly more injections were observed over the course of 1 year compared to PRN (10.25 vs. 7.5, p < 0.0001 and 5.97 vs. 7.5, p = 0.0002, respectively). Conclusion: A switch from PRN to TER in patients treated with aflibercept for AMD appears to be safe. (C) 2016 S. Karger AG, Basel
C1 [Giannakaki-Zimmermann, Helena; Ebneter, Andreas; Munk, Marion R.; Wolf, Sebastian; Zinkernagel, Martin S.] Univ Bern, Univ Hosp Bern, Inselspital, Dept Ophthalmol, CH-3010 Bern, Switzerland.
C3 University of Bern; University Hospital of Bern
RP Giannakaki-Zimmermann, H (通讯作者)，Univ Bern, Univ Hosp Bern, Inselspital, Dept Ophthalmol, CH-3010 Bern, Switzerland.
EM elena.gianna@gmail.com
RI Wolf, Sebastian/B-8782-2008; Ebneter, Andreas/C-5226-2017
OI Wolf, Sebastian/0000-0002-7467-7028; Ebneter,
   Andreas/0000-0001-6666-2558; Zinkernagel, Martin S./0000-0003-3447-2359
FU Novartis (Novartis AG); Bayer AG; Bayer
FX Marion R. Munk received lecturer fees from Novartis (Novartis AG) and
   travel support from Bayer (Bayer AG). Andreas Ebneter received lecturer
   fees and travel support from Bayer AG. Sebastian Wolf is consultant for
   Bayer and Novartis, and grant recipient from Bayer. Martin S.
   Zinkernagel is consultant for Novartis and Bayer AG, grant recipient
   from Bayer and stockholder of Novartis Pharmaceuticals.
CR Abedi F, 2014, RETINA-J RET VIT DIS, V34, P1531, DOI 10.1097/IAE.0000000000000134
   Berg K, 2015, OPHTHALMOLOGY, V122, P146, DOI 10.1016/j.ophtha.2014.07.041
   Calvo P, 2014, J CLIN EXP OPHTHALMO, V5, P324
   Chakravarthy U, 2013, LANCET, V382, P1258, DOI 10.1016/S0140-6736(13)61501-9
   Engelbert M, 2009, RETINA-J RET VIT DIS, V29, P1424, DOI 10.1097/IAE.0b013e3181bfbd46
   Freund KB, 2015, RETINA-J RET VIT DIS, V35, P1489, DOI 10.1097/IAE.0000000000000627
   Fung AT, 2012, EYE, V26, P1181, DOI 10.1038/eye.2012.174
   Lalwani GA, 2009, AM J OPHTHALMOL, V148, P43, DOI 10.1016/j.ajo.2009.01.024
   Martin DF, 2012, OPHTHALMOLOGY, V119, DOI 10.1016/j.ophtha.2012.03.053
   Oubraham H, 2011, RETINA-J RET VIT DIS, V31, P26, DOI 10.1097/IAE.0b013e3181de5609
   Prunte C, 2014, MAC SOC 37 ANN M 201
   Rahimy E, 2016, RETINA-J RET VIT DIS, V36, P875, DOI 10.1097/IAE.0000000000000814
   Spaide R, 2007, AM J OPHTHALMOL, V143, P679, DOI 10.1016/j.ajo.2007.02.024
   Spaide RF, 2009, AM J OPHTHALMOL, V148, P1, DOI 10.1016/j.ajo.2009.04.010
   Stewart MW, 2015, J CLIN MED, V4, P1079, DOI 10.3390/jcm4051079
   Toalster N, 2013, RETINA-J RET VIT DIS, V33, P1351, DOI 10.1097/IAE.0b013e3182831265
   Wykoff CC, 2015, OPHTHALMOLOGY, V122, P2514, DOI 10.1016/j.ophtha.2015.08.009
NR 17
TC 14
Z9 14
U1 0
U2 2
PU KARGER
PI BASEL
PA ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND
SN 0030-3755
EI 1423-0267
J9 OPHTHALMOLOGICA
JI Ophthalmologica
PY 2016
VL 236
IS 4
BP 201
EP 206
DI 10.1159/000452929
PG 6
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA EI5UG
UT WOS:000392559700004
PM 27907924
OA Green Published
DA 2022-11-30
ER

PT J
AU Muller, PL
   Pfau, M
   Moller, PT
   Nadal, J
   Schmid, M
   Lindner, M
   de Sisternes, L
   Stohr, H
   Weber, BHF
   Neuhaus, C
   Herrmann, P
   Schmitz-Valckenberg, S
   Holz, FG
   Fleckenstein, M
AF Mueller, Philipp L.
   Pfau, Maximilian
   Moeller, Philipp T.
   Nadal, Jennifer
   Schmid, Matthias
   Lindner, Moritz
   de Sisternes, Luis
   Stohr, Heidi
   Weber, Bernhard H. F.
   Neuhaus, Christine
   Herrmann, Philipp
   Schmitz-Valckenberg, Steffen
   Holz, Frank G.
   Fleckenstein, Monika
TI Choroidal Flow Signal in Late-Onset Stargardt Disease and Age-Related
   Macular Degeneration: An OCT-Angiography Study
SO INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE
LA English
DT Article
DE optical coherence tomography angiography; ABCA4; retina; AMD; geographic
   atrophy
ID QUANTITATIVE FUNDUS AUTOFLUORESCENCE; INDOCYANINE GREEN ANGIOGRAPHY;
   GEOGRAPHIC ATROPHY; SPECTRAL-DOMAIN; SWEPT-SOURCE; ABCA4 DISEASE; DARK
   ATROPHY; CHORIOCAPILLARIS; GENE; PROGRESSION
AB PURPOSE. To investigate the choroidal blood flow in areas within and adjacent to retinal pigment epithelium (RPE) atrophy secondary to late-onset Stargardt disease (STGD1) and age-related macular degeneration (AMD).
   METHODS. A total of 43 eyes (23 STGD1 and 20 AMD) of patients with RPE atrophy and 25 eyes of healthy controls without ocular pathology underwent multimodal imaging including optical coherence tomography angiography (OCT-A; PLEX Elite 9000 Swept-Source OCT). Using an exploratory approach, choriocapillaris and deeper choroid OCT-A slabs were evaluated in order to detect differences between STGD1 and AMD. The magnitude of absence-of-flow signal (AFS) was investigated in terms of area-fraction and size-frequency distribution.
   RESULTS. Qualitative and quantitative analysis of areas of RPE atrophy revealed more pronounced rarefaction of the choriocapillaris flow signal in STGD1 as compared to AMD (AFS area fraction: 33.15% +/- 6.86% vs. 31.68% +/- 8.39%; P = 0.517), while outside RPE atrophy rarefaction was less pronounced in STGD1 (AFS area fraction: 17.41% +/- 5.67% vs. 21.59% +/- 6.90%; P < 0.001), to the level of nonsignificance compared to controls (13.27% +/- 2.99%, P = 0.368). Given this discrepancy, the ratio of the AFS area fraction within/outside of RPE atrophy could be used to differentiate between STGD1 and AMD with 65.0% sensitivity and 92.3% specificity.
   CONCLUSIONS. Using OCT-A, comparison of choroidal flow signal within and outside the area of RPE atrophy revealed distinct differences between STGD1 and AMD, potentially implicating a differential role of the choroid in the pathogenesis of RPE atrophy in these two diseases.
C1 [Mueller, Philipp L.; Pfau, Maximilian; Moeller, Philipp T.; Lindner, Moritz; Herrmann, Philipp; Schmitz-Valckenberg, Steffen; Holz, Frank G.; Fleckenstein, Monika] Univ Bonn, Dept Ophthalmol, Ernst Abbe Str 2, D-53127 Bonn, Germany.
   [Mueller, Philipp L.; Herrmann, Philipp; Holz, Frank G.] Univ Bonn, Ctr Rare Dis, Bonn, Germany.
   [Pfau, Maximilian; Moeller, Philipp T.; Schmitz-Valckenberg, Steffen; Holz, Frank G.; Fleckenstein, Monika] GRADE Reading Ctr, Bonn, Germany.
   [Nadal, Jennifer; Schmid, Matthias] Univ Hosp Bonn, Inst Med Biometry Informat & Epidemiol, Bonn, Germany.
   [Lindner, Moritz] Univ Oxford, Nuffield Dept Clin Neurosci, Nuffield Lab Ophthalmol, Oxford, England.
   [Lindner, Moritz] Univ Oxford, Nuffield Dept Clin Neurosci, Sleep & Circadian Neurosci Inst, Oxford, England.
   [de Sisternes, Luis] Stanford Univ, Dept Radiol, Stanford, CA 94305 USA.
   [de Sisternes, Luis] Carl Zeiss Meditec Inc, Dublin, CA USA.
   [Stohr, Heidi; Weber, Bernhard H. F.] Univ Regensburg, Inst Human Genet, Regensburg, Germany.
   [Neuhaus, Christine] Ctr Human Genet Bioscientia, Ingelheim, Germany.
C3 University of Bonn; University of Bonn; University of Bonn; University
   of Oxford; University of Oxford; Stanford University; Carl Zeiss AG;
   University of Regensburg
RP Fleckenstein, M (通讯作者)，Univ Bonn, Dept Ophthalmol, Ernst Abbe Str 2, D-53127 Bonn, Germany.
EM Monika.Fleckenstein@ukbonn.de
RI Lindner, Moritz/AAC-8639-2021; Pfau, Maximilian/N-1888-2019; Müller,
   Philipp L./P-3350-2019
OI Lindner, Moritz/0000-0002-4416-3421; Pfau,
   Maximilian/0000-0001-9761-9640; Schmid, Matthias/0000-0002-0788-0317
FU BONFOR GEROK Program of the Faculty of Medicine, University of Bonn
   [O-137.0023, O-137.0022, O-137.0025]; German Research Foundation
   [MU4279/1-1, LI2846/1-1, Ho1926/3-1, FL658/4-1, FL 658/4-2]
FX Supported by the BONFOR GEROK Program of the Faculty of Medicine,
   University of Bonn, Grant O-137.0023 (PLM), Grant O-137.0022 (MP), Grant
   O-137.0025 (MP), and the German Research Foundation Grants MU4279/1-1
   (PLM), LI2846/1-1 (ML), Ho1926/3-1 (FGH), FL658/4-1 (MF), and FL 658/4-2
   (MF). The authors alone are responsible for the writing and content of
   the paper.
CR Allikmets R, 1997, NAT GENET, V15, P236, DOI 10.1038/ng0397-236
   [Anonymous], 1991, OPHTHALMOLOGY, V98, P741
   [Anonymous], 2013, [No title captured]
   Bertelsen M, 2014, INVEST OPHTH VIS SCI, V55, P2766, DOI 10.1167/iovs.13-13391
   Biesemeier A, 2014, NEUROBIOL AGING, V35, P2562, DOI 10.1016/j.neurobiolaging.2014.05.003
   BIRNBACH CD, 1994, OPHTHALMOLOGY, V101, P1211
   Boon CJF, 2007, BRIT J OPHTHALMOL, V91, P1504, DOI 10.1136/bjo.2007.115659
   Boon CJF, 2008, VISION RES, V48, P2569, DOI 10.1016/j.visres.2008.01.010
   Borrelli E, 2017, INVEST OPHTH VIS SCI, V58, P4792, DOI 10.1167/iovs.17-22360
   Burke TR, 2014, INVEST OPHTH VIS SCI, V55, P2841, DOI 10.1167/iovs.13-13624
   Cideciyan AV, 2004, HUM MOL GENET, V13, P525, DOI 10.1093/hmg/ddh048
   DELORI FC, 1995, INVEST OPHTH VIS SCI, V36, P2327
   Delori F, 2011, INVEST OPHTH VIS SCI, V52, P9379, DOI 10.1167/iovs.11-8319
   EAGLE RC, 1980, OPHTHALMOLOGY, V87, P1189
   Fang PP, 2016, OPHTHALMOLOGE, V113, P6, DOI 10.1007/s00347-015-0184-6
   Fleckenstein M, 2016, INVEST OPHTH VIS SCI, V57, P2463, DOI 10.1167/iovs.15-18593
   Fleckenstein M, 2014, INVEST OPHTH VIS SCI, V55, P2911, DOI 10.1167/iovs.13-13409
   Fleckenstein M, 2011, INVEST OPHTH VIS SCI, V52, P3761, DOI 10.1167/iovs.10-7021
   Fujinami K, 2013, INVEST OPHTH VIS SCI, V54, P8181, DOI 10.1167/iovs.13-12104
   Giani A, 2012, INVEST OPHTH VIS SCI, V53, P3999, DOI 10.1167/iovs.11-9258
   Gliem M, 2016, JAMA OPHTHALMOL, V134, P817, DOI 10.1001/jamaophthalmol.2016.1475
   Hamel CP, 2007, ORPHANET J RARE DIS, V2, DOI 10.1186/1750-1172-2-7
   Han ZC, 2014, ADV EXP MED BIOL, V801, P719, DOI 10.1007/978-1-4614-3209-8_90
   Holz FG, 1998, AM J OPHTHALMOL, V125, P227, DOI 10.1016/S0002-9394(99)80095-6
   Holz FG, 2007, AM J OPHTHALMOL, V143, P463, DOI 10.1016/j.ajo.2006.11.041
   Holz FG, 2017, OPHTHALMOLOGY, V124, P464, DOI 10.1016/j.ophtha.2016.12.002
   Hoyng CB, 2016, MACULAR DYSTROPHIES, P25
   Issa PC, 2015, P NATL ACAD SCI USA, V112, P8415, DOI 10.1073/pnas.1506960112
   Kitiratschky VBD, 2008, EUR J HUM GENET, V16, P812, DOI 10.1038/ejhg.2008.23
   KLIEN BA, 1967, AM J OPHTHALMOL, V64, P3, DOI 10.1016/0002-9394(67)93339-9
   Koenekoop Robert K, 2003, Ophthalmic Genet, V24, P75, DOI 10.1076/opge.24.2.75.13996
   Kuehlewein L, 2016, RETINA-J RET VIT DIS, V36, P1216, DOI 10.1097/IAE.0000000000000870
   Kurihara T, 2012, J CLIN INVEST, V122, P4213, DOI 10.1172/JCI65157
   Lambertus S, 2016, INVEST OPHTH VIS SCI, V57, P5186, DOI 10.1167/iovs.16-19833
   Lane M, 2016, INVEST OPHTH VIS SCI, V57, pOCT585, DOI 10.1167/iovs.15-18915
   Lim LS, 2012, LANCET, V379, P1728, DOI 10.1016/S0140-6736(12)60282-7
   Lindner M, 2017, INVEST OPHTH VIS SCI, V58, DOI 10.1167/iovs.16-20980
   Lois N, 2001, ARCH OPHTHALMOL-CHIC, V119, P359, DOI 10.1001/archopht.119.3.359
   McLeod DS, 2009, INVEST OPHTH VIS SCI, V50, P4982, DOI 10.1167/iovs.09-3639
   Miller AR, 2017, INVEST OPHTH VIS SCI, V58, P1499, DOI 10.1167/iovs.16-20969
   Muller PL, 2017, RETINA-J RET VIT DIS, V37, P359, DOI 10.1097/IAE.0000000000001169
   Muller PL, 2015, INVEST OPHTH VIS SCI, V56, P8179, DOI 10.1167/iovs.15-17629
   Mullins RE, 2011, INVEST OPHTH VIS SCI, V52, P1606, DOI 10.1167/iovs.10-6476
   Niu SJ, 2016, OPHTHALMOLOGY, V123, P1737, DOI 10.1016/j.ophtha.2016.04.042
   Pellegrini M, 2016, OPHTHALMOLOGY, V123, P1879, DOI 10.1016/j.ophtha.2016.05.041
   Pfau M, 2017, INVEST OPHTH VIS SCI, V58, pBIO121, DOI 10.1167/iovs.17-21764
   Phansalkar Neerad, 2011, 2011 International Conference on Communications and Signal Processing (ICCSP), P218, DOI 10.1109/ICCSP.2011.5739305
   Pinheiro J, 2014, NLME LINEAR NONLINEA
   Riveiro-Alvarez R, 2013, OPHTHALMOLOGY, V120, P2332, DOI 10.1016/j.ophtha.2013.04.002
   Saint-Geniez M, 2009, P NATL ACAD SCI USA, V106, P18751, DOI 10.1073/pnas.0905010106
   Saksens NTM, 2014, PROG RETIN EYE RES, V39, P23, DOI 10.1016/j.preteyeres.2013.11.001
   Schmitz-Valckenberg S, 2006, INVEST OPHTH VIS SCI, V47, P2648, DOI 10.1167/iovs.05-0892
   Schmitz-Valckenberg S, 2017, OPHTHALMOLOGICA, V237, P11, DOI 10.1159/000455074
   Schmitz-Valckenberg S, 2011, INVEST OPHTH VIS SCI, V52, P7640, DOI 10.1167/iovs.11-7457
   Schmitz-Valckenberg S, 2010, OPHTHALMOLOGY, V117, P1169, DOI 10.1016/j.ophtha.2009.10.044
   Scholl HPN, 2016, SCI TRANSL MED, V8, DOI 10.1126/scitranslmed.aaf2838
   Schulz HL, 2017, INVEST OPHTH VIS SCI, V58, P394, DOI 10.1167/iovs.16-19936
   Schwartz SD, 2012, LANCET, V379, P713, DOI 10.1016/S0140-6736(12)60028-2
   Schwoerer J, 2000, OPHTHALMOLOGICA, V214, P240, DOI 10.1159/000027498
   Smith RT, 2009, AM J OPHTHALMOL, V148, P733, DOI 10.1016/j.ajo.2009.06.028
   Spaide RF, 2016, AM J OPHTHALMOL, V170, P58, DOI 10.1016/j.ajo.2016.07.023
   Strauss O, 2005, PHYSIOL REV, V85, P845, DOI 10.1152/physrev.00021.2004
   Strauss RW, 2016, BRIT J OPHTHALMOL, V100, P956, DOI 10.1136/bjophthalmol-2015-307035
   Strauss RW, 2017, JAMA OPHTHALMOL, V53, P841
   Yaspan BL, 2017, SCI TRANSL MED, V9, DOI 10.1126/scitranslmed.aaf1443
   Yeoh J, 2010, GRAEF ARCH CLIN EXP, V248, P1719, DOI 10.1007/s00417-010-1437-3
   Zernant J, 2017, J MED GENET, V54, P404, DOI 10.1136/jmedgenet-2017-104540
   Zhang QQ, 2018, INVEST OPHTH VIS SCI, V59, P203, DOI 10.1167/iovs.17-22953
NR 68
TC 30
Z9 30
U1 0
U2 4
PU ASSOC RESEARCH VISION OPHTHALMOLOGY INC
PI ROCKVILLE
PA 12300 TWINBROOK PARKWAY, ROCKVILLE, MD 20852-1606 USA
SN 0146-0404
EI 1552-5783
J9 INVEST OPHTH VIS SCI
JI Invest. Ophthalmol. Vis. Sci.
PD MAR
PY 2018
VL 59
IS 4
SI SI
BP AMD122
EP AMD131
DI 10.1167/iovs.18-23819
PG 10
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA GR8YP
UT WOS:000443024700002
PM 30140905
OA Green Published, gold
DA 2022-11-30
ER

PT J
AU Scott, AW
   Bressler, SB
AF Scott, Adrienne W.
   Bressler, Susan B.
TI Long-term follow-up of vascular endothelial growth factor inhibitor
   therapy for neovascular age-related macular degeneration
SO CURRENT OPINION IN OPHTHALMOLOGY
LA English
DT Review
DE aflibercept; age-related macular degeneration; bevacizumab; choroidal
   neovascularization; ranibizumab
ID VERTEPORFIN PHOTODYNAMIC THERAPY; ANTI-VEGF THERAPIES; RANIBIZUMAB;
   BEVACIZUMAB; SAFETY; AFLIBERCEPT; MACULOPATHY; PREVALENCE; TRIAL; EYE
AB Purpose of review
   To discuss the most recent literature regarding the long-term use (>= 52 weeks of follow-up) of antivascular endothelial growth factor (VEGF) therapy for neovascular age-related macular degeneration (NVAMD).
   Recent findings
   Intravitreal ranibizumab has been demonstrated to provide outstanding vision outcomes relative to the standard therapy in patients with NVAMD. The VEGF Trap-Eye: Investigation of Efficacy and Safety in Wet AMD studies showed that patients managed with intravitreal aflibercept achieved visual acuity and anatomic improvements similar to individuals managed with monthly ranibizumab while receiving an average of five fewer injections during the first 12 months of treatment. In the Comparison of AMD Treatment Trials, intravitreal bevacizumab dosed monthly met noninferiority to ranibizumab monthly, as well as noninferiority to ranibizumab dosed as-needed with respect to change in visual acuity 1 year after the treatment initiation. Furthermore, patients switched to as-needed regimens in their second year of follow-up from monthly dosing during the first year demonstrated an incremental loss of visual acuity during the second year of follow-up irrespective of the drug used. To date, trials evaluating anti-VEGF therapy for NVAMD demonstrate a low incidence of serious ocular or systemic adverse events. However, the potential for deleterious effects of long-term (beyond 2 years) pan-VEGF blockade remains unknown.
   Summary
   Patients with NVAMD enjoy heretofore unprecedented vision gains when managed with anti-VEGF therapy, and the limited body of evidence to date regarding long-term anti-VEGF treatment shows these vision gains can be maintained through 2 years. Further investigation is needed to explore the effects of long-term anti-VEGF therapy beyond 2 years.
C1 [Scott, Adrienne W.; Bressler, Susan B.] Johns Hopkins Univ, Sch Med, Wilmer Eye Inst, Retina Div, Baltimore, MD 21205 USA.
C3 Johns Hopkins University; Johns Hopkins Medicine
RP Bressler, SB (通讯作者)，600 North Wolfe St,Maumenee 706, Baltimore, MD 21287 USA.
EM sbressler@jhmi.edu
FU Physician-Scientist Award from Research to Prevent Blindness (RPB);
   Julia G. Levy, PhD Professorship in Ophthalmology from the Johns Hopkins
   University School of Medicine
FX The authors have no proprietary interest in this article. Dr Susan
   Bressler is supported by a Physician-Scientist Award from Research to
   Prevent Blindness (RPB) and the Julia G. Levy, PhD Professorship in
   Ophthalmology from the Johns Hopkins University School of Medicine.
CR Antoszyk AN, 2008, AM J OPHTHALMOL, V145, P862, DOI 10.1016/j.ajo.2007.12.029
   Binder S, 2012, BRIT J OPHTHALMOL, V96, P1, DOI 10.1136/bjophthalmol-2011-301236
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Brown DM, 2009, OPHTHALMOLOGY, V116, P57, DOI 10.1016/j.ophtha.2008.10.018
   Browning DJ, 2012, AM J OPHTHALMOL, V154, P222, DOI 10.1016/j.ajo.2012.04.020
   Chakravarthy U, 2012, OPHTHALMOLOGY, V119, DOI 10.1016/j.ophtha.2012.04.015
   Davis J, 2011, AM J OPHTHALMOL, V152, P509, DOI 10.1016/j.ajo.2011.07.004
   Ferrara N, 2004, NAT REV DRUG DISCOV, V3, P391, DOI 10.1038/nrd1381
   *GEN INC, 2008, AV BEV FULL PRESCR I
   Goldberg RA, 2012, AM J OPHTHALMOL, V153, P204, DOI 10.1016/j.ajo.2011.11.035
   Gordon MS, 2005, ONCOLOGY-BASEL, V69, P25, DOI 10.1159/000088481
   Heier JS, 2012, OPHTHALMOLOGY, V119, P2537, DOI 10.1016/j.ophtha.2012.09.006
   Holz FG, 2011, OPHTHALMOLOGY, V118, P663, DOI 10.1016/j.ophtha.2010.12.019
   Kaiser PK, 2012, GRAEF ARCH CLIN EXP, V250, P1563, DOI 10.1007/s00417-012-2123-4
   Kim H, 2009, MOL VIS, V15
   KLEIN R, 1992, OPHTHALMOLOGY, V99, P933
   Martin DF, 2012, OPHTHALMOLOGY, V119, DOI 10.1016/j.ophtha.2012.03.053
   Martin DF, 2011, NEW ENGL J MED, V364, P1897, DOI 10.1056/NEJMoa1102673
   Mitchell P, 2011, PHARMACOECONOMICS, V29, P107, DOI 10.2165/11585520-000000000-00000
   Patel RD, 2011, SEMIN OPHTHALMOL, V26, P372, DOI 10.3109/08820538.2011.570845
   Regeneron Pharmaceuticals Inc, 2012, 2 YEAR RES PHAS 3 ST
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Scappaticci FA, 2007, JNCI-J NATL CANCER I, V99, P1232, DOI 10.1093/jnci/djm086
   Schmidt-Erfurth U, 2011, OPHTHALMOLOGY, V118, P831, DOI 10.1016/j.ophtha.2010.09.004
   Silva R, 2013, OPHTHALMOLOGY, V120, P130, DOI 10.1016/j.ophtha.2012.07.026
   Singer MA, 2012, OPHTHALMOLOGY, V119, P1175, DOI 10.1016/j.ophtha.2011.12.016
   Tolentino M, 2011, SURV OPHTHALMOL, V56, P95, DOI 10.1016/j.survophthal.2010.08.006
   VINGERLING JR, 1995, OPHTHALMOLOGY, V102, P205
   Wong T, 2008, OPHTHALMOLOGY, V115, P116, DOI 10.1016/j.ophtha.2007.03.008
NR 29
TC 50
Z9 51
U1 1
U2 23
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 1040-8738
EI 1531-7021
J9 CURR OPIN OPHTHALMOL
JI Curr. Opin. Ophthalmol.
PD MAY
PY 2013
VL 24
IS 3
BP 190
EP 196
DI 10.1097/ICU.0b013e32835fefee
PG 7
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 123ML
UT WOS:000317394000003
PM 23492430
DA 2022-11-30
ER

PT J
AU Lee, SJ
   Kim, NR
   Chin, HS
AF Lee, Soo J.
   Kim, Na R.
   Chin, Hee S.
TI LOC387715/HTRA1 polymorphisms, smoking and combined effects on exudative
   age-related macular degeneration in a Korean population
SO CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY
LA English
DT Article
DE age-related macular degeneration; HTRA1; LOC387715; smoking
ID COMPLEMENT-FACTOR-H; HTRA1 PROMOTER POLYMORPHISM; VARIANT; GENE;
   SUSCEPTIBILITY; ASSOCIATION; RISK; CFH; Y402H; INCREASES
AB P>Background:
   This study was to investigate the association of two single nucleotide polymorphisms (SNPs) in LOC387715 and HTRA1 with exudative age-related macular degeneration (AMD) in a Korean population and the gene-gene and gene-environment interactions in the development of AMD.
   Methods:
   We genotyped two SNPs that are located in the LOC387715 locus (rs10490924) and HTRA1 (rs11200638) in 137 cases of exudative AMD and 187 controls.
   Results:
   Both two SNPs were significantly associated with AMD (P = 0.0001). Homozygotes for the risk allele at LOC387715 and HTRA1 had a 3.80-fold and a 4.03-fold increased risk of exudative AMD, respectively, compared with homozygotes for the wild-type allele (P = 0.0001). The joint effects for complement factor H (CFH) Y402H and 10q26 variants indicated an increased risk of exudative AMD. The odds ratios (ORs) of AMD for individuals carrying one-, two- and three-copy risk alleles of CFH Y402H and LOC387715 were 1.08, 3.49 and 3.64, respectively. Also, the combination effect of the CFH Y402H risk alleles with HTRA1 risk alleles was dose-dependent. The interaction analysis between gene and environmental factors showed that among several factors, smoking synergistically increased the susceptibility of AMD for variants of LOC387715 and HTRA1, with OR 8.33 (3.05-22.74) and OR 8.50 (3.07-23.51), respectively.
   Conclusion:
   This study demonstrated the significant association of the 10q26 SNPs (HTRA1 and LOC387715) in an AMD cohort from Korea and was consistent with previous studies from other populations. Also, a statistically significant interaction between genetic and environmental factors was found.
C1 [Lee, Soo J.; Kim, Na R.; Chin, Hee S.] Inha Univ, Sch Med, Dept Ophthalmol, Inchon, South Korea.
   [Kim, Na R.] Yonsei Univ, Coll Med, Inst Vis Res, Dept Ophthalmol, Seoul 120749, South Korea.
C3 Inha University; Yonsei University; Yonsei University Health System
RP Chin, HS (通讯作者)，Inha Univ Hosp, Dept Ophthalmol, 7-206 Shinheung Dong, Inchon, South Korea.
EM hschin@inha.ac.kr
FU Korean Government [KRF-2009-0067460]; Ministry of Education, Science and
   Technology [2009-0082249]
FX This work was supported by a Korea Research Foundation Grant funded by
   the Korean Government (KRF-2009-0067460) and by the Converging Research
   Center Program through the National Research Foundation of Korea (NRF)
   funded by the Ministry of Education, Science and Technology
   (2009-0082249).
CR Anand R, 2000, OPHTHALMOLOGY, V107, P2224
   Bojanowski CM, 2006, ENVIRON MOL MUTAGEN, V47, P594, DOI 10.1002/em.20233
   Chan CC, 2005, HISTOL HISTOPATHOL, V20, P857, DOI 10.14670/HH-20.857
   Conley YP, 2006, HUM MOL GENET, V15, P3206, DOI 10.1093/hmg/ddl396
   Dewan A, 2006, SCIENCE, V314, P989, DOI 10.1126/science.1133807
   Francis PJ, 2008, MOL VIS, V14, P1395
   Gilicze A, 2007, MOL IMMUNOL, V44, P2961, DOI 10.1016/j.molimm.2007.01.004
   Gotoh N, 2006, HUM GENET, V120, P139, DOI 10.1007/s00439-006-0187-0
   Grau S, 2006, J BIOL CHEM, V281, P6124, DOI 10.1074/jbc.M500361200
   Haddad S, 2006, SURV OPHTHALMOL, V51, P316, DOI 10.1016/j.survophthal.2006.05.001
   Hageman GS, 2005, P NATL ACAD SCI USA, V102, P7227, DOI 10.1073/pnas.0501536102
   Haines JL, 2005, SCIENCE, V308, P419, DOI 10.1126/science.1110359
   Hyman L, 2000, ARCH OPHTHALMOL-CHIC, V118, P351, DOI 10.1001/archopht.118.3.351
   Jakobsdottir J, 2005, AM J HUM GENET, V77, P389, DOI 10.1086/444437
   Kanda A, 2007, P NATL ACAD SCI USA, V104, P16227, DOI 10.1073/pnas.0703933104
   Kim NR, 2008, INVEST OPHTH VIS SCI, V49, P2071, DOI 10.1167/iovs.07-1195
   Klein R, 2004, AM J OPHTHALMOL, V137, P486, DOI 10.1016/j.ajo.2003.11.069
   Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557
   Kondo N, 2007, AM J OPHTHALMOL, V144, P608, DOI 10.1016/j.ajo.2007.06.003
   Lau LI, 2006, INVEST OPHTH VIS SCI, V47, P3242, DOI 10.1167/iovs.05-1532
   Maller J, 2006, NAT GENET, V38, P1055, DOI 10.1038/ng1873
   Mullins Robert F., 2007, International Ophthalmology Clinics, V47, P1, DOI 10.1097/IIO.0b013e31802bd3e6
   Postel EA, 2006, OPHTHALMOLOGY, V113, P1504, DOI 10.1016/j.ophtha.2006.02.049
   Rivera A, 2005, HUM MOL GENET, V14, P3227, DOI 10.1093/hmg/ddi353
   Ross RJ, 2007, EXPERT REV OPHTHALMO, V2, P443, DOI 10.1586/17469899.2.3.443
   Schaumberg DA, 2007, ARCH OPHTHALMOL-CHIC, V125, P55, DOI 10.1001/archopht.125.1.55
   Schmidt S, 2006, AM J HUM GENET, V78, P852, DOI 10.1086/503822
   Seddon JM, 2007, JAMA-J AM MED ASSOC, V297, P1793, DOI 10.1001/jama.297.16.1793
   Seddon JM, 2006, HUM HERED, V61, P157, DOI 10.1159/000094141
   Seitsonen SP, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003833
   Sepp T, 2006, INVEST OPHTH VIS SCI, V47, P536, DOI 10.1167/iovs.05-1143
   Smith W, 2001, OPHTHALMOLOGY, V108, P697, DOI 10.1016/S0161-6420(00)00580-7
   Tam POS, 2008, INVEST OPHTH VIS SCI, V49, P2357, DOI 10.1167/iovs.07-1520
   Tuo J, 2008, OPHTHALMOLOGY, V115, P1891, DOI 10.1016/j.ophtha.2008.05.021
   Tuo JS, 2006, P NATL ACAD SCI USA, V103, P9256, DOI 10.1073/pnas.0603485103
   Tuo JS, 2004, PROG RETIN EYE RES, V23, P229, DOI 10.1016/j.preteyeres.2004.02.001
   Wang JJ, 2008, OPHTHALMOLOGY, V115, P693, DOI 10.1016/j.ophtha.2007.05.038
   Xu YL, 2008, MOL VIS, V14, P1373
   Yang ZL, 2006, SCIENCE, V314, P992, DOI 10.1126/science.1133811
   Yoshida T, 2007, MOL VIS, V13, P545
   Zareparsi S, 2005, HUM MOL GENET, V14, P1449, DOI 10.1093/hmg/ddi154
NR 41
TC 17
Z9 20
U1 0
U2 5
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1442-6404
EI 1442-9071
J9 CLIN EXP OPHTHALMOL
JI Clin. Exp. Ophthalmol.
PD OCT
PY 2010
VL 38
IS 7
BP 698
EP 704
DI 10.1111/j.1442-9071.2010.02316.x
PG 7
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 664RC
UT WOS:000282979200010
PM 20456446
DA 2022-11-30
ER

PT J
AU Kowalski, M
   Bielecka-Kowalska, A
   Oszajca, K
   Makandjou-Ola, E
   Jaworski, P
   Bartkowiak, J
   Szemraj, J
AF Kowalski, Michal
   Bielecka-Kowalska, Anna
   Oszajca, Katarzyna
   Makandjou-Ola, Eusebio
   Jaworski, Piotr
   Bartkowiak, Jacek
   Szemraj, Janusz
TI Manganese superoxide dismutase (MnSOD) gene (Ala-9Val, Ile58Thr)
   polymorphism in patients with age-related macular degeneration (AMD)
SO MEDICAL SCIENCE MONITOR
LA English
DT Article
DE AMD; manganese superoxide dismutase; gene polymorphism; gene expression;
   correlation between gene polymorphism and gene expression
ID CHOROIDAL NEOVASCULARIZATION; OXIDATIVE STRESS; ASSOCIATION; EXPRESSION;
   CLASSIFICATION; SCHIZOPHRENIA; PARKINSONISM; MACULOPATHY; DIMORPHISM;
   SOD2
AB Background: Oxidative stress is involved in the pathogenesis of many chronic disorders including cancer, in inflammation, and neurologic diseases. Reactive oxygen species (ROS) may play a major role in age-related macular degeneration (AMD). This study investigated the mRNA and protein profiles of related manganese superoxide dismutase MnSOD in patients with AMD and healthy controls, while ex examining its genetic sequence polymorphism (Ala-9Val, Ile58Thr). Our intent was to find a correlation between the expression of MnSOD genes and nucleotide sequence polymorphisms encoded in the gene of the dry and wet form of AMD.
   Material/Methods: We examined 300 unrelated AMD patients and 300 unrelated healthy controls who gave free con consent to participate in the study. The MnSOD gene polymorphisms were determined by PCR/RFLP method. We also used real-time RT-PCR and ELISA methods to estimate expression of MnSOD mRNA and protein.
   Results: There were statistically significant differences in the genotype distribution between patients with AMD and controls. Our results showed positive correlations between gene sequence polymorphism and the level of MnSOD mRNA and protein expression. The Ala-9Ala genotype and alanine allele (Ala-9Val sequence polymorphism) is much more frequent in AMD patients than in healthy subjects. Healthy controls who are homozygotes Val/Val and heterozygotes Ala/Val showed low lower expression of the MnSOD gene as compared to homozygote Ala/Ala. The lowest expression of MnSOD (homozygotes Val/Val and heterozygotes Ala/Val for wet and dry form of AMD) was not noted in patients with AMD.
   Conclusions: These data suggest a genetic role of MnSOD polymorphism in the development of age-related degeneration.
C1 [Oszajca, Katarzyna; Makandjou-Ola, Eusebio; Jaworski, Piotr; Bartkowiak, Jacek; Szemraj, Janusz] Med Univ Lodz, Dept Med Biochem, PL-92215 Lodz, Poland.
   [Kowalski, Michal; Bielecka-Kowalska, Anna] Med Ctr Sal Med, Lodz, Poland.
C3 Medical University Lodz
RP Szemraj, J (通讯作者)，Med Univ Lodz, Dept Med Biochem, Mazowiecka 6-8 Str, PL-92215 Lodz, Poland.
EM jszemraj@csk.am.lodz.pl
RI Oszajca, Katarzyna Anna/S-9288-2016
OI Oszajca, Katarzyna Anna/0000-0002-7070-8720
FU Medical University of Lodz [502-16-648]
FX This work was supported by a research grant from the Medical University
   of Lodz 502-16-648
CR BIRD AEC, 1995, SURV OPHTHALMOL, V39, P367, DOI 10.1016/S0039-6257(05)80092-X
   BORGSTAHL GEO, 1996, BIOCEMISTRY, V43, P863
   Brunk UT, 2002, FREE RADICAL BIO MED, V33, P611, DOI 10.1016/S0891-5849(02)00959-0
   CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999
   Dong A, 2009, J CELL PHYSIOL, V219, P544, DOI 10.1002/jcp.21698
   Esfandiary H, 2005, BRIT J OPHTHALMOL, V89, P470, DOI 10.1136/bjo.2004.047340
   FREUND KB, 1993, AM J OPHTHALMOL, V115, P786, DOI 10.1016/S0002-9394(14)73649-9
   Galecki P, 2007, ARCH PSYCHIATR PSYCH, V9, P43
   Gottlieb MGV, 2005, GENET MOL RES, V4, P691
   Guyer DR, 1996, OPHTHALMOLOGY, V103, P2054, DOI 10.1016/S0161-6420(96)30388-6
   HALLIWELL B, 1992, J NEUROCHEM, V59, P1609, DOI 10.1111/j.1471-4159.1992.tb10990.x
   Hiroi S, 1999, BIOCHEM BIOPH RES CO, V261, P332, DOI 10.1006/bbrc.1999.1036
   Hitzeroth A, 2007, PROG NEURO-PSYCHOPH, V31, P664, DOI 10.1016/j.pnpbp.2006.12.019
   Hori H, 2000, NEUROPSYCHOPHARMACOL, V23, P170, DOI 10.1016/S0893-133X(99)00156-6
   Kangas-Kontio T, 2009, BRIT J OPHTHALMOL, V93, P1401, DOI 10.1136/bjo.2009.159012
   Kimura K, 2000, AM J OPHTHALMOL, V130, P769, DOI 10.1016/S0002-9394(00)00552-3
   Klaver CCW, 1998, ARCH OPHTHALMOL-CHIC, V116, P653, DOI 10.1001/archopht.116.5.653
   LEMIRE BD, 1989, J BIOL CHEM, V264, P20206
   Marcus DL, 2006, MED SCI MONITOR, V12, pBR8
   Matsumine H, 1997, AM J HUM GENET, V60, P588
   Nemethova M, 2008, CELL BIOL INT, V32, P128, DOI 10.1016/j.cellbi.2007.08.023
   Noack H, 1998, GLIA, V23, P285, DOI 10.1002/(SICI)1098-1136(199808)23:4<285::AID-GLIA1>3.0.CO;2-2
   ShimodaMatsubayashi S, 1997, NEUROLOGY, V49, P1257, DOI 10.1212/WNL.49.5.1257
   ShimodaMatsubayashi S, 1996, BIOCHEM BIOPH RES CO, V226, P561, DOI 10.1006/bbrc.1996.1394
   Sickenberg M, 2001, OPHTHALMOLOGICA, V215, P247, DOI 10.1159/000050869
   Sobkowiak A, 2008, CLIN RHEUMATOL, V27, P827, DOI 10.1007/s10067-007-0796-6
   Ste-Marie L, 2001, BRAIN RES, V918, P10, DOI 10.1016/S0006-8993(01)02903-1
   Sutton A, 2005, PHARMACOGENET GENOM, V15, P311, DOI 10.1097/01213011-200505000-00006
   Tsubota Kazuo, 2007, Nippon Ganka Gakkai Zasshi, V111, P193
   Tuo JS, 2004, PROG RETIN EYE RES, V23, P229, DOI 10.1016/j.preteyeres.2004.02.001
   Wang JJ, 2003, OPHTHALMOLOGY, V110, P1960, DOI 10.1016/S0161-6420(03)00816-9
   Winer J, 1999, ANAL BIOCHEM, V270, P41, DOI 10.1006/abio.1999.4085
   Zelko IN, 2002, FREE RADICAL BIO MED, V33, P337, DOI 10.1016/S0891-5849(02)00905-X
NR 33
TC 27
Z9 28
U1 0
U2 5
PU INT SCIENTIFIC INFORMATION, INC
PI MELVILLE
PA 150 BROADHOLLOW RD, STE 114, MELVILLE, NY 11747 USA
SN 1643-3750
J9 MED SCI MONITOR
JI Med. Sci. Monitor
PY 2010
VL 16
IS 4
BP CR190
EP CR196
PG 7
WC Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Research & Experimental Medicine
GA 580UX
UT WOS:000276477100010
PM 20357718
DA 2022-11-30
ER

PT J
AU Chan, CKW
   Gangwani, RA
   McGhee, SM
   Lian, JX
   Wong, DSH
AF Chan, Christina K. W.
   Gangwani, Rita A.
   McGhee, Sarah M.
   Lian, JinXiao
   Wong, David S. H.
TI Cost-Effectiveness of Screening for Intermediate Age-Related Macular
   Degeneration during Diabetic Retinopathy Screening
SO OPHTHALMOLOGY
LA English
DT Article
ID UTILITY; BURDEN; RISK
AB Purpose: To determine whether screening for age-related macular degeneration (AMD) during a diabetic retinopathy (DR) screening program would be cost effective in Hong Kong.
   Design: We compared and evaluated the impacts of screening, grading, and vitamin treatment for intermediate AMD compared with no screening using a Markov model. It was based on the natural history of AMD in a cohort with a mean age of 62 years, followed up until 100 years of age or death.
   Participants: Subjects attending a DR screening program were recruited.
   Method: A cost-effectiveness analysis was undertaken from a public provider perspective. It included grading for AMD using the photographs obtained for DR screening and treatment with vitamin therapy for those with intermediate AMD. The measures of effectiveness were obtained largely from a local study, but the transition probabilities and utility values were from overseas data. Costs were all from local sources. The main assumptions and estimates were tested in sensitivity analyses.
   Main Outcome Measures: The outcome was cost per quality-adjusted life year (QALY) gained. Both costs and benefits were discounted at 3%. All costs are reported in United States dollars ($).
   Results: The cost per QALY gained through screening for AMD and vitamin treatment for appropriate cases was $12 712 after discounting. This would be considered highly cost effective based on the World Health Organization's threshold of willingness to pay (WTP) for a QALY, that is, less than the annual per capita gross domestic product of $29 889. Because of uncertainty regarding the utility value for those with advanced AMD, we also tested an extreme, conservative value for utility under which screening remained cost effective. One-way sensitivity analyses revealed that, besides utility values, the cost per QALY was most sensitive to the progression rate from intermediate to advanced AMD. The cost-effectiveness acceptability curve showed a WTP for a QALY of $29 000 or more has a more than 86% probability of being cost effective compared with no screening.
   Conclusions: Our analysis demonstrated that AMD screening carried out simultaneously with DR screening for patients with diabetes would be cost effective in a Hong Kong public healthcare setting. Ophthalmology (C) 2015 by the American Academy of Ophthalmology.
C1 [Chan, Christina K. W.; McGhee, Sarah M.; Lian, JinXiao] Univ Hong Kong, Sch Publ Hlth, Hong Kong, Hong Kong, Peoples R China.
   [Gangwani, Rita A.; Wong, David S. H.] Univ Hong Kong, Dept Ophthalmol, Hong Kong, Hong Kong, Peoples R China.
C3 University of Hong Kong; University of Hong Kong
RP Gangwani, RA (通讯作者)，Univ Hong Kong, Dept Ophthalmol, Room 301,Block B,Cyberport 4,100 Cyberport Rd, Hong Kong, Hong Kong, Peoples R China.
EM gangwani@hku.hk
OI LIAN, Jinxiao/0000-0002-6830-4196
FU Health and Health Services Research Fund (HHSRF) of the Hong Kong
   Special Administrative Region Government, Hong Kong, China
FX Supported by the Health and Health Services Research Fund (HHSRF) of the
   Hong Kong Special Administrative Region Government, Hong Kong, China.
CR Age-Related Eye Dis Study Res Grp, 2001, AM J OPHTHALMOL, V132, P668
   Bressler Neil M, 2004, JAMA, V291, P1900, DOI 10.1001/jama.291.15.1900
   Brown MM, 2005, CAN J OPHTHALMOL, V40, P277, DOI 10.1016/S0008-4182(05)80070-5
   Census and Statistics Department, 1971, GOV HONG KONG SPEC A
   Census and Statistics Department. The Government of the Hong Kong Special Administrative Region, 2012, HONG KONG GROSS DOM
   Charkoudian LD, 2008, OPHTHALMOLOGY, V115, P1032, DOI 10.1016/j.ophtha.2007.08.003
   Drummond M. F., 2006, SMJ Singapore Medical Journal, V47, P456
   Fahed DC, 2011, EUR J OPHTHALMOL, V21, P67, DOI 10.5301/EJO.2010.4138
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P564
   Gangwani R, 2014, GRAEF ARCH CLIN EXP, V252, P723, DOI 10.1007/s00417-013-2530-1
   Gordois A, 2012, GLOB PUBLIC HEALTH, V7, P465, DOI 10.1080/17441692.2011.634815
   Hong Kong Administrative Region, SPEC SUPPL 4 GOV HON
   Hong Kong Census and Statistics Department, 2021, HONG KONG ANN DIG ST
   Hopley C, 2004, BRIT J OPHTHALMOL, V88, P450, DOI 10.1136/bjo.2003.035279
   Karnon J, 2008, HEALTH TECHNOL ASSES, V12, p[iii, ix, 124]
   Karnon J, 2009, MED DECIS MAKING, V29, P304, DOI 10.1177/0272989X08327491
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1417, DOI 10.1001/archopht.119.10.1417
   Klaver CCW, 2001, INVEST OPHTH VIS SCI, V42, P2237
   Lian JX, 2013, OPHTHALMOLOGY, V120, P1247, DOI 10.1016/j.ophtha.2012.11.024
   McGhee SM, 2013, 06071021 GOV HONG KO
   Rein DB, 2007, OPHTHALMOLOGY, V114, P1319, DOI 10.1016/j.ophtha.2006.10.041
   Social Welfare Department, SAL SCAL COMM POSTS
   UK National Screening Committee, 2009, ESS EL DEV DIAB RET
   van Leeuwen R, 2005, JAMA-J AM MED ASSOC, V294, P3101, DOI 10.1001/jama.294.24.3101
   Vijan S, 2000, JAMA-J AM MED ASSOC, V283, P889, DOI 10.1001/jama.283.7.889
   WHO Commission on Macroeconomics and Health, 2001, MACR HLTH INV HLTH E
   World Health Organization, 2012, PREV BLINDN VIS IMP
   Yasuda M, 2009, OPHTHALMOLOGY, V116, P2135, DOI 10.1016/j.ophtha.2009.04.017
   Zimmer-Galler IE, 2005, OPHTHAL SURG LAS IM, V36, P228, DOI 10.3928/1542-8877-20050501-09
NR 29
TC 26
Z9 26
U1 1
U2 9
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 0161-6420
EI 1549-4713
J9 OPHTHALMOLOGY
JI Ophthalmology
PD NOV
PY 2015
VL 122
IS 11
BP 2278
EP 2285
DI 10.1016/j.ophtha.2015.06.050
PG 8
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA CU4IQ
UT WOS:000363491800030
PM 26315045
DA 2022-11-30
ER

PT J
AU Gilson, MM
   Bressler, NM
   Jabs, DA
   Solomon, SD
   Thorne, JE
   Wilson, DJ
AF Gilson, Marta M.
   Bressler, Neil M.
   Jabs, Douglas A.
   Solomon, Sharon D.
   Thorne, Jennifer E.
   Wilson, David J.
CA NAPP Trial Research Grp
TI Periocular triamcinolone and photodynamic therapy for subfoveal
   choroidal neovascularization in age-related macular degeneration
SO OPHTHALMOLOGY
LA English
DT Article
ID INTRAVITREAL TRIAMCINOLONE; ACETONIDE; INJECTION; CORTICOSTEROIDS;
   RETROBULBAR; VERTEPORFIN; EDEMA
AB Purpose: To evaluate fluorescein angiographic and visual acuity (VA) outcomes from patients enrolled in a trial of a single periocular corticosteroid injection immediately before photodynamic therapy (PDT) versus PDT alone for subfoveal choroidal neovascularization secondary to age-related macular degeneration (AMD).
   Design: Randomized 2-center clinical trial.
   Participants: Sixty-seven subjects with AMD, subfoveal choroidal neovascularization, and best-corrected VA of 20/20 to 20/320 in the study eye who had received no more than 1 prior PDT treatment.
   Methods: Subjects were randomized to receive PDT alone (no corticosteroid) or a single periocular corticosteroid injection given via the posterior superior sub-Tenon's capsule route before PDT (corticosteroid) and assessed 1, 3, and 6 months after enrollment. Best-corrected VA and intraocular pressure (IOP) measurements were taken during each examination. Color photographs and fluorescein angiograms were taken at baseline and 3 and 6 months.
   Main Outcome Measure: Presence or absence of fluorescein leakage from choroidal neovascularization 3 months after randomization.
   Results: Between the 34 participants randomized to periocular corticosteroid and 33 to no corticosteroid, baseline features appeared balanced. Thirty-three corticosteroid participants and 30 no corticosteroid participants returned for the 3-month follow-up, at which time 56 had fluorescein leakage. Proportions of participants with leakage at 3 months for the 2 treatment groups did not statistically significantly differ; 94% of the corticosteroid group and 90% of the no corticosteroid group had fluorescein leakage at 3 months (P = 0.66). Mean VAs at 3 months after enrollment were 20/100 and 20/125 in the corticosteroid and no corticosteroid groups, respectively, decreasing on average 1.5 and 0.9 lines from baseline (P = 0.50). Adverse events included IOP > 21 mmHg in 7 corticosteroid participants (21%) and 1 (3%) no corticosteroid participant (P < 0.05) and ptosis of the study eyelid in 1 (3%) corticosteroid participant.
   Conclusions: In contrast to previously reported uncontrolled studies and 1 controlled study, this trial did not find a reduction in the amount of fluorescein leakage 3 months after a single periocular injection of corticosteroid and PDT compared with PDT alone. Ophthalmology 2007,114:1713-1721 (c) 2007 by the American Academy of Ophthalmology.
C1 Johns Hopkins Univ, Baltimore, MD USA.
   Oregon Hlth & Sci Univ, Portland, OR USA.
   Johns Hopkins Univ, Sch Med, Baltimore, MD USA.
C3 Johns Hopkins University; Oregon Health & Science University; Johns
   Hopkins University
RP Jabs, DA (通讯作者)，550 N Broadway,Suite 700, Baltimore, MD 21205 USA.
EM djabs@jhmi.edu
CR Arnold J, 2001, AM J OPHTHALMOL, V131, P541
   Arnold JJ, 2004, AM J OPHTHALMOL, V137, P683, DOI 10.1016/j.ajo.2003.11.059
   Barbazetto I, 2003, ARCH OPHTHALMOL-CHIC, V121, P1253
   Blinder KJ, 2003, AM J OPHTHALMOL, V136, P407, DOI 10.1016/S0002-9394(03)00223-X
   Bonini MA, 2005, INVEST OPHTH VIS SCI, V46, P3845, DOI 10.1167/iovs.05-0297
   Bressler NM, 2002, ARCH OPHTHALMOL-CHIC, V120, P1443
   Bressler NM, 1999, ARCH OPHTHALMOL-CHIC, V117, P1329
   Cardillo JA, 2005, OPHTHALMOLOGY, V112, P1557, DOI 10.1016/j.ophtha.2005.03.023
   Challa JK, 1998, AUST NZ J OPHTHALMOL, V26, P277, DOI 10.1111/j.1442-9071.1998.tb01330.x
   Ciulla TA, 2001, ARCH OPHTHALMOL-CHIC, V119, P399, DOI 10.1001/archopht.119.3.399
   *COLL OC MEL, 1995, NTIS PUBL
   Congdon N, 2004, ARCH OPHTHALMOL-CHIC, V122, P477
   Danis RP, 2000, RETINA-J RET VIT DIS, V20, P244, DOI 10.1097/00006982-200003000-00004
   Dees C, 1998, ARCH OPHTHALMOL-CHIC, V116, P1456, DOI 10.1001/archopht.116.11.1456
   DUPONT WD, 1990, CONTROL CLIN TRIALS, V11, P116, DOI 10.1016/0197-2456(90)90005-M
   Flaxel CJ, 1998, EYE, V12, P266, DOI 10.1038/eye.1998.62
   FREEMAN WR, 1987, AM J OPHTHALMOL, V103, P281
   Gillies MC, 2003, ARCH OPHTHALMOL-CHIC, V121, P667, DOI 10.1001/archopht.121.5.667
   Greve MDJ, 2005, ARCH OPHTHALMOL-CHIC, V123, P448
   HELM CJ, 1995, AM J OPHTHALMOL, V120, P55, DOI 10.1016/S0002-9394(14)73759-6
   Hogan A, 2005, BRIT J OPHTHALMOL, V89, P1109, DOI 10.1136/bjo.2004.063024
   Holekamp NM, 2005, AM J OPHTHALMOL, V139, P421, DOI 10.1016/j.ajo.2004.10.005
   HYNDIUK RA, 1968, ARCH OPHTHALMOL-CHIC, V80, P499, DOI 10.1001/archopht.1968.00980050501019
   Jonas JB, 2005, AM J OPHTHALMOL, V139, P1073, DOI 10.1016/j.ajo.2005.01.032
   Kato A, 2005, RETINA-J RET VIT DIS, V25, P503, DOI 10.1097/00006982-200506000-00017
   *MAC PHOT STUD, 1991, NTIS PUBL
   Martidis A, 1999, J OCUL PHARMACOL TH, V15, P425, DOI 10.1089/jop.1999.15.425
   Penfold PL, 1995, AUST NZ J OPHTHALMOL, V23, P293, DOI 10.1111/j.1442-9071.1995.tb00179.x
   Ranson NT, 2002, BRIT J OPHTHALMOL, V86, P527, DOI 10.1136/bjo.86.5.527
   Schmidt-Erfurth U, 2002, ARCH OPHTHALMOL-CHIC, V120, P835
   Smithen LM, 2004, AM J OPHTHALMOL, V138, P884, DOI 10.1016/j.ajo.2004.05.073
   Spaide RF, 2005, OPHTHALMOLOGY, V112, P301, DOI 10.1016/j.ophtha.2004.08.012
   Spaide RF, 2003, OPHTHALMOLOGY, V110, P1517, DOI 10.1016/S0161-6420(03)00544-X
   *SUBM SURG TRIALS, 2005, RETINA, V25, P253
   *SUBM SURG TRIALS, 1998, NTIS PUBL
   Thach AB, 1997, OPHTHALMOLOGY, V104, P2003, DOI 10.1016/S0161-6420(97)30065-7
   Van de Moere A, 2005, OPHTHALMOLOGY, V112, P1897, DOI 10.1016/j.ophtha.2005.06.018
NR 37
TC 11
Z9 11
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 0161-6420
EI 1549-4713
J9 OPHTHALMOLOGY
JI Ophthalmology
PD SEP
PY 2007
VL 114
IS 9
BP 1713
EP 1721
DI 10.1016/j.ophtha.2007.03.071
PG 9
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 206LA
UT WOS:000249183700018
PM 17822977
DA 2022-11-30
ER

PT J
AU Au, A
   Parikh, VS
   Singh, RP
   Ehlers, JP
   Yuan, A
   Rachitskaya, AV
   Sears, JE
   Srivastava, SK
   Kaiser, PK
   Schachat, AP
   Martin, DF
   Modi, Y
AF Au, Adrian
   Parikh, Vishal S.
   Singh, Rishi P.
   Ehlers, Justis P.
   Yuan, Alex
   Rachitskaya, Aleksandra V.
   Sears, Jonathan E.
   Srivastava, Sunil K.
   Kaiser, Peter K.
   Schachat, Andrew P.
   Martin, Daniel F.
   Modi, Yasha
TI Comparison of anti-VEGF therapies on fibrovascular pigment epithelial
   detachments in age-related macular degeneration
SO BRITISH JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
ID INTRAVITREAL AFLIBERCEPT; RANIBIZUMAB; BEVACIZUMAB
AB Background The aim is to compare the therapeutic effects of three antivascular endothelial growth factor (VEGF) drugs (bevacizumab, aflibercept and ranibizumab) on fibrovascular pigment epithelial detachments (fvPEDs) in age-related macular degeneration (AMD).
   Methods This was a retrospective, comparative, consecutive case series of 88 unique eyes with fvPEDs in neovascular AMD treated with anti-VEGF monotherapy for a minimum of 6 months. All eyes were treatment naive. Diagnosis was confirmed retrospectively by fluorescein angiography and spectral-domain optical coherence tomography. Exclusion criteria included serous/drusenoid PEDs or patients who switched anti-VEGF. Mean follow-up across all therapies was 313.9 +/- 85.3 days.
   Results Average age of all patients was 80.6 years. Baseline maximum subfoveal PED height was 326.8 +/- 185.1 mu m, 394.5 +/- 238.6 mu m and 258.0 +/- 145.3 mu m for bevacizumab, aflibercept and ranibizumab, respectively (p=0.05). All patients had subretinal fluid, intraretinal fluid or a combination of the two at an initial presentation. Central retinal thickness decreased at all time points compared with baseline across all three anti-VEGF therapies. Subfoveal PED height decreased in patients treated with aflibercept at all time points and decreased in patients treated with bevacizumab at 1-month, 3-month and 6-month time points. Aflibercept reduced PED height more than bevacizumab at 1-month and 12-month follow-ups (p=0.02 and p=0.03, respectively) and ranibizumab at 1-month and 6-month follow-ups (p=0.03 and p=0.02, respectively). No differences in best-corrected visual acuity were appreciated at any time point between drugs.
   Conclusions There was a significant reduction in subfoveal PED height for aflibercept and bevacizumab compared with baseline. A direct comparison of drugs demonstrated a beneficial reduction of PED height, albeit inconsistently, favouring aflibercept. There were no differences in visual acuity across the groups at any time point.
C1 [Au, Adrian] Case Western Reserve Sch Med, Cleveland, OH USA.
   [Parikh, Vishal S.; Singh, Rishi P.; Ehlers, Justis P.; Yuan, Alex; Rachitskaya, Aleksandra V.; Sears, Jonathan E.; Srivastava, Sunil K.; Kaiser, Peter K.; Schachat, Andrew P.; Martin, Daniel F.; Modi, Yasha] Cleveland Clin Fdn, Cole Eye Inst, 9500 Euclid Ave, Cleveland, OH 44195 USA.
C3 Case Western Reserve University; Cleveland Clinic Foundation
RP Modi, Y (通讯作者)，721 5th Ave,Apt 37F, New York, NY 10022 USA.
EM yasha.modi@gmail.com
RI Au, Adrian/AAE-9654-2019
OI Au, Adrian/0000-0001-8110-9988; Yuan, Alex/0000-0003-0191-8035; Kaiser,
   Peter/0000-0001-5126-045X
FU Carl Zeiss Meditec
FX Support was graciously provided by Carl Zeiss Meditec.
CR Bolz M, 2007, BRIT J OPHTHALMOL, V91, P785, DOI 10.1136/bjo.2006.102467
   Boyer DS, 2009, OPHTHALMOLOGY, V116, P1731, DOI 10.1016/j.ophtha.2009.05.024
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Chan CK, 2015, EYE, V29, P80, DOI 10.1038/eye.2014.233
   Cho HJ, 2016, AM J OPHTHALMOL, V166, P112, DOI 10.1016/j.ajo.2016.03.039
   Dirani A, 2015, AM J OPHTHALMOL, V160, P732, DOI 10.1016/j.ajo.2015.06.025
   Heier JS, 2012, OPHTHALMOLOGY, V119, P2537, DOI 10.1016/j.ophtha.2012.09.006
   Inoue M, 2013, RETINA-J RET VIT DIS, V33, P990, DOI 10.1097/IAE.0b013e3182755793
   Martin DF, 2011, NEW ENGL J MED, V364, P1897, DOI 10.1056/NEJMoa1102673
   Panos GD, 2013, DRUG DES DEV THER, V7, P565, DOI 10.2147/DDDT.S46610
   Patel KH, 2013, EYE, V27, P664, DOI 10.1038/eye.2013.31
   Pauleikhoff D, 2002, GRAEF ARCH CLIN EXP, V240, P533, DOI 10.1007/s00417-002-0505-8
   Veritti D, 2013, RETINA-J RET VIT DIS, V33, P982, DOI 10.1097/IAE.0b013e31826d8ff4
   Yuksel H, 2013, ARQ BRAS OFTALMOL, V76, P209, DOI 10.1590/S0004-27492013000400002
   Zayit-Soudry S, 2007, SURV OPHTHALMOL, V52, P227, DOI 10.1016/j.survophthal.2007.02.008
NR 15
TC 18
Z9 21
U1 0
U2 5
PU BMJ PUBLISHING GROUP
PI LONDON
PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND
SN 0007-1161
EI 1468-2079
J9 BRIT J OPHTHALMOL
JI Br. J. Ophthalmol.
PD JUL
PY 2017
VL 101
IS 7
BP 970
EP 975
DI 10.1136/bjophthalmol-2016-309434
PG 6
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA EY6BX
UT WOS:000404068600022
PM 27913442
DA 2022-11-30
ER

PT J
AU Schmidt-Erfurth, U
   Michels, S
   Michels, R
   Aue, A
AF Schmidt-Erfurth, U
   Michels, S
   Michels, R
   Aue, A
TI Anecortave acetate for the treatment of subfoveal choroidal
   neovascularization secondary to age-related macular degeneration
SO EUROPEAN JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
DE anecortave acetate; age-related macular degeneration; choroidal
   neovascularization
AB PURPOSE. Anecortave acetate is a novel angiostatic cortisene being evaluated clinically for treatment of exudative age-related macular degeneration (ARMD). A randomized, placebo-controlled, efficacy and safety dose duration study of anecortave acetate for depot suspension (3 mg, 15 mg, 30 mg) in this patient population was completed in June 2003. As part of this trial, 128 patients with subfoveal choroidal neovascularization (CNV) secondary to ARMD were enrolled and treated for up to 2 years by 18 clinical sites in the United States and European Union.
   METHODS. Study patients were evaluated clinically with detailed ophthalmic examinations, general physical examinations, assessments of best-corrected logMAR visual acuity, and angiographic evaluations. The Digital Angiography Reading Center (New York City, NY) assessed lesion eligibility while the clinical investigators assessed overall patient eligibility prior to treatment. As part of this study, study medication was delivered as a posterior juxtascleral depot using a specially designed curved cannula at 6-month intervals if in the masked investigator's opinion the patient's lesion could benefit from additional treatment. RESULTS. The 2-year efficacy results of this placebo-con trolled study demonstrated that RETAANE 15 mg (anecortave acetate for depot suspension) was statistically superior to placebo for stabilization of vision (< 3 logMAR line change from baseline) and for inhibition of neovascular lesion growth. There were no serious treatment-related safety issues associated with either the study medication or the procedure for administration.
   RESULTS. The 2-year efficacy results of this placebo-con trolled study demonstrated that RETAANE 15 mg (anecortave acetate for depot suspension) was statistically superior to placebo for stabilization of vision (< 3 logMAR line change from baseline) and for inhibition of neovascular lesion growth. There were no serious treatment-related safety issues associated with either the study medication or the procedure for administration.
   CONCLUSIONS. Anecortave acetate 15 mg for depot suspension is clinically efficacious compared to placebo for treatment of subfoveal exudative ARMD lesions when administered at 6-month intervals as a posterior juxtascleral depot.
C1 Univ Vienna, Dept Ophthalmol, A-1090 Vienna, Austria.
C3 University of Vienna
RP Schmidt-Erfurth, U (通讯作者)，Univ Vienna, Dept Ophthalmol, Waehringer Guertel 18-20, A-1090 Vienna, Austria.
EM ursula.schmidt-erfurth@meduniwien.ac.at
CR Blinder K, 2003, RETINA-J RET VIT DIS, V23, P14
   Clark A F, 1997, Expert Opin Investig Drugs, V6, P1867, DOI 10.1517/13543784.6.12.1867
   McNatt LG, 1999, J OCUL PHARMACOL TH, V15, P413, DOI 10.1089/jop.1999.15.413
   Penn JS, 2001, INVEST OPHTH VIS SCI, V42, P283
   Russell S, 2003, OPHTHALMOLOGY, V110, P2372, DOI 10.1016/j.ophtha.2003.08.020
NR 5
TC 28
Z9 31
U1 0
U2 0
PU SAGE PUBLICATIONS LTD
PI LONDON
PA 1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND
SN 1120-6721
EI 1724-6016
J9 EUR J OPHTHALMOL
JI Eur. J. Ophthalmol.
PD JUL-AUG
PY 2005
VL 15
IS 4
BP 482
EP 485
DI 10.1177/112067210501500411
PG 4
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 945OD
UT WOS:000230510900011
PM 16001382
DA 2022-11-30
ER

PT J
AU Lee, EK
   Yu, HG
AF Lee, Eun Kyoung
   Yu, Hyeong Gon
TI Ganglion Cell-Inner Plexiform Layer and Peripapillary Retinal Nerve
   Fiber Layer Thicknesses in Age-Related Macular Degeneration
SO INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE
LA English
DT Article
DE age-related macular degeneration; ganglion cell-inner plexiform layer;
   glaucoma peripapillary retinal nerve fiber layer; spectral-domain
   optical coherence tomography
ID OPTICAL COHERENCE TOMOGRAPHY; CAUSE-SPECIFIC PREVALENCE; PHOTORECEPTOR
   DEGENERATION; MORPHOMETRIC-ANALYSIS; RETINITIS-PIGMENTOSA; VISUAL-FIELD;
   RISK-FACTORS; GLAUCOMA; DRUSEN; ABNORMALITIES
AB PURPOSE. To investigate changes of inner retinal layers and optic nerve head (ONH) in patients with dry age-related macular degeneration (AMD) and demonstrate the pattern of these changes.
   METHODS. A total of 76 eyes classified as having dry AMD and 76 control eyes were included. Ophthalmologic evaluations included best-corrected visual acuity (BCVA) assessment, spectral-domain optical coherence tomography (SD-OCT), and Humphrey visual field (VF) test. The drusen area and volume were determined using the automated algorithm of the SD-OCT software. Macular ganglion cell-inner plexiform layer (mGCIPL) and peripapillary retinal nerve fiber layer (pRNFL) thicknesses and ONH parameters, as well as VF parameters, were compared between groups.
   RESULTS. Macular GCIPL thickness was significantly lower in eyes with AMD than in controls (73.83 +/- 7.13 vs. 82.00 +/- 4.85 mu m; P < 0.001), and mGCIPL thinning was observed in a ring-shaped pattern around the fovea. The pRNFL thickness was also significantly lower in eyes with AMD than in controls (88.69 +/- 6.93 vs. 93.96 +/- 8.33 mu m; P < 0.001), but no significant difference in ONH parameters was found. An inverse correlation between drusen area and average mGCIPL thickness was found (r = -0.3253; P = 0.0064). Best-corrected visual acuity and VF parameters were worse in AMD eyes than in controls. The pattern of VF defects was mostly consistent with foveal or parafoveal scotoma.
   CONCLUSIONS. In eyes with dry AMD, mGCIPL and pRNFL thicknesses were lower than measurements in control eyes, and the average mGCIPL thickness was negatively correlated with the drusen area. However, the pattern of these changes differed from glaucomatous abnormalities.
C1 [Lee, Eun Kyoung; Yu, Hyeong Gon] Seoul Natl Univ, Coll Med, Dept Ophthalmol, Seoul Natl Univ Hosp, Seoul, South Korea.
C3 Seoul National University (SNU); Seoul National University Hospital
RP Yu, HG (通讯作者)，Seoul Natl Univ Hosp, Dept Ophthalmol, 101 Daehak Ro, Seoul 110744, South Korea.
EM hgonyu@snu.ac.kr
OI Yu, Hyeong Gon/0000-0002-1795-202X
CR BLANKS JC, 1974, J COMP NEUROL, V156, P95, DOI 10.1002/cne.901560108
   Choi YJ, 2013, INVEST OPHTH VIS SCI, V54, P2296, DOI 10.1167/iovs.12-10530
   Gregori G, 2011, OPHTHALMOLOGY, V118, P1373, DOI 10.1016/j.ophtha.2010.11.013
   Hwang YH, 2014, OPHTHALMOLOGY, V121, P1508, DOI 10.1016/j.ophtha.2014.02.019
   Hwang YH, 2014, INVEST OPHTH VIS SCI, V55, P3995, DOI 10.1167/iovs.14-14438
   Jonas JB, 2000, PROG RETIN EYE RES, V19, P1, DOI 10.1016/S1350-9462(99)00002-6
   Jung KI, 2012, INVEST OPHTH VIS SCI, V53, P4813, DOI 10.1167/iovs.12-9908
   Klein ML, 2008, OPHTHALMOLOGY, V115, P1026, DOI 10.1016/j.ophtha.2007.08.030
   Koh VT, 2012, INVEST OPHTH VIS SCI, V53, P5853, DOI 10.1167/iovs.12-10414
   Law SK, 2004, AM J OPHTHALMOL, V138, P38, DOI 10.1016/j.ajo.2004.02.021
   Lee EK, 2014, OPHTHALMOLOGY, V121, P1579, DOI 10.1016/j.ophtha.2014.02.010
   Lund RD, 1997, OPHTHALMIC RES, V29, P305, DOI 10.1159/000268029
   Midena E, 1997, INVEST OPHTH VIS SCI, V38, P469
   MIDENA E, 1994, DOC OPHTHALMOL, V88, P179, DOI 10.1007/BF01204616
   Mwanza JC, 2012, OPHTHALMOLOGY, V119, P1151, DOI 10.1016/j.ophtha.2011.12.014
   Mwanza JC, 2011, INVEST OPHTH VIS SCI, V52, P7872, DOI 10.1167/iovs.11-7896
   Mwanza JC, 2011, INVEST OPHTH VIS SCI, V52, P8323, DOI 10.1167/iovs.11-7962
   Park SC, 2011, OPHTHALMOLOGY, V118, P1782, DOI 10.1016/j.ophtha.2011.02.013
   PAULEIKHOFF D, 1990, AM J OPHTHALMOL, V109, P38, DOI 10.1016/S0002-9394(14)75576-X
   Rahmani B, 1996, OPHTHALMOLOGY, V103, P1721, DOI 10.1016/S0161-6420(96)30435-1
   Ramirez JM, 2001, EXP EYE RES, V73, P601, DOI 10.1006/exer.2001.1061
   Rimayanti U, 2014, GRAEF ARCH CLIN EXP, V252, P563, DOI 10.1007/s00417-013-2496-z
   Santos A, 1997, ARCH OPHTHALMOL-CHIC, V115, P511, DOI 10.1001/archopht.1997.01100150513011
   Schuman SG, 2009, OPHTHALMOLOGY, V116, P488, DOI 10.1016/j.ophtha.2008.10.006
   SOMMER A, 1991, NEW ENGL J MED, V325, P1412, DOI 10.1056/NEJM199111143252004
   STONE JL, 1992, ARCH OPHTHALMOL-CHIC, V110, P1634, DOI 10.1001/archopht.1992.01080230134038
   Strettoi E, 2002, J NEUROSCI, V22, P5492
   Varma R, 2004, OPHTHALMOLOGY, V111, P1439, DOI 10.1016/j.ophtha.2004.01.025
   Villegas-Perez MP, 1998, J COMP NEUROL, V392, P58, DOI 10.1002/(SICI)1096-9861(19980302)392:1<58::AID-CNE5>3.0.CO;2-O
   Yehoshua Z, 2011, OPHTHALMOLOGY, V118, P2434, DOI 10.1016/j.ophtha.2011.05.008
NR 30
TC 57
Z9 59
U1 0
U2 4
PU ASSOC RESEARCH VISION OPHTHALMOLOGY INC
PI ROCKVILLE
PA 12300 TWINBROOK PARKWAY, ROCKVILLE, MD 20852-1606 USA
SN 0146-0404
EI 1552-5783
J9 INVEST OPHTH VIS SCI
JI Invest. Ophthalmol. Vis. Sci.
PD JUN
PY 2015
VL 56
IS 6
BP 3976
EP 3983
DI 10.1167/iovs.15-17013
PG 8
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA CM5PJ
UT WOS:000357740200060
PM 26087362
DA 2022-11-30
ER

PT J
AU Lawrenson, JG
   Evans, JR
AF Lawrenson, John G.
   Evans, Jennifer R.
TI Omega 3 fatty acids for preventing or slowing the progression of
   age-related macular degeneration
SO COCHRANE DATABASE OF SYSTEMATIC REVIEWS
LA English
DT Review
ID POLYUNSATURATED FATTY-ACIDS; PREVALENCE
AB Background
   Evidence from animal models and observational studies in humans has suggested that there is an inverse relationship between dietary intake of omega 3 long-chain polyunsaturated fatty acids (LCPUFA) and risk of developing age-related macular degeneration (AMD) or progressing to advanced AMD.
   Objectives
   To review the evidence that increasing the levels of omega 3 LCPUFA in the diet (either by eating more foods rich in omega 3 or by taking nutritional supplements) prevents AMD or slows the progression of AMD.
   Search methods
   We searched CENTRAL (which contains the Cochrane Eyes and Vision Group Trials Register) (The Cochrane Library 2012, Issue 4), MEDLINE (January 1950 to April 2012), EMBASE (January 1980 to April 2012), Latin American and Caribbean Literature on Health Sciences (LILACS) (January 1982 to April 2012), the metaRegister of Controlled Trials (mRCT) (www. controlled-trials. com), ClinicalTrials.gov (www.clinicaltrials.gov) and the WHO International Clinical Trials Registry Platform (ICTRP) (www.who.int/ictrp/search/en). We did not use any date or language restrictions in the electronic searches for trials. The electronic databases were last searched on 26 April 2012.
   Selection criteria
   We planned to include randomised controlled trials (RCTs) where increased dietary intake of omega 3 fatty acids was compared to placebo or no intervention with the aim of preventing the development of AMD, or slowing its progression.
   Data collection and analysis
   Both authors independently screened titles, abstracts and full-texts of articles to identify studies for inclusion and analysis.
   Main results
   No trials met the selection criteria. The results of a large, multi-centre, randomised trial (AREDS2) that will assess the effects of oral supplementation with omega 3 LCPUFA on progression to advanced AMD are expected in 2013. Two further trials are also ongoing.
   Authors' conclusions
   Until data from RCTs become available for analysis, there is currently no evidence to support increasing levels of omega 3 LCPUFA in the diet for the explicit purpose of preventing or slowing the progression of AMD.
C1 [Lawrenson, John G.] City Univ London, Div Optometry & Visual Sci, London EC1V 0HB, England.
   [Evans, Jennifer R.] London Sch Hyg & Trop Med, ICEH, Cochrane Eyes & Vis Grp, London WC1, England.
C3 City University London; University of London; London School of Hygiene &
   Tropical Medicine
RP Lawrenson, JG (通讯作者)，City Univ London, Div Optometry & Visual Sci, Northampton Sq, London EC1V 0HB, England.
EM j.g.lawrenson@city.ac.uk
OI Lawrenson, John/0000-0002-2031-6390
FU NIHR/Department of Health, UK; Department of Health through National
   Institute for Health Research
FX External sources; NIHR/Department of Health, UK.; JE was employed by the
   Cochrane Eyes and Vision Group when this review was being written.;
   Richard Wormald (Co-ordinating Editor for CEVG) acknowledges financial
   support for his CEVG research sessions from the Department of Health
   through the award made by the National Institute for Health Research to
   Moorfields Eye Hospital NHS Foundation Trust and UCL Institute of
   Ophthalmology for a Specialist Biomedical Research Centre for
   Ophthalmology. The views expressed in this publication are those of the
   authors and not necessarily those of the Department of Health.
CR Bunce C, 2010, EYE, V24, P1692, DOI 10.1038/eye.2010.122
   Burdge GC, 2002, BRIT J NUTR, V88, P355, DOI 10.1079/BJN2002662
   Chong EWT, 2009, ARCH OPHTHALMOL-CHIC, V127, P674, DOI 10.1001/archophthalmol.2009.60
   Christen WG, 2011, ARCH OPHTHALMOL-CHIC, V129, P921, DOI 10.1001/archophthalmol.2011.34
   Evans JR, 2012, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD000253.pub3
   Evans JR, 2012, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD000254.pub3
   Feher J, 2005, OPHTHALMOLOGICA, V219, P154, DOI 10.1159/000085248
   Glanville JM, 2006, J MED LIBR ASSOC, V94, P130
   Higgins JPT, 2002, STAT MED, V21, P1539, DOI 10.1002/sim.1186
   Higgins J, 2012, COCHRANE DB SYST REV, DOI 10.1002/14651858.ED000049
   Hodge WG, 2006, OPHTHALMOLOGY, V113, P1165, DOI 10.1016/j.ophtha.2006.02.043
   Huang LL, 2008, INVEST OPHTH VIS SCI, V49, P3864, DOI 10.1167/iovs.07-1420
   Johnson EJ, 2008, AM J CLIN NUTR, V87, P1521, DOI 10.1093/ajcn/87.5.1521
   Kassoff A, 1999, CONTROL CLIN TRIALS, V20, P573
   Kishan AU, 2011, SURV OPHTHALMOL, V56, P195, DOI 10.1016/j.survophthal.2010.08.008
   KLEIN R, 1991, OPHTHALMOLOGY, V98, P1128
   Koto T, 2007, INVEST OPHTH VIS SCI, V48, P4328, DOI 10.1167/iovs.06-1148
   Lim LS, 2012, LANCET, V379, P1728, DOI 10.1016/S0140-6736(12)60282-7
   Owen CG, 2012, BRIT J OPHTHALMOL, V96, P752, DOI 10.1136/bjophthalmol-2011-301109
   Rudnicka AR, 2012, OPHTHALMOLOGY, V119, P571, DOI 10.1016/j.ophtha.2011.09.027
   SanGiovanni JP, 2009, ARCH OPHTHALMOL-CHIC, V127, P110, DOI 10.1001/archophthalmol.2008.518
   SanGiovanni JP, 2005, PROG RETIN EYE RES, V24, P87, DOI 10.1016/j.preteyeres.2004.06.002
   Scorolli L, 2002, CAN J OPHTHALMOL, V37, P399, DOI 10.1016/S0008-4182(02)80042-4
   Tan JSL, 2009, ARCH OPHTHALMOL-CHIC, V127, P656, DOI 10.1001/archophthalmol.2009.76
   The Nordic Cochrane Centre The Cochrane Collaboration, 2011, REV MAN REVMAN 5 1
   Tuo JS, 2009, AM J PATHOL, V175, P799, DOI 10.2353/ajpath.2009.090089
NR 26
TC 8
Z9 8
U1 0
U2 5
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1469-493X
EI 1361-6137
J9 COCHRANE DB SYST REV
JI Cochrane Database Syst Rev.
PY 2012
IS 11
AR CD010015
DI 10.1002/14651858.CD010015.pub2
PG 18
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine
GA 052LJ
UT WOS:000312198800018
PM 23152282
OA Green Accepted
DA 2022-11-30
ER

PT J
AU Querques, G
   Benlian, P
   Chanu, B
   Portal, C
   Coscas, G
   Soubrane, G
   Souied, EH
AF Querques, G.
   Benlian, P.
   Chanu, B.
   Portal, C.
   Coscas, G.
   Soubrane, G.
   Souied, E. H.
TI Nutritional AMD treatment phase I (NAT-1): feasibility of oral DHA
   supplementation in age-related macular degeneration
SO EUROPEAN JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
DE Age-related macular degeneration; Apoptosis; Dietary supplementation;
   Docosahexaenoic acid; Omega-3; Polyunsaturated fatty acid
ID N-3 FATTY-ACIDS; DIETARY-FAT; RISK-FACTORS; VITAMIN-E;
   CIGARETTE-SMOKING; 5-YEAR INCIDENCE; MACULOPATHY; CAROTENOIDS; RETINA;
   HEALTH
AB PURPOSE. To create a pilot study in order to evaluate the feasibility of a prospective case-control study of oral supplementation with fish oil (docosahexaenoic acid [DHA]; eicosapentaenoic acid [EPA]) in a population with age-related macular degeneration (AMD).
   METHODS. A homogeneous group of 38 patients with drusenoid pigment epithelial detachment in one eye (PED) without choroidal new vessels (CNV) was selected. A complete ophthalmologic examination, and a complete profile of fatty acids in serum (S) and in red blood cell membranes (RBCM), were recorded at day 0 and month 6. In group 1, 22 patients were orally supplemented with EPA (720 mg/day) and DHA (480 mg/day) during 6 months. In group 2, 16 patients were followed as controls. Nutritional recommendations on fish consumption were given to both groups.
   RESULTS. In group 1, after 6 months supplementation we observed a significant blood enrichment in EPA (EPA-S: 2.20 vs 0.79, p<0.0001 and EPA-RBCM: 2.24 vs 0.85, p<0.0001) and in DHA (DHA-S: 2.47 vs 1.56, p<0.0001 and DHA-RBCM: 6.47 vs 4.67, p<0.0001). No change was observed in group 2 despite nutritional recommendations. In this short followup, no evolution to CNV was noted in either of the two groups. Neither side effects nor dropouts were observed in either of the groups.
   CONCLUSIONS. This study supports the feasibility of a long-term double-masked prospective case-control study in an AMD population in order to evaluate a potential benefit from oral supplementation with DHA. (Eur J Ophthalmol 2009; 19: 100-6)
C1 [Querques, G.; Coscas, G.; Soubrane, G.; Souied, E. H.] Univ Paris 12, Dept Ophthalmol, Ctr Hosp Intercommunal, F-94000 Creteil, France.
   [Querques, G.] Univ Foggia, Policlin Riuniti Foggia, Dept Ophthalmol, Foggia, Italy.
   [Chanu, B.] Univ Paris 12, Hop Henri Mondor, Dept Nutr, F-94000 Creteil, France.
   [Portal, C.] Univ Paris 12, Ctr Hosp Intercommunal, Dept Nutr, F-94000 Creteil, France.
C3 Universite Paris-Est-Creteil-Val-de-Marne (UPEC); CHI Creteil;
   University of Foggia; Assistance Publique Hopitaux Paris (APHP);
   Universite Paris-Est-Creteil-Val-de-Marne (UPEC); Hopital Universitaire
   Henri-Mondor - APHP; Universite Paris-Est-Creteil-Val-de-Marne (UPEC);
   CHI Creteil
RP Querques, G (通讯作者)，Univ Paris 12, Dept Ophthalmol, Ctr Hosp Intercommunal, 40 Ave Verdun, F-94000 Creteil, France.
EM giuseppe.querques@hotmail.it
OI Querques, Giuseppe/0000-0002-3292-9581
CR Ambati J, 2003, SURV OPHTHALMOL, V48, P257, DOI 10.1016/S0039-6257(03)00030-4
   Bazan N G, 1989, Prog Clin Biol Res, V312, P95
   Cho E, 2001, AM J CLIN NUTR, V73, P209
   Cho EY, 2004, ARCH OPHTHALMOL-CHIC, V122, P883, DOI 10.1001/archopht.122.6.883
   Connor KM, 2007, NAT MED, V13, P868, DOI 10.1038/nm1591
   Das UN, 2000, PROSTAG LEUKOTR ESS, V63, P351, DOI 10.1054/plef.2000.0226
   DeAngelis MM, 2004, ARCH OPHTHALMOL-CHIC, V122, P575, DOI 10.1001/archopht.122.4.575
   Delcourt C, 1998, ARCH OPHTHALMOL-CHIC, V116, P1031, DOI 10.1001/archopht.116.8.1031
   Delcourt C, 2006, INVEST OPHTH VIS SCI, V47, P2329, DOI 10.1167/iovs.05-1235
   Grundy SM, 2003, CIRCULATION, V107, P1834, DOI 10.1161/01.CIR.0000059746.10326.09
   Haddad S, 2006, SURV OPHTHALMOL, V51, P316, DOI 10.1016/j.survophthal.2006.05.001
   Hodge WG, 2006, OPHTHALMOLOGY, V113, P1165, DOI 10.1016/j.ophtha.2006.02.043
   Jonasson F, 2003, ARCH OPHTHALMOL-CHIC, V121, P379, DOI 10.1001/archopht.121.3.379
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1417, DOI 10.1001/archopht.119.10.1417
   Koto T, 2007, INVEST OPHTH VIS SCI, V48, P4328, DOI 10.1167/iovs.06-1148
   LANDS WEM, 1990, AM J CLIN NUTR, V51, P991, DOI 10.1093/ajcn/51.6.991
   MARESPERLMAN JA, 1995, ARCH OPHTHALMOL-CHIC, V113, P743, DOI 10.1001/archopht.1995.01100060069034
   MARUO T, 1991, JPN J OPHTHALMOL, V35, P268
   Mitchell P, 2002, ARCH OPHTHALMOL-CHIC, V120, P1357, DOI 10.1001/archopht.120.10.1357
   NEURINGER M, 1988, ANNU REV NUTR, V8, P517, DOI 10.1146/annurev.nu.08.070188.002505
   Ouchi M, 2002, OPHTHALMOLOGICA, V216, P363, DOI 10.1159/000066178
   Richer Stuart, 2004, Optometry, V75, P216, DOI 10.1016/S1529-1839(04)70049-4
   ROBISON WG, 1982, RETINA-J RET VIT DIS, V2, P263, DOI 10.1097/00006982-198202040-00012
   Rotstein NP, 2003, INVEST OPHTH VIS SCI, V44, P2252, DOI 10.1167/iovs.02-0901
   SanGiovanni JP, 2007, ARCH OPHTHALMOL-CHIC, V125, P671, DOI 10.1001/archopht.125.5.671
   SanGiovanni JP, 2005, PROG RETIN EYE RES, V24, P87, DOI 10.1016/j.preteyeres.2004.06.002
   SEDDON J, 1994, INVEST OPHTH VIS SCI, V35, P2003
   Seddon JM, 1996, JAMA-J AM MED ASSOC, V276, P1141, DOI 10.1001/jama.276.14.1141
   SEDDON JM, 1994, JAMA-J AM MED ASSOC, V272, P1413, DOI 10.1001/jama.272.18.1413
   Seddon JM, 2001, ARCH OPHTHALMOL-CHIC, V119, P1191, DOI 10.1001/archopht.119.8.1191
   Simopoulos AP, 2001, LIPIDS, V36, pS83, DOI [10.1007/s11745-001-0687-7, 10.1007/s11745-001-0672-1]
   SIMOPOULOS AP, 1991, AM J CLIN NUTR, V54, P438, DOI 10.1093/ajcn/54.3.438
   Smith W, 2000, ARCH OPHTHALMOL-CHIC, V118, P401, DOI 10.1001/archopht.118.3.401
   Solberg Y, 1998, SURV OPHTHALMOL, V42, P535, DOI 10.1016/S0039-6257(98)00002-2
   Souied E, 2001, J FR OPHTALMOL, V24, P875
   Souied EH, 1998, AM J OPHTHALMOL, V125, P353, DOI 10.1016/S0002-9394(99)80146-9
   van Leeuwen R, 2005, JAMA-J AM MED ASSOC, V294, P3101, DOI 10.1001/jama.294.24.3101
   VandenLangenberg GM, 1998, AM J EPIDEMIOL, V148, P204, DOI 10.1093/oxfordjournals.aje.a009625
   YANNUZZI LA, 1992, ARCH OPHTHALMOL-CHIC, V110, P1701
   Yuzawa M, 1997, INT OPHTHALMOL, V21, P1, DOI 10.1023/A:1005845521424
NR 40
TC 20
Z9 21
U1 0
U2 10
PU WICHTIG EDITORE
PI MILAN
PA 72/74 VIA FRIULI, 20135 MILAN, ITALY
SN 1120-6721
J9 EUR J OPHTHALMOL
JI Eur. J. Ophthalmol.
PD JAN-FEB
PY 2009
VL 19
IS 1
BP 100
EP 106
DI 10.1177/112067210901900115
PG 7
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 438ZV
UT WOS:000265596800015
PM 19123156
DA 2022-11-30
ER

PT J
AU Jakobsen, DB
   Torp, TL
   Stefansson, E
   Peto, T
   Grauslund, J
AF Jakobsen, Ditte B.
   Torp, Thomas L.
   Stefansson, Einar
   Peto, Tunde
   Grauslund, Jakob
TI Retinal metabolic and structural alterations in response to aflibercept
   treatment in neovascular age-related macular degeneration
SO ACTA OPHTHALMOLOGICA
LA English
DT Article
DE aflibercept; choroidal neovascularization; disease activity; neovascular
   age-related macular degeneration; retinal oximetry; retinal vascular
   calibre
ID INTRAVITREAL RANIBIZUMAB; OXYGEN-SATURATION; INJECTION; BEVACIZUMAB; EYE
AB Purpose Non-invasive retinal markers of disease activity could pave the way for individualized treatment in neovascular age-related macular degeneration (nAMD). We aimed to evaluate if retinal vascular oxygen saturation and calibres could predict the initial treatment response after a loading phase of intravitreal aflibercept in nAMD. Method A total of 149 eyes were included (nAMD, n = 76; dry AMD, n = 30; normal eyes n = 43). Of these, 57 treatment-naive eyes with nAMD received three monthly injections with 2.0 mg aflibercept and were subsequently stratified according to functional and structural response according to development in best-corrected visual acuity and macular retinal thickness. The retinal vascular oxygen saturation and calibres were measured prior to treatment and 1 month after the third injection. Results Patients with nAMD and dry AMD had higher retinal arteriolar oxygen saturation as compared to normal eyes (94.3% versus 95.2% versus 92.6%, p = 0.04). Thirty-nine (68.4%) and 12 (21.1%) eyes with nAMD were functional and structural responders. After the loading phase, structural nonresponders developed a higher retinal arteriolar (95.3% versus 93.3%, p = 0.03) and venular (64.7% versus 59.4%, p = 0.02) oxygen saturation, and responders developed a lower retinal arteriolar calibre (118.0 versus 114.3 mu m, p < 0.01). In a multiple logistic regression model, increasing retinal venular oxygen saturation associated with a negative structural treatment outcome (odds ratio 1.17 for each 1% increment after the loading phase, 95% confidence interval 1.01-1.36, p = 0.03). Conclusion Changes in the retinal venular oxygen saturation associate independently with initial treatment response in nAMD, but functional and structural retinal measurements prior to treatment could not predict the treatment response.
C1 [Jakobsen, Ditte B.; Torp, Thomas L.; Grauslund, Jakob] Odense Univ Hosp, Dept Ophthalmol, Sdr Blvd 29, DK-5000 Odense C, Denmark.
   [Jakobsen, Ditte B.; Torp, Thomas L.; Peto, Tunde; Grauslund, Jakob] Univ Southern Denmark, Dept Clin Res, Odense, Denmark.
   [Stefansson, Einar] Univ Iceland, Reykjavik, Iceland.
   [Stefansson, Einar] Landspitali Univ Hosp, Reykjavik, Iceland.
   [Peto, Tunde] Queens Univ Belfast, Ctr Publ Hlth, Belfast, Antrim, North Ireland.
C3 University of Southern Denmark; Odense University Hospital; University
   of Southern Denmark; University of Iceland; Landspitali National
   University Hospital; Queens University Belfast
RP Grauslund, J (通讯作者)，Odense Univ Hosp, Dept Ophthalmol, Sdr Blvd 29, DK-5000 Odense C, Denmark.
EM jakob.grauslund@rsyd.dk
RI Grauslund, Jakob/J-1031-2014; Peto, Tunde/M-2081-2013
OI Grauslund, Jakob/0000-0001-5019-0736; Lee Torp,
   Thomas/0000-0002-3556-8531; Peto, Tunde/0000-0001-6265-0381
FU Velux foundation
FX The study was financially supported by the Velux foundation. The study
   was presented at the European Association for Vision and Eye Research
   (EVER) congress in Nice the 29th of September 2017.
CR Adamis AP, 2005, RETINA-J RET VIT DIS, V25, P111, DOI 10.1097/00006982-200502000-00001
   Bek T, 2016, INVEST OPHTH VIS SCI, V57, P5429, DOI 10.1167/iovs.16-20305
   Brown DM, 2009, OPHTHALMOLOGY, V116, P57, DOI 10.1016/j.ophtha.2008.10.018
   Buch H, 2005, OPHTHALMOLOGY, V112, P787, DOI 10.1016/j.ophtha.2004.11.040
   FERRIS FL, 1984, ARCH OPHTHALMOL-CHIC, V102, P1640
   FOLKMAN J, 1987, SCIENCE, V235, P442, DOI 10.1126/science.2432664
   Fontaine O, 2011, INVEST OPHTH VIS SCI, V52, P7400, DOI 10.1167/iovs.10-6646
   Geirsdottir A, 2014, ACTA OPHTHALMOL, V92, P27, DOI 10.1111/aos.12294
   Geirsdottir A, 2012, INVEST OPHTH VIS SCI, V53, P5433, DOI 10.1167/iovs.12-9912
   Heier JS, 2012, OPHTHALMOLOGY, V119, P2537, DOI 10.1016/j.ophtha.2012.09.006
   Hoeg TB, 2016, OPHTHAL EPIDEMIOL, V23, P53, DOI 10.3109/09286586.2015.1066396
   Kurt MM, 2017, OPHTHALMOLOGICA, V238, P147, DOI 10.1159/000477180
   Mendrinos E, 2013, ACTA OPHTHALMOL, V91, pE184, DOI 10.1111/aos.12008
   Micieli JA, 2012, ACTA OPHTHALMOL, V90, pE13, DOI 10.1111/j.1755-3768.2011.02209.x
   Ng EWM, 2005, CAN J OPHTHALMOL, V40, P352, DOI 10.1016/S0008-4182(05)80078-X
   Papadopoulou DN, 2009, OPHTHALMOLOGY, V116, P1755, DOI 10.1016/j.ophtha.2009.03.017
   Pekel G, 2015, INT OPHTHALMOL, V35, P657, DOI 10.1007/s10792-014-9991-z
   Rilven S, 2017, ACTA OPHTHALMOL, V95, P119, DOI 10.1111/aos.13229
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Stefansson E, 2011, PROG RETIN EYE RES, V30, P72, DOI 10.1016/j.preteyeres.2010.09.003
   Tatlipinar S, 2012, CLIN EXP OPTOM, V95, P94, DOI 10.1111/j.1444-0938.2011.00662.x
   Tetikoglu M, 2018, CUTAN OCUL TOXICOL, V37, P84, DOI 10.1080/15569527.2017.1354217
   Wickremasinghe SS, 2012, INVEST OPHTH VIS SCI, V53, P37, DOI 10.1167/iovs.11-7689
NR 23
TC 7
Z9 7
U1 0
U2 3
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1755-375X
EI 1755-3768
J9 ACTA OPHTHALMOL
JI Acta Ophthalmol.
PD AUG
PY 2019
VL 97
IS 5
BP 525
EP 531
DI 10.1111/aos.13996
PG 7
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA IH9DK
UT WOS:000474806400012
PM 30549221
OA Bronze, Green Accepted
DA 2022-11-30
ER

PT J
AU Yanagi, Y
   Fukuda, A
   Barzey, V
   Adachi, K
AF Yanagi, Yasuo
   Fukuda, Aya
   Barzey, Victor
   Adachi, Kenji
TI Cost-effectiveness of intravitreal aflibercept versus other treatments
   for wet age-related macular degeneration in Japan
SO JOURNAL OF MEDICAL ECONOMICS
LA English
DT Article
DE Intravitreal aflibercept injection; wet age-related macular
   degeneration; cost-effectiveness analysis; cost utility analysis;
   quality-adjusted life years
ID VERTEPORFIN PHOTODYNAMIC THERAPY; VISUAL IMPAIRMENT; PEGAPTANIB SODIUM;
   UTILITY VALUES; RANIBIZUMAB; POPULATION; PREVALENCE; MODEL; INJECTION;
   CARE
AB Objective: This analysis estimated the cost-effectiveness of intravitreal aflibercept injection(s) (IAI) for wet age-related macular degeneration (wAMD) compared with other treatments in Japan.
   Methods: This was a cost-utility analysis based on published data. A state-transition cohort model was constructed with six health states based on best-corrected visual acuity in the better-seeing eye. The cycle time was 4 weeks, and the time horizon was 12 years. The model compared IAI 2mg every 8 weeks (2q8) for 2 years after three initial monthly injections, ranibizumab as needed, ranibizumab 0.5mg every 4 weeks (0.5q4), pegaptanib sodium 0.3mg every 6 weeks, verteporfin photodynamic therapy (PDT), and best supportive care, assumed to include medical management and monitoring, but no active therapy. Costs (expressed as Japanese yen [JPY]) and quality-adjusted life years (QALYs) gained were estimated for each treatment and discounted at 2.0%. Input data were obtained from clinical studies, the Japanese drug tariff and social insurance reimbursement schedule, and expert opinion. The analysis was conducted from the societal perspective, including medical costs as well as costs of blindness.
   Results: IAI 2q8 was dominant (i.e. more effective in terms of QALYs and less costly) to all other comparators (ranibizumab as needed, ranibizumab 0.5q4, pegaptanib sodium, PDT, and best supportive care), as shown by the incremental cost-utility ratio (i.e. cost per QALY gained).
   Limitations: The strengths of the analysis include the wide range of comparators evaluated and the use of Japanese-specific utility data. The limitations include the use of one eye, inclusion of published data up to 2 years only, and assumptions on disease course over 5 years.
   Conclusions: IAI 2q8 was more effective in terms of QALYs and less costly compared with other treatments for wAMD in Japan.
C1 [Yanagi, Yasuo] Singapore Natl Eye Ctr, 11 Third Hosp Ave, Singapore 168751, Singapore.
   [Yanagi, Yasuo] Singapore Eye Res Inst, Singapore, Singapore.
   [Yanagi, Yasuo] Duke NUS Natl Univ Singapore, Grad Sch Med, Singapore, Singapore.
   [Fukuda, Aya; Adachi, Kenji] Bayer Yakuhin Ltd, Osaka, Japan.
   [Barzey, Victor] IMS Hlth, London, England.
C3 Singapore National Eye Center; National University of Singapore;
   Singapore National Eye Center; Bayer AG
EM yasuo.yanagi@snec.com.sg
RI Yanagi, Yasuo/AAF-2670-2020; Yanagi, Yasuo/AAA-5441-2022
OI Yanagi, Yasuo/0000-0002-0362-7285
FU Bayer Pharmaceuticals, Japan
FX This study was performed by IMS Health, UK, which was funded by Bayer
   Pharmaceuticals, Japan.
CR Ablonczy Z, 2014, FASEB J, V28, P2369, DOI 10.1096/fj.13-248021
   [Anonymous], 2012, CHIYOD KU
   [Anonymous], 2013, GUID EC EV HEALTHC T
   [Anonymous], 2012, NAT HLTH INS DRUG PR
   Athanasakis K, 2012, CLIN THER, V34, P446, DOI 10.1016/j.clinthera.2012.01.005
   Boyer DS, 2009, OPHTHALMOLOGY, V116, P1731, DOI 10.1016/j.ophtha.2009.05.024
   Brown A, 2008, MANAGEMENT NEOVASCUL
   Brown DM, 2009, OPHTHALMOLOGY, V116, P57, DOI 10.1016/j.ophtha.2008.10.018
   Brown G C, 1999, Trans Am Ophthalmol Soc, V97, P473
   Brown GC, 2007, OPHTHALMOLOGY, V114, P1170, DOI 10.1016/j.ophtha.2006.09.019
   Brown MM, 2001, BRIT J OPHTHALMOL, V85, P327, DOI 10.1136/bjo.85.3.327
   Chappelow AV, 2008, DRUGS, V68, P1029, DOI 10.2165/00003495-200868080-00002
   Colquitt JL, 2008, HEALTH TECHNOL ASSES, V12, P1
   Czoski-Murray C, 2009, VALUE HEALTH, V12, P793, DOI 10.1111/j.1524-4733.2009.00527.x
   Drummond MF, 2005, METHODS EC EVALUATIO
   Earnshaw SR, 2007, CLIN THER, V29, P2096, DOI 10.1016/j.clinthera.2007.09.001
   Elshout M, 2014, GRAEF ARCH CLIN EXP, V252, P1911, DOI 10.1007/s00417-014-2641-3
   Gragoudas ES, 2004, NEW ENGL J MED, V351, P2805, DOI 10.1056/NEJMoa042760
   Heier JS, 2012, OPHTHALMOLOGY, V119, P2537, DOI 10.1016/j.ophtha.2012.09.006
   Heier JS, 2012, ASS RES VIS OPHTH AR
   Ho QT, 2007, INT J BIOCHEM CELL B, V39, P1349, DOI 10.1016/j.biocel.2007.04.010
   Hopley C, 2004, BRIT J OPHTHALMOL, V88, P982, DOI 10.1136/bjo.2003.039131
   Hurley Susan F, 2008, Cost Eff Resour Alloc, V6, P12, DOI 10.1186/1478-7547-6-12
   Iida T, 2014, JHEOR, V2, P41, DOI DOI 10.36469/9887
   Japanese Government Ministry of Health Labour and Welfare, 2010, 21 LIF TABL
   Hernandez-Pastor LJ, 2008, CLIN THER, V30, P2436, DOI 10.1016/j.clinthera.2008.12.025
   Javitt JC, 2008, VALUE HEALTH, V11, P563, DOI 10.1111/j.1524-4733.2007.00283.x
   Kawasaki R, 2008, OPHTHALMOLOGY, V115, P1376, DOI 10.1016/j.ophtha.2007.11.015
   Kourlaba G, 2015, VALUE HEALTH, V18, pA421, DOI 10.1016/j.jval.2015.09.557
   Kovach JL, 2012, J OPHTHALMOL, V2012, DOI 10.1155/2012/786870
   Kulkarni AD, 2005, ADV DRUG DELIVER REV, V57, P1994, DOI 10.1016/j.addr.2005.09.003
   Lang S, 2012, INDIRECT COMP AFLIBE
   Martin DF, 2012, OPHTHALMOLOGY, V119, DOI 10.1016/j.ophtha.2012.03.053
   McCloud C, 2014, OPTOMETRY VISION SCI, V91, P966, DOI 10.1097/OPX.0000000000000320
   Meads C, 2003, Health Technol Assess, V7, pv
   Mitchell P, 2011, PHARMACOECONOMICS, V29, P107, DOI 10.2165/11585520-000000000-00000
   Nakata I, 2013, AM J OPHTHALMOL, V156, P1002, DOI 10.1016/j.ajo.2013.06.007
   National Institute for Health and Clinical Excellence, MAC DEG WET AG REL A
   Neubauer AS, 2007, KLIN MONATSBL AUGENH, V224, P727, DOI 10.1055/s-2007-963470
   Neubauer AS, 2010, CLIN THER, V32, P1343, DOI 10.1016/j.clinthera.2010.07.010
   Ogura Y, 2015, BRIT J OPHTHALMOL, V99, P92, DOI 10.1136/bjophthalmol-2014-305076
   Panchmatia HR, 2016, ACTA OPHTHALMOL, V94, P441, DOI 10.1111/aos.12964
   Resnikoff S, 2004, B WORLD HEALTH ORGAN, V82, P844
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Schmidt-Erfurth U, 2014, OPHTHALMOLOGY, V121, P193, DOI 10.1016/j.ophtha.2013.08.011
   Schmier JK, 2016, PHARMACOECONOMICS, V34, P259, DOI 10.1007/s40273-015-0347-y
   Sharma S, 2002, BRIT J OPHTHALMOL, V86, P493, DOI 10.1136/bjo.86.5.493
   Shiroiwa Takeru, 2013, Cost Eff Resour Alloc, V11, P22, DOI 10.1186/1478-7547-11-22
   Shiroiwa T, 2010, HEALTH ECON, V19, P422, DOI 10.1002/hec.1481
   Wong T, 2008, OPHTHALMOLOGY, V115, P116, DOI 10.1016/j.ophtha.2007.03.008
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
   Yamada M, 2010, OPHTHAL EPIDEMIOL, V17, P50, DOI 10.3109/09286580903450346
   Yanagi Yasuo, 2011, Nippon Ganka Gakkai Zasshi, V115, P825
   Yanagi Y, 2011, JPN J OPHTHALMOL, V55, P35, DOI 10.1007/s10384-010-0893-y
NR 54
TC 5
Z9 7
U1 0
U2 7
PU TAYLOR & FRANCIS LTD
PI ABINGDON
PA 2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND
SN 1369-6998
EI 1941-837X
J9 J MED ECON
JI J. Med. Econ.
PY 2017
VL 20
IS 2
BP 204
EP 212
DI 10.1080/13696998.2016.1245196
PG 9
WC Health Care Sciences & Services; Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Health Care Sciences & Services; General & Internal Medicine
GA EI6UK
UT WOS:000392632500012
PM 27701921
DA 2022-11-30
ER

PT J
AU Gregori, G
   Wang, FH
   Rosenfeld, PJ
   Yehoshua, Z
   Gregori, NZ
   Lujan, BJ
   Puliafito, CA
   Feuer, WJ
AF Gregori, Giovanni
   Wang, Fenghua
   Rosenfeld, Philip J.
   Yehoshua, Zohar
   Gregori, Ninel Z.
   Lujan, Brandon J.
   Puliafito, Carmen A.
   Feuer, William J.
TI Spectral Domain Optical Coherence Tomography Imaging of Drusen in
   Nonexudative Age-Related Macular Degeneration
SO OPHTHALMOLOGY
LA English
DT Article
ID SEGMENTATION
AB Purpose: To measure drusen area and volume in eyes with nonexudative age-related macular degeneration (AMD) using spectral domain optical coherence tomography imaging (SD-OCT).
   Design: Evaluation of diagnostic technology.
   Participants: One hundred three eyes from 74 patients with drusen.
   Methods: Patients with drusen secondary to nonexudative AMD were enrolled in this study. Five separate SD-OCT scans, each consisting of 40 000 uniformly spaced A-scans organized as 200 A-scans in each B-scan and 200 horizontal B-scans, were performed on each eye. Each scan covered a retinal area of 6 X 6 mm centered on the fovea. A novel algorithm was used to quantitatively assess drusen area and volume. Measurements from the entire scans, as well as in regions contained within 3-and 5-mm circles centered on the fovea, were analyzed. Test-retest standard deviations of drusen area and volume measurements were calculated for each eye.
   Main Outcome Measures: Drusen area and volume.
   Results: The algorithm created drusen maps that permitted both qualitative and quantitative assessment of drusen area and volume. Both the qualitative appearance and the quantitative measurements of drusen area and volume were highly reproducible over the 5 different datasets. The intraclass correlation coefficient was >0.99 for both area and volume measurements on the entire dataset as well as the 3-and 5-mm circles. The correlation between lesion size and the test-retest standard deviations can be eliminated by performing a square root transformation of the area measurements and a cube root transformation of the volume measurements. These transformed data allowed for the inclusion of all drusen sizes in the calculation of an estimated single pooled test-retest standard deviation, which will be useful for longitudinal studies of drusen natural history.
   Conclusions: A novel algorithm for the qualitative and quantitative assessment of drusen imaged using SD-OCT was shown to be highly reproducible. The ability to assess drusen volume reliably represents a new quantitative parameter to measure in AMD and may be useful when assessing disease progression, particularly in trials for treatments of nonexudative AMD.
C1 [Gregori, Giovanni; Wang, Fenghua; Rosenfeld, Philip J.; Yehoshua, Zohar; Gregori, Ninel Z.; Lujan, Brandon J.; Puliafito, Carmen A.; Feuer, William J.] Univ Miami, Miller Sch Med, Dept Ophthalmol, Bascom Palmer Eye Inst, Miami, FL 33136 USA.
C3 Bascom Palmer Eye Institute; University of Miami
RP Gregori, G (通讯作者)，Univ Miami, Miller Sch Med, Dept Ophthalmol, Bascom Palmer Eye Inst, 900 NW 17th St, Miami, FL 33136 USA.
EM ggregori@med.miami.edu
FU Carl Zeiss Meditec, Inc., Dublin, California; Research to Prevent
   Blindness. Inc.; NEI [P30 EY014801]; H.A. & Mary K. Chapman Charitable
   Trust; Florman Family Foundation, Inc.; Jerome A. Yavitz Charitable
   Foundation; Emma Clyde Hodge Memorial Foundation; Gemcon Family
   Foundation; Carl and Lily Pforzheimer Foundation, Inc.; NATIONAL EYE
   INSTITUTE [P30EY014801] Funding Source: NIH RePORTER
FX Research supported by a grant from Carl Zeiss Meditec, Inc., Dublin,
   California; an unrestricted grant from Research to Prevent Blindness.
   Inc.; NEI core center grant P30 EY014801 to the University of Miami; the
   H.A. & Mary K. Chapman Charitable Trust; the Florman Family Foundation,
   Inc.; the Jerome A. Yavitz Charitable Foundation; the Emma Clyde Hodge
   Memorial Foundation; the Gemcon Family Foundation; and the Carl and Lily
   Pforzheimer Foundation, Inc.
CR [Anonymous], 2005, ARCH OPHTHALMOL-CHIC, V123, P1570, DOI DOI 10.1001/ARCHOPHT.123.11.1570
   Bartlett H, 2007, SURV OPHTHALMOL, V52, P655, DOI 10.1016/j.survophthal.2007.08.022
   Budenz DL, 2008, OPHTHALMOLOGY, V115, P661, DOI 10.1016/j.ophtha.2007.05.035
   Davis MD, 2005, ARCH OPHTHALMOL-CHIC, V123, P1484
   FLEISS JL, 1986, DESIGN ANAL CLIN EXP, P24
   Freeman SR, 2010, RETINA-J RET VIT DIS, V30, P431, DOI 10.1097/IAE.0b013e3181bd2f94
   Giani A, 2010, RETINA-J RET VIT DIS, V30, P607, DOI 10.1097/IAE.0b013e3181c2e09d
   Ho J, 2009, OPHTHALMOLOGY, V116, P1960, DOI 10.1016/j.ophtha.2009.03.034
   Jiao SL, 2005, OPT EXPRESS, V13, P444, DOI 10.1364/OPEX.13.000444
   Keane PA, 2009, BRIT J OPHTHALMOL, V93, P1461, DOI 10.1136/bjo.2008.155846
   Khanifar AA, 2008, OPHTHALMOLOGY, V115, P1883, DOI 10.1016/j.ophtha.2008.04.041
   KLEIN R, 1991, OPHTHALMOLOGY, V98, P1128
   Lujan BJ, 2008, OPHTHAL SURG LAS IM, V39, pS15, DOI 10.3928/15428877-20080715-01
   Mitchell P, 2005, ARCH OPHTHALMOL-CHIC, V123, P1598, DOI 10.1001/archopht.123.11.1598
   Mylonas G, 2009, BRIT J OPHTHALMOL, V93, P1453, DOI 10.1136/bjo.2008.153643
   Pieroni CG, 2006, BRIT J OPHTHALMOL, V90, P191, DOI 10.1136/bjo.2005.076612
   Seddon JM, 2006, OPHTHALMOLOGY, V113, P260, DOI 10.1016/j.ophtha.2005.11.001
   Szkulmowski M, 2007, J BIOMED OPT, V12, DOI 10.1117/1.2771569
   Wojtkowski M, 2005, OPHTHALMOLOGY, V112, P1734, DOI 10.1016/j.ophtha.2005.05.023
   Yi K, 2009, BRIT J OPHTHALMOL, V93, P176, DOI 10.1136/bjo.2008.137356
NR 20
TC 116
Z9 122
U1 0
U2 13
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 0161-6420
EI 1549-4713
J9 OPHTHALMOLOGY
JI Ophthalmology
PD JUL
PY 2011
VL 118
IS 7
BP 1373
EP 1379
DI 10.1016/j.ophtha.2010.11.013
PG 7
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 786JL
UT WOS:000292303000021
PM 21388687
OA Green Accepted
DA 2022-11-30
ER

PT J
AU Figurska, M
   Stankiewicz, A
AF Figurska, Malgorzata
   Stankiewicz, Andrzej
TI Effectiveness of ranibizumab intravitreal injections for exudative
   age-related macular degeneration treatment: 12-month outcomes
SO MEDICAL SCIENCE MONITOR
LA English
DT Article
DE exudative AMD; ranibizumab; central retinal thickness
ID OPTICAL COHERENCE TOMOGRAPHY; CHOROIDAL NEOVASCULARIZATION;
   VISUAL-ACUITY; VEGF-A; EXPRESSION; LUCENTIS; STRATEGY; IMPACT
AB Background: The aim of this paper was to evaluate functional and anatomical results of intravitreal ranibizumab injections and the course of exudative age-related macular degeneration (AMD) treatment over a 12-month observation period.
   Material/Methods: In 25 patients with active dominantly classic exudative AMD, treatment was performed according to the following schedule: 3 intravitreal injections of 0.5 mg ranibizumab at monthly intervals (saturation phase); further injections were based on activity of the neovascular process. Changes in VA and central retinal thickness (CRT) during treatment were evaluated with ANOVA testing.
   Results: Mean pre-treatment best corrected visual acuity was 0.73 +/- 0.27 logMAR. After the third ranibizumab injection the best results, 0.54 +/- 0.27 logMAR, were seen; 12-month results were 0.58 +/- 0.26 logMAR. Patients had a mean improvement of 10.6 letters at 12 months. In 92% of patients stabilization or improvement of vision was observed. The mean number of injections in the 12-month period was 6.
   Baseline mean CRT was 351.12 +/- 74.15 mu m. After the first ranibizumab injection it decreased significantly to 221.96 +/- 60.85 mu m, after the third injection it was 200.80 +/- 47.63 mu m, and after 12 months it was 213.16 +/- 44.37 mu m. Mean correlations between baseline average CRT and baseline average VA measured in ETDRS letters (p=0.017) and in logMAR scale (p=0.033) and between average CRT after the third injection and average VA in logMAR scale after the third injection (p=0.047) were noted.
   Conclusions: Treatment with intravitreal ranibizumab injections according to the presented scheme provides AMD patients with a chance of stabilization and improvement of the topical state, with a lower number of injections and preserved topical and general safety. Our results suggest that regular monthly controls are necessary to be able react rapidly to the smallest signs of deterioration, not only in visual acuity, but also in OCT images.
C1 [Figurska, Malgorzata; Stankiewicz, Andrzej] Mil Inst Med, Dept Ophthalmol, PL-04141 Warsaw, Poland.
C3 Military Institute of Aviation Medicine
RP Figurska, M (通讯作者)，Mil Inst Med, Dept Ophthalmol, 128 Szaserow Str, PL-04141 Warsaw, Poland.
EM malgorzata-figurska@wp.pl
CR ARIAS L, 2011, RETINA, V10, P1
   Bakri SJ, 2007, OPHTHALMOLOGY, V114, P2179, DOI 10.1016/j.ophtha.2007.09.012
   Bandukwala T, 2010, CAN J OPHTHALMOL, V45, P590, DOI 10.3129/i10-082
   Boyer DS, 2007, OPHTHALMOLOGY, V114, P246, DOI 10.1016/j.ophtha.2006.10.045
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Chen Y, 1999, J MOL BIOL, V293, P865, DOI 10.1006/jmbi.1999.3192
   Cohen SY, 2009, AM J OPHTHALMOL, V148, P409, DOI 10.1016/j.ajo.2009.04.001
   Czarkowska-Paczek B, 2010, MED SCI MONITOR, V16, pBR147
   Dadgostar H, 2009, OPHTHALMOLOGY, V116, P1740, DOI 10.1016/j.ophtha.2009.05.033
   Framme C, 2010, INVEST OPHTH VIS SCI, V51, P1671, DOI 10.1167/iovs.09-4496
   Fung AE, 2007, AM J OPHTHALMOL, V143, P566, DOI 10.1016/j.ajo.2007.01.028
   Holz FG, 2007, AM J OPHTHALMOL, V143, P463, DOI 10.1016/j.ajo.2006.11.041
   Keyt BA, 1996, J BIOL CHEM, V271, P5638, DOI 10.1074/jbc.271.10.5638
   Kiss CG, 2009, INVEST OPHTH VIS SCI, V50, P2376, DOI 10.1167/iovs.08-2017
   Kloos P, 2008, KLIN MONATSBL AUGENH, V225, P385, DOI 10.1055/s-2008-1027252
   Krejca M, 2010, MED SCI MONITOR, V16, pBR89
   Kumar A, 2011, BRIT J OPHTHALMOL, V95, P530, DOI 10.1136/bjo.2009.171868
   Lalwani GA, 2009, AM J OPHTHALMOL, V148, P43, DOI 10.1016/j.ajo.2009.01.024
   LOWE J, 2003, OPHTHALMOL VIS SCI, V44, P1828
   MEYER CH, 2008, INVEST OPHTHALMOL VI, V49
   Mitchell P, 2010, BRIT J OPHTHALMOL, V94, P2, DOI 10.1136/bjo.2009.159160
   Raja MSA, 2010, BRIT J OPHTHALMOL, V94, P1543, DOI 10.1136/bjo.2009.174763
   Regillo CD, 2008, AM J OPHTHALMOL, V145, P239, DOI 10.1016/j.ajo.2007.10.004
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Rosenfeld PJ, 2005, OPHTHAL SURG LAS IM, V36, P331, DOI 10.3928/1542-8877-20050701-14
   Rothenbuehler SP, 2009, AM J OPHTHALMOL, V147, P831, DOI 10.1016/j.ajo.2008.12.005
   Rotsos T, 2010, CLIN OPHTHALMOL, V4, P1271, DOI 10.2147/OPTH.S14684
   Schmidt-Erfurth UM, 2007, ACTA OPHTHALMOL SCAN, V85, P486, DOI 10.1111/j.1600-0420.2007.00979.x
   Spaide R, 2007, AM J OPHTHALMOL, V143, P679, DOI 10.1016/j.ajo.2007.02.024
   Spaide RF, 2009, AM J OPHTHALMOL, V148, P1, DOI 10.1016/j.ajo.2009.04.010
NR 30
TC 8
Z9 8
U1 0
U2 4
PU INT SCIENTIFIC LITERATURE, INC
PI SMITHTOWN
PA 361 FOREST LANE, SMITHTOWN, NY 11787 USA
SN 1234-1010
J9 MED SCI MONITOR
JI Med. Sci. Monitor
PD SEP
PY 2011
VL 17
IS 9
BP CR485
EP CR490
DI 10.12659/MSM.881934
PG 6
WC Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Research & Experimental Medicine
GA 840XT
UT WOS:000296476100010
PM 21873944
OA Green Published, Green Submitted
DA 2022-11-30
ER

PT J
AU Robman, L
   Mahdi, OS
   Wang, JJ
   Burlutsky, G
   Mitchell, P
   Byrne, G
   Guymer, R
   Taylor, H
AF Robman, Luba
   Mahdi, Olaimatu S.
   Wang, Jie Jin
   Burlutsky, George
   Mitchell, Paul
   Byrne, Gerald
   Guymer, Robyn
   Taylor, Hugh
TI Exposure to Chlamydia pneumoniae infection and age-related macular
   degeneration: The blue mountains eye study
SO INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE
LA English
DT Article
ID FACTOR-H POLYMORPHISM; C-REACTIVE PROTEIN; DRUSEN FORMATION;
   RESPIRATORY-INFECTIONS; NEOVASCULAR MEMBRANES; RISK; BIOMARKERS;
   DISEASE; ASSOCIATION; PROGRESSION
AB PURPOSE. To assess cross-sectional and longitudinal associations between exposure to Chlamydia pneumoniae infection and age-related macular degeneration (AMD) in the nested case control sample drawn from the Blue Mountains Eye Study (BMES) cohort.
   METHODS. The BMES examined 3654 persons aged 49 to 97 years during 1992 through 1994 ( BMES I survey). Survivors from this cohort (n = 2335; 75%) and 1174 persons who moved in this area or reached an eligible age were examined during 1997 through 2000 ( BMES II survey, n = 3509). One hundred ninety-seven AMD cases and 433 control subjects matched for age, sex and smoking status, were drawn from the BMES II survey. Photographic macular grading followed the Wisconsin grading system. Plasma samples were analyzed with an enzyme-linked immunosorbent assay to determine antibody titers to the elementary bodies from C. pneumoniae AR39. Associations between seroreactivity to C. pneumoniae and prevalent and incident AMD were assessed by using logistic regression models.
   RESULTS. There were 159 early and 38 late AMD cases. Of them, 87 cases of early and 22 of late AMD developed between the baseline and follow-up examinations. After adjustment for age, gender, and smoking, no significant association was evident between C. pneumoniae antibody titer and any prevalent early or late AMD (OR 1.02, 95% CI 0.66-1.56 comparing upper with lower tertile of antibody titer). Findings were similar when early or late AMD was analyzed separately. Analysis confined to incident AMD also showed no significant association with the incidence of either early ( OR 0.92, 95% CI 0.52-1.64) or late (OR 1.85, 95% CI 0.57-6.05) AMD. The results did not change after adjustment for family history of AMD and cardiovascular disease.
   CONCLUSIONS. In this nested case-control sample of an older Australian population we found no association between C. pneumoniae antibody titers and early AMD. The study has insufficient power to assess an association with late AMD.
C1 Univ Melbourne, Ctr Eye Res Australia, Melbourne, Vic 3002, Australia.
   Univ Tennessee, Ctr Hlth Sci, Dept Mol Sci, Memphis, TN 38163 USA.
   Univ Sydney, Ctr Vis Res, Westmead Millenium Inst, Sydney, NSW 2006, Australia.
C3 Centre for Eye Research Australia; University of Melbourne; University
   of Tennessee System; University of Tennessee Health Science Center;
   University of Sydney; Westmead Institute for Medical Research
RP Guymer, R (通讯作者)，Univ Melbourne, Ctr Eye Res Australia, 32 Gisborne St, Melbourne, Vic 3002, Australia.
EM rhg@unimelb.edu.au
RI Mitchell, Paul/P-1498-2014; wang, jie/GRS-0942-2022; Wang, Jie
   Jin/P-1499-2014
OI Wang, Jie Jin/0000-0001-9491-4898; Guymer, Robyn/0000-0002-9441-4356;
   Taylor, Hugh/0000-0002-9437-784X; Mahdi, Olaimatu
   Sadia/0000-0003-1830-5411
FU NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI042790]
   Funding Source: NIH RePORTER; NIAID NIH HHS [R01 AI042790] Funding
   Source: Medline
CR Anderson DH, 2001, AM J OPHTHALMOL, V131, P767, DOI 10.1016/S0002-9394(00)00961-2
   Crabb JW, 2002, P NATL ACAD SCI USA, V99, P14682, DOI 10.1073/pnas.222551899
   Despriet DDG, 2006, JAMA-J AM MED ASSOC, V296, P301, DOI 10.1001/jama.296.3.301
   Edwards AO, 2005, SCIENCE, V308, P421, DOI 10.1126/science.1110189
   Gold B, 2006, NAT GENET, V38, P458, DOI 10.1038/ng1750
   GRAYSTON J, 2006, P 11 INT S HUM CHLAM, P621
   Gutierrez J, 2002, J BASIC MICROB, V42, P13, DOI 10.1002/1521-4028(200203)42:1<13::AID-JOBM13>3.0.CO;2-J
   Hageman GS, 1999, FASEB J, V13, P477, DOI 10.1096/fasebj.13.3.477
   Hageman GS, 2001, PROG RETIN EYE RES, V20, P705, DOI 10.1016/S1350-9462(01)00010-6
   Hageman GS, 2005, P NATL ACAD SCI USA, V102, P7227, DOI 10.1073/pnas.0501536102
   Haines JL, 2005, SCIENCE, V308, P419, DOI 10.1126/science.1110359
   Ishida O, 2003, BRIT J OPHTHALMOL, V87, P523, DOI 10.1136/bjo.87.5.523
   Johnson LV, 2000, EXP EYE RES, V70, P441, DOI 10.1006/exer.1999.0798
   Johnson LV, 2001, EXP EYE RES, V73, P887, DOI 10.1006/exer.2001.1094
   Kalayoglu MV, 2005, GRAEF ARCH CLIN EXP, V243, P1080, DOI 10.1007/s00417-005-1169-y
   Kalayoglu MV, 2003, ARCH OPHTHALMOL-CHIC, V121, P478, DOI 10.1001/archopht.121.4.478
   Kessler W, 2006, ACTA OPHTHALMOL SCAN, V84, P333, DOI 10.1111/j.1600-0420.2005.00591.x
   Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557
   MAHDI O, 2002, P 10 INT S HUM CHLAM, P329
   Mahdi OS, 2002, CIRCULATION, V106, P1659, DOI 10.1161/01.CIR.0000031567.10814.D8
   Mitchell P, 2002, OPHTHALMOLOGY, V109, P1092, DOI 10.1016/S0161-6420(02)01055-2
   Mullins RF, 2000, FASEB J, V14, P835, DOI 10.1096/fasebj.14.7.835
   Numazaki K, 1996, FEMS IMMUNOL MED MIC, V14, P179, DOI 10.1111/j.1574-695X.1996.tb00285.x
   PENFOLD PL, 1985, GRAEF ARCH CLIN EXP, V223, P69, DOI 10.1007/BF02150948
   Robman L, 2005, AM J EPIDEMIOL, V161, P1013, DOI 10.1093/aje/kwi130
   Seddon JM, 2005, ARCH OPHTHALMOL-CHIC, V123, P774, DOI 10.1001/archopht.123.6.774
   Seddon JM, 2004, JAMA-J AM MED ASSOC, V291, P704, DOI 10.1001/jama.291.6.704
   SILLIS M, 1992, J INFECTION, V25, P77, DOI 10.1016/0163-4453(92)92130-B
   Siscovick DS, 2000, J INFECT DIS, V181, pS417, DOI 10.1086/315623
   Verkooyen RP, 1998, J CLIN MICROBIOL, V36, P2301, DOI 10.1128/JCM.36.8.2301-2307.1998
   Vine AK, 2005, OPHTHALMOLOGY, V112, P2076, DOI 10.1016/j.ophtha.2005.07.004
NR 31
TC 24
Z9 26
U1 0
U2 1
PU ASSOC RESEARCH VISION OPHTHALMOLOGY INC
PI ROCKVILLE
PA 12300 TWINBROOK PARKWAY, ROCKVILLE, MD 20852-1606 USA
SN 0146-0404
EI 1552-5783
J9 INVEST OPHTH VIS SCI
JI Invest. Ophthalmol. Vis. Sci.
PD SEP
PY 2007
VL 48
IS 9
BP 4007
EP 4011
DI 10.1167/iovs.06-1434
PG 5
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 204RO
UT WOS:000249061900015
PM 17724180
DA 2022-11-30
ER

PT J
AU Amin, S
   Chong, NHV
   Bailey, TA
   Zhang, JJ
   Knupp, C
   Cheetham, ME
   Greenwood, J
   Luthert, PJ
AF Amin, S
   Chong, NHV
   Bailey, TA
   Zhang, JJ
   Knupp, C
   Cheetham, ME
   Greenwood, J
   Luthert, PJ
TI Modulation of Sub-RPE deposits in vitro: A potential model for
   age-related macular degeneration
SO INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE
LA English
DT Article
ID RETINAL-PIGMENT EPITHELIUM; BASAL LINEAR DEPOSIT; BRUCHS MEMBRANE;
   EXTRACELLULAR-MATRIX; POSTMORTEM EYES; DRUSEN
AB PURPOSE. Sub-RPE deposits form in a variety of conditions most notably in age-related macular degeneration. The purpose of this study was to generate sub-RPE deposits in vitro and to test the hypotheses that high protein concentrations or retinal homogenate increase deposit formation and that a challenge with tumor necrosis factor (TNF)-alpha or metalloproteinase (MMP)-2 decreases such deposits.
   METHODS. ARPE-19 cells were grown on plastic and on collagen type I- coated membrane inserts in media containing various concentrations of fetal calf serum (FCS), bovine serum albumin, or porcine retinal homogenate. In addition, cells grown on membrane inserts were treated with TNF-alpha or MMP-2. Sub-RPE deposits were assessed by electron microscopy and classified into fibrillar, condensed, banded, and membranous subtypes. The area of the micrograph occupied by each type was estimated with a point-counting technique. MMP-2 activity was assessed in tissue culture supernatants by zymography.
   RESULTS. With increasing time in culture, total deposit formation did not change, but the amount of condensed material deposited by ARPE-19 cells increased while the fibrillar component decreased. Albumin challenge resulted in an increased amount of deposit, predominantly of the membranous type. Challenge with retinal homogenate led to a greater net deposit formation with significant increases in the condensed and banded forms. Cells treated with TNF-alpha or MMP-2 showed a dramatic reduction in all types of sub-RPE deposit. Zymography demonstrated that unchallenged cells produced predominantly MMP-2. Retinal homogenate challenge reduced the total amount of active MMP-2 produced, and TNF-alpha stimulated MMP-9 production.
   CONCLUSIONS. Sub-RPE deposits formed in vitro share ultrastructural features with those seen in vivo. Deposit formation can be modulated by challenge with retinal homogenate, TNF-alpha, or MMP-2. Significantly, the results provide proof of the principle that sub-RPE deposits can be formed and modified in vitro.
C1 UCL, Inst Ophthalmol, Div Pathol, London EC1V 9EL, England.
   UCL, Inst Ophthalmol, Div Cell Biol, London EC1V 9EL, England.
   Univ London Imperial Coll Sci Technol & Med, Div Biomed Sci, Biol Struct & Funct Sect, London, England.
C3 University of London; University College London; University of London;
   University College London; Imperial College London
RP Amin, S (通讯作者)，UCL, Inst Ophthalmol, Div Pathol, London EC1V 9EL, England.
EM s.amin@ucl.ac.uk
RI Cheetham, Michael/B-4672-2011; Chong, Victor/Q-6565-2018; Chong,
   Ngaihang V/A-5141-2009
OI Chong, Victor/0000-0002-7693-522X; Greenwood, John/0000-0003-4496-2984;
   Luthert, Philip/0000-0001-7276-6898; Cheetham,
   Michael/0000-0001-6429-654X
CR [Anonymous], 1998, Ophthalmology, V105, P11
   Berrod J P, 1993, Eur J Ophthalmol, V3, P132
   BIRD AEC, 1995, SURV OPHTHALMOL, V39, P367, DOI 10.1016/S0039-6257(05)80092-X
   Bradley JMB, 2000, INVEST OPHTH VIS SCI, V41, P422
   CAMPOCHIARO PA, 1986, INVEST OPHTH VIS SCI, V27, P1615
   Chader GJ, 2002, VISION RES, V42, P393, DOI 10.1016/S0042-6989(01)00212-7
   Curcio CA, 1999, ARCH OPHTHALMOL-CHIC, V117, P329, DOI 10.1001/archopht.117.3.329
   DAMATO BE, 1990, EYE, V4, P382, DOI 10.1038/eye.1990.51
   Dithmar S, 2000, INVEST OPHTH VIS SCI, V41, P2035
   Dunn KC, 1996, EXP EYE RES, V62, P155, DOI 10.1006/exer.1996.0020
   Evans J, 1996, BRIT J OPHTHALMOL, V80, P9, DOI 10.1136/bjo.80.1.9
   Folk JC, 1999, OPHTHALMOLOGY, V106, P1241, DOI 10.1016/S0161-6420(99)00734-4
   Friberg T R, 1999, Semin Ophthalmol, V14, P45, DOI 10.3109/08820539909056062
   GEARING AJH, 1994, NATURE, V370, P555, DOI 10.1038/370555a0
   GREEN WR, 1993, OPHTHALMOLOGY, V100, P1519
   Guo L, 1999, INVEST OPHTH VIS SCI, V40, P2676
   Hageman GS, 1999, MOL VIS, V5
   Hageman GS, 2001, PROG RETIN EYE RES, V20, P705, DOI 10.1016/S1350-9462(01)00010-6
   Han YP, 2001, J CELL SCI, V114, P131
   HIRANO K, 1989, INVEST OPHTH VIS SCI, V30, P869
   KAJIKAWA K, 1980, LAB INVEST, V43, P410
   Kamei M, 1999, INVEST OPHTH VIS SCI, V40, P2367
   Kigasawa Kazuteru, 1998, Tokai Journal of Experimental and Clinical Medicine, V23, P147
   Kliffen M, 1997, MICROSC RES TECHNIQ, V36, P106, DOI 10.1002/(SICI)1097-0029(19970115)36:2<106::AID-JEMT4>3.0.CO;2-N
   Knupp C, 2002, J STRUCT BIOL, V139, P181, DOI 10.1016/S1047-8477(02)00534-8
   Kuntz CA, 1996, INVEST OPHTH VIS SCI, V37, P1772
   LI W, 1984, EXP EYE RES, V38, P291, DOI 10.1016/0014-4835(84)90167-2
   Loeffler KU, 1998, BRIT J OPHTHALMOL, V82, P1104, DOI 10.1136/bjo.82.10.1104
   LOFFLER KU, 1986, GRAEF ARCH CLIN EXP, V224, P493, DOI 10.1007/BF02154735
   MARSHALL GE, 1994, GRAEF ARCH CLIN EXP, V232, P133, DOI 10.1007/BF00176781
   NEWSOME DA, 1988, EXP EYE RES, V46, P305, DOI 10.1016/S0014-4835(88)80022-8
   Pauleikhoff D., 1994, Ophthalmologe, V91, P730
   SARKS SH, 1976, BRIT J OPHTHALMOL, V60, P324, DOI 10.1136/bjo.60.5.324
   Sethi CS, 2000, BRIT J OPHTHALMOL, V84, P654, DOI 10.1136/bjo.84.6.654
   Spraul CW, 1998, OPHTHALMOLOGE, V95, P73, DOI 10.1007/s003470050240
   Spraul CW, 1999, SURV OPHTHALMOL, V44, pS10, DOI 10.1016/S0039-6257(99)00086-7
   Spraul CW, 1997, ARCH OPHTHALMOL-CHIC, V115, P267, DOI 10.1001/archopht.1997.01100150269022
   Steen B, 1998, INVEST OPHTH VIS SCI, V39, P2194
   STERIO DC, 1984, J MICROSC-OXFORD, V134, P127, DOI 10.1111/j.1365-2818.1984.tb02501.x
   Sternberg P, 2003, OPHTHALMOLOGY, V110, P971, DOI 10.1016/S0161-6420(03)00098-8
   ULBIG MRW, 1993, AM J OPHTHALMOL, V116, P410, DOI 10.1016/S0002-9394(14)71397-2
   VANDERSCHAFT TL, 1994, GRAEF ARCH CLIN EXP, V232, P40, DOI 10.1007/BF00176436
   VANDERSCHAFT TL, 1991, ARCH OPHTHALMOL-CHIC, V109, P420, DOI 10.1001/archopht.1991.01080030122052
   VINDING T, 1990, ACTA OPHTHALMOL, V68, P410
   WEBER BHF, 1994, NAT GENET, V8, P352, DOI 10.1038/ng1294-352
   Yucel YH, 2001, INVEST OPHTH VIS SCI, V42, P3216
NR 46
TC 18
Z9 19
U1 0
U2 2
PU ASSOC RESEARCH VISION OPHTHALMOLOGY INC
PI ROCKVILLE
PA 12300 TWINBROOK PARKWAY, ROCKVILLE, MD 20852-1606 USA
SN 0146-0404
EI 1552-5783
J9 INVEST OPHTH VIS SCI
JI Invest. Ophthalmol. Vis. Sci.
PD MAY
PY 2004
VL 45
IS 5
BP 1281
EP 1288
DI 10.1167/iovs.03-0671
PG 8
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 816BF
UT WOS:000221084700001
PM 15111578
DA 2022-11-30
ER

PT J
AU Elfandi, S
   Ooto, S
   Ueda-Arakawa, N
   Takahashi, A
   Yoshikawa, M
   Nakanishi, H
   Tamura, H
   Oishi, A
   Yamashiro, K
   Yoshimura, N
AF Elfandi, Sufian
   Ooto, Sotaro
   Ueda-Arakawa, Naoko
   Takahashi, Ayako
   Yoshikawa, Munemitsu
   Nakanishi, Hideo
   Tamura, Hiroshi
   Oishi, Akio
   Yamashiro, Kenji
   Yoshimura, Nagahisa
TI Clinical and Genetic Characteristics of Japanese Patients with
   Age-Related Macular Degeneration and Pseudodrusen
SO OPHTHALMOLOGY
LA English
DT Article
ID SUBRETINAL DRUSENOID DEPOSITS; RETICULAR PSEUDODRUSEN; ADAPTIVE OPTICS;
   EYES; PREVALENCE; SENSITIVITY; SUBTYPES
AB Purpose: To investigate differences in clinical characteristics and genotype distribution in Japanese patients with age-related macular degeneration (AMD) and pseudodrusen using multimodal imaging.
   Design: Retrospective, observational case series.
   Participants: A total of 101 patients (101 eyes) with AMD and pseudodrusen.
   Methods: Patients underwent complete ophthalmologic examination, including color fundus photography, infrared reflectance (IR) imaging, fundus autofluorescence, confocal blue reflectance, fluorescein and indocyanine green (ICG) angiography, and spectral-domain optical coherence tomography (SD OCT). Pseudodrusen subtype was identified with multiple imaging techniques. Patients were genotyped to identify major single nucleotide polymorphisms associated with AMD (CFH Y402, CFH I62V, and ARMS2 A69S).
   Main Outcome Measures: Clinical characteristics and genetic distributions of patients with pseudodrusen.
   Results: At least 1 imaging technique identified dot pseudodrusen in all 101 eyes and ribbon pseudodrusen in 53 eyes (52.5%). Forty-eight eyes (47.5%) had only dot pseudodrusen, but no eyes had only ribbon pseudodrusen or midperipheral drusen. Forty-five of 49 bilateral cases (91.8%) had the same pseudodrusen subtype in both eyes. Pseudodrusen subtype did not change during the observation period in 100 eyes (99.0%), but dotdominant type changed to dot-ribbon type in 1 eye (1.0%). The dot and ribbon subtypes were detected in 84 (83.1%) and 51 (96.2%) eyes, respectively, using color fundus photographs. Detection sensitivity of dot pseudodrusen was high for IR (97.0%), confocal blue reflectance (95.1%), fundus autofluorescence (93.1%), and ICG (100%) imaging. Detection sensitivity for ribbon pseudodrusen was high for color fundus photography (96.2%), confocal blue reflectance (94.3%), and fundus autofluorescence (90.6%), but not for IR imaging and ICG angiography. Risk allele frequency of the CFH I62V polymorphism was 79.8% and 67.0% in patients with dotdominant and dot-ribbon pseudodrusen, respectively (P = 0.053). The genotype frequency of CFH Y402H and ARMS2 A69S polymorphisms was not significantly different between the patients with dot-dominant type and dot-ribbon type (P = 0.647 and P = 0.354, respectively).
   Conclusions: Patients with pseudodrusen can be classified with dot-dominant or dot-ribbon type, and these subtypes usually are the same in both eyes. The distribution of CFHI62V polymorphisms may have an association with pseudodrusen subtypes. (C) 2016 by the American Academy of Ophthalmology.
C1 [Elfandi, Sufian; Ooto, Sotaro; Ueda-Arakawa, Naoko; Takahashi, Ayako; Yoshikawa, Munemitsu; Nakanishi, Hideo; Tamura, Hiroshi; Oishi, Akio; Yamashiro, Kenji; Yoshimura, Nagahisa] Kyoto Univ, Grad Sch Med, Dept Ophthalmol & Visual Sci, Kyoto, Japan.
C3 Kyoto University
RP Ooto, S (通讯作者)，Kyoto Univ, Grad Sch Med, Dept Ophthalmol & Visual Sci, Sakyo Ku, 54 Kawahara Cho, Kyoto 6068507, Japan.
EM ohoto@kuhp.kyoto-u.ac.jp
RI Oishi, Akio/AAE-9996-2020; TAMURA, Hiroshi/H-1855-2011
OI Oishi, Akio/0000-0002-0977-9458; TAMURA, Hiroshi/0000-0002-7740-2732;
   Yamashiro, Kenji/0000-0001-9354-8558
FU Topcon Corporation (Tokyo, Japan); Canon (Tokyo, Japan); Nidek
   (Gamagori, Japan)
FX The author(s) have made the following disclosure(s): N.Y.: Financial
   support - Topcon Corporation (Tokyo, Japan), Canon (Tokyo, Japan);
   Financial support and consultant - Nidek (Gamagori, Japan).
CR ARNOLD JJ, 1995, RETINA-J RET VIT DIS, V15, P183, DOI 10.1097/00006982-199515030-00001
   Cohen SY, 2007, BRIT J OPHTHALMOL, V91, P354, DOI 10.1136/bjo.2006.101022
   Kim JH, 2015, RETINA-J RET VIT DIS, V35, P2604, DOI 10.1097/IAE.0000000000000633
   KLEIN R, 1991, OPHTHALMOLOGY, V98, P1128
   Klein R, 2008, AM J OPHTHALMOL, V145, P317, DOI 10.1016/j.ajo.2007.09.008
   MIMOUN G, 1990, J FR OPHTALMOL, V13, P511
   Mrejen S, 2014, OPHTHALMOLOGY, V121, P545, DOI 10.1016/j.ophtha.2013.09.026
   Nakata I, 2013, AM J OPHTHALMOL, V156, P1002, DOI 10.1016/j.ajo.2013.06.007
   Ooto S, 2015, RETINA-J RET VIT DIS, V35, P1726, DOI 10.1097/IAE.0000000000000608
   Ooto S, 2013, AM J OPHTHALMOL, V156, P1184, DOI 10.1016/j.ajo.2013.06.036
   Pumariega NM, 2011, OPHTHALMOLOGY, V118, P1619, DOI 10.1016/j.ophtha.2011.01.029
   Querques G, 2011, RETINA-J RET VIT DIS, V31, P518, DOI 10.1097/IAE.0b013e3181f04974
   Querques G, 2014, BRIT J OPHTHALMOL, V98, P1522, DOI 10.1136/bjophthalmol-2014-305455
   Querques G, 2014, RETINA-J RET VIT DIS, V34, P321, DOI 10.1097/IAE.0b013e3182993df1
   Querques G, 2012, INVEST OPHTH VIS SCI, V53, P1264, DOI 10.1167/iovs.11-9063
   Querques G, 2012, INVEST OPHTH VIS SCI, V53, P1258, DOI 10.1167/iovs.11-8907
   Sarks J, 2011, BRIT J OPHTHALMOL, V95, P979, DOI 10.1136/bjo.2010.194977
   Schmitz-Valckenberg S, 2011, INVEST OPHTH VIS SCI, V52, P5009, DOI 10.1167/iovs.11-7235
   Schmitz-Valckenberg S, 2010, OPHTHALMOLOGY, V117, P1169, DOI 10.1016/j.ophtha.2009.10.044
   Smith RT, 2006, INVEST OPHTH VIS SCI, V47, P5495, DOI 10.1167/iovs.05-1318
   Smith RT, 2011, ARCH OPHTHALMOL-CHIC, V129, P1061, DOI 10.1001/archophthalmol.2011.212
   Smith RT, 2009, AM J OPHTHALMOL, V148, P733, DOI 10.1016/j.ajo.2009.06.028
   SPAIDE RF, 1995, RETINA-J RET VIT DIS, V15, P100, DOI 10.1097/00006982-199515020-00003
   Spaide RF, 2014, RETINA-J RET VIT DIS, V34, P2336, DOI 10.1097/IAE.0000000000000377
   Suzuki M, 2014, AM J OPHTHALMOL, V157, P1005, DOI 10.1016/j.ajo.2014.01.025
   Ueda-Arakawa N, 2014, AM J OPHTHALMOL, V157, P994, DOI 10.1016/j.ajo.2014.01.018
   Ueda-Arakawa N, 2013, RETINA-J RET VIT DIS, V33, P490, DOI 10.1097/IAE.0b013e318276e0ae
   Ueda-Arakawa N, 2013, AM J OPHTHALMOL, V155, P260, DOI 10.1016/j.ajo.2012.08.011
   Vongkulsiri S, 2014, AM J OPHTHALMOL, V158, P710, DOI 10.1016/j.ajo.2014.07.009
   Yannuzzi LA, 2001, RETINA-J RET VIT DIS, V21, P416, DOI 10.1097/00006982-200110000-00003
   Yoneyama S, 2014, GRAEF ARCH CLIN EXP, V252, P1435, DOI 10.1007/s00417-014-2601-y
   Zhang YH, 2014, AM J OPHTHALMOL, V158, P584, DOI 10.1016/j.ajo.2014.05.038
   Zweifel SA, 2010, OPHTHALMOLOGY, V117, P1775, DOI 10.1016/j.ophtha.2010.01.027
   Zweifel SA, 2010, OPHTHALMOLOGY, V117, P303, DOI 10.1016/j.ophtha.2009.07.014
NR 34
TC 9
Z9 9
U1 0
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0161-6420
EI 1549-4713
J9 OPHTHALMOLOGY
JI Ophthalmology
PD OCT
PY 2016
VL 123
IS 10
BP 2205
EP 2212
DI 10.1016/j.ophtha.2016.06.052
PG 8
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA EE3QI
UT WOS:000389509100019
PM 27521170
OA Green Submitted
DA 2022-11-30
ER

PT J
AU Dugel, PU
   Bebchuk, JD
   Nau, J
   Reichel, E
   Singer, M
   Barak, A
   Binder, S
   Jackson, TL
AF Dugel, Pravin U.
   Bebchuk, Judith D.
   Nau, Jeffrey
   Reichel, Elias
   Singer, Michael
   Barak, Adiel
   Binder, Susanne
   Jackson, Timothy L.
CA CABERNET Study Grp
TI Epimacular Brachytherapy for Neovascular Age-related Macular
   Degeneration A Randomized, Controlled Trial (CABERNET)
SO OPHTHALMOLOGY
LA English
DT Article
ID SUBFOVEAL CHOROIDAL NEOVASCULARIZATION; VISUAL IMPAIRMENT;
   RADIATION-THERAPY; ENDOTHELIAL-CELLS; RANIBIZUMAB; IRRADIATION;
   BLINDNESS; EFFICACY; SAFETY; RADIOTHERAPY
AB Purpose: To evaluate the safety and efficacy of epimacular brachytherapy (EMBT) for the treatment of neovascular age-related macular degeneration (AMD).
   Design: Multicenter, randomized, active-controlled, phase III clinical trial.
   Participants: Four hundred ninety-four participants with treatment-naive neovascular AMD.
   Methods: Participants with classic, minimally classic, and occult lesions were randomized in a 2:1 ratio to EMBT or a ranibizumab monotherapy control arm. The EMBT arm received 2 mandated, monthly loading injections of 0.5 mg ranibizumab. The control arm received 3 mandated, monthly loading injections of ranibizumab then quarterly injections. Both arms also received monthly as needed (pro re nata) retreatment.
   Main Outcome Measures: The proportion of participants losing fewer than 15 Early Treatment Diabetic Retinopathy Study (ETDRS) letters from baseline visual acuity (VA) and the proportion gaining more than 15 ETDRS letters from baseline VA.
   Results: At 24 months, 77% of the EMBT group and 90% of the control group lost fewer than 15 letters. This difference did not meet the prespecified 10% noninferiority margin. This end point was noninferior using a 20% margin and a 95% confidence interval for the group as a whole and for classic and minimally classic lesions, but not for occult lesions. The EMBT did not meet the superiority end point for the proportion of participants gaining more than 15 letters (16% for the EMBT group vs. 26% for the control group): this difference was statistically significant (favoring controls) for occult lesions, but not for predominantly classic and minimally classic lesions. Mean VA change was -2.5 letters in the EMBT arm and -4.4 letters in the control arm. Participants in the EMBT arm received a mean of 6.2 ranibizumab injections versus 10.4 in the control arm. At least 1 serious adverse event occurred in 54% of the EMBT arm, most commonly postvitrectomy cataract, versus 18% in the control arm. Mild, nonproliferative radiation retinopathy occurred in 3% of the EMBT participants, but no case was vision threatening.
   Conclusions: The 2-year efficacy data do not support the routine use of EMBT for treatment-naive wet AMD, despite an acceptable safety profile. Further safety review is required.
   Financial Disclosure(s): Proprietary or commercial disclosure may be found after the references. Ophthalmology 2013;120:317-327 (C) 2013 by the American Academy of Ophthalmology.
C1 [Dugel, Pravin U.] Retinal Consultants Arizona, Phoenix, AZ USA.
   [Bebchuk, Judith D.] Stat Collaborat Inc, Washington, DC USA.
   [Nau, Jeffrey] NeoVista Inc, Newark, CA USA.
   [Reichel, Elias] Tufts Med Ctr, Boston, MA USA.
   [Singer, Michael] Med Ctr Ophthalmol Assoc, San Antonio, TX USA.
   [Barak, Adiel] Tel Aviv Univ, Tel Aviv Sourasky Med Ctr, IL-69978 Tel Aviv, Israel.
   [Binder, Susanne] Rudolf Fdn Clin, Ludwig Boltzmann Inst Retinopathy & Biomicroscop, Vienna, Austria.
   [Jackson, Timothy L.] Kings Coll London, London, England.
C3 Tufts Medical Center; Tel Aviv University; Sackler Faculty of Medicine;
   Tel Aviv Sourasky Medical Center; University of London; King's College
   London
RP Jackson, TL (通讯作者)，Kings Coll Hosp London, Dept Ophthalmol, Univ London Kings Coll, Denmark Hill, London SE5 9RS, England.
EM t.jackson1@nhs.net
OI Jackson, Timothy/0000-0001-7618-1555
FU NeoVista
FX Judith D. Bebchuk: Financial support to employer-NeoVista.
CR Abraham P, 2010, AM J OPHTHALMOL, V150, P315, DOI 10.1016/j.ajo.2010.04.011
   ALTMAN R, 1994, BMJ-BRIT MED J, V308, P81, DOI 10.1136/bmj.308.6921.81
   Avila MP, 2012, RETINA-J RET VIT DIS, V32, P10, DOI 10.1097/IAE.0b013e31822528fc
   Bergink GJ, 1998, GRAEF ARCH CLIN EXP, V236, P321, DOI 10.1007/s004170050085
   Bressler NM, 2011, ARCH OPHTHALMOL-CHIC, V129, P709, DOI 10.1001/archophthalmol.2011.140
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Brown DM, 2009, OPHTHALMOLOGY, V116, P57, DOI 10.1016/j.ophtha.2008.10.018
   Bunce C, 2010, EYE, V24, P1692, DOI 10.1038/eye.2010.122
   CHAKRAVARTHY U, 1993, BRIT J OPHTHALMOL, V77, P265, DOI 10.1136/bjo.77.5.265
   Chakravarthy U, 2006, OPHTHALMOLOGY, V113, P1508, DOI 10.1016/j.ophtha.2006.02.064
   Chakravarthy U, 2000, BRIT J RADIOL, V73, P305, DOI 10.1259/bjr.73.867.10817048
   CHAKRAVARTHY U, 1989, CURR EYE RES, V8, P337, DOI 10.3109/02713688908996381
   CHAN RC, 1976, RADIOLOGY, V120, P673, DOI 10.1148/120.3.673
   Congdon N, 2004, ARCH OPHTHALMOL-CHIC, V122, P477
   D'Amico DJ, 2006, OPHTHALMOLOGY, V113, P992, DOI 10.1016/j.ophtha.2006.02.027
   DEGOWIN RL, 1974, J LAB CLIN MED, V84, P42
   Dugel PU, 2012, OPHTHALMOLOGY, V119, DOI 10.1016/j.ophtha.2012.01.014
   Finger RP, 2011, INVEST OPHTH VIS SCI, V52, P4381, DOI 10.1167/iovs.10-6987
   Gunnlaugsdottir E, 2010, ACTA OPHTHALMOL, V88, P358, DOI 10.1111/j.1755-3768.2008.01445.x
   Heimann H, 2007, OPHTHALMOLOGY, V114, P2142, DOI 10.1016/j.ophtha.2007.09.013
   Holz FG, 1999, OPHTHALMOLOGY, V106, P2239
   Jaakkola A, 2005, OPHTHALMOLOGY, V112, P567, DOI 10.1016/j.ophtha.2004.11.029
   Jaakkola A, 1999, ACTA OPHTHALMOL SCAN, V77, P57, DOI 10.1034/j.1600-0420.1999.770113.x
   Kilby W, 2010, TECHNOL CANCER RES T, V9, P433, DOI 10.1177/153303461000900502
   Maguire AM, 2001, RETINA, V2, P1509
   Mao XW, 2006, TECHNOL CANCER RES T, V5, P127, DOI 10.1177/153303460600500206
   Martin DF, 2011, NEW ENGL J MED, V364, P1897, DOI 10.1056/NEJMoa1102673
   Moore R F, 1930, Br J Ophthalmol, V14, P145, DOI 10.1136/bjo.14.4.145
   Moshfeghi DM, 2011, BRIT J OPHTHALMOL, V95, P185, DOI 10.1136/bjo.2009.163907
   Paganetti H, 2002, INT J RADIAT ONCOL, V53, P407, DOI 10.1016/S0360-3016(02)02754-2
   PATZ A, 1985, ARCH OPHTHALMOL-CHIC, V103, P1796, DOI 10.1001/archopht.1985.01050120030015
   Petrarca R, 2011, CLIN OPHTHALMOL, V5, P57, DOI 10.2147/OPTH.S16444
   Prise KM, 1998, INT J RADIAT BIOL, V74, P793, DOI 10.1080/095530098141087
   Regeneron Pharmaceuticals Inc, 2011, EYL FULL PRESCR INF
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Stewart MW, 2012, NAT REV DRUG DISCOV, V11, P269, DOI 10.1038/nrd3700
   Valmaggia C, 2002, AM J OPHTHALMOL, V133, P521, DOI 10.1016/S0002-9394(02)01336-3
   van Ginderdeuren R, 2005, BRIT J OPHTHALMOL, V89, P1306, DOI 10.1136/bjo.2005.068460
   Wickham L, 2007, OPHTHALMOLOGY, V114, P698, DOI 10.1016/j.ophtha.2006.08.042
NR 39
TC 50
Z9 51
U1 0
U2 16
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 0161-6420
EI 1549-4713
J9 OPHTHALMOLOGY
JI Ophthalmology
PD FEB
PY 2013
VL 120
IS 2
BP 317
EP 327
DI 10.1016/j.ophtha.2012.07.068
PG 11
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 085WX
UT WOS:000314646100016
PM 23174399
DA 2022-11-30
ER

PT J
AU Merle, BMJ
   Colijn, JM
   Cougnard-Gregoire, A
   de Koning-Backus, APM
   Delyfer, MN
   Kiefte-de Jong, JC
   Meester-Smoor, M
   Feart, C
   Verzijden, T
   Samieri, C
   Franco, OH
   Korobelnik, JF
   Klaver, CCW
   Delcourt, C
   Ajana, S
   Arango-Gonzalez, B
   Armento, A
   Arndt, V
   Bhatia, V
   Bhattacharya, SS
   Biarnes, M
   Borrell, A
   Buhren, S
   Calado, SM
   Dammeier, S
   de Jong, EK
   De la Cerda, B
   den Hollander, AI
   Diaz-Corrales, FJ
   Diether, S
   Emri, E
   Endermann, T
   Ferraro, LL
   Garcia, M
   Heesterbeek, TJ
   Honisch, S
   Hoyng, CB
   Kersten, E
   Kilger, E
   Langen, H
   Lengyel, I
   Luthert, P
   Maugeais, C
   Mones, J
   Nogoceke, E
   Peto, T
   Pool, FM
   Rodriguez, E
   Ueffing, M
   Bartz-Schmidt, KUU
   van Leeuwen, EM
   Zumbansen, M
   Vasiliev, V
AF Merle, Benedicte M. J.
   Colijn, Johanna M.
   Cougnard-Gregoire, Audrey
   de Koning-Backus, Alexandra P. M.
   Delyfer, Marie-Noelle
   Kiefte-de Jong, Jessica C.
   Meester-Smoor, Magda
   Feart, Catherine
   Verzijden, Timo
   Samieri, Cecilia
   Franco, Oscar H.
   Korobelnik, Jean-Francois
   Klaver, Caroline C. W.
   Delcourt, Cecile
   Ajana, Soufiane
   Arango-Gonzalez, Blanca
   Armento, Angela
   Arndt, Verena
   Bhatia, Vaibhav
   Bhattacharya, Shomi S.
   Biarnes, Marc
   Borrell, Anna
   Buhren, Sebastian
   Calado, Sofia M.
   Dammeier, Sascha
   de Jong, Eiko K.
   De la Cerda, Berta
   den Hollander, Anneke, I
   Diaz-Corrales, Francisco J.
   Diether, Sigrid
   Emri, Eszter
   Endermann, Tanja
   Ferraro, Lucia L.
   Garcia, Miriam
   Heesterbeek, Thomas J.
   Honisch, Sabina
   Hoyng, Carel B.
   Kersten, Eveline
   Kilger, Ellen
   Langen, Hanno
   Lengyel, Imre
   Luthert, Phil
   Maugeais, Cyrille
   Mones, Jordi
   Nogoceke, Everson
   Peto, Tunde
   Pool, Frances M.
   Rodriguez, Eduardo
   Ueffing, Marius
   Bartz-Schmidt, Karl U. Ulrich
   van Leeuwen, Elisabeth M.
   Zumbansen, Markus
   Vasiliev, Vassil
CA EYE-RISK Consortium
TI Mediterranean Diet and Incidence of Advanced Age-Related Macular
   Degeneration: The EYE-RISK Consortium
SO OPHTHALMOLOGY
LA English
DT Article
ID PRIMARY PREVENTION; FISH CONSUMPTION; ASSOCIATION; MACULOPATHY;
   ADHERENCE; PREVALENCE; ZEAXANTHIN; ROTTERDAM; SURVIVAL; DISEASE
AB Purpose: To investigate associations of adherence to the Mediterranean diet (MeDi) with incidence of advanced age-related macular degeneration (AMD; the symptomatic form of AMD) in 2 European population-based prospective cohorts.
   Design: Prospective cohort study of the Rotterdam Study I (RS-I) and the Antioxydants, Lipides Essentiels, Nutrition et Maladies Oculaires (Alienor) Study populations.
   Participants: Four thousand four hundred forty-six participants 55 years of age or older from the RS-I (The Netherlands) and 550 French adults 73 years of age or older from the Alienor Study with complete ophthalmologic and dietary data were included in the present study.
   Methods: Examinations were performed approximately every 5 years over a 21-year period (1990-2011) in RS-I and every 2 years over a 4-year period (2006-2012) in the Alienor Study. Adherence to the MeDi was evaluated using a 9-component score based on intake of vegetables, fruits, legumes, cereals, fish, meat, dairy products, alcohol, and the monounsaturated-to-saturated fatty acids ratio. Associations of incidence of AMD with MeDi were estimated using multivariate Cox proportional hazard models.
   Main Outcomes Measures: Incidence of advanced AMD based on retinal fundus photographs.
   Results: Among the 4996 included participants, 155 demonstrated advanced incident AMD (117 from the RS- I and 38 from the Alienor Study). The mean follow-up time was 9.9 years (range, 0.6-21.7 years) in the RS-I and 4.1 years (range, 2.5-5.0 years) in the Alienor Study. Pooling data for both the RS- I and Alienor Study, participants with a high (range, 6-9) MeDi score showed a significantly reduced risk for incident advanced AMD compared with participants with a low (range, 0-3) MeDi score in the fully adjusted Cox model (hazard ratio, 0.59; 95% confidence interval, 0.37-0.95; P = 0.04 for trend).
   Conclusions: Pooling data from the RS- I and Alienor Study, higher adherence to the MeDi was associated with a 41% reduced risk of incident advanced AMD. These findings support the role of a diet rich in healthful nutrient-rich foods such as fruits, vegetables, legumes, and fish in the prevention of AMD. (C) 2018 by the American Academy of Ophthalmology
C1 [Merle, Benedicte M. J.; Cougnard-Gregoire, Audrey; Delyfer, Marie-Noelle; Feart, Catherine; Samieri, Cecilia; Korobelnik, Jean-Francois; Delcourt, Cecile] Univ Bordeaux, Team LEHA, Bordeaux Populat Hlth Res Ctr, INSERM, Bordeaux, France.
   [Colijn, Johanna M.; de Koning-Backus, Alexandra P. M.; Meester-Smoor, Magda; Verzijden, Timo; Klaver, Caroline C. W.] Erasmus Univ, Med Ctr, Dept Ophthalmol, Rotterdam, Netherlands.
   [Colijn, Johanna M.; de Koning-Backus, Alexandra P. M.; Kiefte-de Jong, Jessica C.; Meester-Smoor, Magda; Verzijden, Timo; Franco, Oscar H.; Klaver, Caroline C. W.] Erasmus Univ, Med Ctr, Dept Epidemiol, Rotterdam, Netherlands.
   [Delyfer, Marie-Noelle; Korobelnik, Jean-Francois] CHU Bordeaux, Serv Ophtalmol, Bordeaux, France.
   [Klaver, Caroline C. W.; de Jong, Eiko K.; den Hollander, Anneke, I; Heesterbeek, Thomas J.; Hoyng, Carel B.; Kersten, Eveline; van Leeuwen, Elisabeth M.] Radhoud Univ, Dept Ophthalmol, Med Ctr, Nijmegen, Netherlands.
   [Merle, Benedicte M. J.; Cougnard-Gregoire, Audrey; Delcourt, Cecile; Ajana, Soufiane] Univ Bordeaux, Team LEHA, Bordeaux Populat Hlth Res Ctr, INSERM,UMR 1219, Bordeaux, France.
   [Arango-Gonzalez, Blanca; Armento, Angela; Dammeier, Sascha; Diether, Sigrid; Honisch, Sabina; Kilger, Ellen; Ueffing, Marius; Bartz-Schmidt, Karl U. Ulrich] Eberhard Karls Univ Tubingen, Ctr Ophthalmol, Inst Ophthalmol Res, Univ Clin Tuebingen, Tubingen, Germany.
   [Arndt, Verena; Endermann, Tanja] AYOXXA Biosyst GmbH, Assay Dev, Cologne, Germany.
   [Bhatia, Vaibhav; Bhattacharya, Shomi S.; Calado, Sofia M.; De la Cerda, Berta; Diaz-Corrales, Francisco J.] Andalusian Mol Biol & Regenerat Med CABIMER, Dept Regenerat & Cell Therapy, Seville, Spain.
   [Biarnes, Marc; Borrell, Anna; Ferraro, Lucia L.; Garcia, Miriam; Mones, Jordi; Rodriguez, Eduardo] Barcelona Mol Fdn, Barcelona, Spain.
   [Buhren, Sebastian] AYOXXA Biosyst GmbH, Business Dev, Cologne, Germany.
   [Colijn, Johanna M.; Meester-Smoor, Magda; Verzijden, Timo; Klaver, Caroline C. W.] Erasmus MC, Dept Epidemiol, Rotterdam, Netherlands.
   [Colijn, Johanna M.; Meester-Smoor, Magda; Verzijden, Timo; Klaver, Caroline C. W.; van Leeuwen, Elisabeth M.] Erasmus MC, Dept Ophthalmol, Rotterdam, Netherlands.
   [den Hollander, Anneke, I] Radhoud Univ, Med Ctr, Dept Human Genet, Nijmegen, Netherlands.
   [Emri, Eszter; Lengyel, Imre; Vasiliev, Vassil] Queens Univ Belfast, Ctr Expt Med, Belfast, Antrim, North Ireland.
   [Langen, Hanno; Maugeais, Cyrille; Nogoceke, Everson] F Hoffmann La Roche Ltd, Roche Innovation Ctr Basel, Basel, Switzerland.
   [Luthert, Phil] UCL, Inst Ophthalmol, London, England.
   [Peto, Tunde] Queens Univ Belfast, Ctr Publ Hlth, Belfast, Antrim, North Ireland.
   [Pool, Frances M.] UCL Inst Opthalmol, Ocular Biol, London, England.
   [Ueffing, Marius; Bartz-Schmidt, Karl U. Ulrich] Univ Med Ctr Tubingen, Dept Ophthalmol, Tubingen, Germany.
   [Zumbansen, Markus] AYOXXA Biosyst GmbH, Res & Dev, Cologne, Germany.
C3 Institut National de la Sante et de la Recherche Medicale (Inserm);
   UDICE-French Research Universities; Universite de Bordeaux; Erasmus
   University Rotterdam; Erasmus MC; Erasmus University Rotterdam; Erasmus
   MC; CHU Bordeaux; Institut National de la Sante et de la Recherche
   Medicale (Inserm); UDICE-French Research Universities; Universite de
   Bordeaux; Eberhard Karls University of Tubingen; Eberhard Karls
   University Hospital; Consejo Superior de Investigaciones Cientificas
   (CSIC); Universidad Pablo de Olavide; University of Sevilla; CSIC -
   Centro Andaluz de Biologia Molecular y Medicina Regenerativa (CABIMER);
   Erasmus University Rotterdam; Erasmus MC; Erasmus University Rotterdam;
   Erasmus MC; Queens University Belfast; Roche Holding; University of
   London; University College London; Queens University Belfast; University
   of London; University College London; Eberhard Karls University of
   Tubingen; Eberhard Karls University Hospital
RP Merle, BMJ (通讯作者)，Univ Bordeaux, ISPED, Lifelong Exposure Hlth & Aging Team, Res Ctr,INSERM,U1219, 146 Rue Leo Saignat,CS61292, F-33076 Bordeaux, France.
EM benediete.merle@u-bordeaux.fr
RI Samieri, Cecilia/T-3267-2019; COUGNARD-GREGOIRE, Audrey/T-4443-2019;
   Lengyel, Imre/B-5217-2009; Arango-Gonzalez, Blanca/AAR-7427-2021;
   Franco, Óscar H/ABE-2305-2020; Merle, Benedicte MJ/AAQ-5021-2021; Emri,
   Eszter/ABE-9363-2020; FEART, Catherine/A-3339-2016; Ajana,
   Soufiane/AAH-5181-2021; Delcourt, Cecile/I-2627-2013; Hollander, Anneke
   den/N-4911-2014; mones, jordi/CAJ-2963-2022; Kersten,
   Eveline/P-8173-2015; Kiefte-de Jong, Jessica/GLV-3216-2022; De la cerda,
   Berta/L-7039-2014; Calado, Sofia M./K-2202-2016; Delyfer,
   Marie-Noelle/T-3304-2019; KOROBELNIK, Jean-Francois/A-5448-2016; Merle,
   Benedicte MJ/F-1247-2015; Diaz-Corrales, Francisco J./L-7559-2014
OI Samieri, Cecilia/0000-0001-9809-7506; COUGNARD-GREGOIRE,
   Audrey/0000-0002-1494-5764; Lengyel, Imre/0000-0001-7467-2174;
   Arango-Gonzalez, Blanca/0000-0002-9045-182X; Franco, Óscar
   H/0000-0002-4606-4929; Merle, Benedicte MJ/0000-0003-1332-0954;
   Delcourt, Cecile/0000-0002-2099-0481; mones, jordi/0000-0003-3685-2160;
   Kiefte-de Jong, Jessica/0000-0002-8136-0918; De la cerda,
   Berta/0000-0001-5603-6473; Calado, Sofia M./0000-0001-5509-4145; Merle,
   Benedicte MJ/0000-0003-1332-0954; Diaz-Corrales, Francisco
   J./0000-0002-5752-0205; de Koning-Backus, Alexandra/0000-0001-5349-5500;
   Biarnes, Marc/0000-0003-2584-4894; FEART, Catherine/0000-0002-7959-1610
FU European Union's Horizon 2020 Research and Innovation Programme
   [634479]; Erasmus Medical Center; Erasmus University, Rotterdam, The
   Netherlands; Organization for the Health Research and Development
   (ZonMw); Research Institute for Diseases in the Elderly (RIDE); Ministry
   of Education, Culture and Science; Ministry for Health, Welfare and
   Sports; European Commission (DG XII); Municipality of Rotterdam,
   Rotterdam, The Netherlands; Oogfonds; Bartimeus Sonneheerdt Vereniging;
   Landelijke Stichting voor Blinden en Slechtzienden; Algemene Nederlandse
   Vereniging Ter Voorkoming Van Blindheid; Novartis Foundation;
   MaculaFonds [2015-36, 2016-19]; Laboratoires Thea; Fondation Voir et
   Entendre; Retina France; Agence Nationale de la Recherche [ANR
   2010-PRSP-011 VISA]; Caisse Nationale pour la Solidarite et l'Autonomie
FX B.M.J.M.: Consultant - Bausch & Lomb (Rochester, New York); Financial
   support e Laboratoires Thea (Clermont-Ferrand, France).; A.C.-G.:
   Financial support -Laboratoires Thea (Clermont-Ferrand, France).;
   O.H.F.: Financial support -Nestle (Vevey,Switzerland).; J.M.: Financial
   support -Bayer (Leverkusen, Germany), Alcon (Hunen-berg, Switzerland),
   Ophthotech (New-York, NY), Notal Vision (Manassas, VA), Novartis (Basel,
   Switzerland), Roche (Basel, Switzerland).; The EYE-RISK project is
   supported by the European Union's Horizon 2020 Research and Innovation
   Programme (grant no.: 634479). The Rotterdam Study is funded by Erasmus
   Medical Center and Erasmus University, Rotterdam, The Netherlands; the
   Organization for the Health Research and Development (ZonMw); the
   Research Institute for Diseases in the Elderly (RIDE); the Ministry of
   Education, Culture and Science; the Ministry for Health, Welfare and
   Sports; the European Commission (DG XII), and the Municipality of
   Rotterdam, Rotterdam, The Netherlands. Additionally, the ophthalmic
   research within the Rotterdam Study was supported by the following
   foundations: Oogfonds; Bartimeus Sonneheerdt Vereniging; Landelijke
   Stichting voor Blinden en Slechtzienden; Algemene Nederlandse Vereniging
   Ter Voorkoming Van Blindheid; Novartis Foundation; and MaculaFonds,
   which contributed through UitZicht (grant nos.: 2015-36 and 2016-19).
   The funding organizations had no role in the design or conduct of this
   research and provided unrestricted grants. The Antioxydants, Lipides
   Essentiels, Nutrition et Maladies Oculaires Study is funded by
   Laboratoires Thea; Fondation Voir et Entendre; Retina France; Agence
   Nationale de la Recherche (ANR 2010-PRSP-011 VISA); and Caisse Nationale
   pour la Solidarite et l'Autonomie. Laboratoires Thea participated in the
   design of the Antioxydants, Lipides Essentiels, Nutrition et Maladies
   Oculaires Study, but none of the sponsors participated in the
   collection, management, statistical analysis, or interpretation of the
   data, or in the preparation, review, or approval of the present
   manuscript.
CR Augood C, 2008, AM J CLIN NUTR, V88, P398, DOI 10.1093/ajcn/88.2.398
   BIRD AEC, 1995, SURV OPHTHALMOL, V39, P367, DOI 10.1016/S0039-6257(05)80092-X
   Cho EY, 2008, AM J CLIN NUTR, V87, P1837, DOI 10.1093/ajcn/87.6.1837
   Chong EWT, 2008, ARCH OPHTHALMOL-CHIC, V126, P826, DOI 10.1001/archopht.126.6.826
   Colijn JM, 2017, OPHTHALMOLOGY, V124, P1753, DOI 10.1016/j.ophtha.2017.05.035
   Dai J, 2008, AM J CLIN NUTR, V88, P1364, DOI 10.3945/ajcn.2008.26528
   Delcourt C, 2010, J NUTR HEALTH AGING, V14, P854, DOI 10.1007/s12603-010-0131-9
   Delcourt C, 2006, INVEST OPHTH VIS SCI, V47, P2329, DOI 10.1167/iovs.05-1235
   Diaz-Lopez A, 2015, DIABETES CARE, V38, P2134, DOI 10.2337/dc15-1117
   Erie JC, 2016, OPHTHALMOLOGY, V123, P1257, DOI 10.1016/j.ophtha.2016.02.015
   Estruch R, 2013, NEW ENGL J MED, V368, P1279, DOI 10.1056/NEJMoa1200303
   Feart C, 2007, BRIT J NUTR, V98, P1046, DOI 10.1017/S0007114507756520
   Feart C, 2009, JAMA-J AM MED ASSOC, V302, P638, DOI 10.1001/jama.2009.1146
   Fung TT, 2005, AM J CLIN NUTR, V82, P163
   Heier JS, 2012, OPHTHALMOLOGY, V119, P2537, DOI 10.1016/j.ophtha.2012.09.006
   Ho L, 2011, ARCH OPHTHALMOL-CHIC, V129, P758, DOI 10.1001/archophthalmol.2011.141
   HOFMAN A, 1991, EUR J EPIDEMIOL, V7, P403, DOI 10.1007/BF00145007
   Hogg RE, 2017, OPHTHALMOLOGY, V124, P82, DOI 10.1016/j.ophtha.2016.09.019
   Ikram MA, 2017, EUR J EPIDEMIOL, V32, P807, DOI 10.1007/s10654-017-0321-4
   KLEIN R, 1991, OPHTHALMOLOGY, V98, P1128
   Klipstein-Grobusch K, 1998, EUR J CLIN NUTR, V52, P588, DOI 10.1038/sj.ejcn.1600611
   Knowler WC, 2002, NEW ENGL J MED, V346, P393, DOI 10.1056/NEJMoa012512
   Lamarca R, 1998, J GERONTOL A-BIOL, V53, pM337, DOI 10.1093/gerona/53A.5.M337
   Lambert JC, 2009, NAT GENET, V41, P1094, DOI 10.1038/ng.439
   Lim LS, 2012, LANCET, V379, P1728, DOI 10.1016/S0140-6736(12)60282-7
   Ma L, 2012, BRIT J NUTR, V107, P350, DOI 10.1017/S0007114511004260
   Mares JA, 2011, ARCH OPHTHALMOL-CHIC, V129, P470, DOI 10.1001/archophthalmol.2010.314
   Mares-Perlman JA, 2001, AM J EPIDEMIOL, V153, P424, DOI 10.1093/aje/153.5.424
   Merle BMJ, 2015, AM J CLIN NUTR, V102, P1196, DOI 10.3945/ajcn.115.111047
   Merle BMJ, 2014, INVEST OPHTH VIS SCI, V55, P2010, DOI 10.1167/iovs.14-13916
   Nunes S, 2018, NUTRITION, V51-52, P6, DOI 10.1016/j.nut.2017.12.010
   Raimundo M, 2018, ACTA OPHTHALMOL, V96, pE926, DOI 10.1111/aos.13775
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Samieri C, 2008, J AM DIET ASSOC, V108, P1461, DOI 10.1016/j.jada.2008.06.437
   Seddon JM, 2003, ARCH OPHTHALMOL-CHIC, V121, P1728, DOI 10.1001/archopht.121.12.1728
   SEDDON JM, 1994, JAMA-J AM MED ASSOC, V272, P1413, DOI 10.1001/jama.272.18.1413
   Seddon JM, 2006, ARCH OPHTHALMOL-CHIC, V124, P995, DOI 10.1001/archopht.124.7.995
   Sobrin L, 2014, PROG RETIN EYE RES, V40, P1, DOI 10.1016/j.preteyeres.2013.12.004
   TRICHOPOULOU A, 1995, BMJ-BRIT MED J, V311, P1457, DOI 10.1136/bmj.311.7018.1457
   Trichopoulou A, 2003, NEW ENGL J MED, V348, P2599, DOI 10.1056/NEJMoa025039
   van Leeuwen R, 2005, JAMA-J AM MED ASSOC, V294, P3101, DOI 10.1001/jama.294.24.3101
   van Leeuwen R, 2003, ARCH OPHTHALMOL-CHIC, V121, P519, DOI 10.1001/archopht.121.4.519
   WILLETT WC, 1995, AM J CLIN NUTR, V61, p1402S, DOI 10.1093/ajcn/61.6.1402S
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
NR 44
TC 56
Z9 56
U1 0
U2 39
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 0161-6420
EI 1549-4713
J9 OPHTHALMOLOGY
JI Ophthalmology
PD MAR
PY 2019
VL 126
IS 3
BP 381
EP 390
DI 10.1016/j.ophtha.2018.08.006
PG 10
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA HM5GZ
UT WOS:000459505400019
PM 30114418
OA Green Accepted
DA 2022-11-30
ER

PT J
AU Chew, EY
AF Chew, Emily Y.
TI Age-related Macular Degeneration: Nutrition, Genes and Deep Learning-The
   LXXVI Edward Jackson Memorial Lecture
SO AMERICAN JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
ID COMPLEMENT FACTOR-H; BETA-CAROTENE; VITAMIN-E; DIABETIC-RETINOPATHY;
   MEDITERRANEAN DIET; EYE DISEASE; FISH CONSUMPTION; NATIONAL-HEALTH;
   GENOMEWIDE SCAN; LUNG-CANCER
AB PURPOSE: To evaluate the importance of nutritional supplements, dietary pattern, and genetic associations in age-related macular degeneration (AMD); and to discuss the technique of artificial intelligence/deep learning to potentially enhance research in detecting and classifying AMD.
   DESIGN: Retrospective literature review.
   METHODS: To review the studies of both prospective and retrospective (post hoc) analyses of nutrition, genetic variants, and deep learning in AMD in both the Age Related Eye Disease Study (AREDS) and AREDS2.
   RESULTS: In addition to demonstrating the beneficial effects of the AREDS and AREDS2 supplements of antioxidant vitamins and zinc (plus copper) for reducing the risk of progression to late AMD, these 2 studies also confirmed the importance of high adherence to Mediterranean diet in reducing progression of AMD in persons with varying severity of disease. In persons with the protective genetic alleles of complement factor H (CFH), the Mediterranean diet had further beneficial effect. However, despite the genetic association with AMD progression, prediction models found genetic information added little to the high predictive value of baseline severity of AMD for disease progression. The technique of deep learning, an arm of artificial intelligence, using color fundus photographs from AREDS/AREDS2 was superior in some cases and noninferior in others to clinical human grading (retinal specialists) and to the gold standard of the certified reading center graders.
   CONCLUSIONS: Counseling individuals affected with AMD regarding the use of the AREDS2 supplements and the beneficial association of the Mediterranean diet is an important public health message. Although genetic testing is important in research, it is not recommended for prediction of disease or to guide therapies and/or dietary interventions in AMD. Techniques in deep learning hold great promise, but further prospective research is required to validate the use of this technique to provide improvement in accuracy and sensitivity/specificity in clinical research and medical management of patients with AMD. Published by Elsevier Inc.
C1 [Chew, Emily Y.] NEI, Clin Trials Branch, Div Epidemiol & Clin Applicat, NIH, Bethesda, MD 20892 USA.
C3 National Institutes of Health (NIH) - USA; NIH National Eye Institute
   (NEI)
RP Chew, EY (通讯作者)，NEI, Div Epidemiol & Clin Applicat, NIH, Bldg 10,Room 3-2531,10 Ctr Dr,MSC 1204, Bethesda, MD 20892 USA.
EM echew@nei.nih.gov
OI Chew, Emily/0000-0003-0999-9802
FU National Eye Institute/National Institutes of Health (NEI/NIH),
   Department of Health and Human Services, Bethesda, Maryland, USA
   [NOI-EY-0-2127, HHS-N-260-2005-00007-C, N01-EY-5-0007]; NIH: Office of
   Dietary Supplements; NIH: National Center for Complementary and
   Alternative Medicine; NIH: National Institute on Aging; NIH: National
   Heart, Lung, and Blood Institute; NIH: National Institute of
   Neurological Disorders and Stroke
FX THE AREDS AND AREDS2 STUDIES WERE SUPPORTED BY INTRAMURAL PROGRAM FUNDS
   AND contracts (AREDS [contract NOI-EY-0-2127] and AREDS2 [contract
   HHS-N-260-2005-00007-C; ADB contract N01-EY-5-0007]) from the National
   Eye Institute/National Institutes of Health (NEI/NIH), Department of
   Health and Human Services, Bethesda, Maryland, USA. Funds were
   generously contributed to these contracts by the following NIH
   institutes: Office of Dietary Supplements; National Center for
   Complementary and Alternative Medicine; National Institute on Aging;
   National Heart, Lung, and Blood Institute; National Institute of
   Neurological Disorders and Stroke.
CR Age-Related Eye Disease Study 2 Research Group, 2013, JAMA, V309, P2005, DOI 10.1001/jama.2013.4997
   Asaoka R, 2016, OPHTHALMOLOGY, V123, P1974, DOI 10.1016/j.ophtha.2016.05.029
   Assel MJ, 2018, OPHTHALMOLOGY, V125, P391, DOI 10.1016/j.ophtha.2017.09.008
   Augood C, 2008, AM J CLIN NUTR, V88, P398, DOI 10.1093/ajcn/88.2.398
   Brown JM, 2018, JAMA OPHTHALMOL, V136, P803, DOI 10.1001/jamaophthalmol.2018.1934
   Burlina P, 2017, COMPUT BIOL MED, V82, P80, DOI 10.1016/j.compbiomed.2017.01.018
   Burlina PM, 2018, JAMA OPHTHALMOL, V136, P1359, DOI 10.1001/jamaophthalmol.2018.4118
   Burlina PM, 2017, JAMA OPHTHALMOL, V135, P1170, DOI 10.1001/jamaophthalmol.2017.3782
   Cerentini A, 2017, STUD HEALTH TECHNOL, V245, P318, DOI 10.3233/978-1-61499-830-3-318
   Chew EY, 2014, JAMA OPHTHALMOL, V132, P142, DOI 10.1001/jamaophthalmol.2013.7376
   Chew EY, 2013, OPHTHALMOLOGY, V120, P1604, DOI 10.1016/j.ophtha.2013.01.021
   Chew EY, 2012, OPHTHALMOLOGY, V119, P2282, DOI 10.1016/j.ophtha.2012.05.027
   Cho EY, 2008, AM J CLIN NUTR, V87, P1837, DOI 10.1093/ajcn/87.6.1837
   Choi JY, 2017, PLOS ONE, V12, DOI [10.1371/journal.pone.0187338, 10.1371/journal.pone.0187336]
   Chong EWT, 2008, ARCH OPHTHALMOL-CHIC, V126, P826, DOI 10.1001/archopht.126.6.826
   Congdon N, 2004, ARCH OPHTHALMOL-CHIC, V122, P477
   Coyner AS, 2019, OPHTHALMOL RETINA, V3, P444, DOI 10.1016/j.oret.2019.01.015
   Csaky K.G., 2017, J VITR DIS, V1, P75, DOI [10.1177/2474126416680671, DOI 10.1177/2474126416680671]
   Delcourt C, 2006, INVEST OPHTH VIS SCI, V47, P2329, DOI 10.1167/iovs.05-1235
   Ding Y, 2017, GENETICS, V206, P119, DOI 10.1534/genetics.116.196998
   Edwards AO, 2005, SCIENCE, V308, P421, DOI 10.1126/science.1110189
   Estruch R, 2018, NEW ENGL J MED, V378, DOI [10.1056/NEJMoa1800389, 10.1056/nejmoa1800389]
   Ferris FL, 2005, ARCH OPHTHALMOL-CHIC, V123, P1570
   Fritsche LG, 2016, NAT GENET, V48, P134, DOI 10.1038/ng.3448
   Gargeya R, 2017, OPHTHALMOLOGY, V124, P962, DOI 10.1016/j.ophtha.2017.02.008
   GOLDBERG J, 1988, AM J EPIDEMIOL, V128, P700, DOI 10.1093/oxfordjournals.aje.a115023
   Govindaiah Arun, 2018, Annu Int Conf IEEE Eng Med Biol Soc, V2018, P702, DOI 10.1109/EMBC.2018.8512379
   Grassmann F, 2018, OPHTHALMOLOGY, V125, P1410, DOI 10.1016/j.ophtha.2018.02.037
   Gulshan V, 2016, JAMA-J AM MED ASSOC, V316, P2402, DOI 10.1001/jama.2016.17216
   Hageman GS, 2005, P NATL ACAD SCI USA, V102, P7227, DOI 10.1073/pnas.0501536102
   Haines JL, 2005, SCIENCE, V308, P419, DOI 10.1126/science.1110359
   HEINONEN OP, 1994, NEW ENGL J MED, V330, P1029
   Kassoff A, 1999, CONTROL CLIN TRIALS, V20, P573
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1417, DOI 10.1001/archopht.119.10.1417
   Keenan TD, 2020, ALZHEIMERS DEMENT, V16, P831, DOI 10.1002/alz.12077
   Keenan TD, 2020, OPHTHALMOLOGY, V127, P1515, DOI 10.1016/j.ophtha.2020.04.030
   Keenan TD, 2019, OPHTHALMOLOGY, V126, P1533, DOI 10.1016/j.ophtha.2019.06.005
   Keenan TD, 2018, OPHTHALMOLOGY, V125, P1913, DOI 10.1016/j.ophtha.2018.05.028
   Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557
   Ma L, 2012, BRIT J NUTR, V107, P350, DOI 10.1017/S0007114511004260
   Majewski J, 2003, AM J HUM GENET, V73, P540, DOI 10.1086/377701
   Mares-Perlman JA, 2001, AM J EPIDEMIOL, V153, P424, DOI 10.1093/aje/153.5.424
   Matsuba S, 2019, INT OPHTHALMOL, V39, P1269, DOI 10.1007/s10792-018-0940-0
   Merle BMJ, 2019, OPHTHALMOLOGY, V126, P381, DOI 10.1016/j.ophtha.2018.08.006
   Merle BMJ, 2015, AM J CLIN NUTR, V102, P1196, DOI 10.3945/ajcn.115.111047
   Merle BMJ, 2014, INVEST OPHTH VIS SCI, V55, P2010, DOI 10.1167/iovs.14-13916
   Muhammad H, 2017, J GLAUCOMA, V26, P1086, DOI 10.1097/IJG.0000000000000765
   Omenn GS, 1996, NEW ENGL J MED, V334, P1150, DOI 10.1056/NEJM199605023341802
   Peng YF, 2019, OPHTHALMOLOGY, V126, P565, DOI 10.1016/j.ophtha.2018.11.015
   Quartilho A, 2016, EYE, V30, P602, DOI 10.1038/eye.2015.288
   Raju M, 2017, STUD HEALTH TECHNOL, V245, P559, DOI 10.3233/978-1-61499-830-3-559
   SanGiovanni JP, 2007, ARCH OPHTHALMOL-CHIC, V125, P1225, DOI 10.1001/archopht.125.9.1225
   SanGiovanni JP, 2007, ARCH OPHTHALMOL-CHIC, V125, P671, DOI 10.1001/archopht.125.5.671
   SanGiovanni JP, 2009, AM J CLIN NUTR, V90, P1601, DOI 10.3945/ajcn.2009.27594
   Seddon JM, 2003, ARCH OPHTHALMOL-CHIC, V121, P1728, DOI 10.1001/archopht.121.12.1728
   Seddon JM, 2003, AM J HUM GENET, V73, P780, DOI 10.1086/378505
   SEDDON JM, 1994, JAMA-J AM MED ASSOC, V272, P1413, DOI 10.1001/jama.272.18.1413
   Seddon JM, 2006, ARCH OPHTHALMOL-CHIC, V124, P995, DOI 10.1001/archopht.124.7.995
   Stone EAA, 2014, RECOMMENDATIONS AM A
   Stone EM, 2015, JAMA OPHTHALMOL, V133, P598, DOI 10.1001/jamaophthalmol.2015.0369
   Takahashi H, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0179790
   Ting DSW, 2017, JAMA-J AM MED ASSOC, V318, P2211, DOI 10.1001/jama.2017.18152
   Treder M, 2018, GRAEF ARCH CLIN EXP, V256, P259, DOI 10.1007/s00417-017-3850-3
   Verghese A, 2018, JAMA-J AM MED ASSOC, V319, P19, DOI 10.1001/jama.2017.19198
   Warwick A, 2018, EYE, V32, P849, DOI 10.1038/eye.2017.245
   Weeks DE, 2004, AM J HUM GENET, V75, P174, DOI 10.1086/422476
   Willett Walter C., 1995, American Journal of Clinical Nutrition, V61, p1402S, DOI 10.1093/ajcn/61.6.1402S
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
   Yan Q, 2018, HUM MOL GENET, V27, P929, DOI 10.1093/hmg/ddy002
   Zareparsi S, 2005, AM J HUM GENET, V77, P149, DOI 10.1086/431426
NR 70
TC 5
Z9 5
U1 1
U2 8
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 0002-9394
EI 1879-1891
J9 AM J OPHTHALMOL
JI Am. J. Ophthalmol.
PD SEP
PY 2020
VL 217
BP 335
EP 347
DI 10.1016/j.ajo.2020.05.042
PG 13
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA NW3NW
UT WOS:000574918000036
PM 32574780
OA Green Accepted
DA 2022-11-30
ER

PT J
AU Emerson, MV
   Lauer, AK
AF Emerson, M. Vaughn
   Lauer, Andreas K.
TI Emerging therapies for the treatment of neovascular age-related macular
   degeneration and diabetic macular edema
SO BIODRUGS
LA English
DT Article
ID ENDOTHELIAL GROWTH-FACTOR; INTRAVITREAL BEVACIZUMAB AVASTIN; ANTI-VEGF
   ANTIBODY; PHASE-I TRIAL; CHOROIDAL NEOVASCULARIZATION; TRIAMCINOLONE
   ACETONIDE; PHOTODYNAMIC THERAPY; OCULAR NEOVASCULARIZATION; LASER
   PHOTOCOAGULATION; RETINOPATHY
AB Diabetic macular edema (DME) and choroidal neovascularization (CNV) associated with age-related macular degeneration (AMD) are the leading causes of vision loss in the industrialized world. The mainstay of treatment for both conditions has been thermal laser photocoagulation, while there have been recent advances in the treatment of CNV using photodynamic therapy with verteporfin. While both of these treatments have prevented further vision loss in a subset of patients, vision improvement is rare. Anti-vascular endothelial growth factor (VEGF)-A therapy has revolutionized the treatment of both conditions. Pegaptanib, an anti-VEGF aptamer, prevents vision loss in CNV, although the performance is similar to that of photodynamic therapy. Ranibizumab, an antibody fragment, and bevacizumab, a full-length humanized monoclonal antibody against VEGF, have both shown promising results, with improvements in visual acuity in the treatment of both diseases. VEGF trap, a modified soluble VEGF receptor analog, binds VEGF more tightly than all other anti-VEGF therapies, and has also shown promising results in early trials. Other treatment strategies to decrease the effect of VEGF have used small interfering RNA to inhibit VEGF production and VEGF receptor production. Corticosteroids have shown efficacy in controlled trials, including anacortave acetate in the treatment and prevention of CNV, and intravitreal triamcinolone acetonide and the fluocinolone acetonide implant in the treatment of DME. Receptor tyrosine kinase inhibitors, such as vatalanib, inhibit downstream effects of VEGF, and have, been effective in the treatment of CNV in early studies. Squalamine lactate inhibits plasma membrane ion channels with downstream effects on VEGF, and has shown promising results with systemic administration. Initial results are also encouraging for other growth factors, including pigment epithelium-derived factor administered via an adenoviral vector. Ruboxistaurin, which decreases protein kinase C activity, has shown positive results in the prevention of diabetic retinopathy progression, and the resolution of DME. Combination therapy has been investigated, and may prove to be quite effective in the management of both DME and AMD-associated CNV, although ongoing and future studies will be crucial to treatment optimization for each condition.
C1 Oregon Hlth & Sci Univ, Casey Eye Inst, Portland, OR 97239 USA.
C3 Oregon Health & Science University
RP Lauer, AK (通讯作者)，Oregon Hlth & Sci Univ, Casey Eye Inst, 3375 SW Terwilliger Blvd, Portland, OR 97239 USA.
CR Abraham P, 2006, OPHTHALMOLOGY, V113, P2221, DOI 10.1016/j.ophtha.2006.07.032
   ADAMIS AP, 1994, AM J OPHTHALMOL, V118, P445, DOI 10.1016/S0002-9394(14)75794-0
   Adamis AP, 2005, RETINA-J RET VIT DIS, V25, P111, DOI 10.1097/00006982-200502000-00001
   ADAMS AP, 2006, AM AC OPHTH ANN M SU
   AGUSTIN AJ, 2006, AM AC OPTH ANN M SUB
   Aiello LP, 2005, DIABETES, V54, P2188
   AIELLO LP, 1994, NEW ENGL J MED, V331, P1480, DOI 10.1056/NEJM199412013312203
   Ambati J, 2003, SURV OPHTHALMOL, V48, P257, DOI 10.1016/S0039-6257(03)00030-4
   [Anonymous], 1994, Arch Ophthalmol, V112, P500
   [Anonymous], 1993, Arch Ophthalmol, V111, P1200
   [Anonymous], RANDOMIZED TRIAL COM
   Arevalo JF, 2007, OPHTHALMOLOGY, V114, P743, DOI 10.1016/j.ophtha.2006.12.028
   Avery RL, 2006, OPHTHALMOLOGY, V113, P363, DOI 10.1016/j.ophtha.2005.11.019
   Bakri SJ, 2006, RETINA-J RET VIT DIS, V26, P519, DOI 10.1097/01.iae.0000225354.92444.7a
   Bashshur ZF, 2006, AM J OPHTHALMOL, V142, P1, DOI 10.1016/j.ajo.2006.02.037
   Blinder KJ, 2003, AM J OPHTHALMOL, V136, P407, DOI 10.1016/S0002-9394(03)00223-X
   Blumenkranz MS, 2001, ARCH OPHTHALMOL-CHIC, V119, P198
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Brown JC, 2004, ARCH OPHTHALMOL-CHIC, V122, P330, DOI 10.1001/archopht.122.3.330
   BRUCKER AJ, 2006, RET SOC CLUB JUL GON
   Bullock William H., 2002, Current Topics in Medicinal Chemistry, V2, P915, DOI 10.2174/1568026023393255
   Campochiaro PA, 2006, HUM GENE THER, V17, P167, DOI 10.1089/hum.2006.17.167
   CARRION ME, 2005, INVEST OPHTH VIS SCI, P46
   Chen Y, 1999, J MOL BIOL, V293, P865, DOI 10.1006/jmbi.1999.3192
   Chew E, 2007, OPHTHALMOLOGY, V114, P1190, DOI 10.1016/j.ophtha.2007.02.010
   Chun DW, 2006, OPHTHALMOLOGY, V113, P1706, DOI 10.1016/j.ophtha.2006.04.033
   Ciulla TA, 2003, RETINA-J RET VIT DIS, V23, P808, DOI 10.1097/00006982-200312000-00011
   Conti SM, 2006, CURR OPIN OPHTHALMOL, V17, P235, DOI 10.1097/01.icu.0000193107.00089.ee
   Cunningham ET, 2005, OPHTHALMOLOGY, V112, P1747, DOI 10.1016/j.ophtha.2005.06.007
   *EARL TREATM DIAB, 1985, ARCH OPHTHALMOL-CHIC, V103, P1796, DOI DOI 10.1001/ARCHOPHT.1985.01050120030015
   Edelman JL, 2005, EXP EYE RES, V80, P249, DOI 10.1016/j.exer.2004.09.013
   Edwards AO, 2005, SCIENCE, V308, P421, DOI 10.1126/science.1110189
   *EYE DIS PREV RES, 2004, ARCH OPHTHALMOL-CHIC, V12, P564
   Ferrara N, 2004, NAT REV DRUG DISCOV, V3, P391, DOI 10.1038/nrd1381
   Ferrara N, 2004, ENDOCR REV, V25, P581, DOI 10.1210/er.2003-0027
   FERRIS FL, 1982, AM J OPHTHALMOL, V94, P91, DOI 10.1016/0002-9394(82)90197-0
   FINE SL, 1982, ARCH OPHTHALMOL-CHIC, V100, P912
   Fong DS, 2007, ARCH OPHTHALMOL-CHIC, V125, P469
   Francis Peter J, 2003, Ophthalmol Clin North Am, V16, P575, DOI 10.1016/S0896-1549(03)00096-8
   FRIEDMAN SM, 2006, AM AC OPHTH ANN M SU
   Fung AE, 2006, BRIT J OPHTHALMOL, V90, P1344, DOI 10.1136/bjo.2006.099598
   Gillies MC, 2006, OPHTHALMOLOGY, V113, P1533, DOI 10.1016/j.ophtha.2006.02.065
   Gragoudas ES, 2004, NEW ENGL J MED, V351, P2805, DOI 10.1056/NEJMoa042760
   Grant MB, 2000, DIABETES CARE, V23, P504, DOI 10.2337/diacare.23.4.504
   GREEN WR, 1993, OPHTHALMOLOGY, V100, P1519
   Hamilton MM, 2006, INVEST OPHTH VIS SCI, V47, P299, DOI 10.1167/iovs.05-0731
   Haritoglou C, 2006, RETINA-J RET VIT DIS, V26, P999, DOI 10.1097/01.iae.0000247165.38655.bf
   HAWKINS BS, 1986, ARCH OPHTHALMOL-CHIC, V104, P694
   Heier JS, 2006, ARCH OPHTHALMOL-CHIC, V124, P1532, DOI 10.1001/archopht.124.11.1532
   Heier JS, 2006, OPHTHALMOLOGY, V113, P633, DOI 10.1016/j.ophtha.2005.10.052
   Hurwitz H, 2004, NEW ENGL J MED, V350, P2335, DOI 10.1056/NEJMoa032691
   IP MS, 2006, RET SOC CLUB JUL GON
   JABS DA, 2006, RET SOC CLUB JUL GON
   Jonas JB, 2003, ARCH OPHTHALMOL-CHIC, V121, P57
   Joondeph BC., 2006, RET SOC CLUB JUL GON
   KAISER K, 2006, AM AC OPHTH ANN M SU
   Kaiser PK, 2001, AM J OPHTHALMOL, V131, P44, DOI 10.1016/S0002-9394(00)00872-2
   Kempen JH, 2004, ARCH OPHTHALMOL-CHIC, V122, P552
   Keyt BA, 1996, J BIOL CHEM, V271, P7788, DOI 10.1074/jbc.271.13.7788
   KING R C, 1963, Br J Ophthalmol, V47, P666, DOI 10.1136/bjo.47.11.666
   Klein R, 2006, OPHTHALMOLOGY, V113, P373, DOI 10.1016/j.ophtha.2005.12.013
   KLEIN R, 1995, OPHTHALMOLOGY, V102, P7
   LANZETTA P, 2006, RET SOC CLUB JUL GON
   LEWIS H, 1990, OPHTHALMOLOGY, V97, P503, DOI 10.1016/S0161-6420(90)32574-5
   Lyons TJ, 2004, INVEST OPHTH VIS SCI, V45, P910, DOI 10.1167/iovs.02-0648
   *MAC PHOT STUD GRO, 1991, ARCH OPHTHALMOL-CHIC, V10, P1220
   Maier P, 2005, GRAEF ARCH CLIN EXP, V243, P593, DOI 10.1007/s00417-004-1021-9
   Martidis A, 2002, OPHTHALMOLOGY, V109, P920, DOI 10.1016/S0161-6420(02)00975-2
   Massin P, 2003, AM J OPHTHALMOL, V135, P169, DOI 10.1016/S0002-9394(02)01837-8
   Michels S, 2006, INVEST OPHTH VIS SCI, V47, P371, DOI 10.1167/iovs.05-0354
   Mori K, 2002, INVEST OPHTH VIS SCI, V43, P2428
   Moshfeghi AA, 2006, OPHTHALMOLOGY, V113, P2002, DOI 10.1016/j.ophtha.2006.05.070
   NGUYEN QD, 2006, RET SOC CLUB JUL GON
   Nguyen QD, 2006, OPHTHALMOLOGY, V113, P1522, DOI 10.1016/j.ophtha.2006.05.055
   POULSEN JE, 1953, DIABETES, V2, P7, DOI 10.2337/diab.2.1.7
   Presta LG, 1997, CANCER RES, V57, P4593
   Rakic JM, 2003, INVEST OPHTH VIS SCI, V44, P3186, DOI 10.1167/iovs.02-1092
   Rich RM, 2006, RETINA-J RET VIT DIS, V26, P495, DOI 10.1097/01.iae.0000225766.75009.3a
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   ROSENFELD PJ, 2006, AM SOC RET SPEC EUR
   Schmidt-Erfurth U, 2003, INVEST OPHTH VIS SCI, V44, P4473, DOI 10.1167/iovs.02-1115
   SCHMIDTERFURTH U, 2006, AM AC OPHTH ANN M SU
   SHAH SM, 2006, RET SOC CLUB JUL GON
   SHAMOON H, 1993, NEW ENGL J MED, V329, P977, DOI 10.1056/nejm199309303291401
   Shen J, 2006, GENE THER, V13, P225, DOI 10.1038/sj.gt.3302641
   Sieving PA, 2006, P NATL ACAD SCI USA, V103, P3896, DOI 10.1073/pnas.0600236103
   SIGURDSSON R, 1980, BRIT J OPHTHALMOL, V64, P392, DOI 10.1136/bjo.64.6.392
   Slakter JS, 2006, OPHTHALMOLOGY, V113, P3, DOI 10.1016/j.ophtha.2005.10.019
   SLAKTER JS, 2006, AM AC OPTH ANN M SUB
   Smith LEH, 1997, SCIENCE, V276, P1706, DOI 10.1126/science.276.5319.1706
   Spaide RF, 2006, RETINA-J RET VIT DIS, V26, P383, DOI 10.1097/00006982-200604000-00001
   Spandau UHM, 2005, BRIT J OPHTHALMOL, V89, P999, DOI 10.1136/bjo.2004.062596
   Stearne MR, 1998, BMJ-BRIT MED J, V317, P703
   STEELE FR, 1993, P NATL ACAD SCI USA, V90, P1526, DOI 10.1073/pnas.90.4.1526
   Tao W, 2002, INVEST OPHTH VIS SCI, V43, P3292
   Wang YS, 2002, GRAEF ARCH CLIN EXP, V240, P42, DOI 10.1007/s00417-001-0398-y
   *WHO, MAGN CAUS VIS IMP
   INTRAVITREAL RANIBIZ
   PHASE 2 EVALUATION A
   EVALUATION VITRECTOM
NR 100
TC 60
Z9 68
U1 1
U2 13
PU ADIS INT LTD
PI NORTHCOTE
PA 5 THE WAREHOUSE WAY, NORTHCOTE 0627, AUCKLAND, NEW ZEALAND
SN 1173-8804
EI 1179-190X
J9 BIODRUGS
JI Biodrugs
PY 2007
VL 21
IS 4
BP 245
EP 257
DI 10.2165/00063030-200721040-00005
PG 13
WC Oncology; Immunology; Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology; Immunology; Pharmacology & Pharmacy
GA 196WR
UT WOS:000248514200005
PM 17628122
DA 2022-11-30
ER

PT J
AU Amadoro, G
   Latina, V
   Balzamino, BO
   Squitti, R
   Varano, M
   Calissano, P
   Micera, A
AF Amadoro, Giuseppina
   Latina, Valentina
   Balzamino, Bijorn Omar
   Squitti, Rosanna
   Varano, Monica
   Calissano, Pietro
   Micera, Alessandra
TI Nerve Growth Factor-Based Therapy in Alzheimer's Disease and Age-Related
   Macular Degeneration
SO FRONTIERS IN NEUROSCIENCE
LA English
DT Review
DE neuroprotection; brain degeneration; trace metals; Alzheimer's disease;
   age-related macular degeneration; nerve growth factor; retinal
   degeneration; biomarkers
ID ENCAPSULATED CELL BIODELIVERY; MILD COGNITIVE IMPAIRMENT;
   MITOCHONDRIAL-DNA DAMAGE; BASAL FOREBRAIN NEURONS; VASCULAR
   RISK-FACTORS; FACTOR GENE-THERAPY; AMYLOID-BETA; OXIDATIVE STRESS;
   CONTROLLED-RELEASE; SPATIAL MEMORY
AB Alzheimer's disease (AD) is an age-associated neurodegenerative disease which is the most common cause of dementia among the elderly. Imbalance in nerve growth factor (NGF) signaling, metabolism, and/or defect in NGF transport to the basal forebrain cholinergic neurons occurs in patients affected with AD. According to the cholinergic hypothesis, an early and progressive synaptic and neuronal loss in a vulnerable population of basal forebrain involved in memory and learning processes leads to degeneration of cortical and hippocampal projections followed by cognitive impairment with accumulation of misfolded/aggregated A beta and tau protein. The neuroprotective and regenerative effects of NGF on cholinergic neurons have been largely demonstrated, both in animal models of AD and in living patients. However, the development of this neurotrophin as a disease-modifying therapy in humans is challenged by both delivery limitations (inability to cross the blood-brain barrier (BBB), poor pharmacokinetic profile) and unwanted side effects (pain and weight loss). Age-related macular degeneration (AMD) is a retinal disease which represents the major cause of blindness in developed countries and shares several clinical and pathological features with AD, including alterations in NGF transduction pathways. Interestingly, nerve fiber layer thinning, degeneration of retinal ganglion cells and changes of vascular parameters, aggregation of A beta and tau protein, and apoptosis also occur in the retina of both AD and AMD. A protective effect of ocular administration of NGF on both photoreceptor and retinal ganglion cell degeneration has been recently described. Besides, the current knowledge about the detection of essential trace metals associated with AD and AMD and their changes depending on the severity of diseases, either systemic or locally detected, further pave the way for a promising diagnostic approach. This review is aimed at describing the employment of NGF as a common therapeutic approach to AMD and AD and the diagnostic power of detection of essential trace metals associated with both diseases. The multiple approaches employed to allow a sustained release/targeting of NGF to the brain and its neurosensorial ocular extensions will be also discussed, highlighting innovative technologies and future translational prospects.
C1 [Amadoro, Giuseppina; Calissano, Pietro] CNR, Inst Translat Pharmacol IFT, Rome, Italy.
   [Amadoro, Giuseppina; Latina, Valentina] European Brain Res Inst, Rome, Italy.
   [Balzamino, Bijorn Omar; Varano, Monica; Micera, Alessandra] IRCCS, Fdn Bietti, Res Labs Ophthalmol, Rome, Italy.
   [Squitti, Rosanna] IRCCS, Ist Ctr San Giovanni Dio Fatebenefratelli, Mol Markers Lab, Brescia, Italy.
C3 Consiglio Nazionale delle Ricerche (CNR); Istituto di Farmacologia
   Traslazionale (IFT-CNR); IRCCS - Fondazione "G.B. Bietti" per lo Studio
   e la Ricerca in Oftalmologia; IRCCS Fatebenefratelli
RP Amadoro, G (通讯作者)，CNR, Inst Translat Pharmacol IFT, Rome, Italy.; Amadoro, G (通讯作者)，European Brain Res Inst, Rome, Italy.; Micera, A (通讯作者)，IRCCS, Fdn Bietti, Res Labs Ophthalmol, Rome, Italy.
EM g.amadoro@inmm.cnr.it; alessandra.micera@fondazionebietti.it
RI LATINA, VALENTINA/ABF-6504-2020; balzamino, bijorn omar/A-4433-2013;
   Amadoro, Giuseppina/ABC-7641-2021
OI LATINA, VALENTINA/0000-0002-6057-6154; balzamino, bijorn
   omar/0000-0002-2254-1647; amadoro, giuseppina/0000-0003-2080-2951;
   Squitti, Rosanna/0000-0002-5624-1140; Varano, Monica/0000-0002-6530-1563
FU Fondo Ordinario Enti [FOE D.M 865/2019]; Regione Lazio, POR FESR Lazio
   2014-2020, "Progetti di Gruppi di Ricerca 2020" [G08487 del 19 luglio
   2020]; Operatori Sanitari Associati (OSA); Italian Ministry of Health
   [RC2765949]; 5xMille 2016
FX This work was supported (in part) by Fondo Ordinario Enti (FOE D.M
   865/2019) funds in the framework of a collaboration agreement between
   the Italian National Research Council and EBRI (2019-2021) and Regione
   Lazio, POR FESR Lazio 2014-2020, "Progetti di Gruppi di Ricerca 2020"
   (Determinazione dirigenziale n.G08487 del 19 luglio 2020) to GA. VL is
   supported by a postdoctoral fellowship by Operatori Sanitari Associati
   (OSA). AM is supported partially by the Italian Ministry of Health
   (RC2765949) and 5xMille 2016 to Fondazione Bietti. The funders had no
   role in the study design, data collection and analysis, decision to
   publish, or preparation of the manuscript.
CR Aberami S, 2019, EXP EYE RES, V186, DOI 10.1016/j.exer.2019.107718
   Aboelnour A, 2016, EXP EYE RES, V147, P138, DOI 10.1016/j.exer.2016.05.015
   Acevedo K, 2019, J BIOL INORG CHEM, V24, P1141, DOI 10.1007/s00775-019-01731-9
   Aloe L, 2015, CURR NEUROPHARMACOL, V13, P294, DOI 10.2174/1570159X13666150403231920
   Aloe L, 2013, BALK MED J, V30, P4, DOI 10.5152/balkanmedj.2013.003
   Ambati J, 2012, NEURON, V75, P26, DOI 10.1016/j.neuron.2012.06.018
   Anand R, 2000, OPHTHALMOLOGY, V107, P2224
   Anderson DH, 2004, EXP EYE RES, V78, P243, DOI 10.1016/j.exer.2003.10.011
   Angelova A, 2013, DRUG DISCOV TODAY, V18, P1263, DOI 10.1016/j.drudis.2013.07.010
   Ashok A, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21197290
   Atwood CS, 2002, PEPTIDES, V23, P1343, DOI 10.1016/S0196-9781(02)00070-0
   Ayton S, 2021, ALZHEIMERS DEMENT, V17, P1244, DOI 10.1002/alz.12282
   Ballinger SW, 1999, EXP EYE RES, V68, P765, DOI 10.1006/exer.1998.0661
   Barreau E, 1996, INVEST OPHTH VIS SCI, V37, P384
   Barron MJ, 2001, INVEST OPHTH VIS SCI, V42, P3016
   Baumann B, 2017, INVEST OPHTH VIS SCI, V58, P4223, DOI 10.1167/iovs.17-21743
   Baumgart Matthew, 2015, Alzheimers Dement, V11, P718, DOI 10.1016/j.jalz.2015.05.016
   Beatty S, 2000, SURV OPHTHALMOL, V45, P115, DOI 10.1016/S0039-6257(00)00140-5
   Biesemeier A, 2015, EXP EYE RES, V137, P39, DOI 10.1016/j.exer.2015.05.019
   Biscetti Leonardo, 2017, Front Biosci (Elite Ed), V9, P174
   Bishop KM, 2008, EXP NEUROL, V211, P574, DOI 10.1016/j.expneurol.2008.03.004
   Blasiak J, 2020, CELL MOL LIFE SCI, V77, P789, DOI 10.1007/s00018-019-03420-x
   Boscolo E, 2007, INT J MOL MED, V19, P581
   Brookmeyer R, 2007, ALZHEIMERS DEMENT, V3, P186, DOI 10.1016/j.jalz.2007.04.381
   Bruni AC, 2020, AGEING RES REV, V64, DOI 10.1016/j.arr.2020.101126
   Buch H, 2005, ACTA OPHTHALMOL SCAN, V83, P400, DOI [10.1111/j.1600-0420.2005.00474.x, 10.1111/j.1600-0420.2005.thesis.x]
   Bush AI, 2013, J ALZHEIMERS DIS, V33, pS277, DOI 10.3233/JAD-2012-129011
   Calissano P, 2010, CELL DEATH DIFFER, V17, P1126, DOI 10.1038/cdd.2010.38
   Calissano P, 2010, DEV NEUROBIOL, V70, P372, DOI 10.1002/dneu.20759
   Calza A, 2011, J OCUL PHARMACOL TH, V27, P209, DOI 10.1089/jop.2010.0139
   Campagne MV, 2014, J PATHOL, V232, P151, DOI 10.1002/path.4266
   Canu N, 2017, INT J MOL SCI, V18, DOI 10.3390/ijms18061319
   Capasso M, 2005, J ALZHEIMERS DIS, V8, P93
   Capsoni S, 2009, J ALZHEIMERS DIS, V16, P371, DOI 10.3233/JAD-2009-0953
   CastelBarthe MN, 1996, NEUROBIOL DIS, V3, P76, DOI 10.1006/nbdi.1996.0008
   Cattaneo A, 2008, J ALZHEIMERS DIS, V15, P255
   Cattaneo A, 2012, MOL NEUROBIOL, V46, P588, DOI 10.1007/s12035-012-8310-9
   Cerman E, 2015, TURK J MED SCI, V45, P1004, DOI 10.3906/sag-1406-146
   Chew EY, 2015, JAMA-J AM MED ASSOC, V314, P791, DOI 10.1001/jama.2015.9677
   Chiaretti A, 2017, BRAIN INJURY, V31, P1538, DOI 10.1080/02699052.2017.1376760
   Choi BS, 2009, BRAIN RES, V1248, P14, DOI 10.1016/j.brainres.2008.10.056
   Cobley JN, 2018, REDOX BIOL, V15, P490, DOI 10.1016/j.redox.2018.01.008
   Coleman HR, 2008, LANCET, V372, P1835, DOI 10.1016/S0140-6736(08)61759-6
   Courtois Y, 2020, M S-MED SCI, V36, P616, DOI 10.1051/medsci/2020096
   Covaceuszach S, 2009, CURR ALZHEIMER RES, V6, P158, DOI 10.2174/156720509787602870
   Crabb JW, 2002, P NATL ACAD SCI USA, V99, P14682, DOI 10.1073/pnas.222551899
   Cuello AC, 2007, CURR ALZHEIMER RES, V4, P351, DOI 10.2174/156720507781788774
   Cuello AC, 2010, J MOL NEUROSCI, V40, P230, DOI 10.1007/s12031-009-9238-z
   Cui QN, 2020, EXP EYE RES, V193, DOI 10.1016/j.exer.2020.107961
   Currais A, 2013, ANTIOXID REDOX SIGN, V19, P813, DOI 10.1089/ars.2012.4996
   da Silva SL, 2014, ALZHEIMERS DEMENT, V10, P485, DOI 10.1016/j.jalz.2013.05.1771
   Dalvi S, 2019, CELL DEATH DISCOV, V5, DOI 10.1038/s41420-019-0171-9
   Desai BS, 2009, J NEURAL TRANSM, V116, P587, DOI 10.1007/s00702-009-0226-9
   Di Fausto V, 2007, EUR J NEUROSCI, V26, P2473, DOI 10.1111/j.1460-9568.2007.05883.x
   Ding JD, 2008, VISION RES, V48, P339, DOI 10.1016/j.visres.2007.07.025
   Ding JD, 2011, P NATL ACAD SCI USA, V108, pE279, DOI 10.1073/pnas.1100901108
   Ding XY, 2009, PROG RETIN EYE RES, V28, P1, DOI 10.1016/j.preteyeres.2008.10.001
   Diouf I, 2020, NEUROBIOL DIS, V139, DOI 10.1016/j.nbd.2020.104810
   Donoso LA, 2006, SURV OPHTHALMOL, V51, P137, DOI 10.1016/j.survophthal.2005.12.001
   Eftimiadi G, 2021, NEURAL REGEN RES, V16, P1740, DOI 10.4103/1673-5374.306062
   EMERICH DF, 1994, J COMP NEUROL, V349, P148, DOI 10.1002/cne.903490110
   Eriksdotter-Jonhagen M, 2012, DEMENT GERIATR COGN, V33, P18, DOI 10.1159/000336051
   Erskine L, 2014, ASN NEURO, V6, DOI 10.1177/1759091414562107
   Esposito G, 2021, ADV EXP MED BIOL, V1331, P265, DOI 10.1007/978-3-030-74046-7_18
   Evans JR, 2017, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD000254.pub4
   Faller P, 2013, INORG CHEM, V52, P12193, DOI 10.1021/ic4003059
   Falsini B, 2016, BRAIN, V139, P404, DOI 10.1093/brain/awv366
   Falsini B, 2016, J TRANSL MED, V14, DOI 10.1186/s12967-015-0750-3
   Faustino C, 2017, PHARMACOL RES, V120, P68, DOI 10.1016/j.phrs.2017.03.020
   Feher J, 2006, NEUROBIOL AGING, V27, P983, DOI 10.1016/j.neurobiolaging.2005.05.012
   Hernandez-Zimbron LF, 2018, OXID MED CELL LONGEV, V2018, DOI 10.1155/2018/8374647
   Fine SL, 2000, NEW ENGL J MED, V342, P483, DOI 10.1056/NEJM200002173420707
   FISCHER W, 1987, NATURE, V329, P65, DOI 10.1038/329065a0
   Fjord-Larsen L, 2010, MOL THER, V18, P2164, DOI 10.1038/mt.2010.154
   Frazzini V, 2006, BIOGERONTOLOGY, V7, P307, DOI 10.1007/s10522-006-9045-7
   Frost S, 2016, CURR ALZHEIMER RES, V13, P1259, DOI 10.2174/1567205013666160603003800
   Ganguly U, 2021, OXID MED CELL LONGEV, V2021, DOI 10.1155/2021/7086512
   Garcia TB, 2017, CYTOKINE GROWTH F R, V34, P43, DOI 10.1016/j.cytogfr.2016.11.005
   Gehrs KM, 2006, ANN MED, V38, P450, DOI 10.1080/07853890600946724
   Gilbert R, 2019, MOL NUTR FOOD RES, V63, DOI 10.1002/mnfr.201801049
   Girijashanker K, 2008, MOL PHARMACOL, V73, P1413, DOI 10.1124/mol.107.043588
   Godley BF, 2005, J BIOL CHEM, V280, P21061, DOI 10.1074/jbc.M502194200
   Golestaneh N, 2017, CELL DEATH DIS, V8, DOI 10.1038/cddis.2016.453
   Goozee K, 2018, MOL PSYCHIATR, V23, P1807, DOI 10.1038/mp.2017.146
   Gungor ED, 2018, J TRACE ELEM MED BIO, V48, P16, DOI 10.1016/j.jtemb.2018.02.019
   Guo L, 2020, SCI REP-UK, V10, DOI 10.1038/s41598-020-60427-2
   Gupta V, 2016, CELL MOL LIFE SCI, V73, P4279, DOI 10.1007/s00018-016-2295-x
   Habiba U, 2020, J ALZHEIMERS DIS, V76, P1135, DOI 10.3233/JAD-191346
   Heesterbeek TJ, 2020, EXP EYE RES, V201, DOI 10.1016/j.exer.2020.108324
   Hill D, 2021, EXPERT OPIN INV DRUG, V30, P571, DOI 10.1080/13543784.2021.1896701
   Hines DJ, 2013, CRIT REV THER DRUG, V30, P257, DOI 10.1615/CritRevTherDrugCarrierSyst.2013006475
   HOFFMAN D, 1993, EXP NEUROL, V122, P100, DOI 10.1006/exnr.1993.1111
   HOFFMAN D, 1990, EXP NEUROL, V110, P39, DOI 10.1016/0014-4886(90)90049-X
   Hsu HW, 2019, TOXICOL SCI, V170, P144, DOI 10.1093/toxsci/kfz084
   Huang EJ, 2001, ANNU REV NEUROSCI, V24, P677, DOI 10.1146/annurev.neuro.24.1.677
   Isas JM, 2010, INVEST OPHTH VIS SCI, V51, P1304, DOI 10.1167/iovs.09-4207
   Jager RD, 2008, NEW ENGL J MED, V358, P2606, DOI 10.1056/NEJMra0801537
   Jindal V, 2015, MOL NEUROBIOL, V51, P885, DOI 10.1007/s12035-014-8733-6
   Johnson LV, 2002, P NATL ACAD SCI USA, V99, P11830, DOI 10.1073/pnas.192203399
   Johnson PJ, 2008, J BIOMED MATER RES A, V86A, P420, DOI 10.1002/jbm.a.31635
   Jonhagen ME, 1998, DEMENT GERIATR COGN, V9, P246, DOI 10.1159/000017069
   Kaarniranta K, 2011, J ALZHEIMERS DIS, V24, P615, DOI 10.3233/JAD-2011-101908
   Kaarniranta Kai, 2010, Front Biosci (Elite Ed), V2, P1374
   Kabir MT, 2021, MOL NEUROBIOL, V58, P1, DOI 10.1007/s12035-020-02096-w
   Katta S, 2009, J GENET, V88, P425, DOI 10.1007/s12041-009-0064-4
   Ke J, 2021, DRUG DISCOV TODAY, V26, P1991, DOI 10.1016/j.drudis.2021.04.025
   Kepp KP, 2019, COORDIN CHEM REV, V397, P168, DOI 10.1016/j.ccr.2019.06.018
   Kim MH, 2016, J EXPO SCI ENV EPID, V26, P214, DOI 10.1038/jes.2014.75
   King A, 2004, PHOTOCHEM PHOTOBIOL, V79, P470, DOI 10.1562/LE-03-17.1
   Kivipelto M, 2001, BMJ-BRIT MED J, V322, P1447, DOI 10.1136/bmj.322.7300.1447
   Kivipelto M, 2002, ANN INTERN MED, V137, P149, DOI 10.7326/0003-4819-137-3-200208060-00006
   Kivipelto M, 2005, ARCH NEUROL-CHICAGO, V62, P1556, DOI 10.1001/archneur.62.10.1556
   Klein R, 2004, AM J OPHTHALMOL, V137, P486, DOI 10.1016/j.ajo.2003.11.069
   Klein RL, 2000, BRAIN RES, V875, P144, DOI 10.1016/S0006-8993(00)02634-2
   KORDOWER JH, 1994, P NATL ACAD SCI USA, V91, P10898, DOI 10.1073/pnas.91.23.10898
   Koronyo-Hamaoui M, 2011, NEUROIMAGE, V54, pS204, DOI 10.1016/j.neuroimage.2010.06.020
   Lambiase A, 2005, INVEST OPHTH VIS SCI, V46, P3800, DOI 10.1167/iovs.05-0301
   Lambiase A, 2007, BRAIN RES, V1127, P45, DOI 10.1016/j.brainres.2006.09.102
   Lambiase A, 2009, ANN I SUPER SANITA, V45, P439
   Lenzi L, 2005, VISION RES, V45, P1491, DOI 10.1016/j.visres.2004.12.020
   Li Y, 2017, FRONT MOL NEUROSCI, V10, DOI 10.3389/fnmol.2017.00339
   Liang FQ, 2003, EXP EYE RES, V76, P397, DOI 10.1016/S0014-4835(03)00023-X
   Lindner MD, 1996, CELL TRANSPLANT, V5, P205, DOI 10.1016/0963-6897(95)02029-2
   LOEFFLER KU, 1993, INVEST OPHTH VIS SCI, V34, P2600
   Logue MW, 2014, NEUROBIOL AGING, V35, DOI 10.1016/j.neurobiolaging.2013.12.007
   Luibl V, 2006, J CLIN INVEST, V116, P378, DOI 10.1172/JCI25843
   Malerba F, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0136425
   Malerba F, 2011, EXPERT OPIN DRUG DEL, V8, P1277, DOI 10.1517/17425247.2011.588204
   Mandel RJ, 2010, CURR OPIN MOL THER, V12, P240
   Marcus M, 2018, NANOMATERIALS-BASEL, V8, DOI 10.3390/nano8090707
   MARKOWSKA AL, 1994, J NEUROSCI, V14, P4815
   Markowska AL, 1996, J NEUROSCI, V16, P3541
   MARTINEZSERRANO A, 1995, NEURON, V15, P473, DOI 10.1016/0896-6273(95)90051-9
   Masters CL, 2015, NAT REV DIS PRIMERS, V1, DOI 10.1038/nrdp.2015.56
   Masuzzo A, 2016, FRONT NEUROL, V7, DOI 10.3389/fneur.2016.00127
   Mathys Zoe K, 2017, Adv Neurobiol, V18, P199, DOI 10.1007/978-3-319-60189-2_10
   Mayeux R, 2012, CSH PERSPECT MED, V2, DOI 10.1101/cshperspect.a006239
   McGeer EG, 2010, J ALZHEIMERS DIS, V19, P355, DOI 10.3233/JAD-2010-1219
   McGeer EG, 2005, NEUROBIOL AGING, V26, pS94, DOI 10.1016/j.neurobiolaging.2005.08.008
   McGeer PL, 2004, ANN NY ACAD SCI, V1035, P104, DOI 10.1196/annals.1332.007
   Mesentier-Louro LA, 2019, MOL NEUROBIOL, V56, P1056, DOI 10.1007/s12035-018-1154-1
   Micera A, 2004, CYTOKINE GROWTH F R, V15, P411, DOI 10.1016/j.cytogfr.2004.09.003
   Micera A, 2007, CYTOKINE GROWTH F R, V18, P245, DOI 10.1016/j.cytogfr.2007.04.004
   Micera A, 2019, CURR ALZHEIMER RES, V16, P1073, DOI 10.2174/1567205016666191023114015
   Miller JW, 2013, AM J OPHTHALMOL, V155, P1, DOI 10.1016/j.ajo.2012.10.018
   Mitra S, 2019, FRONT NEUROSCI-SWITZ, V13, DOI 10.3389/fnins.2019.00038
   Mitter SK, 2014, AUTOPHAGY, V10, P1989, DOI 10.4161/auto.36184
   Mufson EJ, 2019, FRONT NEUROSCI-SWITZ, V13, DOI 10.3389/fnins.2019.00533
   Mufson Elliott J, 2008, Expert Rev Neurother, V8, P1703, DOI 10.1586/14737175.8.11.1703
   Mullins RF, 2000, FASEB J, V14, P835, DOI 10.1096/fasebj.14.7.835
   Nagahara AH, 2009, EXP NEUROL, V215, P153, DOI 10.1016/j.expneurol.2008.10.004
   Newman AB, 2005, J AM GERIATR SOC, V53, P1101, DOI 10.1111/j.1532-5415.2005.53360.x
   Nunomura A, 2001, J NEUROPATH EXP NEUR, V60, P759, DOI 10.1093/jnen/60.8.759
   Ohno-Matsui K, 2011, PROG RETIN EYE RES, V30, P217, DOI 10.1016/j.preteyeres.2011.02.004
   OLSON L, 1992, J NEURAL TRANSM-PARK, V4, P79, DOI 10.1007/BF02257624
   Ong SS, 2019, J NEUROL, V266, P1566, DOI 10.1007/s00415-018-9028-z
   Pardue MT, 2018, PROG RETIN EYE RES, V65, P50, DOI 10.1016/j.preteyeres.2018.02.002
   Park D, 2012, CELL TRANSPLANT, V21, P365, DOI 10.3727/096368911X586765
   Park SW, 2017, ONCOTARGET, V8, P40006, DOI 10.18632/oncotarget.16967
   Patel Ashaben, 2013, World J Pharmacol, V2, P47
   Picard E, 2015, FREE RADICAL BIO MED, V89, P1105, DOI 10.1016/j.freeradbiomed.2015.08.018
   Pinnen F, 2011, ARCH PHARM, V344, P139, DOI 10.1002/ardp.201000209
   Pizzo DP, 2004, NEUROSCIENCE, V124, P743, DOI 10.1016/j.neuroscience.2003.12.041
   Polidori MC, 2001, AGING-CLIN EXP RES, V13, P231, DOI 10.1007/BF03351481
   POWELL EM, 1990, BRAIN RES, V515, P309, DOI 10.1016/0006-8993(90)90612-F
   Prince M., 2013, ALZHEIMERS DIS INT
   Querfurth HW, 2010, NEW ENGL J MED, V362, P329, DOI 10.1056/NEJMra0909142
   Rafii MS, 2018, JAMA NEUROL, V75, P834, DOI 10.1001/jamaneurol.2018.0233
   Rafii MS, 2014, ALZHEIMERS DEMENT, V10, P571, DOI 10.1016/j.jalz.2013.09.004
   Rami A, 2009, NEUROPATH APPL NEURO, V35, P449, DOI 10.1111/j.1365-2990.2009.01034.x
   Reitz C, 2014, BIOCHEM PHARMACOL, V88, P640, DOI 10.1016/j.bcp.2013.12.024
   Roberti G, 2014, J CELL PHYSIOL, V229, P1130, DOI 10.1002/jcp.24573
   Rozzini L, 2018, J ALZHEIMERS DIS, V61, P907, DOI 10.3233/JAD-170552
   Rudnicka AR, 2012, OPHTHALMOLOGY, V119, P571, DOI 10.1016/j.ophtha.2011.09.027
   Ryhanen T, 2009, J CELL MOL MED, V13, P3616, DOI 10.1111/j.1582-4934.2008.00577.x
   Sacchetti M, 2017, CURR EYE RES, V42, P1064, DOI 10.1080/02713683.2017.1279634
   Schulte-Herbruggen O, 2008, CURR ALZHEIMER RES, V5, P38
   Schutt F, 2003, INVEST OPHTH VIS SCI, V44, P3663, DOI 10.1167/iovs.03-0172
   Schutt F, 2002, FEBS LETT, V528, P217, DOI 10.1016/S0014-5793(02)03312-4
   Seddon JM, 2005, ARCH OPHTHALMOL-CHIC, V123, P321, DOI 10.1001/archopht.123.3.321
   Seddon JM, 2016, BRIT J OPHTHALMOL, V100, P1731, DOI 10.1136/bjophthalmol-2016-308624
   SEIGER A, 1993, BEHAV BRAIN RES, V57, P255, DOI 10.1016/0166-4328(93)90141-C
   Sensi SL, 2018, TRENDS PHARMACOL SCI, V39, P1049, DOI 10.1016/j.tips.2018.10.001
   Shu WT, 2018, PHARMACEUTICALS-BASE, V11, DOI 10.3390/ph11040112
   Singh I, 2013, P NATL ACAD SCI USA, V110, P14771, DOI 10.1073/pnas.1302212110
   Siotto M, 2016, J ALZHEIMERS DIS, V50, P1181, DOI 10.3233/JAD-150611
   Sivak JM, 2013, INVEST OPHTH VIS SCI, V54, P871, DOI 10.1167/iovs.12-10827
   Sofroniew MV, 2001, ANNU REV NEUROSCI, V24, P1217, DOI 10.1146/annurev.neuro.24.1.1217
   Song BB, 2012, BIOMATERIALS, V33, P9105, DOI 10.1016/j.biomaterials.2012.08.060
   Song DL, 2012, FREE RADICAL BIO MED, V53, P64, DOI 10.1016/j.freeradbiomed.2012.04.020
   Sparks DL, 2003, P NATL ACAD SCI USA, V100, P11065, DOI 10.1073/pnas.1832769100
   Spires-Jones TL, 2014, NEURON, V82, P756, DOI 10.1016/j.neuron.2014.05.004
   Squitti R, 2020, BIOMOLECULES, V10, DOI 10.3390/biom10081164
   Squitti R, 2018, J TRACE ELEM MED BIO, V45, P181, DOI 10.1016/j.jtemb.2017.11.005
   Squitti R, 2017, CLIN CHEM LAB MED, V55, P1360, DOI 10.1515/cclm-2016-0843
   Squitti R, 2014, ANN NEUROL, V75, P574, DOI 10.1002/ana.24136
   Squitti R, 2013, REJUV RES, V16, P3, DOI 10.1089/rej.2012.1357
   Squitti R, 2012, J TRACE ELEM MED BIO, V26, P93, DOI 10.1016/j.jtemb.2012.04.012
   Squitti Rosanna, 2010, Int J Alzheimers Dis, V2011, P231595, DOI 10.4061/2011/231595
   Telegina DV, 2019, BMC MED GENOMICS, V12, DOI 10.1186/s12920-019-0493-8
   Testa G, 2021, PHARMACOL RES, V169, DOI 10.1016/j.phrs.2021.105662
   Tirassa P, 2011, ARCH ITAL BIOL, V149, P205, DOI 10.4449/aib.v149i1.1359
   Tirassa P, 2018, METHODS MOL BIOL, V1727, P19, DOI 10.1007/978-1-4939-7571-6_2
   Tosi G, 2020, EXPERT OPIN DRUG DEL, V17, P23, DOI 10.1080/17425247.2020.1698544
   Tsiloulis AN, 2016, OPHTHALMIC GENET, V37, P339, DOI 10.3109/13816810.2015.1045525
   Tuszynski MH, 2015, JAMA NEUROL, V72, P1139, DOI 10.1001/jamaneurol.2015.1807
   Tuszynski MH, 2000, CELL TRANSPLANT, V9, P629, DOI 10.1177/096368970000900508
   Tuszynski MH, 2005, NAT MED, V11, P551, DOI 10.1038/nm1239
   TUSZYNSKI MH, 1990, J NEUROSCI, V10, P3604
   Ugarte M, 2013, SURV OPHTHALMOL, V58, P585, DOI 10.1016/j.survophthal.2012.12.002
   Umeda T, 2011, J NEUROSCI RES, V89, P1031, DOI 10.1002/jnr.22640
   Usui H, 2019, J CELL SCI, V132, DOI 10.1242/jcs.215798
   Ventriglia M, 2015, J ALZHEIMERS DIS, V46, P75, DOI 10.3233/JAD-141296
   Wahlberg LU, 2012, J NEUROSURG, V117, P340, DOI 10.3171/2012.2.JNS11714
   Walsh DM, 2004, NEURON, V44, P181, DOI 10.1016/j.neuron.2004.09.010
   Wang L, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0010329
   Wang L, 2021, INT J MOL SCI, V22, DOI 10.3390/ijms22052360
   Wang ZX, 2015, J ALZHEIMERS DIS, V47, P565, DOI 10.3233/JAD-143108
   Wen LY, 2021, PLOS ONE, V16, DOI 10.1371/journal.pone.0250440
   White AR, 1999, J NEUROSCI, V19, P9170
   Williams MA, 2014, J ALZHEIMERS DIS, V42, P909, DOI 10.3233/JAD-140243
   Wills NK, 2008, EXP EYE RES, V86, P41, DOI 10.1016/j.exer.2007.09.005
   Wong E, 2010, NAT NEUROSCI, V13, P805, DOI 10.1038/nn.2575
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
   Woo SJ, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0132771
   Wu EW, 2014, ENVIRON RES, V133, P178, DOI 10.1016/j.envres.2014.05.023
   Wu S, 2008, PATHOBIOLOGY, V75, P186, DOI 10.1159/000124979
   Xu QY, 2018, LIPIDS HEALTH DIS, V17, DOI 10.1186/s12944-017-0647-7
   Yang CY, 2009, BIOMATERIALS, V30, P2881, DOI 10.1016/j.biomaterials.2009.01.056
   Yao D, 2018, BRAIN RES BULL, V143, P1, DOI 10.1016/j.brainresbull.2018.09.003
   Yu HT, 2018, TOXICOL SCI, V164, P250, DOI 10.1093/toxsci/kfy082
   Zhao YZ, 2016, ACTA BIOMATER, V29, P71, DOI 10.1016/j.actbio.2015.10.014
   Zhu JH, 2012, HISTOL HISTOPATHOL, V27, P537, DOI 10.14670/HH-27.537
NR 233
TC 3
Z9 5
U1 4
U2 12
PU FRONTIERS MEDIA SA
PI LAUSANNE
PA AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND
EI 1662-453X
J9 FRONT NEUROSCI-SWITZ
JI Front. Neurosci.
PD SEP 9
PY 2021
VL 15
AR 735928
DI 10.3389/fnins.2021.735928
PG 17
WC Neurosciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Neurosciences & Neurology
GA UU2PI
UT WOS:000698642900001
PM 34566573
OA Green Published, gold
DA 2022-11-30
ER

PT J
AU Liu, YT
   Yang, JY
   Zhou, Y
   Wang, WS
   Zhao, JC
   Yu, WH
   Zhang, DD
   Ding, DY
   Li, XR
   Chen, YX
AF Liu, Yutong
   Yang, Jingyuan
   Zhou, Yang
   Wang, Weisen
   Zhao, Jianchun
   Yu, Weihong
   Zhang, Dingding
   Ding, Dayong
   Li, Xirong
   Chen, Youxin
TI Prediction of OCT images of short-term response to anti-VEGF treatment
   for neovascular age-related macular degeneration using generative
   adversarial network
SO BRITISH JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
ID RANIBIZUMAB; AFLIBERCEPT
AB Background/aims The aim of this study was to generate and evaluate individualised post-therapeutic optical coherence tomography (OCT) images that could predict the short-term response of antivascular endothelial growth factor therapy for typical neovascular age-related macular degeneration (nAMD) based on pretherapeutic images using generative adversarial network (GAN).
   Methods A total of 476 pairs of pretherapeutic and post-therapeutic OCT images of patients with nAMD were included in training set, while 50 pretherapeutic OCT images were included in the tests set retrospectively, and their corresponding post-therapeutic OCT images were used to evaluate the synthetic images. The pix2pixHD method was adopted for image synthesis. Three experiments were performed to evaluate the quality, authenticity and predictive power of the synthetic images by retinal specialists.
   Results We found that 92% of the synthetic OCT images had sufficient quality for further clinical interpretation. Only about 26%-30% synthetic post-therapeutic images could be accurately identified as synthetic images. The accuracy to predict macular status of wet or dry was 0.85 (95% CI 0.74 to 0.95).
   Conclusion Our results revealed a great potential of GAN to generate post-therapeutic OCT images with both good quality and high accuracy.
C1 [Liu, Yutong; Yang, Jingyuan; Yu, Weihong; Chen, Youxin] Peking Union Med Coll Hosp, Ophthalmol, Beijing 100730, Peoples R China.
   [Liu, Yutong; Yang, Jingyuan; Yu, Weihong; Chen, Youxin] Chinese Acad Med Sci, Key Lab Ocular Fundus Dis, Beijing, Peoples R China.
   [Zhou, Yang; Zhao, Jianchun; Ding, Dayong] Visionary Intelligence Ltd, Vistel AI Lab, Beijing, Peoples R China.
   [Wang, Weisen; Li, Xirong] Renmin Univ China, Key Lab DEKE, Beijing, Peoples R China.
   [Zhang, Dingding] Peking Union Med Coll Hosp, Cent Res Lab, Beijing, Peoples R China.
C3 Chinese Academy of Medical Sciences - Peking Union Medical College;
   Peking Union Medical College Hospital; Chinese Academy of Medical
   Sciences - Peking Union Medical College; Renmin University of China;
   Chinese Academy of Medical Sciences - Peking Union Medical College;
   Peking Union Medical College Hospital
RP Yu, WH; Chen, YX (通讯作者)，Peking Union Med Coll Hosp, Ophthalmol, Beijing 100730, Peoples R China.
EM yuwh@pumch.cn; chenyx@pumch.cn
RI Li, Xirong/AAD-3347-2019
OI Li, Xirong/0000-0002-0220-8310; Chen, Youxin/0000-0002-7231-5058
FU Chinese Academy of Medical Sciences Initiative for Innovative Medicine
   (CAMS-I2M) [2018-I2M-AI 001]; Pharmaceutical collaborative innovation
   project of Beijing Science and Technology Commission [Z191100007719002];
   National Key Research and Development Project [SQ2018YFC200148];
   National Natural Science Foundation of China (NSFC) [81670879]; Beijing
   Natural Science Foundation [4202033]
FX Chinese Academy of Medical Sciences Initiative for Innovative Medicine
   (CAMS-I2M, 2018-I2M-AI 001). Pharmaceutical collaborative innovation
   project of Beijing Science and Technology Commission (Z191100007719002).
   National Key Research and Development Project (SQ2018YFC200148).
   National Natural Science Foundation of China (NSFC) (81670879). Beijing
   Natural Science Foundation (4202033)
CR Amoaku WM, 2015, EYE, V29, P721, DOI 10.1038/eye.2015.48
   [Anonymous], 2018, IEEE C COMP VIS PATT
   [Anonymous], 2017, IEEE C COMP VIS PATT
   Ashraf M, 2018, ACTA OPHTHALMOL, V96, P120, DOI 10.1111/aos.13565
   BIRD AEC, 1995, SURV OPHTHALMOL, V39, P367, DOI 10.1016/S0039-6257(05)80092-X
   Bogunovic H, 2017, INVEST OPHTH VIS SCI, V58, P3240, DOI 10.1167/iovs.16-21053
   Busbee BG, 2013, OPHTHALMOLOGY, V120, P1046, DOI 10.1016/j.ophtha.2012.10.014
   Ferrara N, 2003, NAT MED, V9, P669, DOI 10.1038/nm0603-669
   Gharbiya M, 2018, CURR EYE RES, V43, P391, DOI 10.1080/02713683.2017.1405045
   Goodfellow IJ, 2014, ADV NEUR IN, V27, P2672
   Klein R, 2010, ARCH OPHTHALMOL-CHIC, V128, P750, DOI 10.1001/archophthalmol.2010.92
   Maguire MG, 2016, OPHTHALMOLOGY, V123, P1751, DOI 10.1016/j.ophtha.2016.03.045
   Ophthalmology Aao, 2015, SEC AG REL MAC DEG P
   Organization GWH, 2004, PREV BLINDN VIS IMP
   Prahs P, 2018, GRAEF ARCH CLIN EXP, V256, P91, DOI 10.1007/s00417-017-3839-y
   Saito M, 2017, JPN J OPHTHALMOL, V61, P74, DOI 10.1007/s10384-016-0478-5
   Schmidt-Erfurth U, 2018, PROG RETIN EYE RES, V67, P1, DOI 10.1016/j.preteyeres.2018.07.004
   Schmidt-Erfurth U, 2016, PROG RETIN EYE RES, V50, P1, DOI 10.1016/j.preteyeres.2015.07.007
   Schmidt-Erfurth U, 2014, BRIT J OPHTHALMOL, V98, P1144, DOI 10.1136/bjophthalmol-2014-305702
   Sharma S, 2016, OPHTHALMOLOGY, V123, P865, DOI 10.1016/j.ophtha.2015.12.002
   Solomon SD, 2014, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD005139.pub3
   Yamamoto A, 2017, OPHTHALMOLOGICA, V237, P139, DOI 10.1159/000458538
   Zou Hai-dong, 2005, Zhonghua Yan Ke Za Zhi, V41, P15
NR 23
TC 13
Z9 14
U1 4
U2 13
PU BMJ PUBLISHING GROUP
PI LONDON
PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND
SN 0007-1161
EI 1468-2079
J9 BRIT J OPHTHALMOL
JI Br. J. Ophthalmol.
PD DEC
PY 2020
VL 104
IS 12
BP 1735
EP 1740
DI 10.1136/bjophthalmol-2019-315338
PG 6
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA PN2OL
UT WOS:000604324100016
PM 32217538
DA 2022-11-30
ER

PT J
AU Murjaneh, S
   Garcia-Finana, M
   Mahmood, S
   Lenfestey, PM
   Taylor, SA
   Pearce, IA
   Briggs, MC
   Heimann, H
   Harding, SP
AF Murjaneh, S.
   Garcia-Finana, M.
   Mahmood, S.
   Lenfestey, P. M.
   Taylor, S. A.
   Pearce, I. A.
   Briggs, M. C.
   Heimann, H.
   Harding, S. P.
TI Observational prospective study of the effectiveness in routine clinical
   practice of verteporfin photodynamic therapy in patients with
   neovascular age-related macular degeneration
SO BRITISH JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
ID RANIBIZUMAB; MACULOPATHY; PREVALENCE
AB Aims: To investigate effectiveness in routine clinical practice of verteporfin photodynamic therapy (PDT) for neovascular age-related macular degeneration (nAMD).
   Patients and methods: Patients commencing PDT for nAMD in a single UK centre entered a prospective observational 7-year study and were followed for 2 years. Best-corrected visual acuity (BCVA) and contrast sensitivity (CS) were measured at each visit by accredited technicians after full protocol refraction on standardised charts. Reasons for failure to complete the course of therapy were documented.
   Results: 1008 patients entered the study between 1999 and 2006. 81% and 52% completed 12 and 24 months' follow-up respectively (excluding administrative censoring). Results at 12 and 24 months respectively were: maintenance of BCVA 62%, 63%; drop in mean BCVA (letters) 10.1, 9.4; numbers of treatments 2.9, 3.5. The mean CS remained stable. No correlation of change in BCVA outcome between first and second treated eyes in 82 bilateral cases was detected. Loss to follow-up was significantly associated with age, CS and distance from the treating centre.
   Conclusions: PDT delivered in clinical practice is at least as effective as that reported in randomised clinical trials and uses fewer treatments.
C1 [Murjaneh, S.; Mahmood, S.; Lenfestey, P. M.; Taylor, S. A.; Pearce, I. A.; Briggs, M. C.; Heimann, H.; Harding, S. P.] Royal Liverpool Univ Hosp, St Pauls Eye Unit, Liverpool L7 8XP, Merseyside, England.
   [Garcia-Finana, M.] Univ Liverpool, Ctr Med Stat & Hlth Evaluat, Liverpool L69 3BX, Merseyside, England.
C3 Royal Liverpool & Broadgreen University Hospitals NHS Trust; Royal
   Liverpool University Hospital; University of Liverpool; University of
   Liverpool
RP Harding, SP (通讯作者)，Royal Liverpool Univ Hosp, St Pauls Eye Unit, Prescot St, Liverpool L7 8XP, Merseyside, England.
EM s.p.harding@liverpool.ac.uk
RI Heimann, Heinrich/AAP-8747-2020
OI Heimann, Heinrich/0000-0002-3298-4644; Harding,
   Simon/0000-0003-4676-1158
CR [Anonymous], 1991, OPHTHALMOLOGY, V98, P741
   Barnes RM, 2004, EYE, V18, P809, DOI 10.1038/sj.eye.6701329
   Blumenkranz MS, 2001, ARCH OPHTHALMOL-CHIC, V119, P198
   BRESSLER NM, 1988, SURV OPHTHALMOL, V32, P375, DOI 10.1016/0039-6257(88)90052-5
   Bressler NM, 2002, ARCH OPHTHALMOL-CHIC, V120, P1307
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Buggage RR, 1999, ARCH OPHTHALMOL-CHIC, V117, P1239
   FINE SL, 1982, ARCH OPHTHALMOL-CHIC, V100, P912
   Gragoudas ES, 2004, NEW ENGL J MED, V351, P2805, DOI 10.1056/NEJMoa042760
   KLEIN R, 1992, OPHTHALMOLOGY, V99, P933
   McClure ME, 2000, BRIT J OPHTHALMOL, V84, P244, DOI 10.1136/bjo.84.3.244
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Smith DH, 2004, BRIT J OPHTHALMOL, V88, P1107, DOI 10.1136/bjo.2003.023986
   VINGERLING JR, 1995, OPHTHALMOLOGY, V102, P205
NR 14
TC 4
Z9 4
U1 0
U2 2
PU BMJ PUBLISHING GROUP
PI LONDON
PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND
SN 0007-1161
EI 1468-2079
J9 BRIT J OPHTHALMOL
JI Br. J. Ophthalmol.
PD APR
PY 2009
VL 93
IS 4
BP 468
EP 473
DI 10.1136/bjo.2008.141366
PG 6
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 424BI
UT WOS:000264540100014
PM 19074914
DA 2022-11-30
ER

PT J
AU Lee, H
   Jo, A
   Kim, HC
AF Lee, Hyungwoo
   Jo, Aerin
   Kim, Hyung Chan
TI Three-Dimensional Analysis of Morphologic Changes and Visual Outcomes in
   Neovascular Age-Related Macular Degeneration
SO INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE
LA English
DT Article
DE three-dimension; age-related macular degeneration; optical coherence
   tomography
ID OPTICAL COHERENCE TOMOGRAPHY; ENDOTHELIAL GROWTH-FACTOR; POLYPOIDAL
   CHOROIDAL VASCULOPATHY; SUBRETINAL HYPERREFLECTIVE MATERIAL;
   RETINAL-PIGMENT EPITHELIUM; RANIBIZUMAB THERAPY; TREATMENTS TRIALS;
   ACUITY; RELEVANT; EDEMA
AB PURPOSE. To investigate the association of three-dimensionally quantified lesions with bestcorrected visual acuity (BCVA) in typical neovascular age-related macular degeneration (nAMD).
   METHODS. We retrospectively analyzed 65 eyes of 61 typical nAMD patients. Lesions at baseline and month 12 were manually delineated in optical coherence tomography. The volume of intraretinal fluid (IRF), subretinal fluid (SRF), subretinal hyperreflective material (SHRM), and pigment epithelial detachment (PED) were measured. In addition, the areas of external limiting membrane (ELM) and ellipsoid zone (EZ) were calculated.
   RESULTS. At baseline, poor baseline BCVA was associated with increased volume of IRF and SHRM and impaired area of ELM (beta = 0.34, P = 0.001; b = 0.46, P < 0.001; and b = -0.23, P = 0.03, respectively). At month 12, poor BCVA was associated with increased volume of IRF, reduced intact ELM area, and decreased EZ area (beta = 0.24, P = 0.01; b = -0.30, P = 0.02; and b = -0.37, P = 0.004, respectively). Baseline BCVA, volume of IRF, and intact area of ELM were significant predictors for BCVA at month 12 (beta = 0.29, P = 0.01; b = 0.30, P = 0.01; and b = -0.28, P = 0.01). Changes of BCVA were associated with changes of SHRM volume, intact EZ area, and ELM area (beta = 0.35, P = 0.002; b = -0.28, P = 0.01; and b = -0.22, P = 0.048, respectively). The predictive power of volumetric analysis was higher than that of qualitative analysis (R-2 = 0.47 vs. R-2 = 0.37). The volume of SRF and fibrovascular PED showed positive and negative effect on visual outcome each, but they were not strong enough to remain in multivariate model.
   CONCLUSIONS. Best-corrected visual acuity could be explained by three-dimensional optical coherence tomography morphology to a fair degree. In addition, three-dimensional analysis could predict visual outcomes better than qualitative analysis.
C1 [Lee, Hyungwoo; Jo, Aerin; Kim, Hyung Chan] Konkuk Univ, Med Ctr, Dept Ophthalmol, Seoul, South Korea.
C3 Konkuk University; Konkuk University Medical Center
RP Kim, HC (通讯作者)，Konkuk Univ, Med Ctr, 120-1 Neungdong Ro, Seoul 05030, South Korea.
EM eyekim@kuh.ac.kr
CR Amin RH, 1997, INVEST OPHTH VIS SCI, V38, P36
   Charafeddin W, 2015, OSLI RETINA, V46, P523, DOI 10.3928/23258160-20150521-03
   Chiu SJ, 2015, BIOMED OPT EXPRESS, V6, P1172, DOI 10.1364/BOE.6.001172
   Chiu SJ, 2012, INVEST OPHTH VIS SCI, V53, P53, DOI 10.1167/iovs.11-7640
   Coscas F, 2007, AM J OPHTHALMOL, V144, P592, DOI 10.1016/j.ajo.2007.06.014
   Dahrouj M, 2014, INVEST OPHTH VIS SCI, V55, P2269, DOI 10.1167/iovs.13-13334
   Eichler W, 2004, NEUROREPORT, V15, P1633, DOI 10.1097/01.wnr.0000133071.00786.a4
   Fedorov A, 2012, MAGN RESON IMAGING, V30, P1323, DOI 10.1016/j.mri.2012.05.001
   Ferreira A, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0133968
   Golbaz I, 2011, INVEST OPHTH VIS SCI, V52, P1599, DOI 10.1167/iovs.09-5018
   Guidry C, 2002, INVEST OPHTH VIS SCI, V43, P267
   Inoue M, 2013, RETINA-J RET VIT DIS, V33, P990, DOI 10.1097/IAE.0b013e3182755793
   Jaffe GJ, 2013, OPHTHALMOLOGY, V120, P1860, DOI 10.1016/j.ophtha.2013.01.073
   Keane PA, 2009, INVEST OPHTH VIS SCI, V50, P3378, DOI 10.1167/iovs.08-2728
   Kim JH, 2016, GRAEF ARCH CLIN EXP, V254, P2101, DOI 10.1007/s00417-016-3353-7
   Lee JH, 2016, GRAEF ARCH CLIN EXP, V254, P645, DOI 10.1007/s00417-015-3092-1
   Mathew R, 2013, AM J OPHTHALMOL, V155, P720, DOI 10.1016/j.ajo.2012.11.003
   Oishi A, 2010, AM J OPHTHALMOL, V150, P27, DOI 10.1016/j.ajo.2010.02.012
   Pelosini L, 2011, INVEST OPHTH VIS SCI, V52, P2741, DOI 10.1167/iovs.09-4493
   Rasband WS, IMAGEJ VERSION 1 50
   Ristau T, 2013, J CLIN EXP OPHTHALMO, V4, p264J, DOI DOI 10.4172/2155-9570.1000264
   Ritter M, 2014, BRIT J OPHTHALMOL, V98, P1629, DOI 10.1136/bjophthalmol-2014-305186
   Roberts P, 2014, INVEST OPHTH VIS SCI, V55, DOI 10.1167/iovs.14-14293
   Schmidt-Erfurth U, 2015, OPHTHALMOLOGY, V122, P822, DOI 10.1016/j.ophtha.2014.11.017
   Seddon Johanna M., 2004, International Ophthalmology Clinics, V44, P17, DOI 10.1097/00004397-200404440-00004
   Shin HJ, 2011, RETINA-J RET VIT DIS, V31, P1627, DOI 10.1097/IAE.0b013e31820d3d01
   Simader C, 2014, OPHTHALMOLOGY, V121, P1237, DOI 10.1016/j.ophtha.2013.12.029
   Spaide RF, 2016, RETINA-J RET VIT DIS, V36, P1823, DOI 10.1097/IAE.0000000000001158
   Staurenghi G, 2014, OPHTHALMOLOGY, V121, P1572, DOI 10.1016/j.ophtha.2014.02.023
   Waldstein SM, 2016, OPHTHALMOLOGY, V123, P1521, DOI 10.1016/j.ophtha.2016.03.037
   Waldstein SM, 2016, JAMA OPHTHALMOL, V134, P182, DOI 10.1001/jamaophthalmol.2015.4948
   Willoughby AS, 2015, OPHTHALMOLOGY, V122, P1846, DOI 10.1016/j.ophtha.2015.05.042
   Wong CW, 2016, PROG RETIN EYE RES, V53, P107, DOI 10.1016/j.preteyeres.2016.04.002
   Ying GS, 2013, OPHTHALMOLOGY, V120, P122, DOI 10.1016/j.ophtha.2012.07.042
NR 34
TC 14
Z9 14
U1 1
U2 2
PU ASSOC RESEARCH VISION OPHTHALMOLOGY INC
PI ROCKVILLE
PA 12300 TWINBROOK PARKWAY, ROCKVILLE, MD 20852-1606 USA
SN 0146-0404
EI 1552-5783
J9 INVEST OPHTH VIS SCI
JI Invest. Ophthalmol. Vis. Sci.
PD FEB
PY 2017
VL 58
IS 2
DI 10.1167/iovs.16-20637
PG 9
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA EO8LC
UT WOS:000396939600074
PM 28241322
OA gold
DA 2022-11-30
ER

PT J
AU Chen, JQ
   Zhao, L
   Ding, XH
   Wen, Y
   Wang, LD
   Shu, QX
   Xie, WX
   Liu, YY
   Peng, H
AF Chen, Jinquan
   Zhao, Long
   Ding, Xuanheng
   Wen, Yan
   Wang, Lingda
   Shu, Qinxin
   Xie, Wenxi
   Liu, Yanyao
   Peng, H.
TI A beta 1-40 Oligomers Trigger Neutrophil Extracellular Trap Formation
   through TLR4-and NADPH Oxidase-Dependent Pathways in Age-Related Macular
   Degeneration
SO OXIDATIVE MEDICINE AND CELLULAR LONGEVITY
LA English
DT Article
ID BETA; INHIBITION
AB Neutrophils participate in the advancement of the human innate immune system and respond to perceived endogenous and exogenous threats. As a response mechanism, neutrophil extracellular traps (NETs) form near pathogens and surrounding tissues during an immune response. Drusen is an important marker of Age-Related Macular Degeneration (AMD) and plays an important role in the course of AMD. A beta 1-40 is the main component of drusen. However, the relationship between NETs and AMD or A beta 1-40 is unclear. Here, we found elevated levels of NETs in the serum of AMD patients and elevated levels in the serum of mouse models. We also observed the accumulation of neutrophils in the mouse retina. In addition, the production of NETs was inhibited by PAD4 inhibitors, which can alleviate chronic inflammation. Moreover, we confirmed that A beta 1-40 can induce NETs formation via the Toll-like receptor 4 (TLR4) and neutrophil NADPH oxidase (NOX) pathways. Our study confirmed that the formation of NETs is induced by A beta 1-40, and the results suggest that NETs may play a vital role in AMD pathogenesis.
C1 [Chen, Jinquan; Zhao, Long; Ding, Xuanheng; Wen, Yan; Wang, Lingda; Shu, Qinxin; Xie, Wenxi; Liu, Yanyao; Peng, H.] Chongqing Med Univ, Dept Ophthalmol, Affiliated Hosp 1, Chongqing, Peoples R China.
   [Chen, Jinquan; Zhao, Long; Ding, Xuanheng; Wen, Yan; Wang, Lingda; Shu, Qinxin; Xie, Wenxi; Liu, Yanyao; Peng, H.] Chongqing Eye Inst, Chongqing Key Lab Ophthalmol, Chongqing, Peoples R China.
C3 Chongqing Medical University
RP Peng, H (通讯作者)，Chongqing Med Univ, Dept Ophthalmol, Affiliated Hosp 1, Chongqing, Peoples R China.; Peng, H (通讯作者)，Chongqing Eye Inst, Chongqing Key Lab Ophthalmol, Chongqing, Peoples R China.
EM chenj187@163.com; 1434171091@qq.com; 280943648@qq.com; 945264822@qq.com;
   1105881311@qq.com; 595287635@qq.com; xiewenxi128@163.com;
   liuyanyao147@sina.com; pengh9@sina.com
FU National Natural Science Foundation of China [81670881]
FX AcknowledgmentsThis study was supported by funds from the National
   Natural Science Foundation of China (81670881).
CR Estua-Acosta GA, 2019, CELLS-BASEL, V8, DOI 10.3390/cells8090979
   Castanheira FVS, 2019, BLOOD, V133, P2178, DOI 10.1182/blood-2018-11-844530
   Chen X, 2021, IMMUNOL INVEST, V50, P544, DOI 10.1080/08820139.2020.1778720
   Dong YL, 2021, PEDIATR RES, V89, P785, DOI 10.1038/s41390-020-0964-9
   Edwards NJ, 2020, FASEB J, V34, P15753, DOI 10.1096/fj.202000994RR
   Enache TA, 2016, ANAL CHIM ACTA, V926, P36, DOI 10.1016/j.aca.2016.04.015
   Fine N, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.571085
   Fritsche LG, 2014, ANNU REV GENOM HUM G, V15, P151, DOI 10.1146/annurev-genom-090413-025610
   Gao JY, 2018, J NEUROINFLAMM, V15, DOI 10.1186/s12974-018-1062-3
   Ghosh S, 2019, COMMUN BIOL, V2, DOI 10.1038/s42003-019-0588-y
   Hakkim A, 2010, P NATL ACAD SCI USA, V107, P9813, DOI 10.1073/pnas.0909927107
   Kenny EF, 2017, ELIFE, V6, DOI [10.7554/eLife.24437, 10.7554/elife.24437]
   Klopf J, 2021, INT J MOL SCI, V22, DOI 10.3390/ijms22020559
   Lashkari K, 2020, PLOS ONE, V15, DOI 10.1371/journal.pone.0236283
   Lee W, 2019, J EXP MED, V216, P176, DOI 10.1084/jem.20181170
   Lei CY, 2017, NEUROSCIENCE, V360, P48, DOI 10.1016/j.neuroscience.2017.07.053
   Lewis HD, 2015, NAT CHEM BIOL, V11, P189, DOI 10.1038/nchembio.1735
   Liu CQ, 2015, INT J MOL MED, V35, P169, DOI 10.3892/ijmm.2014.1993
   Naaman E, 2020, SCI REP-UK, V10, DOI 10.1038/s41598-020-77712-9
   Niazi S, 2019, ACTA OPHTHALMOL, V97, P558, DOI 10.1111/aos.14072
   Papayannopoulos V, 2018, NAT REV IMMUNOL, V18, P134, DOI 10.1038/nri.2017.105
   Pieterse E, 2016, FRONT IMMUNOL, V7, DOI 10.3389/fimmu.2016.00484
   Ravindran M, 2019, BIOMOLECULES, V9, DOI 10.3390/biom9080365
   Rezar-Dreindl S, 2016, INVEST OPHTH VIS SCI, V57, P4144, DOI 10.1167/iovs.16-19772
   Roos TT, 2021, ACTA NEUROPATHOL, V142, P669, DOI 10.1007/s00401-021-02345-9
   Sun JR, 2020, THERANOSTICS, V10, P11637, DOI 10.7150/thno.48064
   Toomey CB, 2018, PROG RETIN EYE RES, V62, P38, DOI 10.1016/j.preteyeres.2017.09.001
   van der Windt DJ, 2018, HEPATOLOGY, V68, P1347, DOI 10.1002/hep.29914
   Virgili G, 2015, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD006537.pub3
   Wang JY, 2021, FRONT CELL INFECT MI, V11, DOI 10.3389/fcimb.2021.639144
   Wang K, 2017, J BIOCHEM MOL TOXIC, V31, DOI 10.1002/jbt.21887
   Wang LZY, 2019, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.03076
   Zhou X, 2020, CELLS-BASEL, V9, DOI 10.3390/cells9020373
NR 33
TC 0
Z9 0
U1 2
U2 2
PU HINDAWI LTD
PI LONDON
PA ADAM HOUSE, 3RD FLR, 1 FITZROY SQ, LONDON, W1T 5HF, ENGLAND
SN 1942-0900
EI 1942-0994
J9 OXID MED CELL LONGEV
JI Oxidative Med. Cell. Longev.
PD JUN 18
PY 2022
VL 2022
AR 6489923
DI 10.1155/2022/6489923
PG 15
WC Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Cell Biology
GA 2M3WR
UT WOS:000817634400003
PM 35761872
OA Green Published, gold
DA 2022-11-30
ER

PT J
AU McLaughlin, MM
   Paglione, MG
   Slakter, J
   Tolentino, M
   Ye, L
   Xu, CF
   Suttle, AB
   Kim, RY
AF McLaughlin, Megan M.
   Paglione, Marcella G.
   Slakter, Jason
   Tolentino, Michael
   Ye, Li
   Xu, Chun-Fang
   Suttle, A. Benjamin
   Kim, Robert Y.
TI Initial Exploration of Oral Pazopanib in Healthy Participants and
   Patients With Age-Related Macular Degeneration
SO JAMA OPHTHALMOLOGY
LA English
DT Article
ID GROWTH-FACTOR; RANIBIZUMAB; THERAPY; TRIAL; NEOVASCULARIZATION;
   INHIBITOR; EYE
AB IMPORTANCE Neovascular age-related macular degeneration (AMD) is managed with intravitreal anti-vascular endothelial growth factor therapy; however, the burden of care is high and alternate approaches could be beneficial.
   OBJECTIVE To identify an acceptable dose of oral pazopanib for investigation in AMD.
   DESIGN, SETTING, AND PARTICIPANTS Fourteen-day, placebo-controlled, dose-rising study in 72 healthy participants and 28-day phase 2a open-label study in 15 patients with subfoveal choroidal neovascularization secondary to AMD at a clinical unit for healthy participants and outpatient for patients with AMD.
   INTERVENTION Oral pazopanib tablets, 5 to 30 mg daily (healthy participants) and 15 mg daily (patients with AMD).
   MAIN OUTCOMES AND MEASURES Safety, pharmacokinetics, best-corrected visual acuity, central retinal lesion thickness, and central retinal thickness at day 29.
   RESULTS Oral pazopanib up to 30 mg daily in healthy participants and 15 mg daily in patients with AMD was well tolerated. Six of 15 patients received rescue therapy before day 29; all had the CFH Y402H CC "high-risk" genotype for AMD. Nine patients completed the study without rescue with improvements from baseline in best-corrected visual acuity (8 Early Treatment Diabetic Retinopathy Study letters), central retinal lesion thickness (-50.94 mu m), and central retinal thickness (-50.28 mu m). There was a trend for association between the CFH Y402H T allele ("low risk" for AMD, n = 6) and improvement.
   CONCLUSIONS AND RELEVANCE Oral pazopanib (15 mg daily) was well tolerated and resulted in improvements in mean best-corrected visual acuity, central retinal lesion thickness, and central retinal thickness at day 29 in a per-protocol, nonrescued AMD population (n = 9). It is postulated that CFH Y402H genotype may help predict which patients respond to pazopanib. The size and length limitations of this study warrant further investigation to determine if oral pazopanib may be an appropriate treatment for a subset of neovascular patients with AMD or as an adjunct to standard of care.
C1 [McLaughlin, Megan M.; Paglione, Marcella G.; Ye, Li; Kim, Robert Y.] GlaxoSmithKline, King Of Prussia, PA 19406 USA.
   [Slakter, Jason] Vitreous Retina Macula Consultants New York, New York, NY USA.
   [Tolentino, Michael] Ctr Retina & Macular Dis, Winter Haven, FL USA.
   [Xu, Chun-Fang] GlaxoSmithKline, Stevenage, Herts, England.
   [Suttle, A. Benjamin] GlaxoSmithKline, Res Triangle Pk, NC USA.
C3 GlaxoSmithKline; Vitreous Retina Macula Consultants of New York;
   GlaxoSmithKline; GlaxoSmithKline
RP McLaughlin, MM (通讯作者)，GlaxoSmithKline, 2301 Renaissance Blvd, King Of Prussia, PA 19406 USA.
EM megan.m.mclaughlin@gsk.com
OI Xu, Chun-Fang/0000-0002-8747-0683
FU GlaxoSmithKline
FX The study was financially supported by GlaxoSmithKline. Mss McLaughlin
   and Ye and Drs Paglione, Xu, Suttle, and Kim are employees of
   GlaxoSmithKline.
CR Brown D.M., 2009, OPHTHALMOLOGY, V116, pe5
   Brown DM, 2009, OPHTHALMOLOGY, V116, P57, DOI 10.1016/j.ophtha.2008.10.018
   Chen H, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0042464
   Edwards AO, 2005, SCIENCE, V308, P421, DOI 10.1126/science.1110189
   Fine SL, 2000, NEW ENGL J MED, V342, P483, DOI 10.1056/NEJM200002173420707
   Food and Drug Administration, FDA LAB INF
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P564
   Heier JS, 2012, OPHTHALMOLOGY, V119, P2537, DOI 10.1016/j.ophtha.2012.09.006
   Hurwitz HI, 2009, CLIN CANCER RES, V15, P4220, DOI 10.1158/1078-0432.CCR-08-2740
   Jo N, 2006, AM J PATHOL, V168, P2036, DOI 10.2353/ajpath.2006.050588
   Kaiser PK, 2007, OPHTHALMOLOGY, V114, P1868, DOI 10.1016/j.ophtha.2007.04.030
   Klein R, 2005, AM J OPHTHALMOL, V140, P129, DOI 10.1016/j.ajo.2004.12.049
   Kondo N, 2011, OPHTHALMOLOGY, V118, P339, DOI 10.1016/j.ophtha.2010.06.040
   Kumar R, 2007, MOL CANCER THER, V6, P2012, DOI 10.1158/1535-7163.MCT-07-0193
   Matsuoka M, 2004, BRIT J OPHTHALMOL, V88, P809, DOI 10.1136/bjo.2003.032466
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Smailhodzic D, 2012, OPHTHALMOLOGY, V119, P2304, DOI 10.1016/j.ophtha.2012.05.040
   Sternberg CN, 2010, J CLIN ONCOL, V28, P1061, DOI 10.1200/JCO.2009.23.9764
   Takahashi K, 2009, ARCH OPHTHALMOL-CHIC, V127, P494, DOI 10.1001/archophthalmol.2009.27
   Thakkinstian A, 2006, HUM MOL GENET, V15, P2784, DOI 10.1093/hmg/ddl220
   van der Graaf WTA, 2012, LANCET, V379, P1879, DOI 10.1016/S0140-6736(12)60651-5
   Zarbin MA, 2004, ARCH OPHTHALMOL-CHIC, V122, P598, DOI 10.1001/archopht.122.4.598
NR 22
TC 18
Z9 19
U1 0
U2 10
PU AMER MEDICAL ASSOC
PI CHICAGO
PA 515 N STATE ST, CHICAGO, IL 60654-0946 USA
SN 2168-6165
EI 2168-6173
J9 JAMA OPHTHALMOL
JI JAMA Ophthalmol.
PD DEC
PY 2013
VL 131
IS 12
BP 1595
EP 1601
DI 10.1001/jamaophthalmol.2013.5002
PG 7
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 291SU
UT WOS:000329850600016
PM 24113783
OA Bronze
DA 2022-11-30
ER

PT J
AU Wang, SB
   Mitchell, P
   Chiha, J
   Liew, G
   Plant, AJH
   Thiagalingam, A
   Burlutsky, G
   Gopinath, B
AF Wang, Sarah B.
   Mitchell, Paul
   Chiha, Joseph
   Liew, Gerald
   Plant, Adam J. H.
   Thiagalingam, Aravinda
   Burlutsky, George
   Gopinath, Bamini
TI Severity of coronary artery disease is independently associated with the
   frequency of early age-related macular degeneration
SO BRITISH JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
ID BLUE-MOUNTAINS-EYE; CARDIOVASCULAR RISK-FACTORS; C-REACTIVE PROTEIN;
   HEART-DISEASE; ATHEROSCLEROSIS RISK; PRIMARY PREVENTION; TERM INCIDENCE;
   UNITED-STATES; MACULOPATHY; METAANALYSIS
AB Background/aims To describe the prevalence of early, late and any age-related macular degeneration (AMD) in a clinical cohort (Australian Heart Eye Study, AHES) and to determine whether associations exist between extent and severity of coronary artery disease (CAD) and AMD, independent of traditional cardiovascular risk factors.
   Methods The AHES is an observational study that surveyed 1680 participants between 2009 and 2012 who presented to a tertiary referral hospital for the evaluation of potential CAD by coronary angiography. Severity and extent of CAD was assessed using three scoring systems: (1) segment/vessel scores, (2) Gensini and (3) extent scores.
   Results Prevalence of early and late AMD was 5.8% (n=86) and 1.4% (n=21), respectively. After multivariable adjustment, patients with stenosis >50% in any coronary artery segment (vessel score) had approximately twofold higher odds of early AMD, OR 1.95 (95% CI 1.07 to 3.57). Patients with obstructive coronary stenosis in all three main coronary arteries (segment score) had greater than twofold higher likelihood of early AMD, OR 2.67 (95% CI 1.24 to 5.78). Participants in the highest versus lowest tertile of Gensini scores were also twice as likely to have early AMD, multivariable-adjusted OR 2.27 (95% CI 1.12 to 4.58). Extent scores were not associated with AMD. There was no significant association between CAD and late AMD.
   Conclusions Severity of coronary stenosis and the presence of stenotic lesions were independently associated with early AMD. These findings could have potential clinical significance as they suggest that individuals with evidence of CAD may be screened for early AMD.
C1 [Wang, Sarah B.; Mitchell, Paul; Liew, Gerald; Plant, Adam J. H.; Burlutsky, George; Gopinath, Bamini] Univ Sydney, Dept Ophthalmol, Ctr Vis Res, Sydney, NSW 2145, Australia.
   [Wang, Sarah B.; Mitchell, Paul; Liew, Gerald; Plant, Adam J. H.; Burlutsky, George; Gopinath, Bamini] Univ Sydney, Westmead Millennium Inst, Sydney, NSW 2145, Australia.
   [Chiha, Joseph; Thiagalingam, Aravinda] Univ Sydney, Westmead Millennium Inst, Ctr Heart Res, Sydney, NSW 2145, Australia.
C3 University of Sydney; University of Sydney; Westmead Institute for
   Medical Research; University of Sydney; Westmead Institute for Medical
   Research
RP Gopinath, B (通讯作者)，Univ Sydney, Dept Ophthalmol, Ctr Vis Res, Westmead Millennium Inst,Westmead Hosp, Hawkesbury Rd, Sydney, NSW 2145, Australia.
EM bamini.gopinath@sydney.edu.au
RI Gopinath, Bamini/K-4286-2019; Liew, Gerald/AAB-6870-2022; Mitchell,
   Paul/P-1498-2014
OI Gopinath, Bamini/0000-0003-3573-359X; 
CR Cao JJ, 2007, CIRCULATION, V116, P32, DOI 10.1161/CIRCULATIONAHA.106.645606
   Chakravarthy U, 2010, BMC OPHTHALMOL, V10, DOI 10.1186/1471-2415-10-31
   Chong EWT, 2008, AM J OPHTHALMOL, V145, P707, DOI 10.1016/j.ajo.2007.12.005
   Chong EWT, 2008, ARCH OPHTHALMOL-CHIC, V126, P826, DOI 10.1001/archopht.126.6.826
   Chong EWT, 2007, BMJ-BRIT MED J, V335, P755, DOI 10.1136/bmj.39350.500428.47
   Edwards AO, 2005, SCIENCE, V308, P421, DOI 10.1126/science.1110189
   Foran S, 2003, OPHTHALMIC EPIDEMIOL, V10, P215, DOI 10.1076/opep.10.4.215.15906
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P564
   GENSINI GG, 1983, AM J CARDIOL, V51, P606, DOI 10.1016/S0002-9149(83)80105-2
   Gopinath B, 2013, AM J CLIN NUTR, V98, P129, DOI 10.3945/ajcn.112.057091
   KAHN HA, 1977, AM J EPIDEMIOL, V106, P33, DOI 10.1093/oxfordjournals.aje.a112429
   Khuddus MA, 2010, J INTERV CARDIOL, V23, P511, DOI 10.1111/j.1540-8183.2010.00598.x
   Klein R, 2003, OPHTHALMOLOGY, V110, P636, DOI 10.1016/S0161-6420(02)01448-3
   Klein R, 2003, OPHTHALMOLOGY, V110, P25, DOI 10.1016/S0161-6420(02)01565-8
   Klein R, 1999, ARCH OPHTHALMOL-CHIC, V117, P1203
   KLEIN R, 1991, OPHTHALMOLOGY, V98, P1128
   Klein R, 1999, OPHTHALMOLOGY, V106, P1056, DOI 10.1016/S0161-6420(99)90255-5
   Klein R, 2007, ARCH OPHTHALMOL-CHIC, V125, P534, DOI 10.1001/archopht.125.4.534
   Ma L, 2012, BRIT J NUTR, V107, P350, DOI 10.1017/S0007114511004260
   MERZ CNB, 2006, J AM COLL CARDIOL, V47, pS21, DOI [DOI 10.1016/J.JACC.2004.12.084, 10.1016/j.jacc.2004.12.084]
   MITCHELL P, 1995, OPHTHALMOLOGY, V102, P1450
   Neeland IJ, 2012, AM HEART J, V164, P547, DOI 10.1016/j.ahj.2012.07.007
   Norgaz T, 2005, INT HEART J, V46, P639, DOI 10.1536/ihj.46.639
   Patton N, 2006, PROG RETIN EYE RES, V25, P99, DOI 10.1016/j.preteyeres.2005.07.001
   Reynolds HR, 2011, CIRCULATION, V124, P1414, DOI 10.1161/CIRCULATIONAHA.111.026542
   RINGQVIST I, 1983, J CLIN INVEST, V71, P1854, DOI 10.1172/JCI110941
   Seddon JM, 2004, JAMA-J AM MED ASSOC, V291, P704, DOI 10.1001/jama.291.6.704
   Sianos Georgios, 2005, EuroIntervention, V1, P219
   Smith W, 1998, ARCH OPHTHALMOL-CHIC, V116, P583, DOI 10.1001/archopht.116.5.583
   Song YQ, 2004, ANN INTERN MED, V141, P137, DOI 10.7326/0003-4819-141-2-200407200-00013
   SULLIVAN DR, 1990, AM HEART J, V119, P1262, DOI 10.1016/S0002-8703(05)80173-5
   Sun C, 2009, OPHTHALMOLOGY, V116, P1913, DOI 10.1016/j.ophtha.2009.03.046
   Tan JSL, 2008, BRIT J OPHTHALMOL, V92, P509, DOI 10.1136/bjo.2007.131706
   Tan JSL, 2007, OPHTHALMOLOGY, V114, P1143, DOI 10.1016/j.ophtha.2006.09.033
   Tomany SC, 2004, OPHTHALMOLOGY, V111, P1280, DOI 10.1016/j.ophtha.2003.11.010
   VINGERLING JR, 1995, AM J EPIDEMIOL, V142, P404, DOI 10.1093/oxfordjournals.aje.a117648
   Weintraub WS, 2011, J AM COLL CARDIOL, V58, P202, DOI 10.1016/j.jacc.2011.05.001
   Wong TY, 2007, OPHTHALMOLOGY, V114, P86, DOI 10.1016/j.ophtha.2006.06.039
   Wong TY, 2006, ANN INTERN MED, V145, P98, DOI 10.7326/0003-4819-145-2-200607180-00007
NR 39
TC 15
Z9 16
U1 0
U2 2
PU BMJ PUBLISHING GROUP
PI LONDON
PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND
SN 0007-1161
EI 1468-2079
J9 BRIT J OPHTHALMOL
JI Br. J. Ophthalmol.
PD MAR
PY 2015
VL 99
IS 3
BP 365
EP 370
DI 10.1136/bjophthalmol-2014-305793
PG 6
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA CC0AU
UT WOS:000349998000016
PM 25249614
DA 2022-11-30
ER

PT J
AU Smith, BT
   Dhalla, MS
   Shah, GK
   Blinder, KJ
   Ryan, EH
   Mittra, RA
AF Smith, Bradley T.
   Dhalla, Mandeep S.
   Shah, Gaurav K.
   Blinder, Kevin J.
   Ryan, Edwin H.
   Mittra, Robert A.
TI Intravitreal injection of bevacizumab combined with verteporfin
   photodynamic therapy for choroidal neovascularization in age-related
   macular degeneration
SO RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES
LA English
DT Article
DE age-related macular degeneration; bevacizumab; choroidal
   neovascularization; intravitreal injection of triamcinolone; monoclonal
   antibody; pegaptanib; photodynamic therapy; ranibizumab; subretinal
   neovascularization; vascular endothelial growth factor; verteporfin;
   optical coherence tomography
ID COHERENCE TOMOGRAPHY FINDINGS; TRIAMCINOLONE ACETONIDE; RANIBIZUMAB;
   AVASTIN
AB Purpose: To report the outcome for eyes treated with intravitreal injection of bevacizumab combined with verteporfin photodynamic therapy (PDT) for choroidal neovascularization (CNV) in age-related macular degeneration (AMD).
   Study Design and Participants: Interventional, consecutive, retrospective case series including 40 eyes of 40 patients with newly diagnosed juxtafoveal or subfoveal CNV secondary to AMD.
   Methods: The charts of patients treated with a 1.25-mg intravitreal injection of bevacizumab followed by PDT within a 2-week period were reviewed. Main outcome measures were visual acuity stabilization (defined as no change or a gain in visual acuity) and need for retreatment.
   Results: Thirty-three (83%) of 40 eyes had stabilization of visual acuity. Mean improvement in visual acuity was 1.73 lines. Twenty-six eyes (65%) required only a single intravitreal injection of bevacizumab combined with PDT. Of the 23 eyes with 12 months of follow-up, 17 (74%) had stabilization of visual acuity, while 9 (40%) had improvement in visual acuity (mean, 1.22 Snellen lines). Eleven eyes (48%) required only a single combined treatment for CNV resolution at the 12-month follow-up. Fifteen (88%) of 17 eyes with only 6 months of follow-up required only a single combined treatment. There were no complications such as endophthalmitis, uveitis, or ocular hypertension.
   Conclusion: These findings suggest that eyes treated with both intravitreal injection of bevacizumab and PDT require none to a minimal number of re-treatments to have stabilization of vision, even at 12 months of follow-up. Further investigation with large controlled trials is warranted to outline the appropriate treatment paradigm for combination therapy.
C1 [Smith, Bradley T.; Dhalla, Mandeep S.; Shah, Gaurav K.; Blinder, Kevin J.] Barnes Retina Inst, St Louis, MO USA.
   [Smith, Bradley T.; Dhalla, Mandeep S.; Shah, Gaurav K.; Blinder, Kevin J.] Washington Univ, Sch Med, Dept Ophthalmol & Visual Sci, St Louis, MO 63110 USA.
   [Dhalla, Mandeep S.] Retina Grp Florida, Ft Lauderdale, FL USA.
   [Ryan, Edwin H.; Mittra, Robert A.] Vitreoretinal Surg PA, Edina, MN USA.
C3 Washington University (WUSTL); Washington University (WUSTL)
RP Shah, GK (通讯作者)，1600 S Brentwood Blvd,Suite 800, St Louis, MO 63144 USA.
EM gkshah1@gmail.com
RI Mittra, Robert/AAC-8249-2021; Smith, Bradley/ABB-2596-2021
CR Aggio FB, 2006, ACTA OPHTHALMOL SCAN, V84, P831, DOI 10.1111/j.1600-0420.2006.00764.x
   Arnold J, 2001, AM J OPHTHALMOL, V131, P541
   Augustin AJ, 2007, RETINA-J RET VIT DIS, V27, P133, DOI 10.1097/IAE.0b013e3180323de7
   Avery RL, 2006, OPHTHALMOLOGY, V113, P363, DOI 10.1016/j.ophtha.2005.11.019
   Bressler NM, 1999, ARCH OPHTHALMOL-CHIC, V117, P1329
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Chan WM, 2006, BRIT J OPHTHALMOL, V90, P337, DOI 10.1136/bjo.2005.081299
   Chen CY, 2007, AM J OPHTHALMOL, V143, P510, DOI 10.1016/j.ajo.2006.10.004
   Danis RP, 2000, RETINA-J RET VIT DIS, V20, P244, DOI 10.1097/00006982-200003000-00004
   Dhalla MS, 2006, RETINA-J RET VIT DIS, V26, P988, DOI 10.1097/01.iae.0000247164.70376.91
   Fung AE, 2007, AM J OPHTHALMOL, V143, P566, DOI 10.1016/j.ajo.2007.01.028
   Gragoudas ES, 2004, NEW ENGL J MED, V351, P2805, DOI 10.1056/NEJMoa042760
   Greve MDJ, 2005, ARCH OPHTHALMOL-CHIC, V123, P448
   Hashimoto Ichiro, 2002, Journal of Medical Investigation, V49, P61
   ISHIBASHI T, 1985, ARCH OPHTHALMOL-CHIC, V103, P708
   Ishida S, 2003, J EXP MED, V198, P483, DOI 10.1084/jem.20022027
   Jonas JB, 2003, BRIT J OPHTHALMOL, V87, P462, DOI 10.1136/bjo.87.4.462
   Kvanta A, 1996, INVEST OPHTH VIS SCI, V37, P1929
   MILLER JW, 2005, AM SOC RET SPEC ANN
   Moshfeghi AA, 2006, OPHTHALMOLOGY, V113, P2002, DOI 10.1016/j.ophtha.2006.05.070
   Nauck M, 1998, EUR J PHARMACOL, V341, P309, DOI 10.1016/S0014-2999(97)01464-7
   Rechtman E, 2004, BRIT J OPHTHALMOL, V88, P344, DOI 10.1136/bjo.2003.027177
   Rogers AH, 2002, AM J OPHTHALMOL, V134, P566, DOI 10.1016/S0002-9394(02)01566-0
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Rosenfeld PJ, 2005, OPHTHAL SURG LAS IM, V36, P331, DOI 10.3928/1542-8877-20050701-14
   Spaide RF, 2006, AM J OPHTHALMOL, V141, P149, DOI 10.1016/j.ajo.2005.07.025
   Spaide RF, 2005, OPHTHALMOLOGY, V112, P301, DOI 10.1016/j.ophtha.2004.08.012
   Van de Moere A, 2005, OPHTHALMOLOGY, V112, P1897, DOI 10.1016/j.ophtha.2005.06.018
NR 28
TC 38
Z9 39
U1 0
U2 0
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0275-004X
EI 1539-2864
J9 RETINA-J RET VIT DIS
JI Retin.-J. Retin. Vitr. Dis.
PD MAY
PY 2008
VL 28
IS 5
BP 675
EP 681
DI 10.1097/IAE.0b013e31816b316e
PG 7
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 302KQ
UT WOS:000255967600001
PM 18463509
DA 2022-11-30
ER

PT J
AU Choi, W
   Moult, EM
   Waheed, NK
   Adhi, M
   Lee, B
   Lu, CD
   de Carlo, TE
   Jayaraman, V
   Rosenfeld, PJ
   Duker, JS
   Fujimoto, JG
AF Choi, WooJhon
   Moult, Eric M.
   Waheed, Nadia K.
   Adhi, Mehreen
   Lee, ByungKun
   Lu, Chen D.
   de Carlo, Talisa E.
   Jayaraman, Vijaysekhar
   Rosenfeld, Philip J.
   Duker, Jay S.
   Fujimoto, James G.
TI Ultrahigh-Speed, Swept-Source Optical Coherence Tomography Angiography
   in Nonexudative Age-Related Macular Degeneration with Geographic Atrophy
SO OPHTHALMOLOGY
LA English
DT Article
ID BLOOD-FLOW; CHOROIDAL NEOVASCULARIZATION; HUMAN RETINA; SOURCE OCT;
   CHORIOCAPILLARIS; EYES; VASCULATURE; RPE
AB Purpose: To investigate ultrahigh-speed, swept-source optical coherence tomography (SSOCT) angiography for visualizing vascular changes in eyes with nonexudative age-related macular degeneration (AMD) with geographic atrophy (GA).
   Design: Observational, prospective, cross-sectional study.
   Participants: A total of 63 eyes from 32 normal subjects and 12 eyes from 7 patients with nonexudative AMD with GA.
   Methods: A 1050-nm, 400-kHz A-scan rate SSOCT system was used to perform volumetric optical coherence tomography angiography (OCTA) of the retinal and choriocapillaris (CC) vasculatures in normal subjects and patients with nonexudative AMD with GA. Optical coherence tomography angiography using variable interscan time analysis (VISTA) was performed to assess CC alteration and differentiate varying degrees of CC flow impairment. Main Outcome Measures: Qualitative comparison of retinal and CC vasculatures in normal subjects versus those in patients with a clinical diagnosis of nonexudative AMD with GA.
   Results: In all 12 eyes with GA, OCTA showed pronounced CC flow impairment within the region of GA. In 10 of the 12 eyes with GA, OCTA with VISTA showed milder CC flow impairment extending beyond the margin of GA. Of the 5 eyes exhibiting foveal-sparing GA, OCTA showed CC flow within the region of foveal sparing in 4 of the eyes.
   Conclusions: The ability of ultrahigh-speed, swept-source OCTA to noninvasively visualize alterations in the retinal and CC vasculatures makes it a promising tool for assessing nonexudative AMD with GA. Optical coherence tomography angiography using VISTA can distinguish varying degrees of CC alteration and flow impairment and may be useful for elucidating disease pathogenesis, progression, and response to therapy. Ophthalmology 2015; 122:2532-2544 (C) 2015 by the American Academy of Ophthalmology.
C1 [Choi, WooJhon; Moult, Eric M.; Lee, ByungKun; Lu, Chen D.; Fujimoto, James G.] MIT, Dept Elect Engn & Comp Sci, Cambridge, MA 02139 USA.
   [Choi, WooJhon; Moult, Eric M.; Lee, ByungKun; Lu, Chen D.; Fujimoto, James G.] MIT, Elect Res Lab, Cambridge, MA 02139 USA.
   [Moult, Eric M.] Harvard Massachusetts Inst Technol, Div Hlth Sci & Technol, Cambridge, MA USA.
   [Waheed, Nadia K.; Adhi, Mehreen; de Carlo, Talisa E.; Duker, Jay S.] Tufts Univ, Med Ctr, New England Eye Ctr, Boston, MA 02111 USA.
   [Jayaraman, Vijaysekhar] Praevium Res Inc, Santa Barbara, CA USA.
   [Rosenfeld, Philip J.] Univ Miami, Miller Sch Med, Bascom Palmer Eye Inst, Dept Ophthalmol, Miami, FL 33136 USA.
C3 Massachusetts Institute of Technology (MIT); Massachusetts Institute of
   Technology (MIT); Harvard University; Tufts University; Bascom Palmer
   Eye Institute; University of Miami
RP Fujimoto, JG (通讯作者)，MIT, Dept Elect Engn & Comp Sci, 77 Massachusetts Ave,36-345, Cambridge, MA 02139 USA.
EM jgfuji@mit.edu
RI Jayaraman, Vijaysekhar/GLR-7595-2022; Moult, Eric/G-1099-2017; Adhi,
   Mehreen/AAS-9733-2021
OI Moult, Eric/0000-0003-3859-3094; 
FU National Institutes of Health [R01-EY011289-27, R44-EY022864-01,
   R44-EY022864-02, R01-CA075289-16]; Air Force Office of Scientific
   Research [FA9550-10-1-0551, FA9550-12-1-0499]; Samsung Scholarship;
   Natural Sciences and Engineering Research Council of Canada Scholarship;
   NATIONAL CANCER INSTITUTE [R01CA075289] Funding Source: NIH RePORTER;
   NATIONAL EYE INSTITUTE [R01EY011289, R44EY022864] Funding Source: NIH
   RePORTER
FX Supported by the National Institutes of Health (grants nos.
   R01-EY011289-27, R44-EY022864-01, R44-EY022864-02, R01-CA075289-16), Air
   Force Office of Scientific Research (FA9550-10-1-0551 and
   FA9550-12-1-0499), a Samsung Scholarship, and a Natural Sciences and
   Engineering Research Council of Canada Scholarship.
CR Abbey AM, 2015, OSLI RETINA, V46, P18, DOI 10.3928/23258160-20150101-03
   An L, 2008, OPT EXPRESS, V16, P11438, DOI 10.1364/OE.16.011438
   Bhutto I, 2012, MOL ASPECTS MED, V33, P295, DOI 10.1016/j.mam.2012.04.005
   Biesemeier A, 2014, NEUROBIOL AGING, V35, P2562, DOI 10.1016/j.neurobiolaging.2014.05.003
   Bird AC, 2014, JAMA OPHTHALMOL, V132, P338, DOI 10.1001/jamaophthalmol.2013.5799
   BISCHOFF PM, 1985, DOC OPHTHALMOL, V60, P235, DOI 10.1007/BF00157827
   Blatter C, 2012, J BIOMED OPT, V17, DOI 10.1117/1.JBO.17.7.070505
   Choi W, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0081499
   Choi W, 2013, OPT LETT, V38, P338, DOI 10.1364/OL.38.000338
   Fingler J, 2007, OPT EXPRESS, V15, P12636, DOI 10.1364/OE.15.012636
   Fleckenstein M, 2008, INVEST OPHTH VIS SCI, V49, P4137, DOI 10.1167/iovs.08-1967
   FLOWER RW, 1993, INVEST OPHTH VIS SCI, V34, P2720
   Flower RW, 2001, AM J OPHTHALMOL, V132, P85, DOI 10.1016/S0002-9394(01)00872-8
   Grulkowski I, 2012, BIOMED OPT EXPRESS, V3, P2733, DOI 10.1364/BOE.3.002733
   Guizar-Sicairos M, 2008, OPT LETT, V33, P156, DOI 10.1364/OL.33.000156
   Jonathan E, 2011, DYNAMICS FLUCTUATION
   Kim DY, 2013, P NATL ACAD SCI USA, V110, P14354, DOI 10.1073/pnas.1307315110
   Makita S, 2006, OPT EXPRESS, V14, P7821, DOI 10.1364/OE.14.007821
   Makita S, 2011, OPT EXPRESS, V19, P1271, DOI 10.1364/OE.19.001271
   Mariampillai A, 2008, OPT LETT, V33, P1530, DOI 10.1364/OL.33.001530
   McLeod DS, 2009, INVEST OPHTH VIS SCI, V50, P4982, DOI 10.1167/iovs.09-3639
   MCLEOD DS, 1994, INVEST OPHTH VIS SCI, V35, P3799
   McLeod DS, 2002, INVEST OPHTH VIS SCI, V43, P1986
   Moult E, 2014, OSLI RETINA, V45, P496, DOI 10.3928/23258160-20141118-03
   Mullins RF, 2005, MOL VIS, V11, P509
   Mullins RE, 2011, INVEST OPHTH VIS SCI, V52, P1606, DOI 10.1167/iovs.10-6476
   Mullins RF, 2014, ADV EXP MED BIOL, V801, P283, DOI 10.1007/978-1-4614-3209-8_36
   OLVER JM, 1990, EYE, V4, P262, DOI 10.1038/eye.1990.38
   Povazay B, 2007, J BIOMED OPT, V12, DOI 10.1117/1.2773728
   RAMRATTAN RS, 1994, INVEST OPHTH VIS SCI, V35, P2857
   SARKS JP, 1988, EYE, V2, P552, DOI 10.1038/eye.1988.106
   Schwartz DM, 2014, OPHTHALMOLOGY, V121, P180, DOI 10.1016/j.ophtha.2013.09.002
   Sunness JS, 1999, OPHTHALMOLOGY, V106, P910, DOI 10.1016/S0161-6420(99)00509-6
   Tao YK, 2008, OPT EXPRESS, V16, P12350, DOI 10.1364/OE.16.012350
   Tokayer J, 2013, BIOMED OPT EXPRESS, V4, P1909, DOI 10.1364/BOE.4.001909
   Unterhuber A, 2005, OPT EXPRESS, V13, P3252, DOI 10.1364/OPEX.13.003252
   Vakoc BJ, 2009, NAT MED, V15, P1219, DOI 10.1038/nm.1971
   Wolf-Schnurrbusch UEK, 2008, INVEST OPHTH VIS SCI, V49, P3095, DOI 10.1167/iovs.07-1460
   Yu LF, 2010, J BIOMED OPT, V15, DOI 10.1117/1.3302806
   Zhu L, 2006, J BIOMECH ENG-T ASME, V128, P203, DOI 10.1115/1.2165692
NR 40
TC 194
Z9 204
U1 0
U2 21
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 0161-6420
EI 1549-4713
J9 OPHTHALMOLOGY
JI Ophthalmology
PD DEC
PY 2015
VL 122
IS 12
BP 2532
EP 2544
DI 10.1016/j.ophtha.2015.08.029
PG 13
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA CZ4EZ
UT WOS:000367057500033
PM 26481819
OA Green Submitted, Green Accepted
DA 2022-11-30
ER

PT J
AU Lee, J
   Freeman, WR
   Azen, SP
   Chung, EJ
   Koh, HJ
AF Lee, Jonghyun
   Freeman, William R.
   Azen, Stanley P.
   Chung, Eun Jee
   Koh, Hyoung Jun
TI Prospective, randomized clinical trial of intravitreal triamcinolone
   treatment of neovascular age-related macular degeneration - One-year
   results
SO RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES
LA English
DT Article
DE age-related macular degeneration; intravitreal triamcinolone; minimally
   classic or occult; choroidal neovascularization
ID CHOROIDAL NEOVASCULARIZATION; ANECORTAVE ACETATE; VISUAL-ACUITY;
   FOLLOW-UP; ACETONIDE; PREVALENCE; MACULOPATHY; INJECTION; TOXICITY
AB Purpose: To investigate the effect of intravitreal injection of high-dose (20-25 mg) triamcinolone acetonide on minimally classic or occult choroidal neovascularization (CNV) secondary to age-related macular degeneration (AMD).
   Methods: A prospective, double-masked, placebo-controlled, randomized clinical trial included 39 eyes with minimally classic or occult CNV secondary to AMD. The treatment group (21 eyes) received intravitreal injection (20 -25 mg) of triamcinolone acetonide and the control group (18 eyes) received intravitreal injection (500 mu g) of dexamethasone at 6-month intervals. Best-corrected ETDRS (Early Treatment Diabetic Retinopathy Study) score, contrast sensitivity score, and central macular volume were measured at 1 month, 3 months, 6 months, and 12 months.
   Results: Mean baseline best-corrected visual acuity (BCVA [logarithm of the minimal angle of resolution]) was 0.64 (Snellen equivalent, 20/80) in each group. At 1 month, 3 months, and 6 months after the injection, neither group had a significant change in BCVA. At 12 months, mean BCVA +/- SD significantly decreased to 1.06 +/- 0.34 (Snellen equivalent, 20/200) in the treatment group (paired t-test, P < 0.001), whereas it was 0.78 +/- 0.52 (Snellen equivalent, 20/125) in the control group (P = 0.23). The difference was marginally significant (P = 0.06, Student's t-test). Ail phakic eyes in the treatment group developed marked cataract progression.
   Conclusions: Intravitreal injection of high-dose triamcinolone had no beneficial effect on eyes with minimally classic or occult CNV secondary to AMD and was associated with outcomes similar to those associated with intravitreal injection of dexamethasone, which was used as placebo.
C1 Inje Univ, Ilsan Paik Hosp, Coll Med, Dept Ophthalmol, Gyeonggido, South Korea.
   Univ Calif San Diego, Jacobs Retina Ctr, Shiley Eye Ctr, San Diego, CA 92103 USA.
   Univ So Calif, Keck Sch Med, Stat Consultat & Res Ctr, Dept Prevent Med, Los Angeles, CA USA.
   Yonsei Univ, Coll Med, Inst Vis Res, Dept Ophthalmol, Seoul, South Korea.
C3 Inje University; University of California System; University of
   California San Diego; University of Southern California; Yonsei
   University; Yonsei University Health System
RP Koh, HJ (通讯作者)，Yonsei Univ, Coll Med, Dept Ophthalmol, Sodaemungu Shinchondong 134, Seoul 120752, South Korea.
EM hjkoh@yuhs.ac
OI Koh, Hyoung Jun/0000-0002-5932-8516; Chung, Eun Jee/0000-0001-8363-2836
CR Augustin AJ, 2005, GRAEF ARCH CLIN EXP, V243, P9, DOI 10.1007/s00417-004-0961-4
   BRESSLER SB, 1982, AM J OPHTHALMOL, V93, P157, DOI 10.1016/0002-9394(82)90410-X
   Challa JK, 1998, AUST NZ J OPHTHALMOL, V26, P277, DOI 10.1111/j.1442-9071.1998.tb01330.x
   CHYLACK LT, 1993, ARCH OPHTHALMOL-CHIC, V111, P831, DOI 10.1001/archopht.1993.01090060119035
   Congdon N, 2004, ARCH OPHTHALMOL-CHIC, V122, P477
   Danis RP, 2000, RETINA-J RET VIT DIS, V20, P244, DOI 10.1097/00006982-200003000-00004
   FERRIS FL, 1982, AM J OPHTHALMOL, V94, P91, DOI 10.1016/0002-9394(82)90197-0
   Gillies MC, 2003, ARCH OPHTHALMOL-CHIC, V121, P667, DOI 10.1001/archopht.121.5.667
   Jonas JB, 2007, EYE, V21, P387, DOI 10.1038/sj.eye.6702222
   Jonas JB, 2005, AM J OPHTHALMOL, V139, P1073, DOI 10.1016/j.ajo.2005.01.032
   Jonas JB, 2005, EYE, V19, P163, DOI 10.1038/sj.eye.6701438
   Jonas JB, 2004, BRIT J OPHTHALMOL, V88, P1557, DOI 10.1136/bjo.2003.039552
   Jonas JB, 2004, ARCH OPHTHALMOL-CHIC, V122, P218, DOI 10.1001/archopht.122.2.218
   Jonas JB, 2003, BRIT J OPHTHALMOL, V87, P462, DOI 10.1136/bjo.87.4.462
   Jonas JB, 2006, J OCUL PHARMACOL TH, V22, P194, DOI 10.1089/jop.2006.22.194
   KWAK HW, 1992, ARCH OPHTHALMOL-CHIC, V110, P259, DOI 10.1001/archopht.1992.01080140115038
   Matysova L, 2003, ANAL BIOANAL CHEM, V376, P440, DOI 10.1007/s00216-003-1756-x
   MITCHELL P, 1995, OPHTHALMOLOGY, V102, P1450
   Morrison VL, 2006, RETINA-J RET VIT DIS, V26, P339, DOI 10.1097/00006982-200603000-00014
   Penfold PL, 1995, AUST NZ J OPHTHALMOL, V23, P293, DOI 10.1111/j.1442-9071.1995.tb00179.x
   Ranson NT, 2002, BRIT J OPHTHALMOL, V86, P527, DOI 10.1136/bjo.86.5.527
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Russell SR, 2007, SURV OPHTHALMOL, V52, pS79, DOI 10.1016/j.survophthal.2006.11.005
   Schmidt-Erfurth U, 1999, ARCH OPHTHALMOL-CHIC, V117, P1177
   Tetz M R, 1992, Ger J Ophthalmol, V1, P403
   VINGERLING JR, 1995, OPHTHALMOLOGY, V102, P205
NR 26
TC 18
Z9 18
U1 0
U2 1
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0275-004X
J9 RETINA-J RET VIT DIS
JI Retin.-J. Retin. Vitr. Dis.
PD NOV-DEC
PY 2007
VL 27
IS 9
BP 1205
EP 1213
DI 10.1097/IAE.0b013e31815ec367
PG 9
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 238NS
UT WOS:000251455100009
PM 18046226
DA 2022-11-30
ER

PT J
AU Shijo, T
   Sakurada, Y
   Tanaka, K
   Miki, A
   Yoneyama, S
   Machida, Y
   Chubachi, A
   Wakatsuki, Y
   Sugiyama, A
   Onoe, H
   Kikushima, W
   Mori, R
   Kashiwagi, K
AF Shijo, Taiyo
   Sakurada, Yoichi
   Tanaka, Koji
   Miki, Akiko
   Yoneyama, Seigo
   Machida, Yumiko
   Chubachi, Aya
   Wakatsuki, Yu
   Sugiyama, Atsushi
   Onoe, Hajime
   Kikushima, Wataru
   Mori, Ryusaburo
   Kashiwagi, Kenji
TI Drusenoid Pigment Epithelial Detachment: Genetic and Clinical
   Characteristics
SO INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
LA English
DT Article
DE drusenoid pigment epithelial detachment; ARMS2; CFH; reticular
   pseudodrusen
AB Few studies report drusenoid pigment epithelial detachment (DPED) in Asians. In this multicenter study, we report the clinical and genetic characteristics of 76 patients with DPED, and, for comparison, 861 patients with exudative age-related macular degeneration (AMD) were included. On the initial presentation, the mean best-corrected visual acuity was 0.087 +/- 0.17 (logMAR unit), and mean DPED height and width were 210 +/- 132 and 1633 +/- 1114 mu m, respectively. Fifty-one (67%) patients showed macular neovascularization in the contralateral eye. The risk allele frequency of both ARMS2 A69S and CFH I62V was significantly higher in DPED than in typical AMD and polypoidal choroidal vasculopathy (PCV) (ARMS2 A69S risk allele frequency: DPED 77% vs. typical AMD 66% vs. PCV 57%, CFH I62V risk allele frequency: DPED 87% vs. typical AMD 73% vs. PCV 73%), although the risk allele frequency of both genes was similar between the DPED group and retinal angiomatous proliferation (RAP) group (ARMS2 A69S: p = 0.32, CFH I62V, p = 0.11). The prevalence of reticular pseudodrusen (RPD) was highest in RAP (60%), followed by DPED (22%), typical AMD (20%), and PCV (2%). Although the prevalence of RPD differs between DPED and RAP, these entities share a similar genetic background in terms of ARMS2 and CFH genes.
C1 [Shijo, Taiyo; Sakurada, Yoichi; Yoneyama, Seigo; Sugiyama, Atsushi; Kikushima, Wataru; Kashiwagi, Kenji] Univ Yamanashi, Dept Ophthalmol, Fac Med, Kofu, Yamanashi 4008510, Japan.
   [Tanaka, Koji; Machida, Yumiko; Wakatsuki, Yu; Onoe, Hajime; Mori, Ryusaburo] Nihon Univ, Sch Med, Dept Ophthalmol, Tokyo 1738610, Japan.
   [Miki, Akiko; Chubachi, Aya] Kobe Univ, Grad Sch Med, Div Ophthalmol, Dept Surg, Kobe, Hyogo 6500017, Japan.
C3 University of Yamanashi; Nihon University; Kobe University
RP Sakurada, Y (通讯作者)，Univ Yamanashi, Dept Ophthalmol, Fac Med, Kofu, Yamanashi 4008510, Japan.
EM tshijoh@yamanashi.ac.jp; sakurada@yamanashi.ac.jp;
   tanaka.koji@nihon-u.ac.jp; acacyey@med.kobe-u.ac.jp;
   syoneyama@yamanashi.ac.jp; machida.yumiko@nihon-u.ac.jp;
   achuba@med.kobe-u.ac.jp; wakatsuki.yu@nihon-u.ac.jp;
   asugiyama@yamanashi.ac.jp; onoe.hajime@nihon-u.ac.jp;
   wkikushima@yamanashi.ac.jp; mori.ryusaburo@nihon-u.ac.jp;
   kenjik@yamanashi.ac.jp
OI Kashiwagi, Kenji/0000-0001-8506-8503; Tanaka, Koji/0000-0003-3323-4148;
   Sakurada, Yoichi/0000-0002-2894-0454; MIKI, AKIKO/0000-0003-1930-3960
CR Alten F, 2012, RETINA-J RET VIT DIS, V32, P1727, DOI 10.1097/IAE.0b013e3182475b03
   Balaratnasingam C, 2016, INVEST OPHTH VIS SCI, V57, P5479, DOI 10.1167/iovs.16-19816
   CASSWELL AG, 1985, BRIT J OPHTHALMOL, V69, P397, DOI 10.1136/bjo.69.6.397
   Cheng CY, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms7063
   Cukras C, 2010, OPHTHALMOLOGY, V117, P489, DOI 10.1016/j.ophtha.2009.12.002
   Donato L, 2021, INT J MOL SCI, V22, DOI 10.3390/ijms22010070
   Donato L, 2020, ANTIOXIDANTS-BASEL, V9, DOI 10.3390/antiox9111158
   Fritsche LG, 2016, NAT GENET, V48, P134, DOI 10.1038/ng.3448
   Kim JH, 2013, AM J OPHTHALMOL, V155, P743, DOI 10.1016/j.ajo.2012.11.001
   Miki A, 2013, OPHTHALMIC GENET, V34, P146, DOI 10.3109/13816810.2012.749288
   MIMOUN G, 1990, J FR OPHTALMOL, V13, P511
   Roquet W, 2004, BRIT J OPHTHALMOL, V88, P638, DOI 10.1136/bjo.2003.017632
   Sakurada Y, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0149978
   Scimone C, 2020, ANTIOXIDANTS-BASEL, V9, DOI 10.3390/antiox9111154
   Seddon JM, 2007, JAMA-J AM MED ASSOC, V297, P1793, DOI 10.1001/jama.297.16.1793
   Shijo T, 2020, PHARMACEUTICALS-BASE, V13, DOI 10.3390/ph13090257
   Shijo T, 2017, GRAEF ARCH CLIN EXP, V255, P1125, DOI 10.1007/s00417-017-3622-0
   Tan ACS, 2016, AM J OPHTHALMOL, V172, P13, DOI 10.1016/j.ajo.2016.09.004
   Tanaka K, 2011, MOL VIS, V17, P2751
   Tanaka K, 2011, INVEST OPHTH VIS SCI, V52, P7441, DOI 10.1167/iovs.11-7546
   Yoneyama S, 2014, OPHTHALMIC GENET, V35, P151, DOI 10.3109/13816810.2014.921313
   Yu JJ, 2019, OPHTHALMOLOGY, V126, P261, DOI 10.1016/j.ophtha.2018.08.017
NR 22
TC 2
Z9 2
U1 0
U2 0
PU MDPI
PI BASEL
PA ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND
EI 1422-0067
J9 INT J MOL SCI
JI Int. J. Mol. Sci.
PD APR
PY 2021
VL 22
IS 8
AR 4074
DI 10.3390/ijms22084074
PG 9
WC Biochemistry & Molecular Biology; Chemistry, Multidisciplinary
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Chemistry
GA RT3BZ
UT WOS:000644339000001
PM 33920794
OA Green Published, gold
DA 2022-11-30
ER

PT J
AU Dansingani, KK
   Freund, KB
AF Dansingani, Kunal K.
   Freund, K. Bailey
TI Optical Coherence Tomography Angiography Reveals Mature, Tangled
   Vascular Networks in Eyes With Neovascular Age-Related Macular
   Degeneration Showing Resistance to Geographic Atrophy
SO OPHTHALMIC SURGERY LASERS & IMAGING RETINA
LA English
DT Article
ID POLYPOIDAL CHOROIDAL VASCULOPATHY; INDOCYANINE GREEN ANGIOGRAPHY
AB BACKGROUND AND OBJECTIVE: To demonstrate a vascular pattern seen on optical coherence tomography angiography (OCTA) that appears to correlate with reduced rates of geographic atrophy (GA) in eyes receiving long-term anti-vascular endothelial growth factor (VEGF) treatment for neovascular age-related macular degeneration (AMD).
   PATIENTS AND METHODS: Non-consecutive, retrospective cohort study. Patients were included if they had received more than 50 anti-VEGF injections during a period of at least 4 years for neovascular AMD in at least one eye, with absence or minimal progression of GA. Clinical charts and imaging were reviewed retrospectively; study eyes underwent OCTA.
   RESULTS: Nine eyes of eight patients were included. Mean age was 82 years, and mean follow-up of study eyes 9.1 years; study eyes received a mean of 65.8 injections. OCTA revealed tangled networks of neovessels associated with type 1 lesions.
   CONCLUSION: With prolonged anti-VEGF treatment, GA appears to occur less commonly in eyes with type 1 neovascularization. OCTA shows mature tangled vessels with substantial flow within type 1 lesions. Mature, tangled networks may be associated with a decreased likelihood of developing GA despite the presence of choriocapillaris atrophy.
C1 [Dansingani, Kunal K.; Freund, K. Bailey] Vitreous Retina Macular Consultants New York, 460 Pk Ave,Fifth floor, New York, NY 10022 USA.
   [Dansingani, Kunal K.; Freund, K. Bailey] LuEsther T Mertz Retinal Res Ctr, New York, NY USA.
   [Dansingani, Kunal K.] Moorfields Eye Hosp, London, England.
   [Freund, K. Bailey] NYU, Sch Med, Dept Ophthalmol, New York, NY USA.
C3 Vitreous Retina Macula Consultants of New York; University of London;
   University College London; Moorfields Eye Hospital NHS Foundation Trust;
   New York University
RP Freund, KB (通讯作者)，Vitreous Retina Macular Consultants New York, 460 Pk Ave,Fifth floor, New York, NY 10022 USA.
EM kbfnyf@aol.com
RI Dansingani, Kunal/D-1025-2015; Freund, K. Bailey/V-7488-2018
OI Dansingani, Kunal/0000-0002-7430-8601; Freund, K.
   Bailey/0000-0002-7888-9773
FU LuEsther T. Mertz Retinal Research Center; Manhattan Eye, Ear and Throat
   Hospital, New York; Macula Foundation, New York, NY
FX Supported by the LuEsther T. Mertz Retinal Research Center, Manhattan
   Eye, Ear and Throat Hospital, New York, and the Macula Foundation, New
   York, NY. The funding organization had no role in the design of conduct
   of this research.
CR Alasil T, 2015, AM J OPHTHALMOL, V159, P634, DOI 10.1016/j.ajo.2014.12.012
   Chakravarthy U, 2013, LANCET, V382, P1258, DOI 10.1016/S0140-6736(13)61501-9
   CHANG TS, 1994, RETINA-J RET VIT DIS, V14, P114, DOI 10.1097/00006982-199414020-00004
   Dhrami-Gavazi E, 2015, INT J RETIN VITR, V1
   Grunwald JE, 2014, OPHTHALMOLOGY, V121, P150, DOI 10.1016/j.ophtha.2013.08.015
   Querques G, 2012, BRIT J OPHTHALMOL, V96, P1479, DOI 10.1136/bjophthalmol-2012-302191
   REGILLO CD, 1994, OPHTHALMOLOGY, V101, P280
   Rosenfeld PJ, 2011, OPHTHALMOLOGY, V118, P523, DOI 10.1016/j.ophtha.2010.07.011
   Saint-Geniez M, 2009, P NATL ACAD SCI USA, V106, P18751, DOI 10.1073/pnas.0905010106
   Sato T, 2007, RETINA-J RET VIT DIS, V27, P589, DOI 10.1097/01.iae.0000249386.63482.05
   Xu LN, 2015, RETINA-J RET VIT DIS, V35, P176, DOI 10.1097/IAE.0000000000000374
NR 11
TC 45
Z9 47
U1 0
U2 1
PU SLACK INC
PI THOROFARE
PA 6900 GROVE RD, THOROFARE, NJ 08086 USA
SN 2325-8160
EI 2325-8179
J9 OSLI RETINA
JI Ophthalmic Surg. Lasers Imag. Retin.
PD OCT
PY 2015
VL 46
IS 9
BP 907
EP 912
DI 10.3928/23258160-20151008-02
PG 6
WC Ophthalmology; Surgery
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology; Surgery
GA DP9UF
UT WOS:000378842200002
PM 26469229
DA 2022-11-30
ER

PT J
AU Shah, SM
   Starr, MR
   Dalvin, LA
   Comfere, NI
   Abouchehade, JE
   Hodge, DO
   Iezzi, R
   Bakri, SJ
AF Shah, Saumya M.
   Starr, Matthew R.
   Dalvin, Lauren A.
   Comfere, Nneka I.
   Abouchehade, Jackson E.
   Hodge, David O.
   Iezzi, Raymond
   Bakri, Sophie J.
TI INCREASED INCIDENCE OF CUTANEOUS KERATINOCYTIC AND MELANOCYTIC
   MALIGNANCIES IN PATIENTS WITH AGE-RELATED MACULAR DEGENERATION
SO RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES
LA English
DT Article
DE age-related macular degeneration; anti-VEGF; cutaneous malignancy;
   keratinocytic; malignancies; melanocytic
ID VISUAL IMPAIRMENT; OXIDATIVE STRESS; ULTRAVIOLET-RADIATION;
   OLMSTED-COUNTY; RISK-FACTORS; EYE DISEASE; MORTALITY; EXPOSURE;
   PATHOGENESIS; SURVIVAL
AB Purpose: The relationship between age-related macular degeneration (AMD) and malignancy, especially cutaneous malignancies, is not well studied. We investigated a possible association between AMD and cutaneous malignancies. Methods: A retrospective, consecutive review of all patients who had received at least 1 intravitreal injection for wet AMD between January 1, 2004, and December 31, 2013, was conducted using the Rochester Epidemiology Project in Olmsted County, Minnesota. Age- and sex-matched control groups included 473 pre-anti-vascular endothelial growth factor era wet AMD patients, 504 concurrent time dry AMD patients, and 504 patients with no AMD. The rates of AMD and overall malignancy, cutaneous malignancies, and specific types of cutaneous malignancies were compared between groups of patients. Results: Patients with wet AMD incurred an increased rate of overall malignancies compared to patients with dry AMD {52.8% wet AMD (confidence interval [CI]: 48.3-57.2) vs. 43.7% dry AMD (CI: 39.3-48.1); P= 0.003} or those without AMD (52.8% wet AMD [CI: 48.3-57.2] vs. 35.3% no AMD [CI: 31.1-39.7]; P = <0.001). Patients with dry AMD also had higher rates of malignancy than those without AMD (43.7% dry AMD [CI: 39.3-48.1] vs. 35.3% no AMD [CI: 31.1-39.7]; P = 0.007). Rate of cutaneous malignancies was increased in patients with wet AMD compared to patients with dry AMD (24.4% wet AMD [CI: 20.7-28.4] vs. 14.6% dry AMD [CI: 11.5-17.9]; P = <0.001) and those with no AMD (24.4% wet AMD [CI: 20.7-28.4] vs. 9.7% no AMD [CI: 7.3-12.7]; P = <0.001). Conclusion and Relevance: To the best of our knowledge, this is the first report to establish an association between AMD and cutaneous malignancies, supporting a possible discussion of the association when a patient presents with one of the two conditions.
C1 [Shah, Saumya M.] Mayo Clin, Sch Med, Rochester, MN USA.
   [Starr, Matthew R.; Dalvin, Lauren A.; Abouchehade, Jackson E.; Iezzi, Raymond; Bakri, Sophie J.] Mayo Clin, Dept Ophthalmol, 200 First St Southwest, Rochester, MN 55905 USA.
   [Comfere, Nneka I.] Mayo Clin, Dept Dermatol, Rochester, MN USA.
   [Comfere, Nneka I.] Mayo Clin, Dept Lab Med & Pathol, Rochester, MN USA.
   [Hodge, David O.] Mayo Clin, Dept Biomed Stat & Informat, Rochester, MN USA.
C3 Mayo Clinic; Mayo Clinic; Mayo Clinic; Mayo Clinic; Mayo Clinic
RP Bakri, SJ (通讯作者)，Mayo Clin, Dept Ophthalmol, 200 First St Southwest, Rochester, MN 55905 USA.
EM bakri.sophie@mayo.edu
OI Starr, Matthew/0000-0002-3021-5630
FU NIA NIH HHS [R01 AG034676] Funding Source: Medline
CR Ananthaswamy Honnavara N., 2001, Journal of Biomedicine and Biotechnology, V1, P49, DOI 10.1155/S1110724301000122
   [Anonymous], 2014, PEERJ, V2, pe447
   Bak M, 2017, JAMA OPHTHALMOL, V135, P835, DOI 10.1001/jamaophthalmol.2017.2011
   Beatty S, 2000, SURV OPHTHALMOL, V45, P115, DOI 10.1016/S0039-6257(00)00140-5
   Bickers DR, 2006, J INVEST DERMATOL, V126, P2565, DOI 10.1038/sj.jid.5700340
   Blasiak J, 2013, INT J MOL SCI, V14, P2996, DOI 10.3390/ijms14022996
   Bradford Porcia T, 2009, Dermatol Nurs, V21, P170
   Brown DM, 2007, AM J OPHTHALMOL, V144, P627, DOI 10.1016/j.ajo.2007.06.039
   Buch H, 2005, OPHTHALMOLOGY, V112, P305, DOI 10.1016/j.ophtha.2004.08.025
   CAMPION ME, 1992, MAYO CLIN PROC, V67, P5, DOI 10.1016/S0025-6196(12)60270-5
   Chalam KV, 2011, EYE CONTACT LENS, V37, P225, DOI 10.1097/ICL.0b013e31821fbd3e
   Cheung N, 2007, ARCH OPHTHALMOL-CHIC, V125, P1241, DOI 10.1001/archopht.125.9.1241
   Cho BJ, 2014, INVEST OPHTH VIS SCI, V55, P4430, DOI 10.1167/iovs.14-14379
   Clemons TE, 2004, ARCH OPHTHALMOL-CHIC, V122, P716
   Congdon N, 2004, ARCH OPHTHALMOL-CHIC, V122, P477
   Curtis LH, 2010, ARCH OPHTHALMOL-CHIC, V128, P1273, DOI 10.1001/archophthalmol.2010.223
   de Jong PTVM, 2006, NEW ENGL J MED, V355, P1474, DOI 10.1056/NEJMra062326
   Delcourt C, 2001, ARCH OPHTHALMOL-CHIC, V119, P1463
   Elbaz A, 2003, ARCH NEUROL-CHICAGO, V60, P91, DOI 10.1001/archneur.60.1.91
   Heck DE, 2003, J BIOL CHEM, V278, P22432, DOI 10.1074/jbc.C300048200
   Jager RD, 2008, NEW ENGL J MED, V358, P2606, DOI 10.1056/NEJMra0801537
   Kauppinen A, 2016, CELL MOL LIFE SCI, V73, P1765, DOI 10.1007/s00018-016-2147-8
   Keizman D, 2017, CANCER EPIDEM BIOMAR, V26, P743, DOI 10.1158/1055-9965.EPI-16-0759
   KLEIN R, 1995, ARCH OPHTHALMOL-CHIC, V113, P333, DOI 10.1001/archopht.1995.01100030089026
   Klein R, 2013, INVEST OPHTH VIS SCI, V54, DOI 10.1167/iovs.13-12789
   KRICKER A, 1994, CANCER CAUSE CONTROL, V5, P367, DOI 10.1007/BF01804988
   KURLAND LT, 1981, SCI AM, V245, P54, DOI 10.1038/scientificamerican1081-54
   Lim LS, 2012, LANCET, V379, P1728, DOI 10.1016/S0140-6736(12)60282-7
   McGuinness MB, 2017, OPHTHAL EPIDEMIOL, V24, P141, DOI 10.1080/09286586.2016.1259422
   Melton LJ, 1996, MAYO CLIN PROC, V71, P266, DOI 10.4065/71.3.266
   Muzic JG, 2017, MAYO CLIN PROC, V92, P890, DOI 10.1016/j.mayocp.2017.02.015
   Narendhirakannan RT, 2013, INDIAN J CLIN BIOCHE, V28, P110, DOI 10.1007/s12291-012-0278-8
   Nishigori C, 2004, ANTIOXID REDOX SIGN, V6, P561, DOI 10.1089/152308604773934314
   Nita M, 2016, OXID MED CELL LONGEV, V2016, DOI 10.1155/2016/3164734
   PHILLIPS SJ, 1988, MAYO CLIN PROC, V63, P691, DOI 10.1016/S0025-6196(12)65531-1
   Plestina-Borjan I, 2007, COLLEGIUM ANTROPOL, V31, P33
   Resnikoff S, 2004, B WORLD HEALTH ORGAN, V82, P844
   Sui GY, 2013, BRIT J OPHTHALMOL, V97, P389, DOI 10.1136/bjophthalmol-2012-302281
   Tan JSL, 2007, OPHTHALMOLOGY, V114, P1143, DOI 10.1016/j.ophtha.2006.09.033
   Tang L., 2016, J MOL SIGNAL, V11, P1
   Thiagarajan M, 2005, ARCH OPHTHALMOL-CHIC, V123, P1397, DOI 10.1001/archopht.123.10.1397
   Tomany SC, 2004, ARCH OPHTHALMOL-CHIC, V122, P750, DOI 10.1001/archopht.122.5.750
   Wang J, 2016, BIOMED RES INT, V2016, DOI 10.1155/2016/8212063
   Wang PP, 2017, BIOMED RES INT, V2017, DOI 10.1155/2017/3489603
   WEST SK, 1989, ARCH OPHTHALMOL-CHIC, V107, P875, DOI 10.1001/archopht.1989.01070010897038
   Winkler BS, 1999, MOL VIS, V5
   Wu J, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0089600
   Zarbin MA, 2004, ARCH OPHTHALMOL-CHIC, V122, P598, DOI 10.1001/archopht.122.4.598
NR 48
TC 1
Z9 1
U1 3
U2 7
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0275-004X
EI 1539-2864
J9 RETINA-J RET VIT DIS
JI Retin.-J. Retin. Vitr. Dis.
PD MAY
PY 2020
VL 40
IS 5
BP 857
EP 865
DI 10.1097/IAE.0000000000002506
PG 9
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA LL2HK
UT WOS:000531376000009
PM 30986797
OA Green Accepted
DA 2022-11-30
ER

PT J
AU Rowan, S
   Weikel, K
   Chang, ML
   Nagel, BA
   Thinschmidt, JS
   Carey, A
   Grant, MB
   Fliesler, SJ
   Smith, D
   Taylor, A
AF Rowan, Sheldon
   Weikel, Karen
   Chang, Min-Lee
   Nagel, Barbara A.
   Thinschmidt, Jeffrey S.
   Carey, Amanda
   Grant, Maria B.
   Fliesler, Steven J.
   Smith, Donald
   Taylor, Allen
TI Cfh Genotype Interacts With Dietary Glycemic Index to Modulate
   Age-Related Macular Degeneration-Like Features in Mice
SO INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE
LA English
DT Article
DE glycemic index; complement; gene-diet interaction; inflammation; aging
ID COMPLEMENT FACTOR-H; HIGH-FAT DIET; INSULIN-RESISTANCE; OXIDATIVE
   DAMAGE; MODEL; RISK; POLYMORPHISM; INCREASES; AUTOPHAGY; DEPOSIT
AB PURPOSE. Age-related macular degeneration (AMD) is a leading cause of visual impairment worldwide. Genetics and diet contribute to the relative risk for developing AMD, but their interactions are poorly understood. Genetic variations in Complement Factor H (CFH), and dietary glycemic index (GI) are major risk factors for AMD. We explored the effects of GI on development of early AMD-like features and changes to central nervous system (CNS) inflammation in Cfh-null mice.
   METHODS. Aged 11-week-old wild type (WT) C57Bl/6J or Cfh-null mice were group pair-fed high or low GI diets for 33 weeks. At 10 months of age, mice were evaluated for early AMD-like features in the neural retina and RPE by light and electron microscopy. Brains were analyzed for Iba1 macrophage/microglia immunostaining, an indicator of inflammation.
   RESULTS. The 10-month-old WT mice showed no retinal abnormalities on either diet. The Cfh-null mice, however, showed distinct early AMD-like features in the RPE when fed a low GI diet, including vacuolation, disruption of basal infoldings, and increased basal laminar deposits. The Cfh-null mice also showed thinning of the RPE, hypopigmentation, and increased numbers of Iba1-expressing macrophages in the brain, irrespective of diet.
   CONCLUSIONS. The presence of early AMD-like features by 10 months of age in Cfh-null mice fed a low GI diet is surprising, given the apparent protection from the development of such features in aged WT mice or humans consuming lower GI diets. Our findings highlight the need to consider gene-diet interactions when developing animal models and therapeutic approaches to treat AMD.
C1 [Rowan, Sheldon; Weikel, Karen; Chang, Min-Lee; Carey, Amanda; Smith, Donald; Taylor, Allen] Tufts Univ, JM USDA Human Nutr Res Ctr Aging HNRCA, Boston, MA 02111 USA.
   [Nagel, Barbara A.] St Louis Univ, Dept Pathol, St Louis, MO 63103 USA.
   [Thinschmidt, Jeffrey S.; Grant, Maria B.] Univ Florida, Dept Pharmacol & Therapeut, Gainesville, FL USA.
   [Fliesler, Steven J.] Vet Adm Western New York Healthcare Syst, Res Serv, Buffalo, NY USA.
   [Fliesler, Steven J.] SUNY Buffalo, Dept Ophthalmol, Buffalo, NY 14260 USA.
   [Fliesler, Steven J.] SUNY Buffalo, Dept Biochem, Buffalo, NY 14214 USA.
   [Fliesler, Steven J.] SUNY Eye Inst, Buffalo, NY USA.
C3 Tufts University; Saint Louis University; State University System of
   Florida; University of Florida; State University of New York (SUNY)
   System; State University of New York (SUNY) Buffalo; State University of
   New York (SUNY) System; State University of New York (SUNY) Buffalo
RP Taylor, A (通讯作者)，Tufts Univ, JM USDA Human Nutr Res Ctr Aging, Lab Nutr & Vis Res, 711 Washington St, Boston, MA 02111 USA.
EM taylor@tufts.edu
RI Rowan, Sheldon/AAA-3271-2019; Fliesler, Steven J./AAE-9243-2020
OI Rowan, Sheldon/0000-0002-1123-6743; Fliesler,
   Steven/0000-0002-2557-142X; CHANG, MIN-LEE/0000-0001-9868-4030
FU HNRCA [NEI RO1 EY021212, NEI RO1 EY13250, NEI EY007361]; USDA
   [1950-510000-060-01A]; Johnson and Johnson Focused Giving; Alcon
   Laboratories; RPB Unrestricted Grant; Veterans Administration Western
   New York Healthcare System (SJF); NATIONAL EYE INSTITUTE [R01EY007361,
   R01EY021212, R01EY013250] Funding Source: NIH RePORTER
FX Supported by intramural funds from the HNRCA (AT); by NEI RO1 EY021212
   (AT), NEI RO1 EY13250 (AT), NEI EY007361 (SJF), USDA 1950-510000-060-01A
   (AT), Johnson and Johnson Focused Giving (AT); an unrestricted gift from
   Alcon Laboratories (Elkridge, MD; AT), an RPB Unrestricted Grant (SJF),
   and by facilities and resources provided by the Veterans Administration
   Western New York Healthcare System (SJF). The authors alone are
   responsible for the content and writing of the paper.
CR Adams MKM, 2012, HUM MOL GENET, V21, P5229, DOI 10.1093/hmg/dds364
   Card JP, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0021141
   Chiu CJ, 2007, AM J CLIN NUTR, V86, P1210, DOI 10.1093/ajcn/86.4.1210
   Chiu CJ, 2007, AM J CLIN NUTR, V86, P180, DOI 10.1093/ajcn/86.1.180
   Coffey PJ, 2007, P NATL ACAD SCI USA, V104, P16651, DOI 10.1073/pnas.0705079104
   Cousins SW, 2002, EXP EYE RES, V75, P543, DOI 10.1006/exer.2002.2047
   Curcio CA, 1999, ARCH OPHTHALMOL-CHIC, V117, P329, DOI 10.1001/archopht.117.3.329
   Douglas JY, 2012, PROG RETIN EYE RES, V31, P481, DOI 10.1016/j.preteyeres.2012.04.005
   Edwards AO, 2005, SCIENCE, V308, P421, DOI 10.1126/science.1110189
   Espinosa-Heidmann DG, 2006, INVEST OPHTH VIS SCI, V47, P729, DOI 10.1167/iovs.05-0719
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P564
   Fujihara M, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003119
   Hageman GS, 2005, P NATL ACAD SCI USA, V102, P7227, DOI 10.1073/pnas.0501536102
   Haines JL, 2005, SCIENCE, V308, P419, DOI 10.1126/science.1110359
   Handa JT, 2012, MOL ASPECTS MED, V33, P418, DOI 10.1016/j.mam.2012.03.006
   Hillian AD, 2013, J BIOL CHEM, V288, P22565, DOI 10.1074/jbc.M113.465674
   Hollyfield JG, 2008, NAT MED, V14, P194, DOI 10.1038/nm1709
   Kam JH, 2013, AM J PATHOL, V183, P480, DOI 10.1016/j.ajpath.2013.04.008
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1417, DOI 10.1001/archopht.119.10.1417
   Keenan MJ, 2006, OBESITY, V14, P1523, DOI 10.1038/oby.2006.176
   Klein ML, 2008, OPHTHALMOLOGY, V115, P1019, DOI 10.1016/j.ophtha.2008.01.036
   Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557
   Mamane Y, 2009, DIABETES, V58, P2006, DOI 10.2337/db09-0323
   Moreno-Navarrete JM, 2010, DIABETES, V59, P200, DOI 10.2337/db09-0700
   Mendez-Ferrer S, 2008, NATURE, V452, P442, DOI 10.1038/nature06685
   Mitter SK, 2012, ADV EXP MED BIOL, V723, P83, DOI 10.1007/978-1-4614-0631-0_12
   Pennesi ME, 2012, MOL ASPECTS MED, V33, P487, DOI 10.1016/j.mam.2012.06.003
   Pickering MC, 2002, NAT GENET, V31, P424, DOI 10.1038/ng912
   Rakoczy PE, 2006, EXP EYE RES, V82, P741, DOI 10.1016/j.exer.2005.10.012
   Raychaudhuri S, 2011, NAT GENET, V43, P1232, DOI 10.1038/ng.976
   Regmi PR, 2011, J NUTR, V141, P1273, DOI 10.3945/jn.111.140509
   Regmi PR, 2011, J NUTR, V141, P398, DOI 10.3945/jn.110.132449
   Resnikoff S, 2004, B WORLD HEALTH ORGAN, V82, P844
   Schutt F, 2012, INVEST OPHTH VIS SCI, V53, P5354, DOI 10.1167/iovs.12-9845
   Shaw PX, 2012, P NATL ACAD SCI USA, V109, P13757, DOI 10.1073/pnas.1121309109
   Uchiki T, 2012, AGING CELL, V11, P1, DOI 10.1111/j.1474-9726.2011.00752.x
   von Leithner PL, 2009, AM J PATHOL, V175, P412, DOI 10.2353/ajpath.2009.080927
   Wang AL, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0004160
   Weikel KA, 2012, MOL ASPECTS MED, V33, P318, DOI 10.1016/j.mam.2012.03.005
   Weikel KA, 2012, INVEST OPHTH VIS SCI, V53, P622, DOI 10.1167/iovs.11-8545
   Weismann D, 2011, NATURE, V478, P76, DOI 10.1038/nature10449
   Williams JAE, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0068616
   Zeiss CJ, 2010, VET PATHOL, V47, P396, DOI 10.1177/0300985809359598
   Zhang G, 2013, NATURE, V497, P211, DOI 10.1038/nature12143
   Zhao ZY, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0019456
NR 45
TC 13
Z9 13
U1 0
U2 3
PU ASSOC RESEARCH VISION OPHTHALMOLOGY INC
PI ROCKVILLE
PA 12300 TWINBROOK PARKWAY, ROCKVILLE, MD 20852-1606 USA
SN 0146-0404
EI 1552-5783
J9 INVEST OPHTH VIS SCI
JI Invest. Ophthalmol. Vis. Sci.
PD JAN
PY 2014
VL 55
IS 1
BP 492
EP 501
DI 10.1167/iovs.13-12413
PG 10
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA AB6DG
UT WOS:000331877200058
PM 24370827
OA Green Published
DA 2022-11-30
ER

PT J
AU Maruyama-Inoue, M
   Kitajima, Y
   Mohamed, S
   Inoue, T
   Sato, S
   Ito, A
   Yamane, S
   Kadonosono, K
AF Maruyama-Inoue, Maiko
   Kitajima, Yoko
   Mohamed, Shaheeda
   Inoue, Tatsuya
   Sato, Shimpei
   Ito, Arisa
   Yamane, Shin
   Kadonosono, Kazuaki
TI Sensitivity and specificity of high-resolution wide field fundus imaging
   for detecting neovascular age-related macular degeneration
SO PLOS ONE
LA English
DT Article
ID DIABETIC-RETINOPATHY; OPTOS OPTOMAP; PREVALENCE; CLASSIFICATION;
   MACULOPATHY; AGREEMENT; DISEASE; EYE
AB Purpose Early detection and treatment are important management strategies for neovascular age-related macular degeneration (AMD). The purpose of this study was to determine the sensitivity and specificity in detecting neovascular AMD using two wide-field imaging systems: Clarus(TM)(CLARUS 500 (TM), Carl Zeiss Meditec AG, Jena, Germany) and Optos(R)(Optos California(R), Optos PLC, Dunfermline, United Kingdom), compared to conventional digital fundus photographs. Methods We retrospectively analyzed 109 eyes of 73 consecutive patients with neovascular AMD, who underwent standard examination and multimodal imaging, including fundus photography, and optical coherence tomography (OCT). Unmasked graders utilized slit-lamp biomicroscopy and OCT to diagnose neovascular AMD. Masked graders evaluated Clarus(TM), Optos(R), and digital fundus photograph methods to determine the presence of choroidal neovascularization associated with AMD. Sensitivity and specificity analyses were performed using combined fundoscopy and OCT as the reference standard. Results Ninety eyes were diagnosed with neovascular AMD and the remaining 19 eyes were normal based on the reference standard. Of these, neovascular AMD was detected using Clain 94.4% (85/90). The sensitivities of Optos(R)and digital fundus photographs were 81.1% (73/90) and 87.8% (79/90), respectively. The specificities using Clarus(TM), Optos(R), and digital fundus photographs were 89.5% (17/19), 94.7% (18/19), and 89.5% (17/19), respectively. Conclusion Claru(TM), with its ability to image high-resolution wide field fundus, was considered superior for diagnosing neovascular AMD with high sensitivity and specificity. It may be a useful screening tool for early detection of neovascular AMD, facilitating prompt referral and treatment.
C1 [Maruyama-Inoue, Maiko; Inoue, Tatsuya; Ito, Arisa; Yamane, Shin; Kadonosono, Kazuaki] Yokohama City Univ, Dept Ophthalmol, Med Ctr, Yokohama, Kanagawa, Japan.
   [Kitajima, Yoko; Sato, Shimpei] Kanto Rosai Hosp, Dept Ophthalmol, Kawasaki, Kanagawa, Japan.
   [Mohamed, Shaheeda] Chinese Univ Hong Kong, Hong Kong Eye Hosp, Dept Ophthalmol & Visual Sci, Hong Kong, Peoples R China.
C3 Yokohama City University; Chinese University of Hong Kong
RP Maruyama-Inoue, M (通讯作者)，Yokohama City Univ, Dept Ophthalmol, Med Ctr, Yokohama, Kanagawa, Japan.
EM maicoo@urahp.yokohama-cu.ac.jp
CR BIRD AEC, 1995, SURV OPHTHALMOL, V39, P367, DOI 10.1016/S0039-6257(05)80092-X
   Bressler NM, 2003, ARCH OPHTHALMOL-CHIC, V121, P1621
   BRESSLER NM, 1988, SURV OPHTHALMOL, V32, P375, DOI 10.1016/0039-6257(88)90052-5
   COHEN J, 1968, PSYCHOL BULL, V70, P213, DOI 10.1037/h0026256
   Csutak A, 2010, EYE, V24, P1568, DOI 10.1038/eye.2010.85
   Falavarjani KG, 2017, VISION RES, V139, P187, DOI 10.1016/j.visres.2017.02.009
   Freund KB, 2010, RETINA-J RET VIT DIS, V30, P1333, DOI 10.1097/IAE.0b013e3181e7976b
   Gangaputra S, 2011, INVEST OPHTH VIS SCI, V52, P6168, DOI 10.1167/iovs.11-7321
   Heier JS, 2012, OPHTHALMOLOGY, V119, P2537, DOI 10.1016/j.ophtha.2012.09.006
   Hirano T, 2018, BMC OPHTHALMOL, V18, DOI 10.1186/s12886-018-1011-z
   Jain S, 2006, EYE, V20, P471, DOI 10.1038/sj.eye.6701916
   Jung JJ, 2014, AM J OPHTHALMOL, V158, P769, DOI 10.1016/j.ajo.2014.07.006
   KINI MM, 1978, AM J OPHTHALMOL, V85, P28, DOI 10.1016/S0002-9394(14)76661-9
   Maberley DAL, 2005, EYE, V19, P611, DOI 10.1038/sj.eye.6701584
   Mackenzie PJ, 2007, RETINA-J RET VIT DIS, V27, P1119, DOI 10.1097/IAE.0b013e3180592b5c
   Meyer CH, 2010, CLIN EXP OPHTHALMOL, V38, P427, DOI 10.1111/j.1442-9071.2010.02260.x
   MITCHELL P, 1995, OPHTHALMOLOGY, V102, P1450
   Murgatroyd H, 2008, EYE, V22, P344, DOI 10.1038/sj.eye.6702611
   Nagiel A, 2016, RETINA-J RET VIT DIS, V36, P660, DOI 10.1097/IAE.0000000000000937
   Oshima Y, 2001, BRIT J OPHTHALMOL, V85, P1153, DOI 10.1136/bjo.85.10.1153
   Rasmussen ML, 2015, J DIABETES COMPLICAT, V29, P99, DOI 10.1016/j.jdiacomp.2014.08.009
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Wessel MM, 2012, RETINA-J RET VIT DIS, V32, P785, DOI 10.1097/IAE.0b013e3182278b64
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
   Ying GS, 2018, OPHTHALMOL RETINA, V2, P525, DOI 10.1016/j.oret.2017.10.003
NR 25
TC 5
Z9 5
U1 2
U2 3
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD AUG 21
PY 2020
VL 15
IS 8
AR e0238072
DI 10.1371/journal.pone.0238072
PG 14
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA NG6GN
UT WOS:000564080300004
PM 32822418
OA Green Published, gold
DA 2022-11-30
ER

PT J
AU Neffendorf, JE
   Desai, R
   Wang, Y
   Kelly, J
   Murphy, C
   Reeves, BC
   Chakravarthy, U
   Wordsworth, S
   Lewis, C
   Peacock, J
   Uddin, S
   O'Sullivan, JM
   Jackson, TL
AF Neffendorf, James E.
   Desai, Riti
   Wang, Yanzhong
   Kelly, Joanna
   Murphy, Caroline
   Reeves, Barnaby C.
   Chakravarthy, Usha
   Wordsworth, Sarah
   Lewis, Cornelius
   Peacock, Janet
   Uddin, Shahir
   O'Sullivan, Joe M.
   Jackson, Timothy L.
TI StereoTactic radiotherapy for wet Age-Related macular degeneration
   (STAR): study protocol for a randomised controlled clinical trial
SO TRIALS
LA English
DT Article
DE Anti-vascular endothelial growth factor; VEGF; Neovascular age-related
   macular degeneration; Wet age-related macular degeneration; Radiation;
   Ranibizumab; STAR study; Stereotactic radiotherapy
ID X-RAY-IRRADIATION; AMD 6-MONTH SAFETY; RANIBIZUMAB THERAPY
AB Background: The standard of care for neovascular age-related macular degeneration (nAMD) involves ongoing intravitreal injections of anti-angiogenic drugs targeting vascular endothelial growth factor (VEGF). The most commonly used anti-VEGF drugs are ranibizumab, bevacizumab and aflibercept. The main objective of the STAR trial is to determine if stereotactic radiotherapy can reduce the number of anti-VEGF injections that patients with nAMD require.
   Methods/design: STAR is a multicentre, double-masked, randomised, sham-controlled clinical trial. It evaluates a new device (manufactured by Oraya, Newark, CA, USA) designed to deliver stereotactic radiotherapy (SRT) to nAMD lesions. The trial enrols participants with chronic, active nAMD. Participants receive a single SRT treatment (16 Gy or sham) with a concomitant baseline intravitreal injection of 0.5 mg ranibizumab. Thereafter, they attend every month for 24 months, and ranibizumab is administered at the visit if retreatment criteria are met. The primary outcome is the number of pro re nata ranibizumab injections during the first 24 months. Secondary outcomes include visual acuity, lesion morphology, quality of life and safety. Additional visits occur at 36 and 48 months to inspect for radiation retinopathy.
   The target sample size of 411 participants (randomised 2: 1 in favour of radiation) is designed to detect a reduction of 2.5 injections against ranibizumab monotherapy, at 90% power, and a significance level (alpha) of 0.025 (onesided two-sample t test). This gives 97% power to detect non-inferiority of visual acuity at a five-letter margin. The primary analyses will be by intention to treat.
   Discussion: The safety and efficacy outcomes will help determine the role of SRT in the management of chronic, active nAMD.
C1 [Neffendorf, James E.; Desai, Riti; Uddin, Shahir; Jackson, Timothy L.] Kings Coll Hosp London, Dept Ophthalmol, London, England.
   [Neffendorf, James E.; Jackson, Timothy L.] Kings Coll London, Sch Med, London, England.
   [Wang, Yanzhong; Peacock, Janet] Kings Coll London, Div Hlth & Social Care Res, London, England.
   [Kelly, Joanna; Murphy, Caroline] Kings Coll London, Kings Clin Trials Unit, London, England.
   [Reeves, Barnaby C.] Univ Bristol, Sch Clin Sci, Bristol, Avon, England.
   [Chakravarthy, Usha] Queens Univ Belfast, Cent Angiog Resource Facil, Belfast, Antrim, North Ireland.
   [Wordsworth, Sarah] Univ Oxford, Hlth Econ Res Ctr, Oxford, England.
   [Lewis, Cornelius] Kings Coll Hosp London, Med Phys & Engn, London, England.
   [O'Sullivan, Joe M.] Queens Univ Belfast, Ctr Canc Res & Cell Biol, Belfast, Antrim, North Ireland.
C3 King's College Hospital NHS Foundation Trust; King's College Hospital;
   University of London; King's College London; University of London;
   King's College London; University of London; King's College London;
   University of Bristol; Queens University Belfast; University of Oxford;
   King's College Hospital NHS Foundation Trust; King's College Hospital;
   Queens University Belfast
RP Jackson, TL (通讯作者)，Kings Coll Hosp London, Dept Ophthalmol, London, England.; Jackson, TL (通讯作者)，Kings Coll London, Sch Med, London, England.
EM t.jackson1@nhs.net
OI O'Sullivan, Joe/0000-0001-6999-2739; Reeves,
   Barnaby/0000-0002-5101-9487; Desai, Riti/0000-0001-6425-0648;
   Chakravarthy, Usha/0000-0002-2606-3734; Peacock,
   Janet/0000-0002-0310-2518; Wang, Yanzhong/0000-0002-0768-1676; Jackson,
   Timothy/0000-0001-7618-1555; Wordsworth, Sarah/0000-0002-2361-3040
FU UK's National Institute for Health Research (NIHR) Efficacy and
   Mechanism Evaluation (EME) Programme, an NIHR; UK's National Institute
   for Health Research (NIHR) Efficacy and Mechanism Evaluation (EME)
   Programme, an MRC; EME Programme; National Health Service; National
   Institute for Health Research [12/66/22] Funding Source: researchfish
FX The trial's main funder is the UK's National Institute for Health
   Research (NIHR) Efficacy and Mechanism Evaluation (EME) Programme, an
   NIHR and MRC partnership. The EME Programme will fund all research
   costs. Standard treatment costs are funded by the National Health
   Service. Additional service support is provided by the NIHR
   Comprehensive Clinical Research Network. Use of the SRT devices is
   provided free of charge by Oraya Therapy and Carl Zeiss Ltd (Cambridge,
   UK).
CR Aisenbrey S, 2003, GRAEF ARCH CLIN EXP, V241, P269, DOI 10.1007/s00417-003-0634-8
   Amoaku WM, 2015, EYE, V29, P721, DOI 10.1038/eye.2015.48
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Canton VM, 2011, OPHTHAL SURG LAS IM, V42, P468, DOI 10.3928/15428877-20110804-01
   CHAKRAVARTHY U, 1989, CURR EYE RES, V8, P337, DOI 10.3109/02713688908996381
   Chakravarthy U, 2012, OPHTHALMOLOGY, V119, DOI 10.1016/j.ophtha.2012.04.015
   Drummond MF, 2005, METHODS EC EVALUATIO
   Hanlon J, 2011, INVEST OPHTH VIS SCI, V52, P2334, DOI 10.1167/iovs.10-6421
   Jackson TL, 2015, RETINA-J RET VIT DIS, V35, P194, DOI 10.1097/IAE.0000000000000283
   Jackson TL, 2015, OPHTHALMOLOGY, V122, P138, DOI 10.1016/j.ophtha.2014.07.043
   Jackson TL, 2013, OPHTHALMOLOGY, V120, P1893, DOI 10.1016/j.ophtha.2013.02.016
   Klein R, 1999, OPHTHALMOLOGY, V106, P1056, DOI 10.1016/S0161-6420(99)90255-5
   Mangione CM, 2001, ARCH OPHTHALMOL-CHIC, V119, P1050, DOI 10.1001/archopht.119.7.1050
   Martin DF, 2011, NEW ENGL J MED, V364, P1897, DOI 10.1056/NEJMoa1102673
   Miyamoto H, 1999, INVEST OPHTH VIS SCI, V40, P1496
   Canton VM, 2012, OPHTHAL SURG LAS IM, V43, P20, DOI 10.3928/15428877-20111129-01
   Morales-Canton V, 2013, AM J OPHTHALMOL, V155, P1000, DOI 10.1016/j.ajo.2013.01.015
   Moshfeghi AA, 2012, BRIT J OPHTHALMOL, V96, P1320, DOI 10.1136/bjophthalmol-2011-301222
   Moshfeghi DM, 2011, BRIT J OPHTHALMOL, V95, P185, DOI 10.1136/bjo.2009.163907
   National Institute for Health and Care Excellence (NICE), 2013, GUID METH TECHN APPR
   Neffendorf JE, 2015, CLIN OPHTHALMOL, V9, P1829, DOI 10.2147/OPTH.S75638
   Owen CG, 2012, BRIT J OPHTHALMOL, V96, P752, DOI 10.1136/bjophthalmol-2011-301109
   Petrarca R, 2011, CLIN OPHTHALMOL, V5, P57, DOI 10.2147/OPTH.S16444
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Velez-Montoya R, 2014, MACULAR DEGENERATION, V34, P423
   WILLIAMS A, 1990, HEALTH POLICY, V16, P199
NR 26
TC 11
Z9 12
U1 0
U2 4
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
EI 1745-6215
J9 TRIALS
JI Trials
PD NOV 24
PY 2016
VL 17
AR 560
DI 10.1186/s13063-016-1676-7
PG 12
WC Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Research & Experimental Medicine
GA ED0MO
UT WOS:000388536800004
PM 27881184
OA Green Published, gold
DA 2022-11-30
ER

PT J
AU Castillo, MM
   Mowatt, G
   Elders, A
   Lois, N
   Fraser, C
   Hernandez, R
   Amoaku, W
   Burr, JM
   Lotery, A
   Ramsay, CR
   Azuara-Blanco, A
AF Castillo, Mayret M.
   Mowatt, Graham
   Elders, Andrew
   Lois, Noemi
   Fraser, Cynthia
   Hernandez, Rodolfo
   Amoaku, Winfried
   Burr, Jennifer M.
   Lotery, Andrew
   Ramsay, Craig R.
   Azuara-Blanco, Augusto
TI Optical Coherence Tomography for the Monitoring of Neovascular
   Age-Related Macular Degeneration A Systematic Review
SO OPHTHALMOLOGY
LA English
DT Review
ID CHOROIDAL NEOVASCULARIZATION; PHOTODYNAMIC THERAPY; FLUORESCEIN
   ANGIOGRAPHY; LASER PHOTOCOAGULATION; RANIBIZUMAB; LEAKAGE; VERTEPORFIN;
   ACCURACY; DOMAIN
AB Topic: To compare the accuracy of optical coherence tomography (OCT) with alternative tests for monitoring neovascular age-related macular degeneration (nAMD) and detecting disease activity among eyes previously treated for this condition.
   Clinical Relevance: Traditionally, fundus fluorescein angiography (FFA) has been considered the reference standard to detect nAMD activity, but FFA is costly and invasive. Replacement of FFA by OCT can be justified if there is a substantial agreement between tests.
   Methods: Systematic review and meta-analysis. The index test was OCT. The comparator tests were visual acuity, clinical evaluation (slit lamp), Amsler chart, color fundus photographs, infrared reflectance, red-free images and blue reflectance, fundus autofluorescence imaging, indocyanine green angiography (ICGA), preferential hyperacuity perimetry, and microperimetry. We searched the following databases: MEDLINE, MEDLINE In-Process, EMBASE, Biosis, Science Citation Index, the Cochrane Library, Database of Abstracts of Reviews of Effects, MEDION, and the Health Technology Assessment database. The last literature search was conducted in March 2013. We used the Quality Assessment of Diagnostic Accuracy Studies 2 (QUADAS-2) to assess risk of bias.
   Results: We included 8 studies involving more than 400 participants. Seven reported the performance of OCT (3 time-domain [TD] OCT, 3 spectral-domain [SD] OCT, 1 both types) and 1 reported the performance of ICGA in the detection of nAMD activity. We did not find studies directly comparing tests in the same population. The pooled sensitivity and specificity of TD OCT and SD OCT for detecting active nAMD was 85% (95% confidence interval [CI], 72%-93%) and 48% (95% CI, 30%-67%), respectively. One study reported ICGA with sensitivity of 75.9% and specificity of 88.0% for the detection of active nAMD. Half of the studies were considered to have a high risk of bias.
   Conclusions: There is substantial disagreement between OCT and FFA findings in detecting active disease in patients with nAMD who are being monitored. Both methods may be needed to monitor patients comprehensively with nAMD. (C) 2015 by the American Academy of Ophthalmology.
C1 [Castillo, Mayret M.; Mowatt, Graham; Elders, Andrew; Fraser, Cynthia; Hernandez, Rodolfo; Ramsay, Craig R.] Univ Aberdeen, Hlth Serv Res Unit, Aberdeen, Scotland.
   [Elders, Andrew; Azuara-Blanco, Augusto] Glasgow Caledonian Univ, Midwives & Allied Hlth Profess Res Unit, Glasgow G4 0BA, Lanark, Scotland.
   [Lois, Noemi] Queens Univ Belfast, Ctr Med Expt, Belfast, Antrim, North Ireland.
   [Hernandez, Rodolfo] Univ Aberdeen, Hlth Econ Res Unit, Aberdeen, Scotland.
   [Amoaku, Winfried] Univ Nottingham, Dept Ophthalmol, Fac Med & Hlth Sci, Nottingham NG7 2RD, England.
   [Burr, Jennifer M.] Univ St Andrews, Sch Med, St Andrews, Fife, Scotland.
   [Lotery, Andrew] Univ Southampton, Fac Med, Clin Neurosci Res Grp, Southampton SO9 5NH, Hants, England.
C3 University of Aberdeen; Glasgow Caledonian University; Queens University
   Belfast; University of Aberdeen; University of Nottingham; University of
   St Andrews; University of Southampton
RP Azuara-Blanco, A (通讯作者)，Queens Univ Belfast, Belfast, Antrim, North Ireland.
EM a.azuara-blanco@qub.ac.uk
RI Ramsay, Craig/AAD-8249-2021; Elders, Andrew/N-4195-2015
OI Ramsay, Craig/0000-0003-4043-7349; Elders, Andrew/0000-0003-4172-4702;
   Lotery, Andrew/0000-0001-5541-4305; Amoaku,
   Winfried/0000-0001-5028-7984; Hernandez, Rodolfo/0000-0003-2619-8230;
   Azuara-Blanco, Augusto/0000-0002-4805-9322; Burr,
   Jennifer/0000-0002-9478-738X
FU National Institute for Health Research Health Technology Assessment
   (NIHR HTA) Programme [10/57/22]; Chief Scientist Office (CSO) of the
   Scottish Government Health and Social Care Directorates; National
   Institute for Health Research [10/57/22] Funding Source: researchfish;
   Chief Scientist Office [HERU1, NMAHP2] Funding Source: researchfish
FX This article is based on broader research that was funded by the
   National Institute for Health Research Health Technology Assessment
   (NIHR HTA) Programme (project no. 10/57/22) that will be published in
   full in a Health Technology Assessment. The Health Services Research
   Unit is core-funded by the Chief Scientist Office (CSO) of the Scottish
   Government Health and Social Care Directorates. The views and opinions
   expressed therein are those of the authors and do not necessarily
   reflect those of the HTA programme, the NIHR, the National Health
   Service, the Department of Health, or the CSO.
CR American Academy of Ophthalmology Retina/Vitreous Panel, 2011, PREF PRACT PATT GUID
   Bressler NM, 1999, ARCH OPHTHALMOL-CHIC, V117, P1329
   Brown DM, 2009, OPHTHALMOLOGY, V116, P57, DOI 10.1016/j.ophtha.2008.10.018
   Busbee BG, 2013, OPHTHALMOLOGY, V120, P1046, DOI 10.1016/j.ophtha.2012.10.014
   Cohen SY, 2010, AM J OPHTHALMOL, V150, P211, DOI 10.1016/j.ajo.2010.02.019
   Do DV, 2012, OPHTHALMOLOGY, V119, P771, DOI 10.1016/j.ophtha.2011.10.019
   Eter N, 2005, RETINA-J RET VIT DIS, V25, P691, DOI 10.1097/00006982-200509000-00002
   Giani A, 2011, INVEST OPHTH VIS SCI, V52, P5579, DOI 10.1167/iovs.10-6617
   Glasziou P, 2008, ANN INTERN MED, V149, P816, DOI 10.7326/0003-4819-149-11-200812020-00009
   Henschel A, 2009, EUR J OPHTHALMOL, V19, P831, DOI 10.1177/112067210901900523
   Ivan SI, 2012, OPHTHALMOLOGY, V119, P1399, DOI DOI 10.1016/J.0PHTHA.2012.04.015
   Khurana RN, 2010, OPHTHALMOLOGY, V117, P1376, DOI 10.1016/j.ophtha.2009.11.039
   Leeflang MMG, 2008, ANN INTERN MED, V149, P889, DOI 10.7326/0003-4819-149-12-200812160-00008
   Lois N, 2013, RETINA-J RET VIT DIS, V33, P13, DOI 10.1097/IAE.0b013e3182657fff
   Martin DF, 2012, OPHTHALMOLOGY, V119, DOI 10.1016/j.ophtha.2012.03.053
   McBain VA, 2011, RETINA-J RET VIT DIS, V31, P1043, DOI 10.1097/IAE.0b013e3181fe54c7
   Mowatt G, HLTH TECHNO IN PRESS
   Regillo CD, 1998, OPHTHALMOLOGY, V105, P1821, DOI 10.1016/S0161-6420(98)91022-3
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Royal College of Ophthalmologists (UK), 2013, AG REL MAC DEG GUID
   Salinas-Alaman A, 2005, AM J OPHTHALMOL, V140, P23, DOI 10.1016/j.ajo.2005.01.044
   SCHACHAT AP, 1994, ARCH OPHTHALMOL-CHIC, V112, P500
   STERNBERG P, 1991, ARCH OPHTHALMOL-CHIC, V109, P1220
   Van de Moere A, 2006, BRIT J OPHTHALMOL, V90, P304, DOI 10.1136/bjo.2005.079947
   van Velthoven MEJ, 2006, GRAEF ARCH CLIN EXP, V244, P1119, DOI 10.1007/s00417-005-0209-y
   Whiting PF, 2011, ANN INTERN MED, V155, P529, DOI 10.7326/0003-4819-155-8-201110180-00009
NR 26
TC 49
Z9 49
U1 0
U2 27
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0161-6420
EI 1549-4713
J9 OPHTHALMOLOGY
JI Ophthalmology
PD FEB
PY 2015
VL 122
IS 2
BP 399
EP 406
DI 10.1016/j.ophtha.2014.07.055
PG 8
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA AZ5WT
UT WOS:000348290000033
PM 25444343
OA Green Accepted
DA 2022-11-30
ER

PT J
AU Framme, C
   Panagakis, G
   Walter, A
   Gamulescu, MA
   Herrmann, W
   Helbig, H
AF Framme, Carsten
   Panagakis, Georgios
   Walter, Andreas
   Gamulescu, Maria Andreea
   Herrmann, Wolfgang
   Helbig, Horst
TI Interobserver variability for retreatment indications after Ranibizumab
   loading doses in neovascular age-related macular degeneration
SO ACTA OPHTHALMOLOGICA
LA English
DT Article
DE age-related macular degeneration; Anti-VEGF; choroidal
   neovascularization; intravitreal injection; Lucentis; Ranibizumab;
   spectral domain optical coherence tomography
ID CHOROIDAL NEOVASCULARIZATION
AB Purpose: To assess the interobserver variability (IOV) in indicating retreatment for neovascular Age-related macular degeneration 4 weeks after three Ranibizumab loading doses using spectral domain OCT (SD-OCT) as the primary objective diagnostic tool.
   Material and methods: Four observers decided for or against 4th Ranibizumab injection in 108 patients by six different rating rounds (RR) based on the SD-OCT findings after the loading doses. Postoperative OCT images were supplemented consecutively with information from a chart review as the 'patients subjective estimation of vision (SE)', the course of best-corrected visual acuity (BCVA) and the preoperative OCT as well as all information collectively. Agreement rates (AR) and Kappa statistics were calculated.
   Results: Based on post-treatment OCT findings only (RR1), mean reinjection rate of all observers was 37.5%. Adding supplementary information, mean reinjection rate decreased to 20% when all information was available reflecting the 'real' situation (RR 6). Interobserver agreement rates varied from 66.7% to 90.7% depending on rating rounds and interobserver pairs. Mean AR and Kappa values (KV) were as following: AR 81.6%, KV 0.61 (RR1: 'only post-OP OCT'); AR 76.7%, KV 0.33 (RR2: post-OP OCT + SE); AR 80.3%, KV 0.45 (RR3: post-OP OCT + BCVA); AR 80.7%, KV 0.46 (RR4: pre- and post-OP OCT); AR 82.2%, KV 0.49 (RR5: post-OP OCT + SE + BCVA); and finally AR 83.6%, KV 0.47 (RR6: pre- and post-OP OCT + SE + BCVA). The overall mean agreement rate was 80.9% with a Kappa of 0.47.
   Conclusion: IOV for indicating retreatment after three Ranibizumab loading doses reveals only moderate agreement in Kappa statistics, which seems to be too low considering the high costs for retreatments. More concise guidelines based on the post-treatment OCT scans as the presumably most sensitive and noninvasive objective tool to follow choroidal neovascularization activity by judging the course of sub- and intraretinal fluid are necessary.
C1 [Framme, Carsten] Univ Eye Hosp Bern, CH-3010 Bern, Switzerland.
   [Framme, Carsten; Panagakis, Georgios; Walter, Andreas; Gamulescu, Maria Andreea; Herrmann, Wolfgang; Helbig, Horst] Univ Eye Hosp Regensburg, Regensburg, Germany.
C3 University of Bern; University Hospital of Bern; University of
   Regensburg
RP Framme, C (通讯作者)，Univ Eye Hosp Bern, Freiburgstr 10, CH-3010 Bern, Switzerland.
EM carsten.framme@insel.ch
FU Novartis Pharma GmbH, Nuremberg, Germany
FX This study was financially supported by Novartis Pharma GmbH, Nuremberg,
   Germany.
CR Bashshur ZF, 2009, AM J OPHTHALMOL, V148, P59, DOI 10.1016/j.ajo.2009.02.006
   Blumenkranz MS, 2001, ARCH OPHTHALMOL-CHIC, V119, P198
   Bressler Neil M, 2004, JAMA, V291, P1900, DOI 10.1001/jama.291.15.1900
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Framme C, 2010, INVEST OPHTH VIS SCI, V51, P1671, DOI 10.1167/iovs.09-4496
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P564
   Golbaz I, 2009, OPHTHALMOLOGE, V106, P1103, DOI 10.1007/s00347-008-1880-2
   Keane PA, 2008, INVEST OPHTH VIS SCI, V49, P3115, DOI 10.1167/iovs.08-1689
   Kiss CG, 2009, INVEST OPHTH VIS SCI, V50, P2376, DOI 10.1167/iovs.08-2017
   Lalwani GA, 2009, AM J OPHTHALMOL, V148, P43, DOI 10.1016/j.ajo.2009.01.024
   Leydolt C, 2009, ACTA OPHTHALMOL
   Neue Aspekte in der Therapie der neovaskularen altersbedingten Makuladegeneration, 2009, OPHTHALMOLOGE, V106, P457
   Patel PJ, 2009, ACTA OPHTHALMOL
   Regillo CD, 2008, AM J OPHTHALMOL, V145, P239, DOI 10.1016/j.ajo.2007.10.004
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Rothenbuehler SP, 2009, AM J OPHTHALMOL, V147, P831, DOI 10.1016/j.ajo.2008.12.005
   Sayanagi K, 2009, OPHTHALMOLOGY, V116, P947, DOI 10.1016/j.ophtha.2008.11.002
   Schaal KB, 2009, OPHTHALMOLOGE, V106, P334, DOI 10.1007/s00347-008-1802-3
   Schneider U, 2005, ACTA OPHTHALMOL SCAN, V83, P141, DOI 10.1111/j.1600-0420.2005.00443.x
   Spaide RF, 2009, AM J OPHTHALMOL, V148, P1, DOI 10.1016/j.ajo.2009.04.010
   Viera AJ, 2005, FAM MED, V37, P360
NR 21
TC 12
Z9 12
U1 0
U2 1
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1755-375X
EI 1755-3768
J9 ACTA OPHTHALMOL
JI Acta Ophthalmol.
PD FEB
PY 2012
VL 90
IS 1
BP 49
EP 55
DI 10.1111/j.1755-3768.2010.01940.x
PG 7
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 883HK
UT WOS:000299624600030
PM 20716323
OA Bronze
DA 2022-11-30
ER

PT J
AU Baiula, M
   Caligiana, A
   Bedini, A
   Zhao, J
   Santino, F
   Cirillo, M
   Gentilucci, L
   Giacomini, D
   Spampinato, S
AF Baiula, Monica
   Caligiana, Alberto
   Bedini, Andrea
   Zhao, Junwei
   Santino, Federica
   Cirillo, Martina
   Gentilucci, Luca
   Giacomini, Daria
   Spampinato, Santi
TI Leukocyte Integrin Antagonists as a Novel Option to Treat Dry
   Age-Related Macular Degeneration
SO FRONTIERS IN PHARMACOLOGY
LA English
DT Article
DE age-related macular degeneration; retinal pigment epithelium cells;
   leukocyte integrins; inflammation; integrin antagonist; immune cells
AB Age-related macular degeneration (AMD) is a complex multifactorial degenerative disease that leads to irreversible blindness. AMD affects the macula, the central part of the retina responsible for sharp central vision. Retinal pigment epithelium (RPE) is the main cellular type affected in dry AMD. RPE cells form a monolayer between the choroid and the neuroretina and are in close functional relationship with photoreceptors; moreover, RPE cells are part of the blood retina barrier that is disrupted in ocular diseases such as AMD. During ocular inflammation lymphocytes and macrophages are recruited, contact RPE and produce pro-inflammatory cytokines, which play an important role in AMD pathogenesis. The interaction between RPE and immune cells is mediated by leukocyte integrins, heterodimeric transmembrane receptors, and adhesion molecules, including VCAM-1 and ICAM-1. Within this frame, this study aimed to characterize RPE-leukocytes interaction and to investigate any potentially beneficial effects induced by integrin antagonists (DS-70, MN27 and SR714), developed in previous studies. ARPE-19 cells were co-cultured for different incubation times with Jurkat cells and apoptosis and necrosis levels were analyzed by flow cytometry. Moreover, we measured the mRNA levels of the pro-inflammatory cytokine IL-1 beta and the expression of adhesion molecules VCAM-1 and ICAM-1. We found that RPE-lymphocyte interaction increased apoptosis and necrosis levels in RPE cells and the expression of IL-1 beta. This interaction was mediated by the binding of alpha(4)beta(1) and alpha(L)beta(2) integrins to VCAM-1 and ICAM-1, respectively. The blockade of RPE-lymphocyte interaction with blocking antibodies highlighted the pivotal role played by integrins. Therefore, alpha(4)beta(1) and alpha(L)beta(2) integrin antagonists were employed to disrupt RPE-lymphocyte crosstalk. Small molecule integrin antagonists proved to be effective in reducing RPE cell death and expression of IL-1 beta, demonstrating that integrin antagonists could protect RPE cells from detrimental effects induced by the interaction with immune cells recruited to the retina. Overall, the leukocyte integrin antagonists employed in the present study may represent a novel opportunity to develop new drugs to fight dry AMD.
C1 [Baiula, Monica; Caligiana, Alberto; Bedini, Andrea; Spampinato, Santi] Univ Bologna, Dept Pharm & Biotechnol, Lab Cellular & Mol Pharmacol, Bologna, Italy.
   [Zhao, Junwei; Santino, Federica; Gentilucci, Luca] Univ Bologna, Dept Chem G Ciamician, Bologna, Italy.
   [Cirillo, Martina; Giacomini, Daria] Univ Bologna, Dept Chem G Ciamician, Lab Design & Synth Biol Act Cpds, Bologna, Italy.
   [Spampinato, Santi] Univ Bologna, Specilizat Sch Hosp Pharm, Dept Pharm & Biotechnol, Bologna, Italy.
C3 University of Bologna; University of Bologna; University of Bologna;
   University of Bologna
RP Spampinato, S (通讯作者)，Univ Bologna, Dept Pharm & Biotechnol, Lab Cellular & Mol Pharmacol, Bologna, Italy.; Spampinato, S (通讯作者)，Univ Bologna, Specilizat Sch Hosp Pharm, Dept Pharm & Biotechnol, Bologna, Italy.
EM santi.spampinato@unibo.it
RI Caligiana, Alberto/P-7299-2016; Bedini, Andrea/GOE-5419-2022
OI Caligiana, Alberto/0000-0002-1836-6882; /0000-0003-2088-415X
FU University of Bologna [RFO 2018, RFO 2019, RFO 2020]; Fondazione Cassa
   di Risparmio in Bologna [2018/0347]
FX This work was supported by grants from the University of Bologna RFO
   2018, RFO 2019, RFO 2020 to MB and SS; and from a research grant from
   "Fondazione Cassa di Risparmio in Bologna" (2018/0347).
CR Ablonczy Z, 2011, INVEST OPHTH VIS SCI, V52, P8614, DOI 10.1167/iovs.11-8021
   Akyol E, 2020, BIOL-TARGETS THER, V14, P83, DOI 10.2147/BTT.S252581
   Ambati J, 2012, NEURON, V75, P26, DOI 10.1016/j.neuron.2012.06.018
   Baiula M, 2020, PLOS ONE, V15, DOI 10.1371/journal.pone.0237746
   Baiula M, 2019, FRONT CHEM, V7, DOI 10.3389/fchem.2019.00489
   Baiula M, 2016, J MED CHEM, V59, P9721, DOI 10.1021/acs.jmedchem.6b00576
   Baiula M, 2012, BBA-MOL CELL RES, V1823, P1252, DOI 10.1016/j.bbamcr.2012.05.026
   Bamias G, 2013, CURR DRUG TARGETS, V14, P1490, DOI 10.2174/13894501113149990158
   Bedini A, 2008, J NEUROCHEM, V105, P2166, DOI 10.1111/j.1471-4159.2008.05303.x
   Bedini A, 2017, BIOCHEM PHARMACOL, V140, P89, DOI 10.1016/j.bcp.2017.05.021
   Bian ZM, 2018, EXP EYE RES, V170, P29, DOI 10.1016/j.exer.2018.02.014
   Campagne MV, 2014, J PATHOL, V232, P151, DOI 10.1002/path.4266
   Contreras-Ruiz L, 2016, EXP EYE RES, V143, P1, DOI 10.1016/j.exer.2015.10.008
   Cousins SW, 2004, ARCH OPHTHALMOL-CHIC, V122, P1013, DOI 10.1001/archopht.122.7.1013
   Cox BD, 2006, J CELL BIOCHEM, V99, P36, DOI 10.1002/jcb.20956
   Dattoli SD, 2018, BRIT J PHARMACOL, V175, P3891, DOI 10.1111/bph.14458
   De Marco R, 2015, BIOPOLYMERS, V104, P636, DOI 10.1002/bip.22704
   de Souza RG, 2018, J OCUL PHARMACOL TH, V34, P543, DOI 10.1089/jop.2018.0047
   Devine L, 1996, IMMUNOLOGY, V88, P456, DOI 10.1046/j.1365-2567.1996.d01-666.x
   Di Toro R, 2005, EUR J NEUROSCI, V21, P46, DOI 10.1111/j.1460-9568.2004.03828.x
   Doyle SL, 2012, NAT MED, V18, P791, DOI 10.1038/nm.2717
   Elner SG, 2003, EXP EYE RES, V76, P585, DOI 10.1016/S0014-4835(03)00028-9
   Forest DL, 2015, DIS MODEL MECH, V8, P421, DOI 10.1242/dmm.017236
   Fukuoka Y, 2003, CLIN EXP IMMUNOL, V131, P248, DOI 10.1046/j.1365-2249.2003.02087.x
   Gehrs KM, 2006, ANN MED, V38, P450, DOI 10.1080/07853890600946724
   Haber SL, 2019, THER ADV OPHTHALMOL, V11, DOI 10.1177/2515841419870366
   Hanus J, 2015, AGEING RES REV, V24, P286, DOI 10.1016/j.arr.2015.09.002
   Holtkamp GM, 2001, PROG RETIN EYE RES, V20, P29, DOI 10.1016/S1350-9462(00)00017-3
   Hu TT, 2019, EXP EYE RES, V180, P43, DOI 10.1016/j.exer.2018.11.022
   Hubbard AK, 2000, FREE RADICAL BIO MED, V28, P1379, DOI 10.1016/S0891-5849(00)00223-9
   Jonas JB, 2012, ACTA OPHTHALMOL, V90, pe381, DOI 10.1111/j.1755-3768.2012.02414.x
   Jonas JB, 2010, ARCH OPHTHALMOL-CHIC, V128, P1281, DOI 10.1001/archophthalmol.2010.227
   Juel HB, 2012, INVEST OPHTH VIS SCI, V53, P8472, DOI 10.1167/iovs.12-9963
   Kauppinen A, 2012, IMMUNOL LETT, V147, P29, DOI 10.1016/j.imlet.2012.05.005
   Kelly M, 2007, J ALLERGY CLIN IMMUN, V120, P3, DOI 10.1016/j.jaci.2007.05.017
   Khristov V, 2018, METHODS MOL BIOL, V1722, P223, DOI 10.1007/978-1-4939-7553-2_15
   KILLINGSWORTH MC, 1990, EYE, V4, P613, DOI 10.1038/eye.1990.86
   Krauss AH, 2015, INVEST OPHTH VIS SCI, V56, P5888, DOI 10.1167/iovs.15-17249
   LIVERSIDGE J, 1990, IMMUNOLOGY, V71, P390
   Lobaton T, 2014, ALIMENT PHARM THER, V39, P579, DOI 10.1111/apt.12639
   Lopez-Castejon G, 2011, CYTOKINE GROWTH F R, V22, P189, DOI 10.1016/j.cytogfr.2011.10.001
   Martelli G, 2019, J MED CHEM, V62, P10156, DOI 10.1021/acs.jmedchem.9b01000
   Meldolesi J, 2016, PHARMACOL RES, V107, P430, DOI 10.1016/j.phrs.2015.10.019
   MESRI M, 1994, IMMUNOLOGY, V83, P52
   MILLER H, 1986, INVEST OPHTH VIS SCI, V27, P1644
   Penfold PL, 2001, PROG RETIN EYE RES, V20, P385, DOI 10.1016/S1350-9462(00)00025-2
   PLATTS KE, 1995, INVEST OPHTH VIS SCI, V36, P2262
   Raab-Westphal S, 2017, CANCERS, V9, DOI 10.3390/cancers9090110
   Schnichels S, 2021, PROG RETIN EYE RES, V81, DOI 10.1016/j.preteyeres.2020.100880
   Shokoohmand A, 2017, MACROMOL BIOSCI, V17, DOI 10.1002/mabi.201700221
   Strauss O, 2005, PHYSIOL REV, V85, P845, DOI 10.1152/physrev.00021.2004
   Supuran CT, 2019, EXPERT OPIN THER PAT, V29, P761, DOI 10.1080/13543776.2019.1671353
   Tolomelli A, 2017, CANCERS, V9, DOI 10.3390/cancers9070078
   Tolomelli A, 2015, ACS MED CHEM LETT, V6, P701, DOI 10.1021/acsmedchemlett.5b00125
   VANDERSCHAFT TL, 1993, BRIT J OPHTHALMOL, V77, P657, DOI 10.1136/bjo.77.10.657
   Wang HB, 2016, MOL VIS, V22, P189
   Winer J, 1999, ANAL BIOCHEM, V270, P41, DOI 10.1006/abio.1999.4085
   Xu G Z, 1996, Trans Am Ophthalmol Soc, V94, P411
   Yang DL, 2011, INVEST OPHTH VIS SCI, V52, P6026, DOI 10.1167/iovs.10-7023
   Yasukawa T, 2004, CURR EYE RES, V28, P359, DOI 10.1076/ceyr.28.5.359.28678
   Zhu X, 2016, EXP CELL RES, V348, P87, DOI 10.1016/j.yexcr.2016.09.002
NR 61
TC 3
Z9 3
U1 0
U2 1
PU FRONTIERS MEDIA SA
PI LAUSANNE
PA AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND
SN 1663-9812
J9 FRONT PHARMACOL
JI Front. Pharmacol.
PD JAN 29
PY 2021
VL 11
AR 617836
DI 10.3389/fphar.2020.617836
PG 13
WC Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Pharmacology & Pharmacy
GA QF7CC
UT WOS:000617049300001
PM 33584300
OA Green Published, gold
DA 2022-11-30
ER

PT J
AU Schultz, R
   Hasan, S
   Curcio, CA
   Smith, RT
   Meller, D
   Hammer, M
AF Schultz, Rowena
   Hasan, Somar
   Curcio, Christine A.
   Smith, Roland T.
   Meller, Daniel
   Hammer, Martin
TI Spectral and lifetime resolution of fundus autofluorescence in advanced
   age-related macular degeneration revealing different signal sources
SO ACTA OPHTHALMOLOGICA
LA English
DT Article
DE age-related macular degeneration; complete RPE and outer retinal
   atrophy; drusen; fluorescence lifetimes; fundus autofluorescence;
   hyperpigmentation; macular pigment
ID RETINAL-PIGMENT EPITHELIUM; ATROPHY; DRUSEN
AB Purpose To determine the fundus autofluorescence (FAF) lifetimes and spectral characteristics of individual drusen and hyperpigmentation independent of those with retinal pigment epithelium (RPE) in geographic atrophy (GA) areas in late-stage age-related macular degeneration (AMD). Methods Three consecutive patients with complete RPE and outer retinal atrophy (cRORA) exhibiting drusen that were calcified or associated with hyperpigmentation were investigated with multimodal non-invasive ophthalmic imaging including colour fundus photography (CFP), optical coherence tomography (OCT), near-infrared reflectance (NIR), blue FAF and fluorescence lifetime imaging ophthalmoscopy (FLIO). Fluorescence lifetimes were measured in two spectral channels (short-wavelength spectral channel (SSC): 500-560 nm and long-wavelength spectral channel (LSC): 560-720 nm). Results Drusen lacking RPE coverage, as confirmed by CFP and OCT, had longer FAF lifetimes than surrounding cRORA by 127 +/- 66 ps (SSC) and 113 +/- 48 ps (LSC, both p = 0.008 in Wilcoxon test, N = 9) and by 209 +/- 100 ps (SSC) and 121 +/- 56 ps (LSC, p < 0.001, N = 14) in two patients. Hyperpigmentation in CFP in a third patient shows strong FAF with prolonged lifetimes. In the SSC, persistent FAF was found inside cRORA. A crescent-shaped hyperfluorescence in an area of continuous RPE but lacking outer retina was seen in one eye with a history of anti-VEGF treatment. Conclusions Short-wavelength fluorescence in cRORA points to fluorophores beyond RPE organelles. Fluorescence properties of drusen within cRORA differ from in vivo drusen covered by RPE. These limited findings from three patients give new insight into the sources of FAF that can be further elucidated in larger cohorts.
C1 [Schultz, Rowena; Hasan, Somar; Meller, Daniel; Hammer, Martin] Univ Hosp Jena, Dept Ophthalmol, Klinikum 1, D-07747 Jena, Germany.
   [Curcio, Christine A.] Univ Alabama Birmingham, Sch Med, Dept Ophthalmol & Visual Sci, Birmingham, AL USA.
   [Smith, Roland T.] Mt Sinai Hosp, New York Eye & Ear Infirm Mt Sinai, New York, NY 10029 USA.
   [Hammer, Martin] Univ Jena, Ctr Med Opt & Photon, Jena, Germany.
C3 Friedrich Schiller University of Jena; University of Alabama System;
   University of Alabama Birmingham; Icahn School of Medicine at Mount
   Sinai; New York Eye & Ear Infirmary of Mount Sinai; Friedrich Schiller
   University of Jena
RP Hammer, M (通讯作者)，Univ Hosp Jena, Dept Ophthalmol, Klinikum 1, D-07747 Jena, Germany.
EM martin.hammer@med.uni-jena.de
OI Hasan, Somar/0000-0003-2478-7007; Simon, Rowena/0000-0002-1588-6268
FU NIH [1R01EY027948]
FX Dr. Hammer holds patents on FLIO. Dr. Curcio received research support
   from Heidelberg Engineering GmbH, however, not related to this work.
   None of the other authors have to declare a conflict of interests. No
   funding was received directly for this work. Collaboration on
   autofluorescence research was made possible by NIH grant 1R01EY027948
   (cac, rts).
CR Chen L, 2020, OPHTHALMOL RETINA
   Curcio CA, 2018, INVEST OPHTHALMOL VI, V59, pAMD182
   Curcio CA, 2017, INVEST OPHTH VIS SCI, V58, P211, DOI 10.1167/iovs.17-21872
   Dysli C, 2017, RETINA-J RET VIT DIS, V37, P2151, DOI 10.1097/IAE.0000000000001452
   Dysli C, 2017, INVEST OPHTH VIS SCI, V58, P4856, DOI 10.1167/iovs.17-22184
   Dysli C, 2016, INVEST OPHTH VIS SCI, V57, P2479, DOI 10.1167/iovs.15-18381
   Hammer M, 2020, TRANSL VIS SCI TECHN, V9, DOI 10.1167/tvst.9.5.20
   Hammer M, 2018, BIOMED OPT EXPRESS, V9, P3078, DOI 10.1364/BOE.9.003078
   Jaffe G.J., 2020, OPHTHALMOL RETINA
   Park J, 2012, ATHEROSCLEROSIS, V220, P394, DOI 10.1016/j.atherosclerosis.2011.10.034
   Sadda SR, 2018, OPHTHALMOLOGY, V125, P537, DOI 10.1016/j.ophtha.2017.09.028
   Sauer L, 2018, INVEST OPHTH VIS SCI, V59, pAMD65, DOI 10.1167/iovs.17-23764
   Sauer L, 2018, ACTA OPHTHALMOL, V96, P257, DOI 10.1111/aos.13587
   Sauer L, 2015, INVEST OPHTH VIS SCI, V56, P4668, DOI 10.1167/iovs.14-15335
   Schultz R, 2020, INVEST OPHTH VIS SCI, V61, DOI 10.1167/iovs.61.11.9
   Schweitzer D, 2007, MICROSC RES TECHNIQ, V70, P410, DOI 10.1002/jemt.20427
   Sura AA, 2020, INVEST OPHTH VIS SCI, V61, DOI 10.1167/iovs.61.13.19
   Tan ACS, 2018, SCI TRANSL MED, V10, DOI 10.1126/scitranslmed.aat4544
   Tong YH, 2016, RETINA-J RET VIT DIS, V36, pS127, DOI 10.1097/IAE.0000000000001325
   Zanzottera EC, 2016, RETINA-J RET VIT DIS, V36, pS26, DOI 10.1097/IAE.0000000000001330
NR 20
TC 3
Z9 3
U1 0
U2 1
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1755-375X
EI 1755-3768
J9 ACTA OPHTHALMOL
JI Acta Ophthalmol.
PD MAY
PY 2022
VL 100
IS 3
BP E841
EP E846
DI 10.1111/aos.14963
EA JUL 2021
PG 6
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 0L1ID
UT WOS:000673315400001
PM 34258885
OA hybrid
DA 2022-11-30
ER

PT J
AU Messenio, D
   Babbi, A
   Guglielmi, A
   Airaldi, M
AF Messenio, Dario
   Babbi, Alessandro
   Guglielmi, Alessandra
   Airaldi, Matteo
TI Focal electroretinogram and microperimetry testing of
   photoreceptor-retinal pigment epithelium function in intermediate
   age-related macular degeneration
SO ACTA OPHTHALMOLOGICA
LA English
DT Article
DE focal electroretinogram; intermediate AMD; large drusen; macular
   sensitivity; microperimetry
ID MULTIFOCAL ELECTRORETINOGRAM; NORMAL VALUES; SENSITIVITY; DRUSEN;
   DEPOSITS; DISEASE; ATROPHY
AB Purpose To compare the performance of focal electroretinogram (FERG) and fast mesopic microperimetry in evaluating macular function of intermediate age-related macular degeneration (iAMD) subjects with preserved visual acuity. Methods Cross-sectional, observational study. Participants with drusen >125 mu m and VA >= 80 ETDRS letters and age- and sex-comparable healthy subjects were consecutively enrolled in the study. Three photopic FERG recordings of the central 9 degrees of the macula with luminance modulated stimuli flickering at 42.5 Hz and a fast mesopic microperimetry with a custom pattern of 3 central (CS) and 3 paracentral (pCS) stimuli at 1.2 degrees and 6 degrees from fixation were acquired. Results Overall, 112 eyes of 77 participants (age 73.0 +/- 7.1 years, 47 iAMD eyes) were analysed. Mean FERG amplitude, CS and pCS (all p < 0.05) were lower in the iAMD group. A significant association was observed between FERG amplitude and iAMD (OR 9.58, p < 0.001) in multiple logistic regression analysis. Z-scores of FERG were lower than microperimetry in iAMD (p = 0.002) but not for healthy participants. AUC of the ROC curve was greater for FERG than microperimetry (0.895 versus 0.644 and 0.675, both p < 0.05). Conclusion Focal ERG objectively measures a cumulative response originating from the photoreceptor-RPE complex of the central 9 degrees of the macula and demonstrated high accuracy in identifying decreased central macular function in iAMD patients with preserved visual acuity, performing better than fast mesopic microperimetry. Focal ERG should be considered a reliable technique for measuring retinal sensitivity of iAMD patients.
C1 [Messenio, Dario; Babbi, Alessandro; Airaldi, Matteo] Univ Milan, Sacco Hosp, Eye Clin, Dept Biomed & Clin Sci Luigi Sacco, Milan, Italy.
   [Guglielmi, Alessandra] Politecn Milan, Dept Math, Milan, Italy.
C3 University of Milan; Luigi Sacco Hospital; Polytechnic University of
   Milan
RP Airaldi, M (通讯作者)，Sacco Hosp, Eye Clin, Via GB Grassi 74, I-20157 Milan, Italy.
EM matteo.airaldi@hotmail.com
OI Airaldi, Matteo/0000-0001-9010-1208
CR BARON WS, 1979, VISION RES, V19, P479, DOI 10.1016/0042-6989(79)90132-9
   BIRCH DG, 1992, ARCH OPHTHALMOL-CHIC, V110, P1571, DOI 10.1001/archopht.1992.01080230071024
   Chandramohan A, 2016, RETINA-J RET VIT DIS, V36, P1021, DOI 10.1097/IAE.0000000000001002
   CHENG AS, 1993, OPTOMETRY VISION SCI, V70, P89, DOI 10.1097/00006324-199302000-00001
   Choshi T, 2003, JPN J OPHTHALMOL, V47, P356, DOI 10.1016/S0021-5155(03)00073-X
   Coleman HR, 2008, LANCET, V372, P1835, DOI 10.1016/S0140-6736(08)61759-6
   Crabb JW, 2014, CSH PERSPECT MED, V4, DOI 10.1101/cshperspect.a017194
   Crossland M.D., 2012, INVEST OPHTH VIS SCI, V53, P4822
   Curcio CA, 2005, EXP EYE RES, V81, P731, DOI 10.1016/j.exer.2005.04.012
   Denniss J, 2016, OPHTHAL PHYSL OPT, V36, P453, DOI 10.1111/opo.12304
   Falsini B, 1999, GRAEF ARCH CLIN EXP, V237, P193, DOI 10.1007/s004170050218
   Falsini B, 2000, INVEST OPHTH VIS SCI, V41, P1498
   Falsini B, 2007, INVEST OPHTH VIS SCI, V48, P4811, DOI 10.1167/iovs.07-0306
   Ferris FL, 2013, OPHTHALMOLOGY, V120, P844, DOI 10.1016/j.ophtha.2012.10.036
   Gerth C, 2006, ARCH OPHTHALMOL-CHIC, V124, P345, DOI 10.1001/archopht.124.3.345
   Gerth C, 2003, ARCH OPHTHALMOL-CHIC, V121, P1404, DOI 10.1001/archopht.121.10.1404
   Gin TJ, 2011, INVEST OPHTH VIS SCI, V52, P9267, DOI 10.1167/iovs.11-8517
   Haimovici R, 2001, INVEST OPHTH VIS SCI, V42, P1592
   Hirooka K, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0151000
   Huang Shizhou, 2000, Documenta Ophthalmologica, V101, P115
   Jackson GR, 2006, VISION RES, V46, P1422, DOI 10.1016/j.visres.2005.09.003
   Jackson Gregory R, 2008, J Ocul Biol Dis Infor, V1, P7, DOI 10.1007/s12177-008-9002-6
   Kader MA, 2017, EGYPT J CATARACT REF, V23, P72
   Khan KN, 2016, PROG RETIN EYE RES, V53, P70, DOI 10.1016/j.preteyeres.2016.04.008
   Li J, 2001, BRIT J OPHTHALMOL, V85, P287, DOI 10.1136/bjo.85.3.287
   Messenio D, 2013, DOC OPHTHALMOL, V126, P87, DOI 10.1007/s10633-012-9361-y
   Midena E, 2007, BRIT J OPHTHALMOL, V91, P1499, DOI 10.1136/bjo.2007.119685
   Minnella AM, 2020, TRANSL VIS SCI TECHN, V9, DOI 10.1167/tvst.9.10.28
   Mitchell P, 2018, LANCET, V392, P1147, DOI 10.1016/S0140-6736(18)31550-2
   Molina-Martin A, 2017, EUR J OPHTHALMOL, V27, P607, DOI 10.5301/ejo.5000930
   Parisi V, 2020, INVEST OPHTH VIS SCI, V61, DOI 10.1167/iovs.61.5.11
   PAULEIKHOFF D, 1992, OPHTHALMOLOGY, V99, P1548
   SARKS JP, 1988, EYE, V2, P552, DOI 10.1038/eye.1988.106
   Savastano MC, 2020, J CLIN MED, V9, DOI 10.3390/jcm9092973
   SEIPLE WH, 1986, INVEST OPHTH VIS SCI, V27, P1123
   Steinberg JS, 2017, TRANSL VIS SCI TECHN, V6, DOI 10.1167/tvst.6.4.7
   Vujosevic S, 2011, OPHTHALMOLOGICA, V225, P155, DOI 10.1159/000320340
   Wong T, 2008, OPHTHALMOLOGY, V115, P116, DOI 10.1016/j.ophtha.2007.03.008
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
   Wu Z., 2021, OPHTHALMOL RETINA
   Wu ZC, 2014, INVEST OPHTH VIS SCI, V55, P6431, DOI 10.1167/iovs.14-14407
NR 41
TC 0
Z9 0
U1 0
U2 2
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1755-375X
EI 1755-3768
J9 ACTA OPHTHALMOL
JI Acta Ophthalmol.
PD MAY
PY 2022
VL 100
IS 3
BP 277
EP 284
DI 10.1111/aos.14934
EA JUN 2021
PG 8
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 0L1ID
UT WOS:000668098200001
PM 34189851
OA hybrid, Green Published
DA 2022-11-30
ER

PT J
AU Christen, WG
   Cook, NR
   Chiuve, SE
   Ridker, PM
   Gaziano, JM
AF Christen, William G.
   Cook, Nancy R.
   Chiuve, Stephanie E.
   Ridker, Paul M.
   Gaziano, J. Michael
TI Prospective study of plasma homocysteine, its dietary determinants, and
   risk of age-related macular degeneration in men
SO OPHTHALMIC EPIDEMIOLOGY
LA English
DT Article
DE Homocysteine; diet; age-related macular degeneration; case-control
ID FOOD-FREQUENCY QUESTIONNAIRE; PHYSICIANS HEALTH; VITAMINS E;
   RANDOMIZED-TRIAL; FOLIC-ACID; CARDIOVASCULAR-DISEASE; FOLATE;
   PREVENTION; BETAINE; PATHOGENESIS
AB Purpose: Cross-sectional and case-control studies generally support a direct association between elevated plasma homocysteine and age-related macular degeneration (AMD), but data from prospective studies are limited. We examined the prospective relation of plasma homocysteine level, its dietary determinants, and risk of AMD in a large cohort of apparently healthy male physicians.
   Methods: During a mean follow-up of 11.2 years, we identified 146 incident cases of visually significant AMD (responsible for a reduction of visual acuity to 20/30 or worse), and 146 controls matched for age, smoking status, and time of blood draw. We measured concentration of homocysteine in blood samples collected at baseline using an enzymatic assay. and we assessed dietary intake of B vitamins and related compounds betaine and choline with a food frequency questionnaire administered at baseline.
   Results: AMD was not associated with plasma level of homocysteine; the multivariable-adjusted odds ratio (OR) of AMD comparing the highest and lowest quartile of homocysteine was 1.09 (95% confidence interval [95% CI]: 0.52-2.31; p for trend = 0.99). However, AMD was inversely associated with quartile of intake of total folate (OR: 0.55; 95% CI: 0.24-1.23; p for trend = 0.08), vitamin B-6 from food (OR: 0.39; 95% CI: 0.17-0.88; p for trend = 0.01), and betaine (OR: 0.53; 95% CI: 0.22-1.27; p for trend = 0.048).
   Conclusions: These prospective data from a cohort of apparently healthy men do not support a major role for homocysteine in AMD occurrence, but do suggest a possible beneficial role for higher intake of several nutrients involved in homocysteine metabolism.
C1 [Christen, William G.; Cook, Nancy R.; Chiuve, Stephanie E.; Ridker, Paul M.; Gaziano, J. Michael] Harvard Med Sch, Brigham & Womens Hosp, Dept Med, Div Prevent Med, Boston, MA USA.
   [Gaziano, J. Michael] Harvard Med Sch, Brigham & Womens Hosp, Dept Med, Div Aging, Boston, MA USA.
   [Ridker, Paul M.] Harvard Med Sch, Brigham & Womens Hosp, Ctr Cardiovasc Dis Prevent, Boston, MA USA.
   [Ridker, Paul M.] Harvard Med Sch, Brigham & Womens Hosp, Donald W Reynolds Ctr Cardiovasc Res, Boston, MA USA.
   [Cook, Nancy R.; Ridker, Paul M.] Harvard Sch Publ Hlth, Dept Epidemiol, Boston, MA USA.
   [Chiuve, Stephanie E.] Harvard Sch Publ Hlth, Dept Nutr, Boston, MA USA.
C3 Harvard University; Brigham & Women's Hospital; Harvard Medical School;
   Harvard University; Brigham & Women's Hospital; Harvard Medical School;
   Harvard University; Brigham & Women's Hospital; Harvard Medical School;
   Harvard University; Brigham & Women's Hospital; Harvard Medical School;
   Harvard University; Harvard T.H. Chan School of Public Health; Harvard
   University; Harvard T.H. Chan School of Public Health
RP Christen, WG (通讯作者)，900 Commonwealth Ave East, Boston, MA 02215 USA.
EM wchristen@rics.bwh.harvard.edu
RI Stefanadis, Christodoulos/ABH-2232-2020
OI Stefanadis, Christodoulos/0000-0001-5974-6454; Chiuve,
   Stephanie/0000-0002-3524-8917; Venkatasubramanian,
   Siddharth/0000-0002-5860-0768
FU National Eye Institute [CA 097193]; National Institute on Aging [CA
   097193]; National Institutes of Health (Bethesda, MD) [CA 34944, CA
   40360, HL 26490, HL 34595, EY 18820]; BASF Corporation (Florham Park,
   NJ); NATIONAL CANCER INSTITUTE [R01CA097193, R01CA040360] Funding
   Source: NIH RePORTER; NATIONAL EYE INSTITUTE [R01EY018820] Funding
   Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE
   [R01HL034595] Funding Source: NIH RePORTER
FX Supported by grants CA 097193 (which included funding from the National
   Eye Institute and the National Institute on Aging), CA 34944, CA 40360,
   HL 26490, HL 34595, and EY 18820 from the National Institutes of Health
   (Bethesda, MD), an investigator-initiated grant from BASF Corporation
   (Florham Park, NJ), and a gift from ScienceBased Health (Houston, TX).
   Study agents and packaging were provided by BASF Corporation and Pfizer
   (formerly Wyeth, American Home Products, and Lederle) (New York, NY),
   and study packaging was provided by DSM Nutritional Products, Inc.
   (formerly Roche Vitamins) (Parsippany, NJ).
CR [Anonymous], 1989, NEW ENGL J MED, V321, P129, DOI DOI 10.1056/NEJM198907203210301
   Beatty S, 2000, SURV OPHTHALMOL, V45, P115, DOI 10.1016/S0039-6257(00)00140-5
   Bidulescu A, 2009, NUTR J, V8, DOI 10.1186/1475-2891-8-14
   BOUSHEY CJ, 1995, JAMA-J AM MED ASSOC, V274, P1049, DOI 10.1001/jama.274.13.1049
   Cho E, 2006, AM J CLIN NUTR, V83, P905, DOI 10.1093/ajcn/83.4.905
   Christen WG, 2015, OPHTHAL EPIDEMIOL, V22, P85, DOI 10.3109/09286586.2015.1012272
   Christen WG, 2014, OPHTHALMOLOGY, V121, P525, DOI 10.1016/j.ophtha.2013.09.038
   Christen WG, 2012, OPHTHALMOLOGY, V119, P1642, DOI 10.1016/j.ophtha.2012.01.053
   Christen WG, 2010, ARCH OPHTHALMOL-CHIC, V128, P1397, DOI 10.1001/archophthalmol.2010.266
   Clarke R, 2002, JAMA-J AM MED ASSOC, V288, P2015, DOI 10.1001/jama.288.16.2015
   Detopoulou P, 2008, AM J CLIN NUTR, V87, P424, DOI 10.1093/ajcn/87.2.424
   DURRLEMAN S, 1989, STAT MED, V8, P551, DOI 10.1002/sim.4780080504
   Feigl B, 2009, PROG RETIN EYE RES, V28, P63, DOI 10.1016/j.preteyeres.2008.11.004
   FISKERSTRAND T, 1993, CLIN CHEM, V39, P263
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P532
   Friedman E, 2000, AM J OPHTHALMOL, V130, P658, DOI 10.1016/S0002-9394(00)00643-7
   Gaziano JM, 2012, JAMA-J AM MED ASSOC, V308, P1871, DOI 10.1001/jama.2012.14641
   Gaziano JM, 2009, JAMA-J AM MED ASSOC, V301, P52, DOI 10.1001/jama.2008.862
   GLYNN RJ, 1992, ARCH OPHTHALMOL-CHIC, V110, P381, DOI 10.1001/archopht.1992.01080150079033
   Gopinath B, 2017, BRIT J OPHTHALMOL, V101, P1027, DOI 10.1136/bjophthalmol-2016-309490
   Gopinath B, 2013, AM J CLIN NUTR, V98, P129, DOI 10.3945/ajcn.112.057091
   Hageman GS, 2001, PROG RETIN EYE RES, V20, P705, DOI 10.1016/S1350-9462(01)00010-6
   Hennekens CH, 1996, NEW ENGL J MED, V334, P1145, DOI 10.1056/NEJM199605023341801
   Heuberger RA, 2002, AM J CLIN NUTR, V76, P897, DOI 10.1093/ajcn/76.4.897
   Holm PI, 2005, ARTERIOSCL THROM VAS, V25, P379, DOI 10.1161/01.ATV.0000151283.33976.e6
   Huang PR, 2015, SCI REP-UK, V5, DOI 10.1038/srep10585
   Hustad S, 2012, CLIN CHEM, V58, P402, DOI 10.1373/clinchem.2011.174490
   Hutchinson JN, 2014, HUM HERED, V78, P59, DOI 10.1159/000362814
   Joshi R, 2001, FREE RADICAL BIO MED, V30, P1390, DOI 10.1016/S0891-5849(01)00543-3
   Kamburoglu G, 2006, GRAEF ARCH CLIN EXP, V244, P565, DOI 10.1007/s00417-005-0108-2
   Merle BMJ, 2016, AM J CLIN NUTR, V103, P1135, DOI 10.3945/ajcn.115.117606
   Nowak M, 2005, EUR J OPHTHALMOL, V15, P764, DOI 10.1177/112067210501500617
   Oliver VF, 2015, EPIGENETICS-US, V10, P698, DOI 10.1080/15592294.2015.1060388
   RIMM EB, 1992, AM J EPIDEMIOL, V135, P1114, DOI 10.1093/oxfordjournals.aje.a116211
   Rochtchina E, 2007, AM J OPHTHALMOL, V143, P344, DOI 10.1016/j.ajo.2006.08.032
   Schmetterer L, 2001, PROG RETIN EYE RES, V20, P823, DOI 10.1016/S1350-9462(01)00014-3
   Seddon JM, 2011, OPHTHALMOLOGY, V118, P1386, DOI 10.1016/j.ophtha.2010.12.020
   SELHUB J, 1992, AM J CLIN NUTR, V55, P131, DOI 10.1093/ajcn/55.1.131
   Sesso HD, 2008, JAMA-J AM MED ASSOC, V300, P2123, DOI 10.1001/jama.2008.600
   Sesso HD, 2012, JAMA-J AM MED ASSOC, V308, P1751, DOI 10.1001/jama.2012.14805
   Steed MM, 2011, ANTIOXID REDOX SIGN, V15, P1927, DOI 10.1089/ars.2010.3721
   Ullegaddi R, 2004, CLIN SCI, V107, P477, DOI 10.1042/CS20040134
   *USDA, 2004, USDA DAT CHOL CONT C
   WILLETT W, 1986, AM J EPIDEMIOL, V124, P17, DOI 10.1093/oxfordjournals.aje.a114366
   WILLETT WC, 1985, AM J EPIDEMIOL, V122, P51, DOI 10.1093/oxfordjournals.aje.a114086
   Zeisel SH, 2003, J NUTR, V133, P1302
NR 46
TC 10
Z9 10
U1 0
U2 4
PU TAYLOR & FRANCIS INC
PI PHILADELPHIA
PA 530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA
SN 0928-6586
EI 1744-5086
J9 OPHTHAL EPIDEMIOL
JI Ophthalmic Epidemiol.
PY 2018
VL 25
IS 1
BP 79
EP 88
DI 10.1080/09286586.2017.1362009
PG 10
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA FZ6WT
UT WOS:000427741700011
PM 29035128
OA Green Accepted
DA 2022-11-30
ER

PT J
AU Qiu, FF
   Matlock, G
   Chen, Q
   Zhou, KL
   Du, YH
   Wang, X
   Ma, JX
AF Qiu, Fangfang
   Matlock, Greg
   Chen, Qian
   Zhou, Kelu
   Du, Yanhong
   Wang, Xiang
   Ma, Jian-Xing
TI Therapeutic Effects of PPAR alpha Agonist on Ocular Neovascularization
   in Models Recapitulating Neovascular Age-Related Macular Degeneration
SO INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE
LA English
DT Article
DE age-related macular degeneration; PPAR alpha; fenofibrate; inflammation;
   retina; neovascularization
ID RETINAL ANGIOMATOUS PROLIFERATION; DENSITY LIPOPROTEIN RECEPTOR; WNT
   SIGNALING PATHWAY; TISSUE DISTRIBUTION; SUBRETINAL NEOVASCULARIZATION;
   DIABETIC-RETINOPATHY; ACTIVATED RECEPTORS; PATHOGENIC ROLE; FENOFIBRATE;
   EXPRESSION
AB PURPOSE. This study was designed to evaluate effects of fenofibric acid (Feno-FA), a peroxisome proliferator-activated receptor-alpha (PPAR alpha) agonist, on ocular neovascularization (NV) in models recapitulating neovascular age-related macular degeneration (AMD), and to explore whether the effects are PPAR alpha dependent.
   METHODS. Laser-induced choroidal NV (CNV) in rats and very low-density lipoprotein receptor knockout (Vldlr(-/-)) mice received daily intraperitoneal injections of Feno-FA or vehicle. Vascular leakage was examined by fundus fluorescein angiography and permeability assay using Evans blue as tracer. In CNV rats, severity of CNV was evaluated by CNV areas and CNV volume. In Vdlr(-/-) mice, subretinal NV (SRNV) and intraretinal NV (IRNV) were quantified in choroid flat mount and retina flat mount, respectively. Inflammatory factors were measured using Western blotting and retinal leukostasis assay. Further, Ppar alpha(-/-) mice and age-matched wild-type (WT) mice were used for laser-induced CNV and treated with Feno-FA to explore the underlying mechanism.
   RESULTS. Feno-FA significantly reduced vascular leakage in CNV rats and Vidlr(-/-) mice, reduced CNV volume in laser-induced CNV rats, and suppressed SRNV and IRNV in Vidir(-/-) mice. In addition, Feno-FA downregulated the expression of inflammatory factors, including VEGF, TNF-alpha, and intercellular cell adhesion molecule-1 (ICAM-1), in the eyecups of CNV rats and decreased adherent retinal leukocytes in Vldlr(-/-) mice. Furthermore, Ppar alpha(-/-) mice developed more severe CNV compared with WT mice, and PPAR alpha knockout abolished the beneficial effects of Feno-FA on CNV.
   CONCLUSIONS. Feno-FA has therapeutic effects on ocular NV in models recapitulating neovascular AMD through a PPAR alpha-dependent mechanism.
C1 [Qiu, Fangfang; Matlock, Greg; Chen, Qian; Zhou, Kelu; Du, Yanhong; Ma, Jian-Xing] Univ Oklahoma, Hlth Sci Ctr, Dept Physiol, 941 Stanton L Young Blvd,BSEB 328B, Oklahoma City, OK 73104 USA.
   [Wang, Xiang] Univ Oklahoma, Hlth Sci Ctr, Dept Cell Biol, Oklahoma City, OK USA.
C3 University of Oklahoma System; University of Oklahoma Health Sciences
   Center; University of Oklahoma System; University of Oklahoma Health
   Sciences Center
RP Ma, JX (通讯作者)，Univ Oklahoma, Hlth Sci Ctr, Dept Physiol, 941 Stanton L Young Blvd,BSEB 328B, Oklahoma City, OK 73104 USA.
EM Jian-xing-Ma@ouhsc.edu
RI Qiu, Fangfang/GLT-3151-2022; Qiu, Fangfang/GLT-3181-2022
OI Qiu, Fangfang/0000-0002-3584-0275; Qiu, Fangfang/0000-0002-3584-0275
FU National Institutes of Health (NIH) [GM122744, EY018659, EY012231,
   EY019309]; NIH [P30 EY027125]; Juvenile Diabetes Research Foundation
   (JDRF) [2-SRA-2014-147-Q-R]; Oklahoma Center for the Advancement of
   Science and Technology (OCAST) [HR16-041]; NATIONAL EYE INSTITUTE
   [R01EY019309, R01EY018659, R01EY012231] Funding Source: NIH RePORTER;
   NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [P30GM122744] Funding
   Source: NIH RePORTER
FX The authors thank the Diabetic Animal Core facility funded by Grant
   GM122744 for its support.
CR Ambati J, 2012, NEURON, V75, P26, DOI 10.1016/j.neuron.2012.06.018
   Arca M, 2007, FREE RADICAL BIO MED, V42, P698, DOI 10.1016/j.freeradbiomed.2006.12.013
   Auboeuf D, 1997, DIABETES, V46, P1319, DOI 10.2337/diabetes.46.8.1319
   Berger A, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0096494
   Bermig J, 2002, GRAEF ARCH CLIN EXP, V240, P169, DOI 10.1007/s00417-001-0378-2
   Bordet R, 2006, BIOCHEM SOC T, V34, P1341, DOI 10.1042/BST0341341
   Bottoni F, 2005, ARCH OPHTHALMOL-CHIC, V123, P1644, DOI 10.1001/archopht.123.12.1644
   Braissant O, 1996, ENDOCRINOLOGY, V137, P354, DOI 10.1210/en.137.1.354
   Cai X, 2014, BIOMATERIALS, V35, P249, DOI 10.1016/j.biomaterials.2013.10.022
   Castillero E, 2011, AM J PHYSIOL-ENDOC M, V300, pE790, DOI 10.1152/ajpendo.00590.2010
   Chakravarthy U, 2010, BMJ-BRIT MED J, V340, DOI 10.1136/bmj.c981
   Chen XR, 2007, J NEUROTRAUM, V24, P1119, DOI 10.1089/neu.2006.0216
   Chen Y, 2007, J BIOL CHEM, V282, P34420, DOI 10.1074/jbc.M611289200
   Chen Y, 2013, DIABETES, V62, P261, DOI 10.2337/db11-0413
   Chen Y, 2009, MICROVASC RES, V78, P119, DOI 10.1016/j.mvr.2009.02.005
   Del V. C. M., 2008, PPAR RES, V2008
   Donati MC, 2006, OPHTHALMOLOGICA, V220, P31, DOI 10.1159/000089272
   Edelman JL, 2000, EXP EYE RES, V71, P523, DOI 10.1006/exer.2000.0907
   FRYKMAN PK, 1995, P NATL ACAD SCI USA, V92, P8453, DOI 10.1073/pnas.92.18.8453
   Gehrs KM, 2006, ANN MED, V38, P450, DOI 10.1080/07853890600946724
   Giani A, 2011, INVEST OPHTH VIS SCI, V52, P3880, DOI 10.1167/iovs.10-6266
   Ginsberg HN, 2010, NEW ENGL J MED, V362, P1563, DOI 10.1056/NEJMoa1001282
   Gong Y, 2016, EBIOMEDICINE, V13, P201, DOI 10.1016/j.ebiom.2016.09.025
   Heckenlively JR, 2003, RETINA-J RET VIT DIS, V23, P518, DOI 10.1097/00006982-200308000-00012
   Hu WZ, 2008, INVEST OPHTH VIS SCI, V49, P407, DOI 10.1167/iovs.07-0870
   Hu Y, 2013, P NATL ACAD SCI USA, V110, P15401, DOI 10.1073/pnas.1307211110
   Hu Y, 2013, INVEST OPHTH VIS SCI, V54, P141, DOI 10.1167/iovs.12-10281
   Hua J, 2011, INVEST OPHTH VIS SCI, V52, P2809, DOI 10.1167/iovs.10-6496
   Jager RD, 2008, NEW ENGL J MED, V358, P2606, DOI 10.1056/NEJMra0801537
   Jiang AH, 2009, INVEST OPHTH VIS SCI, V50, P844, DOI 10.1167/iovs.08-2447
   Kanda A, 2008, BRIT J OPHTHALMOL, V92, P448, DOI 10.1136/bjo.2007.131581
   Keech AC, 2007, LANCET, V370, P1687, DOI 10.1016/S0140-6736(07)61607-9
   Kim CH, 2010, MOL CELL BIOCHEM, V344, P91, DOI 10.1007/s11010-010-0532-4
   Kim J, 2007, EXP EYE RES, V84, P886, DOI 10.1016/j.exer.2007.01.009
   Kovach JL, 2012, J OPHTHALMOL, V2012, DOI 10.1155/2012/786870
   Lafaut BA, 2000, GRAEF ARCH CLIN EXP, V238, P752, DOI 10.1007/s004170000180
   Lemberger T, 1996, ANN NY ACAD SCI, V804, P231, DOI 10.1111/j.1749-6632.1996.tb18619.x
   Li H, 2017, EUR J PHARMACOL, V812, P155, DOI 10.1016/j.ejphar.2017.07.027
   Lim LS, 2012, LANCET, V379, P1728, DOI 10.1016/S0140-6736(12)60282-7
   LIU JB, 2011, PPAR RES, DOI DOI 10.1155/2011/523520
   Meissner M, 2004, CIRC RES, V94, P324, DOI 10.1161/01.RES.0000113781.08139.81
   Miyachi H, 2003, BIOORG MED CHEM LETT, V13, P3145, DOI 10.1016/S0960-894X(03)00715-7
   Okayasu T, 2008, LIFE SCI, V82, P884, DOI 10.1016/j.lfs.2008.02.002
   Park J, 2016, INVEST OPHTH VIS SCI, V57
   Rath NP, 2005, ACTA CRYSTALLOGR C, V61, pO81, DOI 10.1107/S0108270104032573
   Schoonjans K, 1996, EMBO J, V15, P5336, DOI 10.1002/j.1460-2075.1996.tb00918.x
   Sulaiman RS, 2015, J OCUL PHARMACOL TH, V31, P447, DOI 10.1089/jop.2015.0049
   Telander DG, 2011, SEMIN OPHTHALMOL, V26, P192, DOI 10.3109/08820538.2011.570849
   Varet J, 2003, CELL MOL LIFE SCI, V60, P810, DOI 10.1007/s00018-003-2322-6
   Vlase L, 2010, ARZNEIMITTEL-FORSCH, V60, P560, DOI 10.1055/s-0031-1296325
   Xia CH, 2011, INVEST OPHTH VIS SCI, V52, P6572, DOI 10.1167/iovs.10-7082
   Yamasaki D, 2011, EUR J CELL BIOL, V90, P657, DOI 10.1016/j.ejcb.2011.02.005
   Yannuzzi LA, 2001, RETINA-J RET VIT DIS, V21, P416, DOI 10.1097/00006982-200110000-00003
   Zhang K, 2012, NAT REV DRUG DISCOV, V11, P541, DOI 10.1038/nrd3745
NR 54
TC 25
Z9 25
U1 0
U2 6
PU ASSOC RESEARCH VISION OPHTHALMOLOGY INC
PI ROCKVILLE
PA 12300 TWINBROOK PARKWAY, ROCKVILLE, MD 20852-1606 USA
SN 0146-0404
EI 1552-5783
J9 INVEST OPHTH VIS SCI
JI Invest. Ophthalmol. Vis. Sci.
PD OCT
PY 2017
VL 58
IS 12
BP 5065
EP 5075
DI 10.1167/iovs.17-22091
PG 11
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA FL5JN
UT WOS:000414272100004
PM 28980001
OA gold, Green Published
DA 2022-11-30
ER

PT J
AU Cougnard-Greoire, A
   Merle, BM
   Korobelnik, JF
   Rougier, MB
   Delyfer, MN
   Fert, C
   Le Goff, M
   Dartigues, JF
   Barberger-Gateau, P
   Delcourt, C
AF Cougnard-Gregoire, Audrey
   Merle, Benedicte Mj
   Korobelnik, Jean-Francois
   Rougier, Marie-Benedicte
   Delyfer, Marie-Noelle
   Feart, Catherine
   Le Goff, Melanie
   Dartigues, Jean-Francois
   Barberger-Gateau, Pascale
   Delcourt, Cecile
TI Vitamin D Deficiency in Community-Dwelling Elderly Is Not Associated
   with Age-Related Macular Degeneration
SO JOURNAL OF NUTRITION
LA English
DT Article
DE vitamin D; deficiency; 25-hydroxyvitamin D; age-related macular
   degeneration; elderly; community-dwelling population
ID 3RD NATIONAL-HEALTH; NUTRITION; PREVALENCE; RISK; INFLAMMATION;
   MACULOPATHY; PROGRESSION; OLDER
AB Background: Elderly persons are at elevated risk of vitamin D deficiency, which is involved in various health problems. However, its relation with age-related macular degeneration (AMD) is debated.
   Objectives: We investigated factors associated with plasma 25-hydroxyvitamin D (25(OH)D) deficiency and the associations between plasma 25(OH)D concentrations and AMD in elderly subjects.
   Methods: Antioxydants, Lipides Essentiels, Nutrition et maladies OculaiRes (ALIENOR) is a population-based study on eye diseases performed in elderly residents of Bordeaux, France. Plasma 25(OH)D concentrations were assessed from blood samples and categorized as <25 nmol/L (deficiency), 25-49 nmol/L (insufficiency), or 50 nmol/L (sufficiency). AMD was classified as: no AMD, early AMD, and late AMD. Associations between baseline characteristics and plasma 25(OH)D status were examined with multinomial logistic regression analysis. Associations between AMD and plasma 25(OH)D status were estimated using generalized estimating equation logistic regressions.
   Results: Six hundred ninety-seven subjects with complete data were included. The prevalence of plasma 25(OH)D deficiency and insufficiency were 27.3% and 55.9%, respectively. In multivariate analysis, 25(OH)D deficiency was significantly associated with older age (P = 0.0007), females (P = 0.0007), absence of physical activity (P = 0.01), absence of vitamin D supplementation (P < 0.0001), higher plasma total cholesterol (P = 0.007), use of fibrates (P < 0.0001), lower alcohol consumption (P = 0.02), and season of blood sampling (P < 0.0001). After adjustment for these covariates and dietary omega-3 polyunsaturated fatty acid intake, smoking, and body mass index, no significant associations were found between early AMD and 25(OH)D insufficiency or deficiency (OR: 0.71, P = 0.12; OR: 0.73, P = 0.23, respectively) or with late AMD (OR: 1.04, P = 0.93; OR: 0.74, P = 0.59, respectively).
   Conclusion: These findings underline the very high prevalence of plasma 25(OH)D deficiency in this elderly population but do not support a specific role for vitamin D in AMD.
C1 [Cougnard-Gregoire, Audrey; Merle, Benedicte Mj; Korobelnik, Jean-Francois; Delyfer, Marie-Noelle; Feart, Catherine; Le Goff, Melanie; Dartigues, Jean-Francois; Barberger-Gateau, Pascale; Delcourt, Cecile] Univ Bordeaux, ISPED, Bordeaux, France.
   [Cougnard-Gregoire, Audrey; Merle, Benedicte Mj; Feart, Catherine; Le Goff, Melanie; Dartigues, Jean-Francois; Barberger-Gateau, Pascale; Delcourt, Cecile] INSERM, Ctr INSERM Epidemiol Biostat U897, Bordeaux, France.
   [Korobelnik, Jean-Francois; Rougier, Marie-Benedicte; Delyfer, Marie-Noelle] Bordeaux Univ Hosp, Dept Ophthalmol, Bordeaux, France.
C3 UDICE-French Research Universities; Universite de Bordeaux; Institut
   National de la Sante et de la Recherche Medicale (Inserm); CHU Bordeaux
RP Cougnard-Greoire, A (通讯作者)，Univ Bordeaux, ISPED, Bordeaux, France.
RI KOROBELNIK, Jean-Francois/A-5448-2016; Merle, Benedicte MJ/F-1247-2015;
   COUGNARD-GREGOIRE, Audrey/T-4443-2019; LE GOFF, Mélanie/A-3541-2016;
   DARTIGUES, Jean François/T-4513-2019; Delyfer, Marie-Noelle/T-3304-2019;
   FEART, Catherine/A-3339-2016; Delcourt, Cecile/I-2627-2013; Merle,
   Benedicte MJ/AAQ-5021-2021
OI Merle, Benedicte MJ/0000-0003-1332-0954; COUGNARD-GREGOIRE,
   Audrey/0000-0002-1494-5764; Delcourt, Cecile/0000-0002-2099-0481; Merle,
   Benedicte MJ/0000-0003-1332-0954; FEART, Catherine/0000-0002-7959-1610;
   LE GOFF, Melanie/0000-0003-2848-6287
FU Laboratoires Thea (Clermont-Ferrand, France); Fondation Voir et Entendre
   (Paris, France)
FX Supported by Laboratoires Thea (Clermont-Ferrand, France) and Fondation
   Voir et Entendre (Paris, France).
CR Aberg F, 1998, EUR J CLIN INVEST, V28, P235
   Alperovitch A, 2003, NEUROEPIDEMIOLOGY, V22, P316, DOI 10.1159/000072920
   Baird PN, 2006, HUM MUTAT, V27, P337, DOI 10.1002/humu.20288
   BIRD AEC, 1995, SURV OPHTHALMOL, V39, P367, DOI 10.1016/S0039-6257(05)80092-X
   Brock K, 2010, J STEROID BIOCHEM, V121, P462, DOI 10.1016/j.jsbmb.2010.03.091
   Brouwer-Brolsma EM, 2013, OSTEOPOROSIS INT, V24, P1567, DOI 10.1007/s00198-012-2231-3
   Chaudhuri JR, 2013, J LIPIDS, V2013, DOI 10.1155/2013/623420
   Day S, 2012, ARCH OPHTHALMOL-CHIC, V130, P1070, DOI 10.1001/archophthalmol.2012.439
   Delcourt C, 2010, J NUTR HEALTH AGING, V14, P854, DOI 10.1007/s12603-010-0131-9
   Delcourt C, 2012, ARCH OPHTHALMOL-CHIC, V130, P1077, DOI 10.1001/archophthalmol.2012.420
   Delcourt C, 2011, INVEST OPHTH VIS SCI, V52, P5955, DOI 10.1167/iovs.10-6235
   Feart C, 2007, BRIT J NUTR, V98, P1046, DOI 10.1017/S0007114507756520
   Golan S, 2011, EYE, V25, P1122, DOI 10.1038/eye.2011.174
   Holick MF, 2007, NEW ENGL J MED, V357, P266, DOI 10.1056/NEJMra070553
   Holick MF, 2012, J CLIN ENDOCR METAB, V97, P1153, DOI 10.1210/jc.2011-2601
   Karhapaa P, 2010, J Intern Med, V268, P604, DOI 10.1111/j.1365-2796.2010.02279.x
   Klein R, 2006, OPHTHALMOLOGY, V113, P373, DOI 10.1016/j.ophtha.2005.12.013
   Laird E, 2014, J CLIN ENDOCR METAB, V99, P1807, DOI 10.1210/jc.2013-3507
   Lee V, 2012, NEUROBIOL AGING, V33, P2382, DOI 10.1016/j.neurobiolaging.2011.12.002
   Lips P, 2007, J STEROID BIOCHEM, V103, P620, DOI 10.1016/j.jsbmb.2006.12.076
   Lips P, 2001, ENDOCR REV, V22, P477, DOI 10.1210/er.22.4.477
   Lips P, 2010, J STEROID BIOCHEM, V121, P297, DOI 10.1016/j.jsbmb.2010.02.021
   Martins D, 2007, ARCH INTERN MED, V167, P1159, DOI 10.1001/archinte.167.11.1159
   Merle BMJ, 2013, J NUTR, V143, P505, DOI 10.3945/jn.112.171033
   Millen AE, 2011, ARCH OPHTHALMOL-CHIC, V129, P481, DOI 10.1001/archophthalmol.2011.48
   Morrison Margaux A., 2011, Human Genomics, V5, P538
   Mosekilde L, 2005, CLIN ENDOCRINOL, V62, P265, DOI 10.1111/j.1365-2265.2005.02226.x
   Parekh N, 2007, ARCH OPHTHALMOL-CHIC, V125, P661, DOI 10.1001/archopht.125.5.661
   Pearce SHS, 2010, BRIT MED J, V340, DOI 10.1136/bmj.b5664
   Resnikoff S, 2004, B WORLD HEALTH ORGAN, V82, P844
   Rosen CJ, 2012, J CLIN ENDOCR METAB, V97, P1146, DOI 10.1210/jc.2011-2218
   Scholl HPN, 2007, MOL VIS, V13, P196
   Seddon JM, 2007, JAMA-J AM MED ASSOC, V297, P1793, DOI 10.1001/jama.297.16.1793
   Seddon JM, 2011, OPHTHALMOLOGY, V118, P1386, DOI 10.1016/j.ophtha.2010.12.020
   Song HR, 2014, J KOREAN MED SCI, V29, P149, DOI 10.3346/jkms.2014.29.1.149
   Torres MJ, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0105137
   van Schoor NM, 2014, OSTEOPOROSIS INT, V25, P1483, DOI 10.1007/s00198-014-2651-3
   van Schoor NM, 2011, BEST PRACT RES CL EN, V25, P671, DOI 10.1016/j.beem.2011.06.007
   Youssef DA, 2011, GERIATR GERONTOL INT, V11, P395, DOI 10.1111/j.1447-0594.2011.00716.x
   ZEGER SL, 1988, BIOMETRICS, V44, P1049, DOI 10.2307/2531734
   Zhang MC, 2014, MED SCI MONITOR, V20, P1274, DOI 10.12659/MSM.890930
NR 41
TC 23
Z9 24
U1 1
U2 24
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 0022-3166
EI 1541-6100
J9 J NUTR
JI J. Nutr.
PD AUG
PY 2015
VL 145
IS 8
BP 1865
EP 1872
DI 10.3945/jn.115.214387
PG 8
WC Nutrition & Dietetics
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Nutrition & Dietetics
GA CO3DT
UT WOS:000359037500025
PM 26084364
OA Bronze
DA 2022-11-30
ER

PT J
AU Zhu, MD
   Chew, JK
   Broadhead, GK
   Luo, KH
   Joachim, N
   Hong, T
   Syed, A
   Chang, AA
AF Zhu, Meidong
   Chew, Jamie K.
   Broadhead, Geoffrey K.
   Luo, Kehui
   Joachim, Nichole
   Hong, Thomas
   Syed, Adil
   Chang, Andrew A.
TI Intravitreal Ranibizumab for neovascular Age-related macular
   degeneration in clinical practice: five-year treatment outcomes
SO GRAEFES ARCHIVE FOR CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY
LA English
DT Article
DE Ranibizumab; Neovascular age-related macular degeneration (nAMD);
   As-needed treatment model; Five-year treatment; Exudative age-related
   macular degeneration; Wet macular degeneration
ID THICKNESS MEASUREMENTS; REPRODUCIBILITY; EYES; THERAPY
AB Intravitreal anti-vascular endothelial growth factor (anti-VEGF) agents are the established standard of care for neovascular age-related macular degeneration (nAMD). However, data on long-term outcomes of this therapy are limited. The purpose of this study was to assess the visual and anatomical outcomes and safety profile of intravitreal ranibizumab in treating nAMD over a period of five years.
   208 patients (208 eyes) were included in this retrospective case series study. Intervention was an "as-needed" treatment model. Visual acuity (VA), central macular thickness (CMT), ophthalmic examination, and adverse events (AEs) were assessed in each visit. Snellen VA was converted to Early Treatment Diabetic Retinopathy Study letters for analysis.
   The average VA improved by 1.9 letters after one year (p = 0.017), and decreased by 2.4 letters over five years of treatment (p = 0.043). At the end of year five, 11.1 % of patients (23/208) had improved VA by more than 15 letters and 68.8 % (143/208) had VA improvement or loss less than or equal to 15 letters, while 20.2 % of patients (42/208) had a loss of more than 15 letters. Patients with VA of less than 35 letters at baseline showed significant VA improvement after five years of treatment. There was a positive relationship between injection numbers and VA improvement over the five-year period, after adjusting for age and baseline VA (p < 0.0005). Mean CMT decreased by 28.3 mu m (p < 0.0005) over five years. Ocular AEs, serious adverse events (SAEs), and systemic SAEs occurred in 4.6 %, 0.48 %, and 2 % of patients, respectively, during the follow-up period.
   The use of intravitreal ranibizumab in an as-needed treatment regimen over a five-year period was effective in maintaining vision in patients with nAMD and in reducing macular thickness, with a relatively low rate of adverse and serious adverse events.
C1 [Zhu, Meidong; Chew, Jamie K.; Broadhead, Geoffrey K.; Joachim, Nichole; Hong, Thomas; Syed, Adil; Chang, Andrew A.] Sydney Inst Vis Sci, Sydney, NSW 2000, Australia.
   [Zhu, Meidong; Chew, Jamie K.; Broadhead, Geoffrey K.; Syed, Adil; Chang, Andrew A.] Univ Sydney, Save Sight Inst, Sydney, NSW 2006, Australia.
   [Luo, Kehui] Macquarie Univ, Dept Stat, Sydney, NSW 2109, Australia.
C3 University of Sydney; Macquarie University
RP Chang, AA (通讯作者)，Sydney Inst Vis Sci, Level 13,187 Macquarie St, Sydney, NSW 2000, Australia.
EM achang@sydneyretina.com.au
FU Novartis Pharmaceuticals Australia Pty Limited
FX This research is supported in part by an unrestricted grant from
   Novartis Pharmaceuticals Australia Pty Limited. The sponsor had no role
   in the design or conduct of this research.
CR BLAND JM, 1986, LANCET, V1, P307, DOI 10.1016/s0140-6736(86)90837-8
   Brown DM, 2013, RETINA-J RET VIT DIS, V33, P23, DOI 10.1097/IAE.0b013e318263cedf
   Brown DM, 2009, OPHTHALMOLOGY, V116, P57, DOI 10.1016/j.ophtha.2008.10.018
   Chakravarthy U, 2012, OPHTHALMOLOGY, V119, DOI 10.1016/j.ophtha.2012.04.015
   Chang AA, 2014, OPHTHALMOLOGY, V121, P188, DOI 10.1016/j.ophtha.2013.08.035
   Falk MK, 2013, AM J OPHTHALMOL, V155, P89, DOI 10.1016/j.ajo.2012.06.031
   Folgar FA, 2014, OPHTHALMOLOGY
   Giani A, 2010, AM J OPHTHALMOL, V150, P815, DOI 10.1016/j.ajo.2010.06.025
   Golbaz I, 2011, INVEST OPHTH VIS SCI, V52, P1599, DOI 10.1167/iovs.09-5018
   Gregori NZ, 2010, RETINA-J RET VIT DIS, V30, P1046, DOI 10.1097/IAE.0b013e3181d87e04
   Hatef E, 2012, J OPHTHALMOL, V2012, DOI 10.1155/2012/354783
   Joeres S, 2007, INVEST OPHTH VIS SCI, V48, P4300, DOI 10.1167/iovs.07-0179
   Klein R, 2011, ARCH OPHTHALMOL-CHIC, V129, P75, DOI 10.1001/archophthalmol.2010.318
   Krebs I, 2012, BRIT J OPHTHALMOL, V96, P271, DOI 10.1136/bjo.2010.194662
   Lalwani GA, 2009, AM J OPHTHALMOL, V148, P43, DOI 10.1016/j.ajo.2009.01.024
   Lim LS, 2012, LANCET, V379, P1728, DOI 10.1016/S0140-6736(12)60282-7
   Martin DF, 2012, OPHTHALMOLOGY, V119, DOI 10.1016/j.ophtha.2012.03.053
   Martin DF, 2011, NEW ENGL J MED, V364, P1897, DOI 10.1056/NEJMoa1102673
   Mitchell P, 2010, BRIT J OPHTHALMOL, V94, P2, DOI 10.1136/bjo.2009.159160
   Pushpoth S, 2012, BRIT J OPHTHALMOL, V96, P1469, DOI 10.1136/bjophthalmol-2012-302167
   Rasmussen A, 2013, OPHTHALMOLOGY
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Schachat AP, 2013, AM J OPHTHALMOL, V156, P1, DOI 10.1016/j.ajo.2013.04.009
   Velez-Montoya R, 2013, RETINA-J RET VIT DIS, V33, P1487, DOI 10.1097/IAE.0b013e318271f265
   Wolf-Schnurrbusch UEK, 2009, INVEST OPHTH VIS SCI, V50, P3432, DOI 10.1167/iovs.08-2970
   Wong T, 2008, OPHTHALMOLOGY, V115, P116, DOI 10.1016/j.ophtha.2007.03.008
NR 26
TC 28
Z9 29
U1 0
U2 3
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0721-832X
EI 1435-702X
J9 GRAEF ARCH CLIN EXP
JI Graefes Arch. Clin. Exp. Ophthalmol.
PD AUG
PY 2015
VL 253
IS 8
BP 1217
EP 1225
DI 10.1007/s00417-014-2799-8
PG 9
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA CN9AA
UT WOS:000358736700003
PM 25205618
DA 2022-11-30
ER

PT J
AU Lombardo, M
   Serrao, S
   Lombardo, G
AF Lombardo, Marco
   Serrao, Sebastiano
   Lombardo, Giuseppe
TI Challenges in Age-Related Macular Degeneration: From Risk Factors to
   Novel Diagnostics and Prevention Strategies
SO FRONTIERS IN MEDICINE
LA English
DT Review
DE age-related macular degeneration (AMD); lutein; adaptive optics;
   Resonance Raman (RR) spectroscopy; prevention
ID GENOME-WIDE ASSOCIATION; ZEAXANTHIN SUPPLEMENTATION; LUTEIN
   SUPPLEMENTATION; VITAMIN-A; DIETARY ANTIOXIDANTS; CAROTENOID-PIGMENTS;
   RAMAN MEASUREMENT; ECONOMIC BURDEN; VISUAL-ACUITY; EYE DISEASE
AB Age-related macular degeneration (AMD) is a chronic multifactorial eye disease representing the primary cause of vision loss in people aged 60 years and older. The etiopathogenesis of the disease remains uncertain, with several risk factors contributing to its onset and progression, such as genotype, aging, hypertension, smoking, overweight, and low dietary intake of carotenoids. Since the aging populations of the industrialized world are increasing rapidly, the impact of AMD in the socio-economical life-developed countries is expected to increase dramatically in the next years. In this context, the benefits of prevention and early disease detection for prompt and effective treatment can be enormous to reduce the social and economic burden of AMD. Nutritional and lifestyle changes, including dietary intake of xanthophyll pigments, such as lutein and zeaxanthin, no smoking, and regular exercise, are known to protect from risk of AMD progression from early to advanced disease stages. In this review, we present the clinical outcomes of a pilot study on trans-scleral iontophoresis delivery of lutein in patients with AMD. Topical delivery of lutein directly to the macula may provide a more efficient method for enriching the macular pigment and for achieving greater patient compliance to therapy than oral administration and thus enhancing prevention strategies. Modern diagnostic methodologies shall address the major problem of accurately detecting the risk of transition from intermediate AMD to advanced AMD stages. Adaptive optics retinal imaging and resonance Raman spectroscopy are two highly promising technologies for the objective assessment of patients with AMD. In this review, we present some of their clinical applications for collecting quantitative measurements of retinal cellular changes and macular content of xanthophyll pigments, respectively. In conclusion, there is great expectation that technological advancements in AMD management will deliver improved screening, therapeutic prevention, and diagnostic systems in the coming decade through a pro-active strategy of "treatment for prevention" that will aim to reduce the global burden of vision loss caused by AMD in the elderly.
C1 [Lombardo, Marco; Serrao, Sebastiano] Studio Italiano Oftalmol, Rome, Italy.
   [Lombardo, Marco; Serrao, Sebastiano; Lombardo, Giuseppe] Vis Engn Italy srl, Rome, Italy.
   [Lombardo, Giuseppe] Ist Proc Chim Fisici, CNR IPCF, Messina, Italy.
C3 Consiglio Nazionale delle Ricerche (CNR); Istituto per i Processi
   Chimico-Fisici (IPCF-CNR)
RP Lombardo, M (通讯作者)，Studio Italiano Oftalmol, Rome, Italy.; Lombardo, M; Lombardo, G (通讯作者)，Vis Engn Italy srl, Rome, Italy.; Lombardo, G (通讯作者)，Ist Proc Chim Fisici, CNR IPCF, Messina, Italy.
EM mlombardo@visioeng.it; giuseppe.lombardo@cnr.it
CR Age-Related Eye Disease Study 2 Research Group, 2013, JAMA, V309, P2005, DOI 10.1001/jama.2013.4997
   Arrigo A, 2020, RETINA-J RET VIT DIS, V40, P2263, DOI 10.1097/IAE.0000000000002775
   Baraas RC, 2021, FRONT AGING NEUROSCI, V13, DOI 10.3389/fnagi.2021.732287
   Berendschot TTJM, 2000, INVEST OPHTH VIS SCI, V41, P3322
   Bernstein PS, 2009, ACTA HORTIC, V841, P103
   Bernstein PS, 2004, ARCH BIOCHEM BIOPHYS, V430, P163, DOI 10.1016/j.abb.2004.07.004
   Bernstein PS, 1998, INVEST OPHTH VIS SCI, V39, P2003
   Bhosale P, 2009, BIOCHEMISTRY-US, V48, P4798, DOI 10.1021/bi9004478
   Bian QN, 2012, FREE RADICAL BIO MED, V53, P1298, DOI 10.1016/j.freeradbiomed.2012.06.024
   BONE RA, 1988, INVEST OPHTH VIS SCI, V29, P843
   Boretsky A, 2012, LASER SURG MED, V44, P603, DOI 10.1002/lsm.22070
   Brown Gary C, 2005, Trans Am Ophthalmol Soc, V103, P173
   Carneiro A, 2017, OXID MED CELL LONGEV, V2017, DOI 10.1155/2017/6469138
   Carroll J, 2013, CURR EYE RES, V38, P709, DOI 10.3109/02713683.2013.784792
   Casten Robin J, 2004, Curr Opin Ophthalmol, V15, P181, DOI 10.1097/01.icu.0000120710.35941.3f
   Chakravarthy U, 2010, BMC OPHTHALMOL, V10, DOI 10.1186/1471-2415-10-31
   Chen SF, 2001, CURR EYE RES, V23, P422, DOI 10.1076/ceyr.23.6.422.6963
   Chew EY, 2012, OPHTHALMOLOGY, V119, P2282, DOI 10.1016/j.ophtha.2012.05.027
   Chopdar A, 2003, BRIT MED J, V326, P485, DOI 10.1136/bmj.326.7387.485
   Colijn JM, 2021, OPHTHALMOLOGY, V128, P1039, DOI 10.1016/j.ophtha.2020.11.024
   Colijn JM, 2017, OPHTHALMOLOGY, V124, P1753, DOI 10.1016/j.ophtha.2017.05.035
   Cooper RF, 2016, VISUAL NEUROSCI, V33, DOI 10.1017/S0952523816000018
   Cruess AF, 2008, PHARMACOECONOMICS, V26, P57, DOI 10.2165/00019053-200826010-00006
   Damian I, 2022, LIFE-BASEL, V12, DOI 10.3390/life12030454
   De Koning-Backus APM, 2019, AM J OPHTHALMOL, V198, P70, DOI 10.1016/j.ajo.2018.09.036
   Eljarrat-Binstock E, 2006, J CONTROL RELEASE, V110, P479, DOI 10.1016/j.jconrel.2005.09.049
   Ermakov IV, 2005, J BIOMED OPT, V10, DOI 10.1117/1.2139974
   Ermakov IV, 2005, APPL SPECTROSC, V59, P861, DOI 10.1366/0003702054411616
   Ferris FL, 2005, ARCH OPHTHALMOL-CHIC, V123, P1570
   Ferris FL, 2013, OPHTHALMOLOGY, V120, P844, DOI 10.1016/j.ophtha.2012.10.036
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P564
   Fritsche LG, 2016, NAT GENET, V48, P134, DOI 10.1038/ng.3448
   Gellermann W, 2002, J OPT SOC AM A, V19, P1172, DOI 10.1364/JOSAA.19.001172
   Gocho K, 2013, INVEST OPHTH VIS SCI, V54, P3673, DOI 10.1167/iovs.12-10672
   Godara Pooja, 2010, Ophthalmic Surg Lasers Imaging, V41 Suppl, pS104, DOI 10.3928/15428877-20101031-07
   Granado F, 2007, PUBLIC HEALTH NUTR, V10, P1018, DOI 10.1017/S1368980007662314
   Hammond BR, 2005, J BIOMED OPT, V10, DOI 10.1117/1.2116767
   Jeffery RHC, 2021, ASIA-PAC J OPHTHALMO, V10, P442, DOI 10.1097/APO.0000000000000415
   Ho L, 2011, ARCH OPHTHALMOL-CHIC, V129, P758, DOI 10.1001/archophthalmol.2011.141
   Joachim N, 2015, OPHTHALMOLOGY, V122, P2482, DOI 10.1016/j.ophtha.2015.08.002
   Khachik F, 2006, INVEST OPHTH VIS SCI, V47, P5234, DOI 10.1167/iovs.06-0504
   Kijlstra A, 2012, PROG RETIN EYE RES, V31, P303, DOI 10.1016/j.preteyeres.2012.03.002
   Klein R, 2006, OPHTHALMOLOGY, V113, P373, DOI 10.1016/j.ophtha.2005.12.013
   Koushan K, 2013, NUTRIENTS, V5, P1823, DOI 10.3390/nu5051823
   Land ME, 2014, OPTOMETRY VISION SCI, V91, P939, DOI 10.1097/OPX.0000000000000323
   Landrum JT, 2001, ARCH BIOCHEM BIOPHYS, V385, P28, DOI 10.1006/abbi.2000.2171
   Liu R, 2015, INVEST OPHTH VIS SCI, V56, P252, DOI 10.1167/iovs.14-15553
   Loane E, 2010, INVEST OPHTH VIS SCI, V51, P2636, DOI 10.1167/iovs.09-4397
   Lombardo G, 2016, INVEST OPHTH VIS SCI, V57, P476, DOI 10.1167/iovs.15-18651
   Lombardo M, 2018, J BIOPHOTONICS, V11, DOI 10.1002/jbio.201700095
   Lombardo M, 2013, SENSORS-BASEL, V13, P334, DOI 10.3390/s130100334
   Loprinzi PD, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0125394
   Lucarini M, 2006, INT J VITAM NUTR RES, V76, P103, DOI 10.1024/0300-9831.76.3.103
   Maller JB, 2007, NAT GENET, V39, P1200, DOI 10.1038/ng2131
   Mares JA, 2011, ARCH OPHTHALMOL-CHIC, V129, P470, DOI 10.1001/archophthalmol.2010.314
   Mariotti L, 2016, BIOMED OPT EXPRESS, V7, P2807, DOI 10.1364/BOE.7.002807
   Merle BMJ, 2021, NUTRIENTS, V13, DOI 10.3390/nu13062047
   Moeller SM, 2006, ARCH OPHTHALMOL-CHIC, V124, P1151, DOI 10.1001/archopht.124.8.1151
   Moshfeghi AA, 2020, OSLI RETINA, V51, pS6, DOI 10.3928/23258160-20200401-01
   Mujat M, 2010, OPT EXPRESS, V18, P11607, DOI 10.1364/OE.18.011607
   Murray IJ, 2013, INVEST OPHTH VIS SCI, V54, P1781, DOI 10.1167/iovs.12-10715
   Musch DC, 2014, JAMA OPHTHALMOL, V132, P139, DOI 10.1001/jamaophthalmol.2013.7443
   Myles ME, 2005, ADV DRUG DELIVER REV, V57, P2063, DOI 10.1016/j.addr.2005.08.006
   NIH, 2012, NIH PUBLICATION, V04-4288
   Owen CG, 2012, BRIT J OPHTHALMOL, V96, P752, DOI 10.1136/bjophthalmol-2011-301109
   Rapp LM, 2000, INVEST OPHTH VIS SCI, V41, P1200
   Ratnayake K, 2020, CELL SIGNAL, V69, DOI 10.1016/j.cellsig.2020.109547
   Rein DB, 2009, ARCH OPHTHALMOL-CHIC, V127, P533, DOI 10.1001/archophthalmol.2009.58
   Rein DB, 2006, ARCH OPHTHALMOL-CHIC, V124, P1754, DOI 10.1001/archopht.124.12.1754
   Renzi LM, 2012, LIPIDS HEALTH DIS, V11, DOI 10.1186/1476-511X-11-33
   Rodriguez-Carmona M, 2006, OPHTHAL PHYSL OPT, V26, P137, DOI 10.1111/j.1475-1313.2006.00386.x
   SanGiovanni JP, 2007, ARCH OPHTHALMOL-CHIC, V125, P1225, DOI 10.1001/archopht.125.9.1225
   Sasaki M, 2012, J NUTR BIOCHEM, V23, P423, DOI 10.1016/j.jnutbio.2011.01.006
   SEDDON JM, 1994, JAMA-J AM MED ASSOC, V272, P1413, DOI 10.1001/jama.272.18.1413
   Seddon JM, 2011, OPHTHALMOLOGY, V118, P2203, DOI 10.1016/j.ophtha.2011.04.029
   Sharifzadeh M, 2008, J OPT SOC AM A, V25, P947, DOI 10.1364/JOSAA.25.000947
   Smith W, 2001, OPHTHALMOLOGY, V108, P697, DOI 10.1016/S0161-6420(00)00580-7
   Sobrin L, 2012, OPHTHALMOLOGY, V119, P1874, DOI 10.1016/j.ophtha.2012.03.014
   Sousa-Martins D, 2016, INVEST OPHTH VIS SCI, V57
   Subczynski WK, 2010, ARCH BIOCHEM BIOPHYS, V504, P61, DOI 10.1016/j.abb.2010.05.015
   Tan CS, 2022, CLIN OPHTHALMOL, V16, P917, DOI 10.2147/OPTH.S231913
   Tan JSL, 2008, OPHTHALMOLOGY, V115, P334, DOI 10.1016/j.ophtha.2007.03.083
   Tan TE, 2021, FRONT GENET, V12, DOI 10.3389/fgene.2021.795010
   Thomson LR, 2002, INVEST OPHTH VIS SCI, V43, P3538
   Trieschmann M, 2008, EYE, V22, P132, DOI 10.1038/sj.eye.6702780
   United Nations, 2019, WORLD POPULATION AGI
   Weigert G, 2011, INVEST OPHTH VIS SCI, V52, P8174, DOI 10.1167/iovs.11-7522
   Werner JS, 2000, J OPT SOC AM A, V17, P1918, DOI 10.1364/JOSAA.17.001918
   Widomska Justyna, 2014, J Clin Exp Ophthalmol, V5, P326
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
   World Health Organization, 2012, GLOB DAT VIS IMP 201
   Wu JL, 2019, DRUG DES DEV THER, V13, P2413, DOI 10.2147/DDDT.S206355
   Xu XY, 2020, GRAEF ARCH CLIN EXP, V258, P1931, DOI 10.1007/s00417-020-04774-w
   Yemelyanov AY, 2001, EXP EYE RES, V72, P381, DOI 10.1006/exer.2000.0965
NR 94
TC 2
Z9 2
U1 2
U2 2
PU FRONTIERS MEDIA SA
PI LAUSANNE
PA AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND
EI 2296-858X
J9 FRONT MED-LAUSANNE
JI Front. Med.
PD JUN 6
PY 2022
VL 9
AR 887104
DI 10.3389/fmed.2022.887104
PG 17
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine
GA 2F6FK
UT WOS:000813003100001
PM 35733877
OA gold, Green Published
DA 2022-11-30
ER

PT J
AU Taniguchi, H
   Shiba, T
   Maeno, T
   Takahashi, M
AF Taniguchi, Hikari
   Shiba, Tomoaki
   Maeno, Takatoshi
   Takahashi, Mao
TI Evaluation of Carotid Atherosclerosis, Peripheral Arterial Disease, and
   Chronic Kidney Disease in Patients with Exudative Age-Related Macular
   Degeneration without Coronary Artery Disease or Stroke
SO OPHTHALMOLOGICA
LA English
DT Article
DE Age-related macular degeneration; Carotid atherosclerosis; Chronic
   kidney disease; Mean intima-media thickness; Peripheral arterial disease
ID RENAL-INSUFFICIENCY; VISUAL IMPAIRMENT; MEDIA THICKNESS; FOLLOW-UP;
   RISK; POPULATION; MACULOPATHY; BLINDNESS; CLASSIFICATION; RANIBIZUMAB
AB Purpose: To evaluate the risk factors for acute atherothrombotic events in patients with exudative age-related macular degeneration (AMD) without a history of coronary artery disease or stroke. Methods: Two hundred fifty-nine patents with exudative AMD were evaluated for carotid atherosclerosis, peripheral arterial disease, and chronic kidney disease (CKD). Results: A mean intima-media thickness of >= 1.0 mm was found in 28.2% of patients; 8.9% of patients had severe carotid artery stenosis. The prevalence rates of severe atherosclerosis with a plaque score >10, peripheral arterial disease, and CKD were 16.6, 5.4, and 32%, respectively. Diabetes mellitus and AMD affecting eyes bilaterally were identified as risk factors for abnormal carotid artery thickening, and age and body mass index were identified as risk factors for CKD. Conclusion: The current study confirmed that potentially 30% of patients with exudative AMD without a history of coronary artery disease or stroke have a high risk of acute atherothrombotic events. (C) 2015 S. Karger AG, Basel
C1 [Taniguchi, Hikari; Shiba, Tomoaki; Maeno, Takatoshi] Toho Univ, Sakura Med Ctr, Dept Ophthalmol, Sakura, Chiba 2858741, Japan.
   [Takahashi, Mao] Toho Univ, Sakura Med Ctr, Cardiovasc Ctr, Sakura, Chiba 2858741, Japan.
C3 Toho University; Toho University
RP Shiba, T (通讯作者)，Toho Univ, Sakura Med Ctr, Dept Ophthalmol, 564-1 Shimoshizu, Sakura, Chiba 2858741, Japan.
EM tomoaki-s@sakura.med.toho-u.ac.jp
CR Attebo K, 1996, OPHTHALMOLOGY, V103, P357
   BIRD AEC, 1995, SURV OPHTHALMOL, V39, P367, DOI 10.1016/S0039-6257(05)80092-X
   Bressler NM, 2011, ARCH OPHTHALMOL-CHIC, V129, P709, DOI 10.1001/archophthalmol.2011.140
   Chambless LE, 2000, AM J EPIDEMIOL, V151, P478
   Culleton BF, 1999, KIDNEY INT, V56, P2214, DOI 10.1046/j.1523-1755.1999.00773.x
   FERRIS FL, 1984, ARCH OPHTHALMOL-CHIC, V102, P1640
   Garg AX, 2002, KIDNEY INT, V61, P1486, DOI 10.1046/j.1523-1755.2002.00270.x
   Go AS, 2004, NEW ENGL J MED, V351, P1296, DOI 10.1056/NEJMoa041031
   Gordon MS, 2005, ONCOLOGY-BASEL, V69, P25, DOI 10.1159/000088481
   Gronholdt MLM, 2001, CIRCULATION, V104, P68, DOI 10.1161/hc2601.091704
   HANDA N, 1990, STROKE, V21, P1567, DOI 10.1161/01.STR.21.11.1567
   HANDA N, 1995, STROKE, V26, P1781, DOI 10.1161/01.STR.26.10.1781
   Hood JD, 1998, AM J PHYSIOL-HEART C, V274, pH1054
   Hu CC, 2010, STROKE, V41, P613, DOI 10.1161/STROKEAHA.109.571000
   Ikram MK, 2012, STROKE, V43, P1681, DOI 10.1161/STROKEAHA.112.654632
   Imai E, 2009, CLIN EXP NEPHROL, V13, P621, DOI 10.1007/s10157-009-0199-x
   Kallikazaros I, 1999, STROKE, V30, P1002, DOI 10.1161/01.STR.30.5.1002
   Keith DS, 2004, ARCH INTERN MED, V164, P659, DOI 10.1001/archinte.164.6.659
   KLEIN R, 1995, INVEST OPHTH VIS SCI, V36, P182
   Levey AS, 2005, KIDNEY INT, V67, P2089, DOI 10.1111/j.1523-1755.2005.00365.x
   Munoz B, 2000, ARCH OPHTHALMOL-CHIC, V118, P819, DOI 10.1001/archopht.118.6.819
   NEWMAN AB, 1993, CIRCULATION, V88, P837, DOI 10.1161/01.CIR.88.3.837
   O'Leary DH, 1999, NEW ENGL J MED, V340, P14, DOI 10.1056/NEJM199901073400103
   Ohnishi H, 2010, J ATHEROSCLER THROMB, V17, P751, DOI 10.5551/jat.3731
   STERNBERG P, 1991, ARCH OPHTHALMOL-CHIC, V109, P1220
   Stewart MW, 2012, MAYO CLIN PROC, V87, P77, DOI 10.1016/j.mayocp.2011.10.001
   Sun C, 2009, OPHTHALMOLOGY, V116, P1913, DOI 10.1016/j.ophtha.2009.03.046
   Takiuchi S, 2004, J HUM HYPERTENS, V18, P17, DOI 10.1038/sj.jhh.1001628
   Yoshida I, 2014, GRAEF ARCH CLIN EXP, V252, P1483, DOI 10.1007/s00417-014-2717-0
   Zheng ZJ, 1997, ATHEROSCLEROSIS, V131, P115, DOI 10.1016/S0021-9150(97)06089-9
NR 30
TC 10
Z9 11
U1 0
U2 1
PU KARGER
PI BASEL
PA ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND
SN 0030-3755
EI 1423-0267
J9 OPHTHALMOLOGICA
JI Ophthalmologica
PY 2015
VL 233
IS 3-4
BP 128
EP 133
DI 10.1159/000371716
PG 6
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA CK3LO
UT WOS:000356117800002
PM 25633305
DA 2022-11-30
ER

PT J
AU Jern, I
   Forsell, S
   Norberg, H
AF Jern, Irene
   Forsell, Sara
   Norberg, Helena
TI Eligibility for faricimab in a real-world neovascular age-related
   macular degeneration population: a cross-sectional study
SO BMJ OPEN
LA English
DT Article
DE ophthalmology; public health; clinical trials
ID CATARACT-SURGERY; OUTCOMES; RISK; RANIBIZUMAB; THERAPY; DISEASE
AB Objectives To investigate the eligibility of a real-world neovascular age-related macular degeneration (nAMD) population for the TENAYA and LUCERNE trials (testing faricimab), and to compare the eligible real-world patients to trial participants. Design, settings and participants In this retrospective cross-sectional study, we used data from the Swedish Macula Registry (SMR) between 1 January 2017 and 31 December 2020. Persons were eligible if they fulfilled the main inclusion criteria in TENAYA and LUCERNE: (1) nAMD diagnosis, (2) treatment naive, (3) >= 50 years and (4) best-corrected visual acuity (BCVA) of 78-24 letters. Main outcome measures Characteristics at the original visit of the eligible SMR population and baseline data from the clinical trials were compared. Results In total, 27 962 individuals with nAMD were registered in SMR. A total of 15 399 (55%) individuals were treatment naive; of these, 15 368 (55%) were >= 50 years and 13 265 (47%) also had BCVA of 78-24 letters and fulfilled eligibility. Among treatment-naive individuals, 86% were eligible and the BCVA criterion was the most common reason for non-eligibility. The eligible SMR population was significantly older than either TENAYA or LUCERNE. SMR included more women and patients with worse visual acuity than TENAYA, while SMR patients were diagnosed more quickly than LUCERNE. Conclusions Almost half of the real-world nAMD population in SMR fulfilled the main inclusion criteria of the TENAYA and LUCERNE trials. Among treatment-naive individuals, 86% were eligible. Marginally differences were shown between the eligible SMR population and the trial populations. The SMR population were older and more similar to the population in LUCERNE than TENAYA.
C1 [Jern, Irene; Norberg, Helena] Umea Univ, Dept Integrat Med Biol, Umea, Sweden.
   [Forsell, Sara] Umea Univ, Dept Clin Sci Ophthalmol, Umea, Sweden.
C3 Umea University; Umea University
RP Norberg, H (通讯作者)，Umea Univ, Dept Integrat Med Biol, Umea, Sweden.
EM helena.norberg@umu.se
FU Roche
FX This study was supported by Roche. Roche did not have any role in the
   design or conduct of the study; the collection, management, analysis or
   interpretation of the data; the preparation, review or approval of the
   manuscript; or the decision to submit the manuscript for publication.
CR Boyle J, 2018, PSYCHOL HEALTH MED, V23, P127, DOI 10.1080/13548506.2016.1274040
   Casten RJ, 2013, CURR OPIN OPHTHALMOL, V24, P239, DOI 10.1097/ICU.0b013e32835f8e55
   Chew EY, 2009, OPHTHALMOLOGY, V116, P297, DOI 10.1016/j.ophtha.2008.09.019
   Chia MA, 2022, LANCET, V399, P697, DOI 10.1016/S0140-6736(22)00105-2
   Ciulla TA, 2020, OPHTHALMOL RETINA, V4, P19, DOI 10.1016/j.oret.2019.05.017
   Cugati S, 2006, OPHTHALMOLOGY, V113, P2020, DOI 10.1016/j.ophtha.2006.05.047
   Daien V, 2021, BRIT J OPHTHALMOL, V105, P1475, DOI 10.1136/bjophthalmol-2020-317434
   Daien V, 2018, AM J OPHTHALMOL, V190, P50, DOI 10.1016/j.ajo.2018.03.012
   Droege KM, 2013, GRAEF ARCH CLIN EXP, V251, P1281, DOI 10.1007/s00417-012-2177-3
   Flaxman SR, 2017, LANCET GLOB HEALTH, V5, pE1221, DOI 10.1016/S2214-109X(17)30393-5
   Gohil R, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0129361
   Gopinath B, 2014, MATURITAS, V77, P263, DOI 10.1016/j.maturitas.2013.12.001
   Guarnieri Carol, 2020, J Adv Pract Oncol, V11, P494, DOI 10.6004/jadpro.2020.11.5.5
   Hakansson E, 2021, CARDIOVASC THER, V2021, DOI 10.1155/2021/1894155
   Heier JS, 2022, LANCET, V399, P729, DOI 10.1016/S0140-6736(22)00010-1
   Ho AC, 2017, JAMA OPHTHALMOL, V135, P268, DOI 10.1001/jamaophthalmol.2016.5314
   Ho L, 2008, INVEST OPHTH VIS SCI, V49, P4795, DOI 10.1167/iovs.08-2066
   Keane PA, 2015, CLIN OPHTHALMOL, V9, P353, DOI 10.2147/OPTH.S59012
   Kessel L, 2015, ACTA OPHTHALMOL, V93, P593, DOI 10.1111/aos.12665
   Khanani AM, 2020, OPHTHALMOL RETINA, V4, P122, DOI 10.1016/j.oret.2019.09.009
   Kim JH, 2021, J OPHTHALMOL, V2021, DOI 10.1155/2021/6635467
   Kim LN, 2016, RETINA-J RET VIT DIS, V36, P1418, DOI 10.1097/IAE.0000000000001142
   Klein BEK, 2012, OPHTHALMOLOGY, V119, P1628, DOI 10.1016/j.ophtha.2012.01.050
   Konrat C, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0033559
   Mitchell J, 2006, HEALTH QUAL LIFE OUT, V4, DOI 10.1186/1477-7525-4-97
   Mitchell P, 2018, LANCET, V392, P1147, DOI 10.1016/S0140-6736(18)31550-2
   Norberg H, 2021, EUR J CLIN PHARMACOL, V77, P125, DOI 10.1007/s00228-020-02979-w
   Norberg H, 2018, ESC HEART FAIL, V5, P337, DOI 10.1002/ehf2.12251
   Okada M, 2021, OPHTHALMOLOGY, V128, P234, DOI 10.1016/j.ophtha.2020.07.060
   Polar O, 2017, TURK OFTALMOL DERG, V47, P205, DOI 10.4274/tjo.28003
   Prenner JL, 2015, AM J OPHTHALMOL, V160, P725, DOI 10.1016/j.ajo.2015.06.023
   Schwartz Roy, 2015, Int J Retina Vitreous, V1, P20, DOI 10.1186/s40942-015-0022-7
   Subbiah Ishwaria M, 2018, Oncotarget, V9, P28842, DOI 10.18632/oncotarget.25571
   Westborg IAS., 2020, ANN REPORT SWEDISH M
   Westborg I, 2018, OPHTHAL EPIDEMIOL, V25, P176, DOI 10.1080/09286586.2017.1397701
   Westborg I, 2017, ACTA OPHTHALMOL, V95, P787, DOI 10.1111/aos.13539
   Wykoff CC, 2018, J MANAG CARE SPEC PH, V24, pS3, DOI 10.18553/jmcp.2018.24.2-a.s3
NR 37
TC 0
Z9 0
U1 1
U2 1
PU BMJ PUBLISHING GROUP
PI LONDON
PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND
SN 2044-6055
J9 BMJ OPEN
JI BMJ Open
PD SEP
PY 2022
VL 12
IS 9
AR e065001
DI 10.1136/bmjopen-2022-065001
PG 7
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine
GA 4N2DQ
UT WOS:000853828800006
PM 36096541
OA Green Published, gold
DA 2022-11-30
ER

PT J
AU Arya, S
   Emri, E
   Synowsky, SA
   Shirran, SL
   Barzegar-Befroei, N
   Peto, T
   Botting, CH
   Lengyel, I
   Stewart, AJ
AF Arya, Swati
   Emri, Eszter
   Synowsky, Silvia A.
   Shirran, Sally L.
   Barzegar-Befroei, Neda
   Peto, Tunde
   Botting, Catherine H.
   Lengyel, Imre
   Stewart, Alan J.
TI Quantitative analysis of hydroxyapatite-binding plasma proteins in
   genotyped individuals with late-stage age-related macular degeneration
SO EXPERIMENTAL EYE RESEARCH
LA English
DT Article
DE Drusen; Sub-retinal pigment epithelial deposits; Mineral-protein
   interactions; Retinal disease; Quantitative proteomics
ID COMPLEMENT FACTOR-H; PREGNANCY ZONE PROTEIN; HUMAN BRUCHS MEMBRANE;
   ALZHEIMERS-DISEASE; SELF-ASSOCIATION; DRUSEN; BIOMARKERS; DEPOSITS;
   RISK; POLYMORPHISM
AB Age-related macular degeneration (AMD) is associated with the formation of sub-retinal pigment epithelial (RPE) deposits that block circulatory exchange with the retina. The factors that contribute to deposit formation are not well understood. Recently, we identified the presence of spherular hydroxyapatite (HAP) structures within sub-RPE deposits to which several AMD-associated proteins were bound. This suggested that protein binding to HAP represents a potential mechanism for the retention of proteins in the sub-RPE space. Here we performed quantitative proteomics using Sequential Window Acquisition of all THeoretical fragment-ion spectra-Mass Spectrometry (SWATH-MS) on plasma samples from 23 patients with late-stage neovascular AMD following HAP-binding. Individuals were genotyped for the high risk CFH variant (T1277C) and binding to HAP was compared between wild type and risk variants. From a library of 242 HAP binding plasma proteins (1% false discovery rate), SWATH-MS revealed significant quantitative differences in the abundance of 32 HAP-binding proteins (p < 0.05) between the two homozygous groups. The concentrations of six proteins (FHR1, FHR3, APOC4, C4A, C4B and PZP) in the HAP eluted fractions and whole plasma were further analysed using ELISA and their presence in sections from human cadaver eyes was examined using immunofluorescence. All six proteins were found to be present in the RPE/choroid interface, and four of these (FHR1, FHR3, APOC4 and PZP) were associated with spherules in sub-RPE space. This study provides qualitative and quantitative information relating to the degree by which plasma proteins may contribute to sub-RPE deposit formation through binding to HAP spherules and how genetic differences might contribute to deposit formation.
C1 [Arya, Swati; Stewart, Alan J.] Univ St Andrews, Sch Med, St Andrews KY16 9TF, Fife, Scotland.
   [Emri, Eszter; Peto, Tunde; Lengyel, Imre] Queens Univ Belfast, Ctr Expt Med, Belfast BT9 7JL, Antrim, North Ireland.
   [Synowsky, Silvia A.; Shirran, Sally L.; Botting, Catherine H.] Univ St Andrews, Biomed Sci Res Complex, St Andrews KY16 9ST, Fife, Scotland.
   [Barzegar-Befroei, Neda; Lengyel, Imre] UCL, UCL Inst Ophthalmol, London EC1V 9EL, England.
   [Peto, Tunde] NHS Fdn Trust, Moorfields Eye Hosp, London EC1V 2PD, England.
C3 University of St Andrews; Queens University Belfast; University of St
   Andrews; University of London; University College London; Oxford
   University Hospitals NHS Foundation Trust; University of London;
   University College London; Moorfields Eye Hospital NHS Foundation Trust
RP Stewart, AJ (通讯作者)，Univ St Andrews, Sch Med, St Andrews KY16 9TF, Fife, Scotland.
EM ajs21@st-andrews.ac.uk
RI Stewart, Alan J/B-6569-2008; Peto, Tunde/G-8812-2018; Lengyel,
   Imre/B-5217-2009; Emri, Eszter/ABE-9363-2020
OI Stewart, Alan J/0000-0003-4580-1840; Peto, Tunde/0000-0001-6265-0381;
   Lengyel, Imre/0000-0001-7467-2174; Shirran, Sally/0000-0003-3516-3507
FU Fight for Sight [1586/1587]; "Eye-Risk" a European Union's Horizon 2020
   research and innovation program [634479]; Bill Brown Charitable Trust;
   Mercer Fund; Wellcome Trust [094476/Z/10/Z]; MEH Special Trustees
FX The investigators would like to thank the patients for their donation of
   blood samples for the study. Yash Bansod and Lasse Olesen are
   acknowledged for their technical help with the immunohistochemistry
   examination. We are also grateful to Fight for Sight for financial
   support (project grant to A.J.S and I.L.; grant ref.: 1586/1587). This
   research was also supported by "Eye-Risk" a European Union's Horizon
   2020 research and innovation program (grant ref.: 634479) Bill Brown
   Charitable Trust, MEH Special Trustees and Mercer Fund (I.L). This work
   was also supported by the Wellcome Trust (grant ref.: 094476/Z/10/Z) for
   funding the purchase of the TripleTOF 5600 mass spectrometer at the BSRC
   Mass Spectrometry and Proteomics Facility, University of St Andrews.
CR Anderson DH, 2004, EXP EYE RES, V78, P243, DOI 10.1016/j.exer.2003.10.011
   Baird PN, 2006, HUM MUTAT, V27, P337, DOI 10.1002/humu.20288
   Beattie JR, 2010, FASEB J, V24, P4816, DOI 10.1096/fj.10-166090
   Bird AC, 2003, EYE, V17, P457, DOI 10.1038/sj.eye.6700562
   Bird AC, 2010, J CLIN INVEST, V120, P3033, DOI 10.1172/JCI42437
   Cheung CMG, 2017, J LIPID RES, V58, P1785, DOI 10.1194/jlr.M073684
   Congdon NG, 2003, JAMA-J AM MED ASSOC, V290, P2057, DOI 10.1001/jama.290.15.2057
   Crabb JW, 2002, P NATL ACAD SCI USA, V99, P14682, DOI 10.1073/pnas.222551899
   Cugno M, 2009, TRENDS MOL MED, V15, P69, DOI 10.1016/j.molmed.2008.12.001
   Curcio CA, 2001, INVEST OPHTH VIS SCI, V42, P265
   Curcio CA, 2010, J LIPID RES, V51, P451, DOI 10.1194/jlr.R002238
   Dentchev T, 2003, MOL VIS, V9, P184
   Edwards AO, 2005, SCIENCE, V308, P421, DOI 10.1126/science.1110189
   FARKAS TG, 1971, AM J OPHTHALMOL, V71, P1196, DOI 10.1016/0002-9394(71)90963-9
   Figueiredo JL, 2008, J UROLOGY, V179, P1610, DOI 10.1016/j.juro.2007.11.100
   FOLKERSEN J, 1981, CLIN CHIM ACTA, V110, P139, DOI 10.1016/0009-8981(81)90343-0
   Fritsche LG, 2010, HUM MOL GENET, V19, P4694, DOI 10.1093/hmg/ddq399
   Gu JY, 2010, ADV EXP MED BIOL, V664, P411, DOI 10.1007/978-1-4419-1399-9_47
   Hageman GS, 2001, PROG RETIN EYE RES, V20, P705, DOI 10.1016/S1350-9462(01)00010-6
   Haines JL, 2005, SCIENCE, V308, P419, DOI 10.1126/science.1110359
   Hollyfield JG, 2003, ADV EXP MED BIOL, V533, P83
   Ijsselstijn L, 2011, J PROTEOME RES, V10, P4902, DOI 10.1021/pr200270z
   Kersten E., 2017, SURV OPHTHALMOL, V6257, P30262
   Kim YH, 2009, GRAEF ARCH CLIN EXP, V247, P651, DOI 10.1007/s00417-009-1049-y
   Klaver CCW, 1998, AM J HUM GENET, V63, P200, DOI 10.1086/301901
   Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557
   Kobayashi H, 2014, EXP ANIM TOKYO, V63, P305, DOI 10.1538/expanim.63.305
   Lambert NG, 2016, PROG RETIN EYE RES, V54, P64, DOI 10.1016/j.preteyeres.2016.04.003
   Luibl V, 2006, J CLIN INVEST, V116, P378, DOI 10.1172/JCI25843
   Martinez-Barricarte R, 2012, INVEST OPHTH VIS SCI, V53, P1087, DOI 10.1167/iovs.11-8709
   Nan R, 2013, J BIOL CHEM, V288, P19197, DOI 10.1074/jbc.M113.476143
   Nijholt DAT, 2015, J ALZHEIMERS DIS, V46, P227, DOI 10.3233/JAD-131628
   Owen CG, 2012, BRIT J OPHTHALMOL, V96, P752, DOI 10.1136/bjophthalmol-2011-301109
   Pennington KL, 2016, EYE VISION, V3, DOI 10.1186/s40662-016-0063-5
   Perkins SJ, 2012, IMMUNOBIOLOGY, V217, P281, DOI 10.1016/j.imbio.2011.10.003
   PUCHTLER H, 1978, HISTOCHEMISTRY, V56, P177, DOI 10.1007/BF00495978
   Rudnicka AR, 2012, OPHTHALMOLOGY, V119, P571, DOI 10.1016/j.ophtha.2011.09.027
   SARKS SH, 1976, BRIT J OPHTHALMOL, V60, P324, DOI 10.1136/bjo.60.5.324
   Thompson RB, 2015, P NATL ACAD SCI USA, V112, P1565, DOI 10.1073/pnas.1413347112
   TIMMANN C, 1991, J IMMUNOL, V146, P1265
   Toomey CB, 2015, P NATL ACAD SCI USA, V112, pE3040, DOI 10.1073/pnas.1424391112
   van Asten F, 2018, OPHTHALMOLOGY, V125, P559, DOI 10.1016/j.ophtha.2017.09.023
   Yuan XL, 2010, MOL CELL PROTEOMICS, V9, P1031, DOI 10.1074/mcp.M900523-MCP200
NR 43
TC 4
Z9 5
U1 2
U2 6
PU ACADEMIC PRESS LTD- ELSEVIER SCIENCE LTD
PI LONDON
PA 24-28 OVAL RD, LONDON NW1 7DX, ENGLAND
SN 0014-4835
EI 1096-0007
J9 EXP EYE RES
JI Exp. Eye Res.
PD JUL
PY 2018
VL 172
BP 21
EP 29
DI 10.1016/j.exer.2018.03.023
PG 9
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA GK9AN
UT WOS:000436528900003
PM 29580721
OA Green Accepted, Green Submitted
DA 2022-11-30
ER

PT J
AU Fan, WY
   Abdelfattah, NS
   Uji, A
   Lei, JQ
   Ip, M
   Sadda, SR
   Wykoff, CC
AF Fan, Wenying
   Abdelfattah, Nizar Saleh
   Uji, Akihito
   Lei, Jianqin
   Ip, Michael
   Sadda, SriniVas R.
   Wykoff, Charles C.
CA TREX-AMD Study Grp
TI Subfoveal choroidal thickness predicts macular atrophy in age-related
   macular degeneration: results from the TREX-AMD trial
SO GRAEFES ARCHIVE FOR CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY
LA English
DT Article
DE Choroidal thickness; Macular atrophy; Age-related macular degeneration;
   Neovascular age-related macular degeneration; Treat-and-extend
ID OPTICAL COHERENCE TOMOGRAPHY; GEOGRAPHIC ATROPHY; HEALTHY EYES;
   RANIBIZUMAB; EXTEND
AB Our purpose was to evaluate the relationship between subfoveal choroidal thickness (SCT) and development of macular atrophy (MA) in eyes with age-related macular degeneration (AMD).
   This was a prospective, multicenter study. Sixty participants (120 eyes) in the TREX-AMD trial (NCT01648292) with treatment-na < ve neovascular AMD (NVAMD) in at least one eye were included. SCT was measured by certified reading center graders at baseline using spectral domain optical coherence tomography (SDOCT). The baseline SCT was correlated with the presence of MA at baseline and development of incident MA by month 18. Generalized estimating equations were used to account for information from both eyes.
   Baseline SCT in eyes with MA was statistically significantly less than in those without MA in both the dry AMD (DAMD) (P = 0.04) and NVAMD (P = 0.01) groups. Comparison of baseline SCT between MA developers and non-MA developers revealed a statistically significant difference (P = 0.03). Receiver operating characteristic curve (ROC) analysis showed the cut-off threshold of SCT for predicting the development of MA in cases without MA at baseline was 124 mu m (AUC = 0.772; Sensitivity = 0.923; Specificity = 0.5). Among eyes without MA at baseline, those with baseline SCT ae<currency>124 mu m were 4.3 times more likely to develop MA (Odds ratio: 4.3, 95% confidence interval: 1.6-12, P = 0.005) than those with baseline SCT > 124 mu m.
   Eyes with AMD and MA had less SCT than those without MA. Eyes with less baseline SCT also appear to be at higher risk to develop MA within 18 months.
C1 [Fan, Wenying; Abdelfattah, Nizar Saleh; Uji, Akihito; Lei, Jianqin; Ip, Michael; Sadda, SriniVas R.] Doheny Eye Inst, Doheny Image Reading Ctr, POB 86228, Los Angeles, CA 90086 USA.
   [Fan, Wenying; Abdelfattah, Nizar Saleh; Uji, Akihito; Lei, Jianqin; Ip, Michael; Sadda, SriniVas R.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Ophthalmol, Los Angeles, CA 90095 USA.
   [Fan, Wenying] Capital Med Univ, Beijing Tongren Eye Ctr, Beijing Tongren Hosp, Beijing Ophthalmol & Visual Sci Key Lab, Beijing, Peoples R China.
   [Wykoff, Charles C.] Retina Consultants Houston, Houston, TX USA.
   [Wykoff, Charles C.] Houston Methodist Hosp, Blanton Eye Inst, Houston, TX USA.
   [Wykoff, Charles C.] Weill Cornell Med Coll, Houston, TX USA.
C3 Doheny Eye Institute; University of California System; University of
   California Los Angeles; University of California Los Angeles Medical
   Center; David Geffen School of Medicine at UCLA; Capital Medical
   University; The Methodist Hospital System; The Methodist Hospital -
   Houston; Cornell University
RP Sadda, SR (通讯作者)，Doheny Eye Inst, Doheny Image Reading Ctr, POB 86228, Los Angeles, CA 90086 USA.; Sadda, SR (通讯作者)，Univ Calif Los Angeles, David Geffen Sch Med, Dept Ophthalmol, Los Angeles, CA 90095 USA.
EM ssadda@doheny.org
RI Abdelfattah, Nizar Saleh/H-6908-2019; fan, wenying/GSI-5125-2022
OI Abdelfattah, Nizar Saleh/0000-0002-9396-3054; Wang,
   Rui/0000-0002-0900-7714
FU Carl Zeiss Meditec; Optos; Allergan; Genentech
FX Srinivas Sadda: Consultant for Carl Zeiss Meditec, Optos, Allergan,
   Genentech, Alcon, Novartis and Roche. Research Support: Carl Zeiss
   Meditec, Optos, Allergan and Genentech.
CR Abdelfattah NS, 2017, OPHTHALMOLOGY, V124, P215, DOI 10.1016/j.ophtha.2016.10.002
   Adhi M, 2014, RETINA-J RET VIT DIS, V34, P306, DOI 10.1097/IAE.0b013e3182993e09
   Avery RL, 2006, OPHTHALMOLOGY, V113, P363, DOI 10.1016/j.ophtha.2005.11.019
   Brown JS, 2009, INVEST OPHTH VIS SCI, V50, P5, DOI 10.1167/iovs.08-1779
   Chung SE, 2011, OPHTHALMOLOGY, V118, P840, DOI 10.1016/j.ophtha.2010.09.012
   Danis RP, 2015, CLIN OPHTHALMOL, V9, P2159, DOI 10.2147/OPTH.S92359
   Esmaeelpour M, 2014, INVEST OPHTH VIS SCI, V55, P5074, DOI 10.1167/iovs.14-14646
   Fein JG, 2014, OPHTHAL SURG LAS IM, V45, P32, DOI 10.3928/23258160-20131220-04
   Ferris FL, 2013, OPHTHALMOLOGY, V120, P844, DOI 10.1016/j.ophtha.2012.10.036
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P532
   Friedman E, 1997, AM J OPHTHALMOL, V124, P677, DOI 10.1016/S0002-9394(14)70906-7
   Grossniklaus HE, 2004, AM J OPHTHALMOL, V137, P496, DOI 10.1016/j.ajo.2003.09.042
   Grunwald JE, 1998, INVEST OPHTH VIS SCI, V39, P385
   Grunwald JE, 2014, OPHTHALMOLOGY, V121, P150, DOI 10.1016/j.ophtha.2013.08.015
   Hanus J, 2016, BRIT J OPHTHALMOL, V100, P122, DOI 10.1136/bjophthalmol-2015-306972
   HAYREH SS, 1974, A GRAEF ARCH KLIN EX, V192, P181
   HUANG D, 1991, SCIENCE, V254, P1178, DOI 10.1126/science.1957169
   Jonas JB, 2014, RETINA-J RET VIT DIS, V34, P1149, DOI 10.1097/IAE.0000000000000035
   Kim SW, 2011, RETINA-J RET VIT DIS, V31, P1904, DOI 10.1097/IAE.0b013e31821801c5
   Koizumi H, 2015, AM J OPHTHALMOL, V159, P627, DOI 10.1016/j.ajo.2014.12.025
   Laviers H, 2014, GRAEF ARCH CLIN EXP, V252, P1871, DOI 10.1007/s00417-014-2840-y
   Lee JY, 2013, INVEST OPHTH VIS SCI, V54, P7812, DOI 10.1167/iovs.13-12284
   Legocki AT, 2016, OSLI RETINA, V47, P618, DOI 10.3928/23258160-20160707-02
   Lindner M, 2015, INVEST OPHTH VIS SCI, V56, P875, DOI 10.1167/iovs.14-14933
   Lu LN, 2016, MEDICINE, V95, DOI 10.1097/MD.0000000000002967
   Manjunath V, 2011, AM J OPHTHALMOL, V152, P663, DOI 10.1016/j.ajo.2011.03.008
   Manjunath V, 2010, AM J OPHTHALMOL, V150, P325, DOI 10.1016/j.ajo.2010.04.018
   Mrejen S, 2014, RETINA-J RET VIT DIS, V34, P1560, DOI 10.1097/IAE.0000000000000139
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Sigler EJ, 2013, INVEST OPHTH VIS SCI, V54, P6307, DOI 10.1167/iovs.13-12653
   Wakatsuki Y, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0144156
   Wang JW, 2015, BMC OPHTHALMOL, V15, DOI 10.1186/s12886-015-0110-3
   Wood A, 2011, AM J OPHTHALMOL, V152, P1030, DOI 10.1016/j.ajo.2011.05.021
   Woodman-Pieterse EC, 2015, INVEST OPHTH VIS SCI, V56, P6414, DOI 10.1167/iovs.15-17102
   Wykoff CC, 2015, OPHTHALMOLOGY, V122, P2514, DOI 10.1016/j.ophtha.2015.08.009
   Yiu G, 2015, AM J OPHTHALMOL, V159, P617, DOI 10.1016/j.ajo.2014.12.010
NR 36
TC 13
Z9 14
U1 0
U2 2
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0721-832X
EI 1435-702X
J9 GRAEF ARCH CLIN EXP
JI Graefes Arch. Clin. Exp. Ophthalmol.
PD MAR
PY 2018
VL 256
IS 3
BP 511
EP 518
DI 10.1007/s00417-017-3888-2
PG 8
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA FX4QC
UT WOS:000426062100010
PM 29374796
DA 2022-11-30
ER

PT J
AU Toomey, CB
   Landowski, M
   Klingeborn, M
   Kelly, U
   Deans, J
   Dong, H
   Harrabi, O
   Van Blarcom, T
   Yeung, YA
   Grishanin, R
   Lin, JC
   Saban, DR
   Rickman, CB
AF Toomey, Christopher B.
   Landowski, Michael
   Klingeborn, Mikael
   Kelly, Una
   Deans, John
   Dong, Holly
   Harrabi, Ons
   Van Blarcom, Thomas
   Yeung, Yik Andy
   Grishanin, Ruslan
   Lin, John C.
   Saban, Daniel R.
   Rickman, Catherine Bowes
TI Effect of Anti-C5a Therapy in a Murine Model of Early/Intermediate Dry
   Age-Related Macular Degeneration
SO INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE
LA English
DT Article
DE complement; age related macular degeneration; immunotherapy; monocytosis
ID PIGMENT EPITHELIAL-CELLS; EXPERIMENTAL CHOROIDAL NEOVASCULARIZATION;
   COMPLEMENT FACTOR-H; GENE-EXPRESSION; SODIUM IODATE; AMYLOID-BETA;
   ENDOTHELIAL-CELLS; DRUSEN FORMATION; MOUSE MODEL; C5A
AB PURPOSE. A large body of evidence supports a central role for complement activation in the pathobiology of age-related macular degeneration (AMD), including plasma complement component 5a (C5a). Interestingly, C5a is a chemotactic agent for monocytes, a cell type also shown to contribute to AMD. However, the role monocytes play in the pathogenesis of "dry'' AMD and the pharmacologic potential of targeting C5a to regulate these cells are unclear. We addressed these questions via C5a blockade in a unique model of early/intermediate dry AMD and large panel flow cytometry to immunophenotype monocytic involvement.
   METHODS. Heterozygous complement factor H(Cfh(+/-)) mice aged to 90 weeks were fed a high-fat, cholesterol-enriched diet (Cfh(+/-) similar to HFC) for 8 weeks and were given weekly intraperitoneal injections of 30 mg/kg anti-C5a (4C9, Pfizer). Flow cytometry, retinal pigmented epithelium (RPE) flat mounts, and electroretinograms were used to characterize anti-C5a treatment.
   RESULTS. Aged Cfh(+/-) mice developed RPE damage, sub-RPE basal laminar deposits, and attenuation of visual function and immune cell recruitment to the choroid that was accompanied by expression of inflammatory and extracellular matrix remodeling genes following 8 weeks of HFC diet. Concomitant systemic administration of an anti-C5a antibody successfully inhibited local recruitment of mononuclear phagocytes to the choroid-RPE interface but did not ameliorate these AMD-like pathologies in this mouse model.
   CONCLUSIONS. These results show that immunotherapy targeting C5a is not sufficient to block the development of the AMD-like pathologies observed in Cfh(+/-) similar to HFC mice and suggest that other complement components or molecules/mechanisms may be driving "early'' and "intermediate'' AMD pathologies.
C1 [Toomey, Christopher B.; Landowski, Michael; Klingeborn, Mikael; Kelly, Una; Deans, John; Saban, Daniel R.; Rickman, Catherine Bowes] Duke Univ, Med Ctr, Dept Ophthalmol, Durham, NC 27710 USA.
   [Toomey, Christopher B.; Rickman, Catherine Bowes] Duke Univ, Med Ctr, Dept Cell Biol, Durham, NC 27710 USA.
   [Toomey, Christopher B.] Univ Calif San Diego, Shiley Eye Inst, Dept Ophthalmol, San Diego, CA 92103 USA.
   [Dong, Holly; Harrabi, Ons; Van Blarcom, Thomas; Yeung, Yik Andy; Grishanin, Ruslan; Lin, John C.] Pfizer Inc, Rinat, San Francisco, CA USA.
   [Saban, Daniel R.] Duke Univ, Med Ctr, Dept Immunol, Durham, NC USA.
C3 Duke University; Duke University; University of California System;
   University of California San Diego; Pfizer; Duke University
RP Rickman, CB (通讯作者)，Duke Univ, Med Ctr, Box 3802,AERI Rm 5010, Durham, NC 27710 USA.
EM bowes007@duke.edu
RI Klingeborn, Mikael/AAC-2471-2019
OI Klingeborn, Mikael/0000-0003-2907-0371; Landowski,
   Michael/0000-0003-0151-0689; Bowes Rickman,
   Catherine/0000-0002-8555-9596
FU National Eye Institute [R01 EY026161, P30 EY005722, T32 GM007171];
   Research to Prevent Blindness; BrightFocus Foundation; Foundation
   Fighting Blindness; NATIONAL EYE INSTITUTE [P30EY005722, R01EY026161]
   Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL
   SCIENCES [T32GM007171] Funding Source: NIH RePORTER
FX Supported by National Eye Institute Grants R01 EY026161 (CBR) and P30
   EY005722, T32 GM007171-Medical Scientist Training Program (CBT), an
   unrestricted grant from Research to Prevent Blindness (to the Duke Eye
   Center), a grant from the BrightFocus Foundation (MK), and a grant from
   the Foundation Fighting Blindness (CBR). Pfizer, Inc., owns the
   intellectual properties of the antibodies described in this study.
CR Ambati J, 2003, NAT MED, V9, P1390, DOI 10.1038/nm950
   Anderson DH, 2004, EXP EYE RES, V78, P243, DOI 10.1016/j.exer.2003.10.011
   Boder ET, 1997, NAT BIOTECHNOL, V15, P553, DOI 10.1038/nbt0697-553
   Brockmann C, 2015, GRAEF ARCH CLIN EXP, V253, P1695, DOI 10.1007/s00417-015-3041-z
   Caicedo A, 2005, EXP EYE RES, V81, P38, DOI 10.1016/j.exer.2005.01.013
   Cao SJ, 2016, BRIT J OPHTHALMOL, V100, P713, DOI 10.1136/bjophthalmol-2015-307213
   Carlin LM, 2013, CELL, V153, P362, DOI 10.1016/j.cell.2013.03.010
   Carr AJ, 2011, MOL VIS, V17, P1701
   Chew EY, 2014, JAMA OPHTHALMOL, V132, P272, DOI 10.1001/jamaophthalmol.2013.6636
   Choudhary M, 2016, AGING-US, V8, P1952, DOI 10.18632/aging.101031
   Cortright DN, 2009, CURR EYE RES, V34, P57, DOI 10.1080/02713680802546658
   Coughlin B, 2016, SCI REP-UK, V6, DOI 10.1038/srep23794
   Crabb JW, 2002, P NATL ACAD SCI USA, V99, P14682, DOI 10.1073/pnas.222551899
   Dentchev T, 2003, MOL VIS, V9, P184
   Ding JD, 2015, AM J PATHOL, V185, P29, DOI 10.1016/j.ajpath.2014.08.026
   Ding JD, 2011, P NATL ACAD SCI USA, V108, pE279, DOI 10.1073/pnas.1100901108
   Enzmann V, 2006, EXP EYE RES, V82, P441, DOI 10.1016/j.exer.2005.08.002
   Espinosa-Heidmann DG, 2003, INVEST OPHTH VIS SCI, V44, P3586, DOI 10.1167/iovs.03-0038
   Fernandez-Godino R, 2015, HUM MOL GENET, V24, P5555, DOI 10.1093/hmg/ddv287
   Franco LM, 2009, INVEST OPHTH VIS SCI, V50, P4004, DOI 10.1167/iovs.08-2898
   Fritsche LG, 2014, ANNU REV GENOM HUM G, V15, P151, DOI 10.1146/annurev-genom-090413-025610
   Garland DL, 2014, HUM MOL GENET, V23, P52, DOI 10.1093/hmg/ddt395
   Hageman GS, 2001, PROG RETIN EYE RES, V20, P705, DOI 10.1016/S1350-9462(01)00010-6
   Hasegawa E, 2013, J IMMUNOL, V190, P1778, DOI 10.4049/jimmunol.1202495
   ISHIBASHI T, 1987, INVEST OPHTH VIS SCI, V28, P1116
   Johnson LV, 2000, EXP EYE RES, V70, P441, DOI 10.1006/exer.1999.0798
   Johnson LV, 2001, EXP EYE RES, V73, P887, DOI 10.1006/exer.2001.1094
   Johnson LV, 2002, P NATL ACAD SCI USA, V99, P11830, DOI 10.1073/pnas.192203399
   Kuny S, 2012, INVEST OPHTH VIS SCI, V53, P664, DOI 10.1167/iovs.11-8418
   Kurihara T, 2016, ELIFE, V5, DOI 10.7554/eLife.14319
   Kurji KH, 2010, INVEST OPHTH VIS SCI, V51, P1151, DOI 10.1167/iovs.09-3622
   Lambert V, 2013, NAT PROTOC, V8, P2197, DOI 10.1038/nprot.2013.135
   Lechner J, 2016, IMMUN AGEING, V13, DOI 10.1186/s12979-016-0060-5
   Liu BY, 2011, J TRANSL MED, V9, DOI 10.1186/1479-5876-9-111
   Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262
   Mattapallil MJ, 2012, INVEST OPHTH VIS SCI, V53, P2921, DOI 10.1167/iovs.12-9662
   Merle NS, 2015, FRONT IMMUNOL, V6, DOI 10.3389/fimmu.2015.00257
   Miller JW, 2013, AM J OPHTHALMOL, V155, P1, DOI 10.1016/j.ajo.2012.10.018
   Monk PN, 2007, BRIT J PHARMACOL, V152, P429, DOI 10.1038/sj.bjp.0707332
   Nakai K, 2008, INVEST OPHTH VIS SCI, V49, P3666, DOI 10.1167/iovs.07-1640
   Nozaki M, 2006, P NATL ACAD SCI USA, V103, P2328, DOI 10.1073/pnas.0408835103
   O'Koren EG, 2016, SCI REP-UK, V6, DOI 10.1038/srep20636
   Pennesi ME, 2012, MOL ASPECTS MED, V33, P487, DOI 10.1016/j.mam.2012.06.003
   Pickering MC, 2002, NAT GENET, V31, P424, DOI 10.1038/ng912
   Poor SH, 2014, INVEST OPHTH VIS SCI, V55, P6525, DOI 10.1167/iovs.14-15067
   Rajpal A, 2005, P NATL ACAD SCI USA, V102, P8466, DOI 10.1073/pnas.0503543102
   Reynolds R, 2009, INVEST OPHTH VIS SCI, V50, P5818, DOI 10.1167/iovs.09-3928
   Rudnicka AR, 2012, OPHTHALMOLOGY, V119, P571, DOI 10.1016/j.ophtha.2011.09.027
   Scholl HPN, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002593
   Skeie JM, 2010, INVEST OPHTH VIS SCI, V51, P5336, DOI 10.1167/iovs.10-5322
   Souto FJD, 2011, J VIRAL HEPATITIS, V18, P102, DOI 10.1111/j.1365-2893.2010.01286.x
   Tan PL, 2016, HUM GENOMICS, V10, DOI 10.1186/s40246-016-0079-x
   Toomey CB, 2015, P NATL ACAD SCI USA, V112, pE3040, DOI 10.1073/pnas.1424391112
   Tsau C, 2011, DEVELOPMENT, V138, P3307, DOI 10.1242/dev.066241
   Uehara H, 2013, FASEB J, V27, P76, DOI 10.1096/fj.12-213835
   Van Blarcom T, 2015, J MOL BIOL, V427, P1513, DOI 10.1016/j.jmb.2014.09.020
   van Leeuwen R, 2005, JAMA-J AM MED ASSOC, V294, P3101, DOI 10.1001/jama.294.24.3101
   VandenLangenberg GM, 1998, AM J EPIDEMIOL, V148, P204, DOI 10.1093/oxfordjournals.aje.a009625
   Wang CXZ, 2012, EXP EYE RES, V102, P1, DOI 10.1016/j.exer.2012.06.003
   Wang JM, 2014, INVEST OPHTH VIS SCI, V55, P1941, DOI 10.1167/iovs.13-13075
   Wang JY, 2009, J CELL PHYSIOL, V220, P119, DOI 10.1002/jcp.21742
   Yaspan BL, 2017, SCI TRANSL MED, V9, DOI 10.1126/scitranslmed.aaf1443
   Zhou JH, 2005, MOL VIS, V11, P414
NR 63
TC 13
Z9 13
U1 0
U2 6
PU ASSOC RESEARCH VISION OPHTHALMOLOGY INC
PI ROCKVILLE
PA 12300 TWINBROOK PARKWAY, ROCKVILLE, MD 20852-1606 USA
SN 0146-0404
EI 1552-5783
J9 INVEST OPHTH VIS SCI
JI Invest. Ophthalmol. Vis. Sci.
PD FEB
PY 2018
VL 59
IS 2
BP 662
EP 673
DI 10.1167/iovs.17-23134
PG 12
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA FX8LO
UT WOS:000426346300007
PM 29392311
OA gold, Green Published
DA 2022-11-30
ER

PT J
AU Keenan, TDL
   Goldacre, R
   Goldacre, MJ
AF Keenan, Tiarnan D. L.
   Goldacre, Raph
   Goldacre, Michael J.
TI Associations between obstructive sleep apnoea, primary open angle
   glaucoma and age-related macular degeneration: record linkage study
SO BRITISH JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
ID OXIDATIVE STRESS; OPTIC NEUROPATHY; INCREASED RISK; PREVALENCE; DISEASE
AB Background Primary open angle glaucoma (POAG) is thought to be associated with obstructive sleep apnoea (OSA) but previous studies are conflicting and have methodological limitations. This potential relationship has implications for investigation and treatment strategies, and may provide insights into disease pathogenesis. The relationship between OSA and age-related macular degeneration (AMD) is unknown.
   Methods A sleep apnoea cohort of 67 786 people was constructed from linked English hospital episode statistics (1999-2011). We compared this cohort with a reference cohort (2 684 131 people) for rates of subsequent POAG and AMD. A POAG cohort (comprising 87 435 people) and an AMD cohort (248 408 people) were also constructed and compared with the reference cohort for rates of subsequent sleep apnoea. All analyses were restricted to people aged 55 and over and, within this age range, were age standardised using 5-year age groups.
   Results Risk of POAG following sleep apnoea was not elevated: the rate ratio for POAG was 1.01 (95% Cl 0.85 to 1.19). Similarly, the risk of sleep apnoea following POAG was not elevated: the rate ratio was 1.00 (0.86 to 1.17). These findings held true across subgroup analysis according to sex and age group. By contrast, the risk of AMD following sleep apnoea was significantly elevated, with rate ratio 1.44 (1.32 to 1.57).
   Conclusions Although plausible mechanisms exist to consider a link between OSA and POAG, the two conditions are not positively associated. This holds true in either temporal direction. By contrast, OSA is positively associated with AMD. While potential confounding factors may contribute, obesity does not appear sufficient to explain this association.
C1 [Keenan, Tiarnan D. L.] Univ Manchester, AV Hill Bldg,Oxford Rd, Manchester M13 9PT, Lancs, England.
   [Keenan, Tiarnan D. L.] Royal Bolton Hosp, Bolton, England.
   [Goldacre, Raph; Goldacre, Michael J.] Univ Oxford, Nuffield Dept Populat Hlth, Unit Hlth Care Epidemiol, Oxford, England.
C3 University of Manchester; Royal Bolton Hospital; University of Oxford
RP Keenan, TDL (通讯作者)，Univ Manchester, AV Hill Bldg,Oxford Rd, Manchester M13 9PT, Lancs, England.
EM tiarnan.keenan@doctors.org.uk
OI Goldacre, Raphael/0000-0002-7393-1880
FU English National Institute for Health Research
FX The Unit of Health-Care Epidemiology was funded by the English National
   Institute for Health Research to build the linked data set and to make
   it available for analysis. This study had no specific funding. The views
   expressed in this paper do not necessarily reflect those of the funding
   body.
CR Anderson DH, 2010, PROG RETIN EYE RES, V29, P95, DOI 10.1016/j.preteyeres.2009.11.003
   Aptel F, 2014, SLEEP MED, V15, P576, DOI 10.1016/j.sleep.2013.11.790
   Asker S, 2015, INT J CLIN EXP MED, V8, P11449
   Bendel RE, 2008, EYE, V22, P1105, DOI 10.1038/sj.eye.6702846
   Chakravarthy U, 2010, BMC OPHTHALMOL, V10, DOI 10.1186/1471-2415-10-31
   Eisele HJ, 2015, OXID MED CELL LONGEV, V2015, DOI 10.1155/2015/608438
   Emanuel ME, 2014, CAN J OPHTHALMOL, V49, P506, DOI 10.1016/j.jcjo.2014.10.001
   Fraser CL, 2014, CURR NEUROL NEUROSCI, V14, DOI 10.1007/s11910-014-0465-5
   Geyer O, 2003, AM J OPHTHALMOL, V136, P1093, DOI 10.1016/S0002-9394(03)00709-8
   Girkin CA, 2006, BRIT J OPHTHALMOL, V90, P679, DOI 10.1136/bjo.2005.086082
   Gonzaga C, 2015, J HUM HYPERTENS, V29, P705, DOI 10.1038/jhh.2015.15
   Jarrett SG, 2012, MOL ASPECTS MED, V33, P399, DOI 10.1016/j.mam.2012.03.009
   Keenan TDL, 2015, RETINA-J RET VIT DIS, V35, P2613, DOI 10.1097/IAE.0000000000000651
   Keenan TDL, 2015, BRIT J OPHTHALMOL, V99, P524, DOI 10.1136/bjophthalmol-2014-305863
   Keenan TDL, 2014, JAMA OPHTHALMOL, V132, P63, DOI 10.1001/jamaophthalmol.2013.5696
   Keenan TDL, 2012, BRIT J OPHTHALMOL, V96, P413, DOI 10.1136/bjophthalmol-2011-300338
   Lin CC, 2013, OPHTHALMOLOGY, V120, P1559, DOI 10.1016/j.ophtha.2013.01.006
   Nesmith BLW, 2014, RETINA-J RET VIT DIS, V34, P2423, DOI 10.1097/IAE.0000000000000247
   Perez-Rico C, 2014, GRAEF ARCH CLIN EXP, V252, P1345, DOI 10.1007/s00417-014-2669-4
   Schacknow PN, 2010, GLAUCOMA BOOK: A PRACTICAL, EVIDENCE-BASED APPROACH TO PATIENT CARE, P1, DOI 10.1007/978-0-387-76700-0
   Sergi M, 2007, J GLAUCOMA, V16, P42, DOI 10.1097/01.ijg.0000243472.51461.24
   Shi YH, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0115625
   Spicuzza L, 2015, THER ADV CHRONIC DIS, V6, P273, DOI 10.1177/2040622315590318
   Stein JD, 2011, AM J OPHTHALMOL, V152, P989, DOI 10.1016/j.ajo.2011.04.030
   Wu XH, 2015, INT J CLIN EXP MED, V8, P297
NR 25
TC 24
Z9 24
U1 0
U2 6
PU BMJ PUBLISHING GROUP
PI LONDON
PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND
SN 0007-1161
EI 1468-2079
J9 BRIT J OPHTHALMOL
JI Br. J. Ophthalmol.
PD FEB
PY 2017
VL 101
IS 2
BP 155
EP 159
DI 10.1136/bjophthalmol-2015-308278
PG 5
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA EJ6CO
UT WOS:000393306300013
PM 27044342
DA 2022-11-30
ER

PT J
AU Roberts, P
   Sugita, M
   Deak, G
   Baumann, B
   Zotter, S
   Pircher, M
   Sacu, S
   Hitzenberger, CK
   Schmidt-Erfurth, U
AF Roberts, Philipp
   Sugita, Mitsuro
   Deak, Gabor
   Baumann, Bernhard
   Zotter, Stefan
   Pircher, Michael
   Sacu, Stefan
   Hitzenberger, Christoph K.
   Schmidt-Erfurth, Ursula
TI Automated Identification and Quantification of Subretinal Fibrosis in
   Neovascular Age-Related Macular Degeneration Using
   Polarization-Sensitive OCT
SO INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE
LA English
DT Article
DE polarization-sensitive optical coherence tomography; fibrosis;
   subretinal hyperreflective tissue; choroidal neovascularization;
   age-related macular degeneration
ID OPTICAL COHERENCE TOMOGRAPHY; RETINAL-PIGMENT EPITHELIUM;
   SPECTRAL-DOMAIN OCT; TREATMENTS TRIALS; GEOGRAPHIC ATROPHY;
   RISK-FACTORS; IN-VIVO; RETARDATION; PREVALENCE; DISEASES
AB PURPOSE. To identify and quantify subretinal fibrosis in eyes with advanced neovascular age-related macular degeneration (nAMD) using polarization-sensitive optical coherence tomography (PS-OCT).
   METHODS. Eyes of patients with subretinal fibrosis secondary to nAMD were included in this case series. All patients underwent a complete ophthalmic examination to clearly identify advanced nAMD lesions with fibrosis. Examinations of PS-OCT were performed using a novel system with an integrated eye tracker. Areas of fibrosis in PS-OCT, automatically segmented using a custom-built algorithm, were compared with conventional imaging modalities including spectral-domain OCT, fluorescein angiography, and color fundus photography in their potential to visualize fibrosis in nAMD.
   RESULTS. Fifteen eyes of 15 consecutive patients were included. In polarization-sensitive OCT B-scans, a distinct "column-like'' pattern was observed in averaged axis orientation images. En face analysis provided a precise mapping of the fibrotic scar component. Fibrous tissue was selectively identified by PS-OCT based on birefringence in all lesions, whereas in SD-OCT, subretinal hyperreflective material (SHRM) could not be further classified into scar tissue, fibrovascular material, or other AMD-specific material. Based on simultaneous polarization analyses in PS-OCT, the level of RPE alteration could be evaluated as well, showing thinning and loss of RPE associated with subretinal fibrosis.
   CONCLUSIONS. Using PS-OCT, subretinal fibrosis can be identified as an intrinsically birefringent structure and can be segmented based solely on tissue-specific contrast. Polarization-sensitive OCT offers a unique method to identify clinically relevant components of SHRM (i.e., neovascular tissue versus fibrous tissue) and therefore allows for an optimized disease management and evaluation of therapeutic strategies.
C1 [Roberts, Philipp; Deak, Gabor; Sacu, Stefan; Schmidt-Erfurth, Ursula] Med Univ Vienna, Dept Ophthalmol & Optometry, Waehringer Guertel 18-20, A-1090 Vienna, Austria.
   [Sugita, Mitsuro; Baumann, Bernhard; Zotter, Stefan; Pircher, Michael; Hitzenberger, Christoph K.] Med Univ Vienna, Ctr Med Phys & Biomed Engn, Waehringer Guertel 18-20, A-1090 Vienna, Austria.
   [Sugita, Mitsuro] Canon Inc, Tokyo, Japan.
C3 Medical University of Vienna; Medical University of Vienna; Canon
   Incorporated
RP Schmidt-Erfurth, U (通讯作者)，Med Univ Vienna, Dept Ophthalmol & Optometry, Waehringer Guertel 18-20, A-1090 Vienna, Austria.
EM ursula.schmidt-erfurth@meduniwien.ac.at
OI Hitzenberger, Christoph/0000-0002-6608-8821; Michael,
   Pircher/0000-0001-9285-7527; Baumann, Bernhard/0000-0001-6419-1932;
   Schmidt-Erfurth, Ursula/0000-0002-7788-7311
CR Ahlers C, 2010, INVEST OPHTH VIS SCI, V51, P2149, DOI 10.1167/iovs.09-3817
   Babalola O, 2014, ARCH DERMATOL RES, V306, P1, DOI 10.1007/s00403-013-1417-7
   Baumann B, 2012, BIOMED OPT EXPRESS, V3, P1670, DOI 10.1364/BOE.3.001670
   Baumann B, 2010, J BIOMED OPT, V15, DOI 10.1117/1.3499420
   Bloch SB, 2013, AM J OPHTHALMOL, V156, P116, DOI 10.1016/j.ajo.2013.02.012
   Cense B, 2013, BIOMED OPT EXPRESS, V4, P2296, DOI 10.1364/BOE.4.002296
   Cheung CMG, 2013, AM J OPHTHALMOL, V155, P764, DOI 10.1016/j.ajo.2012.10.013
   Daniel E, 2014, OPHTHALMOLOGY, V121, P656, DOI 10.1016/j.ophtha.2013.10.019
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P532
   Gotzinger E, 2011, OPT EXPRESS, V19, P14568, DOI 10.1364/OE.19.014568
   Gotzinger E, 2008, OPT EXPRESS, V16, P16410, DOI 10.1364/OE.16.016410
   Gotzinger E, 2005, OPT EXPRESS, V13, P10217, DOI 10.1364/OPEX.13.010217
   Grunwald JE, 2014, OPHTHALMOLOGY, V121, P150, DOI 10.1016/j.ophtha.2013.08.015
   Hong YJ, 2014, INVEST OPHTH VIS SCI, V55, P5016, DOI 10.1167/iovs.14-14005
   Jaffe GJ, 2016, OPHTHALMOLOGY, V123, P78, DOI 10.1016/j.ophtha.2015.09.004
   Kawasaki R, 2010, OPHTHALMOLOGY, V117, P921, DOI 10.1016/j.ophtha.2009.10.007
   Keane PA, 2012, SURV OPHTHALMOL, V57, P389, DOI 10.1016/j.survophthal.2012.01.006
   Lammer J, 2013, AM J OPHTHALMOL, V155, P1058, DOI 10.1016/j.ajo.2012.12.017
   Liegl R, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0088203
   Michels S, 2008, BRIT J OPHTHALMOL, V92, P204, DOI 10.1136/bjo.2007.130047
   Miura M, 2008, INVEST OPHTH VIS SCI, V49, P2661, DOI 10.1167/iovs.07-0501
   Pierce MC, 2004, J INVEST DERMATOL, V123, P458, DOI 10.1111/j.0022-202X.2004.23404.x
   Pircher M, 2007, J BIOMED OPT, V12, DOI 10.1117/1.2771560
   Pircher M, 2011, PROG RETIN EYE RES, V30, P431, DOI 10.1016/j.preteyeres.2011.06.003
   Sayegh RG, 2015, INVEST OPHTH VIS SCI, V56, P5246, DOI 10.1167/iovs.14-15114
   Schlanitz FG, 2015, AM J OPHTHALMOL, V160, P335, DOI 10.1016/j.ajo.2015.05.008
   Schmidt-Erfurth U, 2016, PROG RETIN EYE RES, V50, P1, DOI 10.1016/j.preteyeres.2015.07.007
   Schmidt-Erfurth U, 2014, BRIT J OPHTHALMOL, V98, P1144, DOI 10.1136/bjophthalmol-2014-305702
   Schutze C, 2015, AM J OPHTHALMOL, V159, P1100, DOI 10.1016/j.ajo.2015.02.020
   Shah VP, 2014, RETINA-J RET VIT DIS, V34, P1281, DOI 10.1097/IAE.0000000000000166
   Smith W, 2001, OPHTHALMOLOGY, V108, P697, DOI 10.1016/S0161-6420(00)00580-7
   Sugita M, 2014, BIOMED OPT EXPRESS, V5, P106, DOI 10.1364/BOE.5.000106
   Toth LA, 2015, RETINA-J RET VIT DIS, V35, P1957, DOI 10.1097/IAE.0000000000000583
   Willoughby AS, 2015, OPHTHALMOLOGY, V122, P1846, DOI 10.1016/j.ophtha.2015.05.042
   Wojtkowski M, 2002, J BIOMED OPT, V7, P457, DOI 10.1117/1.1482379
   Ying GS, 2014, JAMA OPHTHALMOL, V132, P915, DOI 10.1001/jamaophthalmol.2014.1019
   Zotter S, 2013, INVEST OPHTH VIS SCI, V54, P72, DOI 10.1167/iovs.12-10089
   Zotter S, 2012, BIOMED OPT EXPRESS, V3, P2720, DOI 10.1364/BOE.3.002720
NR 38
TC 32
Z9 33
U1 0
U2 4
PU ASSOC RESEARCH VISION OPHTHALMOLOGY INC
PI ROCKVILLE
PA 12300 TWINBROOK PARKWAY, ROCKVILLE, MD 20852-1606 USA
SN 0146-0404
EI 1552-5783
J9 INVEST OPHTH VIS SCI
JI Invest. Ophthalmol. Vis. Sci.
PD APR
PY 2016
VL 57
IS 4
BP 1699
EP 1705
DI 10.1167/iovs.15-18694
PG 7
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA DL8XY
UT WOS:000375926700023
PM 27064389
OA gold
DA 2022-11-30
ER

PT J
AU Kaneko, H
   Ye, FX
   Ijima, R
   Kachi, S
   Kato, S
   Nagaya, M
   Higuchi, A
   Terasaki, H
AF Kaneko, Hiroki
   Ye, Fuxiang
   Ijima, Ryo
   Kachi, Shu
   Kato, Seiichi
   Nagaya, Masatoshi
   Higuchi, Akiko
   Terasaki, Hiroko
TI Histamine H-4 receptor as a new therapeutic target for choroidal
   neovascularization in age-related macular degeneration
SO BRITISH JOURNAL OF PHARMACOLOGY
LA English
DT Article
ID MOLECULAR-CLONING; EXPRESSION; POTENT; VEGF; PHARMACOLOGY; RANIBIZUMAB;
   SUPPRESSION; MECHANISMS; NEURONS; IMMUNE
AB BACKGROUND AND PURPOSE
   The present treatment for choroidal neovascularization (CNV) associated with age-related macular degeneration (AMD) is not sufficient. Hence, we examined the therapeutic efficacy of reducing histamine H-4 receptor expression on CNV in mice.
   EXPERIMENTAL APPROACH
   H-4 receptor expression was examined in CNVs from patients with AMD. In mice, laser photocoagulation was performed in the retina to induce experimental CNV (laser CNV). Protein and mRNA expression levels were determined and CNV volume measured in wild-type and Hrh4(-/-) mice with laser CNV. The effects of JNJ7777120, an H-4 receptor antagonist, administered intravitreously, on CNV volume and pathological vessel leakage were determined in mice with laser CNV and controls. Fundus imaging, retinal histology and electroretinography were performed on eyes injected with JNJ7777120 to evaluate retinal toxicity.
   KEY RESULTS
   Human H-4 receptors were only confirmed in CNV samples from AMD patients and not in the other subretinal tissues. Mouse H-4 receptors were expressed in retinal pigment epithelium only after inducing laser CNV in wild-type mice, and were co-localized with the macrophage marker F4/80. Laser CNV volume was reduced in Hrh4(-/-) mice compared with that in wild-type mice, and JNJ7777120 suppressed laser-induced CNV volume and pathological CNV leakage in wild-type mice. Also eyes injected with JNJ7777120 did not show retinal degeneration.
   CONCLUSIONS AND IMPLICATIONS
   H-4 receptors are expressed in macrophages that accumulate around CNVs. Suppressing H-4 receptor expression prevented the pathological vessel leakage without showing retinal toxicity, indicating that the H-4 receptor has potential as a novel therapeutic target in AMD.
C1 [Kaneko, Hiroki; Ye, Fuxiang; Ijima, Ryo; Kachi, Shu; Nagaya, Masatoshi; Higuchi, Akiko; Terasaki, Hiroko] Nagoya Univ, Grad Sch Med, Dept Ophthalmol, Nagoya, Aichi 4668550, Japan.
   [Kato, Seiichi] Nagoya Univ Hosp, Dept Pathol & Lab Med, Nagoya, Aichi, Japan.
C3 Nagoya University; Nagoya University
RP Kaneko, H (通讯作者)，Nagoya Univ, Grad Sch Med, Dept Ophthalmol, Showa Ku, 65 Tsuruma Cho, Nagoya, Aichi 4668550, Japan.
EM h-kaneko@med.nagoya-u.ac.jp
RI Kaneko, Hiroki/AHA-2461-2022; KATO, Seiichi/I-7298-2014; Terasaki,
   Hiroko/M-5054-2014; Kaneko, Hiroki/O-7695-2015
OI Kaneko, Hiroki/0000-0003-0731-6465; Kaneko, Hiroki/0000-0003-0731-6465;
   Kato, Seiichi/0000-0001-9713-3691; Ye, Fuxiang/0000-0003-2550-2173
FU Japan Society for the Promotion of Science
FX The authors would like to thank Reona Kimoto, Seina Ito and Kazuko
   Matsuba for technical assistance. This work was supported by a
   Grant-in-Aid for Young Scientist (A) and a Grant-in-Aid for Challenging
   Exploratory Research from the Japan Society for the Promotion of
   Science.
CR Alexander SPH, 2013, BRIT J PHARMACOL, V170, P1459, DOI 10.1111/bph.12445
   Ambati J, 2003, NAT MED, V9, P1390, DOI 10.1038/nm950
   Ambati J, 2003, SURV OPHTHALMOL, V48, P257, DOI 10.1016/S0039-6257(03)00030-4
   Ballerini C, 2013, BRIT J PHARMACOL, V170, P67, DOI 10.1111/bph.12263
   Bird AC, 2010, J CLIN INVEST, V120, P3033, DOI 10.1172/JCI42437
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Carmeliet P, 2011, NATURE, V473, P298, DOI 10.1038/nature10144
   Coge F, 2001, BIOCHEM BIOPH RES CO, V284, P301, DOI 10.1006/bbrc.2001.4976
   Connelly WM, 2009, BRIT J PHARMACOL, V157, P55, DOI 10.1111/j.1476-5381.2009.00227.x
   de Esch IJP, 2005, TRENDS PHARMACOL SCI, V26, P462, DOI 10.1016/j.tips.2005.07.002
   de Jong PTVM, 2006, NEW ENGL J MED, V355, P1474, DOI 10.1056/NEJMra062326
   Desmadryl G, 2012, BRIT J PHARMACOL, V167, P905, DOI 10.1111/j.1476-5381.2012.02049.x
   Dijkstra D, 2007, J ALLERGY CLIN IMMUN, V120, P300, DOI 10.1016/j.jaci.2007.03.024
   Dunford PJ, 2010, ADV EXP MED BIOL, V709, P53
   Gantner F, 2002, J PHARMACOL EXP THER, V303, P300, DOI 10.1124/jpet.102.036939
   Gragoudas ES, 2004, NEW ENGL J MED, V351, P2805, DOI 10.1056/NEJMoa042760
   Gutzmer R, 2005, J IMMUNOL, V174, P5224, DOI 10.4049/jimmunol.174.9.5224
   Ishida S, 2003, J EXP MED, V198, P483, DOI 10.1084/jem.20022027
   Ito T, 2013, AM J PATHOL, V182, P586, DOI 10.1016/j.ajpath.2012.10.012
   Jablonowski JA, 2003, J MED CHEM, V46, P3957, DOI 10.1021/jm0341047
   Kaneko H, 2011, NATURE, V471, P325, DOI 10.1038/nature09830
   Karlstedt K, 2013, BRIT J PHARMACOL, V170, P58, DOI 10.1111/bph.12173
   Kilkenny C, 2010, BRIT J PHARMACOL, V160, P1577, DOI [10.1111/j.1476-5381.2010.00872.x, 10.1113/expphysiol.2010.053793, 10.1113/jphysiol.2010.192278]
   Kingston D, 2009, BLOOD, V114, P835, DOI 10.1182/blood-2009-02-206318
   Kleinman ME, 2008, NATURE, V452, P591, DOI 10.1038/nature06765
   Kleinman ME, 2012, MOL THER, V20, P101, DOI 10.1038/mt.2011.212
   Leurs R, 2009, BRIT J PHARMACOL, V157, P14, DOI 10.1111/j.1476-5381.2009.00250.x
   Marneros AG, 2005, AM J PATHOL, V167, P1451, DOI 10.1016/S0002-9440(10)61231-X
   Lamas DJM, 2013, BRIT J PHARMACOL, V170, P188, DOI 10.1111/bph.12137
   McGrath JC, 2010, BRIT J PHARMACOL, V160, P1573, DOI 10.1111/j.1476-5381.2010.00873.x
   Miyata K, 2007, INVEST OPHTH VIS SCI, V48, P820, DOI 10.1167/iovs.06-0845
   Mizutani T, 2013, INVEST OPHTH VIS SCI, V54, P1564, DOI 10.1167/iovs.11-9095
   Nakamura T, 2000, BIOCHEM BIOPH RES CO, V279, P615, DOI 10.1006/bbrc.2000.4008
   Nakayama T, 2004, J IMMUNOL, V173, P2078, DOI 10.4049/jimmunol.173.3.2078
   Nishiguchi KM, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0013493
   Nishijima K, 2007, AM J PATHOL, V171, P53, DOI 10.2353/ajpath.2007.061237
   Oda T, 2000, J BIOL CHEM, V275, P36781, DOI 10.1074/jbc.M006480200
   Raffetseder U, 2011, NEPHRON EXP NEPHROL, V118, pE100, DOI 10.1159/000324209
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Saint-Geniez M, 2009, P NATL ACAD SCI USA, V106, P18751, DOI 10.1073/pnas.0905010106
   Saint-Geniez M, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003554
   Sakurai E, 2003, INVEST OPHTH VIS SCI, V44, P2743, DOI 10.1167/iovs.02-1246
   Sakurai E, 2003, INVEST OPHTH VIS SCI, V44, P3578, DOI 10.1167/iovs.03-0097
   Takeda A, 2009, NATURE, V460, P225, DOI 10.1038/nature08151
   Tarallo V, 2012, CELL, V149, P847, DOI 10.1016/j.cell.2012.03.036
   Thurmond RL, 2004, J PHARMACOL EXP THER, V309, P404, DOI 10.1124/jpet.103.061754
   Tomida D, 2011, INVEST OPHTH VIS SCI, V52, P3193, DOI 10.1167/iovs.10-6737
   Yanga YL, 2013, P NATL ACAD SCI USA, V110, P12018, DOI 10.1073/pnas.1301331110
   Zampeli E, 2009, BRIT J PHARMACOL, V157, P24, DOI 10.1111/j.1476-5381.2009.00151.x
   Zhang C, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0031207
   Zhang M, 2007, PHARMACOL THERAPEUT, V113, P594, DOI 10.1016/j.pharmthera.2006.11.008
NR 51
TC 16
Z9 20
U1 1
U2 6
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0007-1188
EI 1476-5381
J9 BRIT J PHARMACOL
JI Br. J. Pharmacol.
PD AUG
PY 2014
VL 171
IS 15
BP 3754
EP 3763
DI 10.1111/bph.12737
PG 10
WC Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Pharmacology & Pharmacy
GA AM7ZL
UT WOS:000340087500015
PM 24787705
OA Green Published, Bronze
DA 2022-11-30
ER

PT J
AU Ruiz-Moreno, JM
   Ruiz-Medrano, J
   Lugo, F
   Sirvent, B
   Flores-Moreno, I
AF Ruiz-Moreno, Jose M.
   Ruiz-Medrano, Jorge
   Lugo, Francisco
   Sirvent, Belen
   Flores-Moreno, Ignacio
TI Automatic Quantification Software for Geographic Atrophy Associated with
   Age-Related Macular Degeneration: A Validation Study
SO JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
ID OPTICAL COHERENCE TOMOGRAPHY; FUNDUS AUTOFLUORESCENCE; PREDICTIVE-VALUE;
   SEGMENTATION; CLASSIFICATION; PROGRESSION; IMAGES; TRIAL
AB Context. Geographic atrophy (GA) is usually measured manually using fundus autofluorescence (FAF) images, lacking a reliable, automatic method to do so.Aims. To determine the accuracy and repeatability of new software to automatically quantify GA areas associated to age-related macular degeneration (AMD) by swept-source optical coherence tomography (SS-OCT).Settings and Design. Tertiary referral hospital in Spain. Cross-sectional and noninterventional.Methods and Material. Forty-six eyes from 33 AMD patients with GA, without previous choroidal neovascularization, were scanned using a SS-OCT (Topcon Corporation, Japan), including three consecutive 7 x 7 mm OCT scans. Three independent masked observers manually measured the GA area using FAF images. These measures were compared to the three automatic determinations of the GA. Lesions were classified according to their morphology and number as regular/irregular and single/multiple.Statistical Analysis Used. Intraclass correlation coefficients (ICCs) were estimated to study the agreement between the three physicians in manual measurements. ICC through a two-way mixed effects model was used for the software measures, and Lin's concordance correlation coefficient (CCC) was used to analyse the agreement between the physicians and the software.Results. The mean age was 76.3 +/- 11.7 years. Eighteen cases showed regular lesions, and 30 showed single lesions. The CCC between manual and automatic measures was 0.95 for the whole sample. The CCC for the area according to the lesion type was 0.92 and 0.97; it was 0.99 for single lesions and 0.89 for multiple lesions. The ICC between the three physicians was 0.94 for the whole sample and 0.88 in multiple lesions. The ICC between the three automatic measures for the area was 0.98 for the whole sample, regular or irregular lesions, and single or multiple lesions.Conclusions. The accuracy of this new software is substantial for the area with a high degree of repeatability agreement, being very precise in single lesions.
C1 [Ruiz-Moreno, Jose M.] Castilla La Mancha Univ, Dept Ophthalmol, Albacete, Spain.
   [Ruiz-Moreno, Jose M.; Ruiz-Medrano, Jorge; Sirvent, Belen; Flores-Moreno, Ignacio] Puerta de Hierro Majadahonda Univ Hosp, Madrid, Spain.
   [Ruiz-Moreno, Jose M.; Lugo, Francisco] Vissum Corp, Alicante, Spain.
C3 Universidad de Castilla-La Mancha; Hospital Puerta de
   Hierro-Majadahonda; VISSUM
RP Ruiz-Medrano, J (通讯作者)，Puerta de Hierro Majadahonda Univ Hosp, Madrid, Spain.
EM jorge.ruizmedrano@gmail.com
RI Ruiz-Medrano, Jorge/N-6256-2016
OI Ruiz-Medrano, Jorge/0000-0002-1105-9265; Ruiz-Moreno, Jose
   M/0000-0001-9636-0788
CR Baumann B, 2010, J BIOMED OPT, V15, DOI 10.1117/1.3499420
   BIRD AEC, 1995, SURV OPHTHALMOL, V39, P367, DOI 10.1016/S0039-6257(05)80092-X
   Chaikitmongkol V, 2016, CURR OPIN OPHTHALMOL, V27, P217, DOI 10.1097/ICU.0000000000000259
   Chen Q, 2013, BIOMED OPT EXPRESS, V4, P2729, DOI 10.1364/BOE.4.002729
   Csaky KG, 2008, INVEST OPHTH VIS SCI, V49, P479, DOI 10.1167/iovs.07-1132
   Ferris FL, 2013, OPHTHALMOLOGY, V120, P844, DOI 10.1016/j.ophtha.2012.10.036
   Fleckenstein M, 2008, INVEST OPHTH VIS SCI, V49, P4137, DOI 10.1167/iovs.08-1967
   Gass JD, 1970, STEREOSCOPIC ATLAS M
   Giocanti-Auregan A, 2015, INVEST OPHTH VIS SCI, V56, P8325, DOI 10.1167/iovs.14-15480
   Gobel AP, 2011, OPHTHALMOLOGICA, V226, P182, DOI 10.1159/000330420
   Holz FG, 2014, OPHTHALMOLOGY, V121, P1079, DOI 10.1016/j.ophtha.2013.11.023
   Hwang JC, 2006, INVEST OPHTH VIS SCI, V47, P2655, DOI 10.1167/iovs.05-1027
   Jaffe GJ, 2015, AM J OPHTHALMOL, V160, P1226, DOI 10.1016/j.ajo.2015.08.024
   Kanagasingam Y, 2014, PROG RETIN EYE RES, V38, P20, DOI 10.1016/j.preteyeres.2013.10.002
   Lee N, 2007, P ANN INT IEEE EMBS, P4965, DOI 10.1109/IEMBS.2007.4353455
   Lee N, 2008, CONF REC ASILOMAR C, P655, DOI 10.1109/ACSSC.2008.5074488
   Lindner M, 2015, OPHTHALMOLOGY, V122, P1356, DOI 10.1016/j.ophtha.2015.03.027
   McBride G., 2005, HAM2005062 NIWA, P62
   Niu SJ, 2016, BIOMED OPT EXPRESS, V7, P581, DOI 10.1364/BOE.7.000581
   Panthier C, 2014, RETINA-J RET VIT DIS, V34, P576, DOI 10.1097/01.iae.0000433986.32991.1e
   Pfau M, 2017, INVEST OPHTH VIS SCI, V58, pBIO121, DOI 10.1167/iovs.17-21764
   Ramsey DJ, 2014, RETINA-J RET VIT DIS, V34, P1296, DOI 10.1097/IAE.0000000000000069
   Sadda SR, 2018, OPHTHALMOLOGY, V125, P537, DOI 10.1016/j.ophtha.2017.09.028
   Sayegh RG, 2011, OPHTHALMOLOGY, V118, P1844, DOI 10.1016/j.ophtha.2011.01.043
   Schmitz-Valckenberg S, 2016, RETINA-J RET VIT DIS, V36, P2250, DOI 10.1097/IAE.0000000000001258
   Schmitz-Valckenberg S, 2016, OPHTHALMOLOGY, V123, P361, DOI 10.1016/j.ophtha.2015.09.036
   Schmitz-Valckenberg S, 2011, INVEST OPHTH VIS SCI, V52, P7640, DOI 10.1167/iovs.11-7457
   VONRUCKMANN A, 1995, BRIT J OPHTHALMOL, V79, P407, DOI 10.1136/bjo.79.5.407
   Wu ZC, 2014, OPHTHALMOLOGY, V121, P2415, DOI 10.1016/j.ophtha.2014.06.034
   [No title captured]
NR 30
TC 1
Z9 1
U1 0
U2 0
PU HINDAWI LTD
PI LONDON
PA ADAM HOUSE, 3RD FLR, 1 FITZROY SQ, LONDON, W1T 5HF, ENGLAND
SN 2090-004X
EI 2090-0058
J9 J OPHTHALMOL
JI J. Ophthalmol.
PD AUG 6
PY 2020
VL 2020
AR 8204641
DI 10.1155/2020/8204641
PG 7
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA NE8PZ
UT WOS:000562869000002
PM 32832140
OA Green Published, gold
DA 2022-11-30
ER

PT J
AU Yun, C
   Oh, J
   Choi, KE
   Hwang, SY
   Kim, SW
   Huh, K
AF Yun, Cheolmin
   Oh, Jaeryung
   Choi, Kwang-Eon
   Hwang, Soon-Young
   Kim, Seong-Woo
   Huh, Kuhl
TI Peripapillary choroidal thickness after intravitreal ranibizumab
   injections in eyes with neovascular age-related macular degeneration
SO BMC OPHTHALMOLOGY
LA English
DT Article
DE Age-related macular degeneration; Choroidal thickness; Optical coherence
   tomography; Peripapillary choroidal thickness; Ranibizumab
ID OPTICAL COHERENCE TOMOGRAPHY; ENDOTHELIAL GROWTH-FACTOR; CENTRAL SEROUS
   CHORIORETINOPATHY; PIGMENT EPITHELIAL DETACHMENTS; BLOOD-FLOW; FACTOR
   THERAPY; VEGF; VASCULOPATHY; BLINDNESS; CHORIOCAPILLARIS
AB Background: The purpose of this study was to investigate peripapillary choroidal thickness (CT) in eyes with neovascular age-related macular degeneration (AMD) and to assess whether peripapillary CT is affected by intravitreal injection of ranibizumab (IVR) in eyes with neovascular AMD.
   Methods: Peripapillary and subfoveal CT were measured in spectral domain optical coherence tomography images from 39 eyes of neovascular AMD patients and 39 eyes of age-matched controls retrospectively. The patients were treated with 0.5 mg IVR monthly for 3 months and retreated as needed. Peripapillary CT at baseline, 3 months and 6 months was measured at four locations (superior, nasal, inferior and temporal areas).
   Results: The mean peripapillary and subfoveal baseline CTs of the eyes with neovascular AMD (153.3 +/- 45.3 mu m and 228.6 +/- 78.6 mu m) were not different from those of the controls (149.0 +/- 42.3 mu m and 221.4 +/- 54.1 mu m; P = 0.665 and P = 0.639, respectively). Subfoveal CT decreased at 3 months (213.8 +/- 75.8 mu m, P < 0.001) and 6 months (215.1 +/- 72.8 mu m, P = 0.002) following IVR treatment. Mean peripapillary CT did not show significant changes at 3 months (149.6 +/- 43.8 mu m, P = 0.156) or 6 months (150.0 +/- 43.4 mu m, P = 0.187). Subanalysis revealed that only temporal peripapillary CT decreased from baseline (167.1 +/- 54.5 mu m) to 3 months (159.4 +/- 50.8 mu m, P = 0.010) and was sustained at 6 months (160.6 +/- 49.6, P = 0.026). However, superior, nasal and inferior peripapillary CT did not show significant changes after IVR.
   Conclusions: Changes in peripapillary CT after IVR were limited to the macular area. This result may suggest that IVR does not affect CT outside of the macula in the eyes of patients with neovascular AMD.
C1 [Yun, Cheolmin; Oh, Jaeryung; Choi, Kwang-Eon; Kim, Seong-Woo; Huh, Kuhl] Korea Univ, Coll Med, Dept Ophthalmol, 126-1 Anam Dong 5 Ga, Seoul 136705, South Korea.
   [Hwang, Soon-Young] Korea Univ, Coll Med, Dept Biostat, Seoul 136705, South Korea.
C3 Korea University; Korea University Medicine (KU Medicine); Korea
   University; Korea University Medicine (KU Medicine)
RP Oh, J (通讯作者)，Korea Univ, Coll Med, Dept Ophthalmol, 126-1 Anam Dong 5 Ga, Seoul 136705, South Korea.
EM ojr4991@yahoo.co.kr
RI Oh, Jaeryung/ABD-3090-2021
OI Oh, Jaeryung/0000-0002-1036-6562
FU Korea University [K1421461]
FX This study is supported by a grant from Korea University (K1421461)
CR Ahuja RM, 2000, BRIT J OPHTHALMOL, V84, P479, DOI 10.1136/bjo.84.5.479
   Belkin M, 2013, AM J OPHTHALMOL, V155, P404, DOI 10.1016/j.ajo.2012.09.017
   Berenberg TL, 2012, RETINA-J RET VIT DIS, V32, P25, DOI 10.1097/IAE.0b013e3182150483
   Blaauwgeers HGT, 1999, AM J PATHOL, V155, P421, DOI 10.1016/S0002-9440(10)65138-3
   Bloch SB, 2012, AM J OPHTHALMOL, V153, P209, DOI 10.1016/j.ajo.2011.10.016
   Branchini L, 2013, JAMA OPHTHALMOL, V131, P693, DOI 10.1001/jamaophthalmol.2013.692
   Campbell JP, 2012, ARCH OPHTHALMOL-CHIC, V130, P794, DOI 10.1001/archophthalmol.2011.2480
   Chung SE, 2011, OPHTHALMOLOGY, V118, P840, DOI 10.1016/j.ophtha.2010.09.012
   Ciulla TA, 2001, ACTA OPHTHALMOL SCAN, V79, P108, DOI 10.1034/j.1600-0420.2001.079002108.x
   Freund KB, 2008, RETINA-J RET VIT DIS, V28, P201, DOI 10.1097/IAE.0b013e3181669504
   Freund KB, 2010, RETINA-J RET VIT DIS, V30, P1333, DOI 10.1097/IAE.0b013e3181e7976b
   Friedman E, 1997, AM J OPHTHALMOL, V124, P677, DOI 10.1016/S0002-9394(14)70906-7
   Fung AE, 2007, AM J OPHTHALMOL, V143, P566, DOI 10.1016/j.ajo.2007.01.028
   Grossniklaus HE, 2004, AM J OPHTHALMOL, V137, P496, DOI 10.1016/j.ajo.2003.09.042
   Grunwald JE, 1998, INVEST OPHTH VIS SCI, V39, P385
   Hayreh SS, 2004, INVEST OPHTH VIS SCI, V45, P749, DOI 10.1167/iovs.03-0469
   HAYREH SS, 1990, EYE, V4, P273, DOI 10.1038/eye.1990.39
   Hayreh SS, 2001, PROG RETIN EYE RES, V20, P563, DOI 10.1016/S1350-9462(01)00004-0
   Jonas JB, 2014, RETINA-J RET VIT DIS, V34, P1149, DOI 10.1097/IAE.0000000000000035
   Kim SW, 2011, RETINA-J RET VIT DIS, V31, P1904, DOI 10.1097/IAE.0b013e31821801c5
   Koh AHC, 2013, RETINA-J RET VIT DIS, V33, P686, DOI 10.1097/IAE.0b013e3182852446
   Liang D, 2001, MECH DEVELOP, V108, P29, DOI 10.1016/S0925-4773(01)00468-3
   Lim LS, 2012, LANCET, V379, P1728, DOI 10.1016/S0140-6736(12)60282-7
   Manjunath V, 2011, AM J OPHTHALMOL, V152, P663, DOI 10.1016/j.ajo.2011.03.008
   Margolis R, 2009, AM J OPHTHALMOL, V147, P811, DOI 10.1016/j.ajo.2008.12.008
   Mathis U, 2014, EXP EYE RES, V127, P161, DOI 10.1016/j.exer.2014.07.022
   Mitchell P, 2010, BRIT J OPHTHALMOL, V94, P2, DOI 10.1136/bjo.2009.159160
   Oh Jaeryung, 2013, Korean J Ophthalmol, V27, P172, DOI 10.3341/kjo.2013.27.3.172
   PERKOVICH BT, 1990, RETINA-J RET VIT DIS, V10, P18, DOI 10.1097/00006982-199001010-00003
   Pournaras CJ, 2008, PROG RETIN EYE RES, V27, P284, DOI 10.1016/j.preteyeres.2008.02.002
   ROBERTS WG, 1995, J CELL SCI, V108, P2369
   Sacu S, 2011, INVEST OPHTH VIS SCI, V52, P3046, DOI 10.1167/iovs.10-5842
   Saint-Geniez M, 2006, INVEST OPHTH VIS SCI, V47, P3135, DOI 10.1167/iovs.05-1229
   Saint-Geniez M, 2009, P NATL ACAD SCI USA, V106, P18751, DOI 10.1073/pnas.0905010106
   Sengupta S, 2015, AM J OPHTHALMOL, V160, P203, DOI 10.1016/j.ajo.2015.03.023
   STERNBERG P, 1991, ARCH OPHTHALMOL-CHIC, V109, P1242
   Tan CS, 2012, INVEST OPHTH VIS SCI, V53, P261, DOI 10.1167/iovs.11-8782
   Vujosevic S, 2012, RETINA-J RET VIT DIS, V32, P1781, DOI 10.1097/IAE.0b013e31825db73d
   Weis SM, 2005, NATURE, V437, P497, DOI 10.1038/nature03987
   Yamazaki T, 2012, OPHTHALMOLOGY, V119, P1621, DOI 10.1016/j.ophtha.2012.02.022
   Yokoyama K, 2008, ACTA OPHTHALMOL, V86, P927, DOI 10.1111/j.1755-3768.2008.01187.x
   Yun C, 2016, GRAEF ARCH CLIN EXP, V254, P427, DOI 10.1007/s00417-015-3054-7
   Yun C, 2015, RETINA-J RET VIT DIS, V35, P1860, DOI 10.1097/IAE.0000000000000539
NR 43
TC 4
Z9 4
U1 0
U2 3
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 1471-2415
J9 BMC OPHTHALMOL
JI BMC Ophthalmol.
PD MAR 8
PY 2016
VL 16
AR 25
DI 10.1186/s12886-016-0203-7
PG 10
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA DF7WR
UT WOS:000371568900001
PM 26951107
OA Green Published, gold
DA 2022-11-30
ER

PT J
AU Joeres, S
   Llacer, H
   Heussen, FMA
   Weiss, C
   Kirchhof, B
   Joussen, AM
AF Joeres, S.
   Llacer, H.
   Heussen, F. M. A.
   Weiss, C.
   Kirchhof, B.
   Joussen, A. M.
TI Optical coherence tomography on autologous translocation of choroid and
   retinal pigment epithelium in age-related macular degeneration
SO EYE
LA English
DT Article
DE OCT; age-related macular degeneration; submacular surgery; graft
   translocation
ID PHOTODYNAMIC THERAPY; ULTRAHIGH-RESOLUTION; PERIPHERAL RETINECTOMY;
   READING CHART; NEOVASCULARIZATION; DISEASE; SURGERY; EDEMA
AB Purpose To analyse structural changes after autologous translocation of choroid and retinal pigment epithelium (RPE) in patients with age-related macular degeneration (AMD) using optical coherence tomography (OCT).
   Methods We performed a prospective nonrandomised study in 29 consecutive patients, who underwent submacular surgery with translocation of an autologous full-thickness graft of RPE, Bruch's membrane, and choroid. All patients had recent loss of reading vision due to AMD. OCT was performed before surgery and at 3- and 6-month follow-up to analyse the morphological appearance of the graft and the overlying retina.
   Results Maximum retinal thickness decreased from mean 408 mu m ( standard deviation (SD) 127 mu m) preoperative to mean 373 mu m (SD 104 mu m) at 6-month follow-up (P = 0.094). In 11 cases (40%), a nearly physiological shape of the retina was seen at this time point. A macular hole persisted in two eyes after silicone oil removal. In most eyes, the highly reflective band of the graft presumably corresponding to RPE was continuous with the surrounding RPE band in all six OCT scans. Eyes with flat appearance of the graft at 6-month follow-up (< 300 mu m) showed a significantly better functional outcome than eyes with more prominent grafts. Interestingly, most patients did not complain about metamorphopsia, even though the graft was prominent or wrinkled in some cases.
   Conclusion OCT is a useful tool in monitoring intra- and subretinal changes after subretinal surgery with graft translocation. We demonstrated that graft translocation may lead to a normalisation of retinal thickness and stabilisation of visual acuity.
C1 [Llacer, H.; Joussen, A. M.] Univ Dusseldorf, Dept Ophthalmol, D-40225 Dusseldorf, Germany.
   [Joeres, S.; Llacer, H.; Heussen, F. M. A.; Kirchhof, B.; Joussen, A. M.] Univ Cologne, Dept Vitreoretinal Surg, Ctr Ophthalmol, Cologne, Germany.
   [Weiss, C.] Univ Cologne, KKSK, Cologne, Germany.
C3 Heinrich Heine University Dusseldorf; University of Cologne; University
   of Cologne
RP Joussen, AM (通讯作者)，Univ Dusseldorf, Dept Ophthalmol, Moorenstr 5, D-40225 Dusseldorf, Germany.
EM Joussena@googlemail.com
RI Joussen, Antonia/AAA-6901-2022
OI Heussen, Florian Moritz/0000-0003-0536-9870
CR Arnold J, 2001, AM J OPHTHALMOL, V131, P541
   Binder S, 2004, INVEST OPHTH VIS SCI, V45, P4151, DOI 10.1167/iovs.04-0118
   Bressler NM, 2003, ARCH OPHTHALMOL-CHIC, V121, P1621
   Bressler NM, 1999, ARCH OPHTHALMOL-CHIC, V117, P1329
   Cahill MT, 2003, ARCH OPHTHALMOL-CHIC, V121, P132
   Costa RA, 2003, RETINA-J RET VIT DIS, V23, P159, DOI 10.1097/00006982-200304000-00004
   Eckardt C, 2002, RETINA-J RET VIT DIS, V22, P786, DOI 10.1097/00006982-200212000-00017
   Fukuchi T, 2001, JPN J OPHTHALMOL, V45, P252, DOI 10.1016/S0021-5155(00)00381-6
   Gallemore RP, 2000, RETINA-J RET VIT DIS, V20, P115, DOI 10.1097/00006982-200003000-00001
   Gragoudas ES, 2004, NEW ENGL J MED, V351, P2805, DOI 10.1056/NEJMoa042760
   Hawkins BS, 2004, OPHTHALMOLOGY, V111, P1967, DOI 10.1016/j.ophtha.2004.07.021
   HEE MR, 1995, AM J OPHTHALMOL, V120, P65, DOI 10.1016/S0002-9394(14)73760-2
   Hermann B, 2004, OPT LETT, V29, P2142, DOI 10.1364/OL.29.002142
   JOUSSEN AM, 2006, OPHTHALMOLO IN PRESS
   Joussen AM, 2006, AM J OPHTHALMOL, V142, P17, DOI 10.1016/j.ajo.2006.01.090
   Khurana RN, 2005, OPHTHALMOLOGY, V112, P1586, DOI 10.1016/j.ophtha.2005.04.016
   Ko TH, 2005, OPHTHALMOLOGY, V112, P1922, DOI 10.1016/j.ophtha.2005.05.027
   Krebs I, 2006, GRAEF ARCH CLIN EXP, V244, P863, DOI 10.1007/s00417-005-0155-8
   MAAIJWEE KJM, 2006, BR J OPHTHA IN PRESS
   Massin P, 2003, AM J OPHTHALMOL, V135, P169, DOI 10.1016/S0002-9394(02)01837-8
   Montero JA, 2003, GRAEF ARCH CLIN EXP, V241, P797, DOI 10.1007/s00417-003-0752-3
   Otani T, 1999, AM J OPHTHALMOL, V127, P688, DOI 10.1016/S0002-9394(99)00033-1
   Park CH, 2003, AM J OPHTHALMOL, V136, P830, DOI 10.1016/S0002-9394(03)00723-2
   Pauleikhoff D, 2005, RETINA-J RET VIT DIS, V25, P1065, DOI 10.1097/00006982-200512000-00016
   PULIAFITO CA, 1995, OPHTHALMOLOGY, V102, P217
   Radner T, 1998, KLIN MONATSBL AUGENH, V213, P174, DOI 10.1055/s-2008-1034969
   Rogers AH, 2002, AM J OPHTHALMOL, V134, P566, DOI 10.1016/S0002-9394(02)01566-0
   Roquet W, 2004, BRIT J OPHTHALMOL, V88, P638, DOI 10.1136/bjo.2003.017632
   Sadda SR, 2006, OPHTHALMOLOGY, V113, P285, DOI 10.1016/j.ophtha.2005.10.005
   SADDA SR, 2006, INVEST OPHTH VIS SCI, V48, P839
   Sahni J, 2005, BRIT J OPHTHALMOL, V89, P316, DOI 10.1136/bjo.2004.043364
   Schmidt-Erfurth U, 2005, INVEST OPHTH VIS SCI, V46, P3393, DOI 10.1167/iovs.05-0370
   Stifter E, 2004, GRAEF ARCH CLIN EXP, V242, P31, DOI 10.1007/s00417-003-0776-8
   Terasaki H, 2003, OPHTHALMOLOGY, V110, P2403, DOI 10.1016/S0161-6420(03)00829-7
   Toth CA, 1997, ARCH OPHTHALMOL-CHIC, V115, P1425, DOI 10.1001/archopht.1997.01100160595012
   Van Meurs JC, 2003, AM J OPHTHALMOL, V136, P688, DOI 10.1016/S0002-9394(03)00384-2
NR 36
TC 7
Z9 7
U1 0
U2 1
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 0950-222X
EI 1476-5454
J9 EYE
JI Eye
PD JUN
PY 2008
VL 22
IS 6
BP 782
EP 789
DI 10.1038/sj.eye.6702761
PG 8
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 312HL
UT WOS:000256659800007
PM 17332766
OA Bronze
DA 2022-11-30
ER

PT J
AU Newman, DK
AF Newman, D. K.
TI Photodynamic therapy: current role in the treatment of chorioretinal
   conditions
SO EYE
LA English
DT Article
ID CENTRAL SEROUS CHORIORETINOPATHY; POLYPOIDAL CHOROIDAL VASCULOPATHY;
   RANDOMIZED CLINICAL-TRIAL; HALF-DOSE VERTEPORFIN; INDOCYANINE GREEN
   ANGIOGRAPHY; MACULAR DEGENERATION; PATHOLOGICAL MYOPIA; INTRAVITREAL
   BEVACIZUMAB; LASER PHOTOCOAGULATION; NEOVASCULAR MEMBRANES
AB Verteporfin photodynamic therapy (vPDT) is a selective vaso-occlusive treatment that targets choroidal vascular abnormalities. It was initially developed to treat neovascular age-related macular degeneration using the 'standard' vPDT protocol (verteporfin 6 mg/m(2), vPDT laser fluence 50 J/cm(2)). vPDT therapy has subsequently evolved as an important treatment modality for a range of other chorioretinal conditions including choroidal haemangioma, central serous chorioretinopathy, polypoidal choroidal vasculopathy, and peripapillary choroidal neovascularisation. Various 'safety-enhanced' vPDT protocols have been devised to optimise treatment outcomes, typically using reduced dose verteporfin (verteporfin 3mg/m(2)) or reduced fluence vPDT (vPDT laser fluence 25 J/cm(2)). This paper reviews the current role of vPDT therapy in the treatment of chorioretinal
C1 [Newman, D. K.] Cambridge Univ Hosp NHS Fdn Trust, Addenbrookes Hosp, Dept Ophthalmol, Box 41,Hills Rd, Cambridge CB2 0QQ, England.
C3 Cambridge University Hospitals NHS Foundation Trust; Addenbrooke's
   Hospital; University of Cambridge
RP Newman, DK (通讯作者)，Cambridge Univ Hosp NHS Fdn Trust, Addenbrookes Hosp, Dept Ophthalmol, Box 41,Hills Rd, Cambridge CB2 0QQ, England.
EM douglas.newman@addenbrookes.nhs.uk
CR Alkin Z, 2014, CLIN OPHTHALMOL, V8, P685, DOI 10.2147/OPTH.S58617
   Arnold J, 2001, OPHTHALMOLOGY, V108, P841
   Arnold J, 2001, AM J OPHTHALMOL, V131, P541
   Baba T, 2010, BRIT J OPHTHALMOL, V94, P864, DOI 10.1136/bjo.2009.166025
   Bernstein PS, 2008, RETINA-J RET VIT DIS, V28, P81, DOI 10.1097/IAE.0b013e31815e9351
   Blasi MA, 2010, OPHTHALMOLOGY, V117, P1630, DOI 10.1016/j.ophtha.2009.12.033
   Blinder KJ, 2003, OPHTHALMOLOGY, V110, P667, DOI 10.1016/S0161-6420(02)01998-X
   Blumenkranz MS, 2001, ARCH OPHTHALMOL-CHIC, V119, P198
   Boixadera A, 2009, OPHTHALMOLOGY, V116, P100, DOI 10.1016/j.ophtha.2008.08.029
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Brown DM, 2009, OPHTHALMOLOGY, V116, P57, DOI 10.1016/j.ophtha.2008.10.018
   Brown SB, 2004, LANCET ONCOL, V5, P497, DOI 10.1016/S1470-2045(04)01529-3
   Chan WM, 2008, OPHTHALMOLOGY, V115, P1756, DOI 10.1016/j.ophtha.2008.04.014
   Chan WM, 2008, RETINA-J RET VIT DIS, V28, P85, DOI 10.1097/IAE.0b013e318156777f
   Chan WM, 2004, OPHTHALMOLOGY, V111, P1576, DOI 10.1016/j.ophtha.2003.12.056
   Chan WM, 2003, BRIT J OPHTHALMOL, V87, P1453, DOI 10.1136/bjo.87.12.1453
   Davis SJ, 2014, RETINA-J RET VIT DIS, V34, P2185, DOI 10.1097/IAE.0000000000000206
   Dougherty TJ, 1998, JNCI-J NATL CANCER I, V90, P889, DOI 10.1093/jnci/90.12.889
   Eandi CM, 2007, RETINA-J RET VIT DIS, V27, P825, DOI 10.1097/IAE.0b013e31804b3f70
   Erikitola OC, 2014, EYE, V28, P944, DOI 10.1038/eye.2014.134
   Figueroa MS, 2008, BRIT J OPHTHALMOL, V92, P1244, DOI 10.1136/bjo.2008.144196
   Frau E, 2004, ARCH OPHTHALMOL-CHIC, V122, P1471, DOI 10.1001/archopht.122.10.1471
   Fujita K, 2015, OPHTHALMOLOGY, V122, P555, DOI 10.1016/j.ophtha.2014.09.034
   Fujita K, 2011, RETINA-J RET VIT DIS, V31, P772, DOI 10.1097/IAE.0b013e3181f049d3
   Gomi F, 2008, CURR OPIN OPHTHALMOL, V19, P208, DOI 10.1097/ICU.0b013e3282fb7c33
   Gomi F, 2010, AM J OPHTHALMOL, V150, P48, DOI 10.1016/j.ajo.2010.02.008
   Greve MDJ, 2005, ARCH OPHTHALMOL-CHIC, V123, P448
   Hayashi K, 2009, AM J OPHTHALMOL, V148, P396, DOI 10.1016/j.ajo.2009.03.026
   Heier JS, 2011, OPHTHALMOLOGY, V118, P111, DOI 10.1016/j.ophtha.2010.04.016
   Hirami Y, 2007, RETINA-J RET VIT DIS, V27, P335, DOI 10.1097/01.iae.0000233647.78726.46
   Hoeh AE, 2009, EUR J OPHTHALMOL, V19, P163, DOI 10.1177/112067210901900128
   Jurklies B, 2003, BRIT J OPHTHALMOL, V87, P84, DOI 10.1136/bjo.87.1.84
   Jutley G, 2011, EYE, V25, P675, DOI 10.1038/eye.2011.24
   Kaiser PK, 2012, OPHTHALMOLOGY, V119, P1001, DOI 10.1016/j.ophtha.2012.02.003
   Kang HM, 2013, AM J OPHTHALMOL, V155, P713, DOI 10.1016/j.ajo.2012.10.010
   Karakus SH, 2013, EYE, V27, P612, DOI 10.1038/eye.2013.24
   Koh A, 2012, RETINA-J RET VIT DIS, V32, P1453, DOI 10.1097/IAE.0b013e31824f91e8
   Koh AHC, 2013, RETINA-J RET VIT DIS, V33, P686, DOI 10.1097/IAE.0b013e3182852446
   Kokame GT, 2010, BRIT J OPHTHALMOL, V94, P297, DOI 10.1136/bjo.2008.150029
   Kramer M, 1996, OPHTHALMOLOGY, V103, P427
   Lanzetta P, 2008, EUR J OPHTHALMOL, V18, P934, DOI 10.1177/112067210801800613
   Larsen M, 2012, OPHTHALMOLOGY, V119, P992, DOI 10.1016/j.ophtha.2012.02.002
   Lee MW, 2009, EYE, V23, P145, DOI 10.1038/sj.eye.6702955
   Lim JI, 2014, OPHTHALMOLOGY, V121, P1073, DOI 10.1016/j.ophtha.2013.11.040
   Ma JL, 2014, ACTA OPHTHALMOL, V92, pe594, DOI 10.1111/aos.12482
   Maruko I, 2010, OPHTHALMOLOGY, V117, P1792, DOI 10.1016/j.ophtha.2010.01.023
   Miller JW, 1999, ARCH OPHTHALMOL-CHIC, V117, P1161
   MILLER JW, 1995, ARCH OPHTHALMOL-CHIC, V113, P810, DOI 10.1001/archopht.1995.01100060136048
   Nicolo M, 2014, AM J OPHTHALMOL, V157, P1033, DOI 10.1016/j.ajo.2014.01.022
   Otani A, 2007, AM J OPHTHALMOL, V144, P7, DOI 10.1016/j.ajo.2007.03.014
   Porrini G, 2003, OPHTHALMOLOGY, V110, P674, DOI 10.1016/S0161-6420(02)01968-1
   Regillo C D, 2000, Curr Opin Ophthalmol, V11, P166, DOI 10.1097/00055735-200006000-00002
   Reibaldi M, 2011, AM J OPHTHALMOL, V151, P953, DOI 10.1016/j.ajo.2010.12.007
   Reibaldi M, 2010, AM J OPHTHALMOL, V149, P307, DOI 10.1016/j.ajo.2009.08.026
   Rosenblatt BJ, 2005, RETINA-J RET VIT DIS, V25, P33, DOI 10.1097/00006982-200501000-00004
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Ross A, 2011, CURR OPIN OPHTHALMOL, V22, P166, DOI 10.1097/ICU.0b013e3283459826
   Ruiz-Moreno JM, 2008, BRIT J OPHTHALMOL, V92, P792, DOI 10.1136/bjo.2007.132795
   Schmidt-Erfurth U, 2000, SURV OPHTHALMOL, V45, P195, DOI 10.1016/S0039-6257(00)00158-2
   Schmidt-Erfurth U, 1999, ARCH OPHTHALMOL-CHIC, V117, P1177
   Schmidt-Erfurth UM, 2002, OPHTHALMOLOGY, V109, P2284, DOI 10.1016/S0161-6420(02)01454-9
   Shin JY, 2011, RETINA-J RET VIT DIS, V31, P119, DOI 10.1097/IAE.0b013e3181e378f2
   Sickenberg M, 2000, ARCH OPHTHALMOL-CHIC, V118, P327, DOI 10.1001/archopht.118.3.327
   Silva RM, 2013, RETINA-J RET VIT DIS, V33, P309, DOI 10.1097/IAE.0b013e3182670fbe
   Singh AD, 2004, BRIT J OPHTHALMOL, V88, P1414, DOI 10.1136/bjo.2004.044396
   Smretschnig E, 2013, RETINA-J RET VIT DIS, V33, P316, DOI 10.1097/IAE.0b013e318280769c
   Tozer K, 2013, OPHTHALMOLOGY, V120, P2029, DOI 10.1016/j.ophtha.2013.03.016
   Tseng CC, 2015, BRIT J OPHTHALMOL, V99, P1070, DOI 10.1136/bjophthalmol-2014-305353
   Tsipursky MS, 2011, SURV OPHTHALMOL, V56, P68, DOI 10.1016/j.survophthal.2010.08.002
   Uyama M, 2002, AM J OPHTHALMOL, V133, P639, DOI 10.1016/S0002-9394(02)01404-6
   Vrouenraets MB, 2003, ANTICANCER RES, V23, P505
   Wolf S, 2014, OPHTHALMOLOGY, V121, P682, DOI 10.1016/j.ophtha.2013.10.023
   Wong TY, 2015, BRIT J OPHTHALMOL, V99, P289, DOI 10.1136/bjophthalmol-2014-305131
   Yannuzzi LA, 2003, RETINA-J RET VIT DIS, V23, P288, DOI 10.1097/00006982-200306000-00002
   Yuzawa M, 2003, JPN J OPHTHALMOL, V47, P379, DOI 10.1016/S0021-5155(03)00042-X
   2002, RETINA, V22, P6
NR 76
TC 64
Z9 65
U1 0
U2 11
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 0950-222X
EI 1476-5454
J9 EYE
JI Eye
PD FEB
PY 2016
VL 30
IS 2
BP 202
EP 210
DI 10.1038/eye.2015.251
PG 9
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA DE2HX
UT WOS:000370449500007
PM 26742867
OA Green Published, Bronze
DA 2022-11-30
ER

PT J
AU Zhang, M
   Gong, XW
   Ma, WH
   Wen, LB
   Wang, YJ
   Yao, HB
AF Zhang, Meng
   Gong, Xuewu
   Ma, Wenhui
   Wen, Libo
   Wang, Yuejing
   Yao, Hongbo
TI A Study on the Correlation Between Age-Related Macular Degeneration and
   Alzheimer's Disease Based on the Application of Artificial Neural
   Network
SO FRONTIERS IN PUBLIC HEALTH
LA English
DT Article
DE artificial neural network; age-related macular degeneration; Alzheimer's
   disease; relevance; correlation
ID DIAGNOSIS; MECHANISM
AB Age-related Macular Degeneration (AMD) is a kind of irreversible vision loss or disease caused by retinal pigment epithelial cells and neuroretinal degeneration, which has become the main cause of vision loss and blindness of the elderly over 65 years old in developed countries. The main clinical manifestations are cognitive decline, mental symptoms and behavioral disorders, and the gradual decline of daily living ability. In this paper, a feature extraction method of electroencephalogram (EEG) signal based on multi-spectral image fusion of multi-brain regions is proposed based on artificial neural network (ANN). In this method, the brain is divided into several different brain regions, and the EEG signals of different brain regions are transformed into several multispectral images by combining with the multispectral image transformation method. Using Alzheimer's disease (AD) classification algorithm, the depth residual network model pre-trained in ImageNet was transferred to sMRI data set for fine adjustment, instead of training a brand-new model from scratch. The results show that the proposed method solves the problem of few available medical image samples and shortens the training time of ANN model.
C1 [Zhang, Meng; Wang, Yuejing; Yao, Hongbo] Qiqihar Med Univ, Histol & Embryol Sect, Qiqihar, Peoples R China.
   [Gong, Xuewu] Qiqihar Med Univ, Affiliated Hosp 2, Qiqihar, Peoples R China.
   [Ma, Wenhui] Qiqihar Med Univ, Comp Expt Teaching Ctr, Qiqihar, Peoples R China.
   [Wen, Libo] Qiqihar Med Univ, Physiol Sect, Qiqihar, Peoples R China.
C3 Qiqihar Medical University; Qiqihar Medical University; Qiqihar Medical
   University; Qiqihar Medical University
RP Yao, HB (通讯作者)，Qiqihar Med Univ, Histol & Embryol Sect, Qiqihar, Peoples R China.
EM 22868204@qq.com
RI ma, wenhui/GQZ-0052-2022
FU Natural Science Foundation of Heilongjiang Province [LH2021H122]; Basic
   scientific research Funds of Heilongjiang Provincial undergraduate
   universities science and technology research project: Study on the
   association between Alzheimer's disease and age-related macular
   degeneration based on the down-regulation of Ab6E10 [2020-KYYWF-0012]
FX This work was supported by the Natural Science Foundation of
   Heilongjiang Province: Effects of dihydroartemisinin on the prevention
   and treatment of Alzheimer's disease in mice with age-related macular
   degeneration (Grant No. LH2021H122) and Basic scientific research Funds
   of Heilongjiang Provincial undergraduate universities science and
   technology research project: Study on the association between
   Alzheimer's disease and age-related macular degeneration based on the
   down-regulation of Ab6E10 metabolism by Amylin (Grant No.
   2020-KYYWF-0012).
CR Basher A, 2021, IEEE ACCESS, V9, P29870, DOI 10.1109/ACCESS.2021.3059658
   Bellver-Sanchis A, 2021, EPIGENOMES, V5, DOI 10.3390/epigenomes5020015
   Cheng K, 2020, INDIAN J PHARMACOL, V52, P94, DOI 10.4103/ijp.IJP_515_19
   Choi S, 2020, AM J OPHTHALMOL, V213, P320, DOI 10.1016/j.ajo.2020.01.030
   Duan F, 2020, IEEE T NEUR SYS REH, V28, P2164, DOI 10.1109/TNSRE.2020.3014951
   Fan PH, 2020, SCI REP-UK, V10, DOI 10.1038/s41598-020-63021-8
   Garri DD, 2020, OPHTHALMOL RUSSIA, V17, P20, DOI [10.18008/1816-5095-2020-1-20-31, DOI 10.18008/1816-5095-2020-1-20-31]
   [何欣 He Xin], 2021, [计算机工程, Computer Engineering], V47, P285
   Heo TY, 2020, DIAGNOSTICS, V10, DOI 10.3390/diagnostics10050261
   Hwang DK, 2019, THERANOSTICS, V9, P232, DOI 10.7150/thno.28447
   Jo T., 2019, ALZHEIMERS DIS DEMEN, V15, P409, DOI [10.1016/j.jalz.2019.06.1003, DOI 10.1016/J.JALZ.2019.06.1003]
   Karthikeyan S., 2019, BIOMED PHARMACOL J, V12, P1577, DOI DOI 10.13005/bpj/1788
   Kikuchi M, 2020, HUM MOL GENET, V29, P817, DOI 10.1093/hmg/ddz320
   Kim KM, 2021, J PERS MED, V11, DOI 10.3390/jpm11050321
   Kumar Santosh, 2020, ICDSMLA 2019. Proceedings of the 1st International Conference on Data Science, Machine Learning and Applications. Lecture Notes in Electrical Engineering (LNEE 601), P1590, DOI 10.1007/978-981-15-1420-3_165
   Lin AC, 2021, TRANSL VIS SCI TECHN, V10, DOI 10.1167/tvst.10.6.32
   Liu S, 2019, NEURAL REGEN RES, V14, P1643, DOI 10.4103/1673-5374.255995
   Motozawa N, 2019, OPHTHALMOL THER, V8, P527, DOI 10.1007/s40123-019-00207-y
   Nancy Noella RS., 2020, INT J SCI TECHNOL RE, V9, P3659
   Ong SS, 2019, J NEUROL, V266, P1566, DOI 10.1007/s00415-018-9028-z
   Suarez-Araujo CP, 2021, COMPUT MATH METHOD M, V2021, DOI 10.1155/2021/5545297
   Ralbovsky NM, 2019, J ALZHEIMERS DIS, V71, P1351, DOI 10.3233/JAD-190675
   Rashid E., 2020, STUDIES COMPUTATIONA, P227
   Schwaber EJ, 2020, J ALZHEIMERS DIS, V76, P207, DOI 10.3233/JAD-200111
   Sharunya S R, 2020, INT J ART INTELL, V7, P7, DOI [10.36079/lamintang.ijai-0701.65, DOI 10.36079/LAMINTANG.IJAI-0701.65]
   Song XF, 2021, IEEE J BIOMED HEALTH, V25, P3141, DOI 10.1109/JBHI.2021.3053568
   Swietlik D, 2019, INT J ENV RES PUB HE, V16, DOI 10.3390/ijerph16071303
   Tan HD, 2020, MOL NEUROBIOL, V57, P4488, DOI 10.1007/s12035-020-02024-y
   Vellakani S, 2020, J X-RAY SCI TECHNOL, V28, P975, DOI 10.3233/XST-200697
   Zigunovs M, 2021, ENV TECHNOLOGY RESOU, P205, DOI [10.17770/etr2021vol2.6632, DOI 10.17770/ETR2021VOL2.6632]
NR 30
TC 0
Z9 0
U1 2
U2 2
PU FRONTIERS MEDIA SA
PI LAUSANNE
PA AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND
EI 2296-2565
J9 FRONT PUBLIC HEALTH
JI Front. Public Health
PD JUN 30
PY 2022
VL 10
AR 925147
DI 10.3389/fpubh.2022.925147
PG 12
WC Public, Environmental & Occupational Health
WE Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)
SC Public, Environmental & Occupational Health
GA 2Z7CU
UT WOS:000826731900001
PM 35844883
OA Green Published, gold
DA 2022-11-30
ER

PT J
AU Mantel, I
   Deli, A
   Iglesias, K
   Ambresin, A
AF Mantel, Irmela
   Deli, Angeliki
   Iglesias, Katia
   Ambresin, Aude
TI Prospective study evaluating the predictability of need for retreatment
   with intravitreal ranibizumab for age-related macular degeneration
SO GRAEFES ARCHIVE FOR CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY
LA English
DT Article
DE Neovascular age-related macular degeneration; Ranibizumab; Intravitreal
   injection; PRN treatment regimen; Predictability; Optical coherence
   tomography
ID DOSING REGIMEN; THERAPY; PHARMACOKINETICS; VERTEPORFIN
AB To investigate the rhythm and predictability of the need for retreatment with intravitreal injections of ranibizumab for neovascular age-related macular degeneration (nAMD).
   This prospective study enrolled 39 patients with treatment-na < ve nAMD. After three loading doses of intravitreal ranibizumab, patients underwent an intensified follow-up for 12 months (initially weekly, then with stepwise increases to every 2 weeks and to monthly after each injection). Patients were retreated on an as-needed basis if any fluid or increased central retinal thickness (CRT) (> 50 mu m) was found on spectral domain optical coherence tomography (OCT). Statistical analysis included patients who received at least two retreatments (five injections).
   A mean of 7.5 injections (range 0-12) were given between months 3 and 15. The mean visual acuity increased by 13.1 and 12.6 ETDRS letters at months 12 and 15 respectively. Two or more injection-retreatment intervals were found in 31 patients. The variability of their intra-individual intervals up to 14 weeks was small (SD 0-2.13 weeks), revealing a high regularity of the retreatment rhythm. The SD was correlated with the mean interval duration (r = 0.89, p < 0.001). The first interval was a good predictor of the following intervals (regression coefficient =0.81). One retreatment criterion was stable in 97 % of patients (cysts or subretinal fluid).
   The results of this study demonstrate a high intra-individual predictability of retreatment need with ranibizumab injections for nAMD. These findings may be helpful for developing individualized treatment plans for maintained suppression of disease activity with a minimum of injections and visits.
C1 [Mantel, Irmela; Deli, Angeliki; Ambresin, Aude] Univ Lausanne, Dept Ophthalmol, Jules Gonin Eye Hosp, Lausanne, Switzerland.
   [Iglesias, Katia] Univ Lausanne Hosp, Ctr Clin Epidemiol, Lausanne, Switzerland.
   [Mantel, Irmela] Univ Eye Hosp Jules Gonin, CH-1000 Lausanne 7, Switzerland.
C3 University of Lausanne; University of Lausanne; Centre Hospitalier
   Universitaire Vaudois (CHUV)
RP Mantel, I (通讯作者)，Univ Eye Hosp Jules Gonin, 15 Av France Case postale 133, CH-1000 Lausanne 7, Switzerland.
EM irmela.mantel@fa2.ch
CR Abraham P, 2010, AM J OPHTHALMOL, V150, P315, DOI 10.1016/j.ajo.2010.04.011
   Blick SKA, 2007, DRUGS, V67, P1199, DOI 10.2165/00003495-200767080-00007
   Bressler Neil M, 2004, JAMA, V291, P1900, DOI 10.1001/jama.291.15.1900
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Brown DM, 2009, OPHTHALMOLOGY, V116, P57, DOI 10.1016/j.ophtha.2008.10.018
   Dadgostar H, 2009, OPHTHALMOLOGY, V116, P1740, DOI 10.1016/j.ophtha.2009.05.033
   Engelbert M, 2010, RETINA-J RET VIT DIS, V30, P1368, DOI 10.1097/IAE.0b013e3181d50cbf
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P532
   Fung AE, 2007, AM J OPHTHALMOL, V143, P566, DOI 10.1016/j.ajo.2007.01.028
   Gaudreault J, 2005, INVEST OPHTH VIS SCI, V46, P726, DOI 10.1167/iovs.04-0601
   Gerding H, 2011, GRAEF ARCH CLIN EXP, V249, P653, DOI 10.1007/s00417-011-1636-6
   Gupta OP, 2010, OPHTHALMOLOGY, V117, P2134, DOI 10.1016/j.ophtha.2010.02.032
   Horster R, 2011, GRAEF ARCH CLIN EXP, V249, P645, DOI 10.1007/s00417-010-1588-2
   Holz FG, 2009, INVEST OPHTHALMOL VI, P50
   Lalwani GA, 2009, AM J OPHTHALMOL, V148, P43, DOI 10.1016/j.ajo.2009.01.024
   Mantel I, 2008, OPHTHALMOLOGICA, V222, P321, DOI 10.1159/000144075
   Martin DF, 2011, NEW ENGL J MED, V364, P1897, DOI 10.1056/NEJMoa1102673
   Mordenti J, 1999, TOXICOL PATHOL, V27, P536, DOI 10.1177/019262339902700507
   Oubraham H, 2011, RETINA-J RET VIT DIS, V31, P26, DOI 10.1097/IAE.0b013e3181de5609
   Regillo CD, 2008, AM J OPHTHALMOL, V145, P239, DOI 10.1016/j.ajo.2007.10.004
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
NR 21
TC 46
Z9 50
U1 0
U2 2
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0721-832X
EI 1435-702X
J9 GRAEF ARCH CLIN EXP
JI Graefes Arch. Clin. Exp. Ophthalmol.
PD MAR
PY 2013
VL 251
IS 3
BP 697
EP 704
DI 10.1007/s00417-012-2090-9
PG 8
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 096PY
UT WOS:000315418000011
PM 22733165
OA Green Published, Green Submitted
DA 2022-11-30
ER

PT J
AU Cao, DF
   Leong, B
   Messinger, JD
   Kar, D
   Ach, T
   Yannuzzi, LA
   Freund, KB
   Curcio, CA
AF Cao, Dongfeng
   Leong, Belinda
   Messinger, Jeffrey D.
   Kar, Deepayan
   Ach, Thomas
   Yannuzzi, Lawrence A.
   Freund, K. Bailey
   Curcio, Christine A.
TI Hyperreflective Foci, Optical Coherence Tomography Progression
   Indicators in Age-Related Macular Degeneration, Include
   Transdifferentiated Retinal Pigment Epithelium
SO INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE
LA English
DT Article
DE age-related macular degeneration; hyperreflective foci; retinal pigment
   epithelium; optical coherence tomography; immunohistochemistry;
   retinoids; immune markers; epithelial-mesenchyme transition
ID BASAL LINEAR DEPOSIT; GEOGRAPHIC ATROPHY; HUMAN EYES; CHOROIDAL
   MACROPHAGES; BRUCHS MEMBRANE; CELLS; INFLAMMATION; EXPRESSION; DRUSEN;
   DEDIFFERENTIATION
AB PURPOSE. By optical coherence tomography (OCT) imaging, hyperreflective foci (HRF) indicate progression risk for advanced age-related macular degeneration (AMD) and are in part attributable to ectopic retinal pigment epithelium (RPE). We hypothesized that ectopic RPE are molecularly distinct from in-layer cells and that their cross-retinal course follows Muller glia.
   METHODS. In clinical OCT (61 eyes, 44 patients with AMD, 79.4 +/- 7.7 years; 29 female; follow-up = 4.7 +/- 0.9 years), one HRF type, RPE plume (n = 129 in 4 morphologies), was reviewed. Twenty eyes of 20 donors characterized by ex vivo OCT were analyzed by histology (normal, 4; early/intermediate AMD, 7; geographic atrophy, 6; neovascular AMD, 3). Cryosections were stained with antibodies to retinoid (RPE65, CRALPB) and immune (CD68, CD163) markers. In published RPE cellular phenotypes, red immunoreactivity was assessed semiquantitatively by one observer (none, some cells, all cells).
   RESULTS. Plume morphology evolved over time and many resolved (40%). Trajectories of RPE plume and cellular debris paralleled Muller glia, including near atrophy borders. RPE corresponding to HRF lost immunoreactivity for retinoid markers and gained immunoreactivity for immune markers. Aberrant immunoreactivity appeared in individual in-layer RPE cells and extended to all abnormal phenotypes. Muller glia remained CRALBP positive. Plume cells approached and contacted retinal capillaries.
   CONCLUSIONS. HRF are indicators not predictors of overall disease activity. Gain and loss of function starts with individual in-layer RPE cells and extends to all abnormal phenotypes. Evidence for RPE transdifferentiation, possibly due to ischemia, supports a proposed process of epithelial-mesenchyme transition. Data can propel new biomarkers and therapeutic strategies for AMD.
C1 [Cao, Dongfeng; Messinger, Jeffrey D.; Kar, Deepayan; Curcio, Christine A.] Univ Alabama Birmingham, Sch Med, Dept Ophthalmol & Visual Sci, Birmingham, AL 35233 USA.
   [Leong, Belinda; Yannuzzi, Lawrence A.; Freund, K. Bailey] Vitreous Retina Macula Consultants New York, New York, NY USA.
   [Leong, Belinda] Retina Associates, Sydney, NSW, Australia.
   [Ach, Thomas] Univ Hosp Bonn, Dept Ophthalmol, Bonn, Germany.
   [Yannuzzi, Lawrence A.; Freund, K. Bailey] Manhattan Eye Ear & Throat Hosp, LuEsther T Mertz Retinal Res Ctr, New York, NY 10021 USA.
   [Freund, K. Bailey] NYU, Dept Ophthalmol, Grossman Sch Med, 550 1St Ave, New York, NY 10016 USA.
C3 University of Alabama System; University of Alabama Birmingham; Vitreous
   Retina Macula Consultants of New York; University of Bonn; Manhattan Eye
   Ear & Throat Hospital; New York University
RP Curcio, CA (通讯作者)，Univ Alabama Birmingham, Sch Med, Dept Ophthalmol & Visual Sci, Birmingham, AL 35233 USA.
EM christinecurcio@uabmc.edu
RI Kar, Deepayan/AAX-8374-2020
OI Kar, Deepayan/0000-0003-2176-7430
FU National Institutes of Health (Bethesda, MD, USA) [R01EY015520]; Macula
   Foundation, Inc., New York, New York; Research to Prevent Blindness,
   Inc.; EyeSight Foundation of Alabama; National Institutes of Health
   [R01EY015520, R01EY027948]; IZKF Wurzburg [N-304]
FX Supported by National Institutes of Health (Bethesda, MD, USA) Grant
   R01EY015520 (CAC); The Macula Foundation, Inc., New York, New York; an
   anonymous donor to AMD research at University of Alabama at Birmingham;
   unrestricted funds to the Department of Ophthalmology from Research to
   Prevent Blindness, Inc.; and EyeSight Foundation of Alabama. Acquisition
   of human tissues for immunohistochemistry was funded by National
   Institutes of Health Grants R01EY015520 (CAC) and R01EY027948 (CAC, TA)
   and IZKF Wurzburg (N-304, TA).
CR Ach T, 2015, INVEST OPHTH VIS SCI, V56, P3242, DOI 10.1167/iovs.14-16274
   Balaratnasingam C, 2017, OPHTHALMOLOGY, V124, P644, DOI 10.1016/j.ophtha.2016.12.034
   Balaratnasingam C, 2016, INVEST OPHTH VIS SCI, V57, P5479, DOI 10.1167/iovs.16-19816
   Barros MHM, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0080908
   Bonilha VL, 2020, INVEST OPHTH VIS SCI, V61, DOI 10.1167/iovs.61.8.15
   Chen KC, 2016, AM J OPHTHALMOL, V164, P89, DOI 10.1016/j.ajo.2016.02.002
   Chen L, 2021, OPHTHALMOL RETINA, V5, P730, DOI 10.1016/j.oret.2020.11.006
   Chen L, 2021, INVEST OPHTH VIS SCI, V62, DOI 10.1167/iovs.62.1.33
   Cherepanoff S, 2010, BRIT J OPHTHALMOL, V94, P918, DOI 10.1136/bjo.2009.165563
   Chinchore Y, 2017, ELIFE, V6, DOI 10.7554/eLife.25946
   Chistiakov DA, 2017, LAB INVEST, V97, P4, DOI 10.1038/labinvest.2016.116
   Christenbury JG, 2013, OPHTHALMOLOGY, V120, P1038, DOI 10.1016/j.ophtha.2012.10.018
   Curcio CA, 1999, ARCH OPHTHALMOL-CHIC, V117, P329, DOI 10.1001/archopht.117.3.329
   Curcio CA, 2017, INVEST OPHTH VIS SCI, V58, P211, DOI 10.1167/iovs.17-21872
   Dolz-Marco R, 2017, OPHTHALMOLOGY, V124, P1353, DOI 10.1016/j.ophtha.2017.03.043
   Edwards MM, 2017, INVEST OPHTH VIS SCI, V58, P1352, DOI 10.1167/iovs.16-21229
   ELNER SG, 1992, EXP EYE RES, V55, P21, DOI 10.1016/0014-4835(92)90087-9
   Etzerodt A, 2013, ANTIOXID REDOX SIGN, V18, P2352, DOI 10.1089/ars.2012.4834
   Flaxman SR, 2017, LANCET GLOB HEALTH, V5, pE1221, DOI 10.1016/S2214-109X(17)30393-5
   Freund KB, 2011, RETINA-J RET VIT DIS, V31, P13, DOI 10.1097/IAE.0b013e3181ea48ba
   Ghazi-Nouri SMS, 2003, BRIT J OPHTHALMOL, V87, P488, DOI 10.1136/bjo.87.4.488
   Ghosh S, 2018, INVEST OPHTH VIS SCI, V59, P104, DOI 10.1167/iovs.18-24132
   Gilmore AP, 2005, CELL DEATH DIFFER, V12, P1473, DOI 10.1038/sj.cdd.4401723
   Gocho K, 2013, INVEST OPHTH VIS SCI, V54, P3673, DOI 10.1167/iovs.12-10672
   Guidry C, 2002, INVEST OPHTH VIS SCI, V43, P267
   Guymer RH, 2020, OPHTHALMOLOGY, V127, P394, DOI 10.1016/j.ophtha.2019.09.035
   Holz FG, 2017, OPHTHALMOLOGY, V124, P464, DOI 10.1016/j.ophtha.2016.12.002
   Hurley JB, 2015, J NEUROSCI RES, V93, P1079, DOI 10.1002/jnr.23583
   Jaffe GJ, 5 CAM
   Jakobiec FA, 2021, AM J OPHTHALMOL, V222, P388, DOI 10.1016/j.ajo.2020.09.020
   Jopling C, 2011, NAT REV MOL CELL BIO, V12, P79, DOI 10.1038/nrm3043
   Josifovska N, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0217548
   Karlstetter M, 2015, PROG RETIN EYE RES, V45, P30, DOI 10.1016/j.preteyeres.2014.11.004
   Keane PA, 2012, SURV OPHTHALMOL, V57, P389, DOI 10.1016/j.survophthal.2012.01.006
   Lad EM, 2016, GRAEF ARCH CLIN EXP, V254, P1239, DOI 10.1007/s00417-015-3249-y
   Lamb TD, 2006, INVEST OPHTH VIS SCI, V47, P5138, DOI 10.1167/iovs.06-0849
   Lee B, 2020, TRANSL VIS SCI TECHN, V9, DOI 10.1167/tvst.9.7.12
   Lei JQ, 2017, GRAEF ARCH CLIN EXP, V255, P1551, DOI 10.1007/s00417-017-3693-y
   Li ML, 2018, RETINA-J RET VIT DIS, V38, P1937, DOI 10.1097/IAE.0000000000002182
   Li ML, 2018, OPHTHALMOLOGY, V125, P276, DOI 10.1016/j.ophtha.2017.08.019
   Liu TY, 2005, PROTEINS, V61, P412, DOI 10.1002/prot.20621
   Lujan BJ, 2011, INVEST OPHTH VIS SCI, V52, P1486, DOI 10.1167/iovs.10-5946
   Lutty GA, 2020, EXP EYE RES, V192, DOI 10.1016/j.exer.2020.107939
   Maguire MG, 2016, OPHTHALMOLOGY, V123, P1751, DOI 10.1016/j.ophtha.2016.03.045
   Margeta MA, 2018, GRAEF ARCH CLIN EXP, V256, P2449, DOI 10.1007/s00417-018-4081-y
   Matet A, 2015, AM J OPHTHALMOL, V159, P1142, DOI 10.1016/j.ajo.2015.02.013
   Matsubara JA, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.00574
   McLeod DS, 2016, INVEST OPHTH VIS SCI, V57, P5843, DOI 10.1167/iovs.16-20049
   Mullins RE, 2011, INVEST OPHTH VIS SCI, V52, P1606, DOI 10.1167/iovs.10-6476
   Mullins RF, 2007, INVEST OPHTH VIS SCI, V48, P3372, DOI 10.1167/iovs.06-0868
   Nassisi M, 2019, OPHTHALMOLOGY, V126, P1667, DOI 10.1016/j.ophtha.2019.05.016
   Nicolai U, 1993, Ger J Ophthalmol, V2, P195
   Omri S, 2010, CLIN OPHTHALMOL, V4, P183
   Ouyang YL, 2013, OPHTHALMOLOGY, V120, P2656, DOI 10.1016/j.ophtha.2013.05.029
   Pan WW, 2021, COMMUN BIOL, V4, DOI 10.1038/s42003-021-01765-3
   Pang CE, 2015, OPHTHALMOLOGY, V122, P2316, DOI 10.1016/j.ophtha.2015.07.008
   Paoli P, 2013, BBA-MOL CELL RES, V1833, P3481, DOI 10.1016/j.bbamcr.2013.06.026
   PENFOLD PL, 1985, GRAEF ARCH CLIN EXP, V223, P69, DOI 10.1007/BF02150948
   Pollreisz A, 2020, INVEST OPHTH VIS SCI, V61, DOI 10.1167/iovs.61.8.13
   Polyak S. L., 1941, RETINA-J RET VIT DIS
   RAMRATTAN RS, 1994, INVEST OPHTH VIS SCI, V35, P2857
   Saari John C, 2016, Subcell Biochem, V81, P231
   Sadda SR, 2018, OPHTHALMOLOGY, V125, P537, DOI 10.1016/j.ophtha.2017.09.028
   SARKS JP, 1988, EYE, V2, P552, DOI 10.1038/eye.1988.106
   Schaal KB, 2015, RETINA-J RET VIT DIS, V35, P1339, DOI 10.1097/IAE.0000000000000471
   Schlereth SL, 2016, INVEST OPHTH VIS SCI, V57, P4878, DOI 10.1167/iovs.15-18552
   Seddon JM, 2016, JAMA OPHTHALMOL, V134, P1272, DOI 10.1001/jamaophthalmol.2016.3519
   Sennlaub F, 2013, EMBO MOL MED, V5, P1775, DOI 10.1002/emmm.201302692
   Sheridan C, 2005, ESSENT OPHTHALMOL, P101
   Sheridan CM, 2009, GRAEF ARCH CLIN EXP, V247, P1361, DOI 10.1007/s00417-009-1133-3
   Shirazi MF, 2020, BIOMED OPT EXPRESS, V11, P4520, DOI 10.1364/BOE.393906
   Simsek M, 2018, OSLI RETINA, V49, P716, DOI 10.3928/23258160-20180831-11
   Sparrow JR, 2015, INVEST OPHTH VIS SCI, V56, P5029, DOI 10.1167/iovs.15-16763
   Staurenghi G, 2014, OPHTHALMOLOGY, V121, P1572, DOI 10.1016/j.ophtha.2014.02.023
   Sura AA, 2020, INVEST OPHTH VIS SCI, V61, DOI 10.1167/iovs.61.13.19
   Tan ACS, 2018, SCI TRANSL MED, V10, DOI 10.1126/scitranslmed.aat4544
   Tan ACS, 2018, RETINA-J RET VIT DIS, V38, P1759, DOI 10.1097/IAE.0000000000002016
   Tatar O, 2008, ARCH OPHTHALMOL-CHIC, V126, P782, DOI 10.1001/archopht.126.6.782
   von Lintig J, 2021, PROG RETIN EYE RES, V80, DOI 10.1016/j.preteyeres.2020.100864
   Waldstein SM, 2020, JAMA OPHTHALMOL, V138, P740, DOI 10.1001/jamaophthalmol.2020.1376
   Wu ZC, 2020, OPHTHALMOL RETINA, V4, P568, DOI 10.1016/j.oret.2019.12.011
   Xue YL, 2015, J CLIN INVEST, V125, P727, DOI 10.1172/JCI79651
   Yang J, 2020, NAT REV MOL CELL BIO, V21, P341, DOI 10.1038/s41580-020-0237-9
   Zanzottera EC, 2016, RETINA-J RET VIT DIS, V36, pS12, DOI 10.1097/IAE.0000000000001276
   Zanzottera EC, 2015, INVEST OPHTH VIS SCI, V56, P3253, DOI 10.1167/iovs.15-16431
   Zanzottera EC, 2015, INVEST OPHTH VIS SCI, V56, P3269, DOI 10.1167/iovs.15-16432
   Zhou M, 2020, FRONT CELL DEV BIOL, V8, DOI 10.3389/fcell.2020.00501
NR 87
TC 14
Z9 14
U1 1
U2 2
PU ASSOC RESEARCH VISION OPHTHALMOLOGY INC
PI ROCKVILLE
PA 12300 TWINBROOK PARKWAY, ROCKVILLE, MD 20852-1606 USA
SN 0146-0404
EI 1552-5783
J9 INVEST OPHTH VIS SCI
JI Invest. Ophthalmol. Vis. Sci.
PD AUG
PY 2021
VL 62
IS 10
AR 34
DI 10.1167/iovs.62.10.34
PG 14
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA UP2QS
UT WOS:000695230000034
PM 34448806
OA Green Published, gold
DA 2022-11-30
ER

PT J
AU Ng, TK
   Liang, XY
   Lu, F
   Liu, DTL
   Yam, GHF
   Ma, L
   Tam, POS
   Chen, H
   Cen, LP
   Chen, LJ
   Yang, ZL
   Pang, CP
AF Ng, Tsz Kin
   Liang, Xiao Ying
   Lu, Fang
   Liu, David T. L.
   Yam, Gary H. F.
   Ma, Li
   Tam, Pancy O. S.
   Chen, Haoyu
   Cen, Ling Ping
   Chen, Li Jia
   Yang, Zhenglin
   Pang, Chi Pui
TI Protective effects of an HTRA1 insertion-deletion variant against
   age-related macular degeneration in the Chinese populations
SO LABORATORY INVESTIGATION
LA English
DT Article
ID SERINE-PROTEASE HTRA1; POLYPOIDAL CHOROIDAL VASCULOPATHY; ARMS2;
   EXPRESSION; LOCALIZATION; ASSOCIATION; CLEAVAGE; DISEASE; CANCER
AB Age-related macular degeneration (AMD) is a leading cause of visual impairment and irreversible blindness in most developed countries, affecting about 50 million elderly people worldwide. Retinal pigment epithelial (RPE) cell degeneration is the pathophysiological cause of AMD, leading to geographic atrophy and choroidal neovascularization. We and others have previously identified several polymorphisms on chromosome 10q26 (HTRA1 rs11200638 as well as LOC387715 rs10490924 and c.372_815de1443ins54) associated with AMD. In this study, we confirmed the association of our previously identified HTRA1 insertion-deletion (indel) variant (c.34delCinsTCCT) in 195 exudative AMD patients and 390 controls from the Hong Kong Chinese cohort with additional 168 patients and 210 controls from the Chengdu Chinese cohort and followed by studying its biological functions in RPE cells. Genetic analysis verified the higher prevalence of c.34delCinsTCCT allele in control subjects (8.0%) than in AMD patients (1.9%; P=7.87 x 10(-5), odds ratio = 0.229). This protective effect was validated as the haplotype of the c.34delCinsTCCT allele existed independent of the risk haplotype (P=1.17 x 10(-5)). In vitro studies showed that recombinant HTRA1 c.34delCinsTCCT variant protein was more localized in the endoplasmic reticulum of RPE cells compared with the wild-type protein, and its secretion was delayed. Moreover, ARPE-19 cells expressing HTRA1 c.34delCinsTCCT variant had higher cell viability, lower cell apoptosis and were less responsive to anoikis, supporting its protective role. We revealed a protective AMD-associated HTRA1 variant in Chinese populations and the biological role of HTRA1 in RPE cell degeneration, indicating its involvement in AMD pathogenesis.
C1 [Ng, Tsz Kin; Liang, Xiao Ying; Liu, David T. L.; Yam, Gary H. F.; Ma, Li; Tam, Pancy O. S.; Chen, Li Jia; Pang, Chi Pui] Chinese Univ Hong Kong, Dept Ophthalmol & Visual Sci, Kowloon, Hong Kong, Peoples R China.
   [Lu, Fang; Yang, Zhenglin] Sichuan Key Lab Human Dis Gene Study, Chengdu, Peoples R China.
   [Lu, Fang; Yang, Zhenglin] Sichuan Acad Med Sci, Inst Lab Med, Chengdu, Peoples R China.
   [Lu, Fang; Yang, Zhenglin] Sichuan Prov Peoples Hosp, 32 First Round Rd 2 West, Chengdu, Sichuan, Peoples R China.
   [Chen, Haoyu; Cen, Ling Ping] Shantou Univ, Joint Shantou Int Eye Ctr, Shantou, Peoples R China.
   [Chen, Haoyu; Cen, Ling Ping] Chinese Univ Hong Kong, Shantou, Peoples R China.
C3 Chinese University of Hong Kong; Sichuan Provincial People's Hospital;
   Sichuan Provincial People's Hospital; Shantou University
RP Yang, ZL (通讯作者)，Sichuan Prov Peoples Hosp, 32 First Round Rd 2 West, Chengdu, Sichuan, Peoples R China.; Pang, CP (通讯作者)，Chinese Univ Hong Kong, Dept Ophthalmol & Visual Sci, Hong Kong Eye Hosp, 4-F,147K Argyle St, Kowloon, Hong Kong, Peoples R China.
EM zliny@yahoo.com; cppang@cuhk.edu.hk
RI Ng, Tsz Kin/I-8061-2014; Yam, Gary Hin-Fai/ABE-1710-2020; Cen Ling-Ping,
   Cen Lingping/O-4216-2015; Chen, Haoyu/A-7432-2013; Chen, Li
   Jia/I-5078-2014
OI Ng, Tsz Kin/0000-0001-7863-7229; Cen Ling-Ping, Cen
   Lingping/0000-0003-3876-0606; Chen, Haoyu/0000-0003-0676-4610; Chen, Li
   Jia/0000-0003-3500-5840
FU Health and Medical Research Fund [12130791]; Direct Grant from the
   Medical Panel; Chinese University of Hong Kong [4054119]; General
   Research Fund from the Research Grants Council, Hong Kong [473410];
   National Natural Science Foundation of China [81025006]
FX We express our greatest appreciation to all the participants in the
   study. This study was supported by the Health and Medical Research Fund
   (project number: 12130791 to TKN), the Direct Grant from the Medical
   Panel, the Chinese University of Hong Kong (grant number: 4054119 to
   CPP) and the General Research Fund from the Research Grants Council
   (grant number: 473410 to CPP), Hong Kong and the National Natural
   Science Foundation of China (grant number: 81025006 to ZY).
CR Ajayi F, 2008, AM J OBSTET GYNECOL, V199, DOI 10.1016/j.ajog.2008.04.046
   An E, 2010, INVEST OPHTH VIS SCI, V51, P3379, DOI 10.1167/iovs.09-4853
   Austin BA, 2009, INVEST OPHTH VIS SCI, V50, P2896, DOI 10.1167/iovs.08-2495
   Bakay M, 2002, NEUROMUSCULAR DISORD, V12, pS125, DOI 10.1016/S0960-8966(02)00093-7
   Baldi A, 2002, ONCOGENE, V21, P6684, DOI 10.1038/sj.onc.1205911
   BIRD AEC, 1995, SURV OPHTHALMOL, V39, P367, DOI 10.1016/S0039-6257(05)80092-X
   Chan Chi-Chao, 2007, Trans Am Ophthalmol Soc, V105, P92
   Chien J, 2009, MOL CELL BIOL, V29, P4177, DOI 10.1128/MCB.00035-09
   Clawson GA, 2008, J CELL BIOCHEM, V105, P81, DOI 10.1002/jcb.21804
   Colak D, 2009, GENOMICS, V94, P20, DOI 10.1016/j.ygeno.2009.03.003
   de Jong PTVM, 2006, NEW ENGL J MED, V355, P1474, DOI 10.1056/NEJMra062326
   De Luca A, 2004, J HISTOCHEM CYTOCHEM, V52, P885, DOI 10.1369/jhc.3A6186.2004
   Dewan A, 2006, SCIENCE, V314, P989, DOI 10.1126/science.1133807
   Eigenbrot C, 2012, STRUCTURE, V20, P1040, DOI 10.1016/j.str.2012.03.021
   Friedrich U, 2011, HUM MOL GENET, V20, P1387, DOI 10.1093/hmg/ddr020
   Fritsche LG, 2008, NAT GENET, V40, P892, DOI 10.1038/ng.170
   Gomi M., 2004, CHEM BIO INFORMATICS, V4, P142, DOI DOI 10.1273/CBIJ.4.142
   Grau S, 2005, P NATL ACAD SCI USA, V102, P6021, DOI 10.1073/pnas.0501823102
   Hara K, 2009, NEW ENGL J MED, V360, P1729, DOI 10.1056/NEJMoa0801560
   He XP, 2010, CANCER RES, V70, P3109, DOI 10.1158/0008-5472.CAN-09-3557
   Hu SI, 1998, J BIOL CHEM, V273, P34406, DOI 10.1074/jbc.273.51.34406
   Jones A, 2011, P NATL ACAD SCI USA, V108, P14578, DOI 10.1073/pnas.1102853108
   Kanda A, 2007, P NATL ACAD SCI USA, V104, P16227, DOI 10.1073/pnas.0703933104
   Klein R, 2004, AM J OPHTHALMOL, V137, P486, DOI 10.1016/j.ajo.2003.11.069
   KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0
   Liang XY, 2012, INVEST OPHTH VIS SCI, V53, P3175, DOI 10.1167/iovs.11-8135
   Murwantoko, 2004, BIOCHEM J, V381, P895, DOI 10.1042/BJ20040435
   Ng TK, 2011, INVEST OPHTH VIS SCI, V52, P3706, DOI 10.1167/iovs.10-6773
   NOTHWEHR SF, 1990, J BIOL CHEM, V265, P17202
   Shiga A, 2011, HUM MOL GENET, V20, P1800, DOI 10.1093/hmg/ddr063
   Spiess C, 1999, CELL, V97, P339, DOI 10.1016/S0092-8674(00)80743-6
   Tam POS, 2008, INVEST OPHTH VIS SCI, V49, P2357, DOI 10.1167/iovs.07-1520
   Tocharus J, 2004, DEV GROWTH DIFFER, V46, P257
   Vierkotten S, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0022959
   Wang GF, 2010, HUM GENET, V127, P595, DOI 10.1007/s00439-010-0805-8
   Wang GF, 2009, INVEST OPHTH VIS SCI, V50, P3084, DOI 10.1167/iovs.08-3240
   Yang ZL, 2006, SCIENCE, V314, P992, DOI 10.1126/science.1133811
   Yang ZL, 2010, PLOS GENET, V6, DOI 10.1371/journal.pgen.1000836
   Zumbrunn J, 1996, FEBS LETT, V398, P187, DOI 10.1016/S0014-5793(96)01229-X
   Zurawa-Janicka D, 2010, EXPERT OPIN THER TAR, V14, P665, DOI 10.1517/14728222.2010.487867
NR 40
TC 6
Z9 6
U1 0
U2 8
PU NATURE PUBLISHING GROUP
PI NEW YORK
PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA
SN 0023-6837
EI 1530-0307
J9 LAB INVEST
JI Lab. Invest.
PD JAN
PY 2017
VL 97
IS 1
BP 43
EP 52
DI 10.1038/labinvest.2016.117
PG 10
WC Medicine, Research & Experimental; Pathology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Research & Experimental Medicine; Pathology
GA EH3DE
UT WOS:000391648500005
PM 27841854
OA Bronze
DA 2022-11-30
ER

PT J
AU Luu, CD
   Makeyeva, G
   Caruso, E
   Baglin, E
   Sivarajah, P
   Wu, ZC
   Guymer, RH
AF Luu, Chi D.
   Makeyeva, Galina
   Caruso, Emily
   Baglin, Elizabeth
   Sivarajah, Pyrawy
   Wu, Zhichao
   Guymer, Robyn H.
TI Multi-focal electro-retinogram response following sub-threshold
   nano-second laser intervention in age-related macular degeneration
SO CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY
LA English
DT Article
DE age-related macular degeneration (AMD); electro-retinogram; nanosecond
   laser treatment
ID OPTICAL COHERENCE TOMOGRAPHY; RETICULAR PSEUDODRUSEN; DARK-ADAPTATION;
   RISK-FACTOR; ELECTRORETINOGRAPHY; MICROPERIMETRY; ATROPHY; EYES
AB Importance The effect of sub-threshold nano-second laser (SNL) treatment on retinal function remains unknown. Background SNL treatment has been studied as a potential intervention in intermediate age-related macular degeneration (iAMD). This study investigated the longitudinal effect of SNL treatment on retinal function. Design This was a sub-study of the LEAD trial; a 36-month, multi-centre, randomized and sham-controlled trial. Participants Subjects with iAMD. Methods Eligible participants were assigned randomly to receive SNL or sham treatment to the study eye at 6-monthly visits. Multi-focal electro-retinography (mfERG) was performed at each study visit from a study site. The mfERG responses were grouped into three regions (central, middle and outer rings) and compared between the SNL and sham group. Main Outcome Measures mfERG P1 response amplitude and implicit time. Results Data were collected from 50 subjects (26 in the SNL group, 24 in the sham group). At baseline, the P1 amplitudes of both the study eyes and the fellow eyes were similar between the groups at all rings. In the sham group, the P1 amplitude gradually decreased over time (P< .05). In the SNL group, there was an improvement in P1 amplitude which became statistically significant at the 36-month visit, detected in both the treated and fellow eyes at the central (P= .005) and middle ring (P= .007) but not at the outer ring (P= .070). No difference in P1 implicit time detected between the groups (P> .05). Conclusions and Relevance SNL treatment improved electro-physiological function. mfERG could be useful for monitoring AMD progression and evaluating the efficacy of SNL treatment.
C1 [Luu, Chi D.; Makeyeva, Galina; Caruso, Emily; Baglin, Elizabeth; Sivarajah, Pyrawy; Wu, Zhichao; Guymer, Robyn H.] Royal Victorian Eye & Ear Hosp, Ctr Eye Res Australia, Melbourne, Vic, Australia.
   [Luu, Chi D.; Guymer, Robyn H.] Univ Melbourne, Dept Surg, Ophthalmol, Melbourne, Vic, Australia.
C3 Centre for Eye Research Australia; Royal Victorian Eye & Ear Hospital;
   University of Melbourne
RP Luu, CD (通讯作者)，Ctr Eye Res Australia, Level 8,32 Gisborne St, East Melbourne, Vic 3002, Australia.
EM cluu@unimelb.edu.au
OI Luu, Chi/0000-0002-7604-7097; Guymer, Robyn/0000-0002-9441-4356
FU Bupa Health Foundation; National Health and Medical Research Council
   [APP1027624, APP1104985, GNT1103013]
FX Bupa Health Foundation; National Health and Medical Research Council,
   Grant/Award Numbers: APP1027624, APP1104985, GNT1103013
CR Alten F, 2012, INVEST OPHTH VIS SCI, V53, P6263, DOI 10.1167/iovs.12-10094
   ARNOLD JJ, 1995, RETINA-J RET VIT DIS, V15, P183, DOI 10.1097/00006982-199515030-00001
   Finger RP, 2014, OPHTHALMOLOGY, V121, P1252, DOI 10.1016/j.ophtha.2013.12.034
   Flamendorf J, 2015, OPHTHALMOLOGY, V122, P2053, DOI 10.1016/j.ophtha.2015.06.023
   Gin TJ, 2011, INVEST OPHTH VIS SCI, V52, P9267, DOI 10.1167/iovs.11-8517
   Guymer RH, 2019, OPHTHALMOLOGY, V126, P829, DOI 10.1016/j.ophtha.2018.09.015
   Guymer RH, 2014, CLIN EXP OPHTHALMOL, V42, P466, DOI 10.1111/ceo.12247
   Hogg RE, 2014, OPTOMETRY VISION SCI, V91, P854, DOI 10.1097/OPX.0000000000000287
   Jobling AI, 2015, FASEB J, V29, P696, DOI 10.1096/fj.14-262444
   Klein R, 2008, AM J OPHTHALMOL, V145, P317, DOI 10.1016/j.ajo.2007.09.008
   Lains I, 2017, OPHTHALMOLOGY, V124, P1340, DOI 10.1016/j.ophtha.2017.03.061
   Lek JJ, 2017, OPHTHALMOL RETINA, V1, P227, DOI 10.1016/j.oret.2016.12.001
   Luu CD, 2018, OPHTHALMOL RETINA, V2, P1206, DOI 10.1016/j.oret.2018.06.016
   Sevilla MB, 2016, AM J OPHTHALMOL, V165, P65, DOI 10.1016/j.ajo.2016.02.021
   Tan R, 2018, INVEST OPHTH VIS SCI, V59, P4154, DOI 10.1167/iovs.18-23970
   Vessey KA, 2018, INVEST OPHTH VIS SCI, V59, P731, DOI 10.1167/iovs.17-23098
   Wood JPM, 2013, INVEST OPHTH VIS SCI, V54, P2305, DOI 10.1167/iovs.12-11203
   Wood JPM, 2011, LASER SURG MED, V43, P499, DOI 10.1002/lsm.21087
   Wu ZC, 2019, OPHTHALMOL RETINA, V3, P1026, DOI 10.1016/j.oret.2019.07.008
   Wu ZC, 2015, INVEST OPHTH VIS SCI, V56, P2100, DOI 10.1167/iovs.14-16210
   Wu ZC, 2014, OPHTHALMOLOGY, V121, P2415, DOI 10.1016/j.ophtha.2014.06.034
   Wu ZC, 2014, INVEST OPHTH VIS SCI, V55, P6431, DOI 10.1167/iovs.14-14407
   Wu ZC, 2013, INVEST OPHTH VIS SCI, V54, P2800, DOI 10.1167/iovs.13-11613
   Zhang JJ, 2012, INVEST OPHTH VIS SCI, V53, P2928, DOI 10.1167/iovs.11-8585
NR 24
TC 2
Z9 2
U1 0
U2 1
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1442-6404
EI 1442-9071
J9 CLIN EXP OPHTHALMOL
JI Clin. Exp. Ophthalmol.
PD SEP
PY 2020
VL 48
IS 7
BP 938
EP 945
DI 10.1111/ceo.13823
EA AUG 2020
PG 8
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA NY9LU
UT WOS:000555418400001
PM 32643265
OA Green Published
DA 2022-11-30
ER

PT J
AU Gulaboglu, M
   Cinici, E
   Duysak, L
   Cetin, M
   Kutlu, Z
AF Gulaboglu, Mine
   Cinici, Emine
   Duysak, Lale
   Cetin, Meltem
   Kutlu, Zerrin
TI Determination and comparison of urinary iodine levels in patients with
   age-related macular degeneration and healthy volunteers
SO TRACE ELEMENTS AND ELECTROLYTES
LA English
DT Article
DE dry- and wet-type ARMD; iodine; urine
ID OXIDATIVE STRESS; ANTIOXIDANT; PATHOGENESIS; BIOMARKERS
AB To investigate the urine iodine level of patients with dry- and wet-type age-related macular degeneration (ARMD) and to compare with those of normal healthy volunteers. ARMD is a leading cause of severe vision loss in developed countries and the pathogenesis has not yet been fully clarified. The ciliary body of the eye and lacrimal gland concentrate iodine, and their anti-oxidative capacities are increased by iodine because of its antioxidant properties. Urine samples were received from 23 normal healthy volunteers (group I), 23 patients with wet-type (group II) and, 23 patients with dry- type ARMD (group III). Urinary iodine concentration was determined spectrophotometrically using the Sandell-Kolthoff reaction. The iodine levels were significantly lower in group II (4.04 +/- 1.12 mu g/dL) and in group III (9.73 +/- 1.85 mu g/dL) compared to group I (the control group: 17.21 +/- 1.65 mu g/ dL) (p < 0.001). The iodine levels of group II were lower than those of group III (p < 0.001). Tight junctions between retina pigment epithelial cells promoted by iodine assist in the prevention of fluid passage between the neural retina and the retinal pigment epithelium. Low iodine levels in patients with ARMD may be a possible indication of the degeneration of these tight junctions. Therefore, iodine deficiency could be a risk factor for neovascular ARMD. Urinary iodine excretion is used as the most convenient, rapid, and low-cost laboratory marker to determine iodine deficiency, and it may be used to follow up ARMD. Iodine supplementation might be useful to prevent the development of macular edema associated with ARMD.
C1 [Gulaboglu, Mine; Duysak, Lale; Kutlu, Zerrin] Ataturk Univ, Fac Pharm, Dept Biochem, TR-25240 Erzurum, Turkey.
   [Cinici, Emine] Ataturk Univ, Fac Med, Dept Ophthalmol, Erzurum, Turkey.
   [Cetin, Meltem] Ataturk Univ, Fac Pharm, Dept Pharmaceut Technol, Erzurum, Turkey.
C3 Ataturk University; Ataturk University; Ataturk University
RP Gulaboglu, M (通讯作者)，Ataturk Univ, Fac Pharm, Dept Biochem, TR-25240 Erzurum, Turkey.
EM gulaboglumine@gmail.com
RI KUTLU, Zerrin/ABC-1839-2020; Çetin, Meltem/ABI-4879-2020
FU Ataturk University, Scientific Research Projects Support Centre
   [2014/168]
FX This study was partially supported by Ataturk University, Scientific
   Research Projects Support Centre (project number: 2014/168). The authors
   would like to thank Caroline Walker for English language editing of the
   article.
CR Aceves C, 2005, J MAMMARY GLAND BIOL, V10, P189, DOI 10.1007/s10911-005-5401-5
   Age-Related Eye Dis Study Res Grp, 2001, AM J OPHTHALMOL, V132, P668
   Akkoyun I, 2014, TURK OFTALMOL DERG, V44, P476, DOI 10.4274/tjo.80008
   Algvere PV, 2016, ACTA OPHTHALMOL, V94, P427, DOI 10.1111/aos.13011
   Ambati J, 2012, NEURON, V75, P26, DOI 10.1016/j.neuron.2012.06.018
   Anand R, 2000, OPHTHALMOLOGY, V107, P2224
   [Anonymous], 2014, HUM EVOL
   Ates O, 2008, EURASIAN J MED, V40, P1
   Beatty S, 2000, SURV OPHTHALMOL, V45, P115, DOI 10.1016/S0039-6257(00)00140-5
   Brantley MA, 2012, AM J OPHTHALMOL, V153, P460, DOI 10.1016/j.ajo.2011.08.033
   BRESSLER NM, 1988, SURV OPHTHALMOL, V32, P375, DOI 10.1016/0039-6257(88)90052-5
   de Smet MD, 2010, DEV OPHTHALMOL, V47, P136, DOI 10.1159/000320077
   DUNN JT, 1993, THYROID, V3, P119, DOI 10.1089/thy.1993.3.119
   ELSTNER EF, 1985, OPHTHALMOLOGICA, V191, P122, DOI 10.1159/000309572
   Janos Feher, 2007, Orvosi Hetilap, V148, P2259, DOI 10.1556/OH.2007.28250
   Jarrett SG, 2012, MOL ASPECTS MED, V33, P399, DOI 10.1016/j.mam.2012.03.009
   Kim JY, 1998, YONSEI MED J, V39, P355, DOI 10.3349/ymj.1998.39.4.355
   Kupper FC, 2008, P NATL ACAD SCI USA, V105, P6954, DOI 10.1073/pnas.0709959105
   Lambert NG, 2016, PROG RETIN EYE RES, V54, P64, DOI 10.1016/j.preteyeres.2016.04.003
   Martin TA, 2007, J CELL BIOCHEM, V101, P155, DOI 10.1002/jcb.21162
   Martin TA, 2006, J CELL BIOCHEM, V98, P1308, DOI 10.1002/jcb.20860
   Owen CG, 2012, BRIT J OPHTHALMOL, V96, P752, DOI 10.1136/bjophthalmol-2011-301109
   Plestina-Borjan I, 2015, OXID MED CELL LONGEV, V2015, DOI 10.1155/2015/804054
   Rasmussen LB, 1999, EUR J CLIN NUTR, V53, P401, DOI 10.1038/sj.ejcn.1600762
   Sandberg MA, 2014, JAMA OPHTHALMOL, V132, P1209, DOI 10.1001/jamaophthalmol.2014.1726
   Soriguer F, 2011, BRIT J NUTR, V105, P1783, DOI 10.1017/S0007114510005568
   Tokarz P, 2013, BIOGERONTOLOGY, V14, P461, DOI 10.1007/s10522-013-9463-2
   Tuo JS, 2004, PROG RETIN EYE RES, V23, P229, DOI 10.1016/j.preteyeres.2004.02.001
   Venturi S, 2000, Adv Clin Path, V4, P11
   Venturi S, 2001, BREAST, V10, P379, DOI 10.1054/brst.2000.0267
   Venturi S., 2007, EUROPEAN EPIMARKER, V11, P1
   Winkler R, 2000, CELL BIOCHEM FUNCT, V18, P143, DOI 10.1002/(SICI)1099-0844(200006)18:2<143::AID-CBF857>3.3.CO;2-R
   Yazar Z, 2010, RET VIT, V18, P253
   YOUNG RW, 1987, SURV OPHTHALMOL, V31, P291, DOI 10.1016/0039-6257(87)90115-9
NR 34
TC 1
Z9 1
U1 0
U2 8
PU DUSTRI-VERLAG DR KARL FEISTLE
PI DEISENHOFEN-MUENCHEN
PA BAHNHOFSTRASSE 9 POSTFACH 49, D-82032 DEISENHOFEN-MUENCHEN, GERMANY
SN 0946-2104
J9 TRACE ELEM ELECTROLY
JI Trace Elem. Electrolytes
PY 2017
VL 34
IS 4
BP 166
EP 170
DI 10.5414/TEX01487
PG 5
WC Biochemistry & Molecular Biology; Endocrinology & Metabolism
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Endocrinology & Metabolism
GA FI0ME
UT WOS:000411619300005
DA 2022-11-30
ER

PT J
AU Mathew, R
   Sivaprasad, S
AF Mathew, R.
   Sivaprasad, S.
TI Environmental Amsler test as a monitoring tool for retreatment with
   ranibizumab for neovascular age-related macular degeneration
SO EYE
LA English
DT Article
DE neovascular AMD; environmental Amsler
ID LUCENTIS
AB Purpose To assess the ability of patients to predict the need for retreatment with intravitreal ranibizumab in neovascular age-related macular degeneration (NVAMD) based on their perception of visual deterioration or distortion of objects in their everyday environment (environmental Amsler).
   Methods A questionnaire was given to 89 patients undergoing optical coherence tomography (OCT)-guided retreatment with intravitreal ranibizumab for NVAMD following an initial loading regimen of three injections and with at least 12-month follow-up. The patient's opinion on the need for an injection on the current visit, based on their perception of change in environmental Amsler, was recorded. This subjective measure was compared with the objective evaluation of retreatment, based on predefined retreatment criteria comprising of changes in visual acuity and morphological changes on OCT. The patients were then instructed on the technique of environmental Amsler, and this evaluation was repeated. The sensitivity and specificity of patient prediction were analyzed at baseline and after the training.
   Results The ability of patients to predict disease activity at baseline showed a sensitivity of 61% and specificity of 96.6%. The area under the receiver operating characteristic curve was 0.8. The presence of macular fluid correlated well with the patient's perception of an abnormal environmental Amsler. After training, the sensitivity and specificity improved to 87.5% and 98.5%, respectively.
   Conclusion In real life, most patients are able to predict the reactivation of the disease in NVAMD, after 12-month follow-up, after training to monitor their symptoms using the environmental Amsler test. Eye (2012) 26, 389-393; doi: 10.1038/eye. 2011.326; published online 16 December 2011
C1 [Sivaprasad, S.] Kings Coll Hosp London, Retinal Res Unit, Dept Ophthalmol, Laser & Retinal Res Unit, London SE5 9RS, England.
C3 King's College Hospital NHS Foundation Trust; King's College Hospital
RP Sivaprasad, S (通讯作者)，Kings Coll Hosp London, Retinal Res Unit, Dept Ophthalmol, Laser & Retinal Res Unit, Denmark Hill, London SE5 9RS, England.
EM senswathi@aol.com
RI Sivaprasad, S./D-6876-2015
OI Sivaprasad, S./0000-0001-8952-0659
FU Novartis; Pfizer; Bayer; Allergan
FX Sobha Sivaprasad has received research grants, travel grants and speaker
   fees from Novartis, Pfizer, Bayer and Allergan.
CR ACHARD OA, 1995, AM J OPHTHALMOL, V120, P322, DOI 10.1016/S0002-9394(14)72162-2
   [Anonymous], 2008, RAN CLIN GUID COMM C
   Chang TS, 2007, ARCH OPHTHALMOL-CHIC, V125, P1460, DOI 10.1001/archopht.125.11.1460
   Das R, 2009, RETINA-J RET VIT DIS, V29, P1013, DOI 10.1097/IAE.0b013e3181a91dbf
   FINE AM, 1986, ARCH OPHTHALMOL-CHIC, V104, P513
   Fletcher DC, 2006, OPTOMETRY VISION SCI, V83, P178, DOI 10.1097/01.opx.0000204510.08026.7f
   Fung AE, 2007, AM J OPHTHALMOL, V143, P566, DOI 10.1016/j.ajo.2007.01.028
   Isaac David Leonardo Cruvinel, 2007, Arq. Bras. Oftalmol., V70, P771, DOI 10.1590/S0004-27492007000500009
   R Trevino, 2008, OPTOMETRY, V7, P397
   SCHUCHARD RA, 1993, ARCH OPHTHALMOL-CHIC, V111, P776, DOI 10.1001/archopht.1993.01090060064024
   Trevino R, 2008, OPHTHAL PHYSL OPT, V28, P183, DOI 10.1111/j.1475-1313.2008.00561.x
NR 11
TC 8
Z9 8
U1 0
U2 6
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 0950-222X
J9 EYE
JI Eye
PD MAR
PY 2012
VL 26
IS 3
BP 389
EP 393
DI 10.1038/eye.2011.326
PG 5
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 907PD
UT WOS:000301428900005
PM 22173073
OA Bronze, Green Published
DA 2022-11-30
ER

PT J
AU Vogt, D
   Deiters, V
   Herold, TR
   Guenther, SR
   Kortuem, KU
   Priglinger, SG
   Wolf, A
   Schumann, RG
AF Vogt, Denise
   Deiters, Viktoria
   Herold, Tina R.
   Guenther, Stefanie R.
   Kortuem, Karsten U.
   Priglinger, Siegfried G.
   Wolf, Armin
   Schumann, Ricarda G.
TI Optimal Patient Adherence and Long-Term Treatment Outcomes of
   Neovascular Age-Related Macular Degeneration in Real-Life
SO CURRENT EYE RESEARCH
LA English
DT Article
DE Anti-vascular endothelial growth factor; intravitreal injection;
   neovascular age-related macular degeneration; patient adherence
ID ANTI-VEGF; GEOGRAPHIC ATROPHY; VISUAL-ACUITY; RANIBIZUMAB; GROWTH; AMD;
   WET; EYES
AB Purpose To report on long-term real-life outcomes of anti-vascular endothelial growth factor (anti-VEGF) therapy in neovascular age-related macular degeneration (nAMD) with optimal patient adherence. Methods For this retrospective monocenter study, we identified 3217 eyes of 2793 patients that received a minimum of three intravitreal anti-VEGF injections for nAMD therapy between 2006 and 2014 at the University Eye Hospital Munich. From those, we included eyes with treatment-naive nAMD, follow-up (FU) of >= 60 months and continuous adherence during FU. Primary measures were corrected visual acuity (VA), number of injections and visits as well as treatment regimen. Results We included 161 eyes of 125 patients with a mean FU of 8.0 +/- 2.3 years. Mean VA at baseline was 60.1 letters (Snellen equivalent, 20/63). After the third year, mean VA declined constantly by 2-3 letters per year. After 5 and 8 years, 26.1% and 42.1% had lost at least 3 lines from baseline. Mean cumulative number of injections was 5.3 after the first year, and 23.9, 38.1, 48.5 after 5, 8, and 10 years. "Treat and extent" regimen with higher injection frequency correlated with better function. At time of last FU, 69.8% of eyes were under active treatment. Eyes with >= 70 letters at baseline correlated with better VA at the end of FU. Conclusions Despite optimal patient adherence, visual function declined progressively in real-life nAMD therapy over long-term. The highest impact on treatment success is given by an early treatment start with individual but intensive anti-VEGF therapy.
C1 [Vogt, Denise; Deiters, Viktoria; Herold, Tina R.; Guenther, Stefanie R.; Priglinger, Siegfried G.; Schumann, Ricarda G.] Ludwig Maximilians Univ Munchen, Dept Ophthalmol, Munich, Germany.
   [Kortuem, Karsten U.; Wolf, Armin] Univ Hosp Ulm, Dept Ophthalmol, Ulm, Germany.
   [Schumann, Ricarda G.] Munich Eye & Vasc Med Ctr, Munich, Germany.
C3 University of Munich; Ulm University
RP Vogt, D (通讯作者)，Ludwig Maximilians Univ Munchen, Vitreoretinal Pathol Unit, Dept Ophthalmol, Mathildenstr 8, D-80336 Munich, Germany.
EM denise.vogt@med.uni-muenchen.de
CR Adrian ML, 2019, ACTA OPHTHALMOL, V97, P91, DOI 10.1111/aos.13864
   Bhisitkul RB, 2016, OPHTHALMOLOGY, V123, P1269, DOI 10.1016/j.ophtha.2016.01.033
   Bilgic A, 2021, RETINA-J RET VIT DIS, V41, P1901, DOI 10.1097/IAE.0000000000003106
   Bron AM, 2010, CLIN OPHTHALMOL, V4, P1361, DOI 10.2147/OPTH.S15359
   Brown DM, 2009, OPHTHALMOLOGY, V116, P57, DOI 10.1016/j.ophtha.2008.10.018
   Chandra S, 2021, EYE, V35, P409, DOI 10.1038/s41433-020-0851-y
   Chandra S, 2020, EYE, V34, P1888, DOI 10.1038/s41433-020-0764-9
   Nguyen CL, 2019, OPHTHALMOLOGY, V126, P735, DOI 10.1016/j.ophtha.2018.11.036
   Engelbert M, 2010, RETINA-J RET VIT DIS, V30, P1368, DOI 10.1097/IAE.0b013e3181d50cbf
   Garweg JG, 2016, OPHTHALMOLOGE, V113, P1036, DOI 10.1007/s00347-016-0306-9
   Garweg JG, 2018, GRAEF ARCH CLIN EXP, V256, P823, DOI 10.1007/s00417-018-3907-y
   Gemenetzi M, 2017, EYE, V31, P1, DOI 10.1038/eye.2016.208
   Gillies M, 2020, AM J OPHTHALMOL, V210, P116, DOI 10.1016/j.ajo.2019.10.007
   Grunwald JE, 2017, OPHTHALMOLOGY, V124, P97, DOI 10.1016/j.ophtha.2016.09.012
   Holz FG, 2016, EYE, V30, P1063, DOI 10.1038/eye.2016.90
   Jaffe GJ, 2019, OPHTHALMOLOGY, V126, P252, DOI 10.1016/j.ophtha.2018.08.035
   Keenan TD, 2020, OPHTHALMOL RETINA, V4, P3, DOI 10.1016/j.oret.2019.06.001
   Kuroda Y, 2018, RETINA-J RET VIT DIS, V38, P1743, DOI 10.1097/IAE.0000000000001765
   Mitchell P, 2010, BRIT J OPHTHALMOL, V94, P2, DOI 10.1136/bjo.2009.159160
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Spaide R, 2007, AM J OPHTHALMOL, V143, P679, DOI 10.1016/j.ajo.2007.02.024
   Veluswamy B, 2020, CLIN OPHTHALMOL, V14, P1565, DOI 10.2147/OPTH.S256009
   Wecker T, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-38934-8
   Wecker T, 2017, BRIT J OPHTHALMOL, V101, P353, DOI 10.1136/bjophthalmol-2016-308668
   Weiss M, 2018, RETINA-J RET VIT DIS, V38, P2293, DOI 10.1097/IAE.0000000000001892
   Wong T, 2008, OPHTHALMOLOGY, V115, P116, DOI 10.1016/j.ophtha.2007.03.008
NR 26
TC 0
Z9 0
U1 0
U2 1
PU TAYLOR & FRANCIS INC
PI PHILADELPHIA
PA 530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA
SN 0271-3683
EI 1460-2202
J9 CURR EYE RES
JI Curr. Eye Res.
PD JUN 3
PY 2022
VL 47
IS 6
BP 889
EP 896
DI 10.1080/02713683.2022.2044056
EA APR 2022
PG 8
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 2F3JS
UT WOS:000779774900001
PM 35179427
DA 2022-11-30
ER

PT J
AU Fraccaro, P
   Nicolo, M
   Bonetto, M
   Giacomini, M
   Weller, P
   Traverso, CE
   Prosperi, M
   O'Sullivan, D
AF Fraccaro, Paolo
   Nicolo, Massimo
   Bonetto, Monica
   Giacomini, Mauro
   Weller, Peter
   Traverso, Carlo Enrico
   Prosperi, Mattia
   O'Sullivan, Dympna
TI Combining macula clinical signs and patient characteristics for
   age-related macular degeneration diagnosis: a machine learning approach
SO BMC OPHTHALMOLOGY
LA English
DT Article
DE Age related macular degeneration; Machine learning; Automated diagnosis;
   Statistical learning; macula disease
ID OPTICAL COHERENCE TOMOGRAPHY; CLASSIFICATION; DRUSEN; IMPACT
AB Background: To investigate machine learning methods, ranging from simpler interpretable techniques to complex (non-linear) "black-box" approaches, for automated diagnosis of Age-related Macular Degeneration (AMD).
   Methods: Data from healthy subjects and patients diagnosed with AMD or other retinal diseases were collected during routine visits via an Electronic Health Record (EHR) system. Patients' attributes included demographics and, for each eye, presence/absence of major AMD-related clinical signs (soft drusen, retinal pigment epitelium, defects/pigment mottling, depigmentation area, subretinal haemorrhage, subretinal fluid, macula thickness, macular scar, subretinal fibrosis). Interpretable techniques known as white box methods including logistic regression and decision trees as well as less interpreitable techniques known as black box methods, such as support vector machines (SVM), random forests and AdaBoost, were used to develop models (trained and validated on unseen data) to diagnose AMD. The gold standard was confirmed diagnosis of AMD by physicians. Sensitivity, specificity and area under the receiver operating characteristic (AUC) were used to assess performance.
   Results: Study population included 487 patients (912 eyes). In terms of AUC, random forests, logistic regression and adaboost showed a mean performance of (0.92), followed by SVM and decision trees (0.90). All machine learning models identified soft drusen and age as the most discriminating variables in clinicians' decision pathways to diagnose AMD.
   Conclusions: Both black-box and white box methods performed well in identifying diagnoses of AMD and their decision pathways. Machine learning models developed through the proposed approach, relying on clinical signs identified by retinal specialists, could be embedded into EHR to provide physicians with real time (interpretable) support.
C1 [Fraccaro, Paolo; Weller, Peter; O'Sullivan, Dympna] City Univ London, Ctr Hlth Informat, London EC1V 0HB, England.
   [Fraccaro, Paolo; Prosperi, Mattia] Univ Manchester, Ctr Hlth Informat, Manchester, Lancs, England.
   [Bonetto, Monica; Giacomini, Mauro] Univ Genoa, DIBRIS, I-16132 Genoa, Italy.
   [Nicolo, Massimo; Traverso, Carlo Enrico] Univ Genoa, DiNOGMi, I-16132 Genoa, Italy.
   [Bonetto, Monica; Giacomini, Mauro] Univ Genoa, CEBR, I-16132 Genoa, Italy.
   [Fraccaro, Paolo] Univ Manchester, Primary Care Patient Safety Translat Res Ctr, NIHR, Manchester, Lancs, England.
   [Fraccaro, Paolo; Prosperi, Mattia] Univ Manchester, Hlth eRes Ctr, Manchester, Lancs, England.
C3 City University London; University of Manchester; University of Genoa;
   University of Genoa; University of Genoa; University of Manchester;
   University of Manchester
RP Nicolo, M (通讯作者)，Univ Genoa, DiNOGMi, Lgo P Daneo 3, I-16132 Genoa, Italy.
EM massimonicolo@gmail.com
RI Giacomini, Mauro/D-3194-2013
OI Giacomini, Mauro/0000-0001-5646-2034; Fraccaro,
   Paolo/0000-0002-5213-7071; Nicolo, Massimo/0000-0002-7824-3091;
   O'Sullivan, Dympna/0000-0003-2841-9738; Bonetto,
   Monica/0000-0002-5317-1060
FU DINOGMI; DIBRIS Fund of the University of Genova, Italy
FX This study was supported in part by the DINOGMI and DIBRIS Fund of the
   University of Genova, Italy.
CR Bishop C. M., 2006, PATTERN RECOGN, DOI DOI 10.1117/1.2819119
   Bonetto M, 2014, 2014 IEEE-EMBS INTERNATIONAL CONFERENCE ON BIOMEDICAL AND HEALTH INFORMATICS (BHI), P346, DOI 10.1109/BHI.2014.6864374
   Breiman L, 2001, MACH LEARN, V45, P5, DOI 10.1023/A:1010933404324
   BREIMAN L, 2001, MACH LEARN, V0045
   Breiman L., 1984, CLASSIFICATION REGRE, DOI 10.1201/9781315139470
   Bressler Neil M, 2004, JAMA, V291, P1900, DOI 10.1001/jama.291.15.1900
   CORTES C, 1995, MACH LEARN, V20, P273, DOI 10.1007/BF00994018
   Dimitriadou E, 2004, R PROJECT STAT COMPU
   Fawcett T, 2006, PATTERN RECOGN LETT, V27, P861, DOI 10.1016/j.patrec.2005.10.010
   Ferris FL, 2013, OPHTHALMOLOGY, V120, P844, DOI 10.1016/j.ophtha.2012.10.036
   Fraccaro P, 2013, INFORM HEALTH SOC CA, V38, P313, DOI 10.3109/17538157.2013.812648
   Freund Y, 1997, J COMPUT SYST SCI, V55, P119, DOI 10.1006/jcss.1997.1504
   Friedman J, 2000, ANN STAT, V28, P337, DOI 10.1214/aos/1016218223
   Hee MR, 1998, OPHTHALMOLOGY, V105, P360, DOI 10.1016/S0161-6420(98)93601-6
   Hee MR, 1996, OPHTHALMOLOGY, V103, P1260, DOI 10.1016/S0161-6420(96)30512-5
   Hijazi MHA, 2012, KNOWL-BASED SYST, V29, P83, DOI 10.1016/j.knosys.2011.07.002
   Hornik K, 2009, COMPUTATION STAT, V24, P225, DOI 10.1007/s00180-008-0119-7
   Hosmer DW, 2004, APPL LOGISTIC REGRES, P392
   HOTHORN T, PARTY LAB RECURSIVE
   Kanagasingam Y, 2014, PROG RETIN EYE RES, V38, P20, DOI 10.1016/j.preteyeres.2013.10.002
   Kankanahalli S, 2013, INVEST OPHTH VIS SCI, V54, P1789, DOI 10.1167/iovs.12-10928
   Lamoureux EL, 2011, BRIT J OPHTHALMOL, V95, P666, DOI 10.1136/bjo.2010.185207
   Liu YY, 2011, INVEST OPHTH VIS SCI, V52, P8316, DOI 10.1167/iovs.10-7012
   Mehryar M., 2012, FDN MACHINE LEARNING
   Murdoch IE, 1998, BRIT J OPHTHALMOL, V82, P971, DOI 10.1136/bjo.82.8.971
   Nadeau C, 2003, MACH LEARN, V52, P239, DOI 10.1023/A:1024068626366
   PAULEIKHOFF D, 1990, AM J OPHTHALMOL, V109, P38, DOI 10.1016/S0002-9394(14)75576-X
   Pifer EA, 2005, IMPROVING OUTCOMES C
   Quellec G, 2011, INVEST OPHTH VIS SCI, V52, P2976, DOI 10.1167/iovs.10-6232
   Rein DB, 2009, ARCH OPHTHALMOL-CHIC, V127, P533, DOI 10.1001/archophthalmol.2009.58
   Schlanitz FG, 2011, INVEST OPHTH VIS SCI, V52, P4571, DOI 10.1167/iovs.10-6846
   Serrano-Aguilar P, 2012, BRIT J OPHTHALMOL, V96, P503, DOI 10.1136/bjophthalmol-2011-300660
   Sivasankari S, 2013, INT J ENG TECHNOL, V5, P1462
   Stekhoven DJ, 2012, BIOINFORMATICS, V28, P112, DOI 10.1093/bioinformatics/btr597
   Zheng YL, 2012, INVEST OPHTH VIS SCI, V53, P8310, DOI 10.1167/iovs.12-9576
NR 35
TC 28
Z9 28
U1 0
U2 10
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
EI 1471-2415
J9 BMC OPHTHALMOL
JI BMC Ophthalmol.
PD JAN 27
PY 2015
VL 15
AR 10
DI 10.1186/1471-2415-15-10
PG 9
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA CB8DP
UT WOS:000349859100001
PM 25623470
OA Green Accepted, gold, Green Published
DA 2022-11-30
ER

PT J
AU Tsika, C
   Tsilimbaris, MK
   Makridaki, M
   Kontadakis, G
   Plainis, S
   Moschandreas, J
AF Tsika, Chrysanthi
   Tsilimbaris, Miltiadis K.
   Makridaki, Maria
   Kontadakis, Georgios
   Plainis, Sotiris
   Moschandreas, Joanna
TI Assessment of macular pigment optical density (MPOD) in patients with
   unilateral wet age-related macular degeneration (AMD)
SO ACTA OPHTHALMOLOGICA
LA English
DT Article
DE age-related macular degeneration; heterochromatic flicker photometry;
   lutein; macular pigment optical density; wet AMD; zeaxanthin
ID HETEROCHROMATIC FLICKER PHOTOMETRY; CHOROIDAL BLOOD-FLOW; SERUM
   CONCENTRATIONS; RISK-FACTORS; CAROTENOIDS; MACULOPATHY; LUTEIN;
   ZEAXANTHIN; PATHOGENESIS; POPULATION
AB Purpose: To compare the macular pigment optical density (MPOD) of patients with unilateral wet age-related macular degeneration (AMD) with the MPOD of bilateral dry AMD patients and healthy elderly individuals.
   Methods: The MPOD of 34 patients with unilateral wet AMD was measured in their fellow eye that had the dry form of the disease (study group). The MPOD of the study group was compared with the MPOD of 33 patients with bilateral dry AMD (patients' control group) and 35 elderly subjects without any signs of retinal disease (control group). None of the subjects was under carotenoid supplementation. The MPOD was measured with Heterochromatic Flicker Photometry [QuantifEYE (TM) - MPS 9000 (ZeaVision (c))]. The statistical package SPSS v 17.0 was used for the analysis.
   Results: The overall mean MPOD was 0.52 (SD 0.15). Patients with unilateral wet AMD have significantly higher levels of MPOD in their fellow eye compared with patients with bilateral dry AMD (0.58 versus 0.48, p = 0.026). Mean MPOD of patients with bilateral dry AMD does not differ significantly from that of healthy elderly subjects (0.48 versus 0.50, p = 0.865). In this population sample, no correlation with age was observed, while women have slightly but significantly higher levels of MPOD (0.55 versus 0.49, p = 0.029).
   Conclusion: In the present study, the mean MPOD at the fellow eye of patients with unilateral wet AMD was found to be significantly higher than that of patients with bilateral dry AMD, while no other significant difference emerged between groups. Further investigation is demanded to clarify the role of macular pigment in AMD progression.
C1 [Tsika, Chrysanthi; Tsilimbaris, Miltiadis K.] Univ Hosp Heraklion, Dept Ophthalmol, Fac Med, Iraklion 71003, Greece.
   [Tsika, Chrysanthi; Tsilimbaris, Miltiadis K.; Kontadakis, Georgios; Plainis, Sotiris] Univ Crete, Inst Vis & Opt, Fac Med, Sch Hlth Sci, Iraklion, Greece.
   [Makridaki, Maria] Univ Manchester, Dept Optometry & Neurosci, Fac Life Sci, Manchester, Lancs, England.
   [Moschandreas, Joanna] Univ Crete, Prevent Med & Nutr Clin, Div Social Med, Fac Med,Sch Hlth Sci, Iraklion, Greece.
C3 University Hospital of Heraklion; University of Crete; University of
   Manchester; University of Crete
RP Tsilimbaris, MK (通讯作者)，Univ Hosp Heraklion, Dept Ophthalmol, Fac Med, Iraklion 71003, Greece.
EM tsilimb@med.uoc.gr
RI Kontadakis, Georgios/AAF-7608-2020; Kontadakis, George/AAZ-1764-2020
OI Kontadakis, Georgios/0000-0003-4549-7682; Plainis,
   Sotiris/0000-0002-8304-5073; Tsilimbaris, Miltiadis/0000-0002-0130-1150
CR Age-Related Eye Disease Study Research Group, 2001, ARCH OPHTHALMOL-CHIC, V119, P1439
   Age-Related Eye Disease Study Research Group, 2001, RES AG REL EYE DIS S
   Beatty S, 2000, SURV OPHTHALMOL, V45, P115, DOI 10.1016/S0039-6257(00)00140-5
   Beatty S, 2000, OPHTHAL PHYSL OPT, V20, P105, DOI 10.1016/S0275-5408(99)00039-3
   Beatty S, 2001, INVEST OPHTH VIS SCI, V42, P439
   Beatty S, 2008, INVEST OPHTH VIS SCI, V49, P843, DOI 10.1167/iovs.07-1276
   Berendschot TT, 2005, EXP EYE RES, V81, P602, DOI 10.1016/j.exer.2005.03.019
   Berendschot TTJM, 2004, ARCH BIOCHEM BIOPHYS, V430, P149, DOI 10.1016/j.abb.2004.04.029
   Berendschot TTJM, 2002, INVEST OPHTH VIS SCI, V43, P1928
   Bone RA, 2004, ARCH BIOCHEM BIOPHYS, V430, P137, DOI 10.1016/j.abb.2004.04.003
   Bone RA, 2003, J NUTR, V133, P992, DOI 10.1093/jn/133.4.992
   BONE RA, 1988, INVEST OPHTH VIS SCI, V29, P843
   Ciulla TA, 2004, AM J OPHTHALMOL, V138, P582, DOI 10.1016/j.ajo.2004.05.057
   Curran-Celentano J, 2001, AM J CLIN NUTR, V74, P796
   Darzins P, 1997, OPHTHALMOLOGY, V104, P770, DOI 10.1016/S0161-6420(97)30235-8
   Delori FC, 2004, ARCH BIOCHEM BIOPHYS, V430, P156, DOI 10.1016/j.abb.2004.05.016
   Delori FC, 2001, J OPT SOC AM A, V18, P1212, DOI 10.1364/JOSAA.18.001212
   Elsner H, 2005, INVEST OPHTH VIS SCI, V46
   FRIEDMAN E, 1995, OPHTHALMOLOGY, V102, P640, DOI 10.1016/S0161-6420(95)30974-8
   Friedman E, 1997, AM J OPHTHALMOL, V124, P677, DOI 10.1016/S0002-9394(14)70906-7
   Grunwald JE, 2005, INVEST OPHTH VIS SCI, V46, P1033, DOI 10.1167/iovs.04-1050
   Hammond BR, 2005, OPTOMETRY VISION SCI, V82, P387, DOI 10.1097/01.OPX.0000162652.85875.D2
   Hammond BR, 1996, VISION RES, V36, P2001, DOI 10.1016/0042-6989(95)00290-1
   Hammond BR, 1996, VISION RES, V36, P3003, DOI 10.1016/0042-6989(96)00008-9
   Hammond BR, 2002, INVEST OPHTH VIS SCI, V43, P47
   Hammond BR, 2000, INVEST OPHTH VIS SCI, V41, P1492
   Iannaccone A, 2007, INVEST OPHTH VIS SCI, V48, P1458, DOI 10.1167/iovs.06-0438
   Kanis MJ, 2007, GRAEF ARCH CLIN EXP, V245, P767, DOI 10.1007/s00417-006-0478-0
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1417, DOI 10.1001/archopht.119.10.1417
   Koh HH, 2004, EXP EYE RES, V79, P21, DOI 10.1016/j.exer.2004.03.001
   LaRowe TL, 2008, OPHTHALMOLOGY, V115, P876, DOI 10.1016/j.ophtha.2007.06.015
   Leung Ivan Y-F, 2008, Optometry, V79, P266, DOI 10.1016/j.optm.2007.03.017
   Makridaki M, 2009, OPHTHAL PHYSL OPT, V29, P338, DOI 10.1111/j.1475-1313.2009.00667.x
   Nolan J, 2004, INVEST OPHTH VIS SCI, V45, P3940, DOI 10.1167/iovs.04-0273
   Nolan JM, 2007, EXP EYE RES, V84, P61, DOI 10.1016/j.exer.2006.08.016
   Nolan JM, 2010, OPHTHALMIC RES, V44, P131, DOI 10.1159/000315531
   Pournaras CJ, 2006, INVEST OPHTH VIS SCI, V47, P1581, DOI 10.1167/iovs.05-0434
   Snodderly DM, 2004, INVEST OPHTH VIS SCI, V45, P531, DOI 10.1167/iovs.03-0762
   SNODDERLY DM, 1995, AM J CLIN NUTR, V62, P1448
   SNODDERLY DM, 1984, INVEST OPHTH VIS SCI, V25, P674
   Sommerburg O, 1998, BRIT J OPHTHALMOL, V82, P907, DOI 10.1136/bjo.82.8.907
   Sparrow JR, 2001, INVEST OPHTH VIS SCI, V42, P1356
   Stahl W, 1997, CARCINOGENESIS, V18, P89, DOI 10.1093/carcin/18.1.89
   Stahl W, 2003, MOL ASPECTS MED, V24, P345, DOI 10.1016/S0098-2997(03)00030-X
   Stringham JM, 2008, EXP EYE RES, V87, P445, DOI 10.1016/j.exer.2008.08.005
   Tan JSL, 2008, OPHTHALMOLOGY, V115, P334, DOI 10.1016/j.ophtha.2007.03.083
   TAYLOR HR, 1992, ARCH OPHTHALMOL-CHIC, V110, P99, DOI 10.1001/archopht.1992.01080130101035
   van der Veen RLP, 2009, OPHTHAL PHYSL OPT, V29, P127, DOI 10.1111/j.1475-1313.2008.00618.x
   WEST SK, 1989, ARCH OPHTHALMOL-CHIC, V107, P875, DOI 10.1001/archopht.1989.01070010897038
   Wolf-Schnurrbusch UEK, 2007, INVEST OPHTH VIS SCI, V48, P3783, DOI 10.1167/iovs.06-1218
   Wooten BR, 1999, INVEST OPHTH VIS SCI, V40, P2481
   ZHAO J, 1995, INT OPHTHALMOL, V19, P1, DOI 10.1007/BF00156412
NR 52
TC 12
Z9 13
U1 0
U2 7
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1755-375X
EI 1755-3768
J9 ACTA OPHTHALMOL
JI Acta Ophthalmol.
PD NOV
PY 2011
VL 89
IS 7
BP E573
EP E578
DI 10.1111/j.1755-3768.2011.02170.x
PG 6
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 838ZB
UT WOS:000296332000006
PM 21672183
DA 2022-11-30
ER

PT J
AU Choi, M
   Ahn, S
   Yun, C
   Kim, SW
AF Choi, Mihyun
   Ahn, Somin
   Yun, Cheolmin
   Kim, Seong-Woo
TI Quantitative OCT angiography findings according to pattern
   classification of type 1 neovascularization exudative age-related
   macular degeneration
SO EYE
LA English
DT Article
AB Objectives To define neovascularization (NV) patterns and their association with exudative activity in type 1 neovascular age-related macular degeneration (NVAMD). Methods In optical coherence tomography angiography (OCTA) images of type 1 NVAMD, we stratified NV patterns according to whether they contained core vessel (C+/C-) and fine branching vessels (F+/F-) or not into C - F +, C + F +, and C + F - groups. Qualitative analyses assessing the status of peripheral tiny branching, inner branching capillaries, arcade, loop, and perilesional halo and quantitative analyses considering the NV area, length, density, and numbers of junctions and endpoints (open-ended vessels) in NV were conducted according to NV patterns and the presence of exudation on structural OCT. Results Among 96 eyes, exudation was found in the C - F + (33.3%) and C + F + (47.6%) groups, related to peripheral tiny branching in both groups (p = 0.022 and p < 0.001) and perilesional halo in the C + F + group (p < 0.001). Peripheral arcades, inner branching capillaries, and loops were observed in more than half (68.3%, 58.7%, and 69.8%) in the C + F + group but not related with exudative activity in the C + F + group. In quantitative analysis, the number of endpoints was associated with exudation in univariate and multivariate analyses (p = 0.011 and p = 0.016) in C + F + group. Conclusions After pattern classification, type 1 NV patterns with fine branching vessels were considered to have exudative activity compared to NV without fine branching. The quantitative analysis of type 1 NV according to patterns showed the presence of peripheral tiny branching vessels was associated with NV activity.
C1 [Choi, Mihyun; Ahn, Somin; Kim, Seong-Woo] Korea Univ, Guro Hosp, Coll Med, Dept Ophthalmol, Seoul, South Korea.
   [Yun, Cheolmin] Korea Univ, Ansan Hosp, Coll Med, Dept Ophthalmol, Ansan, South Korea.
C3 Korea University; Korea University Medicine (KU Medicine); Korea
   University; Korea University Medicine (KU Medicine)
RP Kim, SW (通讯作者)，Korea Univ, Guro Hosp, Coll Med, Dept Ophthalmol, Seoul, South Korea.
EM ksw64723@korea.ac.kr
OI Kim, Seong-Woo/0000-0003-0073-5800
FU Bio & Medical Technology Development Program of the NRF - Korean
   government, the Ministry of Science and ICT (MSIP)
   [NRF-2017M3A9E2056458, 2020R1A2C1005729]; Korea University Guro Hospital
   [O2001161]
FX This research was supported in part by the Bio & Medical Technology
   Development Program of the NRF funded in part by the Korean government,
   the Ministry of Science and ICT (MSIP) (NRF-2017M3A9E2056458, and
   2020R1A2C1005729), and was also supported by a Korea University Guro
   Hospital Grant (O2001161).
CR Al-Sheikh M, 2018, RETINA-J RET VIT DIS, V38, P220, DOI 10.1097/IAE.0000000000001628
   An D, 2018, EXP EYE RES, V170, P13, DOI 10.1016/j.exer.2018.02.006
   Carnevali A, 2016, AM J OPHTHALMOL, V169, P189, DOI 10.1016/j.ajo.2016.06.042
   Choi M, 2020, AM J OPHTHALMOL, V213, P109, DOI 10.1016/j.ajo.2020.01.012
   Coscas F, 2019, BRIT J OPHTHALMOL, V103, P1342, DOI 10.1136/bjophthalmol-2018-313065
   Coscas GJ, 2015, RETINA-J RET VIT DIS, V35, P2219, DOI 10.1097/IAE.0000000000000766
   Falavarjani KG, 2017, BRIT J OPHTHALMOL, V101, P989, DOI 10.1136/bjophthalmol-2016-309678
   Farecki ML, 2017, GRAEF ARCH CLIN EXP, V255, P913, DOI 10.1007/s00417-017-3588-y
   Huang D, 2015, RETINA-J RET VIT DIS, V35, P2260, DOI 10.1097/IAE.0000000000000846
   Karacorlu M, 2019, EYE, V33, P1280, DOI 10.1038/s41433-019-0415-1
   Kim SW, 2011, RETINA-J RET VIT DIS, V31, P1904, DOI 10.1097/IAE.0b013e31821801c5
   Kuehlewein L, 2015, AM J OPHTHALMOL, V160, P739, DOI 10.1016/j.ajo.2015.06.030
   Lupidi M, 2018, EUR J OPHTHALMOL, V28, P349, DOI 10.1177/1120672118766807
   Margolis R, 2009, AM J OPHTHALMOL, V147, P811, DOI 10.1016/j.ajo.2008.12.008
   Miere A, 2019, RETINA-J RET VIT DIS, V39, P548, DOI 10.1097/IAE.0000000000001964
   Miere A, 2015, RETINA-J RET VIT DIS, V35, P2275, DOI 10.1097/IAE.0000000000000819
   Patel R, 2018, INVEST OPHTH VIS SCI, V59, P4285, DOI 10.1167/iovs.18-24624
   Richard G, 2015, OPHTHALMOLOGY, V122, P2497, DOI 10.1016/j.ophtha.2015.08.014
   Roberts PK, 2017, RETINA-J RET VIT DIS, V37, P1492, DOI 10.1097/IAE.0000000000001400
   Spaide RF, 2006, AM J OPHTHALMOL, V141, P149, DOI 10.1016/j.ajo.2005.07.025
   Spaide RF, 2015, AM J OPHTHALMOL, V160, P6, DOI 10.1016/j.ajo.2015.04.012
   Sulzbacher F, 2017, ACTA OPHTHALMOL, V95, P414, DOI 10.1111/aos.13364
   Takeuchi J, 2018, OPHTHALMOLOGICA, V240, P90, DOI 10.1159/000487611
   Uchida A, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0218889
   von der Emde L, 2020, OPHTHALMOLOGICA, V243, P120, DOI 10.1159/000503609
   Xu D, 2018, AM J OPHTHALMOL, V187, P10, DOI 10.1016/j.ajo.2017.12.005
   Zhao Z, 2019, OPHTHALMOLOGICA, V242, P178, DOI 10.1159/000497491
   Zudaire E, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0027385
NR 28
TC 0
Z9 0
U1 1
U2 2
PU SPRINGERNATURE
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND
SN 0950-222X
EI 1476-5454
J9 EYE
JI Eye
PD FEB
PY 2022
VL 36
IS 2
BP 414
EP 423
DI 10.1038/s41433-021-01496-z
EA MAR 2021
PG 10
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA YQ7VR
UT WOS:000627194600003
PM 33692535
DA 2022-11-30
ER

PT J
AU Dugel, PU
   Petrarca, R
   Bennett, M
   Barak, A
   Weinberger, D
   Nau, J
   Jackson, TL
AF Dugel, Pravin U.
   Petrarca, Robert
   Bennett, Michael
   Barak, Adiel
   Weinberger, Dov
   Nau, Jeffrey
   Jackson, Timothy L.
TI Macular Epiretinal Brachytherapy in Treated Age-Related Macular
   Degeneration MERITAGE Study: Twelve-Month Safety and Efficacy Results
SO OPHTHALMOLOGY
LA English
DT Article
ID SUBFOVEAL CHOROIDAL NEOVASCULARIZATION; VASCULAR ENDOTHELIAL-CELLS;
   IONIZING-RADIATION; SR-90 BRACHYTHERAPY; DOSING REGIMEN; RANIBIZUMAB;
   BEVACIZUMAB; IRRADIATION; THERAPY; TRIAL
AB Purpose: To evaluate the safety and efficacy of epimacular brachytherapy (EMB) for the treatment of chronic, active, neovascular age-related macular degeneration (AMD).
   Design: Prospective, multicenter, interventional, noncontrolled clinical trial.
   Participants: Fifty-three eyes of 53 participants with neovascular AMD requiring frequent anti-vascular endothelial growth factor (VEGF) retreatment.
   Methods: Participants underwent pars plana vitrectomy with a single 24-Gy dose of EMB delivered using an intraocular, handheld cannula containing a strontium 90/yttrium 90 source positioned over the active lesion. Participants were retreated with ranibizumab administered monthly as needed, using predefined retreatment criteria. Optical coherence tomography (OCT) was undertaken monthly, with images assessed by an independent reading center.
   Main Outcome Measures: Coprimary outcomes at 12 months were proportion of participants with stable vision (losing <15 Early Treatment Diabetic Retinopathy Study [ETDRS] letters) and mean number of anti-VEGF retreatments.
   Results: Before enrollment, participants had received an average of 12.5 anti-VEGF injections. After a single treatment with EMB, 81% maintained stable vision, with a mean of 3.49 anti-VEGF retreatments in 12 months. Mean +/- standard deviation change in visual acuity was -4.0 +/- 15.1 ETDRS letters. Mean +/- standard deviation OCT central retinal thickness increased by 50 +/- 179 mu m. Common adverse events included conjunctival hemorrhage (n = 38), cataract (n = 16), resolving vitreous hemorrhage (n = 6), and eye pain (n = 5).
   Conclusions: Epimacular brachytherapy produces stable visual acuity in most participants with previously treated, active disease. Epimacular brachytherapy may reduce the need for frequent anti-VEGF retreatment.
   Financial Disclosure(s): Proprietary or commercial disclosure may be found after the references. Ophthalmology 2012;xx:xxx (C) 2012 by the American Academy of Ophthalmology.
C1 [Jackson, Timothy L.] Kings Coll Hosp London, Kings Hlth Partners, Dept Ophthalmol, London SE5 9RS, England.
   [Dugel, Pravin U.] Retinal Consultants Arizona, Phoenix, AZ USA.
   [Petrarca, Robert; Jackson, Timothy L.] Kings Coll London, London, England.
   [Bennett, Michael] Retina Inst Hawaii, Honolulu, HI USA.
   [Barak, Adiel] Tel Aviv Univ, Tel Aviv Sourasky Med Ctr, IL-69978 Tel Aviv, Israel.
   [Weinberger, Dov] Rabin Med Ctr, Tel Aviv, Israel.
   [Nau, Jeffrey] NeoVista, Newark, CA USA.
C3 King's College Hospital NHS Foundation Trust; King's College Hospital;
   University of London; King's College London; University of London;
   King's College London; Tel Aviv University; Sackler Faculty of Medicine;
   Tel Aviv Sourasky Medical Center; Rabin Medical Center
RP Jackson, TL (通讯作者)，Kings Coll Hosp London, Kings Hlth Partners, Dept Ophthalmol, Denmark Hill, London SE5 9RS, England.
EM t.jackson1@nhs.net
OI Petrarca, Robert/0000-0001-8693-3423; Jackson,
   Timothy/0000-0001-7618-1555
FU NeoVista, Inc.
FX Timothy L. Jackson - Financial support - NeoVista, Inc.; Pravin Dugel -
   Financial support, Equity owner - NeoVista, Inc.; Michael Bennett -
   Financial support - NeoVista, Inc.; Dov Weinberger - Financial support -
   NeoVista, Inc.; Adiel Barak - Financial support - NeoVista, Inc.;
   Jeffrey Nau - Employee, Patents - NeoVista, Inc.
CR ARCHER D B, 1991, Eye (London), V5, P239
   Avila MP, 2009, BRIT J OPHTHALMOL, V93, P305, DOI 10.1136/bjo.2008.145912
   Avila MP, 2009, RETINA-J RET VIT DIS, V29, P157, DOI 10.1097/IAE.0b013e3181985915
   Bergink GJ, 1998, GRAEF ARCH CLIN EXP, V236, P321, DOI 10.1007/s004170050085
   Boyer DS, 2009, OPHTHALMOLOGY, V116, P1731, DOI 10.1016/j.ophtha.2009.05.024
   Brown DM, 2009, OPHTHALMOLOGY, V116, P57, DOI 10.1016/j.ophtha.2008.10.018
   CHAKRAVARTHY U, 1993, BRIT J OPHTHALMOL, V77, P265, DOI 10.1136/bjo.77.5.265
   CHAKRAVARTHY U, 1989, CURR EYE RES, V8, P337, DOI 10.3109/02713688908996381
   Char DH, 1999, AM J OPHTHALMOL, V127, P574, DOI 10.1016/S0002-9394(99)00038-0
   Chin HS, 2005, RETINA-J RET VIT DIS, V25, P556, DOI 10.1097/00006982-200507000-00002
   CHYLACK LT, 1989, ARCH OPHTHALMOL-CHIC, V107, P991, DOI 10.1001/archopht.1989.01070020053028
   EISSNER G, 1995, BLOOD, V86, P4184, DOI 10.1182/blood.V86.11.4184.bloodjournal86114184
   Engelbert M, 2010, RETINA-J RET VIT DIS, V30, P1368, DOI 10.1097/IAE.0b013e3181d50cbf
   Finger PT, 1999, AM J OPHTHALMOL, V127, P170, DOI 10.1016/S0002-9394(98)00389-4
   Forooghian F, 2009, RETINA-J RET VIT DIS, V29, P723, DOI 10.1097/IAE.0b013e3181a2c1c3
   Gragoudas ES, 2004, NEW ENGL J MED, V351, P2805, DOI 10.1056/NEJMoa042760
   Hallahan D, 1995, BIOCHEM BIOPH RES CO, V217, P784, DOI 10.1006/bbrc.1995.2841
   Hokkanen J, 1997, MED PHYS, V24, P211, DOI 10.1118/1.597927
   Holz FG, 2011, OPHTHALMOLOGY, V118, P663, DOI 10.1016/j.ophtha.2010.12.019
   HOSOI Y, 1993, INT J RADIAT BIOL, V63, P631, DOI 10.1080/09553009314450821
   Jaakkola A, 2005, OPHTHALMOLOGY, V112, P567, DOI 10.1016/j.ophtha.2004.11.029
   Jaakkola A, 1998, GRAEF ARCH CLIN EXP, V236, P24, DOI 10.1007/s004170050038
   KRISHNAN L, 1988, INT J RADIAT ONCOL, V15, P147, DOI 10.1016/0360-3016(88)90359-8
   Lalwani GA, 2009, AM J OPHTHALMOL, V148, P43, DOI 10.1016/j.ajo.2009.01.024
   Maguire AM, 2001, RETINA, V2, P1510
   Martin DF, 2011, NEW ENGL J MED, V364, P1897, DOI 10.1056/NEJMoa1102673
   Mooteri SN, 1996, RADIAT RES, V145, P217, DOI 10.2307/3579177
   PARSONS JT, 1983, INT J RADIAT ONCOL, V9, P609, DOI 10.1016/0360-3016(83)90225-0
   PATZ A, 1985, ARCH OPHTHALMOL-CHIC, V103, P1796, DOI 10.1001/archopht.1985.01050120030015
   Regillo CD, 2008, AM J OPHTHALMOL, V145, P239, DOI 10.1016/j.ajo.2007.10.004
   ROSANDER K, 1995, ACTA ONCOL, V34, P111, DOI 10.3109/02841869509093648
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Rubin DB, 1996, RADIAT RES, V145, P210, DOI 10.2307/3579176
   Tufail A, 2010, BMJ-BRIT MED J, V340, DOI 10.1136/bmj.c2459
   van Ginderdeuren R, 2005, BRIT J OPHTHALMOL, V89, P1306, DOI 10.1136/bjo.2005.068460
   VERHEIJ M, 1994, PROSTAGLANDINS, V48, P351, DOI 10.1016/0090-6980(94)90002-7
NR 36
TC 31
Z9 32
U1 0
U2 4
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0161-6420
EI 1549-4713
J9 OPHTHALMOLOGY
JI Ophthalmology
PD JUL
PY 2012
VL 119
IS 7
DI 10.1016/j.ophtha.2012.01.014
PG 7
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 968UQ
UT WOS:000306011000025
PM 22465819
DA 2022-11-30
ER

PT J
AU Schmucker, C
   Loke, YK
   Ehlken, C
   Agostini, HT
   Hansen, LL
   Antes, G
   Lelgemann, M
AF Schmucker, Christine
   Loke, Yoon K.
   Ehlken, Christoph
   Agostini, Hansjuergen T.
   Hansen, Lutz L.
   Antes, Gerd
   Lelgemann, Monika
TI Intravitreal bevacizumab (Avastin) versus ranibizumab (Lucentis) for the
   treatment of age-related macular degeneration: a safety review
SO BRITISH JOURNAL OF OPHTHALMOLOGY
LA English
DT Review
ID OCCULT CHOROIDAL NEOVASCULARIZATION; RANDOMIZED CLINICAL-TRIAL;
   VERTEPORFIN PHOTODYNAMIC THERAPY; VISION-RELATED FUNCTION; SUBGROUP
   ANALYSIS; VISUAL-ACUITY; TRIAMCINOLONE; SECONDARY; 6-MONTH; INJECTION
AB Aim To conduct a systematic review in order to compare adverse effects (AE) and the reporting of harm in randomised controlled trials (RCTs) and non-RCTs evaluating intravitreal ranibizumab and bevacizumab in age-related macular degeneration.
   Methods Medline, Embase and the Cochrane Library were searched with no limitations of language and year of publication. Studies which compared bevacizumab or ranibizumab as monotherapy with any other control group were included. Case series were included if they met predefined quality standards.
   Results The 2 year results of phase III trials evaluating ranibizumab show that the rates of serious ocular AE were low (<= 2.1%) but indicate major safety concerns (RR 3.13, 95% CI 1.10 to 8.92). A possible signal with regard to thromboembolic events (RR 1.35, 95% CI 0.66 to 2.77) and a significant increase in non-ocular haemorrhage (RR 1.62, 95% CI 1.03 to 2.55) were also noted. In contrast to ranibizumab trials, the RCTs evaluating bevacizumab are of limited value. The main shortcomings are small sample sizes and an apparent lack of rigorous monitoring for AE. A critical assessment of the large number of published case series evaluating bevacizumab also shows that no reliable conclusions on safety can be drawn using this study design. Therefore, any perception that intravitreal bevacizumab injections are not associated with major ocular or systemic AE are not supported by reliable data.
   Conclusion The bevacizumab studies show too many methodological limitations to rule out any major safety concerns. Higher evidence from ranibizumab trials suggests signals for an increased ocular and systemic vascular and haemorrhagic risk which warrants further investigation.
C1 [Schmucker, Christine] Univ Med Ctr Freiburg, German Cochrane Ctr, Inst Med Biometry & Med Informat, Dept Med Biometry & Stat, D-79110 Freiburg, Germany.
   [Loke, Yoon K.] Univ E Anglia, Sch Med, Norwich NR4 7TJ, Norfolk, England.
   [Ehlken, Christoph; Agostini, Hansjuergen T.; Hansen, Lutz L.] Univ Med Ctr Freiburg, Univ Eye Hosp, D-79110 Freiburg, Germany.
   [Lelgemann, Monika] Univ Bremen, Hlth Technol Assessment Ctr, D-2800 Bremen 33, Germany.
C3 University of Freiburg; University of East Anglia; University of
   Freiburg; University of Bremen
RP Schmucker, C (通讯作者)，Univ Med Ctr Freiburg, German Cochrane Ctr, Inst Med Biometry & Med Informat, Dept Med Biometry & Stat, Berliner Allee 29, D-79110 Freiburg, Germany.
EM schmucker@cochrane.de
OI Schmucker, Christine/0000-0002-1188-3158
FU German health insurance fund (Verband der Ersatzkassen e. V. (vdek),
   Berlin, Germany)
FX German health insurance fund (Verband der Ersatzkassen e. V. (vdek),
   Askanischer Platz 1, D-10963 Berlin, Germany).
CR Abraham-Marin ML, 2007, GRAEF ARCH CLIN EXP, V245, P651, DOI 10.1007/s00417-006-0411-6
   Aisenbrey S, 2007, GRAEF ARCH CLIN EXP, V245, P941, DOI 10.1007/s00417-006-0471-7
   Arias L, 2007, EUR J OPHTHALMOL, V17, P992, DOI 10.1177/112067210701700622
   Bashshur ZF, 2008, AM J OPHTHALMOL, V145, P249, DOI 10.1016/j.ajo.2007.09.031
   Bashshur ZF, 2007, ARCH OPHTHALMOL-CHIC, V125, P1357, DOI 10.1001/archopht.125.10.1357
   Bashshur ZF, 2006, AM J OPHTHALMOL, V142, P1, DOI 10.1016/j.ajo.2006.02.037
   Boyer DS, 2007, OPHTHALMOLOGY, V114, P246, DOI 10.1016/j.ophtha.2006.10.045
   Bradburn MJ, 2007, STAT MED, V26, P53, DOI 10.1002/sim.2528
   Bressler Neil M, 2004, JAMA, V291, P1900, DOI 10.1001/jama.291.15.1900
   Bressler NM, 2009, ARCH OPHTHALMOL-CHIC, V127, P13, DOI 10.1001/archophthalmol.2008.562
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Brown DM, 2009, OPHTHALMOLOGY, V116, P57, DOI 10.1016/j.ophtha.2008.10.018
   Chang TS, 2007, ARCH OPHTHALMOL-CHIC, V125, P1460, DOI 10.1001/archopht.125.11.1460
   Chen CY, 2007, AM J OPHTHALMOL, V143, P510, DOI 10.1016/j.ajo.2006.10.004
   Chou R, 2010, J CLIN EPIDEMIOL, V63, P502, DOI 10.1016/j.jclinepi.2008.06.007
   Cleary CA, 2008, EYE, V22, P82, DOI 10.1038/sj.eye.6702936
   Costa RA, 2006, INVEST OPHTH VIS SCI, V47, P4569, DOI 10.1167/iovs.06-0433
   Falkenstein IA, 2007, RETINA-J RET VIT DIS, V27, P701, DOI 10.1097/IAE.0b013e3180654240
   FERRIS FL, 1984, ARCH OPHTHALMOL-CHIC, V102, P1640
   Gartlehner G, 2008, Z EVIDENZ FORTBILD Q, V102, P497, DOI 10.1016/j.zefq.2008.08.028
   Geitzenauer W, 2006, KLIN MONATSBL AUGENH, V223, P822, DOI 10.1055/s-2006-926875
   Giansanti F, 2007, EUR J OPHTHALMOL, V17, P230, DOI 10.1177/112067210701700213
   Golder S, 2008, BRIT J CLIN PHARMACO, V66, P767, DOI 10.1111/j.1365-2125.2008.03272.x
   Goverdhan SV, 2008, BRIT J OPHTHALMOL, V92, P210, DOI 10.1136/bjo.2007.127902
   Hahn R, 2007, OPHTHALMOLOGE, V104, P588, DOI 10.1007/s00347-007-1547-4
   Heier JS, 2006, OPHTHALMOLOGY, V113, P633, DOI 10.1016/j.ophtha.2005.10.052
   Ip MS, 2008, OPHTHALMOLOGY, V115, P1837, DOI 10.1016/j.ophtha.2008.08.012
   Jonas JB, 2007, J OCUL PHARMACOL TH, V23, P240, DOI 10.1089/jop.2006.0146
   KAHN HA, 1977, AM J EPIDEMIOL, V106, P17, DOI 10.1093/oxfordjournals.aje.a112428
   Kaiser PK, 2007, AM J OPHTHALMOL, V144, P850, DOI 10.1016/j.ajo.2007.08.012
   Kaiser PK, 2007, OPHTHALMOLOGY, V114, P1868, DOI 10.1016/j.ophtha.2007.04.030
   KHAN K, 2001, UNDERTAKING SYSTEMAT
   LAZIC R, 2007, COLL ANTROPOL S1, V31, pS315
   Lazic R, 2007, OPHTHALMOLOGY, V114, P1179, DOI 10.1016/j.ophtha.2007.03.006
   Lazic R, 2007, GRAEF ARCH CLIN EXP, V245, P68, DOI 10.1007/s00417-006-0466-4
   Loke YK, 2007, BMC MED RES METHODOL, V7, DOI 10.1186/1471-2288-7-32
   Madhusudhana KC, 2007, BRIT J OPHTHALMOL, V91, P1716, DOI 10.1136/bjo.2006.108639
   R Core Team, 2022, R LANG ENV STAT COMP
   Regillo CD, 2008, AM J OPHTHALMOL, V145, P239, DOI 10.1016/j.ajo.2007.10.004
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Rosenfeld PJ, 2005, OPHTHAL SURG LAS IM, V36, P331, DOI 10.3928/1542-8877-20050701-14
   Sacu S, 2009, EYE, V23, P2223, DOI 10.1038/eye.2008.423
   Schouten JSAG, 2009, GRAEF ARCH CLIN EXP, V247, P1, DOI 10.1007/s00417-008-0952-y
   Steinbrook R, 2006, NEW ENGL J MED, V355, P1409, DOI 10.1056/NEJMp068185
   Suner IJ, 2009, INVEST OPHTH VIS SCI, V50, P3629, DOI 10.1167/iovs.08-3225
   *US BLA, 2010, BL125156 US BLA GEN
   Vedula SS, 2008, COCHRANE DB SYST REV, V2
   Weigert G, 2008, BRIT J OPHTHALMOL, V92, P356, DOI 10.1136/bjo.2007.125823
   Wu L, 2008, GRAEF ARCH CLIN EXP, V246, P81, DOI 10.1007/s00417-007-0660-z
NR 49
TC 62
Z9 64
U1 0
U2 17
PU B M J PUBLISHING GROUP
PI LONDON
PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND
SN 0007-1161
J9 BRIT J OPHTHALMOL
JI Br. J. Ophthalmol.
PD MAR
PY 2011
VL 95
IS 3
BP 308
EP 317
DI 10.1136/bjo.2009.178574
PG 10
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 722NY
UT WOS:000287440400003
PM 20971791
DA 2022-11-30
ER

PT J
AU Moeini, HA
   Masoudpour, H
   Ghanbari, H
AF Moeini, HA
   Masoudpour, H
   Ghanbari, H
TI A study of the relation between body mass index and the incidence of age
   related macular degeneration
SO BRITISH JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
ID BEAVER DAM EYE; RISK-FACTORS; MACULOPATHY; ASSOCIATION; SMOKING;
   PROGRESSION; ROTTERDAM; BLINDNESS; PRESSURE
AB Background: Age related macular degeneration (ARMD) is the most frequent cause of blindness among the elderly. Obesity may be one of the risk factors of ARMD as suggested, yet not proved, by several studies. This study assesses the relation between body mass index (BMI) and the incidence of ARMD
   Methods: This case-control study included 50 patients with ARMD and 80 subjects who were adjusted for age, sex, cigarette smoking, blood pressure, and diabetes. Data analysis was performed by SPSS V9.0 using Student's t and chi(2) tests.
   Results: 42% of the subjects in the case group and 35% of those in the control group were men. Mean age of subjects in the case and control groups was 69.9 years ( 62 - 77 years) and 64.08 years ( 56 - 71 years), respectively. Mean BMI measured 25.38 ( range 21 - 29) and 30.24 ( 26 - 34) in the case and control groups, respectively ( p> 0.05). 12% of subjects in the case group were obese, 42% were overweight, and 14% were lean. 22.5% of subjects in the control group were obese, 45% were overweight, and 7.5% were lean ( p> 0.05).
   Conclusion: 43% of patients in this study were aged 70 years or older, which is similar to other studies. There was no significant difference in BMI between the case and control groups. Recent studies indicate that obesity is a probable risk factor for progression of ARMD, but there is no significant relation with the presence of ARMD. With multifactorial analysis, the authors could identify no significant relation between the presence of ARMD and the studied risk factors.
C1 Isfahan Univ Med Sci, Feiz Hosp, Dept Ophthalmol, Esfahan, Iran.
C3 Isfahan University Medical Science
RP Masoudpour, H (通讯作者)，12 Jomhori Sq,Dr Masoudpour Alley, Esfahan, Iran.
EM masoudpour@yahoo.com
RI ghanbari, heshmatollah/B-5517-2018; ghanbari, Heshmatollah
   Ollah/C-6408-2018
OI ghanbari, heshmatollah/0000-0001-8781-5568; 
CR BECKER KL, 1995, OBESITY PRINCIPLES P, P1155
   CHAN CWC, 1991, AUST NZ J OPHTHALMOL, V19, P321, DOI 10.1111/j.1442-9071.1991.tb00680.x
   COOPER RL, 1990, AUST NZ J OPHTHALMOL, V18, P421, DOI 10.1111/j.1442-9071.1990.tb01828.x
   Gasser P, 1999, J GLAUCOMA, V8, P8
   GHAFOUR IM, 1983, BRIT J OPHTHALMOL, V67, P209, DOI 10.1136/bjo.67.4.209
   HYMAN LG, 1983, AM J EPIDEMIOL, V118, P213, DOI 10.1093/oxfordjournals.aje.a113629
   JOHN RH, 1994, BASIC CLIN SCI COURS
   KAHN HA, 1973, PUBLICATION NIH, V73, P427
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1417, DOI 10.1001/archopht.119.10.1417
   Klaver CCW, 1997, ARCH OPHTHALMOL-CHIC, V115, P945, DOI 10.1001/archopht.1997.01100160115033
   KLEIN R, 1993, AM J EPIDEMIOL, V137, P190, DOI 10.1093/oxfordjournals.aje.a116659
   Klein R, 2003, OPHTHALMOLOGY, V110, P636, DOI 10.1016/S0161-6420(02)01448-3
   Leibowitz H M, 1980, Surv Ophthalmol, V24, P335
   MARESPERLMAN JA, 1993, ARCH OPHTHALMOL-CHIC, V111, P4
   Mori K, 2000, INT J EPIDEMIOL, V29, P661, DOI 10.1093/ije/29.4.661
   PAETKAU ME, 1978, CAN J OPHTHALMOL, V13, P67
   Schaumberg DA, 2001, ARCH OPHTHALMOL-CHIC, V119, P1259
   Seddon JM, 2003, ARCH OPHTHALMOL-CHIC, V121, P1728, DOI 10.1001/archopht.121.12.1728
   Seddon JM, 2003, ARCH OPHTHALMOL-CHIC, V121, P785, DOI 10.1001/archopht.121.6.785
   Smith W, 2001, OPHTHALMOLOGY, V108, P697, DOI 10.1016/S0161-6420(00)00580-7
   van Leeuwen R, 2003, INVEST OPHTH VIS SCI, V44, P3771, DOI 10.1167/iovs.03-0121
   van Leeuwen R, 2003, EUR J EPIDEMIOL, V18, P845, DOI 10.1023/A:1025643303914
   VINDING T, 1992, ACTA OPHTHALMOL, V70, P66
   Wachter A, 2004, OPHTHALMOLOGE, V101, P50, DOI 10.1007/s00347-003-0868-1
   YANNUZZI LA, 1992, ARCH OPHTHALMOL-CHIC, V110, P1701
   YONOFF M, 1999, OPHTHALMOLOGY
NR 26
TC 18
Z9 20
U1 0
U2 6
PU BMJ PUBLISHING GROUP
PI LONDON
PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND
SN 0007-1161
EI 1468-2079
J9 BRIT J OPHTHALMOL
JI Br. J. Ophthalmol.
PD AUG
PY 2005
VL 89
IS 8
BP 964
EP 966
DI 10.1136/bjo.2005.066241
PG 3
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 946CK
UT WOS:000230549500012
PM 16024844
OA Green Published, Green Submitted, Bronze
DA 2022-11-30
ER

PT J
AU Hsu, CR
   Lai, TT
   Hsieh, YT
   Ho, TC
   Yang, CM
   Yang, CH
AF Hsu, Cherng-Ru
   Lai, Tso-Ting
   Hsieh, Yi-Ting
   Ho, Tzyy-Chang
   Yang, Chung-May
   Yang, Chang-Hao
TI Combined quantitative and qualitative optical coherence tomography
   angiography biomarkers for predicting active neovascular age-related
   macular degeneration
SO SCIENTIFIC REPORTS
LA English
DT Article
ID THERAPY; CNV
AB To investigate choroidal neovascularization (CNV) characteristics after anti-vascular endothelial growth factor (anti-VEGF) therapy in patients with neovascular age-related macular degeneration by optical coherence tomography angiography (OCTA) and to assess the potential predictive role of combined qualitative and quantitative biomarkers for disease activity. Patients diagnosed with type 1 or type 2 CNV via multimodal imaging who had received anti-VEGF treatment were retrospectively reviewed. Qualitative and quantitative CNV responses on OCTA after serial injections were analyzed. The enrolled eyes were divided into two groups based on treatment intervals during follow-up, including an active group with less than 12 weeks intervals and a stable group with 12 weeks or longer intervals. Fifty-six eyes of 56 patients were included in the study. Twenty-seven eyes (48.2%) were classified as the "active group", and 29 eyes (51.8%) were categorized as the "silent group". Qualitative biomarkers of CNV showed significant differences between the two groups (branching capillaries: 48.1% vs 6.9%, p = 0.001; anastomoses and loops: 81.5% vs 13.8%, p < 0.001; peripheral arcade: 40.7% vs 10.3%, p = 0.013, and hypointense halo: 81.5% vs 41.4%, p = 0.002). A significantly higher vessel density was found in the active group (median 39.6% vs 30.5%, p = 0.003). "Anastomoses and loops" and "vessel density" predicted an active CNV status with a probability of 93.7% and achieved the best performance. The combination of two potential biomarkers of CNV on OCTA shows good discrimination for the prediction of recurrent exudation auxiliary to structural OCT that might associate with disease activity.
C1 [Hsu, Cherng-Ru; Lai, Tso-Ting; Hsieh, Yi-Ting; Ho, Tzyy-Chang; Yang, Chung-May; Yang, Chang-Hao] Natl Taiwan Univ Hosp, Dept Ophthalmol, 7 Chung Shan South Rd, Taipei, Taiwan.
   [Hsu, Cherng-Ru] Triserv Gen Hosp, Natl Def Med Ctr, Dept Ophthalmol, Taipei, Taiwan.
   [Ho, Tzyy-Chang; Yang, Chung-May; Yang, Chang-Hao] Natl Taiwan Univ, Coll Med, Dept Ophthalmol, Taipei, Taiwan.
C3 National Taiwan University; National Taiwan University Hospital;
   National Defense Medical Center; Tri-Service General Hospital; National
   Taiwan University
RP Yang, CH (通讯作者)，Natl Taiwan Univ Hosp, Dept Ophthalmol, 7 Chung Shan South Rd, Taipei, Taiwan.; Yang, CH (通讯作者)，Natl Taiwan Univ, Coll Med, Dept Ophthalmol, Taipei, Taiwan.
EM chyangoph@ntu.edu.tw
OI YANG, CHUNG-MAY/0000-0003-4082-420X; Hsu, Cherng-Ru/0000-0002-4390-0389;
   YANG, CHANG-HAO/0000-0002-4328-8716
CR Al-Sheikh M, 2018, RETINA-J RET VIT DIS, V38, P220, DOI 10.1097/IAE.0000000000001628
   Arnold JJ, 2015, OPHTHALMOLOGY, V122, P1212, DOI 10.1016/j.ophtha.2015.02.009
   Bae K, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-55871-8
   Cole ED, 2016, RETINA-J RET VIT DIS, V36, pS83, DOI 10.1097/IAE.0000000000001338
   Coscas F, 2019, BRIT J OPHTHALMOL, V103, P1342, DOI 10.1136/bjophthalmol-2018-313065
   Coscas F, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0205513
   Coscas GJ, 2015, RETINA-J RET VIT DIS, V35, P2219, DOI 10.1097/IAE.0000000000000766
   Faatz H, 2019, EYE, V33, P1466, DOI 10.1038/s41433-019-0429-8
   Gess AJ, 2011, SEMIN OPHTHALMOL, V26, P225, DOI 10.3109/08820538.2011.582533
   Karacorlu M, 2019, EYE, V33, P1280, DOI 10.1038/s41433-019-0415-1
   Marques JP, 2016, OPHTHALMIC RES, V55, P145, DOI 10.1159/000442671
   Martin DF, 2011, NEW ENGL J MED, V364, P1897, DOI 10.1056/NEJMoa1102673
   Miere A, 2019, RETINA-J RET VIT DIS, V39, P548, DOI 10.1097/IAE.0000000000001964
   Patel R, 2018, INVEST OPHTH VIS SCI, V59, P4285, DOI 10.1167/iovs.18-24624
   Rispoli M, 2018, OSLI RETINA, V49, P918, DOI 10.3928/23258160-20181203-02
   Roberts PK, 2017, RETINA-J RET VIT DIS, V37, P1492, DOI 10.1097/IAE.0000000000001400
   Spaide RF, 2015, AM J OPHTHALMOL, V160, P6, DOI 10.1016/j.ajo.2015.04.012
   Wecker T, 2017, BRIT J OPHTHALMOL, V101, P353, DOI 10.1136/bjophthalmol-2016-308668
   Wong T, 2008, OPHTHALMOLOGY, V115, P116, DOI 10.1016/j.ophtha.2007.03.008
   Zudaire E, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0027385
NR 20
TC 3
Z9 3
U1 1
U2 1
PU NATURE PORTFOLIO
PI BERLIN
PA HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY
SN 2045-2322
J9 SCI REP-UK
JI Sci Rep
PD SEP 10
PY 2021
VL 11
IS 1
AR 18068
DI 10.1038/s41598-021-97652-2
PG 9
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA UO7IY
UT WOS:000694868000056
PM 34508170
OA Green Published, Green Submitted, gold
DA 2022-11-30
ER

PT J
AU Biswas, L
   Zhou, XZ
   Dhillon, B
   Graham, A
   Shu, XH
AF Biswas, Lincoln
   Zhou, Xinzhi
   Dhillon, Baljean
   Graham, Annette
   Shu, Xinhua
TI Retinal pigment epithelium cholesterol efflux mediated by the 18 kDa
   translocator protein, TSPO, a potential target for treating age-related
   macular degeneration
SO HUMAN MOLECULAR GENETICS
LA English
DT Article
ID LIPOPROTEIN-LIKE PARTICLES; BENZODIAZEPINE-RECEPTOR; APOLIPOPROTEIN-E;
   BRUCHS MEMBRANE; EXPRESSION; MICROGLIA; CELLS; TRANSPORT;
   SUSCEPTIBILITY; ACCUMULATION
AB Cholesterol accumulation beneath the retinal pigment epithelium (RPE) cells is supposed to contribute the pathogenesis of age-related macular degeneration (AMD). Cholesterol efflux genes (APOE and ABCA1) were identified as risk factors for AMD, although how cholesterol efflux influences accumulation of this lipid in sub-RPE deposits remains elusive. The 18 kDa translocator protein, TSPO, is a cholesterol-binding protein implicated in mitochondrial cholesterol transport. Here, we investigate the function of TSPO in cholesterol efflux from the RPE cells. We demonstrate in RPE cells that TSPO specific ligands promoted cholesterol efflux to acceptor (apo) lipoprotein and human serum, while loss of TSPO resulted in impaired cholesterol efflux. TSPO-/- RPE cells also had significantly increased production of reactive oxygen species (ROS) and upregulated expression of proinflammatory cytokines (IL-1 beta and TNF alpha). Cholesterol (oxidized LDL) uptake and accumulation were markedly increased in TSPO-/- RPE cells. Finally, in aged RPE cells, TSPO expression was reduced and cholesterol efflux impaired. These findings provide a new pharmacological concept to treat early AMD patients by stimulating cellular cholesterol removal with TSPO specific ligands or by overexpression of TSPO in RPE cells.
C1 [Biswas, Lincoln; Zhou, Xinzhi; Graham, Annette; Shu, Xinhua] Glasgow Caledonian Univ, Dept Life Sci, Glasgow G4 0BA, Lanark, Scotland.
   [Dhillon, Baljean] Univ Edinburgh, Ctr Clin Brain Sci, Edinburgh EH16 4SB, Midlothian, Scotland.
C3 Glasgow Caledonian University; University of Edinburgh
RP Shu, XH (通讯作者)，Glasgow Caledonian Univ, Dept Life Sci, Glasgow G4 0BA, Lanark, Scotland.
EM xinhua.shu@gcu.ac.uk
OI Biswas, Lincoln/0000-0002-2288-341X
FU Rosetrees Trust; Glasgow Children's Hospital Charity; Fight for Sight,
   Eye Research Fund (Edinburgh and Lothian Health Foundation, ELHF);
   Visual Research Trust; Rosetrees Trust [M160-F1] Funding Source:
   researchfish; Fight for Sight [1419/20, URP12] Funding Source:
   researchfish; Glasgow Children&quot;s Hospital Charity
   [YRSS/PSG/2014/06] Funding Source: researchfish
FX We would like to thank the Rosetrees Trust, the Glasgow Children's
   Hospital Charity, the Fight for Sight, Eye Research Fund (Edinburgh and
   Lothian Health Foundation, ELHF), and the Visual Research Trust for
   supporting this work.
CR Abdelsalam A, 1999, SURV OPHTHALMOL, V44, P1, DOI 10.1016/S0039-6257(99)00072-7
   Chen W, 2010, P NATL ACAD SCI USA, V107, P7401, DOI 10.1073/pnas.0912702107
   Cosenza-Nashat M, 2009, NEUROPATH APPL NEURO, V35, P306, DOI 10.1111/j.1365-2990.2008.01006.x
   Curcio CA, 2005, EXP EYE RES, V81, P731, DOI 10.1016/j.exer.2005.04.012
   Curcio CA, 2009, PROG RETIN EYE RES, V28, P393, DOI 10.1016/j.preteyeres.2009.08.001
   Dupont AC, 2017, INT J MOL SCI, V18, DOI 10.3390/ijms18040785
   Ebrahimi KB, 2013, J PATHOL, V229, P729, DOI 10.1002/path.4128
   Falchi AM, 2007, NEUROPHARMACOLOGY, V53, P318, DOI 10.1016/j.neuropharm.2007.05.016
   Fan JJ, 2015, P NATL ACAD SCI USA, V112, P7261, DOI 10.1073/pnas.1502670112
   Feeney-Burns L., 1984, INVEST OPHTH VIS SCI, V25, P95
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P532
   Gliem M, 2015, INVEST OPHTH VIS SCI, V56, P2664, DOI 10.1167/iovs.14-15733
   Gordiyenko N, 2004, INVEST OPHTH VIS SCI, V45, P2822, DOI 10.1167/iovs.04-0074
   Graham A, 2015, FREE RADICAL BIO MED, V89, P982, DOI 10.1016/j.freeradbiomed.2015.08.010
   Guymer R, 1999, PROG RETIN EYE RES, V18, P59, DOI 10.1016/S1350-9462(98)00012-3
   Hayward C, 2003, HUM MOL GENET, V12, P2657, DOI 10.1093/hmg/ddg289
   Hoppe G, 2004, CELL MOL LIFE SCI, V61, P1664, DOI 10.1007/s00018-004-4080-5
   Hoppe G, 2001, INVEST OPHTH VIS SCI, V42, P2714
   Ikonen E, 2006, PHYSIOL REV, V86, P1237, DOI 10.1152/physrev.00022.2005
   Ishida BY, 2006, BRIT J OPHTHALMOL, V90, P616, DOI 10.1136/bjo.2005.085076
   Ishida BY, 2004, J LIPID RES, V45, P263, DOI 10.1194/jlr.M300306-JLR200
   Ishikawa M, 2016, NEUROPHARMACOLOGY, V111, P142, DOI 10.1016/j.neuropharm.2016.09.001
   Ji B, 2008, J NEUROSCI, V28, P12255, DOI 10.1523/JNEUROSCI.2312-08.2008
   Jobling AI, 2015, FASEB J, V29, P696, DOI 10.1096/fj.14-262444
   Karlstetter M, 2014, J NEUROINFLAMM, V11, DOI 10.1186/1742-2094-11-3
   Lakkaraju A, 2007, P NATL ACAD SCI USA, V104, P11026, DOI 10.1073/pnas.0702504104
   Li CM, 2005, INVEST OPHTH VIS SCI, V46, P2576, DOI 10.1167/iovs.05-0034
   Li F, 2016, BIOCHEMISTRY-US, V55, P2821, DOI 10.1021/acs.biochem.6b00142
   Ma KL, 2008, HEPATOLOGY, V48, P770, DOI 10.1002/hep.22423
   Maiolino G, 2013, MEDIAT INFLAMM, V2013, DOI 10.1155/2013/714653
   Morohaku K, 2014, ENDOCRINOLOGY, V155, P89, DOI 10.1210/en.2013-1556
   Neale BM, 2010, P NATL ACAD SCI USA, V107, P7395, DOI 10.1073/pnas.0912019107
   Papadopoulos V, 2015, MOL CELL ENDOCRINOL, V408, P90, DOI 10.1016/j.mce.2015.03.014
   Pikuleva IA, 2014, PROG RETIN EYE RES, V41, P64, DOI 10.1016/j.preteyeres.2014.03.002
   Ruan XZ, 2006, ARTERIOSCL THROM VAS, V26, P1150, DOI 10.1161/01.ATV.0000217957.93135.c2
   Scholz R, 2015, J NEUROINFLAMM, V12, DOI 10.1186/s12974-015-0422-5
   Sene A, 2013, CELL METAB, V17, P549, DOI 10.1016/j.cmet.2013.03.009
   STEPHENSON DT, 1995, J NEUROSCI, V15, P5263
   Tan LX, 2016, P NATL ACAD SCI USA, V113, P8789, DOI 10.1073/pnas.1523061113
   Taylor JMW, 2014, CLIN SCI, V127, P603, DOI 10.1042/CS20140047
   Tserentsoodol N, 2006, MOL VIS, V12, P1319
   Tserentsoodol N, 2006, MOL VIS, V12, P1306
   Tu LN, 2016, ENDOCRINOLOGY, V157, P1110, DOI 10.1210/en.2015-1795
   Tu LN, 2014, J BIOL CHEM, V289, P27444, DOI 10.1074/jbc.M114.578286
   Vavvas DG, 2016, EBIOMEDICINE, V5, P198, DOI 10.1016/j.ebiom.2016.01.033
   Wang MH, 2014, J NEUROSCI, V34, P3793, DOI 10.1523/JNEUROSCI.3153-13.2014
   Yamada Y, 2008, J NEUROCHEM, V105, P1187, DOI 10.1111/j.1471-4159.2008.05211.x
   Zareparsi S, 2005, HUM MOL GENET, V14, P1449, DOI 10.1093/hmg/ddi154
   Zheng WC, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0037926
NR 49
TC 32
Z9 32
U1 0
U2 5
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 0964-6906
EI 1460-2083
J9 HUM MOL GENET
JI Hum. Mol. Genet.
PD NOV 15
PY 2017
VL 26
IS 22
BP 4327
EP 4339
DI 10.1093/hmg/ddx319
PG 13
WC Biochemistry & Molecular Biology; Genetics & Heredity
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Genetics & Heredity
GA FL7CM
UT WOS:000414403900002
PM 28973423
OA Green Submitted, Green Accepted
DA 2022-11-30
ER

PT J
AU Manousaridis, K
   Manjunath, V
   Talks, J
AF Manousaridis, Kleanthis
   Manjunath, Vina
   Talks, James
TI Information used to decide on retreatment of exudative age-related
   macular degeneration with anti-VEGF in clinical practice
SO EUROPEAN JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
DE Anti-VEGF treatment; Exudative age-related macular degeneration; Fundus
   fluorescein angiography; Optical coherence tomography
ID OPTICAL COHERENCE TOMOGRAPHY; OCCULT CHOROIDAL NEOVASCULARIZATION;
   PIGMENT EPITHELIAL DETACHMENT; FUNDUS FLUORESCEIN ANGIOGRAPHY;
   INTRAVITREAL BEVACIZUMAB; DOSING REGIMEN; RANIBIZUMAB; TRIAL
AB Purpose. To record the information used in order to make a retreatment decision in patients with exudative age-related macular degeneration (AMD) and to assess if an optical coherence tomography (OCT)-only follow-up clinic would suffice.
   Methods. Two hundred patients under treatment with intravitreal anti-vascular endothelial growth factor injections (anti-VEGF) for exudative AMD were included. Each patient had previously received at least 3 intravitreal anti-VEGF injections (loading dose) (range 3-24 injections). Clinicians seeing the patients beyond the third injection were asked to document the criteria used to make a retreatment decision.
   Results. Overall, in 171 (85.5%) cases the retreatment decision was based on OCT findings of intraretinal or subretinal fluid alone. Diagnosis of recurrence requiring treatment would have been missed in 12 cases (6%), if OCT-only data had been used and funduscopy or visual function criteria had been omitted. Decision was based solely on functional criteria in only 2% of the cases. The retreatment decision was based on evaluation of morphologic funduscopic or OCT criteria in 187 (93.5%) cases.
   Conclusions. With the increasing number of patients having follow-up after anti-VEGF treatment, efficient systems of follow-up are required. Although most retreatment decisions could have been made by qualitative assessment of OCT images alone, the examination has considerable limitations. Optical coherence tomography in combination with color fundus photography could serve as screening tools for a rational implementation of other invasive imaging techniques such as fundus fluorescein angiography and indocyanine green angiography in decision-making.
C1 [Manousaridis, Kleanthis; Manjunath, Vina; Talks, James] NHS Fdn Trust, Dept Ophthalmol, Royal Victoria Infirm, Newcastle Upon Tyne Hosp, Newcastle Upon Tyne NE1 4LP, Tyne & Wear, England.
C3 Newcastle University - UK; Newcastle Upon Tyne Hospitals NHS Foundation
   Trust
RP Manousaridis, K (通讯作者)，NHS Fdn Trust, Dept Ophthalmol, Royal Victoria Infirm, Newcastle Upon Tyne Hosp, Queen Victoria Rd, Newcastle Upon Tyne NE1 4LP, Tyne & Wear, England.
EM kleanthis.manousaridis@googlemail.com
CR Ach T, 2010, RETINA-J RET VIT DIS, V30, P1420, DOI 10.1097/IAE.0b013e3181d87e97
   Antcliff RJ, 2000, OPHTHALMOLOGY, V107, P593, DOI 10.1016/S0161-6420(99)00087-1
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Chen E, 2007, RETINA-J RET VIT DIS, V27, P445, DOI 10.1097/01.iae.0000249574.89437.40
   Cho M, 2009, AM J OPHTHALMOL, V148, P70, DOI 10.1016/j.ajo.2009.02.012
   Cohen SY, 2010, AM J OPHTHALMOL, V150, P211, DOI 10.1016/j.ajo.2010.02.019
   Costagliola C, 2009, GRAEF ARCH CLIN EXP, V247, P1031, DOI 10.1007/s00417-009-1081-y
   Fung AE, 2007, AM J OPHTHALMOL, V143, P566, DOI 10.1016/j.ajo.2007.01.028
   Golbaz I, 2011, INVEST OPHTH VIS SCI, V52, P1599, DOI 10.1167/iovs.09-5018
   Holz FG, 2011, OPHTHALMOLOGY, V118, P663, DOI 10.1016/j.ophtha.2010.12.019
   Kaiser PK, 2007, OPHTHALMOLOGY, V114, P1868, DOI 10.1016/j.ophtha.2007.04.030
   Keane PA, 2008, INVEST OPHTH VIS SCI, V49, P3115, DOI 10.1167/iovs.08-1689
   Lalwani GA, 2009, AM J OPHTHALMOL, V148, P43, DOI 10.1016/j.ajo.2009.01.024
   Martin DF, 2011, NEW ENGL J MED, V364, P1897, DOI 10.1056/NEJMoa1102673
   Pedersen KB, 2009, ACTA OPHTHALMOL, V87, P714, DOI 10.1111/j.1755-3768.2008.01346.x
   Prenner JL, 2009, OPHTHALMOLOGY, V116, P1590, DOI 10.1016/j.ophtha.2009.04.007
   Querques G, 2012, GRAEF ARCH CLIN EXP, V250, P479, DOI 10.1007/s00417-011-1831-5
   Querques G, 2011, AM J OPHTHALMOL, V152, P100, DOI 10.1016/j.ajo.2011.01.027
   Regillo CD, 2008, AM J OPHTHALMOL, V145, P239, DOI 10.1016/j.ajo.2007.10.004
   Ritter M, 2010, EYE, V24, P962, DOI 10.1038/eye.2009.265
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Sadda SR, 2006, OPHTHALMOLOGY, V113, P285, DOI 10.1016/j.ophtha.2005.10.005
   Sandhu SS, 2005, BRIT J OPHTHALMOL, V89, P967, DOI 10.1136/bjo.2004.060863
   Sato T, 2004, RETINA-J RET VIT DIS, V24, P910, DOI 10.1097/00006982-200412000-00011
   Schmidt-Erfurth U, 2011, OPHTHALMOLOGY, V118, P831, DOI 10.1016/j.ophtha.2010.09.004
   Thi HCT, 2011, OPHTHAL SURG LAS IM, V42, P498, DOI 10.3928/15428877-20110804-04
   Wong T, 2008, OPHTHALMOLOGY, V115, P116, DOI 10.1016/j.ophtha.2007.03.008
NR 27
TC 3
Z9 3
U1 0
U2 1
PU SAGE PUBLICATIONS LTD
PI LONDON
PA 1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND
SN 1120-6721
EI 1724-6016
J9 EUR J OPHTHALMOL
JI Eur. J. Ophthalmol.
PD JAN-FEB
PY 2013
VL 23
IS 1
BP 108
EP 113
DI 10.5301/ejo.5000190
PG 6
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 224VC
UT WOS:000324917500016
PM 22890600
DA 2022-11-30
ER

PT J
AU Bian, W
   Wan, JL
   Tan, MQ
   Wu, XQ
   Su, J
   Wang, LH
AF Bian, Wei
   Wan, Junli
   Tan, Mingqiong
   Wu, Xiaoqing
   Su, Jun
   Wang, Lihua
TI Patient experience of treatment decision making for wet age-related
   macular degeneration disease: a qualitative study in China
SO BMJ OPEN
LA English
DT Article
DE treatment decision making; age-related macular degeneration; qualitative
   study
ID ANTI-VEGF TREATMENT; PREFERENCES; CHOICE; REHABILITATION; PARTICIPATION;
   INVOLVEMENT; VISION; CANCER; CARE
AB Objectives This study aimed to investigate the experience of patients with wet age-related macular degeneration (wAMD) in treatment decision-making process.
   Design A descriptive qualitative study was designed by using semistructured interviews, and the data analysis was conducted with the thematic analysis approach.
   Participants and setting A convenient and purposive sample of 21 participants diagnosed with wAMD was recruited from May 2018 to September 2018. The study was conducted in the Eye Clinic of Southwest Hospital of Army Medical University in Chongqing located in the southwest of China.
   Results The mean age of the participants was 64.48 years (ranging 50-81 years), and the duration of the disease ranged from 6 months to 48 months. Four major themes were identified from the original data analysis. These themes included facing the darkness (choosing from light and darkness and living in pain), constraints on decision making (doctor-oriented decision making, inadequacy of options and time), weighing alternatives (family influence, financial burden and maintaining social function) and decision-making support (professional decision-making assistance and peer support).
   Conclusion This is a qualitative study attempting to explore the patient experience of treatment decision making for wAMD disease in China. Previous literature has focused on treatment effect and symptoms, rather than the individual experience and the wide contexts from a sociocultural perspective. Further studies, such as cross-sectional studies, can be used to describe the status and determine the influencing factors of decision0making process, so as to develop an impact factor model of decision making and to formulate an intervention for patients with wAMD.
C1 [Bian, Wei; Wan, Junli; Tan, Mingqiong; Su, Jun] Third Mil Med Univ, Amy Med Univ, Southwest Hosp, Southwest Eye Hosp, Chongqing, Peoples R China.
   [Bian, Wei; Wan, Junli; Tan, Mingqiong; Su, Jun] Key Lab Visual Damage & Regenerat & Restorat Chon, Chongqing, Peoples R China.
   [Wu, Xiaoqing] Army Mil Med Univ, Southwest Hosp, Outpatient Dept, Chongqing, Peoples R China.
   [Wang, Lihua] Army Med Univ, Southwest Hosp, Admin Off, Chongqing, Peoples R China.
C3 Army Medical University; Army Medical University; Army Medical
   University
RP Wang, LH (通讯作者)，Army Med Univ, Southwest Hosp, Admin Off, Chongqing, Peoples R China.
EM 3146183418@qq.com
FU Chongqing Technology Innovation and Application Demonstration (Social
   and Livelihood General) Project [cstc2018jscxmsybX0129]; Chongqing
   Social Science Planning Youth Project [2018QNSH42]; Chongqing
   Postgraduate Education and Teaching Reform Project [yjg172013]
FX This study was funded by the Chongqing Technology Innovation and
   Application Demonstration (Social and Livelihood General) Project
   (cstc2018jscxmsybX0129), Chongqing Social Science Planning Youth Project
   (2018QNSH42) and Chongqing Postgraduate Education and Teaching Reform
   Project (yjg172013).
CR Bambara JK, 2009, J VISUAL IMPAIR BLIN, V103, P137, DOI 10.1177/0145482X0910300303
   Bernstein PS, 1996, RETINA-J RET VIT DIS, V16, P112, DOI 10.1097/00006982-199616020-00004
   Bian W, 2018, BMJ OPEN, V8, DOI 10.1136/bmjopen-2017-018756
   Boyle J, 2015, PSYCHOL HEALTH MED, V20, P296, DOI 10.1080/13548506.2014.936886
   Bradley P, 2005, INT C SER, V1282, P211, DOI DOI 10.1016/J.ICS.2005.04.001
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Buetow S, 2010, J HEALTH SERV RES PO, V15, P123, DOI 10.1258/jhsrp.2009.009081
   Clark Noreen M, 2009, Open Nurs J, V3, P65, DOI 10.2174/1874434600903010065
   Danner M, 2017, VALUE HEALTH, V20, P1166, DOI 10.1016/j.jval.2017.04.022
   Ekdahl AW, 2011, BMC GERIATR, V11, DOI 10.1186/1471-2318-11-46
   Emsfors A, 2017, J CLIN NURS, V26, P2680, DOI 10.1111/jocn.13749
   Feely M, 2007, J VISUAL IMPAIR BLIN, V101, P44, DOI 10.1177/0145482X0710100106
   Fisher DE, 2015, OPHTHALMOLOGY, V122, P382, DOI 10.1016/j.ophtha.2014.08.006
   Fraenkel L, 2007, MED DECIS MAKING, V27, P533, DOI 10.1177/0272989x07306784
   Gong HS, 2011, J BONE JOINT SURG AM, V93A, P1527, DOI 10.2106/JBJS.J.00951
   Mestre AG, 2014, ENFERM CLIN, V24, P67, DOI 10.1016/j.enfcli.2013.11.005
   Harding SP, 2010, EYE, V24, P497, DOI 10.1038/eye.2009.316
   Hirpara DH, 2016, CAN J SURG, V59, P197, DOI 10.1503/cjs.013415
   Hubbard G, 2008, EUR J ONCOL NURS, V12, P299, DOI 10.1016/j.ejon.2008.03.004
   Jackson ML, 2006, CAN J OPHTHALMOL, V41, P355, DOI 10.1139/I06-021
   Janzen KJ, 2016, QUALITATIVE REPORT, V21
   Joseph-Williams N, 2014, PATIENT EDUC COUNS, V94, P291, DOI 10.1016/j.pec.2013.10.031
   Lee A, 2008, NEPHROL DIAL TRANSPL, V23, P3953, DOI 10.1093/ndt/gfn365
   McCloud C, 2014, OPTOMETRY VISION SCI, V91, P966, DOI 10.1097/OPX.0000000000000320
   Mitchell P, 2018, LANCET, V392, P1147, DOI 10.1016/S0140-6736(18)31550-2
   Moore LW, 2000, WESTERN J NURS RES, V22, P571, DOI 10.1177/01939450022044601
   Mueller S, 2016, OPHTHALMOLOGY, V123, P876, DOI 10.1016/j.ophtha.2015.12.001
   O'Connor AM, 2009, COCHRANE DB SYST REV, DOI [10.1002/14651858.CD001431.pub2, 10.1002/14651858.CD001431.pub3, 10.1002/14651858.CD001431.pub4]
   Pope C, 2000, BMJ-BRIT MED J, V320, P114, DOI 10.1136/bmj.320.7227.114
   Reeves BC, 2016, BMJ OPEN, V6, DOI 10.1136/bmjopen-2015-010685
   Senra H, 2017, AM J OPHTHALMOL, V177, P213, DOI 10.1016/j.ajo.2017.03.005
   Shum JWH, 2017, BMJ OPEN OPHTHALMOL, V2, DOI 10.1136/bmjophth-2017-000100
   Spatz ES, 2017, JAMA-J AM MED ASSOC, V317, P1309, DOI 10.1001/jama.2017.0616
   Stevens R, 2017, BRIT J VISUAL IMPA, V35, P185, DOI 10.1177/0264619616683989
   Swanson MW, 2012, OPTOMETRY VISION SCI, V89, pE23, DOI 10.1097/OPX.0b013e31826a3d85
   Tak HJ, 2013, JAMA INTERN MED, V173, P1195, DOI 10.1001/jamainternmed.2013.6048
   Tollow P, 2019, PSYCHO-ONCOLOGY, V28, P1328, DOI 10.1002/pon.5086
   Yasmin S, 2012, COMMUNITY EYE HLTH, V25
NR 38
TC 6
Z9 7
U1 1
U2 2
PU BMJ PUBLISHING GROUP
PI LONDON
PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND
SN 2044-6055
J9 BMJ OPEN
JI BMJ Open
PD SEP
PY 2019
VL 9
IS 9
AR e031020
DI 10.1136/bmjopen-2019-031020
PG 7
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)
SC General & Internal Medicine
GA JO7XE
UT WOS:000497787600334
PM 31481567
OA Green Published, gold
DA 2022-11-30
ER

PT J
AU Oliver-Fernandez, M
   Bakal, J
   Segal, S
   Shah, GK
   Dugar, A
   Sharma, S
AF Oliver-Fernandez, M
   Bakal, J
   Segal, S
   Shah, GK
   Dugar, A
   Sharma, S
TI Progression of visual loss and time between initial assessment and
   treatment of wet age-related macular degeneration
SO CANADIAN JOURNAL OF OPHTHALMOLOGY-JOURNAL CANADIEN D OPHTALMOLOGIE
LA English
DT Article
DE age factor; choroidal neovascularization; low vision; macular
   degeneration; pegaptanib; treatment delays
ID SUBFOVEAL CHOROIDAL NEOVASCULARIZATION; LASER PHOTOCOAGULATION;
   PHOTODYNAMIC THERAPY; VERTEPORFIN THERAPY; MEMBRANES; OUTCOMES; ACUITY
AB Purpose: To determine whether the time elapsed from initial (referral) diagnosis of neovascular (wet) age-related macular degeneration (AMD) to assessment and treatment by a retinal specialist is associated with visual deterioration in the intervening period.
   Methods: A prospective pilot study of 38 consecutive AMD patients who presented with newly diagnosed subfoveal choroidal neovascularization was conducted in a tertiary care retinal practice. All eligible subjects underwent clinical examination and digital fluorescein angiography at the time of assessment by a retinal specialist. Correlations were performed to assess the association between continuous independent variables and any visual deterioration since initial diagnosis. Multivariate linear regression models with stepwise techniques were used to evaluate any association between visual progression and time elapsed, while controlling for potential clinical covariates.
   Results: Of the 38 patients, 32 (84%) met the inclusion and exclusion criteria; no differences in important variables were noted between those included and those excluded. The median time between initial diagnosis and referral assessment and treatment was 28 days (interquartile range = 36.5 days); some degree of visual loss developed in 14 (44%) of the subjects. The elapsed time was correlated with progression of visual loss (r = 0.50, P = 0.003). Multivariate linear regression demonstrated that only time elapsed and lesion type based on fluorescein angiography were associated with progression of visual loss (R-2 = 0.49 1, F(4,28) = 6.744, P = 0.00 1); lesion size, age and sex were not significantly associated with progression of visual loss.
   Interpretation: Delay in assessment and treatment of new-onset wet AMD by a retinal specialist is associated with a higher risk of visual loss.
C1 Indiana Univ, Dept Ophthalmol, Indianapolis, IN USA.
   Queens Univ, Cost Effect Ocular Hlth Policy Unit, Kingston, ON, Canada.
   Washington Univ, Barnes Retina Inst, St Louis, MO USA.
   Pfizer Inc, New York, NY USA.
C3 Indiana University System; Indiana University-Purdue University
   Indianapolis; Queens University - Canada; Washington University (WUSTL);
   Pfizer
RP Sharma, S (通讯作者)，Queens Univ, Hop Hotel Dieu, Cost Effect Ocular Hlth Policy Unit, Block 2-224B,166 Brock St, Kingston, ON K7L 5G2, Canada.
RI Bakal, Jeff/ABE-4051-2021
OI Bakal, Jeffrey/0000-0002-3658-2554
CR Armbrecht AM, 2004, BRIT J OPHTHALMOL, V88, P1270, DOI 10.1136/bjo.2003.038604
   Bressler NM, 2002, ARCH OPHTHALMOL-CHIC, V120, P1443
   Bressler NM, 2000, ARCH OPHTHALMOL-CHIC, V118, P488
   Bressler NM, 1999, ARCH OPHTHALMOL-CHIC, V117, P1329
   Brown GC, 2000, ARCH OPHTHALMOL-CHIC, V118, P47
   Childs AL, 2004, AM J OPHTHALMOL, V137, P373, DOI 10.1016/S0002-9394(03)00911-5
   Clemons TE, 2003, ARCH OPHTHALMOL-CHIC, V121, P211
   DAMICO DJ, 2003, OPHTHALMOLOGY, V110, P2384
   Fujii GY, 2003, AM J OPHTHALMOL, V136, P1067, DOI 10.1016/S0002-9394(03)00663-9
   Goldberg RJ, 2002, BEHAV HEALTHC TOM, V11, P11
   Gragoudas ES, 2004, NEW ENGL J MED, V351, P2805, DOI 10.1056/NEJMoa042760
   Hatch WV, 2004, CAN J OPHTHALMOL, V39, P31, DOI 10.1016/S0008-4182(04)80050-4
   KLEIN ML, 1989, OPHTHALMOLOGY, V96, P1416
   Mackenzie PJ, 2002, OPHTHALMOLOGY, V109, P720, DOI 10.1016/S0161-6420(01)01021-1
   Nast S, 2004, CAN J CARDIOL, V20, P325
   *NCQA, 2004, QUAL LETT HEALTHC LE, V16, P12
   Rubin GS, 2002, RETINA-J RET VIT DIS, V22, P536, DOI 10.1097/00006982-200210000-00002
   Russell S, 2003, OPHTHALMOLOGY, V110, P2372, DOI 10.1016/j.ophtha.2003.08.020
   SCHACHAT AP, 1994, ARCH OPHTHALMOL-CHIC, V112, P500
   Sharma S, 2000, CAN J OPHTHALMOL, V35, P267, DOI 10.1016/S0008-4182(00)80077-0
   Smith W, 2001, OPHTHALMOLOGY, V108, P697, DOI 10.1016/S0161-6420(00)00580-7
   STERNBERG P, 1991, ARCH OPHTHALMOL-CHIC, V109, P1220
   VANDER JF, 1989, OPHTHALMOLOGY, V96, P1422
   Zaidi FH, 2004, EYE, V18, P503, DOI 10.1038/sj.eye.6700708
NR 24
TC 33
Z9 33
U1 0
U2 0
PU CANADIAN OPHTHAL SOC
PI OTTAWA
PA 1525 CARLING AVE SUITE 610, OTTAWA, ONTARIO K1Z 8R9, CANADA
SN 0008-4182
J9 CAN J OPHTHALMOL
JI Can. J. Opthalmol.-J. Can. Opthalmol.
PD JUN
PY 2005
VL 40
IS 3
BP 313
EP 319
DI 10.1016/S0008-4182(05)80074-2
PG 7
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 941RH
UT WOS:000230231400007
PM 15947801
DA 2022-11-30
ER

PT J
AU Jin, K
   Yan, Y
   Chen, ML
   Wang, J
   Pan, XJ
   Liu, XD
   Liu, MS
   Lou, LX
   Wang, Y
   Ye, J
AF Jin, Kai
   Yan, Yan
   Chen, Menglu
   Wang, Jun
   Pan, Xiangji
   Liu, Xindi
   Liu, Mushui
   Lou, Lixia
   Wang, Yao
   Ye, Juan
TI Multimodal deep learning with feature level fusion for identification of
   choroidal neovascularization activity in age-related macular
   degeneration
SO ACTA OPHTHALMOLOGICA
LA English
DT Article
DE age-related macular degeneration; choroidal neovascularization activity;
   feature level fusion; multimodal deep learning
ID DISEASES; IMAGES
AB Purpose This study aimed to determine the efficacy of a multimodal deep learning (DL) model using optical coherence tomography (OCT) and optical coherence tomography angiography (OCTA) images for the assessment of choroidal neovascularization (CNV) in neovascular age-related macular degeneration (AMD). Methods This retrospective and cross-sectional study was performed at a multicentre, and the inclusion criteria were age >50 years and a diagnosis of typical neovascular AMD. The OCT and OCTA data for an internal data set and two external data sets were collected. A DL model was developed with a novel feature-level fusion (FLF) method utilized to combine the multimodal data. The results were compared with identification performed by an ophthalmologist. The best model was tested on two external data sets to show its potential for clinical use. Results Our best model achieved an accuracy of 95.5% and an area under the curve (AUC) of 0.9796 on multimodal data inputs for the internal data set, which is comparable to the performance of retinal specialists. The proposed model reached an accuracy of 100.00% and an AUC of 1.0 for the Ningbo data set, and these performance indicators were 90.48% and an AUC of 0.9727 for the Jinhua data set. Conclusion The FLF method is feasible and highly accurate, and could enhance the power of the existing computer-aided diagnosis systems. The bi-modal computer-aided diagnosis (CADx) system for the automated identification of CNV activity is an accurate and promising tool in the realm of public health.
C1 [Jin, Kai; Yan, Yan; Chen, Menglu; Pan, Xiangji; Liu, Xindi; Lou, Lixia; Wang, Yao; Ye, Juan] Zhejiang Univ, Affiliated Hosp 2, Coll Med, Dept Ophthalmol, Hangzhou 310009, Peoples R China.
   [Wang, Jun] Shanghai Jiao Tong Univ, Sch Biomed Engn, Shanghai, Peoples R China.
   [Liu, Mushui] Zhejiang Univ, Coll Comp Sci & Technol, Hangzhou, Peoples R China.
C3 Zhejiang University; Shanghai Jiao Tong University; Zhejiang University
RP Wang, Y; Ye, J (通讯作者)，Zhejiang Univ, Affiliated Hosp 2, Coll Med, Dept Ophthalmol, Hangzhou 310009, Peoples R China.
EM wangyao@zju.edu.cn; yejuan@zju.edu.cn
OI Jin, Kai/0000-0003-4369-2417
FU National Key Research and Development Program of China [2019YFC0118401];
   Zhejiang Provincial Key Research and Development Plan [2019C03020];
   Natural Science Foundation of Zhejiang Province [LQ21H120002]; Medical
   and Health Science and Technology Program of Zhejiang Province
   [2021RC064]; Natural Science Foundation of China [81670888]; ZJU-BIOMIND
   Medical Artificial Intelligence Research
FX This work was financially supported by the National Key Research and
   Development Program of China (grant number 2019YFC0118401), Zhejiang
   Provincial Key Research and Development Plan (grant number 2019C03020),
   Natural Science Foundation of Zhejiang Province (grant number
   LQ21H120002), Medical and Health Science and Technology Program of
   Zhejiang Province (grant number 2021RC064), the Natural Science
   Foundation of China (grant number 81670888) and ZJU-BIOMIND Medical
   Artificial Intelligence Research.
CR Al-Sheikh M, 2018, RETINA-J RET VIT DIS, V38, P220, DOI 10.1097/IAE.0000000000001628
   Arrigo A, 2020, TRANSL VIS SCI TECHN, V9, DOI 10.1167/tvst.9.9.48
   Bae K, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-55871-8
   Burlina PM, 2017, JAMA OPHTHALMOL, V135, P1170, DOI 10.1001/jamaophthalmol.2017.3782
   Chen TT, 2019, LECT NOTES COMPUT SC, V11764, P329, DOI 10.1007/978-3-030-32239-7_37
   Coscas F, 2019, BRIT J OPHTHALMOL, V103, P1342, DOI 10.1136/bjophthalmol-2018-313065
   Coscas GJ, 2015, RETINA-J RET VIT DIS, V35, P2219, DOI 10.1097/IAE.0000000000000766
   Grassmann F, 2018, OPHTHALMOLOGY, V125, P1410, DOI 10.1016/j.ophtha.2018.02.037
   Gualino V, 2019, RETINA-J RET VIT DIS, V39, P1664, DOI 10.1097/IAE.0000000000002220
   Hwang DK, 2019, THERANOSTICS, V9, P232, DOI 10.7150/thno.28447
   Inoue M, 2016, INVEST OPHTH VIS SCI, V57, pOCT314, DOI 10.1167/iovs.15-18900
   Jager RD, 2008, NEW ENGL J MED, V358, P2606, DOI 10.1056/NEJMra0801537
   Kermany DS, 2018, CELL, V172, P1122, DOI 10.1016/j.cell.2018.02.010
   Lee CS, 2017, OPHTHALMOL RETINA, V1, P322, DOI 10.1016/j.oret.2016.12.009
   Maguire MG, 2016, OPHTHALMOLOGY, V123, P1751, DOI 10.1016/j.ophtha.2016.03.045
   Miotto S, 2018, J OCUL PHARMACOL TH, V34, P298, DOI 10.1089/jop.2017.0022
   Mitchell P, 2018, LANCET, V392, P1147, DOI 10.1016/S0140-6736(18)31550-2
   Sandhu HS, 2020, AM J OPHTHALMOL, V216, P201, DOI 10.1016/j.ajo.2020.01.016
   Ting DSW, 2019, BRIT J OPHTHALMOL, V103, P167, DOI 10.1136/bjophthalmol-2018-313173
   Ting DSW, 2017, JAMA-J AM MED ASSOC, V318, P2211, DOI 10.1001/jama.2017.18152
   Treder M, 2018, GRAEF ARCH CLIN EXP, V256, P2053, DOI 10.1007/s00417-018-4098-2
   von der Emde L, 2020, OPHTHALMOLOGICA, V243, P120, DOI 10.1159/000503609
   Wong T, 2008, OPHTHALMOLOGY, V115, P116, DOI 10.1016/j.ophtha.2007.03.008
   Yang J., 2020, BRIT J OPHTHALMOL
   Yoo TK, 2019, MED BIOL ENG COMPUT, V57, P677, DOI 10.1007/s11517-018-1915-z
   Zeydanli EO, 2021, EUR J OPHTHALMOL, V31, P1192, DOI 10.1177/1120672120925790
NR 26
TC 35
Z9 35
U1 3
U2 18
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1755-375X
EI 1755-3768
J9 ACTA OPHTHALMOL
JI Acta Ophthalmol.
PD MAR
PY 2022
VL 100
IS 2
BP E512
EP E520
DI 10.1111/aos.14928
EA JUN 2021
PG 9
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA YX9MP
UT WOS:000664437500001
PM 34159761
DA 2022-11-30
ER

PT J
AU Curcio, CA
   Balaratnasingam, C
   Messinger, JD
   Yannuzzi, LA
   Freund, KB
AF Curcio, Christine A.
   Balaratnasingam, Chandrakumar
   Messinger, Jeffrey D.
   Yannuzzi, Lawrence A.
   Freund, K. Bailey
TI Correlation of Type 1 Neovascularization Associated With Acquired
   Vitelliform Lesion in the Setting of Age-Related Macular Degeneration
SO AMERICAN JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
ID OPTICAL COHERENCE TOMOGRAPHY; POLYPOIDAL CHOROIDAL VASCULOPATHY;
   INDOCYANINE GREEN ANGIOGRAPHY; PIGMENT EPITHELIAL DETACHMENT; OUTER
   RETINAL TUBULATION; CLINICOPATHOLOGICAL CORRELATION; DYSTROPHY;
   CLASSIFICATION; DEPOSITS; DRUSEN
AB PURPOSE: To correlate postmortem histology with previously recorded multimoclal imaging from a patient with type 1 neovascularization (NV) associated with an acquired vitelliform lesion in the setting of age-related macular degeneration (AMD).
   DESIGN: Case study. METHODS: Multimodal imaging that was obtained antemortem was matched with ex vivo and high-resolution histologic images of the preserved donor macula. Anatomic correlates for multimodal imaging findings were then defined.
   RESULTS: Spectral-domain optical coherence tomography (OCT) revealed a split in the retinal pigment epithelium Bruch membrane band. Type 1 NV in this case was composed of 6 layered components: (1) retinal pigment epithelium, (2) basal laminar deposits, (3) fibrovascular membrane, (4) fibrocellular scar, (5) hemorrhage, and (6) Bruch membrane. The anatomic correlates for the hyporeflective band on spectral-domain OCT included a thick basal laminar deposit. Not all structures could be readily separated on the basis of their reflectivity patterns.
   CONCLUSIONS: This is an important clinicopathologic correlation of NV secondary to AMD in the spectral-domain OCT era. Our findings of 6 layers include and extend the anatomic framework encapsulated by the double-layer and triple-layer signs. The resolution of current devices does not always permit distinction of the different layers of NV tissue. Thick basal laminar deposits may appear hyporeflective on spectral-domain OCT and may be confused with fluid from a neovascular process. It will be important to perform a larger dinicopathologic series to aid our anatomic interpretation of spectral-domain OCT images. (C) 2015 by Elsevier Inc. All rights reserved.
C1 [Curcio, Christine A.; Messinger, Jeffrey D.] Univ Alabama Birmingham, Sch Med, Dept Ophthalmol, Birmingham, AL USA.
   [Balaratnasingam, Chandrakumar; Yannuzzi, Lawrence A.; Freund, K. Bailey] Manhattan Eye Ear & Throat Hosp, LuEsther T Mertz Retinal Res Ctr, New York, NY 10021 USA.
   [Balaratnasingam, Chandrakumar; Yannuzzi, Lawrence A.; Freund, K. Bailey] Vitreous Retina Macula Consultants New York, New York, NY 10022 USA.
   [Balaratnasingam, Chandrakumar] Univ Western Australia, Dept Physiol & Pharmacol, Ctr Ophthalmol & Visual Sci, Lions Eye Inst, Perth, WA 6009, Australia.
   [Freund, K. Bailey] NYU, Sch Med, Dept Ophthalmol, New York, NY USA.
C3 University of Alabama System; University of Alabama Birmingham;
   Manhattan Eye Ear & Throat Hospital; Vitreous Retina Macula Consultants
   of New York; Lions Eye Institute; University of Western Australia; New
   York University
RP Freund, KB (通讯作者)，Vitreous Retina Macula Consultants New York, 460 Pk Ave,5th Floor, New York, NY 10022 USA.
EM kbfnyf@aol.com
RI Freund, K. Bailey/V-7488-2018
OI Freund, K. Bailey/0000-0002-7888-9773
FU LUESTHER T. MERTZ RETINAL RESEARCH CENTER, MANHATTAN EYE, EAR AND THROAT
   HOSPITAL, NEW York, New York, USA; Macula Foundation, Inc, New York, New
   York, USA; NEI [EY06109]; Research to Prevent Blindness, Inc; EyeSight
   Foundation of America; NATIONAL EYE INSTITUTE [R01EY006109] Funding
   Source: NIH RePORTER
FX LUESTHER T. MERTZ RETINAL RESEARCH CENTER, MANHATTAN EYE, EAR AND THROAT
   HOSPITAL, NEW York, New York, USA, and The Macula Foundation, Inc, New
   York, New York, USA; NEI EY06109; Research to Prevent Blindness, Inc;
   EyeSight Foundation of America. The funding organizations had no role in
   the design or conduct of this research. K. Bailey Freund is a consultant
   for Genentech (South San: Francisco, California, USA), Optovue (Fremont,
   California, USA), Heidelberg Engineering (Carlsbad, California, USA),
   Optos (Marlborough, Massachusetts, USA), and Thrombogenics (Iselin, New
   Jersey, USA). Lawrence A. Yannuzzi receives an honorarium from Genentech
   (South San Francisco, California, USA) for the retina fellow teaching
   program. The following authors have no financial disclosures: Christine
   A. Curcio, Chandrakumar Balaratnasingam, and Jeffrey D. Messinger. All
   authors attest that they meet the current ICMJE criteria for authorship.
CR Alten F, 2015, BRIT J OPHTHALMOL, V99, P717, DOI 10.1136/bjophthalmol-2014-305339
   BRESSLER SB, 1992, ARCH OPHTHALMOL-CHIC, V110, P827, DOI 10.1001/archopht.1992.01080180099035
   CHANG TS, 1994, RETINA-J RET VIT DIS, V14, P114, DOI 10.1097/00006982-199414020-00004
   Curcio CA, 2005, EXP EYE RES, V80, P761, DOI 10.1016/j.exer.2004.09.017
   Curcio CA, 1999, ARCH OPHTHALMOL-CHIC, V117, P329, DOI 10.1001/archopht.117.3.329
   Curcio CA, 2013, RETINA-J RET VIT DIS, V33, P265, DOI 10.1097/IAE.0b013e31827e25e0
   Dansingani KK, 2015, EYE, V29, P703, DOI 10.1038/eye.2015.27
   Felbor U, 1997, HUM MUTAT, V10, P301, DOI 10.1002/(SICI)1098-1004(1997)10:4<301::AID-HUMU6>3.0.CO;2-J
   Ferris FL, 2013, OPHTHALMOLOGY, V120, P844, DOI 10.1016/j.ophtha.2012.10.036
   Freund KB, 2011, RETINA-J RET VIT DIS, V31, P13, DOI 10.1097/IAE.0b013e3181ea48ba
   Freund KB, 2010, RETINA-J RET VIT DIS, V30, P1333, DOI 10.1097/IAE.0b013e3181e7976b
   Golbaz I, 2011, INVEST OPHTH VIS SCI, V52, P1599, DOI 10.1167/iovs.09-5018
   Green W R, 1977, Trans Am Ophthalmol Soc, V75, P180
   GREEN WR, 1993, OPHTHALMOLOGY, V100, P1519
   Grossniklaus HE, 2006, AM J OPHTHALMOL, V141, P93, DOI 10.1016/j.ajo.2005.07.076
   Haimovici R, 2002, EYE, V16, P7, DOI 10.1038/sj.eye.6700018
   Honda S, 2014, OPHTHALMOLOGICA, V231, P59, DOI 10.1159/000355488
   Jung JJ, 2014, AM J OPHTHALMOL, V158, P769, DOI 10.1016/j.ajo.2014.07.006
   Kawamura A, 2013, ACTA OPHTHALMOL, V91, pe474, DOI 10.1111/aos.12110
   Khan S, 2012, RETINA-J RET VIT DIS, V32, P1057, DOI 10.1097/IAE.0b013e31823beb14
   Klein ML, 2011, AM J OPHTHALMOL, V151, P161, DOI 10.1016/j.ajo.2010.07.020
   Kuntz CA, 1996, INVEST OPHTH VIS SCI, V37, P1772
   Lauer AK, 2000, RETINA-J RET VIT DIS, V20, P492, DOI 10.1097/00006982-200009000-00010
   Lima LH, 2012, RETINA-J RET VIT DIS, V32, P647, DOI 10.1097/IAE.0b013e31823fb847
   Litts KM, 2015, JAMA OPHTHALMOL, V133, P609, DOI 10.1001/jamaophthalmol.2015.126
   Monson DM, 2008, ARCH OPHTHALMOL-CHIC, V126, P1664, DOI 10.1001/archopht.126.12.1664
   Mukai R, 2014, BMC OPHTHALMOL, V14, DOI 10.1186/1471-2415-14-159
   Nakashizuka H, 2008, INVEST OPHTH VIS SCI, V49, P4729, DOI 10.1167/iovs.08-2134
   Ooto S, 2014, JAMA OPHTHALMOL, V132, P806, DOI 10.1001/jamaophthalmol.2014.1871
   PIGUET B, 1995, EYE, V9, P34, DOI 10.1038/eye.1995.5
   POLKINGHORNE PJ, 1989, OPHTHALMOLOGY, V96, P1763
   Querques G, 2008, AM J OPHTHALMOL, V146, P135, DOI 10.1016/j.ajo.2008.02.017
   Querques Giuseppe, 2014, Mol Vis, V20, P575
   Querques G, 2011, AM J OPHTHALMOL, V152, P304, DOI 10.1016/j.ajo.2011.01.047
   Rahimy E, 2014, RETINA-J RET VIT DIS, V34, P1289, DOI 10.1097/IAE.0000000000000130
   Regatieri Caio V, 2011, Ophthalmic Surg Lasers Imaging, V42 Suppl, pS56, DOI 10.3928/15428877-20110627-05
   Sarks JP, 1997, EYE, V11, P515, DOI 10.1038/eye.1997.137
   SARKS SH, 1976, BRIT J OPHTHALMOL, V60, P324, DOI 10.1136/bjo.60.5.324
   Sarks S, 2007, INVEST OPHTH VIS SCI, V48, P968, DOI 10.1167/iovs.06-0443
   Sato T, 2007, RETINA-J RET VIT DIS, V27, P589, DOI 10.1097/01.iae.0000249386.63482.05
   Sayegh RG, 2011, OPHTHALMOLOGY, V118, P1844, DOI 10.1016/j.ophtha.2011.01.043
   Schaal KB, 2015, RETINA-J RET VIT DIS, V35, P1339, DOI 10.1097/IAE.0000000000000471
   SMALL ML, 1976, ARCH OPHTHALMOL-CHIC, V94, P601, DOI 10.1001/archopht.1976.03910030287008
   Spaide RF, 2003, RETINA-J RET VIT DIS, V23, P595, DOI 10.1097/00006982-200310000-00001
   Spaide RF, 2015, AM J OPHTHALMOL, V160, P6, DOI 10.1016/j.ajo.2015.04.012
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
   Zanzottera EC, 2015, INVEST OPHTH VIS SCI, V56, P3253, DOI 10.1167/iovs.15-16431
   Zhang K, 2002, ARCH OPHTHALMOL-CHIC, V120, P485
NR 48
TC 28
Z9 28
U1 0
U2 2
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 0002-9394
EI 1879-1891
J9 AM J OPHTHALMOL
JI Am. J. Ophthalmol.
PD NOV
PY 2015
VL 160
IS 5
BP 1024
EP 1033
DI 10.1016/j.ajo.2015.08.001
PG 10
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA CV0CK
UT WOS:000363914800023
PM 26255578
DA 2022-11-30
ER

PT J
AU Tarmann, L
   Wedrich, A
   Haas, A
   Berghold, A
   Kresse, A
   Vajda, C
   Maier, R
AF Tarmann, Lisa
   Wedrich, Andreas
   Haas, Anton
   Berghold, Andrea
   Kresse, Adelheid
   Vajda, Christian
   Maier, Richard
TI Limited vitrectomy with intravitreal bevacizumab, rt-PA and gas for
   submacular hemorrhage due to age-related macular degeneration
SO SPEKTRUM DER AUGENHEILKUNDE
LA English
DT Article
DE Submacular hemorrhage; Age-related macular degeneration; Limited
   vitrectomy; Bevacizumab; rt-PA
ID TISSUE-PLASMINOGEN ACTIVATOR; TRANSCONJUNCTIVAL SUTURELESS VITRECTOMY;
   SUBRETINAL HEMORRHAGE; PNEUMATIC DISPLACEMENT; PLANA VITRECTOMY;
   NATURAL-HISTORY; INJECTION; MANAGEMENT
AB To investigate the safety and efficacy of limited vitrectomy with intravitreal bevacizumab, recombinant tissue plasminogen activator (rt-PA) and gas for displacement of submacular hemorrhage due to exudative age-related macular degeneration (AMD).
   In this retrospective pilot study 11 eyes of 11 patients with submacular hemorrhage secondary to AMD were analyzed.
   A limited 23 g-one-port pars plana vitrectomy was performed and 50 mu g rt-PA, 1.25 mg bevacizumab and about 1.5 mL of 100 % sulfur hexafluoride (SF6) were injected into the vitreous. The best and the final visual acuity and blood displacement from the fovea were evaluated postoperatively.
   The best postoperative visual acuity (VA) was obtained at a median of 1 month after surgery (range 0.5-6 months) and demonstrated significantly better results than baseline VA for a short period of time (p = 0.04). No statistically significant improvement (p = 0.11) of the final visual acuity at a median of 3 months (range 0.5-6 months) compared to preoperative was found. Final visual acuity improved in 7 eyes, remained stable in 2 eyes and worsened in 2 eyes. Total pneumatic displacement of the submacular hemorrhage was obtained in 5 (46 %) eyes, partial displacement was shown in 2 (18 %) eyes. There was no displacement of the subretinal hemorrhage in 4 (36 %) eyes.
   This surgical procedure seems to have no advantage over intravitreous injection of rt-PA and gas with or without complete vitrectomy concerning displacement rate of submacular hemorrhage and postoperative visual acuity.
C1 [Tarmann, Lisa; Wedrich, Andreas; Haas, Anton; Maier, Richard] Med Univ Graz, Dept Ophthalmol, A-8036 Graz, Austria.
   [Berghold, Andrea] Med Univ Graz, Inst Med Informat Stat & Documentat, A-8036 Graz, Austria.
   [Kresse, Adelheid] Med Univ Graz, Inst Pathophysiol & Immunol, A-8010 Graz, Austria.
C3 Medical University of Graz; Medical University of Graz; Medical
   University of Graz
RP Tarmann, L (通讯作者)，Med Univ Graz, Dept Ophthalmol, Auenbruggerpl 4, A-8036 Graz, Austria.
EM lisa.tarmann@gmx.net
RI Wedrich, Andreas/AAE-9171-2020
CR Arias L, 2010, CLIN OPHTHALMOL, V4, P67
   Auriol S, 2010, J FR OPHTALMOL, V33, P84, DOI 10.1016/j.jfo.2009.12.005
   Avery RL, 1996, RETINA-J RET VIT DIS, V16, P183, DOI 10.1097/00006982-199616030-00001
   BENNETT SR, 1990, AM J OPHTHALMOL, V109, P33, DOI 10.1016/S0002-9394(14)75575-8
   Eckardt C, 2005, RETINA-J RET VIT DIS, V25, P208, DOI 10.1097/00006982-200502000-00015
   Fujii GY, 2002, OPHTHALMOLOGY, V109, P1814, DOI 10.1016/S0161-6420(02)01119-3
   GILLIES A, 1983, ANN OPHTHALMOL, V15, P1068
   Guthoff R, 2011, RETINA-J RET VIT DIS, V31, P36, DOI 10.1097/IAE.0b013e3181e37884
   Haas A, 2010, RETINA-J RET VIT DIS, V30, P112, DOI 10.1097/IAE.0b013e3181b32ebf
   Handwerger BA, 2001, ARCH OPHTHALMOL-CHIC, V119, P28
   Hassan AS, 1999, OPHTHALMOLOGY, V106, P1900, DOI 10.1016/S0161-6420(99)90399-8
   Hattenbach LO, 2001, OPHTHALMOLOGY, V108, P1485, DOI 10.1016/S0161-6420(01)00648-0
   Haupert CL, 2001, AM J OPHTHALMOL, V131, P208, DOI 10.1016/S0002-9394(00)00734-0
   Hesse L, 1999, GRAEF ARCH CLIN EXP, V237, P273, DOI 10.1007/s004170050232
   Hesse L, 1997, ADV THER, V14, P275
   Hillenkamp J, 2010, GRAEF ARCH CLIN EXP, V248, P5, DOI 10.1007/s00417-009-1158-7
   Krebs I, 2007, AM J OPHTHALMOL, V144, P741, DOI 10.1016/j.ajo.2007.07.024
   Krepler K, 2000, RETINA-J RET VIT DIS, V20, P251, DOI 10.1097/00006982-200003000-00005
   Lange C, 2009, GRAEF ARCH CLIN EXP, V247, P137, DOI 10.1007/s00417-008-0926-0
   Lincoff H, 2008, RETINA-J RET VIT DIS, V28, P56, DOI 10.1097/IAE.0b013e31806e60db
   Meyer CH, 2008, ACTA OPHTHALMOL, V86, P490, DOI 10.1111/j.1600-0420.2007.01125.x
   Mozaffarieh M, 2006, GRAEF ARCH CLIN EXP, V244, P1421, DOI 10.1007/s00417-005-0232-z
   Olivier S, 2004, OPHTHALMOLOGY, V111, P1201, DOI 10.1016/j.ophtha.2003.10.020
   Oshima Y, 2007, BRIT J OPHTHALMOL, V91, P193, DOI 10.1136/bjo.2006.101444
   Schulze SD, 2002, GRAEF ARCH CLIN EXP, V240, P717, DOI 10.1007/s00417-002-0516-5
   Scupola A, 1999, OPHTHALMOLOGICA, V213, P97, DOI 10.1159/000027400
   Singh RP, 2006, BRIT J OPHTHALMOL, V90, P429, DOI 10.1136/bjo.2005.085001
   Stopa M, 2007, RETINA-J RET VIT DIS, V27, P370, DOI 10.1097/IAE.0b013e3180439bc9
   TOTH CA, 1991, ARCH OPHTHALMOL-CHIC, V109, P723, DOI 10.1001/archopht.1991.01080050139046
   Treumer F, 2010, BRIT J OPHTHALMOL, V94, P48, DOI 10.1136/bjo.2009.164707
   Verma D, 2002, EYE, V16, P701, DOI 10.1038/sj.eye.6700209
NR 31
TC 1
Z9 1
U1 0
U2 4
PU SPRINGER
PI NEW YORK
PA ONE NEW YORK PLAZA, SUITE 4600, NEW YORK, NY, UNITED STATES
SN 0930-4282
EI 1613-7523
J9 SPEKTRUM AUGENHEILKD
JI Spektrum Augenheilkd.
PD OCT
PY 2012
VL 26
IS 4
BP 197
EP 201
DI 10.1007/s00717-012-0119-4
PG 5
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 025EU
UT WOS:000310169100003
DA 2022-11-30
ER

PT J
AU Maynard, ML
   Zele, AJ
   Feigl, B
AF Maynard, Michelle L.
   Zele, Andrew J.
   Feigl, Beatrix
TI Mesopic Pelli-Robson contrast sensitivity and MP-1 microperimetry in
   healthy ageing and age-related macular degeneration
SO ACTA OPHTHALMOLOGICA
LA English
DT Article
DE contrast sensitivity; macular degeneration; mesopic; microperimetry
ID MEDIATED MULTIFOCAL ELECTRORETINOGRAM; VISUAL-ACUITY; NORMAL VALUES;
   MACULOPATHY; PREVALENCE; EYES
AB PurposeTo determine whether decreasing illumination of the Pelli-Robson contrast sensitivity (CS) chart and MP-1 microperimeter to low mesopic conditions is more sensitive to vision changes occurring with healthy ageing and in early and intermediate age-related macular degeneration (AMD) and whether these mesopic tests can differentiate visual function between healthy older participants with and without AMD risk genotypes.
   MethodsRetinal sensitivity was measured in 98 healthy participants (19-85years) and 21 AMD (AREDS Grade 2/3) patients (73.96.5years) using the Pelli-Robson CS chart and MP-1 microperimeter under low mesopic and standard illumination. The effect of ageing and AMD on retinal sensitivity was estimated using regression analysis. Healthy older participants (>50years; n=24) were genotyped for AMD risk genes CFH and/or ARMS2 and retinal sensitivity was compared between genotypes.
   ResultsWith healthy ageing, photopic and mesopic Pelli-Robson CS showed a similar decline (-0.004 log CS/year). In AMD, photopic CS showed a similar decline to healthy ageing (-0.004 log CS/year) while mesopic CS was significantly reduced (-0.007 log CS/year). Both standard and low mesopic microperimetry showed a significant decline (-0.51 and -0.73% contrast/year) with healthy ageing and greater decline (-0.73 and -0.99% contrast/year) with AMD onset. Pelli-Robson CS and microperimetry sensitivity did not differ between AMD risk genotypes in healthy participants.
   ConclusionsMesopic Pelli-Robson CS detects functional deficits before photopic CS in early and intermediate AMD that can be differentiated from ageing. This test can be easily administered in clinical practice and may provide a means for early detection of retinal dysfunction.
C1 [Maynard, Michelle L.; Zele, Andrew J.; Feigl, Beatrix] Queensland Univ Technol, Inst Hlth & Biomed Innovat, Med Retina & Visual Sci Labs, Brisbane, Qld, Australia.
   [Maynard, Michelle L.; Feigl, Beatrix] Queensland Univ Technol, Sch Biomed Sci, Brisbane, Qld, Australia.
   [Zele, Andrew J.] Queensland Univ Technol, Sch Optometry & Vision Sci, Brisbane, Qld, Australia.
   [Feigl, Beatrix] Queensland Eye Inst, South Brisbane, Qld, Australia.
C3 Queensland University of Technology (QUT); Queensland University of
   Technology (QUT); Queensland University of Technology (QUT); Queensland
   Eye Institute
RP Feigl, B (通讯作者)，Queensland Univ Technol, Inst Hlth & Biomed Innovat, 60 Musk Ave, Brisbane, Qld 4059, Australia.
EM b.feigl@qut.edu.au
OI Maynard, Michelle/0000-0002-7678-3414; Feigl,
   Beatrix/0000-0001-7198-7373; Zele, Andrew/0000-0003-0291-9929
CR Age-Related Eye Dis Study Res Grp, 2001, AM J OPHTHALMOL, V132, P668
   Ardeljan D, 2013, PROG RETIN EYE RES, V37, P68, DOI 10.1016/j.preteyeres.2013.07.003
   CAMPBELL FW, 1965, NATURE, V208, P191, DOI 10.1038/208191a0
   CHENG AS, 1993, OPTOMETRY VISION SCI, V70, P89, DOI 10.1097/00006324-199302000-00001
   CHYLACK LT, 1993, ARCH OPHTHALMOL-CHIC, V111, P831, DOI 10.1001/archopht.1993.01090060119035
   CIE, 1989, 81 CIE CENTR BUR
   Convento E, 2007, PERIMETRY FUNDUS INT, P229
   Curcio CA, 1996, INVEST OPHTH VIS SCI, V37, P1236
   Dinc UA, 2008, EUR J OPHTHALMOL, V18, P595, DOI 10.1177/112067210801800416
   ELLIOTT DB, 1995, OPTOMETRY VISION SCI, V72, P186, DOI 10.1097/00006324-199503000-00006
   Feigl B, 2005, EYE, V19, P431, DOI 10.1038/sj.eye.6701503
   Feigl B, 2004, CURR EYE RES, V29, P327, DOI 10.1080/02713680490516198
   Feigl B, 2011, INVEST OPHTH VIS SCI, V52, P1145, DOI 10.1167/iovs.10-5967
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P564
   Hogg RE, 2006, PROG RETIN EYE RES, V25, P249, DOI 10.1016/j.preteyeres.2005.11.002
   KLEIN R, 1992, OPHTHALMOLOGY, V99, P933
   Lovie-Kitchin Jan, 2005, Clin Exp Optom, V88, P292
   Mantyjarvi M, 2001, J CATARACT REFR SURG, V27, P261, DOI 10.1016/S0886-3350(00)00562-9
   Mares JA, 2011, ARCH OPHTHALMOL-CHIC, V129, P470, DOI 10.1001/archophthalmol.2010.314
   Meleth AD, 2011, INVEST OPHTH VIS SCI, V52, P1119, DOI 10.1167/iovs.10-6075
   Midena E, 2007, BRIT J OPHTHALMOL, V91, P1499, DOI 10.1136/bjo.2007.119685
   Midena E, 2010, OPHTHALMOLOGY, V117, P1571, DOI 10.1016/j.ophtha.2009.12.044
   MITCHELL P, 1995, OPHTHALMOLOGY, V102, P1450
   Mohand-Said S, 2001, PROG RETIN EYE RES, V20, P451, DOI 10.1016/S1350-9462(01)00006-4
   Nebbioso M, 2014, BIOMED RES INT, V2014, P1
   Neelam K, 2009, SURV OPHTHALMOL, V54, P167, DOI 10.1016/j.survophthal.2008.12.003
   Owsley Cynthia, 2003, Ophthalmol Clin North Am, V16, P171, DOI 10.1016/S0896-1549(03)00003-8
   Pardhan S, 1996, CURR EYE RES, V15, P315, DOI 10.3109/02713689609007626
   Parravano M, 2009, RETINA-J RET VIT DIS, V29, P329, DOI 10.1097/IAE.0b013e31819093e6
   PELLI DG, 1988, CLIN VISION SCI, V2, P187
   Petzold A, 2006, OPHTHAL PHYSL OPT, V26, P326, DOI 10.1111/j.1475-1313.2006.00417.x
   Pilotto E, 2013, BRIT J OPHTHALMOL, V201, P2
   Puell MC, 2012, INVEST OPHTH VIS SCI, V53, P7310, DOI 10.1167/iovs.11-8649
   Puell MC, 2004, J REFRACT SURG, V20, P484, DOI 10.3928/1081-597X-20040901-12
   Rivera A, 2005, HUM MOL GENET, V14, P3227, DOI 10.1093/hmg/ddi353
   Rohrschneider K, 2008, PROG RETIN EYE RES, V27, P536, DOI 10.1016/j.preteyeres.2008.07.003
   ROSS JE, 1985, BRIT J OPHTHALMOL, V69, P51, DOI 10.1136/bjo.69.1.51
   Ross RJ, 2007, EXPERT REV OPHTHALMO, V2, P443, DOI 10.1586/17469899.2.3.443
   Seddon JM, 2009, INVEST OPHTH VIS SCI, V50, P2044, DOI 10.1167/iovs.08-3064
   SWANN PG, 1991, OPHTHAL PHYSL OPT, V11, P59, DOI 10.1016/0275-5408(91)90012-8
   Tarita-Nistor L, 2008, RETINA-J RET VIT DIS, V28, P125, DOI 10.1097/IAE.0b013e3180ed4571
   Wu ZC, 2014, OPHTHALMOLOGY, V121, P1612, DOI 10.1016/j.ophtha.2014.02.005
   Zele AJ, 2015, FRONT PSYCHOL, V5, DOI 10.3389/fpsyg.2014.01594
NR 43
TC 19
Z9 19
U1 0
U2 3
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1755-375X
EI 1755-3768
J9 ACTA OPHTHALMOL
JI Acta Ophthalmol.
PD DEC
PY 2016
VL 94
IS 8
BP E772
EP E778
DI 10.1111/aos.13112
PG 7
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA ED1AR
UT WOS:000388576400022
PM 27225020
OA Green Submitted, Bronze
DA 2022-11-30
ER

PT J
AU Boiche, M
   Angioi-Duprez, K
   Conart, JB
   Berrod, JP
AF Boiche, M.
   Angioi-Duprez, K.
   Conart, J-B
   Berrod, J-P
TI Treatment of hematomas in age related macular degeneration by vitrectomy
   and subretinal injection r-tPA: Preliminary results
SO JOURNAL FRANCAIS D OPHTALMOLOGIE
LA English
DT Article
DE AMD; Macular degeneration; R-tPA; Macular hematoma; Vitrectomy; Surgical
   treatment
ID TISSUE-PLASMINOGEN ACTIVATOR; THICK SUBMACULAR HEMORRHAGE; MANAGEMENT;
   INTRAVITREAL; DISPLACEMENT; GAS
AB Introduction. - Macular subretinal hematoma is a complication of age related macular degeneration (AMD) responsible for a severe change in vision. We evaluated anatomic and functional results of surgical treatment of hematoma by vitrectomy, subretinal injection of r-tPA (recombinant tissue plasminogen activator), intravitreal bevacizumab injection and air tamponade.
   Methods. - Retrospective case series including 26 patients with submacular hemorrhage who underwent vitrectomy within 15 days after the onset of symptoms. Optical coherence tomography (OCT) was performed to measure the diameter of the hemorrhage and specify the location in relation to the retinal pigment epithelium. Anatomical success was defined as a total displacement of the hemorrhage out of the fovea at the first postoperative visit. Visual acuity improvement was measured at 1 and 6 months and at final postoperative visit.
   Results. - The procedure resulted in hemorrhage displacement away from the fovea in 20 eyes (81%). Visual acuity significantly improved by 5.8 (+/- 7.2) lines (P = 0.0003) at 1 month post-operatively, 7.4 (+/- 6.7) lines (P = 0.0004) at 6 months and 7.4 (+/- 7.4) lines (P = 0.0002) at the final postoperative visit (16.5 +/- 19.8 months). There was an inverse correlation between hemorrhage diameter and final acuity improvement (Pearson correlation coefficient rho = -0.60 (IC 95% [-0.81; -0.26]; P=0.002)).
   Conclusion. - Vitrectomy with subretinal r-tPA injection was found to be effective for the displacement of AMD hemorrhage in 81% of the patients. Mean final visual acuity improved by more than 7 lines, confirming the efficacy and functional benefit of surgical displacement. (C) 2019 Elsevier Masson SAS. All rights reserved.
C1 [Boiche, M.; Angioi-Duprez, K.; Conart, J-B; Berrod, J-P] CHRU Nancy Brabois, Dept Ophthalmol, Rue Morvan, F-54500 Vandoeuvre Les Nancy, France.
C3 CHU de Nancy
RP Boiche, M (通讯作者)，CHRU Nancy Brabois, Dept Ophthalmol, Rue Morvan, F-54500 Vandoeuvre Les Nancy, France.
EM mathilde.boiche@yahoo.fr
CR Auriol S, 2010, J FR OPHTALMOL, V33, P84, DOI 10.1016/j.jfo.2009.12.005
   Azar G, 2015, EUR J OPHTHALMOL, V25, P163, DOI 10.5301/ejo.5000529
   Chang W, 2014, AM J OPHTHALMOL, V157, P1250, DOI 10.1016/j.ajo.2014.02.007
   De Jong JH, 2016, RETINA-J RET VIT DIS, V36, P914, DOI 10.1097/IAE.0000000000000954
   Dewilde E, 2014, ACTA OPHTHALMOL, V92, pE497, DOI 10.1111/aos.12458
   HANSCOM TA, 1987, ARCH OPHTHALMOL-CHIC, V105, P1722
   Hassan AS, 1999, OPHTHALMOLOGY, V106, P1900, DOI 10.1016/S0161-6420(99)90399-8
   Haupert CL, 2001, AM J OPHTHALMOL, V131, P208, DOI 10.1016/S0002-9394(00)00734-0
   Hesse L, 1999, GRAEF ARCH CLIN EXP, V237, P273, DOI 10.1007/s004170050232
   Scupola A, 1999, OPHTHALMOLOGICA, V213, P97, DOI 10.1159/000027400
   Sobolewska B, 2014, J OCUL PHARMACOL TH, V30, P567, DOI 10.1089/jop.2013.0135
   Stanescu-Segall D, 2016, SURV OPHTHALMOL, V61, P18, DOI 10.1016/j.survophthal.2015.04.004
   TOTH CA, 1991, ARCH OPHTHALMOL-CHIC, V109, P723, DOI 10.1001/archopht.1991.01080050139046
   Treumer F, 2010, BRIT J OPHTHALMOL, V94, P48, DOI 10.1136/bjo.2009.164707
   Treumer F, 2012, BRIT J OPHTHALMOL, V96, P708, DOI 10.1136/bjophthalmol-2011-300655
NR 15
TC 2
Z9 2
U1 0
U2 1
PU MASSON EDITEUR
PI MOULINEAUX CEDEX 9
PA 21 STREET CAMILLE DESMOULINS, ISSY, 92789 MOULINEAUX CEDEX 9, FRANCE
SN 0181-5512
EI 1773-0597
J9 J FR OPHTALMOL
JI J. Fr. Ophthamol.
PD NOV
PY 2019
VL 42
IS 9
BP E391
EP E397
DI 10.1016/j.jfo.2019.07.002
PG 7
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA JH4FF
UT WOS:000492723100001
PM 31471124
DA 2022-11-30
ER

PT J
AU Kodjikian, L
   Decullier, E
   Souied, EH
   Girmens, JF
   Durand, EE
   Chapuis, FR
   Huot, L
AF Kodjikian, Laurent
   Decullier, Evelyne
   Souied, Eric H.
   Girmens, Jean-Francois
   Durand, Emilie E.
   Chapuis, Francois R.
   Huot, Laure
TI Bevacizumab and ranibizumab for neovascular age-related macular
   degeneration: an updated meta-analysis of randomised clinical trials
SO GRAEFES ARCHIVE FOR CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY
LA English
DT Review
DE Bevacizumab; Ranibizumab; Neovascular age-related macular degeneration;
   Meta-analysis
ID ENDOTHELIAL GROWTH-FACTOR; PLASMA-LEVELS
AB Purpose Neovascular age-related macular degeneration (AMD) is the main cause of central vision loss among individuals aged 50 years or older in developed countries. The aim of this study was to review systematically the effect of bevacizumab compared to ranibizumab in patients with AMD at 1 year.
   Methods A systematic review was performed on Medline, Embase, and the Cochrane Library and Trial registers to October 2013. Eligibility criteria for selecting studies were randomised controlled trials (RCT) comparing bevacizumab with ranibizumab in patients with neovascular AMD. Odds ratio (OR) and mean difference (MD) estimates were synthesized under fixed-and random-effects models. Heterogeneity was assessed using the Q statistic and I-2.
   Results Five RCTs were included, representing 2,686 randomised patients. The meta-analysis confirmed the non-inferiority of bevacizumab compared to ranibizumab for change in visual acuity at 1 year (MD 0.57 letters, -1.80 to 0.66, p = 0.37, I-2 = 0 %). Better anatomical results were found for ranibizumab. Bevacizumab was associated with a 34 % increase in the number of patients with at least one serious systemic adverse event (OR 1.34, 1.08 to 1.66, p = 0.01, I-2 = 0 %).
   Conclusions The pooled evidence confirmed that, compared with ranibizumab, bevacizumab was associated with equivalent effects on visual acuity at 1 year and with a higher risk of systemic serious adverse events. The current available data do not show which types of adverse events occur more frequently. In practice, bevacizumab should be used under a risk-management plan until further studies have been carried out to assess accurately the increased risk of systemic adverse events.
C1 [Kodjikian, Laurent] Hop Croix Rousse, Grp Hosp Nord, Hosp Civils Lyon, Serv Ophtalmol, F-69317 Lyon 04, France.
   [Kodjikian, Laurent; Decullier, Evelyne; Chapuis, Francois R.; Huot, Laure] Univ Lyon, F-69007 Lyon, France.
   [Kodjikian, Laurent] CNRS, UMR Mateis 5510, F-69621 Villeurbanne, France.
   [Decullier, Evelyne; Durand, Emilie E.; Chapuis, Francois R.; Huot, Laure] Hosp Civils Lyon, Unite Rech Clin, Pole Informat Med Evaluat Rech, F-69003 Lyon, France.
   [Decullier, Evelyne; Chapuis, Francois R.; Huot, Laure] Univ Lyon 1, EAM Sante Individu Soc 4128, F-69003 Lyon, France.
   [Souied, Eric H.] Ctr Hosp Intercommunal Creteil, Serv Ophtalmol, F-94000 Creteil, France.
   [Souied, Eric H.] Univ Paris Est, CRC, F-94000 Creteil, France.
   [Girmens, Jean-Francois] Ctr Hosp Ophtalmol Quinze Vingts, INSERM DHOS CIC503, F-75012 Paris, France.
C3 CHU Lyon; Centre National de la Recherche Scientifique (CNRS); Institut
   National des Sciences Appliquees de Lyon - INSA Lyon; CHU Lyon;
   UDICE-French Research Universities; Universite Claude Bernard Lyon 1;
   Universite Paris-Est-Creteil-Val-de-Marne (UPEC); CHI Creteil;
   Universite Paris-Est-Creteil-Val-de-Marne (UPEC); CHNO des
   Quinze-Vingts; Institut National de la Sante et de la Recherche Medicale
   (Inserm); UDICE-French Research Universities; Sorbonne Universite
RP Kodjikian, L (通讯作者)，Hop Croix Rousse, Grp Hosp Nord, Hosp Civils Lyon, Serv Ophtalmol, 103 Grande Rue Croix Rousse, F-69317 Lyon 04, France.
EM kodjikian.laurent@wanadoo.fr
RI decullier, evelyne/AAL-5861-2021; Huot, Laure/GLS-5988-2022
OI Huot, Laure/0000-0002-7870-9912; GIRMENS,
   Jean-Francois/0000-0002-9102-8716
FU Novartis; BauschLomb; Thea; Alcon; Allergan; Bayer; Krys group; Zeiss;
   Sanofi-Fovea
FX - LK has been principal investigator for trials sponsored by Novartis,
   Bausch&Lomb, Thea, and Alcon; has sat on advisory boards for Alcon,
   Alimera Sciences, Allergan, Bayer, Bausch&Lomb, Novartis, and Thea; and
   has received lecture fees from Alcon, Allergan, Bayer, Bausch&Lomb, Krys
   group, Novartis, Thea, and Zeiss.; - JFG has sat on advisory boards for
   Novartis; has received lecture fees from Allergan and Bayer; and has
   received consulting fees from Allergan, Bayer, and Sanofi-Fovea
CR Biswas P, 2011, INDIAN J OPHTHALMOL, V59, P191, DOI 10.4103/0301-4738.81023
   Biswas P, 2011, OPHTHALMOLOGY, V118, P600, DOI 10.1016/j.ophtha.2010.10.027
   Carneiro AM, 2012, ACTA OPHTHALMOL, V90, pE25, DOI 10.1111/j.1755-3768.2011.02240.x
   Chakravarthy U, 2012, OPHTHALMOLOGY, V119, DOI 10.1016/j.ophtha.2012.04.015
   Higgins JPT, 2003, BRIT MED J, V327, P557, DOI 10.1136/bmj.327.7414.557
   Kodjikian L, 2013, OPHTHALMOLOGY, V120, P2300, DOI 10.1016/j.ophtha.2013.06.020
   Krebs I, 2013, BRIT J OPHTHALMOL, V97, P266, DOI 10.1136/bjophthalmol-2012-302391
   Macdonald Geraldine, 2012, Cochrane Database Syst Rev, pCD001930, DOI 10.1002/14651858.CD001930.pub3
   Martin DF, 2011, NEW ENGL J MED, V364, P1897, DOI 10.1056/NEJMoa1102673
   Moher David, 2009, BMJ, V339, pb2535, DOI [10.1016/j.ijsu.2010.02.007, 10.1136/bmj.b2535]
   Moshfeghi AA, 2006, OPHTHALMOLOGY, V113, P2002, DOI 10.1016/j.ophtha.2006.05.070
   Schmucker C, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0042701
   Stein JD, 2013, AM J OPHTHALMOL, V155, P688, DOI 10.1016/j.ajo.2012.10.003
   Subramanian ML, 2010, EYE, V24, P1708, DOI 10.1038/eye.2010.147
   Zehetner C, 2013, BRIT J OPHTHALMOL, V97, P454, DOI 10.1136/bjophthalmol-2012-302451
NR 15
TC 26
Z9 28
U1 0
U2 17
PU SPRINGER
PI NEW YORK
PA ONE NEW YORK PLAZA, SUITE 4600, NEW YORK, NY, UNITED STATES
SN 0721-832X
EI 1435-702X
J9 GRAEF ARCH CLIN EXP
JI Graefes Arch. Clin. Exp. Ophthalmol.
PD OCT
PY 2014
VL 252
IS 10
BP 1529
EP 1537
DI 10.1007/s00417-014-2764-6
PG 9
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA AT0NB
UT WOS:000344631600002
PM 25142373
OA Green Published, hybrid
DA 2022-11-30
ER

PT J
AU Keenan, TDL
   Pickford, CE
   Holley, RJ
   Clark, SJ
   Lin, WC
   Dowsey, AW
   Merry, CL
   Day, AJ
   Bishop, PN
AF Keenan, Tiarnan D. L.
   Pickford, Claire E.
   Holley, Rebecca J.
   Clark, Simon J.
   Lin, Wanchang
   Dowsey, Andrew W.
   Merry, Catherine L.
   Day, Anthony J.
   Bishop, Paul N.
TI Age-Dependent Changes in Heparan Sulfate in Human Bruch's Membrane:
   Implications for Age-Related Macular Degeneration
SO INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE
LA English
DT Article
DE Bruch's membrane; heparan sulfate; AMD
ID COMPLEMENT FACTOR-H; RETINAL-PIGMENT EPITHELIUM; ADULT HUMAN RETINA;
   ALZHEIMERS-DISEASE; DIFFERENTIAL DISTRIBUTION; HIGH-RISK; BINDING;
   CHORIOCAPILLARIS; PROTEOGLYCANS; DEPOSITS
AB PURPOSE. Heparan sulfate (HS) has been implicated in age-related macular degeneration (AMD), since it is the major binding partner for complement factor H (CFH) in human Bruch's membrane (BrM), and CFH has a central role in inhibiting complement activation on extracellular matrices. The aim was to investigate potential aging changes in HS quantity and composition in human BrM.
   METHODS. Postmortem human ocular tissue was obtained from donors without known retinal disease. The HS was purified from BrM and neurosensory retina, and after digestion to disaccharides, fluorescently labeled and analyzed by reverse-phase HPLC. The HS and heparanase-1 were detected by immunohistochemistry in macular tissue sections from young and old donors, and binding of exogenously applied recombinant CCP6-8 region of CFH (402Y and 402H variants) was compared.
   RESULTS. Disaccharide analysis demonstrated that the mean quantity of HS in BrM was 50% lower (P = 0.006) in old versus young donors (average 82 vs. 32 years). In addition, there was a small, but significant decrease in HS sulfation in old BrM. Immunohistochemistry revealed approximately 50% (P = 0.02) less HS in macular BrM in old versus young donors, whereas heparanase-1 increased by 24% in old macular BrM (P = 0.56). In young donor tissue the AMD-associated 402H CCP6-8 bound relatively poorly to BrM, compared to the 402Y form. In BrM from old donors, this difference was significantly greater (P = 0.019).
   CONCLUSIONS. The quantity of HS decreases substantially with age in human BrM, resulting in fewer binding sites for CFH and especially affecting the ability of the 402H variant of CFH to bind BrM.
C1 [Keenan, Tiarnan D. L.; Clark, Simon J.; Bishop, Paul N.] Univ Manchester, Inst Human Dev, Ctr Hearing & Vis Res, Manchester M13 9PT, Lancs, England.
   [Keenan, Tiarnan D. L.; Clark, Simon J.; Lin, Wanchang; Dowsey, Andrew W.; Bishop, Paul N.] Univ Manchester, CADET, Manchester M13 9PT, Lancs, England.
   [Keenan, Tiarnan D. L.; Clark, Simon J.; Lin, Wanchang; Dowsey, Andrew W.; Bishop, Paul N.] Cent Manchester Univ Hosp NHS Fdn Trust, Manchester Acad Hlth Sci Ctr, Manchester, Lancs, England.
   [Keenan, Tiarnan D. L.; Bishop, Paul N.] Cent Manchester Univ Hosp NHS Fdn Trust, Manchester Royal Eye Hosp, Manchester, Lancs, England.
   [Keenan, Tiarnan D. L.; Holley, Rebecca J.; Day, Anthony J.] Univ Manchester, Fac Life Sci, Wellcome Trust Ctr Cell Matrix Res, Manchester M13 9PT, Lancs, England.
   [Pickford, Claire E.; Holley, Rebecca J.; Merry, Catherine L.] Univ Manchester, Sch Mat, Manchester M13 9PT, Lancs, England.
   [Lin, Wanchang; Dowsey, Andrew W.] Univ Manchester, Inst Human Dev, Ctr Endocrinol & Diabet, Manchester M13 9PT, Lancs, England.
C3 University of Manchester; University of Manchester; University of
   Manchester; Manchester Royal Eye Hospital; University of Manchester;
   University of Manchester; University of Manchester; University of
   Manchester
RP Bishop, PN (通讯作者)，Univ Manchester, Inst Human Dev, AV Hill Bldg,Oxford Rd, Manchester M13 9PT, Lancs, England.
EM anthony.day@manchester.ac.uk; paul.bishop@manchester.ac.uk
RI Day, Anthony/O-1658-2015
OI Day, Anthony/0000-0002-1415-3134; Bishop, Paul/0000-0001-7937-7932;
   Clark, Simon/0000-0001-8394-8355; merry, catherine/0000-0002-3490-2809;
   Dowsey, Andrew/0000-0002-7404-9128
FU Medical Research Council [G0900592, K004441, G0701165, G0902170]; NIHR
   Manchester Biomedical Research Centre; BBSRC; Wellcome Trust; University
   of Manchester Strategic Fund; Fight for Sight Clinical Fellowship
   [1866]; MRC Career Development Award [MR/K024418/1]; MRC [G0900538,
   G0701165, MR/K004441/1, G0902170, MR/K024418/1] Funding Source: UKRI;
   Medical Research Council [MR/K004441/1, G0900538, MR/K024418/1] Funding
   Source: researchfish; Fight for Sight [1865/66] Funding Source:
   researchfish
FX Supported by the Medical Research Council (Grants G0900592, K004441,
   G0701165 and G0902170), and the NIHR Manchester Biomedical Research
   Centre. The Bioimaging Facility microscopes used in this report were
   purchased with support from the BBSRC, Wellcome Trust and the University
   of Manchester Strategic Fund. TDLK is a recipient of a Fight for Sight
   Clinical Fellowship (1866). SJC is the recipient of an MRC Career
   Development Award (MR/K024418/1).
CR Anderson DH, 2010, PROG RETIN EYE RES, V29, P95, DOI 10.1016/j.preteyeres.2009.11.003
   Blackhall FH, 2001, BRIT J CANCER, V85, P1094, DOI 10.1054/bjoc.2001.2054
   Bland JM, 1996, BRIT MED J, V312, P770
   Booij JC, 2010, PROG RETIN EYE RES, V29, P1, DOI 10.1016/j.preteyeres.2009.08.003
   Bruinsma IB, 2010, ACTA NEUROPATHOL, V119, P211, DOI 10.1007/s00401-009-0577-1
   Bunce C, 2008, EYE, V22, P905, DOI 10.1038/sj.eye.6702767
   Clark SJ, 2006, J BIOL CHEM, V281, P24713, DOI 10.1074/jbc.M605083200
   Clark SJ, 2013, FRONT IMMUNOL, V4, DOI 10.3389/fimmu.2013.00412
   Clark SJ, 2013, J IMMUNOL, V190, P2049, DOI 10.4049/jimmunol.1201751
   Clark SJ, 2011, INVEST OPHTH VIS SCI, V52, P6511, DOI 10.1167/iovs.11-7909
   Clark SJ, 2010, BIOCHEM SOC T, V38, P1342, DOI 10.1042/BST0381342
   Clark SJ, 2010, J BIOL CHEM, V285, P30192, DOI 10.1074/jbc.M110.103986
   Congdon N, 2004, ARCH OPHTHALMOL-CHIC, V122, P477
   Crabb JW, 2002, P NATL ACAD SCI USA, V99, P14682, DOI 10.1073/pnas.222551899
   DAVID G, 1992, J CELL BIOL, V119, P961, DOI 10.1083/jcb.119.4.961
   Day AJ, 2011, EXPERT REV OPHTHALMO, V6, P123, DOI 10.1586/EOP.11.10
   Deakin JA, 2008, GLYCOBIOLOGY, V18, P483, DOI 10.1093/glycob/cwn028
   Donoso LA, 2006, SURV OPHTHALMOL, V51, P137, DOI 10.1016/j.survophthal.2005.12.001
   Edwards AO, 2005, SCIENCE, V308, P421, DOI 10.1126/science.1110189
   Feng CY, 2013, STAT MED, V32, P230, DOI 10.1002/sim.5486
   Feyzi E, 1998, J BIOL CHEM, V273, P13395, DOI 10.1074/jbc.273.22.13395
   Filzmoser P, 2009, SCI TOTAL ENVIRON, V407, P6100, DOI 10.1016/j.scitotenv.2009.08.008
   Fritsche LG, 2013, NAT GENET, V45, P433, DOI 10.1038/ng.2578
   Garland DL, 2014, HUM MOL GENET, V23, P52, DOI 10.1093/hmg/ddt395
   Gerl VB, 2002, INVEST OPHTH VIS SCI, V43, P1104
   Hageman GS, 2006, ANN MED, V38, P592, DOI 10.1080/07853890601097030
   Hageman GS, 2001, PROG RETIN EYE RES, V20, P705, DOI 10.1016/S1350-9462(01)00010-6
   Hageman GS, 2005, P NATL ACAD SCI USA, V102, P7227, DOI 10.1073/pnas.0501536102
   Haines JL, 2005, SCIENCE, V308, P419, DOI 10.1126/science.1110359
   Holley RJ, 2011, J BIOL CHEM, V286, P37515, DOI 10.1074/jbc.M111.287474
   Kaarniranta K, 2011, J ALZHEIMERS DIS, V24, P615, DOI 10.3233/JAD-2011-101908
   Karampelas M, 2013, BRIT J OPHTHALMOL, V97, P1256, DOI 10.1136/bjophthalmol-2013-303219
   KATO M, 1994, J BIOL CHEM, V269, P18881
   Keenan TDL, 2012, INVEST OPHTH VIS SCI, V53, P7528, DOI 10.1167/iovs.12-10797
   Kelly U, 2010, J IMMUNOL, V185, P5486, DOI 10.4049/jimmunol.0903596
   Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557
   Kliffen M, 1996, ARCH OPHTHALMOL-CHIC, V114, P1009, DOI 10.1001/archopht.1996.01100140217021
   Kreuger J, 2012, J HISTOCHEM CYTOCHEM, V60, P898, DOI 10.1369/0022155412464972
   Langford-Smith A, 2014, J INNATE IMMUN, V6, P407, DOI 10.1159/000356513
   Li JP, 2009, THROMB HAEMOSTASIS, V102, P823, DOI 10.1160/TH09-02-0091
   LINDAHL B, 1995, BIOCHEM J, V306, P177, DOI 10.1042/bj3060177
   Lindahl U, 2009, INT REV CEL MOL BIO, V276, P105, DOI 10.1016/S1937-6448(09)76003-4
   Mullins RF, 2012, RECENT ADV BASIC RES
   Mullins RE, 2011, INVEST OPHTH VIS SCI, V52, P1606, DOI 10.1167/iovs.10-6476
   Mullins RF, 2011, EXP EYE RES, V93, P565, DOI 10.1016/j.exer.2011.06.015
   Ohno-Matsui K, 2011, PROG RETIN EYE RES, V30, P217, DOI 10.1016/j.preteyeres.2011.02.004
   Okubo A, 1999, INVEST OPHTH VIS SCI, V40, P443
   Park PJ, 2013, EXP EYE RES, V110, P1, DOI 10.1016/j.exer.2013.01.015
   Prosser BE, 2007, J EXP MED, V204, P2277, DOI 10.1084/jem.20071069
   Raman K, 2010, CURR CHEM BIOL, V4, P20
   RAMRATTAN RS, 1994, INVEST OPHTH VIS SCI, V35, P2857
   Sarrazin S, 2011, COLD SPRING HARB PER, V37
   Schaefer L, 2010, CELL TISSUE RES, V339, P237, DOI 10.1007/s00441-009-0821-y
   Seddon JM, 2013, NAT GENET, V45, P1366, DOI 10.1038/ng.2741
   Seth A, 2008, INVEST OPHTH VIS SCI, V49, P743, DOI 10.1167/iovs.07-1072
   Skeie JM, 2010, INVEST OPHTH VIS SCI, V51, P5336, DOI 10.1167/iovs.10-5322
   Sofat R, 2012, INT J EPIDEMIOL, V41, P250, DOI 10.1093/ije/dyr204
   Theocharis AD, 2010, FEBS J, V277, P3904, DOI 10.1111/j.1742-4658.2010.07800.x
   Williamson KA, 2013, AGING CELL, V12, P139, DOI 10.1111/acel.12031
   Zetser A, 2004, J CELL SCI, V117, P2249, DOI 10.1242/jcs.01068
NR 60
TC 46
Z9 47
U1 1
U2 14
PU ASSOC RESEARCH VISION OPHTHALMOLOGY INC
PI ROCKVILLE
PA 12300 TWINBROOK PARKWAY, ROCKVILLE, MD 20852-1606 USA
SN 0146-0404
EI 1552-5783
J9 INVEST OPHTH VIS SCI
JI Invest. Ophthalmol. Vis. Sci.
PD AUG
PY 2014
VL 55
IS 8
BP 5370
EP 5379
DI 10.1167/iovs.14-14126
PG 10
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA AQ9DV
UT WOS:000343145500093
PM 25074778
DA 2022-11-30
ER

PT J
AU Patel, JJ
   Mendes, MAS
   Bounthavong, M
   Christopher, MLD
   Boggie, D
   Morreale, AP
AF Patel, Jignesh J.
   Mendes, Margaret A. S.
   Bounthavong, Mark
   Christopher, Melissa L. D.
   Boggie, Daniel
   Morreale, Anthony P.
TI Cost-utility analysis of bevacizumab versus ranibizumab in neovascular
   age-related macular degeneration using a Markov model
SO JOURNAL OF EVALUATION IN CLINICAL PRACTICE
LA English
DT Article
DE age-related macular degeneration; bevacizumab; cost-effectiveness
   analysis; cost-utility analysis; ranibizumab
ID ENDOTHELIAL GROWTH-FACTOR; INTRAVITREAL BEVACIZUMAB; CHOROIDAL
   NEOVASCULARIZATION; AVASTIN; VERTEPORFIN; PEGAPTANIB; EXPRESSION;
   DEPRESSION; EFFICACY; THERAPY
AB Objective To evaluate the cost-effectiveness of intravitreal bevacizumab to ranibizumab in patients with neovascular age-related macular degeneration (AMD).
   Methods A cost-utility analysis using a Markov model was performed to evaluate incremental cost-effectiveness ratio [ICER, $ US per quality-adjusted life year (QALY) gained] between bevacizumab and ranibizumab from a US payer perspective. Transition probabilities for ranibizumab and bevacizumab were extrapolated from published studies and local institutional data. Utility values, likewise, were obtained from another published study. Mortality rates were determined from the Centers for Disease Control 2003 Life Tables. Resource utilization and total direct costs were estimated using the Centers for Medicare and Medicaid Services and theVeterans Affairs Decision Support System. Ahypothetical cohort of 1000 patients was simulated through the model for 20 years. Sensitivity analyses were performed using univariate and probabilistic sensitivity analysis (PSA) on all costs, transition probabilities and utility values. An acceptability curve was generated to illustrate the cost-effectiveness probability of bevacizumab to ranibizumab with increasing willingnessto- pay (WTP).
   Results The cost-effectiveness ratios (CER) for bevacizumab and ranibizumab were $ 1405 per QALY and $ 12 177 per QALY, respectively. The ICER for bevacizumab was dominant compared to ranibizumab. The base-case CER was sensitive to drug costs of the study medications with a breakeven point of $ 44 for ranibizumab and $ 2666 for bevacizumab. PSA revealed a 95% probability of bevacizumab being more cost-effective than ranibizumab at a WTP of $ 50 000 per QALY gained.
   Conclusion Based on a WTP defined at $ 50 000 per QALY gained, bevacizumab was cost-effective versus ranibizumab 95% of the time because of lower acquisition costs and increased efficacy.
C1 [Morreale, Anthony P.] Vet Affairs San Diego Healthcare Syst, Serv Pharm, San Diego, CA USA.
   [Mendes, Margaret A. S.; Bounthavong, Mark; Christopher, Melissa L. D.; Boggie, Daniel; Morreale, Anthony P.] Univ Pacific, Thomas J Long Sch Pharm & Hlth Sci, Stockton, CA 95211 USA.
   [Mendes, Margaret A. S.; Bounthavong, Mark; Christopher, Melissa L. D.; Boggie, Daniel; Morreale, Anthony P.] Univ Calif San Diego, Skaggs Sch Pharm & Pharmaceut Sci, San Diego, CA USA.
C3 US Department of Veterans Affairs; Veterans Health Administration (VHA);
   VA San Diego Healthcare System; University of the Pacific; University of
   California System; University of California San Diego
RP Bounthavong, M (通讯作者)，3350 La Jolla Village Dr 119, San Diego, CA 92161 USA.
EM mark.bounthavong@va.gov
OI Bounthavong, Mark/0000-0002-7343-9458
CR Aisenbrey S, 2007, GRAEF ARCH CLIN EXP, V245, P941, DOI 10.1007/s00417-006-0471-7
   Algvere PV, 2008, ACTA OPHTHALMOL, V86, P482, DOI 10.1111/j.1600-0420.2007.01113.x
   Arias L, 2008, BRIT J OPHTHALMOL, V92, P1636, DOI 10.1136/bjo.2008.141721
   ASC procedure list-2006, 2006, ASC PROD LIST 2006
   Avery RL, 2006, OPHTHALMOLOGY, V113, P363, DOI 10.1016/j.ophtha.2005.11.019
   Bashshur ZF, 2008, AM J OPHTHALMOL, V145, P249, DOI 10.1016/j.ajo.2007.09.031
   Binder S., 2009, RANDOMIZED OBSERVER
   Briggs A, 1998, PHARMACOECONOMICS, V13, P397, DOI 10.2165/00019053-199813040-00003
   Briggs AH, 2000, PHARMACOECONOMICS, V17, P479, DOI 10.2165/00019053-200017050-00006
   Brody BL, 2001, OPHTHALMOLOGY, V108, P1893, DOI 10.1016/S0161-6420(01)00754-0
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Brown GC, 2007, OPHTHALMOLOGY, V114, P1170, DOI 10.1016/j.ophtha.2006.09.019
   Brown GC, 2000, ARCH OPHTHALMOL-CHIC, V118, P47
   Brown MM, 2008, OPHTHALMOLOGY, V115, P1039, DOI 10.1016/j.ophtha.2007.08.033
   Brown MM, 2006, CURR OPIN OPHTHALMOL, V17, P257
   Centers for Medicare and Medicaid Services 2006, 2006, ASP PRIC FIL
   Centers for Medicare and Medicaid Services physician fee schedule overview, 2006, CTR MED MED SERV PHY
   Chakravarthy U, 2006, OPHTHALMOLOGY, V113, P1508, DOI 10.1016/j.ophtha.2006.02.064
   Drummond MF, 2005, METHODS EC EVALUATIO
   Emerson MV, 2007, RETINA-J RET VIT DIS, V27, P439, DOI 10.1097/IAE.0b013e31804b3e15
   Fenwick E, 2004, HEALTH ECON, V13, P405, DOI 10.1002/hec.903
   Fleming T., 2007, REDBOOK PHARM FUNDAM
   Fong KCS, 2008, CLIN EXP OPHTHALMOL, V36, P748, DOI 10.1111/j.1442-9071.2008.01873.x
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P564
   Gragoudas ES, 2004, NEW ENGL J MED, V351, P2805, DOI 10.1056/NEJMoa042760
   HOYERT D, 2006, DEATHS FINAL DATA 20, V54
   Ivers RQ, 2003, J AM GERIATR SOC, V51, P356, DOI 10.1046/j.1532-5415.2003.51109.x
   Javitt JC, 2007, OPHTHALMOLOGY, V114, P238, DOI 10.1016/j.ophtha.2006.07.054
   Kliffen M, 1997, BRIT J OPHTHALMOL, V81, P154, DOI 10.1136/bjo.81.2.154
   Lazic R, 2007, OPHTHALMOLOGY, V114, P1179, DOI 10.1016/j.ophtha.2007.03.006
   Madhusudhana KC, 2007, BRIT J OPHTHALMOL, V91, P1716, DOI 10.1136/bjo.2006.108639
   Martin D. F., NCT00593450
   Ng EWM, 2005, CAN J OPHTHALMOL, V40, P352, DOI 10.1016/S0008-4182(05)80078-X
   O'Neill C, 2001, DRUG AGING, V18, P233, DOI 10.2165/00002512-200118040-00001
   Otani A, 2002, MICROVASC RES, V64, P162, DOI 10.1006/mvre.2002.2407
   Raftery J, 2007, BRIT J OPHTHALMOL, V91, P1244, DOI 10.1136/bjo.2007.116616
   Rakic JM, 2003, INVEST OPHTH VIS SCI, V44, P3186, DOI 10.1167/iovs.02-1092
   Rich RM, 2006, RETINA-J RET VIT DIS, V26, P495, DOI 10.1097/01.iae.0000225766.75009.3a
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Rosenfeld PJ, 2005, OPHTHAL SURG LAS IM, V36, P331, DOI 10.3928/1542-8877-20050701-14
   Rovner BW, 2002, ARCH OPHTHALMOL-CHIC, V120, P1041
   Smith DH, 2004, BRIT J OPHTHALMOL, V88, P1107, DOI 10.1136/bjo.2003.023986
   Spaide RF, 2006, RETINA-J RET VIT DIS, V26, P383, DOI 10.1097/00006982-200604000-00001
   Veterans Affairs San Diego Healthcare System Decision Support System cost data, 2007, VET AFF SAN DIEG HEA
   Wells JA, 1996, BRIT J OPHTHALMOL, V80, P363, DOI 10.1136/bjo.80.4.363
   Wolowacz SE, 2007, PHARMACOECONOMICS, V25, P863, DOI 10.2165/00019053-200725100-00005
   Yoganathan P, 2006, RETINA-J RET VIT DIS, V26, P994, DOI 10.1097/01.iae.0000244380.34082.67
   Zhou S., 2006, INVESTIGATIVE OPTHAL, V47
NR 48
TC 32
Z9 34
U1 0
U2 16
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1356-1294
J9 J EVAL CLIN PRACT
JI J. Eval. Clin. Pract.
PD APR
PY 2012
VL 18
IS 2
BP 247
EP 255
DI 10.1111/j.1365-2753.2010.01546.x
PG 9
WC Health Care Sciences & Services; Medical Informatics; Medicine, General
   & Internal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Health Care Sciences & Services; Medical Informatics; General & Internal
   Medicine
GA 902QQ
UT WOS:000301053800006
PM 20846318
DA 2022-11-30
ER

PT J
AU Xu, W
   Grunwald, JE
   Metelitsina, TI
   Dupont, JC
   Ying, GS
   Martin, ER
   Dunaief, JL
   Brucker, AJ
AF Xu, Wei
   Grunwald, Juan E.
   Metelitsina, Tatyana I.
   Dupont, Joan C.
   Ying, Gui-Shuang
   Martin, E. Revell
   Dunaief, Joshua L.
   Brucker, Alexander J.
TI Association of Risk Factors for Choroidal Neovascularization in
   Age-Related Macular Degeneration With Decreased Foveolar Choroidal
   Circulation
SO AMERICAN JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
ID BLOOD-FLOW; CARDIOVASCULAR-DISEASE; VISUAL IMPAIRMENT; 5-YEAR INCIDENCE;
   MACULOPATHY; HYPERTENSION; PREVALENCE; PATHOGENESIS; AMD
AB PURPOSE: To investigate the relationship between known risk factors for age-related macular degeneration (AMD) progression and foveolar choroidal circulation in eyes with nonexudative AMD.
   DESIGN: Cross-sectional study of nonexudative AMD.
   METHODS: Laser Doppler flowmetry measurements of relative choroidal blood velocity, choroidal blood volume (ChBVol), and choroidal blood flow (ChBFlow) were obtained in the center of the fovea of 273 study eyes of 204 AMD patients investigated at the Scheie Eye Institute, University of Pennsylvania Medical School. All study eyes had visual acuity of 20/40 or better, good fixation, no other intraocular pathologic features, and no evidence of choroidal neovascularization. RPE hypertrophy was determined from color fundus photographs by trained masked graders at the Scheie Image Reading Center. Correlation analysis and multivariate linear regression analysis with adjustments for significant covariates were carried out.
   RESULTS: A significant inverse correlation was observed between age and ChBFlow (r = -0.36; P < .0001), and ChBVol (r = -0.28; P < .0001), but not for choroidal blood velocity. A significant inverse correlation was observed between spherical equivalent and ChBFlow (r = -0.21; P = .006) and ChBVol (r = -0.14; P = .04), but not for choroidal blood velocity. ChBFlow and ChBVol were significantly lower in patients with a history of hypertension (P <= .003) and in eyes with retinal pigment epithelium hypertrophy (P <= .04), respectively.
   CONCLUSIONS: All the above-described risk factors for AMD development and progression are associated with decreased choroidal circulatory parameters, suggesting that decreases in choroidal circulatory parameters may be involved in the development of AMD. (Am J Ophthalmol 2010;150:40-47. (C) 2010 by Elsevier Inc. All rights reserved.)
C1 [Xu, Wei; Grunwald, Juan E.; Metelitsina, Tatyana I.; Dupont, Joan C.; Ying, Gui-Shuang; Martin, E. Revell; Dunaief, Joshua L.; Brucker, Alexander J.] Univ Penn, Scheie Eye Inst, Dept Ophthalmol, Sch Med, Philadelphia, PA 19104 USA.
C3 University of Pennsylvania; Pennsylvania Medicine
RP Grunwald, JE (通讯作者)，Univ Penn, Scheie Eye Inst, Dept Ophthalmol, Sch Med, 501 N 39th St, Philadelphia, PA 19104 USA.
EM juangrun@mail.med.upenn.edu
FU NATIONAL INSTITUTES OF HEALTH, BETHESDA, Maryland [NE1 EY12769, 5 P30 EY
   01583]; Vivian Simkins Lasko Research Fund, Philadelphia, Pennsylvania;
   Nina C. Mackall Trust, New York, New York; Research to Prevent
   Blindness, Inc, New York, New York; NATIONAL EYE INSTITUTE [R01EY012769,
   P30EY001583] Funding Source: NIH RePORTER
FX SUPPORTED BY GRANTS NE1 EY12769 AND 5 P30 EY 01583 FROM THE NATIONAL
   INSTITUTES OF HEALTH, BETHESDA, Maryland; the Vivian Simkins Lasko
   Research Fund, Philadelphia, Pennsylvania; the Nina C. Mackall Trust,
   New York, New York; and an Unrestricted Grant from Research to Prevent
   Blindness, Inc, New York, New York. The authors indicate no financial
   conflict of interest. Involved in conception and design of study and
   obtaining funding for the study (J.E.G.); Conduct of study (J.E.G.,
   W.X., T.I.M., J.C.D., G.S.Y., E.R.M., J.L.D., A.J.B.); Collection of
   data (J.E.G., W.X., T.I.M., J.C.D., J.L.D., A.J.B.); Management of data
   (J.E.G., W.X., G.S.Y., E.R.M.); Analysis and interpretation of data
   (J.E.G., W.X., T.I.M., J.C.D., G.S.Y., E.R.M.); Preparation and revision
   of the manuscript (W.X., J.E.G.); Review of the manuscript (J.E.G.,
   T.I.M., J.C.D., G.S.Y., E.R.M., J.L.D., A.J.B.); and Final approval of
   the manuscript (J.E.G., W.X., T.I.M., J.C.D., G.S.Y., E.R.M., J.L.D.,
   A.J.B.). The study was approved by the Institutional Review Boards of
   the University of Pennsylvania in accordance with Health Insurance
   Portability and Accountability Act regulations and the tenets of the
   Declaration of Helsinki.
CR Anand R, 2000, OPHTHALMOLOGY, V107, P2224
   Au Eong KG, 2002, AGE RELATED MACULAR, P389
   Augood CA, 2006, ARCH OPHTHALMOL-CHIC, V124, P529, DOI 10.1001/archopht.124.4.529
   Boker T, 1993, Ger J Ophthalmol, V2, P10
   BRESSLER NM, 1994, RETINA-J RET VIT DIS, V14, P130, DOI 10.1097/00006982-199414020-00006
   Chaine G, 1998, BRIT J OPHTHALMOL, V82, P996, DOI 10.1136/bjo.82.9.996
   Coleman HR, 2008, LANCET, V372, P1835, DOI 10.1016/S0140-6736(08)61759-6
   Complications Age-Related Macular, 2008, OPHTHALMOLOGY, V115, P1474, DOI 10.1016/j.ophtha.2008.03.008
   Congdon N, 2004, ARCH OPHTHALMOL-CHIC, V122, P477
   Davis MD, 2005, ARCH OPHTHALMOL-CHIC, V123, P1484
   Delcourt C, 2001, Ophthalmic Epidemiol, V8, P237, DOI 10.1076/opep.8.4.237.1613
   Ding XY, 2009, PROG RETIN EYE RES, V28, P1, DOI 10.1016/j.preteyeres.2008.10.001
   Ehrlich R, 2009, GRAEF ARCH CLIN EXP, V247, P583, DOI 10.1007/s00417-008-1018-x
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P564
   FRIEDMAN E, 1995, OPHTHALMOLOGY, V102, P640, DOI 10.1016/S0161-6420(95)30974-8
   Friedman E, 1997, AM J OPHTHALMOL, V124, P677, DOI 10.1016/S0002-9394(14)70906-7
   Fujihara M, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003119
   Grunwald JE, 1998, ARCH OPHTHALMOL-CHIC, V116, P150
   Grunwald JE, 1998, INVEST OPHTH VIS SCI, V39, P385
   Grunwald JE, 2005, INVEST OPHTH VIS SCI, V46, P1033, DOI 10.1167/iovs.04-1050
   Hogg RE, 2008, OPHTHALMOLOGY, V115, P1046, DOI 10.1016/j.ophtha.2007.07.031
   Hyman L, 2000, ARCH OPHTHALMOL-CHIC, V118, P351, DOI 10.1001/archopht.118.3.351
   Ikram MK, 2003, INVEST OPHTH VIS SCI, V44, P3778, DOI 10.1167/iovs.03-0120
   Kiel JW, 1997, INVEST OPHTH VIS SCI, V38, P1290
   Klein R, 2007, OPHTHAL EPIDEMIOL, V14, P184, DOI 10.1080/09286580701344381
   Klein Ronald, 2003, Ophthalmology, V110, P1273, DOI 10.1016/S0161-6420(03)00599-2
   Metelitsina TI, 2008, INVEST OPHTH VIS SCI, V49, P358, DOI 10.1167/iovs.07-0526
   Metelitsina TI, 2006, BRIT J OPHTHALMOL, V90, P342, DOI 10.1136/bjo.2005.082974
   Mitchell P, 2002, OPHTHALMOLOGY, V109, P1092, DOI 10.1016/S0161-6420(02)01055-2
   Mukesh BN, 2004, OPHTHALMOLOGY, V111, P1176, DOI 10.1016/j.ophtha.2003.08.042
   Nitsch D, 2009, OPHTHAL EPIDEMIOL, V16, P181, DOI 10.1080/09286580902863064
   Nowak JZ, 2006, PHARMACOL REP, V58, P353
   RAMRATTAN RS, 1994, INVEST OPHTH VIS SCI, V35, P2857
   RIVA CE, 1992, EXP EYE RES, V55, P499, DOI 10.1016/0014-4835(92)90123-A
   RIVA CE, 1994, INVEST OPHTH VIS SCI, V35, P4273
   Riva Charles E., 2001, International Ophthalmology, V23, P183, DOI 10.1023/A:1014433913240
   Ross RD, 1998, AM J OPHTHALMOL, V125, P71, DOI 10.1016/S0002-9394(99)80237-2
   Tomany SC, 2004, OPHTHALMOLOGY, V111, P1280, DOI 10.1016/j.ophtha.2003.11.010
   ZEGER SL, 1986, BIOMETRICS, V42, P121, DOI 10.2307/2531248
NR 39
TC 58
Z9 58
U1 0
U2 7
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 0002-9394
EI 1879-1891
J9 AM J OPHTHALMOL
JI Am. J. Ophthalmol.
PD JUL
PY 2010
VL 150
IS 1
BP 40
EP 47
DI 10.1016/j.ajo.2010.01.041
PG 8
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 624FW
UT WOS:000279803200009
PM 20493466
OA Green Accepted
DA 2022-11-30
ER

PT J
AU Zhang, R
   Wang, LY
   Wang, YF
   Wu, CR
   Lei, CL
   Wang, MX
   Ma, L
AF Zhang, Rui
   Wang, Li-Yuan
   Wang, Ya-Feng
   Wu, Chang-Rui
   Lei, Chun-Ling
   Wang, Ming-Xu
   Ma, Le
TI Associations Between the T280M and V249I SNPs in CX3CR1 and the Risk of
   Age-Related Macular Degeneration
SO INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE
LA English
DT Article
DE age-related macular degeneration; CX3CR1; SNP
ID COMMON VARIANTS; RECEPTOR CX3CR1; POLYMORPHISMS; GENE; MACROPHAGES;
   FRACTALKINE; PROGRESSION; EXPRESSION; DISEASE; MONOCYTES
AB PURPOSE. Two common single nucleotide polymorphisms (SNPs) in the CX3CR1 gene, T280M and V249I, have been reported to affect the risk of age-related macular degeneration (AMD) in several studies. The aim of the present study was to combine all published data on the relationship between these two variants and AMD susceptibility in a meta-analysis to clarify this association.
   METHODS. MEDLINE, EMBASE, and ISI Web of Science were searched for all eligible studies on the relationship between AMD and T280M and V249I variants. The pooled odds ratio (OR) with 95% confidence intervals (CIs) for each SNP in the allele frequency, homozygote, second codominant genotype, and dominant genotype models were calculated to evaluate the strength of this association.
   RESULTS. A total of 3017 AMD cases and 4096 controls from eight studies were involved in this meta-analysis. Both T280M and V249I SNPs exhibited significant associations with increased risk of AMD in the allele (T versus C: OR = 1.43, 95% CI: 1.06-1.91; A versus G: OR = 1.25, 95% CI: 1.01-1.55) and homozygous models (TT versus CC: OR = 2.11, 95% CI: 1.00-4.43; AA versus GG: OR = 1.27, 95% CI: 1.00-1.61), while no significance association was observed for the codominant genotype model. Moreover, studies showing high linkage disequilibrium between these two variants demonstrated a significantly stronger connection between these SNPs and AMD risk, compared with the moderate linkage disequilibrium group.
   CONCLUSIONS. Significant evidence for a relationship between T280M and V249I variants in CX3CR1 in the homozygote state with increased susceptibility to AMD was reported. Further studies are needed to confirm these findings.
C1 [Zhang, Rui; Wang, Li-Yuan; Wang, Ya-Feng; Wang, Ming-Xu; Ma, Le] Xi An Jiao Tong Univ, Sch Publ Hlth, Hlth Sci Ctr, Xian 710061, Shaanxi, Peoples R China.
   [Wu, Chang-Rui] Xi An Jiao Tong Univ, Coll Med, Affiliated Hosp 1, Xian 710061, Shaanxi, Peoples R China.
   [Lei, Chun-Ling] Xi An Jiao Tong Univ, Hosp Xian 4, Xian 710061, Shaanxi, Peoples R China.
C3 Xi'an Jiaotong University; Xi'an Jiaotong University; Xi'an Jiaotong
   University
RP Ma, L (通讯作者)，Xi An Jiao Tong Univ, Sch Publ Hlth, Hlth Sci Ctr, 76 Yanta West Rd, Xian 710061, Shaanxi, Peoples R China.
EM wangmx601@mail.xjtu.edu.cn; male@mail.xjtu.edu.cn
RI wang, yafeng/J-4829-2017
OI ma, le/0000-0001-7592-9779
CR Anastasopoulos E, 2012, CURR EYE RES, V37, P1148, DOI 10.3109/02713683.2012.705413
   BEGG CB, 1994, BIOMETRICS, V50, P1088, DOI 10.2307/2533446
   Chan CC, 2005, HISTOL HISTOPATHOL, V20, P857, DOI 10.14670/HH-20.857
   Chan CC, 2014, ADV EXP MED BIOL, V801, P193, DOI 10.1007/978-1-4614-3209-8_25
   Cherepanoff S, 2010, BRIT J OPHTHALMOL, V94, P918, DOI 10.1136/bjo.2009.165563
   Chu LQ, 2009, OPHTHAL RES, V42, P160, DOI 10.1159/000230878
   Combadiere C, 2007, J CLIN INVEST, V117, P2920, DOI 10.1172/JCI31692
   DeVries ME, 2003, J BIOL CHEM, V278, P11985, DOI 10.1074/jbc.M211422200
   Egger M, 1997, BMJ-BRIT MED J, V315, P629, DOI 10.1136/bmj.315.7109.629
   Faure S, 2000, SCIENCE, V287, P2274, DOI 10.1126/science.287.5461.2274
   Grunin M, 2014, ADV EXP MED BIOL, V801, P199, DOI 10.1007/978-1-4614-3209-8_26
   Gupta D, 2014, ARCH MED RES, V45, P489, DOI 10.1016/j.arcmed.2014.07.005
   Hageman Gregory S., 2011, Human Genomics, V5, P420
   Higgins JPT, 2003, BRIT MED J, V327, P557, DOI 10.1136/bmj.327.7414.557
   Hu JY, 2011, OPHTHAL EPIDEMIOL, V18, P137, DOI 10.3109/09286586.2011.574335
   Jonasson F, 2014, OPHTHALMOLOGY, V121, P1766, DOI 10.1016/j.ophtha.2014.03.013
   Keane PA, 2015, CLIN OPHTHALMOL, V9, P353, DOI 10.2147/OPTH.S59012
   Lee JH, 2014, J RHEUMATOL, V41, P2425, DOI 10.3899/jrheum.130892
   Lim LS, 2012, LANCET, V379, P1728, DOI 10.1016/S0140-6736(12)60282-7
   Liu MM, 2012, HUM GENOMICS, V6, DOI 10.1186/1479-7364-6-13
   Luhmann UFO, 2014, ADV EXP MED BIOL, V801, P427, DOI 10.1007/978-1-4614-3209-8_54
   Mangin B, 2012, HEREDITY, V108, P285, DOI 10.1038/hdy.2011.73
   Matzhold EM, 2009, CYTOKINE, V47, P224, DOI 10.1016/j.cyto.2009.06.010
   McDermott DH, 2003, J CLIN INVEST, V111, P1241, DOI 10.1172/JCI200316790
   Moatti D, 2001, BLOOD, V97, P1925, DOI 10.1182/blood.V97.7.1925
   Patel M, 2008, SEMIN IMMUNOPATHOL, V30, P97, DOI 10.1007/s00281-008-0112-9
   Petersen TR, 2014, J LEUKOCYTE BIOL, V96, P1001, DOI 10.1189/jlb.1A0314-130R
   Qu HQ, 2009, J MED GENET, V46, P553, DOI 10.1136/jmg.2009.067140
   Schaumberg DA, 2014, JAMA OPHTHALMOL, V132, P84, DOI 10.1001/jamaophthalmol.2013.5506
   Schaumberg DA, 2010, ARCH OPHTHALMOL-CHIC, V128, P1462, DOI 10.1001/archophthalmol.2010.261
   Schmitz-Valckenberg S, 2009, SURV OPHTHALMOL, V54, P96, DOI 10.1016/j.survophthal.2008.10.004
   Sennlaub F, 2013, EMBO MOL MED, V5, P1775, DOI 10.1002/emmm.201302692
   Singh N, 2012, GENET TEST MOL BIOMA, V16, P756, DOI 10.1089/gtmb.2011.0256
   Stang A, 2010, EUR J EPIDEMIOL, V25, P603, DOI 10.1007/s10654-010-9491-z
   Tou JS, 2004, FASEB J, V18, P1297, DOI 10.1096/fj.04-1862fje
   Tsai WH, 2014, J CHIN MED ASSOC, V77, P367, DOI 10.1016/j.jcma.2014.04.008
   Wu J, 2014, DIS MARKERS, V2014, DOI 10.1155/2014/913678
   Yang X, 2010, BRIT J OPHTHALMOL, V94, P1211, DOI 10.1136/bjo.2009.165811
   Zarbin MA, 2014, DEV OPHTHALMOL, V53, P1, DOI 10.1159/000358536
   Zerbib J, 2011, EXP EYE RES, V93, P382, DOI 10.1016/j.exer.2011.05.005
NR 40
TC 9
Z9 9
U1 0
U2 10
PU ASSOC RESEARCH VISION OPHTHALMOLOGY INC
PI ROCKVILLE
PA 12300 TWINBROOK PARKWAY, ROCKVILLE, MD 20852-1606 USA
SN 0146-0404
EI 1552-5783
J9 INVEST OPHTH VIS SCI
JI Invest. Ophthalmol. Vis. Sci.
PD AUG
PY 2015
VL 56
IS 9
BP 5590
EP 5598
DI 10.1167/iovs.15-16830
PG 9
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA CT5WW
UT WOS:000362882800070
PM 26305531
DA 2022-11-30
ER

PT J
AU Barbazetto, I
   Saroj, N
   Shapiro, H
   Wong, P
   Freund, KB
AF Barbazetto, Irene
   Saroj, Namrata
   Shapiro, Howard
   Wong, Pamela
   Freund, K. Bailey
TI DOSING REGIMEN AND THE FREQUENCY OF MACULAR HEMORRHAGES IN NEOVASCULAR
   AGE-RELATED MACULAR DEGENERATION TREATED WITH RANIBIZUMAB
SO RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES
LA English
DT Article
DE age-related macular degeneration; choroidal neovascularization;
   ranibizumab; macular hemorrhage
ID SUBRETINAL HEMORRHAGE; NATURAL-HISTORY; VERTEPORFIN
AB Purpose: The purpose of this study was to investigate if monthly intravitreal ranibizumab decreases risk of macular hemorrhages in patients with choroidal neovascularization secondary to age-related macular degeneration.
   Methods: Incidences of macular hemorrhages in the control and ranibizumab groups from three, multicenter, randomized, clinical trials (MARINA, ANCHOR, and PIER) were compared. Two time intervals (Months 0-3 and 5-17) were evaluated to account for transition from monthly to quarterly injections in PIER. Time interval after Month 17 was excluded because of crossover from control to active treatment in all trials.
   Results: Months 0-3: All trials showed higher incidence rates of hemorrhages in control compared with ranibizumab groups (ANCHOR: photodynamic therapy [27.3%], 0.3 mg [8.0%], 0.5 mg [8.6%]; MARINA: sham [18.6%], 0.3 mg [8.8%], 0.5 mg [8.8%]; and PIER: sham [16.1%], 0.3 mg [3.4%], 0.5 mg [3.3%]). In ANCHOR and MARINA, data of Months 5-17 showed higher incidence rates in control compared with monthly ranibizumab groups (ANCHOR: photodynamic therapy [47.8%], 0.3 mg [12.5%], 0.5 mg [12.3%]; and MARINA: sham [38.0%], 0.3 mg [13.2%], 0.5 mg [13.0%]), but this was not seen for quarterly ranibizumab groups in PIER (sham [22.4%], 0.3 mg [23.7%], 0.5 mg [28.3%]).
   Conclusion: Treatment with monthly intravitreal ranibizumab was associated with reduced risk of new macular hemorrhages when compared with photodynamic therapy (ANCHOR) or sham (MARINA and PIER). There was no difference between PIER quarterly ranibizumab-treated and sham patients. RETINA 30: 1376-1385, 2010
C1 [Barbazetto, Irene; Freund, K. Bailey] Vitreous Retina Macula Consultants New York, New York, NY 10022 USA.
   [Saroj, Namrata; Shapiro, Howard; Wong, Pamela] Genentech Inc, San Francisco, CA 94080 USA.
C3 Vitreous Retina Macula Consultants of New York; Roche Holding; Genentech
RP Freund, KB (通讯作者)，Vitreous Retina Macula Consultants New York, 460 Pk Ave,5th Floor, New York, NY 10022 USA.
EM kbfnyf@aol.com
RI Freund, K. Bailey/V-7488-2018
OI Freund, K. Bailey/0000-0002-7888-9773
FU Genentech, Inc., South San Francisco, CA; Novartis Pharma, AG, Basel,
   Switzerland
FX The ANCHOR, MARINA, and PIER studies were funded by Genentech, Inc.,
   South San Francisco, CA, and Novartis Pharma, AG, Basel, Switzerland.
   Genentech designed and oversaw the conduct of the ANCHOR, MARINA, and
   PIER studies and managed and statistically analyzed the data.
CR Avery RL, 1996, RETINA-J RET VIT DIS, V16, P183, DOI 10.1097/00006982-199616030-00001
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Brown DM, 2009, OPHTHALMOLOGY, V116, P57, DOI 10.1016/j.ophtha.2008.10.018
   Davis MD, 2005, ARCH OPHTHALMOL-CHIC, V123, P1484
   Gaudreault J, 2007, RETINA-J RET VIT DIS, V27, P1260, DOI 10.1097/IAE.0b013e318134eecd
   Goverdhan SV, 2008, BRIT J OPHTHALMOL, V92, P210, DOI 10.1136/bjo.2007.127902
   Mozaffarieh M, 2008, OPHTHALMOLOGICA, V222, P199, DOI 10.1159/000126084
   Regillo CD, 2008, AM J OPHTHALMOL, V145, P239, DOI 10.1016/j.ajo.2007.10.004
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Scupola A, 1999, OPHTHALMOLOGICA, V213, P97, DOI 10.1159/000027400
   Yannuzzi LA, 2001, RETINA-J RET VIT DIS, V21, P416, DOI 10.1097/00006982-200110000-00003
NR 11
TC 12
Z9 13
U1 0
U2 1
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0275-004X
EI 1539-2864
J9 RETINA-J RET VIT DIS
JI Retin.-J. Retin. Vitr. Dis.
PD OCT
PY 2010
VL 30
IS 9
BP 1376
EP 1385
DI 10.1097/IAE.0b013e3181dcfb0b
PG 10
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 659JC
UT WOS:000282561800004
PM 20683380
DA 2022-11-30
ER

PT J
AU Wintergerst, MWM
   Schultz, T
   Birtel, J
   Schuster, AK
   Pfeiffer, N
   Schmitz-Valckenberg, S
   Holz, FG
   Finger, RP
AF Wintergerst, Maximilian W. M.
   Schultz, Thomas
   Birtel, Johannes
   Schuster, Alexander K.
   Pfeiffer, Norbert
   Schmitz-Valckenberg, Steffen
   Holz, Frank G.
   Finger, Robert P.
TI Algorithms for the Automated Analysis of Age-Related Macular
   Degeneration Biomarkers on Optical Coherence Tomography: A Systematic
   Review
SO TRANSLATIONAL VISION SCIENCE & TECHNOLOGY
LA English
DT Review
DE automated image analysis; optical coherence tomography; age-related
   macular degeneration
ID PIGMENT EPITHELIAL DETACHMENTS; GEOGRAPHIC ATROPHY SEGMENTATION; SD-OCT;
   SUBRETINAL FLUID; PATHOLOGY DIAGNOSIS; DRUSEN SEGMENTATION; IMAGES;
   EDEMA; REPRODUCIBILITY; QUANTIFICATION
AB Purpose: To assess the quality of optical coherence tomography (OCT) grading algorithms for retinal biomarkers of age-related macular degeneration (AMD).
   Methods: Following a systematic review of the literature data on detection and quantification of AMD retinal biomarkers by available algorithms were extracted and descriptively synthesized. Algorithm quality was assessed using a modified version of the Quality Assessment of Diagnostic Accuracy Studies 2 checklist with a focus on accuracy against established reference standards and risk of bias.
   Results: Thirty five studies reporting computer-aided diagnosis (CAD) tools for qualitative analysis or algorithms for quantitative analysis were identified. Compared with manual assessment in reference standards correlation coefficients ranged from 0.54 to 0.97 for drusen, 0.80 to 0.98 for geographic atrophy (GA), and 0.30 to 0.98 for intra-or subretinal fluid and pigment epithelial detachment (PED) detection by automated algorithms. CAD tools achieved area under the curve (AUC) values of 0.94 to 0.99, sensitivity of 0.90 to 1.00, and specificity of 0.89 to 0.92.
   Conclusions: Automated analysis of AMD biomarkers on OCT is promising. However, most of the algorithm validation was performed in preselected patients, exhibiting the targeted biomarker only. In addition, type and quality of reported algorithm validation varied substantially.
   Translational Relevance: The development of algorithms for combined, simultaneous analysis of multiple AMD biomarkers including AMD staging and the agreement on standardized validation procedures would be of considerable translational value for the clinician and the clinical researcher.
C1 [Wintergerst, Maximilian W. M.; Birtel, Johannes; Schmitz-Valckenberg, Steffen; Holz, Frank G.; Finger, Robert P.] Univ Bonn, Dept Ophthalmol, Bonn, Germany.
   [Schultz, Thomas] Univ Bonn, Dept Comp Sci, Bonn, Germany.
   [Schuster, Alexander K.; Pfeiffer, Norbert] Univ Med Ctr Mainz, Dept Ophthalmol, Mainz, Germany.
C3 University of Bonn; University of Bonn; Johannes Gutenberg University of
   Mainz
RP Finger, RP (通讯作者)，Univ Bonn, Dept Ophthalmol, Chair Ophthalm Epidemiol & Neuroretinal Imagi, Ernst Abbe Str 2, D-53127 Bonn, Germany.
EM robert.finger@ukb.uni-bonn.de
RI Wintergerst, Maximilian/E-5523-2019; Pfeiffer, Norbert/AAO-7586-2020;
   Wintergerst, Maximilian/AAW-2972-2021
OI Wintergerst, Maximilian/0000-0002-2766-7038; Finger, Robert
   P/0000-0003-4253-7597
CR Ahlers C, 2008, BRIT J OPHTHALMOL, V92, P197, DOI 10.1136/bjo.2007.120956
   Albarrak A, 2013, 17 ANN C MED IM UND
   Boykov Y, 2001, IEEE T PATTERN ANAL, V23, P1222, DOI 10.1109/34.969114
   BREIMAN L, 2001, MACH LEARN, V0045
   CASELLES V, 1993, NUMER MATH, V66, P1, DOI 10.1007/BF01385685
   Chen Q, 2013, BIOMED OPT EXPRESS, V4, P2729, DOI 10.1364/BOE.4.002729
   Chen Q, 2013, MED IMAGE ANAL, V17, P1058, DOI 10.1016/j.media.2013.06.003
   Chen XJ, 2012, IEEE T MED IMAGING, V31, P1521, DOI 10.1109/TMI.2012.2191302
   Cherkassky V, 1997, IEEE Trans Neural Netw, V8, P1564, DOI 10.1109/TNN.1997.641482
   Chiu SJ, 2012, INVEST OPHTH VIS SCI, V53, P53, DOI 10.1167/iovs.11-7640
   Chiu SJ, 2010, OPT EXPRESS, V18, P19413, DOI 10.1364/OE.18.019413
   COVER TM, 1967, IEEE T INFORM THEORY, V13, P21, DOI 10.1109/TIT.1967.1053964
   de Sisternes L, 2014, INVEST OPHTH VIS SCI, V55, P7093, DOI 10.1167/iovs.14-14918
   Dijkstra E.W., 1959, NUMER MATH, V1, P269, DOI [10.1007/BF01386390, DOI 10.1007/BF01386390]
   Ding WG, 2013, IEEE ENG MED BIO, P7388, DOI 10.1109/EMBC.2013.6611265
   Diniz B, 2015, EYE, V29, P272, DOI 10.1038/eye.2014.260
   Diniz B, 2014, RETINA-J RET VIT DIS, V34, P55, DOI 10.1097/IAE.0b013e31829d0015
   Dolejsi M, 2010, BIOS 2010 JUN BRNO C
   Farsiu S, 2008, PROC SPIE, V6844, DOI 10.1117/12.768624
   Farsiu S, 2014, OPHTHALMOLOGY, V121, P162, DOI 10.1016/j.ophtha.2013.07.013
   Fernandez DC, 2005, IEEE T MED IMAGING, V24, P929, DOI 10.1109/TMI.2005.848655
   Filho CADG, 2013, OPHTHAL SURG LAS IM, V44, P204, DOI 10.3928/23258160-20130313-12
   Folgar FA, 2016, OPHTHALMOLOGY, V123, P39, DOI 10.1016/j.ophtha.2015.09.016
   Folgar FA, 2012, INVEST OPHTH VIS SCI, V53, P4626, DOI 10.1167/iovs.12-9813
   Garvin MK, 2008, IEEE T MED IMAGING, V27, P1495, DOI 10.1109/TMI.2008.923966
   Gibou F, 2003, J SCI COMPUT, V19, P183, DOI 10.1023/A:1025399807998
   Goldstein T, 2010, J SCI COMPUT, V45, P272, DOI 10.1007/s10915-009-9331-z
   Goldstein T, 2009, SIAM J IMAGING SCI, V2, P323, DOI 10.1137/080725891
   Gregori G, 2014, INVEST OPHTH VIS SCI, V55, P7662, DOI 10.1167/iovs.14-15273
   Gregori G, 2011, OPHTHALMOLOGY, V118, P1373, DOI 10.1016/j.ophtha.2010.11.013
   HARALICK RM, 1973, IEEE T SYST MAN CYB, VSMC3, P610, DOI 10.1109/TSMC.1973.4309314
   HARTIGAN JA, 1985, J CLASSIF, V2, P63, DOI 10.1007/BF01908064
   Hee MR, 1998, OPHTHALMOLOGY, V105, P360, DOI 10.1016/S0161-6420(98)93601-6
   Ho J, 2015, RETINA-J RET VIT DIS, V35, P467, DOI 10.1097/IAE.0000000000000355
   Hu ZH, 2013, INVEST OPHTH VIS SCI, V54, P8375, DOI 10.1167/iovs.13-12552
   Ishikawa H, 2005, INVEST OPHTH VIS SCI, V46, P2012, DOI 10.1167/iovs.04-0335
   Iwama D, 2012, INVEST OPHTH VIS SCI, V53, P1576, DOI 10.1167/iovs.11-8103
   Jain N, 2010, INVEST OPHTH VIS SCI, V51, P4875, DOI 10.1167/iovs.09-4962
   Kanagasingam Y, 2014, PROG RETIN EYE RES, V38, P20, DOI 10.1016/j.preteyeres.2013.10.002
   Kass M., 1987, Proceedings of the First International Conference on Computer Vision (Cat. No.87CH2465-3), P259
   kauai HI, C4 5 PROGRAMS MACHIN
   KLEIN R, 1992, OPHTHALMOLOGY, V99, P933
   Lang A, 2015, BIOMED OPT EXPRESS, V6, P155, DOI 10.1364/BOE.6.000155
   Lecun Y, 1998, P IEEE, V86, P2278, DOI 10.1109/5.726791
   Lee KM, 2009, THESIS
   Lee SY, 2012, INVEST OPHTH VIS SCI, V53, P164, DOI 10.1167/iovs.11-8188
   Li K, 2006, IEEE T PATTERN ANAL, V28, P119, DOI 10.1109/TPAMI.2006.19
   Liu YY, 2011, INVEST OPHTH VIS SCI, V52, P8316, DOI 10.1167/iovs.10-7012
   Liu YY, 2011, MED IMAGE ANAL, V15, P748, DOI 10.1016/j.media.2011.06.005
   Nathoo NA, 2014, AM J OPHTHALMOL, V158, P757, DOI 10.1016/j.ajo.2014.06.021
   Niemeijer M, 2012, INVEST OPHTH VIS SCI, V53, P4074
   Nittala MG, 2012, INVEST OPHTH VIS SCI, V53, P8319, DOI 10.1167/iovs.12-10582
   Niu SJ, 2016, BIOMED OPT EXPRESS, V7, P581, DOI 10.1364/BOE.7.000581
   Penha FM, 2013, RETINA-J RET VIT DIS, V33, P459, DOI 10.1097/IAE.0b013e31827d2657
   Penha FM, 2013, OPHTHAL SURG LAS IM, V44, P10, DOI 10.3928/23258160-20121221-06
   Penha FM, 2012, AM J OPHTHALMOL, V153, P515, DOI 10.1016/j.ajo.2011.08.031
   Pilch M, 2013, INVEST OPHTH VIS SCI, V54, P4385, DOI 10.1167/iovs.12-11396
   Quellec G, 2010, IEEE T MED IMAGING, V29, P1321, DOI 10.1109/TMI.2010.2047023
   Schlanitz FG, 2010, INVEST OPHTH VIS SCI, V51, P6715, DOI 10.1167/iovs.10-5288
   Schutze C, 2011, ACTA OPHTHALMOL, V89, P235, DOI 10.1111/j.1755-3768.2010.01955.x
   Schuman SG, 2009, OPHTHALMOLOGY, V116, P488, DOI 10.1016/j.ophtha.2008.10.006
   Serrano-Aguilar P, 2012, BRIT J OPHTHALMOL, V96, P503, DOI 10.1136/bjophthalmol-2011-300660
   Sethian JA., 1999, LEVEL SET METHODS FA
   Shi F, 2015, IEEE T MED IMAGING, V34, P441, DOI 10.1109/TMI.2014.2359980
   Srinivasan PP, 2014, BIOMED OPT EXPRESS, V5, P3568, DOI 10.1364/BOE.5.003568
   Sun ZL, 2016, SCI REP-UK, V6, DOI 10.1038/srep21739
   Toth C., 2008, INVEST OPHTHALMOL, V49, P5394
   Tsechpenakis G, 2008, LECT NOTES COMPUT SC, V5241, P883, DOI 10.1007/978-3-540-85988-8_105
   Venhuizen FG, 2015, P SOC PHOTO-OPT INS
   Viola P, 2001, P 2001 IEEE INT C S
   Wilkins GR, 2012, IEEE T BIO-MED ENG, V59, P1109, DOI 10.1109/TBME.2012.2184759
   Xu CY, 1998, IEEE T IMAGE PROCESS, V7, P359, DOI 10.1109/83.661186
   Xu XY, 2015, IEEE T MED IMAGING, V34, P1616, DOI 10.1109/TMI.2015.2408632
   Yehoshua Z, 2013, INVEST OPHTH VIS SCI, V54, P2429, DOI 10.1167/iovs.12-11569
   Yehoshua Z, 2013, OSLI RETINA, V44, P127, DOI 10.3928/23258160-20130313-05
   Yehoshua Z, 2011, OPHTHALMOLOGY, V118, P2434, DOI 10.1016/j.ophtha.2011.05.008
   Zhang YG, 2014, EURASIP J ADV SIG PR, DOI 10.1186/1687-6180-2014-17
   Zheng YL, 2013, AM J OPHTHALMOL, V155, P277, DOI 10.1016/j.ajo.2012.07.030
NR 78
TC 27
Z9 27
U1 0
U2 16
PU ASSOC RESEARCH VISION OPHTHALMOLOGY INC
PI ROCKVILLE
PA 12300 TWINBROOK PARKWAY, ROCKVILLE, MD 20852-1606 USA
SN 2164-2591
J9 TRANSL VIS SCI TECHN
JI Transl. Vis. Sci. Technol.
PD JUL
PY 2017
VL 6
IS 4
AR 10
DI 10.1167/tvst.6.4.10
PG 20
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA FH2HH
UT WOS:000410959300010
PM 28729948
OA Green Published, gold
DA 2022-11-30
ER

PT J
AU Parisi, V
   Ziccardi, L
   Costanzo, E
   Tedeschi, M
   Barbano, L
   Manca, D
   Di Renzo, A
   Giorno, P
   Varano, M
   Parravano, M
AF Parisi, Vincenzo
   Ziccardi, Lucia
   Costanzo, Eliana
   Tedeschi, Massimiliano
   Barbano, Lucilla
   Manca, Daniela
   Di Renzo, Antonio
   Giorno, Paola
   Varano, Monica
   Parravano, Mariacristina
TI Macular Functional and Morphological Changes in Intermediate Age-Related
   Maculopathy
SO INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE
LA English
DT Article
DE intermediate AMD; mfERG; SD-OCT; OCT angiography
ID COHERENCE TOMOGRAPHY ANGIOGRAPHY; MULTIFOCAL ELECTRORETINOGRAM; PIGMENT
   EPITHELIUM; VISUAL IMPAIRMENT; RETICULAR DRUSEN; RETINAL FUNCTION;
   DEGENERATION; EYES; LAYER; MFERG
AB PURPOSE. The purpose of this study was to evaluate macular preganglionic function and to verify its relationship with retinal and choroidal morphology in patients with intermediate age-related macular degeneration (iAMD) patients.
   METHODS. All included patients performed multifocal electroretinogram (mfERG) for investigating on macular function from the central 15 degrees of foveal eccentricity, spectral domain optical coherence tomography (SD-OCT) for studying retinal structure, enhanced depth imaging OCT (EDI-OCT) for the measure of choroidal vascularity index (CVI), and OCT-angiography (OCTA) for the evaluation of vessel density (VD) in the superficial and deep capillary plexus, and choriocapillaris (CC) layer.
   RESULTS. Twenty-seven patients with iAMD and 20 age-matched control eyes were analyzed. Significantly (P < 0.01) delayed and reduced mfERG responses in the central 0 to 2.5 degrees, paracentral 2.5 to 5 degrees, and overall 0 to 5 degrees areas, as well as increased CVI values in both foveal (1 mm centered to the fovea) and fovea + parafovea areas (3 mm centered to the fovea), increased foveal and parafoveal (annular area of 1-3 mm centered to the fovea) retinal pigment epithelium thickness, and volume and parafoveal outer retinal volume were found in iAMD eyes as compared to controls. Moreover, iAMD eyes showed significantly (P < 0.01) reduced foveal and parafoveal OCTA-VD values in the CC layer when compared to controls. In the iAMD group, not significant (P > 0.01) correlations were found between morphological and functional parameters.
   CONCLUSIONS. Our findings support a dysfunction of photoreceptors and bipolar cells in both foveal and parafoveal areas in the presence of outer retina, CC, and choroidal structural changes, however, not significantly correlated. The observed enlargement of luminal choroidal area (measured by CVI) is possibly compensatory to CC vascular insufficiency.
C1 [Parisi, Vincenzo; Ziccardi, Lucia; Costanzo, Eliana; Tedeschi, Massimiliano; Barbano, Lucilla; Manca, Daniela; Di Renzo, Antonio; Giorno, Paola; Varano, Monica; Parravano, Mariacristina] IRCCS Fdn Bietti, Via Livenza 1, I-00198 Rome, Italy.
C3 IRCCS - Fondazione "G.B. Bietti" per lo Studio e la Ricerca in
   Oftalmologia
RP Ziccardi, L (通讯作者)，IRCCS Fdn Bietti, Via Livenza 1, I-00198 Rome, Italy.
EM lucia.ziccardi@fondazionebietti.it
RI Di Renzo, Antonio/AAB-4899-2020; Varano, Monica/K-8573-2016; Parisi,
   Vincenzo/J-6137-2018
OI Varano, Monica/0000-0002-6530-1563
FU Italian Ministry of Health; Fondazione Roma
FX The contribution of IRCCS-Fondazione Bietti was supported by the Italian
   Ministry of Health and Fondazione Roma. The authors alone are
   responsible for the content and writing of the paper.
CR Ahn SM, 2018, BMC OPHTHALMOL, V18, DOI 10.1186/s12886-018-0866-3
   BOK D, 1985, INVEST OPHTH VIS SCI, V26, P1659
   Borrelli E, 2018, AM J OPHTHALMOL, V196, P34, DOI 10.1016/j.ajo.2018.08.014
   Borrelli E, 2018, INVEST OPHTH VIS SCI, V59, DOI 10.1167/iovs.18-23943
   BRESSLER NM, 1988, SURV OPHTHALMOL, V32, P375, DOI 10.1016/0039-6257(88)90052-5
   Capuano V, 2016, BRIT J OPHTHALMOL, V100, P677, DOI 10.1136/bjophthalmol-2015-307169
   Chatziralli I, 2018, INT OPHTHALMOL, V38, P1887, DOI 10.1007/s10792-017-0671-7
   Chen CZ, 2004, DOC OPHTHALMOL, V109, P1
   Corvi F, 2018, AM J OPHTHALMOL, V186, P25, DOI 10.1016/j.ajo.2017.11.011
   Corvi F, 2017, BRIT J OPHTHALMOL, V101, P348, DOI 10.1136/bjophthalmol-2016-308548
   Curcio CA, 2001, EYE, V15, P376, DOI 10.1038/eye.2001.140
   Curcio CA, 1996, INVEST OPHTH VIS SCI, V37, P1236
   Esmaeelpour M, 2014, INVEST OPHTH VIS SCI, V55, P5074, DOI 10.1167/iovs.14-14646
   Evans JR, 2002, BRIT J OPHTHALMOL, V86, P795, DOI 10.1136/bjo.86.7.795
   Ferris FL, 2013, OPHTHALMOLOGY, V120, P844, DOI 10.1016/j.ophtha.2012.10.036
   Garcia-Garcia JG, 2013, CLIN OPHTHALMOL, V7, P1303, DOI 10.2147/OPTH.S39258
   Gerth C, 2006, ARCH OPHTHALMOL-CHIC, V124, P345, DOI 10.1001/archopht.124.3.345
   Gin TJ, 2011, INVEST OPHTH VIS SCI, V52, P9267, DOI 10.1167/iovs.11-8517
   Gonzalez-Garcia E, 2016, DOC OPHTHALMOL, V133, P31, DOI 10.1007/s10633-016-9545-y
   Graham KW, 2018, RETINA-J RET VIT DIS, V38, P1751, DOI 10.1097/IAE.0000000000001777
   GREEN WR, 1993, OPHTHALMOLOGY, V100, P1519
   Green WR, 1999, MOL VIS, V3, P5
   Heinemann-Vernaleken B, 2001, GRAEF ARCH CLIN EXP, V239, P556, DOI 10.1007/s004170100308
   Hood DC, 2000, PROG RETIN EYE RES, V19, P607, DOI 10.1016/S1350-9462(00)00013-6
   Hood DC, 2012, DOC OPHTHALMOL, V124, P1, DOI 10.1007/s10633-011-9296-8
   Huang Shizhou, 2000, Documenta Ophthalmologica, V101, P115
   Keenan TD, 2019, RETINA, V40, P632
   Kennedy CJ, 1995, EYE, V9, P763, DOI 10.1038/eye.1995.192
   Klein R, 2007, OPHTHALMOLOGY, V114, P253, DOI 10.1016/j.ophtha.2006.10.040
   Lains I, 2017, AM J OPHTHALMOL, V180, P55, DOI 10.1016/j.ajo.2017.05.021
   Lamin A, 2019, EYE, V33, P428, DOI 10.1038/s41433-018-0234-9
   Lee EK, 2015, INVEST OPHTH VIS SCI, V56, P3976, DOI 10.1167/iovs.15-17013
   Li J, 2001, BRIT J OPHTHALMOL, V85, P287, DOI 10.1136/bjo.85.3.287
   Nittala MG, 2019, OPHTHALMOL RETINA, V3, P112, DOI 10.1016/j.oret.2018.09.017
   Nivison-Smith L, 2018, OPTOMETRY VISION SCI, V95, P648, DOI 10.1097/OPX.0000000000001256
   Nusinowitz S, 2018, CURR EYE RES, V43, P376, DOI 10.1080/02713683.2017.1401646
   Parisi V, 2008, OPHTHALMOLOGY, V115, P324, DOI 10.1016/j.ophtha.2007.05.029
   Parisi V, 2007, RETINA-J RET VIT DIS, V27, P879, DOI 10.1097/IAE.0b013e318042d6aa
   Parisi V, 2012, INVEST OPHTH VIS SCI, V53, P6973, DOI 10.1167/iovs.12-10256
   Parisi V, 2010, CLIN NEUROPHYSIOL, V121, P380, DOI 10.1016/j.clinph.2009.09.032
   Parravano M, 2013, DOC OPHTHALMOL, V127, P217, DOI 10.1007/s10633-013-9404-z
   Resnikoff S, 2004, B WORLD HEALTH ORGAN, V82, P844
   Rimayanti U, 2014, GRAEF ARCH CLIN EXP, V252, P563, DOI 10.1007/s00417-013-2496-z
   Sadigh S, 2013, INVEST OPHTH VIS SCI, V54, P1603, DOI 10.1167/iovs.12-11286
   Schuman SG, 2009, OPHTHALMOLOGY, V116, P488, DOI 10.1016/j.ophtha.2008.10.006
   Sonoda S, 2014, INVEST OPHTH VIS SCI, V55, P3893, DOI 10.1167/iovs.14-14447
   Steinberg JS, 2015, BRIT J OPHTHALMOL, V99, P1289, DOI 10.1136/bjophthalmol-2014-306535
   Steinberg JS, 2015, INVEST OPHTH VIS SCI, V56, P4267, DOI 10.1167/iovs.15-16657
   Toto L, 2017, BRIT J OPHTHALMOL, V101, P774, DOI 10.1136/bjophthalmol-2016-309160
   Toto L, 2016, RETINA-J RET VIT DIS, V36, P1566, DOI 10.1097/IAE.0000000000000962
   Waheed NK, 2016, DEV OPHTHALMOL, V56, P91, DOI 10.1159/000442784
   Wei X, 2017, RETINA-J RET VIT DIS, V37, P1120, DOI 10.1097/IAE.0000000000001312
   Yang SS, 2016, DOC OPHTHALMOL, V132, P17, DOI 10.1007/s10633-016-9523-4
   Yavas GF, 2014, DOC OPHTHALMOL, V129, P167, DOI 10.1007/s10633-014-9460-z
   Yiu G, 2015, AM J OPHTHALMOL, V159, P617, DOI 10.1016/j.ajo.2014.12.010
   Zarbin MA, 2014, DEV OPHTHALMOL, V53, P1, DOI 10.1159/000358536
NR 56
TC 11
Z9 11
U1 0
U2 4
PU ASSOC RESEARCH VISION OPHTHALMOLOGY INC
PI ROCKVILLE
PA 12300 TWINBROOK PARKWAY, ROCKVILLE, MD 20852-1606 USA
SN 0146-0404
EI 1552-5783
J9 INVEST OPHTH VIS SCI
JI Invest. Ophthalmol. Vis. Sci.
PD MAY
PY 2020
VL 61
IS 5
AR 11
DI 10.1167/iovs.61.5.11
PG 10
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA LZ0ET
UT WOS:000540905500012
PM 32396630
OA gold, Green Published
DA 2022-11-30
ER

PT J
AU Treumer, F
   Klatt, C
   Roider, J
   Hillenkamp, J
AF Treumer, F.
   Klatt, C.
   Roider, J.
   Hillenkamp, J.
TI Subretinal coapplication of recombinant tissue plasminogen activator and
   bevacizumab for neovascular age-related macular degeneration with
   submacular haemorrhage
SO BRITISH JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
ID PNEUMATIC DISPLACEMENT; INTRAVITREAL INJECTION; GAS; SURGERY; RABBITS
AB Aim: To evaluate the efficacy and safety of pars plana vitrectomy (ppV) with subretinal coapplication of recombinant tissue plasminogen activator (rtPA) and bevacizumab, and fluid-gas exchange for neovascular age-related macular degeneration (AMD) with submacular haemorrhage (SMH).
   Methods: Consecutive interventional case series of 12 patients with neovascular AMD with SMH with a maximum history of 14 days. All patients underwent ppV with subretinal coapplication of rtPA and bevacizumab, and fluid-gas (20% SF6) exchange. Phakic patients underwent concomitant cataract surgery. Additional injections of bevacizumab were applied intravitreally 4 and 8 weeks postop.
   Results: Complete displacement of SMH from the fovea was achieved in 9 of 12 patients. The mean best-corrected visual acuity (BCVA) improved significantly from preop logMAR 1.9 (range 3.0 to 0.7) to logMAR 1.2 (range 3.0 to 0.3) at 4 weeks postop (p = 0.01) and to logMAR 0.9 (range 1.6 to 0.2) at 12 weeks postop (p = 0.006). The mean improvement of BCVA 4 weeks postop as compared with preop was logMAR 0.7 (range -0.2 to 2.3). The mean improvement of BCVA 12 weeks postop as compared with preop was logMAR 0.96 (range -0.3 to 2.8). Overall, at 12 weeks postop, BCVA had improved in 10 patients, remained unchanged in one patient and worsened in one patient.
   Conclusion: PpV with subretinal coapplication of rtPA and bevacizumab, and fluid-gas exchange effectively displaces SMH and improves visual acuity in most patients.
C1 [Treumer, F.; Klatt, C.; Roider, J.; Hillenkamp, J.] Univ Med Ctr Schleswig Holstein, Dept Ophthalmol, D-24105 Kiel, Germany.
C3 University of Kiel; Schleswig Holstein University Hospital
RP Hillenkamp, J (通讯作者)，Univ Med Ctr Schleswig Holstein, Dept Ophthalmol, Arnold Heller Str 3,Haus 25, D-24105 Kiel, Germany.
EM hillenka@hotmail.com
RI Roider, Johann/E-4513-2010
CR Avery RL, 1996, RETINA-J RET VIT DIS, V16, P183, DOI 10.1097/00006982-199616030-00001
   Bhisitkul RB, 2008, INVEST OPHTH VIS SCI, V49, P4071, DOI 10.1167/iovs.08-1892
   Bressler NM, 2004, OPHTHALMOLOGY, V111, P1993, DOI 10.1016/j.ophtha.2004.07.023
   Chen W, 2007, CHINESE J ORG CHEM, V27, P8
   DEJUAN E, 1988, AM J OPHTHALMOL, V105, P25, DOI 10.1016/0002-9394(88)90116-X
   ELBABA F, 1986, OPHTHALMOLOGY, V93, P1581
   GLATT H, 1982, AM J OPHTHALMOL, V94, P762, DOI 10.1016/0002-9394(82)90301-4
   Handwerger BA, 2001, ARCH OPHTHALMOL-CHIC, V119, P28
   Haupert CL, 2001, AM J OPHTHALMOL, V131, P208, DOI 10.1016/S0002-9394(00)00734-0
   Heiduschka P, 2007, INVEST OPHTH VIS SCI, V48, P2814, DOI 10.1167/iovs.06-1171
   Hesse L, 1999, GRAEF ARCH CLIN EXP, V237, P273, DOI 10.1007/s004170050232
   Ip MS, 2008, OPHTHALMOLOGY, V115, P1837, DOI 10.1016/j.ophtha.2008.08.012
   Jackson TL, 2003, INVEST OPHTH VIS SCI, V44, P2141, DOI 10.1167/iovs.02-1027
   Kamei M, 1999, AM J OPHTHALMOL, V128, P739, DOI 10.1016/S0002-9394(99)00239-1
   LEWIS H, 1994, AM J OPHTHALMOL, V118, P559, DOI 10.1016/S0002-9394(14)76571-7
   Luke M, 2007, BRIT J OPHTHALMOL, V91, P1077, DOI 10.1136/bjo.2006.111260
   Meyer CH, 2008, ACTA OPHTHALMOL, V86, P490, DOI 10.1111/j.1600-0420.2007.01125.x
   Ohji M, 1998, ARCH OPHTHALMOL-CHIC, V116, P1326, DOI 10.1001/archopht.116.10.1326
   Olivier S, 2004, OPHTHALMOLOGY, V111, P1201, DOI 10.1016/j.ophtha.2003.10.020
   Schouten JSAG, 2009, GRAEF ARCH CLIN EXP, V247, P1, DOI 10.1007/s00417-008-0952-y
   TAKEUCHI A, 1994, INVEST OPHTH VIS SCI, V35, P3792
   TOTH CA, 1991, ARCH OPHTHALMOL-CHIC, V109, P723, DOI 10.1001/archopht.1991.01080050139046
   Treumer F, 2007, BRIT J OPHTHALMOL, V91, P349, DOI 10.1136/bjo.2006.102152
   VANDER JF, 1991, OPHTHALMOLOGY, V98, P23
NR 24
TC 47
Z9 50
U1 0
U2 1
PU BMJ PUBLISHING GROUP
PI LONDON
PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND
SN 0007-1161
EI 1468-2079
J9 BRIT J OPHTHALMOL
JI Br. J. Ophthalmol.
PD JAN
PY 2010
VL 94
IS 1
BP 48
EP 53
DI 10.1136/bjo.2009.164707
PG 6
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 544IW
UT WOS:000273650300010
PM 19946027
DA 2022-11-30
ER

PT J
AU Eleftheriadou, M
   Gemenetzi, M
   Lukic, M
   Sivaprasad, S
   Hykin, PG
   Hamilton, RD
   Rajendram, R
   Tufail, A
   Patel, PJ
AF Eleftheriadou, Maria
   Gemenetzi, Maria
   Lukic, Marko
   Sivaprasad, Sobha
   Hykin, Philip G.
   Hamilton, Robin D.
   Rajendram, Ranjan
   Tufail, Adnan
   Patel, Praveen J.
TI Three-Year Outcomes of Aflibercept Treatment for Neovascular Age-Related
   Macular Degeneration: Evidence from a Clinical Setting
SO OPHTHALMOLOGY AND THERAPY
LA English
DT Article
DE Aflibercept; AMD; Anti-VEGF; Clinical settings; Ophthalmology; Real-life
   outcomes
ID LONG-TERM OUTCOMES; CHOROIDAL NEOVASCULARIZATION; VISUAL OUTCOMES;
   7-YEAR OUTCOMES; RANIBIZUMAB; MARINA; EYES; HORIZON; ANCHOR; AMD
AB IntroductionTo report 3-year treatment outcomes with intravitreal aflibercept injections for neovascular age-related macular degeneration (nAMD) in routine clinical practice.MethodsThis was a retrospective, single-centre, non-randomized interventional case series analysis. Data from treatment-naive patients with nAMD treated between 1 October 2013 and 31 February 2014 were included in the analysis. Data including age, gender, vision acuity (VA) measured on Early Treatment of Diabetic Retinopathy Study charts (ETDRS) and injection numbers were recorded. Spectral domain optical coherence tomography (SD-OCT) data including presence or absence of macular fluid and automated central subfield macular thickness (CSMT) at year 1, 2 and 3 were also recorded.ResultsOf the 157 eyes of 148 patients treated, data from 108 eyes of 102 patients were available at 3-year follow-up. The mean (SD) age was 80.6 +/- 8.3years with a mean of 154.5 +/- 5.4weeks follow-up. The mean VA changed from 54.4 +/- 16 letters at baseline to 60.3 +/- 18.1 letters (VA gain 5.9 +/- 13.8 letter gain) at 1year, to 60.8 +/- 17.4 letters (VA gain 6.4 +/- 14.9 letters) at 2years and to 61.0 +/- 16.6 letters (VA gain 6.6 +/- 15.4 letters) at 3years. The reduction in CSMT was 77.9 +/- 101.4 mu m with absence of macular fluid in 71% of eyes. The total mean number of injections was 15.9 +/- 6.1 at year 3.Conclusion p id=Par4 The results suggest that good long-term morphological and functional treatment outcomes can be achieved using aflibercept for nAMD in a clinical setting.
C1 [Eleftheriadou, Maria; Gemenetzi, Maria; Lukic, Marko; Sivaprasad, Sobha; Hykin, Philip G.; Hamilton, Robin D.; Rajendram, Ranjan; Tufail, Adnan; Patel, Praveen J.] Moorfields Eye Hosp NHS Fdn Trust, NIHR Biomed Res Ctr, London, England.
   [Eleftheriadou, Maria; Gemenetzi, Maria; Lukic, Marko; Sivaprasad, Sobha; Hykin, Philip G.; Hamilton, Robin D.; Rajendram, Ranjan; Tufail, Adnan; Patel, Praveen J.] UCL Inst Ophthalmol, London, England.
C3 University of London; University College London; Moorfields Eye Hospital
   NHS Foundation Trust; University of London; University College London
RP Patel, PJ (通讯作者)，Moorfields Eye Hosp NHS Fdn Trust, NIHR Biomed Res Ctr, London, England.; Patel, PJ (通讯作者)，UCL Inst Ophthalmol, London, England.
EM praveen.patel@moorfields.nhs.uk
RI Sivaprasad, S./D-6876-2015
OI Sivaprasad, S./0000-0001-8952-0659; Tufail, Adnan/0000-0001-6131-7640
CR Almuhtaseb H, 2017, EYE, V31, P1582, DOI 10.1038/eye.2017.108
   Arevalo JF, 2016, RETINA-J RET VIT DIS, V36, P859, DOI 10.1097/IAE.0000000000000827
   Berg K, 2017, ACTA OPHTHALMOL, V95, P796, DOI 10.1111/aos.13522
   Bhisitkul RB, 2016, OPHTHALMOLOGY, V123, P1269, DOI 10.1016/j.ophtha.2016.01.033
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Brown DM, 2013, RETINA-J RET VIT DIS, V33, P23, DOI 10.1097/IAE.0b013e318263cedf
   Eleftheriadou M, 2017, AM J OPHTHALMOL, V174, P160, DOI 10.1016/j.ajo.2016.09.038
   Gillies MC, 2015, OPHTHALMOLOGY, V122, P1837, DOI 10.1016/j.ophtha.2015.05.010
   Heier JS, 2012, OPHTHALMOLOGY, V119, P2537, DOI 10.1016/j.ophtha.2012.09.006
   McKibbin M, 2015, EYE, V29, pS1, DOI 10.1038/eye.2015.77
   Mrejen S, 2015, J CLIN MED, V4, P1380, DOI 10.3390/jcm4071380
   Peden MC, 2015, OPHTHALMOLOGY, V122, P803, DOI 10.1016/j.ophtha.2014.11.018
   Rayess N, 2015, AM J OPHTHALMOL, V159, P3, DOI 10.1016/j.ajo.2014.09.011
   Rofagha S, 2013, OPHTHALMOLOGY, V120, P2292, DOI 10.1016/j.ophtha.2013.03.046
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Rosenfeld PJ, 2011, OPHTHALMOLOGY, V118, P523, DOI 10.1016/j.ophtha.2010.07.011
   Schmidt-Erfurth U, 2014, OPHTHALMOLOGY, V121, P193, DOI 10.1016/j.ophtha.2013.08.011
   Singer MA, 2012, OPHTHALMOLOGY, V119, P1175, DOI 10.1016/j.ophtha.2011.12.016
   Wolf S, 2011, BRIT J OPHTHALMOL, V95, P1713, DOI 10.1136/bjophthalmol-2011-300471
NR 19
TC 29
Z9 30
U1 0
U2 2
PU SPRINGER INTERNATIONAL PUBLISHING AG
PI CHAM
PA GEWERBESTRASSE 11, CHAM, CH-6330, SWITZERLAND
SN 2193-8245
EI 2193-6528
J9 OPHTHALMOL THER
JI OPHTHALMOL. THER.
PD DEC
PY 2018
VL 7
IS 2
BP 361
EP 368
DI 10.1007/s40123-018-0139-5
PG 8
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA HD5VN
UT WOS:000452599200013
PM 29982914
OA Green Published, gold
DA 2022-11-30
ER

PT J
AU Schmid-Kubista, KE
   Krebs, I
   Ansari-Shahrezaei, S
   Haas, P
   Hagen, S
   Binder, S
AF Schmid-Kubista, Katharina E.
   Krebs, Ilse
   Ansari-Shahrezaei, Siamak
   Haas, Paulina
   Hagen, Stefan
   Binder, Susanne
TI Comparing Treatment of Neovascular Age-related Macular Degeneration with
   Sequential Intravitreal Avastin and Macugen Versus Intravitreal
   Mono-therapy-A Pilot Study
SO CURRENT EYE RESEARCH
LA English
DT Article
DE Bevacizumab; Pegaptanib; Intravitreal injection; Anti-VEGF; Age-related
   macular degeneration
ID OPTICAL COHERENCE TOMOGRAPHY; BEVACIZUMAB AVASTIN; CHOROIDAL
   NEOVASCULARIZATION; PHOTODYNAMIC THERAPY; PEGAPTANIB; RANIBIZUMAB;
   MACULOPATHY
AB Purpose: To examine if the sequential treatment of Avastin and Macugen is safe and more efficient than the mono-therapies in a prospective randomized masked pilot study.
   Materials and Methods: Subjects with exudative age-related macular degeneration were randomized to receive three intravitreal injections of either 1 mg of Avastin, 0.3 mg Macugen, or first 1 mg Avastin followed by retreatment of 0.3 mg Macugen. Follow-up examinations were performed after 1, 6, 12 weeks, and 6 months.
   Results: Forty-eight subjects were included (13:18:17). Avastin resulted in lasting significant changes in visual acuity at 6 weeks, increase in contrast sensitivity at 6 weeks, and a significant decrease in macular thickness after 6 and 12 weeks. Macugen showed a significant decrease in retinal thickness after 6 weeks, but a significant decrease in visual acuity after 6 months, and a significant decrease in contrast sensitivity after 12 weeks and 6 months. The sequential treatment showed a decrease in retinal thickness after 1 and 12 weeks.
   Conclusion: Avastin alone is more effective in increasing visual acuity and contrast sensitivity and decreasing retinal thickness, than Macugen or the sequential treatment. We conclude that the sequential treatment of Avastin with Macugen is safe, but the single treatment of Avastin is more efficient.
C1 [Schmid-Kubista, Katharina E.; Krebs, Ilse; Ansari-Shahrezaei, Siamak; Haas, Paulina; Hagen, Stefan; Binder, Susanne] Rudolf Fdn Clin, Dept Ophthalmol, Ludwig Boltzmann Inst Retinol & Biomicroscop Lase, A-1030 Vienna, Austria.
C3 Ludwig Boltzmann Institute
RP Schmid-Kubista, KE (通讯作者)，Rudolf Fdn Clin, Dept Ophthalmol, Ludwig Boltzmann Inst Retinol & Biomicroscop Lase, Juchgasse 25, A-1030 Vienna, Austria.
EM kubista@proeyes.at
CR Avery RL, 2006, OPHTHALMOLOGY, V113, P363, DOI 10.1016/j.ophtha.2005.11.019
   Bressler NM, 1999, ARCH OPHTHALMOL-CHIC, V117, P1329
   Bressler SB, 2009, OPHTHALMOLOGY, V116, pS1, DOI 10.1016/j.ophtha.2009.06.045
   Carneiro A, 2009, EXP EYE RES, V88, P522, DOI 10.1016/j.exer.2008.11.011
   Chakravarthy U, 2006, OPHTHALMOLOGY, V113, P1508, DOI 10.1016/j.ophtha.2006.02.064
   Ferrara N, 2006, RETINA-J RET VIT DIS, V26, P859, DOI 10.1097/01.iae.0000242842.14624.e7
   FERRIS FL, 1984, ARCH OPHTHALMOL-CHIC, V102, P1640
   Friberg TR, 2010, BRIT J OPHTHALMOL, V94, P1611, DOI 10.1136/bjo.2009.174946
   Gragoudas ES, 2004, NEW ENGL J MED, V351, P2805, DOI 10.1056/NEJMoa042760
   Hudson PJ, 2003, NAT MED, V9, P129, DOI 10.1038/nm0103-129
   Ip MS, 2008, OPHTHALMOLOGY, V115, P1837, DOI 10.1016/j.ophtha.2008.08.012
   Joeres S, 2008, OPHTHALMOLOGY, V115, P347, DOI 10.1016/j.ophtha.2007.03.082
   Keane PA, 2010, INVEST OPHTH VIS SCI, V51, P5431, DOI 10.1167/iovs.09-4846
   KLEIN R, 1992, OPHTHALMOLOGY, V99, P933
   Manzano RPA, 2006, RETINA-J RET VIT DIS, V26, P257, DOI 10.1097/00006982-200603000-00001
   Ng EWM, 2006, NAT REV DRUG DISCOV, V5, P123, DOI 10.1038/nrd1955
   Radner W, 2002, GRAEF ARCH CLIN EXP, V240, P461, DOI 10.1007/s00417-002-0443-5
   Rosenfeld PJ, 2005, OPHTHAL SURG LAS IM, V36, P331, DOI 10.3928/1542-8877-20050701-14
   Schmid-Kubista KE, 2009, BRIT J OPHTHALMOL, V93, P914, DOI 10.1136/bjo.2008.144410
   Spaide RF, 2006, RETINA-J RET VIT DIS, V26, P383, DOI 10.1097/00006982-200604000-00001
   Tufail A, 2010, BMJ-BRIT MED J, V340, P2459
   Weigert G, 2008, BRIT J OPHTHALMOL, V92, P356, DOI 10.1136/bjo.2007.125823
NR 22
TC 8
Z9 9
U1 0
U2 15
PU INFORMA HEALTHCARE
PI LONDON
PA TELEPHONE HOUSE, 69-77 PAUL STREET, LONDON EC2A 4LQ, ENGLAND
SN 0271-3683
J9 CURR EYE RES
JI Curr. Eye Res.
PD OCT
PY 2011
VL 36
IS 10
BP 958
EP 963
DI 10.3109/02713683.2011.597536
PG 6
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 825MX
UT WOS:000295283300011
PM 21950702
DA 2022-11-30
ER

PT J
AU Sarici, K
   Abraham, JR
   Sevgi, DD
   Lunasco, L
   Srivastava, SK
   Whitney, J
   Cetin, H
   Hanumanthu, A
   Bell, JM
   Reese, JL
   Ehlers, JP
AF Sarici, Kubra
   Abraham, Joseph R.
   Sevgi, Duriye Damla
   Lunasco, Leina
   Srivastava, Sunil K.
   Whitney, Jon
   Cetin, Hasan
   Hanumanthu, Annapurna
   Bell, Jordan M.
   Reese, Jamie L.
   Ehlers, Justis P.
TI Risk Classification for Progression to Subfoveal Geographic Atrophy in
   Dry Age-Related Macular Degeneration Using Machine Learning-Enabled
   Outer Retinal Feature Extraction
SO OPHTHALMIC SURGERY LASERS & IMAGING RETINA
LA English
DT Article
ID CLINICAL-FEATURES; DRUSEN VOLUME; PREDICTION; ZONE; OCT
AB BACKGROUND AND OBJECTIVE: To evaluate the utility of spectral-domain optical coherence tomography biomarkers to predict the development of subfoveal geographic atrophy (sfGA). PATIENTS AND METHODS: This was a retrospective cohort analysis including 137 individuals with dry age-related macular degeneration without sfGA with 5 years of follow-up. Multiple spectral -domain optical coherence tomography quantitative metrics were generated, including ellipsoid zone (EZ) integrity and subretinal pigment epithelium (sub-RPE) compartment features. RESULTS: Reduced mean EZ-RPE central subfield thickness and increased sub-RPE compartment thickness were significantly different between sfGA convertors and nonconvertors at baseline in both 2-year and 5-year sfGA risk assessment. Longitudinal change assessment showed a significantly higher degradation of EZ integrity in sfGA convertors. The predictive performance of a machine learning classification model based on 5-year and 2-year risk conversion to sfGA demonstrated an area under the receiver operating characteristic curve of 0.92 +/- 0.06 and 0.96 +/- 0.04, respectively. CONCLUSIONS: Quantitative outer retinal and subRPE feature assessment using a machine learning- enabled retinal segmentation platform provides multiple parameters that are associated with progression to sfGA.
C1 [Sarici, Kubra; Abraham, Joseph R.; Sevgi, Duriye Damla; Lunasco, Leina; Srivastava, Sunil K.; Whitney, Jon; Cetin, Hasan; Hanumanthu, Annapurna; Bell, Jordan M.; Reese, Jamie L.; Ehlers, Justis P.] Cleveland Clin, Tony & Leona Campane Ctr Excellence Image Guided, Cole Eye Inst, Cleveland, OH 44106 USA.
   [Ehlers, Justis P.] Cleveland Clin, Cole Eye Inst, Vitreoretinal Serv, Cleveland, OH 44106 USA.
C3 Cleveland Clinic Foundation; Cleveland Clinic Foundation
RP Ehlers, JP (通讯作者)，Cleveland Clin, Cole Eye Inst, 2022 East 105th St,1 Bldg, Cleveland, OH 44106 USA.
EM ehlersj@ccf.org
OI Lunasco, Leina/0000-0003-3403-7429; Sarici, Kubra/0000-0001-7088-4356
FU National Institutes of Health/National Eye Institute [K23-EY022947-01A1]
FX Supported by a grant (K23-EY022947-01A1) to Justis P. Ehlers from the
   National Institutes of Health/National Eye Institute.
CR Abdelfattah NS, 2016, INVEST OPHTH VIS SCI, V57, P1839, DOI 10.1167/iovs.15-18572
   Arepalli S, 2018, RETINA-J RET VIT DIS, V38, P1427, DOI 10.1097/IAE.0000000000001716
   Arslan J, 2020, TRANSL VIS SCI TECHN, V9, DOI 10.1167/tvst.9.2.57
   Breiman L., 1996, MACH LEARN, V24, P123, DOI 10.1007/BF00058655
   Cleland SC, 2021, OPHTHALMOL RETINA, V5, P41, DOI 10.1016/j.oret.2020.07.006
   Ebneter A, 2016, INVEST OPHTH VIS SCI, V57, pOCT299, DOI 10.1167/iovs.15-18865
   Ehlers JP JG, 2020, AM SOC RET SPEC ANN
   Ehlers JP, 2021, OPHTHALMOL RETINA, V5, P1204, DOI 10.1016/j.oret.2021.02.012
   Holz FG, 2014, OPHTHALMOLOGY, V121, P1079, DOI 10.1016/j.ophtha.2013.11.023
   Itoh Y, 2016, BRIT J OPHTHALMOL, V100, P295, DOI 10.1136/bjophthalmol-2015-307105
   Liefers B, 2020, OPHTHALMOLOGY, V127, P1086, DOI 10.1016/j.ophtha.2020.02.009
   Niu SJ, 2016, OPHTHALMOLOGY, V123, P1737, DOI 10.1016/j.ophtha.2016.04.042
   Nunes RP, 2013, OSLI RETINA, V44, P344, DOI 10.3928/23258160-20130715-06
   Oishi M, 2017, INVEST OPHTH VIS SCI, V58, P3303, DOI 10.1167/iovs.17-21498
   Pasricha MV, 2021, OPHTHALMOL RETINA, V5, P396, DOI 10.1016/j.oret.2020.12.010
   Pfau M, 2020, JAMA OPHTHALMOL, V138, P1026, DOI 10.1001/jamaophthalmol.2020.2914
   Pfau M, 2020, OPHTHALMOL RETINA, V4, P238, DOI 10.1016/j.oret.2019.09.016
   Pfau M, 2019, RETINA-J RET VIT DIS, V39, P1527, DOI 10.1097/IAE.0000000000002206
   Reiter GS, 2020, INVEST OPHTH VIS SCI, V61, DOI 10.1167/iovs.61.6.11
   Roquet W, 2004, BRIT J OPHTHALMOL, V88, P638, DOI 10.1136/bjo.2003.017632
   Russakoff DB, 2019, INVEST OPHTH VIS SCI, V60, P712, DOI 10.1167/iovs.18-25325
   Saha S, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-47390-3
   Schmidt-Erfurth U, 2020, AM J OPHTHALMOL, V216, P257, DOI 10.1016/j.ajo.2020.03.042
   Schmidt-Erfurth U, 2018, INVEST OPHTH VIS SCI, V59, P3199, DOI 10.1167/iovs.18-24106
   Schwartz SD, 2015, LANCET, V385, P509, DOI 10.1016/S0140-6736(14)61376-3
   Sleiman K, 2017, OPHTHALMOLOGY, V124, P1764, DOI 10.1016/j.ophtha.2017.06.032
   Spaide RF, 2018, SURV OPHTHALMOL, V63, P782, DOI 10.1016/j.survophthal.2018.05.005
   Sunness JS, 2008, OPHTHALMOLOGY, V115, P1480, DOI 10.1016/j.ophtha.2008.03.009
   Sura AA, 2020, INVEST OPHTH VIS SCI, V61, DOI 10.1167/iovs.61.13.19
   Thiele S, 2018, OPHTHALMOLOGICA, V239, P110, DOI 10.1159/000485260
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
   Zanzottera EC, 2016, RETINA-J RET VIT DIS, V36, pS12, DOI 10.1097/IAE.0000000000001276
   Zweifel SA, 2010, OPHTHALMOLOGY, V117, P303, DOI 10.1016/j.ophtha.2009.07.014
NR 33
TC 1
Z9 1
U1 0
U2 0
PU SLACK INC
PI THOROFARE
PA 6900 GROVE RD, THOROFARE, NJ 08086 USA
SN 2325-8160
EI 2325-8179
J9 OSLI RETINA
JI Ophthalmic Surg. Lasers Imag. Retin.
PD JAN
PY 2022
VL 53
IS 1
BP 31
EP 39
DI 10.3928/23258160-20211210-01
PG 9
WC Ophthalmology; Surgery
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology; Surgery
GA ZB1NY
UT WOS:000756618700005
PM 34982004
OA hybrid
DA 2022-11-30
ER

PT J
AU Dos Reis, JS
   Teixeira, AD
   Quaresma, AD
   Almeida, TC
   Arribada, RG
   Neto, JT
   Da Silva, FHR
   Silva-Cunha, A
   De Moura, SAL
   Da Silva, GN
   Fialho, SL
   Silva, GRD
AF Dos Reis, Julia Stephania
   Teixeira, Aniely Dos Reis
   Quaresma, Amanda De Vasconcelos
   Almeida, Tamires Cunha
   Arribada, Raquel Gregorio
   Neto, Julia Teixeira
   Rodrigues Da Silva, Fabio Henrique
   Silva-Cunha, Armando
   Lima De Moura, Sandra Aparecida
   Da Silva, Glenda Nicioli
   Fialho, Silvia Ligorio
   Da Silva, Gisele Rodrigues
TI Sodium butyrate-loaded nanoparticles coated with chitosan for the
   treatment of neovascularization in age-related macular degeneration:
   Ocular biocompatibility and antiangiogenic activity
SO EUROPEAN JOURNAL OF PHARMACEUTICS AND BIOPHARMACEUTICS
LA English
DT Article
DE Double emulsion; Double emulsification and solvent evaporation&nbsp;
   technique; Sodium butyrate; Sodium butyrate-loaded nanoparticles;
   Chitosan; Age-related macular degeneration; Chorioallantoic Membrane
   (CAM); Anti-angiogenic activity
ID CHOROIDAL NEOVASCULARIZATION; BEVACIZUMAB; ANGIOGENESIS; THALIDOMIDE;
   INHIBITION; DELIVERY; CELLS; ACID
AB Sodium butyrate-loaded nanoparticles coated chitosan (NaBu-loaded nanoparticles/CS) were developed to treat the choroidal neovascularization in wet age-related macular degeneration (AMD). The nanoparticles were pro-duced by double emulsification and solvent evaporation technique, optimized by experimental statistical design, characterized by analytical methods, investigated in terms of in vitro and in vivo ocular biocompatibility, and evaluated as an antiangiogenic system in vivo. The NaBu-loaded nanoparticles/CS were 311.1 ?? 3.1 nm in diameter with a 0.208 ?? 0.007 polydispersity index; had a +56.3 ?? 2.6 mV zeta potential; showed a 92.3 % NaBu encapsulation efficiency; and sustained the drug release over 35 days. The NaBu-loaded nanoparticles/CS showed no toxicity to human retinal pigment epithelium cells (ARPE-19 cells); was not irritant to the chorio-allantoic membrane (CAM); did not interfere in the integrity of the retinal layers of rat???s eyes, as detected by the Optical Coherence Tomography and histopathology; and inhibited the angiogenesis in CAM assay. The NaBu-loaded nanoparticles/CS could be a therapeutic alternative to limit the neovascularization in AMD.
   <comment>Superscript/Subscript Available</comment
C1 [Dos Reis, Julia Stephania; Teixeira, Aniely Dos Reis; Quaresma, Amanda De Vasconcelos; Almeida, Tamires Cunha; Lima De Moura, Sandra Aparecida; Da Silva, Glenda Nicioli; Da Silva, Gisele Rodrigues] Univ Fed Ouro Preto, Sch Pharm, BR-35400000 Ouro Preto, MG, Brazil.
   [Arribada, Raquel Gregorio; Neto, Julia Teixeira] Ezequiel Dias Fdn, Pharmaceut Res & Dev, BR-30501010 Belo Horizonte, MG, Brazil.
   [Rodrigues Da Silva, Fabio Henrique] Univ Fed Minas Gerais, Sch Engn, BR-31270901 Belo Horizonte, MG, Brazil.
   [Silva-Cunha, Armando] Univ Fed Minas Gerais, Sch Pharm, BR-31270901 Belo Horizonte, MG, Brazil.
C3 Universidade Federal de Ouro Preto; Universidade Federal de Minas
   Gerais; Universidade Federal de Minas Gerais
RP Silva, GRD (通讯作者)，Univ Fed Ouro Preto, Morro Cruzeiro W-N, BR-35400000 Ouro Preto, MG, Brazil.
EM amanda.quaresma@ufop.edu.br; julia.neto@funed.mg.gov.br;
   armando@farmacia.ufmg.br; sandramoura@ufop.edu.br; nicioli@ufop.edu.br;
   silvia.fialho@funed.mg.gov.br; giselersilva@ufop.edu.br
RI Almeida, Tamires/AAG-7565-2019; Cunha, Armando/G-1157-2012
OI Almeida, Tamires/0000-0002-5584-3609; Cunha, Armando/0000-0002-1161-8936
CR Abrishami M, 2009, RETINA-J RET VIT DIS, V29, P699, DOI 10.1097/IAE.0b013e3181a2f42a
   Al-Zamil WM, 2017, CLIN INTERV AGING, V12, P1313, DOI 10.2147/CIA.S143508
   Alany RG, 2006, J CONTROL RELEASE, V111, P145, DOI 10.1016/j.jconrel.2005.11.020
   Alarcin E, 2020, DRUG DEVELOP RES, V81, P501, DOI 10.1002/ddr.21642
   Belakavadi M, 2005, BIOCHEM BIOPH RES CO, V335, P993, DOI 10.1016/j.bbrc.2005.07.172
   Bhatt P, 2020, AAPS PHARMSCITECH, V21, DOI 10.1208/s12249-020-01836-4
   Cardoso JF, 2021, INT J BIOL MACROMOL, V169, P330, DOI 10.1016/j.ijbiomac.2020.12.057
   Da Silva GR, 2019, EUR J PHARM BIOPHARM, V142, P20, DOI 10.1016/j.ejpb.2019.05.010
   Da Silva MG, 2020, EUR J PHARM SCI, V151, DOI 10.1016/j.ejps.2020.105382
   Di Santo MC, 2020, BIOCHEM BIOPHYS REP, V24, DOI 10.1016/j.bbrep.2020.100842
   Fischer MD, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0007507
   Ganapathy V, 2008, AAPS J, V10, P193, DOI 10.1208/s12248-008-9022-y
   Garcia-Layana A, 2015, J OPHTHALMOL, V2015, DOI 10.1155/2015/412903
   Garcia-Quintanilla L, 2019, PHARMACEUTICS, V11, DOI 10.3390/pharmaceutics11080365
   Gururaj AE, 2003, MOL CELL BIOCHEM, V243, P107, DOI 10.1023/A:1021647726366
   Holz FG, 2018, JAMA OPHTHALMOL, V136, P666, DOI 10.1001/jamaophthalmol.2018.1544
   Honda M, 2011, ARCH OPHTHALMOL-CHIC, V129, P317, DOI 10.1001/archophthalmol.2011.12
   Hwang YS, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0067495
   JENG I, 1984, LIFE SCI, V35, P2143, DOI 10.1016/0024-3205(84)90514-9
   Kim SH, 2007, ONCOL REP, V17, P793
   de Souza SOL, 2018, J MATER SCI-MATER M, V29, DOI 10.1007/s10856-018-6187-5
   Lyzogubov V, 2020, BIOCHEM BIOPH RES CO, V530, P367, DOI 10.1016/j.bbrc.2020.07.140
   Marshall Leisa L, 2013, Consult Pharm, V28, P723, DOI 10.4140/TCP.n.2013.723
   Melo CM, 2020, CARBOHYD POLYM, V230, DOI 10.1016/j.carbpol.2019.115608
   Mitchell P, 2018, LANCET, V392, P1147, DOI 10.1016/S0140-6736(18)31550-2
   Dourado LFN, 2021, BIOMED PHARMACOTHER, V133, DOI 10.1016/j.biopha.2020.110948
   O'Leary F, 2021, FEBS J, DOI 10.1111/febs.16330
   Ogawa H, 2003, FEBS LETT, V554, P88, DOI 10.1016/S0014-5793(03)01110-4
   Pan CK, 2011, J OCUL PHARMACOL TH, V27, P219, DOI 10.1089/jop.2010.0158
   Pandit J, 2017, ARTIF CELL NANOMED B, V45, P1397, DOI 10.1080/21691401.2016.1243545
   Parapini S, 2015, ANTIMICROB AGENTS CH, V59, P4046, DOI 10.1128/AAC.00183-15
   Pereira BG, 2013, BIOMED PHARMACOTHER, V67, P129, DOI 10.1016/j.biopha.2012.08.006
   Pohlmann AR, 2013, EXPERT OPIN DRUG DEL, V10, P623, DOI 10.1517/17425247.2013.769956
   Solano AGR, 2018, AAPS PHARMSCITECH, V19, P1652, DOI 10.1208/s12249-018-0978-3
   Schwartz SD, 2015, LANCET, V385, P509, DOI 10.1016/S0140-6736(14)61376-3
   Senthil V, 2010, J ADV PHARM TECHNOL, V1, P334, DOI 10.4103/0110-5558.72431
   Shelke NB, 2011, DRUG DELIV TRANSL RE, V1, P76, DOI 10.1007/s13346-010-0009-8
   Shu DY, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21124271
   Sobolewska Bianka, 2017, Int J Retina Vitreous, V3, P22, DOI 10.1186/s40942-017-0075-x
   Tarallo V, 2012, CELL, V149, P847, DOI 10.1016/j.cell.2012.03.036
   Tassew NG, 2021, TOXICOL PATHOL, V49, P605, DOI 10.1177/0192623320969667
   Tavares HS, 2021, PHARMAZIE, V76, P68, DOI 10.1691/ph.2021.0100
   Thomas CJ, 2021, MED CLIN N AM, V105, P473, DOI 10.1016/j.mcna.2021.01.003
   Xiao XQ, 2020, OXID MED CELL LONGEV, V2020, DOI 10.1155/2020/6415671
NR 44
TC 1
Z9 1
U1 5
U2 5
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 0939-6411
EI 1873-3441
J9 EUR J PHARM BIOPHARM
JI Eur. J. Pharm. Biopharm.
PD OCT
PY 2022
VL 179
BP 26
EP 36
DI 10.1016/j.ejpb.2022.08.011
PG 11
WC Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Pharmacology & Pharmacy
GA 4V7PL
UT WOS:000859665900002
PM 36041595
DA 2022-11-30
ER

PT J
AU Brody, BL
   Roch-Levecq, AC
   Thomas, RG
   Kaplan, RM
   Brown, SI
AF Brody, BL
   Roch-Levecq, AC
   Thomas, RG
   Kaplan, RM
   Brown, SI
TI Self-management of age-related macular degeneration at the 6-month
   follow-up - A randomized controlled trial
SO ARCHIVES OF OPHTHALMOLOGY
LA English
DT Article
ID QUALITY-OF-LIFE; HEALTH-CARE; CHRONIC DISEASE; VISUAL-ACUITY;
   DEPRESSION; EDUCATION; SUPPORT; INTERVENTION; ARTHRITIS
AB Objective: To assess the effectiveness at the 6-month follow-up of an age-related macular degeneration (AMD) self-management program consisting of health education and enhancement of problem-solving skills in improving quality of life as shown by measures of mood and function.
   Methods: Six-month follow-up data were analyzed from 214 of 252 older adult volunteers (mean age, 80.8 years) with advanced AMD who had been randomly assigned to a 12-hour self-management program (n = 82), a series of 12 hours of tape-recorded health lectures (n = 66), or a waiting list (n = 66). The primary outcome measure was emotional distress (Profile of Mood States). Secondary outcome measures included function (National Eye Institute Visual Function Questionnaire), self-confidence to handle AMD-specific challenges in daily life (AMD Self-efficacy Questionnaire), and depression status on the Structured Clinical Interview for Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition.
   Results: At the 6-month follow-up, participants in the self-management program reported significantly less emotional distress (P=.008), better function (P=.05), and increased self-efficacy (P=.006) compared with control subjects. The latter effects were more pronounced in the depressed than in the nondepressed subjects. Finally, the incidence of clinical depression at the 6-month follow-up was significantly lower in the self-management group (P=.05) than in the control group.
   Conclusion: The sustained positive effects at the 6-month follow-up provide support for the effectiveness of the AMD self-management program in reducing distress and disability, improving self-efficacy, and preventing depression in poorly sighted elderly patients with AMD.
C1 Univ Calif San Diego, Dept Ophthalmol, La Jolla, CA 92093 USA.
   Univ Calif San Diego, Div Biostat, La Jolla, CA 92093 USA.
   Univ Calif San Diego, Div Hlth Care Sci, La Jolla, CA 92093 USA.
   Univ Calif San Diego, Dept Family & Prevent Med, La Jolla, CA 92093 USA.
   Univ Calif San Diego, Dept Neurosci, La Jolla, CA 92093 USA.
C3 University of California System; University of California San Diego;
   University of California System; University of California San Diego;
   University of California System; University of California San Diego;
   University of California System; University of California San Diego;
   University of California System; University of California San Diego
RP Brown, SI (通讯作者)，Univ Calif San Diego, Dept Ophthalmol, 9415 Campus Pt Dr, La Jolla, CA 92093 USA.
EM sbrown@eyecenter.ucsd.edu
RI KAPLAN, Robert/AAK-7342-2021
FU NATIONAL EYE INSTITUTE [R03EY013995, R01EY011924] Funding Source: NIH
   RePORTER; NEI NIH HHS [R01 EY11924, R03 EY13995-01] Funding Source:
   Medline
CR *AM PSYCH ASS, 1994, DIAGN STAT MAN MENT, P317
   BAILEY IL, 1976, AM J OPTOM PHYS OPT, V53, P740
   Bandura Albert., 1992, SELF EFFICACY THOUGH, P3
   Beekman ATF, 2002, ARCH GEN PSYCHIAT, V59, P605, DOI 10.1001/archpsyc.59.7.605
   Bodenheimer T, 2002, JAMA-J AM MED ASSOC, V288, P2469, DOI 10.1001/jama.288.19.2469
   Brody BL, 2002, ARCH OPHTHALMOL-CHIC, V120, P1477, DOI 10.1001/archopht.120.11.1477
   Brody BL, 2001, OPHTHALMOLOGY, V108, P1893, DOI 10.1016/S0161-6420(01)00754-0
   Brody BL, 1999, ANN BEHAV MED, V21, P322, DOI 10.1007/BF02895965
   CLARK NM, 1992, GERONTOLOGIST, V32, P438, DOI 10.1093/geront/32.4.438
   COHEN J, 1977, STAT POW ANL BEH SCI
   Dandona L, 1998, ARCH OPHTHALMOL-CHIC, V116, P545, DOI 10.1001/archopht.116.4.514
   DSouza W, 1996, J ALLERGY CLIN IMMUN, V97, P1085, DOI 10.1016/S0091-6749(96)70262-2
   Fawzy Fawzy I., 1994, General Hospital Psychiatry, V16, P149, DOI 10.1016/0163-8343(94)90098-1
   FAWZY FI, 1990, ARCH GEN PSYCHIAT, V47, P720
   FIRST MB, 1995, USERS GUIDE STRUCTUR, P1
   GILDEN JL, 1992, J AM GERIATR SOC, V40, P147, DOI 10.1111/j.1532-5415.1992.tb01935.x
   Goodwin PJ, 2001, NEW ENGL J MED, V345, P1719, DOI 10.1056/NEJMoa011871
   Gottlieb JL, 2002, JAMA-J AM MED ASSOC, V288, P2233, DOI 10.1001/jama.288.18.2233
   Hollingshead, 1957, 2 FACTOR INDEX SOCIA, P1
   *I MED, 2001, HLTH BEH INT BIOL BE, P334
   KAPLAN RM, 1984, HEALTH PSYCHOL, V3, P223, DOI 10.1037/0278-6133.3.3.223
   KATZMAN R, 1983, AM J PSYCHIAT, V140, P734
   KOENIG HG, 1993, PSYCHOSOMATICS, V34, P61, DOI 10.1016/S0033-3182(93)71928-3
   LORIG K, 1984, GERONTOLOGIST, V24, P455
   LORIG KR, 1993, ARTHRITIS RHEUM, V36, P439, DOI 10.1002/art.1780360403
   Lorig KR, 2001, MED CARE, V39, P1217, DOI 10.1097/00005650-200111000-00008
   Mangione CM, 1998, ARCH OPHTHALMOL-CHIC, V116, P1496, DOI 10.1001/archopht.116.11.1496
   McNair D.M., 1992, POMS MANUAL PROFILE
   MORIN CM, 1993, J CONSULT CLIN PSYCH, V61, P137, DOI 10.1037/0022-006X.61.1.137
   *NATL ADV EY COUNC, 1998, 984288 NIH
   RIES AL, 1995, ANN INTERN MED, V122, P823, DOI 10.7326/0003-4819-122-11-199506010-00003
   Rovner BW, 2002, ARCH OPHTHALMOL-CHIC, V120, P1041
   SCOTT IU, 1994, ARCH OPHTHALMOL-CHIC, V112, P329, DOI 10.1001/archopht.1994.01090150059023
   StatSoft, 2001, STAT VERS 6
NR 34
TC 66
Z9 67
U1 0
U2 10
PU AMER MEDICAL ASSOC
PI CHICAGO
PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA
SN 0003-9950
EI 1538-3601
J9 ARCH OPHTHALMOL-CHIC
JI Arch. Ophthalmol.
PD JAN
PY 2005
VL 123
IS 1
BP 46
EP 53
DI 10.1001/archopht.123.1.46
PG 8
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 886RL
UT WOS:000226245900007
PM 15642811
OA Bronze
DA 2022-11-30
ER

PT J
AU Kang, H
   Byeon, SH
   Kim, SS
   Koh, HJ
   Lee, SC
   Kim, M
AF Kang, Hyunseung
   Byeon, Suk Ho
   Kim, Sung Soo
   Koh, Hyoung Jun
   Lee, Sung Chul
   Kim, Min
TI COMBINING EN FACE OPTICAL COHERENCE TOMOGRAPHY ANGIOGRAPHY WITH
   STRUCTURAL OPTICAL COHERENCE TOMOGRAPHY AND BLOOD FLOW ANALYSIS FOR
   DETECTING CHOROIDAL NEOVASCULAR COMPLEXES IN PIGMENT EPITHELIAL
   DETACHMENTS
SO RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES
LA English
DT Article
DE AngioPlex; OCTA; PED; vPED
ID MACULAR DEGENERATION; VASCULOPATHY; OCT
AB Purpose: This work aimed to describe the morphology of pigment epithelial detachment (PED) using optical coherence tomography angiography and to investigate its potential to detect choroidal neovascularization in various types of PEDs.
   Methods: In this retrospective study, 53 patients diagnosed with PED after undergoing both optical coherence tomography angiography (AngioPlex, CIRRUS HD-OCT) and spectral domain optical coherence tomography (Spectralis SD-OCT) were included.
   Results: Among the 53 eyes, flat vascularized PED (vPED) affected 21 eyes (40%), peaked vPED affected 10 eyes (19%), serous PED affected 12 eyes (23%), drusenoid PED affected 6 eyes (11%), and 4 eyes (7%) had multiple PED subtypes. The main underlying etiologies were pachychoroid spectrum disorder (30.2%), wet age-related macular degeneration (28.3%), central serous chorioretinopathy (18.9%), dry age-related macular degeneration (11.3%), and polypoidal choroidal vasculopathy (11.3%). Optical coherence tomography angiography identified neovascularization in 29 (94%) of the vPED eyes, 2 (17%) of the serous PED eyes, and all 4 (100%) mixed PED eyes.
   Conclusion: Optical coherence tomography angiography successfully identified neovascularization in both vPEDs and PEDs previously considered to be nonneovascular. However, structural OCT and blood flow analysis should be combined to interpret PED-associated neovascularization accurately in the clinic.
C1 [Kang, Hyunseung; Byeon, Suk Ho; Kim, Sung Soo; Koh, Hyoung Jun; Lee, Sung Chul; Kim, Min] Yonsei Univ, Dept Ophthalmol, Inst Vis Res, Gangnam Severance Hosp,Coll Med, 211 Eonjuro, Seoul 135270, South Korea.
C3 Yonsei University; Yonsei University Health System
RP Kim, M (通讯作者)，Yonsei Univ, Dept Ophthalmol, Inst Vis Res, Gangnam Severance Hosp,Coll Med, 211 Eonjuro, Seoul 135270, South Korea.
EM minkim76@gmail.com
OI Kim, Sung Soo/0000-0002-0574-7993; Byeon, suk ho/0000-0001-8101-0830;
   Koh, Hyoung Jun/0000-0002-5932-8516; , Sung Chul/0000-0001-9438-2385;
   Kim, Min/0000-0003-1873-6959
CR Dansingani KK, 2015, AM J OPHTHALMOL, V160, P1243, DOI 10.1016/j.ajo.2015.08.028
   Hanutsaha P, 1998, OPHTHALMOLOGY, V105, P1632, DOI 10.1016/S0161-6420(98)99030-3
   Hata M, 2017, INVEST OPHTH VIS SCI, V58, P292, DOI 10.1167/iovs.16-20967
   Jia YL, 2014, OPHTHALMOLOGY, V121, P1435, DOI 10.1016/j.ophtha.2014.01.034
   Jia YL, 2012, OPT EXPRESS, V20, P4710, DOI 10.1364/OE.20.004710
   Keane PA, 2012, SURV OPHTHALMOL, V57, P389, DOI 10.1016/j.survophthal.2012.01.006
   Kuehlewein L, 2015, AM J OPHTHALMOL, V160, P739, DOI 10.1016/j.ajo.2015.06.030
   Lee Dong Kyu, 2016, Korean J Ophthalmol, V30, P265, DOI 10.3341/kjo.2016.30.4.265
   Lee SY, 2012, INVEST OPHTH VIS SCI, V53, P164, DOI 10.1167/iovs.11-8188
   Lee WK, 2016, RETINA-J RET VIT DIS, V36, pS73, DOI 10.1097/IAE.0000000000001346
   Liang MC, 2016, RETINA-J RET VIT DIS, V36, P2265, DOI 10.1097/IAE.0000000000001102
   McClintic SM, 2015, CLIN OPHTHALMOL, V9, P1299, DOI 10.2147/OPTH.S83701
   Mrejen S, 2013, RETINA-J RET VIT DIS, V33, P1735, DOI 10.1097/IAE.0b013e3182993f66
   Pauleikhoff D, 2002, GRAEF ARCH CLIN EXP, V240, P533, DOI 10.1007/s00417-002-0505-8
   Penha FM, 2012, AM J OPHTHALMOL, V153, P515, DOI 10.1016/j.ajo.2011.08.031
   POLINER LS, 1986, OPHTHALMOLOGY, V93, P543
   Roisman L, 2016, OPHTHALMOLOGY, V123, P1309, DOI 10.1016/j.ophtha.2016.01.044
   Roquet W, 2004, BRIT J OPHTHALMOL, V88, P638, DOI 10.1136/bjo.2003.017632
   Rosenfeld PJ, 2016, DEV OPHTHALMOL, V56, P18, DOI 10.1159/000442773
   SARKS JP, 1988, EYE, V2, P552, DOI 10.1038/eye.1988.106
   SARKS SH, 1973, BRIT J OPHTHALMOL, V57, P951, DOI 10.1136/bjo.57.12.951
   Smretschnig E, 2010, GRAEF ARCH CLIN EXP, V248, P1693, DOI 10.1007/s00417-010-1415-9
   Spaide RF, 2015, JAMA OPHTHALMOL, V133, P45, DOI 10.1001/jamaophthalmol.2014.3616
   Tan ACS, 2016, AM J OPHTHALMOL, V172, P13, DOI 10.1016/j.ajo.2016.09.004
   Veronese C, 2016, RETINA-J RET VIT DIS, V36, P645, DOI 10.1097/IAE.0000000000000914
   Yannuzzi LA, 1999, ARCH OPHTHALMOL-CHIC, V117, P1503
   Zayit-Soudry S, 2007, SURV OPHTHALMOL, V52, P227, DOI 10.1016/j.survophthal.2007.02.008
   Zhang QQ, 2016, SCI REP-UK, V6, DOI 10.1038/srep22017
NR 28
TC 7
Z9 8
U1 0
U2 3
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0275-004X
EI 1539-2864
J9 RETINA-J RET VIT DIS
JI Retin.-J. Retin. Vitr. Dis.
PD AUG
PY 2019
VL 39
IS 8
BP 1551
EP 1561
DI 10.1097/IAE.0000000000002201
PG 11
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA IQ5AL
UT WOS:000480763200019
PM 29863533
DA 2022-11-30
ER

PT J
AU Heesterbeek, TJ
   Rouhi-Parkouhi, M
   Church, SJ
   Lechanteur, YT
   Lores-Motta, L
   Kouvatsos, N
   Clark, SJ
   Bishop, PN
   Hoyng, CB
   den Hollander, AI
   Unwin, RD
   Day, AJ
AF Heesterbeek, Thomas J.
   Rouhi-Parkouhi, Mansour
   Church, Stephanie J.
   Lechanteur, Yara T.
   Lores-Motta, Laura
   Kouvatsos, Nikolaos
   Clark, Simon J.
   Bishop, Paul N.
   Hoyng, Carel B.
   den Hollander, Anneke I.
   Unwin, Richard D.
   Day, Anthony J.
TI Association of plasma trace element levels with neovascular age-related
   macular degeneration
SO EXPERIMENTAL EYE RESEARCH
LA English
DT Article
DE Age-related macular degeneration; Trace elements; Plasma; Barium;
   Cadmium; Chromium
ID RETINAL-PIGMENT EPITHELIUM; AREDS SUPPLEMENTS; OXIDATIVE STRESS;
   WHOLE-BLOOD; ZINC; SERUM; CADMIUM; HEALTH; COPPER; EYE
AB Although the triggers causing angiogenesis in the context of neovascular age-related macular degeneration (nAMD) are not fully understood, oxidative stress is likely involved. Oxidative stress in the eye can occur through exposure of macular tissues to sunlight and local or systemic exposure to oxidative stressors associated with environmental or lifestyle factors. Because trace elements have been implicated as regulators of oxidative stress and cellular antioxidant defense mechanisms, we hypothesized that they may play a role as a risk factor, modifying the progression toward nAMD.
   Herein, we determined whether levels of human plasma trace elements are different in 236 individuals with nAMD compared to 236 age-matched controls without AMD. Plasma levels of 16 trace elements including arsenic, barium, calcium, cadmium, cobalt, chromium, copper, iron, magnesium, manganese, molybdenum, lead, antimony, selenium, vanadium and zinc were measured using inductively coupled plasma mass spectrometry.
   Associations of trace elements with demographic, environmental and lifestyle factors and AMD-associated genetic variants were assessed.
   Elevated levels of barium and cadmium and reduced levels of chromium were observed in nAMD patients compared to controls. Mean plasma concentrations of barium were 1.35 mu g/L (standard deviation [SD] 0.71) in nAMD and 1.15 mu g/L (SD 0.63) in controls (P = 0.001). Mean levels of chromium were 0.37 mu g/L (SD 0.22) in nAMD and 0.46 mu g/L (SD 0.34) in controls (P = 0.001). Median levels for cadmium, which were not normally distributed, were 0.016 mu g/L (interquartile range [IQR] 0.001-0.026) in nAMD and 0.012 mu g/L (IQR 0.001-0.022) in controls (P = 0.002). Comparison of the Spearman's correlation coefficients between nAMD patients and controls identified a difference in correlations for 8 trace elements. Cadmium levels were associated with the smoking status (P < 0.001), while barium levels showed a trend of association with the usage of antihypertensive drugs. None of the AMD-associated genetic variants were associated with any trace element levels.
   In conclusion, in this case-control study we detected elevated plasma levels of barium and cadmium and reduced plasma levels of chromium in nAMD patients. An imbalance in plasma trace elements, which is most likely driven by environmental and lifestyle factors, might have a role in the pathogenesis of AMD. These trace elements may be incorporated as biomarkers into models for prediction of disease risk and progression. Additionally, population-based preventive strategies to decrease Cd exposure, especially by the cessation of smoking, could potentially reduce the burden of nAMD. Future studies are warranted to investigate whether supplementation of Cr would have a beneficial effect on nAMD.
C1 [Heesterbeek, Thomas J.; Lechanteur, Yara T.; Lores-Motta, Laura; Hoyng, Carel B.; den Hollander, Anneke I.] Radboud Univ Nijmegen, Med Ctr, Donders Inst Brain Cognit & Behav, Dept Ophthalmol, Nijmegen, Netherlands.
   [Rouhi-Parkouhi, Mansour; Kouvatsos, Nikolaos; Day, Anthony J.] Univ Manchester, Wellcome Trust Ctr Cell Matrix Res, Div Cell Matrix Biol & Regenerat Med,Sch Biol Sci, Manchester Acad Hlth Sci Ctr,Fac Biol Med & Hlth, Oxford Rd, Manchester M13 9PT, Lancs, England.
   [Day, Anthony J.] Univ Manchester, Manchester Acad Hlth Sci Ctr, Fac Biol Med & Hlth, Lydia Becker Inst Immunol & Inflammat, Oxford Rd, Manchester M13 9PT, Lancs, England.
   [Church, Stephanie J.] Univ Manchester, Fac Biol Med & Hlth, Sch Med Sci, Core Technol Facil,Div Cardiovasc Sci, Grafton St, Manchester M13 9NT, Lancs, England.
   [Lores-Motta, Laura; den Hollander, Anneke I.] Radboud Univ Nijmegen, Med Ctr, Donders Inst Brain Cognit & Behav, Dept Human Genet, Nijmegen, Netherlands.
   [Clark, Simon J.; Bishop, Paul N.] Univ Manchester, Fac Biol Med & Hlth, Sch Biol Sci, Div Evolut & Genom Sci, Manchester M13 9PT, Lancs, England.
   [Clark, Simon J.] Eberhard Karls Univ Tubingen, Inst Ophthalm Res, Elfriede Aulhorn Str 7, D-72076 Tubingen, Germany.
   [Bishop, Paul N.] Manchester Univ NHS Fdn Trust, Manchester Acad Hlth Sci Ctr, Manchester Royal Eye Hosp, Manchester M13 9WL, Lancs, England.
   [Unwin, Richard D.] Univ Manchester, Fac Biol Med & Hlth, Sch Med Sci, Stoller Biomarker Discovery Ctr, CityLabs 1-0,3rd Floor,Nelson St, Manchester M13 9NQ, Lancs, England.
   [Unwin, Richard D.] Univ Manchester, Fac Biol Med & Hlth, Sch Med Sci, Div Canc Sci, CityLabs 1-0,3rd Floor,Nelson St, Manchester M13 9NQ, Lancs, England.
C3 Radboud University Nijmegen; University of Manchester; University of
   Manchester; University of Manchester; Radboud University Nijmegen;
   University of Manchester; Eberhard Karls University of Tubingen;
   Eberhard Karls University Hospital; Manchester Royal Eye Hospital;
   University of Manchester; University of Manchester; University of
   Manchester
RP Day, AJ (通讯作者)，Univ Manchester, Wellcome Trust Ctr Cell Matrix Res, Div Cell Matrix Biol & Regenerat Med,Sch Biol Sci, Manchester Acad Hlth Sci Ctr,Fac Biol Med & Hlth, Oxford Rd, Manchester M13 9PT, Lancs, England.
EM anthony.day@manchester.ac.uk
RI ; Heesterbeek, Thomas Johannes/E-7890-2017
OI Kouvatsos, Nikolaos/0000-0003-0425-1141; Heesterbeek, Thomas
   Johannes/0000-0002-3232-2587; Clark, Simon/0000-0001-8394-8355; Unwin,
   Richard/0000-0001-7955-9111
FU Medical Research Council; Engineering and Physical Sciences Research
   Council [MR/N00583X/1]; Dutch Research Council [016.Vici.170.024];
   Oogfonds, Landelijke Stichting voor Blinden en Slechtzienden; Macula
   Fonds, Vereniging Bartimeus Sonneheerdt (Uitzicht) [2016-02, 2016-26];
   European Union [634479]; MRC [MR/N00583X/1] Funding Source: UKRI
FX This work was co-funded by the Medical Research Council and the
   Engineering and Physical Sciences Research Council grant MR/N00583X/1
   "Manchester Molecular Pathology Innovation Center (MMPathIC): bridging
   the gap between biomarker discovery and health and wealth" to AJD.;
   Dutch Research Council (016.Vici.170.024 to AIdH).; Oogfonds, Landelijke
   Stichting voor Blinden en Slechtzienden, Macula Fonds, Vereniging
   Bartimeus Sonneheerdt (Uitzicht, 2016-02 and 2016-26 to AIdH, CBH).;
   This project has also received funding from the European Union's Horizon
   2020 research and innovation program under grant agreement No. 634479
   (EYE-RISK).
CR Abduljabbar TN, 2019, TALANTA, V204, P663, DOI 10.1016/j.talanta.2019.05.098
   Aberami S, 2019, EXP EYE RES, V186, DOI 10.1016/j.exer.2019.107718
   Abokyi S, 2020, OXID MED CELL LONGEV, V2020, DOI 10.1155/2020/5296341
   Aranaz M, 2020, J PHARMACEUT BIOMED, V177, DOI 10.1016/j.jpba.2019.112857
   Bender R, 2001, J CLIN EPIDEMIOL, V54, P343, DOI 10.1016/S0895-4356(00)00314-0
   BENJAMINI Y, 1995, J R STAT SOC B, V57, P289, DOI 10.1111/j.2517-6161.1995.tb02031.x
   Bergdahl IA, 2006, AM J IND MED, V49, P93, DOI 10.1002/ajim.20253
   BIRD AEC, 1995, SURV OPHTHALMOL, V39, P367, DOI 10.1016/S0039-6257(05)80092-X
   Burke JM, 2005, MOL INTERV, V5, P241, DOI 10.1124/mi.5.4.7
   Cardinault N, 2005, CLIN CHIM ACTA, V357, P34, DOI 10.1016/j.cccn.2005.01.030
   Cesbron A, 2013, J ANAL TOXICOL, V37, P401, DOI 10.1093/jat/bkt046
   Chen L, 2020, RETINA-J RET VIT DIS, V40, P618, DOI 10.1097/IAE.0000000000002657
   Chen XX, 2014, PLOS ONE, V9, DOI [10.1371/journal.pone.0085716, 10.1371/journal.pone.0091809, 10.1371/journal.pone.0103330, 10.1371/journal.pone.0115462, 10.1371/journal.pone.0087752, 10.1371/journal.pone.0091830]
   Chew EY, 2015, OPHTHALMOLOGY, V122, P212, DOI 10.1016/j.ophtha.2014.10.012
   Church SJ, 2015, BIOCHEM BIOPH RES CO, V460, P549, DOI 10.1016/j.bbrc.2015.03.067
   Colijn JM, 2017, OPHTHALMOLOGY, V124, P1753, DOI 10.1016/j.ophtha.2017.05.035
   Cuypers A, 2010, BIOMETALS, V23, P927, DOI 10.1007/s10534-010-9329-x
   Datta S, 2017, PROG RETIN EYE RES, V60, P201, DOI 10.1016/j.preteyeres.2017.03.002
   DAY AJ, 1986, BIOCHEM SOC T, V14, P73, DOI 10.1042/bst0140073
   de Breuk A, 2021, OPHTHALMOLOGY, V128, P1604, DOI 10.1016/j.ophtha.2020.07.037
   Dunaief JL, 2006, INVEST OPHTH VIS SCI, V47, P4660, DOI 10.1167/iovs.06-0568
   Ekmekcioglu C, 2001, NAHRUNG, V45, P309, DOI 10.1002/1521-3803(20011001)45:5&lt;309::AID-FOOD309&gt;3.0.CO;2-0
   Erie JC, 2005, AM J OPHTHALMOL, V139, P888, DOI 10.1016/j.ajo.2004.12.007
   Fritsche LG, 2016, NAT GENET, V48, P134, DOI 10.1038/ng.3448
   GALIN MA, 1962, INVEST OPHTH VISUAL, V1, P142
   Girijashanker K, 2008, MOL PHARMACOL, V73, P1413, DOI 10.1124/mol.107.043588
   Gonzalez-Iglesias H, 2014, METALLOMICS, V6, P201, DOI 10.1039/c3mt00298e
   Gungor ED, 2018, J TRACE ELEM MED BIO, V48, P16, DOI 10.1016/j.jtemb.2018.02.019
   Hahn P, 2003, ARCH OPHTHALMOL-CHIC, V121, P1099, DOI 10.1001/archopht.121.8.1099
   He L, 2006, MOL PHARMACOL, V70, P171, DOI 10.1124/mol.106.021521
   Heesterbeek TJ, 2020, INVEST OPHTH VIS SCI, V61, DOI 10.1167/iovs.61.3.18
   HELSEL DR, 1990, ENVIRON SCI TECHNOL, V24, P1766, DOI 10.1021/es00082a001
   Hyman L, 2000, ARCH OPHTHALMOL-CHIC, V118, P351, DOI 10.1001/archopht.118.3.351
   Jahnen-Dechent W, 2012, CLIN KIDNEY J, V5, P3, DOI 10.1093/ndtplus/sfr163
   Jonas JB, 2017, ASIA-PAC J OPHTHALMO, V6, P493, DOI 10.22608/APO.2017251
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1417, DOI 10.1001/archopht.119.10.1417
   Kim EC, 2014, INVEST OPHTH VIS SCI, V55, P5702, DOI 10.1167/iovs.14-14774
   Kim MH, 2016, J EXPO SCI ENV EPID, V26, P214, DOI 10.1038/jes.2014.75
   Langford-Smith A, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0147576
   Lee YH, 2019, BIOL TRACE ELEM RES, V188, P316, DOI 10.1007/s12011-018-1429-4
   Lengyel I, 2007, EXP EYE RES, V84, P772, DOI 10.1016/j.exer.2006.12.015
   Li HQ, 2019, ENVIRON HEALTH-GLOB, V18, DOI 10.1186/s12940-019-0495-1
   Mayer MJ, 1998, ACTA OPHTHALMOL SCAN, V76, P62, DOI 10.1034/j.1600-0420.1998.760111.x
   Mills C.S., 1988, ZINC HUMAN BIOL
   Nan R, 2013, J BIOL CHEM, V288, P19197, DOI 10.1074/jbc.M113.476143
   Nigra Anne E, 2016, Curr Environ Health Rep, V3, P416, DOI 10.1007/s40572-016-0117-9
   Onderci M, 2003, BIOL TRACE ELEM RES, V92, P139, DOI 10.1385/BTER:92:2:139
   Panattoni LE, 2011, AUST HEALTH REV, V35, P45, DOI 10.1071/AH09845
   Park SJ, 2015, OPHTHALMOLOGY, V122, P129, DOI 10.1016/j.ophtha.2014.07.039
   Pennington KL, 2016, EYE VISION, V3, DOI 10.1186/s40662-016-0063-5
   QUINN RH, 1992, INVEST OPHTH VIS SCI, V33, P3513
   Rabiolo A, 2017, CLIN OPHTHALMOL, V11, P1707, DOI 10.2147/OPTH.S130165
   Rink L., 2011, ZINC IN HUMAN HLTH, P530
   Salmonowicz B, 2014, ADV CLIN EXP MED, V23, P259, DOI 10.17219/acem/37074
   Seddon JM, 2016, BRIT J OPHTHALMOL, V100, P1731, DOI 10.1136/bjophthalmol-2016-308624
   Shaw PX, 2016, AIMS MOL SCI, V3, P196, DOI 10.3934/molsci.2016.2.196
   Song DL, 2018, INVEST OPHTH VIS SCI, V59
   SOWDEN E, 1958, BIOCHEM J, V70, P716, DOI 10.1042/bj0700716
   Stelling MP, 2019, FEBS J, V286, P2950, DOI 10.1111/febs.14986
   Taylor H R, 1990, Trans Am Ophthalmol Soc, V88, P163
   Taylor HR, 1990, T AM OPHTHAL SOC, V88, P173
   TSANG NCK, 1992, DOC OPHTHALMOL, V81, P387
   Tykocki NR, 2017, COMPR PHYSIOL, V7, P485, DOI 10.1002/cphy.c160011
   Ueda Y, 2002, LIFE SCI, V71, P1569, DOI 10.1016/S0024-3205(02)01930-6
   Ugarte M, 2001, PROG NEUROBIOL, V64, P219, DOI 10.1016/S0301-0082(00)00057-5
   van Asten F, 2019, OPHTHALMOLOGY, V126, P1541, DOI 10.1016/j.ophtha.2019.06.004
   van Leeuwen R, 2003, OPHTHALMOLOGY, V110, P1540, DOI 10.1016/S0161-6420(03)00501-3
   Velilla S, 2013, J OPHTHALMOL, V2013, DOI 10.1155/2013/895147
   Wang A.L., 2009, PLOS ONE, V4
   Weismann D, 2011, NATURE, V478, P76, DOI 10.1038/nature10449
   WHO, 1996, TRAC EL HUM NUTR HLT
   Wills NK, 2008, EXP EYE RES, V86, P41, DOI 10.1016/j.exer.2007.09.005
   Wills NK, 2009, EXP EYE RES, V89, P79, DOI 10.1016/j.exer.2009.02.014
   Wu EW, 2014, ENVIRON RES, V133, P178, DOI 10.1016/j.envres.2014.05.023
   Wysokinski D, 2013, EXP EYE RES, V106, P14, DOI 10.1016/j.exer.2012.10.003
   Xu JS, 2017, METALLOMICS, V9, P1106, DOI 10.1039/c7mt00074j
   Ye FX, 2016, FREE RADICAL BIO MED, V94, P121, DOI 10.1016/j.freeradbiomed.2016.02.027
   Yokoi K, 2003, AM J PHYSIOL-ENDOC M, V285, pE1010, DOI 10.1152/ajpendo.00533.2002
   Yuan M., 2010, INVEST OPHTHALMOL VI, V51
   Zhang HM, 2015, CYTOKINE, V76, P549, DOI 10.1016/j.cyto.2015.06.019
   Zhang QY, 2016, INVEST OPHTH VIS SCI, V57, P1276, DOI 10.1167/iovs.15-18637
NR 81
TC 5
Z9 5
U1 2
U2 4
PU ACADEMIC PRESS LTD- ELSEVIER SCIENCE LTD
PI LONDON
PA 24-28 OVAL RD, LONDON NW1 7DX, ENGLAND
SN 0014-4835
EI 1096-0007
J9 EXP EYE RES
JI Exp. Eye Res.
PD DEC
PY 2020
VL 201
AR 108324
DI 10.1016/j.exer.2020.108324
PG 11
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA PI4GK
UT WOS:000601050800008
PM 33098886
OA Green Published, hybrid
DA 2022-11-30
ER

PT J
AU Zhang, JY
   Xie, BQ
   Barba, H
   Nadeem, U
   Movahedan, A
   Deng, NN
   Spedale, M
   D'Souza, M
   Luo, W
   Leone, V
   Chang, EB
   Theriault, B
   Sulakhe, D
   Skondra, D
AF Zhang, Jason Y.
   Xie, Bingqing
   Barba, Hugo
   Nadeem, Urooba
   Movahedan, Asadolah
   Deng, Nini
   Spedale, Melanie
   D'Souza, Mark
   Luo, Wendy
   Leone, Vanessa
   Chang, Eugene B.
   Theriault, Betty
   Sulakhe, Dinanath
   Skondra, Dimitra
TI Absence of Gut Microbiota Is Associated with RPE/Choroid Transcriptomic
   Changes Related to Age-Related Macular Degeneration Pathobiology and
   Decreased Choroidal Neovascularization
SO INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
LA English
DT Article
DE age-related macular degeneration; gut microbiome; germ-free mice;
   RPE-choroid; RNA sequencing; choroidal neovascularization; angiogenesis;
   microglia; gut-retina axis
ID GENE-EXPRESSION; DIETARY-FAT; OBESITY; RISK; ANGIOGENESIS; COMPLEMENT;
   ATROPHY; MODELS
AB Studies have begun to reveal significant connections between the gut microbiome and various retinal diseases, including age-related macular degeneration (AMD). As critical supporting tissues of the retina, the retinal pigment epithelium (RPE) and underlying choroid play a critical role in retinal homeostasis and degeneration. However, the relationship between the microbiome and RPE/choroid remains poorly understood, particularly in animal models of AMD. In order to better elucidate this role, we performed high-throughput RNA sequencing of RPE/choroid tissue in germ-free (GF) and specific pathogen-free (SPF) mice. Furthermore, utilizing a specialized laser-induced choroidal neovascularization (CNV) model that we developed, we compared CNV size and inflammatory response between GF and SPF mice. After correction of raw data, 660 differentially expressed genes (DEGs) were identified, including those involved in angiogenesis regulation, scavenger and cytokine receptor activity, and inflammatory response-all of which have been implicated in AMD pathogenesis. Among lasered mice, the GF group showed significantly decreased CNV lesion size and microglial infiltration around CNV compared to the SPF group. Together, these findings provide evidence for a potential gut-RPE/choroidal axis as well as a correlation with neovascular features of AMD.
C1 [Zhang, Jason Y.; Barba, Hugo; Deng, Nini; Luo, Wendy; Skondra, Dimitra] Univ Chicago, Dept Ophthalmol & Visual Sci, Chicago, IL 60637 USA.
   [Xie, Bingqing; Chang, Eugene B.] Univ Chicago, Dept Med, Chicago, IL 60637 USA.
   [Nadeem, Urooba] Univ Chicago, Dept Pathol, Chicago, IL 60637 USA.
   [Movahedan, Asadolah] Yale Univ, Dept Ophthalmol & Visual Sci, Sch Med, New Haven, CT 06510 USA.
   [Spedale, Melanie; Theriault, Betty] Univ Chicago, Anim Resources Ctr, Chicago, IL 60637 USA.
   [D'Souza, Mark; Sulakhe, Dinanath] Univ Chicago, Duchossois Family Inst, Chicago, IL 60637 USA.
   [Leone, Vanessa] Univ Wisconsin, Dept Anim Biol & Metab, Madison, WI 53706 USA.
   [Chang, Eugene B.] Univ Chicago, Microbiome Ctr, Chicago, IL 60637 USA.
   [Theriault, Betty] Univ Chicago, Dept Surg, Chicago, IL 60637 USA.
C3 University of Chicago; University of Chicago; University of Chicago;
   Yale University; University of Chicago; University of Chicago;
   University of Wisconsin System; University of Wisconsin Madison;
   University of Chicago; University of Chicago
RP Skondra, D (通讯作者)，Univ Chicago, Dept Ophthalmol & Visual Sci, Chicago, IL 60637 USA.
EM dskondra@bsd.uchicago.edu
OI Leone, Vanessa/0000-0003-4012-4377; Zhang, Jason/0000-0003-4632-7730;
   Xie, Bingqing/0000-0001-9246-9321
FU BrightFocus Foundation [M2018042]; NIDDK P30 [DK42086]; University of
   ChicagoWomen's Board; Illinois Society for the Prevention of Blindness
   [FP067271-01-PR, FP105445]; Fight for Sight; FORE-I
FX This research was funded by BrightFocus Foundation "Role of high fat
   diet and gut microbiome in macular degeneration" (Dimitra Skondra, Grant
   Number M2018042), NIDDK P30 (E.B.C., DK42086), FORE-I (Dimitra Skondra),
   The University of ChicagoWomen's Board (Dimitra Skondra), the Illinois
   Society for the Prevention of Blindness (Dimitra Skondra, Grant Number
   FP067271-01-PR and J.Y.Z., FP105445), and Fight for Sight (J.Y.Z.).
CR Abdel-Haq R, 2019, J EXP MED, V216, P41, DOI 10.1084/jem.20180794
   Adams MKM, 2011, AM J EPIDEMIOL, V173, P1246, DOI 10.1093/aje/kwr005
   Al-Zamil WM, 2017, CLIN INTERV AGING, V12, P1313, DOI 10.2147/CIA.S143508
   Andriessen EMMA, 2016, EMBO MOL MED, V8, P1366, DOI 10.15252/emmm.201606531
   Augustin HG, 2009, NAT REV MOL CELL BIO, V10, P165, DOI 10.1038/nrm2639
   Bodnar RJ, 2006, CIRC RES, V98, P617, DOI 10.1161/01.RES.0000209968.66606.10
   Bressler SB, 2009, OPHTHALMOLOGY, V116, pS1, DOI 10.1016/j.ophtha.2009.06.045
   Brown DM, 2007, AM J OPHTHALMOL, V144, P627, DOI 10.1016/j.ajo.2007.06.039
   Campa C, 2010, MEDIAT INFLAMM, V2010, DOI 10.1155/2010/546826
   Campagne MV, 2016, IMMUNOBIOLOGY, V221, P733, DOI 10.1016/j.imbio.2015.11.007
   Chen Yunshun, 2016, F1000Res, V5, P1438, DOI 10.12688/f1000research.8987.2
   Chew EY, 2015, JAMA-J AM MED ASSOC, V314, P791, DOI 10.1001/jama.2015.9677
   Cho E, 2001, AM J CLIN NUTR, V73, P209
   Dhirachaikulpanich D, 2020, FRONT CELL DEV BIOL, V8, DOI 10.3389/fcell.2020.00808
   Dobin A, 2013, BIOINFORMATICS, V29, P15, DOI 10.1093/bioinformatics/bts635
   Doyle SL, 2012, NAT MED, V18, P791, DOI 10.1038/nm.2717
   Edwards AO, 2005, SCIENCE, V308, P421, DOI 10.1126/science.1110189
   Erny D, 2015, NAT NEUROSCI, V18, P965, DOI 10.1038/nn.4030
   Falero-Perez Juliana, 2018, Trends Cell Mol Biol, V13, P27
   Falk MK, 2014, INVEST OPHTH VIS SCI, V55, P4050, DOI 10.1167/iovs.14-14107
   Fischer Andrew H, 2008, CSH Protoc, V2008, DOI 10.1101/pdb.prot4986
   Frankish A, 2019, NUCLEIC ACIDS RES, V47, pD766, DOI 10.1093/nar/gky955
   Garcia-Layana A, 2017, CLIN INTERV AGING, V12, P1579, DOI 10.2147/CIA.S142685
   Grunwald JE, 2014, OPHTHALMOLOGY, V121, P150, DOI 10.1016/j.ophtha.2013.08.015
   Kauppinen A, 2016, CELL MOL LIFE SCI, V73, P1765, DOI 10.1007/s00018-016-2147-8
   Kim J, 2019, SCI ADV, V5, DOI 10.1126/sciadv.aau6732
   Liao DS, 2020, OPHTHALMOLOGY, V127, P186, DOI 10.1016/j.ophtha.2019.07.011
   Luaces-Rodriguez A, 2020, INT J PHARMACEUT, V573, DOI 10.1016/j.ijpharm.2019.118767
   Markomichelakis NN, 2005, AM J OPHTHALMOL, V139, P537, DOI 10.1016/j.ajo.2004.09.058
   Martin DF, 2002, RETINA-J RET VIT DIS, V22, P143
   Movahedan A, 2021, TRANSL VIS SCI TECHN, V10, DOI 10.1167/tvst.10.9.14
   Nadeem U., 2020, BIORXIV, DOI [10.1101/2020.10.01.318949, DOI 10.1101/2020.10.01.318949]
   National Research Council Committee for the Update of the Guide for the C Use of Laboratory A, 2011, NAT AC COLL REP FUND, DOI DOI 10.17226/12910
   Rinninella E, 2018, NUTRIENTS, V10, DOI 10.3390/nu10111677
   Ritchie ME, 2015, NUCLEIC ACIDS RES, V43, DOI 10.1093/nar/gkv007
   Robinson MD, 2010, BIOINFORMATICS, V26, P139, DOI 10.1093/bioinformatics/btp616
   Rowan S, 2017, P NATL ACAD SCI USA, V114, pE4472, DOI 10.1073/pnas.1702302114
   Schindelin J, 2012, NAT METHODS, V9, P676, DOI [10.1038/NMETH.2019, 10.1038/nmeth.2019]
   Schroeder B, 2016, NAT MED, V22, P1079, DOI 10.1038/nm.4185
   Seddon JM, 2003, ARCH OPHTHALMOL-CHIC, V121, P1728, DOI 10.1001/archopht.121.12.1728
   Shannon P, 2003, GENOME RES, V13, P2498, DOI 10.1101/gr.1239303
   Singh A, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-00741-4
   Singh RK, 2017, J TRANSL MED, V15, DOI 10.1186/s12967-017-1175-y
   Smyth GK, 2005, STAT BIOL HEALTH, P397, DOI 10.1007/0-387-29362-0_23
   Sulakhe D, 2014, NUCLEIC ACIDS RES, V42, pD1007, DOI 10.1093/nar/gkt1166
   Szklarczyk D, 2021, NUCLEIC ACIDS RES, V49, pD605, DOI 10.1093/nar/gkaa1074
   Tang YX, 2009, BLOOD, V113, P744, DOI 10.1182/blood-2008-03-145219
   Theriault B, 2015, TRANSPLANT DIRECT, V1, DOI 10.1097/TXD.0000000000000539
   Voigt AP, 2019, P NATL ACAD SCI USA, V116, P24100, DOI 10.1073/pnas.1914143116
   Whitmore SS, 2013, MOL VIS, V19, P2274
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
   Young M, 2014, RETINA-J RET VIT DIS, V34, P1308, DOI 10.1097/IAE.0000000000000081
   Zhang QY, 2016, INVEST OPHTH VIS SCI, V57, P1276, DOI 10.1167/iovs.15-18637
   Zinkernagel MS, 2017, SCI REP-UK, V7, DOI 10.1038/srep40826
NR 54
TC 0
Z9 0
U1 2
U2 2
PU MDPI
PI BASEL
PA ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND
EI 1422-0067
J9 INT J MOL SCI
JI Int. J. Mol. Sci.
PD SEP
PY 2022
VL 23
IS 17
AR 9676
DI 10.3390/ijms23179676
PG 14
WC Biochemistry & Molecular Biology; Chemistry, Multidisciplinary
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Chemistry
GA 4J3NU
UT WOS:000851173900001
PM 36077073
OA gold, Green Published
DA 2022-11-30
ER

PT J
AU Scheffer, M
   Menting, J
   Roodbeen, R
   van Dulmen, S
   van Hecke, M
   Schlingemann, R
   van Nispen, R
   Boeije, H
AF Scheffer, Mariska
   Menting, Juliane
   Roodbeen, Ruud
   van Dulmen, Sandra
   van Hecke, Manon
   Schlingemann, Reinier
   van Nispen, Ruth
   Boeije, Hennie
TI Patients' and health professionals' views on shared decision-making in
   age-related macular degeneration care: A qualitative study
SO OPHTHALMIC AND PHYSIOLOGICAL OPTICS
LA English
DT Article
DE age-related macular degeneration; communication; information provision;
   shared decision-making; visual impairment
ID EXPERIENCE
AB Background Age-related macular degeneration (AMD) is one of the principal causes of irreversible visual impairment in the older adult population. Recent evidence indicates that there are signs of undertreatment and overtreatment, underdiagnosis and insufficient information provision in AMD care. Shared decision-making (SDM) can aid information sharing between patients and health professionals and enhances high-quality care. This research aimed to gain insight into patients' and professionals' views on SDM in AMD care. Methods Semi-structured interviews were conducted with 20 patients with AMD and 19 health professionals in June and July 2020. Participants were recruited through hospitals, professional and patient associations and (social) networks. Sample representativeness was ensured in terms of sociodemographic and disease characteristics for patients, and profession-related characteristics for health professionals. Interviews were analysed according to a predetermined coding framework. Results Although SDM is receiving attention in AMD care, health professionals and patients experienced barriers in making shared decisions. The most common barriers reported included limitations in treatment options, time constraints, strict treatment guidelines and patients' comorbidity. Furthermore, most patients indicated that they were not (fully) informed about all aspects of AMD trajectory, such as the possibility to discontinue therapy or the long-term and invasive character of treatment. Some patients expressed the need for a more empathic and person-centred communication style from their health professional. Conclusion The concerns raised by patients and health professionals suggest that there is room for improvement in delivery of SDM in AMD care. Findings from this study indicate that information provision and communication can be improved.
C1 [Scheffer, Mariska; Menting, Juliane; Boeije, Hennie] Netherlands Inst Hlth Serv Res Nivel, Dept Care & Participat People Chron Condit, Utrecht, Netherlands.
   [Roodbeen, Ruud] Breuer Intraval Res & Consultancy, Dept Res, Groningen, Netherlands.
   [van Dulmen, Sandra] Netherlands Inst Hlth Serv Res Nivel, Dept Commun Healthcare, Utrecht, Netherlands.
   [van Dulmen, Sandra] Radboud Univ Nijmegen, Radboud Inst Hlth Sci, Dept Primary & Community Care, Med Ctr, Nijmegen, Netherlands.
   [van Dulmen, Sandra] Univ Boras, Fac Caring Sci, Boras, Sweden.
   [van Hecke, Manon] Elisabeth TweeSteden Ziekenhuis, Dept Ophthalmol, Tilburg, Netherlands.
   [Schlingemann, Reinier] Univ Amsterdam, Dept Ophthalmol, Amsterdam UMC, Amsterdam, Netherlands.
   [Schlingemann, Reinier] Bergman Clin Ogen, Amsterdam, Netherlands.
   [Schlingemann, Reinier] Univ Lausanne, Jules Gonin Eye Hosp, Dept Ophthalmol, Fondat Asile Aveugles, Lausanne, Switzerland.
   [van Nispen, Ruth] Vrije Univ Amsterdam, Amsterdam Publ Hlth Res Inst, Amsterdam UMC, Dept Ophthalmol, Amsterdam, Netherlands.
C3 Netherlands Institute for Health Services Research; Netherlands
   Institute for Health Services Research; Radboud University Nijmegen;
   University of Boras; Elisabeth-TweeSteden Ziekenhuis (ETZ); University
   of Amsterdam; Vrije Universiteit Amsterdam; University of Lausanne;
   University of Amsterdam; Vrije Universiteit Amsterdam
RP Scheffer, M (通讯作者)，Netherlands Inst Hlth Serv Res Nivel, Dept Care & Participat People Chron Condit, Utrecht, Netherlands.
EM m.scheffer@nivel.nl
RI van Dulmen, A.M./L-4287-2015
OI van Dulmen, A.M./0000-0002-1651-7544; Roodbeen,
   Ruud/0000-0001-7315-4367; van Nispen, Ruth M.A./0000-0003-1227-1177
FU Dutch National Health Care Institute
FX This study was financed by the Dutch National Health Care Institute
CR Ambati J, 2012, NEURON, V75, P26, DOI 10.1016/j.neuron.2012.06.018
   [Anonymous], 2012, VERBI SOFTWARE MAXQD
   [Anonymous], 2011, NED TIJDSCHR GENEES
   [Anonymous], 2019, ZINNIGE ZORG RAPPORT
   Bian W, 2019, BMJ OPEN, V9, DOI 10.1136/bmjopen-2019-031020
   Bomhof-Roordink H, 2019, BMJ OPEN, V9, DOI 10.1136/bmjopen-2019-031763
   de Boer M R, 2005, Ned Tijdschr Geneeskd, V149, P1502
   Dillon L, 2021, OPHTHAL PHYSL OPT, V41, P255, DOI 10.1111/opo.12779
   Eledrisi MS, 2006, AM J MED SCI, V331, P243, DOI 10.1097/00000441-200605000-00002
   Hernandez-Zimbron LF, 2018, OXID MED CELL LONGEV, V2018, DOI 10.1155/2018/8374647
   Garcia-Layana A, 2015, DRUG AGING, V32, P797, DOI 10.1007/s40266-015-0300-y
   Geurts JW, 2017, HEALTH EXPECT, V20, P1201, DOI 10.1111/hex.12527
   Heesterbeek TJ, 2020, OPHTHAL PHYSL OPT, V40, P140, DOI 10.1111/opo.12675
   Hennink M, 2022, SOC SCI MED, V292, DOI 10.1016/j.socscimed.2021.114523
   Jalbert I, 2020, PLOS ONE, V15, DOI 10.1371/journal.pone.0228858
   Kovach JL, 2012, J OPHTHALMOL, V2012, DOI 10.1155/2012/786870
   Legare F, 2008, PATIENT EDUC COUNS, V73, P526, DOI 10.1016/j.pec.2008.07.018
   McCloud C, 2015, EYE, V29, P1561, DOI 10.1038/eye.2015.167
   Nowak JZ, 2006, PHARMACOL REP, V58, P353
   O'Brien MA, 2013, HEALTH EXPECT, V16, P373, DOI 10.1111/j.1369-7625.2011.00712.x
   Paduca A, 2021, BMC MED INFORM DECIS, V21, DOI 10.1186/s12911-021-01469-y
   Pel-Littel RE, 2021, BMC GERIATR, V21, DOI 10.1186/s12877-021-02050-y
   Senra H, 2017, AM J OPHTHALMOL, V177, P213, DOI 10.1016/j.ajo.2017.03.005
   Shaw LT, 2020, EXPERT OPIN INV DRUG, V29, P547, DOI 10.1080/13543784.2020.1763953
   Siminerio LM, 2007, DIABETES EDUCATOR, V33, P152, DOI 10.1177/0145721706298194
   Spencer P, 2013, J MULTIDISCIP HEALTH, V6, P53, DOI 10.2147/JMDH.S35711
   Stiggelbout AM, 2015, PATIENT EDUC COUNS, V98, P1172, DOI 10.1016/j.pec.2015.06.022
   Taylor DJ, 2020, EYE, V34, P461, DOI 10.1038/s41433-019-0445-8
   Wolff JL, 2008, ARCH INTERN MED, V168, P1409, DOI 10.1001/archinte.168.13.1409
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
NR 30
TC 0
Z9 0
U1 1
U2 1
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0275-5408
EI 1475-1313
J9 OPHTHAL PHYSL OPT
JI Ophthalmic Physiol. Opt.
PD SEP
PY 2022
VL 42
IS 5
BP 1015
EP 1022
DI 10.1111/opo.13016
EA JUN 2022
PG 8
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 3O9VT
UT WOS:000811080600001
PM 35938211
OA Green Submitted
DA 2022-11-30
ER

PT J
AU Kubicka-Trzaska, A
   Zuber-Laskawiec, K
   Plutecka, H
   Romanowska-Dixon, B
   Sanak, M
   Karska-Basta, I
AF Kubicka-Trzaska, A.
   Zuber-Laskawiec, K.
   Plutecka, H.
   Romanowska-Dixon, B.
   Sanak, M.
   Karska-Basta, I.
TI ALTERED SERUM LEVELS OF AUTOPHAGY PROTEINS BECLIN-1 AND mTOR IN PATIENTS
   WITH EXUDATIVE AGE-RELATED MACULAR DEGENERATION
SO JOURNAL OF PHYSIOLOGY AND PHARMACOLOGY
LA English
DT Article
DE aging retina; age-related macular degeneration; autophagy biomarkers;
   Beclin-1; mechanistic target of rapamycin
ID PATHOGENESIS; BIOMARKERS; ACTIVATION; RETINA; SYSTEM; DEATH; CELLS;
   ACIDS
AB Autophagy is a key process in the maintenance of cellular survival and homeostasis. Inhibition of autophagy results in degenerative changes resembling ageing. We wondered if autophagy can contribute to the pathogenesis of age-related macular degeneration (AMD). We aimed to investigate the serum concentrations of two key autophagy regulators, Beclin-1 and mechanistic target of rapamycin (mTOR), in patients with exudative AMD. This retrospective case-control study included 38 patients with exudative AMD and 36 sex- and age-matched controls selected among senile cataract patients. Circulating Beclin-1 and mTOR were assessed using an enzyme-linked immunosorbent assay. The proteins levels were correlated with age, sex, duration of ocular symptoms, as well as angiographic and optical coherence tomography findings. Serum Beclin-1 levels were much lower in patients with AMD than in controls (median, 0.100 ng/ml versus 1.123 ng/ml; p = 0.0033), while mTOR levels did not differ (median, 4.377 ng/ml versus 3.608 ng/ml; p = 0.4522). Participants of the study older than 70 years had lower Beclin-1 levels than younger ones (p = 0.0444). However, this difference was the most evident in patients with AMD (p = 0.0024). Serum mTOR levels increased with age. In patients with AMD, lower mTOR levels were associated with drusen, while higher levels were observed in those with a fibrous scar in the contralateral eye (p = 0.0212). Our findings suggest that circulating Beclin-1 decreases with age and that is downregulated in patients with AMD.
C1 [Kubicka-Trzaska, A.; Zuber-Laskawiec, K.; Romanowska-Dixon, B.; Karska-Basta, I.] Jagiellonian Univ, Med Coll, Fac Med, Chair Ophthalmol, 38 Kopernika St, PL-31501 Krakow, Poland.
   [Plutecka, H.; Sanak, M.] Jagiellonian Univ, Med Coll, Fac Med, Div Mol Biol & Clin Genet, Krakow, Poland.
C3 Jagiellonian University; Collegium Medicum Jagiellonian University;
   Jagiellonian University; Collegium Medicum Jagiellonian University
RP Kubicka-Trzaska, A (通讯作者)，Jagiellonian Univ, Med Coll, Fac Med, Chair Ophthalmol, 38 Kopernika St, PL-31501 Krakow, Poland.
EM agnieszka.kubicka-trzaska@uj.edu.pl
RI Karska-Basta, Izabella/AAT-4361-2021
FU Jagiellonian University Medical College [N41/DBS/000310]
FX This work was supported by Jagiellonian University Medical College grant
   (no. N41/DBS/000310 to A. Kubicka-Trzaska).
CR Abrahamsen H, 2012, FEBS LETT, V586, P1584, DOI 10.1016/j.febslet.2012.04.046
   Bellezza I, 2018, FRONT PHARMACOL, V9, DOI 10.3389/fphar.2018.01280
   Bieri G, 2018, MOL NEURODEGENER, V13, DOI 10.1186/s13024-018-0302-4
   Blasiak J, 2020, CELL MOL LIFE SCI, V77, P789, DOI 10.1007/s00018-019-03420-x
   Blasiak J, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20010210
   Blasiak J, 2017, OXID MED CELL LONGEV, V2017, DOI 10.1155/2017/5293258
   Blasiak J, 2014, BIOMED RES INT, V2014, DOI 10.1155/2014/768026
   Castellazzi M, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-56614-5
   Copland DA, 2018, INVEST OPHTH VIS SCI, V59, pAMD83, DOI 10.1167/iovs.18-23893
   Dalal M, 2013, GRAEF ARCH CLIN EXP, V251, P2705, DOI 10.1007/s00417-013-2375-7
   DeAngelis MM, 2017, HUM MOL GENET, V26, pR45, DOI 10.1093/hmg/ddx228
   Ferris FL, 2013, OPHTHALMOLOGY, V120, P844, DOI 10.1016/j.ophtha.2012.10.036
   Fujikake N, 2018, FRONT NEUROSCI-SWITZ, V12, DOI 10.3389/fnins.2018.00255
   Geerlings MJ, 2017, MOL IMMUNOL, V84, P65, DOI 10.1016/j.molimm.2016.11.016
   Golestaneh N, 2017, CELL DEATH DIS, V8, DOI 10.1038/cddis.2016.453
   Hyttinen JMT, 2017, AGEING RES REV, V36, P64, DOI 10.1016/j.arr.2017.03.006
   Kaarniranta K, 2019, BIOCHIMIE, V159, P49, DOI 10.1016/j.biochi.2018.07.010
   Kaarniranta K, 2017, ACTA OPHTHALMOL, V95, P335, DOI 10.1111/aos.13344
   Kaarniranta K, 2017, CELL BIOL TOXICOL, V33, P113, DOI 10.1007/s10565-016-9371-8
   Karska-Basta I, 2020, J PHYSIOL PHARMACOL, V71, P235, DOI 10.26402/jpp.2020.2.07
   Karska-Basta I, 2021, J CLIN MED, V10, DOI 10.3390/jcm10051087
   Kim DT, 2020, CAN J OPHTHALMOL, V55, pE18, DOI 10.1016/j.jcjo.2019.05.008
   Kivinen N, 2018, ACTA OPHTHALMOL, V96, P1, DOI 10.1111/aos.13753
   Kubicka-Trzska A, 2020, POSTEP HIG MED DOSW, V74, P213, DOI 10.5604/01.3001.0014.2495
   Levine B, 2008, CELL, V132, P27, DOI 10.1016/j.cell.2007.12.018
   Levine B, 2017, P NATL ACAD SCI USA, V114, P201, DOI 10.1073/pnas.1619876114
   Li HH, 2015, J TRANSL MED, V13, DOI 10.1186/s12967-015-0726-3
   Li XH, 2020, MOL CANCER, V19, DOI 10.1186/s12943-020-1138-4
   Lieberthal W, 2008, KIDNEY INT, V74, P555, DOI 10.1038/ki.2008.325
   Lin W, 2019, OPHTHALMIC RES, V61, P65, DOI 10.1159/000487486
   Ma D, 2012, TRENDS ENDOCRIN MET, V23, P319, DOI 10.1016/j.tem.2012.03.004
   Masuda T, 2017, OXID MED CELL LONGEV, V2017, DOI 10.1155/2017/9208489
   Mitchell P, 2018, LANCET, V392, P1147, DOI 10.1016/S0140-6736(18)31550-2
   Mitter SK, 2012, ADV EXP MED BIOL, V723, P83, DOI 10.1007/978-1-4614-0631-0_12
   Munz C, 2011, VIRUSES-BASEL, V3, P1166, DOI 10.3390/v3071166
   Naguib M, 2018, DIABETES RES CLIN PR, V143, P56, DOI 10.1016/j.diabres.2018.06.022
   Nobukuni T, 2005, P NATL ACAD SCI USA, V102, P14238, DOI 10.1073/pnas.0506925102
   Perl A, 2015, ANN NY ACAD SCI, V1346, P33, DOI 10.1111/nyas.12756
   Rein DB, 2009, ARCH OPHTHALMOL-CHIC, V127, P533, DOI 10.1001/archophthalmol.2009.58
   Rinninella E, 2018, NUTRIENTS, V10, DOI 10.3390/nu10111677
   Rubinsztein DC, 2011, CELL, V146, P682, DOI 10.1016/j.cell.2011.07.030
   Tanito M, 2009, CLIN LIPIDOL, V4, P821, DOI 10.2217/CLP.09.65
   Vallee A, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21030820
   Velilla S, 2013, J OPHTHALMOL, V2013, DOI 10.1155/2013/895147
   Vladan Bajic, 2012, Med Hypothesis Discov Innov Ophthalmol, V1, P24
   Wang AL, 2009, AUTOPHAGY, V5, P1190, DOI 10.4161/auto.5.8.10087
   Wang M, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0083604
   Wang PP, 2017, BIOMED RES INT, V2017, DOI 10.1155/2017/3489603
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
   Yao JY, 2014, INVEST OPHTH VIS SCI, V55, P3237, DOI 10.1167/iovs.13-13336
   Zhang J, 2015, CELL DEATH DIS, V6, DOI 10.1038/cddis.2015.330
   Zuber-Laskawiec K, 2019, J PHYSIOL PHARMACOL, V70, P779, DOI 10.26402/jpp.2019.5.13
NR 52
TC 5
Z9 5
U1 0
U2 1
PU POLISH PHYSIOLOGICAL SOC
PI GRZEGORZECKA
PA JAGIELLONIAN UNIV SCHOOL MED, INST PHYSIOLOGY, 31-531 KRAKOW, 16
   GRZEGORZECKA, POLAND
SN 0867-5910
J9 J PHYSIOL PHARMACOL
JI J. Physiol. Pharmacol.
PD FEB
PY 2021
VL 72
IS 1
DI 10.26402/jpp.2021.1.09
PG 7
WC Physiology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Physiology
GA SP2CX
UT WOS:000659480900004
PM 34099588
DA 2022-11-30
ER

PT J
AU Maharjan, P
   Kim, D
   Jin, M
   Ko, HJ
   Song, YH
   Lee, Y
   Ahn, BN
   Kim, SK
   Lee, Y
   Shin, MC
   Min, KA
   Yang, J
AF Maharjan, Pooja
   Kim, Daseul
   Jin, Minki
   Ko, Hwi Jin
   Song, Yeong Ho
   Lee, Yoonjin
   Ahn, Byul-Nim
   Kim, Si-Kyung
   Lee, Yujin
   Shin, Meong Cheol
   Min, Kyoung Ah
   Yang, JaeWook
TI Preclinical Evaluation of UDCA-Containing Oral Formulation in Mice for
   the Treatment of Wet Age-Related Macular Degeneration
SO PHARMACEUTICS
LA English
DT Article
DE ocular treatment; ursodeoxycholic acid; tauroursodeoxycholic acid; bile
   acid; age-related macular degeneration; choroidal neovascularization
ID URSODEOXYCHOLIC ACID; BILE-ACIDS; CHOROIDAL NEOVASCULARIZATION;
   TAUROURSODEOXYCHOLIC ACID; MOUSE-LIVER; SOLUBILITY; MECHANISMS;
   THERAPIES; APOPTOSIS
AB As a posterior ocular disease, wet age-related macular degeneration (WAMD) has been known to be related to vision loss, accompanying ocular complications. The intravitreous injection of VEGF antibodies has been reported to be an effective treatment to relieve symptoms of WAMD. However, the limitations of this treatment are high costs and invasiveness. For this reason, oral delivery route can be considered as a cost-effective way and the safest method to deliver drug molecules to the eyes. Accordingly, ursodeoxycholic acid (UDCA) was included in the oral formulation as the potential substance for the cure of WAMD in the animal model. Various pharmacological activities, such as antioxidant or anti-inflammatory effects, have been reported for UDCA and recent reports support the effects of UDCA in ocular treatment. However, due to poor water solubility and low pKa (around 5.0), it has been challenging to formulate aqueous solution of UDCA in the neutral pH range. In the present study, we confirmed the aqueous solubility of the oral UDCA formulation and performed a preclinical study, including pharmacokinetic profiling and WAMD model efficacy study in mice after oral administration of the drug solution. The results demonstrated that the formulation improved bioavailability of UDCA and efficiently delivered UDCA to the eye tissues after oral absorption. UDCA formulation was found to have inhibitory effects of choroidal neovascularization with a functional recovery in mice retinas. Taken together, our results suggest that the oral UDCA formulation could be used as a potent supplement for the cure of WAMD and related retinal diseases.
C1 [Maharjan, Pooja; Kim, Daseul; Jin, Minki; Min, Kyoung Ah] Inje Univ, Coll Pharm, 197 Injero, Gimhae 50834, Gyeongnam, South Korea.
   [Maharjan, Pooja; Kim, Daseul; Jin, Minki; Min, Kyoung Ah] Inje Univ, Inje Inst Pharmaceut Sci & Res, 197 Injero, Gimhae 50834, Gyeongnam, South Korea.
   [Ko, Hwi Jin; Song, Yeong Ho] Yoos Biopharm Inc, Res Inst, 96 Gamasan Ro, Seoul 08501, South Korea.
   [Lee, Yoonjin; Ahn, Byul-Nim; Kim, Si-Kyung; Lee, Yujin; Yang, JaeWook] Inje Univ, Busan Paik Hosp, T2B Infrastruct Ctr Ocular Dis, 75 Bokjiro, Busan 47392, South Korea.
   [Shin, Meong Cheol] Gyeongsang Natl Univ, Coll Pharm, 501 Jinju Daero, Jinju 52828, Gyeongnam, South Korea.
   [Shin, Meong Cheol] Gyeongsang Natl Univ, Res Inst Pharmaceut Sci, 501 Jinju Daero, Jinju 52828, Gyeongnam, South Korea.
   [Yang, JaeWook] Inje Univ, Coll Med, Dept Ophthalmol, 75 Bokjiro, Busan 47392, South Korea.
C3 Inje University; Inje University; Inje University; Gyeongsang National
   University; Gyeongsang National University; Inje University
RP Min, KA (通讯作者)，Inje Univ, Coll Pharm, 197 Injero, Gimhae 50834, Gyeongnam, South Korea.; Min, KA (通讯作者)，Inje Univ, Inje Inst Pharmaceut Sci & Res, 197 Injero, Gimhae 50834, Gyeongnam, South Korea.; Yang, J (通讯作者)，Inje Univ, Busan Paik Hosp, T2B Infrastruct Ctr Ocular Dis, 75 Bokjiro, Busan 47392, South Korea.; Yang, J (通讯作者)，Inje Univ, Coll Med, Dept Ophthalmol, 75 Bokjiro, Busan 47392, South Korea.
EM maharjan.pooja47@gmail.com; k6365d@naver.com; jmk2720@nate.com;
   hwijinko@yoosbiopharm.com; yhssong@yoosbiopharm.com; 5569sy@naver.com;
   icetwig@naver.com; hush222@naver.com; jin49331@nate.com;
   shinmc@gnu.ac.kr; minkahh@inje.ac.kr; eyeyang@inje.ac.kr
RI Shin, Meong Cheol/AAQ-6559-2020
FU National Research Foundation of Korea (NRF) - Ministry of Education,
   Science and Technology [NRF-2017R1C1B5015491]; Korea Health Technology
   R&D Project through the Korea Health Industry Development Institute
   (KHIDI) - Ministry of Health & Welfare, Republic of Korea [HI15C1142];
   Industrial Strategic Technology Development Program - Ministry of Trade,
   Industry & Energy, Republic of Korea [20001252]
FX This research was financially supported by a grant from the Basic
   Science Research Program through the National Research Foundation of
   Korea (NRF) funded by the Ministry of Education, Science and Technology
   (NRF-2017R1C1B5015491) and a grant of the Korea Health Technology R&D
   Project through the Korea Health Industry Development Institute (KHIDI),
   funded by the Ministry of Health & Welfare, Republic of Korea (grant
   number: HI15C1142). This work was also supported by Industrial Strategic
   Technology Development Program funded By the Ministry of Trade, Industry
   & Energy, Republic of Korea (grant number: 20001252).
CR Ackerman HD, 2016, FRONT AGING NEUROSCI, V8, DOI 10.3389/fnagi.2016.00263
   Alnouti Y, 2008, J CHROMATOGR B, V873, P209, DOI 10.1016/j.jchromb.2008.08.018
   Avery RL, 2006, OPHTHALMOLOGY, V113, P363, DOI 10.1016/j.ophtha.2005.11.019
   Beuers U, 2006, NAT CLIN PRACT GASTR, V3, P318, DOI 10.1038/ncpgasthep0521
   Bhutto I, 2012, MOL ASPECTS MED, V33, P295, DOI 10.1016/j.mam.2012.04.005
   Boatright Jeffrey H, 2009, J Ocul Biol Dis Infor, V2, P149
   CAREY MC, 1984, HEPATOLOGY, V4, pS66, DOI 10.1002/hep.1840040812
   Chamulitrat W., 2013, Z GASTROENTEROL, V51, DOI [10.1055/s-0032-1331968, DOI 10.1055/S-0032-1331968]
   Chun HS, 2012, TOXICOLOGY, V292, P105, DOI 10.1016/j.tox.2011.11.020
   Hofmann AF, 2008, CELL MOL LIFE SCI, V65, P2461, DOI 10.1007/s00018-008-7568-6
   Kaiser PK, 2013, OPHTHALMOLOGY, V120, pS11, DOI 10.1016/j.ophtha.2013.01.061
   Kendall C., 2008, INVESTIG OPHTHALMOL, V49, P4932
   Kim D, 2019, PHARMACEUTICS, V11, DOI 10.3390/pharmaceutics11070297
   Kim Sang-Bum, 2019, Journal of Pharmaceutical Investigation, V49, P543, DOI 10.1007/s40005-018-00420-0
   Kulkarni AD, 2005, ADV DRUG DELIVER REV, V57, P1994, DOI 10.1016/j.addr.2005.09.003
   Lim LS, 2012, LANCET, V379, P1728, DOI 10.1016/S0140-6736(12)60282-7
   Maharjan Pooja, 2019, Journal of Pharmaceutical Investigation, V49, P215, DOI 10.1007/s40005-018-0404-6
   Martinez-Moya P, 2013, INT IMMUNOPHARMACOL, V15, P372, DOI 10.1016/j.intimp.2012.11.017
   Ni Z, 2009, OPHTHALMOLOGICA, V223, P401, DOI 10.1159/000228926
   Park IH, 2008, BIOCHEM BIOPH RES CO, V377, P1025, DOI 10.1016/j.bbrc.2008.06.014
   Pei Y.P., 2009, MED AROMATIC PLANT S, V3, P1
   Poupon R, 2012, CLIN RES HEPATOL GAS, V36, pS3, DOI 10.1016/S2210-7401(12)70015-3
   Ramalho RM, 2004, J NEUROCHEM, V90, P567, DOI 10.1111/j.1471-4159.2004.02517.x
   Rodrigues CMP, 2001, EXPERT OPIN INV DRUG, V10, P1243, DOI 10.1517/13543784.10.7.1243
   Sarenac TM, 2018, FRONT PHARMACOL, V9, DOI 10.3389/fphar.2018.00939
   Sauer P, 1999, DIGEST DIS SCI, V44, P817, DOI 10.1023/A:1026686530785
   Spaide RF, 2006, RETINA-J RET VIT DIS, V26, P383, DOI 10.1097/00006982-200604000-00001
   Thao TDH, 2008, BIOCHEM PHARMACOL, V75, P2135, DOI 10.1016/j.bcp.2008.03.008
   Toda T, 2009, DRUG METAB PHARMACOK, V24, P201, DOI 10.2133/dmpk.24.201
   vandeMeeberg PC, 1997, SCAND J GASTROENTERO, V32, P369, DOI 10.3109/00365529709007686
   Verma A, 1999, EUR J GASTROEN HEPAT, V11, P1069, DOI 10.1097/00042737-199910000-00001
   Woo SJ, 2010, J OCUL PHARMACOL TH, V26, P223, DOI 10.1089/jop.2010.0012
   Yu KS, 2018, J NANOMATER, V2018, DOI 10.1155/2018/7130450
NR 34
TC 5
Z9 6
U1 1
U2 7
PU MDPI
PI BASEL
PA ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND
EI 1999-4923
J9 PHARMACEUTICS
JI Pharmaceutics
PD NOV
PY 2019
VL 11
IS 11
AR 561
DI 10.3390/pharmaceutics11110561
PG 20
WC Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Pharmacology & Pharmacy
GA JV3QF
UT WOS:000502280100013
PM 31671869
OA gold, Green Published
DA 2022-11-30
ER

PT J
AU Acharya, UR
   Hagiwara, Y
   Koh, JEW
   Tan, JH
   Bhandary, SV
   Rao, AK
   Raghavendra, U
AF Acharya, U. Rajendra
   Hagiwara, Yuki
   Koh, Joel E. W.
   Tan, Jen Hong
   Bhandary, Sulatha V.
   Rao, A. Krishna
   Raghavendra, U.
TI Automated screening tool for dry and wet age-related macular
   degeneration (ARMD) using pyramid of histogram of oriented gradients
   (PHOG) and nonlinear features
SO JOURNAL OF COMPUTATIONAL SCIENCE
LA English
DT Article
DE Age-related macular degeneration; Ant colony optimization genetic
   algorithm; Fundus image; Particle swarm optimization; Pyramid of
   histograms of oriented gradients; Support vector machine
ID DECISION-SUPPORT-SYSTEM; ENTROPY; SEGMENTATION
AB Aging is the prime cause of age-related macular degeneration (ARMD). There are primarily two types of ARMD: (i) dry, and (ii) wet. The dry ARMD is the common form of ARMD. It typically starts with the formation of small pale yellowish deposits called drusen under the retina, causing atrophy at the macula, which is known as age-related macular degeneration. This, in turn, affects the central vision of a person. The wet ARMD is caused due to the abnormal growth of blood vessels under the retina. These vessels are known as the choroidal neovascular membrane break through the retina and bleed. They finally lead to either scarring at the macula or atrophic changes leading to severe visual impairment. Hence, the wet ARMD progresses faster and leads to an irreversible loss of sight. Therefore, it is advisable to go for routine eye screening, especially for elderly subjects. Although the ARMD cannot be fully cured, an accurate early detection can impede the progression of vision loss. However, manual diagnosis of ARMD is difficult and subjective. Thus, a computer-aided diagnosis (CAD) system can be utilized to automatically screen the eyes and give an accurate diagnosis of the type of ARMD. In this study, we propose a novel technique to identify normal, dry, and wet ARMD. A total of 945 fundus images (404 normal, 517 dry ARMD, and 24 wet ARMD) are used in this proposed framework. The Pyramid of Histograms of Orientation Gradients (PHOG) technique is implemented in this work to capture the subtle changes in the pixels of fundus images. Various nonlinear features are extracted from the PHOG descriptor. To balance the number of images in three classes, an adaptive synthetic sampling (ADASYN) approach is used. Two feature selection techniques namely ant colony optimization genetic algorithm (ACO-GA) and particle swarm optimization (PSO) are used to select the best performing method. The selected features are subjected to analysis of variance (ANOVA) to determine highly significant features for classification. The proposed system has achieved a maximum accuracy of 85.1%, sensitivity of 87.2%, and specificity of 80% using nine features selected by PSO feature selection method with support vector machine (SVM) classifier. It has obtained a maximum accuracy of 83.3%, sensitivity of 82.6%, and specificity of 84.8% using ten features selected by ACO-GA feature selection method with SVM classifier. The proposed CAD system yielded promising performance and thus, can be used as a practical adjunct ARMD screening tool in the clinical setting. (C) 2017 Elsevier B.V. All rights reserved.
C1 [Acharya, U. Rajendra; Hagiwara, Yuki; Koh, Joel E. W.; Tan, Jen Hong] Ngee Ann Polytech, Dept Elect & Comp Engn, Singapore, Singapore.
   [Acharya, U. Rajendra] SIM Univ, Dept Biomed Engn, Sch Sci & Technol, Singapore, Singapore.
   [Acharya, U. Rajendra] Univ Malaya, Fac Engn, Dept Biomed Engn, Kuala Lumpur, Malaysia.
   [Bhandary, Sulatha V.; Rao, A. Krishna] Kasturba Med Coll & Hosp, Dept Ophthalmol, Manipal 576104, Karnataka, India.
   [Raghavendra, U.] Manipal Univ, Manipal Inst Technol, Dept Instrumentat & Control Engn, Manipal 576104, India.
C3 Singapore University of Social Sciences (SUSS); Universiti Malaya;
   Manipal Academy of Higher Education (MAHE); Kasturba Medical College,
   Manipal; Manipal Academy of Higher Education (MAHE)
RP Acharya, UR (通讯作者)，Dept Elect & Comp Engn, 535 Clementi Rd, Singapore 599489, Singapore.
EM aru@np.edu.sg
RI Acharya, Rajendra U/E-3791-2010; Tan, Jenhong/AAD-3664-2020; Tan, Jen
   Hong/ABE-6525-2020
OI Acharya, Rajendra U/0000-0003-2689-8552; Bhandary,
   Sulatha/0000-0002-3150-707X; Hagiwara, Yuki/0000-0002-5418-738X
CR Acharya UR, 2005, J BODYW MOV THER, V9, P134, DOI 10.1016/j.jbmt.2004.04.001
   Acharya UR, 2016, COMPUT BIOL MED, V73, P131, DOI 10.1016/j.compbiomed.2016.04.009
   Acharya UR, 2016, KNOWL-BASED SYST, V99, P146, DOI 10.1016/j.knosys.2016.01.040
   Acharya UR, 2016, INFORM FUSION, V29, P32, DOI 10.1016/j.inffus.2015.09.006
   Acharya UR, 2015, KNOWL-BASED SYST, V88, P85, DOI 10.1016/j.knosys.2015.08.004
   Acharya UR, 2011, PHYSIOL MEAS, V32, P287, DOI 10.1088/0967-3334/32/3/002
   Agurto C, 2011, INVEST OPHTH VIS SCI, V52, P5862, DOI 10.1167/iovs.10-7075
   Alonso J. B., 2005, P 3 INT C NONL SPEEC, P94
   Bandt C, 2002, PHYS REV LETT, V88, DOI 10.1103/PhysRevLett.88.174102
   Bosch A, 2007, P 6 ACM INT C IM VID, P410
   Brown Gary C, 2005, Trans Am Ophthalmol Soc, V103, P173
   Coleman HR, 2008, LANCET, V372, P1835, DOI 10.1016/S0140-6736(08)61759-6
   CORTES C, 1995, MACH LEARN, V20, P273, DOI 10.1007/BF00994018
   Dahl A. A., 2016, MACULAR DEGENERATION
   Dorigo M, 1999, ARTIF LIFE, V5, P137, DOI 10.1162/106454699568728
   Dorigo M., 1992, THESIS
   Fisher DE, 2016, OPHTHALMOLOGY, V123, P1297, DOI 10.1016/j.ophtha.2015.12.026
   Gelman A, 2005, ANN STAT, V33, P1, DOI 10.1214/009053604000001048
   Gheyas IA, 2010, PATTERN RECOGN, V43, P5, DOI 10.1016/j.patcog.2009.06.009
   Haddrill M, ALL VISION WHAT IS A
   He HB, 2009, IEEE T KNOWL DATA EN, V21, P1263, DOI 10.1109/TKDE.2008.239
   He HB, 2008, IEEE IJCNN, P1322, DOI 10.1109/IJCNN.2008.4633969
   Hijazi M. H. A., 2015, INT J SIMUL SYST SCI, P57
   Hijazi MHA, 2010, P INT JOINT C NEUR N, P3501
   Hijazi MHA, 2012, KNOWL-BASED SYST, V29, P83, DOI 10.1016/j.knosys.2011.07.002
   HJORTH B, 1970, ELECTROEN CLIN NEURO, V29, P306, DOI 10.1016/0013-4694(70)90143-4
   Imani M.B., 2012, INT J MACH LEARN COM, V2, P278, DOI DOI 10.7763/IJMLC.2012.V2.130
   Kennedy J., 1995, 1995 IEEE International Conference on Neural Networks Proceedings (Cat. No.95CH35828), P1942, DOI 10.1109/ICNN.1995.488968
   Kose C, 2008, COMPUT BIOL MED, V38, P611, DOI 10.1016/j.compbiomed.2008.02.008
   KOLMOGOROV AN, 1958, DOKL AKAD NAUK SSSR+, V119, P861
   Kose C, 2010, J MED SYST, V34, P1, DOI 10.1007/s10916-008-9210-4
   KOSKO B, 1986, INFORM SCIENCES, V40, P165, DOI 10.1016/0020-0255(86)90006-X
   Lei HS, 2005, LECT NOTES COMPUT SC, V3541, P156
   LEMPEL A, 1976, IEEE T INFORM THEORY, V22, P75, DOI 10.1109/TIT.1976.1055501
   Liang Z. Y., 2010, 32 ANN INT C IEEE EN
   Lim T. H., PROCEEDINGS OF THE E, V36, pS15
   Lingras P, 2007, INFORM SCIENCES, V177, P3782, DOI 10.1016/j.ins.2007.03.028
   Mandelbrot B. B., 1983, GEOMETRY OF NATURE
   MARTINLOF P, 1966, INFORM CONTROL, V9, P602, DOI 10.1016/S0019-9958(66)80018-9
   Marwan N, 2002, PHYS REV E, V66, DOI 10.1103/PhysRevE.66.026702
   Marwan N., CROSS RECURRENCE PLO
   Marwan N, 2007, PHYS REP, V438, P237, DOI 10.1016/j.physrep.2006.11.001
   Mookiah MRK, 2015, KNOWL-BASED SYST, V89, P654, DOI 10.1016/j.knosys.2015.09.012
   Mookiah MRK, 2015, COMPUT BIOL MED, V63, P208, DOI 10.1016/j.compbiomed.2015.05.019
   Mookiah MRK, 2014, COMPUT BIOL MED, V53, P55, DOI 10.1016/j.compbiomed.2014.07.015
   Mookiah MRK, 2014, MED BIOL ENG COMPUT, V52, P781, DOI 10.1007/s11517-014-1180-8
   Oppenheim A. V., 2010, LECT NOTES INTRO COM, P30
   PINCUS SM, 1991, P NATL ACAD SCI USA, V88, P2297, DOI 10.1073/pnas.88.6.2297
   PIZER SM, 1987, COMPUT VISION GRAPH, V39, P355, DOI 10.1016/S0734-189X(87)80186-X
   Renyi A, 4 BERK S, P547
   Richman JS, 2000, AM J PHYSIOL-HEART C, V278, pH2039
   ROSENSTEIN MT, 1993, PHYSICA D, V65, P117, DOI 10.1016/0167-2789(93)90009-P
   Rosso OA, 2001, J NEUROSCI METH, V105, P65, DOI 10.1016/S0165-0270(00)00356-3
   Ryan S. J., 2012, ENHANCED ONLINE FEAT
   SHANNON CE, 1948, BELL SYST TECH J, V27, P623, DOI 10.1002/j.1538-7305.1948.tb00917.x
   Smola AJ, 1998, NEURAL NETWORKS, V11, P637, DOI 10.1016/S0893-6080(98)00032-X
   TSALLIS C, 1988, J STAT PHYS, V52, P479, DOI 10.1007/BF01016429
   Unler A, 2010, EUR J OPER RES, V206, P528, DOI 10.1016/j.ejor.2010.02.032
   Wang X., 2004, INT C EXP MECH, V5852, P462
   WEBBER CL, 1994, J APPL PHYSIOL, V76, P965, DOI 10.1152/jappl.1994.76.2.965
   Wu SD, 2013, PHYSICA A, V392, P5865, DOI 10.1016/j.physa.2013.07.075
   Yaeger L, INTRO TO GENETIC ALG, V3
   ZBILUT JP, 1992, PHYS LETT A, V171, P199, DOI 10.1016/0375-9601(92)90426-M
   Zheng YL, 2012, INVEST OPHTH VIS SCI, V53, P8310, DOI 10.1167/iovs.12-9576
NR 64
TC 16
Z9 16
U1 0
U2 3
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 1877-7503
J9 J COMPUT SCI-NETH
JI J. Comput. Sci.
PD MAY
PY 2017
VL 20
BP 41
EP 51
DI 10.1016/j.jocs.2017.03.005
PG 11
WC Computer Science, Interdisciplinary Applications; Computer Science,
   Theory & Methods
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Computer Science
GA EX3HO
UT WOS:000403123400005
DA 2022-11-30
ER

PT J
AU Dwyer, MA
   Kazmin, D
   Hu, P
   McDonnell, DP
   Malek, G
AF Dwyer, Mary A.
   Kazmin, Dmitri
   Hu, Peng
   McDonnell, Donald P.
   Malek, Goldis
TI Research Resource: Nuclear Receptor Atlas of Human Retinal Pigment
   Epithelial Cells: Potential Relevance to Age-Related Macular
   Degeneration
SO MOLECULAR ENDOCRINOLOGY
LA English
DT Article
ID FACTOR-H POLYMORPHISM; LIVER-X-RECEPTOR; PPAR-GAMMA; CHOROIDAL
   NEOVASCULARIZATION; STARGARDT-DISEASE; GENE-EXPRESSION; ACID RECEPTOR;
   RPE CELLS; APOPTOSIS; MACULOPATHY
AB Retinal pigment epithelial (RPE) cells play a vital role in retinal physiology by forming the outer blood-retina barrier and supporting photoreceptor function. Retinopathies including age-related macular degeneration (AMD) involve physiological and pathological changes in the epithelium, severely impairing the retina and effecting vision. Nuclear receptors (NRs), including peroxisome proliferator-activated receptor and liver X receptor, have been identified as key regulators of physiological pathways such as lipid metabolic dysregulation and inflammation, pathways that may also be involved in development of AMD. However, the expression levels of NRs in RPE cells have yet to be systematically surveyed. Furthermore, cell culture lines are widely used to study the biology of RPE cells, without knowledge of the differences or similarities in NR expression and activity between these in vitro models and in vivo RPE. Using quantitative real-time PCR, we assessed the expression patterns of all 48 members of the NR family plus aryl hydrocarbon receptor and aryl hydrocarbon receptor nuclear translocator in human RPE cells. We profiled freshly isolated cells from donor eyes (in vivo), a spontaneously arising human cell line (in vitro), and primary cell culture lines (in vitro) to determine the extent to which NR expression in the cultured cell lines reflects that of in vivo. To evaluate the validity of using cell culture models for investigating NR receptor biology, we determined transcriptional activity and target gene expression of several moderately and highly expressed NRs in vitro. Finally, we identified a subset of NRs that may play an important role in pathobiology of AMD. (Molecular Endocrinology 25:360-372, 2011)
C1 [Hu, Peng; Malek, Goldis] Duke Univ, Albert Eye Res Inst, Durham, NC 27710 USA.
   [Dwyer, Mary A.; Kazmin, Dmitri; McDonnell, Donald P.] Duke Univ, Dept Pharmacol & Canc Biol, Durham, NC 27710 USA.
   [Hu, Peng; Malek, Goldis] Duke Univ, Dept Ophthalmol, Durham, NC 27710 USA.
   [Malek, Goldis] Duke Univ, Dept Pathol, Durham, NC 27710 USA.
C3 Duke University; Duke University; Duke University; Duke University
RP Malek, G (通讯作者)，Duke Univ, Albert Eye Res Inst, 2351 Erwin Rd,Room 4006, Durham, NC 27710 USA.
EM gmalek@duke.edu
OI Malek, Goldis/0000-0003-0026-2388
FU International Retinal Research Foundation; American Health Assistance
   Foundation-Macular Degeneration Research; National Institutes of Health
   [DK48807]; Research to Prevent Blindness; NATIONAL EYE INSTITUTE
   [R01EY020868, P30EY005722] Funding Source: NIH RePORTER; NATIONAL
   INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R37DK048807,
   R01DK048807] Funding Source: NIH RePORTER
FX This work was supported by the International Retinal Research Foundation
   (to G.M.), American Health Assistance Foundation-Macular Degeneration
   Research (to G.M.), National Institutes of Health Research Grant DK48807
   (to D.P.M.), and unrestricted funds to the Department of Ophthalmology
   from Research to Prevent Blindness.
CR A-Gonzalez N, 2009, IMMUNITY, V31, P245, DOI 10.1016/j.immuni.2009.06.018
   Abeywickrama C, 2007, P NATL ACAD SCI USA, V104, P14610, DOI 10.1073/pnas.0706806104
   Anderson DH, 2010, PROG RETIN EYE RES, V29, P95, DOI 10.1016/j.preteyeres.2009.11.003
   Andreasen EA, 2007, TOXICOL SCI, V95, P215, DOI 10.1093/toxsci/kfl119
   Axel DI, 2001, CARDIOVASC RES, V49, P851, DOI 10.1016/S0008-6363(00)00312-6
   Bensinger SJ, 2009, CELL, V137, P26, DOI 10.1016/j.cell.2009.03.024
   BIRD AEC, 1995, SURV OPHTHALMOL, V39, P367, DOI 10.1016/S0039-6257(05)80092-X
   BLODI CF, 1990, OPHTHALMIC PAED GEN, V11, P49
   Boekhoorn SS, 2007, INVEST OPHTH VIS SCI, V48, P1012, DOI 10.1167/iovs.06-0577
   Booij JC, 2010, PROG RETIN EYE RES, V29, P1, DOI 10.1016/j.preteyeres.2009.08.003
   Bookout Angie L, 2003, Nucl Recept Signal, V1, pe012
   Bookout AL, 2006, CELL, V126, P789, DOI 10.1016/j.cell.2006.06.049
   BOSCH E, 1993, J HISTOCHEM CYTOCHEM, V41, P253, DOI 10.1177/41.2.8419462
   Bustin SA, 2009, CLIN CHEM, V55, P611, DOI 10.1373/clinchem.2008.112797
   Cai JY, 2000, PROG RETIN EYE RES, V19, P205, DOI 10.1016/S1350-9462(99)00009-9
   Carriere V, 2005, J BIOL CHEM, V280, P5406, DOI 10.1074/jbc.M408002200
   Chang JY, 2008, PPAR RES, V2008, DOI 10.1155/2008/720163
   Chappelow AV, 2008, DRUGS, V68, P1029, DOI 10.2165/00003495-200868080-00002
   Chawla A, 2001, SCIENCE, V294, P1866, DOI 10.1126/science.294.5548.1866
   Cheng HC, 2008, MOL VIS, V14, P95
   Crestani M, 2004, BIOCHEM SOC T, V32, P92, DOI 10.1042/BST0320092
   Curcio CA, 1999, ARCH OPHTHALMOL-CHIC, V117, P329, DOI 10.1001/archopht.117.3.329
   Davies Mark R, 2005, J Inflamm (Lond), V2, P15, DOI 10.1186/1476-9255-2-15
   Degner SC, 2009, J NUTR, V139, P26, DOI 10.3945/jn.108.099259
   Dumasia Rupal, 2005, Current Drug Targets - Cardiovascular & Haematological Disorders, V5, P377, DOI 10.2174/156800605774370362
   Dunn KC, 1996, EXP EYE RES, V62, P155, DOI 10.1006/exer.1996.0020
   Edwards Albert O., 2007, Angiogenesis, V10, P119, DOI 10.1007/s10456-007-9064-2
   Edwards AO, 2005, SCIENCE, V308, P421, DOI 10.1126/science.1110189
   Elliot S, 2008, EXP EYE RES, V86, P653, DOI 10.1016/j.exer.2008.01.010
   Feher J, 2006, NEUROBIOL AGING, V27, P983, DOI 10.1016/j.neurobiolaging.2005.05.012
   Ferrington DA, 2006, EXP EYE RES, V83, P638, DOI 10.1016/j.exer.2006.03.003
   Green W R, 1999, Mol Vis, V5, P27
   Hageman GS, 2005, P NATL ACAD SCI USA, V102, P7227, DOI 10.1073/pnas.0501536102
   Haines JL, 2005, SCIENCE, V308, P419, DOI 10.1126/science.1110359
   Hamel CP, 2007, ORPHANET J RARE DIS, V2, DOI 10.1186/1750-1172-2-7
   HE SK, 1994, CURR EYE RES, V13, P257, DOI 10.3109/02713689408995786
   Herzlich AA, 2008, PPAR RES, V2008, DOI 10.1155/2008/389507
   Huang W, 2010, ARTERIOSCL THROM VAS, V30, P1542, DOI 10.1161/ATVBAHA.109.191189
   Hummasti S, 2008, J LIPID RES, V49, P2535, DOI 10.1194/jlr.M800269-JLR200
   Iriyama A, 2008, J BIOL CHEM, V283, P11947, DOI 10.1074/jbc.M708989200
   JAFFE GJ, 1990, ARCH OPHTHALMOL-CHIC, V108, P1163, DOI 10.1001/archopht.1990.01070100119046
   Jarrett SG, 2008, PROG RETIN EYE RES, V27, P596, DOI 10.1016/j.preteyeres.2008.09.001
   Justilien V, 2007, INVEST OPHTH VIS SCI, V48, P4407, DOI 10.1167/iovs.07-0432
   Kasahara E, 2005, INVEST OPHTH VIS SCI, V46, P3426, DOI 10.1167/iovs.05-0344
   Kawai M, 2010, AM J PHYSIOL-ENDOC M, V299, pE3, DOI 10.1152/ajpendo.00157.2010
   Kim E, 2007, BIOCHEM BIOPH RES CO, V361, P323, DOI 10.1016/j.bbrc.2007.06.168
   Kim HK, 2009, J APPL PHYS, V105, DOI 10.1063/1.3124360
   Kim SR, 2007, P NATL ACAD SCI USA, V104, P19273, DOI 10.1073/pnas.0708714104
   King A, 2004, PHOTOCHEM PHOTOBIOL, V79, P470, DOI 10.1562/LE-03-17.1
   Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557
   Klein R, 2007, OPHTHALMOLOGY, V114, P253, DOI 10.1016/j.ophtha.2006.10.040
   Li AC, 2004, J LIPID RES, V45, P2161, DOI 10.1194/jlr.R400010-JLR200
   Lin JM, 2008, AM J OPHTHALMOL, V145, P716, DOI 10.1016/j.ajo.2007.11.006
   Malchiodi-Albedi F, 2008, PPAR RES, V2008, DOI 10.1155/2008/295784
   Marathe C, 2009, J LIPID RES, V50, P214, DOI 10.1194/jlr.M800189-JLR200
   Marek CJ, 2005, BIOCHEM J, V387, P601, DOI 10.1042/BJ20041598
   Marin-Castano ME, 2003, INVEST OPHTH VIS SCI, V44, P50, DOI 10.1167/iovs.01-1276
   Marmorstein AD, 2002, INVEST OPHTH VIS SCI, V43, P2435
   MITCHELL P, 1995, OPHTHALMOLOGY, V102, P1450
   Murata T, 2000, INVEST OPHTH VIS SCI, V41, P2309
   Nagai N, 2006, ARTERIOSCL THROM VAS, V26, P2252, DOI 10.1161/01.ATV.0000240050.15321.fe
   Negishi M, 2004, EXP BIOL MED, V229, P1053, DOI 10.1177/153537020422901010
   Otte C, 2010, J CLIN ENDOCR METAB, V95, P2885, DOI 10.1210/jc.2009-2251
   Palacios Santiago, 2008, BMC Womens Health, V8, P22, DOI 10.1186/1472-6874-8-22
   Qin J, 2010, P NATL ACAD SCI USA, V107, P3687, DOI 10.1073/pnas.0914619107
   Qin SF, 2006, INVEST OPHTH VIS SCI, V47, P5098, DOI 10.1167/iovs.06-0318
   Riserus U, 2008, DIABETES, V57, P332, DOI 10.2337/db07-1318
   RODRIGUES GA, 2010, INVEST OPHTHALMOL VI
   RODRIGUEZBOULAN E, 1989, SCIENCE, V245, P718, DOI 10.1126/science.2672330
   Roehlecke C, 2009, MOL VIS, V15, P1929
   Rotenstreich Y, 2003, OPHTHALMOLOGY, V110, P1151, DOI 10.1016/S0161-6420(03)00333-6
   Roth F, 2004, GRAEF ARCH CLIN EXP, V242, P710, DOI 10.1007/s00417-004-0976-x
   Saishin Y, 2003, J CELL PHYSIOL, V195, P241, DOI 10.1002/jcp.10246
   Seitzman RL, 2008, AM J EPIDEMIOL, V167, P1217, DOI 10.1093/aje/kwn024
   Sprecher DL, 2007, AM J CARDIOL, V100, p20N, DOI 10.1016/j.amjcard.2007.08.009
   Sprecher DL, 2007, ARTERIOSCL THROM VAS, V27, P359, DOI 10.1161/01.ATV.0000252790.70572.0c
   Strauss O, 2005, PHYSIOL REV, V85, P845, DOI 10.1152/physrev.00021.2004
   Streilein JW, 2002, VISION RES, V42, P487, DOI 10.1016/S0042-6989(01)00185-7
   Strunnikova NV, 2004, INVEST OPHTH VIS SCI, V45, pU726
   SZAMIER RB, 1977, INVEST OPHTH VIS SCI, V16, P947
   Szondy Z, 1997, MOL PHARMACOL, V51, P972, DOI 10.1124/mol.51.6.972
   Thorp E, 2007, CIRCULATION, V116, P2182, DOI 10.1161/CIRCULATIONAHA.107.698852
   Tontonoz P, 2003, MOL ENDOCRINOL, V17, P985, DOI 10.1210/me.2003-0061
   Towns R, 1999, BIOL REPROD, V61, P416, DOI 10.1095/biolreprod61.2.416
   Uemura A, 2006, J CLIN INVEST, V116, P369, DOI 10.1172/JCI25964
   Vasireddy V, 2010, PROG RETIN EYE RES, V29, P191, DOI 10.1016/j.preteyeres.2010.01.001
   Wang L, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0010329
   Willermain F, 2006, PROSTAG OTH LIPID M, V80, P136, DOI 10.1016/j.prostaglandins.2006.06.001
   Yamada Y, 2008, J NEUROCHEM, V105, P1187, DOI 10.1111/j.1471-4159.2008.05211.x
   Zarbin MA, 2004, ARCH OPHTHALMOL-CHIC, V122, P598, DOI 10.1001/archopht.122.4.598
   Zelcer N, 2009, SCIENCE, V325, P100, DOI 10.1126/science.1168974
   Zhang CX, 2003, J CELL SCI, V116, P1915, DOI 10.1242/jcs.00390
   Zhang XS, 2006, J ANDROL, V27, P405, DOI 10.2164/jandrol.05165
NR 93
TC 47
Z9 49
U1 0
U2 2
PU ENDOCRINE SOC
PI CHEVY CHASE
PA 8401 CONNECTICUT AVE, SUITE 900, CHEVY CHASE, MD 20815-5817 USA
SN 0888-8809
J9 MOL ENDOCRINOL
JI Mol. Endocrinol.
PD FEB
PY 2011
VL 25
IS 2
BP 360
EP 372
DI 10.1210/me.2010-0392
PG 13
WC Endocrinology & Metabolism
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Endocrinology & Metabolism
GA 711MQ
UT WOS:000286596100014
PM 21239617
OA Green Published, Bronze
DA 2022-11-30
ER

PT J
AU Cohen, SY
   Dubois, L
   Tadayoni, R
   Quentel, G
AF Cohen, Salomon Y.
   Dubois, Lise
   Tadayoni, Ramin
   Quentel, Gabriel
TI Age at Occurrence of Exudative Age-Related Macular Degeneration in a
   Clinical Setting: Difference between 1986 and 2006
SO OPHTHALMOLOGICA
LA English
DT Article
DE Age-related macular degeneration; Ageing; Choroidal neovascularization,
   epidemiology
ID BLUE-MOUNTAINS EYE; CHOROIDAL NEOVASCULARIZATION; LASER
   PHOTOCOAGULATION; RISK-FACTORS; POOLED FINDINGS; 3 CONTINENTS;
   ASSOCIATION; LESIONS; RANIBIZUMAB; VERTEPORFIN
AB Purpose: To our knowledge, there is no published study on the evolution of age of occurrence of exudative age-related macular degeneration (AMD). The present study was performed to test whether or not the average age of patients with newly diagnosed choroidal neovascularization (CNV) due to AMD has changed in a clinical setting during the past 20 years. Methods: Nonrandomized comparative case study. Charts and fluorescein angiograms of consecutive patients diagnosed in 1986 and 2006 in a tertiary care center were analyzed to identify differences in age, gender and type of CNV. Mann-Whitney's nonparametric test was used to compare the statistical distribution of the parameters. chi(2) or Fisher's exact test was used for categorical variables. Results: 357 patients with CNV due to AMD, 79 in 1986, and 278 in 2006 were included. The patients diagnosed in 2006 were 4.7 years older than those diagnosed in 1986 (80.1 +/- 8.9 vs. 75.4 +/- 6.7 years, p < 0.0001). The main increase was in the percentage of patients over 85 years: 11.39% in 1986 versus 26.98% in 2006. There was no significant difference between the two groups as regards gender or type of CNV. Conclusions: In our clinical setting, the average age of patients with newly diagnosed exudative AMD increased significantly between 1986 and 2006. The fact that in the present series more than 1 out of 4 patients was over 85 may have a significant impact on the potential side effects of currently available treatments of exudative AMD. Copyright (C) 2010 S. Karger AG, Basel
C1 [Cohen, Salomon Y.; Dubois, Lise; Quentel, Gabriel] Hop Lariboisiere, AP HP, Ctr Ophtalmol Imagerie & Laser, FR-75015 Paris, France.
   [Cohen, Salomon Y.; Tadayoni, Ramin] Hop Lariboisiere, AP HP, Dept Ophthalmol, FR-75015 Paris, France.
   Univ Paris 07, Paris, France.
C3 Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire
   Lariboisiere-Fernand-Widal - APHP; UDICE-French Research Universities;
   Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP);
   Hopital Universitaire Lariboisiere-Fernand-Widal - APHP; UDICE-French
   Research Universities; Universite Paris Cite; UDICE-French Research
   Universities; Universite Paris Cite
RP Cohen, SY (通讯作者)，Hop Lariboisiere, AP HP, Ctr Ophtalmol Imagerie & Laser, 11 Rue Antoine Bourdelle, FR-75015 Paris, France.
EM sycsyc75@gmail.com
CR Allikmets R, 2000, AM J HUM GENET, V67, P487, DOI 10.1086/303018
   Bressler NM, 1999, ARCH OPHTHALMOL-CHIC, V117, P1329
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Cohen SY, 2007, BRIT J OPHTHALMOL, V91, P1173, DOI 10.1136/bjo.2007.115501
   COSCAS G, 1987, B SOC OPHTALMOL FR, V97, P257
   COSCAS G, 1982, B MEM SOC FR OPHTALM, V94, P149
   CRUESS AF, 1993, ARCH OPHTHALMOL-CHIC, V111, P181
   FERRIS FL, 1984, ARCH OPHTHALMOL-CHIC, V102, P1640
   Gragoudas ES, 2004, NEW ENGL J MED, V351, P2805, DOI 10.1056/NEJMoa042760
   HAWKINS BS, 1990, ARCH OPHTHALMOL-CHIC, V108, P816
   Khan JC, 2006, BRIT J OPHTHALMOL, V90, P75, DOI 10.1136/bjo.2005.073643
   Kinugasa T, 2007, WORLD DEV, V35, P1, DOI 10.1016/j.worlddev.2006.09.002
   Resnikoff S, 2004, B WORLD HEALTH ORGAN, V82, P844
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Seddon JM, 2005, ARCH OPHTHALMOL-CHIC, V123, P321, DOI 10.1001/archopht.123.3.321
   Seddon JM, 2003, ARCH OPHTHALMOL-CHIC, V121, P1728, DOI 10.1001/archopht.121.12.1728
   Seddon JM, 2003, ARCH OPHTHALMOL-CHIC, V121, P785, DOI 10.1001/archopht.121.6.785
   Smith W, 1997, AUST NZ J OPHTHALMOL, V25, pS13
   Smith W, 2001, OPHTHALMOLOGY, V108, P697, DOI 10.1016/S0161-6420(00)00580-7
   STERNBERG P, 1991, ARCH OPHTHALMOL-CHIC, V109, P1220
   Tan JSL, 2007, OPHTHALMOLOGY, V114, P1143, DOI 10.1016/j.ophtha.2006.09.033
   Tomany SC, 2004, OPHTHALMOLOGY, V111, P1280, DOI 10.1016/j.ophtha.2003.11.010
NR 22
TC 0
Z9 0
U1 0
U2 0
PU KARGER
PI BASEL
PA ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND
SN 0030-3755
J9 OPHTHALMOLOGICA
JI Ophthalmologica
PY 2011
VL 225
IS 2
BP 76
EP 80
DI 10.1159/000314707
PG 5
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 666QN
UT WOS:000283132200002
PM 20881441
DA 2022-11-30
ER

PT J
AU Lee, J
   Byeon, SH
AF Lee, Junwon
   Byeon, Suk Ho
TI PREVALENCE AND CLINICAL CHARACTERISTICS OF PACHYDRUSEN IN POLYPOIDAL
   CHOROIDAL VASCULOPATHY Multimodal Image Study
SO RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES
LA English
DT Article
DE choroidal vascular hyperpermeability; pachychoroid; pachydrusen;
   pachyvessel; polypoidal choroidal vasculopathy
ID AGE-RELATED MACULOPATHY; MACULAR DEGENERATION; THICKNESS; DISEASE; EYES
AB Purpose: To investigate the prevalence of a newly defined drusen type, pachydrusen, soft drusen, and subretinal drusenoid deposits in eyes with polypoidal choroidal vasculopathy and fellow eyes and the relationship between each drusen type and the choroidal thickness, vascular morphology, and hyperpermeability.
   Methods: The 169 eyes of 90 patients with polypoidal choroidal vasculopathy were retrospectively reviewed. The prevalence of each drusen type was evaluated using color fundus photography and optical coherence tomography. The choroidal thickness and presence of pachyvessels on optical coherence tomography and choroidal vascular hyperpermeability on indocyanine green angiography were compared among the drusen groups.
   Results: Pachydrusen, soft drusen, and subretinal drusenoid deposits were found in 49.3%, 12.3%, and 6.9% in polypoidal choroidal vasculopathy eyes. The mean subfoveal choroidal thickness of the pachydrusen, soft drusen, and subretinal drusenoid deposit groups was 403.1, 184.4, and 176.4 mu m. The pachydrusen group showed significantly thicker choroid than the others. The choroidal hyperpermeability was noticed at 41.7%, 0%, and 0% and the pachyvessel was observed at 80.6%, 44.4%, and 40% in pachydrusen, soft drusen, and subretinal drusenoid deposit groups, respectively.
   Conclusion: In patients with polypoidal choroidal vasculopathy, pachydrusen was prevalent and associated with thicker choroid. Polypoidal choroidal vasculopathy with pachydrusen was highly associated with choroidal vascular hyperpremeability and pachyvessel morphology than other types of drusen.
C1 [Lee, Junwon; Byeon, Suk Ho] Yonsei Univ, Dept Ophthalmol, Eye & ENT Hosp, Severance Hosp,Inst Vis Res,Coll Med, Seoul, South Korea.
C3 Yonsei University; Yonsei University Health System
RP Byeon, SH (通讯作者)，Yonsei Univ, Dept Ophthalmol, Inst Vis Res, Coll Med, 134 Shinchon Dong, Seoul 03722, South Korea.
EM shbyeon@yuhs.ac.kr
OI Byeon, suk ho/0000-0001-8101-0830; Lee, Junwon/0000-0003-0543-7132
FU Basic Science Research Program through the National Research Foundation
   of Korea (NRF) - Ministry of Science, ICT & Future Planning
   [2017R1A2B4011045]; Korea Health Technology R&D Project through the
   Korea Health Industry Development Institute (KHIDI) - Ministry of Health
   & Welfare, Republic of Korea [H17C1567]
FX Supported by grants from the Basic Science Research Program through the
   National Research Foundation of Korea (NRF) funded by the Ministry of
   Science, ICT & Future Planning (Grant number: 2017R1A2B4011045) and the
   Korea Health Technology R&D Project through the Korea Health Industry
   Development Institute (KHIDI) funded by the Ministry of Health &
   Welfare, Republic of Korea (Grant number: H17C1567).
CR Balaratnasingam C, 2016, RETINA-J RET VIT DIS, V36, P1, DOI 10.1097/IAE.0000000000000774
   Chung SE, 2011, OPHTHALMOLOGY, V118, P840, DOI 10.1016/j.ophtha.2010.09.012
   Hou J, 2011, GRAEF ARCH CLIN EXP, V249, P975, DOI 10.1007/s00417-010-1575-7
   Huang LL, 2016, NAT GENET, V48, P640, DOI 10.1038/ng.3546
   Iwama D, 2008, JPN J OPHTHALMOL, V52, P116, DOI 10.1007/s10384-007-0503-9
   Jirarattanasopa P, 2012, INVEST OPHTH VIS SCI, V53, P3663, DOI 10.1167/iovs.12-9619
   Khan KN, 2016, PROG RETIN EYE RES, V53, P70, DOI 10.1016/j.preteyeres.2016.04.008
   Kim SW, 2011, RETINA-J RET VIT DIS, V31, P1904, DOI 10.1097/IAE.0b013e31821801c5
   KLEIN R, 1991, OPHTHALMOLOGY, V98, P1128
   Koizumi H, 2013, AM J OPHTHALMOL, V155, P305, DOI 10.1016/j.ajo.2012.07.018
   Koizumi H, 2011, GRAEF ARCH CLIN EXP, V249, P1123, DOI 10.1007/s00417-011-1620-1
   Lafaut BA, 2000, GRAEF ARCH CLIN EXP, V238, P752, DOI 10.1007/s004170000180
   Laude A, 2010, PROG RETIN EYE RES, V29, P19, DOI 10.1016/j.preteyeres.2009.10.001
   Lee WK, 2016, RETINA-J RET VIT DIS, V36, pS73, DOI 10.1097/IAE.0000000000001346
   Lima LH, 2010, OPHTHALMOLOGY, V117, P1567, DOI 10.1016/j.ophtha.2009.12.018
   Margolis R, 2009, AM J OPHTHALMOL, V147, P811, DOI 10.1016/j.ajo.2008.12.008
   Maruko I, 2007, AM J OPHTHALMOL, V144, P15, DOI 10.1016/j.ajo.2007.03.047
   Scassellati-Sforzolini B, 2001, RETINA-J RET VIT DIS, V21, P121, DOI 10.1097/00006982-200104000-00004
   Spaide R. F., 2017, RETINA
   SPAIDE RF, 1995, RETINA-J RET VIT DIS, V15, P100, DOI 10.1097/00006982-199515020-00003
   Spaide RF, 2008, AM J OPHTHALMOL, V146, P496, DOI 10.1016/j.ajo.2008.05.032
   Wei WB, 2013, OPHTHALMOLOGY, V120, P175, DOI 10.1016/j.ophtha.2012.07.048
   Wen F, 2004, GRAEF ARCH CLIN EXP, V242, P625, DOI 10.1007/s00417-003-0667-z
NR 23
TC 32
Z9 33
U1 0
U2 4
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0275-004X
EI 1539-2864
J9 RETINA-J RET VIT DIS
JI Retin.-J. Retin. Vitr. Dis.
PD APR
PY 2019
VL 39
IS 4
BP 670
EP 678
DI 10.1097/IAE.0000000000002019
PG 9
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA IQ4TY
UT WOS:000480744900006
PM 29346242
DA 2022-11-30
ER

PT J
AU Sassmannshausen, M
   Behning, C
   Isselmann, B
   Schmid, M
   Finger, RP
   Holz, FG
   Schmitz-Valckenberg, S
   Pfau, M
   Thiele, S
AF Sassmannshausen, Marlene
   Behning, Charlotte
   Isselmann, Ben
   Schmid, Matthias
   Finger, Robert P.
   Holz, Frank G.
   Schmitz-Valckenberg, Steffen
   Pfau, Maximilian
   Thiele, Sarah
CA MACUSTAR Consortium
TI Relative ellipsoid zone reflectivity and its association with disease
   severity in age-related macular degeneration: a MACUSTAR study report
SO SCIENTIFIC REPORTS
LA English
DT Article
ID OPTICAL COHERENCE TOMOGRAPHY; RETICULAR PSEUDODRUSEN; DRUSEN;
   MITOCHONDRIA; PROGRESSION; PIGMENT; RETINA; BANDS; EYES
AB Quantification of the relative ellipsoid zone reflectivity (rEZR) might be a structural surrogate parameter for an early disease progression in the context of age-related macular degeneration (AMD). Within the European multicenter, cross-sectional MACUSTAR study, we have devised an automatic approach to determine the mean rEZR [arbitrary units, AU] at two independent visits in SD-OCT volume scans in study participants. Linear mixed-effects models were applied to analyze the association of AMD stage and AMD associated high-risk features including presence of pigmentary abnormalities, reticular pseudodrusen (RPD), volume of the retinal-pigment-epithelial-drusenoid-complex (RPEDC) with the rEZR. Intra-class correlation coefficients (ICC) were determined for rEZR reliability analysis. Within the overall study cohort (301 participants), we could observe decreased rEZR values (coefficient estimate +/- standard error) of - 8.05 +/- 2.44 AU (p = 0.0011) in the intermediate and of - 22.35 +/- 3.28 AU (p < 0.0001) in the late AMD group. RPD presence was significantly associated with the rEZR in iAMD eyes (- 6.49 +/- 3.14 AU; p = 0.0403), while there was a good ICC of 0.846 (95% confidence interval: 0.809; 0.876) in the overall study cohort. This study showed an association of rEZR with increasing disease severity and the presence of iAMD high-risk features. Further studies are necessary to evaluate the rEZR's value as a novel biomarker for AMD and disease progression.
C1 [Sassmannshausen, Marlene; Isselmann, Ben; Finger, Robert P.; Holz, Frank G.; Schmitz-Valckenberg, Steffen; Pfau, Maximilian; Thiele, Sarah] Univ Bonn, Dept Ophthalmol, Venusberg Campus 1, D-53127 Bonn, Germany.
   [Sassmannshausen, Marlene; Holz, Frank G.; Schmitz-Valckenberg, Steffen; Pfau, Maximilian; Thiele, Sarah] Univ Bonn, Grade Reading Ctr, Bonn, Germany.
   [Behning, Charlotte; Schmid, Matthias] Univ Bonn, Inst Med Biometry Informat & Epidemiol, Bonn, Germany.
   [Schmitz-Valckenberg, Steffen] Univ Utah, John A Moran Eye Ctr, Dept Ophthalmol & Visual Sci, Salt Lake City, UT USA.
   [Pfau, Maximilian] NEI, Ophthalm Genet & Visual Funct Branch, Bethesda, MD 20892 USA.
C3 University of Bonn; University of Bonn; University of Bonn; Utah System
   of Higher Education; University of Utah; National Institutes of Health
   (NIH) - USA; NIH National Eye Institute (NEI)
RP Thiele, S (通讯作者)，Univ Bonn, Dept Ophthalmol, Venusberg Campus 1, D-53127 Bonn, Germany.; Thiele, S (通讯作者)，Univ Bonn, Grade Reading Ctr, Bonn, Germany.
EM sarah.thiele@ukbonn.de
OI Tufail, Adnan/0000-0001-6131-7640; Hogg, Ruth/0000-0001-9413-2669;
   Brazier, John/0000-0001-8645-4780
FU BONFOR GEROK Program, Faculty of Medicine, University of Bonn
   [O-137.0030, O-137.0026]; Anna-Katharina Eichenauer Foundation;
   Maria-von- Linden Program, University of Bonn; German Research
   Foundation (DFG) [TH 2514/2-1]; Innovative Medicines Initiative 2 Joint
   Undertaking [116076]; European Union; EFPIA
FX This work was supported by the BONFOR GEROK Program, Faculty of
   Medicine, University of Bonn, Grant No O-137.0030 to MS and O-137.0026
   to ST; by the Anna-Katharina Eichenauer Foundation to MS, by the
   Maria-von- Linden Program, University of Bonn to ST; by the Dr. Werner
   Jackstadt Nachwuchspreis of the German Retina Society to ST and by the
   German Research Foundation (DFG, TH 2514/2-1) to ST. This project has
   received funding from the Innovative Medicines Initiative 2 Joint
   Undertaking under grant agreement No 116076. This Joint Undertaking
   receives support from the European Union's Horizon 2020 research and
   innovation programme and EFPIA. The sponsors or funding organizations
   had no role in the design or conduct of the MACUSTAR study (project
   number: 116076) research.
CR Allingham MJ, 2019, INVEST OPHTH VIS SCI, V60
   [Anonymous], RECLAIM 2 STUDY EVAL
   Berkowitz BA, 2022, INVEST OPHTH VIS SCI, V63, DOI 10.1167/iovs.63.8.8
   Bonnet C, 2014, RETINA-J RET VIT DIS, V34, P1524, DOI 10.1097/IAE.0000000000000165
   Boretsky A, 2012, LASER SURG MED, V44, P603, DOI 10.1002/lsm.22070
   Borrelli E, 2020, SCI REP-UK, V10, DOI 10.1038/s41598-020-78201-9
   Chen L., 2017, ARXIV
   Chen L, 2020, RETINA-J RET VIT DIS, V40, P618, DOI 10.1097/IAE.0000000000002657
   Corvi F, 2019, RETINA-J RET VIT DIS, V39, P2378, DOI 10.1097/IAE.0000000000002335
   Corvi F, 2017, BRIT J OPHTHALMOL, V101, P770, DOI 10.1136/bjophthalmol-2016-309115
   Curcio CA, 1996, INVEST OPHTH VIS SCI, V37, P1236
   Davis MD, 2005, ARCH OPHTHALMOL-CHIC, V123, P1484
   Ferris FL, 2013, OPHTHALMOLOGY, V120, P844, DOI 10.1016/j.ophtha.2012.10.036
   Finger RP, 2019, OPHTHALMOLOGICA, V241, P61, DOI 10.1159/000491402
   Finger RP, 2014, OPHTHALMOLOGY, V121, P1252, DOI 10.1016/j.ophtha.2013.12.034
   Freund KB, 2011, RETINA-J RET VIT DIS, V31, P13, DOI 10.1097/IAE.0b013e3181ea48ba
   Gass JD., 1977, STEREOSCOPIC ATLAS M, V2
   Gin TJ, 2017, INVEST OPHTH VIS SCI, V58, P2079, DOI 10.1167/iovs.16-20105
   Hoang QV, 2002, VISUAL NEUROSCI, V19, P395, DOI 10.1017/S0952523802194028
   Huang YJ, 1998, INVEST OPHTH VIS SCI, V39, P2405
   Jaiswal M, 2015, PLOS BIOL, V13, DOI 10.1371/journal.pbio.1002197
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1417, DOI 10.1001/archopht.119.10.1417
   Li ML, 2018, RETINA-J RET VIT DIS, V38, P1937, DOI 10.1097/IAE.0000000000002182
   Litts KM, 2018, RETINA-J RET VIT DIS, V38, P445, DOI 10.1097/IAE.0000000000001946
   Lujan BJ, 2011, INVEST OPHTH VIS SCI, V52, P1486, DOI 10.1167/iovs.10-5946
   Narita C, 2020, OPHTHALMOLOGY, V127, P637, DOI 10.1016/j.ophtha.2019.11.007
   Nashine S, 2021, CELLS-BASEL, V10, DOI 10.3390/cells10092483
   Oishi A, 2017, INVEST OPHTH VIS SCI, V58, P2198, DOI 10.1167/iovs.16-20781
   Pfau M, 2020, JAMA OPHTHALMOL, V138, P1026, DOI 10.1001/jamaophthalmol.2020.2914
   Ross DH, 2015, INVEST OPHTH VIS SCI, V56, P4166, DOI 10.1167/iovs.14-15256
   SaSSmannshausen Marlene, 2022, Transl Vis Sci Technol, V11, P27, DOI 10.1167/tvst.11.3.27
   Shi YY, 2019, OPHTHALMOL RETINA, V3, P211, DOI 10.1016/j.oret.2018.10.012
   SHROUT PE, 1979, PSYCHOL BULL, V86, P420, DOI 10.1037/0033-2909.86.2.420
   Spaide RF, 2011, RETINA-J RET VIT DIS, V31, P1609, DOI 10.1097/IAE.0b013e3182247535
   Staurenghi G, 2014, OPHTHALMOLOGY, V121, P1572, DOI 10.1016/j.ophtha.2014.02.023
   Steinberg JS, 2015, BRIT J OPHTHALMOL, V99, P1289, DOI 10.1136/bjophthalmol-2014-306535
   Steinberg JS, 2015, JAMA OPHTHALMOL, V133, P690, DOI 10.1001/jamaophthalmol.2015.0477
   Tan ACS, 2016, AM J OPHTHALMOL, V172, P13, DOI 10.1016/j.ajo.2016.09.004
   Terheyden JH, 2019, OPHTHALMOLOGE, V116, P1186, DOI 10.1007/s00347-019-0907-1
   Terheyden JH, 2020, TRIALS, V21, DOI 10.1186/s13063-020-04595-6
   Terluk MR, 2015, J NEUROSCI, V35, P7304, DOI 10.1523/JNEUROSCI.0190-15.2015
   Thiele Sarah, 2022, Ophthalmol Retina, DOI 10.1016/j.oret.2022.06.001
   Thiele S, 2020, TRANSL VIS SCI TECHN, V9, DOI 10.1167/tvst.9.11.17
   Wu ZC, 2022, PROG RETIN EYE RES, V88, DOI 10.1016/j.preteyeres.2021.101017
   Wu ZC, 2013, INVEST OPHTH VIS SCI, V54, P2800, DOI 10.1167/iovs.13-11613
   Zweifel SA, 2010, OPHTHALMOLOGY, V117, P303, DOI 10.1016/j.ophtha.2009.07.014
NR 46
TC 0
Z9 0
U1 0
U2 0
PU NATURE PORTFOLIO
PI BERLIN
PA HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY
SN 2045-2322
J9 SCI REP-UK
JI Sci Rep
PD SEP 2
PY 2022
VL 12
IS 1
AR 14933
DI 10.1038/s41598-022-18875-5
PG 12
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA 4G8JR
UT WOS:000849436000082
PM 36056113
OA Green Published, Green Accepted, gold
DA 2022-11-30
ER

PT J
AU Hanumunthadu, D
   Ilginis, T
   Restori, M
   Sagoo, MS
   Tufail, A
   Balaggan, KS
   Patel, PJ
AF Hanumunthadu, Daren
   Ilginis, Tomas
   Restori, Marie
   Sagoo, Mandeep S.
   Tufail, Adnan
   Balaggan, Kamaljit S.
   Patel, Praveen J.
TI Repeatability of swept-source optical coherence tomography retinal and
   choroidal thickness measurements in neovascular age-related macular
   degeneration
SO BRITISH JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
ID INTRAVITREAL RANIBIZUMAB; OCT; EYES; REPRODUCIBILITY; SEGMENTATION;
   FIXATION; THERAPY; VOLUME
AB Background The aim was to determine the intrasession repeatability of swept-source optical coherence tomography (SS-OCT)-derived retinal and choroidal thickness measurements in eyes with neovascular age-related macular degeneration (nAMD).
   Methods A prospective study consisting of patients with active nAMD enrolled in the Distance of Choroid Study at Moorfields Eye Hospital, London. Patients underwent three 12x9 mm macular raster scans using the deep range imaging (DRI) OCT-1 SS-OCT (Topcon) device in a single imaging session. Retinal and choroidal thicknesses were calculated for the ETDRS macular subfields. Repeatability was calculated according to methods described by Bland and Altman.
   Results 39 eyes of 39 patients with nAMD were included with a mean (+/- SD) age of 73.9 (+/- 7.2) years. The mean (+/- SD) retinal thickness of the central macular subfield was 225.7 mu m (+/- 12.4 mu m). The repeatability this subfield, expressed as a percentage of the mean central macular subfield thickness, was 23.2%. The percentage repeatability of the other macular subfields ranged from 13.2% to 28.7%. The intrasession coefficient of repeatability of choroidal thickness of the central macular subfield was 57.2 mu m with a mean choroidal thickness (+/- SD) of 181 mu m (+/- 15.8 mu m).
   Conclusions This study suggests that a change >23.2% of retinal thickness and 57.2 mu m choroidal thickness in the central macular subfield is required to distinguish true clinical change from measurement variability when using the DRI OCT-1 device to manage patients with nAMD.
C1 [Hanumunthadu, Daren; Ilginis, Tomas; Restori, Marie; Sagoo, Mandeep S.; Tufail, Adnan; Balaggan, Kamaljit S.; Patel, Praveen J.] Moorfields Eye Hosp NHS Fdn Trust, NIHR Biomed Res Ctr, 162 City Rd, London EC1V 2PD, England.
   [Hanumunthadu, Daren; Ilginis, Tomas; Restori, Marie; Sagoo, Mandeep S.; Tufail, Adnan; Balaggan, Kamaljit S.; Patel, Praveen J.] UCL Inst Ophthalmol, 162 City Rd, London EC1V 2PD, England.
   [Sagoo, Mandeep S.] Barts Hlth NHS Trust, Ophthalmol Dept, London, England.
   [Balaggan, Kamaljit S.] Wolverhampton & Midland Counties Eye Infirm, Wolverhampton, England.
C3 University of London; University College London; Moorfields Eye Hospital
   NHS Foundation Trust; University of London; University College London;
   Barts Health NHS Trust
RP Patel, PJ (通讯作者)，Moorfields Eye Hosp NHS Fdn Trust, NIHR Biomed Res Ctr, 162 City Rd, London EC1V 2PD, England.; Patel, PJ (通讯作者)，UCL Inst Ophthalmol, 162 City Rd, London EC1V 2PD, England.
EM Praveen.patel@moorfields.nhs.uk
OI Tufail, Adnan/0000-0001-6131-7640; Sagoo, Mandeep/0000-0003-1530-3824
FU SalutarisMD; NIHR Biomedical Research Centre at Moorfields Eye Hospital
   NHS Foundation Trust; UCL Institute of Ophthalmology; NIHR Moorfields
   Clinical Research Facility
FX This work was funded by SalutarisMD and supported by the NIHR Biomedical
   Research Centre at Moorfields Eye Hospital NHS Foundation Trust and UCL
   Institute of Ophthalmology and the NIHR Moorfields Clinical Research
   Facility.
CR Adhi M, 2013, CURR OPIN OPHTHALMOL, V24, P213, DOI 10.1097/ICU.0b013e32835f8bf8
   BLAND JM, 1986, LANCET, V1, P307, DOI 10.1016/s0140-6736(86)90837-8
   Bland JM, 1996, BRIT MED J, V313, P106, DOI 10.1136/bmj.313.7049.106
   Brown DM, 2013, OPHTHALMOLOGY, V120, P2013, DOI 10.1016/j.ophtha.2013.02.034
   Comyn O, 2012, INVEST OPHTH VIS SCI, V53, P7754, DOI 10.1167/iovs.12-10895
   de Bruin DM, 2008, INVEST OPHTH VIS SCI, V49, P4545, DOI 10.1167/iovs.07-1553
   Gallego-Pinazo Roberto, 2014, Med Hypothesis Discov Innov Ophthalmol, V3, P111
   Hanumunthadu D, 2016, AM J OPHTHALMOL, V166, P154, DOI 10.1016/j.ajo.2016.03.052
   Heier JS, 2012, OPHTHALMOLOGY, V119, P2537, DOI 10.1016/j.ophtha.2012.09.006
   Kang HM, 2014, AM J OPHTHALMOL, V157, P1013, DOI 10.1016/j.ajo.2014.01.019
   Keane PA, 2009, INVEST OPHTH VIS SCI, V50, P3378, DOI 10.1167/iovs.08-2728
   Kim M, 2013, INDIAN J OPHTHALMOL, V61, P213, DOI 10.4103/0301-4738.97075
   Koizumi H, 2015, AM J OPHTHALMOL, V159, P627, DOI 10.1016/j.ajo.2014.12.025
   Lodge MA, 2008, J NUCL MED, V49, P1620, DOI 10.2967/jnumed.108.052076
   Mansouri K, 2014, AM J OPHTHALMOL, V157, P1022, DOI 10.1016/j.ajo.2014.02.008
   Mathew R, 2012, AM J OPHTHALMOL, V153, P490, DOI 10.1016/j.ajo.2011.08.034
   Matsuo Y, 2013, INVEST OPHTH VIS SCI, V54, P7630, DOI 10.1167/iovs.13-13135
   Midena Edoardo, 2004, Semin Ophthalmol, V19, P55, DOI 10.1080/08820530490882896
   Parravano M, 2010, INVEST OPHTH VIS SCI, V51, P4788, DOI 10.1167/iovs.09-4976
   Patel PJ, 2011, ACTA OPHTHALMOL, V89, P526, DOI 10.1111/j.1755-3768.2009.01761.x
   Rahman W, 2013, GRAEF ARCH CLIN EXP, V251, P1483, DOI 10.1007/s00417-012-2199-x
   Razavi S, 2015, AM J OPHTHALMOL, V160, P1006, DOI 10.1016/j.ajo.2015.08.009
   Shin JY, 2015, ACTA OPHTHALMOL, V93, P524, DOI 10.1111/aos.12653
   Sivaprasad S, 2011, EYE, V25, P1612, DOI 10.1038/eye.2011.223
   Spaide RF, 2009, AM J OPHTHALMOL, V147, P801, DOI 10.1016/j.ajo.2008.12.010
   Tah V, 2014, INDIAN J OPHTHALMOL, V62, P941, DOI 10.4103/0301-4738.143936
   Tufail A, 2010, BMJ-BRIT MED J, V340, DOI 10.1136/bmj.c2459
   Yang Q, 2010, OPT EXPRESS, V18, P21293, DOI 10.1364/OE.18.021293
NR 28
TC 5
Z9 5
U1 0
U2 6
PU BMJ PUBLISHING GROUP
PI LONDON
PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND
SN 0007-1161
EI 1468-2079
J9 BRIT J OPHTHALMOL
JI Br. J. Ophthalmol.
PD MAY
PY 2017
VL 101
IS 5
BP 603
EP 608
DI 10.1136/bjophthalmol-2016-308999
PG 6
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA EW2MQ
UT WOS:000402331100012
PM 27491359
OA Green Submitted
DA 2022-11-30
ER

PT J
AU Litts, KM
   Messinger, JD
   Freund, KB
   Zhang, YH
   Curcio, CA
AF Litts, Katie M.
   Messinger, Jeffrey D.
   Freund, K. Bailey
   Zhang, Yuhua
   Curcio, Christine A.
TI Inner Segment Remodeling and Mitochondrial Translocation in Cone
   Photoreceptors in Age-Related Macular Degeneration With Outer Retinal
   Tubulation
SO INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE
LA English
DT Article
DE age-related macular degeneration; cones; ellipsoid; histology; Muller
   cells; myoid; outer retinal tubulation; photoreceptors; transmission
   electron microscopy
ID OPTICAL-COHERENCE-TOMOGRAPHY; SUBRETINAL DRUSENOID DEPOSITS; EXTERNAL
   LIMITING MEMBRANE; ADAPTIVE-OPTICS; HIGH-RESOLUTION; MORPHOMETRIC
   ANALYSIS; GEOGRAPHIC ATROPHY; OXIDATIVE-STRESS; FISSION; EYES
AB PURPOSE. To quantify impressions of mitochondrial translocation in degenerating cones and to determine the nature of accumulated material in the subretinal space with apparent inner segment (IS)-like features by examining cone IS ultrastructure.
   METHODS. Human donor eyes with advanced age-related macular degeneration (AMD) were screened for outer retinal tubulation (ORT) in macula-wide, high-resolution digital sections. Degenerating cones inside ORT (ORT cones) and outside ORT (non-ORT cones) from AMD eyes and unaffected cones in age-matched control eyes were imaged using transmission electron microscopy. The distances of mitochondria to the external limiting membrane (ELM), cone IS length, and cone IS width at the ELM were measured.
   RESULTS. Outer retinal tubulation and non-ORT cones lose outer segments (OS), followed by shortening of IS and mitochondria. In non-ORT cones, IS broaden. Outer retinal tubulation and non-ORT cone IS myoids become undetectable due to mitochondria redistribution toward the nucleus. Some ORT cones were found lacking IS and containing mitochondria in the outer fiber (between soma and ELM). Unlike long, thin IS mitochondria in control cones, ORT and non-ORT IS mitochondria are ovoid or reniform. Shed IS, some containing mitochondria, were found in the subretinal space.
   CONCLUSIONS. In AMD, macula cones exhibit loss of detectable myoid due to IS shortening in addition to OS loss, as described. Mitochondria shrink and translocate toward the nucleus. As reflectivity sources, translocating mitochondria may be detectable using in vivo imaging to monitor photoreceptor degeneration in retinal disorders. These results improve the knowledge basis for interpreting high-resolution clinical retinal imaging.
C1 [Litts, Katie M.; Messinger, Jeffrey D.; Zhang, Yuhua; Curcio, Christine A.] Univ Alabama Birmingham, Sch Med, Dept Ophthalmol, Birmingham, AL 35294 USA.
   [Litts, Katie M.] Univ Alabama Birmingham, Vis Sci Grad Program, Birmingham, AL 35294 USA.
   [Freund, K. Bailey] Vitreous Retina Macula Consultants New York, New York, NY USA.
C3 University of Alabama System; University of Alabama Birmingham;
   University of Alabama System; University of Alabama Birmingham; Vitreous
   Retina Macula Consultants of New York
RP Curcio, CA (通讯作者)，Univ Alabama Birmingham, Sch Med, Dept Ophthalmol, EyeSight Fdn Alabama,Vis Res Labs, 1670 Univ Blvd Room 360, Birmingham, AL 35294 USA.
EM curcio@uab.edu
RI Litts, Katie M/AAK-1564-2021; Freund, K. Bailey/V-7488-2018
OI Litts, Katie M/0000-0001-6707-8273; Freund, K.
   Bailey/0000-0002-7888-9773
FU Vision Science Graduate Program; US National Institutes of Health
   [EY06019, 5R21EY021903]; International Retina Research Foundation;
   EyeSight Foundation of Alabama; International Retinal Research
   Foundation; National Eye Institute [P30 EY003039]; Arnold and Mabel
   Beckman Initiative for Macular Research; Research to Prevent Blindness;
   Macula Foundation, Inc.; NATIONAL EYE INSTITUTE [R21EY021903,
   P30EY003039] Funding Source: NIH RePORTER
FX Supported by Vision Science Graduate Program (KML); US National
   Institutes of Health Grants EY06019 (CAC) and 5R21EY021903 (YZ);
   International Retina Research Foundation (YZ); EyeSight Foundation of
   Alabama (YZ); unrestricted funds to the Department of Ophthalmology,
   University of Alabama School of Medicine, from Research to Prevent
   Blindness; the EyeSight Foundation of Alabama; and Macula Foundation,
   Inc. (KBF). Acquisition of donor eyes received additional support from
   International Retinal Research Foundation, National Eye Institute Grant
   P30 EY003039, and the Arnold and Mabel Beckman Initiative for Macular
   Research.
CR Balaban RS, 2005, CELL, V120, P483, DOI 10.1016/j.cell.2005.02.001
   Bird AC, 2014, JAMA OPHTHALMOL, V132, P338, DOI 10.1001/jamaophthalmol.2013.5799
   Bossy-Wetzel E, 2003, CURR OPIN CELL BIOL, V15, P706, DOI 10.1016/j.ceb.2003.10.015
   Burke TR, 2013, OPHTHALMIC GENET, V34, P75, DOI 10.3109/13816810.2012.707271
   Burns SA, 2007, J OPT SOC AM A, V24, P1313, DOI 10.1364/JOSAA.24.001313
   Chen DC, 2007, J OPT SOC AM A, V24, P1305, DOI 10.1364/JOSAA.24.001305
   Chen HC, 2006, CURR OPIN CELL BIOL, V18, P453, DOI 10.1016/j.ceb.2006.06.004
   Chen HC, 2009, HUM MOL GENET, V18, pR169, DOI 10.1093/hmg/ddp326
   Curcio CA, 2005, EXP EYE RES, V80, P761, DOI 10.1016/j.exer.2004.09.017
   CURCIO CA, 1993, INVEST OPHTH VIS SCI, V34, P3278
   Curcio CA, 1996, INVEST OPHTH VIS SCI, V37, P1236
   Curcio CA, 1998, INVEST OPHTH VIS SCI, V39, P1085
   Curcio CA, 2001, INVEST OPHTH VIS SCI, V42, P265
   CURCIO CA, 1990, J COMP NEUROL, V292, P497, DOI 10.1002/cne.902920402
   Curcio CA, 2013, RETINA-J RET VIT DIS, V33, P265, DOI 10.1097/IAE.0b013e31827e25e0
   Curcio CA, 2011, INVEST OPHTH VIS SCI, V52, P3943, DOI 10.1167/iovs.10-6377
   Dunaief JL, 2002, ARCH OPHTHALMOL-CHIC, V120, P1435, DOI 10.1001/archopht.120.11.1435
   Duncan JL, 2007, INVEST OPHTH VIS SCI, V48, P3283, DOI 10.1167/iovs.06-1422
   Federico A, 2012, J NEUROL SCI, V322, P254, DOI 10.1016/j.jns.2012.05.030
   Greenberg JP, 2014, JAMA OPHTHALMOL, V132, P437, DOI 10.1001/jamaophthalmol.2013.7987
   GUYTON JR, 1988, J HISTOCHEM CYTOCHEM, V36, P1319, DOI 10.1177/36.10.2458408
   Hermann B, 2004, OPT LETT, V29, P2142, DOI 10.1364/OL.29.002142
   Hoang QV, 2002, VISUAL NEUROSCI, V19, P395, DOI 10.1017/S0952523802194028
   IWASAKI M, 1988, INVEST OPHTH VIS SCI, V29, P671
   Johnson PT, 2005, INVEST OPHTH VIS SCI, V46, P4788, DOI 10.1167/iovs.05-0767
   Johnson PT, 2003, INVEST OPHTH VIS SCI, V44, P4481, DOI 10.1167/iovs.03-0436
   Jonnal RS, 2014, INVEST OPHTH VIS SCI, V55, P7904, DOI 10.1167/iovs.14-14907
   Jung JJ, 2012, ARCH OPHTHALMOL-CHIC, V130, P1618, DOI 10.1001/archophthalmol.2012.1902
   Kim SY, 2002, RETINA-J RET VIT DIS, V22, P471, DOI 10.1097/00006982-200208000-00012
   Kim SY, 2002, RETINA-J RET VIT DIS, V22, P464, DOI 10.1097/00006982-200208000-00011
   Knott AB, 2008, NAT REV NEUROSCI, V9, P505, DOI 10.1038/nrn2417
   Lee W, 2014, INVEST OPHTH VIS SCI, V55, P6139, DOI 10.1167/iovs.14-15126
   Litts KM, 2015, JAMA OPHTHALMOL, V133, P609, DOI 10.1001/jamaophthalmol.2015.126
   Lyamzaev KG, 2008, BBA-BIOENERGETICS, V1777, P817, DOI 10.1016/j.bbabio.2008.03.027
   MacAskill AF, 2010, TRENDS CELL BIOL, V20, P102, DOI 10.1016/j.tcb.2009.11.002
   Maresca A, 2013, MOL CELL NEUROSCI, V55, P62, DOI 10.1016/j.mcn.2012.08.004
   McInnes J, 2013, TRANSL NEURODEGENER, V2, DOI 10.1186/2047-9158-2-12
   Meadway A, 2013, OPT EXPRESS, V21, P29792, DOI 10.1364/OE.21.029792
   Miller DT, 2011, EYE, V25, P321, DOI 10.1038/eye.2011.1
   Mitamura Y, 2013, J OPHTHALMOL, V2013, DOI 10.1155/2013/518170
   Mullins RF, 2006, MOL VIS, V12, P224
   Nag TC, 2006, BRAIN RES BULL, V71, P224, DOI 10.1016/j.brainresbull.2006.09.007
   Nakajima A, 2008, J BIOL CHEM, V283, P24128, DOI 10.1074/jbc.M802996200
   Oak ASW, 2014, RETINA-J RET VIT DIS, V34, P825, DOI 10.1097/IAE.0000000000000121
   Panorgias A, 2013, INVEST OPHTH VIS SCI, V54, P4372, DOI 10.1167/iovs.12-11525
   Pathak D, 2013, ANN NEUROL, V74, P506, DOI 10.1002/ana.24014
   Pesch UEA, 2004, INVEST OPHTH VIS SCI, V45, P4217, DOI 10.1167/iovs.03-1261
   Polyak S. L., 1941, RETINA-J RET VIT DIS
   Putnam NM, 2010, OPT EXPRESS, V18, P24902, DOI 10.1364/OE.18.024902
   Roorda A, 2002, OPT EXPRESS, V10, P405, DOI 10.1364/OE.10.000405
   Rudnicka AR, 2012, OPHTHALMOLOGY, V119, P571, DOI 10.1016/j.ophtha.2011.09.027
   Schaal KB, 2015, RETINA-J RET VIT DIS, V35, P1339, DOI 10.1097/IAE.0000000000000471
   Schuman SG, 2009, OPHTHALMOLOGY, V116, P488, DOI 10.1016/j.ophtha.2008.10.006
   Shelley EJ, 2009, ARCH OPHTHALMOL-CHIC, V127, P483, DOI 10.1001/archophthalmol.2008.622
   Shields CL, 2012, ARCH OPHTHALMOL-CHIC, V130, P850, DOI 10.1001/archophthalmol.2012.1135
   Spaide RF, 2011, RETINA-J RET VIT DIS, V31, P1609, DOI 10.1097/IAE.0b013e3182247535
   Spaide RF, 2010, RETINA-J RET VIT DIS, V30, P1441, DOI 10.1097/IAE.0b013e3181ee5ce8
   Staurenghi G, 2014, OPHTHALMOLOGY, V121, P1572, DOI 10.1016/j.ophtha.2014.02.023
   TUCKER GS, 1986, INVEST OPHTH VIS SCI, V27, P708
   Tychinsky V, 2009, J BIOPHOTONICS, V2, P494, DOI 10.1002/jbio.200910042
   Wang AG, 2006, EXP EYE RES, V83, P1171, DOI 10.1016/j.exer.2006.06.004
   Westermann B, 2010, NAT REV MOL CELL BIO, V11, P872, DOI 10.1038/nrm3013
   Williams DR, 2011, VISION RES, V51, P1379, DOI 10.1016/j.visres.2011.05.002
   Wilson JD, 2005, BIOPHYS J, V88, P2929, DOI 10.1529/biophysj.104.054528
   Wilson JD, 2007, J BIOMED OPT, V12, DOI 10.1117/1.2437765
   Wolff B, 2012, J OPHTHALMOL, V2012, DOI 10.1155/2012/542417
   Xu G Z, 1996, Trans Am Ophthalmol Soc, V94, P411
   Xu GZ, 1996, T AM OPHTHAL SOC, V94, P430
   Youle RJ, 2012, SCIENCE, V337, P1062, DOI 10.1126/science.1219855
   YOUNG RW, 1987, SURV OPHTHALMOL, V31, P291, DOI 10.1016/0039-6257(87)90115-9
   Zawadzki RJ, 2005, OPT EXPRESS, V13, P8532, DOI 10.1364/OPEX.13.008532
   Zayit-Soudry S, 2013, INVEST OPHTH VIS SCI, V54, P7498, DOI 10.1167/iovs.13-12433
   Zhang Y, 2006, OPT EXPRESS, V14, P4380, DOI 10.1364/OE.14.004380
   Zhang YH, 2006, OPT LETT, V31, P1268, DOI 10.1364/OL.31.001268
   Zhang YH, 2014, AM J OPHTHALMOL, V158, P584, DOI 10.1016/j.ajo.2014.05.038
   Zweifel SA, 2009, ARCH OPHTHALMOL-CHIC, V127, P1596, DOI 10.1001/archophthalmol.2009.326
NR 76
TC 58
Z9 60
U1 0
U2 4
PU ASSOC RESEARCH VISION OPHTHALMOLOGY INC
PI ROCKVILLE
PA 12300 TWINBROOK PARKWAY, ROCKVILLE, MD 20852-1606 USA
SN 0146-0404
EI 1552-5783
J9 INVEST OPHTH VIS SCI
JI Invest. Ophthalmol. Vis. Sci.
PD APR
PY 2015
VL 56
IS 4
BP 2243
EP 2253
DI 10.1167/iovs.14-15838
PG 11
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA CJ1NP
UT WOS:000355250700014
PM 25758815
OA Green Published
DA 2022-11-30
ER

PT J
AU Regillo, CD
   Brown, DM
   Abraham, P
   Yue, HB
   Ianchulev, T
   Schneider, S
   Shams, N
AF Regillo, Carl D.
   Brown, David M.
   Abraham, Prema
   Yue, Huibin
   Ianchulev, Tsontcho
   Schneider, Susan
   Shams, Naveed
CA Pier Study Grp
TI Randomized, double-masked, sham-controlled trial of ranibizumab for
   neovascular age-related macular degeneration: PIER study year 1
SO AMERICAN JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
ID LUCENTIS
AB PURPOSE: To evaluate the efficacy and safety of ranibizumab administered monthly for three months and then quarterly in patients with subfoveal choroidal neovascularization (CNV) secondary to age,related macular degeneration (AMD).
   DESIGN: Phase IIIb, multicenter, randomized, double-masked, Sham injection,controlled trial in patients with predominantly or minimally classic or occult with no classic CNV lesions.
   METHODS: Patients were randomized 1:1:1 to 0.3 mg ranibizumab (n = 60), 0.5 mg ranibizumab (n = 61), or sham (n = 63) treatment groups. The primary efficacy endpoint was mean change from baseline visual acuity (VA) at month 12.
   RESULTS: Mean changes from baseline VA at 12 months were -16.3, -1.6, and -0.2 letters for the sham, 0.3 mg, and 0.5 mg groups, respectively (P <= .0001, each ranibizumab dose vs sham). Ranibizumab arrested CNV growth and reduced leakage from CNV. However, the treatment effect declined in the rainibizumab groups during quarterly dosing (e.g., at three months the mean changes from baseline VA had been gains of 2.9 and 4.3 letters for the 0.3 mg and 0.5 mg doses, respectively). Results of subgroups analyses of mean change from baseline VA at 12 months by baseline age, VA, and lesion characteristics were consistent with the overall results. Few serious ocular or nonocular adverse events occurred in any group.
   CONCLUSIONS: Ranibizumab administered monthly for three months and then quarterly provided significant VA benefit to patients with AMD-related subfoveal CNV and was well tolerated. The incidence of serious ocular or nonocular adverse events was low.
C1 [Regillo, Carl D.] Wilmer Eye Inst, Retina Serv, Philadelphia, PA 19107 USA.
   [Brown, David M.] Methodist Hosp, Vitreoretinal Consultants, Houston, TX 77030 USA.
   [Abraham, Prema] BH Reg Eye Inst, Rapid City, SD USA.
   [Yue, Huibin; Ianchulev, Tsontcho; Schneider, Susan; Shams, Naveed] Genentech Inc, San Francisco, CA 94080 USA.
C3 Johns Hopkins University; Johns Hopkins Medicine; The Methodist Hospital
   System; The Methodist Hospital - Houston; Roche Holding; Genentech
RP Regillo, CD (通讯作者)，Wilmer Eye Inst, Retina Serv, 840 Walnut St,Suite 1020, Philadelphia, PA 19107 USA.
EM cregillo@aol.com
CR ALTMAN R, 1994, BMJ-BRIT MED J, V308, P81, DOI 10.1136/bmj.308.6921.81
   Arnold J, 2001, OPHTHALMOLOGY, V108, P841
   Bressler NM, 1999, ARCH OPHTHALMOL-CHIC, V117, P1329
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Fung AE, 2007, AM J OPHTHALMOL, V143, P566, DOI 10.1016/j.ajo.2007.01.028
   Heier JS, 2006, OPHTHALMOLOGY, V113, P633, DOI 10.1016/j.ophtha.2005.10.052
   HOCHBERG Y, 1988, BIOMETRIKA, V75, P800, DOI 10.2307/2336325
   *NOV PHARM CORP, 2005, VIS
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Rosenfeld PJ, 2006, OPHTHALMOLOGY, V113, P623, DOI 10.1016/j.ophtha.2006.01.027
NR 10
TC 653
Z9 700
U1 2
U2 33
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 0002-9394
EI 1879-1891
J9 AM J OPHTHALMOL
JI Am. J. Ophthalmol.
PD FEB
PY 2008
VL 145
IS 2
BP 239
EP 248
DI 10.1016/j.ajo.2007.10.004
PG 10
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 263GG
UT WOS:000253205000011
PM 18222192
DA 2022-11-30
ER

PT J
AU Gonzales, CR
   Adamis, AP
   Cunningham, ET
   D'Amico, DJ
   Goldbaum, M
   Guyer, DR
   Katz, B
   Ng, EWM
   Patel, SC
   Wohlberg, CJ
AF Gonzales, CR
   Adamis, AP
   Cunningham, ET
   D'Amico, DJ
   Goldbaum, M
   Guyer, DR
   Katz, B
   Ng, EWM
   Patel, SC
   Wohlberg, CJ
CA VISION Clin Trial Grp
TI Enhanced efficacy associated with early treatment of neovascular
   age-related macular degeneration with pegaptanib sodium: An exploratory
   analysis
SO RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES
LA English
DT Article
ID ENDOTHELIAL GROWTH-FACTOR; EARLY CHOROIDAL NEOVASCULARIZATION; IRIS
   NEOVASCULARIZATION; NATURAL COURSE; RETINOPATHY; INHIBITION; GLAUCOMA
AB Purpose: To assess the vision benefit of treating early subfoveal choroidal neovascularization secondary to age-related macular degeneration (AMD) with pegaptanib sodium.
   Methods: Exploratory analyses of week 54 vision outcomes (VEGF Inhibition Study in Ocular Neovascularization study) of subject subgroups with early disease who received 0.3 mg of pegaptanib (Groups 1 [n = 34] and 2 [n = 30]) or sham injections (usual care). Two sets of clinical characteristics typical of early disease defined the subgroups.
   Results: Baseline characteristics were generally well balanced between treatment arms. Pegaptanib responder rates (loss of <15 letters of visual acuity) were 76% and 80% in treatment Groups 1 and 2 versus 50% and 57% for usual care Groups 1 and 2 (P = 0.03 and P = 0.05), respectively. Compared with subjects assigned to pegaptanib, those in Groups 1 and 2 receiving usual care on average lost 11.1 letters and 12.7 letters more of visual acuity (P < 0.01 and P < 0.006), respectively. Subjects assigned to usual care were 10 times more likely to have severe vision loss than were those treated with pegaptanib (Group 1, 29% vs. 3%, respectively; P < 0.01). In Group 1, 12% of pegaptanib-treated subjects gained >= 15 letters of visual acuity versus 4% receiving usual care; 20% of Group 2 pegaptanib-treated subjects gained >= 15 letters of visual acuity versus none of the usual care subjects.
   Conclusion: Early detection and treatment with pegaptanib may result in superior vision outcomes in patients with neovascular AMD.
C1 Jules Stein Eye Inst, Los Angeles, CA 90095 USA.
   Univ Calif Los Angeles, David Geffen Sch Med, Dept Ophthalmol, Los Angeles, CA 90095 USA.
C3 University of California System; University of California Los Angeles;
   University of California Los Angeles Medical Center; David Geffen School
   of Medicine at UCLA
RP Gonzales, CR (通讯作者)，Jules Stein Eye Inst, 200 Stein Plaza, Los Angeles, CA 90095 USA.
EM gonzales@jsei.ucla.edu
RI Larsen, Michael/E-9620-2010; Schlingemann, Reinier/E-6287-2013
OI Larsen, Michael/0000-0002-5172-5891; 
CR ADAMIS AP, 1994, AM J OPHTHALMOL, V118, P445, DOI 10.1016/S0002-9394(14)75794-0
   Adamis AP, 1996, ARCH OPHTHALMOL-CHIC, V114, P66, DOI 10.1001/archopht.1996.01100130062010
   AIELLO LP, 1995, P NATL ACAD SCI USA, V92, P10457, DOI 10.1073/pnas.92.23.10457
   AIELLO LP, 1994, NEW ENGL J MED, V331, P1480, DOI 10.1056/NEJM199412013312203
   Amano S, 1998, INVEST OPHTH VIS SCI, V39, P18
   Arnold J, 2001, OPHTHALMOLOGY, V108, P841
   Bressler Neil M, 2002, J Am Board Fam Pract, V15, P142
   Bressler NM, 1996, ARCH OPHTHALMOL-CHIC, V114, P1456, DOI 10.1001/archopht.1996.01100140654002
   BRESSLER NM, 1988, SURV OPHTHALMOL, V32, P375, DOI 10.1016/0039-6257(88)90052-5
   Bressler NM, 1999, ARCH OPHTHALMOL-CHIC, V117, P1329
   BRESSLER NM, 1988, ARCH OPHTHALMOL-CHIC, V106, P1537, DOI 10.1001/archopht.1988.01060140705039
   BRESSLER SB, 1982, AM J OPHTHALMOL, V93, P157, DOI 10.1016/0002-9394(82)90410-X
   BURGESS DB, 1993, ARCH OPHTHALMOL-CHIC, V111, P1189
   Ciulla TA, 1998, SURV OPHTHALMOL, V43, P134, DOI 10.1016/S0039-6257(98)00014-9
   *EYET PHARM PFIZ I, 2004, MAC PACK INS
   FERRIS FL, 1984, ARCH OPHTHALMOL-CHIC, V102, P1640
   Gass JD., 1997, STEREOSCOPIC ATLAS M, V1
   Gragoudas ES, 2004, NEW ENGL J MED, V351, P2805, DOI 10.1056/NEJMoa042760
   Green W R, 1999, Mol Vis, V5, P27
   GREGOR Z, 1977, BRIT J OPHTHALMOL, V61, P141, DOI 10.1136/bjo.61.2.141
   Grossniklaus HE, 1998, AM J OPHTHALMOL, V126, P59, DOI 10.1016/S0002-9394(98)00145-7
   *ICH EXP WORK GROU, ICH HARM TRIP GUID S
   KILLINGSWORTH MC, 1995, GRAEF ARCH CLIN EXP, V233, P313, DOI 10.1007/BF00200479
   KLEIN R, 1995, INVEST OPHTH VIS SCI, V36, P182
   Krzystolik MG, 2002, ARCH OPHTHALMOL-CHIC, V120, P338
   Lafaut BA, 2000, BRIT J OPHTHALMOL, V84, P239, DOI 10.1136/bjo.84.3.239
   LEIBOWITZ HM, 1980, SURV OPHTHALMOL, V24, pS335
   LEUNG DW, 1989, SCIENCE, V246, P1306, DOI 10.1126/science.2479986
   LOWENSTEIN A, 1999, RETINA VITREOUS MACU, V1
   LOZANORECHY D, 1993, AM J OPHTHALMOL, V116, P140, DOI 10.1016/S0002-9394(14)71277-2
   *MAC PHOT STUD GRO, 1977, ARCH OPHTHALMOL-CHIC, V115, P741
   MAGUIRE MG, 1994, ARCH OPHTHALMOL-CHIC, V112, P480
   MALECAZE F, 1994, ARCH OPHTHALMOL-CHIC, V112, P1476, DOI 10.1001/archopht.1994.01090230090028
   *NOV OPHTH INC, 2003, VIS PACK INS
   Pieramici D J, 1998, Curr Opin Ophthalmol, V9, P38, DOI 10.1097/00055735-199806000-00007
   ROY M, 1990, Eye (London), V4, P813
   Sarks JP, 1997, EYE, V11, P515, DOI 10.1038/eye.1997.137
   Schwesinger C, 2001, AM J PATHOL, V158, P1161, DOI 10.1016/S0002-9440(10)64063-1
   Sternberg P, 1996, ARCH OPHTHALMOL-CHIC, V114, P400
   Tolentino MJ, 1996, ARCH OPHTHALMOL-CHIC, V114, P964, DOI 10.1001/archopht.1996.01100140172010
   Tolentino MJ, 2002, AM J OPHTHALMOL, V133, P373, DOI 10.1016/S0002-9394(01)01381-2
   VANDER JF, 1989, OPHTHALMOLOGY, V96, P1422
NR 42
TC 97
Z9 104
U1 0
U2 5
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0275-004X
EI 1539-2864
J9 RETINA-J RET VIT DIS
JI Retin.-J. Retin. Vitr. Dis.
PD OCT-NOV
PY 2005
VL 25
IS 7
BP 815
EP 827
PG 13
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 008AP
UT WOS:000235012900001
PM 16205558
DA 2022-11-30
ER

PT J
AU Mills, E
   Heels-Ansdell, D
   Kelly, S
   Guyatt, G
AF Mills, Edward
   Heels-Ansdell, Diane
   Kelly, Steven
   Guyatt, Gordon
TI A randomized trial of Pegaptanib sodium for age-related macular
   degeneration used an innovative design to explore disease-modifying
   effects
SO JOURNAL OF CLINICAL EPIDEMIOLOGY
LA English
DT Article
DE randomized clinical trial; disease modifying; age-related macular
   degeneration; research methodology; re-randomized
AB Objective: Effectively evaluating disease-modifying effects in clinical trials has posed a problem for clinical trialists and drug development. One method that has been proposed to evaluate disease-modifying effects has been the re-randomization of active group participants to discontinue the intervention after a period sufficient to produce therapeutic effects. We aimed to determine if this design would permit inferences regarding disease modification in a trial evaluating Pegaptanib sodium, an intra-ocular injection, for the treatment of age-related macular degeneration.
   Study Design and Setting: In two identically designed trials, 1,186 patients were randomized to receive 54 weeks of treatment. After 54 weeks, 1,053 were re-randomized to either stay on treatment or discontinue treatment. Patients were seen at multicenter outpatient clinics.
   Results: We found that patients randomized to discontinue treatment after 54 weeks of treatment and followed for a further 48 weeks, were significantly different than the control group (sham) in loss of 15 letters of vision (Relative Risk 0.70, 95% Confidence Interval 0.57-0.88, P = 0.002), indicating that treatment is disease modifying. This effect was consistent throughout our sensitivity analyses.
   Conclusion: This trial is the first example of a clinical trial evaluating disease-modifying effects and this design should influence drug discovery to determine further therapeutic potential of pharmacologic interventions. (c) 2007 Elsevier Inc. All rights reserved.
C1 McMaster Univ, Fac Hlth Sci, Hamilton, ON L8N 3Z5, Canada.
C3 McMaster University
RP Mills, E (通讯作者)，McMaster Univ, Fac Hlth Sci, HSC-2C12,1200 Main St W, Hamilton, ON L8N 3Z5, Canada.
EM millsej@mcmaster.ca
CR Chan AW, 2005, LANCET, V365, P1159, DOI 10.1016/S0140-6736(05)71879-1
   Chapman JA, 2006, ANN PHARMACOTHER, V40, P1322, DOI 10.1345/aph.1G604
   Contopoulos-Ioannidis DG, 2003, AM J MED, V114, P477, DOI 10.1016/S0002-9343(03)00013-5
   Davidson MH, 1999, JAMA-J AM MED ASSOC, V281, P235, DOI 10.1001/jama.281.3.235
   Gragoudas ES, 2004, NEW ENGL J MED, V351, P2805, DOI 10.1056/NEJMoa042760
   Grimes DA, 2005, OBSTET GYNECOL, V105, P1114, DOI 10.1097/01.AOG.0000157445.67309.19
   HEYN RM, 1975, BLOOD, V46, P431
   Leonardi CL, 2005, J AM ACAD DERMATOL, V52, P425, DOI 10.1016/j.jaad.2004.09.029
   Martenyi F, 2002, BRIT J PSYCHIAT, V181, P315, DOI 10.1192/bjp.181.4.315
   McDermott MP, 2002, CONTROL CLIN TRIALS, V23, P635, DOI 10.1016/S0197-2456(02)00238-6
   MILLS EJ, CONT CLIN TRIALS
   Ryttig KR, 1997, INT J OBESITY, V21, P574, DOI 10.1038/sj.ijo.0800444
   Schulz KF, 2002, LANCET, V359, P515, DOI 10.1016/S0140-6736(02)07683-3
   Siderowf A, 2004, ARCH NEUROL-CHICAGO, V61, P561
   Whitehouse PJ, 1998, ALZ DIS ASSOC DIS, V12, P281, DOI 10.1097/00002093-199812000-00007
NR 15
TC 8
Z9 8
U1 0
U2 3
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0895-4356
J9 J CLIN EPIDEMIOL
JI J. Clin. Epidemiol.
PD MAY
PY 2007
VL 60
IS 5
BP 456
EP 460
DI 10.1016/j.jclinepi.2006.09.001
PG 5
WC Health Care Sciences & Services; Public, Environmental & Occupational
   Health
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Health Care Sciences & Services; Public, Environmental & Occupational
   Health
GA 159LV
UT WOS:000245868300004
PM 17419956
DA 2022-11-30
ER

PT J
AU Wang, XY
   Yang, HK
   Yanagisawa, D
   Bellier, JP
   Morino, K
   Zhao, SG
   Liu, P
   Vigers, P
   Tooyama, I
AF Wang, Xiying
   Yang, Hongkuan
   Yanagisawa, Daijiro
   Bellier, Jean-Pierre
   Morino, Katsutaro
   Zhao, Shiguang
   Liu, Ping
   Vigers, Piers
   Tooyama, Ikuo
TI Mitochondrial ferritin affects mitochondria by stabilizing HIF-1 alpha
   in retinal pigment epithelium: implications for the pathophysiology of
   age-related macular degeneration
SO NEUROBIOLOGY OF AGING
LA English
DT Article
DE Mitochondrial ferritin; Mitochondria; Age-related macular degeneration;
   HIF-1 alpha; Neurodegeneration
ID HYPOXIA-INDUCIBLE FACTOR-1; CELLULAR IRON HOMEOSTASIS; OXIDATIVE DAMAGE;
   NEURODEGENERATIVE DISEASES; CYTOCHROME-C; MITOPHAGY; AUTOPHAGY;
   METABOLISM; FISSION; DEGRADATION
AB Mitochondrial ferritin (FtMt) is believed to play an antioxidant role via iron regulation, and FtMt gene mutation has been reported in age-related macular degeneration (AMD). However, little is known about FtMt's functions in the retina and any links to AMD. In this study, we observed age-related increase in FtMt and hypoxia-inducible factor-1 alpha (HIF-1 alpha) in murine retinal pigment epithelium (RPE). FtMt overexpression in ARPE-19 cells stabilized HIF-1 alpha, and increased the secretion of vascular endothelial growth factor. Conversely, HIF-1 alpha stabilization reduced the protein level of the mature, functional form of FtMt. FtMt-overexpressing ARPE-19 cells exhibited less oxidative phosphorylation but unchanged production of adenosine triphosphate, enhanced mitochondrial fission, and triggered mitophagy in a HIF-1 alpha-dependent manner. These findings suggest that increased FtMt in RPE may be protective via triggering mitophagy but cause wet AMD by inducing neovascularization due to increased vascular endothelial growth factor secretion. However, reduced level of functional FtMt in RPE under hypoxia may allow dry AMD through susceptibility to age-related stress. (C) 2016 The Author(s). Published by Elsevier Inc.
C1 [Wang, Xiying; Liu, Ping] Harbin Med Univ, Affiliated Hosp 1, Hosp Eye, Key Lab,Eye Ctr, Harbin, Peoples R China.
   [Yang, Hongkuan; Zhao, Shiguang] Harbin Med Univ, Affiliated Hosp 1, Dept Neurosurg, Harbin, Peoples R China.
   [Yang, Hongkuan; Yanagisawa, Daijiro; Bellier, Jean-Pierre; Vigers, Piers; Tooyama, Ikuo] Shiga Univ Med Sci, Mol Neurosci Res Ctr, Seta Tsukinowa Cho, Otsu, Shiga 5202192, Japan.
   [Morino, Katsutaro] Shiga Univ Med Sci, Dept Internal Med, Otsu, Shiga, Japan.
C3 Harbin Medical University; Harbin Medical University; Shiga University
   of Medical Science; Shiga University of Medical Science
RP Tooyama, I (通讯作者)，Shiga Univ Med Sci, Mol Neurosci Res Ctr, Seta Tsukinowa Cho, Otsu, Shiga 5202192, Japan.; Liu, P (通讯作者)，Harbin Med Univ, Affiliated Hosp 1, Hosp Eye, Harbin 150001, Heilongjiang Pr, Peoples R China.
EM pingliu53@126.com; kinchan@belle.shiga-med.ac.jp
RI MORINO, KATSUTARO/I-3207-2019; Bellier, Jean-Pierre/M-4845-2019
OI MORINO, KATSUTARO/0000-0003-2420-3817; Bellier,
   Jean-Pierre/0000-0002-8758-8075
FU Ministry of Education, Science, Sports, and Culture of Japan (MEXT)
   [26640042]; Otsuka Foundation; Grants-in-Aid for Scientific Research
   [15K16321] Funding Source: KAKEN
FX This study was supported by a Grant-in-Aid for Scientific Research on
   Innovative Areas ("Brain Environment") (MEXT KAKENHI Grant Number
   26640042) (Ikuo Tooyama) from the Ministry of Education, Science,
   Sports, and Culture of Japan (MEXT). Dr Yang Hongkuan was supported by a
   scholarship from the Otsuka Foundation.
CR Allen GFG, 2013, EMBO REP, V14, P1127, DOI 10.1038/embor.2013.168
   Arosio P, 2010, BBA-GEN SUBJECTS, V1800, P783, DOI 10.1016/j.bbagen.2010.02.005
   BLAYNEY L, 1976, CIRC RES, V39, P744, DOI 10.1161/01.RES.39.5.744
   Boulton M, 2001, EYE, V15, P384, DOI 10.1038/eye.2001.141
   Campanella A, 2009, HUM MOL GENET, V18, P1, DOI 10.1093/hmg/ddn308
   Chen HC, 2009, HUM MOL GENET, V18, pR169, DOI 10.1093/hmg/ddp326
   Corsi B, 2002, J BIOL CHEM, V277, P22430, DOI 10.1074/jbc.M105372200
   de Jong PTVM, 2006, NEW ENGL J MED, V355, P1474, DOI 10.1056/NEJMra062326
   Ding WX, 2012, BIOL CHEM, V393, P547, DOI 10.1515/hsz-2012-0119
   Drysdale J, 2002, BLOOD CELL MOL DIS, V29, P376, DOI 10.1006/bcmd.2002.0577
   Duvezin-Caubet S, 2006, J BIOL CHEM, V281, P37972, DOI 10.1074/jbc.M606059200
   Ehses S, 2009, J CELL BIOL, V187, P1023, DOI 10.1083/jcb.200906084
   Forsythe JA, 1996, MOL CELL BIOL, V16, P4604
   Frank M, 2012, BBA-MOL CELL RES, V1823, P2297, DOI 10.1016/j.bbamcr.2012.08.007
   Geirsdottir A, 2014, ACTA OPHTHALMOL, V92, P27, DOI 10.1111/aos.12294
   Greijer AE, 2004, J CLIN PATHOL, V57, P1009, DOI 10.1136/jcp.2003.015032
   Hanna RA, 2012, J BIOL CHEM, V287, P19094, DOI 10.1074/jbc.M111.322933
   Horowitz MP, 2010, J ALZHEIMERS DIS, V20, pS551, DOI 10.3233/JAD-2010-100354
   Jager RD, 2008, NEW ENGL J MED, V358, P2606, DOI 10.1056/NEJMra0801537
   Khansari N, 2009, RECENT PATENTS INFLA, V3, P73, DOI 10.2174/187221309787158371
   Levi S, 2001, J BIOL CHEM, V276, P24437, DOI 10.1074/jbc.C100141200
   Mao K, 2013, DEV CELL, V26, P9, DOI 10.1016/j.devcel.2013.05.024
   McLeod DS, 2009, INVEST OPHTH VIS SCI, V50, P4982, DOI 10.1167/iovs.09-3639
   Neupert W, 2007, ANNU REV BIOCHEM, V76, P723, DOI 10.1146/annurev.biochem.76.052705.163409
   Nie GJ, 2005, BLOOD, V105, P2161, DOI 10.1182/blood-2004-07-2722
   Nixon RA, 2013, NAT MED, V19, P983, DOI 10.1038/nm.3232
   Olichon A, 2003, J BIOL CHEM, V278, P7743, DOI 10.1074/jbc.C200677200
   Palikaras Konstantinos, 2012, Frontiers in Genetics, V3, P297, DOI 10.3389/fgene.2012.00297
   Priault M, 2005, CELL DEATH DIFFER, V12, P1613, DOI 10.1038/sj.cdd.4401697
   Quinsay MN, 2010, J MOL CELL CARDIOL, V48, P1146, DOI 10.1016/j.yjmcc.2009.12.004
   Rambold AS, 2011, P NATL ACAD SCI USA, V108, P10190, DOI 10.1073/pnas.1107402108
   Rubinsztein DC, 2011, CELL, V146, P682, DOI 10.1016/j.cell.2011.07.030
   Santambrogio P, 2007, J HISTOCHEM CYTOCHEM, V55, P1129, DOI 10.1369/jhc.7A7273.2007
   Scherz-Shouval R, 2007, EMBO J, V26, P1749, DOI 10.1038/sj.emboj.7601623
   Snyder AM, 2009, J NEUROPATH EXP NEUR, V68, P1193, DOI 10.1097/NEN.0b013e3181bdc44f
   Stefansson E, 2011, PROG RETIN EYE RES, V30, P72, DOI 10.1016/j.preteyeres.2010.09.003
   Stenirri S, 2012, CLIN CHEM LAB MED, V50, P1021, DOI 10.1515/cclm-2011-0854
   Suen DF, 2008, GENE DEV, V22, P1577, DOI 10.1101/gad.1658508
   Tanaka A, 2010, J CELL BIOL, V191, P1367, DOI 10.1083/jcb.201007013
   Twig G, 2008, EMBO J, V27, P433, DOI 10.1038/sj.emboj.7601963
   Van Laar VS, 2011, HUM MOL GENET, V20, P927, DOI 10.1093/hmg/ddq531
   Walter PB, 2002, P NATL ACAD SCI USA, V99, P2264, DOI 10.1073/pnas.261708798
   WANG GL, 1993, BLOOD, V82, P3610
   Wang LG, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0022325
   Wolin MS, 1998, CIRC RES, V82, P1021, DOI 10.1161/01.RES.82.9.1021
   Wu WS, 2013, ANTIOXID REDOX SIGN, V18, P158, DOI 10.1089/ars.2011.4285
   Yang HK, 2015, J ALZHEIMERS DIS, V45, P797, DOI 10.3233/JAD-142595
   Yang HK, 2013, NEUROSCI RES, V77, P1, DOI 10.1016/j.neures.2013.07.005
   Zhang HF, 2008, J BIOL CHEM, V283, P10892, DOI 10.1074/jbc.M800102200
NR 49
TC 15
Z9 15
U1 2
U2 11
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0197-4580
EI 1558-1497
J9 NEUROBIOL AGING
JI Neurobiol. Aging
PD NOV
PY 2016
VL 47
BP 168
EP 179
DI 10.1016/j.neurobiolaging.2016.07.025
PG 12
WC Geriatrics & Gerontology; Neurosciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Geriatrics & Gerontology; Neurosciences & Neurology
GA EA9PO
UT WOS:000386976500018
PM 27599360
OA hybrid
DA 2022-11-30
ER

PT J
AU Lad, EM
   Boyer, DS
   Heier, JS
   Kornfield, JA
   Kuppermann, BD
   Quiroz-Mercado, H
   Aubel, JM
   Karageozian, LS
   Karageozian, HL
   Sarayba, MA
   Karageozian, VH
   Kaiser, PK
AF Lad, Eleonora M.
   Boyer, David S.
   Heier, Jeffrey S.
   Kornfield, Julie A.
   Kuppermann, Baruch D.
   Quiroz-Mercado, Hugo
   Aubel, Janine M.
   Karageozian, Lisa S.
   Karageozian, Hampar L.
   Sarayba, Melvin A.
   Karageozian, Vicken H.
   Kaiser, Peter K.
TI Color Vision and Microperimetry Changes in Nonexudative Age-Related
   Macular Degeneration After Risuteganib Treatment: Exploratory Endpoints
   in a Multicenter Phase 2a Double-Masked, Randomized, Sham-Controlled,
   Crossover Clinical Trial
SO OPHTHALMIC SURGERY LASERS & IMAGING RETINA
LA English
DT Article
ID VISUAL-ACUITY; DISCRIMINATION; PREVALENCE; DISEASE
AB BACKGROUND AND OBJECTIVE: To explore the association between best-corrected visual acuity (BCVA) improvement and changes in microperimetry (MP) and color vision in patients with nonexudative age-related macular degeneration following administration of two 1.0-mg intravitreal doses of risuteganib. PATIENTS AND METHODS: In a phase 2a, prospective, double-masked, sham-controlled study, eyes with nonexudative age-related macular degeneration and Early Treatment Diabetic Retinopathy Study BCVA between 20/40 and 20/200 were randomized to in-travitreal risuteganib (1.0 mg) or sham injection. The risuteganib group received a second 1.0-mg dose, and patients in the sham group crossed over to receive 1.0 mg of risuteganib at week 16. Exploratory endpoints included changes in color vision and mesopic MP. RESULTS: Thirty-nine patients (risuteganib, n = 25; sham, n = 14) completed the study. There was a significant (P < .05) correlation between BCVA and the total error score (TES) for both Lanthony and Hue Style. Confusion index was close to the criterion for significance (P = .056) in the risuteganib group. All color vision metrics demonstrated a trend toward improvement in risuteganib responders (BCVA letter gain >= 8 letters) and no change in the nonresponders, with significant differences seen in confusion index between the risuteganib and control group (P = .0493) and be-tween responders and nonresponders (P = .0478). MP showed that risuteganib responders improved in mean sensitivity and change in number of loci <= 11 dB and <= 0 dB, whereas nonresponders worsened. CONCLUSION: All color vision and MP parameters tested trended toward improvement in risuteganib-treated patients and risuteganib responders. Statistically significant improvement was evident in two metrics: confusion index (in risuteganib-treated patients and responders) and number of loci with decreased sensitivity (in responders). A significant correlation between BCVA and both TES Lanthony and TES Hue Style in risuteganib patients pro-vides concurrent evidence of objective and subjective im-provement of retinal function.
C1 [Lad, Eleonora M.] Duke Univ Med Ctr DUMC, Durham, NC USA.
   [Boyer, David S.] Retina Vitreous Associates Med Grp, Beverly Hills, CA USA.
   [Heier, Jeffrey S.] Ophthalm Consultants Boston, Boston, MA USA.
   [Kornfield, Julie A.] CALTECH, Pasadena, CA USA.
   [Kuppermann, Baruch D.] Univ Calif Irvine, Irvine, CA USA.
   [Quiroz-Mercado, Hugo] Asociac Evitar Ceguera Mexico, Mexico City, Mexico.
   [Aubel, Janine M.; Karageozian, Lisa S.; Karageozian, Hampar L.; Sarayba, Melvin A.; Karageozian, Vicken H.] Allegro Ophthalm LLC, San Juan Capistrano, CA USA.
   [Kaiser, Peter K.] Cole Eye Inst, Cleveland Hts, OH USA.
   [Lad, Eleonora M.] Duke Eye Ctr, 2351 Erwin Rd, DUMC 3802, Durham, NC 27705 USA.
C3 Retina Vitreous Associates Medical Group; Ophthalmic Consultants of
   Boston; California Institute of Technology; University of California
   System; University of California Irvine; Duke University
RP Lad, EM (通讯作者)，Duke Eye Ctr, 2351 Erwin Rd, DUMC 3802, Durham, NC 27705 USA.
EM nora.lad@duke.edu
CR BOWMAN KJ, 1980, AM J OPTOM PHYS OPT, V57, P145
   BOWMAN KJ, 1980, ACTA OPHTHALMOL, V58, P337
   Boyer DS, 2021, OSLI RETINA, V52, P327, DOI 10.3928/23258160-20210528-05
   Chandramohan A, 2016, RETINA-J RET VIT DIS, V36, P1021, DOI 10.1097/IAE.0000000000001002
   Chen FK, 2011, RETINA-J RET VIT DIS, V31, P371, DOI 10.1097/IAE.0b013e3181e46af3
   Cocce KJ, 2018, AM J OPHTHALMOL, V189, P127, DOI 10.1016/j.ajo.2018.02.012
   Eandi CM, 2016, EUR J PHARMACOL, V787, P78, DOI 10.1016/j.ejphar.2016.03.002
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P564
   Good GW, 2005, OPTOMETRY VISION SCI, V82, P1054, DOI 10.1097/01.opx.0000192351.63069.4a
   Hsu ST, 2019, OPHTHALMOL RETINA, V3, P637, DOI 10.1016/j.oret.2019.03.010
   Kenney CM, 2018, INVEST OPHTH VIS SCI, V59
   Midena E, 2017, EYE, V31, P985, DOI 10.1038/eye.2017.34
   PATZ A, 1985, ARCH OPHTHALMOL-CHIC, V103, P1796, DOI 10.1001/archopht.1985.01050120030015
   Schneider K, 2021, EXP EYE RES, V203, DOI 10.1016/j.exer.2020.108287
   Scilley K, 2002, OPHTHALMOLOGY, V109, P1235, DOI 10.1016/S0161-6420(02)01060-6
   Vemala R, 2017, INVEST OPHTH VIS SCI, V58, P247, DOI 10.1167/iovs.17-21771
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
   Wu ZC, 2015, JAMA OPHTHALMOL, V133, P442, DOI 10.1001/jamaophthalmol.2014.5963
   Yang P, 2020, INVEST OPHTH VIS SCI, V61, DOI 10.1167/iovs.61.10.35
   Zhou D, 2020, INVEST OPHTH VIS SCI, V61
NR 20
TC 0
Z9 0
U1 2
U2 2
PU SLACK INC
PI THOROFARE
PA 6900 GROVE RD, THOROFARE, NJ 08086 USA
SN 2325-8160
EI 2325-8179
J9 OSLI RETINA
JI Ophthalmic Surg. Lasers Imag. Retin.
PD AUG
PY 2022
VL 53
IS 8
BP 430
EP 438
DI 10.3928/23258160-20220725-02
PG 9
WC Ophthalmology; Surgery
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology; Surgery
GA 5B0UX
UT WOS:000863293200004
PM 35951718
OA hybrid
DA 2022-11-30
ER

PT J
AU Machalinska, A
   Kawa, MP
   Marlicz, W
   Machalinski, B
AF Machalinska, Anna
   Kawa, Milosz P.
   Marlicz, Wojciech
   Machalinski, Boguslaw
TI Complement system activation and endothelial dysfunction in patients
   with age-related macular degeneration (AMD): possible relationship
   between AMD and atherosclerosis
SO ACTA OPHTHALMOLOGICA
LA English
DT Review
DE age-related macular degeneration; atherosclerosis; complement system;
   pathogenesis
ID C-REACTIVE-PROTEIN; FACTOR-H POLYMORPHISM; INCIDENT
   MYOCARDIAL-INFARCTION; CARDIOVASCULAR RISK-FACTORS; CHOROIDAL
   BLOOD-FLOW; BLUE-MOUNTAINS-EYE; PROGENITOR CELLS; BRUCHS MEMBRANE; Y402H
   VARIANT; GROWTH-FACTOR
AB . Age-related macular degeneration (AMD) shares several pathological and epidemiological similarities with systemic atherosclerosis (AS). First, an association between AS and AMD is apparent from the analyses of the histological and biochemical structure of atherosclerotic plaques in the vascular walls and retinal drusen, the hallmark of AMD. Second, there is considerable evidence implicating endothelial dysfunction in the pathogenesis of both disorders, and cellular oxidative stress appears to be a common denominator underlying this process. Moreover, there are observations that the complement system (CS) triggering inflammatory response contributes to the onset and advancement of both diseases. The CS plays a role in the generation of drusen and neovascularization in AMD as well as in vascular endothelium activation, cell damage and ultimately atherosclerotic plaque formation in the course of systemic arteriosclerosis. It is widely recognized that both AMD and AS are not only related to local stimulation of the CS, but also result in its systemic activation. In addition, a specific Y402H polymorphism of the complement inhibitor factor H has been found to be associated with the incidence of both AMD and AS. Here, we propose a linking hypothesis between CS activation, endothelial dysfunction and the pathogenesis of two common and age-related pathological processes, AS and AMD. We also discuss the potential therapeutic value of pharmacological modulation of CS activation in these disorders.
C1 [Kawa, Milosz P.; Marlicz, Wojciech; Machalinski, Boguslaw] Pomeranian Med Univ, Dept Gen Pathol, PL-70111 Szczecin, Poland.
   [Machalinska, Anna] Pomeranian Med Univ, Dept Histol & Embryol, PL-70111 Szczecin, Poland.
   [Machalinska, Anna] Pomeranian Med Univ, Dept Ophthalmol, PL-70111 Szczecin, Poland.
C3 Pomeranian Medical University; Pomeranian Medical University; Pomeranian
   Medical University
RP Machalinski, B (通讯作者)，Pomeranian Med Univ, Dept Gen Pathol, Al Powstancow Wlkp 72, PL-70111 Szczecin, Poland.
EM machalin@sci.pam.szczecin.pl
RI Marlicz, Wojciech/G-5007-2013; Kawa, Milosz/O-7715-2014; Machaliński,
   Bogusław/P-3025-2014; Machalinska, Anna/P-6701-2014
OI Marlicz, Wojciech/0000-0002-2649-5967; Machalinski,
   Boguslaw/0000-0002-6013-0419
FU Polish Ministry of Science [N N402 172137]
FX This work was supported by the Polish Ministry of Science (grant: N N402
   172137 to AM).
CR Augood CA, 2006, ARCH OPHTHALMOL-CHIC, V124, P529, DOI 10.1001/archopht.124.4.529
   Booij JC, 2010, PROG RETIN EYE RES, V29, P1, DOI 10.1016/j.preteyeres.2009.08.003
   Boos CJ, 2006, J AM COLL CARDIOL, V48, P1538, DOI 10.1016/j.jacc.2006.02.078
   Bora PS, 2005, J IMMUNOL, V174, P491, DOI 10.4049/jimmunol.174.1.491
   Brantley MA, 2007, OPHTHALMOLOGY, V114, P2168, DOI 10.1016/j.ophtha.2007.09.008
   Brantley MA, 2007, AM J OPHTHALMOL, V144, P404, DOI 10.1016/j.ajo.2007.05.018
   Ciulla TA, 1999, AM J OPHTHALMOL, V128, P75, DOI 10.1016/S0002-9394(99)00061-6
   Clark SJ, 2010, J BIOL CHEM, V285, P30192, DOI 10.1074/jbc.M110.103986
   Connell PP, 2009, J OPHTHALMOL, V2009, DOI 10.1155/2009/360764
   Curcio CA, 2005, EXP EYE RES, V81, P731, DOI 10.1016/j.exer.2005.04.012
   Di Stefano R, 2009, CURR PHARM DESIGN, V15, P1095, DOI 10.2174/138161209787846892
   Donoso LA, 2006, SURV OPHTHALMOL, V51, P137, DOI 10.1016/j.survophthal.2005.12.001
   Duan YK, 2007, OPHTHALMOLOGY, V114, P732, DOI 10.1016/j.ophtha.2006.07.045
   Edwards AO, 2005, SCIENCE, V308, P421, DOI 10.1126/science.1110189
   Ennis S, 2008, LANCET, V372, P1828, DOI 10.1016/S0140-6736(08)61348-3
   Erdbruegger U, 2006, CLIN CHIM ACTA, V373, P17, DOI 10.1016/j.cca.2006.05.016
   Eyries M, 2004, ENDOTHELIUM-J ENDOTH, V11, P133, DOI 10.1080/10623320490482691
   Gehrs KM, 2006, ANN MED, V38, P450, DOI 10.1080/07853890600946724
   Gold B, 2006, NAT GENET, V38, P458, DOI 10.1038/ng1750
   Grunwald JE, 1998, INVEST OPHTH VIS SCI, V39, P385
   Grunwald JE, 2005, INVEST OPHTH VIS SCI, V46, P1033, DOI 10.1167/iovs.04-1050
   Guthikonda Sasidhar, 2006, Curr Atheroscler Rep, V8, P100, DOI 10.1007/s11883-006-0046-4
   Hageman GS, 2001, PROG RETIN EYE RES, V20, P705, DOI 10.1016/S1350-9462(01)00010-6
   Hageman GS, 2005, P NATL ACAD SCI USA, V102, P7227, DOI 10.1073/pnas.0501536102
   Haines JL, 2005, SCIENCE, V308, P419, DOI 10.1126/science.1110359
   Hu CC, 2010, STROKE, V41, P613, DOI 10.1161/STROKEAHA.109.571000
   Hu YH, 2003, CIRCULATION, V108, P3122, DOI 10.1161/01.CIR.0000105722.96112.67
   Hunting CB, 2005, VOX SANG, V88, P1, DOI 10.1111/j.1423-0410.2005.00589.x
   Johnson LV, 2001, EXP EYE RES, V73, P887, DOI 10.1006/exer.2001.1094
   Johnson PT, 2006, P NATL ACAD SCI USA, V103, P17456, DOI 10.1073/pnas.0606234103
   Jylhava J, 2009, CLIN EXP IMMUNOL, V155, P53, DOI 10.1111/j.1365-2249.2008.03752.x
   Jylhava J, 2009, EXP GERONTOL, V44, P297, DOI 10.1016/j.exger.2008.10.006
   Kardys I, 2006, J AM COLL CARDIOL, V47, P1568, DOI 10.1016/j.jacc.2005.11.076
   Kardys I, 2007, AM J CARDIOL, V100, P646, DOI 10.1016/j.amjcard.2007.03.079
   Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557
   Klein R, 2007, ARCH OPHTHALMOL-CHIC, V125, P534, DOI 10.1001/archopht.125.4.534
   Laine M, 2007, J IMMUNOL, V178, P3831, DOI 10.4049/jimmunol.178.6.3831
   Lazar HL, 2004, CIRCULATION, V110, pII274, DOI 10.1161/01.CIR.0000138315.99788.eb
   Liao DP, 2008, OPEN OPHTHALMOL J, V2, P37, DOI 10.2174/1874364100802010037
   Lip PL, 2001, OPHTHALMOLOGY, V108, P705, DOI 10.1016/S0161-6420(00)00663-1
   Machalinska A, 2011, INVEST OPHTH VIS SCI, V52, P93, DOI 10.1167/iovs.10-5756
   Machalinska A, 2009, OPHTHALMIC RES, V42, P54, DOI 10.1159/000219686
   Massa M, 2005, BLOOD, V105, P199, DOI 10.1182/blood-2004-05-1831
   Miller-Kasprzak E, 2007, ARCH IMMUNOL THER EX, V55, P247, DOI 10.1007/s00005-007-0027-5
   Mooijaart SP, 2007, EXP GERONTOL, V42, P1116, DOI 10.1016/j.exger.2007.08.001
   Nakashima Y, 2008, CARDIOVASC RES, V79, P14, DOI 10.1093/cvr/cvn099
   Nguyen-Khoa BA, 2008, ARCH OPHTHALMOL-CHIC, V126, P1280, DOI 10.1001/archopht.126.9.1280
   Ni Z, 2009, OPHTHALMOLOGICA, V223, P401, DOI 10.1159/000228926
   Nicaud V, 2007, J MOL MED-JMM, V85, P771, DOI 10.1007/s00109-007-0185-2
   Niculescu F, 2004, IMMUNOL RES, V30, P73, DOI 10.1385/IR:30:1:073
   Niculescu F, 2001, IMMUNOL RES, V24, P191, DOI 10.1385/IR:24:2:191
   Nozaki M, 2006, P NATL ACAD SCI USA, V103, P2328, DOI 10.1073/pnas.0408835103
   Palikhe A, 2007, AM J CARDIOL, V99, P890, DOI 10.1016/j.amjcard.2006.11.034
   Parker C, 2009, LANCET, V373, P759, DOI 10.1016/S0140-6736(09)60001-5
   Reynolds R, 2009, INVEST OPHTH VIS SCI, V50, P5818, DOI 10.1167/iovs.09-3928
   Ricklin D, 2008, ADV EXP MED BIOL, V632, P273, DOI 10.1007/978-0-387-78952-1_20
   Rohrer B, 2009, INVEST OPHTH VIS SCI, V50, P3056, DOI 10.1167/iovs.08-2222
   Schaumberg DA, 2007, ARCH OPHTHALMOL-CHIC, V125, P300, DOI 10.1001/archopht.125.3.300
   Schepers A, 2006, CIRCULATION, V114, P2831, DOI 10.1161/CIRCULATIONAHA.106.619502
   Schnatbaum K, 2006, BIOORG MED CHEM LETT, V16, P5088, DOI 10.1016/j.bmcl.2006.07.036
   Scholl HPN, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002593
   Seddon JM, 2006, HUM HERED, V61, P157, DOI 10.1159/000094141
   SEIFERT PS, 1989, LAB INVEST, V60, P747
   SEIFERT PS, 1989, ARTERIOSCLEROSIS, V9, P802, DOI 10.1161/01.ATV.9.6.802
   Shagdarsuren E, 2008, CIRCULATION, V117, P70, DOI 10.1161/CIRCULATIONAHA.107.715649
   Sivaprasad S, 2005, CLIN EXP OPHTHALMOL, V33, P518, DOI 10.1111/j.1442-9071.2005.01074.x
   Sivaprasad S, 2007, ARCH OPHTHALMOL-CHIC, V125, P515, DOI 10.1001/archopht.125.4.515
   Smith W, 1998, ARCH OPHTHALMOL-CHIC, V116, P583, DOI 10.1001/archopht.116.5.583
   Spraul CW, 1999, SURV OPHTHALMOL, V44, pS10, DOI 10.1016/S0039-6257(99)00086-7
   Stark K, 2007, CLIN SCI, V113, P213, DOI 10.1042/CS20070028
   Sun C, 2009, OPHTHALMOLOGY, V116, P1913, DOI 10.1016/j.ophtha.2009.03.046
   Szeplaki G, 2009, MOL IMMUNOL, V46, P2784, DOI 10.1016/j.molimm.2009.04.028
   Tamai K, 2002, EXP EYE RES, V74, P301, DOI 10.1006/exer.2001.1121
   Tan JSL, 2008, BRIT J OPHTHALMOL, V92, P509, DOI 10.1136/bjo.2007.131706
   Tan JSL, 2007, OPHTHALMOLOGY, V114, P1143, DOI 10.1016/j.ophtha.2006.09.033
   Umemura T, 2008, AM J HYPERTENS, V21, P1203, DOI 10.1038/ajh.2008.278
   Vakeva AP, 1998, CIRCULATION, V97, P2259, DOI 10.1161/01.CIR.97.22.2259
   Verrier ED, 2004, JAMA-J AM MED ASSOC, V291, P2319, DOI 10.1001/jama.291.19.2319
   Vine AK, 2005, OPHTHALMOLOGY, V112, P2076, DOI 10.1016/j.ophtha.2005.07.004
   VINGERLING JR, 1995, AM J EPIDEMIOL, V142, P404, DOI 10.1093/oxfordjournals.aje.a117648
   Vischer UM, 2006, J THROMB HAEMOST, V4, P1186, DOI 10.1111/j.1538-7836.2006.01949.x
   Voick KA, 2008, AM J HYPERTENS, V21, P533, DOI 10.1038/ajh.2007.81
   von Leithner PL, 2009, AM J PATHOL, V175, P412, DOI 10.2353/ajpath.2009.080927
   Whitehead AJ, 2006, ARCH OPHTHALMOL-CHIC, V124, P1038, DOI 10.1001/archopht.124.7.1038
   Wong TY, 2006, ANN INTERN MED, V145, P98, DOI 10.7326/0003-4819-145-2-200607180-00007
   Wu KHC, 2007, INVEST OPHTH VIS SCI, V48, P1983, DOI 10.1167/iovs.06-0223
   Yates JRW, 2007, NEW ENGL J MED, V357, P553, DOI 10.1056/NEJMoa072618
   Zee RYL, 2006, ATHEROSCLEROSIS, V187, P332, DOI 10.1016/j.atherosclerosis.2005.09.009
NR 88
TC 49
Z9 48
U1 0
U2 21
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1755-375X
EI 1755-3768
J9 ACTA OPHTHALMOL
JI Acta Ophthalmol.
PD DEC
PY 2012
VL 90
IS 8
BP 695
EP 703
DI 10.1111/j.1755-3768.2011.02295.x
PG 9
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 047PI
UT WOS:000311852500029
PM 22067048
OA Bronze
DA 2022-11-30
ER

PT J
AU Armbrust, KR
   Karunadharma, PP
   Terluk, MR
   Kapphahn, RJ
   Olsen, TW
   Ferrington, DA
   Montezuma, SR
AF Armbrust, Karen R.
   Karunadharma, Pabalu P.
   Terluk, Marcia R.
   Kapphahn, Rebecca J.
   Olsen, Timothy W.
   Ferrington, Deborah A.
   Montezuma, Sandra R.
TI No association between cataract surgery and mitochondrial DNA damage
   with age-related macular degeneration in human donor eyes
SO PLOS ONE
LA English
DT Article
ID RETINAL-PIGMENT EPITHELIUM; CIGARETTE-SMOKING; 10-YEAR INCIDENCE;
   PREVALENCE; MACULOPATHY; POPULATION; LENS
AB Purpose
   To determine whether age-related macular degeneration (AMD) severity or the frequency of retinal pigment epithelium mitochondrial DNA lesions differ in human donor eyes that have undergone cataract surgery compared to phakic eyes.
   Methods
   Eyes from human donors aged >= 55 years were obtained from the Minnesota Lions Eye Bank. Cataract surgery status was obtained from history provided to Eye Bank personnel by family members at the time of tissue procurement. Donor eyes were graded for AMD severity using the Minnesota Grading System. Quantitative PCR was performed on DNA isolated from macular punches of retinal pigment epithelium to quantitate the frequency of mitochondrial DNA lesions in the donor tissue. Univariable and multivariable analyses were performed to evaluate for associations between (1) cataract surgery and AMD severity and (2) cataract surgery and mitochondrial DNA lesion frequency.
   Results
   A total of 157 subjects qualified for study inclusion. Multivariable analysis with age, sex, smoking status, and cataract surgery status showed that only age was associated with AMD grade. Multivariable analysis with age, sex, smoking status, and cataract surgery status showed that none of these factors were associated with retinal pigment epithelium mitochondrial DNA lesion frequency.
   Conclusions
   In this study of human donor eyes, neither retinal pigment epithelium mitochondrial DNA damage nor the stage of AMD severity are independently associated with cataract surgery after adjusting for other AMD risk factors. These new pathologic and molecular findings provide evidence against a relationship between cataract surgery and AMD progression and support the idea that cataract surgery is safe in the setting of AMD.
C1 [Armbrust, Karen R.; Karunadharma, Pabalu P.; Terluk, Marcia R.; Kapphahn, Rebecca J.; Olsen, Timothy W.; Ferrington, Deborah A.; Montezuma, Sandra R.] Univ Minnesota, Dept Ophthalmol & Visual Neurosci, Minneapolis, MN 55455 USA.
   [Olsen, Timothy W.] Mayo Clin, Dept Ophthalmol, Rochester, MN USA.
C3 University of Minnesota System; University of Minnesota Twin Cities;
   Mayo Clinic
RP Montezuma, SR (通讯作者)，Univ Minnesota, Dept Ophthalmol & Visual Neurosci, Minneapolis, MN 55455 USA.
EM smontezu@umn.edu
RI Armbrust, Karen/AHB-4705-2022
OI Armbrust, Karen/0000-0001-9381-4756; Ferrington,
   Deborah/0000-0003-2561-7464; Olsen, Timothy/0000-0002-2200-266X
FU Minnesota Lions Vision Foundation; Elaine and Robert Larson Endowed
   Vision Research Chair; Helen Lindsay Family Foundation; Knobloch Chair
   Professorship; ARVO travel award; University of Minnesota Harry Friedman
   resident research award
FX Funding was provided by the Minnesota Lions Vision Foundation, the
   Elaine and Robert Larson Endowed Vision Research Chair and the Helen
   Lindsay Family Foundation (DAF), the Knobloch Chair Professorship (SRM),
   an ARVO travel award (KRA), and the University of Minnesota Harry
   Friedman resident research award (KRA). The funders had no role in study
   design, data collection and analysis, decision to publish, or
   preparation of the manuscript.
CR Ambrose JA, 2004, J AM COLL CARDIOL, V43, P1731, DOI 10.1016/j.jacc.2003.12.047
   Anderson DH, 2002, AM J OPHTHALMOL, V134, P411, DOI 10.1016/S0002-9394(02)01624-0
   Ayala-Torres S, 2000, METHODS, V22, P135, DOI 10.1006/meth.2000.1054
   Casparis H, 2017, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD006757.pub4
   Colijn JM, 2017, OPHTHALMOLOGY, V124, P1753, DOI 10.1016/j.ophtha.2017.05.035
   Cugati S, 2006, OPHTHALMOLOGY, V113, P2020, DOI 10.1016/j.ophtha.2006.05.047
   Decanini A, 2007, AM J OPHTHALMOL, V143, P607, DOI 10.1016/j.ajo.2006.12.006
   Engelmann K., 2012, OXIDATIVE STRESS ENV, P13
   Feher J, 2006, NEUROBIOL AGING, V27, P983, DOI 10.1016/j.neurobiolaging.2005.05.012
   Ferrington DA, 2016, EXP EYE RES, V145, P269, DOI 10.1016/j.exer.2016.01.018
   Gan ATL, 2020, ASIA-PAC J OPHTHALMO, V9, P130, DOI 10.1097/APO.0000000000000275
   Jarrett SG, 2008, PROG RETIN EYE RES, V27, P596, DOI 10.1016/j.preteyeres.2008.09.001
   Javitt JC, 2003, OPHTHALMOLOGY, V110, P1534, DOI 10.1016/S0161-6420(03)00495-0
   Karunadharma PP, 2010, INVEST OPHTH VIS SCI, V51, P5470, DOI 10.1167/iovs.10-5429
   KINI MM, 1978, AM J OPHTHALMOL, V85, P28, DOI 10.1016/S0002-9394(14)76661-9
   Klein BEK, 2012, OPHTHALMOLOGY, V119, P1628, DOI 10.1016/j.ophtha.2012.01.050
   KLEIN BEK, 1992, OPHTHALMOLOGY, V99, P546
   Klein R, 2020, OPHTHALMOLOGY, V127, pS122, DOI 10.1016/j.ophtha.2020.01.033
   Klein R, 2011, ARCH OPHTHALMOL-CHIC, V129, P75, DOI 10.1001/archophthalmol.2010.318
   Lakens D, 2017, SOC PSYCHOL PERS SCI, V8, P355, DOI 10.1177/1948550617697177
   Huynh N, 2014, OPHTHALMOLOGY, V121, P1229, DOI 10.1016/j.ophtha.2013.12.035
   Olsen TW, 2004, INVEST OPHTH VIS SCI, V45, P4484, DOI 10.1167/iovs.04-0342
   R Core Team, 2020, R R PROJ STAT COMP
   Rosenfeld PJ, 2011, AM J OPHTHALMOL, V152, P793, DOI 10.1016/j.ajo.2011.04.025
   Saraf SS, 2015, AM J OPHTHALMOL, V160, P487, DOI 10.1016/j.ajo.2015.06.006
   Seddon JM, 2004, JAMA-J AM MED ASSOC, V291, P704, DOI 10.1001/jama.291.6.704
   Seddon JM, 1996, JAMA-J AM MED ASSOC, V276, P1141, DOI 10.1001/jama.276.14.1141
   Seddon JM, 2006, ARCH OPHTHALMOL-CHIC, V124, P995, DOI 10.1001/archopht.124.7.995
   SPERDUTO RD, 1980, AM J OPHTHALMOL, V90, P86, DOI 10.1016/S0002-9394(14)75081-0
   Tabandeh H, 2012, J CATARACT REFR SURG, V38, P677, DOI 10.1016/j.jcrs.2011.10.036
   Taylor H R, 1990, Trans Am Ophthalmol Soc, V88, P163
   TAYLOR HR, 1992, ARCH OPHTHALMOL-CHIC, V110, P99, DOI 10.1001/archopht.1992.01080130101035
   Terluk MR, 2015, J NEUROSCI, V35, P7304, DOI 10.1523/JNEUROSCI.0190-15.2015
   Tomany SC, 2004, ARCH OPHTHALMOL-CHIC, V122, P750, DOI 10.1001/archopht.122.5.750
   Wickham H, 2009, USE R, P1, DOI 10.1007/978-0-387-98141-3_1
NR 35
TC 0
Z9 0
U1 0
U2 2
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD OCT 19
PY 2021
VL 16
IS 10
AR e0258803
DI 10.1371/journal.pone.0258803
PG 10
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA YZ7WQ
UT WOS:000755683100028
PM 34665838
OA gold, Green Published
DA 2022-11-30
ER

PT J
AU Hanhart, J
   Wiener, R
   Totah, H
   Gelman, E
   Weill, Y
   Abulafia, A
   Zadok, D
AF Hanhart, Joel
   Wiener, Rony
   Totah, Hashem
   Gelman, Evgeny
   Weill, Yishay
   Abulafia, Adi
   Zadok, David
TI Effects of delay in anti-vascular endothelial growth factor intravitreal
   injections for neovascular age-related macular degeneration
SO GRAEFES ARCHIVE FOR CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY
LA English
DT Article
DE AMD; OCT; COVID-19; Anti-VEGF; Delay; Disruption
ID COVID-19; RANIBIZUMAB; CARE
AB Purpose To assess the impact of COVID-19-related delay in intravitreal injection timing on macular structure and visual acuity (VA) among patients treated for neovascular age-related macular degeneration (nvAMD).
   Methods We reviewed demographic and clinical data and macular ocular computerized tomographic images of 34 patients (48 eyes, group A) who did not follow their injection schedule during the first wave of COVID-19 and compared them to 46 patients (71 eyes, group B) who did. Functional worsening was defined as a loss of at least 0.1 in decimal VA. Anatomic worsening was defined as new or increased subretinal/intraretinal fluids or new hemorrhage.
   Results The planned mean +/- standard deviation intervals between the intravitreal injections were 5.7 +/- 2.7 weeks for group A and 5.5 +/- 2.4 weeks for group B (P = 0.60). The actual intervals were 13.6 +/- 6.8 (7.9 +/- 5.2 weeks' delay) and 5.3 +/- 2.4 weeks (no delay), respectively (P < 0.001). The best corrected visual acuity worsened in 23 group A eyes (47.9%) and in 6 group B eyes (8.5%) (odds ratio [OR] 9.97, P < 0.001). Anatomic features indicative of nvAMD worsening were detected in 31 group A eyes (64.6%) and in 16 group B eyes (22.5%) (OR 5.73, P < 0.001). A new macular hemorrhage was observed in 4 group A eyes (8.3%) and in no group B eyes (P = 0.09).
   Conclusion Delay in timely retinal care during the COVID-19 restrictions period resulted in short-term negative outcomes, including macular bleeding, in nvAMD patients.
C1 [Hanhart, Joel; Wiener, Rony; Totah, Hashem; Gelman, Evgeny; Weill, Yishay; Abulafia, Adi; Zadok, David] Hebrew Univ Jerusalem, Shaare Zedek Med Ctr, Dept Ophthalmol, 12 Shmuel Bait St, IL-9103102 Jerusalem, Israel.
C3 Hebrew University of Jerusalem; Shaare Zedek Medical Center
RP Hanhart, J (通讯作者)，Hebrew Univ Jerusalem, Shaare Zedek Med Ctr, Dept Ophthalmol, 12 Shmuel Bait St, IL-9103102 Jerusalem, Israel.
EM hanhart@szmc.org.il
OI Hanhart, Joel/0000-0003-0952-3740
CR Ashkenazy N, 2021, CLIN OPHTHALMOL, V15, P413, DOI 10.2147/OPTH.S296345
   Babu N, 2020, INDIAN J OPHTHALMOL, V68, P1540, DOI 10.4103/ijo.IJO_1673_20
   Borrelli E, 2020, GRAEF ARCH CLIN EXP, V258, P2621, DOI 10.1007/s00417-020-04955-7
   Borrelli E, 2020, GRAEF ARCH CLIN EXP, V258, P2655, DOI 10.1007/s00417-020-04858-7
   Brown DM, 2009, OPHTHALMOLOGY, V116, P57, DOI 10.1016/j.ophtha.2008.10.018
   Carnevali A, 2021, EUR J OPHTHALMOL, V31, P10, DOI 10.1177/1120672120962032
   Chaudhary V, 2020, CAN J OPHTHALMOL, V55, P452, DOI 10.1016/j.jcjo.2020.06.001
   El Hamichi S, 2020, CLIN OPHTHALMOL, V14, P2593, DOI 10.2147/OPTH.S267950
   Gegundez-Fernandez JA, 2021, ACTA OPHTHALMOL, V99, pE973, DOI 10.1111/aos.14752
   Grzybowski A, 2018, OPHTHALMOLOGICA, V239, P181, DOI 10.1159/000486145
   Hattenbach LO, 2020, OPHTHALMOLOGE, V117, P892, DOI 10.1007/s00347-020-01220-4
   Hoeferlin Cory, 2021, SN Compr Clin Med, V3, P3, DOI 10.1007/s42399-020-00633-1
   Koh AHC, 2020, GRAEF ARCH CLIN EXP, V258, P2091, DOI 10.1007/s00417-020-04791-9
   Korobelnik JF, 2020, GRAEF ARCH CLIN EXP, V258, P1149, DOI 10.1007/s00417-020-04703-x
   Madanagopalan VG, 2020, INDIAN J OPHTHALMOL, V68, P1401, DOI 10.4103/ijo.IJO_1221_20
   Mehta H, 2020, CLIN OPHTHALMOL, V14, P3331, DOI 10.2147/OPTH.S275977
   Mehta H, 2018, PROG RETIN EYE RES, V65, P127, DOI 10.1016/j.preteyeres.2017.12.002
   Moussa M, 2021, INT OPHTHALMOL, V41, P1437, DOI 10.1007/s10792-021-01719-y
   Naravane AV, 2021, PLOS ONE, V16, DOI 10.1371/journal.pone.0247161
   Patel RD, 2011, SEMIN OPHTHALMOL, V26, P372, DOI 10.3109/08820538.2011.570845
   Romano F, 2020, OPHTHALMOL RETINA, V4, P1209, DOI 10.1016/j.oret.2020.06.027
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Sacconi R, 2021, EUR J OPHTHALMOL, V31, P849, DOI 10.1177/1120672120963448
   Sindal MD, 2021, INDIAN J OPHTHALMOL, V69, P730, DOI 10.4103/ijo.IJO_2807_20
   Solomon SD, 2019, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD005139.pub4
   Song WL, 2021, OPHTHALMOL RETINA, V5, P975, DOI 10.1016/j.oret.2020.12.020
   Stanescu-Segall D, 2016, SURV OPHTHALMOL, V61, P18, DOI 10.1016/j.survophthal.2015.04.004
   Staurenghi G, 2020, BMC OPHTHALMOL, V20, DOI 10.1186/s12886-019-1251-6
   Toro MD, 2021, EUR J OPHTHALMOL, V31, P5, DOI 10.1177/1120672120960339
   Wasser Lauren M, 2020, SN Compr Clin Med, V2, P2546, DOI 10.1007/s42399-020-00614-4
   Xu D, 2020, CURR OPIN OPHTHALMOL, V31, P427, DOI 10.1097/ICU.0000000000000692
   Yang KB, 2020, FRONT MED-LAUSANNE, V7, DOI 10.3389/fmed.2020.576275
NR 32
TC 2
Z9 2
U1 0
U2 0
PU SPRINGER
PI NEW YORK
PA ONE NEW YORK PLAZA, SUITE 4600, NEW YORK, NY, UNITED STATES
SN 0721-832X
EI 1435-702X
J9 GRAEF ARCH CLIN EXP
JI Graefes Arch. Clin. Exp. Ophthalmol.
PD JUN
PY 2022
VL 260
IS 6
BP 1907
EP 1914
DI 10.1007/s00417-021-05505-5
EA JAN 2022
PG 8
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 0X7EL
UT WOS:000741596000001
PM 35013800
OA Green Published, Bronze
DA 2022-11-30
ER

PT J
AU Guo, MY
   Etminan, M
   Cheng, JZ
   Zafari, Z
   Maberley, DAL
AF Guo, Michael Y.
   Etminan, Mahyar
   Cheng, Jasmine Z.
   Zafari, Zafar
   Maberley, David A. L.
TI One-Year Effectiveness Study of Intravitreous Ranibizumab in Wet
   (Neovascular) Age-Related Macular Degeneration: A Meta-Analysis
SO PHARMACOTHERAPY
LA English
DT Article
DE ranibizumab; anti-VEGF therapy; visual acuity; age-related macular
   degeneration; meta-analysis
ID VERTEPORFIN PLUS RANIBIZUMAB; DAILY CLINICAL-PRACTICE; VISUAL-ACUITY;
   CHOROIDAL NEOVASCULARIZATION; PHOTODYNAMIC THERAPY; 12-MONTH OUTCOMES;
   VS. AFLIBERCEPT; BEVACIZUMAB; EFFICACY; SAFETY
AB PurposeThe clinical efficacy of ranibizumab has been examined by a large number of prospective and retrospective studies to date. This meta-analysis was conducted to summarize the current body of evidence on visual acuity (VA) changes with use of ranibizumab in the treatment of wet (neovascular) age-related macular degeneration (wAMD).
   MethodsA literature review of multiple electronic databases (EMBASE, MEDLINE, MedMEME) was conducted to find randomized controlled trials (RCTs) and observational studies that reported changes in VA while patients with wAMD were on ranibizumab. Study factors analyzed were baseline patient characteristics, study type, sample size, and 12-month change in VA. Data were pooled in a meta-analysis with VA change as the main outcome. Data were then stratified by study design and a meta-regression was conducted to assess 12-month VA change against baseline VA and age.
   ResultsA total of 42 studies were included for analysis. An overall increase of 5.58 letters (95% confidence interval [CI]: 4.42-6.75; p heterogeneity, <0.001) was shown with use of ranibizumab compared to baseline. Improvements in VA were larger for RCTs, at 7.71 letters (95% CI: 6.66-8.76; p heterogeneity, 0.013), compared to observational studies, at 4.85 letters (95% CI: 3.32-6.38; p heterogeneity, <0.001). The meta-regression showed a significant decrease in effect size between baseline VA and 12-month VA change.
   ConclusionThis meta-analysis suggests visual improvements at 12months of 0.5-mg ranibizumab use in patients with wAMD. A higher gain in VA was observed when pooling results from RCTs compared to those in observational studies.
C1 [Guo, Michael Y.; Cheng, Jasmine Z.] Univ British Columbia, Dept Med, Vancouver, BC, Canada.
   [Etminan, Mahyar; Maberley, David A. L.] Univ British Columbia, Dept Ophthalmol & Visual Sci, Vancouver, BC, Canada.
   [Zafari, Zafar] Columbia Univ, Mailman Sch Publ Hlth, New York, NY USA.
C3 University of British Columbia; University of British Columbia; Columbia
   University
RP Etminan, M (通讯作者)，Univ British Columbia, Dept Ophthalmol & Visual Sci, Fac Med, Eye Care Ctr, Room 323-2550 Willow St, Vancouver, BC V5Z 3N9, Canada.
EM etminanm@mail.ubc.ca
OI Etminan, Mahyar/0000-0003-4628-6270
FU Bayer HealthCare
FX The study was part of an initiative to study anti-VEGF therapies, funded
   by an unrestricted grant from Bayer HealthCare.
CR Atmani K, 2010, EYE, V24, P1193, DOI 10.1038/eye.2010.9
   Ba J, 2015, DRUG DES DEV THER, V9, DOI 10.2147/DDDT.S86269
   Bandukwala T, 2010, CAN J OPHTHALMOL, V45, P590, DOI 10.3129/i10-082
   Berg K, 2015, OPHTHALMOLOGY, V122, P146, DOI 10.1016/j.ophtha.2014.07.041
   Brown D.M., 2009, OPHTHALMOLOGY, V116, pe5
   Brown DM, 2015, OPHTHALMOLOGY, V122, P2044, DOI 10.1016/j.ophtha.2015.06.017
   Brown DM, 2009, OPHTHALMOLOGY, V116, P57, DOI 10.1016/j.ophtha.2008.10.018
   Busbee BG, 2013, OPHTHALMOLOGY, V120, P1046, DOI 10.1016/j.ophtha.2012.10.014
   Calvo P, 2015, J OPHTHALMOL, V2015, DOI 10.1155/2015/820605
   Canan H, 2014, CLIN INTERV AGING, V9, P141, DOI 10.2147/CIA.S56863
   Chakravarthy U, 2012, OPHTHALMOLOGY, V119, DOI 10.1016/j.ophtha.2012.04.015
   Chavan R, 2014, CLIN OPHTHALMOL, V8, P717, DOI 10.2147/OPTH.S60763
   Chong V, 2016, EYE, V30, P270, DOI 10.1038/eye.2015.217
   Cohen SY, 2013, GRAEF ARCH CLIN EXP, V251, P2499, DOI 10.1007/s00417-013-2338-z
   Cohen SY, 2013, RETINA-J RET VIT DIS, V33, P474, DOI 10.1097/IAE.0b013e31827b6324
   Cohen SY, 2009, AM J OPHTHALMOL, V148, P409, DOI 10.1016/j.ajo.2009.04.001
   Dugel PU, 2016, CLIN OPHTHALMOL, V10, DOI 10.2147/OPTH.S100764
   Elliott DB, 2016, OPHTHAL PHYSL OPT, V36, P355, DOI 10.1111/opo.12310
   Gabai A, 2014, EUR J OPHTHALMOL, V24, P396, DOI 10.5301/ejo.5000385
   Gillies MC, 2016, OPHTHALMOLOGY, V123, P2545, DOI 10.1016/j.ophtha.2016.08.016
   Gupta B, 2011, BRIT J OPHTHALMOL, V95, P386, DOI 10.1136/bjo.2010.179499
   Heier JS, 2012, OPHTHALMOLOGY, V119, P2537, DOI 10.1016/j.ophtha.2012.09.006
   Iordanous Y, 2014, CAN J OPHTHALMOL, V49, P367, DOI 10.1016/j.jcjo.2014.05.010
   Kaiser PK, 2012, OPHTHALMOLOGY, V119, P1001, DOI 10.1016/j.ophtha.2012.02.003
   Kim JH, 2016, GRAEF ARCH CLIN EXP, V254, P2101, DOI 10.1007/s00417-016-3353-7
   Kodjikian L, 2013, OPHTHALMOLOGY, V120, P2300, DOI 10.1016/j.ophtha.2013.06.020
   Korobelnik JF, 2015, BMC OPHTHALMOL, V15, DOI 10.1186/s12886-015-0035-x
   Krebs I, 2013, ACTA OPHTHALMOL, V91, pE178, DOI 10.1111/aos.12018
   Kumar A, 2011, BRIT J OPHTHALMOL, V95, P530, DOI 10.1136/bjo.2009.171868
   Lala C, 2013, ACTA OPHTHALMOL, V91, P526, DOI 10.1111/j.1755-3768.2012.02457.x
   Larsen M, 2012, OPHTHALMOLOGY, V119, P992, DOI 10.1016/j.ophtha.2012.02.002
   Martin DF, 2011, NEW ENGL J MED, V364, P1897, DOI 10.1056/NEJMoa1102673
   Mendrinos E, 2013, ACTA OPHTHALMOL, V91, pE184, DOI 10.1111/aos.12008
   Panos GD, 2013, DRUG DES DEV THER, V7, P565, DOI 10.2147/DDDT.S46610
   Park DH, 2017, INT OPHTHALMOL, V37, P1205, DOI 10.1007/s10792-016-0391-4
   Piermarocchi S, 2015, ACTA OPHTHALMOL, V93, pE451, DOI 10.1111/aos.12587
   Pushpoth S, 2012, BRIT J OPHTHALMOL, V96, P1469, DOI 10.1136/bjophthalmol-2012-302167
   Qi HJ, 2017, INT J OPHTHALMOL-CHI, V10, P91, DOI 10.18240/ijo.2017.01.15
   Querques G, 2012, GRAEF ARCH CLIN EXP, V250, P479, DOI 10.1007/s00417-011-1831-5
   Rasmussen A, 2017, ACTA OPHTHALMOL, V95, P128, DOI 10.1111/aos.13233
   Razi F, 2016, CLIN OPHTHALMOL, V10, P313, DOI 10.2147/OPTH.S97775
   Roberts P, 2014, INVEST OPHTH VIS SCI, V55, DOI 10.1167/iovs.14-14293
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Ross AH, 2013, EYE, V27, P56, DOI 10.1038/eye.2012.225
   Rothenbuehler SP, 2009, AM J OPHTHALMOL, V147, P831, DOI 10.1016/j.ajo.2008.12.005
   Santarelli M, 2015, EXPERT OPIN PHARMACO, V16, P1769, DOI 10.1517/14656566.2015.1067679
   Scholler A, 2014, WIEN KLIN WOCHENSCHR, V126, P355, DOI 10.1007/s00508-014-0539-z
   Shona O, 2011, CLIN EXP OPHTHALMOL, V39, P5, DOI 10.1111/j.1442-9071.2010.02424.x
   Souied EH, 2015, RETINA-J RET VIT DIS, V35, P1743, DOI 10.1097/IAE.0000000000000548
   Szabo SM, 2015, CURR MED RES OPIN, V31, P2031, DOI 10.1185/03007995.2015.1084909
   Veritti D, 2012, OPHTHALMOLOGICA, V227, P11, DOI 10.1159/000337154
   Westerborg I, 2017, RETINA, P1
   Wickremasinghe SS, 2012, INVEST OPHTH VIS SCI, V53, P37, DOI 10.1167/iovs.11-7689
   Williams PD, 2012, CLIN OPHTHALMOL, V6, P1519, DOI 10.2147/OPTH.S31010
   Zhao JL, 2014, BIODRUGS, V28, P527, DOI 10.1007/s40259-014-0106-1
NR 55
TC 4
Z9 4
U1 0
U2 4
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0277-0008
EI 1875-9114
J9 PHARMACOTHERAPY
JI Pharmacotherapy
PD FEB
PY 2018
VL 38
IS 2
BP 197
EP 204
DI 10.1002/phar.2079
PG 8
WC Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Pharmacology & Pharmacy
GA FV8KS
UT WOS:000424836400008
PM 29286545
DA 2022-11-30
ER

PT J
AU Suzuki, M
   Tsujikawa, M
   Itabe, H
   Du, ZJ
   Xie, P
   Matsumura, N
   Fu, XM
   Zhang, RL
   Sonoda, K
   Egashira, K
   Hazen, SL
   Kamei, M
AF Suzuki, Mihoko
   Tsujikawa, Motokazu
   Itabe, Hiroyuki
   Du, Zhao-Jiang
   Xie, Ping
   Matsumura, Nagakazu
   Fu, Xiaoming
   Zhang, Renliang
   Sonoda, Koh-hei
   Egashira, Kensuke
   Hazen, Stanley L.
   Kamei, Motohiro
TI Chronic photo-oxidative stress and subsequent MCP-1 activation as
   causative factors for age-related macular degeneration
SO JOURNAL OF CELL SCIENCE
LA English
DT Article
DE Age-related macular degeneration; Aging; Neovascularization; Oxidative
   stress; Oxidized phospholipids
ID RETINAL-PIGMENT EPITHELIUM; FACTOR-H POLYMORPHISM; CHOROIDAL
   NEOVASCULARIZATION; OXIDIZED PHOSPHOLIPIDS; ATHEROSCLEROTIC LESIONS;
   RISK; MICE; EYE; LIGHT; ANTIOXIDANTS
AB Age-related macular degeneration (AMD) is the leading cause of blindness among the elderly in developed countries. Although pathogenic factors, such as oxidative stress, inflammation and genetics are thought to contribute to the development of AMD, little is known about the relationships and priorities between these factors. Here, we show that chronic photo-oxidative stress is an environmental factor involved in AMD pathogenesis. We first demonstrated that exposure to light induced phospholipid oxidation in the mouse retina, which was more prominent in aged animals. The induced oxidized phospholipids led to an increase in the expression of monocyte chemoattractant protein-1, which then resulted in macrophage accumulation, an inflammatory process. Antioxidant treatment prevented light-induced phospholipid oxidation and the subsequent increase of monocyte chemoattractant protein-1 (also known as C-C motif chemokine 2; CCL2), which are the beginnings of the light-induced changes. Subretinal application of oxidized phospholipids induced choroidal neovascularization, a characteristic feature of wet-type AMD, which was inhibited by blocking monocyte chemoattractant protein-1. These findings strongly suggest that a sequential cascade from photic stress to inflammatory processes through phospholipid oxidation has an important role in AMD pathogenesis. Finally, we succeeded in mimicking human AMD in mice with low-level, long-term photic stress, in which characteristic pathological changes, including choroidal neovascularization formation, were observed. Therefore, we propose a consecutive pathogenic pathway involving photic stress, oxidation of phospholipids and chronic inflammation, leading to angiogenesis. These findings add to the current understanding of AMD pathology and suggest protection from oxidative stress or suppression of the subsequent inflammation as new potential therapeutic targets for AMD.
C1 [Suzuki, Mihoko; Tsujikawa, Motokazu; Du, Zhao-Jiang; Xie, Ping; Matsumura, Nagakazu; Kamei, Motohiro] Osaka Univ, Grad Sch Med, Dept Ophthalmol, Suita, Osaka 5650871, Japan.
   [Itabe, Hiroyuki] Showa Univ, Sch Pharmaceut Sci, Dept Biol Chem, Shinagawa Ku, Tokyo 1428555, Japan.
   [Fu, Xiaoming; Zhang, Renliang; Hazen, Stanley L.] Cleveland Clin, Ctr Cardiovasc Diagnost & Prevent, Cleveland, OH 44195 USA.
   [Sonoda, Koh-hei] Yamaguchi Univ, Grad Sch Med, Dept Ophthalmol, Ube, Yamaguchi 7558505, Japan.
   [Egashira, Kensuke] Kyushu Univ, Grad Sch Med Sci, Dept Cardiovasc Med, Higashi Ku, Fukuoka 8128582, Japan.
C3 Osaka University; Showa University; Cleveland Clinic Foundation;
   Yamaguchi University; Kyushu University
RP Kamei, M (通讯作者)，Osaka Univ, Grad Sch Med, Dept Ophthalmol, 2-2 Yamadaoka, Suita, Osaka 5650871, Japan.
EM mkamei@ophthal.med.osaka-u.ac.jp
RI Hazen, Stanley L/ABD-5845-2021; 板部板部, 洋之/ABC-7746-2020
OI Xie, Ping/0000-0003-4257-8970
FU Ministry of Education, Science, and Culture of Japan [40281125];
   National Institutes of Health [P01 HL087018-020001]; NATIONAL HEART,
   LUNG, AND BLOOD INSTITUTE [P01HL087018] Funding Source: NIH RePORTER;
   Grants-in-Aid for Scientific Research [21592231] Funding Source: KAKEN
FX This work was supported by a Grant-in-Aid for Scientific Research from
   the Ministry of Education, Science, and Culture of Japan [grant number
   40281125 to M.K.]; and the National Institutes of Health [grant number
   P01 HL087018-020001 to S.L.H.]. Deposited in PMC for release after 12
   months.
CR Ambati J, 2003, NAT MED, V9, P1390, DOI 10.1038/nm950
   Baba T, 2010, AM J PATHOL, V176, P3085, DOI 10.2353/ajpath.2010.090989
   Beatty S, 2000, SURV OPHTHALMOL, V45, P115, DOI 10.1016/S0039-6257(00)00140-5
   Bochkov VN, 2006, CIRC RES, V99, P900, DOI 10.1161/01.RES.0000245485.04489.ee
   Boring L, 1997, J CLIN INVEST, V100, P2552, DOI 10.1172/JCI119798
   CRUICKSHANKS KJ, 1993, ARCH OPHTHALMOL-CHIC, V111, P514, DOI 10.1001/archopht.1993.01090040106042
   Edwards AO, 2005, SCIENCE, V308, P421, DOI 10.1126/science.1110189
   Furnkranz A, 2005, ARTERIOSCL THROM VAS, V25, P633, DOI 10.1161/01.ATV.0000153106.03644.a0
   Grossniklaus HE, 2002, MOL VIS, V8, P119
   Haines JL, 2005, SCIENCE, V308, P419, DOI 10.1126/science.1110359
   Hollyfield JG, 2008, NAT MED, V14, P194, DOI 10.1038/nm1709
   ITABE H, 1994, J BIOL CHEM, V269, P15274
   Kamei M, 2007, INVEST OPHTH VIS SCI, V48, P1801, DOI 10.1167/iovs.06-0699
   Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557
   Lu B, 1998, J EXP MED, V187, P601, DOI 10.1084/jem.187.4.601
   Malek G, 2003, AM J PATHOL, V162, P413, DOI 10.1016/S0002-9440(10)63836-9
   Milton RC, 2005, OPHTHALMOLOGY, V112, P533, DOI 10.1016/j.ophtha.2004.10.047
   Ranchon I, 2003, J NEUROSCI, V23, P6050, DOI 10.1523/JNEUROSCI.23-14-06050.2003
   SanGiovanni JP, 2007, ARCH OPHTHALMOL-CHIC, V125, P1225, DOI 10.1001/archopht.125.9.1225
   Sun MJ, 2006, J BIOL CHEM, V281, P4222, DOI 10.1074/jbc.M509769200
   Suzuki M, 2007, MOL VIS, V13, P772
   Tan JSL, 2008, OPHTHALMOLOGY, V115, P334, DOI 10.1016/j.ophtha.2007.03.083
   TAYLOR HR, 1992, ARCH OPHTHALMOL-CHIC, V110, P99, DOI 10.1001/archopht.1992.01080130101035
   van Leeuwen R, 2005, JAMA-J AM MED ASSOC, V294, P3101, DOI 10.1001/jama.294.24.3101
   Yamada K, 2007, INVEST OPHTH VIS SCI, V48, P1839, DOI 10.1167/iovs.06-1085
   Yates JRW, 2007, NEW ENGL J MED, V357, P553, DOI 10.1056/NEJMoa072618
   Zhou YD, 2011, EXP EYE RES, V93, P636, DOI 10.1016/j.exer.2011.07.017
NR 27
TC 88
Z9 90
U1 0
U2 20
PU COMPANY OF BIOLOGISTS LTD
PI CAMBRIDGE
PA BIDDER BUILDING CAMBRIDGE COMMERCIAL PARK COWLEY RD, CAMBRIDGE CB4 4DL,
   CAMBS, ENGLAND
SN 0021-9533
J9 J CELL SCI
JI J. Cell Sci.
PD MAY 15
PY 2012
VL 125
IS 10
BP 2407
EP 2415
DI 10.1242/jcs.097683
PG 9
WC Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Cell Biology
GA 970CZ
UT WOS:000306107000007
PM 22357958
OA Green Published
DA 2022-11-30
ER

PT J
AU Tong, Y
   Liao, J
   Zhang, YA
   Zhou, J
   Zhang, HY
   Mao, M
AF Tong, Yu
   Liao, Jing
   Zhang, Yuan
   Zhou, Jing
   Zhang, Hengyu
   Mao, Meng
TI LOC387715/HTRA1 gene polymorphisms and susceptibility to age-related
   macular degeneration: A HuGE review and meta-analysis
SO MOLECULAR VISION
LA English
DT Article
ID COMPLEMENT FACTOR-H; APOLIPOPROTEIN-E POLYMORPHISMS; HTRA1 PROMOTER
   POLYMORPHISM; HARDY-WEINBERG EQUILIBRIUM; PUBLIC-HEALTH IMPACT;
   BODY-MASS INDEX; BEAVER DAM EYE; RISK-FACTORS; JAPANESE POPULATION;
   STARGARDT-DISEASE
AB Purpose: To examine the association of age-related macular degeneration (AMD) with HtrA serine peptidase 1 (HTRA1) gene rs11200638 G -> A polymorphism and LOC387715/ARMS2 gene rs10490924 G -> T polymorphisms, and to evaluate the magnitude of the gene effect and the possible genetic mode of action.
   Methods: We searched the US National Library of Medicine's PubMed, Embase, OMIM, ISI Web of Science, and CNKI databases in a systematic manner to retrieve all genetic association studies on the HTRA1 (rs11200638) and LOC387715/ARMS2 (rs10490924) gene polymorphisms and AMD. We performed a meta-analysis conducted with Stata software, version 9.0.
   Results: Individuals who carried the AA and AG genotypes of HTRA1 gene rs11200638 G -> A polymorphism had 2.243 and 8.669 times the risk of developing AMD, respectively, when compared with those who carry the GG genotype. Individuals carrying the TT and TG genotypes of LOC387715/ARMS2 gene rs10490924 G -> T polymorphism had 7.512 and 2.353 times the risk of developing AMD, respectively, compared with those who carry GG genotype. These results suggested a "moderate" codominant, multiplicative genetic mode; that is, both HTRA1 rs11200638 G -> A polymorphism and LOC387715/ARMS2 rs10490924 G -> T polymorphism play important roles in the pathogenesis of AMD. We found no evidence of publication bias. Between-study heterogeneity was found in both allele-based analysis and genotype-based analysis.
   Conclusions: HTRA1 rs11200638 G -> A polymorphism and LOC387715/ARMS2 rs10490924 G -> T polymorphism play important roles in AMD. Gene-gene and gene-environmental interactions, as well as precise mechanisms underlying common variants in the HTRA1 gene and LOC387715/ARMS2 gene, potentially increase the risk of AMD and need further exploration.
C1 [Mao, Meng] Sichuan Univ, W China Univ Hosp 2, Ctr Res Child Dev & Dis, Lab Early Dev & Injuries,Dept Pediat, Chengdu 610041, Peoples R China.
   [Liao, Jing] Sichuan Peoples Prov Hosp, Dept Sci & Technol, Chengdu, Peoples R China.
   [Zhang, Yuan] Wuhou Hlth Bur, Dept Community Hlth, Chengdu, Peoples R China.
   [Zhang, Hengyu] Sichuan Univ, W China Hosp, Dept Lab Med, Chengdu 610064, Peoples R China.
   [Zhang, Hengyu] Sichuan Univ, W China Hosp, Dept Cardiol, Chengdu 610064, Peoples R China.
C3 Sichuan University; Sichuan University; Sichuan University
RP Mao, M (通讯作者)，Sichuan Univ, W China Univ Hosp 2, Ctr Res Child Dev & Dis, Lab Early Dev & Injuries,Dept Pediat, Chengdu 610041, Peoples R China.
EM maomengmaomeng@163.com
FU National Natural Science Foundation of China [30772343, 30800633,
   30700908]; Science and Technology Department of Sichuan Province
   [2007SGY022]; Sichuan Province Science and Technology Foundation for
   Youths [09ZQ026-034]
FX The research was Supported by National Natural Science Foundation of
   China (No. 30772343, No. 30800633 and No. 30700908), Science and
   Technology breakthrough Project of Science and Technology Department of
   Sichuan Province (No. 2007SGY022) and Sichuan Province Science and
   Technology Foundation for Youths (No. 09ZQ026-034). The authors thank
   Dr. Huaigong Chen for checking coding of some of the data. They also
   thank Dr. Kanda and Dr. Hughes who kindly provided genotype and allele
   frequency data for the meta-analyses.
CR Abu Asleh S, 2007, ISRAEL MED ASSOC J, V9, P656
   Allikmets R, 1997, SCIENCE, V277, P1805, DOI 10.1126/science.277.5333.1805
   Anand R, 2000, OPHTHALMOLOGY, V107, P2224
   Arnarsson A, 2006, AM J OPHTHALMOL, V142, P419, DOI 10.1016/j.ajo.2006.04.015
   Ayyagari R, 2001, Ophthalmic Genet, V22, P233, DOI 10.1076/opge.22.4.233.2219
   Baird PN, 2006, INVEST OPHTH VIS SCI, V47, P4194, DOI 10.1167/iovs.05-1285
   Baird PN, 2006, HUM MUTAT, V27, P337, DOI 10.1002/humu.20288
   Bandello F, 2007, INVEST OPHTH VIS SCI, V48, P96, DOI 10.1167/iovs.06-0283
   Barral S, 2006, INVEST OPHTH VIS SCI, V47, P5453, DOI 10.1167/iovs.06-0655
   Barron MJ, 2001, INVEST OPHTH VIS SCI, V42, P3016
   Beatty S, 2000, SURV OPHTHALMOL, V45, P115, DOI 10.1016/S0039-6257(00)00140-5
   Bird AC, 2003, EYE, V17, P457, DOI 10.1038/sj.eye.6700562
   Bonastre J, 2002, Eur J Health Econ, V3, P94, DOI 10.1007/s10198-002-0104-y
   Bressler NM, 2003, ARCH OPHTHALMOL-CHIC, V121, P1621
   Cameron DJ, 2008, ADV EXP MED BIOL, V613, P253, DOI 10.1007/978-0-387-74904-4_29
   Cameron DJ, 2007, CELL CYCLE, V6, P1122, DOI 10.4161/cc.6.9.4157
   Canfield AE, 2007, BIOCHEM SOC T, V35, P669, DOI 10.1042/BST0350669
   Carelli V, 2004, PROG RETIN EYE RES, V23, P53, DOI 10.1016/j.preteyeres.2003.10.003
   Chan Chi-Chao, 2007, Trans Am Ophthalmol Soc, V105, P92
   Chang YC, 2007, DIABETES, V56, P2631, DOI 10.2337/db07-0421
   Chen HY, 2008, VISION RES, V48, P690, DOI 10.1016/j.visres.2007.10.014
   Chen LJ, 2006, MOL VIS, V12, P1536
   Chong EWT, 2008, AM J OPHTHALMOL, V145, P707, DOI 10.1016/j.ajo.2007.12.005
   Churchill AJ, 2006, HUM MOL GENET, V15, P2955, DOI 10.1093/hmg/ddl238
   Conley YP, 2006, HUM MOL GENET, V15, P3206, DOI 10.1093/hmg/ddl396
   Cruess AF, 2008, PHARMACOECONOMICS, V26, P57, DOI 10.2165/00019053-200826010-00006
   De La Paz MA, 1999, OPHTHALMOLOGY, V106, P1531, DOI 10.1016/S0161-6420(99)90449-9
   DeAngelis MM, 2008, OPHTHALMOLOGY, V115, P1209, DOI 10.1016/j.ophtha.2007.10.032
   DeAngelis MM, 2007, ARCH OPHTHALMOL-CHIC, V125, P49, DOI 10.1001/archopht.125.1.49
   DERSIMONIAN R, 1986, CONTROL CLIN TRIALS, V7, P177, DOI 10.1016/0197-2456(86)90046-2
   Despriet DDG, 2008, INVEST OPHTH VIS SCI, V49, P364, DOI 10.1167/iovs.07-0656
   Dewan A, 2007, CURR OPIN GENET DEV, V17, P228, DOI 10.1016/j.gde.2007.04.004
   Dewan A, 2006, SCIENCE, V314, P989, DOI 10.1126/science.1133807
   Douglas IJ, 2007, OPHTHALMOLOGY, V114, P1164, DOI 10.1016/j.ophtha.2006.09.018
   Egger M, 1997, BMJ-BRIT MED J, V315, P629, DOI 10.1136/bmj.315.7109.629
   Egger M, 2003, Health Technol Assess, V7, P1
   EMIGH TH, 1980, BIOMETRICS, V36, P627, DOI 10.2307/2556115
   Evans JR, 2001, PROG RETIN EYE RES, V20, P227, DOI 10.1016/S1350-9462(00)00023-9
   Evans JR, 2005, BRIT J OPHTHALMOL, V89, P550, DOI 10.1136/bjo.2004.049726
   Feher J, 2006, NEUROBIOL AGING, V27, P983, DOI 10.1016/j.neurobiolaging.2005.05.012
   Fisher SA, 2005, HUM MOL GENET, V14, P2257, DOI 10.1093/hmg/ddi230
   Fisher SA, 2007, HUM MUTAT, V28, P406, DOI 10.1002/humu.20464
   Francis PJ, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0001197
   Francis PJ, 2007, HUM HERED, V63, P212, DOI 10.1159/000100046
   Fraser-Bell S, 2006, AM J OPHTHALMOL, V141, P79, DOI 10.1016/j.ajo.2005.08.024
   Friedman DA, 2007, MED HYPOTHESES, V68, P1047, DOI 10.1016/j.mehy.2006.09.049
   Gibbs D, 2008, VISION RES, V48, P685, DOI 10.1016/j.visres.2007.10.022
   Gold B, 2006, NAT GENET, V38, P458, DOI 10.1038/ng1750
   Gottfredsdottir MS, 1999, ACTA OPHTHALMOL SCAN, V77, P422, DOI 10.1034/j.1600-0420.1999.770413.x
   Grau S, 2006, J BIOL CHEM, V281, P6124, DOI 10.1074/jbc.M500361200
   Grizzard WS, 2003, OPHTHAL EPIDEMIOL, V10, P315, DOI 10.1076/opep.10.5.315.17317
   Haddad S, 2006, SURV OPHTHALMOL, V51, P316, DOI 10.1016/j.survophthal.2006.05.001
   Higgins JPT, 2003, BRIT MED J, V327, P557, DOI 10.1136/bmj.327.7414.557
   Higgins JPT, 2002, STAT MED, V21, P1539, DOI 10.1002/sim.1186
   Hughes AE, 2007, PLOS MED, V4, P1993, DOI 10.1371/journal.pmed.0040355
   Jakobsdottir J, 2005, AM J HUM GENET, V77, P389, DOI 10.1086/444437
   KAARE M, 2008, ACTA OPHTHALMOL SCAN, V86, P390
   Kanda A, 2007, P NATL ACAD SCI USA, V104, P16227, DOI 10.1073/pnas.0703933104
   Kaur I, 2008, INVEST OPHTH VIS SCI, V49, P1771, DOI 10.1167/iovs.07-0560
   Kaur I, 2006, INVEST OPHTH VIS SCI, V47, P3729, DOI 10.1167/iovs.05-1430
   Kim NR, 2008, INVEST OPHTH VIS SCI, V49, P2071, DOI 10.1167/iovs.07-1195
   Klaver CCW, 1998, ARCH OPHTHALMOL-CHIC, V116, P1646, DOI 10.1001/archopht.116.12.1646
   Klein R, 2004, AM J OPHTHALMOL, V137, P486, DOI 10.1016/j.ajo.2003.11.069
   KLEIN R, 1992, OPHTHALMOLOGY, V99, P933
   Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557
   Klein R, 2007, OPHTHAL EPIDEMIOL, V14, P184, DOI 10.1080/09286580701344381
   Knudtson MD, 2007, AM J OPHTHALMOL, V143, P1026, DOI 10.1016/j.ajo.2007.01.036
   Kondo N, 2007, AM J OPHTHALMOL, V144, P608, DOI 10.1016/j.ajo.2007.06.003
   Kroemer G, 2000, NAT MED, V6, P513, DOI 10.1038/74994
   Lau J, 1997, ANN INTERN MED, V127, P820, DOI 10.7326/0003-4819-127-9-199711010-00008
   LAU J, 1992, NEW ENGL J MED, V327, P248, DOI 10.1056/NEJM199207233270406
   Leveziel N, 2008, INVEST OPHTH VIS SCI, V49, P3090, DOI 10.1167/iovs.07-1540
   Leveziel N, 2007, MOL VIS, V13, P2153
   Lin JM, 2008, RETINA-J RET VIT DIS, V28, P309, DOI 10.1097/IAE.0b013e31814cef3a
   Lin MT, 2006, NATURE, V443, P787, DOI 10.1038/nature05292
   Lu F, 2007, VISION RES, V47, P3120, DOI 10.1016/j.visres.2007.08.010
   Luo L, 2008, VISION RES, V48, P494, DOI 10.1016/j.visres.2007.11.013
   Ly DH, 2000, SCIENCE, V287, P2486, DOI 10.1126/science.287.5462.2486
   Maller J, 2006, NAT GENET, V38, P1055, DOI 10.1038/ng1873
   MANTEL N, 1959, J NATL CANCER I, V22, P719
   Marx J, 2006, SCIENCE, V314, P405
   Mathura JR, 2000, INVEST OPHTH VIS SCI, V41, P592
   Meyers S M, 1994, Trans Am Ophthalmol Soc, V92, P775
   MEYERS SM, 1995, AM J OPHTHALMOL, V120, P757, DOI 10.1016/S0002-9394(14)72729-1
   Milton RC, 2005, OPHTHALMOLOGY, V112, P533, DOI 10.1016/j.ophtha.2004.10.047
   Minelli C, 2005, STAT MED, V24, P3845, DOI 10.1002/sim.2393
   Miyake K, 2008, J HUM GENET, V53, P174, DOI 10.1007/s10038-007-0231-5
   Moeller SM, 2000, J AM COLL NUTR, V19, p522S, DOI 10.1080/07315724.2000.10718975
   Montes T, 2008, MOL IMMUNOL, V45, P2897, DOI 10.1016/j.molimm.2008.01.027
   Montezuma Sandra R, 2007, Semin Ophthalmol, V22, P229, DOI 10.1080/08820530701745140
   Mori K, 2007, J HUM GENET, V52, P636, DOI 10.1007/s10038-007-0162-1
   Munoz B, 2005, ARCH OPHTHALMOL-CHIC, V123, P1575, DOI 10.1001/archopht.123.11.1575
   Narayanan R, 2007, OPHTHALMOLOGY, V114, P1327, DOI 10.1016/j.ophtha.2006.10.035
   Nowak Mariusz, 2004, Klin Oczna, V106, P427
   Odergren A, 2006, CURR EYE RES, V31, P765, DOI 10.1080/02713680600865045
   Oka C, 2004, DEVELOPMENT, V131, P1041, DOI 10.1242/dev.00999
   Okamoto H, 2006, MOL VIS, V12, P156
   Owen CG, 2003, BRIT J OPHTHALMOL, V87, P312, DOI 10.1136/bjo.87.3.312
   Pallen MJ, 1997, MOL MICROBIOL, V26, P209, DOI 10.1046/j.1365-2958.1997.5601928.x
   Pulido JS, 2007, OPHTHALMIC GENET, V28, P203, DOI 10.1080/13816810701649617
   Rakic J-M, 2006, Bull Soc Belge Ophtalmol, P9
   Rivera A, 2005, HUM MOL GENET, V14, P3227, DOI 10.1093/hmg/ddi353
   Rivera A, 2000, AM J HUM GENET, V67, P800, DOI 10.1086/303090
   Rosenberg T, 1996, ACTA OPHTHALMOL SCAN, V74, P399
   Ross RJ, 2007, EXPERT REV OPHTHALMO, V2, P443, DOI 10.1586/17469899.2.3.443
   Santangelo Susan L, 2005, Ophthalmic Genet, V26, P61, DOI 10.1080/13816810490967944
   Schick JH, 2003, AM J HUM GENET, V72, P1412, DOI 10.1086/375500
   Schmidt S, 2006, AM J HUM GENET, V78, P852, DOI 10.1086/503822
   Schmidt S, 2000, MOL VIS, V6, P287
   Scholl HPN, 2007, MOL VIS, V13, P196
   Schultz Dennis W, 2005, Ophthalmic Genet, V26, P101, DOI 10.1080/13816810590968023
   Seddon JM, 2005, ARCH OPHTHALMOL-CHIC, V123, P321, DOI 10.1001/archopht.123.3.321
   Seddon JM, 2003, AM J HUM GENET, V73, P780, DOI 10.1086/378505
   Seddon JM, 2006, HUM HERED, V61, P157, DOI 10.1159/000094141
   Seddon JM, 2006, ARCH OPHTHALMOL-CHIC, V124, P995, DOI 10.1001/archopht.124.7.995
   Seddon Johanna M., 2004, International Ophthalmology Clinics, V44, P17, DOI 10.1097/00004397-200404440-00004
   Seitsonen S, 2006, MOL VIS, V12, P796
   Simonelli F, 2001, OPHTHALMIC RES, V33, P325, DOI 10.1159/000055688
   Soubrane G, 1996, Rev Prat, V46, P1722
   Souied EH, 2005, MOL VIS, V11, P1135
   Spiegelhalter D., 2003, WINBUGS USER MANUAL
   *STAT CORP, 2005, STAT STAT SOFTW REL
   Sterne JAC, 2008, SYSTEMATIC REV HLTH, DOI DOI 10.1002/9780470693926.CH18
   Stone EM, 2004, NEW ENGL J MED, V351, P346, DOI 10.1056/NEJMoa040833
   Stroup DF, 2000, JAMA-J AM MED ASSOC, V283, P2008, DOI 10.1001/jama.283.15.2008
   Tam POS, 2008, INVEST OPHTH VIS SCI, V49, P2357, DOI 10.1167/iovs.07-1520
   Thakkinstian A, 2006, HUM MOL GENET, V15, P2784, DOI 10.1093/hmg/ddl220
   Thakkinstian A, 2006, AM J EPIDEMIOL, V164, P813, DOI 10.1093/aje/kwj279
   Thornton J, 2005, EYE, V19, P935, DOI 10.1038/sj.eye.6701978
   Tocharus J, 2004, DEV GROWTH DIFFER, V46, P257
   Trikalinos TA, 2006, AM J EPIDEMIOL, V163, P300, DOI 10.1093/aje/kwj046
   Tuo JS, 2006, P NATL ACAD SCI USA, V103, P9256, DOI 10.1073/pnas.0603485103
   Tuo JS, 2004, PROG RETIN EYE RES, V23, P229, DOI 10.1016/j.preteyeres.2004.02.001
   Uka J, 2006, RETINA-J RET VIT DIS, V26, P985, DOI 10.1097/01.iae.0000244068.18520.3e
   VINDING T, 1990, ACTA OPHTHALMOL, V68, P162
   VINGERLING JR, 1995, OPHTHALMOLOGY, V102, P205
   Wallace DC, 2005, ANNU REV GENET, V39, P359, DOI 10.1146/annurev.genet.39.110304.095751
   Weger M, 2007, MOL VIS, V13, P1274
   Wegscheider BJ, 2007, OPHTHALMOLOGY, V114, P738, DOI 10.1016/j.ophtha.2006.07.048
   Xu L, 2006, OPHTHALMOLOGY, V113, P1134, DOI 10.1016/j.ophtha.2006.01.035
   Yang ZL, 2006, SCIENCE, V314, P992, DOI 10.1126/science.1133811
   Yoshida T, 2007, MOL VIS, V13, P545
   Zareparsi S, 2005, HUM MOL GENET, V14, P1449, DOI 10.1093/hmg/ddi154
NR 143
TC 65
Z9 67
U1 0
U2 13
PU MOLECULAR VISION
PI ATLANTA
PA C/O JEFF BOATRIGHT, LAB B, 5500 EMORY EYE CENTER, 1327 CLIFTON RD, N E,
   ATLANTA, GA 30322 USA
SN 1090-0535
J9 MOL VIS
JI Mol. Vis.
PD OCT 5
PY 2010
VL 16
IS 213
BP 1958
EP 1981
PG 24
WC Biochemistry & Molecular Biology; Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Ophthalmology
GA 674DU
UT WOS:000283715100001
PM 21031019
DA 2022-11-30
ER

PT J
AU Ergun, E
   Maar, N
   Ansari-Shahrezaei, S
   Wimpissinger, B
   Krepler, K
   Wedrich, A
   Stur, M
AF Ergun, Erdem
   Maar, Noemi
   Ansari-Shahrezaei, Siamak
   Wimpissinger, Barbara
   Krepler, Katharina
   Wedrich, Andreas
   Stur, Michael
TI Photodynamic therapy with verteporfin and intravitreal triamcinolone
   acetonide in the treatment of neovascular age-related macular
   degeneration
SO AMERICAN JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
ID SUBFOVEAL CHOROIDAL NEOVASCULARIZATION; BRUCHS MEMBRANE; MACROPHAGES
AB PURPOSE: To examine the efficacy of photodynamic therapy (PDT) with verteporfin and intravitreal triamcinolone acetonide in the treatment of neovascular age-related macular degeneration (AMD).
   DESIGN: Retrospective, interventional case series.
   METHODS: Sixty eyes of 56 patients with neovascular AMD were treated with PDT with verteporfin followed by an intravitreal injection of 4 mg triamcinolone ace, tonide. The main outcome measures were visual acuity (VA), retreatment frequency with PDT (and triamcinolone), and frequency of side effects.
   RESULTS: Mean follow,up was 15.9 months (range 12 to 30 months, median 15 months). Twenty-three (38.3%) of 60 eyes had a stable result at 12 months' follow,up (that is, loss/gain < three lines) and 34 (56.7%) of 60 had a loss of 3 lines or more. Three patients (5%) had an improvement of 3 lines or more. Lesion type, patient age, and lesion size had no influence on the outcome, but baseline VA had a statistically significant effect (P = .006). The median number of PDT-intravitreal triamcinolone acetonide treatments was one. One-third (20 of 60) of all eyes had an increase in intraocular pressure (IOP) that required therapy. There were no cases of endophthalmitis, but 13 patients (21.6%) developed severe cataract that required surgery.
   CONCLUSIONS: The combination of PDT and intravitreal triamcinolone acetonide requires careful consideration as a treatment option for neovascular AMD. In our case series, this treatment combination did not prevent a considerable decrease in VA. The main benefit of this combination treatment was a low number of verteporfin treatments. Baseline VA was the main predictor of the final outcome.
C1 Sanatorium Hera, Dept Ophthalmol, A-1090 Vienna, Austria.
   Univ Vienna, Dept Ophthalmol, A-1090 Vienna, Austria.
   Rudolf Fdn, Dept Ophthalmol, Vienna, Austria.
   Graz Univ, Dept Ophthalmol, Graz, Austria.
C3 University of Vienna; University of Graz
RP Ergun, E (通讯作者)，Sanatorium Hera, Dept Ophthalmol, Loeblichgasse 14, A-1090 Vienna, Austria.
EM erdem.ergun@chello.at
RI Wedrich, Andreas/AAE-9171-2020
CR [Anonymous], 1991, Arch Ophthalmol, V109, P1109
   [Anonymous], 1991, Arch Ophthalmol, V109, P1220
   Arnold J, 2001, OPHTHALMOLOGY, V108, P841
   Arnold J, 2001, AM J OPHTHALMOL, V131, P541
   Blumenkranz MS, 2001, ARCH OPHTHALMOL-CHIC, V119, P198
   Bok D, 2005, P NATL ACAD SCI USA, V102, P7053, DOI 10.1073/pnas.0502819102
   Boscia F, 2005, EUR J OPHTHALMOL, V15, P513, DOI 10.1177/112067210501500418
   Bressler NM, 2005, RETINA-J RET VIT DIS, V25, P119
   Bressler NM, 2002, ARCH OPHTHALMOL-CHIC, V120, P1307
   Bressler NM, 1999, ARCH OPHTHALMOL-CHIC, V117, P1329
   Challa JK, 1998, AUST NZ J OPHTHALMOL, V26, P277, DOI 10.1111/j.1442-9071.1998.tb01330.x
   Danis RP, 1996, OPHTHALMOLOGY, V103, P2099, DOI 10.1016/S0161-6420(96)30383-7
   Danis RP, 2000, RETINA-J RET VIT DIS, V20, P244, DOI 10.1097/00006982-200003000-00004
   DASTGHEIB K, 1994, ARCH OPHTHALMOL-CHIC, V112, P813, DOI 10.1001/archopht.1994.01090180111045
   Ergun E, 2004, WIEN KLIN WOCHENSCHR, V116, P737, DOI 10.1007/s00508-004-0262-2
   Greve MDJ, 2005, ARCH OPHTHALMOL-CHIC, V123, P448
   HAWKINS BS, 1993, ARCH OPHTHALMOL-CHIC, V111, P1200
   Jonas JB, 2004, BRIT J OPHTHALMOL, V88, P1557, DOI 10.1136/bjo.2003.039552
   KILLINGSWORTH MC, 1990, EYE, V4, P613, DOI 10.1038/eye.1990.86
   Kvanta A, 1996, INVEST OPHTH VIS SCI, V37, P1929
   MAGUIRE MG, 1994, ARCH OPHTHALMOL-CHIC, V112, P480
   MAGUIRE MG, 1986, ARCH OPHTHALMOL-CHIC, V104, P503
   Michels S, 2003, INVEST OPHTH VIS SCI, V44, P2147, DOI 10.1167/iovs.02-0604
   Oh H, 1999, INVEST OPHTH VIS SCI, V40, P1891
   Penfold PL, 1995, AUST NZ J OPHTHALMOL, V23, P293, DOI 10.1111/j.1442-9071.1995.tb00179.x
   Rechtman E, 2004, BRIT J OPHTHALMOL, V88, P344, DOI 10.1136/bjo.2003.027177
   Rubin GS, 2002, RETINA-J RET VIT DIS, V22, P536, DOI 10.1097/00006982-200210000-00002
   Schmidt-Erfurth U, 2000, SURV OPHTHALMOL, V45, P195, DOI 10.1016/S0039-6257(00)00158-2
   Sharma S, 2001, OPHTHALMOLOGY, V108, P2051, DOI 10.1016/S0161-6420(01)00764-3
   Smithen LM, 2004, AM J OPHTHALMOL, V138, P740, DOI 10.1016/j.ajo.2004.06.067
   Spaide RF, 2005, OPHTHALMOLOGY, V112, P301, DOI 10.1016/j.ophtha.2004.08.012
   Spaide RF, 2003, OPHTHALMOLOGY, V110, P1517, DOI 10.1016/S0161-6420(03)00544-X
   Sternberg P, 1996, ARCH OPHTHALMOL-CHIC, V114, P400
   Wormald R, 2005, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD002030.pub2
   Zawinka C, 2005, RETINA-J RET VIT DIS, V25, P324, DOI 10.1097/00006982-200504000-00012
NR 35
TC 28
Z9 35
U1 0
U2 2
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 0002-9394
EI 1879-1891
J9 AM J OPHTHALMOL
JI Am. J. Ophthalmol.
PD JUL
PY 2006
VL 142
IS 1
BP 10
EP 16
DI 10.1016/j.ajo.2006.02.048
PG 7
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 064HF
UT WOS:000239079100002
PM 16815246
DA 2022-11-30
ER

PT J
AU Corbelli, E
   Sacconi, R
   Battista, M
   Bacherini, D
   Miere, A
   Borrelli, E
   Costanzo, E
   Vella, G
   Parravano, M
   Ziccardi, L
   Sodi, A
   Rizzo, S
   Souied, EH
   Bandello, F
   Querques, G
AF Corbelli, Eleonora
   Sacconi, Riccardo
   Battista, Marco
   Bacherini, Daniela
   Miere, Alexandra
   Borrelli, Enrico
   Costanzo, Eliana
   Vella, Giovanna
   Parravano, Mariacristina
   Ziccardi, Lucia
   Sodi, Andrea
   Rizzo, Stanislao
   Souied, Eric H.
   Bandello, Francesco
   Querques, Giuseppe
TI Choroidal vascularity index in eyes with central macular atrophy
   secondary to age-related macular degeneration and Stargardt disease
SO GRAEFES ARCHIVE FOR CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY
LA English
DT Article
DE Age-related macular degeneration; Choroidal vascularity index;
   Geographic atrophy; Macular atrophy; Stargardt disease
ID INDOCYANINE GREEN ANGIOGRAPHY; DARK ATROPHY; COHERENCE; BINARIZATION;
   LIPOFUSCIN; MUTATIONS; AREA; AMD
AB Purpose To compare macular atrophy (MA) secondary to age-related macular degeneration (AMD) and Stargardt disease (STGD) using the choroidal vascularity index (CVI). Methods In this multicentric retrospective study, two distinct cohorts were collected: patients with MA secondary to AMD and MA secondary to STGD. All patients were investigated using a multimodal imaging approach, including CVI in the subfoveal 1000 mu m area. Of note, the CVI is not influenced by aging, which allows comparisons between different cohorts. Results Seventy eyes were included: 35 eyes of 35 patients (mean age 78 +/- 7 years) in the AMD group and 35 eyes of 35 patients (mean age 41 +/- 16 years, p < 0.001) in the STGD group. Choroidal thickness was significantly lower in the AMD group in comparison to the STGD group (151 +/- 80 mu m vs 353 +/- 105 mu m, p < 0.001). The total choroidal area (TCA) was significantly greater in the STGD group in comparison to the AMD group (1.734 +/- 0.958 mm(2) vs 0.538 +/- 0.391 mm(2), respectively, p < 0.001). Interestingly, the CVI was significantly lower in AMD patients in comparison to STGD patients (27.322 +/- 15.320% vs 49.880 +/- 7.217%, respectively, p < 0.001), and this difference was confirmed in the subgroup of patients over 50 years old. Conclusion Our results corroborate the hypothesis that large choroidal vessels were impaired to a greater extent in AMD than in STGD. CVI may help in differentiating AMD from STGD in the presence of MA, better understanding of the pathogenesis, and monitoring of therapeutic response.
C1 [Corbelli, Eleonora; Sacconi, Riccardo; Battista, Marco; Borrelli, Enrico; Bandello, Francesco; Querques, Giuseppe] Univ Vita Salute San Raffaele, Sch Med, Milan, Italy.
   [Corbelli, Eleonora; Sacconi, Riccardo; Battista, Marco; Borrelli, Enrico; Vella, Giovanna; Bandello, Francesco; Querques, Giuseppe] IRCCS, Div Head & Neck, Ophthalmol Unit, San Raffaele Sci Inst, Milan, Italy.
   [Bacherini, Daniela; Sodi, Andrea] Univ Florence, Dept Neurosci, AOU Careggi, Psychol Drug Res & Child Hlth Eye Clin, Florence, Italy.
   [Miere, Alexandra; Souied, Eric H.] Univ Paris Est Creteil, Dept Ophthalmol, Hosp Intercommunal Creteil, Creteil, France.
   [Costanzo, Eliana; Parravano, Mariacristina; Ziccardi, Lucia] Fdn GB Bietti IRCCS, Rome, Italy.
   [Vella, Giovanna] Univ Pisa, Dept Surg Med Mol Pathol & Crit Area, Ophthalmol, Pisa, Italy.
   [Rizzo, Stanislao] Fdn Policlin Univ A Gemelli IRCCS, UOC Oculist, Rome, Italy.
   [Rizzo, Stanislao] Univ Cattolica Sacro Cuore, Rome, Italy.
   [Rizzo, Stanislao] CNR, Ist Neurosci, Pisa, Italy.
C3 Vita-Salute San Raffaele University; Vita-Salute San Raffaele
   University; IRCCS Ospedale San Raffaele; University of Florence; Azienda
   Ospedaliero Universitaria Careggi; Universite
   Paris-Est-Creteil-Val-de-Marne (UPEC); CHI Creteil; IRCCS - Fondazione
   "G.B. Bietti" per lo Studio e la Ricerca in Oftalmologia; University of
   Pisa; Catholic University of the Sacred Heart; IRCCS Policlinico
   Gemelli; Catholic University of the Sacred Heart; IRCCS Policlinico
   Gemelli; Consiglio Nazionale delle Ricerche (CNR); Istituto di
   Neuroscienze (IN-CNR)
RP Querques, G (通讯作者)，Univ Vita Salute San Raffaele, Sch Med, Milan, Italy.; Querques, G (通讯作者)，IRCCS, Div Head & Neck, Ophthalmol Unit, San Raffaele Sci Inst, Milan, Italy.
EM giuseppe.querques@hotmail.it
RI Miere, Alexandra/AIC-4074-2022
OI Miere, Alexandra/0000-0003-4123-8210; Sacconi,
   Riccardo/0000-0003-2891-2012
CR Agrawal R, 2017, ACTA OPHTHALMOL, V95, pe770, DOI 10.1111/aos.13442
   Agrawal R, 2016, SCI REP-UK, V6, DOI 10.1038/srep21090
   Bandello Francesco, 2017, F1000Res, V6, P245, DOI 10.12688/f1000research.10664.1
   Bhutto I, 2012, MOL ASPECTS MED, V33, P295, DOI 10.1016/j.mam.2012.04.005
   Breher K, 2020, TRANSL VIS SCI TECHN, V9, DOI 10.1167/tvst.9.11.8
   Cideciyan AV, 2004, HUM MOL GENET, V13, P525, DOI 10.1093/hmg/ddh048
   Corbelli E, 2017, INVEST OPHTH VIS SCI, V58, P5201, DOI 10.1167/iovs.17-22508
   FISH G, 1981, BRIT J OPHTHALMOL, V65, P359, DOI 10.1136/bjo.65.5.359
   Fishman GA, 1999, ARCH OPHTHALMOL-CHIC, V117, P504, DOI 10.1001/archopht.117.4.504
   Giani A, 2012, INVEST OPHTH VIS SCI, V53, P3999, DOI 10.1167/iovs.11-9258
   Giannaccare G, 2020, RETINA-J RET VIT DIS, V40, P960, DOI 10.1097/IAE.0000000000002459
   Goud A, 2019, INVEST OPHTH VIS SCI, V60, P3563, DOI 10.1167/iovs.18-26381
   Gune S, 2020, OPHTHALMOLOGY, V127, P523, DOI 10.1016/j.ophtha.2019.09.030
   Iovino C, 2020, J CLIN MED, V9, DOI 10.3390/jcm9020595
   Iovino C, 2019, INVEST OPHTH VIS SCI, V60, P5000, DOI 10.1167/iovs.19-27300
   Klevering BJ, 2005, GRAEF ARCH CLIN EXP, V243, P90, DOI 10.1007/s00417-004-1079-4
   Kocak N, 2021, INT OPHTHALMOL, V41, P825, DOI 10.1007/s10792-020-01636-6
   Machalinska A, 2012, ACTA OPHTHALMOL, V90, P695, DOI 10.1111/j.1755-3768.2011.02295.x
   Mata NL, 2000, P NATL ACAD SCI USA, V97, P7154, DOI 10.1073/pnas.130110497
   Nivison-Smith L, 2020, SCI REP-UK, V10, DOI 10.1038/s41598-020-67829-2
   Nunes RP, 2015, OSLI RETINA, V46, P814, DOI 10.3928/23258160-20150909-05
   Parodi MB, 2019, GRAEF ARCH CLIN EXP, V257, P41, DOI 10.1007/s00417-018-4167-6
   Pellegrini M, 2016, OPHTHALMOLOGY, V123, P1879, DOI 10.1016/j.ophtha.2016.05.041
   Ratra D, 2018, RETINA-J RET VIT DIS, V38, P2395, DOI 10.1097/IAE.0000000000001879
   Rizzo S, 2018, ACTA OPHTHALMOL, V96, pE950, DOI 10.1111/aos.13776
   Sacconi R, 2021, BRIT J OPHTHALMOL, V105, P97, DOI 10.1136/bjophthalmol-2019-315800
   Sacconi R, 2018, RETINA-J RET VIT DIS, V38, P2350, DOI 10.1097/IAE.0000000000001873
   Sacconi R, 2017, OPHTHALMOL THER, V6, P69, DOI 10.1007/s40123-017-0086-6
   Schwoerer J, 2000, OPHTHALMOLOGICA, V214, P240, DOI 10.1159/000027498
   Sonoda S, 2015, AM J OPHTHALMOL, V159, P1123, DOI 10.1016/j.ajo.2015.03.005
   Sonoda S, 2014, INVEST OPHTH VIS SCI, V55, P3893, DOI 10.1167/iovs.14-14447
   Wang DL, 2019, OPHTHALMOL RETINA, V3, P1035, DOI 10.1016/j.oret.2019.07.016
   Wei X, 2019, ACTA OPHTHALMOL, V97, pE116, DOI 10.1111/aos.13836
   Wei X, 2017, RETINA-J RET VIT DIS, V37, P1120, DOI 10.1097/IAE.0000000000001312
   Zhou H, 2020, OPHTHALMOL RETINA, V4, P204, DOI 10.1016/j.oret.2019.09.012
NR 35
TC 2
Z9 2
U1 0
U2 2
PU SPRINGER
PI NEW YORK
PA ONE NEW YORK PLAZA, SUITE 4600, NEW YORK, NY, UNITED STATES
SN 0721-832X
EI 1435-702X
J9 GRAEF ARCH CLIN EXP
JI Graefes Arch. Clin. Exp. Ophthalmol.
PD MAY
PY 2022
VL 260
IS 5
BP 1525
EP 1534
DI 10.1007/s00417-021-05337-3
EA JAN 2022
PG 10
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 0M9EN
UT WOS:000744375300001
PM 35048199
DA 2022-11-30
ER

PT J
AU Huang, YM
   Dou, HL
   Huang, FF
   Xu, XR
   Zou, ZY
   Lin, XM
AF Huang, Yang-Mu
   Dou, Hong-Liang
   Huang, Fei-Fei
   Xu, Xian-Rong
   Zou, Zhi-Yong
   Lin, Xiao-Ming
TI Effect of Supplemental Lutein and Zeaxanthin on Serum, Macular
   Pigmentation, and Visual Performance in Patients with Early Age-Related
   Macular Degeneration
SO BIOMED RESEARCH INTERNATIONAL
LA English
DT Article
ID OPTICAL-DENSITY; EYE DISEASE; ACUITY; CAROTENOIDS
AB Purpose. To compare the 2-year effect of multiple doses of lutein/zeaxanthin on serum, macular pigmentation, and visual performance on patients with early age-related macular degeneration (AMD). Methods. In this randomized, double-blinded, and placebo-controlled trial, 112 early AMD patients randomly received either 10 mg lutein, 20 mg lutein, a combination of lutein (10 mg) and zeaxanthin (10 mg), or placebo daily for 2 years. Serum concentration of lutein/zeaxanthin, macular pigment optical density (MPOD), visual functions including best-spectacle corrected visual acuity (BCVA), contrast sensitivity (CS), flash recovery time (FRT), and vision-related quality of life (VFQ25) was quantified. Results. Serum lutein concentration and MPOD significantly increased in all the active treatment groups. Supplementation with 20 mg lutein was the most effective in increasing MPOD and CS at 3 cycles/degree for the first 48 weeks. However, they both significantly increased to the same peak value following supplementation with either 10 mg or 20 mg lutein during the intervention. No statistical changes of BCVA or FRT were observed during the trial. Conclusions. Long-term lutein supplementation could increase serum lutein concentration, MPOD, and visual sensitivities of early AMD patients. 10 mg lutein daily might be an advisable long-term dosage for early AMD treatment.
C1 [Huang, Yang-Mu; Huang, Fei-Fei; Xu, Xian-Rong; Zou, Zhi-Yong; Lin, Xiao-Ming] Peking Univ, Hlth Sci Ctr, Beijing 100191, Peoples R China.
   [Dou, Hong-Liang] Peking Univ, Hosp 3, Ctr Eye, Beijing 100191, Peoples R China.
C3 Peking University; Peking University
RP Dou, HL (通讯作者)，Peking Univ, Hosp 3, Ctr Eye, 49 Huayuan North Rd, Beijing 100191, Peoples R China.
EM douhongliang3736@sina.cn; linbjmu@bjmu.edu.cn
RI Zou, Zhiyong/P-8066-2019
OI Zou, Zhiyong/0000-0001-5049-5425; Huang, Yangmu/0000-0002-3660-1276
FU National Natural Science Foundation of China [81273063]
FX The authors gratefully acknowledge the financial support from the
   National Natural Science Foundation of China (Grant no. 81273063).
CR Avery RL, 2007, LANCET, V370, P1479, DOI 10.1016/S0140-6736(07)61625-0
   Bartlett HE, 2008, CLIN NUTR, V27, P218, DOI 10.1016/j.clnu.2008.01.003
   Bhosale P, 2009, BIOCHEMISTRY-US, V48, P4798, DOI 10.1021/bi9004478
   Bone RA, 2003, J NUTR, V133, P992, DOI 10.1093/jn/133.4.992
   Bone RA, 2010, ARCH BIOCHEM BIOPHYS, V504, P50, DOI 10.1016/j.abb.2010.06.019
   Cangemi Francis E, 2007, BMC Ophthalmol, V7, P3, DOI 10.1186/1471-2415-7-3
   Carpentier S, 2009, CRIT REV FOOD SCI, V49, P313, DOI 10.1080/10408390802066979
   Chan CWS, 2009, BRIT J OPHTHALMOL, V93, P1431, DOI 10.1136/bjo.2009.158428
   Chew EY, 2013, JAMA-J AM MED ASSOC, V309, P2005, DOI 10.1001/jama.2013.4997
   Chew EY, 2012, OPHTHALMOLOGY, V119, P2282, DOI 10.1016/j.ophtha.2012.05.027
   Chopdar A, 2003, BRIT MED J, V326, P485, DOI 10.1136/bmj.326.7387.485
   Davis MD, 2005, ARCH OPHTHALMOL-CHIC, V123, P1484
   Huang YM, 2013, NUTRITION, V29, P387, DOI 10.1016/j.nut.2012.06.009
   Jeganathan VSE, 2009, CURR OPIN OPHTHALMOL, V20, P223, DOI 10.1097/ICU.0b013e328329b656
   Krinsky NI, 2003, ANNU REV NUTR, V23, P171, DOI 10.1146/annurev.nutr.23.011702.073307
   Kuo HK, 2011, GRAEF ARCH CLIN EXP, V249, P601, DOI 10.1007/s00417-010-1461-3
   Li BX, 2010, PHOTOCH PHOTOBIO SCI, V9, P1418, DOI 10.1039/c0pp00126k
   Lim LS, 2012, LANCET, V379, P1728, DOI 10.1016/S0140-6736(12)60282-7
   Lois N, 2000, BRIT J OPHTHALMOL, V84, P741, DOI 10.1136/bjo.84.7.741
   Loughman J, 2010, VISION RES, V50, P1249, DOI 10.1016/j.visres.2010.04.009
   Ma L, 2012, OPHTHALMOLOGY, V119, P2290, DOI 10.1016/j.ophtha.2012.06.014
   Ma L, 2012, AM J OPHTHALMOL, V154, P625, DOI 10.1016/j.ajo.2012.04.014
   Ma L, 2012, BRIT J NUTR, V107, P350, DOI 10.1017/S0007114511004260
   Murray IJ, 2013, INVEST OPHTH VIS SCI, V54, P1781, DOI 10.1167/iovs.12-10715
   Neuringer M, 2004, INVEST OPHTH VIS SCI, V45, P3234, DOI 10.1167/iovs.02-1243
   Newsome DA, 2009, CURR EYE RES, V34, P162, DOI 10.1080/02713680802647654
   Nolan JM, 2011, VISION RES, V51, P459, DOI 10.1016/j.visres.2010.12.016
   Revicki DA, 2010, INVEST OPHTH VIS SCI, V51, P712, DOI 10.1167/iovs.09-3766
   Richer Stuart, 2004, Optometry, V75, P216, DOI 10.1016/S1529-1839(04)70049-4
   Richer SP, 2011, OPTOMETRY, V82, P667, DOI 10.1016/j.optm.2011.08.008
   ROMANCHIK JE, 1995, J NUTR, V125, P2610
   Rosenthal JM, 2006, INVEST OPHTH VIS SCI, V47, P5227, DOI 10.1167/iovs.05-1513
   Sasamoto Y, 2011, GRAEF ARCH CLIN EXP, V249, P1847, DOI 10.1007/s00417-011-1780-z
   Stringham JM, 2005, NUTR REV, V63, P59, DOI 10.1111/j.1753-4887.2005.tb00122.x
   Trieschmann M, 2006, GRAEF ARCH CLIN EXP, V244, P1565, DOI 10.1007/s00417-006-0289-3
   Trieschmann M, 2007, EXP EYE RES, V84, P718, DOI 10.1016/j.exer.2006.12.010
   Weigert G, 2011, INVEST OPHTH VIS SCI, V52, P8174, DOI 10.1167/iovs.11-7522
   Woo JH, 2009, EYE, V23, P2271, DOI 10.1038/eye.2009.4
   Wooten BR, 2002, PROG RETIN EYE RES, V21, P225, DOI 10.1016/S1350-9462(02)00003-4
NR 39
TC 37
Z9 37
U1 2
U2 27
PU HINDAWI LTD
PI LONDON
PA ADAM HOUSE, 3RD FLR, 1 FITZROY SQ, LONDON, W1T 5HF, ENGLAND
SN 2314-6133
EI 2314-6141
J9 BIOMED RES INT
JI Biomed Res. Int.
PY 2015
VL 2015
AR 564738
DI 10.1155/2015/564738
PG 8
WC Biotechnology & Applied Microbiology; Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biotechnology & Applied Microbiology; Research & Experimental Medicine
GA CD8VX
UT WOS:000351375600001
PM 25815324
OA Green Published, Green Submitted, gold
DA 2022-11-30
ER

PT J
AU Stolba, U
   Krebs, I
   Lamar, PD
   Aggermann, T
   Gruber, D
   Binder, S
AF Stolba, U
   Krebs, I
   Lamar, PD
   Aggermann, T
   Gruber, D
   Binder, S
TI Long term results after transpupillary thermotherapy in eyes with occult
   choroidal neovascularisation associated with age related macular
   degeneration: a prospective trial
SO BRITISH JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
AB Aim: To evaluate long term results after transpupillary thermotherapy (TTT) in eyes with exudative age related macular degeneration.
   Methods: In a prospective clinical study eyes with occult or predominantly occult choroidal neovascularisation and no pretreatment were scheduled to have a TTT with a power of 630 mW. Visual acuity for far and near distances as well as contrast sensitivity were evaluated 6, 12, and 24 months postoperatively and statistically analysed.
   Results: 47 eyes fulfilled the inclusion criteria. Overall, 70% of the patients showed an improved (14%) or had unchanged (56%) ETDRS vision after 24 months. Reading vision was stabilised (51%) or better ( 5%) in 56% of the eyes at this time. However, the increasing number of eyes with severe deterioration resulted in a significant decrease of both parameters over time (p = 0.0002 and p = 0.0003, respectively). Contrast sensitivity could be maintained (70%) or improved (9%) in 79%. Statistical analyses indicated a trend but no significant decrease over time (p = 0.056).
   Conclusion: Although in the majority of patients far and near distance acuity could be stabilised on average a significant decrease over time after TTT was observed. Statistical comparison of months 12 and 24 showed no further deterioration.
C1 Rudolf Fdn Hosp, Dept Ophthalmol, A-1030 Vienna, Austria.
   Rudolf Fdn Hosp, Ludwig Boltzmann Inst Retinol & Biomicroscop Lase, A-1030 Vienna, Austria.
   Univ Vienna, Inst Med Stat, A-1090 Vienna, Austria.
C3 Ludwig Boltzmann Institute; University of Vienna
RP Stolba, U (通讯作者)，Rudolf Fdn Hosp, Dept Ophthalmol, Juchgasse 25, A-1030 Vienna, Austria.
EM ulrike.stolba@wienkav.at
CR Ahuja R M, 2001, Semin Ophthalmol, V16, P81, DOI 10.1076/soph.16.2.81.4215
   Algvere P V, 2001, Semin Ophthalmol, V16, P90, DOI 10.1076/soph.16.2.90.4210
   Algvere PV, 2003, ACTA OPHTHALMOL SCAN, V81, P110, DOI 10.1034/j.1600-0420.2003.00041.x
   Arnold J, 2001, AM J OPHTHALMOL, V131, P541
   Atarashi T, 2004, EYE, V18, P615, DOI 10.1038/sj.eye.6700733
   Auer C, 2002, KLIN MONATSBL AUGENH, V219, P250, DOI 10.1055/s-2002-30649
   Benhamou N, 2004, AM J OPHTHALMOL, V137, P1132, DOI 10.1016/j.ajo.2003.12.044
   Benner JD, 2002, AM J OPHTHALMOL, V134, P765, DOI 10.1016/S0002-9394(02)01694-X
   Blumenkranz MS, 2001, ARCH OPHTHALMOL-CHIC, V119, P198
   Bressler NM, 1999, ARCH OPHTHALMOL-CHIC, V117, P1329
   BRESSLER NM, 1988, ARCH OPHTHALMOL-CHIC, V106, P1537, DOI 10.1001/archopht.1988.01060140705039
   COLEMAN DJ, 1988, OPHTHALMOLOGY, V95, P970
   Connolly BP, 2001, INVEST OPHTH VIS SCI, V42, pS513
   FERRIS FL, 1983, AM J EPIDEMIOL, V118, P132, DOI 10.1093/oxfordjournals.aje.a113624
   Greuloch K, 2003, CAN J OPHTHALMOL, V38, P308, DOI 10.1016/S0008-4182(03)80100-X
   JourneedeKorver JG, 1997, BRIT J OPHTHALMOL, V81, P234, DOI 10.1136/bjo.81.3.234
   Kim J E, 2001, Semin Ophthalmol, V16, P86, DOI 10.1076/soph.16.2.86.4212
   Klein R, 1997, OPHTHALMOLOGY, V104, P7, DOI 10.1016/S0161-6420(97)30368-6
   Krebs I, 2004, OPHTHALMOLOGICA, V218, P185, DOI 10.1159/000076843
   *MAC PHOT STUD GRO, 1993, ARCH OPHTHALMOL-CHIC, V11, P1200
   MAINSTER MA, 1970, J OPT SOC AM, V60, P264, DOI 10.1364/JOSA.60.000264
   Nagpal Manish, 2003, Indian Journal of Ophthalmology, V51, P243
   Newsom RSB, 2001, BRIT J OPHTHALMOL, V85, P173, DOI 10.1136/bjo.85.2.173
   OOSTERHUIS JA, 1995, ARCH OPHTHALMOL-CHIC, V113, P315, DOI 10.1001/archopht.1995.01100030071024
   Park C H, 2001, Semin Ophthalmol, V16, P66, DOI 10.1076/soph.16.2.66.4208
   PULIAFITO CA, 1987, ARCH OPHTHALMOL-CHIC, V105, P424
   Reichel E, 1999, OPHTHALMOLOGY, V106, P1908, DOI 10.1016/S0161-6420(99)90400-1
   Shields CL, 1998, OPHTHALMOLOGY, V105, P581, DOI 10.1016/S0161-6420(98)94008-8
   Sternberg P, 1996, ARCH OPHTHALMOL-CHIC, V114, P400
   Thach AB, 2003, ARCH OPHTHALMOL-CHIC, V121, P817, DOI 10.1001/archopht.121.6.817
   Tranos P, 2004, ACTA OPHTHALMOL SCAN, V82, P585, DOI 10.1111/j.1600-0420.2004.00327.x
NR 31
TC 9
Z9 16
U1 0
U2 2
PU BMJ PUBLISHING GROUP
PI LONDON
PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND
SN 0007-1161
EI 1468-2079
J9 BRIT J OPHTHALMOL
JI Br. J. Ophthalmol.
PD FEB
PY 2006
VL 90
IS 2
BP 158
EP 161
DI 10.1136/bjo.2005.076422
PG 4
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 003ZH
UT WOS:000234721300011
PM 16424525
OA Green Published
DA 2022-11-30
ER

PT J
AU Catchpole, I
   Germaschewski, V
   Kam, JH
   von Leithner, PL
   Ford, S
   Gough, G
   Adamson, P
   Overend, P
   Hilpert, J
   Lopez, FJ
   Ng, YSE
   Coffey, P
   Jeffery, G
AF Catchpole, Ian
   Germaschewski, Volker
   Kam, Jaimie Hoh
   von Leithner, Peter Lundh
   Ford, Susannah
   Gough, Gerald
   Adamson, Peter
   Overend, Philip
   Hilpert, Jan
   Lopez, Francisco J.
   Ng, Yin Shan Eric
   Coffey, Pete
   Jeffery, Glen
TI Systemic Administration of Abeta mAb Reduces Retinal Deposition of Abeta
   and Activated Complement C3 in Age-Related Macular Degeneration Mouse
   Model
SO PLOS ONE
LA English
DT Article
ID AMYLOID PRECURSOR PROTEIN; ALZHEIMERS-DISEASE; FACTOR-H; BETA; DRUSEN;
   POLYMORPHISM; PATHOGENESIS; ASSOCIATION; PATHOLOGY; BRAIN
AB Age-related macular degeneration (AMD) is a leading cause of legal blindness in the Western world. There are effective treatments for the vascular complications of neo-vascular AMD, but no effective therapies are available for the dry/atrophic form of the disease. A previously described transgenic CFH-gene deficient mouse model, (cfh-/-), shows hallmarks of early AMD. The ocular phenotype has been further analysed to demonstrate amyloid beta (A beta) rich basement membrane deposits associated with activated complement C3. Cfh-/- mice were treated systemically in both prophylactic and therapeutic regimes with an anti-A beta monoclonal antibody (mAb), 6F6, to determine the effect on the cfh-/- retinal phenotype. Prophylactic treatment with 6F6 demonstrated a dose dependent reduction in the accumulation of both A beta and activated C3 deposition. A similar reduction in the retinal endpoints could be seen after therapeutic treatment. Serum A beta levels after systemic administration of 6F6 show accumulation of Ab in the periphery suggestive of a peripheral sink mechanism. In summary, anti-A beta mAb treatment can partially prevent or reverse ocular phenotypes of the cfh-/- mouse. The data support this therapeutic approach in humans potentially modulating two key elements in the pathogenesis of AMD - A beta and activated, complement C3.
C1 [Catchpole, Ian; Germaschewski, Volker; Ford, Susannah; Gough, Gerald] Top BioPharm Discovery Res & Dev Unit, King Of Prussia, PA USA.
   [Kam, Jaimie Hoh; von Leithner, Peter Lundh; Ng, Yin Shan Eric; Coffey, Pete; Jeffery, Glen] UCL, Inst Ophthalmol, London, England.
   [Catchpole, Ian; Adamson, Peter; Lopez, Francisco J.] GSK Ophthalmol, King Of Prussia, PA USA.
   [Overend, Philip; Hilpert, Jan] GlaxoSmithKline, BioPharm Discovery Med, Stevenage, Herts, England.
C3 University of London; University College London; GlaxoSmithKline;
   GlaxoSmithKline
RP Catchpole, I (通讯作者)，Top BioPharm Discovery Res & Dev Unit, King Of Prussia, PA USA.
EM ian.r.catchpole@gsk.com
OI Ng, Yin Shan/0000-0002-4982-1999; Coffey, Peter/0000-0002-5427-2939
FU GSK
FX JHK, PLvL, PC & GJ received funding from GSK for this work which was
   performed collaboratively by Institute of Ophthalmology and GSK
   researchers. The funders were actively involved in study design, some
   aspects of experimental end point analysis and in rigorous statistical
   analysis of the data and jointly decided to publish and prepare the
   manuscript with their academic colleagues.; IC, VG, SF, GG, PA, PO, JH
   are or were during some stage of this work employed by GSK who funded
   this study. GSK owns intellectual property on anti-amyloid beta
   monoclonal antibodies. This does not alter the authors' adherence to all
   the PLOS ONE policies on sharing data and materials.
CR Anderson DH, 2004, EXP EYE RES, V78, P243, DOI 10.1016/j.exer.2003.10.011
   Baker ML, 2009, ARCH OPHTHALMOL-CHIC, V127, P667, DOI 10.1001/archophthalmol.2009.30
   Baumritter A, 2007, ARVO M AG EYE MAY 6
   BENJAMINI Y, 1995, J R STAT SOC B, V57, P289, DOI 10.1111/j.2517-6161.1995.tb02031.x
   Bowes Rickman C, 2007, 11 ANN VIS RES C RET
   Coffey PJ, 2007, P NATL ACAD SCI USA, V104, P16651, DOI 10.1073/pnas.0705079104
   Combadiere C, 2007, J CLIN INVEST, V117, P2920, DOI 10.1172/JCI31692
   Dentchev T, 2003, MOL VIS, V9, P184
   Ding JD, 2008, VISION RES, V48, P339, DOI 10.1016/j.visres.2007.07.025
   Ding JD, 2011, P NATL ACAD SCI USA, V108, pE279, DOI 10.1073/pnas.1100901108
   Dutescu RM, 2009, GRAEF ARCH CLIN EXP, V247, P1213, DOI 10.1007/s00417-009-1060-3
   Hageman GS, 2001, PROG RETIN EYE RES, V20, P705, DOI 10.1016/S1350-9462(01)00010-6
   Hamilton G, 2007, NEUROMOL MED, V9, P331, DOI 10.1007/s12017-007-8013-y
   He XY, 2007, J NEUROSCI, V27, P4052, DOI 10.1523/JNEUROSCI.3993-06.2007
   Hoh Kam J, 2012, PATHOGENS TRIG UNPUB
   Howlett DR, 2011, EXP BRAIN RES, V214, P185, DOI 10.1007/s00221-011-2819-4
   Isas JM, 2010, INVEST OPHTH VIS SCI, V51, P1304, DOI 10.1167/iovs.09-4207
   Johnson LV, 2001, EXP EYE RES, V73, P887, DOI 10.1006/exer.2001.1094
   Johnson LV, 2002, P NATL ACAD SCI USA, V99, P11830, DOI 10.1073/pnas.192203399
   Kam JH, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0013127
   KEARNEY JF, 1979, J IMMUNOL, V123, P1548
   Klaver CCW, 1999, AM J EPIDEMIOL, V150, P963
   Kliffen M, 2000, BRIT J OPHTHALMOL, V84, P1415, DOI 10.1136/bjo.84.12.1415
   Koronyo-Hamaoui M, 2011, NEUROIMAGE, V54, pS204, DOI 10.1016/j.neuroimage.2010.06.020
   Le Fur I, 2010, NEUROBIOL AGING, V31, P165, DOI 10.1016/j.neurobiolaging.2008.03.003
   Ling CY, 2008, International Patent Application, Patent No. [WO 2008/110885, 2008110885]
   Liu BQ, 2009, AM J PATHOL, V175, P2099, DOI 10.2353/ajpath.2009.090159
   Liu TR, 2013, INVEST OPHTHMOL VIS, V54, P2225
   LOFFLER KU, 1995, INVEST OPHTH VIS SCI, V36, P24
   Luibl V, 2006, J CLIN INVEST, V116, P378, DOI 10.1172/JCI25843
   Malek G, 2005, P NATL ACAD SCI USA, V102, P11900, DOI 10.1073/pnas.0503015102
   Mullins RF, 2000, FASEB J, V14, P835, DOI 10.1096/fasebj.14.7.835
   Ning A, 2008, INVEST OPHTH VIS SCI, V49, P5136, DOI 10.1167/iovs.08-1849
   Ohno-Matsui K, 2011, PROG RETIN EYE RES, V30, P217, DOI 10.1016/j.preteyeres.2011.02.004
   Perez SE, 2009, INVEST OPHTH VIS SCI, V50, P793, DOI 10.1167/iovs.08-2384
   Petrukhin K, 2007, EXPERT OPIN THER TAR, V11, P625, DOI 10.1517/14728222.11.5.625
   Puzzo D, 2013, J ALZHEIMERS DIS, V33, pS111, DOI 10.3233/JAD-2012-129033
   Puzzo D, 2012, NEUROBIOL AGING, V33, DOI 10.1016/j.neurobiolaging.2011.12.020
   Rodrigues EB, 2007, OPHTHALMOLOGICA, V221, P143, DOI 10.1159/000099293
   Rosenthal A, 2004, International Patent Application, Patent No. [WO 2004/032868, 2004032868]
   Schenk D, 1999, NATURE, V400, P173, DOI 10.1038/22124
   Terai K, 2001, NEUROSCIENCE, V104, P299, DOI 10.1016/S0306-4522(01)00095-1
   von Leithner PL, 2009, AM J PATHOL, V175, P412, DOI 10.2353/ajpath.2009.080927
   Wang J, 2008, J IMMUNOL, V181, P16651
   Wang JY, 2009, J CELL PHYSIOL, V220, P119, DOI 10.1002/jcp.21742
   Yang SP, 2004, NEUROBIOL AGING, V25, P283, DOI 10.1016/S0197-4580(03)00111-8
   Yoshida T, 2005, J CLIN INVEST, V115, P2793, DOI 10.1172/JCI24635
   Zetterberg M, 2008, AM J MED GENET B, V147B, P720, DOI 10.1002/ajmg.b.30668
   Zlokovic BV, 2004, J NEUROCHEM, V89, P807, DOI 10.1111/j.1471-4159.2004.02385.x
NR 49
TC 27
Z9 29
U1 0
U2 7
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD JUN 14
PY 2013
VL 8
IS 6
AR e65518
DI 10.1371/journal.pone.0065518
PG 16
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA 163UV
UT WOS:000320363300020
PM 23799019
OA Green Published, Green Submitted, gold
DA 2022-11-30
ER

PT J
AU Moon, BG
   Joe, SG
   Hwang, JU
   Kim, HK
   Choe, J
   Yoon, YH
AF Moon, Byung Gil
   Joe, Soo Geun
   Hwang, Jong-uk
   Kim, Hong Kyu
   Choe, Jaewon
   Yoon, Young Hee
TI Prevalence and Risk Factors of Early-Stage Age-Related Macular
   Degeneration in Patients Examined at a Health Promotion Center in Korea
SO JOURNAL OF KOREAN MEDICAL SCIENCE
LA English
DT Article
DE Age-Related Macular Degeneration; Gealth Screening Examination; Risk
   Factors
ID BEAVER DAM EYE; RURAL-POPULATION; MACULOPATHY; SMOKING; INDIA
AB We evaluated the prevalence and risk factors for early age-related macular degeneration (AMD) in Koreans 50 yr of age or older who were examined at a single health promotion center. We retrospectively reviewed the records of 10,449 subjects who visited the center over a 6-month period. Fundus photography was performed on all subjects, and systematic risk factor analysis was conducted using a structured questionnaire. All patients (n = 322) were initially diagnosed with drusen or early AMD using fundoscopy; the control group (n = 10,127) were those yielding normal fundoscopy findings. The age-and gender-adjusted prevalence of early AMD was 3.08%. Advanced age, male gender, smoking status, hyperlipidemia, working outdoors, and residence in rural areas were all significantly associated with an increased risk for development of early AMD. Higher-level ingestion of fruit or herbal medication and an increased amount of exercise were associated with a lower risk of early AMD development. In our Korean cohort, consisting principally of relatively healthy, middle-class urban adults, the prevalence of early AMD was 3.08% that is similar to that reported in earlier epidemiological studies. Several modifiable risk factors such as smoking and hyperlipidemia are associated with the prevalence of early AMD in our cohort.
C1 [Moon, Byung Gil; Joe, Soo Geun; Hwang, Jong-uk; Yoon, Young Hee] Univ Ulsan, Coll Med, Asan Med Ctr, Dept Ophthalmol, Seoul 138736, South Korea.
   [Kim, Hong Kyu; Choe, Jaewon] Univ Ulsan, Coll Med, Asan Med Ctr, Hlth Promot Ctr, Seoul 138736, South Korea.
C3 University of Ulsan; Asan Medical Center; University of Ulsan; Asan
   Medical Center
RP Yoon, YH (通讯作者)，Univ Ulsan, Coll Med, Asan Med Ctr, Dept Ophthalmol, 88 Olymp Ro 43 Gil, Seoul 138736, South Korea.
EM yhyoon@amc.seoul.kr
CR Augood CA, 2006, ARCH OPHTHALMOL-CHIC, V124, P529, DOI 10.1001/archopht.124.4.529
   BIRD AEC, 1995, SURV OPHTHALMOL, V39, P367, DOI 10.1016/S0039-6257(05)80092-X
   Chen SJ, 2008, INVEST OPHTH VIS SCI, V49, P3126, DOI 10.1167/iovs.08-1803
   Cohen SY, 2007, BRIT J OPHTHALMOL, V91, P1173, DOI 10.1136/bjo.2007.115501
   Fraser-Bell S, 2006, AM J OPHTHALMOL, V141, P79, DOI 10.1016/j.ajo.2005.08.024
   Gupta SK, 2007, INVEST OPHTH VIS SCI, V48, P1007, DOI 10.1167/iovs.06-0712
   Haines JL, 2005, SCIENCE, V308, P419, DOI 10.1126/science.1110359
   Kernt M, 2010, OPHTHALMOLOGE, V107, P150, DOI 10.1007/s00347-009-1945-x
   Klein R, 1998, AM J EPIDEMIOL, V147, P103
   KLEIN R, 1992, OPHTHALMOLOGY, V99, P933
   Klein R, 2008, ARCH OPHTHALMOL-CHIC, V126, P115, DOI 10.1001/archopht.126.1.115
   Li YB, 2006, AM J OPHTHALMOL, V142, P788, DOI 10.1016/j.ajo.2006.06.001
   Liu Y, 2007, GRAEF ARCH CLIN EXP, V245, P1441, DOI 10.1007/s00417-007-0575-8
   MITCHELL P, 1995, OPHTHALMOLOGY, V102, P1450
   Morris B, 2007, POSTGRAD MED J, V83, P301, DOI 10.1136/pgmj.2006.052944
   Nirmalan PK, 2004, ARCH OPHTHALMOL-CHIC, V122, P581, DOI 10.1001/archopht.122.4.581
   Oshima Y, 2001, BRIT J OPHTHALMOL, V85, P1153, DOI 10.1136/bjo.85.10.1153
   Pascolini D, 2004, OPHTHAL EPIDEMIOL, V11, P67, DOI 10.1076/opep.11.2.67.28158
   Pham TQ, 2009, OPHTHAL EPIDEMIOL, V16, P136, DOI 10.1080/09286580701299395
   SanGiovanni JP, 2007, ARCH OPHTHALMOL-CHIC, V125, P1225, DOI 10.1001/archopht.125.9.1225
   Song SJ, 2009, OPHTHAL EPIDEMIOL, V16, P304, DOI 10.3109/09286580902999413
   Tomany SC, 2004, OPHTHALMOLOGY, V111, P1280, DOI 10.1016/j.ophtha.2003.11.010
   Wong TY, 2006, BRIT J OPHTHALMOL, V90, P506, DOI 10.1136/bjo.2005.083733
NR 23
TC 19
Z9 20
U1 0
U2 7
PU KOREAN ACAD MEDICAL SCIENCES
PI SEOUL
PA 302 75 DONG DU ICHON, DONG YONGSAN KU, SEOUL 140 031, SOUTH KOREA
SN 1011-8934
J9 J KOREAN MED SCI
JI J. Korean Med. Sci.
PD MAY
PY 2012
VL 27
IS 5
BP 537
EP 541
DI 10.3346/jkms.2012.27.5.537
PG 5
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine
GA 938TJ
UT WOS:000303755600014
PM 22563220
OA Green Published, gold
DA 2022-11-30
ER

PT J
AU You, JI
   Kim, K
AF You, Jong In
   Kim, Kiyoung
TI Comparative Analysis of the Clinical Features and Long-Term Outcomes of
   Pachychoroid Neovasculopathy and Type 1 Neovascular Age-Related Macular
   Degeneration
SO JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
ID ENDOTHELIAL GROWTH-FACTOR; SUBFOVEAL CHOROIDAL THICKNESS; THERAPY;
   AFLIBERCEPT
AB Purpose. To evaluate the clinical characteristics and long-term prognosis of pachychoroid neovasculopathy (PCN) when compared with type 1 neovascular age-related macular degeneration (nAMD). Methods. We retrospectively analyzed 30 and 60 patients whose eyes were diagnosed as treatment-naive PCN or type 1 nAMD, respectively. All subjects were followed up for 5 years. Baseline angiographic characteristics and long-term clinical outcomes were compared between the two groups. Results. PCN group consisted of patients of younger age and represented more choroidal vascular hyperpermeability, polypoidal lesion, and history of central serous chorioretinopathy (CSC) at the time of diagnosis (all p < 0.01). During the 5-year follow-up period, individuals in the PCN group received significantly fewer injections and reported better visual acuity compared to individuals in the type 1 nAMD group. A progressive decrease in the subfoveal choroidal thickness was observed in the type 1 nAMD group, while the thick choroid was maintained in the PCN group during the 5-year follow-up period. Conclusions. PCN developed in younger patients with a higher propensity of forming polypoidal lesions and a history of CSC. Long-term outcomes revealed that PCN had a thicker choroid and better visual prognosis with fewer number of intravitreal injection than that of type 1 nAMD.
C1 [You, Jong In; Kim, Kiyoung] Kyung Hee Univ, Kyung Hee Univ Hosp, Dept Ophthalmol, Seoul, South Korea.
C3 Kyung Hee University; Kyung Hee University Hospital
RP Kim, K (通讯作者)，Kyung Hee Univ, Kyung Hee Univ Hosp, Dept Ophthalmol, Seoul, South Korea.
EM pourma@khu.ac.kr
RI KIM, KIYOUNG/GWM-6103-2022
CR Baek J, 2017, RETINA-J RET VIT DIS, V37, P943, DOI 10.1097/IAE.0000000000001284
   Cheung CMG, 2019, EYE, V33, P14, DOI 10.1038/s41433-018-0158-4
   Cho HJ, 2019, J OCUL PHARMACOL TH, V35, P174, DOI 10.1089/jop.2018.0107
   Fung AT, 2012, RETINA-J RET VIT DIS, V32, P1829, DOI 10.1097/IAE.0b013e3182680a66
   Grossniklaus HE, 2004, AM J OPHTHALMOL, V137, P496, DOI 10.1016/j.ajo.2003.09.042
   Grunwald JE, 2014, OPHTHALMOLOGY, V121, P150, DOI 10.1016/j.ophtha.2013.08.015
   Hata M, 2017, INVEST OPHTH VIS SCI, V58, P292, DOI 10.1167/iovs.16-20967
   Hood JD, 1998, AM J PHYSIOL-HEART C, V274, pH1054
   Hosoda Y, 2018, P NATL ACAD SCI USA, V115, P6261, DOI 10.1073/pnas.1802212115
   Jung BJ, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-38504-y
   Karacorlu M, 2018, GRAEF ARCH CLIN EXP, V256, P2319, DOI 10.1007/s00417-018-4144-0
   Kitajima Y, 2020, GRAEF ARCH CLIN EXP, V258, P1279, DOI 10.1007/s00417-020-04661-4
   Koizumi H, 2016, OPHTHALMOLOGY, V123, P617, DOI 10.1016/j.ophtha.2015.10.039
   Matsumoto H, 2018, JPN J OPHTHALMOL, V62, P144, DOI 10.1007/s10384-018-0562-0
   Miyake M, 2015, SCI REP-UK, V5, DOI 10.1038/srep16204
   Padron-Perez N, 2018, INVEST OPHTH VIS SCI, V59, P1119, DOI 10.1167/iovs.17-22144
   Pang CE, 2015, RETINA-J RET VIT DIS, V35, P1, DOI 10.1097/IAE.0000000000000331
   Roy R, 2019, INDIAN J OPHTHALMOL, V67, P1678, DOI 10.4103/ijo.IJO_1481_18
   Ryoo NK, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0209276
   Ting DSW, 2016, AM J OPHTHALMOL, V164, P128, DOI 10.1016/j.ajo.2015.12.024
   Warrow DJ, 2013, RETINA-J RET VIT DIS, V33, P1659, DOI 10.1097/IAE.0b013e3182953df4
   Yamazaki T, 2012, OPHTHALMOLOGY, V119, P1621, DOI 10.1016/j.ophtha.2012.02.022
NR 22
TC 1
Z9 1
U1 0
U2 0
PU HINDAWI LTD
PI LONDON
PA ADAM HOUSE, 3RD FLR, 1 FITZROY SQ, LONDON, W1T 5HF, ENGLAND
SN 2090-004X
EI 2090-0058
J9 J OPHTHALMOL
JI J. Ophthalmol.
PD DEC 3
PY 2020
VL 2020
AR 8865743
DI 10.1155/2020/8865743
PG 6
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA PG6FL
UT WOS:000599829000002
OA gold
DA 2022-11-30
ER

PT J
AU Blaha, M
   Langrova, H
   Blaha, V
   Andrys, C
   Stepanov, A
   Lanska, M
   Vejrazkova, E
   Dlouha, D
   Loefflerova, V
   Studnicka, J
   Kostal, M
AF Blaha, M.
   Langrova, H.
   Blaha, V
   Andrys, C.
   Stepanov, A.
   Lanska, M.
   Vejrazkova, E.
   Dlouha, D.
   Loefflerova, V
   Studnicka, J.
   Kostal, M.
TI Prediction of long-term prognosis of age-related macular degeneration
   treated by hemorheologic therapy using baseline laboratory indicators -
   Experimental-clinical model
SO CLINICAL HEMORHEOLOGY AND MICROCIRCULATION
LA English
DT Article
DE Rheohaemapheresis; age-related macular degeneration; treatment failure;
   prognosis prediction
ID RHEOLOGICAL PARAMETERS; DRY FORM; RHEOHAEMAPHERESIS; HAEMORHEOPHERESIS;
   RHEOPHERESIS; APHERESIS; LDL
AB BACKGROUND + OBJECTIVE: Age-related macular degeneration (AMD) is the most common cause of practical blindness in people over 60 years of age in industrialised countries. We formulated a hypothesis that a group of initial laboratory parameters would be suitable for prediction of prognosis of AMD, allowing for individual modifications in treatment intensity.
   PATIENTS AND METHODS: 66 patients with dry form of AMD were treated using rheohaemapheresis with an individual follow-up period of more than 5 years. The patients' initial laboratory data was split in two subgroups based on treatment success and analysed using discriminant analysis (analysis of the linear and quadratic models using the automated and interactive step-wise approach) by means of the Systat 13 software.
   RESULTS: Prediction of prognosis based on the initial laboratory parameters was correct in 79% of unsuccessfully treated patients, allowing for early detection of high-risk patients. With the use of a quadratic model, the prediction was correct in 100% of unsuccessfully treated patients and in 75% of successfully treated patients.
   CONCLUSION: Implementation of discriminant analysis is a promising method for prediction of prognosis, especially when the patient is at risk of AMD progression, which allows for early and more intensive monitoring and treatment.
C1 [Blaha, M.; Lanska, M.; Vejrazkova, E.; Kostal, M.] Univ Hosp, Dept Internal Med 4, Haematol, Sokolska 581, Hradec Kralove 50005, Czech Republic.
   [Blaha, M.; Langrova, H.; Blaha, V; Andrys, C.; Stepanov, A.; Lanska, M.; Vejrazkova, E.; Studnicka, J.; Kostal, M.] Fac Med Hradec Kralove, Sokolska 581, Hradec Kralove 50005, Czech Republic.
   [Langrova, H.; Stepanov, A.; Studnicka, J.] Univ Hosp, Dept Ophthalmol, Hradec Kralove, Czech Republic.
   [Blaha, V] Univ Hosp, Internal Gerontometab Clin 3, Hradec Kralove, Czech Republic.
   [Andrys, C.] Univ Hosp, Dept Clin Immunol & Allergol, Hradec Kralove, Czech Republic.
   [Dlouha, D.] Inst Clin & Expt Med, Ctr Expt Med, Lab Atherosclerosis Res, Prague, Czech Republic.
   [Loefflerova, V] Liberec Hosp, Dept Ophthalmol, Liberec, Czech Republic.
C3 Charles University Prague; Institute for Clinical & Experimental
   Medicine (IKEM)
RP Vejrazkova, E (通讯作者)，Univ Hosp, Dept Internal Med 4, Haematol, Sokolska 581, Hradec Kralove 50005, Czech Republic.; Vejrazkova, E (通讯作者)，Fac Med Hradec Kralove, Sokolska 581, Hradec Kralove 50005, Czech Republic.
EM eva.vejrazkova@fnhk.cz
RI Blaha, Milan/H-8955-2016; Blaha, Vladimir/C-1151-2016; Vejrazkova,
   Eva/M-1398-2018
OI Blaha, Milan/0000-0003-2330-5838; Blaha, Vladimir/0000-0001-8088-9919;
   Vejrazkova, Eva/0000-0001-6281-8914
FU Czech Ministry of Health [AZV 1729241A]
FX The study was supported by the grant of the Czech Ministry of Health,
   AZV 1729241A.
CR Age-Related Eye Disease Study 2 Research Group, 2013, JAMA, V309, P2005, DOI 10.1001/jama.2013.4997
   Al-Zamil WM, 2017, CLIN INTERV AGING, V12, P1313, DOI 10.2147/CIA.S143508
   Blaha M, 2015, ATHEROSCLEROSIS, V241, pE121, DOI 10.1016/j.atherosclerosis.2015.04.421
   Blaha M, 2013, ATHEROSCLEROSIS SUPP, V14, P179, DOI 10.1016/j.atherosclerosissup.2012.10.023
   Blaha M, 2009, CLIN HEMORHEOL MICRO, V42, P37, DOI 10.3233/CH-2009-1184
   Blaha M, 2008, HAEMATOL-HEMATOL J, V93, P555
   Blaha M, 2012, CLIN HEMORHEOL MICRO, V50, P245, DOI 10.3233/CH-2011-1431
   Borberg H, 2006, TRANSFUS APHER SCI, V34, P41, DOI 10.1016/j.transci.2005.09.001
   Buschini E, 2015, CLIN OPHTHALMOL, V9, P563, DOI 10.2147/OPTH.S59724
   Caimi G, 2019, CLIN HEMORHEOL MICRO, V73, P523, DOI 10.3233/CH-180542
   Klingel R, 2003, TRANSFUS APHER SCI, V29, P71, DOI 10.1016/S1473-0502(03)00101-0
   Koss MJ, 2009, GRAEF ARCH CLIN EXP, V247, P1297, DOI 10.1007/s00417-009-1113-7
   Langrova H, TRENDS CURRENT OPHTH
   Langrova H, 2018, TRENDY SOUDOBE OFTAL
   Lanska M, 2014, TRANSFUZE HEMATOL DN, V20, P67
   Lei BY, 2016, FRONT AGING NEUROSCI, V8, DOI 10.3389/fnagi.2016.00077
   Leung E, 2013, EXPERT REV CLIN PHAR, V6, P565, DOI 10.1586/17512433.2013.829645
   Li XY, 2017, IEEE T BIO-MED ENG, V64, P1906, DOI 10.1109/TBME.2016.2628958
   Lim LS, 2012, LANCET, V379, P1728, DOI 10.1016/S0140-6736(12)60282-7
   Park JW, 2019, CLIN HEMORHEOL MICRO, V73, P19, DOI 10.3233/CH-199216
   Pulido Jose S, 2002, Trans Am Ophthalmol Soc, V100, P85
   Rencova E, 2015, J OPHTHALMOL, V2015, DOI 10.1155/2015/359747
   Rencova E, 2011, ACTA OPHTHALMOL, V89, P463, DOI 10.1111/j.1755-3768.2009.01710.x
   Rozsival P., 2017, PERSONAL
   SCHUFFWERNER P, 1989, EUR J CLIN INVEST, V19, P30, DOI 10.1111/j.1365-2362.1989.tb00192.x
   Schwartz J, 2016, J CLIN APHERESIS, V31, P149, DOI 10.1002/jca.21470
   Studnicka J, 2013, J OPHTHALMOL, V2013, DOI 10.1155/2013/135798
   Wen ZD, 2017, IEEE T IMAGE PROCESS, V26, P3449, DOI 10.1109/TIP.2017.2700761
   Zhang Z, 2018, IEEE T NEUR NET LEAR, V29, P3798, DOI 10.1109/TNNLS.2017.2740224
NR 29
TC 0
Z9 0
U1 1
U2 3
PU IOS PRESS
PI AMSTERDAM
PA NIEUWE HEMWEG 6B, 1013 BG AMSTERDAM, NETHERLANDS
SN 1386-0291
EI 1875-8622
J9 CLIN HEMORHEOL MICRO
JI Clin. Hemorheol. Microcirc.
PY 2020
VL 76
IS 4
BP 573
EP 583
DI 10.3233/CH-209101
PG 11
WC Hematology; Peripheral Vascular Disease
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Hematology; Cardiovascular System & Cardiology
GA PW7IL
UT WOS:000610843900011
PM 32675405
DA 2022-11-30
ER

PT J
AU Ansari, M
   Mckeigue, PM
   Skerka, C
   Hayward, C
   Rudan, I
   Vitart, V
   Polasek, O
   Armbrecht, AM
   Yates, JRW
   Vatavuk, Z
   Bencic, G
   Kolcic, I
   Oostra, BA
   Van Duijn, CM
   Campbell, S
   Stanton, CM
   Huffman, J
   Shu, XH
   Khan, JC
   Shahid, H
   Harding, SP
   Bishop, PN
   Deary, IJ
   Moore, AT
   Dhillon, B
   Rudan, P
   Zipfel, PF
   Sim, RB
   Hastie, ND
   Campbell, H
   Wright, AF
AF Ansari, Morad
   Mckeigue, Paul M.
   Skerka, Christine
   Hayward, Caroline
   Rudan, Igor
   Vitart, Veronique
   Polasek, Ozren
   Armbrecht, Ana-Maria
   Yates, John R. W.
   Vatavuk, Zoran
   Bencic, Goran
   Kolcic, Ivana
   Oostra, Ben A.
   Van Duijn, Cornelia M.
   Campbell, Susan
   Stanton, Chloe M.
   Huffman, Jennifer
   Shu, Xinhua
   Khan, Jane C.
   Shahid, Humma
   Harding, Simon P.
   Bishop, Paul N.
   Deary, Ian J.
   Moore, Anthony T.
   Dhillon, Baljean
   Rudan, Pavao
   Zipfel, Peter F.
   Sim, Robert B.
   Hastie, Nicholas D.
   Campbell, Harry
   Wright, Alan F.
TI Genetic influences on plasma CFH and CFHR1 concentrations and their role
   in susceptibility to age-related macular degeneration
SO HUMAN MOLECULAR GENETICS
LA English
DT Article
ID COMPLEMENT FACTOR-H; TRANSLATIONAL MINIREVIEW SERIES; INSTRUMENTAL
   VARIABLE ANALYSIS; GENOME-WIDE ASSOCIATION; MONOCLONAL-ANTIBODIES;
   GENOTYPE IMPUTATION; BRUCHS MEMBRANE; INFLUENCES RISK; THERAPY; DISEASE
AB It is a longstanding puzzle why non-coding variants in the complement factor H (CFH) gene are more strongly associated with age-related macular degeneration (AMD) than functional coding variants that directly influence the alternative complement pathway. The situation is complicated by tight genetic associations across the region, including the adjacent CFH-related genes CFHR3 and CFHR1, which may themselves influence the alternative complement pathway and are contained within a common deletion (CNP147) which is associated with protection against AMD. It is unclear whether this association is mediated through a protective effect of low plasma CFHR1 concentrations, high plasma CFH or both. We examined the triangular relationships of CFH/CFHR3/CFHR1 genotype, plasma CFH or CFHR1 concentrations and AMD susceptibility in combined case-control (1256 cases, 1020 controls) and cross-sectional population (n = 1004) studies and carried out genome-wide association studies of plasma CFH and CFHR1 concentrations. A non-coding CFH SNP (rs6677604) and the CNP147 deletion were strongly correlated both with each other and with plasma CFH and CFHR1 concentrations. The plasma CFH-raising rs6677604 allele and raised plasma CFH concentration were each associated with AMD protection. In contrast, the protective association of the CNP147 deletion with AMD was not mediated by low plasma CFHR1, since AMD-free controls showed increased plasma CFHR1 compared with cases, but it may be mediated by the association of CNP147 with raised plasma CFH concentration. The results are most consistent with a regulatory locus within a 32 kb region of the CFH gene, with a major effect on plasma CFH concentration and AMD susceptibility.
C1 [Ansari, Morad; Hayward, Caroline; Vitart, Veronique; Campbell, Susan; Stanton, Chloe M.; Huffman, Jennifer; Shu, Xinhua; Hastie, Nicholas D.; Wright, Alan F.] Univ Edinburgh, Inst Genet & Mol Med, MRC Human Genet Unit, Edinburgh EH4 2XU, Midlothian, Scotland.
   [Mckeigue, Paul M.; Rudan, Igor; Campbell, Harry] Univ Edinburgh, Ctr Populat Hlth Sci, Edinburgh EH8 9AG, Midlothian, Scotland.
   [Skerka, Christine; Zipfel, Peter F.] Leibniz Inst Nat Prod Res & Infect Biol, Dept Infect Biol, D-07745 Jena, Germany.
   [Rudan, Igor] Univ Split, Croatian Ctr Global Hlth, Split 21000, Croatia.
   [Polasek, Ozren; Kolcic, Ivana] Univ Split, Sch Med, Split 21000, Croatia.
   [Armbrecht, Ana-Maria; Dhillon, Baljean] Univ Edinburgh, Dept Ophthalmol, Edinburgh EH3 9HA, Midlothian, Scotland.
   [Yates, John R. W.; Khan, Jane C.; Shahid, Humma; Moore, Anthony T.] Univ Cambridge, Cambridge Inst Med Res, Dept Med Genet, Cambridge CB2 0XY, England.
   [Vatavuk, Zoran; Bencic, Goran] Clin Hosp Sestre Milosrdnice, Zagreb, Croatia.
   [Oostra, Ben A.; Van Duijn, Cornelia M.] Erasmus Univ, Dept Clin Genet, NL-3000 CA Rotterdam, Netherlands.
   [Oostra, Ben A.; Van Duijn, Cornelia M.] Erasmus Univ, Dept Epidemiol, NL-3000 CA Rotterdam, Netherlands.
   [Oostra, Ben A.; Van Duijn, Cornelia M.] Erasmus Univ, Dept Biostat, NL-3000 CA Rotterdam, Netherlands.
   [Harding, Simon P.] Univ Liverpool, Dept Ophthalmol, Liverpool L69 3BX, Merseyside, England.
   [Bishop, Paul N.] Univ Manchester, Manchester Acad Hlth Sci Ctr, CMFT, Sch Biomed, Manchester M13 9WL, Lancs, England.
   [Bishop, Paul N.] Manchester Royal Eye Hosp, Manchester M13 9WL, Lancs, England.
   [Deary, Ian J.] Univ Edinburgh, Dept Psychol, MRC Ctr Cognit Ageing & Cognit Epidemiol, Edinburgh EH8 9JZ, Midlothian, Scotland.
   [Rudan, Pavao] Inst Anthropol Res, Zagreb 10000, Croatia.
   [Sim, Robert B.] Univ Leicester, Dept Infect Immun & Inflammat, Leicester LE1 9HN, Leics, England.
   [Yates, John R. W.] UCL, Inst Ophthalmol, London EC1V 9EL, England.
C3 University of Edinburgh; University of Edinburgh; Hans Knoll Institute
   (HKI); University of Split; University of Split; University of
   Edinburgh; University of Cambridge; Erasmus University Rotterdam;
   Erasmus University Rotterdam; Erasmus University Rotterdam; University
   of Liverpool; University of Manchester; Manchester Royal Eye Hospital;
   University of Edinburgh; Institute for Anthropological Research Zagreb;
   University of Leicester; University of London; University College London
RP Campbell, H (通讯作者)，Univ Edinburgh, Ctr Populat Hlth Sci, Edinburgh EH8 9AG, Midlothian, Scotland.
EM harry.campbell@ed.ac.uk; alan.wright@igmm.ed.ac.uk
RI Sim, Bob/A-1354-2008; Rudan, Igor/I-1467-2012; Deary, Ian J/C-6297-2009;
   Hayward, Caroline/M-8818-2016; Polasek, Ozren/B-6002-2011; Campbell,
   Harry/E-2959-2010; Kolcic, Ivana/E-2713-2017
OI Sim, Bob/0000-0002-2855-7455; Rudan, Igor/0000-0001-6993-6884; Deary,
   Ian J/0000-0002-1733-263X; Hayward, Caroline/0000-0002-9405-9550;
   Polasek, Ozren/0000-0002-5765-1862; Campbell, Harry/0000-0002-6169-6262;
   Kolcic, Ivana/0000-0001-7918-6052; Harding, Simon/0000-0003-4676-1158;
   Ansari, Morad/0000-0002-8905-5379; Bishop, Paul/0000-0001-7937-7932; Van
   Duijn, Cornelia/0000-0002-2374-9204
FU Medical Research Council (UK); Scottish Executive (Chief Scientist
   Office); Macula Vision Research Foundation; Macula Disease Society;
   Wellcome Trust; National Institute of Health Research; Republic of
   Croatia Ministry of Science, Education and Sports [108-1080315-0302,
   196-1962766-2751]; EU FP6 project EUROSPAN [LSHG-CT-2006-018947];
   DeutscheForschungsgemeinschaft (DFG) [Sk46]; Wellcome Trust Clinical
   Research Facility (Edinburgh, UK); Department of Health's NIHR
   Biomedical Research Centre for Ophthalmology at Moorfields Eye Hospital;
   UCL Institute of Ophthalmology; MRC [G0800604, G0700704, MC_U138214881,
   MC_PC_U127561128, G0000067, MC_U127584475] Funding Source: UKRI; Medical
   Research Council [G0000067, G0800604, MC_PC_U127561128, MR/K006584/1,
   MC_U127584475, G0700704, MC_U138214881, MC_PC_U127584475, MR/K026992/1]
   Funding Source: researchfish; National Institute for Health Research
   [NF-SI-0507-10204] Funding Source: researchfish
FX This work was supported by grants from the Medical Research Council (UK)
   (A.F.W., N.D.H., J.R.W.Y., A.T.M., P.M.M.), Scottish Executive (Chief
   Scientist Office) (B D., A.F.W.), Macula Vision Research Foundation
   (A.F.W.), Macula Disease Society (J.R.W.Y., A.T.M.), Wellcome Trust
   (H.C., I.R.), National Institute of Health Research (A.T.M.), Republic
   of Croatia Ministry of Science, Education and Sports grants to I.R.
   (108-1080315-0302), P.R.(196-1962766-2751), EU FP6 project EUROSPAN
   (Contract No. LSHG-CT-2006-018947), DeutscheForschungsgemeinschaft (DFG,
   Sk46) (C.S., P.F.Z.), Wellcome Trust Clinical Research Facility
   (Edinburgh, UK) for performing a genome-wide association scan. This
   research has received a proportion of its funding from the Department of
   Health's NIHR Biomedical Research Centre for Ophthalmology at Moorfields
   Eye Hospital and UCL Institute of Ophthalmology (J.R.W.Y.). The views
   expressed in the publication are those of the authors and not
   necessarily those of the Department of Health. The funders had no role
   in study design, data collection and analysis, decision to publish or
   preparation of the manuscript
CR Abarrategui-Garrido C, 2009, BLOOD, V114, P4261, DOI 10.1182/blood-2009-05-223834
   Allikmets R, 2008, NAT GENET, V40, P820, DOI 10.1038/ng0708-820
   Almasy L, 1998, AM J HUM GENET, V62, P1198, DOI 10.1086/301844
   Altshuler DM, 2012, NATURE, V491, P56, DOI 10.1038/nature11632
   Aulchenko YS, 2007, GENETICS, V177, P577, DOI 10.1534/genetics.107.075614
   Aulchenko YS, 2007, BIOINFORMATICS, V23, P1294, DOI 10.1093/bioinformatics/btm108
   Bainbridge JWB, 2008, NEW ENGL J MED, V358, P2231, DOI 10.1056/NEJMoa0802268
   Chen WM, 2007, AM J HUM GENET, V81, P913, DOI 10.1086/521580
   Clark SJ, 2010, J BIOL CHEM, V285, P30192, DOI 10.1074/jbc.M110.103986
   de Cordoba SR, 2008, CLIN EXP IMMUNOL, V151, P1, DOI 10.1111/j.1365-2249.2007.03574.x
   Delaneau O, 2013, NAT METHODS, V10, P5, DOI 10.1038/nmeth.2307
   Despriet DDG, 2006, JAMA-J AM MED ASSOC, V296, P301, DOI 10.1001/jama.296.3.301
   Esparza-Gordillo J, 2004, IMMUNOGENETICS, V56, P77, DOI 10.1007/s00251-004-0660-7
   ESTALLER C, 1991, EUR J IMMUNOL, V21, P799, DOI 10.1002/eji.1830210337
   Foster A, 2005, EYE, V19, P1133, DOI 10.1038/sj.eye.6701973
   Fritsche LG, 2010, HUM MOL GENET, V19, P4694, DOI 10.1093/hmg/ddq399
   Hageman GS, 2001, PROG RETIN EYE RES, V20, P705, DOI 10.1016/S1350-9462(01)00010-6
   Hakobyan S, 2008, INVEST OPHTH VIS SCI, V49, P1983, DOI 10.1167/iovs.07-1523
   Heinen S, 2009, BLOOD, V114, P2439, DOI 10.1182/blood-2009-02-205641
   Hellwage J, 1997, BIOCHEM J, V326, P321, DOI 10.1042/bj3260321
   Herbert AP, 2007, J BIOL CHEM, V282, P18960, DOI 10.1074/jbc.M609636200
   HIGUCHI R, 1993, BIO-TECHNOL, V11, P1026, DOI 10.1038/nbt0993-1026
   Howie B, 2012, NAT GENET, V44, P955, DOI 10.1038/ng.2354
   Howie B, 2011, G3-GENES GENOM GENET, V1, P457, DOI 10.1534/g3.111.001198
   Howie BN, 2009, PLOS GENET, V5, DOI 10.1371/journal.pgen.1000529
   Hughes AE, 2006, NAT GENET, V38, P1173, DOI 10.1038/ng1890
   Isaacs A, 2007, EUR J EPIDEMIOL, V22, P99, DOI 10.1007/s10654-006-9103-0
   Jokiranta TS, 1996, FEBS LETT, V393, P297
   Jozsi M, 2008, BLOOD, V111, P1512, DOI 10.1182/blood-2007-09-109876
   Li M, 2006, NAT GENET, V38, P1049, DOI 10.1038/ng1871
   Licht C, 2005, AM J KIDNEY DIS, V45, P415, DOI 10.1053/j.ajkd.2004.10.018
   Maguire AM, 2008, NEW ENGL J MED, V358, P2240, DOI 10.1056/NEJMoa0802315
   Maller J, 2006, NAT GENET, V38, P1055, DOI 10.1038/ng1873
   Martinez-Barricarte R, 2012, INVEST OPHTH VIS SCI, V53, P1087, DOI 10.1167/iovs.11-8709
   McIntosh J, 2013, BLOOD, V121, P3335, DOI 10.1182/blood-2012-10-462200
   McKeigue PM, 2010, INT J EPIDEMIOL, V39, P907, DOI 10.1093/ije/dyp397
   Montezuma Sandra R, 2007, Semin Ophthalmol, V22, P229, DOI 10.1080/08820530701745140
   Okemefuna AI, 2010, J BIOL CHEM, V285, P1053, DOI 10.1074/jbc.M109.044529
   Palmer TM, 2012, STAT METHODS MED RES, V21, P223, DOI 10.1177/0962280210394459
   Palmer TM, 2011, AM J EPIDEMIOL, V173, P1392, DOI 10.1093/aje/kwr026
   Pechtl IC, 2011, J BIOL CHEM, V286, P11082, DOI 10.1074/jbc.M110.211839
   Penfold PL, 2005, MACULAR DEGENERATION, P25, DOI 10.1007/3-540-26977-0_2
   Pickering MC, 2008, CLIN EXP IMMUNOL, V151, P210, DOI 10.1111/j.1365-2249.2007.03574.x
   Pieramici DJ, 2008, EYE, V22, P1330, DOI 10.1038/eye.2008.88
   Prosser BE, 2007, J EXP MED, V204, P2277, DOI 10.1084/jem.20071069
   Raychaudhuri S, 2011, NAT GENET, V43, P1232, DOI 10.1038/ng.976
   Raychaudhuri S, 2010, NAT GENET, V42, P553, DOI 10.1038/ng0710-553
   Reynolds R, 2009, INVEST OPHTH VIS SCI, V50, P5818, DOI 10.1167/iovs.09-3928
   Scholl HPN, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002593
   Scholl HPN, 2007, MOL VIS, V13, P196
   Seddon JM, 2007, JAMA-J AM MED ASSOC, V297, P1793, DOI 10.1001/jama.297.16.1793
   Seddon JM, 2013, JAMA OPHTHALMOL, V131, P448, DOI 10.1001/jamaophthalmol.2013.2578
   SIM E, 1983, BIOSCIENCE REP, V3, P1119, DOI 10.1007/BF01120205
   SIM RB, 1993, METHOD ENZYMOL, V223, P13
   Sivakumaran TA, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0025598
   SKERKA C, 1991, J BIOL CHEM, V266, P12015
   Theodoratou E, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0037662
   Tortajada A, 2009, HUM MOL GENET, V18, P3452, DOI 10.1093/hmg/ddp289
   Vitart V, 2008, NAT GENET, V40, P437, DOI 10.1038/ng.106
   Wehby GL, 2008, STAT MED, V27, P2745, DOI 10.1002/sim.3255
   Weismann D, 2011, NATURE, V478, P76, DOI 10.1038/nature10449
   Yates JRW, 2007, NEW ENGL J MED, V357, P553, DOI 10.1056/NEJMoa072618
   Zipfel PF, 2007, PLOS GENET, V3, P387, DOI 10.1371/journal.pgen.0030041
   Zipfel PF, 1999, IMMUNOL TODAY, V20, P135, DOI 10.1016/S0167-5699(98)01432-7
NR 64
TC 65
Z9 67
U1 0
U2 19
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 0964-6906
EI 1460-2083
J9 HUM MOL GENET
JI Hum. Mol. Genet.
PD DEC 1
PY 2013
VL 22
IS 23
BP 4857
EP 4869
DI 10.1093/hmg/ddt336
PG 13
WC Biochemistry & Molecular Biology; Genetics & Heredity
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Genetics & Heredity
GA 251ZD
UT WOS:000326973000017
PM 23873044
OA Green Published, Green Submitted, hybrid
DA 2022-11-30
ER

PT J
AU Xu, NN
   Bo, QY
   Shao, R
   Liang, J
   Zhai, YQ
   Yang, SQ
   Wang, FH
   Sun, XD
AF Xu, Nana
   Bo, Qiyu
   Shao, Rong
   Liang, Jian
   Zhai, Yuanqi
   Yang, Shiqi
   Wang, Fenghua
   Sun, Xiaodong
TI Chitinase-3-Like-1 Promotes M2 Macrophage Differentiation and Induces
   Choroidal Neovascularization in Neovascular Age-Related Macular
   Degeneration
SO INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE
LA English
DT Article
DE choroidal neovascularization (CNV); M2 macrophage; chitinase 3-like-1
   (CHI3L1); age-related macular degeneration (AMD); angiogenesis
ID TISSUE RESPONSES; VEGF; POLARIZATION; ACTIVATION; 3-LIKE-1; GROWTH;
   ANGIOGENESIS; GLIOBLASTOMA; RECRUITMENT; INHIBITION
AB PURPOSE. Choroidal neovascularization (CNV) is the principal pathological factor contributing to blindness in neovascular age-related macular degeneration (nAMD). Infiltration of M2 macrophage is thought to contribute to CNV progress, although the way that regulates its differentiation remains unclear. Here, we investigate the role of CHI3L1 in M2 differentiation and angiogenesis in CNV.
   METHODS. Serums from nAMD patients were tested for CHI3L1 expression. Mice were subjected to laser injury to induce CN'V, and lesion expansion were tracked using fundus fluorescence angiography (FFA) and immunofluorescence analysis. Several strategies were taken to verify the contribution of M2 macrophage and CHI3L1: macrophage depletion by clodrosome, local CHI3L1 inhibition using intravitreally injection neutralize antibody (mAY), and depletion of CHI3L1 receptor (IL13-Ra2) by small-interfering RNA (siRNA). Tuber analysis was used to further determine angiogenetic effect of CHI3L1. Anti-VEGFA was used as positive control for mAY.
   RESULTS. Serum levels of CHI3L1 were highly elevated in nAMD patients. CHI3L1 was expressed by infiltrating M2 macrophages and was elevated as CNV progress in a mice model. System macrophage depletion and local suppression of CHI3L1 alleviated CNV formation while enhancing anti-VEGFA therapeutic effect. Stimulation of macrophage with recombinant CHI3L1 activated MAPK signaling cascade and induced transition to M2, while siRNA knockdown of IL13-Ra2 abolished it. In an in vitro coculture system, supernatants from CHI3L1-stimulated M2 macrophages and promoted tube vascularization.
   CONCLUSIONS. These results unveil novel angiogenic regulation of CHI3L1 and M2 polarized macrophages in CNV development. These mechanistic insights may point to CHI3L1 as a new therapeutic target for treatment for nAMD.
C1 [Xu, Nana; Bo, Qiyu; Yang, Shiqi; Wang, Fenghua; Sun, Xiaodong] Shanghai Jiao Tong Univ, Shanghai Gen Hosp, Sch Med, Dept Ophthalmol, Shanghai, Peoples R China.
   [Xu, Nana; Bo, Qiyu; Yang, Shiqi; Wang, Fenghua; Sun, Xiaodong] Shanghai Engn Ctr Visual Sci & Photomed, Shanghai, Peoples R China.
   [Shao, Rong] Shanghai Jiao Tong Univ, Dept Pharmacol, Sch Med, Shanghai, Peoples R China.
   [Shao, Rong] Shanghai Jiao Tong Univ, Xinhua Hosp, Dept Surg, Sch Med, Shanghai, Peoples R China.
   [Liang, Jian; Zhai, Yuanqi; Sun, Xiaodong] Shanghai Key Lab Ocular Fundus Dis, Shanghai, Peoples R China.
C3 Shanghai Jiao Tong University; Shanghai Jiao Tong University; Shanghai
   Jiao Tong University
RP Sun, XD (通讯作者)，Shanghai Jiao Tong Univ, Sch Med, Shanghai First Peoples Hosp,Shanghai Engn Ctr Vis, Shanghai Gen Hosp,Dept Ophthalmol,Shanghai Key La, 100 Hai Ning Rd, Shanghai 200080, Peoples R China.; Wang, FH (通讯作者)，Shanghai Jiao Tong Univ, Shanghai Engn Ctr Visual Sci & Photomed, Sch Med, Shanghai First Peoples Hosp,Shanghai Gen Hosp,Dep, 100 Hal Ning Rd, Shanghai 200080, Peoples R China.
EM shretina@sjtu.edu.cn; xdsun@sjtu.edu.cn
RI Yang, Shiqi/CAI-7690-2022
FU National Natural Science Foundation of China [81730026, 81470640];
   Project for Engineering and Technology Research Center of Shanghai
   [16dz2251500]; National Key R&D Program of China [2016 YFC 0904800]
FX Supported by the National Natural Science Foundation of China (81730026
   and 81470640), Project for Engineering and Technology Research Center of
   Shanghai (16dz2251500), and National Key R&D Program of China (2016 YFC
   0904800).
CR Ambati J, 2013, NAT REV IMMUNOL, V13, P438, DOI 10.1038/nri3459
   Amit I, 2016, NAT IMMUNOL, V17, P18, DOI 10.1038/ni.3325
   Cao XG, 2011, PATHOL INT, V61, P528, DOI 10.1111/j.1440-1827.2011.02695.x
   Cherepanoff S, 2010, BRIT J OPHTHALMOL, V94, P918, DOI 10.1136/bjo.2009.165563
   Di Rosa M, 2013, INFLAMMATION, V36, P482, DOI 10.1007/s10753-012-9569-8
   Eleftheriadou M, 2018, OPHTHALMOL THER, V7, P361, DOI 10.1007/s40123-018-0139-5
   Feng YF, 2018, FASEB J, V32, P1626, DOI 10.1096/fj.201700640R
   Ferrara N, 2016, NAT REV DRUG DISCOV, V15, P385, DOI 10.1038/nrd.2015.17
   Fritsche LG, 2014, ANNU REV GENOM HUM G, V15, P151, DOI 10.1146/annurev-genom-090413-025610
   Giancipoli E, 2018, J OPHTHALMOL, V2018, DOI 10.1155/2018/5612342
   Guo JX, 2017, J OCUL PHARMACOL TH, V33, P50, DOI 10.1089/jop.2016.0153
   He CH, 2013, CELL REP, V4, P830, DOI 10.1016/j.celrep.2013.07.032
   He LZ, 2013, AM J PATHOL, V182, P2407, DOI 10.1016/j.ajpath.2013.02.032
   Jaffe GJ, 2017, OPHTHALMOLOGY, V124, P224, DOI 10.1016/j.ophtha.2016.10.010
   Kawada M, 2012, ONCOGENE, V31, P3111, DOI 10.1038/onc.2011.498
   Kelly J, 2007, J CLIN INVEST, V117, P3421, DOI 10.1172/JCI32430
   Lechner J, 2015, SCI REP-UK, V5, DOI 10.1038/srep16754
   Lee CM, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms12752
   Lee CG, 2010, ALLERGY ASTHMA IMMUN, V2, P20, DOI 10.4168/aair.2010.2.1.20
   Lee CG, 2009, J EXP MED, V206, P1149, DOI 10.1084/jem.20081271
   Li L, 2015, EXP EYE RES, V136, P116, DOI 10.1016/j.exer.2015.04.020
   Makin RD, 2018, INVEST OPHTH VIS SCI, V59, P5795, DOI 10.1167/iovs.18-25215
   Natoli R, 2017, INVEST OPHTH VIS SCI, V58, P2977, DOI 10.1167/iovs.17-21672
   Ngernyuang N, 2018, NEOPLASIA, V20, P182, DOI 10.1016/j.neo.2017.11.011
   Ohashi T, 2017, CANCER SCI, V108, P1128, DOI 10.1111/cas.13244
   Outtz HH, 2011, BLOOD, V118, P3436, DOI 10.1182/blood-2010-12-327015
   Peterson TE, 2016, P NATL ACAD SCI USA, V113, P4470, DOI 10.1073/pnas.1525349113
   Rehli M, 2003, J BIOL CHEM, V278, P44058, DOI 10.1074/jbc.M306792200
   Roszer T, 2015, MEDIAT INFLAMM, V2015, DOI 10.1155/2015/816460
   Saint-Geniez M, 2006, INVEST OPHTH VIS SCI, V47, P3135, DOI 10.1167/iovs.05-1229
   Schmittgen TD, 2008, NAT PROTOC, V3, P1101, DOI 10.1038/nprot.2008.73
   Sene A, 2013, CELL METAB, V17, P549, DOI 10.1016/j.cmet.2013.03.009
   Shan Z, 2018, HEPATOLOGY, V67, P2384, DOI 10.1002/hep.29733
   Shao R, 2009, ONCOGENE, V28, P4456, DOI 10.1038/onc.2009.292
   Shao R, 2015, ONCOTARGET, V6, P40507, DOI 10.18632/oncotarget.5943
   Shi Q, 2015, INVEST OPHTH VIS SCI, V56, P7728, DOI 10.1167/iovs.15-17677
   Vasudev NS, 2013, BRIT J CANCER, V109, P1230, DOI 10.1038/bjc.2013.429
   Wang E, 2017, INVEST OPHTH VIS SCI, V58, DOI 10.1167/iovs.16-21082
   Zhang F, 2009, P NATL ACAD SCI USA, V106, P6152, DOI 10.1073/pnas.0813061106
   Zhang PF, 2018, INFLAMMATION, V41, P143, DOI 10.1007/s10753-017-0672-8
   Zhao MM, 2016, INVEST OPHTH VIS SCI, V57, P2955, DOI 10.1167/iovs.15-18505
   Zhou Y, 2015, J CLIN INVEST, V125, P3178, DOI 10.1172/JCI79792
   Zhou Y, 2014, SCI TRANSL MED, V6, DOI 10.1126/scitranslmed.3007096
   Zhou YD, 2015, INVEST OPHTH VIS SCI, V56, P4767, DOI 10.1167/iovs.14-16012
   Zhu Y, 2015, NEUROBIOL DIS, V74, P114, DOI 10.1016/j.nbd.2014.10.024
NR 45
TC 23
Z9 24
U1 1
U2 10
PU ASSOC RESEARCH VISION OPHTHALMOLOGY INC
PI ROCKVILLE
PA 12300 TWINBROOK PARKWAY, ROCKVILLE, MD 20852-1606 USA
SN 0146-0404
EI 1552-5783
J9 INVEST OPHTH VIS SCI
JI Invest. Ophthalmol. Vis. Sci.
PD NOV
PY 2019
VL 60
IS 14
BP 4596
EP 4605
DI 10.1167/iovs.19-27493
PG 10
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA JS4YT
UT WOS:000500313300009
PM 31675076
OA gold
DA 2022-11-30
ER

PT J
AU Kaya, F
AF Kaya, F.
TI Change in choroidal thickness after intravitreal injection for treatment
   of neovascular age-related macular degeneration: Ranibizumab versus
   aflibercept
SO JOURNAL FRANCAIS D OPHTALMOLOGIE
LA English
DT Article
DE Ranibizumab; Aflibercept; Choroidal thickness; Neovascular age-related
   macular degeneration
ID CHORIOCAPILLARIS; BEVACIZUMAB; THERAPY; BINDING; VEGF; EYES
AB Purpose. - To compare the changes in subfoveal choroidal thickness after intravitreal ranibizumab or aflibercept injections for neovascular age-related macular degeneration (nAMD).
   Methods. - In this retrospective study, 28 eyes with nAMD treated with 3 consecutive monthly injections of ranibizumab (IVR) and 24 eyes with nAMD treated with 3 consecutive monthly injections of aflibercept (IVA) between September 2012 and June 2016 were reviewed. The follow-up time was 6 months. Changes in two groups' best-corrected visual acuity (BCVA) and subfoveal choroidal thickness by using enhanced depth imaging optical coherence tomography at 1st, 3rd and 6th months were recorded and compared.
   Results. - Choroidal thickness decreased significantly in eyes treated with IVR (P=0.015, 0.01 and 0.01, respectively) or IVA (P=0.001, 0.001 and < 0.001, respectively) at 1, 3 and 6 months examination but IVA treated eyes presented a significantly further reduction in choroidal thickness when compared with ranibizumab (P=0.03, 0,04 and 0.03, respectively). There was no significant difference between aflibercept and ranibizumab group when change in BCVA from baseline compared at 1, 3 and 6th months (P=0.54, 0.06 and 0.37, respectively). There was no correlation between change in choroidal thickness and the BCVA outcomes in either group.
   Conclusions. - Subfoveal choroidat thickness decreased significantly after both of IVR and IVA injections in patients with nAMD. In conclusion, intravitreal injections of ranibizumab or aflibercept affect not only neovascular lesion but also the underlying choroid. (C) 2017 Elsevier Masson SAS. All rights reserved.
C1 [Kaya, F.] Hop Nisa, Serv Ophtalmol, TR-34196 Istanbul, Turkey.
   [Kaya, F.] Univ Istanbul Medipol, Clin Univ Ophtalmol, Fac Med, TR-34196 Istanbul, Turkey.
C3 Nisa Hospital; Istanbul Medipol University
RP Kaya, F (通讯作者)，Nisa Hastanesi Goz Serv, Fatih Cad,Okul Sk 1,, TR-34196 Istanbul, Turkey.
EM drfarukkaya@yahoo.com
CR Ardeljan D, 2013, PROG RETIN EYE RES, V37, P68, DOI 10.1016/j.preteyeres.2013.07.003
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Browning DJ, 2012, AM J OPHTHALMOL, V154, P222, DOI 10.1016/j.ajo.2012.04.020
   Coleman DJ, 2013, BRIT J OPHTHALMOL, V97, P1020, DOI 10.1136/bjophthalmol-2013-303143
   Delaey C, 2000, OPHTHALMIC RES, V32, P249, DOI 10.1159/000055622
   Ferrara N, 2006, RETINA-J RET VIT DIS, V26, P859, DOI 10.1097/01.iae.0000242842.14624.e7
   Fung AE, 2007, AM J OPHTHALMOL, V143, P566, DOI 10.1016/j.ajo.2007.01.028
   Funk M, 2009, OPHTHALMOLOGY, V116, P2393, DOI 10.1016/j.ophtha.2009.05.039
   Gharbiya M, 2014, BIOMED RES INT, V54, P2737
   GIOVANNINI A, 1994, OPHTHALMOLOGICA, V208, P185, DOI 10.1159/000310483
   Julien S, 2014, BRIT J OPHTHALMOL, V98, P813, DOI 10.1136/bjophthalmol-2013-304019
   Kang HM, 2014, AM J OPHTHALMOL, V157, P1013, DOI 10.1016/j.ajo.2014.01.019
   Kim SW, 2011, RETINA-J RET VIT DIS, V31, P1904, DOI 10.1097/IAE.0b013e31821801c5
   Koizumi H, 2008, GRAEF ARCH CLIN EXP, V246, P515, DOI 10.1007/s00417-007-0705-3
   Lutty G, 1999, Mol Vis, V5, P35
   Manjunath V, 2011, AM J OPHTHALMOL, V152, P663, DOI 10.1016/j.ajo.2011.03.008
   McLeod DS, 2009, INVEST OPHTH VIS SCI, V50, P4982, DOI 10.1167/iovs.09-3639
   Metelitsina TI, 2008, INVEST OPHTH VIS SCI, V49, P358, DOI 10.1167/iovs.07-0526
   Miller JW, 2013, AM J OPHTHALMOL, V155, P1, DOI 10.1016/j.ajo.2012.10.018
   Mitchell P, 2010, BRIT J OPHTHALMOL, V94, P2, DOI 10.1136/bjo.2009.159160
   Papadopoulos N, 2012, ANGIOGENESIS, V15, P171, DOI 10.1007/s10456-011-9249-6
   Peters S, 2007, AM J OPHTHALMOL, V143, P995, DOI 10.1016/j.ajo.2007.03.007
   RAMRATTAN RS, 1994, INVEST OPHTH VIS SCI, V35, P2857
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   SARKS SH, 1976, BRIT J OPHTHALMOL, V60, P324, DOI 10.1136/bjo.60.5.324
   Schraermeyer U, 2013, EXPERT OPIN BIOL TH, V13, P157, DOI 10.1517/14712598.2012.748741
   Shimomura Y, 2009, GRAEF ARCH CLIN EXP, V247, P1089, DOI 10.1007/s00417-009-1054-1
   Spaide RF, 2008, AM J OPHTHALMOL, V146, P496, DOI 10.1016/j.ajo.2008.05.032
   Stewart MW, 2008, BRIT J OPHTHALMOL, V92, P667, DOI 10.1136/bjo.2007.134874
   Xu W, 2010, AM J OPHTHALMOL, V150, P40, DOI 10.1016/j.ajo.2010.01.041
   Yamazaki T, 2012, OPHTHALMOLOGY, V119, P1621, DOI 10.1016/j.ophtha.2012.02.022
NR 31
TC 10
Z9 10
U1 1
U2 3
PU MASSON EDITEUR
PI MOULINEAUX CEDEX 9
PA 21 STREET CAMILLE DESMOULINS, ISSY, 92789 MOULINEAUX CEDEX 9, FRANCE
SN 0181-5512
EI 1773-0597
J9 J FR OPHTALMOL
JI J. Fr. Ophthamol.
PD DEC
PY 2017
VL 40
IS 10
BP 832
EP 838
DI 10.1016/j.jfo.2017.04.014
PG 7
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA FP2XB
UT WOS:000417482200016
PM 29113742
DA 2022-11-30
ER

PT J
AU Lai, TT
   Hsieh, YT
   Yang, CM
   Ho, TC
   Yang, CH
AF Lai, Tso-Ting
   Hsieh, Yi-Ting
   Yang, Chung-May
   Ho, Tzyy-Chang
   Yang, Chang-Hao
TI Biomarkers of optical coherence tomography in evaluating the treatment
   outcomes of neovascular age-related macular degeneration: a real-world
   study
SO SCIENTIFIC REPORTS
LA English
DT Article
ID PIGMENT EPITHELIAL DETACHMENT; VISUAL-ACUITY; INTRAVITREAL AFLIBERCEPT;
   DOSING REGIMEN; VISION LOSS; RANIBIZUMAB; THERAPY
AB This study evaluated the characteristic changes in optical coherence tomography (OCT) biomarkers in neovascular age-related macular degeneration (nAMD) treated with anti-vascular endothelial growth factor drugs and their relationship with visual outcomes at 1-year follow-up in a real-world setting. We retrospectively reviewed the medical records of 126 eyes with nAMD treated with either intravitreal ranibizumab or aflibercept, including ophthalmologic examinations and spectral-domain OCT at baseline and months 3, 6, and 12 after first injection. Treatment response of intraretinal cysts (IRCs), subretinal fluid (SRF), and pigment epithelial detachment (PED), and the correlation between best-corrected visual acuity (BCVA) changes and these OCT biomarkers were analyzed. After an average of 5.1 +/- 1.5 injections, 33.3% of eyes with PED showed resolution at month 12, a significantly lower proportion than for IRCs (53.8%) or SRF (51.6%). BCVA improvement at 1 year was negatively associated with PED at baseline and with IRCs or PED at month 12. Persistence of IRCs at month 12 was associated with degeneration morphology of IRCs at baseline and non-resolved cysts at month 3 after loading. In conclusions, IRCs and PED are associated with poor visual improvement in nAMD in a real-world setting. Both IRCs and SRF responded better than PED to anti-VEGF therapy.
C1 [Lai, Tso-Ting; Hsieh, Yi-Ting; Yang, Chung-May; Ho, Tzyy-Chang; Yang, Chang-Hao] Natl Taiwan Univ Hosp, Dept Ophthalmol, Taipei, Taiwan.
   [Yang, Chung-May; Yang, Chang-Hao] Natl Taiwan Univ, Dept Ophthalmol, Coll Med, Taipei, Taiwan.
   [Lai, Tso-Ting] Natl Taiwan Univ, Grad Inst Clin Med, Coll Med, Taipei, Taiwan.
C3 National Taiwan University; National Taiwan University Hospital;
   National Taiwan University; National Taiwan University
RP Yang, CH (通讯作者)，Natl Taiwan Univ Hosp, Dept Ophthalmol, Taipei, Taiwan.; Yang, CH (通讯作者)，Natl Taiwan Univ, Dept Ophthalmol, Coll Med, Taipei, Taiwan.
EM chyangoph@ntu.edu.tw
RI Yang, Chang-Hao/AAR-3759-2021; Yang, Chung-May/AAV-3737-2020
OI YANG, CHANG-HAO/0000-0002-4328-8716; YANG,
   CHUNG-MAY/0000-0003-4082-420X; Lai, Tso-Ting/0000-0002-8247-7018
CR Bloch SB, 2013, ACTA OPHTHALMOL, V91, P42, DOI 10.1111/j.1755-3768.2011.02268.x
   Bolz M, 2010, BRIT J OPHTHALMOL, V94, P185, DOI 10.1136/bjo.2008.143974
   Cho HJ, 2016, AM J OPHTHALMOL, V166, P112, DOI 10.1016/j.ajo.2016.03.039
   Chong V, 2016, EYE, V30, P1526, DOI 10.1038/eye.2016.202
   Clemens CR, 2012, BRIT J OPHTHALMOL, V96, P1088, DOI 10.1136/bjophthalmol-2011-301415
   Ferreira A, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0133968
   Fung AE, 2007, AM J OPHTHALMOL, V143, P566, DOI 10.1016/j.ajo.2007.01.028
   Hata M, 2017, RETINA-J RET VIT DIS, V37, P1320, DOI 10.1097/IAE.0000000000001370
   Heier JS, 2012, OPHTHALMOLOGY, V119, P2537, DOI 10.1016/j.ophtha.2012.09.006
   Holz FG, 2011, OPHTHALMOLOGY, V118, P663, DOI 10.1016/j.ophtha.2010.12.019
   Kim YM, 2012, AM J OPHTHALMOL, V154, P164, DOI 10.1016/j.ajo.2012.01.030
   Lotery A, 2017, EYE, V31, P1697, DOI 10.1038/eye.2017.143
   Mathew R, 2013, AM J OPHTHALMOL, V155, P720, DOI 10.1016/j.ajo.2012.11.003
   Oishi A, 2013, GRAEF ARCH CLIN EXP, V251, P435, DOI 10.1007/s00417-012-2034-4
   Oishi A, 2010, AM J OPHTHALMOL, V150, P27, DOI 10.1016/j.ajo.2010.02.012
   Pauleikhoff D, 2002, GRAEF ARCH CLIN EXP, V240, P533, DOI 10.1007/s00417-002-0505-8
   Querques G, 2011, AM J OPHTHALMOL, V152, P100, DOI 10.1016/j.ajo.2011.01.027
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Sarwar S, 2016, COCHRANE DB SYST REV, V2
   Schmidt-Erfurth U, 2016, PROG RETIN EYE RES, V50, P1, DOI 10.1016/j.preteyeres.2015.07.007
   Schmidt-Erfurth U, 2015, OPHTHALMOLOGY, V122, P822, DOI 10.1016/j.ophtha.2014.11.017
   Shaikh AH, 2015, OSLI RETINA, V46, P62, DOI 10.3928/23258160-20150101-10
   Simader C, 2014, OPHTHALMOLOGY, V121, P1237, DOI 10.1016/j.ophtha.2013.12.029
   Sivaprasad S, 2013, AM J OPHTHALMOL, V155
   Waldstein SM, 2016, OPHTHALMOLOGY, V123, P1521, DOI 10.1016/j.ophtha.2016.03.037
   Waldstein SM, 2016, JAMA OPHTHALMOL, V134, P182, DOI 10.1001/jamaophthalmol.2015.4948
   Yonekawa Y, 2015, J CLIN MED, V4, P343, DOI 10.3390/jcm4020343
NR 27
TC 31
Z9 31
U1 0
U2 1
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 2045-2322
J9 SCI REP-UK
JI Sci Rep
PD JAN 24
PY 2019
VL 9
AR 529
DI 10.1038/s41598-018-36704-6
PG 10
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA HI6GY
UT WOS:000456553400094
PM 30679743
OA Green Published, gold
DA 2022-11-30
ER

PT J
AU Abecasis, GR
   Yashar, BM
   Zhao, Y
   Ghiasvand, NM
   Zareparsi, S
   Branham, KEH
   Reddick, AC
   Trager, EH
   Yoshida, S
   Bahling, J
   Filippova, E
   Elner, S
   Johnson, MW
   Vine, AK
   Sieving, PA
   Jacobson, SG
   Richards, JE
   Swaroop, A
AF Abecasis, GR
   Yashar, BM
   Zhao, Y
   Ghiasvand, NM
   Zareparsi, S
   Branham, KEH
   Reddick, AC
   Trager, EH
   Yoshida, S
   Bahling, J
   Filippova, E
   Elner, S
   Johnson, MW
   Vine, AK
   Sieving, PA
   Jacobson, SG
   Richards, JE
   Swaroop, A
TI Age-related macular degeneration: A high-resolution genome scan for
   susceptibility loci in a population enriched for late-stage disease
SO AMERICAN JOURNAL OF HUMAN GENETICS
LA English
DT Article
ID BEAVER DAM EYE; NONPARAMETRIC LINKAGE ANALYSIS; RISK-FACTORS; FAMILIAL
   AGGREGATION; MACULOPATHY; DRUSEN; STRATEGIES; PREVALENCE; DEPOSITS;
   GENETICS
AB Age-related macular degeneration (AMD) is a complex multifactorial disease that affects the central region of the retina. AMD is clinically heterogeneous, leading to geographic atrophy (GA) and/or choroidal neovascularization (CNV) at advanced stages. Considerable data exists in support of a genetic predisposition for AMD. Recent linkage studies have provided evidence in favor of several AMD susceptibility loci. We have performed a high-resolution (5-cM) genome scan of 412 affected relative pairs that were enriched for late-stage disease ( GA and/or CNV). Nonparametric linkage analysis was performed using two different diagnostic criteria and also by dividing the affected individuals according to GA or CNV phenotype. Our results demonstrate evidence of linkage in regions that were suggested in at least one previous study at chromosomes 1q ( 236 - 240 cM in the Marshfield genetic map), 5p ( 40 - 50 cM), and 9q ( 111 cM). Multipoint analysis of affected relatives with CNV provided evidence of additional susceptibility loci on chromosomes 2p ( 10 cM) and 22q ( 25 cM). A recently identified Gln5345Arg change in HEMICENTIN-1 on chromosome 1q25 was not detected in 274 affected members in the restricted group with AMD, 346 additional patients with AMD, and 237 unaffected controls. Our results consolidate the chromosomal locations of several AMD susceptibility loci and, together with previous reports, should facilitate the search for disease-associated sequence variants.
C1 Univ Michigan, WK Kellogg Eye Ctr, Dept Ophthalmol & Visual Sci, Ann Arbor, MI 48105 USA.
   Univ Michigan, Dept Biostat, Ann Arbor, MI 48105 USA.
   Univ Michigan, Dept Human Genet, Ann Arbor, MI 48105 USA.
   Univ Michigan, Dept Epidemiol, Ann Arbor, MI 48105 USA.
   Univ Penn, Scheie Eye Inst, Philadelphia, PA 19104 USA.
C3 University of Michigan System; University of Michigan; University of
   Michigan System; University of Michigan; University of Michigan System;
   University of Michigan; University of Michigan System; University of
   Michigan; University of Pennsylvania
RP Swaroop, A (通讯作者)，Univ Michigan, WK Kellogg Eye Ctr, Dept Ophthalmol & Visual Sci, 1000 Wall St, Ann Arbor, MI 48105 USA.
EM swaroop@umich.edu
RI Abecasis, Goncalo R/B-7840-2010
OI Johnson, Mark W/0000-0001-9720-8761; Yashar, Beverly
   M./0000-0003-0807-3258; Yoshida, Shigeo/0000-0003-1049-8909; Swaroop,
   Anand/0000-0002-1975-1141; Branham, Kari/0000-0002-2492-254X; Abecasis,
   Goncalo/0000-0003-1509-1825; Jacobson, Samuel/0000-0003-2122-169X
FU NATIONAL EYE INSTITUTE [F32EY014085] Funding Source: NIH RePORTER;
   NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERS
   [Z01DC000065, ZIADC000065] Funding Source: NIH RePORTER; NEI NIH HHS
   [F32 EY014085, F32-EY014085] Funding Source: Medline
CR Abecasis GR, 2002, NAT GENET, V30, P97, DOI 10.1038/ng786
   Abecasis GR, 2001, EUR J HUM GENET, V9, P130, DOI 10.1038/sj.ejhg.5200594
   Abecasis GR, 2001, BIOINFORMATICS, V17, P742, DOI 10.1093/bioinformatics/17.8.742
   Allikmets R, 2000, AM J HUM GENET, V67, P487, DOI 10.1086/303018
   Ambati J, 2003, SURV OPHTHALMOL, V48, P257, DOI 10.1016/S0039-6257(03)00030-4
   Bird AC, 2003, EYE, V17, P457, DOI 10.1038/sj.eye.6700562
   BIRD AEC, 1995, SURV OPHTHALMOL, V39, P367, DOI 10.1016/S0039-6257(05)80092-X
   BRESSLER NM, 1988, SURV OPHTHALMOL, V32, P375, DOI 10.1016/0039-6257(88)90052-5
   Cai JY, 2000, PROG RETIN EYE RES, V19, P205, DOI 10.1016/S1350-9462(99)00009-9
   Crabb JW, 2002, P NATL ACAD SCI USA, V99, P14682, DOI 10.1073/pnas.222551899
   DeWan AT, 2002, AM J HUM GENET, V70, P101, DOI 10.1086/324774
   Epstein MP, 2000, AM J HUM GENET, V67, P1219, DOI 10.1016/S0002-9297(07)62952-8
   Evans JR, 2001, PROG RETIN EYE RES, V20, P227, DOI 10.1016/S1350-9462(00)00023-9
   Gorin MB, 1999, MOL VIS, V5, pU31
   Green W R, 1999, Mol Vis, V5, P27
   Hageman GS, 2001, PROG RETIN EYE RES, V20, P705, DOI 10.1016/S1350-9462(01)00010-6
   Hekimi S, 2003, SCIENCE, V299, P1351, DOI 10.1126/science.1082358
   Hirvela H, 1996, OPHTHALMOLOGY, V103, P871, DOI 10.1016/S0161-6420(96)30593-9
   Johnson LV, 2002, P NATL ACAD SCI USA, V99, P11830, DOI 10.1073/pnas.192203399
   Klaver CCW, 1998, ARCH OPHTHALMOL-CHIC, V116, P1646, DOI 10.1001/archopht.116.12.1646
   Klein ML, 1998, ARCH OPHTHALMOL-CHIC, V116, P1082, DOI 10.1001/archopht.116.8.1082
   Klein R, 1997, OPHTHALMOLOGY, V104, P7, DOI 10.1016/S0161-6420(97)30368-6
   KLEIN R, 1992, OPHTHALMOLOGY, V99, P933
   Kong A, 1997, AM J HUM GENET, V61, P1179, DOI 10.1086/301592
   Kruglyak L, 1998, AM J HUM GENET, V62, P994, DOI 10.1086/301792
   Majewski J, 2003, AM J HUM GENET, V73, P540, DOI 10.1086/377701
   Malek G, 2003, AM J PATHOL, V162, P413, DOI 10.1016/S0002-9440(10)63836-9
   MILLER SA, 1988, NUCLEIC ACIDS RES, V16, P1215, DOI 10.1093/nar/16.3.1215
   *NAT ADV EYE COUNC, 1998, PUBL NAT ADV EYE COU
   Prevent Blindness America National Eye Institute, 2002, VIS PROBL US PREV AD
   RISCH N, 1990, AM J HUM GENET, V46, P229
   Schick JH, 2003, AM J HUM GENET, V72, P1412, DOI 10.1086/375500
   Schmidt Silke, 2002, Ophthalmic Genet, V23, P209, DOI 10.1076/opge.23.4.209.13883
   Schultz DW, 2003, HUM MOL GENET, V12, P3315, DOI 10.1093/hmg/ddg348
   Seddon JM, 2003, AM J HUM GENET, V73, P780, DOI 10.1086/378505
   Seddon JM, 1997, AM J OPHTHALMOL, V123, P199, DOI 10.1016/S0002-9394(14)71036-0
   Sengul H, 2001, AM J HUM GENET, V69, P179, DOI 10.1086/321264
   Smith W, 2001, OPHTHALMOLOGY, V108, P697, DOI 10.1016/S0161-6420(00)00580-7
   Stone EM, 2001, HUM MOL GENET, V10, P2285, DOI 10.1093/hmg/10.20.2285
   Sullivan PF, 2003, AM J MED GENET B, V121B, P89, DOI 10.1002/ajmg.b.20069
   VINGERLING JR, 1995, OPHTHALMOLOGY, V102, P205
   WEBER BHF, 1994, NAT GENET, V8, P352, DOI 10.1038/ng1294-352
   Weeks DE, 2000, HUM MOL GENET, V9, P1329, DOI 10.1093/hmg/9.9.1329
   Weeks DE, 2001, AM J OPHTHALMOL, V132, P682, DOI 10.1016/S0002-9394(01)01214-4
   Weir BS, 1990, GENETIC DATA ANAL
   WHITTEMORE AS, 1994, BIOMETRICS, V50, P118, DOI 10.2307/2533202
   Yoshida S, 2002, INVEST OPHTH VIS SCI, V43, P2554
NR 47
TC 117
Z9 125
U1 0
U2 6
PU CELL PRESS
PI CAMBRIDGE
PA 50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA
SN 0002-9297
EI 1537-6605
J9 AM J HUM GENET
JI Am. J. Hum. Genet.
PD MAR
PY 2004
VL 74
IS 3
BP 482
EP 494
DI 10.1086/382786
PG 13
WC Genetics & Heredity
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Genetics & Heredity
GA 801TP
UT WOS:000220118500015
PM 14968411
OA Green Published, Bronze
DA 2022-11-30
ER

PT J
AU Sakurada, Y
   Sugiyama, A
   Kikushima, W
   Yoneyama, S
   Tanabe, N
   Matsubara, M
   Iijima, H
AF Sakurada, Yoichi
   Sugiyama, Atsushi
   Kikushima, Wataru
   Yoneyama, Seigo
   Tanabe, Naohiko
   Matsubara, Mio
   Iijima, Hiroyuki
TI Pseudodrusen pattern and development of late age-related macular
   degeneration in the fellow eye of the unilateral case
SO JAPANESE JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
DE Pseudodrusen pattern; Ribbon-dominant type; Dot-dominant type; Choroidal
   neovascularization; Geographic atrophy
ID POLYPOIDAL CHOROIDAL VASCULOPATHY; RETICULAR PSEUDODRUSEN; JAPANESE
   PATIENTS; PREVALENCE; SUBTYPES
AB Purpose To investigate whether the development of late age-related macular degeneration (AMD) in fellow eyes with pseudodrusen is associated with the pseudodrusen pattern in patients with unilateral exudative AMD. Study design Retrospective observational study. Methods A retrospective analysis was performed on 73 patients with unilateral exudative AMD showing pseudodrusen in their fellow eyes. Eyes were classified according to pseudodrusen pattern, which was determined based on maximum pseudodrusen ribbon length. Results During the mean follow-up period of 35.5 +/- 18.6 months, 21 (28.8%) eyes developed late AMD. Among these eyes, 15 (71%) developed exudative AMD and six (29%) developed geographic atrophy (GA). Development of late AMD in fellow eyes occurred with significantly more prevalence in patients showing a ribbon-dominant type pseudodrusen pattern in their fellow eye than dot-dominant type (P=0.0005, log-rank test). Cox-regression analysis revealed that development of late AMD in fellow eyes is associated with the presence of ribbon-dominant pseudodrusen in the fellow eyes (hazard ratio 4.15, 95% confidence interval (CI) 1.59-10.8), along with older age (hazard ratio 1.10, 95% CI 1.03-1.17), a history of smoking (hazard ratio 17.2, 95% CI 1.11-263), the presence of large soft drusen in the fellow eye. (hazard ratio 5.49, 95% CI 1.29-21.1) and retinal angiomatous proliferation (hazard ratio 5.02, 95% CI 1.90-13.2) Conclusions Fellow eyes with ribbon-dominant pseudodrusen in patients with unilateral exudative AMD are likely to develop late AMD.
C1 [Sakurada, Yoichi; Sugiyama, Atsushi; Kikushima, Wataru; Yoneyama, Seigo; Tanabe, Naohiko; Matsubara, Mio; Iijima, Hiroyuki] Univ Yamanashi, Dept Ophthalmol, Fac Med, Chuo, Yamanashi, Japan.
C3 University of Yamanashi
RP Sakurada, Y (通讯作者)，Univ Yamanashi, Dept Ophthalmol, Fac Med, Chuo, Yamanashi, Japan.
EM sakurada@yamanashi.ac.jp
CR Elfandi S, 2016, OPHTHALMOLOGY, V123, P2205, DOI 10.1016/j.ophtha.2016.06.052
   Ferris FL, 2005, ARCH OPHTHALMOL-CHIC, V123, P1570
   Finger RP, 2014, OPHTHALMOLOGY, V121, P1252, DOI 10.1016/j.ophtha.2013.12.034
   Hogg RE, 2014, OPHTHALMOLOGY, V121, P1748, DOI 10.1016/j.ophtha.2014.03.015
   Kim JH, 2015, RETINA-J RET VIT DIS, V35, P2604, DOI 10.1097/IAE.0000000000000633
   Kim JH, 2013, AM J OPHTHALMOL, V155, P743, DOI 10.1016/j.ajo.2012.11.001
   MIMOUN G, 1990, J FR OPHTALMOL, V13, P511
   Nathoo NA, 2014, AM J OPHTHALMOL, V158, P757, DOI 10.1016/j.ajo.2014.06.021
   Oshima Y, 2001, BRIT J OPHTHALMOL, V85, P1153, DOI 10.1136/bjo.85.10.1153
   Sakurada Y, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0149978
   Shijo T, 2017, GRAEF ARCH CLIN EXP, V255, P1125, DOI 10.1007/s00417-017-3622-0
   Solomon SD, 2007, ARCH OPHTHALMOL-CHIC, V125, P1323
   Suzuki M, 2014, AM J OPHTHALMOL, V157, P1005, DOI 10.1016/j.ajo.2014.01.025
   Ueda-Arakawa N, 2013, AM J OPHTHALMOL, V155, P260, DOI 10.1016/j.ajo.2012.08.011
   Ueta T, 2008, AM J OPHTHALMOL, V146, P96, DOI 10.1016/j.ajo.2008.03.002
   Wong T, 2008, OPHTHALMOLOGY, V115, P116, DOI 10.1016/j.ophtha.2007.03.008
   Yoneyama S, 2014, GRAEF ARCH CLIN EXP, V252, P1435, DOI 10.1007/s00417-014-2601-y
   Zhou Q, 2016, OPHTHALMOLOGY, V123, P1530, DOI 10.1016/j.ophtha.2016.02.043
   Zhou Q, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0149030
   Zweifel SA, 2010, OPHTHALMOLOGY, V117, P303, DOI 10.1016/j.ophtha.2009.07.014
NR 20
TC 9
Z9 9
U1 0
U2 1
PU SPRINGER JAPAN KK
PI TOKYO
PA SHIROYAMA TRUST TOWER 5F, 4-3-1 TORANOMON, MINATO-KU, TOKYO, 105-6005,
   JAPAN
SN 0021-5155
EI 1613-2246
J9 JPN J OPHTHALMOL
JI Jpn. J. Ophthalmol.
PD SEP
PY 2019
VL 63
IS 5
BP 374
EP 381
DI 10.1007/s10384-019-00680-9
PG 8
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA IU6NF
UT WOS:000483702300003
PM 31267312
DA 2022-11-30
ER

PT J
AU Li, HL
   Chintalapudi, SR
   Jablonski, MM
AF Li, Huiling
   Chintalapudi, Sumana R.
   Jablonski, Monica M.
TI Current drug and molecular therapies for the treatment of atrophic
   age-related macular degeneration: phase I to phase III clinical
   development
SO EXPERT OPINION ON INVESTIGATIONAL DRUGS
LA English
DT Review
DE Atrophic age-related macular degeneration; geographic atrophy;
   complement; inflammation; visual cycle modulators; antioxidants; toxic
   by-products; vascular enhancers; stem cell therapy; gene therapy
ID RETINAL-PIGMENT EPITHELIUM; FACTOR-H POLYMORPHISM; CHOROIDAL BLOOD-FLOW;
   GEOGRAPHIC ATROPHY; OXIDATIVE STRESS; MITOCHONDRIAL DYSFUNCTION;
   COMPLEMENT INHIBITION; 7-YEAR OUTCOMES; BINDING-PROTEIN; RPE LIPOFUSCIN
AB Introduction: Age-related macular degeneration (AMD) is the leading cause of vision loss among the elderly. Atrophic AMD, including early, intermediate and geographic atrophy (GA), accounts for similar to 90% of all cases. It is a multifactorial degeneration characterized by chronic inflammation, oxidative stress and aging components. Although no FDA-approved treatment yet exists for the late stage of atrophic AMD, multiple pathological mechanisms are partially known and several promising therapies are in various stages of development.
   Areas covered: Underlying mechanisms that define atrophic AMD will help provide novel therapeutic targets that will address this largely unmet clinical need. The purpose of this paper is to review current promising drugs that are being evaluated in clinical trials. Because no pharmacological treatments are currently available for late stage of atrophic AMD, any new therapy would have extensive market potential.
   Expert opinion: The number of AMD patients is predicted to increase to similar to 30 million worldwide by 2020. In response to this enormous unmet clinical need, new promising therapies are being developed and evaluated in clinical trials. We propose that the assessment of novel interventions will also need to consider the genotypes of participants, as the benefit may be determined by polymorphisms in an individual's genetic background.
C1 [Li, Huiling] Cent S Univ, Xiangya Hosp 2, Dept Ophthalmol, Changsha, Hunan, Peoples R China.
   [Chintalapudi, Sumana R.; Jablonski, Monica M.] Univ Tennessee, Hlth Sci Ctr, Dept Ophthalmol, Hamilton Eye Inst, Memphis, TN USA.
   [Chintalapudi, Sumana R.; Jablonski, Monica M.] Univ Tennessee, Hlth Sci Ctr, Dept Anat & Neurobiol, Memphis, TN USA.
   [Jablonski, Monica M.] Univ Tennessee, Hlth Sci Ctr, Dept Pharmaceut Sci, Memphis, TN USA.
C3 Central South University; University of Tennessee System; University of
   Tennessee Health Science Center; University of Tennessee System;
   University of Tennessee Health Science Center; University of Tennessee
   System; University of Tennessee Health Science Center
RP Jablonski, MM (通讯作者)，Univ Tennessee, Hlth Sci Ctr, Hamilton Eye Inst, 930 Madison Ave,Suite 710, Memphis, TN 38163 USA.
EM mjablonski@uthsc.edu
RI Chintalapudi, Sumana Rameshbabu/AAJ-4008-2021
OI Chintalapudi, Sumana Rameshbabu/0000-0003-1079-0950
FU Research to Prevent Blindness, New York NY
FX The authors were funded by an unrestricted grant from Research to
   Prevent Blindness, New York NY.
CR Anderson DH, 2010, PROG RETIN EYE RES, V29, P95, DOI 10.1016/j.preteyeres.2009.11.003
   [Anonymous], 2005, Drugs R D, V6, P116
   Baglietto L, 2000, CANCER DETECT PREV, V24, P369
   Barot M, 2011, CURR EYE RES, V36, P1069, DOI 10.3109/02713683.2011.607536
   Beatty S, 2000, SURV OPHTHALMOL, V45, P115, DOI 10.1016/S0039-6257(00)00140-5
   Bergmann M, 2004, FASEB J, V18, P562, DOI 10.1096/fj.03-0289fje
   Bhisitkul RB, 2016, OPHTHALMOLOGY, V123, P1269, DOI 10.1016/j.ophtha.2016.01.033
   Bhutto IA, 2016, BRIT J OPHTHALMOL, V100, P720, DOI 10.1136/bjophthalmol-2015-308290
   Boltz A, 2010, INVEST OPHTH VIS SCI, V51, P4220, DOI 10.1167/iovs.09-4968
   Bressler Neil M, 2004, JAMA, V291, P1900, DOI 10.1001/jama.291.15.1900
   Camerini T, 2001, J CLIN ONCOL, V19, P1664, DOI 10.1200/JCO.2001.19.6.1664
   Cao SJ, 2013, AM J OPHTHALMOL, V156, P1176, DOI 10.1016/j.ajo.2013.08.003
   Carrion A, 2014, INVEST OPHTH VIS SCI, V55
   Cashman SM, 2011, PLOS ONE, V28
   Cherepanoff S, 2010, BRIT J OPHTHALMOL, V94, P918, DOI 10.1136/bjo.2009.165563
   Cheung CMG, 2013, AM J OPHTHALMOL, V155, P764, DOI 10.1016/j.ajo.2012.10.013
   Choi AMK, 2013, NEW ENGL J MED, V368, P651, DOI [10.1056/NEJMra1205406, 10.1056/NEJMc1303158]
   Conley B, 2000, J CLIN ONCOL, V18, P275, DOI 10.1200/JCO.2000.18.2.275
   Crabb JW, 2002, P NATL ACAD SCI USA, V99, P14682, DOI 10.1073/pnas.222551899
   Cuenca N, 2013, INVEST OPHTH VIS SCI, V54, P6745, DOI 10.1167/iovs.13-12860
   Cuervo AM, 2014, CELL RES, V24, P92, DOI 10.1038/cr.2013.153
   Damico FM, 2012, ARQ BRAS OFTALMOL, V75, P71, DOI 10.1590/S0004-27492012000100016
   Garcia CAD, 2014, OSLI RETINA, V45, P18, DOI 10.3928/23258160-20131217-01
   de Jong PTVM, 2006, NEW ENGL J MED, V355, P1474, DOI 10.1056/NEJMra062326
   Ding JD, 2008, VISION RES, V48, P339, DOI 10.1016/j.visres.2007.07.025
   Doyle SL, 2012, NAT MED, V18, P791, DOI 10.1038/nm.2717
   Ebrahimi KB, 2011, LIPIDS, V2011
   Edwards AO, 2005, SCIENCE, V308, P421, DOI 10.1126/science.1110189
   Evans JB, 2013, NAT REV DRUG DISCOV, V12, P501, DOI 10.1038/nrd4038
   Evans JR, 2004, OPHTHALMOLOGY, V111, P513, DOI 10.1016/j.ophtha.2003.07.012
   Fagerness JA, 2009, EUR J HUM GENET, V17, P100, DOI 10.1038/ejhg.2008.140
   Feher J, 2006, NEUROBIOL AGING, V27, P983, DOI 10.1016/j.neurobiolaging.2005.05.012
   Ferris FL, 2013, OPHTHALMOLOGY, V120, P844, DOI 10.1016/j.ophtha.2012.10.036
   FORMELLI F, 1993, J CLIN ONCOL, V11, P2036, DOI 10.1200/JCO.1993.11.10.2036
   Fritsche LG, 2008, NAT GENET, V40, P892, DOI 10.1038/ng.170
   Fritsche LG, 2016, NAT GENET, V48, P134, DOI 10.1038/ng.3448
   Fritsche LG, 2013, NAT GENET, V45, P433, DOI 10.1038/ng.2578
   Gehrs KM, 2006, ANN MED, V38, P450, DOI 10.1080/07853890600946724
   Grunwald JE, 2005, INVEST OPHTH VIS SCI, V46, P1033, DOI 10.1167/iovs.04-1050
   Gupta N, 2012, SCI TRANSL MED, V4, DOI 10.1126/scitranslmed.3004373
   Hageman GS, 2005, P NATL ACAD SCI USA, V102, P7227, DOI 10.1073/pnas.0501536102
   Haines JL, 2005, SCIENCE, V308, P419, DOI 10.1126/science.1110359
   Hariri A, 2015, OPHTHALMOLOGY, V122, P407, DOI 10.1016/j.ophtha.2014.08.035
   Hollyfield JG, 2008, NAT MED, V14, P194, DOI 10.1038/nm1709
   Holz FG, 2014, OPHTHALMOLOGY, V121, P1079, DOI 10.1016/j.ophtha.2013.11.023
   Jager RD, 2008, NEW ENGL J MED, V358, P2606, DOI 10.1056/NEJMra0801537
   Johnson L, 2016, INVEST OPHTH VIS SCI, V57
   Johnson LV, 2001, EXP EYE RES, V73, P887, DOI 10.1006/exer.2001.1094
   Johnson PT, 2005, INVEST OPHTH VIS SCI, V46, P4788, DOI 10.1167/iovs.05-0767
   Kanda A, 2007, P NATL ACAD SCI USA, V104, P16227, DOI 10.1073/pnas.0703933104
   Kaneko H, 2011, NATURE, V471, P325, DOI 10.1038/nature09830
   Khandhadia S, 2010, EXPERT REV MOL MED, V12, DOI 10.1017/S146239941000164X
   Kim DD, 2006, CLIN IMMUNOL, V118, P127, DOI 10.1016/j.clim.2005.10.014
   Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557
   Krishnan T, 2010, INVEST OPHTH VIS SCI, V51, P701, DOI 10.1167/iovs.09-4114
   Kubota R, 2014, RETINA-J RET VIT DIS, V34, P603, DOI 10.1097/01.iae.0000434565.80060.f8
   Kubota R, 2012, RETINA-J RET VIT DIS, V32, P183, DOI 10.1097/IAE.0b013e318217369e
   Lambert NG, 2016, PROG RETIN EYE RES, V54, P64, DOI 10.1016/j.preteyeres.2016.04.003
   Levy O, 2015, EMBO MOL MED, V7, P211, DOI 10.15252/emmm.201404524
   Leyhe T, 2014, ALZHEIMERS RES THER, V6, DOI 10.1186/alzrt249
   Lin MT, 2006, NATURE, V443, P787, DOI 10.1038/nature05292
   Fanjul-Moles ML, 2016, OXID MED CELL LONGEV, V2016, DOI 10.1155/2016/7420637
   Mariani L, 1996, TUMORI, V82, P444, DOI 10.1177/030089169608200506
   Mata NL, 2013, RETINA-J RET VIT DIS, V33, P498, DOI 10.1097/IAE.0b013e318265801d
   McGill TJ, 2012, EUR J NEUROSCI, V35, P468, DOI 10.1111/j.1460-9568.2011.07970.x
   Mitter SK, 2014, AUTOPHAGY, V10, P1989, DOI 10.4161/auto.36184
   Newman AM, 2012, GENOME MED, V4, DOI [10.1186/PREACCEPT-1418491035586234, 10.1186/gm315]
   Nitsch D, 2008, OPHTHALMOLOGY, V115, P1904, DOI 10.1016/j.ophtha.2008.06.035
   Owen CG, 2012, BRIT J OPHTHALMOL, V96, P752, DOI 10.1136/bjophthalmol-2011-301109
   Parmeggiani F, 2012, MEDIAT INFLAMM, V2012, DOI 10.1155/2012/546786
   Petrukhin K, 2007, EXPERT OPIN THER TAR, V11, P625, DOI 10.1517/14728222.11.5.625
   Quadro L, 2004, J LIPID RES, V45, P1975, DOI 10.1194/jlr.M400137-JLR200
   Ramirez C, 2016, J OCUL PHARMACOL TH, V32, P102, DOI 10.1089/jop.2015.0083
   Ribatti D, 2003, CANCER LETT, V197, P181, DOI 10.1016/S0304-3835(03)00105-8
   Rofagha S, 2013, OPHTHALMOLOGY, V120, P2292, DOI 10.1016/j.ophtha.2013.03.046
   Sadiq MA, 2015, EXPERT OPIN DRUG SAF, V14, P1147, DOI 10.1517/14740338.2015.1041916
   Schmitz-Valckenberg S, 2010, OPHTHALMOLOGE, V107, P1016, DOI 10.1007/s00347-010-2160-5
   Schmitz-Valckenberg S, 2009, SURV OPHTHALMOL, V54, P96, DOI 10.1016/j.survophthal.2008.10.004
   Schwartz SD, 2012, LANCET, V379, P713, DOI 10.1016/S0140-6736(12)60028-2
   Seddon JM, 2003, ARCH OPHTHALMOL-CHIC, V121, P785, DOI 10.1001/archopht.121.6.785
   Selden NR, 2013, J NEUROSURG-PEDIATR, V11, P643, DOI 10.3171/2013.3.PEDS12397
   Singer Michael, 2014, F1000Prime Rep, V6, P29, DOI 10.12703/P6-29
   Sogna I, 2009, RECENT RESULTS CANC, V181, P71
   Song WK, 2015, STEM CELL REP, V4, P860, DOI 10.1016/j.stemcr.2015.04.005
   Sparrow JR, 2005, EXP EYE RES, V80, P595, DOI 10.1016/j.exer.2005.01.007
   Strunnikova NV, 2010, HUM MOL GENET, V19, P2468, DOI 10.1093/hmg/ddq129
   Tan PL, 2016, HUM GENOMICS, V10, DOI 10.1186/s40246-016-0079-x
   Tanito M, 2007, INVEST OPHTH VIS SCI, V48, P1900, DOI 10.1167/iovs.06-1057
   Tarallo V, 2012, CELL, V149, P847, DOI 10.1016/j.cell.2012.03.036
   Uchida N, 2012, SCI TRANSL MED, V4, DOI 10.1126/scitranslmed.3004371
   Vogel S, 2002, BIOCHEMISTRY-US, V41, P15360, DOI 10.1021/bi0268551
   Volz C, 2015, EUR J PHARM BIOPHARM, V95, P158, DOI 10.1016/j.ejpb.2015.02.020
   Wang JJ, 2007, OPHTHALMOLOGY, V114, P92, DOI 10.1016/j.ophtha.2006.07.017
   Wheeler L, 2003, SURV OPHTHALMOL, V48, pS47, DOI 10.1016/S0039-6257(03)00004-3
   Wong T, 2008, OPHTHALMOLOGY, V115, P116, DOI 10.1016/j.ophtha.2007.03.008
   Wong WT, 2010, INVEST OPHTH VIS SCI, V51, P6131, DOI 10.1167/iovs.10-5637
   Yehoshua Z, 2014, OPHTHALMOLOGY, V121, P693, DOI 10.1016/j.ophtha.2013.09.044
   Zhou JL, 2008, PHOTOCHEM PHOTOBIOL, V84, P75, DOI 10.1111/j.1751-1097.2007.00205.x
NR 98
TC 14
Z9 14
U1 3
U2 16
PU TAYLOR & FRANCIS LTD
PI ABINGDON
PA 2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND
SN 1354-3784
EI 1744-7658
J9 EXPERT OPIN INV DRUG
JI Expert Opin. Investig. Drugs
PY 2017
VL 26
IS 10
BP 1103
EP 1114
DI 10.1080/13543784.2017.1369042
PG 12
WC Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Pharmacology & Pharmacy
GA FG1LX
UT WOS:000409558700002
PM 28816076
DA 2022-11-30
ER

PT J
AU Schmidt-Erfurth, U
   Wolf, S
AF Schmidt-Erfurth, U.
   Wolf, S.
CA PROTECT Study Grp
TI Same-day administration of verteporfin and ranibizumab 0.5 mg in
   patients with choroidal neovascularisation due to age-related macular
   degeneration
SO BRITISH JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
ID RANDOMIZED CLINICAL-TRIALS; PHOTODYNAMIC THERAPY; HYPOXIA
AB Objective: To evaluate safety of same-day administration of verteporfin and ranibizumab.
   Methods: Prospective, open-label, multicentre study; patients with predominantly classic (n = 13) or occult (n = 19) choroidal neovascularisation secondary to age-related macular degeneration received standard-fluence verteporfin at baseline and months 3, 6 and 9, based on fluorescein angiography (FA). Ranibizumab 0.5 mg was administered at baseline and months 1, 2 and 3.
   Main outcome measure: The incidence of severe vision loss (best-corrected visual acuity (BCVA) loss >= 30 letters; primary safety assessment).
   Results: No severe vision loss due to ocular inflammation or uveitis occurred. One patient had moderate vision loss (BCVA loss >= 15 letters). Three patients had mild/moderate uveitis. Two serious ocular adverse events occurred (retinal pigment epithelial tear and moderate BCVA decrease). No systemic adverse events occurred. At 9 months, all lesions were inactive with no recurrent leakage on FA and optical coherence tomography; macular oedema and subretinal fluid resolved. The mean BCVA measured at 2 m improved by 6.9 letters at 4 months and 2.4 letters at 9 months.
   Conclusions/application to clinical practice: Same-day verteporfin and ranibizumab was safe and not associated with severe vision loss or severe ocular inflammation. Lesions stabilized, with minimal treatment required after month 3.
C1 [Schmidt-Erfurth, U.] Univ Vienna, Dept Ophthalmol, Univ Klin Augenheilkunde & Optometrie, AKH Vienna, A-1090 Vienna, Austria.
   [Wolf, S.] Univ Bern, Inselspital, Klin & Poliklin Augenheilkunde, CH-3010 Bern, Switzerland.
C3 University of Vienna; University of Bern; University Hospital of Bern
RP Schmidt-Erfurth, U (通讯作者)，Univ Vienna, Dept Ophthalmol, Univ Klin Augenheilkunde & Optometrie, AKH Vienna, Wahringer Gurtel 18-20, A-1090 Vienna, Austria.
EM ursula.schmidt-erfurth@meduniwien.ac.at
RI Wolf, Sebastian/B-8782-2008
OI Wolf, Sebastian/0000-0002-7467-7028
FU Novartis Pharma AG, Basel, Switzerland; Pfizer Inc.; Allergan Inc.
FX Funding: This study was supported by Novartis Pharma AG, Basel,
   Switzerland.; Competing interests: US-E is an inventor on the patent on
   the use of verteporfin in ocular vascular disease under the guidelines
   of the Wellman Laboratories patent policy/Harvard Medical School. She
   has received financial support from Novartis Pharma AG for travel
   expenses and contributions to conferences and advisory boards and
   institutional support for commercially sponsored studies. SW has
   received financial support from Novartis Pharma AG for travel expenses
   and contributions to conferences and advisory boards and institutional
   support for commercially sponsored studies. He has received financial
   support from Pfizer Inc. and Allergan Inc. for travel expenses and
   advisory boards.
CR Arnold J, 2001, AM J OPHTHALMOL, V131, P541
   Blumenkranz MS, 2001, ARCH OPHTHALMOL-CHIC, V119, P198
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Chakravarthy U, 2006, OPHTHALMOLOGY, V113, P1508, DOI 10.1016/j.ophtha.2006.02.064
   Forsythe JA, 1996, MOL CELL BIOL, V16, P4604
   Gollnick SO, 2003, BRIT J CANCER, V88, P1772, DOI 10.1038/sj.bjc.6600864
   Greve MDJ, 2005, ARCH OPHTHALMOL-CHIC, V123, P448
   Heier JS, 2006, ARCH OPHTHALMOL-CHIC, V124, P1532, DOI 10.1001/archopht.124.11.1532
   Kaiser PK, 2006, GRAEF ARCH CLIN EXP, V244, P1132, DOI 10.1007/s00417-005-0199-9
   LANZETTA P, 2007, INVEST OPHTHALMOL VI, V48
   Michels S, 2003, INVEST OPHTH VIS SCI, V44, P2147, DOI 10.1167/iovs.02-0604
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Schmidt-Erfurth U, 2000, SURV OPHTHALMOL, V45, P195, DOI 10.1016/S0039-6257(00)00158-2
   Schmidt-Erfurth U, 2002, ARCH OPHTHALMOL-CHIC, V120, P835
   Schmidt-Erfurth U, 2005, OPHTHALMOLOGY, V112, P2061, DOI 10.1016/j.ophtha.2005.09.007
   Schmidt-Erfurth U, 2003, INVEST OPHTH VIS SCI, V44, P4473, DOI 10.1167/iovs.02-1115
   SLAKTER JS, 2007, INVEST OPHTHALMOL VI, V48
   WANG GL, 1993, P NATL ACAD SCI USA, V90, P4304, DOI 10.1073/pnas.90.9.4304
NR 18
TC 33
Z9 36
U1 0
U2 0
PU B M J PUBLISHING GROUP
PI LONDON
PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND
SN 0007-1161
J9 BRIT J OPHTHALMOL
JI Br. J. Ophthalmol.
PD DEC
PY 2008
VL 92
IS 12
BP 1628
EP 1635
DI 10.1136/bjo.2007.135277
PG 8
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 376ZW
UT WOS:000261222500014
PM 18772178
DA 2022-11-30
ER

PT J
AU Khalid, S
   Akram, MU
   Hassan, T
   Nasim, A
   Jameel, A
AF Khalid, Samina
   Akram, M. Usman
   Hassan, Taimur
   Nasim, Ammara
   Jameel, Amina
TI Fully Automated Robust System to Detect Retinal Edema, Central Serous
   Chorioretinopathy, and Age Related Macular Degeneration from Optical
   Coherence Tomography Images
SO BIOMED RESEARCH INTERNATIONAL
LA English
DT Article
ID CLASSIFICATION
AB Maculopathy is the excessive damage to macula that leads to blindness. It mostly occurs due to retinal edema (RE), central serous chorioretinopathy (CSCR), or age related macular degeneration (ARMD). Optical coherence tomography (OCT) imaging is the latest eye testing technique that can detect these syndromes in early stages. Many researchers have used OCT images to detect retinal abnormalities. However, to the best of our knowledge, no research that presents a fully automated system to detect all of these macular syndromes is reported. This paper presents the world's first ever decision support system to automatically detect RE, CSCR, and ARMD retinal pathologies and healthy retina from OCT images. The automated disease diagnosis in our proposed system is based on multilayered support vector machines (SVM) classifier trained on 40 labeled OCT scans (10 healthy, 10 RE, 10 CSCR, and 10 ARMD). After training, SVM forms an accurate decision about the type of retinal pathology using 9 extracted features. We have tested our proposed system on 2819 OCT scans (1437 healthy, 640 RE, and 742 CSCR) of 502 patients from two different datasets and our proposed system correctly diagnosed 2817/2819 subjects with the accuracy, sensitivity, and specificity ratings of 99.92%, 100%, and 99.86%, respectively.
C1 [Khalid, Samina] Mirpur Univ Sci & Technol, Dept Comp Sci & Informat Technol, Mirpur, Pakistan.
   [Khalid, Samina] Bahria Univ, Dept Software Engn, Islamabad, Pakistan.
   [Akram, M. Usman; Hassan, Taimur] Natl Univ Sci & Technol, Dept Comp Engn, Islamabad, Pakistan.
   [Hassan, Taimur; Nasim, Ammara] Bahria Univ, Dept Elect Engn, Islamabad, Pakistan.
   [Jameel, Amina] Bahria Univ, Dept Comp Engn, Islamabad, Pakistan.
C3 National University of Sciences & Technology - Pakistan
RP Khalid, S (通讯作者)，Mirpur Univ Sci & Technol, Dept Comp Sci & Informat Technol, Mirpur, Pakistan.; Khalid, S (通讯作者)，Bahria Univ, Dept Software Engn, Islamabad, Pakistan.
EM samina.csit@must.edu.pk
RI Hassan, Taimur/AAO-3928-2020; Akram, Muhammad Usman/AAD-7343-2020;
   Khalid, Samina/AAV-3527-2021
OI Hassan, Taimur/0000-0002-5896-8677; Akram, Muhammad
   Usman/0000-0002-6208-7231; Khalid, Samina/0000-0003-4771-6842
CR Ahlers C, 2009, ACTA OPHTHALMOL, V87, P511, DOI 10.1111/j.1755-3768.2008.01468.x
   [Anonymous], 2011, PAKIISTAN J OPHTHALM
   CANNY J, 1986, IEEE T PATTERN ANAL, V8, P679, DOI 10.1109/TPAMI.1986.4767851
   Fan RE, 2008, J MACH LEARN RES, V9, P1871
   Farsiu S, 2014, OPHTHALMOLOGY, V121, P162, DOI 10.1016/j.ophtha.2013.07.013
   Fernandez DC, 2005, INVEST OPHTH VIS SCI, V46
   Ferrara D, 2014, OPHTHALMOLOGY, V121, P719, DOI 10.1016/j.ophtha.2013.10.014
   Hannouche RZ, 2008, ARQ BRAS OFTALMOL, V71, P759, DOI 10.1590/S0004-27492008000500030
   Hassan B, 2016, J OPT SOC AM A, V33, P455, DOI 10.1364/JOSAA.33.000455
   Hassan T., 2015, P 12 IEEE INT C IM S
   Helmy YM, 2013, CLIN OPHTHALMOL, V7, P1731, DOI 10.2147/OPTH.S47987
   Hirai FE, 2008, AM J OPHTHALMOL, V145, P700, DOI 10.1016/j.ajo.2007.11.019
   J S., 2015, INT J RES MED SCI, V3, P1885, DOI [10.18203/2320-6012.ijrms20150296, DOI 10.18203/2320-6012.IJRMS20150296]
   Jager R. D., 2008, NEW ENGL J MED, V358, P2544
   Khan A., 2011, PAK J OPHTHALMOL, V27, P155
   Knutsson H., 1989, Proceedings of 6th Scandinavian Conference on Image Analysis, P244
   Lim J., 1990, 2 DIMENSIONAL SIGNAL
   Mitarai K, 2006, GRAEF ARCH CLIN EXP, V244, P1415, DOI 10.1007/s00417-006-0277-7
   Mokwa NF, 2013, J OPHTHALMOL, V2013, DOI 10.1155/2013/385915
   Nicholson B, 2013, SURV OPHTHALMOL, V58, P103, DOI 10.1016/j.survophthal.2012.07.004
   Sahar S., 2015, P INT C SOFTW ENG KN
   Saine P. J., 2006, OPHTHALMIC PHOTOGRAP, V2, P70
   Sezgin M, 2004, J ELECTRON IMAGING, V13, P146, DOI 10.1117/1.1631315
   Shrestha A, 2012, NEPAL J OPHTHALMOL, V4, P128, DOI 10.3126/nepjoph.v4i1.5864
   Srinivasan PP, 2014, BIOMED OPT EXPRESS, V5, P3568, DOI 10.1364/BOE.5.003568
   Sugmk J., 2014, P 7 BIOM ENG INT C B
   Teke MY, 2014, INT J OPHTHALMOL-CHI, V7, P350, DOI 10.3980/j.issn.2222-3959.2014.02.29
   Wani JS, 2015, J EVOL MED DENT SCI-, V4, P7801, DOI 10.14260/jemds/2015/1135
   Wilkins GR, 2012, IEEE T BIO-MED ENG, V59, P1109, DOI 10.1109/TBME.2012.2184759
   Zhang L, 2015, I S BIOMED IMAGING, P1494, DOI 10.1109/ISBI.2015.7164160
   Zhang W, 2008, INT J OPHTHALMOL-CHI, V1, P370
NR 31
TC 22
Z9 23
U1 0
U2 3
PU HINDAWI LTD
PI LONDON
PA ADAM HOUSE, 3RD FLR, 1 FITZROY SQ, LONDON, W1T 5HF, ENGLAND
SN 2314-6133
EI 2314-6141
J9 BIOMED RES INT
JI Biomed Res. Int.
PY 2017
VL 2017
AR 7148245
DI 10.1155/2017/7148245
PG 15
WC Biotechnology & Applied Microbiology; Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biotechnology & Applied Microbiology; Research & Experimental Medicine
GA ER8YI
UT WOS:000399109100001
PM 28424788
OA Green Published, gold, Green Submitted
DA 2022-11-30
ER

PT J
AU Rizzolo, LJ
   Nasonkin, IO
   Adelman, RA
AF Rizzolo, Lawrence J.
   Nasonkin, Igor O.
   Adelman, Ron A.
TI Retinal Cell Transplantation, Biomaterials, and In Vitro Models for
   Developing Next-generation Therapies of Age-related Macular Degeneration
SO STEM CELLS TRANSLATIONAL MEDICINE
LA English
DT Review
DE retina; retinal pigment epithelium; age-related macular degeneration;
   tissue scaffolds; cell transplantation; stem cells; biomaterials
ID EPITHELIUM-DERIVED FACTOR; EMBRYONIC STEM-CELLS; PIGMENT EPITHELIUM;
   MOLECULAR SIGNATURE; TIGHT JUNCTIONS; RPE; CHORIOCAPILLARIS; MEMBRANE;
   DIFFERENTIATION; EXPRESSION
AB Retinal pigment epithelium (RPE) cells grown on a scaffold, an RPE patch, have potential to ameliorate visual impairment in a limited number of retinal degenerative conditions. This tissue-replacement therapy is suited for age-related macular degeneration (AMD), and related diseases. RPE cells must be transplanted before the disease reaches a point of no return, represented by the loss of photoreceptors. Photoreceptors are specialized, terminally differentiated neurosensory cells that must interact with RPE's apical processes to be functional. Human photoreceptors are not known to regenerate. On the RPE's basal side, the RPE transplant must induce the reformation of the choriocapillaris, thereby re-establishing the outer blood-retinal barrier. Because the scaffold is positioned between the RPE and choriocapillaris, it should ideally degrade and be replaced by the natural extracellular matrix that separates these tissues. Besides biodegradable, the scaffolds need to be nontoxic, thin enough to not affect the focal length of the eye, strong enough to survive the transplant procedure, yet flexible enough to conform to the curvature of the retina. The challenge is patients with progressing AMD treasure their remaining vision and fear that a risky surgical procedure will further degrade their vision. Accordingly, clinical trials only treat eyes with severe impairment that have few photoreceptors to interact with the transplanted patch. Although safety has been demonstrated, the cell-replacement mechanism and efficacy remain difficult to validate. This review covers the structure of the retina, the pathology of AMD, the limitations of cell therapy approaches, and the recent progress in developing retinal therapies using biomaterials.
C1 [Rizzolo, Lawrence J.; Adelman, Ron A.] Yale Univ, Dept Ophthalmol & Visual Sci, New Haven, CT USA.
   [Rizzolo, Lawrence J.] Yale Univ, Dept Surg, New Haven, CT 06520 USA.
   [Nasonkin, Igor O.] Phythera Therapeut LLC, San Leandro, CA USA.
C3 Yale University; Yale University
RP Rizzolo, LJ (通讯作者)，24 Long Hill Farm, Guilford, CT 06437 USA.; Nasonkin, IO (通讯作者)，Phythera Therapeut, 3021 Teagarden St, San Leandro, CA 92612 USA.
EM lawrence.rizzolo@yale.edu; inasonkin@phytheratx.com
OI Rizzolo, Lawrence/0000-0002-2393-8419
FU Alonzo Family Fund; Newman's Own Foundation; Leir Foundation; Research
   to Prevent Blindness (Yale University)
FX The work in the authors laboratory has been funded by the Alonzo Family
   Fund (L.J.R.), Newman's Own Foundation and Leir Foundation (R.A.A.), and
   Research to Prevent Blindness (Yale University).
CR Aboulizadeh E, 2020, STEM CELL REP, V15, P482, DOI 10.1016/j.stemcr.2020.06.019
   Ach T, 2014, INVEST OPHTH VIS SCI, V55, P4832, DOI 10.1167/iovs.14-14802
   Achberger K, 2019, ELIFE, V8, DOI 10.7554/eLife.46188
   Akhtar T, 2019, STEM CELL RES, V39, DOI 10.1016/j.scr.2019.101491
   Ambati J, 2012, NEURON, V75, P26, DOI 10.1016/j.neuron.2012.06.018
   [Anonymous], 2020, UN NEWS
   Apel P, 2001, RADIAT MEAS, V34, P559, DOI 10.1016/S1350-4487(01)00228-1
   Assawachananont J, 2014, STEM CELL REP, V2, P662, DOI 10.1016/j.stemcr.2014.03.011
   Ben M'Barek K, 2017, SCI TRANSL MED, V9, DOI 10.1126/scitranslmed.aai7471
   Benedicto I, 2017, NAT COMMUN, V8, DOI 10.1038/ncomms15374
   Bharti K, 2022, RES SQUARE, DOI [10.21203/rs.3.rs-135775/v1, DOI 10.21203/RS.3.RS-135775/V1]
   Bhutto I, 2012, MOL ASPECTS MED, V33, P295, DOI 10.1016/j.mam.2012.04.005
   Biesemeier A, 2014, NEUROBIOL AGING, V35, P2562, DOI 10.1016/j.neurobiolaging.2014.05.003
   Blaauwgeers HGT, 1999, AM J PATHOL, V155, P421, DOI 10.1016/S0002-9440(10)65138-3
   Bonilha VL, 2014, EXP EYE RES, V126, P38, DOI 10.1016/j.exer.2013.09.015
   Capowski EE, 2019, DEVELOPMENT, V146, DOI 10.1242/dev.171686
   Chaudhary R, 2020, TRANSL VIS SCI TECHN, V9, DOI 10.1167/tvst.9.3.23
   Chen XY, 2020, CURR EYE RES, V45, P1390, DOI 10.1080/02713683.2020.1740744
   Chew EY, 2019, OPHTHALMOLOGY, V126, P540, DOI 10.1016/j.ophtha.2018.09.041
   Chirco KR, 2017, EYE, V31, P10, DOI 10.1038/eye.2016.216
   Chung M, 2018, ADV HEALTHC MATER, V7, DOI 10.1002/adhm.201700028
   da Cruz L, 2018, NAT BIOTECHNOL, V36, P1, DOI 10.1038/nbt.4114
   Davis RJ, 2017, STEM CELL REP, V9, P42, DOI 10.1016/j.stemcr.2017.05.016
   Ebneter A, 2016, INVEST OPHTH VIS SCI, V57, pOCT299, DOI 10.1167/iovs.15-18865
   Eiraku M, 2011, NATURE, V472, P51, DOI 10.1038/nature09941
   Fields MA, 2020, PROG RETIN EYE RES, V76, DOI 10.1016/j.preteyeres.2019.100803
   Finnemann SC, 1997, P NATL ACAD SCI USA, V94, P12932, DOI 10.1073/pnas.94.24.12932
   Galloway CA, 2018, INVEST OPHTH VIS SCI, V59, P2792, DOI 10.1167/iovs.17-23157
   Galloway CA, 2017, P NATL ACAD SCI USA, V114, pE8214, DOI 10.1073/pnas.1710430114
   Gambril JA, 2019, INVEST OPHTH VIS SCI, V60, P2481, DOI 10.1167/iovs.19-26949
   Ghareeb AE, 2020, STEM CELL TRANSL MED, V9, P1531, DOI 10.1002/sctm.20-0201
   Ghezzi D, 2015, FRONT NEUROSCI-SWITZ, V9, DOI 10.3389/fnins.2015.00290
   Ghosh Fredrik, 2011, Tissue Eng Part A, V17, P1675, DOI 10.1089/ten.TEA.2008.0450
   Hallam D, 2018, STEM CELLS, V36, P1535, DOI 10.1002/stem.2883
   Hambright D, 2012, MOL VIS, V18, P920
   Heier J.S., 2017, CELLULAR THERAPIES R, P95
   Heier JS, 2020, OPHTHALMOL RETINA, V4, P384, DOI 10.1016/j.oret.2019.11.011
   Hernandez-Pinto A, 2019, EXP EYE RES, V184, P24, DOI 10.1016/j.exer.2019.04.008
   Higuchi A, 2017, TRENDS BIOTECHNOL, V35, P1102, DOI 10.1016/j.tibtech.2017.06.016
   HOLLYFIELD JG, 1974, J EXP ZOOL, V189, P357, DOI 10.1002/jez.1401890309
   Hongisto H, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-06233-9
   Hotaling NA, 2016, J OCUL PHARMACOL TH, V32, P272, DOI 10.1089/jop.2015.0157
   Hussain AA, 2010, EXP EYE RES, V90, P703, DOI 10.1016/j.exer.2010.02.013
   Idelson M, 2018, STEM CELL REP, V11, P681, DOI 10.1016/j.stemcr.2018.07.009
   Idrees Sana, 2019, Int Ophthalmol Clin, V59, P221, DOI 10.1097/IIO.0000000000000258
   Jablonski MM, 2000, J NEUROSCI, V20, P7149
   Jha BS, 2015, CURR STEM CELL REP, V1, P79, DOI 10.1007/s40778-015-0014-4
   Johnson LV, 2011, P NATL ACAD SCI USA, V108, P18277, DOI 10.1073/pnas.1109703108
   Jones BW, 2005, EXP EYE RES, V81, P123, DOI 10.1016/j.exer.2005.03.006
   Kamao H, 2017, INVEST OPHTH VIS SCI, V58, P211, DOI 10.1167/iovs.16-19778
   Kamao H, 2014, STEM CELL REP, V2, P205, DOI 10.1016/j.stemcr.2013.12.007
   Kashani AH, 2020, OPHTHALMOL RETINA, V4, P264, DOI 10.1016/j.oret.2019.09.017
   Kashani AH, 2018, SCI TRANSL MED, V10, DOI 10.1126/scitranslmed.aao4097
   Koss MJ, 2016, GRAEF ARCH CLIN EXP, V254, P1553, DOI 10.1007/s00417-016-3386-y
   Lakkaraju A, 2020, PROG RETIN EYE RES, V78, DOI 10.1016/j.preteyeres.2020.100846
   Lee IK, 2021, SCI ADV, V7, DOI 10.1126/sciadv.abf0344
   Li R, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0023148
   Liao JL, 2010, HUM MOL GENET, V19, P4229, DOI 10.1093/hmg/ddq341
   Lu B, 2009, STEM CELLS, V27, P2126, DOI 10.1002/stem.149
   Lu B, 2012, BIOMED MICRODEVICES, V14, P659, DOI 10.1007/s10544-012-9645-8
   Mandai M, 2017, NEW ENGL J MED, V376, P1038, DOI 10.1056/NEJMoa1608368
   Manian KV, 2021, CELL STEM CELL, V28, P846, DOI 10.1016/j.stem.2021.02.006
   Marneros AG, 2005, AM J PATHOL, V167, P1451, DOI 10.1016/S0002-9440(10)61231-X
   Matsumoto E, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0212369
   McClements ME, 2020, FRONT NEUROSCI-SWITZ, V14, DOI 10.3389/fnins.2020.570909
   McGill TJ, 2019, TRANSL VIS SCI TECHN, V8, DOI 10.1167/tvst.8.3.43
   McGill TJ, 2012, EUR J NEUROSCI, V35, P468, DOI 10.1111/j.1460-9568.2011.07970.x
   McHugh KJ, 2014, INVEST OPHTH VIS SCI, V55, P1754, DOI 10.1167/iovs.13-12833
   McLelland BT, 2018, INVEST OPHTH VIS SCI, V59, P2586, DOI 10.1167/iovs.17-23646
   McUsic AC, 2012, BIOMATERIALS, V33, P1396, DOI 10.1016/j.biomaterials.2011.10.083
   Mitrousis N, 2020, BIOMATERIALS, V257, DOI 10.1016/j.biomaterials.2020.120233
   Miyagishima KJ, 2016, STEM CELL TRANSL MED, V5, P1562, DOI 10.5966/sctm.2016-0037
   Molday RS, 2015, J CELL SCI, V128, P4039, DOI 10.1242/jcs.175687
   Murali A, 2020, EUR J OPHTHALMOL, V30, P1195, DOI 10.1177/1120672120919337
   Nakano T, 2012, CELL STEM CELL, V10, P771, DOI 10.1016/j.stem.2012.05.009
   Nasonkin I, 1998, HUM GENET, V102, P21, DOI 10.1007/s004390050649
   Nasonkin IO, 2013, DEVELOPMENT, V140, P1330, DOI 10.1242/dev.086603
   Nazari H, 2015, PROG RETIN EYE RES, V48, P1, DOI 10.1016/j.preteyeres.2015.06.004
   Neves J, 2016, SCIENCE, V353, DOI 10.1126/science.aaf3646
   Nickerson PEB, 2018, FRONT NEURAL CIRCUIT, V12, DOI 10.3389/fncir.2018.00017
   Niknejad H, 2008, EUR CELLS MATER, V15, P88
   Nommiste B, 2017, PROG BRAIN RES, V231, P225, DOI 10.1016/bs.pbr.2017.03.003
   Occelli LM., 2021, JOVE-J VIS EXP, V174
   Peng SM, 2013, STEM CELL TRANSL MED, V2, P534, DOI 10.5966/sctm.2012-0134
   Pennington KL, 2016, EYE VISION, V3, DOI 10.1186/s40662-016-0063-5
   Pilgrim MG, 2017, INVEST OPHTH VIS SCI, V58, DOI 10.1167/iovs.16-21060
   Radisic M, 2019, ELIFE, V8, DOI 10.7554/eLife.51183
   Radtke ND, 2008, AM J OPHTHALMOL, V146, P172, DOI 10.1016/j.ajo.2008.04.009
   Ribeiro J, 2021, CELL REP, V35, DOI 10.1016/j.celrep.2021.109022
   Rizzolo LJ, 2014, EXP EYE RES, V126, P16, DOI 10.1016/j.exer.2013.12.018
   Rizzolo LJ, 2011, PROG RETIN EYE RES, V30, P296, DOI 10.1016/j.preteyeres.2011.06.002
   Saint-Geniez M, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003554
   Schwartz SD, 2016, INVEST OPHTH VIS SCI, V57, DOI 10.1167/iovs.15-18681
   Schwartz SD, 2012, LANCET, V379, P713, DOI 10.1016/S0140-6736(12)60028-2
   Seddon Johanna M, 2016, JAMA Ophthalmol, V134, P1272, DOI 10.1001/jamaophthalmol.2016.3519
   Seiler MJ, 2014, GRAEF ARCH CLIN EXP, V252, P1079, DOI 10.1007/s00417-014-2638-y
   Seiler MJ, 2012, PROG RETIN EYE RES, V31, P661, DOI 10.1016/j.preteyeres.2012.06.003
   Sharma R, 2020, ANNU REV PHARMACOL, V60, P553, DOI 10.1146/annurev-pharmtox-010919-023245
   Sharma R, 2019, SCI TRANSL MED, V11, DOI 10.1126/scitranslmed.aat5580
   Shirai H, 2016, P NATL ACAD SCI USA, V113, pE81, DOI 10.1073/pnas.1512590113
   Singh D, 2020, INVEST OPHTH VIS SCI, V61, DOI 10.1167/iovs.61.13.9
   Singh D, 2018, BIOMATERIALS, V154, P158, DOI 10.1016/j.biomaterials.2017.10.052
   Singh R., 2021, STEM CELLS DEV
   Singh RK, 2021, STEM CELLS DEV, V30, P399, DOI 10.1089/scd.2020.0085
   Singh RK, 2021, J OCUL PHARMACOL TH, V37, P147, DOI 10.1089/jop.2020.0016
   Singh RK, 2019, STEM CELLS DEV, V28, P1151, DOI 10.1089/scd.2019.0090
   Singh RK, 2014, INVEST OPHTH VIS SCI, V55, P3081, DOI 10.1167/iovs.13-13728
   Sommer JR, 2011, BRIT J OPHTHALMOL, V95, P1749, DOI 10.1136/bjophthalmol-2011-300417
   Spaide RF, 2020, OPHTHALMOLOGY, V127, P616, DOI 10.1016/j.ophtha.2019.11.004
   STEELE FR, 1993, P NATL ACAD SCI USA, V90, P1526, DOI 10.1073/pnas.90.4.1526
   Stern JH, 2018, CELL STEM CELL, V22, P834, DOI 10.1016/j.stem.2018.05.013
   Strauss O, 2005, PHYSIOL REV, V85, P845, DOI 10.1152/physrev.00021.2004
   Strunnikova NV, 2010, HUM MOL GENET, V19, P2468, DOI 10.1093/hmg/ddq129
   Sun R, 2008, MOL VIS, V14, P2237
   Tarau IS, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20143578
   Thomas BB, 2016, INVEST OPHTH VIS SCI, V57, P2877, DOI 10.1167/iovs.16-19238
   Volpert Katja N, 2009, J Ocul Biol Dis Infor, V2, P1, DOI 10.1007/s12177-009-9014-x
   Wahlin KJ, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-00774-9
   White CE, 2017, J TISSUE ENG, V8, DOI 10.1177/2041731417720841
   Wiley LA, 2015, CSH PERSPECT MED, V5, DOI 10.1101/cshperspect.a017160
   Winkler PA, 2020, CELLS-BASEL, V9, DOI 10.3390/cells9040882
   Yao J, 2015, TISSUE ENG PT A, V21, P1247, DOI [10.1089/ten.tea.2013.0720, 10.1089/ten.TEA.2013.0720]
   Ye K, 2020, SCI REP-UK, V10, DOI 10.1038/s41598-020-70979-y
   Yeo NJY, 2019, FRONT PHARMACOL, V10, DOI 10.3389/fphar.2019.01363
   Zadeh MA, 2019, DRUG DISCOV TODAY, V24, P1669, DOI 10.1016/j.drudis.2019.04.009
   Zhong XF, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms5047
NR 126
TC 1
Z9 1
U1 2
U2 4
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 2157-6564
EI 2157-6580
J9 STEM CELL TRANSL MED
JI Stem Cells Transl. Med.
PD MAR 31
PY 2022
VL 11
IS 3
BP 269
EP 281
DI 10.1093/stcltm/szac001
EA MAR 2022
PG 13
WC Cell & Tissue Engineering
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Cell Biology
GA 0E0UX
UT WOS:000763016900001
PM 35356975
OA Green Published, gold
DA 2022-11-30
ER

PT J
AU Jemni-Damer, N
   Guedan-Duran, A
   Fuentes-Andion, M
   Serrano-Bengoechea, N
   Alfageme-Lopez, N
   Armada-Maresca, F
   Guinea, GV
   Perez-Rigueiro, J
   Rojo, F
   Gonzalez-Nieto, D
   Kaplan, DL
   Panetsos, F
AF Jemni-Damer, Nahla
   Guedan-Duran, Atocha
   Fuentes-Andion, Maria
   Serrano-Bengoechea, Nora
   Alfageme-Lopez, Nuria
   Armada-Maresca, Felix
   Guinea, Gustavo V.
   Perez-Rigueiro, Jose
   Rojo, Francisco
   Gonzalez-Nieto, Daniel
   Kaplan, David L.
   Panetsos, Fivos
TI Biotechnology and Biomaterial-Based Therapeutic Strategies for
   Age-Related Macular Degeneration. Part I: Biomaterials-Based Drug
   Delivery Devices
SO FRONTIERS IN BIOENGINEERING AND BIOTECHNOLOGY
LA English
DT Review
DE retinal pigment epithelium; Bruch&#8217; s membrane; retina;
   biomaterials; neuroprotection; ocular drug delivery; nanocarriers; VEGF
ID DEXAMETHASONE INTRAVITREAL IMPLANT; COMPLEMENT FACTOR-H; FLUOCINOLONE
   ACETONIDE IMPLANT; ENDOTHELIAL GROWTH-FACTOR; POSTERIOR SEGMENT;
   CONTROLLED-RELEASE; SUSTAINED DELIVERY; OXIDATIVE STRESS; CHOROIDAL
   NEOVASCULARIZATION; PLGA NANOPARTICLES
AB Age-related Macular Degeneration (AMD) is an up-to-date untreatable chronic neurodegenerative eye disease of multifactorial origin, and the main causes of blindness in over 65 years old people. It is characterized by a slow progression and the presence of a multitude of factors, highlighting those related to diet, genetic heritage and environmental conditions, present throughout each of the stages of the illness. Current therapeutic approaches, mainly consisting of intraocular drug delivery, are only used for symptoms relief and/or to decelerate the progression of the disease. Furthermore, they are overly simplistic and ignore the complexity of the disease and the enormous differences in the symptomatology between patients. Due to the wide impact of the AMD and the up-to-date absence of clinical solutions, the development of biomaterials-based approaches for a personalized and controlled delivery of therapeutic drugs and biomolecules represents the main challenge for the defeat of this neurodegenerative disease. Here we present a critical review of the available and under development AMD therapeutic approaches, from a biomaterials and biotechnological point of view. We highlight benefits and limitations and we forecast forthcoming alternatives based on novel biomaterials and biotechnology methods. In the first part we expose the physiological and clinical aspects of the disease, focusing on the multiple factors that give origin to the disorder and highlighting the contribution of these factors to the triggering of each step of the disease. Then we analyze available and under development biomaterials-based drug-delivery devices (DDD), taking into account the anatomical and functional characteristics of the healthy and ill retinal tissue.
C1 [Jemni-Damer, Nahla; Guedan-Duran, Atocha; Fuentes-Andion, Maria; Serrano-Bengoechea, Nora; Alfageme-Lopez, Nuria; Panetsos, Fivos] Univ Complutense Madrid, Neurocomp & Neurorobot Res Grp, Madrid, Spain.
   [Jemni-Damer, Nahla; Guedan-Duran, Atocha; Fuentes-Andion, Maria; Serrano-Bengoechea, Nora; Alfageme-Lopez, Nuria; Panetsos, Fivos] Inst Hlth Res San Carlos Clin Hosp IdISSC, Innovat Grp, Madrid, Spain.
   [Guedan-Duran, Atocha; Kaplan, David L.] Tufts Univ, Dept Biochem Engn, Medford, MA 02155 USA.
   [Serrano-Bengoechea, Nora; Alfageme-Lopez, Nuria; Guinea, Gustavo V.; Perez-Rigueiro, Jose; Rojo, Francisco; Gonzalez-Nieto, Daniel; Panetsos, Fivos] Silk Biomed SL, Madrid, Spain.
   [Armada-Maresca, Felix] La Paz Univ Hosp, Ophthalmol Serv, Madrid, Spain.
   [Guinea, Gustavo V.; Perez-Rigueiro, Jose; Rojo, Francisco; Gonzalez-Nieto, Daniel] Univ Politecn Madrid, Ctr Biomed Technol, Madrid, Spain.
   [Guinea, Gustavo V.; Perez-Rigueiro, Jose; Rojo, Francisco] Univ Politecn Madrid, Civil Engn Super Sch, Dept Mat Sci, Madrid, Spain.
   [Guinea, Gustavo V.; Perez-Rigueiro, Jose; Rojo, Francisco; Gonzalez-Nieto, Daniel] Biomat & Nanomed CIBER BBN, Biomed Res Networking Ctr Bioengn, Madrid, Spain.
C3 Complutense University of Madrid; Tufts University; Hospital
   Universitario La Paz; Universidad Politecnica de Madrid; Centro de
   Tecnologia Biomedica (CTB); Universidad Politecnica de Madrid; CIBER -
   Centro de Investigacion Biomedica en Red; CIBERBBN
RP Panetsos, F (通讯作者)，Univ Complutense Madrid, Neurocomp & Neurorobot Res Grp, Madrid, Spain.; Panetsos, F (通讯作者)，Inst Hlth Res San Carlos Clin Hosp IdISSC, Innovat Grp, Madrid, Spain.; Panetsos, F (通讯作者)，Silk Biomed SL, Madrid, Spain.
EM fivos@ucm.es
OI Guedan Duran, Atocha/0000-0002-0544-9574; Fuentes-Andion,
   Maria/0000-0002-3059-8360; Panetsos, Fivos/0000-0003-0897-411X
FU Spanish Ministerio de Economia y Competitividad [MAT2016-76847-R,
   MAT2016-79832-R, MAT2015-66666-C3-3-R]; Comunidad de Madrid, Spain
   [Neurocentro-B2017/BrMD-3760, IND2018/BrMD-9804]; National Institutes of
   Health [P41EB002520]; Spanish Ministerio de Economia y Competitividad;
   Comunidad de Madrid, Spain
FX The authors gratefully acknowledge financial support received from the
   Spanish Ministerio de Economia y Competitividad through grants
   MAT2016-76847-R, MAT2016-79832-R and MAT2015-66666-C3-3-R; from the
   Comunidad de Madrid, Spain through grants Neurocentro-B2017/BrMD-3760
   and IND2018/BrMD-9804, from the National Institutes of Health
   (P41EB002520); and predoctoral FPI grant from the Spanish Ministerio de
   Economia y Competitividad (AG-D) and research contract from the
   Comunidad de Madrid, Spain (MF-A).
CR Abrishami M, 2009, RETINA-J RET VIT DIS, V29, P699, DOI 10.1097/IAE.0b013e3181a2f42a
   Adams CM, 2018, J MED CHEM, V61, P1622, DOI 10.1021/acs.jmedchem.7b01731
   Agrawal AK, 2012, EXPERT OPIN DRUG DEL, V9, P383, DOI 10.1517/17425247.2012.665367
   Alexander A, 2014, EUR J PHARM BIOPHARM, V88, P575, DOI 10.1016/j.ejpb.2014.07.005
   Ambati J, 2012, NEURON, V75, P26, DOI 10.1016/j.neuron.2012.06.018
   Ameeduzzafar, 2016, DRUG DELIV, V23, P710, DOI 10.3109/10717544.2014.923065
   Anderson DH, 2002, AM J OPHTHALMOL, V134, P411, DOI 10.1016/S0002-9394(02)01624-0
   [Anonymous], 2013, NANOMATERIALS DRUG D
   Anwary M, 2018, ARTIF CELL NANOMED B, V46, P1074, DOI 10.1080/21691401.2018.1478845
   Ardeljan D, 2013, PROG RETIN EYE RES, V37, P68, DOI 10.1016/j.preteyeres.2013.07.003
   Arranz-Romera A, 2019, J CONTROL RELEASE, V297, P26, DOI 10.1016/j.jconrel.2019.01.012
   Awwad S, 2019, EUR J PHARM SCI, V137, DOI 10.1016/j.ejps.2019.104993
   Awwad S, 2018, MACROMOL BIOSCI, V18, DOI 10.1002/mabi.201700255
   Awwad S, 2015, J PHARM SCI-US, V104, P3330, DOI 10.1002/jps.24480
   Bahram M., 2016, EMERGING CONCEPTS AN, DOI 10.5772/64301
   Baino F, 2020, BIOENGINEERING-BASEL, V7, DOI 10.3390/bioengineering7030065
   Bansal P, 2016, J OCUL PHARMACOL TH, V32, P135, DOI 10.1089/jop.2015.0133
   Basuki JS, 2017, ANGEW CHEM INT EDIT, V56, P966, DOI 10.1002/anie.201610618
   Beatty S, 2000, SURV OPHTHALMOL, V45, P115, DOI 10.1016/S0039-6257(00)00140-5
   Bernards DA, 2012, NANO LETT, V12, P5355, DOI 10.1021/nl302747y
   Bezatis A, 2013, ACTA OPHTHALMOL, V91, pE340, DOI 10.1111/aos.12020
   Bhatt P, 2019, AAPS PHARMSCITECH, V20, DOI 10.1208/s12249-019-1474-0
   Bhavsar AR, 2009, ARCH OPHTHALMOL-CHIC, V127, P1581, DOI 10.1001/archophthalmol.2009.304
   Bourges JL, 2006, ADV DRUG DELIVER REV, V58, P1182, DOI 10.1016/j.addr.2006.07.026
   Boyer DS, 2011, RETINA-J RET VIT DIS, V31, P915, DOI 10.1097/IAE.0b013e318206d18c
   Bressler NM, 2002, ARCH OPHTHALMOL-CHIC, V120, P1443
   Bringmann A, 2009, PROG RETIN EYE RES, V28, P423, DOI 10.1016/j.preteyeres.2009.07.001
   Burke J, 1996, SURV OPHTHALMOL, V41, pS9, DOI 10.1016/S0039-6257(96)82027-3
   Callanan DG, 2008, ARCH OPHTHALMOL-CHIC, V126, P1191, DOI 10.1001/archopht.126.9.1191
   Campbell M, 2013, ADV EXP MED BIOL, V763, P70
   Campochiaro PA, 2019, OPHTHALMOLOGY, V126, P1141, DOI 10.1016/j.ophtha.2019.03.036
   Campochiaro PA, 2012, OPHTHALMOLOGY, V119, P2125, DOI 10.1016/j.ophtha.2012.04.030
   Campochiaro PA, 2011, OPHTHALMOLOGY, V118, P626, DOI 10.1016/j.ophtha.2010.12.028
   Casado Jose Manuel Ribera, 2009, Servir, V57, P46
   Chan A, 2011, CLIN OPHTHALMOL, V5, P1043, DOI 10.2147/OPTH.S13775
   Chang D, 2019, DRUG DISCOV TODAY, V24, P1470, DOI 10.1016/j.drudis.2019.05.037
   Cherry JD, 2014, J NEUROINFLAMM, V11, DOI 10.1186/1742-2094-11-98
   ClinicalTrials.gov, 2020, COMB RAN IL DIAB MAC
   ClinicalTrials.gov, 2020, PHAS 3 STUD EV PORT
   ClinicalTrials.gov, 2020, EXT STUD PORT DEL SY
   ClinicalTrials.gov, 2020, FLUOC AC DIAB MAC ED
   ClinicalTrials.gov, 2020, 20089 TA KUC COMB IN
   ClinicalTrials.gov, 2020, SAF EFF STUD BRIM IN
   Crouch RK, 2015, PROG MOL BIOL TRANSL, V134, P449, DOI 10.1016/bs.pmbts.2015.06.005
   Cuenca N, 2014, PROG RETIN EYE RES, V43, P17, DOI 10.1016/j.preteyeres.2014.07.001
   Cunha-Vaz J, 2011, EUR J OPHTHALMOL, V21, pS3, DOI 10.5301/EJO.2010.6049
   Damian Javier, 2006, Aten Primaria, V38, P51, DOI 10.1157/13090016
   Daneault V, 2016, J PHYSIOL ANTHROPOL, V35, DOI 10.1186/s40101-016-0091-9
   Davis BM, 2014, SMALL, V10, P1575, DOI 10.1002/smll.201303433
   Deb PK, 2018, ADV PHARM PROD DEVL, P57, DOI 10.1016/B978-0-12-814423-7.00002-2
   del Amo EM, 2008, DRUG DISCOV TODAY, V13, P135, DOI 10.1016/j.drudis.2007.11.002
   Desai T., 2014, ZORDERA
   Ding SY, 2016, NAT REV MATER, V1, DOI [10.1038/natrevmats.2016.21, 10.1038/natrevmats.2016.71]
   Drapala PW, 2014, PHARM RES-DORDR, V31, P742, DOI 10.1007/s11095-013-1195-0
   Ebrahim S, 2005, SURV OPHTHALMOL, V50, P167, DOI 10.1016/j.survophthal.2004.12.006
   Edington M, 2017, EXPERT OPIN DRUG MET, V13, P1217, DOI 10.1080/17425255.2017.1404987
   Evans JR, 2004, BRIT J OPHTHALMOL, V88, P365, DOI 10.1136/bjo.2003.019927
   Eyewire News, 2020, OC THER ANN DOS 1 PA
   Falavarjani KG, 2013, EYE, V27, P787, DOI 10.1038/eye.2013.107
   Fenton C, 2006, DRUG AGING, V23, P421, DOI 10.2165/00002512-200623050-00006
   Ferris FL, 2005, ARCH OPHTHALMOL-CHIC, V123, P1570
   Fleckenstein M, 2018, OPHTHALMOLOGY, V125, P369, DOI 10.1016/j.ophtha.2017.08.038
   Fomina N, 2010, J AM CHEM SOC, V132, P9540, DOI 10.1021/ja102595j
   Freund KB, 2013, EXPERT OPIN PHARMACO, V14, P1017, DOI 10.1517/14656566.2013.787410
   Friedman D. S., 2012, VISION PROBLEMS US
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P564
   Fuchs H, 2017, J OCUL PHARMACOL TH, V33, P115, DOI 10.1089/jop.2016.0083
   Galante R, 2018, J BIOMED MATER RES B, V106, P2472, DOI 10.1002/jbm.b.34048
   Gao H, 2002, ARCH OPHTHALMOL-CHIC, V120, P797
   Garciia M. A., 2013, GACETA OPTOMETRIIA O, V487, P24
   Gaudana R, 2009, PHARM RES-DORDR, V26, P1197, DOI 10.1007/s11095-008-9694-0
   Ghasemi Falavarjani Khalil, 2009, J Ophthalmic Vis Res, V4, P191
   Grossniklaus HE, 2002, MOL VIS, V8, P119
   Gutierrez-Hernandez JC, 2014, TRANSL VIS SCI TECHN, V3, DOI 10.1167/tvst.3.4.1
   Haghjou Nahid, 2011, J Ophthalmic Vis Res, V6, P317
   Haller JA, 2010, OPHTHALMOLOGY, V117, P1134, DOI 10.1016/j.ophtha.2010.03.032
   Hammer N, 2015, MACROMOL BIOSCI, V15, P405, DOI 10.1002/mabi.201400379
   Handa JT, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-11262-1
   Hans ML, 2002, CURR OPIN SOLID ST M, V6, P319, DOI 10.1016/S1359-0286(02)00117-1
   Hanus J, 2015, AGEING RES REV, V24, P286, DOI 10.1016/j.arr.2015.09.002
   Herrero-Vanrell R, 2001, ADV DRUG DELIVER REV, V52, P5, DOI 10.1016/S0169-409X(01)00200-9
   Herrero-Vanrell R, 2014, PROG RETIN EYE RES, V42, P27, DOI 10.1016/j.preteyeres.2014.04.002
   Honda M, 2013, INT J NANOMED, V8, P495, DOI 10.2147/IJN.S30725
   HORA MS, 1990, PHARMACEUT RES, V7, P1190, DOI 10.1023/A:1015948829632
   Hu CC, 2019, TECHNOL HEALTH CARE, V27, pS153, DOI 10.3233/THC-199015
   Humayun M, 2014, TRANSL VIS SCI TECHN, V3, DOI 10.1167/tvst.3.6.5
   IAPB Vision Atlas, 2017, GLOB VIS DAT MAPS
   Imperiale JC, 2018, J CONTROL RELEASE, V285, P106, DOI 10.1016/j.jconrel.2018.06.031
   Jackson TL, 2017, JAMA OPHTHALMOL, V135, P761, DOI 10.1001/jamaophthalmol.2017.1571
   Jaffe GJ, 2000, INVEST OPHTH VIS SCI, V41, P3569
   Jager RD, 2008, NEW ENGL J MED, V358, P2606, DOI 10.1056/NEJMra0801537
   Jager RD, 2004, RETINA-J RET VIT DIS, V24, P676, DOI 10.1097/00006982-200410000-00002
   Jarrett SG, 2012, MOL ASPECTS MED, V33, P399, DOI 10.1016/j.mam.2012.03.009
   JARRETT T, 2017, INVEST OPHTH VIS SCI, V58
   Jeffries AM, 2014, J PHYSIOL-PARIS, V108, P3, DOI 10.1016/j.jphysparis.2013.10.001
   Jiang SR, 2019, MACROMOL MATER ENG, V304, DOI 10.1002/mame.201900087
   Jonas JB, 2017, ASIA-PAC J OPHTHALMO, V6, P493, DOI 10.22608/APO.2017251
   Kandatsu N, 2005, ANESTHESIOLOGY, V102, P1182, DOI 10.1097/00000542-200506000-00018
   Kane FE, 2008, EXPERT OPIN DRUG DEL, V5, P1039, DOI 10.1517/17425247.5.9.1039 
   Kang DJJ, 2008, T AM OPHTHAL SOC, V106, P206
   Kang-Mieler JJ, 2020, EYE, V34, P1371, DOI 10.1038/s41433-020-0809-0
   Kang-Mieler JJ, 2017, EXPERT OPIN DRUG DEL, V14, P611, DOI 10.1080/17425247.2016.1227785
   Kang-Mieler JJ, 2014, EXPERT OPIN DRUG DEL, V11, P1647, DOI 10.1517/17425247.2014.935338
   Kanjickal D, 2008, J BIOMED MATER RES A, V87A, P608, DOI 10.1002/jbm.a.31811
   Karajanagi SS, 2011, BIOTECHNOL BIOENG, V108, P1716, DOI 10.1002/bit.23105
   Khan JC, 2006, BRIT J OPHTHALMOL, V90, P75, DOI 10.1136/bjo.2005.073643
   Kim CE, 2017, SCI REP-UK, V7, DOI 10.1038/srep44364
   Kinnunen K, 2012, ACTA OPHTHALMOL, V90, P299, DOI 10.1111/j.1755-3768.2011.02179.x
   Kirchhof S, 2015, EUR J PHARM BIOPHARM, V96, P217, DOI 10.1016/j.ejpb.2015.07.024
   Kirchhof S, 2015, EUR J PHARM BIOPHARM, V95, P227, DOI 10.1016/j.ejpb.2015.05.016
   Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557
   Klein R, 2011, ARCH OPHTHALMOL-CHIC, V129, P75, DOI 10.1001/archophthalmol.2010.318
   Koerselman M, 2020, OSTEOARTHR CARTILAGE, V28, pS37
   Kuno N, 2010, DRUG AGING, V27, P117, DOI 10.2165/11530970-000000000-00000
   Kuppermann BD, 2007, ARCH OPHTHALMOL-CHIC, V125, P309, DOI 10.1001/archopht.125.3.309
   la Cour M, 2002, DRUG AGING, V19, P101, DOI 10.2165/00002512-200219020-00003
   Lai JY, 2013, J MATER SCI-MATER M, V24, P2201, DOI 10.1007/s10856-013-4961-y
   Lajavardi L, 2007, INVEST OPHTH VIS SCI, V48, P3230, DOI 10.1167/iovs.06-1305
   Lance KD, 2016, DRUG DELIV TRANSL RE, V6, P771, DOI 10.1007/s13346-016-0298-7
   Lance KD, 2015, INVEST OPHTH VIS SCI, V56, P7331, DOI 10.1167/iovs.15-17757
   Li FF, 2012, OPEN OPHTHALMOL J, V6, P54, DOI 10.2174/1874364101206010054
   Lim JI, 2015, BRIT J OPHTHALMOL, V99, P618, DOI 10.1136/bjophthalmol-2014-306002
   Lim JI, 1999, AM J OPHTHALMOL, V127, P288, DOI 10.1016/S0002-9394(98)00443-7
   Lim JH, 2012, AM J OPHTHALMOL, V153, P678, DOI 10.1016/j.ajo.2011.09.013
   Lin MT, 2006, NATURE, V443, P787, DOI 10.1038/nature05292
   Linsley CS, 2017, THER DELIV, V8, P89, DOI 10.4155/tde-2016-0060
   Liu JX, 2019, INT J PHARMACEUT, V563, P228, DOI 10.1016/j.ijpharm.2019.04.012
   Liu WQ, 2019, TRANSL VIS SCI TECHN, V8, DOI 10.1167/tvst.8.1.12
   Liu WQ, 2019, CURR EYE RES, V44, P264, DOI 10.1080/02713683.2018.1533983
   Lo R, 2009, BIOMED MICRODEVICES, V11, P959, DOI 10.1007/s10544-009-9313-9
   Lovett ML, 2015, EUR J PHARM BIOPHARM, V95, P271, DOI 10.1016/j.ejpb.2014.12.029
   Machinaga N, 2018, TRANSL VIS SCI TECHN, V7, DOI 10.1167/tvst.7.4.21
   Mainardes RM, 2005, CURR DRUG TARGETS, V6, P363, DOI 10.2174/1389450053765914
   Mandal A, 2018, ADV DRUG DELIVER REV, V126, P67, DOI 10.1016/j.addr.2018.01.008
   Mandal A, 2017, J CONTROL RELEASE, V248, P96, DOI 10.1016/j.jconrel.2017.01.012
   Manoharan C, 2009, J PHARM SCI-US, V98, P529, DOI 10.1002/jps.21445
   Marin-Teva JL, 2011, NEURON GLIA BIOL, V7, P25, DOI 10.1017/S1740925X12000014
   Martin DF, 2012, OPHTHALMOLOGY, V119, DOI 10.1016/j.ophtha.2012.03.053
   Mason JO, 2008, RETINA-J RET VIT DIS, V28, P564, DOI 10.1097/IAE.0b013e3181633fee
   Matanovic MR, 2014, INT J PHARMACEUT, V472, P262, DOI 10.1016/j.ijpharm.2014.06.029
   McConnell V, 2005, Ulster Med J, V74, P82
   McLaughlin MM, 2013, JAMA OPHTHALMOL, V131, P1595, DOI 10.1001/jamaophthalmol.2013.5002
   Medina C, 2007, BRIT J PHARMACOL, V150, P552, DOI 10.1038/sj.bjp.0707130
   Mi FL, 2002, BIOMATERIALS, V23, P3257, DOI 10.1016/S0142-9612(02)00084-4
   Michalska-Malecka K, 2015, EUR GERIATR MED, V6, P69, DOI 10.1016/j.eurger.2014.09.007
   MOGHIMI SM, 1989, BIOCHIM BIOPHYS ACTA, V984, P384
   MORITERA T, 1991, INVEST OPHTH VIS SCI, V32, P1785
   Mu HJ, 2018, DRUG DELIV, V25, P1372, DOI 10.1080/10717544.2018.1474967
   Narvekar P, 2019, ASSAY DRUG DEV TECHN, V17, P167, DOI 10.1089/adt.2019.920
   Nash B, 2011, J ANAT, V219, P44, DOI 10.1111/j.1469-7580.2010.01330.x
   Navratil T., 2014, ONDRUGDELIVERY, V48, P10
   Nayak K, 2018, BIOMED PHARMACOTHER, V107, P1564, DOI 10.1016/j.biopha.2018.08.138
   Nowak JZ, 2006, PHARMACOL REP, V58, P353
   Nozaki M, 2006, P NATL ACAD SCI USA, V103, P2328, DOI 10.1073/pnas.0408835103
   Nussenblatt RB, 2007, AM J OPHTHALMOL, V144, P618, DOI 10.1016/j.ajo.2007.06.025
   Oo C, 2016, EXPERT REV CLIN PHAR, V9, P747, DOI 10.1586/17512433.2016.1160778
   Osswald CR, 2017, CURR EYE RES, V42, P1293, DOI 10.1080/02713683.2017.1302590
   Osswald CR, 2016, CURR EYE RES, V41, P1216, DOI 10.3109/02713683.2015.1101140
   Osswald CR, 2015, ANN BIOMED ENG, V43, P2609, DOI 10.1007/s10439-015-1314-7
   OTX-IVT, 2020, ANTIVEGF ANT IMPL OC
   Pan CK, 2011, J OCUL PHARMACOL TH, V27, P219, DOI 10.1089/jop.2010.0158
   Pandit J, 2017, ARTIF CELL NANOMED B, V45, P1397, DOI 10.1080/21691401.2016.1243545
   Patel Ashaben, 2013, World J Pharmacol, V2, P47
   Pirmoradi FN, 2011, LAB CHIP, V11, P2744, DOI 10.1039/c1lc20134d
   Polazzi E, 2010, PROG NEUROBIOL, V92, P293, DOI 10.1016/j.pneurobio.2010.06.009
   Qin X, 2017, WOODHEAD PUBL SER TE, V186, P41, DOI 10.1016/B978-0-08-100907-9.00003-9
   Qiu FF, 2019, MOL PHARMACEUT, V16, P1958, DOI 10.1021/acs.molpharmaceut.8b01319
   Querques L, 2013, OPHTHALMOLOGICA, V229, P21, DOI 10.1159/000342160
   Radhakrishnan K, 2017, DRUG DISCOV TODAY, V22, P416, DOI 10.1016/j.drudis.2016.10.015
   Rakesh T., 2019, BIOMATERIALS BIONANO
   Rathnasamy G, 2019, PROG NEUROBIOL, V173, P18, DOI 10.1016/j.pneurobio.2018.05.006
   Ratnapriya R, 2013, CLIN GENET, V84, P160, DOI 10.1111/cge.12206
   Rauck BM, 2014, INVEST OPHTH VIS SCI, V55, P469, DOI 10.1167/iovs.13-13120
   Risau W, 1997, NATURE, V386, P671, DOI 10.1038/386671a0
   Rivera A, 2005, HUM MOL GENET, V14, P3227, DOI 10.1093/hmg/ddi353
   Rupenthal ID, 2017, CURR OPIN PHARMACOL, V36, P44, DOI 10.1016/j.coph.2017.08.003
   Sahoo SK, 2008, DRUG DISCOV TODAY, V13, P144, DOI 10.1016/j.drudis.2007.10.021
   Sakurai E, 2001, OPHTHALMIC RES, V33, P31, DOI 10.1159/000055638
   Santhanam S, 2016, ACTA BIOMATER, V43, P327, DOI 10.1016/j.actbio.2016.07.051
   Saraf A, 2009, TISSUE ENG PART C-ME, V15, P333, DOI 10.1089/ten.tec.2008.0422
   Schlesinger E, 2015, MAT SCI ENG C-MATER, V57, P232, DOI 10.1016/j.msec.2015.07.027
   Schmit-Eilenberger VK, 2015, CLIN OPHTHALMOL, V9, P801, DOI 10.2147/OPTH.S79785
   Seah I, 2020, EYE, V34, P1341, DOI 10.1038/s41433-020-0770-y
   Sergejeva O, 2016, MEDICINA-LITHUANIA, V52, P79, DOI 10.1016/j.medici.2016.02.004
   Shah SS, 2010, EXPERT REV OPHTHALMO, V5, P75, DOI 10.1586/EOP.09.70
   Sharpe LA, 2014, EXPERT OPIN DRUG DEL, V11, P901, DOI 10.1517/17425247.2014.902047
   Shen J, 2018, PHARM RES-DORDR, V35, DOI 10.1007/s11095-018-2498-y
   Spaide RF, 2017, RETINA-J RET VIT DIS, V37, P609, DOI 10.1097/IAE.0000000000001575
   Su XY, 2015, BIOMACROMOLECULES, V16, P3093, DOI 10.1021/acs.biomac.5b01091
   Tabandeh H, 2014, RETINA-J RET VIT DIS, V34, P18, DOI 10.1097/IAE.0000000000000008
   Tanetsugu Y, 2017, BIOL PHARM BULL, V40, P145, DOI 10.1248/bpb.b16-00437
   Tang B, 2020, J CLIN MED, V9, DOI 10.3390/jcm9020462
   Tang Y, 2016, MOL NEUROBIOL, V53, P1181, DOI 10.1007/s12035-014-9070-5
   Tarallo V, 2012, CELL, V149, P847, DOI 10.1016/j.cell.2012.03.036
   Thornton J, 2005, EYE, V19, P935, DOI 10.1038/sj.eye.6701978
   Turturro SB, 2011, BIOMATERIALS, V32, P3620, DOI 10.1016/j.biomaterials.2011.01.058
   Varshochian R, 2015, J BIOMED MATER RES A, V103, P3148, DOI 10.1002/jbm.a.35446
   Varshochian R, 2013, EUR J PHARM SCI, V50, P341, DOI 10.1016/j.ejps.2013.07.014
   Huu VAN, 2015, J CONTROL RELEASE, V200, P71, DOI 10.1016/j.jconrel.2015.01.001
   Vilhardt F, 2017, BRIT J PHARMACOL, V174, P1719, DOI 10.1111/bph.13426
   Villegas VM, 2017, EXPERT OPIN DRUG DEL, V14, P273, DOI 10.1080/17425247.2016.1213240
   Wang CH, 2012, BIOMACROMOLECULES, V13, P40, DOI 10.1021/bm2009558
   Wang K, 2018, J BIOMED MATER RES A, V106, P2795, DOI 10.1002/jbm.a.36450
   Wang YF, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-08690-4
   Whitcup SM, 2015, ANN NY ACAD SCI, V1358, P1, DOI 10.1111/nyas.12824
   Wilkinson C., 2017, RYANS RETINA, V6th
   William F. R., 2012, INVEST OPHTHALMOL VI, V53
   Wills NK, 2008, EXP EYE RES, V86, P41, DOI 10.1016/j.exer.2007.09.005
   Winkler BS, 1999, MOL VIS, V5
   World Health Organization, 2018, PRIOR EYE DIS
   Xu X, 2013, INT J BIOL MACROMOL, V60, P272, DOI 10.1016/j.ijbiomac.2013.05.034
   Xue K, 2019, BIOMATER SCI-UK, V7, P4603, DOI 10.1039/c9bm01049a
   Yandrapu SK, 2013, MOL PHARMACEUT, V10, P4676, DOI 10.1021/mp400487f
   YANG H, 2014, INVEST OPHTH VIS SCI, V55
   Yang PT, 2019, INT CONF WIREL OPT, P276, DOI 10.1080/10837450.2018.1545236
   Yasukawa T, 2004, PROG RETIN EYE RES, V23, P253, DOI 10.1016/j.preteyeres.2004.02.003
   YATVIN MB, 1980, SCIENCE, V210, P1253, DOI 10.1126/science.7434025
   Ye Z, 2015, INT J OPHTHALMOL-CHI, V8, P653, DOI 10.3980/j.issn.2222-3959.2015.04.02
   Yeo Y, 2004, ARCH PHARM RES, V27, P1, DOI 10.1007/BF02980037
   Yu J, 2014, INT J PHARMACEUT, V470, P151, DOI 10.1016/j.ijpharm.2014.04.053
   Yu Y, 2019, BIOENG TRANSL MED, V4, DOI 10.1002/btm2.10128
   Yu Y, 2015, TRANSL VIS SCI TECHN, V4, DOI 10.1167/tvst.4.2.5
   Zareparsi S, 2005, AM J HUM GENET, V77, P149, DOI 10.1086/431426
NR 223
TC 4
Z9 4
U1 2
U2 10
PU FRONTIERS MEDIA SA
PI LAUSANNE
PA AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND
SN 2296-4185
J9 FRONT BIOENG BIOTECH
JI Front. Bioeng. Biotechnol.
PD NOV 3
PY 2020
VL 8
AR 549089
DI 10.3389/fbioe.2020.549089
PG 27
WC Biotechnology & Applied Microbiology; Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biotechnology & Applied Microbiology; Science & Technology - Other
   Topics
GA OT3YE
UT WOS:000590785100001
PM 33224926
OA gold, Green Published
DA 2022-11-30
ER

PT J
AU Dolar-Szczasny, J
   Bucolo, C
   Zweifel, S
   Carnevali, A
   Rejdak, R
   Zaluska, W
   Czarnek-Chudzik, A
   Toro, MD
AF Dolar-Szczasny, Joanna
   Bucolo, Claudio
   Zweifel, Sandrine
   Carnevali, Adriano
   Rejdak, Robert
   Zaluska, Wojciech
   Czarnek-Chudzik, Aleksandra
   Toro, Mario Damiano
TI Evaluation of Aqueous Flare Intensity in Eyes Undergoing Intravitreal
   Bevacizumab Therapy to Treat Neovascular Age-Related Macular
   Degeneration
SO FRONTIERS IN PHARMACOLOGY
LA English
DT Article
DE bevacizumab; neovascular age-related macular degeneration; laser-flare
   photometry; intraocular inflammation; blood-aqueous barrier integrity
ID ANTI-VEGF AGENTS; INJECTION; RANIBIZUMAB; PHOTOMETRY; TOXICITY
AB Purpose: To evaluate the effect of repeated intravitreal bevacizumab injections on blood-aqueous barrier permeability in eyes with neovascular age-related macular degeneration (AMD).
   Patients and Methods: Forty-eight consecutive patients with neovascular AMD received 3 intravitreal bevacizumab injections (1 mg) every 30-40 days. Subjects were followed for a period of 4 months and were examined at baseline, 1 day and 1 month after each injection. A control group comprised of 19 neovascular AMD patients waiting to begin anti-vascular endothelial growth factor (VEGF) therapy. Anterior chamber (AC) inflammation was evaluated with biomicroscopy and laser flare photometry.
   Results: None of the subjects treated with bevacizumab had detectable ocular inflammation during follow-up. An analysis for variance (ANOVA) of the mixed-effects model has shown neither an effect between treatment and control group (p = 0.921), nor over the time course of the follow-up (p = 0.773). Before treatment, median AC inflammation was 6.7 photons/ms (range: 3.5-18.2 photons/ms). One month after the first, second, and third injections, median laser flare was 6.4, 6.8, and 6.6 photons/ms, respectively, none of which were significantly different from baseline (all p > 0.05). Blood-aqueous barrier permeability did not change between injections and was not different from the control group.
   Conclusion: Inflammation induced by intravitreal bevacizumab was not detected by examination or flare photometry. This suggests that monthly bevacizumab dosing seems to be safe. The absence of AC inflammation could also reflect the known anti-inflammatory properties of anti-VEGF agents.
C1 [Dolar-Szczasny, Joanna; Rejdak, Robert; Toro, Mario Damiano] Med Univ Lublin, Dept Gen Ophthalmol, Lublin, Poland.
   [Bucolo, Claudio] Univ Catania, Sect Pharmacol, Dept Biomed & Biotechnol Sci, Catania, Italy.
   [Zweifel, Sandrine; Toro, Mario Damiano] Univ Zurich, Dept Ophthalmol, Zurich, Switzerland.
   [Carnevali, Adriano] Magna Graecia Univ Catanzaro, Dept Ophthalmol, Catanzaro, Italy.
   [Zaluska, Wojciech] Med Univ Lublin, Dept Nephrol, Lublin, Poland.
   [Czarnek-Chudzik, Aleksandra] Med Univ Lublin, Dept Diagnost & Microsurg Glaucoma, Lublin, Poland.
   [Toro, Mario Damiano] Cardinal Stefan Wyszynski Univ, Coll Med, Fac Med Sci, Warsaw, Poland.
C3 Medical University of Lublin; University of Catania; University of
   Zurich; Magna Graecia University of Catanzaro; Medical University of
   Lublin; Medical University of Lublin; Cardinal Stefan Wyszynski
   University in Warsaw
RP Dolar-Szczasny, J; Toro, MD (通讯作者)，Med Univ Lublin, Dept Gen Ophthalmol, Lublin, Poland.; Toro, MD (通讯作者)，Univ Zurich, Dept Ophthalmol, Zurich, Switzerland.; Toro, MD (通讯作者)，Cardinal Stefan Wyszynski Univ, Coll Med, Fac Med Sci, Warsaw, Poland.
EM joannaszczasny@op.pl; toro.mario@email.it
OI Dolar-Szczasny, Joanna/0000-0003-4206-4371; Zaluska,
   Wojciech/0000-0001-6043-3236; Rejdak, Robert/0000-0003-3321-2723
CR Adamis AP, 2005, RETINA-J RET VIT DIS, V25, P111, DOI 10.1097/00006982-200502000-00001
   Agrawal S, 2013, MEDIAT INFLAMM, V2013, DOI 10.1155/2013/943409
   [Anonymous], 2020, BEOVU UPDATE ASRS ME
   Avery Robert L, 2014, Retina, V34 Suppl 12, pS1, DOI 10.1097/IAE.0000000000000399
   Baumal CR, 2020, OPHTHALMOLOGY, V127, P1345, DOI 10.1016/j.ophtha.2020.04.017
   Berg K, 2015, OPHTHALMOLOGY, V122, P146, DOI 10.1016/j.ophtha.2014.07.041
   Blaha GR, 2015, RETINA-J RET VIT DIS, V35, P577, DOI 10.1097/IAE.0000000000000334
   Center for Drug Evaluation and Research, 2019, FDA DRUG SAFETY COMM
   Chong DY, 2010, RETINA-J RET VIT DIS, V30, P1432, DOI 10.1097/IAE.0b013e3181dc04da
   Conti B, 1997, EUR J PHARM SCI, V5, P287, DOI 10.1016/S0928-0987(97)00023-7
   Dossarps D, 2015, AM J OPHTHALMOL, V160, P17, DOI 10.1016/j.ajo.2015.04.013
   Dugel P.U., 2017, 2020 M MAC SOC MARCH
   Errera MH, 2014, J FR OPHTALMOL, V37, P30, DOI 10.1016/j.jfo.2013.02.008
   Falavarjani KG, 2013, EYE, V27, P787, DOI 10.1038/eye.2013.107
   Figurska M, 2020, EUR J OPHTHALMOL, V30, P586, DOI 10.1177/1120672119874598
   Grzybowski A, 2018, OPHTHALMOLOGICA, V239, P181, DOI 10.1159/000486145
   Haug Sara J, 2020, Am J Ophthalmol Case Rep, V18, P100680, DOI 10.1016/j.ajoc.2020.100680
   Kiss C, 2006, RETINA-J RET VIT DIS, V26, P877, DOI 10.1097/01.iae.0000237080.10627.b7
   KUBOTA T, 1994, JPN J OPHTHALMOL, V38, P67
   Ladas JG, 2005, SURV OPHTHALMOL, V50, P27, DOI 10.1016/j.survophthal.2004.10.004
   Manzano RPA, 2006, RETINA-J RET VIT DIS, V26, P257, DOI 10.1097/00006982-200603000-00001
   Martin DF, 2020, OPHTHALMOLOGY, V127, pS135, DOI 10.1016/j.ophtha.2020.01.029
   Martin DF, 2012, OPHTHALMOLOGY, V119, DOI 10.1016/j.ophtha.2012.03.053
   Martin DF, 2011, NEW ENGL J MED, V364, P1897, DOI 10.1056/NEJMoa1102673
   Mekjavic PJ, 2019, VALUE HEALTH REG ISS, V19, P1, DOI 10.1016/j.vhri.2018.11.002
   Merani Rohan, 2015, Int J Retina Vitreous, V1, P9
   Ores R, 2022, OCUL IMMUNOL INFLAMM, V30, P118, DOI 10.1080/09273948.2020.1792511
   Platania CBM, 2015, FRONT PHARMACOL, V6, DOI [10.3389/fphar.2015.00248, 10.3389/tphar.7015.00248]
   Plyukhova AA, 2020, J CLIN MED, V9, DOI 10.3390/jcm9051522
   Reibaldi M, 2019, J CLIN MED, V8, DOI 10.3390/jcm8071031
   Reibaldi M, 2014, RETINA-J RET VIT DIS, V34, P490, DOI 10.1097/IAE.0b013e3182a0e446
   Rosenfeld PJ, 2005, OPHTHALMOLOGY, V112, P1048, DOI 10.1016/j.ophtha.2005.01.043
   Toro MD, 2021, EUR J OPHTHALMOL, V31, P5, DOI 10.1177/1120672120960339
   Tugal-Tutkun Ilknur, 2010, International Ophthalmology, V30, P453, DOI 10.1007/s10792-009-9310-2
   Williams PD, 2016, RETINA-J RET VIT DIS, V36, P909, DOI 10.1097/IAE.0000000000000801
   Xu WQ, 2010, CAN J OPHTHALMOL, V45, P386, DOI 10.3129/i10-024
   Yeniad B, 2011, EUR J OPHTHALMOL, V21, P156, DOI 10.5301/EJO.2010.5239
   Yousef YA, 2020, MEDICINE, V99, DOI 10.1097/MD.0000000000019623
NR 38
TC 5
Z9 5
U1 0
U2 0
PU FRONTIERS MEDIA SA
PI LAUSANNE
PA AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND
SN 1663-9812
J9 FRONT PHARMACOL
JI Front. Pharmacol.
PD APR 30
PY 2021
VL 12
AR 656774
DI 10.3389/fphar.2021.656774
PG 7
WC Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Pharmacology & Pharmacy
GA SB5AW
UT WOS:000650007900001
PM 33995079
OA Green Accepted, Green Published, gold
DA 2022-11-30
ER

PT J
AU Shah, N
   Dakin, SC
   Dobinson, S
   Tufail, A
   Egan, CA
   Anderson, RS
AF Shah, Nilpa
   Dakin, Steven C.
   Dobinson, Sarah
   Tufail, Adnan
   Egan, Catherine A.
   Anderson, Roger S.
TI Visual acuity loss in patients with age-related macular degeneration
   measured using a novel high-pass letter chart
SO BRITISH JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
DE Vision; Macula; Degeneration
ID VANISHING OPTOTYPE LETTERS; TEST-RETEST VARIABILITY; CHOROIDAL
   NEOVASCULARIZATION; CONTRAST SENSITIVITY; FLICKER PERIMETRY;
   IDENTIFICATION; REPEATABILITY; MACULOPATHY; RELIABILITY; RESOLUTION
AB Background/aims Conventional Logarithm of the Minimum Angle of Resolution (logMAR) acuity is the current gold standard for assessing visual function in age-related macular degeneration (AMD). However, visual acuity (VA) often remains normal' when measured with these charts, even with advanced retinal changes. We wished to investigate how VA measurements with the Moorfields Acuity Chart (MAC), which employs high-pass filtered letters, compares to conventional letter charts in subjects with AMD.
   Methods Monocular best-corrected VA measurements and test-retest variability (TRV) were compared for conventional and MAC charts in 38 normal observers (mean age 52.1years) and 80 patients (mean age 80.6years) with varying degrees of acuity loss owing to AMD. Methods of Bland-Altman and ordinary least-squares regression were employed for data analysis.
   Results A proportional bias was confirmed between conventional and MAC measurements (r(2)=0.133, p=0.001) such that MAC acuity was -0.45 logMAR worse' at the 0.00 logMAR acuity level, but only -0.26 logMAR worse' at the 1.00 logMAR level. The mean bias was much smaller in the normal subject group (-0.16 logMAR). Similar TRV (ranging from 0.09 to +/- 0.12 logMAR) was found for both charts in both subject groups.
   Conclusions VA measurements with the MAC chart appear to be more sensitive to functional loss in AMD compared with conventional letter charts, with similar TRV. Simulations indicate this may be because the high-pass filtered letters are more vulnerable to undersampling as a result of retinal cell loss in the disease process.
C1 [Shah, Nilpa; Dakin, Steven C.; Dobinson, Sarah; Tufail, Adnan; Egan, Catherine A.; Anderson, Roger S.] Moorfields Eye Hosp NHS Fdn Trust, NIHR Biomed Res Ctr, 11-43 Bath St, London EC1V 9EL, England.
   [Shah, Nilpa; Dakin, Steven C.; Dobinson, Sarah; Tufail, Adnan; Egan, Catherine A.; Anderson, Roger S.] UCL Inst Ophthalmol, 11-43 Bath St, London EC1V 9EL, England.
   [Dakin, Steven C.] Univ Auckland, Dept Optometry & Vis Sci, Auckland, New Zealand.
   [Anderson, Roger S.] Univ Ulster, Sch Biomed Sci, Vis Sci Res Grp, Coleraine, Londonderry, North Ireland.
C3 University of London; University College London; Moorfields Eye Hospital
   NHS Foundation Trust; University of London; University College London;
   University of Auckland; Ulster University
RP Shah, N (通讯作者)，Moorfields Eye Hosp NHS Fdn Trust, NIHR Biomed Res Ctr, 11-43 Bath St, London EC1V 9EL, England.; Shah, N (通讯作者)，UCL Inst Ophthalmol, 11-43 Bath St, London EC1V 9EL, England.
EM nilpa.shah@ucl.ac.uk
RI ; Dakin, Steven/B-7610-2008
OI Shah, Nilpa/0000-0003-3127-500X; Egan, Catherine/0000-0001-5593-1169;
   Tufail, Adnan/0000-0001-6131-7640; Dakin, Steven/0000-0002-3548-9104
FU Fight for Sight studentship; Special Trustees of Moorfields Eye Hospital
   NHS Foundation Trust [1973]; Fight for Sight [1973] Funding Source:
   researchfish
FX This research was supported by a Fight for Sight studentship and by the
   Special Trustees of Moorfields Eye Hospital NHS Foundation Trust (grant
   number 1973).
CR Age-Related Eye Dis Study Res Grp, 2001, AM J OPHTHALMOL, V132, P668
   Anderson RS, 1999, J OPT SOC AM A, V16, P2334, DOI 10.1364/JOSAA.16.002334
   Anderson RS, 1999, VISION RES, V39, P4141, DOI 10.1016/S0042-6989(99)00160-1
   Anderson RS, 1999, J OPT SOC AM A, V16, P2321, DOI 10.1364/JOSAA.16.002321
   BLAND JM, 1986, LANCET, V1, P307, DOI 10.1016/s0140-6736(86)90837-8
   BRESSLER SB, 1982, AM J OPHTHALMOL, V93, P157, DOI 10.1016/0002-9394(82)90410-X
   CAMPBELL FW, 1966, J PHYSIOL-LONDON, V186, P558, DOI 10.1113/jphysiol.1966.sp008056
   Demirel S, 2012, VISION RES, V59, P9, DOI 10.1016/j.visres.2012.02.010
   Doris N, 2001, BRIT J OPHTHALMOL, V85, P184, DOI 10.1136/bjo.85.2.184
   ELLIOTT DB, 1988, OPHTHAL PHYSL OPT, V8, P397, DOI 10.1111/j.1475-1313.1988.tb01176.x
   Ergun E, 2003, OPHTHALMOLOGY, V110, P65, DOI 10.1016/S0161-6420(02)01566-X
   Feigl B, 2004, CURR EYE RES, V29, P327, DOI 10.1080/02713680490516198
   GERVAIS MJ, 1984, J EXP PSYCHOL HUMAN, V10, P655, DOI 10.1037/0096-1523.10.5.655
   Hazel CA, 2002, OPTOMETRY VISION SCI, V79, P788, DOI 10.1097/00006324-200212000-00011
   Hogg R, 2003, BRIT J OPHTHALMOL, V87, P609, DOI 10.1136/bjo.87.5.609
   HOWLAND B, 1978, VISION RES, V18, P1063, DOI 10.1016/0042-6989(78)90036-6
   Keane PA, 2012, SURV OPHTHALMOL, V57, P389, DOI 10.1016/j.survophthal.2012.01.006
   KLEIN R, 1995, INVEST OPHTH VIS SCI, V36, P182
   KLEINER RC, 1988, ARCH OPHTHALMOL-CHIC, V106, P55
   Laidlaw DAH, 2003, BRIT J OPHTHALMOL, V87, P1232, DOI 10.1136/bjo.87.10.1232
   LOVIEKITCHIN JE, 1988, OPHTHAL PHYSL OPT, V8, P363, DOI 10.1111/j.1475-1313.1988.tb01170.x
   Luu CD, 2013, INVEST OPHTH VIS SCI, V54, P3560, DOI 10.1167/iovs.12-10465
   Midena E, 1997, INVEST OPHTH VIS SCI, V38, P469
   Neelam K, 2009, SURV OPHTHALMOL, V54, P167, DOI 10.1016/j.survophthal.2008.12.003
   Patel PJ, 2008, INVEST OPHTH VIS SCI, V49, P4347, DOI 10.1167/iovs.08-1935
   Phipps JA, 2004, INVEST OPHTH VIS SCI, V45, P3355, DOI 10.1167/iovs.04-0253
   Qiu F, 2009, CLIN EXP OPTOM, V92, P90, DOI 10.1111/j.1444-0938.2008.00343.x
   Ravikumar S, 2010, J VISION, V10, DOI 10.1167/10.14.18
   REEVES BC, 1993, OPHTHAL PHYSL OPT, V13, P17, DOI 10.1111/j.1475-1313.1993.tb00421.x
   Rosser DA, 2003, INVEST OPHTH VIS SCI, V44, P3278, DOI 10.1167/iovs.02-1100
   Shah N, 2014, INVEST OPHTH VIS SCI, V55, P1386, DOI 10.1167/iovs.13-13340
   Shah N, 2012, INVEST OPHTH VIS SCI, V53, P7063, DOI 10.1167/iovs.12-9864
   Shah N, 2011, OPHTHAL PHYSL OPT, V31, P17, DOI 10.1111/j.1475-1313.2010.00806.x
   STANGOS N, 1995, OPHTHALMOLOGICA, V209, P194, DOI 10.1159/000310612
   Sunness JS, 1999, OPHTHALMOLOGY, V106, P1768, DOI 10.1016/S0161-6420(99)90340-8
   VandenBosch ME, 1997, EYE, V11, P411, DOI 10.1038/eye.1997.87
   Wolffsohn JS, 2006, BRIT J OPHTHALMOL, V90, P432, DOI 10.1136/bjo.2005.085787
   Wong T, 2008, OPHTHALMOLOGY, V115, P116, DOI 10.1016/j.ophtha.2007.03.008
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
   Wu ZC, 2013, INVEST OPHTH VIS SCI, V54, P7378, DOI 10.1167/iovs.13-12617
NR 40
TC 19
Z9 21
U1 0
U2 14
PU BMJ PUBLISHING GROUP
PI LONDON
PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND
SN 0007-1161
EI 1468-2079
J9 BRIT J OPHTHALMOL
JI Br. J. Ophthalmol.
PD OCT
PY 2016
VL 100
IS 10
BP 1346
EP 1352
DI 10.1136/bjophthalmol-2015-307375
PG 7
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA DX8YW
UT WOS:000384679400008
PM 26846435
DA 2022-11-30
ER

PT J
AU Schmidt-Erfurth, U
   Chong, V
   Loewenstein, A
   Larsen, M
   Souied, E
   Schlingemann, R
   Eldem, B
   Mones, J
   Richard, G
   Bandello, F
AF Schmidt-Erfurth, Ursula
   Chong, Victor
   Loewenstein, Anat
   Larsen, Michael
   Souied, Eric
   Schlingemann, Reinier
   Eldem, Bora
   Mones, Jordi
   Richard, Gisbert
   Bandello, Francesco
TI Guidelines for the management of neovascular age-related macular
   degeneration by the European Society of Retina Specialists (EURETINA)
SO BRITISH JOURNAL OF OPHTHALMOLOGY
LA English
DT Review
ID ENDOTHELIAL GROWTH-FACTOR; OPTICAL COHERENCE TOMOGRAPHY;
   TISSUE-PLASMINOGEN ACTIVATOR; EXPERIMENTAL CHOROIDAL NEOVASCULARIZATION;
   VERTEPORFIN PHOTODYNAMIC THERAPY; INTRAVITREAL BEVACIZUMAB THERAPY;
   VISION-RELATED FUNCTION; PARS-PLANA VITRECTOMY; QUALITY-OF-LIFE;
   SUBMACULAR HEMORRHAGE
AB Age-related macular degeneration (AMD) is still referred to as the leading cause of severe and irreversible visual loss world-wide. The disease has a profound effect on quality of life of affected individuals and represents a major socioeconomic challenge for societies due to the exponential increase in life expectancy and environmental risks. Advances in medical research have identified vascular endothelial growth factor (VEGF) as an important pathophysiological player in neovascular AMD and intraocular inhibition of VEGF as one of the most efficient therapies in medicine. The wide introduction of anti-VEGF therapy has led to an overwhelming improvement in the prognosis of patients affected by neovascular AMD, allowing recovery and maintenance of visual function in the vast majority of patients. However, the therapeutic benefit is accompanied by significant economic investments, unresolved medicolegal debates about the use of off-label substances and overwhelming problems in large population management. The burden of disease has turned into a burden of care with a dissociation of scientific advances and real-world clinical performance. Simultaneously, ground-breaking innovations in diagnostic technologies, such as optical coherence tomography, allows unprecedented high-resolution visualisation of disease morphology and provides a promising horizon for early disease detection and efficient therapeutic follow-up. However, definite conclusions from morphologic parameters are still lacking, and valid biomarkers have yet to be identified to provide a practical base for disease management. The European Society of Retina Specialists offers expert guidance for diagnostic and therapeutic management of neovascular AMD supporting healthcare givers and doctors in providing the best state-of-the-art care to their patients.
C1 [Schmidt-Erfurth, Ursula] Med Univ, Dept Ophthalmol, Vienna, Austria.
   [Chong, Victor] Oxford Univ Hosp, Oxford Eye Hosp, Oxford, England.
   [Loewenstein, Anat] Tel Aviv Med Ctr & Sch Med, Dept Ophthalmol, Tel Aviv, Israel.
   [Larsen, Michael] Glostrup Cty Hosp, Dept Ophthalmol, Copenhagen, Denmark.
   [Larsen, Michael] Univ Copenhagen, Copenhagen, Denmark.
   [Souied, Eric] Hop Intercommunal Creteil, Paris, France.
   [Schlingemann, Reinier] Univ Amsterdam, Acad Med Ctr, Med Retina Unit, NL-1105 AZ Amsterdam, Netherlands.
   [Schlingemann, Reinier] Univ Amsterdam, Acad Med Ctr, Ocular Angiogenesis Grp, Dept Ophthalmol, NL-1105 AZ Amsterdam, Netherlands.
   [Eldem, Bora] Hacettepe Univ, Sch Med, Dept Ophthalmol, Ankara, Turkey.
   [Mones, Jordi] Director Inst Macula & Retina, Ctr Med TEKNON, Barcelona, Spain.
   [Richard, Gisbert] Univ Med Ctr Hamburg Eppendorf, Dept Ophthalmol, Hamburg, Germany.
   [Bandello, Francesco] Univ Vita Salute, Dept Ophthalmol, Milan, Italy.
   [Bandello, Francesco] Ist Sci San Raffaele, I-20132 Milan, Italy.
C3 Tel Aviv University; Sackler Faculty of Medicine; University of
   Copenhagen; University of Copenhagen; Universite
   Paris-Est-Creteil-Val-de-Marne (UPEC); CHI Creteil; University of
   Amsterdam; Academic Medical Center Amsterdam; University of Amsterdam;
   Academic Medical Center Amsterdam; Hacettepe University; University of
   Hamburg; University Medical Center Hamburg-Eppendorf; Vita-Salute San
   Raffaele University; Vita-Salute San Raffaele University; IRCCS Ospedale
   San Raffaele
RP Schmidt-Erfurth, U (通讯作者)，Med Univ Vienna, Dept Ophthalmol, Waehringer Guertel 18-20, A-1090 Vienna, Austria.
EM ursula.schmidt-erfurth@meduniwien.ac.at
RI bandello, francesco/AAH-2405-2019; Chong, Victor/Q-6565-2018; mones,
   jordi/CAJ-2963-2022; Stefanadis, Christodoulos/ABH-2232-2020; Larsen,
   Michael/E-9620-2010
OI bandello, francesco/0000-0003-3238-9682; Chong,
   Victor/0000-0002-7693-522X; mones, jordi/0000-0003-3685-2160;
   Stefanadis, Christodoulos/0000-0001-5974-6454; Larsen,
   Michael/0000-0002-5172-5891; Schmidt-Erfurth, Ursula/0000-0002-7788-7311
CR Abedi F, 2014, RETINA-J RET VIT DIS, V34, P1531, DOI 10.1097/IAE.0000000000000134
   Abraham-Marin ML, 2007, GRAEF ARCH CLIN EXP, V245, P651, DOI 10.1007/s00417-006-0411-6
   Amissah-Arthur KN, 2012, EYE, V26, P394, DOI 10.1038/eye.2011.335
   [Anonymous], 1991, Arch Ophthalmol, V109, P1109
   [Anonymous], 1991, Arch Ophthalmol, V109, P1220
   Arias L, 2010, CLIN OPHTHALMOL, V4, P67
   Arnold J, 2001, AM J OPHTHALMOL, V131, P541
   Avery RL, 1996, RETINA-J RET VIT DIS, V16, P183, DOI 10.1097/00006982-199616030-00001
   Avery RL, 2006, OPHTHALMOLOGY, V113, P363, DOI 10.1016/j.ophtha.2005.11.019
   Avery RL, 2014, BRIT J OPHTHALMOL, V98, P7, DOI 10.1136/bjophthalmol-2013-303844
   Bakri SJ, 2014, OPHTHALMOLOGY, V121, P1102, DOI 10.1016/j.ophtha.2013.11.029
   BENNETT SR, 1990, AM J OPHTHALMOL, V109, P33, DOI 10.1016/S0002-9394(14)75575-8
   Bloch SB, 2012, AM J OPHTHALMOL, V153, P209, DOI 10.1016/j.ajo.2011.10.016
   Blumenkranz MS, 2001, ARCH OPHTHALMOL-CHIC, V119, P198
   Bressler NM, 2010, OPHTHALMOLOGY, V117, P747, DOI 10.1016/j.ophtha.2009.09.002
   Bressler NM, 2004, OPHTHALMOLOGY, V111, P1993, DOI 10.1016/j.ophtha.2004.07.023
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Brown DM, 2009, OPHTHALMOLOGY, V116, P57, DOI 10.1016/j.ophtha.2008.10.018
   Busbee BG, 2013, OPHTHALMOLOGY, V120, P1046, DOI 10.1016/j.ophtha.2012.10.014
   Campbell JP, 2012, ARCH OPHTHALMOL-CHIC, V130, P794, DOI 10.1001/archophthalmol.2011.2480
   Cao JT, 2010, INVEST OPHTH VIS SCI, V51, P6009, DOI 10.1167/iovs.09-4956
   Carneiro AM, 2012, ACTA OPHTHALMOL, V90, pE25, DOI 10.1111/j.1755-3768.2011.02240.x
   Chakravarthy U, 2006, OPHTHALMOLOGY, V113, P1508, DOI 10.1016/j.ophtha.2006.02.064
   Chakravarthy U, 2013, LANCET, V382, P1258, DOI 10.1016/S0140-6736(13)61501-9
   Chakravarthy U, 2012, OPHTHALMOLOGY, V119, DOI 10.1016/j.ophtha.2012.04.015
   Chang TS, 2007, ARCH OPHTHALMOL-CHIC, V125, P1460, DOI 10.1001/archopht.125.11.1460
   Chen CY, 2007, RETINA-J RET VIT DIS, V27, P321, DOI 10.1097/01.iae.0000237586.48231.75
   Chen Y, 1999, J MOL BIOL, V293, P865, DOI 10.1006/jmbi.1999.3192
   Cheung CMG, 2013, AM J OPHTHALMOL, V155, P764, DOI 10.1016/j.ajo.2012.10.013
   Chew EY, 2014, OPHTHALMOLOGY, V121, P535, DOI 10.1016/j.ophtha.2013.10.027
   Cho H, 2013, BRIT J OPHTHALMOL, V97, P1032, DOI 10.1136/bjophthalmol-2013-303344
   Choma MA, 2003, OPT EXPRESS, V11, P2183, DOI 10.1364/OE.11.002183
   Cilley JC, 2007, EXPERT OPIN BIOL TH, V7, P739, DOI 10.1517/14712598.7.5.739
   Coscas F, 2012, RETINA-J RET VIT DIS, V32, P1069, DOI 10.1097/IAE.0b013e318240a529
   Coscas G, 1982, Bull Mem Soc Fr Ophtalmol, V94, P149
   Day S, 2011, AM J OPHTHALMOL, V152, P1014, DOI 10.1016/j.ajo.2011.05.008
   DEJUAN E, 1988, AM J OPHTHALMOL, V105, P25, DOI 10.1016/0002-9394(88)90116-X
   Do DV, 2013, CURR OPIN OPHTHALMOL, V24, P244, DOI 10.1097/ICU.0b013e32835fd7dd
   Dugel PU, 2013, OPHTHALMOLOGY, V120, P317, DOI 10.1016/j.ophtha.2012.07.068
   Dugel PU, 2012, OPHTHALMOLOGY, V119, DOI 10.1016/j.ophtha.2012.01.014
   Ferrara N, 2003, NAT MED, V9, P669, DOI 10.1038/nm0603-669
   Ferrara N, 2007, ANNU REV MED, V58, P491, DOI 10.1146/annurev.med.58.061705.145635
   Fine HF, 2010, RETINA-J RET VIT DIS, V30, P1588, DOI 10.1097/IAE.0b013e3181e2263c
   FINE SL, 1982, ARCH OPHTHALMOL-CHIC, V100, P912
   Frennesson C, 2010, ACTA OPHTHALMOL, V88, P420, DOI 10.1111/j.1755-3768.2009.01576.x
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P564
   Fung AE, 2007, AM J OPHTHALMOL, V143, P566, DOI 10.1016/j.ajo.2007.01.028
   Gaudreault J, 2005, INVEST OPHTH VIS SCI, V46, P726, DOI 10.1167/iovs.04-0601
   Gess AJ, 2011, SEMIN OPHTHALMOL, V26, P225, DOI 10.3109/08820538.2011.582533
   Giani A, 2012, INVEST OPHTH VIS SCI, V53, P7637, DOI 10.1167/iovs.12-10047
   GLATT H, 1982, AM J OPHTHALMOL, V94, P762, DOI 10.1016/0002-9394(82)90301-4
   Golbaz I, 2011, INVEST OPHTH VIS SCI, V52, P1599, DOI 10.1167/iovs.09-5018
   Gonzalez S, 2012, AM J OPHTHALMOL, V153, P196, DOI 10.1016/j.ajo.2011.11.023
   Gopalakrishan M, 2007, RETINA-J RET VIT DIS, V27, P329, DOI 10.1097/01.iae.0000231544.43093.40
   Gragoudas ES, 2004, NEW ENGL J MED, V351, P2805, DOI 10.1056/NEJMoa042760
   Ha SO, 2014, INTERN EMERG MED, V9, P325, DOI 10.1007/s11739-013-1019-6
   Hassan AS, 1999, OPHTHALMOLOGY, V106, P1900, DOI 10.1016/S0161-6420(99)90399-8
   Hattenbach LO, 2001, OPHTHALMOLOGY, V108, P1485, DOI 10.1016/S0161-6420(01)00648-0
   Haupert CL, 2001, AM J OPHTHALMOL, V131, P208, DOI 10.1016/S0002-9394(00)00734-0
   Hawkes N, 2012, BRIT MED J, V344, DOI 10.1136/bmj.e3275
   HAWKINS BS, 1986, ARCH OPHTHALMOL-CHIC, V104, P694
   Heier JS, 2006, ARCH OPHTHALMOL-CHIC, V124, P1532, DOI 10.1001/archopht.124.11.1532
   Heier JS, 2012, OPHTHALMOLOGY, V119, P2537, DOI 10.1016/j.ophtha.2012.09.006
   Heier JS, 2011, OPHTHALMOLOGY, V118, P1098, DOI 10.1016/j.ophtha.2011.03.020
   Hochman MA, 1997, SURV OPHTHALMOL, V42, P195, DOI 10.1016/S0039-6257(97)00089-1
   Holash J, 2002, P NATL ACAD SCI USA, V99, P11393, DOI 10.1073/pnas.172398299
   Holekamp NM, 2014, AM J OPHTHALMOL, V157, P825, DOI 10.1016/j.ajo.2013.12.018
   Holz FG, 2011, OPHTHALMOLOGY, V118, P663, DOI 10.1016/j.ophtha.2010.12.019
   Husain D, 2005, ARCH OPHTHALMOL-CHIC, V123, P509, DOI 10.1001/archopht.123.4.509
   IBANEZ HE, 1995, ARCH OPHTHALMOL-CHIC, V113, P62, DOI 10.1001/archopht.1995.01100010064022
   Inai T, 2004, AM J PATHOL, V165, P35, DOI 10.1016/S0002-9440(10)63273-7
   Jackson TL, 2012, RAD CNV CABERNET MER
   Jansen RM, 2013, MED LAW, V32, P65
   Johnson DW, 2013, AMER MADE MUSIC SER, P205
   Kaiser PK, 2012, OPHTHALMOLOGY, V119, P1001, DOI 10.1016/j.ophtha.2012.02.003
   Kaiser PK, 2009, CURR MED RES OPIN, V25, P1853, DOI 10.1185/03007990903038616
   Kashani AH, 2009, INVEST OPHTH VIS SCI, V50, P3366, DOI 10.1167/iovs.08-2691
   Kawasaki R, 2010, OPHTHALMOLOGY, V117, P921, DOI 10.1016/j.ophtha.2009.10.007
   Keane PA, 2008, INVEST OPHTH VIS SCI, V49, P3115, DOI 10.1167/iovs.08-1689
   Keane PA, 2012, SURV OPHTHALMOL, V57, P389, DOI 10.1016/j.survophthal.2012.01.006
   Khurana RN, 2010, OPHTHALMOLOGY, V117, P1376, DOI 10.1016/j.ophtha.2009.11.039
   Kiss CG, 2009, INVEST OPHTH VIS SCI, V50, P2376, DOI 10.1167/iovs.08-2017
   Klein R, 2013, AM J OPHTHALMOL, V156, P1010, DOI 10.1016/j.ajo.2013.06.004
   Kodjikian L, 2013, OPHTHALMOLOGY, V120, P2300, DOI 10.1016/j.ophtha.2013.06.020
   Koh AHC, 2013, RETINA-J RET VIT DIS, V33, P686, DOI 10.1097/IAE.0b013e3182852446
   Krause L, 2013, CURR MED RES OPIN, V29, P1391, DOI 10.1185/03007995.2013.832184
   Krzystolik MG, 2002, ARCH OPHTHALMOL-CHIC, V120, P338
   Kuhli-Hattenbach C, 2010, AM J OPHTHALMOL, V149, P316, DOI 10.1016/j.ajo.2009.08.033
   Kumar N, 2013, RETINA-J RET VIT DIS, V33, P1605, DOI 10.1097/IAE.0b013e31828e8551
   Larsen M, 2012, OPHTHALMOLOGY, V119, P992, DOI 10.1016/j.ophtha.2012.02.002
   Malamos P, 2009, INVEST OPHTH VIS SCI, V50, P4926, DOI 10.1167/iovs.09-3610
   Martin DF, 2012, OPHTHALMOLOGY, V119, DOI 10.1016/j.ophtha.2012.03.053
   Martin DF, N ENGL J MED
   Mathew R, 2014, OPHTHALMOLOGICA, V231, P153, DOI 10.1159/000355091
   Matsuyama K, 2010, BRIT J OPHTHALMOL, V94, P1215, DOI 10.1136/bjo.2008.156810
   Miskala PH, 2004, OPHTHALMOLOGY, V111, P1981, DOI 10.1016/j.ophtha.2004.07.022
   Moshfeghi AA, 2005, EXPERT OPIN INV DRUG, V14, P671, DOI 10.1517/13543784.14.5.671
   Moshfeghi AA, 2012, BRIT J OPHTHALMOL, V96, P1320, DOI 10.1136/bjophthalmol-2011-301222
   Moshfeghi AA, 2011, RETINA-J RET VIT DIS, V31, P662, DOI 10.1097/IAE.0b013e31821067c4
   Nguyen QD, 2006, OPHTHALMOLOGY, V113, P1522, DOI 10.1016/j.ophtha.2006.05.055
   Nguyen QD, 2009, OPHTHALMOLOGY, V116, P2141, DOI 10.1016/j.ophtha.2009.04.030
   Ohji M, 1998, ARCH OPHTHALMOL-CHIC, V116, P1326, DOI 10.1001/archopht.116.10.1326
   Oshima Y, 2007, BRIT J OPHTHALMOL, V91, P193, DOI 10.1136/bjo.2006.101444
   Papadopoulos N, 2012, ANGIOGENESIS, V15, P171, DOI 10.1007/s10456-011-9249-6
   Parravano M, 2012, EUR J OPHTHALMOL, V22, P598, DOI 10.5301/ejo.5000087
   Patel PJ, 2012, RETINA, DOI [10.1097/IAE.0b013e31823f0ba3, DOI 10.1097/IAE.0B013E31823F0BA3]
   Petrarca R, 2011, CLIN OPHTHALMOL, V5, P57, DOI 10.2147/OPTH.S16444
   PEYMAN GA, 1991, OPHTHALMIC SURG LAS, V22, P575
   Querques G, 2011, OPHTHALMIC RES, V46, P152, DOI 10.1159/000325027
   Querques G, 2010, RETINA-J RET VIT DIS, V30, P222, DOI 10.1097/IAE.0b013e3181bceef0
   Regillo CD, 2008, AM J OPHTHALMOL, V145, P239, DOI 10.1016/j.ajo.2007.10.004
   Rein DB, 2009, ARCH OPHTHALMOL-CHIC, V127, P533, DOI 10.1001/archophthalmol.2009.58
   Rofagha S, 2013, OPHTHALMOLOGY, V120, P2292, DOI 10.1016/j.ophtha.2013.03.046
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Rosenfeld PJ, 2011, OPHTHALMOLOGY, V118, P523, DOI 10.1016/j.ophtha.2010.07.011
   Rosenfeld PJ, 2005, OPHTHAL SURG LAS IM, V36, P331, DOI 10.3928/1542-8877-20050701-14
   Sadda SR, 2010, GRAEF ARCH CLIN EXP, V248, P175, DOI 10.1007/s00417-009-1193-4
   Saishin Y, 2003, J CELL PHYSIOL, V195, P241, DOI 10.1002/jcp.10246
   Sander B, 2009, ACTA OPHTHALMOL, V87, P245, DOI 10.1111/j.1755-3768.2008.01386.x
   Schmidt-Erfurth U, 2014, PARADIGM SHIFT MANAG
   Schmidt-Erfurth U, 2014, OPHTHALMOLOGY, V121, P193, DOI 10.1016/j.ophtha.2013.08.011
   Schmidt-Erfurth U, 2011, OPHTHALMOLOGY, V118, P831, DOI 10.1016/j.ophtha.2010.09.004
   Schmidt-Erfurth UM, 2007, ACTA OPHTHALMOL SCAN, V85, P486, DOI 10.1111/j.1600-0420.2007.00979.x
   Schmucker C, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0042701
   Seddon JM, 2003, ARCH OPHTHALMOL-CHIC, V121, P785, DOI 10.1001/archopht.121.6.785
   Seddon JM, 1996, JAMA-J AM MED ASSOC, V276, P1141, DOI 10.1001/jama.276.14.1141
   Segal O, 2013, ISR MED ASSOC J, V15, P352
   Shultz RW, 2011, SEMIN OPHTHALMOL, V26, P361, DOI 10.3109/08820538.2011.585368
   Silva R, 2013, OPHTHALMOLOGY, V120, P130, DOI 10.1016/j.ophtha.2012.07.026
   Silva RA, 2011, SEMIN OPHTHALMOL, V26, P121, DOI 10.3109/08820538.2011.554486
   Simader C, 2014, OPHTHALMOLOGY, V121, P1237, DOI 10.1016/j.ophtha.2013.12.029
   Singer MA, 2012, OPHTHALMOLOGY, V119, P1175, DOI 10.1016/j.ophtha.2011.12.016
   Smith W, 2001, OPHTHALMOLOGY, V108, P697, DOI 10.1016/S0161-6420(00)00580-7
   Spilsbury K, 2000, AM J PATHOL, V157, P135, DOI 10.1016/S0002-9440(10)64525-7
   Stefanadis C, 2012, INT J CARDIOL, V154, P341, DOI 10.1016/j.ijcard.2011.10.115
   Stein JD, 2014, OPHTHALMOLOGY, V121, P936, DOI 10.1016/j.ophtha.2013.10.037
   Stewart MW, 2008, BRIT J OPHTHALMOL, V92, P667, DOI 10.1136/bjo.2007.134874
   Stewart MA, 2011, ADV GLOB CHANGE RES, V45, P1, DOI [10.1007/978-94-007-0934-8_1, 10.4081/eye.2011.e5]
   Stewart MW, 2012, RETINA-J RET VIT DIS, V32, P434, DOI 10.1097/IAE.0B013E31822C290F
   Stifter E, 2007, AM J OPHTHALMOL, V144, P886, DOI 10.1016/j.ajo.2007.07.034
   Thi HCT, 2011, OPHTHAL SURG LAS IM, V42, P498, DOI 10.3928/15428877-20110804-04
   Tozer K, 2013, OPHTHALMOLOGY, V120, P2029, DOI 10.1016/j.ophtha.2013.03.016
   Treumer F, 2010, BRIT J OPHTHALMOL, V94, P48, DOI 10.1136/bjo.2009.164707
   Van der Reis MI, 2011, RETINA-J RET VIT DIS, V31, P1449, DOI 10.1097/IAE.0b013e3182278ab4
   Vos T, 2012, LANCET, V380, P2163, DOI 10.1016/S0140-6736(12)61729-2
   Winnik S, 2013, INT J CARDIOL, V168, P2453, DOI 10.1016/j.ijcard.2013.03.010
   Yannuzzi Lawrence A, 2012, Retina, V32 Suppl 1, P416
   Ying GS, 2013, OPHTHALMOLOGY, V120, P122, DOI 10.1016/j.ophtha.2012.07.042
   Yonekawa Y, 2013, AM J OPHTHALMOL, V156, P29, DOI 10.1016/j.ajo.2013.03.030
   Yu LL, 2011, BIOCHEM BIOPH RES CO, V408, P276, DOI 10.1016/j.bbrc.2011.04.014
   Zayit-Soudry S, 2010, RETINA-J RET VIT DIS, V30, P671, DOI 10.1097/IAE.0b013e3181c0858c
   Zehetner C, 2013, BRIT J OPHTHALMOL, V97, P454, DOI 10.1136/bjophthalmol-2012-302451
NR 152
TC 341
Z9 363
U1 3
U2 32
PU BMJ PUBLISHING GROUP
PI LONDON
PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND
SN 0007-1161
EI 1468-2079
J9 BRIT J OPHTHALMOL
JI Br. J. Ophthalmol.
PD SEP
PY 2014
VL 98
IS 9
BP 1144
EP 1167
DI 10.1136/bjophthalmol-2014-305702
PG 24
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA AN3QW
UT WOS:000340504400003
PM 25136079
OA hybrid, Green Published
HC Y
HP N
DA 2022-11-30
ER

PT J
AU Babanejad, M
   Moein, H
   Akbari, MR
   Badiei, A
   Yaseri, M
   Soheilian, M
   Najmabadi, H
AF Babanejad, Mojgan
   Moein, Hamidreza
   Akbari, Mohammad R.
   Badiei, Azadeh
   Yaseri, Mehdi
   Soheilian, Masoud
   Najmabadi, Hossein
TI Investigating the CFH Gene Polymorphisms as a Risk Factor for
   Age-related Macular Degeneration in an Iranian Population
SO OPHTHALMIC GENETICS
LA English
DT Article
DE Age-related macular degeneration; association study; CFH gene; Iran;
   polymorphisms; susceptibility
ID COMPLEMENT-FACTOR-H; HEMICENTIN-1 GENES; Y402H POLYMORPHISM; CHINESE
   POPULATION; STRONG ASSOCIATION; UNITED-STATES; VARIANT; SUSCEPTIBILITY;
   METAANALYSIS; PREVALENCE
AB Background: Age-related macular degeneration (AMD) is a complex disorder which results in irreversible vision loss and progressive impairment of central vision. Disease susceptibility is influenced by multiple genetic and environmental factors. Single nucleotide polymorphisms (SNP) in the complement factor H gene are the most important genetic risk factors. We conducted a case-control study to investigate the association four SNPs (dbSNP ID: rs800292, rs1061170, rs2274700 and rs3753395) of CFH gene with AMD in the Iranian population.
   Materials and Methods: We recruited 100 AMD patients and 100 age-and sex-matched normal controls. Direct sequencing for three SNPs (rs800292, rs2274700 and rs3753395) and restriction fragment length polymorphism utilized for rs1061170. Allele and genotype frequencies of SNPs were calculated and tested for departure from Hardy-Weinberg equilibrium using the Chi-square test. An allelic and genotypic association was compared by logistic regression analysis using the SNPassoc.
   Results: According to our results, the frequencies of risk allele for all SNPs (G, G, A, and C alleles of rs800292, rs2274700, rs3753395 and rs1061170, respectively) were significantly higher in AMD patients (p value < 0.001). AMD individuals who had at least one copy of the C allele of rs1061170 had an increased risk of disease compared with cases with the T allele. Other studied polymorphisms showed the same association.
   Conclusion: Our results suggest the contribution of all four predicted CFH polymorphisms in AMD susceptibility among the Iranian population. This association with CFH may lead to early detection and new strategies for prevention and treatment of AMD.
C1 [Babanejad, Mojgan; Badiei, Azadeh; Najmabadi, Hossein] Univ Social Welf & Rehabil Sci, Genet Res Ctr, Tehran, Iran.
   [Moein, Hamidreza; Soheilian, Masoud] Shahid Beheshti Univ Med Sci, Ophthalm Res Ctr, Tehran, Iran.
   [Moein, Hamidreza; Soheilian, Masoud] Shahid Beheshti Univ Med Sci, Dept Ophthalmol, Tehran, Iran.
   [Akbari, Mohammad R.] Univ Toronto, Womens Coll Hosp, Womens Coll Res Inst, Toronto, ON, Canada.
   [Yaseri, Mehdi] Univ Tehran Med Sci, Dept Epidemiol & Biostat, Tehran, Iran.
C3 Shahid Beheshti University Medical Sciences; Shahid Beheshti University
   Medical Sciences; University of Toronto; University Toronto Affiliates;
   Womens College Hospital; Tehran University of Medical Sciences
RP Najmabadi, H (通讯作者)，Univ Social Welf & Rehabil Sci, Med & Mol Genet, Koodakyar St,Daneshjoo Blvd, Tehran 1985713834, Iran.; Najmabadi, H (通讯作者)，Univ Social Welf & Rehabil Sci, Genet Res Ctr, Koodakyar St,Daneshjoo Blvd, Tehran 1985713834, Iran.; Najmabadi, H (通讯作者)，Univ Social Welf & Rehabil Sci, Natl Prenatal Reference Lab, Koodakyar St,Daneshjoo Blvd, Tehran 1985713834, Iran.; Soheilian, M (通讯作者)，Shahid Beheshti Univ, Ophthalmol, Ophthalm Res Ctr, Labbafinejad Med Ctr, Pasdaran Ave,Boostan 9 St,16666, Tehran, Iran.; Soheilian, M (通讯作者)，Shahid Beheshti Univ, Labbafinejad Med Ctr, Dept Ophthalmol, Pasdaran Ave,Boostan 9 St,16666, Tehran, Iran.
EM masoud_soheilian@yahoo.com; hnajm12@yahoo.com
RI Babanejad, Mojgan/AAY-1405-2020; Najmabadi, Hossein/P-8182-2017; Yaseri,
   Mehdi/I-1645-2018; Soheilian, Masoud/AAW-4743-2020; Babanejad,
   Mojgan/X-9925-2018
OI Yaseri, Mehdi/0000-0002-4066-873X; Soheilian,
   Masoud/0000-0001-7508-426X; Najmabadi, Hossein/0000-0002-6084-7778;
   Babanejad, Mojgan/0000-0003-2532-4303
CR Adams MKM, 2012, HUM MOL GENET, V21, P5229, DOI 10.1093/hmg/dds364
   Anderson DH, 2010, PROG RETIN EYE RES, V29, P95, DOI 10.1016/j.preteyeres.2009.11.003
   Buentello-Volante B, 2012, MOL VIS, V18, P2518
   Congdon N, 2004, ARCH OPHTHALMOL-CHIC, V122, P477
   de Cordoba SR, 2008, CLIN EXP IMMUNOL, V151, P1, DOI 10.1111/j.1365-2249.2007.03574.x
   Donoso LA, 2010, SURV OPHTHALMOL, V55, P227, DOI 10.1016/j.survophthal.2009.11.001
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P564
   Fuse N, 2006, AM J OPHTHALMOL, V142, P1074, DOI 10.1016/j.ajo.2006.07.030
   Gorin MB, 2012, MOL ASPECTS MED, V33, P467, DOI 10.1016/j.mam.2012.04.004
   Hageman GS, 2005, P NATL ACAD SCI USA, V102, P7227, DOI 10.1073/pnas.0501536102
   Haines JL, 2005, SCIENCE, V308, P419, DOI 10.1126/science.1110359
   Jager RD, 2008, NEW ENGL J MED, V358, P2606, DOI 10.1056/NEJMra0801537
   Klein R, 2010, ARCH OPHTHALMOL-CHIC, V128, P750, DOI 10.1001/archophthalmol.2010.92
   Lau LI, 2006, INVEST OPHTH VIS SCI, V47, P3242, DOI 10.1167/iovs.05-1532
   Li M, 2006, NAT GENET, V38, P1049, DOI 10.1038/ng1871
   Liu XQ, 2010, RETINA-J RET VIT DIS, V30, P1177, DOI 10.1097/IAE.0b013e3181cea676
   Magnusson KP, 2006, PLOS MED, V3, P109, DOI 10.1371/journal.pmed.0030005
   MILLER SA, 1988, NUCLEIC ACIDS RES, V16, P1215, DOI 10.1093/nar/16.3.1215
   Mori K, 2010, OPHTHALMOLOGY, V117, P928, DOI 10.1016/j.ophtha.2009.10.001
   Quan YL, 2012, INT J OPHTHALMOL-CHI, V5, P242, DOI 10.3980/j.issn.2222-3959.2012.02.25
   Ratnapriya R, 2013, CLIN GENET, V84, P160, DOI 10.1111/cge.12206
   Seitsonen S, 2006, MOL VIS, V12, P796
   Sepp T, 2006, INVEST OPHTH VIS SCI, V47, P536, DOI 10.1167/iovs.05-1143
   Sharma NK, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0070193
   Simonelli F, 2006, BRIT J OPHTHALMOL, V90, P1142, DOI 10.1136/bjo.2006.096487
   Souied EH, 2005, MOL VIS, V11, P1135
   Swaroop A, 2009, ANNU REV GENOM HUM G, V10, P19, DOI 10.1146/annurev.genom.9.081307.164350
   Thakkinstian A, 2006, HUM MOL GENET, V15, P2784, DOI 10.1093/hmg/ddl220
   Tian J, 2012, INVEST OPHTH VIS SCI, V53, P4262, DOI 10.1167/iovs.11-8542
   Wang ZF, 2004, CELL, V119, P831, DOI 10.1016/j.cell.2004.11.010
   Yuan DQ, 2013, MOL VIS, V19, P374
   Yucel D, 2012, OPHTHALMIC GENET, V33, P144, DOI 10.3109/13816810.2012.660225
   Zareparsi S, 2005, AM J HUM GENET, V77, P149, DOI 10.1086/431426
   Zipfel PF, 2002, BIOCHEM SOC T, V30, P971, DOI 10.1042/bst0300971
   Ziskind A, 2008, OPHTHALMIC GENET, V29, P117, DOI 10.1080/13816810802216472
NR 35
TC 7
Z9 7
U1 0
U2 5
PU TAYLOR & FRANCIS INC
PI PHILADELPHIA
PA 530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA
SN 1381-6810
EI 1744-5094
J9 OPHTHALMIC GENET
JI Ophthalmic Genet.
PY 2016
VL 37
IS 2
BP 144
EP 149
DI 10.3109/13816810.2014.955585
PG 6
WC Genetics & Heredity; Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Genetics & Heredity; Ophthalmology
GA DK2HD
UT WOS:000374734400004
PM 25612476
DA 2022-11-30
ER

PT J
AU Kim, KL
   Park, SP
AF Kim, Kyoung Lae
   Park, Sung Pyo
TI Association between serum vitamin D deficiency and age-related macular
   degeneration in Koreans: Clinical case-control pilot study
SO MEDICINE
LA English
DT Article
DE 25-hydroxyvitamin D; age-related macular degeneration; serum vitamin D
   deficiency; subretinal fibrosis
ID INFLAMMATION; RISK; EXPOSURE; DRUSEN; EYE
AB The objective of this study was to evaluate the association between serum vitamin D deficiency and age-related macular degeneration (AMD) in Koreans through a clinical case-control pilot study. The study included 96 patients: 30 with late AMD, 32 with early AMD, and 34 normal controls. The patients with late AMD were divided into 2 subgroups based on the presence or absence of subretinal fibrosis on optical coherence tomography (OCT) images. We measured 25-hydroxyvitamin D levels in the serum of all patients during the same season to rule out seasonal variation of serum vitamin D level. Serum vitamin D deficiency was defined as a serum 25-hydroxyvitamin D level below 20ng/mL. Serum vitamin D deficiency had a tendency to increase the risk of early AMD, although with borderline significance [odds ratio (OR)=3.59; 95% confidence interval (95% CI) 0.95-13.58; P=.060]. It was significantly associated with a greater risk of late AMD (OR=3.61; 95%CI 1.04-12.51; P=.043). Among the 2 subgroups of patients with late AMD, those with subretinal fibrosis present on the OCT images showed a greater risk of serum vitamin D deficiency than the normal controls (OR=7.54; 95% CI 1.34-42.51). However, there was no significant association between serum vitamin D deficiency and late AMD without subretinal fibrosis (OR=1.89; 95% CI 0.40-8.92). Serum vitamin D deficiency may increase the risk of early and late AMD in Koreans, and may also be associated with subretinal fibrosis in this population.
C1 [Kim, Kyoung Lae; Park, Sung Pyo] Hallym Univ, Coll Med, Dept Ophthalmol, Kangdong Sacred Heart Hosp, 150 Seongan Ro, Seoul 134701, South Korea.
C3 Hallym University
RP Park, SP (通讯作者)，Hallym Univ, Coll Med, Dept Ophthalmol, Kangdong Sacred Heart Hosp, 150 Seongan Ro, Seoul 134701, South Korea.
EM eyepyo@gmail.com
FU Hallym University Research Fund [HURF-2015-46]
FX This study was supported by the Hallym University Research Fund
   (HURF-2015-46). The funding organization had no role in the design or
   implementation of this study.
CR Albert DM, 2007, INVEST OPHTH VIS SCI, V48, P2327, DOI 10.1167/iovs.06-1210
   Anderson DH, 2002, AM J OPHTHALMOL, V134, P411, DOI 10.1016/S0002-9394(02)01624-0
   Biernacka A, 2011, GROWTH FACTORS, V29, P196, DOI 10.3109/08977194.2011.595714
   Bikle D, 2009, J CLIN ENDOCR METAB, V94, P26, DOI 10.1210/jc.2008-1454
   Cho BJ, 2014, INVEST OPHTH VIS SCI, V55, P1101, DOI 10.1167/iovs.13-13096
   Choi HS, 2011, J CLIN ENDOCR METAB, V96, P643, DOI 10.1210/jc.2010-2133
   Dawson-Hughes B, 2005, OSTEOPOROSIS INT, V16, P713, DOI 10.1007/s00198-005-1867-7
   Firrincieli D, 2014, CLIN RES HEPATOL GAS, V38, P5, DOI 10.1016/j.clinre.2013.10.004
   Fletcher AE, 2008, ARCH OPHTHALMOL-CHIC, V126, P1396, DOI 10.1001/archopht.126.10.1396
   Holick MF, 2007, NEW ENGL J MED, V357, P266, DOI 10.1056/NEJMra070553
   Itty S, 2014, RETINA-J RET VIT DIS, V34, P1779, DOI 10.1097/IAE.0000000000000178
   Johnson LV, 2000, EXP EYE RES, V70, P441, DOI 10.1006/exer.1999.0798
   Joseph AJ, 2009, INDIAN J MED RES, V130, P133
   Kawasaki R, 2010, OPHTHALMOLOGY, V117, P921, DOI 10.1016/j.ophtha.2009.10.007
   Kim EC, 2014, INVEST OPHTH VIS SCI, V55, P4823, DOI 10.1167/iovs.14-14763
   Kim NR, 2008, INVEST OPHTH VIS SCI, V49, P2071, DOI 10.1167/iovs.07-1195
   Klein R, 2004, AM J OPHTHALMOL, V137, P486, DOI 10.1016/j.ajo.2003.11.069
   Lee V, 2012, NEUROBIOL AGING, V33, P2382, DOI 10.1016/j.neurobiolaging.2011.12.002
   Lin AMY, 2005, ANN NY ACAD SCI, V1053, P319, DOI 10.1196/annals.1344.028
   MACLAUGHLIN J, 1985, J CLIN INVEST, V76, P1536, DOI 10.1172/JCI112134
   Matthias W, 2013, DERMATOENDOCRINOLOGY, V5, P51
   McKay GJ, 2017, OPHTHALMOLOGY, V124, P90, DOI 10.1016/j.ophtha.2016.09.007
   Millen AE, 2017, J NUTR HEALTH AGING, V21, P772, DOI 10.1007/s12603-016-0827-6
   Mithal A, 2009, OSTEOPOROSIS INT, V20, P1807, DOI 10.1007/s00198-009-0954-6
   Montezuma Sandra R, 2007, Semin Ophthalmol, V22, P229, DOI 10.1080/08820530701745140
   Munger KL, 2006, JAMA-J AM MED ASSOC, V296, P2832, DOI 10.1001/jama.296.23.2832
   Park SJ, 2014, OPHTHALMOLOGY, V121, P1756, DOI 10.1016/j.ophtha.2014.03.022
   Pittas AG, 2007, DIABETES CARE, V30, P980, DOI 10.2337/dc06-1994
   Seddon JM, 2006, OPHTHALMOLOGY, V113, P260, DOI 10.1016/j.ophtha.2005.11.001
   Singh A, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0070948
   Singh A, 2012, AM J OPHTHALMOL, V154, P193, DOI 10.1016/j.ajo.2012.01.036
   Steen B, 1998, INVEST OPHTH VIS SCI, V39, P2194
NR 32
TC 7
Z9 7
U1 0
U2 5
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0025-7974
EI 1536-5964
J9 MEDICINE
JI Medicine (Baltimore)
PD AUG
PY 2018
VL 97
IS 33
AR e11908
DI 10.1097/MD.0000000000011908
PG 5
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine
GA GR0ZS
UT WOS:000442255600040
PM 30113489
OA Green Published, gold
DA 2022-11-30
ER

PT J
AU Nazemi, PP
   Fink, W
   Lim, JI
   Sadun, AA
AF Nazemi, PP
   Fink, W
   Lim, JI
   Sadun, AA
TI Scotomas of age-related macular degeneration detected and characterized
   by means of a novel three-dimensional computer-automated visual field
   test
SO RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES
LA English
DT Article
DE three-dimensional computer-based threshold Amsler grid test; age-related
   macular degeneration (AMD); Amsler grid; contrast sensitivity; exudative
   AMD; nonexudative AMD; perimetry; scotomas; visual fields; visual field
   testing
ID LASER ENTOPTIC PERIMETRY; PREVALENCE; GLAUCOMA; EYE
AB Purpose: We used the recently devised three-dimensional computer-based threshold Amsler grid test to acquire and identify typical patterns of visual field defects (scotomas) caused by age-related macular degeneration (AMD).
   Methods: Patients with AMD traced on a computer touch screen the borders of those areas on an Amsler grid that were missing from their field of vision. Scotomas were repeatedly outlined and recorded at different grid contrast levels. The resulting three-dimensional "hole" in the central 25 degrees of the visual field was further characterized by its slope, location, shape, and depth. The results were compared with fundus photographs and fluorescein angiograms.
   Results: Twenty-five patients and 41 eyes were examined. The three-dimensional depictions consistently demonstrated central scotomas with "scallop"-shaped borders and steplike patterns, with either steep slopes or a combination of steep and shallow slopes. The steep slopes corresponded to nonexudative AMD, while the shallow slopes indicated exudative AMD.
   Conclusion: The three-dimensional computer-automated threshold Amsler grid test may demonstrate characteristic scotoma patterns in patients with AMD that conform to the respective fluorescein angiograms. The test shows promise as an effective tool in accurately evaluating, characterizing, and monitoring scotomas in patients with AMD. It may have the potential as a screening tool for the early diagnosis of AMD.
C1 Univ So Calif, Dept Ophthalmol & Neurol Surg, Doheny Eye Inst, Los Angeles, CA 90033 USA.
   Univ So Calif, Keck Sch Med, Los Angeles, CA 90033 USA.
   CALTECH, Pasadena, CA 91125 USA.
C3 Doheny Eye Institute; University of Southern California; University of
   Southern California; California Institute of Technology
RP Sadun, AA (通讯作者)，Univ So Calif, Dept Ophthalmol & Neurol Surg, Doheny Eye Inst, 1450 San Pablo St,DEI 5802, Los Angeles, CA 90033 USA.
EM asadun@usc.edu
CR AMSLER M, 1953, BRIT J OPHTHALMOL, V37, P521, DOI 10.1136/bjo.37.9.521
   Fahimi A, 2001, INVEST OPHTH VIS SCI, V42, pS149
   FERIS FL, 1984, ARCH OPHTHALMOL-CHIC, V102, P1640
   Fink W, 2000, INVEST OPHTH VIS SCI, V41, pS311
   Fink W, 2004, J BIOMED OPT, V9, P149, DOI 10.1117/1.1625952
   FINK W, 2002, 15 INT PER SOC M JUN
   Henney JE, 2000, JAMA-J AM MED ASSOC, V283, P2779, DOI 10.1001/jama.283.21.2779
   KAHN HA, 1977, AM J EPIDEMIOL, V106, P17, DOI 10.1093/oxfordjournals.aje.a112428
   KAHN HA, 1973, DHEW PUBLICATION
   KLEIN BE, 1982, ARCH OPHTHALMOL-CHIC, V100, P571
   KLEIN R, 1992, OPHTHALMOLOGY, V99, P933
   Leibowitz H M, 1980, Surv Ophthalmol, V24, P335
   *NAT CTR HLTH STAT, 1990, HLTH US 1989
   Plummer DJ, 2000, ARCH OPHTHALMOL-CHIC, V118, P1205
   Plummer DJ, 2000, OPHTHALMOLOGY, V107, P1693, DOI 10.1016/S0161-6420(00)00248-7
   SCHUCHARD RA, 1993, ARCH OPHTHALMOL-CHIC, V111, P776, DOI 10.1001/archopht.1993.01090060064024
   Sobolewski P, 1999, Klin Oczna, V101, P255
   SOMMER A, 1991, NEW ENGL J MED, V325, P1412, DOI 10.1056/NEJM199111143252004
   WALL M, 1986, ARCH OPHTHALMOL-CHIC, V104, P520, DOI 10.1001/archopht.1986.01050160076015
   WALL M, 1987, OPHTHALMOLOGY, V94, P1126
NR 20
TC 20
Z9 22
U1 0
U2 4
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3261 USA
SN 0275-004X
J9 RETINA-J RET VIT DIS
JI Retin.-J. Retin. Vitr. Dis.
PD JUN
PY 2005
VL 25
IS 4
BP 446
EP 453
DI 10.1097/00006982-200506000-00009
PG 8
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 008AN
UT WOS:000235012700009
PM 15933591
OA Green Submitted
DA 2022-11-30
ER

PT J
AU Witkin, AJ
   Rayess, N
   Garg, SJ
   Maguire, JI
   Storey, P
   Kaiser, RS
   Hsu, J
   Vander, JF
   Ho, AC
AF Witkin, Andre J.
   Rayess, Nadim
   Garg, Sunir J.
   Maguire, Joseph I.
   Storey, Philip
   Kaiser, Richard S.
   Hsu, Jason
   Vander, James F.
   Ho, Allen C.
TI Alternating Bi-Weekly Intravitreal Ranibizumab and Bevacizumab for
   Refractory Neovascular Age-Related Macular Degeneration with Pigment
   Epithelial Detachment
SO SEMINARS IN OPHTHALMOLOGY
LA English
DT Article
DE Bevacizumab; bi-weekly; neovascular age-related macular degeneration;
   pigment epithelial detachment; ranibizumab; refractory
ID ANTI-VEGF THERAPY; CHOROIDAL NEOVASCULARIZATION; 2.0 MG; TACHYPHYLAXIS;
   VERTEPORFIN; INJECTION
AB Objective: To describe visual and anatomical outcomes following bi-weekly intravitreal ranibizumab/bevacizumab injections in eyes with refractory neovascular age-related macular degeneration (AMD) and pigment epithelial detachment (PED). Design: Retrospective, consecutive, interventional case series. Participants: Eighteen patients diagnosed with neovascular AMD that were refractory to anti-VEGF therapy and received alternating biweekly ranibizumab/bevacizumab injections were included. Methods: Patients with neovascular AMD and PED that were refractory to at least 11 monthly ranibizumab or bevacizumab injections were included in this study at a large, single retina practice. Following inclusion, patients received four bi-weekly alternating ranibizumab/bevacizumab intravitreal injections. After completing a course of four bi-weekly injections, patients were treated with variable regimens of intravitreal anti-vascular endothelial growth factor (VEGF) therapy. The primary outcomes of the study included change in visual acuity (VA) and central foveal thickness (CFT) at eight weeks follow-up. Results: Study eyes had previously received a mean of 22 intravitreal anti-VEGF injections. At enrollment, mean VA was 20/95 and mean CFT was 455 mu m. After four bi-weekly anti-VEGF injections, mean VA improved to 20/65 (p<0.001), and mean CFT decreased to 387 mu m (p=0.029). In patients with PED, there was a mean 27.9% reduction in height (p=0.046) at eight weeks' follow-up. Conclusions: Four injections of bi-weekly alternating ranibizumab/bevacizumab improved visual acuity and reduced macular thickness in a number of patients with refractory neovascular AMD and PED.
C1 [Witkin, Andre J.] Tufts Med Ctr, Dept Ophthalmol, Boston, MA USA.
   [Rayess, Nadim; Garg, Sunir J.; Maguire, Joseph I.; Storey, Philip; Kaiser, Richard S.; Hsu, Jason; Vander, James F.; Ho, Allen C.] Mid Atlantic Retina, Retina Serv, Wills Eye Hosp, Philadelphia, PA USA.
C3 Tufts Medical Center; Jefferson University
RP Garg, SJ (通讯作者)，Wills Eye Hosp & Res Inst, Retina Serv, Ophthalmol, 840 Walnut St,Suite 1020, Philadelphia, PA 19107 USA.
EM sunirgarg@yahoo.com
OI Ho, Allen/0000-0003-3921-608X
FU Wills Eye Innovation Grant
FX The authors acknowledge funding support from Wills Eye Innovation Grant.
CR Arora S, 2011, EYE, V25, P1034, DOI 10.1038/eye.2011.115
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Chen E, 2007, RETINA-J RET VIT DIS, V27, P445, DOI 10.1097/01.iae.0000249574.89437.40
   Curtis LH, 2010, ARCH OPHTHALMOL-CHIC, V128, P1273, DOI 10.1001/archophthalmol.2010.223
   Eghoj MS, 2012, BRIT J OPHTHALMOL, V96, P21, DOI 10.1136/bjo.2011.203893
   Forooghian F, 2009, RETINA-J RET VIT DIS, V29, P723, DOI 10.1097/IAE.0b013e3181a2c1c3
   Freeman WR, 2011, RETINA-J RET VIT DIS, V31, P1812, DOI 10.1097/IAE.0b013e31821987a4
   Fung AT, 2012, EYE, V26, P1181, DOI 10.1038/eye.2012.174
   Fung AE, 2007, AM J OPHTHALMOL, V143, P566, DOI 10.1016/j.ajo.2007.01.028
   Garg S, 2008, CLIN EXP OPHTHALMOL, V36, P252, DOI 10.1111/j.1442-9071.2008.01710.x
   Gasperini JL, 2012, BRIT J OPHTHALMOL, V96, P14, DOI 10.1136/bjo.2011.204685
   Golbaz I, 2011, INVEST OPHTH VIS SCI, V52, P1599, DOI 10.1167/iovs.09-5018
   Gupta OP, 2010, OPHTHALMOLOGY, V117, P2134, DOI 10.1016/j.ophtha.2010.02.032
   Hau VS, 2012, ASRS ANN M LAS VEG N
   Kaiser PK, 2012, OPHTHALMOLOGY, V119, P1001, DOI 10.1016/j.ophtha.2012.02.003
   Ladas ID, 2009, RETINA-J RET VIT DIS, V29, P313, DOI 10.1097/IAE.0b013e31819a5f98
   Lalwani GA, 2009, AM J OPHTHALMOL, V148, P43, DOI 10.1016/j.ajo.2009.01.024
   Martin DF, 2012, OPHTHALMOLOGY, V119, DOI 10.1016/j.ophtha.2012.03.053
   Ritter M, 2010, EYE, V24, P962, DOI 10.1038/eye.2009.265
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Schaal S, 2008, OPHTHALMOLOGY, V115, P2199, DOI 10.1016/j.ophtha.2008.07.007
   Shah CP, 2012, ASRS ANN M LAS VEG N
   Singh CN, 2008, RETINA-J RET VIT DIS, V28, P789, DOI 10.1097/IAE.0b013e31817082d7
   Stewart MW, 2012, RETINA-J RET VIT DIS, V32, P434, DOI 10.1097/IAE.0B013E31822C290F
   Wykoff CC, 2013, OPHTHAL SURG LAS IM, V44, P121, DOI 10.3928/23258160-20130313-04
NR 25
TC 4
Z9 4
U1 0
U2 0
PU TAYLOR & FRANCIS INC
PI PHILADELPHIA
PA 530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA
SN 0882-0538
EI 1744-5205
J9 SEMIN OPHTHALMOL
JI Semin. Ophthalmol.
PY 2017
VL 32
IS 3
BP 309
EP 315
DI 10.3109/08820538.2015.1072222
PG 7
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA ES8KZ
UT WOS:000399807200011
PM 26337539
DA 2022-11-30
ER

PT J
AU Javadzadeh, A
   Ghorbanihaghjo, A
   Rashtchizadeh, N
   Rafeey, M
   Rahimi-Ardabili, B
AF Javadzadeh, Alireza
   Ghorbanihaghjo, Amir
   Rashtchizadeh, Nadereh
   Rafeey, Mandana
   Rahimi-Ardabili, Babak
TI Enhanced susceptibility of low-density lipoprotein to oxidation in wet
   type age-related macular degeneration in male patients
SO SAUDI MEDICAL JOURNAL
LA English
DT Article
ID RISK-FACTORS; CARDIOVASCULAR-DISEASE; 5-YEAR INCIDENCE; MACULOPATHY;
   EYE; ATHEROSCLEROSIS; HYPERTENSION; PROGRESSION
AB Objectives: To determine the susceptibility of low-density lipoprotein (LDL) to oxidation in the plasma of male patients with wet type age related macular degeneration (AMD) and in a similar control group, in order to evaluate the LDL oxidative status as risk factor of AMD.
   Methods: We conducted this study in the Retina Service, Department of Ophthalmology, Nikookari Eye Hospital - Drug of Applied Research Center, Tabriz University of Medical Sciences, Tabriz, Iran during the period between October 2004 and December 2005. Sixty male patients with AMD (mean age 67 16 years) with BMI 4.1 +/- 1.3 were selected as the patient group. The control group consisted of 60 males, apparently healthy, and without ophthalmologic signs and family history of AMD. Low-density lipoprotein was isolated by gradient ultracentrifugation and susceptibility of LDL to in vitro copper - mediated oxidation was assayed by measuring conjugated dienes production (lag phase duration) at 234 nm. Lipid and lipoproteins were determined by standard methods.
   Results: Comparing with control, significant reduction in the duration of lag phase (p < 0.004) and a significant increase in LDL-C concentrations (P=0.006), were noticed. No significant change in cholesterol (p > 0.3), triglyceride (p > 0.1) and high density lipoprotein cholesterol (p > 0.1) levels were found between control and patient groups. A significant negative correlation between Lag phase and LDL-C levels (p=0.004, r=-0.364) was found in the patient group.
   Conclusions: The increased LDL concentration and enhanced susceptibility of LDL to oxidation may play a roll in the wet type AMD process.
C1 Tabriz Univ Med Sci, Dept Ophthalmol, Nikookari Hosp, Drug Appl Res Ctr, Tabriz, Iran.
   Tabriz Univ Med Sci, Gastroenterol & Liver Res Ctr, Tabriz, Iran.
C3 Tabriz University of Medical Science; Tabriz University of Medical
   Science
RP Javadzadeh, A (通讯作者)，Tabriz Univ Med Sci, Dept Ophthalmol, Nikookari Hosp, Drug Appl Res Ctr, Tabriz, Iran.
EM javadzadehalireza@yahoo.com
RI rafeey, mandana/Y-7267-2019; Javadzadeh, Alireza/L-6424-2017;
   Rashtchizadeh, Nadereh/L-7691-2017; Rafeey, Mandana/G-1847-2010
OI rafeey, mandana/0000-0001-7312-466X; Javadzadeh,
   Alireza/0000-0002-5151-6125; Rashtchizadeh, Nadereh/0000-0003-2878-3847;
   ghorbanihaghjo, amir/0000-0001-6742-0526; Rafeey,
   Mandana/0000-0002-9855-0187
CR Belda Sanchis J I, 2001, Arch Soc Esp Oftalmol, V76, P13
   BIRD AEC, 1995, SURV OPHTHALMOL, V39, P367, DOI 10.1016/S0039-6257(05)80092-X
   BLUMENKRANZ MS, 1986, OPHTHALMOLOGY, V93, P552
   BRESSLER NM, 1995, OPHTHALMOLOGY, V102, P1206, DOI 10.1016/S0161-6420(95)30889-5
   CRUICKSHANKS KJ, 1993, ARCH OPHTHALMOL-CHIC, V111, P514, DOI 10.1001/archopht.1993.01090040106042
   Curcio CA, 1999, ARCH OPHTHALMOL-CHIC, V117, P329, DOI 10.1001/archopht.117.3.329
   deJong PTVM, 1996, OPHTHALMOLOGY, V103, P196
   DeRijke YB, 1995, CLIN CHIM ACTA, V243, P137, DOI 10.1016/0009-8981(95)06163-0
   FEENEYBURNS L, 1985, AM J OPHTHALMOL, V100, P686, DOI 10.1016/0002-9394(85)90625-7
   Friedman E, 1997, AM J OPHTHALMOL, V124, P677, DOI 10.1016/S0002-9394(14)70906-7
   FRIEDMAN E, 1998, AGE RELATED MACULAR, P173
   Hirvela H, 1996, OPHTHALMOLOGY, V103, P871, DOI 10.1016/S0161-6420(96)30593-9
   HYMAN L, 1987, EYE, V1, P330, DOI 10.1038/eye.1987.53
   Hyman L, 2000, ARCH OPHTHALMOL-CHIC, V118, P351, DOI 10.1001/archopht.118.3.351
   HYMAN LG, 1983, AM J EPIDEMIOL, V118, P213, DOI 10.1093/oxfordjournals.aje.a113629
   Ikeda T, 2001, AM J OPHTHALMOL, V132, P191, DOI 10.1016/S0002-9394(01)00975-8
   Karmansky I, 1996, CLIN BIOCHEM, V29, P573, DOI 10.1016/S0009-9120(96)00072-0
   Kimura K, 2000, AM J OPHTHALMOL, V130, P769, DOI 10.1016/S0002-9394(00)00552-3
   KLEIN R, 1993, AM J EPIDEMIOL, V137, P190, DOI 10.1093/oxfordjournals.aje.a116659
   Klein R, 1997, OPHTHALMOLOGY, V104, P7, DOI 10.1016/S0161-6420(97)30368-6
   KLEIN R, 1995, OPHTHALMOLOGY, V102, P371
   KLEIN R, 1992, OPHTHALMOLOGY, V99, P933
   Klein R, 1997, OPHTHALMOLOGY, V104, P1804, DOI 10.1016/S0161-6420(97)30023-2
   KLEIN R, 1993, OPHTHALMOLOGY, V100, P406
   Menendez R, 2000, BRIT J CLIN PHARMACO, V50, P255, DOI 10.1046/j.1365-2125.2000.00250.x
   PIGUET B, 1993, BRIT J OPHTHALMOL, V77, P400, DOI 10.1136/bjo.77.7.400
   Ross RD, 1998, AM J OPHTHALMOL, V125, P71, DOI 10.1016/S0002-9394(99)80237-2
   Seddon JM, 1997, AM J OPHTHALMOL, V123, P199, DOI 10.1016/S0002-9394(14)71036-0
   SILVESTRI G, 1994, EYE, V8, P564, DOI 10.1038/eye.1994.138
   Smith W, 1998, ARCH OPHTHALMOL-CHIC, V116, P583, DOI 10.1001/archopht.116.5.583
   SPERDUTO RD, 1986, ARCH OPHTHALMOL-CHIC, V104, P216
   TIELSCH JA, 1995, PREVENT BLINDNESS AM, P1
   TSANG NCK, 1992, DOC OPHTHALMOL, V81, P387
   van Leeuwen R, 2003, INVEST OPHTH VIS SCI, V44, P3771, DOI 10.1167/iovs.03-0121
   VINDING T, 1992, ACTA OPHTHALMOL, V70, P66
   VINGERLING JR, 1995, AM J EPIDEMIOL, V142, P404, DOI 10.1093/oxfordjournals.aje.a117648
   YANNUZZI LA, 1992, ARCH OPHTHALMOL-CHIC, V110, P1701
NR 37
TC 6
Z9 6
U1 0
U2 1
PU SAUDI MED J
PI RIYADH
PA ARMED FORCES HOSPITAL, PO BOX 7897,, RIYADH 11159, SAUDI ARABIA
SN 0379-5284
J9 SAUDI MED J
JI Saudi Med. J.
PD FEB
PY 2007
VL 28
IS 2
BP 221
EP 224
PG 4
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine
GA 148HY
UT WOS:000245066600010
PM 17268700
DA 2022-11-30
ER

PT J
AU Fonteh, CN
   Palestine, AG
   Wagner, BD
   Patnaik, JL
   Mathias, MT
   Mandava, N
   Baldermann, R
   Lynch, AM
AF Fonteh, Cheryl N.
   Palestine, Alan G.
   Wagner, Brandie D.
   Patnaik, Jennifer L.
   Mathias, Marc T.
   Mandava, Naresh
   Baldermann, Rebecca
   Lynch, Anne M.
CA Univ Colorado Retina Res Grp
TI Sex Differences in RANTES (CCL5) in Patients With Intermediate
   Age-Related Macular Degeneration (AMD) and Controls With no AMD
SO TRANSLATIONAL VISION SCIENCE & TECHNOLOGY
LA English
DT Article
DE age-related macular degeneration; sex differences; RANTES
ID C-REACTIVE PROTEIN; RISK-FACTORS; EYE DISEASE; CHEMOKINES; ASSOCIATION;
   PROFILE; GENDER
AB Purpose: To determine if there are sex differences in levels of regulated upon activation, normal T cell expressed and secreted (RANTES) in patients with intermediate age-related macular degeneration (iAMD) and in controls with no AMD. Methods: Patients with iAMD and controls defined by multi-modal imaging were recruited into a Colorado AMD registry. Plasma levels of the chemokine RANTES were measured using a multiplex assay. A nonparametric (rank-based) regression model was fit to RANTES with a sex by AMD category interaction. Results: The plasma level of RANTES was significantly higher in the control group in comparison with the iAMD group. When moderated by sex, RANTES was significantly lower (P = 0.005) in males (median, 4525.6 pg/mL; interquartile range, 2589-7861 pg/mL) compared with females (median, 6686 pg/mL; interquartile range, 3485-12488 pg/mL) within the iAMD cohort. No significant difference was found in levels of RANTES between males and females in the control group. Conclusions: We found that levels of RANTES were moderated by sex in cases with iAMD with lower levels in males compared with females. The findings illustrate the importance of including sex as a biological variable in AMD research. There is a need for further studies of RANTES, stratified by sex, in the advanced phenotypes of AMD. Translational Relevance: The biomarker RANTES identified in the plasma of patients with iAMD reflects systemic alterations when stratified by sex.
C1 [Fonteh, Cheryl N.; Palestine, Alan G.; Wagner, Brandie D.; Patnaik, Jennifer L.; Mathias, Marc T.; Mandava, Naresh; Lynch, Anne M.] Univ Colorado, Dept Ophthalmol, Sch Med, Aurora, CO 80045 USA.
   [Wagner, Brandie D.] Univ Colorado, Colorado Sch Publ Hlth, Sch Med, Aurora, CO 80045 USA.
   [Baldermann, Rebecca] Univ Colorado, Colorado Clin & Translat Sci Inst, Anschutz Med Campus, Aurora, CO 80045 USA.
C3 University of Colorado System; University of Colorado Anschutz Medical
   Campus; Colorado School of Public Health; University of Colorado System;
   University of Colorado Anschutz Medical Campus; University of Colorado
   System; University of Colorado Anschutz Medical Campus
RP Fonteh, CN (通讯作者)，Univ Colorado, Dept Ophthalmol, Div Ophthalm Epidemiol, Sch Med, Mail Stop F731,1675 Aurora Court, Aurora, CO 80045 USA.
EM cheryl.fonteh@cuanschutz.edu
FU National Eye Institute of the National Institutes of Health
   [R01EY032456]; Research to Prevent Blindness; NIH/NCATS Colorado CTSA
   Grant [UL1 TR002535]; Frederic C. Hamilton Macular Degeneration Center;
   Sue Anschutz-Rogers Eye Center Research Fund
FX Supported by the National Eye Institute of the National Institutes of
   Health under award number R01EY032456 (AML) , a Research to Prevent
   Blind-ness grant to the Department of Ophthalmology, University of
   Colorado, the Frederic C. Hamilton Macular Degeneration Center, Sue
   Anschutz-Rogers Eye Center Research Fund, and by NIH/NCATS Colorado CTSA
   Grant Number UL1 TR002535.
CR Anand R, 2000, OPHTHALMOLOGY, V107, P2224
   Angum F, 2020, CUREUS, V12, DOI 10.7759/cureus.8094
   Badacz R, 2019, J PHYSIOL PHARMACOL, V70, P545, DOI 10.26402/jpp.2019.4.06
   Bandinelli F, 2012, CLIN EXP RHEUMATOL, V30, pS44
   Brown CJ, 1996, J NATL CANCER I, V88, P480, DOI 10.1093/jnci/88.8.480
   Canoui-Poitrine F, 2011, NEUROLOGY, V77, P1165, DOI 10.1212/WNL.0b013e31822dc7c8
   Cavusoglu E, 2007, ARTERIOSCL THROM VAS, V27, P929, DOI 10.1161/01.ATV.0000258789.21585.76
   Clayton JA, 2015, CURR EYE RES, V40, P102, DOI 10.3109/02713683.2014.986333
   de Ferranti S, 2002, CLIN CHIM ACTA, V317, P1, DOI 10.1016/S0009-8981(01)00797-5
   de Jager SCA, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0045804
   Donoso LA, 2006, SURV OPHTHALMOL, V51, P137, DOI 10.1016/j.survophthal.2005.12.001
   Ferris FL, 2013, OPHTHALMOLOGY, V120, P844, DOI 10.1016/j.ophtha.2012.10.036
   Fischer FR, 2001, J IMMUNOL, V167, P1637, DOI 10.4049/jimmunol.167.3.1637
   Fritsche LG, 2016, NAT GENET, V48, P134, DOI 10.1038/ng.3448
   Heesterbeek TJ, 2020, OPHTHAL PHYSL OPT, V40, P140, DOI 10.1111/opo.12675
   Huang CL, 2021, LANCET, V397, P220, DOI 10.1016/S0140-6736(20)32656-8
   Jin JM, 2020, FRONT PUBLIC HEALTH, V8, DOI 10.3389/fpubh.2020.00152
   Kobusiak-Prokopowicz M, 2007, EUR J INTERN MED, V18, P288, DOI 10.1016/j.ejim.2007.02.001
   Koper-Lenkiewicz OM, 2019, BIOMED RES INT, V2019, DOI 10.1155/2019/3026453
   Lam H, 2009, AM J OPHTHALMOL, V147, P198, DOI 10.1016/j.ajo.2008.08.032
   Lambert NG, 2016, PROG RETIN EYE RES, V54, P64, DOI 10.1016/j.preteyeres.2016.04.003
   Lipkova J, 2015, CLIN EXP MED, V15, P405, DOI 10.1007/s10238-014-0294-5
   Lopes GS, 2020, PHARMACOGEN PERS MED, V13, P71, DOI 10.2147/PGPM.S239222
   Lynch AM, 2020, BMJ OPEN OPHTHALMOL, V5, DOI 10.1136/bmjophth-2019-000361
   Lynch AM, 2020, EUR J OPHTHALMOL, V30, P1061, DOI 10.1177/1120672119857896
   Lynch AM, 2019, RETINA-J RET VIT DIS, V39, P656, DOI 10.1097/IAE.0000000000002023
   Lynch AM, 2019, TRANSL VIS SCI TECHN, V8, DOI 10.1167/tvst.8.1.14
   Mauvais-Jarvis F, 2020, LANCET, V396, P565, DOI 10.1016/S0140-6736(20)31561-0
   Meleth AD, 2005, INVEST OPHTH VIS SCI, V46, P4295, DOI 10.1167/iovs.04-1057
   Miller LR, 2017, FASEB J, V31, P29, DOI 10.1096/fj.201600781R
   Nagineni CN, 2015, AGING DIS, V6, P444, DOI 10.14336/AD.2015.0323
   National institute of health, OFFICE WOMENS RES
   Nielsen MK, 2020, INVEST OPHTH VIS SCI, V61, DOI 10.1167/iovs.61.4.28
   Oertelt-Prigione S, 2012, AUTOIMMUN REV, V11, pA479, DOI 10.1016/j.autrev.2011.11.022
   Owen CG, 2012, BRIT J OPHTHALMOL, V96, P752, DOI 10.1136/bjophthalmol-2011-301109
   Palestine AG, 2021, FRONT MED-LAUSANNE, V8, DOI 10.3389/fmed.2021.710595
   Pinto-Fraga J, 2018, OCUL SURF, V16, P368, DOI 10.1016/j.jtos.2018.05.001
   Reale M, 2009, BRAIN BEHAV IMMUN, V23, P55, DOI 10.1016/j.bbi.2008.07.003
   Ridker PM, 2009, CLIN CHEM, V55, P209, DOI 10.1373/clinchem.2008.119214
   Sasaki M, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-017-18487-4
   Shah D, 2011, IMMUNOBIOLOGY, V216, P1010, DOI 10.1016/j.imbio.2011.04.001
   Suffee N, 2011, BIOCHEM SOC T, V39, P1649, DOI 10.1042/BST20110651
   Tereshchenko IP, 2011, MEDIAT INFLAMM, V2011, DOI 10.1155/2011/525691
   Testelmans D, 2013, CYTOKINE, V62, P210, DOI 10.1016/j.cyto.2013.02.021
   Vladan B, 2013, MED HYPOTHESIS DISCO, V2, P82
   Wagner BD, 2022, OPHTHAL EPIDEMIOL, V29, P139, DOI 10.1080/09286586.2021.1910314
   Zetterberg M, 2016, MATURITAS, V83, P19, DOI 10.1016/j.maturitas.2015.10.005
NR 47
TC 1
Z9 1
U1 0
U2 1
PU ASSOC RESEARCH VISION OPHTHALMOLOGY INC
PI ROCKVILLE
PA 12300 TWINBROOK PARKWAY, ROCKVILLE, MD 20852-1606 USA
SN 2164-2591
J9 TRANSL VIS SCI TECHN
JI Transl. Vis. Sci. Technol.
PD FEB
PY 2022
VL 11
IS 2
AR 12
DI 10.1167/tvst.11.2.12
PG 9
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA YY3TL
UT WOS:000754713400001
PM 35133404
OA gold, Green Published
DA 2022-11-30
ER

PT J
AU Benisek, DA
   Manzitti, J
   Scorsetti, D
   Ascarza, AMR
   Ascarza, AA
   Rancano, DG
   Quercia, R
   Gismondi, MR
   Total, MAC
   Scorsetti, ML
   Spitzer, E
   Lombas, C
   Deprati, M
   Penna, MI
   Fernandez, F
   Tinelli, MA
AF Benisek, Daniel A.
   Manzitti, Julio
   Scorsetti, Daniel
   Rousselot Ascarza, Andres M.
   Ascarza, Amalia A.
   Gomez Rancano, Diego
   Quercia, Romina
   Ramirez Gismondi, Matias
   Carpio Total, Mateo A.
   Scorsetti, Maria L.
   Spitzer, Eduardo
   Lombas, Carola
   Deprati, Matias
   Ines Penna, Maria
   Fernandez, Francisco
   Tinelli, Marcelo A.
TI Safety and clinical effectiveness of intravitreal administration of
   bevacizumab (Lumiere((R))) in patients with neovascular age-related
   macular degeneration
SO EXPERIMENTAL AND THERAPEUTIC MEDICINE
LA English
DT Article
DE neovascular age-related macular degeneration; bevacizumab; intravitreal
   anti-VEGF therapy; visual acuity; central retinal thickness
ID ENDOTHELIAL GROWTH-FACTOR; INTRAOCULAR-PRESSURE ELEVATION; ANTI-VEGF
   INJECTIONS; PLASMA-LEVELS; MYOCARDIAL-INFARCTION; SUSTAINED ELEVATION;
   RANIBIZUMAB; SURVIVAL; STROKE
AB The present study was an open-label, prospective, uncontrolled and multicenter clinical trial to investigate the safety and effectiveness of bevacizumab (Lumiere((R))) administered by the intravitreal route for the treatment of neovascular age-related macular degeneration (nAMD). A total of 22 patients without previous treatment with anti-vascular endothelial growth factor were recruited. Monthly therapy with 1.25 mg intravitreal bevacizumab was applied. Adverse events (AE), visual acuity (VA) and central retinal thickness (CRT) were assessed at baseline, day 1 and day 28 after each injection. A total of 87 AEs were reported; most of them were not serious (96.6%), expected (65.5%) and occurred after the third injection (56.3%). The most frequent AE was 'conjunctival hemorrhage' (29.9% of AEs), attributed to the injection procedure. Treatment was not suspended due to safety reasons in any case. After six months, a statistically significant gain of +8.2 (SD +/- 8.8) letters and a CRT reduction of -75.50 mu m (SD +/- 120.3) were achieved with unilateral therapy. VA improvement and CRT reduction were also achieved with bilateral therapy, although to a lesser extent. The results of the present study suggested that therapy with a minimum of 3 doses of bevacizumab over a 6-month period was well tolerated and resulted in a sustained response regarding VA improvement and CRT reduction from the beginning of therapy compared with the baseline value. The study protocol was registered at clinicaltrials.gov (ref. no. NCT03668054).
C1 [Benisek, Daniel A.; Rousselot Ascarza, Andres M.; Ascarza, Amalia A.; Gomez Rancano, Diego] Consultorios Oftalmol Benisek Ascarza, C1115ABB, Buenos Aires, DF, Argentina.
   [Manzitti, Julio; Quercia, Romina; Ramirez Gismondi, Matias] Consultorio Oftalmol Julio Manzitti, C1124AAG, Buenos Aires, DF, Argentina.
   [Scorsetti, Daniel; Carpio Total, Mateo A.; Scorsetti, Maria L.] Inst Scorsetti, C1120AAC, Buenos Aires, DF, Argentina.
   [Spitzer, Eduardo; Lombas, Carola; Tinelli, Marcelo A.] Lab Elea Phoenix SA, Clin Res Dept, Av Gral Juan Gregorio Lemos 2809,B1613AUE, Los Polvorines, Argentina.
   [Deprati, Matias; Ines Penna, Maria] Lab Elea Phoenix SA, Hlth Dept, Los Polvorines, Argentina.
   [Fernandez, Francisco] Lab Elea Phoenix SA, Pharmacovigilance Dept, B1613AUE, Buenos Aires, DF, Argentina.
RP Tinelli, MA (通讯作者)，Lab Elea Phoenix SA, Clin Res Dept, Av Gral Juan Gregorio Lemos 2809,B1613AUE, Los Polvorines, Argentina.
EM tinellim@elea.com
FU Laboratorio Elea-Phoenix S.A. (Argentina)
FX The present study was funded by Laboratorio Elea-Phoenix S.A.
   (Argentina).
CR Adelman RA, 2010, J OCUL PHARMACOL TH, V26, P105, DOI 10.1089/jop.2009.0076
   Age-Related Eye Dis Study Res Grp, 2001, AM J OPHTHALMOL, V132, P668
   Alexandru Malciolu Radu, 2016, Rom J Ophthalmol, V60, P9
   Bakri SJ, 2019, OPHTHALMOLOGY, V126, P55, DOI 10.1016/j.ophtha.2018.07.028
   Beato J, 2016, OPHTHALMIC RES, V56, P30, DOI 10.1159/000444395
   Beatty S, 2000, SURV OPHTHALMOL, V45, P115, DOI 10.1016/S0039-6257(00)00140-5
   Berg K, 2015, OPHTHALMOLOGY, V122, P146, DOI 10.1016/j.ophtha.2014.07.041
   Bro T, 2020, GRAEF ARCH CLIN EXP, V258, P503, DOI 10.1007/s00417-019-04569-8
   Carneiro AM, 2012, ACTA OPHTHALMOL, V90, pE25, DOI 10.1111/j.1755-3768.2011.02240.x
   Chakravarthy U, 2012, OPHTHALMOLOGY, V119, DOI 10.1016/j.ophtha.2012.04.015
   Chen HX, 2009, NAT REV CLIN ONCOL, V6, P465, DOI 10.1038/nrclinonc.2009.94
   Choi DY, 2011, RETINA-J RET VIT DIS, V31, P1028, DOI 10.1097/IAE.0b013e318217ffde
   Dedania VS, 2015, RETINA-J RET VIT DIS, V35, P841, DOI 10.1097/IAE.0000000000000520
   Domigan CK, 2015, J CELL SCI, V128, P2236, DOI 10.1242/jcs.163774
   Enseleit F, 2017, OPHTHALMOLOGICA, V238, P205, DOI 10.1159/000478665
   Etminan M, 2016, AM J OPHTHALMOL, V163, P53, DOI 10.1016/j.ajo.2015.11.030
   Ferrara N, 2004, NAT REV DRUG DISCOV, V3, P391, DOI 10.1038/nrd1381
   FERRIS FL, 1984, ARCH OPHTHALMOL-CHIC, V102, P1640
   Foss AJE, 2015, TRIALS, V16, DOI 10.1186/s13063-015-0608-2
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P564
   Gianniou C, 2015, EYE, V29, P342, DOI 10.1038/eye.2014.258
   Good TJ, 2011, BRIT J OPHTHALMOL, V95, P1111, DOI 10.1136/bjo.2010.180729
   Heinemann V, 2010, ONCOLOGY-BASEL, V79, P118, DOI 10.1159/000314993
   Hoang QV, 2013, RETINA-J RET VIT DIS, V33, P179, DOI 10.1097/IAE.0b013e318261a6f7
   Holz FG, 2014, J CLIN INVEST, V124, P1430, DOI 10.1172/JCI71029
   ICH, 2022, MEDDRA HIER MED DICT
   Jain P, 2017, INDIAN J OPHTHALMOL, V65, P596, DOI 10.4103/ijo.IJO_992_16
   Jan Sanaullah, 2016, J Ayub Med Coll Abbottabad, V28, P364
   Johnson DR, 2013, CANCER-AM CANCER SOC, V119, P3489, DOI 10.1002/cncr.28259
   Kiss S, 2018, CLIN OPHTHALMOL, V12, P1625, DOI 10.2147/OPTH.S169143
   Kodjikian L, 2013, OPHTHALMOLOGY, V120, P2300, DOI 10.1016/j.ophtha.2013.06.020
   Krebs I, 2013, BRIT J OPHTHALMOL, V97, P266, DOI 10.1136/bjophthalmol-2012-302391
   Kwon JW, 2018, MEDICINE, V97, DOI 10.1097/MD.0000000000010198
   Martin DF, 2011, NEW ENGL J MED, V364, P1897, DOI 10.1056/NEJMoa1102673
   Mathalone N, 2012, GRAEF ARCH CLIN EXP, V250, P1435, DOI 10.1007/s00417-012-1981-0
   Matsuyama K, 2010, BRIT J OPHTHALMOL, V94, P1215, DOI 10.1136/bjo.2008.156810
   Modi YS, 2015, DRUG SAFETY, V38, P279, DOI 10.1007/s40264-015-0273-0
   Moja L, 2014, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD011230.pub2
   Muller S, 2017, GRAEF ARCH CLIN EXP, V255, P2237, DOI 10.1007/s00417-017-3739-1
   Ng WY, 2015, AM J OPHTHALMOL, V159, P557, DOI 10.1016/j.ajo.2014.12.005
   Olsen TW, 2020, OPHTHALMOLOGY, V127, pP1, DOI 10.1016/j.ophtha.2019.09.024
   Poku E, 2014, BMJ OPEN, V4, DOI 10.1136/bmjopen-2014-005244
   Rosenfeld PJ, 2005, OPHTHAL SURG LAS IM, V36, P331, DOI 10.3928/1542-8877-20050701-14
   Ross EL, 2016, JAMA OPHTHALMOL, V134, P888, DOI 10.1001/jamaophthalmol.2016.1669
   Sagiv O, 2017, OPHTHALMOLOGICA, V238, P217, DOI 10.1159/000479437
   Schauwvlieghe AME, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0153052
   Segal O, 2013, ISR MED ASSOC J, V15, P352
   Sengul A, 2017, EYE, V31, P677, DOI 10.1038/eye.2016.305
   Senra H, 2016, GRAEF ARCH CLIN EXP, V254, P1873, DOI 10.1007/s00417-016-3384-0
   Sniegowski M, 2010, OPEN OPHTHALMOL J, V4, P28, DOI 10.2174/1874364101004010028
   Solomon SD, 2019, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD005139.pub4
   Tufail A, 2010, BMJ-BRIT MED J, V340, DOI 10.1136/bmj.c2459
   Wang W, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0109744
   Wen JC, 2017, INVEST OPHTH VIS SCI, V58, P1893, DOI 10.1167/iovs.16-20786
   Zarbin MA, 1998, EUR J OPHTHALMOL, V8, P199, DOI 10.1177/112067219800800401
   Zechariah A, 2013, STROKE, V44, P1690, DOI 10.1161/STROKEAHA.111.000240
   Zehetner C, 2013, BRIT J OPHTHALMOL, V97, P454, DOI 10.1136/bjophthalmol-2012-302451
NR 57
TC 0
Z9 1
U1 0
U2 2
PU SPANDIDOS PUBL LTD
PI ATHENS
PA POB 18179, ATHENS, 116 10, GREECE
SN 1792-0981
EI 1792-1015
J9 EXP THER MED
JI Exp. Ther. Med.
PD DEC
PY 2020
VL 20
IS 6
AR 162
DI 10.3892/etm.2020.9291
PG 10
WC Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Research & Experimental Medicine
GA OZ9VS
UT WOS:000595267100039
PM 33093900
OA gold, Green Published
DA 2022-11-30
ER

PT J
AU Sengul, EA
   Artunay, O
   Kockar, A
   Afacan, C
   Rasier, R
   Gun, P
   Yalcin, NG
   Yuzbasioglu, E
AF Sengul, Elvan Alper
   Artunay, Ozgur
   Kockar, Alev
   Afacan, Ceyda
   Rasier, Rifat
   Gun, Palmet
   Yalcin, Nazli Gul
   Yuzbasioglu, Erdal
TI Correlation of neutrophil/lymphocyte and platelet/lymphocyte ratio with
   visual acuity and macular thickness in age-related macular degeneration
SO INTERNATIONAL JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
DE age-related macular degeneration; inflammation; neutrophil-to-lymphocyte
   ratio; platelet-to-lymphocyte ratio
ID NEUTROPHIL-LYMPHOCYTE RATIO; CORONARY-ARTERY-DISEASE; COMPLEMENT
   FACTOR-H; ULCERATIVE-COLITIS; ASSOCIATION; SEVERITY; INFLAMMATION;
   PLATELET; AMD; ATHEROSCLEROSIS
AB AIM: To investigate the place of neutrophil-to-lymphocyte ratio (NLR) and platelet-to-lymphocyte ratio (PLR) in the diagnosis of and prognosis for neovascular age-related macular degeneration (AMD).
   METHODS: One hundred AMD patients and 100 healthy controls were included in the study. Blood samples were obtained from the venous blood, which is used for routine analysis, and these samples were subjected to complete blood count. NLR was defined as the neutrophil count divided by the number of lymphocytes, and PLR was defined as the platelet count divided by the number of lymphocytes.
   RESULTS: No statistically significant difference was observed between the two groups under consideration in terms of demographic features (P>0.05). The average NLR in the patient group was found to be significantly higher than that in the healthy control group (P<0.05). The average PLR was significantly higher in the patient group as compared to the control group (P<0.05). As best corrected visual acuity (BCVA) increased, both NLR and PLR decreased (significant negative correlations at 49.8% and 63.0%, respectively), whereas as central macular thickness (CMT) increased, both NLR and PLR increased (significant positive correlations at 59.3% and 70.0%, respectively).
   CONCLUSION: NLR and PLR levels are higher among neovascular AMD patients as compared to healthy control group. NLR and PLR levels were found to be inversely proportional to BCVA and directly proportional to CMT.
C1 [Sengul, Elvan Alper; Kockar, Alev; Rasier, Rifat; Yalcin, Nazli Gul; Yuzbasioglu, Erdal] Istanbul Bilim Univ, Med Fac, Ophthalmol Dept, Abidei Hurriyet St, TR-34381 Istanbul, Turkey.
   [Artunay, Ozgur] Haydarpasa Numune Training & Res Hosp, Ophthalmol Dept, TR-34668 Istanbul, Turkey.
   [Afacan, Ceyda] Mimar Sinan Fine Arts Univ, Dept Stat, TR-34427 Istanbul, Turkey.
   [Gun, Palmet] Istanbul Bilim Univ, Med Fac, Biochem Dept, TR-34381 Istanbul, Turkey.
C3 Demiroglu Bilim University; Istanbul Haydarpasa Numune Training &
   Research Hospital; Mimar Sinan Guzel Sanatlar University; Demiroglu
   Bilim University
RP Sengul, EA (通讯作者)，Istanbul Bilim Univ, Med Fac, Ophthalmol Dept, Abidei Hurriyet St, TR-34381 Istanbul, Turkey.
EM ealper_sengul@yahoo.com
RI Koçkar, Alev/GPX-8090-2022; Rasier, Rifat/AHB-8857-2022; Rasier,
   Rifat/AAK-4259-2021
OI Koçkar, Alev/0000-0002-1457-8511; Rasier, Rifat/0000-0003-0963-7991;
   sengul, elvan alper/0000-0003-1313-6970
CR Acikgoz N, 2016, ANGIOLOGY, V67, P297, DOI 10.1177/0003319715611805
   Akboga MK, 2016, PLATELETS, V27, P178, DOI 10.3109/09537104.2015.1064518
   Akboga MK, 2016, ANGIOLOGY, V67, P89, DOI 10.1177/0003319715583186
   Azab B, 2012, J THROMB THROMBOLYS, V34, P326, DOI 10.1007/s11239-012-0718-6
   Brantley MA, 2012, AM J OPHTHALMOL, V153, P460, DOI 10.1016/j.ajo.2011.08.033
   Buschini E, 2011, PROG NEUROBIOL, V95, P14, DOI 10.1016/j.pneurobio.2011.05.011
   Celikbilek M, 2013, J CLIN LAB ANAL, V27, P72, DOI 10.1002/jcla.21564
   Chen M, 2015, J LEUKOCYTE BIOL, V98, P713, DOI 10.1189/jlb.3RI0615-239R
   Dasch B, 2005, ARCH OPHTHALMOL-CHIC, V123, P1501, DOI 10.1001/archopht.123.11.1501
   Dewan A, 2007, CURR OPIN GENET DEV, V17, P228, DOI 10.1016/j.gde.2007.04.004
   Dikmetas O, 2013, MOL VIS, V19, P2571
   Ferrington DA, 2016, PROG RETIN EYE RES, V51, P69, DOI 10.1016/j.preteyeres.2015.09.002
   Gemenetzi M, 2016, EYE, V30, P1, DOI 10.1038/eye.2015.203
   Hecker LA, 2010, HUM MOL GENET, V19, P209, DOI 10.1093/hmg/ddp472
   Ilhan N, 2014, OCULAR IMMUNOLOGY IN, P1, DOI 10.3109/09273948.2014.970283
   Jenne CN, 2013, INT J LAB HEMATOL, V35, P254, DOI 10.1111/ijlh.12084
   Johnson PT, 2006, P NATL ACAD SCI USA, V103, P17456, DOI 10.1073/pnas.0606234103
   Kaarniranta K, 2011, J ALZHEIMERS DIS, V24, P615, DOI 10.3233/JAD-2011-101908
   Klein R, 2008, OPHTHALMOLOGY, V115, P1742, DOI 10.1016/j.ophtha.2008.03.021
   Klinger MHF, 2002, J INTERF CYTOK RES, V22, P913, DOI 10.1089/10799900260286623
   Kurtul Bengi Ece, 2016, Korean J Ophthalmol, V30, P377
   Lian L, 2015, CANCER BIOMARK, V15, P899, DOI 10.3233/CBM-150534
   Liu TYA, 2013, JAMA OPHTHALMOL, V131, P335, DOI 10.1001/jamaophthalmol.2013.818
   Lotery A, 2007, BRIT J OPHTHALMOL, V91, P1303, DOI 10.1136/bjo.2007.116939
   Machalinska A, 2012, ACTA OPHTHALMOL, V90, P695, DOI 10.1111/j.1755-3768.2011.02295.x
   Mercan R, 2016, J CLIN LAB ANAL, V30, P597, DOI 10.1002/jcla.21908
   Mitta VP, 2013, JAMA OPHTHALMOL, V131, P507, DOI 10.1001/jamaophthalmol.2013.2303
   Nita M, 2014, MEDIAT INFLAMM, V2014, DOI 10.1155/2014/930671
   Papa A, 2008, CLIN CHIM ACTA, V395, P27, DOI 10.1016/j.cca.2008.04.019
   Perkins SJ, 2012, IMMUNOBIOLOGY, V217, P281, DOI 10.1016/j.imbio.2011.10.003
   Piippo N, 2014, BBA-MOL CELL RES, V1843, P3038, DOI 10.1016/j.bbamcr.2014.09.015
   Qin S, 2008, J INFLAMM RES, V1, P49
   Reynolds R, 2009, INVEST OPHTH VIS SCI, V50, P5818, DOI 10.1167/iovs.09-3928
   Stanton CM, 2011, INVEST OPHTH VIS SCI, V52, P8828, DOI 10.1167/iovs.11-7933
   Tamhane UU, 2008, AM J CARDIOL, V102, P653, DOI 10.1016/j.amjcard.2008.05.006
   Torun S, 2012, CLIN RES HEPATOL GAS, V36, P491, DOI 10.1016/j.clinre.2012.06.004
   Unlu M, 2015, CARDIOLOGY, V133, P56, DOI 10.1159/000438981
   Wang X, 2016, ONCOTARGETS THER, V9, P5761, DOI 10.2147/OTT.S106296
   Yayla C, 2016, BIOMARK MED, V10, P367, DOI 10.2217/bmm-2015-0016
   Yuksel M, 2015, ANATOL J CARDIOL, V15, P640, DOI 10.5152/akd.2014.5565
NR 40
TC 18
Z9 18
U1 1
U2 4
PU IJO PRESS
PI XI AN
PA NO 269 YOUYI EAST RD, XI AN, 710054, PEOPLES R CHINA
SN 2222-3959
EI 2227-4898
J9 INT J OPHTHALMOL-CHI
JI Int. J. Ophthalmol.
PD MAY 18
PY 2017
VL 10
IS 5
BP 754
EP 759
DI 10.18240/ijo.2017.05.16
PG 6
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA EV2AW
UT WOS:000401556300016
PM 28546933
OA Green Published, Green Submitted, gold
DA 2022-11-30
ER

PT J
AU Mantel, I
AF Mantel, Irmela
TI Optimizing the Anti-VEGF Treatment Strategy for Neovascular Age-Related
   Macular Degeneration: From Clinical Trials to Real-Life Requirements
SO TRANSLATIONAL VISION SCIENCE & TECHNOLOGY
LA English
DT Article
DE age-related macular degeneration; anti-VEGF treatment; variable dosing
   regimen; real life; treatment outcome
ID INTRAVITREAL RANIBIZUMAB; REGIMEN; BEVACIZUMAB; BURDEN
AB This Perspective discusses the pertinence of variable dosing regimens with anti-vascular endothelial growth factor (VEGF) for neovascular age-related macular degeneration (nAMD) with regard to real-life requirements. After the initial pivotal trials of anti-VEGF therapy, the variable dosing regimens pro re nata (PRN), Treat-and-Extend, and Observe-and-Plan, a recently introduced regimen, aimed to optimize the anti-VEGF treatment strategy for nAMD. The PRN regimen showed good visual results but requires monthly monitoring visits and can therefore be difficult to implement. Moreover, application of the PRN regimen revealed inferior results in real-life circumstances due to problems with resource allocation. The Treat-and-Extend regimen uses an interval based approach and has become widely accepted for its ease of preplanning and the reduced number of office visits required. The parallel development of the Observe-and-Plan regimen demonstrated that the future need for retreatment (interval) could be reliably predicted. Studies investigating the observe-and-plan regimen also showed that this could be used in individualized fixed treatment plans, allowing for dramatically reduced clinical burden and good outcomes, thus meeting the real life requirements. This progressive development of variable dosing regimens is a response to the real-life circumstances of limited human, technical, and financial resources. This includes an individualized treatment approach, optimization of the number of retreatments, a minimal number of monitoring visits, and ease of planning ahead. The Observe-and-Plan regimen achieves this goal with good functional results.
C1 [Mantel, Irmela] Univ Lausanne, Dept Ophthalmol, Lausanne, Switzerland.
   [Mantel, Irmela] Fdn Asile Aveugles, Jules Gonin Eye Hosp, Lausanne, Switzerland.
C3 University of Lausanne
RP Mantel, I (通讯作者)，Univ Eye Hosp Jules Gonin, Lausanne, Switzerland.
EM irmela.mantel@fa2.ch
CR Abraham P, 2010, AM J OPHTHALMOL, V150, P315, DOI 10.1016/j.ajo.2010.04.011
   Bressler NM, 2013, OPHTHALMOLOGY, V120, P160, DOI 10.1016/j.ophtha.2012.07.027
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Busbee BG, 2013, OPHTHALMOLOGY, V120, P1046, DOI 10.1016/j.ophtha.2012.10.014
   Chakravarthy U, 2012, OPHTHALMOLOGY, V119, DOI 10.1016/j.ophtha.2012.04.015
   Fung AE, 2007, AM J OPHTHALMOL, V143, P566, DOI 10.1016/j.ajo.2007.01.028
   Gianniou C, 2015, EYE, V29, P342, DOI 10.1038/eye.2014.258
   Gupta OP, 2010, OPHTHALMOLOGY, V117, P2134, DOI 10.1016/j.ophtha.2010.02.032
   Mantel I, 2014, BRIT J OPHTHALMOL, V98, P1192, DOI 10.1136/bjophthalmol-2013-304556
   Mantel I, 2013, GRAEF ARCH CLIN EXP, V251, P697, DOI 10.1007/s00417-012-2090-9
   Martin DF, 2011, NEW ENGL J MED, V364, P1897, DOI 10.1056/NEJMoa1102673
   Menke MN, 2014, BRIT J OPHTHALMOL, V98, P1197, DOI 10.1136/bjophthalmol-2013-304775
   Rayess N, 2015, AM J OPHTHALMOL, V159, P3, DOI 10.1016/j.ajo.2014.09.011
   Regillo CD, 2008, AM J OPHTHALMOL, V145, P239, DOI 10.1016/j.ajo.2007.10.004
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Rosenfeld PJ, 2011, OPHTHALMOLOGY, V118, P523, DOI 10.1016/j.ophtha.2010.07.011
   Schmidt-Erfurth U, 2011, OPHTHALMOLOGY, V118, P831, DOI 10.1016/j.ophtha.2010.09.004
   Shienbaum G, 2012, AM J OPHTHALMOL, V153, P468, DOI 10.1016/j.ajo.2011.08.011
   Tufail A, 2014, OPHTHALMOLOGY, V121, P1092, DOI 10.1016/j.ophtha.2013.11.031
   Wolf A, 2014, GRAEF ARCH CLIN EXP, V252, P647, DOI 10.1007/s00417-013-2562-6
NR 20
TC 38
Z9 40
U1 0
U2 1
PU ASSOC RESEARCH VISION OPHTHALMOLOGY INC
PI ROCKVILLE
PA 12300 TWINBROOK PARKWAY, ROCKVILLE, MD 20852-1606 USA
SN 2164-2591
J9 TRANSL VIS SCI TECHN
JI Transl. Vis. Sci. Technol.
PD MAY
PY 2015
VL 4
IS 3
AR 6
DI 10.1167/tvst.4.3.6
PG 7
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA ED2FM
UT WOS:000388659300006
PM 26069865
OA Green Published
DA 2022-11-30
ER

PT J
AU Nielsen, MK
   Subhi, Y
   Molbech, CR
   Falk, MK
   Nissen, MH
   Sorensen, TL
AF Nielsen, Marie Krogh
   Subhi, Yousif
   Molbech, Christopher Rue
   Falk, Mads Kruger
   Nissen, Mogens Holst
   Sorensen, Torben Lykke
TI Chemokine Profile and the Alterations in CCR5-CCL5 Axis in Geographic
   Atrophy Secondary to Age-Related Macular Degeneration
SO INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE
LA English
DT Article
DE age-related macular degeneration; geographic atrophy; neovascular AMD;
   chemokine; chemokine receptor
ID BLOOD-BRAIN-BARRIER; T-CELLS; CCR5; EXPRESSION; MONOCYTES; DISEASE;
   PROTEIN; LESIONS; RISK
AB PURPOSE. Geographic atrophy (GA) secondary to age-related macular degeneration (AMD) is a progressive disease with no treatment option. Previous studies show chemokine-mediated recruitment of immune cells in the retina, and therefore we investigated systemic levels of chemokines and chemokine receptors in patients with GA.
   METHODS. This observational prospective study was conducted at a single center. We included 122 participants with no immune disease: 41 participants with GA and no choroidal neovascularization, 51 patients with neovascular AMD, and 30 healthy control individuals. Flow cytometric analysis was used to detect expression level of C-C chemokine receptor (CCR)1, CCR2, CCR3, CCR5, and C-X-C motif chemokine receptor (CXCR)3 on peripheral blood mononuclear cells (CD14+ monocytes, CD4+ T cells, CD8+ T cells). Plasma levels of C-C motif ligand (CCL)11, C-X-C motif chemokine (CXCL)10, and CCL5 were measured by specific immunoassays. Enlargement rate of GA lesion was measured from autofluorescence images.
   RESULTS. Participants with GA have a specific chemokine profile with a higher expression of CCR5 than healthy controls in peripheral blood mononuclear cells, and a higher plasma levels of CCL-5. Further, GA was associated with higher monocytic expression of CCR2 than in neovascular AMD. We found that a high expression level of CCR5 on CD8+ T cells was associated with slower enlargement rate of atrophic lesion.
   CONCLUSIONS. The study showed an association between systemic chemokine profile and GA formation. Further studies are needed to fully elucidate the possible role of systemic chemokine regulation in mediating pathogenesis of GA.
C1 [Nielsen, Marie Krogh; Subhi, Yousif; Molbech, Christopher Rue; Falk, Mads Kruger; Sorensen, Torben Lykke] Zealand Univ Hosp, Dept Ophthalmol, Clin Eye Res Div, Vestermarksvej 23, DK-4000 Roskilde, Denmark.
   [Molbech, Christopher Rue; Nissen, Mogens Holst; Sorensen, Torben Lykke] Univ Copenhagen, Dept Clin Med, Copenhagen, Denmark.
   [Nissen, Mogens Holst] Univ Copenhagen, Dept Immunol & Microbiol, Eye Res Unit, Copenhagen, Denmark.
C3 University of Copenhagen; University of Copenhagen
RP Nielsen, MK (通讯作者)，Zealand Univ Hosp, Dept Ophthalmol, Clin Eye Res Div, Vestermarksvej 23, DK-4000 Roskilde, Denmark.
EM mariekroghnielsen@gmail.com
RI Subhi, Yousif/ABG-6330-2020
OI Subhi, Yousif/0000-0001-6620-5365
FU Velux Foundation; Region Zealand; Ojenfonden
FX Supported by the Velux Foundation, Ojenfonden, and the Region Zealand.
   None of the funding bodies had any role in design, execution, or
   interpretation of the research performed.
CR Belnoue E, 2003, BLOOD, V101, P4253, DOI 10.1182/blood-2002-05-1493
   Bruban J, 2011, NEUROBIOL DIS, V42, P55, DOI 10.1016/j.nbd.2011.01.004
   Cardona Sandra M, 2013, Methods Mol Biol, V1013, P1, DOI 10.1007/978-1-62703-426-5_1
   Castanheira FVES, 2019, SHOCK, V52, pE100, DOI 10.1097/SHK.0000000000001301
   Choi DY, 2013, NEUROBIOL DIS, V49, P159, DOI 10.1016/j.nbd.2012.08.001
   Cohen J., 1988, STAT POWER ANAL SOCI, V2nd
   Combadiere C, 2007, J CLIN INVEST, V117, P2920, DOI 10.1172/JCI31692
   Cougnard-Gregoire A, 2013, INVEST OPHTH VIS SCI, V54, P1905, DOI 10.1167/iovs.12-10192
   Crane IJ, 1998, CELL IMMUNOL, V184, P37, DOI 10.1006/cimm.1997.1235
   Danish Ophthalmological Society, TREATM REC INCL MED
   Falk MK, 2014, INVEST OPHTH VIS SCI, V55, P4050, DOI 10.1167/iovs.14-14107
   Ferguson AR, 2010, J IMMUNOL, V184, P4079, DOI 10.4049/jimmunol.0901903
   Gamo K, 2008, J NEUROSCI, V28, P11980, DOI 10.1523/JNEUROSCI.2920-08.2008
   Glass WG, 2006, J EXP MED, V203, P35, DOI 10.1084/jem.20051970
   Griffith JW, 2014, ANNU REV IMMUNOL, V32, P659, DOI 10.1146/annurev-immunol-032713-120145
   Grunin M, 2012, INVEST OPHTH VIS SCI, V53, P5292, DOI 10.1167/iovs.11-9165
   Guillonneau X, 2017, PROG RETIN EYE RES, V61, P98, DOI 10.1016/j.preteyeres.2017.06.002
   Hulley SB., 2013, DESIGNING CLIN RES E, V4th, P79
   Kaiser Peter K, 2009, Trans Am Ophthalmol Soc, V107, P311
   Lad EM, 2015, GRAEF ARCH CLIN EXP, V253, P1941, DOI 10.1007/s00417-015-3094-z
   Larena M, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0044834
   Martin-Blondel G, 2016, NAT REV NEUROL, V12, P95, DOI 10.1038/nrneurol.2015.248
   Meucci O, 1998, P NATL ACAD SCI USA, V95, P14500, DOI 10.1073/pnas.95.24.14500
   Nagineni CN, 2015, AGING DIS, V6, P444, DOI 10.14336/AD.2015.0323
   Nielsen MK, 2019, INVEST OPHTH VIS SCI, V60, P202, DOI 10.1167/iovs.18-25878
   Nielsen MK, 2019, CLIN EXP OPHTHALMOL, V47, P69, DOI 10.1111/ceo.13362
   Rentzos M, 2007, ACTA NEUROL SCAND, V116, P374, DOI 10.1111/j.1600-0404.2007.00894.x
   Rifai N, 2001, CLIN CHEM, V47, P28
   Robbie SJ, 2016, NEUROBIOL AGING, V40, P110, DOI 10.1016/j.neurobiolaging.2015.12.019
   Ross RJ, 2008, EXP EYE RES, V86, P675, DOI 10.1016/j.exer.2008.01.014
   Sakurada Y, 2015, OPHTHALMIC RES, V53, P2, DOI 10.1159/000365487
   Seddon JM, 2006, OPHTHALMOLOGY, V113, P260, DOI 10.1016/j.ophtha.2005.11.001
   Sennlaub F, 2013, EMBO MOL MED, V5, P1775, DOI 10.1002/emmm.201302692
   Singh T, 2011, AGEING RES REV, V10, P319, DOI 10.1016/j.arr.2010.11.002
   Subhi Y, 2019, ACTA OPHTHALMOL, V97, P99, DOI 10.1111/aos.13886
   Subhi Yousif, 2016, Dan Med J, V63
   Subhi Y, 2017, ACTA OPHTHALMOL, V95, P472, DOI 10.1111/aos.13330
   Takeda A, 2009, NATURE, V460, P225, DOI 10.1038/nature08151
   Tripathy D, 2010, NEUROBIOL AGING, V31, P8, DOI 10.1016/j.neurobiolaging.2008.03.009
   Ubogu EE, 2006, CELL IMMUNOL, V243, P19, DOI 10.1016/j.cellimm.2006.12.001
   Ubogu EE, 2006, J NEUROIMMUNOL, V179, P132, DOI 10.1016/j.jneuroim.2006.06.004
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
   Yates CC, 2012, BIRTH DEFECTS RES C, V96, P325, DOI 10.1002/bdrc.21024
   Yates-Binder CC, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0040812
NR 44
TC 9
Z9 9
U1 0
U2 3
PU ASSOC RESEARCH VISION OPHTHALMOLOGY INC
PI ROCKVILLE
PA 12300 TWINBROOK PARKWAY, ROCKVILLE, MD 20852-1606 USA
SN 0146-0404
EI 1552-5783
J9 INVEST OPHTH VIS SCI
JI Invest. Ophthalmol. Vis. Sci.
PD APR
PY 2020
VL 61
IS 4
AR 28
DI 10.1167/iovs.61.4.28
PG 7
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA LR3XI
UT WOS:000535625700025
PM 32324857
OA Green Published, gold
DA 2022-11-30
ER

PT J
AU Pfau, M
   Lindner, M
   Goerdt, L
   Thiele, S
   Nadal, J
   Schmid, M
   Schmitz-Valckenberg, S
   Sadda, SR
   Holz, FG
   Fleckenstein, M
AF Pfau, Maximilian
   Lindner, Moritz
   Goerdt, Lukas
   Thiele, Sarah
   Nadal, Jennifer
   Schmid, Matthias
   Schmitz-Valckenberg, Steffen
   Sadda, Srinivas R.
   Holz, Frank G.
   Fleckenstein, Monika
CA Fundus Autofluorescence Age-Rela
TI PROGNOSTIC VALUE OF SHAPE-DESCRIPTIVE FACTORS FOR THE PROGRESSION OF
   GEOGRAPHIC ATROPHY SECONDARY TO AGE-RELATED MACULAR DEGENERATION
SO RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES
LA English
DT Article
DE age-related macular degeneration; circularity; fundus autofluorescence;
   geographic atrophy; perimeter; progression rates
ID OPTICAL COHERENCE TOMOGRAPHY; RETINAL-PIGMENT EPITHELIUM; FUNDUS
   AUTOFLUORESCENCE PATTERNS; NATURAL-HISTORY; EYE DISEASE; GROWTH;
   CLASSIFICATION; ENLARGEMENT; PREDICTORS; EVOLUTION
AB Purpose: To systematically compare the prognostic value of multiple shape-descriptive factors in the natural course of the disease.
   Methods: A total of 296 eyes of 201 patients (female patients 130; mean age: 72.2 +/- 13.08 years) with a median follow-up of 2.38 years from 2 prospective, noninterventional natural history studies (Fundus-Autofluorescence-in-Age-related-Macular-Degeneration [clinicaltrials.gov identifier NCT00393692], Directional-Spread-in-Geographic-Atrophy [NCT02051998]) were included in the analysis. Serial fundus autofluorescence images were annotated using semiautomated image analysis software to determine the lesion area, circularity, perimeter, and caliper diameters. These variables and the fundus autofluorescence phenotype were evaluated for prediction of the future square root progression rates using linear mixed-effects models.
   Results: For the combined model, leave-one-out cross validation on patient level (Scenario 1: previously unknown patient) resulted in a goodness-to-fit (R-2 value) of 0.244 and leave-one-out cross validation on visit level (Scenario 2: previous observation of the patient) in a R-2 value of 0.391. This indicated that shape-descriptive factors could explain 24.4% of the variance in geographic atrophy progression in previously unknown patients and 39.1% in patients with previous observation.
   Conclusion: These findings confirm the relevance of shape-descriptive factors and previous progression as prognostic variables for geographic atrophy progression. However, a substantial part of the remaining variation in geographic atrophy progression seems to depend on other variables, some of which are visible in optical coherence tomography.
C1 [Pfau, Maximilian; Lindner, Moritz; Goerdt, Lukas; Thiele, Sarah; Schmitz-Valckenberg, Steffen; Holz, Frank G.; Fleckenstein, Monika] Univ Bonn, Dept Ophthalmol, Ernst Abbe St 2, D-53127 Bonn, Germany.
   [Lindner, Moritz] Univ Oxford, Nuffield Lab Ophthalmol, Nuffield Dept Clin Neurosci, Sleep & Circadian Neurosci Inst, Oxford, England.
   [Nadal, Jennifer; Schmid, Matthias] Univ Bonn, Inst Med Biometry Informat & Epidemiol, Bonn, Germany.
   [Sadda, Srinivas R.] Univ Calif Los Angeles, Doheny Eye Inst, Los Angeles, CA USA.
C3 University of Bonn; University of Oxford; University of Bonn; Doheny Eye
   Institute; University of California System; University of California Los
   Angeles
RP Fleckenstein, M (通讯作者)，Univ Bonn, Dept Ophthalmol, Ernst Abbe St 2, D-53127 Bonn, Germany.
EM monika.fleckenstein@ukbonn.de
RI Lindner, Moritz/AAC-8639-2021
OI Lindner, Moritz/0000-0002-4416-3421; Schmid,
   Matthias/0000-0002-0788-0317
FU Faculty of Medicine, University of Bonn [O-137.0022, O-137.0025,
   O-137.0020]; DFG [FL 658/4-1, FL 658/4-2, Ho1926/3-1]
FX Supported by BONFOR GEROK Program, Faculty of Medicine, University of
   Bonn, Grant No. O-137.0022, O-137.0025 (to M.P.) and Grant No.
   O-137.0020 (to M.L.), DFG Grant FL 658/4-1 and FL 658/4-2 DFG Grant
   Ho1926/3-1.
CR Ach T, 2015, INVEST OPHTH VIS SCI, V56, P3242, DOI 10.1167/iovs.14-16274
   Batioglu F, 2014, OPHTHALMIC RES, V52, P53, DOI 10.1159/000361077
   Biarnes M, 2015, AM J OPHTHALMOL, V160, P345, DOI 10.1016/j.ajo.2015.05.009
   Bindewald A, 2005, INVEST OPHTH VIS SCI, V46, P3309, DOI 10.1167/iovs.04-0430
   BLAIR CJ, 1975, ARCH OPHTHALMOL-CHIC, V93, P19, DOI 10.1001/archopht.1975.01010020023003
   BLAND JM, 1986, LANCET, V1, P307, DOI 10.1016/s0140-6736(86)90837-8
   Caire J, 2014, JAMA OPHTHALMOL, V132, P528, DOI 10.1001/jamaophthalmol.2013.8175
   Cheung LK, 2013, PHARMACOTHERAPY, V33, P838, DOI 10.1002/phar.1264
   Deckert A, 2005, BMC Ophthalmol, V5, P8, DOI 10.1186/1471-2415-5-8
   DELORI FC, 1995, INVEST OPHTH VIS SCI, V36, P718
   Dolz-Marco R, 2017, OPHTHALMOLOGY, V124, P1353, DOI 10.1016/j.ophtha.2017.03.043
   Domalpally A, 2013, OPHTHALMOLOGY, V120, P2666, DOI 10.1016/j.ophtha.2013.07.047
   Dreyhaupt J, 2005, OPHTHAL EPIDEMIOL, V12, P353, DOI 10.1080/09286580591005723
   Dysli C, 2016, INVEST OPHTH VIS SCI, V57, P2479, DOI 10.1167/iovs.15-18381
   Edwards MM, 2017, INVEST OPHTH VIS SCI, V58, P1352, DOI 10.1167/iovs.16-21229
   Feret L. R., 1931, ASS INT ESSAI MAT ZU, V2, P428
   Ferris FL, 2013, OPHTHALMOLOGY, V120, P844, DOI 10.1016/j.ophtha.2012.10.036
   Feuer WJ, 2013, JAMA OPHTHALMOL, V131, P110, DOI 10.1001/jamaophthalmol.2013.572
   Fleckenstein M, 2016, INVEST OPHTH VIS SCI, V57, P2463, DOI 10.1167/iovs.15-18593
   Fleckenstein M, 2014, INVEST OPHTH VIS SCI, V55, P2911, DOI 10.1167/iovs.13-13409
   Fleckenstein M, 2011, INVEST OPHTH VIS SCI, V52, P3761, DOI 10.1167/iovs.10-7021
   Freund KB, 2008, RETINA-J RET VIT DIS, V28, P201, DOI 10.1097/IAE.0b013e3181669504
   Fritsche LG, 2012, INVEST OPHTH VIS SCI, V53, P2112, DOI 10.1167/iovs.11-8785
   Gass J D, 1972, Trans Am Ophthalmol Soc, V70, P409
   Grassmann F, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0126636
   Holz FG, 2007, AM J OPHTHALMOL, V143, P463, DOI 10.1016/j.ajo.2006.11.041
   Holz FG, 2017, OPHTHALMOLOGY, V124, P464, DOI 10.1016/j.ophtha.2016.12.002
   Jeong YJ, 2014, EYE, V28, P209, DOI 10.1038/eye.2013.275
   Joachim N, 2013, OPHTHALMOLOGY, V120, P2042, DOI 10.1016/j.ophtha.2013.03.029
   Klein ML, 2010, OPHTHALMOLOGY, V117, P1554, DOI 10.1016/j.ophtha.2009.12.012
   Klein R, 2008, AM J OPHTHALMOL, V146, P692, DOI 10.1016/j.ajo.2008.05.050
   Klein R, 2007, OPHTHALMOLOGY, V114, P253, DOI 10.1016/j.ophtha.2006.10.040
   Lambert NG, 2016, PROG RETIN EYE RES, V54, P64, DOI 10.1016/j.preteyeres.2016.04.003
   Li ML, 2018, OPHTHALMOLOGY, V125, P276, DOI 10.1016/j.ophtha.2017.08.019
   Lim LS, 2012, LANCET, V379, P1728, DOI 10.1016/S0140-6736(12)60282-7
   Lindblad AS, 2009, ARCH OPHTHALMOL-CHIC, V127, P1168, DOI 10.1001/archophthalmol.2009.198
   Lindner M, 2015, OPHTHALMOLOGY, V122, P1356, DOI 10.1016/j.ophtha.2015.03.027
   Lindner M, 2015, INVEST OPHTH VIS SCI, V56, P875, DOI 10.1167/iovs.14-14933
   Marsiglia M, 2013, INVEST OPHTH VIS SCI, V54, P7362, DOI 10.1167/iovs.12-11073
   Mauschitz MM, 2012, INVEST OPHTH VIS SCI, V53, P4932, DOI 10.1167/iovs.12-9711
   MCLEOD DS, 1994, INVEST OPHTH VIS SCI, V35, P3799
   Mones J, 2018, BRIT J OPHTHALMOL, V102, P388, DOI 10.1136/bjophthalmol-2017-310268
   Moussa K, 2013, RETINA-J RET VIT DIS, V33, P1590, DOI 10.1097/IAE.0b013e31828d6052
   Niu SJ, 2016, OPHTHALMOLOGY, V123, P1737, DOI 10.1016/j.ophtha.2016.04.042
   Niu SJ, 2016, BIOMED OPT EXPRESS, V7, P581, DOI 10.1364/BOE.7.000581
   Oishi M, 2017, INVEST OPHTH VIS SCI, V58, P3303, DOI 10.1167/iovs.17-21498
   Pfau M, 2017, INVEST OPHTH VIS SCI, V58, pBIO121, DOI 10.1167/iovs.17-21764
   Sadda SR, 2018, OPHTHALMOLOGY, V125, P537, DOI 10.1016/j.ophtha.2017.09.028
   Sadda SR, 2016, RETINA-J RET VIT DIS, V36, P1806, DOI 10.1097/IAE.0000000000001283
   SARKS JP, 1988, EYE, V2, P552, DOI 10.1038/eye.1988.106
   Sayegh RG, 2011, OPHTHALMOLOGY, V118, P1844, DOI 10.1016/j.ophtha.2011.01.043
   SCHATZ H, 1989, OPHTHALMOLOGY, V96, P1541
   Schmitz-Valckenberg S, 2006, INVEST OPHTH VIS SCI, V47, P2648, DOI 10.1167/iovs.05-0892
   Schmitz-Valckenberg S, 2017, OPHTHALMOLOGICA, V237, P11, DOI 10.1159/000455074
   Schmitz-Valckenberg S, 2016, RETINA-J RET VIT DIS, V36, P2250, DOI 10.1097/IAE.0000000000001258
   Schmitz-Valckenberg S, 2016, OPHTHALMOLOGICA, V235, P215, DOI 10.1159/000445217
   Schmitz-Valckenberg S, 2016, OPHTHALMOLOGY, V123, P361, DOI 10.1016/j.ophtha.2015.09.036
   Schmitz-Valckenberg S, 2011, INVEST OPHTH VIS SCI, V52, P7640, DOI 10.1167/iovs.11-7457
   Schneider CA, 2012, NAT METHODS, V9, P671, DOI 10.1038/nmeth.2089
   Scholl HPN, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0007418
   Smailhodzic D, 2011, INVEST OPHTH VIS SCI, V52, P8908, DOI 10.1167/iovs.11-7926
   Spaide RF, 2013, RETINA-J RET VIT DIS, V33, P1800, DOI 10.1097/IAE.0b013e31829c3765
   Sunness JS, 2007, OPHTHALMOLOGY, V114, P271, DOI 10.1016/j.ophtha.2006.09.016
   Sunness JS, 1999, MOL VIS, V5
   Sunness JS, 1999, OPHTHALMOLOGY, V106, P1768, DOI 10.1016/S0161-6420(99)90340-8
   Team RC, 2013, R LANG ENV STAT COMP
   TORCZYNSKI E, 1976, AM J OPHTHALMOL, V81, P428, DOI 10.1016/0002-9394(76)90298-1
   VONRUCKMANN A, 1995, BRIT J OPHTHALMOL, V79, P407, DOI 10.1136/bjo.79.5.407
   Xu LN, 2013, RETINA-J RET VIT DIS, V33, P1850, DOI 10.1097/IAE.0b013e31828991b2
   Yehoshua Z, 2011, OPHTHALMOLOGY, V118, P679, DOI 10.1016/j.ophtha.2010.08.018
   Zanzottera EC, 2016, RETINA-J RET VIT DIS, V36, pS26, DOI 10.1097/IAE.0000000000001330
   Zanzottera EC, 2015, INVEST OPHTH VIS SCI, V56, P3253, DOI 10.1167/iovs.15-16431
   Zanzottera EC, 2015, INVEST OPHTH VIS SCI, V56, P3269, DOI 10.1167/iovs.15-16432
NR 73
TC 34
Z9 34
U1 0
U2 2
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0275-004X
EI 1539-2864
J9 RETINA-J RET VIT DIS
JI Retin.-J. Retin. Vitr. Dis.
PD AUG
PY 2019
VL 39
IS 8
BP 1527
EP 1539
DI 10.1097/IAE.0000000000002206
PG 13
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA IQ5AL
UT WOS:000480763200017
PM 29781974
OA Green Submitted
DA 2022-11-30
ER

PT J
AU Gong, J
   Cai, H
   Noggle, S
   Paull, D
   Rizzolo, LJ
   Del Priore, LV
   Fields, MA
AF Gong, Jie
   Cai, Hui
   Noggle, Scott
   Paull, Daniel
   Rizzolo, Lawrence J.
   Del Priore, Lucian, V
   Fields, Mark A.
CA NYSCF Global Stem Cell Array Team
TI Stem cell-derived retinal pigment epithelium from patients with
   age-related macular degeneration exhibit reduced metabolism and matrix
   interactions
SO STEM CELLS TRANSLATIONAL MEDICINE
LA English
DT Article
DE age-related macular degeneration; aging; Bruch's membrane; induced
   pluripotent stem cells; nonenzymatic nitration; retinal pigment
   epithelium
ID EXTRACELLULAR-MATRIX; OXIDATIVE STRESS; BRUCHS MEMBRANE;
   GENE-EXPRESSION; COMPLEMENT; RPE; REATTACHMENT; ACTIVATION; COLLAGEN;
   PATHWAY
AB Modeling age-related macular degeneration (AMD) is challenging, because it is a multifactorial disease. To focus on interactions between the retinal pigment epithelium (RPE) and Bruch's membrane, we generated RPE from AMD patients and used an altered extracellular matrix (ECM) that models aged Bruch's membrane. Induced pluripotent stem cells (iPSCs) were generated from fibroblasts isolated from AMD patients or age-matched (normal) controls. RPE derived from iPSCs were analyzed by morphology, marker expression, transepithelial electrical resistance (TER), and phagocytosis of rod photoreceptor outer segments. Cell attachment and viability was tested on nitrite-modified ECM, a typical modification of aged Bruch's membrane. DNA microarrays with hierarchical clustering and analysis of mitochondrial function were used to elucidate possible mechanisms for the observed phenotypes. Differentiated RPE displayed cell-specific morphology and markers. The TER and phagocytic capacity were similar among iPSC-derived RPE cultures. However, distinct clusters were found for the transcriptomes of AMD and control iPSC-derived RPE. AMD-derived iPSC-RPE downregulated genes responsible for metabolic-related pathways and cell attachment. AMD-derived iPSC-RPE exhibited reduced mitochondrial respiration and ability to attach and survive on nitrite-modified ECM. Cells that did attach induced the expression of complement genes. Despite reprogramming, iPSC derived from AMD patients yielded RPE with a transcriptome that is distinct from that of age-matched controls. When challenged with an AMD-like modification of Bruch's membrane, AMD-derived iPSC-RPE activated the complement immune system.
C1 [Gong, Jie; Cai, Hui; Rizzolo, Lawrence J.; Del Priore, Lucian, V; Fields, Mark A.] Yale Univ, Sch Med, Dept Ophthalmol & Visual Sci, 300 George St,Suite 8100, New Haven, CT 06511 USA.
   [Noggle, Scott; Paull, Daniel; NYSCF Global Stem Cell Array Team] New York Stem Cell Fdn NYSCF Res Inst, New York, NY USA.
   [Rizzolo, Lawrence J.] Yale Univ, Sch Med, Dept Surg, New Haven, CT 06510 USA.
C3 Yale University; Yale University
RP Fields, MA (通讯作者)，Yale Univ, Sch Med, Dept Ophthalmol & Visual Sci, 300 George St,Suite 8100, New Haven, CT 06511 USA.
EM mark.fields@yale.edu
OI Noggle, Scott/0000-0002-0374-2240; Rizzolo, Lawrence/0000-0002-2393-8419
FU Alonzo Family Fund; Research to Prevent Blindness
FX Alonzo Family Fund; Research to Prevent Blindness
CR Aach J, 2000, GENOME RES, V10, P431, DOI 10.1101/gr.10.4.431
   Bailey AJ, 1998, MECH AGEING DEV, V106, P1, DOI 10.1016/S0047-6374(98)00119-5
   Ban Y, 2000, AM J PHYSIOL-CELL PH, V279, pC744, DOI 10.1152/ajpcell.2000.279.3.C744
   Beatty S, 2000, SURV OPHTHALMOL, V45, P115, DOI 10.1016/S0039-6257(00)00140-5
   Benedicto I, 2017, NAT COMMUN, V8, DOI 10.1038/ncomms15374
   Blasiak Janusz, 2013, Front Biosci (Schol Ed), V5, P412
   Booij JC, 2010, PROG RETIN EYE RES, V29, P1, DOI 10.1016/j.preteyeres.2009.08.003
   BORLAND C, 1987, INT J EPIDEMIOL, V16, P31, DOI 10.1093/ije/16.1.31
   Cai H, 2018, JOVE-J VIS EXP, DOI 10.3791/57084
   Cai H, 2012, FRONT AGING NEUROSCI, V4, DOI 10.3389/fnagi.2012.00008
   Chen L, 2003, BRIT J OPHTHALMOL, V87, P212, DOI 10.1136/bjo.87.2.212
   Comoglio PM, 2003, CURR OPIN CELL BIOL, V15, P565, DOI 10.1016/S0955-0674(03)00096-6
   Del Priore LV, 1998, ARCH OPHTHALMOL-CHIC, V116, P335, DOI 10.1001/archopht.116.3.335
   Del Priore LV, 2002, CURR EYE RES, V25, P79
   Fernandez-Godino R, 2018, ADV EXP MED BIOL, V1074, P29, DOI 10.1007/978-3-319-75402-4_4
   Fernandez-Godino R, 2018, HUM MOL GENET, V27, P147, DOI 10.1093/hmg/ddx392
   Ferrington DA, 2017, REDOX BIOL, V13, P255, DOI 10.1016/j.redox.2017.05.015
   Ferris FL, 2013, OPHTHALMOLOGY, V120, P844, DOI 10.1016/j.ophtha.2012.10.036
   Fields MA, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0177763
   Fields MA, 2015, INVEST OPHTH VIS SCI, V56, P4231, DOI 10.1167/iovs.15-16438
   Galloway CA, 2017, P NATL ACAD SCI USA, V114, pE8214, DOI 10.1073/pnas.1710430114
   Golestaneh N, 2016, J TRANSL MED, V14, DOI 10.1186/s12967-016-1101-8
   Gong J, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0143272
   Gullapalli Vamsi K, 2004, Trans Am Ophthalmol Soc, V102, P123
   Hazim RA, 2017, STEM CELL RES THER, V8, DOI 10.1186/s13287-017-0652-9
   Ho TC, 1997, INVEST OPHTH VIS SCI, V38, P1110
   Hotaling NA, 2016, J OCUL PHARMACOL TH, V32, P272, DOI 10.1089/jop.2015.0157
   Johnson LV, 2011, P NATL ACAD SCI USA, V108, P18277, DOI 10.1073/pnas.1109703108
   Kannan R, 2016, BBA-GEN SUBJECTS, V1860, P258, DOI 10.1016/j.bbagen.2015.05.016
   Kase S, 2010, BLOOD, V115, P3398, DOI 10.1182/blood-2009-01-197095
   Kunchithapautham K, 2014, J BIOL CHEM, V289, P14534, DOI 10.1074/jbc.M114.564674
   MARSHALL GE, 1992, BRIT J OPHTHALMOL, V76, P607, DOI 10.1136/bjo.76.10.607
   Mitchell P, 2018, LANCET, V392, P1147, DOI 10.1016/S0140-6736(18)31550-2
   Moreira EF, 2015, TRANSL VIS SCI TECHN, V4, DOI 10.1167/tvst.4.5.10
   Murdaugh LS, 2010, EXP EYE RES, V90, P564, DOI 10.1016/j.exer.2010.01.014
   Nakata K, 2005, EXP EYE RES, V80, P821, DOI 10.1016/j.exer.2004.12.011
   Nashine S, 2019, EXP EYE RES, V189, DOI 10.1016/j.exer.2019.107701
   Newman AM, 2012, GENOME MED, V4, DOI [10.1186/PREACCEPT-1418491035586234, 10.1186/gm315]
   Nguyen HV, 2015, J CLIN MED, V4, P567, DOI 10.3390/jcm4040567
   Oliver VF, 2015, EPIGENETICS-US, V10, P698, DOI 10.1080/15592294.2015.1060388
   Paik DC, 2001, CONNECT TISSUE RES, V42, P111, DOI 10.3109/03008200109014253
   Parsons JT, 2003, J CELL SCI, V116, P1409, DOI 10.1242/jcs.00373
   PAULEIKHOFF D, 1990, OPHTHALMOLOGY, V97, P171
   Paull D, 2015, NAT METHODS, V12, P885, DOI [10.1038/NMETH.3507, 10.1038/nmeth.3507]
   Pelgrom LR, 2016, METHODS MOL BIOL, V1390, P273, DOI 10.1007/978-1-4939-3335-8_17
   Peng SM, 2013, STEM CELL TRANSL MED, V2, P534, DOI 10.5966/sctm.2012-0134
   Peng SM, 2012, INVEST OPHTH VIS SCI, V53, P5016, DOI 10.1167/iovs.11-8311
   Petit V, 2000, BIOL CELL, V92, P477, DOI 10.1016/S0248-4900(00)01101-1
   Pilgrim MG, 2017, INVEST OPHTH VIS SCI, V58, DOI 10.1167/iovs.16-21060
   Porter LF, 2019, CLIN EPIGENETICS, V11, DOI 10.1186/s13148-019-0608-2
   Ricklin D, 2010, NAT IMMUNOL, V11, P785, DOI 10.1038/ni.1923
   Saini JS, 2017, CELL STEM CELL, V20, P635, DOI 10.1016/j.stem.2016.12.015
   Singh R, 2013, INVEST OPHTH VIS SCI, V54, P6767, DOI 10.1167/iovs.13-11943
   Slenter DN, 2018, NUCLEIC ACIDS RES, V46, pD661, DOI 10.1093/nar/gkx1064
   Solberg Y, 1998, SURV OPHTHALMOL, V42, P535, DOI 10.1016/S0039-6257(98)00002-2
   Song MJ, 2016, BRAIN RES, V1638, P2, DOI 10.1016/j.brainres.2015.12.011
   Spraul CW, 1999, SURV OPHTHALMOL, V44, pS10, DOI 10.1016/S0039-6257(99)00086-7
   Tang SB, 2016, J MED CHEM, V59, P2, DOI 10.1021/acs.jmedchem.5b00789
   TATE DJ, 1995, INVEST OPHTH VIS SCI, V36, P1271
   Tezel TH, 1997, GRAEF ARCH CLIN EXP, V235, P41, DOI 10.1007/BF01007836
   Thao MT, 2018, NITRIC OXIDE-BIOL CH, V79, P51, DOI 10.1016/j.niox.2018.07.006
   Wang Z, 2005, CURR EYE RES, V30, P691, DOI 10.1080/02713680590968259
   Wang Z, 2007, EXP MOL MED, V39, P74, DOI 10.1038/emm.2007.9
   Wei L, 2013, ASIA-PAC J OPHTHALMO, V2, P269, DOI 10.1097/APO.0b013e31829e2793
   Zarbin Marco A, 2003, Trans Am Ophthalmol Soc, V101, P499
   Zeiss CJ, 2010, VET PATHOL, V47, P396, DOI 10.1177/0300985809359598
   Zhao C, 2011, AGING-US, V3, P346, DOI 10.18632/aging.100303
NR 67
TC 23
Z9 23
U1 1
U2 4
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 2157-6564
EI 2157-6580
J9 STEM CELL TRANSL MED
JI Stem Cells Transl. Med.
PD MAR
PY 2020
VL 9
IS 3
BP 364
EP 376
DI 10.1002/sctm.19-0321
EA DEC 2019
PG 13
WC Cell & Tissue Engineering
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Cell Biology
GA KM7XL
UT WOS:000502622500001
PM 31840941
OA Green Published, gold
DA 2022-11-30
ER

PT J
AU Chen, H
   Yu, KD
   Xu, GZ
AF Chen, Han
   Yu, Ke-Da
   Xu, Ge-Zhi
TI Association between Variant Y402H in Age-Related Macular Degeneration
   (AMD) Susceptibility Gene CFH and Treatment Response of AMD: A
   Meta-Analysis
SO PLOS ONE
LA English
DT Article
ID COMPLEMENT FACTOR-H; PHOTODYNAMIC THERAPY; INTRAVITREAL RANIBIZUMAB;
   LOC387715 GENOTYPES; POLYMORPHISM; BEVACIZUMAB; RISK
AB Purpose: To investigate the association between polymorphism rs1061170 (T1277C, Y402H) in age-related macular degeneration (AMD) susceptibility gene Complement Factor H (CFH) and treatment response of neovascular AMD.
   Methods: We performed a literature-based meta-analysis including 10 published association studies involving 1,510 patients. Treatments included anti-VEGF (bevacizumab and ranibizumab) or photodynamic therapy. Summary odds ratios (ORs) and 95% confidence intervals (CIs) were estimated using fixed- and random-effects models. Q-statistic test was used to assess heterogeneity.
   Results: Polymorphism rs1061170 showed a significant summary OR of 1.68 (95% CI, 1.09 to 2.60; P = 0.020; CC versus TT; random-effects) for treatment response of neovascular AMD with heterogeneity of 0.09. In subgroup analysis, rs1061170 was more likely to be a predictor of response to anti-VEGF therapy (P = 0.011). However, heterozygous TC genotype was not associated with altered treatment response (OR = 1.18, 95% CI, 0.95 to 1.47; P = 0.145; fixed-effects). Influence analysis indicated the robustness of our findings.
   Conclusions: rs1061170 might be associated with treatment response of neovascular AMD, especially for the anti-VEGF agents. It might be the first meta-analytically confirmed genetic marker predictive for AMD treatment response though a further validation in larger studies is needed.
C1 [Chen, Han; Xu, Ge-Zhi] Fudan Univ, Dept Ophthalmol, Eye Ear Nose & Throat Hosp, Shanghai 200433, Peoples R China.
   [Yu, Ke-Da] Fudan Univ, Shanghai Canc Ctr, Shanghai 200433, Peoples R China.
   [Yu, Ke-Da] Fudan Univ, Inst Canc, Shanghai 200433, Peoples R China.
C3 Fudan University; Fudan University; Fudan University
RP Chen, H (通讯作者)，Fudan Univ, Dept Ophthalmol, Eye Ear Nose & Throat Hosp, Shanghai 200433, Peoples R China.
EM fudanchenhan@gmail.com; yukd@shca.org.cn; xugezhi@gmail.com
FU National Basic Research grants of China [81170857]; Program Of Shanghai
   Subject Chief Scientist [09XD1400900]
FX This work was supported by National Basic Research grants of China
   (81170857, 2011) and Program Of Shanghai Subject Chief Scientist (A
   type, 09XD1400900). The funders had no role in study design, data
   collection and analysis, decision to publish, or preparation of the
   manuscript.
CR Brantley MA, 2009, EYE, V23, P626, DOI 10.1038/eye.2008.28
   Brantley MA, 2007, OPHTHALMOLOGY, V114, P2168, DOI 10.1016/j.ophtha.2007.09.008
   Cheung C.M., 2011, ARCH OPHTHALMOL
   Ding XY, 2009, PROG RETIN EYE RES, V28, P1, DOI 10.1016/j.preteyeres.2008.10.001
   Edwards AO, 2005, SCIENCE, V308, P421, DOI 10.1126/science.1110189
   Feng XF, 2009, OPHTHALMOLOGY, V116, P1908, DOI 10.1016/j.ophtha.2009.03.011
   Goverdhan SV, 2008, EYE, V22, P849, DOI 10.1038/sj.eye.6702830
   Haines JL, 2005, SCIENCE, V308, P419, DOI 10.1126/science.1110359
   Imai Daisuke, 2010, J Ocul Biol Dis Infor, V3, P53, DOI 10.1007/s12177-010-9055-1
   Klein ML, 2008, OPHTHALMOLOGY, V115, P1019, DOI 10.1016/j.ophtha.2008.01.036
   Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557
   Kloeckener-Gruissem B, 2011, INVEST OPHTH VIS SCI, V52, P4694, DOI 10.1167/iovs.10-6080
   Laine M, 2007, J IMMUNOL, V178, P3831, DOI 10.4049/jimmunol.178.6.3831
   Lee AY, 2009, BRIT J OPHTHALMOL, V93, P610, DOI 10.1136/bjo.2008.150995
   McKibbin M, 2012, BRIT J OPHTHALMOL, V96, P208, DOI 10.1136/bjo.2010.193680
   Mori K, 2010, OPHTHALMOLOGY, V117, P928, DOI 10.1016/j.ophtha.2009.10.001
   Nischler C, 2011, ACTA OPHTHALMOL, V89, pE344, DOI 10.1111/j.1755-3768.2010.02080.x
   Orlin A, 2012, RETINA-J RET VIT DIS, V32, P4, DOI 10.1097/IAE.0b013e31822a2c7c
   Rudnicka AR, 2012, OPHTHALMOLOGY, V119, P571, DOI 10.1016/j.ophtha.2011.09.027
   Seitsonen SP, 2007, EUR J OPHTHALMOL, V17, P943, DOI 10.1177/112067210701700612
   Skerka C, 2007, MOL IMMUNOL, V44, P3398, DOI 10.1016/j.molimm.2007.02.012
   Stroup DF, 2000, JAMA-J AM MED ASSOC, V283, P2008, DOI 10.1001/jama.283.15.2008
   Teper SJ, 2010, MOL VIS, V16, P2598
   Thakkinstian A, 2011, AM J EPIDEMIOL, V173, P1365, DOI 10.1093/aje/kwr025
   Ting AYC, 2009, CURR OPIN OPHTHALMOL, V20, P369, DOI 10.1097/ICU.0b013e32832f8016
   Tsuchihashi T, 2011, OPHTHALMOLOGY, V118, P93, DOI 10.1016/j.ophtha.2010.04.007
   Yachimski P, 2009, GASTROINTEST ENDOSC, V69, P205, DOI 10.1016/j.gie.2008.05.032
   Yu KD, 2011, BREAST CANCER RES TR, V127, P577, DOI 10.1007/s10549-011-1361-1
   Zhou P, 2011, FASEB J, V25, P3489, DOI 10.1096/fj.11-189258
   Ziegler A, 2011, BREAST CANCER RES TR, V128, P197, DOI 10.1007/s10549-010-1295-z
NR 30
TC 40
Z9 47
U1 0
U2 8
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD AUG 14
PY 2012
VL 7
IS 8
AR e42464
DI 10.1371/journal.pone.0042464
PG 7
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA 988OQ
UT WOS:000307500800012
PM 22905135
OA Green Published, Green Submitted, gold
DA 2022-11-30
ER

PT J
AU Lanzetta, P
   Mitchell, P
   Wolf, S
   Veritti, D
AF Lanzetta, Paolo
   Mitchell, Paul
   Wolf, Sebastian
   Veritti, Daniele
TI Different antivascular endothelial growth factor treatments and regimens
   and their outcomes in neovascular age-related macular degeneration: a
   literature review
SO BRITISH JOURNAL OF OPHTHALMOLOGY
LA English
DT Review
DE Drugs; Macula; Neovascularisation; Treatment Medical
ID ANTIRETROVIRAL THERAPY; RANIBIZUMAB TREATMENT; VEGF TRAP; BEVACIZUMAB;
   EFFICACY; VERTEPORFIN; BLINDNESS; SAFETY; TRIAL
AB Antivascular endothelial growth factor (anti-VEGF) therapy has revolutionised the treatment of wet age-related macular degeneration (wAMD). Recent research has focused on evaluating competing agents and alternative dosage regimens, providing evidence to help determine optimal treatment strategies. We therefore conducted a review of clinical research studies in wAMD published since 2008 that compared anti-VEGF dosing regimens and therapies; seven studies met our inclusion criteria. Data on baseline disease characteristics, disease outcomes, safety (ocular and systemic) and treatment burden (injection and visit frequencies) were extracted on patients treated with ranibizumab 0.5mg, bevacizumab 1.25mg or aflibercept 2.0mg for up to 2years. For ranibizumab and bevacizumab, visual and anatomical outcomes at 1 and 2years were superior using scheduled monthly (or 4 weekly (q4w)) compared with as needed or scheduled quarterly dosing regimens. Treatment outcomes were generally better for both drugs when more aggressive retreatment criteria were used, which resulted in more frequent injections. Bevacizumab, however, was associated with a 30-35% elevated rate of serious systemic adverse events compared with ranibizumab, regardless of dosing interval; further study in larger patient populations will be required to determine the validity of this finding. Intravitreal aflibercept injection every 8 weeks was non-inferior to ranibizumab q4w on all visual and anatomical endpoints at week 52, had a similar safety profile and required five fewer anti-VEGF injections.
C1 [Lanzetta, Paolo; Veritti, Daniele] Univ Udine, Dept Ophthalmol, I-33100 Udine, Italy.
   [Mitchell, Paul] Univ Sydney, Dept Ophthalmol, Sydney, NSW 2006, Australia.
   [Wolf, Sebastian] Univ Bern, Dept Ophthalmol, Bern, Switzerland.
C3 University of Udine; University of Sydney; University of Bern
RP Lanzetta, P (通讯作者)，Univ Udine, Dept Ophthalmol, Piazzale S Maria Misericordia, I-33100 Udine, Italy.
EM paolo.lanzetta@uniud.it
RI Mitchell, Paul/P-1498-2014; Wolf, Sebastian/B-8782-2008
OI Wolf, Sebastian/0000-0002-7467-7028; VERITTI,
   Daniele/0000-0003-0148-5348
FU Bayer HealthCare Pharmaceuticals
FX Medical writing support was provided by William Kadish, MD, and Tiffany
   DeSimone, PhD, of PAREXEL. PAREXEL was funded by Bayer HealthCare
   Pharmaceuticals.
CR Abraham P, 2010, AM J OPHTHALMOL, V150, P315, DOI 10.1016/j.ajo.2010.04.011
   Almony A, 2011, CAN J OPHTHALMOL, V46, P182, DOI 10.3129/i10-095
   American Academy of Ophthalmology Retina Panel, PREF PRACT PATT GUID
   [Anonymous], 2011, EYLEA
   [Anonymous], 2013, LUC SUMM PROD CHAR
   [Anonymous], LUCENTS RAN INJ
   Australian Therapeutic Goods Administration, FIN DEC REAS DEC DEL
   Bangsberg DR, 2001, AIDS, V15, P1181, DOI 10.1097/00002030-200106150-00015
   Bloch SB, 2012, AM J OPHTHALMOL, V153, P209, DOI 10.1016/j.ajo.2011.10.016
   Boyer DS, 2009, OPHTHALMOLOGY, V116, P1731, DOI 10.1016/j.ophtha.2009.05.024
   Brand CS, 2012, EYE, V26, pS1, DOI 10.1038/eye.2012.32
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Brown DM, 2009, OPHTHALMOLOGY, V116, P57, DOI 10.1016/j.ophtha.2008.10.018
   Chakravarthy U, 2012, OPHTHALMOLOGY, V119, DOI 10.1016/j.ophtha.2012.04.015
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P564
   Gater A, 2011, THROMB HAEMOSTASIS, V106, P398, DOI 10.1160/TH11-03-0193
   Gross R, 2001, AIDS, V15, P2109, DOI 10.1097/00002030-200111090-00006
   Heier JS, 2012, OPHTHALMOLOGY, V119, P2537, DOI 10.1016/j.ophtha.2012.09.006
   Holz FG, 2011, OPHTHALMOLOGY, V118, P663, DOI 10.1016/j.ophtha.2010.12.019
   Holz FG, 2010, INVEST OPHTH VIS SCI, V51, P405, DOI 10.1167/iovs.09-3813
   International Diabetes Federation, IDF DIABETES ATLAS, V9th
   Kawasaki R, 2010, OPHTHALMOLOGY, V117, P921, DOI 10.1016/j.ophtha.2009.10.007
   Korobelnik JF, 2011, EUR SOC RET SPEC C M
   Lalwani GA, 2009, AM J OPHTHALMOL, V148, P43, DOI 10.1016/j.ajo.2009.01.024
   Martin DF, 2012, OPHTHALMOLOGY, V119, DOI 10.1016/j.ophtha.2012.03.053
   Martin DF, 2011, NEW ENGL J MED, V364, P1897, DOI 10.1056/NEJMoa1102673
   Michalova K, 2009, EYE, V23, P1633, DOI 10.1038/eye.2009.175
   Mitchell P, 2010, BRIT J OPHTHALMOL, V94, P2, DOI 10.1136/bjo.2009.159160
   Mitchell P, 2011, CURR MED RES OPIN, V27, P1465, DOI 10.1185/03007995.2011.585394
   Montgomery Alan A, 2003, BMC Med Res Methodol, V3, P26, DOI 10.1186/1471-2288-3-26
   Nguyen QD, 2011, ADD RES VIS OPHTH MA
   Oishi A, 2011, EUR J OPHTHALMOL, V21, P777, DOI 10.5301/EJO.2011.7430
   Oubraham H, 2011, RETINA-J RET VIT DIS, V31, P26, DOI 10.1097/IAE.0b013e3181de5609
   Papadopoulos N, 2012, ANGIOGENESIS, V15, P171, DOI 10.1007/s10456-011-9249-6
   Prokofyeva E, 2012, OPHTHALMIC RES, V47, P171, DOI 10.1159/000329603
   Regillo CD, 2008, AM J OPHTHALMOL, V145, P239, DOI 10.1016/j.ajo.2007.10.004
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Rotsos T, 2010, CLIN OPHTHALMOL, V4, P1271, DOI 10.2147/OPTH.S14684
   Royal College of Ophthalmologists, AG REL MAC DEG GUID
   Schmidt-Erfurth U, 2011, OPHTHALMOLOGY, V118, P831, DOI 10.1016/j.ophtha.2010.09.004
   Singer MA, 2012, OPHTHALMOLOGY, V119, P1175, DOI 10.1016/j.ophtha.2011.12.016
   Skaat A, 2012, AM J OPHTHALMOL, V153, P214, DOI 10.1016/j.ajo.2011.08.035
   Stewart MW, 2008, BRIT J OPHTHALMOL, V92, P667, DOI 10.1136/bjo.2007.134874
   Stewart MW, 2012, RETINA-J RET VIT DIS, V32, P434, DOI 10.1097/IAE.0B013E31822C290F
   Subramanian ML, 2009, AM J OPHTHALMOL, V148, P875, DOI 10.1016/j.ajo.2009.07.009
NR 45
TC 38
Z9 39
U1 0
U2 21
PU BMJ PUBLISHING GROUP
PI LONDON
PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND
SN 0007-1161
EI 1468-2079
J9 BRIT J OPHTHALMOL
JI Br. J. Ophthalmol.
PD DEC
PY 2013
VL 97
IS 12
BP 1497
EP 1507
DI 10.1136/bjophthalmol-2013-303394
PG 11
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 250UJ
UT WOS:000326881000004
PM 23929309
DA 2022-11-30
ER

PT J
AU Wu, ZC
   Ayton, LN
   Guymer, RH
   Luu, CD
AF Wu, Zhichao
   Ayton, Lauren N.
   Guymer, Robyn H.
   Luu, Chi D.
TI Relationship Between the Second Reflective Band on Optical Coherence
   Tomography and Multifocal Electroretinography in Age-Related Macular
   Degeneration
SO INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE
LA English
DT Article
DE age-related macular degeneration; optical coherence tomography;
   multifocal electroretinography; IS/OS; inner segment ellipsoids
ID RETINAL-DETACHMENT; SENSITIVITY; AUTOFLUORESCENCE
AB PURPOSE. The second hyper-reflective on spectral domain optical coherence tomography (SD-OCT) has been suggested to correlate with the photoreceptor inner segment ellipsoids (ISe). The purpose of our study was to determine the relationship between the intensity of the ISe band and retinal function measured by multifocal electroretinography (mfERG) in patients with early age-related macular degeneration (AMD).
   METHODS. A high-resolution horizontal line scan through the fovea on SD-OCT and an mfERG recording were performed in one eye of 29 early AMD and 31 control participants. The relative intensity of the ISe band within 1000 mu m of the fovea was quantified using ImageJ. The relationships between the relative intensity of the ISe band and the mfERG response parameters (P1 amplitude and implicit time) within the three central hexagons along the horizontal axis were determined.
   RESULTS. In normal participants, the relative intensity of the ISe band was significantly correlated with age (r = 0.634, P < 0.001) and also exhibited a topographic variation. On average, the relative intensity of the ISe band was significantly lower in patients with early AMD (1.77 +/- 0.26) compared to control subjects (1.95 +/- 0.27, P < 0.001) of a similar age range. The relative intensity of the ISe band was correlated significantly with the mfERG P1 implicit time (r = -0.745, P < 0.001), but not P1 amplitude (r = 0.144, P = 0.281).
   CONCLUSIONS. The relative intensity of the ISe band reduced with age and further in early AMD. The relative intensity was significantly correlated with mfERG P1 implicit time.
C1 [Wu, Zhichao; Ayton, Lauren N.; Guymer, Robyn H.; Luu, Chi D.] Univ Melbourne, Royal Victorian Eye & Ear Hosp, Ctr Eye Res Australia, Victoria, East Melbourne, Australia.
C3 Centre for Eye Research Australia; Royal Victorian Eye & Ear Hospital;
   University of Melbourne
RP Luu, CD (通讯作者)，Ctr Eye Res Australia, Macular Res Unit, Level 1,32 Gisborne St, East Melbourne, Vic 3002, Australia.
EM cluu@unimelb.edu.au
RI Ayton, Lauren/AAV-2977-2021
OI Ayton, Lauren/0000-0001-9907-084X; Guymer, Robyn/0000-0002-9441-4356;
   Luu, Chi/0000-0002-7604-7097
FU National Health and Medical Research Council (NHMRC) [1027624, 529905];
   Macular Degeneration Foundation Research Grant; NHMRC Centre for
   Clinical Research Excellence Award [529923]
FX Supported by the National Health and Medical Research Council (NH&MRC)
   Project Grant (1027624), Macular Degeneration Foundation Research Grant,
   NH&MRC practitioner fellowship (#529905; RHG). Centre for Eye Research
   Australia (CERA) receives Operational Infrastructure Support from the
   Victorian Government and is supported by a NHMRC Centre for Clinical
   Research Excellence Award (#529923).
CR Birch DG, 2011, INVEST OPHTH VIS SCI, V52, P7141, DOI 10.1167/iovs.11-7509
   Chen WC, 2012, RETINA-J RET VIT DIS, V32, P1733, DOI 10.1097/IAE.0b013e318242b81a
   Delolme MP, 2012, AM J OPHTHALMOL, V153, P128, DOI 10.1016/j.ajo.2011.06.010
   Drexler W, 2003, ARCH OPHTHALMOL-CHIC, V121, P695, DOI 10.1001/archopht.121.5.695
   Feigl B, 2007, EYE, V21, P689, DOI 10.1038/sj.eye.6702389
   Fernandez EJ, 2008, OPT EXPRESS, V16, P11083, DOI 10.1364/OE.16.011083
   Ferris FL, 2005, ARCH OPHTHALMOL-CHIC, V123, P1570
   Fritsche LG, 2008, NAT GENET, V40, P892, DOI 10.1038/ng.170
   Gerth C, 2003, ARCH OPHTHALMOL-CHIC, V121, P1404, DOI 10.1001/archopht.121.10.1404
   Gloesmann M, 2003, INVEST OPHTH VIS SCI, V44, P1696, DOI 10.1167/iovs.02-0654
   Harrison WW, 2011, INVEST OPHTH VIS SCI, V52, P772, DOI 10.1167/iovs.10-5931
   Hartmann KI, 2011, RETINA-J RET VIT DIS, V31, P1323, DOI 10.1097/IAE.0b013e31820a6850
   Hoang QV, 2002, VISUAL NEUROSCI, V19, P395, DOI 10.1017/S0952523802194028
   Hood DC, 2011, INVEST OPHTH VIS SCI, V52, P9703, DOI 10.1167/iovs.11-8650
   Kanda A, 2007, P NATL ACAD SCI USA, V104, P16227, DOI 10.1073/pnas.0703933104
   Kim SW, 2012, BRIT J OPHTHALMOL, V96, P350, DOI 10.1136/bjo.2011.204503
   Lai WW, 2010, BRIT J OPHTHALMOL, V94, P311, DOI 10.1136/bjo.2009.163584
   Landa G, 2011, RETINA-J RET VIT DIS, V31, P364, DOI 10.1097/IAE.0b013e3181e91132
   Lenassi E, 2012, INVEST OPHTH VIS SCI, V53, P47, DOI 10.1167/iovs.11-8048
   Lu RW, 2012, J BIOMED OPT, V17, DOI 10.1117/1.JBO.17.6.060504
   Oishi A, 2010, AM J OPHTHALMOL, V150, P27, DOI 10.1016/j.ajo.2010.02.012
   Querques L, 2012, AM J OPHTHALMOL, V153, P1110, DOI 10.1016/j.ajo.2011.11.002
   Smith AJ, 2008, OPHTHALMOLOGY, V115, P1923, DOI 10.1016/j.ophtha.2008.05.025
   Spaide RF, 2011, RETINA-J RET VIT DIS, V31, P1609, DOI 10.1097/IAE.0b013e3182247535
   Takayama K, 2012, RETINA-J RET VIT DIS, V32, P1973, DOI 10.1097/IAE.0b013e318251a38b
   Testa F, 2012, INVEST OPHTH VIS SCI, V53, P4409, DOI 10.1167/iovs.11-8201
   Uji A, 2012, AM J OPHTHALMOL, V153, P710, DOI 10.1016/j.ajo.2011.08.041
   WINSTON R, 1971, J OPT SOC AM, V61, P1120, DOI 10.1364/JOSA.61.001120
   Wong IY, 2012, CURR OPIN OPHTHALMOL, V23, P210, DOI 10.1097/ICU.0b013e3283524162
   Yamaike N, 2009, RETINA-J RET VIT DIS, V29, P757, DOI 10.1097/IAE.0b013e31819d4fbf
NR 30
TC 33
Z9 36
U1 0
U2 2
PU ASSOC RESEARCH VISION OPHTHALMOLOGY INC
PI ROCKVILLE
PA 12300 TWINBROOK PARKWAY, ROCKVILLE, MD 20852-1606 USA
SN 0146-0404
EI 1552-5783
J9 INVEST OPHTH VIS SCI
JI Invest. Ophthalmol. Vis. Sci.
PD APR
PY 2013
VL 54
IS 4
BP 2800
EP 2806
DI 10.1167/iovs.13-11613
PG 7
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 156KV
UT WOS:000319821700047
PM 23532524
DA 2022-11-30
ER

PT J
AU Szabo, SM
   Janssen, PA
   Khan, K
   Potter, MJ
   Lord, SR
AF Szabo, Shelagh M.
   Janssen, Patricia A.
   Khan, Karim
   Potter, Michael J.
   Lord, Stephen R.
TI Older women with age-related macular degeneration have a greater risk of
   falls: A Physiological Profile Assessment study
SO JOURNAL OF THE AMERICAN GERIATRICS SOCIETY
LA English
DT Article
DE age-related macular degeneration (AMD); falls; elderly; prevention
ID PHYSICAL-ACTIVITY SCALE; LOW-BONE-MASS; VISUAL IMPAIRMENT; POSTURAL
   STABILITY; ELDERLY PASE; PEOPLE; PREVALENCE; FRACTURES; VISION; ADULTS
AB OBJECTIVES: To determine whether older women with exudative age-related macular degeneration (AMD) are at greater risk of falls.
   DESIGN: Cross-sectional study.
   SETTING: A hospital-based ophthalmology clinic in Vancouver, Canada.
   PARTICIPANTS: One hundred fifteen older (aged >= 70) community-dwelling women with exudative AMD (AMD cohort) and two control groups: 54 community-dwelling women without exudative AMD drawn from the same community (non-AMD cohort) and 341 community-dwelling Australian women (Australian normative cohort).
   MEASUREMENTS: Participants were assessed for falls risk using the short-form Physiological Profile Assessment (PPA), which provides a fall risk index score and subcomponent measures of vision, proprioception, strength, reaction time, and postural sway.
   RESULTS: The mean fall risk index score in the AMD cohort (3.20) was significantly greater than that of the non-AMD cohort (1.21; P <.001), and fall risk scores increased with age to a greater extent in the AMD cohort. The higher fall risk scores in the AMD cohort resulted from significantly worse performance on each PPA test, not just the test of vision. The AMD cohort also performed worse than the Australian normative cohort in tests of vision, reaction time, and postural sway.
   CONCLUSION: Older women with AMD have impaired balance, slow visual reaction times, and poor vision, which in combination result in a significantly greater risk of falls than population norms. These deficits are clearly indicated in the physiological falls profile for the group. Strategies to enhance balance may be particularly beneficial to prevent falls in this group.
C1 [Szabo, Shelagh M.; Janssen, Patricia A.] Univ British Columbia, Dept Hlth Care & Epidemiol, Vancouver, BC V6T 1W5, Canada.
   [Szabo, Shelagh M.; Potter, Michael J.] Univ British Columbia, Dept Ophthalmol & Visual Sci, Vancouver, BC V5Z 1M9, Canada.
   [Szabo, Shelagh M.; Janssen, Patricia A.; Khan, Karim] Vancouver Coastal Hlth Res Inst, Bone Hlth Res Grp, Vancouver, BC, Canada.
   [Lord, Stephen R.] Univ New S Wales, Prince Wales Med Res Inst, Sydney, NSW, Australia.
C3 University of British Columbia; University of British Columbia;
   Vancouver Coastal Health Research Institute; Prince Wales Medical
   Research Institute; University of New South Wales Sydney
RP Szabo, SM (通讯作者)，450-688 W Hastings St, Vancouver, BC, Canada.
EM shelaghs@telus.net
RI Janssen, Patricia/B-1036-2018; Lord, Stephen R/C-9612-2011
OI Janssen, Patricia/0000-0002-4178-1195; Lord, Stephen
   R/0000-0002-7111-8802
CR Bressler NM, 1999, ARCH OPHTHALMOL-CHIC, V117, P1329
   Brown MM, 2002, ARCH OPHTHALMOL-CHIC, V120, P481
   Campbell AJ, 2005, BMJ-BRIT MED J, V331, P817, DOI 10.1136/bmj.38601.447731.55
   CAMPBELL AJ, 1989, J GERONTOL, V44, pM112, DOI 10.1093/geronj/44.4.m112
   Carroll Norman V, 2005, J Manag Care Pharm, V11, P307
   CURRIE CT, 1984, ARCH EMERG MED, V1, P205
   Dandona L, 1998, ARCH OPHTHALMOL-CHIC, V116, P545, DOI 10.1001/archopht.116.4.514
   Duan YK, 2007, OPHTHALMOLOGY, V114, P732, DOI 10.1016/j.ophtha.2006.07.045
   ELLIOTT DB, 1995, OPHTHAL PHYSL OPT, V15, P553, DOI 10.1016/0275-5408(95)00025-9
   Foley SJ, 2006, OSTEOARTHR CARTILAGE, V14, P533, DOI 10.1016/j.joca.2005.12.007
   Gehrs KM, 2006, ANN MED, V38, P450, DOI 10.1080/07853890600946724
   Ivers RQ, 1998, J AM GERIATR SOC, V46, P58
   Kassoff A, 1999, CONTROL CLIN TRIALS, V20, P573
   Klein BEK, 2003, OPHTHALMOLOGY, V110, P644, DOI 10.1016/S0161-6420(02)01935-8
   Klein BEK, 1998, OPHTHALMOLOGY, V105, P160, DOI 10.1016/S0161-6420(98)91911-X
   KLEIN R, 1992, OPHTHALMOLOGY, V99, P933
   KOSOROK MR, 1992, AM J PUBLIC HEALTH, V82, P1263, DOI 10.2105/AJPH.82.9.1263
   Lin MY, 2004, J AM GERIATR SOC, V52, P1996, DOI 10.1111/j.1532-5415.2004.52554.x
   Liu-Ambrose T, 2004, J AM GERIATR SOC, V52, P657, DOI 10.1111/j.1532-5415.2004.52200.x
   Liu-Ambrose TYL, 2005, J AM GERIATR SOC, V53, P1767, DOI 10.1111/j.1532-5415.2005.53525.x
   LORD SR, 1994, J AM GERIATR SOC, V42, P1110, DOI 10.1111/j.1532-5415.1994.tb06218.x
   Lord SR, 2000, GERONTOLOGY, V46, P306, DOI 10.1159/000022182
   LORD SR, 1994, AGE AGEING, V23, P452, DOI 10.1093/ageing/23.6.452
   LORD SR, 1991, AGE AGEING, V20, P175, DOI 10.1093/ageing/20.3.175
   LORD SR, 1994, MED J AUSTRALIA, V160, P684, DOI 10.5694/j.1326-5377.1994.tb125905.x
   Lord SR, 2003, PHYS THER, V83, P237, DOI 10.1093/ptj/83.3.237
   LORD SR, 1993, AUST J PUBLIC HEALTH, V17, P240, DOI 10.1111/j.1753-6405.1993.tb00143.x
   LORD SR, 1991, J AM GERIATR SOC, V39, P1194, DOI 10.1111/j.1532-5415.1991.tb03574.x
   Lord SR, 2001, J AM GERIATR SOC, V49, P508, DOI 10.1046/j.1532-5415.2001.49107.x
   Mackenzie PJ, 2002, OPHTHALMOLOGY, V109, P720, DOI 10.1016/S0161-6420(01)01021-1
   MAHONEY F I, 1965, Md State Med J, V14, P61
   Mangione CM, 2001, ARCH OPHTHALMOL-CHIC, V119, P1050, DOI 10.1001/archopht.119.7.1050
   MITCHELL P, 1995, OPHTHALMOLOGY, V102, P1450
   Nazemi PP, 2005, RETINA-J RET VIT DIS, V25, P446, DOI 10.1097/00006982-200506000-00009
   NEVITT MC, 1989, JAMA-J AM MED ASSOC, V261, P2663, DOI 10.1001/jama.261.18.2663
   Owen D H, 1985, Clin Geriatr Med, V1, P581
   POWELL LE, 1995, J GERONTOL A-BIOL, V50, pM28, DOI 10.1093/gerona/50A.1.M28
   SALIVE ME, 1994, J AM GERIATR SOC, V42, P287, DOI 10.1111/j.1532-5415.1994.tb01753.x
   Salter AE, 2006, OSTEOPOROSIS INT, V17, P672, DOI 10.1007/s00198-005-0032-7
   SATTIN RW, 1990, AM J EPIDEMIOL, V131, P1028, DOI 10.1093/oxfordjournals.aje.a115594
   Singer BR, 1998, J BONE JOINT SURG BR, V80B, P243, DOI 10.1302/0301-620X.80B2.7762
   *STAT CAN, 2006, CAN POP
   Stevens JA, 2005, INJURY PREV, V11, P115, DOI 10.1136/ip.2004.005835
   Sturnieks DL, 2004, J RHEUMATOL, V31, P2272
   TINETTI ME, 1988, NEW ENGL J MED, V319, P1701, DOI 10.1056/NEJM198812293192604
   TINETTI ME, 1994, J GERONTOL, V49, pM140, DOI 10.1093/geronj/49.3.M140
   TOBIS JS, 1981, ARCH PHYS MED REHAB, V62, P619
   TOBIS JS, 1990, ARCH PHYS MED REHAB, V71, P144
   VELLAS B, 1987, AGE AGEING, V16, P189, DOI 10.1093/ageing/16.3.189
   Wang JJ, 2000, CLIN EXP OPHTHALMOL, V28, P268, DOI 10.1046/j.1442-9071.2000.00315.x
   WASHBURN RA, 1993, J CLIN EPIDEMIOL, V46, P153, DOI 10.1016/0895-4356(93)90053-4
   Washburn RA, 1999, J CLIN EPIDEMIOL, V52, P643, DOI 10.1016/S0895-4356(99)00049-9
   Wong TY, 2006, ANN INTERN MED, V145, P98, DOI 10.7326/0003-4819-145-2-200607180-00007
NR 53
TC 41
Z9 42
U1 0
U2 18
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0002-8614
EI 1532-5415
J9 J AM GERIATR SOC
JI J. Am. Geriatr. Soc.
PD MAY
PY 2008
VL 56
IS 5
BP 800
EP 807
DI 10.1111/j.1532-5415.2008.01666.x
PG 8
WC Geriatrics & Gerontology; Gerontology
WE Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)
SC Geriatrics & Gerontology
GA 295PI
UT WOS:000255486000003
PM 18363677
DA 2022-11-30
ER

PT J
AU Knudtson, MD
   Klein, R
   Klein, BEK
AF Knudtson, M. D.
   Klein, R.
   Klein, B. E. K.
TI Physical activity and the 15-year cumulative incidence of age-related
   macular degeneration: the Beaver Dam Eye Study
SO BRITISH JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
ID RISK-FACTORS; MACULOPATHY
AB Background: Cardiovascular disease and age-related macular degeneration (AMD) may share common risk factors. Physical activity improves the cardiovascular risk profile; however, there have been few studies investigating a relationship between physical activity and the long-term incidence of AMD.
   Methods: The 15-year cumulative incidence of AMD was determined through four examination phases at 5-year intervals of a population-based study conducted in Beaver Dam, Wisconsin, USA, initiated in 1988-90 (n = 3874 men and women between ages 43 and 86 years). Early AMD (pigment abnormalities or soft indistinct drusen), exudative AMD and geographic atrophy were determined by grading stereoscopic colour fundus photographs. Measures of physical activity were obtained through a questionnaire administered at the baseline examination.
   Results: After controlling for age, sex, history of arthritis, systolic blood pressure, body mass index, smoking and education, people with an active lifestyle (defined as regular activity >= 3 times/week) at baseline were less likely to develop exudative AMD (odds ratio (OR) 0.3, 95% confidence interval (CI) 0.1 to 0.7) compared with people without an active lifestyle. After multivariate adjustment, increased categories of number of blocks walked per day decreased the risk of exudative AMD (OR 0.7, 95% CI 0.6 to 0.97). Physical activity was not related to the incidence of early AMD or pure geographic atrophy.
   Conclusions: These data show a protective effect of physical activity for incident exudative AMD, independent of body mass index and other confounders. They also suggest a possible modifiable behaviour that might be protective against developing AMD.
C1 Univ Wisconsin, Sch Med & Publ Hlth, Dept Ophthalmol & Visual Sci, Madison, WI 53726 USA.
C3 University of Wisconsin System; University of Wisconsin Madison
RP Knudtson, MD (通讯作者)，Univ Wisconsin, Sch Med & Publ Hlth, Dept Ophthalmol & Visual Sci, 610 N Walnut St,4th Floor WARF, Madison, WI 53726 USA.
EM knudtson@epi.ophth.wisc.edu
FU NEI NIH HHS [EY06594, U10 EY006594] Funding Source: Medline
CR Gooley TA, 1999, STAT MED, V18, P695, DOI 10.1002/(SICI)1097-0258(19990330)18:6<695::AID-SIM60>3.0.CO;2-O
   Klein R, 2003, ARCH OPHTHALMOL-CHIC, V121, P674, DOI 10.1001/archopht.121.5.674
   KLEIN R, 1991, OPHTHALMOLOGY, V98, P1128
   KLEIN R, 1995, BEAVER DAM EYE STU 2
   KLEIN R, 1991, BEAVER DAM EYE STUDY
   Klein R, 1999, BEAVER DAM EYE STUDY
   Klein Ronald, 2003, Ophthalmology, V110, P1273, DOI 10.1016/S0161-6420(03)00599-2
   Smith W, 1998, ARCH OPHTHALMOL-CHIC, V116, P583, DOI 10.1001/archopht.116.5.583
   Snow K K, 1999, Ophthalmic Epidemiol, V6, P125, DOI 10.1076/opep.6.2.125.1558
   Warburton DER, 2006, CAN MED ASSOC J, V174, P801, DOI 10.1503/cmaj.051351
   YANNUZZI LA, 1992, ARCH OPHTHALMOL-CHIC, V110, P1701
NR 11
TC 73
Z9 74
U1 0
U2 12
PU B M J PUBLISHING GROUP
PI LONDON
PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND
SN 0007-1161
J9 BRIT J OPHTHALMOL
JI Br. J. Ophthalmol.
PD DEC
PY 2006
VL 90
IS 12
BP 1461
EP 1463
DI 10.1136/bjo.2006.103796
PG 3
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 106WX
UT WOS:000242133800007
PM 17077116
OA Green Published
DA 2022-11-30
ER

PT J
AU Midena, E
   Varano, M
   Pilotto, E
   Staurenghi, G
   Camparini, M
   Pece, A
   Parodi, MB
   Vadala, M
   Donati, S
   Frizziero, L
   Fiorencis, A
   Marini, MG
   Reale, L
AF Midena, Edoardo
   Varano, Monica
   Pilotto, Elisabetta
   Staurenghi, Giovanni
   Camparini, Monica
   Pece, Alfredo
   Battaglia Parodi, Maurizio
   Vadala, Maria
   Donati, Simone
   Frizziero, Luisa
   Fiorencis, Alessandra
   Marini, Maria Giulia
   Reale, Luigi
TI Real-life patient journey in neovascular age-related macular
   degeneration: a narrative medicine analysis in the Italian setting
SO EYE
LA English
DT Article
ID ANTI-VEGF TREATMENT; EXPERIENCES; DEPRESSION; OUTCOMES; ANXIETY; IMPACT
AB Objectives To investigate the real-life experience of patients affected by neovascular age-related macular degeneration (nAMD), in the healthcare pathway for the management of the disease, using a "patient journey" and narrative method approach. Methods The patient journey of subjects affected by nAMD was designed using a process-mapping methodology involving a team from 11 Italian centres. Subsequently, narratives were collected from nAMD patients and family members. The interviews were analyzed using the narrative medicine methodology. Results Eleven specialized retina centres across Italy were involved and 205 narratives collected. In 29% of cases, patients underestimated their symptoms or attributed them to non-pathological causes, thus delaying the specialist consultation. The delay in accessing to care was due to a lack of awareness of this disease (50% of the participants didn't know what nAMD is) and to critical issues faced at first visit (long waiting lists, failed diagnosis, underestimation of the problem). Despite anti-VEGF therapies were perceived as effective in improving or stabilizing vision in 91% of narratives collected, 77% of patients still reduced or ceased daily activities such as reading and driving. Within the pathway of care there was not a multidisciplinary approach, and the patients were treated just by the ophthalmologist. Conclusions nAMD may significantly affect the quality of life of affected patients, both from a functional and psychological point of view. The narrative medicine approach highlights some critical points in the healthcare journey of nAMD patients and represents a useful background in implementing patient management algorithms and pathways of care.
C1 [Midena, Edoardo; Pilotto, Elisabetta] Univ Padua, Dept Ophthalmol, Padua, Italy.
   [Midena, Edoardo; Varano, Monica; Frizziero, Luisa] IRCCS Fdn Bietti, Rome, Italy.
   [Staurenghi, Giovanni] Univ Milan, Luigi Sacco Hosp, Dept Biomed Clin Sci Luigi Sacco, Eye Clin, Milan, Italy.
   [Camparini, Monica] Univ Parma, Dept Biol Biotechnol & Translat Sci, Ophthalmol Unit, Parma, Italy.
   [Pece, Alfredo] Melegnano Hosp, Dept Ophthalmol, Milan, Italy.
   [Battaglia Parodi, Maurizio] Osped San Raffaele, Dept Ophthalmol, Milan, Italy.
   [Vadala, Maria] Univ Palermo, Dipartimento Biomed Sperimentale & Neurosci Clin, Palermo, Italy.
   [Donati, Simone] Univ Insubria, Dept Med & Surg, Ophthalmol Clin, Varese, Italy.
   [Fiorencis, Alessandra; Marini, Maria Giulia; Reale, Luigi] Istud Fdn, Milan, Italy.
C3 University of Padua; IRCCS - Fondazione "G.B. Bietti" per lo Studio e la
   Ricerca in Oftalmologia; University of Milan; Luigi Sacco Hospital;
   University of Parma; Vita-Salute San Raffaele University; IRCCS Ospedale
   San Raffaele; University of Palermo; University of Insubria
RP Midena, E (通讯作者)，Univ Padua, Dept Ophthalmol, Padua, Italy.; Midena, E (通讯作者)，IRCCS Fdn Bietti, Rome, Italy.
EM edoardo.midena@unipd.it
RI Donati, Simone/K-4382-2019; Frizziero, Luisa/AAB-3249-2020; Vadalà,
   Maria/AAT-1084-2021
OI Donati, Simone/0000-0002-6920-7021; VADALA', Maria/0000-0002-2726-698X;
   Varano, Monica/0000-0002-6530-1563; Fiorencis,
   Alessandra/0000-0001-9859-5070; Battaglia Parodi,
   Maurizio/0000-0002-0385-7961
FU Fondazione Roma; Ministry of Health
FX The research contribution by the G.B. Bietti Foundation was supported by
   Fondazione Roma and Ministry of Health. The authors acknowledge Manuella
   Walker-medical writer and patient communication-for the revision of the
   paper.
CR Barach P, 2006, QUAL SAF HEALTH CARE, V15, pI10, DOI 10.1136/qshc.2005.015859
   Ben-Tovim DI, 2008, MED J AUSTRALIA, V188, pS14
   Blaha GR, 2011, RETINA-J RET VIT DIS, V31, P535, DOI 10.1097/IAE.0b013e3181eac724
   Boyle J, 2015, PSYCHOL HEALTH MED, V20, P296, DOI 10.1080/13548506.2014.936886
   Burton AE, 2013, BRIT J VISUAL IMPA, V31, P178, DOI 10.1177/0264619613490517
   Charon R, 2012, ACAD MED, V87, P342, DOI 10.1097/ACM.0b013e3182446fbb
   Chua PYS, 2009, ARCH OPHTHALMOL-CHIC, V127, P939, DOI 10.1001/archophthalmol.2009.139
   Cook HL, 2008, BRIT MED BULL, V85, P127, DOI 10.1093/bmb/ldn012
   Creswell J., 2003, QUALITATIVE QUANTITA, V2nd
   Dawson SR, 2014, BMC OPHTHALMOL, V14, DOI 10.1186/1471-2415-14-78
   Eramudugolla R, 2013, FRONT AGING NEUROSCI, V5, DOI 10.3389/fnagi.2013.00056
   Finger RP, 2008, QUAL LIFE RES, V17, P559, DOI 10.1007/s11136-008-9327-4
   Manchaiah VKC, 2011, CLIN OTOLARYNGOL, V36, P227, DOI 10.1111/j.1749-4486.2011.02320.x
   Marini, 2015, NARRATIVE MED BRIDGI
   McCloud C, 2015, EYE, V29, P1561, DOI 10.1038/eye.2015.167
   Real E, 2013, J BIOMED OPT, V18, DOI 10.1117/1.JBO.18.12.126003
   Rovner BW, 2014, OPHTHALMOLOGY, V121, P2204, DOI 10.1016/j.ophtha.2014.05.002
   Sbaraini A, 2011, BMC MED RES METHODOL, V11, DOI 10.1186/1471-2288-11-128
   Senra H, 2016, GRAEF ARCH CLIN EXP, V254, P1873, DOI 10.1007/s00417-016-3384-0
   Taylor DJ, 2020, EYE, V34, P461, DOI 10.1038/s41433-019-0445-8
   Trebble TM, 2010, BMJ-BRIT MED J, V341, DOI 10.1136/bmj.c4078
   Varano M, 2016, CLIN OPHTHALMOL, V10, P257, DOI 10.2147/OPTH.S92616
   Watling CJ, 2012, MED TEACH, V34, P850, DOI 10.3109/0142159X.2012.704439
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
   Wykoff CC, 2018, J MANAG CARE SPEC PH, V24, pS3, DOI 10.18553/jmcp.2018.24.2-a.s3
   Ying GS, 2018, OPHTHALMOL RETINA, V2, P525, DOI 10.1016/j.oret.2017.10.003
NR 26
TC 5
Z9 5
U1 2
U2 4
PU SPRINGERNATURE
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND
SN 0950-222X
EI 1476-5454
J9 EYE
JI Eye
PD JAN
PY 2022
VL 36
IS 1
BP 182
EP 192
DI 10.1038/s41433-021-01470-9
EA MAR 2021
PG 11
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA YA9VP
UT WOS:000625621600003
PM 33674730
DA 2022-11-30
ER

PT J
AU Schultz, NM
   Bhardwaj, S
   Barclay, C
   Gaspar, L
   Schwartz, J
AF Schultz, Neil M.
   Bhardwaj, Shweta
   Barclay, Claudia
   Gaspar, Luis
   Schwartz, Jason
TI Global Burden of Dry Age-Related Macular Degeneration: A Targeted
   Literature Review
SO CLINICAL THERAPEUTICS
LA English
DT Review
DE burden; costs; dry age-related macular degeneration; epidemiology;
   management; quality of life
ID RISK-FACTORS; EYE DISEASE; PREVALENCE; HEALTH; POPULATION; PATIENT;
   COSTS; AREDS
AB Purpose: Age-related macular degeneration (AMD) is a leading cause of blindness, particularly in higher income countries. Although dry AMD accounts for 85% to 90% of AMD cases, a comprehensive understanding of the global dry AMD burden is needed. Methods: A targeted literature review was conducted in PubMed, MEDLINE, Embase, and the Cochrane Database of Systematic Reviews (19952019) to identify data on the epidemiology, management, and humanistic and economic burden of dry AMD in adults. A landscape analysis of patient reported outcome (PRO) instruments in AMD was also conducted via searches in PubMed (1995-2019), ClinicalTrials.gov, PROQOLID, PROLABELS, and health technology assessment reports (2008-2018). Findings: Thirty-seven of 4205 identified publications were included in the review. Dry AMD prevalence was 0.44% globally, varied across ethnic groups, and increased with age. Patients with dry AMD had higher risks of all-cause mortality (hazard ratio [HR] = 1.46; 95% CI, 0.99-2.16) and tobacco-related (HR = 2.86; 95% CI, 1.15-7.09) or cancer deaths (HR = 3.37; 95% CI, 1.56-7.29; P = 0.002) than those without dry AMD. Smoking, increasing age or cholesterol levels, and obesity are key risk factors for developing dry AMD. No treatment guidelines were identified for dry AMD specifically; management focuses on risk factor reduction and use of dietary supplements. In the United States and Italy, direct medical costs and health care resource utilization were lower in patients with dry versus wet AMD. Patients with dry AMD, particularly advanced disease, experienced significant visual function impairment. Dry AMD symptoms included reduced central vision, decreased ability to see at night, increased visual blurriness, distortion of straight lines and text, and faded color vision. Most PRO instruments used in AMD evaluations covered few, if any, of the identified symptoms reported by patients with dry AMD. Although the Quality of Life and Vision Function Questionnaire, 25-item National Eye Institute Vision Function Questionnaire, Low Vision Quality of Life, Impact of Vision Impairment-Very Low Vision, and Functional Reading Independence Index had strong content validity and psychometric properties in patients with dry AMD, they retained limited coverage of salient concepts. Implications: Despite dry AMD accounting for most AMD cases, there are substantial gaps in the published literature, particularly the humanistic and economic burden of disease and the lack of differentiation among dry, wet, or unspecified dry AMD. The significant burden of illness alludes to a high unmet need for tolerable and effective treatment options, as well as PRO instruments with more coverage of dry AMD symptoms and salient concepts. (Clin Ther. 2021;43:1792- 1808.) (c) 2021 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC ND license ( http://creativecommons.org/licenses/bync-nd/4.0/ )
C1 [Schultz, Neil M.; Schwartz, Jason] Astellas Pharma Inc, 1 Astellas Way, Northbrook, IL 60062 USA.
   [Bhardwaj, Shweta; Barclay, Claudia] IQVIA, London, England.
   [Gaspar, Luis] IQVIA, Reading, Berks, England.
C3 Astellas Pharmaceuticals; IQVIA; IQVIA
RP Schultz, NM (通讯作者)，Astellas Pharma Inc, 1 Astellas Way, Northbrook, IL 60062 USA.
EM neil.schultz@astellas.com
FU Astellas Pharma Inc.
FX This study was funded by Astellas Pharma Inc. The study sponsor provided
   input on the study design, the interpretation of data, the writing of
   the manuscript, and the decision to submit the manuscript for
   publication.
CR Ambati J, 2012, NEURON, V75, P26, DOI 10.1016/j.neuron.2012.06.018
   [Anonymous], 2018, PRESCRIBING INFORM
   Bandello Francesco, 2017, F1000Res, V6, P245, DOI 10.12688/f1000research.10664.1
   Bonastre J, 2002, Eur J Health Econ, V3, P94, DOI 10.1007/s10198-002-0104-y
   Bourne RRA, 2013, LANCET GLOB HEALTH, V1, pE339, DOI 10.1016/S2214-109X(13)70113-X
   Brouwers MC, 2010, CAN MED ASSOC J, V182, pE839, DOI 10.1503/cmaj.090449
   Brown MM, 2005, CAN J OPHTHALMOL, V40, P277, DOI 10.1016/S0008-4182(05)80070-5
   Butt T, 2013, OPTOMETRY VISION SCI, V90, P855, DOI 10.1097/OPX.0b013e3182962318
   Chew EY, 2014, JAMA OPHTHALMOL, V132, P272, DOI 10.1001/jamaophthalmol.2013.6636
   Cho BJ, 2014, INVEST OPHTH VIS SCI, V55, P1101, DOI 10.1167/iovs.13-13096
   Choudhury F, 2016, JAMA OPHTHALMOL, V134, P683, DOI 10.1001/jamaophthalmol.2016.0794
   Colijn JM, 2017, OPHTHALMOLOGY, V124, P1753, DOI 10.1016/j.ophtha.2017.05.035
   Danis RP, 2015, CLIN OPHTHALMOL, V9, P2159, DOI 10.2147/OPTH.S92359
   Dawson SR, 2014, BMC OPHTHALMOL, V14, DOI 10.1186/1471-2415-14-78
   Evans JR, 2012, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD000254.pub3
   Eylea, 2019, PRESCRIBING INFORM
   FDA Ctr Drug Evaluation Res, 2006, HEALTH QUAL LIFE OUT, V4, DOI 10.1186/1477-7525-4-79
   Hernandez-Zimbron LF, 2018, OXID MED CELL LONGEV, V2018, DOI 10.1155/2018/8374647
   FERRIS FL, 1984, ARCH OPHTHALMOL-CHIC, V102, P1640
   Food Drug Administration, 2018, PED PROD DEV
   Freeman WR, 2018, 2018 AAO M RET SUBSP
   Garattini Livio, 2004, Eur J Health Econ, V5, P22
   Halpern MT, 2006, HEALTH CARE FINANC R, V27, P37
   Keenan TD, 2018, OPHTHALMOLOGY, V125, P1913, DOI 10.1016/j.ophtha.2018.05.028
   Korb CA, 2014, GRAEF ARCH CLIN EXP, V252, P1403, DOI 10.1007/s00417-014-2591-9
   LeMer Y, 2018, SUBRETINAL IMPLANTAT
   Macugen, 2016, PRESCRIBING INFORM
   Mangione CM, 1999, AM J OPHTHALMOL, V128, P45, DOI 10.1016/S0002-9394(99)00169-5
   Martin DF, 2012, OPHTHALMOLOGY, V119, DOI 10.1016/j.ophtha.2012.03.053
   McGuinness MB, 2017, EYE, V31, P1345, DOI 10.1038/eye.2017.139
   McGuinness MB, 2017, OPHTHAL EPIDEMIOL, V24, P141, DOI 10.1080/09286586.2016.1259422
   Milton RC, 2005, OPHTHALMOLOGY, V112, P533, DOI 10.1016/j.ophtha.2004.10.047
   Mones J, 2018, COMPLEMENT C5 INHIBI
   Nakata I, 2013, AM J OPHTHALMOL, V156, P1002, DOI 10.1016/j.ajo.2013.06.007
   National Institute for Health and Care Excellence, 2015, SINGL TECHN APPR US
   National Institute for Health and Care Excellence, 2016, NICE INT PROC GUID
   National Institute for Health and Care Excellence (NICE), 2018, NICE GUID NG 82 AG R
   Olsen TW, 2020, OPHTHALMOLOGY, V127, pP1, DOI 10.1016/j.ophtha.2019.09.024
   Papudesu C, 2018, OPHTHALMOLOGY, V125, P512, DOI 10.1016/j.ophtha.2017.10.028
   Pascolini D, 2012, GLOBAL DATA VISUAL I
   Sacconi R, 2017, OPHTHALMOL THER, V6, P69, DOI 10.1007/s40123-017-0086-6
   Schmier J, 2017, VALUE HEALTH, V20, pA160
   Schmier JK, 2006, PHARMACOECONOMICS, V24, P319, DOI 10.2165/00019053-200624040-00003
   Schmier JK, 2017, QUAL LIFE RES, V26, P123
   Schmier JK, 2012, AM J OPHTHALMOL, V154, P675, DOI 10.1016/j.ajo.2012.04.017
   Schultz NM, 2021, OPHTHALMOL THER, V10, P151, DOI 10.1007/s40123-020-00325-y
   Scottish Intercollegiate Guidelines Network, METHODOLOGY CHECKLIS
   Taylor DJ, 2016, BMJ OPEN, V6, DOI 10.1136/bmjopen-2016-011504
   Tomany SC, 2004, OPHTHALMOLOGY, V111, P1280, DOI 10.1016/j.ophtha.2003.11.010
   Varma R, 2016, JAMA OPHTHALMOL, V134, P571, DOI 10.1001/jamaophthalmol.2016.0588
   Wang F, 2015, INVEST OPHTH VIS SCI, V56
   Wei YL, 2018, MEDICINE, V97, DOI 10.1097/MD.0000000000010422
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
   Wright CB, 2017, HANDB EXP PHARMACOL, V242, P321, DOI 10.1007/164_2016_36
NR 54
TC 8
Z9 8
U1 3
U2 4
PU ELSEVIER
PI BRIDGEWATER
PA 685 ROUTE 202-206, BRIDGEWATER, NJ 08807 USA
SN 0149-2918
EI 1879-114X
J9 CLIN THER
JI Clin. Ther.
PD OCT
PY 2021
VL 43
IS 10
BP 1792
EP +
DI 10.1016/j.clinthera.2021.08.011
EA NOV 2021
PG 27
WC Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Pharmacology & Pharmacy
GA XB1UR
UT WOS:000721120000019
PM 34548176
OA hybrid
DA 2022-11-30
ER

PT J
AU Choi, EY
   Kim, TY
   Lee, CS
AF Choi, Eun Young
   Kim, Tae Young
   Lee, Christopher Seungkyu
TI Predictive Factors for Long-Term Outcomes of Cataract Surgery in
   Patients Receiving Active Treatment for Neovascular Age-Related Macular
   Degeneration
SO JOURNAL OF CLINICAL MEDICINE
LA English
DT Article
DE neovascular age-related macular degeneration; cataract surgery;
   anti-vascular endothelial growth factor therapy; visual acuity;
   predictive factors
ID RANIBIZUMAB-TREATED PATIENTS; ENDOTHELIAL GROWTH-FACTOR; ANCHOR; MARINA
AB Background: the safety and efficacy of cataract surgery in eyes with exudative neovascular age-related macular degeneration (nAMD), receiving active treatment, remain unclear. We evaluated the long-term outcomes and associated predictive factors of cataract surgery in eyes with exudative nAMD. Methods: this retrospective cohort study included 65 eyes (61 patients) treated with anti-vascular endothelial growth factor (VEGF) injections within six months preoperatively. Changes in best-corrected visual acuity (BCVA) and anti-VEGF treatment patterns from before to up to four years after surgery were assessed. Predictive factors were identified in association with one-year surgical outcomes. Results: the BCVA improved at six months (p < 0.001) and was maintained for three years postoperatively. The interval between anti-VEGF injections increased 3.4 times postoperatively (p = 0.001). Risk factors for poor BCVA were low preoperative BCVA (p < 0.001) and prolonged nAMD duration (p = 0.003). Prolonged nAMD duration and short exudation-free period were associated with more frequent postoperative anti-VEGF treatments (p = 0.028 and p = 0.003, respectively). AMD subtypes were not associated with both vision and injection pattern outcomes. Conclusions: patients with cataracts receiving nAMD treatment can safely undergo surgery with favorable long-term visual benefits. The preoperative BCVA, nAMD duration, and exudation-free period are potential predictors of surgery outcomes.
C1 [Choi, Eun Young; Lee, Christopher Seungkyu] Yonsei Univ, Severance Eye Hosp, Coll Med, Dept Ophthalmol, 50-1 Yonseiro, Seoul 03722, South Korea.
   [Kim, Tae Young] Yonsei Univ, Gangnam Severance Hosp, Coll Med, Dept Ophthalmol, 211 Eonjuro, Seoul 06273, South Korea.
C3 Yonsei University; Yonsei University Health System; Yonsei University;
   Yonsei University Health System
RP Lee, CS (通讯作者)，Yonsei Univ, Severance Eye Hosp, Coll Med, Dept Ophthalmol, 50-1 Yonseiro, Seoul 03722, South Korea.
EM eunyoung.choi86@gmail.com; ANDREWTY2@yuhs.ac; sklee219@yuhs.ac
RI Choi, Eun Young/Y-5204-2018
OI Choi, Eun Young/0000-0002-1668-6452; Lee,
   Christopher/0000-0001-5054-9470
FU National Research Foundation of Korea [NRF-2019R1A2C2002393]; Ministry
   of Science and Information Communication Technology
FX This research was supported by the National Research Foundation of Korea
   (NRF-2019R1A2C2002393), which is funded by the Ministry of Science and
   Information Communication Technology.
CR Armbrecht AM, 2003, J CATARACT REFR SURG, V29, P686, DOI 10.1016/S0886-3350(02)01650-4
   Baatz H, 2008, INVEST OPHTH VIS SCI, V49, P1079, DOI 10.1167/iovs.07-0557
   Bourne RRA, 2017, LANCET GLOB HEALTH, V5, pE888, DOI 10.1016/S2214-109X(17)30293-0
   Brunner S, 2013, OPHTHALMOLOGICA, V229, P86, DOI 10.1159/000345492
   Casparis H, 2017, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD006757.pub4
   Davis Geetha, 2016, Mo Med, V113, P58
   Fricke TR, 2018, OPHTHALMOLOGY, V125, P1492, DOI 10.1016/j.ophtha.2018.04.013
   Grixti Andre, 2014, ISRN Ophthalmol, V2014, P417603, DOI 10.1155/2014/417603
   Ho JD, 2018, ACTA OPHTHALMOL, V96, pe213, DOI 10.1111/aos.13511
   Hooper CY, 2009, CLIN EXP OPHTHALMOL, V37, P570, DOI 10.1111/j.1442-9071.2009.02095.x
   Kessel L, 2015, ACTA OPHTHALMOL, V93, P593, DOI 10.1111/aos.12665
   Lamoureux EL, 2007, OPTOMETRY VISION SCI, V84, P683, DOI 10.1097/OPX.0b013e31812f755f
   Lee TG, 2014, GRAEF ARCH CLIN EXP, V252, P1573, DOI 10.1007/s00417-014-2624-4
   Muzyka-Wozniak M, 2011, EUR J OPHTHALMOL, V21, P766, DOI 10.5301/EJO.2011.6389
   Rofagha S, 2013, OPHTHALMOLOGY, V120, P2292, DOI 10.1016/j.ophtha.2013.03.046
   Rosenfeld PJ, 2011, AM J OPHTHALMOL, V152, P793, DOI 10.1016/j.ajo.2011.04.025
   Saraf SS, 2015, AM J OPHTHALMOL, V160, P487, DOI 10.1016/j.ajo.2015.06.006
   Starr MR, 2018, AM J OPHTHALMOL, V192, P91, DOI 10.1016/j.ajo.2018.05.014
   Sul S, 2019, TURK OFTALMOL DERG, V49, P15, DOI 10.4274/tjo.galenos.2018.76429
   Tabandeh H, 2012, J CATARACT REFR SURG, V38, P677, DOI 10.1016/j.jcrs.2011.10.036
   Tan CS, 2015, BRIT J OPHTHALMOL, V99, P624, DOI 10.1136/bjophthalmol-2014-305674
   Wecker T, 2017, BRIT J OPHTHALMOL, V101, P353, DOI 10.1136/bjophthalmol-2016-308668
NR 22
TC 0
Z9 0
U1 1
U2 1
PU MDPI
PI BASEL
PA ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND
EI 2077-0383
J9 J CLIN MED
JI J. Clin. Med.
PD JUL
PY 2021
VL 10
IS 14
AR 3124
DI 10.3390/jcm10143124
PG 8
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine
GA TN9NP
UT WOS:000676552800001
PM 34300289
OA gold, Green Published
DA 2022-11-30
ER

PT J
AU Richardson, AJ
   Islam, FMA
   Aung, KZ
   Guymer, RH
   Baird, PN
AF Richardson, Andrea J.
   Islam, F. M. Amirul
   Aung, Khin Zaw
   Guymer, Robyn H.
   Baird, Paul N.
TI An Intergenic Region between the tagSNP rs3793917 and rs11200638 in the
   HTRA1 Gene Indicates Association with Age- Related Macular Degeneration
SO INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE
LA English
DT Article
ID COMPLEMENT FACTOR-H; GENOMEWIDE-SCAN; PROMOTER POLYMORPHISM; EXTENDED
   FAMILIES; SUSCEPTIBILITY; RISK; VARIANT; 10Q26; LOC387715; ARMS2
AB PURPOSE. There is still a debate as to whether the LOC387715 or HTRA1 genes represent the key significant association identified with age-related macular degeneration (AMD) on the long arm of chromosome 10, region 26.
   METHODS. An Australian patient cohort was genotyped by using tagged single nucleotide polymorphisms (tSNPs) to identify a causal SNP within this region.
   RESULTS. Multiple tSNPs across the region showed association with AMD with the tSNP rs3793917 (odds ratio [OR], 3.45; 95% confidence interval [CI], 2.36-5.05, P = 2.8 x 10(-13)) having the highest association with AMD. This tSNP occurred in the intergenic region between the LOC387715 and HTRA1 genes. A second tSNP rs2672587 (OR, 2.92; 95% CI, 2.04-4.17; P = 7.7 x 10(-11)) located in intron 1 of the HTRA1 gene had the second highest association with AMD. After logistic regression analysis, the only tSNP to survive covariate testing was rs3793917, which occurred in the same LD block as the HTRA1 promoter SNP rs11200638 (r(2) = 0.88, D' = 0.97).
   CONCLUSIONS. The findings indicate that the intergenic region between the tSNP rs3793917 and the SNP rs11200638 in the HTRA1 gene is the most likely site explaining the significant association with AMD. (Invest Ophthalmol Vis Sci. 2010;51:4932-4936) DOI:10.1167/iovs.09-5114
C1 [Richardson, Andrea J.; Islam, F. M. Amirul; Aung, Khin Zaw; Guymer, Robyn H.; Baird, Paul N.] Univ Melbourne, Ctr Eye Res Australia, Royal Victorian Eye & Ear Hosp, Melbourne, Vic 3002, Australia.
   [Islam, F. M. Amirul] Univ So Queensland, Dept Math Comp & Stat, Toowoomba, Qld 4350, Australia.
C3 Centre for Eye Research Australia; Royal Victorian Eye & Ear Hospital;
   University of Melbourne; University of Southern Queensland
RP Richardson, AJ (通讯作者)，Univ Melbourne, Ctr Eye Res Australia, Royal Victorian Eye & Ear Hosp, 32 Gisborne St, Melbourne, Vic 3002, Australia.
EM andreajr@unimelb.edu.au
RI Islam, Fakir M Amirul/P-6665-2015
OI Islam, Fakir M Amirul/0000-0003-3897-3302; Guymer,
   Robyn/0000-0002-9441-4356; Baird, Paul/0000-0002-1305-3502
FU Practitioner Fellowship [529905]; J. A. COM Foundation; Department of
   Innovation Industry, Science and Research in Australia; Department of
   Biotechnology (DBT), Government of India [BF010019]
FX Supported by Practitioner Fellowship 529905 (RHG); the J. A. COM
   Foundation; the Australia-India Strategic Research Fund funded through
   the Department of Innovation Industry, Science and Research in
   Australia; and the Department of Biotechnology (DBT), Government of
   India (BF010019).
CR Aung KZ, 2009, OPHTHAL EPIDEMIOL, V16, P254, DOI [10.3109/09286580902864419, 10.1080/09286580902864419]
   Baird PN, 2006, INVEST OPHTH VIS SCI, V47, P4194, DOI 10.1167/iovs.05-1285
   DeAngelis MM, 2008, OPHTHALMOLOGY, V115, P1209, DOI 10.1016/j.ophtha.2007.10.032
   Dewan A, 2006, SCIENCE, V314, P989, DOI 10.1126/science.1133807
   Dudbridge F, 2003, GENET EPIDEMIOL, V25, P115, DOI 10.1002/gepi.10252
   Francis PJ, 2008, HUM MOL GENET, V17, P2673, DOI 10.1093/hmg/ddn167
   Fritsche LG, 2008, NAT GENET, V40, P892, DOI 10.1038/ng.170
   Gabriel SB, 2002, SCIENCE, V296, P2225, DOI 10.1126/science.1069424
   Gibbs D, 2008, VISION RES, V48, P685, DOI 10.1016/j.visres.2007.10.022
   Hughes AE, 2007, PLOS MED, V4, P1993, DOI 10.1371/journal.pmed.0040355
   Iyengar SK, 2004, AM J HUM GENET, V74, P20, DOI 10.1086/380912
   Kanda A, 2007, P NATL ACAD SCI USA, V104, P16227, DOI 10.1073/pnas.0703933104
   Kaur I, 2008, INVEST OPHTH VIS SCI, V49, P1771, DOI 10.1167/iovs.07-0560
   Kenealy SJ, 2004, MOL VIS, V10, P57
   Kortvely E, 2010, INVEST OPHTH VIS SCI, V51, P79, DOI 10.1167/iovs.09-3850
   Lu F, 2007, VISION RES, V47, P3120, DOI 10.1016/j.visres.2007.08.010
   Majewski J, 2003, AM J HUM GENET, V73, P540, DOI 10.1086/377701
   Rivera A, 2005, HUM MOL GENET, V14, P3227, DOI 10.1093/hmg/ddi353
   Seddon JM, 2003, AM J HUM GENET, V73, P780, DOI 10.1086/378505
   Tam POS, 2008, INVEST OPHTH VIS SCI, V49, P2357, DOI 10.1167/iovs.07-1520
   Wang GF, 2009, INVEST OPHTH VIS SCI, V50, P3084, DOI 10.1167/iovs.08-3240
   Weeks DE, 2004, AM J HUM GENET, V75, P174, DOI 10.1086/422476
   Yang ZL, 2006, SCIENCE, V314, P992, DOI 10.1126/science.1133811
   Yoshida T, 2007, MOL VIS, V13, P545
NR 24
TC 13
Z9 15
U1 0
U2 2
PU ASSOC RESEARCH VISION OPHTHALMOLOGY INC
PI ROCKVILLE
PA 12300 TWINBROOK PARKWAY, ROCKVILLE, MD 20852-1606 USA
SN 0146-0404
J9 INVEST OPHTH VIS SCI
JI Invest. Ophthalmol. Vis. Sci.
PD OCT
PY 2010
VL 51
IS 10
BP 4932
EP 4936
DI 10.1167/iovs.09-5114
PG 5
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 655UI
UT WOS:000282275500009
PM 20445115
DA 2022-11-30
ER

PT J
AU Ando, S
   Hashida, N
   Yamashita, D
   Kawabata, T
   Asao, K
   Kawasaki, S
   Sakurai, K
   Yoshimori, T
   Nishida, K
AF Ando, Satoru
   Hashida, Noriyasu
   Yamashita, Daisuke
   Kawabata, Tsuyoshi
   Asao, Kazunobu
   Kawasaki, Satoshi
   Sakurai, Kazushi
   Yoshimori, Tamotsu
   Nishida, Kohji
TI Rubicon regulates A2E-induced autophagy impairment in the retinal
   pigment epithelium implicated in the pathology of age-related macular
   degeneration
SO BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS
LA English
DT Article
DE Autophagy; Rubicon; Retinal degeneration; A2E; Retinal pigment
   epithelium
AB Waste product deposition and light stress in the retinal pigment epithelium (RPE) are crucial factors in the pathogenesis of various retinal degenerative diseases, including age-related macular degeneration (AMD), a leading cause of vision loss in elderly individuals worldwide. Given that autophagy in the RPE suppresses waste accumulation, determining the molecular mechanism by which autophagy is compromised in degeneration is necessary. Using polarized human RPE sheets, we found that bis-reti-noid N-retinyl-N-retinylidene ethanolamine (A2E), a major toxic fluorophore of lipofuscin, causes significant impairment of autophagy and the simultaneous upregulation of Rubicon, a negative regulator of autophagy. Importantly, this impairment was reversed in Rubicon-specific siRNA-treated RPE sheets. In a retinal functional analysis using electroretinograms (ERGs), mice with the RPE-specific deletion of Rubicon showed no significant differences from control cre-expressing mice but presented partially but significantly enhanced amplitudes compared with Atg7 knockout mice. We also found that an inflammatory reaction in the retina in response to chronic blue light irradiation was alleviated in mice with the RPE-specific deletion of Rubicon. In summary, we propose that upregulating basal autophagy by targeting Rubicon is beneficial for protecting the RPE from functional damage with ageing and the inflammatory reaction caused by light-induced cellular stress.
   (c) 2021 Elsevier Inc. All rights reserved.
C1 [Ando, Satoru; Hashida, Noriyasu; Yamashita, Daisuke; Asao, Kazunobu; Kawasaki, Satoshi; Sakurai, Kazushi; Nishida, Kohji] Osaka Univ, Dept Ocular Immunol & Regenerat Med, Grad Sch Med, Suita, Osaka, Japan.
   [Ando, Satoru; Yamashita, Daisuke; Sakurai, Kazushi] Otsuka Pharmaceut Co Ltd, Ako Res Inst, Ako, Hyogo, Japan.
   [Hashida, Noriyasu; Asao, Kazunobu; Kawasaki, Satoshi; Nishida, Kohji] Osaka Univ, Dept Ophthalmol, Grad Sch Med, 2-2 Yamadaoka, Suita, Osaka 5650871, Japan.
   [Kawabata, Tsuyoshi] Nagasaki Univ, Atom Bomb Dis Inst, Dept Stem Cell Biol, Nagasaki, Nagasaki, Japan.
   [Yoshimori, Tamotsu] Osaka Univ, Dept Genet, Grad Sch Med, Suita, Osaka, Japan.
   [Nishida, Kohji] Osaka Univ, Inst Open & Transdisciplinary Res Initiat OTRI, Integrated Frontier Res Med Sci Div, Suita, Osaka, Japan.
C3 Osaka University; Otsuka Pharmaceutical; Osaka University; Nagasaki
   University; Osaka University; Osaka University
RP Hashida, N; Nishida, K (通讯作者)，Osaka Univ, Dept Ophthalmol, Grad Sch Med, 2-2 Yamadaoka, Suita, Osaka 5650871, Japan.
EM nhashida@ophthal.med.osaka-u.ac.jp; knishida@ophthal.med.osaka-u.ac.jp
OI Yamashita, Daisuke/0000-0001-6054-5617
CR Ablonczy Z, 2013, INVEST OPHTH VIS SCI, V54, P5535, DOI 10.1167/iovs.13-12250
   Boya P, 2016, PROG RETIN EYE RES, V55, P206, DOI 10.1016/j.preteyeres.2016.08.001
   Gao JY, 2015, MEDIAT INFLAMM, V2015, DOI 10.1155/2015/690243
   Gensler G, 2018, OPHTHALMOL RETINA, V2, P441, DOI 10.1016/j.oret.2017.08.015
   Iacovelli J, 2011, INVEST OPHTH VIS SCI, V52, P1378, DOI 10.1167/iovs.10-6347
   Kim JY, 2013, CELL, V154, P365, DOI 10.1016/j.cell.2013.06.012
   Kolosova NG, 2012, AM J PATHOL, V181, P472, DOI 10.1016/j.ajpath.2012.04.018
   Komatsu M, 2005, J CELL BIOL, V169, P425, DOI 10.1083/jcb.200412022
   Mao Yingyu, 2013, Methods Mol Biol, V935, P285, DOI 10.1007/978-1-62703-080-9_20
   Martinez J, 2015, NAT CELL BIOL, V17, P893, DOI 10.1038/ncb3192
   Mizushima N, 2008, NATURE, V451, P1069, DOI 10.1038/nature06639
   Mizushima N, 2011, CELL, V147, P728, DOI 10.1016/j.cell.2011.10.026
   Nakamura S, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-08729-6
   Parish CA, 1998, P NATL ACAD SCI USA, V95, P14609, DOI 10.1073/pnas.95.25.14609
   Sonoda S, 2009, NAT PROTOC, V4, P662, DOI 10.1038/nprot.2009.33
   Sparrow JR, 1999, INVEST OPHTH VIS SCI, V40, P2988
   Suzuki M, 2012, J CELL SCI, V125, P2407, DOI 10.1242/jcs.097683
   Tanaka S, 2016, HEPATOLOGY, V64, P1994, DOI 10.1002/hep.28820
   Yao JY, 2015, AUTOPHAGY, V11, P939, DOI 10.1080/15548627.2015.1041699
   Zhang Y, 2017, MOL VIS, V23, P228
NR 20
TC 4
Z9 4
U1 0
U2 3
PU ACADEMIC PRESS INC ELSEVIER SCIENCE
PI SAN DIEGO
PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA
SN 0006-291X
EI 1090-2104
J9 BIOCHEM BIOPH RES CO
JI Biochem. Biophys. Res. Commun.
PD APR 30
PY 2021
VL 551
BP 148
EP 154
DI 10.1016/j.bbrc.2021.02.148
EA MAR 2021
PG 7
WC Biochemistry & Molecular Biology; Biophysics
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Biophysics
GA RA6QZ
UT WOS:000631542700001
PM 33740621
DA 2022-11-30
ER

PT J
AU Goverdhan, SV
   Khakoo, SI
   Gaston, H
   Chen, XL
   Lotery, AJ
AF Goverdhan, Srinivas V.
   Khakoo, Salim I.
   Gaston, Hannah
   Chen, Xiaoli
   Lotery, Andrew J.
TI Age-Related Macular Degeneration Is Associated with the HLA-Cw*0701
   Genotype and the Natural Killer Cell Receptor AA Haplotype
SO INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE
LA English
DT Article
ID SEQUENCE-SPECIFIC PRIMERS; HLA CLASS-I; BRUCHS MEMBRANE; T-CELLS; VISUAL
   IMPAIRMENT; KIR; DISEASE; GENES; DRUSEN; POLYMORPHISMS
AB PURPOSE. To determine the association of human leukocyte antigen (HLA) C and its cognate killer cell immunoglobulin-like receptor (KIR) ligands with age-related macular degeneration (AMD).
   METHODS. HLA class I allele groups including the HLA-C principal alleles were genotyped in a cohort of 104 AMD cases and 93 controls by using the PCR-SSP (sequence-specific primers) method. This cohort was then genotyped for 16 KIR genes by PCR-SSP. Frequencies of the tested HLA/ KIR alleles were then compared between patients with AMD and normal control subjects. HLA-C1, -Cw* 07, and -Cw* 0701 genotypes and their combinations with KIR genotypes/ haplotypes were tested for association with AMD. Probabilities were obtained with a two-tailed chi(2) test and Bonferroni correction applied for multiple testing (P-c).
   RESULTS. The HLA-Cw* 0701 allele, in combination with the inhibitory KIR AA haplotype was associated with AMD after logistic regression analysis (P = 0.006, P-c = 0.036, OR = 4.35, 95% CI = 1.41-13.44).
   CONCLUSIONS. The HLA-Cw* 0701 allele and KIR haplotype AA are associated with AMD. This genotype combination suggests that natural killer cells have a role in the pathogenesis of AMD. Replication studies are needed to confirm these novel HLA-KIR associations with AMD. (Invest Ophthalmol Vis Sci. 2008; 49: 5077-5082) DOI: 10.1167/iovs.08-1837
C1 [Goverdhan, Srinivas V.; Chen, Xiaoli; Lotery, Andrew J.] Univ Southampton, Div Clin Neurosci, Southampton Gen Hosp, Southampton SO16 6YD, Hants, England.
   [Gaston, Hannah; Lotery, Andrew J.] Univ Southampton, Southampton Eye Unit, Southampton Gen Hosp, Southampton SO16 6YD, Hants, England.
   [Khakoo, Salim I.] Univ London Imperial Coll Sci Technol & Med, Div Med, London, England.
C3 University of Southampton; University of Southampton; Imperial College
   London
RP Lotery, AJ (通讯作者)，Univ Southampton, Div Clin Neurosci, Southampton Gen Hosp, Level D,S Lab & Path Block,Mailpoint 806, Southampton SO16 6YD, Hants, England.
EM a.j.lotery@southampton.ac.uk
OI Lotery, Andrew/0000-0001-5541-4305; Khakoo, Salim/0000-0002-4057-9091
FU Southampton Wellcome Trust Clinical Research Facility; American Health
   Assistance Foundation; Wellcome Trust; Lord Sandberg; Brian Mercer Trust
FX Supported by the American Health Assistance Foundation, the Wellcome
   Trust, Lord Sandberg, and the Brian Mercer Trust.
CR Ambati J, 2003, NAT MED, V9, P1390, DOI 10.1038/nm950
   Bateman AC, 1996, HISTOPATHOLOGY, V28, P169, DOI 10.1046/j.1365-2559.1996.277323.x
   BAUDOUIN C, 1992, JPN J OPHTHALMOL, V36, P443
   Boyton RJ, 2006, AM J RESP CRIT CARE, V173, P327, DOI 10.1164/rccm.200501-124OC
   Bunce M, 1995, TISSUE ANTIGENS, V46, P355, DOI 10.1111/j.1399-0039.1995.tb03127.x
   Carrington M, 2006, CURR TOP MICROBIOL, V298, P225
   Dabil H, 2003, HUM IMMUNOL, V64, P960, DOI 10.1016/S0198-8859(03)00175-7
   Darke C, 1998, EXP CLIN IMMUNOGENET, V15, P69, DOI 10.1159/000019057
   DASTGHEIB K, 1994, ARCH OPHTHALMOL-CHIC, V112, P813, DOI 10.1001/archopht.1994.01090180111045
   Denis L, 2005, TISSUE ANTIGENS, V66, P267, DOI 10.1111/j.1399-0039.2005.00473.x
   DUVALL J, 1985, ARCH OPHTHALMOL-CHIC, V103, P694, DOI 10.1001/archopht.1985.01050050086024
   Finch T, 1997, EXP CLIN IMMUNOGENET, V14, P250
   Gomez-Lozano N, 2002, TISSUE ANTIGENS, V59, P184, DOI 10.1034/j.1399-0039.2002.590302.x
   Goverdhan SV, 2005, INVEST OPHTH VIS SCI, V46, P1726, DOI 10.1167/iovs.04-0928
   Hageman GS, 2001, PROG RETIN EYE RES, V20, P705, DOI 10.1016/S1350-9462(01)00010-6
   Hiby SE, 2004, J EXP MED, V200, P957, DOI 10.1084/jem.20041214
   Howell WM, 2002, P NUTR SOC, V61, P447, DOI 10.1079/PNS2002186
   Ioannidis JPA, 2001, NAT GENET, V29, P306, DOI 10.1038/ng749
   Khakoo SI, 2006, IMMUNOL REV, V214, P186, DOI 10.1111/j.1600-065X.2006.00459.x
   KILLINGSWORTH MC, 1990, EYE, V4, P613, DOI 10.1038/eye.1990.86
   Klaver CCW, 1998, ARCH OPHTHALMOL-CHIC, V116, P653, DOI 10.1001/archopht.116.5.653
   Luszczek W, 2004, HUM IMMUNOL, V65, P758, DOI 10.1016/j.humimm.2004.05.008
   Marsh SGE, 2003, HUM IMMUNOL, V64, P648, DOI 10.1016/S0198-8859(03)00067-3
   MILLER SA, 1988, NUCLEIC ACIDS RES, V16, P1215, DOI 10.1093/nar/16.3.1215
   Mullins RF, 2000, FASEB J, V14, P835, DOI 10.1096/fasebj.14.7.835
   Namekawa T, 2000, J IMMUNOL, V165, P1138, DOI 10.4049/jimmunol.165.2.1138
   Nelson GW, 2004, J IMMUNOL, V173, P4273, DOI 10.4049/jimmunol.173.7.4273
   PENFOLD PL, 1985, GRAEF ARCH CLIN EXP, V223, P69, DOI 10.1007/BF02150948
   Penfold PL, 2001, PROG RETIN EYE RES, V20, P385, DOI 10.1016/S1350-9462(00)00025-2
   Snyder MR, 2003, J EXP MED, V197, P437, DOI 10.1084/jem.20020383
   STREILEIN JW, 1992, J NEUROIMMUNOL, V39, P185, DOI 10.1016/0165-5728(92)90253-H
   Thorsby E, 1997, HUM IMMUNOL, V53, P1, DOI 10.1016/S0198-8859(97)00024-4
   TIELSCH JM, 1995, NEW ENGL J MED, V332, P1205, DOI 10.1056/NEJM199505043321806
   van der Slik AR, 2003, DIABETES, V52, P2639, DOI 10.2337/diabetes.52.10.2639
   Vely F, 2001, J IMMUNOL, V166, P2487, DOI 10.4049/jimmunol.166.4.2487
   2006, ALLELE FREQUENCIES W
NR 36
TC 16
Z9 17
U1 0
U2 2
PU ASSOC RESEARCH VISION OPHTHALMOLOGY INC
PI ROCKVILLE
PA 12300 TWINBROOK PARKWAY, ROCKVILLE, MD 20852-1606 USA
SN 0146-0404
J9 INVEST OPHTH VIS SCI
JI Invest. Ophthalmol. Vis. Sci.
PD NOV
PY 2008
VL 49
IS 11
BP 5077
EP 5082
DI 10.1167/iovs.08-1837
PG 6
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 366RX
UT WOS:000260502200052
PM 18515573
OA Green Accepted
DA 2022-11-30
ER

PT J
AU Chiang, TTK
   Keenan, TD
   Agron, E
   Liao, J
   Klein, B
   Chew, EY
   Cukras, CA
   Wong, WT
AF Chiang, Trent Tsun-Kang
   Keenan, Tiarnan D.
   Agron, Elvira
   Liao, Jennifer
   Klein, Brandon
   Chew, Emily Y.
   Cukras, Catherine A.
   Wong, Wai T.
TI Macular Thickness in Intermediate Age-Related Macular Degeneration Is
   Influenced by Disease Severity and Subretinal Drusenoid Deposit Presence
SO INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE
LA English
DT Article
DE reticular pseudodrusen; subretinal drusenoid deposits; intermediate
   age-related macular degeneration; optical coherence tomography; outcome
   measures; macular thickness
ID OUTER RETINAL ATROPHY; RETICULAR PSEUDODRUSEN; INFLAMMATION;
   ASSOCIATION; PREVALENCE; SCALE
AB PURPOSE. To investigate how macular thickness varies with intermediate age-related macular degeneration (iAMD) severity and the presence of subretinal drusenoid deposits (SDDs).
   METHODS. A longitudinal prospective study of 143 participants >50 years of age with no to intermediate AMD who were followed with multimodal imaging and functional testing. Participants were stratified by iAMD severity according to imaging features. Macular thicknesses measurements over the central circles with 1-mm, 3-mm, and 6-mm diameters obtained from ocular coherence tomography imaging were compared across severity categories using cross-sectional (143 eyes) and longitudinal (subset of 77 eyes followed for 4 years) multivariate analyses.
   RESULTS. Compared with control eyes without large drusen or SDDs (Group 0), central maculas of lower risk eyes with unilateral large drusen (Group 1) were thicker (P = 0.014), whereas higher risk eyes with SDDs (Group SDD) were thinner (P = 0.02) in cross-sectional multivariate analyses. In longitudinal analyses, maculas with SDDs thinned more rapidly over 4 years relative to control eyes (P = 0.0058), which did not show significant thinning. More rapid central macular thinning was associated with worse baseline best-corrected visual acuity (BCVA) (P = 0.016) and more rapid BCVA decline (P = 0.0059).
   CONCLUSIONS. Macular thickness in iAMD varies with disease severity, showing small increases in eyes with large drusen and decreases in eyes with SDDs. Active processes possibly related to neuroinflammation and neurodegeneration may be contributory. Longitudinal central macular thickness evaluation is an accessible outcome measure relevant to functional measures and is potentially useful for iAMD interventional studies.
C1 [Chiang, Trent Tsun-Kang; Liao, Jennifer; Klein, Brandon; Wong, Wai T.] NEI, Neuron Glia Interact Retinal Dis, NIH, 6 Ctr Dr,Bldg 6,Room 217, Bethesda, MD 20892 USA.
   [Keenan, Tiarnan D.; Agron, Elvira; Chew, Emily Y.; Cukras, Catherine A.] NEI, Div Epidemiol & Clin Applicat, NIH, 10 Ctr Dr,MSC 1204,Bldg 10,10 CRC,Room 3-253, Bethesda, MD 20892 USA.
C3 National Institutes of Health (NIH) - USA; NIH National Eye Institute
   (NEI); National Institutes of Health (NIH) - USA; NIH National Eye
   Institute (NEI)
RP Wong, WT (通讯作者)，NEI, Neuron Glia Interact Retinal Dis, NIH, 6 Ctr Dr,Bldg 6,Room 217, Bethesda, MD 20892 USA.; Cukras, CA (通讯作者)，NEI, Div Epidemiol & Clin Applicat, NIH, 10 Ctr Dr,MSC 1204,Bldg 10,10 CRC,Room 3-253, Bethesda, MD 20892 USA.
EM cukrasc@nei.nih.gov; wongw@nih.gov
FU National Eye Institute Intramural Research Program, National Institutes
   of Health; Doris Duke Charitable Foundation; Genentech; American
   Association for Dental Research; Colgate-Palmolive Company; Elsevier;
   National Institutes of Health (NIH) Medical Research Scholars Program -
   NIH
FX Supported by funds from the National Eye Institute Intramural Research
   Program, National Institutes of Health and through the National
   Institutes of Health (NIH) Medical Research Scholars Program, a
   public-private partnership supported jointly by the NIH and generous
   contributions to the Foundation for the NIH from the Doris Duke
   Charitable Foundation, Genentech, the American Association for Dental
   Research, the Colgate-Palmolive Company, Elsevier, alumni of student
   research programs, and other individual supporters via contributions to
   the Foundation for the National Institutes of Health.
CR Abdolrahimzadeh S, 2019, EYE, V33, P1290, DOI 10.1038/s41433-019-0405-3
   Acton JH, 2012, OPTOMETRY VISION SCI, V89, P1050, DOI 10.1097/OPX.0b013e31825da18c
   Ahn SM, 2018, BMC OPHTHALMOL, V18, DOI 10.1186/s12886-018-0866-3
   Behbehani R, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0172120
   Chen M, 2015, J LEUKOCYTE BIOL, V98, P713, DOI 10.1189/jlb.3RI0615-239R
   Cherepanoff S, 2010, BRIT J OPHTHALMOL, V94, P918, DOI 10.1136/bjo.2009.165563
   Cicinelli MV, 2018, BRIT J OPHTHALMOL, V102, P1192, DOI 10.1136/bjophthalmol-2017-311317
   Clark ME, 2011, BRIT J OPHTHALMOL, V95, P1427, DOI 10.1136/bjo.2010.190355
   Crabb JW, 2002, P NATL ACAD SCI USA, V99, P14682, DOI 10.1073/pnas.222551899
   Davis MD, 2005, ARCH OPHTHALMOL-CHIC, V123, P1484
   Ding JD, 2014, ADV EXP MED BIOL, V801, P213, DOI 10.1007/978-1-4614-3209-8_28
   Edwards MM, 2016, EXP EYE RES, V150, P44, DOI 10.1016/j.exer.2015.07.016
   Ferris FL, 2005, ARCH OPHTHALMOL-CHIC, V123, P1570
   Finger RP, 2019, OPHTHALMOLOGICA, V241, P61, DOI 10.1159/000491402
   Finger RP, 2016, OPHTHALMOLOGY, V123, P599, DOI 10.1016/j.ophtha.2015.10.029
   Flamendorf J, 2015, OPHTHALMOLOGY, V122, P2053, DOI 10.1016/j.ophtha.2015.06.023
   Garg A, 2013, INVEST OPHTH VIS SCI, V54, P7075, DOI 10.1167/iovs.13-12474
   Gil JQ, 2017, EYE, V31, P364, DOI 10.1038/eye.2016.207
   Gupta N, 2003, EXP EYE RES, V76, P463, DOI 10.1016/S0014-4835(02)00332-9
   Kawasaki R, 2010, OPHTHALMOLOGY, V117, P921, DOI 10.1016/j.ophtha.2009.10.007
   Keenan TD, 2020, RETINA-J RET VIT DIS, V40, P632, DOI 10.1097/IAE.0000000000002434
   Klein R, 1999, PROG RETIN EYE RES, V18, P371, DOI 10.1016/S1350-9462(98)00025-1
   Lamin A, 2019, EYE, V33, P428, DOI 10.1038/s41433-018-0234-9
   Mitchell P, 2018, LANCET, V392, P1147, DOI 10.1016/S0140-6736(18)31550-2
   Nusinowitz S, 2018, CURR EYE RES, V43, P376, DOI 10.1080/02713683.2017.1401646
   Penfold PL, 1997, INVEST OPHTH VIS SCI, V38, P2125
   Pennesi ME, 2012, MOL ASPECTS MED, V33, P487, DOI 10.1016/j.mam.2012.06.003
   Querques G, 2012, INVEST OPHTH VIS SCI, V53, P1258, DOI 10.1167/iovs.11-8907
   Ramon C, 2019, CLIN EXP OPTOM, V102, P601, DOI 10.1111/cxo.12894
   Rogala J, 2015, INVEST OPHTH VIS SCI, V56, P1689, DOI 10.1167/iovs.14-16221
   Sadda SR, 2018, OPHTHALMOLOGY, V125, P537, DOI 10.1016/j.ophtha.2017.09.028
   Sadigh S, 2015, CURR EYE RES, V40, P398, DOI 10.3109/02713683.2014.925934
   Sadigh S, 2013, INVEST OPHTH VIS SCI, V54, P1603, DOI 10.1167/iovs.12-11286
   Schaal KB, 2016, OPHTHALMOLOGY, V123, P1060, DOI 10.1016/j.ophtha.2016.01.034
   Schuman SG, 2009, OPHTHALMOLOGY, V116, P488, DOI 10.1016/j.ophtha.2008.10.006
   Sennlaub F, 2013, EMBO MOL MED, V5, P1775, DOI 10.1002/emmm.201302692
   Sivaprasad S, 2016, SURV OPHTHALMOL, V61, P521, DOI 10.1016/j.survophthal.2016.02.005
   Spaide RF, 2018, RETINA-J RET VIT DIS, V38, P891, DOI 10.1097/IAE.0000000000001732
   Spaide RF, 2013, RETINA-J RET VIT DIS, V33, P1800, DOI 10.1097/IAE.0b013e31829c3765
   Sullivan R, 2003, INVEST OPHTH VIS SCI, V44, P856, DOI 10.1167/iovs.02-0416
   Sunness JS, 1999, MOL VIS, V5
   Toto L, 2017, BRIT J OPHTHALMOL, V101, P774, DOI 10.1136/bjophthalmol-2016-309160
   Wong T, 2008, OPHTHALMOLOGY, V115, P116, DOI 10.1016/j.ophtha.2007.03.008
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
NR 44
TC 6
Z9 6
U1 0
U2 3
PU ASSOC RESEARCH VISION OPHTHALMOLOGY INC
PI ROCKVILLE
PA 12300 TWINBROOK PARKWAY, ROCKVILLE, MD 20852-1606 USA
SN 0146-0404
EI 1552-5783
J9 INVEST OPHTH VIS SCI
JI Invest. Ophthalmol. Vis. Sci.
PD JUN
PY 2020
VL 61
IS 6
AR 59
DI 10.1167/iovs.61.6.59
PG 10
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA MD7MJ
UT WOS:000544154500059
PM 32602904
OA gold, Green Published
DA 2022-11-30
ER

PT J
AU Tao, Y
   Jiang, PF
   Wei, YH
   Wang, P
   Suns, XL
   Wang, H
AF Tao, Yuan
   Jiang, Pengfei
   Wei, Yuhua
   Wang, Ping
   Suns, Xiaoling
   Wang, Hong
TI alpha-Lipoic Acid Treatment Improves Vision-Related Quality of Life in
   Patients with Dry Age-Related Macular Degeneration
SO TOHOKU JOURNAL OF EXPERIMENTAL MEDICINE
LA English
DT Article
DE alpha-lipoic acid; age-related macular degeneration; antioxidant; Low
   Vision Quality of Life; superoxide dismutase
ID PIGMENT EPITHELIAL-CELLS; MITOCHONDRIAL-DNA DAMAGE; ANTIOXIDANT ENZYMES;
   LIPID-PEROXIDATION; OXIDATIVE STRESS; (R)-ALPHA-LIPOIC ACID;
   SUPEROXIDE-DISMUTASE; NITRIC-OXIDE; PROTECTION; EXPRESSION
AB Dry form of age-related macular degeneration (AMD) constitutes 90% of AMD cases, and it is characterized by the formation of drusen under the retina and the slow breakdown of the light-sensing cells in the macula, which causes a gradual loss of central vision. Since oxidative stress is involved in the pathogenesis of dry AMD, a-lipoic acid (LA) with antioxidant properties was selected, and its effect on anti-oxidative markers and visual quality in patients with dry AMD was assessed. A total of 100 dry AMD patients (60-83 years old) were randomly assigned to LA treatment group (n = 50) and placebo control group (n = 50). We measured the serum superoxide dismutase (SOD) activity, an important marker of antioxidant defense, best-corrected visual acuity (BCVA), contrast sensitivity, and Chinese-Version Low Vision Quality of Life (CLVQOL) before and after LA or placebo intervention. Pearson correlation coefficients were calculated to explore the relationship between contrast sensitivity values and CLVQOL scores. There was a statistically significant increase in serum SOD activity after LA intervention. The CLVQOL score was improved significantly after LA treatment. The contrast sensitivity measured at middle and low spatial frequency was significantly higher after LA treatment. CLVQOL scores were positively correlated with contrast sensitivity at low spatial frequency (3 eye/degree) in LA-treated group. These results indicate that LA treatment improves vision-related quality of life in patients with dry AMD probably by increasing antioxidant activity. Thus, LA can be regarded as a promising agent for the treatment of AMD.
C1 [Tao, Yuan] Second Peoples Hosp Jinan City, Dept Opthalmol, Jinan, Shandong, Peoples R China.
   [Jiang, Pengfei] Yantai Yuhuangding Hosp, Dept Opthalmol, Yantai, Shandong, Peoples R China.
   [Wei, Yuhua] Shandong Univ, Qilu Hosp, Dept Med, Jinan, Shandong, Peoples R China.
   [Wang, Ping] Shandong Univ, Qilu Hosp, Dept Surg, Jinan, Shandong, Peoples R China.
   [Suns, Xiaoling] Yantai Yuhuangding Hosp, Dept Surg, Yantai, Shandong, Peoples R China.
   [Wang, Hong] Shandong Univ, Qilu Hosp, Dept Opthalmol, 107 Wenhuaxi Rd, Jinan 250012, Shandong, Peoples R China.
C3 Shandong University; Shandong University; Shandong University
RP Wang, H (通讯作者)，Shandong Univ, Qilu Hosp, Dept Opthalmol, 107 Wenhuaxi Rd, Jinan 250012, Shandong, Peoples R China.
EM whqilu@163.com
FU Science and Technology Development Planning of Shandong Province
   [2012GSF11853]
FX This study was partially supported by Science and Technology Development
   Planning of Shandong Province (2012GSF11853).
CR Baskol G, 2006, OPHTHALMOLOGICA, V220, P12, DOI 10.1159/000089269
   BIRD AEC, 1995, SURV OPHTHALMOL, V39, P367, DOI 10.1016/S0039-6257(05)80092-X
   Buettner GR, 2011, ANTI-CANCER AGENT ME, V11, P341
   Chong EWT, 2007, BMJ-BRIT MED J, V335, P755, DOI 10.1136/bmj.39350.500428.47
   Coleman HR, 2008, LANCET, V372, P1835, DOI 10.1016/S0140-6736(08)61759-6
   DelaPaz MA, 1996, BRIT J OPHTHALMOL, V80, P445, DOI 10.1136/bjo.80.5.445
   Delcourt C, 1999, OPHTHALMOLOGY, V106, P215, DOI 10.1016/S0161-6420(99)90059-3
   Evereklioglu C, 2003, DOC OPHTHALMOL, V106, P129, DOI 10.1023/A:1022512402811
   Feher J, 2006, NEUROBIOL AGING, V27, P983, DOI 10.1016/j.neurobiolaging.2005.05.012
   Ferris FL, 2013, OPHTHALMOLOGY, V120, P844, DOI 10.1016/j.ophtha.2012.10.036
   Flora SJS, 2009, OXID MED CELL LONGEV, V2, P191, DOI 10.4161/oxim.2.4.9112
   Fujita H, 2008, BRAIN RES, V1206, P1, DOI 10.1016/j.brainres.2008.01.081
   GAILLARD ER, 1995, PHOTOCHEM PHOTOBIOL, V61, P448, DOI 10.1111/j.1751-1097.1995.tb02343.x
   Ghibu S, 2009, J CARDIOVASC PHARM, V54, P391, DOI 10.1097/FJC.0b013e3181be7554
   Goraca A, 2011, PHARMACOL REP, V63, P849
   Goralska M, 2003, EXP EYE RES, V76, P241, DOI 10.1016/S0014-4835(02)00307-X
   Jager RD, 2008, NEW ENGL J MED, V358, P2606, DOI 10.1056/NEJMra0801537
   Jarrett SG, 2012, MOL ASPECTS MED, V33, P399, DOI 10.1016/j.mam.2012.03.009
   Jarrett SG, 2008, PROG RETIN EYE RES, V27, P596, DOI 10.1016/j.preteyeres.2008.09.001
   Jia LH, 2007, INVEST OPHTH VIS SCI, V48, P339, DOI 10.1167/iovs.06-0248
   Jia LH, 2011, AGING CLIN EXP RES, V23, P264, DOI 10.1007/BF03324965
   Jin GF, 2001, CURR EYE RES, V23, P11, DOI 10.1076/ceyr.23.1.11.5423
   Justilien V, 2007, INVEST OPHTH VIS SCI, V48, P4407, DOI 10.1167/iovs.07-0432
   Kasahara E, 2005, INVEST OPHTH VIS SCI, V46, P3426, DOI 10.1167/iovs.05-0344
   Khansari N, 2009, RECENT PATENTS INFLA, V3, P73, DOI 10.2174/187221309787158371
   Liang FQ, 2005, EXP EYE RES, V80, P113, DOI 10.1016/j.exer.2004.08.017
   Liu JK, 2008, NEUROCHEM RES, V33, P194, DOI 10.1007/s11064-007-9403-0
   Mejico LJ, 2004, AM J OPHTHALMOL, V137, P908, DOI 10.1016/j.ajo.2003.12.038
   Nelson KC, 2002, INVEST OPHTH VIS SCI, V43, P3550
   Nowak JZ, 2006, PHARMACOL REP, V58, P353
   Nowak M, 2003, EUR J OPHTHALMOL, V13, P281, DOI 10.1177/112067210301300307
   Organisciak DT, 2010, PROG RETIN EYE RES, V29, P113, DOI 10.1016/j.preteyeres.2009.11.004
   Pelli DG, 2013, VISION RES, V90, P10, DOI 10.1016/j.visres.2013.04.015
   Rochette L, 2013, MOL NUTR FOOD RES, V57, P114, DOI 10.1002/mnfr.201200608
   Smith AR, 2004, CURR MED CHEM, V11, P1135, DOI 10.2174/0929867043365387
   SNODDERLY DM, 1995, AM J CLIN NUTR, V62, P1448
   TATE DJ, 1995, INVEST OPHTH VIS SCI, V36, P1271
   Tokarz P, 2013, BIOGERONTOLOGY, V14, P461, DOI 10.1007/s10522-013-9463-2
   Totan Y, 2001, BRIT J OPHTHALMOL, V85, P1426, DOI 10.1136/bjo.85.12.1426
   Vincent AM, 2008, CURR DRUG TARGETS, V9, P94, DOI 10.2174/138945008783431754
   Voloboueva LA, 2005, INVEST OPHTH VIS SCI, V46, P4302, DOI 10.1167/iovs.04-1098
   Wolffsohn JS, 2000, AM J OPHTHALMOL, V130, P793, DOI 10.1016/S0002-9394(00)00610-3
   Yang YM, 2010, MOLECULES, V15, P6332, DOI 10.3390/molecules15096332
   Zou HD, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0028597
NR 44
TC 8
Z9 8
U1 0
U2 9
PU TOHOKU UNIV MEDICAL PRESS
PI SENDAI
PA 2-1, SEIRYO-MACHI, AOBA-KU, SENDAI, MIYAGI 980-8575, JAPAN
SN 0040-8727
EI 1349-3329
J9 TOHOKU J EXP MED
JI Tohoku J. Exp. Med.
PD NOV
PY 2016
VL 240
IS 3
BP 209
EP 214
DI 10.1620/tjem.240.209
PG 6
WC Medicine, General & Internal; Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine; Research & Experimental Medicine
GA EE5XP
UT WOS:000389683200004
PM 27840374
OA gold
DA 2022-11-30
ER

PT J
AU Rossi, M
   Puccini, R
   Romagnoli, MC
   Di Maria, C
   Mattei, P
   Bernini, M
   Marconcini, C
   Santoro, G
AF Rossi, Marco
   Puccini, Rodolfo
   Romagnoli, Maria Chiara
   Di Maria, Cinzia
   Mattei, Paola
   Bernini, Matteo
   Marconcini, Claudio
   Santoro, Gino
TI Acute and Subacute Effect of Rheopheresis on Microvascular Endothelial
   Function in Patients Suffering From Age-related Macular Degeneration
SO THERAPEUTIC APHERESIS AND DIALYSIS
LA English
DT Article
DE Acetylcholine iontophoresis; Age-related macular degeneration; Laser
   Doppler flowmetry; Microvascular endothelial function; Rheopheresis
   treatment; Skin microcirculation
ID SODIUM-NITROPRUSSIDE; REACTIVE HYPEREMIA; ACETYLCHOLINE; IONTOPHORESIS;
   DYSFUNCTION; MACULOPATHY; RESPONSES; MECHANISM; ARTERY
AB This study was performed on seven patients affected by the atrophic form of age-related macular degeneration (AF-ARMD). The patients under investigation belonged to a larger study aimed at evaluating the efficacy of rheopheresis treatment (RT) on the visual function of AF-ARMD patients. Following the protocol of the larger study, patients received RT twice a week, every two weeks, for a total of ten treatments, as well as high-dose supplementation with zinc and vitamins A, E and beta-carotene. Recruited patients underwent skin laser Doppler flowmetry coupled with skin iontophoresis of the endothelium-dependent vasodilator acetylcholine (ACh) and a test of skin post-ischemic reactive hyperemia, before and after the first RT (time 1: all seven patients) and the fifth RT (time 2: six patients). A significantly higher absolute (anova for repeated measures) and relative (percentage change from the baseline) skin blood flux response (SBFR) to ACh iontophoresis was observed after RT, compared to before RT at time 1 (679 +/- 43% and 436 +/- 78%, respectively; P < 0.05), as well as before RT at time 2 compared to before RT at time 1 (683 +/- 74% and 436 +/- 78%, respectively; P < 0.05). Absolute and relative SBFR to ischemia did not differ either after RT compared to before RT at time 1, or before RT at time 2 compared to before RT at time 1. These findings are consistent with an acute and subacute beneficial effect of RT on skin microvascular endothelial function in the studied AF-ARMD patients.
C1 [Rossi, Marco; Di Maria, Cinzia; Santoro, Gino] Univ Pisa, Dipartimento Med Interna, I-56100 Pisa, Italy.
   [Puccini, Rodolfo; Mattei, Paola; Bernini, Matteo] Pisa Hosp, Kidney Transplant & Dialysis Sect Apheresis Treat, Nephrol Unit, Pisa, Italy.
   [Romagnoli, Maria Chiara] Pisa Hosp, Ophthalm Surg Unit, Pisa, Italy.
   [Marconcini, Claudio] Pontedera Hosp, Ophthalmol Unit, Pontedera, Italy.
C3 University of Pisa
RP Rossi, M (通讯作者)，Univ Pisa, Dipartimento Med Interna, Via Roma 67, I-56100 Pisa, Italy.
EM mrossi@int.med.unipi.it
CR Age-Related Eye Dis Study Res Grp, 2001, AM J OPHTHALMOL, V132, P668
   Balletshofer BM, 2005, THER APHER DIAL, V9, P385, DOI 10.1111/j.1744-9987.2005.00316.x
   Binggeli C, 2003, J AM COLL CARDIOL, V42, P71, DOI 10.1016/S0735-1097(03)00505-9
   Cracowski JL, 2006, TRENDS PHARMACOL SCI, V27, P503, DOI 10.1016/j.tips.2006.07.008
   Fell AJ, 2002, OPHTHALMOLOGE, V99, P780, DOI 10.1007/s00347-002-0614-0
   Ferrannini M, 2007, INT J ARTIF ORGANS, V30, P923, DOI 10.1177/039139880703001010
   Gori T, 2006, CLIN HEMORHEOL MICRO, V35, P509
   HOLOWATZ LA, 2005, J PHYSL, V15, P965
   Jung F, 2001, MICROVASC RES, V62, P154, DOI 10.1006/mvre.2001.2325
   Kalia YN, 2004, ADV DRUG DELIVER REV, V56, P619, DOI 10.1016/j.addr.2003.10.026
   KLEIN R, 1993, AM J EPIDEMIOL, V137, P190, DOI 10.1093/oxfordjournals.aje.a116659
   Klingel R, 2002, THER APHER, V6, P271, DOI 10.1046/j.1526-0968.2002.00418.x
   Klingel R, 2000, Ther Apher, V4, P348, DOI 10.1046/j.1526-0968.2000.004005348.x
   Klingel T, 2003, THER APHER DIAL, V7, P444, DOI 10.1046/j.1526-0968.2003.00082.x
   Lip PL, 2001, OPHTHALMOLOGY, V108, P705, DOI 10.1016/S0161-6420(00)00663-1
   MORRIS SJ, 1995, DIABETOLOGIA, V38, P1337, DOI 10.1007/BF00401767
   NILSSON GE, 1980, IEEE T BIO-MED ENG, V27, P597, DOI 10.1109/TBME.1980.326582
   PATTERSON GC, 1956, CLIN SCI, V15, P17
   Pulido J, 2005, J CLIN APHERESIS, V20, P185, DOI 10.1002/jca.20047
   Pulido JS, 2005, CAN J OPHTHALMOL, V40, P332, DOI 10.1016/S0008-4182(05)80076-6
   Rossi M, 2008, RHEUMATOLOGY, V47, P1012, DOI 10.1093/rheumatology/ken117
   Rossi M, 2004, CLIN HEMORHEOL MICRO, V31, P303
   Shamim-Uzzaman QA, 2002, CLIN SCI, V103, P267, DOI 10.1042/cs1030267
   SPERDUTO RD, 1986, ARCH OPHTHALMOL-CHIC, V104, P216
   Tee Get Bee Yvonne, 2004, Journal of Pharmacological and Toxicological Methods, V50, P73, DOI 10.1016/j.vascn.2004.02.002
   TUR E, 1991, DIABETES CARE, V14, P958, DOI 10.2337/diacare.14.11.958
NR 26
TC 3
Z9 3
U1 0
U2 0
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1744-9979
EI 1744-9987
J9 THER APHER DIAL
JI Ther. Apher. Dial.
PD DEC
PY 2009
VL 13
IS 6
BP 540
EP 548
DI 10.1111/j.1744-9987.2009.00705.x
PG 9
WC Hematology; Urology & Nephrology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Hematology; Urology & Nephrology
GA 525CS
UT WOS:000272191300008
PM 19954479
DA 2022-11-30
ER

PT J
AU Kang, SJ
   Schmack, I
   Benson, HE
   Grossniklaus, HE
AF Kang, S. J.
   Schmack, I.
   Benson, H. E.
   Grossniklaus, H. E.
TI Histopathological findings in postmortem eyes after photodynamic therapy
   for choroidal neovascularisation in age-related macular degeneration:
   report of two cases
SO BRITISH JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
ID SUBMACULAR SURGERY TRIALS; VERTEPORFIN; MEMBRANES; EXPRESSION
AB Background: To report the histopathological findings after photodynamic therapy (PDT) in eyes obtained postmortem with choroidal neovascularisation (CNV) secondary to age-related macular degeneration (AMD).
   Methods: Two eyes were obtained postmortem from two patients with CNV secondary to AMD. Both of the patients had been treated with PDT. Serial sections through the posterior poles were obtained and stained with haematoxylin-eosin, periodic acid-Schiff, Masson trichrome or phosphotungstic acid haematoxylin (PTAH). Two-dimensional reconstructions were prepared and compared with fluorescein angiograms.
   Results: The interval between PDT and death was 3 months and 17 months in each patient, respectively. Light-microscopic examination showed that CNV enveloped with retinal pigment epithelium (RPE) in both eyes. The average size of the CNV was 550x280 mu m. One eye had combined (subRPE/subretinal) growth pattern CNV, and the other eye had both type I (subRPE) and combined growth pattern CNV. All specimens contained fibrous proliferation and patent vascular channels within the CNV, and there was no thrombus formation within the vascular channels. No apparent abnormalities in the choroid were observed by light microscopy.
   Conclusions: Although involution with fibrous tissue proliferation occurred, PDT did not result in permanent occlusion of the vascular channels in the CNV. Our findings indicate that PDT may accelerate involution of CNV, thus limiting its size and preserving photoreceptors.
C1 Emory Univ, Sch Med, Emory Eye Ctr, Dept Ophthalmol, Atlanta, GA 30322 USA.
   Univ Heidelberg, Dept Ophthalmol, Heidelberg, Germany.
C3 Emory University; Ruprecht Karls University Heidelberg
RP Grossniklaus, HE (通讯作者)，Emory Univ, Sch Med, Emory Eye Ctr, Dept Ophthalmol, 1365-B Clifton Rd, Atlanta, GA 30322 USA.
EM ophtheg@emory.edu
CR Blumenkranz MS, 2001, ARCH OPHTHALMOL-CHIC, V119, P198
   Bressler NM, 2000, INVEST OPHTH VIS SCI, V41, P624
   Costa RA, 2003, RETINA-J RET VIT DIS, V23, P159, DOI 10.1097/00006982-200304000-00004
   Gelisken F, 2004, BRIT J OPHTHALMOL, V88, P207, DOI 10.1136/bjo.2003.018754
   Ghazi NG, 2001, RETINA-J RET VIT DIS, V21, P478, DOI 10.1097/00006982-200110000-00010
   Grossniklaus HE, 2006, AM J OPHTHALMOL, V141, P93, DOI 10.1016/j.ajo.2005.07.076
   Grossniklaus HE, 2005, ARCH OPHTHALMOL-CHIC, V123, P914
   Grossniklaus HE, 2002, RETINA-J RET VIT DIS, V22, P818, DOI 10.1097/00006982-200212000-00027
   Grossniklaus HE, 2004, AM J OPHTHALMOL, V137, P496, DOI 10.1016/j.ajo.2003.09.042
   Grossniklaus HE, 2002, MOL VIS, V8, P119
   Husain D, 1999, INVEST OPHTH VIS SCI, V40, P2322
   Klais CM, 2005, ARCH OPHTHALMOL-CHIC, V123, P1149, DOI 10.1001/archopht.123.8.1149
   Kramer M, 1996, OPHTHALMOLOGY, V103, P427
   Moshfeghi DM, 2003, AM J OPHTHALMOL, V135, P343, DOI 10.1016/S0002-9394(02)01936-0
   Schmidt-Erfurth U, 2002, ARCH OPHTHALMOL-CHIC, V120, P835
   Schmidt-Erfurth U, 2005, OPHTHALMOLOGY, V112, P2061, DOI 10.1016/j.ophtha.2005.09.007
   Schnurrbusch UEK, 2001, BRIT J OPHTHALMOL, V85, P1086, DOI 10.1136/bjo.85.9.1086
   Tatar O, 2006, AM J OPHTHALMOL, V142, P95, DOI 10.1016/j.ajo.2006.01.085
   Tatar O, 2006, ARCH OPHTHALMOL-CHIC, V124, P815, DOI 10.1001/archopht.124.6.815
   Tzekov R, 2006, INVEST OPHTH VIS SCI, V47, P377, DOI 10.1167/iovs.05-0838
   Yu SY, 2006, RETINA-J RET VIT DIS, V26, P531, DOI 10.1097/00006982-200605000-00006
NR 21
TC 4
Z9 4
U1 0
U2 3
PU BMJ PUBLISHING GROUP
PI LONDON
PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND
SN 0007-1161
EI 1468-2079
J9 BRIT J OPHTHALMOL
JI Br. J. Ophthalmol.
PD DEC
PY 2007
VL 91
IS 12
BP 1602
EP 1606
DI 10.1136/bjo.2007.121830
PG 5
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 232PS
UT WOS:000251032200013
PM 17567659
OA Green Published
DA 2022-11-30
ER

PT J
AU Lala, C
   Framme, C
   Wolf-Schnurrbusch, UEK
   Wolf, S
AF Lala, Ceklic
   Framme, Carsten
   Wolf-Schnurrbusch, Ute E. K.
   Wolf, Sebastian
TI Three-year results of visual outcome with disease activity-guided
   ranibizumab algorithm for the treatment of exudative age-related macular
   degeneration
SO ACTA OPHTHALMOLOGICA
LA English
DT Article
DE antivascular endothelial growth factor; exudative age-related macular
   degeneration; optical coherence tomography; visual acuity
AB Purpose: To evaluate 3-year follow-up treatment outcomes with ranibizumab (Lucentis((R))) 0.5mg administered either monthly or quarterly on a pro re nata (PRN) basis according to a disease activity-guided monitoring and treatment algorithm. Methods: A total of 316 treatment-naive eyes of 316 patients with exudative age-related macular degeneration met the criteria for inclusion in this retrospective, interventional case series. Patients were treated with ranibizumab 0.5mg according to a disease activity-guided algorithm with monthly monitoring. Optical coherence tomography and fluorescein angiography were routinely used to assess disease activity: active lesions were treated with a series of three monthly injections, whereas inactive lesions were treated with quarterly injections. Results: Mean Early Treatment Diabetic Retinopathy Study best-corrected visual acuity improved from 52 letters at baseline to 59 letters at 12months, achieved with a mean of 7.1injections, 61 letters at 24months with a mean of 5.0 injections administered in the second year and 60 letters at 36months with a mean number of 5.2 injections. Conclusions: Monthly visits and a morphology-driven PRN regimen with 3 injections in case of recurrence plus quarterly injections in case of inactive CNV resulted in an average VA gain of 7-9 letters that could be maintained over 3 years.
C1 [Lala, Ceklic; Framme, Carsten; Wolf-Schnurrbusch, Ute E. K.; Wolf, Sebastian] Univ Bern, Univ Klin Augenheilkunde, CH-3010 Bern, Switzerland.
   [Lala, Ceklic] Eye Clin Kasindo, Clin Ctr Eastern Sarajevo, E Sarajevo, Bosnia & Herceg.
C3 University of Bern
RP Wolf, S (通讯作者)，Univ Bern, Inselspital, Univ Klin Augenheilkunde, CH-3010 Bern, Switzerland.
EM sebastian.wolf@insel.ch
RI Wolf, Sebastian/B-8782-2008
OI Wolf, Sebastian/0000-0002-7467-7028
FU Novartis Pharma AG; International Council of Ophthalmology; Helmerich
   Foundation
FX The authors would like to thank Reinhard Ruhl for the help in data
   acquisition and his contributions in supporting the study. Additionally,
   we would like to acknowledge Laura Saunderson of Chameleon
   Communications International, who provided medical writing services with
   funding from Novartis Pharma AG. Participation in this study for Lala
   Ceklic has been supported by International Council of Ophthalmology and
   Helmerich Foundation.
CR Biarnes M, 2011, EUR J OPHTHALMOL, V21, P282, DOI 10.5301/EJO.2010.5766
   Bressler SB, 2009, OPHTHALMOLOGY, V116, pS1, DOI 10.1016/j.ophtha.2009.06.045
   Brown DM, 2009, OPHTHALMOLOGY, V116, P57, DOI 10.1016/j.ophtha.2008.10.018
   Brown MM, 2005, CAN J OPHTHALMOL, V40, P277, DOI 10.1016/S0008-4182(05)80070-5
   Cruess AF, 2008, PHARMACOECONOMICS, V26, P57, DOI 10.2165/00019053-200826010-00006
   Dadgostar H, 2009, OPHTHALMOLOGY, V116, P1740, DOI 10.1016/j.ophtha.2009.05.033
   Holz FG, 2011, OPHTHALMOLOGY, V118, P663, DOI 10.1016/j.ophtha.2010.12.019
   Holz FG, 2010, INVEST OPHTH VIS SCI, V51, P405, DOI 10.1167/iovs.09-3813
   Menghini M, 2010, KLIN MONATSBL AUGENH, V227, P244, DOI 10.1055/s-0029-1245203
   Mitchell P, 2010, BRIT J OPHTHALMOL, V94, P2, DOI 10.1136/bjo.2009.159160
   Nowak JZ, 2006, PHARMACOL REP, V58, P353
   Regillo CD, 2008, AM J OPHTHALMOL, V145, P239, DOI 10.1016/j.ajo.2007.10.004
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Schmidt-Erfurth U, 2011, OPHTHALMOLOGY, V118, P831, DOI 10.1016/j.ophtha.2010.09.004
NR 14
TC 21
Z9 22
U1 0
U2 4
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1755-375X
J9 ACTA OPHTHALMOL
JI Acta Ophthalmol.
PD SEP
PY 2013
VL 91
IS 6
BP 526
EP 530
DI 10.1111/j.1755-3768.2012.02457.x
PG 5
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 202GG
UT WOS:000323201500025
PM 22697404
OA Bronze
DA 2022-11-30
ER

PT J
AU Choi, EJ
   Choi, GW
   Kim, JH
   Jang, HW
   Lee, JH
   Bae, HJ
   Kim, YG
   Lee, YB
   Cho, HY
AF Choi, Eun-Jeong
   Choi, Go-Wun
   Kim, Ju Hee
   Jang, Hee-Woon
   Lee, Ju-Hee
   Bae, Hyun Ju
   Kim, Young Gwan
   Lee, Yong-Bok
   Cho, Hea-Young
TI A Novel Eye Drop Candidate for Age-Related Macular Degeneration
   Treatment: Studies on its Pharmacokinetics and Distribution in Rats and
   Rabbits
SO MOLECULES
LA English
DT Article
DE CK41016; dry age-related macular generation; pharmacokinetics; tissue
   distribution; Caco-2
ID RETINAL-PIGMENT EPITHELIUM; P-GLYCOPROTEIN EXPRESSION; GEOGRAPHIC
   ATROPHY; TRANSPORTERS; EFFICACY; OT-551
AB Age-related macular degeneration (AMD) is wearing down of macula of retina, causing a blur or loss of vision in the center of the visual field. It can be categorized into dry or wet AMD. Until now, medical treatments for dry AMD have not been developed yet. The aim of this study was to evaluate pharmacokinetics (PKs) and tissue distribution of CK41016, a novel candidate for dry AMD, after intravenous (IV) or eye drop administration in rats and rabbits. In addition, a simple and sensitive bioanalytical method for CK41016 using ultra performance liquid chromatography-tandem mass spectrometer (UPLC-MS/MS) was developed. PK parameters were estimated by compartmental analysis using a WinNonlin((R)) software version 8.1 (a Certara (TM) company). A PK model of CK41016 was well-described by the two-compartment model. The tissue-to-plasma partition coefficient (Kp) of CK41016 was the highest in the vitreous humor of rats and the cornea of rabbits after eye drop administration. In addition, the Caco-2 cell transporter assay confirmed that CK41016 was not an active substrate for the efflux transporter. In summary, the PKs and tissue distribution of CK41016 were successfully evaluated and investigated whether this drug was a substrate of efflux transporters.
C1 [Choi, Eun-Jeong; Choi, Go-Wun; Kim, Ju Hee; Jang, Hee-Woon; Cho, Hea-Young] CHA Univ, Coll Pharm, 335 Pangyo Ro, Seongnam Si 13488, Gyeonggi Do, South Korea.
   [Lee, Ju-Hee; Bae, Hyun Ju; Kim, Young Gwan] Kukje Pharma R&D Ctr, Sanseong Ro 47, Ansan 15438, Gyeonggi Do, South Korea.
   [Lee, Yong-Bok] Chonnam Natl Univ, Coll Pharm, 77 Yongbong Ro, Gwangju 61186, South Korea.
C3 Pochon Cha University; Chonnam National University
RP Cho, HY (通讯作者)，CHA Univ, Coll Pharm, 335 Pangyo Ro, Seongnam Si 13488, Gyeonggi Do, South Korea.
EM choiej5048@gmail.com; gwchoi153@gmail.com; 20135107@ppharm.org;
   heewoon21@gmail.com; jhlee@kukjepharm.co.kr; hjbae1201@gmail.com;
   ykkim@kukjepharm.co.kr; leeyb@chonnam.ac.kr; hycho@cha.ac.kr
RI Lee, Yong-Bok/AAR-8501-2020
OI Lee, Yong-Bok/0000-0002-0797-5324
FU Kukje Pharmaceutical Co., Korea
FX This research was supported by the Kukje Pharmaceutical Co., Korea.
CR Bandello Francesco, 2017, F1000Res, V6, P245, DOI 10.12688/f1000research.10664.1
   Boddu Sai H S, 2014, Recent Pat Drug Deliv Formul, V8, P27
   Boyer D, 2015, CLIN OPHTHALMOL, V9, P1099, DOI 10.2147/OPTH.S86208
   Brazier Yvette, 2018, MED NEWS TODAY
   Carr AJF, 2013, TRENDS NEUROSCI, V36, P385, DOI 10.1016/j.tins.2013.03.006
   Constable PA, 2006, EXP EYE RES, V83, P24, DOI 10.1016/j.exer.2005.10.029
   FDA, 2018, GUID IND BIOAN METH
   Food and Drug Administration, 2017, GUID IND IN VITR MET
   Giacomini KM, 2010, NAT REV DRUG DISCOV, V9, P215, DOI 10.1038/nrd3028
   Heier JS, 2012, OPHTHALMOLOGY, V119, P2537, DOI 10.1016/j.ophtha.2012.09.006
   Holz FG, 2018, JAMA OPHTHALMOL, V136, P666, DOI 10.1001/jamaophthalmol.2018.1544
   Ivandic BT, 2008, PHOTOMED LASER SURG, V26, P241, DOI 10.1089/pho.2007.2132
   Jang KH, 2019, EXP EYE RES, V180, P8, DOI 10.1016/j.exer.2018.11.026
   Kassa E, 2019, EXPERT OPIN BIOL TH, V19, P335, DOI 10.1080/14712598.2019.1575358
   Kennedy BG, 2002, MOL VIS, V8, P422
   Koss MJ, 2009, GRAEF ARCH CLIN EXP, V247, P1297, DOI 10.1007/s00417-009-1113-7
   Mitra AK, 2009, PHARM RES-DORDR, V26, P1192, DOI 10.1007/s11095-009-9862-x
   Prahs P, 2010, GRAEF ARCH CLIN EXP, V248, P651, DOI 10.1007/s00417-009-1208-1
   Qureshi MA, 2015, J CATARACT REFR SURG, V41, P2125, DOI 10.1016/j.jcrs.2015.03.021
   Rencova E, 2015, J OPHTHALMOL, V2015, DOI 10.1155/2015/359747
   Rickman CB, 2013, INVEST OPHTH VIS SCI, V54, pORSF68, DOI 10.1167/iovs.13-12757
   Schwartz SD, 2016, INVEST OPHTH VIS SCI, V57, DOI 10.1167/iovs.15-18681
   Tanito M, 2010, EXP EYE RES, V91, P111, DOI 10.1016/j.exer.2010.04.012
   Taskintuna I, 2016, MIDDLE EAST AFR J OP, V23, P13, DOI 10.4103/0974-9233.173134
   Thomasy SM, 2016, J OCUL PHARMACOL TH, V32, P28, DOI 10.1089/jop.2015.0071
   Tsai CH, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19092830
   Velez-Montoya R, 2013, RETINA-J RET VIT DIS, V33, P1487, DOI 10.1097/IAE.0b013e318271f265
   Virgili G, 2015, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD006537.pub3
   Wong WT, 2010, INVEST OPHTH VIS SCI, V51, P6131, DOI 10.1167/iovs.10-5637
NR 29
TC 2
Z9 2
U1 2
U2 7
PU MDPI
PI BASEL
PA ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND
EI 1420-3049
J9 MOLECULES
JI Molecules
PD FEB 1
PY 2020
VL 25
IS 3
AR 663
DI 10.3390/molecules25030663
PG 18
WC Biochemistry & Molecular Biology; Chemistry, Multidisciplinary
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Chemistry
GA KO2MV
UT WOS:000515384800233
PM 32033125
OA Green Published, gold
DA 2022-11-30
ER

PT J
AU Wolf, S
   Bandello, F
   Loewenstein, A
   Slakter, J
   Katz, T
   Sowade, O
   Korobelnik, JF
AF Wolf, Sebastian
   Bandello, Francesco
   Loewenstein, Anat
   Slakter, Jason
   Katz, Todd
   Sowade, Olaf
   Korobelnik, Jean-Francois
TI Baseline Characteristics of the Fellow Eye in Patients with Neovascular
   Age-Related Macular Degeneration: Post Hoc Analysis of the VIEW Studies
SO OPHTHALMOLOGICA
LA English
DT Article
DE Anti-VEGF agents; Best-corrected visual acuity; Bilateral disease;
   Choroidal neovascularization; Fellow eye; Intravitreal aflibercept;
   Neovascular age-related macular degeneration; Pooled analysis;
   Ranibizumab
ID CHOROIDAL NEOVASCULARIZATION; VEGF-TRAP; RANIBIZUMAB
AB Purpose: The aim was to describe baseline characteristics of the fellow eye of patients with neovascular age-related macular degeneration (nAMD). Methods: A pooled, post hoc analysis of patients with nAMD enrolled in the VIEW studies was carried out. The VIEW studies compared intravitreal aflibercept (monthly or every 2 months after 3 monthly injections) with monthly ranibizumab. Baseline choroidal neovascularization (CNV) status of fellow eyes and baseline best corrected visual acuity (BCVA) and lens status of all eyes were evaluated. Additional analyses evaluated the presence of drusen and pigment in fellow eyes. Results: When comparing both eyes, baseline BCVA was worse in 23.8% of fellow eyes and in 75.2% of study eyes. Lens status of fellow eyes and study eyes was similar. Baseline visual acuity of the study eye and that of the fellow eye were not correlated. Most fellow eyes had signs of early AMD, with 34.6% (n = 843) of fellow eyes having evidence of scarring. Conclusions: In patients in the VIEW studies, most fellow eyes had evidence of AMD, highlighting the importance of examining both eyes, with close follow-up thereafter, in order to detect and treat CNV earlier as needed. (C) 2016 S. Karger AG, Basel
C1 [Wolf, Sebastian] Univ Bern, Inselspital, Univ Hosp Bern, Dept Ophthalmol, Bern, Switzerland.
   [Bandello, Francesco] Univ Vita, Salute Sci Inst, Dept Ophthalmol, Milan, Italy.
   [Loewenstein, Anat] Tel Aviv Med Ctr & Sch Med, Dept Ophthalmol, Tel Aviv, Israel.
   [Slakter, Jason] Vitreous Retina Macula Consultants New York, New York, NY USA.
   [Katz, Todd] Bayer Pharmaceut, Whippany, NJ USA.
   [Sowade, Olaf] Bayer Pharmaceut, Berlin, Germany.
   [Korobelnik, Jean-Francois] CHU Bordeaux, Serv Ophtalmol, Bordeaux, France.
   [Korobelnik, Jean-Francois] Univ Bordeaux, ISPED, Bordeaux, France.
   [Korobelnik, Jean-Francois] INSERM, U1219, Bordeaux Populat Hlth Res Ctr, Bordeaux, France.
C3 University of Bern; University Hospital of Bern; Tel Aviv University;
   Sackler Faculty of Medicine; Vitreous Retina Macula Consultants of New
   York; Bayer AG; Bayer Healthcare Pharmaceuticals; Bayer AG; Bayer
   Healthcare Pharmaceuticals; CHU Bordeaux; UDICE-French Research
   Universities; Universite de Bordeaux; Institut National de la Sante et
   de la Recherche Medicale (Inserm); UDICE-French Research Universities;
   Universite de Bordeaux
RP Korobelnik, JF (通讯作者)，CHU Bordeaux, Hop Pellegrin, Serv Ophtalmol, Pl Amelie Raba Leon, FR-33000 Bordeaux, France.
EM jean-francois.korobelnik@chu-bordeaux.fr
RI Wolf, Sebastian/B-8782-2008; KOROBELNIK, Jean-Francois/A-5448-2016;
   Meyer, Carsten/A-3981-2017; bandello, francesco/AAH-2405-2019
OI Wolf, Sebastian/0000-0002-7467-7028; Meyer, Carsten/0000-0002-0530-5298;
   bandello, francesco/0000-0003-3238-9682; Korobelnik,
   Jean-Francois/0000-0002-4438-9535
CR Amissah-Arthur KN, 2012, EYE, V26, P394, DOI 10.1038/eye.2011.335
   Barbazetto IA, 2010, AM J OPHTHALMOL, V149, P939, DOI 10.1016/j.ajo.2010.01.007
   Brown DM, 2007, AM J OPHTHALMOL, V144, P627, DOI 10.1016/j.ajo.2007.06.039
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Congdon NG, 2003, JAMA-J AM MED ASSOC, V290, P2057, DOI 10.1001/jama.290.15.2057
   Heier JS, 2012, OPHTHALMOLOGY, V119, P2537, DOI 10.1016/j.ophtha.2012.09.006
   Holash J, 2002, P NATL ACAD SCI USA, V99, P11393, DOI 10.1073/pnas.172398299
   Maguire MG, 2013, OPHTHALMOLOGY, V120, P2035, DOI 10.1016/j.ophtha.2013.03.017
   Maguire MG, 1997, ARCH OPHTHALMOL-CHIC, V115, P741
   Papadopoulos N, 2012, ANGIOGENESIS, V15, P171, DOI 10.1007/s10456-011-9249-6
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Solomon SD, 2007, ARCH OPHTHALMOL-CHIC, V125, P1323
   Wang JJ, 2007, OPHTHALMOLOGY, V114, P92, DOI 10.1016/j.ophtha.2006.07.017
NR 13
TC 4
Z9 4
U1 0
U2 3
PU KARGER
PI BASEL
PA ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND
SN 0030-3755
EI 1423-0267
J9 OPHTHALMOLOGICA
JI Ophthalmologica
PY 2016
VL 236
IS 2
BP 95
EP 99
DI 10.1159/000447725
PG 5
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA DY1RG
UT WOS:000384871500006
PM 27449643
OA Green Published
DA 2022-11-30
ER

PT J
AU Balci, S
   Sahin, O
   Ozcaliskan, S
   Sevik, MO
   Mangan, MS
AF Balci, Sevcan
   Sahin, Ozlem
   Ozcaliskan, Sehnaz
   Sevik, Mehmet Orkun
   Mangan, Mehmet Serhat
TI Immediate changes in blood pressure during intravitreal anti-VEGF
   agents' applications in exudative age-related macular degeneration
   patients
SO INTERNATIONAL OPHTHALMOLOGY
LA English
DT Article
DE Anti-vascular endothelial growth factor; Bevacizumab; Ranibizumab;
   Systemic arterial blood pressure
ID ENDOTHELIAL GROWTH-FACTOR; BEVACIZUMAB AVASTIN; ANGIOGENESIS; SAFETY
AB Purpose To determine the short-term changes in systemic arterial blood pressure (SABP) during intravitreal anti-vascular endothelial growth factor (anti-VEGF) injection in patients with exudative age-related macular degeneration (ARMD). Materials and methods This study retrospectively reviewed the data of 550 patients with exudative ARMD, who received intravitreal anti-VEGF (bevacizumab or ranibizumab; selected randomly) injections. Patients with hypertension on medication with antihypertensive drugs were assigned to the hypertension group (HTG; n = 278); those with normal blood pressure and not on antihypertensive drugs were assigned to the normotensive group (NTG; n = 272). The SABP levels were measured 30 min before anti-VEGF injection (baseline = B), during anti-VEGF injection (DI), as well as 30th (I30) and 60th (I60) min after anti-VEGF injection. Results Both groups had significantly higher systolic blood pressure (SBP) at DI than that of the baseline values (p < 0.001), whereas the diastolic blood pressures (DBP) increased significantly at DI, I30, and I60 compared with baseline (p < 0.001). In NTG, SBP was significantly higher in patients at I30 (p = 0.019), whereas that in HTG was significantly higher at all measurements (p < 0.05) only in patients who received intravitreal bevacizumab injection. Conclusion Our study results show that intravitreal anti-VEGF injection is associated with a short-term increase in SABP. To prevent potential systemic complications during anti-VEGF administration, the systemic status of patients with ARMD should be evaluated before the injection and those with a risk of high SABP during injection should be closely monitored.
C1 [Balci, Sevcan; Ozcaliskan, Sehnaz; Mangan, Mehmet Serhat] Univ Hlth Sci, Haydarpasa Numune Training & Res Hosp, Dept Ophthalmol, Tibbiye Cad 40 Uskudar, TR-34668 Istanbul, Turkey.
   [Sahin, Ozlem; Sevik, Mehmet Orkun] Marmara Univ, Sch Med, Dept Ophthalmol, Istanbul, Turkey.
C3 Istanbul Haydarpasa Numune Training & Research Hospital; Marmara
   University
RP Balci, S (通讯作者)，Univ Hlth Sci, Haydarpasa Numune Training & Res Hosp, Dept Ophthalmol, Tibbiye Cad 40 Uskudar, TR-34668 Istanbul, Turkey.
EM www.svcnyldz@hotmail.com
RI Mangan, Mehmet Serhat/ABI-4022-2020; Ozcaliskan, Sehnaz/AAA-1305-2021;
   Ozcaliskan, Sehnaz/ABC-9911-2020
OI Mangan, Mehmet Serhat/0000-0001-7720-9003; Ozcaliskan,
   Sehnaz/0000-0002-3783-3570; Yildiz Balci, Sevcan/0000-0002-1695-0583;
   SEVIK, Mehmet Orkun/0000-0001-7130-4798
CR Abdel-Qadir H, 2017, CANCER TREAT REV, V53, P120, DOI 10.1016/j.ctrv.2016.12.002
   AIELLO LP, 1994, NEW ENGL J MED, V331, P1480, DOI 10.1056/NEJM199412013312203
   Avery RL, 2017, RETINA-J RET VIT DIS, V37, P1847, DOI 10.1097/IAE.0000000000001493
   Avery RL, 2016, JAMA OPHTHALMOL, V134, P21, DOI 10.1001/jamaophthalmol.2015.4070
   Berger V, 2019, JAMA OPHTHALMOL, V137, P87, DOI 10.1001/jamaophthalmol.2018.4892
   Carneiro AM, 2012, ACTA OPHTHALMOL, V90, pE25, DOI 10.1111/j.1755-3768.2011.02240.x
   Demircelik G, 2009, RET VIT, V17, P269
   Ferrara N, 2001, AM J PHYSIOL-CELL PH, V280, pC1358, DOI 10.1152/ajpcell.2001.280.6.C1358
   Fogli S, 2018, EYE, V32, P1010, DOI 10.1038/s41433-018-0021-7
   Henry TD, 2003, CIRCULATION, V107, P1359, DOI 10.1161/01.CIR.0000061911.47710.8A
   Laragh JH, 1995, HYPERTENSION PATHOPH, P1897
   Ng EWM, 2005, CAN J OPHTHALMOL, V40, P352, DOI 10.1016/S0008-4182(05)80078-X
   Rasier R, 2009, EYE, V23, P1714, DOI 10.1038/eye.2008.360
   Rich RM, 2006, RETINA-J RET VIT DIS, V26, P495, DOI 10.1097/01.iae.0000225766.75009.3a
   Risimic D, 2013, HELL J CARDIOL, V54, P435
   Sengul A, 2017, EYE, V31, P677, DOI 10.1038/eye.2016.305
   Van der Reis MI, 2011, RETINA-J RET VIT DIS, V31, P1449, DOI 10.1097/IAE.0b013e3182278ab4
NR 17
TC 1
Z9 1
U1 0
U2 0
PU SPRINGER
PI DORDRECHT
PA VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS
SN 0165-5701
EI 1573-2630
J9 INT OPHTHALMOL
JI Int. Ophthalmol.
PD OCT
PY 2020
VL 40
IS 10
BP 2515
EP 2522
DI 10.1007/s10792-020-01431-3
EA JUN 2020
PG 8
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA NS0QD
UT WOS:000537656700001
PM 32495059
DA 2022-11-30
ER

PT J
AU Diez, GR
   Uranga, RM
   Mateos, MV
   Giusto, NM
   Salvador, GA
AF Rodriguez Diez, G.
   Uranga, R. M.
   Mateos, M. V.
   Giusto, N. M.
   Salvador, G. A.
TI Differential participation of phospholipase A(2) isoforms during
   iron-induced retinal toxicity. Implications for age-related macular
   degeneration
SO NEUROCHEMISTRY INTERNATIONAL
LA English
DT Article
DE Retina; Iron; PLA(2); Oxidative stress; AMD; COX-2
ID ACTIVATED PROTEIN-KINASE; OXIDATIVE STRESS; CELL-DEATH; INFLAMMATORY
   RESPONSES; POTENTIAL FACTOR; PHOTORECEPTOR; HOMEOSTASIS; EXPRESSION;
   PATHWAY; PHOSPHATIDYLCHOLINE
AB Both elevated iron concentrations and the resulting oxidative stress condition are common signs in retinas of patients with age-related macular degeneration (AMD). The role of phospholipase A(2) (PLA(2)) during iron-induced retinal toxicity was investigated. To this end, isolated retinas were exposed to increasing Fe2+ concentrations (25, 200 or 800 mu M) or to the vehicle, and lipid peroxidation levels, mitochondrial function, and the activities of cytosolic PLA(2) (cPLA(2)) and calcium-independent PLA(2) (iPLA(2)) were studied. Incubation with Fe2+ led to a time- and concentration-dependent increase in retinal lipid peroxidation levels whereas retinal cell viability was only affected after 60 min of oxidative injury.
   A differential release of arachidonic acid (AA) and palmitic acid (PAL) catalyzed by cPLA(2) and iPLA(2) activities, respectively, was also observed in microsomal and cytosolic fractions obtained from retinas incubated with iron. AA release diminished as the association of cyclooxigenase-2 increased in microsomes from retinas exposed to iron. Retinal lipid peroxidation and cell viability were also analyzed in the presence of cPLA(2) inhibitor, arachidonoyl trifluoromethyl ketone (ATK), and in the presence of iPLA(2) inhibitor, bromoenol lactone (BEL). ATK decreased lipid peroxidation levels and also ERK1/2 activation without affecting cell viability. BEL showed the opposite effect on lipid peroxidation. Our results demonstrate that iPLA(2) and cPLA(2) are differentially regulated and that they selectively participate in retinal signaling in an experimental model resembling AMD. (C) 2012 Elsevier Ltd. All rights reserved.
C1 [Salvador, G. A.] Univ Nacl Sur, Inst Invest Bioquim Bahia Blanca, Ctr Cient & Tecnol CONICET Bahia Blanca, RA-8000 Bahia Blanca, Buenos Aires, Argentina.
   Consejo Nacl Invest Cient & Tecn, RA-8000 Bahia Blanca, Buenos Aires, Argentina.
C3 Consejo Nacional de Investigaciones Cientificas y Tecnicas (CONICET);
   National University of the South; Consejo Nacional de Investigaciones
   Cientificas y Tecnicas (CONICET)
RP Salvador, GA (通讯作者)，Univ Nacl Sur, Inst Invest Bioquim Bahia Blanca, Ctr Cient & Tecnol CONICET Bahia Blanca, Edificio E1,Camino Carrindanga Km 7, RA-8000 Bahia Blanca, Buenos Aires, Argentina.
EM salvador@criba.edu.ar
RI Salvador, Gabriela/GOJ-7718-2022; Uranga, Romina M/A-7660-2011
OI Uranga, Romina Maria/0000-0002-8113-4646; Mateos, Melina
   Valeria/0000-0003-0822-0975
FU Universidad Nacional del Sur; Consejo Nacional de Investigaciones
   Cientificas y Tecnicas (CONICET) [PIP 11220090100687]; Fundacion
   Florencio Fiorini; Agencia Nacional de Promocion Cientifica y
   Tecnologica (ANPCYT) [PICT-2010-0936]
FX This work was supported by Grants from the Universidad Nacional del Sur,
   the Consejo Nacional de Investigaciones Cientificas y Tecnicas [Grant
   No. PIP 11220090100687] (CONICET), the Fundacion Florencio Fiorini and
   the Agencia Nacional de Promocion Cientifica y Tecnologica [Grant No.
   PICT-2010-0936] (ANPCYT).
CR Adibhatla RM, 2010, ANTIOXID REDOX SIGN, V12, P125, DOI [10.1089/ars.2009.2668, 10.1089/ARS.2009.2668]
   Alexander LD, 2004, KIDNEY INT, V65, P551, DOI 10.1111/j.1523-1755.2004.00405.x
   Balsinde J, 2006, BBA-MOL CELL BIOL L, V1761, P1344, DOI 10.1016/j.bbalip.2006.07.013
   Bazan NG, 2009, J LIPID RES, V50, pS400, DOI 10.1194/jlr.R800068-JLR200
   Blasiak J, 2011, FRONT BIOSCI-LANDMRK, V16, P1551, DOI 10.2741/3804
   Burke JE, 2009, J LIPID RES, V50, pS237, DOI 10.1194/jlr.R800033-JLR200
   Burke JE, 2009, CARDIOVASC DRUG THER, V23, P49, DOI 10.1007/s10557-008-6132-9
   Chakraborti S, 2003, CELL SIGNAL, V15, P637, DOI 10.1016/S0898-6568(02)00144-4
   Dunaief JL, 2005, OPHTHALMOLOGY, V112, P1062, DOI 10.1016/j.ophtha.2004.12.029
   Dunaief JL, 2006, INVEST OPHTH VIS SCI, V47, P4660, DOI 10.1167/iovs.06-0568
   Fang IM, 2007, EXP EYE RES, V85, P667, DOI 10.1016/j.exer.2007.07.021
   Farooqui AA, 2006, PHARMACOL REV, V58, P591, DOI 10.1124/pr.58.3.7
   Feder JN, 1998, P NATL ACAD SCI USA, V95, P1472, DOI 10.1073/pnas.95.4.1472
   Feder JN, 1996, NAT GENET, V13, P399, DOI 10.1038/ng0896-399
   FOLCH J, 1957, J BIOL CHEM, V226, P497
   Franchi A, 2000, MEDICINA-BUENOS AIRE, V60, P580
   Garcia-Castineiras S, 2010, EXP EYE RES, V90, P664, DOI 10.1016/j.exer.2010.03.003
   Ghosh M, 2006, PROG LIPID RES, V45, P487, DOI 10.1016/j.plipres.2006.05.003
   Hadziahmetovic M, 2008, INVEST OPHTH VIS SCI, V49, P2728, DOI 10.1167/iovs.07-1472
   Hahn P, 2004, P NATL ACAD SCI USA, V101, P13850, DOI 10.1073/pnas.0405146101
   He XN, 2007, PROG RETIN EYE RES, V26, P649, DOI 10.1016/j.preteyeres.2007.07.004
   Kashiwagi T, 2000, ACTA NEUROBIOL EXP, V60, P9
   Kaufmann WE, 1997, PROSTAG OTH LIPID M, V54, P601, DOI 10.1016/S0090-6980(97)00128-7
   Kishimoto K, 2010, J NEUROINFLAMM, V7, DOI 10.1186/1742-2094-7-42
   Kolko M, 2009, EXP EYE RES, V89, P383, DOI 10.1016/j.exer.2009.04.002
   Kolko M, 2007, INVEST OPHTH VIS SCI, V48, P1401, DOI 10.1167/iovs.06-0865
   LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0
   Leslie CC, 1997, J BIOL CHEM, V272, P16709, DOI 10.1074/jbc.272.27.16709
   Linkous AG, 2010, JNCI-J NATL CANCER I, V102, P1398, DOI 10.1093/jnci/djq290
   LOWRY OH, 1951, J BIOL CHEM, V193, P265
   Lukinova N, 2009, INVEST OPHTH VIS SCI, V50, P1440, DOI 10.1167/iovs.08-2545
   Uranga RM, 2009, TOXICOL SCI, V111, P331, DOI 10.1093/toxsci/kfp152
   Mariggio S, 2006, CELL SIGNAL, V18, P2200, DOI 10.1016/j.cellsig.2006.05.003
   Mateos MV, 2008, NEUROCHEM INT, V53, P199, DOI 10.1016/j.neuint.2008.07.005
   Morgan NV, 2006, NAT GENET, V38, P752, DOI 10.1038/ng1826
   Moses GSD, 2006, J NEUROINFLAMM, V3, DOI 10.1186/1742-2094-3-28
   Nicotra A, 2005, BBA-MOL CELL BIOL L, V1733, P172, DOI 10.1016/j.bbalip.2004.12.017
   Pete MJ, 1996, BBA-LIPID LIPID MET, V1299, P325, DOI 10.1016/0005-2760(95)00225-1
   Salvador GA, 2006, EXP EYE RES, V83, P202, DOI 10.1016/j.exer.2005.12.006
   Salvador GA, 2011, NEUROTOXICOLOGY, V32, P75, DOI 10.1016/j.neuro.2010.11.006
   Stahl W, 2005, BBA-MOL BASIS DIS, V1740, P101, DOI 10.1016/j.bbadis.2004.12.006
   Sun GY, 2007, J NEUROCHEM, V103, P1, DOI 10.1111/j.1471-4159.2007.04670.x
   Sun GY, 2010, NEUROMOL MED, V12, P133, DOI 10.1007/s12017-009-8092-z
   Svensson CI, 2005, NEUROSCIENCE, V133, P543, DOI 10.1016/j.neuroscience.2005.01.024
   Tanito M, 2008, EXP EYE RES, V87, P292, DOI 10.1016/j.exer.2008.06.002
   Uranga RM, 2007, J NEUROSCI RES, V85, P2924, DOI 10.1002/jnr.21406
   Usui S, 2009, MOL THER, V17, P778, DOI 10.1038/mt.2009.47
   Wang JM, 2010, BIOCHIMIE, V92, P611, DOI 10.1016/j.biochi.2010.04.007
   Wong RW, 2007, RETINA-J RET VIT DIS, V27, P997, DOI 10.1097/IAE.0b013e318074c290
   Yagami T, 2002, MOL PHARMACOL, V61, P114, DOI 10.1124/mol.61.1.114
   Yang LP, 2008, J NEUROSCI RES, V86, P910, DOI 10.1002/jnr.21535
   Zhao Z, 2011, J NEUROCHEM, V116, P1057, DOI 10.1111/j.1471-4159.2010.07160.x
   Zhu XD, 2001, J IMMUNOL, V167, P461, DOI 10.4049/jimmunol.167.1.461
NR 53
TC 12
Z9 12
U1 0
U2 3
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0197-0186
EI 1872-9754
J9 NEUROCHEM INT
JI Neurochem. Int.
PD OCT
PY 2012
VL 61
IS 5
BP 749
EP 758
DI 10.1016/j.neuint.2012.06.012
PG 10
WC Biochemistry & Molecular Biology; Neurosciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Neurosciences & Neurology
GA 035KS
UT WOS:000310946100016
PM 22732705
DA 2022-11-30
ER

PT J
AU Csader, S
   Korhonen, S
   Kaarniranta, K
   Schwab, U
AF Csader, Susanne
   Korhonen, Sonja
   Kaarniranta, Kai
   Schwab, Ursula
TI The Effect of Dietary Supplementations on Delaying the Progression of
   Age-Related Macular Degeneration: A Systematic Review and Meta-Analysis
SO NUTRIENTS
LA English
DT Review
DE age-related macular degeneration; omega-3 fatty acids; supplements;
   carotenoids; meta-analysis; xanthophylls
ID PIGMENT OPTICAL-DENSITY; CLINICAL-TRIAL; VISUAL-ACUITY; LUTEIN
   SUPPLEMENTATION; ZEAXANTHIN; PLACEBO; ZINC; AMD; CAROTENOIDS;
   MACULOPATHY
AB Purpose: Age-related macular degeneration (AMD) is a neurodegenerative ophthalmic disease. The purpose of this systematic review (SR) and meta-analysis was to evaluate if dietary supplementation alone or in combinations might delay the progression of any of the stages of AMD. Methods: A SR and meta-analysis identifying cohort studies and randomized controlled trials (RCTs) evaluating the effect of supplements in patients diagnosed with AMD. PubMed, Scopus, Web of Science, CINAHL, and Cochrane were searched through 8th October 2021. Results: Twenty studies, examining 5634 participants ranging from 55 to 80 years, were included in the SR. Eight studies were selected for meta-analysis (414 and 216 subjects in the intervention and control groups). Lutein and zeaxanthin plus n-3 long-chain polyunsaturated fatty acids (n-3 LC-PUFA) supplementation showed significant improvements in best-corrected visual acuity (BCVA) (SMD: -1.99, 95% CI: -3.33, -0.65) compared to the control group. Multifocal electroretinogram results (mfERG) were significantly improved overall (SMD: 4.59, 95% CI: 1.75, 7.43) after lutein plus zeaxanthin supplementation. Conclusions: Combinations of lutein and zeaxanthin with n-3 LC-PUFA might be beneficial in preventing AMD progression and deterioration of visual function. Our results encourage initiating further studies with combinations of n-3 LC-PUFA, lutein, and zeaxanthin especially in early AMD patients.
C1 [Csader, Susanne; Schwab, Ursula] Univ Eastern Finland, Sch Med, Inst Publ Hlth & Clin Nutr, Kuopio 70211, Finland.
   [Korhonen, Sonja] Univ Eastern Finland, Fac Hlth Sci, Sch Pharm, Kuopio 70211, Finland.
   [Kaarniranta, Kai] Univ Eastern Finland, Sch Med, Inst Clin Med, Dept Ophthalmol, Kuopio 70211, Finland.
   [Kaarniranta, Kai] Kuopio Univ Hosp, Dept Ophthalmol, Kuopio 70211, Finland.
   [Schwab, Ursula] Kuopio Univ Hosp, Dept Med Endocrinol & Clin Nutr, Kuopio 70211, Finland.
C3 University of Eastern Finland; University of Eastern Finland; University
   of Eastern Finland; Kuopio University Hospital; University of Eastern
   Finland; Kuopio University Hospital; University of Eastern Finland
RP Schwab, U (通讯作者)，Univ Eastern Finland, Sch Med, Inst Publ Hlth & Clin Nutr, Kuopio 70211, Finland.; Schwab, U (通讯作者)，Kuopio Univ Hosp, Dept Med Endocrinol & Clin Nutr, Kuopio 70211, Finland.
EM ursula.schwab@uef.fi
OI Kaarniranta, Kai/0000-0003-2600-8679; Schwab, Ursula/0000-0003-1838-7525
FU doctoral school of Health Sciences, UEF, Finland; Sokeain Ystavat ry/De
   Blindas Vanner sr foundation; Academy of Finland [333302]; Kuopio
   University Hospital VTR grant [5503770]; Sigrid Juselius Foundation;
   Paivikki, and Sakari Sohlberg Foundation; Finnish Eye Foundation
FX This work has received funding from the doctoral school of Health
   Sciences, UEF, Finland, the Sokeain Ystavat ry/De Blindas Vanner sr
   foundation, the Academy of Finland (333302), the Kuopio University
   Hospital VTR grant (5503770), the Sigrid Juselius Foundation, the
   Paivikki, and Sakari Sohlberg Foundation, and the Finnish Eye
   Foundation.
CR Allegrini D, 2021, J MED FOOD, DOI 10.1089/jmf.2020.0199
   Alpha-Tocopherol Beta Carotene Cancer Prevention Study Group, 1994, N Engl J Med, V330, P1029, DOI 10.1056/NEJM199404143301501
   Awh CC, 2013, OPHTHALMOLOGY, V120, P2317, DOI 10.1016/j.ophtha.2013.07.039
   Bartlett HE, 2007, EUR J CLIN NUTR, V61, P1121, DOI 10.1038/sj.ejcn.1602626
   Beatty S, 2013, OPHTHALMOLOGY, V120, P600, DOI 10.1016/j.ophtha.2012.08.040
   Beck RW, 2003, AM J OPHTHALMOL, V135, P194, DOI 10.1016/S0002-9394(02)01825-1
   Berrow EJ, 2013, BRIT J NUTR, V109, P2008, DOI 10.1017/S0007114512004187
   Blasiak J, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21144994
   Bone RA, 2001, INVEST OPHTH VIS SCI, V42, P235
   Borenstein M, 2010, RES SYNTH METHODS, V1, P97, DOI 10.1002/jrsm.12
   Castenmiller JJM, 1998, ANNU REV NUTR, V18, P19, DOI 10.1146/annurev.nutr.18.1.19
   Chew EY, 2022, JAMA OPHTHALMOL, V140, P692, DOI 10.1001/jamaophthalmol.2022.1640
   Chew EY, 2013, JAMA-J AM MED ASSOC, V309, P2005, DOI 10.1001/jama.2013.4997
   Curcio CA, 2009, PROG RETIN EYE RES, V28, P393, DOI 10.1016/j.preteyeres.2009.08.001
   Dawczynski J, 2013, GRAEF ARCH CLIN EXP, V251, P2711, DOI 10.1007/s00417-013-2376-6
   DeAngelis MM, 2017, HUM MOL GENET, V26, pR45, DOI 10.1093/hmg/ddx228
   Fenwick EK, 2017, JAMA OPHTHALMOL, V135, P469, DOI 10.1001/jamaophthalmol.2017.0266
   Hernandez-Zimbron LF, 2018, OXID MED CELL LONGEV, V2018, DOI 10.1155/2018/8374647
   Fleckenstein M, 2021, NAT REV DIS PRIMERS, V7, DOI 10.1038/s41572-021-00265-2
   French SA, 2019, BMC PUBLIC HEALTH, V19, DOI 10.1186/s12889-019-6546-2
   Garcia-Layana A, 2017, CLIN INTERV AGING, V12, P1579, DOI 10.2147/CIA.S142685
   Garcia-Layana A, 2013, NUTRIENTS, V5, P543, DOI 10.3390/nu5020543
   Gliemann L, 2016, FREE RADICAL BIO MED, V98, P165, DOI 10.1016/j.freeradbiomed.2016.03.037
   Grzybowski A, 2018, OPHTHALMOLOGICA, V239, P181, DOI 10.1159/000486145
   Huang YM, 2015, BRIT J OPHTHALMOL, V99, P371, DOI 10.1136/bjophthalmol-2014-305503
   Jaisankar D, 2018, INDIAN J OPHTHALMOL, V66, P976, DOI 10.4103/ijo.IJO_1265_17
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1417, DOI 10.1001/archopht.119.10.1417
   Klein R, 2006, OPHTHALMOLOGY, V113, P373, DOI 10.1016/j.ophtha.2005.12.013
   Lai TYY, 2007, SURV OPHTHALMOL, V52, P61, DOI 10.1016/j.survophthal.2006.10.005
   Li T., 2021, BMJ, V372, pn160, DOI [10.1136/bmj.n160, DOI 10.1136/BMJ.N71]
   Ma L, 2012, OPHTHALMOLOGY, V119, P2290, DOI 10.1016/j.ophtha.2012.06.014
   Macdonald Geraldine, 2012, Cochrane Database Syst Rev, pCD001930, DOI 10.1002/14651858.CD001930.pub3
   Mcguinness MB, 2017, AM J OPHTHALMOL, V180, P29, DOI 10.1016/j.ajo.2017.05.016
   Metzler M, 2013, BIOFACTORS, V39, P14, DOI 10.1002/biof.1042
   Mitchell P, 2018, LANCET, V392, P1147, DOI 10.1016/S0140-6736(18)31550-2
   Moran NE, 2018, ADV NUTR, V9, P465, DOI 10.1093/advances/nmy025
   Murray IJ, 2013, INVEST OPHTH VIS SCI, V54, P1781, DOI 10.1167/iovs.12-10715
   Nashine S, 2021, CELLS-BASEL, V10, DOI 10.3390/cells10092483
   Newsome DA, 2008, CURR EYE RES, V33, P591, DOI 10.1080/02713680802178437
   Ling CNY, 2021, INT J OBESITY, V45, P1863, DOI 10.1038/s41366-021-00829-y
   Ouzzani M, 2016, SYST REV-LONDON, V5, DOI 10.1186/s13643-016-0384-4
   Page MJ, 2021, PLOS MED, V18, DOI 10.1371/journal.pmed.1003583
   Parisi V, 2008, OPHTHALMOLOGY, V115, P324, DOI 10.1016/j.ophtha.2007.05.029
   Parravano M, 2019, ADV THER, V36, P2493, DOI 10.1007/s12325-019-01016-2
   Peddada KV, 2019, INT OPHTHALMOL, V39, P725, DOI 10.1007/s10792-018-0845-y
   Piatti A, 2020, EUR J OPHTHALMOL, V30, P376, DOI 10.1177/1120672119836007
   Piermarocchi S, 2012, EUR J OPHTHALMOL, V22, P216, DOI 10.5301/ejo.5000069
   Querques G, 2009, EUR J OPHTHALMOL, V19, P100, DOI 10.1177/112067210901900115
   Querques G, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0149219
   Richer Stuart, 2004, Optometry, V75, P216, DOI 10.1016/S1529-1839(04)70049-4
   Rickman CB, 2013, INVEST OPHTH VIS SCI, V54, pORSF68, DOI 10.1167/iovs.13-12757
   Rodrigues EB, 2009, PROG RETIN EYE RES, V28, P117, DOI 10.1016/j.preteyeres.2008.11.005
   Salehi B, 2018, BIOMEDICINES, V6, DOI 10.3390/biomedicines6030091
   Schmidt-Erfurth U, 2014, BRIT J OPHTHALMOL, V98, P1144, DOI 10.1136/bjophthalmol-2014-305702
   Souied EH, 2013, OPHTHALMOLOGY, V120, P1619, DOI 10.1016/j.ophtha.2013.01.005
   Stahl A, 2020, DTSCH ARZTEBL INT, V117, P513, DOI 10.3238/arztebl.2020.0513
   Sterne JAC, 2019, BMJ-BRIT MED J, V366, DOI 10.1136/bmj.l4898
   Sterne JAC, 2016, BMJ-BRIT MED J, V355, DOI 10.1136/bmj.i4919
   Thomas CJ, 2021, MED CLIN N AM, V105, P473, DOI 10.1016/j.mcna.2021.01.003
   van Asten F, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0197670
   van den Berg H, 1999, NUTR REV, V57, P1, DOI 10.1111/j.1753-4887.1999.tb01769.x
   Vishwanathan R, 2013, INVEST OPHTH VIS SCI, V54, P3985, DOI 10.1167/iovs.12-11552
   Warwick A, 2018, EYE, V32, P849, DOI 10.1038/eye.2017.245
   Weigert G, 2011, INVEST OPHTH VIS SCI, V52, P8174, DOI 10.1167/iovs.11-7522
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
   Yip JLY, 2021, BMJ OPEN OPHTHALMOL, V6, DOI 10.1136/bmjophth-2020-000585
   Zhang QY, 2016, INVEST OPHTH VIS SCI, V57, P1276, DOI 10.1167/iovs.15-18637
   Zhang XZ, 2012, AM J OPHTHALMOL, V154, pS53, DOI 10.1016/j.ajo.2011.08.045
NR 68
TC 0
Z9 0
U1 1
U2 1
PU MDPI
PI BASEL
PA ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND
EI 2072-6643
J9 NUTRIENTS
JI Nutrients
PD OCT
PY 2022
VL 14
IS 20
AR 4273
DI 10.3390/nu14204273
PG 19
WC Nutrition & Dietetics
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Nutrition & Dietetics
GA 5P8FU
UT WOS:000873381100001
PM 36296956
OA gold, Green Published
DA 2022-11-30
ER

PT J
AU Geng, ZH
   Walsh, PJ
   Truong, V
   Hill, C
   Ebeling, M
   Kapphahn, RJ
   Montezuma, SR
   Yuan, C
   Roehrich, H
   Ferrington, DA
   Dutton, JR
AF Geng, Zhouhui
   Walsh, Patrick J.
   Truong, Vincent
   Hill, Caitlin
   Ebeling, Mara
   Kapphahn, Rebecca J.
   Montezuma, Sandra R.
   Yuan, Ching
   Roehrich, Heidi
   Ferrington, Deborah A.
   Dutton, James R.
TI Generation of retinal pigmented epithelium from iPSCs derived from the
   conjunctiva of donors with and without age related macular degeneration
SO PLOS ONE
LA English
DT Article
ID PLURIPOTENT STEM-CELLS; DIRECTED DIFFERENTIATION; CLINICAL-TRIALS;
   DERIVATION; EXPRESSION; CULTURE
AB Fidelity in pluripotent stem cell differentiation protocols is necessary for the therapeutic and commercial use of cells derived from embryonic and induced pluripotent stem cells. Recent advances in stem cell technology, especially the widespread availability of a range of chemically defined media, substrates and differentiation components, now allow the design and implementation of fully defined derivation and differentiation protocols intended for replication across multiple research and manufacturing locations. In this report we present an application of these criteria to the generation of retinal pigmented epithelium from iPSCs derived from the conjunctiva of donors with and without age related macular degeneration. Primary conjunctival cells from human donors aged 70-85 years were reprogrammed to derive multiple iPSC lines that were differentiated into functional RPE using a rapid and defined differentiation protocol. The combination of defined iPSC derivation and culture with a defined RPE differentiation protocol, reproducibly generated functional RPE from each donor without requiring protocol adjustments for each individual. This successful validation of a standardized, iPSC derivation and RPE differentiation process demonstrates a practical approach for applications requiring the cost-effective generation of RPE from multiple individuals such as drug testing, population studies or for therapies requiring patient-specific RPE derivations. In addition, conjunctival cells are identified as a practical source of somatic cells for deriving iPSCs from elderly individuals.
C1 [Geng, Zhouhui; Walsh, Patrick J.; Truong, Vincent; Hill, Caitlin; Dutton, James R.] Univ Minnesota, Stem Cell Inst, Minneapolis, MN 55455 USA.
   [Ebeling, Mara; Kapphahn, Rebecca J.; Montezuma, Sandra R.; Yuan, Ching; Ferrington, Deborah A.] Univ Minnesota, Dept Ophthalmol & Visual Neurosci, Minneapolis, MN USA.
   [Roehrich, Heidi] Univ Minnesota, Histol Core Vis Res, Minneapolis, MN USA.
C3 University of Minnesota System; University of Minnesota Twin Cities;
   University of Minnesota System; University of Minnesota Twin Cities;
   University of Minnesota System; University of Minnesota Twin Cities
RP Dutton, JR (通讯作者)，Univ Minnesota, Stem Cell Inst, Minneapolis, MN 55455 USA.
EM dutto015@umn.edu
OI Ferrington, Deborah/0000-0003-2561-7464
FU Elaine and Robert Larson Endowed Vision Research Chair; Regenerative
   Medicine Minnesota [MRM 2015 5337]; Research to Prevent Blindness; Core
   Grant for Vision Research from the National Eye Institute [P30-EY11374]
FX This work was supported by funds from the Elaine and Robert Larson
   Endowed Vision Research Chair (to DAF) and an anonymous donor for
   Macular Degeneration Research. This work was supported in part by a
   grant from Regenerative Medicine Minnesota (MRM 2015 5337 to DAF and
   JRD), an unrestricted grant from Research to Prevent Blindness to the
   Department of Ophthalmology and Visual Neurosciences and the Core Grant
   for Vision Research from the National Eye Institute (P30-EY11374). The
   funders had no role in study design, data collection and analysis,
   decision to publish, or preparation of the manuscript.
CR Buchholz DE, 2013, STEM CELL TRANSL MED, V2, P384, DOI 10.5966/sctm.2012-0163
   Carpenter MK, 2015, STEM CELL TRANSL MED, V4, P381, DOI 10.5966/sctm.2014-0202
   Daley GQ, 2016, STEM CELL REP, V6, P787, DOI 10.1016/j.stemcr.2016.05.001
   Decanini A, 2007, AM J OPHTHALMOL, V143, P607, DOI 10.1016/j.ajo.2006.12.006
   Ferrer M, 2014, STEM CELL TRANSL MED, V3, P911, DOI 10.5966/sctm.2013-0192
   French A, 2015, STEM CELL TRANSL MED, V4, P217, DOI 10.5966/sctm.2014-0233
   Idelson M, 2009, CELL STEM CELL, V5, P396, DOI 10.1016/j.stem.2009.07.002
   Kamao H, 2014, STEM CELL REP, V2, P205, DOI 10.1016/j.stemcr.2013.12.007
   Karakousis PC, 2001, MOL VIS, V7, P154
   Kawasaki H, 2002, P NATL ACAD SCI USA, V99, P1580, DOI 10.1073/pnas.032662199
   Klimanskaya I, 2004, CLONING STEM CELLS, V6, P217, DOI 10.1089/1536230042323420
   Leach LL, 2015, INVEST OPHTH VIS SCI, V56, P1002, DOI 10.1167/iovs.14-15835
   Lebkowski Jane, 2011, Regen Med, V6, P11, DOI 10.2217/rme.11.77
   Maruotti J, 2015, P NATL ACAD SCI USA, V112, P10950, DOI 10.1073/pnas.1422818112
   Maruotti J, 2013, STEM CELL TRANSL MED, V2, P341, DOI 10.5966/sctm.2012-0106
   Miyagishima KJ, 2016, STEM CELLS TRANSL ME
   Nordgaard CL, 2006, INVEST OPHTH VIS SCI, V47, P815, DOI 10.1167/iovs.05-0976
   Olsen TW, 2004, INVEST OPHTH VIS SCI, V45, P4484, DOI 10.1167/iovs.04-0342
   Parinot C, 2014, JOVE-J VIS EXP, DOI 10.3791/52100
   Parr AM, 2016, METHODS MOL BIOL, V1357, P221, DOI 10.1007/7651_2015_243
   Pennington BO, 2015, STEM CELL TRANSL MED, V4, P165, DOI 10.5966/sctm.2014-0179
   Priest CA, 2015, REGEN MED, V10, P939, DOI 10.2217/rme.15.57
   Salomonis N, 2016, STEM CELL REP, V7, P110, DOI 10.1016/j.stemcr.2016.05.006
   Schulz TC, 2015, STEM CELL TRANSL MED, V4, P927, DOI 10.5966/sctm.2015-0058
   Schwartz SD, 2014, LANCET
   Schwartz SD, 2012, LANCET, V379, P713, DOI 10.1016/S0140-6736(12)60028-2
   Strauss O, 2005, PHYSIOL REV, V85, P845, DOI 10.1152/physrev.00021.2004
   Terluk MR, 2015, J NEUROSCI, V35, P7304, DOI 10.1523/JNEUROSCI.0190-15.2015
   Trokovic R, 2015, STEM CELL RES, V15, P254, DOI 10.1016/j.scr.2015.06.001
   Voltzke K., 2016, CELLULAR THERAPY PRI, P771
   Whiting P, 2015, PHILOS T R SOC B, V370, DOI 10.1098/rstb.2014.0375
   Yang J, 2014, GRAEF ARCH CLIN EXP, V252, P423, DOI 10.1007/s00417-014-2575-9
   Zarbin M, 2016, TRENDS MOL MED, V22, P115, DOI 10.1016/j.molmed.2015.12.007
NR 33
TC 19
Z9 20
U1 0
U2 7
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD MAR 10
PY 2017
VL 12
IS 3
AR e0173575
DI 10.1371/journal.pone.0173575
PG 20
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA EN6CJ
UT WOS:000396091800052
PM 28282420
OA gold, Green Published, Green Submitted
DA 2022-11-30
ER

PT J
AU Xin, XL
   Sun, YY
   Li, SR
   Xu, H
   Zhang, DF
AF Xin, Xueling
   Sun, Yongye
   Li, Shiru
   Xu, Hui
   Zhang, Dongfeng
TI AGE-RELATED MACULAR DEGENERATION AND THE RISK OF ALL-CAUSE AND
   CARDIOVASCULAR MORTALITY A Meta-Analysis of Cohort Studies
SO RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES
LA English
DT Article
DE age-related macular degeneration; mortality; meta-analysis
ID CORONARY-HEART-DISEASE; VISUAL IMPAIRMENT; VISION IMPAIRMENT; EYE
   DISEASES; HIP FRACTURE; DEPRESSION; MACULOPATHY; POPULATION; PREVALENCE;
   PROGRESSION
AB Purpose: We evaluated the association between age-related macular degeneration (AMD) and the risk of all-cause and cardiovascular mortality by meta-analyses of data from prospective studies.
   Methods: A literature search was performed in PubMed, Web of Science, Embase, Cocharne Library, and China National Knowledge Infrastructure for relevant articles published up to December 2016. We estimated hazard ratios with 95% confidence intervals with fixed-effect models and conducted meta-regression to explore the potential sources of heterogeneity. Small-study effect was estimated by Egger's test and funnel plot.
   Results: We identified 13 population-based prospective cohort studies that examined the relationship between AMD and all-cause and cardiovascular mortality. Overall, the hazard ratios (95% confidence intervals) of all-cause mortality and cardiovascular mortality associated with any AMD were 1.15 (1.05-1.27) and 1.05 (95% confidence intervals: 0.87-1.26), respectively. The risk of all-cause mortality and cardiovascular mortality associated with early AMD were 1.08 (1.00-1.18) and 1.05 (0.89-1.24), and the associations with late AMD were 1.23 (1.11-1.36) and 1.28 (1.04-1.57), respectively. No evidence of small-study effect was found.
   Conclusion: This meta-analysis indicated that AMD, especially late AMD, was associated with increased risk of all-cause mortality and cardiovascular mortality based on comparisons with people who did not have AMD and who were of similar age and sex.
C1 [Xin, Xueling; Li, Shiru; Xu, Hui; Zhang, Dongfeng] Qingdao Univ, Sch Publ Hlth, Dept Epidemiol & Hlth Stat, Qingdao, Shandong, Peoples R China.
   [Sun, Yongye] Qingdao Univ, Inst Med Nutr, Sch Publ Hlth, Qingdao, Shandong, Peoples R China.
C3 Qingdao University; Qingdao University
RP Zhang, DF (通讯作者)，Qingdao Univ, Coll Publ Hlth, Dept Epidemiol & Hlth Stat, 38 Dengzhou Rd, Qingdao 266021, Shandong, Peoples R China.
EM zhangdf1961@126.com
CR Ahto M, 2007, INT J GERIATR PSYCH, V22, P757, DOI 10.1002/gps.1735
   BIRD AEC, 1995, SURV OPHTHALMOL, V39, P367, DOI 10.1016/S0039-6257(05)80092-X
   Borger PH, 2003, OPHTHALMOLOGY, V110, P1292, DOI 10.1016/S0161-6420(03)00450-0
   Brody BL, 2001, OPHTHALMOLOGY, V108, P1893, DOI 10.1016/S0161-6420(01)00754-0
   Buch H, 2005, OPHTHALMOLOGY, V112, P305, DOI 10.1016/j.ophtha.2004.08.025
   Buch H, 2001, ACTA OPHTHALMOL SCAN, V79, P441, DOI 10.1034/j.1600-0420.2001.790503.x
   Buch H, 2001, OPHTHALMOLOGY, V108, P2347, DOI 10.1016/S0161-6420(01)00823-5
   Casten R, 2008, J VISUAL IMPAIR BLIN, V102, P591, DOI 10.1177/0145482X0810201003
   Chiang PPC, 2013, OPHTHALMOLOGY, V120, P415, DOI 10.1016/j.ophtha.2012.07.077
   CUMMINGS SR, 1995, NEW ENGL J MED, V332, P767, DOI 10.1056/NEJM199503233321202
   Egger M, 1997, BMJ-BRIT MED J, V315, P629, DOI 10.1136/bmj.315.7109.629
   FELSON DT, 1989, J AM GERIATR SOC, V37, P495, DOI 10.1111/j.1532-5415.1989.tb05678.x
   Fisher DE, 2015, OPHTHALMOLOGY, V122, P382, DOI 10.1016/j.ophtha.2014.08.006
   Gangnon RE, 2012, ARCH OPHTHALMOL-CHIC, V130, P1169, DOI 10.1001/archophthalmol.2012.693
   Gopinath B, 2016, MATURITAS, V84, P63, DOI 10.1016/j.maturitas.2015.11.001
   Higgins JPT, 2004, STAT MED, V23, P1663, DOI 10.1002/sim.1752
   Higgins JPT, 2003, BRIT MED J, V327, P557, DOI 10.1136/bmj.327.7414.557
   Higgins JPT, 2002, STAT MED, V21, P1539, DOI 10.1002/sim.1186
   Khanna RC, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0078002
   Kishan AU, 2011, SURV OPHTHALMOL, V56, P195, DOI 10.1016/j.survophthal.2010.08.008
   Lamoureux EL, 2008, OPHTHALMOLOGY, V115, P1973, DOI 10.1016/j.ophtha.2008.05.005
   Lim LS, 2012, LANCET, V379, P1728, DOI 10.1016/S0140-6736(12)60282-7
   McCarty CA, 2001, BRIT J OPHTHALMOL, V85, P322, DOI 10.1136/bjo.85.3.322
   Moher D, 2009, PLOS MED, V6, DOI [10.1136/bmj.b4037, 10.1371/journal.pmed.1000097]
   NEVITT MC, 1989, JAMA-J AM MED ASSOC, V261, P2663, DOI 10.1001/jama.261.18.2663
   Pathai S, 2013, AGEING RES REV, V12, P490, DOI 10.1016/j.arr.2012.11.002
   Pedula KL, 2015, J AM GERIATR SOC, V63, P910, DOI 10.1111/jgs.13405
   Penninx BWJH, 2001, ARCH GEN PSYCHIAT, V58, P221, DOI 10.1001/archpsyc.58.3.221
   Pulska T, 1999, BRIT MED J, V318, P432, DOI 10.1136/bmj.318.7181.432
   Siantar RG, 2015, SCI REP-UK, V5, DOI 10.1038/srep16304
   Snow K K, 1999, Ophthalmic Epidemiol, V6, P125, DOI 10.1076/opep.6.2.125.1558
   Thiagarajan M, 2005, ARCH OPHTHALMOL-CHIC, V123, P1397, DOI 10.1001/archopht.123.10.1397
   TINETTI ME, 1986, AM J MED, V80, P429, DOI 10.1016/0002-9343(86)90717-5
   Wang JJ, 2007, OPHTHALMOLOGY, V114, P92, DOI 10.1016/j.ophtha.2006.07.017
   Wang JJ, 1999, INVEST OPHTH VIS SCI, V40, P12
   Wang XZ, 2014, OPHTHALMOLOGY, V121, P1837, DOI 10.1016/j.ophtha.2014.03.017
   Wong TY, 2007, OPHTHALMOLOGY, V114, P86, DOI 10.1016/j.ophtha.2006.06.039
   Wong TY, 2006, ANN INTERN MED, V145, P98, DOI 10.7326/0003-4819-145-2-200607180-00007
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
   Xu L, 2008, OPHTHALMOLOGICA, V222, P378, DOI 10.1159/000151468
NR 40
TC 9
Z9 9
U1 0
U2 9
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0275-004X
EI 1539-2864
J9 RETINA-J RET VIT DIS
JI Retin.-J. Retin. Vitr. Dis.
PD MAR
PY 2018
VL 38
IS 3
BP 497
EP 507
DI 10.1097/IAE.0000000000001741
PG 11
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)
SC Ophthalmology
GA GP2AB
UT WOS:000440619200011
PM 28665868
DA 2022-11-30
ER

PT J
AU Holz, FG
   Tadayoni, R
   Beatty, S
   Berger, AR
   Cereda, MG
   Hykin, P
   Hoyng, CB
   Wittrup-Jensen, K
   Altemark, A
   Nilsson, J
   Kim, K
   Sivaprasad, S
AF Holz, Frank G.
   Tadayoni, Ramin
   Beatty, Stephen
   Berger, Alan R.
   Cereda, Matteo G.
   Hykin, Philip
   Hoyng, Carel B.
   Wittrup-Jensen, Kim
   Altemark, Andreas
   Nilsson, Jonas
   Kim, Kun
   Sivaprasad, Sobha
TI Identifying Predictors of Anti-VEGF Treatment Response in Patients with
   Neovascular Age-Related Macular Degeneration through Discriminant and
   Principal Component Analysis
SO OPHTHALMIC RESEARCH
LA English
DT Article
DE AURA; Intravitreal ranibizumab; Neovascular age-related macular
   degeneration
ID INTRAVITREAL RANIBIZUMAB; VISUAL-ACUITY; OUTCOMES; LIFE; AMD
AB Objective: AURA was an observational study that monitored visual acuity outcomes following ranibizumab use in neovascular age-related macular degeneration patients over 2 years. The aim of this analysis was to identify factors that were predictive of visual acuity outcomes in AURA. Methods: The correlation between the baseline characteristics, the use of resources and the visual acuity outcomes in AURA was explored using principal component analysis (PCA) and partial least-squares-discriminant analysis (PLS-DA). The response variables analysed were mean change in visual acuity over 2 years (analysed via PCA) and no decline in visual acuity at 2 years compared with baseline (analysed via PLS-DA). Results: The AURA dataset comprised 2,227 patients and 132 variables. Using PCA and PLS-DA, we found that the number of ranibizumab injections, clinic and monitoring visits, number of optical coherence tomography scans and ophthalmoscopies correlated with a change in visual acuity at Years 1 and 2, and are therefore key drivers of treatment success. Conclusion: This is a novel approach to graphically explore relationships between multiple correlated covariates and outcomes in real-life ophthalmology studies. It identified a number of variables that are positively linked with treatment outcomes. (C) 2016 S. Karger AG, Basel
C1 [Holz, Frank G.] Univ Bonn, Dept Ophthalmol, Bonn, Germany.
   [Wittrup-Jensen, Kim; Altemark, Andreas] Bayer Pharmaceut, Berlin, Germany.
   [Tadayoni, Ramin] Univ Paris 07, Hop Lariboisiere, AP HP, Dept Ophthalmol,Sorbonne Paris Cite, Paris, France.
   [Beatty, Stephen] Inst Eye Surg, Dept Ophthalmol, Waterford, Ireland.
   [Berger, Alan R.] Univ Toronto, Dept Ophthalmol & Vis Sci, Toronto, ON, Canada.
   [Berger, Alan R.] St Michaels Hosp, Toronto, ON, Canada.
   [Cereda, Matteo G.] Univ Milan, Luigi Sacco Hosp, Dept Biomed & Clin Sci Luigi Sacco, Milan, Italy.
   [Hykin, Philip; Sivaprasad, Sobha] Moorfields Eye Hosp, NIHR Biomed Ctr Res Ophthalmol, London, England.
   [Sivaprasad, Sobha] Kings Coll Hosp London, Dept Ophthalmol, London, England.
   [Hoyng, Carel B.] Radboud Univ Nijmegen Med Ctr, Dept Ophthalmol, Nijmegen, Netherlands.
   [Nilsson, Jonas] Real World Strategy & Analyt, Mapi Grp, Stockholm, Sweden.
   [Kim, Kun] AstraZeneca Nord Balt, Hlth Econ, Sodertalje, Sweden.
C3 University of Bonn; Bayer AG; Bayer Healthcare Pharmaceuticals;
   Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire
   Lariboisiere-Fernand-Widal - APHP; UDICE-French Research Universities;
   Universite Paris Cite; University of Toronto; University of Toronto;
   University Toronto Affiliates; Saint Michaels Hospital Toronto;
   University of Milan; Luigi Sacco Hospital; University of London;
   University College London; Moorfields Eye Hospital NHS Foundation Trust;
   King's College Hospital NHS Foundation Trust; King's College Hospital;
   Radboud University Nijmegen; AstraZeneca
RP Sivaprasad, S (通讯作者)，Kings Coll Hosp London, Denmark Hill, London SE5 9RS, England.
EM senswathi@aol.com
RI Sivaprasad, S./D-6876-2015
OI Sivaprasad, S./0000-0001-8952-0659
FU Bayer Pharmaceuticals
FX Medical writing assistance was provided by PAREXEL and was funded by
   Bayer Pharmaceuticals.
CR Bloch SB, 2013, ACTA OPHTHALMOL, V91, P42, DOI 10.1111/j.1755-3768.2011.02268.x
   Bro R, 2014, ANAL METHODS-UK, V6, P2812, DOI 10.1039/c3ay41907j
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Cohen SY, 2013, RETINA-J RET VIT DIS, V33, P474, DOI 10.1097/IAE.0b013e31827b6324
   Holz FG, 2016, EYE, V30, P1063, DOI 10.1038/eye.2016.90
   Holz FG, 2016, BRIT J OPHTHALMOL, V100, P1623, DOI 10.1136/bjophthalmol-2015-308166
   Holz FG, 2015, BRIT J OPHTHALMOL, V99, P220, DOI 10.1136/bjophthalmol-2014-305327
   Martin DF, 2012, OPHTHALMOLOGY, V119, DOI 10.1016/j.ophtha.2012.03.053
   Rakic JM, 2013, CLIN OPHTHALMOL, V7, P1849, DOI 10.2147/OPTH.S49385
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Sedghipour MR, 2012, CLIN OPHTHALMOL, V6, P1499, DOI 10.2147/OPTH.S34907
   Wolf A, 2014, GRAEF ARCH CLIN EXP, V252, P647, DOI 10.1007/s00417-013-2562-6
   Ziemssen F, 2015, OPHTHALMOLOGE, V112, P246, DOI 10.1007/s00347-014-3217-7
NR 13
TC 5
Z9 5
U1 0
U2 2
PU KARGER
PI BASEL
PA ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND
SN 0030-3747
EI 1423-0259
J9 OPHTHALMIC RES
JI Ophthalmic Res.
PY 2017
VL 58
IS 1
BP 49
EP 55
DI 10.1159/000449001
PG 7
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA EX6OX
UT WOS:000403362700008
PM 27832661
DA 2022-11-30
ER

PT J
AU Tatlipinar, S
   Shah, SM
   Campochiaro, PA
   Nguyen, QD
AF Tatlipinar, Sinan
   Shah, Syed Mahmood
   Campochiaro, Peter A.
   Nguyen, Quan Dong
TI Intraobserver repeatability of automated versus adjusted optical
   coherence tomography measurements in patients with neovascular
   age-related macular degeneration
SO OPHTHALMOLOGICA
LA English
DT Article
DE neovascular age-related macular degeneration; optical coherence
   tomography; repeatability, automated vs. adjusted optical coherence
   tomography measurements
ID CHOROIDAL NEOVASCULARIZATION; REPRODUCIBILITY; EDEMA
AB Aim: To assess the intraobserver repeatability of automated versus adjusted optical coherence tomography ( OCT) measurements in patients with neovascular age- related macular degeneration ( NVAMD). Methods: Ten eyes with NVAMD from 10 consecutive patients underwent two OCT measurements within 5 days by a single operator. Automated and adjusted central 1- mm foveal thickness and automated and adjusted total macular volume were measured in each study eye. The term 'adjusted' refers to manually corrected values, in which the interface landmarks for measurements are selected by the operator using Stratus (R) scan profiling and custom software. Bland- Altman method and bootstrap comparison of intraclass correlations ( ICCs) were used for repeatability analysis. Results: Bland- Altman comparison did not reveal any statistically significant difference in any parameter, when results at first and second examination were compared ( p > 0.05), indicating that the repeated measurements are similar. Further analysis was conducted using the bootstrap comparison of ICCs. The difference between adjusted and automated foveal thickness ICCs ( r = 0.945 and 0.635, respectively) was significant ( p = 0.031), indicating higher repeatability for adjusted foveal thickness. The ICCs for adjusted and automated total macular volume ( r = 0.873 and 0.863, respectively) showed no statistically significant difference ( p = 0.881). Conclusion: The repeatability of adjusted retinal thickness measurements, in which the errors of retinal boundary detection by OCT analysis software is corrected by the operator using scan profiling, is found to be higher than that of automated ones in this small group of NVAMD patients when performed by a single experienced operator. Copyright (c) 2006 S. Karger AG, Basel.
C1 Johns Hopkins Univ, Sch Med, Wilmer Eye Inst, Retina Serv, Baltimore, MD 21218 USA.
   Johns Hopkins Univ, Sch Med, Dept Neurosci, Baltimore, MD 21218 USA.
   Pamukkale Univ, Sch Med, Dept Ophthalmol, Denizli, Turkey.
C3 Johns Hopkins University; Johns Hopkins Medicine; Johns Hopkins
   University; Pamukkale University
RP Nguyen, QD (通讯作者)，Johns Hopkins Univ Hosp, Wilmer Eye Inst, 600 N Wolfe St,Maumenee 721, Baltimore, MD 21287 USA.
EM qnguyen4@jhmi.edu
RI Shah, Syed/K-2672-2018
FU NEI NIH HHS [EY 13552] Funding Source: Medline; NATIONAL EYE INSTITUTE
   [K23EY013552] Funding Source: NIH RePORTER
CR Campochiaro PA, 2004, INVEST OPHTH VIS SCI, V45, P922, DOI 10.1167/iovs.03-0955
   Ge J, 1999, Yan Ke Xue Bao, V15, P153
   Giovannini A, 1999, BRIT J OPHTHALMOL, V83, P438, DOI 10.1136/bjo.83.4.438
   Gurses-Ozden R, 2004, J GLAUCOMA, V13, P238
   Hee MR, 1996, OPHTHALMOLOGY, V103, P1260, DOI 10.1016/S0161-6420(96)30512-5
   HEE MR, 1995, ARCH OPHTHALMOL-CHIC, V113, P325, DOI 10.1001/archopht.1995.01100030081025
   HUANG D, 1991, SCIENCE, V254, P1178, DOI 10.1126/science.1957169
   KLEIN R, 1992, OPHTHALMOLOGY, V99, P933
   LEIBOWITZ HM, 1980, SURV OPHTHALMOL S, V24, P428
   Massin P, 2001, ARCH OPHTHALMOL-CHIC, V119, P1135, DOI 10.1001/archopht.119.8.1135
   PULIAFITO CA, 1995, OPHTHALMOLOGY, V102, P217
   Rogers AH, 2002, AM J OPHTHALMOL, V134, P566, DOI 10.1016/S0002-9394(02)01566-0
   Sadda SR, 2006, OPHTHALMOLOGY, V113, P285, DOI 10.1016/j.ophtha.2005.10.005
   Ting TD, 2002, ARCH OPHTHALMOL-CHIC, V120, P731
   Van Kerckhoven W, 2001, Bull Soc Belge Ophtalmol, P75
NR 15
TC 7
Z9 7
U1 0
U2 2
PU KARGER
PI BASEL
PA ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND
SN 0030-3755
J9 OPHTHALMOLOGICA
JI Ophthalmologica
PY 2007
VL 221
IS 4
BP 227
EP 232
DI 10.1159/000101923
PG 6
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 181KE
UT WOS:000247434800002
PM 17579287
DA 2022-11-30
ER

PT J
AU Feigl, B
   Brown, B
   Lovie-Kitchin, J
   Swann, P
AF Feigl, B
   Brown, B
   Lovie-Kitchin, J
   Swann, P
TI Adaptation responses in early age-related maculopathy
SO INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE
LA English
DT Article
ID MEDIATED MULTIFOCAL ELECTRORETINOGRAM; CHOROIDAL BLOOD-FLOW; RETINAL
   FUNCTION; FELLOW EYES; CONE; ERG; TOPOGRAPHY; PERFUSION; DRUSEN;
   SENSITIVITY
AB PURPOSE. To investigate the global-flash multifocal electroretinogram (mfERG) in early age-related maculopathy ( ARM).
   METHODS. Thirty-two eyes from 20 healthy control subjects and 12 age-matched subjects with early ARM were investigated with the conventional and the global-flash mfERG. Early ARM subjects were graded according to an international grading system. The conventional mfERG consisted of 103 hexagons flickering according to a pseudorandom m-sequence. The global-flash mfERG paradigm used four frames starting with the conventional m-sequence stimulation, followed by a dark frame, a global flash, and another dark frame. The responses include a direct response (DR) and a later induced component (IC). The first-order kernel peak-to-trough response densities of the conventional mfERG (N1P1), the global-flash DR and IC, and the implicit times of the conventional P1, global-flash DR, and IC peak were analyzed after averaging the results into five groups according to five field locations: a central area and four quadrants.
   RESULTS. There was a significant reduction of the global-flash mfERG DR response density ( P <= 0.05) in the early ARM group compared with the control group. Neither the IC response density nor DR and IC implicit times were significantly impaired. However, the superior retina showed longer implicit times than did the inferior retina for the DR in the early ARM group. There was no significant correlation between funduscopic features and the central averaged responses of the global-flash mfERG ( for the DR response density: r = - 0.19, P = 0.3, or for the DR implicit time: r = - 0.18, P = 0.3). None of the conventional mfERG parameters was significantly different between the two groups.
   CONCLUSIONS. The global-flash mfERG detects deficits in early ARM before the conventional mfERG. Retinal ischemia may play a role in producing function impairment in ARM.
C1 Queensland Univ Technol, Sch Optometry, Ctr Hlth Res, Brisbane, Qld, Australia.
C3 Queensland University of Technology (QUT)
RP Feigl, B (通讯作者)，Queensland Univ Technol, Ctr Hlth Res, Sch Optometry, Victoria Pk Rd, Kelvin Grove, Qld 4059, Australia.
EM b.feigl@qut.edu.au
OI Feigl, Beatrix/0000-0001-7198-7373
CR Age-Related Eye Dis Study Res Grp, 2001, AM J OPHTHALMOL, V132, P668
   BAILEY IL, 1976, AM J OPTOM PHYS OPT, V53, P740
   Bearse MA, 2004, INVEST OPHTH VIS SCI, V45, P296, DOI 10.1167/iovs.03-0424
   Bearse MA, 1996, J OPT SOC AM A, V13, P634
   BROWN B, 1986, AM J OPTOM PHYS OPT, V63, P450
   Chen CZ, 2004, DOC OPHTHALMOL, V109, P1
   Chung HS, 1999, INVEST OPHTH VIS SCI, V40, P2448
   Ciulla TA, 1999, AM J OPHTHALMOL, V128, P75, DOI 10.1016/S0002-9394(99)00061-6
   Ciulla TA, 2001, ACTA OPHTHALMOL SCAN, V79, P108, DOI 10.1034/j.1600-0420.2001.079002108.x
   Cringle SJ, 2002, INVEST OPHTH VIS SCI, V43, P1922
   Del Priore LV, 2002, INVEST OPHTH VIS SCI, V43, P3312
   Feigl B, 2005, EYE, V19, P431, DOI 10.1038/sj.eye.6701503
   Feigl B, 2004, CURR EYE RES, V29, P327, DOI 10.1080/02713680490516198
   FEIGL B, 2004, EYE             0924
   Fortune B, 2002, INVEST OPHTH VIS SCI, V43, P2638
   FRIEDMAN E, 1995, OPHTHALMOLOGY, V102, P640, DOI 10.1016/S0161-6420(95)30974-8
   Gerth C, 2003, ARCH OPHTHALMOL-CHIC, V121, P1404, DOI 10.1001/archopht.121.10.1404
   GREENSTEIN VC, 1989, INVEST OPHTH VIS SCI, V30, P1732
   Grunwald JE, 1998, INVEST OPHTH VIS SCI, V39, P385
   Grunwald JE, 2005, INVEST OPHTH VIS SCI, V46, P1033, DOI 10.1167/iovs.04-1050
   HAYREH SS, 1990, EYE, V4, P273, DOI 10.1038/eye.1990.39
   Hood DC, 1999, VISION RES, V39, P2285, DOI 10.1016/S0042-6989(98)00296-X
   Hood DC, 2002, INVEST OPHTH VIS SCI, V43, P1673
   Hood DC, 2000, PROG RETIN EYE RES, V19, P607, DOI 10.1016/S1350-9462(00)00013-6
   Huang Shizhou, 2000, Documenta Ophthalmologica, V101, P115
   Kassoff A, 2001, AM J OPHTHALMOL, V131, P167
   Li J, 2001, BRIT J OPHTHALMOL, V85, P287, DOI 10.1136/bjo.85.3.287
   Linsenmeier RA, 2000, INVEST OPHTH VIS SCI, V41, P3117
   PALMOWSKI A, 2001, OSA TECHNICAL DIGEST, P32
   Palmowski AM, 2002, OPHTHALMIC RES, V34, P83, DOI 10.1159/000048333
   Palmowski AM, 1997, INVEST OPHTH VIS SCI, V38, P2586
   Parks S, 1996, BRIT J OPHTHALMOL, V80, P831, DOI 10.1136/bjo.80.9.831
   PAULEIKHOFF D, 1990, OPHTHALMOLOGY, V97, P171
   PAULEIKHOFF D, 1990, AM J OPHTHALMOL, V109, P211, DOI 10.1016/S0002-9394(14)75989-6
   Penrose PJ, 2003, RETINA-J RET VIT DIS, V23, P503, DOI 10.1097/00006982-200308000-00010
   Phipps JA, 2003, INVEST OPHTH VIS SCI, V44, P2277, DOI 10.1167/iovs.02-0769
   Remky A, 2005, BRIT J OPHTHALMOL, V89, P464, DOI 10.1136/bjo.2004.050260
   Remky A, 2001, BRIT J OPHTHALMOL, V85, P1432, DOI 10.1136/bjo.85.12.1432
   REMULLA JFC, 1995, BRIT J OPHTHALMOL, V79, P558, DOI 10.1136/bjo.79.6.558
   SANDBERG MA, 1993, INVEST OPHTH VIS SCI, V34, P3477
   Sarks SH, 1999, BRIT J OPHTHALMOL, V83, P358, DOI 10.1136/bjo.83.3.358
   Seeliger MW, 1998, INVEST OPHTH VIS SCI, V39, P718
   Shimada Y, 2005, GRAEF ARCH CLIN EXP, V243, P132, DOI 10.1007/s00417-004-1072-y
   Shimada Y, 2001, BRIT J OPHTHALMOL, V85, P414, DOI 10.1136/bjo.85.4.414
   SUNNESS JS, 1989, APPL OPTICS, V28, P1158, DOI 10.1364/AO.28.001158
   SUNNESS JS, 1988, ARCH OPHTHALMOL-CHIC, V106, P1081, DOI 10.1001/archopht.1988.01060140237032
   SUTTER E, 1999, OSA TECHNICAL DIGEST, P52
   SUTTER EE, 1992, VISION RES, V32, P433, DOI 10.1016/0042-6989(92)90235-B
   Sutter Erich, 2000, Documenta Ophthalmologica, V100, P49, DOI 10.1023/A:1002702917233
   Tzekov RT, 2004, GRAEF ARCH CLIN EXP, V242, P549, DOI 10.1007/s00417-004-0892-0
   Verdon WA, 1998, DOC OPHTHALMOL, V95, P73, DOI 10.1023/A:1001732613424
NR 51
TC 23
Z9 24
U1 0
U2 3
PU ASSOC RESEARCH VISION OPHTHALMOLOGY INC
PI ROCKVILLE
PA 12300 TWINBROOK PARKWAY, ROCKVILLE, MD 20852-1606 USA
SN 0146-0404
EI 1552-5783
J9 INVEST OPHTH VIS SCI
JI Invest. Ophthalmol. Vis. Sci.
PD DEC
PY 2005
VL 46
IS 12
BP 4722
EP 4727
DI 10.1167/iovs.05-0795
PG 6
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 988FV
UT WOS:000233578600053
PM 16303971
OA Green Submitted
DA 2022-11-30
ER

PT J
AU Broadhead, GK
   Hong, T
   Grigg, JR
   McCluskey, P
   Schlub, TE
   Spooner, K
   Chang, AA
AF Broadhead, Geoffrey K.
   Hong, Thomas
   Grigg, John R.
   McCluskey, Peter
   Schlub, Timothy E.
   Spooner, Kimberly
   Chang, Andrew A.
TI Does functional assessment predict everyday visual functioning? Visual
   function testing and quality of life in mild/moderate age-related
   macular degeneration
SO INTERNATIONAL OPHTHALMOLOGY
LA English
DT Article
DE Age-related macular degeneration; Visual function questionnaire-25;
   Quality of life; Perimetry
ID MULTIFOCAL ELECTRORETINOGRAPHY; FLICKER PERIMETRY; ISCEV STANDARD; EYE
   DISEASE; MICROPERIMETRY; QUESTIONNAIRE; ASSOCIATION; IMPACT
AB Purpose To prospectively assess correlations between self-reported vision-related quality of life (VR-QoL) and clinical functional assessments in mild/moderate age-related macular degeneration (AMD). Methods Cross-sectional analysis of 64 participants with bilateral mild/moderate AMD. Microperimetry (MP), flicker perimetry (FP), multifocal electroretinogram (mfERG) findings, best-corrected visual acuity (BCVA) and the National Eye Institute Visual-Function Questionnaire-25 (NEI VFQ-25) were assessed for correlation between clinical testing results and NEI VFQ-25 findings. Results MP findings in the better eye were weakly correlated with NEI VFQ-25 subscales for colour, general, near and distance vision (p < 0.05 andR(2) < 0.3 for all). FP findings and mfERG response density were not correlated with any subscale, apart from mfERG ring 1 response density and general health (p < 0.05,R-2 = 0.41). mfERG latency was weakly correlated with general vision in the better eye in rings 2 and 4 (p < 0.05,R-2 < 0.2). Conclusion Functional assessment in mild/moderate AMD is at best, weakly correlated with patient-reported VR-QoL. Despite the growing awareness of the importance of VR-QoL outcomes in improving patient outcomes and satisfaction, surrogate markers of these outcomes remain elusive, and testing of VR-QoL in regular clinical settings remains difficult.
C1 [Broadhead, Geoffrey K.; Grigg, John R.; McCluskey, Peter; Spooner, Kimberly; Chang, Andrew A.] Univ Sydney, Save Sight Inst, Sydney, NSW, Australia.
   [Broadhead, Geoffrey K.; Hong, Thomas; Spooner, Kimberly; Chang, Andrew A.] Sydney Inst Vis Sci, Sydney, NSW, Australia.
   [Broadhead, Geoffrey K.; Hong, Thomas; Spooner, Kimberly; Chang, Andrew A.] Sydney Retina Clin & Day Surg, Level 13,187 Macquarie St, Sydney, NSW 2000, Australia.
   [Schlub, Timothy E.] Univ Sydney, Sydney Sch Publ Hlth, Sydney, NSW, Australia.
C3 University of Sydney; University of Sydney
RP Chang, AA (通讯作者)，Sydney Retina Clin & Day Surg, Level 13,187 Macquarie St, Sydney, NSW 2000, Australia.
EM achang@sydneyretina.com.au
CR Age-Related Eye Dis Study Res Grp, 2001, AM J OPHTHALMOL, V132, P668
   Brown GC, 2000, CAN J OPHTHALMOL, V35, P127, DOI 10.1016/S0008-4182(00)80005-8
   Chandramohan A, 2016, RETINA-J RET VIT DIS, V36, P1021, DOI 10.1097/IAE.0000000000001002
   Chun YS, 2019, ACTA OPHTHALMOL, V97, pE772, DOI 10.1111/aos.14020
   Clemons TE, 2003, ARCH OPHTHALMOL-CHIC, V121, P211
   Denniss J, 2018, INVEST OPHTH VIS SCI, V59, P4590, DOI 10.1167/iovs.18-24861
   Gin TJ, 2011, INVEST OPHTH VIS SCI, V52, P9267, DOI 10.1167/iovs.11-8517
   Hirneiss C, 2014, CLIN OPHTHALMOL, V8, P1703, DOI 10.2147/OPTH.S64200
   Hochberg C, 2012, INVEST OPHTH VIS SCI, V53, P3201, DOI 10.1167/iovs.12-9469
   Hood DC, 2012, DOC OPHTHALMOL, V124, P1, DOI 10.1007/s10633-011-9296-8
   Khanna CL, 2018, JAMA OPHTHALMOL, V136, P348, DOI 10.1001/jamaophthalmol.2018.0012
   Klein R, 2013, OPHTHALMOLOGY, V120, P1210, DOI 10.1016/j.ophtha.2012.11.041
   Marmor MF, 2009, DOC OPHTHALMOL, V118, P69, DOI 10.1007/s10633-008-9155-4
   McClure ME, 2000, BRIT J OPHTHALMOL, V84, P244, DOI 10.1136/bjo.84.3.244
   Parisi V, 2007, RETINA-J RET VIT DIS, V27, P879, DOI 10.1097/IAE.0b013e318042d6aa
   Phipps JA, 2004, INVEST OPHTH VIS SCI, V45, P3355, DOI 10.1167/iovs.04-0253
   Pilotto E, 2013, CAN J OPHTHALMOL, V48, P386, DOI 10.1016/j.jcjo.2013.03.022
   Popescu ML, 2011, INVEST OPHTH VIS SCI, V52, P7168, DOI 10.1167/iovs.11-7564
   Roh M, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0196481
   Scott IU, 2017, AM J OPHTHALMOL, V184, P147, DOI 10.1016/j.ajo.2017.10.008
   Thompson AC, 2018, INVEST OPHTH VIS SCI, V59, P289, DOI 10.1167/iovs.17-22528
   Trillo AH, 2012, INVEST OPHTH VIS SCI, V53, P4234, DOI 10.1167/iovs.12-9580
   Wu ZC, 2015, INVEST OPHTH VIS SCI, V56, P115, DOI 10.1167/iovs.14-15614
   Wu ZC, 2014, INVEST OPHTH VIS SCI, V55, P6431, DOI 10.1167/iovs.14-14407
NR 24
TC 1
Z9 1
U1 0
U2 3
PU SPRINGER
PI DORDRECHT
PA VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS
SN 0165-5701
EI 1573-2630
J9 INT OPHTHALMOL
JI Int. Ophthalmol.
PD DEC
PY 2020
VL 40
IS 12
BP 3241
EP 3249
DI 10.1007/s10792-020-01508-z
EA JUL 2020
PG 9
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA PB5UO
UT WOS:000548461500001
PM 32666168
DA 2022-11-30
ER

PT J
AU Yamashita, M
   Matsumoto, M
   Hayakawa, M
   Sakai, K
   Fujimura, Y
   Ogata, N
AF Yamashita, Mariko
   Matsumoto, Masanori
   Hayakawa, Masaki
   Sakai, Kazuya
   Fujimura, Yoshihiro
   Ogata, Nahoko
TI Intravitreal injection of aflibercept, an anti-VEGF antagonist,
   down-regulates plasma von Willebrand factor in patients with age-related
   macular degeneration
SO SCIENTIFIC REPORTS
LA English
DT Article
ID COMPLEMENT FACTOR-H; ENDOTHELIAL GROWTH-FACTOR; FACTOR MULTIMERS; GENE
   POLYMORPHISMS; VONWILLEBRAND-FACTOR; JAPANESE POPULATION; RISK-FACTORS;
   RANIBIZUMAB; DISEASE; ASSOCIATION
AB We investigated the association between von Willebrand factor (VWF) and exudative age-related macular degeneration (AMD) in 114 Japanese patients. Intravitreal injection of vascular endothelial growth factor (VEGF) inhibitor is the most effective therapy for AMD. Therefore, we analyzed changes of VWF antigen (VWF:Ag) and VWF multimers (VWFMs) after intravitreal injection of aflibercept, an anti-VEGF antagonist. The relationship between polymorphisms in complement factor H (p.Y402H and p.I62V) and AMD was previously reported. In our patients, p.I62V, but not p.Y402H, was significantly associated with an increased risk of AMD. Pre-treatment plasma levels of VWF: Ag in patients with AMD were significantly higher than those in controls. Unusually large VWFMs (UL-VWFMs) were detected in the majority of AMD patients with concurrent vitreous or subretinal hemorrhage. After intravitreal injection of aflibercept, plasma levels of VWF: Ag and VEGF-A were significantly decreased. UL-VWFMs disappeared after aflibercept injection in three cases, but persisted even 1 month after injection in the other five cases. In conclusion, plasma VWF: Ag levels were significantly elevated in patients with AMD, and decreased after intravitreal aflibercept injection. VWF may play an important role in the pathophysiology of AMD, and aflibercept might improve AMD by reducing plasma levels of VWF in addition to VEGF-A.
C1 [Yamashita, Mariko] Nara Med Univ, Dept Ophthalmol, Kashihara, Nara, Japan.
   [Matsumoto, Masanori; Hayakawa, Masaki; Sakai, Kazuya] Nara Med Univ, Dept Blood Transfus Med, Kashihara, Nara, Japan.
   [Fujimura, Yoshihiro] Japanese Red Cross Kinki Block Blood Ctr, Ibaraki, Japan.
C3 Nara Medical University; Nara Medical University
RP Matsumoto, M (通讯作者)，Nara Med Univ, Dept Blood Transfus Med, Kashihara, Nara, Japan.
EM mmatsumo@naramed-u.ac.jp
RI Sakai, Kazuya/M-6602-2019
OI Sakai, Kazuya/0000-0003-0523-7931
FU Ministry of Education, Culture, Sports, Science and Technology of Japan;
   Takeda Science Foundation; Grants-in-Aid for Scientific Research
   [15K10843] Funding Source: KAKEN
FX This study was partially supported by grants from the Ministry of
   Education, Culture, Sports, Science and Technology of Japan; and the
   Takeda Science Foundation. The authors thank to Drs. Ayami Isonishi and
   Yoko Yoshida for their technical assistance.
CR Ahn JK, 2009, AM J OPHTHALMOL, V148, P718, DOI 10.1016/j.ajo.2009.06.012
   AIELLO LP, 1995, P NATL ACAD SCI USA, V92, P10457, DOI 10.1073/pnas.92.23.10457
   Aoki A, 2015, INVEST OPHTH VIS SCI, V56, P2580, DOI 10.1167/iovs.14-16339
   Bressler Neil M, 2004, JAMA, V291, P1900, DOI 10.1001/jama.291.15.1900
   BUDDE U, 1990, THROMB HAEMOSTASIS, V63, P312
   Dong JF, 2002, BLOOD, V100, P4033, DOI 10.1182/blood-2002-05-1401
   Edwards AO, 2005, SCIENCE, V308, P421, DOI 10.1126/science.1110189
   Feng SJ, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0073715
   GILL JC, 1987, BLOOD, V69, P1691
   Gotoh N, 2006, HUM GENET, V120, P139, DOI 10.1007/s00439-006-0187-0
   Haines JL, 2005, SCIENCE, V308, P419, DOI 10.1126/science.1110359
   Hogg RE, 2008, OPHTHALMOLOGY, V115, P1046, DOI 10.1016/j.ophtha.2007.07.031
   Kato S, 2006, TRANSFUSION, V46, P1444, DOI 10.1111/j.1537-2995.2006.00914.x
   Kim NR, 2008, INVEST OPHTH VIS SCI, V49, P2071, DOI 10.1167/iovs.07-1195
   Kitchens JW, 2016, OPHTHALMOLOGY, V123, P1511, DOI 10.1016/j.ophtha.2016.02.046
   Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557
   Kliffen M, 1997, BRIT J OPHTHALMOL, V81, P154, DOI 10.1136/bjo.81.2.154
   Lim LS, 2012, LANCET, V379, P1728, DOI 10.1016/S0140-6736(12)60282-7
   Lip PL, 2001, OPHTHALMOLOGY, V108, P705, DOI 10.1016/S0161-6420(00)00663-1
   Matsumoto M, 2005, PATHOPHYSIOL HAEMO T, V34, P35, DOI 10.1159/000088546
   Moake JL, 2002, NEW ENGL J MED, V347, P589, DOI 10.1056/NEJMra020528
   Ng TK, 2008, INVEST OPHTH VIS SCI, V49, P3312, DOI 10.1167/iovs.07-1517
   Nolasco L, 2013, ARTERIOSCL THROM VAS, V33, P2524, DOI 10.1161/ATVBAHA.113.302280
   Ohkuma Y, 2014, CLIN OPHTHALMOL, V8, P143, DOI 10.2147/OPTH.S56483
   Okamoto H, 2006, MOL VIS, V12, P156
   Papadopoulos N, 2012, ANGIOGENESIS, V15, P171, DOI 10.1007/s10456-011-9249-6
   Randi AM, 2017, J THROMB HAEMOST, V15, P13, DOI 10.1111/jth.13551
   Rondaij MG, 2006, ARTERIOSCL THROM VAS, V26, P1002, DOI 10.1161/01.ATV.0000209501.56852.6c
   RUGGERI ZM, 1980, J CLIN INVEST, V65, P1318, DOI 10.1172/JCI109795
   Sadler JE, 1998, ANNU REV BIOCHEM, V67, P395, DOI 10.1146/annurev.biochem.67.1.395
   Sawada O, 2010, RETINA-J RET VIT DIS, V30, P1034, DOI 10.1097/IAE.0b013e3181ce74c8
   Schmid MK, 2015, BRIT J OPHTHALMOL, V99, P141, DOI 10.1136/bjophthalmol-2014-305149
   Takahashi Kanji, 2008, Nippon Ganka Gakkai Zasshi, V112, P1076
   Wang XY, 2014, AM J OPHTHALMOL, V158, P738, DOI 10.1016/j.ajo.2014.06.009
   Warren CM, 2003, ELECTROPHORESIS, V24, P1695, DOI 10.1002/elps.200305392
   Yamashiro K, 2011, INVEST OPHTH VIS SCI, V52, P8780, DOI 10.1167/iovs.11-8205
   Yasuda M, 2009, OPHTHALMOLOGY, V116, P2135, DOI 10.1016/j.ophtha.2009.04.017
   Yoshida I, 2014, GRAEF ARCH CLIN EXP, V252, P1483, DOI 10.1007/s00417-014-2717-0
   Zehetner C, 2015, ACTA OPHTHALMOL, V93, pE154, DOI 10.1111/aos.12604
NR 39
TC 6
Z9 6
U1 0
U2 0
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 2045-2322
J9 SCI REP-UK
JI Sci Rep
PD JAN 24
PY 2018
VL 8
AR 1491
DI 10.1038/s41598-018-19473-0
PG 9
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA FT4VT
UT WOS:000423154000021
PM 29367644
OA gold, Green Published, Green Submitted
DA 2022-11-30
ER

PT J
AU de Jong, S
   de Breuk, A
   Bakker, B
   Katti, S
   Hoyng, CB
   Nilsson, SC
   Blom, AM
   van den Heuvel, LP
   den Hollander, AI
   Volokhina, EB
AF de Jong, Sarah
   de Breuk, Anita
   Bakker, Bjorn
   Katti, Suresh
   Hoyng, Carel B.
   Nilsson, Sara C.
   Blom, Anna M.
   van den Heuvel, Lambert P.
   den Hollander, Anneke I.
   Volokhina, Elena B.
TI Functional Analysis of Variants in Complement Factor I Identified in
   Age-Related Macular Degeneration and Atypical Hemolytic Uremic Syndrome
SO FRONTIERS IN IMMUNOLOGY
LA English
DT Article
DE complement factor I; genetic variants; age-related macular degeneration;
   atypical hemolytic uremic syndrome; functional analysis
ID RARE GENETIC-VARIANTS; CFI GENE; MUTATIONS; MACULOPATHY; ACTIVATION;
   DISEASES
AB Complement factor I (FI) is a central inhibitor of the complement system, and impaired FI function increases complement activation, contributing to diseases such as age-related macular degeneration (AMD) and atypical hemolytic uremic syndrome (aHUS). Genetic variation in complement factor I (CFI) has been identified in both AMD and aHUS, with more than half of these variants leading to reduced FI secretion levels. For many of the variants with normal FI secretion, however, functional implications are not yet known. Here we studied 11 rare missense variants, with FI secretion levels comparable to wildtype, but a predicted damaging effects based on the Combined Annotation Dependent Depletion (CADD) score. Three variants (p.Pro50Ala, p.Arg339Gln, and p.Ser570Thr) were analyzed in plasma and serum samples of carriers affected by AMD. All 11 variants (nine for the first time in this study) were recombinantly expressed and the ability to degrade C3b was studied with the C3b degradation assay. The amount of degradation was determined by measuring the degradation product iC3b with ELISA. Eight of 11 (73%) mutant proteins (p.Pro50Ala, p.Arg339Gln, p.Ile340Thr, p.Gly342Glu, p.Gly349Arg, p.Arg474Gln, p.Gly487Cys, and p.Gly512Ser) showed significantly impaired C3b degradation, and were therefore classified as likely pathogenic. Our data indicate that genetic variants in CFI with a CADD score >20 are likely to affect FI function, and that monitoring iC3b in a degradation assay is a useful tool to establish the pathogenicity of CFI variants in functional studies.
C1 [de Jong, Sarah; de Breuk, Anita; Bakker, Bjorn; Hoyng, Carel B.; den Hollander, Anneke I.] Radboud Univ Nijmegen Med Ctr, Donders Inst Brain Cognit & Behav, Dept Ophthalmol, Nijmegen, Netherlands.
   [Katti, Suresh] Gemini Therapeut Inc, Cambridge, MA USA.
   [Nilsson, Sara C.; Blom, Anna M.] Lund Univ, Dept Translat Med, Malmo, Sweden.
   [van den Heuvel, Lambert P.; Volokhina, Elena B.] Radboud Univ Nijmegen Med Ctr, Amalia Childrens Hosp, Nijmegen, Netherlands.
   [van den Heuvel, Lambert P.; Volokhina, Elena B.] Radboud Univ Nijmegen Med Ctr, Radboud Inst Mol Life Sci, Nijmegen, Netherlands.
   [van den Heuvel, Lambert P.; Volokhina, Elena B.] Radboud Univ Nijmegen Med Ctr, Dept Lab Med, Nijmegen, Netherlands.
   [den Hollander, Anneke I.] Radboud Univ Nijmegen Med Ctr, Dept Human Genet, Nijmegen, Netherlands.
C3 Radboud University Nijmegen; Lund University; Radboud University
   Nijmegen; Radboud University Nijmegen; Radboud University Nijmegen;
   Radboud University Nijmegen
RP Volokhina, EB (通讯作者)，Radboud Univ Nijmegen Med Ctr, Amalia Childrens Hosp, Nijmegen, Netherlands.; Volokhina, EB (通讯作者)，Radboud Univ Nijmegen Med Ctr, Radboud Inst Mol Life Sci, Nijmegen, Netherlands.; Volokhina, EB (通讯作者)，Radboud Univ Nijmegen Med Ctr, Dept Lab Med, Nijmegen, Netherlands.
RI Blom, Anna/AFS-7343-2022; Blom, Anna/B-9607-2009; Blom,
   Anna/AFS-7369-2022
OI Blom, Anna/0000-0002-1348-1734; 
CR Bergseth G, 2013, MOL IMMUNOL, V56, P232, DOI 10.1016/j.molimm.2013.05.221
   Bienaime F, 2010, KIDNEY INT, V77, P339, DOI 10.1038/ki.2009.472
   BIRD AEC, 1995, SURV OPHTHALMOL, V39, P367, DOI 10.1016/S0039-6257(05)80092-X
   Bresin E, 2013, J AM SOC NEPHROL, V24, P475, DOI 10.1681/ASN.2012090884
   Corominas J, 2018, OPHTHALMOLOGY, V125, P1433, DOI 10.1016/j.ophtha.2018.03.040
   de Breuk A, 2021, OPHTHALMOLOGY, V128, P1604, DOI 10.1016/j.ophtha.2020.07.037
   de Jong S, 2020, HUM MOL GENET, V29, P2313, DOI 10.1093/hmg/ddaa114
   Fritsche LG, 2016, NAT GENET, V48, P134, DOI 10.1038/ng.3448
   Geerlings MJ, 2017, JAMA OPHTHALMOL, V135, P39, DOI 10.1001/jamaophthalmol.2016.4604
   Haerynck F, 2013, J CLIN IMMUNOL, V33, P1293, DOI 10.1007/s10875-013-9944-8
   Hallam TM, 2020, INVEST OPHTH VIS SCI, V61, DOI 10.1167/iovs.61.6.18
   Java A, 2020, TRANSL VIS SCI TECHN, V9, DOI 10.1167/tvst.9.9.37
   Kavanagh D, 2008, MOL IMMUNOL, V45, P95, DOI 10.1016/j.molimm.2007.05.004
   Kavanagh D, 2015, HUM MOL GENET, V24, P3861, DOI 10.1093/hmg/ddv091
   Khan AH, 2021, HUM MUTAT, V42, P1139, DOI 10.1002/humu.24242
   KLEIN R, 1991, OPHTHALMOLOGY, V98, P1128
   Krieger E, 2014, BIOINFORMATICS, V30, P2981, DOI 10.1093/bioinformatics/btu426
   Manders P., 2018, OPEN J BIORESOUR, V5, P2, DOI [10.5334/ojb.36, DOI 10.5334/OJB.36]
   Merle NS, 2015, FRONT IMMUNOL, V6, DOI 10.3389/fimmu.2015.00262
   Mitchell P, 2018, LANCET, V392, P1147, DOI 10.1016/S0140-6736(18)31550-2
   Nilsson SC, 2007, MOL IMMUNOL, V44, P1835, DOI 10.1016/j.molimm.2006.10.005
   Nilsson SC, 2011, MOL IMMUNOL, V48, P1611, DOI 10.1016/j.molimm.2011.04.004
   Nilsson SC, 2010, J BIOL CHEM, V285, P6235, DOI 10.1074/jbc.M109.097212
   Nilsson SC, 2010, EUR J IMMUNOL, V40, P172, DOI 10.1002/eji.200939280
   Noris M, 2010, AM J TRANSPLANT, V10, P1517, DOI 10.1111/j.1600-6143.2010.03156.x
   Noris M, 2015, AM J KIDNEY DIS, V66, P359, DOI 10.1053/j.ajkd.2015.03.040
   Ristau T, 2014, INVEST OPHTH VIS SCI, V55, P210, DOI 10.1167/iovs.13-13248
   Saksens NTM, 2016, JAMA OPHTHALMOL, V134, P287, DOI 10.1001/jamaophthalmol.2015.5592
   Szarvas N, 2016, MOL IMMUNOL, V71, P10, DOI 10.1016/j.molimm.2016.01.003
   van de Ven JPH, 2013, NAT GENET, V45, P813, DOI 10.1038/ng.2640
   van Leeuwen R, 2003, OPHTHALMOLOGY, V110, P1540, DOI 10.1016/S0161-6420(03)00501-3
   Wong EKS, 2018, SEMIN IMMUNOPATHOL, V40, P49, DOI 10.1007/s00281-017-0663-8
   WONG MJ, 1995, MOL IMMUNOL, V32, P379, DOI 10.1016/0161-5890(94)00151-P
   Xue XG, 2017, NAT STRUCT MOL BIOL, V24, P643, DOI 10.1038/nsmb.3427
NR 34
TC 0
Z9 0
U1 0
U2 1
PU FRONTIERS MEDIA SA
PI LAUSANNE
PA AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND
SN 1664-3224
J9 FRONT IMMUNOL
JI Front. Immunol.
PD JAN 5
PY 2022
VL 12
AR 789897
DI 10.3389/fimmu.2021.789897
PG 10
WC Immunology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Immunology
GA YK4RC
UT WOS:000745201000001
PM 35069568
OA Green Published, gold
DA 2022-11-30
ER

PT J
AU Keenan, TD
   Klein, B
   Agron, E
   Chew, EY
   Cukras, CA
   Wong, WT
AF Keenan, Tiarnan D.
   Klein, Brandon
   Agron, Elvira
   Chew, Emily Y.
   Cukras, Catherine A.
   Wong, Wai T.
TI CHOROIDAL THICKNESS AND VASCULARITY VARY WITH DISEASE SEVERITY AND
   SUBRETINAL DRUSENOID DEPOSIT PRESENCE IN NONADVANCED AGE-RELATED MACULAR
   DEGENERATION
SO RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES
LA English
DT Article
DE age-related macular degeneration; choroidal thickness; choroidal
   vascularity index; reticular pseudodrusen; subretinal drusenoid deposits
ID OPTICAL COHERENCE TOMOGRAPHY; RETICULAR PSEUDODRUSEN; HEALTHY EYES;
   GEOGRAPHIC ATROPHY; BINARIZATION; ASSOCIATION; VOLUME; SEX
AB Purpose: To investigate how choroidal features vary with age-related macular degeneration (AMD) severity in early-intermediate disease. Methods: One hundred fifty-one eyes of 151 participants >50 years with no to intermediate AMD were analyzed with enhanced depth imaging optical coherence tomography. Mean macular choroidal thickness (CT), choroidal vascular thickness (CV), and choroidal vascularity index (CVI) were determined, and statistical associations were calculated. Results: Decreased CT and CV were associated with increased axial length (+30 and +14 mu m/mm, respectively; P < 0.0001 each), whereas decreased CVI was associated with increased age (+0.1%/year; P = 0.004). Compared with eyes with no/early AMD (Group 0), eyes with large drusen without late AMD in the fellow eye (Group 1) showed increased CV and CVI (+22 mu m, P = 0.03 and +2.2%, P = 0.02, respectively). However, eyes with large drusen and late AMD in the fellow eye (Group 2) resembled Group 0. Eyes with subretinal drusenoid deposits demonstrated lower mean CT/CV/CVI than Group 0 (-57 mu m, P = 0.02; -31 mu m, P = 0.02; -3.6%, P = 0.007). Conclusion: Early AMD progression seems associated with biphasic alterations in choroidal dimensions, increasing during early drusen formation but decreasing thereafter. Subretinal drusenoid deposits are independently associated with marked reductions in all choroidal parameters. Changes in choroidal vascular anatomy may drive or reflect the pathobiology of AMD progression.
C1 [Keenan, Tiarnan D.; Agron, Elvira; Chew, Emily Y.; Cukras, Catherine A.] NEI, Div Epidemiol & Clin Applicat, NIH, Bethesda, MD 20892 USA.
   [Klein, Brandon; Wong, Wai T.] NEI, Unit Neuron Glia Interact Retinal Dis, NIH, 6 Ctr Dr,6-217, Bethesda, MD 20892 USA.
C3 National Institutes of Health (NIH) - USA; NIH National Eye Institute
   (NEI); National Institutes of Health (NIH) - USA; NIH National Eye
   Institute (NEI)
RP Cukras, CA (通讯作者)，NEI, Div Epidemiol & Clin Applicat, NIH, Bethesda, MD 20892 USA.; Wong, WT (通讯作者)，NEI, Unit Neuron Glia Interact Retinal Dis, NIH, 6 Ctr Dr,6-217, Bethesda, MD 20892 USA.
EM cukrasc@nei.nih.gov; wongw@nei.nih.gov
RI Wong, Wai/B-6118-2017
OI Wong, Wai/0000-0003-0681-4016
FU National Eye Institute Intramural Research Program - Bayer Global
   Ophthalmology Awards Program; NATIONAL EYE INSTITUTE [ZIAEY000509]
   Funding Source: NIH RePORTER
FX Supported by the National Eye Institute Intramural Research Program. The
   sponsor or funding organization had no role in the design or conduct of
   this research. T. D. Keenan was partly funded by an award from the Bayer
   Global Ophthalmology Awards Program.
CR Abbey AM, 2015, OSLI RETINA, V46, P18, DOI 10.3928/23258160-20150101-03
   Adhi M, 2014, AM J OPHTHALMOL, V157, P1272, DOI 10.1016/j.ajo.2014.02.034
   Agrawal R, 2016, SCI REP-UK, V6, DOI 10.1038/srep21090
   Alten F, 2014, INVEST OPHTH VIS SCI, V55, P6073, DOI 10.1167/iovs.13-13804
   Barteselli G, 2012, OPHTHALMOLOGY, V119, P2572, DOI 10.1016/j.ophtha.2012.06.065
   Broadhead GK, 2017, OPHTHALMIC RES, V58, P27, DOI 10.1159/000464447
   Chen FK, 2012, INVEST OPHTH VIS SCI, V53, P975, DOI 10.1167/iovs.11-8771
   Chirco KR, 2017, EYE, V31, P10, DOI 10.1038/eye.2016.216
   Chung SE, 2011, OPHTHALMOLOGY, V118, P840, DOI 10.1016/j.ophtha.2010.09.012
   Congdon N, 2004, ARCH OPHTHALMOL-CHIC, V122, P477
   Corvi F, 2017, BRIT J OPHTHALMOL, V101, P348, DOI 10.1136/bjophthalmol-2016-308548
   Esmaeelpour M, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0099690
   Flamendorf J, 2015, OPHTHALMOLOGY, V122, P2053, DOI 10.1016/j.ophtha.2015.06.023
   Fritsche LG, 2016, NAT GENET, V48, P134, DOI 10.1038/ng.3448
   Fritsche LG, 2014, ANNU REV GENOM HUM G, V15, P151, DOI 10.1146/annurev-genom-090413-025610
   Fujiwara T, 2009, AM J OPHTHALMOL, V148, P445, DOI 10.1016/j.ajo.2009.04.029
   Garg A, 2013, INVEST OPHTH VIS SCI, V54, P7075, DOI 10.1167/iovs.13-12474
   GROSSNIKLAUS HE, 1992, RETINA-J RET VIT DIS, V12, P127, DOI 10.1097/00006982-199212020-00009
   Haas P, 2014, INVEST OPHTH VIS SCI, V55, P2674, DOI 10.1167/iovs.13-13338
   Jackson Gregory R, 2008, J Ocul Biol Dis Infor, V1, P7, DOI 10.1007/s12177-008-9002-6
   Jonas JB, 2014, RETINA-J RET VIT DIS, V34, P1149, DOI 10.1097/IAE.0000000000000035
   Kim SW, 2011, RETINA-J RET VIT DIS, V31, P1904, DOI 10.1097/IAE.0b013e31821801c5
   Lains I, 2017, AM J OPHTHALMOL, V180, P55, DOI 10.1016/j.ajo.2017.05.021
   Lee JY, 2013, INVEST OPHTH VIS SCI, V54, P7812, DOI 10.1167/iovs.13-12284
   Lindner M, 2015, INVEST OPHTH VIS SCI, V56, P875, DOI 10.1167/iovs.14-14933
   Manjunath V, 2011, AM J OPHTHALMOL, V152, P663, DOI 10.1016/j.ajo.2011.03.008
   Masuda N, 2017, CLIN OPHTHALMOL, V11, P791, DOI 10.2147/OPTH.S135160
   Mullins RF, 2014, ADV EXP MED BIOL, V801, P283, DOI 10.1007/978-1-4614-3209-8_36
   Ooto S, 2015, CURR EYE RES, V40, P213, DOI 10.3109/02713683.2014.952828
   Querques G, 2012, INVEST OPHTH VIS SCI, V53, P1258, DOI 10.1167/iovs.11-8907
   Seddon JM, 2016, JAMA OPHTHALMOL, V134, P1272, DOI 10.1001/jamaophthalmol.2016.3519
   Sigler EJ, 2013, INVEST OPHTH VIS SCI, V54, P6307, DOI 10.1167/iovs.13-12653
   Sonoda S, 2015, AM J OPHTHALMOL, V159, P1123, DOI 10.1016/j.ajo.2015.03.005
   Sonoda S, 2014, INVEST OPHTH VIS SCI, V55, P3893, DOI 10.1167/iovs.14-14447
   Spaide RF, 2008, AM J OPHTHALMOL, V146, P496, DOI 10.1016/j.ajo.2008.05.032
   Spaide RF, 2018, RETINA-J RET VIT DIS, V38, P708, DOI 10.1097/IAE.0000000000001689
   Spaide RF, 2013, RETINA-J RET VIT DIS, V33, P1800, DOI 10.1097/IAE.0b013e31829c3765
   Switzer DW, 2012, RETINA-J RET VIT DIS, V32, P1265, DOI 10.1097/IAE.0b013e31824453ac
   Tan KA, 2016, SURV OPHTHALMOL, V61, P566, DOI 10.1016/j.survophthal.2016.02.007
   Thorell MR, 2015, OSLI RETINA, V46, P513, DOI 10.3928/23258160-20150521-02
   Ueda-Arakawa N, 2014, AM J OPHTHALMOL, V157, P994, DOI 10.1016/j.ajo.2014.01.018
   Whitmore SS, 2015, PROG RETIN EYE RES, V45, P1, DOI 10.1016/j.preteyeres.2014.11.005
   Wood A, 2011, AM J OPHTHALMOL, V152, P1030, DOI 10.1016/j.ajo.2011.05.021
   Yiu G, 2015, AM J OPHTHALMOL, V159, P617, DOI 10.1016/j.ajo.2014.12.010
   Yiu G, 2014, JAMA OPHTHALMOL, V132, P174, DOI 10.1001/jamaophthalmol.2013.7288
   Yun C, 2016, INVEST OPHTH VIS SCI, V57, P6604, DOI 10.1167/iovs.16-19989
   Zeng SM, 2016, J PATHOL, V238, P446, DOI 10.1002/path.4669
   Zhao J, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-22745-4
   Zheng F, 2016, INVEST OPHTH VIS SCI, V57, P6256, DOI 10.1167/iovs.16-20161
NR 49
TC 25
Z9 25
U1 0
U2 3
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0275-004X
EI 1539-2864
J9 RETINA-J RET VIT DIS
JI Retin.-J. Retin. Vitr. Dis.
PD APR
PY 2020
VL 40
IS 4
BP 632
EP 642
DI 10.1097/IAE.0000000000002434
PG 11
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA LB2WI
UT WOS:000524497800005
PM 30664125
OA Green Accepted
DA 2022-11-30
ER

PT J
AU Gorski, M
   Gunther, F
   Winkler, TW
   Weber, BHF
   Heid, IM
AF Gorski, Mathias
   Guenther, Felix
   Winkler, Thomas W.
   Weber, Bernhard H. F.
   Heid, Iris M.
TI On the differences between mega- and meta-imputation and analysis
   exemplified on the genetics of age-related macular degeneration
SO GENETIC EPIDEMIOLOGY
LA English
DT Article
DE age-related macular degeneration; genome-wide association studies;
   Genotype-imputation; mega-analysis; meta-analysis
ID GENOME-WIDE ASSOCIATION; METAANALYSIS; VISUALIZATION; EFFICIENCY
AB While current genome-wide association analyses often rely on meta-analysis of study-specific summary statistics, individual participant data (IPD) from multiple studies increase options for modeling. When multistudy IPD is available, however, it is unclear whether this data is to be imputed and modeled across all participants (mega-imputation and mega-analysis) or study-specifically (meta-imputation and meta-analysis). Here, we investigated different approaches toward imputation and analysis using 52,189 subjects from 25 studies of the International Age-related Macular Degeneration (AMD) Genomics Consortium including, 16,144 AMD cases and 17,832 controls for association analysis. From 27,448,454 genetic variants after 1,000-Genomes-based imputation, mega-imputation yielded similar to 400,000 more variants with high imputation quality (mostly rare variants) compared to meta-imputation. For AMD signal detection (P < 5 x 10(-8)) in mega-imputed data, most loci were detected with mega-analysis without adjusting for study membership (40 loci, including 34 known); we considered these loci genuine, since genetic effects and P-values were comparable across analyses. In meta-imputed data, we found 31 additional signals, mostly near chromosome tails or reference panel gaps, which disappeared after accounting for interaction of whole-genome amplification (WGA) with study membership or after excluding studies with WGA-participants. For signal detection with multistudy IPD, we recommend mega-imputation and mega-analysis, with meta-imputation followed by meta-analysis being a computationally appealing alternative.
C1 [Gorski, Mathias; Guenther, Felix; Winkler, Thomas W.; Heid, Iris M.] Univ Regensburg, Dept Genet Epidemiol, Franz Josef Strauss Allee 11, D-93053 Regensburg, Germany.
   [Guenther, Felix] Ludwig Maximilians Univ Munchen, Dept Stat, Stat Consulting Unit StaBLab, Munich, Germany.
   [Weber, Bernhard H. F.] Univ Regensburg, Inst Human Genet, Regensburg, Germany.
C3 University of Regensburg; University of Munich; University of Regensburg
RP Heid, IM (通讯作者)，Univ Regensburg, Dept Genet Epidemiol, Franz Josef Strauss Allee 11, D-93053 Regensburg, Germany.
EM iris.heid@klinik.uni-regensburg.de
OI Winkler, Thomas/0000-0003-0292-5421
FU Deutsche Forschungsgemeinschaft [DFG HE3690/5-1]; National Institutes of
   Health; Advancing genomics through the AMD Genomics Consortium
   [RES511967, NIH-2017 R01]
FX Deutsche Forschungsgemeinschaft, Grant/Award Number: DFG HE3690/5-1;
   National Institutes of Health; Advancing genomics through the AMD
   Genomics Consortium, Grant/Award Numbers: RES511967, NIH-2017 R01
CR Bycroft C, 2018, NATURE, V562, P203, DOI 10.1038/s41586-018-0579-z
   Delaneau O, 2012, NAT METHODS, V9, P179, DOI [10.1038/NMETH.1785, 10.1038/nmeth.1785]
   Devlin B, 1999, BIOMETRICS, V55, P997, DOI 10.1111/j.0006-341X.1999.00997.x
   FIRTH D, 1993, BIOMETRIKA, V80, P27, DOI 10.1093/biomet/80.1.27
   Fritsche LG, 2016, NAT GENET, V48, P134, DOI 10.1038/ng.3448
   Greiser KH, 2014, EUR J EPIDEMIOL, V29, P371, DOI 10.1007/s10654-014-9890-7
   Klarin D, 2018, NAT GENET, V50, P1514, DOI 10.1038/s41588-018-0222-9
   Lappalainen I, 2015, NAT GENET, V47, P692, DOI 10.1038/ng.3312
   Li Y, 2010, GENET EPIDEMIOL, V34, P816, DOI 10.1002/gepi.20533
   Lin DY, 2010, BIOMETRIKA, V97, P321, DOI 10.1093/biomet/asq006
   Lin DY, 2010, GENET EPIDEMIOL, V34, P60, DOI 10.1002/gepi.20435
   MacArthur J, 2017, NUCLEIC ACIDS RES, V45, pD896, DOI 10.1093/nar/gkw1133
   Mahajan A, 2018, NAT GENET, V50, P1505, DOI 10.1038/s41588-018-0241-6
   Mathew T, 1999, BIOMETRICS, V55, P1221, DOI 10.1111/j.0006-341X.1999.01221.x
   Olkin I, 1998, BIOMETRICS, V54, P317, DOI 10.2307/2534018
   Pruim RJ, 2010, BIOINFORMATICS, V26, P2336, DOI 10.1093/bioinformatics/btq419
   Rice K, 2018, J R STAT SOC A STAT, V181, P205, DOI 10.1111/rssa.12275
   Rich SS, 2016, NAT GENET, V48, P702, DOI 10.1038/ng.3582
   Scott RA, 2017, DIABETES, V66, P2888, DOI 10.2337/db16-1253
   Sung YJ, 2014, GENET EPIDEMIOL, V38, P369, DOI 10.1002/gepi.21800
   Turcot V, 2018, NAT GENET, V50, P26, DOI 10.1038/s41588-017-0011-x
   Verma SS, 2014, FRONT GENET, V5, DOI 10.3389/fgene.2014.00370
   Visscher PM, 2017, AM J HUM GENET, V101, P5, DOI 10.1016/j.ajhg.2017.06.005
   Willer CJ, 2010, BIOINFORMATICS, V26, P2190, DOI 10.1093/bioinformatics/btq340
   Winkler TW, 2015, BIOINFORMATICS, V31, P259, DOI 10.1093/bioinformatics/btu621
   Winkler TW, 2014, NAT PROTOC, V9, P1192, DOI 10.1038/nprot.2014.071
   Xie YR, 2014, HUM HERED, V78, P73, DOI 10.1159/000363337
NR 27
TC 1
Z9 1
U1 0
U2 2
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0741-0395
EI 1098-2272
J9 GENET EPIDEMIOL
JI Genet. Epidemiol.
PD JUL
PY 2019
VL 43
IS 5
BP 559
EP 576
DI 10.1002/gepi.22204
PG 18
WC Genetics & Heredity; Mathematical & Computational Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Genetics & Heredity; Mathematical & Computational Biology
GA IH1ND
UT WOS:000474256700008
PM 31016765
OA Green Published, hybrid
DA 2022-11-30
ER

PT J
AU Calzetti, G
   Mora, P
   Borrelli, E
   Sacconi, R
   Ricciotti, G
   Carta, A
   Gandolfi, S
   Querques, G
AF Calzetti, Giacomo
   Mora, Paolo
   Borrelli, Enrico
   Sacconi, Riccardo
   Ricciotti, Guido
   Carta, Arturo
   Gandolfi, Stefano
   Querques, Giuseppe
TI Short-term changes in retinal and choroidal relative flow volume after
   anti-VEGF treatment for neovascular age-related macular degeneration
SO SCIENTIFIC REPORTS
LA English
DT Article
ID INTRAVITREAL BEVACIZUMAB AVASTIN(R); LASER SPECKLE FLOWGRAPHY;
   RETROBULBAR BLOOD-FLOW; RANIBIZUMAB INJECTION; CIRCULATION;
   CHORIOCAPILLARIS; DENSITY; MODEL; EYES
AB The effects of anti-vascular endothelial growth factor (anti-VEGF) agents on the native ocular vasculature are poorly understood. This pilot study aimed to assess short-term changes in retinal and choroidal perfusion after anti-VEGF treatment for neovascular exudative age-related macular degeneration (nAMD) using the relative flow volume (RFV) parameter derived from laser speckle flowgraphy. Ten treatment-naive nAMD patients underwent measurements of mean, maximum, minimum, and differential RFV within a retinal arteriolar segment and a choroidal vessel segment outside the neovascular area. Measurement of retinal RFV (rRFV), choroidal RFV (cRFV), and subfoveal choroidal thickness (SCT) was repeated 9 and 35 days after a single anti-VEGF injection. The treatment caused a statistically significant decrease in the mean rRFV, mean cRFV, and SCT during the follow-up (p < 0.05). At the intermediate visit, the mean cRFV and SCT were - 17.6% and - 6.4% compared to baseline, respectively. However, at the final measurement, the mean cRFV was not different from the baseline value, which indicated waning of the anti-VEGF effect. In conclusion, a single anti-VEGF injection in treatment-naive nAMD resulted in a decrease in retinal arteriolar and choroidal perfusion, according to the RFV parameter, which is a promising tool to simultaneously assess retinal and choroidal perfusion changes in response to anti-VEGF therapy.
C1 [Calzetti, Giacomo; Mora, Paolo; Ricciotti, Guido; Carta, Arturo; Gandolfi, Stefano] Univ Hosp Parma, Dept Ophthalmol, Parma, Italy.
   [Calzetti, Giacomo] Inst Mol & Clin Ophthalmol Basel, Basel, Switzerland.
   [Borrelli, Enrico; Sacconi, Riccardo; Querques, Giuseppe] Univ Vita Salute San Raffaele, Sch Med, Milan, Italy.
   [Borrelli, Enrico; Sacconi, Riccardo; Querques, Giuseppe] IRCCS San Raffaele Sci Inst, Div Head & Neck, Ophthalmol Unit, Milan, Italy.
C3 University of Parma; University Hospital of Parma; Vita-Salute San
   Raffaele University; Vita-Salute San Raffaele University; IRCCS Ospedale
   San Raffaele
RP Querques, G (通讯作者)，Univ Vita Salute San Raffaele, Sch Med, Milan, Italy.; Querques, G (通讯作者)，IRCCS San Raffaele Sci Inst, Div Head & Neck, Ophthalmol Unit, Milan, Italy.
EM giuseppe.querques@hotmail.it
RI Calzetti, Giacomo/AAO-7409-2021; Ricciotti, Guido/GVU-1322-2022
OI Calzetti, Giacomo/0000-0003-1391-9510; Sacconi,
   Riccardo/0000-0003-2891-2012
CR Aizawa N, 2014, INVEST OPHTH VIS SCI, V55, P7991, DOI 10.1167/iovs.14-15373
   Barak A, 2012, EUR J OPHTHALMOL, V22, P423, DOI 10.5301/ejo.5000074
   Bonnin P, 2010, ACTA OPHTHALMOL, V88, P641, DOI 10.1111/j.1755-3768.2009.01526.x
   Borrelli E, 2018, RETINA-J RET VIT DIS, V38, P1968, DOI 10.1097/IAE.0000000000002198
   Calzetti G, 2022, ACTA OPHTHALMOL, V100, pE181, DOI 10.1111/aos.14862
   Calzetti G, 2020, TRANSL VIS SCI TECHN, V9, DOI 10.1167/tvst.9.5.9
   Calzetti G, 2021, ACTA OPHTHALMOL, V99, pE445, DOI 10.1111/aos.14555
   Calzetti G, 2018, BRIT J OPHTHALMOL, V102, P1679, DOI 10.1136/bjophthalmol-2017-311750
   Carta A, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0208145
   Cennamo G, 2020, OPHTHALMOL THER, V9, P77, DOI 10.1007/s40123-019-00221-0
   Cicinelli MV, 2020, RETINA-J RET VIT DIS, V40, P499, DOI 10.1097/IAE.0000000000002452
   Colantuono D, 2021, EUR J OPHTHALMOL, V31, P2474, DOI 10.1177/1120672120968758
   de Vries VA, 2020, SCI REP-UK, V10, DOI 10.1038/s41598-020-70269-7
   Fontaine O, 2011, INVEST OPHTH VIS SCI, V52, P7400, DOI 10.1167/iovs.10-6646
   Hikichi T, 2019, INVEST OPHTH VIS SCI, V60, P1088, DOI 10.1167/iovs.18-24522
   Hosseini H, 2012, RETINA-J RET VIT DIS, V32, P967, DOI 10.1097/IAE.0b013e31822c28d6
   Jeon SJ, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-53354-4
   Kojima, 2000, Jpn J Ophthalmol, V44, P318, DOI 10.1016/S0021-5155(00)00158-1
   Kuroda F, 2020, SCI REP-UK, V10, DOI 10.1038/s41598-020-57583-w
   Lim LS, 2012, LANCET, V379, P1728, DOI 10.1016/S0140-6736(12)60282-7
   Luft N, 2016, INVEST OPHTH VIS SCI, V57, P5417, DOI 10.1167/iovs.16-19896
   Mastropasqua L, 2017, RETINA-J RET VIT DIS, V37, P247, DOI 10.1097/IAE.0000000000001145
   Micieli JA, 2012, ACTA OPHTHALMOL, V90, pE13, DOI 10.1111/j.1755-3768.2011.02209.x
   Mottet B, 2018, ACTA OPHTHALMOL, V96, pE783, DOI 10.1111/aos.13763
   Mursch-Edlmayr AS, 2020, CURR EYE RES, V45, P1438, DOI 10.1080/02713683.2020.1752390
   Mursch-Edlmayr AS, 2020, BRIT J OPHTHALMOL, V104, P53, DOI 10.1136/bjophthalmol-2019-313919
   Nitta F, 2014, CLIN OPHTHALMOL, V8, P1119, DOI 10.2147/OPTH.S62022
   Okuno T, 2002, JPN J OPHTHALMOL, V46, P170, DOI 10.1016/S0021-5155(01)00498-1
   Papadopoulou DN, 2009, OPHTHALMOLOGY, V116, P1755, DOI 10.1016/j.ophtha.2009.03.017
   Querques G, 2015, OPHTHALMIC RES, V53, P194, DOI 10.1159/000379754
   Rechtman E, 2011, CLIN OPHTHALMOL, V5, P37, DOI 10.2147/OPTH.S15810
   Resch MD, 2020, PLOS ONE, V15, DOI 10.1371/journal.pone.0229388
   Rispoli M, 2018, OSLI RETINA, V49, P918, DOI 10.3928/23258160-20181203-02
   Sacconi R, 2021, BRIT J OPHTHALMOL, V105, P97, DOI 10.1136/bjophthalmol-2019-315800
   Saint-Geniez M, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003554
   Sakalar YB, 2013, J CLIN ULTRASOUND, V41, P32, DOI 10.1002/jcu.21989
   Shiga Y, 2014, INVEST OPHTH VIS SCI, V55, P3899, DOI 10.1167/iovs.14-14116
   Sugiyama T, 2014, PHOTONICS, V1, P220, DOI 10.3390/photonics1030220
   Tan BY, 2020, ANN TRANSL MED, V8, DOI 10.21037/atm-20-3246
   Toklu Y, 2011, ACTA OPHTHALMOL, V89, pE41, DOI 10.1111/j.1755-3768.2010.02075.x
   Vosborg F, 2020, EUR J OPHTHALMOL, V30, P235, DOI 10.1177/1120672119858891
   Wang L, 2012, INVEST OPHTH VIS SCI, V53, P8303, DOI 10.1167/iovs.12-10911
   Wickremasinghe SS, 2012, CLIN EXP OPHTHALMOL, V40, P59, DOI 10.1111/j.1442-9071.2011.02613.x
   Witkowska KJ, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0184772
   Yuksel K, 2013, J OCUL PHARMACOL TH, V29, P723, DOI 10.1089/jop.2013.0051
NR 45
TC 0
Z9 0
U1 0
U2 2
PU NATURE PORTFOLIO
PI BERLIN
PA HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY
SN 2045-2322
J9 SCI REP-UK
JI Sci Rep
PD DEC 9
PY 2021
VL 11
IS 1
AR 23723
DI 10.1038/s41598-021-03179-x
PG 7
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA XM1BK
UT WOS:000728570400003
PM 34887454
OA gold, Green Published
DA 2022-11-30
ER

PT J
AU Leaderer, D
   Cashman, SM
   Kumar-Singh, R
AF Leaderer, Derek
   Cashman, Siobhan M.
   Kumar-Singh, Rajendra
TI Topical application of a G-Quartet aptamer targeting nucleolin
   attenuates choroidal neovascularization in a model of age-related
   macular degeneration
SO EXPERIMENTAL EYE RESEARCH
LA English
DT Article
DE AS1411; Laser-induced choroidal neovascularization (CNV); Nucleolin;
   Age-related macular degeneration (AMD); Aptamer
ID ENDOTHELIAL GROWTH-FACTOR; SURFACE-EXPRESSED NUCLEOLIN; MEMBRANE ATTACK
   COMPLEX; G-RICH OLIGONUCLEOTIDES; INTRAVITREAL INJECTIONS;
   ANTIANGIOGENIC ACTIVITY; PROTEIN NUCLEOLIN; VEGF; BEVACIZUMAB; BINDING
AB Choroidal neovascularization (CNV) associated with the 'wet' form of age related macular degeneration (AMD) is one of the most common causes of central vision loss among the elderly. The 'wet' form of AMD is currently treated by intravitreal delivery of anti-VEGF agents. However, intravitreal injections are associated with complications and long-term inhibition of VEGF leads to macular atrophy. Thus, there is currently an unmet need for the development of therapies for CNV that target molecules other than VEGF. Here, we describe nucleolin as a novel target for the 'wet' form of AMD. Nucleolin was found on the surface of endothelial cells that migrate from the choroid into the subretinal space in the laser-induced model of 'wet' AMD. AS1411 is a previously described G-quartet oligonucleotide that has been shown to bind nucleolin. We found that AS1411 inhibited the formation of tubes by human umbilical vein endothelial cells (HUVECs) by approximately 27.4% in vitro. AS 1411 co-localized with the site of laser induced CNV in vivo. Intravitreally injected AS1411 inhibited laser-induced CNV by 37.6% and attenuated infiltration of macrophages by 40.3%. Finally, topical application of AS 1411 led to a 43.4% reduction in CNV. Our observations have potential implications for the development of therapies for CNV and specifically for the 'wet' form of AMD. (C) 2015 Elsevier Ltd. All rights reserved.
C1 [Leaderer, Derek; Cashman, Siobhan M.; Kumar-Singh, Rajendra] Tufts Univ, Sackler Sch Grad Biomed Sci, Dept Dev Mol & Chem Biol, Program Genet,Sch Med, Boston, MA 02111 USA.
C3 Tufts University
RP Kumar-Singh, R (通讯作者)，Tufts Univ, Sackler Sch Grad Biomed Sci, Dept Dev Mol & Chem Biol, Program Genet,Sch Med, 136 Harrison Ave, Boston, MA 02111 USA.
EM Rajendra.Kumar-Singh@tufts.edu
OI Kumar-Singh, Rajendra/0000-0002-7754-0713
FU Paul and Phyllis Fireman Foundation; Department of Defense/TATRC
   [W81XWH-12-1-0374]; National Institutes of Health/NEI [EY021805,
   EY013837]; Ellison Foundation; NATIONAL EYE INSTITUTE [R01EY013837,
   R01EY021805] Funding Source: NIH RePORTER
FX This study was supported by grants to R.K.S from The Paul and Phyllis
   Fireman Foundation, The Department of Defense/TATRC (W81XWH-12-1-0374),
   The National Institutes of Health/NEI (EY021805 and EY013837) and The
   Ellison Foundation.
CR Abdelmohsen K, 2012, RNA BIOL, V9, P799, DOI 10.4161/rna.19718
   Bates PJ, 2009, EXP MOL PATHOL, V86, P151, DOI 10.1016/j.yexmp.2009.01.004
   Bates PJ, 1999, J BIOL CHEM, V274, P26369, DOI 10.1074/jbc.274.37.26369
   Bhutto I, 2012, MOL ASPECTS MED, V33, P295, DOI 10.1016/j.mam.2012.04.005
   Birke K, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0076766
   Campochiaro PA, 2014, OPHTHALMOLOGY, V121, P1783, DOI 10.1016/j.ophtha.2014.03.021
   Cashman SM, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0019078
   Casten RJ, 2013, CURR OPIN OPHTHALMOL, V24, P239, DOI 10.1097/ICU.0b013e32835f8e55
   Cloutier F, 2012, INVEST OPHTH VIS SCI, V53, P1195, DOI 10.1167/iovs.11-9064
   Conley SM, 2010, PROG RETIN EYE RES, V29, P376, DOI 10.1016/j.preteyeres.2010.04.004
   Espinosa-Heidmann DG, 2003, INVEST OPHTH VIS SCI, V44, P3586, DOI 10.1167/iovs.03-0038
   Esposito CL, 2011, DISCOV MED, V11, P487
   Ferrara N, 2010, NAT MED, V16, P1107, DOI 10.1038/nm1010-1107
   Funk M, 2009, OPHTHALMOLOGY, V116, P2393, DOI 10.1016/j.ophtha.2009.05.039
   Goldstein JE, 2012, ARCH OPHTHALMOL-CHIC, V130, P1028, DOI 10.1001/archophthalmol.2012.1197
   Grossniklaus HE, 2010, PROG RETIN EYE RES, V29, P500, DOI 10.1016/j.preteyeres.2010.05.003
   Heiduschka P, 2007, INVEST OPHTH VIS SCI, V48, P2814, DOI 10.1167/iovs.06-1171
   Hirano K, 2005, J BIOL CHEM, V280, P39284, DOI 10.1074/jbc.M505275200
   Hollander BA, 1999, CELL MOTIL CYTOSKEL, V43, P114, DOI 10.1002/(SICI)1097-0169(1999)43:2<114::AID-CM3>3.0.CO;2-M
   Hovanessian AG, 2006, CELL RES, V16, P174, DOI 10.1038/sj.cr.7310024
   Hovanessian AG, 2000, EXP CELL RES, V261, P312, DOI 10.1006/excr.2000.5071
   Hovanessian AG, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0015787
   Huang Y, 2006, BLOOD, V107, P3564, DOI 10.1182/blood-2005-07-2961
   Keane PA, 2012, J OPHTHALMOL, V2012, DOI 10.1155/2012/483034
   Kiuchi K, 2008, INVEST OPHTH VIS SCI, V49, P1705, DOI 10.1167/iovs.07-0089
   Kurihara T, 2012, J CLIN INVEST, V122, P4213, DOI 10.1172/JCI65157
   Lambert V, 2013, NAT PROTOC, V8, P2197, DOI 10.1038/nprot.2013.135
   Legrand D, 2004, EUR J BIOCHEM, V271, P303, DOI 10.1046/j.1432-1033.2003.03929.x
   Lim LS, 2012, LANCET, V379, P1728, DOI 10.1016/S0140-6736(12)60282-7
   Lipo E, 2013, INVEST OPHTH VIS SCI, V54, P7107, DOI 10.1167/iovs.13-12923
   Liu J, 2011, J BIOL CHEM, V286, P20991, DOI 10.1074/jbc.M111.226266
   Lu F, 2009, GRAEF ARCH CLIN EXP, V247, P171, DOI 10.1007/s00417-008-0936-y
   Martin DF, 2011, NEW ENGL J MED, V364, P1897, DOI 10.1056/NEJMoa1102673
   Mathalone N, 2012, GRAEF ARCH CLIN EXP, V250, P1435, DOI 10.1007/s00417-012-1981-0
   Nishijima K, 2007, AM J PATHOL, V171, P53, DOI 10.2353/ajpath.2007.061237
   Nozaki M, 2006, J CLIN INVEST, V116, P422, DOI 10.1172/JCI26316
   Papadopoulou DN, 2009, OPHTHALMOLOGY, V116, P1755, DOI 10.1016/j.ophtha.2009.03.017
   Penfold PL, 2001, PROG RETIN EYE RES, V20, P385, DOI 10.1016/S1350-9462(00)00025-2
   Rosenberg JE, 2014, INVEST NEW DRUG, V32, P178, DOI 10.1007/s10637-013-0045-6
   Sacu S, 2011, INVEST OPHTH VIS SCI, V52, P3046, DOI 10.1167/iovs.10-5842
   Saint-Geniez M, 2009, P NATL ACAD SCI USA, V106, P18751, DOI 10.1073/pnas.0905010106
   Saint-Geniez M, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003554
   Sakurai E, 2003, INVEST OPHTH VIS SCI, V44, P3578, DOI 10.1167/iovs.03-0097
   Sampat KM, 2010, CURR OPIN OPHTHALMOL, V21, P178, DOI 10.1097/ICU.0b013e328338679a
   Sheu SJ, 2009, MOL VIS, V15, P1897
   Tolentino M, 2011, SURV OPHTHALMOL, V56, P95, DOI 10.1016/j.survophthal.2010.08.006
   Ueta T, 2011, OPHTHALMOLOGY, V118, P2093, DOI 10.1016/j.ophtha.2011.06.001
   Ueta T, 2009, OPHTHALMOLOGY, V116, P362, DOI 10.1016/j.ophtha.2008.09.046
   Xu XH, 2001, J BIOL CHEM, V276, P43221, DOI 10.1074/jbc.M104446200
NR 49
TC 8
Z9 9
U1 0
U2 19
PU ACADEMIC PRESS LTD- ELSEVIER SCIENCE LTD
PI LONDON
PA 24-28 OVAL RD, LONDON NW1 7DX, ENGLAND
SN 0014-4835
EI 1096-0007
J9 EXP EYE RES
JI Exp. Eye Res.
PD NOV
PY 2015
VL 140
BP 171
EP 178
DI 10.1016/j.exer.2015.09.005
PG 8
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA CV4TP
UT WOS:000364259700019
PM 26368850
OA Green Accepted, Bronze
DA 2022-11-30
ER

PT J
AU Forte, R
   Bonavolonta, P
   Benayoun, Y
   Adenis, JP
   Robert, PY
AF Forte, Raimondo
   Bonavolonta, Paola
   Benayoun, Yohan
   Adenis, Jean Paul
   Robert, Pierre-Yves
TI Intravitreal Ranibizumab and Bevacizumab in Combination with
   Full-Fluence Verteporfin Therapy and Dexamethasone for Exudative
   Age-Related Macular Degeneration
SO OPHTHALMIC RESEARCH
LA English
DT Article
DE Anti-vascular-endothelial-growth-factor antibody; Foveal thickness;
   Optical coherence tomography; Retreatment; Triple therapy
ID SUBFOVEAL CHOROIDAL NEOVASCULARIZATION; RANDOMIZED CLINICAL-TRIALS;
   PHOTODYNAMIC THERAPY; TRIAMCINOLONE ACETONIDE; TRIPLE THERAPY;
   INJECTION; AVASTIN; OCCULT; SECONDARY; LUCENTIS
AB Purpose: To evaluate the efficacy and safety of triple therapy with intravitreal anti-vascular-endothelial-growth-factor (VEGF) antibody, dexamethasone and verteporfin photodynamic therapy (PDT) for exudative age-related macular degeneration (AMD). Methods: Retrospective, comparative, interventional study. Records of treatment-naive patients who received intravitreal bevacizumab or ranibizumab in monotherapy or in combination with dexamethasone and full-fluence verteporfin PDT in triple therapy were reviewed. log-MAR visual acuity, foveal thickness (FT) on optical coherence tomography, intraocular pressure and endophthalmitis occurrence were recorded. Results: Sixty-one eyes were included in the triple-therapy group, 40 eyes were included in the monotherapy group. The mean follow-up was 14.1 +/- 3.4 months in the triple-therapy group and 16.3 +/- 4.1 months in the monotherapy group. The triple-therapy group enjoyed a lower total number of treatments (1.92 +/- 0.44 vs. 3.12 +/- 0.37, p < 0.001) and a longer time before first retreatment (5.4 +/- 3.3 vs. 3.6 +/- 2.5 months, p = 0.001). A significant improvement of visual acuity and FT was present in both groups during the 12 months following first treatment. No adverse effects were observed. Conclusion: The combination of intravitreal bevacizumab or ranibizumab with dexamethasone and full-fluence PDT for exudative AMD provided visual and anatomic improvement and a good safety profile. Triple therapy may reduce the number of retreatments when compared to anti-VEGF alone. Copyright (C) 2010 S. Karger AG, Basel
C1 [Forte, Raimondo; Bonavolonta, Paola] Univ Naples Federico II, Eye Dept, IT-80131 Naples, Italy.
   [Benayoun, Yohan; Adenis, Jean Paul; Robert, Pierre-Yves] Univ Hosp, Eye Dept, Limoges, France.
C3 University of Naples Federico II; CHU Limoges
RP Forte, R (通讯作者)，Univ Naples Federico II, Dipartimento Sci Oftalmol, Via Pansini 5, IT-80131 Naples, Italy.
EM raifor@hotmail.com
RI ROBERT, Pierre-Yves/O-8597-2016; Bonavolontà, Paola/N-3954-2016
OI Bonavolontà, Paola/0000-0002-3326-4825
CR Ahmadieh Hamid, 2007, BMC Ophthalmol, V7, P10, DOI 10.1186/1471-2415-7-10
   Augustin AJ, 2006, AM J OPHTHALMOL, V141, P638, DOI 10.1016/j.ajo.2005.11.058
   Augustin AJ, 2006, OPHTHALMOLOGY, V113, P14, DOI 10.1016/j.ophtha.2005.09.002
   Augustin AJ, 2007, RETINA-J RET VIT DIS, V27, P133, DOI 10.1097/IAE.0b013e3180323de7
   Avery RL, 2006, OPHTHALMOLOGY, V113, P363, DOI 10.1016/j.ophtha.2005.11.019
   Bakri SJ, 2009, RETINA-J RET VIT DIS, V29, P573, DOI 10.1097/IAE.0b013e3181a46a8a
   Blumenkranz MS, 2001, ARCH OPHTHALMOL-CHIC, V119, P198
   Boyer DS, 2007, OPHTHALMOLOGY, V114, P246, DOI 10.1016/j.ophtha.2006.10.045
   Bressler NM, 2002, ARCH OPHTHALMOL-CHIC, V120, P1307
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Ferrara N, 2006, RETINA-J RET VIT DIS, V26, P859, DOI 10.1097/01.iae.0000242842.14624.e7
   Fong DS, 2010, OPHTHALMOLOGY, V117, P298, DOI 10.1016/j.ophtha.2009.07.023
   Fung AE, 2006, BRIT J OPHTHALMOL, V90, P1344, DOI 10.1136/bjo.2006.099598
   Fung AE, 2007, AM J OPHTHALMOL, V143, P566, DOI 10.1016/j.ajo.2007.01.028
   Gragoudas ES, 2004, NEW ENGL J MED, V351, P2805, DOI 10.1056/NEJMoa042760
   Greve MDJ, 2005, ARCH OPHTHALMOL-CHIC, V123, P448
   Heier JS, 2006, ARCH OPHTHALMOL-CHIC, V124, P1532, DOI 10.1001/archopht.124.11.1532
   Kaiser PK, 2006, GRAEF ARCH CLIN EXP, V244, P1132, DOI 10.1007/s00417-005-0199-9
   Kaiser PK, 2005, CURR MED RES OPIN, V21, P705, DOI 10.1185/030079905X43659
   Lazic R, 2007, OPHTHALMOLOGY, V114, P1179, DOI 10.1016/j.ophtha.2007.03.006
   Lazic R, 2007, GRAEF ARCH CLIN EXP, V245, P68, DOI 10.1007/s00417-006-0466-4
   Maier MM, 2009, KLIN MONATSBL AUGENH, V226, P496, DOI 10.1055/s-0028-1109463
   Michels S, 2005, OPHTHALMOLOGY, V112, P1035, DOI 10.1016/j.ophtha.2005.02.007
   Moshfeghi AA, 2006, OPHTHALMOLOGY, V113, P2002, DOI 10.1016/j.ophtha.2006.05.070
   Nicolo M, 2006, RETINA-J RET VIT DIS, V26, P58, DOI 10.1097/00006982-200601000-00010
   Potter MJ, 2007, BRIT J OPHTHALMOL, V91, P753, DOI 10.1136/bjo.2006.110239
   Rechtman E, 2004, BRIT J OPHTHALMOL, V88, P344, DOI 10.1136/bjo.2003.027177
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Rosenfeld PJ, 2006, AM J OPHTHALMOL, V142, P141, DOI 10.1016/j.ajo.2006.03.036
   Rosenfeld PJ, 2005, OPHTHAL SURG LAS IM, V36, P331, DOI 10.3928/1542-8877-20050701-14
   Ruiz-Moreno JM, 2006, EUR J OPHTHALMOL, V16, P426, DOI 10.1177/112067210601600311
   Schmidt-Erfurth U, 2002, ARCH OPHTHALMOL-CHIC, V120, P835
   Schmidt-Erfurth U, 2003, INVEST OPHTH VIS SCI, V44, P4473, DOI 10.1167/iovs.02-1115
   Smith BT, 2008, RETINA-J RET VIT DIS, V28, P675, DOI 10.1097/IAE.0b013e31816b316e
   Spaide RF, 2005, OPHTHALMOLOGY, V112, P301, DOI 10.1016/j.ophtha.2004.08.012
   Spaide RF, 2003, OPHTHALMOLOGY, V110, P1517, DOI 10.1016/S0161-6420(03)00544-X
   Spaide R, 2007, AM J OPHTHALMOL, V143, P679, DOI 10.1016/j.ajo.2007.02.024
   Yip PP, 2009, BRIT J OPHTHALMOL, V93, P754, DOI 10.1136/bjo.2008.150987
NR 38
TC 12
Z9 12
U1 0
U2 5
PU KARGER
PI BASEL
PA ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND
SN 0030-3747
EI 1423-0259
J9 OPHTHALMIC RES
JI Ophthalmic Res.
PY 2011
VL 45
IS 3
BP 129
EP 134
DI 10.1159/000318877
PG 6
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 758IE
UT WOS:000290157000003
PM 20847575
DA 2022-11-30
ER

PT J
AU SanGiovanni, JP
   Chew, EY
   Clemons, TE
   Davis, MD
   Ferris, FL
   Gensler, GR
   Kurinij, N
   Lindblad, AS
   Milton, RC
   Seddon, JM
   Sperduto, RD
AF SanGiovanni, John Paul
   Chew, Emily Y.
   Clemons, Traci E.
   Davis, Matthew D.
   Ferris, Frederick L., III
   Gensler, Gary R.
   Kurinij, Natalie
   Lindblad, Anne S.
   Milton, Roy C.
   Seddon, Johanna M.
   Sperduto, Robert D.
CA Age-Related Eye Dis Study Res Grp
TI The relationship of dietary lipid intake and age-related macular
   degeneration in a case-control study - AREDS report no. 20
SO ARCHIVES OF OPHTHALMOLOGY
LA English
DT Article
ID POLYUNSATURATED FATTY-ACIDS; PROLIFERATOR-ACTIVATED RECEPTORS; 3RD
   NATIONAL-HEALTH; DOCOSAHEXAENOIC ACID; NUTRITIONAL MANIPULATION; RETINAL
   PHOTORECEPTORS; PRIMATE RETINAS; MACULOPATHY; N-3; ZEAXANTHIN
AB Objective: To evaluate the association of lipid intake with baseline severity of age-related macular degeneration (AMD) in the Age-Related Eye Disease Study (AREDS).
   Methods: Age-Related Eye Disease Study participants aged 60 to 80 years at enrollment (N = 4519) provided estimates of habitual nutrient intake through a self-administered serniquantitative food frequency questionnaire. Stereoscopic color fundus photographs were used to categorize participants into 4 AMD severity groups and a control group (participants with <15 small drusen).
   Results: Dietary total omega-3 long-chain polyunsaturated fatty acid (LCPUFA) intake was inversely associated with neovascular (NV) AMD (odds ratio [OR], 0.61; 95% confidence interval [CI], 0.41-0.90), as was docosahexaenoic acid, a retinal w-3 LCPUFA (OR, 0.54; 95% CI, 0.36-0.80), comparing highest vs; lowest quintile of intake, after adjustment for total energy intake and covariates. Higher fish consumption, both total and broiled/baked, was also inversely associated with NV AMD (OR, 0.61; 95% CI, 0.37-1.00 and OR, 0.65; 95% CI, 0.45-0.93, respectively). Dietary arachidonic acid was directly associated with NV AMD prevalence (OR, 1.54; 95% CI, 1.04-2.29). No statistically significant relationships existed for the other lipids or AMD groups.
   Conclusion: Higher intake of omega-3 LCPUFAs and fish was associated with decreased likelihood of having NV AMD.
C1 EMMES Corp, AREDS Coordinating Ctr, Rockville, MD 20850 USA.
C3 Emmes Corporation
RP SanGiovanni, JP (通讯作者)，EMMES Corp, AREDS Coordinating Ctr, 401 N Washington St,Suite 700, Rockville, MD 20850 USA.
RI SanGiovanni, John Paul/AAU-3895-2020; SanGiovanni, John Paul/A-7605-2008
OI Ferris, Frederick/0000-0002-4933-0639
FU Intramural NIH HHS [ZIA EY000489-01, Z99 EY999999] Funding Source:
   Medline
CR Age-Related Eye Dis Study Res Grp, 2001, AM J OPHTHALMOL, V132, P668
   Anand R, 2000, OPHTHALMOLOGY, V107, P2224
   Badawi AF, 1998, CARCINOGENESIS, V19, P905, DOI 10.1093/carcin/19.5.905
   Bisogno T, 1999, ARCH BIOCHEM BIOPHYS, V370, P300, DOI 10.1006/abbi.1999.1410
   Calder PC, 2001, LIPIDS, V36, P1007, DOI 10.1007/s11745-001-0812-7
   Chen Y, 1996, J BIOL CHEM, V271, P20507, DOI 10.1074/jbc.271.34.20507
   Cho E, 2001, AM J CLIN NUTR, V73, P209
   de Urquiza AM, 2000, SCIENCE, V290, P2140, DOI 10.1126/science.290.5499.2140
   DREYER C, 1993, BIOL CELL, V77, P67, DOI 10.1016/S0248-4900(05)80176-5
   FLIESLER SJ, 1983, PROG LIPID RES, V22, P79
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P564
   Hamid R, 1999, INT J ONCOL, V14, P523
   Heuberger RA, 2001, ARCH OPHTHALMOL-CHIC, V119, P1833, DOI 10.1001/archopht.119.12.1833
   Kassoff A, 1999, CONTROL CLIN TRIALS, V20, P573
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1417, DOI 10.1001/archopht.119.10.1417
   Kim HY, 2001, J MOL NEUROSCI, V16, P223, DOI 10.1385/JMN:16:2-3:223
   KLEIN R, 1992, OPHTHALMOLOGY, V99, P1686
   KLEIN R, 1992, OPHTHALMOLOGY, V99, P933
   KLEIN R, 1991, OPHTHALMOLOGY, V98, P1128
   Krinsky NI, 2003, ANNU REV NUTR, V23, P171, DOI 10.1146/annurev.nutr.23.011702.073307
   KURINLJ N, 1998, INT C DIET ASS METH
   LANDS WEM, 1999, ANTIOXIDANT STATUS D, P299
   Lecomte M, 1996, J NEUROCHEM, V66, P2160
   Leung IYF, 2005, EXP EYE RES, V81, P513, DOI 10.1016/j.exer.2005.03.009
   LIN DS, 1994, INVEST OPHTH VIS SCI, V35, P794
   Lin QO, 1999, BIOCHEMISTRY-US, V38, P185, DOI 10.1021/bi9816094
   Litman BJ, 1996, LIPIDS, V31, pS193, DOI 10.1007/BF02637075
   Litman BJ, 2001, J MOL NEUROSCI, V16, P237, DOI 10.1385/JMN:16:2-3:237
   Mares-Perlman JA, 2001, AM J EPIDEMIOL, V153, P424, DOI 10.1093/aje/153.5.424
   MARESPERLMAN JA, 1995, ARCH OPHTHALMOL-CHIC, V113, P743, DOI 10.1001/archopht.1995.01100060069034
   Mukherjee PK, 2004, P NATL ACAD SCI USA, V101, P8491, DOI 10.1073/pnas.0402531101
   *NAT ADV EY COUNC, 1999, NIH PUBL
   Neuringer M, 2004, INVEST OPHTH VIS SCI, V45, P3234, DOI 10.1167/iovs.02-1243
   NEURINGER M, 1986, P NATL ACAD SCI USA, V83, P4021, DOI 10.1073/pnas.83.11.4021
   Neuringer M, 1993, LIPIDS LEARNING BRAI, P134
   Niu SL, 2004, J BIOL CHEM, V279, P31098, DOI 10.1074/jbc.M404376200
   PAWLOSKY RJ, 1995, AM J CLIN NUTR, V61, P1284, DOI 10.1093/ajcn/61.6.1284
   Politi LE, 2001, INVEST OPHTH VIS SCI, V42, P3008
   ROSE DP, 1995, JNCI-J NATL CANCER I, V87, P587, DOI 10.1093/jnci/87.8.587
   Rose DP, 1999, INT J ONCOL, V15, P1011
   ROSNER B, 1988, AM J EPIDEMIOL, V127, P377, DOI 10.1093/oxfordjournals.aje.a114811
   Rotstein NP, 1997, J NEUROCHEM, V69, P504
   Rotstein NP, 1996, J NEUROCHEM, V66, P1851
   Rotstein NP, 1998, INVEST OPHTH VIS SCI, V39, P2750
   Salem N, 2001, LIPIDS, V36, P945, DOI 10.1007/s11745-001-0805-6
   SANDERS TAB, 1989, J INTERN MED, V225, P99, DOI 10.1111/j.1365-2796.1989.tb01442.x
   SanGiovanni JP, 2005, PROG RETIN EYE RES, V24, P87, DOI 10.1016/j.preteyeres.2004.06.002
   Seddon J, 2001, RETINA-J RET VIT DIS, P1039
   Seddon JM, 2003, ARCH OPHTHALMOL-CHIC, V121, P1728, DOI 10.1001/archopht.121.12.1728
   SEDDON JM, 1994, JAMA-J AM MED ASSOC, V272, P1413, DOI 10.1001/jama.272.18.1413
   Seddon JM, 2001, ARCH OPHTHALMOL-CHIC, V119, P1191, DOI 10.1001/archopht.119.8.1191
   Serhan CN, 2004, LIPIDS, V39, P1125, DOI 10.1007/s11745-004-1339-7
   Smith W, 2000, ARCH OPHTHALMOL-CHIC, V118, P401, DOI 10.1001/archopht.118.3.401
   Snellen ELM, 2002, ACTA OPHTHALMOL SCAN, V80, P368, DOI 10.1034/j.1600-0420.2002.800404.x
   Snow K K, 1999, Ophthalmic Epidemiol, V6, P125, DOI 10.1076/opep.6.2.125.1558
   Yazulla S, 1999, J COMP NEUROL, V415, P80, DOI 10.1002/(SICI)1096-9861(19991206)415:1<80::AID-CNE6>3.0.CO;2-H
   YU K, 1995, J BIOL CHEM, V270, P23975, DOI 10.1074/jbc.270.41.23975
   2002, PREVENT BLINDNESS AM
NR 58
TC 228
Z9 238
U1 0
U2 22
PU AMER MEDICAL ASSOC
PI CHICAGO
PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA
SN 0003-9950
EI 1538-3601
J9 ARCH OPHTHALMOL-CHIC
JI Arch. Ophthalmol.
PD MAY
PY 2007
VL 125
IS 5
BP 671
EP 679
DI 10.1001/archopht.125.5.671
PG 9
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 165XI
UT WOS:000246340200011
PM 17502507
OA Bronze
DA 2022-11-30
ER

PT J
AU Moriarty-Craige, SE
   Ha, KN
   Sternberg, P
   Lynn, M
   Bressler, S
   Gensler, G
   Jones, DP
AF Moriarty-Craige, Siobhan E.
   Ha, Khoi-Nguyen
   Sternberg, Paul, Jr.
   Lynn, Michael
   Bressler, Susan
   Gensler, Gary
   Jones, Dean P.
TI Effects of long-term zinc supplementation on plasma thiol metabolites
   and redox status in patients with age-related macular degeneration
SO AMERICAN JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
ID PIGMENT EPITHELIAL-CELLS; OXIDATIVE STRESS; CYSTEINE/CYSTINE REDOX;
   GLUTATHIONE; ANTIOXIDANT; RPE; PROTECTION; DECLINE; PATHWAY; EVENTS
AB PURPOSE: To determine the effects of zinc supplemen, tation on plasma thiol metabolites and their redox status in a cohort of patients with age-related macular degeneration (AMD).
   DESIGN: Randomized clinical trial that evaluated the effects of high doses of zinc and antioxidants on plasma biomarkers of oxidative stress.
   METHODS: This was an ancillary study of the AgeRelated Eye Disease Study (AREDS). Subjects with AMD were randomized to one of four treatment groups: (1) antioxidants (vitamin C, 500 mg; vitamin E, 400 IU; and beta carotene, 15 mg), (2) zinc (80 mg zinc oxide, 2 mg cupric oxide), (3) antioxidants plus zinc, or (4) placebo. At 20 and 80 months after randomization, blood specimens were collected and analyzed for glutathione (GSH), oxidized glutathione (GSSG), cysteine (Cys), and cystine (CySS).
   RESULTS: Although zinc supplementation had no apparent effect on plasma thiol/disulfide redox status at the first blood draw, the group of patients receiving zinc supplementation at the second blood draw had significantly less CySS compared with those not receiving zinc (54.9 vs 64.1 mu M; P = .01). There was a time, dependent oxidation of the plasma GHS pool and was not affected by zinc supplementation. 0
   CONCLUSIONS: Because increased CySS level is as, sociated with aging, oxidative stress, and age-related diseases, the apparent prevention of increased CySS by zinc supplementation warrants additional investigation.
C1 Vanderbilt Univ, Inst Eye, Ctr Med, Nashville, TN 37232 USA.
   Emory Univ, Sch Med, Dept Med, Atlanta, GA 30322 USA.
   Emory Univ, Dept Biostat, Rollins Sch Publ Hlth, Atlanta, GA 30322 USA.
   Johns Hopkins Univ, Sch Med, Wilmer Ophthalmol Inst, Baltimore, MD USA.
   EMMES Corp, Rockville, MD USA.
C3 Vanderbilt University; Emory University; Emory University; Rollins
   School Public Health; Johns Hopkins University; Johns Hopkins Medicine;
   Emmes Corporation
RP Sternberg, P (通讯作者)，Vanderbilt Univ, Inst Eye, Ctr Med, 8000 Med Ctr E,N Tower, Nashville, TN 37232 USA.
EM paul.sternberg@vanderbilt.edu
FU NEI NIH HHS [EY06360, EY07892, P30 EY008126, EY08126, P30 EY006360, R01
   EY007892] Funding Source: Medline; NATIONAL EYE INSTITUTE [P30EY008126,
   R29EY007892, R01EY007892] Funding Source: NIH RePORTER
CR Ashfaq S, 2006, J AM COLL CARDIOL, V47, P1005, DOI 10.1016/j.jacc.2005.09.063
   Beatty S, 2000, SURV OPHTHALMOL, V45, P115, DOI 10.1016/S0039-6257(00)00140-5
   Cai JY, 2000, PROG RETIN EYE RES, V19, P205, DOI 10.1016/S1350-9462(99)00009-9
   Evans JR, 2001, PROG RETIN EYE RES, V20, P227, DOI 10.1016/S1350-9462(00)00023-9
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P564
   Go YM, 2005, CIRCULATION, V111, P2973, DOI 10.1161/CIRCULATIONAHA.104.515155
   Grahn BH, 2001, J AM COLL NUTR, V20, P106, DOI 10.1080/07315724.2001.10719022
   Ha KN, 2006, INVEST OPHTH VIS SCI, V47, P2709, DOI 10.1167/iovs.05-1322
   Jiang SN, 2005, INVEST OPHTH VIS SCI, V46, P1054, DOI 10.1167/iovs.04-0949
   Jonas CR, 2000, AM J CLIN NUTR, V72, P181
   Jones DP, 2000, FREE RADICAL BIO MED, V28, P625, DOI 10.1016/S0891-5849(99)00275-0
   Jones DP, 1998, CLIN CHIM ACTA, V275, P175, DOI 10.1016/S0009-8981(98)00089-8
   Jones DP, 2002, FREE RADICAL BIO MED, V33, P1290, DOI 10.1016/S0891-5849(02)01040-7
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1417, DOI 10.1001/archopht.119.10.1417
   Liang FQ, 2003, EXP EYE RES, V76, P397, DOI 10.1016/S0014-4835(03)00023-X
   Moriarty SE, 2003, FREE RADICAL BIO MED, V35, P1582, DOI 10.1016/j.freeradbiomed.2003.09.006
   Moriarty-Craige SE, 2005, AM J OPHTHALMOL, V140, P1020, DOI 10.1016/j.ajo.2005.06.043
   NEWSOME DA, 1988, ARCH OPHTHALMOL-CHIC, V106, P192
   Nkabyo YS, 2005, AM J PHYSIOL-GASTR L, V289, pG70, DOI 10.1152/ajpgi.00280.2004
   Pastore A, 2003, CLIN CHIM ACTA, V333, P19, DOI 10.1016/S0009-8981(03)00200-6
   PRESTERA T, 1993, P NATL ACAD SCI USA, V90, P2965, DOI 10.1073/pnas.90.7.2965
   Samiec PS, 1998, FREE RADICAL BIO MED, V24, P699, DOI 10.1016/S0891-5849(97)00286-4
   Sasaki H, 2002, J BIOL CHEM, V277, P44765, DOI 10.1074/jbc.M208704200
   Sato H, 2005, J BIOL CHEM, V280, P37423, DOI 10.1074/jbc.M506439200
   VandenLangenberg GM, 1998, AM J EPIDEMIOL, V148, P204, DOI 10.1093/oxfordjournals.aje.a009625
   VANLEEUWEN R, 2005, JAMA-J AM MED ASSOC, V28, P3101
   VANWART HE, 1990, P NATL ACAD SCI USA, V87, P5578, DOI 10.1073/pnas.87.14.5578
NR 27
TC 25
Z9 28
U1 0
U2 3
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0002-9394
J9 AM J OPHTHALMOL
JI Am. J. Ophthalmol.
PD FEB
PY 2007
VL 143
IS 2
BP 206
EP 211
DI 10.1016/j.ajo.2006.09.056
PG 6
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 137CV
UT WOS:000244271400002
PM 17157802
OA Green Accepted
DA 2022-11-30
ER

PT J
AU Bair, PJ
   Hsia, NY
   Lin, CL
   Yang, YC
   Shen, TC
   Li, CY
AF Bair, Pei-Jane
   Hsia, Ning-Yi
   Lin, Cheng-Li
   Yang, Yu-Cih
   Shen, Te-Chun
   Li, Chi-Yuan
TI Population-based retrospective cohort study on risk of age-related
   macular degeneration in people with chronic obstructive pulmonary
   disease
SO SCIENTIFIC REPORTS
LA English
DT Article
ID SYSTEMIC INFLAMMATION; ASSOCIATION; COMORBIDITIES; MACULOPATHY;
   EMPHYSEMA
AB Chronic obstructive pulmonary disease (COPD) and age-related macular degeneration (AMD) are both common diseases of the elderly people. COPD induced systemic inflammation and hypoxia may have an impact on the development of AMD. This study investigated the possible association between COPD and subsequent risk of AMD. A retrospective cohort study was conducted based on the data from the National Health Insurance Research Database in Taiwan. The COPD cohort comprised 24,625 adult patients newly diagnosed during 2000-2012, whereas age-, gender-, and the year of diagnosis-matched non-COPD cohort comprised 49,250 individuals. Incident AMD was monitored to the end of 2013. A Cox proportional hazards model was applied to evaluate the risk of AMD. The COPD cohort showed 1.25 times higher AMD incidence than the non-COPD cohort (4.80 versus 3.83 per 1000 person-years, adjusted hazard ratio (HR)=1.20 [95% confident interval (CI)=1.10-1.32]). Stratified analyses for age, gender, and presence of comorbidity resulted in significant adjusted HRs in most subgroups. Further analysis revealed that the COPD group had an increased risk of both the exudative and non-exudative types of AMD (adjusted HRs=1.49 [95% CI=1.13-1.96] and 1.15 [95% CI=1.05-1.26], respectively). COPD patients have an increased risk for AMD development. Clinicians should provide adequate care for the ocular health to these patients.
C1 [Bair, Pei-Jane; Li, Chi-Yuan] China Med Univ, Coll Med, Grad Inst Biomed Sci, 91 Hsueh Shih Rd, Taichung 404, Taiwan.
   [Bair, Pei-Jane] Show Chwan Mem Hosp, Dept Ophthalmol, 542,Sect 1,Chung Shan Rd, Changhua 500, Taiwan.
   [Hsia, Ning-Yi] China Med Univ Hosp, Dept Ophthalmol, 2 Yude Rd, Taichung 404, Taiwan.
   [Hsia, Ning-Yi; Shen, Te-Chun; Li, Chi-Yuan] China Med Univ, Coll Med, Sch Med, 91 Hsueh Shih Rd, Taichung 404, Taiwan.
   [Lin, Cheng-Li; Yang, Yu-Cih] China Med Univ Hosp, Management Off Hlth Data, 2 Yude Rd, Taichung 404, Taiwan.
   [Shen, Te-Chun] China Med Univ Hosp, Dept Internal Med, Div Pulm & Crit Care Med, 2 Yude Rd, Taichung 404, Taiwan.
C3 China Medical University Taiwan; Show Chwan Memorial Hospital; China
   Medical University Taiwan; China Medical University Hospital - Taiwan;
   China Medical University Taiwan; China Medical University Taiwan; China
   Medical University Hospital - Taiwan; China Medical University Taiwan;
   China Medical University Hospital - Taiwan
RP Shen, TC (通讯作者)，China Med Univ, Coll Med, Sch Med, 91 Hsueh Shih Rd, Taichung 404, Taiwan.; Shen, TC (通讯作者)，China Med Univ Hosp, Dept Internal Med, Div Pulm & Crit Care Med, 2 Yude Rd, Taichung 404, Taiwan.
EM chestshen@gmail.com
OI Shen, Te-Chun/0000-0002-9427-1068
FU Taiwan Ministry of Health and Welfare Clinical Trial and Research Center
   of Excellence [MOHW109-TDU-B-212-114004]; China Medical University
   Hospital [DMR-110-033]
FX This study is supported by Taiwan Ministry of Health and Welfare
   Clinical Trial and Research Center of Excellence
   (MOHW109-TDU-B-212-114004) and China Medical University Hospital
   (DMR-110-033).
CR Abd AJ, 2017, DRUG DISCOV TODAY, V22, P1671, DOI 10.1016/j.drudis.2017.07.010
   Al-Zamil WM, 2017, CLIN INTERV AGING, V12, P1313, DOI 10.2147/CIA.S143508
   Ambati J, 2013, NAT REV IMMUNOL, V13, P438, DOI 10.1038/nri3459
   Arjamaa O, 2009, AGEING RES REV, V8, P349, DOI 10.1016/j.arr.2009.06.002
   Barnes PJ, 2009, EUR RESPIR J, V33, P1165, DOI 10.1183/09031936.00128008
   Blasiak J, 2014, BIOMED RES INT, V2014, DOI 10.1155/2014/768026
   Byun MK, 2017, INT J CHRONIC OBSTR, V12, P669, DOI 10.2147/COPD.S130790
   Cavailles A, 2013, EUR RESPIR REV, V22, P454, DOI 10.1183/09059180.00008612
   Chakravarthy U, 2010, BMC OPHTHALMOL, V10, DOI 10.1186/1471-2415-10-31
   Cugati S, 2006, OPHTHALMOLOGY, V113, P2020, DOI 10.1016/j.ophtha.2006.05.047
   Ho TW, 2018, INT J CHRONIC OBSTR, V13, P3055, DOI 10.2147/COPD.S174265
   Hsing AW, 2015, JAMA INTERN MED, V175, P1527, DOI 10.1001/jamainternmed.2015.3540
   Inghammar M, 2014, BMC INFECT DIS, V14, DOI 10.1186/1471-2334-14-163
   KAHN HA, 1977, AM J EPIDEMIOL, V106, P33, DOI 10.1093/oxfordjournals.aje.a112429
   Karadag F, 2009, INT J CLIN PRACT, V63, P275, DOI 10.1111/j.1742-1241.2007.01501.x
   Kauppinen A, 2016, CELL MOL LIFE SCI, V73, P1765, DOI 10.1007/s00018-016-2147-8
   Klein R, 2003, ARCH OPHTHALMOL-CHIC, V121, P674, DOI 10.1001/archopht.121.5.674
   Klein R, 2008, ARCH OPHTHALMOL-CHIC, V126, P840, DOI 10.1001/archopht.126.6.840
   Klein R, 2010, ARCH OPHTHALMOL-CHIC, V128, P472, DOI 10.1001/archophthalmol.2010.25
   Lim LS, 2012, LANCET, V379, P1728, DOI 10.1016/S0140-6736(12)60282-7
   Lindberg A, 2012, BMC PULM MED, V12, DOI 10.1186/1471-2466-12-1
   Miller J, 2013, RESP MED, V107, P1376, DOI 10.1016/j.rmed.2013.05.001
   Mitchell P, 1998, OPHTHALMOLOGY, V105, P1359, DOI 10.1016/S0161-6420(98)98013-7
   Rabe KF, 2017, LANCET, V389, P1931, DOI 10.1016/S0140-6736(17)31222-9
   Rozing MP, 2020, PROG RETIN EYE RES, V76, DOI 10.1016/j.preteyeres.2019.100825
   SANDBERG MA, 1993, OPHTHALMOLOGY, V100, P1009
   Seddon JM, 2003, ARCH OPHTHALMOL-CHIC, V121, P785, DOI 10.1001/archopht.121.6.785
   Seddon JM, 1996, JAMA-J AM MED ASSOC, V276, P1141, DOI 10.1001/jama.276.14.1141
   Smith W, 2001, OPHTHALMOLOGY, V108, P697, DOI 10.1016/S0161-6420(00)00580-7
   Snow K K, 1999, Ophthalmic Epidemiol, V6, P125, DOI 10.1076/opep.6.2.125.1558
   Su VYF, 2019, AGING-US, V11, P3650, DOI 10.18632/aging.102004
   Sun KT, 2020, RETINA-J RET VIT DIS, V40, P2312, DOI 10.1097/IAE.0000000000002750
   Zlateva GP, 2007, RETINA-J RET VIT DIS, V27, P1292, DOI 10.1097/01.iae.0000300915.81866.b8
NR 33
TC 1
Z9 1
U1 1
U2 6
PU NATURE RESEARCH
PI BERLIN
PA HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY
SN 2045-2322
J9 SCI REP-UK
JI Sci Rep
PD JUL 23
PY 2021
VL 11
IS 1
AR 15079
DI 10.1038/s41598-021-94657-9
PG 7
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA TS0YL
UT WOS:000679383500013
PM 34302051
OA Green Published, gold
DA 2022-11-30
ER

PT J
AU Sun, TT
   Wei, QQ
   Gao, P
   Zhang, YJ
   Peng, Q
AF Sun, Tingting
   Wei, Qingquan
   Gao, Peng
   Zhang, Yongjie
   Peng, Qing
TI Cytokine and Chemokine Profile Changes in Patients with Neovascular
   Age-Related Macular Degeneration After Intravitreal Ranibizumab
   Injection for Choroidal Neovascularization
SO DRUG DESIGN DEVELOPMENT AND THERAPY
LA English
DT Article
DE choroidal neovascularization; CNV; neovascular age-related macular
   degeneration; nAMD; ranibizumab; cytokines
ID ENDOTHELIAL GROWTH-FACTOR; INFLAMMATORY CYTOKINES; MOLECULAR REGULATION;
   ANGIOGENESIS; CELLS
AB Objective: To investigate the concentrations of cytokine and chemokines profiling in aqueous humor for choroidal neovascularization (CNV) due to neovascular age-related macular degeneration (nAMD) before and during Intravitreal injection of ranibizumab (IVR) and its relation with the disease's active state.
   Methods: The cytokine levels in aqueous humour were detected by the Bio-Plex (R) 200 System and the Bio-Plex (TM) Human Cytokine Standard 27-Plex, Group I. Aqueous humour samples of experimental group were collected from 19 patients diagnosed nAMD at baseline and at 1 month after IVR. Aqueous humour samples of control group were collected from 20 patients undergoing cataract surgery.
   Results: Aqueous humor levels of basic fibroblast growth factor (basic FGF) and RANTES were significantly lower in nAMD patients than in the control group (P=0.044 and P<0.001, respectively). Vascular endothelial growth factor-A (VEGF-A) was significantly higher in nAMD patients than in the control group (P < 0.001). The average Eotaxin levels were significantly higher in nAMD patients after IVR than before (P=0.03). Contrarily, the average VEGF-A levels were significantly lower in AMD patients after IVR than before (P < 0.001).
   Conclusion: Angiogenic, growth factors and inflammatory are involved in the formation of neovascularization of AMD patients. IVR did not cause significant differences in any growth factors or inflammatory cytokines in nAMD patients with the exception of VEGF.
C1 [Sun, Tingting; Wei, Qingquan; Gao, Peng; Peng, Qing] Tongji Univ, Shanghai Peoples Hosp 10, Dept Ophthalmol, Shanghai 200072, Peoples R China.
   [Zhang, Yongjie] Nanjing Med Univ, Dept Human Anat, Nanjing 211166, Jiangsu, Peoples R China.
C3 Tongji University; Nanjing Medical University
RP Peng, Q (通讯作者)，Tongji Univ, Shanghai Peoples Hosp 10, Dept Ophthalmol, Shanghai 200072, Peoples R China.; Zhang, YJ (通讯作者)，Nanjing Med Univ, Dept Human Anat, Nanjing 211166, Jiangsu, Peoples R China.
EM zhangyongjie@njmu.edu.cn; pengqing@tongji.edu.cn
OI Peng, Qing/0000-0002-6991-9432
FU National Natural Science Foundation of China [81470025, 81472081];
   Shanghai Municipal Planning Commission of Science and Research Fund
   [SHDC2020CR5014, ZY-ZWB-1001-CPJS10]
FX This work was financially supported by Grants from the National Natural
   Science Foundation of China (81470025 and 81472081), and Shanghai
   Municipal Planning Commission of Science and Research Fund (No.
   SHDC2020CR5014 and No. ZY-ZWB-1001-CPJS10). Tingting Sun, Qingquan Wei,
   and Peng Gao are co-first authors for this study.
CR Adams RH, 2007, NAT REV MOL CELL BIO, V8, P464, DOI 10.1038/nrm2183
   Adler MW, 2005, AAPS J, V7, pE865, DOI 10.1208/aapsj070484
   Agawa T, 2014, RETINA-J RET VIT DIS, V34, P1811, DOI 10.1097/IAE.0000000000000157
   Allouche Michele, 1995, Progress in Growth Factor Research, V6, P35, DOI 10.1016/0955-2235(95)00041-0
   Baltus T, 2005, J LEUKOCYTE BIOL, V78, P435, DOI 10.1189/jlb.0305141
   BIKFALVI A, 1994, LEUKEMIA, V8, P523
   Bikfalvi A, 1997, ENDOCR REV, V18, P26, DOI 10.1210/er.18.1.26
   Deshauer C, 2015, STRUCTURE, V23, P1066, DOI 10.1016/j.str.2015.03.024
   Desire L, 1998, EXP CELL RES, V241, P210, DOI 10.1006/excr.1998.4048
   Duncan DS, 2018, FRONT NEUROSCI-SWITZ, V12, DOI 10.3389/fnins.2018.00702
   Ferrara N, 2006, RETINA-J RET VIT DIS, V26, P859, DOI 10.1097/01.iae.0000242842.14624.e7
   Gale RP, 2020, BRIT J OPHTHALMOL, V104, P493, DOI 10.1136/bjophthalmol-2019-314251
   Griffith JW, 2014, ANNU REV IMMUNOL, V32, P659, DOI 10.1146/annurev-immunol-032713-120145
   Guo SC, 2019, BMC OPHTHALMOL, V19, DOI 10.1186/s12886-019-1101-6
   Guyot Melanie, 2015, Methods Mol Biol, V1332, P3, DOI 10.1007/978-1-4939-2917-7_1
   Handa JT, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-11262-1
   Heier JS, 2006, OPHTHALMOLOGY, V113, P633, DOI 10.1016/j.ophtha.2005.10.052
   Jabs DA, 2019, AM J OPHTHALMOL, V199, P230, DOI 10.1016/j.ajo.2018.12.002
   Kauppinen A, 2016, CELL MOL LIFE SCI, V73, P1765, DOI 10.1007/s00018-016-2147-8
   Kawasaki R, 2010, OPHTHALMOLOGY, V117, P921, DOI 10.1016/j.ophtha.2009.10.007
   Lin N, 1997, EXP EYE RES, V64, P239, DOI 10.1006/exer.1996.0208
   LOGAN A, 1991, ANN NY ACAD SCI, V638, P474, DOI 10.1111/j.1749-6632.1991.tb49073.x
   McColl BK, 2004, APMIS, V112, P463, DOI 10.1111/j.1600-0463.2004.apm11207-0807.x
   Oynebraten I, 2015, SCI REP-UK, V5, DOI 10.1038/srep09261
   Roh MI, 2010, GRAEF ARCH CLIN EXP, V248, P635, DOI 10.1007/s00417-009-1254-8
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Sakamoto S, 2018, BRIT J OPHTHALMOL, V102, P448, DOI 10.1136/bjophthalmol-2017-310284
   Scotti F, 2019, GRAEF ARCH CLIN EXP, V257, P899, DOI 10.1007/s00417-018-04230-w
   Shiraki Y, 2016, J OPHTHALMOL, V2016, DOI 10.1155/2016/3573142
   Takeda A, 2009, NATURE, V460, P225, DOI 10.1038/nature08151
   Tong JP, 2006, AM J OPHTHALMOL, V141, P456, DOI 10.1016/j.ajo.2005.10.012
   Wada I, 2019, GRAEF ARCH CLIN EXP, V257, P1411, DOI 10.1007/s00417-019-04361-8
   Wong T, 2008, OPHTHALMOLOGY, V115, P116, DOI 10.1016/j.ophtha.2007.03.008
   Yin HF, 2016, SCI REP-UK, V6, DOI 10.1038/srep31880
NR 34
TC 0
Z9 0
U1 0
U2 3
PU DOVE MEDICAL PRESS LTD
PI ALBANY
PA PO BOX 300-008, ALBANY, AUCKLAND 0752, NEW ZEALAND
SN 1177-8881
J9 DRUG DES DEV THER
JI Drug Des. Dev. Ther.
PY 2021
VL 15
BP 2457
EP 2467
DI 10.2147/DDDT.S307657
PG 11
WC Chemistry, Medicinal; Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Pharmacology & Pharmacy
GA ST2YK
UT WOS:000662315200001
PM 34140764
OA Green Published, gold
DA 2022-11-30
ER

PT J
AU Piccardi, M
   Marangoni, D
   Minnella, AM
   Savastano, MC
   Valentini, P
   Ambrosio, L
   Capoluongo, E
   Maccarone, R
   Bisti, S
   Falsini, B
AF Piccardi, M.
   Marangoni, D.
   Minnella, A. M.
   Savastano, M. C.
   Valentini, P.
   Ambrosio, L.
   Capoluongo, E.
   Maccarone, R.
   Bisti, S.
   Falsini, B.
TI A Longitudinal Follow-Up Study of Saffron Supplementation in Early
   Age-Related Macular Degeneration: Sustained Benefits to Central Retinal
   Function
SO EVIDENCE-BASED COMPLEMENTARY AND ALTERNATIVE MEDICINE
LA English
DT Article
ID COMPLEMENT FACTOR-H; MACULOPATHY; SENSITIVITY; GENE; CAROTENOIDS;
   SYSTEM; LIGHT
AB Objectives. In a previous randomized clinical trial (Falsini et al. (2010)), it was shown that short-term Saffron supplementation improves retinal flicker sensitivity in early age-related macular degeneration (AMD). The aim of this study was to evaluate whether the observed functional benefits from Saffron supplementation may extend over a longer follow-up duration. Design. Longitudinal, interventional open-label study. Setting. Outpatient ophthalmology setting. Participants. Twenty-nine early AMD patients (age range: 55-85 years) with a baseline visual acuity >0.3. Intervention. Saffron oral supplementation (20 mg/day) over an average period of treatment of 14 (+/-2) months. Measurements. Clinical examination and focal-electroretinogram-(fERG-) derived macular (18 degrees) flicker sensitivity estimate (Falsini et al. (2010)) every three months over a followup of 14 (+/-2) months. Retinal sensitivity, the reciprocal value of the estimated fERG amplitude threshold, was the main outcome measure. Results. After three months of supplementation, mean fERG sensitivity improved by 0.3 log units compared to baseline values (P < 0.01), and mean visual acuity improved by two Snellen lines compared to baseline values (0.75 to 0.9, P < 0.01). These changes remained stable over the followup period. Conclusion. These results indicate that in early AMD Saffron supplementation induces macular function improvements from baseline that are extended over a long-term followup.
C1 [Piccardi, M.; Marangoni, D.; Minnella, A. M.; Savastano, M. C.; Valentini, P.; Falsini, B.] Univ Cattolica Sacro Cuore, Dipartimento Sci Otorinolaringoiatr & Oftalmol, I-00168 Rome, Italy.
   [Piccardi, M.; Capoluongo, E.] Univ Cattolica Sacro Cuore, Ist Biochim Clin, I-00168 Rome, Italy.
   [Ambrosio, L.] Univ Naples Federico II, Dipartimento Sci & Oftalmol, I-580131 Naples, Italy.
   [Maccarone, R.] Univ Aquila, Dipartimento Sci & Tecnol Biomed, I-67100 Laquila, Italy.
   [Bisti, S.] Univ Aquila, DISCAB, I-67100 Laquila, Italy.
   [Bisti, S.] Australian Natl Univ, ARC Ctr Excellence Vis Sci, Canberra, ACT 0200, Australia.
   [Bisti, S.] Ist Nazl Biostrutture & Biosistemi, I-00136 Rome, Italy.
   [Falsini, B.] Univ Cattolica Sacro Cuore, Ist Oftalmol, I-00168 Rome, Italy.
C3 Catholic University of the Sacred Heart; IRCCS Policlinico Gemelli;
   Catholic University of the Sacred Heart; IRCCS Policlinico Gemelli;
   University of Naples Federico II; Consiglio Nazionale delle Ricerche
   (CNR); Istituto di Tecnologie Biomediche (ITB-CNR); University of
   L'Aquila; University of L'Aquila; Australian National University;
   Catholic University of the Sacred Heart; IRCCS Policlinico Gemelli
RP Falsini, B (通讯作者)，Univ Cattolica Sacro Cuore, Dipartimento Sci Otorinolaringoiatr & Oftalmol, I-00168 Rome, Italy.
EM bfalsini@rm.unicatt.it
RI minnella, angelo maria/AAQ-6250-2020; Savastano, Maria
   Cristina/I-5355-2015; Piccardi, Marco/AAA-7849-2019; Falsini,
   Benedetto/V-1070-2019; Falsini, Benedetto/AAC-5907-2022; Ambrosio,
   Lucia/F-2345-2018
OI minnella, angelo maria/0000-0001-5896-5313; Savastano, Maria
   Cristina/0000-0003-1397-4333; Falsini, Benedetto/0000-0002-1694-1062;
   Ambrosio, Lucia/0000-0001-5488-8429; CAPOLUONGO, Ettore
   Domenico/0000-0003-4402-8403; PICCARDI, Marco/0000-0002-9836-7534;
   MACCARONE, Rita/0000-0003-0648-3771; Falsini,
   Benedetto/0000-0002-3569-4968
FU company Hortus Novus
FX We thank the company Hortus Novus for kindly providing the saffron pills
   and giving support to this study.
CR BIRD AEC, 1995, SURV OPHTHALMOL, V39, P367, DOI 10.1016/S0039-6257(05)80092-X
   Falsini B, 2003, OPHTHALMOLOGY, V110, P51, DOI 10.1016/S0161-6420(02)01547-6
   Falsini B, 2000, INVEST OPHTH VIS SCI, V41, P1498
   Falsini B, 2010, INVEST OPHTH VIS SCI, V51, P6118, DOI 10.1167/iovs.09-4995
   FIORENTINI A, 1981, INVEST OPHTH VIS SCI, V21, P490
   Giaccio M, 2004, CRIT REV FOOD SCI, V44, P155, DOI 10.1080/10408690490441433
   Hageman GS, 2005, P NATL ACAD SCI USA, V102, P7227, DOI 10.1073/pnas.0501536102
   Hollyfield JG, 2008, NAT MED, V14, P194, DOI 10.1038/nm1709
   Kanakis CD, 2007, CELL BIOCHEM BIOPHYS, V49, P29, DOI 10.1007/s12013-007-0037-2
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1417, DOI 10.1001/archopht.119.10.1417
   Laabich A, 2006, INVEST OPHTH VIS SCI, V47, P3156, DOI 10.1167/iovs.05-1621
   Maccarone R, 2008, INVEST OPHTH VIS SCI, V49, P1254, DOI 10.1167/iovs.07-0438
   Natoli R, 2010, MOL VIS, V16, P1801
   Ochiai T, 2007, BBA-GEN SUBJECTS, V1770, P578, DOI 10.1016/j.bbagen.2006.11.012
   Parisi V, 2008, OPHTHALMOLOGY, V115, P324, DOI 10.1016/j.ophtha.2007.05.029
   Richer Stuart, 2004, Optometry, V75, P216, DOI 10.1016/S1529-1839(04)70049-4
   Rivera A, 2005, HUM MOL GENET, V14, P3227, DOI 10.1093/hmg/ddi353
   SEIPLE W, 1992, VISION RES, V32, P2043, DOI 10.1016/0042-6989(92)90065-Q
   SEIPLE WH, 1993, INVEST OPHTH VIS SCI, V34, P2638
   Weismann D, 2011, NATURE, V478, P76, DOI 10.1038/nature10449
   Wong WT, 2010, INVEST OPHTH VIS SCI, V51, P6131, DOI 10.1167/iovs.10-5637
NR 21
TC 61
Z9 61
U1 2
U2 17
PU HINDAWI LTD
PI LONDON
PA ADAM HOUSE, 3RD FLR, 1 FITZROY SQ, LONDON, W1T 5HF, ENGLAND
SN 1741-427X
EI 1741-4288
J9 EVID-BASED COMPL ALT
JI Evid.-based Complement Altern. Med.
PY 2012
VL 2012
AR 429124
DI 10.1155/2012/429124
PG 9
WC Integrative & Complementary Medicine
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Integrative & Complementary Medicine
GA 989PH
UT WOS:000307572000001
PM 22852021
OA Green Published, Green Submitted, gold
DA 2022-11-30
ER

PT J
AU Garweg, JG
   Gerhardt, C
AF Garweg, Justus G.
   Gerhardt, Christin
TI Disease stability and extended dosing under anti-VEGF treatment of
   exudative age-related macular degeneration (AMD) - a meta-analysis
SO GRAEFES ARCHIVE FOR CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY
LA English
DT Article
DE Age-related macular degeneration (AMD); Neovascular AMD;
   Treat-and-extend; Ranibizumab; Aflibercept; Brolucizumab
ID ENDOTHELIAL GROWTH-FACTOR; RANIBIZUMAB TREATMENT; FOLLOW-UP; CHOROIDAL
   NEOVASCULARIZATION; PROSPECTIVE TRIAL; AFLIBERCEPT; OUTCOMES; THERAPY;
   BEVACIZUMAB; WET
AB Purpose To assess disease stability (absence of intra- and/or subretinal fluid) and the portion of eyes being capable to extend their treatment interval to >= 12 weeks in exudative age-related macular degeneration (AMD).
   Methods A systematic literature search was performed in NCBI, PubMed, CENTRAL, and to identify clinical studies reporting treatment outcomes for ranibizumab, aflibercept, and brolucizumab in exudative AMD under a treat-and-extend protocol and a follow-up of >= 12 months. Weighted mean differences and subgroup comparisons were used to integrate the different studies.
   Results This meta-analysis refers to 29 published series, including 27 independent samples and 5629 patients. In the pooled group, disease stability was reported in 62.9% and 56.0%, respectively, after 12 and 24 months of treatment, whereas treatment intervals were extended to >= 12 weeks in 37.7% and 42.6%, respectively. Ranibizumab, aflibercept, and brolucizumab differed regarding their potential to achieve disease stability (56.3%, 64.5%, and 71.5% after 12, and 50.0%, 52.7% and 75.7% after 24 months; p = < 0.001) and to allow an interval extension to >= 12 weeks (28.6%, 34.2%, and 53.3% after 12, and 34.2%, 47.7%, and 41.7% after 24 months; p = < 0.001).
   Conclusion The portion of eyes achieving disease stability regressed in the second year, whereas the portion of eyes under a >= 12-week interval increased. This discrepancy may reflect the challenges in balancing between under-treatment and a reduced treatment burden.
C1 [Garweg, Justus G.; Gerhardt, Christin] Swiss Eye Inst, Rotkreuz, Switzerland.
   [Garweg, Justus G.; Gerhardt, Christin] Lindenhofspital, Berner Augenklin, Bern, Switzerland.
   [Garweg, Justus G.] Univ Bern, Dept Ophthalmol, Inselspital, Bern, Switzerland.
C3 University of Bern
RP Garweg, JG (通讯作者)，Swiss Eye Inst, Rotkreuz, Switzerland.; Garweg, JG (通讯作者)，Lindenhofspital, Berner Augenklin, Bern, Switzerland.; Garweg, JG (通讯作者)，Univ Bern, Dept Ophthalmol, Inselspital, Bern, Switzerland.
EM Justus.garweg@augenklinik-bern.ch
OI Schild, Christin/0000-0001-7705-1103
FU Bern University of Applied Sciences
FX Open Access funding provided by Bern University of Applied Sciences.
CR Al-Khersan H, 2019, EXPERT OPIN PHARMACO, V20, P1879, DOI 10.1080/14656566.2019.1636031
   Amoaku WM, 2015, EYE, V29, P721, DOI 10.1038/eye.2015.48
   Ashraf M, 2018, ACTA OPHTHALMOL, V96, P120, DOI 10.1111/aos.13565
   Barthelmes D, 2018, GRAEF ARCH CLIN EXP, V256, P1839, DOI 10.1007/s00417-018-4061-2
   Barthelmes D, 2018, RETINA-J RET VIT DIS, V38, P20, DOI 10.1097/IAE.0000000000001496
   Bayer Schweiz AG, 2020, SUPPLEMENT OPHTA 2 2
   Berg K, 2017, ACTA OPHTHALMOL, V95, P796, DOI 10.1111/aos.13522
   Berg K, 2016, OPHTHALMOLOGY, V123, P51, DOI 10.1016/j.ophtha.2015.09.018
   Berg K, 2015, OPHTHALMOLOGY, V122, P146, DOI 10.1016/j.ophtha.2014.07.041
   Boulanger-Scemama E, 2015, J FR OPHTALMOL, V38, P620, DOI 10.1016/j.jfo.2014.11.015
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Campochiaro PA, 2016, OPHTHALMOLOGY, V123, pS78, DOI 10.1016/j.ophtha.2016.04.056
   COHEN J, 1960, EDUC PSYCHOL MEAS, V20, P37, DOI 10.1177/001316446002000104
   Cui J, 2018, EYE, V32, P391, DOI 10.1038/eye.2017.187
   Dadgostar H, 2008, EYE, V22, P761, DOI 10.1038/eye.2008.86
   Decroos FC, 2017, AM J OPHTHALMOL, V180, P142, DOI 10.1016/j.ajo.2017.06.002
   Dugel PU, 2020, OPHTHALMOLOGY, V127, P72, DOI 10.1016/j.ophtha.2019.04.017
   Dugel PU, 2017, OPHTHALMOLOGY, V124, P1296, DOI 10.1016/j.ophtha.2017.03.057
   Dugel PU, 2020, HAWK HARRIER 96 WEEK
   Eleftheriadou M, 2018, OPHTHALMOL THER, V7, P361, DOI 10.1007/s40123-018-0139-5
   Essex RW, 2016, OPHTHALMOLOGY, V123, P2393, DOI 10.1016/j.ophtha.2016.07.012
   Faatz H, 2019, BMJ OPEN OPHTHALMOL, V4, DOI 10.1136/bmjophth-2019-000369
   Fauser S, 2014, AM J OPHTHALMOL, V158, P532, DOI 10.1016/j.ajo.2014.05.025
   Finger R, 2012, BRIT J OPHTHALMOL, V96, P997, DOI 10.1136/bjophthalmol-2011-301201
   Frennesson C, 2010, ACTA OPHTHALMOL, V88, P420, DOI 10.1111/j.1755-3768.2009.01576.x
   Garweg JG, 2016, OPHTHALMOLOGE, V113, P1036, DOI 10.1007/s00347-016-0306-9
   Garweg JG, 2018, GRAEF ARCH CLIN EXP, V256, P823, DOI 10.1007/s00417-018-3907-y
   Garweg JG, 2017, J OCUL PHARMACOL TH, V33, P773, DOI 10.1089/jop.2017.0006
   Gemenetzi M, 2017, OPHTHALMOL THER, V6, P79, DOI 10.1007/s40123-017-0087-5
   Gillies MC, 2020, OPHTHALMOLOGY, V127, P198, DOI 10.1016/j.ophtha.2019.08.023
   Gillies MC, 2019, JAMA OPHTHALMOL, V137, P372, DOI 10.1001/jamaophthalmol.2018.6776
   Gohil R, 2016, PATIENT PREFER ADHER, V10, P949, DOI 10.2147/PPA.S105536
   Grisanti Salvatore, 2007, Indian Journal of Ophthalmology, V55, P417
   Guymer RH, 2019, OPHTHALMOLOGY, V126, P723, DOI 10.1016/j.ophtha.2018.11.025
   Hanhart J, 2017, BMC OPHTHALMOL, V17, DOI 10.1186/s12886-017-0586-0
   Hatz, 2019, EURETINA PAR FRANC S
   Hatz, 2019, ASS RES VIS OPHT ANN
   Heier JS, 2012, OPHTHALMOLOGY, V119, P2537, DOI 10.1016/j.ophtha.2012.09.006
   Jorstad OK, 2017, ACTA OPHTHALMOL, V95, P460, DOI 10.1111/aos.13480
   Kertes PJ, 2020, JAMA OPHTHALMOL, V138, P244, DOI 10.1001/jamaophthalmol.2019.5540
   Kertes PJ, 2019, OPHTHALMOLOGY, V126, P841, DOI 10.1016/j.ophtha.2019.01.013
   Khurana RN, 2019, AM J OPHTHALMOL, V200, P161, DOI 10.1016/j.ajo.2019.01.005
   Kim LN, 2016, RETINA-J RET VIT DIS, V36, P1418, DOI 10.1097/IAE.0000000000001142
   Kumar N, 2013, OPHTHALMOLOGY, V120, P334, DOI 10.1016/j.ophtha.2012.07.076
   McClintic SM, 2018, OPHTHALMOL RETINA, V2, P931, DOI 10.1016/j.oret.2018.01.014
   Mehta H, 2018, PROG RETIN EYE RES, V65, P127, DOI 10.1016/j.preteyeres.2017.12.002
   Michels Stephan, 2006, Expert Opin Investig Drugs, V15, P779, DOI 10.1517/13543784.15.7.779
   Miere A, 2018, J OPHTHALMOL, V2018, DOI 10.1155/2018/3751702
   Mitchell P, 2020, INVEST OPHTH VIS SCI, V61
   Ohji, 2018, 2 DIFFERENT TREAT EX
   Ohji M, 2020, ADV THER, V37, P1173, DOI 10.1007/s12325-020-01236-x
   Okada M, 2018, AM J OPHTHALMOL, V192, P184, DOI 10.1016/j.ajo.2018.05.026
   Pierce CA, 2008, ORGAN RES METHODS, V11, P188, DOI 10.1177/1094428106296641
   Regillo CD, 2015, AM J OPHTHALMOL, V160, P1014, DOI 10.1016/j.ajo.2015.07.034
   Richard G, 2015, OPHTHALMOLOGY, V122, P2497, DOI 10.1016/j.ophtha.2015.08.014
   Rofagha S, 2013, OPHTHALMOLOGY, V120, P2292, DOI 10.1016/j.ophtha.2013.03.046
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Rosenfeld PJ, 2005, OPHTHAL SURG LAS IM, V36, P331, DOI 10.3928/1542-8877-20050701-14
   Sadda SR, 2018, OPHTHALMOLOGY, V125, P878, DOI 10.1016/j.ophtha.2017.12.026
   Sagiv O, 2017, OPHTHALMOLOGICA, V238, P217, DOI 10.1159/000479437
   Sahni J, 2019, OPHTHALMOLOGY, V126, P1155, DOI 10.1016/j.ophtha.2019.03.023
   Schmidt-Erfurth U, 2014, OPHTHALMOLOGY, V121, P193, DOI 10.1016/j.ophtha.2013.08.011
   Silva R, 2018, OPHTHALMOLOGY, V125, P57, DOI 10.1016/j.ophtha.2017.07.014
   Singer MA, 2012, OPHTHALMOLOGY, V119, P1175, DOI 10.1016/j.ophtha.2011.12.016
   Singh RP, 2018, AM J OPHTHAL CLIN TR, V1, DOI 10.25259/AJOCT-2-2018
   Solomon SD, 2019, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD005139.pub4
   Souied EH, 2014, AM J OPHTHALMOL, V158, P724, DOI 10.1016/j.ajo.2014.05.037
   Staurenghi G, 2020, BMC OPHTHALMOL, V20, DOI 10.1186/s12886-019-1251-6
   Stewart MW, 2008, BRIT J OPHTHALMOL, V92, P667, DOI 10.1136/bjo.2007.134874
   Stoller GL, 2016, JAMA OPHTHALMOL, V134, P545, DOI 10.1001/jamaophthalmol.2016.0379
   Taipale C, 2020, ACTA OPHTHALMOL, V98, P267, DOI 10.1111/aos.14231
   Toalster N, 2013, RETINA-J RET VIT DIS, V33, P1351, DOI 10.1097/IAE.0b013e3182831265
   Traine PG, 2019, OPHTHALMOL RETINA, V3, P393, DOI 10.1016/j.oret.2019.01.018
   Uchida A, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0218889
   Villegas VM, 2017, EXPERT OPIN DRUG DEL, V14, P273, DOI 10.1080/17425247.2016.1213240
   Nguyen V, 2019, OPHTHALMOLOGY, V126, P64, DOI 10.1016/j.ophtha.2018.08.023
   Wykoff CC, 2018, BRIT J OPHTHALMOL, V102, P460, DOI 10.1136/bjophthalmol-2017-310822
   Wykoff CC, 2017, OPHTHALMOL RETINA, V1, P314, DOI 10.1016/j.oret.2016.12.004
   Wykoff CC, 2018, J MANAG CARE SPEC PH, V24, pS3, DOI 10.18553/jmcp.2018.24.2-a.s3
   Wykoff CC, 2015, OPHTHALMOLOGY, V122, P2514, DOI 10.1016/j.ophtha.2015.08.009
NR 80
TC 5
Z9 6
U1 0
U2 4
PU SPRINGER
PI NEW YORK
PA ONE NEW YORK PLAZA, SUITE 4600, NEW YORK, NY, UNITED STATES
SN 0721-832X
EI 1435-702X
J9 GRAEF ARCH CLIN EXP
JI Graefes Arch. Clin. Exp. Ophthalmol.
PD AUG
PY 2021
VL 259
IS 8
BP 2181
EP 2192
DI 10.1007/s00417-020-05048-1
EA FEB 2021
PG 12
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA TX9FL
UT WOS:000613999100003
PM 33528645
OA hybrid, Green Published
DA 2022-11-30
ER

PT J
AU Wysokinski, D
   Synowiec, E
   Chmielewska, M
   Wozniak, K
   Zaras, M
   Sklodowska, A
   Blasiak, J
   Szaflik, J
   Szaflik, JP
AF Wysokinski, Daniel
   Synowiec, Ewelina
   Chmielewska, Marta
   Wozniak, Katarzyna
   Zaras, Malgorzata
   Sklodowska, Anna
   Blasiak, Janusz
   Szaflik, Jerzy
   Szaflik, Jacek Pawel
TI Lack of association between the c.544G > A polymorphism of the heme
   oxygenase-2 gene and age-related macular degeneration
SO MEDICAL SCIENCE MONITOR
LA English
DT Article
DE heme oxygenase-2; HMOX2 gene; age-related macular degeneration (AMD);
   genetic polymorphism; Iron metabolism
ID CARBON-MONOXIDE; OXIDATIVE STRESS; IRON ACCUMULATION; EPITHELIAL-CELLS;
   NITRIC-OXIDE; EYE DISEASE; INFLAMMATION; TOXICITY; PROTECTS; RETINA
AB Background: Age-related macular degeneration (AMD) is a primary cause of blindness among the elderly in developed countries. The nature of AMD is complex and includes both environmental and hereditary factors. Oxidative stress is thought to be essential in AMD pathogenesis. Iron is suggested to be implicated in the pathogenesis of AMD through the catalysis of the production of reactive oxygen species, which can damage the retina. Heme oxygenase-2 is capable of degradation of heme producing free iron ions, thus, diversity in heme oxygenase-2 gene may contribute to AMD. In the present work we analyzed the association between the c.544G>A polymorphism of the heme oxygenase-2 gene (HMOX2) (rs1051308) and AMD.
   Material/Methods: This study enrolled 276 AMD patients and 105 sex- and age-matched controls. Genotyping of the polymorphism was performed with restriction fragment length polymorphism polymerase chain reaction (RFLP-PCR) on DNA isolated from peripheral blood.
   Results: We did not find any association between the genotypes of the c.544G>A polymorphism and the occurrence of AMD. This lack of association was independent of potential AMD risk factors: tobacco smoking, sex and age. Moreover, we did not find any association between AMD and smoking in our study population.
   Conclusions: The results suggest that the c.544G>A polymorphism of the heme oxygenase-2 gene is not associated with AMD in this Polish subpopulation.
C1 [Zaras, Malgorzata; Sklodowska, Anna; Szaflik, Jerzy; Szaflik, Jacek Pawel] Med Univ Warsaw, Dept Ophthalmol, PL-03709 Warsaw, Poland.
   [Zaras, Malgorzata; Sklodowska, Anna; Szaflik, Jerzy; Szaflik, Jacek Pawel] SPKSO Hosp, PL-03709 Warsaw, Poland.
   [Wysokinski, Daniel; Synowiec, Ewelina; Chmielewska, Marta; Wozniak, Katarzyna; Blasiak, Janusz] Univ Lodz, Dept Mol Genet, PL-90131 Lodz, Poland.
C3 Medical University of Warsaw; University of Lodz
RP Szaflik, JP (通讯作者)，Med Univ Warsaw, Dept Ophthalmol, Sierakowskiego 13, PL-03709 Warsaw, Poland.
EM szaflik@ophthalmology.pl
RI Wozniak, Katarzyna/R-9226-2018
OI Wozniak, Katarzyna/0000-0001-6666-7973; Blasiak,
   Janusz/0000-0001-9539-9584; Synowiec, Ewelina/0000-0002-0730-4491;
   Szaflik, Jerzy/0000-0002-7601-1326; Bielska, Marta/0000-0003-1446-532X
FU Polish Ministry of Science and Higher Education [N N402 248 336]
FX The study was supported by the grant N N402 248 336 from the Polish
   Ministry of Science and Higher Education
CR Abraham NG, 2008, PHARMACOL REV, V60, P79, DOI 10.1124/pr.107.07104
   Augustin AJ, 2009, EXPERT OPIN THER TAR, V13, P641, DOI 10.1517/14728220902942322
   Basuroy S, 2006, AM J PHYSIOL-CELL PH, V291, pC897, DOI 10.1152/ajpcell.00032.2006
   Bellner L, 2009, J PHARMACOL EXP THER, V331, P925, DOI 10.1124/jpet.109.158352
   Bilban M, 2006, IMMUNITY, V24, P601, DOI 10.1016/j.immuni.2006.03.012
   Buch H, 2005, ACTA OPHTHALMOL SCAN, V83, P409, DOI 10.1111/J.1600-0420.2005.00492.x
   Cao LX, 2000, VISUAL NEUROSCI, V17, P319, DOI 10.1017/S0952523800173018
   Chang EF, 2003, J NEUROSCI, V23, P3689
   Coban E, 2010, MED SCI MONITOR, V16, pCR92
   Coleman HR, 2008, LANCET, V372, P1835, DOI 10.1016/S0140-6736(08)61759-6
   Dennery PA, 1998, J CLIN INVEST, V101, P1001, DOI 10.1172/JCI448
   Ding XY, 2009, PROG RETIN EYE RES, V28, P1, DOI 10.1016/j.preteyeres.2008.10.001
   Fang AM, 2009, MOL VIS, V15, P2710
   Foresti R, 2004, BIOCHEM SOC SYMP, V71, P177, DOI 10.1042/bss0710177
   Hadziahmetovic M, 2011, INVEST OPHTH VIS SCI, V52, P959, DOI 10.1167/iovs.10-6207
   Hadziahmetovic M, 2011, INVEST OPHTH VIS SCI, V52, P109, DOI 10.1167/iovs.10-6113
   Hollyfield JG, 2008, NAT MED, V14, P194, DOI 10.1038/nm1709
   Justilien V, 2007, INVEST OPHTH VIS SCI, V48, P4407, DOI 10.1167/iovs.07-0432
   Kanda A, 2007, P NATL ACAD SCI USA, V104, P16227, DOI 10.1073/pnas.0703933104
   Kent M, 2010, J AM ANIM HOSP ASSOC, V46, P259, DOI 10.5326/0460259
   Kim HS, 2006, BIOCHEM BIOPH RES CO, V344, P1172, DOI 10.1016/j.bbrc.2006.03.180
   Klein R, 2003, OPHTHALMOLOGY, V110, P636, DOI 10.1016/S0161-6420(02)01448-3
   Kowalski M, 2010, MED SCI MONITOR, V16, pCR190
   Kumar S, 2005, TOXICOL LETT, V157, P175, DOI 10.1016/j.toxlet.2005.03.004
   Lakkisto P, 2010, EUR J PHARMACOL, V635, P156, DOI 10.1016/j.ejphar.2010.02.050
   Liutkeviciene R, 2010, MEDICINA-LITHUANIA, V46, P89, DOI 10.3390/medicina46020013
   Loh A, 2009, BBA-GEN SUBJECTS, V1790, P637, DOI 10.1016/j.bbagen.2008.11.001
   Ma N, 2004, J NEUROCYTOL, V33, P407, DOI 10.1007/s11068-004-4206-6
   Milton RC, 2005, OPHTHALMOLOGY, V112, P533, DOI 10.1016/j.ophtha.2004.10.047
   Oates PS, 2006, WORLD J GASTROENTERO, V12, P4281, DOI 10.3748/wjg.v12.i27.4281
   Papanikolaou G, 2005, TOXICOL APPL PHARM, V202, P199, DOI 10.1016/j.taap.2004.06.021
   Parfenova H, 2008, CURR PHARM DESIGN, V14, P443, DOI 10.2174/138161208783597380
   Piantadosi CA, 2008, FREE RADICAL BIO MED, V45, P562, DOI 10.1016/j.freeradbiomed.2008.05.013
   Qin S, 2007, DRUG DEVELOP RES, V68, P213, DOI 10.1002/ddr.20185
   Rueff-Barroso CR, 2010, MED SCI MONITOR, V16, pBR218
   Seddon JM, 2004, JAMA-J AM MED ASSOC, V291, P704, DOI 10.1001/jama.291.6.704
   Seddon JM, 2006, ARCH OPHTHALMOL-CHIC, V124, P995, DOI 10.1001/archopht.124.7.995
   Tracz MJ, 2007, J AM SOC NEPHROL, V18, P414, DOI 10.1681/ASN.2006080894
   Tuo JS, 2006, P NATL ACAD SCI USA, V103, P9256, DOI 10.1073/pnas.0603485103
   Turkseven S, 2007, J CELL BIOCHEM, V100, P815, DOI 10.1002/jcb.21138
   Unno M, 2007, NAT PROD REP, V24, P553, DOI 10.1039/b604180a
   Vine AK, 2005, OPHTHALMOLOGY, V112, P2076, DOI 10.1016/j.ophtha.2005.07.004
   Wagener FADTG, 2003, PHARMACOL REV, V55, P551, DOI 10.1124/pr.55.3.5
   Yamada Y, 2008, J NEUROCHEM, V105, P1187, DOI 10.1111/j.1471-4159.2008.05211.x
   Yu DY, 2001, PROG RETIN EYE RES, V20, P175, DOI 10.1016/S1350-9462(00)00027-6
   Zhu YQ, 2008, BIOCHEMISTRY-US, V47, P2231, DOI 10.1021/bi7023817
NR 46
TC 4
Z9 4
U1 0
U2 0
PU INT SCIENTIFIC LITERATURE, INC
PI SMITHTOWN
PA 361 FOREST LANE, SMITHTOWN, NY 11787 USA
SN 1643-3750
J9 MED SCI MONITOR
JI Med. Sci. Monitor
PD AUG
PY 2011
VL 17
IS 8
BP CR449
EP CR455
DI 10.12659/MSM.881906
PG 7
WC Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Research & Experimental Medicine
GA 833QJ
UT WOS:000295899700013
PM 21804464
OA Green Published, Green Submitted
DA 2022-11-30
ER

PT J
AU Kim, JE
   Shah, KB
   Han, DP
   Connor, TB
AF Kim, Judy E.
   Shah, Kekul B.
   Han, Dennis P.
   Connor, Thomas B., Jr.
TI Transpupillary thermotherapy with indocyanine green dye enhancement for
   the treatment of occult subfoveal choroidal Neovascularization in
   age-related macular degeneration
SO OPHTHALMIC SURGERY LASERS & IMAGING
LA English
DT Article
ID DIODE-LASER PHOTOCOAGULATION; PHOTODYNAMIC THERAPY; THRESHOLD
   PARAMETERS; VERTEPORFIN THERAPY; TEMPERATURE; LESIONS
AB BACKGROUND AND OBJECTIVES: Transpupillary thermotherapy (TTT) with indocyanine green (ICG) dye enhancement (TTT+) and TTT alone were compared for safety and effectiveness as a treatment of occult subfoveal choroidal neovascularization in age-related macular degeneration.
   PATIENTS AND METHODS: Twenty-one patients were randomized to receive TTT (12 eyes) or TTT+ (9 eyes) and observed for at least 6 months. ETDRS visual acuity and fluorescein and ICG angiography were obtained every 3 months.
   RESULTS: The median initial visual acuity was 20/80 in the TTT group and 20/100 in the TTT+ group. At 6 months, loss of less than 3 lines of visual acuity was present in 7 of 12 eyes (58%) in the TTT group and 5 of 9 eyes (56%) in the TTT+ group. At the final examination, there was no active choroidal neovascularization exudation in 6 of 12 eyes (50%) in the TTT group and 5 of 9 eyes (56%) in the TTT+ group. The median final visual acuity was 20/125 in the TTT group and 20/160 in the TTT+ group. Ocular or systemic complications were not encountered in either group. m
   CONCLUSION: TTT with ICG dye enhancement was as safe and effective as TTT alone in this study. However, modifications of treatment protocol would be needed to see whether there is any advantage to using ICG dye enhancement.
C1 Med Coll Wisconsin, Inst Eye, Milwaukee, WI 53226 USA.
C3 Medical College of Wisconsin
RP Kim, JE (通讯作者)，Med Coll Wisconsin, Inst Eye, 925 N 87th St, Milwaukee, WI 53226 USA.
CR Ahuja R M, 2001, Semin Ophthalmol, V16, P81, DOI 10.1076/soph.16.2.81.4215
   Arnold J, 2001, AM J OPHTHALMOL, V131, P541
   Bressler NM, 1999, ARCH OPHTHALMOL-CHIC, V117, P1329
   Costa RA, 2002, CURR EYE RES, V25, P287, DOI 10.1076/ceyr.25.5.287.13496
   Costa RA, 2001, CURR EYE RES, V23, P271, DOI 10.1076/ceyr.23.4.271.5449
   Costa RA, 2001, AM J OPHTHALMOL, V132, P557, DOI 10.1016/S0002-9394(01)01138-2
   Falsini B, 2003, INVEST OPHTH VIS SCI, V44, P2133, DOI 10.1167/iovs.02-0716
   Gragoudas ES, 2004, NEW ENGL J MED, V351, P2805, DOI 10.1056/NEJMoa042760
   HAWKINS BS, 1993, ARCH OPHTHALMOL-CHIC, V111, P1200
   HO AC, 1994, OPHTHALMOLOGY, V101, P534
   Ibarra MS, 2004, INVEST OPHTH VIS SCI, V45, P3678, DOI 10.1167/iovs.04-0436
   MAINSTER MA, 1970, J OPT SOC AM, V60, P264, DOI 10.1364/JOSA.60.000264
   Mainster MA, 2000, OPHTHALMIC SURG LAS, V31, P359
   Margherio RR, 2000, RETINA-J RET VIT DIS, V20, P325, DOI 10.1097/00006982-200007000-00001
   Miura S, 2003, INVEST OPHTH VIS SCI, V44, P2716, DOI 10.1167/iovs.02-1210
   Obana A, 2000, JPN J OPHTHALMOL, V44, P668, DOI 10.1016/S0021-5155(00)00274-4
   Peyman GA, 2003, RETINA-J RET VIT DIS, V23, P378, DOI 10.1097/00006982-200306000-00015
   Peyman GA, 2003, RETINA-J RET VIT DIS, V23, P371, DOI 10.1097/00006982-200306000-00014
   Reichel E, 1999, OPHTHALMOLOGY, V106, P1908, DOI 10.1016/S0161-6420(99)90400-1
   REICHEL E, 1994, OPHTHALMIC SURG LAS, V25, P195
   REICHEL E, 2005, RET SOC 38 ANN SCI M
   Sharma S, 2001, OPHTHALMOLOGY, V108, P2051, DOI 10.1016/S0161-6420(01)00764-3
   Stollberger R, 1998, JMRI-J MAGN RESON IM, V8, P188, DOI 10.1002/jmri.1880080132
   Thompson JT, 2001, AM J OPHTHALMOL, V131, P662, DOI 10.1016/S0002-9394(00)00879-5
NR 24
TC 4
Z9 4
U1 0
U2 0
PU SLACK INC
PI THOROFARE
PA 6900 GROVE RD, THOROFARE, NJ 08086 USA
SN 1542-8877
J9 OPHTHAL SURG LAS IM
JI Ophthalmic Surg. Lasers Imaging
PD JUL-AUG
PY 2006
VL 37
IS 4
BP 272
EP 277
DI 10.3928/15428877-20060701-02
PG 6
WC Ophthalmology; Surgery
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology; Surgery
GA 070ZY
UT WOS:000239567600002
PM 16898386
DA 2022-11-30
ER

PT J
AU Farinha, C
   Cachulo, ML
   Coimbra, R
   Alves, D
   Nunes, S
   Pires, I
   Marques, JP
   Costa, J
   Martins, A
   Sobral, I
   Barreto, P
   Lains, I
   Figueira, J
   Ribeiro, L
   Cunha-Vaz, J
   Silva, R
AF Farinha, Claudia
   Cachulo, Maria Luz
   Coimbra, Rita
   Alves, Dalila
   Nunes, Sandrina
   Pires, Isabel
   Marques, Joao Pedro
   Costa, Jose
   Martins, Amelia
   Sobral, Isa
   Barreto, Patricia
   Lains, Ines
   Figueira, Joao
   Ribeiro, Luisa
   Cunha-Vaz, Jose
   Silva, Rufino
TI Age-Related Macular Degeneration Staging by Color Fundus Photography vs.
   Multimodal Imaging-Epidemiological Implications (The Coimbra Eye
   Study-Report 6)
SO JOURNAL OF CLINICAL MEDICINE
LA English
DT Article
DE age-related macular degeneration; AMD staging; multimodal Imaging; early
   AMD; late AMD
ID COIMBRA EYE; SEVERITY SCALE; RISK-FACTORS; MACULOPATHY; PREVALENCE;
   CLASSIFICATION; PROGRESSION; PORTUGAL
AB Epidemiology of age-related macular degeneration (AMD) is based on staging systems relying on color fundus photography (CFP). We aim to compare AMD staging using CFP to multimodal imaging with optical coherence tomography (OCT), infra-red (IR), and fundus autofluorescence (FAF), in a large cohort from the Epidemiologic AMD Coimbra Eye Study. All imaging exams from the participants of this population-based study were classified by a central reading center. CFP images were graded according to the International Classification and Grading System for AMD and staged with Rotterdam classification. Afterward, CFP images were reviewed with OCT, IR, and FAF and stage update was performed if necessary. Early and late AMD prevalence was compared in a total of 1616 included subjects. In CFP-based grading, the prevalence was 14.11% for early AMD (n = 228) and 1.05% (n = 17) for late AMD, nine cases (0.56%) had neovascular AMD (nAMD) and eight (0.50%) geographic atrophy (GA). Using multimodal grading, the prevalence increased to 14.60% for early AMD (n = 236) and 1.61% (n = 26) for late AMD, with 14 cases (0.87%) of nAMD and 12 (0.74%) of GA. AMD staging was more accurate with the multimodal approach and this was especially relevant for late AMD. We propose that multimodal imaging should be adopted in the future to better estimate and compare epidemiological data in different populations.
C1 [Farinha, Claudia; Cachulo, Maria Luz; Coimbra, Rita; Alves, Dalila; Nunes, Sandrina; Pires, Isabel; Marques, Joao Pedro; Costa, Jose; Martins, Amelia; Sobral, Isa; Barreto, Patricia; Figueira, Joao; Ribeiro, Luisa; Cunha-Vaz, Jose; Silva, Rufino] AIBILI Assoc Innovat & Biomed Res Light & Image, P-3000548 Coimbra, Portugal.
   [Farinha, Claudia; Cachulo, Maria Luz; Pires, Isabel; Marques, Joao Pedro; Sobral, Isa; Figueira, Joao; Silva, Rufino] Ctr Hosp & Univ Coimbra CHUC, Dept Ophthalmol, P-3004561 Coimbra, Portugal.
   [Farinha, Claudia; Cachulo, Maria Luz; Pires, Isabel; Marques, Joao Pedro; Costa, Jose; Figueira, Joao; Ribeiro, Luisa; Cunha-Vaz, Jose; Silva, Rufino] Univ Coimbra FMUC, Fac Med, P-3000370 Coimbra, Portugal.
   [Lains, Ines] Harvard Med Sch, Massachusetts Eye & Ear, Boston, MA 02114 USA.
   [Ribeiro, Luisa; Silva, Rufino] Univ Coimbra iCBR FMUC, Fac Med, Coimbra Inst Clin & Biomed Res, P-3000548 Coimbra, Portugal.
C3 Universidade de Coimbra; Universidade de Coimbra; Centro Hospitalar e
   Universitario de Coimbra (CHUC); Universidade de Coimbra; Harvard
   University; Harvard Medical School; Massachusetts Eye & Ear Infirmary;
   Universidade de Coimbra
RP Farinha, C (通讯作者)，AIBILI Assoc Innovat & Biomed Res Light & Image, P-3000548 Coimbra, Portugal.; Farinha, C (通讯作者)，Ctr Hosp & Univ Coimbra CHUC, Dept Ophthalmol, P-3004561 Coimbra, Portugal.; Farinha, C (通讯作者)，Univ Coimbra FMUC, Fac Med, P-3000370 Coimbra, Portugal.
EM cvfarinha@aibili.pt; mluzcachulo@gmail.com; racoimbra@aibili.pt;
   dalves@aibili.pt; sandrina@aibili.pt; isabel.maravilha@sapo.pt;
   marquesjoaopedro@gmail.com; jfcosta@aibili.pt;
   martins.amelia9@gmail.com; isagabrielag@gmail.com; pbarreto@aibili.pt;
   ineslains@gmail.com; joaofigueira@oftalmologia.co.pt; lr@aibili.pt;
   cunhavaz@aibili.pt; rufino.silva@oftalmologia.co.pt
RI Marques, João Pedro/J-3584-2012; Farinha, Claudia/R-1392-2017
OI Marques, João Pedro/0000-0002-1014-0483; Farinha,
   Claudia/0000-0003-4596-0913; Pires, Isabel/0000-0002-5764-0178;
   Figueira, Joao P/0000-0002-3511-1515; Ribeiro, Maria
   Luisa/0000-0002-5801-8487
FU Novartis
FX This Investigator Initiated Study was financially supported by Novartis.
CR Age-Related Eye Dis Study Res Grp, 2001, AM J OPHTHALMOL, V132, P668
   Augood CA, 2006, ARCH OPHTHALMOL-CHIC, V124, P529, DOI 10.1001/archopht.124.4.529
   BIRD AEC, 1995, SURV OPHTHALMOL, V39, P367, DOI 10.1016/S0039-6257(05)80092-X
   Brandl C, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-26629-5
   Cachulo MD, 2016, ACTA OPHTHALMOL, V94, pE442, DOI 10.1111/aos.12950
   Cachulo MD, 2015, OPHTHALMOLOGICA, V233, P119, DOI 10.1159/000371584
   Colijn JM, 2017, OPHTHALMOLOGY, V124, P1753, DOI 10.1016/j.ophtha.2017.05.035
   Davis MD, 2005, ARCH OPHTHALMOL-CHIC, V123, P1484
   Ferris FL, 2005, ARCH OPHTHALMOL-CHIC, V123, P1570
   Ferris FL, 2013, OPHTHALMOLOGY, V120, P844, DOI 10.1016/j.ophtha.2012.10.036
   Garrity ST, 2018, INVEST OPHTH VIS SCI, V59, pAMD48, DOI 10.1167/iovs.18-24158
   Hogg RE, 2019, INVEST OPHTH VIS SCI, V60
   Holz FG, 2017, OPHTHALMOLOGY, V124, P464, DOI 10.1016/j.ophtha.2016.12.002
   Joachim N, 2015, OPHTHALMOLOGY, V122, P2482, DOI 10.1016/j.ophtha.2015.08.002
   Klaver CCW, 2001, INVEST OPHTH VIS SCI, V42, P2237
   KLEIN R, 1991, OPHTHALMOLOGY, V98, P1128
   Klein R, 2007, OPHTHALMOLOGY, V114, P253, DOI 10.1016/j.ophtha.2006.10.040
   Klein R, 2014, OPHTHAL EPIDEMIOL, V21, P14, DOI 10.3109/09286586.2013.867512
   Farinha CVL, 2019, OPHTHALMIC RES, V61, P226, DOI 10.1159/000496393
   Marques J.P., 2013, ISRN OPHTHALMOL, V2013
   Nunes S, 2018, NUTRITION, V51-52, P6, DOI 10.1016/j.nut.2017.12.010
   Raimundo M, 2018, ACTA OPHTHALMOL, V96, pE926, DOI 10.1111/aos.13775
   Rudnicka AR, 2015, AM J OPHTHALMOL, V160, P85, DOI 10.1016/j.ajo.2015.04.003
   Sadda SR, 2018, OPHTHALMOLOGY, V125, P537, DOI 10.1016/j.ophtha.2017.09.028
   Saunier V, 2018, JAMA OPHTHALMOL, V136, P473, DOI 10.1001/jamaophthalmol.2018.0504
   Spaide RF, 2018, RETINA-J RET VIT DIS, V38, P891, DOI 10.1097/IAE.0000000000001732
   Tomany SC, 2004, OPHTHALMOLOGY, V111, P1280, DOI 10.1016/j.ophtha.2003.11.010
   Tsikata E, 2017, TRANSL VIS SCI TECHN, V6, DOI 10.1167/tvst.6.2.3
   van Leeuwen R, 2003, ARCH OPHTHALMOL-CHIC, V121, P519, DOI 10.1001/archopht.121.4.519
   VINGERLING JR, 1995, OPHTHALMOLOGY, V102, P205
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
NR 31
TC 6
Z9 6
U1 3
U2 3
PU MDPI
PI BASEL
PA ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND
EI 2077-0383
J9 J CLIN MED
JI J. Clin. Med.
PD MAY
PY 2020
VL 9
IS 5
AR 1329
DI 10.3390/jcm9051329
PG 11
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine
GA LY0OO
UT WOS:000540223800086
PM 32370299
OA Green Published, gold
DA 2022-11-30
ER

PT J
AU Urata, CN
   Mazzoli, LS
   Kasahara, N
AF Urata, Carla N.
   Mazzoli, Livia S.
   Kasahara, Niro
TI A Comparative Analysis of the Fear of Falling Between Glaucoma and
   Age-Related Macular Degeneration Patients From a Developing Country
SO TRANSLATIONAL VISION SCIENCE & TECHNOLOGY
LA English
DT Article
DE glaucoma; age-related macular degeneration; fear of falling
ID OLDER-ADULTS; CONTRAST SENSITIVITY; EFFICACY SCALE; PREVALENCE; DISEASE;
   BRAZIL
AB Purpose: Falls are very prevalent in the older population. Visually impaired elderly patients are prone to falls as the result of visual loss and ageing. The purpose of the study was to compare the fear of falling (FoF) between primary open angle glaucoma (POAG) and age-related macular degeneration (ARMD) patients who live in a developing country.
   Methods: This was a cross-sectional observational study. After a complete eye examination including measurement of best-corrected visual acuity, ophthalmoscopy, and automated visual field, all subjects completed the Fall Efficacy Scale International Brazil (FES-I-Brazil) questionnaire.
   Results: The sample comprised 64 patients with POAG, 48 with ARMD, and 52 controls. All groups were matched for age, sex, comorbidity, and ethnic distribution. The FES-I score was 24.6 +/- 8.7, 25.3 +/- 6.3, and 24.2 +/- 7.7 for glaucoma, ARMD, and controls, respectively (P = 0.894). A post hoc analysis comparing all subjects with advanced visual field defect (mean deviation [MD], < - 12 dB) revealed a higher FES-I score in ARMD patients as compared to POAG ones (46.2 +/- 16.8 and 24.0 +/- 7.7 for ARMD and POAG, respectively, P < 0.001).
   Conclusion: In this cohort of elderly subjects with eye diseases, the FoF was similar among groups; however, ARMD patients with more compromised visual field had higher FoF as compared to POAG patients and controls.
C1 [Urata, Carla N.; Mazzoli, Livia S.; Kasahara, Niro] Irmandade Santa Casa Misericordia Sao Paulo, Sao Paulo, Brazil.
   [Kasahara, Niro] Santa Casa Sao Paulo Sch Med Sci, Sao Paulo, Brazil.
RP Kasahara, N (通讯作者)，Rua Sao Mauro 292, BR-02526050 Sao Paulo, Brazil.
EM niro.kasahara@fcmsantacasasp.edu.br
RI Kasahara, Niro/P-4631-2019
OI Kasahara, Niro/0000-0003-4101-0304
CR Adachi S, 2018, BMC OPHTHALMOL, V18, DOI 10.1186/s12886-018-0706-5
   BIRD AEC, 1995, SURV OPHTHALMOL, V39, P367, DOI 10.1016/S0039-6257(05)80092-X
   Black AA, 2011, OPHTHAL PHYSL OPT, V31, P283, DOI 10.1111/j.1475-1313.2010.00811.x
   Camargos FFO, 2010, BRAZ J PHYS THER, V14, P237, DOI 10.1590/S1413-35552010000300010
   Delbaere K, 2010, AGE AGEING, V39, P210, DOI 10.1093/ageing/afp225
   Dhital A, 2010, EYE, V24, P1437, DOI 10.1038/eye.2010.60
   Donoghue OA, 2014, GERIATR GERONTOL INT, V14, P827, DOI 10.1111/ggi.12174
   Ekici F, 2015, JAMA OPHTHALMOL, V133, P1377, DOI 10.1001/jamaophthalmol.2015.3426
   Halil M, 2006, ARCH GERONTOL GERIAT, V43, P351, DOI 10.1016/j.archger.2005.12.005
   Han BH, 2014, J COMMUN HEALTH, V39, P1241, DOI 10.1007/s10900-014-9852-8
   Hill KD, 2018, BMC GERIATR, V18, DOI 10.1186/s12877-017-0683-1
   Kendrick D, 2014, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD009848.pub2
   Lach HW, 2005, PUBLIC HEALTH NURS, V22, P45, DOI 10.1111/j.0737-1209.2005.22107.x
   LENNERSTRAND G, 1989, ACTA OPHTHALMOL, V67, P225
   Macedo Barbara Gazolla de, 2012, Rev. bras. geriatr. gerontol., V15, P265
   Nguyen AM, 2005, BMC GERIATR, V15, P64
   O'Donnell O, 2007, CAD SAUDE PUBLICA, V23, P2820, DOI 10.1590/S0102-311X2007001200003
   Parry SW, 2013, BMJ-BRIT MED J, V346, DOI 10.1136/bmj.f2933
   Ramulu PY, 2012, OPHTHALMOLOGY, V119, DOI 10.1016/j.ophtha.2012.01.037
   Siqueira FV, 2011, CAD SAUDE PUBLICA, V27, P1819, DOI 10.1590/S0102-311X2011000900015
   Tan PJ, 2014, BMC GERIATR, V14, DOI 10.1186/1471-2318-14-78
   TEOH SL, 1990, BRIT J OPHTHALMOL, V74, P215, DOI 10.1136/bjo.74.4.215
   Turano KA, 1999, INVEST OPHTH VIS SCI, V40, P2803
   United Nations Department of Economic and Social Affairs Population Division, 2017, ESAPWP248 UN DEP EC
   van Landingham SW, 2014, BMC OPHTHALMOL, V14, DOI 10.1186/1471-2415-14-10
   Vos T, 2015, LANCET, V386, P743, DOI 10.1016/S0140-6736(15)60692-4
   Wang MY, 2012, INVEST OPHTH VIS SCI, V53, P7967, DOI 10.1167/iovs.12-10701
NR 27
TC 1
Z9 1
U1 0
U2 1
PU ASSOC RESEARCH VISION OPHTHALMOLOGY INC
PI ROCKVILLE
PA 12300 TWINBROOK PARKWAY, ROCKVILLE, MD 20852-1606 USA
SN 2164-2591
J9 TRANSL VIS SCI TECHN
JI Transl. Vis. Sci. Technol.
PD OCT
PY 2018
VL 7
IS 5
AR 17
DI 10.1167/tvst.7.5.17
PG 8
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA GW9UU
UT WOS:000447352100005
PM 30280002
OA gold, Green Published
DA 2022-11-30
ER

PT J
AU Ma, YY
   Huang, JN
   Zhu, BJ
   Sun, Q
   Miao, YY
   Zou, HD
AF Ma, Yingyan
   Huang, Jiannan
   Zhu, Bijun
   Sun, Qian
   Miao, Yuyu
   Zou, Haidong
TI Cataract surgery in patients with bilateral advanced age-related macular
   degeneration: Measurement of visual acuity and quality of life
SO JOURNAL OF CATARACT AND REFRACTIVE SURGERY
LA English
DT Article
ID CONTRAST SENSITIVITY; MACULOPATHY; VISION; QUESTIONNAIRE; IMPAIRMENT;
   OUTCOMES; IMPACT
AB PURPOSE: To measure the change in visual acuity and vision-related quality of life in patients with both age-related cataract and bilateral age-related macular degeneration (AMD) after cataract surgery.
   SETTING: Department of Ophthalmology, Shanghai General Hospital, Shanghai Jiao Tong University, Shanghai, China.
   DESIGN: Prospective case series.
   METHODS: Patients with age-related cataract and bilateral advanced AMD who were diagnosed and treated between January 2006 and January 2012 were enrolled. The patients had successful phacoemulsification with foldable posterior chamber intraocular lens implantation. The corrected distance visual acuity (CDVA) and vision-related quality of life measured by the Chinese-version Low Vision Quality of Life (CLVQOL) questionnaire were collected. The Wilcoxon signed-rank test was used to compare the differences. Binary logistic regression analysis was performed to explore potential factors associated with the change in CLVQOL scores..
   RESULTS: Sixty eyes of 51 patients were included. The CDVA improved significantly (median difference 0.30 logMAR; range 0 to 1.38 logMAR; P<.001). The CLVQOL composite scores and the 4 subscale scores improved significantly (all P<.001). A greater increase in the CLVQOL scores was associated with inferior preoperative logMAR CDVA in the more severely affected eye (regression coefficient 3.36; P<.001).
   CONCLUSIONS: Cataract surgery improved visual acuity and the vision-related quality of life in patients with both age-related cataract and bilateral advanced AMD. Thus, it is beneficial for patients with coexistent advanced AMD to have cataract surgery. (C) 2015 ASCRS and ESCRS
C1 [Ma, Yingyan; Huang, Jiannan; Zou, Haidong] Shanghai Jiao Tong Univ, Shanghai Gen Hosp, Shanghai Eye Hosp, Shanghai Eye Dis Prevent & Treatment Ctr, Shanghai 200080, Peoples R China.
   [Ma, Yingyan; Huang, Jiannan; Zhu, Bijun; Sun, Qian; Miao, Yuyu; Zou, Haidong] Shanghai Jiao Tong Univ, Shanghai Gen Hosp, Dept Ophthalmol, Shanghai 200080, Peoples R China.
C3 Shanghai Jiao Tong University; Shanghai Jiao Tong University
RP Zou, HD (通讯作者)，Shanghai Jiao Tong Univ, Dept Ophthalmol, Shanghai Gen Hosp, 100 Haining Rd, Shanghai 200080, Peoples R China.
EM zouhaidong@hotmail.com
OI Zou, Haidong/0000-0002-6831-7560
CR Armbrecht AM, 2000, BRIT J OPHTHALMOL, V84, P1343, DOI 10.1136/bjo.84.12.1343
   Bansback N, 2007, QUAL LIFE RES, V16, P533, DOI 10.1007/s11136-006-9126-8
   BIRD AEC, 1995, SURV OPHTHALMOL, V39, P367, DOI 10.1016/S0039-6257(05)80092-X
   Cahill MT, 2005, OPHTHALMOLOGY, V112, P152, DOI 10.1016/j.ophtha.2004.06.036
   Casten RJ, 2013, CURR OPIN OPHTHALMOL, V24, P239, DOI 10.1097/ICU.0b013e32835f8e55
   Chiang PPC, 2013, OPHTHALMOLOGY, V120, P415, DOI 10.1016/j.ophtha.2012.07.077
   de Jong PTVM, 2013, OPHTHALMOLOGY AGEING, P33
   El Mallah MK, 2001, OPTOMETRY VISION SCI, V78, P683, DOI 10.1097/00006324-200109000-00014
   Emery JM, 1979, PHACOEMULSIFICATION, P45
   Fletcher DC, 2006, OPTOMETRY VISION SCI, V83, P178, DOI 10.1097/01.opx.0000204510.08026.7f
   Forooghian F, 2009, OPHTHALMOLOGY, V116, P2093, DOI 10.1016/j.ophtha.2009.04.033
   Frick KD, 2007, ARCH OPHTHALMOL-CHIC, V125, P544, DOI 10.1001/archopht.125.4.544
   Gutierrez P, 1997, ARCH OPHTHALMOL-CHIC, V115, P777, DOI 10.1001/archopht.1997.01100150779014
   HOLLADAY JT, 1991, AM J OPHTHALMOL, V111, P372, DOI 10.1016/S0002-9394(14)72328-1
   Knudtson MD, 2005, ARCH OPHTHALMOL-CHIC, V123, P807, DOI 10.1001/archopht.123.6.807
   Lamoureux EL, 2007, OPTOMETRY VISION SCI, V84, P683, DOI 10.1097/OPX.0b013e31812f755f
   Lundstrom M, 2002, BRIT J OPHTHALMOL, V86, P1330, DOI 10.1136/bjo.86.12.1330
   Lundstrom M, 2013, J CATARACT REFR SURG, V39, P673, DOI 10.1016/j.jcrs.2012.11.026
   Mitchell J, 2006, HEALTH QUAL LIFE OUT, V4, DOI 10.1186/1477-7525-4-97
   Monestam E, 2012, J CATARACT REFR SURG, V38, P409, DOI 10.1016/j.jcrs.2011.09.041
   Pham TQ, 2007, EYE, V21, P324, DOI 10.1038/sj.eye.6702171
   Pham TQ, 2005, CLIN EXP OPHTHALMOL, V33, P360, DOI 10.1111/j.1442-9071.2005.01031.x
   RUBIN GS, 1993, ARCH OPHTHALMOL-CHIC, V111, P56, DOI 10.1001/archopht.1993.01090010060027
   Shuttleworth GN, 1998, BRIT J OPHTHALMOL, V82, P611, DOI 10.1136/bjo.82.6.611
   SUNNESS JS, 1985, ARCH OPHTHALMOL-CHIC, V103, P811
   Wolffsohn JS, 2000, AM J OPHTHALMOL, V130, P793, DOI 10.1016/S0002-9394(00)00610-3
   World Health Organization, 2008, ICD UPD REV PLATF CH
   Zou H, 2005, QUAL LIFE RES, V14, P1633, DOI 10.1007/s11136-004-0026-5
   Zou H-d, 2004, ZHONG HUA YAN DI BIN, V20, P303
   Zou H-d, 2005, ZHONG GUO SHI YONG Y, V23, P117
   Zou HD, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0028597
NR 31
TC 9
Z9 11
U1 0
U2 8
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0886-3350
EI 1873-4502
J9 J CATARACT REFR SURG
JI J. Cataract. Refract. Surg.
PD JUN
PY 2015
VL 41
IS 6
BP 1248
EP 1255
DI 10.1016/j.jcrs.2014.09.046
PG 8
WC Ophthalmology; Surgery
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology; Surgery
GA CO3CZ
UT WOS:000359035500019
PM 26189380
DA 2022-11-30
ER

PT J
AU Ueta, T
AF Ueta, Takashi
TI Protocol Systemic Vascular Safety of Ranibizumab for Age-related Macular
   Degeneration: Systematic Review and Meta-analysis of Randomized Trials
SO OPHTHALMOLOGY
LA English
DT Article
ID GROWTH-FACTOR INHIBITORS; CEREBROVASCULAR ACCIDENTS; EDEMA; LASER
AB Background: Vascular endothelial growth factor (VEGF) inhibitors have drastically changed the way to treat exudative age-related macular degeneration (AMD) since the appearance of ranibizumab in 2006.(1,2) Ranibizumab is a VEGF inhibitor that has been most intensively evaluated in various randomized trials. Other VEGF inhibitors including off-label bevacizumab and recently introduced aflibercept have established their usefulness in comparison with ranibizumab. Despite the unquestionable effectiveness, the increased risk of systemic vascular events has been hotly discussed but remained unclear.(3-6)
   Ranibizumab has also been tested for other pathologies including diabetic macular edema and retinal vein occlusion through phase III randomized trials. In those trials patients with high risk for systemic vascular events were excluded from the trials.(8-12) In contrast, in most of the trials for AMD, there has been no exclusion criterion for systemic vascular conditions. However, considering that a majority of patients with exudative AMD is considerably old (>75 years old), intensive treatment with ranibizumab might lead to increased systemic vascular risks. In that case we may also need to take systemic vascular risks into account to treat AMD patients with VEGF inhibitors.
   Review Objectives: To conduct a meta-analysis of randomized trials of ranibizumab for AMD and assess whether ranibizumab treatment affects the systemic vascular risk or mortality.
   Methods: The study will be conducted according to the PRISMA statement and will be reported according to the PRISMA reporting guideline.
C1 [Ueta, Takashi] Univ Tokyo, Grad Sch Med, Dept Ophthalmol, Tokyo, Japan.
   [Ueta, Takashi] Univ Tokyo, Fac Med, Tokyo 113, Japan.
C3 University of Tokyo; University of Tokyo
RP Ueta, T (通讯作者)，Univ Tokyo, Grad Sch Med, Dept Ophthalmol, Tokyo, Japan.
EM ueta-tky@umin.ac.jp
CR Bressler NM, 2012, RETINA-J RET VIT DIS, V32, P1821, DOI 10.1097/IAE.0b013e31825db6ba
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Campbell RJ, 2012, BMJ-BRIT MED J, V344, DOI 10.1136/bmj.e4203
   Clinicaltrials.gov, EFF SAF RAN INTR INJ
   Elman MJ, 2010, OPHTHALMOLOGY, V117, P1064, DOI 10.1016/j.ophtha.2010.02.031
   Kemp A, 2013, RETINA-J RET VIT DIS, V33, P920, DOI 10.1097/IAE.0b013e318276e07b
   Massin P, 2010, DIABETES CARE, V33, P2399, DOI 10.2337/dc10-0493
   Mitchell P, 2011, OPHTHALMOLOGY, V118, P615, DOI 10.1016/j.ophtha.2011.01.031
   Nguyen QD, 2009, OPHTHALMOLOGY, V116, P2175, DOI 10.1016/j.ophtha.2009.04.023
   Nguyen QD, 2012, OPHTHALMOLOGY, V119, P789, DOI 10.1016/j.ophtha.2011.12.039
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Ueta T, 2009, OPHTHALMOLOGY, V116, P362, DOI 10.1016/j.ophtha.2008.09.046
NR 12
TC 1
Z9 1
U1 0
U2 4
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0161-6420
EI 1549-4713
J9 OPHTHALMOLOGY
JI Ophthalmology
PD NOV
PY 2014
VL 121
IS 11
PG 7
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA AS8DM
UT WOS:000344480400025
DA 2022-11-30
ER

PT J
AU Stravalaci, M
   Ferrara, M
   Pathak, V
   Davi, F
   Bottazzi, B
   Mantovani, A
   Medina, RJ
   Romano, MR
   Inforzato, A
AF Stravalaci, Matteo
   Ferrara, Mariantonia
   Pathak, Varun
   Davi, Francesca
   Bottazzi, Barbara
   Mantovani, Alberto
   Medina, Reinhold J.
   Romano, Mario R.
   Inforzato, Antonio
TI The Long Pentraxin PTX3 as a New Biomarker and Pharmacological Target in
   Age-Related Macular Degeneration and Diabetic Retinopathy
SO FRONTIERS IN PHARMACOLOGY
LA English
DT Review
DE age-related macular degeneration; diabetic retinopathy; complement;
   inflammation; PTX3
ID PIGMENT EPITHELIAL-CELLS; COMPLEMENT FACTOR-H; ENDOTHELIAL
   GROWTH-FACTOR; INNATE IMMUNITY; DENSITY-LIPOPROTEINS; GLOBAL PREVALENCE;
   CIGARETTE-SMOKE; RECOGNITION; SERUM; IDENTIFICATION
AB Age related macular degeneration (AMD) and diabetic retinopathy (DR) are multifactorial, neurodegenerative and inflammatory diseases of the eye primarily involving cellular and molecular components of the outer and inner blood-retina barriers (BRB), respectively. Largely contributed by genetic factors, particularly polymorphisms in complement genes, AMD is a paradigm of retinal immune dysregulation. DR, a major complication of diabetes mellitus, typically presents with increased vascular permeability and occlusion of the retinal vasculature that leads, in the proliferative form of the disease, to neovascularization, a pathogenic trait shared with advanced AMD. In spite of distinct etiology and clinical manifestations, both pathologies share common drivers, such as chronic inflammation, either of immune (in AMD) or metabolic (in DR) origin, which initiates and propagates degeneration of the neural retina, yet the underlying mechanisms are still unclear. As a soluble pattern recognition molecule with complement regulatory functions and a marker of vascular damage, long pentraxin 3 (PTX3) is emerging as a novel player in ocular homeostasis and a potential pharmacological target in neurodegenerative disorders of the retina. Physiologically present in the human eye and induced in inflammatory conditions, this protein is strategically positioned at the BRB interface, where it acts as a "molecular trap" for complement, and modulates inflammation both in homeostatic and pathological conditions. Here, we discuss current viewpoints on PTX3 and retinal diseases, with a focus on AMD and DR, the roles therein proposed for this pentraxin, and their implications for the development of new therapeutic strategies.
C1 [Stravalaci, Matteo; Davi, Francesca; Bottazzi, Barbara; Mantovani, Alberto; Inforzato, Antonio] IRCCS Humanitas Res Hosp, Rozzano, Italy.
   [Ferrara, Mariantonia; Romano, Mario R.] Humanitas Gavazzeni Castelli, Eye Ctr, Bergamo, Italy.
   [Pathak, Varun; Medina, Reinhold J.] Queens Univ Belfast, Wellcome Wolfson Inst Experimental Med, Sch Med Dent & Biomed Sci, Belfast, Antrim, North Ireland.
   [Mantovani, Alberto; Romano, Mario R.; Inforzato, Antonio] Humanitas Univ, Dept Biomed Sci, Rozzano, Italy.
   [Mantovani, Alberto] Queen Mary Univ London, William Harvey Res Inst, London, England.
C3 Queens University Belfast; Humanitas University; IRCCS Humanitas
   Research Hospital; University of London; Queen Mary University London
RP Inforzato, A (通讯作者)，IRCCS Humanitas Res Hosp, Rozzano, Italy.; Inforzato, A (通讯作者)，Humanitas Univ, Dept Biomed Sci, Rozzano, Italy.
EM antonio.inforzato@humanitasresearch.it
RI Stravalaci, Matteo/AAB-8963-2019; Inforzato, Antonio/ABG-4513-2020;
   Mantovani, Alberto/HCI-7449-2022; Ferrara, Mariantonia/AEC-7557-2022
OI Stravalaci, Matteo/0000-0002-5636-4204; Inforzato,
   Antonio/0000-0001-8110-0027; Mantovani, Alberto/0000-0001-5578-236X;
   Ferrara, Mariantonia/0000-0002-1191-4989; Davi,
   Francesca/0000-0002-4593-7089
FU Fondazione Beppe and Nuccy Angiolini; Prize Project for Scientific
   Research from the Italian Society of Ophthalmology (SOI); Wellcome Trust
   Institutional Strategic Support Fund [QUB-ISSF-204835/Z/16/Z]; Diabetes
   UK [20/0006162]; Dunhill Medical Trust [RPFG 1910/199]; MRC
   [MR/S036695/]; BBSRC [BB/T000805/1]
FX The article's publication fees are funded by Fondazione Beppe and Nuccy
   Angiolini. MRR is recipient of a Prize Project for Scientific Research
   from the Italian Society of Ophthalmology (SOI) that funded a technician
   (FD) and the most recent work on PTX3 and AMD (Stravalaci et al., 2020).
   The financial support of Fondazione Beppe and Nuccy Angiolini to AI is
   greatly acknowledged. VP is recipient of a Research Fellowship from the
   Wellcome Trust Institutional Strategic Support Fund
   QUB-ISSF-204835/Z/16/Z. RJM is funded by Diabetes UK 20/0006162, the
   Dunhill Medical Trust RPFG 1910/199, MRC MR/S036695/, and BBSRC
   BB/T000805/1.
CR Acar IE, 2020, OPHTHALMOLOGY, V127, P1693, DOI 10.1016/j.ophtha.2020.06.020
   Ambati J, 2013, NAT REV IMMUNOL, V13, P438, DOI 10.1038/nri3459
   An EY, 2008, MOL VIS, V14, P2292
   Armento A, 2021, CELL MOL LIFE SCI, V78, P4487, DOI 10.1007/s00018-021-03796-9
   Armento A, 2020, SCI REP-UK, V10, DOI 10.1038/s41598-020-67292-z
   Bally I, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.00461
   Baranova NS, 2014, J BIOL CHEM, V289, P30481, DOI 10.1074/jbc.M114.568154
   Behnke V, 2020, CELL MOL LIFE SCI, V77, P781, DOI 10.1007/s00018-019-03419-4
   Bottazzi B, 2016, J HEPATOL, V64, P1416, DOI 10.1016/j.jhep.2016.02.029
   Braunschweig A, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0023991
   BREVIARIO F, 1992, J BIOL CHEM, V267, P22190
   Brown EE, 2019, REDOX BIOL, V24, DOI 10.1016/j.redox.2019.101201
   Camozzi M, 2006, J BIOL CHEM, V281, P22605, DOI 10.1074/jbc.M601023200
   Cavelti-Weder C, 2012, DIABETES CARE, V35, P1654, DOI 10.2337/dc11-2219
   Ceravolo I, 2020, DIAGNOSTICS, V10, DOI 10.3390/diagnostics10060413
   Cheung N, 2010, LANCET, V376, P124, DOI 10.1016/S0140-6736(09)62124-3
   Chodkowski A, 2018, CLIN DIABETOL, V7, P196, DOI 10.5603/DK.2018.0016
   Clark SJ, 2018, SEMIN IMMUNOPATHOL, V40, P65, DOI 10.1007/s00281-017-0649-6
   Clark SJ, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.01778
   Clark SJ, 2014, J IMMUNOL, V193, P4962, DOI 10.4049/jimmunol.1401613
   Clark SJ, 2010, BIOCHEM SOC T, V38, P1342, DOI 10.1042/BST0381342
   Costagliola C, 2013, EXP EYE RES, V110, P50, DOI 10.1016/j.exer.2013.02.004
   Daigo K, 2016, IMMUNOL REV, V274, P202, DOI 10.1111/imr.12476
   Deban L, 2010, NAT IMMUNOL, V11, P328, DOI 10.1038/ni.1854
   Deban L, 2008, J IMMUNOL, V181, P8433, DOI 10.4049/jimmunol.181.12.8433
   Donath MY, 2011, NAT REV IMMUNOL, V11, P98, DOI 10.1038/nri2925
   Doni A, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.00712
   Doni A, 2017, SEMIN CELL DEV BIOL, V61, P31, DOI 10.1016/j.semcdb.2016.07.026
   Elbana KA, 2019, DIABETES METAB SYND, V13, P2361, DOI 10.1016/j.dsx.2019.06.007
   Erdenen F, 2018, METAB SYNDR RELAT D, V16, P358, DOI 10.1089/met.2018.0023
   Fields MA, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0177763
   Forrester JV, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.583687
   Fritsche LG, 2016, NAT GENET, V48, P134, DOI 10.1038/ng.3448
   Fumagalli S, 2015, FRONT NEUROL, V6, DOI 10.3389/fneur.2015.00081
   Garlanda C, 2018, PHYSIOL REV, V98, P623, DOI 10.1152/physrev.00016.2017
   Goldfine AB, 2013, ANN INTERN MED, V159, P1, DOI 10.7326/0003-4819-159-1-201307020-00003
   Govetto A, 2020, AM J OPHTHALMOL, V212, P43, DOI 10.1016/j.ajo.2019.12.010
   Gungel H, 2021, CURR EYE RES, V46, P818, DOI 10.1080/02713683.2020.1836228
   Haapasalo K, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.01750
   Hageman GS, 2005, P NATL ACAD SCI USA, V102, P7227, DOI 10.1073/pnas.0501536102
   Hokazono K, 2018, ARCH MED RES, V49, P123, DOI 10.1016/j.arcmed.2018.06.003
   Hwang N, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20236028
   Inforzato A, 2008, J BIOL CHEM, V283, P10147, DOI 10.1074/jbc.M708535200
   Inforzato A, 2006, BIOCHEMISTRY-US, V45, P11540, DOI 10.1021/bi0607453
   Inforzato A, 2010, J BIOL CHEM, V285, P17681, DOI 10.1074/jbc.M109.085639
   Juel HB, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0132800
   Khalaf Nervana, 2017, Electron Physician, V9, P5031, DOI 10.19082/5031
   Kinuthia UM, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.564077
   Kwon W, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.604205
   Larsen CM, 2007, NEW ENGL J MED, V356, P1517, DOI 10.1056/NEJMoa065213
   Lorenzi M, 2007, EXP DIABETES RES, DOI 10.1155/2007/61038
   Lueck K, 2011, EYE, V25, P1074, DOI 10.1038/eye.2011.109
   Lueck K, 2015, OPHTHALMIC RES, V54, P195, DOI 10.1159/000439596
   Ma YJ, 2009, J BIOL CHEM, V284, P28263, DOI 10.1074/jbc.M109.009225
   Ma YJ, 2013, J IMMUNOL, V191, P1324, DOI 10.4049/jimmunol.1300382
   Ma YJ, 2011, J BIOL CHEM, V286, P3405, DOI 10.1074/jbc.M110.190637
   Mutlu M, 2017, EYE, V31, P1463, DOI 10.1038/eye.2017.87
   Natoli R, 2017, MOL NEURODEGENER, V12, DOI 10.1186/s13024-017-0175-y
   Nauta AJ, 2003, EUR J IMMUNOL, V33, P465, DOI 10.1002/immu.200310022
   Norata GD, 2008, ARTERIOSCL THROM VAS, V28, P925, DOI 10.1161/ATVBAHA.107.160606
   Ogura S, 2020, FASEB J, V34, P10117, DOI 10.1096/fj.202000807R
   Parente R, 2017, CELL MOL LIFE SCI, V74, P1605, DOI 10.1007/s00018-016-2418-4
   Parmeggiani F, 2013, MEDIAT INFLAMM, V2013, DOI 10.1155/2013/435607
   Pietkiewicz J, 2008, POSTEP HIG MED DOSW, V62, P511
   Pietras-Baczewska A, 2021, LIFE-BASEL, V11, DOI 10.3390/life11050453
   Porte R, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.00794
   Presta M, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.02327
   Rask-Madsen C, 2013, CELL METAB, V17, P20, DOI 10.1016/j.cmet.2012.11.012
   Ristagno G, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.00823
   Rubino M, 2017, ONCOIMMUNOLOGY, V6, DOI 10.1080/2162402X.2017.1333215
   Rusnati M, 2004, BLOOD, V104, P92, DOI 10.1182/blood-2003-10-3433
   Sapieha P, 2012, BLOOD, V120, P2182, DOI 10.1182/blood-2012-04-396846
   Scarchilli L, 2007, J BIOL CHEM, V282, P30161, DOI 10.1074/jbc.M703738200
   Scholz R, 2015, J NEUROINFLAMM, V12, DOI 10.1186/s12974-015-0422-5
   Schreur V, 2020, RETINA-J RET VIT DIS, V40, P1565, DOI 10.1097/IAE.0000000000002626
   Semeraro F, 2019, DIABETES METAB, V45, P517, DOI 10.1016/j.diabet.2019.04.002
   Semeraro F, 2015, J DIABETES RES, V2015, DOI 10.1155/2015/582060
   Semeraro F, 2014, DIABETES METAB, V40, P445, DOI 10.1016/j.diabet.2014.04.005
   Shahulhameed S, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.00154
   Sharma Yashodhara, 2012, J Ocul Biol Dis Infor, V5, P63, DOI 10.1007/s12177-013-9104-7
   Sitnilska V, 2021, GRAEF ARCH CLIN EXP, V259, P623, DOI 10.1007/s00417-020-04910-6
   Sivapathasuntharam C, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-018-37673-6
   Stitt AW, 2016, PROG RETIN EYE RES, V51, P156, DOI 10.1016/j.preteyeres.2015.08.001
   Stravalaci M, 2020, FRONT PHARMACOL, V11, DOI 10.3389/fphar.2020.591908
   Subedi L, 2020, ANTIOXIDANTS-BASEL, V9, DOI 10.3390/antiox9090792
   Swinkels M, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-017-18395-7
   Toro MD, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20143503
   Wang L, 2016, J PATHOL, V240, P495, DOI 10.1002/path.4811
   Wang L, 2014, FREE RADICAL BIO MED, V70, P155, DOI 10.1016/j.freeradbiomed.2014.01.015
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
   Woo JM, 2013, MOL VIS, V19, P303
   Woodell A, 2014, ADV EXP MED BIOL, V801, P301, DOI 10.1007/978-1-4614-3209-8_38
   Wu J, 2021, BIOMED RES INT, V2021, DOI 10.1155/2021/6648191
   Yamada Y, 2008, J NEUROCHEM, V105, P1187, DOI 10.1111/j.1471-4159.2008.05211.x
   Yang HS, 2014, INVEST OPHTH VIS SCI, V55, P5989, DOI 10.1167/iovs.14-14864
   Yau JWY, 2012, DIABETES CARE, V35, P556, DOI 10.2337/dc11-1909
   Zhou W, 2016, GENET TEST MOL BIOMA, V20, P149, DOI 10.1089/gtmb.2015.0238
NR 97
TC 2
Z9 2
U1 4
U2 7
PU FRONTIERS MEDIA SA
PI LAUSANNE
PA AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND
EI 1663-9812
J9 FRONT PHARMACOL
JI Front. Pharmacol.
PD JAN 7
PY 2022
VL 12
AR 811344
DI 10.3389/fphar.2021.811344
PG 9
WC Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Pharmacology & Pharmacy
GA YL5WA
UT WOS:000745960200001
PM 35069222
OA gold, Green Published
DA 2022-11-30
ER

PT J
AU Sawa, M
   Iwata, E
   Ishikawa, K
   Gomi, F
   Nishida, K
   Terasaki, H
AF Sawa, Miki
   Iwata, Eiji
   Ishikawa, Kohei
   Gomi, Fumi
   Nishida, Kohji
   Terasaki, Hiroko
TI Comparison of different treatment intervals between bevacizumab
   injection and photodynamic therapy in combined therapy for age-related
   macular degeneration
SO JAPANESE JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
DE Age-related macular degeneration; Polypoidal choroidal vasculopathy;
   Bevacizumab; Photodynamic therapy; Treatment interval
ID POLYPOIDAL CHOROIDAL VASCULOPATHY; ENDOTHELIAL GROWTH-FACTOR;
   INTRAVITREAL BEVACIZUMAB; FOLLOW-UP; VERTEPORFIN; NEOVASCULARIZATION;
   PENETRATION; EXPRESSION; AVASTIN
AB To compare the results of combination therapy with different intervals between intravitreal bevacizumab and photodynamic therapy (PDT) with verteporfin for age-related macular degeneration.
   Treatment-na < ve eyes (n = 184) with 12 months' follow-up were included in this retrospective case series. Eyes were classified according to the interval between bevacizumab and PDT administration: group D1, 1-day interval (n = 116); group D7, 7-day interval (n = 68). The study was conducted at two hospitals, with group D1 evaluated in one hospital and group D7 evaluated in the other. The main outcome measure was comparison of the increases in best-corrected visual acuity (BCVA) of the two groups 3 and 12 months after the initial treatment by means of analysis of covariance (ANCOVA).
   Group D1 gained 1.3 lines and group D7 gained 1.5 lines of BCVA at 3 months; group D1 gained 0.8 lines and group D7 gained 1.4 lines at 12 months. There was a significant difference between the groups in the increased BCVA levels at 3 months (P = 0.0450) and a trend toward significance at 12 months (P = 0.0516). ANCOVA analysis revealed that baseline BCVA, hemorrhagic pigment epithelial detachment, subretinal fluid, lesion size, and a 7-day treatment interval were significantly correlated with the increase in the BCVA at 3 months.
   A 7-day treatment interval might offer slightly better visual acuity gain in the short term than a 1-day interval.
C1 [Sawa, Miki; Gomi, Fumi; Nishida, Kohji] Osaka Univ, Grad Sch Med, Dept Ophthalmol, Suita, Osaka 5650871, Japan.
   [Iwata, Eiji; Ishikawa, Kohei; Terasaki, Hiroko] Nagoya Univ, Grad Sch Med, Dept Ophthalmol, Nagoya, Aichi 4648601, Japan.
C3 Osaka University; Nagoya University
RP Sawa, M (通讯作者)，Osaka Univ, Grad Sch Med, Dept Ophthalmol, Room E7,2-2 Yamadaoka, Suita, Osaka 5650871, Japan.
EM sawamiki@ophthal.med.osaka-u.ac.jp
RI Terasaki, Hiroko/M-5054-2014
OI Nishida, Kohji/0000-0001-9069-3610; Gomi, Fumi/0000-0003-0807-8817
CR AKAIKE H, 1974, IEEE T AUTOMAT CONTR, VAC19, P716, DOI 10.1109/TAC.1974.1100705
   Akaza E, 2011, JPN J OPHTHALMOL, V55, P39, DOI 10.1007/s10384-010-0886-x
   [Anonymous], 1999, ARCH OPHTHALMOL, V117, P1329
   Bressler NM, 2003, ARCH OPHTHALMOL-CHIC, V121, P1621
   Costa RA, 2007, GRAEF ARCH CLIN EXP, V245, P1273, DOI 10.1007/s00417-007-0557-x
   Goldenberg DT, 2011, RETINA-J RET VIT DIS, V31, P393, DOI 10.1097/IAE.0b013e3181e586b2
   Gomi F, 2010, AM J OPHTHALMOL, V150, P48, DOI 10.1016/j.ajo.2010.02.008
   Gragoudas ES, 2004, NEW ENGL J MED, V351, P2805, DOI 10.1056/NEJMoa042760
   Heiduschka P, 2007, INVEST OPHTH VIS SCI, V48, P2814, DOI 10.1167/iovs.06-1171
   HENDERSON BW, 1992, PHOTOCHEM PHOTOBIOL, V55, P145, DOI 10.1111/j.1751-1097.1992.tb04222.x
   Honda S, 2009, JPN J OPHTHALMOL, V53, P593, DOI 10.1007/s10384-009-0741-0
   Kaiser PK, 2009, OPHTHALMOLOGY, V116, P747, DOI 10.1016/j.ophtha.2008.12.057
   Ladas ID, 2007, RETINA-J RET VIT DIS, V27, P891, DOI 10.1097/IAE.0b013e3180ca9ad9
   Nguyen QD, 2009, OPHTHALMOLOGY, V116, P2141, DOI 10.1016/j.ophtha.2009.04.030
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Rosenfeld PJ, 2005, OPHTHAL SURG LAS IM, V36, P331, DOI 10.3928/1542-8877-20050701-14
   Rudnisky CJ, 2010, RETINA-J RET VIT DIS, V30, P548, DOI 10.1097/IAE.0b013e3181bcf1b8
   Saito M, 2010, AM J OPHTHALMOL, V149, P472, DOI 10.1016/j.ajo.2009.09.016
   Sato T, 2010, AM J OPHTHALMOL, V149, P947, DOI 10.1016/j.ajo.2009.12.038
   Schmidt-Erfurth U, 2005, OPHTHALMOLOGY, V112, P2061, DOI 10.1016/j.ophtha.2005.09.007
   Schmidt-Erfurth U, 2003, INVEST OPHTH VIS SCI, V44, P4473, DOI 10.1167/iovs.02-1115
   Shahar J, 2006, RETINA-J RET VIT DIS, V26, P262, DOI 10.1097/00006982-200603000-00002
   Tatar O, 2006, ARCH OPHTHALMOL-CHIC, V124, P815, DOI 10.1001/archopht.124.6.815
   Uehara M, 2001, EUR J CANCER, V37, P2111, DOI 10.1016/S0959-8049(01)00243-X
   Yannuzzi LA, 2000, OPHTHALMOLOGY, V107, P767, DOI 10.1016/S0161-6420(99)00173-6
NR 25
TC 4
Z9 4
U1 0
U2 5
PU SPRINGER JAPAN KK
PI TOKYO
PA CHIYODA FIRST BLDG EAST, 3-8-1 NISHI-KANDA, CHIYODA-KU, TOKYO, 101-0065,
   JAPAN
SN 0021-5155
J9 JPN J OPHTHALMOL
JI Jpn. J. Ophthalmol.
PD SEP
PY 2012
VL 56
IS 5
BP 470
EP 475
DI 10.1007/s10384-012-0154-3
PG 6
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 005CI
UT WOS:000308727600009
PM 22678809
DA 2022-11-30
ER

PT J
AU Altunel, O
   Irgat, SG
   Ozcura, F
AF Altunel, Orhan
   Irgat, Saadet Gultekin
   Ozcura, Fatih
TI Objective evaluation of changes in lens clarity after repeated
   injections of ranibizumab in patients with neovascular age-related
   macular degeneration
SO GRAEFES ARCHIVE FOR CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY
LA English
DT Article
DE Cataract; Lens densitometry; Ranibizumab; Scheimpflug imaging
ID ENDOTHELIAL GROWTH-FACTOR; CHOROIDAL NEOVASCULARIZATION; OPACITIES;
   SYSTEM; REPEATABILITY; VERTEPORFIN
AB Purpose To objectively evaluate changes in lens densitometry in eyes with neovascular age-related macular degeneration (n-AMD) treated with repeated intravitreal ranibizumab injections during a 12-month period and to compare the results with those in untreated healthy fellow eyes and healthy control eyes.
   Methods In this prospective study, the 36 treated eyes and the 37 untreated fellow eyes of 38 patients with n-AMD and the 32 control eyes of 32 healthy individuals were analyzed. Lens densitometry was evaluated using the Scheimpflug imaging. All data in both groups regarding lens densitometry were recorded at baseline and 12 months.
   Results The mean densitometry of zone 1 in the treated eyes of patients had increased significantly at 12 months compared with the baseline (baseline: 9.3 +/- 1.5, 12 months: 11.9 +/- 1.7, p = .004) and was significantly greater than those measurements in the fellow eyes (9.8 +/- 1.6 p = .02) and control eyes (9.6 +/- 1.9, p = .01) at 12 months as well. There were no significant differences in terms of densitometry values between the fellow and control eyes at baseline and 12 months (for all, p > .05).
   Conclusions Our results objectively demonstrate early nuclear lens density changes using with Scheimpflug images in eyes with n-AMD that were treated with repeated ranibizumab injections for 12 months.
C1 [Altunel, Orhan; Irgat, Saadet Gultekin; Ozcura, Fatih] Kutahya Hlth Sci Univ, Dept Ophthalmol, Sch Med, Kutahya, Turkey.
C3 Kutahya Health Sciences University
RP Altunel, O (通讯作者)，Kutahya Hlth Sci Univ, Dept Ophthalmol, Sch Med, Kutahya, Turkey.
EM orhan_altunel@hotmail.com
CR Anayol MA, 2016, J CATARACT REFR SURG, V42, P1477, DOI 10.1016/j.jcrs.2016.08.018
   Bandello F, 2020, BRIT J OPHTHALMOL, V104, P64, DOI 10.1136/bjophthalmol-2019-313907
   Beebe DC, 2011, PHILOS T R SOC B, V366, P1293, DOI 10.1098/rstb.2010.0228
   Boyer DS, 2009, OPHTHALMOLOGY, V116, P1731, DOI 10.1016/j.ophtha.2009.05.024
   Bressler NM, 1996, ARCH OPHTHALMOL-CHIC, V114, P1456, DOI 10.1001/archopht.1996.01100140654002
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Brown DM, 2009, OPHTHALMOLOGY, V116, P57, DOI 10.1016/j.ophtha.2008.10.018
   CHYLACK LT, 1993, ARCH OPHTHALMOL-CHIC, V111, P831, DOI 10.1001/archopht.1993.01090060119035
   Ferrara N, 2009, EUR CYTOKINE NETW, V20, P158, DOI 10.1684/ecn.2009.0170
   Grewal DS, 2009, OPHTHALMOLOGY, V116, P1436, DOI 10.1016/j.ophtha.2009.03.002
   Grisanti S, 2008, PROG RETIN EYE RES, V27, P372, DOI 10.1016/j.preteyeres.2008.05.002
   Harocopos GJ, 2004, INVEST OPHTH VIS SCI, V45, P77, DOI 10.1167/iovs.03-0820
   Hernandez-Pastor LJ, 2008, AM J HEALTH-SYST PH, V65, P1805, DOI 10.2146/ajhp070342
   Jager RD, 2008, NEW ENGL J MED, V358, P2606, DOI 10.1056/NEJMra0801537
   Jun JH, 2016, CLIN OPHTHALMOL, V10, P1167, DOI 10.2147/OPTH.S103443
   Kastner C, 2013, CURR EYE RES, V38, P1057, DOI 10.3109/02713683.2013.803288
   Kirkwood BJ, 2009, J CATARACT REFR SURG, V35, P1210, DOI 10.1016/j.jcrs.2009.03.017
   Kirwan JF, 2003, OPHTHALMIC EPIDEMIOL, V10, P259, DOI 10.1076/opep.10.4.259.15908
   Mato-Gondelle T, 2018, RETINA-J RET VIT DIS, V38, P1962, DOI 10.1097/IAE.0000000000001819
   Pei X, 2008, BRIT J OPHTHALMOL, V92, P1471, DOI 10.1136/bjo.2007.136978
   Rabsilber TM, 2006, J CATARACT REFR SURG, V32, P456, DOI 10.1016/j.jcrs.2005.12.103
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Shui YB, 2003, INVEST OPHTH VIS SCI, V44, P3911, DOI 10.1167/iovs.02-1226
   Singer MA, 2012, OPHTHALMOLOGY, V119, P1175, DOI 10.1016/j.ophtha.2011.12.016
   Singerman LJ, 2008, BRIT J OPHTHALMOL, V92, P1606, DOI 10.1136/bjo.2007.132597
   Tan AC, 2008, J CATARACT REFR SURG, V34, P1948, DOI 10.1016/j.jcrs.2008.06.037
   Atilgan CU, 2020, THER ADV OPHTHALMOL, V12, DOI 10.1177/2515841420950857
   Veloso CE, 2015, OPHTHALMOLOGY, V122, P1569, DOI 10.1016/j.ophtha.2015.04.028
   Weiner X, 2014, J CATARACT REFR SURG, V40, P756, DOI 10.1016/j.jcrs.2013.10.039
   Wong AL, 2009, BRIT J OPHTHALMOL, V93, P61, DOI 10.1136/bjo.2008.137653
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
   Zhao XY, 2021, BMJ OPEN, V11, DOI 10.1136/bmjopen-2020-040906
NR 32
TC 0
Z9 0
U1 0
U2 0
PU SPRINGER
PI NEW YORK
PA ONE NEW YORK PLAZA, SUITE 4600, NEW YORK, NY, UNITED STATES
SN 0721-832X
EI 1435-702X
J9 GRAEF ARCH CLIN EXP
JI Graefes Arch. Clin. Exp. Ophthalmol.
PD SEP
PY 2022
VL 260
IS 9
BP 2897
EP 2904
DI 10.1007/s00417-022-05668-9
EA APR 2022
PG 8
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 4A4EX
UT WOS:000784626000001
PM 35445877
DA 2022-11-30
ER

PT J
AU Ling, Y
   Xiong, F
AF Ling, Yu
   Xiong, Fei
TI Associations of TLR4 gene polymorphisms with the risk of age-related
   macular degeneration in a Chinese Han population
SO MEDICINE
LA English
DT Article
DE age-related macular degeneration; haplotypes; polymorphisms; TLR4
ID TOLL-LIKE RECEPTORS; SUSCEPTIBILITY; DISEASE; EXPRESSION; VARIANTS;
   CELLS; CD14
AB The study was designed to reveal the relationship of toll-like receptor 4 (TLR4, rs1927914 and rs1927907) polymorphisms with risk of age-related macular degeneration (AMD), as well as the adjustment of this association by some environmental and lifestyle factors in Chinese Han population.
   TLR4 polymorphisms were genotyped by polymerase chain reaction-restricted fragment length polymorphisms and direct sequencing method in 138 AMD patients and 146 healthy controls. Genotype distribution in the control group was checked with Hardy-Weinberg equilibrium. Association of TLR4 polymorphisms and AMD risk was evaluated by chi(2) test and adjusted by age and sex, smoking and drinking. Odds ratio (OR) with 95% confidence interval (95% CI) was used to represent the association strength. Logistic regressive analysis was used to calculate the adjusted OR values.
   CC genotype of rs1927914 had significantly lower frequency in AMD patients (P=.010), indicated a negative association with AMD risk (crude: OR=0.358, 95% CI=0.162-0.791; adjusted: OR=0.355, 95% CI=0.160-0.789). C allele of rs1927914 might decrease the susceptibility of AMD (crude: OR=0.698, 95% CI=0.497-0.982; adjusted: OR=0.698, 95% CI=0.495-0.984). No significant association has been discovered between TLR4 rs1927907 polymorphism and AMD susceptibility. Strong linkage disequilibrium existed between rs1927914 and rs1927907 polymorphisms. C-C haplotype was negatively associated with AMD risk (OR=0.242, 95% CI=0.121-0.485; OR=0.242, 95% CI=0.120-0.488).
   CC genotype and C allele of rs1927914 were significantly associated with the decreased AMD susceptibility.
C1 [Ling, Yu; Xiong, Fei] Aerosp Ctr Hosp, Dept Ophthalmol, Beijing, Peoples R China.
RP Ling, Y (通讯作者)，Aerosp Ctr Hosp, Dept Ophthalmol, Beijing 100049, Peoples R China.
EM gfder99df@163.com
CR Chen C, 2017, MOL MED REP, V15, P2289, DOI 10.3892/mmr.2017.6252
   Chen L, 2016, MOL MED REP, V13, P3249, DOI 10.3892/mmr.2016.4890
   Chen W, 2010, P NATL ACAD SCI USA, V107, P7401, DOI 10.1073/pnas.0912702107
   Chen YH, 2010, MOL INTERV, V10, P271, DOI 10.1124/mi.10.5.4
   Cho YE, 2009, INVEST OPHTH VIS SCI, V50, P5614, DOI 10.1167/iovs.09-3688
   Cook DN, 2004, NAT IMMUNOL, V5, P975, DOI 10.1038/ni1116
   Despriet DDG, 2008, INVEST OPHTH VIS SCI, V49, P364, DOI 10.1167/iovs.07-0656
   Ferronato S, 2013, J HUM GENET, V58, P812, DOI 10.1038/jhg.2013.98
   Fritsche LG, 2014, ANNU REV GENOM HUM G, V15, P151, DOI 10.1146/annurev-genom-090413-025610
   Garcia-Layana A, 2017, CLIN INTERV AGING, V12, P1579, DOI 10.2147/CIA.S142685
   Gata V, 2017, J BUON, V22, P1092
   Gu L, 2018, NEUROL SCI, V39, P127, DOI 10.1007/s10072-017-3151-y
   Guven M, 2016, CURR EYE RES, V41, P856, DOI 10.3109/02713683.2015.1067326
   Kauppinen A, 2016, CELL MOL LIFE SCI, V73, P1765, DOI 10.1007/s00018-016-2147-8
   Kohno H, 2013, J BIOL CHEM, V288, P15326, DOI 10.1074/jbc.M112.448712
   Lana TP, 2018, OPHTHALMIC GENET, V39, P46, DOI 10.1080/13816810.2017.1354382
   Liutkeviciene Rasa, 2017, Acta Med Litu, V24, P75, DOI 10.6001/actamedica.v24i2.3487
   Ma BF, 2015, INT J CLIN EXP PATHO, V8, P9592
   Mai K, 2014, J INFLAMM-LOND, V11, DOI 10.1186/1476-9255-11-20
   Mitchell P, 2018, LANCET, V392, P1147, DOI 10.1016/S0140-6736(18)31550-2
   Nussenblatt RB, 2009, CURR OPIN INVEST DR, V10, P434
   Ozato K, 2002, BIOTECHNIQUES, P66
   Robinson E, 2015, J APPL PHYSIOL, V119, P508, DOI 10.1152/japplphysiol.00334.2015
   Sarli A, 2017, CLIN OPHTHALMOL, V11, P1347, DOI 10.2147/OPTH.S134538
   Seddon JM, 2006, OPHTHALMOLOGY, V113, P260, DOI 10.1016/j.ophtha.2005.11.001
   Singh K, 2013, BIOMED RES INT, V2013, DOI 10.1155/2013/318686
   Wang HY, 2014, BMC MED GENET, V15, DOI 10.1186/s12881-014-0123-4
   Xu H, 2017, RHEUMATOL INT, V37, P1909, DOI 10.1007/s00296-017-3815-1
   Yu H, 2016, J ORAL SCI, V58, P555, DOI 10.2334/josnusd.16-0187
   Zareparsi S, 2005, HUM MOL GENET, V14, P1449, DOI 10.1093/hmg/ddi154
   Zhang KY, 2018, INT OPHTHALMOL, V38, P1659, DOI 10.1007/s10792-017-0639-7
   Zhang L, 2015, INT J CLIN EXP MED, V8, P7849
   Zhao J, 2015, NEUROL SCI, V36, P1659, DOI 10.1007/s10072-015-2227-9
   Zhou LT, 2016, SPRINGERPLUS, V5, DOI 10.1186/s40064-016-3177-2
NR 34
TC 3
Z9 3
U1 0
U2 0
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0025-7974
EI 1536-5964
J9 MEDICINE
JI Medicine (Baltimore)
PD MAY
PY 2019
VL 98
IS 19
AR e15583
DI 10.1097/MD.0000000000015583
PG 5
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine
GA IF5HN
UT WOS:000473112000091
PM 31083239
OA Green Published, gold
DA 2022-11-30
ER

PT J
AU Almeida, LN
   Melilo-Carolino, R
   Veloso, CE
   Pereira, PA
   Miranda, DM
   De Marco, LA
   Nehemy, MB
AF Almeida, Luciana N.
   Melilo-Carolino, Rachel
   Veloso, Carlos E.
   Pereira, Patricia A.
   Miranda, Debora M.
   De Marco, Luiz Armando
   Nehemy, Marcio Bittar
TI Homozygosity for the +674C > T polymorphism on VEGF gene is associated
   with age-related macular degeneration in a Brazilian cohort
SO GRAEFES ARCHIVE FOR CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY
LA English
DT Article
DE AMD; Genetics; VEGF gene; VEGF; Polymorphism; CNV; Brazilian population
ID ENDOTHELIAL GROWTH-FACTOR; COMPLEMENT; DISEASE; SYSTEM; RISK
AB To investigate the association between VEGF gene polymorphism and age-related macular degeneration (AMD) in a Brazilian cohort.
   We examined 160 affected individuals and 140 sex- and age-matched controls recruited at the Vision Institute and the Retina Department, So Geraldo Hospital, Minas Gerais Federal University, Brazil, between 2007 and 2011. Genotyping for the VEGF rs1413711 single nucleotide polymorphism (SNP) (+674C > T) was performed. The incidence rate ratios and 95% confidence interval (CI) for AMD for this genotype was calculated. The odds ratio (OR) was also assessed by using logistic regression, controlling for CFH and LOC387715 risk genotype.
   We observed a prevalence of homozygosity (TT genotype) of 18.1% for rs1413711 among AMD cases compared with 5.8% among controls (P < 0.002). The ORs for this polymorphism were 3.6 (95%CI 1.6-8.2) for homozygous subjects and 1.5 (95%CI 1.1-2.1, P < 0.01) if the subject had at least one risk allele. When we studied separately exudative and dry AMD groups, this polymorphism was statistically significant for both groups. Controlling for CFH and LOC387715 risk genotype the OR was 3.0 for VEGF homozygous, and the OR increases if the patient is homozygous for the three genes.
   The present data suggests that VEGF TT genotype is associated with AMD among Brazilian patients.
C1 [Almeida, Luciana N.; Veloso, Carlos E.; Nehemy, Marcio Bittar] Univ Fed Minas Gerais, Fac Med, Dept Ophthalmol, BR-30130100 Belo Horizonte, MG, Brazil.
   [Melilo-Carolino, Rachel; Pereira, Patricia A.; De Marco, Luiz Armando] Univ Fed Minas Gerais, Fac Med, Dept Surg, BR-30130100 Belo Horizonte, MG, Brazil.
   [Miranda, Debora M.] Univ Fed Minas Gerais, Fac Med, Dept Pediat, BR-30130100 Belo Horizonte, MG, Brazil.
C3 Universidade Federal de Minas Gerais; Universidade Federal de Minas
   Gerais; Universidade Federal de Minas Gerais
RP Almeida, LN (通讯作者)，Univ Fed Minas Gerais, Fac Med, Dept Ophthalmol, Av Alfredo Balena 190, BR-30130100 Belo Horizonte, MG, Brazil.
EM luciananfalmeida@gmail.com
RI DE MARCO, LUIZ/H-6275-2012; Miranda, Debora/G-1241-2012; Nehemy,
   Marcio/ABD-5089-2021; Veloso, Carlos Eduardo dos Reis/E-1815-2016;
   Miranda, Debora/AAQ-1952-2020
OI DE MARCO, LUIZ/0000-0003-2535-7439; Miranda, Debora/0000-0002-7081-8401;
   Veloso, Carlos Eduardo dos Reis/0000-0002-8817-7200; Miranda,
   Debora/0000-0002-7081-8401; Nehemy, Marcio/0000-0002-4104-0346
FU CNPq; INCT in Molecular Medicine; FAPEMIG, Brazil
FX Supported in part by grants from CNPq, INCT in Molecular Medicine and
   FAPEMIG, Brazil.
CR Boekhoorn SS, 2008, OPHTHALMOLOGY, V115, P1899, DOI 10.1016/j.ophtha.2008.06.026
   Churchill AJ, 2006, HUM MOL GENET, V15, P2955, DOI 10.1093/hmg/ddl238
   Fang AM, 2009, MOL VIS, V15, P2710
   Fish G, 2003, OPHTHALMOLOGY, V110, P979, DOI 10.1016/S0161-6420(03)00085-X
   Frank RN, 1997, OPHTHALMIC RES, V29, P341, DOI 10.1159/000268032
   de Almeida LNF, 2009, ARQ BRAS OFTALMOL, V72, P567, DOI 10.1590/S0004-27492009000400027
   Galan A, 2010, OPHTHALMOLOGY, V117, P1769, DOI 10.1016/j.ophtha.2010.01.030
   Haines JL, 2006, INVEST OPHTH VIS SCI, V47, P329, DOI 10.1167/iovs.05-0116
   Harper SJ, 2008, NAT REV CANCER, V8, P880, DOI 10.1038/nrc2505
   Hecker LA, 2010, HUM MOL GENET, V19, P209, DOI 10.1093/hmg/ddp472
   Janik-Papis K, 2009, EXP MOL PATHOL, V87, P234, DOI 10.1016/j.yexmp.2009.09.005
   Jiang H, 2009, RETINA-J RET VIT DIS, V29, P974, DOI 10.1097/IAE.0b013e3181a3b90e
   Lee AY, 2010, BRIT J OPHTHALMOL, V94, P915, DOI 10.1136/bjo.2009.172007
   Lin JM, 2008, AM J OPHTHALMOL, V145, P1045, DOI 10.1016/j.ajo.2008.01.027
   Penn JS, 2008, PROG RETIN EYE RES, V27, P331, DOI 10.1016/j.preteyeres.2008.05.001
   Pugh CW, 2003, NAT MED, V9, P677, DOI 10.1038/nm0603-677
   Qiu Y, 2009, BIOCHEM SOC T, V37, P1207, DOI 10.1042/BST0371207
   Reynolds R, 2009, INVEST OPHTH VIS SCI, V50, P5818, DOI 10.1167/iovs.09-3928
   Richardson AJ, 2007, MOL VIS, V13, P2148
   Schaumberg DA, 2007, ARCH OPHTHALMOL-CHIC, V125, P55, DOI 10.1001/archopht.125.1.55
   Seddon JM, 2006, OPHTHALMOLOGY, V113, P260, DOI 10.1016/j.ophtha.2005.11.001
   Seddon JM, 2006, RETINA, P1017
   Seddon JM, 2009, INVEST OPHTH VIS SCI, V50, P2044, DOI 10.1167/iovs.08-3064
   Wang GF, 2009, INVEST OPHTH VIS SCI, V50, P3084, DOI 10.1167/iovs.08-3240
NR 24
TC 20
Z9 21
U1 0
U2 0
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0721-832X
EI 1435-702X
J9 GRAEF ARCH CLIN EXP
JI Graefes Arch. Clin. Exp. Ophthalmol.
PD FEB
PY 2012
VL 250
IS 2
BP 185
EP 189
DI 10.1007/s00417-011-1807-5
PG 5
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 892MP
UT WOS:000300290600004
PM 21881842
DA 2022-11-30
ER

PT J
AU Kozak, I
   Cheng, L
   Cochran, DE
   Freeman, WR
AF Kozak, I.
   Cheng, L.
   Cochran, D. E.
   Freeman, W. R.
TI Phase I clinical trial results of verteporfin enhanced feeder vessel
   therapy in subfoveal choroidal neovascularisation in age related macular
   degeneration
SO BRITISH JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
ID CHORIOCAPILLARIS BLOOD-FLOW; PHOTODYNAMIC THERAPY; PHOTOCOAGULATION;
   OCCLUSION; SECONDARY
AB Aims: To investigate the safety and effectiveness of extrafoveal photodynamic therapy (PDT) occlusion of feeder vessels (FVs) in patients with subfoveal choroidal neovascularisation (CNV) as a result of age related macular degeneration.
   Methods: FVs were identified using dynamic fluorescein and indocyanine green angiography with scanning laser ophthalmoscope. The standard doses of verteporfin and laser wavelength were used. The light dose was escalated by increasing the duration of the light dose so the light regimen was 50 J/cm(2) for patients 1 and 2; 100 J/cm(2) for patients 3, 4, 5; 125 J/cm(2) for patients 6 and 7; and 150 J/cm(2) for patients 8 and 9. Patients were examined at weeks 1, 4, and 12.
   Results: The mean improvement on EDTRS chart 3 months after treatment was an increase of 2.1 lines (p=0.07). Closure of the FV was achieved angiographically in three eyes at various light doses, in three eyes the FV was hypoperfused, and in three eyes the vessels were were neither closed nor hypoperfused. At the last follow up all FVs were reperfused. There was no evidence of retinal damage.
   Conclusion: Verteporfin enhanced FV therapy does not cause subfoveal retinal damage and may have potential to improve central vision in subfoveal CNV caused by exudative macular degeneration. It is not recommended as a monotherapy for CNV.
C1 Univ Calif San Diego, Shiley Eye Ctr, Jacobs Retina Ctr, La Jolla, CA 92037 USA.
C3 University of California System; University of California San Diego
RP Kozak, I (通讯作者)，Univ Calif San Diego, Shiley Eye Ctr, Jacobs Retina Ctr, 0946,9415 Campus Point Dr, La Jolla, CA 92037 USA.
EM ikozak@eyecenter.ucsd.edu
RI Kozak, Igor/AAC-4645-2019
CR Arnold J, 2001, AM J OPHTHALMOL, V131, P541
   BAUMAL CR, 2001, RETINAL PIGMENT EPIT, P587
   Blumenkranz MS, 2001, ARCH OPHTHALMOL-CHIC, V119, P198
   Bressler NM, 1999, ARCH OPHTHALMOL-CHIC, V117, P1329
   Coscas F, 2003, J FR OPHTALMOL, V26, P602
   Costa RA, 2002, INVEST OPHTH VIS SCI, V43, pU590
   Costa RA, 2003, OPHTHALMOLOGY, V110, P1192, DOI 10.1016/S0161-6420(03)00263-X
   Flower RW, 2001, AM J OPHTHALMOL, V132, P85, DOI 10.1016/S0002-9394(01)00872-8
   Flower RW, 2000, AM J OPHTHALMOL, V129, P501, DOI 10.1016/S0002-9394(99)00411-0
   GREEN WR, 1993, OPHTHALMOLOGY, V100, P1519
   Mantel I, 2003, J FR OPHTALMOL, V26, P493
   Mennel S, 2005, GRAEF ARCH CLIN EXP, V243, P68, DOI 10.1007/s00417-004-0964-1
   Michels S, 2006, INVEST OPHTH VIS SCI, V47, P371, DOI 10.1167/iovs.05-0354
   REICHEL E, 1994, OPHTHALMIC SURG LAS, V25, P195
   Schmidt-Erfurth U, 2002, INVEST OPHTH VIS SCI, V43, P830
   Schmidt-Erfurth U, 1998, GRAEF ARCH CLIN EXP, V236, P365, DOI 10.1007/s004170050092
   SCHOTZERSCHREHA.U, 2002, GRAEFES ARCH CLIN EX, V240, P748
   SEDDON JM, 2001, RETINA, P1039
   Shiraga F, 1998, OPHTHALMOLOGY, V105, P662, DOI 10.1016/S0161-6420(98)94021-0
   Sickenberg M, 2004, J FR OPHTALMOL, V27, P93, DOI 10.1016/S0181-5512(04)96100-1
   Staurenghi G, 1998, OPHTHALMOLOGY, V105, P2297, DOI 10.1016/S0161-6420(98)91232-5
   Staurenghi G, 2002, AM J OPHTHALMOL, V133, P801, DOI 10.1016/S0002-9394(02)01436-8
   Tzekov R, 2006, INVEST OPHTH VIS SCI, V47, P377, DOI 10.1167/iovs.05-0838
   Wolfe JD, 2004, EXP EYE RES, V79, P631, DOI 10.1016/j.exer.2004.05.018
NR 24
TC 10
Z9 10
U1 0
U2 0
PU BMJ PUBLISHING GROUP
PI LONDON
PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND
SN 0007-1161
EI 1468-2079
J9 BRIT J OPHTHALMOL
JI Br. J. Ophthalmol.
PD SEP
PY 2006
VL 90
IS 9
BP 1152
EP 1156
DI 10.1136/bjo.2006.095141
PG 5
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 076ZP
UT WOS:000239997700025
PM 16774958
OA Green Published, Green Submitted
DA 2022-11-30
ER

PT J
AU KARGER, AB
   GUAN, WH
   NOMURA, SO
   WEIR, NL
   KLEIN, BEK
   BURKE, GL
   JOHNSON, WC
   TSAI, MY
AF KARGER, A. M. Y. B.
   GUAN, W. E. I. H. U. A.
   NOMURA, S. A. R. A. H. O.
   WEIR, N. A. T. A. L. I. E. L.
   KLEIN, B. A. R. B. A. R. A. E. K.
   BURKE, G. R. E. G. O. R. Y. L.
   JOHNSON, W. C. R. A. I. G.
   TSAI, M. I. C. H. A. E. L. Y.
TI ASSOCIATION OF PLASMA omega-3 FATTY ACIDS WITH EARLY AGE-RELATED MACULAR
   DEGENERATION IN THE MULTI-ETHNIC STUDY OF ATHEROSCLEROSIS
SO RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES
LA English
DT Article
DE age-related macular degeneration; DHA; EPA; Multi-Ethnic Study of
   Atherosclerosis; omega-3 fatty acids
ID POLYUNSATURATED FATTY-ACIDS; LONG-CHAIN; EICOSAPENTAENOIC ACID;
   DOCOSAHEXAENOIC ACID; EYE DISEASE; RISK; PROGRESSION; PREVALENCE; HEALTH
AB Purpose: To examine the association between omega-3 polyunsaturated fatty acids, docosahexaenoic acid, and eicosapentaenoic acid and age-related macular degeneration (AMD) in the Multi-Ethnic Study of Atherosclerosis cohort. Methods: Multi-Ethnic Study of Atherosclerosis is a multicenter, prospective cohort study designed to identify risk factors for cardiovascular disease in four ethnic groups. Six thousand eight hundred and fourteen participants of White, African American, Hispanic/Latino, and Chinese descent, aged 45-84 years, were recruited, with those found to have cardiovascular disease excluded. Our study population included all Multi-Ethnic Study of Atherosclerosis participants with baseline polyunsaturated fatty acid measurements and retinal photography at Examination 5 (n = 3,772). Fundus photographs were assessed for AMD using a standard grading protocol. Relative risk regression (log link) determined associations between polyunsaturated fatty acid levels and AMD. Results: There was a significant association between increasing docosahexaenoic acid levels and increasing docosahexaenoic acid + eicosapentaenoic acid levels with reduced risk for early AMD (n = 214 participants with early AMD, of which n = 99 (46.3%) are non-White). Eicosapentaenoic acid levels alone were not significantly associated with AMD. Conclusion: Our analysis suggests increasing levels of docosahexaenoic acid are associated with reduced risk for early AMD in a multiethnic cohort. This represents the first racially diverse study demonstrating an association between omega-3 polyunsaturated fatty acids and AMD risk.
C1 [KARGER, A. M. Y. B.; NOMURA, S. A. R. A. H. O.; WEIR, N. A. T. A. L. I. E. L.; TSAI, M. I. C. H. A. E. L. Y.] Univ Minnesota, Dept Lab Med & Pathol, Minneapolis, MN 55455 USA.
   [GUAN, W. E. I. H. U. A.] Univ Minnesota, Sch Publ Hlth, Div Biostat, Minneapolis, MN USA.
   [KLEIN, B. A. R. B. A. R. A. E. K.] Univ Wisconsin, Dept Ophthalmol & Visual Sci, Madison, WI USA.
   [BURKE, G. R. E. G. O. R. Y. L.] Wake Forest Sch Med, Div Publ Hlth Sci, Winston Salem, NC 27101 USA.
   [JOHNSON, W. C. R. A. I. G.] Univ Washington, Dept Biostat, Seattle, WA 98195 USA.
C3 University of Minnesota System; University of Minnesota Twin Cities;
   University of Minnesota System; University of Minnesota Twin Cities;
   University of Wisconsin System; University of Wisconsin Madison; Wake
   Forest University; University of Washington; University of Washington
   Seattle
RP TSAI, MY (通讯作者)，Univ Minnesota, Dept Lab Med & Pathol, 420 Delaware St SE,Mayo Mail Code 609, Minneapolis, MN 55455 USA.
EM karge026@umn.edu; wguan@umn.edu; oppe0020@umn.edu; weirx065@umn.edu;
   kleinb@epi.ophth.wisc.edu; gburke@wakehealth.edu; wcraigj@uw.edu;
   tsaix001@umn.edu
OI Karger, Amy/0000-0002-2781-3824
FU National Heart, Lung, and Blood Institute [75N92020D00001,
   HHSN268201500003I, N01-HC-95159]; National Center for Advancing
   Translational Sciences (NCATS) [UL1-TR-000040, UL1-TR-001079,
   UL1-TR-001420];  [75N92020D00005];  [N01-HC-95160];  [75N92020D00002]; 
   [N01-HC-95161];  [75N92020D00003];  [N01-HC-95162];  [75N92020D00006]; 
   [N01-HC-95163];  [75N92020D00004];  [N01-HC95164];  [75N92020D00007]; 
   [N01-HC-95165];  [N01-HC-95166];  [N01-HC-95167];  [N01-HC-95168]; 
   [N01-HC-95169]
FX Supported by contracts 75N92020D00001, HHSN268201500003I, N01-HC-95159,
   75N92020D00005, N01-HC-95160, 75N92020D00002, N01-HC-95161,
   75N92020D00003, N01-HC-95162, 75N92020D00006, N01-HC-95163,
   75N92020D00004, N01-HC95164, 75N92020D00007, N01-HC-95165, N01-HC-95166,
   N01-HC-95167, N01-HC-95168, and N01-HC-95169 from the National Heart,
   Lung, and Blood Institute and by Grants UL1-TR-000040, UL1-TR-001079,
   and UL1-TR-001420 from the National Center for Advancing Translational
   Sciences (NCATS). The authors thank the other investigators, the staff,
   and the participants of the MESA study for their valuable contributions.
   A full list of participating MESA investigators and institutions can be
   found at http://www.mesa-nhlbi.org.
CR Age-Related Eye Disease Study 2 Research Group, 2013, JAMA, V309, P2005, DOI 10.1001/jama.2013.4997
   Agron E, 2021, OPHTHALMOLOGY, V128, P425, DOI 10.1016/j.ophtha.2020.08.018
   Augood C, 2008, AM J CLIN NUTR, V88, P398, DOI 10.1093/ajcn/88.2.398
   Bhatt DL, 2019, NEW ENGL J MED, V380, P11, DOI 10.1056/NEJMoa1812792
   Bhatt DL, 2017, CLIN CARDIOL, V40, P138, DOI 10.1002/clc.22692
   Bild DE, 2002, AM J EPIDEMIOL, V156, P871, DOI 10.1093/aje/kwf113
   Bonds DE, 2014, JAMA INTERN MED, V174, P763, DOI 10.1001/jamainternmed.2014.328
   Cao J, 2006, CLIN CHEM, V52, P2265, DOI 10.1373/clinchem.2006.072322
   Christen WG, 2011, ARCH OPHTHALMOL-CHIC, V129, P921, DOI 10.1001/archophthalmol.2011.34
   Djousse L, 2014, EUR J NUTR, V53, P1403, DOI 10.1007/s00394-013-0642-3
   Fisher DE, 2016, OPHTHALMOLOGY, V123, P1297, DOI 10.1016/j.ophtha.2015.12.026
   Flaxman SR, 2017, LANCET GLOB HEALTH, V5, pE1221, DOI 10.1016/S2214-109X(17)30393-5
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P564
   Ho L, 2011, ARCH OPHTHALMOL-CHIC, V129, P758, DOI 10.1001/archophthalmol.2011.141
   Klein R, 2006, OPHTHALMOLOGY, V113, P373, DOI 10.1016/j.ophtha.2005.12.013
   Liu AH, 2010, J LIPID RES, V51, P3217, DOI 10.1194/jlr.M007518
   Merle BMJ, 2014, INVEST OPHTH VIS SCI, V55, P2010, DOI 10.1167/iovs.14-13916
   Merle BMJ, 2013, J NUTR, V143, P505, DOI 10.3945/jn.112.171033
   Ng ALK, 2019, NUTRIENTS, V11, DOI 10.3390/nu11081720
   Orban T, 2015, FASEB J, V29, P4579, DOI 10.1096/fj.15-275289
   Reid M, 2019, SLEEP, V42, DOI 10.1093/sleep/zsy194
   Reynolds R, 2013, OPHTHALMOLOGY, V120, P1020, DOI 10.1016/j.ophtha.2012.10.020
   SanGiovanni JP, 2009, AM J CLIN NUTR, V90, P1601, DOI 10.3945/ajcn.2009.27594
   SanGiovanni JP, 2005, PROG RETIN EYE RES, V24, P87, DOI 10.1016/j.preteyeres.2004.06.002
   Serra-Majem L, 2012, BRIT J NUTR, V107, pS64, DOI 10.1017/S000711451200147X
   Tan JSL, 2009, ARCH OPHTHALMOL-CHIC, V127, P656, DOI 10.1001/archophthalmol.2009.76
   Aung T, 2018, JAMA CARDIOL, V3, P225, DOI 10.1001/jamacardio.2017.5205
   Tikellis G, 2007, EYE, V21, P169, DOI 10.1038/sj.eye.6702151
   van Leeuwen EM, 2018, PROG RETIN EYE RES, V67, P56, DOI 10.1016/j.preteyeres.2018.04.006
   Wu J, 2017, OPHTHALMOLOGY, V124, P634, DOI 10.1016/j.ophtha.2016.12.033
NR 30
TC 0
Z9 0
U1 1
U2 1
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0275-004X
EI 1539-2864
J9 RETINA-J RET VIT DIS
JI Retin.-J. Retin. Vitr. Dis.
PD JUL
PY 2022
VL 42
IS 7
BP 1384
EP 1391
DI 10.1097/IAE.0000000000003465
PG 8
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 2F9XK
UT WOS:000813255200020
PM 35271555
DA 2022-11-30
ER

PT J
AU Semeraro, F
   Morescalchi, F
   Duse, S
   Gambicorti, E
   Romano, MR
   Costagliola, C
AF Semeraro, Francesco
   Morescalchi, Francesco
   Duse, Sarah
   Gambicorti, Elena
   Romano, Mario R.
   Costagliola, Ciro
TI Systemic thromboembolic adverse events in patients treated with
   intravitreal anti-VEGF drugs for neovascular age-related macular
   degeneration: an overview
SO EXPERT OPINION ON DRUG SAFETY
LA English
DT Review
DE aflibercept; age-related macular degeneration; anti-VEGF; bevacizumab;
   hypertension; myocardial infarction; pegaptanib; ranibizumab; side
   effects; stroke
ID ENDOTHELIAL GROWTH-FACTOR; VERTEPORFIN PHOTODYNAMIC THERAPY;
   VASCULAR-PERMEABILITY FACTOR; QUALITY-OF-LIFE; CHOROIDAL
   NEOVASCULARIZATION; MYOCARDIAL-INFARCTION; BEVACIZUMAB AVASTIN;
   PEGAPTANIB SODIUM; FACTOR INHIBITORS; OCULAR NEOVASCULARIZATION
AB Introduction: Anti-VEGF therapy improved the quality of life for millions of patients suffering from wet age-related macular degeneration (wet-AMD); unfortunately, this therapy involves multiple injections over many years. The administration of anti-VEGF can overcome the blood-retinal barrier with agents entering the systemic circulation and causing a significant decrease in VEGF serum concentration. Although circulating VEGF protects the integrity and patency of vessels, prolonged anti-VEGF treatment has the potential to increase the risk of thromboembolic events.
   Areas covered: In this review, we discuss the safety data from recent trials involving available anti-VEGF drugs.
   Expert opinion: During the 2 years of follow-up in the relevant clinical trials, the rates of serious adverse events such as stroke, heart attack and death were similar for patients treated with different anti-VEGF drugs. Moreover the arterial thrombotic risk appears sufficiently low when compared with the natural incidence of arterial thrombotic events in this category of elderly patients and acceptably balanced against the advantage of improved vision. Since the use of these drugs is likely to become increasingly widespread and prolonged, it is desirable that the scientific community improves the pharmacovigilance program on all anti-VEGF drugs, expanding knowledge with studies that compares head to head all four compounds belonging to anti-VEGF armamentarium.
C1 [Semeraro, Francesco; Morescalchi, Francesco; Duse, Sarah; Gambicorti, Elena] Univ Brescia, Ophthalmol Clin, Dept Med & Surg Specialties, Spedali Civili Brescia, I-25123 Brescia, Italy.
   [Romano, Mario R.; Costagliola, Ciro] Univ Molise, Ophthalmol Clin, Dept Hlth Sci, Campobasso, Italy.
   [Romano, Mario R.] Ist Clin Humanitas, Dept Ophthalmol, Milan, Italy.
C3 University of Brescia; University of Molise; IRCCS Humanitas Research
   Hospital
RP Duse, S (通讯作者)，Univ Brescia, Ophthalmol Clin, Dept Med & Surg Specialties, Spedali Civili Brescia, Piazzale Spedali Civili 1, I-25123 Brescia, Italy.
EM sarah.duse@alice.it
RI Costagliola, Ciro/G-5707-2012; Semeraro, Francesco fs/K-8667-2016
OI Costagliola, Ciro/0000-0001-8477-6188; Semeraro, Francesco
   fs/0000-0002-2275-4917
CR Abraham P, 2010, AM J OPHTHALMOL, V150, P315, DOI 10.1016/j.ajo.2010.04.011
   Ahfat FG, 2013, EYE, V27, P289, DOI 10.1038/eye.2013.1
   Alexander SL, 2007, OPHTHALMOLOGY, V114, P2174, DOI 10.1016/j.ophtha.2007.09.017
   ALON T, 1995, NAT MED, V1, P1024, DOI 10.1038/nm1095-1024
   Antoszyk AN, 2008, AM J OPHTHALMOL, V145, P862, DOI 10.1016/j.ajo.2007.12.029
   Apte RS, 2007, OPHTHALMOLOGY, V114, P1702, DOI 10.1016/j.ophtha.2007.02.021
   Avery RL, 2013, BR J OPHTHALMOL
   Beaumont PE, 2014, OPHTHALMOLOGY, V121, pE4, DOI 10.1016/j.ophtha.2013.09.020
   Becerra EM, 2011, CURR DRUG TARGETS, V12, P149
   Benjamin LE, 1999, J CLIN INVEST, V103, P159, DOI 10.1172/JCI5028
   Binder S, 2012, BRIT J OPHTHALMOL, V96, P1, DOI 10.1136/bjophthalmol-2011-301236
   Biswas P, 2011, INDIAN J OPHTHALMOL, V59, P191, DOI 10.4103/0301-4738.81023
   Bombeli T, 1997, BLOOD, V89, P2429, DOI 10.1182/blood.V89.7.2429
   Boyer DS, 2009, OPHTHALMOLOGY, V116, P1731, DOI 10.1016/j.ophtha.2009.05.024
   Boyer DS, 2008, ANN M AM ACAD OPHTH
   Brechner RJ, 2011, AM J OPHTHALMOL, V151, P887, DOI 10.1016/j.ajo.2010.11.017
   Brown D.M., 2009, OPHTHALMOLOGY, V116, pe5
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Brown DM, 2009, OPHTHALMOLOGY, V116, P57, DOI 10.1016/j.ophtha.2008.10.018
   Campbell RJ, 2012, BMJ-BRIT MED J, V344, DOI 10.1136/bmj.e4203
   Chakravarthy U, 2006, OPHTHALMOLOGY, V113, P1508, DOI 10.1016/j.ophtha.2006.02.064
   Chakravarthy U, 2013, LANCET, V382, P1258, DOI 10.1016/S0140-6736(13)61501-9
   Ciulla TA, 2009, CURR OPIN OPHTHALMOL, V20, P158, DOI 10.1097/ICU.0b013e32832d25b3
   Costa RA, 2007, GRAEF ARCH CLIN EXP, V245, P1273, DOI 10.1007/s00417-007-0557-x
   Costagliola C, 2012, EXPERT OPIN BIOL TH, V12, P1299, DOI 10.1517/14712598.2012.707176
   Costagliola C, 2010, BRIT J OPHTHALMOL, V94, P180, DOI 10.1136/bjo.2009.159343
   Curtis LH, 2010, ARCH OPHTHALMOL-CHIC, V128, P1273, DOI 10.1001/archophthalmol.2010.223
   Dhalla MS, 2006, RETINA-J RET VIT DIS, V26, P988, DOI 10.1097/01.iae.0000247164.70376.91
   Duan YK, 2007, OPHTHALMOLOGY, V114, P732, DOI 10.1016/j.ophtha.2006.07.045
   European Medicines Agency (EMEA), 2007, RAN LUCCNT SUMM PROD
   FERRARA N, 1989, BIOCHEM BIOPH RES CO, V161, P851, DOI 10.1016/0006-291X(89)92678-8
   Ferrara N, 2002, SEMIN ONCOL, V29, P10, DOI 10.1053/sonc.2002.37264
   Ferrara N, 2003, NAT MED, V9, P669, DOI 10.1038/nm0603-669
   Finger RP, 2013, ACTA OPHTHALMOL, V91, P540, DOI 10.1111/j.1755-3768.2012.02493.x
   Fong DS, 2010, OPHTHALMOLOGY, V117, P298, DOI 10.1016/j.ophtha.2009.07.023
   Genentech Inc., 2004, AV TM BEV INTR US PA
   Gerber HP, 1998, J BIOL CHEM, V273, P30336, DOI 10.1074/jbc.273.46.30336
   Gillies MC, 2007, NEW ENGL J MED, V356, P748
   Gordon JD, 1996, J CLIN ENDOCR METAB, V81, P353, DOI 10.1210/jc.81.1.353
   Gragoudas ES, 2004, NEW ENGL J MED, V351, P2805, DOI 10.1056/NEJMoa042760
   Gu X, 2013, CURR EYE RES
   Hara R, 2010, GRAEF ARCH CLIN EXP, V248, P931, DOI 10.1007/s00417-010-1343-8
   Heier JS, 2012, OPHTHALMOLOGY, V119, P2537, DOI 10.1016/j.ophtha.2012.09.006
   Holz FG, 2011, OPHTHALMOLOGY, V118, P663, DOI 10.1016/j.ophtha.2010.12.019
   Hwang DJ, 2012, J KOREAN MED SCI, V27, P1580, DOI 10.3346/jkms.2012.27.12.1580
   Inai T, 2004, AM J PATHOL, V165, P35, DOI 10.1016/S0002-9440(10)63273-7
   Infanger M, 2007, CARDIOVASC PATHOL, V16, P291, DOI 10.1016/j.carpath.2007.04.001
   Ishibashi Tatsuro, 2011, Nippon Ganka Gakkai Zasshi, V115, P122
   Jivraj J, 2013, CAN J OPHTHALMOL, V48, P269, DOI 10.1016/j.jcjo.2013.03.007
   Kaiser PK, 2012, OPHTHALMOLOGY, V119, P1001, DOI 10.1016/j.ophtha.2012.02.003
   Kamba T, 2006, AM J PHYSIOL-HEART C, V290, pH560, DOI 10.1152/ajpheart.00133.2005
   KECK PJ, 1989, SCIENCE, V246, P1309, DOI 10.1126/science.2479987
   Kemp A, 2013, RETINA-J RET VIT DIS, V33, P920, DOI 10.1097/IAE.0b013e318276e07b
   Ko J, 2005, J SURG RES, V129, P251, DOI 10.1016/j.jss.2005.05.006
   Kodjikian L, 2013, OPHTHALMOLOGY, V120, P2300, DOI 10.1016/j.ophtha.2013.06.020
   Krebs I, 2013, BRIT J OPHTHALMOL, V97, P266, DOI 10.1136/bjophthalmol-2012-302391
   Kronmal RA, 1998, STROKE, V29, P887, DOI 10.1161/01.STR.29.5.887
   Lalwani GA, 2009, AM J OPHTHALMOL, V148, P43, DOI 10.1016/j.ajo.2009.01.024
   Landa G, 2009, OPHTHALMOLOGICA, V223, P370, DOI 10.1159/000227783
   Larsen M, 2012, OPHTHALMOLOGY, V119, P992, DOI 10.1016/j.ophtha.2012.02.002
   Lazic R, 2007, OPHTHALMOLOGY, V114, P1179, DOI 10.1016/j.ophtha.2007.03.006
   LEUNG DW, 1989, SCIENCE, V246, P1306, DOI 10.1126/science.2479986
   Li J, 2013, INT J OPHTHALMOL-CHI, V6, P169, DOI 10.3980/j.issn.2222-3959.2013.02.12
   Liew G, 2007, NEW ENGL J MED, V356, P747
   Lim JY, 2012, ACTA OPHTHALMOL, V90, P61, DOI 10.1111/j.1755-3768.2009.01841.x
   Longo R., 2002, Angiogenesis, V5, P237, DOI 10.1023/A:1024532022166
   Martin DF, 2012, OPHTHALMOLOGY, V119, DOI 10.1016/j.ophtha.2012.03.053
   Martin DF, 2011, NEW ENGL J MED, V364, P1897, DOI 10.1056/NEJMoa1102673
   Mathew RS, 2011, OPHTHAL PHYSL OPT, V31, P375, DOI 10.1111/j.1475-1313.2011.00848.x
   Mitchell P, 2010, BRIT J OPHTHALMOL, V94, P2, DOI 10.1136/bjo.2009.159160
   Monsky WL, 1999, CANCER RES, V59, P4129
   Moreira IS, 2007, ANTI-CANCER AGENT ME, V7, P223
   Nguyen-Khoa BA, 2008, ARCH OPHTHALMOL-CHIC, V126, P1280, DOI 10.1001/archopht.126.9.1280
   OCONNOR CM, 1990, J AM COLL CARDIOL, V16, P533, DOI 10.1016/0735-1097(90)90338-P
   Parmeggiani F, 2012, MEDIAT INFLAMM, V2012, DOI 10.1155/2012/546786
   Potter MJ, 2010, BRIT J OPHTHALMOL, V94, P174, DOI 10.1136/bjo.2008.155531
   Raftery J, 2007, BRIT J OPHTHALMOL, V91, P1244, DOI 10.1136/bjo.2007.116616
   Rawlings Kimberly, 2006, FDA APPROVES NEW BIO
   Rezzola S, 2013, ANGIOGENESIS
   Rinaldi M, 2013, RETINA-J RET VIT DIS, V33, P397, DOI 10.1097/IAE.0b013e318261a73c
   Rinaldi M, 2012, BRIT J CLIN PHARMACO, V74, P940, DOI 10.1111/j.1365-2125.2012.04291.x
   Roberts WG, 1997, CANCER RES, V57, P765
   ROSE G, 1989, INT J EPIDEMIOL, V18, pS174
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Rosengart TK, 1999, CIRCULATION, V100, P468, DOI 10.1161/01.CIR.100.5.468
   Russell DA, 2008, BRIT J SURG, V95, P576, DOI 10.1002/bjs.6100
   Scappaticci FA, 2007, JNCI-J NATL CANCER I, V99, P1232, DOI 10.1093/jnci/djm086
   Schmidt-Erfurth U, 2014, OPHTHALMOLOGY, V121, P193, DOI 10.1016/j.ophtha.2013.08.011
   Schmidt-Erfurth U, 2011, OPHTHALMOLOGY, V118, P831, DOI 10.1016/j.ophtha.2010.09.004
   Semeraro F, 2013, DRUG DES DEV THER, V7, P711, DOI 10.2147/DDDT.S40215
   Semeraro F, 2011, CURR VASC PHARMACOL, V9, P629, DOI 10.2174/157016111796642670
   SENGER DR, 1983, SCIENCE, V219, P983, DOI 10.1126/science.6823562
   Shah AR, 2009, BRIT J OPHTHALMOL, V93, P1027, DOI 10.1136/bjo.2008.149674
   Silva R, 2013, OPHTHALMOLOGY, V120, P130, DOI 10.1016/j.ophtha.2012.07.026
   Singer MA, 2012, OPHTHALMOLOGY, V119, P1175, DOI 10.1016/j.ophtha.2011.12.016
   Singerman LJ, 2008, BRIT J OPHTHALMOL, V92, P1606, DOI 10.1136/bjo.2007.132597
   Spielberg L, 2010, GRAEF ARCH CLIN EXP, V248, P943, DOI 10.1007/s00417-009-1256-6
   Stacker SA, 2001, NAT MED, V7, P186, DOI 10.1038/84635
   Steinbrook R, 2006, NEW ENGL J MED, V355, P1409, DOI 10.1056/NEJMp068185
   Stepien KE, 2009, RETINA-J RET VIT DIS, V29, P1067, DOI 10.1097/IAE.0b013e3181b1bb06
   Stewart MW, 2012, MAYO CLIN PROC, V87, P77, DOI 10.1016/j.mayocp.2011.10.001
   Stewart MW, 2012, RETINA, V32, P343
   Swaroop A, 2009, ANNU REV GENOM HUM G, V10, P19, DOI 10.1146/annurev.genom.9.081307.164350
   Takahashi H, 2005, CLIN SCI, V109, P227, DOI 10.1042/CS20040370
   Tsuchihashi T, 2013, CLIN OPHTHALMOL, V7, P615, DOI 10.2147/OPTH.S43566
   Tufail A, 2010, BMJ-BRIT MED J, V340, pc2459
   Tunon J, 2009, SURV OPHTHALMOL, V54, P339, DOI 10.1016/j.survophthal.2009.02.003
   Tziros C, 2006, CURR DRUG TARGETS, V7, P1243, DOI 10.2174/138945006778559111
   Ueta T, 2014, OPHTHALMOLOGY, V121, pE5, DOI 10.1016/j.ophtha.2013.09.019
   Ueta T, 2009, OPHTHALMOLOGY, V116, P362, DOI 10.1016/j.ophtha.2008.09.046
   van Wijngaarden P, 2005, JAMA-J AM MED ASSOC, V293, P1509, DOI 10.1001/jama.293.12.1509
   Wong TY, 2007, LANCET, V370, P204, DOI 10.1016/S0140-6736(07)61104-0
   Wong TY, 2006, ANN INTERN MED, V145, P98, DOI 10.7326/0003-4819-145-2-200607180-00007
   Wu L, 2008, GRAEF ARCH CLIN EXP, V246, P81, DOI 10.1007/s00417-007-0660-z
   Yoshida Y, 2013, JPN J OPHTHALMOL, V57, P283, DOI 10.1007/s10384-013-0234-z
   Yuan F, 1996, P NATL ACAD SCI USA, V93, P14765, DOI 10.1073/pnas.93.25.14765
   Zehetner C, 2013, BRIT J OPHTHALMOL, V97, P454, DOI 10.1136/bjophthalmol-2012-302451
   Ziemssen Focke, 2009, International Ophthalmology, V29, P213, DOI 10.1007/s10792-008-9221-7
   Zlokovic BV, 2006, NAT MED, V12, P390, DOI 10.1038/nm0406-390
NR 119
TC 36
Z9 36
U1 1
U2 20
PU TAYLOR & FRANCIS LTD
PI ABINGDON
PA 2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND
SN 1474-0338
EI 1744-764X
J9 EXPERT OPIN DRUG SAF
JI Expert Opin. Drug Saf.
PD JUN
PY 2014
VL 13
IS 6
BP 785
EP 802
DI 10.1517/14740338.2014.911284
PG 18
WC Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Pharmacology & Pharmacy
GA AI0IV
UT WOS:000336531500012
PM 24809388
DA 2022-11-30
ER

PT J
AU Rubowitz, A
   Esa, S
   Fradkin, M
   Moisseiev, E
AF Rubowitz, Alexander
   Esa, Saleh
   Fradkin, Maayan
   Moisseiev, Elad
TI Neovascular age-related macular degeneration presenting at extremities
   of age: a comparative study
SO GRAEFES ARCHIVE FOR CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY
LA English
DT Article
DE Age-related macular degeneration; Elderly; Extremities of age;
   Neovascular; Presentation; Young
ID INTRAVITREAL RANIBIZUMAB; RISK ALLELES; BEVACIZUMAB; PREVALENCE; CFH;
   ASSOCIATION; VEGFA; ARMS2
AB Purpose To compare the characteristics and response to treatment between patients with NVAMD presenting at the extremities of the AMD age spectrum.
   Methods Fifty-four eyes of 47 patients were included in this retrospective study, divided by age at NVAMD presentation under 65 (n= 15) or over 85 (n= 39) years. All patients were initially treated with 3 monthly bevacizumab injections, followed by a PRN protocol. Clinical parameters and OCT characteristics were recorded and analyzed at presentation, after the initial 3 monthly injections and at 1 year.
   Results At presentation, patients in the young group had significantly higher rates of subretinal fluid (p= 0.005), a polypoidal choroidal vasculopathy-like pattern (p< 0.01) and a history of smoking (p= 0.004). Submacular hemorrhage and pigment epithelial detachments were more common in young patients, and intraretinal fluid was more common in elderly patients (all with borderline statistical significance). VA improved significantly more in the younger patients at 3 months and 1 year (p= 0.001 and 0.002, respectively), despite similar treatment protocols and mean number of injections. Bilateral involvement at baseline was more common in elderly patients (p= 0.008). The differences in OCT characteristics between groups remained throughout the study period.
   Conclusion There are considerable differences in the clinical manifestations and response to treatment between NVAMD patients at the extremities of the AMD age spectrum. Different pathophysiological, systemic, and genetic factors may play a role in such patients.
C1 [Rubowitz, Alexander; Esa, Saleh; Fradkin, Maayan; Moisseiev, Elad] Meir Med Ctr, Dept Ophthalmol, 59 Tshernichovsky St, IL-4428164 Kefar Sava, Israel.
   [Rubowitz, Alexander; Moisseiev, Elad] Tel Aviv Univ, Sackler Sch Med, Tel Aviv, Israel.
C3 Tel Aviv University; Tel Aviv University; Sackler Faculty of Medicine
RP Moisseiev, E (通讯作者)，Meir Med Ctr, Dept Ophthalmol, 59 Tshernichovsky St, IL-4428164 Kefar Sava, Israel.; Moisseiev, E (通讯作者)，Tel Aviv Univ, Sackler Sch Med, Tel Aviv, Israel.
EM elad_moi@netvision.net.il
CR Arias L, 2008, BRIT J OPHTHALMOL, V92, P1636, DOI 10.1136/bjo.2008.141721
   Boyer DS, 2007, OPHTHALMOLOGY, V114, P246, DOI 10.1016/j.ophtha.2006.10.045
   Bressler Neil M, 2004, JAMA, V291, P1900, DOI 10.1001/jama.291.15.1900
   Fasler K, 2019, BMJ OPEN, V9, DOI 10.1136/bmjopen-2018-027441
   FERRIS FL, 1984, ARCH OPHTHALMOL-CHIC, V102, P1640
   Finger RP, 2014, SURV OPHTHALMOL, V59, P1, DOI 10.1016/j.survophthal.2013.03.009
   Grassmann F, 2020, HUM GENET, V139, P401, DOI 10.1007/s00439-019-02029-1
   Guber J, 2014, OPEN OPHTHALMOL J, V8, P3, DOI 10.2174/1874364101408010003
   Gupta B, 2011, BRIT J OPHTHALMOL, V95, P386, DOI 10.1136/bjo.2010.179499
   Habibi I, 2016, KLIN MONATSBL AUGENH, V233, P465, DOI 10.1055/s-0041-111801
   Haga A, 2018, ACTA OPHTHALMOL, V96, pE393, DOI 10.1111/aos.13607
   Holladay JT, 1997, J REFRACT SURG, V13, P388
   KAHN HA, 1977, AM J EPIDEMIOL, V106, P17, DOI 10.1093/oxfordjournals.aje.a112428
   Kang S, 2009, JPN J OPHTHALMOL, V53, P389, DOI 10.1007/s10384-009-0670-y
   Kim JH, 2019, GRAEF ARCH CLIN EXP, V257, P891, DOI 10.1007/s00417-018-04228-4
   KLEIN R, 1992, OPHTHALMOLOGY, V99, P933
   Lechanteur YTE, 2015, JAMA OPHTHALMOL, V133, P533, DOI 10.1001/jamaophthalmol.2015.18
   Li JQ, 2019, BR J OPHTHALMOL, DOI 10.1136/bjophthalmol-2019-314422
   Mekjavic PJ, 2011, ACTA OPHTHALMOL, V89, P647, DOI 10.1111/j.1755-3768.2009.01740.x
   Melamud A, 2008, AM J OPHTHALMOL, V146, P91, DOI 10.1016/j.ajo.2008.03.014
   Okada M, 2018, AM J OPHTHALMOL, V192, P184, DOI 10.1016/j.ajo.2018.05.026
   Schulze-Bonsel K, 2006, INVEST OPHTH VIS SCI, V47, P1236, DOI 10.1167/iovs.05-0981
   Smailhodzic D, 2012, OPHTHALMOLOGY, V119, P2304, DOI 10.1016/j.ophtha.2012.05.040
   Subhi Y, 2017, J OPHTHALMOL, V2017, DOI 10.1155/2017/7194927
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
   Wykoff CC, 2015, OPHTHALMOLOGY, V122, P2514, DOI 10.1016/j.ophtha.2015.08.009
   Yamashiro K, 2012, AM J OPHTHALMOL, V154, P125, DOI 10.1016/j.ajo.2012.01.010
   Ying GS, 2015, OPHTHALMOLOGY, V122, P2523, DOI 10.1016/j.ophtha.2015.08.015
NR 28
TC 0
Z9 0
U1 0
U2 0
PU SPRINGER
PI NEW YORK
PA ONE NEW YORK PLAZA, SUITE 4600, NEW YORK, NY, UNITED STATES
SN 0721-832X
EI 1435-702X
J9 GRAEF ARCH CLIN EXP
JI Graefes Arch. Clin. Exp. Ophthalmol.
PD NOV
PY 2020
VL 258
IS 11
BP 2399
EP 2405
DI 10.1007/s00417-020-04893-4
EA AUG 2020
PG 7
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA OH1OE
UT WOS:000560977200001
PM 32813106
DA 2022-11-30
ER

PT J
AU Navarro-Partida, J
   Altamirano-Vallejo, JC
   Franco, LAA
   Gonzalez-Cortes, J
   Hernandez-Da Mota, S
   Garcia-Aguirre, JG
   Azuara-Galindo, CD
   Castro-Castaneda, CR
   Armendariz-Borunda, J
   Santos, A
AF Navarro-Partida, Jose
   Altamirano-Vallejo, Juan Carlos
   Aceves Franco, Luis Abraham
   Gonzalez-Cortes, Jesus
   Hernandez-Da Mota, Sergio
   Garcia-Aguirre, Jose Gerardo
   Azuara-Galindo, Carlos David
   Castro-Castaneda, Carlos Rodrigo
   Armendariz-Borunda, Juan
   Santos, Arturo
TI Topical Triamcinolone Acetonide-Loaded Liposome Formulation Used as an
   Adjuvant to Intravitreal Ranibizumab Therapy for Neovascular Age-Related
   Macular Degeneration
SO PHARMACEUTICS
LA English
DT Article
DE triamcinolone acetonide; liposomes; neovascular age-related macular
   degeneration; wet macular degeneration; adjuvant therapy; ranibizumab
ID ENDOTHELIAL GROWTH-FACTOR; FLUOCINOLONE ACETONIDE; POSTERIOR SEGMENT;
   DOSING REGIMEN; BEVACIZUMAB; INJECTION; CELLS; PHARMACOKINETICS;
   DELIVERY; OUTCOMES
AB Novel strategies have been developed to reduce or avoid intravitreal injections (IVTs) of the antiangiogenic (ranibizumab (RBZ)) and anti-inflammatory (triamcinolone acetonide (TA)) agents used to treat vitreoretinal diseases. One of the strategies includes liposomes. This study evaluated the safety and efficacy of a topical triamcinolone-loaded liposome formulation (TALF) as an adjuvant to intravitreal RBZ therapy in treatment- naive patients with neovascular age-related macular degeneration (nAMD). Subjects were randomly assigned to the RBZ-TALF or the RBZ-pro re nata (RBZ-PRN) groups. Patients from the RBZ-TALF group were instructed to apply TALF for 12 months after a single dose of RBZ. Patients from the RBZ-PRN group received three monthly RBZ-IVTs. Retreatment with RBZ was considered in the case of nAMD reactivation. Regarding safety, non-ocular abnormalities were observed during TALF therapy. Concerning efficacy, non-significant differences were identified in terms of visual acuity or central foveal thickness when the RBZ-PRN and RBZ-TALF groups were compared. It is worth noting that the average number of RBZ injections was significantly lower in the RBZ-TALF group (2.5 +/- 1.4 vs. 6.1 +/- 1.3 IVTs; p = 0.0004). Therefore, TALF used as an adjuvant to RBZ reduces the need for RBZ-IVT retreatment with optimal visual and anatomic results.
C1 [Navarro-Partida, Jose; Altamirano-Vallejo, Juan Carlos; Aceves Franco, Luis Abraham; Garcia-Aguirre, Jose Gerardo; Castro-Castaneda, Carlos Rodrigo; Armendariz-Borunda, Juan; Santos, Arturo] Tecnol Monterrey, Escuela Med & Ciencias Salud, Monterrey 64849, Mexico.
   [Navarro-Partida, Jose; Altamirano-Vallejo, Juan Carlos; Aceves Franco, Luis Abraham; Santos, Arturo] Hosp Puerta Hierro, Ctr Retina Med & Quirurg SC, Zapopan 45116, Mexico.
   [Gonzalez-Cortes, Jesus] Univ Autonoma Nuevo Leon, Fac Med, Monterrey 64460, Mexico.
   [Gonzalez-Cortes, Jesus] Univ Autonoma Nuevo Leon, Hosp Univ Dr Jose Eleuterio Gonzalez, Monterrey 64460, Mexico.
   [Hernandez-Da Mota, Sergio] Clin David, Unidad Oftalmol, Serv Retina, Morelia 58280, Michoacan, Mexico.
   [Garcia-Aguirre, Jose Gerardo] Asociac Evitar Ceguera Mexico IAP, Mexico City 04030, DF, Mexico.
   [Azuara-Galindo, Carlos David] ISSSTE Clin Hosp Constituc Monterrey, Monterrey 64530, Mexico.
   [Armendariz-Borunda, Juan] Univ Guadalajara, Inst Mol Biol & Gene Therapy, Dept Mol Biol & Genom, Sierra Mojada 950,Edificio Q Tercer Piso, Guadalajara 44340, Mexico.
C3 Tecnologico de Monterrey; Universidad Autonoma de Nuevo Leon;
   Universidad Autonoma de Nuevo Leon; University Hospital Autonomous
   University of Nuevo Leon; Universidad de Guadalajara
RP Santos, A (通讯作者)，Tecnol Monterrey, Escuela Med & Ciencias Salud, Monterrey 64849, Mexico.; Santos, A (通讯作者)，Hosp Puerta Hierro, Ctr Retina Med & Quirurg SC, Zapopan 45116, Mexico.
EM josenavarro@tec.mx; jcaltamirano@e-retina.com; A00832512@tec.mx;
   jesus.gonzalezcrt@uanl.edu.mx; tolodamota@yahoo.com.mx;
   jose.garcia.aguirre@tec.mx; cazuaramd@smq.com.mx;
   crodrigocastro@gmail.com; armdbo@gmail.com; arturo.santos@tec.mx
RI Da Mota, Sergio Hernandez/AAG-7538-2019; Santos, Arturo/GQQ-1431-2022
OI NAVARRO-PARTIDA, JOSE/0000-0002-3895-821X; Garcia-Aguirre,
   Gerardo/0000-0001-6056-9475; Armendariz-Borunda,
   Juan/0000-0002-7101-9943; Hernandez-Da Mota, Sergio/0000-0001-5882-3462;
   Castro-Castaneda, Carlos Rodrigo/0000-0003-0280-8727
CR Abdelfattah NS, 2016, RETINA-J RET VIT DIS, V36, P1843, DOI 10.1097/IAE.0000000000001059
   Ahmadieh H, 2011, RETINA-J RET VIT DIS, V31, P1819, DOI 10.1097/IAE.0b013e31820d58f2
   Altamirano-Vallejo JC, 2018, J OCUL PHARMACOL TH, V34, P416, DOI 10.1089/jop.2017.0099
   Arikan G, 2011, INT J OPHTHALMOL-CHI, V4, P402, DOI 10.3980/j.issn.2222-3959.2011.04.16
   Azad Rajvardhan, 2007, Indian Journal of Ophthalmology, V55, P441
   Barthelmes D, 2018, RETINA-J RET VIT DIS, V38, P20, DOI 10.1097/IAE.0000000000001496
   Bisht R, 2018, WIRES NANOMED NANOBI, V10, DOI 10.1002/wnan.1473
   Brand C, 2016, INVEST OPHTH VIS SCI, V57
   Bravo-Osuna I, 2016, DRUG DELIV TRANSL RE, V6, P686, DOI 10.1007/s13346-016-0336-5
   Bressler Neil M, 2004, JAMA, V291, P1900, DOI 10.1001/jama.291.15.1900
   Brooks HL, 2004, ARCH OPHTHALMOL-CHIC, V122, P1801, DOI 10.1001/archopht.122.12.1801
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Campochiaro PA, 2019, OPHTHALMOLOGY, V126, P1141, DOI 10.1016/j.ophtha.2019.03.036
   Campochiaro PA, 2013, OPHTHALMOLOGY, V120, P583, DOI 10.1016/j.ophtha.2012.09.014
   Campochiaro PA, 2012, OPHTHALMOLOGY, V119, P2125, DOI 10.1016/j.ophtha.2012.04.030
   Chakravarthy U, 2013, LANCET, V382, P1258, DOI 10.1016/S0140-6736(13)61501-9
   Chan CKM, 2005, EYE, V19, P625, DOI 10.1038/sj.eye.6701585
   Chen YX, 2012, THER CLIN RISK MANAG, V8, P343, DOI 10.2147/TCRM.S32801
   Chu YK, 2008, EYE, V22, P895, DOI 10.1038/sj.eye.6702802
   Colucciello M, 2008, J OCUL PHARMACOL TH, V24, P15, DOI 10.1089/jop.2007.0080
   Droege KM, 2013, GRAEF ARCH CLIN EXP, V251, P1281, DOI 10.1007/s00417-012-2177-3
   Dugel PU, 2020, OPHTHALMOLOGY, V127, P72, DOI 10.1016/j.ophtha.2019.04.017
   Ebrahem Q, 2006, INVEST OPHTH VIS SCI, V47, P4935, DOI 10.1167/iovs.05-1651
   Edelman JL, 2005, EXP EYE RES, V80, P249, DOI 10.1016/j.exer.2004.09.013
   el Matri L, 2010, GRAEF ARCH CLIN EXP, V248, P779, DOI 10.1007/s00417-010-1302-4
   Espinosa-Heidmann DG, 2005, EXP EYE RES, V80, P369, DOI 10.1016/j.exer.2004.10.005
   Falavarjani KG, 2013, EYE, V27, P787, DOI 10.1038/eye.2013.107
   Fangueiro JF, 2016, CURR PHARM DESIGN, V22, P1135, DOI 10.2174/1381612822666151216145900
   FLOMAN N, 1977, INVEST OPHTH VIS SCI, V16, P69
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P564
   Fung AE, 2007, AM J OPHTHALMOL, V143, P566, DOI 10.1016/j.ajo.2007.01.028
   Gaudana R, 2009, PHARM RES-DORDR, V26, P1197, DOI 10.1007/s11095-008-9694-0
   Gaudreault J, 2005, INVEST OPHTH VIS SCI, V46, P726, DOI 10.1167/iovs.04-0601
   Gillies MC, 2015, OPHTHALMOLOGY, V122, P1837, DOI 10.1016/j.ophtha.2015.05.010
   Gonzalez-De la Rosa A, 2019, J OCUL PHARMACOL TH, V35, P106, DOI 10.1089/jop.2018.0101
   Gopal Lekha, 2007, Indian Journal of Ophthalmology, V55, P431
   Grossniklaus HE, 2004, AM J OPHTHALMOL, V137, P496, DOI 10.1016/j.ajo.2003.09.042
   Grossniklaus HE, 2002, MOL VIS, V8, P119
   Grzybowski A, 2018, OPHTHALMOLOGICA, V239, P181, DOI 10.1159/000486145
   Hauser D, 2008, RETINA-J RET VIT DIS, V28, P825, DOI 10.1097/IAE.0b013e318165767e
   Heier JS, 2012, OPHTHALMOLOGY, V119, P2537, DOI 10.1016/j.ophtha.2012.09.006
   Holz FG, 2011, OPHTHALMOLOGY, V118, P663, DOI 10.1016/j.ophtha.2010.12.019
   Humayun M, 2014, TRANSL VIS SCI TECHN, V3, DOI 10.1167/tvst.3.6.5
   Johnston RL, 2017, ADV THER, V34, P703, DOI 10.1007/s12325-017-0483-1
   Jonas JB, 2006, J OCUL PHARMACOL TH, V22, P194, DOI 10.1089/jop.2006.22.194
   Jonas JB, 2017, ASIA-PAC J OPHTHALMO, V6, P493, DOI 10.22608/APO.2017251
   Jonas JB, 2010, ACTA OPHTHALMOL, V88, P630, DOI 10.1111/j.1755-3768.2008.01502.x
   Kamppeter BA, 2008, OPHTHALMOLOGY, V115, P1372, DOI 10.1016/j.ophtha.2008.01.019
   Kane FE, 2015, J OCUL PHARMACOL TH, V31, P11, DOI 10.1089/jop.2014.0100
   Kang BS, 2001, BIOL PHARM BULL, V24, P701, DOI 10.1248/bpb.24.701
   KILLINGSWORTH MC, 1995, GRAEF ARCH CLIN EXP, V233, P313, DOI 10.1007/BF00200479
   Kumar R, 2019, MICRO NANO TECHNOL, P249, DOI 10.1016/B978-0-12-814033-8.00008-4
   Lalwani GA, 2009, AM J OPHTHALMOL, V148, P43, DOI 10.1016/j.ajo.2009.01.024
   Li J, 2019, DRUG DELIV, V26, P188, DOI 10.1080/10717544.2019.1571122
   Lyall DAM, 2012, EYE, V26, P1517, DOI 10.1038/eye.2012.199
   Martin DF, 2012, OPHTHALMOLOGY, V119, DOI 10.1016/j.ophtha.2012.03.053
   Matsuda S, 2005, INVEST OPHTH VIS SCI, V46, P1062, DOI 10.1167/iovs.04-0761
   Meyer CH, 2011, ACTA OPHTHALMOL, V89, P70, DOI 10.1111/j.1755-3768.2010.02064.x
   Mishra GP, 2011, J DRUG DELIV, V2011, DOI 10.1155/2011/863734
   Mitchell P, 2010, BRIT J OPHTHALMOL, V94, P2, DOI 10.1136/bjo.2009.159160
   Munk MR, 2016, ACTA OPHTHALMOL, V94, pE757, DOI 10.1111/aos.13157
   Navarro-Partida J, 2021, PHARMACEUTICS, V13, DOI 10.3390/pharmaceutics13030322
   Navarro-Partida J, 2020, J OCUL PHARMACOL TH, V36, P393, DOI 10.1089/jop.2019.0143
   Obata R, 2007, BRIT J OPHTHALMOL, V91, P100, DOI 10.1136/bjo.2006.098004
   Pacella E, 2013, CLIN OPHTHALMOL, V7, P1423, DOI 10.2147/OPTH.S48364
   Pearson PA, 2011, OPHTHALMOLOGY, V118, P1580, DOI 10.1016/j.ophtha.2011.02.048
   Platania CBM, 2015, FRONT PHARMACOL, V6, DOI [10.3389/fphar.2015.00248, 10.3389/tphar.7015.00248]
   Regillo CD, 2008, AM J OPHTHALMOL, V145, P239, DOI 10.1016/j.ajo.2007.10.004
   Resnikoff S, 2004, B WORLD HEALTH ORGAN, V82, P844
   Riazi-Esfahani Mohammad, 2008, J Ophthalmic Vis Res, V3, P95
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Sarao V, 2014, SCI WORLD J, DOI 10.1155/2014/989501
   Sheridan CM, 2006, INVEST OPHTH VIS SCI, V47, P1642, DOI 10.1167/iovs.05-0779
   Shubber S, 2015, PHARM RES-DORDR, V32, P516, DOI 10.1007/s11095-014-1481-5
   Smithen LM, 2004, AM J OPHTHALMOL, V138, P740, DOI 10.1016/j.ajo.2004.06.067
   Stewart MW, 2012, RETINA-J RET VIT DIS, V32, P434, DOI 10.1097/IAE.0B013E31822C290F
   Tao Y, 2010, J OCUL PHARMACOL TH, V26, P207, DOI 10.1089/jop.2009.0131
   Tsilimbaris MK, 2016, J OPHTHALMOL, V2016, DOI 10.1155/2016/4367631
   Tsutsumi-Miyahara C, 2004, BRIT J OPHTHALMOL, V88, P1217, DOI 10.1136/bjo.2003.036392
   Umland SP, 1997, J ALLERGY CLIN IMMUN, V100, P511, DOI 10.1016/S0091-6749(97)70144-1
   Valamanesh F, 2009, MOL VIS, V15, P2634
   Veritti D, 2012, EXPERT OPIN DRUG SAF, V11, P331, DOI 10.1517/14740338.2012.635141
   Wang JL, 2013, MEDIAT INFLAMM, V2013, DOI 10.1155/2013/780634
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
   Wykoff CC, 2015, OPHTHALMOLOGY, V122, P2514, DOI 10.1016/j.ophtha.2015.08.009
NR 85
TC 3
Z9 3
U1 2
U2 5
PU MDPI
PI BASEL
PA ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND
EI 1999-4923
J9 PHARMACEUTICS
JI Pharmaceutics
PD SEP
PY 2021
VL 13
IS 9
AR 1491
DI 10.3390/pharmaceutics13091491
PG 15
WC Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Pharmacology & Pharmacy
GA UY3SP
UT WOS:000701447800001
PM 34575567
OA gold, Green Published
DA 2022-11-30
ER

PT J
AU Karampelas, M
   Sim, DA
   Keane, PA
   Papastefanou, VP
   Sadda, SR
   Tufail, A
   Dowler, J
AF Karampelas, Michael
   Sim, Dawn A.
   Keane, Pearse A.
   Papastefanou, Vasilios P.
   Sadda, Srinivas R.
   Tufail, Adnan
   Dowler, Jonathan
TI Evaluation of retinal pigment epithelium-Bruch's membrane complex
   thickness in dry age-related macular degeneration using optical
   coherence tomography
SO BRITISH JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
DE Imaging; Retina
ID MORPHOMETRIC-ANALYSIS; HIGH-SPEED; IN-VIVO; RESOLUTION; EYES
AB Aim To compare retinal pigment epithelium-Bruch's membrane (RPE-BM) complex thickness in patients with early and intermediate dry age-related macular degeneration (AMD) and age-matched controls using spectral domain optical coherence tomography (SD-OCT).
   Methods In this retrospective, cross-sectional study, 25 patients with dry AMD and 25 controls were recruited. SD-OCT scans were manually segmented by two independent investigators. Thickness values were calculated for the nine Early Treatment Diabetic Retinopathy Study (ETDRS) subfields.
   Results RPE-BM thickness was significantly thicker in the dry AMD group (32.3, 30.6 and 28.4m for central, inner and outer subfields, respectively) compared with the normal eyes (22.7, 21.8 and 21.6m, respectively). RPE-BM thickness was positively correlated with age in the normal group but not in the AMD group. RPE-BM thickness in the dry AMD group was negatively correlated with visual acuity in the central and inner subfields but not in the outer. We observed good intraobserver and inter-observer reliability for both groups in all ETDRS subfields.
   Conclusions This study reports novel data concerning RPE-BM segmentation in dry AMD and performs a direct comparison with age-matched normal controls. Our findings confirm the electron and light microscopy derived data and also establish the value of OCT in the quantification of the RPE-BM complex.
C1 [Karampelas, Michael; Sim, Dawn A.; Keane, Pearse A.; Papastefanou, Vasilios P.; Tufail, Adnan; Dowler, Jonathan] Moorfields Eye Hosp NHS Fdn Trust, NIHR Biomed Res Ctr Ophthalmol, London, England.
   [Karampelas, Michael; Sim, Dawn A.; Keane, Pearse A.; Papastefanou, Vasilios P.; Tufail, Adnan; Dowler, Jonathan] UCL Inst Ophthalmol, London, England.
   [Sim, Dawn A.; Keane, Pearse A.; Tufail, Adnan] UCL, Inst Ophthalmol, London, England.
   [Sadda, Srinivas R.] Univ So Calif, Keck Sch Med, Doheny Eye Inst, Dept Ophthalmol, Los Angeles, CA 90033 USA.
C3 University of London; University College London; Moorfields Eye Hospital
   NHS Foundation Trust; University of London; University College London;
   University of London; University College London; Doheny Eye Institute;
   University of Southern California
RP Karampelas, M (通讯作者)，Moorfields NHS Fdn Trust, NIHR Biomed Res Ctr Ophthalmol, 162 City Rd, London EC1V 2PD, England.
EM michael.karampelas@moorfields.nhs.uk
RI Keane, Pearse/AAE-5709-2019; PAPASTEFANOU, VASILIOS/AAN-9779-2020
OI Keane, Pearse/0000-0002-9239-745X; Tufail, Adnan/0000-0001-6131-7640
FU Fight For Sight UK [1987]; Department of Health's NIHR Biomedical
   Research Centre for Ophthalmology at Moorfields Eye Hospital; UCL
   Institute of Ophthalmology; Academy of Medical Sciences (AMS)
   [AMS-SGCL6-Keane] Funding Source: researchfish; National Institute for
   Health Research [CL-2010-18-004] Funding Source: researchfish
FX DAS receives funding from Fight For Sight UK, Grant 1987. PAK, DAS and
   AT have received a proportion of their funding from the Department of
   Health's NIHR Biomedical Research Centre for Ophthalmology at Moorfields
   Eye Hospital and UCL Institute of Ophthalmology. The views expressed in
   the publication are those of the author and not necessarily those of the
   Department of Health.
CR Age-Related Eye Dis Study Res Grp, 2001, AM J OPHTHALMOL, V132, P668
   Anand R, 2000, OPHTHALMOLOGY, V107, P2224
   Bird AC, 2010, J CLIN INVEST, V120, P3033, DOI 10.1172/JCI42437
   Bland JM, 1996, BRIT MED J, V313, P744
   Booij JC, 2010, PROG RETIN EYE RES, V29, P1, DOI 10.1016/j.preteyeres.2009.08.003
   CAMPOCHIARO PA, 1986, INVEST OPHTH VIS SCI, V27, P1615
   Donoso LA, 2006, SURV OPHTHALMOL, V51, P137, DOI 10.1016/j.survophthal.2005.12.001
   Drexler W, 2003, ARCH OPHTHALMOL-CHIC, V121, P695, DOI 10.1001/archopht.121.5.695
   Ferris FL, 2005, ARCH OPHTHALMOL-CHIC, V123, P1570
   Green W R, 1977, Trans Am Ophthalmol Soc, V75, P180
   Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557
   Okubo A, 1999, INVEST OPHTH VIS SCI, V40, P443
   Pappuru RR, 2011, INVEST OPHTH VIS SCI, V52, P6743, DOI 10.1167/iovs.10-6723
   Pascolini D, 2004, OPHTHAL EPIDEMIOL, V11, P67, DOI 10.1076/opep.11.2.67.28158
   PULIAFITO CA, 1995, OPHTHALMOLOGY, V102, P217
   RAMRATTAN RS, 1994, INVEST OPHTH VIS SCI, V35, P2857
   Sadda SR, 2010, INVEST OPHTH VIS SCI, V51, P1071, DOI 10.1167/iovs.09-4325
   SARKS JP, 1988, EYE, V2, P552, DOI 10.1038/eye.1988.106
   Shen JK, 2007, HISTOL HISTOPATHOL, V22, P1301, DOI 10.14670/HH-22.1301
   Solomon SD, 2009, RETINA-J RET VIT DIS, V29, P1080, DOI 10.1097/IAE.0b013e3181b1baeb
   Spaide RF, 2011, RETINA-J RET VIT DIS, V31, P1609, DOI 10.1097/IAE.0b013e3182247535
   Spraul CW, 1999, SURV OPHTHALMOL, V44, pS10, DOI 10.1016/S0039-6257(99)00086-7
   Srinivasan VJ, 2006, INVEST OPHTH VIS SCI, V47, P5522, DOI 10.1167/iovs.06-0195
   VANDERSCHAFT TL, 1992, OPHTHALMOLOGY, V99, P278
   Zawadzki RJ, 2005, OPT EXPRESS, V13, P8532, DOI 10.1364/OPEX.13.008532
NR 25
TC 38
Z9 38
U1 0
U2 11
PU BMJ PUBLISHING GROUP
PI LONDON
PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND
SN 0007-1161
EI 1468-2079
J9 BRIT J OPHTHALMOL
JI Br. J. Ophthalmol.
PD OCT
PY 2013
VL 97
IS 10
BP 1256
EP 1261
DI 10.1136/bjophthalmol-2013-303219
PG 6
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 221EA
UT WOS:000324639200009
PM 23843264
DA 2022-11-30
ER

PT J
AU Okubo, A
   Hirakawa, M
   Ito, M
   Sameshima, M
   Sakamoto, T
AF Okubo, Akiko
   Hirakawa, Mayumi
   Ito, Motoko
   Sameshima, Munefumi
   Sakamoto, Taiji
TI Clinical features of early and late stage polypoidal choroidal
   vasculopathy characterized by lesion size and disease duration
SO GRAEFES ARCHIVE FOR CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY
LA English
DT Article
DE polypoidal choroidal vasculopathy; clinical feature; lesion size;
   disease duration; stage
ID PIGMENT EPITHELIAL DETACHMENTS; CLINICOPATHOLOGICAL CORRELATION; MACULAR
   DEGENERATION
AB Background The pathogenesis of polypoidal choroidal vasculopathy (PCV), and even its clinical features, are controversial. Previous histopathological studies have identified different features; either dilated choroidal vessels or intra-Bruch's neovascularization. These differences might be partly attributable to the influence of the disease stage. We therefore evaluated the clinical features of early and late stage PCV.
   Methods The medical records of 110 eyes of 97 PCV patients were retrospectively reviewed. The time between the subjective onset of visual abnormality and examination at our clinic and the greatest linear dimension of the total lesion at the first examination were investigated. The period of disturbed vision and lesion size data were placed in ascending order to determine the first quartile point. Eyes with both values at or below the first quartile point were classified as 'small-short' (early stage). Eyes with both values equal to at least the third quartile point were classified as 'large-long' (late stage). Fundus photography, indocyanine green and fluorescein angiography, visual acuity, and clinical course were compared.
   Results Twelve eyes from 12 patients were small-short cases (period of disturbed vision of 1 month or less, lesion size 2.0 disc diameters or less). Eleven eyes from ten patients were large-long cases (period of disturbed vision 36 months or more, lesion size at least 5.0 disc diameters). The large-long eyes were characterized by occult choroidal neovascular membrane or scar tissue secondary to exudative age-related macular degeneration. Noticeable in the small-short eyes were atrophic changes in the retinal pigment epithelium, choroidal vessel hyperpermeability and pulsation. The visual prognosis and clinical course were different between the groups.
   Conclusions The difference of clinical features between the groups might reflect different disease stages, although not all of the features observed in the small-short group appeared to represent the early stages of those recorded in the large-long group. Thus, the variation in histopathologic features among previous reports might be partly attributable to differences in disease stage.
C1 [Okubo, Akiko; Hirakawa, Mayumi; Ito, Motoko; Sameshima, Munefumi; Sakamoto, Taiji] Kagoshima Univ, Grad Sch Med, Dept Ophthalmol, Kagoshima 8908520, Japan.
C3 Kagoshima University
RP Okubo, A (通讯作者)，Kagoshima Univ, Grad Sch Med, Dept Ophthalmol, 8-35-1 Sakuragaoka, Kagoshima 8908520, Japan.
EM akiko@m2.kufm.kagoshima-u.ac.jp
CR GREEN WR, 1993, OPHTHALMOLOGY, V100, P1519
   KLEINER RC, 1990, RETINA-J RET VIT DIS, V10, P9, DOI 10.1097/00006982-199001010-00002
   Kuroiwa S, 2004, CLIN EXP OPHTHALMOL, V32, P297, DOI 10.1111/j.1442-9071.2004.00827.x
   Kwok AKH, 2002, BRIT J OPHTHALMOL, V86, P892, DOI 10.1136/bjo.86.8.892
   Lafaut BA, 2000, RETINA-J RET VIT DIS, V20, P650, DOI 10.1097/00006982-200011000-00010
   MACCUMBER MW, 1994, RETINA-J RET VIT DIS, V14, P143, DOI 10.1097/00006982-199414020-00007
   Nakajima M, 2004, JPN J OPHTHALMOL, V48, P249, DOI 10.1007/s10384-003-0057-4
   Okubo A, 2005, OPHTHALMOLOGY, V112, P1436, DOI 10.1016/j.ophtha.2005.03.017
   Okubo A, 2002, BRIT J OPHTHALMOL, V86, P1093, DOI 10.1136/bjo.86.10.1093
   PERKOVICH BT, 1990, RETINA-J RET VIT DIS, V10, P18, DOI 10.1097/00006982-199001010-00003
   Rosa RH, 2002, ARCH OPHTHALMOL-CHIC, V120, P502
   Sho K, 2003, ARCH OPHTHALMOL-CHIC, V121, P1392, DOI 10.1001/archopht.121.10.1392
   SPAIDE RF, 1995, RETINA-J RET VIT DIS, V15, P100, DOI 10.1097/00006982-199515020-00003
   Spraul CW, 1997, KLIN MONATSBL AUGENH, V210, P405, DOI 10.1055/s-2008-1035085
   STERN RM, 1985, AM J OPHTHALMOL, V100, P560, DOI 10.1016/0002-9394(85)90682-8
   Terasaki H, 2002, BRIT J OPHTHALMOL, V86, P321, DOI 10.1136/bjo.86.3.321
   Uyama M, 1999, ARCH OPHTHALMOL-CHIC, V117, P1035
   Wen F, 2004, GRAEF ARCH CLIN EXP, V242, P625, DOI 10.1007/s00417-003-0667-z
   Yannuzzi LA, 1997, ARCH OPHTHALMOL-CHIC, V115, P478, DOI 10.1001/archopht.1997.01100150480005
   YANNUZZI LA, 1990, RETINA-J RET VIT DIS, V10, P1, DOI 10.1097/00006982-199001010-00001
   Yuzawa M, 2005, BRIT J OPHTHALMOL, V89, P602, DOI 10.1136/bjo.2004.049296
NR 21
TC 23
Z9 26
U1 0
U2 2
PU SPRINGER
PI NEW YORK
PA ONE NEW YORK PLAZA, SUITE 4600, NEW YORK, NY, UNITED STATES
SN 0721-832X
EI 1435-702X
J9 GRAEF ARCH CLIN EXP
JI Graefes Arch. Clin. Exp. Ophthalmol.
PD APR
PY 2008
VL 246
IS 4
BP 491
EP 499
DI 10.1007/s00417-007-0680-8
PG 9
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 277XV
UT WOS:000254248900003
PM 17917739
DA 2022-11-30
ER

PT J
AU Yoon, SM
   Lee, BL
   Guo, YR
   Choung, SY
AF Yoon, Sun-Myung
   Lee, Bom-
   Guo, Yuan-Ri
   Choung, Se-Young
TI Preventive effect of Vaccinium uliginosum L. extract and its fractions
   on age-related macular degeneration and its action mechanisms
SO ARCHIVES OF PHARMACAL RESEARCH
LA English
DT Article
DE Age-related macular degeneration (AMD); A2E; Blue light; Vaccinium
   uliginosum L. (V.U); ARPE-19 cell
ID PIGMENT EPITHELIAL-CELLS; LIGHT-INDUCED DAMAGE; INDUCED APOPTOSIS; A2E;
   MACULOPATHY; PREVALENCE; RETINA; RPE; PHOTOOXIDATION; ABNORMALITIES
AB Age-related macular degeneration (AMD) is the leading cause of vision loss and blindness among the elderly. Although the pathogenesis of this disease remains still obscure, several researchers have report that death of retinal pigmented epithelium (RPE) caused by excessive accumulation of A2E is crucial determinants of AMD. In this study, the preventive effect of Vaccinium uliginosum L. (V.U) extract and its fractions on AMD was investigated in blue light-irradiated human RPE cell (ARPE-19 cells). Blue light-induced RPE cell death was significantly inhibited by the treatment of V.U extract or its fraction. To identify the mechanism, FAB-MS analysis revealed that V.U inhibits the photooxidation of N-retinyl-N-retinylidene ethanolamine (A2E) induced by blue light in cell free system. Moreover, monitoring by quantitative HPLC also revealed that V.U extract and its fractions reduced intracellular accumulation of A2E, suggesting that V.U extract and its fractions inhibit not only blue light-induced photooxidation, but also intracellular accumulation of A2E, resulting in RPE cell survival after blue light exposure. A2E-laden cell exposed to blue light induced apoptosis by increasing the cleaved form of caspase-3, Bax/Bcl-2. Additionally, V.U inhibited by the treatment of V.U extract or quercetin-3-O-arabinofuranoside. These results suggest that V.U extract and its fractions have preventive effect on blue light-induced damage in RPE cells and AMD.
C1 [Yoon, Sun-Myung; Lee, Bom-; Choung, Se-Young] Kyung Hee Univ, Dept Life & Nanopharmaceut Sci Pharm, Seoul, South Korea.
   [Guo, Yuan-Ri; Choung, Se-Young] Kyung Hee Univ, Dept Prevent Pharm & Toxicol, Coll Pharm, Seoul 02447, South Korea.
C3 Kyung Hee University; Kyung Hee University
RP Choung, SY (通讯作者)，Kyung Hee Univ, Dept Life & Nanopharmaceut Sci Pharm, Seoul, South Korea.
EM sychoung@khu.ac.kr
RI Choung, Young/AAH-9208-2020
OI Guo, Yuan-Ri/0000-0002-1410-288X; Choung, Se Young/0000-0001-7619-6263
CR Algvere PV, 2006, ACTA OPHTHALMOL SCAN, V84, P4, DOI 10.1111/j.1600-0420.2005.00627.x
   Avalle LB, 2004, EXP EYE RES, V78, P895, DOI 10.1016/j.exer.2003.10.023
   Ben-Shabat S, 2002, ANGEW CHEM INT EDIT, V41, P814, DOI 10.1002/1521-3773(20020301)41:5<814::AID-ANIE814>3.0.CO;2-2
   Bhosale P, 2009, ARCH BIOCHEM BIOPHYS, V483, P175, DOI 10.1016/j.abb.2008.09.012
   Bian QN, 2012, FREE RADICAL BIO MED, V53, P1298, DOI 10.1016/j.freeradbiomed.2012.06.024
   Chu W, 2011, BIOMOLECULAR CLIN AS
   Congdon N, 2004, ARCH OPHTHALMOL-CHIC, V122, P477
   Dillon J, 2004, EXP EYE RES, V79, P537, DOI 10.1016/j.exer.2004.06.024
   DOREY CK, 1989, INVEST OPHTH VIS SCI, V30, P1691
   Gaillard ER, 2004, EXP EYE RES, V79, P313, DOI 10.1016/j.exer.2004.05.005
   GORGELS TGMF, 1995, INVEST OPHTH VIS SCI, V36, P851
   Grimm C, 2001, INVEST OPHTH VIS SCI, V42, P497
   HAM WT, 1976, NATURE, V260, P153, DOI 10.1038/260153a0
   Jang YJ, 2015, BIOMOL THER, V23, P407, DOI 10.4062/biomolther.2015.075
   Jang YP, 2005, PHOTOCHEM PHOTOBIOL, V81, P529, DOI 10.1562/2004-12-14-RA-402.1
   Kim MJ, 2012, EVID-BASED COMPL ALT, V2012, P7
   Kim YH, 2009, J MED FOOD, V12, P885, DOI 10.1089/jmf.2008.1127
   KLEIN R, 1992, OPHTHALMOLOGY, V99, P933
   Liang FQ, 2003, EXP EYE RES, V76, P397, DOI 10.1016/S0014-4835(03)00023-X
   Liu J, 2010, J FOOD SCI, V75, pH103, DOI 10.1111/j.1750-3841.2010.01546.x
   MITCHELL P, 1995, OPHTHALMOLOGY, V102, P1450
   Parish CA, 1998, P NATL ACAD SCI USA, V95, P14609, DOI 10.1073/pnas.95.25.14609
   Petrukhin K, 2007, EXPERT OPIN THER TAR, V11, P625, DOI 10.1517/14728222.11.5.625
   Rozanowska M, 2005, PHOTOCHEM PHOTOBIOL, V81, P1305, DOI 10.1562/2004-11-13-IR-371
   Shi L, 2010, BRAIN RES, V1352, P255, DOI 10.1016/j.brainres.2010.07.009
   Sparrow JR, 2010, J LIPID RES, V51, P247, DOI 10.1194/jlr.R000687
   Sparrow JR, 2003, VISION RES, V43, P2983, DOI 10.1016/S0042-6989(03)00475-9
   Sparrow JR, 2003, J BIOL CHEM, V278, P18207, DOI 10.1074/jbc.M300457200
   Sparrow JR, 2001, INVEST OPHTH VIS SCI, V42, P1356
   Sparrow JR, 2000, INVEST OPHTH VIS SCI, V41, P1981
   STEINMETZ RL, 1993, BRIT J OPHTHALMOL, V77, P549, DOI 10.1136/bjo.77.9.549
   Sunness JS, 1997, OPHTHALMOLOGY, V104, P1677, DOI 10.1016/S0161-6420(97)30079-7
   Suter M, 2000, J BIOL CHEM, V275, P39625, DOI 10.1074/jbc.M007049200
   VANNORREN D, 1990, VISION RES, V30, P1517, DOI 10.1016/0042-6989(90)90032-G
   Vingerling JR, 1995, EPIDEMIOL REV, V17, P347, DOI 10.1093/oxfordjournals.epirev.a036198
   VINGERLING JR, 1995, OPHTHALMOLOGY, V102, P205
   Wenzel A, 2005, PROG RETIN EYE RES, V24, P275, DOI 10.1016/j.preteyeres.2004.08.002
   Westlund B, 2009, APOPTOSIS, V14, P31, DOI 10.1007/s10495-008-0285-7
   Winkler BS, 1999, MOL VIS, V5
   Zarbin MA, 2012, PATHOGENESIS AGE REL
   Zhou JL, 2006, REJUV RES, V9, P256, DOI 10.1089/rej.2006.9.256
NR 41
TC 23
Z9 23
U1 2
U2 15
PU PHARMACEUTICAL SOC KOREA
PI SEOUL
PA 1489-3 SUHCHO-DONG, SUHCHO-KU, SEOUL 137-071, SOUTH KOREA
SN 0253-6269
EI 1976-3786
J9 ARCH PHARM RES
JI Arch. Pharm. Res.
PD JAN
PY 2016
VL 39
IS 1
BP 21
EP 32
DI 10.1007/s12272-015-0683-7
PG 12
WC Chemistry, Medicinal; Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Pharmacology & Pharmacy
GA DB0LR
UT WOS:000368200100003
PM 26589689
DA 2022-11-30
ER

PT J
AU Parodi, MB
   Virgili, G
   Evans, JR
AF Parodi, M. B.
   Virgili, G.
   Evans, J. R.
TI Laser treatment of drusen to prevent progression to advanced age-related
   macular degeneration
SO COCHRANE DATABASE OF SYSTEMATIC REVIEWS
LA English
DT Review
ID PIGMENT EPITHELIAL ABNORMALITIES; CHOROIDAL NEOVASCULARIZATION; SOFT
   DRUSEN; PROPHYLACTIC TREATMENT; GRID PHOTOCOAGULATION; MACULOPATHY;
   RISK; EYE; REDUCTION; BURDEN
AB Background
   Drusen are amorphous yellowish deposits beneath the sensory retina. People with drusen, particularly large drusen, are at higher risk of developing age-related macular degeneration (AMD). The most common complication in AMD is choroidal neovascularisation (CNV), the growth of new blood vessels in the centre of the macula. The risk of CNV is higher among patients who are already affected by CNV in one eye.
   It has been observed clinically that laser photocoagulation of drusen leads to their disappearance and may prevent the occurrence of advanced disease (CNV or geographic atrophy) associated with visual loss.
   Objectives
   To examine the effectiveness and adverse effects of laser photocoagulation of drusen in AMD.
   Search strategy
   We searched CENTRAL, MEDLINE and EMBASE on 14 November 2008.
   Selection criteria
   Randomised controlled trials (RCTs) of laser treatment of drusen in AMD in which laser treatment had been compared with no intervention or sham treatment. Two types of trials were included. Some trials studied one eye of each patient (unilateral studies); other studies recruited patients with bilateral drusen and randomised one eye to photocoagulation or control and the fellow eye to the other group.
   Data collection and analysis
   Two review authors independently selected studies and extracted data. We pooled data from unilateral and bilateral studies using a random-effects model. For the bilateral studies, we estimated the within-patient correlation coefficient from one study and assumed it was valid for the others.
   Main results
   We found nine studies which randomised 2216 people: four unilateral trials, three bilateral trials and two trials that included both a unilateral and a bilateral study arm.
   Overall, the studies were of moderate quality. Only half of the trials reported adequate allocation sequence generation, allocation concealment and masking of visual acuity outcome assessors.
   Although two (of the nine) studies reported significant drusen disappearance at two years, photocoagulation did not appear to affect the development of CNV at two years follow up (nine studies, 1767 people followed up, odds ratio (OR) 1.04, 95% CI 0.71 to 1.51) or the loss of three or more lines of visual acuity (six studies, 1628 people followed up, OR 1.17, 95% CI 0.75 to 1.82).
   Authors'conclusions
   The trials included in this review confirm the clinical observation that laser photocoagulation of drusen leads to their disappearance. However, there is no evidence that this subsequently results in a reduction in the risk of developing CNV, geographic atrophy or visual acuity loss.
C1 [Parodi, M. B.] Univ Udine, Dept Ophthalmol, I-33100 Udine, Italy.
   [Virgili, G.] Univ Florence, Eye Clin, Dept Neurootoophthalmol Surg Sci, Florence, Italy.
   [Evans, J. R.] London Sch Hyg & Trop Med, ICEH, Cochrane Eyes & Vis Grp, London WC1, England.
C3 University of Udine; University of Florence; University of London;
   London School of Hygiene & Tropical Medicine
RP Parodi, MB (通讯作者)，Univ Udine, Dept Ophthalmol, Piazzale Santa Maria Misericordia, I-33100 Udine, Italy.
EM maubp@yahoo.it
RI Parodi, Maurizio Battaglia/K-7876-2016; Evans, Jennifer/F-4672-2012;
   Bacherini, Daniela/T-6009-2019; Virgili, Gianni/P-6607-2014
OI Evans, Jennifer/0000-0002-6137-2030; Virgili,
   Gianni/0000-0002-9960-2989; Battaglia Parodi,
   Maurizio/0000-0002-0385-7961
CR Abdelsalam A, 1999, SURV OPHTHALMOL, V44, P1, DOI 10.1016/S0039-6257(99)00072-7
   Alexander J, 2004, INVESTIGATIVE OPHTHA, V45
   [Anonymous], 1998, Ophthalmology, V105, P1364
   [Anonymous], 1998, Ophthalmology, V105, P11
   BRESSLER NM, 1995, ARCH OPHTHALMOL-CHIC, V113, P301, DOI 10.1001/archopht.1995.01100030055022
   BRESSLER NM, 1994, RETINA-J RET VIT DIS, V14, P130, DOI 10.1097/00006982-199414020-00006
   BRESSLER SB, 1995, INVESTIGATIVE OPHTHA
   Brown MM, 2006, CURR OPIN OPHTHALMOL, V17, P257
   Chakravarthy Usha, 2005, Curr Opin Ophthalmol, V16, P179, DOI 10.1097/01.icu.0000163035.37957.c2
   Chong EWT, 2007, BMJ-BRIT MED J, V335, P755, DOI 10.1136/bmj.39350.500428.47
   Cleasby G W, 1979, Mod Probl Ophthalmol, V20, P141
   Complications of Age-Related Macular Degeneration Prevention Trial Study Group, 2004, Clin Trials, V1, P91
   DUVALL J, 1985, ARCH OPHTHALMOL-CHIC, V103, P694, DOI 10.1001/archopht.1985.01050050086024
   Elbourne DR, 2002, INT J EPIDEMIOL, V31, P140, DOI 10.1093/ije/31.1.140
   Evans JR, 2006, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD000254.pub2
   Figueroa M, 2004, BRIT J OPHTHALMOL, V88, P792, DOI 10.1136/bjo.2003.033837
   Figueroa M, 2006, AM J OPHTHALMOL, V141, P863, DOI 10.1016/j.ajo.2005.11.049
   Figueroa MS, 1997, RETINA-J RET VIT DIS, V17, P378
   FIGUEROA MS, 1994, RETINA-J RET VIT DIS, V14, P391, DOI 10.1097/00006982-199414050-00001
   Fine SL, 2001, INVESTIGATIVE OPHTHA, V42
   Frennesson C, 1998, BRIT J OPHTHALMOL, V82, P1169, DOI 10.1136/bjo.82.10.1169
   Frennesson CI, 2003, ACTA OPHTHALMOL SCAN, V81, P449, DOI 10.1034/j.1600-0420.2003.00143.x
   Frennesson I C, 1996, Eur J Ophthalmol, V6, P307
   FRENNESSON IC, 1995, BRIT J OPHTHALMOL, V79, P905, DOI 10.1136/bjo.79.10.905
   Friberg TR, 2006, OPHTHALMOLOGY, V113, P612, DOI 10.1016/j.ophtha.2005.10.066
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P564
   GASS JDM, 1973, ARCH OPHTHALMOL-CHIC, V90, P206
   Glanville JM, 2006, J MED LIBR ASSOC, V94, P130
   Gross-Jendroska M, 1998, AM J OPHTHALMOL, V126, P77, DOI 10.1016/S0002-9394(98)00061-0
   Grunwald JE, 2004, INVESTIGATIVE OPHTHA, V45
   Guidry C, 2002, INVEST OPHTH VIS SCI, V43, P267
   Guymer RH, 2001, BRIT J OPHTHALMOL, V85, P40, DOI 10.1136/bjo.85.1.40
   Hassell JB, 2006, BRIT J OPHTHALMOL, V90, P593, DOI 10.1136/bjo.2005.086595
   Higgins JPT, 2008, COCHRANE HDB SYSTEMA
   Ho AC, 1999, OPHTHALMOLOGY, V106, P1367, DOI 10.1016/S0161-6420(99)00735-6
   Ho AC, 1998, AM ACAD OPHTHALMOLOG, P127
   HOLZ FG, 1994, OPHTHALMOLOGY, V101, P1522
   Kaiser RS, 2001, ARCH OPHTHALMOL-CHIC, V119, P826
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1417, DOI 10.1001/archopht.119.10.1417
   Kertes PJ, 2006, EVIDENCE BASED OPHTH, V7, P135
   Klein R, 2004, AM J OPHTHALMOL, V137, P486, DOI 10.1016/j.ajo.2003.11.069
   Little HL, 1997, OPHTHALMOLOGY, V104, P623, DOI 10.1016/S0161-6420(97)30261-9
   LITTLE HL, 1995, AM ACAD OPHTHALMOLOG, P120
   Maguire M, 2004, OPHTHALMOLOGY, V111, P1307
   Maguire MG, 1997, ARCH OPHTHALMOL-CHIC, V115, P741
   Mangione CM, 1999, AM J OPHTHALMOL, V128, P45, DOI 10.1016/S0002-9394(99)00169-5
   *NORD COCHR CTR C, 2008, ERV MAN REVMAN 5 0
   Olk RJ, 1999, OPHTHALMOLOGY, V106, P2082, DOI 10.1016/S0161-6420(99)90487-6
   Owen CG, 2003, BRIT J OPHTHALMOL, V87, P312, DOI 10.1136/bjo.87.3.312
   Owens SL, 2006, AM J OPHTHALMOL, V141, P276, DOI 10.1016/j.ajo.2005.08.019
   Owens SL, 2003, EYE, V17, P623, DOI 10.1038/sj.eye.6700442
   Owens SL, 1999, AM J OPHTHALMOL, V127, P681, DOI 10.1016/S0002-9394(99)00043-4
   Park DW, 2006, OPHTHALMOLOGY, V113, P1974, DOI 10.1016/j.ophtha.2006.08.015
   PAULDRACH AW, 1990, ASP C SER, V7, P171
   PAULEIKHOFF D, 1990, AM J OPHTHALMOL, V109, P211, DOI 10.1016/S0002-9394(14)75989-6
   Phipps JA, 2003, INVEST OPHTH VIS SCI, V44, P2277, DOI 10.1167/iovs.02-0769
   Prenner JL, 2003, RETINA-J RET VIT DIS, V23, P307, DOI 10.1097/00006982-200306000-00004
   Regillo CD, 2003, EVIDENCE BASED EYE C, V4, P204
   Rodanant N, 2002, AM J OPHTHALMOL, V134, P577, DOI 10.1016/S0002-9394(02)01691-4
   Rosenbaltt BJ, 2001, INVESTIGATIVE OPHTHA, V42
   Sarks SH, 1999, BRIT J OPHTHALMOL, V83, P358, DOI 10.1136/bjo.83.3.358
   Sarraf D, 1999, RETINA-J RET VIT DIS, V19, P513, DOI 10.1097/00006982-199911000-00006
   Sbarbaro JA, 2004, INVESTIGATIVE OPHTHA, V45
   SIGELMAN J, 1991, OPHTHALMOLOGY, V98, P1379
   Sivagnanavel V, 2004, INVESTIGATIVE OPHTHA, V45
   Smith W, 2001, OPHTHALMOLOGY, V108, P697, DOI 10.1016/S0161-6420(00)00580-7
   Sternberg P, 2003, OPHTHALMOLOGY, V110, P971, DOI 10.1016/S0161-6420(03)00098-8
   Stoltz RA, 2004, INVESTIGATIVE OPHTHA, V45
   Vingerling JR, 1996, ARCH OPHTHALMOL-CHIC, V114, P1193, DOI 10.1001/archopht.1996.01100140393005
   Wetzig P C, 1994, Trans Am Ophthalmol Soc, V92, P299
   White IR, 2008, STAT MED, V27, P711, DOI 10.1002/sim.3008
   Ying GS, 2005, INVEST OPHTH VIS SCI, V46
   YOUNG GP, 1987, DIAGN CYTOPATHOL, V3, P1, DOI 10.1002/dc.2840030102
NR 73
TC 24
Z9 24
U1 0
U2 10
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1469-493X
EI 1361-6137
J9 COCHRANE DB SYST REV
JI Cochrane Database Syst Rev.
PY 2009
IS 3
AR CD006537
DI 10.1002/14651858.CD006537.pub2
PG 56
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine
GA 471EE
UT WOS:000268037500005
PM 19588397
OA Green Accepted, Green Submitted
DA 2022-11-30
ER

PT J
AU Landa, G
   Springer, A
   Bukelman, A
   Pollack, A
AF Landa, G.
   Springer, A.
   Bukelman, A.
   Pollack, A.
TI The diagnostic contribution of indocyanine green to fluorescein
   angiography in fellow drusen eyes of patients with wet age-related
   macular degeneration
SO EUROPEAN JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
DE indocyanine green angiography; fluorescein angiography; wet age-related
   macular degeneration
ID POLYPOIDAL CHOROIDAL VASCULOPATHY; GRADING SYSTEM; CLINICAL-TRIAL;
   NEOVASCULARIZATION; VIDEOANGIOGRAPHY; MACULOPATHY; OCCULT; AREDS;
   DISEASE
AB PURPOSE. To assess the contribution of indocyanine green angiography (ICGA) to fluorescein angiography (FA) in evaluating fellow drusen eyes of patients with wet age-related macular degeneration (AMD) in the other eye.
   METHODS. The records of paired FA and ICGA of patients with dry AMD in one eye and wet AMD in the other eye were retrospectively reviewed. Based on color fundus photographs, drusen were graded to low, moderate, or high grade of severity on FA. The FA and ICGA findings were compared.
   RESULTS. Fifty-two pairs of eyes were included. Fluorescein angiography showed drusen of low severity in 11 (21.2%) eyes, of moderate severity in 31 (59.6%), and of high severity in 10 (19.2%). Leakage on both FA and ICGA was not demonstrated in any case of drusen of low or moderate severity. Only in 2 out of 10 eyes from the high severity group, 3.8% of the eyes of the whole study population, did ICGA reveal occult choroidal neovascularization (CNV) that was not observed on FA.
   CONCLUSIONS. In selected eyes with drusen of high grade severity, ICGA may detect occult CNV, unrecognized clinically or by FA. ICGA had a small contribution to the diagnosis of occult CNV in fellow drusen eyes with any degree of severity.
C1 Kaplan Med Ctr, Dept Ophthalmol, IL-76100 Rehovot, Israel.
C3 Hebrew University of Jerusalem; Kaplan Medical Center
RP Landa, G (通讯作者)，Kaplan Med Ctr, Dept Ophthalmol, POB 1, IL-76100 Rehovot, Israel.
EM doctor.landa@gmail.com
CR Arnold J, 2001, AM J OPHTHALMOL, V131, P541
   Arnold JJ, 1997, AM J OPHTHALMOL, V124, P344, DOI 10.1016/S0002-9394(14)70826-8
   BIRD AEC, 1995, SURV OPHTHALMOL, V39, P367, DOI 10.1016/S0039-6257(05)80092-X
   BRESSLER SB, 1990, ARCH OPHTHALMOL-CHIC, V108, P1442, DOI 10.1001/archopht.1990.01070120090035
   Chang AA, 2003, CLIN EXP OPHTHALMOL, V31, P300, DOI 10.1046/j.1442-9071.2003.00664.x
   Ciardella AP, 2004, SURV OPHTHALMOL, V49, P25, DOI 10.1016/j.survophthal.2003.10.007
   Clemons TE, 2003, ARCH OPHTHALMOL-CHIC, V121, P211
   FREUND KB, 1993, AM J OPHTHALMOL, V115, P786, DOI 10.1016/S0002-9394(14)73649-9
   GUYER DR, 1993, CURR OPIN OPHTHALMOL, V4, P3, DOI 10.1097/00055735-199306000-00002
   GUYER DR, 1994, OPHTHALMOLOGY, V101, P1727
   Hanutsaha P, 1998, OPHTHALMOLOGY, V105, P1632, DOI 10.1016/S0161-6420(98)99030-3
   Kassoff A, 1999, CONTROL CLIN TRIALS, V20, P573
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1417, DOI 10.1001/archopht.119.10.1417
   KLEIN R, 1991, OPHTHALMOLOGY, V98, P1128
   REGILLO CD, 1994, OPHTHALMOLOGY, V101, P280
   Schneider U, 2001, OPHTHALMOLOGE, V98, P1186, DOI 10.1007/s003470170012
   Schneider U, 1997, INT OPHTHALMOL, V21, P79, DOI 10.1023/A:1005848806641
   Stanga PE, 2003, OPHTHALMOLOGY, V110, P15, DOI 10.1016/S0161-6420(02)01563-4
   Staurenghi G, 1998, OPHTHALMOLOGY, V105, P2297, DOI 10.1016/S0161-6420(98)91232-5
   van Leeuwen R, 2003, ARCH OPHTHALMOL-CHIC, V121, P519, DOI 10.1001/archopht.121.4.519
   Yannuzzi LA, 1999, ARCH OPHTHALMOL-CHIC, V117, P1503
   Yannuzzi LA, 2001, RETINA-J RET VIT DIS, V21, P416, DOI 10.1097/00006982-200110000-00003
   YANNUZZI LA, 1992, RETINA-J RET VIT DIS, V12, P191, DOI 10.1097/00006982-199212030-00003
NR 23
TC 5
Z9 5
U1 0
U2 2
PU WICHTIG EDITORE
PI MILAN
PA 72/74 VIA FRIULI, 20135 MILAN, ITALY
SN 1120-6721
J9 EUR J OPHTHALMOL
JI Eur. J. Ophthalmol.
PD JUL-AUG
PY 2007
VL 17
IS 4
BP 615
EP 619
DI 10.1177/112067210701700421
PG 5
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 220FX
UT WOS:000250143700021
PM 17671939
DA 2022-11-30
ER

PT J
AU Khan, JC
   Thurlby, DA
   Shahid, H
   Clayton, DG
   Yates, JRW
   Bradley, M
   Moore, AT
   Bird, AC
AF Khan, JC
   Thurlby, DA
   Shahid, H
   Clayton, DG
   Yates, JRW
   Bradley, M
   Moore, AT
   Bird, AC
CA Genetic Factors AMD Study
TI Smoking and age related macular degeneration: the number of pack years
   of cigarette smoking is a major determinant of risk for both geographic
   atrophy and choroidal neovascularisation
SO BRITISH JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
ID COMPLEMENT FACTOR-H; VISUAL IMPAIRMENT; MACULOPATHY; PREVALENCE;
   POPULATION; POLYMORPHISM; INCREASES; NICOTINE; VARIANT; HEALTH
AB Background/aims: There is evidence that smoking is a risk factor for age related macular degeneration ( AMD). However, not all studies have demonstrated this association and several key questions about the role of smoking in AMD have still to be determined. The aim of this study was to further investigate this relation for both choroidal neovascularisation ( CNV) and geographic atrophy ( GA).
   Methods: To investigate the relation between smoking and the risk of developing age related macular degeneration ( AMD) in white people, 435 cases with end stage AMD were compared with 280 controls. All subjects had graded stereoscopic colour fundus photography and AMD was defined as the presence of GA or CNV. Smoking history was assessed using multiple parameters in a detailed questionnaire.
   Results: Comparison of current and former smokers with non-smokers was consistent with smoking being a risk factor for AMD but did not reach statistical significance. There was a strong association between AMD and pack years of cigarette smoking ( p = 0.002), the odds ratio increasing with the amount smoked; for subjects with more than 40 pack years of smoking the odds ratio was 2.75 ( 95% CI 1.22 to 6.20) compared with non-smokers. Both types of AMD showed a similar relation; smoking more than 40 pack years of cigarettes was associated with an odds ratio of 3.43 ( 95% CI 1.28 to 9.20) for GA and 2.49 ( 95% CI 1.06 to 5.82) for CNV. Stopping smoking was associated with reduced odds of AMD and the risk in those who had not smoked for over 20 years was comparable to non-smokers. The risk profile was similar for males and females. Passive smoking exposure was associated with an increased risk of AMD ( OR 1.87; 95% CI 1.03 to 3.40) in non-smokers.
   Conclusions: The authors have demonstrated a strong association between the risk of both GA and CNV and pack years of cigarette smoking. This provides support for a causal relation between smoking and AMD. They also show an increased risk for AMD in non-smokers exposed to passive smoking. Stopping smoking appears to reduce the risk of developing AMD.
C1 Univ Cambridge, Dept Med Genet, Cambridge CB2 1TN, England.
   Univ Cambridge, Ctr Appl Med Stat, Inst Publ Hlth, Cambridge CB2 1TN, England.
   UCL, Inst Ophthalmol, London, England.
   Moorfields Eye Hosp, London, England.
C3 University of Cambridge; University of Cambridge; University of London;
   University College London; University of London; University College
   London; Moorfields Eye Hospital NHS Foundation Trust
RP Yates, JRW (通讯作者)，Univ Cambridge, Addenbrookes Hosp, Dept Med Genet, Box 134, Cambridge CB2 2QQ, England.
EM jrwy1@cam.ac.uk
FU MRC [G0000067] Funding Source: UKRI; Medical Research Council [G0000067]
   Funding Source: Medline
CR Anand R, 2000, OPHTHALMOLOGY, V107, P2224
   Bailey TA, 2004, INVEST OPHTH VIS SCI, V45, P675, DOI 10.1167/iovs.03-0351
   Bernaards CM, 2001, ADDICTION, V96, P1653, DOI 10.1046/j.1360-0443.2001.9611165311.x
   BIRD AEC, 1995, SURV OPHTHALMOL, V39, P367, DOI 10.1016/S0039-6257(05)80092-X
   BLUMENKRANZ MS, 1986, OPHTHALMOLOGY, V93, P552
   Buch H, 2001, OPHTHALMOLOGY, V108, P2347, DOI 10.1016/S0161-6420(01)00823-5
   Chaine G, 1998, BRIT J OPHTHALMOL, V82, P996, DOI 10.1136/bjo.82.9.996
   Christen WG, 1996, JAMA-J AM MED ASSOC, V276, P1147, DOI 10.1001/jama.276.14.1147
   Delcourt C, 1998, ARCH OPHTHALMOL-CHIC, V116, P1031, DOI 10.1001/archopht.116.8.1031
   Edwards AO, 2005, SCIENCE, V308, P421, DOI 10.1126/science.1110189
   Esparza-Gordillo J, 2004, IMMUNOGENETICS, V56, P77, DOI 10.1007/s00251-004-0660-7
   Evans J, 1996, BRIT J OPHTHALMOL, V80, P9, DOI 10.1136/bjo.80.1.9
   Evans J., 1995, STUDIES MED POPULATI, V57
   Hageman GS, 2005, P NATL ACAD SCI USA, V102, P7227, DOI 10.1073/pnas.0501536102
   Haines JL, 2005, SCIENCE, V308, P419, DOI 10.1126/science.1110359
   Hawkins BS, 1999, MOL VIS, V5
   HYMAN LG, 1983, AM J EPIDEMIOL, V118, P213, DOI 10.1093/oxfordjournals.aje.a113629
   KAHN HA, 1977, AM J EPIDEMIOL, V106, P17, DOI 10.1093/oxfordjournals.aje.a112428
   Klaver CCW, 1998, ARCH OPHTHALMOL-CHIC, V116, P653, DOI 10.1001/archopht.116.5.653
   KLEIN R, 1993, AM J EPIDEMIOL, V137, P190, DOI 10.1093/oxfordjournals.aje.a116659
   KLEIN R, 1992, OPHTHALMOLOGY, V99, P933
   Klein R, 1999, OPHTHALMOLOGY, V106, P1056, DOI 10.1016/S0161-6420(99)90255-5
   Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557
   LEUREDUPREE AE, 1981, INVEST OPHTH VIS SCI, V21, P1
   MALTZMAN BA, 1979, ANN OPHTHALMOL, V11, P1197
   McCarty CA, 2001, ARCH OPHTHALMOL-CHIC, V119, P1455
   McCarty CA, 2001, BRIT J OPHTHALMOL, V85, P322, DOI 10.1136/bjo.85.3.322
   MITCHELL P, 1995, OPHTHALMOLOGY, V102, P1450
   Sastry BVR, 1998, J OCUL PHARMACOL TH, V14, P447, DOI 10.1089/jop.1998.14.447
   Seddon JM, 1996, JAMA-J AM MED ASSOC, V276, P1141, DOI 10.1001/jama.276.14.1141
   Smith MR, 2003, ATHEROSCLEROSIS, V169, P331, DOI 10.1016/S0021-9150(03)00200-4
   Smith W, 1996, ARCH OPHTHALMOL-CHIC, V114, P1518, DOI 10.1001/archopht.1996.01100140716016
   Smith W, 2001, OPHTHALMOLOGY, V108, P697, DOI 10.1016/S0161-6420(00)00580-7
   Suner IJ, 2004, INVEST OPHTH VIS SCI, V45, P311, DOI 10.1167/iovs.03-0733
   VINGERLING JR, 1995, OPHTHALMOLOGY, V102, P205
   Vingerling JR, 1996, ARCH OPHTHALMOL-CHIC, V114, P1193, DOI 10.1001/archopht.1996.01100140393005
   Wald NJ, 1997, BMJ-BRIT MED J, V314, P1860, DOI 10.1136/bmj.314.7098.1860
   WEST SK, 1989, ARCH OPHTHALMOL-CHIC, V107, P875, DOI 10.1001/archopht.1989.01070010897038
   YANNUZZI LA, 1992, ARCH OPHTHALMOL-CHIC, V110, P1701
   Zareparsi S, 2005, AM J HUM GENET, V77, P149, DOI 10.1086/431426
NR 40
TC 274
Z9 285
U1 2
U2 23
PU BMJ PUBLISHING GROUP
PI LONDON
PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND
SN 0007-1161
EI 1468-2079
J9 BRIT J OPHTHALMOL
JI Br. J. Ophthalmol.
PD JAN
PY 2006
VL 90
IS 1
BP 75
EP 80
DI 10.1136/bjo.2005.073643
PG 6
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 993YD
UT WOS:000233994900021
PM 16361672
OA Green Published, Bronze
DA 2022-11-30
ER

PT J
AU Chen, S
   Zhou, Y
   Zhou, LC
   Guan, YH
   Zhang, Y
   Han, XZ
AF Chen, Shang
   Zhou, Yue
   Zhou, Lichun
   Guan, Yanhui
   Zhang, Yu
   Han, Xiuzhen
TI Anti-neovascularization effects of DMBT in age-related macular
   degeneration by inhibition of VEGF secretion through ROS-dependent
   signaling pathway
SO MOLECULAR AND CELLULAR BIOCHEMISTRY
LA English
DT Article
DE Choroidal neovascularization; DMBT; Hypoxia; VEGF; HIF-1 alpha
ID ENDOTHELIAL GROWTH-FACTOR; RETINAL-PIGMENT EPITHELIUM; OXIDATIVE STRESS;
   HYPOXIC CONDITIONS; ANGIOGENESIS; TREHALOSE; CELLS; AMD; EXPRESSION;
   INVASION
AB Choroidal neovascularization (CNV) is the hallmark of late-staged wet age-related macular degeneration (AMD). Vascular endothelial growth factor (VEGF) is a key component in the development and progression of wet AMD. DMBT, 6,6'-bis(2,3-dimethoxybenzoyl)-alpha,alpha-d-trehalose, had been proved that it could suppress tumor angiogenesis and metastasis by inhibiting production of VEGF. But the effects of DMBT on CNV were not known. This study was to investigate effects and mechanisms of DMBT on CNV in vitro and in vivo. Results showed that DMBT could inhibit migration and tube formation of RF/6A cells under ARPE-19 hypoxia conditioned medium. DMBT could reduce lesion area in laser-induced CNV model mice. ELISA and Western blotting assay showed that DMBT markedly inhibited secretion of VEGF in vitro and in vivo. Furthermore, DMBT restrained ROS level under hypoxia via suppressing Nrf2/HO-1 pathway. DMBT effectively suppressed hypoxia-induced the up-regulation of p-Akt, p-NF-kappa B, and HIF-1 alpha. These results suggest that DMBT can inhibit CNV by down-regulation of VEGF in retina through Akt/NF-kappa B/HIF-1 alpha and ERK/Nrf2/HO-1/HIF-1 alpha pathway. DMBT might be a promising lead molecule for anti-CNV and serve as a therapeutic agent to inhibit CNV.
C1 [Chen, Shang; Zhou, Yue; Zhou, Lichun; Guan, Yanhui; Zhang, Yu; Han, Xiuzhen] Shandong Univ, Sch Pharmaceut Sci, Dept Pharmacol, 44 West Wenhua Rd, Jinan 250012, Shandong, Peoples R China.
   [Zhou, Yue] Shandong Univ, Sch Pharmaceut Sci, Dept Clin Pharm, 44 West Wenhua Rd, Jinan 250012, Shandong, Peoples R China.
   [Han, Xiuzhen] Minist Educ, Key Lab Chem Biol Nat Prod, Jinan, Shandong, Peoples R China.
   [Chen, Shang] Yamaguchi Univ, Grad Sch Med, Dept Ophthalmol, Minamikoguchi 1-1-1, Ube, Yamaguchi 7558505, Japan.
C3 Shandong University; Shandong University; Yamaguchi University
RP Han, XZ (通讯作者)，Shandong Univ, Sch Pharmaceut Sci, Dept Pharmacol, 44 West Wenhua Rd, Jinan 250012, Shandong, Peoples R China.; Han, XZ (通讯作者)，Minist Educ, Key Lab Chem Biol Nat Prod, Jinan, Shandong, Peoples R China.
EM xzyhan@sdu.edu.cn
RI Zhou, Yue/AAQ-3903-2021
FU Natural Science Foundation of Shandong Province [ZR2013HM084]; Key
   Research and Development Program of Shandong Province of P. R. China
   [2016GSF201152]
FX This work was supported by Natural Science Foundation of Shandong
   Province (No. ZR2013HM084) and Key Research and Development Program of
   Shandong Province (2016GSF201152) of P. R. China. Compounds DMBT used in
   this study were synthesized by Prof. Zhaopeng Liu, Department of
   Medicinal Chemistry, School of Pharmaceutical Sciences, Shandong
   University. Thanks are due to Dr. Yanai at the Department of
   Ophthalmology, Graduate School of Medicine, Yamaguchi University, for
   his help and guide in this study.
CR Al-Latayfeh M, 2012, CSH PERSPECT MED, V2, DOI 10.1101/cshperspect.a006411
   Arjamaa O, 2009, AGEING RES REV, V8, P349, DOI 10.1016/j.arr.2009.06.002
   Bhutto I, 2012, MOL ASPECTS MED, V33, P295, DOI 10.1016/j.mam.2012.04.005
   Campa C, 2011, CURR DRUG TARGETS, V12, P173, DOI 10.2174/138945011794182674
   Campochiaro PA, 2013, J MOL MED, V91, P311, DOI 10.1007/s00109-013-0993-5
   Cervellati F, 2014, FREE RADICAL RES, V48, P303, DOI 10.3109/10715762.2013.867484
   Chen Z, 2013, J CLIN INVEST, V123, P1057, DOI 10.1172/JCI65344
   de Jong PTVM, 2006, NEW ENGL J MED, V355, P1474, DOI 10.1056/NEJMra062326
   Donato AJ, 2015, J MOL CELL CARDIOL, V89, P122, DOI 10.1016/j.yjmcc.2015.01.021
   Handa JT, 2012, MOL ASPECTS MED, V33, P418, DOI 10.1016/j.mam.2012.03.006
   Igarashi Y, 2009, J NAT PROD, V72, P980, DOI 10.1021/np9000575
   Jiang YL, 2011, BIOORG MED CHEM LETT, V21, P1089, DOI 10.1016/j.bmcl.2010.12.133
   Kim JH, 2014, ANTIOXID REDOX SIGN, V21, P2469, DOI 10.1089/ars.2014.5856
   Kim JH, 2012, FREE RADICAL BIO MED, V53, P629, DOI 10.1016/j.freeradbiomed.2012.04.019
   Kim SH, 2016, REDOX BIOL, V10, P211, DOI 10.1016/j.redox.2016.10.008
   Kinnunen K, 2012, ACTA OPHTHALMOL, V90, P299, DOI 10.1111/j.1755-3768.2011.02179.x
   Kurihara T, 2014, ADV EXP MED BIOL, V801, P275, DOI 10.1007/978-1-4614-3209-8_35
   Lim LS, 2012, LANCET, V379, P1728, DOI 10.1016/S0140-6736(12)60282-7
   Loboda A, 2016, CELL MOL LIFE SCI, V73, P3221, DOI 10.1007/s00018-016-2223-0
   Fanjul-Moles ML, 2016, OXID MED CELL LONGEV, V2016, DOI 10.1155/2016/7420637
   Luyckx J, 2011, CLIN OPHTHALMOL, V5, P577, DOI 10.2147/OPTH.S18827
   Orobia AJM, 2017, CLIN OPHTHALMOL, V11, P347, DOI 10.2147/OPTH.S125203
   Nowak JZ, 2014, ACTA POL PHARM, V71, P900
   Paeng SH, 2015, INT J MOL MED, V35, P1419, DOI 10.3892/ijmm.2015.2116
   Park H, 2015, INT J MOL MED, V36, P301, DOI 10.3892/ijmm.2015.2202
   Pennington KL, 2016, EYE VISION, V3, DOI 10.1186/s40662-016-0063-5
   Rosen R, 2015, BIOMED RES INT, V2015, DOI 10.1155/2015/687386
   Russo MA, 2015, ENDOCR METAB IMMUNE, V15, P171, DOI 10.2174/1871530315666150316120112
   Salminen A, 2008, CELL MOL LIFE SCI, V65, P1049, DOI 10.1007/s00018-008-7461-3
   Takeuchi K, 2011, INVEST OPHTH VIS SCI, V52, P6987, DOI 10.1167/iovs.11-7478
   Takeuchi K, 2010, EXP EYE RES, V91, P567, DOI 10.1016/j.exer.2010.07.002
   Tang LL, 2014, CHEM-BIOL INTERACT, V222, P7, DOI 10.1016/j.cbi.2014.08.004
   Tang LL, 2013, FOOD CHEM TOXICOL, V56, P204, DOI 10.1016/j.fct.2013.02.032
   Wang HB, 2016, MOL VIS, V22, P189
   Wang HB, 2016, MOL VIS, V22, P116
   Wu HQ, 2017, J MOL NEUROSCI, V61, P449, DOI 10.1007/s12031-017-0885-1
   Wu JM, 2016, INT J BIOL SCI, V12, P1363, DOI 10.7150/ijbs.16334
NR 37
TC 8
Z9 8
U1 2
U2 18
PU SPRINGER
PI DORDRECHT
PA VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS
SN 0300-8177
EI 1573-4919
J9 MOL CELL BIOCHEM
JI Mol. Cell. Biochem.
PD NOV
PY 2018
VL 448
IS 1-2
BP 225
EP 235
DI 10.1007/s11010-018-3328-6
PG 11
WC Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Cell Biology
GA GV8JK
UT WOS:000446385800021
PM 29446046
DA 2022-11-30
ER

PT J
AU Ding, JD
   Johnson, LV
   Herrmann, R
   Farsiu, S
   Smith, SG
   Groelle, M
   Mace, BE
   Sullivan, P
   Jamison, JA
   Kelly, U
   Harrabi, O
   Bollini, SS
   Dilley, J
   Kobayashi, D
   Kuang, B
   Li, WL
   Pons, J
   Lin, JC
   Rickman, CB
AF Ding, Jin-Dong
   Johnson, Lincoln V.
   Herrmann, Rolf
   Farsiu, Sina
   Smith, Stephanie G.
   Groelle, Marybeth
   Mace, Brian E.
   Sullivan, Patrick
   Jamison, Jeffrey A.
   Kelly, Una
   Harrabi, Ons
   Bollini, Sangeetha Subbarao
   Dilley, Jeanette
   Kobayashi, Dione
   Kuang, Bing
   Li, Wenlin
   Pons, Jaume
   Lin, John C.
   Rickman, Catherine Bowes
TI Anti-amyloid therapy protects against retinal pigmented epithelium
   damage and vision loss in a model of age-related macular degeneration
SO PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF
   AMERICA
LA English
DT Article
ID COMPLEMENT FACTOR-H; APOLIPOPROTEIN-E GENE; ALZHEIMERS-DISEASE; MOUSE
   MODEL; TRANSGENIC MICE; DIETARY-FAT; TARGETED REPLACEMENT; MICROARRAY
   ANALYSIS; BETA IMMUNIZATION; DRUSEN FORMATION
AB Age-related macular degeneration (AMD) is a leading cause of visual dysfunction worldwide. Amyloid beta (A beta) peptides, A beta 1-40 (A beta 40) and A beta 1-42 (A beta 42), have been implicated previously in the AMD disease process. Consistent with a pathogenic role for A beta, we show here that a mouse model of AMD that invokes multiple factors that are known to modify AMD risk (aged human apolipoprotein E 4 targeted replacement mice on a high-fat, cholesterol-enriched diet) presents with A beta-containing deposits basal to the retinal pigmented epithelium (RPE), histopathologic changes in the RPE, and a deficit in scotopic electroretinographic response, which is reflective of impaired visual function. Strikingly, these electroretinographic deficits are abrogated in a dose-dependent manner by systemic administration of an antibody targeting the C termini of A beta 40 and A beta 42. Concomitant reduction in the levels of A beta and activated complement components in sub-RPE deposits and structural preservation of the RPE are associated with anti-A beta 40/42 antibody immunotherapy and visual protection. These observations are consistent with the reduction in amyloid plaques and improvement of cognitive function in mouse models of Alzheimer's disease treated with anti-A beta antibodies. They also implicate A beta in the pathogenesis of AMD and identify A beta as a viable therapeutic target for its treatment.
C1 [Harrabi, Ons; Bollini, Sangeetha Subbarao; Dilley, Jeanette; Kobayashi, Dione; Pons, Jaume; Lin, John C.] Pfizer Inc, Rinat, San Francisco, CA 94080 USA.
   [Ding, Jin-Dong; Herrmann, Rolf; Farsiu, Sina; Smith, Stephanie G.; Groelle, Marybeth; Kelly, Una; Rickman, Catherine Bowes] Duke Univ, Duke Eye Ctr, Dept Ophthalmol, Durham, NC 27710 USA.
   [Johnson, Lincoln V.] Univ Calif Santa Barbara, Neurosci Res Inst, Ctr Study Macular Degenerat, Santa Barbara, CA 93106 USA.
   [Mace, Brian E.; Sullivan, Patrick] Duke Univ, Durham Vet Affairs Hosp Med Ctr, Dept Med, Div Geriatr, Durham, NC 27705 USA.
   [Jamison, Jeffrey A.] MPI Res Inc, Ophthy DS Inc, Mattawan, MI 49071 USA.
   [Kuang, Bing; Li, Wenlin] Pfizer Inc, Worldwide Res & Dev, La Jolla, CA 92121 USA.
   [Rickman, Catherine Bowes] Duke Univ, Dept Cell Biol, Durham, NC 27710 USA.
C3 Pfizer; Duke University; University of California System; University of
   California Santa Barbara; Duke University; Pfizer; Duke University
RP Lin, JC (通讯作者)，Pfizer Inc, Rinat, San Francisco, CA 94080 USA.
EM john.lin@pfizer.com; bowes007@duke.edu
RI Jamison, Jeffrey/Q-3152-2019; Ding, Jindong/B-3324-2008
OI Ding, Jindong/0000-0003-0427-0369; Farsiu, Sina/0000-0003-4872-2902;
   Bowes Rickman, Catherine/0000-0002-8555-9596; kobayashi,
   dione/0000-0002-5541-7175
FU Pfizer Inc.; National Institutes of Health [R24 EY017404, R01 EY019038,
   P30 EY005722]; Research to Prevent Blindness, Inc.; Core Grants to the
   Duke Eye Center; RPB Special Scholars Award; Ruth and Milton Steinbach
   Fund; Macular Vision Research Foundation; NATIONAL EYE INSTITUTE
   [R01EY019038, R24EY017404, P30EY005722] Funding Source: NIH RePORTER
FX O.H., S.S.B., J.D., D.K., B.K., W.L., J.P., and J.C.L. are full-time
   employees of Pfizer Inc., and Pfizer Inc. owns the intellectual
   properties of the antibodies described herein. L.V.J. and C. B. R. have
   received research funding from Pfizer Inc.; We gratefully acknowledge
   support from generous benefactors of the University of California Santa
   Barbara Center for the Study of Macular Degeneration, Zhe Chen for
   generating the human APP plasmid, Likun (Sam) Xi for his help with the
   RPE cell segmentation, Mark Gilbert for assistance with FACS, and
   Danielle Pappas for helping with mouse serum ELISA. This work was
   supported by National Institutes of Health Grants R24 EY017404 (to
   L.V.J.), R01 EY019038 (to C. B. R.), and P30 EY005722 (to Duke Eye
   Center), the Research to Prevent Blindness, Inc. (RPB) Core Grants to
   the Duke Eye Center, the RPB Special Scholars Award (to C. B. R.), The
   Ruth and Milton Steinbach Fund (to C. B. R.), and the Macular Vision
   Research Foundation (to C.B.R.).
CR Al-Hussaini H, 2009, EXP EYE RES, V88, P610, DOI 10.1016/j.exer.2008.09.021
   Allikmets R, 2000, AM J HUM GENET, V67, P487, DOI 10.1086/303018
   Anderson DH, 2004, EXP EYE RES, V78, P243, DOI 10.1016/j.exer.2003.10.011
   Anderson DH, 2001, AM J OPHTHALMOL, V131, P767, DOI 10.1016/S0002-9394(00)00961-2
   Armour KL, 2003, MOL IMMUNOL, V40, P585, DOI 10.1016/j.molimm.2003.08.004
   Armour KL, 2002, BIOCHEM SOC T, V30, P495, DOI 10.1042/bst0300495
   Armour KL, 1999, EUR J IMMUNOL, V29, P2613, DOI 10.1002/(SICI)1521-4141(199908)29:08<2613::AID-IMMU2613>3.0.CO;2-J
   Baird PN, 2006, HUM MUTAT, V27, P337, DOI 10.1002/humu.20288
   Bruban J, 2009, AGING CELL, V8, P162, DOI 10.1111/j.1474-9726.2009.00456.x
   Carty NC, 2006, J NEUROINFLAMM, V3, DOI 10.1186/1742-2094-3-11
   DeMattos RB, 2001, P NATL ACAD SCI USA, V98, P8850, DOI 10.1073/pnas.151261398
   DeMattos RB, 2002, SCIENCE, V295, P2264, DOI 10.1126/science.1067568
   Dentchev T, 2003, MOL VIS, V9, P184
   Dewan A, 2006, SCIENCE, V314, P989, DOI 10.1126/science.1133807
   Ding JD, 2008, VISION RES, V48, P339, DOI 10.1016/j.visres.2007.07.025
   Edwards AO, 2005, SCIENCE, V308, P421, DOI 10.1126/science.1110189
   Feigl B, 2005, EYE, V19, P431, DOI 10.1038/sj.eye.6701503
   Ferrer I, 2004, BRAIN PATHOL, V14, P11, DOI 10.1111/j.1750-3639.2004.tb00493.x
   FRIEDMAN E, 1968, ARCH OPHTHALMOL-CHIC, V79, P315, DOI 10.1001/archopht.1968.03850040317017
   Fritsche LG, 2009, HUM MUTAT, V30, P1048, DOI 10.1002/humu.20957
   Gehrs KM, 2006, ANN MED, V38, P450, DOI 10.1080/07853890600946724
   Gold B, 2006, NAT GENET, V38, P458, DOI 10.1038/ng1750
   Gragoudas ES, 2004, NEW ENGL J MED, V351, P2805, DOI 10.1056/NEJMoa042760
   Haas P, 2011, ACTA OPHTHALMOL, V89, P335, DOI 10.1111/j.1755-3768.2009.01697.x
   Hageman GS, 1999, FASEB J, V13, P477, DOI 10.1096/fasebj.13.3.477
   Hageman GS, 2005, P NATL ACAD SCI USA, V102, P7227, DOI 10.1073/pnas.0501536102
   Haines JL, 2005, SCIENCE, V308, P419, DOI 10.1126/science.1110359
   Hardy J, 2002, SCIENCE, V297, P353, DOI 10.1126/science.1072994
   Herrmann R, 2010, J NEUROSCI, V30, P3239, DOI 10.1523/JNEUROSCI.4775-09.2010
   Hooper CY, 2003, CLIN EXP OPHTHALMOL, V31, P376, DOI 10.1046/j.1442-9071.2003.00683.x
   Isas JM, 2010, INVEST OPHTH VIS SCI, V51, P1304, DOI 10.1167/iovs.09-4207
   Jager RD, 2008, NEW ENGL J MED, V358, P2606, DOI 10.1056/NEJMra0801537
   Johnson LV, 2000, EXP EYE RES, V70, P441, DOI 10.1006/exer.1999.0798
   Johnson LV, 2002, P NATL ACAD SCI USA, V99, P11830, DOI 10.1073/pnas.192203399
   Kanda A, 2007, P NATL ACAD SCI USA, V104, P16227, DOI 10.1073/pnas.0703933104
   Klein BEK, 2002, OPHTHALMOLOGY, V109, P2052, DOI 10.1016/S0161-6420(02)01249-6
   KLEIN R, 1992, OPHTHALMOLOGY, V99, P933
   Klein R, 1997, OPHTHALMOLOGY, V104, P1804, DOI 10.1016/S0161-6420(97)30023-2
   Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557
   Kurji KH, 2010, INVEST OPHTH VIS SCI, V51, P1151, DOI 10.1167/iovs.09-3622
   Lemere CA, 2003, NEUROBIOL DIS, V14, P10, DOI 10.1016/S0969-9961(03)00044-5
   Luibl V, 2006, J CLIN INVEST, V116, P378, DOI 10.1172/JCI25843
   Malek G, 2006, ADV EXP MED BIOL, V572, P109
   Malek G, 2005, P NATL ACAD SCI USA, V102, P11900, DOI 10.1073/pnas.0503015102
   Malek G, 2008, ADV EXP MED BIOL, V613, P165, DOI 10.1007/978-0-387-74904-4_18
   MARESPERLMAN JA, 1995, ARCH OPHTHALMOL-CHIC, V113, P743, DOI 10.1001/archopht.1995.01100060069034
   Mastellos D, 2004, MOL IMMUNOL, V40, P1213, DOI 10.1016/j.molimm.2003.10.019
   Mordenti J, 1999, TOXICOL PATHOL, V27, P536, DOI 10.1177/019262339902700507
   Mullins RF, 2000, FASEB J, V14, P835, DOI 10.1096/fasebj.14.7.835
   Nicoll JAR, 2003, NAT MED, V9, P448, DOI 10.1038/nm840
   NIEMEYER G, 1998, DIGIT J OPHTHALMOL, V4
   Orgogozo JM, 2003, NEUROLOGY, V61, P46, DOI 10.1212/01.WNL.0000073623.84147.A8
   Owsley C, 2007, OPHTHALMOLOGY, V114, P1728, DOI 10.1016/j.ophtha.2006.12.023
   Penfold PL, 2001, PROG RETIN EYE RES, V20, P385, DOI 10.1016/S1350-9462(00)00025-2
   Prins ND, 2010, ALZHEIMERS RES THER, V2, DOI 10.1186/alzrt28
   Rivera A, 2005, HUM MOL GENET, V14, P3227, DOI 10.1093/hmg/ddi353
   Sakaguchi H, 2002, EXP EYE RES, V74, P547, DOI 10.1006/exer.2002.1186
   Schmidt Silke, 2002, Ophthalmic Genet, V23, P209, DOI 10.1076/opge.23.4.209.13883
   Seddon JM, 2003, ARCH OPHTHALMOL-CHIC, V121, P1728, DOI 10.1001/archopht.121.12.1728
   Seddon JM, 2001, ARCH OPHTHALMOL-CHIC, V119, P1191, DOI 10.1001/archopht.119.8.1191
   Stone EM, 2004, NEW ENGL J MED, V351, P346, DOI 10.1056/NEJMoa040833
   Sullivan PM, 1997, J BIOL CHEM, V272, P17972, DOI 10.1074/jbc.272.29.17972
   Swaroop A, 2009, ANNU REV GENOM HUM G, V10, P19, DOI 10.1146/annurev.genom.9.081307.164350
   TSO MOM, 1967, ARCH OPHTHALMOL-CHIC, V78, P641, DOI 10.1001/archopht.1967.00980030643016
   Vasilevko V, 2007, J NEUROSCI, V27, P13376, DOI 10.1523/JNEUROSCI.2788-07.2007
   VINGERLING JR, 1995, AM J EPIDEMIOL, V142, P404, DOI 10.1093/oxfordjournals.aje.a117648
   VINGERLING JR, 1995, OPHTHALMOLOGY, V102, P205
   Wang JY, 2009, J CELL PHYSIOL, V220, P119, DOI 10.1002/jcp.21742
   Wilcock DM, 2004, J NEUROSCI, V24, P6144, DOI 10.1523/JNEUROSCI.1090-04.2004
   Wilcock DM, 2006, J NEUROSCI, V26, P5340, DOI 10.1523/JNEUROSCI.0695-06.2006
   Yang ZL, 2006, SCIENCE, V314, P992, DOI 10.1126/science.1133811
   Yates JRW, 2007, NEW ENGL J MED, V357, P553, DOI 10.1056/NEJMoa072618
   Yoshida T, 2005, J CLIN INVEST, V115, P2793, DOI 10.1172/JCI24635
   Zareparsi S, 2005, HUM MOL GENET, V14, P1449, DOI 10.1093/hmg/ddi154
   Zareparsi S, 2004, INVEST OPHTH VIS SCI, V45, P1306, DOI 10.1167/iovs.03-1253
NR 75
TC 160
Z9 164
U1 0
U2 10
PU NATL ACAD SCIENCES
PI WASHINGTON
PA 2101 CONSTITUTION AVE NW, WASHINGTON, DC 20418 USA
SN 0027-8424
J9 P NATL ACAD SCI USA
JI Proc. Natl. Acad. Sci. U. S. A.
PD JUL 12
PY 2011
VL 108
IS 28
BP E279
EP E287
DI 10.1073/pnas.1100901108
PG 9
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA 791BO
UT WOS:000292635200005
PM 21690377
OA Green Published, Bronze
DA 2022-11-30
ER

PT J
AU Horani, M
   Mahmood, S
   Aslam, TM
AF Horani, Mania
   Mahmood, Sajjad
   Aslam, Tariq M.
TI A Review of Macular Atrophy of the Retinal Pigment Epithelium in
   Patients with Neovascular Age-Related Macular Degeneration: What is the
   Link? Part II
SO OPHTHALMOLOGY AND THERAPY
LA English
DT Review
DE Aflibercept; Anti-VEGF; Bevacizumab; Macular atrophy; Macular atrophy
   incidence; Macular atrophy progression; Neovascular age-related macular
   degeneration; Ranibizumab; Subfoveal choroidal thickness; Subretinal
   hyperreflective material
ID ENDOTHELIAL GROWTH-FACTOR; FUNDUS AUTOFLUORESCENCE PATTERNS; 2.0 MG
   RANIBIZUMAB; GEOGRAPHIC ATROPHY; CHOROIDAL NEOVASCULARIZATION;
   INTRAVITREAL BEVACIZUMAB; 7-YEAR OUTCOMES; EYE DISEASE; FACTOR VEGF;
   PROGRESSION
AB Introduction To explore the potential link between macular atrophy (MA) of the retinal pigment epithelium (RPE) in patients with neovascular age-related macular degeneration (nAMD) and anti-vascular endothelial growth factor (anti-VEGF) treatment. Methods Through a balanced overview of the field from a largely clinical perspective, we looked at available evidence on the topic of MA correlation with anti-VEGF therapy and examined possible risk factors for MA development in the context of nAMD treatment with anti-VEGF. Results Links have been reported to connect both MA incidence and progression to treatment frequency and to the anti-VEGF drug type. Conclusions All reports agree on the fact that de novo development of MA in anti-VEGF-treated eyes is frequent and multifactorial. Research data shows an expansion of atrophy during anti-VEGF treatment. There are mixed conclusions about the correlation of MA incidence or progression with treatment-related risk factors. It mostly appears that there is no straightforward link. More clinical research is still needed to further understand this association.
C1 [Horani, Mania] Manchester Univ Fdn NHS Trust, Manchester Royal Eye Hosp, Manchester, Lancs, England.
   [Mahmood, Sajjad; Aslam, Tariq M.] Manchester Univ Fdn NHS Trust, Manchester Royal Eye Hosp, Manchester Acad Hlth Sci Ctr, Manchester, Lancs, England.
   [Aslam, Tariq M.] Univ Manchester, Sch Hlth Sci, Fac Biol Med & Hlth, Div Pharm & Optometry, Manchester, Lancs, England.
C3 Manchester Royal Eye Hospital; Manchester Royal Eye Hospital; University
   of Manchester; University of Manchester
RP Horani, M (通讯作者)，Manchester Univ Fdn NHS Trust, Manchester Royal Eye Hosp, Manchester, Lancs, England.
EM mania.horani@mft.nhs.uk
RI Mahmood, Sajjad/AAK-7645-2021; Aslam, Tariq/A-8532-2016
OI Aslam, Tariq/0000-0002-9739-7280; Horani, Mania/0000-0003-4774-7614
CR Abdelfattah NS, 2017, OPHTHALMOLOGY, V124, P215, DOI 10.1016/j.ophtha.2016.10.002
   Abdelfattah NS, 2016, RETINA-J RET VIT DIS, V36, P1843, DOI 10.1097/IAE.0000000000001059
   Arevalo JF, 2016, RETINA-J RET VIT DIS, V36, P859, DOI 10.1097/IAE.0000000000000827
   Bailey C, 2019, OPHTHALMOLOGY, V126, P75, DOI 10.1016/j.ophtha.2018.07.013
   Bhisitkul RB, 2016, OPHTHALMOLOGY, V123, P1269, DOI 10.1016/j.ophtha.2016.01.033
   Bhisitkul RB, 2015, AM J OPHTHALMOL, V159, P915, DOI 10.1016/j.ajo.2015.01.032
   Bhutto I, 2012, MOL ASPECTS MED, V33, P295, DOI 10.1016/j.mam.2012.04.005
   Bindewald A, 2005, BRIT J OPHTHALMOL, V89, P874, DOI 10.1136/bjo.2004.057794
   Bird AC, 2014, JAMA OPHTHALMOL, V132, P338, DOI 10.1001/jamaophthalmol.2013.5799
   Brown DM, 2009, OPHTHALMOLOGY, V116, P57, DOI 10.1016/j.ophtha.2008.10.018
   Busbee BG, 2013, OPHTHALMOLOGY, V120, P1046, DOI 10.1016/j.ophtha.2012.10.014
   Chakravarthy U, 2015, HEALTH TECHNOL ASSES, V19, P1, DOI 10.3310/hta19780
   Chakravarthy U, 2013, LANCET, V382, P1258, DOI 10.1016/S0140-6736(13)61501-9
   Channa R, 2015, AM J OPHTHALMOL, V159, P9, DOI 10.1016/j.ajo.2014.09.012
   Cho HJ, 2015, AM J OPHTHALMOL, V159, P285, DOI 10.1016/j.ajo.2014.10.035
   Danis RP, 2015, CLIN OPHTHALMOL, V9, P2159, DOI 10.2147/OPTH.S92359
   Davis MD, 2005, ARCH OPHTHALMOL-CHIC, V123, P1484
   De Cilla S, 2017, CELL PHYSIOL BIOCHEM, V42, P1725, DOI 10.1159/000479441
   Dhrami-Gavazi Elona, 2015, Int J Retina Vitreous, V1, P15
   Domalpally A, 2018, OPHTHALMOL RETINA, V2, P1021, DOI 10.1016/j.oret.2018.04.009
   Fan WY, 2018, GRAEF ARCH CLIN EXP, V256, P511, DOI 10.1007/s00417-017-3888-2
   Fleckenstein M, 2010, OPHTHALMOLOGE, V107, P1007, DOI 10.1007/s00347-010-2159-y
   Fleckenstein M, 2018, OPHTHALMOLOGY, V125, P369, DOI 10.1016/j.ophtha.2017.08.038
   Gillies MC, 2015, OPHTHALMOLOGY, V122, P1837, DOI 10.1016/j.ophtha.2015.05.010
   Gobel AP, 2011, OPHTHALMOLOGICA, V226, P182, DOI 10.1159/000330420
   Grunwald JE, 2017, OPHTHALMOLOGY, V124, P97, DOI 10.1016/j.ophtha.2016.09.012
   Grunwald JE, 2015, OPHTHALMOLOGY, V122, P809, DOI 10.1016/j.ophtha.2014.11.007
   Grunwald JE, 2014, OPHTHALMOLOGY, V121, P150, DOI 10.1016/j.ophtha.2013.08.015
   Hata M, 2017, RETINA-J RET VIT DIS, V37, P2069, DOI 10.1097/IAE.0000000000001457
   Ho AC, 2014, OPHTHALMOLOGY, V121, P2181, DOI 10.1016/j.ophtha.2014.05.009
   Holz FG, 2007, AM J OPHTHALMOL, V143, P463, DOI 10.1016/j.ajo.2006.11.041
   Holz FG, 2015, INVEST OPHTH VIS SCI, V56
   Horani M, 2019, OPHTHALMOL THER, V8, P235, DOI 10.1007/s40123-019-0177-7
   Joachim N, 2013, OPHTHALMOLOGY, V120, P2042, DOI 10.1016/j.ophtha.2013.03.029
   Julien S, 2014, BRIT J OPHTHALMOL, V98, P813, DOI 10.1136/bjophthalmol-2013-304019
   Kaya F, 2017, J FR OPHTALMOL, V40, P832, DOI 10.1016/j.jfo.2017.04.014
   Kim JH, 2016, BRIT J OPHTHALMOL, V100, P1634, DOI 10.1136/bjophthalmol-2015-308074
   Klein R, 2008, AM J OPHTHALMOL, V146, P692, DOI 10.1016/j.ajo.2008.05.050
   Kuroda Y, 2018, RETINA-J RET VIT DIS, V38, P1743, DOI 10.1097/IAE.0000000000001765
   Kuroda Y, 2016, AM J OPHTHALMOL, V161, P94, DOI 10.1016/j.ajo.2015.09.032
   Lalwani GA, 2009, AM J OPHTHALMOL, V148, P43, DOI 10.1016/j.ajo.2009.01.024
   Lee JY, 2014, OPHTHALMOLOGY, V121, P2423, DOI 10.1016/j.ophtha.2014.06.013
   Li A, 2018, OPHTHALMOL RETINA, V2, P550, DOI 10.1016/j.oret.2017.10.010
   Lindblad AS, 2009, ARCH OPHTHALMOL-CHIC, V127, P1168, DOI 10.1001/archophthalmol.2009.198
   Lois N, 2013, RETINA-J RET VIT DIS, V33, P13, DOI 10.1097/IAE.0b013e3182657fff
   Maguire MG, 2016, OPHTHALMOLOGY, V123, P1751, DOI 10.1016/j.ophtha.2016.03.045
   Mantel I, 2019, RETINA-J RET VIT DIS, V39, P906, DOI 10.1097/IAE.0000000000002054
   Mantel I, 2019, BRIT J OPHTHALMOL, V103, P900, DOI 10.1136/bjophthalmol-2018-312430
   Martin DF, 2012, OPHTHALMOLOGY, V119, DOI 10.1016/j.ophtha.2012.03.053
   Mastropasqua L, 2017, RETINA-J RET VIT DIS, V37, P247, DOI 10.1097/IAE.0000000000001145
   Mazaraki K, 2015, BRIT J OPHTHALMOL, V99, P1341, DOI 10.1136/bjophthalmol-2015-306636
   McLeod DS, 2009, INVEST OPHTH VIS SCI, V50, P4982, DOI 10.1167/iovs.09-3639
   McLeod DS, 2002, INVEST OPHTH VIS SCI, V43, P1986
   Mones Jordi, 2021, Retin Cases Brief Rep, V15, P778, DOI 10.1097/ICB.0000000000000888
   Munk MR, 2016, ACTA OPHTHALMOL, V94, pE757, DOI 10.1111/aos.13157
   Nishijima K, 2007, AM J PATHOL, V171, P53, DOI 10.2353/ajpath.2007.061237
   Pfau M, 2020, OPHTHALMOL RETINA, V4, P238, DOI 10.1016/j.oret.2019.09.016
   Picton F, 2014, INVEST OPHTH VIS SCI, V55
   Rebhun CB, 2020, RETINA-J RET VIT DIS, V40, P266, DOI 10.1097/IAE.0000000000002402
   Rich RM, 2006, RETINA-J RET VIT DIS, V26, P495, DOI 10.1097/01.iae.0000225766.75009.3a
   Rofagha S, 2013, OPHTHALMOLOGY, V120, P2292, DOI 10.1016/j.ophtha.2013.03.046
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Rosenfeld PJ, 2011, OPHTHALMOLOGY, V118, P523, DOI 10.1016/j.ophtha.2010.07.011
   Sadda SR, 2018, OPHTHALMOLOGY, V125, P878, DOI 10.1016/j.ophtha.2017.12.026
   Sadda SR, 2018, OPHTHALMOLOGY, V125, P537, DOI 10.1016/j.ophtha.2017.09.028
   Saint-Geniez M, 2009, P NATL ACAD SCI USA, V106, P18751, DOI 10.1073/pnas.0905010106
   Sarks J, 2006, BRIT J OPHTHALMOL, V90, P442, DOI 10.1136/bjo.2005.083022
   SARKS JP, 1988, EYE, V2, P552, DOI 10.1038/eye.1988.106
   Sarraf D, 2016, OPHTHALMOLOGY, V123, P2213, DOI 10.1016/j.ophtha.2016.07.007
   Schaal KB, 2017, AM J OPHTHALMOL, V174, P145, DOI 10.1016/j.ajo.2016.11.002
   Schmidt-Erfurth U, 2014, OPHTHALMOLOGY, V121, P193, DOI 10.1016/j.ophtha.2013.08.011
   Schmidt-Erfurth U, 2011, OPHTHALMOLOGY, V118, P831, DOI 10.1016/j.ophtha.2010.09.004
   Schmitz-Valckenberg S, 2011, INVEST OPHTH VIS SCI, V52, P1, DOI 10.1167/iovs.10-5619
   Schutze C, 2015, AM J OPHTHALMOL, V159, P1100, DOI 10.1016/j.ajo.2015.02.020
   SHIMA DT, 1995, MOL MED, V1, P182, DOI 10.1007/BF03401566
   Singer MA, 2012, OPHTHALMOLOGY, V119, P1175, DOI 10.1016/j.ophtha.2011.12.016
   Sitnilska V, 2019, OPHTHALMOLOGICA, V241, P154, DOI 10.1159/000492924
   Spilsbury K, 2000, AM J PATHOL, V157, P135, DOI 10.1016/S0002-9440(10)64525-7
   Sunness JS, 2007, OPHTHALMOLOGY, V114, P271, DOI 10.1016/j.ophtha.2006.09.016
   Takasago Y, 2019, RETINA-J RET VIT DIS, V39, P296, DOI 10.1097/IAE.0000000000001980
   Tanaka E, 2015, OPHTHALMOLOGY, V122, P153, DOI 10.1016/j.ophtha.2014.07.046
   Thavikulwat AT, 2017, OPHTHALMOL RETINA, V1, P34, DOI 10.1016/j.oret.2016.09.005
   Toth CA, 2019, OPHTHALMOL RETINA, V3, P316, DOI 10.1016/j.oret.2018.11.011
   Wada I, 2019, GRAEF ARCH CLIN EXP, V257, P1411, DOI 10.1007/s00417-019-04361-8
   Willoughby AS, 2015, OPHTHALMOLOGY, V122, P1846, DOI 10.1016/j.ophtha.2015.05.042
   Wons J, 2017, J OPHTHALMOL, V2017, DOI 10.1155/2017/7432739
   Wu ZC, 2014, OPHTHALMOLOGY, V121, P2415, DOI 10.1016/j.ophtha.2014.06.034
   Xu LN, 2015, RETINA-J RET VIT DIS, V35, P176, DOI 10.1097/IAE.0000000000000374
   Xu LN, 2013, RETINA-J RET VIT DIS, V33, P1850, DOI 10.1097/IAE.0b013e31828991b2
   Yehoshua Z, 2015, OSLI RETINA, V46, P413, DOI 10.3928/23258160-20150422-03
   Yehoshua Z, 2011, OPHTHALMOLOGY, V118, P679, DOI 10.1016/j.ophtha.2010.08.018
   Young M, 2014, RETINA-J RET VIT DIS, V34, P1308, DOI 10.1097/IAE.0000000000000081
   Zanzottera EC, 2016, RETINA-J RET VIT DIS, V36, pS12, DOI 10.1097/IAE.0000000000001276
   Zanzottera EC, 2016, RETINA-J RET VIT DIS, V36, pS26, DOI 10.1097/IAE.0000000000001330
   Zarubina AV, 2017, INVEST OPHTH VIS SCI, V58, P6038, DOI 10.1167/iovs.17-22378
NR 97
TC 4
Z9 5
U1 0
U2 1
PU SPRINGER INTERNATIONAL PUBLISHING AG
PI CHAM
PA GEWERBESTRASSE 11, CHAM, CH-6330, SWITZERLAND
SN 2193-8245
EI 2193-6528
J9 OPHTHALMOL THER
JI OPHTHALMOL. THER.
PD MAR
PY 2020
VL 9
IS 1
BP 35
EP 75
DI 10.1007/s40123-019-00227-8
PG 41
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA KT2AP
UT WOS:000518815200004
PM 31907843
OA Green Published, gold
DA 2022-11-30
ER

PT J
AU Takanashi, M
   Sudo, K
   Ueda, S
   Ohno, SI
   Yamada, Y
   Osakabe, Y
   Goto, H
   Matsunaga, Y
   Ishikawa, A
   Usui, Y
   Kuroda, M
AF Takanashi, Masakatsu
   Sudo, Katsuko
   Ueda, Shinobu
   Ohno, Shin-Ichiro
   Yamada, Yuko
   Osakabe, Yasuhiro
   Goto, Hiroshi
   Matsunaga, Yoshimichi
   Ishikawa, Akio
   Usui, Yoshihiko
   Kuroda, Masahiko
TI Novel Types of Small RNA Exhibit Sequence-and Target-dependent
   Angiogenesis Suppression Without Activation of Toll-like Receptor 3 in
   an Age-related Macular Degeneration (AMD) Mouse Model
SO MOLECULAR THERAPY-NUCLEIC ACIDS
LA English
DT Article
DE innate immune; molecular target therapy; RNAi; TLR
ID NF-KAPPA-B; DOUBLE-STRANDED-RNA; ENDOTHELIAL GROWTH-FACTOR; DENDRITIC
   CELLS; CHOROIDAL NEOVASCULARIZATION; IMMUNODEFICIENCY-VIRUS;
   EPITHELIAL-CELLS; GENE-EXPRESSION; IFN-BETA; TLR3
AB RNA interference (RNAi) has become a powerful tool for suppressing gene expression in vitro and in vivo. A great deal of evidence has demonstrated the potential for the use of synthetic small interfering RNAs (siRNAs) as therapeutic agents. However, the application of siRNA to clinical medicine is still limited, mainly due to sequence-independent suppression of angiogenesis mediated by Toll-like receptor 3 (TLR3). Here, we describe novel types of synthetic RNA, named nkRNA and PnkRNA, that exhibit sequence-specific gene silencing through RNAi without activating TLRs or RIG-I-like receptor signaling. In addition, we confirmed the therapeutic effect for the novel types of RNA in an animal model of age-related macular degeneration (AMD) without retinal degeneration. These data indicate that nkRNA and PnkRNA are of great potential utility as therapies against blinding choroidal neovascularization due to AMD.
C1 [Takanashi, Masakatsu; Ueda, Shinobu; Ohno, Shin-Ichiro; Yamada, Yuko; Osakabe, Yasuhiro; Ishikawa, Akio; Kuroda, Masahiko] Tokyo Med Univ, Dept Mol Pathol, Tokyo 1608402, Japan.
   [Sudo, Katsuko] Tokyo Med Univ, Anim Res Ctr, Tokyo 1608402, Japan.
   [Goto, Hiroshi; Matsunaga, Yoshimichi; Usui, Yoshihiko] Tokyo Med Univ, Dept Ophthalmol, Tokyo 1608402, Japan.
C3 Tokyo Medical University; Tokyo Medical University; Tokyo Medical
   University
RP Kuroda, M (通讯作者)，Tokyo Med Univ, Dept Mol Pathol, Shinjuku Ku, 6-1-1 Shinjuku, Tokyo 1608402, Japan.
EM kuroda@tokyo-med.ac.jp
RI 慎一郎, 大野/AAI-7736-2021; /AAD-1824-2020
OI Ohno, Shin-ichiro/0000-0003-1064-4750
FU Japan Society for Promotion of Science (JSPS); Strategic Research
   Foundation Grant-aided Project for Private Universities from Ministry of
   Education, Culture, Sports, Science and Technology, Japan (MEXT)
FX This research was supported in part by Grants-in-Aid for scientific
   research (B) and Grant-in-Aid for Exploratory Research from Japan
   Society for the Promotion of Science (JSPS) and supported in part by
   Strategic Research Foundation Grant-aided Project for Private
   Universities from the Ministry of Education, Culture, Sports, Science
   and Technology, Japan (MEXT).
CR Al-Salleeh F, 2008, J IMMUNOL, V181, P4523, DOI 10.4049/jimmunol.181.7.4523
   Alexopoulou L, 2001, NATURE, V413, P732, DOI 10.1038/35099560
   Ando T, 2013, SCI REP-UK, V3, DOI 10.1038/srep02559
   Asmal M, 2011, J VIROL, V85, P5465, DOI 10.1128/JVI.00313-11
   Bell JK, 2006, P NATL ACAD SCI USA, V103, P8792, DOI 10.1073/pnas.0603245103
   Bell JK, 2006, J ENDOTOXIN RES, V12, P375, DOI 10.1179/096805106X118780
   Botos I, 2009, BBA-GENE REGUL MECH, V1789, P667, DOI 10.1016/j.bbagrm.2009.06.005
   Carter JG, 2015, ANGIOGENESIS, V18, P23, DOI 10.1007/s10456-014-9444-3
   Cross JL, 2008, J IMMUNOL, V180, P8020, DOI 10.4049/jimmunol.180.12.8020
   de Bouteiller O, 2005, J BIOL CHEM, V280, P38133, DOI 10.1074/jbc.M507163200
   Drosopoulos WC, 1998, J MOL MED-JMM, V76, P604, DOI 10.1007/s001090050257
   Duluc D, 2009, EUR J IMMUNOL, V39, P2877, DOI 10.1002/eji.200838610
   Fitzgerald KA, 2003, J EXP MED, V198, P1043, DOI 10.1084/jem.20031023
   Gautier G, 2005, J EXP MED, V201, P1435, DOI 10.1084/jem.20041964
   Hamasaki T, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0042655
   Harada K, 2007, HEPATOLOGY, V46, P1146, DOI 10.1002/hep.21797
   Hoebe K, 2004, J ENDOTOXIN RES, V10, P130, DOI 10.1179/096805104225004031
   Hsieh MY, 2014, J BIOL CHEM, V289, P9208, DOI 10.1074/jbc.M113.508663
   Ishitsuka T, 2009, BIOL PHARM BULL, V32, P1004, DOI 10.1248/bpb.32.1004
   Ito Y, 2013, OPHTHALMOLOGICA, V230, P215, DOI 10.1159/000354092
   John S, 2013, J OPHTHALMOL, V2013, DOI 10.1155/2013/465169
   Kaiser WJ, 2008, J IMMUNOL, V181, P6427, DOI 10.4049/jimmunol.181.9.6427
   Kawai T, 2008, ANN NY ACAD SCI, V1143, P1, DOI 10.1196/annals.1443.020
   Kleinman ME, 2008, NATURE, V452, P591, DOI 10.1038/nature06765
   Kubarenko A, 2007, BIOCHEM SOC T, V35, P1515, DOI 10.1042/BST0351515
   Lenert PS, 2010, MEDIAT INFLAMM, V2010, DOI 10.1155/2010/986596
   Leonard JN, 2008, P NATL ACAD SCI USA, V105, P258, DOI 10.1073/pnas.0710779105
   Leonard Joshua N., 2009, V517, P55, DOI 10.1007/978-1-59745-541-1_4
   Li QH, 2008, MOL THER, V16, P1688, DOI 10.1038/mt.2008.164
   Matsumoto M, 2011, REV MED VIROL, V21, P67, DOI 10.1002/rmv.680
   Okahira S, 2005, DNA CELL BIOL, V24, P614, DOI 10.1089/dna.2005.24.614
   Osterlund P, 2005, J VIROL, V79, P9608, DOI 10.1128/JVI.79.15.9608-9617.2005
   Pietila TE, 2007, J IMMUNOL, V178, P253, DOI 10.4049/jimmunol.178.1.253
   Qi RS, 2012, J BIOL CHEM, V287, P32617, DOI 10.1074/jbc.M112.387803
   Sarkar SN, 2007, J BIOL CHEM, V282, P3423, DOI 10.1074/jbc.C600226200
   Seya T, 2009, IMMUNOL REV, V227, P44, DOI 10.1111/j.1600-065X.2008.00723.x
   Szabo A, 2013, AM J CLIN EXP IMMUNO, V2, P195
   Waisbourd M, 2007, DRUG AGING, V24, P643, DOI 10.2165/00002512-200724080-00003
   Wei TD, 2011, J MOL MODEL, V17, P27, DOI 10.1007/s00894-010-0697-5
   Yamamoto M, 2003, SCIENCE, V301, P640, DOI 10.1126/science.1087262
   Yazama H, 2015, INT J CLIN ONCOL, V20, P438, DOI 10.1007/s10147-014-0734-y
NR 41
TC 10
Z9 10
U1 0
U2 3
PU NATURE PUBLISHING GROUP
PI NEW YORK
PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA
SN 2162-2531
J9 MOL THER-NUCL ACIDS
JI Mol. Ther.-Nucl. Acids
PD OCT 20
PY 2015
VL 4
AR e258
DI 10.1038/mtna.2015.34
PG 7
WC Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Research & Experimental Medicine
GA DC0MW
UT WOS:000368912600001
PM 26484944
OA Green Published, gold
DA 2022-11-30
ER

PT J
AU Kim, JH
   Kang, SW
   Kim, JR
   Chang, YS
AF Kim, J. H.
   Kang, S. W.
   Kim, J-R
   Chang, Y. S.
TI Influence of image compression on the interpretation of spectral-domain
   optical coherence tomography in exudative age-related macular
   degeneration
SO EYE
LA English
DT Article
ID SUBFOVEAL CHOROIDAL THICKNESS; DIABETIC-RETINOPATHY; DATA EXPLOSION;
   TIME-DOMAIN; CT; NEOVASCULARIZATION; DIAGNOSIS
AB Purpose To evaluate the effect of image compression of spectral-domain optical coherence tomography (OCT) images in the examination of eyes with exudative age-related macular degeneration (AMD).
   Methods Thirty eyes from 30 patients who were diagnosed with exudative AMD were included in this retrospective observational case series. The horizontal OCT scans centered at the center of the fovea were conducted using spectral-domain OCT. The images were exported to Tag Image File Format (TIFF) and 100, 75, 50, 25 and 10% quality of Joint Photographic Experts Group (JPEG) format. OCT images were taken before and after intravitreal ranibizumab injections, and after relapse. The prevalence of subretinal and intraretinal fluids was determined. Differences in choroidal thickness between the TIFF and JPEG images were compared with the intra-observer variability.
   Results The prevalence of subretinal and intraretinal fluids was comparable regardless of the degree of compression. However, the chorio-scleral interface was not clearly identified in many images with a high degree of compression. In images with 25 and 10% quality of JPEG, the difference in choroidal thickness between the TIFF images and the respective JPEG images was significantly greater than the intra-observer variability of the TIFF images (P = 0.029 and P = 0.024, respectively).
   Conclusions In OCT images of eyes with AMD, 50% of the quality of the JPEG format would be an optimal degree of compression for efficient data storage and transfer without sacrificing image quality.
C1 [Kim, J. H.; Chang, Y. S.] Konyang Univ, Kims Eye Hosp, Coll Med, Dept Ophthalmol, Seoul, South Korea.
   [Kang, S. W.; Kim, J-R] Sungkyunkwan Univ, Sch Med, Samsung Med Ctr, Dept Ophthalmol, Seoul 135710, South Korea.
   [Chang, Y. S.] Konyang Univ, Coll Med, Dept Ophthalmol, Taejon, South Korea.
C3 Konyang University; Konyang University Hospital; Sungkyunkwan University
   (SKKU); Samsung Medical Center; Konyang University; Konyang University
   Hospital
RP Kang, SW (通讯作者)，Sungkyunkwan Univ, Sch Med, Samsung Med Ctr, Dept Ophthalmol, 50 Irwon Dong, Seoul 135710, South Korea.
EM swkang@skku.edu
FU Kim's Eye Hospital Research Center
FX This study is supported by Kim's Eye Hospital Research Center.
CR Ahn SJ, 2013, INVEST OPHTH VIS SCI, V54, P2115, DOI 10.1167/iovs.12-11542
   Alam S, 2006, OPHTHALMOLOGY, V113, P1425, DOI 10.1016/j.ophtha.2006.03.020
   Baker CF, 2004, CAN J OPHTHALMOL, V39, P746, DOI 10.1016/S0008-4182(04)80068-1
   Basu A, 2003, DIABETIC MED, V20, P766, DOI 10.1046/j.1464-5491.2003.01022.x
   Chung SE, 2011, OPHTHALMOLOGY, V118, P840, DOI 10.1016/j.ophtha.2010.09.012
   Conrath J, 2007, EYE, V21, P487, DOI 10.1038/sj.eye.6702238
   Cukras C, 2010, EYE, V24, P775, DOI 10.1038/eye.2009.211
   Flint AC, 2012, BMC MED IMAGING, V12, DOI 10.1186/1471-2342-12-24
   Khurana RN, 2010, OPHTHALMOLOGY, V117, P1376, DOI 10.1016/j.ophtha.2009.11.039
   Kim JH, 2013, GRAEF ARCH CLIN EXP, V251, P1091, DOI 10.1007/s00417-012-2147-9
   Koizumi H, 2011, GRAEF ARCH CLIN EXP, V249, P1123, DOI 10.1007/s00417-011-1620-1
   Lee KH, 2005, J DIGIT IMAGING, V18, P188, DOI 10.1007/s10278-005-5163-z
   Manivannan A, 2005, AM J OPHTHALMOL, V140, P525, DOI 10.1016/j.ajo.2005.02.055
   Nassif N, 2004, OPT LETT, V29, P480, DOI 10.1364/OL.29.000480
   Querques G, 2011, OPHTHALMIC RES, V46, P152, DOI 10.1159/000325027
   Rubin GD, 2000, EUR J RADIOL, V36, P74, DOI 10.1016/S0720-048X(00)00270-9
   Rudnisky CJ, 2007, OPHTHALMOLOGY, V114, P1748, DOI 10.1016/j.ophtha.2006.12.010
   Sayanagi K, 2009, OPHTHALMOLOGY, V116, P947, DOI 10.1016/j.ophtha.2008.11.002
   Spaide RF, 2008, AM J OPHTHALMOL, V146, P496, DOI 10.1016/j.ajo.2008.05.032
   Tappeiner C, 2008, INVEST OPHTH VIS SCI, V49, P1609, DOI 10.1167/iovs.07-1264
   Woo HS, 2007, AM J ROENTGENOL, V189, P535, DOI 10.2214/AJR.07.2304
NR 21
TC 2
Z9 2
U1 1
U2 8
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 0950-222X
EI 1476-5454
J9 EYE
JI Eye
PD JUL
PY 2014
VL 28
IS 7
BP 825
EP 831
DI 10.1038/eye.2014.102
PG 7
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA AL5LT
UT WOS:000339175900009
PM 24788012
OA Green Published, Bronze
DA 2022-11-30
ER

PT J
AU Almuhtaseb, H
   Kanavati, S
   Rufai, SR
   Lotery, AJ
AF Almuhtaseb, H.
   Kanavati, S.
   Rufai, S. R.
   Lotery, A. J.
TI One-year real-world outcomes in patients receiving fixed-dosing
   aflibercept for neovascular age related macular degeneration
SO EYE
LA English
DT Article
AB Purpose To investigate 1-year visual and anatomic outcomes of intravitreal aflibercept for neovascular age-related macular degeneration (nAMD) given at a fixed 8-weekly interval.
   Methods Retrospective, single-practice data analysis from an electronic medical record system of 255 eyes (223 patients) with treatment-naive nAMD receiving 8-weekly aflibercept.
   Results Mean logarithm of the minimum angle of resolution best- corrected visual acuity (BCVA) improved from 0.66 at baseline to 0.50 at month 11 (P<0.0001). Mean central retinal thickness (CRT) decreased from 311 mu m at baseline to 211 mu m at month 11 (P<0.0001). Our mean VA gain of eight ETDRS letters was comparable to the VIEW 1 and VIEW 2 Trials' results at the end of year 1. After loading at month 5, mean BCVA was 0.48 (P<0.0001), and mean CRT was 235 mu m. At month 5, 143 eyes (56%) were inactive defined by the absence of macular haemorrhage and intraretinal fluid (IRF) and subretinal fluid (SRF) on optical coherence tomography, and 112 eyes (44%) remained active. At month 11, 136 eyes (53%) were inactive, and 119 eyes (47%) remained active. At month 11, 77% of inactive eyes after loading remained inactive, and 77% of the active eyes after loading remained active. At month 11, mean BCVA of the inactive group was 0.51, and mean BCVA of the active group was 0.48 (P= 0.54).
   Conclusions Aflibercept administered by fixed dosing over 1 year improved VA and macular morphology in treatment- naive eyes. Active lesions at month 11 do not have worse VA outcomes compared with inactive lesions. The macular status after loading is a reliable indicator of disease activity at the end of year 1.
C1 [Almuhtaseb, H.; Kanavati, S.; Rufai, S. R.; Lotery, A. J.] Univ Hosp Southampton NHS Fdn Trust, Eye Unit, Southampton, Hants, England.
   [Almuhtaseb, H.; Rufai, S. R.; Lotery, A. J.] Univ Southampton, Clin & Expt Sci, Southampton SO16 6YD, Hants, England.
C3 University of Southampton; University Hospital Southampton NHS
   Foundation Trust; University of Southampton
RP Lotery, AJ (通讯作者)，Univ Southampton, Clin & Expt Sci, Southampton SO16 6YD, Hants, England.
EM a.j.lotery@soton.ac.uk
RI Rufai, Sohaib/ABA-4740-2020
OI Rufai, Sohaib/0000-0001-8134-6393; Kanavati, Sam/0000-0001-8973-7786
FU National Institute for Health Research [ACF-2016-11-001,
   NF-SI-0515-10020] Funding Source: researchfish
CR Brown DM, 2009, OPHTHALMOLOGY, V116, P57, DOI 10.1016/j.ophtha.2008.10.018
   Heier JS, 2012, OPHTHALMOLOGY, V119, P2537, DOI 10.1016/j.ophtha.2012.09.006
   Lalwani GA, 2009, AM J OPHTHALMOL, V148, P43, DOI 10.1016/j.ajo.2009.01.024
   Owen CG, 2012, BRIT J OPHTHALMOL, V96, P752, DOI 10.1136/bjophthalmol-2011-301109
   Rudge JS, 2008, ANGIOGENESIS, P415
   Schmidt-Erfurth U, 2014, OPHTHALMOLOGY, V121, P193, DOI 10.1016/j.ophtha.2013.08.011
   Talks JS, 2016, OPHTHALMOLOGY, V123, P337, DOI 10.1016/j.ophtha.2015.09.039
   Tufail A, 2014, OPHTHALMOLOGY, V121, P1092, DOI 10.1016/j.ophtha.2013.11.031
   Wykoff CC, 2015, OPHTHALMOLOGY, V122, P2514, DOI 10.1016/j.ophtha.2015.08.009
NR 9
TC 22
Z9 24
U1 0
U2 2
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 0950-222X
EI 1476-5454
J9 EYE
JI Eye
PD JUN
PY 2017
VL 31
IS 6
BP 878
EP 883
DI 10.1038/eye.2017.6
PG 6
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA EX2ON
UT WOS:000403066000008
PM 28186507
OA Green Published, Green Accepted, Bronze
DA 2022-11-30
ER

PT J
AU Garweg, JG
   Niderprim, SA
   Russ, HM
   Pfister, IB
AF Garweg, Justus G.
   Niderprim, Sophie A.
   Russ, Hanna Maria
   Pfister, Isabel B.
TI Comparison of Strategies of Treatment with Ranibizumab in
   Newly-Diagnosed Cases of Neovascular Age-Related Macular Degeneration
SO JOURNAL OF OCULAR PHARMACOLOGY AND THERAPEUTICS
LA English
DT Article
DE wet age-related macular degeneration; intravitreal injections;
   Ranibizumab; pro-re-nata; PRN; treat-and-extend
ID GROWTH-FACTOR THERAPY; TREATMENT REGIMEN; PROSPECTIVE TRIAL; EXTEND
   REGIMEN; OUTCOMES; ATROPHY; ANCHOR; MARINA; WET
AB Purpose: In several case-studies improved outcomes have been reported after switching from a pro-re-nata (PRN)- to a treat-and-extend (T&E)-based therapeutic approach in cases of neovascular age-related macular degeneration (nAMD). We therefore wished to compare the effects of instigating 2 different protocols in newly-diagnosed nAMD undergoing treatment with Ranibizumab. Methods: The outcomes of a PRN- and a T&E-based regime were retrospectively compared in treatment-naive eyes under therapy with Ranibizumab for minimally 12 months in a routine clinical setting. The primary outcome measures included the proportion of the eyes with intraretinal fluid in OCT and visual stability after the initial drug-loading phase. Results: The comparative case-series included 107 eyes (PRN: 68; T&E: 39). During the 2-year follow-up period, a similar number of clinical examinations were performed in the 2 groups (PRN: 14.06.2; T&E 13.4 +/- 4.4; P=0.97), whereas the number of injections that were administered differed for the first (PRN: 5.5 +/- 2.0 vs. T&E 6.8 +/- 2.4; P=0.008) and the second year (PRN: 1.9 +/- 2.0 vs. T&E 3.8 +/- 2.3; P=0.002). The proportion of eyes with intraretinal fluid after the initial drug-loading phase remained stable (PRN: from 33.8% to 36.4%; T&E: from 25.6% to 29.0%); so, too, did the central retinal thickness and the visual acuity. Conclusion: Despite a limited sample size, this retrospective analysis revealed the anatomical and the functional improvements during the 2-year follow-up period to be not roughly different for the 2 strategies. However, when the PRN-approach is instigated, the risk of under-treatment due to lapses in visits or to over-extensions in the intervals between treatments may be underestimated.
C1 [Garweg, Justus G.; Niderprim, Sophie A.; Pfister, Isabel B.] Swiss Eye Inst, Rotkreuz, Switzerland.
   [Garweg, Justus G.; Niderprim, Sophie A.; Pfister, Isabel B.] Lindenhofspital, Berner Augenklin, Bremgartenstr 119, CH-3012 Bern, Switzerland.
   [Garweg, Justus G.; Niderprim, Sophie A.; Russ, Hanna Maria; Pfister, Isabel B.] Univ Bern, Bern, Switzerland.
   [Russ, Hanna Maria] Univ Hosp Lubeck, Clin Radiol & Nucl Med, Lubeck, Germany.
   [Russ, Hanna Maria] Dept Intervent Radiol, Lubeck, Germany.
C3 University of Bern; University of Lubeck
RP Garweg, JG (通讯作者)，Lindenhofspital, Berner Augenklin, Bremgartenstr 119, CH-3012 Bern, Switzerland.
EM justus.garweg@swiss-eye-institute.com
CR Abedi F, 2014, RETINA-J RET VIT DIS, V34, P1531, DOI 10.1097/IAE.0000000000000134
   Bhisitkul RB, 2015, AM J OPHTHALMOL, V159, P915, DOI 10.1016/j.ajo.2015.01.032
   Boyer DS, 2009, OPHTHALMOLOGY, V116, P1731, DOI 10.1016/j.ophtha.2009.05.024
   Brown DM, 2013, RETINA-J RET VIT DIS, V33, P23, DOI 10.1097/IAE.0b013e318263cedf
   Chakravarthy U, 2013, LANCET, V382, P1258, DOI 10.1016/S0140-6736(13)61501-9
   Chin-Yee D, 2016, BRIT J OPHTHALMOL, V100, P914, DOI 10.1136/bjophthalmol-2015-306987
   Garweg JG, 2016, OPHTHALMOLOGE, V113, P1036, DOI 10.1007/s00347-016-0306-9
   Gregori NZ, 2010, RETINA-J RET VIT DIS, V30, P1046, DOI 10.1097/IAE.0b013e3181d87e04
   Gupta OP, 2010, OPHTHALMOLOGY, V117, P2134, DOI 10.1016/j.ophtha.2010.02.032
   Haller JA, 2013, OPHTHALMOLOGY, V120, pS3, DOI 10.1016/j.ophtha.2013.01.057
   Hatz K, 2016, BRIT J OPHTHALMOL, V100, P1341, DOI 10.1136/bjophthalmol-2015-307299
   Holz FG, 2015, BRIT J OPHTHALMOL, V99, P220, DOI 10.1136/bjophthalmol-2014-305327
   Holz FG, 2011, OPHTHALMOLOGY, V118, P663, DOI 10.1016/j.ophtha.2010.12.019
   Holz FG, 2010, INVEST OPHTH VIS SCI, V51, P405, DOI 10.1167/iovs.09-3813
   Martin DF, 2011, NEW ENGL J MED, V364, P1897, DOI 10.1056/NEJMoa1102673
   Mitchell P, 2010, BRIT J OPHTHALMOL, V94, P2, DOI 10.1136/bjo.2009.159160
   Oubraham H, 2011, RETINA-J RET VIT DIS, V31, P26, DOI 10.1097/IAE.0b013e3181de5609
   Rofagha S, 2013, OPHTHALMOLOGY, V120, P2292, DOI 10.1016/j.ophtha.2013.03.046
   Schachat AP, 2013, AM J OPHTHALMOL, V156, P1, DOI 10.1016/j.ajo.2013.04.009
   Spaide R, 2007, AM J OPHTHALMOL, V143, P679, DOI 10.1016/j.ajo.2007.02.024
   Toalster N, 2013, RETINA-J RET VIT DIS, V33, P1351, DOI 10.1097/IAE.0b013e3182831265
   Wykoff CC, 2015, OPHTHALMOLOGY, V122, P2514, DOI 10.1016/j.ophtha.2015.08.009
NR 22
TC 9
Z9 9
U1 0
U2 3
PU MARY ANN LIEBERT, INC
PI NEW ROCHELLE
PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA
SN 1080-7683
EI 1557-7732
J9 J OCUL PHARMACOL TH
JI J. Ocular Pharmacol. Ther.
PD DEC
PY 2017
VL 33
IS 10
BP 773
EP 778
DI 10.1089/jop.2017.0006
PG 6
WC Ophthalmology; Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology; Pharmacology & Pharmacy
GA FQ0OH
UT WOS:000418056100008
PM 28953427
DA 2022-11-30
ER

PT J
AU Bonastre, J
   Le Pen, C
   Soubrane, G
   Quentel, G
AF Bonastre, J
   Le Pen, C
   Soubrane, G
   Quentel, G
TI The burden of age-related macular degeneration - Results of a cohort
   study in two french referral centres
SO PHARMACOECONOMICS
LA English
DT Article
ID SUBFOVEAL CHOROIDAL NEOVASCULARIZATION; COST-EFFECTIVENESS; VISUAL
   IMPAIRMENT; RISK-FACTORS; EYE DISEASE; PREVALENCE; MACULOPATHY;
   POPULATION; OLDER; THERAPY
AB Objective: To describe the economic impact of age-related macular degeneration (AMD) and to assess its medical and non-medical costs.
   Design and settings: An observational study was carried out in 105 patients in two French centres in a sample of 105 French patients. All consecutive patients, consulting during a 3-week period, were included provided they were 60 years of age or older and they presented an exudative form of AMD with a distant visual acuity in the best eye less than or equal to 20/40. Data collected included clinical items, treatment modalities, medical follow-up, transport costs, impact of AMD on living conditions and welfare payments related to visual impairment. Costs were presented in 2000 values.
   Perspective: General payer perspective (Social Security, private health insurance and patient).
   Results: Mean age was 79.3 years and ranged from 62.8-95 years. Average length of disease evolution was 3.5 years. During a 3-month period, patients had a mean of 2.6 visits to the ophthalmologist. Thirty percent of the patients used vascular medications and 72.4% had been previously treated by laser photocoagulation. Only 10% had benefited from visual rehabilitation. Annual AMD cost per patient was 3660.29 euros (EUR) [95% CI: 2881.92-4438.62]. Half of these annual costs were medical costs. Other major cost components were home help costs EUR904.91 (95% Cl: 478.88-1330.94] and transport costs for care EUR542.73 [95% CI: 146.31-939.14]. Non-medical costs were significantly higher for patients with more severe disease.
   Conclusions: The economic argument that costs are higher in patients with the lowest visual acuity emphasises the necessity of early detection and treatment of patients with AMD.
C1 CLP Sante, F-75016 Paris, France.
   Univ Paris 09, Paris, France.
   Univ Paris 12, Dept Ophthalmol, Ctr Hosp Intercommunal Creteil, Creteil, France.
   Ctr Ophtalmol Imagerie & Laser, Paris, France.
C3 UDICE-French Research Universities; PSL Research University Paris;
   Universite Paris-Dauphine; Universite Paris-Est-Creteil-Val-de-Marne
   (UPEC); CHI Creteil
RP Le Pen, C (通讯作者)，CLP Sante, 9-11 Rue Mont Aigoual, F-75016 Paris, France.
OI bonastre, julia/0000-0001-9884-0072
CR ALIGNON A, 2000, 1345 CREDES
   Allikmets R, 1999, EUR J OPHTHALMOL, V9, P255, DOI 10.1177/112067219900900401
   ARNOLD JJ, 1999, CLIN EVID, V2, P247
   BRESSLER NM, 1988, SURV OPHTHALMOL, V32, P375, DOI 10.1016/0039-6257(88)90052-5
   Bressler NM, 1999, ARCH OPHTHALMOL-CHIC, V117, P1329
   BRESSLER SB, 1982, AM J OPHTHALMOL, V93, P157, DOI 10.1016/0002-9394(82)90410-X
   Brown GC, 2000, OPHTHALMOLOGY, V107, P1374, DOI 10.1016/S0161-6420(00)00169-X
   Chaine G, 1998, BRIT J OPHTHALMOL, V82, P996, DOI 10.1136/bjo.82.9.996
   Ciulla TA, 1998, SURV OPHTHALMOL, V43, P134, DOI 10.1016/S0039-6257(98)00014-9
   COHEN SY, 1999, VIEILLISSEMENT OEIL, P319
   COSCAS G, 1999, DEGENERESCENCES MASC
   Delcourt C, 1999, ARCH OPHTHALMOL-CHIC, V117, P1384, DOI 10.1001/archopht.117.10.1384
   Delcourt C, 1998, ARCH OPHTHALMOL-CHIC, V116, P1031, DOI 10.1001/archopht.116.8.1031
   DICKINSON AJ, 1997, EYE 3, V11, P315
   Evans J, 1996, BRIT J OPHTHALMOL, V80, P9, DOI 10.1136/bjo.80.1.9
   Fine SL, 2000, NEW ENGL J MED, V342, P483, DOI 10.1056/NEJM200002173420707
   GIBSON JM, 1985, T OPHTHAL SOC UK, V104, P196
   Hirvela H, 1996, OPHTHALMOLOGY, V103, P871, DOI 10.1016/S0161-6420(96)30593-9
   Husain D, 1997, SEMIN OPHTHALMOL, V12, P14
   Jonasson F, 1987, Acta Ophthalmol Suppl, V182, P44
   KAHN HA, 1977, AM J EPIDEMIOL, V106, P17, DOI 10.1093/oxfordjournals.aje.a112428
   KLEIN BE, 1982, ARCH OPHTHALMOL-CHIC, V100, P571
   Klein R, 1998, ARCH OPHTHALMOL-CHIC, V116, P506, DOI 10.1001/archopht.116.4.506
   KLEIN R, 1992, OPHTHALMOLOGY, V99, P933
   LePen C, 1999, PHARMACOECONOMICS, V16, P59, DOI 10.2165/00019053-199916010-00006
   MAGUIRE MG, 1994, ARCH OPHTHALMOL-CHIC, V112, P480
   MARTINEZ GS, 1982, AM J OPHTHALMOL, V94, P181, DOI 10.1016/0002-9394(82)90073-3
   MITCHELL P, 1995, OPHTHALMOLOGY, V102, P1450
   *PROGR MED SYST IN, FRENCH MIN HLTH DAT
   Reidy A, 1998, BRIT MED J, V316, P1643, DOI 10.1136/bmj.316.7145.1643
   Scott LJ, 2000, DRUG AGING, V16, P139, DOI 10.2165/00002512-200016020-00005
   Sharma S, 2001, OPHTHALMOLOGY, V108, P2051, DOI 10.1016/S0161-6420(01)00764-3
   Soubrane G, 1997, DEV OPHTHALMOL, V29, P78
   SOUBRANE G, 1995, AFFECTIONES ACQUISES
   STERNBERG P, 1991, ARCH OPHTHALMOL-CHIC, V109, P1220
   *UN CAISS NAT SEC, 2001, TAR INT PREST SAN
   *UN CAISS NAT SEC, 2000, NOM GEN ACT PROF NOM
   VanNewkirk MR, 2000, OPHTHALMOLOGY, V107, P1593, DOI 10.1016/S0161-6420(00)00175-5
   VINDING T, 1989, ACTA OPHTHALMOL, V67, P609
   Vingerling JR, 1995, EPIDEMIOL REV, V17, P347, DOI 10.1093/oxfordjournals.epirev.a036198
   VINGERLING JR, 1995, OPHTHALMOLOGY, V102, P205
   WU LZ, 1987, JPN J OPHTHALMOL, V31, P349
   VIDAL 2000
NR 43
TC 41
Z9 41
U1 0
U2 4
PU ADIS INTERNATIONAL LTD
PI AUCKLAND
PA 41 CENTORIAN DR, PRIVATE BAG 65901, MAIRANGI BAY, AUCKLAND 10, NEW
   ZEALAND
SN 1170-7690
J9 PHARMACOECONOMICS
JI Pharmacoeconomics
PY 2003
VL 21
IS 3
BP 181
EP 190
DI 10.2165/00019053-200321030-00003
PG 10
WC Economics; Health Care Sciences & Services; Health Policy & Services;
   Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Business & Economics; Health Care Sciences & Services; Pharmacology &
   Pharmacy
GA 651MB
UT WOS:000181322800003
PM 12558468
DA 2022-11-30
ER

PT J
AU Pfau, M
   von der Emde, L
   de Sisternes, L
   Hallak, JA
   Leng, T
   Schmitz-Valckenberg, S
   Holz, FG
   Fleckenstein, M
   Rubin, DL
AF Pfau, Maximilian
   von der Emde, Leon
   de Sisternes, Luis
   Hallak, Joelle A.
   Leng, Theodore
   Schmitz-Valckenberg, Steffen
   Holz, Frank G.
   Fleckenstein, Monika
   Rubin, Daniel L.
TI Progression of Photoreceptor Degeneration in Geographic Atrophy
   Secondary to Age-related Macular Degeneration
SO JAMA OPHTHALMOLOGY
LA English
DT Article
ID SUBRETINAL DRUSENOID DEPOSITS; AUTOFLUORESCENCE; SENSITIVITY;
   IMPAIRMENT; THICKNESS; AREAS
AB IMPORTANCE Sensitive outcome measures for disease progression are needed for treatment trials in geographic atrophy (GA) secondary to age-related macular degeneration (AMD).
   OBJECTIVE To quantify photoreceptor degeneration outside regions of GA in eyes with nonexudative AMD, to evaluate its association with future GA progression, and to characterize its spatio-temporal progression.
   DESIGN, SETTING, AND PARTICIPANTS Monocenter cohort study (Directional Spread in Geographic Atrophy [NCT02051998]) and analysis of data from a normative data study at a tertiary referral center. One hundred fifty-eight eyes of 89 patients with a mean (SD) age of 77.7 (7.1) years, median area of GA of 8.87 mm(2) (IQR, 4.09-15.60), and median follow-up of 1.1 years (IQR, 0.52-1.7 years), as well as 93 normal eyes from 93 participants.
   EXPOSURES Longitudinal spectral-domain optical coherence tomography (SD-OCT) volume scans (121 B-scans across 30 degrees x25 degrees) were segmented with a deep-learning pipeline and standardized in a pointwise manner with age-adjusted normal data (z scores). Outer nuclear layer (ONL), photoreceptor inner segment (IS), and outer segment (OS) thickness were quantified along evenly spaced contour lines surrounding GA lesions. Linear mixed models were applied to assess the association between photoreceptor-related imaging features and GA progression rates and characterize the pattern of photoreceptor degeneration over time.
   MAIN OUTCOMES AND MEASURES Association of ONL thinning with follow-up time (after adjusting for age, retinal topography [z score], and distance to the GA boundary).
   RESULTS The study included 158 eyes of 89 patients (51 women and 38 men) with a mean (SD) age of 77.7 (7.1) years. The fully automated B-scan segmentation was accurate (dice coefficient, 0.82; 95% CI, 0.80-0.85; compared with manual markings) and revealed a marked interpatient variability in photoreceptor degeneration. The ellipsoid zone (EZ) loss-to-GA boundary distance and OS thickness were prognostic for future progression rates. Outer nuclear layer and IS thinning over time was significant even when adjusting for age and proximity to the GA boundary (estimates of -0.16 mu m/y; 95% CI, -0.30 to -0.02; and -0.17 mu m/y; 95% CI, -0.26 to -0.09).
   CONCLUSIONS AND RELEVANCE Distinct and progressive alterations of photoreceptor laminae (exceeding GA spatially) were detectable and quantifiable. The degree of photoreceptor degeneration outside of regions of retinal pigment epithelium atrophy varied markedly between eyes and was associated with future GA progression. Macula-wide photoreceptor laminae thinning represents a potential candidate end point to monitor treatment effects beyond mere GA lesion size progression.
C1 [Pfau, Maximilian; Rubin, Daniel L.] Stanford Univ, Dept Biomed Data Sci, Stanford, CA 94305 USA.
   [Pfau, Maximilian; von der Emde, Leon; Schmitz-Valckenberg, Steffen; Holz, Frank G.; Fleckenstein, Monika] Univ Bonn, Dept Ophthalmol, Bonn, Germany.
   [de Sisternes, Luis] Carl Zeiss Meditec Inc, Res & Dev, Dublin, CA USA.
   [Hallak, Joelle A.] Univ Illinois, Dept Ophthalmol & Visual Sci, Chicago, IL USA.
   [Leng, Theodore] Stanford Univ, Sch Med, Byers Eye Inst Stanford, Palo Alto, CA 94304 USA.
   [Schmitz-Valckenberg, Steffen; Fleckenstein, Monika] Univ Utah, John A Moran Eye Ctr, Salt Lake City, UT USA.
C3 Stanford University; University of Bonn; Carl Zeiss AG; University of
   Illinois System; University of Illinois Chicago; University of Illinois
   Chicago Hospital; Stanford University; Utah System of Higher Education;
   University of Utah
RP Rubin, DL (通讯作者)，Stanford Univ, Med Sch Off Bldg MSOB,1265Welch Rd,Room X-335,MC, Stanford, CA 94305 USA.
EM dlrubin@stanford.edu
FU German Research Foundation [PF950/1-1, FL 658/4-1, FL 658/4-2];
   Association of Rhine-Westphalian Ophthalmologists, Recklinghausen
FX This work was supported by the German Research Foundation grant
   PF950/1-1 to MP and grant FL 658/4-1 and FL 658/4-2 to Dr Fleckenstein,
   and by the Association of Rhine-Westphalian Ophthalmologists,
   Recklinghausen.
CR Bakri SJ, 2019, OPHTHALMOLOGY, V126, P55, DOI 10.1016/j.ophtha.2018.07.028
   Chakravarthy U, 2018, OPHTHALMOLOGY, V125, P842, DOI 10.1016/j.ophtha.2017.11.036
   Chen L, 2020, RETINA-J RET VIT DIS, V40, P618, DOI 10.1097/IAE.0000000000002657
   Cheung LK, 2013, PHARMACOTHERAPY, V33, P838, DOI 10.1002/phar.1264
   Curcio Christine A, 2018, Invest Ophthalmol Vis Sci, V59, pAMD160, DOI 10.1167/iovs.18-24882
   Dolz-Marco R, 2018, AM J OPHTHALMOL, V193, P166, DOI 10.1016/j.ajo.2018.06.020
   Domalpally A, 2019, OPHTHALMOLOGY, V126, P1659, DOI 10.1016/j.ophtha.2019.07.022
   Domalpally A, 2013, OPHTHALMOLOGY, V120, P2666, DOI 10.1016/j.ophtha.2013.07.047
   Fang LY, 2017, BIOMED OPT EXPRESS, V8, P2732, DOI 10.1364/BOE.8.002732
   Fleckenstein M, 2016, INVEST OPHTH VIS SCI, V57, P2463, DOI 10.1167/iovs.15-18593
   Gin TJ, 2017, INVEST OPHTH VIS SCI, V58, P2079, DOI 10.1167/iovs.16-20105
   Groll A, 2014, STAT COMPUT, V24, P137, DOI 10.1007/s11222-012-9359-z
   Holz FG, 2007, AM J OPHTHALMOL, V143, P463, DOI 10.1016/j.ajo.2006.11.041
   Holz FG, 2018, JAMA OPHTHALMOL, V136, P666, DOI 10.1001/jamaophthalmol.2018.1544
   Holz FG, 2014, J CLIN INVEST, V124, P1430, DOI 10.1172/JCI71029
   Kunzel SH, 2020, INVEST OPHTH VIS SCI, V61, DOI 10.1167/iovs.61.5.63
   Li ML, 2018, RETINA-J RET VIT DIS, V38, P1937, DOI 10.1097/IAE.0000000000002182
   Lindner M, 2018, INVEST OPHTH VIS SCI, V59, DOI 10.1167/iovs.17-23203
   Lindner M, 2017, INVEST OPHTH VIS SCI, V58, pBIO61, DOI 10.1167/iovs.16-21210
   Lindner M, 2015, OPHTHALMOLOGY, V122, P1356, DOI 10.1016/j.ophtha.2015.03.027
   Lu CD, 2017, INVEST OPHTH VIS SCI, V58, P4632, DOI 10.1167/iovs.17-22171
   Maloca PM, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0220063
   Moult EM, 2020, AM J OPHTHALMOL, V214, P172, DOI 10.1016/j.ajo.2019.12.006
   Muller PL, 2018, INVEST OPHTH VIS SCI, V59, pAMD122, DOI 10.1167/iovs.18-23819
   Nassisi M, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0212563
   Neely D, 2017, RETINA-J RET VIT DIS, V37, P1329, DOI 10.1097/IAE.0000000000001454
   Niu SJ, 2016, OPHTHALMOLOGY, V123, P1737, DOI 10.1016/j.ophtha.2016.04.042
   Niu SJ, 2014, COMPUT BIOL MED, V54, P116, DOI 10.1016/j.compbiomed.2014.08.028
   Nunes RP, 2013, OSLI RETINA, V44, P344, DOI 10.3928/23258160-20130715-06
   Owsley C, 2007, OPHTHALMOLOGY, V114, P1728, DOI 10.1016/j.ophtha.2006.12.023
   Pfau M, 2020, AM J OPHTHALMOL, V217, P162, DOI 10.1016/j.ajo.2020.04.003
   Pfau M, 2020, OPHTHALMOL RETINA, V4, P238, DOI 10.1016/j.oret.2019.09.016
   Pfau M, 2019, INVEST OPHTH VIS SCI, V60, P3992, DOI 10.1167/iovs.19-27178
   Pfau M, 2020, RETINA-J RET VIT DIS, V40, P169, DOI 10.1097/IAE.0000000000002337
   Pfau M, 2018, EYE, V32, P1819, DOI 10.1038/s41433-018-0183-3
   Pfau M, 2019, RETINA-J RET VIT DIS, V39, P1527, DOI 10.1097/IAE.0000000000002206
   Pfau M, 2017, INVEST OPHTH VIS SCI, V58, pBIO121, DOI 10.1167/iovs.17-21764
   Rasmussen A, 2013, OPHTHALMOLOGY, V120, P2630, DOI 10.1016/j.ophtha.2013.05.018
   Sadda SR, 2018, OPHTHALMOLOGY, V125, P537, DOI 10.1016/j.ophtha.2017.09.028
   Schmitz-Valckenberg S, 2011, INVEST OPHTH VIS SCI, V52, P7640, DOI 10.1167/iovs.11-7457
   Sivaprasad S, 2018, AM J OPHTHALMOL, V190, P1, DOI 10.1016/j.ajo.2018.03.006
   Spaide RF, 2018, SURV OPHTHALMOL, V63, P782, DOI 10.1016/j.survophthal.2018.05.005
   Spaide RF, 2013, RETINA-J RET VIT DIS, V33, P1800, DOI 10.1097/IAE.0b013e31829c3765
   Steinberg JS, 2016, AM J OPHTHALMOL, V168, P52, DOI 10.1016/j.ajo.2016.04.025
   Takahashi A, 2016, AM J OPHTHALMOL, V168, P260, DOI 10.1016/j.ajo.2016.06.006
   Thulliez M, 2019, OPHTHALMOL RETINA, V3, P478, DOI 10.1016/j.oret.2019.01.024
   Toth CA, 2019, OPHTHALMOL RETINA, V3, P316, DOI 10.1016/j.oret.2018.11.011
   von der Emde L, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-47565-y
   Zadeh SG, 2017, LECT NOTES COMPUT SC, V10553, P65, DOI 10.1007/978-3-319-67558-9_8
   Zanzottera EC, 2016, RETINA-J RET VIT DIS, V36, pS26, DOI 10.1097/IAE.0000000000001330
   Zhang YH, 2020, OPHTHALMOL RETINA, V4, P274, DOI 10.1016/j.oret.2019.10.012
NR 51
TC 20
Z9 20
U1 0
U2 4
PU AMER MEDICAL ASSOC
PI CHICAGO
PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA
SN 2168-6165
EI 2168-6173
J9 JAMA OPHTHALMOL
JI JAMA Ophthalmol.
PD OCT
PY 2020
VL 138
IS 10
BP 1026
EP 1034
DI 10.1001/jamaophthalmol.2020.2914
PG 9
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA PO1YX
UT WOS:000604967700008
PM 32789526
OA Bronze, Green Published
DA 2022-11-30
ER

PT J
AU Delcourt, C
   Carriere, I
   Cristol, JP
   Lacroux, A
   Gerber, M
AF Delcourt, C.
   Carriere, I.
   Cristol, J-P
   Lacroux, A.
   Gerber, M.
CA POLANUT Study Grp
TI Dietary fat and the risk of age-related maculopathy: the POLANUT Study
SO EUROPEAN JOURNAL OF CLINICAL NUTRITION
LA English
DT Article
DE age-related maculopathy; dietary fat; unsaturated fats; epidemiology
ID MACULAR DEGENERATION; FISH INTAKE; PATHOGENESIS; ASSOCIATION; ALLELES;
   HEALTH
AB This study aimed at assessing the associations of dietary fat with the risk of age-related maculopathy (ARM), in the framework of a population-based study from southern France. Nutritional data were collected using a dietitian-administered food-frequency questionnaire. ARM was classified from retinal photographs using the international classification and included neovascular agerelated macular degeneration, geographic atrophy, soft indistinct drusen, soft distinct drusen associated with pigmentary abnormalities. After multivariate adjustment, high total, saturated and monounsaturated fat intake were associated with increased risk for ARM (odds ratio (OR) 4.74, P = 0.007; OR=2.70, P=0.04; and OR=3.50, P=0.03, respectively). Total polyunsaturated fatty acid was not significantly associated with ARM. Total and white fish intake was not significantly associated with ARM, but fatty fish intake (more than once a month versus less than once a month) was associated with a 60% reduction in risk for ARM (OR = 0.42, P = 0.01).
C1 Univ Bordeaux 2, INSERM, U593, F-33076 Bordeaux, France.
   INSERM, Res Unit U593 Epidemiol Publ Hlth & Dev, Bordeaux, France.
   INSERM, E361, Montpellier, France.
   Univ Montpellier 1, Montpellier, France.
   Lapeyronie Univ Hosp, Biochem Lab, Montpellier, France.
   IRD UR 024 Epidemiol & Prevent, Montpellier 5, France.
   INSERM, CRLC, Ctr Canc Res, Montpellier 5, France.
C3 Institut National de la Sante et de la Recherche Medicale (Inserm);
   UDICE-French Research Universities; Universite de Bordeaux; Institut
   National de la Sante et de la Recherche Medicale (Inserm); Institut
   National de la Sante et de la Recherche Medicale (Inserm); Universite de
   Montpellier; Universite de Montpellier; Universite de Montpellier; CHU
   de Montpellier; Institut de Recherche pour le Developpement (IRD);
   Institut National de la Sante et de la Recherche Medicale (Inserm);
   Universite de Montpellier
RP Delcourt, C (通讯作者)，Univ Bordeaux 2, INSERM, U593, 146 Rue Leo Saignat, F-33076 Bordeaux, France.
EM Cecile.Delcourt@isped.u-bordeaux2.fr
RI Delcourt, Cecile/I-2627-2013; Carrière, Isabelle/W-8728-2019
OI Delcourt, Cecile/0000-0002-2099-0481; Carriere,
   Isabelle/0000-0002-3617-0752
CR Baird PN, 2004, INVEST OPHTH VIS SCI, V45, P1311, DOI 10.1167/iovs.03-1121
   BIRD AEC, 1995, SURV OPHTHALMOL, V39, P367, DOI 10.1016/S0039-6257(05)80092-X
   Cho E, 2001, AM J CLIN NUTR, V73, P209
   Daures J P, 2000, J Epidemiol Biostat, V5, P109
   Delcourt C, 2005, AM J OPHTHALMOL, V140, P924, DOI 10.1016/j.ajo.2005.05.002
   Delcourt C, 1998, ARCH OPHTHALMOL-CHIC, V116, P1031, DOI 10.1001/archopht.116.8.1031
   Donoso LA, 2006, SURV OPHTHALMOL, V51, P137, DOI 10.1016/j.survophthal.2005.12.001
   Espinosa-Heidmann DG, 2004, INVEST OPHTH VIS SCI, V45, P260, DOI 10.1167/iovs.03-0910
   Heuberger RA, 2001, ARCH OPHTHALMOL-CHIC, V119, P1833, DOI 10.1001/archopht.119.12.1833
   Klein R, 2004, AM J OPHTHALMOL, V137, P486, DOI 10.1016/j.ajo.2003.11.069
   Malek G, 2005, P NATL ACAD SCI USA, V102, P11900, DOI 10.1073/pnas.0503015102
   MARESPERLMAN JA, 1995, ARCH OPHTHALMOL-CHIC, V113, P743, DOI 10.1001/archopht.1995.01100060069034
   Resnikoff S, 2004, B WORLD HEALTH ORGAN, V82, P844
   SanGiovanni JP, 2005, PROG RETIN EYE RES, V24, P87, DOI 10.1016/j.preteyeres.2004.06.002
   Seddon JM, 2003, ARCH OPHTHALMOL-CHIC, V121, P1728, DOI 10.1001/archopht.121.12.1728
   Seddon JM, 2001, ARCH OPHTHALMOL-CHIC, V119, P1191, DOI 10.1001/archopht.119.8.1191
   Smith W, 2000, ARCH OPHTHALMOL-CHIC, V118, P401, DOI 10.1001/archopht.118.3.401
   Willett W., 2013, NUTR EPIDEMIOLOGY, V3rd
   Zareparsi S, 2004, INVEST OPHTH VIS SCI, V45, P1306, DOI 10.1167/iovs.03-1253
NR 19
TC 49
Z9 51
U1 0
U2 4
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 0954-3007
J9 EUR J CLIN NUTR
JI Eur. J. Clin. Nutr.
PD NOV
PY 2007
VL 61
IS 11
BP 1341
EP 1344
DI 10.1038/sj.ejcn.1602685
PG 4
WC Nutrition & Dietetics
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Nutrition & Dietetics
GA 226VD
UT WOS:000250615700014
PM 17299457
OA Green Submitted
DA 2022-11-30
ER

PT J
AU Riecke, J
   Valmaggia, C
AF Riecke, Julian
   Valmaggia, Christophe
TI "Treat-and-Extend" Regimen for Exudative Age-Related Macular
   Degeneration: A Two-Year Retrospective Follow-up Study
SO KLINISCHE MONATSBLATTER FUR AUGENHEILKUNDE
LA English
DT Article
DE age-related macular degeneration; "treat-and-extend" regimen;
   anti-vascular endothelial growth factor; real-life data
ID INTRAVITREAL AFLIBERCEPT; OUTCOMES; THERAPY
AB Background After the introduction of a "treat-and-extend" regimen (T&E) with aflibercept for exudative age-related macular degeneration, naive eyes were compared with eyes pretreated with a "pro re nata" scheme (PRN). Patients and Methods The Ethics Committee of Eastern Switzerland approved the retrospective single-centre study (EKOS20/084, project ID: 2020-01193). The study included 342 eyes of 303 patients newly treated with or switched to T&E between January 2018 and March 2018 at the Eye Clinic of the Cantonal Hospital St. Gallen. The gender distribution of the treated eyes was 63.5% (n = 217) female and 36.5% (n = 125) male. The mean age was 81.6 years (SD = 8.6 years). The collective was divided into three groups: 1) naive, untreated eyes (n = 92), 2) eyes with <= 6 previous treatments with PRN (n = 37), 3) eyes with > 6 previous treatments with PRN (n = 213). The following parameters were analysed up to December 2019: the evolution of visual acuity, the number of intravitreal injections, the number of recurrences, the duration of the follow-up, the dropout rate, and the duration of the last treatment interval. Results During the observation period, group 1 showed a statistically significant improvement in visual acuity of + 1.5 ETDRS, while groups 2 and 3 showed a decrease in visual acuity of - 2.9 and - 3.7 ETDRS, respectively. Group 1 had better development of visual acuity than groups 2 and 3 (p = 0.005), while groups 2 and 3 were not significantly different (p = 0.92). The other parameters examined in the three groups did not differ significantly between groups. Conclusions Treatment with aflibercept in T&E shows significantly better visual acuity in naive eyes than in eyes pretreated with PRN.
C1 [Riecke, Julian] Vista Klin AG, Eye Clin, Binningen, Switzerland.
   [Valmaggia, Christophe] Cantonal Hosp St Gallen, Eye Clin, Rorschacher Str 95, CH-9007 St Gallen, Switzerland.
C3 Kantonsspital St. Gallen
RP Valmaggia, C (通讯作者)，Cantonal Hosp St Gallen, Eye Clin, Rorschacher Str 95, CH-9007 St Gallen, Switzerland.
EM christophe.valmaggia@kssg.ch
CR Arnold JJ, 2015, OPHTHALMOLOGY, V122, P1212, DOI 10.1016/j.ophtha.2015.02.009
   Boyle J, 2018, PSYCHOL HEALTH MED, V23, P127, DOI 10.1080/13548506.2016.1274040
   Ebneter A, 2020, SCI REP-UK, V10, DOI 10.1038/s41598-020-76354-1
   Hatz K, 2016, BRIT J OPHTHALMOL, V100, P1341, DOI 10.1136/bjophthalmol-2015-307299
   Jaggi D, 2022, BRIT J OPHTHALMOL, V106, P246, DOI 10.1136/bjophthalmol-2020-316514
   Kvannli L, 2017, ACTA OPHTHALMOL, V95, P678, DOI 10.1111/aos.13356
   Lanzetta P, 2017, GRAEF ARCH CLIN EXP, V255, P1259, DOI 10.1007/s00417-017-3647-4
   Lorentzen TD, 2018, RETINA-J RET VIT DIS, V38, P2363, DOI 10.1097/IAE.0000000000001872
   Maruko I, 2020, OPHTHALMOL RETINA, V4, P767, DOI 10.1016/j.oret.2020.03.010
   Mones J, 2020, OPHTHALMOLOGICA, V243, P1, DOI 10.1159/000502747
   Ohji M, 2020, ADV THER, V37, P2184, DOI 10.1007/s12325-020-01298-x
   Ohji M, 2020, ADV THER, V37, P1173, DOI 10.1007/s12325-020-01236-x
   Prenner JL, 2015, AM J OPHTHALMOL, V160, P725, DOI 10.1016/j.ajo.2015.06.023
   Solomon SD, 2019, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD005139.pub4
   Traine PG, 2019, OPHTHALMOL RETINA, V3, P393, DOI 10.1016/j.oret.2019.01.018
NR 15
TC 0
Z9 0
U1 1
U2 1
PU GEORG THIEME VERLAG KG
PI STUTTGART
PA RUDIGERSTR 14, D-70469 STUTTGART, GERMANY
SN 0023-2165
EI 1439-3999
J9 KLIN MONATSBL AUGENH
JI Klinische Monatsblat. Augenheilkunde
PD APR
PY 2022
VL 239
IS 04
BP 494
EP 499
DI 10.1055/a-1770-4037
PG 6
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 0U1CA
UT WOS:000787394100033
PM 35472793
DA 2022-11-30
ER

PT J
AU Han, XK
   Ong, JS
   Hewitt, AW
   Gharahkhani, P
   MacGregor, S
AF Han, Xikun
   Ong, Jue-Sheng
   Hewitt, Alex W.
   Gharahkhani, Puya
   MacGregor, Stuart
TI The effects of eight serum lipid biomarkers on age-related macular
   degeneration risk: a Mendelian randomization study
SO INTERNATIONAL JOURNAL OF EPIDEMIOLOGY
LA English
DT Article
DE Lipids; age-related macular degeneration; Mendelian randomization;
   causal effect; UK Biobank
AB Background: Age-related macular degeneration (AMD) is a leading cause of vision loss. Whereas lipids have been studied extensively to understand their effects on cardiovascular diseases, their relationship with AMD remains unclear.
   Methods: Two-sample Mendelian randomization (MR) analyses were performed to systematically evaluate the causal relationships between eight serum lipid biomarkers, consisting of apolipoprotein A1 (ApoA1), apolipoprotein B (ApoB), total cholesterol (CHOL), high-density lipoprotein cholesterol (HDL-C), direct low-density lipoprotein cholesterol (LDL-C), lipoprotein A [Lp(a)], triglycerides (TG) and non-HDL cholesterol (non-HDL-C), and the risk of different AMD stages and subtypes. We derived 64-407 genetic instruments for eight serum lipid biomarkers in 419 649 participants of European descent from the UK Biobank cohort. We conducted genome-wide association studies (GWAS) for 12 711 advanced AMD cases [8544 choroidal neovascularization (CNV) and 2656 geographic atrophy (GA) specific AMD subtypes] and 5336 intermediate AMD cases with 14 590 controls of European descent from the International AMD Genomics Consortium.
   Results: Higher genetically predicted HDL-C and ApoA1 levels increased the risk of all AMD subtypes. LDL-C, ApoB, CHOL and non-HDL-C levels were associated with decreased risk of intermediate and GA AMD but not with CNV. Genetically predicted TG levels were associated with decreased risk of different AMD subtypes. Sensitivity analyses revealed no evidence for directional pleiotropy effects. In our multivariable MR analyses, adjusting for the effects of correlated lipid biomarkers yielded similar results.
   Conclusion: These results suggest the role of lipid metabolism in drusen formation and particularly in AMD development at the early and intermediate stages. Mechanistic studies are warranted to investigate the utility of lipid pathways for therapeutic treatment in preventing AMD. (C) The Author(s) 2020; all rights reserved.
C1 [Han, Xikun; Ong, Jue-Sheng; Gharahkhani, Puya; MacGregor, Stuart] QIMR Berghofer Med Res Inst, Stat Genet, 300 Herston Rd, Brisbane, Qld 4006, Australia.
   [Han, Xikun] Univ Queensland, Sch Med, Brisbane, Qld, Australia.
   [Hewitt, Alex W.] Univ Tasmania, Menzies Inst Med Res, Hobart, Tas, Australia.
   [Hewitt, Alex W.] Univ Melbourne, Ctr Eye Res Australia, Melbourne, Vic, Australia.
C3 QIMR Berghofer Medical Research Institute; University of Queensland;
   University of Tasmania; Menzies Institute for Medical Research; Centre
   for Eye Research Australia; University of Melbourne
RP Han, XK (通讯作者)，QIMR Berghofer Med Res Inst, Stat Genet, 300 Herston Rd, Brisbane, Qld 4006, Australia.
EM Xikun.Han@qimrberghofer.edu.au
RI Han, Xikun/AAN-9012-2020; Macgregor, Stuart/C-6442-2009; Ong, Jue
   Sheng/B-3595-2018
OI Han, Xikun/0000-0002-3823-7308; Macgregor, Stuart/0000-0001-6731-8142;
   Ong, Jue Sheng/0000-0002-6062-710X; Gharahkhani,
   Puya/0000-0002-4203-5952
FU National Eye Institute; University of Queensland Research Training
   Scholarship; QIMR Berghofer PhD Top Up Scholarship; Australian National
   Health and Medical Research Council (NHMRC) Fellowships; NHMRC [1116360,
   1150144, 1123248]
FX This work was conducted using the UK Biobank Resource (application
   number 25331). For the AMD datasets, all contributing sites and
   additional funding information are acknowledged in this publication:
   Fritsche et al. (2016) Nature Genetics 48 134-143, (doi :
   10.1038/ng.3448). The International AMD Genomics consortium's web page
   is: http://eaglep.case.edu/iamdgc_web/, and additional information is
   available on: http://csg.sph.umich.edu/abecasis/public/amd2015/.The AMD
   case-control datasets used for the analyses described in this manuscript
   were obtained from the NEI Study of Age-Related Macular Degeneration
   (NEI-AMD) Database found at
   https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi? study_
   id=phs001039.v1.p1 through dbGaP accession number 20740. Funding support
   for NEI-AMD was provided by the National Eye Institute. We would like to
   thank NEI-AMD participants and the NEI-AMD Research Group for their
   valuable contribution to this research. X.H. is supported by the
   University of Queensland Research Training Scholarship and QIMR
   Berghofer PhD Top Up Scholarship. S.M. and A.W.H. are supported by
   Australian National Health and Medical Research Council (NHMRC)
   Fellowships. We acknowledge funding from NHMRC grants [1116360, 1150144
   and 1123248].
CR Anand R, 2000, OPHTHALMOLOGY, V107, P2224
   Angelica M.D., 2008, ARTERIOSCL THROM VAS, V141, P520
   Aulchenko YS, 2007, BIOINFORMATICS, V23, P1294, DOI 10.1093/bioinformatics/btm108
   Berglund L, 2004, ARTERIOSCL THROM VAS, V24, P2219, DOI 10.1161/01.ATV.0000144010.55563.63
   Bowden J, 2015, INT J EPIDEMIOL, V44, P512, DOI 10.1093/ije/dyv080
   Brion MJA, 2013, INT J EPIDEMIOL, V42, P1497, DOI 10.1093/ije/dyt179
   Burgess S, 2017, OPHTHALMOLOGY, V124, P1165, DOI 10.1016/j.ophtha.2017.03.042
   Burgess S, 2017, EPIDEMIOLOGY, V28, P30, DOI 10.1097/EDE.0000000000000559
   Burgess S, 2015, EUR J EPIDEMIOL, V30, P543, DOI 10.1007/s10654-015-0011-z
   Burgess S, 2013, GENET EPIDEMIOL, V37, P658, DOI 10.1002/gepi.21758
   Bycroft C, 2018, NATURE, V562, P203, DOI 10.1038/s41586-018-0579-z
   Chakravarthy U, 2010, BMC OPHTHALMOL, V10, DOI 10.1186/1471-2415-10-31
   Clarke R, 2009, NEW ENGL J MED, V361, P2518, DOI 10.1056/NEJMoa0902604
   Colijn JM, 2019, OPHTHALMOLOGY, V126, P393, DOI 10.1016/j.ophtha.2018.09.045
   Complications Age-Related Macular, 2008, OPHTHALMOLOGY, V115, P1474, DOI 10.1016/j.ophtha.2008.03.008
   Craig JE, 2020, NAT GENET, V52, P160, DOI 10.1038/s41588-019-0556-y
   Curcio Christine A, 2018, Invest Ophthalmol Vis Sci, V59, pAMD160, DOI 10.1167/iovs.18-24882
   Curcio CA, 2011, BRIT J OPHTHALMOL, V95, P1638, DOI 10.1136/bjophthalmol-2011-300344
   Davey Smith G, 2014, HUM MOL GENET, V23, pR89, DOI 10.1093/hmg/ddu328
   Davies NM, 2018, BMJ-BRIT MED J, V362, DOI 10.1136/bmj.k601
   de Jong PTVM, 2006, NEW ENGL J MED, V355, P1474, DOI 10.1056/NEJMra062326
   Fan Q, 2017, INT J EPIDEMIOL, V46, P1891, DOI 10.1093/ije/dyx189
   Ferris FL, 2013, OPHTHALMOLOGY, V120, P844, DOI 10.1016/j.ophtha.2012.10.036
   Friberg TR, 2012, INVEST OPHTH VIS SCI, V53, P1742, DOI 10.1167/iovs.11-9338
   Fritsche LG, 2016, NAT GENET, V48, P134, DOI 10.1038/ng.3448
   Garcia-Layana A, 2017, CLIN INTERV AGING, V12, P1579, DOI 10.2147/CIA.S142685
   Han XK, 2020, J HUM GENET, V65, P657, DOI 10.1038/s10038-020-0750-x
   Handa JT, 2017, BBA-MOL CELL BIOL L, V1862, P430, DOI 10.1016/j.bbalip.2016.07.013
   Hemani G, 2018, ELIFE, V7, DOI 10.7554/eLife.34408
   Klein R, 1999, PROG RETIN EYE RES, V18, P371, DOI 10.1016/S1350-9462(98)00025-1
   Klein R, 2019, OPHTHALMOLOGY, V126, P752, DOI 10.1016/j.ophtha.2018.12.026
   Lim LS, 2012, LANCET, V379, P1728, DOI 10.1016/S0140-6736(12)60282-7
   Liu DJ, 2017, NAT GENET, V49, P1758, DOI 10.1038/ng.3977
   Loh PR, 2015, NAT GENET, V47, P284, DOI 10.1038/ng.3190
   MacGregor S, 2018, NAT GENET, V50, P1067, DOI 10.1038/s41588-018-0176-y
   Martin DF, 2011, NEW ENGL J MED, V364, P1897, DOI 10.1056/NEJMoa1102673
   Mitchell P, 2018, LANCET, V392, P1147, DOI 10.1016/S0140-6736(18)31550-2
   Moriarty PM, 2017, ARTERIOSCL THROM VAS, V37, P580, DOI 10.1161/ATVBAHA.116.308704
   Neale BM, 2010, P NATL ACAD SCI USA, V107, P7395, DOI 10.1073/pnas.0912019107
   Park JH, 2010, NAT GENET, V42, P570, DOI 10.1038/ng.610
   PAULEIKHOFF D, 1990, OPHTHALMOLOGY, V97, P171
   Pingault JB, 2018, NAT REV GENET, V19, P566, DOI 10.1038/s41576-018-0020-3
   Purcell S, 2007, AM J HUM GENET, V81, P559, DOI 10.1086/519795
   Rao VS, 2011, CARDIOL RES PRACT, V2011, DOI 10.4061/2011/295976
   Rees JMB, 2017, STAT MED, V36, P4705, DOI 10.1002/sim.7492
   Ridker PM, 2005, JAMA-J AM MED ASSOC, V294, P326, DOI 10.1001/jama.294.3.326
   Sanderson E, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-10679-y
   Sanderson E, 2019, INT J EPIDEMIOL, V48, P713, DOI 10.1093/ije/dyy262
   Schooling CM, 2019, BIAS COMPETING RISK, DOI [10.1101/716621v2, DOI 10.1101/716621V2]
   van Leeuwen EM, 2018, PROG RETIN EYE RES, V67, P56, DOI 10.1016/j.preteyeres.2018.04.006
   Vavvas DG, 2016, EBIOMEDICINE, V5, P198, DOI 10.1016/j.ebiom.2016.01.033
   Verbanck M, 2018, NAT GENET, V50, P693, DOI 10.1038/s41588-018-0099-7
   Wang L, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0010329
   Wang YF, 2016, NUTRIENTS, V8, DOI 10.3390/nu8100663
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
   Wu YD, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-09572-5
   Xu QY, 2018, LIPIDS HEALTH DIS, V17, DOI 10.1186/s12944-017-0647-7
   Yavorska OO, 2017, INT J EPIDEMIOL, V46, P1734, DOI 10.1093/ije/dyx034
   Zuber V, 2020, HIGH THROUGHPUT MULT, DOI [10.1101/2020.02.10.20021691, DOI 10.1101/2020.02.10.20021691]
   Zuber V, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-019-13870-3
NR 60
TC 9
Z9 9
U1 1
U2 5
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 0300-5771
EI 1464-3685
J9 INT J EPIDEMIOL
JI Int. J. Epidemiol.
PD FEB
PY 2021
VL 50
IS 1
BP 325
EP 336
DI 10.1093/ije/dyaa178
PG 12
WC Public, Environmental & Occupational Health
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Public, Environmental & Occupational Health
GA RJ0HN
UT WOS:000637284400039
PM 33211829
OA Bronze
DA 2022-11-30
ER

PT J
AU Luo, D
   Deng, TT
   Yuan, W
   Deng, H
   Meng, H
   Jin, M
AF Luo Dan
   Deng Tingting
   Yuan Wei
   Deng Hui
   Meng Huan
   Jin Ming
TI Effects of Huangban Bianxing One decoction combined with ranibi-zumab on
   treating exudative age-related macular degeneration
SO JOURNAL OF TRADITIONAL CHINESE MEDICINE
LA English
DT Article
DE Macular degeneration; Ranibizumab; Visual acuity; Treatment outcome;
   Safty; Huangban Bianxing One decoction
ID PANAX-NOTOGINSENG SAPONINS; CHOROIDAL NEOVASCULARIZATION; PHOTODYNAMIC
   THERAPY; ANGELICA SINENSIS; BLOOD-FLOW; INFLAMMATION; BEVACIZUMAB;
   RADIX; EYES
AB OBJECTIVE: To evaluate the clinical efficacy and safety of Chinese medicine formula Huangban Bianxing One decoction (HBOD) combined with ranibizumab for treating exudative age-related macular degeneration (AMD) patients.
   METHODS: Totally 75 cases with exudative AMD (75 eyes) were enrolled in this study and randomly divided into two groups to receive either HBOD with ranibizumab or only ranibizumab. Early treatment diabetic retinopathy study (ETDRS) letters for the best corrected visual acuity, center macular thickness (CMT), height of the lesion, fundus hemorrhage area, fundus fluorescein leakage area as the main outcomes and safety indexes were estimated and compared before and after treatment for 3 or 6 months.
   RESULTS: Comparing with the before treatment, ETDRS letter scores of both groups after treatment at month 3 obtained a greater improvement (P < 0.05), but the significant improvement only existed in the HBOD+ ranibizumab group at month 6 (P < 0.01), and better than the ranibizumab group (P < 0.05). At month 3, the CMT and lesion height of both groups were significantly lower than those before treatment (P < 0.01 or P < 0.05) and the HBOD + ranibizumab group had a similar result at month 6 (P < 0.01). The hemorrhage area and fluorescein leakage area of the HBOD + ranibizumab group were also significantly reduced and also smaller than those of the ranibizumab group at month 6 (P < 0.01 or P < 0.05). During treatment, no significant adverse events relating to HBOD or ranibizumab treatment were elucidated.
   CONCLUSION: HBOD combined with ranibizumab can improve visual acuity and reduce hemorrhage and fluorescein leakage of patients with exudative AMD. These results also indicated that HBOD may function as an effective and safe adjuvant drug for exudative AMD. (C) 2019 JTCM. All rights reserved.
C1 [Luo Dan; Yuan Wei; Deng Hui; Meng Huan; Jin Ming] China Japan Friendship Hosp, Dept Ophthalmol, Beijing 100029, Peoples R China.
   [Luo Dan] Beijing Changping Hosp Tradit Chinese Med, Dept Ophthalmol, Beijing 102200, Peoples R China.
   [Deng Tingting] China Japan Friendship Hosp, Inst Clin Med Sci, Beijing 100029, Peoples R China.
C3 China-Japan Friendship Hospital; China-Japan Friendship Hospital
RP Jin, M (通讯作者)，China Japan Friendship Hosp, Dept Ophthalmol, Beijing 100029, Peoples R China.
EM jinming57@163.com
CR [Anonymous], 1997, CLIN RES GUID PRINC, V3, P205
   Blasiak J, 2014, BIOMED RES INT, V2014, DOI 10.1155/2014/768026
   Bressler NM, 1999, ARCH OPHTHALMOL-CHIC, V117, P1329
   Bromfield SG, 2013, CURR EYE RES, V38, P1283, DOI 10.3109/02713683.2013.822086
   Campochiaro PA, 2000, J CELL PHYSIOL, V184, P301, DOI 10.1002/1097-4652(200009)184:3<301::AID-JCP3>3.0.CO;2-H
   Chang YC, 2014, FRONT AGING NEUROSCI, V6, DOI 10.3389/fnagi.2014.00191
   Chen YQ, 2014, MOL MED REP, V10, P1400, DOI 10.3892/mmr.2014.2328
   Curtis LH, 2012, AM J OPHTHALMOL, V153, P1116, DOI 10.1016/j.ajo.2011.11.032
   FRIEDMAN E, 1995, OPHTHALMOLOGY, V102, P640, DOI 10.1016/S0161-6420(95)30974-8
   Gao Dong, 2005, Zhongguo Zhong Xi Yi Jie He Za Zhi, V25, P912
   George PP, 2014, INDIAN J OPHTHALMOL, V62, P761, DOI 10.4103/0301-4738.138615
   Grunwald JE, 2005, INVEST OPHTH VIS SCI, V46, P1033, DOI 10.1167/iovs.04-1050
   Han CC, 2012, INFLAMMATION, V35, P913, DOI 10.1007/s10753-011-9393-6
   Han DM, 2015, MOL MED REP, V11, P2896, DOI 10.3892/mmr.2014.3046
   Jager RD, 2008, NEW ENGL J MED, V358, P2606, DOI 10.1056/NEJMra0801537
   Jin M, 2012, J TRANSL MED, V10, DOI 10.1186/1479-5876-10-118
   Jin Ming, 2009, Zhongguo Zhong Xi Yi Jie He Za Zhi, V29, P540
   Kauppinen A, 2016, CELL MOL LIFE SCI, V73, P1765, DOI 10.1007/s00018-016-2147-8
   Li FM, 2004, CHINESE OPHTHALMOLOG, P565
   Li XJ, 2008, ZHONG GUO ZHONG YI Y, V18, P240
   Li ZY, 2015, ZHANG JY COMPLETE WO, P1245
   Lim LS, 2012, LANCET, V379, P1728, DOI 10.1016/S0140-6736(12)60282-7
   Mullins RE, 2011, INVEST OPHTH VIS SCI, V52, P1606, DOI 10.1167/iovs.10-6476
   Ohkura N, 2012, BLOOD COAGUL FIBRIN, V23, P254, DOI 10.1097/MBC.0b013e3283504148
   Ohkura N, 2011, BLOOD COAGUL FIBRIN, V22, P631, DOI 10.1097/MBC.0b013e328349a22c
   Potter MJ, 2007, BRIT J OPHTHALMOL, V91, P753, DOI 10.1136/bjo.2006.110239
   Qi HJ, 2017, INT J OPHTHALMOL-CHI, V10, P91, DOI 10.18240/ijo.2017.01.15
   Roberts P, 2014, INVEST OPHTH VIS SCI, V55, DOI 10.1167/iovs.14-14293
   Russo A, 2013, MEDIAT INFLAMM, V2013, DOI 10.1155/2013/476525
   Schmidt-Erfurth U, 2014, BRIT J OPHTHALMOL, V98, P1144, DOI 10.1136/bjophthalmol-2014-305702
   Shao AW, 2014, INT J MED SCI, V11, P1073, DOI 10.7150/ijms.9282
   Shi Xu-qin, 2012, Yaoxue Xuebao, V47, P1375
   Solomon SG, 2014, FRONT NEURAL CIRCUIT, V8, DOI 10.3389/fncir.2014.00096
   Sulaiman RS, 2014, EXP EYE RES, V129, P161, DOI 10.1016/j.exer.2014.10.002
   Ventrice P, 2013, J PHARMACOL PHARMACO, V4, pS38, DOI 10.4103/0976-500X.120947
   Wang B, 2014, ARCH PHARM RES, V37, P793, DOI 10.1007/s12272-014-0336-2
   Wang HY, 2013, INT J OPHTHALMOL-CHI, V6, P600, DOI 10.3980/j.issn.2222-3959.2013.05.09
   Wang QL, 2015, BRIT J OPHTHALMOL, V99, P119, DOI 10.1136/bjophthalmol-2014-305813
   Wang SS, 2013, EXPERT OPIN THER PAT, V23, P269, DOI 10.1517/13543776.2013.751972
   Weber M, 2014, J FR OPHTALMOL, V37, P566, DOI 10.1016/j.jfo.2014.06.001
   Wu B, 1991, Yan Ke Xue Bao, V7, P199
   Yang XC, 2014, EVID-BASED COMPL ALT, V2014, DOI 10.1155/2014/204840
   Yang XB, 2007, BIOL PHARM BULL, V30, P1884, DOI 10.1248/bpb.30.1884
   Ying GS, 2014, JAMA OPHTHALMOL, V132, P915, DOI 10.1001/jamaophthalmol.2014.1019
   Zarbin MA, 2004, ARCH OPHTHALMOL-CHIC, V122, P598, DOI 10.1001/archopht.122.4.598
   Zhang Feng, 2012, Zhonghua Yan Ke Za Zhi, V48, P103
   Zhang KY, 2018, INT OPHTHALMOL, V38, P1659, DOI 10.1007/s10792-017-0639-7
   Zhang M, 2004, CHIN J OCUL FUNDUS, V20, P5
   Zhou NN, 2014, PHYTOMEDICINE, V21, P1189, DOI 10.1016/j.phymed.2014.05.004
NR 49
TC 2
Z9 3
U1 0
U2 4
PU JOURNAL TRADITIONAL CHINESE MED
PI BEIJING
PA 16 NANXIAOJIE, DONGZHIMEN NEI, BEIJING, 100700, PEOPLES R CHINA
SN 0255-2922
EI 1577-7014
J9 J TRADIT CHIN MED
JI J. Tradit. Chin. Med.
PD DEC
PY 2019
VL 39
IS 6
BP 892
EP 901
PG 10
WC Integrative & Complementary Medicine
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Integrative & Complementary Medicine
GA KC1LJ
UT WOS:000506947800017
PM 32186161
DA 2022-11-30
ER

PT J
AU Prager, F
   Michels, S
   Simader, C
   Geitzenauer, W
   Schmidt-Erfurth, U
   Simader, C
AF Prager, Franz
   Michels, Stephan
   Simader, Christian
   Geitzenauer, Wolfgang
   Schmidt-Erfurth, Ursula
   Simader, Christian
TI Changes in retinal sensitivity in patients with neovascular age-related
   macular degeneration after systemic bevacizumab (Avastin) therapy
SO RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES
LA English
DT Article
DE microperimetry; macular function; retinal sensitivity; bevacizumab; VEGF
ID SCANNING LASER MICROPERIMETRY; CHOROIDAL NEOVASCULARIZATION;
   INTRAVITREAL BEVACIZUMAB; FUNDUS PERIMETRY; OPHTHALMOSCOPE; RANIBIZUMAB;
   VERTEPORFIN
AB Objective: To evaluate changes in central retinal sensitivity in patients with neovascular age-related macular degeneration after systemic bevacizumab (Avastin; Genentech, Inc., South San Francisco, CA) therapy.
   Methods: For all eyes, the central 12 x 12 visual field was recorded using the MP 1 Microperimeter (Nidek, Gamagori, Japan) at baseline and 1 week, 1 month, 3 months, and 6 months after initial treatment. Patients received systemic anti-vascular endothelial growth factor (VEGF) therapy with three initial bevacizumab infusions at 2-week intervals. Retreatment during follow-up was performed only in cases of choroidal neovascularization recurrence. Seven patients (12 eyes) received bevacizumab infusions at a dose of 5 mg/kg, and 7 patients (9 eyes), at a dose of 2.5 mg/kg.
   Results: Of 41 stimulation points, a mean absolute scotoma of 15 missed stimulation points was measured at baseline, which decreased to 10 missed stimulation points at month 3 (-5; P = 0.005) and to 11 stimulation points at month 6 (-4; P = 0.106). The mean absolute scotoma size (in % of total tested area) decreased from 33% to 22% (-11 %; P = 0.011) at month 3 and to 23% (-10%, P = 0.123) at month 6. Mean differential light threshold increased significantly throughout the observation period from 3.8 dB at baseline to 5.5dB (+1.7dB; P=0.012) at month 6.
   Conclusions: Systemic bevacizumab therapy induced a significant increase in mean retinal sensitivity at month 6 of follow-up and a significant decrease of mean absolute scotoma size at month 3. The MP 1 Microperimeter proved to be a valuable tool in the evaluation of functional benefits and retinal safety of anti-VEGF therapy with systemic bevacizumab.
C1 [Michels, Stephan] Univ Zurich Hosp, Dept Ophthalmol, CH-8091 Zurich, Switzerland.
   [Prager, Franz; Simader, Christian; Geitzenauer, Wolfgang; Schmidt-Erfurth, Ursula; Simader, Christian] Med Univ Vienna, Dept Ophthalmol & Optometry, Vienna, Austria.
C3 University of Zurich; University Zurich Hospital; Medical University of
   Vienna
RP Michels, S (通讯作者)，Univ Zurich Hosp, Dept Ophthalmol, Frauenklin Str 24, CH-8091 Zurich, Switzerland.
EM stephan.michels@usz.ch
OI Simader, Christian/0000-0002-1784-2883
CR Bashshur ZF, 2006, AM J OPHTHALMOL, V142, P1, DOI 10.1016/j.ajo.2006.02.037
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   CHAKRAVARTHY U, 2006, OPHTHALMOLOGY, V25, DOI UNSP 1508.E1-1508.E25
   Costa RA, 2006, INVEST OPHTH VIS SCI, V47, P4569, DOI 10.1167/iovs.06-0433
   Ergun E, 2003, OPHTHALMOLOGY, V110, P65, DOI 10.1016/S0161-6420(02)01566-X
   Gragoudas ES, 2004, NEW ENGL J MED, V351, P2805, DOI 10.1056/NEJMoa042760
   Klaver CCW, 1998, ARCH OPHTHALMOL-CHIC, V116, P653, DOI 10.1001/archopht.116.5.653
   Michels S, 2005, OPHTHALMOLOGY, V112, P1035, DOI 10.1016/j.ophtha.2005.02.007
   Midena Edoardo, 2004, Semin Ophthalmol, V19, P55, DOI 10.1080/08820530490882896
   MOSHFEGHI AA, 2002, OPHTHALMOLOGY, V113
   Rich RM, 2006, RETINA-J RET VIT DIS, V26, P495, DOI 10.1097/01.iae.0000225766.75009.3a
   Rohrschneider K, 1998, AM J OPHTHALMOL, V126, P52, DOI 10.1016/S0002-9394(98)00065-8
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Rosenfeld PJ, 2005, OPHTHAL SURG LAS IM, V36, P331, DOI 10.3928/1542-8877-20050701-14
   Schmidt-Erfurth UM, 2004, OPHTHALMOLOGY, V111, P931, DOI 10.1016/j.ophtha.2003.12.025
   Schneider U, 1996, GRAEF ARCH CLIN EXP, V234, P612, DOI 10.1007/BF00185293
   SCHNEIDER U, 1993, KLIN MONATSBL AUGENH, V203, P212, DOI 10.1055/s-2008-1045670
   Springer C, 2006, OPHTHALMOLOGE, V103, P214, DOI 10.1007/s00347-005-1261-z
   Tezel TH, 1996, OPHTHALMOLOGY, V103, P1829, DOI 10.1016/S0161-6420(96)30419-3
   Varano M, 1998, Semin Ophthalmol, V13, P203, DOI 10.3109/08820539809056054
NR 20
TC 26
Z9 27
U1 0
U2 3
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0275-004X
J9 RETINA-J RET VIT DIS
JI Retin.-J. Retin. Vitr. Dis.
PD MAY
PY 2008
VL 28
IS 5
BP 682
EP 688
DI 10.1097/IAE.0b013e318161dc70
PG 7
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 302KQ
UT WOS:000255967600002
PM 18463510
DA 2022-11-30
ER

PT J
AU Keenan, TD
   Agron, E
   Domalpally, A
   Clemons, TE
   van Asten, F
   Wong, WT
   Danis, RG
   Sadda, S
   Rosenfeld, PJ
   Klein, ML
   Ratnapriya, R
   Swaroop, A
   Ferris, FL
   Chew, EY
AF Keenan, Tiarnan D.
   Agron, Elvira
   Domalpally, Amitha
   Clemons, Traci E.
   van Asten, Freekje
   Wong, Wai T.
   Danis, Ronald G.
   Sadda, SriniVas
   Rosenfeld, Philip J.
   Klein, Michael L.
   Ratnapriya, Rinki
   Swaroop, Anand
   Ferris, Frederick L., III
   Chew, Emily Y.
CA AREDS2 Res Grp
TI Progression of Geographic Atrophy in Age-related Macular Degeneration
   AREDS2 Report Number 16
SO OPHTHALMOLOGY
LA English
DT Article
ID FUNDUS AUTOFLUORESCENCE IMAGES; EYE DISEASE; APOLIPOPROTEIN-E;
   END-POINTS; COMPLEMENT; PHOTOGRAPHS; GROWTH; INFLAMMATION; ASSOCIATION;
   DEFINITION
AB Purpose: To analyze the prevalence, incidence, and clinical characteristics of eyes with geographic atrophy (GA) in age-related macular degeneration (AMD), including clinical and genetic factors affecting enlargement.
   Design: Prospective cohort study within a controlled clinical trial.
   Participants: Age-Related Eye Disease Study 2 (AREDS2) participants, aged 50-85 years.
   Methods: Baseline and annual stereoscopic color fundus photographs were evaluated for GA presence and area. Analyses included GA prevalence and incidence rates, Kaplan-Meier rates, mixed-model regression, and multivariable analysis of the square root of GA, area adjusted for covariates, including clinical/imaging characteristics and genotype.
   Main Outcome Measures: (1) Presence or development of GA; (2) change in the square root of GA area over time.
   Results: At baseline, 517 eyes (6.2%) of 411 participants (9.8%) had pre-existing GA (without neovascular AMD), with the following characteristics: 33% central, 67% noncentral; and the following configurations: 36% small, 26% solid/unifocal, 24% multifocal, 9% horseshoe/ring, and 6% indeterminate. Of the remaining 6530 eyes at risk, 1099 eyes (17.3%) of 883 participants developed incident GA without prior neovascular disease during mean follow-up of 4.4 years. The Kaplan-Meier rate of incident GA was 19% of eyes at 5 years. In eyes with incident GA, 4-year risk of subsequent neovascular AMD was 29%. In eyes with incident noncentral GA, 4-year risk of central involvement was 57%. GA enlargement rate (following square root transformation) was similar in eyes with pre-existing GA (0.29 mm/year; 95% confidence interval 0.27-0.30) and incident GA (0.28 mm/year; 0.27-0.30). In the combined group, GA enlargement was significantly faster with noncentrality, multifocality, intermediate baseline size, and bilateral GA (P < 0.0001 for interaction in each case) but not with AREDS2 treatment assignment (P = 0.33) or smoking status (P = 0.05). Enlargement was significantly faster with ARMS2 risk (P < 0.0001), C3 non-risk (P = 0.0002), and APOE non-risk (P = 0.001) genotypes.
   Conclusions: Analyses of AREDS2 data on natural history of GA provide representative data on GA evolution and enlargement. GA enlargement, which was influenced by lesion features, was relentless, resulting in rapid central vision loss. The genetic variants associated with faster enlargement were partially distinct from those associated with risk of incident GA. These findings are relevant to further investigations of GA pathogenesis and clinical trial planning. Published by Elsevier on behalf of the American Academy of Ophthalmology
C1 [Keenan, Tiarnan D.; Agron, Elvira; Ferris, Frederick L., III; Chew, Emily Y.] NEI, Div Epidemiol & Clin Applicat, NIH, Bethesda, MD 20892 USA.
   [Domalpally, Amitha; Danis, Ronald G.] Univ Wisconsin, Fundus Photog Reading Ctr, Madison, WI USA.
   [Clemons, Traci E.] Emmes Corp, Rockville, MD USA.
   [van Asten, Freekje; Ratnapriya, Rinki; Swaroop, Anand] NEI, Neurobiol Neurodegenerat & Repair Lab, NIH, Bethesda, MD 20892 USA.
   [Wong, Wai T.] NEI, Unit Microglia, NIH, Bethesda, MD 20892 USA.
   [Sadda, SriniVas] Doheny Eye Inst, 1355 San Pablo St, Los Angeles, CA 90033 USA.
   [Rosenfeld, Philip J.] Univ Miami, Miller Sch Med, Bascom Palmer Eye Inst, Miami, FL 33136 USA.
   [Klein, Michael L.] Casey Eye Inst, Portland, OR USA.
   [Klein, Michael L.] Devers Eye Clin, Portland, OR USA.
C3 National Institutes of Health (NIH) - USA; NIH National Eye Institute
   (NEI); University of Wisconsin System; University of Wisconsin Madison;
   Emmes Corporation; National Institutes of Health (NIH) - USA; NIH
   National Eye Institute (NEI); National Institutes of Health (NIH) - USA;
   NIH National Eye Institute (NEI); Doheny Eye Institute; Bascom Palmer
   Eye Institute; University of Miami; Devers Eye Institute
RP Chew, EY (通讯作者)，NEI, Div Epidemiol & Clin Applicat, NIH, CRC, Bldg 10,Room 3-2531,10 Ctr Dr,MSC 1204, Bethesda, MD 20892 USA.
EM echew@nei.nih.gov
RI Hunter, Allan/AAJ-5848-2020; Wong, Wai/B-6118-2017
OI Domalpally, Amitha/0000-0002-8145-9619; Hubschman,
   Jean-Pierre/0000-0002-8631-3467; DiLoreto, David/0000-0002-1787-8069;
   Russell, Stephen/0000-0003-3776-1367; Ratnapriya,
   Rinki/0000-0002-0469-4631; Ferris, Frederick/0000-0002-4933-0639; Scott,
   Ingrid/0000-0002-3908-7153; Keenan, Tiarnan/0000-0002-2253-1772; Chaum,
   Edward/0000-0003-3542-8376; Elman, Michael/0000-0001-7726-9508; Ho,
   Allen/0000-0003-3921-608X; Folk, James/0000-0002-6271-2906; Wong,
   Wai/0000-0003-0681-4016; Chalam, K V/0000-0002-0004-9416; Wolfe,
   Jeremy/0000-0003-2781-7152; Bailey, Steven/0000-0003-4949-1464; Zarbin,
   Marco/0000-0002-7811-7132
FU Bayer Global Ophthalmology Awards Program; Intramural Research Program
   of the National Eye Institute [EY000546]; Nederlandse Oogonderzoek
   Stichting; Dr. P. Binkhorst Stichting; Stichting Dondersfonds; Prins
   Bernhard Cultuurfonds; Stichting A.F. Deutman Oogheelkunde
   Researchfonds; Astellas Institute for Regenerative Medicine (AIRM); Carl
   Zeiss Medictec; Genentech; Tyrogenex; National Eye Institute/National
   Institutes of Health (NIH), Department of Health and Human Services,
   Bethesda, Maryland [HHS-N-260-2005-00007-C, NO1-EY-5-0007]; Office of
   Dietary Supplements, National Center for Complementary and Alternative
   Medicine; National Institute on Aging; National Heart, Lung, and Blood
   Institute; National Institute of Neurological Disorders and Stroke;
   NATIONAL EYE INSTITUTE [ZIAEY000554, ZIAEY000489, ZIAEY000546] Funding
   Source: NIH RePORTER
FX The authors made the following disclosures: T.D.K.: Partly funded by an
   award from the Bayer Global Ophthalmology Awards Program.r F.v.A.:
   Research funding - Intramural Research Program of the National Eye
   Institute (EY000546); Grants - Nederlandse Oogonderzoek Stichting, Dr.
   P. Binkhorst Stichting, Stichting Dondersfonds, Prins Bernhard
   Cultuurfonds and Stichting A.F. Deutman Oogheelkunde Researchfonds.r
   P.R.: Consultant - Acuela, Apellis Boehringer-Ingetheim, Carol Zeiss
   Meditec, Cell Cure Neurosciences, Chengdu Kanghong Biotech, Isarna
   Therapeutics, Genetech, Healios K.K., Hemera Biosciences, F.
   Hoffman-LaRoche Ltd, Ocudyne, Ocunexus, Tyrogenex, Unity Biotechnology;
   Research support - Astellas Institute for Regenerative Medicine (AIRM),
   Carl Zeiss Medictec, Genentech, Tyrogenex; Equity interest: Apellis,
   Digisight, Ocudyne.r Supported by intramural program funds and contracts
   from the National Eye Institute/National Institutes of Health (NIH),
   Department of Health and Human Services, Bethesda, Maryland (contract
   HHS-N-260-2005-00007-C; ADB contract NO1-EY-5-0007). Funds were
   generously contributed to these contracts by the following NIH
   institutes: Office of Dietary Supplements, National Center for
   Complementary and Alternative Medicine; National Institute on Aging;
   National Heart, Lung, and Blood Institute; and National Institute of
   Neurological Disorders and Stroke. The sponsors and funding
   organizations participated in the design and conduct of the study; data
   collection, management, analysis, and interpretation; and the
   preparation, review, and approval of the manuscript.
CR Age-Related Eye Dis Study Res Grp, 2001, AM J OPHTHALMOL, V132, P668
   Anderson DH, 2010, PROG RETIN EYE RES, V29, P95, DOI 10.1016/j.preteyeres.2009.11.003
   Biarnes M, 2015, AM J OPHTHALMOL, V160, P345, DOI 10.1016/j.ajo.2015.05.009
   Bird AC, 2014, JAMA OPHTHALMOL, V132, P338, DOI 10.1001/jamaophthalmol.2013.5799
   Caire J, 2014, JAMA OPHTHALMOL, V132, P528, DOI 10.1001/jamaophthalmol.2013.8175
   Calippe B, 2017, IMMUNITY, V46, P261, DOI 10.1016/j.immuni.2017.01.006
   Chakravarthy U, 2010, BMC OPHTHALMOL, V10, DOI 10.1186/1471-2415-10-31
   Chew EY, 2012, OPHTHALMOLOGY, V119, P2282, DOI 10.1016/j.ophtha.2012.05.027
   Csaky K, 2017, INVEST OPHTH VIS SCI, V58, P3456, DOI 10.1167/iovs.17-22339
   Danis RP, 2015, CLIN OPHTHALMOL, V9, P2159, DOI 10.2147/OPTH.S92359
   Danis RP, 2013, INVEST OPHTH VIS SCI, V54, P4548, DOI 10.1167/iovs.13-11804
   Ding Y, 2017, GENETICS, V206, P119, DOI 10.1534/genetics.116.196998
   Dithmar S, 2000, INVEST OPHTH VIS SCI, V41, P2035
   Domalpally A, 2016, OPHTHALMOLOGY, V123, P2401, DOI 10.1016/j.ophtha.2016.06.025
   Feuer WJ, 2013, JAMA OPHTHALMOL, V131, P110, DOI 10.1001/jamaophthalmol.2013.572
   Fritsche LG, 2016, NAT GENET, V48, P134, DOI 10.1038/ng.3448
   GASS JDM, 1973, ARCH OPHTHALMOL-CHIC, V90, P206
   Grassmann F, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0126636
   Holz FG, 2007, AM J OPHTHALMOL, V143, P463, DOI 10.1016/j.ajo.2006.11.041
   Holz FG, 2017, OPHTHALMOLOGY, V124, P464, DOI 10.1016/j.ophtha.2016.12.002
   Humphries MM, 2012, EUR J HUM GENET, V20, P64, DOI 10.1038/ejhg.2011.151
   Joachim N, 2013, OPHTHALMOLOGY, V120, P2042, DOI 10.1016/j.ophtha.2013.03.029
   Kam JH, 2013, AM J PATHOL, V183, P480, DOI 10.1016/j.ajpath.2013.04.008
   Kawa MP, 2014, J IMMUNOL RES, V2014, DOI 10.1155/2014/483960
   Khanifar AA, 2012, RETINA-J RET VIT DIS, V32, P1884, DOI 10.1097/IAE.0b013e3182509778
   Klein ML, 2008, OPHTHALMOLOGY, V115, P1026, DOI 10.1016/j.ophtha.2007.08.030
   Klein ML, 2010, OPHTHALMOLOGY, V117, P1554, DOI 10.1016/j.ophtha.2009.12.012
   Klein R, 2008, AM J OPHTHALMOL, V146, P692, DOI 10.1016/j.ajo.2008.05.050
   Levy O, 2015, J NEUROSCI, V35, P13568, DOI 10.1523/JNEUROSCI.2468-15.2015
   Levy O, 2015, EMBO MOL MED, V7, P211, DOI 10.15252/emmm.201404524
   Lindblad AS, 2009, ARCH OPHTHALMOL-CHIC, V127, P1168, DOI 10.1001/archophthalmol.2009.198
   Micklisch S, 2017, J NEUROINFLAMM, V14, DOI 10.1186/s12974-016-0776-3
   Ong JM, 2003, CURR EYE RES, V27, P15, DOI 10.1076/ceyr.27.2.15.15460
   Ong JM, 2001, INVEST OPHTH VIS SCI, V42, P1891
   Roisman L, 2016, OPHTHALMOLOGY, V123, P1309, DOI 10.1016/j.ophtha.2016.01.044
   Rudnicka AR, 2012, OPHTHALMOLOGY, V119, P571, DOI 10.1016/j.ophtha.2011.09.027
   Sadda SR, 2018, OPHTHALMOLOGY, V125, P537, DOI 10.1016/j.ophtha.2017.09.028
   Sadda SR, 2016, RETINA-J RET VIT DIS, V36, P1806, DOI 10.1097/IAE.0000000000001283
   Schaal KB, 2016, OPHTHALMOLOGY, V123, P1060, DOI 10.1016/j.ophtha.2016.01.034
   Schmitz-Valckenberg S, 2016, RETINA-J RET VIT DIS, V36, P2250, DOI 10.1097/IAE.0000000000001258
   Schmitz-Valckenberg S, 2016, OPHTHALMOLOGY, V123, P361, DOI 10.1016/j.ophtha.2015.09.036
   Sleiman K, 2017, OPHTHALMOLOGY, V124, P1764, DOI 10.1016/j.ophtha.2017.06.032
   Sun S, 2017, STEM CELL RES THER, V8, DOI 10.1186/s13287-017-0584-4
   Sunness JS, 2007, OPHTHALMOLOGY, V114, P271, DOI 10.1016/j.ophtha.2006.09.016
   Sunness Janet S, 2008, J Vis Impair Blind, V102, P679
   Sunness JS, 1999, INVEST OPHTH VIS SCI, V40, P1761
   Swaroop A, 2009, ANNU REV GENOM HUM G, V10, P19, DOI 10.1146/annurev.genom.9.081307.164350
   Wang GF, 2014, EXP EYE RES, V119, P1, DOI 10.1016/j.exer.2013.11.009
   Yaspan BL, 2017, SCI TRANSL MED, V9, DOI 10.1126/scitranslmed.aaf1443
   Yehoshua Z, 2015, OSLI RETINA, V46, P772, DOI 10.3928/23258160-20150730-15
   Yehoshua Z, 2014, OPHTHALMOLOGY, V121, P693, DOI 10.1016/j.ophtha.2013.09.044
   Yehoshua Z, 2011, SEMIN OPHTHALMOL, V26, P167, DOI 10.3109/08820538.2011.577132
   Yehoshua Z, 2011, OPHTHALMOLOGY, V118, P679, DOI 10.1016/j.ophtha.2010.08.018
   Yu MZ, 2012, INVEST OPHTH VIS SCI, V53, P7684, DOI 10.1167/iovs.12-10069
NR 54
TC 75
Z9 76
U1 0
U2 8
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 0161-6420
EI 1549-4713
J9 OPHTHALMOLOGY
JI Ophthalmology
PD DEC
PY 2018
VL 125
IS 12
BP 1913
EP 1928
DI 10.1016/j.ophtha.2018.05.028
PG 16
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA HA5AF
UT WOS:000450278400018
PM 30060980
OA Green Accepted
DA 2022-11-30
ER

PT J
AU Liu, K
   Song, YP
   Xu, GZ
   Ye, J
   Wu, ZF
   Liu, XL
   Dong, XG
   Zhang, MZ
   Xing, YQ
   Zhu, SP
   Chen, X
   Shen, YC
   Huang, HY
   Yu, LY
   Ke, ZH
   Rosenfeld, PJ
   Kaiser, PK
   Ying, GS
   Sun, XD
   Xu, X
AF Liu, Kun
   Song, Yanping
   Xu, Gezhi
   Ye, Jian
   Wu, Zhifeng
   Liu, Xiaoling
   Dong, Xiaoguang
   Zhang, Mingzhi
   Xing, Yiqiao
   Zhu, Shaoping
   Chen, Xia
   Shen, Yinchen
   Huang, Hengye
   Yu, Liyun
   Ke, Zunhong
   Rosenfeld, Philip J.
   Kaiser, Peter K.
   Ying, Guishuang
   Sun, Xiaodong
   Xu, Xun
CA PHOENIX Study Grp
TI Conbercept for Treatment of Neovascular Age-related Macular
   Degeneration: Results of the Randomized Phase 3 PHOENIX Study
SO AMERICAN JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
ID RANIBIZUMAB; VEGF; PHARMACOKINETICS; INJECTION; EFFICACY; THERAPY;
   SAFETY
AB PURPOSE: Age-related macular degeneration (AMD) can cause irreversible vision loss leading to blindness. We aim to evaluate the efficacy and safety of intravitreal injections of 0.5 mg conbercept, a new anti vascular endothelial growth factor (anti-VEGF) drug, for treatment of AMD on a schedule more manageable for patients.
   DESIGN: A prospective, double-masked, multicenter, sham-controlled, phase III randomized trial.
   METHODS: PATIENTS: Patients with choroidal neovascularization (CNV) secondary to AMD were enrolled and randomized to the conbercept group or the sham control group. INTERVENTION: The conbercept group received intravitreal injections of conbercept (0.5 mg) once monthly for the first 3 months, then once quarterly until month 12 (3 + Q3M). The sham group received first 3 monthly sham injections and then 3 monthly injections of conbercept (0.5 mg) followed by quarterly administrations until month 12. MAIN OUTCOME MEASURES: The primary endpoint was mean change from baseline in best-corrected visual acuity (BCVA) at month 3.
   RESULTS: A total of 114 patients (91.9%) from 9 sites in China completed the 12-month study. At the 3-month primary endpoint, the mean changes in BCVA from baseline were + 9.20 letters in the conbercept group and + 2.02 letters in the sham group, respectively (P <.001). At 12 months, the mean changes from baseline in BCVA letter score were + 9.98 letters in the conbercept group and + 8.81 letters in the sham group (P =.64). The most common ocular adverse events were associated with intravitreal injections, such as conjunctival hemorrhage, and increased intraocular pressure.
   CONCLUSIONS: A conbercept dosing regimen of 3 initial monthly administrations followed by quarterly treatments is effective for treatment of AMD. In previous reports, other anti-VEGF agents were unable to maintain similar clinical benefits with the same regimen. (C) 2018 Elsevier Inc. All rights reserved.)
C1 [Liu, Kun; Zhu, Shaoping; Chen, Xia; Shen, Yinchen; Sun, Xiaodong; Xu, Xun] Shanghai Gen Hosp, Shanghai Engn Ctr Visual Sci & Photomed, Shanghai Key Lab Ocular Fundus Dis, Dept Ophthalmol, 100 Haining Rd, Shanghai 200080, Peoples R China.
   [Song, Yanping] Guangzhou Mil, Wuhan Gen Hosp, Dept Ophthalmol, Wuhan, Hubei, Peoples R China.
   [Xu, Gezhi] Fudan Univ, Dept Ophthalmol, Eye & ENT Hosp, Shanghai, Peoples R China.
   [Ye, Jian] Third Mil Med Univ, Daping Hosp, Inst Surg Res, Dept Ophthalmol, Chongqing, Peoples R China.
   [Wu, Zhifeng] Nanjing Med Univ, Wuxi Peoples Hosp 2, Dept Ophthalmol, Wuxi, Jiangsu, Peoples R China.
   [Liu, Xiaoling] Wenzhou Med Univ, Sch Optometry & Ophthalmol, Wenzhou, Zhejiang, Peoples R China.
   [Liu, Xiaoling] Wenzhou Med Univ, Hosp Eye, Wenzhou, Zhejiang, Peoples R China.
   [Dong, Xiaoguang] Qingdao Eye Hosp, Shandong Eye Inst, Dept Ophthalmol, Qingdao, Shandong, Peoples R China.
   [Zhang, Mingzhi] Joint Shantou Int Eye Ctr, Shantou, Guangdong, Peoples R China.
   [Xing, Yiqiao] Wuhan Univ, Renmin Hosp, Dept Ophthalmol, Wuhan, Hubei, Peoples R China.
   [Huang, Hengye] Shanghai Jiao Tong Univ, Sch Med, Sch Publ Hlth, Shanghai, Peoples R China.
   [Yu, Liyun; Ke, Zunhong] Chengdu Kanghong Biotechnol Inc, Chengdu, Sichuan, Peoples R China.
   [Rosenfeld, Philip J.] Univ Miami, Miller Sch Med, Bascom Palmer Eye Inst, Miami, FL 33136 USA.
   [Kaiser, Peter K.] Cleveland Clin, Cole Eye Inst, Cleveland, OH 44106 USA.
   [Ying, Guishuang] Univ Penn, Dept Ophthalmol, Ctr Preventat Ophthalmol & Biostat, Philadelphia, PA 19104 USA.
C3 Fudan University; Army Medical University; Nanjing Medical University;
   Wenzhou Medical University; Wenzhou Medical University; Shandong First
   Medical University & Shandong Academy of Medical Sciences; Wuhan
   University; Shanghai Jiao Tong University; Bascom Palmer Eye Institute;
   University of Miami; Cleveland Clinic Foundation; University of
   Pennsylvania
RP Xu, X (通讯作者)，Shanghai Gen Hosp, Shanghai Engn Ctr Visual Sci & Photomed, Shanghai Key Lab Ocular Fundus Dis, Dept Ophthalmol, 100 Haining Rd, Shanghai 200080, Peoples R China.
EM drxuxun@sjtu.edu.cn
RI wu, zhi/GXH-3041-2022
FU CHENGDU KANGHONG BIOTECHNOLOGY INC (CHENGDU, SICHUAN, China)
FX THIS WORK WAS SUPPORTED BY CHENGDU KANGHONG BIOTECHNOLOGY INC (CHENGDU,
   SICHUAN, China). The sponsor participated in the design of the study,
   conducting the study, data collection, data management, and preparation
   of the manuscript. The corresponding author had full access to all the
   data in the study and had final responsibility for the decision to
   submit for publication.
CR Brown DM, 2009, OPHTHALMOLOGY, V116, P57, DOI 10.1016/j.ophtha.2008.10.018
   Cahuzac V, 2018, OPHTHALMOLOGICA, V25, P1
   Campagne MV, 2014, J PATHOL, V232, P151, DOI 10.1002/path.4266
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P532
   Gonzalez VH, 2016, AM J OPHTHALMOL, V172, P72, DOI 10.1016/j.ajo.2016.09.012
   Haller JA, 2013, OPHTHALMOLOGY, V120, pS3, DOI 10.1016/j.ophtha.2013.01.057
   Heier JS, 2012, OPHTHALMOLOGY, V119, P2537, DOI 10.1016/j.ophtha.2012.09.006
   Hernandez-Pastor LJ, 2008, AM J HEALTH-SYST PH, V65, P1805, DOI 10.2146/ajhp070342
   Hikichi T, 2018, BRIT J OPHTHALMOL, V102, P97, DOI 10.1136/bjophthalmol-2017-310448
   Jaffe GJ, 2017, OPHTHALMOLOGY, V124, P224, DOI 10.1016/j.ophtha.2016.10.010
   Jager RD, 2004, RETINA-J RET VIT DIS, V24, P676, DOI 10.1097/00006982-200410000-00002
   Kawasaki R, 2010, OPHTHALMOLOGY, V117, P921, DOI 10.1016/j.ophtha.2009.10.007
   Li H, 2012, EXP EYE RES, V97, P154, DOI 10.1016/j.exer.2011.09.002
   Li XX, 2014, OPHTHALMOLOGY, V121, P1740, DOI 10.1016/j.ophtha.2014.03.026
   Lu XM, 2015, DRUG DES DEV THER, V9, DOI 10.2147/DDDT.S67536
   Martin DF, 2011, NEW ENGL J MED, V364, P1897, DOI 10.1056/NEJMoa1102673
   Mordenti J, 1999, TOXICOL PATHOL, V27, P536, DOI 10.1177/019262339902700507
   Qu JF, 2016, RETINA-J RET VIT DIS, V36, P926, DOI 10.1097/IAE.0000000000000875
   Regillo CD, 2008, AM J OPHTHALMOL, V145, P239, DOI 10.1016/j.ajo.2007.10.004
   Schmidt-Erfurth U, 2011, OPHTHALMOLOGY, V118, P831, DOI 10.1016/j.ophtha.2010.09.004
   Spilsbury K, 2000, AM J PATHOL, V157, P135, DOI 10.1016/S0002-9440(10)64525-7
   Yu DC, 2012, MOL THER, V20, P938, DOI 10.1038/mt.2011.285
   Zhang M, 2011, OPHTHALMOLOGY, V118, P672, DOI 10.1016/j.ophtha.2010.08.008
   Zhang M, 2009, PHARM RES-DORDR, V26, P204, DOI 10.1007/s11095-008-9718-9
   Zou Hai-dong, 2005, Zhonghua Yan Ke Za Zhi, V41, P15
NR 25
TC 75
Z9 83
U1 5
U2 23
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 0002-9394
EI 1879-1891
J9 AM J OPHTHALMOL
JI Am. J. Ophthalmol.
PD JAN
PY 2019
VL 197
BP 156
EP 167
DI 10.1016/j.ajo.2018.08.026
PG 12
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA HF6UK
UT WOS:000454373600019
PM 30148987
DA 2022-11-30
ER

PT J
AU Lin, SY
   Lin, CL
   Chang, CH
   Wu, HC
   Lin, CH
   Kao, CH
AF Lin, S. -Y.
   Lin, C. -L.
   Chang, C. -H.
   Wu, H. -C.
   Lin, C. -H.
   Kao, C. -H.
TI Risk of age-related macular degeneration in patients with prostate
   cancer: a nationwide, population-based cohort study
SO ANNALS OF ONCOLOGY
LA English
DT Article
DE prostate cancer; age-related macular degeneration; cohort study
ID OXIDATIVE STRESS; TESTOSTERONE DEFICIENCY; INSULIN-RESISTANCE;
   DIHYDROTESTOSTERONE; DISEASE; TRIAL; SEX
AB Background: Prostate cancer (PC) can be related to increased systemic oxidative stress and dihydrotestosterone level, which are also reported to be involved in the pathogenesis of age-related macular degeneration (AMD). We conducted a cohort study to determine whether patients with PC have an increased risk of AMD.
   Patients and methods: Data were collected from the Taiwan Longitudinal Health Insurance Database for the 1999-2010 period. The study PC cohort comprised 22 084 patients aged >= 18 years with a first diagnosis of PC. The comparison cohort consisted of age-, occupation-, and urbanization level-matched patients at a ratio of 1 : 1. The primary outcome was the incidence of AMD, which was evaluated using Kaplan-Meier survival analysis and proportional hazards modeling.
   Results: The mean follow-up periods (standard deviation) for the patients with AMD in the age-, occupation-, and urbanization level-matched PC cohort and non-PC cohorts were 4.69 (2.90) and 5.51 (2.82) years. The mean age of the PC cohort was 73.9 years and that of the non-PC cohort was 73.2 years, with approximately 85.9% of the patients aged >65 years. The PC cohort had a higher risk of AMD than did the propensity score-matched non-PC cohort with an adjusted hazard ratio of 1.25 (95% confidence interval, 1.12-1.39). Compared with PC cohort receiving no injection hormone therapy, the PC cohort receiving injection hormone therapy had a lower risk of AMD (adjusted hazard ratio, 0.56; 95% confidence interval, 0.41-0.76).
   Conclusion: PC is associated with an increased risk of AMD. Patients with PC receiving injected form of androgen deprivation therapy had a lower risk of AMD than patients with PC not receiving injected form of androgen-deprivation therapy.
C1 [Lin, S. -Y.] China Med Univ, Inst Clin Med Sci, Coll Med, Taichung, Taiwan.
   [Lin, S. -Y.] China Med Univ Hosp, Div Nephrol, Taichung, Taiwan.
   [Lin, S. -Y.] China Med Univ Hosp, Kidney Inst, Taichung, Taiwan.
   [Lin, C. -L.] China Med Univ Hosp, Management Off Hlth Data, Taichung, Taiwan.
   [Lin, C. -L.] China Med Univ, Coll Med, Taichung, Taiwan.
   [Chang, C. -H.; Wu, H. -C.] China Med Univ Hosp, Dept Urol, Taichung, Taiwan.
   [Lin, C. -H.] China Med Univ Hosp, Family Med, Taichung, Taiwan.
   [Kao, C. -H.] China Med Univ, Grad Inst Clin Med Sci, Coll Med, Taichung, Taiwan.
   [Kao, C. -H.] China Med Univ, Sch Med, Coll Med, Taichung, Taiwan.
   [Kao, C. -H.] China Med Univ Hosp, Dept Nucl Med, Taichung, Taiwan.
   [Kao, C. -H.] China Med Univ Hosp, PET Ctr, Taichung, Taiwan.
   [Kao, C. -H.] Asia Univ, Dept Bioinformat & Med Engn, Taichung, Taiwan.
C3 China Medical University Taiwan; China Medical University Taiwan; China
   Medical University Hospital - Taiwan; China Medical University Taiwan;
   China Medical University Hospital - Taiwan; China Medical University
   Taiwan; China Medical University Hospital - Taiwan; China Medical
   University Taiwan; China Medical University Taiwan; China Medical
   University Hospital - Taiwan; China Medical University Taiwan; China
   Medical University Hospital - Taiwan; China Medical University Taiwan;
   China Medical University Taiwan; China Medical University Taiwan; China
   Medical University Hospital - Taiwan; China Medical University Taiwan;
   China Medical University Hospital - Taiwan; Asia University Taiwan
RP Kao, CH (通讯作者)，China Med Univ, Grad Inst Clin Med Sci, 2 Yuh Der Rd, Taichung 404, Taiwan.; Kao, CH (通讯作者)，China Med Univ, Sch Med, 2 Yuh Der Rd, Taichung 404, Taiwan.
EM d10040@mail.cmuh.org.tw
FU Taiwan Ministry of Health and Welfare Clinical Trial Center
   [MOHW106-TDU-B-212-113 004]; China Medical University Hospital; Academia
   Sinica Taiwan Biobank Stroke Biosignature Project [BM10601010036];
   Taiwan Clinical Trial Consortium for Stroke [MOST 106-2321-B-039-005];
   Tseng-Lien Lin Foundation, Taichung, Taiwan; Taiwan Brain Disease
   Foundation, Taipei, Taiwan; Katsuzo and Kiyo AoshimaMemorial Funds,
   Japan
FX This study was supported in part by Taiwan Ministry of Health and
   Welfare Clinical Trial Center (MOHW106-TDU-B-212-113 004), China Medical
   University Hospital, Academia Sinica Taiwan Biobank Stroke Biosignature
   Project (BM10601010036), Taiwan Clinical Trial Consortium for Stroke
   (MOST 106-2321-B-039-005), Tseng-Lien Lin Foundation, Taichung, Taiwan
   (no grant numbers apply), Taiwan Brain Disease Foundation, Taipei,
   Taiwan (no grant numbers apply), and Katsuzo and Kiyo AoshimaMemorial
   Funds, Japan (no grant numbers apply). The funders had no role in study
   design, data collection and analysis, decision to publish, or
   preparation of the manuscript. No additional external funding received
   for this study.
CR Aydin A, 2006, CLIN BIOCHEM, V39, P176, DOI 10.1016/j.clinbiochem.2005.11.018
   Beatty S, 2000, SURV OPHTHALMOL, V45, P115, DOI 10.1016/S0039-6257(00)00140-5
   Casagrande S, 2012, BEHAV ECOL SOCIOBIOL, V66, P1319, DOI 10.1007/s00265-012-1387-3
   Chang KH, 2011, P NATL ACAD SCI USA, V108, P13728, DOI 10.1073/pnas.1107898108
   Chopdar A, 2003, BRIT MED J, V326, P485, DOI 10.1136/bmj.326.7387.485
   Cooper DA, 1999, NUTR REV, V57, P201, DOI 10.1111/j.1753-4887.1999.tb06944.x
   Defay R, 2004, ANN EPIDEMIOL, V14, P202, DOI 10.1016/S1047-2797(03)00130-3
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1417, DOI 10.1001/archopht.119.10.1417
   Khandrika L, 2009, CANCER LETT, V282, P125, DOI 10.1016/j.canlet.2008.12.011
   Khera M, 2014, EUR UROL, V65, P115, DOI 10.1016/j.eururo.2013.08.015
   Lee MN, 2008, J VET SCI, V9, P247, DOI 10.4142/jvs.2008.9.3.247
   Li XQ, 2011, INVEST OPHTH VIS SCI, V52, P8438, DOI 10.1167/iovs.11-8108
   Lim LS, 2012, LANCET, V379, P1728, DOI 10.1016/S0140-6736(12)60282-7
   Lin JN, 2015, LANCET ONCOL, V16, P1335, DOI 10.1016/S1470-2045(15)00060-1
   Lin SY, 2016, AM J TRANSPLANT, V16, P2925, DOI 10.1111/ajt.13822
   Liu SH, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0011302
   Martin DF, 2012, OPHTHALMOLOGY, V119, DOI 10.1016/j.ophtha.2012.03.053
   Muller RL, 2012, EUR UROL, V62, P757, DOI 10.1016/j.eururo.2012.05.025
   Nishiyama T, 2004, CLIN CANCER RES, V10, P7121, DOI 10.1158/1078-0432.CCR-04-0913
   Schwartz SD, 2015, LANCET, V385, P509, DOI 10.1016/S0140-6736(14)61376-3
   Traish AM, 2009, J ANDROL, V30, P23, DOI 10.2164/jandrol.108.005751
   Wheeler L, 2003, SURV OPHTHALMOL, V48, pS47, DOI 10.1016/S0039-6257(03)00004-3
   Yu TM, 2016, LANCET ONCOL, V17, pE476, DOI 10.1016/S1470-2045(16)30528-9
   Yu TM, 2016, SCI REP-UK, V6, DOI 10.1038/srep21312
   Zhang K, 2011, P NATL ACAD SCI USA, V108, P6241, DOI 10.1073/pnas.1018987108
   Zitzmann M, 2009, NAT REV ENDOCRINOL, V5, P673, DOI 10.1038/nrendo.2009.212
NR 26
TC 6
Z9 6
U1 0
U2 5
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 0923-7534
EI 1569-8041
J9 ANN ONCOL
JI Ann. Oncol.
PD OCT
PY 2017
VL 28
IS 10
BP 2575
EP 2580
DI 10.1093/annonc/mdx402
PG 6
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA FI3AQ
UT WOS:000411827200036
PM 28961846
OA Bronze
DA 2022-11-30
ER

PT J
AU Karthikeyan, B
   Harini, L
   Krishnakumar, V
   Kannan, VR
   Sundar, K
   Kathiresan, T
AF Karthikeyan, Bose
   Harini, Lakshminarasimhan
   Krishnakumar, Vaithilingam
   Kannan, Velu Rajesh
   Sundar, Krishnan
   Kathiresan, Thandavarayan
TI Insights on the involvement of (-)-epigallocatechin gallate in ER
   stress-mediated apoptosis in age-related macular degeneration
SO APOPTOSIS
LA English
DT Article
DE AMD; Akt; Caspase; EGCG; ER-mitochondrial tether site; Intracellular
   calcium; ROS
ID ENDOPLASMIC-RETICULUM STRESS; OXIDATIVE STRESS;
   EPIGALLOCATECHIN-3-GALLATE EGCG; SIGNALING PATHWAYS; CELLS;
   NANOPARTICLES; POLYPHENOLS; CASPASE-12
AB Endoplasmic reticulum (ER) stress-mediated apoptosis is a well-known factor in the pathogenesis of age-related macular degeneration (AMD). ER stress leads to accumulation of misfolded proteins, which in turn activates unfolded protein response (UPR) of the cell for its survival. The prolonged UPR of ER stress promotes cell death; however, the transition between adaptation and ER stress-induced apoptosis has not been clearly understood. Hence, the present study investigates the regulatory effect of (-)-epigallocatechin gallate (EGCG) on ER stress-induced by hydrogen peroxide (H2O2) and disturbance of calcium homeostasis by thapsigargin (TG) in mouse retinal pigment epithelial (MRPE) cells. The oxidant molecules influenced MRPE cells showed an increased level of intracellular calcium [Ca2+](i) in ER and transferred to mitochondria through ER-mitochondrial tether site then increased ROS production. EGCG restores [Ca2+](i) homeostasis by decreasing ROS production through inhibition of prohibitin1 which regulate ER-mitochondrial tether site and inhibit apoptosis. Effect of EGCG on ER stress-mediated apoptosis was elucidated by exploring the UPR signalling pathways. EGCG downregulated GRP78, CHOP, PERK, ERO1 alpha, IRE1 alpha, cleaved PARP, cleaved caspase 3, caspase 12 and upregulated expression of calnexinin MRPE cells. In addition to this, inhibition of apoptosis by EGCG was also confirmed with expression of proteins Akt, PTEN and GSK3 beta. MRPE cells with EGCG upregulates phosphorylation of Akt at ser473 and phospho ser380 of PTEN, but phosphorylation at ser9 of GSK3 beta was inhibited. Further, constitutively active (myristoylated) CA-Akt transfected in MRPE cells had an increased Akt activity in EGCG influenced cells. These findings strongly suggest that antioxidant molecules inhibit cell death through the proper balancing of [Ca2+](i) and ROS production in order to maintain UPR of ER in MRPE cells. Thus, modulation of UPR signalling may provide a potential target for the therapeutic approaches of AMD.
C1 [Karthikeyan, Bose; Harini, Lakshminarasimhan; Sundar, Krishnan; Kathiresan, Thandavarayan] Kalasalingam Univ, Dept Biotechnol, Krishnankoil 626126, Tamil Nadu, India.
   [Karthikeyan, Bose] Cleveland Clin, Cole Eye Inst, Dept Ophthalm Res, Cleveland, OH 44195 USA.
   [Krishnakumar, Vaithilingam; Kannan, Velu Rajesh] Bharathidasan Univ, Dept Microbiol, Tiruchirappalli 620024, Tamil Nadu, India.
   [Sundar, Krishnan; Kathiresan, Thandavarayan] Kalasalingam Univ, Int Res Ctr, Krishnankoil 626126, Tamil Nadu, India.
C3 Kalasalingam Academy of Research & Education; Cleveland Clinic
   Foundation; Bharathidasan University; Kalasalingam Academy of Research &
   Education
RP Kathiresan, T (通讯作者)，Kalasalingam Univ, Dept Biotechnol, Krishnankoil 626126, Tamil Nadu, India.; Kathiresan, T (通讯作者)，Kalasalingam Univ, Int Res Ctr, Krishnankoil 626126, Tamil Nadu, India.
EM t.kathiresan@klu.ac.in
RI Bose, Karthikeyan/GRN-8684-2022; Sundar, Krishnan/E-2748-2015
OI Sundar, Krishnan/0000-0001-7156-1057
FU Department of Science and Technology (SERB) of India
   [SB/FT/LS-204/2012]; Council of Scientific and Industrial Research
   (CSIR), India [09/1012 (0005) 2K11-EMR-I]
FX This study was supported in part by a Grant-in-Aid from Department of
   Science and Technology (SERB) of India (SB/FT/LS-204/2012) to T. K. B.
   K. is the recipient of senior research fellowship (09/1012 (0005)
   2K11-EMR-I) from the Council of Scientific and Industrial Research
   (CSIR), India.
CR Abrahan CE, 2010, INVEST OPHTH VIS SCI, V51, P1171, DOI 10.1167/iovs.09-3909
   Ambati J, 2013, NAT REV IMMUNOL, V13, P438, DOI 10.1038/nri3459
   Bae JH, 2002, BIOCHEM BIOPH RES CO, V290, P1506, DOI 10.1006/bbrc.2002.6372
   Bose K, 2016, ARTIF CELL NANOMED B, V44, P1764, DOI 10.3109/21691401.2015.1102739
   Brantley MA, 2012, AM J OPHTHALMOL, V153, P460, DOI 10.1016/j.ajo.2011.08.033
   Brewster JL, 2006, MOL CELL NEUROSCI, V32, P242, DOI 10.1016/j.mcn.2006.04.006
   Brown MK, 2012, FRONT PHYSIOL, V3, DOI 10.3389/fphys.2012.00263
   Causin P, 2015, BIOMECHANICS MODELIN, V15, P525
   Chan CM, 2008, MOL VIS, V14, P2528
   Chen C, 2014, ANTIOXID REDOX SIGN, V20, P2091, DOI 10.1089/ars.2013.5240
   Cheng CWJ, 2015, EUR J PHARMACOL, V770, P16
   Choi YT, 2001, LIFE SCI, V70, P603, DOI 10.1016/S0024-3205(01)01438-2
   Fritsche LG, 2014, ANNU REV GENOM HUM G, V15, P151, DOI 10.1146/annurev-genom-090413-025610
   Goetz JG, 2007, J CELL SCI, V120, P3553, DOI 10.1242/jcs.03486
   Hanus J, 2015, INVEST OPHTH VIS SCI, V56, P5048, DOI 10.1167/iovs.15-16401
   He SK, 2008, GRAEF ARCH CLIN EXP, V246, P677, DOI 10.1007/s00417-008-0770-2
   He Y, 2014, INVEST OPHTH VIS SCI, V55, DOI 10.1167/iovs.14-14696
   Hetz C, 2012, NAT REV MOL CELL BIO, V13, P89, DOI 10.1038/nrm3270
   Higdon JV, 2003, CRIT REV FOOD SCI, V43, P89, DOI 10.1080/10408690390826464
   Hogg RE, 2006, PROG RETIN EYE RES, V25, P249, DOI 10.1016/j.preteyeres.2005.11.002
   Hu P, 2004, J BIOL CHEM, V279, P49420, DOI 10.1074/jbc.M407700200
   Huber AL, 2013, MOL CELL, V49, P1049, DOI 10.1016/j.molcel.2013.01.009
   Juel HB, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0064619
   Karthikeyan B, 2016, BIOL TRACE ELEM RES, V170, P390, DOI 10.1007/s12011-015-0493-2
   Karthikeyan B, 2010, EXP EYE RES, V91, P769, DOI 10.1016/j.exer.2010.09.003
   Kathiria AS, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0031231
   Khan N, 2006, CANCER RES, V66, P2500, DOI 10.1158/0008-5472.CAN-05-3636
   Kim MJ, 2009, AM J CHINESE MED, V37, P723, DOI 10.1142/S0192415X09007193
   Lee JH, 2015, ONCOTARGET, V6, P9701, DOI 10.18632/oncotarget.3832
   Lee YW, 2010, CYTOKINE, V49, P73, DOI 10.1016/j.cyto.2009.08.009
   Libby RT, 2010, ADV EXP MED BIOL, V664, P403, DOI 10.1007/978-1-4419-1399-9_46
   Lim LS, 2012, LANCET, V379, P1728, DOI 10.1016/S0140-6736(12)60282-7
   Logue SE, 2013, APOPTOSIS, V18, P537, DOI 10.1007/s10495-013-0818-6
   Mandel SA, 2008, J ALZHEIMERS DIS, V15, P211
   Nagle DG, 2006, PHYTOCHEMISTRY, V67, P1849, DOI 10.1016/j.phytochem.2006.06.020
   Nakagawa T, 2000, NATURE, V403, P98, DOI 10.1038/47513
   Olchawa MM, 2015, FREE RADICAL BIO MED, V89, P873, DOI 10.1016/j.freeradbiomed.2015.10.411
   Saadat KASM, 2014, FEBS OPEN BIO, V4, P1007, DOI 10.1016/j.fob.2014.11.003
   Salminen A, 2010, MOL MED, V16, P535, DOI 10.2119/molmed.2010.00070
   Schroder M, 2005, ANNU REV BIOCHEM, V74, P739, DOI 10.1146/annurev.biochem.73.011303.074134
   Simo R, 2010, J BIOMED BIOTECHNOL, DOI 10.1155/2010/190724
   Strauss O, 2005, PHYSIOL REV, V85, P845, DOI 10.1152/physrev.00021.2004
   Sunness JS, 1999, MOL VIS, V5
   Sur A, 2014, P NATL ACAD SCI USA, V111, P16754, DOI 10.1073/pnas.1419576111
   Swaroop A, 2009, ANNU REV GENOM HUM G, V10, P19, DOI 10.1146/annurev.genom.9.081307.164350
   Szegezdi E, 2003, ANN NY ACAD SCI, V1010, P186, DOI 10.1196/annals.1299.032
   Szegezdi E, 2006, EMBO REP, V7, P880, DOI 10.1038/sj.embor.7400779
   Theiss AL, 2011, BBA-MOL CELL RES, V1813, P1137, DOI 10.1016/j.bbamcr.2011.01.033
   Whitcup SM, 2013, INT J INFLAMM, V2013, DOI 10.1155/2013/348092
   Yang Seong-Won, 2007, Korean J Ophthalmol, V21, P232, DOI 10.3341/kjo.2007.21.4.232
   Yao JQ, 2013, PROTEOM CLIN APPL, V7, P550, DOI 10.1002/prca.201200012
   Zarbin MA, 2004, ARCH OPHTHALMOL-CHIC, V122, P598, DOI 10.1001/archopht.122.4.598
   Zarbin MA, 2010, RETINA-J RET VIT DIS, V30, P1350, DOI 10.1097/IAE.0b013e3181f57e30
   Zhang SX, 2014, EXP EYE RES, V125, P30, DOI 10.1016/j.exer.2014.04.015
NR 54
TC 18
Z9 19
U1 1
U2 22
PU SPRINGER
PI DORDRECHT
PA VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS
SN 1360-8185
EI 1573-675X
J9 APOPTOSIS
JI Apoptosis
PD JAN
PY 2017
VL 22
IS 1
BP 72
EP 85
DI 10.1007/s10495-016-1318-2
PG 14
WC Biochemistry & Molecular Biology; Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Cell Biology
GA EI2IH
UT WOS:000392309800005
PM 27778132
DA 2022-11-30
ER

PT J
AU Xue, CC
   Cui, J
   Gao, LQ
   Zhang, C
   Dou, HL
   Chen, DN
   Wang, YX
   Jonas, JB
AF Xue, Can Can
   Cui, Jing
   Gao, Li Qin
   Zhang, Chun
   Dou, Hong Liang
   Chen, Dong Ning
   Wang, Ya Xing
   Jonas, Jost B.
TI Peripheral Monocyte Count and Age-Related Macular Degeneration. The
   Tongren Health Care Study
SO AMERICAN JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
ID RISK; HYDROXYAPATITE; PREVALENCE; ACTIVATION; CALCIUM; CHINA; BLOOD
AB PURPOSE: To assess potential associations between the prevalence of age-related macular degeneration (AMD) and systemic parameters in a Chinese population.
   DESIGN: Cross-sectional study.
   METHODS: The Tongren Health Care Study included individuals attending regular health care check-up exam-inations in the Beijing Tongren Hospital from 2017 to 2019. Detailed medical examinations and ophthalmic examinations were applied, including fundus photography. AMD was evaluated according to the Beckman Initiative guidelines.
   RESULTS: The study included 7,719 participants (mean age: 60.5 +/- 8.1 years; range: 50-97 years). The preva-lence of any, early, intermediate, and late AMD was 1,607 of 7,719 (20.8%; 95% confidence interval [CI]: 20.1%, 21.9%), 832 of 7,719 (10.8%; 95% CI: 10.1%, 11.5%), 733 of 7,719 (9.5%; 95% CI: 8.9%, 10.2%), and 42 of 7,719 (0.50%; 95% CI: 0.40%, 0.70%), respectively. In multivariate analysis, the prevalence of any AMD in-creased with higher blood monocyte count (odds ratio [OR]:3.49; 95% CI: 2.26, 5.38; P < .001), after adjust-ing for older age (OR: 1.06; 95% CI: 1.05, 1.07; P < .001), higher serum concentration of calcium (OR: 2.52; 95% CI: 1.32, 4.84; P = .005), high-density lipoproteins (OR: 1.39; 95% CI: 1.19, 1.61; P < .001), and lower lipoprotein a (OR: 0.99; 95% CI: 0.98, 0.99; P = .02). Similar findings were obtained for the prevalence of in-termediate and late AMD combined. The association between higher monocyte count and higher AMD prevalence showed the highest odds ratio for the age group of 50-59 years (any AMD: OR: 4.35, P < .001; interme-diate and late AMD: OR: 6.14, P < .001). Individuals with a monocyte count of >= 0.5 x 10(9)/L as compared to participants with a monocyte of 0.1-0.4 x 10(9)/L had a 1.45-fold increased risk for any AMD (OR: 1.45; 95% CI: 1.27, 1.64; P < .001) and 1.58 fold increase risk for intermediate/late AMD (OR: 1.58; 95% CI: 1.33, 1.87; P < .001).
   CONCLUSION: A higher prevalence of early AMD, intermediate AMD, late AMD, and any AMD was as-sociated with a higher peripheral monocyte count. In agreement with previous studies, the observation suggests monocytes playing a role in the pathogenesis of AMD. (C) 2021 Else-vier Inc. All rights reserved.
C1 [Xue, Can Can; Wang, Ya Xing; Jonas, Jost B.] Capital Med Univ, Beijing Inst Ophthalmol, Beijing Tongren Hosp, Beijing Ophthalmol & Visual Sci Key Lab, Beijing, Peoples R China.
   [Cui, Jing; Chen, Dong Ning] Capital Med Univ, Dept Phys Examinat, Beijing Tongren Hosp, Beijing, Peoples R China.
   [Gao, Li Qin] Capital Med Univ, Dept Ophthalmol, Beijing Tongren Hosp, Beijing, Peoples R China.
   [Xue, Can Can; Zhang, Chun; Dou, Hong Liang] Peking Univ Third Hosp, Dept Ophthalmol, Beijing, Peoples R China.
   [Jonas, Jost B.] Heidelberg Univ, Dept Ophthalmol, Med Fac Mannheim, Mannheim, Germany.
   [Jonas, Jost B.] Inst Clin & Sci Ophthalmol & Acupuncture Jonas &, Heidelberg, Germany.
   [Jonas, Jost B.] Inst Mol & Clin Ophthalmol, Basel, Switzerland.
C3 Capital Medical University; Capital Medical University; Capital Medical
   University; Peking University; Ruprecht Karls University Heidelberg
RP Chen, DN; Wang, YX (通讯作者)，Beijing Tongren Hosp, 1 Dongjiaomin Lane, Beijing 100730, Peoples R China.
EM tr13501082964@163.com; tr13501082964@163.com
RI wang, YA XING/K-9671-2016; Xue, Cancan/GXG-2544-2022
OI wang, YA XING/0000-0003-2749-7793; Jonas, Jost/0000-0003-2972-5227; Xue,
   Cancan/0000-0002-2747-6215
FU Major Research Funding of Beijing Institute of Ophthalmology [2019002]
FX Major Research Funding of Beijing Institute of Ophthalmology, #2019002.
CR Ban N, 2018, JCI INSIGHT, V3, DOI 10.1172/jci.insight.120824
   Beguier F, 2020, IMMUNITY, V53, P429, DOI 10.1016/j.immuni.2020.07.021
   Behnke V, 2020, CELL MOL LIFE SCI, V77, P781, DOI 10.1007/s00018-019-03419-4
   Brelen ME, 2019, JAMA OPHTHALMOL, V137, P550, DOI 10.1001/jamaophthalmol.2019.0291
   Cherepanoff S, 2010, BRIT J OPHTHALMOL, V94, P918, DOI 10.1136/bjo.2009.165563
   Colijn JM, 2019, OPHTHALMOLOGY, V126, P393, DOI 10.1016/j.ophtha.2018.09.045
   Cousins SW, 2004, ARCH OPHTHALMOL-CHIC, V122, P1013, DOI 10.1001/archopht.122.7.1013
   Espinosa-Heidmann DG, 2003, INVEST OPHTH VIS SCI, V44, P3586, DOI 10.1167/iovs.03-0038
   Feng C, 2020, MECH AGEING DEV, V191, DOI 10.1016/j.mad.2020.111353
   Ferris FL, 2013, OPHTHALMOLOGY, V120, P844, DOI 10.1016/j.ophtha.2012.10.036
   Flaxman SR, 2017, LANCET GLOB HEALTH, V5, pE1221, DOI 10.1016/S2214-109X(17)30393-5
   Fletcher EL, 2020, OPHTHAL PHYSL OPT, V40, P128, DOI 10.1111/opo.12671
   Flinn JM, 2014, METALLOMICS, V6, P1223, DOI 10.1039/c4mt00058g
   Gopinath B, 2014, BRIT J NUTR, V111, P1673, DOI 10.1017/S000711451300408X
   Guillonneau X, 2017, PROG RETIN EYE RES, V61, P98, DOI 10.1016/j.preteyeres.2017.06.002
   Jin GM, 2018, BRIT J OPHTHALMOL, V102, P625, DOI 10.1136/bjophthalmol-2017-310368
   Jonas JB, 2010, ARCH OPHTHALMOL-CHIC, V128, P1281, DOI 10.1001/archophthalmol.2010.227
   Kakigi CLM, 2015, JAMA OPHTHALMOL, V133, P746, DOI 10.1001/jamaophthalmol.2015.0514
   Kapellos TS, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.02035
   Keel S, 2017, JAMA OPHTHALMOL, V135, P1242, DOI 10.1001/jamaophthalmol.2017.4182
   Kersten E, 2018, SURV OPHTHALMOL, V63, P9, DOI 10.1016/j.survophthal.2017.05.003
   Lambert NG, 2016, PROG RETIN EYE RES, V54, P64, DOI 10.1016/j.preteyeres.2016.04.003
   Lechner J, 2017, J NEUROINFLAMM, V14, DOI 10.1186/s12974-017-0820-y
   Lengyel, JAMA OPHTHALMOL, P2021, DOI [10.1001/jamaophthalmol.2019.2725. 2019.09.19, DOI 10.1001/JAMAOPHTHALMOL.2019.2725.2019.09.19]
   Levey AS, 2009, ANN INTERN MED, V150, P604, DOI 10.7326/0003-4819-150-9-200905050-00006
   Liberale L, 2017, EUR J CLIN INVEST, V47, P702, DOI 10.1111/eci.12795
   Merle BMJ, 2017, INVEST OPHTH VIS SCI, V58, P4569, DOI 10.1167/iovs.17-21673
   Mimura T, 2019, OPHTHALMOLOGICA, V241, P81, DOI 10.1159/000490153
   Mitchell P, 2018, LANCET, V392, P1147, DOI 10.1016/S0140-6736(18)31550-2
   Nasir K, 2005, ARTERIOSCL THROM VAS, V25, P1966, DOI 10.1161/01.ATV.0000175296.02550.e4
   Nielsen MK, 2020, INVEST OPHTH VIS SCI, V61, DOI 10.1167/iovs.61.4.28
   Paun CC, 2015, INVEST OPHTH VIS SCI, V56, P7766, DOI 10.1167/iovs.15-17035
   Pilgrim MG, 2017, INVEST OPHTH VIS SCI, V58, DOI 10.1167/iovs.16-21060
   Rozing MP, 2020, PROG RETIN EYE RES, V76, DOI 10.1016/j.preteyeres.2019.100825
   Sakurai E, 2003, INVEST OPHTH VIS SCI, V44, P3578, DOI 10.1167/iovs.03-0097
   Scott MKD, 2019, LANCET RESP MED, V7, P497, DOI 10.1016/S2213-2600(18)30508-3
   Shigeta K, 2016, ANN SURG ONCOL, V23, P4115, DOI 10.1245/s10434-016-5354-5
   Subhi Y, ACTA OPHTHALMOL, V2021, DOI [10.1111/ aos. 14402. 2020.03.16, DOI 10.1111/AOS.14402.2020.03.16]
   Subhi Y, 2017, INVEST OPHTH VIS SCI, V58, P5242, DOI 10.1167/iovs.17-22479
   Tan ACS, 2018, SCI TRANSL MED, V10, DOI 10.1126/scitranslmed.aat4544
   Thompson RB, 2015, P NATL ACAD SCI USA, V112, P1565, DOI 10.1073/pnas.1413347112
   Tisdale AK, 2019, JAMA OPHTHALMOL, V137, P543, DOI 10.1001/jamaophthalmol.2019.0292
   ULSHAFER RJ, 1987, INVEST OPHTH VIS SCI, V28, P683
   Viera AJ, 2005, FAM MED, V37, P360
   Wang KT, 2020, DIAGNOSTICS, V10, DOI 10.3390/diagnostics10050287
   Wang YF, 2016, NUTRIENTS, V8, DOI 10.3390/nu8100663
   Xu L, 2006, BRIT J OPHTHALMOL, V90, P1087, DOI 10.1136/bjo.2006.096123
NR 47
TC 2
Z9 2
U1 0
U2 3
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 0002-9394
EI 1879-1891
J9 AM J OPHTHALMOL
JI Am. J. Ophthalmol.
PD JUL
PY 2021
VL 227
BP 143
EP 153
DI 10.1016/j.ajo.2021.03.010
EA APR 2021
PG 11
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA SP2EZ
UT WOS:000659487300016
PM 33737032
DA 2022-11-30
ER

PT J
AU Gurubaran, IS
   Helotera, H
   Marry, S
   Koskela, A
   Hyttinen, JMT
   Paterno, JJ
   Urtti, A
   Chen, M
   Xu, HP
   Kauppinen, A
   Kaarniranta, K
AF Gurubaran, Iswariyaraja Sridevi
   Helotera, Hanna
   Marry, Stephen
   Koskela, Ali
   Hyttinen, Juha M. T.
   Paterno, Jussi J.
   Urtti, Arto
   Chen, Mei
   Xu, Heping
   Kauppinen, Anu
   Kaarniranta, Kai
TI Oxidative Stress and Mitochondrial Damage in Dry Age-Related Macular
   Degeneration Like NFE2L2/PGC-1 alpha (-/-) Mouse Model Evoke Complement
   Component C5a Independent of C3
SO BIOLOGY-BASEL
LA English
DT Article
DE aging; oxidative stress; mitochondrial damage; age-related macular
   degeneration; inflammation; complement system; Toll-like receptors;
   complement factor H; thrombin; C-reactive protein; receptor for advanced
   glycation end products
ID GLYCATION END-PRODUCTS; TOLL-LIKE RECEPTOR-3; PIGMENT EPITHELIAL-CELLS;
   REACTIVE PROTEIN; FACTOR-H; INNATE IMMUNITY; CHRONIC INFLAMMATION; NLRP3
   INFLAMMASOME; ACTIVATION; SYSTEM
AB Simple Summary Age-related macular degeneration (AMD) is an eye disease that results in permanent loss of vision due to degeneration in the central portion of the retina called the macula. Patients with severe visual loss have reduced quality of life and the risk of death is 2.4 times higher than the general population. Currently, there is no treatment to stop or cure dry AMD. Aging-associated chronic oxidative stress and inflammation are known to be involved in AMD pathology. To investigate the molecular mechanism behind the cause and to develop novel therapy, we have created and validated an animal model mimicking clinical features of dry AMD. Here, we show previously unknown thrombin-mediated complement component C5a activation in the degenerative retina without upregulation of C3. Our model might provide insight into AMD progression and help to develop novel therapies. Aging-associated chronic oxidative stress and inflammation are known to be involved in various diseases, e.g., age-related macular degeneration (AMD). Previously, we reported the presence of dry AMD-like signs, such as elevated oxidative stress, dysfunctional mitophagy and the accumulation of detrimental oxidized materials in the retinal pigment epithelial (RPE) cells of nuclear factor erythroid 2-related factor 2, and a peroxisome proliferator-activated receptor gamma coactivator 1-alpha (NFE2L2/PGC1 alpha) double knockout (dKO) mouse model. Here, we investigated the dynamics of inflammatory markers in one-year-old NFE2L2/PGC1 alpha dKO mice. Immunohistochemical analysis revealed an increase in levels of Toll-like receptors 3 and 9, while those of NOD-like receptor 3 were decreased in NFE2L2/PGC1 alpha dKO retinal specimens as compared to wild type animals. Further analysis showed a trend towards an increase in complement component C5a independent of component C3, observed to be tightly regulated by complement factor H. Interestingly, we found that thrombin, a serine protease enzyme, was involved in enhancing the terminal pathway producing C5a, independent of C3. We also detected an increase in primary acute phase C-reactive protein and receptor for advanced glycation end products in NFE2L2/PGC1 alpha dKO retina. Our main data show C5 and thrombin upregulation together with decreased C3 levels in this dry AMD-like model. In general, the retina strives to mount an orchestrated inflammatory response while attempting to maintain tissue homeostasis and resolve inflammation.
C1 [Gurubaran, Iswariyaraja Sridevi; Koskela, Ali; Hyttinen, Juha M. T.; Paterno, Jussi J.] Univ Eastern Finland, Inst Clin Med, Dept Ophthalmol, Kuopio 70210, Finland.
   [Helotera, Hanna] Roche Oy, Dept Ophthalmol, Espoo 02100, Finland.
   [Marry, Stephen; Chen, Mei; Xu, Heping] Queens Univ Belfast, Sch Med, Wellcome Wolfson Inst Expt Med, Belfast BT9 7BL, Antrim, North Ireland.
   [Urtti, Arto; Kauppinen, Anu] Univ Eastern Finland, Fac Hlth Sci, Sch Pharm, Kuopio 70210, Finland.
   [Kaarniranta, Kai] Univ Eastern Finland, Dept Ophthalmol, Kuopio 70210, Finland.
   [Kaarniranta, Kai] Kuopio Univ Hosp, Kuopio 70210, Finland.
C3 University of Eastern Finland; Roche Holding; Queens University Belfast;
   University of Eastern Finland; University of Eastern Finland; Kuopio
   University Hospital; University of Eastern Finland
RP Kaarniranta, K (通讯作者)，Univ Eastern Finland, Dept Ophthalmol, Kuopio 70210, Finland.; Kaarniranta, K (通讯作者)，Kuopio Univ Hosp, Kuopio 70210, Finland.
EM raja.sridevigurubaran@uef.fi; hanna.helotera@roche.com;
   s.marry@qub.ac.uk; ali.koskela@uef.fi; juha.hyttinen@uef.fi;
   jussi.paterno@uef.fi; arto.urtti@uef.fi; m.chen@qub.ac.uk;
   heping.xu@qub.ac.uk; anu.kauppinen@uef.fi; kai.kaarniranta@uef.fi
RI Xu, Heping/A-4430-2008
OI Xu, Heping/0000-0003-4000-931X; , Mei/0000-0001-5661-1386; Hyttinen,
   Juha/0000-0002-3414-4032; Marry, Stephen/0000-0002-0769-1444; Sridevi
   Gurubaran, Iswariyaraja/0000-0003-1863-9550
FU European Union [722717]; Academy of Finland [296840, 297267, 307341,
   328443, 333302]; Kuopio University Hospital VTR grant [5503743]; Sigrid
   Juselius Foundation; Paivikki and Sakari Sohlberg Foundation; Emil
   Aaltonen Foundation; Finnish Cultural Foundation; Finnish Eye
   Foundation; University of Eastern Finland
FX This project has received funding from the European Union's Horizon 2020
   research and innovation programme under the Marie Sklodowska-Curie grant
   agreement No. 722717, the Academy of Finland (296840, 297267, 307341,
   328443, 333302), the Kuopio University Hospital VTR grant (5503743), the
   Sigrid Juselius Foundation, the Paivikki and Sakari Sohlberg Foundation,
   the Emil Aaltonen Foundation, the University of Eastern Finland
   strategical support, the Finnish Cultural Foundation, and the Finnish
   Eye Foundation.
CR Abramson JL, 2005, ATHEROSCLEROSIS, V178, P115, DOI 10.1016/j.atherosclerosis.2004.08.007
   Al-Zamil WM, 2017, CLIN INTERV AGING, V12, P1313, DOI 10.2147/CIA.S143508
   Amara U, 2010, J IMMUNOL, V185, P5628, DOI 10.4049/jimmunol.0903678
   Amarante-Mendes GP, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.02379
   Banevicius M, 2018, MED SCI MONITOR, V24, P190, DOI 10.12659/MSM.905311
   Bao WDN, 2016, SCI REP-UK, V6, DOI 10.1038/srep22579
   Bhutto IA, 2011, BRIT J OPHTHALMOL, V95, P1323, DOI 10.1136/bjo.2010.199216
   Borras C, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-50420-9
   Borysiewicz E, 2013, J NEUROIMMUNOL, V255, P54, DOI 10.1016/j.jneuroim.2012.11.002
   Cavassani KA, 2008, J EXP MED, V205, P2609, DOI 10.1084/jem.20081370
   Celkova L, 2015, J CLIN MED, V4, P172, DOI 10.3390/jcm4010172
   Cervantes-Gracia K, 2020, VESSEL PLUS, VPlus4, P27, DOI [10.20517/2574-1209.2020.22, DOI 10.20517/2574-1209.2020.22]
   Chen JF, 2012, GENE, V496, P128, DOI 10.1016/j.gene.2011.12.039
   Chen M, 2007, EXP EYE RES, V84, P635, DOI 10.1016/j.exer.2006.11.015
   Chen M, 2015, J LEUKOCYTE BIOL, V98, P713, DOI 10.1189/jlb.3RI0615-239R
   Chen YX, 2018, FRONT PHYSIOL, V9, DOI 10.3389/fphys.2018.01487
   Chirco KR, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.00539
   Colak E, 2012, BIOCHEM MEDICA, V22, P39
   Cottone S, 2006, AM J HYPERTENS, V19, P313, DOI 10.1016/j.amjhyper.2005.09.005
   Ding ZF, 2013, SCI REP-UK, V3, DOI 10.1038/srep01077
   Ehrlich R, 2008, CLIN INTERV AGING, V3, P473
   Felszeghy S, 2019, REDOX BIOL, V20, P1, DOI 10.1016/j.redox.2018.09.011
   Ferreira VP, 2010, MOL IMMUNOL, V47, P2187, DOI 10.1016/j.molimm.2010.05.007
   Foronjy RF, 2016, AM J PHYSIOL-LUNG C, V311, pL154, DOI 10.1152/ajplung.00073.2016
   Furman D, 2019, NAT MED, V25, P1822, DOI 10.1038/s41591-019-0675-0
   Ge X, 2013, BMC NEUROL, V13, DOI 10.1186/1471-2377-13-110
   Geerlings MJ, 2017, MOL IMMUNOL, V84, P65, DOI 10.1016/j.molimm.2016.11.016
   Gehrs KM, 2006, ANN MED, V38, P450, DOI 10.1080/07853890600946724
   Glenn JV, 2009, BBA-GEN SUBJECTS, V1790, P1109, DOI 10.1016/j.bbagen.2009.04.016
   Goel R, 2002, J BIOL CHEM, V277, P18640, DOI 10.1074/jbc.M108995200
   Gong T, 2020, NAT REV IMMUNOL, V20, P95, DOI 10.1038/s41577-019-0215-7
   Guo CY, 2013, NEURAL REGEN RES, V8, P2003, DOI 10.3969/j.issn.1673-5374.2013.21.009
   Gurubaran IS, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21061976
   Hageman GS, 2005, P NATL ACAD SCI USA, V102, P7227, DOI 10.1073/pnas.0501536102
   Hajishengallis G, 2016, IMMUNOL REV, V274, P233, DOI 10.1111/imr.12467
   Hajishengallis G, 2010, TRENDS IMMUNOL, V31, P154, DOI 10.1016/j.it.2010.01.002
   Hecquet C, 2002, INVEST OPHTH VIS SCI, V43, P3091
   Heesterbeek TJ, 2020, OPHTHAL PHYSL OPT, V40, P140, DOI 10.1111/opo.12675
   Herbert AP, 2015, J IMMUNOL, V195, P4986, DOI 10.4049/jimmunol.1501388
   Huber-Lang M, 2006, NAT MED, V12, P682, DOI 10.1038/nm1419
   Issa PC, 2011, GRAEF ARCH CLIN EXP, V249, P163, DOI 10.1007/s00417-010-1568-6
   Jarva H, 1999, J IMMUNOL, V163, P3957
   Kaarniranta K, 2009, J MOL MED, V87, P117, DOI 10.1007/s00109-008-0418-z
   Kaarniranta K., 2020, PROG RETIN EYE RES, V79, P100858, DOI [10.1016/j.preteyeres.2020.100858, DOI 10.1016/j.preteyeres.2020.100858]
   Kaarniranta K, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20102374
   Kaarniranta K, 2019, BIOCHIMIE, V159, P49, DOI 10.1016/j.biochi.2018.07.010
   Kaarniranta Kai, 2010, Front Biosci (Elite Ed), V2, P1374
   Kauppinen A, 2016, CELL MOL LIFE SCI, V73, P1765, DOI 10.1007/s00018-016-2147-8
   Khandhadia S, 2012, IMMUNOBIOLOGY, V217, P127, DOI 10.1016/j.imbio.2011.07.019
   Knickelbein Jared E, 2015, Int Ophthalmol Clin, V55, P63, DOI 10.1097/IIO.0000000000000073
   Koarai A, 2010, AM J RESP CELL MOL, V42, P651, DOI 10.1165/rcmb.2008-0345OC
   Kopp A, 2012, BIOMOLECULES, V2, P46, DOI 10.3390/biom2010046
   Krisinger MJ, 2012, BLOOD, V120, P1717, DOI 10.1182/blood-2012-02-412080
   Li X, 2020, IUBMB LIFE, V72, P1023, DOI 10.1002/iub.2239
   Lo Gullo A, 2014, CLIN EXP RHEUMATOL, V32, P922
   Lu G, 2020, ARQ NEURO-PSIQUIAT, V78, P76, DOI [10.1590/0004-282X20190151, 10.1590/0004-282x20190151]
   Luu J, 2018, P NATL ACAD SCI USA, V115, P2866, DOI 10.1073/pnas.1721033115
   Mahajan N, 2010, INT J CARDIOL, V142, P273, DOI 10.1016/j.ijcard.2009.01.008
   McCausland MR, 2020, AIDS, V34, P815, DOI 10.1097/QAD.0000000000002499
   McHarg S, 2015, MOL IMMUNOL, V67, P43, DOI 10.1016/j.molimm.2015.02.032
   Metzemaekers M, 2020, CELL MOL IMMUNOL, V17, P433, DOI 10.1038/s41423-020-0412-0
   Minihane AM, 2015, BRIT J NUTR, V114, P999, DOI 10.1017/S0007114515002093
   Mitchell P, 2018, LANCET, V392, P1147, DOI 10.1016/S0140-6736(18)31550-2
   MOLD C, 1984, J IMMUNOL, V133, P882
   Oberg BP, 2004, KIDNEY INT, V65, P1009, DOI 10.1111/j.1523-1755.2004.00465.x
   OHTSUKA H, 1993, IMMUNOLOGY, V80, P140
   Palma-Nicolas JP, 2008, BIOSCIENCE REP, V28, P307, DOI 10.1042/BSR20080083
   Pang QW, 2020, FRONT MED-LAUSANNE, V7, DOI 10.3389/fmed.2020.583943
   Paradela-Dobarro B, 2013, EUR J PHARM SCI, V49, P512, DOI 10.1016/j.ejps.2013.05.001
   Park DH, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.01007
   Parmeggiani F, 2013, MEDIAT INFLAMM, V2013, DOI 10.1155/2013/435607
   Parrales A, 2011, BBA-MOL CELL RES, V1813, P1758, DOI 10.1016/j.bbamcr.2011.06.009
   Patel AK, 2013, MOL IMMUNOL, V54, P122, DOI 10.1016/j.molimm.2012.11.005
   Puy C, 2021, J IMMUNOL, V206, P1784, DOI 10.4049/jimmunol.2000398
   Rajendran K, 2012, THROMB J, V10, DOI 10.1186/1477-9560-10-13
   Sato T, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-55191-x
   Seddon JM, 2004, JAMA-J AM MED ASSOC, V291, P704, DOI 10.1001/jama.291.6.704
   Seddon JM, 2007, JAMA-J AM MED ASSOC, V297, P1793, DOI 10.1001/jama.297.16.1793
   Shaw PX, 2016, AIMS MOL SCI, V3, P196, DOI 10.3934/molsci.2016.2.196
   Silwal P, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.01649
   Sivaprasad S, 2006, EYE, V20, P867, DOI 10.1038/sj.eye.6702176
   Song WC, 2012, TOXICOL PATHOL, V40, P174, DOI 10.1177/0192623311428478
   Tan W, 2020, INT J BIOL SCI, V16, P2989, DOI 10.7150/ijbs.49890
   Toomey CB, 2018, PROG RETIN EYE RES, V62, P38, DOI 10.1016/j.preteyeres.2017.09.001
   Wang MM, 2018, MOL MED REP, V18, P1867, DOI 10.3892/mmr.2018.9089
   Wang XL, 2018, BRAIN BEHAV IMMUN, V67, P324, DOI 10.1016/j.bbi.2017.09.009
   Witko-Sarsat V, 2000, LAB INVEST, V80, P617, DOI 10.1038/labinvest.3780067
   Wu JL, 2019, DRUG DES DEV THER, V13, P2413, DOI 10.2147/DDDT.S206355
   Xu HP, 2016, EUR J PHARMACOL, V787, P94, DOI 10.1016/j.ejphar.2016.03.001
   Xu HP, 2009, PROG RETIN EYE RES, V28, P348, DOI 10.1016/j.preteyeres.2009.06.001
   Younessi P, 2011, IRAN J MED SCI, V36, P154
   Zhang YK, 2021, ADV EXP MED BIOL, V1256, P121, DOI 10.1007/978-3-030-66014-7_5
   Zhao CC, 2020, MOL IMMUNOL, V125, P24, DOI 10.1016/j.molimm.2020.06.016
   Zhong Y, 2006, HYPERTENSION, V48, P504, DOI 10.1161/01.HYP.0000234904.43861.f7
   Zwarthoff SA, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.01691
NR 95
TC 2
Z9 2
U1 1
U2 2
PU MDPI
PI BASEL
PA ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND
EI 2079-7737
J9 BIOLOGY-BASEL
JI Biology-Basel
PD JUL
PY 2021
VL 10
IS 7
AR 622
DI 10.3390/biology10070622
PG 14
WC Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Life Sciences & Biomedicine - Other Topics
GA TN0XM
UT WOS:000675967700001
PM 34356477
OA Green Published, gold
DA 2022-11-30
ER

PT J
AU Nassisi, M
   Lei, JQ
   Abdelfattah, NS
   Karamat, A
   Balasubramanian, S
   Fan, WY
   Uji, A
   Marion, KM
   Baker, K
   Huang, XW
   Morgenthien, E
   Sadda, SR
AF Nassisi, Marco
   Lei, Jianqin
   Abdelfattah, Nizar Saleh
   Karamat, Ayesha
   Balasubramanian, Siva
   Fan, Wenying
   Uji, Akihito
   Marion, Kenneth M.
   Baker, Kirstie
   Huang, Xiwen
   Morgenthien, Elizabeth
   Sadda, Srinivas R.
TI OCT Risk Factors for Development of Late Age-Related Macular
   Degeneration in the Fellow Eyes of Patients Enrolled in the HARBOR Study
SO OPHTHALMOLOGY
LA English
DT Article
ID PIGMENT EPITHELIAL DETACHMENT; 2.0 MG RANIBIZUMAB; RETICULAR
   PSEUDODRUSEN; PROGRESSION; NEOVASCULARIZATION; ASSOCIATION; ATROPHY;
   EFFICACY; DISEASE; SAFETY
AB Purpose: To evaluate the relationship between OCT features and progression to late age related-macular degeneration (AMD) in the fellow eyes of patients enrolled in the Study of Ranibizumab Administered Monthly or on an As-needed Basis in Patients With Subfoveal Neovascular AMD (HARBOR) (ClinicalTrials.gov identifier, NCT00891735).
   Design: Post hoc analysis of a phase 3 multicenter, prospective, randomized, double-masked, active treatment-controlled clinical trial.
   Participants: Evaluable patients (n = 501) with macular neovascularization (MNV) secondary to neovascular AMD and early or intermediate AMD in the fellow eye.
   Methods: Volume OCT scans from 501 fellow eyes of 501 patients with MNV were reviewed. Baseline OCT features that were assessed included intraretinal hypereflective foci (IHRF), hyporeflective foci (hRF) within drusenoid lesions (DLs), subretinal drusenoid deposits (SDDs), and drusen volume (DV) of 0.03 mm(3) or more. OCT images obtained at months 6, 12, 18, and 24 were graded by masked graders for late AMD (defined as MNV, complete retinal pigment epithelium and photoreceptor atrophy [cRORA], or both). Participant demographic characteristics (age, gender, and smoke exposure) and baseline OCT features were correlated with progression to late AMD.
   Main Outcome Measures: Incidence of late AMD, hazard ratio (HR) for demographics, and OCT risk factors.
   Results: At month 24, 33.13% of eyes (166/501) demonstrated late AMD: 20.96% (105/501) demonstrated cRORA, whereas 12.18% (61/501) demonstrated MNV. Baseline demographic factors were not associated significantly with development of late AMD, whereas significant associations were identified for all OCT features. Intraretinal hypereflective foci had an HR of 5.21 (95% confidence interval [CI], 3.29-8.26), hRF within DLs had an HR of 2.42 (95% CI, 1.74-3.38), SDD had an HR of 1.95 (95% CI, 1.34-2.82), and DV of 0.03 mm(3) or more had an HR of 1.46 (95% CI, 1.03-2.07). The correlation remained significant when considering only the progression to cRORA and MNV alone, except for DV, which was not associated significantly with progression to MNV.
   Conclusions: We confirmed that 4 previously reported OCT risk factors were associated with progression to late AMD in the fellow eyes of patients newly diagnosed with MNV. Although outcomes of more than 2 years were not evaluated, these findings may help to identify high-risk AMD patients. (C) 2019 by the American Academy of Ophthalmology
C1 [Nassisi, Marco; Lei, Jianqin; Abdelfattah, Nizar Saleh; Karamat, Ayesha; Balasubramanian, Siva; Fan, Wenying; Uji, Akihito; Marion, Kenneth M.; Baker, Kirstie; Huang, Xiwen; Sadda, Srinivas R.] Doheny Eye Inst, Doheny Image Reading Ctr, Los Angeles, CA 90033 USA.
   [Nassisi, Marco; Lei, Jianqin; Abdelfattah, Nizar Saleh; Karamat, Ayesha; Balasubramanian, Siva; Fan, Wenying; Uji, Akihito; Marion, Kenneth M.; Baker, Kirstie; Huang, Xiwen; Sadda, Srinivas R.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Ophthalmol, Los Angeles, CA 90095 USA.
   [Lei, Jianqin] Xi An Jiao Tong Univ, Affiliated Hosp 1, Dept Ophthalmol, Xian, Shaanxi, Peoples R China.
   [Fan, Wenying] Capital Med Univ, Beijing Tongren Hosp, Beijing Tongren Eye Ctr, Beijing Ophthalmol & Visual Sci Key Lab, Beijing, Peoples R China.
   [Morgenthien, Elizabeth] Genentech Inc, San Francisco, CA 94080 USA.
C3 Doheny Eye Institute; University of California System; University of
   California Los Angeles; University of California Los Angeles Medical
   Center; David Geffen School of Medicine at UCLA; Xi'an Jiaotong
   University; Capital Medical University; Roche Holding; Genentech
RP Sadda, SR (通讯作者)，Doheny Eye Inst, 1355 San Pablo St,Suite 211, Los Angeles, CA 90033 USA.
EM SSadda@doheny.org
RI fan, wenying/GSI-5125-2022; Abdelfattah, Nizar Saleh/H-6908-2019;
   Nassisi, Marco/P-9939-2019
OI Abdelfattah, Nizar Saleh/0000-0002-9396-3054; Nassisi,
   Marco/0000-0002-9354-9005
CR Abdelfattah NS, 2016, INVEST OPHTH VIS SCI, V57, P1839, DOI 10.1167/iovs.15-18572
   Barbazetto IA, 2010, AM J OPHTHALMOL, V149, P939, DOI 10.1016/j.ajo.2010.01.007
   Bressler NM, 2003, ARCH OPHTHALMOL-CHIC, V121, P1621
   Busbee BG, 2013, OPHTHALMOLOGY, V120, P1046, DOI 10.1016/j.ophtha.2012.10.014
   de Sisternes L, 2014, INVEST OPHTH VIS SCI, V55, P7093, DOI 10.1167/iovs.14-14918
   Finger RP, 2016, OPHTHALMOLOGY, V123, P599, DOI 10.1016/j.ophtha.2015.10.029
   Ho AC, 2014, OPHTHALMOLOGY, V121, P2181, DOI 10.1016/j.ophtha.2014.05.009
   Jack LS, 2016, DEV OPHTHALMOL, V55, P302, DOI 10.1159/000438954
   Jung JJ, 2014, AM J OPHTHALMOL, V158, P769, DOI 10.1016/j.ajo.2014.07.006
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1417, DOI 10.1001/archopht.119.10.1417
   Kim JH, 2016, RETINA-J RET VIT DIS, V36, P1506, DOI 10.1097/IAE.0000000000000932
   Klein R, 1997, OPHTHALMOLOGY, V104, P7, DOI 10.1016/S0161-6420(97)30368-6
   Lee SY, 2012, INVEST OPHTH VIS SCI, V53, P164, DOI 10.1167/iovs.11-8188
   Lei JQ, 2017, GRAEF ARCH CLIN EXP, V255, P1551, DOI 10.1007/s00417-017-3693-y
   Leuschen JN, 2013, OPHTHALMOLOGY, V120, P140, DOI 10.1016/j.ophtha.2012.07.004
   Maguire MG, 2013, OPHTHALMOLOGY, V120, P2035, DOI 10.1016/j.ophtha.2013.03.017
   Marsiglia M, 2013, INVEST OPHTH VIS SCI, V54, P7362, DOI 10.1167/iovs.12-11073
   Nagiel A, 2015, RETINA-J RET VIT DIS, V35, P638, DOI 10.1097/IAE.0000000000000488
   Nassisi M, 2018, INVEST OPHTH VIS SCI, V59, P3431, DOI 10.1167/iovs.18-24143
   Ouyang YL, 2013, OPHTHALMOLOGY, V120, P2656, DOI 10.1016/j.ophtha.2013.05.029
   Sadda SR, 2018, OPHTHALMOLOGY, V125, P537, DOI 10.1016/j.ophtha.2017.09.028
   Spaide RF, 2018, SURV OPHTHALMOL, V63, P782, DOI 10.1016/j.survophthal.2018.05.005
   Wong RW, 2007, RETINA-J RET VIT DIS, V27, P997, DOI 10.1097/IAE.0b013e318074c290
   Wu ZC, 2014, OPHTHALMOLOGY, V121, P2415, DOI 10.1016/j.ophtha.2014.06.034
   Zhou Q, 2016, OPHTHALMOLOGY, V123, P1530, DOI 10.1016/j.ophtha.2016.02.043
NR 25
TC 51
Z9 52
U1 0
U2 3
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 0161-6420
EI 1549-4713
J9 OPHTHALMOLOGY
JI Ophthalmology
PD DEC
PY 2019
VL 126
IS 12
BP 1667
EP 1674
DI 10.1016/j.ophtha.2019.05.016
PG 8
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA JP0KL
UT WOS:000497960600021
PM 31281056
DA 2022-11-30
ER

PT J
AU Kim, LN
   Mehta, H
   Barthelmes, D
   Nguyen, V
   Gillies, MC
AF Kim, Leah N.
   Mehta, Hemal
   Barthelmes, Daniel
   Vuong Nguyen
   Gillies, Mark C.
TI METAANALYSIS OF REAL-WORLD OUTCOMES OF INTRAVITREAL RANIBIZUMAB FOR THE
   TREATMENT OF NEOVASCULAR AGE-RELATED MACULAR DEGENERATION
SO RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES
LA English
DT Review
DE age-related macular degeneration; neovascular; observational;
   ranibizumab; real-world outcomes
ID QUALITY-OF-LIFE; CLINICAL-PRACTICE; EXUDATIVE AMD; VISUAL-ACUITY;
   FOLLOW-UP; THERAPY; EXPERIENCE; REGIMEN; BURDEN; SAFETY
AB Purpose: To report the efficacy and safety of intravitreal ranibizumab for neovascular age-related macular degeneration (nAMD) in real-world practice.
   Methods: Metaanalysis of similar to 26,360 patients from 42 real-world observational studies reporting outcomes of intravitreal ranibizumab for nAMD published between 2007 and 2015. Baseline demographics, lesion type, and visual acuity (VA) were recorded. The weighted mean was calculated for change in VA and frequency of injections and visits during year 1, year 2, and >= 3 years. Local and systemic adverse events were recorded.
   Results: The mean change in VA for patients receiving a treat-and-extend regimen was +8.8 (95% confidence interval [CI]: 5.8 to 11.8), +6.7 (95% CI: 3.2 to 10.1), and +5.4 (95% CI: -4.1 to 14.9) Early Treatment Diabetic Retinopathy Study (ETDRS) letters at 1 year (n = 1,539), 2 years (n = 2,521), and >= 3 years (n = 1,298), in comparison with +3.5 (95% CI: 2.0 to 5.0), +1.3 (95% CI: 21.6 to 4.2), and 21.9 (95% CI: 29.8 to 6.0) ETDRS letters for pro re nata at 1 year (n = 20,247), 2 years (n = 14,408), and >3 years (n = 11,714). Treat-and-extend patients received on average more injections (6.9 vs. 4.7) but had fewer visits (7.6 vs. 9.2) in the first year. Baseline characteristics were similar between the regimens. The reported rate of endophthalmitis was 17 of 66,176 intravitreal injections (0.026%).
   Conclusion: Intravitreal ranibizumab for nAMD prevents severe visual loss in real-world practice. Patients can achieve visual gain from baseline, but the extent to which these are maintained in the long term may depend on the frequency of injections.
C1 [Kim, Leah N.; Mehta, Hemal; Barthelmes, Daniel; Vuong Nguyen; Gillies, Mark C.] Univ Sydney, Save Sight & Eye Hlth Inst, Macula Res Grp, Sydney, NSW 2000, Australia.
   [Mehta, Hemal] Royal Free London NHS Fdn Trust, Dept Ophthalmol, London, England.
   [Barthelmes, Daniel] Univ Zurich, Univ Zurich Hosp, Dept Ophthalmol, Zurich, Switzerland.
C3 University of Sydney; University of London; University College London;
   Royal Free London NHS Foundation Trust; University of Zurich; University
   Zurich Hospital
RP Mehta, H (通讯作者)，Univ Sydney, Save Sight & Eye Hlth Inst, Macula Res Grp, Sydney, NSW 2000, Australia.
EM HM@cantab.net
OI Nguyen, Vuong/0000-0001-9070-9803; Kim, Leah/0000-0002-3829-1697
FU National Health and Medical Research Council Clinical Fellowship
FX Professor Gillies and Dr Barthelmes own copyright for software that is
   used to track outcomes of the treatment of macular degeneration. The
   other authors have no proprietary or commercial interest in any
   materials discussed in this article. Professor Gillies is a Sydney
   Medical School Foundation Fellow and is supported by an National Health
   and Medical Research Council Clinical Fellowship. The views expressed in
   the publication are those of the authors and not necessarily those of
   the National Health and Medical Research Council.
CR Abedi F, 2014, RETINA-J RET VIT DIS, V34, P1531, DOI 10.1097/IAE.0000000000000134
   Lopez-Lopez JA, 2014, BRIT J MATH STAT PSY, V67, P30, DOI 10.1111/bmsp.12002
   Arnold JJ, 2015, OPHTHALMOLOGY, V122, P1212, DOI 10.1016/j.ophtha.2015.02.009
   Bandukwala T, 2010, CAN J OPHTHALMOL, V45, P590, DOI 10.3129/i10-082
   Barthelmes D, 2015, BRIT J OPHTHALMOL, V99, P359, DOI 10.1136/bjophthalmol-2014-305514
   Barthelmes D, 2014, OPHTHALMOLOGY, V121, P2073, DOI 10.1016/j.ophtha.2014.05.007
   Bellerive C, 2012, CAN J OPHTHALMOL, V47, P165, DOI 10.1016/j.jcjo.2012.01.011
   Biarnes M, 2011, EUR J OPHTHALMOL, V21, P282, DOI 10.5301/EJO.2010.5766
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Cohen SY, 2013, RETINA-J RET VIT DIS, V33, P474, DOI 10.1097/IAE.0b013e31827b6324
   Cohen SY, 2009, AM J OPHTHALMOL, V148, P409, DOI 10.1016/j.ajo.2009.04.001
   Dadgostar H, 2009, OPHTHALMOLOGY, V116, P1740, DOI 10.1016/j.ophtha.2009.05.033
   Engelbert M, 2010, RETINA-J RET VIT DIS, V30, P1368, DOI 10.1097/IAE.0b013e3181d50cbf
   Falk MK, 2013, AM J OPHTHALMOL, V155, P89, DOI 10.1016/j.ajo.2012.06.031
   Finger RP, 2013, ACTA OPHTHALMOL, V91, P540, DOI 10.1111/j.1755-3768.2012.02493.x
   Frennesson CI, 2014, ACTA OPHTHALMOL, V92, P216, DOI 10.1111/aos.12091
   Furukawa TA, 2006, J CLIN EPIDEMIOL, V59, P7, DOI 10.1016/j.jclinepi.2005.06.006
   Gillies MC, 2015, OPHTHALMOLOGY, V122, P589, DOI 10.1016/j.ophtha.2014.10.001
   Gillies MC, 2014, OPHTHALMOLOGY, V121, P676, DOI 10.1016/j.ophtha.2013.09.050
   Gillies MC, 2013, INVEST OPHTH VIS SCI, V54, P5754, DOI 10.1167/iovs.13-11993
   Gillies MC, 2013, RETINA, P1
   Gupta OP, 2010, OPHTHALMOLOGY, V117, P2134, DOI 10.1016/j.ophtha.2010.02.032
   Guyatt GH, 2008, BRIT MED J, V336, P924, DOI 10.1136/bmj.39489.470347.AD
   Heimes B, 2011, GRAEF ARCH CLIN EXP, V249, P639, DOI 10.1007/s00417-010-1524-5
   Higgins JPT, 2002, STAT MED, V21, P1539, DOI 10.1002/sim.1186
   Hjelmqvist L, 2011, J OPHTHALMOL, V2011, DOI 10.1155/2011/405724
   Holz FG, 2015, BRIT J OPHTHALMOL, V99, P220, DOI 10.1136/bjophthalmol-2014-305327
   Holz FG, 2013, BRIT J OPHTHALMOL, V97, P1161, DOI 10.1136/bjophthalmol-2013-303232
   Katz G, 2012, RETINA-J RET VIT DIS, V32, P293, DOI 10.1097/IAE.0b013e31821e20b0
   Lee AY, 2015, BRIT J OPHTHALMOL, V99, P1045, DOI 10.1136/bjophthalmol-2014-306229
   Mantel I, 2014, BRIT J OPHTHALMOL, V98, P1192, DOI 10.1136/bjophthalmol-2013-304556
   Menghini M, 2014, PLOS ONE, V7
   Michalova K, 2009, EYE, V23, P1633, DOI 10.1038/eye.2009.175
   Muniraju R, 2013, OPHTHALMOLOGICA, V230, P27, DOI 10.1159/000350238
   Oubraham H, 2011, RETINA-J RET VIT DIS, V31, P26, DOI 10.1097/IAE.0b013e3181de5609
   Pascolini D, 2012, BRIT J OPHTHALMOL, V96, P614, DOI 10.1136/bjophthalmol-2011-300539
   Philbrook HT, 2007, J CLIN EPIDEMIOL, V60, P228, DOI 10.1016/j.jclinepi.2006.06.018
   Pushpoth S, 2012, BRIT J OPHTHALMOL, V96, P1469, DOI 10.1136/bjophthalmol-2012-302167
   Querques G, 2010, BRIT J OPHTHALMOL, V94, P292, DOI 10.1136/bjo.2009.170670
   Rakic JM, 2013, CLIN OPHTHALMOL, V7, P1849, DOI 10.2147/OPTH.S49385
   Rayess N, 2015, AM J OPHTHALMOL, V159, P3, DOI 10.1016/j.ajo.2014.09.011
   Rodrigues IA, 2016, AM J OPHTHALMOL, V168, P1, DOI 10.1016/j.ajo.2016.04.012
   Rofagha S, 2013, OPHTHALMOLOGY, V120, P2292, DOI 10.1016/j.ophtha.2013.03.046
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Rothenbuehler SP, 2009, AM J OPHTHALMOL, V147, P831, DOI 10.1016/j.ajo.2008.12.005
   Rotsos T, 2010, CLIN OPHTHALMOL, V4, P1271, DOI 10.2147/OPTH.S14684
   Silva R, 2013, OPHTHALMOLOGY, V120, P130, DOI 10.1016/j.ophtha.2012.07.026
   Solomon SD, 2014, COCHRANE DB SYST REV, V8, P1
   Souied EH, 2015, RETINA, P1
   Team RC, 2015, R A LANG ENV STAT CO
   Toalster N, 2013, RETINA-J RET VIT DIS, V33, P1351, DOI 10.1097/IAE.0b013e3182831265
   Tufail A, 2014, OPHTHALMOLOGY, V121, P1092, DOI 10.1016/j.ophtha.2013.11.031
   van Asten F, 2015, ACTA OPHTHALMOL, V93, P126, DOI 10.1111/aos.12610
   van Buuren S, 2011, J STAT SOFTW, V45, P1
   Viechtbauer W, 2010, J STAT SOFTW, V36, P1, DOI 10.18637/jss.v036.i03
   Wolf A, 2014, GRAEF ARCH CLIN EXP, V252, P647, DOI 10.1007/s00417-013-2562-6
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
   Zarranz-Ventura J, 2014, OPHTHALMOLOGY, V121, P1966, DOI 10.1016/j.ophtha.2014.04.026
NR 58
TC 112
Z9 112
U1 0
U2 8
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0275-004X
EI 1539-2864
J9 RETINA-J RET VIT DIS
JI Retin.-J. Retin. Vitr. Dis.
PD AUG
PY 2016
VL 36
IS 8
BP 1418
EP 1431
PG 14
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA DS7MI
UT WOS:000380967200018
PM 27388744
OA Green Accepted
DA 2022-11-30
ER

PT J
AU Ristau, T
   Paun, C
   Ersoy, L
   Hahn, M
   Lechanteur, Y
   Hoyng, C
   de Jong, EK
   Daha, MR
   Kirchhof, B
   den Hollander, AI
   Fauser, S
AF Ristau, Tina
   Paun, Constantin
   Ersoy, Lebriz
   Hahn, Moritz
   Lechanteur, Yara
   Hoyng, Carel
   de Jong, Eiko K.
   Daha, Mohamed R.
   Kirchhof, Bernd
   den Hollander, Anneke I.
   Fauser, Sascha
TI Impact of the Common Genetic Associations of Age-Related Macular
   Degeneration upon Systemic Complement Component C3d Levels
SO PLOS ONE
LA English
DT Article
ID FACTOR-H POLYMORPHISM; ALTERNATIVE PATHWAY; HAPLOTYPE RECONSTRUCTION;
   RISK; VARIANT; ACTIVATION; RECOGNITION; DRUSEN
AB Age-related macular degeneration (AMD) is a common condition that leads to severe vision loss and dysregulation of the complement system is thought to be associated with the disease. To investigate associations of polymorphisms in AMD susceptibility genes with systemic complement activation, 2655 individuals were genotyped for 32 single nucleotide polymorphisms (SNPs) in or near 23 AMD associated risk genes. Component 3 (C3) and its catabolic fragment C3d were measured in serum and AMD staging was performed using multimodal imaging. The C3d/C3 ratio was calculated and associations with environmental factors, SNPs and various haplotypes of complement factor H (CFH) genes and complement factor B (CFB) genes were analyzed. Linear models were built to measure the influence of genetic variants on the C3d/C3 ratio. The study cohort included 1387 patients with AMD and 1268 controls. Higher C3d/C3 ratios were found for current smoker (p = 0.002), higher age (p = 1.56x10(-7)), AMD phenotype (p = 1.15x10(-11)) and the two SNPs in the C3 gene rs6795735 (p = 0.04) and rs2230199 (p = 0.04). Lower C3d/C3 ratios were found for diabetes (p = 2.87x10(-6)), higher body mass index (p = 1.00x10(-13)), the SNPs rs1410996 (p = 0.0001), rs800292 (p = 0.003), rs12144939 (p = 4.60x10(-6)) in CFH, rs4151667 (p = 1.01x10(-5)) in CFB and individual haplotypes in CFH and CFB. The linear model revealed a corrected R-square of 0.063 including age, smoking status, gender, and genetic polymorphisms explaining 6.3% of the C3d/C3 ratio. After adding the AMD status the corrected R-square was 0.067. In conclusion, none of the evaluated genetic polymorphisms showed an association with increased systemic complement activation apart from two SNPs in the C3 gene. Major genetic and non-genetic factors for AMD were not associated with systemic complement activation.
C1 [Ristau, Tina; Ersoy, Lebriz; Kirchhof, Bernd; Fauser, Sascha] Univ Hosp Cologne, Dept Ophthalmol, Cologne, Germany.
   [Paun, Constantin; Lechanteur, Yara; Hoyng, Carel; de Jong, Eiko K.; den Hollander, Anneke I.] Radboud Univ Nijmegen, Med Ctr, Dept Ophthalmol, NL-6525 ED Nijmegen, Netherlands.
   [Hahn, Moritz] Univ Cologne, Inst Med Stat Informat & Epidemiol, D-50931 Cologne, Germany.
   [Daha, Mohamed R.] Leiden Univ Nijmegen, Med Ctr, Dept Nephrol, Leiden, Netherlands.
C3 University of Cologne; Radboud University Nijmegen; University of
   Cologne
RP Fauser, S (通讯作者)，Univ Hosp Cologne, Dept Ophthalmol, Cologne, Germany.
EM sascha.fauser@uk-koeln.de
RI Hollander, Anneke den/N-4911-2014; Lechanteur, Yara/ABB-6875-2020;
   Hoyng, C.B./H-8050-2014; de Jong, Eiko/P-3407-2015; Lehtimäki,
   Terho/AAD-1094-2022
OI Lechanteur, Yara/0000-0003-0951-4625; de Jong, Eiko/0000-0001-6520-0407;
   Lehtimäki, Terho/0000-0002-2555-4427
FU Retinovit Foundation, Germany
FX This work was supported by the Retinovit Foundation, Germany. The
   funders had no role in study design, data collection and analysis,
   decision to publish, or preparation of the manuscript.
CR Edwards AO, 2005, SCIENCE, V308, P421, DOI 10.1126/science.1110189
   Gold B, 2006, NAT GENET, V38, P458, DOI 10.1038/ng1750
   Hageman GS, 2001, PROG RETIN EYE RES, V20, P705, DOI 10.1016/S1350-9462(01)00010-6
   Haines JL, 2005, SCIENCE, V308, P419, DOI 10.1126/science.1110359
   Hawkins JR, 2002, HUM MUTAT, V19, P543, DOI 10.1002/humu.10060
   Hecker LA, 2010, HUM MOL GENET, V19, P209, DOI 10.1093/hmg/ddp472
   Johnson PT, 2006, P NATL ACAD SCI USA, V103, P17456, DOI 10.1073/pnas.0606234103
   Khandhadia S, 2012, IMMUNOBIOLOGY, V217, P127, DOI 10.1016/j.imbio.2011.07.019
   Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557
   Maller JB, 2007, NAT GENET, V39, P1200, DOI 10.1038/ng2131
   Nozaki M, 2006, P NATL ACAD SCI USA, V103, P2328, DOI 10.1073/pnas.0408835103
   Pangburn MK, 2000, IMMUNOPHARMACOLOGY, V49, P149, DOI 10.1016/S0162-3109(00)80300-8
   Reynolds R, 2009, INVEST OPHTH VIS SCI, V50, P5818, DOI 10.1167/iovs.09-3928
   Scholl HPN, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002593
   SCHREIBER RD, 1978, P NATL ACAD SCI USA, V75, P3948, DOI 10.1073/pnas.75.8.3948
   Seddon JM, 2005, ARCH OPHTHALMOL-CHIC, V123, P321, DOI 10.1001/archopht.123.3.321
   Smailhodzic D, 2012, OPHTHALMOLOGY, V119, P339, DOI 10.1016/j.ophtha.2011.07.056
   Stephens M, 2003, AM J HUM GENET, V73, P1162, DOI 10.1086/379378
   Stephens M, 2001, AM J HUM GENET, V68, P978, DOI 10.1086/319501
   van de Ven JPH, 2013, NAT GENET, V45, P813, DOI 10.1038/ng.2640
   Yates JRW, 2007, NEW ENGL J MED, V357, P553, DOI 10.1056/NEJMoa072618
   Zipfel PF, 2008, VACCINE, V26, pI67, DOI 10.1016/j.vaccine.2008.11.015
NR 22
TC 39
Z9 39
U1 0
U2 4
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD MAR 27
PY 2014
VL 9
IS 3
AR e93459
DI 10.1371/journal.pone.0093459
PG 9
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA AE0SW
UT WOS:000333677500126
PM 24675670
OA Green Submitted, gold, Green Published
DA 2022-11-30
ER

PT J
AU Baranano, AE
   Keane, PA
   Ruiz-Garcia, H
   Walsh, AC
   Sadda, SR
AF Baranano, Anne E.
   Keane, Pearse A.
   Ruiz-Garcia, Humberto
   Walsh, Alexander C.
   Sadda, Srinivas R.
TI Impact of scanning density on spectral domain optical coherence
   tomography assessments in neovascular age-related macular degeneration
SO ACTA OPHTHALMOLOGICA
LA English
DT Article
DE age-related macular degeneration; choroidal neovascularization; optical
   coherence Tomography; scanning density; spectral domain; vascular
   endothelial growth factor
ID QUANTITATIVE SUBANALYSIS; RANIBIZUMAB; REPRODUCIBILITY
AB Purpose: To determine the effect of optical coherence tomography (OCT) B-scan density on the qualitative assessment of neovascular age-related macular degeneration (AMD).
   Methods: Data were collected from 59 patients imaged with Topcon 3D OCT-1000 (128 B-scans x 512 A-scans). Custom software was used to generate less dense subsets of scans: 1/16 (eight B-scans), 1/8 (16 B-scans), 1/4 (32 B-scans) and 1/2 (64 B-scans). At each B-scan density, scans were assessed for cystoid spaces, subretinal fluid (SRF), subretinal tissue (SRT) and pigment epithelium detachment (PED). For each sampling density, sensitivity, specificity and predictive values were calculated using the full volume scan (128 B-scans) as the reference standard.
   Results: For cystoid spaces, the detection sensitivity was 76.3% at 1/16 density; this rose to 89.5% with a 1/4 density. For SRF, the detection sensitivity was 75.0% at a 1/16 density; this increased to 91.1% with 1/4 density. For PED, even at the lowest sampling density (1/16) the detection sensitivity was 86.4%; this rose to 94.9% at 1/4 density. For SRT, detection sensitivity at a 1/16 density was 64.7% and only rose above 90% with the densest sampling subset (1/2).
   Conclusions: Use of scanning protocols with reduced sampling densities resulted in decreased detection of key features of neovascular AMD; despite this, a sampling density reduced to 1/4 appeared to allow accurate assessment for most features. Current management of neovascular AMD is dependent on qualitative assessment of OCT images; with the recent proliferation of OCT systems, optimization and standardization of scanning protocols may be of value.
C1 [Baranano, Anne E.; Keane, Pearse A.; Ruiz-Garcia, Humberto; Walsh, Alexander C.; Sadda, Srinivas R.] Univ So Calif, Keck Sch Med, Doheny Eye Inst, Doheny Image Reading Ctr, Los Angeles, CA 90033 USA.
   [Keane, Pearse A.] Moorfields Eye Hosp NHS Fdn Trust, NIHR Biomed Res Ctr Ophthalmol, London, England.
   [Keane, Pearse A.] UCL Inst Ophthalmol, London, England.
C3 Doheny Eye Institute; University of Southern California; University of
   London; University College London; Moorfields Eye Hospital NHS
   Foundation Trust; University of London; University College London
RP Sadda, SR (通讯作者)，Doheny Eye Inst DEI 3623, 1450 San Pablo St, Los Angeles, CA 90033 USA.
EM ssadda@doheny.org
RI Keane, Pearse/AAE-5709-2019
OI Keane, Pearse/0000-0002-9239-745X
FU Carl Zeiss Meditec; Optos; Optovue Inc.; Department of Health's NIHR
   Biomedical Research Centre for Ophthalmology at Moorfields Eye Hospital;
   UCL Institute of Ophthalmology; Academy of Medical Sciences (AMS)
   [AMS-SGCL6-Keane] Funding Source: researchfish; National Institute for
   Health Research [CL-2010-18-004] Funding Source: researchfish
FX Drs Walsh and Sadda are co-inventors of Doheny intellectual property
   related to optical coherence tomography that has been licensed by Topcon
   Medical Systems and are members of the scientific advisory board for
   Heidelberg Engineering. Dr Sadda also receives research support from
   Carl Zeiss Meditec, Optos, and Optovue Inc.; This research has received
   a proportion of its funding from the Department of Health's NIHR
   Biomedical Research Centre for Ophthalmology at Moorfields Eye Hospital
   and UCL Institute of Ophthalmology. The views expressed in the
   publication are those of the authors and not necessarily those of the
   Department of Health.
CR Ahlers Christian, 2008, Ophthalmology, V115, pe39, DOI 10.1016/j.ophtha.2008.05.017
   Boyer DS, 2009, OPHTHALMOLOGY, V116, P1731, DOI 10.1016/j.ophtha.2009.05.024
   Bressler NM, 2009, OPHTHALMOLOGY, V116, pS15, DOI 10.1016/j.ophtha.2009.06.048
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Drexler W, 2008, PROG RETIN EYE RES, V27, P45, DOI 10.1016/j.preteyeres.2007.07.005
   Eriksson U, 2011, ACTA OPHTHALMOL
   Fung AE, 2007, AM J OPHTHALMOL, V143, P566, DOI 10.1016/j.ajo.2007.01.028
   Golbaz I, 2010, INVEST OPHTH VIS SCI, V52, P1599
   Grover S, 2009, AM J OPHTHALMOL, V148, P266, DOI 10.1016/j.ajo.2009.03.006
   Gupta OP, 2010, OPHTHALMOLOGY, V117, P2134, DOI 10.1016/j.ophtha.2010.02.032
   Holz FG, 2009, INVEST OPHTH VIS SCI, V50, P3095
   Jager RD, 2008, NEW ENGL J MED, V358, P2606, DOI 10.1056/NEJMra0801537
   Joeres S, 2007, INVEST OPHTH VIS SCI, V48, P4300, DOI 10.1167/iovs.07-0179
   Keane PA, 2010, EYE, V24, P422, DOI 10.1038/eye.2009.309
   Keane PA, 2008, INVEST OPHTH VIS SCI, V49, P3115, DOI 10.1167/iovs.08-1689
   Keane PA, 2010, INVEST OPHTH VIS SCI, V51, P5431, DOI 10.1167/iovs.09-4846
   Keane Pearse A, 2009, Int Ophthalmol Clin, V49, P61, DOI 10.1097/IIO.0b013e31819fd54f
   Keane PA, 2009, AM J OPHTHALMOL, V148, P242, DOI 10.1016/j.ajo.2009.03.004
   Keane PA, 2008, OPHTHALMOLOGY, V115, P2206, DOI 10.1016/j.ophtha.2008.08.016
   Kiernan DF, 2010, AM J OPHTHALMOL, V149, P18, DOI 10.1016/j.ajo.2009.08.037
   Lalwani GA, 2009, AM J OPHTHALMOL, V148, P43, DOI 10.1016/j.ajo.2009.01.024
   Manjunath V, 2010, AM J OPHTHALMOL, V150, P325, DOI 10.1016/j.ajo.2010.04.018
   Menke MN, 2011, ACTA OPHTHALMOL, V89, P346, DOI 10.1111/j.1755-3768.2009.01692.x
   Mitchell P, 2010, BRIT J OPHTHALMOL, V94, P2, DOI 10.1136/bjo.2009.159160
   Patel PJ, 2011, ACTA OPHTHALMOL, V89, P526, DOI 10.1111/j.1755-3768.2009.01761.x
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Sadda SR, 2007, INVEST OPHTH VIS SCI, V48, P839, DOI 10.1167/iovs.06-0554
   Sadda SR, 2006, OPHTHALMOLOGY, V113, P1187, DOI 10.1016/j.ophtha.2005.12.020
   Sadda SR, 2010, INVEST OPHTH VIS SCI, V51, P1071, DOI 10.1167/iovs.09-4325
   Sakamoto A, 2008, OPHTHALMOLOGY, V115, P1071, DOI 10.1016/j.ophtha.2007.09.001
   Sayanagi K, 2009, OPHTHALMOLOGY, V116, P947, DOI 10.1016/j.ophtha.2008.11.002
   Singer M, 2009, INVEST OPHTH VIS SCI, V50, P3093
   Spaide RF, 2009, AM J OPHTHALMOL, V147, P644, DOI 10.1016/j.ajo.2008.10.005
   Wolff B, 2011, ACTA OPHTHALMOL, V89, pE496, DOI 10.1111/j.1755-3768.2011.02144.x
   Zarbin MA, 2010, RETINA-J RET VIT DIS, V30, P1350, DOI 10.1097/IAE.0b013e3181f57e30
NR 35
TC 18
Z9 18
U1 0
U2 3
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1755-375X
EI 1755-3768
J9 ACTA OPHTHALMOL
JI Acta Ophthalmol.
PD JUN
PY 2012
VL 90
IS 4
BP E274
EP E280
DI 10.1111/j.1755-3768.2012.02398.x
PG 7
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 980OQ
UT WOS:000306903100004
PM 22429902
DA 2022-11-30
ER

PT J
AU Soysal, Y
   Inan, UU
   Kusbeci, T
   Imirzalioglu, N
AF Soysal, Yasemin
   Inan, Umit Ubeyt
   Kusbeci, Tuncay
   Imirzalioglu, Necat
TI Age-Related Macular Degeneration and Association of CFH Y402H and
   LOC387715 A69S Polymorphisms in a Turkish Population
SO DNA AND CELL BIOLOGY
LA English
DT Article
ID COMPLEMENT-FACTOR-H; HTRA1 PROMOTER POLYMORPHISM; GENE; RISK;
   SUSCEPTIBILITY; VARIANT; INCREASES; HAPLOTYPE; DRUSEN
AB Age-related macular degeneration (AMD) is a disease with multifactorial etiology characterized by irreversible loss of central visual acuity. The discovery of susceptive single-nucleotide polymorphisms (SNPs) has progressed our understanding of AMD. Complement factor H (CFH) gene Y402H polymorphism and high-temperature requirement A-1 (HTRA1) LOC387715 gene A69S polymorphisms are the most important SNPs reported in the literature. Determination of genetic risk factors and genotype-phenotype relationship in AMD may result in rapid and cost-effective therapeutic applications for young and old population. In this study, we hypothesized a potential association between CFH gene Y402H and HTRA1 LOC387715 gene A69S polymorphism in Turkish AMD patients. In blood samples from a total of 252 individuals, 147 clinically diagnosed as AMD and the others control, polymorphic sites in CFH, Y402H (Tsp509I T/C), and HTRA1, LOC387715 A69S (FnuHI G/T), were determined by polymerase chain reaction-restriction fragment length polymorphism analysis. There was significant difference between CFH genotypes in the AMD group, TT 21.8%, TC 48.3%, and CC 29.9%, and in the control subjects, TT 45% (p = 0.003), TC 41% (p = 0.0001), and CC 14% (p = 0.0001). Further, the A69S polymorphism of LOC387715 was investigated and found to be significantly associated with AMD. LOC387715 genotypes in the AMD group were GG 30.6%, GT 38.1%, and TT 31.3% and in the control subjects were GG 59% (p = 0.027), GT 39% (p = 0.0001), and TT 2% (p = 0.0001), respectively. We also found that Y402H C and A69S T allele were associated with AMD. This is the first study showing that Y402H and LOC387715 are associated with AMD in Turkish population.
C1 [Soysal, Yasemin; Imirzalioglu, Necat] Afyon Kocatepe Univ, Fac Med, Dept Med Genet, TR-03200 Afyon, Turkey.
   [Inan, Umit Ubeyt; Kusbeci, Tuncay] Afyon Kocatepe Univ, Fac Med, Dept Ophthalmol, Ahmet Necdet Sezer Arastirma Hastanesi, TR-03200 Afyon, Turkey.
C3 Afyon Kocatepe University; Afyon Kocatepe University
RP Soysal, Y (通讯作者)，Afyon Kocatepe Univ, Fac Med, Dept Med Genet, Ali Cetinkaya Kampusu,Dekanlik Binasi, TR-03200 Afyon, Turkey.
EM yasemin_soysal@yahoo.com
RI Kusbeci, Tuncay/AAO-1012-2020
OI Kusbeci, Tuncay/0000-0002-5169-4140
FU Afyon Kocatepe University [08.TIP.08]
FX This study was supported by the Afyon Kocatepe University Research Fund
   with code number 08.TIP.08.
CR [Anonymous], 2000, Community Eye Health, V13, P17
   Baird PN, 2006, INVEST OPHTH VIS SCI, V47, P4194, DOI 10.1167/iovs.05-1285
   Bergeron-Sawitzke J, 2009, EUR J HUM GENET, V17, P1190, DOI 10.1038/ejhg.2009.23
   Chu J, 2008, CHINESE MED J-PEKING, V121, P2525, DOI 10.1097/00029330-200812020-00011
   Conley YP, 2005, HUM MOL GENET, V14, P1991, DOI 10.1093/hmg/ddi204
   Dewan A, 2006, SCIENCE, V314, P989, DOI 10.1126/science.1133807
   Fisher SA, 2005, HUM MOL GENET, V14, P2257, DOI 10.1093/hmg/ddi230
   Frank R N, 2000, Trans Am Ophthalmol Soc, V98, P109
   GAUDERMAN WJ, 2006, QUANTO 1 1 COMPUTER
   Gotoh N, 2006, HUM GENET, V120, P139, DOI 10.1007/s00439-006-0187-0
   Hageman GS, 2001, PROG RETIN EYE RES, V20, P705, DOI 10.1016/S1350-9462(01)00010-6
   Hageman GS, 2005, P NATL ACAD SCI USA, V102, P7227, DOI 10.1073/pnas.0501536102
   Haines JL, 2005, SCIENCE, V308, P419, DOI 10.1126/science.1110359
   Hughes AE, 2007, PLOS MED, V4, P1993, DOI 10.1371/journal.pmed.0040355
   Jiang H, 2009, RETINA-J RET VIT DIS, V29, P974, DOI 10.1097/IAE.0b013e3181a3b90e
   Katta S, 2009, J GENET, V88, P425, DOI 10.1007/s12041-009-0064-4
   Klaver CCW, 1998, ARCH OPHTHALMOL-CHIC, V116, P1646, DOI 10.1001/archopht.116.12.1646
   Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557
   Lau LI, 2006, INVEST OPHTH VIS SCI, V47, P3242, DOI 10.1167/iovs.05-1532
   Lee WC, 2003, AM J EPIDEMIOL, V158, P397, DOI 10.1093/aje/kwg150
   Liutkeviciene R, 2010, MEDICINA-LITHUANIA, V46, P89, DOI 10.3390/medicina46020013
   Magnusson KP, 2006, PLOS MED, V3, P109, DOI 10.1371/journal.pmed.0030005
   Penfold PL, 2001, PROG RETIN EYE RES, V20, P385, DOI 10.1016/S1350-9462(00)00025-2
   Postel EA, 2005, AM J OPHTHALMOL, V139, P820, DOI 10.1016/j.ajo.2004.12.029
   Postel EA, 2006, OPHTHALMOLOGY, V113, P1504, DOI 10.1016/j.ophtha.2006.02.049
   Pulido JS, 2007, OPHTHALMIC GENET, V28, P203, DOI 10.1080/13816810701649617
   Rivera A, 2005, HUM MOL GENET, V14, P3227, DOI 10.1093/hmg/ddi353
   Ross RJ, 2007, INVEST OPHTH VIS SCI, V48, P1128, DOI 10.1167/iovs.06-0999
   Schmidt S, 2006, AM J HUM GENET, V78, P852, DOI 10.1086/503822
   Scholl HPN, 2007, MOL VIS, V13, P196
   Seddon JM, 1997, AM J OPHTHALMOL, V123, P199, DOI 10.1016/S0002-9394(14)71036-0
   Seddon JM, 2007, JAMA-J AM MED ASSOC, V297, P1793, DOI 10.1001/jama.297.16.1793
   Seitsonen SP, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003833
   Sepp T, 2006, INVEST OPHTH VIS SCI, V47, P536, DOI 10.1167/iovs.05-1143
   Shuler RK, 2007, ARCH OPHTHALMOL-CHIC, V125, P63, DOI 10.1001/archopht.125.1.63
   Simonelli F, 2006, BRIT J OPHTHALMOL, V90, P1142, DOI 10.1136/bjo.2006.096487
   Souied EH, 2005, MOL VIS, V11, P1135
   Tedeschi-Blok N, 2007, OPHTHALMOLOGY, V114, P99, DOI 10.1016/j.ophtha.2006.07.043
   Varma R, 2004, OPHTHALMOLOGY, V111, P1288, DOI 10.1016/j.ophtha.2004.01.023
   WEITER JJ, 1986, INVEST OPHTH VIS SCI, V27, P145
   Yoshida T, 2007, MOL VIS, V13, P545
   Yoshimura N, 2010, CLIN EXP OPHTHALMOL, V38, P1, DOI 10.1111/j.1442-9071.2009.02225.x
   Zareparsi S, 2005, AM J HUM GENET, V77, P149, DOI 10.1086/431426
NR 43
TC 12
Z9 12
U1 0
U2 1
PU MARY ANN LIEBERT, INC
PI NEW ROCHELLE
PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA
SN 1044-5498
EI 1557-7430
J9 DNA CELL BIOL
JI DNA Cell Biol.
PD MAR
PY 2012
VL 31
IS 3
BP 322
EP 329
DI 10.1089/dna.2011.1214
PG 8
WC Biochemistry & Molecular Biology; Cell Biology; Genetics & Heredity
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Cell Biology; Genetics & Heredity
GA 906PG
UT WOS:000301358100011
PM 21790300
DA 2022-11-30
ER

PT J
AU Xu, D
   Davila, JP
   Rahimi, M
   Rebhun, CB
   Alibhai, AY
   Waheed, NK
   Sarraf, D
AF Xu, David
   Davila, Juan Pablo
   Rahimi, Mansour
   Rebhun, Carl B.
   Alibhai, A. Yasin
   Waheed, Nadia K.
   Sarraf, David
TI Long-term Progression of Type 1 Neovascularization in Age-related
   Macular Degeneration Using Optical Coherence Tomography Angiography
SO AMERICAN JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
ID ENDOTHELIAL GROWTH-FACTOR; PIGMENT EPITHELIAL DETACHMENT; CHOROIDAL
   NEOVASCULARIZATION; FOLLOW-UP; RANIBIZUMAB; THERAPY; EYE; SECONDARY
AB PURPOSE: To analyze the long-term growth patterns of type 1 neovascularization (NV) in eyes with age-related macular degeneration (AMD) receiving anti-vascular endothelial growth factor (VEGF) therapy.
   DESIGN: Retrospective cohort study.
   METHODS: Patients were enrolled from 2 eye centers and underwent optical coherence tomography angiography (OCTA) imaging with follow-up greater than 1 year. Choroidal neovascularization (CNV) was manually segmented on OCTA images and compared between time points. CNV growth was subdivided into 3 categories based on OCTA area measurement: CNV doubling, modest growth of less than 50%, and shrinkage. These growth rates were correlated with OCTA morphologic features.
   RESULTS: Forty-one eyes were analyzed. Mean CNV area was 1.60 +/- 1.84 mm(2) at baseline and 1.80 +/- 1.84 mm(2) at 1 year. Thirty-three eyes (80%) displayed an increase in CNV area at 1 year with a mean increase of 0.20 +/- 0.38 mm(2) (P = .001). Eleven eyes (27%) underwent CNV doubling, 19 eyes (46%) illustrated modest growth, and 6 (15%) showed shrinkage. Anatomic features including a capillary fringe (odds ratio [OR] = 5.3, P = .036) and immature lesion morphology (OR = 4.2, P = .015) were significantly associated with CNV doubling. CNV growth occurred in 3 predominant patterns: "symmetric" growth, "asymmetric" growth, and "finger-like projections," which reflected the orientation of expansion of CNV. "Symmetric" and "asymmetric" growth together correlated with greater frequency of CNV doubling (OR = 15, P = .0048).
   CONCLUSION: OCTA provides noninvasive measurement of the area of neovascular lesions in AMD. Sustained growth of type 1 NV can be identified in the majority of lesions (80%) that display characteristic patterns of progression despite ongoing anti-VEGF therapy. (C) 2017 Elsevier Inc. All rights reserved.
C1 [Xu, David; Davila, Juan Pablo; Rahimi, Mansour; Sarraf, David] Univ Calif Los Angeles, David Geffen Sch Med, Stein Eye Inst, Los Angeles, CA 90095 USA.
   [Rebhun, Carl B.; Alibhai, A. Yasin; Waheed, Nadia K.] Tufts Med Ctr, New England Eye Ctr, Boston, MA USA.
   [Sarraf, David] Greater Los Angeles Vet Adm Healthcare Ctr, Los Angeles, CA USA.
C3 University of California System; University of California Los Angeles;
   University of California Los Angeles Medical Center; David Geffen School
   of Medicine at UCLA; Tufts Medical Center; US Department of Veterans
   Affairs; Veterans Health Administration (VHA); VA Greater Los Angeles
   Healthcare System
RP Sarraf, D (通讯作者)，Stein Eye Inst, 200 Stein Plaza, Los Angeles, CA 90095 USA.
EM dsarraf@ucla.edu
OI Xu, David/0000-0003-3649-4746
FU ALLERGAN (DUBLIN, IRELAND); HEIDELBERG ENGINEERING (Franklin,
   Massachusetts, USA); Regeneron (Tarrytown, New York, USA); Genentech
   (San Francisco, California, USA); Optovue (Fremont, California, USA)
FX D.S. RECEIVES RESEARCH GRANTS FROM ALLERGAN (DUBLIN, IRELAND),
   HEIDELBERG ENGINEERING (Franklin, Massachusetts, USA), Regeneron
   (Tarrytown, New York, USA), Genentech (San Francisco, California, USA),
   and Optovue (Fremont, California, USA).
CR Al-Sheikh M, 2017, RETINA
   Anand R, 2000, OPHTHALMOLOGY, V107, P2224
   Arnold J, 2001, AM J OPHTHALMOL, V131, P541
   Brown DM, 2007, AM J OPHTHALMOL, V144, P627, DOI 10.1016/j.ajo.2007.06.039
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Christenbury JG, 2017, RETINA
   Cole ED, 2016, RETINA-J RET VIT DIS, V36, pS83, DOI 10.1097/IAE.0000000000001338
   Coscas G, 2015, OPHTHALMIC RES, V54, P57, DOI 10.1159/000433547
   Coscas GJ, 2015, RETINA-J RET VIT DIS, V35, P2219, DOI 10.1097/IAE.0000000000000766
   Dansingani KK, 2015, OSLI RETINA, V46, P907, DOI 10.3928/23258160-20151008-02
   de Carlo Talisa E, 2015, Int J Retina Vitreous, V1, P5
   de Carlo TE, 2015, OPHTHALMOLOGY, V122, P1228, DOI 10.1016/j.ophtha.2015.01.029
   Engelbert M, 2010, RETINA-J RET VIT DIS, V30, P1368, DOI 10.1097/IAE.0b013e3181d50cbf
   Faridi A, 2017, OPHTHALMOL RETINA, V1, P294, DOI 10.1016/j.oret.2017.02.007
   Ferrara N, 2006, RETINA-J RET VIT DIS, V26, P859, DOI 10.1097/01.iae.0000242842.14624.e7
   Grossniklaus HE, 2004, AM J OPHTHALMOL, V137, P496, DOI 10.1016/j.ajo.2003.09.042
   Heier JS, 2012, OPHTHALMOLOGY, V119, P2537, DOI 10.1016/j.ophtha.2012.09.006
   Huang D, 2015, RETINA-J RET VIT DIS, V35, P2260, DOI 10.1097/IAE.0000000000000846
   Jia YL, 2014, OPHTHALMOLOGY, V121, P1435, DOI 10.1016/j.ophtha.2014.01.034
   Jung JJ, 2014, AM J OPHTHALMOL, V158, P769, DOI 10.1016/j.ajo.2014.07.006
   Kuehlewein L, 2015, RETINA-J RET VIT DIS, V35, P2229, DOI 10.1097/IAE.0000000000000835
   Kuehlewein L, 2015, AM J OPHTHALMOL, V160, P739, DOI 10.1016/j.ajo.2015.06.030
   Lumbroso B, 2015, RETINA-J RET VIT DIS, V35, P2242, DOI 10.1097/IAE.0000000000000879
   MAGUIRE MG, 1994, ARCH OPHTHALMOL-CHIC, V112, P480
   Martin DF, 2012, OPHTHALMOLOGY, V119, DOI 10.1016/j.ophtha.2012.03.053
   Moult E, 2014, OSLI RETINA, V45, P496, DOI 10.3928/23258160-20141118-03
   Muakkassa NW, 2015, RETINA-J RET VIT DIS, V35, P2252, DOI 10.1097/IAE.0000000000000836
   Nagiel A, 2015, RETINA-J RET VIT DIS, V35, P638, DOI 10.1097/IAE.0000000000000488
   Pauleikhoff D, 2005, RETINA-J RET VIT DIS, V25, P1065, DOI 10.1097/00006982-200512000-00016
   Phasukkijwatana N, 2017, BRIT J OPHTHALMOL, V101, P597, DOI 10.1136/bjophthalmol-2016-308815
   Rahimy E, 2014, RETINA-J RET VIT DIS, V34, P1289, DOI 10.1097/IAE.0000000000000130
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Rosenfeld PJ, 2016, INVEST OPHTH VIS SCI, V57, pOCT14, DOI 10.1167/iovs.16-19969
   Sarks JP, 1997, EYE, V11, P515, DOI 10.1038/eye.1997.137
   Schneider EW, 2014, INVEST OPHTH VIS SCI, V55, P542, DOI 10.1167/iovs.13-13034
   Schneider U, 2005, ACTA OPHTHALMOL SCAN, V83, P141, DOI 10.1111/j.1600-0420.2005.00443.x
   Spaide RF, 2006, AM J OPHTHALMOL, V141, P149, DOI 10.1016/j.ajo.2005.07.025
   Spaide RF, 2015, AM J OPHTHALMOL, V160, P6, DOI 10.1016/j.ajo.2015.04.012
   Sulzbacher F, 2017, ACTA OPHTHALMOL, V95, P414, DOI 10.1111/aos.13364
   Tokizawa R, 2016, INVEST OPHTH VIS SCI, V57
   Witmer AN, 2003, PROG RETIN EYE RES, V22, P1, DOI 10.1016/S1350-9462(02)00043-5
   Xu LN, 2015, RETINA-J RET VIT DIS, V35, P176, DOI 10.1097/IAE.0000000000000374
NR 42
TC 58
Z9 60
U1 0
U2 3
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 0002-9394
EI 1879-1891
J9 AM J OPHTHALMOL
JI Am. J. Ophthalmol.
PD MAR
PY 2018
VL 187
BP 10
EP 20
DI 10.1016/j.ajo.2017.12.005
PG 11
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA FZ1IP
UT WOS:000427330400007
PM 29269100
DA 2022-11-30
ER

PT J
AU Cicinelli, MV
   Rabiolo, A
   Marchese, A
   de Vitis, L
   Carnevali, A
   Querques, L
   Bandello, F
   Querques, G
AF Cicinelli, Maria Vittoria
   Rabiolo, Alessandro
   Marchese, Alessandro
   de Vitis, Luigi
   Carnevali, Adriano
   Querques, Lea
   Bandello, Francesco
   Querques, Giuseppe
TI Choroid morphometric analysis in non-neovascular age-related macular
   degeneration by means of optical coherence tomography angiography
SO BRITISH JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
ID RETICULAR PSEUDODRUSEN; OCT-ANGIOGRAPHY; CHORIOCAPILLARIS; THICKNESS;
   DISEASE; EYES; MACULOPATHY; DRUSEN; FLUORESCEIN; PREVALENCE
AB Aims To describe the vascular changes in patients affected by non-neovascular age-related macular degeneration (AMD), featuring reticular pseudodrusen (RPD), drusen, or both RPD and drusen by means of optical coherence tomography angiography (OCT-A).
   Methods Cross-sectional observational case series. Patients with non-neovascular AMD presenting at the Medical Retina Service of the Department of Ophthalmology, University Vita-Salute San Raffaele in Milan were recruited. Patients underwent best-corrected visual acuity, biomicroscopy, infrared reflectance, short-wavelength fundus autofluorescence and OCT-A (AngioPlex, CIRRUS HD-OCT 5000, Carl Zeiss Meditech, Dublin, USA). Main outcome was quantification of vessel density, stromal tissue, and vascular/stromal (V/S) ratio at the choriocapillaris (CC), the Sattler and Haller's and the whole choroid layers among different groups of patients with non-neovascular AMD by means of binarised OCTA scans.
   Results 45 eyes of 34 patients were enrolled (15 eyes of 11 patients with RPD, group 1; 15 eyes of 11 patients with drusen, group 2; 15 eyes of 12 patients with mixed phenotype, group 3). The CC, the Sattler and Haller's and the whole choroid vessel density were reduced in all groups of patients (p=0.023, p=0.007 and p=0.011 in group 1, group 2 and group 3 for the CC; p=0.021, p=0.037 and p=0.043 in group 1, group 2 and group 3 for the Sattler and Haller's density; p=0.016, p=0.002 and p<0.001 in group 1, group 2 and group 3 for the choroidal density), with significantly lower V/S ratios compared with healthy controls.
   Conclusions Patients with non-neovascular AMD show significant choroidal vascular depletion and fibrotic replacement, suggesting a possible role in the pathogenesis and progression of the disease.
C1 [Cicinelli, Maria Vittoria; Rabiolo, Alessandro; Marchese, Alessandro; de Vitis, Luigi; Querques, Lea; Bandello, Francesco; Querques, Giuseppe] Univ Vita Salute, San Raffaele Sci Inst, Dept Ophthalmol, Milan, Italy.
   [Carnevali, Adriano] Magna Graecia Univ Catanzaro, Dept Ophthalmol, Catanzaro, Italy.
C3 Vita-Salute San Raffaele University; IRCCS Ospedale San Raffaele; Magna
   Graecia University of Catanzaro
RP Querques, G (通讯作者)，Univ Vita Salute, IRCCS Osped San Raffaele, Dept Ophthalmol, Via Olgettina 60, I-20132 Milan, Italy.
EM giuseppe.querques@hotmail.it
RI Rabiolo, Alessandro/J-2831-2019; Marchese, Alessandro/AAG-7231-2019; De
   Vitis, Luigi Antonio/I-1667-2016; bandello, francesco/AAH-2405-2019;
   cicinelli, maria vittoria/M-1611-2019
OI De Vitis, Luigi Antonio/0000-0003-3778-8666; bandello,
   francesco/0000-0003-3238-9682; cicinelli, maria
   vittoria/0000-0003-2938-0409; Marchese, Alessandro/0000-0001-7716-7261;
   Rabiolo, Alessandro/0000-0002-7772-5929; Querques,
   Giuseppe/0000-0002-3292-9581
CR Abdolrahimzadeh S, 2016, RETINA, V12, P2329
   Alten F, 2016, GRAEF ARCH CLIN EXP, V254, P2165, DOI 10.1007/s00417-016-3375-1
   Alten F, 2013, INVEST OPHTH VIS SCI, V54, P3250, DOI 10.1167/iovs.13-11923
   Arnold JJ, 1997, AM J OPHTHALMOL, V124, P344, DOI 10.1016/S0002-9394(14)70826-8
   ARNOLD JJ, 1995, RETINA-J RET VIT DIS, V15, P183, DOI 10.1097/00006982-199515030-00001
   Battaglia Parodi M, 2016, BR J OPHTHALMOL
   Biesemeier A, 2014, NEUROBIOL AGING, V35, P2562, DOI 10.1016/j.neurobiolaging.2014.05.003
   Corvi F, 2016, BR J OPHTHALMOL
   Davis MD, 2005, ARCH OPHTHALMOL-CHIC, V123, P1484
   Ferris FL, 2013, OPHTHALMOLOGY, V120, P844, DOI 10.1016/j.ophtha.2012.10.036
   Flores-Moreno I, 2013, BRIT J OPHTHALMOL, V97, P1010, DOI 10.1136/bjophthalmol-2012-302836
   Fong AHC, 2011, RETINA-J RET VIT DIS, V31, P502, DOI 10.1097/IAE.0b013e3182083beb
   Gliem M, 2016, JAMA OPHTHALMOL, V134, P817, DOI 10.1001/jamaophthalmol.2016.1475
   Grewal DS, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0092841
   KLEIN R, 1992, OPHTHALMOLOGY, V99, P933
   KLEIN R, 1991, OPHTHALMOLOGY, V98, P1128
   Kur J, 2012, PROG RETIN EYE RES, V31, P377, DOI 10.1016/j.preteyeres.2012.04.004
   Linsenmeier RA, 2000, INVEST OPHTH VIS SCI, V41, P3117
   Manjunath V, 2011, AM J OPHTHALMOL, V152, P663, DOI 10.1016/j.ajo.2011.03.008
   May CA, 2005, J ANAT, V207, P381, DOI 10.1111/j.1469-7580.2005.00460.x
   McLeod DS, 2009, INVEST OPHTH VIS SCI, V50, P4982, DOI 10.1167/iovs.09-3639
   Mullins RE, 2011, INVEST OPHTH VIS SCI, V52, P1606, DOI 10.1167/iovs.10-6476
   Pauleikhoff D, 1999, ARCH OPHTHALMOL-CHIC, V117, P1353, DOI 10.1001/archopht.117.10.1353
   Piltz-Seymour IR, 2001, AM J OPHTHALMOL, V132, P63, DOI 10.1016/S0002-9394(01)00871-6
   Querques G, 2014, RETINA-J RET VIT DIS, V34, P321, DOI 10.1097/IAE.0b013e3182993df1
   Querques G, 2012, INVEST OPHTH VIS SCI, V53, P6017, DOI 10.1167/iovs.12-9692
   Querques G, 2012, INVEST OPHTH VIS SCI, V53, P1258, DOI 10.1167/iovs.11-8907
   Savastano MC, 2015, RETINA-J RET VIT DIS, V35, P2196, DOI 10.1097/IAE.0000000000000635
   Sonoda S, 2014, INVEST OPHTH VIS SCI, V55, P3893, DOI 10.1167/iovs.14-14447
   Spaide RF, 2008, AM J OPHTHALMOL, V146, P496, DOI 10.1016/j.ajo.2008.05.032
   Spaide RF, 2015, JAMA OPHTHALMOL, V133, P45, DOI 10.1001/jamaophthalmol.2014.3616
   Staurenghi G, 2014, OPHTHALMOLOGY, V121, P1572, DOI 10.1016/j.ophtha.2014.02.023
   Tan KA, 2016, SURV OPHTHALMOL, V61, P566, DOI 10.1016/j.survophthal.2016.02.007
   Ueda-Arakawa N, 2014, AM J OPHTHALMOL, V157, P994, DOI 10.1016/j.ajo.2014.01.018
   Zheng F, 2016, OSLI RETINA, V47, P517, DOI 10.3928/23258160-20160601-02
   Zweifel SA, 2010, OPHTHALMOLOGY, V117, P1775, DOI 10.1016/j.ophtha.2010.01.027
NR 36
TC 60
Z9 60
U1 0
U2 5
PU BMJ PUBLISHING GROUP
PI LONDON
PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND
SN 0007-1161
EI 1468-2079
J9 BRIT J OPHTHALMOL
JI Br. J. Ophthalmol.
PD SEP
PY 2017
VL 101
IS 9
BP 1193
EP 1200
DI 10.1136/bjophthalmol-2016-309481
PG 8
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA FE5BJ
UT WOS:000408226700008
PM 28057649
DA 2022-11-30
ER

PT J
AU Feng, KM
   Chien, WC
   Chen, JT
   Chen, YH
   Chung, CH
   Sun, CA
   Chen, CL
AF Feng, Kathy Ming
   Chien, Wu-Chien
   Chen, Jiann-Torng
   Chen, Yi-Hao
   Chung, Chi-Hsiang
   Sun, Chien-An
   Chen, Ching-Long
TI The impact of glucosamine on age-related macular degeneration in
   patients: A nationwide, population-based cohort study
SO PLOS ONE
LA English
DT Article
ID RISK-FACTORS; DISEASE BURDEN; TNF-ALPHA; PREVALENCE; INFLAMMATION;
   SULFATE; ICAM-1
AB Purpose To analyze the association between glucosamine (GlcN) use and the risk of age-related macular degeneration (AMD) using claims data from the National Health Insurance Research Database (NHIRD).
   Methods A retrospective, population-based study was conducted with NHIRD data from a 14-year period (2000-2013). Chi-squared and Student's t-tests were used to evaluate differences between the study and comparison cohorts for categorical and continuous variables, respectively. Risk factors for disease development were examined by the adjusted hazard ratio (aHR) with 95% confidence interval. Kaplan-Meier analysis was performed to compare the cumulative risk of AMD between the two cohorts.
   Results In total, 1,344 patients with GlcN treatment were enrolled in the study cohort and 5,376 patients without GlcN use were enrolled in the comparison cohort. The incidence rate of AMD was lower with GlcN use (3.65%) than without GlcN use (5.26%) (P = 0.014). GlcN use was associated with a lower risk of developing AMD among patients with hyperlipidemia, coronary artery disease, chronic obstructive pulmonary disease, stroke, other neurological disorders, or degenerative arthritis. Although the incidence of wet type AMD did not significantly differ (P = 0.91), the incidence of dry type AMD was lower in patients with GlcN use (2.9%) than those without GlcN use (4.84%) (P = 0.003). Kaplan-Meier analysis similarly revealed a lower rate of dry type AMD in patients with GlcN use compared to those without GlcN use (log-rank P = 0.004).
   Conclusions GlcN treatment can decrease the risk of developing dry type AMD. Further prospective controlled studies are needed to determine the effectiveness of GlcN treatment in patients with AMD and the associated mechanism.
C1 [Feng, Kathy Ming; Chen, Jiann-Torng; Chen, Yi-Hao; Chen, Ching-Long] Triserv Gen Hosp, Natl Def Med Ctr, Dept Ophthalmol, Taipei, Taiwan.
   [Chien, Wu-Chien; Chung, Chi-Hsiang] Triserv Gen Hosp, Natl Def Med Ctr, Dept Med Res, Taipei, Taiwan.
   [Chien, Wu-Chien; Chung, Chi-Hsiang] Natl Def Med Ctr, Sch Publ Hlth, Taipei, Taiwan.
   [Chien, Wu-Chien] Taiwanese Injury Prevent & Safety Promot Assoc, Taipei, Taiwan.
   [Chien, Wu-Chien] Natl Def Med Ctr, Grad Inst Life Sci, Taipei, Taiwan.
   [Sun, Chien-An] Fu Jen Catholic Univ, Coll Med, Dept Publ Hlth, New Taipei, Taiwan.
   [Sun, Chien-An] Fu Jen Catholic Univ, Coll Med, Big Data Res Ctr, New Taipei, Taiwan.
C3 National Defense Medical Center; Tri-Service General Hospital; National
   Defense Medical Center; Tri-Service General Hospital; National Defense
   Medical Center; National Defense Medical Center; Fu Jen Catholic
   University; Fu Jen Catholic University
RP Chen, CL (通讯作者)，Triserv Gen Hosp, Natl Def Med Ctr, Dept Ophthalmol, Taipei, Taiwan.
EM doc30881@mail.ndmctsgh.edu.tw
RI Chung, Chi-Hsiang/AAY-3386-2021
FU Ministry of Science and Technology, Taiwan, Republic of China [MOST
   107-2314-B-016 -031-MY3]; Tri-Service General Hospital, Taiwan, Republic
   of China [TSGH-D-110112, TSGHD-110109, TSGH-B-110012]; Ministry of
   National Defense, Taiwan, Republic of China [MND-MAB-110-084,
   MAB-E-110001]
FX This research was supported in part by Grant MOST 107-2314-B-016
   -031-MY3 from the Ministry of Science and Technology, Taiwan, Republic
   of China; Grant TSGH-D-110112, TSGHD-110109, TSGH-B-110012 from the
   Tri-Service General Hospital, Taiwan, Republic of China; Grant
   MND-MAB-110-084, MAB-E-110001 from the Ministry of National Defense,
   Taiwan, Republic of China. All the funders had no role in study design,
   data collection and analysis, decision to publish, or preparation of the
   manuscript.
CR Al-Zamil WM, 2017, CLIN INTERV AGING, V12, P1313, DOI 10.2147/CIA.S143508
   Anderson JW, 2005, FOOD CHEM TOXICOL, V43, P187, DOI 10.1016/j.fct.2004.11.006
   Barnes PJ, 2017, CLIN SCI, V131, P1541, DOI 10.1042/CS20160487
   BIRD AEC, 1995, SURV OPHTHALMOL, V39, P367, DOI 10.1016/S0039-6257(05)80092-X
   Chakravarthy U, 2010, BMC OPHTHALMOL, V10, DOI 10.1186/1471-2415-10-31
   Chang YH, 2008, INVEST OPHTH VIS SCI, V49, P5441, DOI 10.1167/iovs.08-1784
   Chen CL, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19051416
   Chen CL, 2012, INVEST OPHTH VIS SCI, V53, P2281, DOI 10.1167/iovs.11-9291
   Chen J.-T., 2018, J MED SCI, V38, P16, DOI [10.4103/jmedsci.jmedsci_138_17, DOI 10.4103/JMEDSCI.JMEDSCI_138_17, 10.4103/jmedsci.jmedsci%5F138%5F17, DOI 10.4103/JMEDSCI.JMEDSCI%5F138%5F17]
   Chen JT, 2006, INVEST OPHTH VIS SCI, V47, P664, DOI 10.1167/iovs.05-1008
   Chen SJ, 2008, INVEST OPHTH VIS SCI, V49, P3126, DOI 10.1167/iovs.08-1803
   Cheung CMG, 2012, ARCH OPHTHALMOL-CHIC, V130, P480, DOI 10.1001/archophthalmol.2011.376
   Chou LY, 2020, MOLECULES, V25, DOI 10.3390/molecules25163667
   Datta S, 2017, PROG RETIN EYE RES, V60, P201, DOI 10.1016/j.preteyeres.2017.03.002
   FERRIS FL, 1984, ARCH OPHTHALMOL-CHIC, V102, P1640
   Gouze JN, 2002, FEBS LETT, V510, P166, DOI 10.1016/S0014-5793(01)03255-0
   Isas JM, 2010, INVEST OPHTH VIS SCI, V51, P1304, DOI 10.1167/iovs.09-4207
   Jager RD, 2008, NEW ENGL J MED, V358, P2606, DOI 10.1056/NEJMra0801537
   Kauppinen A, 2016, CELL MOL LIFE SCI, V73, P1765, DOI 10.1007/s00018-016-2147-8
   Klein R, 2008, ARCH OPHTHALMOL-CHIC, V126, P840, DOI 10.1001/archopht.126.6.840
   Klein R, 2010, ARCH OPHTHALMOL-CHIC, V128, P750, DOI 10.1001/archophthalmol.2010.92
   Li ZH, 2020, ANN RHEUM DIS, V79, P829, DOI 10.1136/annrheumdis-2020-217176
   Ma H, 2019, BMJ-BRIT MED J, V365, DOI 10.1136/bmj.l1628
   Majumder S, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0025416
   Mitchell P, 2018, LANCET, V392, P1147, DOI 10.1016/S0140-6736(18)31550-2
   Nevado-Holgado AJ, 2016, BMJ OPEN, V6, DOI 10.1136/bmjopen-2016-012177
   Prenner JL, 2015, AM J OPHTHALMOL, V160, P725, DOI 10.1016/j.ajo.2015.06.023
   Reginster JY, 2012, RHEUMATOL INT, V32, P2959, DOI 10.1007/s00296-012-2416-2
   Reginster JY, 2001, LANCET, V357, P251, DOI 10.1016/S0140-6736(00)03610-2
   Rong SS, 2019, BRIT J OPHTHALMOL, V103, P1777, DOI 10.1136/bjophthalmol-2018-313277
   Smith W, 2001, OPHTHALMOLOGY, V108, P697, DOI 10.1016/S0161-6420(00)00580-7
   Thornton J, 2005, EYE, V19, P935, DOI 10.1038/sj.eye.6701978
   Velez-Montoya R, 2014, RETINA-J RET VIT DIS, V34, P423, DOI 10.1097/IAE.0000000000000036
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
NR 34
TC 1
Z9 1
U1 0
U2 4
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD MAY 19
PY 2021
VL 16
IS 5
AR e0251925
DI 10.1371/journal.pone.0251925
PG 15
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA SW6NP
UT WOS:000664630900079
PM 34010361
OA gold, Green Published
DA 2022-11-30
ER

PT J
AU Kawashima, Y
   Hata, M
   Oishi, A
   Ooto, S
   Yamashiro, K
   Tamura, H
   Miyata, M
   Uji, A
   Ueda-Arakawa, N
   Tsujikawa, A
AF Kawashima, Yu
   Hata, Masayuki
   Oishi, Akio
   Ooto, Sotaro
   Yamashiro, Kenji
   Tamura, Hiroshi
   Miyata, Manabu
   Uji, Akihito
   Ueda-Arakawa, Naoko
   Tsujikawa, Akitaka
TI Association of Vascular Versus Avascular Subreti nal Hyperreflective
   Material With Aflibercept Response in Age-related Macular Degeneration
SO AMERICAN JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
ID POLYPOIDAL CHOROIDAL VASCULOPATHY; COHERENCE TOMOGRAPHY ANGIOGRAPHY;
   EXTERNAL LIMITING MEMBRANE; TREATMENTS TRIALS; FLUORESCEIN ANGIOGRAPHY;
   VISION LOSS; NEOVASCULARIZATION; RANIBIZUMAB; OUTCOMES; THERAPY
AB PURPOSE: To investigate flow signal within subretinal hyperreflective material (SHRM) using optical coherence tomography angiography (OCTA) and its association with aflibercept treatment responses in treatment-naive neovascular age-related macular degeneration (nAMD).
   DESIGN: Prospective consecutive interventional case series.
   METHODS: Forty-four eyes of 44 patients with treatment-naive nAMD manifesting SHRM on OCT were studied. All patients underwent OCTA and received 3 monthly aflibercept injections. The intrinsic flow signals within SHRM were quantitatively analyzed using OCTA, and eyes were classified into the vascular and avascular SHRM groups.
   RESULTS: Of 44 eyes, 21 (47.7%) and 23 (52.3%) showed vascular SHRM and avascular SHRM, respectively. Compared with eyes with avascular SHRM, eyes with vascular SHRM showed higher rates of external limiting membrane (ELM) disruption owing to SHRM (P = .015), classic choroidal neovascularization (CNV) (85.7% vs 26.1%, P = .87 x 10(-4)), and intraretinal fluid (P = .008) at baseline. After 3 aflibercept injections, 38 eyes (86.4%) showed dry macula despite persistent SHRM in 24 eyes (54.5%). Compared with the eyes with resolved SHRM, those with persistent SHRM showed higher rate of vascular SHRM (75.0% vs 15.0%, P = .86 x 10(-4)), classic CNV (P = .032), absence of polypoidal lesion (P = .020), ELM disruption owing to SHRM (P = .042), and intraretinal fluid (P = .008). Dry macula after loading injections was significantly associated with SHRM resolution (P = .025).
   CONCLUSIONS: In nAMD, SHRM can be categorized as vascular and avascular by quantitative OCTA analysis. Vascular SHRM persisted after treatment and was associated with failure to achieve dry macula, suggesting that vascular SHRM is predictive of lower response to anti-VEGF therapy. (C) 2017 Elsevier Inc. All rights reserved.
C1 [Kawashima, Yu; Hata, Masayuki; Oishi, Akio; Ooto, Sotaro; Yamashiro, Kenji; Tamura, Hiroshi; Miyata, Manabu; Uji, Akihito; Ueda-Arakawa, Naoko; Tsujikawa, Akitaka] Kyoto Univ, Grad Sch Med, Dept Ophthalmol & Visual Sci, Kyoto, Japan.
C3 Kyoto University
RP Hata, M (通讯作者)，Kyoto Univ, Grad Sch Med, Dept Ophthalmol & Visual Sci, Sakyo Ku, 54 Kawahara Cho, Kyoto 6068507, Japan.
EM trj74h6@kuhp.kyoto-u.ac.jp
RI Miyata, Manabu/U-9008-2018; Oishi, Akio/AAE-9996-2020; TAMURA,
   Hiroshi/H-1855-2011
OI Oishi, Akio/0000-0002-0977-9458; TAMURA, Hiroshi/0000-0002-7740-2732;
   Tsujikawa, Akitaka/0000-0003-0779-7799; Yamashiro,
   Kenji/0000-0001-9354-8558; Miyata, Manabu/0000-0002-7574-1749
FU Japan Society for the Promotion of Science, Tokyo, Japan [24791847];
   Innovative Techno-Hub for Integrated Medical Bio-Imaging of the Project
   for Developing Innovation Systems, from the Ministry of Education,
   Culture, Sports, Science, and Technology (MEXT), Tokyo, Japan;
   Grants-in-Aid for Scientific Research [26861451] Funding Source: KAKEN
FX THIS RESEARCH WAS SUPPORTED IN PART BY A GRANT-IN-AID FOR SCIENTIFIC
   RESEARCH (NO. 24791847) from the Japan Society for the Promotion of
   Science, Tokyo, Japan, and the Innovative Techno-Hub for Integrated
   Medical Bio-Imaging of the Project for Developing Innovation Systems,
   from the Ministry of Education, Culture, Sports, Science, and Technology
   (MEXT), Tokyo, Japan.
CR Bourne RRA, 2013, LANCET GLOB HEALTH, V1, pE339, DOI 10.1016/S2214-109X(13)70113-X
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   BUNTMILAM AH, 1985, INVEST OPHTH VIS SCI, V26, P1377
   Chae B, 2015, INVEST OPHTH VIS SCI, V56, P5040, DOI 10.1167/iovs.15-16494
   Dansingani KK, 2016, AM J OPHTHALMOL, V169, P235, DOI 10.1016/j.ajo.2016.06.031
   Grunwald JE, 2012, OPHTHALMOLOGY, V119, P1634, DOI 10.1016/j.ophtha.2012.02.013
   Hata M, 2017, RETINA-J RET VIT DIS, V37, P1320, DOI 10.1097/IAE.0000000000001370
   Heier JS, 2012, OPHTHALMOLOGY, V119, P2537, DOI 10.1016/j.ophtha.2012.09.006
   Kawashima Y, 2015, GRAEF ARCH CLIN EXP, V253, P1471, DOI 10.1007/s00417-014-2838-5
   Koizumi H, 2016, OPHTHALMOLOGY, V123, P617, DOI 10.1016/j.ophtha.2015.10.039
   Malihi M, 2017, BRIT J OPHTHALMOL, V101, P45, DOI 10.1136/bjophthalmol-2016-309094
   Marmor MF, 1999, DOC OPHTHALMOL, V97, P239, DOI 10.1023/A:1002192829817
   Miyata M, 2016, AM J OPHTHALMOL, V165, P108, DOI 10.1016/j.ajo.2016.03.009
   Murakami T, 2011, AM J OPHTHALMOL, V151, P310, DOI 10.1016/j.ajo.2010.08.022
   Oishi A, 2015, AM J OPHTHALMOL, V159, P853, DOI 10.1016/j.ajo.2015.01.018
   Oishi A, 2010, AM J OPHTHALMOL, V150, P27, DOI 10.1016/j.ajo.2010.02.012
   Ooto S, 2011, RETINA-J RET VIT DIS, V31, P527, DOI 10.1097/IAE.0b013e3181eef2db
   Ristau T, 2014, OPHTHALMOLOGICA, V231, P37, DOI 10.1159/000354551
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Schmidt-Erfurth U, 2014, OPHTHALMOLOGY, V121, P193, DOI 10.1016/j.ophtha.2013.08.011
   Shah N, 2016, OPHTHALMOLOGY, V123, P858, DOI 10.1016/j.ophtha.2015.11.030
   Shah VP, 2014, RETINA-J RET VIT DIS, V34, P1281, DOI 10.1097/IAE.0000000000000166
   STERNBERG P, 1991, ARCH OPHTHALMOL-CHIC, V109, P1242
   Tamura H, 2007, BRIT J OPHTHALMOL, V91, P1152, DOI 10.1136/bjo.2006.112318
   UGA S, 1973, INVEST OPHTH VISUAL, V12, P295
   Willoughby AS, 2015, OPHTHALMOLOGY, V122, P1846, DOI 10.1016/j.ophtha.2015.05.042
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
NR 27
TC 16
Z9 16
U1 0
U2 6
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0002-9394
EI 1879-1891
J9 AM J OPHTHALMOL
JI Am. J. Ophthalmol.
PD SEP
PY 2017
VL 181
BP 61
EP 70
DI 10.1016/j.ajo.2017.06.015
PG 10
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA FH1CV
UT WOS:000410878200009
PM 28669776
OA Green Submitted
DA 2022-11-30
ER

PT J
AU Klimscha, S
   Waldstein, SM
   Schlegl, T
   Bogunovic, H
   Sadeghipour, A
   Philip, AM
   Podkowinski, D
   Pablik, E
   Zhang, L
   Abramoff, MD
   Sonka, M
   Gerendas, BS
   Schmidt-Erfurth, U
AF Klimscha, Sophie
   Waldstein, Sebastian M.
   Schlegl, Thomas
   Bogunovic, Hrvoje
   Sadeghipour, Amir
   Philip, Ana-Maria
   Podkowinski, Dominika
   Pablik, Eleonore
   Zhang, Li
   Abramoff, Michael D.
   Sonka, Milan
   Gerendas, Bianca S.
   Schmidt-Erfurth, Ursula
TI Spatial Correspondence Between Intraretinal Fluid, Subretinal Fluid, and
   Pigment Epithelial Detachment in Neovascular Age-Related Macular
   Degeneration
SO INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE
LA English
DT Article
DE optical coherence tomography; automated image analysis; age-related
   macular; degeneration; intraretinal cystoid fluid; subretinal fluid
ID VISUAL-ACUITY; CHOROIDAL NEOVASCULARIZATION; TREATMENTS TRIALS;
   MORPHOLOGY
AB PURPOSE. To identify the spatial distribution of exudative features of choroidal neovascularization in neovascular age-related macular degeneration (nAMD) based on the localization of intraretinal cystoid fluid (IRC), subretinal fluid (SRF), and pigment-epithelial detachment (PED).
   METHODS. This retrospective cross-sectional study included spectral-domain optical coherence tomography volume scans (6 X 6 mm) of 1341 patients with treatment-naive nAMD. IRC, SRF, and PED were detected on a per-voxel basis using fully automated segmentation algorithms. Two subsets of 37 volumes each were manually segmented to validate the automated results. The spatial correspondence of components was quantified by computing proportions of IRC, SRF-, or PED-presenting A-scans simultaneously affected by the respective other pathomorphologic components on a per-patient basis. The median across the population is reported. Odds ratios between pairs of lesions were calculated and tested for significance pixel wise.
   RESULTS. Automated image segmentation was successful in 1182 optical coherence tomography volumes, yielding more than 61 million A-scans for analysis. Overall, 81% of eyes showed IRC, 95% showed SRF, and 92% showed PED. IRC-presenting A-scans also showed SRF in a median 2.5%, PED in 32.9%. Of the SRF-presenting A-scans, 0.3% demonstrated IRC, 1.4% FED. Of the PED-presenting A-scans, 5.2% contained IRC, 2.0% SRF Similar patterns were observed in the manually segmented subsets and via pixel-wise odds ratio analysis.
   CONCLUSIONS. Automated analyses of large-scale datasets in a cross-sectional study 01 1182 patients with active treatment-naive nAMD demonstrated low spatial correlation of SRF with MC and PED in contrast to increased colocalization of IRC and PED. These morphological associations may contribute to our understanding of functional deficits in nAMD.
C1 [Klimscha, Sophie; Waldstein, Sebastian M.; Schlegl, Thomas; Bogunovic, Hrvoje; Sadeghipour, Amir; Philip, Ana-Maria; Podkowinski, Dominika; Gerendas, Bianca S.; Schmidt-Erfurth, Ursula] Med Univ Vienna, Christian Doppler Lab Ophthalm Image Anal, Vienna Reading Ctr, Dept Ophthalmol & Optometry, Vienna, Austria.
   [Pablik, Eleonore] Med Univ Vienna, Ctr Med Stat Informat & Intelligent Syst, Vienna, Austria.
   [Zhang, Li; Abramoff, Michael D.; Sonka, Milan] Univ Iowa, Dept Elect & Comp Engn, Iowa City, IA 52242 USA.
C3 Medical University of Vienna; Medical University of Vienna; University
   of Iowa
RP Schmidt-Erfurth, U (通讯作者)，Med Univ Vienna, Dept Ophthalmol, Spitalgasse 23, A-1090 Vienna, Austria.
EM ursula.schmidt-erfurth@meduniwien.ac.at
RI Bogunovic, Hrvoje/J-3445-2014; Abramoff, Michael D/A-5836-2009
OI Bogunovic, Hrvoje/0000-0002-9168-0894; Abramoff, Michael
   D/0000-0002-3490-0037; Gerendas, Bianca S./0000-0001-8940-8130;
   Schmidt-Erfurth, Ursula/0000-0002-7788-7311; Riedl,
   Sophie/0000-0003-0003-0886; Schlegl, Thomas/0000-0003-0706-7876
FU Austrian Federal Ministry of Science, Research and Economy; National
   Foundation for Research, Technology and Development
FX The authors thank the Austrian Federal Ministry of Science, Research and
   Economy and the National Foundation for Research, Technology and
   Development for support.; Supported by the Austrian Federal Ministry of
   Science, Research and Economy and the National Foundation for Research,
   Technology and Development. The funding organizations had no role in the
   design or conduct of the study.
CR Deo RC, 2015, CIRCULATION, V132, P1920, DOI 10.1161/CIRCULATIONAHA.115.001593
   Engelbert M, 2010, RETINA-J RET VIT DIS, V30, P1368, DOI 10.1097/IAE.0b013e3181d50cbf
   Freund KB, 2010, RETINA-J RET VIT DIS, V30, P1333, DOI 10.1097/IAE.0b013e3181e7976b
   Garvin MK, 2009, IEEE T MED IMAGING, V28, P1436, DOI 10.1109/TMI.2009.2016958
   Gianniou C, 2015, RETINA-J RET VIT DIS, V35, P1195, DOI 10.1097/IAE.0000000000000465
   Jaffe GJ, 2013, OPHTHALMOLOGY, V120, P1860, DOI 10.1016/j.ophtha.2013.01.073
   Kanagasingam Y, 2014, PROG RETIN EYE RES, V38, P20, DOI 10.1016/j.preteyeres.2013.10.002
   Lee K, 2010, IEEE T MED IMAGING, V29, P159, DOI 10.1109/TMI.2009.2031324
   Sadda ST, 2014, AM AC OPHTH ANN M RE
   Sato T, 2015, RETINA-J RET VIT DIS, V35, P1292, DOI 10.1097/IAE.0000000000000505
   Schlegl Thomas, 2015, Inf Process Med Imaging, V24, P437, DOI 10.1007/978-3-319-19992-4_34
   Schmidt-Erfurth U, 2016, PROG RETIN EYE RES, V50, P1, DOI 10.1016/j.preteyeres.2015.07.007
   Schmidt-Erfurth U, 2015, OPHTHALMOLOGY, V122, P822, DOI 10.1016/j.ophtha.2014.11.017
   Schmidt-Erfurth U, 2014, BRIT J OPHTHALMOL, V98, P1144, DOI 10.1136/bjophthalmol-2014-305702
   Segal O, 2016, RETINA-J RET VIT DIS, V36, P259, DOI 10.1097/IAE.0000000000000690
   Sharma S, 2016, OPHTHALMOLOGY, V123, P865, DOI 10.1016/j.ophtha.2015.12.002
   Simader C, 2014, OPHTHALMOLOGY, V121, P1237, DOI 10.1016/j.ophtha.2013.12.029
   Sulzbacher F, 2015, INVEST OPHTH VIS SCI, V56, P1158, DOI 10.1167/iovs.14-14298
   Waldstein SM, 2016, JAMA OPHTHALMOL, V134, P182, DOI 10.1001/jamaophthalmol.2015.4948
   Waldstein SM, 2016, OPHTHALMOLOGY, V123, P60, DOI 10.1016/j.ophtha.2015.09.013
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
   Zhang L, 2014, INVEST OPHTH VIS SCI, V55, P2329, DOI 10.1167/iovs.13-13048
NR 22
TC 23
Z9 24
U1 0
U2 0
PU ASSOC RESEARCH VISION OPHTHALMOLOGY INC
PI ROCKVILLE
PA 12300 TWINBROOK PARKWAY, ROCKVILLE, MD 20852-1606 USA
SN 0146-0404
EI 1552-5783
J9 INVEST OPHTH VIS SCI
JI Invest. Ophthalmol. Vis. Sci.
PD AUG
PY 2017
VL 58
IS 10
BP 4039
EP 4048
DI 10.1167/iovs.16-20201
PG 10
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA FH2AG
UT WOS:000410940400024
PM 28813577
OA gold
DA 2022-11-30
ER

PT J
AU Park, SS
   Truong, SN
   Zawadzki, RJ
   Alam, S
   Choi, SS
   Telander, DG
   Werner, JS
   Morse, LS
AF Park, Susanna S.
   Truong, Steven N.
   Zawadzki, Robert J.
   Alam, Suhail
   Choi, Stacey S.
   Telander, David G.
   Werner, John S.
   Morse, Lawrence S.
TI High-Resolution Fourier-Domain Optical Coherence Tomography of Choroidal
   Neovascular Membranes Associated with Age-Related Macular Degeneration
SO INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE
LA English
DT Article
ID CLINICOPATHOLOGICAL CORRELATION; PATHOLOGICAL FEATURES; RANIBIZUMAB;
   VERTEPORFIN; PREVALENCE; FREQUENCY; THERAPY
AB PURPOSE. To investigate the use of high-resolution Fourier-domain optical coherence tomography (Fd-OCT) to image choroidal neovascular membranes (CNVMs) associated with exudative age-related macular degeneration (eAMD).
   METHODS. An Fd-OCT instrument with axial resolution of 4 to 4.5 mu m and transverse resolution of 10 to 15 mu m was used to image 21 eyes (19 subjects) with newly diagnosed eAMD. A raster series of 100 B-scans separated by 60 mu m was used to study the growth pattern of CNVM and associated morphologic changes. CNVM size was determined using 250 to 300 serial virtual C-scans of reconstructed three-dimensional macular volume.
   RESULTS. A highly reflective subretinal and/or subretinal pigment epithelial (RPE) lesion that co-localized with the CNVM seen on fluorescein angiography was detected in all eyes by Fd-OCT. Although a combined subretinal and sub-RPE growth pattern of various degrees was noted in 15 (71%) eyes, a statistically significant difference in the distribution of growth pattern was noted when classic CNVM was compared with occult CNVM (chi(2) = 10.4, df = 2, P < 0.005). Classic lesions had >90% subretinal growth pattern, whereas occult lesions had a more variable growth pattern. Angiographic CNVM size correlated with size on Fd-OCT but correlation was better for classic CNVM (classic, r = 0.99, P < 0.0001; nonclassic, r = 0.78, P < 0.001).
   CONCLUSIONS. Fd-OCT is a promising potential alternative modality to visualize CNVM with AMD. Angiographic lesion size and type correlated with growth pattern and size of CNVM on Fd-OCT, with correlation being stronger for classic lesions. (Invest Ophthalmol Vis Sci. 2010;51:4200-4206) DOI:10.1167/iovs.09-4256
C1 [Park, Susanna S.; Truong, Steven N.; Zawadzki, Robert J.; Alam, Suhail; Choi, Stacey S.; Telander, David G.; Werner, John S.; Morse, Lawrence S.] Univ Calif, Dept Ophthalmol & Vis Sci, Davis Med Ctr, Sacramento, CA 95817 USA.
RP Park, SS (通讯作者)，Univ Calif, Dept Ophthalmol & Vis Sci, Davis Med Ctr, 4860 Y St,Suite 2400, Sacramento, CA 95817 USA.
EM susanna.park@ucdmc.ucdavis.du
RI Zawadzki, Robert/E-7534-2011; Zawadzki, Robert J./S-3236-2019
OI Zawadzki, Robert/0000-0002-9574-156X; Zawadzki, Robert
   J./0000-0002-9574-156X; Morse, Lawrence/0000-0002-1758-2348
FU National Eye Institute, Bethesda, MD [EY014743]; Research to Prevent
   Blindness (RPB), New York, NY; RPB; NATIONAL EYE INSTITUTE [R01EY014743]
   Funding Source: NIH RePORTER
FX Supported by Grant EY014743 (JSW) from the National Eye Institute,
   Bethesda, MD, and an unrestricted departmental grant from Research to
   Prevent Blindness (RPB), New York, NY. JSW is the recipient of an RPB
   Senior Scientist Award.
CR Alam S, 2006, OPHTHALMOLOGY, V113, P1425, DOI 10.1016/j.ophtha.2006.03.020
   [Anonymous], 1993, Arch Ophthalmol, V111, P1200
   BRESSLER SB, 1992, ARCH OPHTHALMOL-CHIC, V110, P827, DOI 10.1001/archopht.1992.01080180099035
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Chen YL, 2009, OPT EXPRESS, V17, P4046, DOI 10.1364/OE.17.004046
   de Bruin DM, 2008, INVEST OPHTH VIS SCI, V49, P4545, DOI 10.1167/iovs.07-1553
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P564
   GASS JDM, 1994, AM J OPHTHALMOL, V118, P285, DOI 10.1016/S0002-9394(14)72951-4
   GREEN WR, 1993, OPHTHALMOLOGY, V100, P1519
   GREEN WR, 1985, OPHTHALMOLOGY, V92, P615
   GREENLEE WF, 1991, RISK ANAL, V11, P565, DOI 10.1111/j.1539-6924.1991.tb00642.x
   Grossniklaus HE, 1998, AM J OPHTHALMOL, V126, P59, DOI 10.1016/S0002-9394(98)00145-7
   Grossniklaus HE, 2006, AM J OPHTHALMOL, V141, P93, DOI 10.1016/j.ajo.2005.07.076
   GROSSNIKLAUS HE, 1992, AM J OPHTHALMOL, V114, P464, DOI 10.1016/S0002-9394(14)71859-8
   GROSSNIKLAUS HE, 1994, OPHTHALMOLOGY, V101, P1099
   Grossniklaus HE, 1998, ARCH OPHTHALMOL-CHIC, V116, P745, DOI 10.1001/archopht.116.6.745
   Hermans P, 2003, OPHTHALMOLOGE, V100, P378, DOI 10.1007/s00347-002-0742-6
   Hughes EH, 2005, AM J OPHTHALMOL, V139, P344, DOI 10.1016/j.ajo.2004.07.058
   Lafaut BA, 2000, BRIT J OPHTHALMOL, V84, P239, DOI 10.1136/bjo.84.3.239
   Landa G, 2009, OPHTHALMOLOGICA, V223, P370, DOI 10.1159/000227783
   Liakopoulos S, 2008, INVEST OPHTH VIS SCI, V49, P5048, DOI 10.1167/iovs.08-1877
   Margherio RR, 2000, RETINA-J RET VIT DIS, V20, P325, DOI 10.1097/00006982-200007000-00001
   Menke MN, 2008, BRIT J OPHTHALMOL, V92, P1492, DOI 10.1136/bjo.2008.141242
   Nassif NA, 2004, OPT EXPRESS, V12, P367, DOI 10.1364/OPEX.12.000367
   Olsen TW, 2004, OPHTHALMOLOGY, V111, P250, DOI 10.1016/j.ophtha.2003.05.030
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Sayanagi K, 2009, BRIT J OPHTHALMOL, V93, P622, DOI 10.1136/bjo.2008.151977
   Sayanagi K, 2009, OPHTHALMOLOGY, V116, P947, DOI 10.1016/j.ophtha.2008.11.002
   Smith AJ, 2008, OPHTHALMOLOGY, V115, P1923, DOI 10.1016/j.ophtha.2008.05.025
   STERNBERG P, 1991, ARCH OPHTHALMOL-CHIC, V109, P1242
   Sternberg P, 1996, ARCH OPHTHALMOL-CHIC, V114, P400
   Stopa M, 2008, RETINA-J RET VIT DIS, V28, P298, DOI 10.1097/IAE.0b013e3181567798
   Submacular Surgery Trials Research Group, 2006, OPHTHALMOLOGY, V113
   Truong SN, 2007, RETINA-J RET VIT DIS, V27, P915, DOI 10.1097/IAE.0b013e31805468fd
   Witkin AJ, 2009, OPHTHALMOLOGY, V116, P956, DOI 10.1016/j.ophtha.2008.12.018
   Wojtkowski M, 2002, J BIOMED OPT, V7, P457, DOI 10.1117/1.1482379
   ZAWADZKI RJ, 2005, OPHTHALMIC TECHNOLOG, V15, P5688
   Zawinka C, 2005, RETINA-J RET VIT DIS, V25, P324, DOI 10.1097/00006982-200504000-00012
NR 38
TC 22
Z9 23
U1 0
U2 0
PU ASSOC RESEARCH VISION OPHTHALMOLOGY INC
PI ROCKVILLE
PA 12300 TWINBROOK PARKWAY, ROCKVILLE, MD 20852-1606 USA
SN 0146-0404
EI 1552-5783
J9 INVEST OPHTH VIS SCI
JI Invest. Ophthalmol. Vis. Sci.
PD AUG
PY 2010
VL 51
IS 8
BP 4200
EP 4206
DI 10.1167/iovs.09-4256
PG 7
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 629JT
UT WOS:000280194100052
PM 20220054
OA Green Submitted, Green Published
DA 2022-11-30
ER

PT J
AU Garas, A
   Papp, A
   Hollo, G
AF Garas, Anita
   Papp, Andras
   Hollo, Gabor
TI Influence of Age-related Macular Degeneration on Macular Thickness
   Measurement Made With Fourier-domain Optical Coherence Tomography
SO JOURNAL OF GLAUCOMA
LA English
DT Article
DE glaucoma; RTVue Fourier-domain optical coherence tomography; age-related
   macular degeneration; macular thickness
ID GLAUCOMA DIAGNOSIS; VISUAL-ACUITY; WORLDWIDE; PEOPLE; NUMBER; EYE
AB Purpose: To evaluate the influence of age-related macular degeneration (AMD) on macular thickness measurement made with Fourier-domain optical coherence tomography (RTVue-OCT) to detect glaucoma.
   Methods: One nonglaucomatous eye of 79 white persons was imaged. This comprised 25 healthy eyes, 19 eyes with early/intermediate AMD (geographic atrophy excluded), 16 eyes with subfoveal choroidal neovascularization (CNV), and 19 CNV eyes after intravitreal antiangiogenic treatment [CNV-antivascular endothelial growth factor (VEGF)].
   Results: Compared with the age-matched controls, no difference in any nerve fiber layer and optic disc parameter was seen for any AMD group. No macular retinal segmentation error was detected in the control group. Localized inner retinal image segmentation errors topographically related to AMD were detected in 8 eyes with drusen (42.1%), all 16 CNV eyes (100%) and 17 eyes in the CNV-anti-VEGF group (89.5%; chi(2) test, P<0.001 for all comparisons). The average macular thickness parameters did not differ between the control and the AMD groups (analysis of variance, P>0.05). In contrast, all pattern-based ganglion cell complex (GCC) parameters were significantly higher (more abnormal) in the CNV and CNV-anti-VEGF group than in the control eyes (Mann-Whitney test, Bonferroni correction, P<0.001). For GCC focal loss volume, the only pattern-based parameter classified by the software, the frequency of "borderline" and "outside normal limits" classifications was significantly greater in each AMD group than in the control group (chi(2) test, Bonferroni correction, P <= 0.03).
   Conclusions: In nonglaucomatous eyes, AMD significantly influences the pattern-based inner macular thickness parameters of the RTVue optical coherence tomograph and the software-provided classification of GCC focal loss volume, for detection of glaucoma.
C1 [Garas, Anita; Papp, Andras; Hollo, Gabor] Semmelweis Univ, Dept Ophthalmol, H-1083 Budapest, Hungary.
C3 Semmelweis University
RP Hollo, G (通讯作者)，Semmelweis Univ, Dept Ophthalmol, Tomo U 25-29, H-1083 Budapest, Hungary.
EM hg@szem1.sote.hu
CR Al-Hussaini H, 2009, EXP EYE RES, V88, P610, DOI 10.1016/j.exer.2008.09.021
   American Academy of Ophthalmology Retina Panel, 2008, AG REL MAC DEG PREF
   Attebo K, 1996, OPHTHALMOLOGY, V103, P357
   Chang RT, 2009, OPHTHALMOLOGY, V116, P2294, DOI 10.1016/j.ophtha.2009.06.012
   Cho JW, 2010, INVEST OPHTH VIS SCI, V51, P6401, DOI 10.1167/iovs.09-5035
   Garas A, 2010, OPHTHALMOLOGY, V117, P738, DOI 10.1016/j.ophtha.2009.08.039
   Gonzalez-Garcia AO, 2009, AM J OPHTHALMOL, V147, P1067, DOI 10.1016/j.ajo.2008.12.032
   Kawasaki R, 2010, OPHTHALMOLOGY, V117, P921, DOI 10.1016/j.ophtha.2009.10.007
   Kim NR, 2010, INVEST OPHTH VIS SCI, V51, P4646, DOI 10.1167/iovs.09-5053
   Klaver CCW, 1998, ARCH OPHTHALMOL-CHIC, V116, P653, DOI 10.1001/archopht.116.5.653
   KLEIN R, 1995, INVEST OPHTH VIS SCI, V36, P182
   Leung CKS, 2009, OPHTHALMOLOGY, V116, P1257, DOI 10.1016/j.ophtha.2009.04.013
   Moreno-Montanes J, 2010, INVEST OPHTH VIS SCI, V51, P335, DOI 10.1167/iovs.08-2988
   Mori S, 2010, J GLAUCOMA, V19, P528, DOI 10.1097/IJG.0b013e3181ca7acf
   Parikh RS, 2010, BRIT J OPHTHALMOL, V94, P197, DOI 10.1136/bjo.2008.143602
   Park SB, 2009, ARCH OPHTHALMOL-CHIC, V127, P1603, DOI 10.1001/archophthalmol.2009.296
   Pauleikhoff D, 2005, RETINA-J RET VIT DIS, V25, P1065, DOI 10.1097/00006982-200512000-00016
   Quigley HA, 2006, BRIT J OPHTHALMOL, V90, P262, DOI 10.1136/bjo.2005.081224
   Quigley HA, 1996, BRIT J OPHTHALMOL, V80, P389, DOI 10.1136/bjo.80.5.389
   Rao HL, 2010, OPHTHALMOLOGY, V117, P1692, DOI 10.1016/j.ophtha.2010.01.031
   Reus NJ, 2010, OPHTHALMOLOGY, V117, P717, DOI 10.1016/j.ophtha.2009.09.026
   Sehi M, 2009, AM J OPHTHALMOL, V148, P597, DOI 10.1016/j.ajo.2009.05.030
   Seong M, 2010, INVEST OPHTH VIS SCI, V51, P1446, DOI 10.1167/iovs.09-4258
   Tan O, 2009, OPHTHALMOLOGY, V116, P2305, DOI 10.1016/j.ophtha.2009.05.025
   Topouzis F, 2008, AM J OPHTHALMOL, V145, P327, DOI 10.1016/j.ajo.2007.09.013
NR 25
TC 10
Z9 11
U1 0
U2 10
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 1057-0829
J9 J GLAUCOMA
JI J. Glaucoma
PD MAR
PY 2013
VL 22
IS 3
BP 195
EP 200
DI 10.1097/IJG.0b013e31824083e6
PG 6
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 098CH
UT WOS:000315522300005
PM 22314250
DA 2022-11-30
ER

PT J
AU Schmitz-Valckenberg, S
   Fleckenstein, M
   Gobel, AP
   Hohman, TC
   Holz, FG
AF Schmitz-Valckenberg, Steffen
   Fleckenstein, Monika
   Goebel, Arno P.
   Hohman, Thomas C.
   Holz, Frank G.
TI Optical Coherence Tomography and Autofluorescence Findings in Areas with
   Geographic Atrophy Due to Age-Related Macular Degeneration
SO INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE
LA English
DT Article
ID RETINAL-PIGMENT EPITHELIUM; BEAVER DAM EYE; FUNDUS AUTOFLUORESCENCE;
   VISUAL-ACUITY; PROGRESSION; RANIBIZUMAB; ENLARGEMENT; DISEASE
AB PURPOSE. To analyze outer retinal changes within the atrophic lesion in patients with geographic atrophy (GA) secondary to age-related macular degeneration.
   METHODS. Twenty-one simultaneously obtained fundus autofluorescence (FAF, excitation, 488 nm; emission, 500-700 nm) and spectral-domain optical coherence tomography (SD-OCT) scans (Spectralis HRA + OCT; Heidelberg Engineering, Heidelberg, Germany) of 21 GA patients (mean age, 75.1 +/- 7.4 years) were included and separately exported. Two readers independently graded the following parameters: width of the atrophic lesion on the FAF image at the site where the SD-OCT scan had been placed; and on the SD-OCT image, widths of the linear disruption of the outer nuclear layer, the external limiting membrane, and the inner and outer segments of the photoreceptor layer (IPRL) and width of the disruption of choroidal signal enhancement.
   RESULTS. The mean width of the atrophic lesion by FAF imaging was 2.83 mm (95% confidence interval, 2.37-3.29). The linear disruption of choroidal hyperreflectivity showed the closest agreement with 2.83 mm (2.37-3.28), whereas the linear width of disrupted IPRL was larger (3.10 mm; 2.65-3.55). Overall, the width of the atrophic lesion correlated significantly with all five SD-OCT parameters (P < 0.0001, r = 0.96-0.99).
   CONCLUSIONS. These findings demonstrate that the atrophic lesions identified with FAF represent irreversible underlying outer retinal damage. The observation that the width of the atrophic lesion identified with FAF, although significantly correlated but not identical with the width of disruption within the cellular layers of the retina, is consistent with the dynamic nature of the disease. (ClinicalTrials.gov numbers, NCT00393692, NCT00599846.) (Invest Ophthalmol Vis Sci. 2011; 52: 1-6) DOI: 10.1167/iovs.10-5619
C1 [Schmitz-Valckenberg, Steffen; Fleckenstein, Monika; Goebel, Arno P.; Holz, Frank G.] Univ Bonn, Dept Ophthalmol, D-53127 Bonn, Germany.
   [Schmitz-Valckenberg, Steffen; Fleckenstein, Monika; Goebel, Arno P.; Holz, Frank G.] Univ Bonn, Grade Reading Ctr, D-53127 Bonn, Germany.
   [Hohman, Thomas C.] Alcon Res Ltd, Ft Worth, TX USA.
C3 University of Bonn; University of Bonn; Novartis; Alcon
RP Schmitz-Valckenberg, S (通讯作者)，Univ Bonn, Dept Ophthalmol, Ernst Abbe Str 2, D-53127 Bonn, Germany.
EM steffen.schmitz-valckenberg@ukb.uni-bonn.de
OI Fleckenstein, Monika/0000-0001-8321-8037
FU DFG (German Research Foundation) [SPP 1088, Ho 1926/1-3]; Integrated
   Project "EVI-GENORET" [LSHG-CT-2005-512036]; EU
FX Supported by DFG (German Research Foundation), Research Priority Program
   Age-Related Macular Degeneration Grants SPP 1088, Ho 1926/1-3, and EU
   FP6; and Integrated Project "EVI-GENORET" Grant LSHG-CT-2005-512036.
CR Bearelly S, 2009, OPHTHALMOLOGY, V116, P1762, DOI 10.1016/j.ophtha.2009.04.015
   BLAND JM, 1986, LANCET, V1, P307, DOI 10.1016/s0140-6736(86)90837-8
   Boulton M, 2001, EYE, V15, P384, DOI 10.1038/eye.2001.141
   Brar M, 2009, AM J OPHTHALMOL, V148, P439, DOI 10.1016/j.ajo.2009.04.022
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Davis MD, 2005, ARCH OPHTHALMOL-CHIC, V123, P1484
   Deckert A, 2005, BMC Ophthalmol, V5, P8, DOI 10.1186/1471-2415-5-8
   DELORI FC, 1995, INVEST OPHTH VIS SCI, V36, P718
   Douglas IJ, 2007, OPHTHALMOLOGY, V114, P1164, DOI 10.1016/j.ophtha.2006.09.018
   Fleckenstein M, 2008, INVEST OPHTH VIS SCI, V49, P4137, DOI 10.1167/iovs.08-1967
   GREEN WR, 1993, OPHTHALMOLOGY, V100, P1519
   Helb HM, 2009, ACTA OPHTHALMOL
   Holz FG, 2007, AM J OPHTHALMOL, V143, P463, DOI 10.1016/j.ajo.2006.11.041
   Klein R, 2008, AM J OPHTHALMOL, V146, P692, DOI 10.1016/j.ajo.2008.05.050
   Klein R, 2007, OPHTHALMOLOGY, V114, P253, DOI 10.1016/j.ophtha.2006.10.040
   Klein R, 2006, AM J OPHTHALMOL, V142, P539, DOI 10.1016/j.ajo.2006.06.015
   Lujan BJ, 2009, OPHTHAL SURG LAS IM, V40, P96, DOI 10.3928/15428877-20090301-16
   Pirbhai A, 2005, AM J OPHTHALMOL, V139, P455, DOI 10.1016/j.ajo.2004.09.077
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   SARKS JP, 1988, EYE, V2, P552, DOI 10.1038/eye.1988.106
   SARKS SH, 1976, BRIT J OPHTHALMOL, V60, P324, DOI 10.1136/bjo.60.5.324
   SCHATZ H, 1989, OPHTHALMOLOGY, V96, P1541
   Schmidt-Erfurth U, 2005, INVEST OPHTH VIS SCI, V46, P3393, DOI 10.1167/iovs.05-0370
   Schmitz-Valckenberg S, 2002, GRAEF ARCH CLIN EXP, V240, P73, DOI 10.1007/s00417-001-0413-3
   Schmitz-Valckenberg S, 2006, INVEST OPHTH VIS SCI, V47, P2648, DOI 10.1167/iovs.05-0892
   Schmitz-Valckenberg S, 2009, SURV OPHTHALMOL, V54, P96, DOI 10.1016/j.survophthal.2008.10.004
   Scholl HPN, 2003, GRAEF ARCH CLIN EXP, V241, P39, DOI 10.1007/s00417-002-0602-8
   Sunness JS, 2007, OPHTHALMOLOGY, V114, P271, DOI 10.1016/j.ophtha.2006.09.016
   Sunness JS, 1999, INVEST OPHTH VIS SCI, V40, pS314
   Sunness JS, 1997, OPHTHALMOLOGY, V104, P1677, DOI 10.1016/S0161-6420(97)30079-7
   Sunness JS, 1999, OPHTHALMOLOGY, V106, P1768, DOI 10.1016/S0161-6420(99)90340-8
   VONRUCKMANN A, 1995, BRIT J OPHTHALMOL, V79, P407, DOI 10.1136/bjo.79.5.407
   Wolf-Schnurrbusch UEK, 2008, INVEST OPHTH VIS SCI, V49, P3095, DOI 10.1167/iovs.07-1460
NR 33
TC 60
Z9 61
U1 0
U2 2
PU ASSOC RESEARCH VISION OPHTHALMOLOGY INC
PI ROCKVILLE
PA 12300 TWINBROOK PARKWAY, ROCKVILLE, MD 20852-1606 USA
SN 0146-0404
J9 INVEST OPHTH VIS SCI
JI Invest. Ophthalmol. Vis. Sci.
PD JAN
PY 2011
VL 52
IS 1
BP 1
EP 6
DI 10.1167/iovs.10-5619
PG 6
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 702VW
UT WOS:000285925000001
PM 20688734
DA 2022-11-30
ER

PT J
AU Edwards, DRV
   Gallins, P
   Polk, M
   Ayala-Haedo, J
   Schwartz, SG
   Kovach, JL
   Spencer, K
   Wang, GF
   Agarwal, A
   Postel, EA
   Haines, JL
   Pericak-Vance, M
   Scott, WK
AF Edwards, Digna R. Velez
   Gallins, Paul
   Polk, Monica
   Ayala-Haedo, Juan
   Schwartz, Stephen G.
   Kovach, Jaclyn L.
   Spencer, Kylee
   Wang, Gaofeng
   Agarwal, Anita
   Postel, Eric A.
   Haines, Jonathan L.
   Pericak-Vance, Margaret
   Scott, William K.
TI Inverse Association of Female Hormone Replacement Therapy with
   Age-Related Macular Degeneration and Interactions with ARMS2
   Polymorphisms
SO INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE
LA English
DT Article
ID COMPLEMENT FACTOR-H; ALPHA GENE POLYMORPHISMS; RISK-FACTORS;
   POSTMENOPAUSAL WOMEN; ESTROGEN-RECEPTOR; EYE DISEASE; VISUAL IMPAIRMENT;
   CARDIOVASCULAR-DISEASE; FAMILIAL AGGREGATION; REPRODUCTIVE FACTORS
AB PURPOSE. To investigate whether female reproductive history and hormone replacement therapy (HRT) or birth control pills (BCPs) influence risk for age-related macular degeneration (AMD) and whether genetic factors interact with HRT to modulate AMD risk. \
   METHODS. Related and unrelated female participants (n = 799) were examined and data were analyzed with generalized estimating equations with adjustment for age and smoking. Individuals with AMD grades 1 to 2 were considered to be unaffected (n = 239) and those with grades 3 to 5 were considered affected (n = 560).
   RESULTS. When comparing all cases with controls, significant inverse associations were observed for HRT (odds ratio [OR] = 0.65, 95% CI 0.48-0.90, P = 0.008) and BCPs (OR = 0.60, 95% CI 0.36-0.10, P = 0.048). When analyses were stratified by AMD severity (early versus geographic atrophy versus neovascular), the inverse association remained significant (HRT OR = 0.45, 95% CI 0.30-0.66, P < 0.0001; BCP OR = 0.55, 95% CI 0.32-0.96, P = 0.036) only when comparing neovascular AMD with the control. All pair-wise HRT-genotype and BCP-genotype interactions were examined, to determine whether HRT or BCP modifies the effect of established genetic risk factors. The strongest interactions were observed for HRT x ARMS2 coding SNP (R73H) rs10490923 (P = 0.007) and HRT x ARMS2 intronic SNP rs17623531 (P = 0.019).
   CONCLUSIONS. These findings provide the first evidence suggesting that ARMS2 interacts with HRT to modulate AMD risk and are consistent with previous reports demonstrating a protective relationship between exogenous estrogen use and neovascular AMD. These results highlight the genetic and environmental complexity of the etiologic architecture of AMD; however, further replication is necessary to validate them. (Invest Ophthalmol Vis Sci. 2010; 51:1873-1879) DOI: 10.1167/iovs.09-4000
C1 [Edwards, Digna R. Velez; Gallins, Paul; Polk, Monica; Ayala-Haedo, Juan; Wang, Gaofeng; Pericak-Vance, Margaret; Scott, William K.] Univ Miami, Dr John T Macdonald Fdn, Dept Human Genet, Miami, FL USA.
   [Edwards, Digna R. Velez; Gallins, Paul; Polk, Monica; Ayala-Haedo, Juan; Wang, Gaofeng; Pericak-Vance, Margaret; Scott, William K.] Univ Miami, John P Hussman Inst Human Genom, Miami, FL USA.
   [Schwartz, Stephen G.; Kovach, Jaclyn L.] Univ Miami, Miller Sch Med, Bascom Palmer Eye Inst, Miami, FL 33136 USA.
   [Spencer, Kylee; Agarwal, Anita; Haines, Jonathan L.] Vanderbilt Univ, Ctr Human Genet Res, Nashville, TN USA.
   [Postel, Eric A.] Duke Univ, Duke Eye Ctr, Durham, NC USA.
C3 University of Miami; University of Miami; Bascom Palmer Eye Institute;
   University of Miami; Vanderbilt University; Duke University
RP Scott, WK (通讯作者)，Miami Inst Human Genom, 1501 NW 10th Ave,Biomed Res Bldg BRB 414, Miami, FL 33136 USA.
EM bscott@med.miami.edu
RI Velez Edwards, Digna/C-1090-2012; Haines, Jonathan/C-3374-2012
OI Haines, Jonathan/0000-0002-4351-4728; Scott, William/0000-0001-9336-6404
FU National Eye Institute [EY12118, P30EY014801]; National Center for
   Research Resources [M01 RR-00095]; Research to Prevent Blindness, New
   York, NY; NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR000095] Funding
   Source: NIH RePORTER; NATIONAL EYE INSTITUTE [U10EY012118, R01EY012118,
   P30EY014801] Funding Source: NIH RePORTER
FX Supported by National Eye Institute Grant EY12118 (MP-V, JLH); National
   Center for Research Resources Grant M01 RR-00095 to Vanderbilt
   University; and National Eye Institute Center Grant P30EY014801; and by
   an unrestricted grant to the University of Miami from Research to
   Prevent Blindness, New York, NY.
CR Akcay T, 2000, J TOXICOL ENV HEAL A, V59, P1, DOI 10.1080/009841000157023
   Ambati J, 2003, SURV OPHTHALMOL, V48, P257, DOI 10.1016/S0039-6257(03)00030-4
   [Anonymous], 2000, OPHTHALMOLOGY, V107, P2224
   Attebo K, 1996, OPHTHALMOLOGY, V103, P357
   Barrett JC, 2005, BIOINFORMATICS, V21, P263, DOI 10.1093/bioinformatics/bth457
   Benjamini Y, 2001, BEHAV BRAIN RES, V125, P279, DOI 10.1016/S0166-4328(01)00297-2
   BIRD AEC, 1995, SURV OPHTHALMOL, V39, P367, DOI 10.1016/S0039-6257(05)80092-X
   Boekhoorn SS, 2007, INVEST OPHTH VIS SCI, V48, P1012, DOI 10.1167/iovs.06-0577
   Buch H, 2005, OPHTHALMOLOGY, V112, P305, DOI 10.1016/j.ophtha.2004.08.025
   Dewan A, 2006, SCIENCE, V314, P989, DOI 10.1126/science.1133807
   Espeland MA, 2004, JAMA-J AM MED ASSOC, V291, P2959, DOI 10.1001/jama.291.24.2959
   Feskanich D, 2008, ARCH OPHTHALMOL-CHIC, V126, P519, DOI 10.1001/archopht.126.4.519
   Fraser-Bell S, 2006, AM J OPHTHALMOL, V141, P79, DOI 10.1016/j.ajo.2005.08.024
   Freeman EE, 2005, OPHTHAL EPIDEMIOL, V12, P37, DOI 10.1080/09286580490907779
   Gabriel SB, 2002, SCIENCE, V296, P2225, DOI 10.1126/science.1069424
   GRAY RH, 1994, EYE, V8, P368, DOI 10.1038/eye.1994.83
   Grodstein F, 1996, NEW ENGL J MED, V335, P453, DOI 10.1056/NEJM199608153350701
   Grodstein F, 1997, NEW ENGL J MED, V336, P1769, DOI 10.1056/NEJM199706193362501
   Haan MN, 2006, ARCH OPHTHALMOL-CHIC, V124, P988, DOI 10.1001/archopht.124.7.988
   Haines JL, 2005, SCIENCE, V308, P419, DOI 10.1126/science.1110359
   Hancock DB, 2007, GENET EPIDEMIOL, V31, P883, DOI 10.1002/gepi.20249
   Hirschhorn JN, 2002, GENET MED, V4, P45, DOI 10.1097/00125817-200203000-00002
   Hyman L, 1992, AGE RELATED MACULAR, P1
   Ioannidis JPA, 2007, HUM HERED, V64, P203, DOI 10.1159/000103512
   Jakobsdottir J, 2005, AM J HUM GENET, V77, P389, DOI 10.1086/444437
   Kassoff A, 1999, CONTROL CLIN TRIALS, V20, P573
   Klaver CCW, 1998, ARCH OPHTHALMOL-CHIC, V116, P653, DOI 10.1001/archopht.116.5.653
   Klaver CCW, 1998, ARCH OPHTHALMOL-CHIC, V116, P1646, DOI 10.1001/archopht.116.12.1646
   Klein BEK, 2000, AM J OPHTHALMOL, V130, P322, DOI 10.1016/S0002-9394(00)00474-8
   KLEIN R, 1991, OPHTHALMOLOGY, V98, P1128
   KLEIN R, 1994, ARCH OPHTHALMOL-CHIC, V112, P191, DOI 10.1001/archopht.1994.01090140067025
   Milton RC, 2005, OPHTHALMOLOGY, V112, P533, DOI 10.1016/j.ophtha.2004.10.047
   Mosca L, 1997, CIRCULATION, V96, P2468
   Munaut C, 2001, BRIT J OPHTHALMOL, V85, P877, DOI 10.1136/bjo.85.7.877
   Munoz B, 2000, ARCH OPHTHALMOL-CHIC, V118, P819, DOI 10.1001/archopht.118.6.819
   Ogueta SB, 1999, INVEST OPHTH VIS SCI, V40, P1906
   Postel EA, 2005, AM J OPHTHALMOL, V139, P820, DOI 10.1016/j.ajo.2004.12.029
   Pulido JS, 2007, MAYO CLIN PROC, V82, P301, DOI 10.4065/82.3.301
   Rakic JM, 2003, INVEST OPHTH VIS SCI, V44, P1740, DOI 10.1167/iovs.02-0775
   Rivera A, 2005, HUM MOL GENET, V14, P3227, DOI 10.1093/hmg/ddi353
   Rossouw JE, 2002, JAMA-J AM MED ASSOC, V288, P321, DOI 10.1001/jama.288.3.321
   Schmidt S, 2006, AM J HUM GENET, V78, P852, DOI 10.1086/503822
   Schmidt S, 2000, MOL VIS, V6, P287
   Schuit SCE, 2005, EUR J ENDOCRINOL, V153, P327, DOI 10.1530/eje.1.01973
   Seddon JM, 1997, AM J OPHTHALMOL, V123, P199, DOI 10.1016/S0002-9394(14)71036-0
   Sepp T, 2006, INVEST OPHTH VIS SCI, V47, P536, DOI 10.1167/iovs.05-1143
   Shuler RK, 2008, AM J OPHTHALMOL, V145, P303, DOI 10.1016/j.ajo.2007.09.027
   Smith W, 2001, OPHTHALMOLOGY, V108, P697, DOI 10.1016/S0161-6420(00)00580-7
   Snow KK, 2002, AM J OPHTHALMOL, V134, P842, DOI 10.1016/S0002-9394(02)01755-5
   Snow KK, 2000, INT J FERTIL WOMEN M, V45, P301
   SPENCER G, 1989, PROJECTIONS POPULA P, V25, P1018
   Spencer KL, 2008, HUM MOL GENET, V17, P1821, DOI 10.1093/hmg/ddn075
   Spencer KL, 2008, HUM MOL GENET, V17, P971, DOI 10.1093/hmg/ddm369
   Spencer KL, 2007, HUM MOL GENET, V16, P1986, DOI 10.1093/hmg/ddm146
   Spencer KL, 2007, INVEST OPHTH VIS SCI, V48, P4277, DOI 10.1167/iovs.06-1427
   Stefanick ML, 2005, FERTIL STERIL, V83, P853, DOI 10.1016/j.fertnstert.2005.01.084
   SUBBIAH MTR, 1993, J CLIN ENDOCR METAB, V77, P1095, DOI 10.1210/jc.77.4.1095
   Subbiah MTR, 1998, P SOC EXP BIOL MED, V217, P23
   TIELSCH JM, 1995, NEW ENGL J MED, V332, P1205, DOI 10.1056/NEJM199505043321806
   Yang ZL, 2006, SCIENCE, V314, P992, DOI 10.1126/science.1133811
   Yannuzzi LA, 1996, ARCH OPHTHALMOL-CHIC, V114, P545
   YANNUZZI LA, 1994, AM J OPHTHALMOL, V118, P754
   1992, ARCH OPHTHALMOL, V110, P1701
   1995, JAMA, V273, P199
NR 64
TC 25
Z9 25
U1 1
U2 3
PU ASSOC RESEARCH VISION OPHTHALMOLOGY INC
PI ROCKVILLE
PA 12300 TWINBROOK PARKWAY, ROCKVILLE, MD 20852-1606 USA
SN 0146-0404
EI 1552-5783
J9 INVEST OPHTH VIS SCI
JI Invest. Ophthalmol. Vis. Sci.
PD APR
PY 2010
VL 51
IS 4
BP 1873
EP 1879
DI 10.1167/iovs.09-4000
PG 7
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 574ND
UT WOS:000275995800010
PM 19933179
OA Green Published
DA 2022-11-30
ER

PT J
AU Sagiv, O
   Zloto, O
   Moroz, I
   Moisseiev, J
AF Sagiv, Oded
   Zloto, Ofira
   Moroz, Iris
   Moisseiev, Joseph
TI Different Clinical Courses on Long-Term Follow-Up of Age-Related Macular
   Degeneration Patients Treated with Intravitreal Anti-Vascular
   Endothelial Growth Factor Injections
SO OPHTHALMOLOGICA
LA English
DT Article
DE Age-related macular degeneration; Anti-vascular endothelial growth
   factor; Bevacizumab; Long-term follow-up
ID RANIBIZUMAB; OUTCOMES; THERAPY; EYES; EFFICACY; SAFETY; TRIAL; AMD
AB Purpose: To assess the long-term outcome of neovascular age-related macular degeneration (AMD) treated with multiple intravitreal anti-vascular endothelial growth factor (VEGF) injections. Methods: All patients treated with over 30 intravitreal anti-VEGF injections for neovascular AMD between 2007 and 2014 were retrospectively reviewed. Results: A total of 67 eyes received 2,960 (mean 45 +/- 9.1 per eye) anti-VEGF injections. Eyes with good final visual acuity (VA) had better initial VA (p = 0.020) and maintained it. Patients with moderate-to-poor final VA improved significantly after the first 3 monthly injections, and thereafter deteriorated consistently, mostly during the third (p = 0.019) and fourth (p = 0.006) years. Eyes with worse final VA had more intraretinal fluid (p = 0.05) and subretinal fibrosis (p = 0.04). Conclusion: Two distinct clinical courses were identified: good final VA was associated with initial and long-term stability of good VA; eyes with worse final VA had worse initial VA, progressive deterioration following the initial improvement, and more scarring and intraretinal fluid. This probably underscores the long-term benefits of early detection and treatment. (C) 2017 S. Karger AG, Basel
C1 [Sagiv, Oded] Sheba Med Ctr, Goldschleger Eye Inst, IL-52621 Tel Hashomer, Israel.
   Tel Aviv Univ, Sackler Fac Med, Tel Aviv, Israel.
C3 Chaim Sheba Medical Center; Tel Aviv University; Sackler Faculty of
   Medicine
RP Sagiv, O (通讯作者)，Sheba Med Ctr, Goldschleger Eye Inst, IL-52621 Tel Hashomer, Israel.
EM odedsagiv@gmail.com
CR Boyer DS, 2009, OPHTHALMOLOGY, V116, P1731, DOI 10.1016/j.ophtha.2009.05.024
   Brown DM, 2009, OPHTHALMOLOGY, V116, P57, DOI 10.1016/j.ophtha.2008.10.018
   Busbee BG, 2013, OPHTHALMOLOGY, V120, P1046, DOI 10.1016/j.ophtha.2012.10.014
   Dakin HA, 2014, BMJ OPEN, V4, DOI 10.1136/bmjopen-2014-005094
   Ferrara N, 2004, NAT REV DRUG DISCOV, V3, P391, DOI 10.1038/nrd1381
   Gillies MC, 2015, OPHTHALMOLOGY, V122, P1837, DOI 10.1016/j.ophtha.2015.05.010
   Heier JS, 2012, OPHTHALMOLOGY, V119, P2537, DOI 10.1016/j.ophtha.2012.09.006
   Heimes B, 2011, GRAEF ARCH CLIN EXP, V249, P639, DOI 10.1007/s00417-010-1524-5
   Holz FG, 2011, OPHTHALMOLOGY, V118, P663, DOI 10.1016/j.ophtha.2010.12.019
   Kim H, 2009, MOL VIS, V15
   Lalwani GA, 2009, AM J OPHTHALMOL, V148, P43, DOI 10.1016/j.ajo.2009.01.024
   Lee AY, 2015, BRIT J OPHTHALMOL, V99, P1045, DOI 10.1136/bjophthalmol-2014-306229
   Martin DF, 2012, OPHTHALMOLOGY, V119, DOI 10.1016/j.ophtha.2012.03.053
   Menke MN, 2014, BRIT J OPHTHALMOL, V98, P1197, DOI 10.1136/bjophthalmol-2013-304775
   Munk MR, 2016, ACTA OPHTHALMOL, V94, pE757, DOI 10.1111/aos.13157
   Peden MC, 2015, OPHTHALMOLOGY, V122, P803, DOI 10.1016/j.ophtha.2014.11.018
   Regillo CD, 2008, AM J OPHTHALMOL, V145, P239, DOI 10.1016/j.ajo.2007.10.004
   Rofagha S, 2013, OPHTHALMOLOGY, V120, P2292, DOI 10.1016/j.ophtha.2013.03.046
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Schmidt-Erfurth U, 2011, OPHTHALMOLOGY, V118, P831, DOI 10.1016/j.ophtha.2010.09.004
   Singer MA, 2012, OPHTHALMOLOGY, V119, P1175, DOI 10.1016/j.ophtha.2011.12.016
   Tufail A, 2014, OPHTHALMOLOGY, V121, P1092, DOI 10.1016/j.ophtha.2013.11.031
   Wong T, 2008, OPHTHALMOLOGY, V115, P116, DOI 10.1016/j.ophtha.2007.03.008
NR 23
TC 6
Z9 6
U1 0
U2 0
PU KARGER
PI BASEL
PA ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND
SN 0030-3755
EI 1423-0267
J9 OPHTHALMOLOGICA
JI Ophthalmologica
PY 2017
VL 238
IS 4
BP 217
EP 225
DI 10.1159/000479437
PG 9
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA FK9LQ
UT WOS:000413833100005
PM 28926846
DA 2022-11-30
ER

PT J
AU Charafeddin, W
   Nittala, MG
   Oregon, A
   Sadda, SR
AF Charafeddin, Wissam
   Nittala, Muneeswar Gupta
   Oregon, Aldo
   Sadda, SriniVas R.
TI Relationship Between Subretinal Hyperreflective Material Reflectivity
   and Volume in Patients With Neovascular Age-Related Macular Degeneration
   Following Anti-Vascular Endothelial Growth Factor Treatment
SO OPHTHALMIC SURGERY LASERS & IMAGING RETINA
LA English
DT Article
ID OPTICAL COHERENCE TOMOGRAPHY; ANTI-VEGF THERAPY; CHOROIDAL
   NEOVASCULARIZATION; QUANTITATIVE SUBANALYSIS; RETINAL MORPHOLOGY; VISUAL
   FUNCTION; RANIBIZUMAB; DOMAIN; OCT; PREVALENCE
AB BACKGROUND AND OBJECTIVE: To assess the relationship between subretinal hyperreflective material (SRHM) reflectivity and volume in patients treated with anti-vascular endothelial growth factor (VEGF) therapy for choroidal neovascularization secondary to exudative age-related macular degeneration (AMD).
   PATIENTS AND METHODS: Data from 17 eyes of 16 patients with neovascular AMD undergoing anti-VEGF therapy were collected retrospectively. Optical coherence tomography (OCT) data were obtained using the Cirrus HD-OCT (Carl Zeiss Meditec, Dublin, CA) 512 x 128 macular cube protocol. Detailed manual segmentation was performed for each case using customized grading software.
   RESULTS: The mean macular volume declined from 10.4 mm 3 at baseline to 9.6 mm 3 at 12 months. SRHM volume declined from 0.33 mm 3 to 0.12 mm 3, whereas reflectivity increased from 0.48 to 0.64 units (P = .012). SRHM reflectivity correlated positively with logarithm of the minimum angle of resolution (logMAR) acuity (r = .49, P = .04) but correlated with SRHM volume (r = -0.50, P = .04) only at baseline.
   CONCLUSION: SRHM reflectivity, which correlated partially with SRHM volume, appears to carry independent information regarding disease activity. SRHM reflectivity may be useful for monitoring disease activity and response to therapy.
C1 [Charafeddin, Wissam; Nittala, Muneeswar Gupta; Oregon, Aldo; Sadda, SriniVas R.] Doheny Eye Inst, Los Angeles, CA 90033 USA.
   [Sadda, SriniVas R.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Ophthalmol, Los Angeles, CA 90095 USA.
   [Charafeddin, Wissam; Oregon, Aldo] Univ Guadalajara, Guadalajara 44430, Jalisco, Mexico.
C3 Doheny Eye Institute; University of California System; University of
   California Los Angeles; University of California Los Angeles Medical
   Center; David Geffen School of Medicine at UCLA; Universidad de
   Guadalajara
RP Sadda, SR (通讯作者)，Doheny Eye Inst, 1450 San Pablo St, Los Angeles, CA 90033 USA.
RI Nittala, Muneeswar/AAT-7533-2020
FU Carl Zeiss Meditec; Optos; Alcon; Roche; Regeneron; Allergan; Genentech
FX Dr. Sadda is a consultant for and receives research support from Carl
   Zeiss Meditec, Optos, Alcon, Roche, Regeneron, Allergan, and Genentech.
   The remaining other authors report no relevant financial disclosures.
CR Akagi-Kurashige Y, 2012, GRAEF ARCH CLIN EXP, V250, P1129, DOI 10.1007/s00417-012-1928-5
   Baranano AE, 2012, ACTA OPHTHALMOL, V90, pE274, DOI 10.1111/j.1755-3768.2012.02398.x
   Bolz M, 2008, OPHTHALMOLOGE, V105, P650, DOI 10.1007/s00347-007-1639-1
   BRESSLER NM, 1988, SURV OPHTHALMOL, V32, P375, DOI 10.1016/0039-6257(88)90052-5
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Freund KB, 2010, RETINA-J RET VIT DIS, V30, P1333, DOI 10.1097/IAE.0b013e3181e7976b
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P532
   Fung AE, 2007, AM J OPHTHALMOL, V143, P566, DOI 10.1016/j.ajo.2007.01.028
   Giani A, 2011, INVEST OPHTH VIS SCI, V52, P5579, DOI 10.1167/iovs.10-6617
   Giani A, 2011, RETINA-J RET VIT DIS, V31, P942, DOI 10.1097/IAE.0b013e31820a68cc
   Hu ZH, 2013, OSLI RETINA, V44, pS5, DOI 10.3928/23258160-20131101-02
   Joeres S, 2007, INVEST OPHTH VIS SCI, V48, P4300, DOI 10.1167/iovs.07-0179
   Keane PA, 2010, EYE, V24, P422, DOI 10.1038/eye.2009.309
   Keane PA, 2008, INVEST OPHTH VIS SCI, V49, P3115, DOI 10.1167/iovs.08-1689
   Keane PA, 2010, INVEST OPHTH VIS SCI, V51, P5431, DOI 10.1167/iovs.09-4846
   Keane PA, 2008, OPHTHALMOLOGY, V115, P2206, DOI 10.1016/j.ophtha.2008.08.016
   Khurana RN, 2010, OPHTHALMOLOGY, V117, P1376, DOI 10.1016/j.ophtha.2009.11.039
   Kiss CG, 2009, INVEST OPHTH VIS SCI, V50, P2376, DOI 10.1167/iovs.08-2017
   KLEIN R, 1992, OPHTHALMOLOGY, V99, P933
   Lalwani GA, 2009, AM J OPHTHALMOL, V148, P43, DOI 10.1016/j.ajo.2009.01.024
   Lee K, 2013, INVEST OPHTH VIS SCI, V54, P4808, DOI 10.1167/iovs.13-12211
   Lee SY, 2012, INVEST OPHTH VIS SCI, V53, P164, DOI 10.1167/iovs.11-8188
   Lujan BJ, 2011, INVEST OPHTH VIS SCI, V52, P1486, DOI 10.1167/iovs.10-5946
   Martin DF, 2012, OPHTHALMOLOGY, V119, DOI 10.1016/j.ophtha.2012.03.053
   Neudorfer M, 2012, INVEST OPHTH VIS SCI, V53, P3104, DOI 10.1167/iovs.11-8700
   Ouyang YL, 2013, GRAEF ARCH CLIN EXP, V251, P2311, DOI 10.1007/s00417-013-2308-5
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Sadda SR, 2007, INVEST OPHTH VIS SCI, V48, P839, DOI 10.1167/iovs.06-0554
   Sadda SR, 2010, GRAEF ARCH CLIN EXP, V248, P175, DOI 10.1007/s00417-009-1193-4
   Shah AR, 2009, OPHTHALMOLOGY, V116, P1901, DOI 10.1016/j.ophtha.2009.03.055
   Shin HJ, 2011, RETINA-J RET VIT DIS, V31, P1627, DOI 10.1097/IAE.0b013e31820d3d01
   Spaide RF, 2006, RETINA-J RET VIT DIS, V26, P383, DOI 10.1097/00006982-200604000-00001
   Ting TD, 2002, ARCH OPHTHALMOL-CHIC, V120, P731
   Witkin AJ, 2009, OPHTHALMOLOGY, V116, P956, DOI 10.1016/j.ophtha.2008.12.018
   Wong T, 2008, OPHTHALMOLOGY, V115, P116, DOI 10.1016/j.ophtha.2007.03.008
   You JY, 2012, CURR EYE RES, V37, P438, DOI 10.3109/02713683.2011.647227
NR 36
TC 31
Z9 31
U1 0
U2 1
PU SLACK INC
PI THOROFARE
PA 6900 GROVE RD, THOROFARE, NJ 08086 USA
SN 2325-8160
EI 2325-8179
J9 OSLI RETINA
JI Ophthalmic Surg. Lasers Imag. Retin.
PD MAY
PY 2015
VL 46
IS 5
BP 523
EP 530
DI 10.3928/23258160-20150521-03
PG 8
WC Ophthalmology; Surgery
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology; Surgery
GA CO6UQ
UT WOS:000359292500003
PM 26057755
DA 2022-11-30
ER

PT J
AU Despriet, DDG
   Klaver, CCW
   Witteman, JCM
   Bergen, AAB
   Kardys, I
   de Maat, MPM
   Boekhoorn, SS
   Vingerling, JR
   Hofman, A
   Oostra, BA
   Uitterlinden, AG
   Stijnen, T
   van Duijn, CM
   de Jong, PTVM
AF Despriet, Dominiek D. G.
   Klaver, Caroline C. W.
   Witteman, Jacqueline C. M.
   Bergen, Arthur A. B.
   Kardys, Isabella
   de Maat, Moniek P. M.
   Boekhoorn, Sharmila S.
   Vingerling, Johannes R.
   Hofman, Albert
   Oostra, Ben A.
   Uitterlinden, Andre G.
   Stijnen, Theo
   van Duijn, Cornelia M.
   de Jong, Paulus T. V. M.
TI Complement factor H polymorphism, complement activators, and risk of
   age-related macular degeneration
SO JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
LA English
DT Article
ID C-REACTIVE PROTEIN; CORONARY-HEART-DISEASE; GENOMEWIDE-SCAN; FAMILIAL
   AGGREGATION; SUSCEPTIBILITY LOCI; EXTENDED FAMILIES; CRP LEVELS;
   MACULOPATHY; POPULATION; GENE
AB Context The evidence that inflammation is an important pathway in age-related macular degeneration (AMD) is growing. Recent case-control studies demonstrated an association between the complement factor H (CFH) gene, a regulator of complement, and AMD.
   Objectives To assess the associations between the CFH gene and AMD in the general population and to investigate the modifying effect of smoking, serum inflammatory markers, and genetic variation of C-reactive protein (CRP).
   Design, Setting, and Participants Population-based, prospective cohort study of individuals aged 55 years or older (enrollment between March 20, 1990, and July 31, 1993, and 3 follow-up examinations that were performed between September 1, 1993, and December 31, 2004) in Rotterdam, the Netherlands. The CFH Y402H polymorphism was determined in a total of 5681 individuals. Information on smoking, erythrocyte sedimentation rate, CRP serum levels, and haplotypes of the CRP gene were assessed at baseline.
   Main Outcome Measures All severity stages of prevalent and incident AMD, graded according to the international classification and grading system for AMD.
   Results The frequency of CFH Y402H was 36.2% (4116/11 362 alleles). At baseline, there were 2062 persons (36.3%) with any type of AMD (prevalent cases), including 78 (1.4%) with late AMD (stage 4). During follow-up (mean, 8 years; median, 10 years), 1649 (35.5%) of 4642 participants progressed to a higher stage of AMD (incident cases), including 93 (5.6%) who developed late AMD. The odds ratio (OR) of AMD increased in an allele-dose manner with 2.00 (95% confidence interval [CI], 1.56-2.55) for stage 2 AMD, 4.58 (95% CI, 2.82-7.44) for stage 3 AMD, and 11.02 (95% CI, 6.82-11.81) for stage 4 (late, vision threatening) AMD for homozygous persons. Cumulative risks calculated by Kaplan-Meier analysis of late AMD by age 95 years were 48.3% for homozygotes, 42.6% for heterozygotes, and 21.9% for noncarriers. The population-attributable risk for CFH Y402H was 54.0%. Elevated erythrocyte sedimentation rates further increased the OR to 20.2 (95% CI, 9.5-43.0), elevated serum CRP levels to 27.7 (95% CI, 10.7-72.0), and smoking to 34.0 (95% CI, 13.0-88.6) for homozygotes compared with noncarriers without these determinants. The CRP haplotypes conferring high levels of CRP significantly increased the effect of CFH Y402H (P<.01).
   Conclusions The CFH Y402H polymorphism may account for a substantial proportion of AMD in individuals similar to those in the Rotterdam Study and may confer particular risk in the presence of environmental and genetic stimulators of the complement cascade.
C1 Netherlands Inst Neurosci, Dept Mol & Clin Ophthalmogenet, NL-1105 BA Amsterdam, Netherlands.
   Erasmus MC, Dept Epidemiol & Biostat, Rotterdam, Netherlands.
   Erasmus MC, Dept Ophthalmol, Rotterdam, Netherlands.
   Erasmus MC, Dept Hematol, Rotterdam, Netherlands.
   Erasmus MC, Dept Clin Genet, Rotterdam, Netherlands.
   Erasmus MC, Dept Internal Med, Rotterdam, Netherlands.
   Univ Amsterdam, Acad Med Ctr, Dept Clin Genet, NL-1105 AZ Amsterdam, Netherlands.
   Univ Amsterdam, Acad Med Ctr, Dept Ophthalmol, NL-1105 AZ Amsterdam, Netherlands.
C3 Royal Netherlands Academy of Arts & Sciences; Netherlands Institute for
   Neuroscience (NIN-KNAW); Erasmus University Rotterdam; Erasmus MC;
   Erasmus University Rotterdam; Erasmus MC; Erasmus University Rotterdam;
   Erasmus MC; Erasmus University Rotterdam; Erasmus MC; Erasmus University
   Rotterdam; Erasmus MC; University of Amsterdam; Academic Medical Center
   Amsterdam; Vrije Universiteit Amsterdam; University of Amsterdam;
   Academic Medical Center Amsterdam
RP de Jong, PTVM (通讯作者)，Netherlands Inst Neurosci, Dept Mol & Clin Ophthalmogenet, Meibergdreef 47, NL-1105 BA Amsterdam, Netherlands.
EM p.dejong@nin.knaw.nl
RI Klaver, Caroline C.W./A-2013-2016; Bergen, Arthur/J-3637-2013
OI Klaver, Caroline/0000-0002-2355-5258; Van Duijn,
   Cornelia/0000-0002-2374-9204; Bergen, Arthur/0000-0002-6333-9576
CR Abecasis GR, 2004, AM J HUM GENET, V74, P482, DOI 10.1086/382786
   Ambati J, 2003, NAT MED, V9, P1390, DOI 10.1038/nm950
   BIRD AEC, 1995, SURV OPHTHALMOL, V39, P367, DOI 10.1016/S0039-6257(05)80092-X
   Black S, 2004, J BIOL CHEM, V279, P48487, DOI 10.1074/jbc.R400025200
   Brull DJ, 2003, ARTERIOSCL THROM VAS, V23, P2063, DOI 10.1161/01.ATV.0000084640.21712.9C
   Carlson CS, 2005, AM J HUM GENET, V77, P64, DOI 10.1086/431366
   de Cordoba SR, 2004, MOL IMMUNOL, V41, P355, DOI 10.1016/j.molimm.2004.02.005
   Edwards AO, 2005, SCIENCE, V308, P421, DOI 10.1126/science.1110189
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P564
   Giannakis E, 2001, INT IMMUNOPHARMACOL, V1, P433, DOI 10.1016/S1567-5769(00)00040-0
   Hageman GS, 2001, PROG RETIN EYE RES, V20, P705, DOI 10.1016/S1350-9462(01)00010-6
   Hageman GS, 2005, P NATL ACAD SCI USA, V102, P7227, DOI 10.1073/pnas.0501536102
   Haines JL, 2005, SCIENCE, V308, P419, DOI 10.1126/science.1110359
   HEIBA IM, 1994, GENET EPIDEMIOL, V11, P51, DOI 10.1002/gepi.1370110106
   HOFMAN A, 1991, EUR J EPIDEMIOL, V7, P403, DOI 10.1007/BF00145007
   Iyengar SK, 2004, AM J HUM GENET, V74, P20, DOI 10.1086/380912
   Kardys I, 2006, EUR HEART J, V27, P1331, DOI 10.1093/eurheartj/ehl018
   KEW RR, 1985, J CLIN INVEST, V75, P1000, DOI 10.1172/JCI111760
   Klaver CCW, 1998, ARCH OPHTHALMOL-CHIC, V116, P1646, DOI 10.1001/archopht.116.12.1646
   Klein ML, 1998, ARCH OPHTHALMOL-CHIC, V116, P1082, DOI 10.1001/archopht.116.8.1082
   Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557
   Magnusson KP, 2006, PLOS MED, V3, P109, DOI 10.1371/journal.pmed.0030005
   Majewski J, 2003, AM J HUM GENET, V73, P540, DOI 10.1086/377701
   Rivera A, 2005, HUM MOL GENET, V14, P3227, DOI 10.1093/hmg/ddi353
   Rothman KJ., 2008, MODERN EPIDEMIOLOGY, V3
   Seddon JM, 2005, ARCH OPHTHALMOL-CHIC, V123, P774, DOI 10.1001/archopht.123.6.774
   Seddon JM, 2003, AM J HUM GENET, V73, P780, DOI 10.1086/378505
   Seddon JM, 1997, AM J OPHTHALMOL, V123, P199, DOI 10.1016/S0002-9394(14)71036-0
   Souied EH, 2005, MOL VIS, V11, P1135
   Stephens M, 2001, AM J HUM GENET, V68, P978, DOI 10.1086/319501
   van der Vaart H, 2005, RESP RES, V6, DOI 10.1186/1465-9921-6-22
   van Leeuwen R, 2003, ARCH OPHTHALMOL-CHIC, V121, P519, DOI 10.1001/archopht.121.4.519
   Weber JL, 2001, ADV GENET, V42, P77, DOI 10.1016/S0065-2660(01)42016-5
   Weeks DE, 2004, AM J HUM GENET, V75, P174, DOI 10.1086/422476
   Zareparsi S, 2005, AM J HUM GENET, V77, P149, DOI 10.1086/431426
NR 35
TC 262
Z9 285
U1 0
U2 17
PU AMER MEDICAL ASSOC
PI CHICAGO
PA 515 N STATE ST, CHICAGO, IL 60610-0946 USA
SN 0098-7484
J9 JAMA-J AM MED ASSOC
JI JAMA-J. Am. Med. Assoc.
PD JUL 19
PY 2006
VL 296
IS 3
BP 301
EP 309
DI 10.1001/jama.296.3.301
PG 9
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine
GA 064LA
UT WOS:000239089900022
PM 16849663
OA Bronze
DA 2022-11-30
ER

EF